{"title": "PDF", "author": "PDF", "url": "https://67congreso.sefh.es/img/libro-comunicaciones-67-congreso.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "2\n3\n4\n5\n7COMUNICACIONES CIENT\u00cdFICAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 34\nCLASIFICACI\u00d3N: ADHERENCIA  .................................................................................................................................. 34\n62\ufffd AN\u00c1LISIS DE PERSISTENCIA Y COSTE DE SECUKINUMAB EN ARTRITIS PSORI\u00c1SICA, ESPONDILITIS ANQUILOS -\nANTE Y PSORIASIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 34\n311\ufffd ADHERENCIA EN HEMOFILIA A CON TERAPIA NO FACTORIAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 34\n523\ufffd ADHERENCIA A ANTINEOPL\u00c1SICOS ORALES EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO EN \nESPA\u00d1A \u2013 ESTUDIO LOADH  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 35\n524\ufffd COLIRIO DE ATROPINA AL 0,01%: GRADO DE ADHERENCIA AL TRATAMIENTO Y PERFIL DE SEGURIDAD\nEN PACIENTES CON MIOP\u00cdA INFANTIL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 36\n578\ufffd ADHERENCIA AL TRATAMIENTO CON ANTINEOPL\u00c1SICOS POR V\u00cdA ORAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 36\n750\ufffd AN\u00c1LISIS Y SEGUIMIENTO DE LOS PACIENTES VIH NO ADHERENTES AL TRATAMIENTO ANTIRRETROVIRAL EN \nUN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 37\n899\ufffd ANALISIS DE LA EXPERIENCIA DE USO DE SACUBITRILO/VALSART\u00c1N: EN BUSCA DE LA ADECUACI\u00d3N  \nTERAP\u00c9UTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 38\n953\ufffd ESTUDIO DE ADHERENCIA EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA MEDIANTE LA ESCALA VISUAL  \nANAL\u00d3GICA DE ADHERENCIA Y LA CALCULADORA ADHECUAR\u00ae  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 39\n1043. IMPACTO DE LA COVID-19 EN LA ADHERENCIA AL TRATAMIENTO DE LA HIPERTENSI\u00d3N PULMONAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 39\n1113. P\u00c9RDIDA DE ADHERENCIA A UN ANTICUERPO MONOCLONAL INHIBIDOR DE PCSK9 (PROPROTE\u00cdNA CONVER -\nTASA SUBTILISINA/KEXINA TIPO 9) Y AL TRATAMIENTO HIPOLIPEMIANTE CONCOMITANTE.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 40\n1266 \ufffd ACTIVACI\u00d3N DEL PACIENTE ONCOL\u00d3GICO Y ADHERENCIA TERAP\u00c9UTICA A ANTINEOPL\u00c1SICOS ORALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 41\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS  ............................................... 41\n99. TERAPIAS INMUNOMODULADORAS Y VACUNACI\u00d3N COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 41\n120\ufffd BENEFICIO CL\u00cdNICO PERCIBIDO POR LOS PACIENTES EN LA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA  \nONCOL\u00d3GICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 42\n221\ufffd USO DEL MEPOLIZUMAB EN EL TRATAMIENTO DEL ASMA EOSINOF\u00cdLICA GRAVE \ufffd EFECTIVIDAD Y\nSEGURIDAD \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 43\n314\ufffd UPADACITINIB EN ARTRITIS REUMATOIDE: EVALUACI\u00d3N DE LA EFECTIVIDAD Y SEGURIDAD EN LA PR\u00c1CTICA \nCL\u00cdNICA HABITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 43\n329\ufffd EXPERIENCIA CL\u00cdNICA CON DARVADSTROCEL EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 44\n351\ufffd EVALUACI\u00d3N CL\u00cdNICA Y ECON\u00d3MICA TRAS LA INCORPORACI\u00d3N DE UN FARMAC\u00c9UTICO A UNA UNIDAD DE \nHOSPITALIZACI\u00d3N A DOMICILIO PEDI\u00c1TRICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 45\n385. \u00bfEXISTEN DISCREPANCIAS EN EL AJUSTE DE DOSIS DE LOS NUEVOS ANTICOAGULANTES ORALES (NACOS) \nENTRE LAS DISTINTAS ECUACIONES DE FILTRADO GLOMERULAR?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 46\n540. INTERVENCI\u00d3N FARMAC\u00c9UTICA EN LA PLANTA DE ONCO-HEMATOLOG\u00cdA.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 46\n547. INCIDENCIA DE REACTIVACI\u00d3N DE VIRUS HERPES-ZOSTER EN PACIENTES TRATADOS CON INHIBIDORES DE \nJAK-KINASA: RESULTADOS EN VIDA REAL.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 47\n622. PROTOCOLO DE MANEJO PERIOPERATORIO DE LA ANEMIA EN FRACTURA DE CADERA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 48\n639. PROGRAMA DE OPTIMIZACI\u00d3N DE ANTIBI\u00d3TICOS (PROA) Y CONCILIACI\u00d3N ANTIMICROBIANA EN EL ALTA \nHOSPITALARIA EN SERVICIOS QUIR\u00daRGICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 48\n645\ufffd CONCILIACI\u00d3N DE LA MEDICACI\u00d3N AL INGRESO: DETECCI\u00d3N Y AN\u00c1LISIS DE DISCREPANCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 49\n662\ufffd EFECTIVIDAD Y SEGURIDAD DE FREMANEZUMAB EN PACIENTES CON MIGRA\u00d1A CR\u00d3NICA REFRACTARIA A \nLARGO PLAZO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 50\n666\ufffd REVERSI\u00d3N DE F\u00c1RMACOS ANTICOAGULANTES EN PACIENTES CON FRACTURA DE CADERA QUE REQUIEREN \nINTERVENCI\u00d3N QUIR\u00daRGICA PRECOZ  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 51\n668. \u00bfINFLUYE EL NIVEL DE COMPLEJIDAD ASISTENCIAL DEL HOSPITAL EN LAS INTERVENCIONES\nFARMAC\u00c9UTICAS?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 51ANCHORANCHOR8676. AN\u00c1LISIS COMPARATIVO DE TRES PROGRAMAS FARMACOCIN\u00c9TICOS EN EL AJUSTE DE FENITO\u00cdNA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 52\n683\ufffd EVALUACI\u00d3N DE LA INFORMACI\u00d3N REPORTADA POR EL PACIENTE EN TRATAMIENTO ANTIRRETROVIRAL: \nCALIDAD DE VIDA Y ADHERENCIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 53\n694\ufffd EFECTIVIDAD Y SEGURIDAD DE ANTIFIBR\u00d3TICOS EN EL TRATAMIENTO DE LA FIBROSIS PULMONAR\nIDIOP\u00c1TICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 53\n708\ufffd EVALUACI\u00d3N DE LA EFICACIA Y SEGURIDAD DE BIOL\u00d3GICOS EN ASMA T2 EOSINOF\u00cdLICA EN PR\u00c1CTICA\nCL\u00cdNICA HABITUAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 54\n711\ufffd EXPERENCIA REPORTADA POR EL PACIENTE SOBRE EL PROTOCOLO DE ANALGESIA DE CIRUG\u00cdA MAYOR AMBU -\nLATORIA: HERRAMIENTA DE MEJORA CONTINUA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 55\n773. EVALUACI\u00d3N EX VIVO DE LA EFICACIA DE UN NUEVO HIDROGEL TERMO-SENSIBLE DESARROLLADO COMO \nFORMULACI\u00d3N MAGISTRAL PARA INYECCI\u00d3N SUBMUCOSA EN POLIPECTOM\u00cdAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 55\n814\ufffd AN\u00c1LISIS DE PRESCRIPCI\u00d3N, EFICACIA Y SEGURIDAD DE ALIROCUMAB Y EVOLOCUMAB EN EL TRATAMIENTO \nDE LA HIPERCOLESTEROLEMIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 56\n841. MEJORA DE LA TERAPIA FARMACOGERI\u00c1TRICA DE LAS PERSONAS MAYORES QUE VIVEN EN RESIDENCIAS A \nTRAV\u00c9S DE LA ATENCI\u00d3N FARMAC\u00c9UTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 57\n850\ufffd OPTIMIZACI\u00d3N DE LA UTILIZACI\u00d3N DE METADONA EN UN CENTRO PENITENCIARIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 58\n893\ufffd ADECUACI\u00d3N DE LA TERAPIA ANTIPLAQUETARIA DUAL A LAS GU\u00cdAS EUROPEAS DE PR\u00c1CTICA CL\u00cdNICA EN \nSINDROME CORONARIO AGUDO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 58\n904\ufffd VALIDACI\u00d3N FARMACE\u00daTICA DE LA HIPOPOTASEMIA EN EL PACIENTE HOSPITALIZADO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 59\n918\ufffd VALORACI\u00d3N DEL DOLOR TRAS LA IMPLANTACI\u00d3N DE UN NUEVO PROTOCOLO DE ANALGESIA EN\nCES\u00c1REAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 60\n927\ufffd INTERVENCIONES FARMAC\u00c9UTICAS REALIZADAS EN EL SENO DE UN EQUIPO MULTIDISCIPLINAR EN MEDICI -\nNA INTERNA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 61\n1013 \ufffd EDOXABAN Y DABIGATRAN EN PACIENTES DE EDAD AVANZADA CON FIBRILACI\u00d3N AURICULAR NO VALVU -\nLAR: EFECTIVIDAD Y SEGURIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 62\n1046. EFECTIVIDAD DE CASIRIVIMAB/IMDEVIMAB Y SOTROVIMAB FRENTE AL COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 62\n1048 \ufffd AN\u00c1LISIS DE RESULTADOS DE UN PROGRAMA DE CONCILIACI\u00d3N DE F\u00c1RMACOS ANTIPARKINSONIANOS: \nIDENTIFICACI\u00d3N Y PREVENCI\u00d3N DE ERRORES DE MEDICACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 63\n1059 \ufffd RIESGO DE TRANSFUSI\u00d3N SANGU\u00cdNEA EN PACIENTES CON ANTIAGREGANTES Y ANTICOAGULANTES TRAS LA \nINTERVENCI\u00d3N POR FRACTURA DE CADERA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 64\n1073 \ufffd AN\u00c1LISIS DE LA CARGA ANTICOLIN\u00c9RGICA EN PACIENTES ANCIANOS POLIMEDICADOS QUE HAN SUFRIDO \nUNA CA\u00cdDA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 64\n1084 \ufffd ESTUDIO DE FARMACOVIGILANCIA INTENSIVA EN PACIENTES CON FIBROSIS QU\u00cdSTICA EN TRATAMIENTO \nCON ELEXACAFTOR/TEZACAFTOR/IVACAFTOR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 65\n1089 \ufffd AN\u00c1LISIS DE INTERACCIONES EN PACIENTES QUE RECIBEN TRATAMIENTO PARA EL C\u00c1NCER DE PR\u00d3STATA \nCON ANTIANDR\u00d3GENOS DE SEGUNDA GENERACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 66\n1121 \ufffd EVALUACI\u00d3N DE LA SEGURIDAD DE LOS ANTAGONISTAS DE RECEPTORES DE ENDOTELINA EN PACIENTES \nCON HIPERTENSI\u00d3N PULMONAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 66\n1146. EVALUACI\u00d3N DE LA CALIDAD DE VIDA EN PACIENTES VIH MEDIANTE EL CUESTIONARIO MOS-SF-30  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 67\n1199. ADECUACI\u00d3N DEL TRATAMIENTO CON ANTICOAGULANTES ORALES DE ACCCI\u00d3N DIRECTA (ACOD) EN PACI -\nENTES HOPITALIZADOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 68\n1246 \ufffd AN\u00c1LISIS DE LA EFECTIVIDAD Y SEGURIDAD DE CAPSAICINA PARCHE EN EL DOLOR NEUROP\u00c1TICO PERIF\u00c9RI -\nCO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 68\n1292 \ufffd LARVATERAPIA: EFECTIVIDAD Y SEGURIDAD EN EL TRATAMIENTO DE \u00daLCERAS VASCULARES CR\u00d3NICAS RE -\nFRACTARIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 69\n1318 \ufffd EVALUACI\u00d3N DE RESULTADOS EN SALUD EN ASMA GRAVE NO CONTROLADA EN BASE A CRITERIOS CUANTI -\nTATIVOS FEOSSCORE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 70\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL  ................................................................................. 70\n93. ANTIAGREGACION EN PACIENTES RESIDENCIADOS CON FIBRILACI\u00d3N AURICULAR. \u00bfSE SIGUEN LAS RECOMEN -\nDACIONES DE LAS GU\u00cdAS ACTUALES?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 70\n118. SOBREPRESCRIPCI\u00d3N Y RIESGO DE INTOXICACI\u00d3N \u00bfESTAMOS ANTE UNA PANDEMIA DE DEFICIT DE\nVITAMINA D?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 719159\ufffd EFECTIVIDAD Y SEGURIDAD DE LOS INHIBIDORES DE PROPROTE\u00cdNA CONVERTASA SUBTILISINA/KEXINA EN LA \nPR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 72\n167\ufffd EFECTIVIDAD Y SEGURIDAD DE USO DE ERENUMAB EN LA PROFILAXIS DE LA MIGRA\u00d1A: PERSPECTIVA DE LA \nCALIDAD DE VIDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 72\n169\ufffd DESARROLLO DE UN MODELO PREDICTIVO DE RIESGO DE RECONSULTAS A URGENCIAS BASADO EN LA \nFARMACOTERAPIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 73\n185\ufffd CONCILIACI\u00d3N DE LA MEDICACI\u00d3N EN LAS TRANSICIONES ASISTENCIALES DE LOS USUARIOS PROCEDENTES \nDE CENTROS RESIDENCIALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 73\n199\ufffd REVISI\u00d3N FARMACOTERAP\u00c9UTICA DE PACIENTES EN TRATAMIENTO CON ESPIRONOLACTONA E HIPERPOTA -\nSEMIA ASOCIADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 74\n204\ufffd PREVALENCIA DE PRESCRIPCIONES POTENCIALMENTE INAPROPIADAS EN PACIENTES HOSPITALIZADOS DE \nEDAD AVANZADA \u00bfINFLUYE LA INSTITUCIONALIZACI\u00d3N?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 75\n208\ufffd ADECUACI\u00d3N DEL TRATAMIENTO HIPOLIPEMIANTE EN ATENCI\u00d3N PRIMARIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 76\n247\ufffd IMPACTO DE UNA INTERVENCI\u00d3N DE DESPRESCRIPCI\u00d3N EN UN HOSPITAL DE NEURORREHABILITACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd76\n260\ufffd EVALUACI\u00d3N DE LA ATENCI\u00d3N FARMAC\u00c9UTICA REALIZADA A CENTROS SOCIOSANITARIOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 77\n315\ufffd APLICACI\u00d3N DE UN PROTOCOLO DE DEPRESCRIPCI\u00d3N DE ANTIPSIC\u00d3TICOS EN PACIENTES CON DEMENCIA EN \nEL \u00c1MBITO DE UN CENTRO SOCIOSANITARIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 78\n350\ufffd AN\u00c1LISIS DE LA PERSISTENCIA DE PACIENTES EN TRATAMIENTO CON LURASIDONA EN UN CENTRO DE REHA -\nBILITACI\u00d3N PSICOSOCIAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 78\n394\ufffd AN\u00c1LISIS Y ADECUACI\u00d3N DE LOS TRATAMIENTOS ANTIDIAB\u00c9TICOS ORALES EN PACIENTES\nINSTITUCIONALIZADOS SEG\u00daN SU FRAGILIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 79\n402. PATIENT-REPORTED OUTCOMES MEASURES PARA EL SEGUIMIENTO DEL PACIENTE CON ASMA GRAVE. CON -\nSENSO DE EXPERTOS Y PACIENTES \ufffd \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 80\n418\ufffd EVALUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE LAXANTES Y FACTORES ASOCIADOS A SU USO EN CENTROS RESIDEN -\nCIALES DE PERSONAS MAYORES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 80\n439\ufffd PROGRAMA DE DESPRESCRIPCI\u00d3N EN CENTROS SOCIOSANITARIOS RESIDENCIALES \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 81\n489. \u00bfC\u00d3MO SE DIAGNOSTICAN LAS INFECCIONES DEL TRACTO URINARIO EN LAS RESIDENCIAS DE MAYORES?+  \ufffd\ufffd\ufffd\ufffd82\n501\ufffd POLIFARMACIA Y F\u00c1RMACOS INAPROPIADOS EN PACIENTES CON DISFAGIA OROFAR\u00cdNGEA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 82\n526\ufffd AN\u00c1LISIS DEL TRATAMIENTO ANTICOAGULANTE EN PACIENTES INGRESADOS MAYORES DE 65 A\u00d1OS CON \nFIBRILACI\u00d3N AURICULAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 83\n603\ufffd DISFAGIA: OPORTUNIDADES DE INTERVENCI\u00d3N SOBRE EL TRATAMIENTO FARMACOL\u00d3GICO EN PACIENTES \nAMBULATORIOS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 84\n619\ufffd UTILIZACI\u00d3N DE GABAPENTINA Y PREGABALINA EN PACIENTES HOSPITALIZADOS EN UNA UNIDAD DE AGU -\nDOS DE GERIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 84\n700\ufffd IMPLANTACI\u00d3N DE UNA PROGRAMA ASISTENCIAL DE APOYO A RESIDENCIAS SOCIOSANITARIAS: IMPLI -\nCACI\u00d3N DEL SERVICIO DE FARMACIA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 85\n710\ufffd REVISI\u00d3N DE LA TERAPIA F\u00c9RRICA ENDOVENOSA EN PACIENTES HEMODIALIZADOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 86\n783\ufffd OPTIMIZACI\u00d3N DEL TRATAMIENTO DE LA DIABETES MELLITUS TIPO 2 EN ATENCI\u00d3N PRIMARIA: APORTACI\u00d3N \nDEL FARMAC\u00c9UTICO ESPECIALISTA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 86\n787\ufffd CONCILIACI\u00d3N FARMAC\u00c9UTICA EN LAS TRANSICIONES ASISTENCIALES DEL PACIENTE QUIR\u00daRGICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 87\n870. CARGA ANTICOLIN\u00c9RGICA: \u00bfCU\u00c1L ES SU PAPEL EN EL RIESGO DE CA\u00cdDAS?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 88\n875\ufffd EVALUACI\u00d3N DE ANTIPSIC\u00d3TICOS DEPOT EN UN \u00c1REA DE SALUD \ufffd \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 89\n900. PANDEMIA COVID-19 Y UTILIZACI\u00d3N DE PSICOF\u00c1RMACOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 90\n903\ufffd DETECCI\u00d3N DE MEDICAMENTOS POTENCIALMENTE INADECUADOS DURANTE EL INGRESO Y EFECTO DE LAS \nINTERVENCIONES FARMAC\u00c9UTICAS SOBRE EL TRATAMIENTO AL ALTA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 90\n917\ufffd CARACTERIZACI\u00d3N DE LA CALIDAD DE VIDA Y NECESIDADES DEL PACIENTE ONCOL\u00d3GICO CON DIABETES \ufffd\ufffd\ufffd\ufffd91\n935\ufffd EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON \u00c1CIDO OBETIC\u00d3LICO EN PACIENTES CON COLANGITIS BILIAR \nPRIMARIA EN UN HOSPITAL TERCIARIO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 92\n938\ufffd PREVALENCIA DE HIPOMAGNESEMIA Y D\u00c9FICIT DE VITAMINA B12 EN PACIENTES CON INHIBIDORES DE LA \nBOMBA DE PROTONES \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 93\n943\ufffd RESULTADOS DE REVISI\u00d3N MULTIDISCIPLINAR DE LA TERAPIA FARMACOL\u00d3GICA EN PACIENTES FR\u00c1GILES \nPOLIMEDICADOS DE UNA UNIDAD HOSPITALARIA DE ALTA COMPLEJIDAD \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 9310962\ufffd AN\u00c1LISIS DE RECOMENDACIONES SOBRE ANALG\u00c9SICOS OPIOIDES Y ANSIOL\u00cdTICOS HIPN\u00d3TICO SEDANTES \nREALIZADAS POR EL SERVICIO DE FARMACIA SOBRE PACIENTES CR\u00d3NICOS COMPLEJOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 94\n965\ufffd INTERVENCI\u00d3N FARMAC\u00c9UTICA SOBRE LA REDUCCI\u00d3N DE MEDICACI\u00d3N DE ALTO RIESGO EN EL PACIENTE \nC\u00d3NICO COMPLEJO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 95\n973\ufffd AN\u00c1LISIS DE LA UTILIZACI\u00d3N DE LAXANTES EN ATENCI\u00d3N PRIMARIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 95\n991. \u00c1NALISIS DEL USO DE INHIBIDORES DE LA BOMBA DE PROTONES EN PACIENTES CR\u00d3NICOS COMPLEJOS  \ufffd\ufffd\ufffd\ufffd\ufffd96\n999\ufffd OPTIMIZACI\u00d3N DE RECURSOS EN LA ATENCI\u00d3N DE UNA RESIDENCIA SOCIOSANITARIA POR UN SERVICIO DE \nFARMACIA HOSPITALARIA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 97\n1025. CONCILIACI\u00d3N DEL TRATAMIENTO DOMICILIARIO AL INGRESO \u00bfQU\u00c9 OPINAN LOS PROFESIONALES DE EN -\nFERMER\u00cdA?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 97\n1034. ESTUDIO DE UTILIZACI\u00d3N DE DAPAGLIFLOCINA EN INSUFICIENCIA CARD\u00cdACA CR\u00d3NICA \u00bfC\u00d3MO SE EST\u00c1 PRE -\nSCRIBIENDO?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 98\n1088. CARACTER\u00cdSTICAS Y VACUNACI\u00d3N DE LOS PACIENTES COVID-19 INMUNOCOMPETENTES VERSUS INMUNO -\nDEPRIMIDOS EN UN HOSPITAL TERCIARIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 99\n1126 \ufffd AN\u00c1LISIS DEL FALLO DE TRATAMIENTO A MEPOLIZUMAB O BENRALIZUMAB EN PACIENTES CON ASMA \nGRAVE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 99\n1127 \ufffd INFLUENCIA DE LA COVID EN ENFERMOS MENTALES \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 100\n1128 \ufffd ESTUDIO SOBRE LA ADECUACI\u00d3N DEL TRATAMIENTO ANALG\u00c9SICO EN ANCIANOS\nINSTITUCIONALIZADOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 101\n1167 \ufffd PATR\u00d3N DEL USO DE DIUR\u00c9TICOS EN INSUFICIENCIA CARD\u00cdACA AVANZADA EN HOSPITAL DE D\u00cdA DE\nPACIENTE CR\u00d3NICO COMPLEJO Y FR\u00c1GIL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 101\n1239 \ufffd EVALUACI\u00d3N DE LA PERSISTENCIA DE F\u00c1RMACOS UTILIZADOS EN PRIMERA LINEA EN ESCLEROSIS\nM\u00daLTIPLE \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 102\n1262 \ufffd AN\u00c1LISIS DE USO Y DOSIS EMPLEADAS DE ANTIPSIC\u00d3TICOS EN PERSONAS MAYORES INSTITUCIONALIZADAS \nEN CENTROS RESIDENCIALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 103\n1291 \ufffd EVALUACI\u00d3N DE LA PERSISTENCIA DE TRATAMIENTOS DE PRIMERA LINEA DE ESCLEROSIS MULTIPLE: COM -\nPARACI\u00d3N CON EL EDSS BASAL DEL PACIENTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 104\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS  .............................................................................................. 105\n59\ufffd ACONTECIMIENTOS ADVERSOS POR MEDICAMENTOS COMO MOTIVO DE ASISTENCIA A URGENCIAS \ufffd PROYEC -\nTO FARMURG  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 105\n108\ufffd IMPLANTACI\u00d3N DE UN PROGRAMA DE REVISI\u00d3N DE URINOCULTIVOS EN PACIENTES CON INFECCI\u00d3N URI -\nNARIA AL ALTA DEL SERVICIO DE URGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 105\n137\ufffd APLICABILIDAD DE UN MODELO PREDICTIVO DE PAT\u00d3GENOS MULTIRRESISTENTES EN INFECCIONES DEL \nTRACTO URINARIO EN UN SERVICIO DE URGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 106\n156\ufffd DETECCI\u00d3N DE PROBLEMAS DE SALUD RELACIONADOS CON EL MEDICAMENTO MEDIANTE DIAGN\u00d3STICOS \nALERTANTES EN URGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 106\n323. DISE\u00d1O DE UNA METODOLOG\u00cdA DE REGISTRO PARA EVALUAR SEGURIDAD E IMPACTO CL\u00cdNICO-ECON\u00d3MICO \nDE LAS INTERVENCIONES FARMAC\u00c9UTICAS EN URGENCIAS: PROYECTO INTERFAR \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 107\n349\ufffd IMPACTO CL\u00cdNICO DE LOS PROBLEMAS RELACIONADOS CON LOS ANTICOAGULANTES EN UN SERVICIO DE \nURGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 108\n503\ufffd PERSPECTIVA DE G\u00c9NERO Y PROBLEMAS DE SALUD RELACIONADOS CON LOS MEDICAMENTOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 109\n515\ufffd AN\u00c1LISIS DE LAS INTERVENCIONES FARMAC\u00c9UTICAS RELACIONADAS CON INTERACCIONES RELEVANTES EN \nEL SERVICIO DE URGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 110\n542\ufffd RECONSULTAS POR HEMORRAGIAS DIGESTIVAS CAUSADAS POR ANTICOAGULANTES DE ACCI\u00d3N DIRECTA  \ufffd\ufffd\ufffd\ufffd110\n626\ufffd EFICACIA Y SEGURIDAD DE METOTREXATO INTRAMUSCULAR EN R\u00c9GIMEN DE DOSIS \u00daNICA EN GESTACI\u00d3N \nECT\u00d3PICA EXTRAUTERINA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 111\n735\ufffd AN\u00c1LISIS DE PRESCRIPCI\u00d3N DE DIGOXINA AL ALTA EN UN SERVICIO DE URGENCIAS TRAS IMPLANTACI\u00d3N DE \nUN PROTOCOLO DE FIBRILACI\u00d3N AURICULAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 112\n772. ADECUACION DE LA UTILIZACION DEL COMPLEJO PROTROMBINICO EN EL SERVICIO DE URGENCIAS DE UN \nHOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 112\n800\ufffd AN\u00c1LISIS DE PROBLEMAS DE SALUD RELACIONADOS CON LA MEDICACI\u00d3N EN UN SERVICIO DE\nURGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 11311884\ufffd ESTUDIO DESCRIPTIVO DE LAS ASISTENCIAS EN URGENCIAS POR EVENTOS ADVERSOS ASOCIADOS A LA \nMEDICACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 114\n970\ufffd AN\u00c1LISIS DEL USO DE METADONA PARA EL DESTETE DIFICULTOSO DE LA SEDOANALGESIA EN UNA UNIDAD \nDE CUIDADOS INTENSIVOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 115\n1267 \ufffd ATENCI\u00d3N FARMAC\u00c9UTICA TEMPRANA EN URGENCIAS: AN\u00c1LISIS DE LOS FACTORES PREDISPONENTES AL \nINGRESO EN UN SOCIOSANITARIO ADSCRITO AL MISMO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 115\n1277 \ufffd EVALUACI\u00d3N DE LA ADECUACI\u00d3N A UN PROTOCOLO DE TRATAMIENTO EMP\u00cdRICO DE NEUMON\u00cdA ADQUIRI -\nDA EN LA COMUNIDAD AL INGRESO HOSPITALARIO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 116\n1280 \ufffd EVALUACI\u00d3N DEL IMPACTO CL\u00cdNICO, ECON\u00d3MICO Y ORGANIZATIVO DE LAS INTERVENCIONES FARMAC\u00c9UTI -\nCAS EN URGENCIAS: METODOLOG\u00cdA CLEO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 117\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS  ............................................... 118\n63. \u00bfQU\u00c9 OCURRE TRAS COMPLETAR UN A\u00d1O DE TRATAMIENTO CON LOS ANTICUERPOS MONOCLONALES ANTI-\nCGRP PREVENTIVOS DE LOS ATAQUES DE MIGRA\u00d1A?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 118\n65\ufffd EFECTIVIDAD Y SEGURIDAD DE ERENUMAB EN PACIENTES CON MIGRA\u00d1A CR\u00d3NICA O EPIS\u00d3DICA EN UN HOS -\nPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 118\n102\ufffd UTILIZACI\u00d3N DE OCRELIZUMAB EN GLOMERULONEFRITIS REFRACTARIA: A PROP\u00d3SITO DE 2 CASOS\nCL\u00cdNICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 119\n105\ufffd ANALISIS DEL USO DE GALCANEZUMAB EN VIDA REAL EN PACIENTES CON MIGRA\u00d1A CR\u00d3NICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 120\n111\ufffd DUPILUMAB Y SU USO A LARGO PLAZO EN DERMATITIS AT\u00d3PICA: EFECTIVIDAD Y SEGURIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 120\n126\ufffd ESTUDIO EN VIDA REAL \ufffd EFECTIVIDAD Y SEGURIDAD DE FREMANEZUMAB EN PROFILAXIS DE LA\nMIGRA\u00d1A  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 121\n129. EFECTIVIDAD Y SEGURIDAD DE LA VACUNACI\u00d3N COVID-19 EN PACIENTES CON ENFERMEDADES INMUNOME -\nDIADAS A TRATAMIENTO BIOL\u00d3GICO: ESTUDIO BIOVACOVID \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 122\n134\ufffd AN\u00c1LISIS DE LA PERSISTENCIA DE PACIENTES EN TRATAMIENTO CON CARIPRAZINA EN UN CENTRO DE REHA -\nBILITACI\u00d3N PSICOSOCIAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 123\n143\ufffd EVALUACI\u00d3N DE LA EFICACIA Y PERSISTENCIA DEL GUSELKUMAB EN PSORIASIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 123\n160\ufffd USO Y PERFIL DE SEGURIDAD DE UPADACITINIB EN LA PR\u00c1CTICA CL\u00cdNICA REAL \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 124\n174\ufffd ANTICUERPOS DIRIGIDOS CONTRA EL P\u00c9PTIDO RELACIONADO CON EL GEN DE LA CALCITONINA COMO \nTRATAMIENTO PREVENTIVO PARA MIGRA\u00d1A: EFECTIVIDAD Y SEGURIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 125\n178\ufffd EVALUACI\u00d3N DE LA EFECTIVIDAD Y SEGURIDAD EN EL SWITCH A INFLIXIMAB BIOSIMILAR EN LA ENFERME -\nDAD INFLAMATORIA INTESTINAL E IMPACTO ECON\u00d3MICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 125\n188\ufffd EFICACIA DEL DUPILUMAB EN DERMATITIS AT\u00d3PICA EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 126\n190\ufffd CALIDAD DE VIDA PERCIBIDA POR PACIENTES CON ENFERMEDADES INFLAMATORIAS INMUNOMEDIADAS EN \nTRATAMIENTO CON TERAPIAS BIOL\u00d3GICAS Y PEQUE\u00d1AS MOL\u00c9CULAS DIRIGIDAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 127\n217\ufffd EXPERIENCIA DE USO DE ERENUMAB EN LA PROFILAXIS DE LA MIGRA\u00d1A: EFECTIVIDAD, SEGURIDAD Y COM -\nPARACI\u00d3N CON LOS ENSAYOS CL\u00cdNICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 127\n289\ufffd EVALUACI\u00d3N DE LA CALIDAD DE VIDA PERCIBIDA POR EL PACIENTE EN TRATAMIENTO CON ERENUMAB  \ufffd\ufffd\ufffd\ufffd128\n300\ufffd IMPACTO DE LA INTEGRACI\u00d3N DEL FARMAC\u00c9UTICO EN LA TOMA DE DECISIONES Y SEGUIMIENTO CL\u00cdNICO \nDEL PACIENTE CON PSORIASIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 129\n327. RELACI\u00d3N ENTRE LA PRESENCIA DE ANTICUERPOS ANTI-INFLIXIMAB Y LA APARICI\u00d3N DE REACCIONES\nADVERSAS EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 129\n356\ufffd EVALUACI\u00d3N DE LA CALIDAD DEL SUE\u00d1O EN PACIENTES CON PATOLOG\u00cdA REUMATOL\u00d3GICA INFLAMATORIA \nEN TRATAMIENTO CON TERAPIAS BIOL\u00d3GICAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 130\n371\ufffd RESULTADOS EN SALUD DE UPADACITINIB EN DERMATITS ATOPICA GRAVE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 131\n407\ufffd EFECTIVIDAD Y SEGURIDAD DE ERENUMAB EN EL TRATAMIENTO PREVENTIVO DE LA MIGRA\u00d1A  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 131\n443. EFECTIVIDAD Y SEGURIDAD DEL DUPILUMAB OFF-LABEL EN NI\u00d1O/AS \u2264 6 A\u00d1OS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 132\n487\ufffd EXPERIENCIA EN LA UTILIZACION DE SIPONIMOD EN EL TRATAMIENTO DE ESCLEROSIS M\u00daLITPLE\nSECUNDARIA PROGRESIVA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 133\n491\ufffd AN\u00c1LISIS DE VARIABLES PREDICTORAS DE CONCENTRACIONES TERAP\u00c9UTICAS DE USTEKINUMAB EN LA FASE \nDE INDUCCI\u00d3N EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 133\n493\ufffd EFICACIA Y SEGURIDAD DEL DUPILUMAB EN DERMATITIS ATOPICA EN PRACTICA CLINICA HABITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 13412519\ufffd CALIDAD DE VIDA EN PACIENTES CON ARTRITIS REUMATOIDE EN TRATAMIENTO CON F\u00c1RMACOS BIOL\u00d3GI -\nCOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 135\n549\ufffd RESULTADOS REPORTADOS POR LOS PACIENTES CON DERMATITIS AT\u00d3PICA EN TRATAMIENTO\nCON DUPILUMAB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 135\n562\ufffd EFECTIVIDAD, SEGURIDAD Y ADHERENCIA DE DUPILUMAB EN PACIENTES CON DERMATITIS AT\u00d3PICA EN LA \nPR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 136\n566\ufffd UTILIZACI\u00d3N DE TILDRAKIZUMAB EN PACIENTES CON PSORIASIS EN PLACAS DE MODERADA A GRAVE EN UN \nHOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 137\n572\ufffd USO DE CLADRIBINA PARA EL TRATAMIENTO DE ESCLEROSIS M\u00daLTIPLE REMITENTE RECURRENTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 138\n574. EFICACIA Y SEGURIDAD DE RISANKIZUMAB EN PACIENTES CON PSORIASIS MODERADA-GRAVE EN UN HOSPI -\nTAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 138\n580\ufffd EXPERIENCIA DE USO DE CLADRIBINA EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 139\n582\ufffd EVALUACI\u00d3N DE LOS RESULTADOS EN SALUD PERCIBIDOS POR EL PACIENTE CON ARTRITIS REUMATOIDE\nANTES DE INICIAR TERAPIA DIRIGIDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 140\n585\ufffd DARVADSTROCEL EN PACIENTES CON F\u00cdSTULAS EN ENFERMEDAD DE CROHN: RESULTADOS EN PR\u00c1CTICA \nCL\u00cdNICA HABITUAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 140\n593\ufffd EXPERIENCIA CL\u00cdNICA DEL CAMBIO A ADALIMUMAB BIOSIMILAR EN ENFERMEDAD INFLAMATORIA\nINTESTINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 141\n606\ufffd INFLIXIMAB EN EL TRATAMIENTO DE PRIMERA L\u00cdNEA DE F\u00c1RMACOS BIOL\u00d3GICOS EN ENFERMEDAD DE \nCROHN MODERADA O SEVERA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 142\n607. APORTACI\u00d3N FARMAC\u00c9UTICA EN LA PREVENCI\u00d3N DE INTERACCIONES ENTRE CARBIDOPA-LEVODOPA\nY ALIMENTOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 143\n654\ufffd SIPONIMOD EN EMSP: EFECTIVIDAD Y SEGURIDAD EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 143\n684\ufffd REINICIO DE TERAPIA BIOL\u00d3GICA EN PROFILAXIS DE MIGRA\u00d1A TRAS UN A\u00d1O DE TRATAMIENTO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 144\n689\ufffd ATENCI\u00d3N FARMAC\u00c9UTICA BASADA EN RESULTADOS Y EXPERIENCIAS COMUNICADAS POR LOS PACIENTES\nDE ESCLEROSIS M\u00daLTIPLE EN EL ENTORNO MULTIDISCIPLINAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 145\n690\ufffd EVALUACI\u00d3N DE LA PERSISTENCIA AL TRATAMIENTO MODIFICADOR DE LA ENFERMEDAD EN PACIENTES\nCON ESCLEROSIS M\u00daLTIPLE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 146\n698. EFECTO DE LOS INHIBIDORES DE JANUS KINASA SOBRE EL NIVEL DE GLICEMIA EN PACIENTES DIAB\u00c9TICOS \nCON ENFERMEDADES REUM\u00c1TICAS INMUNOMEDIADAS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 146\n712\ufffd EFECTIVIDAD Y SEGURIDAD EN VIDA REAL DE TOFACITINIB, BARICITINIB Y UPADACITINIB EN PACIENTES\nCON ARTRITIS REUMATOIDE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 147\n718\ufffd EXPERIENCIA DE USO EN VIDA REAL DE GALCANEZUMAB EN PROFILAXIS DE LA MIGRA\u00d1A REFRACTARIA  \ufffd\ufffd\ufffd148\n731\ufffd EFECTIVIDAD DEL TRATAMIENTO CON INHIBIDORES DE INTERLEUCINAS 17 Y 23 EN PSORIASIS EN PLACAS: \nPERSPECTIVA DEL PACIENTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 149\n733. RESULTADOS EN VIDA REAL DEL SWITCH ENTRE LOS ANTICUERPOS MONOCLONALES ANTI-CGRP PARA PRO -\nFILAXIS DE LA MIGRA\u00d1A  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 149\n734\ufffd TRATAMIENTOS MODIFICADORES DE LA ENFERMEDAD EN PACIENTES CON ESCLEROSIS M\u00daLTIPLE EN ESPA -\n\u00d1A: ESTUDIO EM-POINT  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 150\n740. EXPERIENCIA DE USO DE DUPILUMAB EN PACIENTES CON DERMATITIS AT\u00d3PICA MODERADA-GRAVE \nTRAS 52 SEMANAS DE TRATAMIENTO: EFECTIVIDAD Y SEGURIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 151\n754. USO DE RISANKIZUMAB EN PSORIASIS MODERADA - GRAVE EN VIDA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 152\n755\ufffd EXPERIENCIA DE USO DE ALIROCUMAB Y EVOLOCUMAB A LARGO PLAZO EN PACIENTES TRATADOS\nDURANTE 5 A\u00d1OS: EFECTIVIDAD Y SEGURIDAD \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 152\n781\ufffd EVOLUCI\u00d3N DE LA PENETRACI\u00d3N DE BIOSIMILARES EN ENFERMEDADES INMUNOMEDIADAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 153\n795. UTILIZACI\u00d3N DE PSICOF\u00c1RMACOS EN CONDICIONES OFF-LABEL EN UNA UNIDAD DE PSIQUIATR\u00cdA\nINFANTO-JUVENIL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 154\n818\ufffd OPTIMIZACI\u00d3N DEL TRATAMIENTO DE PACIENTES CON ARTRITIS REUMATOIDE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 154\n819\ufffd EXPERIENCIA DE USO CON DUPILUMAB: EFECTIVIDAD, SEGURIDAD Y ADHERENCIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 155\n823\ufffd PERSISTENCIA DEL TRATAMIENTO CON BIOSIMILARES TRAS EL SWITCH DEL F\u00c1RMACO ORIGINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 15613854\ufffd EFECTIVIDAD, SEGURIDAD Y ADHERENCIA DE DUPILUMAB EN PACIENTES CON DERMATITIS AT\u00d3PICA\nMODERADA-GRAVE EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 156\n863. PERSISTENCIA Y MOTIVOS DE CAMBIO DE F\u00c1RMACOS BIOL\u00d3GICOS E INHIBIDORES DE JANUS QUINASAS EN \nPACIENTES CON ARTRITIS REUMATOIDE \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 157\n871. IMPACTO DEL TRABAJO MULTIDISCIPLINAR EN LA ADECUACI\u00d3N DEL USO DE BENZODIACEPINAS EN UN\nCENTRO PENITENCIARIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 158\n902. PERSISTENCIA Y SEGURIDAD DE LOS INHIBIDORES DE LA QUINASA JANUS EN ARTRITIS REUMATOIDE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 158\n936\ufffd EXPERIENCIA DE LA TERAPIA BIOL\u00d3GICA EN PACIENTES CON HIDRADENITIS SUPURATIVA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 159\n954\ufffd PERSISTENCIA DE IXEKIZUMAB EN PACIENTES CON PSORIASIS, ARTRITIS PSORI\u00c1SICA Y ESPONDILITIS\nANQUILOSANTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 160\n956\ufffd FUNCIONES DE UNA COMISI\u00d3N DE ENFERMEDADES AUTOINMUNES DEL ADULTO Y EFECTO CL\u00cdNICO DE LOS \nTRATAMIENTOS AUTORIZADOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 161\n977. GRAVEDAD DE INFECCI\u00d3N POR SARS-COV2 E INFLUENCIA DE PSICOF\u00c1RMACOS EN POBLACI\u00d3N\nPSIQUI\u00c1TRICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 161\n981\ufffd RESULTADOS EN SALUD EN EL TRATAMIENTO PROFIL\u00c1CTICO DE LA MIGRA\u00d1A CON ERENUMAB,\nFREMANEZUMAB Y GALCANEZUMAB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 162\n1010 \ufffd SEGUIMIENTO DE EFICACIA DE MEPOLIZUMAB EN ASMA GRAVE NO CONTROLADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 163\n1031 \ufffd TRATAMIENTO BIOL\u00d3GICO DE RINOSINUSITIS CR\u00d3NICA CON P\u00d3LIPOS NASALES Y S\u00cdNTOMAS ASOCIADOS\nEN PACIENTES CON ASMA GRAVE NO CONTROLADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 164\n1056. EVALUACI\u00d3N DE LA EFECTIVIDAD Y SEGURIDAD DE LOS INHIBIDORES DE LAS JANUS KINASAS EN ARTRITIS \nREUMATOIDE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 164\n1067 \ufffd EXPERIENCIA DE UTILIZACI\u00d3N DE TERAPIA BIOL\u00d3GICA DUAL EN EL TRATAMIENTO DE PACIENTES CON\nENFERMEDAD INFLAMATORIA INTESTINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 165\n1075 \ufffd RESULTADOS DE LA IMPLANTACI\u00d3N DE UN PROGRAMA MULTIDISCIPLINAR DE MONITORIZACI\u00d3N\nTERAP\u00c9UTICA TEMPRANA PROACTIVA DE INFLIXIMAB EN ENFERMEDAD INFLAMATORIA INTESTINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 166\n1087 \ufffd RELACI\u00d3N DE LAS CONCENTRACIONES PLASM\u00c1TICAS DE OMALIZUMAB EN PACIENTES ASM\u00c1TICOS\nCON EL CONTROL DEL ASMA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 167\n1107 \ufffd OCRELIZUMAB EN ESCLEROSIS M\u00daLTIPLE, AN\u00c1LISIS DE EFICTIVIDAD Y SEGURIDAD POR INDICACIONES  \ufffd\ufffd\ufffd167\n1124 \ufffd LOS ANTICUERPOS FRENTE AL CGRP EN LA MIGRA\u00d1A EN PRIMERA L\u00cdNEA Y M\u00c1S ALL\u00c1: DATOS DE VIDA\nREAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 168\n1130. EFECTIVIDAD Y SEGURIDAD DE DUPILUMAB A CORTO Y LARGO PLAZO: \u00bfSE CUMPLEN LOS OBJETIVOS TERA -\nP\u00c9UTICOS?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 169\n1135 \ufffd IMPACTO ECON\u00d3MICO Y EN CALIDAD DE VIDA TRAS SWITCH DE ADALIMUMAB A ADALIMUMAB BIOSIMILAR \nEN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 170\n1181 \ufffd RESULTADOS DE EFECTIVIDAD EN VIDA REAL DEL TRATAMIENTO CON INHIBIDORES DE LA INTERLEUCINA 23 \nEN PACIENTES CON PSORIASIS MODERADA GRAVE \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 170\n1193 \ufffd PR\u00c1CTICA CLINICA REAL CON BELIMUMAB EN LUPUS ERITEMATOSO SIST\u00c9MICO EN UN HOSPITAL DE\nTERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 171\n1194. EFECTIVIDAD Y SEGURIDAD DEL TRATAMIENTO CON INHIBIDORES DE LA JAK EN ARTRITIS REUMATOIDE EN \nPR\u00c1CTICA CL\u00cdNICA HABITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 172\n1206 \ufffd UTILIZACI\u00d3N DE PROPRANOLOL EN EL TRATAMIENTO DE LA SINTOMATOLOG\u00cdA PERIF\u00c9RICA DE LA\nANSIEDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 173\n1209 \ufffd EFICACIA DEL ADALIMUMAB EN EL TRATAMIENTO DE LAS UVE\u00cdTIS NO INFECCIOSAS REFRACTARIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 173\n1220 \ufffd EXPERIENCIA DE USO DE ANTICUERPOS MONOCLONALES CONTRA EL P\u00c9PTIDO RELACIONADO CON EL GEN \nDE LA CALCITONINA EN LA MIGRA\u00d1A \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 174\n1222. EFECTIVIDAD Y SEGURIDAD DE GUSELKUMAB EN PACIENTES CON PSORIASIS MODERADA-GRAVE CONTRO -\nLADA CON USTEKINUMAB: ESTRATEGIA COSTE-EFECTIVIDAD.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 174\n1281 \ufffd DUPILUMAB EN DERMATITIS AT\u00d3PICA GRAVE: RESULTADOS DE UTILIZACI\u00d3N EN LA PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd175\n1313 \ufffd PROMS EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL Y TRATAMIENTO CON F\u00c1RMACOS \nBIOL\u00d3GICOS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 17614CLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS  ........................................................... 177\n130\ufffd TRATAMIENTO T\u00d3PICO DE LAS ICTIOSIS CONG\u00c9NITAS: IMPACTO EN LA CALIDAD DE VIDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 177\n145\ufffd RESULTADOS EN SALUD DEL USO DE IDEBENONA EN NEUROPAT\u00cdAS \u00d3PTICAS MITOCONDRIALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 177\n510\ufffd EFECTIVIDAD Y SEGURIDAD DE ELEXACAFTOR/TEZACAFTOR/IVACAFTOR EN EL TRATAMIENTO DE LA FIBROSIS \nQU\u00cdSTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 178\n558\ufffd EVALUACI\u00d3N DE LA EFECTIVIDAD DE NINTEDANIB Y PIRFENIDONA EN FIBROSIS PULMONAR IDIOP\u00c1TICA  \ufffd\ufffd\ufffd179\n569\ufffd EVALUACI\u00d3N DE LA EFICACIA DEL TRATAMIENTO CON NUSINERSEN EN PACIENTES CON ATROFIA MUSCULAR \nESPINAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 179\n581\ufffd USO DE DEFIBROTIDE EN PACIENTES SOMETIDOS A TRASPLANTE DE PROGENITORES HEMATOPOY\u00c9TICOS  \ufffd\ufffd\ufffd\ufffd180\n587. USO DE CANNABIDIOL EN EL S\u00cdNDROME DE LENNOX-GASTAUT  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 181\n648\ufffd EFECTIVIDAD Y SEGURIDAD DE RITUXIMAB EN EL TRATAMIENTO DE LA GLOMERULONEFRITIS REFRACTARIA, \nEXPERIENCIA DE UN HOSPITAL DE TERCER NIVEL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 181\n663\ufffd TOCILIZUMAB EN ORBITOPAT\u00cdA TIROIDEA MODERADA O GRAVE: EST\u00c1NDAR DE TRATAMIENTO EN PACIENTES \nREFRACTARIOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 182\n685\ufffd EFECTIVIDAD Y SEGURIDAD DE TIOSULFATO S\u00d3DICO EN CALCIFILAXIS NO UR\u00c9MICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 183\n691\ufffd IMPACTO DE LOS MEDICAMENTOS HU\u00c9RFANOS EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 184\n704\ufffd EFECTIVIDAD Y SEGURIDAD A LARGO PLAZO DE \u00c1CIDO OBETIC\u00d3LICO EN COLANGITIS BILIAR PRIMARIA  \ufffd\ufffd\ufffd\ufffd184\n760\ufffd EFICACIA Y SEGURIDAD DE ALPELISIB UTILIZADO FUERA DE INDICACI\u00d3N EN PACIENTES CON S\u00cdNDROMES DE \nSOBRECRECIMIENTO ASOCIADOS A PIK3CA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 185\n831\ufffd EFECTIVIDAD Y SEGURIDAD DE DARVADSTROCEL EN LA PR\u00c1CTICA CL\u00cdNICA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 186\n857\ufffd EXPERIENCIA DE USO DE BUROSUMAB EN LA PR\u00c1CTICA CL\u00cdNICA EN EL RAQUITISMO HIPOFOSFAT\u00c9MICO \nLIGADO AL CROMOSOMA X  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 187\n883\ufffd EFECTIVIDAD Y SEGURIDAD DE ESTATINAS T\u00d3PICAS EN PACIENTES TRASTORNOS DE LA\nQUERATINIZACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 188\n886\ufffd EFECTIVIDAD Y SEGURIDAD DE ELEXACAFTOR/TEZACAFTOR/IVACAFTOR EN PACIENTES CON FIBROSIS\nQU\u00cdSTICA Y DETERIORO SEVERO DE LA FUNCI\u00d3N PULMONAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 188\n891\ufffd ELEXACAFTOR/TEZACAFTOR/IVACAFTOR EN FIBROSIS QU\u00cdSTICA: RESULTADOS EN VIDA REAL EN UN HOSPITAL \nDE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 189\n971\ufffd ESTUDIO DE PERSISTENCIA Y TOXICIDAD A TRATAMIENTOS ANTIFIBR\u00d3TICOS EN FIBROSIS PULMONAR\nIDIOP\u00c1TICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 190\n972\ufffd MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE ECULIZUMAB EN PACIENTES CON S\u00cdNDROME HEMOL\u00cdTICO\nUR\u00c9MICO AT\u00cdPICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 191\n993\ufffd LANADELUMAB COMO PROFILAXIS A LARGO PLAZO EN EL ANGIOEDEMA HEREDITARIO: PRIMEROS\nRESULTADOS DE EFECTIVIDAD Y SEGURIDAD EN PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 191\n1033 \ufffd PROFILAXIS DE MICROANGIOPAT\u00cdA TROMB\u00d3TICA CON ECULIZUMAB EN PACIENTES TRASPLANTADOS\nRENALES CON S\u00cdNDROME HEMOL\u00cdTICO UR\u00c9MICO AT\u00cdPICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 192\n1119 \ufffd EFECTIVIDAD Y SEGURIDAD DE TEZACAFTOR/IVACAFTOR/ELEXACAFTOR EN LA PR\u00c1CTICA REAL \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 193\n1142 \ufffd FORMULACION MAGISTRAL EN EL TRATAMIENTO DE LAS ENFERMEDADES RARAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 193\n1208. EFECTIVIDAD Y SEGURIDAD DE IVACAFTOR TEZACAFTOR Y ELEXACAFTOR (KAFTRIO\u00ae) EN PACIENTES CON \nFIBROSIS QU\u00cdSTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 194\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS  ........................................................................................................................ 195\n302. VALIDACI\u00d3N DE UNA ESCALA ACTUALIZADA PARA EVALUAR LA COMPLEJIDAD DE LOS ENSAYOS CL\u00cdNICOS EN \nUN SERVICIO DE FARMACIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 195\n373\ufffd EVALUACI\u00d3N DEL GRADO DE SATISFACCI\u00d3N DE LOS PACIENTES EXTERNOS INCLUIDOS EN ENSAYOS CL\u00cdNICOS \nATENDIDOS EN UNA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 196\n614\ufffd SATISFACCI\u00d3N DEL PACIENTE AMBULATORIO CON EL \u00c1REA DE ENSAYOS CL\u00cdNICOS DE UN SERVICIO DE \nFARMACIA, EN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 196\n642\ufffd CARACTER\u00cdSTICAS DE LOS ENSAYOS CL\u00cdNICOS CON MEDICAMENTOS INICIADOS EN ONCOHEMATOLOG\u00cdA \nDURANTE EL 2021  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 197\n786\ufffd EVALUACI\u00d3N DEL PROCESO DE CONSENTIMIENTO INFORMADO EN PACIENTES QUE PARTICIPAN EN ENSAYOS \nCL\u00cdNICOS CON MEDICAMENTOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 19815790\ufffd AN\u00c1LISIS DEL NIVEL DE COMPRENSI\u00d3N QUE TIENEN LOS PACIENTES DE LOS PRINCIPALES ASPECTOS DE UN \nENSAYO CL\u00cdNICO CON MEDICAMENTOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 198\n867\ufffd ERRORES DE PRESCRIPCI\u00d3N EN F\u00c1RMACOS ORALES DE ENSAYO CL\u00cdNICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 199\n923\ufffd EVALUACI\u00d3N DEL AHORRO ECON\u00d3MICO EN MEDICACI\u00d3N DERIVADO DE LA PARTICIPACI\u00d3N EN ENSAYOS \nCL\u00cdNICOS HEMATOL\u00d3GICOS EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 200\n933\ufffd EVALUACI\u00d3N DE LA LEGIBILIDAD Y COMPRENSIBILIDAD DEL ETIQUETADO DE MEDICAMENTOS EN INVESTIG -\nACI\u00d3N CL\u00cdNICA POR PACIENTES DE ENSAYOS CL\u00cdNICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 200\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA  .................................... 201\n38. COMPARACI\u00d3N INDIRECTA DE NIVOLUMAB+IPILIMUMAB+QUIMIOTERAPIA FRENTE A \nPEMBROLIZUMAB+QUIMIOTERAPIA EN PRIMERA L\u00cdNEA DE C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO ESCAMOSO \nESTADIO IV  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 201\n89\ufffd ANTIRETROVIRAL THERAPY OPTIMISATION STRATEGIES IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED \nPATIENTS: A DECISIVE TASK FOR HOSPITAL PHARMACISTS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 202\n121. ADECUACI\u00d3N DE PRESCRIPCIONES DE CICLOSILICATO DE ZIRCONIO-SODIO SEG\u00daN CONDICIONES DEL IN -\nFORME DE POSICIONAMIENTO TERAP\u00c9UTICO MEDIANTE MUESTREO PARA ACEPTACI\u00d3N DE LOTES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 202\n225\ufffd COMPARACI\u00d3N INDIRECTA DE BARICITINIB, TOFACITINIB Y UPADACITINIB PARA EL TRATAMIENTO DE ARTRI -\nTIS REUMATOIDE EN EL PACIENTE RESISTENTE A TRATAMIENTOS BIOL\u00d3GICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 203\n249\ufffd RESULTADOS EN SALUD DEL TRATAMIENTO DE LA DERMATITIS AT\u00d3PICA CON DUPILUMAB EN EDAD\nPEDI\u00c1TRICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 204\n307. COMPARACI\u00d3N INDIRECTA AJUSTADA ENTRE POMALIDOMIDA+BORTEZOMIB+DEXAMETASONA Y DARATUM\nUMAB+BORTEZOMIB+DEXAMETASONA PARA EL TRATAMIENTO DEL MIELOMA M\u00daLTIPLE RECIDIVANTE/REFRAC -\nTARIO EN 2\u00aa L\u00cdNEA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 204\n333\ufffd AN\u00c1LISIS DE LA IMPLANTACI\u00d3N DEL USO DEL FACTOR VIII DE VIDA MEDIA EXTENDIDA EN PACIENTES CON \nHEMOFILIA A SEVERA MODERADA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 205\n369. COMPARACI\u00d3N INDIRECTA AJUSTADA DE CEMIPLIMAB Y ATEZOLIZUMAB EN EL TRATAMIENTO DE PRIMERA \nL\u00cdNEA DEL C\u00c1NCER DE PULM\u00d3N METAST\u00c1SICO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 206\n411. COMPARACI\u00d3N INDIRECTA AJUSTADA DE LA EFICACIA DE LOS INHIBIDORES DE JANUS QUINASAS PARA EL \nTRATAMIENTO DE LA ARTRITIS REUMATOIDE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 207\n420\ufffd DESCRIPCI\u00d3N Y EVALUACI\u00d3N DE LA PARTICIPACI\u00d3N DEL FARMAC\u00c9UTICO EN EL COMIT\u00c9 DE BIOL\u00d3GICOS DEL \nHOSPITAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 207\n432\ufffd EFICACIA COMPARADA DE ABROCITINIB, BARICITINIB Y UPADACITINIB EN COMBINACI\u00d3N CON CORTICOIDES \nT\u00d3PICOS PARA EL TRATAMIENTO DE LA DERMATITIS AT\u00d3PICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 208\n437\ufffd CUANTIFICACI\u00d3N DEL VALOR SOCIAL QUE SUPONE LOGRAR UNA RESPUESTA COMPLETA EN LOS PACIENTES \nCON PSORIASIS EN PLACAS MODERADA-GRAVE EN ESPA\u00d1A.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 209\n445\ufffd EVOLUCI\u00d3N Y RESULTADOS REPORTADOS TRAS EL INTERCAMBIO DE TRATAMIENTO DEL MEDICAMENTO DE \nREFERENCIA A BIOSIMILAR EN PACIENTES CON PATOLOG\u00cdA INFLAMATORIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 209\n604. AN\u00c1LISIS DE COSTE-EFECTIVIDAD DE DUPILUMAB EN EL TRATAMIENTO DE LA DERMATITIS AT\u00d3PICA EN NI -\n\u00d1OS Y ADOLESCENTES EN ESPA\u00d1A  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 210\n727\ufffd OPTIMIZACI\u00d3N DE COSTES EN EL TRATAMIENTO CON NATALIZUMAB PARENTERAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 211\n728\ufffd AN\u00c1LISIS DE UNA GESTI\u00d3N PROTOCOLIZADA DE LOS DESABASTECIMIENTOS DE MEDICAMENTOS Y SUS CON -\nSECUENCIAS CL\u00cdNICAS Y ECON\u00d3MICAS \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 211\n748\ufffd EFECTIVIDAD Y SEGURIDAD DE UPADACITINIB EN LA PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 212\n757\ufffd RITUXIMAB EN EL TRATAMIENTO DE LAS GLOMERULONEFRITIS: EFECTIVIDAD Y SEGURIDAD \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 213\n851\ufffd EFECTIVIDAD, SEGURIDAD Y COSTE DE LEVOSIMEND\u00c1N EN HOSPITAL DE D\u00cdA EN PACIENTES CON INSUFICIEN -\nCIA CARDIACA AVANZADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 214\n1022 \ufffd EVALUACI\u00d3N DEL USO DE FILGRASTIM EN EL TRATAMIENTO DE INFERTILIDAD DE CAUSA DESCONOCIDA EN \nPACIENTES CON RECEPTORES KIR TIPO INHIBIDOR \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 214\n1023 \ufffd AN\u00c1LISIS DE MINIMIZACI\u00d3N DE COSTES ASOCIADO AL INTERCAMBIO A MEDICAMENTOS BIOSIMILARES \nANTI-FACTOR DE NECROSIS TUMORAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 215\n1055 \ufffd EVALUACI\u00d3N DE SOLICITUDES INDIVIDUALIZADAS DE MEDICAMENTOS DE ALTO IMPACTO Y MEDICAMEN -\nTOS EN SITUACIONES ESPECIALES EN UN HOSPITAL DE TERCER NIVEL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 216161079. COMPARACI\u00d3N INDIRECTA AJUSTADA ENTRE ANTICUERPOS MONOCLONALES PARA EL TRATAMIENTO DE LA \nRINUSITIS CR\u00d3NICA CON POLIPOSIS NASAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 216\n1152 \ufffd EVALUACI\u00d3N DE LA EFICACIA Y SEGURIDAD DEL IMPLANTE INTRAV\u00cdTREO DE DEXAMETASONA EN EDEMA \nMACULAR EN UN HOSPITAL COMARCAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 217\n1158 \ufffd DISE\u00d1O, IMPLANTACI\u00d3N E IMPACTO ECON\u00d3MICO DEL SWITCH DE INFLIXIMAB EN EL SERVICIO DE REUMA -\nTOLOG\u00cdA EN UN HOSPITAL MEDIANO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 218\n1179 \ufffd REVISI\u00d3N DEL USO DE INMUNOGLOBULINAS INESPEC\u00cdFICAS EN EL CONTEXTO DE DESABASTECIMIENTO \nMUNDIAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 219\n1221 \ufffd IMPACTO DE LOS ACCESOS GESTIONADOS COMO HERRAMIENTA EN LA INCORPORACI\u00d3N SOSTENIBLE DE LA \nINNOVACI\u00d3N TERAP\u00c9UTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 219\n1252 \ufffd USO RACIONAL DE ETELCALCETIDA EN HIPERPARATIROIDISMO SECUNDARIO EN PACIENTES EN HEMODI\u00c1LISIS  220\n1264 \ufffd AN\u00c1LISIS DE EFECTIVIDAD Y SEGURIDAD DE OCRELIZUMAB: DATOS EN VIDA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 221\n1265 \ufffd IMPACTO EN LOS REINGRESOS POR INSUFICIENCIA CARDIACA CONGESTIVA TRAS LA INTRODUCCI\u00d3N DE \nDAPAGLIFOZINA EN LA GU\u00cdA FARMACOTERAP\u00c9UTICA DEL CENTRO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 221\n1269 \ufffd EXPERIENCIA DE USO DE OMALIZUMAB EN EL TRATAMIENTO DE LA URTICARIA CR\u00d3NICA ESPONT\u00c1NEA  \ufffd\ufffd222\n1284 \ufffd EVALUACI\u00d3N DE LOS COMPARADORES EMPLEADOS EN LOS ESTUDIOS PIVOTALES DE NUEVOS MEDICAMEN -\nTOS E INDICACIONES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 223\n1286 \ufffd EVALUACI\u00d3N DE LA ADECUACI\u00d3N, EFECTIVIDAD Y SEGURIDAD DEL ANT\u00cdDOTO IDARUCIZUMAB EN REVER -\nSI\u00d3N URGENTE DE ANTICOAGULACI\u00d3N EN UN HOSPITAL TERCIARIO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 223\n1315 \ufffd EXPERIENCIA DE USO DE FREMANEZUMAB EN EL TRATAMIENTO DE LA MIGRA\u00d1A CR\u00d3NICA Y EPIS\u00d3DICA  224\n1317. AN\u00c1LISIS EN VIDA REAL DE LA EFICACIA DE NUEVOS TRATAMIENTOS COVID-19 EN UN HOSPITAL\nDE 3 NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 225\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N  ................................................................................................... 226\n58. EFECTIVIDAD Y SEGURIDAD DE COLIRIO DE CICLOSPORINA EN VEH\u00cdCULO ACUOSO (L\u00c1GRIMAS\nARTIFICIALES)  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 226\n78\ufffd ESTUDIO DE DISPERSI\u00d3N DE MEDICAMENTOS PELIGROSOS ORALES PARA ADMINISTRACI\u00d3N INMEDIATA  \ufffd\ufffd\ufffd\ufffd226\n86\ufffd ENSAYO IN VITRO DE FORMACI\u00d3N DE UN FARMACOBEZOAR TRAS LA INGESTA MASIVA DE COMPRIMIDOS DE \n\u00c1CIDO VALPROICO DE LIBERACI\u00d3N PROLONGADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 227\n95\ufffd FORMULACI\u00d3N DE C\u00c1PSULAS PARA LA DESENSIBILIZACI\u00d3N A PROGEST\u00c1GENOS EN PACIENTES CON HIPERSEN -\nSIBILIDAD A PROGESTERONA END\u00d3GENA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 228\n110\ufffd REFORMULACI\u00d3N DE SIROLIMUS T\u00d3PICO: ESTABILIDAD QU\u00cdMICA, F\u00cdSICA Y MICROBIOL\u00d3GICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 228\n152\ufffd IMPACTO DE LA FORMULACI\u00d3N MAGISTRAL SOBRE EL USO DE SONDAS PARA ADMINISTRACI\u00d3N ENTERAL  229\n171. ESTABILIDAD F\u00cdSICO-QU\u00cdMICA DE UNA MEZCLA DE TRAMADOL, DEXKETOPROFENO Y METADONA EN DOS \nTIPOS DE INFUSORES ELASTOM\u00c9RICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 230\n234. ESTABILIDAD MICROBIOL\u00d3GICA DE NITROPRUSIATO S\u00d3DICO 600 \u039cG/ML JERINGA INTRACAVERNOSA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 231\n268\ufffd DESARROLLO GAL\u00c9NICO, EFECTIVIDAD Y SEGURIDAD DE GENTAMICINA SULFATO 0,5% F\u00d3RMULA MAGISTRAL \nT\u00d3PICA EN EL TRATAMIENTO DE LA ENFERMEDAD DE HAILEY-HAILEY .  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 231\n340\ufffd AN\u00c1LISIS DE LAS COMPLICACIONES M\u00c1S FRECUENTES EN PACIENTES CON NUTRICI\u00d3N PARENTERAL DOMI -\nCILIARIA EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 232\n355\ufffd DESARROLLO GALENICO DE UNA CREMA DE COLISTINA 0,1% PARA EL TRATAMIENTO TOPICO DE PSEUDOMO -\nNAS MULTIRRESISTENTES EN ULCERAS POR PRESION  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 233\n382. EXPERIENCIA DE EMPLEO DE \u00c1CIDOS GRASOS OMEGA-3 EN PACIENTES MENORES DE 3 MESES CON DA\u00d1O \nHEP\u00c1TICO ASOCIADO A FALLO INTESTINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 234\n384\ufffd VALIDACI\u00d3N GAL\u00c9NICA DE UN SPRAY ORAL DE INDOMETACINA 0,25% COMO ALTERNATIVA TERAP\u00c9UTICA \nPARA MUCOSITIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 234\n398. VALIDACI\u00d3N GAL\u00c9NICA DEL COLIRIO DE INTERFER\u00d3N ALFA-2B A PARTIR DE LA ESPECIALIDAD\nDE BIOFERON  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 235\n413\ufffd ESTANDARIZACION Y DESARROLLO GAL\u00c9NICO DE SUPLEMENTOS ORALES DE ELECTROLITOS PARA PEDIATRIA \nY NEONATOLOGIA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 236\n446\ufffd REFORMULACI\u00d3N DE IMIQUIMOD EN \u00d3VULOS VAGINALES PARA EL TRATAMIENTO DE CONDILOMAS PRODU -\nCIDOS POR EL VIRUS DEL PAPILOMA HUMANO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 23717459\ufffd EVALUACION DE LAS RECOMENDACIONES NUTRICIONALES EN PACIENTES CRITICOS: REFORMULANDO LA \nPRACTICA CLINICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 237\n464\ufffd VALIDACI\u00d3N GAL\u00c9NICA DE DISTINTAS F\u00d3RMULAS MAGISTRALES DE COLIRIOS DE GANCICLOVIR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 238\n478\ufffd OPTIMIZACI\u00d3N DE LA ELABORACI\u00d3N DE OMEPRAZOL 2 MG/ML SUSPENSI\u00d3N ORAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 239\n486\ufffd EFECTIVIDAD Y SEGURIDAD DE LA TOXINA BOTUL\u00cdNICA EN PACIENTES CON HIPERTON\u00cdA DEL M\u00daSCULO CRI -\nCOFAR\u00cdNGEO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 240\n496\ufffd ALGORITMO DE DECISI\u00d3N EN LA PRESCRIPCI\u00d3N DE NUTRICI\u00d3N ENTERAL EN NI\u00d1OS MAYORES DE 1 A\u00d1O  \ufffd\ufffd240\n497\ufffd VANCOMICINA EN EXCIPIENTE ADHESIVO PARA EL TRATAMIENTO DE LA COLITIS PSEUDOMEMBRANOSA  \ufffd\ufffd241\n500\ufffd UTILIZACI\u00d3N DE COLIRIO DE INSULINA ELABORADO COMO FORMULACI\u00d3N MAGISTRAL EN EL TRATAMIENTO \nDE LA DESEPITELIZACI\u00d3N CORNEAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 242\n504. \u00bfALTERNATIVAS AL COLIRIO DE INTERFERON ALFA 2B? A PROP\u00d3SITO DE UN CASO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 242\n514\ufffd DISE\u00d1O Y VALIDACI\u00d3N GAL\u00c9NICA DE UNA SUSPENSI\u00d3N OLEOSA ORAL DE CLOFAZIMINA PARA SU USO EN \nPEDIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 243\n551\ufffd EFECTIVIDAD DE LA NUTRICI\u00d3N PARENTERAL INTRADI\u00c1LISIS EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 244\n555\ufffd ESTABILIDAD DE UNA SOLUCI\u00d3N DE MEROPENEM 50 MG/ML PARA EL TRATAMIENTO DE INFECCIONES\nOCULARES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 244\n556\ufffd FABRICACI\u00d3N DE FORMAS FARMAC\u00c9UTICAS SEMIS\u00d3LIDAS ESF\u00c9RICAS MEDIANTE UTILIZACI\u00d3N DE MOLDES \nDISE\u00d1ADOS POR IMPRESORA 3D PARA DIAGN\u00d3STICO DE DISFAGIA POR FLUOROSCOPIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 245\n590\ufffd ESTABILIDAD QU\u00cdMICA Y COMPATIBILIDAD F\u00cdSICA DE FUROSEMIDA EN CLORURO S\u00d3DICO 0,9% E HIPERT\u00d3NI -\nCO PARA EL TRATAMIENTO DE LA INSUFICIENCIA CARDIACA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 246\n602\ufffd AN\u00c1LISIS DEL SOPORTE NUTRICIONAL DESDE UN ENFOQUE MULTIDISCIPLINAR EN PACIENTES CON\nANOREXIA NERVIOSA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 246\n615\ufffd SOLUCI\u00d3N OFT\u00c1LMICA DE EDTA 2% EN QUERATOPAT\u00cdA C\u00c1LCICA EN BANDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 247\n635\ufffd USO DEL COLIRIO DE INSULINA EN DEFECTOS EPITELIALES CORNEALES PERSISTENTES A OTROS TRATAMIEN -\nTOS FARMACOL\u00d3GICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 248\n670\ufffd AN\u00c1LISIS COMPARATIVO DE RECURSOS FARMAC\u00c9UTICOS DEDICADOS A ONCOLOG\u00cdA Y A NUTRICI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 249\n686\ufffd ESTUDIO DE PH Y OSMOLARIDAD DE LOS F\u00c1RMACOS EMPLEADOS EN EMERGENCIAS METAB\u00d3LICAS PARA\nSU ADMINISTRACI\u00d3N POR SONDA NASOG\u00c1STRICA Y POSTPIL\u00d3RICA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 250\n705\ufffd DESARROLLO DE UNA SUSPENSI\u00d3N T\u00d3PICA DE SIMVASTATINA Y COLESTEROL PARA LA POROQUERATOSIS \nACT\u00cdNICA SUPERFICIAL DISEMINADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 251\n726\ufffd NUTRICI\u00d3N PARENTERAL TOTAL EN PACIENTE QUIR\u00daRGICO: ADECUACI\u00d3N A LAS GU\u00cdAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 251\n732\ufffd FORMULACI\u00d3N DE CREMA DE COLESTEROL AL 2% Y SIMVASTATINA AL 2% EN EL TRATAMIENTO DE LA PORO -\nQUERATOSIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 252\n743\ufffd LACA DE U\u00d1AS DE ANFOTERICINA B AL 2% PARA ONICOMICOSIS RESISTENTE AL TRATAMIENTO HABITUAL  \ufffd\ufffd\ufffd\ufffd253\n749\ufffd EVALUACI\u00d3N DE LOS EFECTOS DE LA FARMACOTERAPIA EN LA DISFAGIA Y ANOREXIA EN UNA POBLACI\u00d3N \nANCIANA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 254\n802\ufffd FORMULACI\u00d3N DE ALPURINOL CREMA COMO OPCI\u00d3N DE TRATAMIENTO EN LA ERITRODISESTESIA PALMO -\nPLANTAR \ufffd A PROPOSITO DE UN CASO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 254\n840\ufffd EFECTIVIDAD Y SEGURIDAD DE TIOSULFATO S\u00d3DICO INTRAVENOSO EN EL TRATAMIENTO DE LA\nCALCIFILAXIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 255\n849\ufffd FORMULACI\u00d3N DE SUPOSITORIOS VAGINALES DE IMIQUIMOD PARA NEOPLASIA VAGINAL INTRAEPITELIAL \nPOR VIRUS DEL PAPILOMA HUMANO: A PROP\u00d3SITO DE UN CASO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 256\n931\ufffd EFECTIVIDAD DE LA INSULINA T\u00d3PICA EN \u00daLCERAS NEUROTR\u00d3FICAS Y DEFECTOS DEL EPITELIO CORNEAL\nSIN RESPUESTA A OTROS ABORDAJES TERAP\u00c9UTICOS.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 256\n959\ufffd EVOLUCI\u00d3N DE LOS NIVELES PLASM\u00c1TICOS DE \u00c1CIDO \u00daRICO EN UNA COHORTE DE PACIENTES CON SOPORTE \nNUTRICIONAL PARENTERAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 257\n986\ufffd VALIDACI\u00d3N DE UN M\u00c9TODO ESPECTROFOTOM\u00c9TRICO PARA EL CONTROL DE CALIDAD DE UN COLIRIO DE \nMEDROXIPROGESTERONA 2%  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 258\n996\ufffd PRUEBAS EPICUT\u00c1NEAS, INTRAEPID\u00c9RMICAS E INTRAD\u00c9RMICAS DE ALERGIA ELABORADAS EN UN SERVICIO \nDE FARMACIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 259\n997\ufffd BIOIMPEDANCIA EL\u00c9CTRICA Y NUTRICI\u00d3N PARENTERAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 259181006 \ufffd CARACTERIZACI\u00d3N FISICOQU\u00cdMICA Y DE ABSORCI\u00d3N GASTROINTESTINAL DE F\u00d3RMULAS ORALES L\u00cdQUIDAS \nDEL FORMULARIO NACIONAL PARA UNA ADMINISTRACI\u00d3N SEGURA POR SONDA ENTERAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 260\n1016 \ufffd ESTRATEGIA DE OPTIMIZACI\u00d3N DEL FRACCIONAMIENTO DE EMICIZUMAB EN PEDIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 261\n1029 \ufffd BUDESONIDA VISCOSA: AN\u00c1LISIS DEL PERFIL DEL PACIENTE, EFECTIVIDAD Y SEGURIDAD EN EL TRATAMIEN -\nTO DE LA ESOFAGITIS EOSINOF\u00cdLICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 262\n1041 \ufffd ELABORACI\u00d3N DE DILUCIONES PARA EL ESTUDIO DE HIPERSENSIBILIDAD A VACUNAS ARNM FRENTE A\nSARS-COV-2 Y EVALUACI\u00d3N DE LA RESPUESTA.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 262\n1054 \ufffd AN\u00c1LISIS DESCRIPTIVO DE LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO DE \u00daLCERAS CORNEALES CON \nCOLIRIO DE INSULINA 25 UI/ML  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 263\n1058. VALORACI\u00d3N DEL RIESGO NUTRICIONAL DE PACIENTES CON INFECCION POR SARS-COV-2 INGRESADOS EN \nUNIDAD DE CUIDADOS INTENSIVOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 263\n1060 \ufffd DISE\u00d1O Y VALIDACI\u00d3N GAL\u00c9NICA DE UNA NUEVA SUSPENSI\u00d3N ORAL DE AMIODARONA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 264\n1098 \ufffd F\u00d3RMULA MAGISTRAL GEL GLUCOSA 40% EST\u00c9RIL PARA EL TRATAMIENTO DE HIPOGLUCEMIA EN NEONA -\nTOS Y RECI\u00c9N NACIDOS A T\u00c9RMINO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 265\n1115 \ufffd ADECUACI\u00d3N DE LAS PRESCRIPCIONES DE NUTRICI\u00d3N PARENTERAL NEONATAL EN UN HOSPITAL DE TERCER \nNIVEL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 265\n1116 \ufffd NUTRICI\u00d3N PARENTERAL ADITIVADA CON OCTRE\u00d3TIDO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE \nINJERTO CONTRA HU\u00c9SPED DIGESTIVA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 266\n1139 \ufffd FORMULACI\u00d3N T\u00d3PICA DE SIMVASTATINA 2% Y COLESTEROL 2% PARA EL TRATAMIENTO DE LA POROQUERA -\nTOSIS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 267\n1175 \ufffd ESTUDIO DE ESTABILIDAD FISICOQU\u00cdMICA DE UN COLIRIO DE CICLOSPORINA 0,5 MG/ML MEDIANTE CRO -\nMATOGRAF\u00cdA L\u00cdQUIDA DE ALTA RESOLUCI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 268\n1213 \ufffd VALIDACI\u00d3N GAL\u00c9NICA DE UNA SUSPENSI\u00d3N DE BOSENT\u00c1N A PARTIR DE COMPRIMIDOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 269\n1271 \ufffd EFECTIVIDAD DE COLIRIO DE INSULINA EN DEFECTOS EPITELIALES CORNEALES PERSISTENTES\nREFRACTARIOS A TRATAMIENTO CONVENCIONAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 269\n1287 \ufffd INSULINA T\u00d3PICA EN EL TRATAMIENTO DE DEFECTOS EPITELIALES OCULARES PERSISTENTES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 270\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS  271\n15\ufffd PRELIMINARY EVALUATION OF AN AUTOMATIZED INTERVENTION TO SWITCH ANTIBIOTICS FROM ENDOVE -\nNOUS TO ORAL ROUTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 271\n106\ufffd AN\u00c1LISIS DEL PRIMER A\u00d1O DE UN PROYECTO DE TELEFARMACIA ASOCIADO A RESULTADOS REPORTADOS \nPOR LOS PACIENTES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 271\n132\ufffd UTILIDAD DE LOS F\u00d3RUMS COMO FUENTE DE INFORMACI\u00d3N SOBRE LA SEGURIDAD DE LOS MEDICAMENTOS \nEN LA POBLACI\u00d3N PEDI\u00c1TRICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 272\n239\ufffd AN\u00c1LISIS DE LOS DESABASTECIMIENTOS DE MEDICAMENTOS QUE REQUIEREN IMPORTACI\u00d3N Y DISPEN -\nSACI\u00d3N EN LOS SERVICIOS DE FARMACIA, EN UN \u00c1REA GEOGR\u00c1FICA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 273\n306. EVOLUCI\u00d3N DEL GASTO ECON\u00d3MICO DURANTE LAS DIFERENTES OLEADAS DE LA PANDEMIA POR COVID-19 \nEN UN HOSPITAL COMARCAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 274\n410\ufffd EVALUACI\u00d3N DE IMPLEMENTACI\u00d3N DE UN PROGRAMA DE TELEFARMACIA EN PACIENTES VIH  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 274\n579\ufffd EL \u00c1RBOL DE LA FARMACIA HOSPITALARIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 275\n608\ufffd GESTI\u00d3N DE LOS INCIDENTES DE SUMINISTRO EN LA ADQUISICI\u00d3N DE MEDICAMENTOS E IMPACTO DE LAS \nESTRATEGIAS DE ACTUACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 276\n617. DESARROLLO DE UN ESCRITORIO VIRTUAL COMO ENTORNO PERSONAL DE APRENDIZAJE EN UN SERVICIO DE \nFARMACIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 276\n658\ufffd AN\u00c1LISIS DE LOS INDICADORES DE CONTINUIDAD ASISTENCIAL DEL CONTRATO PROGRAMA TRAS LA IM -\nPLANTACI\u00d3N DE MEDIDAS FORMATIVAS Y DE SEGUIMIENTO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 277\n677\ufffd ANALISIS DE LA ACTIVIDAD DE UN SERVICIO DE FARMACIA DE UN HOSPITAL COMARCAL EN BASE A UNI -\nDADES RELATIVAS DE VALOR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 278\n768\ufffd SILICON NEWS: CREANDO REDES CON 19 CENTROS HOSPITALARIOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 278\n835\ufffd REVISI\u00d3N DE LA GESTI\u00d3N DE MEDICAMENTOS NO INCLUIDOS EN GU\u00cdA FARMACOTERAP\u00c9UTICA, COMO ME -\nJORA EN LA SELECCI\u00d3N Y ADQUISICI\u00d3N DE MEDICAMENTOS.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 279\n861\ufffd EVALUACION DE LAS CITAS DE PACIENTES EXTERNOS DE LA UNIDAD DE FARMACIA AMBULATORIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 280\n890\ufffd CONTROL DE CALIDAD EN EL REGISTRO DE LOS PROTOCOLOS DE ELABORACI\u00d3N EN MEZCLAS INTRAVENOSAS  \ufffd\ufffd\ufffd28119984\ufffd CREACI\u00d3N DE UNA AGENDA PARA LA ORGANIZACI\u00d3N DE LA ATENCI\u00d3N AL PACIENTE EXTERNO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 281\n1014 \ufffd RESULTADOS DE ENCUESTA DE DIGITALIZACI\u00d3N EN LA UNIDAD DE PACIENTES EXTERNOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 282\n1210 \ufffd REFORMULANDO EL CIRCUITO TERAP\u00c9UTICO DE TOXINA BOTUL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 283\n1249 \ufffd AN\u00c1LISIS MODAL DE FALLOS Y EFECTOS DE LA PREPARACI\u00d3N DE ANTINEOPL\u00c1SICOS MANUAL ASISTIDA CON \nCONTROL GRAVIM\u00c9TRICO FRENTE A LA ROBOTIZADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 283\n1283 \ufffd ATENCI\u00d3N FARMAC\u00c9UTICA AL PACIENTE AMBULATORIO MEDIANTE CONSULTAS TELEF\u00d3NICAS Y DISPEN -\nSACI\u00d3N DE LA MEDICACI\u00d3N A DOMICILIO. \u00bfQU\u00c9 OPINAN LOS PACIENTES?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 284\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA  ...................................... 285\n116\ufffd FRECUENCIA Y RELEVANCIA CL\u00cdNICA DE LAS VARIANTES DEL GEN DPYD EN PACIENTES CON TUMORES\nS\u00d3LIDOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 285\n138\ufffd DESARROLLO DE UN MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE LITIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 286\n181\ufffd DISE\u00d1O DE UN MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE VANCOMICINA EN PACIENTES OBESOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd286\n232\ufffd ASOCIACI\u00d3N ENTRE LA EFECTIVIDAD CL\u00cdNICA Y MICROBIOL\u00d3GICA DEL TRATAMIENTO CON VANCOMICINA Y \nLAS CONCENTRACIONES PLASM\u00c1TICAS EN PACIENTES NEONATOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 287\n379\ufffd AN\u00c1LISIS DEL GENOTIPADO DE POLIMORFISMOS DEL GEN DE LA DIHIDROPIRIMIDINA DESHIDROGENASA \n(DPD) ANTES DE LA ADMINISTRACI\u00d3N DE FLUOROPIRIMIDINAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 288\n588\ufffd MODELIZACI\u00d3N FARMACOCIN\u00c9TICA POBLACIONAL DE FIBRIN\u00d3GENO EN PACIENTES CON HIPOFIBRINOGEN -\nEMIA ADQUIRIDA POR HEMORRAGIA GRAVE O CIRUG\u00cdA MAYOR \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 289\n657\ufffd OPTIMIZACI\u00d3N POSOL\u00d3GICA DE LINEZOLID EN PACIENTES CR\u00cdTICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 290\n672\ufffd COMPARACI\u00d3N ENTRE PAUTA POSOL\u00d3GICA DE VANCOMICINA RECOMENDADA Y PAUTA NECESARIA PARA \nALCANZAR OBJETIVOS TERAP\u00c9UTICOS EN UNA POBLACI\u00d3N DE NEONATOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 290\n713. JUSTIFICACION DE LA MONITORIZACION FARMACOCINETICA DE LINEZOLID Y VORICONAZOL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 291\n742\ufffd DESARROLLO DE UN MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE ISAVUCONAZOL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 292\n763\ufffd MONITORIZACION DE LAS CONCENTRACIONES PLASMATICAS DE VORICONAZOL EN PACIENTE CRITICO CON \nASPERGILOSIS PULMONAR ASOCIADA A COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 292\n776\ufffd INFLUENCIA DE LA DOSIS DE CARGA EN LAS CONCENTRACIONES PLASM\u00c1TICAS DE VANCOMICINA EN PACIEN -\nTES CON HEMODI\u00c1LISIS CONVENCIONAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 293\n789\ufffd UTILIDAD DE LA MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE TEICOPLANINA DETERMINADA POR LA\nREDUCCI\u00d3N DE PRESCRIPCI\u00d3N DE AMIKACINA EN PACIENTES CON TRASPLANTE ALOG\u00c9NICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 294\n794\ufffd EVALUACI\u00d3N DE LA DOSIFICACI\u00d3N DE LEVETIRACETAM EN PACIENTES CR\u00cdTICOS CON FUNCI\u00d3N RENAL NOR -\nMAL O AUMENTADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 294\n828. NIVELES DE DIGOXINA OBTENIDOS MEDIANTE UN MODELO MATEM\u00c1TICO \u00bfSE CORRELACIONAN CON LOS \nNIVELES OBTENIDOS MEDIANTE METODOS ANAL\u00cdTICOS?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 295\n866\ufffd MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE MEROPENEM EN PLASMA Y L\u00cdQUIDO PERITONEAL EN UN\nPACIENTE CON PERITONITIS: A PROP\u00d3SITO DE UN CASO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 296\n874\ufffd COMPARACI\u00d3N DE UNA T\u00c9CNICA ELISA TRADICIONAL VERSUS UNA T\u00c9CNICA \u201cPOINT OF CARE\u201d EN LA DETER -\nMINACI\u00d3N DE NIVELES DE INFLIXIMAB \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 297\n888\ufffd IMPACTO CL\u00cdNICO DE LA INDIVIDUALIZACI\u00d3N DEL TRATAMIENTO CON FLUOROPIRIMIDINAS GUIADO POR \nESTUDIO FARMACOGEN\u00c9TICO DEL GEN DPYD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 297\n895\ufffd DESARROLLO DE UN M\u00c9TODO DE DETERMINACI\u00d3N DE EXPRESI\u00d3N DEL GEN FLT3 NO MUTADO EN PACIENTES \nCON LEUCEMIA MIELOIDE AGUDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 298\n942. AJUSTE DE LA CONCENTRACI\u00d3N PLASM\u00c1TICA DE LITIO EN TRES PROGRAMAS FARMACOCIN\u00c9TICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 299\n949\ufffd MONITORIZACI\u00d3N DE LA ACTIVIDAD DE LA ASPARRAGINASA PARA LA DETECCI\u00d3N DE PACIENTES PEDI\u00c1TRI -\nCOS INACTIVADORES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 299\n952. MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE PIPERACILINA-TAZOBACTAM EN PACIENTES CR\u00cdTICOS CON \nFUNCI\u00d3N RENAL CONSERVADA \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 300\n961\ufffd MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE AMINOGLUC\u00d3SIDOS EN CENTROS SOCIOSANITARIOS \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 301\n980\ufffd MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA PROACTIVA EN LA OPTIMIZACI\u00d3N DE LA ANTIBIOTERAPIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 302\n1038 \ufffd FARMACOCIN\u00c9TICA POBLACIONAL DE INFLIXIMAB EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTES -\nTINAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 302\n1049 \ufffd INFLAMACI\u00d3N COMO FACTOR DE RIESGO EN LA INTOXICACI\u00d3N POR VORICONAZOL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 303201050 \ufffd RESULTADOS DE UNA INTERVENCI\u00d3N FARMACOTERAP\u00c9UTICA REALIZADA EN PACIENTES ANCIANOS EN \nTRATAMIENTO CR\u00d3NICO CON DIGOXINA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 304\n1066. PACIENTES EN TRATAMIENTO CON ADALIMUMAB CON ENFERMEDAD INFLAMATORIA INTESTINAL, \u00bfINFLUYE \nEL INDICE DE MASA CORPORAL EN LAS CONCENTRACIONES?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 304\n1101 \ufffd GENOTIPADO DPYD COMO GU\u00cdA PARA LA DOSIFICACI\u00d3N INDIVIDUALIZADA DE FLUOROPIRIMIDINAS EN \nPACIENTES ONCOL\u00d3GICOS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 305\n1106. MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE LAMOTRIGINA Y LEVETIRACETAM EN MUJERES EMBARAZADAS  \ufffd\ufffd306\n1117 \ufffd ALTO RIESGO DE TOXICITAT HEMATOL\u00d3GICA EN PACIENTES CON SOBREEXPOSICI\u00d3N PLASM\u00c1TICA A LINE -\nZOLID  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 306\n1156 \ufffd MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE CONCENTRACIONES DE GENTAMICINA Y MEROPENEM EN L\u00cdQUI -\nDO CEFALORRAQU\u00cdDEO EN UN PACIENTE PEDI\u00c1TRICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 307\n1163 \ufffd ESTUDIO CIN\u00c9TICO DEL VORICONAZOL EN PACIENTES CON ECMO Y ASPERGILLOSIS PULMONAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 308\n1187 \ufffd EFECTIVIDAD Y SEGURIDAD DE PEMBROLIZUMAB, PEMETREXED Y PLATINO EN PRIMERA L\u00cdNEA EN C\u00c1NCER \nDE PULM\u00d3N NO MICROC\u00cdTICO NO ESCAMOSO METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 308\n1192 \ufffd FARMACOGEN\u00c9TICA DEL SIPONIMOD: IMPLEMENTACI\u00d3N DE RECOMENDACIONES INDIVIDUALIZADAS DE \nTRATAMIENTO CON SIPONIMOD BASADAS EN EL GENOTIPO CYP2C9  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 309\n1251 \ufffd UTILIDAD E IMPACTO DE LA MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE VORICONAZOL EN PACIENTES \nPEDI\u00c1TRICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 310\n1255. FACTORES DE RIESGO ASOCIADOS AL DESARROLLO DE ANTICUERPOS ANTI-INFLIXIMAB EN ENFERMEDAD \nINFLAMATORIA INTESTINAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 311\n1259 \ufffd COMPARACI\u00d3N DE LOS CRITERIOS PREDICTORES DE NEFROTOXICIDAD EN PACIENTES CON\nMONITORIZACI\u00d3N PLASM\u00c1TICA DE VANCOMICINA E IDENTIFICACI\u00d3N DE FACTORES DE RIESGO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 311\n1302 \ufffd CARACTERIZACI\u00d3N FARMACOCIN\u00c9TICA DE RITUXIMAB EN PACIENTES CON ENFERMEDADES\nGLOMERULARES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 312\n1308. EVALUACI\u00d3N DE RESULTADOS DE LA OPTIMIZACI\u00d3N FARMACOCIN\u00c9TICA Y FARMACODIN\u00c1MICA (PK/PD) DE \nDAPTOMICINA EN LA PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 313\n1311. ESTUDIO COMPARATIVO DEL MANEJO FARMACOTERAP\u00c9UTICO DE LAS FLUOROPIRIMIDINAS TRAS LA IM -\nPLANTACI\u00d3N DEL GENOTIPADO DPYD EN LA PR\u00c1CTICA CL\u00cdNICA ASISTENCIAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 314\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA  .................................................................................................................... 315\n45\ufffd INTENSIDAD DE DOSIS DE PALBOCICLIB EN PACIENTES CON C\u00c1NCER DE MAMA METAST\u00c1SICO: 328 PACIENTES \nTRATADOS EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 315\n61. EFICACIA Y SEGURIDAD DE IMATINIB EN ENFERMEDAD DE INJERTO CONTRA RECEPTOR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 315\n64\ufffd EFECTIVIDAD Y SEGURIDAD DE OSIMERTINIB EN PRIMERA Y SEGUNDA L\u00cdNEA EN PACIENTES DIAGNOTICADOS \nDE C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO EGFR+  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 316\n82\ufffd EVALUACI\u00d3N DE LA EFICACIA, SEGURIDAD Y LA TOLERABILIDAD DE SORAFENIB EN PACIENTES CON CARCINO -\nMA HEPATOCELULAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 316\n103\ufffd EXPERIENCIA MULTIDISCIPLINAR DEL TRATAMIENTO CON CISPLATINO INTRAPERIC\u00c1RDICO EN EL DERRAME \nPERIC\u00c1RDICO MALIGNO: EVALUACI\u00d3N DE EFICACIA, SEGURIDAD Y SUPERVIVENCIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 317\n117\ufffd EFECTIVIDAD Y SEGURIDAD DE LA INMUNOTERAPIA EN EL TRATAMIENTO DE PRIMERA L\u00cdNEA DEL C\u00c1NCER DE \nPULM\u00d3N NO MICROC\u00cdTICO NO ESCAMOSO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 318\n119\ufffd EVENTOS ADVERSOS GRAVES DURANTE EL TRATAMIENTO CON NIVOLUMAB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 318\n122\ufffd ADMINISTRACI\u00d3N DE GLUCOCORTICOIDES Y SU IMPACTO EN LA EFECTIVIDAD DE LA INMUNOTERAPIA EN \nC\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 319\n128\ufffd EFICACIA Y SEGURIDAD DE OBINUTUZUMAB EN LA LEUCEMIA LINFOC\u00cdTICA CR\u00d3NICA EN LA PRACTICA CLI -\nNICA HABITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 320\n166\ufffd CIRUG\u00cdA CITORREDUCTORA SEGUIDA DE QUIMIOTERAPIA INTRAPERITONEAL HIPERT\u00c9RMICA EN EL TRATA -\nMIENTO DE LA CARCINOMATOSIS PERITONEAL; EXPERIENCIA CL\u00cdNICA EN LA VIDA REAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 320\n197. PROGRAMA DE MEDICI\u00d3N DE RESULTADOS INFORMADOS POR EL PACIENTE (PROMS) CON HERRAMIENTA \nPROCTCAE EN PACIENTES CON LINFOMA EN TERAPIA INTRAVENOSA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 321\n214\ufffd ADECUACI\u00d3N DEL PROTOCOLO INTERNO LOCAL CON INHIBIDORES DE LA TIROSIN KINASA EN LEUCEMIA \nMIELOIDE CR\u00d3NICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 322\n238\ufffd EFECTIVIDAD Y SEGURIDAD DE BELANTAMAB MAFODOTINA EN PACIENTES CON MIELOMA M\u00daLTIPLE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 32221244\ufffd ANALISIS DE EFICACIA Y SEGURIDAD DE LOS INHIBIDORES DE CICLINAS 4/6 EN CANCER DE MAMA METASTA -\nSICO EN PRACTICA CLINICA HABITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 323\n274\ufffd LORLATINIB EN CANCER DE PULM\u00d3N NO MICROC\u00cdTICO: EXPERIENCIA EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL  \ufffd\ufffd\ufffd324\n281\ufffd EFECTIVIDAD Y SEGURIDAD DE SELUMETINIB EN PR\u00c1CTICA CL\u00cdNICA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 324\n287\ufffd EXPERIENCIA DE USO DE DAROLUTAMIDA EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA RESISTENTE A LA CAS -\nTRACI\u00d3N DE ALTO RIESGO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 325\n290\ufffd EFECTIVIDAD Y SEGURIDAD DE LETERMOVIR EN LA PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 326\n299. VALOR DEL RATIO NEUTR\u00d3FILO/LINFOCITO (NLR) COMO BIOMARCADOR PREDICTIVO EN INMUNOTERAPIA \nEN PACIENTES DE C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 327\n310\ufffd VALOR PREDICTIVO DEL INDICE DE MASA CORPORAL Y DE LA COMPOSICI\u00d3N CORPORAL EN LA RESPUESTA AL \nTRATAMIENTO CON INMUNOTERAPIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 327\n316\ufffd EFECTIVIDAD Y SEGURIDAD DE AVELUMAB COMO TRATAMIENTO DE MANTENIMIENTO EN PACIENTES CON \nCARCINOMA UROTELIAL LOCALMENTE AVANZADO O METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 328\n321\ufffd TOLERANCIA DE RIBOCICLIB FRENTE PALBOCICLIB EN CANCER DE MAMA MESTAST\u00c1SICO HORMONODEPEN -\nDIENTE HER2 NEGATIVO EN PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 329\n338\ufffd EXPERIENCIA DE USO DE LUSPATERCEPT EN PACIENTES CON ANEMIA POR S\u00cdNDROME MIELODISPL\u00c1SICO CON \nP\u00c9RDIDA DE RESPUESTA A ERITROPOYETINA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 329\n358\ufffd ADHERENCIA Y CALIDAD DE VIDA EN PACIENTES CON LEUCEMIA LINFOC\u00cdTICA CR\u00d3NICA TRATADOS CON ANTI -\nNEOPL\u00c1SICOS ORALES \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 330\n375\ufffd REAL WORLD SETTING OF OSIMERTINIB FOR NON SMALL CELL LUNG CANCER \ufffd \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 331\n378\ufffd EFECTIVIDAD Y SEGURIDAD DE NIVOLUMAB EN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 331\n395. EFICACIA DE LA VACUNACI\u00d3N FRENTE A COVID-19 EN PACIENTES CON PATOLOG\u00cdAS HEMATOL\u00d3GICAS EN \nTRATAMIENTO CON RITUXIMAB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 332\n428\ufffd DESABASTECIMIENTO DE MITOMICINA: BUSCANDO LA OPORTUNIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 333\n460\ufffd EFECTIVIDAD Y SEGURIDAD DE DURVALUMAB EN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO: EXPERIENCIA EN \nLA PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 333\n469\ufffd ACTIVIDAD DE TEBENTAFUSP EN EL TRATAMIENTO DEL MELANOMA UVEAL METAST\u00c1TICO: AN\u00c1LISIS\nRETROSPECTIVO DE LA EXPERIENCIA DE UN HOSPITAL MONOGR\u00c1FICO ONCOL\u00d3GICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 334\n474\ufffd SEGURIDAD Y EFECTIVIDAD DE OLAPARIB EN MANTENIMIENTO EN PACIENTES CON C\u00c1NCER DE OVARIO \nTRATADAS PREVIAMENTE CON PLATINO EN RECA\u00cdDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 335\n488\ufffd TOXICIDAD DE DIFERENTES ESQUEMAS DE QUIMIOTERAPIA Y TRASTUZUMAB EN 645 PACIENTES CON\nADENOCARCINOMA G\u00c1STRICO AVANZADO HER2-POSITIVO (HER2+) DEL REGISTRO AGAMENON-SEOM  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 335\n498\ufffd EFECTIVIDAD DE CARBOPLATINO ASOCIADO A TAXANO EN EL TRATAMIENTO NEOADYUVANTE DEL C\u00c1NCER \nDE MAMA TRIPLE NEGATIVO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 336\n521\ufffd AN\u00c1LISIS DEL PATR\u00d3N DE AUTORIZACI\u00d3N DE LOS TRATAMIENTOS FARMACOL\u00d3GICOS PARA EL MIELOMA \nM\u00daLTIPLE \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 337\n533\ufffd AN\u00c1LISIS GEN\u00c9TICO PARA EVITAR TOXICIDADES: FLUOROPIRIMIDINAS Y EL GEN DE LA DIHIDROPIRIMIDINA \nDESHIDROGENASA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 338\n534\ufffd ESTUDIO COMPARATIVO DE EFECTIVIDAD Y SEGURIDAD DE FOSAPREPITANT/ONDANSETRON/DEXAMETA -\nSONA Y NETUPITANT/PALONOSETRON/DEXAMETASONA EN LA PREVENCI\u00d3N DE N\u00c1USEAS Y V\u00d3MITOS INDUCIDOS \nPOR QUIMIOTERAPIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 339\n536\ufffd ATENCI\u00d3N FARMAC\u00c9UTICA A PACIENTES EN EL CICLO 2 DE TRATAMIENTO ORAL EN UNA UNIDAD DE FARMA -\nCIA ONCOHEMATOL\u00d3GICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 340\n538. \u00bfINFLUYE LA REALIZACI\u00d3N DEL AN\u00c1LISIS DEL GEN DE LA DIHIDROPIRIMIDINA DESHIDROGENASA EN LA RE -\nDUCCI\u00d3N DE TOXICIDAD ASOCIADA A FLUOROPIRIMIDINAS?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 340\n553\ufffd LETERMOVIR COMO PROFILAXIS DE LA INFECCI\u00d3N DE CITOMEGALOVIRUS EN PACIENTES SOMETIDOS A \nTRASPLANTE HEMATOPOY\u00c9TICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 341\n557\ufffd EFECTIVIDAD Y SEGURIDAD CARDIOVASCULAR DE IBRUTINIB EN LEUCEMIA LINF\u00c1TICA CR\u00d3NICA: DATOS EN \nVIDA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 342\n573\ufffd EFICACIA Y SEGURIDAD DE LA COMBINACI\u00d3N DE NIVOLUMAB E IPILIMUMAB EN MELANOMA UVEAL METAS -\nT\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 342\n576\ufffd AN\u00c1LISIS EN VIDA REAL DEL PERFIL DE SEGURIDAD DE IBRUTINIB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 34322584\ufffd CYTOKINE RELEASE SYNDROME IN HEMATOLOGICAL PATIENTS TREATED WITH TOCILIZUMAB \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 344\n589\ufffd RESULTADOS EN VIDA REAL DE DARATUMUMAB EN PACIENTES CON MIELOMA M\u00daLTIPLE EN RECA\u00cdDA/RE -\nFRACTARIO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 344\n596. REAL-LIFE EXPERIENCE ON EFFECTIVENESS AND SAFETY OF ALPELISIB IN ADVANCED OR METASTATIC PIK3CA \nMUTATED BREAST CANCER  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 345\n598\ufffd QUIMIOEMBOLIZACI\u00d3N TRANSARTERIAL CON MICROESFERAS PARA EL TRATAMIENTO DEL HEPATOCARCI -\nNOMA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 346\n601\ufffd AN\u00c1LISIS DEL USO DE LA INMUNOTERAPIA ONCOL\u00d3GICA EN UNA COMUNIDAD AUT\u00d3NOMA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 347\n621\ufffd AN\u00c1LISIS DEL USO Y EFECTIVIDAD DE GLUCARPIDASA EN EL TRATAMIENTO DE INTOXICACI\u00d3N POR METO -\nTREXATO A ALTAS DOSIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 347\n624\ufffd DOSIFICACI\u00d3N DE F\u00c1RMACOS ANTINEOPL\u00c1SICOS EN PACIENTES OBESOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 348\n627\ufffd AN\u00c1LISIS DE LA INCIDENCIA DE EFECTOS ADVERSOS EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA RESISTENTE A \nLA CASTRACI\u00d3N METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 349\n629\ufffd IMPACTO DEL CONSUMO DE ANTIBI\u00d3TICOS EN LA EFECTIVIDAD DE LA INMUNOTERAPIA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 349\n640\ufffd EFECTIVIDAD Y SEGURIDAD DE AVELUMAB EN EL TRATAMIENTO DE MANTENIMIENTO DE PRIMERA L\u00cdNEA \nDEL CARCINOMA UROTERIAL LOCALMENTE AVANZADO O METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 350\n644. NIVOLUMAB: \u00bfDIFERENCIA EN EFECTOS ADVERSOS ENTRE MUJERES Y HOMBRES? EXPERIENCIA EN PR\u00c1CTICA \nCL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 350\n659\ufffd FACTORES PREDICTIVOS DE RESPUESTA A QUIMIOTERAPIA COMBINADA CON TRASTUZUMAB EN PACIENTES \nCON C\u00c1NCER G\u00c1STRICO AVANZADO HER2 POSITIVO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 352\n660\ufffd PERFIL DE EFECTIVIDAD Y TOXICIDAD DE ESQUEMAS DE PRIMERA L\u00cdNEA EN ADENOCARCINOMA GAS -\nTROESOF\u00c1GICO AVANZADO HER2 NEGATIVO \ufffd DATOS DE 1343 PACIENTES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 353\n669\ufffd SEGUIMIENTO DE LA EFECTIVIDAD Y SEGURIDAD DEL USO DE NIVOLUMAB EN HEPATOCARCINOMA AVAN -\nZADO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 353\n682. RESULTADOS SEROL\u00d3GICOS TRAS VACUNACI\u00d3N COVID-19 EN PACIENTES SOMETIDOS A TRASPLANTE \nAUT\u00d3LOGO DE PROGENITORES HEMATOPOY\u00c9TICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 354\n687. TRAMETINIB EN PACIENTES PEDI\u00c1TRICOS CON GLIOMA DE BAJO GRADO: EXPERIENCIA DE 4 A\u00d1OS DE USO EN \nPR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 355\n692\ufffd USO DE AZACITIDINA EN UNA UNIDAD DE HOSPITALIZACI\u00d3N A DOMICILIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 356\n696. EVALUACI\u00d3N DEL EFECTO PREVENTIVO DE LA CREMA DE VITAMINA E-ALANTO\u00cdNA EN EL DESARROLLO DE \nERITRODISESTESIA PALMO-PLANTAR POR CAPECITABINA.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 357\n703\ufffd REGORAFENIB Y TRIFLURIDINA/TIPIRACILO EN EL C\u00c1NCER COLORRECTAL METAST\u00c1SICO: EFECTIVIDAD EN \nVIDA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 357\n709. EVALUAR LA EFECTIVIDAD DEL DOBLE BLOQUEO ANTIHER2 CON TRASTUZUMAB+PERTUZUMAB+QUIMIOTER\nAPIA EN LA NEOADYUVANCIA DEL C\u00c1NCER DE MAMA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 358\n729\ufffd ESTUDIO DE INCIDENCIA DE ERRORES Y TIEMPOS DE PREPARACI\u00d3N DE MEZCLAS ONCOHEMATOLOGICAS EN \nEL \u00c1REA DE ELABORACI\u00d3N DE UN HOSPITAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 359\n737\ufffd EFICACIA Y SEGURIDAD EN VIDA REAL DE DURVALUMAB COMO TERAPIA DE CONSOLIDACI\u00d3N EN C\u00c1NCER DE \nPULM\u00d3N NO MICROC\u00cdTICO ESTADIO III  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 360\n744\ufffd RESULTADOS INICIALES DE APALUTAMIDA EN C\u00c1NCER DE PR\u00d3STATA HORMONOSENSIBLE METAST\u00c1SICO  \ufffd\ufffd360\n746\ufffd TOXICIDAD HEMATOL\u00d3GICA DE DARATUMUMAB SEG\u00daN ADMINISTRACI\u00d3N INTRAVENOSA O\nSUBCUTANEA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 361\n766\ufffd EXPERIENCIA DE USO DE NIRAPARIB EN EL TRATAMIENTO DE MANTENIMIENTO DEL C\u00c1NCER DE OVARIO DE \nALTO GRADO EN RECA\u00cdDA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 362\n769\ufffd EVALUACI\u00d3N DEL TRATAMIENTO ADYUVANTE CON INMUNOTERAPIA EN PACIENTES CON MELANOMA DE \nALTO RIESGO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 362\n778\ufffd EXPERIENCIA DE USO DE APALUTAMIDA EN EL TRATAMIENTO DEL C\u00c1NCER DE PR\u00d3STATA HORMONOSENSIBLE \nMETAST\u00c1SICO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 363\n798\ufffd ESTUDIO EN VIDA REAL DE TRIFLURIDINA/TIPIRACILO EN PACIENTES CON C\u00c1NCER COLORRECTAL METAST\u00c1SI -\nCO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 364\n805\ufffd PERFIL DE SEGURIDAD DE PEGASPARGASA EN UNA COHORTE DE PACIENTES EN UN HOSPITAL DE TERCER \nNIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 36523832\ufffd AN\u00c1LISIS DE LA EFECTIVIDAD DE LOS INHIBIDORES DE TIROSINA QUINASA A DOSIS REDUCIDAS EN PACIEN -\nTES CON LEUCEMIA MIELOIDE CR\u00d3NICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 366\n833\ufffd EFECTIVIDAD Y SEGURIDAD DE DURVALUMAB EN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 366\n837\ufffd EFECTIVIDAD Y SEGURIDAD DE TRASTUZUMAB EMTANSINA EN SEGUNDA L\u00cdNEA EN C\u00c1NCER DE MAMA \nMETAST\u00c1SICO HER2 POSITIVO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 367\n915. INFUSI\u00d3N DE LINFOCITOS T VIRUS ESPEC\u00cdFICOS: TRATAMIENTO DE INFECCIONES EN EL POST-ALOTRASPLAN -\nTE DE PROGENITORES HEMATOPOY\u00c9TICOS EN PEDIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 368\n964\ufffd IMPACTO DE LOS INHIBIDORES DE LA BOMBA DE PROTONES EN LA SUPERVIVENCIA LIBRE DE PROGRESI\u00d3N \nEN EL TRATAMIENTO CON PALBOCICLIB \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 369\n989\ufffd RESULTADOS EN VIDA REAL DE TRABECTEDINA PARA SARCOMAS AVANZADOS DE PARTES BLANDAS \ufffd M\u00c1S \nALL\u00c1 DEL LIPOSARCOMA Y LEIOMIOSARCOMA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 369\n994\ufffd TOXICIDAD DE LA INMUNOTERAPIA EN LA PR\u00c1CTICA CL\u00cdNICA EN MELANOMA METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 370\n1009 \ufffd BELANTAMAB MAFODOTINA EN MIELOMA MULTIPLE: SEGURIDAD Y EFECTIVIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 371\n1017 \ufffd IMPLEMENTACI\u00d3N DEL GENOTIPADO DE UGT ANTICIPADO EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 371\n1030 \ufffd EXPERIENCIA DE USO DE NIVOLUMAB EN PACIENTES CON LINFOMA DE HODGKIN CL\u00c1SICO EN RECA\u00cdDA O \nREFRACTARIOS EN UN HOSPITAL ONCOHEMATOL\u00d3GICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 372\n1035. EFECTIVIDAD Y SEGURIDAD DE TRASTUZUMAB-EMTANSINA EN SEGUNDA L\u00cdNEA DE C\u00c1NCER DE MAMA \nMETAST\u00c1SICO TRAS PRIMERA LINEA CON DOBLE BLOQUEO HER-2.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 373\n1051 \ufffd EFECTIVIDAD Y SEGURIDAD DE PALBOCICLIB EN C\u00c1NCER DE MAMA METAST\u00c1SICO O LOCALMENTE AVAN -\nZADO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 374\n1063. TOXICIDAD AUTO-INFORMADA POR LAS PACIENTES (PRO-CTCAE) EN TRATAMIENTO CON INHIBIDORES DE \nCICLINAS EN C\u00c1NCER DE MAMA METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 374\n1071 \ufffd EFECTIVIDAD DE PALBOCICLIB CON TRATAMIENTO HORMONAL VS TRATAMIENTO HORMONAL EN PRIMERA \nL\u00cdNEA EN C\u00c1NCER DE MAMA AVANZADO O METAST\u00c1SICO (HR+/HER2-)  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 375\n1085 \ufffd EFICACIA DEL TRATAMIENTO DE ABIRATERONA CON PREDNISONA Y ENZALUTAMIDA EN PACIENTES CON \nC\u00c1NCER DE PR\u00d3STATA RESISTENTE A LA CASTACI\u00d3N METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 376\n1092 \ufffd EFECTIVIDAD DE ERIBULINA EN C\u00c1NCER DE MAMA METAST\u00c1SICO \ufffd RESULTADOS EN LA PR\u00c1CTICA CLINICA \nREAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 376\n1094 \ufffd INHIBIDORES DE QUINASAS DEPENDIENTES DE CICLINAS EN C\u00c1NCER DE MAMA: PERSISTENCIA AL TRATA -\nMIENTO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 377\n1104 \ufffd EFECTIVIDAD Y SEGURIDAD DEL ESQUEMA VRD EN PACIENTES CON MIELOMA M\u00daLTIPLE CANDIDATOS A \nTRASPLANTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 378\n1114 \ufffd EVALUACI\u00d3N CL\u00cdNICA Y ECON\u00d3MICA DE LA IMPLANTACI\u00d3N DE UN PROTOCOLO DE REGIMEN POSOL\u00d3GICO \nDE PEMBROLIZUMAB POR PESO CORPORAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 378\n1131 \ufffd DESCRIPCI\u00d3N Y AN\u00c1LISIS DE LOS MOTIVOS DE RETRASO EN LA ADMINISTRACI\u00d3N DE TRATAMIENTOS ANTI -\nNEOPL\u00c1SICOS INTRAVENOSOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 379\n1151 \ufffd EVALUACI\u00d3N DE EFECTIVIDAD Y SEGURIDAD DE CAPLACIZUMAB EN EL TRATAMIENTO DE LA P\u00daRPURA \nTROMBOCITOP\u00c9NICA TROMB\u00d3TICA ADQUIRIDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 380\n1170 \ufffd DETECCI\u00d3N Y CONTROL DE N\u00c1USEAS NO RELACIONADAS DIRECTAMENTE CON EL TRATAMIENTO QUI -\nMIOTER\u00c1PICO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 381\n1172. EVALUACI\u00d3N DE EFECTIVIDAD Y SEGURIDAD DE RUXOLITINIB EN LA ENFERMEDAD DE INJERTO CONTRA \nRECEPTOR CR\u00d3NICA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 382\n1177 \ufffd EFECTIVIDAD Y ADHERENCIA DE PALBOCICLIB EN EL TRATAMIENTO DE PRIMERA L\u00cdNEA DE C\u00c1NCER DE \nMAMA METAST\u00c1SICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 382\n1190 \ufffd EVALUACI\u00d3N DE LA EFECTIVIDAD, SEGURIDAD Y ADHERENCIA EN PACIENTES TRATADAS CON TUCATINIB EN \nUN HOSPITAL TERCIARIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 383\n1191 \ufffd PERFIL DE SEGURIDAD DEL TRATAMIENTO CON APALUTAMIDA EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA  \ufffd\ufffd\ufffd384\n1207. IMPACTO ECON\u00d3MICO DEL ESQUEMA AZACITIDINA-VENETOCLAX EN LMA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 384\n1216. COMPARACI\u00d3N DE LA TOXICIDAD AUTO-INFORMADA (PRO-CTCAE) DE PALBOCICLIB/RIBOCICLIB PARA \nC\u00c1NCER DE MAMA CON LA RECOGIDA POR EL CL\u00cdNICO (ESCALA CTCAE)  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 385\n1219 \ufffd BENEFICIO CL\u00cdNICO DE F\u00c1RMACOS ONCOL\u00d3GICOS CON INFORMES DE POSICIONAMIENTO TERAPEUTICO Y \nDECISION DE FINANCIACION EN ESPA\u00d1A EN EL PERIODO 2013-2021  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 386241224 \ufffd COMPARACI\u00d3N DE CRITERIOS DE DOSIFICACI\u00d3N DE ANTINEOPL\u00c1SICOS EN REG\u00cdMENES DE ACONDICIONA -\nMIENTO PREVIO AL TRASPLANTE DE PROGENITORES HEMATOPOY\u00c9TICOS EN PACIENTES OBESOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 387\n1242 \ufffd ADECUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE ANTIEM\u00c9TICOS EN F\u00c1RMACOS ANTINEOPL\u00c1SICOS POR V\u00cdA ORAL  387\n1282 \ufffd EFECTOS ADVERSOS INMUNOMEDIADOS ASOCIADOS A LOS INHIBIDORES DE CHECKPOINTS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 388\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)  ...................... 389\n71\ufffd AN\u00c1LISIS DE LA EFECTIVIDAD Y FACTORES DE RIESGO DE MORTALIDAD RELACIONADOS CON EL USO DE TIGE -\nCICLINA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 389\n73\ufffd AN\u00c1LISIS DESCRIPTIVO DE UNA COHORTE DE PACIENTES TRATADOS CON TIGECICLINA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 389\n75. IMPACTO EN EL CONSUMO DE TIGECICLINA TRAS LA EMISI\u00d3N DE ALERTAS DE SEGURIDAD EIMPLEMENTA-\nCI\u00d3N DEL PROGRAMA OPTIMIZACI\u00d3N DE ANTIBI\u00d3TICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 390\n136\ufffd VARIACI\u00d3N DEL GASTO FARMACEUTICO COMO CONSECUENCIA DE LA RETIRADA DE CEFTOLOZANO/TAZO -\nBACTAM  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 391\n179\ufffd APLICACI\u00d3N DE NUEVOS INDICADORES EN LA MONITORIZACI\u00d3N DEL USO DE ANTIMICROBIANOS EN CUIDA -\nDOS INTENSIVOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 392\n180. PROFILAXIS PRE-EXPOSICI\u00d3N DE PACIENTES VIH: SEGUIMIENTO FARMACOTERAP\u00c9UTICO EN PR\u00c1CTICA HA -\nBITUAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 393\n198\ufffd HIPERPOTASEMIA POR COTRIMOXAZOL: ALGUNOS ASPECTOS A TENER EN CUENTA DURANTE LA\nVALIDACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 393\n223. USO DE SOTROVIMAB EN PACIENTES CON COVID-19: RESULTADOS INICIALES EN VIDA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 394\n226\ufffd USO DE TOCILIZUMAB DE FORMA PRECOZ EN EL TRATAMIENTO DE PACIENTES CON NEUMON\u00cdA GRAVE POR \nCOVID-19 EN UN HOSPITAL COMARCAL.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 395\n235\ufffd AN\u00c1LISIS DE EFECTIVIDAD Y VALOR PREDICTIVO POSITIVO DE ALERTAS PROA EN UNA HERRAMIENTA DE \nAYUDA A LA PRESCRIPCI\u00d3N DE ANTIMICROBIANOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 395\n288. AN\u00c1LISIS DEL CONSUMO DE ANTIBI\u00d3TICOS SEG\u00daN LA CLASIFICACI\u00d3N AWARE (ACCES, WATCH AND REVERSE) \nEN UN HOSPITAL PEDI\u00c1TRICO DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 396\n318\ufffd MACHINE LEARNING Y EVALUACI\u00d3N DE FACTORES ASOCIADOS CON LA FALTA DE EFICACIA AL TRATAMIENTO \nCON TOCILIZUMAB EN PACIENTES CON SARS-COV-2  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 397\n322\ufffd VANCOMICINA ORAL PARA EL TRATAMIENTO DE LAS INFECCIONES POR CLOSTRIDIOIDES DIFFICILE: EFECTIVI -\nDAD Y SEGURIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 397\n325. EXPERIENCIA USO DE ANTICUERPOS MONOCLONALES FRENTE AL COVID-19 EN LA PR\u00c1CTICA CL\u00cdNICA EN UN \nHOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 398\n339\ufffd PROFILAXIS ANTIBI\u00d3TICA QUIR\u00daRGICA: UNA ASIGNATURA PENDIENTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 399\n343\ufffd BEZLOTOXUMAB: AN\u00c1LISIS DE EFECTIVIDAD Y SEGURIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 399\n363. \u00bfINFLUYE LA VACUNACI\u00d3N FRENTE AL COVID-19 EN LA NECESIDAD DE USAR LOS TRATAMIENTOS M\u00c1S FRE -\nCUENTEMENTE EMPLEADOS PARA ESTA INFECCI\u00d3N?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 400\n365. RESULTADOS DE LA IMPLEMENTACI\u00d3N DE LA PROFILAXIS PRE-EXPOSICI\u00d3N AL VIH EN UN HOSPITAL DE \nTERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 401\n374\ufffd FACTORES DE RIESGO PARA EL DESARROLLO DE ASPERGILOSIS PULMONAR EN PACIENTES CON INFECCI\u00d3N \nPOR COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 402\n376\ufffd EFECTO A LARGO PLAZO DE TOCILIZUMAB SOBRE MORTALIDAD, TASA DE REINGRESO, PERSISTENCIA DE S\u00cdN -\nTOMAS Y FUNCI\u00d3N PULMONAR EN PACIENTES SARS-COV-2  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 402\n383\ufffd AN\u00c1LISIS DEL TRATAMIENTO EMP\u00cdRICO DE LAS INFECCIONES URINARIAS EN UN CENTRO\nSOCIOSANITARIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 403\n401\ufffd EXPERIENCIA DE USO EN VIDA REAL DE SOTROVIMAB PARA EL TRATAMIENTO DE LA INFECCI\u00d3N POR\nSARS-COV2.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 404\n404. ADECUACI\u00d3N, SEGURIDAD Y EFECTIVIDAD DE LA PROFILAXIS PRE-EXPOSICI\u00d3N AL VIH Y CARACTERIZACI\u00d3N \nDE LAS ENFERMEDADES DE TRANSMISI\u00d3N SEXUAL REPORTADAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 404\n436\ufffd SEGUIMIENTO FARMACOTERAP\u00c9UTICO MULTIDISCIPLINAR AL PACIENTE EN TRATAMIENTO ANTIVIRAL CON -\nTRA LA HEPATITIS C  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 405\n499. DATOS EN VIDA REAL DEL USO DE NIRMATRELVIR/RITONAVIR PARA LA ENFERMEDAD POR COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 406\n517\ufffd ESTUDIO DESCRIPTIVO DE LA BACTERIEMIA ASOCIADA A CAT\u00c9TER EN UN HOSPITAL DE SEGUNDO NIVEL EN \n2021  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 40725552. SARS-COV-2 INFECTIONS AND HOSPITALIZATIONS AMONG PEOPLE AGED \u226560 YEARS, BY VACCINATION STATUS \nIN A TERTIARY HOSPITAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 407\n575\ufffd CONSULTA MULTIDISCIPLINAR DE INFECCIONES DE TRANSMISI\u00d3N SEXUAL: ESTUDIO DESCRIPTIVO DE PACI -\nENTES TRATADOS CON PROFILAXIS PRE-EXPOSICI\u00d3N A VIH  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 408\n618\ufffd EVALUACI\u00d3N DEL TRATAMIENTO PROFIL\u00c1CTICO PREEXPOSICI\u00d3N AL VIH EN UN HOSPITAL DE SEGUNDO\nNIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 409\n628\ufffd AN\u00c1LISIS DE LA UTILIZACI\u00d3N Y EFECTIVIDAD DE FIDAXOMICINA EN INFECCI\u00d3N POR CLOSTRIDIOIDES DIFFI -\nCILE EN UNA COHORTE DE PR\u00c1CTICA CL\u00cdNICA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 410\n634\ufffd IMPACTO DE LA RESISTENCIA A F\u00c1RMACOS ANTIMICROBIANOS EN LA ESTANCIA/ MORTALIDAD HOSPITAL -\nARIA A PARTIR DEL CONJUNTO MINIMO B\u00c1SICO DE DATOS.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 410\n641\ufffd POLIFARMACIA Y PATRONES DE POLIFARMACIA EN UNA COHORTE DE PACIENTES VIH \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 411\n674\ufffd ESTUDIO DE UTILIZACI\u00d3N DE SOTROVIMAB EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 412\n675\ufffd EFECTIVIDAD, SEGURIDAD Y ADHERENCIA DE LA PROFILAXIS PREEXPOSICI\u00d3N AL VIH \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 412\n681\ufffd EVALUACI\u00d3N DE LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON ANAKINRA EN PACIENTES CON NEUMO -\nNIA SARS-COV 2  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 413\n699\ufffd EFECTIVIDAD DE DOLUTEGRAVIR/LAMIVUDINA FRENTE A DOLUTEGRAVIR/ ABACAVIR/ LAMIVUDINA EN UNA \nCOHORTE REAL DE PACIENTES NAIVE CON VIH-1. \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 414\n719\ufffd PERFIL DE USUARIOS DE LA PROFILAXIS PREEXPOSICI\u00d3N AL VIH EN UNA CONSULTA MONOGR\u00c1FICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 415\n722\ufffd BEZLOTOXUMAB EN PREVENCI\u00d3N DE RECURRENCIAS DE INFECCI\u00d3N POR CLOSTRIDIOIDES DIFFICILE \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 415\n730. REMDESIDIVIR EN PACIENTES CON NEUMON\u00cdA POR COVID-19: UTILIZACI\u00d3N Y AN\u00c1LISIS DE FACTORES PRE -\nDICTORES DE RECUPERACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 416\n741\ufffd OPTIMIZACI\u00d3N DEL USO DE ANTIMICROBIANOS EN LA UNIDAD DE MEDICINA INTENSIVA: CUESTI\u00d3N DE \nEQUIPO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 417\n751. INFLUENCIA DE LA INFECCI\u00d3N POR SARS-COV2 EN EL USO DE CEFTAZIDIMA-AVIBACTAM EN EL PACIENTE \nCR\u00cdTICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 417\n753. EVALUACI\u00d3N DE LA EFECTIVIDAD SEGURIDAD Y ADHERENCIA DE LA PROFILAXIS PREEXPOSICION AL VIH-1  \ufffd\ufffd\ufffd\ufffd418\n761. EVALUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE SULFAMETOXAZOL-TRIMETOPRIMA Y OPTIMIZACI\u00d3N POSOL\u00d3GICA EN \nUN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 419\n788\ufffd USO DE MEDICACI\u00d3N PSIQUIATRICA E INTERACCIONES FARMACOL\u00d3GICAS EN PACIENTES CON INFECCI\u00d3N \nPOR VHC TRATADOS CON ANTIVIRALES DE ACCI\u00d3N DIRECTA PANGENOT\u00cdPICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 419\n792\ufffd EFECTIVIDAD, SEGURIDAD Y AHORRO POR D\u00cdAS DE HOSPITALIZACI\u00d3N EVITADOS CON DALBAVANCINA EN \nINDICACIONES NO INCLUIDAS EN FICHA T\u00c9CNICA \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 420\n793. \u00bfLA COVID-19 HA IMPACTADO SOLAMENTE A NIVEL INTRAHOSPITALARIO?: CAMBIOS EN EL PERFIL DE LOS \nPACIENTES CON TRATAMIENTO ANTIBI\u00d3TICO DOMICILIARIO ENDOVENOSO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 421\n799\ufffd ESTUDIO DE UTILIZACI\u00d3N, EFECTIVIDAD Y SEGURIDAD DE CASIRIVIMAB/IMDEVIMAB EN EL TRATAMIENTO \nDEL COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 422\n812\ufffd UTILIZACION DE ANFOTERICINA B DEOXICOLATO INTRAVESICAL EN INFECCIONES POR CANDIDA EN UN HOS -\nPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 422\n825\ufffd HOSPITALIZACI\u00d3N A DOMICILIO: EVOLUCI\u00d3N DE UN PROGRAMA DE TRATAMIENTO ANTIBI\u00d3TICO DOMICILI -\nARIO ENDOVENOSO (2020-2022)  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 423\n826\ufffd EVALUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE ANTIBI\u00d3TICOS AL ALTA EN PACIENTES CON INFECCI\u00d3N RESPIRATORIA \nEN EL SERVICIO DE URGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 424\n830\ufffd ESTUDIO DE UTILIZACI\u00d3N, EFECTIVIDAD Y SEGURIDAD DE CEFIDEROCOL EN VIDA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 425\n838\ufffd EVALUACI\u00d3N DEL TRATAMIENTO CON REMDESIVIR EN PACIENTES INGRESADOS DURANTE LA SEXTA OLA DE \nLA PANDEMIA COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 425\n868. EFECTIVIDAD Y SEGURIDAD DEL USO OFF-LABEL DE DAPTOMICINA EN POBLACI\u00d3N NEONATAL: AN\u00c1LISIS DE \nSERIES DE CASOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 426\n881. IMPACTO DEL TRATAMIENTO CR\u00d3NICO CON F\u00c1RMACOS ANTI-CD20 EN LA EVOLUCI\u00d3N CL\u00cdNICA DE LOS PACI -\nENTES CON INFECCION POR SARS-COV-2  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 427\n914. TRATAMIENTO CON MOLNUPIRAVIR DE LA INFECCI\u00d3N POR SARS-COV2 EN PACIENTES INMUNODEPRIMIDOS \n\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 42826932. APLICACI\u00d3N DE UN PROTOCOLO DE ADMINISTRACI\u00d3N DE ANTIBI\u00d3TICOS \u0392-LACT\u00c1MICOS EN PACIENTES AL\u00c9R -\nGICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 428\n979. MANEJO DE TUBERCULOSIS MULTIRESISTENTE: A PROP\u00d3SITO DE UN CASO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 429\n987. BITERAPIA EN EL PACIENTE NA\u00cfVE: ESTUDIO DE EFECTIVIDAD DE LA COMBINACI\u00d3N DOLUTEGRAVIR-LAMIVU -\nDINA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 430\n1001 \ufffd AN\u00c1LISIS COMPARATIVO DE LAS BITERAPIAS BASADAS EN DOLUTEGRAVIR EN PACIENTES QUE VIVEN CON \nINFECCI\u00d3N POR VIH EN PR\u00c1CTICA CLINICA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 430\n1003 \ufffd EFECTIVIDAD Y SEGURIDAD DE LA BITERAPIA CON DOLUTEGRAVIR/LAMIVUDINA EN PACIENTES CON VIH \nPRETRATADOS, VIROL\u00d3GICAMENTE SUPRIMIDOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 431\n1026 \ufffd AN\u00c1LISIS GLOBAL Y POR SUBGRUPOS DE LA EFECTIVIDAD Y SEGURIDAD DE BEZLOTOXUMAB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 432\n1072 \ufffd TRATAMIENTO EMP\u00cdRICO EN PACIENTES CON NEUMON\u00cdA EN EL SERVICIO DE URGENCIAS: ADECUACI\u00d3N A \nLAS GU\u00cdAS DE TERAP\u00c9UTICA ANTIMICROBIANA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 433\n1074 \ufffd PERFUSION CONTINUA VS PERFUSION INTERMITENTE DE LA VANCOMICINA EN UNA COHORTE DE PACIEN -\nTES PEDI\u00c1TRICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 433\n1077 \ufffd EXPERIENCIA CL\u00cdNICA CON EL USO DE DALBAVANCINA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 434\n1093 \ufffd PRESCRIPCI\u00d3N DE F\u00c1RMACOS QUE PROLONGAN EL INTERVALO QT EN PACIENTES MAYORES DE 50 A\u00d1OS \nCON VIH  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 435\n1112. AN\u00c1LISIS DE EFECTIVIDAD Y SEGURIDAD DE SOTROVIMAB EN PACIENTES AFECTADOS POR SARS-COV-2 \ufffd\ufffd\ufffd435\n1141. \u00bfES ADECUADO EL TRATAMIENTO DE LA INFECCI\u00d3N POR CLOSTRIDIOIDES DIFFICILE EN NUESTRO\nHOSPITAL?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 436\n1153. \u00bfC\u00d3MO AFECTA LA MAYOR COMPLEJIDAD DE LOS PACIENTES AL TRATAMIENTO ANTIBI\u00d3TICO DOMICILIARIO \nENDOVENOSO?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 437\n1166 \ufffd AN\u00c1LISIS DEL USO EN VIDA REAL DE TOCILIZUMAB Y BARICITINIB EN PACIENTES CON NEUMON\u00cdA\nCOVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 438\n1204 \ufffd EFECTIVIDAD Y SEGURIDAD DEL PASO PRECOZ DE LA ANTIBIOTERAPIA A V\u00cdA ORAL EN NEUMOLOG\u00cdA: AN\u00c1LI -\nSIS DE PROPENSIONES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 438\n1212 \ufffd EVALUACI\u00d3N DE LAS INTERVENCIONES PROA EN VALIDACI\u00d3N FARMAC\u00c9UTICA VERSUS LAS REALIZADAS POR \nUN PROA MULTIDISCIPLINAR Y SU GRADO DE ACEPTACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 439\n1235 \ufffd ANEMIA HEMOL\u00cdTICA INDUCIDA POR CEFTRIAXONA: A PROPOSITO DE UN CASO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 441\n1244 \ufffd AN\u00c1LISIS DE LA EFECTIVIDAD DEL SWITCH A BITERAPIA BASADA EN DOLUTEGRAVIR/RILPIVIRINA EN UN \nHOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 441\n1247 \ufffd ESTUDIO SOBRE EFECTOS ADVERSOS DE LA ANTIBIOTERAPIA INHALADA EN PACIENTES CON ENFERMEDAD \nPULMONAR OBSTRUCTIVA CR\u00d3NICA Y/O BRONQUIECTASIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 442\n1254 \ufffd COMPARACI\u00d3N DEL PATR\u00d3N DE RESISTENCIAS ANTIMICROBIANAS DE UN CENTRO SOCIOSANITARIO Y SU \nHOSPITAL DE REFERENCIA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 443\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS  .................................................................................................... 444\n90\ufffd EXPERIENCIA DE LA UTILIZACI\u00d3N DE LONOCTOCOG ALFA EN LA PROFILAXIS DEL SANGRADO PERIOPERATORIO \nEN PACIENTES CON HEMOFILIA A  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 444\n191. EFICIENCIA DEL AJUSTE FARMACOCIN\u00c9TICO INDIVIDUALIZADO FRENTE A DOSIFICACI\u00d3N CONVENCIONAL DE \nDOS CONCENTRADOS DE FIX DE VIDA MEDIA EXTENDIDA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 444\n230\ufffd EVALUACI\u00d3N Y COMPARACI\u00d3N DEL PERFIL FARMACOCIN\u00c9TICO DE DOS CONCENTRADOS DE FIX DE VIDA ME -\nDIA EXTENDIDA EN PACIENTES CON HEMOFILIA B  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 445\n330. AJUSTE FARMACOCIN\u00c9TICO EN PACIENTES CON HEMOFILIA B DE CONCENTRADOS DE FIX DE VIDA MEDIA \nEXTENDIDA MEDIANTE DIFERENTES MODELOS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 446\n364\ufffd AN\u00c1LISIS DE NIVELES S\u00c9RICOS DE VANCOMICINA EN UNA UNIDAD DE CUIDADOS INTENSIVOS\nNEONATALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 446\n387\ufffd USO DE MODULADORES DEL CFTR EN PEDIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 447\n595\ufffd ADECUACI\u00d3N DEL USO DE INMUNOGLOBULINAS INESPEC\u00cdFICAS INTRAVENOSAS EN PEDIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 448\n651\ufffd USO DE ECULIZUMAB PARA LA MICROANGIOPAT\u00cdA TROMB\u00d3TICA EN PACIENTES PEDI\u00c1TRICOS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 448\n661. EFECTIVIDAD A LARGO PLAZO DE LUMACAFTOR-IVACAFTOR EN PACIENTES CON FIBROSIS QU\u00cdSTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 449\n679\ufffd ESTANDARIZACI\u00d3N Y CARACTERIZACI\u00d3N DE LA TERAPIA INTRAVENOSA EN PEDIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 450\n752\ufffd USO DE TOFACITINIB EN PACIENTES PEDI\u00c1TRICOS CON DIAGN\u00d3STICO DE ALOPECIA AREATA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 45027976\ufffd INDIVIDUALIZACI\u00d3N DE LOS TRATAMIENTOS EN HEMOFILIA \ufffd INTERVENCI\u00d3N DEL FARMAC\u00c9UTICO\nHOSPITALARIO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 451\n1008. EXPERIENCIA DE USO DE LA PAUTA SNAP DE N-ACETILCISTE\u00cdNA EN INTOXICACI\u00d3N POR PARACETAMOL EN \nPEDIATR\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 452\n1019 \ufffd DISE\u00d1O DE UNA HERRAMIENTA INFORM\u00c1TICA PARA DETERMINAR LA OSMOLALIDAD DE LAS FORMAS \nFARMAC\u00c9UTICAS L\u00cdQUIDAS ORALES EN RECI\u00c9N NACIDOS PRET\u00c9RMINO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 453\n1097 \ufffd ESTUDIO DE UTILIZACI\u00d3N DE DEFIBROTIDE EN PEDIATR\u00cdA Y CUMPLIMIENTO DE UNA NUEVA ESCALA DIAG -\nN\u00d3STICA DEL S\u00cdNDROME OCLUSIVO SINUSOIDAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 453\n1234 \ufffd VALIDACI\u00d3N DE LAS DOSIS DIARIAS DEFINIDAS DE ANTIMICROBIANOS EN POBLACI\u00d3N PEDI\u00c1TRICA \ufffd FASE II \nDEL PROYECTO KIDDDS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 454\n1258. IDENTIFICACI\u00d3N DE \u00c1REAS DE MEJORA PARA LA OPTIMIZACI\u00d3N DE TRATAMIENTOS CON INMUNOGLOBULI -\nNAS \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 455\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL  ......................... 455\n50\ufffd EVALUACI\u00d3N DE LA EXPERIENCIA DE LOS PACIENTES CON LA ATENCI\u00d3N COORDINADA Y CENTRADA EN LA\nPERSONA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 455\n57. DOSE BANDING DE MEZCLAS INTRAVENOSAS DE 5-FLUOROURACILO, OXALIPLATINO, PACLITAXEL Y GEMCITA -\nBINA: IMPLANTACI\u00d3N Y EVALUACI\u00d3N DE LA EFICIENCIA Y SEGURIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 456\n101. EFICACIA Y SEGURIDAD DE CLADRIBINA EN ESCLEROSIS M\u00daLTIPLE: \u00bfQU\u00c9 OBSERVAMOS M\u00c1S ALL\u00c1 DE LOS\n2 A\u00d1OS?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 457\n124\ufffd INCORPORACI\u00d3N DEL FARMAC\u00c9UTICO A UNA CONSULTA M\u00c9DICA DE ATENCI\u00d3N AL PACIENTE VIH \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 458\n165\ufffd APLICACI\u00d3N DE UN PROTOCOLO CL\u00cdNICO DE PRESCRIPCI\u00d3N DE INMUNOGLOBULINAS INTRAVENOSAS: EVI -\nDENCIA DE USO Y CONSUMO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 458\n257. FARMACOVIGILANCIA DE VACUNAS COVID-19 DESDE EL INICIO DEL PER\u00cdODO DE VACUNACI\u00d3N A NIVEL DE \nUN CENTRO DE FARMACOVIGILANCIA AUTON\u00d3MICO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 459\n265\ufffd ESTUDIO DE LOS FACTORES DE RIESGO DE HEMORRAGIAS DIGESTIVAS EN PACIENTES QUE ACUDEN AL SERVI -\nCIO DE URGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 460\n279\ufffd TRATAMIENTO CON UREA EN LA HIPONATREMIA DEBIDA AL S\u00cdNDROME DE SECRECI\u00d3N INADECUADA DE \nHORMONA ANTIDIUR\u00c9TICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 460\n283\ufffd DESCRIPCI\u00d3N DEL USO DE F\u00c1RMACOS ANTICOLIN\u00c9RGICOS EN PACIENTES GERI\u00c1TRICOS INSTITUCIONALIZA -\nDOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 461\n292. EVALUACI\u00d3N DE LA SEGURIDAD DE NATALIZUMAB EN ESCLEROSIS M\u00daLTIPLE REMITENTE-RECURRENTE  \ufffd\ufffd\ufffd\ufffd462\n335\ufffd SATISFACCI\u00d3N PERCIBIDA POR LOS PACIENTES: COMPARACI\u00d3N ENTRE DOS MODELOS DE ATENCI\u00d3N FARMA -\nC\u00c9UTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 463\n475. \u00bfSABEN LOS PACIENTES C\u00d3MO ELIMINAR CORRECTAMENTE LOS RESIDUOS QUE GENERAN SUS MEDICAMEN -\nTOS PARENTERALES DE DISPENSACI\u00d3N HOSPITAL\u00c0RIA?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 463\n483\ufffd USO DE ATROPINA, EFEDRINA Y FENILEFRINA EN QUIR\u00d3FANO Y AN\u00c1LISIS DEL IMPACTO ECON\u00d3MICO AL SUS -\nTITUIR SUS PRESENTACIONES POR JERINGAS PRECARGADAS.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 464\n492\ufffd EVALUACI\u00d3N DEL SISTEMA DE UTILIZACI\u00d3N DE MEDICAMENTOS EN UN SERVICIO DE MEDICINA INTENSIVA Y \nDEFINICI\u00d3N DE ESTRATEGIAS DE MEJORA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 465\n494\ufffd SEGURIDAD EN VIDA REAL DEL TRATAMIENTO CON TOFACITINIB: A PROP\u00d3SITO DE UNA ALERTA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 465\n522\ufffd SEGURIDAD EN VIDA REAL DEL TRATAMIENTO CON IVACAFTOR/TEZACAFTOR/ELEXACAFTOR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 466\n539\ufffd CUESTIONARIO DE AUTOEVALUACI\u00d3N DE SEGURIDAD DE UTILIZACI\u00d3N MEDICAMENTOS EN HOSPITALES \ufffd \nHERRAMIENTA PARA AN\u00c1LISIS DE RESULTADOS Y DEFINIR ESTRATEGIAS DE MEJORA.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 467\n563\ufffd EVALUACI\u00d3N DE LA CALIDAD DE VIDA DE LOS PACIENTES CON TROMBOCITOPENIA INMUNE PRIMARIA ATEN -\nDIDOS EN LA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 468\n650\ufffd ANALISIS Y DESCRIPCI\u00d3N DE LAS NOTIFICACIONES DE ERRORES DE MEDICACION EN UN HOSPITAL COMAR -\nCAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 469\n671. EFECTOS ADVERSOS DE LA VACUNACI\u00d3N ANTI-MENINGOC\u00d3CICA B EN PACIENTES PREMATUROS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 469\n673\ufffd ESTUDIO DE DISTRIBUCI\u00d3N E IDENTIFICACI\u00d3N DE LOS MEDICAMENTOS DE ALTO RIESGO EN SISTEMAS AU -\nTOMATIZADOS DE DISPENSACI\u00d3N DE MEDICAMENTOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 470\n714\ufffd REACCIONES INFUSIONALES DE F\u00c1RMACOS ADMINISTRADOS EN HOSPITAL DE D\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 47128720. ESTUDIO DE UTILIZACI\u00d3N DE ANTIDEPRESIVOS DURANTE LA PANDEMIA DE COVID-19 EN LA REGI\u00d3N DE \nMURCIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 471\n738. SATISFACCI\u00d3N PERCIBIDA POR EL PERSONAL DEL SERVICIO DE FARMACIA COMO M\u00c9TODO DE MEJORA DE LA \nCALIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 472\n747\ufffd EVALUACI\u00d3N DE LA SEGURIDAD DEL ETIQUETADO Y ENVASADO DE LOS MEDICAMENTOS DE ALTO RIESGO \nDISPONIBLES EN UN HOSPITAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 473\n803\ufffd CALIDAD DE VIDA, ACTIVIDAD F\u00cdSICA Y FATIGA EN PACIENTES CON C\u00c1NCER DE MAMA EN TRATAMIENTO CON \nANTINEOPL\u00c1SICOS ORALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 473\n822. ADECUACI\u00d3N DE LA CLASIFICACI\u00d3N DE LA PHARMACEUTICAL-CARE-NETWORK-EUROPE A LOS PROBLEMAS \nRELACIONADOS CON LA MEDICACI\u00d3N EN EL \u00c1REA DE PACIENTES EXTERNOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 474\n910. VACUNAS FRENTE A LA COVID-19: PERFIL DE SEGURIDAD TRAS UN A\u00d1O DE SEGUIMIENTO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 475\n969. RELACI\u00d3N ENTRE INFECCI\u00d3N POR COVID-19 Y EFECTOS ADVERSOS A LA VACUNA FRENTE AL SARS-COV-2 EN \nPR\u00c1CTICA REAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 476\n1000 \ufffd AN\u00c1LISIS Y ADECUACI\u00d3N DE TRATAMIENTOS EN PACIENTES UROL\u00d3GICOS CON INSUFICIENCIA RENAL EN \nCOLABORACI\u00d3N CON EL SERVICIO DE NEFROLOG\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 476\n1027 \ufffd ANALISIS Y ADECUACION MULTIDISCIPLINAR DE TRATAMIENTOS EN PACIENTES CON INSUFICIENCIA RENAL \nDE LOS SERVICIOS DE CIRUGIA GENERAL, VASCULAR Y ANESTESIOLOGIA \ufffd \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 477\n1105. TERAPIA RADIONUCL\u00cdDICA DE RECEPTORES PEPT\u00cdDICOS. EVALUACI\u00d3N DE LA SEGURIDAD DE [177LU]LU-\nOXODOTREOTIDA EN TUMORES NEUROENDOCRINOS EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 478\n1120 \ufffd IMPACTO DE UN PROGRAMA DE FORMACI\u00d3N DE T\u00c9CNICOS DE FARMACIA PARA ELABORACI\u00d3N DE PRE -\nPARADOS EST\u00c9RILES EN CABINA DE FLUJO LAMINAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 478\n1165. SOFTWARE PARA LA MEJORA EN LA SEGURIDAD Y TRAZABILIDAD DE TRATAMIENTOS ONCOHEMATOLOGICOS \ufffd\ufffd479\n1180 \ufffd GESTI\u00d3N DE RIESGO EN EL USO DE TERAPIAS BIOL\u00d3GICAS, INMUNOSUPRESORAS E INMUNOMODULADO -\nRAS EN REFERENCIA AL ESTADO INMUNO-INFECCIOSO DEL PACIENTE.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 480\n1195 \ufffd SWITCH DE HORMONA DEL CRECIMIENTO RECOMBINANTE ORIGINAL AL BIOSIMILAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 481\n1257 \ufffd AN\u00c1LISIS DE LOS PACIENTES EN TRATAMIENTO CON TOFACITINIB: APLICANDO NUEVAS PRECAUCIONES DE \nUSO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 481\n1272 \ufffd NUEVA ALERTA DE SEGURIDAD DE TOFACITINIB: AN\u00c1LISIS DE LOS PACIENTES EN RIESGO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 482\n1274 \ufffd PATIENT REPORTED OUTCOMES EN PACIENTES CON ASMA GRAVE EN TRATAMIENTO CON F\u00c1RMACOS\nBIOL\u00d3GICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 483\n1293 \ufffd RELEVANCIA CL\u00cdNICA DE LA INTERACCI\u00d3N FARMACOL\u00d3GICA ENTRE MIRTAZAPINA Y LINEZOLID  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 484\nCOMUNICACIONES OPERATIVAS \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 486\nCLASIFICACI\u00d3N: ADHERENCIA  ................................................................................................................................. 486\n229\ufffd IMPLANTACI\u00d3N DE UN CIRCUITO PARA LA PRESCRIPCI\u00d3N, DISPENSACI\u00d3N Y ADMINISTRACI\u00d3N AMBULATORIA \nDE BUPRENORFINA INYECTABLE DE LIBERACI\u00d3N PROLONGADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 486\n1295. DISE\u00d1O, IMPLANTACI\u00d3N Y RESULTADOS PRELIMINARES DE UN PROTOCOLO PARA IDENTIFICAR Y MEJORAR \nLA ADHERENCIA EN PACIENTES CON TERAPIA ANTIRRETROVIRAL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 486\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS  .............................................. 487\n209. IMPLANTACI\u00d3N DE UNA TELECONSULTA DE PRE-INGRESO EN PACIENTES CON CIRUG\u00cdA VASCULAR\nPROGRAMADA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 487\n324\ufffd IMPLANTACI\u00d3N DE LA ATENCI\u00d3N FARMAC\u00c9UTICA EN UNA UNIDAD DE HOSPITALIZACI\u00d3N A DOMICILIO \nPEDI\u00c1TRICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 488\n416\ufffd IMPLANTACI\u00d3N DE UNA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA PREVIA A LA ADMINISTRACI\u00d3N DE CIL -\nGAVIMAB/TIXAGEVIMAB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 489\n785\ufffd SEGUIMIENTO MULTIDISCIPLINAR DEL PACIENTE CON MIGRA\u00d1A TRATADO CON ANTICUERPOS MONOCLO -\nNALES ANTI-CGRP . DESCRIPCI\u00d3N, EVALUACI\u00d3N Y REDISE\u00d1O DEL PROCESO. GESTI\u00d3N EXPECTATIVAS.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 490\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL  ................................................................................ 491\n248\ufffd PROGRAMA DE CONCILIACI\u00d3N DE LA MEDICACI\u00d3N AL ALTA HOSPITALARIA A PERSONAS INSTITUCIONALIZA -\nDAS EN CENTROS SOCIOSANITARIOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 491\n282\ufffd INTEGRACI\u00d3N DE UN FARMAC\u00c9UTICO EN LOS EQUIPOS DE ATENCI\u00d3N PRIMARIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 49229352\ufffd EVALUACI\u00d3N DEL GRADO DE DESNUTRICI\u00d3N DE LOS USUARIOS DE CENTROS SOCIOSANITARIOS CON SERVI -\nCIO DE FARMACIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 493\n570\ufffd REVISI\u00d3N Y ADECUACI\u00d3N DE LA MEDICACI\u00d3N EN PACIENTES HOSPITALIZADOS A CONSECUENCIA DE UNA CA\u00cdDA \ufffd 494\n813. ATENCION FARMAC\u00c9UTICA HOSPITALARIA A PERSONAS MAYORES QUE VIVEN EN RESIDENCIAS \u00bfUN OBJE -\nTIVO POSIBLE?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 495\n958\ufffd INTEGRACI\u00d3N DEL FARMAC\u00c9UTICO EN LA UNIDAD DE HOSPITALIZACI\u00d3N DE GERIATR\u00cdA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 496\n1042 \ufffd LAZOS DESDE LA URGENCIA, HOSPITALIZACI\u00d3N HASTA LA ATENCI\u00d3N PRIMARIA: CIRCUITO DE COLABO -\nRACI\u00d3N Y COMUNICACI\u00d3N ENTRE DISTINTOS \u00c1MBITOS ASISTENCIALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 496\n1091. PROGRAMA DE COORDINACI\u00d3N ASISTENCIAL PARA LA MEJORA DE LA FARMACOTERAPIA EN EL PACIENTE \nMAYOR POLIMEDICADO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 497\n1185. INTERVENCI\u00d3N FARMAC\u00c9UTICA PARA LA MEJORA DE LA PRESCRIPCI\u00d3N EN PACIENTES POLIMEDICADOS A \nTRAV\u00c9S DE UN APLICATIVO WEB  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 498\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS  .............................................................................................. 499\n240\ufffd ACTUALIZACI\u00d3N DE UN MANUAL DE ESTANDARIZACI\u00d3N DE PERFUSIONES DE MEDICAMENTOS DE ALTO \nRIESGO Y CREACI\u00d3N DE NOMOGRAMAS DE ADMINISTRACI\u00d3N \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 499\n739. APLICACI\u00d3N DE UN SISTEMA DE TRIAJE FARMAC\u00c9UTICO EN EL SERVICIO DE URGENCIAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 500\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS  ............................................... 501\n717\ufffd IMPLEMENTACI\u00d3N DE LA MONITORIZACI\u00d3N DE NIVELES PLASM\u00c1TICOS DE ARIPIPRAZOL, PALIPERIDONA Y \nRISPERIDONA EN UNIDADES DE HOSPITALIZACI\u00d3N PSIQUI\u00c1TRICA Y SALUD MENTAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 501\n1069 \ufffd CONSTITUCI\u00d3N DE COMIT\u00c9 MULTIDISCIPLINAR DE ASMA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 502\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS  ........................................................... 503\n922. EPILEPSIA REFRACTARIA EN S\u00cdNDROME LENNOX-GASTAUT: NUEVOS RETOS CON LA ATENCI\u00d3N FARMAC\u00c9U -\nTICA AL PACIENTE EXTERNO PEDIATRICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 503\n1076 \ufffd TERAPIA GENICA EN EL PACIENTE PEDIATRICO CON ATROFIA MEDULAR ESPINAL: ATENCION FARMACEUTICA \nY GARANTIA DE CALIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 504\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS  ........................................................................................................................ 505\n43. MEJORA DE LA CALIDAD EN EL MANEJO DE MEDICAMENTOS EN INVESTIGACI\u00d3N: ADAPTACI\u00d3N AL AUMENTO Y \nCOMPLEJIDAD DE ENSAYOS CL\u00cdNICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 505\n164\ufffd CREACI\u00d3N DE UNA SALA BLANCA Y ESTANDARIZACI\u00d3N DE PNTS PARA LA FABRICACI\u00d3N DE MEDICAMENTOS \nEN UNA UNIDAD DE INVESTIGACI\u00d3N CL\u00cdNICA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 505\n447\ufffd DIGITALIZACI\u00d3N DE PROCEDIMIENTOS ADMINISTRATIVOS DEL \u00c1REA DE ENSAYOS CL\u00cdNICOS DEL SERVICIO DE \nFARMACIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 506\n505. MEJORAS EN LA REVISI\u00d3N DE LA MEDICACI\u00d3N DOMICILIARIA EN EL PER\u00cdODO DE SCREENING DE PACIENTES \nCANDIDATOS A ENSAYO CL\u00cdNICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 507\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA  .................................... 508\n16\ufffd ALGORITMOS DE TRATAMIENTOS BASADOS EN POSICIONAMIENTO Y FINANCIACI\u00d3N COMO HERRAMIENTA DE \nAPOYO A LA PRESCRIPCI\u00d3N Y VALIDACI\u00d3N ONCOHEMATOL\u00d3GICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 508\n46\ufffd NORMALIZACI\u00d3N DE LA GESTI\u00d3N DE LOS MEDICAMENTOS EN SITUACIONES ESPECIALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 509\n262\ufffd PROGRAMA INTEGRAL DE GESTI\u00d3N DE USO DE INMUNOGLOBULINAS INTRAVENOSAS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 510\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N  ................................................................................................... 511\n297\ufffd IMPLANTACI\u00d3N DE UN PROTOCOLO DE MEDICI\u00d3N DEL GASTO ENERG\u00c9TICO EN REPOSO A TRAV\u00c9S DE CALO -\nRIMETR\u00cdA INDIRECTA EN PACIENTE CR\u00cdTICO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 511\n354\ufffd ESTANDARIZACI\u00d3N DE DOSIS PRECARGADAS DE METOTREXATO PARA ADMINISTRACI\u00d3N INSTRAMUSCULAR \nEN GESTACI\u00d3N ECT\u00d3PICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 512\n433\ufffd ADMINISTRACI\u00d3N SEGURA DE MEDICAMENTOS POR DISPOSITIVOS PARA ALIMENTACION ENTERAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 513\n448\ufffd IMPLANTACI\u00d3N DE UNA CONSULTA DE SEGUIMIENTO NUTRICIONAL SEMANAL EN PACIENTES CON PSORIASIS \nMODERADA-GRAVE CON SOBREPESO EN TRATAMIENTO CON F\u00c1RMACOS BIOL\u00d3GICOS.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 514\n1171 \ufffd ACTUALIZACI\u00d3N DEL PROCEDIMIENTO DE NUTRICI\u00d3N PARENTERAL DOMICILIARIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 515\n1198 \ufffd REVISI\u00d3N DEL PLAZO DE VALIDEZ DE F\u00d3RMULAS ORALES L\u00cdQUIDAS ELABORADAS POR UN SERVICIO DE \nFARMACIA TRAS APERTURA DE ENVASES MULTIDOSIS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 51630CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS  517\n79\ufffd AUTOMATIZACI\u00d3N DE LA ELABORACI\u00d3N DE ANTINEOPL\u00c1SICOS \ufffd EXPERIENCIA EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd517\n163\ufffd DESARROLLO DE UNA APLICACI\u00d3N M\u00d3VIL PARA ADMINISTRACI\u00d3N DE MEDICAMENTOS EN PACIENTES CON \nDISFAGIA \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 518\n233\ufffd PROFESIONALIZACI\u00d3N DEL USO DE REDES SOCIALES EN UN SERVICIO DE FARMACIA HOSPITALARIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 519\n243\ufffd REFORM\u00daLATE DE FORMA SOSTENIBLE EN LA IDENTIFICACI\u00d3N DE F\u00c1RMACOS: REETIQUETAR EN LUGAR DE \nREENVASAR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 519\n334\ufffd DISE\u00d1O, DESARROLLO E IMPLEMENTACI\u00d3N DE LA TELEFARMACIA EN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 520\n409\ufffd EXPERIENCIA DE LIDERAZGO EN LA GESTI\u00d3N Y OPTIMIZACI\u00d3N DE TERAPIAS DE ALTO IMPACTO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 521\n511\ufffd DESARROLLO DE UNA APLICACI\u00d3N M\u00d3VIL DE MAPEO DE LAS MOCHILAS DE URGENCIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 522\n512. CIRCUITO DE PRESCRIPCI\u00d3N, VALIDACI\u00d3N Y DISPENSACI\u00d3N DE NIRMATRELVIR/RITONAVIR (PAXLOVID\u00ae) PARA \nLA INFECCI\u00d3N POR SARS-COV-2: COORDINANDO NIVELES ASISTENCIALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 523\n715\ufffd IMPLANTACI\u00d3N DE UNA APLICACI\u00d3N EN LOS SISTEMAS AUTOM\u00c1TICOS DE DISPENSACI\u00d3N QUE PERMITE \nGESTIONAR LA TOTALIDAD DE PRESCRIPCIONTES ACTIVAS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 524\n721. OPTIMIZACI\u00d3N DE LOS SISTEMAS AUTOMATIZADOS DE DISPENSACI\u00d3N (SAD): CREACI\u00d3N DE UNA HERRA -\nMIENTA PARA SU AGILIZACI\u00d3N Y SISTEMATIZACI\u00d3N \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 524\n810\ufffd CREACI\u00d3N DE UNA UNIDAD DE CONDUCTAS ADICTIVAS DEPENDIENTE DEL SERVICIO DE FARMACIA DE UN \nHOSPITAL DE TERCER NIVEL \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 525\n859\ufffd IMPLANTACI\u00d3N DE LA SALUD M\u00d3VIL EN LA ATENCI\u00d3N DEL PACIENTE RECEPTOR DE TRASPLANTE ALOG\u00c9NICO \nDE PROGENITORES HEMATOPOY\u00c9TICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 526\n887\ufffd PROCEDIMIENTO PARA LA INTERCAMBIABILIDAD DE MEDICAMENTOS BIOL\u00d3GICOS: SOSTENIBILIDAD DEL \nSISTEMA DE SALUD CASTELLANO MANCHEGO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 527\n911\ufffd DISMINUCI\u00d3N DE LOS ERRORES DE MEDICACI\u00d3N RELACIONADOS CON LA INTRODUCCI\u00d3N DE NUEVAS PRE -\nSENTACIONES DE F\u00c1RMACOS MEDIANTE LA METODOLOG\u00cdA LEAN A3  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 528\n925\ufffd CENTRALIZACI\u00d3N DE LA PREPARACI\u00d3N DE F\u00c1RMACOS EST\u00c9RILES DE DOS HOSPITALES COMARCALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 529\n1015 \ufffd IMPLEMENTACI\u00d3N DE UN SISTEMA DE DISPENSACI\u00d3N DE MEDICAMENTOS EN UNA RESIDENCIA SOCIOS -\nANITARIA GUIADA POR UN PROGRAMA DE BIG DATA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 530\n1125 \ufffd IMPLANTACI\u00d3N DE UN MODELO DE TELEFARMACIA EN COLABORACI\u00d3N CON LA FARMACIA COMUNITARIA \nEN UN HOSPITAL DE TERCER NIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 530\n1306. TELETRABAJO EN FARMACIA HOSPITALARIA, \u00bfPOSIBILIDAD O REALIDAD?  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 531\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA  ...................................... 532\n543. IMPLEMENTACI\u00d3N DEL GENOTIPADO DEL CYP3A5 PARA EL AJUSTE DE LA DOSIS INICIAL DE TACROLIMUS EN \nPACIENTES TRASPLANTADO CARDIACOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 532\n548\ufffd IMPLEMENTACI\u00d3N DE ESTUDIOS FARMACOGEN\u00c9TICOS EN PSIQUIATR\u00cdA PARA LA OPTIMIZACI\u00d3N DEL TRATA -\nMIENTO CON PSICOF\u00c1RMACOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 533\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA  .................................................................................................................... 534\n664\ufffd COMUNIDAD VIRTUAL PARA EL APOYO INTEGRAL A PACIENTES CON C\u00c1NCER DE MAMA \ufffd \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 534\n1070 \ufffd AN\u00c1LISIS DE LOS RESULTADOS TRAS LA IMPLANTACI\u00d3N DE UN CIRCUITO DE ADMINISTRACI\u00d3N DE TRATA -\nMIENTOS ONCO-HEMATOL\u00d3GICOS EN PAUTA DE DESENSIBILIZACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 535\n1081 \ufffd DISPENSACI\u00d3N DE LA PREMEDICACI\u00d3N DE LOS ESQUEMAS CON DARATUMUMAB SUBCUT\u00c1NEO EN LA CON -\nSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 536\n1226 \ufffd IMPACTO DE UNA APLICACI\u00d3N M\u00d3VIL EN EL CONTROL DE LA ADHERENCIA AL TRATAMIENTO Y EN LA CO -\nMUNICACI\u00d3N PACIENTE-FARMAC\u00c9UTICO HOSPITALARIO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 537\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)  ...................... 538\n170. CIRCUITO TRATAMIENTOS FRENTE A COVID-19 EN PACIENTE HOSPITALIZADO EN UN HOSPITAL DE TERCER \nNIVEL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 538\n808\ufffd OPTIMIZACI\u00d3N DEL CIRCUITO DE ELABORACI\u00d3N Y SEGUIMIENTO DE SELLADOS CON ANTIBI\u00d3TICOS PARA LAS \nINFECCIONES DE CAT\u00c9TER VENOSO CENTRAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 538\n845\ufffd IMPLANTACI\u00d3N DE LA PRESCRIPCI\u00d3N ELECTR\u00d3NICA ASISTIDA CON ALGORITMOS DE DECISI\u00d3N PARA LOS \nPROTOCOLOS DE PROFILAXIS ANTIBI\u00d3TICA EN CIRUG\u00cdA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 539\n846\ufffd DISE\u00d1O E IMPLANTACI\u00d3N DE PRESCRIPCI\u00d3N ELECTR\u00d3NICA ASISTIDA CON ALGORITMOS DE DECISI\u00d3N PARA \nDESESCALADA SEG\u00daN MALDI-TOF EN EL TRATAMIENTO DE BACTERIEMAS.  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 54031CLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS  .................................................................................................... 541\n852\ufffd INMUNOGLOBULINAS HUMANAS: ESTRATEGIA PARA FOMENTAR EL USO EFICIENTE DE LOS RECURSOS \ufffd  \ufffd\ufffd\ufffd\ufffd541\n920\ufffd IMPLANTACI\u00d3N DE PR\u00c1CTICAS SEGURAS DE UTILIZACI\u00d3N DE MEDICAMENTOS EN LA URGENCIA PEDI\u00c1TRICA  \ufffd\ufffd\ufffd\ufffd\ufffd542\n995\ufffd ESTRATEGIA PARA LA OPTIMIZACI\u00d3N DEL USO DE INMUNOGLOBULINA IV  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 543\n998\ufffd REVISI\u00d3N DE LA COMPATIBILIDAD DE F\u00c1RMACOS DE ADMINISTRACI\u00d3N INTRAVENOSA EN NEONATOLOG\u00cdA\nE INCORPORACI\u00d3N A LA PR\u00c1CTICA CL\u00cdNICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 544\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL  ......................... 544\n76\ufffd IMPLANTACI\u00d3N DE UN PROCEDIMIENTO PARA LA MANIPULACI\u00d3N SEGURA DE MEDICAMENTOS PELIGROSOS \nEN UN HOSPITAL PSIQUIATRICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 544\n87\ufffd IMPLEMENTACI\u00d3N DE PROTOCOLOS DE PRESCRIPCI\u00d3N ELECTR\u00d3NICA EN EL PACIENTE TRASPLANTADO\nRENAL  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 545\n192\ufffd ELABORACION DE UNA GUIA PARA LA ADMINISTRACION DE MEDICAMENTOS POR V\u00cdA SUBCUTANEA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 546\n193\ufffd IMPLANTACI\u00d3N DE UNA ESTRATEGIA MULTIDISCIPLINAR PARA LA OPTIMIZACI\u00d3N DEL USO DE PSICOF\u00c1RMA -\nCOS EN UN CENTRO PENITENCIARIO \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 547\n423\ufffd HUMANIZACION DEL AREA DE PACIENTES EXTERNOS: DESARROLLO Y ANALISIS DE UN PROCEDIMIENTO DE \nDISPENSACION MEDIANTE LA COORDINACION ENTRE NIVELES ASISTENCIALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 548\n430\ufffd IMPLEMENTACION DE UN PROTOCOLO DE ANALGESIA MEDIANTE LA ELABORACION DE UNA MEZCLA INTRA -\nVENOSA TERNARIA DE ANALGESIA CONTROLADA POR PACIENTE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 549\n643\ufffd IMPLANTACI\u00d3N DE UN PROCEDIMIENTO DE IDENTIFICACI\u00d3N Y MANIPULACI\u00d3N SEGURA DE MEDICAMENTOS \nBIOPELIGROSOS EN UN HOSPITAL DE MEDIA ESTANCIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 550\n678\ufffd OPTIMIZACI\u00d3N DEL CIRCUITO DE ESTUPEFACIENTES APLICANDO EL SISTEMA DE GESTI\u00d3N DE CALIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd551\n774. IMPROVING ONCOLOGY PATIENT JOURNEY USING LEAN METHODOLOGY  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 552\n780\ufffd IMPLANTACI\u00d3N DE LA METODOLOG\u00cdA NOT TO DO EN UN SERVICIO DE FARMACIA HOSPITALARIA \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 552\n1136 \ufffd INCORPORACI\u00d3N DEL VISADO DE PRESCRIPCIONES A LA CARTERA DE SERVICIOS DE FARMACIA: AN\u00c1LISIS DE \nLA PRESCRIPCI\u00d3N DE ANTICOAGULANTES ORALES DIRECTOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 553\n1143. IMPLANTACI\u00d3N DE UN PROTOCOLO DE MANEJO SEGURO DE MEDICAMENTOS DE ALTO RIESGO Y PELIGRO -\nSOS EN UN CENTRO DE ATENCI\u00d3N INTERMEDIA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 554\n1157 \ufffd APLICACI\u00d3N DE LA METODOLOG\u00cdA LEAN A UNA UNIDAD MULTIDISCIPLINAR DE ASMA GRAVE  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 555\n1164 \ufffd ELABORACI\u00d3N DE MATERIAL AUDIOVISUAL PARA PACIENTES SOMETIDAS A TECNICAS DE REPRODUCCI\u00d3N \nASISTIDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 556\nCOMUNICACIONES DE T\u00c9CNICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 559\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL  ................................................................................ 559\n458\ufffd RELACI\u00d3N ENTRE MEDICACI\u00d3N TRITURADA Y DISFAGIA EN UN CENTRO DE ESTANCIAS TEMPORALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 559\n847\ufffd TRATAMIENTO FARMACOL\u00d3GICO DE LOS PACIENTES CON ENFERMEDAD DE ALZHEIMER EN CATALU\u00d1A DU -\nRANTE EL PER\u00cdODO DE LA PANDEMIA DE COVID-19  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 559\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS  .............................................................................................. 560\n84\ufffd ESTUDIO DE LA COMPATIBILIDAD F\u00cdSICA DE F\u00c1RMACOS ADMINISTRADOS EN Y EN UNA UNIDAD DE PACIENTES \nCR\u00cdTICOS ADULTOS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 560\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS  ........................................................................................................................ 561\n451\ufffd FORMULARIO DE REGISTRO DE RETORNO A PROMOTOR DE MEDICACI\u00d3N DE ENSAYO CL\u00cdNICO \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 561\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N  ................................................................................................... 562\n94\ufffd IMPORTANCIA DEL T\u00c9CNICO DE FARMACIA EN EL CIRCUITO DE VALIDACI\u00d3N DE NUTRICI\u00d3N PARENTERAL: CON -\nTROL DE CALIDAD GRAVIM\u00c9TRICO \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 562\n162\ufffd DISPENSACI\u00d3N SEGURA Y TRAZABILIDAD ELECTR\u00d3NICA DE F\u00d3RMULAS MAGISTRALES A PACIENTES EXTER -\nNOS EN UN HOSPITAL \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 562\n252\ufffd DISE\u00d1O E IMPLEMENTACI\u00d3N DE UN PLAN DE FORMACI\u00d3N PARA ESTUDIANTES DE T\u00c9CNICO DE GRADO SUPE -\nRIOR EN EL \u00c1REA DE PREPARACI\u00d3N  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 563\n467\ufffd DISE\u00d1O Y ELABORACI\u00d3N DE FLUCITOSINA 15,5% CREMA PARA EL TRATAMIENTO DE VULVOVAGINITIS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 564\n482\ufffd RELEVANCIA DE LA VALIDACI\u00d3N GAL\u00c9NICA DE F\u00d3RMULAS MAGISTRALES CON DISTINTOS PRINCIPIOS ACTI -\nVOS DE PARTIDA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 565\n490\ufffd VALIDACI\u00d3N GAL\u00c9NICA DE COLIRIO DE VANCOMICINA 50MG/ML EN CONGELADOR  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 56532530. INDIVIDUALIZACI\u00d3N DE DOSIS DE ENOXAPARINA 20MG/ML JERINGAS EN NEONATOS Y LACTANTES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 566\n1103 \ufffd CREACI\u00d3N DE UNA BASE DE DATOS EN \u00c1REA DE FARMACOTECNIA PARA LA GESTION E IMPRESION DE CITAS \nDE F\u00d3RMULAS MAGISTRALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 566\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS  567\n200\ufffd SEGUIMIENTO DE LAS PREPARACIONES ELABORADAS EN EL SERVICIO DE FARMACIA A TRAV\u00c9S DE UNA APLI -\nCACI\u00d3N PARA DISPOSITIVOS M\u00d3VILES \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 567\n1240. OPTIMIZACI\u00d3N DEL TIEMPO Y MEJORA DE LA SEGURIDAD TRAS CLASIFICAR POR PRINCIPIO ACTIVO LOS \nMEDICAMENTOS ANTINEOPL\u00c1SICOS EN LA SALA BLANCA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 568\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA  .................................................................................................................... 568\n422\ufffd EL ROL DEL T\u00c9CNICO DE FARMACIA EN UNA UNIDAD DE PACIENTES EXTERNOS ONCOHEMATOL\u00d3GICOS  \ufffd\ufffd\ufffd\ufffd568\n1007 \ufffd DESENSIBILIZACI\u00d3N DE CITOST\u00c1TICOS EN BOLSA \u00daNICA: AN\u00c1LISIS DEL IMPACTO EN EL TIEMPO DE ELABO -\nRACI\u00d3N \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 569\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL  ......................... 570\n466\ufffd IMPLICACI\u00d3N DEL T\u00c9CNICO EN LA GESTI\u00d3N DE MEDICAMENTOS CADUCADOS EN EL SERVICIO DE FARMACIA \n\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 570\n559\ufffd SATISFACCI\u00d3N PERCIBIDA POR LOS PACIENTES EXTERNOS EN LA UNIDAD DE PACIENTES EXTERNOS DEL SER -\nVICIO DE FARMACIA DE DOS HOSPITALES \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 570\n1238 \ufffd ACCESOS VASCULARES Y ADMINISTRACI\u00d3N DE MEDICAMENTOS DURANTE EL INGRESO HOSPITALARIO  \ufffd\ufffd\ufffd571\n1256 \ufffd ASSESSING SYRINGE ACCURACY: REDUCING DOSE ERRORS AND INCREASING SAFETY  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 572\n1261 \ufffd EL T\u00c9CNICO DE FARMACIA EN EL REENVASADO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 572\nPROYECTOS I+I  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 575\nCLASIFICACI\u00d3N: ADHERENCIA  ................................................................................................................................. 575\n586. PROGRAMA DE ATENCI\u00d3N FARMAC\u00c9UTICA PARA MEJORAR LA ADHERENCIA AL TRATAMIENTO INMUNOSU -\nPRESOR EN PACIENTES TRASPLANTADOS RENALES  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 575\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS;  PRODUCTOS SANITARIOS  .576\n824\ufffd TRANSFORMACI\u00d3N DIGITAL DE LA GU\u00cdA FARMACOTERAP\u00c9UTICA MEDIANTE EL DESARROLLO DE UN AGENTE \nCONVERSACIONAL BASADO EN LA INTELIGENCIA ARTIFICIAL \ufffd \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 576\n811\ufffd MAPA DEL MEDICAMENTO: INCORPORACI\u00d3N DE UNA HERRAMIENTA INTELIGENTE A LA VALIDACI\u00d3N FARMA -\nC\u00c9UTICA  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 577\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA  .................................................................................................................... 578\n438\ufffd PROYECTO QUAD: IMPLANTACI\u00d3N DE UN PROGRAMA DE ADMINISTRACI\u00d3N DE QUIMIOTERAPIA A DOMI -\nCILIO EN PACIENTES HEMATOL\u00d3GICOS CON SISTEMA DE TRAZABILIDAD  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 578\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL  ......................... 580\n144\ufffd IMPLEMENTACI\u00d3N DE UNA HERRAMIENTA DE SALUD M\u00d3VIL PARA EL SEGUIMIENTO FARMACOTERAP\u00c9UTICO \nDE LOS PACIENTES CON C\u00c1NCER COLORRECTAL EN TRATAMIENTO QUIMIOTER\u00c1PICO  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 580\n541\ufffd ELABORACI\u00d3N CENTRALIZADA EN EL SERVICIO DE FARMACIA Y EVALUACI\u00d3N DEL USO DE PLASMA RICO EN \nPLAQUETAS EN PATOLOG\u00cdAS MUSCULOESQUEL\u00c9TICAS \ufffd  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 582\nCASOS CL\u00cdNICOS  \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd\ufffd 58534COMUNICACIONES CIENT\u00cdFICAS\nCLASIFICACI\u00d3N: ADHERENCIA\nCLASIFICACI\u00d3N: ADHERENCIA\n62. AN\u00c1LISIS DE PERSISTENCIA Y COSTE DE SECUKINUMAB EN ARTRITIS PSORI\u00c1SICA, ESPONDILITIS \nANQUILOSANTE Y PSORIASIS \nAUTORES\nS\u00c1NCHEZ MART\u00cdNEZ, R; GARC\u00cdA MOLINA, A; ANT\u00d3N HERN\u00c1NDEZ, M; JIM\u00c9NEZ ESPINOSA, \u00c1; CORTELL FUSTER, C; \nTORRECILLA JUNYENT , T; AL\u00d3S ALMI\u00d1ANA, M\nHOSPITAL CL\u00cdNICO UNIVERSITARIO \ufffd AV\ufffd BLASCO IB\u00c1\u00d1EZ, 17 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nDeterminar la persistencia al tratamiento con secukinumab y el coste por tratamiento persistente en sus indicaciones \naprobadas: artritis psori\u00e1sica (APs), espondiloartritis (EA) y psoriasis.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo, retrospectivo, en el que se incluyeron los pacientes adultos con APs, EA y psoriasis \ntratados con secukinumab entre 01/11/2017 y 31/08/2021. Se consideraron las variables demogr\u00e1ficas de edad y \nsexo\ufffd Las variables principales fueron la persistencia del tratamiento con secukinumab y el coste anual por tratamiento \npersistente. El an\u00e1lisis de la persistencia del tratamiento se hizo mediante la prueba de Kaplan-Meier para cada \nindicaci\u00f3n, considerando como evento la interrupci\u00f3n del tratamiento con secukinumab\ufffd El coste por tratamiento \npersistente se calcul\u00f3 en base a la probabilidad de persistencia, la cual se estim\u00f3 con el \u00e1rea bajo la curva para cada \nuna de las tres curvas obtenidas en el an\u00e1lisis de Kaplan-Meier. Las variables secundarias recogidas fueron diagn\u00f3stico, \nduraci\u00f3n del tratamiento con secukinumab, interrupci\u00f3n del tratamiento, motivo de suspensi\u00f3n y l\u00edneas previas de \ntratamiento\ufffd\nRESULTADOS\nSe incluyeron 138 pacientes con secukinumab con una media de edad de 52,2 \u00b1 13,9 a\u00f1os, de los cuales 67 (48,6%) \nfueron mujeres. La persistencia media del tratamiento con secukinumab en APs fue de 36,5 (IC95% 30,7-42,2) meses, \npara EA fue de 39,7 (IC95% 34,3-45,2) meses y en psoriasis fue de 40,4 (IC95% 35,1-45,7) meses. Para ninguno de los \ntres diagn\u00f3sticos se alcanz\u00f3 la mediana de persistencia. No se pudo establecer una relaci\u00f3n entre la edad, el sexo, la \nindicaci\u00f3n y la l\u00ednea de tratamiento con la persistencia de secukinumab.  \nEl coste anual por tratamiento persistente, calculado en base a la probabilidad de persistencia fue de 11\ufffd064 euros para \nAPs, 8\ufffd183 euros para EA y de 15\ufffd420 euros para psoriasis\ufffd  \n34 pacientes de los 138 (24,6%) interrumpieron el tratamiento con secukinumab, con una media de duraci\u00f3n de 15,5 \u00b1 \n12,8 meses. De estos 34 pacientes, 25 (73,5%) lo suspendieron por fracaso terap\u00e9utico, 4 (11,8%) lo hicieron por reacci\u00f3n \nadversa, 3 pacientes (8,8%) lo hicieron por falta de adherencia y uno (2,9%) abandon\u00f3 por estabilidad de la enfermedad \nsin tratamiento. Un paciente (2,9%) se perdi\u00f3 a lo largo del seguimiento. En los 25 pacientes en los que hubo fracaso \nterap\u00e9utico, 11 estaban recibiendo secukinumab como 1\u00aa l\u00ednea (44%) con una persistencia media de 20,5 \u00b1 15,0 meses, y \n14 pacientes (56%) estaban recibiendo secukinumab en 2\u00aa l\u00ednea, con una persistencia media de 14,5 \u00b1 10,7 meses.\nCONCLUSIONES\nLa persistencia media del tratamiento con secukinumab fue mayor para psoriasis en comparaci\u00f3n con APs y EA, sin \nalcanzar significaci\u00f3n estad\u00edstica (p > 0,05). El coste anual por tratamiento persistente m\u00e1s elevado fue para psoriasis. Se \nrequieren m\u00e1s estudios con datos en vida real y de mayor tama\u00f1o muestral para poder establecer los factores que juegan \nun papel clave en la persistencia del tratamiento con secukinumab\ufffd\nCLASIFICACI\u00d3N: ADHERENCIA\n311. ADHERENCIA EN HEMOFILIA A CON TERAPIA NO FACTORIAL \nAUTORES\nJOY CARMONA, P; OCA\u00d1A G\u00d3MEZ, M\u00c1; D\u00cdAZ D\u00cdAZ, CL; R\u00cdOS DE PAZ, M; \u00c1LVAREZ TOSCO, KI; ESQUIVEL NEGR\u00cdN, J; \nMART\u00cdN L\u00d3PEZ, A; MERINO ALONSO, FJ\nCOMPLEJO HOSPITAL UNIVERSITARIO NTRA SRA DE CANDELARIA. CTRA. DEL ROSARIO, 145 SANTA CRUZ DE \nTENERIFE \ufffd SANTA CRUZ DE TENERIFE\nOBJETIVOS\nEvaluar la adherencia tras el cambio a terapia no factorial con emicizumab en la profilaxis de los episodios de sangrado en \nuna selecci\u00f3n de pacientes con Hemofilia A en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo donde se hace el seguimiento de los pacientes con terapia no sustitutiva desde su \ninicio hasta el momento.  \n \nSe inicia el tratamiento con una dosis de carga de 4 administraciones semanales de 3 mg/Kg v\u00eda subcut\u00e1nea, la mayor\u00eda 35de ellas administradas en consulta de coagulopat\u00edas para formaci\u00f3n en autoadministraci\u00f3n y seguimiento de posibles \nincidencias. Posteriormente se administran 4 dosis quincenales de 3 mg/Kg, seguidas de la dosis de mantenimiento de 6 \nmg/Kg mensual\ufffd  \nLos m\u00e9todos utilizados para medir la adherencia son:  \n1\ufffd Dispensaciones desde el servicio de farmacia: se citan en farmacia cada dos meses con una semana de antelaci\u00f3n \nal d\u00eda de la administraci\u00f3n, y se realizan un total de 6 dispensaciones al a\u00f1o para 12 administraciones (24 en la pauta \nquincenal).  \n2. Registro de administraciones: en los inicios, se entrega un diario de administraciones personalizado para cada paciente, \ny en \u00e9l se registra la administraci\u00f3n (d\u00eda, lugar del pinchazo, dosis, viales utilizados con lote y caducidad) adem\u00e1s de poner \nlas pegatinas de los viales con el c\u00f3digo de barras para una mejor trazabilidad.  \n3. Control de niveles en el estado estacionario: nivel valle del anticuerpo monoclonal en sangre.\nRESULTADOS\nDesde 2019 se han incorporado pacientes de forma paulatina, con un total de 17 pacientes en la actualidad: 16 tienen \npauta de mantenimiento mensual y s\u00f3lo uno quincenal.  \nDispensaciones desde farmacia: 100% en asistencias hasta el momento, sin incidencias excepto alg\u00fan cambio de hora y/o \nfecha, y las dispensaciones coinciden con las dosis a administrar. \nRegistro de administraciones: cada 6 meses se cita al paciente en la consulta de coagulopat\u00edas, y se solicita al paciente o \ncuidador que traiga el diario de control de administraciones, observ\u00e1ndose que el 100% de los pacientes tiene un registro \nexhaustivo de su tratamiento.  \nLos niveles valle de emicizumab en el estado estacionario se han obtenido dentro de rango seg\u00fan ficha t\u00e9cnica (20 \na 40 mcg/ml), con una media de 36,6 mcg/ml y un rango entre 21,3 - 46,7 mcg/ml. Ning\u00fan dato refiere falta de \nadministraci\u00f3n\ufffd\nCONCLUSIONES\nEl emicizumab es un anticuerpo monoclonal humanizado biespec\u00edfico usado como tratamiento en hemofilia A, y \nque seg\u00fan ficha t\u00e9cnica la dosis total se puede administrar de forma semanal, quincenal o cada 28 d\u00edas. Desde su \ncomercializaci\u00f3n, han existido reticencias a la administraci\u00f3n mensual, puesto que este perfil de paciente acostumbra \na administrarse el tratamiento factorial repetidas veces en semana, y por ello, la administraci\u00f3n mensual podr\u00eda \nllegar a generar una falsa seguridad, lo cual supone una preocupaci\u00f3n en cuanto a la adherencia. En nuestro caso, la \nadministraci\u00f3n mensual no ha generado ning\u00fan problema de adherencia, adem\u00e1s de ser efectivo y mejorar la calidad de \nvida de los pacientes\ufffd\nCLASIFICACI\u00d3N: ADHERENCIA\n523. ADHERENCIA A ANTINEOPL\u00c1SICOS ORALES EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO \nMICROC\u00cdTICO EN ESPA\u00d1A \u2013 ESTUDIO LOADH \nAUTORES\nMANGUES-BAFALLUY , I; BERN\u00c1RDEZ FERR\u00c1N, B; ARENAZA PE\u00d1A, A; NAVARRO RUIZ, A; MART\u00cdN CONDE, MT; RUBIO \nSALVADOR, AR; RIUS , J; GILABERT SOTOCA, M\nHOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA \ufffd AVDA \ufffd ALCALDE ROVIRA ROURE, 80 LLEIDA \ufffd LLEIDA\nOBJETIVOS\nEl objetivo de este estudio es medir la adherencia de los pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico locamente \navanzado o metast\u00e1sico (CPNM) tratados con inhibidores de tirosina quinasa (TKI), as\u00ed como evaluar la influencia de las \ncaracter\u00edsticas del paciente y su tratamiento sobre la misma, y detectar oportunidades de mejora de la intervenci\u00f3n \nfarmac\u00e9utica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo, multic\u00e9ntrico, en el que participaron 6 hospitales espa\u00f1oles. Se incluyeron pacientes \nadultos diagnosticados con CPNM tratados o que iniciaron tratamiento con TKI administrado de forma oral, prescrito por \nel onc\u00f3logo seg\u00fan la pr\u00e1ctica cl\u00ednica habitual.  \nLa informaci\u00f3n del paciente se recogi\u00f3 en la visita de selecci\u00f3n y en visitas mensuales durante tres meses consecutivos \nmediante atenci\u00f3n farmac\u00e9utica virtual o presencial, en las que se hizo tambi\u00e9n un recuento de comprimidos \ndispensados no utilizados. La variable principal fue el porcentaje de adherencia calculado como: (N unidades dispensadas \n- N unidades no utilizadas)/(N d\u00edas de tratamiento * N unidades prescritas cada d\u00eda)*100. Se consider\u00f3 como punto \nde corte de adherencia adecuada > 80%. Se utiliz\u00f3 el estad\u00edstico Chi-cuadrado para comparar la adherencia entre los \ndiferentes subgrupos. Se consider\u00f3 un nivel de significaci\u00f3n estad\u00edstica de p < 0,05.\nRESULTADOS\nSe han incluido 100 pacientes, entre diciembre-2019 y julio-2021. En 82 casos se dispuso de datos de adherencia en este \ncorte de datos preliminar de abril 2022. La edad media fue de 66 a\u00f1os (DE 13,2; 56,1% \u226465), 64,6% mujeres, 54,9% no \nfumadores, 91,5% con met\u00e1stasis y con 33,5 meses de tiempo medio desde el diagn\u00f3stico del CPNM. El 52,4% era na\u00efve \na TKI, el 45,1% recibi\u00f3 TKI-EGFR de 3\u00aa generaci\u00f3n, 23,2% TKI-EGFR de 1\u00aa-2\u00aa generaci\u00f3n, 29,3% TKI-ALK y 2,4% otro TKI. El \ntiempo medio desde el inicio del TKI fue de 14,3 (DE 19,8) meses y el 80,5% r ecibi\u00f3 tratamiento concomitante.  \nEl 67,1% de los pacientes present\u00f3 una adherencia > 80% (media del 80,6%). El porcentaje de pacientes con adherencia > \n80% fue significativamente mayor en los na\u00efve a TKI que los pretratados (81,4% vs 51,3%; p=0,004), con una adherencia \nmedia de 85,0% vs 75,8%\ufffd  36Otros subgrupos en los que el porcentaje de pacientes con adherencia > 80% fue mayor, aunque las diferencias no fueron \nestad\u00edsticamente significativas, fueron los pacientes con edad \u226465 a\u00f1os, (69,6% vs 63,9%), un diagn\u00f3stico m\u00e1s reciente en \nel tiempo (26,2 vs 48,4 meses) y que hab\u00edan recibido medicaci\u00f3n concomitante (65,2% vs 75,0%).  \nLas actividades de intervenci\u00f3n farmac\u00e9utica en la \u00faltima visita tuvieron un impacto significativo en la mejora de la \nadherencia adecuada de los pacientes (73,8% vs 42,9%; p=0,024). La informaci\u00f3n sobre la medicaci\u00f3n es la intervenci\u00f3n \nque parece influir m\u00e1s en la adherencia > 80% (77,8% vs 48,0), seguida de la intervenci\u00f3n de revisi\u00f3n (75,0% vs 62,8%), \nde adherencia (71,8% vs 65,0%) y de conciliaci\u00f3n (71,4% vs 67,2%).\nCONCLUSIONES\nAproximadamente 1/3 de pacientes con CPNM tratados con TKIs orales presentan una adherencia sub\u00f3ptima, \nespecialmente aquellos pacientes que ya han recibido m\u00e1s de una l\u00ednea de tratamiento. La intervenci\u00f3n farmac\u00e9utica \ninfluye en la mejor adherencia de los pacientes, siendo la informaci\u00f3n sobre la medicaci\u00f3n la intervenci\u00f3n que m\u00e1s \nimpacta\ufffd\nCLASIFICACI\u00d3N: ADHERENCIA\n524. COLIRIO DE ATROPINA AL 0,01%: GRADO DE ADHERENCIA AL TRATAMIENTO Y PERFIL DE SEGURIDAD \nEN PACIENTES CON MIOP\u00cdA INFANTIL \nAUTORES\nBARCIA MART\u00cdN, MI; AGUILAR GUISADO, C; S\u00c1NCHEZ SU\u00c1REZ, S; GARC\u00cdA GIMENO, MM\nHOSPITAL DE EL ESCORIAL. CTRA. GUADARRAMA-S. LORENZO DE EL ESCORIAL, KM. 6,2 SAN LORENZO DE EL \nESCORIAL \ufffd MADRID\nOBJETIVOS\nAnalizar el grado de adherencia al tratamiento y el perfil de seguridad en pacientes con miop\u00eda infantil tratados con colirio \nde atropina al 0,01%\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 todos los pacientes con miop\u00eda infantil tratados con colirio de atropina al \n0,01%, desde su incorporaci\u00f3n en el hospital en diciembre 2019 hasta marzo 2022 inclusive.  \nDe la historia cl\u00ednica electr\u00f3nica se recogieron las siguientes variables: fecha de nacimiento, sexo, fecha de inicio de \ntratamiento, fecha de suspensi\u00f3n y motivo si proced\u00eda, fecha de \u00faltima dispensaci\u00f3n y efectos adversos. Para evaluar \nel grado de adherencia al tratamiento se calcul\u00f3 el n\u00famero de envases te\u00f3ricos que se deber\u00edan haber dispensado por \npaciente y se compar\u00f3 con el n\u00famero real de colirios dispensados. Se elabor\u00f3 una base de datos con dichas variables y \nse analizaron los resultados con Excel\u00ae. Para las variables cuantitativas se calcul\u00f3 media/mediana y desviaci\u00f3n est\u00e1ndar/\nrango; las variables cualitativas se expresaron mediante frecuencias relativas y porcentuales. La seguridad se evalu\u00f3 \nmediante el perfil de efectos adversos.\nRESULTADOS\nDurante el periodo de estudio, iniciaron tratamiento 76 pacientes con una media de edad de 12,7 a\u00f1os (DE: 2,1); 52,6% \nni\u00f1as\ufffd  \nLa mediana de duraci\u00f3n en tratamiento con colirio de atropina fue de 8,9 meses (rango: 0,3-26,7). Actualmente, \ncontin\u00faan tratamiento el 65,8% (50/76). Del 34,2% (26/76) restante: 12 suspendieron tratamiento por falta de adherencia \nal mismo, 8 por falta de eficacia (cinco aumentaron dosis a 0,05%), 5 por toxicidad asociada (mayoritariamente irritaci\u00f3n \nocular y picor) y 1 por traslado a otro centro.  \nLa mediana global del grado de adherencia al tratamiento fue 98,3% (rango: 24-100). La mediana del grado de adherencia \ncalculada sin contar con 4 pacientes que solo recibieron un mes de tratamiento, para evitar sobreestimar el dato, fue \n97,9% (rango: 24-100). \nEn cuanto a seguridad, en el 10,5% (8/76) de los pacientes se registr\u00f3 al menos un efecto adverso: 6 pacientes \npresentaron irritaci\u00f3n ocular y picor (3 de los cuales suspendieron tratamiento), 1 paciente present\u00f3 irritaci\u00f3n ocular \ne inflamaci\u00f3n de p\u00e1rpados y 1 present\u00f3 mareos y cefalea (motivo de suspensi\u00f3n de tratamiento en los dos \u00faltimos \npacientes mencionados). Ninguno de los efectos registrados result\u00f3 grave. Estos efectos adversos remitieron tanto en los \ntres pacientes que continuaron con el tratamiento como en aquellos que lo suspendieron.\nCONCLUSIONES\nEl colirio de atropina al 0,01%, constituye una opci\u00f3n en el tratamiento para disminuir la progresi\u00f3n de la miop\u00eda infantil. \nPara conseguir el m\u00e1ximo beneficio de un medicamento, es fundamental conseguir una buena adherencia al tratamiento. \nDe acuerdo con los datos obtenidos, es un tratamiento bien tolerado, al que los pacientes presentan un alto grado de \nadherencia global. Dado el amplio rango observado en el porcentaje de adherencia, ser\u00eda importante realizar un an\u00e1lisis \nde subgrupos para poder detectar caracter\u00edsticas comunes entre los pacientes que presentan de manera individual menor \ngrado de adherencia al tratamiento.\nCLASIFICACI\u00d3N: ADHERENCIA\n578. ADHERENCIA AL TRATAMIENTO CON ANTINEOPL\u00c1SICOS POR V\u00cdA ORAL \nAUTORES\nTALENS BOLOS, A; BEJERANO MART\u00cdNEZ, M; LE\u00d3N MURCIANO, I; BERNABEU MARTINEZ, MA; RUIZ DE APODACA \nROSA, F; GARCIA MONSALVE, A; LOPEZ PINTOR, E; LUMBRERAS LACARRA, B\nHOSPITAL GENERAL DE ELDA-VIRGEN DE LA SALUD. CTRA. ELDA A SAX, S/N ELDA. ALICANTE37OBJETIVOS\nLos antineopl\u00e1sicos orales aportan comodidad, aumentando la calidad de vida de los pacientes con c\u00e1ncer, aunque \nla falta de adherencia conlleva importantes consecuencias cl\u00ednicas, sociales y econ\u00f3micas. El objetivo principal de \neste trabajo es evaluar la adherencia al tratamiento con antineopl\u00e1sicos orales mediante tres m\u00e9todos de medida de \nadherencia diferentes y describir las variables sociodemogr\u00e1ficas y cl\u00ednicas asociadas.\nMATERIALES Y M\u00c9TODOS\nEstudio transversal descriptivo realizado entre el 01/02/2021 y el 31/10/2021 en cuatro hospitales de la Comunidad \nValenciana. Se incluyeron pacientes en tratamiento con antineopl\u00e1sicos orales de los grupos L01 y L02 de la clasificaci\u00f3n \nATC que acud\u00edan a recoger la medicaci\u00f3n a las unidades de pacientes externos de los servicios de farmacia de los \nhospitales participantes y que aceptaron voluntariamente participar en el estudio. Se excluyeron aquellos pacientes que \nllevaban menos de 3 meses de tratamiento y/o con imposibilidad de contestar a las preguntas\ufffd Se recogieron variables \ncl\u00ednicas y sociodemogr\u00e1ficas y se estim\u00f3 la adherencia a trav\u00e9s de tres m\u00e9todos: 1) el cuestionario de Morisky-Green \n(MMAS-4), 2) el registro de dispensaciones de tratamiento, con la recogida o el env\u00edo de la medicaci\u00f3n, y 3) el recuento \nde comprimidos, clasificando a los pacientes cuyo recuento fuera > 90% como adherentes. El an\u00e1lisis estad\u00edstico del \nestudio se ha realizado mediante IBM SPSS v.21.\nRESULTADOS\nSe incluyeron 268 pacientes, 52,6% hombres y con una edad media de 64,1\u00b112,4 a\u00f1os. El 88,4% viv\u00edan con su familia, \nel 17,9% no ten\u00edan estudios, y el 56,7% se encontraban jubilados en el momento del estudio. El 60,8% de los pacientes \npertenec\u00eda al servicio de oncolog\u00eda y los diagn\u00f3sticos m\u00e1s comunes fueron leucemia (18,2%), c\u00e1ncer de mama o de \novario (18,2%) y mieloma m\u00faltiple (15,9%), en un 82,8% el objetivo era paliativo y en un 67,8% el primer tratamiento fue \noral. Seg\u00fan el cuestionario de Morisky-Green un 82,2% de los pacientes eran adherentes, un 95,2% seg\u00fan el registro de \ndispensaci\u00f3n y un 69,3% present\u00f3 un recuento de comprimidos > 90% por tanto, eran adherentes. Se observ\u00f3 que las \nmujeres ten\u00edan tendencia a ser m\u00e1s adherentes que los hombres (p=0,01).\nCONCLUSIONES\nEn general, los pacientes en tratamiento con antineopl\u00e1sicos orales son una poblaci\u00f3n con alta adherencia, donde las \ntasas oscilan, entre el 69% y el 95%, en funci\u00f3n del m\u00e9todo de medida empleado y el punto de corte establecido. Las \nmujeres parecen ser m\u00e1s adherentes que los hombres.  \nEs necesario estandarizar los puntos de corte y disponer de herramientas v\u00e1lidas y fiables para evaluar adherencia en esta \npoblaci\u00f3n que permita poder comparar entre distintos estudios. Con ello, establecer estrategias para mejorarla, optimizar \nlos resultados en salud y reducir costes sanitarios\ufffd\nCLASIFICACI\u00d3N: ADHERENCIA\n750. AN\u00c1LISIS Y SEGUIMIENTO DE LOS PACIENTES VIH NO ADHERENTES AL TRATAMIENTO \nANTIRRETROVIRAL EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nFERNANDEZ MARTINEZ, IM; GARC\u00cdA LAGUNAR, MH; GARC\u00cdA MATILLAS, CN; FERN\u00c1NDEZ VELA, J; TAMBOLEO \nS\u00c1NCHEZ, IJ; MIRA SIRVENT , MC\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nEstimar el grado de adherencia al tratamiento antirretroviral (TAR) de los pacientes infectados por el virus de la \ninmunodeficiencia humana (VIH) que hace un a\u00f1o presentaban una mala adherencia con el objetivo de conocer si la \nintervenci\u00f3n realizada desde entonces ha resultado en una mejora de esta.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que evalu\u00f3 la adherencia de los pacientes VIH que hace un a\u00f1o se hab\u00edan clasificado \ncomo malos adherentes en un hospital de tercer nivel, que supon\u00edan el 15% del total de pacientes VIH en tratamiento con \nTAR\ufffd \nLa adherencia se estim\u00f3 con el m\u00e9todo indirecto de la raz\u00f3n de posesi\u00f3n de medicaci\u00f3n (RPM) definida como el \nporcentaje de d\u00edas cubiertos con la medicaci\u00f3n dispensada respecto al total de d\u00edas con la medicaci\u00f3n prescrita x 100. Se \ndefini\u00f3 mala adherencia como RPM < 80%, una adherencia media como una RPM entre 80-95% y una buena adherencia \ncomo una RPM \u2265 95%.  \nSe llev\u00f3 a cabo un seguimiento estrecho de estos pacientes desde la Unidad de Pacientes Externos (UPE) del servicio de \nfarmacia de forma conjunta con el servicio de medicina infecciosa entre marzo de 2021 y abril de 2022 con citas m\u00e1s \nfrecuentes con el fin de mejorar su adherencia.  \nLos datos se obtuvieron del registro de dispensaci\u00f3n a pacientes externos del Servicio de Farmacia (Savac\u00ae) y de la \nhistoria cl\u00ednica electr\u00f3nica (Selene\u00ae). El an\u00e1lisis estad\u00edstico se realiz\u00f3 a trav\u00e9s del programa eSPSS v25.0\u00ae mostrando \nlas variables continuas, como media y desviaci\u00f3n est\u00e1ndar y las variables categ\u00f3ricas, como n\u00famero y frecuencia. \nSe estudiaron las diferencias en el a\u00f1o previo y posterior mediante la prueba estad\u00edstica de Wilcoxon para variables \nordinales\ufffd\nRESULTADOS\nSe realiz\u00f3 un seguimiento de un total de 94 pacientes (71,9% varones) con una edad media de 47,1\u00b111,3 a\u00f1os, \nclasificados como malos adherentes por presentar una RPM < 80% en el a\u00f1o previo.  38La adherencia media del total de los pacientes durante el periodo de seguimiento fue del 63,1\u00b133,3% observ\u00e1ndose un \ncambio estad\u00edsticamente significativo con respecto al a\u00f1o previo (p=0,002). Del total, el 48,9% de los pacientes (n=46) \nhab\u00edan mejorado su adherencia durante el periodo de estudio, presentando una media de RPM de 89,8\u00b110,9%: el 46,5% \nde estos pacientes se clasificaron como buenos adherentes (\u2265 95%); el 34,9% como adherentes medios (80-95%) y el \n18,6% como malos adherentes ( < 80%). Sin embargo, el 26,6% de los pacientes (n=25) hab\u00edan empeorado la RPM (media \nde 36,4\u00b119,2%) y en un 24,5% (n=23) no se observ\u00f3 cambios (media de la RPM de 32\u00b134,9%).\nCONCLUSIONES\nCerca de la mitad de los pacientes con una RPM < 80% en el a\u00f1o previo han mejorado su adherencia en el \u00faltimo a\u00f1o \ndebido al seguimiento e intervenci\u00f3n tanto por parte del servicio de medicina infecciosa en la consulta m\u00e9dica como \nen la UPE en la consulta de atenci\u00f3n farmac\u00e9utica haciendo hincapi\u00e9 en la importancia del cumplimiento del TAR en las \nrespuestas virol\u00f3gica e inmunol\u00f3gica\ufffd  \nSin embargo, es necesario buscar nuevas f\u00f3rmulas para mejorar la adherencia en la otra mitad de los pacientes que \ntodav\u00eda presentan una mala adherencia al TAR.\nCLASIFICACI\u00d3N: ADHERENCIA\n899. ANALISIS DE LA EXPERIENCIA DE USO DE SACUBITRILO/VALSART\u00c1N: EN BUSCA DE LA ADECUACI\u00d3N \nTERAP\u00c9UTICA \nAUTORES\nHERNANDO MART\u00cdNEZ, P; MERO\u00d1O SAURA, MA; FERN\u00c1NDEZ-BRAVO RODRIGO, J; SORIA MART\u00cdN, A; MART\u00cd GIL, C; \nMARCOS P\u00c9REZ, G; LAFARGA LAPIEZA, V; BARREDA HERN\u00c1NDEZ, D\nHOSPITAL GENERAL VIRGEN DE LA LUZ \ufffd HERMANDAD DONANTES DE SANGRE, 1 CUENCA \ufffd CUENCA\nOBJETIVOS\nEl objetivo de este estudio fue describir la experiencia de uso de sacubitrilo/valsart\u00e1n en pacientes con diagn\u00f3stico de \ninsuficiencia card\u00edaca cr\u00f3nica sintom\u00e1tica (ICC) y analizar la adecuaci\u00f3n de prescripci\u00f3n seg\u00fan los criterios establecidos en \nel Informe de Posicionamiento Terap\u00e9utico (IPT) de la AEMPS.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo en un hospital de nivel-II. Se incluyeron pacientes hospitalizados entre agosto\u201921-\nabril\u201922 con prescripciones de sacubitrilo/valsart\u00e1n en sus diferentes dosis 24/26mg, 49/51mg y 97/103mg. Los datos \nfueron recogidos desde el programa Farmatools\u00ae y la historia cl\u00ednica informatizada Mambrino XXI\u00ae.  \n \nEn cuanto a los pacientes se analizaron variables demogr\u00e1ficas (sexo, edad), indicaci\u00f3n, servicio prescriptor, primera \nprescripci\u00f3n, dosis inicial y titulaci\u00f3n de dosis. Para analizar la adecuaci\u00f3n al IPT se establecieron los siguientes criterios: \nfracci\u00f3n de eyecci\u00f3n del ventr\u00edculo izquierdo (FEVI) < 35%, p\u00e9ptido natriur\u00e9tico cerebral (NTproBNP > 400pg/ml) y si \nten\u00edan un mal control sintom\u00e1tico a pesar de estar en tratamiento con dosis estables de IECAs/ARA-II combinado con \nbeta-bloqueantes y antagonistas de la aldosterona. Para la determinaci\u00f3n de la seguridad del estudio de analizar\u00f3 la \naparici\u00f3n de efectos adversos y continuaci\u00f3n de tratamiento tras el alta hospitalaria se utilizaron para determinar la \nseguridad del estudio\ufffd\nRESULTADOS\nSe incluyeron 61 pacientes, de los cuales 44(72%) eran hombres, con una mediana de edad de 71 a\u00f1os (40-93). Los \nservicios prescriptores mayoritarios fueron Cardiolog\u00eda (55,7%)y Medicina Interna (32,8%).  \nEl 70,5% de los pacientes recibieron la dosis de 24/26mg, siendo 53% primeras prescripciones\ufffd El 23% recibieron la dosis \nde 49/51mg siendo en su mayor\u00eda continuaciones, salvo 2(14,3%) prescripciones de inicio. La titulaci\u00f3n de la dosis se \nrealiz\u00f3 en 32,8% de los pacientes, de los cuales, el 25% alcanz\u00f3 dosis objetivo de 97/103mg. \nEl criterio de FEVI < 35% se cumpli\u00f3 en el 70,5% de pacientes, frente a 24,6% con FEVI > 35% y en 4,9% pacientes no \nestaba filiada. La determinaci\u00f3n de NTproBNP > 400pg/ml se cumpli\u00f3 en un 90,2%, en 4,9% no hab\u00eda sido analizada. El \n85,2% hab\u00edan sido tratados previamente con IECA/ARA-II combinado con beta-bloqueantes, frente a 14,8% de pacientes \nnaive\ufffd  \nEn 15(24,6%) pacientes se observ\u00f3 la aparici\u00f3n de reacciones adversas, principalmente mareo, hipotensi\u00f3n e \nhiperpotasemia, de los cuales 10(67%) suspendieron el tratamiento. Del balance global, 15(24,6%) suspendieron el \ntratamiento y en 9,8% pacientes se redujo la dosis.\nCONCLUSIONES\nSe observ\u00f3 una adecuaci\u00f3n al IPT en todos los aspectos mencionados en, al menos, un 70% de los pacientes, con un \nmenor cumplimiento en la FEVI\ufffd  \nDestac\u00f3 el uso continuado de las dosis m\u00e1s bajas, a pesar de que, en ficha t\u00e9cnica se indica \u00fanicamente como tratamiento \nde inicio, pudiendo relacionarse en parte, a la incidencia de efectos adversos. Menos de la d\u00e9cima parte del total toler\u00f3 la \ntitulaci\u00f3n de dosis hasta alcanzar la dosis objetivo.  \nLa validaci\u00f3n farmac\u00e9utica tiene una labor fundamental en el refuerzo del cumplimiento del IPT por parte de los \nprescriptores, necesario para lograr una mayor eficiencia en el uso de este f\u00e1rmaco, as\u00ed como realizar estudios de \nefectividad, seguridad y adherencia a largo plazo, para evidenciar el papel de sacubitrilo/valsart\u00e1n en el tratamiento de la \nICC\ufffd39CLASIFICACI\u00d3N: ADHERENCIA\n953. ESTUDIO DE ADHERENCIA EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA MEDIANTE LA ESCALA VISUAL \nANAL\u00d3GICA DE ADHERENCIA Y LA CALCULADORA ADHECUAR\u00ae \nAUTORES\nTOUR\u00cdS LORES, M; CASTRO BALADO, A; GARC\u00cdA QUINTANILLA, L; VARELA REY , I; L\u00d3PEZ MONTERO, E; SOTO BASELGA, \nI; BERN\u00c1RDEZ FERR\u00c1N, B; ZARRA FERRO, I\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE SANTIAGO. CHOUPANA, S/N SANTIAGO DE COMPOSTELA. A CORU\u00d1A\nOBJETIVOS\nLa adherencia a los tratamientos es un elemento fundamental en la consecuci\u00f3n de los objetivos terap\u00e9uticos, siendo \nel factor modificable que m\u00e1s impacta en la obtenci\u00f3n de los mismos, con una especial importancia en los tratamientos \noncol\u00f3gicos. El objetivo de este estudio es analizar la adherencia a los tratamientos orales en pacientes con c\u00e1ncer de \npr\u00f3stata y a tratamiento con los nuevos agentes dirigidos al receptor de andr\u00f3genos (ARTA).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, de corte transversal, de medici\u00f3n de la adherencia mediante doble m\u00e9todo: Escala Visual \nAnal\u00f3gica de adherencia (EVA) y calculadora de adherencia ADHeCuaR\u00ae. La herramienta ADHeCUAR es una hoja excel \nque permite calcular el porcentaje de adherencia teniendo en cuenta la cantidad de f\u00e1rmaco dispensada entre fechas, \nel n\u00famero de comprimidos sobrantes y la pauta posol\u00f3gica. En caso de un resultado menor al 90%, permite orientar las \ncausas de no adherencia. Durante el mes de abril 2022 se entrevist\u00f3 a pacientes diagnosticados de c\u00e1ncer de pr\u00f3stata a \ntratamiento con abiraterona (AA), enzalutamida (ENZ), apalutamida (APA) o darolutamida (DAR), y a seguimiento desde \nla consulta de farmacia oncol\u00f3gica\ufffd Se entreg\u00f3 a los pacientes un impreso con la escala EVA graduada de 0 a 100, dividida \nen intervalos de 10, y acompa\u00f1ada de una frase de normalizaci\u00f3n de la falta de adherencia.  \nLos datos de dispensaciones realizadas se obtuvieron del programa de prescripci\u00f3n electr\u00f3nica (Silicon\u00ae) y los par\u00e1metros \ndemogr\u00e1ficos, as\u00ed como el subtipo patol\u00f3gico: resistente a la castraci\u00f3n (CPCR), hormonosensible (PCHSm) o no \nmetast\u00e1sico (CPCCM0), de la historia electr\u00f3nica (IANUS). Para el an\u00e1lisis de datos se utiliz\u00f3 el paquete estad\u00edstico SPSS-\nStatistics V.26 (IBM Inc., Armonk, NY , USA).\nRESULTADOS\nSe entrevistaron 45 pacientes con una media de edad de 74 a\u00f1os (rango: 47-91). Fueron tratados con AA 14 pacientes \n(31,8 %), con ENZ 19 (43,2 %), con APA 7 (15,9 %) y con DAR 4 (9,1 %). El 40,9 % eran pacientes CPRCm, el 47,7 % CPHSm \ny el 11,4 % CPRCM0\ufffd La media de duraci\u00f3n de tratamiento con AA, ENZ, APA y DAR fue de 688,1, 607,2, 218,6 y 278,5 \nd\u00edas, respectivamente. La mediana global de adherencia obtenida seg\u00fan la EVA fue de 100 \u00b1 1,5 % (90-100), mientras que \nla obtenida mediante la herramienta ADHeCuaR\u00ae fue de 100 \u00b1 4,48 (90-107). Las medianas de adherencia por f\u00e1rmacos \nseg\u00fan EVA fueron del 100% para AA, ENZ, DAR y APA. Seg\u00fan la herramienta ADHeCuaR\u00ae, las medianas de adherencia \nfueron de 100% para AA, ENZ y APA y del 96,5% para DAR \ufffd\nCONCLUSIONES\nLos resultados de adherencia obtenidos en nuestra cohorte de pacientes son muy elevados, a pesar de la elevada edad \nde nuestros pacientes y la complejidad de los tratamientos pautados. El seguimiento estrecho de los pacientes con este \ntipo de mediciones, as\u00ed como las dispensaciones mensuales de medicaci\u00f3n y una consulta monogr\u00e1fica de pacientes con \nc\u00e1ncer de pr\u00f3stata, permiten contribuir a estos resultados.\nCLASIFICACI\u00d3N: ADHERENCIA\n1043. IMPACTO DE LA COVID-19 EN LA ADHERENCIA AL TRATAMIENTO DE LA HIPERTENSI\u00d3N PULMONAR \nAUTORES\nRODR\u00cdGUEZ RAMALLO, H; RODR\u00cdGUEZ DE FRANCISCO, L; FERN\u00c1NDEZ GONZ\u00c1LEZ, M; SU\u00c1REZ CASILLAS, P; LORA \nESCOBAR, SJ; SANTOS RAMOS, B\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nNo se dispone de estudios del impacto de la pandemia por COVID-19 en la adherencia de los pacientes de hipertensi\u00f3n \npulmonar (HP), los objetivos del presente estudio son:  \n(1) Estimar la adherencia al tratamiento con vasodilatadores pulmonares de una cohorte de pacientes de HP .  \n(2) Estimar el posible impacto negativo de la pandemia por COVID-19 en la adherencia.  \n(3) Comparar nuestros resultados de adherencia con la bibliograf\u00eda disponible.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de una cohorte de pacientes tratados en un hospital de tercer nivel. Se incluyeron a \npacientes adultos diagnosticados de HP con dispensaciones de vasodilatadores pulmonares en el servicio de farmacia en \nlos dos periodos de estudio: marzo 2019-2020 (pre-pandemia) y marzo 2020-2021. \nLos f\u00e1rmacos considerados fueron sildenafilo, riociguat, bosentan, ambrisentan e iloprost. El resto de vasodilatadores \npulmonares fueron excluidos del an\u00e1lisis por el bajo n\u00ba de pacientes en tratamiento. Adem\u00e1s de la recogida de variables \ndemogr\u00e1ficas y cl\u00ednicas, se estim\u00f3 la adherencia al tratamiento mediante:  \n\u25cf Porcentaje de dosis cubiertas por dispensaciones, definido como: \n(n\u00ba de unidades dispensadas X 100)/(n\u00ba te\u00f3rico de unidades necesarias para la administraci\u00f3n de la posolog\u00eda prescrita \nen el periodo fijado).  40\u25cf Dos personas de forma independiente identificaron anomal\u00edas en la adherencia estimada, confirmando los casos de \nadherencias extremas mediante la consulta de la historia cl\u00ednica.  \nSe compar\u00f3 la adherencia estimada entre los dos periodos. Se consider\u00f3 que el cambio fue significativo si superaba \nel 10%. Los datos se recogieron de la historia cl\u00ednica y farmacoterap\u00e9utica (Diraya\u00ae) y del m\u00f3dulo de dispensaci\u00f3n \nindividualizada (Athos Prisma\u00ae).\nRESULTADOS\nSe incluyeron a 109 pacientes, 71,6 % eran mujeres, edad media de 61,0 (\u00b117,5) a\u00f1os. Los pacientes eran atendidos en las \nunidades de Cardiolog\u00eda (33,9%), Medicina Interna (33,9%), Neumolog\u00eda (30,3%) y otros (1.8%).  \nLos pacientes, de acuerdo con la clasificaci\u00f3n cl\u00ednica de la HP [Simonneau G, et al. 2017] se clasifican como: tipo I (52,3%), \ntipo II (23,9%), tipo III (2,8%), tipo IV (13,8%) y un (5,5%) sin e tiolog\u00eda conocida.  \nLa media de adherencia estimada:  \n\u25cf En el periodo previo a la pandemia fue 97,5% (\u00b17,8), 96,1% (\u00b15,6), 95,8% (\u00b17,1), 94,4% (\u00b113,2) y 93,1% (\u00b19,1).  \n\u25cf En el periodo posterior a la pandemia fue 95,1% (\u00b18,6), 97,2% (\u00b14,9), 95,5% (\u00b19,8), 97,2% (\u00b17,9) y 94,7% (\u00b17,9).  \nPara sildenafilo (n=86), bosentan (n=35), Ambrisentan (n=19), riociguat (n=9) e iloprost (n=4) respectivamente.  \nSe encontraron cambios significativos en la adherencia estimada tras la pandemia por COVID-19 en un 14,7% de los \npacientes, con un aumento de la adherencia en el 9,2% y una disminuci\u00f3n en el 5,5% restante.\nCONCLUSIONES\nEn la cohorte estudiada, la adherencia estimada mediante el n\u00famero de unidades dispensadas fue muy alta. En el an\u00e1lisis \ndescriptivo de las medias, no se observ\u00f3 una disminuci\u00f3n significativa en la adherencia tras la pandemia por COVID-19.  \nEn comparaci\u00f3n con estudios previamente publicados, nuestros pacientes registraron una adherencia muy alta [Ivarsson \nB, et al. 2018, Kjellstr\u00f6m B, et al. 2020].\nCLASIFICACI\u00d3N: ADHERENCIA\n1113. P\u00c9RDIDA DE ADHERENCIA A UN ANTICUERPO MONOCLONAL INHIBIDOR DE PCSK9 (PROPROTE\u00cdNA \nCONVERTASA SUBTILISINA/KEXINA TIPO 9) Y AL TRATAMIENTO HIPOLIPEMIANTE CONCOMITANTE. \nAUTORES\nFLORIDO FRANCISCO, M; S\u00c1NCHEZ G\u00d3MEZ, E; BLANCO ESPESO, T; RODR\u00cdGUEZ JORGE, M\nHOSPITAL GENERAL JUAN RAM\u00d3N JIMENEZ. RONDA NORTE, S/N HUELVA. HUELVA\nOBJETIVOS\nDescribir el grado de adherencia a los tratamientos hipolipemiantes (anticuerpos monoclonales inhibidores de \nPCSK9[IPCSK9] y estatinas), adem\u00e1s de las principales variables relacionadas con la situaci\u00f3n cl\u00ednica en pacientes con \nhipercolesterolemia familiar heterocigota o enfermedad cardiovascular establecida.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, realizado en un hospital de primer nivel, donde se incluyeron a pacientes que \nhab\u00edan iniciado tratamiento con un IPCSK9 desde Mayo del 2019 a Marzo de 2021. Se recogieron las siguientes variables: \nedad, diagn\u00f3stico principal, acontecimientos vasculares mayores(muerte cardiovascular, infarto de miocardio y ictus), \ntipo de prevenci\u00f3n, n\u00famero de medicamentos en receta electr\u00f3nica, polimedicaci\u00f3n(\u22656 medicamentos), n\u00famero \nde patolog\u00edas concomitantes, concentraci\u00f3n LDL(C-LDL), cumplimiento del objetivo terap\u00e9utico (C-LDL seg\u00fan riesgo \ncardiovascular), indicaci\u00f3n de IPCSK9 (intolerancia a estatinas o mal control de C-LDL[C-LDL superior a 100 mg/dl con \nla dosis m\u00e1xima tolerada de estatinas]) y si hab\u00eda sido rechazado previamente el tratamiento con IPCSK9 por baja \nadherencia a estatinas. Posteriormente se cuantific\u00f3 la adherencia a ambos tratamientos a trav\u00e9s de los registros de \ndispensaci\u00f3n, consider\u00e1ndose como no adherentes aquellos con un porcentaje menor del 85% del cociente: d\u00edas con \nmedicaci\u00f3n retirada/d\u00edas totales. Finalmente se clasific\u00f3 a los no adherentes seg\u00fan el tipo de incumplimiento terap\u00e9utico: \nparcial, espor\u00e1dico, secuencial o completo. Los datos se recogieron a trav\u00e9s de la historia cl\u00ednica, ATHOS-PRISMA 2.0, \nreceta XXI de DIRAYA y fueron procesados mediante Excel 2019\u00ae\ufffd\nRESULTADOS\nSe identificaron a 31 pacientes, mediana de edad 61 a\u00f1os (Rango intercuart\u00edlico [RIQ]=65,5-53). Los diagn\u00f3sticos \nprincipales fueron: 25(80,6%) enfermedad cardiovascular establecida y 6(19,4%) hipercolesterolemia familiar \nheterocigota. Durante el estudio 2(6,5%) pacientes presentaron acontecimientos vasculares mayores, de los cuales uno \nera adherente a ambas terapias y el otro no adherente al IPKCS9. El tipo de prevenci\u00f3n m\u00e1s com\u00fan fue la secundaria \npresentada en 26(83,9%) de los pacientes. La mediana de medicamentos en receta electr\u00f3nica fue 8 ([RIQ]=12-5,5) y \nhubo 23(74,2%) pacientes polimedicados. La mediana de patolog\u00edas concomitantes fue 4 ([RIQ]=5-3,5). La mediana \nde C-LDL fue 84 mg/dl ([RIQ]=98 mg/dl-61mg/dl). No se alcanz\u00f3 el objetivo terap\u00e9utico en 20(64,5%) pacientes. La \nindicaci\u00f3n fue en 13(41,9%) pacientes por intolerancia a estatinas y en 18(58,1%) por mal control de C-LDL, de los cuales \nninguno hab\u00eda sido rechazado previamente a iniciar IPKCS9 por adherencia insuficiente a estatinas. De todos los pacientes \nen tratamiento con estatinas(n=18) fueron adherentes 16(88,9%) y con IPKCS(n=31) fueron adherentes 25(80,6%), \nninguno de ellos fue no adherente a ambas terapias simult\u00e1neamente. En la cohorte de pacientes no adherentes(n=8) a \nalguno de los dos tratamientos, 3(37,5%) presentaron incumplimiento espor\u00e1dico, 2(25%) parcial y 3(37,5%) completo, \nadem\u00e1s 7(87,5%) estaban polimedicados y ten\u00edan 4 o m\u00e1s patolog\u00edas concomitantes.41CONCLUSIONES\nSe ha observado buena adherencia a ambas terapias, siendo la estatina el f\u00e1rmaco que mostr\u00f3 mayor grado de \nadherencia. La p\u00e9rdida de adherencia est\u00e1 \u00edntimamente relacionada con un mayor n\u00famero de medicamentos prescritos y \nmayor n\u00famero de patolog\u00edas concomitantes. Adem\u00e1s en un alto porcentaje de pacientes a pesar de la buena adherencia \na ambos tratamientos no se consigue el objetivo terap\u00e9utico.\nCLASIFICACI\u00d3N: ADHERENCIA\n1266. ACTIVACI\u00d3N DEL PACIENTE ONCOL\u00d3GICO Y ADHERENCIA TERAP\u00c9UTICA A ANTINEOPL\u00c1SICOS \nORALES \nAUTORES\nPOLO DUR\u00c1N, J; BRAVO CRESPO, C; S\u00c1EZ BELL\u00d3, M; RICOY SANZ, I; MARINEZ ALBALADEJO, P; S\u00c1NCHEZ GONZ\u00c1LEZ, \nJL; HERMENEGILDO CAUDEVILLA, M; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEvaluar la activaci\u00f3n del paciente oncol\u00f3gico en tratamiento con antineopl\u00e1sicos orales (AOs) y su relaci\u00f3n con la \nadherencia terap\u00e9utica. Analizar la influencia de factores demogr\u00e1ficos, cl\u00ednicos y farmacoterap\u00e9uticos en ambas \nvariables\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional transversal realizado en un hospital terciario (abril 2021 \u2013 abril 2022). Se incluyeron pacientes \noncol\u00f3gicos en tratamiento con AOs al menos durante tres meses previos, atendidos en la Unidad de Atenci\u00f3n \nFarmac\u00e9utica a Pacientes Externos del Servicio de Farmacia. Los pacientes firmaron un consentimiento escrito para \nparticipar en el estudio.  \nLa activaci\u00f3n del paciente para autogestionar su salud se midi\u00f3 mediante el cuestionario PAM-13 (pacientes activados si \npuntuaci\u00f3n \u226555,2 y no activados \u226455,1). Se consideraron adherentes aquellos pacientes adherentes seg\u00fan el cuestionario \nMorisky-Green y con una tasa de posesi\u00f3n de la medicaci\u00f3n a 12 meses \u226580%.  \nA partir de los cuestionarios, se recogieron variables demogr\u00e1ficas: sexo, edad (categorizando como anciano/a si \u226575 \na\u00f1os), nivel educativo (sin estudios, estudios primarios, secundarios o universitarios), situaci\u00f3n laboral (empleado activo, \nbaja, desempleado, jubilado, otros), domicilio (urbano, rural). Consultando la historia cl\u00ednica, se obtuvieron variables \ncl\u00ednicas: diagn\u00f3stico, estado funcional (escala ECOG -Eastern Cooperative Oncology Group-), pluripatolog\u00eda (2 o m\u00e1s \nenfermedades cr\u00f3nicas, excluyendo hipertensi\u00f3n, dislipemia, hiperuricemia e hipotiroidismo tratados y controlados), \ningreso hospitalario o episodio de urgencias (\u00faltimos 3 meses), respuesta cl\u00ednica actual (seg\u00fan criterios RECIST), l\u00ednea \nde tratamiento; y variables farmacoterap\u00e9uticas: f\u00e1rmaco, tiempo de tratamiento, n\u00famero de comprimidos/c\u00e1psulas al \nd\u00eda, intervalo posol\u00f3gico, pauta posol\u00f3gica discontinua, 2 o m\u00e1s antineopl\u00e1sicos orales concomitantes, polimedicaci\u00f3n \n(6 o m\u00e1s medicamentos concomitantes), cambio o inicio de tratamiento (\u00faltimos 3 meses), toxicidad grado \u2265 2 ( \u00faltimos \n3 meses, seg\u00fan criterios CTCAE -Common Terminology Criteria for Adverse Events-), ajuste de dosis o atraso de ciclo \n(\u00faltimos 3 meses).  \nAn\u00e1lisis estad\u00edstico mediante el programa R (versi\u00f3n 4.0.4.): variables cuantitativas (media, Intervalo de Confianza -IC- \n95%), categ\u00f3ricas (frecuencia, %), significaci\u00f3n p < 0,050. Las variables categ\u00f3ricas se compararon mediante Chi-cuadrado \n(correcci\u00f3n de Yates si frecuencias esperadas < 5). Se compararon variables continuas entre los diferentes grupos de las \nvariables categ\u00f3ricas dicot\u00f3micas (activaci\u00f3n, adherencia) mediante la prueba t de Student de variables independientes.\nRESULTADOS\nSe incluyeron 70 pacientes, 67% mujeres, con una media de 66 a\u00f1os, IC95% (63-69). Un 74% de los pacientes se \nconsideraron adherentes y el 70% activados. Un 84% de los pacientes activados presentaba una adecuada adherencia frente \nal 52% de los pacientes no activados (p=0,006). Se identific\u00f3 una menor adherencia en pacientes ancianos \u226575 a\u00f1os (54% \nversus 85%, p=0,005). Los pacientes que recib\u00edan una segunda l\u00ednea de tratamiento o posteriores fueron menos adherentes \nque los que se encontraban en primera l\u00ednea (60% versus 85%, p=0,018). La activaci\u00f3n del paciente fue menor en aquellos \ncon toxicidades grado \u22652, los cuales requirieron ajuste de dosis o retrasos de ciclo (42% versus 76%, p=0,018).\nCONCLUSIONES\nLos pacientes oncol\u00f3gicos activados son significativamente m\u00e1s adherentes al tratamiento con AOs que los menos \nactivados. Aquellos pacientes ancianos y que han recibido al menos una l\u00ednea previa de tratamiento tienen mayor riesgo \nde presentar una inadecuada adherencia terap\u00e9utica. Los pacientes que han sufrido toxicidades moderadas-graves \npueden estar menos activados.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n99. TERAPIAS INMUNOMODULADORAS Y VACUNACI\u00d3N COVID-19 \nAUTORES\nF\u00d3RNEAS SANGIL, A; APARICIO CARRE\u00d1O, C; FUERTES CAMPORRO, S; G\u00c1NDARA ANDE, A; PAMP\u00cdN S\u00c1NCHEZ, R; \nFERN\u00c1NDEZ GONZ\u00c1LEZ, A; FERN\u00c1NDEZ GONZ\u00c1LEZ, B; AYASTUY RUIZ, A\nHOSPITAL DE CABUE\u00d1ES. LOS PRADOS, 395 GIJ\u00d3N. ASTURIAS42OBJETIVOS\nEvaluar las intervenciones farmac\u00e9uticas realizadas sobre las terapias inmunomoduladoras de Hospital de D\u00eda (HD) \npotencialmente inapropiadas de acuerdo a los posicionamientos de las Sociedades Cient\u00edficas en t\u00e9rminos de vacunaci\u00f3n \nfrente a la COVID-19.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo en el que se incluyeron todos los pacientes ambulatorios que acudieron al HD para la administraci\u00f3n \nde tratamiento inmunomodulador en un hospital de tercer nivel entre enero del 2021 y enero de 2022.  \nPrevia elaboraci\u00f3n de los tratamientos se revisaron los siguientes datos mediante el aplicativo inform\u00e1tico del hospital: \nedad, g\u00e9nero, servicio prescriptor, tratamiento inmunomodulador y fecha de administraci\u00f3n, pauta y fecha de vacunaci\u00f3n \nfrente a la COVID-19 y repercusi\u00f3n de la intervenci\u00f3n (aplazamiento del f\u00e1rmaco o de la vacuna).  \nLas intervenciones se hicieron teniendo en cuenta las recomendaciones de los posicionamientos de las Sociedades \nCient\u00edficas correspondientes. Previo acuerdo con los m\u00e9dicos, se contempl\u00f3 el retraso temporal del f\u00e1rmaco o de \nla vacuna con el fin de optimizar la eficacia de la vacunaci\u00f3n, si la situaci\u00f3n cl\u00ednica del paciente lo permitiese. Las \nintervenciones se realizaron de manera telef\u00f3nica contactando con el m\u00e9dico prescriptor y con el personal de enfermer\u00eda \nde HD registr\u00e1ndose en la historia cl\u00ednica del paciente.  \nPosteriormente se hizo un seguimiento de los pacientes observando si desarrollaron infecci\u00f3n por COVID-19 en los tres \nmeses siguientes\ufffd\nRESULTADOS\nSe realizaron 19 intervenciones en 19 pacientes de un total de 742 que acudieron a administrarse el tratamiento al \nHD (2,6%). Los pacientes presentaban una mediana de edad de 67 a\u00f1os (18-77), siendo el 63,1% hombres y el 36,9% \nmujeres.  \nLos tratamientos que coincidieron con la vacunaci\u00f3n frente a COVID-19 fueron infliximab (47,2%), abatacept (21%), \nrituximab (10,6%), adalimumab (5,3%), natalizumab (5,3%), mepolizumab (5,3%) e inmunoglobulina humana (5,3%). \nEl 47,5% de las intervenciones fueron realizadas al Servicio de Digestivo, 36,8% al Servicio de Reumatolog\u00eda, 10,5% al \nServicio de Neurolog\u00eda y 5,2% al Servicio de Neumolog\u00eda.  \nEl 100% de las intervenciones fueron aceptadas, resultando en un 73,7% de los casos en el aplazamiento de la \nadministraci\u00f3n del f\u00e1rmaco y en el 26,3% en el aplazamiento de la vacuna.  \nEl 89,5% de los pacientes no desarrollaron infecci\u00f3n por COVID-19 en los tres meses siguientes a la intervenci\u00f3n. En el \n10,5% que desarrollaron la infecci\u00f3n, fue de car\u00e1cter leve.\nCONCLUSIONES\nLa colaboraci\u00f3n multidisciplinar entre el equipo farmac\u00e9utico, m\u00e9dico y de enfermer\u00eda consigui\u00f3 dar una atenci\u00f3n de \ncalidad al paciente, optimizando la eficacia de la vacunaci\u00f3n frente a la COVID-19.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n120. BENEFICIO CL\u00cdNICO PERCIBIDO POR LOS PACIENTES EN LA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA \nONCOL\u00d3GICA \nAUTORES\nALONSO CASTA\u00d1\u00c9, MD; FERN\u00c1NDEZ CA\u00d1ABATE, S; CORRAL ALAEJOS, A; JIMENEZ CASAUS, J; GODA MONTIJANO, G; \nROLDAN GONZALEZ, JS; GIL NAVARRO, I; GIL VALI\u00d1O, C\nCOMPLEJO ASISTENCIAL DE ZAMORA. AVDA. REQUEJO, 35 ZAMORA. ZAMORA\nOBJETIVOS\nNuestro objetivo fue medir la calidad de vida/beneficio cl\u00ednico de los pacientes oncol\u00f3gicos a trav\u00e9s del cuestionario \nvalidado \u201cEuropean organization for research and treatment of cancer quality life questionnaire core 30\u201d EORTC QLQ-C30 \ny hacer una comparaci\u00f3n entre los distintos tumores.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y transversal. Se aplic\u00f3 el EORTC QLQ-C30 a todos los pacientes oncol\u00f3gicos con tratamiento \ncitost\u00e1tico oral con los siguientes tumores: mama, colon-rectal, pr\u00f3stata, g\u00e1strico, ovario y pulm\u00f3n. El cuestionario \nconsta de 30 \u00edtems que refleja la dimensionalidad m\u00faltiple de la calidad de vida. Lleva incorporadas cinco subescalas \nfuncionales (f\u00edsica, laboral, cognitiva, emocional y social), tres subescalas sintom\u00e1ticas (fatiga, dolor, nauseas y v\u00f3mitos) \ny la subescala de calidad de vida global (que recoge la salud y la calidad de vida). Los restantes \u00edtems eval\u00faan de forma \nindividual s\u00edntomas adicionales (disnea, p\u00e9rdida de apetito, trastornos de sue\u00f1o, estre\u00f1imiento y diarrea), as\u00ed como el \nimpacto econ\u00f3mico observado que se deriva de la enfermedad y su tratamiento. Para la interpretaci\u00f3n de los resultados, \nlas puntuaciones de los cuestionarios se transformaron en una puntuaci\u00f3n en escala de 0-100, siendo 100 un estado \n\u00f3ptimo tanto en la escala global como funcional. En la escala de s\u00edntomas, un valor de 100 corresponder\u00eda a una mayor \nsintomatolog\u00eda. Para el an\u00e1lisis estad\u00edstico se utiliz\u00f3 el programa Jamovi\u00ae.\nRESULTADOS\n73 pacientes contestaron an\u00f3nimamente al cuestionario. La media de edad fue de 71,5 a\u00f1os (Standard deviation (SD) \n11,5); 77,1 (SD 20,3) escala f\u00edsica; 74,4 (SD 29) actividad/laboral; 77,7 (SD 22,2) emocional; 82,6 (SD 24,6) cognitiva; \n74,7 (SD 29,3) social, con una media global funcional de 77,3 (SD 20,1). Escala sintom\u00e1tica: 40 (SD 28) fatiga; 9,37 (SD \n18) nauseas/v\u00f3mitos; 26,7 (SD 26,6) dolor; 19,2 (SD 25,4) disnea; 33,3 (SD 30,4) insomnio; 20,1 (SD 28,2) p\u00e9rdida de \napetito; 22,8 (SD 29,3) estre\u00f1imiento; 15,5 (SD 26,7) dificultades econ\u00f3micas, con una media global sintom\u00e1tica 22,7 (SD 4315,9). Estado de salud general: 57,2 (SD 22,1). Los pacientes que presentaron una mayor calidad de vida fueron pr\u00f3stata \n(66,6) seguido de g\u00e1strico (64,8); colonrectal (59,5); ovario (50); mama (48,1) y pulm\u00f3n (47,8). Los pacientes con mayor \nsintomatolog\u00eda fueron los de ovario (50,9) seguidos de los de pulm\u00f3n (31,4); colonrectal (23); mama (21,8); g\u00e1strico \n(14,6) y pr\u00f3stata (13,9). Se encontraron diferencias estad\u00edsticamente significativas en la escala funcional (p=0.029) y \nsintom\u00e1tica (0.003) entre los pacientes de pulm\u00f3n y pr\u00f3stata no as\u00ed en la calidad de vida (p=0.052).\nCONCLUSIONES\nEn general todos los pacientes en tratamiento con citost\u00e1ticos orales presentan una calidad de vida por encima \nde la media, con excelente escala funcional y muy poca sintomatolog\u00eda. Los PROs (Resultados Reportados por los \nPacientes) constituyen un componente esencial de la atenci\u00f3n oncol\u00f3gica de calidad y centrada en el paciente. Por ello \nconsideramos un aspecto fundamental su implantaci\u00f3n en las consultas de atenci\u00f3n farmac\u00e9utica y su integraci\u00f3n en la \nhistoria cl\u00ednica electr\u00f3nica como una nueva forma de complementar la eficacia y seguridad de los f\u00e1rmacos.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n221. USO DEL MEPOLIZUMAB EN EL TRATAMIENTO DEL ASMA EOSINOF\u00cdLICA GRAVE. EFECTIVIDAD Y \nSEGURIDAD. \nAUTORES\nD\u00cdAZ-CALDER\u00d3N HORCADA, CI; NAVARRO AZNAREZ, H; PE\u00d1AS FERN\u00c1NDEZ, A; HERRANZ BAYO, E; AGUIL\u00d3 LAFARGA, \nI; PERALES PASCUAL, J; L\u00d3PEZ P\u00c9REZ, A; ABAD BA\u00d1UELOS, B\nHOSPITAL UNIVERSITARIO MIGUEL SERVET . P\u00ba DE ISABEL LA CAT\u00d3LICA, 1-3 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nEl objetivo principal del estudio es evaluar la adecuaci\u00f3n del uso del mepolizumab conforme a las condiciones de uso \nestablecidas por la Comisi\u00f3n de Uso Racional del Medicamento de la comunidad (CURMP) acordes con las del SNS.  \nComo objetivos secundarios, evaluar la efectividad y seguridad en condiciones habituales de la pr\u00e1ctica cl\u00ednica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, unic\u00e9ntrico de pacientes > 12 a\u00f1os tratados al menos 6 meses con mepolizumab \nentre Junio del 2017 y Abril del 2022 diagnosticados de Asma Eosinof\u00edlica Refractaria Grave. Los criterios de autorizaci\u00f3n \nestablecidas por la CURMP son: recuento eosin\u00f3filos en sangre \u2265500 c\u00e9l/\u03bcL, siendo \u2265300c\u00e9l/\u03bcL para aquellos que hayan \nrecibido corticoides sist\u00e9micos en los 3 meses previos. Hayan tenido \u22654 exacerbaciones en los 12 meses previos con \nuso de corticoides o requerido corticoides orales (OCS) equivalentes a 5 mg de prednisona en los 6 meses previos. Las \nvariables recopiladas en el momento del inicio del tratamiento a trav\u00e9s de la Historia Cl\u00ednica Electr\u00f3nica (HCE) fueron: n\u00ba \nde exacerbaciones graves y hospitalizaciones en el \u00faltimo a\u00f1o, n\u00ba eosin\u00f3filos y uso de corticoides de forma mantenida.  \nLas variables demogr\u00e1ficas recogidas: sexo, edad, peso y tabaquismo. Las variables resultado para valorar la efectividada \nlos 6 meses de iniciar el tratamiento fueron: eosinofilia, n\u00famero de exacerbaciones y hospitalizaciones/visitas a \nurgencias, FEV1 y los cambios de tratamiento de base\ufffd Para evaluar la seguridad se recogieron los efectos adversos \npotencialmente relacionados con mepolizumab.  \nAn\u00e1lisis estad\u00edstico IBM SPSS Statistics v27.\nRESULTADOS\n25 pacientes con peso medio de 76 kg(47-104), 20(80%) mujeres, con una mediana de edad de 53 a\u00f1os. 28%(7) \nexfumadores. Las condiciones de utilizaci\u00f3n se cumplieron en el 100% de los pacientes. 68%(17) presentaban al inicio de \ntratamiento de un recuento de eosin\u00f3filos \u2265500 c\u00e9l/\u03bcL. El resto un 32%(8) tuvieron \u22654 o m\u00e1s exacerbaciones en el a\u00f1o \nanterior que requirieron hospitalizaci\u00f3n/visita a urgencias o uso de corticoides orales de mantenimiento.  \n83% de los pacientes presentaban una funci\u00f3n pulmonar reducida, con un FEV1 medio al inicio del 64%(43-95%). El FEV1 \nfue del 89%(33-112%) (p < 0,05), el recuento de eosin\u00f3filos se redujo de 704 c\u00e9l/\u03bcL(100-1900) a 80 c\u00e9l/\u03bcL(0-200) (p < \n0,05) y el n\u00ba exacerbaciones de 3,2(0-5) a 0,4(0-2) (p < 0,05) a las 32 semanas de tratamiento. Se suspendi\u00f3 a 6 pacientes, \ncon una mediana de duraci\u00f3n del tratamiento de 9,5 meses(6-24). La actitud terap\u00e9utica tras la discontinuaci\u00f3n de \nmepolizumab fue: inicio con benralizumab(5) y no tratar con biol\u00f3gico(1). Se observaron reacciones adversas en 2 \npacientes sin requerir la retirada del tratamiento: pico de fiebre aislado 38\u00b0C(1) y reacci\u00f3n en el lugar de inyecci\u00f3n(1).\nCONCLUSIONES\nSeg\u00fan las condiciones de utilizaci\u00f3n del f\u00e1rmaco se iniciaron correctamente la totalidad de los tratamientos.  \nEl uso del mepolizumab ha sido efectivo en la reducci\u00f3n del n\u00famero de exacerbaciones y de los ingresos hospitalarios/\nvisitas a urgencias as\u00ed como del uso de corticoides. Tambi\u00e9n redujo los valores de eosin\u00f3filos, variable cl\u00ednica \ncondicionante del asma eosinof\u00edlica grave. La FEV1 tambi\u00e9n aument\u00f3. Todo ello de forma estad\u00edsticamente significativa.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n314. UPADACITINIB EN ARTRITIS REUMATOIDE: EVALUACI\u00d3N DE LA EFECTIVIDAD Y SEGURIDAD EN LA \nPR\u00c1CTICA CL\u00cdNICA HABITUAL \nAUTORES\nHERRANZ BAYO, E; AGUIL\u00d3 LAFARGA, I; NAVARRO AZNAREZ, H; D\u00cdAZ-CALDER\u00d3N HORCADA, CI; PE\u00d1AS FERNANDEZ, \nA; PERALES PASCUAL, J; PINILLA RELLO, A; ABAD BA\u00d1UELOS, B\nHOSPITAL UNIVERSITARIO MIGUEL SERVET . P\u00ba DE ISABEL LA CAT\u00d3LICA, 1-3 ZARAGOZA. ZARAGOZA44OBJETIVOS\nDescribir el perfil de utilizaci\u00f3n, efectividad y seguridad de upadacitinib en artritis reumatoide (AR) en la pr\u00e1ctica cl\u00ednica \nde un hospital terciario.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo y retrospectivo de los pacientes con AR tratados con upadacitinib desde el 01/02/2021 hasta el \n01/04/2022. Las variables recogidas fueron: sexo, edad, tiempo desde el diagn\u00f3stico al inicio del tratamiento, tiempo en \ntratamiento, tratamiento biol\u00f3gico previo, metotrexato concomitante y efectos adversos (EA). La efectividad se midi\u00f3 \npor la variaci\u00f3n en el DAS28-PCR (Disease Activity Score 28 CRP) a los 6, 9 y 12 meses; tambi\u00e9n se determinaron los \nreactantes de fase aguda (RFA): prote\u00edna C reactiva (PCR) y velocidad de sedimentaci\u00f3n glomerular (VSG).  \nFuentes de datos: programa Dispensaci\u00f3n Pacientes Externos e historia cl\u00ednica. Recogida de datos: Excel\u00ae.\nRESULTADOS\n13 pacientes recibieron upadacitinib para AR. M\u00e1s de la mitad eran mujeres (76,9%), con una edad media de 58,5\u00b114,9 \na\u00f1os. La mediana de tiempo desde el diagn\u00f3stico al inicio del tratamiento fue 7,2 a\u00f1os (2,9-17,9). La mediana en tiempo \nde tratamiento fue 11 meses (3-14). \nTodos los pacientes hab\u00edan estado en tratamiento previo con un biol\u00f3gico, siendo upadacitinib 2\u00aa l\u00ednea en 2 (15,4%), 3\u00aa \nen 4 (30,8%) y 4\u00aa o m\u00e1s en 7 (53,9%). El 69,2% se encontraba en tratamiento concomitante con metotrexato. Al inicio del \ntratamiento (n=13) el 76,9% presentaba un DAS28 > 5.1 (alta actividad) y el 23,1% entre 4.0-5.1 (moderada actividad).  \nTras 6 meses (n=11), 6/7 pacientes (85,7%) mejoraron > 1,4 puntos el DAS28, alcanzando la remisi\u00f3n (DAS28 < 2,6) en 5/6 \n(83,3%) y solamente 1/7 (14,3%) no respondi\u00f3 al tratamiento. 2/8 (25,0%) ten\u00edan elevados los RFA.  \nA los 9 meses (n=6) solo estaba registrado en la historia cl\u00ednica electr\u00f3nica el valor de DAS28 en 2 pacientes, 1 de ellos \nmantuvo la remisi\u00f3n y otro pas\u00f3 de remisi\u00f3n a una AR de moderada actividad (DAS28=3,4). No obstante, solo 2/6 (33,3%) \nten\u00edan los RFA elevados.  \nDe los 3 pacientes que completaron los 12 meses del estudio, se mantuvo la remisi\u00f3n (DAS28 < 2,6) en 2/3 (66,7%).  \n4/13 pacientes (30,8%) suspendieron el tratamiento (50% por ineficacia y 50% por EA).  \n8/13 (61,5%) presentaron alg\u00fan EA, siendo el m\u00e1s frecuente las infecciones (50,0%). En todos los pacientes se \nmantuvieron dentro de los l\u00edmites normales el recuento absoluto de linfocitos (RAL) y de neutr\u00f3filos (RAN), la \nhemoglobina y las transaminasas; el colesterol total aument\u00f3 > 200 mg/dl en 2/13 (15,4%).\nCONCLUSIONES\nUpadacitinib se prescribe en pacientes con un \u00edndice de actividad muy elevado y que han fracasado a otros tratamientos \nbiol\u00f3gicos; pese a este mal pron\u00f3stico se ha alcanzado la remisi\u00f3n completa a los 6 meses hasta en el 83,3%, pero todav\u00eda \nse necesita un periodo de estudio mayor para comprobar que esta remisi\u00f3n se mantiene. Respecto a su posible alteraci\u00f3n \nen los par\u00e1metros bioqu\u00edmicos no se ha observado ninguno salvo el colesterol en el 15,4%, y solamente destaca como \nefectos adversos el aumento de la incidencia de infecciones\ufffd\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n329. EXPERIENCIA CL\u00cdNICA CON DARVADSTROCEL EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nPOLO MONTANERO, P; RUIZ CALDES, MJ; MILLAN SCHEIDING, M; GARC\u00cdA PELLICER, J; POVEDA ANDR\u00c9S, JL; RIBES \nARTERO, H; FERN\u00c1NDEZ S\u00c1NCHEZ, M; GUERRERO HURTADO, E\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nAnalizar la eficacia de darvadstrocel en pacientes con diagn\u00f3stico de f\u00edstula perianal compleja en enfermedad de Crohn \nleve o moderada, y valorar los costes del tratamiento en funci\u00f3n del acuerdo de riesgo compartido del medicamento.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo realizado entre diciembre 2019 - febrero 2022 (27 meses) en pacientes con f\u00edstula \nperianal compleja en enfermedad de Crohn y con valoraci\u00f3n CDAI \u2264 220, que han recibido tratamiento con 120 millones \nde c\u00e9lulas de darvadstrocel en dosis \u00fanica. Se han analizado variables demogr\u00e1ficas (sexo, edad), caracterizaci\u00f3n de la \nenfermedad (terapias previas), respuesta al tratamiento medida por RMN a los 6 meses post-administraci\u00f3n y coste de \nlos tratamientos administrados en funci\u00f3n de los acuerdos de riesgo compartido (ARC). En este punto se ha considerado \nel PVL financiado menos el RDL 8/2010 m\u00e1s un 4% IVA, siendo el coste total de 37.140,48 euros y con pagos de un 40% \nen la administraci\u00f3n y un 60% a los 6 meses tras confirmaci\u00f3n de la resoluci\u00f3n completa de la f\u00edstula.  \nTodo el procedimiento se lleva a cabo bajo la coordinaci\u00f3n de un equipo multidisciplinar formado por cirujanos, \ncoloproct\u00f3logos y el servicio de farmacia\ufffd\nRESULTADOS\nDurante el periodo de estudio se analizaron un total de 11 pacientes (63,6% hombres y el 36,4% mujeres) con una media \nde edad de 39 a\u00f1os \u00b1 8 con diagn\u00f3stico cl\u00ednico y de imagen de f\u00edstula perianal compleja en enfermedad de Crohn.  \nLos tratamientos de los pacientes previos a la administraci\u00f3n de darvadstrocel han sido: 90,9% (10 pacientes) tratados \ncon infliximab, un 81,8% (9 pacientes) con adalimumab, un 36,4% (4 pacientes) con ustekinumab y un 9,1% (1 paciente) \ncon vedolizumab.  \nLa eficacia al tratamiento, considerada como cierre completo de la f\u00edstula a los 6 meses, se ha alcanzado en un 45,5% (5 \npacientes), un 36,4% (4 pacientes) presentan buena evoluci\u00f3n con posible respuesta completa al final del tratamiento. \nEn los dos casos restantes no se ha alcanzado el objetivo debido a que 1 paciente no ha obtenido respuesta, y el otro \npaciente se encuentra en seguimiento\ufffd  45Tras la administraci\u00f3n de darvadstrocel, contin\u00faan con el tratamiento previo, un 10% de los tratados con infliximab, un \n55,5% con adalimumab, 75% con ustekinumab y un 100% de los tratados con Vedolizumab.  \nEl coste total del tratamiento de los 11 pacientes ha sido 259.983,36 euros, considerando los acuerdos de riesgo \ncompartido, siendo clave la coordinaci\u00f3n con el servicio de farmacia a la hora de la petici\u00f3n del f\u00e1rmaco y la propuesta de \nquir\u00f3fano del paciente.\nCONCLUSIONES\nEl tratamiento con darvadstrocel presenta una alternativa terap\u00e9utica eficaz para los pacientes con diagn\u00f3stico de f\u00edstula \nperianal compleja en enfermedad de Crohn leve o moderada. Pese a su elevado coste los tratamientos de terapias \ndirigidas como el darvadstrocel suponen un alto beneficio para los pacientes al ser tratamiento dirigido a enfermedades \ncon alto impacto en el deterioro de la calidad de vida del paciente\ufffd\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n351. EVALUACI\u00d3N CL\u00cdNICA Y ECON\u00d3MICA TRAS LA INCORPORACI\u00d3N DE UN FARMAC\u00c9UTICO A UNA \nUNIDAD DE HOSPITALIZACI\u00d3N A DOMICILIO PEDI\u00c1TRICA \nAUTORES\nRANZ ORTEGA, P; CABRERA L\u00d3PEZ, I; AG\u00daNDEZ REIGOSA, B; GONZ\u00c1LEZ ANDR\u00c9S, D; AG\u00dc\u00cd CALLEJAS, AM; POZAS DEL \nRIO, M\nHOSPITAL INFANTIL UNIVERSITARIO NI\u00d1O JESUS. AV . MEN\u00c9NDEZ PELAYO, 65 MADRID. MADRID\nOBJETIVOS\nLa incorporaci\u00f3n del farmac\u00e9utico a la Unidad de Hospitalizaci\u00f3n a Domicilio (UHAD) pedi\u00e1trica ha supuesto la validaci\u00f3n \nfarmac\u00e9utica diaria, seguimiento farmacoterap\u00e9utico, la implantaci\u00f3n de sesiones multidisciplinares,estrategia de \neducaci\u00f3n sanitaria para el paciente y personal sanitario, conciliaci\u00f3n de la medicaci\u00f3n cr\u00f3nica y la elaboraci\u00f3n de \nmezclas intravenosas (MIV) en el Servicio de Farmacia. \nEsto \u00faltimo supone aumentar la estabilidad microbiol\u00f3gica de las MIV ( > 24h),si la fisicoqu\u00edmica lo permite, evitando as\u00ed \nel desplazamiento diario injustificado del personal de enfermer\u00eda, en aquellos pacientes estables cl\u00ednicamente. \n \nSe pretende evaluar el impacto cl\u00ednico y econ\u00f3mico de dicha incorporaci\u00f3n. Los objetivos de este estudio son:  \n\u2022 Analizar las intervenciones farmac\u00e9uticas (IF) en la UHAD  \n\u2022 Cuantificar el coste potencialmente evitado (CPE) en estancias hospitalarias a trav\u00e9s de la prevenci\u00f3n de problemas \nrelacionados con los medicamentos (PRM) \n\u2022 Determinar el ahorro econ\u00f3mico por la elaboraci\u00f3n de mezclas intravenosas (MIV) en el Servicio de Farmacia\nMATERIALES Y M\u00c9TODOS\nEstudio observacional,descriptivo,longitudinal,retrospectivo.Se incluyeron todas las IF realizadas en los pacientes \ningresados en la UHAD desde marzo 2021 hasta abril 2022.  \nLas variables recogidas fueron: demogr\u00e1ficas, las relacionadas con el medicamento implicado, tipo de IF, significaci\u00f3n \ncl\u00ednica y el grado de aceptaci\u00f3n.  \n \nEl an\u00e1lisis del CPE se realiz\u00f3 mediante la clasificaci\u00f3n de Overhage que relaciona la gravedad del PRM con el riesgo de \nincrementar la estancia. Se excluyeron del an\u00e1lisis, aquellos PRM no descritos en la clasificaci\u00f3n.  \n \nEl ahorro econ\u00f3mico por la elaboraci\u00f3n de MIV, se calcul\u00f3 mediante los d\u00edas elaborados de MIV/paciente y el coste/hora/\nenfermer\u00eda UHAD (acorde con los criterios de ingreso de UHAD: m\u00e1ximo 30 min de desplazamiento).No se incluyeron los \ngastos de desplazamiento ni las visitas justificadas.  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 con Stata 16.0.\nRESULTADOS\nSe realizaron 147 IF en 586 pacientes ingresados en UHAD (25%). El grado aceptaci\u00f3n fue alto (81.6%), mientras que el \n4% no fueron aceptadas.Los medicamentos mayormente implicados pertenec\u00edan al grupo J (55.9%).  \n \nLos tipos de IF fueron: efectividad (44%), seguridad (16%), conciliaci\u00f3n medicaci\u00f3n (20%), monitorizaci\u00f3n farmacocin\u00e9tica \n(13%) y educaci\u00f3n sanitaria (7%).  \nEl 60% de las IF de efectividad estaban relacionadas con la posolog\u00eda, fundamentalmente con la dosis, mientras que el \n31% con la indicaci\u00f3n\ufffd El 52% de las IF de seguridad, se deben a errores de prescripci\u00f3n\ufffd  \n \nDurante el proceso de conciliaci\u00f3n,se realizaron 1.5 IF/paciente conciliado, todas ellas relacionadas con la efectividad: \n52.4% indicaci\u00f3n y el 47.6% con la posolog\u00eda. Los medicamentos implicados pertenec\u00edan al grupo N (42.9%) y al A \n(38,1%). \n \n70.9% fueron significativas, 17.8% ligeramente significativas y el 11,2% muy significativas, de estas el 66,7% relacionadas \ncon la indicaci\u00f3n y el 60% pertenec\u00edan a medicamentos del grupo J.  \n \nEl CPE en estancias hospitalarias por los PRM detectados en las IF asciende a 33.030\u20ac. Aunque el 38% de las IF no se han 46cuantificado porque no figuran en la clasificaci\u00f3n de Overhage. \n \nEl ahorro econ\u00f3mico derivado de la elaboraci\u00f3n centralizada de las MIV en el Servicio Farmacia es de 6849\u20ac.\nCONCLUSIONES\n\u2022 La incorporaci\u00f3n del farmac\u00e9utico a UHAD presenta un impacto cl\u00ednico y econ\u00f3mico beneficioso  \n \n\u2022 Es necesario estandarizar la metodolog\u00eda del c\u00e1lculo del ahorro econ\u00f3mico derivado de la actividad farmac\u00e9utica\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n385. \u00bfEXISTEN DISCREPANCIAS EN EL AJUSTE DE DOSIS DE LOS NUEVOS ANTICOAGULANTES ORALES \n(NACOS) ENTRE LAS DISTINTAS ECUACIONES DE FILTRADO GLOMERULAR? \nAUTORES\nALONSO CASTA\u00d1\u00c9, M; DEL NOGAL LABRADOR, F; CORRAL ALAEJOS, A; JIMENEZ CASAUS, J; GIL VALI\u00d1O, I; FERN\u00c1NDEZ \nCA\u00d1ABATE, S; GODA MONTIJANO, G; GIL VALI\u00d1O, C\nCOMPLEJO ASISTENCIAL DE ZAMORA. AVDA. REQUEJO, 35 ZAMORA. ZAMORA\nOBJETIVOS\nLos NACOS son f\u00e1rmacos que deben dosificarse en base a la indicaci\u00f3n cl\u00ednica y la funci\u00f3n renal del paciente. La tasa \nde filtraci\u00f3n glomerular (TFG) puede calcularse en base a varias ecuaciones que utilizan par\u00e1metros distintos. Nuestro \nobjetivo fue evaluar si hay disparidad entre estas ecuaciones en la dosificaci\u00f3n de los NACOS.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, retrospectivo y transversal en la que se revisaron las historias cl\u00ednicas de los pacientes que \ningresaron en nuestro hospital con NACOS durante el \u00faltimo a\u00f1o. Las variables recogidas fueron altura (cm), peso (kg), \ncreatinina (mg/dl), edad, sexo, concentraci\u00f3n en sangre de urea (mg/dl) y alb\u00famina (g/dl), NACO, dosis, aclaramiento de \ncreatinina calculado seg\u00fan las siguientes ecuaciones: Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (ml/\nmin/1.73m2), Modification of Diet in Renal Disease Study Equation (MDRD-4) (ml/min/1.73m2), Cockcroft-Gault (CG) \n(ml/min), Jelliffe (ml/min) y en caso de obesidad la ecuaci\u00f3n de Salazar (ml/min). Para el an\u00e1lisis estad\u00edstico se utiliz\u00f3 el \nprograma Jamovi\u00ae.\nRESULTADOS\nSe revisaron un total de 89 pacientes, el 57.3% (51) eran hombres, la media de edad fue de 81.1 a\u00f1os (Standard deviation \n(SD) 8.4). Estaban en tratamiento con apixaban el 34.8% (31), 20.2% (18) con dabigatran; 22.5% (20) con edoxaban y el \n22.4% (20) con rivaroxaban. El aclaramiento renal medio fue de 55.3 ml/min (SD 21.2) seg\u00fan la ecuaci\u00f3n CKD-EPI, 60.8 \nml/min (SD 24.1) para MDRD, 48.6 ml/min (SD 21.1) para Cockroft-Gault y 41.1 ml/min (SD 17.4) para Jelliffe, en s\u00f3lo \n2 pacientes se calcul\u00f3 el filtrado glomerular seg\u00fan la ecuaci\u00f3n de Salazar por ser obesos con una media de 92.3 ml/\nmin. En 6 pacientes (6.7%) el tratamiento estaba contraindicado (CI) en base alguna de las ecuaciones: 1 (1.1%) seg\u00fan \nJelliffe, 3 (3.4%) para Jelliffe y Cockcroft-Gault y 2 (2.2%) CI para las f\u00f3rmulas de CKD-EPI, Cockcroft-Gault y Jelliffe. En 13 \npacientes (14.5%) se requiri\u00f3 una reducci\u00f3n de dosis: 8 (8.9%) seg\u00fan Jelliffe, 1 (1.1%) para CKD-EPI y MDRD, 1 (1.1%) para \nCockcroft-Gault y 3 (3.4%) para Jelliffe y Cockcroft-Gault. No se requiri\u00f3 ning\u00fan ajuste de dosis en 70 de los pacientes \n(78.7%). Se utiliz\u00f3 la prueba T-Student encontrando diferencias estad\u00edsticamente significativas entre las distintas \necuaciones (p < 0.001).\nCONCLUSIONES\nLa dosis requerida de un NACO puede variar de forma sustancial en funci\u00f3n de la ecuaci\u00f3n utilizada pudiendo llegar \na tener repercusi\u00f3n cl\u00ednica. Seg\u00fan ficha t\u00e9cnica la ecuaci\u00f3n que deber\u00eda utilizarse para el ajuste de dosis de NACOS es \nCG, as\u00ed como para la mayor\u00eda de ajuste de dosis en insuficiencia renal. Ser\u00edan recomendables nuevos estudios para \ndeterminar las implicaciones cl\u00ednicas de estas discrepancias y las dosis \u00f3ptimas de estos f\u00e1rmacos seg\u00fan el m\u00e9todo de \nestimaci\u00f3n de TFG empleado.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n540. INTERVENCI\u00d3N FARMAC\u00c9UTICA EN LA PLANTA DE ONCO-HEMATOLOG\u00cdA. \nAUTORES\nALMANCHEL RIVADENEYRA, A; TENA ALEJANDRE, P; DUQUE AGUILAR, JJ; GONZ\u00c1LEZ BARTOLOM\u00c9, J; CABA \nHERN\u00c1NDEZ, C; FREN\u00c1NDEZ LIS\u00d3N, LC\nHOSPITAL SAN PEDRO DE ALCANTARA. AV .PABLO NARANJO, S/N C\u00c1CERES. C\u00c1CERES\nOBJETIVOS\nAnalizar el impacto de la intervenci\u00f3n farmac\u00e9utica en los pacienes hospitalizados en la planta de onco-hematolog\u00eda, \nmediante la revisi\u00f3n de las prescripciones de los pacientes onco-hematol\u00f3gicos. Evaluar el impacto en la seguridad del \npaciente\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y prospectivo de las prescripciones de los pacientes ingresados a cargo de los servicios \nde hematolog\u00eda y oncolog\u00eda en nuestro hospital, realizadas del 04/10/21 al 28/02/22. Se recogieron los siguientes \ndatos: sexo, edad, intervenciones realizadas y los resultados de las mismas. Los datos se obtuvieron del programa de 47prescripci\u00f3n electr\u00f3nica para pacientes ingresados y la historia cl\u00ednica electr\u00f3nica. Las interacciones farmacol\u00f3gicas (IF) \nse analizaron a trav\u00e9s de la base de datos de IF Lexicomp\u00ae y se clasificaron seg\u00fan su grado de riesgo. El riesgo se codific\u00f3 \ncomo A: \u201cNo se ha descrito interacci\u00f3n\u201d, B: \u201cNo es necesario modificar la terapia\u201d, C: \u201cSe recomienda monitorizar la \nterapia\u201d, D: \u201cConsiderar modificaci\u00f3n de la terapia\u201d, X: \u201cEvitar la combinaci\u00f3n\u201d.\nRESULTADOS\nDurante el periodo de estudio ingresaron un total de 240 pacientes (57,5% hombres) con una media de edad de 60,59 \na\u00f1os \u00b1 14,2 SD \ufffd \nSe realizaron un total de 121 intervenciones, siendo aceptadas 116 (95,86%). \nTipo de intervenci\u00f3n realizada: ajuste de dosis: 26 (aceptadas: 26/26), modificaci\u00f3n intervalo posol\u00f3gico: 13 (aceptadas: \n13/13), interacci\u00f3n entre medicamentos prescritos: 41 (aceptadas: 39/41), sustituci\u00f3n medicamento prescrito: 16 \n(aceptadas 15/16), manejo medicaci\u00f3n, condiciones de uso: 12 (aceptadas 12/12), duplicidad de tratamiento: 7 \n(aceptadas 7/7), error de indicaci\u00f3n: 2 (aceptadas 2/2), otros: 4 (aceptadas 3/4).  \nEl 33,88% (41/121) de las intervenciones realizadas se debieron a interacciones entre medicamentos, las cuales fueron \nresueltas mediante: cambio de tratamiento: 26/41 (63,41%), suspensi\u00f3n de tratamiento: 6/41 (14,63%) y reducci\u00f3n de \ndosis: 7/41 (17,07%). La intervenci\u00f3n fue rechazada en 2/41 casos (4,87%). \nEl grupo con mayor n\u00famero de intervenciones fue: antimic\u00f3ticos para uso sist\u00e9mico, derivado de triazol (ATC: J02AC04) \ncon un 48,78% (20/41), con las siguientes proporciones: posaconazol 45% (9/20), isavuconazol 15% (3/20), voriconazol \n35% (7/20) y fluconazol 5% (1/20). El segundo grupo: agentes modificadores de los l\u00edpidos: Inhibidores de la HMG-CoA \nreductasa (ATC: C10AA05) con un 14,63% (6/41) y el tercer grupo: inhibidores de la bomba de protones (ATC: A02BC01) \ncon un 12,19% (5/21) de interacciones.  \nEn funci\u00f3n del riesgo, las intervenciones realizadas fueron registradas como categor\u00eda X: 21/41, categor\u00eda D: 13/41 y \ncategor\u00eda C: 7/41. La enzima mayoritariamente responsable fue el CYP3A4.\nCONCLUSIONES\nEl elevado n\u00famero de intervenciones aceptadas permite reducir el riesgo de toxicidad en los pacientes onco-\nhematol\u00f3gicos hospitalizados y hace evidente la importancia de realizar esta validaci\u00f3n, que permite optimizar el \ntratamiento\ufffd  \nLa integraci\u00f3n del farmac\u00e9utico como parte del equipo multidisciplinar de atenci\u00f3n al paciente onco-hematol\u00f3gico resulta \nde utilidad para evitar problemas relacionados con el medicamento (PRM).\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n547. INCIDENCIA DE REACTIVACI\u00d3N DE VIRUS HERPES-ZOSTER EN PACIENTES TRATADOS CON \nINHIBIDORES DE JAK-KINASA: RESULTADOS EN VIDA REAL. \nAUTORES\nRIOJA CARRERA, M; ARAG\u00d3N GRACIA, I; REY MONTALB\u00c1N, RL; G\u00d3MEZ G\u00d3MEZ, D; S\u00c1NCHEZ GUND\u00cdN, J; ILLARO \nURANGA, A; FERN\u00c1NDEZ MART\u00cdNEZ, V; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nEvaluar la incidencia de reactivaci\u00f3n del virus herpes-zoster (VVZ) entre los pacientes tratados con inhibidores de la Jak-\nKinasa (JAKi) en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional y unic\u00e9ntrico. Se incluyeron pacientes adultos en tratamiento con tofacitinib, \nbaricitinib, upadacitinib y filgotinib desde el inicio de su uso hasta abril 2022.  \nLos datos se extrajeron de la historia cl\u00ednica electr\u00f3nica (Altamira\u00ae) y del programa de prescripci\u00f3n electr\u00f3nica asistida \n(PEA\u00ae), recogi\u00e9ndose: edad, sexo, f\u00e1rmaco, indicaci\u00f3n, tiempo en tratamiento, aparici\u00f3n del efecto adverso y como \nconsecuencia, la suspensi\u00f3n o no del tratamiento\ufffd  \nSe realiz\u00f3 un an\u00e1lisis estad\u00edstico mediante el test chi-cuadrado de Pearson utilizando el programa Statistical Package for \nthe Social Sciences (SPSS) para analizar la incidencia de reactivaci\u00f3n de VVZ en funci\u00f3n del f\u00e1rmaco, indicaci\u00f3n y duraci\u00f3n \nde tratamiento\ufffd\nRESULTADOS\nSe incluyeron 276 pacientes. La media de edad fue 57,3 a\u00f1os (14-86). 211 (76,45%) fueron mujeres y 65 (23,55%) \nhombres. 106 (38,4%) recibieron tofacitinib, 132 (47,82%) baricitinib, 31 (11,23%) upadacitinib y 7 (2,53%) filgotinib. \nLa indicaci\u00f3n de tratamiento fue artritis reumatoide en 195 (70,65%), artritis psori\u00e1sica en 45 (16,3%), espondilitis \nanquilosante 11 (3,98%), colitis ulcerosa 6 (2,17%), arteritis de c\u00e9lulas gigantes 3 (1,09%), uve\u00edtis 3 (1,09%) y otras \nindicaciones 13 (4,71%). 169 (61,23%) pacientes llevaban menos de 1 a\u00f1o en tratamiento en el momento del estudio, \nmientras que 107 (38,77%) llevaban m\u00e1s de 1 a\u00f1o en tratamiento con el JAKi. \nNo hubo diferencias estad\u00edsticamente significativas (p= 0,686) en cuanto a la reactivaci\u00f3n del VVZ en funci\u00f3n del \ntratamiento, siendo 9 (3,3%) los casos totales: 4 en el grupo de tofacitinib y 5 en el grupo de baricitinib. Solo en uno \nde los casos la reactivaci\u00f3n del VVZ supuso la suspensi\u00f3n definitiva del f\u00e1rmaco, suponiendo en los 8 casos restantes la \nsuspensi\u00f3n temporal hasta la resoluci\u00f3n de la infecci\u00f3n.  \nTampoco se obtuvieron diferencias estad\u00edsticamente significativas en las diferentes indicaciones (p= 0,679) ni en la \nduraci\u00f3n del tratamiento (p=0,717), aunque en este \u00faltimo caso llama la atenci\u00f3n que el 66,7% de los casos de VVZ \naparecieron en pacientes con un tiempo de tratamiento menor a un a\u00f1o.48CONCLUSIONES\nLa incidencia de reactivaci\u00f3n del virus herpes-zoster en nuestra poblaci\u00f3n, tratada con JAKi, es similar a la experimentada \nen los ensayos cl\u00ednicos, sin que se pueda establecer un factor determinante en funci\u00f3n del tratamiento, indicaci\u00f3n o \ntiempo en tratamiento con JAKi. Son necesarios estudios observacionales con mayor n\u00famero de pacientes para poder \nafianzar estos resultados.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n622. PROTOCOLO DE MANEJO PERIOPERATORIO DE LA ANEMIA EN FRACTURA DE CADERA \nAUTORES\nMART\u00cdN SANZ, P; J\u00cdMENEZ DOM\u00cdNGUEZ, C; VICENTE OLIVEROS, N; PALOMAR FERN\u00c1NDEZ, C; \u00c1LVAREZ NEBRADA, L; \n\u00c1LVAREZ D\u00cdAZ, A; DELGADO SILVEIRA, E\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nMedir el cumplimiento de un protocolo de anemia en el manejo del paciente perioperatorio de fractura de cadera.  \nComparar el porcentaje de pacientes con anemia posquir\u00fargica antes y despu\u00e9s de la implantaci\u00f3n del protocolo.  \nEvaluar la seguridad del hierro durante el proceso del perioperatorio.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de cohortes que incluy\u00f3 a pacientes mayores de 69 a\u00f1os ingresados por fractura de \ncadera, antes y despu\u00e9s de la implementaci\u00f3n de un protocolo de manejo de perioperatorio de anemia (febrero a junio \nde 2019 y 2021).  \nSe consider\u00f3 que cumplimiento del protocolo si: se midi\u00f3 la hemoglobina (Hb) en urgencias e iniciaron la ferroterapia \nendovenosa (hierro sacarosa (peso < 50 kg) o hierro carboximaltosa (\u226550 kg)) si los valores < 13g/dL. Y si a los 7 d\u00edas del \ningreso, se midi\u00f3 la ferritina s\u00e9rica, \u00edndice de saturaci\u00f3n de transferrina y Hb para indicar una segunda dosis de hierro.  \nEn un cuestionario dise\u00f1ado con el software RedCap\u00a9, se recogieron las siguientes variables de la historia cl\u00ednica \nelectr\u00f3nica: edad, sexo, hb (al ingreso, a los siete d\u00edas, al alta) y reacciones adversas a medicamentos (RAMS).  \nSe defini\u00f3 la presencia de anemia si Hb < 13g/dL en hombres y 12g/dL en mujeres. \nSe realiz\u00f3 un an\u00e1lisis estad\u00edstico descriptivo con Microsoft Excel\u00ae.\nRESULTADOS\nSe incluyeron 399 pacientes, 200 en la cohorte de 2019 y 199 en la de 2021. La cohorte de 2019 present\u00f3 un 60% de \nmujeres y la edad media fue 85.80\u00b16,8a\u00f1os. La cohorte del 2021 present\u00f3 un 70% mujeres, edad media 85.99\u00b16,8 a\u00f1os. \nUn total de 53% de pacientes presentaron anemia prequir\u00fargica en el grupo de 2019, y un 36% en el del 2021. Adem\u00e1s, \nun 49% de pacientes de la muestra total del 2019 presentaron anemia al alta (74,5% mujeres) y un 91,5% en el 2021 \n(73,22% mujeres). \nEn la cohorte del 2021, tras la implantaci\u00f3n del protocolo, observamos un porcentaje de incumplimiento del protocolo de \nun 45,6 % (n=90), atribuible a que no se inici\u00f3 la ferroterapia endovenosa en urgencias en un 99% de estos casos.  \nDe los pacientes que cumplieron el protocolo, el 75% (N=45) la Hb era superior a 13 mg/dl en el ingreso y requirieron \nhierro a los 7 d\u00edas.  \nNo se describieron RAMS con el manejo de ambas presentaciones.\nCONCLUSIONES\nEl cumplimiento del protocolo ha sido bajo, y el porcentaje de pacientes con anemia al alta durante el 2021 en \ncomparaci\u00f3n con el otro grupo ha sido elevado. Ambos resultados deber\u00edan analizarse en estudios posteriores por la \nelevada diferencia entre ambos grupos y establecer una posible causalidad\ufffd  \nEl manejo de la medicaci\u00f3n ha resultado seguro al no detectar ninguna reacci\u00f3n adversa.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n639. PROGRAMA DE OPTIMIZACI\u00d3N DE ANTIBI\u00d3TICOS (PROA) Y CONCILIACI\u00d3N ANTIMICROBIANA EN \nEL ALTA HOSPITALARIA EN SERVICIOS QUIR\u00daRGICOS \nAUTORES\nSANTOS RODR\u00cdGUEZ, C; JOVER S\u00c1ENZ, AJ; RAMOS GIL, M\u00c1; PALOMERA FERN\u00c1NDEZ, M; INV\u00caNCIO DA COSTA, LF; \nBARDOLL CUCALA, M; CANO MARR\u00d3N, SM; SCHOENENBERGER ARNAIZ, JA\nHOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA \ufffd AVDA \ufffd ALCALDE ROVIRA ROURE, 80 LLEIDA \ufffd LLEIDA\nOBJETIVOS\nAunque las intervenciones PROA para mejorar el uso de antibi\u00f3ticos en pacientes hospitalizados est\u00e1n bien establecidas, \nla interfaz entre el hospital y la comunidad sigue siendo un desaf\u00edo y expone a los pacientes a da\u00f1os potenciales. Estudios \nrecientes sugieren que entre el 30% y el 40% de las prescripciones de antibi\u00f3ticos que se asocian con una estancia \nhospitalaria ocurren despu\u00e9s del alta, y la idoneidad de \u00e9stas es inadecuada entre el 50% y el 70% de las ocasiones, por \nduraciones m\u00e1s prolongadas de lo necesario y abuso de quinolonas.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo de intervenci\u00f3n de 15 meses de duraci\u00f3n cuyo objetivo fue calcular el ahorro en el uso de \nantibi\u00f3ticos que comporta la intervenci\u00f3n. Intervenci\u00f3n: 1.- revisi\u00f3n diaria del total de prescripciones de antibi\u00f3ticos en \npacientes ingresados en urolog\u00eda y otorrinolaringolog\u00eda (ORL). 2.- Asesor\u00eda diaria escrita virtual no impositiva en historia 49cl\u00ednica informatizada SAP \u201cSystems, Applications, Products in Data Processing\u201d. 3.- Conciliaci\u00f3n al alta y entrega de la \ncantidad en unidosis de antibi\u00f3tico necesario para finalizar el tratamiento, con educaci\u00f3n informativa, oral y escrita, al \npaciente. 4.- Notificaci\u00f3n informatizada de la conciliaci\u00f3n a su m\u00e9dico de cupo de Medicina Familiar. Variables principales: \ndiferencia en las Dosis Diarias Definidas (DDDs) de antibi\u00f3ticos dispensados y en los d\u00edas de tratamiento con antibi\u00f3ticos \nal alta (DOTs), en los pacientes con intervenci\u00f3n respecto a los valores que se hubieran obtenido sin ella, de acuerdo con \nlos envases comercializados de antibi\u00f3ticos que contengan la m\u00ednima cantidad de comprimidos o c\u00e1psulas de antibi\u00f3ticos, \nque se hubieran prescrito en el sistema de receta electr\u00f3nica de atenci\u00f3n primaria.\nRESULTADOS\nSe han incluido 258 pacientes, de los cuales 187 (72,48%) fueron pacientes con infecciones de tipo urol\u00f3gico. Las \nentidades infecciosas tratadas m\u00e1s frecuentes fueron pielonefritis y abscesos amigdalinos, diagnosticadas en 77 (29,8%) \ny 36 (13,9%) casos, respectivamente. Amoxicilina-clavul\u00e1nico y cefuroxima-axetilo fueron los antibi\u00f3ticos m\u00e1s prescritos \ny dispensados en 66 (25,6%) y 62 (24,0%) casos, respectivamente. La media de los d\u00edas de tratamiento con antibi\u00f3ticos \nal alta fue de 7,5\u00b14,2 d\u00edas. En t\u00e9rminos absolutos se redujo el consumo de antibi\u00f3ticos en 1008 DDDs y 732 DOTs \ndurante el periodo estudiado, lo que represent\u00f3 respecto a los valores te\u00f3ricos sin intervenci\u00f3n un 26,0% y un 28,0%, \nrespectivamente. Se disminuyeron de forma estad\u00edsticamente significativa (p < 0,0001 t-test para datos apareados), las \nDDDs por paciente y d\u00eda (de 14,9\u00b17,1 a 11,2\u00b16,5) y los DOTs por paciente y d\u00eda (de 10,3\u00b15,2 a 7,5\u00b14,2).\nCONCLUSIONES\nNuestra experiencia sugiere c\u00f3mo la conciliaci\u00f3n antimicrobiana en la transici\u00f3n del alta, realizada por un PROA \nhospitalario, resulta una medida eficaz en la optimizaci\u00f3n de la terapia, al poder reducir en una cuarta parte la posibilidad \nde exposici\u00f3n a antibi\u00f3ticos.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n645. CONCILIACI\u00d3N DE LA MEDICACI\u00d3N AL INGRESO: DETECCI\u00d3N Y AN\u00c1LISIS DE DISCREPANCIAS \nAUTORES\nLAR\u00cdA CAMPA\u00d1A, C; API\u00d1\u00c1NIZ API\u00d1\u00c1NIZ, R; HURTADO G\u00d3MEZ, MF; BERENGUER TORRIJO, N; VALERO GRACIA, MS\nHOSPITAL SAN PEDRO. CTRA. DE PIQUERAS, 98 LOGRO\u00d1O. LA RIOJA\nOBJETIVOS\nAnalizar el impacto cl\u00ednico y econ\u00f3mico de un proceso de conciliaci\u00f3n de la medicaci\u00f3n al ingreso hospitalario. \nSecundariamente se estudiaron los f\u00e1rmacos implicados y los problemas relacionados con la medicaci\u00f3n (PRM) \ndetectados\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio aleatorizado realizado durante 3 meses (datos de marzo-mayo 2018) en un Hospital General de 600 camas en los \nServicios de Cardiolog\u00eda, Cirug\u00eda, Medicina Intensiva y Medicina Interna. La medicaci\u00f3n de los pacientes se revis\u00f3 con el \nprograma de prescripci\u00f3n electr\u00f3nica del hospital. Se analizaron:  \n- Discrepancias no justificadas y errores de conciliaci\u00f3n (EC).  \n- F\u00e1rmacos implicados en los EC.  \n- PRM detectados.  \n- Duraci\u00f3n de la estancia hospitalaria y n\u00ba reingresos a los 30 d\u00edas.  \n- Ahorro econ\u00f3mico estimado derivado de la instauraci\u00f3n del programa de conciliaci\u00f3n de la medicaci\u00f3n al ingreso.\nRESULTADOS\nSe realiz\u00f3 conciliaci\u00f3n de la medicaci\u00f3n al ingreso hospitalario a 178 pacientes, de ellos 89 pertenecieron al grupo control \n(GC) y 89 al grupo intervenci\u00f3n (GI). Respecto a las variables g\u00e9nero, pluripatolog\u00eda, polimedicaci\u00f3n e \u00edndice de Charlson, \nambos grupos mostraron homogeneidad (p > 0,05). La edad media de los pacientes fue de 72,9 \u00b1 5,3 a\u00f1os y el tiempo \nmedio de la entrevista cl\u00ednica 10,5 \u00b1 3,9 minutos.  \nEn el GI se detectaron 345 discrepancias no justificadas (3,9 discrepancias/paciente) de las cuales el 143 (41,5%) \nresultaron ser EC. El 39,2% de los f\u00e1rmacos implicados en los EC deb\u00edan conciliarse en las primeras 4 horas del ingreso \nhospitalario y el 11,9% de los mismos eran asociaci\u00f3n de varios principios activos.  \nEntre los 153 PRM detectados en los pacientes del GI destacaron: \n- Interacciones graves (39,2%)  \n- Detecci\u00f3n de intolerancia o alergia a un principio activo (11,8%) \n- F\u00e1rmacos no disponibles en el hospital (10,5%) \n- Probabilidad de efectos adversos graves (7,2%)  \n- F\u00e1rmacos de baja utilidad terap\u00e9utica (6,6%) \nHubo diferencias significativas en la duraci\u00f3n de la estancia hospitalaria, 6,9 \u00b1 4 d\u00edas en GI vs 9,9 \u00b1 3,7 en GC (p < 0,05). El \ncoste medio de ingreso hospitalario por paciente fue de 614 \u20ac/d\u00eda, por lo que el ahorro estimado como consecuencia de \nla intervenci\u00f3n farmac\u00e9utica realizada en el GI fue de 1.842 \u20ac/paciente, es decir, un ahorro total estimado de 163.938 \u20ac \nsi se tiene en cuenta la totalidad de pacientes del GI. Tambi\u00e9n hubo diferencias significativas en el n\u00famero de reingresos \nhospitalarios a los 30 d\u00edas del alta: 18 (20,2%) en GI y 38 (42,7%) en GC (p < 0,05).\nCONCLUSIONES\n- El 41,5% de las discrepancias no justificadas detectadas en el proceso de conciliaci\u00f3n terminaron confirm\u00e1ndose como \nEC. El 39,2% de los f\u00e1rmacos implicados deb\u00edan conciliarse en las primeras 4 horas del ingreso (seg\u00fan gu\u00edas oficiales de \nconciliaci\u00f3n de la medicaci\u00f3n).  50- La conciliaci\u00f3n de la medicaci\u00f3n no solo es \u00fatil a la hora de detectar EC, sino tambi\u00e9n PRM que pueden tener \nconsecuencias importantes en la salud y evoluci\u00f3n cl\u00ednica de los pacientes. \n- Implantar un proceso normalizado de conciliaci\u00f3n de la medicaci\u00f3n al ingreso supondr\u00eda una mejor Atenci\u00f3n \nFarmac\u00e9utica a los pacientes y un ahorro econ\u00f3mico importante a nivel hospitalario.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n662. EFECTIVIDAD Y SEGURIDAD DE FREMANEZUMAB EN PACIENTES CON MIGRA\u00d1A CR\u00d3NICA \nREFRACTARIA A LARGO PLAZO \nAUTORES\nCAVADA CARRANZA, I; MART\u00cdN BARBERO, ML; LOZANO ROS, A; BUEND\u00cdA MORENO, JA; RIOJA DIEZ, Y; HERRANZ \nALONSO, A; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nEl abordaje de la migra\u00f1a cr\u00f3nica refractaria(MCR) implica, tratamientos sintom\u00e1ticos para la fase aguda y tratamientos \npreventivos. Dentro de estos \u00faltimos, encontramos los nuevos anticuerpos monoclonales(AC).  \nObjetivo: Evaluar efectividad y seguridad de Fremanezumab(\u00fanico AC incluido en Gu\u00eda Farmacoterap\u00e9utica) en pacientes \ncon MCR tratados en nuestro hospital.\nMATERIALES Y M\u00c9TODOS\nSe realiza un estudio observacional, retrospectivo, donde se incluyeron pacientes tratados con Fremanezumab desde \nnoviembre-2020 hasta enero-2022. Para su inicio deb\u00edan tener \u226515 d\u00edas migra\u00f1a al mes(DMM) y haber recibido \u22653 \npreventivos, incluyendo toxina-botul\u00ednica, durante \u22653 meses. Se analizaron las variables demogr\u00e1ficas, DMM, intensidad-\ndolor(EVA), tratamientos previos preventivos/sintom\u00e1ticos, cuestionarios espec\u00edficos de discapacidad: Migraine dissability \nAssessment Scale(MIDAS) y calidad de vida: Headache Impact Test(HIT6).  \n \nSe evalu\u00f3 en consulta de atenci\u00f3n farmac\u00e9utica la eficacia y seguridad cada 3 meses:  \n \n- Variables-efectividad: disminuci\u00f3n de \u2265 50% DDM, reducci\u00f3n escala EVA, disminuci\u00f3n consumo medicaci\u00f3n sintom\u00e1tica, \ndisminuci\u00f3n \u2265 30% MIDAS y \u22655 puntos HIT6 del basal.  \n- Variables-seguridad: Reacciones adversas(RA) y suspensiones tratamiento.  \n \nPara la obtenci\u00f3n de datos se desarroll\u00f3 una plataforma inform\u00e1tica de registro de datos en salud compartida con el \nservicio de Neurolog\u00eda.\nRESULTADOS\nSe incluyeron 61 pacientes(88% mujeres), con una media de edad 50.3\u00b111.5 a\u00f1os, media de DMM 26.1\u00b16.3 y media de \nEVA 8\ufffd1\u00b11\ufffd1\ufffd  \n \nEl n\u00famero medio de medicamentos fue 7.3\u00b12.2 preventivos y 2.3\u00b11.4 sintom\u00e1ticos. El consumo medio de medicaci\u00f3n \nsintom\u00e1tica fue de 19.2\u00b18.6d\u00edas/mes.  \nLas puntuaciones medias basales de escalas espec\u00edficas fueron, MIDAS: 98.2\u00b155.3(Discapacidad grave) y HIT6: \n69.5\u00b15.6(Impacto muy grave). \n \nEn el momento del an\u00e1lisis un 29% de los pacientes acaban de iniciar el f\u00e1rmaco, 16% se encontraba en mes 3, 20% en \nmes 6, 20% en mes 9 y 15% en mes 12 de tratamiento. Por lo que la evaluaci\u00f3n de resultados se realiz\u00f3 en 43 pacientes. \n \nEl tiempo medio de tratamiento con fremanezumab fue de 6.4\u00b13.3 meses. Se observ\u00f3 una disminuci\u00f3n en los DMM de \n12.4\u00b110.2 del basal, un 69.1% de los pacientes obtuvieron una reducci\u00f3n superior al 50% DMM basal. El EVA se redujo \n1.7\u00b12.6 y el consumo de medicaci\u00f3n disminuy\u00f3 12.6\u00b18.5 d\u00edas/mes respecto al basal.  \n \nUn 71% de pacientes experimentaron una reducci\u00f3n \u226530% del MIDAS basal(media MIDAS: 40.7\u00b147.2) y el 61.9% \nobtuvieron una reducci\u00f3n \u22655 puntos respecto al HIT6 basal(media HIT6:48.7\u00b115.7).  \n \nLa suspensi\u00f3n del tratamiento por falta de respuesta se produjo en un 21% de los pacientes y un 25% de los pacientes \nexperimentaron alguna RA, siendo 44% estre\u00f1imiento, 38% reacciones d\u00e9rmicas en lugar de administraci\u00f3n y 18% \npalpitaciones y/o taquicardias. Ning\u00fan paciente suspendi\u00f3 el tratamiento por RA.\nCONCLUSIONES\nFremanezumab se posiciona como una estrategia efectiva y segura en pacientes con MCR. Se observa un beneficio claro \nen disminuci\u00f3n DMM y/o en intensidad del dolor, reflejado en escalas espec\u00edficas de discapacidad y calidad de vida. Los \nresultados obtenidos, concuerdan con la evidencia disponible. En los pacientes en los que no se obtiene beneficio, habr\u00eda \nque valorar la posibilidad de switch a otros anticuerpos.  \nEl trabajo coordinado con el Servicio de Neurolog\u00eda y el registro de datos com\u00fan en la plataforma inform\u00e1tica creada \naporta un beneficio para tomar decisiones, minimizar variabilidad en pr\u00e1ctica cl\u00ednica y optimizar tratamientos.51CLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n666. REVERSI\u00d3N DE F\u00c1RMACOS ANTICOAGULANTES EN PACIENTES CON FRACTURA DE CADERA QUE \nREQUIEREN INTERVENCI\u00d3N QUIR\u00daRGICA PRECOZ \nAUTORES\nRAMOS RODRIGUEZ, J; SERRANO SANZ, J; GAMALERO , V; G\u00d3MEZ VALENT , M; MARTINEZ SA\u00d1UDO, L; ROVIRA \nMEDINA, T; OLIVER CERVELL\u00d3, M; FERN\u00c1NDEZ MOLINA, S\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\nEstimar el coste de la reversi\u00f3n del f\u00e1rmaco anticoagulante y la consecuente disminuci\u00f3n potencial de estancia \nhospitalaria por cirug\u00eda precoz.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional, en el cual se evalu\u00f3 el n\u00famero de pacientes geri\u00e1tricos candidatos a cirug\u00eda de \nfractura de cadera durante el a\u00f1o 2020\ufffd  \n \nSe registraron el n\u00famero de pacientes, los d\u00edas entre ingreso y cirug\u00eda, el f\u00e1rmaco anticoagulante utilizado de manera \ncr\u00f3nica, la estrategia farmacol\u00f3gica de reversi\u00f3n, el coste te\u00f3rico estimado de dicha estrategia a partir del Precio de Venta \ndel Laboratorio (PVL) y los potenciales d\u00edas de ingreso ahorrados. La estrategia de reversi\u00f3n se calcul\u00f3 de la siguiente \nmanera:  \n \n- > Dosis fijas de complejo protromb\u00ednico (CCP , 2000UI) para pacientes anticoagulados con apixaban, rivaroxaban y \nedoxab\u00e1n: coste 840 \u20ac  \n \n- > Dosis 25 UI/kg de CCP para pacientes anticoagulados con acenocumarol y warfarina: suponiendo un peso de 80 kg y \nun \u00edndice internacional normalizado (INR, por sus siglas en ingl\u00e9s) en rango 2 - 4: coste 840 \u20ac  \n \n- > Dosis de 5 gr de idarucizumab para anticoagulados con dabigatran: coste 3000\u20ac\nRESULTADOS\nSe evaluaron un total de 319 pacientes candidatos a intervenci\u00f3n quir\u00fargica (IQ), de los cuales 82 (25.7%) estaban \nanticoagulados. Se excluyeron 3 pacientes debido a que no se realiz\u00f3 la IQ, por lo que el an\u00e1lisis final se realiz\u00f3 con 79 \npacientes: 37 (48,6%) estaban anticoagulados con acenocumarol, 18 (22.8%) con apixaban, 14 (17.8%) con rivaroxaban, 7 \n(8.9%) con dabigatran y 3 (3.8 %) con edodaxan (3).  \n \nEn el 86% de los casos (68) no se consigui\u00f3 el objetivo de IQ en menos de 48 horas. El tiempo medio entre ingreso e IQ \nfue de 3.7 d\u00edas (rango 2-14).  \n \nEl coste total estimado de la reversi\u00f3n del anticoagulante para IQ precoz ascender\u00eda a 79.320 \u20ac, lo que supondr\u00eda 1004,05 \n\u20ac por paciente. Suponiendo que la IQ se podr\u00eda realizar en las primeras 6-12 horas desde el ingreso una vez revertido el \nefecto anticoagulante, el ahorro estimado de d\u00edas de hospitalizaci\u00f3n totales ser\u00eda de 292,3.\nCONCLUSIONES\nLa cirug\u00eda precoz en fractura de cadera en las primeras 48 horas de ingreso disminuye las complicaciones de pacientes de \nedad avanzada. Estrategias como \u00e9stas en pacientes anticoagulados tienen un impacto econ\u00f3mico en coste de f\u00e1rmacos \nrelevante pero nos permitir\u00eda disminuir los d\u00edas de estancia hospitalaria.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n668. \u00bfINFLUYE EL NIVEL DE COMPLEJIDAD ASISTENCIAL DEL HOSPITAL EN LAS INTERVENCIONES \nFARMAC\u00c9UTICAS? \nAUTORES\nSU\u00d1ER BARRIGA, H; PLO SECO, I; CONDE GINER, S; SANJU\u00c1N BELDA, A; SACANELLA ANGL\u00c9S, I; LLORET LLORCA, A; \nCORT\u00c9S S\u00c1NCHEZ, CJ; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA\nOBJETIVOS\nDescribir y comparar las intervenciones farmac\u00e9uticas (IF) realizadas desde el servicio de Farmacia en un hospital de \ntercer nivel (HTN) y en un hospital comarcal de proximidad (HCP) y su grado de aceptaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se analizaron las IF realizadas entre enero y marzo de 2022 en el \ntratamiento de los pacientes ingresados en un HTN (383 camas) y en un HCP (76 camas agudos + 77 convalescencia) \ndurante el proceso de validaci\u00f3n farmac\u00e9utica. Posteriormente se evalu\u00f3 el grado de aceptaci\u00f3n. Los datos fueron \nextra\u00eddos del programa de prescripci\u00f3n electr\u00f3nica Silicon\u00ae utilizando el aplicativo SAP-BO.52RESULTADOS\nSe revisaron una media de 11,95 l\u00edneas de tratamiento por paciente en el HTN y 20,53 en el HCP .  \nEn el HTN se registraron un total de 649 IF, con un grado de aceptaci\u00f3n del 87,5%. Desglosando por tipo, un 30,1% \npropon\u00edan modificar la pauta, 26,5% fueron discrepancias en la conciliaci\u00f3n al ingreso, 11,7% cambiar de medicamento, \n8,2% iniciar un tratamiento, 19,3% suspender tratamiento, 3,4% mantenerlo y 0,8% monitorizar. Los servicios en los \nque se realiz\u00f3 mayor n\u00famero de IF fueron cirug\u00eda vascular (31,4%), cirug\u00eda general (9,1%), neumolog\u00eda (7,4%), medicina \ninterna (7,1%) y traumatolog\u00eda (4,3%). Los tres grupos terap\u00e9uticos m\u00e1s involucrados fueron el grupo J01 antibacterianos \nsist\u00e9micos (25,7%), el grupo B01 antitromb\u00f3ticos (14,4%) y el grupo N02 analg\u00e9sicos (5,3%).  \nEn el HCP se registraron un total de 95 IF con un grado de aceptaci\u00f3n del 85,3%. Por tipo de IF se observ\u00f3 que el 28,5% \npropon\u00edan modificar la pauta, 4,2% fueron discrepancias en la conciliaci\u00f3n al ingreso, 29,5% cambiar de medicamento, \n8,4% iniciar un nuevo tratamiento, 16,8% suspenderlo, 4,2% mantenerlo y 7,4% monitorizar. Los servicios en los que se \nrealizaron m\u00e1s IF fueron medicina interna (23,2%), cirug\u00eda general (20%), convalescencia (17,9%), traumatolog\u00eda (17,9%) \ny paliativos (2,1%). Los antibacterianos sist\u00e9micos (32,6%), los antitromb\u00f3ticos (10,9%) y el grupo B05 sustitutivos del \nplasma (9,8%) fueron los grupos terap\u00e9uticos m\u00e1s intervenidos.\nCONCLUSIONES\nLa disparidad entre las IF realizadas por servicio en cada uno de los hospitales puede deberse a la mayor proporci\u00f3n de \npacientes quir\u00fargicos ingresados en el HTN as\u00ed como a la integraci\u00f3n de un farmac\u00e9utico en el equipo multidisciplinar de \nneumolog\u00eda. El perfil de paciente ingresado en el HCP hace que la duraci\u00f3n media de ingreso en este hospital sea m\u00e1s \nlarga, lo cual explica el mayor n\u00famero de l\u00edneas de tratamiento validadas por paciente. La similitud tanto en el grado de \naceptaci\u00f3n como en el tipo de intervenci\u00f3n y los grupos terap\u00e9uticos involucrados podr\u00eda indicar que la IF aumenta la \nseguridad de los tratamientos independientemente del tipo de hospital en el que est\u00e9 ingresado el paciente.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n676. AN\u00c1LISIS COMPARATIVO DE TRES PROGRAMAS FARMACOCIN\u00c9TICOS EN EL AJUSTE DE FENITO\u00cdNA \nAUTORES\nARAG\u00d3N GRACIA, I; HOYO MU\u00d1OZ, \u00c1; DOMINGUEZ GARC\u00cdA, A; SALCEDO MINGOARRANZ, AL; VALERO DOMINGUEZ, \nM; HERRERO AMBROSIO, A; GARCIA DIAZ, B\nHOSPITAL SEVERO OCHOA \ufffd AV\ufffd DE ORELLANA, S/N LEGAN\u00c9S \ufffd MADRID\nOBJETIVOS\nComparaci\u00f3n de tres programas farmacocin\u00e9ticos para analizar su exactitud y precisi\u00f3n en la estimaci\u00f3n de los niveles \nplasm\u00e1ticos de fenito\u00edna.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyeron los pacientes ingresados en un hospital de segundo nivel con \nal menos un nivel de fenito\u00edna entre 2012 y 2021.  \nLas variables recogidas fueron: sexo, edad, albuminemia, creatinina s\u00e9rica, v\u00eda de administraci\u00f3n, fecha y concentraci\u00f3n \nplasm\u00e1tica de fenito\u00edna, nivel predicho en tres programas farmacocin\u00e9ticos (A, B y C) y medicaci\u00f3n concomitante de los \npacientes (carbapenems, \u00e1cido valproico, AINE, macr\u00f3lidos, carbamazepina y barbit\u00faricos).  \nSe emple\u00f3 la teor\u00eda de los errores de predicci\u00f3n de Sheiner y Beal para estimar la bondad de ajuste: la exactitud se \ncalcul\u00f3 con el error medio de predicci\u00f3n (EMP) y la precisi\u00f3n con el error absoluto medio de predicci\u00f3n (EAMP) y la ra\u00edz \ncuadrada del error cuadr\u00e1tico medio de predicci\u00f3n (RECMP). \nSe calcul\u00f3 la precisi\u00f3n y exactitud en aquellos pacientes de los que se dispon\u00eda de 2 o m\u00e1s determinaciones de fenito\u00edna \nplasm\u00e1tica.\nRESULTADOS\nSe incluyeron 131 concentraciones s\u00e9ricas de fenito\u00edna de 43 pacientes, de las cuales el 40,5% correspondieron a \nadministraciones orales y el 59,5% a dosis intravenosas\ufffd  \nLa edad media de los pacientes fue 70,9 a\u00f1os (25-97) y con peso medio 71,7 Kg (40-97). los siguientes valores anal\u00edticos: \nalb\u00famina media 3,5 g/dL (2,3-5,5), creatinina media 0,88 mg/dL (0,29-5,33) y bilirrubina media 0,4 mg/dL (0,1-1,6). Siete \npacientes (16%) recibieron barbit\u00faricos, 7 (16%) AINE, 7 (16%) valproico, 4 (9%) carbamazepina, 3 (7%) macr\u00f3lidos y 1 \n(2%) carbapenems.  \n \nEl programa farmacocin\u00e9tico A tiene en cuenta la creatinina s\u00e9rica y el peso como covariables con influencia en el \najuste farmacocin\u00e9tico. El programa B considera, adem\u00e1s de la creatinina s\u00e9rica y el peso, la edad, la albuminemia y la \nadministraci\u00f3n de carbapenems, valproico, AINE, macr\u00f3lidos, carbamazepina y barbit\u00faricos como factores influyentes en \nla concentraci\u00f3n plasm\u00e1tica. Por \u00faltimo, el programa C tiene en cuenta la creatinina s\u00e9rica, el peso y la alb\u00famina.  \nEl software C mostr\u00f3 una mayor exactitud y precisi\u00f3n que los programas A y B:  \nExactitud: EMP -0,11, -0,18 y -0,20 para C, A y B respectivamente. \nPrecisi\u00f3n: EAMP 1,16, 1,32 y 1,27 y RECMP 1,60, 1,95, 1,72 para C, A y B respectivamente. \n \nPacientes con 2 o m\u00e1s determinaciones: 28 \nExactitud: EMP -0,12, -0,21 y -0,12 para C, A y B respectivamente. \nPrecisi\u00f3n: EAMP 1,30, 1,47 y 1,33 y RECMP 1,70, 2,07 y 1,73 para C, A y B respectivamente.53CONCLUSIONES\nLos tres programas farmacocin\u00e9ticos muestran una mayor exactitud que precisi\u00f3n.  \nAunque el software C ha obtenido los mejores resultados, la precisi\u00f3n de los tres programas empeora en los pacientes \nque presentan m\u00e1s de una concentraci\u00f3n plasm\u00e1tica de fenito\u00edna.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n683. EVALUACI\u00d3N DE LA INFORMACI\u00d3N REPORTADA POR EL PACIENTE EN TRATAMIENTO \nANTIRRETROVIRAL: CALIDAD DE VIDA Y ADHERENCIA \nAUTORES\nFERN\u00c1NDEZ NAVARRO, A; MOSAMIO CHARLES, P; FERN\u00c1NDEZ LASTRA, C; MARI\u00d1O HERN\u00c1NDEZ, E; QUI\u00d1ONES \nRIBAS, C\nHOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nOBJETIVOS\nObtener informaci\u00f3n adicional desde el \u00e1rea de dispensaci\u00f3n ambulatoria de la consulta externa de farmacia (CEF) sobre \nadherencia y calidad de vida de pacientes que conviven con el VIH (PCV) mediante el uso de resultados comunicados por \nlos pacientes (Patient-reported outcome measures (PROM)).\nMATERIALES Y M\u00c9TODOS\nEstudio transversal descriptivo mediante la realizaci\u00f3n de una entrevista. Los pacientes invitados a participar fueron \naquellos que acudieron a la CEF para la dispensaci\u00f3n de antirretrovirales durante noviembre de 2021. Se escogieron \ndos PROM, uno correspondiente a calidad de vida en PCV (MOS-HIV), y otro de adherencia (test de Morisky-Green). Se \nformularon preguntas b\u00e1sicas para crear un perfil de paciente (edad, g\u00e9nero, orientaci\u00f3n sexual, a\u00f1os de diagn\u00f3stico \ny a\u00f1os en tratamiento). A su vez, se registr\u00f3 la informaci\u00f3n sobre el tratamiento actual y la carga viral, disponible en el \nhistorial cl\u00ednico. Previamente se obtuvieron el aval del comit\u00e9 de \u00e9tica del centro (C\u00f3digo: PI-21-316) y el consentimiento \ninformado y por escrito de los participantes.\nRESULTADOS\nSe entrevist\u00f3 a un total de 34 pacientes: edad promedio 44 a\u00f1os (16 pacientes < de 40 a\u00f1os, 14 entre 41-60 a\u00f1os y 4 > de \n61), 24 homosexuales, 8 heterosexuales y 2 con una orientaci\u00f3n distinta no mencionada. La informaci\u00f3n de los pacientes \nsobre cu\u00e1ndo fueron diagnosticados de VIH fue muy diversa, siendo los m\u00e1s frecuentes: 27% hab\u00edan sido diagnosticados \nhace m\u00e1s de 20 a\u00f1os, seguidos de dos grupos (24% cada uno) donde indicaban que su diagn\u00f3stico hab\u00eda sido entre 1-5 \na\u00f1os y 6-10 a\u00f1os.  \nSe determin\u00f3 la calidad de vida con el PROM MOS-HIV, donde se puntuaron del 0 al 100 diferentes indicadores de calidad \nde vida. La calidad de vida f\u00edsica rond\u00f3 el 78%, la psicol\u00f3gica el 76%, y la total aproximadamente el 75%. Con estos \nresultados, se compar\u00f3 adem\u00e1s la calidad de vida entre los diferentes perfiles establecidos, no encontr\u00e1ndose diferencias \nsignificativas entre los grupos.  \nRespecto a la adherencia se compar\u00f3 el promedio obtenido en el test de Morisky-Green con el de los diferentes perfiles \nde pacientes, la adherencia fue mayor en mujeres, y en los pacientes mayores de 61 a\u00f1os y en tratamiento hace m\u00e1s de \n20 a\u00f1os\ufffd\nCONCLUSIONES\nLos PROM sobre adherencia y calidad de vida aplicados pueden ser una herramienta \u00fatil para el farmac\u00e9utico para \nabordar de forma m\u00e1s efectiva la atenci\u00f3n farmac\u00e9utica al PCV en tratamiento antiretroviral. Su uso en la pr\u00e1ctica cl\u00ednica \nasistencial permite recopilar m\u00e1s datos sobre el paciente y realizar una actuaci\u00f3n cl\u00ednica profesional m\u00e1s centrada en sus \nnecesidades reales. Se pone de manifiesto la necesidad de sistematizar y digitalizar la realizaci\u00f3n de \u00e9stos dado la baja \nparticipaci\u00f3n.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n694. EFECTIVIDAD Y SEGURIDAD DE ANTIFIBR\u00d3TICOS EN EL TRATAMIENTO DE LA FIBROSIS PULMONAR \nIDIOP\u00c1TICA \nAUTORES\nMORENO RAMOS, C; DOM\u00cdNGUEZ SANTANA, CM; R\u00cdOS S\u00c1NCHEZ, E; BORRERO RUBIO, JM\nHOSPITAL DE ESPECIALIDADES DE PUERTO REAL \ufffd CTRA \ufffd NACIONAL IV, KM \ufffd 665 PUERTO REAL \ufffd C\u00c1DIZ\nOBJETIVOS\nAnalizar la efectividad y seguridad del tratamiento con los antifibr\u00f3ticos nintedanib y pirfenidona en la fibrosis pulmonar \nidiop\u00e1tica (FPI).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 a los pacientes diagnosticados de FPI en tratamiento con nintedanib y \npirfenidona desde enero-2017 a mayo-2022. Los datos obtenidos fueron recogidos a partir de la historia cl\u00ednica digital \n\u00fanica (Diraya\u00ae) y del programa de prescripci\u00f3n de pacientes externos (Dominion Farmatools\u00ae). Se registraron las \nsiguientes variables: sexo, edad, f\u00e1rmaco, duraci\u00f3n del tratamiento, switching de antifibr\u00f3tico y motivo. Como variables \nde efectividad se emple\u00f3 la capacidad vital forzada (CVF) al inicio y a los 6-12 meses, y la capacidad de difusi\u00f3n del \nmon\u00f3xido de carbono (DLCO) al inicio y a los 6-12 meses. Se considerara falta de respuesta si acontece una reducci\u00f3n 54de CVF > 10% o de DLCO \u226515% en un periodo interanual o inferior. Respecto a la seguridad, fueron recogidos los efectos \nadversos as\u00ed como las reducciones o suspensiones del antifibr\u00f3tico empleado debido a estos efectos.\nRESULTADOS\nSe incluyeron 32 pacientes (87,5% hombres y 12,5% mujeres), con una mediana de edad de 69 a\u00f1os (58-86), de los cuales \n7 pacientes recibieron nintedanib y 25 pirfenidona como primer tratamiento antifibr\u00f3tico. La mediana de duraci\u00f3n del \ntratamiento fue de 6 meses (3-13) en el caso de nintedanib y 23,5 meses (1-58) con pirfenidona. Se realiz\u00f3 un switching \nen 3 casos (2 pacientes pasaron de nintedanib a pirfenidona y 1 de pirfenidona a nintedanib), debido a la presencia \nde reacciones adversas. La mediana de CVF al inicio fue 65% (58,6-77) y 69% (41-92,3) para nintedanib y pirfenidona \nrespectivamente. A los 6-12 meses la CVF se situ\u00f3 en 61% (48-67) con nintedanib y 71,5% (45-106,1) con pirfenidona. \nLa mediana de DLCO al inicio fue 40% (34-68) para nintedanib y 62% (27-87) para pirfenidona. A los 6-12 meses los \nvalores de DLCO alcanzaron 37% (33-49) y 51% (37-86) para nintedanib y pirfenidona, respectivamente. No hubo falta \nde respuesta en ning\u00fan paciente. Un 71,9% de los pacientes manifest\u00f3 al menos una reacci\u00f3n adversa (57,1% con \nnintedanib, 76% con pirfenidona), siendo la m\u00e1s frecuente la aparici\u00f3n de lesiones cut\u00e1neas por fotosensibilidad en \nlos pacientes tratados con pirfenidona (40%) seguido por las reacciones de tipo gastrointestinal (42,9% en el grupo de \nnintedanib y 36% en pirfenidona). Se realiz\u00f3 una reducci\u00f3n de dosis en un paciente con nintedanib, as\u00ed como en 6 casos \nen tratamiento con pirfenidona\ufffd El tratamiento con nintedanib se suspendi\u00f3 en un paciente debido a reacciones adversas \n(aumento de transaminasas). En el caso de pirfenidona se suspendi\u00f3 en 6 pacientes (por erupci\u00f3n cut\u00e1nea y reacciones \ngastrointestinales).\nCONCLUSIONES\n1. Ambos f\u00e1rmacos antifibr\u00f3ticos mostraron efectividad en CVF y DLCO tras la reevaluaci\u00f3n a los 6-12 meses, ya que \nning\u00fan paciente tuvo falta de respuesta en ambas variables.  \n2. La seguridad de estos f\u00e1rmacos es la principal limitaci\u00f3n, ya que m\u00e1s de dos tercios de los pacientes tuvieron al menos \nuna reacci\u00f3n adversa, requiriendo en algunos casos, incluso suspensi\u00f3n del antifibr\u00f3tico. El principal efecto adverso de \npirfenidona fueron las lesiones cut\u00e1neas, y de nintedanib las reacciones gastrointestinales.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n708. EVALUACI\u00d3N DE LA EFICACIA Y SEGURIDAD DE BIOL\u00d3GICOS EN ASMA T2 EOSINOF\u00cdLICA EN \nPR\u00c1CTICA CL\u00cdNICA HABITUAL. \nAUTORES\nMONJE LOPEZ, AE; ZARATE , B; GARIN , N; OJEDA , S; CURTO , E; ZAYAS , M; PLAZA MORAL, V\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEl asma grave no controlada (AGNC) T2 eosinof\u00edlica es una patolog\u00eda grave con novedades terap\u00e9uticas recientes. Los \nresultados en salud de los f\u00e1rmacos que act\u00faan en la v\u00eda de la IL-5 son limitados en la pr\u00e1ctica cl\u00ednica habitual hasta el \nmomento\ufffd  \nEl objetivo del estudio fue evaluar la eficacia en pr\u00e1ctica cl\u00ednica habitual de mepolizumab, benralizumab y reslizumab \nen pacientes con AGNC eosinof\u00edlica a nivel de exacerbaciones y otros par\u00e1metros cl\u00ednicos de inter\u00e9s. Como objetivo \nsecundario se evalu\u00f3 su seguridad\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional, unic\u00e9ntrico, multidisciplinar, en condiciones de pr\u00e1ctica cl\u00ednica habitual. Se \nincluyeron pacientes adultos con AGNC eosinof\u00edlica tratados con mepolizumab, benralizumab y reslizumab desde 2017. El \nperiodo de seguimiento fue de 4 meses, momento en el que el equipo cl\u00ednico reevalu\u00f3 su eficacia y seguridad. Los datos \nse obtuvieron mediante revisi\u00f3n de la historia cl\u00ednica electr\u00f3nica, el registro de tratamientos de CatSalut y la base GEMA-\nDATA \ufffd \nSe recogieron variables demogr\u00e1ficas generales (sexo, edad, IMC, tabaquismo), condiciones potencialmente relacionadas \ncon el asma (alergia, EREA, poliposis, reflujo gastroesof\u00e1gico). Las variables seleccionadas para valorar la efectividad \nfueron: exacerbaciones, eosinofilia, FEV1, resultados del ACT y cambios en farmacoterapia (disminuci\u00f3n del uso de \ncorticoides orales).  \nSe realizaron pruebas T para muestras relacionadas para evaluar la efectividad del f\u00e1rmaco durante el periodo de estudio \n(exacerbaciones, eosinofilia, ACT, FEV1) mediante SPSS\u00ae v25. No se analizaron las diferencias entre f\u00e1rmacos por tama\u00f1o \nlimitado de la muestra de los subgrupos\ufffd\nRESULTADOS\nDe un total de 61 pacientes, 33 recibieron mepolizumab, 25 benralizumab y 3 reslizumab durante el periodo de estudio. \nDe estos, 39 (64%) fueron mujeres y 22 (36%) hombres, con una edad media de inicio del asma de 53 a\u00f1os (30-70), IMC \nmedio de 29 kg/m2 (19-52). Cinco pacientes eran fumadores. Respecto a las condiciones asociadas al asma se encontr\u00f3: \npoliposis (32), reflujo gastroesof\u00e1gico (26), alergia (25), EREA (11). \nTras el periodo de seguimiento, el n\u00famero de exacerbaciones disminuy\u00f3 de 3,49 a 0,12 (p < 0,0001 ajustado por periodo). \nRespecto a otras variables de inter\u00e9s, se obtuvieron los siguientes valores basales: eosinofilia de 758 c\u00e9l/\u00b5L (20-7460; SD \n1057,380), ACT de 14 (5-24; SD 5,177), FEV1 de 2031 mL (760,0-4580,0; SD 913,05). Tras el periodo de seguimiento estos \ndos par\u00e1metros mejoraron: eosinofilia: 69 c\u00e9l/\u00b5L (0-670; SD 122,382), ACT de 20 (6-25; SD 5,6) y FEV1 de 2425 (1020-\n4640; SD 800,92) (p < 0,002). De los 28 pacientes en tratamiento con corticoides orales al iniciar terapia con biol\u00f3gico, 12 \n(42,85%) pudieron disminuir/parar la dosis tras la mejora cl\u00ednica obtenida con el f\u00e1rmaco.  55Tras evaluaci\u00f3n cl\u00ednica, el equipo cl\u00ednico multidisciplinar consider\u00f3 que 49 pacientes fueron respondedores, 10 fueron \nrespondedores parciales y 2 no respondedores, por lo que se suspendi\u00f3 el tratamiento a estos \u00faltimos.  \nSe detectaron efectos adversos en 2 pacientes: algias en extremidades, vasculitis de debut.\nCONCLUSIONES\nEl tratamiento con anticuerpos monoclonales anti IL-5 en AGNC eosinof\u00edlica es eficaz y aumenta la calidad de vida, ya que \nconlleva una mejora en exacerbaciones, par\u00e1metros cl\u00ednicos y s\u00edntomas en la mayor\u00eda de pacientes en condiciones de \npr\u00e1ctica cl\u00ednica habitual. Adem\u00e1s, la frecuencia de efectos adversos es baja.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n711. EXPERENCIA REPORTADA POR EL PACIENTE SOBRE EL PROTOCOLO DE ANALGESIA DE CIRUG\u00cdA \nMAYOR AMBULATORIA: HERRAMIENTA DE MEJORA CONTINUA \nAUTORES\nGUEMBE ZABALETA, MB; LALUEZA BROTO, P; CORTES DE HARO, M; SALGADO ALGABA, I; GARCIA PORTABELLA, M; \nGOMEZ ALONSO, J; PUERTAS SANJUAN, A; GORGAS TORNER, MQ\nH. UNIVERSITARI DE TRAUMATOLOG\u00cdA DE LA VALL D`HEBRON. PASSEIG VALL D`HEBRON 119-129 BARCELONA. \nBARCELONA\nOBJETIVOS\nLos mecanismos de medici\u00f3n de la experiencia reportada por paciente (PREMS) permiten identificar puntos de mejora de \ndiferentes intervenciones sanitarias y, en nuestro caso, se ha utilizado para evaluar el protocolo analg\u00e9sico aprobado para \npacientes de Cirug\u00eda Mayor ambulatoria (CMA) y detectar opciones de mejora.  \nObjetivo: an\u00e1lisis de la adecuaci\u00f3n del protocolo analg\u00e9sico en CMA, as\u00ed como la adherencia al tratamiento analg\u00e9sico y \nsu eficacia en el dolor mediante un cuestionario validado vinculado a PREMS.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo unic\u00e9ntrico en un hospital de tercer nivel, de pacientes intervenidos de CMA (ortop\u00e9dica, pl\u00e1stica y \ndermatol\u00f3gica) durante diciembre-2021 y enero-22.  \nLos procedimientos quir\u00fargicos (PQ) fueron clasificados seg\u00fan el dolor postoperatorio (2 leve, 20 moderado y 14 intenso) \ny se les asign\u00f3 uno de los 7 kits de analgesia dise\u00f1ados seg\u00fan el protocolo. A cada paciente se le entreg\u00f3 una infograf\u00eda \ncon la indicaci\u00f3n de cada f\u00e1rmaco (rescates analg\u00e9sicos, gastroprotecci\u00f3n, antiemesis y conciliaci\u00f3n de sue\u00f1o), posolog\u00eda \ny administraci\u00f3n. Tras 24h del PQ se realiz\u00f3 la entrevista validada vinculada al PREMS. El cuestionario era una versi\u00f3n \nmodificada del \u201cMedication Adherence Questionnaire\u201d, incluyendo preguntas de adherencia, compresi\u00f3n de la infograf\u00eda \ny control del dolor \ufffd \nSe recogieron datos demogr\u00e1ficos, relacionados con el PQ, el tratamiento y los incluidos en el cuestionario. Las variables \ncuantitativas se expresan como medias (desviaci\u00f3n est\u00e1ndar) o medianas (rango intercuart\u00edlico).\nRESULTADOS\nSe incluyeron 100 pacientes (51% mujeres; edad mediana 56 (43,3-67,75) a\u00f1os). Del total, 79 fueron intervenciones \ntraumatol\u00f3gicas (23% dolor intenso, 43% dolor moderado; 4% dolor leve), 11 cirug\u00edas pl\u00e1sticas (100% dolor leve) y 10 \ndermatol\u00f3gicas (30% dolor intenso, 10%, dolor moderado y 60% dolor leve). \nEl 28% de PQ no recibieron un kit adecuado al tipo de dolor asignado. El 18% (14 pacientes) de las cirug\u00edas traum\u00e1ticas \n(cirug\u00eda de mano y pie) recibieron un kit de potencia leve en lugar de moderado y el 50% de ellos presentaron dolor \npostquir\u00fargico. Adem\u00e1s, todas las cirug\u00edas pl\u00e1sticas recibieron un kit de dolor moderado aun habi\u00e9ndose clasificado su \nintervenci\u00f3n como leve y no presentaron dolor postquir\u00fargico.  \nEn cuanto al an\u00e1lisis del cuestionario, el 100% de los pacientes entendieron las instrucciones, y el 80% siguieron el \ntratamiento (13% no tuvieron dolor). Solo 2 pacientes presentaron reacciones adversas al metamizol e ibuprofeno \n(nauseas, reacci\u00f3n cut\u00e1nea). La valoraci\u00f3n global del PREMS fue muy satisfactoria (9,18 \u00b1 1.2).  \nEl 40% de las intervenciones traum\u00e1ticas (retirada material osteos\u00edntesis, s\u00edndrome t\u00fanel carpiano, cirug\u00eda mano y \nartroscopia de rodilla y hombro) presentaron dolor postquir\u00fargico pese a una correcta prescripci\u00f3n del kit analg\u00e9sico.\nCONCLUSIONES\nLos cuestionarios vinculados a PREMS constituyen una herramienta \u00fatil en el seguimiento de la implementaci\u00f3n de los \nnuevos protocolos analg\u00e9sicos en la CMA. \nBuena adherencia de los pacientes a los kits analg\u00e9sicos protocolizados con alto grado de satisfacci\u00f3n, si bien se sugiere la \nnecesidad de reclasificaci\u00f3n de la intensidad de dolor asociada a cirug\u00edas de mano, pie y pl\u00e1sticas.  \nEn aquellos PQ con dolor postquir\u00fargico, se plantean acciones de mejora mediante la implementaci\u00f3n de analgesia \ninvasiva (bombas elastom\u00e9ricas para analgesia endovenosa y perineural).\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n773. EVALUACI\u00d3N EX VIVO DE LA EFICACIA DE UN NUEVO HIDROGEL TERMO-SENSIBLE DESARROLLADO \nCOMO FORMULACI\u00d3N MAGISTRAL PARA INYECCI\u00d3N SUBMUCOSA EN POLIPECTOM\u00cdAS. \nAUTORES\nVARELA REY , I; DE LA IGLESIA GARC\u00cdA, D; GONZALEZ BARCIA, M; MONTESERIN RON, L; MEJUTO FERNANDEZ, R; \nOTERO ESPINAR, FJ; ZARRA FERRO, I; FERNANDEZ FERREIRO, A\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE SANTIAGO. CHOUPANA, S/N SANTIAGO DE COMPOSTELA. A CORU\u00d1A56OBJETIVOS\nLa inyecci\u00f3n de soluciones en la submucosa intestinal durante la resecci\u00f3n endosc\u00f3pica de p\u00f3lipos permite mejorar la \nvisibilidad del p\u00f3lipo, facilitando su extirpaci\u00f3n y disminuyendo el riesgo de perforaci\u00f3n. Para ello, es necesario que sea \nf\u00e1cil de administrar a trav\u00e9s del cat\u00e9ter del endoscopio y que la elevaci\u00f3n producida sea duradera. El objetivo de este \ntrabajo fue evaluar la eficacia ex vivo de un hidrogel termo-sensible desarrollado como formulaci\u00f3n magistral (FM) y \ncompararlo con las soluciones actualmente empleadas en la pr\u00e1ctica cl\u00ednica: gelafundina (GA), soluci\u00f3n salina (SSF) y \nProducto comercial (BE).\nMATERIALES Y M\u00c9TODOS\nEstudio experimental multic\u00e9ntrico. Se realiz\u00f3 un dise\u00f1o de mezclas para desarrollar un hidrogel inteligente \ntermosensible, compuesto por Pluronic (PL) ,\u00e1cido hialur\u00f3nico (AH) y azul de metileno (AM) como colorante.  \nPara evaluar su eficacia ex vivo, se parte de un equipo multidisciplinar formado por farmac\u00e9uticos y gastroenter\u00f3logos \ny un dise\u00f1o de estudio prospectivo. Se utilizan porciones de est\u00f3mago de cerdo a las que se les aplica tensi\u00f3n \nconstante (150 N a cada lado) durante todo el ensayo, con el fin de simular las condiciones de elasticidad in vivo. El \nmodelo se introduce en una estufa a 37\u00baC y se inyectan en cada porci\u00f3n 2 ml del hidrogel desarrollado o 2 ml de la \nsoluciones comparadora (GA, SSF y BE, todas con azul de metileno). Se graba durante durante 60 minutos para medir \nposteriormente la elevaci\u00f3n de cada sustancia (altura) a diferentes tiempos mediante procesado de imagen con el \nprograma ImageJ (Image Processing and Analysis in Java). Cada ensayo se llev\u00f3 a cabo por triplicado para alcanzar un \ntama\u00f1o muestral y reproducibilidad adecuada\ufffd Los datos se muestran como la media \u00b1 SD del % de mantenimiento de la \nelevaci\u00f3n con respecto al inicio. El an\u00e1lisis estad\u00edstico se llev\u00f3 a cabo mediante test Bonferroni.\nRESULTADOS\nEl pol\u00edmero termo-inteligente desarrollado como FM es fluido a temperatura ambiente, lo que permite que sea f\u00e1cil \nde administrar a trav\u00e9s del cat\u00e9ter, sin embargo, al entrar en contacto con la submucosa y alcanzar los 37\u00baC, gelifica y \nprovoca la elevaci\u00f3n del p\u00f3lipo durante periodos de tiempo m\u00e1s prolongados y de forma m\u00e1s constante que que las \nsoluciones comparadoras. El % de mantenimiento de la elevaci\u00f3n a los 15 min fue de 80\u00b18% para el nuevo hidrogel \nfrente a 68\u00b17% para BE, 56\u00b112% para GA (p < 0,05%) y 49\u00b16% para SSF (p < 0,01%). A los 40 min se mantuvo el 68\u00b19% \ncon el nuevo hidrogel frente a 60\u00b13% con BE, 46\u00b111% con GA y 28\u00b16% con SSF (p < 0,001%). A los 60 min, se mantuvo un \n57\u00b14% con el nuevo hidrogel frente a 49\u00b13% con BE, 40\u00b112% con GA y 6\u00b18% con SSF (p < 0,0001%).\nCONCLUSIONES\nEl hidrogel desarrollado ha demostrado mantener durante m\u00e1s tiempo la elevaci\u00f3n de la mucosa en comparaci\u00f3n con \notros productos usados en pr\u00e1ctica cl\u00ednica. Por ello, la utilizaci\u00f3n cl\u00ednica de este nuevo hidrogel como FM podr\u00eda ser \nde gran utilidad durante la resecci\u00f3n endosc\u00f3pica de p\u00f3lipos. Recientes estudios in vivo precl\u00ednicos de seguridad y \nefectividad desarrollados por el grupo han ratificado la efectividad de estos resultados ex vivo.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n814. AN\u00c1LISIS DE PRESCRIPCI\u00d3N, EFICACIA Y SEGURIDAD DE ALIROCUMAB Y EVOLOCUMAB EN EL \nTRATAMIENTO DE LA HIPERCOLESTEROLEMIA \nAUTORES\nTORRALBA FERN\u00c1NDEZ, L; DOM\u00cdNGUEZ BARAHONA, A; TOLEDO DAVIA, MA; L\u00d3PEZ \u00c1LVAREZ, R; JIM\u00c9NEZ M\u00c9NDEZ, \nC; FERN\u00c1NDEZ-CORADA S\u00c1NCHEZ, A; BL\u00c1ZQUEZ ROMERO, C; MOYA G\u00d3MEZ, P\nCOMPLEJO HOSPITALARIO DE TOLEDO. AVDA. DE BARBER, 30 TOLEDO. TOLEDO\nOBJETIVOS\nAnalizar el perfil de prescripci\u00f3n, la eficacia y la seguridad de los anticuerpos monoclonales inhibidores de la proprote\u00edna \nconvertasa subtilisina-kexina tipo 9 (IPCSK9) en el tratamiento de la hipercolesterolemia, as\u00ed como comparar los \nresultados obtenidos con los distintos f\u00e1rmacos.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo llevado a cabo desde enero de 2019 hasta enero de 2022, en el que \nse incluyeron los pacientes de un hospital de tercer nivel tratados con IPCSK9 durante al menos un a\u00f1o. Las variables \nanalizadas fueron: sexo, edad, IPCSK9 prescrito (alirocumab o evolocumab), indicaci\u00f3n, reacciones adversas, valores de \ncolesterol total (CT) y colesterol LDL (c-LDL) en las semanas 0 y 52; y comparaci\u00f3n de los resultados obtenidos con los de \nlos estudios pivotales\ufffd  \nLos datos se recogieron a trav\u00e9s del m\u00f3dulo de dispensaci\u00f3n electr\u00f3nica a pacientes externos y de la historia cl\u00ednica \ninformatizada. El procesamiento de datos se realiz\u00f3 en una tabla Excel\u00ae y el an\u00e1lisis estad\u00edstico fue llevado a cabo con \nel programa SPSS\u00ae v.22.0. Las pruebas estad\u00edsticas empleadas fueron la t de Student para muestras apareadas y el test \nANOVA \ufffd\nRESULTADOS\nSe analizaron 120 pacientes: 75 hombres (62,5%) y 45 mujeres (37,5%). La mediana de edad fue de 59,44 a\u00f1os (Rango \nIntercuart\u00edlico (RIQ): 66,94.-49,75). 62 pacientes (51,7%) estaban en tratamiento con evolocumab y 58 (48,3%) con \nalirocumab. En cuanto a las indicaciones, el 56,7% de los pacientes presentaba hipercolesterolemia primaria y el 43,4% \nten\u00edan enfermedad ateroscler\u00f3tica establecida.  \nLa mediana de disminuci\u00f3n de c-LDL con evolocumab fue de 74,50 mg/dl (RIQ: 45,75-115,25) y de 64,50 mg/dl (RIQ: \n37,25-104,50) con alirocumab.  57Los valores de reducci\u00f3n de CT fueron 79 mg/dl (RIQ: 47,75-110) con evolocumab y 59,50 mg/dl (RIQ: 27,73-103,75) con \nalirocumab\ufffd  \nLa reducci\u00f3n de cLDL y CT a la semana 52 con ambos tratamientos fue estad\u00edsticamente significativa (p < 0,05).  \nNo se observaron diferencias significativas entre alirocumab y evolocumab en cuanto a disminuci\u00f3n de valores de CT (p > \n0,05) y c-LDL (p > 0,05).  \nEl estudio ODYSSEY LONG TERM mostr\u00f3 una reducci\u00f3n de los resultados de c-LDL con alirocumab de 61,3% a las 52 \nsemanas, mientras que, en nuestro estudio, la reducci\u00f3n obtenida fue de un 45,83%.  \nLa reducci\u00f3n de la concentraci\u00f3n de c-LDL con evolocumab a las 52 semanas en los estudios OSLER-2 y DESCARTES fue de \n52,3% y 57,5%, respectivamente. En nuestro caso, los valores de c-LDL disminuyeron un 53,49%.  \nEn cuanto a la evaluaci\u00f3n de la seguridad, 4 pacientes (3,33%) presentaron intolerancia a alirocumab: reacciones de \nhipersensibilidad, mialgias, estornudos y astenia. En 3 pacientes (2,5%) se observ\u00f3 intolerancia a evolocumab: reacciones \nde hipersensibilidad, diarrea y mialgias.\nCONCLUSIONES\nAlirocumab y evolocumab han demostrado reducir significativamente los niveles de CT y c-LDL. La respuesta producida \npor ambos f\u00e1rmacos es similar, sin apreciarse diferencias significativas. En comparaci\u00f3n con los estudios pivotales, \nevolocumab redujo el c-LDL de forma semejante, mientras que alirocumab lo hizo en menor medida. \u00danicamente en \nun reducido porcentaje de pacientes se produjo intolerancia a alguno de los f\u00e1rmacos, siendo necesario interrumpir el \ntratamiento\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n841. MEJORA DE LA TERAPIA FARMACOGERI\u00c1TRICA DE LAS PERSONAS MAYORES QUE VIVEN EN \nRESIDENCIAS A TRAV\u00c9S DE LA ATENCI\u00d3N FARMAC\u00c9UTICA \nAUTORES\nESTEBAN-CASADO , S; TEJEDOR-PRADO , P; SUCH-D\u00cdAZ , A; LOZANO-ROSIQUE , I; BRA\u00d1AS-BAZT\u00c1N , F; ESCOBAR-\nRODR\u00cdGUEZ , I\nHOSPITAL INFANTA LEONOR \ufffd GRAN V\u00cdA DEL ESTE, 80 MADRID \ufffd MADRID\nOBJETIVOS\nAnalizar las recomendaciones de atenci\u00f3n farmac\u00e9uticas(RAF) realizadas dentro de un proceso de atenci\u00f3n sanitaria al \npaciente mayor que vive en residencias y que son derivados a nuestro centro.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo prospectivo, realizado entre mayo-diciembre2021 en un hospital de complejidad intermedia en el que \nse analizaron las RAF del tratamiento habitual (TH) y agudo (TA) realizadas en coordinaci\u00f3n con geriatr\u00eda de enlace con \nresidencias (GER), sobre los pacientes derivados desde las residencias a nuestro centro por cualquier causa.  \nTodos los d\u00edas laborables se revisaron los pacientes derivados y que continuaban en el hospital en ese momento. Las RAF \nse incorporaron a la historia cl\u00ednica electr\u00f3nica(HCE).  \nDe HCE se recogieron variables demogr\u00e1ficas (edad y fecha de nacimiento) y del informe de derivaci\u00f3n de residencia el \nTH\ufffd \nLas RAF se categorizaron en: Desprescripci\u00f3n, reducci\u00f3n dosis/intensidad del TH (RD/I-TH), error de prescripci\u00f3n TH \n(EP-TH), problema salud insuficientemente tratado (PSIT), error prescripci\u00f3n TA (EP-TA), duplicidades/interacciones, \nprobabilidad de efectos adversos (PEA), modificaciones en receta electr\u00f3nica(MUP) y otros.  \nLas RAF se clasificaron por grupos de medicamentos(GdM): Anticoagulantes/antiagregantes, antidiab\u00e9ticos, \nantihipertensivos, antiarr\u00edtmicos, antidemencia/antipsic\u00f3ticos, hipn\u00f3ticos-sedantes/antidepresivos, gabapentanoides, \nmedicamentos con efectos anticolin\u00e9rgicos (anticolin\u00e9rgicos), opioides, inhibidores de la bomba de protones(IBP), \nantimicrobianos, antidislip\u00e9micos y miscel\u00e1nea.  \nUna RAF se consider\u00f3 aceptada cuando se inclu\u00eda en las recomendaciones de GER \u00f3 en el informe de alta, o conllevaba un \ncambio en el TA o en receta electr\u00f3nica\ufffd \nLas variables cuantitativas se describen mediana y rango intercuart\u00edlico(IQR) y las cualitativas mediante frecuencia y \nporcentajes. El an\u00e1lisis estad\u00edstico se realiz\u00f3 a trav\u00e9s del software STATAv.16.1\nRESULTADOS\nDurante el per\u00edodo de estudio se llev\u00f3 a cabo la revisi\u00f3n de 378 asistencias sanitarias en 254pacientes diferentes \n[73,2%mujeres. Mediana edad: 88,8a\u00f1os (IQR:83,6-92,7)]; con una mediana de 9 medicamentos cr\u00f3nicos/paciente \n(IQR:6-12). \nSe realizaron un total de 734 RFA (81,9% sobre TH). Por categor\u00eda RAF, la distribuci\u00f3n fue: desprescripci\u00f3n 37,7%; EP-TH \n24,5%; RD/I-TH 13,9%; EP-TA 8,3%; PSIT 5,0%; PEA 4,1%; MUP 2,72%; duplicidades/interacciones 2,0%; otros 1,6%. \nLa frecuencia de RAF por GdM se distribuy\u00f3: Miscel\u00e1nea 19,4%; hipn\u00f3ticos-sedantes/antidepresivos 12,5%; \nanticoagulantes/antiagregantes 12,4%; antidemencia/antipsic\u00f3ticos 10,6%; IBP 7,9%; antihipertensivos 7,5%; \nantidislip\u00e9micos: 6,5%; opioides 4,6%; antimicrobianos 4,4%; gabapentanoides 4,2%, antidiab\u00e9ticos 4,1%; antiarr\u00edtmicos \n3,1%; anticolin\u00e9rgicos 2,7%. \nEl grado de aceptaci\u00f3n(GA) fue del 52,4%; siendo del 60,2% sobre el TA y 50,6% en el TH.  \nPor categor\u00eda RAF, las 4categor\u00edas con mayor GA fueron: Otros (63,0%), PSIT (64,9%), EP-TH (58,3%%) y RD/I-TH (56,9%). \nPor GdM, los 4 grupos con mayor GA fueron: Antimicrobianos (71,9%), antiarr\u00edtmicos (78,3%), antidiab\u00e9ticos (60%) y \nanticoagulantes/antiagregantes (58,2%).  58Las categor\u00edas RAF con menor GA fueron desprescripci\u00f3n (45,5%) y MUP (35,0%) y por GdM: gabapentanoides (38,7%) y \nanticolin\u00e9rgicos (35,0%).\nCONCLUSIONES\nNuestra poblaci\u00f3n de estudio son personas de una edad muy avanzada y con elevada polifarmacia, lo que hace necesario \ntomar medidas para reducir prescripciones inapropiadas. Sin embargo; observamos que la desprescripci\u00f3n es una de las \nRAF con menor aceptaci\u00f3n y los gabapentanoides y anticolin\u00e9rgicos, los GdM con menor aceptaci\u00f3n. Ello demuestra una \nvez m\u00e1s que la prescripci\u00f3n es un acto de menor dificultad que la desprescripci\u00f3n, haciendo necesario incidir para que \nesta dificultosa acci\u00f3n vaya calando entre los prescriptores.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n850. OPTIMIZACI\u00d3N DE LA UTILIZACI\u00d3N DE METADONA EN UN CENTRO PENITENCIARIO \nAUTORES\nGARC\u00cdA RODICIO, S; LLAVERO SUBIRATS, H; GONZ\u00c1LEZ BORIS, O; NOGU\u00c9 PUJADAS, E; BAGUER CANALETA, N; DIEZ \nVALLEJO, C; DORD\u00c0 BENITO, A; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nValorar el resultado de las recomendaciones farmac\u00e9uticas unidas a la implicaci\u00f3n de enfermer\u00eda en la optimizaci\u00f3n de \nuso de metadona en un Centro Penitenciario (CP).\nMATERIALES Y M\u00c9TODOS\nEstudio longitudinal de un a\u00f1o de duraci\u00f3n con dos cortes transversales, basal (momento de la intervenci\u00f3n- abril 2021) \ny un a\u00f1o despu\u00e9s. En ambos cortes se recogieron datos demogr\u00e1ficos (edad, sexo), cl\u00ednicos (funci\u00f3n renal y hep\u00e1tica), \ny tratamiento farmacol\u00f3gico completo. La intervenci\u00f3n se bas\u00f3 en una reuni\u00f3n multidisciplinar, para la actualizaci\u00f3n \ndel protocolo de metadona en el centro. La farmac\u00e9utica revis\u00f3 todos los tratamientos activos para la detecci\u00f3n de \noportunidades de mejora, y la enfermera referente se implic\u00f3 activamente en el seguimiento y cuidado de los internos. \nSe estableci\u00f3 una sistem\u00e1tica de revisi\u00f3n y actualizaci\u00f3n peri\u00f3dica de los tratamientos activos.\nRESULTADOS\nEn abril de 2021 se identificaron 42/697 (6%;IC95%:4,3-7,8) internos en tratamiento con metadona con una dosis \nmediana de 42 [5-110] mg. La relaci\u00f3n hombre:mujer fue 14:1, siendo \u00e9sta en la globalidad del centro de 9:1. La edad \nmedia fue 43 [27-64] a\u00f1os. Se propuso en 8/42 pacientes, plantear un descenso de dosis por llevar en tratamiento \nestable (m\u00e1s de 6 meses) con dosis iguales o inferiores a 15 mg. Se identificaron 19/42 internos con posibles \ninteracciones relevantes por riesgo de prolongaci\u00f3n del intervalo QT: 2 con citalopram + quetiapina + metadona; 1 con \nclopromazina + quetiapina + metadona y 16 con quetiapina. Adem\u00e1s 30/42 (71%) ten\u00edan prescrito benzodiacepinas, \n3/30 dos benzodiazepinas. Tras la entrevista con la enfermera referente, los 8 pacientes con dosis inferiores a 15 \nmg, comenzaron pautas descendentes, planificadas con descensos de 5 mg cada dos o tres semanas, y seguimiento \nindividualizado con el m\u00e9dico y la enfermera. En todos ellos se retir\u00f3 la metadona. Se revisaron las dosis de quetiapina de \ntodos los internos, sin encontrar ninguna con dosis superiores a 300 mg. Se retir\u00f3 la quetiapina en el interno que llevaba \nasociada la clorpormazina.  \nEn abril de 2022, contin\u00faan en el centro 28 internos del corte de internos inicial, 2/28 han incrementado la dosis, 7/28 \nmantienen la misma dosis, 8/42 la han disminuido y a 11/28 se les ha retirado (8 de la propuesta inicial + 3 a lo largo del \na\u00f1o).  \nActualmente en el centro hay 32/679 (4,7%; IC95%:3,1-6,3) internos en tratamiento con metadona, con una dosis \nmediana de 45 [5-100] mg. En proporci\u00f3n contin\u00faa habiendo m\u00e1s hombres (16:1, siendo en la globalidad del centro de \n9:1) y la edad media es de 46 [31-65] a\u00f1os. Todos los internos con dosis menores de 15 mg est\u00e1n en pauta descendente. \nHay 10/32 quetiapina, ninguno con dosis supraterap\u00e9uticas, y 1 interno con citalopram + quetiapina + metadona \n(contin\u00faa de la cohorte inicial). Respecto al uso de benzodiacepinas, hay 22/32 (69%) internos en tratamiento, ninguno \ncon asociaci\u00f3n de 2\ufffd\nCONCLUSIONES\nLa intervenci\u00f3n multidisciplinar, con papel activo de enfermer\u00eda, m\u00e9dico y farmac\u00e9utico, permite optimizar el uso de \nmetadona en un CP , evitando prolongar tratamientos innecesarios, ajustar dosis y reducir el riesgo de interacciones \npotenciales\ufffd\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n893. ADECUACI\u00d3N DE LA TERAPIA ANTIPLAQUETARIA DUAL A LAS GU\u00cdAS EUROPEAS DE PR\u00c1CTICA \nCL\u00cdNICA EN SINDROME CORONARIO AGUDO. \nAUTORES\nSU\u00d1ER BARRIGA, H; CORT\u00c9S S\u00c1NCHEZ, CJ; SANJU\u00c1N BELDA, A; SACANELLA ANGL\u00c9S, I; PLO SECO, I; ESTEVE PITARCH, \nE; BOADA HERN\u00c1NDEZ, P; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA\nOBJETIVOS\nLa terapia antiplaquetaria dual (DAPT) con \u00e1cido acetilsalic\u00edlico m\u00e1s un inhibidor del receptor plaquetario P2Y12, \nconstituye el principal tratamiento para pacientes con s\u00edndrome coronario agudo (SCA).  59El objetivo es evaluar el grado de adecuaci\u00f3n de la DAPT prescrita a pacientes con diagn\u00f3stico de SCA en un hospital de \ntercer nivel a las gu\u00edas de pr\u00e1ctica cl\u00ednica de la Sociedad Europea de Cardiolog\u00eda (ESC).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo en el que se recogieron datos de pacientes ingresados en la planta de cardiolog\u00eda \nen abril 2022 con diagn\u00f3stico de SCA: angina inestable o infarto agudo de miocardio con o sin elevaci\u00f3n del segmento ST \n(IAMCEST, IAMSEST). Las variables recogidas fueron datos demogr\u00e1ficos (sexo, edad) y cl\u00ednicos (diagn\u00f3stico, tratamiento \ndurante el ingreso, factores de riesgo cardiovascular(FRCV): HTA, FA, DM2, DLP , IRC, ictus). Para cada paciente se calcul\u00f3 \nriesgo isqu\u00e9mico (seg\u00fan Escala GRACE) y hemorr\u00e1gico (seg\u00fan CRUSADE-Bleeding score). Se consider\u00f3 paciente de alto \nriesgo cardiovascular aquel con 3 o m\u00e1s de los FRCV descritos. El grado de adecuaci\u00f3n se valor\u00f3 haciendo uso de las gu\u00edas \npor diagn\u00f3stico y seg\u00fan riesgo isqu\u00e9mico-hemorr\u00e1gico del paciente.  \nLos datos fueron extra\u00eddos de la historia cl\u00ednica mediante el aplicativo SAP\u00ae y del programa de prescripci\u00f3n electr\u00f3nica \nSilicon\u00ae. Para el c\u00e1lculo del riesgo hemorr\u00e1gico e isqu\u00e9mico se utilizaron las calculadoras de la Sociedad andaluza de \nmedicina intensiva y unidades coronarias. El an\u00e1lisis estad\u00edstico descriptivo de los datos se realiz\u00f3 con el programa Stata \nv.15.0\u00ae. Las variables cualitativas fueron presentadas como frecuencias absolutas y porcentajes. Las cuantitativas como \nmedia \u00b1 desviaci\u00f3n est\u00e1ndar o mediana (rango) seg\u00fan prueba de normalidad Shapiro-Wilk.\nRESULTADOS\nSe recogieron un total de 30 pacientes con diagn\u00f3stico de SCA, de los cuales 86,67%(26) eran hombres con una edad \nmedia de 65,16 \u00b1 13,65 a\u00f1os, el 20%(6) con diagn\u00f3stico de angina inestable, 20%(6) IAMCEST y 60%(18) IAMSEST. \nTodos los pacientes estaban en tratamiento con DAPT y el 26,67%(8) adem\u00e1s estaban anticoagulados post intervenci\u00f3n \ncoronaria percut\u00e1nea. El 50%(15) eran pacientes con riesgo isqu\u00e9mico bajo, el 4,67%(14) medio y el 3,33%(1) alto. \nRespecto al riesgo hemorr\u00e1gico en el 23,33%(7) era bajo, en el 26,67%(8) medio y en el 50%(15) elevado. Solamente el \n26,67%(8) se consider\u00f3 paciente de alto riesgo cardiovascular.  \nSe observ\u00f3 una no-adecuaci\u00f3n de la DAPT prescrita del 30%(9) con la gu\u00edas ESC. Desglosando por diagn\u00f3stico, de los \npacientes con angina inestable el 66,67%(4/6), de los IAMSEST el 70,59%(12/17) y de los IAMCEST el 71,42%(5/7) de las \nprescripciones no se adecuaron a estas gu\u00edas.\nCONCLUSIONES\nNuestros resultados demuestran la importancia de realizar una correcta validaci\u00f3n farmac\u00e9utica durante el ingreso \nhospitalario. El estudio de los factores de riesgo de estos pacientes y la integraci\u00f3n del farmac\u00e9utico en el equipo \nmultidisciplinar podr\u00eda ser clave en reducir las discrepancias respecto a las gu\u00edas de pr\u00e1ctica cl\u00ednica, evitar la disparidad \nde criterios entre profesionales y, adem\u00e1s, facilitar\u00eda el seguimiento farmacoterap\u00e9utico para la optimizaci\u00f3n de la DAPT. \nNo obstante, con el fin de fortalecer nuestros resultados y extraer conclusiones m\u00e1s significativas, ser\u00eda necesaria la \nrealizaci\u00f3n de estudios con un mayor n\u00famero de pacientes y a largo plazo.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n904. VALIDACI\u00d3N FARMACE\u00daTICA DE LA HIPOPOTASEMIA EN EL PACIENTE HOSPITALIZADO \nAUTORES\nRUBIO RUIZ, L; SOL\u00cdS CU\u00d1ADO, S; V\u00c1ZQUEZ S\u00c1NCHEZ, R; IB\u00c1\u00d1EZ HERAS, N; HIJAZI VEGA, M; BARROSO TORREJ\u00d3N, \nV; S\u00c1NCHEZ VALERO, J; MOLINA GARC\u00cdA, T\nHOSPITAL UNIVERSITARIO DE GETAFE \ufffd CRTRA DE TOLEDO, KM \ufffd 12,5 GETAFE \ufffd MADRID\nOBJETIVOS\nLa hipopotasemia es una alteraci\u00f3n electrol\u00edtica (AE) frecuente en el paciente hospitalizado (PH) y puede desencadenar \ngraves alteraciones card\u00edacas y musculares. Entre sus causas encontramos ayuno, f\u00e1rmacos, v\u00f3mitos o diarrea. Es \nimportante si existe hipomagnesemia corregirla ya que sino la hipopotasemia puede ser refractaria al tratamiento. Los \nobjetivos de este trabajo son:  \n \n-Evaluar y vigilar la hipopotasemia en el PH.  \n \n-Estudiar las principales causas y analizar los f\u00e1rmacos potencialmente implicados (FPI).  \n \n-Analizar las intervenciones farmac\u00e9uticas (IF) realizadas determinando su grado de aceptaci\u00f3n (GA) y evaluar la \nnormalizaci\u00f3n de los niveles de potasio (K).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y prospectivo realizado entre octubre 2021-enero 2022. Se evaluaron pacientes \nhospitalizados con hipopotasemia a partir de las 24 horas de ingreso, excluyendo pacientes cr\u00edticos y neonatos. Se \nrevisaron diariamente los pacientes con K < 3,5mEq/L con la ayuda del localizador de AE del sistema de historia cl\u00ednica \nelectr\u00f3nica (HCE). El grado de hipopotasemia se clasific\u00f3 como: leve(3-3,5mEq/L); moderado(2,5-2,9mEq/L) y grave( < \n2,5mEq/L).  \n \nSe recogieron las variables: edad, sexo, fecha de ingreso, fecha de aparici\u00f3n de hipopotasemia, niveles de K (el d\u00eda del \nan\u00e1lisis y a los cuatro d\u00edas), FPI prescritos, niveles de magnesio (Mg), v\u00f3mitos, diarrea, ayuno y suplementos previos \nprescritos de K o Mg\ufffd  \n 60En los pacientes con hipopotasemia se realizaron las siguientes IF: se recomend\u00f3 prescribir suplementos de K (orales o \nintravenosos); determinaci\u00f3n anal\u00edtica de niveles de Mg y si hipomagnesemia se recomendaban suplementos de Mg. En \nel caso de que el paciente tuviera FPI prescritos, si era posible, se propon\u00edan alternativas.  \n \nSe realiz\u00f3 un seguimiento de la recuperaci\u00f3n de los niveles a los cuatro d\u00edas siguientes a la intervenci\u00f3n, y se determin\u00f3 el \nGA de la intervenci\u00f3n\ufffd\nRESULTADOS\nSe analizaron 107 pacientes. 62,6% eran hombres y la edad media de 74 a\u00f1os. Las alteraciones fueron clasificadas seg\u00fan \ngravedad: 69,2% leves; 26,2% moderadas y 4,7% graves. Los FPI prescritos con mayor frecuencia fueron: 53,3% diur\u00e9ticos; \n43% insulina; 28% laxantes; 23,4% agonistas beta-2; 10,3% vitamina B12/\u00e1cido f\u00f3lico y 3,4% diur\u00e9ticos ahorradores de K. \n72% de los pacientes estaban en tratamiento con dos o m\u00e1s FPI.13% de los pacientes analizados presentaban v\u00f3mitos y \ndiarreas y 10,7% ayuno\ufffd  \n \nEn todos los pacientes analizados se realiz\u00f3 vigilancia activa de los niveles de K y se realiz\u00f3 en el 44,8% IF. La \nrecomendaci\u00f3n de un suplemento de K supuso el 78% de las intervenciones realizadas, el 17,2% de las intervenciones \nestaban relacionadas con la monitorizaci\u00f3n o suplementaci\u00f3n de Mg. El 52% de las intervenciones realizadas fueron \naceptadas por el prescriptor y en el 80% se observ\u00f3 una recuperaci\u00f3n de los niveles de potasio frente al 39,1% de los \npacientes con intervenci\u00f3n no aceptada\ufffd\nCONCLUSIONES\nLa hipopotasemia es m\u00e1s frecuente en hombres de edad avanzada, se asocia al tratamiento con determinados f\u00e1rmacos \nsiendo los m\u00e1s frecuentes diur\u00e9ticos, insulina y laxantes. Es habitual la prescripci\u00f3n de dos o FPI en el desarrollo de esta \nAE\ufffd  \n \nDisponer de herramientas de ayuda a la validaci\u00f3n farmac\u00e9utica en la HCE puede favorecer la detecci\u00f3n y el seguimiento \nde AE que, si no se consideran, pueden desencadenar graves consecuencias.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n918. VALORACI\u00d3N DEL DOLOR TRAS LA IMPLANTACI\u00d3N DE UN NUEVO PROTOCOLO DE ANALGESIA EN \nCES\u00c1REAS \nAUTORES\nMONTES CASAS, M; OLLER CODINA, M; LOPEZ VI\u00d1ALS, M; AYESTARAN ALTUNA, A; FIERRO BANZO, AJ; GARCIA \nPORTA, R; OLIVER SINTES, C; SANTILLANA MONTAL, M\nHOSPITAL DE BARCELONA \ufffd AV\ufffd DIAGONAL, 656 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nDeterminar el control del dolor y el uso de rescates con morfina subcut\u00e1nea tras la implantaci\u00f3n de un protocolo nuevo \nde analgesia en ces\u00e1reas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, prospectivo realizado de enero a diciembre de 2021.  \nVariables recogidas: farmacoterap\u00e9uticas (analgesia pautada y de rescate) y la intensidad del dolor, que se midi\u00f3 con la \nEscala Visual Anal\u00f3gica (EVA). \nLa informaci\u00f3n la obtuvo la enfermera del control de dolor revisando la historia cl\u00ednica de enfermer\u00eda y entrevistando a \nlas pacientes\ufffd \n \nEn 2021 se implantaron tres protocolos de analgesia para ces\u00e1reas consensuados con Anestesia y Farmacia. La base \nconsist\u00eda en dexketoprofeno 50 mg/8h intravenoso alternado con paracetamol 1g/6h iv y adem\u00e1s: \nProtocolo 1: anestesia locoregional con morfina intratecal 100-150 mcg y morfina 4 mg subcut\u00e1nea de rescate \n(m\u00e1ximo/4h).  \nProtocolo 2: anestesia locoregional con morfinal peridural 3 mg y morfina 4 mg sc de rescate (m\u00e1ximo/4h)  \nProtocolo 3: anestesia intra/peridural, general y/o IMC mayor de 35 con morfina iv 1 mg/10 kg de peso y bomba de \nmorfina PCA (analgesia controlada por el paciente) con una tasa de 0,5 mg/h, bolus de 0,5 mg y 10 bolus m\u00e1ximo/hora \ncon tiempo de cierre de 5 minutos.  \nEl protocolo aprobado anteriormente consist\u00eda en dexketoprofeno iv 50 mg/8h, morfina sc 1 mg/10 kg de peso si precisa \n(m\u00e1ximo/4 horas) y paracetamol 1 g iv/6h si EVA mayor de 4 a los 30 min de la morfina.  \n \nEl personal de enfermer\u00eda registr\u00f3 el EVA de los pacientes al d\u00eda siguiente de la ces\u00e1rea y calcul\u00f3 la media diaria, si \u00e9sta \nera inferior a cuatro se consider\u00f3 dolor controlado. Tambi\u00e9n se recogi\u00f3 el uso de rescates de morfina subcut\u00e1nea en estas \npacientes\ufffd\nRESULTADOS\nSe incluyeron 242 pacientes, 173 con protocolo 1, 47 con protocolo 2 y 22 con protocolo 3\ufffd  \nEl dolor se control\u00f3 en un 79,2% (137), 87,2% (41) y 63,6% (14) respectivamente, siendo mejor el resultado con \nel protocolo 2. En el caso de pacientes a los que se administr\u00f3 el protocolo 3, se observ\u00f3 un resultado similar \nindependientemente que la anestesia fuera intradural , peridural o general (62,5%,63,6% y 66,7% respectivamente). 61Con la implantaci\u00f3n de los nuevos protocolos la media de EVA disminuyo de 3,6 en 2019 a 2,9 en 2021,  \nEn relaci\u00f3n con las necesidades de morfina sc de rescate, la precisaron un 10% (18) de pacientes con el protocolo 1, 15% \n(7) con el protocolo 2 y 32% (7) con el protocolo 3. Se observ\u00f3 que de los 22 pacientes con este \u00faltimo protocolo s\u00f3lo en \n2 se instaur\u00f3 la bomba PCA a criterio del anestesi\u00f3logo\ufffd\nCONCLUSIONES\nCon la implantaci\u00f3n de estos protocolos, se observ\u00f3 una mejor\u00eda en la puntuaci\u00f3n de EVA, as\u00ed como un dolor mejor \ncontrolado en un gran porcentaje de pacientes. El alto uso de rescates de morfina en el protocolo 3 podr\u00eda ser debido al \nbajo uso de la bomba PCA.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n927. INTERVENCIONES FARMAC\u00c9UTICAS REALIZADAS EN EL SENO DE UN EQUIPO MULTIDISCIPLINAR \nEN MEDICINA INTERNA. \nAUTORES\nYBA\u00d1EZ GARCIA, L; NIETO , A; FERNANDEZ RUIZ MORON, A; MANZANO LORENZO, R; CORAZON VILLANUEVA, J; \nSANCHEZ OCANA MARTIN, N; MOLINERO MU\u00d1OZ, M; MARTINEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nDescribir y analizar la actividad realizada por el farmac\u00e9utico en una unidad de medicina interna.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, prospectivo. Se incluyeron los pacientes ingresados en una unidad de medicina \ninterna del 1 de abril al 5 de mayo de 2022. El farmac\u00e9utico realizaba conciliaci\u00f3n al ingreso (presencial o telem\u00e1tica), al \nalta cuando hubiese cambios en el tratamiento habitual y estaba presente durante la prescripci\u00f3n de los tratamientos, de \nforma que las intervenciones pod\u00edan realizarse de forma presencial a tiempo real en el momento de la prescripci\u00f3n.  \nSe registraron las intervenciones farmac\u00e9uticas realizadas y se clasificaron en funci\u00f3n del momento en el que se \nrealizaron: conciliaci\u00f3n al ingreso, intervenciones realizadas durante el ingreso o en la conciliaci\u00f3n al alta y si fueron \naceptadas o no\ufffd\nRESULTADOS\nSe incluyeron 29 pacientes (18 mujeres), la mediana de edad fue de 81, 4 a\u00f1os (57-97). La mediana de f\u00e1rmacos \nque tomaban como parte de su tratamiento habitual fue de 8. 9 pacientes cumpl\u00edan criterios de polimedicaci\u00f3n (5-9 \nf\u00e1rmacos) y 13 de hiperpolimedicaci\u00f3n (9 o m\u00e1s medicamentos). La conciliaci\u00f3n de forma presencial al ingreso solo se \nrealiz\u00f3 en 9 pacientes. En el resto de pacientes tuvo que realizarse de forma telem\u00e1tica con los datos disponibles en la \naplicaci\u00f3n del M\u00f3dulo \u00danico de Prescripci\u00f3n, por no ser el paciente capaz de realizar la entrevista y no haber familiar \ndisponible. Sobre estos pacientes se han realizado un total de 33 intervenciones de las cuales 29 fueron aceptadas. \nClasificaci\u00f3n de las intervenciones: \nConciliaci\u00f3n al ingreso: 9 pacientes, 10 intervenciones, 8 aceptadas: \nTratamiento habitual no prescrito: 5 \nDiscrepancia posol\u00f3gica o forma farmac\u00e9utica: 3  \nDuplicidad terap\u00e9utica: 1  \nMedicamento innecesario: 1  \nConciliaci\u00f3n al alta: 4 pacientes presenciales, 2 pacientes derivados para conciliaci\u00f3n en atenci\u00f3n primaria (AP). \nAceptadas 3, 2 de AP pendientes\ufffd \nTratamiento al alta no prescrito en tarjeta sanitaria: 2 \nSimplificaci\u00f3n de tratamiento: 1 \nCambios en la medicaci\u00f3n habitual no relacionados con la patolog\u00eda de ingreso: 3 (una en consulta, dos derivados a \nfarmacia AP). \nIntervenciones durante el ingreso: 20 intervenciones sobre 16 pacientes\ufffd 17 aceptadas\ufffd  \nSuspender tratamiento: 6 \nCambio forma farmac\u00e9utica: 2  \nDosificaci\u00f3n: 2  \nInteracciones: 2 \nOptimizaci\u00f3n terapia antibi\u00f3tica: 6  \nRecomendaciones coste-eficiencia: 2\nCONCLUSIONES\nLa formaci\u00f3n de un equipo multidisciplinar que integre al farmac\u00e9utico en medicina interna permite transmitir \nlas discrepancias al prescriptor en el momento en el que se est\u00e1 decidiendo el tratamiento, de forma que pueden \nrazonarse los distintos puntos de vista. Como esto sucede en el mismo momento de la prescripci\u00f3n, en el caso de que \nse produjese alg\u00fan error de medicaci\u00f3n, se detectar\u00eda antes de que llegue al paciente. Adem\u00e1s, la informaci\u00f3n que tiene \nel farmac\u00e9utico del paciente es mayor que en la validaci\u00f3n tradicional, lo que permite que la intervenci\u00f3n se realice \nde forma m\u00e1s individualizada. Esto cobra todav\u00eda una mayor importancia teniendo en cuenta la gran prevalencia de la \npolifarmacia en los pacientes que ingresan en estas unidades de hospitalizaci\u00f3n.v62CLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1013. EDOXABAN Y DABIGATRAN EN PACIENTES DE EDAD AVANZADA CON FIBRILACI\u00d3N AURICULAR \nNO VALVULAR: EFECTIVIDAD Y SEGURIDAD \nAUTORES\nGEMENO L\u00d3PEZ, E; \u00c1LVAREZ PINHEIRO, CG; GUIJARRO MART\u00cdNEZ, P; MONTERO ERRASQU\u00cdN, B; MOLINA MENDOZA, \nMD; \u00c1LVAREZ D\u00cdAZ, AM; DELGADO SILVEIRA, E\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nEstudiar la efectividad y seguridad del edoxaban y el dabigatran en pacientes de 85 o m\u00e1s a\u00f1os con fibrilaci\u00f3n auricular \nno valvular (FANV) durante el primer a\u00f1o de tratamiento. Estudiar las interacciones cl\u00ednicamente relevantes relacionadas. \nCuantificar la utilizaci\u00f3n de recursos sanitarios asociados\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo de los pacientes de 85 o m\u00e1s a\u00f1os con FANV que iniciaron tratamiento con edoxaban \no dabigatran en 2019 en el \u00e1rea de influencia de un hospital de tercer nivel. A trav\u00e9s de la historia cl\u00ednica electr\u00f3nica \nse recogieron caracter\u00edsticas sociodemogr\u00e1ficas, comorbilidades, datos anal\u00edticos previos al inicio del f\u00e1rmaco, escalas \nde evaluaci\u00f3n del riesgo tromb\u00f3tico y hemorr\u00e1gico, n\u00famero de f\u00e1rmacos, interacciones de relevancia cl\u00ednica, f\u00e1rmacos \nimplicados en dichas interacciones, visitas a urgencias durante el primer a\u00f1o de tratamiento y relaci\u00f3n de las mismas con \neventos tromb\u00f3ticos y hemorr\u00e1gicos y hospitalizaciones relacionadas. La efectividad se midi\u00f3 en el n\u00famero de eventos \ntromb\u00f3ticos y hemorr\u00e1gicos y la seguridad tambi\u00e9n con las interacciones de los f\u00e1rmacos\nRESULTADOS\nSe incluyeron 137 pacientes, 41 con dabigatran y 96 con edoxaban (56,9% mujeres, edad media 89 \u00b13 a\u00f1os). El 83,9% \neran hipertensos, el 48,2% eran dislip\u00e9micos, 35,8% eran diab\u00e9ticos, el 25,5% obesos y un 8% no presentaban ning\u00fan \nfactor de riesgo cardiovascular \ufffd \nEl 76,6% de los pacientes acudieron a urgencias durante el primer a\u00f1o del tratamiento (68,6% edoxaban y 31,4% \ndabigatran), ingresando el 61% (29,7% dabigatran y 70,3% edoxaban). De las hospitalizaciones, el motivo de ingreso \nen el 23,4% fue un evento tromb\u00f3tico (53,3%) o hemorr\u00e1gico (46,7%), en su mayor\u00eda hemorragia mayor con sangrado \nintracraneal o digestivo. Los que presentaron el evento ten\u00edan alto riesgo tromb\u00f3tico (CHADsVASc entre 4-8) y \nhemorr\u00e1gico (HASBLED entre 2-7). \nLa mediana de f\u00e1rmacos prescritos de forma cr\u00f3nica fue 8 \u00b1 3,5. El 85,4% presentaban polifarmacia (\u22655 f\u00e1rmacos) y \npolifarmacia extrema (\u226510 f\u00e1rmacos) el 33,6%. Se encontraron interacciones cl\u00ednicamente relevantes en el 35,8% de los \npacientes, de las cuales un 69,4% aumentaban el riesgo de sangrado, un 4,1% aumentaban riesgo de trombo y 26,5% \npacientes presentaron ambas interacciones. Se encontraron 51% interacciones con edoxaban (todas aumentaban riesgo \nde sangrado) y 49% interacciones con dabigatran. El f\u00e1rmaco que interaccionaba m\u00e1s frecuentemente con edoxaban \nfue el metamizol (36%), aumentando riesgo de sangrado. Los f\u00e1rmacos que m\u00e1s frecuentemente interaccionaron \ncon dabigatran fueron metamizol (41,7%) aumentando el riesgo de sangrado y estatinas (20,8%) e IBPs (58,3%) que \naumentaban el riesgo de tromboembolismo\nCONCLUSIONES\nLa mayor\u00eda de los pacientes acudieron a urgencias durante el primer a\u00f1o de tratamiento, ingresando dos tercios de los \npacientes con edoxaban y un tercio de los pacientes con dabigatran\ufffd  \nUn cuarto de los ingresos hospitalarios se relacionaron con eventos tromb\u00f3ticos y hemorr\u00e1gicos.  \nCasi todos los pacientes que iniciaron anticoagulante presentaban polifarmacia, con interacciones que aumentaban el \nriesgo de sangrado en casi tres cuartos de ellos. El metamizol interaccionaba con mayor frecuencia con el edoxaban y los \nIBPs con el dabigatran\ufffd  \nEs necesario profundizar en los motivos de las mayores complicaciones con edoxaban\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1046. EFECTIVIDAD DE CASIRIVIMAB/IMDEVIMAB Y SOTROVIMAB FRENTE AL COVID-19 \nAUTORES\nTRIGO VICENTE, C; CABIA FERN\u00c1NDEZ, L; \u00c1LVAREZ NONAY , A; BANDR\u00c9S LISO, AC; DEL CORRAL BEAMONTE, E\nUNIDAD USO RACIONAL DEL MEDICAMENTO DE ARAG\u00d3N\nOBJETIVOS\nAn\u00e1lisis de la efectividad de los anticuerpos monoclonales disponibles, casirivimab/ imdevimab y sotrovimab, para el \ntratamiento de los pacientes infectados por COVID-19.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, retrospectivo para la valoraci\u00f3n de la efectividad de los anticuerpos monoclonales disponibles para \nel tratamiento de la infecci\u00f3n por COVID-19 de los pacientes tratados en Arag\u00f3n desde 1 Agosto 2021 a 15 Abril 2022. \nSe ha estudiado la edad media de los pacientes, sexo, d\u00edas inicio desde la aparici\u00f3n de los s\u00edntomas hasta la instauraci\u00f3n \ndel tratamiento (\u2264 o > 7 d\u00edas), gravedad de la enfermedad, definida por requerimiento de oxigeno suplementario o no \n(moderado-grave o leve, respectivamente), variante del virus, cumplimiento de los criterios de priorizaci\u00f3n del grupo de \nexpertos de la Agencia Espa\u00f1ola del Medicamento (AEMPS), serolog\u00eda anti IgG antiesp\u00edcula S, mortalidad y mortalidad a \nlos 30 d\u00edas.63RESULTADOS\nHan sido tratados 69 pacientes, de los que el 43,48% fueron mujeres y el 56,52% hombres, con una edad media de 64,48 \na\u00f1os. El 46,38% (32 pacientes) recibieron tratamiento con el anticuerpo monoclonal dentro de los primeros 7 d\u00edas desde \nel inicio de los s\u00edntomas: un 28% (9 pacientes) ten\u00edan enfermedad leve y un 72% (23 pacientes) ten\u00edan enfermedad grave \nantes de iniciar el tratamiento. De los pacientes con > 7 d\u00edas desde el inicio de los s\u00edntomas (37 pacientes, 53,62%), \nun 16% (6 pacientes) ten\u00edan enfermedad leve y un 84% (31 pacientes) ten\u00edan enfermedad grave. El 33,33% de los \npacientes eran positivos para la variante Omicron, y en el 11,59% para la variante Delta. En el resto de los casos no fue \ndeterminada, ya que en ese momento la variante Omicron era la cepa prevalente. El 86,96% de los pacientes cumplieron \ncon alguno de los criterios de priorizaci\u00f3n del grupo de expertos de la AEMPS. El 94,2% no presentaba anticuerpos IgG \nantiesp\u00edcula S. Fallecieron un total de 18 pacientes (26,09%), con una mortalidad a los 30 d\u00edas tras recibir el tratamiento \ncon el anticuerpo monoclonal de un 66,67% (12 pacientes). Todos los pacientes fallecidos eran pacientes con enfermedad \nmoderada-grave.\nCONCLUSIONES\nS\u00f3lo los pacientes que iniciaron tratamiento con enfermedad moderada-grave fueron los que presentaron una mayor \nmortalidad, independientemente de la fecha del inicio de los s\u00edntomas. No se registr\u00f3 ning\u00fan fallecimiento en los \npacientes con enfermedad leve, siendo por tanto primordial el acceso temprano a estos f\u00e1rmacos con objeto de evitar el \nriesgo de progresi\u00f3n y muerte por la infecci\u00f3n\ufffd\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1048. AN\u00c1LISIS DE RESULTADOS DE UN PROGRAMA DE CONCILIACI\u00d3N DE F\u00c1RMACOS \nANTIPARKINSONIANOS: IDENTIFICACI\u00d3N Y PREVENCI\u00d3N DE ERRORES DE MEDICACI\u00d3N \nAUTORES\nVIUDEZ MART\u00cdNEZ, A; RAM\u00cdREZ L\u00d3PEZ, A; L\u00d3PEZ-NIETO SEMPERE, J; BELTR\u00c1 PIC\u00d3, I; ESPADAS GARC\u00cdA, I; MATEO \nGARC\u00cdA, M; CLIMENT GRANA, E; RIERA , G\nHOSPITAL GENERAL UNIVERSITARIO DE ALICANTE \ufffd AV\ufffd PINTOR BAEZA, 12 ALICANTE/ALACANT \ufffd ALICANTE\nOBJETIVOS\nIdentificar los tipos de errores de conciliaci\u00f3n con la medicaci\u00f3n antiparkinsoniana en el momento del ingreso. Evaluar la \nefectividad del programa de conciliaci\u00f3n en la prevenci\u00f3n de errores con da\u00f1o potencial en el paciente.\nMATERIALES Y M\u00c9TODOS\nDise\u00f1o:  \nEstudio prospectivo, de intervenci\u00f3n, basado en el proceso de conciliaci\u00f3n, de un a\u00f1o de duraci\u00f3n (febrero 2021- enero \n2022) en un hospital de tercer nivel.  \nPoblaci\u00f3n de estudio:  \nPacientes hospitalizados durante el per\u00edodo del estudio con al menos un f\u00e1rmaco antiparkinsoniano prescrito en el \nmomento del ingreso\ufffd  \nIntervenci\u00f3n realizada: \nCaptaci\u00f3n de los casos en el momento del ingreso mediante el sistema de prescripci\u00f3n electr\u00f3nica asistida, y posterior \nrevisi\u00f3n del tratamiento prescrito, comparaci\u00f3n con el tratamiento domiciliario, la situaci\u00f3n actual en el momento del \ningreso y el interrogatorio del farmac\u00e9utico al paciente/cuidador.  \nSe registraron las variables demogr\u00e1ficas de los pacientes, los datos del episodio de hospitalizaci\u00f3n, motivo de ingreso, \nmedicamentos antiparkinsonianos y tipos de errores de conciliaci\u00f3n.  \nLas discrepancias encontradas se clasificaron seg\u00fan el f\u00e1rmaco, dosis, forma de liberaci\u00f3n, pauta posol\u00f3gica, horario \nde administraci\u00f3n, u omisi\u00f3n. Tambi\u00e9n se identificaron posibles contraindicaciones con otros medicamentos para \nrecomendar alternativas terap\u00e9uticas y evitar su administraci\u00f3n.  \nLa efectividad se evalu\u00f3 mediante la medici\u00f3n del n\u00famero de dosis err\u00f3neas de f\u00e1rmacos antiparkinsonianos administradas \nhasta la conciliaci\u00f3n, el n\u00famero de dosis err\u00f3neas evitadas durante el ingreso debido al programa de conciliaci\u00f3n, as\u00ed como \nel n\u00famero de dosis correctas administradas hasta el alta que no requirieron de intervenci\u00f3n farmac\u00e9utica.  \nAn\u00e1lisis de datos: \nPara el an\u00e1lisis de los datos se utilizaron programas inform\u00e1ticos corporativos de an\u00e1lisis de datos, como Excel.\nRESULTADOS\nSe registraron 171 episodios de hospitalizaci\u00f3n correspondientes a 132 pacientes (73 hombres (55,3%)), con una edad \nmedia de 78,7 a\u00f1os (desviaci\u00f3n est\u00e1ndar: 8,3 a\u00f1os) y una estancia media de 8,8 d\u00edas (desviaci\u00f3n est\u00e1ndar: 7,4); el 25,7% \nde los pacientes evaluados ten\u00edan > = 2 f\u00e1rmacos antiparkinsonianos.  \nEl programa de conciliaci\u00f3n de medicaci\u00f3nf\u00e1rmacos antiparkinsonianos permiti\u00f3 identificar que m\u00e1s de un 50% de las \nprescripciones al ingreso conten\u00eda, al menos, un error. Los errores identificados con mayor frecuencia fueron: de horario \n(41,9 %), pauta posol\u00f3gica (21,2%), dosis (19,6%), forma de liberaci\u00f3n (7,3%) y principio activo (1,7%). Asimismo, evit\u00f3 la \nadministraci\u00f3n de m\u00e1s de 2700 dosis err\u00f3neas/a\u00f1o, lo que supone un 60% del total de dosis administradas de f\u00e1rmacos \nantiparkinsonianos durante este per\u00edodo.\nCONCLUSIONES\nLa implementaci\u00f3n de programas de conciliaci\u00f3n estructurados y la revisi\u00f3n terap\u00e9utica ligada a la prescripci\u00f3n permiten \nidentificar y prevenir errores de medicaci\u00f3n de forma eficaz en el momento del ingreso. \nEl farmac\u00e9utico, en colaboraci\u00f3n con el equipo asistencial, es un agente de salud clave en la seguridad del paciente.64CLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1059. RIESGO DE TRANSFUSI\u00d3N SANGU\u00cdNEA EN PACIENTES CON ANTIAGREGANTES Y ANTICOAGULANTES \nTRAS LA INTERVENCI\u00d3N POR FRACTURA DE CADERA \nAUTORES\nMIRANDA MAGA\u00d1A, M; MU\u00d1OZ BARROSO, M; ESPINA LOZANO, JM; FAUS FELIPE, V; GUERADO PARRA, E; TORTAJADA \nGOITIA, B\nCOMPLEJO HOSPITAL COSTA DEL SOL. CRTRA NACIONAL 340, KM. 187 MARBELLA. MALAGA\nOBJETIVOS\nAntiagregantes (AA) y anticoagulantes orales (ACO) juegan un papel crucial en la prevenci\u00f3n de enfermedades \ntromboemb\u00f3licas, sin embargo, su uso en el entorno periquir\u00fargico es complejo y puede ocasionar eventos \nhemorr\u00e1gicos. El objetivo del estudio fue analizar la influencia de su uso en el sangrado de los pacientes sometidos a \nintervenci\u00f3n quir\u00fargica por fractura de cadera, medido a trav\u00e9s de la probabilidad de recibir una transfusi\u00f3n sangu\u00ednea \ntras la intervenci\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo y observacional. Se seleccion\u00f3 aleatoriamente una cohorte de 30 pacientes mayores de 65 a\u00f1os que \ningresaron en nuestro centro tras sufrir una fractura de cadera\ufffd Se recogieron las variables: tratamiento domiciliario con \nun f\u00e1rmaco anticoagulante o antiagregante, valor de hemoglobina previa al ingreso, \u00edndice de Charlson, y si precisaron \nde la administraci\u00f3n de hierro o de una transfusi\u00f3n sangu\u00ednea durante la estancia hospitalaria. Algunos estudios han \nmostrado una relaci\u00f3n entre anticoagulaci\u00f3n y eventos tromboemb\u00f3licos, si bien \u00e9sta se ha mostrado independiente del \ntiempo en el que se suspende el tratamiento previo a la intervenci\u00f3n quir\u00fargica. Para estudiar la posible relaci\u00f3n entre \nAA y ACO de manera independiente de otros factores de confusi\u00f3n que podr\u00edan afectar al resultado, se llev\u00f3 a cabo un \nmodelo de regresi\u00f3n lineal m\u00faltiple entre la necesidad de transfusi\u00f3n sangu\u00ednea y el resto de covariables descritas. El \nnivel de significaci\u00f3n estad\u00edstica para los diferentes an\u00e1lisis fue de p < 0,05. El an\u00e1lisis estad\u00edstico se llev\u00f3 a cabo mediante \nel sistema SPSS\ufffd\nRESULTADOS\nEl estudio incluy\u00f3 30 pacientes, edad media 79 a\u00f1os (DE +/- 7) 73% mujeres. La media del \u00edndice de Charlson fue de 5 (IC \n4,2-5,5). Al 34 % de los pacientes con ACO y AA se les hubo de trasfundir sangre, mientras que en el resto de pacientes no \nantiagregados o anticoagulados el porcentaje de transfusi\u00f3n fue del 15%. Pese a ello, en el modelo de regresi\u00f3n m\u00faltiple \nno hubo asociaci\u00f3n entre la toma de anticoagulantes y la transfusi\u00f3n sangu\u00ednea, pero s\u00ed con el \u00edndice de Charlson, que fue \nla \u00fanica variable que alcanz\u00f3 significaci\u00f3n estad\u00edstica en el modelo conjunto.\nCONCLUSIONES\nLos pacientes que toman anticoagulantes orales tienen mayor riesgo de sangrado durante una intervenci\u00f3n por fractura \nde cadera y requieren transfusi\u00f3n sangu\u00ednea. Sin embargo, este hecho puede deberse m\u00e1s a la comorbilidad del paciente \nque a la toma de la medicaci\u00f3n.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1073. AN\u00c1LISIS DE LA CARGA ANTICOLIN\u00c9RGICA EN PACIENTES ANCIANOS POLIMEDICADOS QUE HAN \nSUFRIDO UNA CA\u00cdDA. \nAUTORES\nSALDA\u00d1A SORIA, R; MARTINEZ-BROCAL OGAYAR, I; GONZ\u00c1LEZ PADILLA, M; JURADO ROMERO, \u00c1\nHOSPITAL VIRGEN DE LA VICTORIA \ufffd COLONIA DE STA INES, S/N M\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\nAnalizar la carga anticolin\u00e9rgica del tratamiento domiciliario que recib\u00edan pacientes ancianos polimedicados previamente \na ser intervenidos de cirug\u00eda por fractura de cadera.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional llevado a cabo en un hospital general de especialidades entre enero de 2021 y marzo \nde 2022. Se elabor\u00f3 una base de datos que conten\u00eda: N\u00famero de historia de todos los pacientes mayores de 75 a\u00f1os \nque se iban a intervenir de cirug\u00eda de cadera, edad, sexo, n\u00famero de medicamentos prescritos en domicilio y n\u00famero \nde medicamentos con carga anticolin\u00e9rgica en cualquiera de las escalas (ACB, ARS, CHEW, ADS, AAS, ALS, CRAS, DURAN \ny ABC). Mediante la calculadora Anticholinergic Burden Calculator, medimos la carga anticolin\u00e9rgica de cada uno de los \nmedicamentos que recib\u00eda cada paciente previamente al ingreso y la carga anticolin\u00e9rgica acumulada para cada una de \nlas escalas mencionadas. Se elabor\u00f3 una tabla con el n\u00famero y porcentaje de pacientes con riesgo alto, moderado, bajo o \nnulo de presentar efectos adversos anticolin\u00e9rgicos derivados de su medicaci\u00f3n.\nRESULTADOS\nSe registraron un total de 411 pacientes en el periodo de estudio, la media de edad de los pacientes estudiados fue de 81 \na\u00f1os, el 22,33% eran hombres y el 77,67% mujeres. El 79,85% de los pacientes recibi\u00f3 al menos un f\u00e1rmaco que afectaba \na su carga anticolin\u00e9rgica. La media de medicamentos que tomaban los pacientes en domicilio fue de un 8,1 (1-20), y la \nmedia de medicamentos con carga anticolin\u00e9rgica fue de 2,1 (0-9). El 44,34% de los pacientes presentaba riesgo de tener \ncarga anticolin\u00e9rgica alta, moderada o baja. Las distintas escalas presentaron diferencias en los porcentajes de pacientes \nincluidos en los tres tipos de riesgo. La escala ABC identific\u00f3 un 27,74% de pacientes en riesgo alto, mientras que la escala 65ARS identific\u00f3 un 3,41% en este mismo grupo. Un 19,46% de pacientes estaban en riesgo moderado seg\u00fan la escala ALS, \nmientras que las escalas Duran y ABC no identificaron pacientes en este mismo nivel de riesgo. Seg\u00fan la escala ADS un \n30,17% de pacientes estaban en riesgo bajo, mientras que seg\u00fan la escala ABC no hab\u00eda pacientes en este nivel de riesgo. \nLa escala que detect\u00f3 menor porcentaje de pacientes con ausencia de riesgo fue la ADS con un 42,09% y la que detect\u00f3 \nun mayor porcentaje de pacientes con esta condici\u00f3n fue la escala AAS con un 78,35%.\nCONCLUSIONES\nLas numerosas escalas que miden la carga anticolin\u00e9rgica son una herramienta de apoyo fundamental para la toma de \ndecisiones en el manejo farmacoterap\u00e9utico del paciente anciano fr\u00e1gil polimedicado. Sin embargo, debido a que existen \ndiferencias notables en c\u00f3mo clasifican las distintas escalas a los pacientes (riesgo alto, moderado o bajo) ser\u00e1 necesario \ntambi\u00e9n tener en cuenta variables cl\u00ednicas relevantes, tales como el deterioro cognitivo y el estado funcional de cada \npaciente para poder hacer recomendaciones de intervenci\u00f3n farmacoterap\u00e9utica en funci\u00f3n de la carga anticolin\u00e9rgica \nobtenida\ufffd\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1084. ESTUDIO DE FARMACOVIGILANCIA INTENSIVA EN PACIENTES CON FIBROSIS QU\u00cdSTICA EN \nTRATAMIENTO CON ELEXACAFTOR/TEZACAFTOR/IVACAFTOR \nAUTORES\nDEL VALLE MORENO, P; SU\u00c1REZ CASILLAS, P; LORA ESCOBAR, SJ; \u00c1LVAREZ DEL VAYO BENITO, C; ARAUJO RODR\u00cdGUEZ, \nFJ; CARRASCO HERN\u00c1NDEZ, L; DELGADO PECEILL\u00cdN, I\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nEl reducido tama\u00f1o muestral de los ensayos cl\u00ednicos pivotales de muchos medicamentos hace dif\u00edcil detectar reacciones \nadversas de baja frecuencia, por lo que es imprescindible una farmacovigilancia activa, especialmente en los primeros \na\u00f1os post-comercializaci\u00f3n para completar mediante la notificaci\u00f3n de reacciones adversas (RAMs) el perfil de seguridad \ndel f\u00e1rmaco en una poblaci\u00f3n m\u00e1s amplia.  \nEl objetivo es analizar las RAMs registradas en una poblaci\u00f3n de pacientes con fibrosis qu\u00edstica tras iniciar tratamiento con \nelexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA), en una consulta de Atenci\u00f3n Farmac\u00e9utica de un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional de cuatro meses de duraci\u00f3n (enero 2022-abril 2022). Desde la consulta de Atenci\u00f3n \nFarmac\u00e9utica se impuls\u00f3 la realizaci\u00f3n de un programa de farmacovigilancia intensiva y voluntaria en los pacientes \nambulatorios con fibrosis qu\u00edstica que iniciaran tratamiento con ELX/TEZ/IVA.  \nEn la primera consulta se explic\u00f3 detalladamente al paciente la forma de administraci\u00f3n del medicamento, la frecuencia, \nlas posibles interacciones con otros medicamentos/alimentos y los efectos adversos m\u00e1s frecuentes. Adicionalmente, se \nresolvieron las dudas que pudiera plantear el paciente y se le indic\u00f3 que realizara un diario con cualquier s\u00edntoma o signo \nque identificara tras iniciar el tratamiento. A las cuatro semanas se recogieron todas las RAMs descritas por los pacientes \nen ese periodo de tiempo. Se cre\u00f3 una base de datos con la herramienta Excel para su registro, caracterizaci\u00f3n y posterior \nnotificaci\u00f3n al Sistema Espa\u00f1ol de Farmacovigilancia.\nRESULTADOS\nUn total de 106 pacientes (59% hombres) iniciaron tratamiento con ELX/TEZ/IVA durante el per\u00edodo de estudio. El 23% \neran menores de 16 a\u00f1os y el 77% adultos\ufffd  \nUn 54% de los pacientes experimentaron alg\u00fan tipo de RAM. La edad media de pacientes con RAMs fue de 24 a\u00f1os y la \nedad en la que se dieron con mayor frecuencia fue a los 16 a\u00f1os.  \nDel total de RAMs descritas por los pacientes, un 73% no aparecen en la ficha t\u00e9cnica del medicamento, entre ellas: \np\u00e1pulas cut\u00e1neas, urticaria, rash cut\u00e1neo, tos seca, alteraci\u00f3n del estado an\u00edmico, dolor testicular, visi\u00f3n borrosa \npersistente, cansancio, parestesia en dedos, mucosidad en heces, disminuci\u00f3n de la l\u00edbido, estre\u00f1imiento, p\u00e9rdida \nde olfato, dolor de pecho y garganta, temblor, hemoptisis. Se produjo un embarazo en paciente en tratamiento \nanticonceptivo oral. En 2 pacientes las RAMs experimentadas provocaron la suspensi\u00f3n del tratamiento (2%). De las \nRAMs descritas en ficha t\u00e9cnica, un 37% fueron trastornos digestivos, un 37% trastornos de la piel y un 27% trastornos \nneurol\u00f3gicos\ufffd  \nAplicando el algoritmo de evaluaci\u00f3n de causalidad de Karch y Lasagna, un 73% ser\u00edan RAMs condicionales y un 27% \nposibles\ufffd\nCONCLUSIONES\nLos datos obtenidos en vida real de ELX/TEZ/IVA, han permitido generar se\u00f1ales al sistema de farmacovigilancia de \nposibles RAMs no descritas en ficha t\u00e9cnica. \nLa frecuencia de posibles RAMs a las cuatro semanas en nuestra poblaci\u00f3n fue menor que en el ensayo cl\u00ednico pivotal \na las 24 semanas (54% vs 93%), por lo que consideramos necesario continuar incluyendo el an\u00e1lisis detallado de la \nmedicaci\u00f3n concomitante para mayor conocimiento del perfil de seguridad a medio\u2013largo plazo y del papel de posibles \ninteracciones no descritas con repercusi\u00f3n cl\u00ednica.66CLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1089. AN\u00c1LISIS DE INTERACCIONES EN PACIENTES QUE RECIBEN TRATAMIENTO PARA EL C\u00c1NCER DE \nPR\u00d3STATA CON ANTIANDR\u00d3GENOS DE SEGUNDA GENERACI\u00d3N \nAUTORES\nPARADAS PALOMO, JD; ESPINOSA BOSCH, M; FERN\u00c1NDEZ CUERVA, C; MU\u00d1OZ CASTILLO, IM\nHOSPITAL GENERAL \ufffd AV\ufffd CARLOS HAYA, S/N M\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\nRevisi\u00f3n del tratamiento habitual en los pacientes con c\u00e1ncer de pr\u00f3stata cuando inician tratamiento con antiandr\u00f3genos \nde segunda generaci\u00f3n (NSAA en ingl\u00e9s) y evaluaci\u00f3n de las interacciones farmacol\u00f3gicas.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y restrospectivo de interacciones en pacientes que inician tratamiento oral para el \nc\u00e1ncer de pr\u00f3stata con NSAA (apalutamida, enzalutamida o abiraterona) en el \u00e1rea de pacientes externos del Servicio de \nFarmacia de un Hospital de tercer nivel desde febrero 2021 hasta abril 2022.  \nVariables estudiadas: demogr\u00e1ficas (sexo y edad); farmacoterap\u00e9uticas (n\u00famero y tipo de medicamentos que toma el \npaciente habitualmente); interacciones (n\u00famero, tipo (farmacocin\u00e9tica o farmacodin\u00e1mica) y clase (clase D (Considerar \nmodificaci\u00f3n de la terapia), clase C (monitorizar terapia) y clase B (no necesita ning\u00fan tipo de acci\u00f3n)).  \nLos datos fueron obtenidos del programa de prescripci\u00f3n electr\u00f3nica y dispensaci\u00f3n a pacientes externos, de los informes \nde conciliaci\u00f3n en la historia cl\u00ednica electr\u00f3nica y del programa de prescripci\u00f3n electr\u00f3nica en receta XXI. El estudio de \ninteracciones se realiz\u00f3 con Lexicomp.  \nSe realiz\u00f3 estad\u00edstica descriptiva de las variables de estudio. El an\u00e1lisis de los datos se hizo mediante el programa SSPS \nversi\u00f3n 20\ufffd\nRESULTADOS\nSe incluyeron 42 pacientes varones con c\u00e1ncer de pr\u00f3stata (22 con abiraterona, 11 con apalutamida y 9 con \nenzalutamida). La edad media de los pacientes fue de 74,6 \u00b1 8,2 a\u00f1os. La media de medicamentos que tomaban los \npacientes antes de iniciar tratamiento con apalutamida, enzalutamida o abiraterona era de 8,8 \u00b1 5,2. El 21,4% de los \npacientes tomaba habitualmente menos de 5 medicamentos y el 78,5% 5 o m\u00e1s. \nSe detectaron un total de 348 interacciones de las cuales 243 fueron de tipo farmacodin\u00e1micas (ninguna por NSSA). 105 \nde tipo farmacocin\u00e9ticas, de las cuales el porcentaje de implicaci\u00f3n de NSAA difiere entre los principios activos: 87% \nApalutamida; 68% enzalutamida y 21% Abiraterona.  \nSe detectaron 18 interacciones de tipo X, 34 de clase D, 245 de clase C y 48 de clase B, de las cuales 6 (33,3%), 5 (14,7%), \n39 (15,9%) y 3 (6,3%) fueron respectivamente con NSSA. \nLos principales grupos de f\u00e1rmacos implicados en las interacciones con apalutamida, enzalutamida o abiraterona \nfueron: inhibidores de la bomba de protones y antiespasm\u00f3dicos urinarios (19,3%); antihipertensivos (15,4%); \nansiol\u00edticos/antidepresivos (11,5%); analg\u00e9sicos opi\u00e1ceos y estatinas (9,6%); anticoagulantes orales de acci\u00f3n directa y \nantihistam\u00ednicos H1 de segunda generaci\u00f3n (4%); antidiab\u00e9ticos orales, diur\u00e9ticos, corticoides y AINEs (1,9%). \nSe consideran altamente importantes las interacciones con medicamentos anticoagulantes que han requerido cambios en \nel tratamiento concomitante de numerosos pacientes\ufffd\nCONCLUSIONES\nLos NNSA son f\u00e1rmacos con gran potencial de interacci\u00f3n cl\u00ednicamente relevantes con diferentes grupos terap\u00e9uticos. \nLos pacientes con c\u00e1ncer de pr\u00f3stata tienen edad media avanzada y con alto porcentaje de polimedicaci\u00f3n. Ambas \ncircunstancias hacen imprescindibles la conciliaci\u00f3n de los tratamientos.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1121. EVALUACI\u00d3N DE LA SEGURIDAD DE LOS ANTAGONISTAS DE RECEPTORES DE ENDOTELINA EN \nPACIENTES CON HIPERTENSI\u00d3N PULMONAR \nAUTORES\nBUSTO IGLESIAS, M; SUAREZ ARTIME, P; VARELA REY , I; CAJADE PASCUAL, F; PUENTE IGLESIAS, M; ZARRA FERRO, I\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE SANTIAGO. CHOUPANA, S/N SANTIAGO DE COMPOSTELA. A CORU\u00d1A\nOBJETIVOS\nLos antagonistas de receptores de endotelina (ARE): el bosent\u00e1n, ambrisent\u00e1n y macitent\u00e1n, son f\u00e1rmacos empleados \ncomo primera l\u00ednea en el tratamiento de la hipertensi\u00f3n pulmonar (HP), en monoterapia o en asociaci\u00f3n con otros \ntratamientos vasodilatadores. El objetivo de este estudio es comparar los efectos adversos (EA) producidos por estos tres \nf\u00e1rmacos en los pacientes de nuestra \u00e1rea sanitaria.\nMATERIALES Y M\u00c9TODOS\nSe trata de un estudio retrospectivo observacional, de nueve a\u00f1os de seguimiento (enero de 2013 a mayo de 2022) en el \ncual se incluyeron pacientes con diagn\u00f3stico de HP , a tratamiento activo con un ARE. Durante el tiempo de seguimiento \nse monitoriz\u00f3 la aparici\u00f3n de EA habituales al tratamiento con ARE: par\u00e1metros de funci\u00f3n hep\u00e1tica (GOT/AST y GPT/\nALT), valores de hemoglobina, edemas en miembros inferiores (MMII), hipotensi\u00f3n arterial, cefaleas\u2026 Adicionalmente \nse registr\u00f3 si la reacci\u00f3n adversa fue motivo de retirada o de cambio por otro ARE. Para la recogida de datos se utiliz\u00f3 la \nhistoria cl\u00ednica electr\u00f3nica (IANUS) y los registros de dispensaci\u00f3n del programa de prescripci\u00f3n electr\u00f3nica SILICON.67RESULTADOS\nSe incluyeron 24 pacientes con una media de edad de 62 a\u00f1os (37-91) a\u00f1os. El 50% iniciaron tratamiento con bosent\u00e1n \n(n=12), el 33% de los sujetos iniciaron tratamiento con ambrisent\u00e1n (n=8), y solamente 17% iniciaron tratamiento con \nmacitent\u00e1n desde el principio (n=4). Dentro de los 12 pacientes tratados con bosent\u00e1n, el 67% sufrieron alg\u00fan tipo \nde reacci\u00f3n adversa (n=8), y en el 58% de ellos la gravedad del EA condujo a una suspensi\u00f3n del tratamiento (n=7). \nSe detectaron 3 casos de hepatotoxicidad, 2 casos de edemas MMII, 1 caso de hipotensi\u00f3n, 1 caso de reacci\u00f3n de \nhipersensibilidad, y 1 caso de cefalea intensa asociada a mareo. En los 8 pacientes tratados con ambrisent\u00e1n, el 50% \n(n=4) de ellos sufrieron alg\u00fan EA al medicamento, pero en ning\u00fan caso fueron lo suficientemente graves para suponer la \nretirada del ambrisent\u00e1n. Se registraron fundamentalmente episodios de cefalea, mareos y edemas de MMII. Respecto a \nlos 4 pacientes que iniciaron tratamiento con macitent\u00e1n, se detectaron EA en el 50% de ellos (n=2), un caso de cefaleas \ny otro caso de edemas en MMII y empeoramiento de la disnea que requiri\u00f3 de la suspensi\u00f3n el tratamiento. De los 7 \npacientes que necesitaron suspender el tratamiento con bosent\u00e1n debido a sus EA, en el 86% (n=6) se inici\u00f3 tratamiento \ncon macitent\u00e1n, de los cuales el 50% (n=3) sufri\u00f3 alg\u00fan tipo de EA, siendo necesario suspender el tratamiento en el 17% \n(n=1) por hepatotoxicidad.\nCONCLUSIONES\nLos EA m\u00e1s frecuentes fueron: las cefaleas, los edemas en MMII y la hepatotoxicidad. En nuestra cohorte de pacientes el \nambrisent\u00e1n ha mostrado un mejor perfil de seguridad que el bosent\u00e1n y macitent\u00e1n, ya que a pesar de que la tasa de EA \nfue similar, los EA del ambrisent\u00e1n no alcanzaron la gravedad para requerir la interrupci\u00f3n del tratamiento. Dentro de las \nlimitaciones del estudio, destacar el peque\u00f1o n\u00famero de pacientes incluidos, y las diferencias de edad entre los grupos, \nas\u00ed como en el tipo de hipertensi\u00f3n pulmonar.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1146. EVALUACI\u00d3N DE LA CALIDAD DE VIDA EN PACIENTES VIH MEDIANTE EL CUESTIONARIO MOS-\nSF-30 \nAUTORES\nMERCADAL ORFILA, G; SERRANO LOPEZ DE LAS HAZAS, JI; MAESTRE FULLANA, MA; MATEU AMENGUAL, F\nHOSPITAL MATEU ORFILA \ufffd RONDA MALB\u00daGER, 1 MAH\u00d3N \ufffd ILLES BALEARS\nOBJETIVOS\nLa atenci\u00f3n sanitaria basada en valor, destaca por la necesidad de evaluar los resultados reportados por los propios \npacientes, y as\u00ed en \u00faltima instancia mejorar su calidad de vida  \nEl paciente VIH ha cronificado la enfermedad, y debe ser la calidad de vida uno de los aspectos que debemos evaluar para \nmejorarla \nEntre los cuestionarios de calidad de vida para los pacientes VIH+ destaca la adaptaci\u00f3n del Medical Outcomes Study \nSurvey-Short Form 30 Items (MOS-SF-30), debido a sus buenos indicadores psicom\u00e9tricos.  \nEl objetivo del estudio fue evaluar la calidad de vida de una cohorte de pacientes VIH, as\u00ed como determinar los factores \npron\u00f3sticos asociados a una peor calidad de vida.\nMATERIALES Y M\u00c9TODOS\nSe incluyeron pacientes atendidos en las consultas externas de Farmacia Hospitalaria de 3 hospitales p\u00fablicos de una \ncomunidad aut\u00f3noma, en el periodo Enero \u2013 Abril de 2022.  \nSe recogieron las variables sexo, edad, l\u00ednea de tratamiento, fumador, nivel de estudios, situaci\u00f3n laboral, consumo de \nalcohol y los resultados del cuestionario MOS-SF-30 que de forma global punt\u00faa desde 0 a 100 , siendo 100 la mejor \ncalidad de vida posible\ufffd  \nEl cuestionario se envi\u00f3 basalmente por medio de una plataforma telem\u00e1tica que permite el env\u00edo automatizado y \nprogramado\ufffd  \nSe analizaron los resultados por medio de SPSS v28. Las variables continuas se resumir\u00e1n con media y desviaci\u00f3n t\u00edpica y \nlas variables categ\u00f3ricas con frecuencias absolutas y relativas.  \nPara estudiar las diferencias entre las medidas de las variables continuas se utilizar\u00e1 una prueba de t-Student y para \nevaluar la independencia de los efectos encontrados en el an\u00e1lisis bivariante se realizar\u00e1 una regresi\u00f3n lineal.\nRESULTADOS\nDe 119 pacientes a los que se envi\u00f3 el cuestionario, contestaron 57 (47,89%). \nEl 45,6% estaba en la franja de edad 19-50 a\u00f1os, 22,8 % mujeres, 36,8 % en primera l\u00ednea de tratamiento, 52,6% estaban \nocupados, 67,7% ten\u00edan educaci\u00f3n secundaria o inferior, 29,8% fumadores, 19,3% abstemios.  \nLa puntuaci\u00f3n global media obtenida del cuestionario MOS-SF-30 , fue de 76,03 + 18,5  \nEl an\u00e1lisis univariante mostr\u00f3 peores puntuaciones de forma estad\u00edsticamente significativa en mujeres (66,3 +25) vs \nhombres (78,9 +15,2) p=0,015 , en fumadores (65,82 +23,64) vs no fumadores (83,27+12,21), p=0,005, en parados (70,92 \n+21,8) vs ocupados (80,63 +13,75) p=0,024, y en pacientes en segunda o posteriores l\u00edneas de tratamiento antirretroviral \n(72,58 +20,9) vs pacientes en primera l\u00ednea (81,95 +11,81) , p=0,033.  \nNo obstante la regresi\u00f3n lineal, s\u00f3lo incluy\u00f3 en el modelo como factores que influ\u00edan en el score global del MOS-SF-30: \ng\u00e9nero y fumar .\nCONCLUSIONES\nNuestros hallazgos apuntan peores puntuaciones en calidad de vida medida con el cuestionario MOS-SF-30 en mujeres y \npacientes fumadores\ufffd 68Tambi\u00e9n observamos una tendencia a peores resultados en pacientes en segundos o posteriores l\u00edneas de tratamiento, \nas\u00ed como en pacientes sin ocupaci\u00f3n laboral.  \nEl perfil de pacientes detectado con peor calidad de vida, debe ayudarnos a estratificar los pacientes atendidos en las \nconsultas externas de farmacia hospitalaria,  \nEsto \u00faltimo, unido al modelo CMO (capacidad-motivaci\u00f3n-oportunidad) nos permitir\u00e1 mejorar el abordaje asistencial de \naquellos pacientes VIH que presenten necesidades espec\u00edficas.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1199. ADECUACI\u00d3N DEL TRATAMIENTO CON ANTICOAGULANTES ORALES DE ACCCI\u00d3N DIRECTA (ACOD) \nEN PACIENTES HOPITALIZADOS \nAUTORES\n\u00c1LVAREZ N\u00da\u00d1EZ, L; VIUDEZ MART\u00cdNEZ, A; BOLEA LACUEVA, A; RUIZ EL JERCHE, S; L\u00d3PEZ-NIETO SEMPERE, J; PIC\u00d3 BELTR\u00c1, \nI; RIERA SENDRA, G; CLIMENT GRANA, E\nHOSPITAL GENERAL UNIVERSITARIO DE ALICANTE \ufffd AV\ufffd PINTOR BAEZA, 12 ALICANTE/ALACANT \ufffd ALICANTE\nOBJETIVOS\nAnalizar los tratamientos con ACOD en cuanto a indicaci\u00f3n, dosificaci\u00f3n seg\u00fan situaci\u00f3n del paciente y \ncontraindicaciones, y proponer cambios en el tratamiento prescrito\ufffd  \nEvaluar la adherencia terap\u00e9utica y detectar posibles interacciones medicamentosas.\nMATERIALES Y M\u00c9TODOS\nEstudio transversal, unic\u00e9ntrico, de intervenci\u00f3n, de 6 meses de duraci\u00f3n (agosto 2021\u2013enero 2022). Se incluyeron \npacientes ingresados, en tratamiento con alguno de los ACOD (apixab\u00e1n, edoxab\u00e1n, rivaroxab\u00e1n o dabigatr\u00e1n).  \nSe recogieron las siguientes variables: edad, sexo, fecha de ingreso, fecha de evaluaci\u00f3n, f\u00e1rmaco, pauta posol\u00f3gica, \npuntuaci\u00f3n CHA2DS2VASc, puntuaci\u00f3n HAS-BLED, motivo de ingreso, cirug\u00edas pendientes, persona responsable de la \nmedicaci\u00f3n, tomas olvidadas en el \u00faltimo mes, aclaramiento de creatinina (ClCr), requerimiento de ajuste de dosis, \nprescripci\u00f3n concomitante de antiagregantes, interacciones, dosis err\u00f3neas durante el ingreso y tipo de error. \nSe extrajeron los datos a trav\u00e9s de la prescripci\u00f3n electr\u00f3nica del hospital, la historia cl\u00ednica y una entrevista con cada \npaciente. Se evalu\u00f3 la pauta posol\u00f3gica e indicaci\u00f3n de los ACOD teniendo en cuenta la situaci\u00f3n cl\u00ednica de cada paciente.  \nLa adherencia al tratamiento se evalu\u00f3 en aquellos pacientes que ya estaban en tratamiento domiciliario con el ACOD.\nRESULTADOS\nSe incluyeron 84 pacientes, 31 mujeres (37%), con una mediana de edad de 80 a\u00f1os (RI: 67-85), CHA2DS2-VASc 3.9\u00b11,5 y \nHAS-BLED de 2,4 \u00b11,0, en tratamiento con apixab\u00e1n (n= 43), dabigatr\u00e1n (n=11), edoxab\u00e1n (n=12) o rivaroxab\u00e1n (n=18). 39 \npacientes (46%) ten\u00edan un ClCr < 60 mL/min.  \n13 (15%) pacientes requirieron un ajuste de dosis, 5 un aumento y 8 una reducci\u00f3n de la dosis y en un paciente estaba \ncontraindicado el tratamiento por una insuficiencia renal grave.  \nEl n\u00famero total de dosis err\u00f3neas administradas durante el ingreso fue 34.  \n76 pacientes (90%) estaban en tratamiento domiciliario con ACOD. De estos, 50 pacientes (66%) eran ellos mismos \nresponsables de su medicaci\u00f3n. 20 pacientes (26%) afirmaban haber olvidado alguna dosis en el \u00faltimo mes.  \n8 pacientes estaban en tratamiento concomitante con antiagregantes, y no se detect\u00f3 ninguna interacci\u00f3n farmacol\u00f3gica \ncl\u00ednicamente relevante.\nCONCLUSIONES\nLa funci\u00f3n del farmac\u00e9utico en tareas como la conciliaci\u00f3n de medicaci\u00f3n al ingreso es fundamental y tiene un gran \nimpacto sobre la reducci\u00f3n de errores de medicaci\u00f3n\ufffd  \nLa evaluaci\u00f3n temprana del tratamiento con ACOD en el momento del ingreso del paciente disminuye sustancialmente el \nn\u00famero de dosis err\u00f3neas por paciente.  \nEs necesario reforzar la adherencia en los pacientes en tratamiento con ACOD, debido al elevado n\u00famero de olvidos de \ntomas y a la grave repercusi\u00f3n de los mismos\ufffd\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1246. AN\u00c1LISIS DE LA EFECTIVIDAD Y SEGURIDAD DE CAPSAICINA PARCHE EN EL DOLOR NEUROP\u00c1TICO \nPERIF\u00c9RICO \nAUTORES\nASENJO , S\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nLa Asociaci\u00f3n Internacional para el Estudio del Dolor define el dolor neurop\u00e1tico (DN) como aquel causado por una lesi\u00f3n \no enfermedad del sistema nervioso somatosensorial, a nivel central o perif\u00e9rico (DNP).  \nEl dolor post-traum\u00e1tico y post-quir\u00fargico si no son bien tratados en la fase aguda tienen potencial de progresi\u00f3n a dolor \nneurop\u00e1tico cr\u00f3nico.  \nCapsaicina parche cut\u00e1neo est\u00e1 indicado para el tratamiento del DNP en adultos, s\u00f3lo o en combinaci\u00f3n con otros \nmedicamentos para el tratamiento del dolor \ufffd  \nValorar la efectividad y seguridad del tratamiento t\u00f3pico de capsaicina parche en pacientes con DNP localizado. Debido al 69incremento del consumo de dicho f\u00e1rmaco durante los \u00faltimos a\u00f1os, a pesar de que los estudios que eval\u00faan su eficacia \nno siempre aportan resultados concluyentes, se plantea este an\u00e1lisis en nuestro hospital.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio retrospectivo descriptivo de todos los pacientes que fueron tratados con capsaicina parche desde el \na\u00f1o 2019 al 2021. Se estudiaron variables sociodemogr\u00e1ficas, servicios m\u00e9dicos prescriptores, mejor\u00eda de la percepci\u00f3n \ndel dolor mediante la escala visual anal\u00f3gica (EVA) puntuada de 1 a 10 y efectos adversos m\u00e1s frecuentes. Los parches \nson administrados por personal de enfermer\u00eda especializado bajo la supervisi\u00f3n de un facultativo. Se realiza seguimiento \ntelef\u00f3nico a la semana de la administraci\u00f3n para valorar efectos secundarios y mejora de la percepci\u00f3n del dolor.\nRESULTADOS\nLos pacientes que se trataron con capsaicina parche en el periodo de estudio fueron: 442 pacientes: 289 mujeres (65,4%), \ncon una media de edad de 60,4 a\u00f1os y 138 hombres (31.2%) con una media de edad de 60,3 a\u00f1os.  \nLos servicios m\u00e9dicos responsables de la prescripci\u00f3n fueron: Rehabilitaci\u00f3n (45%), Trauma Rodilla (23,7%), Trauma \nextremidad superior/pie (20,8%), Trauma cadera (2,7%) y Trauma raquis (7,7%).  \nLa media de puntuaci\u00f3n en la escala EVA al iniciar el tratamiento era de 6,9/10 y a la semana seguimiento fue de 5,5/10\ufffd \nUn 45,3 % de los pacientes describi\u00f3 una mejor\u00eda en la escala EVA y un 18,4 % de ellos redujo su escala de puntuaci\u00f3n en \nm\u00e1s de 3. \nLos efectos adversos m\u00e1s frecuentes que presentaron los pacientes fueron: picor/escozor (35,5%), eritema (20,6%) y un \n15,4% no experiment\u00f3 ning\u00fan efecto adverso.  \nEn cuanto al porcentaje de pacientes que no contin\u00faan con el tratamiento tras la primera sesi\u00f3n, se observaron en 2019 \n(45,5%), 2020 (36,1%) y 2021 (29 %).\nCONCLUSIONES\nEl tratamiento con parches de capsaicina es un tratamiento seguro y relativamente bien tolerado en pacientes con DNL.  \nSe observa un porcentaje moderado de pacientes que mejor\u00f3 la percepci\u00f3n del dolor as\u00ed como un bajo \u00edndice de efectos \nsecundarios\ufffd  \nSi se decide iniciar el tratamiento, se debe evaluar de forma peri\u00f3dica la necesidad de continuaci\u00f3n. Es llamativo el \nporcentaje de pacientes con una s\u00f3lo administraci\u00f3n que no contin\u00faan con lo que supone por su alto coste.  \nSe recomienda restringir su utilizaci\u00f3n al tratamiento del DNP en segunda l\u00ednea, identificarlo con escalas espec\u00edficas \ncomo el cuestionario DN4 y siempre que se haya fracasado previamente a otros medicamentos de primera l\u00ednea para la \nindicaci\u00f3n de DN\ufffd\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1292. LARVATERAPIA: EFECTIVIDAD Y SEGURIDAD EN EL TRATAMIENTO DE \u00daLCERAS VASCULARES \nCR\u00d3NICAS REFRACTARIAS \nAUTORES\nP\u00c9REZ RODR\u00cdGUEZ, A; YOLDI MART\u00cdN-CALPENA, RP; RU\u00cdZ MART\u00cdNEZ, D; GORAN , RE; CERC\u00d3S LLETI, AC; CAMPILLOS \nALONSO, P; MART\u00cdNEZ PERELL\u00d3, I; CLIMENTE MARTI, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEvaluar la efectividad y seguridad de la larvaterapia con larvas de \u201cLucilia sericata\u201d en \u00falceras vasculares complejas \nrefractarias al desbridamiento convencional\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional, retrospectivo, de 15 meses de duraci\u00f3n (enero 2021-mayo 2022), que incluy\u00f3 \npacientes con \u00falceras vasculares cr\u00f3nicas de evoluci\u00f3n t\u00f3rpida tras desbridamiento quir\u00fargico que recibieron \nlarvaterapia. Las curas se hicieron con ap\u00f3sitos est\u00e9riles de 100-300 larvas, con recambios cada 5-7 d\u00edas.  \nLas variables recogidas se agruparon en: paciente (sexo, edad, movilidad, comorbilidades, farmacoterapia concomitante), \nlarvaterapia (duraci\u00f3n), \u00falcera y caracterizaci\u00f3n cl\u00ednica antes y despu\u00e9s de larvaterapia (antecedentes, etiolog\u00eda, \ngravedad, localizaci\u00f3n, duraci\u00f3n, \u00e1rea, presencia de necrosis/esfacelos [ < \u00f3 > 50% del \u00e1rea], granulaci\u00f3n [ < \u00f3 > 50% del \n\u00e1rea]), efectividad (incidencia y tiempo hasta revascularizaci\u00f3n, cierre y/o injerto) y seguridad (exudado, condiciones de \npiel periulceral, reacciones adversas). Las variables categ\u00f3ricas se expresan como frecuencias (%) y las cuantitativas como \nmediana y rango intercuart\u00edlico (RIQ).\nRESULTADOS\nSe evalu\u00f3 un total de 8 pacientes (66 a\u00f1os [RIQ 17], 75% hombres, 50% movilidad conservada, 37,5% apoyo ortoprot\u00e9sico \ny 12,5% silla de ruedas). Todos presentaban factores de riesgo cardiovascular: DM2 (87,5%, de los cuales 71,4% con \nneuropat\u00eda diab\u00e9tica), dislipemia (87,5%), HTA (87,5%), antecedentes de tabaquismo (75%) y patolog\u00eda cardio-renal \n(75%). Todos presentaban alg\u00fan antecedente vascular, con \u00falceras previas en 5 casos (62,5%). Adem\u00e1s, 6 pacientes (75%) \nrecib\u00edan tratamiento concomitante con anticoagulantes (50%) y antiagregantes (83%). \nLa etiolog\u00eda de las \u00falceras tratadas fue la isquemia arterial con amenaza de extremidad (6 pacientes [75%]), \u00falcera \ndiab\u00e9tica (1 paciente [12,5%]) y embolo-cardiog\u00e9nica (1 paciente [12,5%]). Todas ellas estaban localizadas en miembros \ninferiores, eran de gravedad elevada en 6 pacientes (75%, entendido como alto riesgo de amputaci\u00f3n en un a\u00f1o), larga \nevoluci\u00f3n ( > 6 meses) en 3 (37,5%) y superficie considerable ( > 5 cm2) en 7 pacientes (87,5%).  \nPese a que, actualmente, el 50% de pacientes contin\u00faan con larvaterapia, en todos ya se observa una reducci\u00f3n de la 70superficie de la \u00falcera, con disminuci\u00f3n superior al 50% del tejido necr\u00f3tico y esfacelos, un aumento mayor al 50% de la \ngranulaci\u00f3n, con reducci\u00f3n de exudado y sin empeoramiento de la piel sana periulceral\ufffd  \nEn los pacientes en los que se ha completado el seguimiento (50%), la mediana de duraci\u00f3n de larvaterapia fue 14 \n(RIQ 0) d\u00edas. En 2 de los 3 pacientes candidatos a revascularizaci\u00f3n (67%), se alcanz\u00f3 el objetivo con \u00e9xito y, en 2 de \n4 pacientes (50%) se obtuvo evoluci\u00f3n satisfactoria y tendencia al cierre. En 1 de 4, se consigui\u00f3 el cierre completo \ny reconstrucci\u00f3n mediante injerto de colgajo microvascular mediante cirug\u00eda pl\u00e1stica. No se observaron reacciones \nadversas, empeoramiento de la piel periulceral o presencia de exudado en ning\u00fan paciente.\nCONCLUSIONES\nSeg\u00fan los resultados evaluados en una muestra limitada de pacientes, la larvaterapia puede ser una alternativa efectiva \ny segura en \u00falceras vasculares complejas refractarias al desbridamiento convencional, que facilita la eliminaci\u00f3n del \ntejido necr\u00f3tico, el proceso de granulaci\u00f3n y la revascularizaci\u00f3n, lo que permite el cierre completo e injerto a tiempo en \npacientes que estar\u00edan abocados a la amputaci\u00f3n de su extremidad.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n1318. EVALUACI\u00d3N DE RESULTADOS EN SALUD EN ASMA GRAVE NO CONTROLADA EN BASE A CRITERIOS \nCUANTITATIVOS FEOSSCORE \nAUTORES\nJOY CARMONA, P; PLASENCIA GARC\u00cdA, I; DE LORENZO , I; GARC\u00cdA ROBAINA, JC; D\u00cdAZ P\u00c9REZ, D; MERINO ALONSO, J; \nGONZ\u00c1LEZ , J\nHOSPITAL DE OFRA \ufffd LA CUESTA, S/N SANTA CRUZ DE TENERIFE \ufffd SANTA CRUZ DE TENERIFE\nOBJETIVOS\nLos criterios FEOS (acr\u00f3nimo de Funci\u00f3n pulmonar, Exacerbaciones, Orales corticoides y S\u00edntomas) se trata de una \nvariable cuantitativa de respuesta al tratamiento con terapia biol\u00f3gica en pacientes con asma grave no controlada \n(AGNC). El objetivo de este estudio es evaluar la respuesta utilzando los criterios FEOS.\nMATERIALES Y M\u00c9TODOS\nSe incluyeron pacientes diagnosticados de AGNC quie iniciaron tratamiento con terapia biol\u00f3gica (TB) desde enero 2020 \nhasta abril 2021 al permitir evaluaci\u00f3n tras un a\u00f1o de tratamiento. Los par\u00e1metros de respuesta utilizados se basan en \nla Gu\u00eda Espa\u00f1ola para el Manejo del Asma (GEMA 5.2): Test de Control del Asma (ACT) > = 20 o al menos mejor\u00eda de 3 \npuntos; suspensi\u00f3n completa de corticoides orales (CO) o al menos en un 50%, 0 exacerbaciones o al menos reducci\u00f3n \ndel 50%, Fracci\u00f3n de volumen exalado en el primer segundo (FEV1) > = 80% o al menos mejor\u00eda en un 20%.  \nLos datos antropom\u00e9tricos, anal\u00edticos y cl\u00ednicos se obtuvieron de la Historia Cl\u00ednica Electr\u00f3nica (HCE), mientras que los \ncriterios FEOS se obtuvieron en la p\u00e1gina FEOSSCORE.com que van de 0-100.\nRESULTADOS\nSe incluyeron 57 pacientes, un 68% mujeres y con una media de edad de 50 a\u00f1os (desviaci\u00f3n est\u00e1ndar:17). 12 pacientes \nno fueron valorables (3 por falta de datos, 3 suspendidos por toxicidad y 6 por suspenderse entre 5-7 meses por falta de \nrespuesta). De los 45 pacientes evaluados, la media de FEOSSCORE fue de 82, de ellos se consideraron respondedores \n38 (84%), cuya media de FEOSSCORE fue de 88 y 7 (16%) no respondedores, con una media de FEOSSCORE de 51 (46-\n56). De los respondedores, 29 (76%) presentaron respuesta completa al cumplir todos los criterios de la GEMA 5.2 con \nuna media FEOSSCORE de 94 (80-100), mientras que 9 (24%) respondieron de forma parcial (cumplieron al menos 2 \ncriterios) presentando una media FEOSSCORE de 67 (51-81). 11 pacientes (38%) obtuvieron un FEOSCORE m\u00e1ximo de \n100. 3 pacientes (33%) cumplieron s\u00f3lo 2 de los 4 criterios, en todos ellos por el FEV1, adem\u00e1s del ACT en 2 de ellos y las \nexacerbaciones en otro. 6 pacientes (67%) cumplieron 3 de los cuatro criterios, 4(66%) no cumplieron el objetivo de ACT, \n1 por CO (17%) y 1 por FEV1 (17%).\nCONCLUSIONES\nA pesar de que los ensayos cl\u00ednicos pivotales de los diferentes anticuerpos monoclonales incluyeron como objetivo \nprimario reducci\u00f3n de exacerbaciones, las gu\u00edas cl\u00ednicas recomiendan exigir respuesta completa.  \nLos criterios FEOSSCORE permiten obtener datos de respuesta cuantitativa pero a\u00fan no se han establecido puntos de corte.  \nEn base a nuestros resultados, respuestas completas se obtendr\u00edan con FEOSSCORE entre 80 y 100, mientras que los no \nrespondedores muestran valores < 56 puntos.  \nDesde los Servicios de Farmacia dentro de los equipos multidisciplinares debemos fomentar el empleo de herramientas \nque ayuden en la evaluaci\u00f3n de resultados en salud.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n93. ANTIAGREGACION EN PACIENTES RESIDENCIADOS CON FIBRILACI\u00d3N AURICULAR. \u00bfSE SIGUEN LAS \nRECOMENDACIONES DE LAS GU\u00cdAS ACTUALES? \nAUTORES\nLOIZAGA DIAZ, I; TAMAYO ORBEGOZO, E; BASKARAN KALTZAKORTA, Z; P\u00c9REZ ESPA\u00d1A, Z; REVUELTA AMALLO, A; \nINCL\u00c1N CONDE, M; DOM\u00cdNGUEZ MEN\u00c9NDEZ, JA; AGUIRREZABAL ARREDONDO, A\nHOSPITAL DE BASURTO \ufffd AV\ufffd MONTEVIDEO, 18 BILBAO \ufffd VIZCAYA71OBJETIVOS\nIdentificar a los pacientes con diagn\u00f3stico de fibrilaci\u00f3n auricular (FA) en tratamiento con f\u00e1rmacos antiagregantes \nplaquetarios y sin tratamiento anticoagulante oral (ACO) y determinar, si los hubiese, los diferentes diagn\u00f3sticos que \njustifiquen la prescripci\u00f3n del tratamiento antiagregante.  \nIdentificar los motivos de no prescripci\u00f3n del tratamiento anticoagulante y su consonancia con lo descrito en las gu\u00edas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluye a todos los pacientes residenciados a fecha de abril de 2022 en centros, \ncon dep\u00f3sitos de medicamentos adscritos a un servicio de farmacia de un hospital terciario, con diagn\u00f3stico de FA y \ntratamiento activo con medicaci\u00f3n antiagregante. Se excluyeron aquellos pacientes que estaban a su vez en tratamiento \nanticoagulante. \nEstos datos se obtuvieron de una consulta inform\u00e1tica (Oracle Analytics\u00ae) y se procedi\u00f3 a su posterior revisi\u00f3n en la \nhistoria cl\u00ednica.\nRESULTADOS\nSe revisaron 46 pacientes con diagn\u00f3stico de FA y tratamiento antiagregante, de los cuales 7 se excluyeron por estar, \nadem\u00e1s, en tratamiento anticoagulante. De los 39 restantes, el 56,4% (n=22) hab\u00edan sido tratados con anterioridad con \nACOs y el 33.3% (n=13) ten\u00eda prescritos f\u00e1rmacos antiagregantes motivados \u00fanicamente por el diagn\u00f3stico de FA, el resto \nde diagn\u00f3sticos m\u00e1s habituales fueron cardiopat\u00eda isqu\u00e9mica, accidente cerebrovascular, accidente isqu\u00e9mico transitorio \no isquemia cr\u00f3nica de las extremidades.  \nLos motivos del cambio o del no inicio del tratamiento anticoagulante fueron: 7 fragilidad, 5 hemorragias (1 de ellas \nhemorragia cerebral), 5 negativa del paciente, 3 riesgo de ca\u00eddas, 4 riesgo de sangrado, 2 no indicaci\u00f3n, en 13 casos el \nmotivo no quedo reflejado en la historia por lo que se desconoce.\nCONCLUSIONES\nLas actuales Gu\u00edas ESC 2020 sobre diagn\u00f3stico y tratamiento de la FA desaconsejan el uso del tratamiento antiagregante \nplaquetario para la prevenci\u00f3n del ictus. Sin embargo, son varios los pacientes tratados con medicaci\u00f3n antiagregante sin \notra indicaci\u00f3n complementaria que lo justifique.  \nAlgunos de los motivos que llevaron al cambio de tratamiento o al no inicio del mismo (riesgo de ca\u00eddas, fragilidad, riesgo \nde sangrado) no son justificaci\u00f3n suficiente para no anticoagular seg\u00fan lo recomendado en las citadas gu\u00edas.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n118. SOBREPRESCRIPCI\u00d3N Y RIESGO DE INTOXICACI\u00d3N \u00bfESTAMOS ANTE UNA PANDEMIA DE DEFICIT \nDE VITAMINA D? \nAUTORES\nALONSO CASTA\u00d1\u00c9, MD; CORRAL ALAEJOS, A; FERN\u00c1NDEZ CA\u00d1ABATE, S; JIMENEZ CASAUS, J; GODA MONTIJANO, G; \nGIL NAVARRO, I; ROLDAN GONZALEZ, JS; GIL VALI\u00d1O, C\nCOMPLEJO ASISTENCIAL DE ZAMORA. AVDA. REQUEJO, 35 ZAMORA. ZAMORA\nOBJETIVOS\nLa suplementaci\u00f3n con vitamina D a los pacientes diagnosticados \u201canal\u00edticamente\u201d como deficientes se encuentra \nen entredicho. Seg\u00fan las \u00faltimas recomendaciones s\u00f3lo se deber\u00eda suplementar con niveles inferiores a 10-12 ng/\nml, adem\u00e1s no existe evidencia que apoye la causalidad de niveles bajos de vitamina D con patolog\u00eda extra\u00f3sea. \nDada la alerta emitida por la Agencia Espa\u00f1ola del Medicamento (03/2019), en la que se notificaron casos graves de \nhipercalcemia por sobredosis, nuestro objetivo fue revisar las prescripciones de vitamina D, determinar cu\u00e1les son \nadecuadas, si existe riesgo de intoxicaci\u00f3n e intervenir para su deprescripci\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, retrospectivo y transversal, en el que se revisaron las prescripciones cr\u00f3nicas de vitamina D a trav\u00e9s \nde la historia cl\u00ednica electr\u00f3nica tanto de pacientes ingresados como externos. Las variables recogidas fueron: edad, \nsexo, niveles de inicio de vitamina D antes suplementaci\u00f3n, niveles actuales, adherencia, duraci\u00f3n del tratamiento, \nintervenci\u00f3n farmac\u00e9utica y deprescripci\u00f3n. Para el an\u00e1lisis estad\u00edstico se utiliz\u00f3 el programa Jamovi\u00ae.\nRESULTADOS\nSe revisaron un total de 87 prescripciones de vitamina D. La media de edad fue de 64.9 a\u00f1os (Standard deviation (SD) 13.3) \nsiendo el 58.6% (51) mujeres. La adherencia global fue del 96% (SD 11.7). Los niveles medios de inicio de suplementaci\u00f3n \nde vitamina D fueron de 21.4 ng/ml (SD 6.71) y los actuales 43.8 ng/ml (SD 12.3). 3.74 a\u00f1os (SD 1.54) de media llevaban los \npacientes en tratamiento. S\u00f3lo 13.8 % (12) ten\u00edan indicaci\u00f3n de suplementaci\u00f3n y 27.6 % (24) presentaban niveles actuales \nsuperiores a 50 ng/ml y por lo tanto riesgo de toxicidad. S\u00f3lo 3 pacientes presentaban hipervitaminosis D ( > 70 ng/ml). Se \nrealizaron 27 intervenciones farmac\u00e9uticas para su deprescripci\u00f3n, de las que fueron aceptadas 11.\nCONCLUSIONES\nLa mayor\u00eda de los pacientes no tienen indicaci\u00f3n de suplementaci\u00f3n de vitamina D. Seg\u00fan el Institute of Medicine (IOM) \nla prevalencia de d\u00e9ficit de vitamina D est\u00e1 sobreestimada porque los puntos de corte son demasiado elevados, en las \nanal\u00edticas de nuestro hospital este corte est\u00e1 entre 30-70 ng/ml cuando recientes revisiones asocian niveles superiores \na 50 ng/ml con efectos adversos y toxicidad (hipercalcemia, nefrolitiasis, calcificaciones de partes blandas, anorexia, \np\u00e9rdida de peso, poliuria, problemas cardiacos\u2026) por ello los farmac\u00e9uticos hospitalarios debemos fomentar una \nsuplementaci\u00f3n adecuada\ufffd72CLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n159. EFECTIVIDAD Y SEGURIDAD DE LOS INHIBIDORES DE PROPROTE\u00cdNA CONVERTASA SUBTILISINA/\nKEXINA EN LA PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nCARRI\u00d3N MADRO\u00d1AL, IM; CASARRUBIOS L\u00c1ZARO, GI; TARD\u00c1GUILA MOLINA, P; MART\u00cdNEZ RUIZ, E; BLANCO \nCRESPO, M; HORTA HERN\u00c1NDEZ, AM\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nAnalizar la efectividad y seguridad del tratamiento con inhibidores de la proprote\u00edna convertasa subtilisina/kexina tipo 9 \n(IPCSK9) en la pr\u00e1ctica cl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo-descriptivo de los pacientes tratados con IPCSK9 en un hospital de segundo nivel \n(Marzo 2016-Marzo 2022). Se recogieron las siguientes variables: edad y sexo, indicaci\u00f3n (prevenci\u00f3n secundaria (PS) \nen pacientes con enfermedad cardiovascular (CV) establecida, hipercolesterolemia familiar heterocig\u00f3tica (HFhe) y \ndislipemia mixta), riesgo CV al inicio seg\u00fan la escala de Framingham, valores colesterol c-LDL al inicio, reducci\u00f3n c-LDL, \nintolerancia a estatinas, tipo de IPCSK9 prescrito y tratamiento hipolipemiante concomitante, duraci\u00f3n de tratamiento, \noptimizaci\u00f3n de dosis, efectos adversos (EAs) registrados, y otras variables de resultados como mortalidad o evento \ncardiovascular \ufffd \nLos datos se obtuvieron a trav\u00e9s del programa corporativo Farmatools\u00ae y de la historia cl\u00ednica electr\u00f3nica Mambrino \nXXI\u00ae, y se recogieron y analizaron con Excel Microsoft Office 2010\u00ae. Se emplearon las pruebas t-student para muestras \nemparejadas y Chi-cuadrado considerando un \u03b1 < 0,05.\nRESULTADOS\nSe incluyeron 75 pacientes (64% varones) con una mediana de edad de 60 a\u00f1os [Rango intercuart\u00edlico (RIC): 42-83]. Las \nindicaciones del tratamiento fueron: PS (72%), HFhe (16%), dislipemia mixta (12%). El 64% presentaba intolerancia a \nestatinas. Al inicio del tratamiento, el 48% presentaba riesgo CV alto en los pr\u00f3ximos 10 a\u00f1os.  \nEl 53% de los pacientes estaba en tratamiento con evolocumab 140 mg/14 d\u00edas y 47% con alirocumab. El 66% de los \npacientes con alirocumab recibieron 75 mg/14 d\u00edas y el 34% 150 mg/14 d\u00edas. Once pacientes precisaron espaciamiento \nde dosis por niveles c-LDL muy inferiores al objetivo y 7 pacientes aumento de alirocumab 75 mg a 150 mg por respuesta \nsub\u00f3ptima. \nLa mediana de utilizaci\u00f3n de los IPCSK9 fue de 2,1 a\u00f1os (RIC: 0,7-3,6). El 79% present\u00f3 una adherencia > 90% en el \u00faltimo \na\u00f1o\ufffd  \nEn relaci\u00f3n al tratamiento hipolipemiante concomitante, el 21% de los pacientes ten\u00eda asociada estatina y ezetimiba, el \n17% ezetimiba, el 9% estatina, y el 5% fibratos. Los niveles iniciales medios de c-LDL fueron de 135,4 mg/dl (DE\u00b141,4). \nLa reducci\u00f3n media de los niveles de c-LDL con alirocumab fue de 74,7 mg/dl (DE\u00b142,1) y con evolocumab 68,8 mg/\ndl (DE\u00b139,6), sin diferencias estad\u00edsticamente significativas (p=0,89). El 78% de los pacientes alcanz\u00f3 el nivel objetivo \n< 100 mg/dl, 55% objetivo < 70 mg/dl y el 33% objetivo < 55 mg/dl, no encontr\u00e1ndose diferencias estad\u00edsticamente \nsignificativas entre ambos f\u00e1rmacos al comparar los subgrupos de pacientes (p=0,64, 0,14, 0,34 respectivamente).  \nDurante el periodo de estudio, el 93% no present\u00f3 EAs a IPCSK9 (2 pacientes presentaron elevaci\u00f3n transaminasas, \n2 cefalea, y 1 artralgia); 2 pacientes tuvieron que suspender IPCSK9 (alirocumab) por hepatotoxicidad. Por \u00faltimo, \n3 pacientes sufrieron eventos cardiovasculares y 2 fallecieron por complicaciones relacionadas con un evento \ncardiovascular \ufffd\nCONCLUSIONES\nAlirocumab y evolocumab han mostrado una alta reducci\u00f3n de c-LDL en nuestra poblaci\u00f3n, siendo PS la indicaci\u00f3n \nmayoritaria. Un alto porcentaje de pacientes presentaba intolerancia a estatinas. En cuanto a seguridad, ambos f\u00e1rmacos \nhan sido bien tolerados. Ser\u00eda necesario un estudio posterior para poder evaluar la optimizaci\u00f3n de las pautas posol\u00f3gicas \nen el control CV \ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n167. EFECTIVIDAD Y SEGURIDAD DE USO DE ERENUMAB EN LA PROFILAXIS DE LA MIGRA\u00d1A: \nPERSPECTIVA DE LA CALIDAD DE VIDA \nAUTORES\nVARELA FERN\u00c1NDEZ, R; S\u00c1EZ HORTELANO, JC; DE CASTRO AVEDILLO, C; CASAS FERN\u00c1NDEZ, X; V\u00c9LEZ BLANCO, A; \nRODR\u00cdGUEZ FERN\u00c1NDEZ, Z; ORTEGA VAL\u00cdN, L; ORTIZ DE URBINA GONZ\u00c1LEZ, JJ\nCOMPLEJO ASISTENCIAL UNIVERSITARIO DE LE\u00d3N. ALTOS DE LA NAVA S/N LE\u00d3N. LE\u00d3N\nOBJETIVOS\nEvaluaci\u00f3n de la efectividad y la seguridad de erenumab en la profilaxis de la migra\u00f1a seg\u00fan la evidencia cl\u00ednica disponible \nen un hospital de tercer nivel desde una perspectiva de la mejora la calidad de vida.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un intervalo de tiempo de dos a\u00f1os (enero 2020-diciembre de 2021), en el \nque se incluyeron todos los pacientes que completaron el tratamiento con erenumab para la migra\u00f1a. Las variables \nincluidas en el estudio fueron edad, sexo, duraci\u00f3n, reinicio/suspensi\u00f3n, n\u00famero de migra\u00f1as e intensidad, n\u00famero de 73cefaleas e intensidad, asistencia en urgencias y evaluaci\u00f3n del estado de salud del paciente, utilizando como referencia el \ncuestionario EQ-5D-5L, formado por dos partes, el sistema descriptivo y la Escala Visual Anal\u00f3gica (EVA).\nRESULTADOS\nSe incluyeron 42 pacientes (71.42% mujeres), cuya mediana de edad era 43 a\u00f1os (21-67). 38 pacientes completaron \nel tratamiento (90.47%), 3 pacientes suspendieron el tratamiento por ineficacia (7.14%) y 1 paciente abandon\u00f3 el \ntratamiento por intolerancia (2.38%). 5 de los pacientes que completaron el tratamiento volvieron a reiniciarlo tras \nreevaluaci\u00f3n neurol\u00f3gica (13.16%). Se ha observado una reducci\u00f3n en la frecuencia e intensidad de las migra\u00f1as del \n78.06% y 36.29%, respectivamente. Tambi\u00e9n se ha observado una reducci\u00f3n en la frecuencia e intensidad de las cefaleas \ndel 66.78% y 76.70%. Le evaluaci\u00f3n del estado de salud indica que se ha producido una mejora de la calidad de vida del \n30\ufffd75%\ufffd\nCONCLUSIONES\nErenumab mostr\u00f3 efectividad y seguridad en la mayor\u00eda de los pacientes como tratamiento profil\u00e1ctico de la migra\u00f1a \ntras un a\u00f1o de tratamiento, con una reducci\u00f3n significativa de la frecuencia e intensidad de los ataques de migra\u00f1a y las \ncefaleas. Asimismo, se observ\u00f3 una mejora significativa en la calidad de vida del paciente, con una reducci\u00f3n importante \nde la discapacidad asociada a la migra\u00f1a\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n169. DESARROLLO DE UN MODELO PREDICTIVO DE RIESGO DE RECONSULTAS A URGENCIAS BASADO \nEN LA FARMACOTERAPIA \nAUTORES\nRUIZ RAMOS, J; VELA VALLESPIN, E; MONTERDE PRAT , D; L\u00d3PEZ VINARDELL, L; MANGUES BAFALLUY , MA; CLERIES \nESCAYOLA, M; JUANES BORREGO, A\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLos problemas de salud relacionados con medicamentos (PSM) son un motivo frecuente de consulta a los servicios de \nurgencias (SU). No obstante, la informaci\u00f3n disponible sobre factores de riesgo asociados con las nuevas visitas a SU \nbasados en la farmacoterapia del paciente es limitada. El objetivo del estudio es desarrollar un modelo predictivo de \nriesgo de reconsulta a los SU a 30 d\u00edas en base al tratamiento farmacoterap\u00e9utico de los pacientes.\nMATERIALES Y M\u00c9TODOS\nEstudio de cohorte retrospectivo con pacientes que acudieron los SU de Catalu\u00f1a (Periodo: 2019) con nivel de triaje \nde 1-3. Se cre\u00f3 un modelo de predicci\u00f3n de reconsulta a 30 d\u00edas en una cohorte de derivaci\u00f3n (60%) mediante un \nmodelo de regresi\u00f3n log\u00edstica, siendo validada en una muestra de validaci\u00f3n (40%). A las variables incluidas en el \nan\u00e1lisis multivariante se les asign\u00f3 una puntuaci\u00f3n entera proporcional al coeficiente de regresi\u00f3n. Las variables \nsociodemogr\u00e1ficas consideradas en este estudio fueron edad, sexo y nivel de ingresos, carga de multimorbilidad con \nbase en los Grupos de Morbilidad Ajustados (GMA). Cuarenta y cuatro grupos de f\u00e1rmacos asociados con PSMs fueron \nevaluados\ufffd\nRESULTADOS\nSe incluyeron 851.649 pacientes [201.445 (23,6%) con > 9 f\u00e1rmacos prescritos al alta], de los cuales 134.560 (15,8%) \nrevisitaron el SU a los 30 d\u00edas. Las cuatro variables evaluadas (sexo, edad, GMA y nivel de ingresos) y 34 grupos ATC \nse asociaron a riesgo de reconsulta y se combinaron en una puntuaci\u00f3n final (PSM-Score). Los f\u00e1rmacos con mayor \npuntuaci\u00f3n de riesgo fueron laxantes osm\u00f3ticos (RR:1,421(IC95%:1,264-1,596)), antibi\u00f3ticos b-lact\u00e1micos (1,333(1,123-\n1,583)), pirazolonas (1,282 (1,256-1,309)), heparinas (1,150 (1,112-1,190) y litio (1,146 (1,000-1,315)) El modelo alcanz\u00f3 \nvalores de \u00e1rea bajo la curva operativa del receptor (AUROC) de 0,648 (IC95%: 0,646-0,650) en la cohorte de referencia \ny 0,647 (0,644-0,649) en la de derivaci\u00f3n. Se generaron tres categor\u00edas de riesgo, con los siguientes riesgos estimados de \nreconsulta al SU a 30 d\u00edas: bajo riesgo: 10,2%; riesgo intermedio: 18,3%; y alto riesgo: 28,4%.\nCONCLUSIONES\nLa puntuaci\u00f3n PSM-Score identifica a los pacientes con alto riesgo de volver a visitar el SU dentro de los 30 d\u00edas en base a \nla farmacoterapia, siendo una herramienta \u00fatil para priorizar las intervenciones desde estas unidades.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n185. CONCILIACI\u00d3N DE LA MEDICACI\u00d3N EN LAS TRANSICIONES ASISTENCIALES DE LOS USUARIOS \nPROCEDENTES DE CENTROS RESIDENCIALES \nAUTORES\nTAMAYO ORBEGOZO, E; LOIZAGA D\u00cdAZ, I; BASKARAN KALTZAKORTA, Z; REVUELTA AMALLO, A; VILA GALLEGO, C; \nVARA URRUCHUA, M; INCL\u00c1N CONDE, M; AGUIRREZABAL ARREDONDO, A\nHOSPITAL DE BASURTO \ufffd AV\ufffd MONTEVIDEO, 18 BILBAO \ufffd VIZCAYA\nOBJETIVOS\nDetectar, clasificar y solventar errores de conciliaci\u00f3n en las diferentes transiciones asistenciales de usuarios procedentes \nde centros sociosanitarios para favorecer la continuidad asistencial y la seguridad de la persona institucionalizada.74MATERIALES Y M\u00c9TODOS\nEstudio prospectivo de 8 meses de duraci\u00f3n (1 de mayo al 31 de diciembre de 2021) en el que se realiz\u00f3 la conciliaci\u00f3n \nde la medicaci\u00f3n de los usuarios procedentes de 22 centros residenciales con dep\u00f3sito de medicamentos vinculado a un \nServicio de Farmacia Hospitalario, con un total de 2712 plazas. A trav\u00e9s de una consulta inform\u00e1tica (Oracle Analytics\u00ae) \nse recibi\u00f3 diariamente un listado de pacientes que tuvieron contacto con cualquier hospital o centro de la red de salud el \nd\u00eda anterior. Se revis\u00f3 la medicaci\u00f3n de los pacientes al ingreso en planta, al alta o tras su estancia en Urgencias. As\u00ed como \nla medicaci\u00f3n de los pacientes que acudieron a consultas externas. Todas las discrepancias se registraron en las historias \ncl\u00ednicas de los pacientes y se inform\u00f3 de ello al m\u00e9dico responsable de la residencia o al especialista.\nRESULTADOS\nDurante el periodo de estudio se revisaron 2982 episodios de hospitalizaci\u00f3n que inclu\u00edan ingresos, altas y estancias en \nUrgencias, y 5057 episodios de consultas externas\ufffd  \nDe todos ellos, se intervino en 284 ocasiones con una aceptaci\u00f3n global del 68,26%. En cuanto al sexo, 173 (60,9%) \nfueron mujeres y 111 (39,1%) hombres. En cuanto al tipo de transici\u00f3n, 121 de las intervenciones (42,6%) fueron al alta, \n96 (33,8%) al ingreso y 67 (23,7%) tras una consulta externa.  \nEl n\u00famero y tipo de errores de conciliaci\u00f3n con su respectivo porcentaje de aceptaci\u00f3n fueron los siguientes:  \n130 errores por diferente v\u00eda, dosis o frecuencia (60,9%), 76 errores de omisi\u00f3n (72,2%), 64 errores de duraci\u00f3n diferente \n(76,19%), 8 errores de duplicidad (57,14%) y 6 errores de comisi\u00f3n (100%).  \nEn 97 ocasiones, adem\u00e1s de registrarlo en la historia cl\u00ednica, tambi\u00e9n se notific\u00f3 por correo electr\u00f3nico y en 14 ocasiones \npor tel\u00e9fono al m\u00e9dico prescriptor o responsable, puesto que se consideraron errores que se deb\u00edan aclarar con cierta \nurgencia\ufffd\nCONCLUSIONES\nConsideramos que el grado de aceptaci\u00f3n de las intervenciones fue satisfactoria.  \nGracias a estas intervenciones, en la mayor\u00eda de los casos, se ha conseguido que los errores de medicaci\u00f3n derivados de \nlas transiciones asistenciales no lleguen al paciente\ufffd \nLas transiciones asistenciales son frecuentes en los usuarios de los centros residenciales, adem\u00e1s la polimedicaci\u00f3n es \nhabitual en este tipo de pacientes. Por todo ello, la integraci\u00f3n del farmac\u00e9utico hospitalario en el equipo asistencial del \ncentro residencial es fundamental para mejorar la comunicaci\u00f3n entre el centro hospitalario y residencial y mejorar as\u00ed la \ncalidad y seguridad en los tratamientos de los usuarios de estos centros\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n199. REVISI\u00d3N FARMACOTERAP\u00c9UTICA DE PACIENTES EN TRATAMIENTO CON ESPIRONOLACTONA E \nHIPERPOTASEMIA ASOCIADA \nAUTORES\nCENTELLES ORIA, M; CANELLES G\u00c1MIR, JM; BALLESTA L\u00d3PEZ, O; GUERRERO HURTADO, E; MART\u00cdN CEREZUELA, M; \nBELTR\u00c1N GARC\u00cdA, I; VALDIVIESO MART\u00cdNEZ, B; POVEDA ANDR\u00c9S, JL\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEl tratamiento con dosis inadecuadas de espironolactona, la falta de control de los niveles de potasio y el tratamiento \nconcomitante (TC) con otros diur\u00e9ticos ahorradores de potasio (DAP), f\u00e1rmacos betabloqueantes, inhibidores \nde la enzima convertidora de angiotensina (IECA), antagonistas de los receptores de la angiotensina II (ARAII) y \nantiinflamatorios no esteroideos (AINE) pueden aumentar el riesgo de hiperpotasemia.  \nObjetivo: Detectar aquellos pacientes que presenten hiperpotasemia asociada al tratamiento con espironolactona. \nDeterminar el grado de aceptaci\u00f3n de las propuestas de intervenci\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y prospectivo, llevado a cabo en el Departamento de Salud de un hospital terciario de marzo a \nmayo de 2021\ufffd \nSe incluyeron los pacientes > 18 a\u00f1os que en marzo de 2021 estuvieran en tratamiento con espironolactona y presentaran \nun nivel s\u00e9rico de potasio (K+) > 5.5 meq/L en la \u00faltima anal\u00edtica.  \nSe realiz\u00f3 una revisi\u00f3n farmacoterap\u00e9utica (RF) y un informe individualizado por paciente con propuestas de intervenci\u00f3n. \nDicho informe se envi\u00f3 al responsable de la prescripci\u00f3n mediante el escritorio REFAR\u00ae en caso de m\u00e9dico de atenci\u00f3n \nprimaria o mediante carta personalizada en caso de atenci\u00f3n especializada (AE). El m\u00e9dico valor\u00f3 cada caso con la \naceptaci\u00f3n o no de la propuesta\ufffd  \nLa variables recogidas fueron: Edad, sexo, K+ en \u00faltima anal\u00edtica, dosis de espironolactona, diagn\u00f3stico principal y TC con: \nDAP , betabloqueantes, IECA/ARA II y AINES. Se obtuvieron del programa Data Warehouse del hospital, de la plataforma \nAlumbra\u00ae y de la historia cl\u00ednica electr\u00f3nica.  \nLos datos se procesaron mediante el programa Excel\u00ae. Los resultados se expresaron en mediana y rango intercuart\u00edlico \n(RIQ), media y desviaci\u00f3n est\u00e1ndar (DE) y porcentaje.\nRESULTADOS\nSe detectaron 39 pacientes, de 80 (RIQ=71-84) a\u00f1os, 17 (43.6%) mujeres, cuya \u00faltima anal\u00edtica sangu\u00ednea mostraba \nK+ de 5.7 (DE=0.3) meq/L. El diagn\u00f3stico principal fue hipertensi\u00f3n arterial (41.0%), insuficiencia card\u00edaca (20.5%) e \ninsuficiencia card\u00edaca + hipertensi\u00f3n arterial (38.5%). En todos los casos la dosis de espironolactona se adecu\u00f3 a las \nrecomendaciones de ficha t\u00e9cnica.  75Treinta y tres pacientes recib\u00edan TC que potencialmente pod\u00eda producir hiperpotasemia: Siete (17.9%) betabloqueante, \nuno (2.6%) betabloqueante+AINE, trece (33.3%) betabloqueante+IECA/ARA II y doce (30.8%) IECA/ARA II. \nTras la RF, se recomend\u00f3 en todos los pacientes la interrupci\u00f3n temporal o definitiva y/o la disminuci\u00f3n de la dosis de \nespironolactona o TC. En once (28.2%) de ellos, adem\u00e1s se recomend\u00f3 la solicitud de nuevo control de potasio. Los \npacientes estaban asignados a 36 m\u00e9dicos, 9 (25%) de ellos AE.  \nEl m\u00e9dico acept\u00f3 el 79.5% de las propuestas: En trece (33.3%) se interrumpi\u00f3 el tratamiento con espironolactona, en \ndoce (30.8%) se solicit\u00f3 nuevo control de potasio (en dos de ellos se a\u00f1adi\u00f3 resincalcio y dieta pobre en potasio), en \ncinco (12.8%) se disminuy\u00f3 la dosis y en tres (7.7%) se retir\u00f3 el TC. En algunos casos hubo m\u00e1s de una intervenci\u00f3n. No se \nrecibi\u00f3 respuesta por parte de cuatro (10.3%) m\u00e9dicos y cuatro (10.3%) mantuvieron la prescripci\u00f3n.\nCONCLUSIONES\nLa RF del tratamiento cr\u00f3nico por parte del farmac\u00e9utico junto con un equipo multidisciplinar ha permitido detectar \nhiperpotasemia en pacientes tratados con espironolactona, traduci\u00e9ndose en la optimizaci\u00f3n del tratamiento y mejora en \nla seguridad\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n204. PREVALENCIA DE PRESCRIPCIONES POTENCIALMENTE INAPROPIADAS EN PACIENTES \nHOSPITALIZADOS DE EDAD AVANZADA \u00bfINFLUYE LA INSTITUCIONALIZACI\u00d3N? \nAUTORES\nDE AGUSTIN SIERRA, L; RODRIGUEZ SALAZAR, J; MONTERO PASTOR, B; IZQUIERDO GARCIA, E; ALVARO ALONSO, EA; \nPRIETO ROMAN, S; RODRIGUEZ ESCOBAR, I; GARCIA DIAZ, B\nHOSPITAL INFANTA LEONOR \ufffd GRAN V\u00cdA DEL ESTE, 80 MADRID \ufffd MADRID\nOBJETIVOS\nEstimar la prevalencia de prescripciones potencialmente inapropiadas (PPIs) en mayores de 80 a\u00f1os con polifarmacia, \nantes del ingreso en planta, durante la estancia hospitalaria y en la prescripci\u00f3n al alta, mediante la aplicaci\u00f3n de los \ncuestionarios PRISCUS, STOPP y Beers. Comparar la prevalencia de PPIs en el grupo de pacientes provenientes de su \ndomicilio particular con el grupo de pacientes institucionalizados.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo, realizado en un hospital universitario de segundo nivel, durante 2017.  \nCriterios de inclusi\u00f3n: edad avanzada (\u2265 80 a\u00f1os, polimedicados (\u2265 5 f\u00e1rmacos), ingresos v\u00eda urgencias en un servicio \nm\u00e9dico (Medicina Interna, Geriatr\u00eda, Digestivo, Neumolog\u00eda y Cardiolog\u00eda) y con una duraci\u00f3n del ingreso \u2265 48 horas. \nSe analizaron las prescripciones farmacol\u00f3gicas en el momento del ingreso, a las 48 horas y al alta, utilizando los criterios \nPRISCUS, STOPP (versi\u00f3n 2, 2015) y Beers (versi\u00f3n 2019) para identificar las PPIs. \nTanto la informaci\u00f3n relativa al tratamiento como la informaci\u00f3n cl\u00ednica se obtuvieron a partir de la historia cl\u00ednica \nelectr\u00f3nica y el visor de historia cl\u00ednica de atenci\u00f3n primaria.  \nLos datos fueron analizados utilizando SPSS versi\u00f3n 20 (IBM Corp. Armonk, NY). Mediante regresi\u00f3n bivariante y \nmultivariante (m\u00e9todos de pasos hacia delante) se analizaron las variables que influyen significativamente en la presencia \nde PPI\ufffd\nRESULTADOS\nEn el estudio se incluyeron 365 pacientes, de los cuales, el 16,7% (61) proven\u00edan de residencias. La media de edad del \ngrupo de pacientes institucionalizados fue superior (88,62 a\u00f1os) frente al grupo de pacientes procedentes de domicilio \nparticular (86,6 a\u00f1os).  \nAplicando los criterios PRISCUS la prevalencia total de PPIs en pacientes provenientes de su domicilio particular fue 39,8 \n% vs. un 52,45% en pacientes institucionalizados (p > 0,05). La prevalencia con los STOPP fue de un 72,7% vs. 85,24% \n(p=0,04) y con criterios de Beers fue de 89,8% vs. 86,88% (p > 0,05).  \nAnalizando las prescripciones desde el ingreso hasta el alta se observ\u00f3 una disminuci\u00f3n en los valores de prevalencia con \nlas 3 herramientas de diagn\u00f3stico, obteni\u00e9ndose valores m\u00ednimos al alta: PRISCUS ingreso 29,94% vs. 50,81% (p=0,001) \ny al alta 2,96% vs. 1,63% (p > 0,05); STOPP ingreso 61,84% vs. 72,13% (p > 0,05) y al alta 9,53% Vs 13,11% (p > 0,05), por \n\u00faltimo, Beers ingreso 89,47% Vs 86,88% (p > 0,05) y al alta 9,21% Vs 14,75% (p > 0,05), respectivamente.  \nEn el an\u00e1lisis multivariante se analizaron las prescripciones mediante criterios PRISCUS, STOPP y Beers, ajustando por la \nvariable procedencia del paciente no pudi\u00e9ndose establecer una correlaci\u00f3n entre el origen del paciente y la presencia de \nPPIs\nCONCLUSIONES\nLos criterios STOPP y Beers detectan de forma similiar la presencia de PPIs en la poblaci\u00f3n\ufffd Ambos criterios, detectan \nmayor n\u00famero de PPIs con respecto a los criterios PRISCUS. La prevalencia de PPI en pacientes institucionalizados fue \nsuperior a la detectada en el grupo proveniente de su domicilio particular, pero no se ha podido establecer una relaci\u00f3n \nestad\u00edsticamente significativa entre la detecci\u00f3n de PPIs con la procedencia del paciente.76CLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n208. ADECUACI\u00d3N DEL TRATAMIENTO HIPOLIPEMIANTE EN ATENCI\u00d3N PRIMARIA \nAUTORES\nSALOM GARRIGUES, C; CAMPABADAL PRATS, C; BEJARANO ROMERO, F; CONDE GINER, S; CASTILLO PALOMARES, \nML; MARCO BAS, N; SU\u00d1ER BARRIGA, H; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA\nOBJETIVOS\nAdecuar el tratamiento hipolipemiante en atenci\u00f3n primaria (AP) en t\u00e9rminos de eficacia, seguridad, conveniencia y \ncoste \ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo (junio 2021-abril 2022) realizado en un \u00e1rea de AP , con datos obtenidos de la historia cl\u00ednica \ninformatizada.  \nSe incluyeron pacientes con hipolipemiantes no recomendados seg\u00fan la gu\u00eda de la instituci\u00f3n, identificados en el per\u00edodo \njunio-octubre 2021. En nuestro territorio se priorizan simvastatina, pravastatina, atorvastatina \u226540mg y gemfibrozilo.  \nSe recogieron datos de variables demogr\u00e1ficas (edad y sexo), variables anal\u00edticas como lipoprote\u00ednas de baja densidad \n(LDL) y triglic\u00e9ridos (TG), indicaci\u00f3n, h\u00e1bito tab\u00e1quico, insuficiencia renal (IR), \u00edndice de masa corporal (IMC) y adherencia \nal tratamiento, entre otras necesarias para la valoraci\u00f3n, adem\u00e1s de f\u00e1rmacos implicados e intervenci\u00f3n (propuesta, \nmotivo de la propuesta, aceptaci\u00f3n e implementaci\u00f3n a los 6 meses).  \nLa prescripci\u00f3n se valid\u00f3 por el farmac\u00e9utico y se propusieron las intervenciones al m\u00e9dico.\nRESULTADOS\nSe incluyeron 440 pacientes, de 66,5 (11,1 DE) a\u00f1os, 53,9% hombres, asignados a 20 m\u00e9dicos de 11 centros de salud, con \nuna poblaci\u00f3n de referencia de 27\ufffd840 pacientes\ufffd \nLa media del LDL era de 96,8 (36,02 DE) mg/dL y los TG de 137 (95-193) mg/dL. El 57,3% de los pacientes en tratamiento \npor prevenci\u00f3n primaria y el 12,3% por hipertrigliceridemia. El 36,4% eran fumadores, el 16,1% con IR y el IMC fue de \n27,6 (5,3 DE) kg/m2. No eran adherentes 18,9% pacientes, con un 8% recogiendo menos del 25% de la medicaci\u00f3n.  \nSe sugirieron 493 intervenciones: la principal fue cambiar por equivalente terap\u00e9utico, 37,9%; seguida de interrumpir el \nf\u00e1rmaco, 23,5%; intensificar posolog\u00eda, 13,8%; revalorar indicaci\u00f3n, 9,1%; cambiar por otro principio activo, 7,9%; reducir \nposolog\u00eda, 5,9%; e iniciar f\u00e1rmaco, 1,9%. Las intervenciones implicaban mayoritariamente: el 40,1% a atorvastatina, \n19,3% a rosuvastatina, 18% a ezetimiba, 15,2% a fenofibrato, 3,8% a pitavastatina y 1,6% a lovastatina. Los motivos fueron \nadecuaci\u00f3n a las recomendaciones el 42,1%, exceso de control el 13,1%, falta de control objetivo el 11,3%, no indicaci\u00f3n \nel 9,8%, falta de control anal\u00edtico el 9,4%, no adherencia el 8,8%, simplificaci\u00f3n terap\u00e9utica el 5,1%, efecto adverso el \n0,2% e IR el 0,2%. Los f\u00e1rmacos finales eran principalmente: 38,7% atorvastatina, 18,5% rosuvastatina, 14,8% ezetimiba, \n13,2% fenofibrato, 4,1% pravastatina, 3,8% simvastatina, 3.5% pitavastatina y 1,4% lovastatina.  \nEl m\u00e9dico acept\u00f3 el 95,7% de las intervenciones e implement\u00f3 a los 6 meses el 46,4%, con un aumento del porcentaje de \nf\u00e1rmacos recomendados del 72,3% al 75,2% y un ahorro econ\u00f3mico anual estimado de 7.037 \u20ac. Este ser\u00eda te\u00f3ricamente \nde 14.598,5 \u20ac si todas las propuestas aceptadas se implementaran.\nCONCLUSIONES\nLa prescripci\u00f3n de hipolipemiantes no se adec\u00faa a los est\u00e1ndares recomendados, posiblemente por desconocimiento de \nlas recomendaciones institucionales, magnificaci\u00f3n en la percepci\u00f3n de los efectos adversos de los tratamientos cl\u00e1sicos, \nprescripci\u00f3n inducida e inercia terap\u00e9utica. La revisi\u00f3n de las prescripciones por el farmac\u00e9utico especialista es un valor \na\u00f1adido en la optimizaci\u00f3n del tratamiento de estos pacientes mediante un equipo multidisciplinar.  \nSer\u00e1 interesante volver a realizar el an\u00e1lisis al a\u00f1o, cuando todos los pacientes deber\u00edan haber recibido una visita, as\u00ed \ncomo evaluar el control del perfil lip\u00eddico despu\u00e9s de la intervenci\u00f3n.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n247. IMPACTO DE UNA INTERVENCI\u00d3N DE DESPRESCRIPCI\u00d3N EN UN HOSPITAL DE \nNEURORREHABILITACI\u00d3N. \nAUTORES\nCLOT SILLA, E; MART\u00cdNEZ SANTANA, VM; CATTANEO , G; OPISSO SALLERAS, E; POSADA CASAJUANA, CD; NAVAS \nJURADO, A; QUI\u00d1ONEZ MENDOZA, D; VENTURA RUIZ, X\nINSTITUT GUTTMANN \ufffd CAMI CAN RUTI, S/N BADALONA \ufffd BARCELONA\nOBJETIVOS\nEvaluar el impacto de una estrategia activa de asesoramiento en desprescripci\u00f3n sobre el n\u00famero de medicamentos \nprescritos al alta hospitalaria respecto a los prescritos al ingreso.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo realizado en un hospital de neurorrehabilitaci\u00f3n de 152 camas entre los meses de enero de \n2021 y marzo de 2022. La intervenci\u00f3n consisti\u00f3 en revisi\u00f3n de la medicaci\u00f3n en la proximidad del alta sugiriendo al \nprescriptor la interrupci\u00f3n de tratamientos innecesarios (duplicidad, ausencia de indicaci\u00f3n, medicaci\u00f3n inapropiada, \nbuen control del dolor, ritmo deposicional adecuado) que involucren a f\u00e1rmacos de las siguientes familias: analg\u00e9sicos, \nbenzodiazepinas, laxantes, antiepil\u00e9pticos, antihipertensivos, antiulcerosos e hipolipemiantes. Se excluyeron las \nprescripciones con frecuencia en dosis \u00fanica o si precisa. Las diferencias entre en n\u00famero de f\u00e1rmacos al ingreso y al 77alta se evaluaron mediante t-test, ANOVA (corregido por edad, sexo y n\u00famero de f\u00e1rmacos al ingreso) para discernir en \nqu\u00e9 diagn\u00f3stico la tasa de desprescripci\u00f3n es mayor, chi-cuadrado para verificar el grado de desprescripci\u00f3n de cada \ngrupo terap\u00e9utico y regresi\u00f3n m\u00faltiple para identificar las variables relacionadas con la desprescripci\u00f3n. Los an\u00e1lisis se \nrealizaron con el programa SPSS v28 estableci\u00e9ndose significaci\u00f3n estad\u00edstica si p < 0,05.\nRESULTADOS\nSe revisaron las prescripciones de 685 pacientes, 485 hombres y 200 mujeres (70,8% y 29,2% respectivamente) con \nuna edad media de 48,4 a\u00f1os (rango: 2-87 a\u00f1os; DE: 16,8 a\u00f1os). Los pacientes ingresaron con diagn\u00f3stico de ictus \n(176; 25,7%), paraplejia (154, 22,5%), tetraplejia (98, 14,3%), da\u00f1o cerebral traum\u00e1tico (97, 14,2%), da\u00f1o cerebral no \ntraum\u00e1tico (78, 11,4%), miopat\u00eda (27, 3,9%), s\u00edndrome de Guillain-Barr\u00e9 (20, 2,9%) y otros diagn\u00f3sticos (35, 5,1%). Se \nobserv\u00f3, tras la intervenci\u00f3n, una diferencia estad\u00edsticamente significativa entre la media de f\u00e1rmacos al ingreso y al alta \n[12,69 vs 4,76 (DE: 8,52 vs 3,43); t = 27,604; p < 0.001). Los pacientes con da\u00f1o cerebral traum\u00e1tico fueron aquellos a \nlos que m\u00e1s f\u00e1rmacos se pudo desprescribir respecto a otros diagn\u00f3sticos (p < 0,001) mientras que a los pacientes con \ntetraplejia fue al grupo de pacientes a quienes menos f\u00e1rmacos se pudieron suspender. El grupo m\u00e1s desprescrito fue \nel de analg\u00e9sicos con un 72,6% de desprescripci\u00f3n respecto al ingreso seguidos de benzodiazepinas (59,94%), laxantes \n(55,96%), antiepil\u00e9pticos (51,99%), antihipertensivos (49,79%), antiulcerosos (39,41%) e hipolipemiantes (33,52%). \nLas variables m\u00e1s influyentes sobre el potencial de desprescripci\u00f3n fueron: mayor n\u00famero de f\u00e1rmacos prescritos al \ningreso asociado a mayor desprescripci\u00f3n (\u03b2=0,931; p < 0,001) y mayor edad asociada a menor \u00edndice de desprescripci\u00f3n \n(\u03b2=0,063; p < 0,001).\nCONCLUSIONES\nLa implementaci\u00f3n de una estrategia de asesoramiento para fomentar la desprescripci\u00f3n activa, reduce de forma \nsignificativa el n\u00famero de medicamentos prescritos al alta hospitalaria, reduciendo el riesgo de polimedicaci\u00f3n y sus \ninconvenientes asociados\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n260. EVALUACI\u00d3N DE LA ATENCI\u00d3N FARMAC\u00c9UTICA REALIZADA A CENTROS SOCIOSANITARIOS \nAUTORES\nCOBAS BELSO, M; GEMIO ZUMALAVE, PR; CARMONA OYAGA, P; N\u00da\u00d1EZ CERUELO, I; MIR\u00d3N ELORRIAGA, G; PALACIOS \nFILARDO, M; MART\u00cdN TORRENTE, A; IBARRA BARRUETA, O\nHOSPITAL GALDAKAO-USANSOLO. BARRIO LABEAGA, S/N. GALDAKAO. VIZCAYA\nOBJETIVOS\nDescribir la poblaci\u00f3n sobre las que se han realizado intervenciones farmac\u00e9uticas, as\u00ed como el tipo y grado de aceptaci\u00f3n \npor parte de los profesionales de los centros sociosanitarios (CSS).\nMATERIALES Y M\u00c9TODOS\nComo resultado del desarrollo y aplicaci\u00f3n de una legislaci\u00f3n relativa a la atenci\u00f3n sanitaria a usuarios de CSS, se \nadhieren al servicio de farmacia un total de 24 CSS sobre los que se realizaron tareas de atenci\u00f3n farmac\u00e9utica (AF).  \nEstudio descriptivo retrospectivo en el que se analizan todas las intervenciones farmac\u00e9uticas realizadas desde marzo del \n2021 a marzo del 2022 a trav\u00e9s de la aplicaci\u00f3n de validaci\u00f3n farmac\u00e9utica VALFAR.  \nLas variables recogidas fueron: edad, sexo, n\u00ba de prescripciones por usuario, grupos terap\u00e9uticos ATC m\u00e1s prescritos, \nn\u00famero de intervenciones farmac\u00e9uticas realizadas, tipo de intervenci\u00f3n farmac\u00e9utica y porcentaje de aceptaci\u00f3n de las \nintervenciones farmac\u00e9uticas.\nRESULTADOS\nSe incluyeron un total de 1483 usuarios de residencia correspondientes a 24 CSS sobre los que se realiz\u00f3 la actividad.  \nLa edad media de los pacientes fue de 80 \u00b115 a\u00f1os, siendo un 64% mujeres y un 36% hombres. El n\u00famero medio de \nf\u00e1rmacos prescritos para cada usuario fue de 8\u00b14. De esos f\u00e1rmacos prescritos, los mayoritarios por grupo terap\u00e9utico \nATC fueron: N05 (antipsic\u00f3ticos) 13%, N06 (antidepresivos) 9%, A02 (agentes para el tratamiento de alteraciones \ncausadas por \u00e1cidos) 6%, B01 (agentes antitromb\u00f3ticos) 5% y N02 (analg\u00e9sicos) 5%.  \nSe realizaron un total de 946 intervenciones a 596 usuarios diferentes (40% del censo). Las principales intervenci\u00f3n \nfarmac\u00e9utica fueron: adecuaci\u00f3n de los medicamentos a la gu\u00eda farmacoterap\u00e9utica (33%), conciliaci\u00f3n del tratamiento \nen transiciones asistenciales (27%), adecuaci\u00f3n de la medicaci\u00f3n en usuarios con m\u00e1s de 10 f\u00e1rmacos prescritos de forma \ncr\u00f3nica (7%), revisi\u00f3n/suspensi\u00f3n de medicamentos con duraci\u00f3n m\u00e1xima recomendada (6%), indicaci\u00f3n de inicio de \ntratamiento con inhibidor de la bomba de protones (IBPs) (5%), revisi\u00f3n de dosis de medicamentos con dosis m\u00e1xima \nrecomendada (4%) e indicaci\u00f3n de suspender IBPs (4%).  \nSe aceptaron un total de 566 intervenciones de las 946 propuestas, lo que supuso un grado de aceptaci\u00f3n por parte de \nlos cl\u00ednicos de un 60%.\nCONCLUSIONES\nEl perfil de usuarios de CSS se corresponde con lo descrito anteriormente en otros estudios (altamente polimedicados, \ncon gran protagonismo de los medicamentos antipsic\u00f3ticos).  \nLa mayor\u00eda de las intervenciones fueron motivadas por medicamentos no incluidos en la gu\u00eda farmacoterap\u00e9utica, lo que \nest\u00e1 relacionado con el inicio del proyecto.78CLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n315. APLICACI\u00d3N DE UN PROTOCOLO DE DEPRESCRIPCI\u00d3N DE ANTIPSIC\u00d3TICOS EN PACIENTES CON \nDEMENCIA EN EL \u00c1MBITO DE UN CENTRO SOCIOSANITARIO. \nAUTORES\nBELTR\u00c1 PIC\u00d3, I; ESPADAS GARC\u00cdA, I; JAVALOYES TORMO, A; PASCUAL MART\u00cdNEZ, M; ORTIZ S\u00c1EZ, P; C\u00c1NOVES \nESCOLANO, M\u00c1; RIZO CERD\u00c1, \u00c1\nHOSPITAL GENERAL UNIVERSITARIO DE ALICANTE \ufffd AV\ufffd PINTOR BAEZA, 12 ALICANTE/ALACANT \ufffd ALICANTE\nOBJETIVOS\nLa demencia es una enfermedad neurodegenerativa que afecta a un elevado n\u00famero de pacientes institucionalizados \nen residencias de personas mayores. Suele cursar con s\u00edntomas psicol\u00f3gicos y conductuales (SPCD) como alucinaciones, \ndelirios, agresividad, agitaci\u00f3n, etc\ufffd  \nPara aquellos s\u00edntomas no controlables mediante medidas no farmacol\u00f3gicas, las gu\u00edas de pr\u00e1ctica cl\u00ednica recomiendan \nel uso de antipsic\u00f3ticos a dosis bajas, titulando la dosis en funci\u00f3n de las necesidades. No obstante, su prescripci\u00f3n \ncomporta un mayor riesgo de eventos cerebrovasculares y card\u00edacos como efectos adversos, por lo que tras la resoluci\u00f3n \no mejora de la sintomatolog\u00eda, se recomienda su retirada mediante reducci\u00f3n gradual de dosis (RGD).  \nEl objetivo fue la aplicaci\u00f3n de un protocolo de deprescripci\u00f3n en residentes diagnosticados de demencia, en tratamiento \ncon antipsic\u00f3ticos por SPCD.\nMATERIALES Y M\u00c9TODOS\nDise\u00f1o del estudio: Estudio de intervenci\u00f3n no comparativo (febrero 2022-mayo 2022). \nCriterios de inclusi\u00f3n: Diagn\u00f3stico de demencia, en tratamiento con \u22651 antipsic\u00f3tico, estabilidad cl\u00ednica > 3 meses. \nCriterios de exclusi\u00f3n: Pacientes con SPCD activos o diagn\u00f3stico de patolog\u00eda psiqui\u00e1trica previo.  \nVariables recogidas: Sexo, edad, situaci\u00f3n cl\u00ednica, antipsic\u00f3ticos prescritos, duraci\u00f3n del tratamiento, indicaci\u00f3n de \nprescripci\u00f3n y dosis de antipsic\u00f3ticos.  \nLos datos fueron obtenidos de la historia cl\u00ednica del paciente y de su historial farmacoterap\u00e9utico.  \nAcorde al protocolo establecido, la dosis se redujo un 50% cada 15 d\u00edas hasta su retirada o reducci\u00f3n a dosis m\u00ednima \neficaz. \nEl an\u00e1lisis estad\u00edstico se llev\u00f3 a cabo mediante el software estad\u00edstico R.\nRESULTADOS\nDe los 35 usuarios, 13 fueron mujeres (37,1%). La edad media fue de 81,8 \u00b1 8,5 a\u00f1os. Los residentes diagnosticados de \ndemencia en tratamiento con antipsic\u00f3ticos fueron 17 (48,5%), 2 (5,7%) ten\u00edan prescrito m\u00e1s de 1 antipsic\u00f3tico y 2 (5,7%) \nten\u00edan prescritos antipsic\u00f3ticos t\u00edpicos. La mediana de duraci\u00f3n del tratamiento fue de 20.2 meses (rango 6-48).  \nLos candidatos a desprescripci\u00f3n fueron 8 (22,9%). De ellos, 6 (75%) estaban en tratamiento con quetiapina (dosis \nmedia 70 mg/d\u00eda, rango 25-300) y 2 (25%) en tratamiento con risperidona (dosis media 1,5 mg/d\u00eda, rango 0.5-2,25). Se \nsuspendi\u00f3 el tratamiento en 3 pacientes, observando mejor\u00eda cognitiva en uno de ellos. En los 5 pacientes restantes la \nreducci\u00f3n se realiz\u00f3 hasta alcanzar la dosis m\u00ednima eficaz. Todos los pacientes presentaron estabilidad cl\u00ednica durante el \nperiodo de seguimiento posterior de 4 meses\ufffd  \nLimitaciones: El juicio cl\u00ednico fue la \u00fanica herramienta empleada para evaluar la evoluci\u00f3n tras la deprescripci\u00f3n. Una \nalternativa cuantificable podr\u00eda ser la evaluaci\u00f3n neuropsiqui\u00e1trica pre- y post- deprescripci\u00f3n mediante el Inventario \nNeuropsiqui\u00e1trico de Cummings o el mini examen cognoscitivo de lobo.\nCONCLUSIONES\nEs necesario un seguimiento estrecho de los pacientes con SPCD en tratamiento con antipsic\u00f3ticos. \u00c9stos deben ser \nprescritos durante el menor tiempo posible y a la dosis m\u00ednima eficaz, con el objetivo de reducir al m\u00ednimo la aparici\u00f3n \nde efectos adversos. La aplicaci\u00f3n de protocolos de desprescripci\u00f3n es una herramienta \u00fatil y eficaz en la reducci\u00f3n de la \npolifarmacia\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n350. AN\u00c1LISIS DE LA PERSISTENCIA DE PACIENTES EN TRATAMIENTO CON LURASIDONA EN UN CENTRO \nDE REHABILITACI\u00d3N PSICOSOCIAL. \nAUTORES\nMART\u00cdNEZ CRESPO, A; CI\u00c9RCOLES RODR\u00cdGUEZ, P; LOZANO ORT\u00cdZ, R; APESTEGU\u00cdA TOM\u00c1S, I\nCENTRO DE REHABILITACION PSICOSOCIAL NUESTRA SE\u00d1ORA DEL PILAR. DUQUESA DE VILLAHERMOSA, 66-68 \nZARAGOZA \ufffd ZARAGOZA\nOBJETIVOS\nEl objetivo principal del trabajo ha consistido en evaluar la persistencia del tratamiento con lurasidona, un nuevo \nantipsic\u00f3tico que se empez\u00f3 a comercializar en Espa\u00f1a en el a\u00f1o 2019, como marcador subrogado de efectividad y, \nsecundariamente, su uso terap\u00e9utico en las distintas indicaciones.\nMATERIALES Y M\u00c9TODOS\nEstudio ambispectivo realizado sobre una muestra compuesta por todos los pacientes de un Centro Neuropsiquiatrico en \ntratamiento con lurasidona, ya fuera en el momento de ingresar o durante su estancia en el Centro\ufffd El estudio se inici\u00f3 el \n5/12/2019 y se cerr\u00f3 el 22/4/2022. Se excluyeron aquellos pacientes que llevaban menos de 30 d\u00edas desde el inicio del \ntratamiento, y aquellos de los que no se pudo averiguar la duraci\u00f3n del mismo.  79De cada paciente se recopil\u00f3 la siguiente informaci\u00f3n: edad, sexo, continuaci\u00f3n o no del tratamiento (como variable \nprincipal para valorar la persistencia del tratamiento e indirectamente su efectividad), causa de la discontinuaci\u00f3n (en \ncaso de que se suspendiera el tratamiento), duraci\u00f3n del tratamiento, n\u00famero de antipsic\u00f3ticos utilizados en el momento \nde la prescripci\u00f3n de lurasidona e indicaci\u00f3n con la que se ha usado dicho antipsic\u00f3tico.  \nLos datos se obtuvieron del m\u00f3dulo de dosis unitarias del programa Dominion\u00ae y de la historia cl\u00ednica electr\u00f3nica, \npresent\u00e1ndose como media \u00b1 desviaci\u00f3n est\u00e1ndar (los cuantitativos) o como porcentaje (los cualitativos).  \nPara medir la fracci\u00f3n de pacientes que todav\u00eda se mantienen en tratamiento (persistencia), se utiliz\u00f3 el m\u00e9todo de \nKaplan-Meier que es un estimador no param\u00e9trico de la funci\u00f3n de persistencia en relaci\u00f3n con el tiempo y que admite \nuna representaci\u00f3n gr\u00e1fica de la misma.\nRESULTADOS\nMuestra final compuesta por 34 pacientes, edad 46.88 \u00b1 12.93 a\u00f1os, 58.82%(n=20) hombres, n\u00famero de antipsic\u00f3ticos \nutilizados al iniciar la prescripci\u00f3n de lurasidona (incluida lurasidona) era de 2.59 \u00b1 1.13. Se utiliz\u00f3 en monoterapia en 6 \npacientes\ufffd \nLa indicaci\u00f3n principal para la que se utiliz\u00f3 lurasidona fue de esquizofrenia, que es la aprobada en ficha t\u00e9cnica, en 15 \npacientes; fuera de ficha t\u00e9cnica (19): Trastorno esquizoafectivo (5), trastorno bipolar (7), delirio (2), psicosis (3), trastorno \nde personalidad (2).  \nEn el momento del cierre del estudio continuaban con el tratamiento 13 pacientes (38.24 %). Los d\u00edas de permanencia del \ntratamiento en la totalidad de los pacientes fueron 227.12 \u00b1 219.12. En los pacientes que contin\u00faan con el tratamiento \nfue de 336.23 \u00b1 221.37, en los que se suspendi\u00f3 159.57\u00b1 193.10.  \nMediante la curva de persistencia de Kaplan-Meier, se calcul\u00f3 una mediana de duraci\u00f3n del tratamiento con lurasidona \nde 204 d\u00edas (IC 95 % = 55.6-352.3).  \nLas causas de suspensi\u00f3n del tratamiento fueron: falta efectividad en 12 pacientes, falta adherencia 4, fallecimiento \ndel paciente (por hipoxemia) 1, efectos adversos 2 (parkinsonismo y posible efecto extrapiramidal), simplificaci\u00f3n del \ntratamiento 2\ufffd\nCONCLUSIONES\nLa mediana de duraci\u00f3n del tratamiento con lurasidona fue de 204 d\u00edas durante un periodo de estudio de 873 dias.  \nLa lurasidona puede ser una buena alternativa antipsic\u00f3tica efectiva en pacientes psiqui\u00e1tricos complejos.  \nEl uso de lurasidona no se ajusta a la indicaci\u00f3n de la ficha t\u00e9cnica en un 55.9 % de los pacientes.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n394. AN\u00c1LISIS Y ADECUACI\u00d3N DE LOS TRATAMIENTOS ANTIDIAB\u00c9TICOS ORALES EN PACIENTES \nINSTITUCIONALIZADOS SEG\u00daN SU FRAGILIDAD \nAUTORES\nAGUST\u00cd SASTRE, A; GUARDINO CUS\u00d3, M; LLAGOSTERA PUJOL, B; PLANA LLAURAD\u00d3, C; PUERTA BRAVO, L; ROVIRA \nVERG\u00c9S, O\nGRUP MUTUAM\nOBJETIVOS\nAnalizar la adecuaci\u00f3n de f\u00e1rmacos antidiab\u00e9ticos orales (ADO) en pacientes institucionalizados en hospitales de atenci\u00f3n \nintermedia (HAI) y residencias geri\u00e1tricas (RG) seg\u00fan su fragilidad, para detectar oportunidades de optimizaci\u00f3n y \nsimplificaci\u00f3n de los tratamientos con el fin de minimizar los efectos adversos y mejorar los resultados en salud.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo multic\u00e9ntrico en el que se realiz\u00f3 un corte transversal de los pacientes ingresados en \n2 HAI y 3 RG en tratamiento con \u22651 ADO o \u22651 ADO e insulina. Se recogieron los datos de la Historia Cl\u00ednica Informatizada \ny se registraron las siguientes variables: edad, sexo, \u00edndice de fragilidad (IF-CSS), tratamiento antidiab\u00e9tico, dosis diaria, \nvalor y fecha de Hb1Ac y filtrado glomerular (FG) calculado con la f\u00f3rmula CKD-EPI.  \nSe determinaron los objetivos de control metab\u00f3lico (OCM) en funci\u00f3n del \u00edndice de fragilidad IF-CSS: IF-CSS < 0,2, \nOCM=Hb1Ac < 7%; IF-CSS 0,2-0,35, OCM=Hb1Ac 7-7,5%; IF-CSS 0,36-0,5, OCM=Hb1Ac 7,5-8%; IF-CSS > 0,5, el OCM \nser\u00e1 mantener glucemias por debajo de 200mg/dl y evitar hipoglucemias. Se consideran pacientes candidatos a una \nsimplificaci\u00f3n de tratamiento aquellos con valores Hb1Ac < OCM.\nRESULTADOS\nSe incluyeron en el estudio 86 pacientes, 57% mujeres, con una edad media de 79\u00b111.6 a\u00f1os y una fragilidad media \nde 0,39\u00b10,14. De estos, el 72,1% ten\u00edan anal\u00edticas actualizadas el \u00faltimo a\u00f1o, y 10 pacientes (11,6%) no ten\u00edan ning\u00fan \nregistro de Hb1Ac\ufffd  \nDe acuerdo a la clasificaci\u00f3n de pacientes seg\u00fan fragilidad y cumplimiento de OCM: IF-CSS < 0,2, n=8 (37,5% dentro del \nOCM (D-OCM)); IF-CSS 0,2-0,35, n=21 (9,5% D-OCM); IF-CSS 0,36-0,5, n=25 (16% D-OCM); IF-CSS > 0,5, n=22 (OCM no \nvalorable).  \nSolamente 18 (23,7%) pacientes se encuentran en un objetivo metab\u00f3lico (D-OCM) ajustado a su fragilidad. Un total de \n44 (57,9%) pacientes presentan Hb1Ac < OCM y son candidatos a simplificaci\u00f3n de tratamiento. Se encuentran 14 (18,4%) \npacientes con Hb1Ac > OCM y ser\u00e1n candidatos a revisi\u00f3n del tratamiento ya que no est\u00e1 dando los resultados esperados.  \nSeg\u00fan el tratamiento antidiab\u00e9tico, 40 pacientes (47%) ten\u00edan prescrito un ADO, 22 (26%) un ADO+insulina, 15 (17%) dos \nADO, 7(8%) dos ADO+insulina, y 2 (2%) tres ADO. Un total de 25 (29,1%) tratamientos requer\u00edan de ajuste de dosis seg\u00fan \nvalores de FG, de los cuales 4 (16%) presentaban una dosis inadecuada.80CONCLUSIONES\nSolamente el 23,7% de los tratamientos con ADO en pacientes institucionalizados est\u00e1 ajustado a las recomendaciones de \nOCM en funci\u00f3n de la fragilidad\ufffd  \nEl 57,9% de los pacientes pueden beneficiarse de una simplificaci\u00f3n del tratamiento antidiab\u00e9tico ya que presentan una \nHb1Ac por debajo del OCM, y en el 18,4% de los pacientes es necesaria la revisi\u00f3n del tratamiento antidiab\u00e9tico por falta \nde resultados. Las principales estrategias de intervenci\u00f3n farmac\u00e9utica en pacientes en tratamiento con ADO deben estar \ncentradas en la optimizaci\u00f3n y la revisi\u00f3n de los tratamientos. Para ello, puede ser necesaria la revisi\u00f3n y solicitud si fuera \nnecesario de controles anal\u00edticos, ya que se ha visto que el 11,6% de los pacientes no tiene ning\u00fan registro de Hb1Ac.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n402. PATIENT-REPORTED OUTCOMES MEASURES PARA EL SEGUIMIENTO DEL PACIENTE CON ASMA \nGRAVE. CONSENSO DE EXPERTOS Y PACIENTES. \nAUTORES\nMU\u00d1OZ GARC\u00cdA, M; MART\u00cdNEZ MORAG\u00d3N, E; ANTEPARA ERCORECA, I; PREGO DE LA IGLESIA, C; BENEDITO PALOS, L\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nEl asma grave puede impactar negativamente en el paciente. Por ello, nuestro objetivo es consensuar las herramientas \n(Patient-Reported Outcomes Measures, PROM) m\u00e1s adecuadas y factibles para evaluar, en pr\u00e1ctica cl\u00ednica, los resultados \ncentrados en el paciente (Patient-Reported Outcomes, PRO), desde la perspectiva del paciente y profesional sanitario.\nMATERIALES Y M\u00c9TODOS\nA partir de una revisi\u00f3n de la literatura, un grupo focal con 4 pacientes y un grupo nominal con expertos (9 farmac\u00e9uticos \nhospitalarios, 4 alerg\u00f3logos, 4 neum\u00f3logos y 2 enfermeros), se elabor\u00f3 un cuestionario Delphi para valorar la adecuaci\u00f3n \ny factibilidad de empleo de los PROM (escala Likert 1=totalmente acuerdo; 9=totalmente desacuerdo) para la evaluaci\u00f3n \nde los siguientes PRO: s\u00edntomas espec\u00edficos del asma grave (opresi\u00f3n en el pecho, sibilancias, dificultad para respirar, tos \ny despertares nocturnos), s\u00edntomas asociados a comorbilidades (taponamiento de nariz, problemas de sue\u00f1o, cansancio, \nalteraci\u00f3n gusto/olfato, ansiedad y depresi\u00f3n) y otros PRO (calidad de vida relacionada con la salud, satisfacci\u00f3n con el \ntratamiento, adherencia terap\u00e9utica, impacto laboral/acad\u00e9mico y conocimiento del paciente sobre la enfermedad). \nLos PROM se clasificaron en esenciales para cualquier paciente con asma grave (ACT, mini-AQLQ, EQ-5D, MRC, TAI y \nMorisky-Green, adem\u00e1s de revisar el registro de dispensaci\u00f3n) a utilizar en cada visita de seguimiento (trimestralmente) \ny complementarios ante determinadas circunstancias (SNOT-22: s\u00edntomas nasales acompa\u00f1antes; PSQI: problemas de \nsue\u00f1o; HADS: s\u00edntomas psiqui\u00e1tricos; WPAI: afectaci\u00f3n laboral/acad\u00e9mica; TQSM-9: satisfacci\u00f3n tratamiento; cuestionario \nde conocimiento del paciente sobre el asma de B\u00e1ez-Salda\u00f1a et al., 2007).  \nSe estableci\u00f3 consenso para aquellas cuestiones con un porcentaje de respuesta \u226575 en el extremo de acuerdo o \ndesacuerdo. En la segunda ronda se incluyeron preguntas para explorar los motivos de no conformidad. Un comit\u00e9 \ncient\u00edfico constituido por una farmac\u00e9utica hospitalaria, un alerg\u00f3logo y una neum\u00f3loga supervis\u00f3 todas las fases del \nestudio y valid\u00f3 el consenso\ufffd\nRESULTADOS\nEl cuestionario Delphi fue respondido por 63 profesionales (25 farmac\u00e9uticos hospitalarios, 14 alerg\u00f3logos, 13 \nneum\u00f3logos y 11 enfermeros) y 5 pacientes (edad media 46 a\u00f1os [rango 26-63]; tiempo de diagn\u00f3stico 15 a\u00f1os \n[DE=10]). La tasa de respuesta en segunda ronda fue del 96,8%. Se alcanz\u00f3 consenso en la relevancia de todos los PRO \ny la adecuaci\u00f3n de los PROM propuestos. Sin embargo, no se alcanz\u00f3 consenso acerca de la factibilidad de uso de los \ncuestionarios SNOT-22 (74%), TQSM-9 (70%), B\u00e1ez-Salda\u00f1a (69%), EQ-5D (67%), PSQI (64%), HADS (64%) y WPAI (49%) en \npr\u00e1ctica cl\u00ednica. Las principales razones transmitidas fueron la falta de tiempo en consulta, de personal de soporte y de \nintegraci\u00f3n autom\u00e1tica de resultados en la historia cl\u00ednica, y el desconocimiento por parte del profesional sanitario.\nCONCLUSIONES\nEl consenso alcanzado evidencia la relevancia de incorporar la perspectiva del paciente durante el seguimiento del asma \ngrave mediante la recogida de los PRO \ufffd Para ello, existe acuerdo en emplear los PROM considerados como esenciales \n(ACT, TAI, mini-AQLQ, MCR y Morisky-Green), adem\u00e1s de revisar el registro de dispensaci\u00f3n. Sin embargo, el empleo de \nlos PROM complementarios no se consider\u00f3 factible en pr\u00e1ctica cl\u00ednica, debido principalmente a cuestiones relacionadas \ncon la falta de tiempo en consulta.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n418. EVALUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE LAXANTES Y FACTORES ASOCIADOS A SU USO EN CENTROS \nRESIDENCIALES DE PERSONAS MAYORES \nAUTORES\nINDO VAZQUEZ, E; FERRO URIGUEN, A; BEOBIDE TELLERIA, I; LASO LUCAS, E; MIR\u00d3 ISASI, B\nHOSPITAL RICARDO BERMINGHAM (FUNDACI\u00d3N MATIA). CAMINO DE LOS PINOS, 35 DONOSTIA-SAN SEBASTI\u00c1N. \nGUIP\u00daZCOA\nOBJETIVOS\nEl estre\u00f1imiento es un s\u00edndrome geri\u00e1trico que afecta a uno de cada cinco adultos y lo sufren el 50-75% de las personas \ninstitucionalizadas. El objetivo principal de este trabajo ha sido conocer la prevalencia de prescripci\u00f3n de laxantes en \npersonas mayores que viven en centros residenciales y los factores que se asocian a su uso.81MATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio transversal multic\u00e9ntrico en las unidades gerontol\u00f3gicas y psicogeri\u00e1tricas de 7 centros \nresidenciales. A fecha de 21 de marzo de 2022, se analiz\u00f3 la prescripci\u00f3n de los diferentes grupos terap\u00e9uticos de \nlaxantes seg\u00fan la clasificaci\u00f3n Anat\u00f3mico, Terap\u00e9utico y Qu\u00edmica (ATC) de la Organizaci\u00f3n Mundial de la Salud , as\u00ed como \nlos principales f\u00e1rmacos con potencial riesgo astringente (anti\u00e1cidos (A02A), diur\u00e9ticos (C03), calcios antagonistas (C08), \nantiespasm\u00f3dicos urinarios (G04BB), antiinflamatorios no esteroideos (M01A), opioides (N02A), agentes anticolin\u00e9rgicos \nantiparkinsonianos (N04A) y agentes dopamin\u00e9rgicos (N05B), antipsic\u00f3ticos (N05A), benzodiacepinas (N05B) y an\u00e1logos \n(N05C), inhibidores selectivos de la reabsorci\u00f3n de serotonina (N06AB), antidepresivos tric\u00edclicos (N06AA), otros \nantidepresivos (N06AX) y antihistam\u00ednicos (R06)). Para el an\u00e1lisis comparativo entre las personas consumidoras de \nlaxantes y no consumidoras se utilizaron las pruebas de chi cuadrado y la U-Mann Whitney. Una p < 0,05 se consider\u00f3 \nestad\u00edsticamente significativa (SPSS v20.0).\nRESULTADOS\nSe analizaron un total de 648 residentes, con una mediana de edad de 87 a\u00f1os siendo el 72,7% mujeres. La prevalencia \nde prescripci\u00f3n de al menos un laxante de forma cr\u00f3nica fue del 56,14%, siendo los osm\u00f3ticos (A06AD) los m\u00e1s utilizados \ncon una frecuencia del 95,73%. Ser mujer, tener una peor reserva cognitiva (GDS \u22656) y una dependencia severa/\nmuy severa (\u00cdndice de Barthel \u226435) se asociaron con un mayor consumo de laxantes, con los siguientes resultados \nrespectivamente: OR 1,8 (IC 95% 1,3-2,6), OR 1,8 (IC 95% 1,3-2,5) y OR 2,2 (IC 95% 1,6-3,0).  \nPor otra parte, los antipsic\u00f3ticos (N05A) y otros antidepresivos (N06AX) fueron los grupos de f\u00e1rmacos con potencial \nriesgo astringente que se asociaron con un mayor consumo de laxantes; OR 1,5 (IC 95% 1,1-2,1) y OR 1,4 (IC 95% 1,1-1,9), \nrespectivamente. Asimismo, la acumulaci\u00f3n de \u22652 f\u00e1rmacos con potencial riesgo astringente tambi\u00e9n se relacion\u00f3 con un \nmayor consumo de laxantes OR 1,8 (IC 95% 1,1-3,0).\nCONCLUSIONES\nEn este estudio se ha podido constatar una alta prevalencia de uso de los laxantes as\u00ed como una correcta adhesi\u00f3n a las \ngu\u00edas de pr\u00e1ctica cl\u00ednica, con una primera intenci\u00f3n de uso de los f\u00e1rmacos laxantes osm\u00f3ticos. El uso de laxantes ha \nsido relacionado con personas con un peor estado de salud y tambi\u00e9n con la toma de diversos f\u00e1rmacos con actividad \nastringente. Estos \u00faltimos pueden ser objeto de una adecuaci\u00f3n terap\u00e9utica con el fin de evitar una nueva cascada \nterap\u00e9utica.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n439. PROGRAMA DE DESPRESCRIPCI\u00d3N EN CENTROS SOCIOSANITARIOS RESIDENCIALES. \nAUTORES\nMU\u00d1OZ CEJUDO, BM; LUQUE JIMENEZ, M; JIMENEZ LOPEZ, Y; GARCIA GOMEZ, N; GARCIA AGUDO, S\nHOSPITAL COMARCAL SAN AGUST\u00cdN. AV . DE SAN CRISTOBAL, S/N LINARES. JA\u00c9N\nOBJETIVOS\nDesarrollo de un programa de desprescripci\u00f3n basado en la evaluaci\u00f3n de la carga anticolin\u00e9rgica (CA) de residentes \nde centros sociosanitarios (CSS), identificaci\u00f3n de los f\u00e1rmacos implicados en el incremento de la CA y propuesta de \nestrategias para la reducci\u00f3n de la CA \ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio longitudinal, observacional y prospectivo realizado por el servicio de farmacia de un hospital de tercer nivel \nentre enero y abril de 2022, en dos CSS. Todos los residentes que ingresaron en los CSS durante este periodo fueron \nincluidos\ufffd Se recogieron las siguientes variables: sexo, edad, tratamiento farmacol\u00f3gico y CA \ufffd Se calcul\u00f3 la CA mediante \nla herramienta Anticholinergic Burder Calculator, bas\u00e1ndonos en la escala Drug Burden Index (DBI). Se estratific\u00f3 a los \nresidentes seg\u00fan el riesgo anticolin\u00e9rgico (RA) asociado a su medicaci\u00f3n: sin riesgo (valor=0), bajo riesgo (valor=1), riesgo \nmedio (valor=2) y alto riesgo (valor\u22653). A los residentes con CA > 2 se evalu\u00f3 que f\u00e1rmacos estaban implicados en el \naumento de la CA y se determin\u00f3 cu\u00e1les de ellos fueron los grupos m\u00e1s prevalentes. Se realizaron recomendaciones de \ndesprescripci\u00f3n para reducir la CA de estos residentes y se evalu\u00f3 su aceptaci\u00f3n por parte del equipo m\u00e9dico de los CSS y \nespecialistas prescriptores\ufffd\nRESULTADOS\nSe incluyeron un total de 276 residentes: 62,68% mujeres, edad media 80,73\u00b111,7 a\u00f1os y media de medicamentos/\nresidente de 7,85\u00b12,20 medicamentos. La media de f\u00e1rmacos que aportaban CA fue 2,54\u00b11,20. Presentaron un RA alto \n148 residentes (53,62%), medio 79 residentes (28,62%) y sin riesgo 49 residentes (17,75%). El n\u00famero de residentes \ncon CA > 2 fue 36 (13,04%). El total de f\u00e1rmacos prescritos implicados en el incremento de CA fue 68, siendo los m\u00e1s \nfrecuentes: 15 antipsic\u00f3ticos (46,67% quetiapina, 33,33% pimozida, 20% amitriptilina), 12 opioides (66,67% fentanilo, \n33,33% morfina), 10 benzodiazepinas (48,55% clorazepato) y 10 antidepresivos (62% inhibidores de la recaptaci\u00f3n de \nserotonina). Tras evaluar los datos analizados, se propusieron al m\u00e9dico prescriptor 45 intervenciones farmac\u00e9uticas: \n15 relacionadas con la reducci\u00f3n paulatina de la dosis hasta la m\u00ednima eficaz \u00f3 suspensi\u00f3n y 30 relacionadas con la \npropuesta de alternativas terap\u00e9uticas de menor potencia anticolin\u00e9rgica. El grado de aceptaci\u00f3n por parte del m\u00e9dico \nprescriptor fue de un 100%. Se consigui\u00f3 que el n\u00famero de residentes con CA > 2 se redujera un 58,33%.\nCONCLUSIONES\nSe evidencia la importancia del papel del farmac\u00e9utico en el programa de desprescripci\u00f3n en pacientes cr\u00f3nicos. La \nrevisi\u00f3n de la CA ha resultado ser una herramienta eficaz para conseguir el objetivo, optimizar la terapia farmacol\u00f3gica \ny mejorar la seguridad de los residentes. Por todo \u00e9sto, se decide la implantaci\u00f3n de este programa para su seguimiento 82continuado y se propone la reuni\u00f3n peri\u00f3dica entre farmac\u00e9utico y m\u00e9dicos de CSS para la revisi\u00f3n conjunta de \nresidentes polimedicados\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n489. \u00bfC\u00d3MO SE DIAGNOSTICAN LAS INFECCIONES DEL TRACTO URINARIO EN LAS RESIDENCIAS DE \nMAYORES?+ \nAUTORES\nLLANOS GARC\u00cdA, MT; ESCUDERO BROCAL, A; GONZ\u00c1LEZ MART\u00cdNEZ, M; RUIZ DE HOYOS, M; MAYORGA BAJO, I; \nHERN\u00c1NDEZ GU\u00cdO, A; CAPILLA SANTAMARIA, E; ARANGUREN OYARZ\u00c1BAL, A\nSERVICIO MADRILE\u00d1O DE SALUD \ufffd AVENIDA DE MANUEL FRAGA IRIBARNE 2 MADRID \ufffd MADRID\nOBJETIVOS\nEvaluar los criterios cl\u00ednicos y anal\u00edticos con los que se realiza el diagn\u00f3stico de infecci\u00f3n del tracto urinario (ITU) y se \ninicia tratamiento antibi\u00f3tico en Residencias de mayores (RM), y establecer acciones de mejora.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo y multic\u00e9ntrico de pr\u00e1ctica cl\u00ednica real en 24 RM. Se incluyeron los usuarios \ninstitucionalizados en RM que iniciaron tratamiento antibi\u00f3tico para tratar una ITU entre el 01/04/2022 y el 20/04/2022. \nSe recogieron los siguientes datos de la historia cl\u00ednica, relacionados con el residente: edad, sexo, deterioro cognitivo \n(DC), sonda vesical; con el centro: residencia, m\u00e9dico; criterios cl\u00ednicos de diagn\u00f3stico de ITU registrados en la historia \ncl\u00ednica: espec\u00edficos (presencia de disuria aguda, fiebre +/- empeoramiento de urgencia miccional, de aumento de \nfrecuencia miccional de hematuria macrosc\u00f3pica), inespec\u00edficos; criterios anal\u00edticos: realizaci\u00f3n de tira reactiva (TR) o \nsedimento (presencia de nitritos, leucocitos), realizaci\u00f3n de urinocultivo [presencia de bacteriuria, microrganismo aislado \n(MO)].\nRESULTADOS\nSe registraron un total de 184 tratamientos, de 179 residentes, el 77% mujeres. La mediana de edad fue de 88 a\u00f1os \n(64-103); 67% con DC y 5% con sonda vesical. El 90% de los casos fueron diagnosticados en la RM. En residentes con \nDC, el diagn\u00f3stico se realiz\u00f3 por criterios cl\u00ednicos de diagn\u00f3stico espec\u00edficos (fiebre, disuria +/- alguno de los otros tres) \nen un 23 %, por criterios inespec\u00edficos en un 65% y sin ning\u00fan registro el 10%; mientras que en usuarios sin DC solo un \n45 % cumpl\u00eda criterios cl\u00ednicos de diagn\u00f3stico espec\u00edficos, un 34% fue diagnosticado por criterios inespec\u00edficos y 19% \nsin ning\u00fan registro. Dentro de los criterios inespec\u00edficos, de forma global, destacaron decaimiento (28%), deterioro \ncl\u00ednico (11%), orina maloliente (7%) e inquietud (7%). Se realizaron 139 TR, 62% positivas a leucocitos m\u00e1s nitritos, \n25% a leucocitos solos, 1% a nitritos solos, 6% negativo a ambos y 6% sin resultados. Se realizaron 15 sedimentos, 36% \npositivos a leucocitos m\u00e1s nitritos; a 10 registros se les realiz\u00f3 TR y sedimento, el 60% positivos a leucocitos m\u00e1s nitritos. \nSe realiz\u00f3 urinocultivo al 29% de los casos, con una presencia de bacteriuria en el 57%; los MO detectados fueron en su \nmayor\u00eda enterobacterias (Escherichia coli 63%, Proteus Mirabilis 21%, Klebsiella pneumoniae 17%) de las cuales 5 fueron \nproductoras de BLEE y 1 Klebsiella Pneumonie R OXA \ufffd\nCONCLUSIONES\nLa mayor\u00eda de diagn\u00f3sticos de ITU se realizan con criterios cl\u00ednicos inespec\u00edficos; esto no se justifica en residentes sin \nDC seg\u00fan las recomendaciones actuales, lo cual genera excesiva realizaci\u00f3n de pruebas diagn\u00f3sticas innecesarias y una \nsobreutilizaci\u00f3n de antibi\u00f3ticos. Es importante mejorar el registro de criterios por los que se instaura el tratamiento \nantibi\u00f3tico y, sobre todo, reforzar los m\u00e9todos de diagn\u00f3stico de ITU para frenar el aumento de las resistencias a \nantibi\u00f3ticos en RM.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n501. POLIFARMACIA Y F\u00c1RMACOS INAPROPIADOS EN PACIENTES CON DISFAGIA OROFAR\u00cdNGEA \nAUTORES\nRODR\u00cdGUEZ-MAR\u00cdN , M; MART\u00cdN SANZ, P; DELGADO-SILVEIRA , E; MORA-RIVAS , E; MONTES-JOVELLAR GONZ\u00c1LEZ, \nLE; MOLINA MENDOZA, D; MU\u00d1OZ GARC\u00cdA, M; \u00c1LVAREZ D\u00cdAZ, A\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nAnalizar la prevalencia, en pacientes con disfagia orofar\u00edngea (DO), de polifarmacia ( > de 5 f\u00e1rmacos cr\u00f3nicos) y de \nf\u00e1rmacos inapropiados en la DO (causantes de xerostom\u00eda, sedaci\u00f3n, esofagitis, da\u00f1o muscular y efectos anticolin\u00e9rgicos).  \nClasificar y cuantificar los f\u00e1rmacos que agravan o potencian la aparici\u00f3n la DO (anticolin\u00e9rgicos y resto de medicamentos) \npor grupos terap\u00e9uticos y por mecanismo de acci\u00f3n responsable.  \nCalcular el riesgo anticolin\u00e9rgico (AR) de los f\u00e1rmacos inapropiados en DO, empleando diferentes escalas anticolin\u00e9rgicas.\nMATERIALES Y M\u00c9TODOS\nSe llev\u00f3 a cabo un estudio retrospectivo observacional en un hospital general terciario. Se seleccionaron los pacientes \ndiagnosticados con DO en la consulta de otorrinolaringolog\u00eda, espec\u00edfica de disfagia, entre los a\u00f1os 2019 y 2021. \nLos datos cl\u00ednicos, demogr\u00e1ficos y farmacoterap\u00e9uticos se obtuvieron a trav\u00e9s de la historia cl\u00ednica electr\u00f3nica y de la \nreceta electr\u00f3nica. El AR se calcul\u00f3 con la \u201canticholinergic burden calculator\u201d (disponible en: www.anticholinergicscales.\nes) Los grupos terap\u00e9uticos se clasificaron seg\u00fan la clasificaci\u00f3n ATC, y el mecanismo de acci\u00f3n que agrava o potencia la \naparici\u00f3n de DO fue consultado en la bibliograf\u00eda.83RESULTADOS\nSe reclutaron 103 pacientes, 8 (7,8%) se descartaron porque no hubo acceso a la receta electr\u00f3nica. De los 96 restantes, \n53 (51,5%) fueron mujeres. La mediana de edad fue de 74,1 [rango intercuartilico 70,7-89,9 a\u00f1os].  \nUn total de 69 (66,9%) pacientes eran polimedicados con una mediana de 8 f\u00e1rmacos (rango 0-22 f\u00e1rmacos). De \u00e9stos \nuna mediana de 2 f\u00e1rmacos inapropiados en la DO (rango entre 0-8). \nOchocientas treinta y cuatro prescripciones fueron analizadas encontr\u00e1ndose 331 (39,7%) que podr\u00edan ser medicaci\u00f3n \nque potencialmente pudiera ocasionar DO.  \nEn cuanto a mecanismos por los que eran inapropiados en la DO se hall\u00f3 84 (25,4%) pod\u00edan causar da\u00f1o muscular, 64 \n(19,3%) por poder desencadenar xerostom\u00eda, 62 (18,7%) por tener acci\u00f3n sedante y 34 (10,3%) por causar esofagitis.  \nEn referencia a los f\u00e1rmacos anticolin\u00e9rgicos prescritos, se encontr\u00f3 que 45 (43,7%) pacientes ten\u00edan un alto AR, 24 \n(23,3%) ten\u00edan un riesgo medio y 34 (33%) pacientes ten\u00edan bajo riesgo, siendo mayoritariamente hombres (56%).  \nCon relaci\u00f3n a los grupos terap\u00e9uticos inapropiados en la DO, los mayoritarios fueron estatinas habiendo 37 (11,8%), 31 \n(9,4%) corticoides y 28 (8,5%) benzodiacepinas.  \nLos medicamentos con mayor potencial de causar AR fueron: atorvastatina y \u00e1cido acetil salic\u00edlico, estando ambos en 18 \nprescripciones (7,7%), seguido del lorazepam en 15 (6,4%) y la metformina en 14 (5,9%).\nCONCLUSIONES\nSe observa que hay un alto porcentaje de pacientes con DO que est\u00e1n polimedicados, encontr\u00e1ndose en la pr\u00e1ctica \ntotalidad al menos un f\u00e1rmaco inapropiado en dicha enfermedad.  \nM\u00e1s de una cuarta parte de las prescripciones son potencialmente provocadoras de DO, siendo la mayoritaria por el \nmecanismo anticolin\u00e9rgico.  \nDe los pacientes estudiados, casi la mitad presentaban un elevado riesgo seg\u00fan la calculadora anticolin\u00e9rgica.  \nUna revisi\u00f3n del tratamiento farmacol\u00f3gico susceptible de agravar o provocar la DO podr\u00eda llevarse a cabo para intentar \nreducir el riesgo en estos pacientes\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n526. AN\u00c1LISIS DEL TRATAMIENTO ANTICOAGULANTE EN PACIENTES INGRESADOS MAYORES DE 65 \nA\u00d1OS CON FIBRILACI\u00d3N AURICULAR \nAUTORES\nRIZO GOMEZ, A; BARRANTES GONZALEZ, M; MENSA VENDRELL, M; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nAnalizar el tipo de tratamiento anticoagulante en pacientes mayores de 65 a\u00f1os con fibrilaci\u00f3n auricular (FA) ingresados \nen el Servicio de Medicina Interna de un hospital general de agudos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo y descriptivo realizado que incluy\u00f3 a pacientes mayores de 65 a\u00f1os con tratamiento \nanticoagulante por fibrilaci\u00f3n auricular (FA). Se recogieron los datos de la prescripci\u00f3n electr\u00f3nica y de la historia cl\u00ednica \ndurante un periodo de 6 meses (agosto 2021-enero 2022). Variables analizadas: edad, sexo, nivel de complejidad seg\u00fan \nGMA (Grupo de Morbilidad Ajustado), tratamiento anticoagulante y estimaci\u00f3n del filtrado glomerular (FGe) seg\u00fan la \nf\u00f3rmula CKD-EPI. El riesgo cardioemb\u00f3lico se calcul\u00f3 con la escala CHA2DS2-VASc y el riesgo hemorr\u00e1gico con la escala \nHAS-BLED. El an\u00e1lisis de los datos se realiz\u00f3 con Excel mediante estad\u00edstica descriptiva con medidas de centralizaci\u00f3n \n(media), desviaci\u00f3n (SD: desviaci\u00f3n est\u00e1ndar) y frecuencia.\nRESULTADOS\nSe incluyeron un total de 132 pacientes. La media de edad fue de 86,5 a\u00f1os (SD=6,9), 57,6% (n=76) mujeres. El 55,3% \n(n=73) de los pacientes presentaban un GMA de 4 o 5 (nivel de complejidad alto). La media de la escala CHA2DS2-VASc \nfue 4,9 (SD=1,3) y la escala HAS-BLED de 2,6 (SD=0,9). Respecto a la funci\u00f3n renal, el 49% (n=65) de los pacientes ten\u00edan \nun FGe CKD-EPI < 50 ml/min/1,73m2. Durante el ingreso se requiri\u00f3 ajustar la dosis del anticoagulante por insuficiencia \nrenal en el 16% (n=21) de los pacientes. El tratamiento anticoagulante prescrito previo al ingreso fue: edoxab\u00e1n: 31% \n(n=36), apixab\u00e1n: 25,9% (n=30), acenocumarol: 24,1% (n=28), rivaroxab\u00e1n: 11,2% (n=13) y dabigatr\u00e1n: 7,8% (n=9). \nSe realiz\u00f3 intercambio de anticoagulante oral a enoxaparina durante el ingreso en el 27,6% (n=32) de los pacientes. \nSe inici\u00f3 tratamiento anticoagulante en 16 pacientes (6 pacientes con FA sin tratamiento previo y 10 pacientes con \ndiagn\u00f3stico de FA durante el ingreso). En estos pacientes, el tratamiento de inicio prescrito fue: enoxaparina: 56,3% (n=9), \nacenocumarol: 12,5% (n=2), apixab\u00e1n: 12,5% (n=2), edoxab\u00e1n: 12,5% (n=2) y rivaroxab\u00e1n: 6,3% (n=1).\nCONCLUSIONES\nLa mayor\u00eda de los pacientes con FA estaban anticoagulados con anticoagulantes orales de acci\u00f3n directa (75,9%). \nEn un porcentaje elevado de pacientes (27,6%) se intercambi\u00f3 el anticoagulante oral por enoxaparina al ingreso y \naproximadamente la mitad de los pacientes (56%) que iniciaron tratamiento anticoagulante en el ingreso lo hicieron con \nenoxaparina. El riesgo cardioemb\u00f3lico, el riesgo de sangrado y el nivel de complejidad de los pacientes fue alto, por lo \nque la revisi\u00f3n del tratamiento anticoagulante por parte de un farmac\u00e9utico cl\u00ednico y el consenso con el equipo m\u00e9dico es \nfundamental\ufffd84CLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n603. DISFAGIA: OPORTUNIDADES DE INTERVENCI\u00d3N SOBRE EL TRATAMIENTO FARMACOL\u00d3GICO EN \nPACIENTES AMBULATORIOS. \nAUTORES\nPRADO MONTES, P; LAGO RIVERO, N; ROMERO VENTOSA, EY; ALFONS\u00cdN LARA, M; ROBLES TORRES, D; COU\u00d1AGO \nFERN\u00c1NDEZ, M; CASTRO N\u00da\u00d1EZ, MI; MART\u00cdNEZ L\u00d3PEZ DE CASTRO, N\nHOSPITAL \u00c1LVARO CUNQUEIRO \ufffd ESTRADA DE CLARA CAMPOAMOR, 341 VIGO \ufffd PONTEVEDRA\nOBJETIVOS\nAnalizar las intervenciones dirigidas a la adaptaci\u00f3n del tratamiento farmacol\u00f3gico en pacientes con disfagia desde la \nconsulta externa de nutrici\u00f3n (CEN) del Servicio de Farmacia (SF), su grado de aceptaci\u00f3n y b\u00fasqueda de necesidades.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y descriptivo, en el que se analizaron las intervenciones realizadas sobre el \ntratamiento farmacol\u00f3gico de pacientes con disfagia atendidos en la CEN del SF durante el a\u00f1o 2021\ufffd  \nSe registraron datos sociodemogr\u00e1ficos, procedencia del paciente, causa de la disfagia, datos del medicamento, \nintervenci\u00f3n realizada y estado de aceptaci\u00f3n.  \nSe revisaron los cursos cl\u00ednicos y las notas emitidas por el farmac\u00e9utico que conten\u00edan las intervenciones dirigidas a los \nm\u00e9dicos de atenci\u00f3n primaria y cuidadores.\nRESULTADOS\nSe realizaron 113 intervenciones relacionadas con la adaptaci\u00f3n del tratamiento farmacol\u00f3gico en 86 pacientes con \ndisfagia de edades comprendidas entre 31 y 96 a\u00f1os. El 59,3% eran mujeres. El 27,9% estaban institucionalizados en \nresidencias sociosanitarias, y el 72,1% eran pacientes ambulatorios\ufffd  \nLas causas de la disfagia fueron neurol\u00f3gicas (80%), por procesos degenerativos no filiados (11,6%), neoplasias (3,5%) \ny otras causas (4,6%). El 31,4% de los pacientes fue derivado a la CEN del SF tras alta hospitalaria, el 24,4% de atenci\u00f3n \nprimaria, el 19,8% de residencias sociosanitarias, el 19,8% de consultas externas de otras especialidades y no constaban \ndatos del 4,7%\ufffd \nSe identificaron 20 principios activos, 14 grupos terap\u00e9uticos y 9 formas farmac\u00e9uticas. El grupo terap\u00e9utico sobre el que \nse realizaron m\u00e1s intervenciones fue inhibidores de la bomba de protones (46,9%) seguido de antian\u00e9micos (19,5%). \nLa distribuci\u00f3n de intervenciones por forma farmac\u00e9utica fue: c\u00e1psulas gastrorresistentes (48,7%), comprimidos \ngastrorresistentes (17,8%), comprimidos de liberaci\u00f3n modificada (15%), c\u00e1psulas de liberaci\u00f3n modificada \n(6,2%),c\u00e1psulas blandas (4,4%), comprimidos recubiertos (3,5%), c\u00e1psula dura (pellets+c\u00e1psula blanda) (1,8%), \ncomprimidos (0,9%), comprimidos solubles (0,9%) y c\u00e1psulas duras (0,9%). \nLas intervenciones realizadas fueron: cambio de medicamento (43,4%), cambio de presentaci\u00f3n (39,8%), \nrecomendaciones de administraci\u00f3n (13,3%), cambios de presentaci\u00f3n+recomendaciones de administraci\u00f3n (2,7%) y \nsuspensi\u00f3n del medicamento (0,8%). Se aceptaron el 53,1%, no constaban datos del estado del 0,9% , y el 46% fueron \nrechazadas.  \nSe aceptaron el 100% de las recomendaciones de administraci\u00f3n, suspensi\u00f3n de medicamentos y cambios de \npresentaci\u00f3n+recomendaciones de administraci\u00f3n, el 44,9% de los cambios de medicamento y el 42,% de los cambios de \npresentaci\u00f3n. El tiempo medio entre la realizaci\u00f3n de la intervenci\u00f3n y su aceptaci\u00f3n fue de 24,5 d\u00edas .\nCONCLUSIONES\nUn alto porcentaje de las intervenciones realizadas fueron aceptadas.  \nM\u00e1s de la mitad se realizaron en pacientes derivados tras alta hospitalaria o institucionalizados en residencias \nsociosanitarias, lo que aumenta la importancia de la conciliaci\u00f3n entre niveles asistenciales en estos pacientes.  \nSe crea la necesidad de disponer de una gu\u00eda de administraci\u00f3n de medicamentos en pacientes con disfagia, \nespecialmente en patolog\u00eda neurol\u00f3gica, as\u00ed como contemplar en la evaluaci\u00f3n de medicamentos para su inclusi\u00f3n en la \ngu\u00eda farmacoterap\u00e9utica del hospital la posible adaptaci\u00f3n en situaci\u00f3n de disfagia.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n619. UTILIZACI\u00d3N DE GABAPENTINA Y PREGABALINA EN PACIENTES HOSPITALIZADOS EN UNA UNIDAD \nDE AGUDOS DE GERIATR\u00cdA \nAUTORES\nMART\u00cdN SANZ, P; RODR\u00cdGUEZ D\u00cdAZ-PAV\u00d3N, \u00c1; RODR\u00cdGUEZ MAR\u00cdN, M; GUIJARRO MART\u00cdNEZ, P; MOLINA MENDOZA, \nMD; GARZA MART\u00cdNEZ, AJ; \u00c1LVAREZ D\u00cdAZ, A; DELGADO SILVEIRA, E\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nAnalizar la prevalencia de uso general de pregabalina y gabapentina seg\u00fan indicaciones de ficha t\u00e9cnica y fuera de ella \n(off-label).  \nDeterminar el porcentaje de desprescripci\u00f3n en los pacientes en los que no aporta beneficio o presentan efectos \nadversos\ufffd  \nDescribir la mejor\u00eda sintom\u00e1tica a los 6 meses del inicio de la prescripci\u00f3n.  \nDescribir la frecuencia de efectos adversos de estos f\u00e1rmacos.85MATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio descriptivo retrospectivo con pacientes ingresados en la Unidad de Agudos de Geriatr\u00eda (UAG) \ndurante 8 meses (enero-agosto 2021). Para ello se revisaron las historias cl\u00ednicas electr\u00f3nicas, as\u00ed como el hist\u00f3rico \nde prescripci\u00f3n. Se excluyeron los reingresos en menos de 3 meses, y los \u00e9xitus en el hospital. Se analizaron las \nprescripciones de gabapentina y pregabalina al ingreso y al alta, as\u00ed como las indicaciones para las que fueron prescritas, \nclasific\u00e1ndolas seg\u00fan si estaban recogidas en ficha t\u00e9cnica (FT) o no (off-label). Se revis\u00f3 si hubo mejor\u00eda sintom\u00e1tica o no \na los 6 meses del inicio de la prescripci\u00f3n. Adem\u00e1s, se analiz\u00f3 el porcentaje de desprescripci\u00f3n de estos f\u00e1rmacos al alta y \nsi se produjeron efectos adversos recogidos en ficha t\u00e9cnica desde su prescripci\u00f3n inicial.\nRESULTADOS\nSe obtuvo un total de 393 pacientes. El 65,4% eran mujeres, con edad media de 92\u00b16,9 a\u00f1os.  \nDieciocho pacientes (4,5%) estaban en tratamiento con gabapentinoides (12 pregabalina y 6 gabapentina). Quince \npacientes ten\u00edan indicaciones seg\u00fan FT para ambos gabapentinoides (83,3%); de estas prescripciones doce correspond\u00edan \na pregabalina en rango de dosis de 25-300 mg diarios y tres a gabapentina en rango de dosis de 300-400mg/8h.  \nDe las quince prescripciones recogimos un 66,6% para dolor neurop\u00e1tico perif\u00e9rico, 20% para s\u00edntomas conductuales y \npsicol\u00f3gicos de la demencia y un 6,6% para trastorno de ansiedad generalizado (TAAG).  \nEn cuanto a los usos fuera de indicaci\u00f3n de FT se recogieron 3 prescripciones (16,6%): 1 de gabapentina para TAAG, 1 de \npregabalina para s\u00edndrome de piernas inquietas (SPI) y otra pregabalina para prurito cr\u00f3nico (pautada al alta).  \nDe las 18 prescripciones totales se suspendieron 2 por ausencia de beneficio cl\u00ednico (1 pregabalina y una gabapentina, \nambas para indicaci\u00f3n de dolor neurop\u00e1tico perif\u00e9rico. El resto se mantuvieron al alta (88,2%).  \nCinco pacientes (29,4%) describieron mejor\u00eda en su sintomatolog\u00eda; 3 de ellos en uso indicado para neuropat\u00eda perif\u00e9rica, \n1 fuera de indicaci\u00f3n para TAAG (gabapentina) y otro para SPI (pregabalina).  \nS\u00f3lo se descubri\u00f3 un efecto adverso en un paciente que present\u00f3 astenia por pregabalina prescrito para neuropat\u00eda \nperif\u00e9rica\nCONCLUSIONES\nEn la UAG se observ\u00f3 una prevalencia de uso de gabapentinoides baja. La mayor parte de las prescripciones estaban \nseg\u00fan indicaciones de FT. \nNo fue necesario hacer desprescripci\u00f3n en la mayor\u00eda de pacientes ya que estaban indicadas y se observ\u00f3 beneficio \ncl\u00ednico, tanto en usos seg\u00fan FT como off-label.  \nEstos f\u00e1rmacos se toleran bien en la mayor\u00eda de los pacientes.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n700. IMPLANTACI\u00d3N DE UNA PROGRAMA ASISTENCIAL DE APOYO A RESIDENCIAS SOCIOSANITARIAS: \nIMPLICACI\u00d3N DEL SERVICIO DE FARMACIA. \nAUTORES\nROTEA SALVO, S; MARTINEZ PRADEDA, A; FEIJOO VILANOVA, P; LUACES RODR\u00cdGUEZ, A; V\u00c1ZQUEZ L\u00d3PEZ, C; Y\u00c1\u00d1EZ \nRUBAL, JC; V\u00c1ZQUEZ RODR\u00cdGUEZ, P; MART\u00cdN HERRANZ, I\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nSe describe la aportaci\u00f3n del Servicio de Farmacia a la formaci\u00f3n de un Equipo Asistencial de Apoyo a Residencias \nSociosanitarias (RSS) cuya meta principal es desarrollar y promover circuitos de comunicaci\u00f3n fluidos entre el entorno \nsanitario y el social\ufffd\nMATERIALES Y M\u00c9TODOS\nSe constituye la \u201cUnidad de Coordinaci\u00f3n y apoyo asistencial a residencias sociosanitarias\u201d formado por profesionales \nde Medicina Interna, Hospitalizaci\u00f3n a Domicilio, Psiquiatr\u00eda, Trabajo Social y Farmacia. Se establece un farmac\u00e9utico de \nreferencia para coordinar toda la actividad relacionada con la atenci\u00f3n farmac\u00e9utica y que a su vez sirva de enlace entre \nlas residencias con prestaci\u00f3n farmac\u00e9utica y los farmac\u00e9uticos responsables de las mismas. Los recursos materiales \ndisponibles son 68 RSS (titularidad p\u00fablica y privada) con 4.000 camas, 2 Hospitales. Recursos humanos del Servicio de \nFarmacia: 9 farmac\u00e9uticos de atenci\u00f3n especializada y 6 de atenci\u00f3n primaria a tiempo parcial. Medicina Interna crea \nun buz\u00f3n de interconsultas para profesionales de las RSS que precisan apoyo en gesti\u00f3n de problemas m\u00e9dicos que se \nresuelven telem\u00e1ticamente o bien a trav\u00e9s de una evaluaci\u00f3n presencial en el hospital de d\u00eda. El Servicio de Farmacia crea \nuna cartera de servicios para establecer las l\u00edneas maestras en las que se sustenta la atenci\u00f3n farmac\u00e9utica en las RSS.\nRESULTADOS\nLa cartera de servicios consiste en: desarrollo de una Gu\u00eda Farmacoterap\u00e9utica, protocolos de intercambio terap\u00e9utico, \ntratamiento y seguimiento de pacientes con una patolog\u00eda y/o tratamiento determinado, incorporaci\u00f3n de sistemas \nelectr\u00f3nicos de prescripci\u00f3n, promover y participar en iniciativas sobre coordinaci\u00f3n e integraci\u00f3n entre niveles \nasistenciales, desarrollar programas de calidad para minimizar errores de medicaci\u00f3n y mejorar los procesos relacionados \ncon el uso de medicamentos, realizar conciliaci\u00f3n de la medicaci\u00f3n al ingreso y entre transiciones asistenciales, \noptimizaci\u00f3n de proceso de dispensaci\u00f3n y administraci\u00f3n de medicamentos as\u00ed como facilitar el acceso a determinados \nmedicamentos que requieren gestiones especiales: medicamentos de Diagn\u00f3stico Hospitalario/Uso Hospitalario, \nmedicamentos extranjeros, acceso al programa de farmacocin\u00e9tica cl\u00ednica e individualizaci\u00f3n posol\u00f3gica, coordinaci\u00f3n \ncon la Unidad de Nutrici\u00f3n, mejora de la comunicaci\u00f3n entre profesionales sanitarios de distintos niveles asistenciales y 86colaborar en l\u00edneas de formaci\u00f3n en aspectos relacionados con la farmacoterapia de los pacientes cr\u00f3nicos. Respecto a \nla dispensaci\u00f3n de medicamentos que prescribi\u00f3 la internista, y que buscaban disminuir la frecuentaci\u00f3n de urgencias, \nse\u00f1alar que de marzo de 2021 a mayo de 2022 se valid\u00f3 y dispens\u00f3 medicaci\u00f3n para 83 pacientes. 51 mujeres. Edad \n80\u00b114 (36-109 a\u00f1os). El tipo de medicaci\u00f3n dispensada: Antibioticoterapia 47,3%, Sedaci\u00f3n terminal 31%, Sueroterapia \n12,6%, Diur\u00e9ticos 5,7%, Otros (corticoides, digoxina intravenosa) 3,4%.\nCONCLUSIONES\n- La designaci\u00f3n de un equipo de trabajo multidisciplinar en la atenci\u00f3n de pacientes de RSS es beneficioso para la \ninstituci\u00f3n y para el paciente, con impacto en la gesti\u00f3n de ingreso directo evitando paso por Urgencias y permitiendo la \nadecuaci\u00f3n de los tratamientos\ufffd  \n- La existencia de una cartera de servicios como la descrita, permite homogeneizar la asistencia de pacientes de las RSS lo \nque permite mejorar la continuidad y calidad asistencial.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n710. REVISI\u00d3N DE LA TERAPIA F\u00c9RRICA ENDOVENOSA EN PACIENTES HEMODIALIZADOS \nAUTORES\nCEBRI\u00c1N , L; COLOM , R; VALCUENDE , A; ORTEGA , A; GRA\u00d1A , JM; SARRI\u00d3 , G; S\u00c1NCHEZ , A\nHOSPITAL UNIVERSITARIO DE LA RIBERA \ufffd CRTRA CORBERA, KM \ufffd 1 ALZIRA \ufffd VALENCIA\nOBJETIVOS\nLos pacientes con enfermedad renal cr\u00f3nica en programas de hemodi\u00e1lisis (HD) sufren como complicaci\u00f3n frecuente \nanemia. El tratamiento con hierro endovenoso (Fe EV) corrige los niveles de hemoglobina (Hb), los dep\u00f3sitos f\u00e9rricos y \nasegurar la eritropoyesis. Sin embargo, a pesar del estrecho control, existen casos donde no se realiza un ajuste de Fe, por \nejemplo Herranz N. et al, en 60 pacientes, comunican un 74,5% de episodios de ferropenia donde no se aument\u00f3 la pauta \nde Fe EV y solo se disminuy\u00f3 la dosis en un 23,8% de los episodios de sobrecarga\ufffd \nEl objetivo del presente estudio es describir la utilizaci\u00f3n de hierro sacarosa en pacientes en HD.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo de los pacientes incluidos en el programa de HD durante el 2021 en un hospital \nuniversitario de 300 camas\ufffd  \nSe recogieron las siguientes variables: edad, sexo, n\u00famero de meses en HD, valor medio anual de Hb, ferritina, \u00edndice \nde saturaci\u00f3n de transferrina (IST) y Fe, pauta de hierro sacarosa administrada y acceso vascular, cat\u00e9ter venoso central \n(CVC) o f\u00edstula arterio-venosa (FAV).  \nSe registraron las intervenciones realizadas por parte del Servicio de Nefrolog\u00eda (inicio, ajuste o fin de la pauta de Fe EV) \nuna vez identificados los pacientes con ferropenia (funcional o absoluta) y sobrecarga f\u00e9rrica. Se defini\u00f3 el d\u00e9ficit de Fe \nfuncional como ferritina > 100ng/mL e IST < 20%, el d\u00e9ficit de Fe absoluto como ferritina < 100ng/mL e IST < 20% y la \nsobrecarga f\u00e9rrica como ferritina > 500ng/mL e IST > 30%.  \nLos datos obtenidos se extrajeron del registro de pacientes de la Unidad de Hemodi\u00e1lisis y del programa de gesti\u00f3n SIAS \nCl\u00ednico. El an\u00e1lisis estad\u00edstico se realiz\u00f3 mediante Chi-cuadrado.\nRESULTADOS\nSe incluyeron en el estudio los 163 pacientes que se encontraban en el programa de HD. La media de edad de 69 a\u00f1os \n(26-93) y la distribuci\u00f3n por sexo fue 53 mujeres (33%) y 110 hombres (67%).  \nEn el 62% de los pacientes el acceso vascular fue FAV y 36% CVC. Se analizaron las alteraciones f\u00e9rricas en ambos grupos, \nno hallando diferencias estad\u00edsticamente significativas (p=0,2).  \nSe analizaron 1.956 anal\u00edticas, encontrando 81 pacientes (49,7%) con alteraci\u00f3n en los dep\u00f3sitos de hierro. En un 16,0% \n(26 pacientes) se trat\u00f3 de un d\u00e9ficit funcional y en un 4,3% (7 pacientes) un d\u00e9ficit absoluto. La pauta de Fe EV se ajust\u00f3 \nen el 57,6% de los casos\ufffd  \nPor otra parte 48 pacientes (29,4%) presentaron sobrecarga f\u00e9rrica, disminuy\u00e9ndose la dosis de Fe EV en el 79,2% de los \ncasos\ufffd\nCONCLUSIONES\nExiste un elevado porcentaje de accesos vasculares por FAV, indicador de calidad de la unidad.  \nCasi la mitad de los pacientes en hemodi\u00e1lisis sufren alteraciones f\u00e9rricas necesitando ajustes en la terapia con Fe EV, \nsiendo la sobrecarga f\u00e9rrica la alteraci\u00f3n m\u00e1s frecuente. \nAunque nuestros datos reflejan un elevado porcentaje de ajustes posol\u00f3gico en la terapia de Fe EV, a pesar del estrecho \nseguimiento anal\u00edtico mensual, existe a\u00fan un porcentaje de pacientes en los cuales necesit\u00e1ndose un ajuste en la terapia \nf\u00e9rrica, no se realizaron modificaciones en su tratamiento, datos que avalan los hallados por otros grupos de trabajo.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n783. OPTIMIZACI\u00d3N DEL TRATAMIENTO DE LA DIABETES MELLITUS TIPO 2 EN ATENCI\u00d3N PRIMARIA: \nAPORTACI\u00d3N DEL FARMAC\u00c9UTICO ESPECIALISTA \nAUTORES\nCONDE GINER, S; SALOM GARRIGUES, C; MARCO BAS, N; CAMPABADAL PRATS, C; SU\u00d1ER BARRIGA, H; SACANELLA \nANGL\u00c8S, I; BEJARANO ROMERO, F; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA87OBJETIVOS\nAnalizar el impacto de las intervenciones farmac\u00e9uticas realizadas para adecuar el tratamiento hipoglucemiante de los \npacientes atendidos en Atenci\u00f3n Primaria (AP) con diabetes mellitus tipo 2 (DM2).\nMATERIALES Y M\u00c9TODOS\nSe trata de un estudio prospectivo (junio 2021 \u2013 abril 2022) realizado en un \u00e1rea de AP . Se incluyeron pacientes con DM2 \nen tratamiento con hipoglucemiantes orales y/o insulina, identificados en el per\u00edodo junio-octubre 2021.  \n \nSe recogieron variables demogr\u00e1ficas (edad y sexo), anal\u00edticas (hemoglobina glicosilada (HbA1c)), cl\u00ednicas (insuficiencia \nrenal (IR), medida por presentar un filtrado glomerular menor de 60ml/min; \u00edndice de masa corporal (IMC)); \ncomorbilidades (pacientes cr\u00f3nico complejo (PCC)) y la adherencia al tratamiento, seg\u00fan el recuento de medicaci\u00f3n \nretirada de la farmacia, a partir de la historia cl\u00ednica informatizada.  \nTras la recogida de datos, se realizaron propuestas de optimizaci\u00f3n del tratamiento al m\u00e9dico de AP (MAP) en reuniones \npresenciales, registr\u00e1ndose el tipo de intervenci\u00f3n realizada, su aceptaci\u00f3n y el grado de implementaci\u00f3n 6 meses tras la \npropuesta\ufffd\nRESULTADOS\nSe incluyeron 532 pacientes, de 69 (53-85) a\u00f1os y 225 (71%) mujeres, asignados a 21 MAP de 11 centros de salud. La \nHbA1c previa a la intervenci\u00f3n fue de 7,59% (6,17-9,01). El 26% de los pacientes presentaron IR y el IMC fue de 30,29 \n(24,73-35,85) kg/m2. Un 16% de los pacientes estaban catalogados como PCC. Un 23% de los pacientes presentaron una \nadherencia menor al 80%.  \n \nSe realizaron 693 intervenciones, con los siguientes grados de aceptaci\u00f3n e implementaci\u00f3n:  \n- Interrumpir f\u00e1rmaco (298, 43%), 92% aceptaci\u00f3n, 54% implementaci\u00f3n  \n- intensificar posolog\u00eda (113, 13%), 89% aceptaci\u00f3n, 55 % implementaci\u00f3n  \n- cambio por equivalente terap\u00e9utico (90, 13%), 90% aceptaci\u00f3n, 52% implementaci\u00f3n  \n- cambiar por otra mol\u00e9cula (81, 12%), 90% aceptaci\u00f3n, 55% implementaci\u00f3n  \n- revalorar indicaci\u00f3n (66, 10%), 94% aceptaci\u00f3n, 71% implementaci\u00f3n  \n- iniciar f\u00e1rmaco (30, 4%), 73% aceptaci\u00f3n, 77% implementaci\u00f3n  \n- desintensificar posolog\u00eda (15, 2%), 86% aceptaci\u00f3n, 62% implementaci\u00f3n.  \n \nLos grupos terap\u00e9uticos implicados en las propuestas implementadas fueron (n, %):  \n- inhibidores de la dipeptidil peptidasa 4 (iDPP4): 185, 59%  \n- inhibidores del cotransportador de sodio y glucosa tipo 2 (iSGLT2): 36, 12%  \n- sulfonilureas: 30, 10%  \n- repaglinida: 22, 7% \n- insulina: 16, 5%  \n- agonistas de los receptores del p\u00e9ptido similar a GLP-1 (arGLP1): 12, 4%  \n- metformina: 7, 2%  \n- otros: 4, 1%  \n \nEl tratamiento final incluy\u00f3 los siguientes grupos terap\u00e9uticos, observ\u00e1ndose un incremento de los f\u00e1rmacos de primera \nl\u00ednea como metformina, sulfonilureas e iSGLT2 (n, %): \n- sulfonilureas: 41, 24%  \n- iSGLT2: 32, 19%  \n- insulina: 30, 18%  \n- iDPP4: 23, 13%  \n- repaglinida: 22, 13% \n- metformina: 17, 10%  \n- arGLP1: 5, 3%  \n \nTras la implementaci\u00f3n de las propuestas se estim\u00f3 un ahorro econ\u00f3mico anual de 107418\u20ac.\nCONCLUSIONES\nLa revisi\u00f3n del tratamiento de la DM2 por el farmac\u00e9utico especialista, de acuerdo con la situaci\u00f3n cl\u00ednica del paciente, \naporta un valor a\u00f1adido en la optimizaci\u00f3n del tratamiento de estos pacientes. Ser\u00e1 interesante analizar el control de \nla HbA1c despu\u00e9s de la intervenci\u00f3n. Adem\u00e1s, deber\u00eda ser estudiada la discrepancia entre los grados de aceptaci\u00f3n e \nimplementaci\u00f3n por parte del MAP \ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n787. CONCILIACI\u00d3N FARMAC\u00c9UTICA EN LAS TRANSICIONES ASISTENCIALES DEL PACIENTE QUIR\u00daRGICO \nAUTORES\nSOMOZA FERN\u00c1NDEZ, B; RIBED S\u00c1NCHEZ, A; GIM\u00c9NEZ MANZORRO, \u00c1; FERRIS VILLANUEVA, M; GARC\u00cdA S\u00c1NCHEZ, \nS; DE VEGA SAN VICENTE, F; HERRANZ ALONSO, A; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID88OBJETIVOS\nLos pacientes quir\u00fargicos sufren numerosas transiciones asistenciales durante su proceso perioperatorio, momentos \nclave en los que se pueden producir errores de medicaci\u00f3n potenciales en relaci\u00f3n a su tratamiento cr\u00f3nico. La \nconciliaci\u00f3n de la medicaci\u00f3n es una pr\u00e1ctica recomendada para disminuir estos errores. \nEl objetivo fue analizar los errores de medicaci\u00f3n detectados durante la conciliaci\u00f3n farmac\u00e9utica de la medicaci\u00f3n \ncr\u00f3nica en las transiciones asistenciales de pacientes intervenidos de cirug\u00eda de pr\u00f3tesis de rodilla (PTR) y calcular el \nahorro derivado.\nMATERIALES Y M\u00c9TODOS\nSe cre\u00f3 un grupo de trabajo multidisciplinar (traumat\u00f3logos, farmac\u00e9uticos y anestesistas) y se redact\u00f3 un protocolo \nde manejo de medicaci\u00f3n cr\u00f3nica periporeratoria. En marzo de 2021 se implant\u00f3 una escuela de pacientes (consulta \nmultidisciplinar donde traumatolog\u00eda y farmacia explican a los pacientes en qu\u00e9 consiste su cirug\u00eda). En la escuela el \nfarmac\u00e9utico obtiene presencialmente el historial farmacoterap\u00e9utico y realiza in situ de manera individualizada la \nconciliaci\u00f3n preoperatoria de la medicaci\u00f3n cr\u00f3nica, resolviendo las posibles dudas del paciente. Dicha consulta se \nregistra en la historia cl\u00ednica, quedando disponible para cualquier profesional sanitario de cara a futuras transiciones \nasistenciales. Posteriormente el farmac\u00e9utico realiza la conciliaci\u00f3n post cirug\u00eda.  \nSe realiz\u00f3 un an\u00e1lisis de las intervenciones farmac\u00e9uticas realizadas en las transiciones asistenciales (precirug\u00eda y \nal ingreso) en los pacientes atendidos en la escuela de marzo de 2021 a marzo de 2022. Los errores de medicaci\u00f3n \ndetectados fueron clasificados en funci\u00f3n de la gravedad NCCMERP y probabilidad de evento adverso, consensuada \ncon el Servicio de Anestesia. Se calcul\u00f3 el ahorro de los errores evitados, multiplicando la probabilidad de aparici\u00f3n del \nevento adverso asociado al error por el coste evitado (entre 3.315 y 5.584 euros seg\u00fan el Ministerio de Sanidad, Consumo \ny Bienestar Social).\nRESULTADOS\nSe atendi\u00f3 a 133 pacientes, con una mediana de edad de 73 a\u00f1os (RIC=65-77) y un n\u00famero de f\u00e1rmacos cr\u00f3nicos de 6 \n(RIC=3-9).  \nEn la escuela, el 80,3% de pacientes necesitaba modificaci\u00f3n prequir\u00fargica de la medicaci\u00f3n cr\u00f3nica seg\u00fan el protocolo. \nSe detectaron 165 errores de medicaci\u00f3n. El 65,3% correspond\u00edan a pacientes que iban a tomar su medicaci\u00f3n el d\u00eda \nde la cirug\u00eda y no deb\u00edan; en el 32,1% de los casos se trataba de medicaci\u00f3n que deb\u00eda continuarse pero los pacientes \npretend\u00edan suspender. \nUn total de 120 intervenciones fueron significativas (gravedad D, E y F) y 3 serias (G-H), implicando que la cirug\u00eda se \nhabr\u00eda suspendido: a 2 pacientes se les paut\u00f3 terapia puente no necesaria y 1 paciente no iba a suspender rivaroxab\u00e1n.  \nTodos los pacientes fueron conciliados tras la cirug\u00eda, detect\u00e1ndose 82 errores: 77 de gravedad significativa y 5 de \ngravedad seria\ufffd  \nLos errores potenciales de medicaci\u00f3n detectados supusieron un ahorro de entre 140.932 y 237.394 euros.\nCONCLUSIONES\nLa mayor\u00eda de los pacientes intervenidos de PTR son de edad avanzada, polimedicados y requieren modificaci\u00f3n \nprequir\u00fargica de su tratamiento cr\u00f3nico. La detecci\u00f3n de errores de medicaci\u00f3n de gravedad significativa y/o seria, as\u00ed \ncomo el ahorro derivado de las intervenciones farmac\u00e9uticas realizadas, recalcan la importancia de la participaci\u00f3n activa \ny presencial del farmac\u00e9utico en la conciliaci\u00f3n durante las transiciones asistenciales.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n870. CARGA ANTICOLIN\u00c9RGICA: \u00bfCU\u00c1L ES SU PAPEL EN EL RIESGO DE CA\u00cdDAS? \nAUTORES\nRUBIO CALVO, D; MARTOS ROSA, A; AZNAR GARC\u00cdA, M; BRETONES PEDRINACI, JI; HERRERA EXP\u00d3SITO, M\nCOMPLEJO HOSPITALARIO DE PONIENTE. CRTA. DE ALMERIMAR, S/N EJIDO, EL. ALMER\u00cdA\nOBJETIVOS\nLos traumatismos provocados por ca\u00eddas accidentales son uno de los motivos m\u00e1s habituales de consulta en los servicios \nde traumatolog\u00eda, siendo la poblaci\u00f3n anciana especialmente susceptible. Se estipula que la carga anticolin\u00e9rgica, entre \notros factores, puede contribuir a incrementar este riesgo de ca\u00edda. El objetivo de este estudio es analizar si existe \nuna mayor carga anticolin\u00e9rgica en aquellos pacientes que requieren ingreso tras una ca\u00edda accidental en la unidad de \ntraumatolog\u00eda (UT) con respecto a otros servicios de hospitalizaci\u00f3n con similar perfil de pacientes.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo realizado en un hospital comarcal durante los meses de marzo y abril de 2022. Se \nincluyeron todos los pacientes ingresados en la UT que cumplieran con los siguientes criterios: Edad \u2265 65 a\u00f1os, no \ninstitucionalizados, polimedicados ( > 5 medicamentos activos de tratamiento domiciliario), independientes para las \nactividades de la vida diaria e ingreso derivado por traumatismo tras ca\u00edda accidental. Las ca\u00eddas relacionadas con el \nconsumo de alcohol, accidentes cardiovasculares e hipoglucemias, fueron excluidas del estudio. Como grupo comparador \nse tomaron pacientes con los mismos criterios mencionadas que ingresaron en la unidad de medicina interna (UMI) por \ndescompensaci\u00f3n de su patolog\u00eda basal. Las variables analizadas fueron: datos demogr\u00e1ficos, n\u00famero de medicamentos \nprescritos, estratificaci\u00f3n de la carga anticolin\u00e9rgica seg\u00fan los criterios de \u201cAnticholinergic burden calculator\u201d (ACB): sin \ncarga, baja, media, alta. Y n\u00famero de f\u00e1rmacos que punt\u00faan en ACB. Se compar\u00f3 la carga anticolin\u00e9rgica entre ambos \nservicios mediante la prueba chi-cuadrado empleando el programa IBM SPSS Statistics\u00aeV.26.89RESULTADOS\nSe recogieron un total de 63 pacientes: Ingresados en UT: 32(50,8%) de los cuales 18(56,25%) eran mujeres. Edad media \n80\u00b18 a\u00f1os, rango de edad 68-92 a\u00f1os. Media de f\u00e1rmacos prescritos 9,6\u00b13,48. Carga anticolin\u00e9rgica seg\u00fan ACB: Sin carga \n9(28,12%); Baja 9(28,12%); Media 8(25%); Alta 6(18,8%). Media de f\u00e1rmacos que punt\u00faan en ACB (2,34\u00b11,09). Pacientes \ningresados en UMI: 31(49,2%) de los cuales 15(48,38%) eran mujeres. Edad media 81\u00b16, rango de edad 66-89 a\u00f1os. \nMedia de f\u00e1rmacos prescritos 11,05\u00b13,82 Carga anticolin\u00e9rgica: Sin carga 11(35,5%); Baja 11(35,5%); Media 4(13%); Alta \n5(16%). Media de f\u00e1rmacos que punt\u00faan en ACB (1,14\u00b11,01). An\u00e1lisis global de la carga anticolin\u00e9rgica: p=0,366. An\u00e1lisis \nen subgrupo carga media/alta: p=0,225.\nCONCLUSIONES\nLa carga anticolin\u00e9rgica fue similar en ambas unidades de hospitalizaci\u00f3n y no se encontraron diferencias \nestad\u00edsticamente significativas de manera global (p=0,366). En el conjunto de pacientes que presentaba una carga \nanticolin\u00e9rgica media o alta tampoco se hallaron diferencias estad\u00edsticamente significativas (p=0,225). Los resultados \nobtenidos no permiten afirmar que exista una mayor carga anticolin\u00e9rgica en los pacientes ingresados en la UT, por lo \nque su papel en el riesgo de ca\u00eddas es inconcluso. En definitiva, para determinar de manera contundente qu\u00e9 papel juega \nla carga anticolin\u00e9rgica en el riesgo de ca\u00eddas en los pacientes de edad avanzada, ser\u00eda necesario: Una mayor muestra \nde pacientes; Calculadoras de carga anticolin\u00e9rgica que estratifiquen de manera m\u00e1s exacta el riesgo acumulativo de \npadecer efectos adversos anticolin\u00e9rgicos; E identificar otras posibles causas que incrementen el riesgo de ca\u00eddas.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n875. EVALUACI\u00d3N DE ANTIPSIC\u00d3TICOS DEPOT EN UN \u00c1REA DE SALUD. \nAUTORES\nHERNANDEZ SANCHEZ, M; LACRUZ GUZMAN, D; GUTIERREZ SANCHEZ, JA; TORRANO BELMONTE, P; FRUCTUOSO \nGONZALEZ, L; IBA\u00d1EZ CATURLA, J; CARVAJAL SANCHEZ, MA; PACHECO LOPEZ, P\nHOSPITAL J.M. MORALES MESEGUER. AV . MARQU\u00c9S DE LOS V\u00c9LEZ, S/N. MURCIA. MURCIA\nOBJETIVOS\nValorar si las prescripciones de antipsic\u00f3ticos depot se adecuan a la pauta posol\u00f3gica autorizada en ficha t\u00e9cnica y \nracionalizar su utilizaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de los pacientes con prescripciones activas de paliperidona y aripiprazol depot \nerr\u00f3neas en un \u00e1rea de salud y comunicaci\u00f3n de las mismas a los m\u00e9dicos responsables.  \nA trav\u00e9s de la aplicaci\u00f3n inform\u00e1tica de gesti\u00f3n de recetas se identificaron las prescripciones err\u00f3neas de paliperidona \ny aripiprazol depot en noviembre de 2021 y se comunicaron a los m\u00e9dicos responsables. Se valor\u00f3 la aceptaci\u00f3n de las \nrecomendaciones tras la comunicaci\u00f3n. Se recogieron datos de variables demogr\u00e1ficas (sexo y edad), pauta prescrita, \nservicio prescriptor y diagn\u00f3stico utilizando el programa de historia cl\u00ednica electr\u00f3nica. Adem\u00e1s, se registraron los efectos \nadversos producidos tras la administraci\u00f3n del f\u00e1rmaco en los pacientes estudiados.\nRESULTADOS\nDe los 73 pacientes con prescripciones err\u00f3neas, 42 fueron de paliperidona mensual (57,5%), 20 de paliperidona \ntrimestral (27,4%) y 11 de aripiprazol (15,1%). En todos los casos, el servicio prescriptor fue psiquiatr\u00eda. \nLa edad media de los pacientes con prescripciones err\u00f3neas de paliperidona mensual fue de 52,8 a\u00f1os, siendo el 73,8 \n% de los pacientes hombres. Las pautas err\u00f3neas m\u00e1s frecuentes fueron 300 mg cada 28 d\u00edas (46,6%) y 300 mg cada 21 \nd\u00edas (19,1%). Los diagn\u00f3sticos mayoritarios fueron esquizofrenia paranoide (73,8%), trastorno de la personalidad (9,5%) \ny esquizofrenia ligada a trastorno bipolar (4,8%). Los efectos adversos m\u00e1s frecuentes identificados fueron dislipemia \n(26,2%), anemia (17%), leucopenia y neutropenia (7,1%) y aumento de transaminasas (4,8%). No obstante, solo el 11,9 % \nde las prescripciones fueron modificadas.  \nEl 75% de los pacientes con prescripciones err\u00f3neas de paliperidona trimestral fueron hombres, con una edad media de \n45,1 a\u00f1os. Las pautas posol\u00f3gicas err\u00f3neas identificadas fueron 525 mg cada 28 d\u00edas (20%) y 525 mg cada 78 d\u00edas (20%). \nLos diagn\u00f3sticos m\u00e1s frecuentes fueron esquizofrenia (50%) y retraso mental asociado a componente psiqui\u00e1trico (15%). \nLos efectos adversos que se observaron con mayor frecuencia fueron dislipemia (25%), anemia (15%) y parkinsonismo \n(10%). El 35% de las prescripciones fueron modificadas.  \nEn cuanto a las prescripciones err\u00f3neas de aripiprazol, el 63,3% de los pacientes fueron hombres con una edad media \nde 46,5 a\u00f1os. Las pautas err\u00f3neas m\u00e1s frecuentes fueron 800 mg cada 28 d\u00edas (45.5%) y 600 mg cada 28 d\u00edas (36.4%). \nLos diagn\u00f3sticos mayoritarios fueron esquizofrenia (54,5%) y trastorno de la personalidad (18,2%). Las reacciones \nadversas identificadas con mayor frecuencia fueron dislipemia (18,2%) y alteraciones en las enzimas hep\u00e1ticas, anemia y \nalteraciones en el n\u00famero de plaquetas (9,1%). En este caso el 18,2% de las prescripciones fueron modificadas.\nCONCLUSIONES\nLos resultados obtenidos en el estudio muestran que a\u00fan se siguen produciendo un elevado n\u00famero de errores en la \nprescripci\u00f3n de antipsic\u00f3ticos depot a pesar de las recomendaciones dadas a los m\u00e9dicos prescriptores. Por lo tanto, \ncontin\u00faa siendo necesaria la realizaci\u00f3n de intervenciones farmac\u00e9uticas de manera frecuente con el objetivo de mejorar \nla calidad y seguridad de las prescripciones, favoreciendo el uso racional de los medicamentos\ufffd90CLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n900. PANDEMIA COVID-19 Y UTILIZACI\u00d3N DE PSICOF\u00c1RMACOS \nAUTORES\nDEL VALLE MORENO, P; HEVIA \u00c1LVAREZ, E; P\u00c9REZ BLANCO, JL\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nDesde el comienzo de la pandemia de COVID-19 se ha comunicado repetidamente un incremento progresivo del \nconsumo de psicof\u00e1rmacos en Espa\u00f1a. Seg\u00fan el informe de \u201cConsumo de f\u00e1rmacos ansiol\u00edticos e hipn\u00f3ticos en Receta \nOficial y Mutuas\u201d de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS), se ha producido un aumento \ndel 7% desde 2019 hasta 2021. \nEl objetivo principal es analizar la utilizaci\u00f3n de psicof\u00e1rmacos (ansiol\u00edticos e hipn\u00f3ticos) a nivel provincial y en un hospital \nde tercer nivel y conocer su evoluci\u00f3n comparada con el consumo nacional\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo en el que se analizaron los datos de consumo de psicof\u00e1rmacos prescritos a trav\u00e9s de receta oficial, \na nivel nacional, provincial y en consultas externas de un hospital de tercer nivel durante el periodo de tiempo en que se \ndesarrolla la pandemia COVID-19 (2019-2021). \nSe realiz\u00f3 la extracci\u00f3n de datos de consumo a trav\u00e9s de la base de datos de facturaci\u00f3n de recetas de la Comunidad \nAut\u00f3noma. Los psicof\u00e1rmacos seleccionados fueron los grupos terap\u00e9uticos N05B y N05C correspondientes a ansiol\u00edticos \ne hipn\u00f3ticos. Los datos nacionales se obtuvieron del Observatorio del Uso de Medicamentos de la AEMPS.  \nLas variables utilizadas fueron las DDD por 1.000 habitantes y d\u00eda (DHD) y el porcentaje de incremento de 2021 respecto \na 2019. A partir de las DDD aportadas por la base de datos, se realiz\u00f3 el c\u00e1lculo de las DHD para poder comparar con los \ndatos de la AEMPS. El n\u00famero de habitantes provincial se obtuvo del Instituto Nacional de Estad\u00edstica (INE) y la poblaci\u00f3n \nde referencia del hospital de la memoria publicada el \u00faltimo a\u00f1o.\nRESULTADOS\nEl consumo nacional de ansiol\u00edticos e hipn\u00f3ticos en DHD fue de 86,93 en 2019, 90,6 en 2020 y 93,05 en 2021. El \nincremento en el consumo fue de un 7%\ufffd  \nEn la provincia, el consumo de ansiol\u00edticos e hipn\u00f3ticos en DHD fue de 97,17 en 2019, 103,28 en 2020 y 107,34 en 2021. \nEl aumento en el consumo fue de un 10%\ufffd  \nEn el hospital de referencia, el consumo de ansiol\u00edticos en DHD fue de 5,43 en 2019, 5,87 en 2020 y 6,22 en 2021. El \nincremento en el consumo fue de un 15%\ufffd\nCONCLUSIONES\nLa utilizaci\u00f3n de psicof\u00e1rmacos (ansiol\u00edticos e hipn\u00f3ticos) ha experimentado un aumento a todos los niveles desde que \nempez\u00f3 la pandemia de COVID-19 hasta la actualidad.  \nLa provincia tiene un incremento superior que la media nacional y es m\u00e1s significativo a nivel intrahospitalario.  \nSe considera necesario la implementaci\u00f3n de intervenciones que permitan asegurar la adecuaci\u00f3n de los tratamientos y \nque garanticen la correcta utilizaci\u00f3n de estos f\u00e1rmacos.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n903. DETECCI\u00d3N DE MEDICAMENTOS POTENCIALMENTE INADECUADOS DURANTE EL INGRESO Y \nEFECTO DE LAS INTERVENCIONES FARMAC\u00c9UTICAS SOBRE EL TRATAMIENTO AL ALTA. \nAUTORES\nYBA\u00d1EZ GARC\u00cdA, L; NIETO , A; FERNANDEZ RUIZ MORON, A; SANCHEZ OCA\u00d1A MARTIN, N; MOLINERO MU\u00d1OZ, M; \nDE LA TORRE ORTIZ, M; MANZANO LORENZO, R; MARTINEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nAnalizar la prescripci\u00f3n de medicamentos potencialmente inadecuados (MPI) seg\u00fan criterios STOPP-START y STOPP-\nFRAIL como tratamiento habitual en los pacientes mayores de 65 a\u00f1os que ingresan en una unidad de medicina interna y \nevaluar el grado de aceptaci\u00f3n de las intervenciones realizadas sobre ellos.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo. Se incluyeron los pacientes en un \u00e1rea de medicina interna del 1 de abril al 5 de mayo \nde 2022. El farmac\u00e9utico trabajando en el equipo realiz\u00f3 conciliaci\u00f3n del tratamiento de forma presencial o mediante la \nrevisi\u00f3n del M\u00f3dulo \u00danico de Prescripci\u00f3n. Se analiz\u00f3 de forma individualizada el tratamiento de cada paciente, teniendo \nen cuenta edad y comorbilidad\ufffd\nRESULTADOS\nSe incluyeron 26 pacientes (16 mujeres), la mediana de edad fue de 81,9 a\u00f1os (67-97). La mediana de f\u00e1rmacos que \ntomaban como parte de su tratamiento habitual fue de 8 (0-22). Se detect\u00f3 polifarmacia en 9 pacientes (5-9 f\u00e1rmacos) e \nhiperpolifarmacia en 13 (9 o m\u00e1s medicamentos).  \nSe detectaron MPI en 11 pacientes, sobre los que se realizaron intervenciones farmac\u00e9uticas (IF):  \nTrece MPI seg\u00fan criterios STOPP-START de los cuales:  \n\u2022 Uso de benzodiacepinas de vida media larga durante m\u00e1s de un mes: 7 pacientes (aceptadas 2).  91\u2022 Inhibidor de la bomba de protones (IBP) en uso cr\u00f3nico sin indicaci\u00f3n: 3 pacientes (aceptadas 3).  \n\u2022 Duplicidad terap\u00e9utica: 2 pacientes (aceptadas 2).  \n\u2022 Ipratropio en paciente con glaucoma: 1 paciente (no realizada IF durante el ingreso).  \nTres MPI seg\u00fan criterios STOPP-FRAIL: \n\u2022 Memantina en paciente con demencia avanzada: 2 pacientes. (aceptada 1) \n\u2022 Nitrofuranto\u00edna profil\u00e1ctica, de la cual existe una alerta de la Agencia Espa\u00f1ola del Medicamento y Producto Sanitario \ncontraindicando su uso en profilaxis. (aceptada 1)  \nEl tipo de intervenci\u00f3n m\u00e1s frecuente y con menor grado de aceptaci\u00f3n fue la que se realiz\u00f3 sobre el uso de \nbenzodiazepinas de vida media larga en uso prolongado. El siguiente criterior STOPP sobre el que se realiz\u00f3 un mayor \nn\u00famero de IF fue el uso de IBP sin indicaci\u00f3n. El porcentaje total de aceptaci\u00f3n general de las IF fue del 62,5% durante el \ningreso, sin embargo, de cara al alta, el tratamiento habitual solo se modific\u00f3 en 3 pacientes.\nCONCLUSIONES\nCasi la mitad de los pacientes analizados ten\u00edan medicaci\u00f3n potencialmente inadecuada seg\u00fan criterios STOPP START \ny STOPP FRAIL como parte de su tratamiento habitual. El grado de aceptaci\u00f3n de las intervenciones realizadas sobre \nel tratamiento habitual de los pacientes es inferior al de las intervenciones realizadas sobre el tratamiento del ingreso \n(87%), lo que puede deberse a que al ser el ingreso una situaci\u00f3n de inestabilidad cl\u00ednica y no ser el prescriptor \nresponsable del ingreso el prescriptor de la medicaci\u00f3n habitual, hay m\u00e1s reticencias al cambio, lo que se traduce en \nun bajo n\u00famero de pacientes a los que se les modifica el tratamiento al alta pese a haber sido aceptada la IF durante el \ningreso, indicando todo ello que es necesario fomentar la continuidad entre niveles asistenciales.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n917. CARACTERIZACI\u00d3N DE LA CALIDAD DE VIDA Y NECESIDADES DEL PACIENTE ONCOL\u00d3GICO CON \nDIABETES \nAUTORES\nSOMOZA FERN\u00c1NDEZ, B; REVUELTA HERRERO, JL; MARZAL ALFARO, B; CANTERO MART\u00cdN, M; VILLANUEVA BUENO, \nC; JEREZ GILARRANZ, Y; HERRANZ ALONSO, A; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nEl manejo inadecuado de la glucemia en pacientes oncol\u00f3gicos diab\u00e9ticos se asocia a una mayor morbi-mortalidad y peor \ncalidad de vida. Desde el hospital de d\u00eda oncol\u00f3gico se puede mejorar el control del paciente oncol\u00f3gico con diabetes con \nmedidas espec\u00edficamente enfocadas a sus necesidades.  \nEl objetivo fue caracterizar a los pacientes diab\u00e9ticos que reciben tratamiento en un hospital de d\u00eda oncol\u00f3gico, evaluar \nel impacto de la diabetes en su calidad de vida, e identificar posibles necesidades no cubiertas de cara al manejo del \ntratamiento antidiab\u00e9tico.\nMATERIALES Y M\u00c9TODOS\nSe trata de un estudio observacional descriptivo en el que se incluyeron pacientes diab\u00e9ticos que acudieron a \nrecibir tratamiento antineopl\u00e1sico al hospital de d\u00eda oncol\u00f3gico (octubre 2021 - abril 2022). Se recogieron variables \nsociodemogr\u00e1ficas, cl\u00ednicas y farmacoterap\u00e9uticas. En cuanto a los resultados de calidad de vida, se evaluaron tres \ncuestionarios validados: WHO-5 (bienestar), PHQ-9 (depresi\u00f3n) y PAID (problemas relacionados con la diabetes).\nRESULTADOS\nSe incluyeron 51 pacientes. La mediana de edad fue 70 a\u00f1os (RIC=62-76) y un 23,5% eran mujeres. El 78% ten\u00eda un \nECOG\u22641, el 20% un ECOG=2 y el 2% un ECOG=3.  \nEl 45% de los pacientes recib\u00edan seguimiento de su diabetes por su m\u00e9dico de atenci\u00f3n primaria, el 31% por endocrino, \nel 18% por oncolog\u00eda y el 6% por enfermer\u00eda de atenci\u00f3n primaria. La mediana de meses trascurridos desde el \u00faltimo \ncontrol fue 3 (RIC=1-10). La mediana de tiempo desde la \u00faltima determinaci\u00f3n de hemoglobina glicosilada fue 18 meses \n(RIC=6-32), y el valor medio fue 7,15% (DE=1%).  \nEl 92,1% de los pacientes presentaban comorbilidades: el 74,5% hipertensi\u00f3n arterial, el 68,6% dislipemia, el 19,6% \ninsuficiencia renal leve, el 13,7% cardiopat\u00eda y el 3,9% enfermedad arterial perif\u00e9rica. \nLa adherencia autorreferida media al tratamiento antidiab\u00e9tico fue 96,66%. El 43,1% de los pacientes estaban en \ntratamiento con un \u00fanico antidiab\u00e9tico oral (ADO), el 15,7% con dos o m\u00e1s ADOS, el 25,5% recib\u00edan ADOS e insulina y el \n15,7% insulina en monoterapia. La mediana del n\u00famero de f\u00e1rmacos concomitantes fue 11 (RIC=7-14). \nS\u00f3lo un 31,4% de los pacientes hab\u00eda recibido informaci\u00f3n sobre c\u00f3mo manejar su diabetes el d\u00eda de administraci\u00f3n de la \nquimioterapia (toma de medicaci\u00f3n antidiab\u00e9tica habitual, no ayuno).  \nEn cuanto a los resultados de calidad de vida, la puntuaci\u00f3n media en el WHO-5 fue 17,6 puntos (DE=5,4); dicha \npuntuaci\u00f3n se asocia a un nivel de malestar destacable. La puntuaci\u00f3n media PHQ-9 fue 6,6 puntos (DE=4,8), compatible \ncon depresi\u00f3n leve, mientras que la obtenida en el cuestionario PAID fue 5,6 puntos (DE=8,6): los pacientes encuestados \nno asociaban su diabetes a un gran malestar emocional\ufffd\nCONCLUSIONES\nLos pacientes presentaron un elevado \u00edndice de comorbilidades. La mayor\u00eda no hab\u00eda recibido informaci\u00f3n acerca del \nmanejo de la diabetes previo a la administraci\u00f3n de tratamiento. Aunque la diabetes no tuvo un gran impacto en la \ncalidad de vida, los pacientes refirieron un nivel de malestar destacable y depresi\u00f3n leve. \nEstos resultados sugieren la necesidad de ofrecer informaci\u00f3n al paciente oncol\u00f3gico respecto al manejo de la diabetes e \nimplantar programas de atenci\u00f3n integral para una poblaci\u00f3n de pacientes tan espec\u00edfica y vulnerable.92CLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n935. EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON \u00c1CIDO OBETIC\u00d3LICO EN PACIENTES CON \nCOLANGITIS BILIAR PRIMARIA EN UN HOSPITAL TERCIARIO. \nAUTORES\nBOO RODRIGUEZ, J; ROS OLASO, A; BERISTAIN ARAMENDI, I; ECEIZA DIEZ, A; GONZALEZ FERNANDEZ, T; GAYAN \nLERA, MJ; CASTIELLA EGUZKIZA, A\nHOSPITAL DONOSTIA-DONOSTIA OSPITALEA. P\u00ba DR. BEGUIRISTAIN, 109 DONOSTIA-SAN SEBASTI\u00c1N. GUIP\u00daZCOA\nOBJETIVOS\nEl \u00e1cido obetic\u00f3lico(AO) est\u00e1 indicado para el tratamiento de pacientes con colangitis biliar primaria(CBP) refractarios/\nintolerantes a \u00e1cido ursodesoxic\u00f3lico(AUDC).  \n \nLa incertidumbre con respecto a la eficacia y seguridad de los tratamientos prolongados con AO y la ausencia de \nalternativas terap\u00e9uticas, son dudas que se plantean en la actualidad en la practica cl\u00ednica para el correcto manejo de \nestos pacientes\ufffd \n \nEl objetivo es evaluar la eficacia y seguridad del tratamiento con \u00e1cido obetic\u00f3lico en pacientes con colangitis biliar \nprimaria en un hospital terciario.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 pacientes con diagn\u00f3stico de CBP con al menos 6 meses de tratamiento \ncon AO y previamente tratados con AUDC. Fecha del estudio: 2018-2022. \n \nSe recogieron datos demogr\u00e1ficos de los pacientes, sobre su tratamiento habitual y del tratamiento con AO: fecha de \ninicio/fin de tratamiento, duraci\u00f3n, dosis, pautas de administraci\u00f3n y adherencia.  \n \nPara evaluar la eficacia, se consider\u00f3 eficaz: \n- La reducci\u00f3n, en al menos un 15% con respecto al valor basal, de los par\u00e1metros anal\u00edticos: fosfatasa alcalina(FA), \ngammaglutamil transpeptidasa(GGT), aspartato aminotransferasa(AST) a los 6,12 y > 12 meses de tratamiento. En los que \nfue eficaz, se calcul\u00f3 la media del % de reducci\u00f3n.  \n- Niveles de bilirrubina total(BT) < a 1,1 mg/dL a lo largo del tratamiento.  \n \nPara evaluar la seguridad, se analiz\u00f3 la aparici\u00f3n de efectos adversos(EA) e interacciones farmacol\u00f3gicas.\nRESULTADOS\nSe incluyeron 23 pacientes: Todos alcanzaron los 6 meses de tratamiento, 15(65%) los 12 meses de tratamiento y 14(61%) \n> de 12 meses. 22(96%) fueron mujeres. La media de edad fue de 61 a\u00f1os (42-76). Todos llevaron previamente AUDC, con \nuna adherencia media > del 80%.  \n \nTodos empezaron con la dosis est\u00e1ndar de 5 mg/24 h. En 14(61%), se aument\u00f3 hasta 10 mg/24h por falta de eficacia. La \nadherencia media fue del 94%.  \n \nLa aparici\u00f3n de EA (prurito e intolerancia digestiva) oblig\u00f3 a cambiar la pauta a 5 mg/48 h en 2(8,7%). Suspendieron el \ntratamiento 3(13%), siendo los motivos intolerancia 2(66,6%) e ineficacia 1(33,3%). No hubo interacciones farmacol\u00f3gicas \nrelevantes\ufffd \n \nA continuaci\u00f3n, se muestran los resultados de eficacia: \n \nN\u00ba pacientes con una reducci\u00f3n de al menos 15%: 6 meses(N=23) 12 meses(N=15) > 12 meses(N=14)  \nFosfatasa alcalina(FA): 14(61%) 11(73%) 9(64%)  \nGammaglutamil transpeptidasa(GGT): 21(91%) 15(100%) 12(86%)  \nAspartato aminotransferasa(AST): 14 (61%) 11 (73%) 9 (64%) \n \n \nPara FA: 6 meses(N=14) 12 meses(N=11) > 12 meses(N=9)  \nMedia del % de reducci\u00f3n en pacientes que responden 31%(15-43) 38%(21-54) 50%(29-67) \n \nPara GGT: 6 meses(N=21) 12 meses(N=15) > 12 meses(N=12)  \nMedia del % de reducci\u00f3n en pacientes que responden 49% (17-72) 62%(41-93) 69%(28-91) \n \nPara AST: 6 meses(N=14) 12 meses(N=11) > 12 meses(N=9)  \nMedia del % de reducci\u00f3n en pacientes que responden 35% (19-54) 34% (18-53) 43% (15-68) \n \nTodos presentaron niveles de BT < a 1,1 mg/dL durante el tratamiento.93CONCLUSIONES\nA la espera de tener mayor n\u00famero de pacientes y experiencia, los resultados sugieren que el AO consigue reducir los \nPA relacionados con la enfermedad sin comprometer la salud de los pacientes, siendo esta reducci\u00f3n mayor en aquellos \npacientes con > de 12 meses de tratamiento.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n938. PREVALENCIA DE HIPOMAGNESEMIA Y D\u00c9FICIT DE VITAMINA B12 EN PACIENTES CON INHIBIDORES \nDE LA BOMBA DE PROTONES. \nAUTORES\nCORRALES KROHNERT , S; MIRANDA DEL CERRO, A; TARDAGUILA MOLINA, P; CASARRUBIOS LAZARO, GI; MARTINEZ \nRUIZ, E; DEAN BARAHONA, C; CODONAL DEMETRIO, A; MART\u00cdN ALCALDE, E\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nLos inhibidores de la bomba de protones (IBPs) son f\u00e1rmacos ampliamente utilizados de forma cr\u00f3nica, pero no exentos \nde efectos secundarios\ufffd Dos de estos efectos son:  \n\u2022 La disminuci\u00f3n de la absorci\u00f3n de B12 al disminuir la secreci\u00f3n g\u00e1strica de \u00e1cido.  \n\u2022 Riesgo de hipomagnesiemia grave. \nEl objetivo de este estudio es analizar la prevalencia de deficiencia de vitamina B12 e hipomagnesemia en pacientes \ngeri\u00e1tricos tratados con inhibidores de la bomba de protones (IBPs).\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo-retrospectivo realizado desde Enero 2022 hasta Abril 2022. Se incluyeron los pacientes que ingresaron \nen el servicio de geriatr\u00eda a los que se les realiz\u00f3 conciliaci\u00f3n de la medicaci\u00f3n desde el servicio de farmacia. \nSe confirm\u00f3 el tratamiento cr\u00f3nico de los pacientes al momento del ingreso mediante entrevista con el paciente \ny/o cuidador y los datos se recogieron en el programa Microsoft Excell\u00ae. Posteriormente, de todos los pacientes en \ntratamiento con IBP , se revisaron las anal\u00edticas, tratamientos y los informes de alta desde la historia cl\u00ednica electr\u00f3nica. \nLas variables recogidas fueron: demogr\u00e1ficas, n\u00famero de f\u00e1rmacos que toma el paciente, si estaba en tratamiento con \nIBP , niveles de vitamina B12 y su suplementaci\u00f3n, niveles de magnesio y su suplementaci\u00f3n y la desprescripci\u00f3n al alta\ufffd\nRESULTADOS\nSe incluyeron 246 pacientes con una mediana de edad de 90 a\u00f1os (RIC: 86-92). El 54% fueron mujeres. La mediana de \nf\u00e1rmacos prescritos por paciente fue de 9 (RIC: 7-11). \nEl 74% de los pacientes ten\u00edan prescrito y tomaban alg\u00fan IBP . \n\u2022 El 37% presentaban o hab\u00edan presentado en los meses previos d\u00e9ficit de vitamina B12 (nivel < 200 pg/mL). De ellos, el \n24% ya hab\u00edan iniciado suplementaci\u00f3n antes del ingreso, y el 60% fueron suplementados durante el ingreso o al alta. \n\u2022 En el caso de la hipomagnesemia, en el 69% de los pacientes en tratamiento con IBP se solicitaron niveles de magnesio \ndurante el ingreso o en los meses previos. De ellos, el 19% de los pacientes presentaban hipomagnesemia (niveles < 1,8 \nmg/dL). Solo el 8% fue suplementado durante el ingreso. \nDe cara al alta se suspendi\u00f3 el IBP en el 5% de los pacientes del estudio\ufffd\nCONCLUSIONES\n- Existe un gran porcentaje de pacientes geri\u00e1tricos polimedicados en tratamiento con IBPs.  \n- M\u00e1s de un tercio de ellos presentaban deficiencia de vitamina B12 y requirieron suplementaci\u00f3n.  \n- La hipomagnesemia se detect\u00f3 en menos de un tercio de los pacientes. Estos datos podr\u00edan estar infraestimados \npuesto que no se realizaba la determinaci\u00f3n de hipomagnesemia de manera rutinaria. En la mayor\u00eda de los casos, la \nhipomagnesemia fue leve y no se necesit\u00f3 suplementar durante el ingreso. \n- Ser\u00eda recomendable analizar la adecuaci\u00f3n de la prescripci\u00f3n de IBP en pacientes geri\u00e1tricos, para potenciar su \ndeprescripci\u00f3n en los casos no indicados\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n943. RESULTADOS DE REVISI\u00d3N MULTIDISCIPLINAR DE LA TERAPIA FARMACOL\u00d3GICA EN PACIENTES \nFR\u00c1GILES POLIMEDICADOS DE UNA UNIDAD HOSPITALARIA DE ALTA COMPLEJIDAD \nAUTORES\nVARAS P\u00c9REZ, A; BRIEVA HERRERO, T; CEBRI\u00c1N ALCAIDE, C; FOLGUEIRAS AMADOR, L; GARRIDO FERN\u00c1NDEZ, R; \nFERN\u00c1NDEZ ESP\u00cdNOLA, S\nHOSPITAL COMARCAL DE ANTEQUERA. AV .DEL POETA MU\u00d1OZ ROJAS, S/N ANTEQUERA. MALAGA\nOBJETIVOS\nResoluci\u00f3n de discrepancias del tratamiento farmacol\u00f3gico\ufffd  \nReducci\u00f3n de medicaci\u00f3n potencialmente inapropiada\ufffd  \nReducci\u00f3n justificada de medicaci\u00f3n total y de alto riesgo (AR).\nMATERIALES Y M\u00c9TODOS\nSe seleccionaron a todos los pacientes que ingresaron en la Unidad de Alta Complejidad (UAC) de nuestro centro \nhospitalario desde el 1 noviembre de 2021 al 31 de abril de 2022. Los criterios de inclusi\u00f3n fueron: m\u00e1s de 6 f\u00e1rmacos 94prescritos en domicilio y escala EPADI > 5 puntos; y los criterios de exclusi\u00f3n: mal pron\u00f3stico (seg\u00fan criterio m\u00e9dico), alta \n< 48 horas e ingreso en UCI. \nSe recogieron todas las patolog\u00edas de la historia cl\u00ednica, toda la medicaci\u00f3n presente en prescripci\u00f3n electr\u00f3nica, se \ncotejaron en la entrevista farmacoterap\u00e9utica (FT) realizada por el equipo de enfermeras de Farmacia y se registraron las \ndiscrepancias detectadas relacionadas con la medicaci\u00f3n\ufffd  \nEl equipo de farmac\u00e9uticos realizaba un informe FT sobre medicaci\u00f3n potencialmente inapropiada seg\u00fan establecen \nlos criterios START/STOPP y LESS-CHRON. Dicho informe se a\u00f1ad\u00eda a la historia cl\u00ednica para que todos los profesionales \ntuvieran acceso a \u00e9l y se realizasen los cambios oportunos de la prescripci\u00f3n.\nRESULTADOS\nUn total de 178 pacientes fueron ingresados en la UAC durante el periodo estudiado, habi\u00e9ndose excluido 42 de ellos \n(24 por mal pron\u00f3stico, 8 por ingreso < 48 horas, 5 por tener < 6 f\u00e1rmacos, 4 por tener un EPADI < 5 y 1 ingreso en UCI), \nresultando aptos para la revisi\u00f3n 136 pacientes, con una media de edad de 84.2 a\u00f1os [56-95], siendo el 50% mujeres. La \nmedia de f\u00e1rmacos al ingreso fue de 12.68 y al alta 10.25, logr\u00e1ndose una reducci\u00f3n de 2.43 (19%) f\u00e1rmacos; la media \nde discrepancias relacionadas con la medicaci\u00f3n fue de 2.32 al ingreso y de 0.53 al alta, alcanz\u00e1ndose una reducci\u00f3n de \n1.79 (77%) discrepancias; el promedio de medicaci\u00f3n potencialmente inapropiada al ingreso fue de 3,3 y al alta de 1,86, \nobjetiv\u00e1ndose una reducci\u00f3n de 1,44 (44%) f\u00e1rmacos potencialmente inapropiados y en cuanto al n\u00famero de f\u00e1rmacos \nde AR se pas\u00f3 de 4,1 en el momento del ingreso a 3,22 al alta, reduci\u00e9ndose en 0,88 (21%) medicamentos de AR.\nCONCLUSIONES\nLa intervenci\u00f3n de un equipo multidisciplinar del Servicio de Farmacia, en la revisi\u00f3n sistematizada de la FT de los \npacientes polimedicados de una Unidad de Alta Complejidad ha logrado, en nuestro corte de pacientes, mejorar de forma \nsignificativa variables relacionadas con la medicaci\u00f3n: aproximadamente 3 de cada 4 discrepancias se resolvieron, se \nredujo a casi la mitad la MPI y se redujo una quinta parte la medicaci\u00f3n total, as\u00ed como la de alto riesgo.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n962. AN\u00c1LISIS DE RECOMENDACIONES SOBRE ANALG\u00c9SICOS OPIOIDES Y ANSIOL\u00cdTICOS HIPN\u00d3TICO \nSEDANTES REALIZADAS POR EL SERVICIO DE FARMACIA SOBRE PACIENTES CR\u00d3NICOS COMPLEJOS \nAUTORES\nS\u00c1NCHEZ PASCUAL, B; SALVADOR LLANA, I; ZAMORANO MENDEZ, P; HERRERA CARRANZA, S; SANZ M\u00c1RQUEZ, S; \nP\u00c9REZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nAnalizar las intervenciones sobre f\u00e1rmacos ansiol\u00edticos hipn\u00f3tico-sedantes y analg\u00e9sicos opioides realizadas por el servicio \nde farmacia (SF) en pacientes cr\u00f3nicos complejos (PCC).  \nEvaluar las diferencias de prescripci\u00f3n e intervenci\u00f3n sobre estos f\u00e1rmacos a nivel hospitalario (NH) y domiciliario.\nMATERIALES Y M\u00c9TODOS\nLos PCC requieren especial seguimiento por sus comorbilidades, polifarmacia y generalmente, edad avanzada. Para \noptimizar su tratamiento se cre\u00f3 una marca en la historia cl\u00ednica electr\u00f3nica (HCE) que los identificaba como tal, \nincluy\u00e9ndolos en un listado revisado por el SF para su conciliaci\u00f3n. Estudio descriptivo prospectivo realizado entre enero \ny final de abril de 2022 en un hospital de tercer nivel en que se analizaron las intervenciones del SF sobre los f\u00e1rmacos \nsedantes (FS) de los PCC. Se consideraron FS: analg\u00e9sicos opioides (OP) (grupo N02AA) y ansiol\u00edticos hipn\u00f3tico-sedantes \n(grupos N05B y N05B1C) seg\u00fan clasificaci\u00f3n Anat\u00f3mica Terap\u00e9utica Qu\u00edmica. \nSe recogieron: sexo, edad, n\u00famero f\u00e1rmacos domiciliarios, n\u00famero f\u00e1rmacos sedantes domiciliarios (FSD), tipo FSD, \nn\u00famero f\u00e1rmacos hospitalarios, n\u00famero f\u00e1rmacos sedantes hospitalarios (FSH), tipo FSH, intervenci\u00f3n sobre FS, lugar, \ntipo de intervenci\u00f3n y aceptaci\u00f3n. Los datos fueron recogidos de la HCE, la tarjeta sanitaria electr\u00f3nica y del m\u00f3dulo de \nunidosis\ufffd  \nLas intervenciones farmac\u00e9uticas se realizaron por comunicaci\u00f3n verbal y/o escrita en la HCE, en los FSH y mediante su \ninclusi\u00f3n en el informe de alta en los FSD. El seguimiento de la aceptaci\u00f3n se realiz\u00f3 revisando el tratamiento hospitalario \ny domiciliario el mes siguiente a la intervenci\u00f3n\ufffd\nRESULTADOS\nSe revisaron 50 pacientes (68%(34/50) mujeres, mediana edad 84 a\u00f1os (Rango intercuart\u00edlico (RIC):78-86,5)). Mediana \nde tratamientos cr\u00f3nicos 14 f\u00e1rmacos (RIC:11-17) y 1 FSD (RIC:0-2). El 72%(36/50) de los pacientes ten\u00edan FSD. A NH la \nmediana de f\u00e1rmacos fue 15 (RIC12-18) y 1 FSH (RIC:0-1).  \nA NH los FS m\u00e1s prescritos fueron: benzodiacepinas (BZD) 46,6%(21/45), OP 42,22%(19/45), f\u00e1rmacos Z (FZ) 6,66%(3/45) \ny clometiazol 4,44%(2/45). En domicilio OP y BZD fueron prescritos en igual proporci\u00f3n 44,8%(26/58) seguidos \nde FZ 6,89%(4/58) y clometiazol 3,57%(2/58). El FSH m\u00e1s prescrito fue lorazepam 20,9%(9/45) y el FSD tramadol \n24,17%(14/58).  \nSe realizaron 26 intervenciones sobre FS llevadas a cabo sobre el 34%(17/50) de los pacientes. El 69,23%(18/26) de las \nintervenciones fueron a nivel domiciliario\ufffd  \nLos motivos de intervenci\u00f3n fueron: desprescripci\u00f3n 37,5%(3/8) en ingresados frente 50%(9/18) en domicilio, reducci\u00f3n \nde dosis 12,5%(1/8) en ingresados frente 33,33%(6/18) en domicilio, vigilancia y desprescripci\u00f3n de f\u00e1rmacos que elevan \nla carga anticolin\u00e9rgica 12,5%(1/8) hospital frente 11,11%(2/18) domicilio, sustituci\u00f3n 12,5%(1/8) ingresados frente \n5,55%(1/18) domicilio y vigilar interacci\u00f3n 25%(2/8) ingresados frente 0% domicilio.  95A NH el 50%(4/8) de las intervenciones fueron de OP con aceptaci\u00f3n del 100%(4/4) y el 50%(4/8) de BZD aceptaci\u00f3n \n50%(2/4). En domicilio el grupo con mayor intervenci\u00f3n fueron las BZD 72,22%(13/18), aceptaci\u00f3n 38,4%(5/13), seguidas \nde OP 16,66%(3/18) y FZ 11,11%(2/18) con aceptaci\u00f3n del 100% ambos. La aceptaci\u00f3n global fue del 61,5%(16/26) \nsiendo m\u00e1s frecuente a NH 75%(6/8) que domiciliario 55,55%(10/18).\nCONCLUSIONES\nLa intervenci\u00f3n m\u00e1s frecuente (tanto a NH como domiciliario) fue la desprescripci\u00f3n. El contacto directo farmac\u00e9utico-\nm\u00e9dico a NH permiti\u00f3 obtener una mayor aceptaci\u00f3n con respecto al domicilio donde este contacto es indirecto, a trav\u00e9s \ndel informe de alta\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n965. INTERVENCI\u00d3N FARMAC\u00c9UTICA SOBRE LA REDUCCI\u00d3N DE MEDICACI\u00d3N DE ALTO RIESGO EN EL \nPACIENTE C\u00d3NICO COMPLEJO \nAUTORES\nVARAS P\u00c9REZ, A; CEBRI\u00c1N ALCAIDE, C; FOLGUEIRAS AMADOR, L; FERN\u00c1NDEZ ESP\u00cdNOLA, S\nHOSPITAL COMARCAL DE ANTEQUERA. AV .DEL POETA MU\u00d1OZ ROJAS, S/N ANTEQUERA. MALAGA\nOBJETIVOS\nReducir la carga de medicaci\u00f3n de alto riesgo en pacientes polimedicados con criterios de fragilidad que ingresan en \nnuestro centro hospitalario.\nMATERIALES Y M\u00c9TODOS\nSe seleccionaron todos los pacientes que ingresaron en el centro hospitalario durante los \u00faltimos 6 meses desde la fecha \nde corte (1 de mayo de 2022) y entre ellos los que cumpl\u00edan los criterios de fragilidad, seg\u00fan la escala EPADI, que tuvieran \nun m\u00ednimo de 10 f\u00e1rmacos activos en la prescripci\u00f3n electr\u00f3nica y alguno de los cuales considerado como de alto riesgo \nseg\u00fan el Instituto de Uso Seguro de Medicamentos (IUSM). El farmac\u00e9utico llevaba a cabo recomendaciones orientadas a \nla reducci\u00f3n de la medicaci\u00f3n de AR, atendiendo a los criterios de eficacia, seguridad, necesidad y adecuaci\u00f3n sobre cada \nuna de los f\u00e1rmacos en cuesti\u00f3n, agrup\u00e1ndolos por grupo farmacol\u00f3gico. A diario se realizaba una reuni\u00f3n presencial \npara debatir con los prescriptores a cargo de los pacientes seleccionados y de forma interdisciplinar se determinaba la \ncontinuaci\u00f3n o el inicio del tratamiento farmacoterap\u00e9utico correspondiente.\nRESULTADOS\nEn el periodo de estudio seleccionado se registraron 241 pacientes que cumpl\u00edan criterios de fragilidad (EPADI\u22655), \npolifarmacia (\u226510 f\u00e1rmacos) y al menos un f\u00e1rmaco considerado de alto riesgo por el IUSM. El 65% (157 pacientes) \npresentaba en el momento del ingreso 3 o m\u00e1s f\u00e1rmacos de AR y el 40% (96 pacientes) 5 o m\u00e1s. El promedio de este \ntipo de medicamentos fue de 4,3 por paciente [1-9] y la moda de 4. Tras la intervenci\u00f3n por parte del farmac\u00e9utico en \nel equipo interdisciplinar, se produjo un 28% (1,2 f\u00e1rmacos de AR por paciente) la medicaci\u00f3n objeto del estudio [0-6], \nlogr\u00e1ndose que el porcentaje con \u22653 f\u00e1rmacos de AR pasara del 65%(157) al 47% (113 pacientes) y que los que los que \nten\u00edan prescritos al ingreso \u22655 f\u00e1rmacos de AR pasaran del 40% (n=96) al 30% (n=72). En t\u00e9rminos globales, el grupo \nfarmacol\u00f3gico que registr\u00f3 una mayor deprescripci\u00f3n durante el ingreso hospitalario fueron los AINES (16%) y las BDZ \n(8,9%), siendo los ACO/NACOs el \u00fanico grupo terap\u00e9utico que present\u00f3 un incremento positivo en la transici\u00f3n asistencial \n(+4,2%).\nCONCLUSIONES\nLa intervenci\u00f3n multidisciplinar, llevada a cabo por un farmac\u00e9utico hospitalario podr\u00eda reducir la medicaci\u00f3n de AR en \npacientes cr\u00f3nicos complejos, con posibles beneficios que ello podr\u00eda reportar. Ser\u00eda muy interesante correlacionar dicha \nreducci\u00f3n de f\u00e1rmacos de AR con variables en salud.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n973. AN\u00c1LISIS DE LA UTILIZACI\u00d3N DE LAXANTES EN ATENCI\u00d3N PRIMARIA \nAUTORES\nSALVADOR LLANA, I; MESEGUER BARROS, CM; SILVA RI\u00c1DIGOS, GM; JAMART S\u00c1NCHEZ, L; ESCUDERO VILAPLANA, \nB; PICAZO SANCHIZ, G; PEREZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nDescribir la utilizaci\u00f3n de laxantes, el perfil de consumidores y el grado de adecuaci\u00f3n a las gu\u00edas de pr\u00e1ctica cl\u00ednica(GPC) \nen un \u00e1rea de salud.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo trasversal en un \u00e1rea de salud que cubre 747.179 habitantes. Se incluyeron todos los \npacientes identificados a trav\u00e9s del sistema de facturaci\u00f3n de recetas dispensadas en oficinas de farmacia con cargo \nal sistema p\u00fablico de salud de la Comunidad, con al menos una dispensaci\u00f3n de laxantes (Sistema de Clasificaci\u00f3n \nAnat\u00f3mica (c\u00f3digo ATC-OMS): A06A) en el periodo diciembre/2021 a febrero/2022 (ambos inclusive). Se recogieron \nvariables relacionadas con el paciente (sexo, edad (dividi\u00e9ndose en tres grupos etarios ( < 18a\u00f1os; 18-74 y > 74)), \ntipo de laxante por subgrupo ATC (A06A:lubricantes y emolientes, A06B:estimulantes, A06AC:formadores del bolo, \nA06AD:osm\u00f3ticos, A06AG:enemas, A06AH:antagonistas de receptores opioides perif\u00e9ricos y A06AX:otros), principio 96activo y n\u00famero de envases. Se revis\u00f3 historia cl\u00ednica para analizar indicaci\u00f3n (en caso de indicaci\u00f3n financiada) y grado \nde adecuaci\u00f3n a las GPC vigentes. Se analizaron los datos con los programas Stata\u00ae v12 y Excel\u00ae.\nRESULTADOS\nSe realizaron 1.505 dispensaciones de laxantes a 1.371 pacientes diferentes(un 0,37% respecto a la poblaci\u00f3n \nconsumidora del \u00e1rea(370.500)). Un 63,65%(958) a mujeres. La media de edad fue:69\u00b114,37a\u00f1os. Por grupo etario un \n67,24%(1012) pacientes de edad avanzada ( > 74a\u00f1os), 32,62%(491) adultos(18-74a\u00f1os) y 0,13%(2)pedi\u00e1tricos( < 18a\u00f1os). \nPor tipo de laxante, el 62,06%(934) fueron formadores del bolo(Ispaghula), 24,05%(362) osm\u00f3ticos (lactulosa(79,28%), \nmacrogol(14,36%) y lactitol(6,35%)), 11,43%(172) otros agentes (linaclotida), 1,13%(17) enemas(laurilsulfato(82,35%) \ny fosfato de sodio(17,65%)), 0,53%(8) laxantes de contacto(bisacodilo(87,5%) y picosulfato de sodio(12,5%)), 0,53%(8) \nantagonistas opioides(naloxegol) y 0,27%(4) suavizantes-emolientes(parafina blanda).Respecto al estado de financiaci\u00f3n, \nel 44,05%(663) se hab\u00edan pautado bajo una indicaci\u00f3n financiada: 50,68%(336) de las indicaciones financiadas fueron \nde Isphagula para la Enfermedad Inflamatoria Intestinal (35,97% de las prescripciones de Isphagula); 25,94%(172) \nfue linaclotida para el tratamiento del S\u00edndrome Inflamatorio Intestinal(SII) refractario (100% de las prescripciones de \nlinaclotida); 22,78%(151) lactulosa y lactitol para la encefalopat\u00eda portosist\u00e9mica y paraplejia (supuso 48,71% de las \nprescripciones de lactulosa y lactitol) y 0,6%(4) tratamiento del estre\u00f1imiento inducido por opioides en pacientes adultos \noncol\u00f3gicos con respuesta inadecuada a laxantes (50% de las prescripciones de naloxegol). Respecto a la adecuaci\u00f3n a \nlas recomendaciones de las GPC, un 86,11%(1296) de los laxantes pautados, se ajustaban a la primera l\u00ednea establecida \n(formadores del bolo y osm\u00f3ticos). Macrogol y lactulosa (de elecci\u00f3n entre los osm\u00f3ticos), se ajust\u00f3 un 93,64%(339). La \nrecomendaci\u00f3n de evitar enemas de fosfato y parafinas en pacientes de edad avanzada, supuso una inadecuaci\u00f3n del \n1,23%(17).\nCONCLUSIONES\nEl consumo de laxantes supone un peque\u00f1o porcentaje respecto al consumo global. Su uso es m\u00e1s marcado en mujeres \ny en poblaci\u00f3n mayor. Los m\u00e1s utilizados son los de primera l\u00ednea seg\u00fan las GPC. En un porcentaje muy elevado, los \nformadores del bolo y osm\u00f3ticos se pautaron fuera de indicaci\u00f3n financiada, quiz\u00e1s por tratarse del tratamiento m\u00e1s \ngeneralizado de inicio. Linaclotida, siempre se ha prescrito en condiciones de financiaci\u00f3n, posiblemente por su posici\u00f3n \nen l\u00edneas m\u00e1s avanzadas de tratamiento.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n991. \u00c1NALISIS DEL USO DE INHIBIDORES DE LA BOMBA DE PROTONES EN PACIENTES CR\u00d3NICOS \nCOMPLEJOS \nAUTORES\nSALVADOR LLANA, I; S\u00c1NCHEZ PASCUAL, B; HERRERA CARRANZA, S; ZAMORANO M\u00c9NDEZ, P; SANZ M\u00c1RQUEZ, S; \nP\u00c9REZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nAnalizar el uso de inhibidores de la bomba de protones(IBPs) en domicilio y al ingreso de Pacientes Cr\u00f3nicos \nComplejos(PCC) seg\u00fan las recomendaciones consensuadas entre el Servicio de Farmacia y Digestivo y conocer el impacto \nsobre los niveles de magnesio(Mg2+) y VitaminaB12(VitB12) de pacientes tratados y no tratados con IBPs.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo, realizado en los PCC ingresados entre 1/julio/2021-31/diciembre/2021 en un \nhospital de tercer nivel. Se recogi\u00f3: sexo, edad, servicio cl\u00ednico, n\u00famero de medicamentos cr\u00f3nicos, consumo de IBPs \ncr\u00f3nicos y al ingreso, consumo de f\u00e1rmacos gastrolesivos(FGL)cr\u00f3nicos y al ingreso y niveles de Mg2+ y VitB12. Se usaron \ncomo referencia las recomendaciones de uso seguro de IBPs del hospital (paciente > 65 a\u00f1os, consumo de FGL y/o \npatolog\u00eda digestiva). Los datos fueron obtenidos a trav\u00e9s de la historia cl\u00ednica y de la receta electr\u00f3nica. Se procesaron los \ndatos a trav\u00e9s de Excel\u00ae.\nRESULTADOS\nEn este periodo de tiempo, ingresaron 57 PCC(64,9% mujeres) con una mediana de edad de 83 a\u00f1os(Rango \nIntercuart\u00edlico(RIC):77,5-87). La mediana de f\u00e1rmacos cr\u00f3nicos fue de 14(RIC:10-16,5). Los principales servicios \ncl\u00ednicos fueron Urgencias(63,15%) y Medicina Interna(15,78%). Un 85,96%(49) consum\u00edan IBP cr\u00f3nicos, de los cu\u00e1les \nun 95,91%(47/49) ten\u00edan > 65 a\u00f1os. De los pacientes PCC, un 26,31%(15) estaban en tratamiento cr\u00f3nico con 1FGL, \nun 35,08%(20/57) con 2, un 5,26%(3/57) con 3 y un 7,17%(4/57) con 4. Los FGL cr\u00f3nicos m\u00e1s habituales fueron \nanticoagulantes(27), Antiinflamatorios No Esteroideos(AINES)(25), Inhibidores Selectivos Recaptaci\u00f3n Serotonina(ISRS)\n(12), antiagregantes(9) y corticoides(7). Un 15,78%(9) no cumpl\u00edan criterios de uso de IBPs seg\u00fan recomendaciones del \nhospital. Un 78,94%(45) se les paut\u00f3 un IBP al ingreso. De los PCC, un 26,31%(15) estaban en tratamiento al ingreso con \n1 FGL, un 35,08%(20/57) con 2, un 22,8%(13/57) con 3 y un 1,7%(1/57) con 4. Los FGL al ingreso m\u00e1s habituales fueron \nanticoagulantes(35), AINES(24), ISRS(12), antiagregantes(7) y corticoides(20). Un 22,8%(13) no cumpl\u00edan criterios de uso \nde IBPs seg\u00fan recomendaciones del hospital. Al ingreso, se mantuvo el 79,59%(39/49) de los IBPs cr\u00f3nicos. La mediana \nde los niveles de Mg2+ y vitB12 en pacientes con IBPs cr\u00f3nicos, fue de Mg2+=2mg/dL(RIC:1,67-2,32) y vitB12= 417pg/\nmL(RIC:267-562) frente la mediana en pacientes sin IBPs que fue de Mg2+=2,1mg/dL(RIC:1,72-2,27) y vitB12=351,5pg/\nmL(RIC:272-658). En total se hicieron 8 IF relacionadas con la prescripci\u00f3n inadecuada de IBPS (6 al ingreso y 2 sobre la \nprescripci\u00f3n cr\u00f3nica). 5 intervenciones estaban relacionadas con la reducci\u00f3n de dosis, 1 relacionada con el ajuste de \npresentaci\u00f3n y 2 sobre la ausencia de prescripci\u00f3n al ingreso. Se aceptaron el 75%(6/8).97CONCLUSIONES\nUn elevado porcentaje de PCC mantiene el IBP al ingreso. Los FGL m\u00e1s ampliamente usados son los anticoagulantes \ny AINEs. No se observ\u00f3 d\u00e9ficit de Mg2+y/oVitB12 ni en los pacientes tratados ni en los no tratados con IBPs cr\u00f3nicos. \nSi bien el uso de IBPs est\u00e1 justificado en la mayor\u00eda de PCC, debido fundamentalmente a la edad avanzada y el uso \nextendido de FGL, el papel del farmac\u00e9utico en la revisi\u00f3n y conciliaci\u00f3n es fundamental para evitar su uso inadecuado.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n999. OPTIMIZACI\u00d3N DE RECURSOS EN LA ATENCI\u00d3N DE UNA RESIDENCIA SOCIOSANITARIA POR UN \nSERVICIO DE FARMACIA HOSPITALARIA. \nAUTORES\nRICO GUTI\u00c9RREZ, T; AMOR\u00d3S PAREDES, A; TOLOSA MART\u00cdNEZ, C; SANZ RODR\u00cdGUEZ, SM; COLOMA PERAL, R; RUIZ \nMOLINA, F; VIDAL IGLESIAS, M; CRIADO ILLANA, MT\nCOMPLEJO ASITENCIAL DE SEGOVIA. CTRA.DE AVILA, S/N SEGOVIA. SEGOVIA\nOBJETIVOS\nAn\u00e1lisis de los beneficios obtenidos con la dispensaci\u00f3n y administraci\u00f3n de antibi\u00f3ticos parenterales en un centro \nsociosanitario dependiente de un servicio de farmacia de hospital.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, retrospectivo de los tratamientos antibi\u00f3ticos administrados a los pacientes \ningresados en la Residencia Mixta de Personas Mayores (RMPM). As\u00ed como de otros beneficios aportados durante el a\u00f1o \n2021. Los datos, tanto de prescripci\u00f3n como de intervenciones farmac\u00e9uticas, se obtuvieron del m\u00f3dulo de unidosis del \nprograma inform\u00e1tico Farmatools\u00aev2.6 del centro.\nRESULTADOS\nEn la RMPM, durante el a\u00f1o 2021, se administraron 282 tratamientos antibi\u00f3ticos en 104 pacientes. Todos ellos siguieron \nla siguiente distribuci\u00f3n: amoxicilina oral (1); cloxacilina oral (10); amoxicilina/clavul\u00e1nico oral (41), amoxicilina/\nclavul\u00e1nico intravenoso (3), piperacilina/tazobactam (3); cefuroxima oral (39); cefditoreno oral (3), ceftriaxona (12); \nimipenem/cilastatina (6), ertapenem (14), meropenem (5); trimetoprim/sulfametoxazol oral (15); clindamicina oral (5); \namikacina (4), gentamicina (5), tobramicina (1); ciprofloxacino oral (8), levofloxacino oral (16), levofloxacino intravenoso \n(2); vancomicina oral (1); metronidazol oral (1); nitrofuranto\u00edna (9); fosfomicina 500 mg (54), fosfomicina trometamol 3 g \n(8) y linezolid oral (4). La media de duraci\u00f3n de tratamiento fue de 10 d\u00edas.  \n \nDel total de pacientes que recibieron antibioterapia, un 52,9% fue por v\u00eda parenteral. La distribuci\u00f3n de los antibi\u00f3ticos \nparenterales por tipo fue: penicilinas combinadas con beta-lactamasas 10,9%, cefalosporinas de 3\u00aa generaci\u00f3n 21,8%, \ncarbapen\u00e9micos 45,5%, aminogluc\u00f3sidos el 18,2% (que fueron monitorizados en su totalidad), y quinolonas intravenosas \nel 3,6%. El total de d\u00edas en los que se administraron tratamientos parenterales fue de 573. Seg\u00fan los decretos 78/2008 y \n83/2013 publicados en el Bocyl, el coste de cada d\u00eda de hospitalizaci\u00f3n en el Complejo Hospitalario de Segovia ser\u00eda de \n400,38 \u20ac (tramo 2), consigui\u00e9ndose un ahorro por ingresos hospitalarios evitados de 229.417,74 \u20ac. Asimismo, el coste \ndel transporte sanitario en ambulancia no asistida para el servicio urbano ser\u00eda de 55,31 \u20ac. De todos los pacientes con \ntratamiento antibi\u00f3tico por v\u00eda parenteral, s\u00f3lo 3 (1,06% de los tratamientos) requirieron ingreso hospitalario, por lo que \nel coste evitado en transporte (ida y vuelta) del resto de los tratamientos (52) habr\u00eda sido de 5.752 \u20ac.\nCONCLUSIONES\nLa mayor\u00eda de los tratamientos parenterales administrados correspondieron a antibi\u00f3ticos que no tienen alternativa oral. \nSu administraci\u00f3n en la residencia supuso un importante ahorro en costes de hospitalizaci\u00f3n as\u00ed como en transporte \nsanitario. Adem\u00e1s, las camas no ocupadas en el hospital fueron destinadas a la atenci\u00f3n de otros pacientes, cuesti\u00f3n \nespecialmente importante durante la pandemia COVID-19. Por otro lado, el hecho de depender de un servicio de \nfarmacia hospitalaria proporcion\u00f3 otros beneficios para el paciente derivados de la atenci\u00f3n farmac\u00e9utica (ajuste a \nfunci\u00f3n renal, tratamientos dirigidos para evitar la selecci\u00f3n de mutantes resistentes, monitorizaci\u00f3n farmacocin\u00e9tica, \netc.). Por lo expuesto anteriormente podemos objetivar que la colaboraci\u00f3n entre profesionales sanitarios, as\u00ed como la \ngesti\u00f3n desde los servicios de farmacia de hospital en las residencias, consigue una optimizaci\u00f3n en la atenci\u00f3n de los \npacientes junto con una importante reducci\u00f3n de costes para el sistema sanitario.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1025. CONCILIACI\u00d3N DEL TRATAMIENTO DOMICILIARIO AL INGRESO \u00bfQU\u00c9 OPINAN LOS PROFESIONALES \nDE ENFERMER\u00cdA? \nAUTORES\nAMORES DEL REY , L; S\u00c1NCHEZ CADENA, A; PALACIOS MOYA, E; RODR\u00cdGUEZ MART\u00cdNEZ, M\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nEvaluar la importancia asignada a la conciliaci\u00f3n de la medicaci\u00f3n domiciliaria al ingreso por parte de los profesionales de \nenfermer\u00eda, as\u00ed como las tareas desempe\u00f1adas por los mismos en esta \u00e1rea, con el objetivo final de implantar acciones de \nmejora en los circuitos ya establecidos.98MATERIALES Y M\u00c9TODOS\nDise\u00f1o de un formulario online an\u00f3nimo y voluntario con Google distribuido al personal de enfermer\u00eda de planta de \nhospitalizaci\u00f3n en los meses de abril y mayo de 2022 en un hospital de tercer nivel.  \nDicho formulario consta de 10 preguntas, 7 de ellas con respuesta m\u00faltiple (nunca, a veces, siempre), 1 con escala \nnum\u00e9rica (0-5) y 2 con respuesta dicot\u00f3mica (si/no). El formulario recoge los siguientes \u00edtems: \u201cpregunta al paciente por \nsu medicaci\u00f3n domiciliaria\u201d, \u201cla comprueba visualmente\u201d, \u201cconfirma con paciente/cuidador la medicaci\u00f3n domiciliaria \nque debe tomar durante el ingreso\u201d, \u201crevisa interacciones medicamentosas y contraindicaciones de la medicaci\u00f3n \ndomiciliaria durante el proceso agudo\u201d, \u201ccomprueba alergias medicamentosas\u201d, \u201ccomunicaci\u00f3n entre enfermer\u00eda y \nprescriptor respecto a la conciliaci\u00f3n\u201d, \u201cimportancia asignada a la conciliaci\u00f3n\u201d, \u201cgrado de aceptaci\u00f3n de la opini\u00f3n de \nenfermer\u00eda por el facultativo especialista respecto a la conciliaci\u00f3n\u201d y \u201ccreaci\u00f3n de grupos de trabajo entre farmac\u00e9uticos \ny enfermer\u00eda\u201d.\nRESULTADOS\nLa encuesta fue cumplimentada por 65 enfermeros de distintos servicios. El 98,5% afirma preguntar por las alergias \nmedicamentosas de los pacientes, siendo esta la pregunta mejor valorada por enfermer\u00eda, seguida con un 92,3% de \naceptaci\u00f3n, la posibilidad de crear grupos de trabajo en los que farmac\u00e9uticos y enfermeros trabajen juntos para abordar \nla conciliaci\u00f3n. Los peores resultados se encontraron en el apartado de la comunicaci\u00f3n entre enfermer\u00eda y facultativo \nm\u00e9dico, solo el 30,8% la consideran buena, seguido de la aceptaci\u00f3n sobre la opini\u00f3n de enfermer\u00eda, donde el 24,6% \nconsidera que su opini\u00f3n nunca es tenida en cuenta. \nEl 67,7% de los encuestados pregunta siempre por la medicaci\u00f3n domiciliaria a los pacientes de nuevo ingreso y el \n27,7% solo a veces. Adem\u00e1s, el 58,6% siempre la comprueba visualmente mientras que el 6,2% nunca. En cuanto a las \ninteracciones farmacol\u00f3gicas, el 29,2% de los encuestados nunca las revisa y el 52,3% a veces, sin embargo, el 40,6% \nafirma comprobar siempre posibles contraindicaciones de la medicaci\u00f3n domiciliaria pautada durante el proceso agudo, \nmientras que el 21,9% nunca lo hace.  \nEn t\u00e9rminos globales, el 73,8% de los encuestados se\u00f1ala con la m\u00e1xima puntuaci\u00f3n la importancia de la conciliaci\u00f3n del \ntratamiento en pacientes ingresados\ufffd\nCONCLUSIONES\nLos resultados obtenidos nos han permitido conocer la percepci\u00f3n del personal de enfermer\u00eda, as\u00ed como su grado de \nimplicaci\u00f3n en la conciliaci\u00f3n del tratamiento domiciliario. De acuerdo con estos, podemos concluir que enfermer\u00eda es \nconsciente de la importancia que tiene la conciliaci\u00f3n del tratamiento domiciliario al ingreso, identific\u00e1ndose \u00e1reas en \nlas que nuestra aportaci\u00f3n como farmac\u00e9uticos optimizar\u00eda el proceso: evaluar las interacciones y contraindicaciones \nmedicamentosas en el proceso agudo y potenciar la comunicaci\u00f3n con los facultativos m\u00e9dicos. Por todo ello, la actividad \nde enfermer\u00eda no deber\u00eda ser excluyente con la nuestra como farmac\u00e9uticos emergiendo la posibilidad de crear grupos de \ntrabajo conjuntos para abordar la conciliaci\u00f3n del tratamiento domiciliario al ingreso.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1034. ESTUDIO DE UTILIZACI\u00d3N DE DAPAGLIFLOCINA EN INSUFICIENCIA CARD\u00cdACA CR\u00d3NICA \u00bfC\u00d3MO \nSE EST\u00c1 PRESCRIBIENDO? \nAUTORES\nSAEZ-TORRES DE VICENTE, M; LOPEZ-VI\u00d1AU LOPEZ, T; NIEVAS BA\u00d1OS, AB; MANCILLA MONTERO, E\nHOSPITAL REINA SOF\u00cdA \ufffd AV\ufffd MEN\u00c9NDEZ PIDAL, S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA\nOBJETIVOS\nEn febrero de 2022 se public\u00f3 el informe de posicionamiento terap\u00e9utico (IPT) de dapagliflocina en el tratamiento de \nla insuficiencia card\u00edaca cr\u00f3nica , en el cual recomiendan su uso en pacientes sintom\u00e1ticos con fracci\u00f3n de eyecci\u00f3n \ndel ventr\u00edculo izquierdo reducida (FEVI) \u2264 40% mal controlados, de forma que contin\u00faen sintom\u00e1ticos con grado II-III \nde la escala New York Heart Association (NYHA) pese al tratamiento con dosis estables de f\u00e1rmacos inhibidores de la \nenzima convertidora de angiotensina (IECA) o antagonistas del receptor de angiotensina (ARA-II) en combinaci\u00f3n con \nbetabloqueantes y antagonistas de los receptores de mineralocorticoides (ARM). El objetivo de este estudio fue evaluar la \nadecuaci\u00f3n de las prescripciones de dapagliflocina en IC-FEr a los criterios de uso del IPT en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio descriptivo retrospectivo de utilizaci\u00f3n de dapagliflocina en IC-FEr. Para ello se incluyeron los \npacientes en tratamiento con dapagliflocina pertenecientes al servicio de cardiolog\u00eda entre febrero y abril de 2022 con \ndiagn\u00f3stico de IC-FEr. Se utiliz\u00f3 el programa de base de datos Microstrategy\u00ae, as\u00ed como la historia cl\u00ednica informatizada \nDiraya\u00ae, para recoger los datos de edad, sexo, grado NYHA, FEVI, tratamiento previo con IECA/ARA II Y ARM\ufffd \nPosteriormente evaluamos la adecuaci\u00f3n de las condiciones de uso de dapagliflocina en nuestros pacientes respecto a las \nrecomendaciones de uso del IPT \ufffd\nRESULTADOS\nSe incluyeron 100 pacientes con una mediana de edad de 63 a\u00f1os (rango 20-88), siendo el 60% hombres. El 65% \npresentaban diagn\u00f3stico de IC NYHA II, 26% NYHA III, 8 % NYHA I y 1% NYHA IV. Del total de pacientes, la FEVI fue menor \ndel 40% en el 84%, un 2% no hab\u00eda recibido tratamiento previo con IECA/ARA II, y un 9% no hab\u00eda recibido tratamiento \ncon ARM. Se encontr\u00f3 que en un 4% de los pacientes la dapagliflocina no fue prescrita como tercer escal\u00f3n al ser \nprescrita de forma simult\u00e1nea con un ARM. El 68% de pacientes estaba en tratamiento concomitante de dapagliflocina \ncon sacubitrilo/valsartan. Con estos datos se observ\u00f3 que un 21% de las prescripciones no se adecuaba a los criterios de \nuso del IPT en cuanto a FEVI y tratamiento previo con IECA/ARA II y ARM\ufffd99CONCLUSIONES\nDe nuestro estudio se concluye que la mayor\u00eda de pacientes cumplieron las recomendaciones de uso de dapagliflocina \nseg\u00fan el IPT. No obstante, en m\u00e1s de la mitad de los pacientes dapagliflocina se emple\u00f3 de forma concomitante con \nsacubitrilo-valsart\u00e1n. Actualmente la eficacia de esta combinaci\u00f3n es limitada y supone un alto impacto presupuestario, \npor lo que el IPT no recomienda su empleo de forma generalizada. Consideramos necesario la realizaci\u00f3n de futuros \nestudios que eval\u00faen la adecuaci\u00f3n de esta terapia combinada en nuestro grupo de pacientes, que ha resultado ser \nmayor de lo esperado\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1088. CARACTER\u00cdSTICAS Y VACUNACI\u00d3N DE LOS PACIENTES COVID-19 INMUNOCOMPETENTES VERSUS \nINMUNODEPRIMIDOS EN UN HOSPITAL TERCIARIO \nAUTORES\nDROZDZ VERGARA, A; S\u00c1NCHEZ SERRANO, JL; ORTIZ NAVARRO, MR; SERNA SERRANO, B; DEL POZO CARLAVILLA, C; \nCOLLADO SANZ, JM; TEBAR MART\u00cdNEZ, E; ALABORT AYLL\u00d3N, H\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE ALBACETE. HERMANOS FALC\u00d3, S/N. ALBACETE. ALBACETE\nOBJETIVOS\nLa estrategia de vacunaci\u00f3n nacional recomienda administrar dosis de recuerdo (DR) a los 5 meses tras la pauta completa \nde primovacunaci\u00f3n (PCP). En pacientes inmunodeprimidos (PIMD) la PCP se define como: dos dosis m\u00e1s una dosis \nadicional (DA). Nuestro objetivo es analizar y conocer las caracter\u00edsticas y vacunaci\u00f3n frente a COVID-19 de los pacientes \ninmunocompetentes (PIMC) versus PIMD ingresados en un hospital de tercer nivel durante la sexta ola por SARS-CoV-2.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y transversal. Se incluyeron los pacientes adultos ingresados el 10/01/2022 con \ndiagn\u00f3stico confirmado por PCR-SARS-CoV-2. Se dividieron en dos grupos: PIMC y PIMD. Las variables analizadas \nfueron: sexo, edad, d\u00edas de ingreso (DI), DI en la Unidad de Cuidados Intensivos (UCI), comorbilidades/condiciones de \ninmunosupresi\u00f3n, PCP , dosis de recuerdo (DR) en PIMC (a fecha del estudio no hab\u00edan transcurrido 5 meses desde la \ninmunizaci\u00f3n con DA en PIMD) y mortalidad. Los datos se obtuvieron de la historia cl\u00ednica digitalizada. Las variables \ncuantitativas se expresaron en mediana (rango intercuartil) y las cualitativas en valor absoluto (relativo).\nRESULTADOS\nSe incluyeron un total de 81 pacientes: 55 PIMC (67,9%), 68 a\u00f1os (58-80), 18 (32,7%) mujeres y 26 PIMD (32,1%), 78 a\u00f1os \n(65-83), 10 (38%) mujeres. \nLos PIMC presentaron una mediana de 15 DI (10-22). El 36,4% requiri\u00f3 ingreso en UCI. Comorbilidades: hipertensi\u00f3n \nn=29 (52,7%), seguida de diabetes n=20 (36,4%) y obesidad n=17 (30,9%). PCP n=35 (63,6%): n=6 (17,1%) < 60 a\u00f1os, \nn=21 (60%) 60-80 a\u00f1os, n=8 (22,9%) > 80 a\u00f1os; n=10 (28,6%) mujer es. No vacunados n=16 (29,1%): n=8 (50%) < 60 a\u00f1os, \nn=6 (37,5%) 60-80 a\u00f1os y n=2 (12,5%) > 80 a\u00f1os. DR n=13 (23,6%): n=1 (7,7%) < 60 a\u00f1os, n=6 (46,1%) 60-80 a\u00f1os y n=6 \n(46.1%) > 80 a\u00f1os. Mortalidad n=6 (10,9%): n=2 (33,3%) 60-80 a\u00f1os y n=4 (66,6%) > 80 a\u00f1os.  \nLos P\u00ccMD presentaron una mediana de 12 DI (7-23). El 19,2% requiri\u00f3 ingreso en UCI. Principales condiciones de \ninmunosupresi\u00f3n: enfermedad oncohematol\u00f3gica en los \u00faltimos 5 a\u00f1os n=9 (34,6%) y tratamiento activo con \ninmunosupresores/corticoides a dosis altas n=6 (23,1%). PCP n=15 (57,7%): n=2 (13,3%) < 60 a\u00f1os, n=5 (33,3%) 60-80 \na\u00f1os, n=8 (53,3%) > 80 a\u00f1os; n=7 (46,7%) mujeres. No vacunados: n=1 (3,8%) 60-80. Mortalidad n=6 (23,1%): n=1 (16,7%) \n60-80 a\u00f1os y n=5 (83,3%) > 80 a\u00f1os.\nCONCLUSIONES\nLos pacientes inmunocompetentes mostraron un mayor porcentaje de PCP , posiblemente por la DA que forma parte de \nla pauta completa en inmucomprometidos. Los inmunocompetentes presentaron un 29,1% de no vacunados frente al \n3,8% de los inmunodeprimidos. No obstante, estos \u00faltimos mostraron una mortalidad superior, siendo el grupo de edad \nmayoritario el de > 80 a\u00f1os en ambos casos.  \nLa poblaci\u00f3n inmunodeprimida con m\u00e1s de 80 a\u00f1os es la m\u00e1s vulnerable a la COVID-19 por una mayor p\u00e9rdida de la \nprotecci\u00f3n con el tiempo. Por tanto, ser\u00eda candidata a una inmunizaci\u00f3n de recuerdo m\u00e1s frecuente. No obstante, es \nnecesaria la realizaci\u00f3n de m\u00e1s estudios para confirmar dicha afirmaci\u00f3n.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1126. AN\u00c1LISIS DEL FALLO DE TRATAMIENTO A MEPOLIZUMAB O BENRALIZUMAB EN PACIENTES CON \nASMA GRAVE \nAUTORES\nNAVARRETE-ROUCO , ME; AUSIN , P; CARBALLO , N\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nMepolizumab y benralizumab se unen de forma espec\u00edfica a la IL5 o al receptor IL5 respectivamente, y ambos tienen \nindicaci\u00f3n en pacientes con asma grave no controlada (AGNC). Sin embargo, un porcentaje de estos pacientes no \nresponde al tratamiento\ufffd  \nEvaluar el porcentaje de pacientes con fallo de tratamiento a mepolizumab y benralizumab y describir las decisiones \nterap\u00e9uticas tomadas tras el fallo.100MATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital de tercer nivel durante el periodo 2017-2022. Se incluy\u00f3 a \ntodos los pacientes con AGNC tratados con mepolizumab o benralizumab.  \nSe registraron los pacientes con suspensi\u00f3n de tratamiento y los motivos de esta suspensi\u00f3n: efectos adversos, falta de \nadherencia, embarazo, exitus o inefectividad.  \nSe analiz\u00f3 espec\u00edficamente los pacientes que suspendieron el f\u00e1rmaco por inefectividad, entendi\u00e9ndose por inefectividad: \nno mejor\u00eda de ACT en mas de 4 puntos y/o no disminuci\u00f3n de exacerbaciones en al menos 50% a los 6 meses de \ntratamiento\ufffd  \nDatos recogidos (basales y en el momento de la suspensi\u00f3n): duraci\u00f3n de tratamiento (DT), FEV1, crisis ( > 2 crisis en a\u00f1o \nprevio), necesidad de corticoides sist\u00e9micos (CS), Asthma control test (ACT) y eosinofilia.  \nSe realiz\u00f3 un an\u00e1lisis estad\u00edstico descriptivo. Variables categ\u00f3ricas: frecuencia (%), y variables cuantitativas: media (\u00b1 \ndesviaci\u00f3n est\u00e1ndar).\nRESULTADOS\nEl n\u00famero total de pacientes que recibieron mepolizumab fue 26(46%) y benralizumab 30(54%).  \nMepolizumab: suspendieron el tratamiento 11(42%). Los motivos fueron: falta de adherencia 2(8%), embarazo 1(4%), \ne inefectividad 8(31%). De estos 8 pacientes, la DT fue 14,3(\u00b112,7) meses. Estado basal: FEV1 50(\u00b120)%, crisis8(100%) \npacientes, CS 6(75%) pacientes, ACT 12(\u00b18) y eosinofilia 641(\u00b1230)ucL. En el momento de la suspensi\u00f3n: FEV1 53(\u00b16) \n%, crisis y CS igual al basal, ACT 13(\u00b15) y eosinofilia 121(\u00b1221)ucL. Se decidi\u00f3 cambio a benralizumab en 5(63%) y \na dupilumab en 3(37%) pacientes. Dos de los pacientes en tratamiento con benralizumab no respondieron a este \ntratamiento y se decidi\u00f3 cambio a dupilumab\ufffd  \nBenralizumab: suspendieron el tratamiento 10(33%). Los motivos fueron: efecto adverso 2(7%), falta de adherencia \n1(3%), embarazo 1(3%), exitus 1(3%) e inefectividad 5(17%). De estos 5 pacientes, la DT fue 7,2(\u00b13,5) meses. Estado basal: \nFEV1 54(\u00b118)%, crisis ( > 2 crisis a\u00f1o previo) 4(80%) pacientes, CS 3(60%) pacientes, ACT 11(\u00b16) y eosinofilia 740(\u00b1172)\nucL. En el momento de la suspensi\u00f3n: FEV1 53(\u00b117) %, crisis y CS igual al basal, ACT 15(\u00b14) y eosinofilia 30(\u00b167)ucL. Se \ndecidi\u00f3 cambio a mepolizumab en 1(20%) y a dupilumab en 4 (80%) pacientes. Al final del estudio, todos los pacientes \ncontinuaron en la misma situaci\u00f3n.\nCONCLUSIONES\nEl tratamiento biol\u00f3gico no es efectivo en todos los pacientes con asma grave pero afortunadamente tenemos diferentes \ntratamientos con distintas dianas terap\u00e9uticas. Una evaluaci\u00f3n cl\u00ednica es imprescindible para decidir la continuaci\u00f3n, \ncambio de biol\u00f3gico o cese de tratamiento\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1127. INFLUENCIA DE LA COVID EN ENFERMOS MENTALES. \nAUTORES\nGONZALEZ PRIETO, MDP\nHH. HH. SGDO. C. DE JES\u00daS. COMPLEJO ASISTENCIAL BENITO MENNI. JARDINES, 1 CIEMPOZUELOS. MADRID\nOBJETIVOS\nDeterminar los cambios en la carga antipsic\u00f3tica en pacientes psiqui\u00e1tricos que han sufrido el Covid -19.\nMATERIALES Y M\u00c9TODOS\nAunque se habla de enfermedad mental como consecuencia de sufrir la covid-19 o durante su recuperaci\u00f3n, hay pocos \nestudios de las consecuencias de esta enfermedad en enfermos mentales. Considerando la carga antipsic\u00f3tica como el \nindicador de la psicosis y sus cambios como la evoluci\u00f3n en la enfermedad se desarrolla el presente trabajo.  \nSe selecciona un grupo de pacientes con enfermedad mental grave, ingresados a 1 de abril 2022 en un hospital \npsiqui\u00e1trico, que han sufrido la covid-19, y que permanezcan ingresados desde el 2019.  \nSon un total de 78, de los que 89% son mujeres y el 11% hombres. M\u00e1s de la mitad, 39, padecen esquizofrenia, el resto \nson otras enfermedades mentales graves\ufffd \nEl rango de edad est\u00e1 entre 59 y 95 a\u00f1os. El 50% son pacientes mayores de 75 a\u00f1os, y solo el 23% son menores de 70 \na\u00f1os\ufffd  \nSe realiza un corte trasversal de los tratamientos, a 1 de abril, de los a\u00f1os 2019-2020-2021 y 2022. Se calcula la dosis \ndiaria de los medicamentos antipsic\u00f3ticos, N05A, seg\u00fan la clasificaci\u00f3n anat\u00f3mica de medicamentos (ATC).  \nLas dosis diarias se pasan a dosis equivalentes de olanzapina, seg\u00fan el Consenso internacional de expertos sobre dosis \nde antipsic\u00f3ticos y sus equivalencias (Am J Psychiatry 2010), Se calcula el sumatorio de las dosis de antipsic\u00f3tico (carga \nantipsic\u00f3tica) a 1 de abril de los a\u00f1os estudiados.  \nLos sumatorios de las cargas antipsic\u00f3ticas de cada a\u00f1o, variables independientes, se analizan por SPSS para buscar \nrepresi\u00f3n lineal y correlaciones, siendo la variable dependiente la carga antipsic\u00f3tica en 2022.\nRESULTADOS\nEl modelo indica que hay regresi\u00f3n lineal de la variable dependiente, carga antipsic\u00f3tica del 2022, de un 84% con las \ncargas antipsic\u00f3ticas de los a\u00f1os 2021,2020, 2019. Por tanto, la carga antipsic\u00f3tica no se ve influenciada por haber sufrido \nla enfermedad, por la situaci\u00f3n de confinamiento y las restricciones en los tres \u00faltimos a\u00f1os.  \nEn las correlaciones, la edad correlaciona negativamente con la carga antipsic\u00f3tica, lo que implica una relaci\u00f3n indirecta. \nLas correlaciones entre las variables carga antipsic\u00f3tica en los diferentes a\u00f1os con edad son superiores a 0,7.101CONCLUSIONES\nEl an\u00e1lisis estad\u00edstico de la prescripci\u00f3n de antipsic\u00f3ticos avala la situaci\u00f3n de linealidad que en general hemos tenido \ndurante la pandemia en nuestro centro\ufffd  \nLa percepci\u00f3n de normalidad, salvo por la indumentaria EPI, en la atenci\u00f3n sanitaria de nuestros pacientes, ha sido \nconstante durante los tres \u00faltimos a\u00f1os. Si bien el estudio podr\u00eda tener importantes sesgos como la edad y/o otras \ncomorbilidades, el haber sufrido la enfermedad covid-19 no ha supuesto un empeoramiento de los estados psic\u00f3ticos de \nnuestros pacientes\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1128. ESTUDIO SOBRE LA ADECUACI\u00d3N DEL TRATAMIENTO ANALG\u00c9SICO EN ANCIANOS \nINSTITUCIONALIZADOS \nAUTORES\nROCHINA ASTORGA, A; ESPERT ROIG, M; IB\u00c1\u00d1EZ CARRILLO, M; GUTI\u00c9RREZ PALOMO, S; GONZ\u00c1LEZ FERN\u00c1NDEZ, A; \nNAVARRO RUIZ, A\nHOSPITAL GENERAL DE ELCHE \ufffd CAM\u00cd DE L\u00b4AMAZARA, 11 ELCHE/ELX \ufffd ALICANTE\nOBJETIVOS\nValorar el grado de adecuaci\u00f3n de la prescripci\u00f3n de analg\u00e9sicos en ancianos institucionalizados seg\u00fan las \nrecomendaciones de la Gu\u00eda de Buena Pr\u00e1ctica Cl\u00ednica para el tratamiento del dolor cr\u00f3nico en el anciano, como fase \ninicial para el desarrollo de un programa de mejora de la calidad de la analgesia cr\u00f3nica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en pacientes ancianos institucionalizados en un centro sociosanitario entre enero de \n2021 y abril de 2022 que tengan registrada al menos una valoraci\u00f3n del dolor. Se recogieron los siguientes datos: sexo, \nedad, IMC, pauta analg\u00e9sica basal y de rescate y f\u00e1rmacos coadyuvantes (principio activo, dosis, frecuencia). Para medir \nel dolor se utilizaron: la Escala Visual Anal\u00f3gica (EVA) y la Paint Assessment in Advanced Dementia (PAINAD). Se defini\u00f3 \nausencia de dolor o dolor leve las puntuaciones de 0-2, dolor moderado de 3-7 y dolor severo de 8-10. \nLa adecuaci\u00f3n a las recomendaciones se determin\u00f3 de acuerdo a las siguientes condiciones: indicaci\u00f3n de analg\u00e9sicos no \nopioides \u00b1 coadyuvantes para dolor leve, indicaci\u00f3n de analg\u00e9sicos no opioides \u00b1 opioides d\u00e9biles \u00b1 coadyuvantes para \ndolor moderado e indicaci\u00f3n de analg\u00e9sicos no opioides \u00b1 opioides mayores \u00b1 coadyuvantes para dolor severo.\nRESULTADOS\nSe incluyeron 81 pacientes, el 72,8% mujeres, con una media de edad de 80,9 \u00b1 10,6 a\u00f1os y un IMC de 26,5 \u00b1 6,5 m2.  \nSeg\u00fan la valoraci\u00f3n del dolor:  \n- 63 (77,8%) pacientes presentaban dolor leve, 22 con tratamiento farmacol\u00f3gico basal (54% paracetamol, 9% metamizol, \n22% opioides y 59% coadyuvantes) y 8 con pauta de rescate (75% paracetamol).  \n- 14 (17,3%) pacientes presentaban dolor moderado, 10 con tratamiento farmacol\u00f3gico basal (50% paracetamol, 10% \nAINEs, 10% metamizol, 50% opioides, 30% coadyuvantes) y 5 con pauta de rescate (60% metamizol).  \n- 4 (4,9%) pacientes presentaban dolor severo, 2 con tratamiento farmacol\u00f3gico basal (50% paracetamol, 50% opioides y \n30% coadyuvantes) y 1 con pauta de rescate con fentanilo sublingual.  \nSeg\u00fan los resultados de las escala EVA/PAINAD, la prescripci\u00f3n fue inadecuada en el 31,8% de los pacientes con dolor leve \ndebido al uso innecesario de opioides y en el 40,9% debido al uso de pauta basal en lugar de rescate\ufffd En los pacientes con \ndolor moderado, la prescripci\u00f3n fue inadecuada en el 20% de los casos debido al uso no indicado de opioides mayores y \nen el 35,7% debido a falta de tratamiento analg\u00e9sico. El 50% de los pacientes con dolor severo no ten\u00eda prescrito ning\u00fan \ntratamiento analg\u00e9sico. Del 50% restante, la mitad estaba en tratamiento \u00fanicamente con analg\u00e9sicos no opioides.\nCONCLUSIONES\nEl grado de adecuaci\u00f3n de la prescripci\u00f3n de analg\u00e9sicos fue superior al 55% en los pacientes con dolor leve o moderado. \nSin embargo, este valor se reduce en el caso de pacientes con dolor severo\ufffd Es fundamental tener un seguimiento \nde la evoluci\u00f3n del dolor en los pacientes institucionalizados en centros sociosanitarios para instaurar una pauta \nindividualizada y reducir as\u00ed las consecuencias cl\u00ednicas y sociales del inadecuado control del dolor y los posibles efectos \nadversos de las terapias utilizadas.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1167. PATR\u00d3N DEL USO DE DIUR\u00c9TICOS EN INSUFICIENCIA CARD\u00cdACA AVANZADA EN HOSPITAL DE D\u00cdA \nDE PACIENTE CR\u00d3NICO COMPLEJO Y FR\u00c1GIL \nAUTORES\nORTONOBES ROIG, S; HERRANZ MART\u00cdNEZ, S; BRAVO CA\u00d1AS, G; SOLER-BLANCO , N; MORENO-ARI\u00d1O , M; SANTOS \nL\u00d3PEZ, S; COMET MONTE, R; G\u00d3MEZ-VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\n- Describir los pacientes con insuficiencia cardiaca avanzada (ICA).  \n- Analizar el perfil de pacientes con ICA seg\u00fan respuesta y variaci\u00f3n en la prescripci\u00f3n de diur\u00e9ticos.102MATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en Hospital de D\u00eda de Paciente Cr\u00f3nico Complejo y Fr\u00e1gil (HDPCC-Fr\u00e1gil). \nEl HDPCC-Fr\u00e1gil est\u00e1 integrado por un equipo multidisciplinar de m\u00e9dicos, farmac\u00e9uticas y enfermeras. Se incluyeron \npacientes con ICA y su seguimiento hasta fecha del estudio. Variables registradas: sociodemogr\u00e1ficas, comorbilidades, \npar\u00e1metros anal\u00edticos, diur\u00e9ticos prescritos. Variables cuantitativas expresadas como mediana (rango intercuartil); \nvariables cualitativas como valor relativo. Comparaciones variables cuantitativas con prueba de Mann-Whitney-Wilcoxon; \ntest Chi-cuadrado para cualitativas.\nRESULTADOS\nSe incluyeron 54 pacientes, edad 88 (83-89) a\u00f1os y 64,8% mujeres. Comorbilidades principales: hipertensi\u00f3n 92,6%, \nfibrilaci\u00f3n auricular 75,9%, hipertensi\u00f3n pulmonar 55,6%, diabetes 46,3% y dislipemia 42,6%. Ausencia de cuidador \n53,7%. Fracci\u00f3n eyecci\u00f3n ventricular izquierda (FEVI) 60% (48-65%), ferropenia 63,0%, ingresos previos HDPCC-Fr\u00e1gil 1 \n(1-2). Mortalidad 11,1%.  \nPeso inicial 71,1 (58,9-83,0) kg. Anal\u00edtica inicial: NT-proBNP 4290 (1385-7675) pg/mL; filtrado glomerular (FG) 35,2 (27,3-\n52,2) ml/min; natremia 140 (139-142) mEq/L; potasemia 4,2 (3,9-4,6) mEq/L. Prescripci\u00f3n de diur\u00e9ticos iniciales [% de \npacientes; dosis (mg)]: furosemida [85,2%; 100 (80-120)], torasemida [9,3%; 40 (25-40)], hidroclorotiazida [24,1%; 12,5 \n(12,5-25)], espironolactona/eplerenona [35,2%; 25 (25-25)], empaglifozina [11,1%; 10 (10-10)], dapaglifozina [1,9%; 10 \n(10-10)], acetazolamida [1,9%; 250 (250-250)]. N\u00famero de diur\u00e9ticos iniciales prescritos/paciente 2 (1-2). Seguimiento: \n127,5 (69,0-199,5) d\u00edas.  \nPeso post-seguimiento 65,8 (56,5-82,0) kg. Anal\u00edtica post-seguimiento: NT-proBNP 3048 (1255-5863); FG 35,0 (23,2-\n42,5); natremia 140 (137-141); potasemia 4,3 (4,0-4,6). Prescripci\u00f3n de diur\u00e9ticos post-seguimiento [% de pacientes; \ndosis]: furosemida [70,4%; 100 (80-120)], torasemida [27,8%; 30 (30-40)], hidroclorotiazida [37,0%; 12,5 (12,5-25)], \nespironolactona/eplerenona [33,3%; 25 (25-25)], empaglifozina [18,5%; 10 (10-10)], dapaglifozina [5,6%; 10 (10-10)], \nacetazolamida [ninguna]. N\u00famero de diur\u00e9ticos post-seguimiento prescritos/paciente 2 (1-2). En post-seguimiento: \nel 94,7% de pautas con furosemida y el 66,7% con espironolactona/eplerenona eran de mantenimiento; mientras \nque el 66,7% de torasemida, el 55,0% de hidroclorotiazida y el 53,9% de empaglifozina/dapaglifozina eran nuevas \nprescripciones\ufffd  \nSe agruparon los pacientes en funci\u00f3n del peso final respecto del inicial: p\u00e9rdida \u2264 1kg (26, 48,1%) vs p\u00e9rdida > 1kg (28, \n51,9%). S\u00f3lo se encontraron diferencias significativas en: ausencia de cuidador 69,2% vs 39,3% (p=0,03); ferropenia 50,0% \nvs 75,0% (p=0,05); ingresos previos HDPCC-Fr\u00e1gil 2 (1-3) vs 1 (0-1) (p=0,02); peso inicial 61,0 (50,7-73,6) vs 74,4 (65,0-\n91,0) (p < 0,01); potasemia inicial 4,2 (3,9-4,5) vs 4,5 (4,0-4,9) (p=0,05); prescripci\u00f3n espironolactona/eplerenona inicial \n19,2% vs 50,0% (p=0,02); n\u00famero de diur\u00e9ticos post-seguimiento 1,5 (1-2) vs 2 (2-2,5) (p=0,04).\nCONCLUSIONES\n- La mayoria de los pacientes con ICA en seguimiento en HDPCC-Fr\u00e1gil son mujeres a\u00f1osas, con muchas comorbilidades y \ncon FEVI preservada\ufffd  \n- Los pacientes con mayor p\u00e9rdida de peso part\u00edan de mayor peso inicial, indicando un estado de congesti\u00f3n mayor. Por \nello, requirieron de un n\u00famero mayor de diur\u00e9ticos. Paralelamente, este grupo de pacientes presenta mayor ferropenia, \nm\u00e1s ingresos previos y ausencia de cuidador, factores de mala evoluci\u00f3n de ICA. \n- Se observ\u00f3 un cambio en el patr\u00f3n de diur\u00e9ticos, aumentando prescripciones de torasemida, hidroclorotiazida y \nempaglifozina/dapaglifozina a expensas de furosemida y espironolactona/eplerenona; aunque el tipo de diur\u00e9ticos no \ncausa diferencias en mejorar la congesti\u00f3n cardiaca.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1239. EVALUACI\u00d3N DE LA PERSISTENCIA DE F\u00c1RMACOS UTILIZADOS EN PRIMERA LINEA EN ESCLEROSIS \nM\u00daLTIPLE \nAUTORES\nMART\u00cdNEZ SOTO, AM; GARCIA CORONEL, M; ORTIZ FERN\u00c1NDEZ, P; PASTOR MONDEJAR, C; FERN\u00c1NDEZ-VILLACA\u00d1AS \nFERN\u00c1NDEZ, P; CABALLERO REQUEJO, C; ONTENIENTE CANDELA, M; URBIETA SANZ, E\nHOSPITAL GENERAL UNIVERSITARIO REINA SOFIA. AV . INTENDENTE JORGE PALACIOS, 1 MURCIA. MURCIA\nOBJETIVOS\nAnte la dificultad de medir resultados en salud de los tratamientos modificadores de la enfermedad (TME), la persistencia \nde los mismos podr\u00eda representar una buena medida indirecta. \nEl objetivo del presente estudio fue evaluar la persistencia del tratamiento de algunos de los f\u00e1rmacos empleados en el \ntratamiento de primera l\u00ednea de la esclerosis m\u00faltiple (EM).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo, desarrollado en un hospital de referencia de \u00e1rea en el periodo comprendido entre \njunio de 2007 y mayo de 2022. Se incluyeron pacientes con diagn\u00f3stico de EM en tratamiento activo con acetato de \nglatir\u00e1mero(AG), Teriflunomida y dimetilfumarato en el a\u00f1o 2017.  \nMediante el programa de gesti\u00f3n del Servicio de Farmacia, SAVAC\u00ae y la historia cl\u00ednica informatizada (Selene\u00ae), se \nobtuvieron variables demogr\u00e1ficas (edad y sexo), cl\u00ednicas (diagn\u00f3stico) y relacionadas con la farmacoterapia (fecha de \ninicio y fin de tratamiento en caso de suspensi\u00f3n)  \nLas variables categ\u00f3ricas se presentaron como n\u00fameros absolutos y porcentajes, mientras que las variables continuas se \nexpresaron como valores medios o medianas, junto con medidas de variabilidad expresadas como desviaci\u00f3n est\u00e1ndar \n(DE) o rango intercuart\u00edlico (IQR).  103Se utiliz\u00f3 el estimador de Kaplan-Meier para generar curvas de supervivencia global de AG, teriflunomida y \ndimetilfumarato. Se us\u00f3 la prueba de Long Rank para comparar las curvas de supervivencia de los distintos f\u00e1rmacos.  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 con el programa SPSS para paquete de Windows (versi\u00f3n 23.0; SPSS Inc., Chicago, IL, \nEE.UU).\nRESULTADOS\nSe incluyeron 104 pacientes, de los cuales el 66,3% eran mujeres. La edad media fue de 43,6 a\u00f1os (DE: 9,6). El 25% \nestaba en tratamiento con dimetilfumarato, 42,3% con AG y el 32,7% con teriflunomida. En el 50% de los casos estos \ntratamientos fueron empleados como primera l\u00ednea.  \nLa media de persistencia del tratamiento en meses fue 26.65 (DE: 3.22).  \nDurante el periodo de seguimiento suspendieron el tratamiento el 50% de los pacientes en tratamiento con AG, el 38,5% \nde los pacientes con dimetilfumarato y el 52,9% de los pacientes en tratamiento con teriflunomida. Siendo la mediana del \ntiempo de supervivencia para AG de 75,5 (IC95%: 25,5 - 125,4) meses, para teriflunomida la mediana de supervivencia \nfue 44,7 (IC95%: 23,4 - 65,9) meses, no pudi\u00e9ndose determinar la mediana para dimetilfumarato por no alcanzar el 50% \nde los eventos, siendo la media para este 90,837(73,3 -108,3) meses. No se encontraron diferencias significativas entre la \npersistencia de los f\u00e1rmacos analizados (p = 0,258).\nCONCLUSIONES\nNo se encontraron diferencias en t\u00e9rminos de persistencia del tratamiento entre los distintos f\u00e1rmacos analizados \npudiendo concluir que la supervivencia del tratamiento para \u00e9stos es similar. Ser\u00eda necesario ampliar el tiempo de \nseguimiento para alcanzar la mediana de persistencia para dimetilfumarato.  \nNuestro estudio presenta limitaciones, por lo que ser\u00edan necesarios estudios prospectivos en vida real.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1262. AN\u00c1LISIS DE USO Y DOSIS EMPLEADAS DE ANTIPSIC\u00d3TICOS EN PERSONAS MAYORES \nINSTITUCIONALIZADAS EN CENTROS RESIDENCIALES. \nAUTORES\nS\u00c1EZ RODR\u00cdGUEZ, MI; FERRO URIGEN, A; MIRANDA MAGA\u00d1A, M; SALAMANCA CASADO, A; TORTAJADA GOITIA, B\nCOMPLEJO HOSPITAL COSTA DEL SOL. CRTRA NACIONAL 340, KM. 187 MARBELLA. MALAGA\nOBJETIVOS\nAnalizar la prescripci\u00f3n de antipsic\u00f3ticos en personas mayores que viven en centros residenciales, comparar las dosis \nequipotentes de los f\u00e1rmacos m\u00e1s empleados y su ajuste a las dosis m\u00e1ximas recomendadas.\nMATERIALES Y M\u00c9TODOS\nEstudio transversal multic\u00e9ntrico realizado en unidades gerontol\u00f3gicas (UG) y unidades psicogeri\u00e1tricas (UPSI) de 7 \ncentros residenciales, en marzo de 2020. Se estudi\u00f3 la prevalencia de uso de antipsic\u00f3ticos, los diferentes f\u00e1rmacos \nempleados y las dosis utilizadas para los dos f\u00e1rmacos m\u00e1s prescritos: quetiapina y risperidona.  \n \nSe llev\u00f3 a cabo una comparaci\u00f3n entre las dosis empleadas de risperidona y quetiapina, utilizando la dosis equivalente \ndescrita en la bibliograf\u00eda (1mg= 75mg quetiapina) (Woods S. Chlorpromazine equivalent doses for the newer atypical \nantipsychotics. J Clin Psychiatry. 2003;64:663\u20137). Para el an\u00e1lisis comparativo entre las dosis equivalentes medias de \nquetiapina y risperidona se emple\u00f3 la t\u00e9cnica de t-student (significaci\u00f3n estad\u00edstica: p < 0,05). \n \nPor otra parte se determinaron las dosis m\u00e1ximas recomendadas para tratar s\u00edntomas psicoconductuales asociados a \nla demencia: 2 mg/d\u00eda de risperidona y 150 mg-350mg/d\u00eda de quetiapina (se estudiaron ambos puntos de corte por \ndiferencias en la bibliograf\u00eda); y se estudi\u00f3 el grado de adecuaci\u00f3n de las prescripciones a estas dosis.\nRESULTADOS\nSe incluyeron en el estudio 674 pacientes, 511 (75,8%) ingresados en UG.  \n \nLa prevalencia de uso de antipsic\u00f3ticos fue de 287 prescripciones (42,58%), con la siguiente distribuci\u00f3n de principios \nactivos (n\u00ba de prescripciones en UG (%), n\u00ba de prescripciones en UPSI (%), total (%): \n \n\u2022 Quetiapina: 81 (15,9%) 73 (44,8%) 154 (22,8%)  \n\u2022 Risperidona: 36 (7%) 32 (19,6%) 68 (10,1%) \n\u2022 Olanzapina: 11 (2,2%) 16 (9,8%) 27 (4%)  \n\u2022 Clozapina: 6 (1,2%) 5 (3%) 11 (1,6%) \n\u2022 Aripiprazol: 9 (1,8%) 1 (0,6%) 10 (1,4%)  \n\u2022 Haloperidol: 6 (1,2%) 0 6 (0,8%)  \n\u2022 Levomepromazina: 3 (0,6%) 0 3 (0,4%)  \n\u2022 Paliperidona: 2 (0,4%) 0 2 (0,3%)  \n\u2022 Sulpirida: 1 (0,2%) 1 (0,6%) 2 (0,3%)  \n\u2022 Asenapina: 2 (0,4%) 0 2 (0,3%)  \n\u2022 Zuclopentixol: 1 (0,2%) 0 1 (0,1%)  \n\u2022 Tiaprida: 1 (0,2%) 0 1 (0,1%) \n 104Las dosis empleadas, expresadas en dosis equivalente de risperidona, fueron 1,25 mg/d para risperidona y 2,41 mg/d \npara quetiapina, observ\u00e1ndose una diferencia medias de 1,16mg (\u00b10,61; p < 0,05).  \n \nRespecto al grado de ajuste de las dosis a las dosis m\u00e1xima, se detectaron 6 prescripciones de risperidona (8,8%) con una \ndosis \u2265 2mg/d, 5 de ellas en UPSI. En cuanto a la quetiapina, 23 pacientes (15 de ellos en UPSI) recib\u00edan una dosis entre \n150-300 mg/d de quetiapina; y 12 pacientes (la mitad de ellos en UPSI) superaban una dosis diaria de 300mg.\nCONCLUSIONES\nEn este estudi\u00f3 se ha podido constatar una alta prevalencia de uso de antipsic\u00f3ticos, y de manera especial en las UPSI, \nsiendo el f\u00e1rmaco m\u00e1s empleado en ambas unidades la quetiapina seguido de la risperidona.  \n \nLas dosis equivalentes de quetiapina resultaron ser superiores a las de risperidona, asimismo, los pacientes tratados \ncon risperidona se ajustaron en mayor medida al rango terap\u00e9utico recomendado. Este hecho puede estar ligado a las \ndiferencias en el mecanismo de acci\u00f3n de ambos f\u00e1rmacos, y a la aparici\u00f3n de reacciones adversas que pueda ser en \nmuchos casos el limitante de aumento de dosis mayores.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1291. EVALUACI\u00d3N DE LA PERSISTENCIA DE TRATAMIENTOS DE PRIMERA LINEA DE ESCLEROSIS \nMULTIPLE: COMPARACI\u00d3N CON EL EDSS BASAL DEL PACIENTE \nAUTORES\nMART\u00cdNEZ SOTO, AM; GARCIA CORONEL, M; ORTIZ FERN\u00c1NDEZ, P; FERN\u00c1NDEZ-VALLACA\u00d1AS FERN\u00c1NDEZ, P; \nPASTOR MONDEJAR, C; CABALLERO REQUEJO, C; ONTENIENTE CANDELA, M; URBIETA SANZ, E\nHOSPITAL GENERAL UNIVERSITARIO REINA SOFIA. AV . INTENDENTE JORGE PALACIOS, 1 MURCIA. MURCIA\nOBJETIVOS\nEl objetivo del presente estudio fue evaluar la persistencia del tratamiento con f\u00e1rmacos de primera l\u00ednea en esclerosis \nm\u00faltiple (EM) y evaluar si exist\u00eda relaci\u00f3n entre \u00e9sta y el EDSS que presentaron los pacientes al inicio de tratamiento.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo, desarrollado en un hospital de referencia de \u00e1rea en el periodo comprendido entre \njunio de 2007 y mayo de 2022. Se incluyeron pacientes con diagn\u00f3stico de EM en tratamiento activo con acetato de \nglatir\u00e1mero(AG), Teriflunomida y dimetilfumarato en el a\u00f1o 2017.  \nMediante el programa de gesti\u00f3n del Servicio de Farmacia, SAVAC\u00ae y la historia cl\u00ednica informatizada (Selene\u00ae), se \nobtuvieron variables demogr\u00e1ficas (edad y sexo), cl\u00ednicas (diagn\u00f3stico) y relacionadas con la farmacoterapia (fecha de \ninicio y fin de tratamiento en caso de suspensi\u00f3n).  \nLas variables categ\u00f3ricas se presentaron como n\u00fameros absolutos y porcentajes, mientras que las variables continuas se \nexpresaron como valores medios o medianas, junto con medidas de variabilidad expresadas como desviaci\u00f3n est\u00e1ndar \n(DE) o rango intercuart\u00edlico (IQR).  \nSe utiliz\u00f3 el estimador de Kaplan-Meier para generar curvas de supervivencia global de AG y de supervivencia de AG en \nfunci\u00f3n del EDSS basal\ufffd Se us\u00f3 la prueba de Long Rank para comparar curvas de supervivencia entre los pacientes con \nEDSS basal \u22652 y < 2.\nRESULTADOS\nSe incluyeron 104 pacientes, de los cuales el 66,3% eran mujeres. La edad media fue de 43,6 a\u00f1os (DE: 9,6). El 25% \nestaba en tratamiento con dimetilfumarato, 42,3% con AG y el 32,7% con teriflunomida. En el 50% de los casos estos \ntratamientos fueron empleados como primera l\u00ednea.  \nLos TME previos fueron (AG) 19,2%, interfer\u00f3n-beta-1A 14,4%, dimetilfumarato 2,0% y teriflunomida 2,0%, interfer\u00f3n \nbeta-1B 2,0% y fingolimod 1,9% de los pacientes. \nEl 60,6% de los pacientes presentaba un EDSS < 2, siendo en el 35,7% de los pacientes \u2265 2. \nLa media para el tiempo de supervivencia del tratamiento fue 89,7(IC95%: 72,192 - 107,304).  \nDurante el periodo de seguimiento suspendieron el tratamiento el 44,0% de los pacientes con EDSS basal < 2 y el 60,7% \nde los pacientes con EDSS basal\u22652. Siendo la media del tiempo de supervivencia del tratamiento para los pacientes \ncon EDSS < 2 de 101,9(IC95%: 81,963 - 121,794) y para EDSS \u22652 la media fue 57,5 (IC95%: 37,2 - 77,9). No encontrando \ndiferencias significativas entre ambos grupos (p=0,132).\nCONCLUSIONES\nAnte la dificultad de medir resultados en salud de los tratamientos modificadores de la enfermedad (TME), la persistencia \nde los mismos podr\u00eda representar una buena medida indirecta, al igual que poder relacionar \u00e9sta con las caracter\u00edsticas o \nsituaci\u00f3n cl\u00ednica del paciente. \nEl porcentaje de pacientes que continuaron en tratamiento con los distintos f\u00e1rmacos evaluados es elevado, por lo que \npodemos concluir que se trata de f\u00e1rmacos con elevada persistencia en el tratamiento de la EM.  \nNo se encontraron diferencias en cuanto a la persistencia entre los pacientes que presentaron EDSS basal < 2 que en los \nque era mayor. \nNuestro estudio presenta limitaciones propias de un estudio retrospectivo, por lo que ser\u00edan necesarios estudios \nprospectivos en vida real.105CLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n59. ACONTECIMIENTOS ADVERSOS POR MEDICAMENTOS COMO MOTIVO DE ASISTENCIA A URGENCIAS. \nPROYECTO FARMURG \nAUTORES\nRUIZ RAMOS, J; SANTOLAYA PERR\u00cdN, MR; DE LORENZO PINTO, A; GARC\u00cdA MARTIN, MA; SEMPERE SERRANO, P; \nCALDERON HERNANZ, B; VALLVE ALCON, E; ALONSO DIEZ, M\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLos acontecimientos adversos por medicamentos (AAM) son una causa conocida de asistencia a los servicios de \nurgencias. El proyecto FARM-URG, coordinado por el grupo REDFASTER, tiene el objetivo de evaluar la prevalencia de \nestos AAM, as\u00ed como identificar los f\u00e1rmacos m\u00e1s frecuentemente implicados en los mismos. El objetivo de este estudio \nes mostrar los resultados de los registros anuales realizados en el periodo 2020-2022.\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico transversal realizado en servicios de urgencias de hospitales espa\u00f1oles. Un d\u00eda al a\u00f1o se obtuvieron \nlos datos de pacientes censados en el servicio de urgencias a las 12:00, sobre los cuales se identificaci\u00f3n aquellos \npacientes que consultaron por AAM. Se revisaron las historias cl\u00ednicas retrospectivamente y se registraron los datos en la \nplataforma REDCap\u00ae\ufffd\nRESULTADOS\n32 hospitales participaron en el estudio, evaluando 4752 pacientes, de los cuales 366 (7,70%) consultaron el SU por un \nAAM (2020:8,34%; 2021:7,54%; 2022:7,32%). Las ca\u00eddas (29; 8,0%) y las hemorragias digestivas (26; 7,1%) fueron los \nAAM m\u00e1s frecuentes. El grupo de f\u00e1rmacos antitromb\u00f3ticos fue responsable de la mayor parte de estos episodios, siendo \nacenocumarol (13,7%) el principal f\u00e1rmaco implicado. Los anticoagulantes de acci\u00f3n directa presentaron un incremento \nprogresivo de a lo largo de los a\u00f1os (3,5%; 3,6% y 5,9%). Los f\u00e1rmacos hipn\u00f3tico-sedante (13,1%) y los b-bloqueantes \n(8,8%) fueron los siguientes grupos implicados en m\u00e1s casos. 54 (14,8%) de los AAM fueron causados por f\u00e1rmacos con \nprescripci\u00f3n inapropiada seg\u00fan los criterios STOPP-START. 68 de 221 (23,5%) pacientes valorables volvieron a visitar el \nservicio de urgencias antes de los 30 d\u00edas del alta.\nCONCLUSIONES\nLos AAM son un motivo frecuente de visita a los servicios de urgencias, estando asociados a una frecuencia de \nreconsultas a 30 d\u00edas. El proyecto FARM-URG permite obtener informaci\u00f3n peri\u00f3dica de los mismos, siendo una \nherramienta de utilidad para priorizar medidas preventivas.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n108. IMPLANTACI\u00d3N DE UN PROGRAMA DE REVISI\u00d3N DE URINOCULTIVOS EN PACIENTES CON \nINFECCI\u00d3N URINARIA AL ALTA DEL SERVICIO DE URGENCIAS \nAUTORES\nMEDINA CATAL\u00c1N, D; RUIZ RAMOS, J; JUANES BORREGO, A; L\u00d3PEZ VINARDELL, L; HERRERA MATEO, S; PEREIRA \nBATISTA, CS; SANTOS PUIG, M; MANGUES BAFALLUY , MA\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nDescribir y evaluar los resultados de la implantaci\u00f3n de un programa de revisi\u00f3n de urinocultivos en pacientes que \nconsultan el servicio de urgencias hospitalario (SUH) con una infecci\u00f3n del tracto urinario (ITU) y que son dados de alta \ncon tratamiento antibi\u00f3tico emp\u00edrico a la espera de filiar el microorganismo causal.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Se incluyeron pacientes adultos que ingresaron en el SUH con diagn\u00f3stico de ITU \ny sedimento de orina positivo entre octubre/2021 y abril/2022. El programa implantado consisti\u00f3 en una revisi\u00f3n diaria \nde los urinocultivos positivos a cepas multirresistentes y P . aeruginosa obtenidos en el SUH y listados por el servicio de \nmicrobiolog\u00eda, con posterior intervenci\u00f3n por parte del farmac\u00e9utico en caso de que \u00e9ste detectase que el tratamiento \nantibi\u00f3tico con el que el paciente fue dado de alta fuera inadecuado seg\u00fan la sensibilidad del microorganismo aislado. \nEn caso afirmativo, se avis\u00f3 al facultativo de urgencias en caso de alta a domicilio con tratamiento oral, o al centro \nsocio-sanitario en caso de alta con tratamiento intravenoso. Como variable principal, se evalu\u00f3 la adecuaci\u00f3n en la \nprescripci\u00f3n del tratamiento antibi\u00f3tico emp\u00edrico seg\u00fan el resultado del urinocultivo con posterior correcci\u00f3n en caso de \ntratamiento inadecuado. Como variables secundarias, se analizaron los principales pat\u00f3genos aislados y la proporci\u00f3n de \nmultirresistencias. Se utiliz\u00f3 la historia cl\u00ednica informatizada para extraer tales datos.\nRESULTADOS\nSe incluyeron en el estudio 1122 pacientes, con una edad media de 77,6 (DE: 16,9) a\u00f1os. El microorganismo m\u00e1s \nfrecuentemente aislado en los urinocultivos fue Escherichia coli (59,9%), con un 22,8% de multirresistencias (la gran \nmayor\u00eda [93,3%] de tipo beta-lactamasa de espectro extendido [BLEE]) seguido de Klebsiella pneumoniae (13,0%), \ncon un 27,0% de multirresistencias, y Proteus mirabilis (7,5%), con un 20,7% de multirresistencias. En cuanto a cocos 106grampositivos, a destacar Enterococcus faecalis (6,8%), siendo todos los aislados multisensibles. Respecto a la variable \nprincipal, se obtuvieron un total de 234 (20,9%) aislamientos de pat\u00f3geno multirresistente, de los cuales 118 (50,4%) \nfueron alta con tratamiento inapropiado y en los que se intervino avisando al centro de salud en el cual se hab\u00eda \ntrasladado al paciente desde el SUH para terminar el tratamiento antibi\u00f3tico, as\u00ed como al m\u00e9dico prescriptor en caso de \nque el paciente hubiera marchado a domicilio con tratamiento antiinfeccioso por v\u00eda oral para modificaci\u00f3n de receta o \ninicio de antibioterapia intravenosa en domicilio.\nCONCLUSIONES\nEl programa implantado sobre revisi\u00f3n de urinocultivos de pacientes altados del SUH con tratamiento antibi\u00f3tico \nemp\u00edrico de ITU permiti\u00f3 detectar y adecuar la cobertura antiinfecciosa en la mitad (50,4%) de los pacientes que \npresentaron un aislamiento de pat\u00f3geno multirresistente, los cuales no estaban correctamente tratados. Podr\u00eda ser de \nutilidad evaluar el uso de herramientas que puedan cribar a pacientes con alto riesgo de infecci\u00f3n por microorganismos \nmultirresistentes para realizar una mejor orientaci\u00f3n de la antibioterapia emp\u00edrica inicial.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n137. APLICABILIDAD DE UN MODELO PREDICTIVO DE PAT\u00d3GENOS MULTIRRESISTENTES EN INFECCIONES \nDEL TRACTO URINARIO EN UN SERVICIO DE URGENCIAS \nAUTORES\nMEDINA CATAL\u00c1N, D; RUIZ RAMOS, J; JUANES BORREGO, A; L\u00d3PEZ VINARDELL, L; HERRERA MATEO, S; PEREIRA \nBATISTA, CS; SANTOS PUIG, M; MANGUES BAFALLUY , MA\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nConocer la aplicabilidad en la pr\u00e1ctica cl\u00ednica real del modelo predictivo de riesgo de infecci\u00f3n por microorganismos \nmultirresistentes (MR) desarrollado por Gonz\u00e1lez Del Castillo et al (1) en infecciones del tracto urinario (ITU) en un \nservicio de urgencias hospitalario (SUH).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Se incluyeron pacientes adultos que ingresaron en el SUH con diagn\u00f3stico de ITU y \nsedimento de orina positivo entre octubre/2021 y enero/2022. Como variable principal, se evalu\u00f3 el \u00e1rea bajo la curva \nde caracter\u00edstica operativa del receptor (AUC-ROC), considerando la infecci\u00f3n por pat\u00f3geno resistente como la variable \ndependiente y la puntuaci\u00f3n en la escala del modelo predictivo empleada como independiente. Se utiliz\u00f3 la historia \ncl\u00ednica informatizada para extraer tales datos, y \u00e9stos se analizaron mediante el software estad\u00edstico Stata v.15.0.\nRESULTADOS\nSe incluyeron en el estudio 201 pacientes, con una edad media de 77,8 (DE:16,2) a\u00f1os, siendo m\u00e1s de la mitad mayores \nde 80 a\u00f1os (52,2%). En cuanto a antecedentes incluidos en el modelo, casi un tercio de los individuos tuvo alg\u00fan ingreso \nhospitalario en los 3 meses previos (30,3%), un 39,3% fue tratado con antibi\u00f3tico durante el mismo periodo, un 12,4% \ntuvo historia de ITU de repetici\u00f3n en el \u00faltimo a\u00f1o, y un 11,9% del total present\u00f3 aislamiento de pat\u00f3geno multirresistente \ndurante los 6 meses previos. Una parte importante de los pacientes presentaban demencia y dependencia (40,3% y 56,7%, \nrespectivamente), estando un 28,9% institucionalizados en residencia en el momento del inicio de la infecci\u00f3n. La mitad \nde los individuos present\u00f3 una puntuaci\u00f3n en la escala del modelo predictivo > 10 (50,8%), teniendo una probabilidad de \npat\u00f3geno MR \u226533% de acuerdo al modelo utilizado. El AUC-ROC obtenido fue de 0,82 (95%IC 0,76-0,88), siendo el punto \nde corte \u00f3ptimo de 11 puntos, con una sensibilidad del 82,3% y una especificidad del 74,6%. Por tanto, en pacientes cuyo \nvalor en la puntuaci\u00f3n obtenida sea \u226511 puntos, la probabilidad de \u00e9xito de realizar una cobertura de m\u00e1s amplio espectro \npara tratar la ITU por sospecha de pat\u00f3geno multirresistente ser\u00e1 en tres cuartas partes de los pacientes.\nCONCLUSIONES\nEl uso en la pr\u00e1ctica cl\u00ednica real del modelo predictivo desarrollado por Gonz\u00e1lez Del Castillo et al (1) puede proporcionar \nuna mejor tasa de \u00e9xito en el tratamiento emp\u00edrico de pacientes que acuden al SUH con diagn\u00f3stico de ITU con pat\u00f3geno \npendiente de filiar y con antecedentes que pueden predisponer a microorganismos multirresistentes. \u00c9ste puede ser de \nutilidad tanto para evitar un mal uso de antibi\u00f3ticos de amplio espectro en pacientes sin riesgo establecido, como para \ncubrir correctamente a aquellos que puedan presentar una infecci\u00f3n grave y en los cuales una correcta cobertura inicial \npueda condicionar su evoluci\u00f3n cl\u00ednica. Para ello, se ha establecido en este estudio un punto de corte superior o igual a \n11 puntos para realizar, con una buena sensibilidad y especificidad, una cobertura de m\u00e1s amplio espectro.  \n(1) Gonz\u00e1lez Del Castillo J, Juli\u00e1n-Jim\u00e9nez A, Gamazo-Del Rio JJ, et al. A multidrug-resistant microorganism infection risk \nprediction model: development and validation in an emergency medicine population. Eur J Clin Microbiol Infect Dis. \n2020;39(2):309-323.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n156. DETECCI\u00d3N DE PROBLEMAS DE SALUD RELACIONADOS CON EL MEDICAMENTO MEDIANTE \nDIAGN\u00d3STICOS ALERTANTES EN URGENCIAS \nAUTORES\nSANTOS PUIG, M; PUIG CAMPMANY , M; MANGUES BAFALLUY , MA; JUANES BORREGO, A; RUIZ RAMOS, J; L\u00d3PEZ \nVINARDELL, L; MEDINA CATAL\u00c1N, D\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA107OBJETIVOS\nLos Problemas de Salud relacionados con los Medicamentos (PSM) causan el 20% de las consultas en los Servicios de \nUrgencias Hospitalarios (SUH) consider\u00e1ndose, en su mayor\u00eda, evitables. Iniciar un programa de prevenci\u00f3n secundaria \nbasado en la atenci\u00f3n farmac\u00e9utica sobre estos enfermos disminuye el riesgo de reingreso. Es por ello importante \ndisponer de herramientas que faciliten la detecci\u00f3n de PSM que causan consulta a los SUH 24 horas al d\u00eda y no solamente \ndurante la asistencia ordinaria del personal de farmacia. Por este motivo proponemos la detecci\u00f3n de PSM a trav\u00e9s de \ndiagn\u00f3sticos alertantes \u201cCIE-10\u201d obtenidos de bases de datos de codificaci\u00f3n m\u00e9dica de forma posterior al alta. \nEvaluar la efectividad de c\u00f3digos diagn\u00f3sticos CIE-10 para identificar Problemas de Salud relacionados con el \nMedicamento en pacientes que consultan los servicios de urgencias.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo llevado a cabo en un hospital universitario de tercer nivel. Se incluyeron pacientes \nadultos identificados tras buscar en la base de datos del hospital Datawarehouse, SAP Business Object con 10 c\u00f3digos \ndiagn\u00f3sticos CIE-10 m\u00e1s prevalentes asociados con PSM en nuestro entorno del 21/03/22 al 30/04/22.  \nLa verificaci\u00f3n de PSM se realiz\u00f3 tras revisi\u00f3n de historia cl\u00ednica y confirmaci\u00f3n con equipo multidisciplinar (m\u00e9dico/\nfarmac\u00e9utico del SUH).  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 mediante el programa Stata v.13.0. Para cada diagn\u00f3stico se calcul\u00f3 la prevalencia de \ncada c\u00f3digo CIE-10 en ese periodo de tiempo y su eficacia a la hora de relacionarlo con un PSM. Se realizar\u00e1 un an\u00e1lisis \nestratificado con variables de sexo.\nRESULTADOS\nSe revisaron un total de 247 casos, y se detectaron 70 PSM (28.3%, 34 mujeres y 36 hombres, mediana edad 74 a\u00f1os, \nIQ 62-86). Sobre los 70 PSM revisados, se realiz\u00f3 intervenci\u00f3n farmac\u00e9utica (entrevista telef\u00f3nica a las 48h de alta) en \n63 casos. La intervenci\u00f3n consisti\u00f3 en conciliaci\u00f3n de la medicaci\u00f3n y revisi\u00f3n centrada en la persona y se intervino \nadicionalmente en 24 casos mediante: cambio de medicaci\u00f3n (9 casos, 37.5%) tras consulta con urgenci\u00f3logo u otro \nespecialista, contacto con el farmac\u00e9utico de atenci\u00f3n primaria u otro servicio (14, 58.33%) u otras (4.16%).  \nDe entre los diferentes c\u00f3digos CIE-10, el 67.14% de PSM se encontraron en 3 CIES: I16.9_Crisis Hipertensiva (n=23, \n32.85%); K59.00_Estre\u00f1imiento (n=18, 25.71%); R001_Bradicardia (n=6, 8.57%).  \nEn la estratificaci\u00f3n por sexo se observ\u00f3 que en I16.9_Crisis Hipertensiva los resultados fueron similares (n=11, 42.53% \nhombres, n=12, 57.44% mujeres). En K59.00_Estre\u00f1imiento la prevalencia de PSM era mayor en mujeres (n=12, 66,66% \nmujeres, n=6, 33.33% hombres) y que la R001_Bradicardia era m\u00e1s frecuente en hombres (n=4, 62.5% hombres, n=2 \nmujeres 37.5%). \nLos CIE con una mayor frecuencia de aparici\u00f3n de PSM fueron E87.1_Hipoosmolaridad e Hiponatremia con un 100% (2 \nPSM de 2 casos), I95.1_Hipotensi\u00f3n ortost\u00e1tica 80% (4 PSM en 5 casos) y R001_Bradicardia no especificada (6 PSM de 8 \ncasos).\nCONCLUSIONES\nLos c\u00f3digos CIE-10 son una buena herramienta para detectar PSM y permiten intervenir sobre pacientes dados de alta, \nampliando la capacidad de detecci\u00f3n\ufffd\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n323. DISE\u00d1O DE UNA METODOLOG\u00cdA DE REGISTRO PARA EVALUAR SEGURIDAD E IMPACTO CL\u00cdNICO-\nECON\u00d3MICO DE LAS INTERVENCIONES FARMAC\u00c9UTICAS EN URGENCIAS: PROYECTO INTERFAR. \nAUTORES\nRAMOS RODR\u00cdGUEZ, J; BONETE S\u00c1NCHEZ, M; VALLVE ALC\u00d3N, E; DE LORENZO PINTO, A; CALDER\u00d3N HERN\u00c1NZ, B; \nRU\u00cdZ RAMOS, J; SANTOLAYA PERRIN, MR; CAMPINO VILLEGAS, A\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\nDise\u00f1ar una metodolog\u00eda para el registro de las intervenciones farmac\u00e9uticas (IFs) realizadas en el Servicio de Urgencias \n(SU), identificar las situaciones cl\u00ednicas en las que m\u00e1s se interviene, y evaluar el impacto cl\u00ednico y econ\u00f3mico de estas IFs.\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico, observacional y prospectivo de registro de IFs durante 2 meses (12 abril - 11 junio 2021).  \n \nTras revisi\u00f3n y discusi\u00f3n de la evidencia disponible, el dise\u00f1o de la metodolog\u00eda se obtuvo por consenso del grupo \ncoordinador de Redfaster. Se identificaron un total de 39 tipos diferentes de IFs, agrupadas en 5 categor\u00edas principales: \nPrevenci\u00f3n de Reacciones Adversas (PRA), Utilizaci\u00f3n de Recursos (UR), Optimizaci\u00f3n del Tratamiento (OT), Atenci\u00f3n \nFarmac\u00e9utica (AF) y Tareas de Soporte (TS).  \n \nEl impacto cl\u00ednico se evalu\u00f3 conforme a la calidad de la evidencia y fuerza de recomendaci\u00f3n asociado a cada IF seg\u00fan \nel sistema GRADE. El c\u00e1lculo del impacto econ\u00f3mico se evalu\u00f3 a partir del coste en d\u00f3lares de cada IF, referenciado por \nHammond et al (Pharmacotherapy. 2019;39(3):215-231) y se traslad\u00f3 al cambio en euros actualizado en junio 2021.  \n \nEn cada IF se registr\u00f3 patolog\u00eda y f\u00e1rmaco asociado, proactividad y aceptaci\u00f3n. Se recogieron datos demogr\u00e1ficos de cada \ncentro y profesionales participantes: validaci\u00f3n farmac\u00e9utica presencial en el SU, a\u00f1os de experiencia profesional y horas de \nla jornada dedicadas a la AF en esta \u00e1rea, n\u00famero total de urgencias anuales atendidas y promedio anual de visitas diarias.108RESULTADOS\n46 farmac\u00e9uticos de 37 hospitales de Espa\u00f1a y Portugal participaron en el estudio, realizando un total de 5667 IFs.  \n \nEl 87% (4907) de las IFs fueron aceptadas y el 95% (5402) se realizaron de forma proactiva.  \n \nEl 36,5%(2068) de las IFs correspondieron a TS, el 35,9% (2035) fueron de OT, el 22,4% (1269) PRA, el 2,4% (135) AF, el \n1,3% (75) UR y el 1,5% (85) no se pudieron categorizar.  \n \nEl nivel de evidencia del 94,5 % de las IFs fue de III, seguido de 4,2% nivel IV, 1,2% nivel Ib y 0,1% IIa\ufffd E \n \nEl impacto econ\u00f3mico total de las IFs durante el periodo de estudio se estim\u00f3 como un ahorro te\u00f3rico potencial de \n2.056.920\u20ac.  \n \nLa mayor\u00eda de los profesionales (39%) dedicaban entre 2 y 4 horas a la AF en el SU, el 27% menos de 2 horas, el 20% entre \n4 y 6 horas y el 15% m\u00e1s 6 horas. El promedio de visitas diarias al SU fue de 281 (127-487).\nCONCLUSIONES\nLa aplicaci\u00f3n de una metodolog\u00eda de registro precisa, \u00e1gil y homog\u00e9nea permite justificar la necesidad de invertir m\u00e1s \ntiempo y recursos para la AF en el SU, con el consecuente beneficio para los pacientes, profesionales y sistema sanitario. \nAdem\u00e1s, la AF en el SU facilita la optimizaci\u00f3n de tratamiento por parte del equipo multidisciplinar y supone un ahorro \nsignificativo de los costes asociados a la asistencia sanitaria.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n349. IMPACTO CL\u00cdNICO DE LOS PROBLEMAS RELACIONADOS CON LOS ANTICOAGULANTES EN UN \nSERVICIO DE URGENCIAS \nAUTORES\nRODR\u00cdGUEZ ALARC\u00d3N, A; BARCEL\u00d3 VIDAL, J; NAVARRETE ROUCO, E; AGUIRRE TEJEDO, A; DOMINGO TORRELL, L; \nCIRERA LORENZO, I; GRAU CERRATO, S; FERR\u00c1NDEZ QUIRANTE, O\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEn el Servicio de Urgencias (SU) un 10% de los problemas relacionados con la medicaci\u00f3n (PRM) detectados est\u00e1n \nrelacionados con anticoagulantes. Estos f\u00e1rmacos constituyen un grupo farmacol\u00f3gico de riesgo debido a que est\u00e1n \nimplicados frecuentemente en resultados negativos relacionados con la medicaci\u00f3n (RNM).  \n \nEl objetivo fue evaluar el impacto cl\u00ednico de los PRM asociados a f\u00e1rmacos anticoagulantes detectados en un SU.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional en un hospital universitario de tercer nivel. Se incluyeron los PRM relacionados con \nanticoagulantes detectados en el SU durante el per\u00edodo junio 2020-diciembre 2021.  \n \nDe forma rutinaria, las prescripciones farmacol\u00f3gicas son revisadas diariamente por los farmac\u00e9uticos. Ante la detecci\u00f3n \nde un PRM, se realiza una recomendaci\u00f3n mediante una anotaci\u00f3n en el curso cl\u00ednico.  \n \nDatos recogidos: demogr\u00e1ficos, tipo de asistencia (m\u00e9dica/quir\u00fargica), f\u00e1rmacos anticoagulantes (mecanismo de acci\u00f3n, \nv\u00eda de administraci\u00f3n, indicaci\u00f3n), PRM detectado (clasificaci\u00f3n Pharmaceutical Care Network Europe Classification), tipo \nde intervenci\u00f3n, resultado de la intervenci\u00f3n, RNM\ufffd \n \nEstad\u00edstica: datos expresados en media (desviaci\u00f3n est\u00e1ndar) y frecuencias absolutas. An\u00e1lisis bivariado mediante Chi-\ncuadrado\ufffd\nRESULTADOS\nSe registraron 159 PRM, 87(54,7%) mujeres, edad 78,5(12,9) a\u00f1os. Asistencia en servicios quir\u00fargicos 48(30,2%). \nF\u00e1rmacos anticoagulantes: Anti-Xa 134 (84,3%), de los cuales 81 subcut\u00e1neos y 53 orales; anti-vitamina K 20(12,6%) \ny antitrombina 5(3,1%). En 117 (73,6%) casos se indic\u00f3 por anticoagulaci\u00f3n, principalmente en fibrilaci\u00f3n auricular \n79(67,5%) seguido de patolog\u00eda tromb\u00f3tica 26(22,2%), y como profilaxis en 42(26,4%). \n \nLos PRM detectados fueron: sobredosificaci\u00f3n en 77(48,4%) casos, infradosificaci\u00f3n 20(12,6%), duplicidad terap\u00e9utica \n8(5%), dosis incorrecta 5(3,1%) y discordancia pauta-curso cl\u00ednico 2(1,3%). Otros PRM: alteraciones anal\u00edticas 28(17,6%), \nerrores de conciliaci\u00f3n 10(6,3%), efectividad 5(3,1%) e interacciones 3(1,9%). \n \nIntervenciones: reducci\u00f3n de dosis 72(45,3%) (64(88,9%) pacientes recibieron ajustes por funci\u00f3n renal y/o peso), \nmonitorizaci\u00f3n de niveles (INR) 30(18,9%), aumento de dosis 13(8,2%), correcci\u00f3n error de prescripci\u00f3n 11(6,9%), \nsuspensi\u00f3n f\u00e1rmaco 9(5,7%), ampliaci\u00f3n intervalo de administraci\u00f3n 8(5%), sustituci\u00f3n de f\u00e1rmaco 7(4,4%), otras 9 \n(5,7%). Del total de intervenciones, 121(80,6%) fueron aceptadas.  \n 109Se detectaron 17(10,7%) RNM: hematomas 8(47,1%), melenas 5(29,4%), hematuria 3(17,6%), rectorragias 2(11,8%), \nplaquetopenia 2(11,8%), hemorragia 1(5,9%), con una media de aparici\u00f3n de 4,89(3,12) d\u00edas.  \n \nSe registr\u00f3 mayor frecuencia de RNM en los servicios quir\u00fargicos frente a los m\u00e9dicos (24,2% vs. 9%, respectivamente; \np=0,032) y en PRM por errores de pauta (p=0,032), donde destacan 13 complicaciones en pacientes sobredosificados.  \n \nA pesar de observarse un mayor porcentaje de RNM en pacientes con recomendaciones no aceptadas, no hubo \ndiferencias significativas (5/24(20,8%) vs. 12/109(11%), p=0,293).\nCONCLUSIONES\nEl 10% de los pacientes que presentaron alg\u00fan PRM relacionado con f\u00e1rmacos anticoagulantes desarrollaron un RNM.  \n \nLos servicios quir\u00fargicos y la sobredosificaci\u00f3n de f\u00e1rmacos anticoagulantes se asociaron con la aparici\u00f3n de RNM.  \n \nA pesar de no alcanzar significaci\u00f3n estad\u00edstica, un 20% de los pacientes con recomendaciones farmac\u00e9uticas no \naceptadas presentaron alg\u00fan RNM.  \n \nEstos resultados ponen de manifiesto la relevancia de una monitorizaci\u00f3n estrecha del tratamiento con f\u00e1rmacos \nanticoagulantes.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n503. PERSPECTIVA DE G\u00c9NERO Y PROBLEMAS DE SALUD RELACIONADOS CON LOS MEDICAMENTOS \nAUTORES\nOJEDA GIL, S; JUANES BORREGO, AM; RUIZ RAMOS, J; PUIG CAMPMANY , M; L\u00d3PEZ VINARDELL, L; MONJE L\u00d3PEZ, \u00c1; \nTORRECILLA VALL-LLOSSERA, B; MANGUES BAFALLUY , MA\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nAnalizar y caracterizar las diferencias por g\u00e9nero en pacientes con Problemas de Salud relacionados con los \nMedicamentos (PSMs) que causan una primera consulta a un Servicio de Urgencias Hospitalario (SUH).  \nIncluir la perspectiva de g\u00e9nero en la evaluaci\u00f3n en t\u00e9rminos de reconsulta y reingreso temprano, por cualquier causa y \npor PSM, del programa de prevenci\u00f3n secundaria de iatrogenia farmacol\u00f3gica \u201cC\u00f3digo Medicamento\u201d (CM), que incluye \nrevisi\u00f3n de la farmacoterapia centrada en la persona, coordinaci\u00f3n asistencial y visita telef\u00f3nica al alta\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio exploratorio observacional realizado en un hospital universitario terciario para identificar posibles diferencias \nrelevantes por g\u00e9nero en pacientes con PSMs que causan consultas al SUH y evaluar la efectividad del programa CM.  \nSe incluyeron todos los pacientes donde se aplic\u00f3 el programa CM en 2021 tras haber consultado el SUH por un primer \nPSM como diagn\u00f3stico primario o secundario.  \nSe analizaron las caracter\u00edsticas socio-demogr\u00e1ficas de los pacientes, la farmacoterapia en t\u00e9rminos de grupo ATC, \nsiempre que estuviera relacionada con al menos 10 consultas al SUH, y el \u00edndice de reconsulta y reingreso temprano (a 30 \nd\u00edas) tanto por cualquier causa, como por PSMs, en funci\u00f3n del g\u00e9nero. Se compar\u00f3 mediante prueba de Chi-Cuadrado \nlas variables cualitativas expresadas en forma de proporci\u00f3n. Las cuantitativas expresadas como media/desviaci\u00f3n \nest\u00e1ndar (SD) se compararon mediante el test \u201ct\u201d de datos independientes. Se evalu\u00f3 la significaci\u00f3n bilateral de las \npruebas estad\u00edsticas para un nivel inferior al 5%.\nRESULTADOS\nDurante el a\u00f1o 2021, 798 pacientes fueron incluidos en el programa CM tras consultar el SUH por un PSM: 449 mujeres \n(56.3%) y 349 hombres (43.7%). \nTen\u00edan una edad promedio de 78.7 a\u00f1os (80,9 las mujeres (SD 13.17692) y 75.7 los hombres (SD 15.83415); t < 0,01), 210 \npacientes (24,2%) presentaban alg\u00fan tipo de deterioro cognitivo (122 mujeres 25,1% y 88 hombres 23,15%). Tomaban \nal inicio del episodio de urgencias un promedio de 8.7 medicamentos cr\u00f3nicos. (9.0 las mujeres (SD 4.096285) y 8.27 los \nhombres (SD 4.350768); t < 0,01). \nNo hubo diferencias estad\u00edsticamente significativas entre g\u00e9neros con la muestra estudiada a nivel de consultas al \nSUH por PSMs. Solo destaca la prevalencia en mujeres del grupo ATC N02B (Otros analg\u00e9sicos, donde se incluyen el \n\u00e1cido acetilsalic\u00edlico y las pirazolonas) (mujeres 1,1% vs hombres 0,57%; p = 0,0359). Se observa tendencia al alza en la \nprevalencia en mujeres de los grupos N02A (Opioides) y C03 (Diur\u00e9ticos).  \nEl programa CM fue igual de efectivo, en mujeres y hombres, evaluado en t\u00e9rminos de reconsultas y reingresos \ntempranos, tanto por cualquier causa (16,9% mujeres vs 16,3% hombres p = 0.703 en reconsultas; 3,79% mujeres vs \n7,16% hombres p = 0.566 en reingresos), como por PSM (5,3% mujeres vs 6,3% hombres p = 0,566 en reconsultas; 0,9% \nmujeres vs 1,15% hombres p = 0.649 en reingresos).\nCONCLUSIONES\nNo existen diferencias estad\u00edsticamente significativas entre pacientes que consultan el SUH por PSMs de los grupos ATC \nseleccionados para el estudio, exceptuando el grupo N02B\ufffd  \nEl programa CM es igual de eficaz en ambos g\u00e9neros, evaluado en t\u00e9rminos de reconsultas y reingresos tempranos.110CLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n515. AN\u00c1LISIS DE LAS INTERVENCIONES FARMAC\u00c9UTICAS RELACIONADAS CON INTERACCIONES \nRELEVANTES EN EL SERVICIO DE URGENCIAS \nAUTORES\nFONT TARRES, N; PUIVECINO MORENO, C; CASTELLANOS CLEMENTE, Y; GARC\u00cdA GIL, M\nHOSPITAL DE FUENLABRADA \ufffd CAMINO DEL MOLINO, 2 FUENLABRADA \ufffd MADRID\nOBJETIVOS\nAnalizar las interacciones relevantes detectadas en el \u00e1rea de Urgencias entre la medicaci\u00f3n cr\u00f3nica del paciente y el \ntratamiento prescrito en el Servicio de Urgencias (SUH).\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo. Se seleccionaron todos los pacientes vistos en Urgencias y que ten\u00edan registro de intervenciones \nrelacionadas con interacciones relevantes seg\u00fan Lexicomp\u00ae Drug Interactions, evidencia buena o excelente y categor\u00edas C \n(monitorizaci\u00f3n), D (valorar modificaci\u00f3n del tratamiento) o X (Evitar la combinaci\u00f3n) entre enero 2021 y abril 2022. \nComo variables principales se analizaron el n\u00famero de intervenciones relacionadas con interacciones relevantes, \ncategor\u00eda (C,D,X) y principales grupos terap\u00e9uticos.  \nLas variables secundarias analizadas fueron porcentaje de intervenciones relacionadas con la efectividad y seguridad, tipo \nde recomendaciones efectuadas, grado de aceptaci\u00f3n y acontecimiento adversos medicamentosos (AAM) derivados de \nlas interacciones no aceptadas\ufffd  \nLos datos se obtienen mediante formularios del \u00e1rea de atenci\u00f3n farmac\u00e9utica registrados en el programa de historia \ncl\u00ednica electr\u00f3nica. El an\u00e1lisis de datos se realiza mediante estad\u00edstica descriptiva en Excel.\nRESULTADOS\nEn el periodo de estudio se realizaron 44 intervenciones relacionadas con interacciones relevantes en el SUH detectadas \nen 34 pacientes (detecci\u00f3n de 1 interacci\u00f3n en 26 pacientes; 2 interacciones en 6 pacientes; 3 interacciones en 2 \npacientes).  \nDe las interacciones detectadas, 14/44 (31,8%) eran categor\u00eda C, 13/44 (29,5%) de categor\u00eda D, y 17/44 (38,6%) de \ncategor\u00eda X.  \nLos principales grupos terap\u00e9uticos relacionados fueron: antibi\u00f3ticos (20/44), como linezolid (8) y claritromicina (5); \nantidepresivos (16/44), como sertralina (4); opioides (9/44), antipsic\u00f3ticos (6/44) e inmunosupresores (5/44). \nEl 86,4% (38/44) de las intervenciones estaban relacionadas con la seguridad y el 18,6% (7) con la efectividad del \ntratamiento\ufffd  \nDe las recomendaciones emitidas por parte del farmac\u00e9utico del SUH: 36,4% monitorizaci\u00f3n (16/44); 34,0% cambio de \nmedicamento (15/44); 22,7% suspender medicamento (10/44); 4,5% modificar horario/pauta (2/44); 2,3% modificaci\u00f3n \nde dosis (1/44).  \nEl 84,0% de las intervenciones fueron aceptadas (37/44). No se detectaron AAM relacionados con las intervenciones no \naceptadas\ufffd\nCONCLUSIONES\nCuatro de cada diez interacciones relevantes detectadas por el farmac\u00e9utico del SUH son de categor\u00eda X seg\u00fan Lexicomp\u00ae \nDrug Interactions, en su mayor\u00eda relacionadas con la seguridad. Los principales grupos terap\u00e9uticos asociados son \nantibi\u00f3ticos, antidepresivos y opioides. Las recomendaciones m\u00e1s frecuentemente emitidas por el farmac\u00e9utico del SUH \nfueron monitorizaci\u00f3n, cambio y suspensi\u00f3n de medicamentos, con un grado de aceptaci\u00f3n muy elevado. Parece que la \ndetecci\u00f3n de interacciones relevantes por parte del farmac\u00e9utico del SUH, podr\u00eda estar relacionada con una reducci\u00f3n de \nla aparici\u00f3n de acontecimientos adversos asociados a medicamentos\ufffd\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n542. RECONSULTAS POR HEMORRAGIAS DIGESTIVAS CAUSADAS POR ANTICOAGULANTES DE ACCI\u00d3N \nDIRECTA \nAUTORES\nTORRECILLA VALL-LLOSSERA, B; RUIZ RAMOS, J; JUANES BORREGO, A; L\u00d3PEZ VINARDELL, L; PUIG CAMPMANY , M; \nOJEDA GIL, S; MONJE L\u00d3PEZ, \u00c1; MANGUES BAFALLUY , MA\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLas hemorragias digestivas (HD) secundarias al tratamiento anticoagulante son un motivo frecuente de consulta a los \nservicios de urgencias (SU). Si bien existen diversos estudios sobre el riesgo de HD secundaria a los anticoagulantes de \nacci\u00f3n directa (ACODs), las cifras de riesgo real podr\u00edan estar subestimadas.  \n \nEl objetivo de este estudio es describir el efecto del cambio de los ACODs al alta de los pacientes que consultan al SU por \nHD secundaria al tratamiento con ACODs, as\u00ed como evaluar los factores de riesgo asociados a reconsulta por HD a estas \nunidades\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo donde se incluyeron pacientes que estaban en tratamiento con ACODs y que \nacudieron al SU por HD. El estudio se realiz\u00f3 entre mayo 2017 y marzo 2022 en un hospital universitario de 644 camas, 111con cerca de 140\ufffd000 visitas a urgencias anuales\ufffd  \n \nSe analiz\u00f3 el impacto del cambio de anticoagulante al alta y los factores de riesgo (comorbilidades y medicaci\u00f3n) de estos \npacientes sobre la reconsulta al SU a 90 d\u00edas mediante el registro de consultas hospitalarias no programadas, en base a \nlos datos obtenidos en el sistema electr\u00f3nico de historia cl\u00ednica compartida del Instituto Catal\u00e1n de la Salud (CatSalut).  \n \nEl an\u00e1lisis de datos se llev\u00f3 a cabo a trav\u00e9s del programa estad\u00edstico Stata 13.0. Para evaluar los factores de riesgo \nasociados a reconsulta al SU se realiz\u00f3 un an\u00e1lisis multivariante mediante regresi\u00f3n log\u00edstica, incluyendo en el modelo \naquellas variables con un valor de p < 0,2 en an\u00e1lisis univariante previo. Se evaluaron los siguientes factores: edad, \nsexo, ACO al ingreso, ACO al alta, polifarmacia ( > 9 medicamentos), enfermedades de base del paciente, medicaci\u00f3n \ngastrolesiva al alta (antiagregantes, antiinflamatorios no-esteroideos, antidepresivos) y protecci\u00f3n g\u00e1strica (inhibidores de \nla bomba de protones).\nRESULTADOS\nSe incluyeron 86 pacientes con una edad media de 84 (DE:6,5) a\u00f1os.  \n \nLos pacientes sin cambio de ACODs al alta (n=41, el 47,71% de los pacientes) presentaron m\u00e1s episodios de reconsulta \nal SU relacionados con HD (n=10, 22,7%) durante los 90 d\u00edas posteriores al alta que los que recibieron un cambio de \nanticoagulante (n=35, 40,7%) o supresi\u00f3n del mismo (n=10, 11,6%) con un 18,2% y 10% de reconsultas al SU relacionadas \ncon HD respectivamente. No obstante, estas diferencias no fueron estad\u00edsticamente significativas (p=0,442 y p=0,398, \nrespectivamente). \n \nRespecto al an\u00e1lisis de factores de riesgo de reconsulta, en el an\u00e1lisis multivariante, la prescripci\u00f3n de menos de 10 \nmedicamentos al alta [OR para polifarmacia=0,22 (IC95%=0,06-0,77)] la presencia de ICC [OR:5,27 (1,36-20,44)] y la \nprescripci\u00f3n de antiagregantes [OR=5,48 (1,08-27,60)] se asociaron a un mayor riesgo de reconsulta por nuevos episodios \nde HD a 90 d\u00edas, sin encontrar asociaci\u00f3n significativa entre el cambio en la terapia anticoagulante con el riesgo de \nreconsulta [OR:1.65 (0,66-4,12); p=0.282)].\nCONCLUSIONES\nEl cambio de tratamiento anticoagulante tras un episodio de sangrado por ACOD no supone una reducci\u00f3n significativa \ndel riesgo de reconsultas a urgencias por eventos hemorr\u00e1gicos. Los pacientes con menos de 10 medicamentos al alta, \ncon diagn\u00f3stico de ICC y los que est\u00e1n en tratamiento concomitante con antiagregantes presentan un mayor riesgo de \nreconsulta por HD a 90 d\u00edas.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n626. EFICACIA Y SEGURIDAD DE METOTREXATO INTRAMUSCULAR EN R\u00c9GIMEN DE DOSIS \u00daNICA EN \nGESTACI\u00d3N ECT\u00d3PICA EXTRAUTERINA \nAUTORES\nESTRADA NIETO, L; BOSCH PELIGERO, M; DE DIEGO BURILLO, R; MART\u00cdN VAL, A; TERRICABRAS MAS, E; GARC\u00cdA-\nCASTI\u00d1EIRA , C; BOCOS-BAELO , A; QUI\u00d1ONES RIBAS, C\nHOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nOBJETIVOS\nEl abordaje de la gestaci\u00f3n extrauterina (GEU) incluye la administraci\u00f3n de metotrexato (MTX) intramuscular (IM) 50 \nmg/m2 en r\u00e9gimen de dosis \u00fanica (DU) cuando la hormona gonadotropina cori\u00f3nica humana (\u03b2-hCG) es < 5000 UI/l al \ndiagn\u00f3stico. Actualmente existe controversia sobre la posible dosis m\u00e1xima de 100 mg en pacientes obesas. El objetivo \ndel estudio es evaluar la eficacia y seguridad del MTX en DU en GEU.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo, realizado en un hospital de tercer nivel. Se incluyeron las pacientes \ncon GEU tratadas con r\u00e9gimen de DU de MTX IM entre enero 2019 y diciembre 2021. Las variables recogidas fueron: \nlocalizaci\u00f3n de GEU, dosis, superficie corporal (SC), \u00edndice de masa corporal (IMC), \u03b2-hCG los d\u00edas 0, 4, 7 y 14 post-MTX, \neficacia del tratamiento (valorada como necesidad de segunda dosis o cirug\u00eda post-MTX) y efectos adversos. La obtenci\u00f3n \nde datos se realiz\u00f3 mediante revisi\u00f3n de historia cl\u00ednica conjuntamente con el Servicio de Ginecolog\u00eda y Obstetricia.\nRESULTADOS\nSe incluyeron 54 pacientes con edad media de 33 a\u00f1os. La localizaci\u00f3n de la GEU fue tub\u00e1rica en 44 pacientes (81,48%), \nno especificada en nueve pacientes (16,67%) y ov\u00e1rica en un paciente (1,85%). La dosis media de MTX fue 86,08 mg \n(rango: 70-120 mg) y tres pacientes (5,55%) recibieron una dosis > 100 mg por presentar SC > 2 m2.  \nEn relaci\u00f3n a la eficacia, seis pacientes (11,11%) precisaron cirug\u00eda post-MTX y 11 pacientes (20,37%) requirieron segunda \ndosis de MTX. Las causas de cirug\u00eda fueron: dos descensos de \u03b2-hCG entre los d\u00edas 4-7 post-MTX < 15%, tres GEU \naccidentada y un antecedente de GEU. Las causas de segunda dosis fueron: 10 descensos de \u03b2-hCG entre los d\u00edas 4-7 \npost-MTX < 15% y un \u03b2-hCG muy elevado.  \nDiez pacientes (18,52%) eran obesas (IMC > 30), de las cuales dos (20%) requirieron una dosis > 100 mg seg\u00fan SC \n(rango: 104,5-120 mg) y tres (30%) recibieron una segunda dosis de MTX (rango: 87,5-100 mg). Cinco pacientes (9,26%) \nrecibieron el r\u00e9gimen de DU a pesar de tener \u03b2-hCG \u22655000 UI/l al diagn\u00f3stico, de las cuales solo una (20%) requiri\u00f3 una \nsegunda dosis\ufffd  112Con respecto a la seguridad, ocho pacientes (14,81%) con anal\u00edtica previa normal, de las cuales tres eran obesas (una con \ndosis > 100mg), presentaron elevaci\u00f3n de alanina aminotransferasa (ALT) post-MTX. La elevaci\u00f3n de ALT coincidi\u00f3 con la \nnecesidad de segunda administraci\u00f3n de MTX en tres pacientes y con el uso de dosis > 100 mg en dos pacientes. No se \nrealiz\u00f3 anal\u00edtica de seguimiento en siete pacientes (12,96%).\nCONCLUSIONES\nEl 68,52% de pacientes present\u00f3 una evoluci\u00f3n favorable y el 85,19% tuvo un buen perfil de seguridad. El 80% de \npacientes con \u03b2-hCG \u22655000 UI/l al diagn\u00f3stico tuvieron una respuesta favorable a pesar de recibir el r\u00e9gimen de MTX en \nDU por SC, por lo que no deber\u00eda descartarse su uso en casos de contraindicaci\u00f3n de cirug\u00eda. Pocas pacientes requirieron \ndosis > 100 mg seg\u00fan SC pese a tener obesidad y solo una present\u00f3 efectos secundarios.  \nEn general, el uso de MTX IM en r\u00e9gimen de DU ha demostrado ser eficaz y seguro en pacientes con GEU.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n735. AN\u00c1LISIS DE PRESCRIPCI\u00d3N DE DIGOXINA AL ALTA EN UN SERVICIO DE URGENCIAS TRAS \nIMPLANTACI\u00d3N DE UN PROTOCOLO DE FIBRILACI\u00d3N AURICULAR \nAUTORES\nTORO BLANCH, C; DORD\u00c0 BENITO, A; GISPERT AMETLLER, \u00c0; LAFUENTE GONZALEZ, B; MARTIN BESAL\u00da, I; NADAL \nFONTAN\u00c9, E; VILA CURRIUS, M; SUBIRANA BATLLE, C\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nEn el Servicio de Urgencias (SU) de nuestro hospital se elabor\u00f3 un protocolo para el manejo de la fibrilaci\u00f3n auricular \n(FA). La digoxina es un f\u00e1rmaco de estrecho margen terap\u00e9utico utilizado para el control de la frecuencia card\u00edaca. Se \nhan publicado algunos estudios cuyos resultados muestran un posible incremento de mortalidad en los pacientes con FA \ntratados con digoxina. Por este motivo, es preferible evitar su uso a largo plazo si se dispone de otras alternativas.  \nAlgunas herramientas utilizadas para la detecci\u00f3n de medicamentos potencialmente inapropiados (MPI) como los \ncriterios PRISCUS o START/STOPP desaconsejan su uso en pacientes mayores, especialmente en insuficiencia renal.  \n- Evaluar el impacto en la prescripci\u00f3n de digoxina a largo plazo tras la implantaci\u00f3n de un protocolo para el manejo de la \nFA\ufffd \n- Analizar la adecuaci\u00f3n, la duraci\u00f3n y los motivos de discontinuaci\u00f3n de las prescripciones de digoxina al alta tras la \nimplantaci\u00f3n del protocolo\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio pre-post intervenci\u00f3n en el que se recogieron las prescripciones de digoxina al alta desde el SU antes (10/2019-\n09/2020) y despu\u00e9s (10/2020-09/2021) de implantar el protocolo. Posteriormente se analizaron las prescripciones de \ndigoxina al alta realizadas durante el per\u00edodo post-intervenci\u00f3n. Las variables recogidas fueron: edad, sexo, antecedentes \nde inter\u00e9s, motivo de consulta, medicaci\u00f3n habitual, funci\u00f3n renal, tipo de FA, estrategia terap\u00e9utica y posolog\u00eda. Se \ndetermin\u00f3 si la indicaci\u00f3n y la posolog\u00eda eran correctos seg\u00fan los criterios del protocolo y de forma consensuada con una \nm\u00e9dico del SU y dos farmac\u00e9uticas. Se identificaron las prescripciones de digoxina consideradas MPI seg\u00fan los criterios \nSTOPP y los criterios PRISCUS\ufffd\nRESULTADOS\nDurante el per\u00edodo pre-intervenci\u00f3n, se realizaron 25 prescripciones al alta de digoxina por FA desde el SU, representando \nel 41,7% del total de prescripciones de digoxina realizadas en el hospital. En el per\u00edodo post-intervenci\u00f3n, se realizaron 14 \n(25,5% del total del hospital), lo que supone una disminuci\u00f3n del 44% en el SU. El n\u00famero de pacientes que acudieron al \nSU por FA en los 2 per\u00edodos fue 716 y 873, respectivamente. \nDe los 14 pacientes del per\u00edodo post-intervenci\u00f3n, la edad media fue de 84,1 a\u00f1os y el 92,8% fueron mujeres. Se \nconsider\u00f3 que la indicaci\u00f3n y la posolog\u00eda al alta fueron adecuados en un 71,4% i 41,6%, respectivamente. En el 50% de \nlos casos la duraci\u00f3n fue < 30 d\u00edas. Los motivos de discontinuaci\u00f3n fueron: cambio a betabloqueante (28,6%), intoxicaci\u00f3n \ndigit\u00e1lica (21,4%) siendo motivo de reconsulta al SU en < 30 d\u00edas, ablaci\u00f3n (14,3%). El resto continuaban con tratamiento \nactivo > 6 meses (21,4%) o no constaba el motivo de retirada (14,3%). \nEl 21,4% y el 28,6% de los casos cumpl\u00edan los criterios STOPP y los criterios PRISCUS, respectivamente, por lo que se \nconsideraron MPI\ufffd\nCONCLUSIONES\nLa implantaci\u00f3n de un protocolo para el manejo de la FA en el SU posiblemente ha influido en la disminuci\u00f3n de la \nprescripci\u00f3n de digoxina al alta desde el SU \ufffd En el 71,4% de los casos, la indicaci\u00f3n de digoxina se consider\u00f3 adecuada\ufffd Se \ndebe mejorar el ajuste posol\u00f3gico de digoxina en pacientes de edad avanzada con insuficiencia renal.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n772. ADECUACION DE LA UTILIZACION DEL COMPLEJO PROTROMBINICO EN EL SERVICIO DE URGENCIAS \nDE UN HOSPITAL DE TERCER NIVEL \nAUTORES\nDORD\u00c0 BENITO, A; TORO BLANCH, C; BRUGUERA TEIXIDOR, M; MARTIN BESALU, I; NADAL FONTANE, E; FUERTES \nIZQUIERDO, N; FAYET P\u00c9REZ, A; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA113OBJETIVOS\nEn nuestro hospital se elabor\u00f3 un protocolo para el manejo de hemorragia, intervenci\u00f3n quir\u00fargica o procedimiento \ninvasivo urgente en pacientes anticoagulados donde se posicionan los medicamentos que se utilizan para revertir el \nefecto anticoagulante: vitamina K, complejo protromb\u00ednico (CP) y reversores espec\u00edficos de anticoagulantes de acci\u00f3n \ndirecta (ACOD). Adem\u00e1s, el CP es uno de los f\u00e1rmacos con mayor impacto econ\u00f3mico en el Servicio de Urgencias (SU) de \nnuestro hospital.  \nLos objetivos son: describir el perfil de utilizaci\u00f3n y evaluar la adecuaci\u00f3n de uso del CP en el SU seg\u00fan el protocolo \naprobado\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se analizaron todas las prescripciones de CP en el SU durante un per\u00edodo \nde 6 meses (08/2021-02/2022). Las variables recogidas de cada paciente fueron: edad, peso, INR inicial, tratamiento \nanticoagulante habitual, indicaci\u00f3n del f\u00e1rmaco, hora y fecha de administraci\u00f3n del f\u00e1rmaco y hora de la prueba o \nintervenci\u00f3n quir\u00fargica requerida.  \nPara evaluar la adecuaci\u00f3n de uso se tuvo en cuenta el tipo de tratamiento anticoagulante habitual, el estado de \ncoagulaci\u00f3n mediante el INR (para antagonistas de la vitamina K (AVK)) as\u00ed como la gravedad de la hemorragia o el grado \nde urgencia de la intervenci\u00f3n / procedimiento invasivo\ufffd\nRESULTADOS\nSe incluyeron 61 pacientes con una edad media\u00b1SD de 79,9\u00b111,9 a\u00f1os de los cuales un 63,9% (39) eran hombres. Un \n83,6% (51) estaba en tratamiento con AVK, un 6,6% (4) con un ACOD y el 9,8% (6) no llevaba tratamiento anticoagulante. \nUn 44,3% (27) de los pacientes requiri\u00f3 CP por una hemorragia, de las cuales un 81,5% (22) fuer grave y un 18,5% (5) \nmoderada. Un 54,1% (33) de los pacientes lo requiri\u00f3 por una intervenci\u00f3n/procedimiento invasivo, de los cuales un \n70,6% (24) era urgente, 20,6% (7) era emergente y un 5,9% (2) era diferida. En un paciente sin hemorragia se utiliz\u00f3 para \nrevertir INR extremadamente elevado. El 70,6% (36) de los pacientes con AVK hab\u00edan recibido previamente vitamina K.  \nEn un 67,2% (41) de los casos se consider\u00f3 que el uso del CP fue adecuado y en un 27,9% (17) se utiliz\u00f3 la dosis \nestablecida seg\u00fan el protocolo. De los pacientes que no recibieron una dosis correcta, un 75,0% (33) fueron \ninfradosificados. De los casos en los que se consider\u00f3 que la indicaci\u00f3n no era la adecuada, en un 92,86% (13) fue por no \nhaber recibido previamente vitamina K.  \nNinguno de los pacientes que estaban en tratamiento con ACOD recibieron una dosis correcta de CP (25UI/kg), siendo \ntodas inferiores, con una media de 14,3\u00b11,7UI/kg\ufffd No obstante, ninguno recibi\u00f3 dosis adicionales de CP \ufffd\nCONCLUSIONES\nLa mayor\u00eda de los pacientes que recibieron CP estaban en tratamiento con AVK. La indicaci\u00f3n de uso de CP se consider\u00f3 \nadecuada en el 66,1% de los casos. En cambio, la mayor\u00eda de los pacientes recibieron dosis inferiores a las establecidas en \nel protocolo\ufffd  \nComo acciones de mejora, se propone hacer difusi\u00f3n de esta revisi\u00f3n en una sesi\u00f3n de servicio e incorporar las \nposolog\u00edas seg\u00fan tipo de anticoagulante y estado de coagulaci\u00f3n en el programa de prescripci\u00f3n electr\u00f3nica asistida del \ncentro\ufffd\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n800. AN\u00c1LISIS DE PROBLEMAS DE SALUD RELACIONADOS CON LA MEDICACI\u00d3N EN UN SERVICIO DE \nURGENCIAS \nAUTORES\nL\u00d3PEZ VINARDELL, L; MEDINA CATAL\u00c1N, D; RUIZ RAMOS, J; BL\u00c1ZQUEZ ANDION, M; SANTOS PUIG, M; MANGUES \nBAFALLUY , MA; PUIG CAMPMANY , M; JUANES BORREGO, A\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nIdentificar las principales causas de Problemas de Salud relacionados con la Medicaci\u00f3n (PSMs) que generan consulta \nal Servicio de Urgencias (SU) y los principales grupos farmacol\u00f3gicos (GFT) implicados, as\u00ed como analizar el n\u00famero de \nreconsultas al SU a los 30 d\u00edas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Se incluyeron pacientes adultos que consultaron el SU de un hospital terciario con \ndiagn\u00f3stico primario o secundario de PSMs seg\u00fan la orientaci\u00f3n diagn\u00f3stica m\u00e9dica (Febrero/2021-Marzo/2022). Las \nvariables analizadas fueron edad, sexo, comorbilidades, Grupo de Morbilidad Ajustado (GMA), motivo de consulta al SU, \ntipo de PSM (eficacia, seguridad y necesidad), causa de PSM (prescripci\u00f3n, adherencia o RAM), f\u00e1rmacos potencialmente \nasociados a PSMs y cambios en el tratamiento al alta. Para extraer tales datos se utiliz\u00f3 la historia cl\u00ednica informatizada, \nla informaci\u00f3n de la receta electr\u00f3nica y se realiz\u00f3 una entrevista al paciente/cuidador durante la estancia en el SU y a las \n48h del alta. Para el estudio de las variables relacionadas con el riesgo de reconsultas a los 30 d\u00edas, se realiz\u00f3 un an\u00e1lisis \nmultivariante incluyendo las variables con un valor de p < 0,2 en un an\u00e1lisis univariante previo (software estad\u00edstico Stata \nv.15.0).\nRESULTADOS\nSe incluyeron 761 pacientes, 55% mujeres, edad media 78 a\u00f1os [472 (62%) > 80a\u00f1os], 314 (41%) con > 9 f\u00e1rmacos, \n83% con GMA 3-4 y con las siguientes comorbilidades HTA 75%, DM 30%, IRC 26%, ICC 21%, accidente cerebro 114vascular (ACV) 14%. Las principales causas de consulta al SU fueron 21% por hemorragia digestiva/alteraci\u00f3n de la \ncoagulaci\u00f3n, 10% estre\u00f1imiento, 10% alteraci\u00f3n de la tensi\u00f3n arterial (TA), 9% alteraci\u00f3n de la frecuencia cardiaca (FC), \n8% descompensaci\u00f3n glic\u00e9mica, 6% hiponatremia, 5% convulsi\u00f3n/trastornos del movimiento, 5% ACV, 3% confusi\u00f3n/\nagitaci\u00f3n. El 44% de los PSMs se relacionaron con una prescripci\u00f3n inadecuada, 17% con un problema de adherencia, \n29% con una RAM y un 9% por causa desconocida. En cuanto el tipo de PSMs un 58% fueron de seguridad, 27% de \nnecesidad y 14% de eficacia. Se detectaron 12 grupos ATC (m\u00e1s prevalentes: ATC C 31%, B 25%, N 18% y A 15%) y 62 GFT \nasociados a PSMs (m\u00e1s prevalentes: 11% agentes antitromb\u00f3ticos, 11% diur\u00e9ticos, 8% insulina e hipoglucemiantes orales, \n7% IECA/ARAII, 6% laxantes, 6% beta bloqueantes, 5% antiepil\u00e9pticos, 3% opioides, 3% antipsic\u00f3ticos y 3% antidepresivos. \nAl alta se modific\u00f3 el f\u00e1rmaco causante de PSM en el 30% de los casos, se retir\u00f3 en el 26%, se a\u00f1adi\u00f3 un nuevo f\u00e1rmaco \nen el 19% y no se realiz\u00f3 ning\u00fan cambio en el 25%. Reconsultaron a los 30 d\u00edas 169 (22%) pacientes, 63 (8%) por un PSM. \nEl an\u00e1lisis multivariante no asoci\u00f3 ninguna variable a un mayor riesgo de reconsulta a 30 d\u00edas.\nCONCLUSIONES\nLos grupos ATC A, B, C y N son los m\u00e1s implicados en las consultas al SU por PSMS. Los principales motivos de consulta al \nSU fueron hemorragia digestiva, estre\u00f1imiento, alteraci\u00f3n de la TA y/o FC, descompensaci\u00f3n glic\u00e9mica e hiponatremia. La \nmayor\u00eda de los PSMs fueron de seguridad y relacionados con un problema de prescripci\u00f3n. No se asoci\u00f3 ninguna variable \na un mayor riesgo de reconsulta a 30 d\u00edas.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n884. ESTUDIO DESCRIPTIVO DE LAS ASISTENCIAS EN URGENCIAS POR EVENTOS ADVERSOS ASOCIADOS \nA LA MEDICACI\u00d3N \nAUTORES\nMIEDES , J; BOSCH , C; BARCEL\u00d3-VIDAL , J; CARBALLO , N; SALA , M; GRAU , S; FERRANDEZ , O\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLos eventos adversos (EA) a la medicaci\u00f3n pueden ser prevenibles o no prevenibles. Se estim\u00f3 el n\u00famero de visitas al \nServicio de Urgencias (SU) relacionadas con EA en un 4%(IC95%: 3,1-5,0) por cada 1000 individuos-a\u00f1o (Shehab N, et al. \nJAMA 2016).  \n \nEl objetivo fue identificar los principales f\u00e1rmacos implicados en la aparici\u00f3n de EA que provocan asistencias al SU, y \ndefinir el tipo de EA producido.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional en un hospital universitario de terciario. Se incluyeron pacientes atendidos en el SU \npor un EA durante el periodo enero 2017-mayo 2019. \nSe clasificaron los EA como reacci\u00f3n adversa a la medicaci\u00f3n (RAM) o error de medicaci\u00f3n (EM).  \n \nSe consider\u00f3 como RAM cualquier respuesta nociva, no prevenible y no intencionada a un medicamento y se clasificaron \nseg\u00fan Aronson y Edwards (A: dosis-dependiente; B: idiosincr\u00e1sicas; C: relacionada con dosis y tiempo tras administraci\u00f3n \ncr\u00f3nica; D: retardadas; E: relacionadas con la retirada; F: falta de eficacia) y seg\u00fan gravedad (criterios de la OMS).  \n \nSe clasific\u00f3 como EM cualquier incidente prevenible no intencionado que puede da\u00f1ar o dar lugar a una utilizaci\u00f3n \ninadecuada de los medicamentos, de acuerdo al National Coordinating Council for Medication Error Reporting: error \npotencial (A: capacidad de causar error), error sin da\u00f1o (B: error sin alcanzar al paciente; C: error alcanza al paciente sin \nda\u00f1o; D: error que requiere monitorizaci\u00f3n) y error con da\u00f1o (E: da\u00f1o temporal; F: da\u00f1o temporal con hospitalizaci\u00f3n/\nprolongaci\u00f3n de hospitalizaci\u00f3n; G: da\u00f1o permanente; H: compromete la vida del paciente). \n \nVariables recogidas: demogr\u00e1ficas, f\u00e1rmacos implicados (grupo terap\u00e9utico) en EM y RAMs. Variables categ\u00f3ricas \nexpresadas como porcentajes y continuas como media y desviaci\u00f3n est\u00e1ndar.\nRESULTADOS\nSe incluyeron 169(39%) de 433 pacientes identificados. Edad media 51,9(22,6) a\u00f1os, 97(57,4%) fueron mujeres.  \n \nSe identificaron 129(76,3%) RAM, siendo 120(93,1%) de tipo A, 8(6,2%) C y 1(0,7%) B. Los f\u00e1rmacos mayoritariamente \nimplicados fueron opioides 17(13,2%), antiepil\u00e9pticos 15(11,6%), antipsic\u00f3ticos 13(10,1%) y betalact\u00e1micos 7(5,4%).  \nSeg\u00fan gravedad, los opioides estuvieron implicados en 15(88,2%) moderadas y 2(11,8%) leves; antiepil\u00e9pticos en \n7(46,6%) moderadas, 6(40%) leves y 2(13,3%) graves; antipsic\u00f3ticos en 9 (69,2%) moderadas, 2(15,4%) leves y 2(15,4%) \ngraves; betalact\u00e1micos 100% fueron moderadas. Las 4 graves requirieron ingreso con monitorizaci\u00f3n continua.  \n \nCuarenta(23,6%) pacientes presentaron EM, siendo 24(60,0%) categor\u00eda E, 9(22,0%) C, 3(7,3%) D y F, y 2(4,9%) A. El 55% \nfueron relacionados con una dosis incorrecta\ufffd  \nLos f\u00e1rmacos implicados m\u00e1s frecuentemente fueron los antipsic\u00f3ticos 6(15,0%), gluc\u00f3sidos card\u00edacos 3(7,5%), \nansiol\u00edticos 2(5,0%) y betalact\u00e1micos 2(5,0%).  \nLa gravedad en antipsic\u00f3ticos, gluc\u00f3sidos cardiot\u00f3nicos y betalact\u00e1micos fue al 100% sin da\u00f1o, mientras que ansiol\u00edticos \nun 50% fueron error potencial\ufffd  \n 115Del total EA, 8(4,7%) requirieron ingreso hospitalario, prolongando su estancia una media de 20,5(25,5) d\u00edas. F\u00e1rmacos \nimplicados: 2(22,2%) digoxina, 4(44,4%) litio, 1 (11,1%) \u00e1cido valproico y 1(11,1%) fenito\u00edna.\nCONCLUSIONES\n- Las visitas a urgencias derivadas de un EA fueron mayoritariamente por una RAM, siendo los antiepil\u00e9pticos y \nantipsic\u00f3ticos los grupos farmacol\u00f3gicos implicados con gravedad elevada.  \n- La mayor\u00eda de EM fueron errores con da\u00f1o y relacionados con una dosificaci\u00f3n incorrecta.  \n- Los EA derivados de f\u00e1rmacos de estrecho margen terap\u00e9utico estuvieron relacionados con el ingreso hospitalario de los \npacientes\ufffd\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n970. AN\u00c1LISIS DEL USO DE METADONA PARA EL DESTETE DIFICULTOSO DE LA SEDOANALGESIA EN UNA \nUNIDAD DE CUIDADOS INTENSIVOS \nAUTORES\nBETANCOR GARC\u00cdA, T; GONZALEZ GARC\u00cdA, I; D\u00cdAZ D\u00cdAZ, CL; ESQUIVEL NEGR\u00cdN, J; SANTOS FAGUNDO, A; MERINO \nALONSO, FJ\nHOSPITAL NUESTRA SE\u00d1ORA DE CANDELARIA \ufffd CTRA \ufffd DEL ROSARIO, 145 SANTA CRUZ DE TENERIFE \ufffd SANTA CRUZ DE \nTENERIFE\nOBJETIVOS\nAnalizar el uso de metadona para el destete de perfusi\u00f3n de opioides en una unidad de cr\u00edticos.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo observacional en el que se analiz\u00f3 el uso de metadona v\u00eda enteral para destete dificultoso de opioides \nen el periodo comprendido entre agosto de 2021 y marzo de 2022. Se recogieron datos demogr\u00e1ficos y cl\u00ednicos de los \npacientes y se registraron los f\u00e1rmacos analg\u00e9sicos y sedantes recibidos. Las variables cuantitativas se expresaron como \nmedia \u00b1 desviaci\u00f3n est\u00e1ndar (DE) y las variables cuantitativas como porcentaje.\nRESULTADOS\nDurante el periodo de estudio 13 pacientes recibieron metadona con este prop\u00f3sito, 11 de ellos hombres (84.6%), con una edad \nmedia de 54\u00b115 a\u00f1os de edad. La metadona se inici\u00f3 tras una media de 42\u00b118 d\u00edas del ingreso en UCI y 36\u00b112 d\u00edas de la intubaci\u00f3n \norotraqueal. Al momento del inicio de la metadona, todos los pacientes hab\u00edan recibido perfusi\u00f3n continua de opioides (duraci\u00f3n \nmedia de 45\u00b127 d\u00edas) y perfusi\u00f3n continua de midazolam (25\u00b113 d\u00edas); adem\u00e1s, doce pacientes (92.3%) hab\u00edan recibido propofol \n(12\u00b15 d\u00edas ) y diez pacientes (76-9%) recibieron dexmedetomidina (7\u00b15 d\u00edas). En cuanto a otros medicamentos, once pacientes \nhab\u00edan recibido bloqueantes neuromusculares en perfusi\u00f3n continua, tres ketamina, ocho clonidina, y once otras benzodiazepinas \n(clorazepato dipot\u00e1sico, diazepam, alprazolam, clonazepam, lorazepam y/o lormetazepam).  \nLa dosis inicial de metadona fue de 23\u00b17 mg, dividida en 3-4 tomas diarias. A los dos d\u00edas del inicio de metadona, los \npacientes recibieron un 15\u00b122% de la dosis diaria previa de opioides en perfusi\u00f3n continua, a los cuatro d\u00edas, solo \nun paciente permanec\u00eda en tratamiento con perfusi\u00f3n de opioides, representando un 2.3\u00b19% de la dosis previa de \nla totalidad de pacientes. Adem\u00e1s, al inicio de la metadona, cuatro pacientes se encontraban en tratamiento con \nmidazolam, los cuales al segundo d\u00eda recibieron el 42.5\u00b145.2% de la dosis diaria inicial, al cuarto d\u00eda este f\u00e1rmaco se hab\u00eda \nsuspendido en todos los pacientes\ufffd Nueve pacientes se encontraban en tratamiento con propofol, recibiendo el segundo \nd\u00eda el 43.2\u00b145.4% de la dosis previa y el cuarto d\u00eda el 16.2\u00b126.1% de la dosis, al sexto d\u00eda ning\u00fan paciente continuaba con \neste f\u00e1rmaco. Finalmente, cinco pacientes recib\u00edan tratamiento con dexmedetomidina, consigui\u00e9ndose reducir la dosis a \nun 72.2\u00b137.4% al segundo d\u00eda y al 43.7\u00b147.3% el cuarto d\u00eda, d\u00eda en el que solo un paciente segu\u00eda recibiendo el f\u00e1rmaco. \nEn ning\u00fan paciente se report\u00f3 efectos adversos atribuibles a la metadona. La dosis de metadona se redujo gradualmente \nen intervalos de 48-72 horas, hasta la total suspensi\u00f3n, siendo la duraci\u00f3n media de tratamiento de 14\u00b15.3 d\u00edas. El \ntiempo entre el inicio de la metadona y la desconexi\u00f3n total de la ventilaci\u00f3n mec\u00e1nica fue de 11\u00b18.2 d\u00edas.\nCONCLUSIONES\nLa metadona result\u00f3 ser una medida eficaz en pacientes con destete dificultoso de la analgosedaci\u00f3n, consiguiendo la \nsuspensi\u00f3n de estos f\u00e1rmacos en un periodo corto de tiempo y sin reportarse efectos adversos.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n1267. ATENCI\u00d3N FARMAC\u00c9UTICA TEMPRANA EN URGENCIAS: AN\u00c1LISIS DE LOS FACTORES \nPREDISPONENTES AL INGRESO EN UN SOCIOSANITARIO ADSCRITO AL MISMO \nAUTORES\nGOZALO ESTEVE, I; SOLER BLANCO, N; RAMOS RODR\u00cdGUEZ, J; ORTONOBES ROIG, S; G\u00d3MEZ VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\nLa atenci\u00f3n farmac\u00e9utica temprana (AFT) realizada en los servicios de urgencias (SU) permite detectar problemas \nrelacionados con el medicamento (PRM) de forma precoz y evitar as\u00ed posibles reacciones adversas medicamentosas.  \nPara optimizar el tiempo dedicado a la AFT en el SU, los objetivos de nuestro estudio fueron: \n\u2022 Describir los pacientes que acuden al SU con previsi\u00f3n de ingreso al centro sociosanitario (SS)  \n\u2022 Analizar diferencias cl\u00ednicas y farmacol\u00f3gicas entre los que finalmente ingresaron en el sociosanitario(SS) y los que no116MATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo realizado en un hospital universitario de 500 camas de agudos y 300 de SS. Se \nincluyeron aquellos pacientes que acudieron al SU durante febrero-abril 2022 con petici\u00f3n de ingreso a SS  \nSe recogieron variables sociodemogr\u00e1ficas (sexo, edad) y cl\u00ednicas (clasificaci\u00f3n PCC/maca, motivo de ingreso, estancia en \nSU, destino al alta) disponibles en el momento del triaje as\u00ed como farmacol\u00f3gicas (n\u00famero PRM).  \nAn\u00e1lisis de las variables cuantitativas mediante el T- student y cualitativas con el test Chi-cuadrado.\nRESULTADOS\nSe realiz\u00f3 AFT en 478 pacientes, 275 (57,50%) mujeres. La edad media fue de 85,08 (DE 8,49) a\u00f1os. 240 (50,20%) \ncalificados PCC (paciente cr\u00f3nico complejo) y 35 (7,30%) MACA (enfermedad cr\u00f3nica avanzada).  \nSe agruparon los motivos de ingreso en: patolog\u00eda respiratoria 136 (28,50%), cardiovascular 94 (19,70%), infecciosa 67 \n(14,00%), alteraciones psicoconductuales 49 (10,30%), digestiva 42 (8,80%), hemost\u00e1sica 32 (6,70%) y otros (neurol\u00f3gica, \nendocrinol\u00f3gica, osteoarticular, onco-hematol\u00f3gica) 58 (12,10%). La estancia media en urgencias fue 2,53 (DE 1,27) d\u00edas. \nSe detectaron un total de 454 PRM, con una media de 1,12 (DE 1,19) PRM/paciente. \nFinalmente ingresaron en el SS 338 (70,70%) pacientes. El resto: 66 (13,80%) fueron dados de alta, 37 (7,70%) ingresaron \nen otras plantas hospitalizaci\u00f3n, 25 (5,20%) fueron exitus, y 12 (2,50%) fueron traslados.  \nComparando entre ingresados en SS vs no SS, se encontraron diferencias significativas en la detecci\u00f3n de PRM/paciente: \n1,22 (DE 0,06) vs 1,10 (DE 0,10) (p=0,03). \nNo se encontraron diferencias significativas en la clasificaci\u00f3n PCC/MACA (p= 0,242), los motivos de ingreso (p=0,347) ni \nen la estancia media en el SU: 2,56 (DE 1,22) vs 2,46 (DE 1,40) d\u00edas (p=0,440)\nCONCLUSIONES\n\u2022 Las principales patolog\u00edas que motivaron ingreso fueron la respiratoria y cardiovascular. La estancia media en urgencias \nfue dos d\u00edas y medio y se detect\u00f3 m\u00e1s de un PRM/ paciente \n\u2022 Casi el 30% de los pacientes con solicitud de ingresos en SS finalmente no ingresaron en el mismo.  \n\u2022 El n\u00famero de PRM/paciente fue mayor en los pacientes con ingreso en SS, reforzando la necesidad de priorizar la AFT \nen los mismos\ufffd  \n\u2022 Ninguna de las variables analizadas pudo usarse como factor predisponente a ingreso en SS.  \n\u2022 Se deber\u00edan analizar otras variables descritas en la bibliograf\u00eda, como el n\u00famero de f\u00e1rmacos prescritos o ingresos en \nlos \u00faltimos 3 meses, y valorar si predicen mejor los pacientes que acaban ingresando en urgencias\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n1277. EVALUACI\u00d3N DE LA ADECUACI\u00d3N A UN PROTOCOLO DE TRATAMIENTO EMP\u00cdRICO DE NEUMON\u00cdA \nADQUIRIDA EN LA COMUNIDAD AL INGRESO HOSPITALARIO. \nAUTORES\nMOLINA MART\u00cdNEZ, M; PONS MART\u00cdNEZ, L; CAMPILLO L\u00d3PEZ, J; ZAYAS SORIANO, M; BONETE S\u00c1NCHEZ, M; \nGONZ\u00c1LEZ L\u00d3PEZ, A; PLANELLES DE CASTRO, M; AZNAR SALIENTE, T\nHOSPITAL UNIVERSITARIO SAN JUAN DE ALICANTE. CTRA. ALICANTE-VALENCIA S/N SANT JOAN DALACANT . ALICANTE\nOBJETIVOS\nLa implantaci\u00f3n y difusi\u00f3n local de un protocolo espec\u00edfico de tratamiento emp\u00edrico de la neumon\u00eda adquirida en la \ncomunidad (NAC) mejora la prescripci\u00f3n antibi\u00f3tica y el pron\u00f3stico del paciente. \nEl objetivo es evaluar la adecuaci\u00f3n al protocolo de tratamiento emp\u00edrico de NAC al ingreso en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 pacientes adultos que ingresaron en el hospital con cualquier diagn\u00f3stico \nde neumon\u00eda en el mes de diciembre de 2021.  \nSe recogieron variables demogr\u00e1ficas (sexo, edad), cl\u00ednicas (cormobilidades, presi\u00f3n arterial, frecuencia cardiaca, \ntemperatura corporal, diagn\u00f3stico al ingreso, tratamiento antibi\u00f3tico al ingreso y estancia hospitalaria) y anal\u00edticas \n(hematocrito, urea, glucosa, pH arterial). Para evaluar el pron\u00f3stico de los pacientes se utiliz\u00f3 la escala FINE, que \nestratifica a los pacientes en 3 grupos: \n- Grupo 1: pacientes que reciben tratamiento ambulatorio.  \n- Grupo 2: requieren ingreso hospitalario.  \n- Grupo 3: precisan ingreso en unidad de cuidados intensivos.  \nEl protocolo de tratamiento consist\u00eda en:  \n- Pacientes del Grupo 1: Levofloxacino; Amoxicilina/clavul\u00e1nico + Claritromicina o Azitromicina.  \n- Pacientes del Grupo 2: Levofloxacino; Amoxicilina/clavul\u00e1nico + Azitromicina; Ceftriaxona + Azitromicina.  \n- Pacientes del Grupo 3: Levofloxacino + Ceftriaxona.  \n- Pacientes con factores de riesgo de infecci\u00f3n por Pseudomona aeruginosa: Ceftazidima o Imipenem + Levofloxacino o \nTobramicina, sin importar el grupo FINE al que pertenecen. \nSe defini\u00f3 como no adecuaci\u00f3n al protocolo, cualquier tratamiento o combinaci\u00f3n de antibi\u00f3ticos diferente a los \nexpuestos o la falta de prescripci\u00f3n de tratamiento antibi\u00f3tico.\nRESULTADOS\nSe incluyeron 50 pacientes (56% hombres) con una media de edad de 72,58 (\u00b114,64) a\u00f1os.  \nLa adherencia al protocolo fue del 54%. Se observ\u00f3 una disminuci\u00f3n del tiempo de hospitalizaci\u00f3n de 0,95 d\u00edas en los \npacientes en los que se cumpl\u00eda el protocolo.  117Las desviaciones del protocolo m\u00e1s significativas fueron: betalact\u00e1mico Amoxicilina/Clavul\u00e1nico o Ceftriaxona) \nen monoterapia (39%), carbapenems en monoterapia (9%), Betalact\u00e1mico + Levofloxacino (17%), combinaci\u00f3n \nantipseudom\u00f3nica en pacientes sin factores de riesgo de P . aeruginosa (9%) e ingreso sin tratamiento antibi\u00f3tico (4%).\nCONCLUSIONES\nExiste un alto porcentaje de falta de adecuaci\u00f3n al protocolo de NAC en nuestro centro.  \nCabe se\u00f1alar el frecuente uso de betalact\u00e1micos en monoterapia (no recomendado debido a la alta incidencia de NAC \nat\u00edpicas), as\u00ed como el uso no indicado de antibi\u00f3ticos de amplio espectro (carbapenems), lo cual favorece la aparici\u00f3n de \nresistencias\ufffd  \nLa terapia antibi\u00f3tica inapropiada tiene un impacto negativo sobre el pron\u00f3stico de los pacientes y la ecolog\u00eda de los \nantibi\u00f3ticos, as\u00ed como sobre la estancia media y los costes asociados.  \nLa implementaci\u00f3n de un protocolo deber\u00eda acompa\u00f1arse de estrategias de divulgaci\u00f3n para mejorar la formaci\u00f3n del \nmayor n\u00famero de personas implicadas en el proceso. El farmac\u00e9utico debe participar activamente en este proceso para \nmejorar la pr\u00e1ctica cl\u00ednica asistencial.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n1280. EVALUACI\u00d3N DEL IMPACTO CL\u00cdNICO, ECON\u00d3MICO Y ORGANIZATIVO DE LAS INTERVENCIONES \nFARMAC\u00c9UTICAS EN URGENCIAS: METODOLOG\u00cdA CLEO. \nAUTORES\nGARC\u00cdA PASTOR, C; RAMOS RODR\u00cdGUEZ, J; GOZALO ESTEVE, I; SOLER BLANCO, N; ORTONOBES ROIG, S; G\u00d3MEZ \nVALENT , M; DE CASTRO JULVE, M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\nAnalizar y describir la actividad del farmac\u00e9utico cl\u00ednico en el servicio de urgencias (SU) documentando las intervenciones \nfarmac\u00e9uticas (IF) realizadas y evaluar el impacto cl\u00ednico, econ\u00f3mico y organizativo asociado.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo en el que se documentaron todas las IF realizadas de 8:00 a 15:00 h por 3 \nfarmac\u00e9uticos en el per\u00edodo 13 - 29 Abril de 2022 (13 d\u00edas).  \n \nLas variables analizadas fueron: edad, IF, problema relacionado con los medicamentos (PRM), patolog\u00eda (Clasificaci\u00f3n \nInternacional de Enfermedades (CIE-10)), f\u00e1rmaco asociado al PRM, proactividad y aceptaci\u00f3n de la IF e impacto cl\u00ednico, \necon\u00f3mico y organizativo a partir de la metodolog\u00eda CLEO (Eur J Hosp Pharm. 2021 Jul;28(4):193-200. doi: 10.1136/\nejhpharm-2020-002642).\nRESULTADOS\nDurante el periodo de estudio, se realizaron un total de 241 IF en 165 pacientes con edad media de 84 a\u00f1os (DE15).  \n \nEl 41,9% (101) tuvieron un impacto cl\u00ednico mayor, 34% (82) moderado, 21,6% (52) menor y 2,5% (6) nulo. \n \nEl 69,7% (168) de las IF supon\u00edan un aumento del coste del tratamiento y/o monitorizaci\u00f3n, 17% (41) no supon\u00edan \nvariaci\u00f3n en el coste del tratamiento y/o monitorizaci\u00f3n y el 13,3% (32) consegu\u00edan que el coste del tratamiento y/o \nmonitorizaci\u00f3n disminuyese.  \n \nCon respecto al impacto organizativo, el 100% (241) de las IF mejoraron la calidad de la asistencia sanitaria.  \n \nLa atenci\u00f3n farmac\u00e9utica se realiz\u00f3 en 61 patolog\u00edas diferentes, relacionadas con 128 f\u00e1rmacos, 25 PRM y 15 tipos de IF. \nDe los 128 f\u00e1rmacos en los que se intervino, el 24,8% (31) eran f\u00e1rmacos de alto riesgo. Las patolog\u00edas en las que m\u00e1s \nse intervino fueron la diabetes mellitus (10,3%), la embolia y trombosis arterial (9,1%), la fibrilaci\u00f3n auricular (7,4%) y el \ndolor (6,2%).  \n \nDentro de los PRM m\u00e1s comunes, los 2 con mayor n\u00famero de IF fueron la indicaci\u00f3n de tratamiento para una condici\u00f3n \nno tratada (20,3%) y la omisi\u00f3n de un f\u00e1rmaco del tratamiento cr\u00f3nico (20,3%).  \n \nEl 100% (241) de las IF fueron proactivas, el 78% (188) aceptadas, 17,1% (43) estaba justificada la no aceptaci\u00f3n y 4,1% \n(10) fueron no aceptadas.\nCONCLUSIONES\nEl uso de la metodolog\u00eda CLEO para la evaluaci\u00f3n del impacto de las IF en urgencias supone un avance en el \u00e1mbito de la \nfarmacia cl\u00ednica, ya que es una herramienta validada, fiable y aplicable en pr\u00e1ctica cl\u00ednica habitual.  \n \nEl porcentaje de IF realizadas con un impacto cl\u00ednico mayor (41,9%) muestra el valor que aporta la farmacia cl\u00ednica en un \nentorno de alta complejidad asistencial como representan los servicios de urgencias.118CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n63. \u00bfQU\u00c9 OCURRE TRAS COMPLETAR UN A\u00d1O DE TRATAMIENTO CON LOS ANTICUERPOS MONOCLONALES \nANTI-CGRP PREVENTIVOS DE LOS ATAQUES DE MIGRA\u00d1A? \nAUTORES\nFRESAN RESTITUTO, D; LACALLE FABO, E; GO\u00d1I INDURAIN, N; PINO RAMOS, A; ERDOZAIN SANCLEMENTE, S; ORTEGA \nBELIO, I; MARTIN BUJANDA, M; SAROBE CARRICAS, MT\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nTras incorporar en 2019 de los anticuerpos monoclonales anti p\u00e9ptido relacionado con el gen de la calcitonina (AMC anti-\nGCRP) galcanezumab, erenumab y fremanezumab a las opciones terap\u00e9uticas preventivas de los pacientes con migra\u00f1a, \ntodav\u00eda existen incertidumbres sobre la duraci\u00f3n \u00f3ptima del tratamiento. El Grupo de Estudio de Cefaleas de la Sociedad \nEspa\u00f1ola de Neurolog\u00eda (GECSEN) plantea en su \u00faltimo \u201cManual de Pr\u00e1ctica Cl\u00ednica de Cefaleas\u201d mantenerlos de 6 a 12 \nmeses y los Informes de Posicionamiento Terap\u00e9utico del Ministerio de Sanidad, Consumo y Bienestar Social reevaluar \nperi\u00f3dicamente su necesidad si a los 3 meses existe beneficio terap\u00e9utico.  \nEl objetivo de este estudio consiste en analizar qu\u00e9 ocurre con los pacientes que completan los 12 meses de tratamiento.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional realizado en un hospital terciario con consulta monogr\u00e1fica de cefaleas entre \ndiciembre-2019 y abril-2022. Se incluyen los pacientes que han iniciado tratamiento hasta abril del 2021 para poder \nhaber completado el a\u00f1o de tratamiento.  \nEl protocolo del hospital contempla emplear los AMC anti-GCRP hasta un m\u00e1ximo de 12 meses si demuestran efectividad \ny seguridad en la evaluaci\u00f3n que se realiza a los 3 meses del inicio. Se considera efectivo aquel tratamiento que consigue \nreducir los d\u00edas de migra\u00f1a al mes al menos en un 50% respecto a la situaci\u00f3n basal y/o una mejora significativa en la \ncalidad de vida (evaluada por las escalas HIT6 y MIDAS).\nRESULTADOS\n240 pacientes iniciaron tratamiento con AMC anti-CGRP hasta abril-2021, de los cuales el 74% (n:177) lo mantuvo durante \n12 meses\ufffd  \nDe estos 177 el 68% (n: 121) ha reintroducido el tratamiento, manteniendo el mismo AMC anti-CGRP en 98 pacientes y \ncambiando a otro con diferente mecanismo de acci\u00f3n (antiligando/antirreceptor) en 23: 44 pacientes lo mantienen de \nforma cr\u00f3nica (porque el tratamiento ha mostrado efectividad en los \u00faltimos meses) o cambian directamente a otro AMC \n(porque la efectividad del primero fue disminuyendo en el transcurso de los 12 meses); 17 reinician antes de 3 meses \n(media: 1,65 meses (1-2)); 44 entre 3 y 5 meses (media: 4,02 meses (3-5)) y 16 en \u2265 6 meses (media: 8,06 meses (6-15)).  \nEl 32% (n: 56) de los pacientes que completa un a\u00f1o de tratamiento no lo ha reiniciado: 9 se encuentran en un periodo \ninferior a 3 meses de haber finalizado el tratamiento; 16 entre 3 y 5 meses y 31 en \u2265 6 meses, llevando 14 un a\u00f1o o m\u00e1s.\nCONCLUSIONES\nEl 74% (177/240) de los pacientes que inicia tratamiento con un ACM anti-CGRP completa el a\u00f1o de tratamiento con \neficacia y seguridad y la probabilidad de reintroducirlo a posteriori es del 50% (121/240). \nEl 18% (44/240) contin\u00faa el tratamiento de forma cr\u00f3nica sin interrupci\u00f3n, el 7% (17/240) lo reintroduce antes de los 3 \nmeses tras finalizar el primer ciclo, el 18% (44/240) entre los 3-5 meses y el 7% (16/240) a partir de los 6 meses. \nSe mantiene estabilidad cl\u00ednica al menos durante 3 meses en el 70% (119/168) de pacientes que finalizan el a\u00f1o de \ntratamiento y desciende al 31% a los 6 meses (47/152).\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n65. EFECTIVIDAD Y SEGURIDAD DE ERENUMAB EN PACIENTES CON MIGRA\u00d1A CR\u00d3NICA O EPIS\u00d3DICA \nEN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nJIM\u00c9NEZ L\u00d3PEZ, Y; P\u00c9REZ CANO, E; MU\u00d1OZ CID, CL; GARC\u00cdA G\u00d3MEZ, N\nCOMPLEJO HOSPITALARIO DE JA\u00c9N. AV . DEL EJ\u00c9RCITO ESPA\u00d1OL, 10 JA\u00c9N. JA\u00c9N\nOBJETIVOS\nErenumab es un anticuerpo monoclonal que inhibe la actividad del p\u00e9ptido relacionado con el gen de la calcitonina \n(CGRP), que ha demostrado tener un papel importante en la cefalea migra\u00f1osa. El objetivo del estudio fue evaluar la \nefectividad y seguridad de erenumab en la profilaxis de la migra\u00f1a en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio observacional retrospectivo en un hospital terciario. El estudio incluy\u00f3 a todos los pacientes tratados \ncon erenumab (pauta posol\u00f3gica: 70mg/mes o 140 mg/mes) desde septiembre de 2019 hasta febrero de 2022. Se \nexcluyeron los pacientes que no llevaran al menos 3 meses de tratamiento o por ausencia de datos debido a la falta de \nrevisiones posteriores\ufffd \nLas variables se consultaron en la historia cl\u00ednica digitalizada de los pacientes: edad, sexo, tratamientos previos que \nfracasaron, n\u00famero de administraciones de erenumab, dosis, d\u00edas de migra\u00f1a al mes (DMM) antes del tratamiento y 3 119meses despu\u00e9s del inicio, y reacciones adversas (RA).  \nLas variables de efectividad y seguridad fueron: reducci\u00f3n de los DMM al menos un 50% y la reducci\u00f3n al menos un 75% \ncon respecto al valor basal, y la tasa de RA, respectivamente.\nRESULTADOS\nEl estudio incluy\u00f3 a 38 pacientes cuya edad media fue de 51 a\u00f1os. 32 pacientes eran mujeres y 6 eran hombres. \n33 pacientes padec\u00edan migra\u00f1a cr\u00f3nica (de los cuales 8 ten\u00edan migra\u00f1a cr\u00f3nica refractaria) y 5 pacientes padec\u00edan \nmigra\u00f1a epis\u00f3dica con una frecuencia mayor de cefaleas. Todos los pacientes hab\u00edan tenido \u2265 3 tratamientos previos y el \n92% de ellos hab\u00edan sido tratados con toxina botul\u00ednica. El n\u00famero medio de administraciones de erenumab fue de 11.  \n24 pacientes recibieron desde el inicio 140 mg de erenumab/mes. Los 14 restantes empezaron con una pauta de 70 mg, \naumentando todos ellos finalmente a 140 mg.  \nLa frecuencia media de migra\u00f1as previa al inicio de tratamiento era de 16,3 DMM, y a los tres meses se observ\u00f3 una \nreducci\u00f3n media de -7,2 DMM. 21 pacientes (55,3%) redujeron su DMM al menos un 50% y, de estos, 13 pacientes \n(34,2%) alcanzaron una reducci\u00f3n \u2265 75%. 17 pacientes (44,7%) no notaron mejor\u00eda con respecto al valor basal.  \nEn cuanto a seguridad, 7 pacientes (18,4%) informaron de RA leves: 4 pacientes sufrieron insomnio, 2 estre\u00f1imiento y \notro tuvo v\u00e9rtigo.\nCONCLUSIONES\nEl tratamiento con erenumab ha sido efectivo en el 55,3% de los pacientes revisados, los cuales han reducido los DMM al \nmenos un 50%\ufffd  \nPodemos considerarlo un f\u00e1rmaco seguro ya que s\u00f3lo el 18,4% de los pacientes presentaron RA leve que no requirieron \nintervenci\u00f3n\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n102. UTILIZACI\u00d3N DE OCRELIZUMAB EN GLOMERULONEFRITIS REFRACTARIA: A PROP\u00d3SITO DE 2 CASOS \nCL\u00cdNICOS. \nAUTORES\nPAU PARRA, A; DEL R\u00cdO GUTI\u00c9RREZ, JM; RAMOS TERRADAS, N; AGRAZ PAMPLONA, I; GORGAS TORNER, MQ; \nMONTORO RONSANO, JB\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nOcrelizumab es un anticuerpo monoclonal humanizado espec\u00edfico frente a linfocitos B CD20+, provocando su depleci\u00f3n a \ntrav\u00e9s de la fagocitosis y citotoxicidad celular dependiente de anticuerpos, citotoxicidad dependiente del complemento \ny la apoptosis. Un \u00fanico caso cl\u00ednico publicado describe su utilizaci\u00f3n en glomerulonefritis membranosa anti-PLA2R \npositivo, indicaci\u00f3n no autorizada (INA), en una paciente diagnosticada posteriormente de EM, evidenci\u00e1ndose remisi\u00f3n \nde la nefropat\u00eda. Comparado con rituximab, otro anticuerpo anti-CD20 utilizado en glomerulonefritis, presenta menor \ninmunogenicidad, as\u00ed como una mayor y m\u00e1s prolongada depleci\u00f3n de linfocitos B CD20+. El objetivo es describir el uso \nde ocrelizumab en 2 pacientes con glomerulonefritis refractaria a tratamientos convencionales.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional, incluyendo variables cl\u00ednicas, anal\u00edticas y tratamientos previos, obtenido de la \nhistoria cl\u00ednica electr\u00f3nica. Ocrelizumab interviene en el reconocimiento de CD20 en el ensayo de determinaci\u00f3n de \npoblaciones linfocitarias, por lo que se eval\u00faa su efecto mediante la depleci\u00f3n de linfocitos B CD19+.\nRESULTADOS\nPaciente 1:  \n \nMujer de 35 a\u00f1os diagnosticada de glomerulonefritis focal y segmentaria, con s\u00edndrome nefr\u00f3tico de inicio en la infancia, \npresentando desde entonces varios brotes. Desde hace 7 a\u00f1os mantiene enfermedad activa sin remisi\u00f3n completa, \nrecibiendo tratamiento con m\u00faltiples f\u00e1rmacos: corticoides, azatioprina, tacrolimus, ciclosporina, micofenolato de mofetilo, \nomalizumab, rituximab, tocilizumab y ofatumumab (logrando con este una remisi\u00f3n parcial), as\u00ed como plasmaf\u00e9resis. Ante \ns\u00edndrome nefr\u00f3tico refractario, con ganancia de peso, edemas, mala tolerancia a diur\u00e9ticos y recidiva bioqu\u00edmica (proteinuria \n12.5 g/d\u00eda, microalbuminuria 2.5 mg/min y alb\u00famina s\u00e9rica 1,9 g/dL), aunque con la funci\u00f3n renal preservada, se indica \ninicio de ocrelizumab. Se administran 2 dosis de ocrelizumab 300 mg v\u00eda intravenosa separadas 14 d\u00edas, con una correcta \ntolerancia. A los 3 meses de recibir ocrelizumab, destaca una reducci\u00f3n de la proteinuria del 68% (12.1 g/d\u00eda\u21923.9 g/d\u00eda) y \nun ligero incremento de la alb\u00famina (1.9 g/dL\u21922.5 g/dL), con depleci\u00f3n de linfocitos B CD19+ y aparente remisi\u00f3n cl\u00ednica.  \n \nPaciente 2:  \n \nMujer de 43 a\u00f1os, diagnosticada de glomerulonefritis membranosa con dep\u00f3sito de anticuerpos anti-PLA2R y s\u00edndrome \nnefr\u00f3tico refractario al tratamiento farmacol\u00f3gico convencional, recibiendo previamente micofenolato de mofetilo, \ntacrolimus, corticoides y rituximab, presentando con este una reacci\u00f3n infusional grave (disnea, opresi\u00f3n precordial \ny estridor), obligando a la suspensi\u00f3n del tratamiento. Se administra ocrelizumab (300mg/14 d\u00edas), con una correcta \ntolerancia. A nivel anal\u00edtico, se observa disminuci\u00f3n de la proteinuria del 79% (3.9 g/24h\u21920.8 g/24h), alb\u00famina s\u00e9rica \nestable (3.4 g/dL\u21923.5 g/dL) y funci\u00f3n renal preservada, con depleci\u00f3n de linfocitos B CD19+ y aparente remisi\u00f3n cl\u00ednica.  \n \nEn ambas pacientes la intenci\u00f3n es repetir la administraci\u00f3n de ocrelizumab cada 14 d\u00edas (2 dosis) a los 6 meses.120CONCLUSIONES\n-El efecto de ocrelizumab en la depleci\u00f3n de linfocitos B CD20+, implicados en diversas enfermedades sist\u00e9micas con \nafectaci\u00f3n renal, le confiere actividad inmunomoduladora.  \n-Dada la falta de opciones terap\u00e9uticas en pacientes con glomerulonefritis y s\u00edndrome nefr\u00f3tico refractario a terapias \nconvencionales, ocrelizumab constituye una alternativa de tratamiento, especialmente en intolerancia a rituximab.  \n-En nuestros pacientes, ocrelizumab parece ser eficaz y seguro, mostrando una marcada reducci\u00f3n de la proteinuria y \nremisi\u00f3n cl\u00ednica, aunque es indispensable realizar estudios que avalen su uso en esta indicaci\u00f3n.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n105. ANALISIS DEL USO DE GALCANEZUMAB EN VIDA REAL EN PACIENTES CON MIGRA\u00d1A CR\u00d3NICA \nAUTORES\nTARD\u00c1GUILA MOLINA, P; BLANCO CRESPO, M; CODONAL DEMETRIO, A; CORRALES KROHNERT , S; MART\u00cdNEZ RUIZ, \nE; CASARRUBIOS L\u00c1ZARO, GI; CARRASCO CORRAL, T\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\n- Analizar la efectividad de galcanezumab en la profilaxis de la migra\u00f1a cr\u00f3nica despu\u00e9s de un a\u00f1o de seguimiento.  \n- Evaluar la respuesta a otros anticuerpos monoclonares anti-p\u00e9ptido relacionado con el gen de la calcitonina (CGRP) tras \nfracaso a dicho f\u00e1rmaco.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional-retrospectivo de enero de 2020 a abril de 2022. Se incluyeron los pacientes que iniciaron \ngalcanezumab y que desde el inicio del tratamiento hubiese pasado al menos un a\u00f1o.  \nLas variables analizadas fueron: demogr\u00e1ficas, d\u00edas migra\u00f1a/mes (DMM) basal, tres meses despu\u00e9s del tratamiento, tasa \nde respuesta objetiva (TRO) > 50%, duraci\u00f3n y motivo de suspensi\u00f3n.  \nSe realiz\u00f3 el test del impacto funcional (HIT-6) basal vs a los tres meses de tratamiento. Este test consta de 6 preguntas \ncuya puntuaci\u00f3n presenta un rango entre 36 y 78 ( < 49= poco o ning\u00fan impacto, 50-55= cierto impacto, 56-59= impacto \nimportante, > 60= impacto muy severo).  \nLas variables cuantitativas se expresaron en mediana (rango intercuartil) y las cualitativas en valor absoluto.\nRESULTADOS\nSe incluyeron 44 pacientes. Mediana de edad 48 a\u00f1os (42-58), 78% mujeres. Mediana de duraci\u00f3n de galcanezumab: 6 \nmeses (3-12). Mediana de DMM basal: 15 (14-17) vs 5 (3-8) tras tres meses de tratamiento. El 80% present\u00f3 TRO > 50% \ncon una mediana de reducci\u00f3n del 70% (60-75). La mediana de puntuaci\u00f3n HIT-6 basal fue de 72 (68-78) vs 48 (48-56) a \nlos tres meses\ufffd  \nEl 18% de los pacientes contin\u00faan con tratamiento activo, manteniendo efectividad el 84%, mediana DMM: 3 (3-4).  \nUn 82% discontinuaron el tratamiento. Los motivos fueron:  \n\u2022 Decisi\u00f3n del neur\u00f3logo (58%). En estos pacientes:  \no Un 38% reiniciaron galcanezumab. El 88% present\u00f3 TRO > 50%, con una mediana de reducci\u00f3n del 80% (54-84).  \no Un 5% reinici\u00f3 fremanezumab. El 100% present\u00f3 TRO > 50%, con una reducci\u00f3n del 84%.  \no El resto (57%), no han precisado iniciar de nuevo tratamiento con anti-CGRP . Mediana de meses sin tratamiento tras la \nsuspensi\u00f3n: 10 (8-12).  \n \n\u2022 Falta de efectividad (22%) y p\u00e9rdida de respuesta a partir de los 3 meses de tratamiento (14%). En estos pacientes:  \n \no Un 54% cambi\u00f3 a fremanezumab: El 57% present\u00f3 una TRO > 50% con una mediana de reducci\u00f3n del 66% (16-74).  \no Un 23% cambi\u00f3 a erenumab: La TRO > 50% se consigui\u00f3 en un paciente, con una reducci\u00f3n del 66%.  \n \n\u2022 Efectos adversos (6%): El m\u00e1s frecuente fue el v\u00e9rtigo.\nCONCLUSIONES\nUn elevado porcentaje de pacientes presentaron buena respuesta a galcanezumab, con una mejor\u00eda en puntuaci\u00f3n HIT-6 \ny un impacto funcional de la migra\u00f1a bajo despu\u00e9s de 3 meses.  \nEn el periodo de este estudio, un elevado porcentaje de pacientes que recibi\u00f3 profilaxis con galcanezumab de forma \ntemporal, no requiri\u00f3 acudir de nuevo a la consulta de neurolog\u00eda. La mayor\u00eda de los pacientes que precisaron \nreintroducir galcanezumab tras dicha suspensi\u00f3n alcanzaron TRO > 50%.  \nAproximadamente la mitad de los pacientes que reinician terapia con un anti-CGRP diferente tras fracaso a galcanezumab \nalcanzaron TRO > 50%. Sin embargo el porcentaje de reducci\u00f3n de los d\u00edas de migra\u00f1a fue inferior en estos pacientes \nrespecto a los que tuvieron una respuesta inicial a galcanezumab.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n111. DUPILUMAB Y SU USO A LARGO PLAZO EN DERMATITIS AT\u00d3PICA: EFECTIVIDAD Y SEGURIDAD \nAUTORES\nS\u00c1NCHEZ GUND\u00cdN, J; ILLARO URANGA, A; G\u00d3MEZ G\u00d3MEZ, D; BARBADILLO VILLANUEVA, S; FERN\u00c1NDEZ MART\u00cdNEZ, \nV; RIOJA CARRERA, M; DEL R\u00cdO ORTEGA, P; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA121OBJETIVOS\nEstudiar la efectividad y seguridad de dupilumab en dermatitis at\u00f3pica (DA) moderada-grave a corto y largo plazo.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo de pacientes en tratamiento con dupilumab para DA moderada-grave durante 52 \nsemanas en un hospital de tercer nivel. \nVariables recogidas: edad, sexo, uso previo de corticoides t\u00f3picos y ciclosporina, posolog\u00eda, fecha de inicio del tratamiento \ny duraci\u00f3n del mismo\ufffd  \nLa efectividad se evalu\u00f3 con las escalas EASI (Eczema Area and Severity Index) e IGA (Investigator Global Assessment) en \nsemanas 16, 24 y 52. Se consider\u00f3 un tratamiento efectivo cuando se hab\u00eda reducido el EASI un 50% (EASI50) y cuando se \nhab\u00eda reducido el IGA \u22652 puntos. Tambi\u00e9n se recogieron datos de EASI75, EASI90 y EASI100 en las mismas semanas.  \nPara evaluar la seguridad, se recogieron los efectos adversos (EA) referidos por el paciente y se revisaron las anal\u00edticas \ndurante el periodo del estudio\ufffd  \nLos datos se obtuvieron del Sistema de Informaci\u00f3n para determinar el Valor Terap\u00e9utico en Pr\u00e1ctica Cl\u00ednica Real de \nMedicamentos de Alto Impacto Sanitario y Econ\u00f3mico (VALTERMED), historia cl\u00ednica electr\u00f3nica (Altamira\u00ae) y m\u00f3dulo de \nprescripci\u00f3n electr\u00f3nica asistida (PEA\u00ae). \nPara el an\u00e1lisis estad\u00edstico se utilizaron medidas de tendencia central y dispersi\u00f3n.\nRESULTADOS\nSe incluyeron 22 pacientes con DA moderada-grave en tratamiento con dupilumab. La edad media fue de 36\u00b113 a\u00f1os con \npredominio masculino (77%). Todos los pacientes hab\u00edan sido tratados previamente con corticoides t\u00f3picos y ciclosporina, \nsin \u00e9xito. En cuanto a la posolog\u00eda, todas fueron acorde a ficha t\u00e9cnica, sin intensificaciones ni optimizaciones.  \nEfectividad: en semana 0, los datos de EASI e IGA fueron de 34.0\u00b18.6 y 3.7\u00b10.4, respectivamente, datos que se redujeron \nen semana 16 (EASI 5.2\u00b13.8 e IGA 1.1\u00b10.4). En semanas 24 y 52, sigui\u00f3 reduci\u00e9ndose el EASI (4.9\u00b12.7 y 3.4\u00b12.9) y el IGA \nse mantuvo (1.1\u00b10.4 y 1.1\u00b10.3). Todos los pacientes consiguieron desde la semana 16 alcanzar EASI50 y reducir el IGA \n\u22652 puntos. En cuanto al EASI75, este se alcanz\u00f3 en el 77% de los pacientes en semana 16, 90% en semana 24 y 95% en \nsemana 52. Respecto al EASI90, se alcanz\u00f3 en el 27% de los pacientes en semana 16, 24% en semana 24 y 45% en semana \n52. S\u00f3lo un paciente alcanz\u00f3 EASI100 en semana 52. A fecha fin de estudio, todos los pacientes continuaban tratamiento \ntras una mediana de 66 semanas (52-74).  \nSeguridad: El 77% de los pacientes presentaron EA, principalmente eosinofilia (recuento absoluto de eosin\u00f3filos > \n1000c\u00e9l/mcL; 54%) y conjuntivitis (50%). 1 paciente tuvo que interrumpir el tratamiento entre semana 8 y 29 por EA \n(artralgias y malestar general).\nCONCLUSIONES\nDupilumab resulta ser un f\u00e1rmaco efectivo para la DA moderada-grave, efectividad que se mantiene tras un a\u00f1o \nde tratamiento. Estos resultados son alentadores en esta patolog\u00eda tan limitante a nivel cut\u00e1neo y con tan marcada \nafectaci\u00f3n psicosocial, sin embargo, ser\u00eda retador intentar alcanzar EASI90 o incluso EASI100, mejoras que se persiguen \nen otras patolog\u00edas cut\u00e1neas. En cuanto al perfil de seguridad, \u00e9ste fue similar al descrito en otros estudios. Finalmente, \nser\u00edan necesarios estudios con mayor n\u00famero de pacientes para confirmar estos resultados.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n126. ESTUDIO EN VIDA REAL. EFECTIVIDAD Y SEGURIDAD DE FREMANEZUMAB EN PROFILAXIS DE LA \nMIGRA\u00d1A. \nAUTORES\nBLANCO GARC\u00cdA, P; FERN\u00c1NDEZ PE\u00d1A, S; GUITI\u00c1N BERMEJO, C; FIJ\u00d3 PRIETO, A; \u00c1LVAREZ GRANDE, B; GONZ\u00c1LEZ \nGONZ\u00c1LEZ, C; QUEIPO GARC\u00cdA, E; S\u00c1NCHEZ S\u00c1NCHEZ, MT\nHOSPITAL CLINICO UNIVERSITARIO DE VALLADOLID. AV . RAM\u00d3N Y CAJAL, 3 VALLADOLID. VALLADOLID\nOBJETIVOS\nAnalizar la efectividad y seguridad del tratamiento con fremanezumab en profilaxis de migra\u00f1a cr\u00f3nica y epis\u00f3dica en un \nhospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, en el que fueron incluidos todos los pacientes que iniciaron tratamiento con \nfremanezumab durante el periodo del estudio (Diciembre 2020-Marzo 2022). Se excluyeron pacientes que hab\u00edan \nrecibido previamente tratamiento con f\u00e1rmacos antagonistas del p\u00e9ptido relacionado con el gen de la calcitonina (CGRP). \nTambi\u00e9n se excluyeron aquellos que no hab\u00edan cumplido 6 meses de tratamiento al finalizar el estudio. Variables de \nefectividad: n\u00ba migra\u00f1as mensuales, % reducci\u00f3n de migra\u00f1as/mes a los 6 meses de tratamiento respecto al n\u00famero \nmigra\u00f1as/mes basal. Variables de seguridad: presencia de efectos adversos (EA), tipo de EA, retirada del tratamiento por \nEA\ufffd \nLos datos se obtuvieron de la historia cl\u00ednica electr\u00f3nica, informaci\u00f3n de los pacientes proporcionada en los seguimientos \nde atenci\u00f3n farmac\u00e9utica y calendarios de cefaleas mensuales cumplimentados por los pacientes.  \nSe registraron los datos en una base dise\u00f1ada a tal efecto. Para las variables cuantitativas se realiz\u00f3 un an\u00e1lisis descriptivo \nde las medidas de tendencia central y de dispersi\u00f3n, y para variables cualitativas frecuencias y porcentajes.\nRESULTADOS\n55 pacientes fueron tratados durante el periodo de estudio. Se excluyeron: 9 pacientes por haber recibido tratamiento \nprevio con antagonistas CGRP y 5 por no haber recibido al menos 6 meses de tratamiento. Finalmente, se incluyeron 41 122pacientes: 38 (92,7%) mujeres, media de edad 48,6\u00b111,2 a\u00f1os. 35 (85,4%) pacientes con diagn\u00f3stico de migra\u00f1a cr\u00f3nica \ncon una mediana de 14 (9-17,5) migra\u00f1as mensuales antes de iniciar el tratamiento; 6 (14,6%) pacientes con migra\u00f1a \nepis\u00f3dica con una mediana de 14 (9-16) migra\u00f1as mensuales previas al inicio de tratamiento. Los pacientes hab\u00edan sido \ntratados previamente con una media de 4 \u00b1 1,3 tratamientos\ufffd  \nEfectividad: 15 (36,6%) pacientes tuvieron una respuesta > 75% en reducci\u00f3n del n\u00famero de migra\u00f1as respecto al basal, \n17 (41,5%) pacientes tuvieron una reducci\u00f3n \u226550-75%, 3 (7,3%) reducci\u00f3n 30-50%, y 6 (14,6%) no tuvieron respuesta \nconsiderando la reducci\u00f3n mensual del n\u00famero de migra\u00f1as. Tras 6 meses de tratamiento, la mediana de migra\u00f1as/mes \nen migra\u00f1a cr\u00f3nica fue de 4 (3-6,5), y de 4 (2-5,5) en migra\u00f1a epis\u00f3dica. \nSeguridad: 10 (24,4%) pacientes presentaron alg\u00fan EA durante el periodo de estudio, de car\u00e1cter leve y en ning\u00fan caso se \nsuspendi\u00f3 el tratamiento. Los EA m\u00e1s frecuentes fueron: 4 (9,75%) estre\u00f1imiento, 4 (9,75%) picor o prurito en la administraci\u00f3n.\nCONCLUSIONES\nLos pacientes de nuestro estudio est\u00e1n m\u00e1s pretratados que los incluidos en los ensayos cl\u00ednicos.  \nRespecto a la efectividad, en m\u00e1s del 80% de los pacientes se redujo el n\u00ba de migra\u00f1as, siendo esta reducci\u00f3n superior al \n50% en m\u00e1s de \u00be partes de los pacientes a pesar de ser pacientes m\u00e1s pretratados que los incluidos en los ensayos. La \nmediana de migra\u00f1as se redujo de 14 migra\u00f1as/mes a 4 con el tratamiento.  \nRespecto a la seguridad, pocos pacientes tuvieron EA, todos ellos leves. Casi un 10% de los pacientes ha referido \nestre\u00f1imiento, EA no recogido en la ficha t\u00e9cnica del medicamento.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n129. EFECTIVIDAD Y SEGURIDAD DE LA VACUNACI\u00d3N COVID-19 EN PACIENTES CON ENFERMEDADES \nINMUNOMEDIADAS A TRATAMIENTO BIOL\u00d3GICO: ESTUDIO BIOVACOVID. \nAUTORES\nBARCA DIEZ, C; PROUPIN CANTELAR, IC; BUSTELO PAZ, F; GONZALEZ FREIRE, L; CASTRO LUACES, S; BOULLOSA LALE, \nS; VEIGA VILLAVERDE, AB; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA\nOBJETIVOS\nLa eficacia y seguridad de las vacunas COVID-19 comercializadas en Espa\u00f1a est\u00e1 demostrada en los ensayos pivotales que \nhan llevado a la aprobaci\u00f3n de las mismas. Sin embargo, no se dispone de informaci\u00f3n espec\u00edfica a cerca de la vacunaci\u00f3n \nCOVID-19 en pacientes con enfermedades inmunomediadas (EI).  \nCon este estudio se pretende evaluar la efectividad y seguridad de las vacunas COVID-19 en pacientes con EI que se \nencuentran a tratamiento con f\u00e1rmacos biol\u00f3gicos (FB).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo descriptivo en el que se incluyeron a pacientes con EI a tratamiento con FB que hayan \nrecibido al menos una dosis de alguna de las vacunas COVID-19 comercializadas en Espa\u00f1a.  \nSe recogieron las siguientes variables: edad, sexo, EI, FB, pauta de vacunaci\u00f3n, infecci\u00f3n COVID-19 post-vacuna, \nreacciones adversas observadas tras la vacunaci\u00f3n\ufffd  \nLos datos demogr\u00e1ficos y cl\u00ednicos se obtuvieron revisando la historia cl\u00ednica de los pacientes seleccionados.  \nPara evaluar la efectividad se comprob\u00f3 el n\u00famero de pacientes que se hab\u00edan infectado por SARS-CoV-2 tras la \nvacunaci\u00f3n y si la infecci\u00f3n curso de manera asintom\u00e1tica, con s\u00edntomas leves o requiri\u00f3 ingreso hospitalario.  \nPara evaluar la seguridad se realiz\u00f3, durante la pr\u00e1ctica farmac\u00e9utica habitual, una entrevista normalizada a cerca de las \nreacciones adversas observadas los siete primeros d\u00edas tras la vacunaci\u00f3n COVID-19.  \nEste estudio fue aprobado por el Comit\u00e9 de \u00e9tica de la investigaci\u00f3n con medicamentos con el c\u00f3digo: 2021/435.\nRESULTADOS\nSe incluyeron 106 pacientes (52,8% mujeres), con una mediana de edad de 53 a\u00f1os (21-76). Las EI m\u00e1s frecuentes fueron: \nartritis reumatoide (33%), artritis psori\u00e1sica (15%), psoriasis (15%) y enfermedad de Crohn (11,3%). Los FB m\u00e1s utilizados \nfueros: adalimumab (33,9%), etanercept (25,5%), abatacept (7,5%), ixekizumab (6,6%), secukinumab (6,6%), golimumab \n(5,7%) y ustekinumab (4,7%).  \nLa pauta de vacunaci\u00f3n fue completa en 105 pacientes (99%). Las pautas m\u00e1s frecuentes fueron: 2 dosis de Comirnaty\u00ae \n(Pfizer-BioNTech) + 1 dosis de Spikevax\u00ae (Moderna) (43,4%); 3 dosis de Comirnaty\u00ae (24,5%); 2 dosis de Vaxzevria\u00ae \n(Oxford/Astrazeneca) + 1 de Spikevax\u00ae (9,4%) y 2 dosis de Vaxzevria\u00ae + 1 de Comirnaty\u00ae (9,4%).  \nTras recibir alguna dosis de las vacunas COVID-19 se infectaron 22 pacientes (20,75%): 2 tras la primera dosis, 6 tras \nla segunda dosis y 14 tras la tercera dosis. Los pacientes infectados presentaron sintomatolog\u00eda leve (77,3%) o fueron \nasintom\u00e1ticos (22,7%). Ning\u00fan paciente requiri\u00f3 ingreso hospitalario.  \nLas reacciones adversas m\u00e1s habituales fueron: dolor en el punto de inyecci\u00f3n (79,2%), fatiga (48%), malestar general \n(42,4%), mialgias (35,8%), cefalea (33%), artralgias (25,5%), fiebre (21,7%), prurito (11,3%), n\u00e1useas o v\u00f3mitos (9,4%), y \nlinfadenopat\u00edas (9,4%).\nCONCLUSIONES\nEl 79,25% de los pacientes estudiados no se infectaron por SARS-CoV-2 tras la vacunaci\u00f3n. En cuanto a los pacientes \ninfectados la mayor\u00eda curs\u00f3 la enfermedad con sintomatolog\u00eda leve y ninguno requiri\u00f3 ingreso hospitalario.  \nLas reacciones adversas fueron similares a las descritas en la poblaci\u00f3n general siendo las m\u00e1s frecuentes dolor en el \npunto de inyecci\u00f3n, fatiga y malestar general.  \nLas vacunas COVID-19 resultaron efectivas y seguras en los pacientes con EI a tratamiento con FB incluidos en el estudio.123CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n134. AN\u00c1LISIS DE LA PERSISTENCIA DE PACIENTES EN TRATAMIENTO CON CARIPRAZINA EN UN CENTRO \nDE REHABILITACI\u00d3N PSICOSOCIAL. \nAUTORES\nMART\u00cdNEZ CRESPO, A; ARANDA CA\u00d1ADA, E; LOZANO ORT\u00cdZ, R; APESTEGU\u00cdA TOMAS, I\nCENTRO DE REHABILITACION PSICOSOCIAL NUESTRA SE\u00d1ORA DEL PILAR. DUQUESA DE VILLAHERMOSA, 66-68 \nZARAGOZA \ufffd ZARAGOZA\nOBJETIVOS\nEl objetivo principal del trabajo ha consistido en evaluar la persistencia del tratamiento con cariprazina, un nuevo \nantipsic\u00f3tico que se empez\u00f3 a comercializar en Espa\u00f1a en el a\u00f1o 2019, como marcador subrogado de efectividad y, \nsecundariamente, su uso terap\u00e9utico en las distintas indicaciones.\nMATERIALES Y M\u00c9TODOS\nEstudio ambispectivo realizado sobre una muestra compuesta por todos los pacientes de un Centro Neuropsiquiatrico en \ntratamiento con cariprazina, ya fuera en el momento de ingresar o durante su estancia en el Centro. El estudio se inici\u00f3 el \n28/10/2019 y se cerr\u00f3 el 22/4/2022. Se excluyeron aquellos pacientes que llevaban menos de 30 d\u00edas desde el inicio del \ntratamiento, y aquellos de los que no se pudo averiguar la duraci\u00f3n del mismo.  \nDe cada paciente se recopil\u00f3 la siguiente informaci\u00f3n: edad, sexo, continuaci\u00f3n o no del tratamiento (como variable \nprincipal para valorar la persistencia del tratamiento e indirectamente su efectividad), causa de la discontinuaci\u00f3n (en \ncaso de que se suspendiera el tratamiento), duraci\u00f3n del tratamiento, n\u00famero de antipsic\u00f3ticos utilizados en el momento \nde la prescripci\u00f3n de cariprazina e indicaci\u00f3n con la que se ha usado dicho antipsic\u00f3tico.  \nLos datos se obtuvieron del m\u00f3dulo de dosis unitarias del programa Dominion\u00ae y de la historia cl\u00ednica electr\u00f3nica, \npresent\u00e1ndose como media \u00b1 desviaci\u00f3n est\u00e1ndar (los cuantitativos) o como porcentaje (los cualitativos).  \nPara medir la fracci\u00f3n de pacientes que todav\u00eda se mantienen en tratamiento (persistencia), se utiliz\u00f3 el m\u00e9todo de \nKaplan-Meier que es un estimador no param\u00e9trico de la funci\u00f3n de persistencia en relaci\u00f3n con el tiempo y que admite \nuna representaci\u00f3n gr\u00e1fica de la misma.\nRESULTADOS\nMuestra final compuesta por 51 pacientes, edad 46.41 \u00b1 14.39 a\u00f1os, 64.71%(n=33) hombres, n\u00famero de antipsic\u00f3ticos \nutilizados al iniciar la prescripci\u00f3n de cariprazina (incluida cariprazina) era de 2.63 \u00b1 0.89. Se utiliz\u00f3 en monoterapia en 3 \npacientes\ufffd \nLa indicaci\u00f3n principal para la que se utiliz\u00f3 cariprazina fue de esquizofrenia, que es la aprobada en ficha t\u00e9cnica, en 25 \npacientes; fuera de ficha t\u00e9cnica (26): Trastorno esquizoafectivo (8), trastorno bipolar (6), trastorno obsesivo compulsivo \n(3), delirio (2), trastornos de somatizaci\u00f3n (2), psicosis (4), trastorno de personalidad (1).  \nEn el momento del cierre del estudio continuaban con el tratamiento 23 pacientes (45.1 %). Los d\u00edas de permanencia del \ntratamiento en la totalidad de los pacientes fueron 276.63 \u00b1236.32. En los pacientes que contin\u00faan con el tratamiento \nfue de 401.26 \u00b1 233.34, en los que se suspendi\u00f3 174.25\u00b1186.96.  \nMediante la curva de persistencia de Kaplan-Meier, se calcul\u00f3 una mediana de duraci\u00f3n del tratamiento con cariprazina \nde 380 d\u00edas (IC 95 % = 230.9-529.0).  \nLas causas de suspensi\u00f3n del tratamiento fueron: falta efectividad en 17 pacientes, falta adherencia 3, desconocida 6, \ndescompensaci\u00f3n org\u00e1nica que oblig\u00f3 a suspender todo el tratamiento 1, efectos adversos 1.\nCONCLUSIONES\nLa mediana de duraci\u00f3n del tratamiento con cariprazina fue de 380 d\u00edas durante un periodo de estudio de 905 dias.  \nLa cariprazina puede ser una buena alternativa antipsic\u00f3tica efectiva en pacientes psiqui\u00e1tricos complejos.  \nEl uso de cariprazina no se ajustaba a la indicaci\u00f3n de la ficha t\u00e9cnica en un 50,98 % de los pacientes.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n143. EVALUACI\u00d3N DE LA EFICACIA Y PERSISTENCIA DEL GUSELKUMAB EN PSORIASIS \nAUTORES\nSU\u00c1REZ CASILLAS, P; BARRIGA RODR\u00cdGUEZ, P; SORIANO MART\u00cdNEZ, M\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nAnalizar la eficacia cl\u00ednica y persistencia en pacientes con psoriasis de moderada a grave tratados con guselkumab en \nnuestro centro\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo donde se incluyeron los pacientes adultos diagnosticados de psoriasis moderada-\ngrave tratados con guselkumab desde abril de 2019 hasta marzo de 2022. \nLos datos se obtuvieron de la historia cl\u00ednica digital y del programa de farmacia de pacientes externos. Las variables \nrecogidas fueron las siguientes: datos demogr\u00e1ficas (sexo y edad), tratamientos biol\u00f3gicos previos, tiempo de tratamiento \ncon guselkumab, cambios en la posolog\u00eda y medidas de las escalas de gravedad de la psoriasis (PASI (Psoriasis Area and \nSeverity Index) y BSA (Body Surface Area) previas a iniciar guselkumab, durante y hasta su discontinuaci\u00f3n o fecha fin del \nestudio\ufffd  124La medida de la eficacia del guselkumab se realiz\u00f3 seg\u00fan los resultados de PASI (Psoriasis Area and Severity Index) y \nBSA (Body Surface Area) obtenidos durante el periodo en el que el paciente ha estado con dicho f\u00e1rmaco. Estas escalas \ndefinen como psoriasis moderada-grave un PASI y/o BSA superior al 10%. La persistencia se defini\u00f3 como el tiempo de \ntratamiento (en meses) de manera ininterrumpida durante el periodo estudiado.\nRESULTADOS\nSe incluyeron un total de 41 pacientes (58% hombres) con una media de edad de 53,90 a\u00f1os \u00b1 15,12. El 90,24% hab\u00eda \nrecibido al menos 2 tratamientos biol\u00f3gicos previos\ufffd  \nEn cuanto a la gravedad de la psoriasis, el 70,73% (29) de los pacientes presentaban un PASI y/o BSA > 10% previo al inicio \ndel tratamiento con guselkumab. Al finalizar el estudio, el 100% de los pacientes que continuaron con el tratamiento \nobtuvieron un PASI y/o BSA < 10%. \nLa persistencia media global del tratamiento con guselkumab fue de 21,4 meses (rango: 3-34,4). 4 pacientes (9,75%) \ndiscontinuaron con el f\u00e1rmaco por ineficacia con un tiempo de tratamiento medio de 13 meses (rango: 3,3-26,4). El resto \n(37) continu\u00f3 con guselkumab con una media de duraci\u00f3n de 20,1 meses (rango: 3-34,4) hasta la fecha fin del estudio, y \nel 51,35% (19) de estos pacientes ampliaron la administraci\u00f3n del f\u00e1rmaco de 8 semanas a 10, 12 o 16 semanas.\nCONCLUSIONES\nEl tratamiento con guselkumab se ha mostrado eficaz en los pacientes con psoriasis moderada-grave, manteniendo, en la \nmayor\u00eda de los casos, la mejor\u00eda cl\u00ednica alcanzada, y permitiendo la continuaci\u00f3n del f\u00e1rmaco a largo plazo.  \nLa ampliaci\u00f3n del intervalo de administraci\u00f3n con guselkumab es una estrategia que en pacientes seleccionados mejora la \nrelaci\u00f3n de coste-eficacia del tratamiento, lo que permitir\u00eda tratar a m\u00e1s pacientes con un importante ahorro econ\u00f3mico.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n160. USO Y PERFIL DE SEGURIDAD DE UPADACITINIB EN LA PR\u00c1CTICA CL\u00cdNICA REAL \nAUTORES\nMU\u00d1OZ CID, CL; GARCIA G\u00d3MEZ, N; \u00d3RPEZ RAM\u00cdREZ, \u00c1; CAO VI\u00d1A, V; GUTIERREZ LUCENA, L; JEREZ ROJAS, J\nCOMPLEJO HOSPITALARIO DE JA\u00c9N. AV . DEL EJ\u00c9RCITO ESPA\u00d1OL, 10 JA\u00c9N. JA\u00c9N\nOBJETIVOS\nUpadacitinib es un inhibidor de las Janus quinasas (JAK), enzimas involucradas en los procesos inflamatorios y asociados a \nla patogenia de las enfermedades sist\u00e9micas inmunomediadas. Han demostrado beneficio en enfermedades reum\u00e1ticas, \npero tambi\u00e9n puede conllevar un aumento de infecciones, alteraciones anal\u00edticas y del riesgo tromboemb\u00f3lico asociados \na su uso. Nuestro objetivo es analizar el manejo y el perfil de seguridad de upadacitinib en la pr\u00e1ctica real en el \ntratamiento de enfermedades reum\u00e1ticas en pacientes adultos tratados en nuestro hospital.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 a todos los pacientes que fueron tratados con upadacitinib desde febrero \ndel 2021 hasta abril de 2022 en un hospital de tercer nivel. Los datos analizados se obtuvieron de la historia cl\u00ednica del \npaciente. Los datos demogr\u00e1ficos y variables cl\u00ednicas recogidas en una base de datos de elaboraci\u00f3n propia fueron: edad, \nsexo, diagn\u00f3stico del paciente, f\u00e1rmacos modificadores de enfermedad (FAME) tradicionales previos, FAME biol\u00f3gicos \nprevios, tratamientos concomitantes con upadacitinib, marcadores biol\u00f3gicos reum\u00e1ticos, dosis y fecha de inicio de \nupadacitinib, comorbilidades del paciente, alteraciones anal\u00edticas y motivo de suspensi\u00f3n, en aquellos casos que se haya \nfinalizado el tratamiento.\nRESULTADOS\nSe incluyeron 28 pacientes (85,7% mujeres) con upadacitinib, con una edad media de 56 a\u00f1os. El 17,8% de nuestros \npacientes eran > 65 a\u00f1os. 21 pacientes padec\u00edan eran AR, de los cuales el 5 ten\u00edan el Factor Reum\u00e1tico (FR) positivo, \n4 ten\u00edan los Anticuerpos anti-p\u00e9ptidos citrulinados (ACPA) positivos y otros 5 ten\u00edan ambos marcadores positivos; 5 \npacientes padec\u00edan Espondilitis Anquilosante (EA) y dos artritis psori\u00e1sica. 82,1% se prescribi\u00f3 upadacitinib tras el fracaso \na otros FAME biol\u00f3gicos, con una media de 2 biol\u00f3gicos previos. 5 pacientes tuvieron upadacitinib de 2\u00aa l\u00ednea de iJAK, \nmientras que el resto fueron en 1\u00aa l\u00ednea de iJAK.  \nEn el 57,1% se utiliz\u00f3 el iJAK en monoterapia, 21,4% se tom\u00f3 conjuntamente con leflunomida y otro 21,4% con \nmetotrexate. Los corticoides diarios se utilizaron en el 53,5% de los pacientes con upadacitinib y el 21,4% llevaba AINE \ndiarios. Todos los pacientes tomaban 15 mg de upadacitinib al d\u00eda. En cuanto a las comorbilidades basales: 4 pacientes \neran hipertensos, 2 dislip\u00e9micos y el uno diab\u00e9tico.  \nNo encontramos alteraciones anal\u00edticas relevantes (hemoglobina, leucocitos, linfocitos, neutr\u00f3filos, creatinina) tras \ntres meses de tratamiento. Todos los pacientes continuaban con el tratamiento al finalizar el estudio, excepto uno que \nse le suspendi\u00f3 por progresi\u00f3n de la enfermedad. No se identific\u00f3 ninguna reacci\u00f3n adversa importante (fen\u00f3menos \ntromboemb\u00f3licos, eventos cardiovasculares mayores, infecciones) o reacciones adversas graves durante el seguimiento.\nCONCLUSIONES\nNuestra experiencia con upadacitinib en enfermedades reum\u00e1ticas es que se tiende al uso cuando han fallado a los FAME \ntradicionales y a otros FAME biol\u00f3gicos en pacientes < 65 a\u00f1os. A pesar de que se trata de una muestra peque\u00f1a, se han \nobservado un buen perfil de seguridad en estos pacientes.125CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n174. ANTICUERPOS DIRIGIDOS CONTRA EL P\u00c9PTIDO RELACIONADO CON EL GEN DE LA CALCITONINA \nCOMO TRATAMIENTO PREVENTIVO PARA MIGRA\u00d1A: EFECTIVIDAD Y SEGURIDAD \nAUTORES\nCANALEJO FUENTES, MJ; ONTA\u00d1\u00d3N NASARRE, A; HERRERO MU\u00d1OZ, N; GARC\u00cdA GIL, M; CALLE DE MIGUEL, C; \nLATORRE GONZ\u00c1LEZ, G\nHOSPITAL DE FUENLABRADA \ufffd CAMINO DEL MOLINO, 2 FUENLABRADA \ufffd MADRID\nOBJETIVOS\nEvaluar la efectividad y seguridad del tratamiento con erenumab, fremanezumab y galcanezumab en prevenci\u00f3n de la \nmigra\u00f1a\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, llevado a cabo en un hospital de segundo nivel desde diciembre 2019 hasta marzo \n2021. Se incluyeron todos los pacientes diagnosticados de migra\u00f1a que presentaron m\u00e1s de 8 d\u00edas de migra\u00f1a al mes \n(DMM) y tres o m\u00e1s fracasos de tratamiento previos (siendo uno de ellos toxina botul\u00ednica en migra\u00f1a cr\u00f3nica), que \niniciaron tratamiento con anticuerpos dirigidos contra el p\u00e9ptido relacionado con gen de calcitonina (anti-CGRP).  \nLa variable principal de efectividad medida fue la reducci\u00f3n de DMM en mes 3, 6 y 12 de tratamiento respecto al \nn\u00famero de DMM pretratamiento. Los pacientes se clasificaron en tres grupos: respondedor (reducci\u00f3n de DMM \u2265 50%), \nrespondedor parcial (reducci\u00f3n de DMM < 50% pero reducci\u00f3n de intensidad de crisis) y no respondedor (beneficio nulo).  \nLas variables secundarias de efectividad medidas fueron: mejor\u00eda significativa de las escalas de calidad de vida HIT-\n6 (eval\u00faa impacto de cefalea) y MIDAS (eval\u00faa discapacidad producida por la migra\u00f1a) en mes 6 de tratamiento (se \nconsideran criterios de mejor\u00eda significativa una reducci\u00f3n \u2265 30% en MIDAS y una reducci\u00f3n \u2265 5 puntos en HIT-6 respecto \na pretratamiento) y porcentaje de pacientes que discontinuaron tratamiento en mes 3 y 6 por inefectividad.  \nPara la evaluaci\u00f3n de seguridad se registraron efectos adversos relacionados con el tratamiento y porcentaje de pacientes \nque discontinu\u00f3 tratamiento por efectos adversos.  \nLos datos fueron obtenidos de Historia Cl\u00ednica Electr\u00f3nica y del programa de dispensaci\u00f3n de Farmacia.  \nEl an\u00e1lisis estad\u00edstico de los datos se realiz\u00f3 mediante an\u00e1lisis descriptivo de frecuencias.\nRESULTADOS\nSe incluyeron 67 pacientes, 89,7% (60/67) mujeres, mediana de edad 46 a\u00f1os (21-70).  \nUn 73,1% (49/67) de pacientes presentaba migra\u00f1a cr\u00f3nica al inicio de tratamiento.  \nUn 52,23% (35/67) de pacientes estaba en tratamiento con erenumab, un 35,82% (24/67) con galcanezumab y un 11,94% \n(8/67) con fremanezumab.  \nUn 59,7% (40/67) tuvo reducci\u00f3n de DMM > 50% en mes 3 de tratamiento, un 62,68% (42/67) en mes 6 y un 52,23% \n(35/67) en mes 12. Un 28,35% (19/67) consigui\u00f3 reducci\u00f3n de DMM < 50% en mes 3, un 26,86% (18/67) en mes 6 y un \n31,34% (21/67) en mes 12.  \nLas escalas HIT-6 y MIDAS fueron correctamente cumplimentadas (pretratamiento y en mes 6 de tratamiento) en 76,11% \n(51/67) de pacientes. Tras 6 meses de tratamiento, un 68,62% (35/51) y un 86,27% (44/51) alcanz\u00f3 mejor\u00eda significativa \nen escala HIT-6 y MIDAS, respectivamente.  \nUn 8,9% (6/67) de pacientes discontinu\u00f3 tratamiento en mes 3 por inefectividad y un 7,46% (5/67) en mes 6 por la misma \ncausa\ufffd  \nLos efectos adversos presentados mayoritariamente fueron estre\u00f1imiento en 28,4% (19/67), siendo 63,15% (12/19) \npor erenumab; y reacci\u00f3n en punto de inyecci\u00f3n en 7,46% (5/67). Un 4,47% (3/67) discontinu\u00f3 tratamiento por efectos \nadversos\ufffd\nCONCLUSIONES\nEn nuestra serie, m\u00e1s de la mitad de los pacientes son respondedores al tratamiento con f\u00e1rmacos anti-CGRP y uno de \ncada cuatro son respondedores parciales. Estos f\u00e1rmacos aportan mayor calidad de vida a los pacientes con un perfil de \nreacciones adversas favorable\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n178. EVALUACI\u00d3N DE LA EFECTIVIDAD Y SEGURIDAD EN EL SWITCH A INFLIXIMAB BIOSIMILAR EN LA \nENFERMEDAD INFLAMATORIA INTESTINAL E IMPACTO ECON\u00d3MICO \nAUTORES\nFERNANDEZ ARBERAS, N; PEREZ PEREZ, D; BALDOMINOS UTRILLA, G; GONZALEZ TRIGUEROS, C; URE\u00d1A AGUILERA, \nI; BERMEJO LORERO, B\nHOSPITAL UNIVERSITARIO PR\u00cdNCIPE DE ASTURIAS. CTRA. ALCAL\u00c1-MECO, S/N ALCAL\u00c1 DE HENARES. MADRID\nOBJETIVOS\nEl switch del medicamento biol\u00f3gico de referencia a su alternativa biosimilar a\u00fan plantea preocupaciones entre algunos \nprofesionales sanitarios. Sin embargo, cada vez hay evidencia m\u00e1s robusta que avala el switch entre el medicamento \noriginal y su biosimilar \ufffd  \nTras una reuni\u00f3n con el Servicio de Digestivo, se acuerda el switch de infliximab original (IFXo) a infliximab biosimilar \n(IFXb) en los pacientes con diagn\u00f3stico de enfermedad inflamatoria intestinal (EII). El objetivo de este trabajo es evaluar \nla efectividad y seguridad del switch, as\u00ed como conocer el impacto econ\u00f3mico derivado del mismo.126MATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo (julio 2021 - abril 2022). Se incluye a los pacientes con EII en tratamiento con IFXo.  \nLa variable de valoraci\u00f3n para la efectividad son los valores de calprotectina fecal (CPF), de prote\u00edna C reactiva \n(PCR), niveles de infliximab, aparici\u00f3n de anticuerpos anti-infliximab, as\u00ed como la intensificaci\u00f3n del tratamiento o su \ninterrupci\u00f3n. Para la seguridad, se contabilizan las reacciones adversas descritas en la historia cl\u00ednica electr\u00f3nica. Para el \nan\u00e1lisis estad\u00edstico se utiliza la comparaci\u00f3n de medias t de Student. \nSe recogen las pautas previo al switch, a\u00f1os de tratamiento con IFXo y meses de tratamiento con IFXb tras el switch.  \nLos recursos materiales utilizados son la historia cl\u00ednica electr\u00f3nica y la aplicaci\u00f3n de pacientes ambulantes.\nRESULTADOS\nDe los 39 pacientes del Servicio de Digestivo a los que se realiza de forma gradual el switch, 21 pacientes est\u00e1n en \ntratamiento a dosis est\u00e1ndar (5mg/kg/8 semanas) y 18 pacientes en tratamiento intensificado (dosis 10mg/kg y/o cada \n6 semanas). La media de a\u00f1os en tratamiento con IFXo es de 10 a\u00f1os para estos pacientes y la media de tiempo de \ntratamiento con el biosimilar tras el switch es de 6,2 meses.  \nDe los 39 pacientes, en 24 de ellos, tenemos datos disponibles sobre la CPF. La media de CPF pre y post switch fue de 611 \ny 368 \u00b5g/g respectivamente (p > 0,05). Respecto a los valores de PCR, tenemos datos disponibles de 25 pacientes de los \n39, la media de PCR pre y post switch fue de 10 mg/L y 9,3 mg/L respectivamente (p > 0,05). \nEn cuanto a los niveles de infliximab, s\u00f3lo tenemos datos en 4 pacientes, siendo la media pre y post switch de 3,09 mg/L y \n4,16 mg/L respectivamente (p > 0,05). \nNo se ha detectado el desarrollo de anticuerpos tras el switch en ning\u00fan paciente. Tampoco se han producido \nintensificaciones de tratamiento desde el switch ni interrupciones por falta de eficacia.  \nEn cuanto a la seguridad, no se ha notificado en la historia cl\u00ednica, ninguna reacci\u00f3n adversa rese\u00f1able en los pacientes en \nlos que se ha realizado el switch.  \nEn cuanto al impacto econ\u00f3mico, se estima que el ahorro debido al switch en estos 39 pacientes es de 211.000 \u20ac anuales.\nCONCLUSIONES\nEn nuestra poblaci\u00f3n de pacientes no hay diferencias estad\u00edsticamente significativas en cuanto a la efectividad ni se han \ninformado de problemas de seguridad tras el switch. Esto se acompa\u00f1a de un importante ahorro econ\u00f3mico. Es preciso \nun mayor tiempo de evaluaci\u00f3n que confirme los resultados obtenidos.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n188. EFICACIA DEL DUPILUMAB EN DERMATITIS AT\u00d3PICA EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL \nAUTORES\nP\u00c9REZ REYES, S; CANTARELLI , L; GARC\u00cdA GIL, S; JOY CARMONA, P; NAVARRO D\u00c1VILA, MA; OTAZO P\u00c9REZ, SM; NAZCO \nCASARIEGO, GJ; PE\u00d1A OG\u00c1YAR, A\nCOMPLEJO HOSPITAL UNIVERSITARIO NTRA SRA DE CANDELARIA. CTRA. DEL ROSARIO, 145 SANTA CRUZ DE \nTENERIFE \ufffd SANTA CRUZ DE TENERIFE\nOBJETIVOS\nDupilumab ha demostrado eficacia en pacientes diagnosticados con dermatitis at\u00f3pica (DA) con respuesta inadecuada o \nintolerancia a la ciclosporina A (CsA).  \nEl objetivo principal del presente estudio fue evaluar la eficacia de dupilumab en pacientes con intolerancia o respuesta \ninadecuada a la ciclosporina A en la pr\u00e1ctica cl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio observacional retrospectivo unic\u00e9ntrico de 22 meses de duraci\u00f3n ( enero 2020-octubre 2021). Los \nsujetos incluidos fueron pacientes diagnosticados de EA que tras una respuesta inadecuada o intolerancia a la CsA fueron \ntratados con dupilumab. Los datos cl\u00ednicos se obtuvieron a trav\u00e9s de la historia cl\u00ednica electr\u00f3nica en SAP\u00ae. La eficacia se \nevalu\u00f3 utilizando las puntuaciones EASI (Eczema Area and Severity Index) e IGA (Investigator \u0301 s Global Assessment) en las \nsemanas 16,24 y 52\ufffd  \nSe evalu\u00f3 el logro de una mejora de \u2265 50% en EASI en comparaci\u00f3n con el valor inicial (EASI 50), EASI 75 y EASI 90. Los \npacientes tambi\u00e9n se consideraron respondedores si lograron un IGA de 0-1.\nRESULTADOS\nSe incluyeron un total de 29 pacientes con una edad media de 35,3 a\u00f1os (19-59), el 75,8% de los pacientes eran hombres \ny el tiempo medio de diagn\u00f3stico de la dermatitis at\u00f3pica fue de 5,6 a\u00f1os (1,3-21,7). \nEl tiempo medio de tratamiento con dupilumab en los pacientes incluidos fue de 11,8 meses (3,7-17,1). En la semana 16, \nel 89,6% de los pacientes incluidos alcanzaron un EASI 50, el 65,5% alcanzaron un EASI 75 y el 37,9% un EASI 90. El 58,6 \nde los pacientes logr\u00f3 un IGA de 0-1 en la semana 16 y en la semana 24, mientras que en la semana 52 el porcentaje fue \nligeramente inferior (37,9%) logrando un IGA 0-1. As\u00ed mismo, a la semana 24 el 55,1% de los pacientes alcanz\u00f3 un EASI 75 \ny el 41,3% un EASI 90\ufffd Por otro lado, el 37,9% y el 24,1% de los pacientes lograron un EASI 75 y EASI 90 en la semana 52\ufffd\nCONCLUSIONES\nEl ensayo cl\u00ednico \u201cLiberty ad Caf\u00e9\u201d demostr\u00f3 el logro en la EASI 75 en la semana 16 aproximadamente en el 60% de los \npacientes, EASI 50 en el 85% de los casos y EASI 90 en un 40% aproximadamente\ufffd Los resultados obtenidos en nuestro \nestudio son muy similares a los observados en el ensayo cl\u00ednico. Se sugiere limitar el uso de dupilumab a las condiciones \nestablecidas por los ensayos cl\u00ednicos debido principalmente al potencial impacto econ\u00f3mico en los sistemas de salud.127CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n190. CALIDAD DE VIDA PERCIBIDA POR PACIENTES CON ENFERMEDADES INFLAMATORIAS \nINMUNOMEDIADAS EN TRATAMIENTO CON TERAPIAS BIOL\u00d3GICAS Y PEQUE\u00d1AS MOL\u00c9CULAS \nDIRIGIDAS \nAUTORES\nCALVO-GARCIA , A; CHAMORRO DE VEGA, E; ROMERO JIM\u00c9NEZ, R; FERN\u00c1NDEZ PACHECO GARCIA-VALDECASAS, M; \nHERRERO MU\u00d1OZ, N; MU\u00d1OZ CUADRADO, \u00c1; CASADO G\u00d3MEZ, A; RAM\u00cdREZ HERR\u00c1IZ, E\nHOSPITAL UNIVERSITARIO DE LA PRINCESA \ufffd DIEGO DE LE\u00d3N, 62 MADRID \ufffd MADRID\nOBJETIVOS\nEvaluar la calidad de vida relacionada con la salud (CVRS) de pacientes con las enfermedades inflamatorias \ninmunomediadas (IMIDs) m\u00e1s frecuentes en Espa\u00f1a: enfermedad inflamatoria intestinal (EII), psoriasis (Ps), \nespodiloartropat\u00edas (EspA), artritis reumatoide (AR) y artritis psori\u00e1sica (APs). Determinar factores que puedan influir en \nla CVRS\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo y multicentrico en contexto de real-world evidence. Se incluyeron pacientes con \ndiagn\u00f3stico de EII, Ps, EspA, AR o APs con un m\u00ednimo de tres dispensaciones en el Servicio de Farmacia. La CVRS fue \nevaluada usando dos m\u00e9todos :  \n- Cuestionario EurQol (versi\u00f3n EQ-5D-5L) que consta de un sistema descriptivo con 5 dimensiones (movilidad, \nautocuidado, actividades habituales, dolor/malestar y ansiedad/depresi\u00f3n) con una escala Likert de 5 niveles de \nrespuesta, siendo 0 el mejor estado o sin problemas y 5 el peor estado o invalidez y una escala anal\u00f3gica visual (EVA) de 0 \na 100, siendo 0 la peor salud y 100 la mejor. \n- Cuestionarios de CVRS espec\u00edficos por patolog\u00eda: Cuestionario de Enfermedad Inflamatoria Intestinal (CCVEII-9) \n(0=mala/100=buena CVRS) para EII, Dermatology Life Quality Index (DLQI) (0=buena/30=mala) para Ps, Ankylosing \nSpondylitis Quality of Life (ASQoL) (0=buena/18=mala) para EspA, Quality of Life-Rheumatoid Arthritis (QoL-AR) \n(1=mala/10=buena) para AR y Psoriatic Arthritis Quality of Life (PsAQoL) (0=buena/20=mala) para APs.  \nLas variables se expresaron en medias (desviaci\u00f3n est\u00e1ndar). Para comparaci\u00f3n de CVRS entre patolog\u00edas se utiliz\u00f3 la \nprueba estad\u00edstica ANOVA, para la relaci\u00f3n de EQ-5D-5L con variables cuantitativas, la correlaci\u00f3n de Pearson y con \nvariables cualitativas la t-Student.\nRESULTADOS\nSe incluyeron 578 pacientes, 293 (50,7%) hombres, con una edad media de 49,8 (12,3) a\u00f1os. La distribuci\u00f3n por patolog\u00eda \nfue: EII=146 (25,3%), Ps=114 (19,7%), ESART=108 (18,7%), AR=107 (18,5%) y APs=103 (17,8%) pacientes. La puntuaci\u00f3n \nmedia del EQ-5D-5L fue 0,771 (0,2): 2,177 en dimensi\u00f3n dolor/malestar, 1,727 actividades cotidianas, 1,724 ansiedad/\ndepresi\u00f3n, 1,550 movilidad y 1,300 autocuidado. Ps e EII fueron las IMIDs con mayor puntuaci\u00f3n del EQ-5D-5L, 0,87 \n(0,17) y 0,81 (0,20), respectivamente. Ambas fueron significativamente mayores (p > 0,05) que la puntuaci\u00f3n obtenida en \nAPs (0,73 [0,24]), AR (0,72 [0,25]) y ESART (0,71 [0,21]).  \nLa puntuaci\u00f3n media de EVA fue 71,5 (20,0). Ps obtuvo la puntuaci\u00f3n m\u00e1s alta, 76,9 (17,6), seguida de EII 72,8 (19,7), \nAPs 70,3 (19,3), ESART 69,0 (19,9), y AR con 67,5 (22,5) puntos. Solo se encontraron diferencias significativas entre Ps y \nAR (p=0,024). Las puntuaciones medias para los cuestionarios espec\u00edficos fueron: CCVEII-9=64,1 (9,8); DLQI=3,1 (4,9); \nASQoL=6,0 (5,2); QoL-AR= 6,9 (1,8) y PsAQol= 6,6 (5,7).  \nLos factores relacionados con peor CVRS fueron: g\u00e9nero femenino (p=0,002), gravedad moderada/severa (p < 0,001), \nedad avanzada (P < 0,001) y mayor n\u00famero f\u00e1rmacos previos (p < 0,001). La mayor duraci\u00f3n del tratamiento actual se \nrelacion\u00f3 con mejor CVRS (p=0,005).\nCONCLUSIONES\nLos resultados del estudio muestran que los pacientes con IMIDs tienen afectaci\u00f3n en su CVRS, principalmente en la \ndimensi\u00f3n dolor/malestar, siendo las patolog\u00edas con componente reum\u00e1tico las que presentan mayor afectaci\u00f3n. Existen \nfactores que predisponen peor CVRS como g\u00e9nero, severidad de la enfermedad, edad y tratamientos previos. Estos \nhallazgos pueden ser de utilidad para la toma de decisiones en el manejo de estos pacientes.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n217. EXPERIENCIA DE USO DE ERENUMAB EN LA PROFILAXIS DE LA MIGRA\u00d1A: EFECTIVIDAD, SEGURIDAD \nY COMPARACI\u00d3N CON LOS ENSAYOS CL\u00cdNICOS. \nAUTORES\nFRESAN RESTITUTO, D; LACALLE FABO, E; ORTEGA BELIO, I; MART\u00cdN BUJANDA, M; PINO RAMOS, A; ERDOZAIN \nSANCLEMENTE, S; GO\u00d1I INDURAIN, N\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nLa aprobaci\u00f3n de erenumab para la profilaxis de la migra\u00f1a en pacientes con migra\u00f1a cr\u00f3nica se sustenta en 1 ensayo \ncl\u00ednico (EC) pivotal de 12 semanas de duraci\u00f3n que eval\u00faa la eficacia y 2 EC que eval\u00faan la seguridad.  \nEl objetivo de este estudio consiste en analizar la efectividad y seguridad en vida real del tratamiento con erenumab tras \n3 y 12 meses de tratamiento (duraci\u00f3n recomendada por el Grupo de Estudio de Cefaleas de la Sociedad Espa\u00f1ola de \nNeurolog\u00eda (GECSEN) en su \u00faltimo \u201cManual de Pr\u00e1ctica Cl\u00ednica de Cefaleas\u201d) y comparar los resultados con los EC.128MATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional realizado en un hospital terciario con consulta monogr\u00e1fica de cefaleas entre \ndiciembre del 2019 y abril del 2022\ufffd  \nEl protocolo del hospital contempla el uso de erenumab hasta un m\u00e1ximo de 12 meses si el tratamiento resulta efectivo y \nseguro en la evaluaci\u00f3n que se realiza a los 3 meses desde el inicio.  \nLas variables de eficacia empleadas en los EC son la reducci\u00f3n de los d\u00edas de migra\u00f1a al mes (DMM) y la reducci\u00f3n de los \nDMM al menos en un 50% respecto a la situaci\u00f3n basal. Sin embargo, en la pr\u00e1ctica cl\u00ednica real los pacientes se muestran \nsatisfechos cuando mejoran la calidad de vida con el tratamiento, ya sea por disminuir los d\u00edas de migra\u00f1a, de cefalea o su \nintensidad. Por ello, se considera efectivo aquel tratamiento que consigue reducir los DMM \u226550% respecto a la situaci\u00f3n \nbasal y/o una mejora significativa en la calidad de vida (evaluada por las escalas HIT6 y MIDAS).\nRESULTADOS\n71 pacientes (79% mujeres, edad media 52,2 a\u00f1os (25-83)) con migra\u00f1a cr\u00f3nica inician tratamiento con erenumab 140 \nmg, de los que 68 llevan al menos 3 meses de tratamiento y 54 podr\u00edan haber completado el a\u00f1o de tratamiento. El 85% \nhab\u00eda llevado previamente otro anticuerpo monoclonal (AMC) profil\u00e1ctico.  \nUn 51% consigue reducir los DMM \u226550% tras 3 meses de tratamiento en comparaci\u00f3n con un 41% de los EC. Teniendo \nen cuenta la mejora significativa en la calidad de vida la efectividad asciende a un 76% (persistencia a los 3 meses: 52/68 \npacientes). Un 51% (28/54) consigue completar los 12 meses de tratamiento con efectividad y seguridad.  \n26 pacientes suspenden erenumab antes de completar los 12 meses: 23 por falta de eficacia (FE), 1 por efectos adversos \n(EA) (v\u00e9rtigos) y 2 por FE+EA (reacci\u00f3n local y estre\u00f1imiento).  \nUn 46% de los pacientes reporta EA en los EC (incidencia de los m\u00e1s frecuentes: 1-7%). El 14% de la poblaci\u00f3n de estudio \npresenta EA (v\u00e9rtigos: 5, estre\u00f1imiento: 4, astenia: 1, reacci\u00f3n local; 1), siendo motivo de suspensi\u00f3n de tratamiento en \nun 6%\ufffd\nCONCLUSIONES\nLa experiencia en vida real parece indicar que la efectividad del tratamiento con AMC para la profilaxis de migra\u00f1a va m\u00e1s \nall\u00e1 de reducir los DMM.  \nErenumab es un tratamiento efectivo y bien tolerado en la profilaxis de la migra\u00f1a cr\u00f3nica, mostrando superioridad en \nvida real respecto a los EC\ufffd  \nSe requieren estudios con un mayor n\u00famero de pacientes para confirmar estos resultados.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n289. EVALUACI\u00d3N DE LA CALIDAD DE VIDA PERCIBIDA POR EL PACIENTE EN TRATAMIENTO CON \nERENUMAB \nAUTORES\nV\u00c9LEZ BLANCO, A; LLAMAS LORENZANA, S; CASAS FERN\u00c1NDEZ, X; RODR\u00cdGUEZ FERN\u00c1NDEZ, Z; S\u00c1EZ HORTELANO, \nJC; VARELA FERN\u00c1NDEZ, R; GUTI\u00c9RREZ GUTI\u00c9RREZ, E; ORTIZ DE URBINA GONZ\u00c1LEZ, JJ\nCOMPLEJO ASISTENCIAL UNIVERSITARIO DE LE\u00d3N. ALTOS DE LA NAVA S/N LE\u00d3N. LE\u00d3N\nOBJETIVOS\nLa migra\u00f1a es una enfermedad cr\u00f3nica altamente incapacitante. El objetivo del tratamiento con erenumab es reducir la \nfrecuencia, intensidad y duraci\u00f3n de las crisis de migra\u00f1a, de forma que mejore la calidad de vida, reduciendo el impacto \nde la enfermedad en la funcionalidad del paciente\ufffd \nEl objetivo fue evaluar la calidad de vida percibida por el paciente previo al inicio de tratamiento con erenumab y tras 12 \nmeses\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo en el cual se incluyeron pacientes con migra\u00f1a cr\u00f3nica o epis\u00f3dica de alta frecuencia \ntratados con erenumab desde su inclusi\u00f3n en la gu\u00eda farmacoterap\u00e9utica del hospital (agosto 2020) hasta diciembre \n2021, que hubieran cumplido 12 meses de tratamiento.  \nSe recogen datos demogr\u00e1ficos (sexo; edad), cl\u00ednicos (tipo de migra\u00f1a; d\u00edas mensuales de migra\u00f1a e intensidad de la \nmisma al inicio del tratamiento y a los 12 meses) y se realiz\u00f3 el cuestionario EuroQol-5D para valorar la calidad de vida \npercibida por el paciente al inicio del tratamiento y tras 12 meses\ufffd \nCon el cuestionario EQ-5D-5L el propio individuo valora su estado de salud, primero en niveles de gravedad, valorando \nmovilidad, cuidado personal, actividades cotidianas, dolor/malestar y ansiedad/depresi\u00f3n, y en segundo lugar en una \nescala anal\u00f3gica visual (EVA) que va de 0 a 100 (peor y mejor estado de salud imaginable, respectivamente). Para el \nc\u00e1lculo de estado de salud se utiliz\u00f3 el Crosswalk Index Value Calculator y para el an\u00e1lisis de datos el SPSS Statistics \nv28\ufffd0\ufffd1\ufffd1\ufffd\nRESULTADOS\nSe analizaron 22 pacientes con una mediana de edad de 51 a\u00f1os (RIQ:47,25-58,5) siendo un 81,82% (n=18) mujeres.  \nEl 86,36% (n=19) diagnosticados de migra\u00f1a cr\u00f3nica y un 13,64% (n=3) de migra\u00f1a epis\u00f3dica de alta frecuencia. 2 \npacientes (9,09%) suspendieron el tratamiento antes de finalizar los 12 meses por falta de respuesta, los cuales han sido \nexcluidos del an\u00e1lisis.  \nLa reducci\u00f3n media de migra\u00f1as mensuales fue de 10,35 d\u00edas (6,67-14,02). La media de intensidad de las migra\u00f1as antes \ndel tratamiento era de 8,4 (7,77-9,03); y al mes 12 de 5,18 (4,08-6,27).  \nEl n\u00famero de pacientes que refleja no tener problemas relacionados con la movilidad, cuidado personal, actividades 129cotidianas, dolor/malestar y ansiedad/depresi\u00f3n ha aumentado y/o mantenido tras los 12 meses de tratamiento en \ncomparaci\u00f3n con el basal: 60% (n=12) vs 70% (n=14); 75% (n=15) vs 75% (n=15); 30% (n=6) vs 60% (n=12); 10% (n=2) vs \n40% (n=8); y 20% (n=4) vs 35% (n=7), respectivamente.  \nLa media del cuestionario EQ-5D antes de haber iniciado erenumab fue de 0,5694 (-0,008 \u2013 1) y 12 meses despu\u00e9s de \n0,7198 (-0,096 \u2013 1). Consider\u00e1ndose la mejora en la calidad de vida estad\u00edsticamente significativo (p < 0,01).  \nEl valor medio de la escala EVA antes de iniciar el tratamiento fue 50% (10-95%) y tras 12 meses 65,75% (15-100%). \nConsider\u00e1ndose esta mejora en la calidad de vida estad\u00edsticamente significativa (p=0,008).\nCONCLUSIONES\nEs importante realizar estudios que incluyan una mayor muestra, pero en nuestra experiencia el tratamiento con \nerenumab ha supuesto una gran mejora en la calidad de vida de los pacientes con migra\u00f1a, consiguiendo reducir as\u00ed el \nimpacto de su enfermedad en su d\u00eda a d\u00eda.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n300. IMPACTO DE LA INTEGRACI\u00d3N DEL FARMAC\u00c9UTICO EN LA TOMA DE DECISIONES Y SEGUIMIENTO \nCL\u00cdNICO DEL PACIENTE CON PSORIASIS. \nAUTORES\nZURITA ALONSO, B; MART\u00cd NAVARRO, M; CAMPOS BAETA, Y; ESTELRICH ROSSI, M; GORRINDO RUIZ, L\nFUNDACI\u00d3 HOSPITAL SANT JOAN DE D\u00c9U. AV . MANCOMUNITATS COMARCALS, 1 MARTORELL. BARCELONA\nOBJETIVOS\nEn el a\u00f1o 2020 se detect\u00f3 que el seguimiento cl\u00ednico del paciente con psoriasis en nuestro hospital era deficiente debido \na la elevada carga asistencial del m\u00e9dico. A finales de 2020 se impuls\u00f3 la figura del farmac\u00e9utico cl\u00ednico y actualmente se \ntrabaja de forma multidisciplinar tanto en la selecci\u00f3n del tratamiento como en el seguimiento del mismo.  \nEl objetivo del estudio es comprobar si la integraci\u00f3n del farmac\u00e9utico ha mejorado el seguimiento de los pacientes con \npsoriasis en tratamiento biol\u00f3gico activo.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo comparativo de corte transversal 2019 vs 2021 realizado en un hospital comarcal de \nnivel II con 2.421 pacientes externos anuales activos.  \nSe contabiliz\u00f3: el n\u00famero de pacientes activos con tratamiento biol\u00f3gico para la psoriasis, las visitas con el dermat\u00f3logo, \nlas dispensaciones, las visitas de inicio y de seguimiento con el farmac\u00e9utico, las intervenciones del farmac\u00e9utico \ndesglosadas por tipo. Tambi\u00e9n se evaluaron los f\u00e1rmacos biol\u00f3gicos seg\u00fan su mecanismo de acci\u00f3n.\nRESULTADOS\nEl n\u00famero de pacientes con psoriasis tratados aument\u00f3 de 100 (2019) a 143 (2021). Tambi\u00e9n aument\u00f3 el n\u00famero de \nvisitas del dermat\u00f3logo manteni\u00e9ndose la ratio visitas/paciente: 2,96 en 2019 versus 2,98 en 2021.  \nEl n\u00famero de visitas de inicio con el farmac\u00e9utico aument\u00f3 de 41 a 53 y el de vistas de seguimiento de 126 a 227. El \nn\u00famero total de intervenciones farmac\u00e9uticas fue de 35 en el a\u00f1o 2019 y de 119 en el 2021. El n\u00famero de intervenciones \nfarmac\u00e9uticas increment\u00f3 de 0,35 a 0,83 por paciente (aumento del 137%). Se clasificaron en: valoraci\u00f3n de la \nefectividad (14 vs 50), adherencia (8 vs 17), recomendaci\u00f3n vacunal (0 vs 6), notificaci\u00f3n de reacciones adversas (2 vs 8), \nreprogramaci\u00f3n de visitas (5 vs 20), recomendaciones de administraci\u00f3n y conservaci\u00f3n (4 vs 15), proposici\u00f3n de cambios \nposol\u00f3gicos (2 vs 3).  \nEl n\u00famero de dispensaciones aument\u00f3 (544 vs 699) siendo la ratio dispensaciones/paciente similar (5,44 vs 4,89).  \nRespecto al tipo de f\u00e1rmaco dispensado, la proporci\u00f3n de pacientes con anti-TNF y anti-IL-17 se mantuvo (antiTNF: 25% \nvs 26%; anti-IL-17: 18% vs 13%). El principal cambio fue la disminuci\u00f3n en la utilizaci\u00f3n de los anti-IL-12/23 (56% vs 39%) \na favor de los m\u00e1s novedosos anti-IL-23 (1% vs 22%).\nCONCLUSIONES\nLa integraci\u00f3n del farmac\u00e9utico en el seguimiento cl\u00ednico de los pacientes con psoriasis en tratamiento biol\u00f3gico activo \nha aumentado el n\u00famero de consultas por parte del paciente acerca de su patolog\u00eda y su medicaci\u00f3n. Esto ha conducido \na un mayor n\u00famero de intervenciones por parte del farmac\u00e9utico para mejorar la efectividad y seguridad de los \ntratamientos. Este aumento de consultas no parece que est\u00e9 relacionado con la complejidad de los tratamientos ni con el \nn\u00famero de dispensaciones presenciales, sino a una mayor relaci\u00f3n farmac\u00e9utico-paciente. \nConsideramos que podr\u00eda ser interesante analizar si el mayor seguimiento cl\u00ednico por parte del farmac\u00e9utico puede tener \nrepercusi\u00f3n en el mejor control cl\u00ednico de la enfermedad as\u00ed como en el grado de satisfacci\u00f3n de los pacientes con las \nconsultas de atenci\u00f3n farmac\u00e9utica.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n327. RELACI\u00d3N ENTRE LA PRESENCIA DE ANTICUERPOS ANTI-INFLIXIMAB Y LA APARICI\u00d3N DE \nREACCIONES ADVERSAS EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL \nAUTORES\nL\u00d3PEZ NOGUERA, Q; LARREA URTARAN, X; ESP\u00cdN MART\u00cd, G; TORREALBA MEDINA, LDV; CASTELL\u00d3 NORIA, \u00c0; D\u00cdEZ \nVALLEJO, C; SUBIRANA BATLLE, C; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA130OBJETIVOS\nEl Infliximab puede producir reacciones de hipersensibilidad tard\u00eda y de immunogenicidad. Adem\u00e1s, los pacientes que \ndesarrollan anticuerpos frente a infliximab tienen mayor probabilidad, aproximadamente 2-3 veces superior, de presentar \nreacciones adversas a medicamentos (RAM) relacionadas con la perfusi\u00f3n.  \nEl objetivo del estudio es determinar si los pacientes que desarrollan anticuerpos frente a infliximab presentan mayor \nriesgo de desarrollar RAMs con la perfusi\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional en pacientes adultos con enfermedad inflamatoria intestinal. Se incluyeron pacientes \ncon enfermedad de Crohn (EC), colitis ulcerosa (CU) y colitis indeterminada que recibieron infliximab v\u00eda intravenosa \nen hospital de d\u00eda entre enero de 2016 y diciembre de 2020. Se recogieron datos demogr\u00e1ficos (edad y sexo), cl\u00ednicos \n(antecedentes de alergias, tipo de enfermedad intestinal inflamatoria, clasificaci\u00f3n de Montreal, \u00edndice de Harvey \nBradshaw en EC, \u00edndice de mayo en CU, tratamientos biol\u00f3gicos previos), anal\u00edticos (presencia de anticuerpos anti-\ninfliximab), posol\u00f3gicos (pauta de Infliximab, n\u00famero de dosis administradas) y el n\u00famero de RAMs producidas.  \nPara el an\u00e1lisis estad\u00edstico se utilizaron valores de media, desviaci\u00f3n est\u00e1ndar (DE), riesgo absoluto (RA) y odd ratio (OR).\nRESULTADOS\nSe incluyeron 119 pacientes con enfermedad inflamatoria intestinal (42 diagnosticados de CU, 74 de EC y 3 de colitis \nindeterminada). La media de edad \u00b1 DE de 46 \u00b1 17 a\u00f1os y el 46% fueron mujeres. Del total de 119 pacientes, 20 \npresentaron antecedentes de alergia a medicamentos o alimentos\ufffd  \nDe los pacientes con EC, el 70,3% tuvieron una edad de diagn\u00f3stico entre 17 y 40 a\u00f1os (A2), el 44,6% tuvieron una \nlocalizaci\u00f3n \u00edleon terminal (L1) y el 44,6% un patr\u00f3n inflamatorio (B1). La puntuaci\u00f3n media \u00b1 DE en el \u00edndice de Harvey \nfue de 7,1 \u00b1 3,7\ufffd  \nDe los pacientes con CU, el 61,9% tuvieron una gravedad leve (S1) y el 42,9% una extensi\u00f3n extensa (E3). La puntuaci\u00f3n \nmedia \u00b1 DE en el Mayo parcial fue de 3,7 \u00b1 2,3\ufffd  \nEl 79,8% de los pacientes recibi\u00f3 infliximab como primera l\u00ednea al tratamiento biol\u00f3gico, las dosis fueron entre 5-10mg/kg \ncon un intervalo ajustado seg\u00fan cl\u00ednica. El 60,5% (n=72/119) de los pacientes suspendi\u00f3 el tratamiento durante el periodo \nde estudio, 22 por falta de respuesta a infliximab, 19 por inmunogenicidad (anticuerpos anti-infliximab), 16 por RAM y 15 \npor otros motivos.  \nSe realizaron 1.909 infusiones de infliximab en 119 pacientes y se analizaron anticuerpos a infliximab a 89 pacientes. El \n30,3% de los pacientes presentaron anticuerpos positivos para infliximab ( > 1ng/mL) y 6/27 presentaron una RAM (RA de \n22,2% IC95 (6,5%-37,9%)). El 69,7% no presentaron anticuerpos anti-infliximab y 6/62 presentaron una RAM (RA de 9,7% \nIC95 (2,3%-17,0%)) que representa una OR de 2,67 IC95 (0,77\u20139,19).\nCONCLUSIONES\nNo se han observado diferencias significativas en cuanto a la aparici\u00f3n de RAMs entre pacientes que presentan \nanticuerpos positivos a infliximab y los que no. Sin embargo, la probabilidad de RAMs en pacientes con anticuerpos \npositivos es mayor tal y como se especifica en ficha t\u00e9cnica.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n356. EVALUACI\u00d3N DE LA CALIDAD DEL SUE\u00d1O EN PACIENTES CON PATOLOG\u00cdA REUMATOL\u00d3GICA \nINFLAMATORIA EN TRATAMIENTO CON TERAPIAS BIOL\u00d3GICAS \nAUTORES\nCHAMORRO DE VEGA, E; FERRIS VILLANUEVA, M; ROMERO JIMENEZ, RM; LOBATO MATILLA, E; L\u00d3PEZ ESTEBAN, A; \nHERRANZ ALONSO, A; SANJURJO SAEZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nDescribir los resultados de calidad del sue\u00f1o en salud de pacientes con enfermedad inflamatoria reumatol\u00f3gica (EIR) en \ntratamiento con terapias biol\u00f3gicas (TB).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo, de pacientes con EIR tratados en un centro multidisciplinar en un hospital de tercer \nnivel. Se incluyeron pacientes con artritis reumatoide (AR), espondiloartritis (EspA), artritis psori\u00e1sica (APs), lupus \neritematoso sist\u00e9mico (LES) y uve\u00edtis no infecciosa (UNI) que llevaran al menos 4 meses en tratamiento con terapias \nbiol\u00f3gicas (TB) entre el 01/03/2022 y el 30/04/2022 y que estuvieran en seguimiento telem\u00e1tico a trav\u00e9s de la App \nE-Midcare\u00ae. Se recogieron variables demogr\u00e1ficas, cl\u00ednicas y farmacol\u00f3gicas de la historia cl\u00ednica y de la app. Para \nla evaluaci\u00f3n de la calidad del sue\u00f1o se utiliz\u00f3 el cuestionario ISI (Insomnia Severity Index). La calidad del sue\u00f1o se \ncorrelacion\u00f3 con el estado an\u00edmico (HAD: Hospital Anxiety and Depression Scale), la calidad de vida EuroQol-EQ-5D-EVA, \nel dolor (EVA) y el uso de corticoides sist\u00e9micos y medicamentos hipn\u00f3ticos/ansiol\u00edticos y antidepresivos.  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 con SPSS 18.0.\nRESULTADOS\nSe evalu\u00f3 la calidad del sue\u00f1o en 76 pacientes. El 63,2% eran mujeres y la edad media fue 49,6 a\u00f1os (DS 10,0). Los \ndiagn\u00f3sticos fueron: 25,0% (AR), 40,8% (ESART), 19,7% (APS), 11,8% (LES) y 2,7% (UNI). El X% eran mujeres, con una \nmediana de edad de X a\u00f1os (RIC x-x). Las TB m\u00e1s frecuentes fueron: anti-TNF (73,7%), belimumab (11,8%), anti-IL17 \n(6,6%), anti-JAK (3,9%), anti IL-6 (2,6%) y anti-CD80 (1,3%). El 26,3% de los pacientes estaban en tratamiento con 131corticoides (dosis media 7,1 mg/d\u00eda -DS 6,2-), el 17,1 con ansiol\u00edticos/hipn\u00f3ticos y el 14,8% con antidepresivos. El uso de \ncorticoides era m\u00e1s frecuente en los pacientes con LES (77,8%) (p < 0,001) \nLa media de puntuaci\u00f3n global en el ISI fue 12,3 (DE 6,8). Desglosado por patolog\u00edas, la media de puntuaci\u00f3n en el ISI \nfue 12,5 (DE 6,8) en AR, 11,9 (DE 7,8) en EspA, 12,5 (DE 6,2) en APS y 13 (DE 5,2) en LES. Globalmente, el 39,5% de los \npacientes, ten\u00edan un insomnio cl\u00ednico moderado o grave (puntuaci\u00f3n ISI 15-28), 47,4% en AR, 38,7% en EspA, 40,0% en \nAPs y 33,3% en LES. La media de puntuaci\u00f3n en el HAD fue 16,8 (DE 7,9) y el 76,0% present\u00f3 una puntuaci\u00f3n HAD > 11. La \nmedia de calidad de vida EuroQol-EQ-5D-EVA y de EVA-dolor fue 63,0 (DE 25,1) y 3,9 (DE 3,3), respectivamente. \nLos pacientes con m\u00e1s insomnio presentaban peor estado emocional seg\u00fan la escala HAD, peor calidad de vida EuroQol-\nEQ-5D-EVA y m\u00e1s dolor (p < 0,001). El 100% de los pacientes con insomnio grave ten\u00edan un HAD > 11 (p=0,001). Los \npacientes con insomnio moderado-grave tomaban m\u00e1s frecuentemente ansiol\u00edticos (p=0,001).\nCONCLUSIONES\nLa prevalencia de insomnio en las patolog\u00edas reumatol\u00f3gicas inflamatorias es elevada. Los pacientes con insomnio \npresentaron peores resultados de calidad de vida en el cuestionario HAD y en el EuroQol-EQ-5D-EVA, as\u00ed como mayor \n\u00edndice de dolor medido en la escala EVA.  \nResulta urgente implantar medidas de educaci\u00f3n sanitaria y de optimizaci\u00f3n del tratamiento farmacol\u00f3gico para el \ninsomnio destinadas a mejorar la calidad del sue\u00f1o en esta poblaci\u00f3n de pacientes.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n371. RESULTADOS EN SALUD DE UPADACITINIB EN DERMATITS ATOPICA GRAVE \nAUTORES\nGEA NAVARRETE, S; MENGUAL SENDRA, A; LEGIDO PERDICES, E; RUBIO ALONSO, L; GONZALEZ MATEO, A; SOLER \nCOMPANYS, E\nHOSPITAL ARNAU DE VILANOVA \ufffd SAN CLEMENTE, 12 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEstudiar la efectividad de upadacitinib en dermatitis at\u00f3pica (DA) moderada a grave, el perfil de seguridad y la \nadherencia.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un departamento de salud de 350000 habitantes. Se incluyeron todos los \npacientes que iniciaron tratamiento con upadacitinib para DA desde diciembre 2020 hasta abril 2022, tanto en uso \nfuera de indicaci\u00f3n como una vez financiado para DA. Se revisaron las historias cl\u00ednicas electr\u00f3nicas y las dispensaciones \ndesde el servicio de farmacia. Se recogieron variables demogr\u00e1ficas (edad y sexo), farmacoterapeuticas (posolog\u00eda, \ntratamiento t\u00f3pico y sist\u00e9mico previo). La efectividad se midi\u00f3 comparando los valores basales y a las 12, 16 y 52 \nsemanas de la puntuaci\u00f3n EASI (Eczema Area and Severity Index), el valor PGA (Physician Global Assesment) y el BSA \n(Body Surface Area). La seguridad se evalu\u00f3 registrando los efectos adversos relacionados con el tratamiento. Se \nconsideraron adherentes aquellos pacientes que ten\u00edan un cumplimiento terap\u00e9utico \u2265 90% medido indirectamente \nmediante las dispensaciones realizadas. Los criterios cl\u00ednicos requeridos para el inicio del tratamiento fueron puntuaci\u00f3n \nEASI \u2265 21, PGA \u2265 3, BSA \u2265 10%, ser refractarios a medicaci\u00f3n t\u00f3pica y con respuesta insatisfactoria o contraindicaci\u00f3n de \nciclosporina\ufffd\nRESULTADOS\nSe incluyeron 6 pacientes (4 mujeres) con mediana de edad de 42 (25 \u2013 45) a\u00f1os. La dosis inicial en todos los casos fue \n15 mg al d\u00eda. Todos los pacientes hab\u00edan recibido tratamiento t\u00f3pico previo, 2 pacientes hab\u00edan recibido ciclosporina con \nmala tolerancia, 2 con respuesta insatisfactoria y en 2 estaba contraindicada. La mediana de las variables basales en el \nmomento de prescripci\u00f3n de upadacinib fue: EASI 27,5 (21 \u2013 35,5), IGA 4 (3 \u2013 4), BSA 24,5 (12 \u2013 40). A las 12 semanas de \ntratamiento, se reevaluaron las variables resultando en una mediana de EASI de 4,5 (0,2 \u2013 6,7), BSA 5,5 (3 \u2013 10), IGA 2 (1-\n3). Todos los pacientes alcanzaron EASI 50 (reducci\u00f3n del 50% del valor de EASI basal) en la semana 12, 5 alcanzaron EASI \n75 y 3 una reducci\u00f3n de al menos 2 puntos en el valor de PGA \ufffd En la semana 16 de tratamiento, todos los pacientes se \nmanten\u00edan estables, aunque un paciente precis\u00f3 aumento de dosis. En la semana 52, 4 pacientes se manten\u00edan estables \ny 2 pacientes hab\u00edan discontinuado el tratamiento, uno de ellos por mala tolerancia y otro por ineficacia. Todos los \npacientes presentaron una correcta adherencia. Los efectos adversos registrados fueron acn\u00e9 leve (n=2), herpes zoster sin \nsecuelas (n=2) y cefalea leve (n=1).\nCONCLUSIONES\nTeniendo presente la limitaci\u00f3n del tama\u00f1o muestral, los datos de efectividad y seguridad de upadacitinib en nuestros \npacientes son equiparables a los reflejados en los ensayos cl\u00ednicos pivotales.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n407. EFECTIVIDAD Y SEGURIDAD DE ERENUMAB EN EL TRATAMIENTO PREVENTIVO DE LA MIGRA\u00d1A \nAUTORES\nMAR\u00cdN VENTURA, L; GARC\u00cdA-L\u00d3PEZ , L; COLOMA PERAL, R; TOLOSA MART\u00cdNEZ, C; HERN\u00c1NDEZ L\u00d3PEZ, A; P\u00c9REZ \nROBRES, Y; AMOR\u00d3S P\u00c9REZ, A; SANZ RODR\u00cdGUEZ, SM\nCOMPLEJO ASITENCIAL DE SEGOVIA. CTRA.DE AVILA, S/N SEGOVIA. SEGOVIA132OBJETIVOS\nAnalizar la efectividad y seguridad de erenumab en los pacientes con m\u00e1s de 8 episodios de migra\u00f1a epis\u00f3dica de alta \nfrecuencia (ME) o cr\u00f3nica (MC) y con fracaso a 3 o m\u00e1s l\u00edneas de tratamientos preventivos, siendo uno de ellos la toxina \nbotul\u00ednica en MC, seg\u00fan el protocolo elaborado por nuestro hospital.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, prospectivo, en el que se incluyeron todos los pacientes en tratamiento con erenumab \ndesde el 1 de febrero de 2020 al 1 de febrero de 2022. La posolog\u00eda de erenumab fue 70 mg cada 4 semanas durante \nun a\u00f1o como m\u00e1ximo. El escalado de dosis a 140 mg se hizo seg\u00fan criterio m\u00e9dico. En casos de ineficacia se permiti\u00f3 \nrealizar un \u00fanico cambio a galcanezumab. Los pacientes fueron evaluados cada 3 meses. La efectividad se defini\u00f3 como \nla reducci\u00f3n de al menos un 50% de los d\u00edas mensuales de migra\u00f1a (DMM) a los 3, 6, 9 y 12 meses con respecto al basal. \nSe recogieron las siguientes variables: edad, sexo, tipo de migra\u00f1a, n\u00famero de tratamientos preventivos, cambios de \ndosis y f\u00e1rmaco, DMM y efectos secundarios. Los datos se obtuvieron del programa inform\u00e1tico de Gesti\u00f3n de Pacientes \nExternos y de la historia cl\u00ednica informatizada. El an\u00e1lisis estad\u00edstico se llev\u00f3 a cabo con el programa SPSS.22\u00ae\nRESULTADOS\nSe incluyeron 67 pacientes (84% mujeres) con una media de edad de 49 \u00b1 12 a\u00f1os. 57/67 pacientes (85%) hab\u00edan \nutilizado previamente 4 o m\u00e1s f\u00e1rmacos preventivos. De los 23 pacientes con ME, se aument\u00f3 la dosis de erenumab \na 140 mg en 9 pacientes (39%) pacientes. La media basal de DMM fue de 11,4 \u00b1 3,4 d\u00edas. El n\u00famero de pacientes con \ntratamiento activo que alcanzaron una reducci\u00f3n de al menos el 50% de los DMM fue: a los 3 meses 15/23 pacientes \n(65%), a los 6 meses 15/21 (71%), a los 9 meses 11/16 (69%) y a los 12 meses 7/11 (64%). De los 44 pacien tes con MC, \nse aument\u00f3 la dosis de erenumab a 140 mg en 23 (52%) pacientes. La media basal de DMM fue de 18,2 \u00b1 6,9 d\u00edas. \nEl n\u00famero de pacientes con tratamiento activo que alcanzaron una reducci\u00f3n de al menos el 50% de los DMM fue: \na los 3 meses 29/44 pacientes (66%), a los 6 meses 26/36 (72%), a los 9 meses 23/29 (79%) y a los 12 meses 14/18 \n(78%). Los principales efectos adversos fueron estre\u00f1imiento (17%) y reacci\u00f3n cut\u00e1nea en el lugar de inyecci\u00f3n (5%). \nSe realiz\u00f3 cambio a galcanezumab en 7 pacientes: 4 por ineficacia y 3 por reacciones cut\u00e1neas. S\u00f3lo 1 paciente obtuvo \nuna reducci\u00f3n DMM del 63% a los 12 meses y 3 pacientes suspendieron definitivamente el tratamiento por reacciones \ncut\u00e1neas.\nCONCLUSIONES\nErenumab es un f\u00e1rmaco efectivo y seguro en nuestros pacientes, tanto en ME como en MC.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n443. EFECTIVIDAD Y SEGURIDAD DEL DUPILUMAB OFF-LABEL EN NI\u00d1O/AS \u2264 6 A\u00d1OS \nAUTORES\nOLIVES CASASNOVAS, R; ORTEGA GARC\u00cdA, MP; BETORET VILAR, M; FUSTER TALENS, R; BAS CASTILLO, A; LAGU\u00cdA \nSANCHEZ, R; ZARAGOZ\u00c1 GONZ\u00c1LEZ, M; BLASCO SEGURA, P\nCONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA \ufffd AV\ufffd TRES CRUCES, S/N VALENCIA \ufffd VALENCIA\nOBJETIVOS\nDupilumab es un anticuerpo monoclonal humano anti-receptor alfa de la interleucina-4 que inhibe la se\u00f1alizaci\u00f3n IL-4/IL-\n13. No est\u00e1 indicado en menores de 6 a\u00f1os con dermatitis at\u00f3pica (DA) u otras manifestaciones cl\u00ednicas at\u00edpicas de la DA \ncomo puede ser el eczema numular at\u00f3pico (ENA).  \nEl objetivo del estudio es evaluar la efectividad y seguridad de dupilumab en ni\u00f1os/as \u22646 a\u00f1os, siendo esta una situaci\u00f3n \noff-label.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo que incluye todos los pacientes \u22646 a\u00f1os tratados con dupilumab desde que estuvo disponible como \nmedicamento extranjero (julio 2017), en un hospital que atiende a una poblaci\u00f3n de 367.000 pacientes.  \nSe han recogido variables demogr\u00e1ficas (sexo, edad diagn\u00f3stico, edad inicio de dupilumab); diagn\u00f3stico, comorbilidades, \ntratamientos previos y concomitantes; variables cl\u00ednicas al inicio EASI (Eczema Area and Severity Index), IGA (Investigator\u2019s \nGlobal Assessment) y BSA (Body Surface Area); efectos adversos. La efectividad se ha medido a las 16, 24 y 52 semanas \nmediante la reducci\u00f3n del 50% del EASI (EASI-50) y la reducci\u00f3n \u2265 2 puntos del IGA (IGA-2).\nRESULTADOS\n6 pacientes (4 ni\u00f1as), 4 DA y 2 ENA. La mediana de edad al diagn\u00f3stico fue de 3 a\u00f1os (0-4) y al inicio con dupilumab de 5 \na\u00f1os (2-6). Al inicio del tratamiento la mediana de EASI era 23,5 (21-50) (todos \u226521), PGA 4 (3-4) y BSA 40% (30-70). Dos \nhab\u00edan sido tratados previamente con ciclosporina y todos continuaron con tratamientos t\u00f3picos. A 30-04-2022, todos \ncontinuaban con dupilumab, con una mediana de duraci\u00f3n de 15,3 (5-37) meses y con una dosis de mantenimiento de \n300mg mensuales en 5 casos y 200mg mensuales en un caso. Las dosis iniciales difirieron en los pacientes debido a la \nfalta de datos, 1 inici\u00f3 con 75 mg quincenal 22 semanas y luego pas\u00f3 a 300 mg/mensual; 3 hicieron inducci\u00f3n, 2 con \n300mg semana 0-2 y 1 con 300 mg y 2 no hicieron inducci\u00f3n.  \nLa semana 16 la mediana de EASI fue de 1 (1-9) y los/as 6 ni\u00f1os/as hab\u00edan alcanzado el EASI-50 y el IGA-2. A la semana \n24, tenemos resultados de 4 pacientes con mediana de EASI de 1,5 (1-9) que mantuvieron el EASI-50 y alcanzaron el IGA-\n2. A la semana 52, solo disponemos de datos de 2 pacientes, ambos manteniendo el EASI-50 y uno de ellos logr\u00f3 el IGA-2.  \nNing\u00fan paciente suspendi\u00f3 el tratamiento por efectos adversos ni se han reportado.133CONCLUSIONES\nLa evidencia de uso de dupilumab en \u2264 6 a\u00f1os es escasa. Solamente hay publicado un estudio abierto de fase 2 de una \ndosis \u00fanica en ni\u00f1os de 6 meses a < 6 a\u00f1os con DA grave y est\u00e1n pendiente de publicaci\u00f3n un ensayo cl\u00ednico fase 3 y un \nestudio abierto de seguridad a largo plazo. Se trata de un grupo de edad con escasas opciones de tratamiento y mal perfil \nde seguridad (corticoides, inmunosupresores). En nuestra serie de casos, dupilumab ha sido un tratamiento efectivo, \ntodos han alcanzado el EASI-50 y el IGA-2 a las 16 semanas con un efecto mantenido al menos hasta las 24 semanas, y \nadem\u00e1s ha sido seguro.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n487. EXPERIENCIA EN LA UTILIZACION DE SIPONIMOD EN EL TRATAMIENTO DE ESCLEROSIS M\u00daLITPLE \nSECUNDARIA PROGRESIVA \nAUTORES\nTEJADA MARIN, D; PRECIADO GOLDARACENA, J; RODR\u00cdGUEZ ESQU\u00cdROZ, A; ERDOZAIN SANCLEMENTE, S; PINO \nRAMOS, A; DE LA RIVA BOHIGAS, R; LAMAS PILLO, A; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDescribir el uso y analizar la efectividad y seguridad del tratamiento con siponimod en pacientes diagnosticados de \nesclerosis m\u00faltiple secundaria progresiva (EMSP) con enfermedad activa en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, retrospectivo de pacientes que iniciaron tratamiento con siponimod desde su \ninclusi\u00f3n en gu\u00eda farmacoterap\u00e9utica en junio de 2021. Se analizaron variables demogr\u00e1ficas (edad y sexo), diagn\u00f3stico, \ntiempo desde el diagn\u00f3stico hasta el inicio de siponimod, n\u00famero de tratamientos previos y tratamiento inmediatamente \nanterior, genotipo del polimorfismo de CYP2C9 y dosis de mantenimiento. La efectividad se analiz\u00f3 mediante la \nevaluaci\u00f3n del riesgo de progresi\u00f3n de la discapacidad confirmada (PDC) a los 3 y 6 meses, determinada como un \nincremento de al menos 1 punto en la Expanded Disability Status Scale (EDSS) con respecto al inicio (o de 0,5 puntos en \npacientes con EDSS \u2265 5,5) y aumento del volumen de lesiones en T2 en resonancia magn\u00e9tica (RM) desde el inicio de \ntratamiento. La seguridad se determin\u00f3 mediante el registro de efectos adversos, aparici\u00f3n de bradiarritmias y an\u00e1lisis de \ntransaminasas (ALT y AST) basales y a los 6 meses.\nRESULTADOS\nSe incluyeron 5 pacientes con una mediana de edad de 44 [38-55] a\u00f1os, 80% mujeres (n=4), diagnosticados de EMSP con \nenfermedad activa. El tiempo medio desde el diagn\u00f3stico hasta el inicio del tratamiento con siponimod fue de 17 a\u00f1os. \nCon respecto a los tratamientos previos, un paciente (20%) hab\u00eda recibido 4 tratamientos previos, 2 (40%) recibieron \n3 y 2 (40%) hab\u00edan recibido 2. Los f\u00e1rmacos inmediatamente anteriores fueron fingolimod (80%) y natalizumab (20%), \ncumpli\u00e9ndose en este \u00faltimo el periodo de aclaramiento de 8-12 semanas requerido. El 80% (n=4) presentaba un \ngenotipo CYP2C9*1/*1, mientras que un paciente (20%) presentaba CYP2C9 *1/*2. Por tanto, en todos ellos la dosis de \nmantenimiento fue de 2 mg/d\u00eda. Respecto a la efectividad, la media de EDSS al inicio de tratamiento fue de 6,4 puntos, \nmanteni\u00e9ndose a los 3 meses (6,2 puntos) y presentando un ligero descenso a los 6 meses (5,8 puntos) sin objetivarse \nen ning\u00fan caso PDC a los 3 ni a los 6 meses. En las RM posteriores al inicio del tratamiento con siponimod no se observ\u00f3 \naumento del volumen de lesiones en T2 en ning\u00fan paciente. Los efectos adversos notificados fueron estre\u00f1imiento (20%) \ny debilidad generalizada (20%), sin presentar ning\u00fan paciente bradiarritmias. Los valores de ALT y AST se mantuvieron en \nrango adecuado tras 3 y 6 meses de iniciar siponimod\ufffd\nCONCLUSIONES\nLa experiencia en el uso de siponimod en pacientes diagnosticados EMSP con enfermedad activa muestra una buena \nrespuesta cl\u00ednica con una estabilizaci\u00f3n en la progresi\u00f3n de la enfermedad, manteniendo el EDSS y disminuyendo \nla actividad en la RM. En cuanto a la seguridad, los efectos adversos fueron leves, sin ocasionar interrupci\u00f3n del \ntratamiento; si bien, es necesario realizar una vigilancia intensiva para detectar efectos adversos que pudieran aparecer \na largo plazo, as\u00ed como estudios con mayor n\u00famero de pacientes que consoliden nuestra experiencia y permitan obtener \nconclusiones de mayor relevancia\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n491. AN\u00c1LISIS DE VARIABLES PREDICTORAS DE CONCENTRACIONES TERAP\u00c9UTICAS DE USTEKINUMAB \nEN LA FASE DE INDUCCI\u00d3N EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL. \nAUTORES\nGARC\u00cdA CASANUEVA, JC; APARICIO PE\u00d1ACOBA, R; S\u00c1NCHEZ HERNANDEZ, JG; SAEZ FERNANDEZ, EM; PRIETO \nVICENTE, V; RECAREY GERPE, V; L\u00d3PEZ ALVAREZ, M; OTERO LOPEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nUstekinumab ha supuesto un avance en el tratamiento de la enfermedad inflamatoria intestinal (EII). Aunque se dispone \nde evidencia de la utilidad de la monitorizaci\u00f3n de las concentraciones s\u00e9ricas de ustekinumab (CSU) para reducir \nsu variabilidad y ajustar la dosis en la fase de mantenimiento, existen pocos estudios sobre su utilidad en la fase de \ninducci\u00f3n. El objetivo del estudio fue evaluar la variabilidad de las CSU en pacientes con EII en la fase de inducci\u00f3n 134e identificar los posibles factores que contribuyen a la misma y condicionan el que se alcancen concentraciones \nterap\u00e9uticamente adecuadas.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo de 4 a\u00f1os (2018-2022). Se incluyeron pacientes adultos con EII moderada o grave, que iniciaron \ntratamiento con ustekinumab con la pauta indicada en ficha t\u00e9cnica y en los que se realiz\u00f3 un primer control de CSU en la \nsemana 4 de la fase de inducci\u00f3n. El estudio cont\u00f3 con la autorizaci\u00f3n del CEIm del centro.  \nSe recogieron datos demogr\u00e1ficos, de tratamiento, cl\u00ednicos y biomarcadores de actividad [alb\u00famina s\u00e9rica, prote\u00edna C \nreactiva (PCR) y calprotectina fecal (CF)] basales. Se determinaron las CSU mediante t\u00e9cnica de inmunoabsorci\u00f3n ligada a \nenzimas (ELISA). Se estableci\u00f3 una CSU > 15 \u00b5g/mL en semana 4 como terap\u00e9uticamente adecuada (Hanzel et al. 2021).  \nPara identificar posibles factores asociados a CSU adecuadas en semana 4, se realiz\u00f3 un an\u00e1lisis de regresi\u00f3n log\u00edstica \nunivariante y multivariante. Adem\u00e1s, se compararon las diferentes variables recogidas entre los pacientes con CSU \nadecuadas e inadecuadas, mediante la prueba t o la prueba de Wilcoxon para las variables continuas, y la prueba de chi-\ncuadrado o la prueba exacta de Fisher para las categ\u00f3ricas. Los an\u00e1lisis estad\u00edsticos fueron realizados en R v4.1\nRESULTADOS\nSe incluyeron 73 pacientes (35 mujeres), 52 con enfermedad de Crohn y 21 con colitis ulcerosa, con una mediana (rango \nintercuartilico) de edad de 54 (43-68) a\u00f1os. Doce pacientes no hab\u00edan recibido terapia con un biol\u00f3gico previamente. La \nCSU media (DE) en la semana 4 fue de 15,7 (7,1) \u00b5g/mL. Un total de 29 pacientes (39,7%) presentaron CSU no adecuadas \nen semana 4\ufffd  \nLos pacientes con CSU no adecuadas presentaban antes de iniciar el tratamiento unos valores basales [mediana (RIC)] de \nPCR m\u00e1s elevados [1,75 (0,23-2,79) mg/dL vs 0,39 (0,16-0,74) mg/dL; p=0,004) y unos valores menores de alb\u00famina [3,9 \n(3,4-4,2) g/dL vs 4,3 (4,1-4,5) g/dL; p=0,001] y de hemoglobina [12,9 (11,1-14) g/dL vs 14,1 (13,4-15,1) g/dL; p=0,001]. \nEn el an\u00e1lisis de regresi\u00f3n log\u00edstica, la presencia de valores basales elevados de PCR y reducidos de alb\u00famina se asociaron \na una mayor probabilidad de CSU inadecuadas en semana 4 [odd ratio (OR): 0,53; IC95%: 0,46-0,57; p=0,008 y OR:2,29 ; \nIC95%: 1,05-3,87; p=0,001 ].\nCONCLUSIONES\nEn esta cohorte limitada de pacientes se observ\u00f3 una elevada variabilidad de las CSU en la semana 4, presentando un \nalto porcentaje de pacientes CSU infraterap\u00e9uticas. La albumina y la PCR basales resultaron ser los principales par\u00e1metros \npredictores de CSU terap\u00e9uticas. La monitorizaci\u00f3n temprana de las CSU en la fase de inducci\u00f3n podr\u00eda ser \u00fatil como \nherramienta predictiva de la respuesta al tratamiento.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n493. EFICACIA Y SEGURIDAD DEL DUPILUMAB EN DERMATITIS ATOPICA EN PRACTICA CLINICA HABITUAL \nAUTORES\nPENA VILLANUEVA, P; GONZALEZ MARTINEZ, J; SAGRISTA GARCIA, M; PANES RODRIGUEZ, A; RUIZ POZA, D; TERR\u00c9 \nOMHE, S; VAZQUEZ VAZQUEZ, A; MARTINEZ BERNABE, EM\nHOSPITAL COMARCAL DE BLANES \ufffd CRTRA CALA DE SANT FRANCES, 5 BLANES \ufffd GIRONA\nOBJETIVOS\nDeterminar la eficacia y seguridad del dupilumab en el tratamiento de la dermatitis at\u00f3pica grave en dos hospitales \ncomarcales\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en dos hospitales comarcales pertenecientes a la misma corporaci\u00f3n \nsanitaria, que atienden a una poblaci\u00f3n de 195.000 habitantes. Se incluy\u00f3 a todos los pacientes mayores de 6 a\u00f1os con \ndermatitis at\u00f3pica que iniciaron tratamiento con dupilumab desde su comercializaci\u00f3n. Se excluyeron aquellos pacientes \nque hubiesen recibido menos de 7 dosis.  \nSe recogieron de la Historia Cl\u00ednica Electr\u00f3nica los siguientes datos: sexo, edad actual, n\u00famero de dosis recibidas. Como \nvariables cl\u00ednicas se registr\u00f3 las siguientes escalas: EASI (Eczema Area and Severity Index), PGA (Physician\u2019s Global \nAsessment), BSA (Body Surface Area), DLQI (Dermatology Life Quality Index) y el NRS (Numerical Rate Scale) de prurito \ny si tiene tratamiento concomitante con corticoides t\u00f3picos. Tambi\u00e9n se registr\u00f3 si se suspendi\u00f3 el tratamiento con su \nmotivo, y la aparici\u00f3n de reacciones adversas (RAM). Todas las variables cl\u00ednicas (excepto el BSA) se valoraron previas al \ninicio y a las 16 semanas\ufffd  \nEl tratamiento se consider\u00f3 eficaz si a las 16 semanas el paciente presentaba dos criterios: una reducci\u00f3n del EASI \u226550%, \nadem\u00e1s de una reducci\u00f3n del PGA \u22652 puntos.  \nPara valorar la seguridad se tuvo en cuenta s\u00f3lo aquellos efectos adversos que requirieron una consulta m\u00e9dica. \nLas variables se registraron en una hoja de c\u00e1lculo\nRESULTADOS\nDe un total de 13 pacientes que iniciaron tratamiento, se excluy\u00f3 3 por no haber recibido al menos 7 dosis. Eran 8 \nmujeres y 2 hombres, con una media de edad de 34,4 a\u00f1os (rango de 11-54). La media de EASI fue 49,9 (25-72), la media \nde PGA fue 3,9 (3-4), la media de BSA fue 51,8 (18-100), la media de DLQI fue 23,9 (10-30) y la media de prurito 8,9 (8-\n10).  \nA las 16 semanas se hizo seguimiento a los 10 pacientes, estableciendo que el tratamiento fue eficaz en el 90%. En \nel paciente que no fue eficaz se suspendi\u00f3. La media de EASI fue 10,9 (1-55), la media de PGA fue 1,3 (1-4), la media \nde DLQI fue 5,9 (1-25) y la media de prurito fue 2,6 (0-8). 2 pacientes pudieron suspender el tratamiento t\u00f3pico con \ncorticoides.  135Respecto a la seguridad, 5 pacientes presentaron conjuntivitis, 1 paciente present\u00f3 un eccema y 1 present\u00f3 efluvio \ntel\u00f3geno. Ninguna de estas RAM se consideraron tan graves como para requerir la suspensi\u00f3n del tratamiento.\nCONCLUSIONES\nEl tratamiento con dupilumab ha resultado eficaz y seguro en la mayor\u00eda de los pacientes tratados, aunque ser\u00edan \nnecesarios m\u00e1s estudios y de mayor duraci\u00f3n para poder establecer la utilidad de estos f\u00e1rmacos en condiciones de \npr\u00e1ctica cl\u00ednica y su seguridad a largo plazo.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n519. CALIDAD DE VIDA EN PACIENTES CON ARTRITIS REUMATOIDE EN TRATAMIENTO CON F\u00c1RMACOS \nBIOL\u00d3GICOS \nAUTORES\nGRAMAGE CARO, T; V\u00c9LEZ D\u00cdAZ-PALLAR\u00c9S, M; L\u00d3PEZ ARIAS, D; MART\u00cdN SANTAMAR\u00cdA, A; S\u00c1NCHEZ-PRIETO L\u00d3PEZ \nDE LA VIEJA, P; SEGURA N\u00da\u00d1EZ, I; ESCRIG LARENA, I; \u00c1LVAREZ D\u00cdAZ, A\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nAnalizar la calidad de vida (CV) de pacientes con Artritis Reumatoide (AR) en tratamiento con f\u00e1rmacos biol\u00f3gicos y \ncompararla con la poblaci\u00f3n general\ufffd  \nDeterminar la asociaci\u00f3n de factores relacionados con la CV \ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo y transversal realizado en pacientes con AR en tratamiento con f\u00e1rmacos biol\u00f3gicos a los que se les \ndispens\u00f3 medicaci\u00f3n en la consulta de pacientes externos o en el hospital de d\u00eda.  \nSe incluyeron de manera aleatoria pacientes \u226518 a\u00f1os que otorgaron su consentimiento y fueron contactados \ntelef\u00f3nicamente entre mayo y junio de 2021.  \nSe recogieron variables mediante entrevista (edad, sexo, peso, altura e \u00edndice de masa corporal (IMC)), nivel de estudios, \nantecedentes de fumador, convivencia y necesidad de cuidador), de la historia cl\u00ednica (tiempo desde el diagn\u00f3stico, \nn\u00famero de f\u00e1rmacos prescritos, medicamento biol\u00f3gico, l\u00ednea de tratamiento, tiempo de utilizaci\u00f3n del biol\u00f3gico, \nresultado de DAS28 y comorbilidades) y mediante cuestionarios (dolor, discapacidad y adherencia). Para evaluar la \ncalidad de vida se emple\u00f3 el cuestionario EQ-5D-5L. Para el dolor la escala visual anal\u00f3gica (EVA), para la discapacidad el \nHealth Assessment Questionnaire (HAQ), y Morisky-Green y registro de dispensaciones para la adherencia al tratamiento. \nSe consider\u00f3 a un paciente adherente si fue adherente por ambos m\u00e9todos .  \nSe compararon los resultados de CV con los de la poblaci\u00f3n general espa\u00f1ola (Encuesta Nacional de Salud en Espa\u00f1a \n2011/12, \u00faltimos datos publicados por el Ministerio de Sanidad). Se analiz\u00f3 la relaci\u00f3n de las variables con la CV mediante \nregresi\u00f3n lineal con STATA_v13. El estudio fue aprobado por el Comit\u00e9 \u00c9tico de Investigaci\u00f3n de Medicamentos.\nRESULTADOS\nSe incluyeron 106 pacientes, 84% mujeres, mediana de edad 60(50-72) a\u00f1os, IMC 25,6(22,0-29,8). El 36,8% ten\u00eda estudios \nde bachillerato, el 53,8% hab\u00eda fumado alguna vez, el 79,2% viv\u00eda acompa\u00f1ado y el 7,9% precisaba cuidador. El tiempo \ndesde el diagn\u00f3stico fue de 12(8-17) a\u00f1os y el n\u00famero de f\u00e1rmacos prescritos 8(5-12). El principio activo mayoritario fue \netanercept (22,6%), principalmente en primera l\u00ednea de tratamiento (64,2%). El tiempo desde el inicio del biol\u00f3gico fue \n4(1-8) a\u00f1os. La mayor\u00eda de pacientes (54,7%) present\u00f3 un DAS28 < 2,6 (AR en remisi\u00f3n). La comorbilidad m\u00e1s frecuente \nfue la cardiovascular (55,6%). La mediana de HAQ fue 0,625(0-1,5) y el EVA de 4,5(1-6). El 77,4% present\u00f3 buena \nadherencia.  \nLa CV de los pacientes con AR fue inferior a la de la poblaci\u00f3n general en todos los \u00edtems del EQ-5D-5L (70,78 vs. 89,86), \ntanto en mujeres (67,66 vs 87,31) como en hombres (87,09 vs 92,56). En cuanto a la escala EVA del cuestionario EQ-5D-\n5L tambi\u00e9n mostraron menores puntuaciones (66,69 vs 73,16) en mujeres (65,95 vs 71,46) y hombres (70,58 vs 74,97). \nPrincipalmente se vieron afectadas las esferas de dolor/malestar (1,3/5) y movilidad (0,9/5).  \nLa CV fue menor en mujeres (p=0,0084), aument\u00f3 con el nivel de estudios (p=0,0022) y disminuy\u00f3 con el dolor (p=0,0000) \ny la discapacidad (p=0,0000).\nCONCLUSIONES\nLos pacientes con AR tienen peor CV que la poblaci\u00f3n general, especialmente en las esferas de dolor y movilidad.  \nLa CV disminuye en mujeres, pacientes con niveles bajos de estudios, con mayor discapacidad y con mayor intensidad del \ndolor \ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n549. RESULTADOS REPORTADOS POR LOS PACIENTES CON DERMATITIS AT\u00d3PICA EN TRATAMIENTO CON \nDUPILUMAB \nAUTORES\nRAM\u00cdREZ HERR\u00c1IZ, E; RUIZ GARC\u00cdA, S; GARC\u00cdA PERALO, A; CHICHARRO MANSO, P; RUIZ MART\u00cdNEZ, \u00cd; SORIANO \nCOLADO, JM; MORELL BALADR\u00d3N, A\nHOSPITAL UNIVERSITARIO DE LA PRINCESA \ufffd DIEGO DE LE\u00d3N, 62 MADRID \ufffd MADRID136OBJETIVOS\nLa dermatitis at\u00f3pica (DA) es una enfermedad inflamatoria cut\u00e1nea de curso cr\u00f3nico y recidivante que se caracteriza por \nla presencia de xerosis, prurito intenso y lesio\u00acnes cut\u00e1neas producidas por interacciones entre defectos en la barrera \ncut\u00e1nea y desregula\u00acci\u00f3n del sistema inmune.  \nLos resultados en salud desde la perspectiva del paciente (PRO) incluyen todas aquellas evaluaciones del estado de salud \ndel pa\u00acciente que condicionan su enfermedad y su tratamiento, informadas directamente por este. La medida de estos \nPRO se denomina PROMs\ufffd  \nEl objetivo principal fue registrar y evaluar los PROMs de pacientes con DA en tratamiento con dupilumab dispensado \ndesde las consultas de farmacia hospitalaria. Como objetivo secundario el caracterizar el perfil sociodemogr\u00e1fico de los \npacientes incluidos en el estudio\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional ambispectivo y unic\u00e9ntrico de cuatro meses de duraci\u00f3n (octubre 2021-enero 2022) en pacientes \ncon DA en tratamiento con dupilumab\ufffd  \nVariables recogidas: edad, sexo, fecha de inicio de tratamiento, antecedentes familiares y comorbilidades. La informaci\u00f3n \nse recopil\u00f3 de la historia cl\u00ednica electr\u00f3nica y del programa de prescripci\u00f3n de pacientes externos (Farmatools). Los \npacientes cumplimentaron dos cuestionarios: de calidad de vida (DLQI) y de medida de gravedad del eczema (POEM) \nbasal, a los 4,6 y 12 meses. Ambos cuestionarios contienen respuestas cualitativas o categ\u00f3ricas que se convierten en \npuntuaci\u00f3n num\u00e9rica, otorgando un valor num\u00e9rico final que a mayor puntuaci\u00f3n indica peor calidad de vida y mayor \nseveridad del eczema. \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 con el paquete SPSS versi\u00f3n 19.0.\nRESULTADOS\nSe incluyeron 23 pacientes con una mediana de edad de 30 a\u00f1os (IQR=25-51). 16 pacientes eran varones (70%) y 9 \n(39%) ten\u00edan antecedentes familiares. Respecto al tratamiento previo, 20 (87%) hab\u00edan utilizado corticoides y 21 (91%) \ninmunosupresores\ufffd \nEn relaci\u00f3n a las comorbilidades, 15 (65%) ten\u00edan rinoconjuntivitis, 10 (43%) padec\u00edan asma, 5 (22%) patolog\u00eda ocular, 4 \n(17%) ansiedad y 2 (9%) depresi\u00f3n.  \nLa mediana de tiempo de tratamiento en semanas fue de 34,14 (IQR=15-47,14).  \nLos valores de DLQI obtenidos fueron: 13,0 en el basal, 3,0 a los 4 meses, 2,0 a los 6 meses y 1,0 a los 12 meses, \nencontr\u00e1ndose diferencias estad\u00edsticamente significativas entre todas las medidas frente a la basal (p < 0,05).  \nLos valores de POEM obtenidos fueron: 22,0 en el basal, 6,5 a los 4 meses, 6,0 a los 6 meses y 5,0 a los 12 meses, \nencontr\u00e1ndose diferencias estad\u00edsticamente significativas entre todas las medidas frente a la basal (p < 0,05).\nCONCLUSIONES\nEs importante incluir la opini\u00f3n del paciente para conseguir mejorar los resultados de su patolog\u00eda.  \nDupilumab mejora la calidad de vida y la gravedad de la DA medida por DLQI y POEM. \nLas comorbilidades m\u00e1s frecuentes son: rinoconjuntivitis, asma y patolog\u00eda ocular. \nLos PROM han demostrado utilidad como medida de efectividad complementaria a la descrita por el cl\u00ednico.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n562. EFECTIVIDAD, SEGURIDAD Y ADHERENCIA DE DUPILUMAB EN PACIENTES CON DERMATITIS \nAT\u00d3PICA EN LA PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nSOCIAS CA\u00d1ELLAS, CM; RIERA ARMENGOL, P; MASIP TORN\u00c9, M; SERRA BALDRICH, E; SPERTINO , JL; ROE CRESPO, \nE; PAG\u00c8S PUIGDEMONT , N\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nDupilumab, un anti-IL-4/13, es un anticuerpo monoclonal aprobado para el tratamiento de la dermatitis at\u00f3pica (DA) \nde moderada a grave. En nuestro centro, el Servicio de Farmacia realiza la educaci\u00f3n sanitaria de este tratamiento y el \nseguimiento farmacoterap\u00e9utico. Hasta el momento, se dispone de pocos estudios en los que se haya evaluado su uso en \nla pr\u00e1ctica cl\u00ednica real.  \n \nEl objetivo de este estudio fue evaluar la efectividad, seguridad y el impacto del grado de adherencia en la efectividad del \ntratamiento con dupilumab en pacientes con DA en la pr\u00e1ctica cl\u00ednica.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo y descriptivo realizado en un hospital terciario. Se incluyeron todos los pacientes con DA que \niniciaron tratamiento con dupilumab hasta noviembre del 2021. Se registraron las siguientes variables, obtenidas a \npartir de la historia cl\u00ednica informatizada: edad, sexo, tratamientos previos, Eczema Area and Severity Index (EASI) y \nDermatology Life Quality Index (DLQI) basal y en la primera visita de seguimiento (16 semanas), reacciones adversas y \ngrado de adherencia terap\u00e9utica (calculada mediante el m\u00e9todo Medication Possession Ratio [MPR] a partir del registro \nde dispensaciones).  \n \nLa variable principal fue la efectividad del tratamiento determinada por el cambio en el valor EASI y DLQI a las 16 sema-\nnas respecto al basal. Las variables secundarias fueron el n\u00famero y tipo de efectos adversos (EA) y el grado de adherencia \nterap\u00e9utica durante el periodo de seguimiento.137RESULTADOS\nSe incluyeron 45 pacientes. La media (\u00b1DE) de edad fue de 41\u00b118 a\u00f1os, siendo un 56% hombres. Como tratamientos \nt\u00f3picos previos, el 100% hab\u00eda recibido corticoides; y un 60%, tacrolimus. Por otra parte, el 71% hab\u00eda recibido \nfototerapia; En cuanto al tratamiento sist\u00e9mico, un 78% hab\u00eda recibido corticoides; un 71%, ciclosporina; un 31%, \nmicofenolato de mofetilo; un 29%, azatioprina; y un 27%, metotrexato.  \n \nLos valores basales de EASI y DLQI medios (\u00b1DE) eran de 33\u00b111 y 18\u00b15, respectivamente. En la primera visita de \nseguimiento fueron 7\u00b16 y 6\u00b14, respectivamente. La reducci\u00f3n del EASI y DLQI fue estad\u00edsticamente significativa (p < \n0,001). Un 18% de los pacientes (N=8) presentaron EA durante este periodo: conjuntivitis (N=4), psoriasis paradoxal \n(N=2), blefaritis (N=1), reacci\u00f3n en el punto de inyecci\u00f3n (N=1).  \n \nLa media (\u00b1 DE) del MPR fue 99\u00b113%, lo que demuestra una elevada adherencia terap\u00e9utica. Ning\u00fan paciente present\u00f3 \nun MPR < 75% por lo que no podemos determinar el impacto de esta variable en la efectividad del tratamiento.  \nUn 9% de los pacientes (N=4) suspendieron el tratamiento antes de las 16 semanas: 2, por EA; 2, por decisi\u00f3n propia; y 1 \npor decisi\u00f3n m\u00e9dica al presentar remisi\u00f3n completa.\nCONCLUSIONES\nEn la pr\u00e1ctica cl\u00ednica real, dupilumab es un f\u00e1rmaco efectivo y seguro. Los pacientes tratados con este f\u00e1rmaco \nexperimentaron una mejor\u00eda estad\u00edsticamente significativa tanto del EASI como DLQI a las 16 semanas de tratamiento. \nPor otra parte, los pacientes mostraron elevadas tasas de adherencia terap\u00e9utica.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n566. UTILIZACI\u00d3N DE TILDRAKIZUMAB EN PACIENTES CON PSORIASIS EN PLACAS DE MODERADA A \nGRAVE EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nMERCH\u00c1N FLORES, A; SOPENA CARRERA, L; MAGALL\u00d3N MARTINEZ, A; CASTELLANOS SASTRE, J; ESPINOSA MORER, \nMK; FRUTOS P\u00c9REZ-SURIO, AJ; FRESQUET MOLINA, R; VARELA MART\u00cdNEZ, I\nHOSPITAL CL\u00cdNICO UNIVERSITARIO LOZANO BLESA. SAN JUAN BOSCO, 15 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nTildrakizumab es un anticuerpo monoclonal anti Interleucina 23 indicado para el tratamiento de psoriasis en placas \nde moderada a grave en adultos candidatos a tratamiento sist\u00e9mico. El objetivo de este trabajo es evaluar la eficacia y \nseguridad de tildrakizumab.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo y unic\u00e9ntrico que incluy\u00f3 a todos los pacientes que recibieron tildrakizumab en un \nhospital de tercer nivel desde octubre de 2019 hasta el 10 de mayo de 2022. \nVariables registradas: demogr\u00e1ficas (edad, sexo), cl\u00ednicas (antecedente de artritis psori\u00e1sica (AP) y puntuaci\u00f3n \nPsoriasis Area Severity Index (PASI)), de tratamiento (tiempo con tildrakizumab, n\u00famero de l\u00ednea de tratamiento, tipo \nde tratamiento anterior y motivo del cambio de este a tildrakizumab). La eficacia se calcul\u00f3 con el PASI 75, 90 y 100 \n(proporci\u00f3n de pacientes que consiguieron reducci\u00f3n de al menos 75%, 90% y 100% del PASI basal en las semanas 16 y \n28), y el porcentaje de pacientes que alcanzaron una puntuaci\u00f3n del Static Physician Global Assessment (sPGA) 0 o 1 (piel \nblanqueada o casi blanqueada) en la semana 16 y 28. Como variables de seguridad se registraron las reacciones adversas \n(RA).\nRESULTADOS\nSe incluyeron 23 pacientes con una mediana de edad de 53 a\u00f1os (23-83), siendo el 65,2% mujeres. La mediana de tiempo \nde duraci\u00f3n con tildrakizumab fue de 6,5 (0,3-26,4) meses y la mediana del tratamiento anterior de 7 (1,8-152,7) meses. \nTodos los pacientes llevaron pauta de mantenimiento de 100 mg cada 12 semanas\ufffd Al inicio del tratamiento, el 13,0% \n(3) ten\u00edan antecedentes de artritis psori\u00e1sica. La mediana de PASI al inicio fue de 6,6 (2-27,6). Del total de los pacientes, \nel 91,3% (21) recibieron tratamiento sist\u00e9mico previo; el 86,9% (20) tratamiento biol\u00f3gico; el 78,2% (18) con antiTNF\u03b1 y \nel 30,4% (7) con fototerapia. El motivo de cambio a tildrakizumab fue fracaso del tratamiento anterior en el 100% de los \npacientes\ufffd \nDel total de pacientes incluidos en el presente estudio, en la semana 16 se obtuvo el PASI y el sPGA de 13 y 11 pacientes, \nrespectivamente. El porcentaje de pacientes que alcanzaron el PASI 75 fue del 84,6% (11) y, dentro de estos, el 46,1% (6) \nalcanzaron el PASI 90. Ninguno de ellos logr\u00f3 el PASI 100. Por su parte, el 72,7% (8) obtuvieron una puntuaci\u00f3n sPGA de 0 \no 1\ufffd  \nEn la semana 28, se registr\u00f3 el PASI en 9 pacientes y el sPGA en 7. Se observ\u00f3 que el 77,7% (7) de los sujetos alcanzaron el \nPASI 75, el 44,4% (4) el PASI 90 y el 22,2% (2) el PASI 100, objetiv\u00e1ndose adem\u00e1s que el 71,4% (5) obtuvieron un sPGA de \n0 o 1\ufffd  \nEl 17,3% (4) de los pacientes interrumpieron el tratamiento, siendo la causa el fracaso en el 100% de los casos.  \nRespecto a la seguridad, ninguno de los sujetos experiment\u00f3 alg\u00fan efecto adverso a tildrakizumab.\nCONCLUSIONES\nTildrakizumab ha mostrado ser una opci\u00f3n efectiva y segura en el tratamiento para la psoriasis en nuestros pacientes.138CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n572. USO DE CLADRIBINA PARA EL TRATAMIENTO DE ESCLEROSIS M\u00daLTIPLE REMITENTE RECURRENTE \nAUTORES\nPERPINY\u00c0 GOMBAU, M; ARTIME RODRIGUEZ-HERMIDA, F; COMA PUNSET , M; OLMO MARTINEZ, M; MALLA CANET , \nMD; CASTELLO NORIA, A; DIEZ VALLEJO, C; SACREST G\u00dcELL, R\nHOSPITAL SANTA CATERINA. AVDA. DOCTOR CASTANY (P . H. MART\u00cd I JULI\u00c0), S/N SALT . GIRONA\nOBJETIVOS\nEvaluar la respuesta y seguridad de cladribina en el tratamiento de la esclerosis m\u00faltiple remitente recurrente (EMRR)\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, retrospectivo y observacional de pacientes diagnosticados de EMRR, que iniciaron tratamiento \ncon cladribina entre 2019 y hasta octubre 2021 para poder evaluar la respuesta al menos a los 6 meses del inicio de \ntratamiento\ufffd  \nLas variables recogidas fueron: edad al inicio del tratamiento y sexo, a\u00f1os de evoluci\u00f3n de EMRR, tratamientos previos y \nmotivo del \u00faltimo cambio, escala EDSS basal, 48 y 96 semanas del inicio de tratamiento. Adem\u00e1s se evalu\u00f3 la estabilidad \nradiol\u00f3gica mediante resonancia magn\u00e9tica (RM) en cada a\u00f1o de tratamiento. Se revisaron los efectos adversos (EA) \ndurante el tratamiento\ufffd  \nPara la recogida de datos se utiliz\u00f3 la historia cl\u00ednica.\nRESULTADOS\nSe evaluaron 29 pacientes con una edad media de 39.8 a\u00f1os (19-55) y 69% eran mujeres. La media de evoluci\u00f3n de la \nEMRR hasta el inicio de tratamiento con cladribina fue de 10.1 a\u00f1os (3-30).  \nEl n\u00famero medio de tratamientos previos fue de 2.2 (1-4). El 13.8% tuvo un tratamiento previo, el 62.1% tuvo dos, el \n10.3% tuvo tres y el 13.8% tuvo cuatro. El 68.9% de los pacientes fueron tratados con f\u00e1rmacos considerados de primera \nl\u00ednea. El 34.5% cambiaron a cladribina por EA (4 infecciones recurrentes, 2 linfopenias, 2 intolerancias g\u00e1stricas, 1 sincope \ny 1 bradicardia) y el 65.5% cambi\u00f3 por aparici\u00f3n de nuevas lesiones y/o brote. El EDSS medio basal fue 2.1 (0-4,5).  \nEl 72.4% (n=21) de los pacientes cumplieron 48 semanas de tratamiento con una media de EDSS 2.5 (1-5,5) y de estos, \nel 42.9% presentaron nuevas lesiones. El 14.3% requirieron un cambio de tratamiento por fracaso terap\u00e9utico, 4.8% \nabandon\u00f3 y el 4.8% cambi\u00f3 por diagn\u00f3stico de hepatitis autoinmune concomitante. \nEl 44.8% (n=13) de los pacientes hicieron 96 semanas de tratamiento con una media de EDSS 2.2 (0-5,5), y de estos, el \n53\ufffd8% mantuvieron estabilidad radiol\u00f3gica, 15\ufffd4% presentaron nuevas lesiones y un cambio de tratamiento y 30\ufffd8% \nten\u00edan pendiente de informar la resonancia.  \nEl 10\ufffd3% presentaron un brote durante el periodo de estudio\ufffd  \nDurante el periodo de estudio, el 44.8% mantuvieron EDSS, el 34.5% mejoraron su puntuaci\u00f3n y el 20.7% empeoraron.  \nEl 20.7% (n=6) de los pacientes presentaron EA leves durante todo el tratamiento (3 linfopenias, 1 herpes zoster, 1 \nerupci\u00f3n cut\u00e1nea y 1 otras)\nCONCLUSIONES\nEn nuestra poblaci\u00f3n, el tratamiento con cladribina mantuvo la escala EDSS sin progresi\u00f3n con una toxicidad aceptable, \naunque el porcentaje de pacientes con nuevas lesiones en la RM a las 48 semanas fue considerable, no implic\u00f3 una \np\u00e9rdida de respuesta dada la baja tasa de brotes. \nSe necesita ampliar el periodo de estudio y un mayor tama\u00f1o de muestra para confirmar la respuesta al tratamiento a \nlargo plazo.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n574. EFICACIA Y SEGURIDAD DE RISANKIZUMAB EN PACIENTES CON PSORIASIS MODERADA-GRAVE EN \nUN HOSPITAL DE TERCER NIVEL \nAUTORES\nSOPENA CARRERA, L; VILLAGRASA BOLI, P; BULARCA , EA; MAGALL\u00d3N MART\u00cdNEZ, A; JUEZ SANTAMAR\u00cdA, C; VINUESA \nHERNANDO, JM; G\u00d3MEZ RIVAS, P; PASCUAL MART\u00cdNEZ, O\nHOSPITAL CL\u00cdNICO UNIVERSITARIO LOZANO BLESA. SAN JUAN BOSCO, 15 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nLa psoriasis es una enfermedad cut\u00e1nea inflamatoria cr\u00f3nica que afecta al 1,5-3% de la poblaci\u00f3n mundial.  \nEl objetivo de este estudio es evaluar la eficacia y seguridad de risankizumab en pacientes con psoriasis moderada \u2013 grave \ny comparar los resultados con el estudio pivotal ULTIMMA-1.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo (Mayo 2019 - Mayo 2022). Variables recogidas del paciente: sexo, edad. Variables \nfarmacol\u00f3gicas: tiempo con risankizumab, n\u00famero de l\u00ednea de tratamiento, tipo de tratamiento anterior y motivo del \ncambio de este a risankizumab.  \nVariables cl\u00ednicas al inicio: antecedente de artritis psori\u00e1sica (AP) y puntuaci\u00f3n Psoriasis Area Severity Index (PASI).  \nLa eficacia se midi\u00f3 seg\u00fan la proporci\u00f3n de pacientes que consiguieron una reducci\u00f3n de al menos el 75% del PASI basal \n(PASI 75), el 90% (PASI 90) y el 100% (PASI 100), y una puntuaci\u00f3n static physician global assessment (sPGA) 0 o 1 (piel \nblanqueada o casi blanqueada) en la semana 16. Una reducci\u00f3n de PASI menor al 75% se consider\u00f3 no respondedor al \ntratamiento. La seguridad se evalu\u00f3 seg\u00fan los efectos adversos (EA).139RESULTADOS\nSe incluyeron 45 pacientes, 47,78% hombres. Mediana de edad al inicio del tratamiento de 54 (23 - 82) a\u00f1os. Mediana de \ntiempo de duraci\u00f3n con risankizumab de 10,87 (1,18 \u2013 19,03) meses y mediana de l\u00ednea de tratamiento de 3 (2 - 12).  \nTodos los pacientes recibieron tratamiento sist\u00e9mico anterior. El 82,22% hab\u00eda recibido tratamiento biol\u00f3gico: 77,78% \nanti-TNF\u03b1 (60,00% adalimumab, 35,56% etanercept, 2,22% infliximab y certolizumab respectivamente), 22,22% \nustekinumab, 15,56% secukinumab, 6,67% ixekizumab, 4,44% brodalumab y guselkumab respectivamente y 2,22% \ntildrakizumab. El 73,33% hab\u00eda recibido tratamiento inmunosupresor sist\u00e9mico (46,67% apremilast, 17,78% metotrexato \ny 8,89% ciclosporina).  \nEl motivo de cambio fue fracaso secundario en el 82,22% de los pacientes, 11,11% por evitar un aumento de riesgo de EA \npor padecer otras patolog\u00edas concomitantes y 4,44% por fracaso primario y EA al tratamiento anterior respectivamente.  \nAl inicio, la mediana PASI fue de 8 (1 \u2013 21,80) y el 11,11% ten\u00eda antecedente de AP .  \n33 pacientes llegaron a la semana 16, y de estos el 78% alcanzaron el PASI 75, el 60,61% el PASI 90 y el 54,55% el PASI \n100\ufffd  \nSe interrumpi\u00f3 risankizumab en un paciente por ineficacia.  \nEl 70% de los pacientes consigui\u00f3 una PGA 0 o 1 en la semana 16\ufffd  \nLos EA observados fueron aumento de peso y p\u00e9rdida de apetito en un 7,14% para ambos.\nCONCLUSIONES\nEn comparaci\u00f3n al ensayo pivotal, en nuestro grupo de pacientes la mediana PASI al inicio fue inferior (vs 17,8). Sin \nembargo, el porcentaje de antecedente de AP fue mayor (vs 9,80%) as\u00ed como el porcentaje de pacientes que hab\u00edan \nrecibido tratamiento sist\u00e9mico anteriormente (vs 69,10%).  \nEn nuestro estudio risankizumab ha demostrado ser eficaz ya que el porcentaje de pacientes que alcanzan el PASI 75 en \nla semana 16 es elevado. No obstante, en comparaci\u00f3n con ULTIMMA-1, las variables de efectividad fueron inferiores en \nnuestro estudio (vs PASI 75 86,80%, PASI 90 87,80%, sPGA 87,80%) aunque PASI 100 fue superior (vs 35,90%).  \nRisankizumab ha resultado seguro con una baja frecuencia de EA.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n580. EXPERIENCIA DE USO DE CLADRIBINA EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nSOPENA CARRERA, L; GARC\u00c9S REDONDO, M; I\u00d1IGUEZ MART\u00cdNEZ, C; MAGALL\u00d3N MART\u00cdNEZ, A; PARDO JARIO, P; \nAPESTEGUIA EL BUSTO, A; BONAGA SERRANO, B; ALLENDE BANDR\u00c9S, MA\nHOSPITAL CL\u00cdNICO UNIVERSITARIO LOZANO BLESA. SAN JUAN BOSCO, 15 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nLa esclerosis m\u00faltiple (EM) es una enfermedad cr\u00f3nica, inflamatoria, desmielinizante y degenerativa que afecta a 2,5 \nmillones de personas en el mundo. El objetivo de este estudio es analizar la eficacia y seguridad de la cladribina y \ncomparar los resultados con el estudio pivotal CLARITY \ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo (Octubre 2017 - Mayo 2022).  \nSe recogieron las siguientes variables: sexo, edad, tiempo desde diagn\u00f3stico de EM hasta inicio de cladribina, puntuaci\u00f3n \nen la Escala Expandida del Estado de Discapacidad (EDSS) al inicio y n\u00famero de brotes el a\u00f1o previo, n\u00famero de pacientes \ntratados con tratamientos modificadores de la enfermedad (TME) anteriormente y l\u00ednea de tratamiento.  \nPara evaluar la eficacia se midi\u00f3 la EDSS a los 24 meses, la tasa anualizada de brotes (TAB) y el n\u00famero de brotes el primer \na\u00f1o de tratamiento (entre tandas), el segundo (al finalizar) y el tercero.  \nLa seguridad se evalu\u00f3 seg\u00fan los efectos adversos (EA) seg\u00fan NCI Common terminology Criteria for Adverse Events 4.0.\nRESULTADOS\nSe recogieron 24 pacientes (14 mujeres), de los cuales 15 completaron los dos ciclos de cladribina. Mediana de edad al \ninicio del tratamiento de 35,50 (23 - 56) a\u00f1os. Mediana de tiempo desde diagn\u00f3stico hasta inicio de cladribina 3,50 (0 - \n22) a\u00f1os, EDSS 1,5 (0 \u2013 6,5) y n\u00famero de brotes a\u00f1o previo a cladribina 2 (0 - 3).  \nEl 75% de los pacientes fue tratado con TME anteriormente y la mediana de l\u00ednea de tratamiento con cladribina fue de 2 \n(1 - 5).  \nMediana de mejor\u00eda en la EDSS de los 15 pacientes que llegaron a completar los dos ciclos de cladribina fue de 0 (-0,5 - \n2): misma puntuaci\u00f3n (8), mejor\u00eda de 1 punto (3), mejor\u00eda de 0,5 puntos (2).  \nLa TAB fue de 0,14. Porcentaje de pacientes libres de brotes a los 24 meses de 86,67%, a los 12 meses (n=18) 88,89% y a \nlos 36 meses (n=7) 71,43%.  \nSe interrumpi\u00f3 cladribina en un paciente tras la primera tanda por aparici\u00f3n de 2 brotes y 3 pacientes a los 3 a\u00f1os \ncambiaron a ocrelizumab por fracaso a cladribina.  \nEA m\u00e1s observado linfopenia (66,67%): Grado 1 (37,5%), Grado 3 (16,67%), Grado 2 (12,5%).\nCONCLUSIONES\nEn comparaci\u00f3n con el estudio CLARITY , nuestro grupo de pacientes se caracteriza por una menor duraci\u00f3n de EM desde \nel diagn\u00f3stico (vs 8,7 a\u00f1os) y una menor puntuaci\u00f3n en la EDSS [vs 3 (0 - 6)]. Sin embargo, es mayor el porcentaje de los \npacientes tratados con TME en nuestro hospital (vs 33%).  \nRespecto a la eficacia, la TAB de nuestro estudio es igual a la del ensayo pivotal y el porcentaje de pacientes libres de \nprogresi\u00f3n a los 24 meses es ligeramente superior (vs 79,70%).  140Se ha podido evaluar la eficacia a los 3 a\u00f1os (al igual que en el estudio pivotal CLARITY-EXT) en 7 pacientes. Sin embargo, \nse necesita mayor tiempo para evaluar la eficacia a largo plazo.  \nLa linfopenia tambi\u00e9n fue el EA m\u00e1s importante en el ensayo CLARITY , pero nuestros pacientes han presentado menor \nporcentaje de linfopenia grado 3 (vs 25%).\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n582. EVALUACI\u00d3N DE LOS RESULTADOS EN SALUD PERCIBIDOS POR EL PACIENTE CON ARTRITIS \nREUMATOIDE ANTES DE INICIAR TERAPIA DIRIGIDA \nAUTORES\nRODR\u00cdGUEZ ESQU\u00cdROZ, A; ARRONDO VELASCO, A; TEJADA MAR\u00cdN, D; DE LA RIVA BOHIGAS, R; CALVO ARBELOA, M; \nGO\u00d1I INDURAIN, N; LAMAS PILLO, A; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nEvaluar los resultados en salud percibidos por el paciente (PROs) en pacientes diagnosticados de artritis reumatoide (AR) \nque van a iniciar tratamiento con una terapia dirigida y relacionarlo con diferentes variables cl\u00ednicas y sociodemogr\u00e1ficas.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo observacional. Se incluyeron pacientes diagnosticados de AR que iban a iniciar un tratamiento \ndirigido, biol\u00f3gico o sint\u00e9tico.  \nSe recogieron variables sociodemogr\u00e1ficas (edad y sexo) y cl\u00ednicas (tratamiento recibido, PROs, si eran na\u00efve/pretratados, \nterapias concomitantes). Los PROs se evaluaron mediante el cuestionario espec\u00edfico de AR Rheumathoid Arthritis Impact \nDisease (RAID), realizado por un farmac\u00e9utico durante la consulta de inicio de tratamiento en el Servicio de Farmacia.  \nSe realiz\u00f3 un an\u00e1lisis descriptivo y se realiz\u00f3 una diferencia de medias de los resultados del cuestionario, tanto de \nla puntuaci\u00f3n final como de los diferentes dominios del cuestionario, seg\u00fan variables demogr\u00e1ficas y cl\u00ednicas de los \npacientes. Se utiliz\u00f3 el programa estad\u00edstico SPSS. Se asumi\u00f3 un nivel de confianza del 95%.\nRESULTADOS\nSe reclutaron 56 pacientes, con una media de edad de 57.8\u00b113.0 a\u00f1os. Cuarenta y cuatro pacientes (78.6%) eran mujeres, \n31 (55.4%) hab\u00edan sido tratados previamente con terapias dirigidas, 28 (50%) tomaban de forma concomitante f\u00e1rmacos \nantirreum\u00e1ticos modificadores de la enfermedad convencionales (FAMEc) y 37 (66.1%) corticoesteroides.  \nSe obtuvo un valor medio final en el cuestionario de 5.79\u00b12.13 puntos. Al observar los diferentes dominios del \ncuestionario se obtuvieron los siguientes valores medios: dolor 6.41\u00b12.33; incapacidad funcional 6.07\u00b12.66; fatiga \n5.93\u00b12.66; sue\u00f1o 5.50\u00b13.29; bienestar f\u00edsico 5.88\u00b12.55; bienestar emocional 5.27\u00b12.84 y afrontamiento 4.84\u00b12.76.  \nAl analizar los resultados seg\u00fan diferentes variables, se observaron diferencias estad\u00edsticamente significativas en la \ncalidad de vida (CV) seg\u00fan el sexo, donde se aprecia una peor CV en mujeres, y en funci\u00f3n de si los pacientes eran na\u00efve \no pretratados para terapias dirigidas, donde se ve una mejor CV en pacientes na\u00efve. Se observ\u00f3 una correlaci\u00f3n negativa \nentre la edad y el dolor (coeficiente correlaci\u00f3n de Pearson -0.278, R2=6%, p-valor 0.038). Tambi\u00e9n se ve una cierta \ntendencia a una correlaci\u00f3n negativa entre la edad y el bienestar f\u00edsico (-0.233, R2=3.7%, p-valor 0.084) y la edad y el \nafrontamiento de la enfermedad (-0.245, R2=4.3%, p-valor 0.069), aunque no fue estad\u00edsticamente significativo. El resto \nde variables analizadas no mostraron diferencias estad\u00edsticamente significativas.\nCONCLUSIONES\n- Al inicio del tratamiento, los pacientes con AR le dan una puntuaci\u00f3n a la percepci\u00f3n del impacto de la enfermedad \nsobre su CV de 5.78 en el cuestionario RAID, clasificado como impacto moderado.  \n- Los dominios del cuestionario m\u00e1s afectados en nuestros pacientes son: dolor > incapacidad funcional > fatiga > \nbienestar f\u00edsico > sue\u00f1o > bienestar emocional > afrontamiento.  \n- Las mujeres perciben una mayor afectaci\u00f3n de su CV que los hombres en la muestra analizada.  \n- Los pacientes que han tenido terapias previas presentan una peor CV. \n- Es necesario analizar una muestra mayor para observar mayores diferencias entre la CV y el resto de variables \nanalizadas.  \n- Es evidente el impacto negativo en la CV de los pacientes con AR, por lo tanto, es importante tenerla en cuenta en la \ntoma de decisiones, al igual que otros par\u00e1metros cl\u00ednicos y anal\u00edticos objetivos.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n585. DARVADSTROCEL EN PACIENTES CON F\u00cdSTULAS EN ENFERMEDAD DE CROHN: RESULTADOS EN \nPR\u00c1CTICA CL\u00cdNICA HABITUAL. \nAUTORES\nBUSTELO PAZ, F; BARCA DIEZ, C; PROUPIN CANTELAR, IC; FRANCO SANDAR, B; GONZALEZ FREIRE, L; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA\nOBJETIVOS\nNuestra \u00e1rea sanitaria es referencia como servicio de salud para la administraci\u00f3n de Darvadstrocel, presentando \nacreditaci\u00f3n por el grupo espa\u00f1ol de rehabilitaci\u00f3n multimodal(GERM).  \nLa financiaci\u00f3n de Darvadstrocel se lleva acabo mediante acuerdo por pago por resultados a trav\u00e9s de Valtermed. En caso \nde falta de efectividad en el sexto mes de tratamiento solo se abonar\u00e1 al laboratorio un 40% del precio total.  141El objetivo de este estudio es evaluar la efectividad tras 6, 12 y 24 meses del inicio de tratamiento, valorar las reacciones \nadversas y analizar el coste mediante pago por resultados/riesgo compartido.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo descriptivo que incluy\u00f3 6 pacientes tratados con Darvadstrocel desde el a\u00f1o 2019 en el \u00e1rea \nsanitaria. Para la recogida de datos se revis\u00f3 la historia cl\u00ednica electr\u00f3nica. \n \nLas variables cuantitativas se expresaron como mediana y percentil 25 y 75 mientras que las variables cualitativas se \nexpresaron como porcentajes. \n \nLa efectividad se evalu\u00f3 mediante la remisi\u00f3n combinada, definida como el cierre cl\u00ednico de todas las f\u00edstulas tratadas y la \nausencia de abscesos mayores de 2 cm confirmada mediante resonancia magn\u00e9tica(RM). El cierre de alguna f\u00edstula y no \nde su totalidad se registr\u00f3 como respuesta parcial\ufffd  \n \nLa seguridad se analiz\u00f3 mediante el registro de efectos adversos definidos como m\u00e1s comunes seg\u00fan ficha t\u00e9cnica: riesgo \nde infecciones (especialmente absceso anal) y proctalgia.\nRESULTADOS\nDe los 6 pacientes seleccionados se descart\u00f3 1 por no disponer de datos de seguimiento dada la reciente administraci\u00f3n \ndel medicamento. La mediana de edad de los 5 pacientes restantes fue de 32,5 a\u00f1os (28,5-48,5) y 50% eran mujeres. Un \n25% de los pacientes fue tratado secuencialmente con tres tratamientos biol\u00f3gicos previos a darvadstrocel (infliximab, \nadalimumab y ustekinumab), un 50% con dos tratamientos (infliximab y adalimumab) y el 25% restante con uno \n(infliximab).  \n \nA los 6 meses tras el inicio de tratamiento se alcanz\u00f3 respuesta completa en 3 pacientes (60%) mientras que en 2 \npacientes (40%) se obtuvo respuesta parcial.  \n \nEl 100% de pacientes con respuesta completa mantuvieron \u00e9sta en el mes 12. En el mes 24 solo se dispone de datos de \nun paciente, que mantuvo la respuesta. \n \nDe los dos pacientes con respuesta parcial uno de ellos precis\u00f3 retratamiento 12 meses despu\u00e9s, que tras 6 meses de \nevoluci\u00f3n se obtuvo respuesta completa\ufffd \n \nNo se detectaron efectos adversos relevantes en ning\u00fan paciente durante todo el per\u00edodo de estudio.  \n \nEl coste del Darvadstrocel fue del 100% del coste total del tratamiento en los pacientes que obtuvieron respuesta \ncompleta (3) y del 40% en el caso de los pacientes con respuesta parcial (2).\nCONCLUSIONES\nEl tratamiento se mostr\u00f3 efectivo, destacando el mantenimiento de la respuesta a largo plazo en pacientes que \nobtuvieron respuesta completa tras 6 meses\ufffd \n \nDarvadstrocel no comprometi\u00f3 la seguridad de los pacientes, dada la ausencia de reacciones adversas relevantes \ndestacables\ufffd  \n \nEl coste del medicamento fue del 76% del total de los tratamientos implantados en el \u00e1rea sanitaria, mostrando el \nbeneficio de la financiaci\u00f3n por pago por resultados.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n593. EXPERIENCIA CL\u00cdNICA DEL CAMBIO A ADALIMUMAB BIOSIMILAR EN ENFERMEDAD INFLAMATORIA \nINTESTINAL \nAUTORES\nFERN\u00c1NDEZ MART\u00cdNEZ, V; RAMIS BARCEL\u00d3, MB; ILLARO URANGA, A; G\u00d3MEZ G\u00d3MEZ, D; S\u00c1NCHEZ GUNDIN, J; \nP\u00c9REZ-PERI\u00c1\u00d1EZ ORRILLO, L; REY MONTALB\u00c1N, RL; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nEvaluar el cambio terap\u00e9utico de adalimumab original a adalimumab biosimilar en pacientes con Enfermedad \nInflamatoria Intestinal.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo que incluy\u00f3 a todos los pacientes con Enfermedad de Crohn (EC) o \ncolitis ulcerosa (CU) en tratamiento de mantenimiento con adalimumab original, cuya prescripci\u00f3n se modific\u00f3 al f\u00e1rmaco \nbiosimilar sin alterar la posolog\u00eda. El per\u00edodo de estudio comprendi\u00f3 los 6 meses anteriores y posteriores al cambio. \nLos datos se extrajeron del programa de prescripci\u00f3n electr\u00f3nica asistida y de la historia cl\u00ednica e incluyeron edad, sexo, \npatolog\u00eda, posolog\u00eda, evoluci\u00f3n cl\u00ednica, satisfacci\u00f3n del paciente con el cambio y motivo de suspensi\u00f3n del tratamiento.  \nPara la valoraci\u00f3n de la evoluci\u00f3n cl\u00ednica se tuvieron en cuenta la situaci\u00f3n cl\u00ednica reflejada por el m\u00e9dico (clasificada 142en mejor, mantenida o peor) y los valores anal\u00edticos de prote\u00edna C reactiva (PCR) (mg/dl) anteriores y posteriores al \ncambio. Se compar\u00f3 el valor anal\u00edtico de PCR al cambio con el obtenido tras 3 y 6 meses de tratamiento con biosimilar. Se \nexcluyeron los pacientes con intensificaciones de dosis durante los 12 meses del estudio. El an\u00e1lisis estad\u00edstico se realiz\u00f3 \nmediante la prueba t de Student de comparaci\u00f3n indirecta de medias para muestras emparejadas, estableci\u00e9ndose el \nl\u00edmite de significaci\u00f3n estad\u00edstica en p < 0,05.\nRESULTADOS\nSe incluyeron 79 pacientes (41 mujeres) cuya edad media fue de 47\u00b114 a\u00f1os. De ellos, 67 con diagn\u00f3stico de EC y 12 de CU.  \nA los 3 meses de tratamiento con adalimumab biosimilar (N=49), el valor medio de PCR vari\u00f3 de 0,4 [\u00b1 0,53 (mg/dl)] \na 0,46 [\u00b1 1,04 (mg/dl)] (p= 0,7198). Tampoco se encontraron diferencias estad\u00edsticamente significativas a los 6 meses \n(N=29), cuando el valor medio de PCR aument\u00f3 de 0,45 [\u00b1 0,66 (mg/dl)] a 0,49 [\u00b1 0,54 (mg/dl)] (p= 0,1406).  \nDurante el per\u00edodo de estudio, la situaci\u00f3n cl\u00ednica de 60 pacientes se mantuvo, 8 experimentaron mejor\u00eda cl\u00ednica y 11 \nempeoraron. En 12 de ellos se suspendi\u00f3 el f\u00e1rmaco biosimilar: 3 por resoluci\u00f3n de la enfermedad (situaci\u00f3n cl\u00ednica \nmantenida respecto al original), 1 por intolerancia y 8 por fracaso terap\u00e9utico (5 empeoraron y 3 ya fracasaron con el \noriginal).  \nCon adalimumab biosimilar, un total de 19 pacientes experimentaron molestias en el lugar de inyecci\u00f3n y 2 pacientes \nmanifestaron dificultades para la administraci\u00f3n.\nCONCLUSIONES\nAdalimumab biosimilar ha demostrado mantener los mismos valores de efectividad que la mol\u00e9cula original en pacientes \ncon Enfermedad Inflamatoria Intestinal, lo que sugiere una equivalencia terap\u00e9utica entre ambos. Por otro lado, la \nincidencia de reacciones adversas en el lugar de inyecci\u00f3n con el biosimilar puede comprometer la satisfacci\u00f3n de los \npacientes y debe ser un factor para tener en cuenta a la hora de seleccionar el f\u00e1rmaco.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n606. INFLIXIMAB EN EL TRATAMIENTO DE PRIMERA L\u00cdNEA DE F\u00c1RMACOS BIOL\u00d3GICOS EN ENFERMEDAD \nDE CROHN MODERADA O SEVERA \nAUTORES\nMART\u00cdN L\u00d3PEZ, M; MART\u00cdNEZ DE ARRIBA, R; DE LA MAZA URIARTE, I\nHOSPITAL SANTIAGO APOSTOL \ufffd CTRA \ufffd DE ORON, S/N MIRANDA DE EBRO \ufffd BURGOS\nOBJETIVOS\nAnalizar la persistencia de infliximab como f\u00e1rmaco biol\u00f3gico de primera l\u00ednea en pacientes con enfermedad de Crohn y \nlos motivos de suspensi\u00f3n del tratamiento.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo en un hospital comarcal. Se recogieron los siguientes datos de la historia cl\u00ednica \ny del m\u00f3dulo de dispensaci\u00f3n a pacientes ambulantes: sexo, edad, intervenciones quir\u00fargicas previas o posteriores al \ntratamiento con infliximab en primera l\u00ednea de f\u00e1rmacos biol\u00f3gicos, localizaci\u00f3n y tipo de lesiones seg\u00fan la clasificaci\u00f3n \nde Montreal, fecha de inicio y fecha de fin de tratamiento con infliximab y motivo de suspensi\u00f3n del f\u00e1rmaco.  \nSe incluyeron los pacientes que hab\u00edan recibido tratamiento con infliximab entre febrero de 2007 y abril de 2022. \nPara el an\u00e1lisis estad\u00edstico se utiliz\u00f3 Stata v.15.\nRESULTADOS\nEn el periodo de estudio, 53 pacientes recibieron infliximab: 34 (64%) hombres, mediana de edad 39 a\u00f1os (28-51).  \n9 pacientes (17%) requirieron intervenci\u00f3n quir\u00fargica antes de comenzar tratamiento con infliximab. En ellos, se mantuvo \nla respuesta durante una media de 33 meses desde el inicio del tratamiento\ufffd  \n26 pacientes (49%) ten\u00edan afectaci\u00f3n ileal, 6 col\u00f3nica (11%), 17 ileocol\u00f3nica (32%), 1 afectaci\u00f3n a nivel del tracto \ngastrointestinal superior (2%) y 3 perianal (6%). 22 pacientes presentaban enfermedad estenosante (42%), 16 penetrante \n(30%) y 15 de tipo inflamatorio (28%).  \n17 pacientes se encuentran actualmente en tratamiento, tras 31 meses de mediana (21-52). \nEn 32 pacientes se suspendi\u00f3 infliximab tras una mediana de 25 meses (15-53) de tratamiento. Los motivos de \nfinalizaci\u00f3n fueron: mal control de la enfermedad a pesar de niveles normales de f\u00e1rmaco (11%, n=6), presencia de \nanticuerpos antif\u00e1rmaco a pesar de intensificaci\u00f3n de la pauta (13%, n=7), empeoramiento de la cl\u00ednica o aumento de \nla calprotectina (26%, n=14), abandono voluntario de seguimiento por parte del paciente (6%, n=3) y reacci\u00f3n al\u00e9rgica \nrelacionada con la administraci\u00f3n (3%, n=2).  \n4 pacientes (8%) han suspendido infliximab por remisi\u00f3n de la enfermedad, tras una media de 58 meses (27-92) de \ntratamiento y mantienen la respuesta tras una media de 29 meses (7-55). En 3 de ellos se mantiene tratamiento en \nmonoterapia con azatioprina.\nCONCLUSIONES\nNuestro estudio muestra que infliximab es efectivo en el control de la enfermedad de Crohn moderada a severa en \npacientes que han sido refractarios al tratamiento con inmunosupresores convencionales.  \nEn los pacientes que hab\u00edan sido sometidos a resecci\u00f3n ileocol\u00f3nica, el tratamiento con infliximab tambi\u00e9n mantuvo la \nrespuesta tras la intervenci\u00f3n\ufffd  \nPor otra parte, la persistencia de la remisi\u00f3n de la enfermedad una vez suspendido infliximab es una posible l\u00ednea de \nestudio para la optimizaci\u00f3n en el tratamiento de estos pacientes. El hecho de suspender infliximab una vez alcanzada y 143mantenida la remisi\u00f3n de la enfermedad puede ser interesante para evitar problemas de inmunogenicidad al f\u00e1rmaco y \npoder recurrir a esta misma l\u00ednea de tratamiento en caso de reactivaci\u00f3n de la enfermedad. Esto es un punto de inter\u00e9s \ndebido a la escasez de f\u00e1rmacos disponibles para esta patolog\u00eda.  \nLas limitaciones de nuestro estudio son el peque\u00f1o tama\u00f1o muestral y el hecho de no disponer de las serolog\u00edas \nantif\u00e1rmaco en todos los pacientes.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n607. APORTACI\u00d3N FARMAC\u00c9UTICA EN LA PREVENCI\u00d3N DE INTERACCIONES ENTRE CARBIDOPA-\nLEVODOPA Y ALIMENTOS \nAUTORES\nFERN\u00c1NDEZ MART\u00cdNEZ, V; RAMIS BARCEL\u00d3, MB; VILLACA\u00d1AS PALOMARES, MV; SANGRADOR RASERO, AM; \nFERN\u00c1NDEZ MART\u00cdNEZ, C; P\u00c9REZ-PERI\u00c1\u00d1EZ ORRILLO, L; ARAG\u00d3N GRACIA, I; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nLa levodopa se absorbe principalmente en el intestino delgado a trav\u00e9s de un mecanismo de transporte por el que \ncompite con los amino\u00e1cidos de la dieta, pudiendo reducirse su efecto terap\u00e9utico. La ficha t\u00e9cnica recomienda su \nadministraci\u00f3n en ayunas o con dieta pobre en prote\u00ednas.  \nEl objetivo de este estudio es analizar el impacto de las intervenciones farmac\u00e9uticas en el n\u00famero interacciones \npotenciales entre carbidopa-levodopa y las prote\u00ednas de la dieta.\nMATERIALES Y M\u00c9TODOS\nEstudio de intervenci\u00f3n, prospectivo, desarrollado durante los meses de febrero y marzo de 2022 en el que se analiz\u00f3 \nla prescripci\u00f3n de los pacientes en tratamiento con carbidopa-levodopa oral y se realiz\u00f3 una intervenci\u00f3n farmac\u00e9utica \nrecomendando su administraci\u00f3n en ayunas\ufffd  \nSe incluyeron todos los pacientes ingresados con enfermedad de Parkinson tratados con carbidopa-levodopa durante los \nmeses de estudio\ufffd  \nSe extrajeron del programa de prescripci\u00f3n electr\u00f3nica asistida los siguientes datos: sexo, edad y prescripci\u00f3n m\u00e9dica. \nLos pacientes ingresados durante el mes febrero formaron parte del grupo control (no intervenci\u00f3n), en cambio, se emiti\u00f3 \nla siguiente recomendaci\u00f3n farmac\u00e9utica para los pacientes ingresados durante el mes de marzo (grupo de intervenci\u00f3n): \n\u201cLa administraci\u00f3n en ayunas puede potenciar el efecto terap\u00e9utico de levodopa, valore prescripci\u00f3n antes de las \ncomidas\u201d \ufffd  \nDicha recomendaci\u00f3n se realiz\u00f3 a trav\u00e9s de un mensaje al m\u00e9dico prescriptor. Se verific\u00f3 la aceptaci\u00f3n de la misma y la \ncorrespondiente modificaci\u00f3n de la prescripci\u00f3n m\u00e9dica durante el ingreso y al alta hospitalaria, compar\u00e1ndola con las \ndel grupo control\ufffd\nRESULTADOS\nEl grupo control se compuso de 68 pacientes (40 mujeres), con una mediana de edad de 80 (59-96) a\u00f1os. En el grupo de \nintervenci\u00f3n se incluyeron 51 pacientes (27 hombres) en tratamiento con carbidopa-levodopa. La mediana de edad fue \nde 78 (57-92) a\u00f1os.  \nEn el momento del ingreso, el 1,5% y el 2% de cada grupo ten\u00eda prescrito carbidopa-levodopa en ayunas \nrespectivamente.\u00ac\u00ac\u00ac \nTras la recomendaci\u00f3n, al 31 % de los pacientes intervenidos se les cambi\u00f3 la prescripci\u00f3n, de los cuales un 81 % fueron \ndados de alta con la modificaci\u00f3n para administrar carbidopa-levodopa antes de las comidas.\nCONCLUSIONES\nLa realizaci\u00f3n de esta recomendaci\u00f3n farmac\u00e9utica reduce el n\u00famero de interacciones potenciales entre carbidopa-\nlevodopa y los alimentos de la dieta, aunque existe un amplio margen de mejora que requiere la revisi\u00f3n del circuito de \ncontacto con el m\u00e9dico especialista. En este sentido, la estancia hospitalaria puede suponer un punto de inflexi\u00f3n en la \noptimizaci\u00f3n de este tratamiento cr\u00f3nico.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n654. SIPONIMOD EN EMSP: EFECTIVIDAD Y SEGURIDAD EN UN HOSPITAL DE TERCER NIVEL. \nAUTORES\nORTOLL POLO, V; ARN\u00c1IZ D\u00cdEZ, S; REVILLA CUESTA, N; DE FRUTOS DEL POZO, M; VICENTE GONZ\u00c1LEZ, B; S\u00c1NCHEZ \nLUQUE, L; INFANTE CAMARERO, A; CASTA\u00d1O RODR\u00cdGUEZ, B\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS\nOBJETIVOS\nDescribir la efectividad y seguridad de siponimod en pacientes con Esclerosis M\u00faltiple Secundaria Progresiva (EMSP) en \nbase a los criterios de financiaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital de 3er nivel. Se seleccionaron todos los pacientes que iniciaron \ntratamiento con siponimod, de acuerdo a los criterios de financiaci\u00f3n, desde julio de 2021 hasta febrero de 2022. \nConsultando historia cl\u00ednica y programa de gesti\u00f3n de pacientes externos se registraron: datos demogr\u00e1ficos, fecha de 144diagn\u00f3stico de Esclerosis M\u00faltiple Remitente Recidivante (EMRR), fecha de progresi\u00f3n a EMSP , l\u00edneas de tratamiento \nprevias, EDSS al inicio de tratamiento con siponimod, EDSS a los tres meses del inicio y efectos adversos\ufffd\nRESULTADOS\nSe incluyeron 16 pacientes (87,5% mujeres) con una edad mediana de edad de 51 a\u00f1os (32-66). La mediana del tiempo \ndesde el diagn\u00f3stico de EMRR hasta progresi\u00f3n a ESMP fue de 12 a\u00f1os (1-18). El n\u00famero medio de l\u00edneas previas \nfue de 1,8 (DS 0,66). La puntuaci\u00f3n media de EDSS al inicio de tratamiento fue de 5,1 (DS 1,13). Todos los pacientes \nmantuvieron el mismo EDSS a los tres meses del inicio. Se describieron los siguientes efectos adversos: Linfopenia ( < \n1000 c\u00e9lulas/103\u00b5L) en 14 pacientes (87,5 %) de los cuales en uno se redujo la dosis por presentar < 200 c\u00e9lulas/103\u00b5L, \nalteraciones hep\u00e1ticas en 4 pacientes (25%), cefalea en 2 pacientes (11,8%), mareo en 1 paciente (6,2%) y edema macular \nen otro (6,2%).\nCONCLUSIONES\nEl tratamiento con siponimod fue efectivo en el retraso de la progresi\u00f3n de discapacidad, si bien el estudio podr\u00eda \ncompletarse con m\u00e1s datos a largo plazo para verificar el mantenimiento de la efectividad.  \nLa incidencia de linfopenia, alteraciones hep\u00e1ticas y edema macular fue muy superior a la observada en los ensayos \npivotales. El perfil de efectos adversos del tratamiento sugiere la necesidad de un estrecho seguimiento de los pacientes.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n684. REINICIO DE TERAPIA BIOL\u00d3GICA EN PROFILAXIS DE MIGRA\u00d1A TRAS UN A\u00d1O DE TRATAMIENTO \nAUTORES\nGONZ\u00c1LEZ ESCRIBANO, C; NOTARIO DONGIL, C; P\u00c9REZ F\u00c1CILA, A; SAIZ MOLINA, JJ; PROY VEGA, B; MARCOS DE LA \nTORRE, A\nHOSPITAL GENERAL LA MANCHA CENTRO. AVENIDA DE LA CONSTITUCI\u00d3N, 3 ALC\u00c1ZAR DE SAN JUAN. CIUDAD REAL\nOBJETIVOS\nLos anticuerpos monoclonales (ACM) contra el p\u00e9ptido relacionado con el gen de la calcitonina (CGRP) han demostrado \nser eficaces y seguros en profilaxis de migra\u00f1a. En pacientes respondedores, la duraci\u00f3n de tratamiento no se extiende \nm\u00e1s all\u00e1 de un a\u00f1o por falta de evidencia de uso a largo plazo. Sin embargo, algunos sujetos se ven obligados a reiniciar \ntratamiento debido a p\u00e9rdida de respuesta. El objetivo del estudio fue analizar aquellos pacientes que hab\u00edan reiniciado \ntratamiento con ACM contra el CGRP para la profilaxis de migra\u00f1a.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, de 26 meses de duraci\u00f3n (5 marzo 2020 - 5 mayo 2022) en un hospital de tercer \nnivel. Se incluyeron todos aquellos pacientes diagnosticados de migra\u00f1a cr\u00f3nica (MC) o epis\u00f3dica (ME) que hab\u00edan \niniciado tratamiento con erenumab o galcanezumab y que tras un a\u00f1o hab\u00edan finalizado el mismo por descanso \nterap\u00e9utico.  \nAquellos pacientes con una reducci\u00f3n > 50% en los d\u00edas mensuales de migra\u00f1a (DMM) eran considerados muy \nrespondedores. La no respuesta al tratamiento y la respuesta parcial se defini\u00f3 como pacientes con una reducci\u00f3n < 30% \ny de 30-50% en los DMM, respectivamente.  \nVariables: sexo, edad, tipo de migra\u00f1a, duraci\u00f3n de tratamiento y reinicio, tasa de respuesta antes y despu\u00e9s del descanso \nterap\u00e9utico.  \nLos datos fueron recolectados a trav\u00e9s del m\u00f3dulo de pacientes externos del programa inform\u00e1tico Farmatools\u00ae y la \nhistoria cl\u00ednica informatizada, Mambrino XXI\u00ae.\nRESULTADOS\nSe incluyeron 31 pacientes (90% mujeres, 10% hombres) con una mediana de edad de 50 a\u00f1os (34-72). De ellos, el 52% \npresentaba MC y el 48% ME. El 39% y 61% de pacientes recibieron erenumab y galcanezumab respectivamente. \nDe los pacientes que completaron el a\u00f1o de tratamiento, un 52% reinici\u00f3 por empeoramiento de la migra\u00f1a. Todos los \npacientes coincid\u00edan en que tras un mes de la suspensi\u00f3n del ACM, la frecuencia e intensidad de las crisis eran mayores. 2 \npacientes tuvieron que acudir a urgencias tras sufrir una crisis severa. \nLa mediana de tiempo que transcurri\u00f3 hasta el reinicio del tratamiento fue de 4 (1-6) y 3(1-9) meses para erenumab y \ngalcanezumab, respectivamente. El 44% de pacientes reiniciaron erenumab (80% MC, 20% ME) y el 56% galcanezumab \n(44% MC, 56% ME). Previo al reinicio del tratamiento tras completar el a\u00f1o, el 79% presentaron muy buena respuesta \nal tratamiento (27% erenumab, 73% galcanezumab) y el 21% respondieron parcialmente (67% erenumab, 33% \ngalcanezumab). Tras el reinicio, el 38% de pacientes (34% erenumab, 66% galcanezumab) que tuvieron revisi\u00f3n \npresentaron buena respuesta al tratamiento. El 62% est\u00e1n pendientes de la revaluaci\u00f3n.\nCONCLUSIONES\nEn base a los resultados de nuestro estudio, se observ\u00f3 que el 52% de los pacientes analizados sufrieron reca\u00edda cl\u00ednica \ny fue necesario reiniciar el tratamiento. Asimismo, estos pacientes presentaron de nuevo una respuesta terap\u00e9utica \nadecuada, consiguiendo una reducci\u00f3n precoz en el n\u00famero de d\u00edas de cefaleas y migra\u00f1as al mes. Se desconoce el \nmantenimiento de la respuesta tras la suspensi\u00f3n del tratamiento, por ello es fundamental el an\u00e1lisis de los resultados en \nestos pacientes que contribuya a generar nuevas evidencias.145CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n689. ATENCI\u00d3N FARMAC\u00c9UTICA BASADA EN RESULTADOS Y EXPERIENCIAS COMUNICADAS POR LOS \nPACIENTES DE ESCLEROSIS M\u00daLTIPLE EN EL ENTORNO MULTIDISCIPLINAR \nAUTORES\nD\u00cdAZ RUIZ, P; HERN\u00c1NDEZ P\u00c9REZ, MA; VILLAR VAN DEN WEYGERT , C; SOL\u00c9 VIOLAN, C; SU\u00c1REZ GONZ\u00c1LEZ, M; \nGONZ\u00c1LEZ CH\u00c1VEZ, J; MERINO ALONSO, J\nCOMPLEJO HOSPITAL UNIVERSITARIO NTRA SRA DE CANDELARIA. CTRA. DEL ROSARIO, 145 SANTA CRUZ DE \nTENERIFE \ufffd SANTA CRUZ DE TENERIFE\nOBJETIVOS\nExponer los resultados obtenidos del seguimiento de pacientes con esclerosis m\u00faltiple (EM) en la consulta de atenci\u00f3n \nfarmac\u00e9utica (AF) en coordinaci\u00f3n con el equipo asistencial multidisciplinar a trav\u00e9s una plataforma digital en la que \ncomunican sus experiencias (PREMS, patient reported experience) y resultados (PROMs, patient reported outcomes) en \ndiferentes aspectos relacionados con su patolog\u00eda.\nMATERIALES Y M\u00c9TODOS\nSe seleccionaron pacientes de EM en tratamiento con f\u00e1rmacos modificadores de la enfermedad (FME) para hacer \nseguimiento telem\u00e1tico de su proceso farmacoterap\u00e9utico a trav\u00e9s de la consulta de atenci\u00f3n farmac\u00e9utica telem\u00e1tica en \ncoordinaci\u00f3n con el resto del equipo asistencial.  \n \nEste seguimiento se hace mediante cuestionarios digitades admisnitrados on-line a trav\u00e9s de la plataforma de PROMS y \nPREMS: MIRIEM\u00ae\ufffd  \nLa frecuencia de cumplimentaci\u00f3n de los mismos es semestral o anual en funci\u00f3n de la estabilidad cl\u00ednica del paciente.  \n \nLos cuestionarios administrados fueron los siguientes:  \n- MusiQuol: The Multiple Sclerosis International Quality Of Life questionnaire \n- EuroQuol -5D: European Quality of Life-5 Dimensions  \n- MFIS: Modified Fatigue Impact Scale \n- TSQM: Treatment Satisfaction Questionnaire for Medication (version 1.4)  \n- SMAQ: Simplified Medication Adherence Questionnaire \n- HRPM: Health Related Productivity Questionnaire  \n \nLos resultados de los mismos son incluidos en la historia cl\u00ednica del paciente por parte de la farmac\u00e9utica del equipo \nmultidisciplinar y los cambios relevantes detectados son comunicados al equipo asistencial para intervenir al respecto.\nRESULTADOS\nN=76 pacientes son seguidos en la consulta de AF utilizando la medida de PROMs Y PREMs a trav\u00e9s de MIRIEM\u00ae. La edad \nmedia de los pacientes fue de 42 a\u00f1os (Rango:25-57). Con una mediana de 9,7 a\u00f1os desde el diagn\u00f3stico (Rango:1-21). \nEl promedio de seguimiento en MIRIEM\u00ae es de 13 meses (Rango:24-1). Los resultados globales de estos cuestionarios \nfueron:  \n \n- MusiQuol: 69,56/100 \n- EuroQuol-5D: 63,5/100 \n- MFIS: 36,36/84  \n- TSQM: 78,57/100  \n- SMAQ: 81% con 100% de adherencia \n- HRPM: 38,7 % en desempleo, 62,8 % impide trabajar con normalidad  \n \nA trav\u00e9s de este seguimiento se han detectado N=6 pacientes en los que hab\u00eda disminuido la satisfacci\u00f3n con la \nmedicaci\u00f3n a trav\u00e9s de TSQM 1.4 de forma dr\u00e1stica en el \u00faltimo a\u00f1o ( > 10 puntos):  \n- En 4 pacientes debido a efectos adversos se cambi\u00f3 a otro FME de la misma l\u00ednea terap\u00e9utica \n- 1 de ellos la causa era p\u00e9rdida de eficacia y cambi\u00f3 a otro FME de mayor eficacia \n- En 1 paciente la intervenci\u00f3n no deriv\u00f3 en cambio terap\u00e9utico pero s\u00ed en mayor seguimiento terap\u00e9utico.  \nSe detectaron n=3 pacientes que disminuyeron su productividad por desempleo y se incluyeron en el programa de env\u00edo \na domicilio de FME\ufffd  \nEn cuanto a la adherencia se observ\u00f3 disminuci\u00f3n en n=5 pacientes, en los que se ha intervenido intensificando el \nseguimiento terap\u00e9utico.\nCONCLUSIONES\nEn general nuestros pacientes con EM presentan valores de calidad de vida y de productividad bajos para su edad, \nmostrando adherencia y satisfacci\u00f3n con la medicaci\u00f3n aceptables.  \nLa AF en EM mediante la monitorizaci\u00f3n de PROMS Y PREMS on-line permite seguir a un gran n\u00famero de pacientes y \ndetectar cu\u00e1les precisan mayor seguimiento por aspectos cl\u00ednicos, personales y sociosanitarios, todo ello debe estar \nrespaldado por el equipo multidisciplinar para poder intervenir al respecto.146CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n690. EVALUACI\u00d3N DE LA PERSISTENCIA AL TRATAMIENTO MODIFICADOR DE LA ENFERMEDAD EN \nPACIENTES CON ESCLEROSIS M\u00daLTIPLE \nAUTORES\nMART\u00cdN BARBERO, ML; NARRILLOS MORAZA, \u00c1; G\u00d3MEZ COSTAS, D; GARC\u00cdA DOM\u00cdNGUEZ, JM; MART\u00cdNEZ GIN\u00c9S, \nML; PABLO CUELLO, J; GOICOCHEA BRICE\u00d1O, H; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nAnte la dificultad de medir los resultados en salud de los tratamientos modificadores de la enfermedad (TME), la \npersistencia a los TME podr\u00eda constituir una buena medida indirecta. Nuestro objetivo es analizar la persistencia y \nmotivos de discontinuaci\u00f3n en pacientes con esclerosis m\u00faltiple remitente recurrente (EMRR).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo en pacientes con EMRR que iniciaron TME con interfer\u00f3n-\u03b2 (INF-\u03b2), acetato \nglatir\u00e1mero (AG), teriflunomida (TRF), dimetilfumarato (DMF), fingolimod (FTY), natalizumab (NTZ) y alemtuzumab (ALZ) \ndesde Enero de 2016 a Diciembre de 2020 en nuestro centro\ufffd  \nLa persistencia a TME se defini\u00f3 como el tiempo transcurrido desde el inicio hasta la discontinuaci\u00f3n del TME, estimada \nmediante el an\u00e1lisis de supervivencia de Kaplan-Meier.  \nLas variables analizadas fueron: demogr\u00e1ficas (sexo, edad), Escala Expandida del Estado de Discapacidad (EDSS) en el \ninicio, experiencia previa con TME, persistencia global y por TME, porcentaje de pacientes que contin\u00faan TME y causas de \ndiscontinuaci\u00f3n. Los datos se obtuvieron de la Historia Cl\u00ednica Electr\u00f3nica.  \nLa muestra fue dividida entre pacientes na\u00efve (PN) y pacientes que ven\u00edan de TME previo (PPrev).\nRESULTADOS\nSe incluyeron 492 pacientes con EMRR. El 69% eran mujeres y la edad media 40,4 a\u00f1os ( \u00b110,1). El tiempo medio de \nseguimiento fue 21,9 meses. 250 pacientes eran na\u00efve (50,8%).  \nEn PN, la EDSS media era significativamente menor que en los PPrev (1,2 \u00b11,2 vs 2,1 \u00b11,75). En PN el f\u00e1rmaco m\u00e1s \nprescrito fue INF-\u03b2 (85 pacientes) seguido de AG. En PPrev el m\u00e1s frecuente fue TRF (84 pacientes) seguido de DMF.  \nLa persistencia media de toda la muestra fue 21,9( \u00b113,7) meses. En PN la persistencia media fue de 20,7(\u00b113,5), siendo \nmayor para DMF (36,2 [30,3-42,1]) meses y AG (34,8[29,5-40,2]) meses, aunque sin diferencias significativas. \nEn PPrev la persistencia media fue de 23,1(\u00b113,9), siendo significativamente mayor para ALZ (47,9[44,1-51,7]). No se \nvieron diferencias significativas entre la persistencia de PN que iniciaron terapias de segunda l\u00ednea vs primera l\u00ednea (orales \no inyectables).  \nAl final del per\u00edodo de estudio, 166 (33,7%) de los pacientes suspendieron tratamiento, tras un tiempo medio de \nseguimento de 16,3 meses\ufffd  \nEn PN, suspendieron un 36% de los pacientes, por Eventos Adversos (EA) (17,6%) y por ineficacia (14,8%).  \nEn PPrev suspendieron un 31,5% de los pacientes, 13,7% por EA y 12% por ineficacia.  \nLa persistencia fue significativamente mayor en los que interrumpen por ineficacia que en los que interrrumpen por EA, \nen PN (20,5 \u00b110) vs (11,6 \u00b110,5), y en PPrev (21,1 \u00b19,9) vs (10,6 \u00b19,7).\nCONCLUSIONES\nEn nuestra muestra, la persistencia a tratamiento fue elevada\ufffd En PN, se observ\u00f3 una tendencia a una mayor persistencia \ncon DMF y AG. En PPrev, alemtuzumab mostr\u00f3 una mayor persistencia, seguido de DMF. No hubo diferencias entre \nsuspensi\u00f3n por EA o ineficacia aunque la persistencia fue mayor en caso de suspensi\u00f3n por ineficacia.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n698. EFECTO DE LOS INHIBIDORES DE JANUS KINASA SOBRE EL NIVEL DE GLICEMIA EN PACIENTES \nDIAB\u00c9TICOS CON ENFERMEDADES REUM\u00c1TICAS INMUNOMEDIADAS. \nAUTORES\nMART\u00cdNEZ MOLINA, C; ORTIZ DE JUANA, M\u00c0; VALLEZ VALERO, L; GAS\u00d3 GAGO, \u00cd; GARRIDO ALEJOS, G; MANGUES \nBAFALLUY , MA; COROMINAS MACIAS, H; VIDAL ALCORISA, S\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nExiste evidencia sobre el v\u00ednculo de la desregulaci\u00f3n de la v\u00eda de se\u00f1alizaci\u00f3n JAK-STAT y la disfunci\u00f3n de las c\u00e9lulas beta \npancre\u00e1ticas, tanto en diabetes mellitus tipo 1 (DM1) como tipo 2 (DM2). Casos de hipoglucemia han sido reportados en \nla literatura tras iniciar tratamiento con inhibidor de Janus kinasa (iJAK). El presente estudio pretende evaluar y describir \nel efecto de los iJAK de primera generaci\u00f3n, tofacitinib y baricitinib, sobre el nivel de glicemia en pacientes diab\u00e9ticos con \nenfermedades reum\u00e1ticas inmunomediadas.\nMATERIALES Y M\u00c9TODOS\nEn equipo multidisciplinar, m\u00e9dicos reumat\u00f3logos y farmac\u00e9uticos de un hospital terciario junto con miembros de un \ninstituto de investigaci\u00f3n, desarrollaron el presente estudio. El estudio, observacional retrospectivo (Septiembre/2017-\nMayo/2022), incluy\u00f3 todos los pacientes reumatol\u00f3gicos con comorbilidad diab\u00e9tica (DM1 o DM2) tratados con \ntofacitinib o baricitinib. Datos demogr\u00e1ficos, cl\u00ednicos y farmacol\u00f3gicos se recogieron de la historia cl\u00ednica electr\u00f3nica y \nfueron transcritos a una hoja de c\u00e1lculo Excel\u00ae. De cada paciente se registraron valores de glucosa y de hemoglobina 147glicosilada (HbA1c) previamente al inicio de tratamiento con iJAK (tiempo 0) y a los meses 6 (tiempo 6) y 12 (tiempo 12) \nde tratamiento. Las medias de dichos valores fueron comparadas mediante t-Student para muestras emparejadas con el \nprograma estad\u00edstico GraphPad\u00ae.\nRESULTADOS\nDe un total de 169 pacientes reumatol\u00f3gicos en tratamiento con iJAK, se seleccionaron 17(10%) por presentar \ncomorbilidad diab\u00e9tica: 8(47%) pacientes con tofacitinib; 9(53%) pacientes con baricitinib.  \nEl grupo tofacitinib (TOFA), lo constituyen 7(88%) pacientes con artritis reumatoide y 1(12%) paciente con artritis \npsori\u00e1sica; siendo 4(50%) los pacientes en tratamiento concomitante con glucocorticoides. En TOFA, existen 2(25%) \npacientes con DM1 y 6(75%) pacientes con DM2; 3(38%) pacientes con insulinoterapia y 7(88%) pacientes con \nantidiab\u00e9tico oral (ADO). La media de edad en TOFA es de 68(SD:12)a\u00f1os, siendo 3(38%) las mujeres. La media de \npersistencia al tratamiento con tofacitinib es de 592(SD:510)d\u00edas.  \nEl grupo baricitinib (BARI), lo constituyen 9(100%) pacientes con artritis reumatoide; siendo 7(78%) los pacientes en \ntratamiento concomitante con glucocorticoides. En BARI, existen 9(100%) pacientes con DM2; 3(33%) pacientes con \ninsulinoterapia y 8(84%) con ADO. La media de edad en BARI es de 61(SD:23)a\u00f1os, siendo 5(56%) las mujeres. La media \nde persistencia al tratamiento con baricitinib es de 615(SD:492)d\u00edas.  \nEl an\u00e1lisis estad\u00edstico del conjunto TOFA+BARI para los tiempos 0, 6 y 12, mostr\u00f3 una tendencia de reducci\u00f3n significativa \nen el valor medio de glucosa a los 6 meses de tratamiento con iJAK: de 8,36(SD:3,00)mmol/L a 6,79(SD:1,86)mmol/L \n(p=0,06); no se observaron diferencias estad\u00edsticamente significativas en cuanto valores medios de HbA1c. Se observ\u00f3 \n\u00fanicamente en BARI tendencia de reducci\u00f3n significativa en el valor medio de HbA1c a los 6 meses de tratamiento: de \n7,26(SD:0,70)% a 6,87(SD:0,70)% (p=0,06).  \nLa comparaci\u00f3n estad\u00edstica entre TOFA y BARI, no mostr\u00f3 diferencias significativas entre los valores medios de glucosa ni \nentre los valores medios de HbA1c\ufffd\nCONCLUSIONES\nSeg\u00fan los resultados de nuestro estudio, el tratamiento con iJAK podr\u00eda favorecer la sensibilidad a la insulina en pacientes \ncon DM1 y DM2. Son necesarios m\u00e1s estudios que apoyen estos hallazgos y determinen el posible impacto sobre la \nnecesidad de ajuste de medicaci\u00f3n antidiab\u00e9tica.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n712. EFECTIVIDAD Y SEGURIDAD EN VIDA REAL DE TOFACITINIB, BARICITINIB Y UPADACITINIB EN \nPACIENTES CON ARTRITIS REUMATOIDE \nAUTORES\nMO\u00d1INO DOM\u00cdNGUEZ, LM; MART\u00cdNEZ SU\u00c1REZ, A; OLIVA S\u00c1NCHEZ, M; CALLEJA HERN\u00c1NDEZ, M\u00c1; MERINO \nBOH\u00d3RQUEZ, V\nHOSPITAL VIRGEN MACARENA \ufffd AV\ufffd DOCTOR FEDRIANI, 3 SEVILLA \ufffd SEVILLA\nOBJETIVOS\nAnalizar la efectividad y seguridad de los inhibidores de Janus quinasas en pacientes con Artritis Reumatoide (AR).\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo de pacientes con artritis reumatoide (AR) tratados con tofacitinib, baricitinib o \nupadacitinib en un hospital terciario.  \nSe recogieron variables sociodemogr\u00e1ficas, cl\u00ednicas y de laboratorio.  \nLa efectividad, establecida mediante el \u201cDisease Activity Score 28\u201d (DAS28), se defini\u00f3 como: \n-la existencia de diferencias estad\u00edsticamente significativas (p < 0,05) entre DAS28 inicial (DAS28basal), DAS28 a los 6 \nmeses (DAS28_6M) y a los 12 meses (DAS28_12M). \n-la reducci\u00f3n de DAS28 en m\u00e1s de 1,2 puntos respecto a DAS28basal y adem\u00e1s DAS28_12M < 3,2 (respuesta clasificada \ncomo \u201cbuena\u201d seg\u00fan criterios EULAR).  \nLa seguridad se evalu\u00f3 por el n\u00famero y tipo de reacciones adveras que aparecieron en los 12 primeros meses de \ntratamiento y las reducciones de dosis y discontinuaciones por toxicidad.  \nPara el an\u00e1lisis estad\u00edstico se us\u00f3 la prueba t-student para muestras relacionadas en el programa SPSS\u00ae.\nRESULTADOS\nSe incluyeron 67 pacientes, 21 recibieron tofacitinib [90.5% mujeres, mediana de edad 64 a\u00f1os (RIC: 55-72)], 28 pacientes \nbaricitinib [78,6% mujeres, 69 a\u00f1os (RIC:62-76)] y 18 pacientes upadacitinib [88,9% mujeres, 64,5 a\u00f1os (RIC:56-69)].  \nSe obtuvieron los siguientes resultados de efectividad de tofacitinib, baricitinib y upadacitinib, respectivamente. DAS28_\nbasal: 4,30 \u00b1 1,37, 4,73 \u00b1 1,22 y 4,87 \u00b1 1,63; DAS28_6M: 3,62\u00b11,35, 3,18 \u00b1 1,23* y 2,67 \u00b1 0,99* y DAS28_12M: 3,66 \u00b1 1,43 \ny 2,99 \u00b1 1,43* (*p < 0,05). No se calcul\u00f3 DAS28_12M de upadacitinib ya que solo 38,9%(n=7) pacientes llevaban 12 meses \nen tratamiento\ufffd  \nA los 12 meses, 28,6%(n=6) y 42,9%(n=12) de pacientes consiguieron buena respuesta EULAR con tofacitinib y baricitinib, \nrespectivamente. De los pacientes que llevaban > 12 meses con upadacitinib, 42,9%(n=3) consigui\u00f3 buena respuesta. \nEl 6%(n=4) de los pacientes discontinuaron por falta de efectividad [14,3%(n=3) con tofacitinib y 3,6%(n=1) con \nbaricitinib].  \nEn cuanto a seguridad, se desarrollan efectos adversos (EAs) en 47,8%(n=32) pacientes. \nEn el grupo de tofacitinib, 66,7%(n=14) sufrieron EAs, siendo las m\u00e1s frecuentes, infecciones (14,3%,n=3), \nhipercolesterolemia (9,5%,n=2) y alteraciones en el hemograma [4,5%(n=1) linfopenia y anemia].  14875%(n=21) de pacientes con baricitinib sufrieron EAs. 35,7%(n=10) infecciones, 14,3%(n=4) anemia, 10,7%(n=3) \nlinfopenia y 10,7%(n=3) hipercolesterolemia.  \nEn cuanto a upadacitinib, 22,2%(n=4) tuvieron EAs, [alteraciones anal\u00edticas [(16,6%(n=3) hipercolesterolemia y \n5,55%(n=1) anemia]. \nDos pacientes sufrieron eventos card\u00edacos con tofacitinib y baricitinib (tromboembolismo pulmonar masivo e \nhipertensi\u00f3n arterial, respectivamente). \nUn 9,5%(n=2) y un 7,1%(n=2) de pacientes necesitaron una reducci\u00f3n de dosis por aparici\u00f3n de reacciones adversas en \ntofacitinib y baricitinib, respectivamente. Un 28%(n=6) tuvo que discontinuar por toxicidad en el grupo de tofacitinib \nfrente a un 17,8%(n=5) en baricitinib. No hubo discontinuaciones con upadacitinib.\nCONCLUSIONES\nSe puede concluir que la efectividad de baricitinib y upadacinib es mayor que la de tofacitinib, con la limitaci\u00f3n de que \nhay pocos pacientes que lleven m\u00e1s de 12 meses en tratamiento con upadacitinib.  \nBaricitinib produjo m\u00e1s EAs. Sin embargo, los de tofacitinib fueron m\u00e1s graves y dieron lugar a m\u00e1s discontinuaciones.  \nPodemos concluir que en nuestra poblaci\u00f3n upadacitinib es el m\u00e1s seguro y eficaz, aunque el n\u00famero de pacientes y el \ntiempo de tratamiento son limitaciones del estudio.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n718. EXPERIENCIA DE USO EN VIDA REAL DE GALCANEZUMAB EN PROFILAXIS DE LA MIGRA\u00d1A \nREFRACTARIA. \nAUTORES\nROSADO ANC\u00cdN, M; G\u00d3MEZ UGARTONDO, E; VALDAZO MART\u00cdN, C; SANTAOLALLA S\u00c1NCHEZ, A; ARENALES C\u00c1CERES, \nP; RISUE\u00d1O G\u00d3MEZ, B; NOGALES GARCIA, M; MART\u00cdNEZ MART\u00cdNEZ, C\nHOSPITAL TXAGORRITXU. JOS\u00c9 ATXOTEGUI, S/N VITORIA-GASTEIZ. \u00c1LAVA\nOBJETIVOS\nAnalizar eficacia y seguridad de galcanezumab, utilizado seg\u00fan el protocolo de un hospital terciario, en profilaxis de la \nmigra\u00f1a refractaria\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, en un hospital terciario, que incluye a los pacientes que iniciaron tratamiento \ncon galcanezumab entre marzo de 2020 y marzo de 2021. El protocolo de la comunidad aut\u00f3noma posiciona el uso de \ngalcanezumab para profilaxis de migra\u00f1a cr\u00f3nica y epis\u00f3dica de alta frecuencia, con un promedio de D\u00edas de Migra\u00f1a al \nMes(pDMM) \u2265 8 y \u2265 3 fracasos de tratamientos previos(siendo uno toxina botul\u00ednica, en migra\u00f1a cr\u00f3nica).  \nLos pacientes recibieron una dosis de carga de 240 mg y, posteriormente, 120 mg al mes. Seg\u00fan el protocolo del hospital, \nsalvo ineficacia o intolerancia, se suspende la terapia tras 12 meses. En caso de respuesta parcial y sospecha de paciente \nrespondedor lento, se valora prolongarla 6 meses\ufffd \nSe recogieron datos demogr\u00e1ficos, pDMM previos y tratamientos antimigra\u00f1osos recibidos.  \nLa variable principal de eficacia fue la reducci\u00f3n \u226550% (r50) del pDMM recogida en el mes 1(M1), en el mes 3(M3) y en \ndistintos tiempos, seg\u00fan criterio m\u00e9dico, tras el mes 4(M > 4). Para evaluar la eficacia, tambi\u00e9n se consideraron variables \nsubjetivas(VS): Menor Intensidad de los Episodios de Migra\u00f1a(MIEM) y cambios en la puntuaci\u00f3n de la Escala Visual \nAnal\u00f3gica del dolor(EVA), en el cuestionario de Evaluaci\u00f3n de la Discapacidad por Migra\u00f1a(MIDAS) y en Examen del \nImpacto del Dolor de Cabeza(HIT-6). Sin embargo, estas VS no siempre se registraron, por lo que no se pudo realizar un \nan\u00e1lisis sistem\u00e1tico.  \nSe recogieron tambi\u00e9n los efectos adversos(EA) y la duraci\u00f3n y el motivo de suspensi\u00f3n del tratamiento.\nRESULTADOS\nMuestra de 29 pacientes:21 mujeres(72.4%) y 8 hombres(27.6%), con una mediana de edad de 50 a\u00f1os(rango \nintercuart\u00edlico 44-57). Hab\u00edan probado una media de 6(\u00b11.99) tratamientos preventivos:topiramato(el82.8%),betabloqu\neantes(el72.4%),flunarizina(el82.8%),valproato(el48.3%),amitriptilina(el79.3%),zonisamida(el27.6%) y otros con menor \nfrecuencia\ufffd  \nEn el M3, 14 pacientes(el48.3%) consiguieron una r50 del pDMM y,8 de ellos(el27.6%), lo consiguieron desde el M1. 9 \nde los pacientes(el31%) que no alcanzaron la r50 en el M3 percibieron una MIEM, por lo que el 79.3% obtuvieron alg\u00fan \nbeneficio en M3. En M > 4, otros 7(el24.1%) consiguieron la r50 y,2 de ellos(el6.9%), se consideraron respondedores \nlentos, ya que alcanzaron el objetivo m\u00e1s tarde de los 12 meses.8 fueron los pacientes(el27.6%) que no consiguieron una \nr50,aunque 3 de ellos(el10.3%) percibieron una MIEM o mejoraron la puntuaci\u00f3n de la EVA, del cuestionario MIDAS o del \nHIT-6.  \nPor tanto, solo 5 pacientes(el17.2%) no obtuvieron ning\u00fan beneficio y suspendieron el tratamiento por ineficacia. 22 \npacientes(el76%) lo suspendieron al cumplir la duraci\u00f3n establecida,1 paciente dej\u00f3 de recogerlo por error y otro lo \nalarg\u00f3 3 meses por cefalea post-COVID.  \nNo hubo EA graves que obligasen a finalizar el tratamiento, siendo los m\u00e1s frecuentes: mareos/v\u00e9rtigos(34.5%),estre\u00f1imi\nento(13.8%),diarrea(3.4%),n\u00e1useas(6.9%),cansancio(3.4%) y dolor o reacci\u00f3n en el lugar de la inyecci\u00f3n(10.3%).\nCONCLUSIONES\nGalcanezumab consigui\u00f3 una r50 del pDMM en la mayor\u00eda de los pacientes (el72.4%) y no ocasion\u00f3 EA graves en la \nmuestra estudiada, pero es necesario continuar evaluando eficacia y seguridad en muestras mayores. \nEn pacientes respondedores, deber\u00e1 analizarse el pDMM tras finalizar el tratamiento y la necesidad de reiniciarlo.149CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n731. EFECTIVIDAD DEL TRATAMIENTO CON INHIBIDORES DE INTERLEUCINAS 17 Y 23 EN PSORIASIS EN \nPLACAS: PERSPECTIVA DEL PACIENTE \nAUTORES\nANGUITA MONTENEGRO, B; LUQUE JIM\u00c9NEZ, M; AREAS DEL AGUILA, VL; PALACIOS MOYA, E; GARC\u00cdA ARPA, M; \nS\u00c1NCHEZ CAMINERO, MP; RODR\u00cdGUEZ MART\u00cdNEZ, M\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nLos inhibidores de interleucinas 17 (anti IL-17), Secukinumab, Ixekizumab y Brodalumab, y 23 (anti IL-23), Guselkumab y \nRisankizumab, est\u00e1n indicados para el tratamiento de Psoriasis en placas moderada/grave (PPMG). El \u00edndice Psoriasis Area \nSeverity Index, (PASI), y la evaluaci\u00f3n de la calidad de vida (CV) son herramientas para medir la eficacia de estos f\u00e1rmacos, \ndefinida como reducci\u00f3n 90-100% del PASI y una puntuaci\u00f3n\u22641 en el cuestionario de CV Dermatology Life Quality Index \n(DLQI). El objetivo de este trabajo es determinar la efectividad de los anti IL-17 y anti IL-23 en el tratamiento de pacientes \ncon PPMG en la pr\u00e1ctica cl\u00ednica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional transversal (noviembre 2021-abril 2022) que incluy\u00f3 pacientes adultos diagnosticados de PPMG en \ntratamiento con anti IL-17 o anti IL-23 durante al menos 12 semanas, en seguimiento en las consultas de Dermatolog\u00eda \n(CD) y Atenci\u00f3n Farmac\u00e9utica (CAF) de un hospital de tercer nivel.  \nLas variables recogidas fueron: demogr\u00e1ficas, comorbilidades, tratamientos previos y actual, duraci\u00f3n y adherencia \nal tratamiento con anti IL-17 y 23, medida a trav\u00e9s de los registros de dispensaci\u00f3n definida como d\u00edas cubiertos con \nla medicaci\u00f3n dispensada/intervalo de reposici\u00f3n x 100, y dimensiones contempladas en el cuestionario DLQI con \npuntuaci\u00f3n \u22651.  \nSe analiz\u00f3 la efectividad mediante la reducci\u00f3n del PASI (historia cl\u00ednica) y medida de CV con el cuestionario DLQI en la \nCAF o CD \ufffd\nRESULTADOS\nSe incluyeron 41 pacientes, de los cuales fue posible realizar el cuestionario DLQI a 40 (tasa de respuesta 97,6%): 65% \nhombres, edad media 54 a\u00f1os (DE=13). Presentaron las comorbilidades: h\u00e1bitos t\u00f3xicos 37,5%, artritis psori\u00e1sica 35%, \ndislipemia 32,5%, psiqui\u00e1tricas 25%, hipertensi\u00f3n arterial 25%, Diabetes Mellitus 7,5%. Un 70% recibieron tratamiento \nprevio con otros f\u00e1rmacos biol\u00f3gicos. El medicamento anti IL-17 o IL-23 utilizado fue: Ixekizumab 35%, Guselkumab 25%, \nSecukinumab 17,5%, Brodalumab 15% y Risankizumab 7,5%, siendo el tiempo medio con estos f\u00e1rmacos de 25 meses \n(DE 17) y la mediana de adherencia 100% (RIC 84-100). La efectividad, expresada como medianas, fue reducci\u00f3n de PASI \n94,6% (RIC 76,8-100%) y DLQI 1 (RIC 0-2,75), presentando DLQI\u22641 el 60%. Las dimensiones de salud m\u00e1s afectadas fueron \ns\u00edntomas y percepciones (41%), actividades de la vida diaria (20%) y molestias ocasionadas con el tratamiento (12,5%).\nCONCLUSIONES\nLos anti IL-17 y anti IL-23 son un tratamiento efectivo en PPMG en segunda l\u00ednea y en pacientes con comorbilidades que \npueden modificar el curso de la enfermedad, logrando el objetivo fijado en la mayor\u00eda de los pacientes. Estos perciben \nuna mejor\u00eda en su CV aunque se ven afectados en su vida diaria por los s\u00edntomas y las molestias del tratamiento. Este \nestudio presenta limitaciones por tratarse de un estudio unic\u00e9ntrico y disponer de una peque\u00f1a muestra de pacientes. \nSer\u00eda necesario un mayor reclutamiento de pacientes en un estudio multic\u00e9ntrico que permita comparar la efectividad \nentre los distintos f\u00e1rmacos ya que la evidencia disponible es muy limitada. Con este trabajo queremos resaltar la \nimportancia de la creaci\u00f3n de equipos multidisciplinares Farmacia-Dermatolog\u00eda para la evaluaci\u00f3n de la efectividad de \nlos tratamientos con el objetivo final de optimizar la CV en PPMG.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n733. RESULTADOS EN VIDA REAL DEL SWITCH ENTRE LOS ANTICUERPOS MONOCLONALES ANTI-CGRP \nPARA PROFILAXIS DE LA MIGRA\u00d1A \nAUTORES\nALFONS\u00cdN LARA, M; \u00c1LVAREZ PAYERO, M; PARADELA CARREIRO, A; L\u00d3PEZ-GIL OTERO, MDM; ROBLES TORRES, D; \nPRADO MONTES, P; COU\u00d1AGO FERN\u00c1NDEZ, M; MART\u00cdNEZ L\u00d3PEZ DE CASTRO, N\nHOSPITAL \u00c1LVARO CUNQUEIRO \ufffd ESTRADA DE CLARA CAMPOAMOR, 341 VIGO \ufffd PONTEVEDRA\nOBJETIVOS\nRecientemente se han a\u00f1adido al arsenal terap\u00e9utico para el tratamiento preventivo de la migra\u00f1a los anticuerpos \nmonoclonales(AM) dirigidos a bloquear el p\u00e9ptido asociado al gen de la calcitonina (CGRP) circulante (fremanezumab y \ngalcanezumab) o su receptor (erenumab). Los ensayos cl\u00ednicos han demostrado la superioridad de estos frente a placebo, \npero existe muy poca evidencia sobre la eficacia y seguridad de la secuenciaci\u00f3n de estos tras ineficacia o intolerancia a \nuno de ellos. El objetivo de este estudio es describir la efectividad en vida real y seguridad de dicha secuenciaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital de tercer nivel. Se incluyeron pacientes \u226518 a\u00f1os con migra\u00f1a \nepis\u00f3dica de alta frecuencia o cr\u00f3nica (MC), tratados secuencialmente con \u22653dosis de al menos dos AM-anti-CGRP entre \nenero 2020 y abril 2022\ufffd \nVariables extra\u00eddas de historia cl\u00ednica electr\u00f3nica y programa de dispensaci\u00f3n ambulatoria: edad, sexo, tipo migra\u00f1a, 150tratamientos previos, AM-anti-CGRP empleados, duraci\u00f3n de tratamiento, motivo cambio, tipo de respuesta (completa \n(RC):reducci\u00f3n \u226550% del n.\u00ba d\u00edas mensuales de migra\u00f1a (DMM) respecto al basal; parcial (RP):reducci\u00f3n \u226530%- < 50% \nDMM) y reacciones adversas (RA) descritas en el curso cl\u00ednico.\nRESULTADOS\nSe incluyeron un total de 10 pacientes (100% MC): 90% mujeres, edad media: 47,1\u00b110,1 a\u00f1os. DMM_basal:22,1\u00b1 8,3 d\u00edas, \ncon 10,3\u00b13,7 tratamientos preventivos previos.  \nEl primer AM-anti-CGRP utilizado fue erenumab 70mg (n=8) con incremento de dosis a 140mg en 7pacientes y \ngalcanezumab (n=2). DMM_3meses (considerando el aumento de dosis de erenumab): 22,7\u00b17,1 d\u00edas. Aun as\u00ed, se \nmantuvieron activos 8,5\u00b12,8 meses. La ineficacia fue el motivo de secuenciaci\u00f3n en el 100% de pacientes.  \nEl segundo AM-anti-CGRP fue galcanezumab (n=7), fremanezumab (n=1) y erenumab 140mg (n=2), duraci\u00f3n media de \ntratamiento:8,4\u00b13,7 meses. A los 3meses, solo se observ\u00f3 una RC (reducci\u00f3n_DMM:93,3%) con galcanezumab y dos RP \nen pacientes con erenumab y fremanezumab con reducci\u00f3n_DMM:30,8% y 44,4%, respectivamente. A los 6meses, estos \n3 pacientes alcanzaron RC con una reducci\u00f3n_DMM para galcanezumab:90%, erenumab:73,1% y fremanezumab:55,6%. \nEn la fecha de corte del estudio, dos de los pacientes manten\u00edan el segundo AM (enerumab y fremanezumab), con una \nduraci\u00f3n media de tratamiento de: 9,5\u00b12,8 meses\ufffd  \nDos pacientes fueron tratados con un tercer AM (fremanezumab) y s\u00f3lo uno tuvo respuesta (RC) a los 3meses, \nperdi\u00e9ndose \u00e9sta a los 6 meses.  \nRespecto a seguridad, se observ\u00f3 una reacci\u00f3n cut\u00e1nea con fremanezumab y un episodio vertiginoso leve con erenumab. \nNo se discontinu\u00f3 ning\u00fan tratamiento por RA.\nCONCLUSIONES\nS\u00f3lo 30% de los pacientes alcanzaron alg\u00fan tipo de respuesta con el segundo AM a los 3 meses. Entre los respondedores, \nparece que se mantiene al menos 6-9meses. \nAunque el switch entre AM con distinto mecanismo de acci\u00f3n podr\u00eda plantearse como una opci\u00f3n terap\u00e9utica tras \nfracasar un primer AM, la tasa de fracaso al switch ha sido muy alta, aunque el bajo tama\u00f1o muestral unido al corto \nperiodo de seguimiento, no permite extraer conclusiones sobre la validez de esta pr\u00e1ctica. Debido al alto coste de estos \ntratamientos, y hasta disponer de mayor evidencia, conviene protocolizar esta pr\u00e1ctica desde las Comisiones Farmacia. \nDesde el punto de vista de seguridad, son tratamientos en general bien tolerados\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n734. TRATAMIENTOS MODIFICADORES DE LA ENFERMEDAD EN PACIENTES CON ESCLEROSIS M\u00daLTIPLE \nEN ESPA\u00d1A: ESTUDIO EM-POINT \nAUTORES\nESTEBAN-CASADO , S; SANTIAGO-P\u00c9REZ , A; \u00c1LVAREZ-PAYERO , M; AR\u00c9VALO-BERNAB\u00c9 , AG; PADULLES-ZAMORA , N; \nMART\u00cdN-BARBERO , ML; ESCOLANO-PUEYO , A; GUTIERREZ-GUTIERREZ , E\nHOSPITAL INFANTA LEONOR \ufffd GRAN V\u00cdA DEL ESTE, 80 MADRID \ufffd MADRID\nOBJETIVOS\nEste trabajo forma parte del estudio EM-POINT, cuyo objetivo principal es conocer el patr\u00f3n de utilizaci\u00f3n de \ntratamientos modificadores de la enfermedad (DMT) prescrito en pacientes con diagn\u00f3stico de esclerosis m\u00faltiple (EM) \nen los hospitales espa\u00f1oles.  \nComo objetivo secundario se estableci\u00f3 determinar la prevalencia de polifarmacia y polifarmacia extrema.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, transversal y multic\u00e9ntrico. Se incluyeron todos los pacientes con diagn\u00f3stico de EM y DMT activo \na los que se dispens\u00f3 tratamiento en las consultas de pacientes externos del servicio de farmacia o fue administrado en \nlos hospitales de d\u00eda de los centros participantes durante la semana del corte transversal prefijado en la segunda semana \nde febrero2021\ufffd  \nSe excluyeron los pacientes ingresados en el per\u00edodo de estudio y aquellos incluidos en ensayos cl\u00ednicos.  \nSe recogieron variables demogr\u00e1ficas (edad, sexo); cl\u00ednicas (Expanded Disability Status Scale (EDSS), forma de \npresentaci\u00f3n de la enfermedad y comorbilidades) y farmacoterap\u00e9uticas (DMT y tratamientos concomitantes). Se \ndefinieron la presencia de polifarmacia y polifarmacia extrema como la prescripci\u00f3n de > 5 f\u00e1rmacos y > 10 f\u00e1rmacos, \nrespectivamente. \n \nEl tama\u00f1o muestral se calcul\u00f3 en base a la incidencia de EM en Espa\u00f1a y su poblaci\u00f3n total, estimando que el 50% de los \npacientes presentasen polifarmacia, una precisi\u00f3n del 5% y un intervalo de confianza del 95%.  \nLas variables cuantitativas se describen mediante media y desviaci\u00f3n est\u00e1ndar (DE) para las variables que siguen una \ndistribuci\u00f3n normal y como mediana y rango intercuart\u00edlico (IQR) para aquellas que no siguen una distribuci\u00f3n normal. \nLas variables cualitativas se describen mediante frecuencia y porcentajes. \nEl manejo de datos y el an\u00e1lisis estad\u00edstico se ha realizado usando el software R-Studio v.1.1.456.\nRESULTADOS\nSe incluyeron 1407 pacientes (68,0% mujeres) de los 57 centros participantes, siendo representadas 15 de las \ncomunidades aut\u00f3nomas. La mediana de edad fue de 45,6 a\u00f1os (IQR: 38,2\u201353,2). El 35,5% de los pacientes no ten\u00edan \nninguna comorbilidad, el 24,7% ten\u00edan una y el 39,8% al menos 2. La comorbilidad m\u00e1s frecuente fue la depresi\u00f3n y otros \ntrastornos del SNC(28,4%).  151La puntuaci\u00f3n EDSS mediana fue de 2,0 (IQR 1,0\u20133,5). La forma de presentaci\u00f3n de la enfermedad se distribuy\u00f3: \nremitente recurrente(89,3%); secundaria progresiva(7,2%); primaria progresiva(2,6%) y recidivante progresiva(1,0%). \nLos DMT m\u00e1s prescritos fueron dimetilfumarato (19,1%) y teriflunomida (14,0%). El resto se distribuy\u00f3 de la siguiente \nmanera: acetato de glatir\u00e1mero(11,1%); natalizumab intravenoso(10,8%); fingolimod(10,6%); interferon beta-1a \nsubcut\u00e1neo(9,8%); interferon beta-1b subcut\u00e1neo(6,0%); interferon beta-1a intramuscular (5,5 %); ocrelizumab (4,7%); \notros (3,6%); interferon beta-1a pegilado(3,5%); cladribina(1,3%) y alemtuzumab(0,1%).  \nLa mediana del n\u00famero de f\u00e1rmacos concomitantes fue de 3,0 f\u00e1rmacos (IQR: 1,0\u20136,0); siendo la presencia de \npolifarmacia del 32,7% y de polifarmacia extrema del 8,1%\ufffd\nCONCLUSIONES\nDimetilfumarato y teriflunomida son los DMT m\u00e1s utilizados, lo que tiene relaci\u00f3n con su utilizaci\u00f3n en diagn\u00f3sticos m\u00e1s \nrecientes y en pacientes con menor discapacidad\ufffd  \nLa prescripci\u00f3n de cladribina y alemtuzumab queda infrarrepresentada debido a que sus intervalos de administraci\u00f3n son \nmuy amplios y el dise\u00f1o del estudio es tranversal\ufffd  \nLa prevalencia de polifarmacia encontrada ha sido inferior a la descrita en la literatura. Este hecho puede deberse a la \nmenor edad y menor discapacidad de nuestra poblaci\u00f3n\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n740. EXPERIENCIA DE USO DE DUPILUMAB EN PACIENTES CON DERMATITIS AT\u00d3PICA MODERADA-\nGRAVE TRAS 52 SEMANAS DE TRATAMIENTO: EFECTIVIDAD Y SEGURIDAD \nAUTORES\nS\u00c1NCHEZ LUQUE, L; ARNAIZ DIEZ, S; REVILLA CUESTA, N; INFANTE CAMARERO, A; VICENTE GONZ\u00c1LEZ, B; DE FRUTOS \nDEL POZO, M; IZQUIERDO ACOSTA, L; ALAMO GONZALEZ, O\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS\nOBJETIVOS\nEvaluar la efectividad y seguridad de dupilumab tras 52 semanas de tratamiento en pacientes con Dermatitis At\u00f3pica \nmoderada-grave.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo en el que se incluyeron todos los pacientes con dermatitis at\u00f3pica moderada-grave \ntratados durante 52 semanas con dupilumab\ufffd  \nSe recogieron variables demogr\u00e1ficas [edad, sexo]; fecha de inicio de tratamiento; duraci\u00f3n del tratamiento, medicaci\u00f3n \nprevia; las variables c\u00ednicas requeridas en la aplicaci\u00f3n Valtermed [EASI-50: \u00c1rea de eccema e \u00edndice de gravedad (0-70 \npuntos), PGA: Physician Global Assessment (0-4 puntos), BSA: Porcentaje de superficie corporal afectada (esta \u00faltima \nrequerida s\u00f3lo al inicio de tratamiento)], el cumplimiento de los requisitos incluidos en la aplicaci\u00f3n Valtermed que \nindican continuar con el tratamiento a las 16 semanas (alcanzar el EASI-50 respecto a su valoraci\u00f3n inicial basal y una \nreducci\u00f3n en el PGA \u2265 2 puntos respecto a su valoraci\u00f3n inicial basal) y mantenimiento de estos valores en las mediciones \na las 24 y 52 semanas\ufffd  \nSe registraron las reacciones adversas para evaluar la seguridad del f\u00e1rmaco.  \nLos datos se recogieron a partir de la historia cl\u00ednica de los pacientes y del programa de dispensaci\u00f3n de medicamentos a \npacientes externos del hospital.\nRESULTADOS\nSe incluyeron un total de 19 pacientes, siendo el 47% (n=9) hombres, con una mediana de edad de 30 a\u00f1os (17-65). \nEl 100%(n=19) de los pacientes recibieron ciclosporina previamente, el 58% (n=11) corticoides orales, el 42% (n=8) \nomalizumab, el 21%(n=4) metotrexato oral y tacr\u00f3limus t\u00f3pico, 16% (n=3) fototerapia, y el 5%(n=1) leflunomida. De los \n19 pacientes, el 68,4% (n=13) alcanzaron las 16 semanas de tratamiento, el 52,6% (n=10) alcanzaron las 24 semanas. El \n26,8% (n=7) restante, completaron tratamiento con dupilumab tras 52 semanas.  \nPara los pacientes tratados durante 52 semanas la mediana de EASI fue 27 (24-38) al inicio del tratamiento, de 6 (3-13) \nen la semana 16 y de 5(1-7) en la semana 52; el 100% de los pacien tes alcanzaron un EASI-50 en las primeras 16 semanas \nque se mantuvo hasta semana 52. El 94% (n=6) de los pacientes presentaron un PGA de 4 al inicio del tratamiento y el \n100% (n=7) presentaron un PGA 1 en la semana 16, que se mantuvo hasta la semana 52. La mediana del BSA fue de 40% \n(25-70%) al inicio y de 15% (9-28%) a las 16 semanas de tratamiento, sin embargo, no se registr\u00f3 a partir de la semana \n16. Todos los pacientes cumplieron los criterios exigidos para continuar el tratamiento a las 16 semanas y se mantuvieron \nhasta la semana 52.  \nEn cuanto a la seguridad, el 57 % de los pacientes sufrieron conjuntivitis como efecto adverso, sin embargo, se obtuvo \nmejor\u00eda con la administraci\u00f3n de l\u00e1grimas artificiales.\nCONCLUSIONES\nDupilumab ha demostrado efectividad para el tratamiento de la Dermatitis At\u00f3pica dado la considerable disminuci\u00f3n de \nlas variables cl\u00ednicas durante las 16 primeras semanas que se ha conseguido mantener en el tiempo. Adem\u00e1s, presenta \nventajas de tolerabilidad respecto a las alternativas actuales, con una menor incidencia de efectos adversos (controlables \ncon l\u00e1grimas artificiales), lo que puede contribuir a mejorar la adherencia y persistencia del tratamiento.152CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n754. USO DE RISANKIZUMAB EN PSORIASIS MODERADA - GRAVE EN VIDA REAL \nAUTORES\nGARC\u00cdA GOMEZ, N; GUTI\u00c9RREZ LUCENA, L; CONTRERAS COLLADO, R; JIM\u00c9NEZ L\u00d3PEZ, Y; P\u00c9REZ CANO, E; CAO VI\u00d1A, \nV; PLAZA ARBEO, A\nHOSPITAL UNIVERSITARIO M\u00c9DICO- QUIR\u00daRGICO. AV . DEL EJ\u00c9RCITO ESPA\u00d1OL, 10 JA\u00c9N. JA\u00c9N\nOBJETIVOS\nRisankizumab es un anticuerpo monoclonal humanizado de tipo inmunoglobulina G1 (IgG1) selectivo, dirigido contra \n(IL)-23 indicado en el tratamiento de la psoriasis en placas de moderada a grave en adultos que sean candidatos a \ntratamiento sist\u00e9mico. La dosis recomendada es de 150 mg en inyecci\u00f3n subcut\u00e1nea en las semanas 0 y 4, seguida de una \ndosis de mantenimiento cada 12 semanas\ufffd  \nEl objetivo es analizar el perfil de utilizacion de risankizumab en un hospital de tercer nivel, as\u00ed como evaluar la \nefectividad y seguridad del tratamiento en psoriasis moderada a grave en la pr\u00e1ctica cl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y descriptivo en el que se incluyeron todos los pacientes a los que se les prescribi\u00f3 \nrisankizumab desde el a\u00f1o 2020 hasta enero de 2022. \nLos datos se obtuvieron de la historia cl\u00ednica digital (DIRAYA) y del programa de prescripci\u00f3n electr\u00f3nica (ATHOS\u2122 \nPRISMA). \nLas variables recogidas fueron: sexo, edad, tratamiento sist\u00e9mico previo, fecha de inicio de tratamiento y siguientes dosis \nadministradas, PASI (Psoriasis Area and Severity Index) basal y posterior al inicio de tratamiento, BSA (Body Surface Area) \ny reacciones adversas medicamentosas (RAM).  \nLa efectividad se obtuvo a partir del tiempo que se tard\u00f3 en alcanzar niveles de PASI100 y la seguridad de las RAM \ndetectadas, comparandolas con las descritas en ficha tecnica.\nRESULTADOS\nSe incluyeron 19 pacientes (38,8% hombres y 63,2% mujeres) con una media de edad de 48 a\u00f1os (rango 24-72 a\u00f1os).  \nLos agentes biol\u00f3gicos usados en lineas anteriores fueron aquellos que actuan contra el factor de necrosis tumoral \nalfa (etanercept (36,8%), adalimumab (31,6%)), IL-12 y IL-23 (ustekinumab (26,3%)), IL-17 (secukinumab (21%), \nixekizumab(5,3%)) y la IL-23 (guselkumab (5,3%)). Adem\u00e1s el 57,9 % de los pacientes habian recibido tratamiento no \nbiologico previo con metotrexato (n=8) y/o ciclosporina (n=5).  \nEl 5,3% de los pacientes recibieron risankizumab como primera linea de tratamiento biologico, el 52,6% como segunda, el \n31,6% como tercera y el 10,5% como quinta y sexta linea.  \nEl PASI y el BSA basal medio fue de 7,1 y 8,8%, respectivamente. El 68,4% de los pacientes alcanzaron niveles de PASI100 \nen una media de 23 semanas, de estos el 46,1% sigue manteniendolos en la semana 56\ufffd  \nSe registr\u00f3 una media de 12 semanas de diferencia entre las fechas de dispensaci\u00f3n de la medicaci\u00f3n, lo que ratifica la \nbuena adherencia posol\u00f3gica al tratamiento.  \nRespecto a la seguridad, se registraron RAM de hiperlipemia (n=2), aumento de biblirrubina(n=1), cefalea (n=1) y v\u00e9rtigo \n(n=1). Solamente un paciente tuvo que cesar el tratamiento.\nCONCLUSIONES\nLa efectividad de risankizumab en psoriasis moderada a grave en pacientes refractarios a m\u00e1s de un f\u00e1rmaco biol\u00f2gico \nfue elevada, ya que m\u00e1s de la mitad de ellos consiguieron alcanzar niveles de PASI100. Respecto a la seguridad, el \ntratamiento fue bien tolerado, detectandose 4 RAM, 3 de ellas no descritas en ficha t\u00e9cnica.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n755. EXPERIENCIA DE USO DE ALIROCUMAB Y EVOLOCUMAB A LARGO PLAZO EN PACIENTES TRATADOS \nDURANTE 5 A\u00d1OS: EFECTIVIDAD Y SEGURIDAD. \nAUTORES\nS\u00c1NCHEZ LUQUE, L; ORTOLL POLO, V; REVILLA CUESTA, N; INFANTE CAMARERO, A; VICENTE GONZALEZ, B; DE \nFRUTOS DEL POZO, M; CASTA\u00d1O RODRIGUEZ, B; ARNAIZ DIEZ, S\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS\nOBJETIVOS\nAnalizar efectividad y seguridad a largo plazo de los inhibidores de PCSK9, alirocumab y evolocumab (IPCSK9), en \npacientes tratados durante 5 a\u00f1os seg\u00fan las condiciones de financiaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo en un hospital de tercer nivel en el que se incluyeron pacientes tratados \ncon IPCSK9 durante al menos 5 a\u00f1os de acuerdo a las condiciones de financiaci\u00f3n.  \nVariables recogidas: Demogr\u00e1ficas [sexo, edad]; fecha de inicio de tratamiento; diagn\u00f3stico seg\u00fan la indicaci\u00f3n financiada \ndel IPCSK9 (enfermedad cardiovascular establecida [ECVe] o hipercolesterolemia familiar heterocig\u00f3tica [HFHe]), factores \nde riesgo y medici\u00f3n de cLDL al inicio del tratamiento, a los 6 meses y a los 5 a\u00f1os. Se calcul\u00f3 el porcentaje de reducci\u00f3n \ndel c-LDL desde el inicio hasta los 5 a\u00f1os. Se recogieron reacciones adversas documentadas en la historia cl\u00ednica.  153Los datos se han recogido a partir de la historia cl\u00ednica de los pacientes y del programa de dispensaci\u00f3n de medicamentos \na pacientes externos del Servicio de Farmacia\ufffd\nRESULTADOS\nSe obtuvieron datos de 26 pacientes (20 hombres) con una mediana de edad de 70 a\u00f1os (46-86). 15 pacientes (58%) con \nECVe, 8 (31%) con HFHe y 3 (12%) con ambos diagn\u00f3sticos. Como factores de riesgo registrados: 11 (52%) presentaban \nhipertensi\u00f3n, 3 (14%) diabetes mellitus, 3 (14%) obesidad y 12 (57%) ning\u00fan factor de riesgo.  \nEn ECVe la media del LDL al inicio fue de 126mg/dl (SD=18), a los 6 meses de 46mg/dl (SD=24) y a los 5 a\u00f1os de 50mg/\ndl (SD=18); en HFHe fue de 170mg/dl (SD=39) al inicio, 118mg/dl (SD=38) a los 6 meses y 97mg/dl (56) a los 5 a\u00f1os; en \nlos pacientes con ambos diagn\u00f3sticos fue de 124mg/dl (SD=20) al inicio, 29mg/dl (SD=18) a los 6 meses y de 26mg/dl \n(SD=14) a los 5 a\u00f1os.  \nEl porcentaje de reducci\u00f3n de cLDL calculado en ECVe a los 6 meses fue del 63% (IC95%: 39-87) consiguiendo mantener \nuna reducci\u00f3n a los 5 a\u00f1os del 60% (IC95%: 35-85) desde el inicio de tratamiento. En HFHe la reducci\u00f3n a los 6 meses \nfue del 30% (IC95%: -2-62) logrando mantener una reducci\u00f3n del 43% (IC95%: 9-77) a los 5 a\u00f1os; y en los pacientes con \nambos diagn\u00f3sticos la reducci\u00f3n fue del 77% (IC95%: 29-124) a los 6 meses, alcanzando el 79% (IC95%: 33-125) a los 5 \na\u00f1os desde el inicio\ufffd  \nDe los 26 pacientes, 4 (15%) presentaron miopat\u00edas como efecto adverso.\nCONCLUSIONES\nAmbos IPCSK9 han mostrado una reducci\u00f3n de los niveles de cLDL estad\u00edsticamente significativa y mantenida tras 5 \na\u00f1os de tratamiento en todas las indicaciones. El porcentaje de reducci\u00f3n del cLDL de los IPCSK9 se corresponde con el \nrecogido en datos publicados\ufffd  \nEl tratamiento a largo plazo muestra una excelente tolerancia, con miopat\u00eda como principal efecto adverso comunicado. \nNo obstante, existe incertidumbre por las repercusiones de mantener niveles de LDL notablemente bajos.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n781. EVOLUCI\u00d3N DE LA PENETRACI\u00d3N DE BIOSIMILARES EN ENFERMEDADES INMUNOMEDIADAS \nAUTORES\nL\u00d3PEZ CENTENO, B; ALIOTO , D; ALONSO CASTRO, V; GARC\u00cdA CEREZUELA, MD; MAROTO GARC\u00cdA, E; ROSAS ESPINOZA, \nC; ARANGUREN OYARZ\u00c1BAL, A; CALVO ALC\u00c1NTARA, MJ\nSERVICIO MADRILE\u00d1O DE SALUD \ufffd AVENIDA DE MANUEL FRAGA IRIBARNE 2 MADRID \ufffd MADRID\nOBJETIVOS\nDescribir la evoluci\u00f3n de la penetraci\u00f3n de f\u00e1rmacos biosimilares (BS) utilizados en enfermedades inmunomediadas \n[(FAR-IMID): infliximab, etanercept y adalimumab] mediante el an\u00e1lisis de los resultados de los Indicadores de Utilizaci\u00f3n \nde Medicamentos implantados en los hospitales de una Comunidad Aut\u00f3noma (CA).\nMATERIALES Y M\u00c9TODOS\nLos Indicadores de Utilizaci\u00f3n de FAR-IMID biosimilares se elaboraron con la participaci\u00f3n de un grupo de trabajo \nformado por farmac\u00e9uticos hospitalarios de distintos hospitales y servicios centrales del Servicio de Salud.  \nDefiniciones: 1) Porcentaje de pacientes totales (inicios y seguimientos) tratados con FAR-IMID biosimilar respecto al total \nde pacientes en tratamiento con FAR-IMID (BS + no BS) y 2) Porcentaje de pacientes na\u00efve que inician tratamiento con \nFAR-IMID biosimilar respecto al total de pacientes na\u00efve que inician tratamiento con FAR-IMID (BS + no BS).  \nLos indicadores permiten el seguimiento de dos escenarios: la introducci\u00f3n de biosimilares en pacientes nuevos y los \ncambios en pacientes en tratamiento con buen control de la enfermedad\ufffd  \nFuente de datos: plataforma web donde se registran dichos indicadores de forma independiente para cada uno de los \nf\u00e1rmacos incluidos en ellos, recalcul\u00e1ndose autom\u00e1ticamente los indicadores agrupadores.\nRESULTADOS\nEntre 2019-2021, la evoluci\u00f3n del n\u00famero de pacientes tratados con FAR-IMID ha sido incremental, aumentando un \n19,2% (2.442) frente al a\u00f1o 2019 y un 11,1% (1.698) frente al 2020. En relaci\u00f3n a los pacientes que utilizaron BS, este \nincremento ha sido a\u00fan mayor: 82,5% (4.569) y 26,7% (2.699) frente al 2019 y 2020, respectivamente. Respecto a la \nevoluci\u00f3n de ambos indicadores frente al 2019, el indicador de pacientes totales aument\u00f3 23 puntos porcentuales (66,3% \nvs 43,2%) y el de pacientes na\u00efve 7,7 (99,1% vs 91,4%).  \nDurante el a\u00f1o 2021, 15.249 pacientes fueron tratados con FAR-IMID en los hospitales de la CA, utiliz\u00e1ndose en un 57,6% \nadalimumab, en un 21,8% infliximab y en un 20,6% etanercept.  \nDe ellos 10.107 (66,3%) utilizaron BS en su terapia. De ellos, el 32,8% de los pacientes fueron na\u00efve y el 67,2% restante \npacientes en seguimiento con terapias ya implantadas. La variabilidad en los resultados de los distintos hospitales oscila \nentre el 37,8%-97%. La distribuci\u00f3n en la utilizaci\u00f3n de los BS por f\u00e1rmaco fue: 54,5% adalimumab BS, 27,5% infliximab BS \ny 18% etanercept BS\ufffd  \nRespecto al indicador de pacientes na\u00efve, de los 3.345 pacientes que iniciaron tratamiento con FAR-IMID, 3.315 (99,1%) \nlo hicieron con BS, con una menor variabilidad entre hospitales (94,1%-100%). En este caso tambi\u00e9n adalimumab fue el \nf\u00e1rmaco m\u00e1s utilizado (70,3%) seguido por infliximab (17%) y etanercept (12,7%), con una distribuci\u00f3n muy similar por \nf\u00e1rmaco respecto a la utilizaci\u00f3n de los BS.\nCONCLUSIONES\nLa introducci\u00f3n de FAR-IMID biosimilares en los pacientes na\u00efve ha sido \u00e1gil, mientras que en los pacientes con \ntratamientos ya instaurados ha sido m\u00e1s lenta y existe mayor variabilidad entre hospitales.  154Ambos indicadores son una herramienta \u00fatil para conocer el patr\u00f3n de introducci\u00f3n de los BS en enfermedades IMID y su \nevoluci\u00f3n. Adem\u00e1s, su seguimiento peri\u00f3dico ayuda a fomentar la utilizaci\u00f3n de los medicamentos BS en la CA y pueden \nser un modelo a seguir para su evaluaci\u00f3n en otras patolog\u00edas.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n795. UTILIZACI\u00d3N DE PSICOF\u00c1RMACOS EN CONDICIONES OFF-LABEL EN UNA UNIDAD DE PSIQUIATR\u00cdA \nINFANTO-JUVENIL \nAUTORES\nAG\u00dc\u00cd CALLEJAS, AM; POZAS DEL R\u00cdO, MT; GONZ\u00c1LEZ ANDR\u00c9S, D; ECH\u00c1VARRI DE MIGUEL, M; RIVA DE LA HOZ, B; \nRANZ ORTEGA, P; PINILLA LEBRERO, G; ARRIETA LOITEGUI, M\nHOSPITAL INFANTIL UNIVERSITARIO NI\u00d1O JESUS. AV . MEN\u00c9NDEZ PELAYO, 65 MADRID. MADRID\nOBJETIVOS\nAnalizar la prevalencia y el perfil de la utilizaci\u00f3n de psicof\u00e1rmacos en condiciones no autorizadas (off-label) en ni\u00f1os y \nadolescentes ingresados en una unidad de psiquiatr\u00eda infanto-juvenil.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo de tres meses de duraci\u00f3n (1 de enero a 31 de marzo de 2022). Se \nincluyeron pacientes de entre 0-18 a\u00f1os de edad ingresados en una unidad de psiquiatr\u00eda infanto-juvenil de 31 camas. Se \nevalu\u00f3 la prescripci\u00f3n de los f\u00e1rmacos pertenecientes a los grupos terap\u00e9uticos N05 y N06 del Sistema de Clasificaci\u00f3n \nAnat\u00f3mica, Terap\u00e9utica y Qu\u00edmica (ATC). El uso off-label fue definido como cualquier uso de un f\u00e1rmaco comercializado \ny no detallado en ficha t\u00e9cnica (FT) seg\u00fan indicaci\u00f3n, grupo de edad o ambos. Se consider\u00f3 como prescripci\u00f3n a toda \naquella introducci\u00f3n o cambio de presentaci\u00f3n comercial que suponga un cambio de principio activo, dosis o v\u00eda de \nadministraci\u00f3n\ufffd  \nLas variables recogidas fueron: edad, sexo, diagn\u00f3stico psiqui\u00e1trico principal y diagn\u00f3sticos secundarios. Para cada \nf\u00e1rmaco, se recopil\u00f3 la informaci\u00f3n de indicaci\u00f3n terap\u00e9utica y empleo en poblaci\u00f3n pedi\u00e1trica recogida en la FT \nautorizada por la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. El tratamiento de los datos recogidos se \nrealiz\u00f3 a trav\u00e9s del paquete inform\u00e1tico Microsoft Excel.\nRESULTADOS\nSe analizaron un total de 166 pacientes, siendo 2 de cada 10, hombres, y el resto, mujeres. Se contabilizaron 149 ingresos \ny 2.353 estancias. La media de edad de los pacientes fue de 14,4 a\u00f1os (intervalo: 7-18 a\u00f1os). Se analizaron un total de \n612 prescripciones que implicaron 29 principios activos diferentes. \nCada paciente recibi\u00f3 una media de 3,7 prescripciones de psicof\u00e1rmacos. El 86% de los pacientes tuvieron al menos una \nprescripci\u00f3n off-label. Se encontraron 295 prescripciones de psicof\u00e1rmacos (48.2%) en condiciones off-label: el 22% (65) \npor indicaci\u00f3n diferente a la aprobada, el 38% (112) por edad y el 40% (118) por ambas categor\u00edas.  \nLos grupos terap\u00e9uticos de la clasificaci\u00f3n ATC con mayor n\u00famero de prescripciones fuera de FT fueron, en orden \ndecreciente, N05C (Hipn\u00f3ticos y sedantes) con un 100% (64) de sus prescripciones off-label, N06A (Antidepresivos) y \nN05A (Antipsic\u00f3ticos) con un 78% (41) y 71% (185), respectivamente, y N05B (Ansiol\u00edticos) con un 3% (5).  \nDe entre los 10 principios activos con mayor n\u00famero de prescripciones, todas las correspondientes a olanzapina, \nmelatonina, y lormetazepam se realizaron en condiciones no autorizadas, mientras que todas las correspondientes a \nlorazepam, diazepam y clorazepato dipot\u00e1sico se encontraron dentro de las especificaciones de FT. Risperidona tuvo el \n78% (36) de sus prescripciones off-label, seguido de aripiprazol con un 71% (17), fluoxetina con un 7% (4) y finalmente \nsertralina con un 6% (4).\nCONCLUSIONES\nEste an\u00e1lisis preliminar permite documentar la situaci\u00f3n de utilizaci\u00f3n de psicof\u00e1rmacos en pediatr\u00eda y evidenciar el \namplio uso en la pr\u00e1ctica cl\u00ednica de psicof\u00e1rmacos en condiciones off-label.  \nLa prescripci\u00f3n de psicof\u00e1rmacos en condiciones no autorizadas se distribuye de forma heterog\u00e9nea entre los principios \nactivos de los grupos terap\u00e9uticos N05 y N06 de la clasificaci\u00f3n ATC, siendo los principios activos del grupo N05C \n(Hipn\u00f3ticos y sedantes) los que m\u00e1s prescripciones off-label re\u00fanen.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n818. OPTIMIZACI\u00d3N DEL TRATAMIENTO DE PACIENTES CON ARTRITIS REUMATOIDE \nAUTORES\nG\u00d3MEZ G\u00d3MEZ, D; COL\u00d3N L\u00d3PEZ DE DICASTILLO, A; AYESTAR\u00c1N GONZ\u00c1LEZ, MB; BLANCO ALONSO, R; AURRECOECHEA \nAGUINAGA, E; MATA ARN\u00c1IZ, MC; VALERO DOM\u00cdNGUEZ, M; PARRA ALONSO, EC\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nImplantar y monitorizar una estrategia de optimizaci\u00f3n de f\u00e1rmacos modificadores de la enfermedad (FAME) biol\u00f3gicos y \nsint\u00e9ticos dirigidos en pacientes con artritis reumatoide (AR).\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico y prospectivo, en 3 hospitales p\u00fablicos de nuestra regi\u00f3n, que incluy\u00f3 a todos los pacientes con \nAR en tratamiento con FAME biol\u00f3gicos o sint\u00e9ticos dirigidos. Previo a la implantaci\u00f3n de la estrategia se elabor\u00f3 un \nprotocolo multidisciplinar en el que se definieron criterios de remisi\u00f3n cl\u00ednica, tiempo m\u00ednimo de mantenimiento de 155remisi\u00f3n cl\u00ednica para el inicio de la optimizaci\u00f3n y las pautas posol\u00f3gicas de optimizaci\u00f3n para cada f\u00e1rmaco.  \nEl per\u00edodo de seguimiento comprendi\u00f3 6 meses (jun/21-dic/21). Los datos se extrajeron del programa de prescripci\u00f3n \nelectr\u00f3nica asistida y de la historia cl\u00ednica e incluyeron centro, medicamento, posolog\u00eda y motivos de cambios posol\u00f3gicos. \nAdem\u00e1s, para cada f\u00e1rmaco, se estableci\u00f3 como comparador la pauta posol\u00f3gica est\u00e1ndar seg\u00fan ficha t\u00e9cnica y el coste \nunitario\ufffd  \nAl inicio del estudio, y con periodicidad trimestral, se obtuvieron el n\u00famero de pacientes en tratamiento, optimizados \ne intensificados para cada f\u00e1rmaco para calcular el porcentaje de optimizaci\u00f3n e intensificaci\u00f3n de cada medicamento \nrespecto a la pauta indicada en ficha t\u00e9cnica. A partir del coste unitario de cada medicamento, se calcul\u00f3 tambi\u00e9n el coste \nanual te\u00f3rico de los tratamientos y el coste anual real teniendo en cuenta la pauta posol\u00f3gica de cada paciente\ufffd\nRESULTADOS\nSe incluyeron 14 medicamentos utilizados en AR, seg\u00fan protocolo de uso corporativo, con un total de 738 pacientes en \ntratamiento durante esos 6 meses\ufffd  \nTras comenzar con la estrategia, el porcentaje de pacientes optimizados evolucion\u00f3 de un 18,8% (basal) a un 23,1% (mes \n3) y a un 25,2% (mes 6) mientras que el porcentaje de pacientes intensificados disminuy\u00f3 de un 1,2% (basal) a un 1% \n(mes 3) y a un 0,5% (mes 6). A nivel de costes, con la implementaci\u00f3n de esta estrategia, se pas\u00f3 de unos ahorros te\u00f3ricos \nanuales de 538.810\u20ac (basal) a 652.510\u20ac (mes 6), lo que en t\u00e9rminos relativos ser\u00eda pasar de un 9,4% de ahorro anual \n(basal) a un 10,82% en el mes 3 (mejora de 83.828\u20ac respecto al basal) y a un 11,77% en el mes 6 (mejora de 29.872\u20ac \nrespecto al mes 3 y de 113.700\u20ac respecto al basal).  \nLos f\u00e1rmacos con mayor porcentaje de pacientes optimizados, a los 6 meses de comenzar la estrategia, fueron \nadalimumab original (52,2%), etanercept original (46,4%) y tocilizumab subcut\u00e1neo (41,4%) mientras que los f\u00e1rmacos \nque mayor evoluci\u00f3n obtuvieron, desde los valores basales a los de los 6 meses, fueron adalimumab original (incremento \nde un 16,8%), adalimumab biosimilar (incremento de un 15,2%) y etanercept original (incremento de un 11,5%).\nCONCLUSIONES\nLa implantaci\u00f3n de una estrategia de optimizaci\u00f3n en AR ha demostrado, en nuestra regi\u00f3n, ser una medida efectiva que \nha permitido aumentar el n\u00famero de pacientes que se mantienen en remisi\u00f3n cl\u00ednica a un coste de tratamiento menor. \nUn protocolo cl\u00ednico y una monitorizaci\u00f3n peri\u00f3dica bajo objetivos son claves para el \u00e9xito de la estrategia. Los f\u00e1rmacos \nde mayor experiencia de uso son los que acumulan mayor porcentaje de optimizaci\u00f3n\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n819. EXPERIENCIA DE USO CON DUPILUMAB: EFECTIVIDAD, SEGURIDAD Y ADHERENCIA \nAUTORES\nGARRETA BENTANACHS, C; GALOFR\u00c9 MESTRE, L; L\u00d3PEZ GARCIA, B; DEL ESTAL JIMENEZ, J; S\u00c1NCHEZ DORREGO, L; \nESTEBAN GONZ\u00c1LEZ, C; G\u00d3MEZ VALENT , M; GONZ\u00c1LEZ VALDIVIESO, J\nHOSPITAL UNIVERSITARI SAGRAT COR \ufffd VILADOMAT , 288 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEvaluar la efectividad, seguridad y adherencia de dupilumab tras un a\u00f1o de tratamiento en pacientes adultos \ndiagnosticados de dermatitis at\u00f3pica grave (DAG) que hab\u00edan fracasado previamente al tratamiento convencional.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y multic\u00e9ntrico, llevado a cabo en dos hospitales de segundo nivel. Se incluyeron \ntodos los pacientes adultos diagnosticados de DAG tratados con dupilumab durante 52 semanas. Los criterios de inicio de \ntratamiento fueron: no respuesta al tratamiento t\u00f3pico (TT) convencional (corticoides e inmunosupresores) y ciclosporina \noral (CO) o contraindicaci\u00f3n, definido como un valor en escalas EASI (Eczema Area and Severity Index) \u226521, PGA (Physician \nGlobal Assessment) \u22653 y BSA (Body Superficial Area) \u226510%. \nLas variables principales de efectividad fueron alcanzar el EASI-50, (reducci\u00f3n del 50% del EASI basal), y una disminuci\u00f3n \n\u22652 puntos en escala PGA, ambos en la semana 16 y mantenido hasta la 52.  \nSe recogieron variables de la historia cl\u00ednica y del m\u00f3dulo de dispensaci\u00f3n a pacientes externos: sexo, edad, tratamientos \nprevios, EASI, PGA al inicio a las 16, 24 y 52 semanas de tratamiento, tratamientos concomitantes y reacciones adversas\ufffd \nAdem\u00e1s, se recogi\u00f3 el porcentaje de adherencia al tratamiento seg\u00fan los registros de dispensaci\u00f3n del servicio de \natenci\u00f3n a pacientes externos\ufffd\nRESULTADOS\nSe incluyeron 17 pacientes (53% hombres) con una media de edad de 46 a\u00f1os (SD 16), de los cuales s\u00f3lo 1 no complet\u00f3 \nlas 52 semanas de tratamiento. El 100% de los pacientes hab\u00eda recibido previamente TT, un 65% corticoides sist\u00e9micos, un \n59% fototerapia, un 94% CO, un 65% metotrexato, un 24% azatioprina y un 12% omalizumab, fracasando al tratamiento \nen todos los casos\ufffd  \nLos par\u00e1metros medios al iniciar dupilumab eran EASI 26 (SD 5,5) y PGA 4 (SD 0).  \nEn la semana 16, el 100% de los pacientes alcanz\u00f3 el EASI-50 (un 35,3% logr\u00f3 un EASI-75 y el 47% un EASI-90), y el 100% \nde los pacientes logr\u00f3 una disminuci\u00f3n de PGA \u22652. Respecto a la semana 52, el 100% mantuvo un EASI-50 (un 68,75% \nconsigui\u00f3 un EASI-90), y se mantuvo en el 100% de los pacientes la disminuci\u00f3n de PGA \u22652.  \nSe produjeron reacciones adversas de tipo oft\u00e1lmico en el 53% de los pacientes (6 presentaron conjuntivitis, 2 irritaci\u00f3n \nocular y 1 prurito). Presentaron fiebre 2 pacientes, 2 astenia, 2 diarrea, y se report\u00f3 1 caso de n\u00e1useas, fotosensibilidad, \nherpes, flushing facial/escote y reacci\u00f3n local en la zona de administraci\u00f3n. Un paciente tuvo que suspender el \ntratamiento en la semana 37 por afectaci\u00f3n oft\u00e1lmica grave. La adherencia al tratamiento fue del 100% en todos los \npacientes\ufffd156CONCLUSIONES\nLos datos obtenidos muestran que Dupilumab es efectivo en todos los pacientes con formas graves de dermatitis at\u00f3pica \nrefractaria a tratamiento previo convencional, acorde a los datos de los estudios publicados\ufffd  \nSe considera un f\u00e1rmaco seguro y bien tolerado, aunque la afectaci\u00f3n oft\u00e1lmica es frecuente, tal y como est\u00e1 descrito en \nlos ensayos\ufffd  \nAdem\u00e1s, los pacientes mostraron excelente adherencia al tratamiento.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n823. PERSISTENCIA DEL TRATAMIENTO CON BIOSIMILARES TRAS EL SWITCH DEL F\u00c1RMACO ORIGINAL \nAUTORES\nS\u00c1NCHEZ DORREGO, L; GALOFR\u00c9 MESTRE, L; SEGU\u00cd SOLANES, C; SOSA PONS, A; DE TEMPLE PLA, M; MONTOLIU \nALC\u00d3N, P; RUDI SOLA, N; GONZ\u00c1LEZ VALDIVIESO, J\nHOSPITAL UNIVERSITARI SAGRAT COR \ufffd VILADOMAT , 288 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEvaluar la persistencia y los motivos de finalizaci\u00f3n de tratamiento con adalimumab y etanercept biosimilar (AB y EB) tras \nrealizar el switch del f\u00e1rmaco original (FO) en pacientes con enfermedades inmunomediadas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y multic\u00e9ntrico llevado a cabo en dos centros de segundo nivel. Se incluyeron \ntodos los pacientes en tratamiento activo con adalimumab original (AO) y etanercept original (EO) entre marzo 2019 y \ndiciembre 2021, a los que se realiz\u00f3 switch al f\u00e1rmaco biosimilar (FB) correspondiente. Se hizo seguimiento durante al \nmenos 6 meses\ufffd \n \nLas variables registradas fueron: sexo, edad, FO, tiempo de tratamiento con el FO previo switch, FB, efectos adversos, \nduraci\u00f3n del tratamiento con el FB, y servicio referente. Todos los datos se obtuvieron a partir de la historia cl\u00ednica de \npacientes y del programa de dispensaci\u00f3n de la unidad de atenci\u00f3n farmac\u00e9utica a pacientes externos. La persistencia \nse estim\u00f3 midiendo la duraci\u00f3n de tiempo desde el inicio del FB hasta la interrupci\u00f3n o fin del seguimiento (entre 6 y 35 \nmeses). Se registr\u00f3 el motivo de la interrupci\u00f3n (falta de efectividad o respuesta, intolerancia o efectos adversos), si se \nreiniciaba el FO de nuevo, la fecha del cambio, y la persistencia de \u00e9ste durante al menos 6 meses.\nRESULTADOS\nSe incluyeron un total de 83 pacientes, un 54% hombres, con una media de edad de 53,6 a\u00f1os (SD 17,7). El 53% \ndiagnosticados de patolog\u00eda inmunomediada dermatol\u00f3gica, el 33% reumatol\u00f3gica y el 14% digestiva. \n \nLa duraci\u00f3n media del tratamiento con el FO previo switch fue de 5 a\u00f1os (SD 2,5). El 66% (n=55) de los pacientes \nsiguieron en tratamiento con el FB post switch, con una media de 20 meses (SD 8), pero un 34% (n=28) interrumpieron \nel tratamiento con el FB a los 9 meses de media (SD 6,5) tras el switch. Los motivos fueron 19% por inefectividad o no \nrespuesta al FB, 6% por fallo secundario, y un 8% por intolerancia o reacciones adversas. El 54% de estos pacientes que \ninterrumpieron el FB ten\u00edan patolog\u00eda dermatol\u00f3gica. \n \nDe los 16 pacientes con ineficacia o no respuesta al FB, se reinici\u00f3 tratamiento con el FO en el 81,3%, y el 100% de \n\u00e9stos contin\u00faan desde entonces con el tratamiento (m\u00e1s de 6 meses) y se mantienen estables con su patolog\u00eda de base \ncontrolada\ufffd  \n \nLas reacciones adversas registradas con los FB fueron: un caso de lesiones d\u00e9rmicas, dos de dolor/rigidez articular, y uno \nde cefalea\ufffd\nCONCLUSIONES\nTras el cambio del FO al FB la mayor\u00eda de pacientes se mantienen estables, aunque existe un riesgo de p\u00e9rdida de \nefectividad, intolerancia o aparici\u00f3n de efectos adversos, mayoritariamente en el grupo de pacientes con patolog\u00eda \ndermatol\u00f3gica. En todos los casos en los que se reinici\u00f3 el FO por ineficacia, s\u00e9 volvi\u00f3 a controlar la enfermedad. En estos \ncasos debe valorarse tambi\u00e9n un posible efecto nocebo.  \n \nNo se reportaron efectos secundarios graves con los FB, por lo que se considera seguro el switch.  \n \nPor su contribuci\u00f3n a la sostenibilidad del sistema sanitario, el switch a FB de etanercept y adalimumab debe valorarse.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n854. EFECTIVIDAD, SEGURIDAD Y ADHERENCIA DE DUPILUMAB EN PACIENTES CON DERMATITIS \nAT\u00d3PICA MODERADA-GRAVE EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL \nAUTORES\nLOSA L\u00d3PEZ, L; VIDAL SARRO, D; PUEBLA VILLAESCUSA, A; MURGADELLA SANCHO, A; GRACIA GARCIA, B; HIDALGO \nALBERT , E\nHOSPITAL DE SANT JOAN DESPI MOISES BROGGI. AVENIDA JACINT VERDAGUER 90 SANT JOAN DESP\u00cd. BARCELONA157OBJETIVOS\nEvaluar la efectividad, seguridad y adherencia del tratamiento con dupilumab en pacientes con dermatitis at\u00f3pica (DA) \nmoderada-grave en la pr\u00e1ctica cl\u00ednica.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional de pacientes con DA moderada-grave tratados con dupilumab en un hospital de \nsegundo nivel entre marzo del 2020 y diciembre del 2021. \nLos pacientes que iniciaron dupilumab cumplieron los siguientes criterios: EASI\u226521 (Eczema Areas and Severity Index), \nPGA\u22653 (Physician\u2019s Global Assesment), BSA\u226510 (Body Surface Area), DLQI\u226510 (Dermatology Life Quality Index) y NRS del \nprurito\u22655 (Numerical Rating Scale).  \nLas variables analizadas fueron las variables demogr\u00e1ficas y farmacoterap\u00e9uticas: edad, sexo, posolog\u00eda, tratamientos \nprevios; variables cl\u00ednicas: EASI-50, EASI-75, EASI-90 y porcentaje de reducci\u00f3n \u2265 2 puntos en el PGA en semana 16, 24 y \n52 respecto al inicio de tratamiento; variable de seguridad: efectos adversos (EA) reportados por el paciente; variable de \nadherencia: grado de adherencia valorado seg\u00fan registros de dispensaci\u00f3n ambulatoria.  \nLos datos se recopilaron de las historias cl\u00ednicas informatizadas y se analizaron con Excel.\nRESULTADOS\n-Muestra: 22 pacientes, 55% hombres, edad media: 39 (18-74).  \n-Posolog\u00eda de dupilumab: 600 mg seguido de 300 mg cada 2 semanas por v\u00eda subcut\u00e1nea. En 2 pacientes se optimiz\u00f3 el \ntratamiento a 300 mg cada 3 semanas\ufffd  \n-Tratamientos previos: corticoides orales (100%), ciclosporina (82%), fototerapia (50%), metotrexato (27%) y micofenolato \n(5%).  \n- Efectividad: 100% de los pacientes alcanzaron EASI-50 y el 100% obtuvieron una reducci\u00f3n de \u2265 2 puntos en la \nescala PGA. 59% alcanzaron el EASI-75 en semana 16 (n=22), 90% en la semana 24 (n=20) y semana 52 (n=11) y 50% \nconsiguieron el EASI-90 en semana 16 (n=22), 72% en la semana 24 (n=20) y 90% en semana 52 (n=11). \n- EA: sequedad ocular (23%), dolor leve en la zona de inyecci\u00f3n (14%), enrojecimiento ocular (9%), conjuntivitis (9%) y \nblefaritis (4%).  \n-Adherencia: 21 pacientes presentaron \u2265 90% de adherencia y en 1 paciente fue del 87%. La mediana de adherencia en \nlas dispensaciones de farmacia fue del 98%\ufffd  \nNo se produjo discontinuaci\u00f3n del tratamiento en ning\u00fan paciente.\nCONCLUSIONES\nEn nuestro estudio duplimab result\u00f3 ser efectivo en pacientes con dermatitis at\u00f3pica moderada-grave en la pr\u00e1ctica \ncl\u00ednica, permitiendo la utilizaci\u00f3n de una pauta optimizada una vez alcanzada la estabilidad cl\u00ednica.  \nSe considera un f\u00e1rmaco seguro y bien tolerado ya que los efectos adversos a nivel de la zona de inyecci\u00f3n y oculares no \nsupusieron en ning\u00fan caso una suspensi\u00f3n del tratamiento.  \nTodos los pacientes contin\u00faan en tratamiento y mantienen una buena adherencia.  \nSon necesarios estudios de persistencia con mayor n\u00famero de pacientes para confirmar los resultados obtenidos.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n863. PERSISTENCIA Y MOTIVOS DE CAMBIO DE F\u00c1RMACOS BIOL\u00d3GICOS E INHIBIDORES DE JANUS \nQUINASAS EN PACIENTES CON ARTRITIS REUMATOIDE. \nAUTORES\nORTEGA ARMI\u00d1ANA, AM; SANCHO ART\u00c9S, A; S\u00c1NCHEZ ALCARAZ, A; SARRI\u00d3 MONT\u00c9S, G; VALCUENDE ROSIQUE, A; \nCOLOM MORENO, RM; CEBRI\u00c1N LARA, L; PELUFO PELLICER, A\nHOSPITAL UNIVERSITARIO DE LA RIBERA \ufffd CRTRA CORBERA, KM \ufffd 1 ALZIRA \ufffd VALENCIA\nOBJETIVOS\nEvaluar la persistencia y los motivos de cambio de tratamiento de los f\u00e1rmacos antirreum\u00e1ticos modificadores de \nla enfermedad biol\u00f3gicos, inhibidores de TNF alfa (FAMEb iTNF), inhibidores de Janus quinasas (iJAK) y otros FAME \nbiol\u00f3gicos no iTNF (FAMEb no iTNF) en pacientes con artritis reumatoide (AR).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital comarcal. Se incluyeron pacientes con diagn\u00f3stico de AR, que \niniciaron tratamiento con un FAMEb o un iJAK entre enero-2020 y diciembre-2021, con seguimiento hasta abril-2022. Se \nregistraron variables demogr\u00e1ficas (edad, sexo), cl\u00ednicas (diagn\u00f3stico) y del tratamiento (tipo de FAME (iTNF, FAMEb no \niTNF o iJAK), l\u00ednea de tratamiento (1\u00aa vs sucesiva), fecha inicio y fin y motivo de fin (fallo 1\u00ba, fallo 2\u00ba, reacci\u00f3n adversa y \notro)). Los c\u00e1lculos estad\u00edsticos se realizaron con Stata 14.2. Las variables categ\u00f3ricas se expresaron como frecuencias \n(%) y las cuantitativas como media (IC95%) o mediana (RIQ). Se determin\u00f3 la tasa de persistencia a 6 y 12 meses y \ntasa de discontinuaci\u00f3n seg\u00fan motivo de fin. Se realiz\u00f3 un an\u00e1lisis de supervivencia (Kaplan-Meier) para determinar la \npersistencia mediana del tratamiento y se aplic\u00f3 log-rank test para valorar la significaci\u00f3n de las diferencias en funci\u00f3n del \ntipo de FAME, la l\u00ednea de tratamiento, la edad y el sexo.\nRESULTADOS\nSe incluyeron 100 pacientes (78% mujeres), con edad media de 56,2 a\u00f1os (IC95% 53,9-58,5). Se registraron un total de \n146 l\u00edneas de tratamiento, el 41% 1\u00aa l\u00ednea (85% iTNF). El 47% de los tratamientos fueron iTNF, 31% iJAK y 22% FAMEb no \niTNF. La mediana de tiempo de seguimiento fue de 15,3 meses (14,1-16,4). Las tasas de persistencia global a 6 y 12 meses 158fueron del 66,7% (58,4-74,9) y 54,6% (44,2-64,8), respectivamente. La mediana de persistencia fue de 13,3 meses (9,3-\nNA). Los motivos de finalizaci\u00f3n del tratamiento fueron: 52% fallo 1\u00ba (47% iTNF), 16% fallo 2\u00ba (46% iTNF), 24% reacci\u00f3n \nadversa (37% FAMEb no iTNF) y 8% por otros motivos (47% iTNF). Seg\u00fan tipo de FAME, la persistencia mediana fue de \n13,3 meses (8,5-NA) con iTNF, 10,2 meses (4,7-NA) con FAMEb no iTNF y no se alcanz\u00f3 con iJAK. No se encontraron \ndiferencias estad\u00edsticamente significativas entre ellos (iJAK vs iTNF p=0,53; iTNF vs otro FAMEb p=0,47; iJAK vs otro FAMEb \np=0,22). La persistencia fue similar independientemente de la l\u00ednea de tratamiento (1\u00aaL 13,3 meses (8,4-NA) vs sucesiva \n14,7 meses (8,7-NA), p=0,95). Tampoco se encontraron diferencias significativas en funci\u00f3n de la edad o el sexo (p > 0,05).\nCONCLUSIONES\nLa persistencia mediana del tratamiento con FAMEb o iJAK en pacientes con AR es de 13,3 meses, sin hallar diferencias \nsignificativas en funci\u00f3n del tipo de FAME, la l\u00ednea de tratamiento, la edad o el sexo.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n871. IMPACTO DEL TRABAJO MULTIDISCIPLINAR EN LA ADECUACI\u00d3N DEL USO DE BENZODIACEPINAS \nEN UN CENTRO PENITENCIARIO \nAUTORES\nGARC\u00cdA RODICIO, S; ABDO , IJ; MARISCOT BAS, C; RAVETLLAT ADELL, N; SOLE CARBO, C; P\u00c9REZ PLASENCIA, A; \nSACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nEl primer periodo de confinamiento por COVID-19 supuso un aumento en el uso de benzodiacepinas (bzd) en un Centro \nPenitenciario (CP).  \nEl presente trabajo tiene por objetivo analizar el impacto del trabajo multidisciplinar realizado en el centro durante dos \na\u00f1os para la optimizaci\u00f3n del uso de bzd.\nMATERIALES Y M\u00c9TODOS\nEstudio longitudinal de 24 meses de duraci\u00f3n. Realizaci\u00f3n de 9 cortes transversales (inicio y cada 3 meses) a partir de \nabril de 2020\ufffd  \nEl impacto de la intervenci\u00f3n se cuantific\u00f3 con 4 indicadores principales: % de internos con bzd, % internos con dosis \nsupraterap\u00e9uticas, % internos con 2 bzd y % internos con 3 o m\u00e1s bzd.  \nAs\u00ed, en cada corte se identificaron los pacientes en tratamiento con alprazolam, clorazepato dipot\u00e1sico, clonazepam, \ndiazepam, lorazepam o lormetazeptam, y se recogi\u00f3: n\u00famero total de pacientes tratados, aquellos con dosis \nsupraterap\u00e9uticas (seg\u00fan ficha t\u00e9cnica, excepto en el clorazepato dipot\u00e1sico que se estableci\u00f3 150 mg como dosis \nm\u00e1xima) y las asociaciaciones de benzodiazepinas. Paralelamente se registr\u00f3 el n\u00famero de internos con antipsic\u00f3ticos.  \nA lo largo de todo el periodo de estudio, el equipo m\u00e9dico y el equipo de Salud Mental fueron informados por la \nfarmac\u00e9utica de la evoluci\u00f3n de los datos. Adem\u00e1s, se realizaron cuatro sesiones cl\u00ednicas, una sesi\u00f3n formativa a los \ninternos en el m\u00f3dulo con mayor utilizaci\u00f3n de benzodiacepinas, y sesiones psicoeducativas individualizadas tanto por el \npersonal medico como por la psic\u00f3loga del centro de adicciones\ufffd\nRESULTADOS\nEn abril de 2020 se identificaron 296 pacientes en tratamiento con bzd (40,7% de la poblaci\u00f3n reclusa), 87 con dosis \nsupraterap\u00e9tucas (29,4% de los tratados), 50 con 2 benzodiazepinas (17%) y 0,7% con 3 benzodiacepinas. Los resultados \nobtenidos en los 8 cortes posteriores fueron:  \n-% internos con bzd: 40,6%, 39,0%, 36,3%, 35,5%, 37,2%, 34,3%, 35,0%, 31,8%.  \n-% internos con dosis supraterap\u00e9uticas: 27,7%, 25,7%, 17,9%, 14,1%, 12,5%, 10,0 %, 11,5%, 11,4%.  \n-% internos con 2 bzd: 16,3%, 13,4%, 11,6%, 9,2%, 9,7%, 7,7%, 6,9%, 7,4%.  \n-% internos con 3 bzd: 0,7%, 0,7%, 0,4%, 0%, 0%, 0%, 0,5%,0%.  \nEl % de intenos con antipsic\u00f3ticos en los 9 cortes fue: 26,8%, 26,1%, 25,2%, 26,8%, 26%, 24,1%, 28,1%, 28,8%, 28,3%.\nCONCLUSIONES\nEl trabajo multidisciplinar permite optimizar la utilizaci\u00f3n de bzd en un CP . A lo largo de los dos a\u00f1os de seguimiento \nhan disminuido de forma significativa los internos con benzodiacepinas, los internos con dosis supraterap\u00e9uticas y las \nasociaciones de benzodiacepinas. Se observa un aumento del uso de antipsic\u00f3ticos, que tendr\u00e1 que ser analizado con \nmayor profundidad\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n902. PERSISTENCIA Y SEGURIDAD DE LOS INHIBIDORES DE LA QUINASA JANUS EN ARTRITIS REUMATOIDE \nAUTORES\nP\u00c9REZ MART\u00cdN, CY; GONZ\u00c1LEZ CH\u00c1VEZ, J; SU\u00c1REZ GONZ\u00c1LEZ, M; D\u00cdAZ RUIZ, P; \u00c1LVAREZ TOSCO, KI; JOY CARMONA, \nP; MART\u00cdN L\u00d3PEZ, A\nCOMPLEJO HOSPITAL UNIVERSITARIO NTRA SRA DE CANDELARIA. CTRA. DEL ROSARIO, 145 SANTA CRUZ DE \nTENERIFE \ufffd SANTA CRUZ DE TENERIFE159OBJETIVOS\nEvaluar la persistencia y seguridad de los tratamientos con los inhibidores de la quinasa janus (JAKi) en pacientes con \nartritis reumatoide teniendo en cuenta el uso de f\u00e1rmacos modificadores de la enfermedad (FAME) concomitantes y \nFAME biol\u00f3gicos (FAMEb) previos. Analizar los motivos de la suspensi\u00f3n y las reacciones adversas encontradas durante el \nperiodo de estudio\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo donde se incluyeron pacientes con artritis reumatoide (AR) tratados con JAKi desde \ndiciembre de 2017 hasta abril de 2022 en un hospital de tercer nivel. Se excluyeron los pacientes que llevaban menos \nde 3 meses de tratamiento para el an\u00e1lisis de la persistencia. Variables: demogr\u00e1ficas (edad y sexo), factor reumatoide \n(FR), anticuerpos antip\u00e9ptidos c\u00edclicos citrulinados (anti-CPP), duraci\u00f3n del tratamiento de tofacitinib (TOF), baricitinib \n(BAR) y upadacitinib (UPA), suspensi\u00f3n y motivo, l\u00ednea de tratamiento (naive o FAME biol\u00f3gicos previos), tratamiento \nconcomitante con FAME convencionales (FAMEc) y reacciones adversas. Se realiz\u00f3 un an\u00e1lisis descriptivo inicial a trav\u00e9s \nde la media y mediana para la variable num\u00e9rica de la edad y el porcentaje (%) para las cualitativas. An\u00e1lisis estad\u00edstico \nrealizado con IBM SPSS/PC (versi\u00f3n 28.0).\nRESULTADOS\nSe incluyeron 37 pacientes con una media de edad de 52 a\u00f1os [22-78], siendo el 78,3% mujeres, 75% seropositivos para \nel FR y 56.7% con anti-CCP . La muestra estaba compuesta por 15 pacientes con TOF, 12 con BAR y 10 con UPA. El 60% de \nlos pacientes se encontraba en tratamiento concomitante con FAMEc\ufffd \nEl 58,8% (n=10) suspendieron por ineficacia, el 35,3% (n=6) por reacciones adversas, siendo en estos casos por \ninfecciones, y 1 paciente suspendi\u00f3 por perforaci\u00f3n gastrointestinal.  \nEn el an\u00e1lisis estad\u00edstico de Kaplan-Meier para los JAKi, observamos que el uso de estos f\u00e1rmacos en segunda l\u00ednea, \ndonde no se alcanz\u00f3 la mediana, se asocia a mayor persistencia del tratamiento frente al uso en tercera l\u00ednea (p=0,038) \ncon una mediana de 13 meses. Por otro lado, en el uso en cuarta l\u00ednea, con una mediana de 6 meses, tambi\u00e9n \nobservamos una duraci\u00f3n menor del tratamiento frente a los de segunda l\u00ednea (p=0,035).\nCONCLUSIONES\nEn nuestro hospital, los JAKi se emplean, salvo excepciones, tras fracaso a FAMEb previo. En este estudio se observ\u00f3, con \nla limitaci\u00f3n del tama\u00f1o muestral, que el uso de los JAKi en l\u00edneas tempranas de tratamiento en AR podr\u00eda mejorar la \npersistencia, siendo menor el fracaso terap\u00e9utico y su suspensi\u00f3n. La ineficacia fue la principal raz\u00f3n de la suspensi\u00f3n de \nlos tratamientos y el principal efecto adverso que compromet\u00eda la continuidad fueron las infecciones. En nuestra pr\u00e1ctica \ncl\u00ednica los JAKi parecen ser seguros y eficaces, pero se necesitan estudios a largo plazo y monitorizaci\u00f3n estrecha de \neventos adversos, al ser algunas de estas mol\u00e9culas de reciente incorporaci\u00f3n como UPA y tras las alertas de seguridad \nestablecidas para TOF \ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n936. EXPERIENCIA DE LA TERAPIA BIOL\u00d3GICA EN PACIENTES CON HIDRADENITIS SUPURATIVA \nAUTORES\nVALCARCE PARDEIRO, N; RODR\u00cdGUEZ RODR\u00cdGUEZ, A; L\u00d3PEZ SANDOMINGO, L; RODR\u00cdGUEZ PEN\u00cdN, I\nCOMPLEJO HOSPITALARIO ARQUITECTO MARCIDE-PROF . NOVOA SANTOS. CTRA. DE SAN PEDRO DE LEIXA, S/N \nFERROL \ufffd A CORU\u00d1A\nOBJETIVOS\nLa hidradenitis supurativa (HS) es una enfermedad cut\u00e1nea inflamatoria cr\u00f3nica, recurrente, que impacta en la calidad de \nvida de los pacientes. En los casos m\u00e1s graves se utilizan f\u00e1rmacos biol\u00f3gicos siendo adalimumab el \u00fanico autorizado. El \nobjetivo del estudio fue revisar el tratamiento biol\u00f3gico (TB) utilizado en pacientes diagnosticados de HS, su efectividad y \nseguridad\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo de todos los pacientes con HS y TB desde Julio/2015 hasta Marzo/2022 en un hospital de segundo \nnivel. De la historia cl\u00ednica electr\u00f3nica y del programa de dispensaci\u00f3n se obtuvieron: variables demogr\u00e1ficas, factores de \nriesgo, comorbilidades, localizaci\u00f3n, gravedad seg\u00fan estadio Hurley, adecuaci\u00f3n de la prescripci\u00f3n, respuesta terap\u00e9utica \nseg\u00fan evaluaci\u00f3n del cl\u00ednico (ausencia de lesiones, enfermedad leve, moderada o grave), seguridad y adherencia\nRESULTADOS\nIncluidos 17 pacientes (diez mujeres y siete hombres) con mediana de edad 46 a\u00f1os (RIQ: 16). Trece (76%) fumadores \nactivos, tres (18%) no fumadores y un ex-fumador. Al diagn\u00f3stico once (65%) eran obesos y seis (35%) ten\u00edan sobrepeso. \nSeis pacientes presentaban dislipemia, cuatro s\u00edndrome ansioso-depresivo, dos esquizofrenia, dos diabetes, uno VIH, \nuno proctitis ulcerosa y cinco ausencia de comorbilidades. La distribuci\u00f3n m\u00e1s frecuente en mujeres fue regiones axilar \n(70%), inguinal (70%) y submamaria (35%); en hombres regiones gl\u00fatea y perianal (86%). Se clasificaron en estadio III de \nHurley 15 pacientes (88%) y dos se categorizaron como HS grave. Previo al inicio de TB cuatro pacientes (23%) recibieron \nretinoides y todos recibieron antibi\u00f3ticos t\u00f3picos y sist\u00e9micos (doxiciclina; clindamicina + rifampicina). El motivo de inicio \nde TB fue la intolerancia a tratamiento antibi\u00f3tico, respuesta inadecuada a \u00e9ste o reca\u00eddas frecuentes tras suspenderlo. El \ntiempo medio desde el diagn\u00f3stico hasta el inicio de TB fue: ocho a\u00f1os (3 pacientes), cinco a\u00f1os (1), 2-3 a\u00f1os (7), un a\u00f1o \n(1), < 1 a\u00f1o (5). El primer biol\u00f3gico prescrito fue adalimumab en 16 pacientes (94%) e infliximab en uno (con respuesta \nsub\u00f3ptima y sustituido a los diez meses por adalimumab). Once pacientes (65%) continuaron con adalimumab (diez de \nellos con biosimilar), nueve con afectaci\u00f3n leve (81%) y dos (18%) sin datos de eficacia (inicios recientes). En seis casos 160(35%) se discontinu\u00f3 adalimumab [p\u00e9rdida de respuesta (3); ausencia de respuesta (2) y efectos adversos (1)] y se inici\u00f3 \nustekinumab (en segunda l\u00ednea, fuera de ficha t\u00e9cnica). Dos pacientes fracasaron a ustekinumab (uno inici\u00f3 secukinumab \ncon buena respuesta y otro estaba pendiente de iniciar). Tres pacientes mantuvieron la enfermedad en estadio leve y uno \nalcanz\u00f3 remisi\u00f3n de las lesiones. S\u00f3lo se registraron eventos adversos con adalimumab: psoriasis palmoplantar y reacci\u00f3n \nen el punto de inyecci\u00f3n (1); cefalea recurrente (1). Todos los pacientes excepto uno mantuvieron una adherencia al \ntratamiento del 95%\nCONCLUSIONES\nAdalimumab fue la primera opci\u00f3n de TB y consigui\u00f3 disminuir la gravedad en un elevado porcentaje de pacientes \naunque no se dispuso de una escala objetiva para medir la respuesta. Las segundas y terceras l\u00edneas utilizaron \nanticuerpos off-label. La falta de respuesta de un biol\u00f3gico no excluir\u00eda la eficacia potencial de otro. La TB fue una opci\u00f3n \nde tratamiento segura en pacientes con HS grave\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n954. PERSISTENCIA DE IXEKIZUMAB EN PACIENTES CON PSORIASIS, ARTRITIS PSORI\u00c1SICA Y \nESPONDILITIS ANQUILOSANTE \nAUTORES\nMART\u00cdNEZ MARCOS, JM; GARC\u00cdA LAGUNAR, MH; CONESA NICOLAS, E; ASENSI CANT\u00d3, A; FERN\u00c1NDEZ MART\u00cdNEZ, \nIM; GARC\u00cdA MATILLAS, CN\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nDeterminar la persistencia de ixekizumab utilizado en psoriasis, artritis psori\u00e1sica (AP) y espondilitis anquilosante (EA) en \nun hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de los pacientes con psoriasis, AP y EA tratados con ixekizumab desde marzo-2017 \nhasta mayo-2022. Las variables recogidas fueron: sexo, edad, diagn\u00f3stico, fecha de inicio, l\u00ednea de tratamiento, duraci\u00f3n \ndel mismo, n\u00famero de pacientes que han suspendido el tratamiento y motivo, persistencia global a los 12 meses \n(definida como meses de tratamiento ininterrumpido). Se excluyeron los pacientes que iniciaron el tratamiento en los \n\u00faltimos 12 meses.  \n \nLos datos se obtuvieron del programa de gesti\u00f3n farmacoterap\u00e9utica y de la historia cl\u00ednica electr\u00f3nica. El an\u00e1lisis \nestad\u00edstico se realiz\u00f3 con el programa SPSS Statistics\u00aev23.0.\nRESULTADOS\nHan sido tratados con ixekizumab 82 pacientes, de los que 64 llevaban en tratamiento 12 o m\u00e1s meses. La edad media \nfue 51,7+12,5 a\u00f1os. 36 eran hombres (56,3%). 45 pacientes (70,3%) presentaban psoriasis, 17 (26,6%) AP y 2 (3,1%) \nEA. 11 pacientes (17,2%) recibieron ixekizumab en primera l\u00ednea de tratamiento, 11 (17,2%) en segunda, 17 (26,6%) en \ntercera, 8 (12,4%) en cuarta y 17 (26,6%) en quinta o posterior. La duraci\u00f3n media del tratamiento es de 21,0\u00b116,9 meses \ncon una tasa de discontinuaci\u00f3n del 53,1%.  \n30 pacientes contin\u00faan el tratamiento con una duraci\u00f3n media de 32,9\u00b115,1 meses. 34 pacientes discontinuaron siendo \nla duraci\u00f3n 10,5\u00b110,0 meses\ufffd  \nDe los 34 pacientes que suspendieron el tratamiento, 8 (23,5%) lo hicieron por fallo primario (duraci\u00f3n media 4,6\u00b12,6 \nmeses) y 5 (14,7%) por fallo secundario (duraci\u00f3n media 20,6\u00b19,3 meses). El resto de discontinuaciones fueron por: \nventana terap\u00e9utica (11,8%,n=4), p\u00e9rdida de seguimiento (11,8%,n=4), mala adherencia (8,8%,n=3), cirug\u00eda (8,8%,n=3), \ninfecci\u00f3n (8,8%,n=3), reacci\u00f3n en la inyecci\u00f3n (5,9%,n=2), intento de embarazo (2,9%,n=1) y \u00e9xitus (2,9%,n=1). De \u00e9stos, \n9 pacientes han reiniciado posteriormente el tratamiento [cirug\u00eda(n=2), ventana terap\u00e9utica(n=2), mala adherencia(n=2), \nintento de embarazo(n=1), infecci\u00f3n(n=1), p\u00e9rdida de seguimiento(n=1)].  \nLa persistencia global a los 12 meses fue de 9,4\u00b13,8 meses con un 39,1% (n=25) de discontinuaciones.  \nLa persistencia por patolog\u00eda fue de 9,5\u00b13,6 meses en psoriasis; 9,2\u00b14,3 meses en AP y 8,0\u00b15,6 meses en EA sin \ndiferencias significativas (p=0,887).  \nLa persistencia por l\u00ednea de tratamiento fue 10,3\u00b12,8 meses en primera l\u00ednea; 9,7\u00b13,9 meses en segunda, 8,2\u00b13,7 meses \nen tercera; 10,6\u00b13,9 meses en cuarta y 9,3\u00b14,4 meses en quinta l\u00ednea o posteriores sin diferencias significativas (p=0,389).  \nLa persistencia de los pacientes con fallo primario fue 4,6\u00b12,6 meses y la de los pacientes con fallo secundario fue \n11,8\u00b10,4 meses\ufffd\nCONCLUSIONES\nLa mayor\u00eda de los pacientes tratados con ixekizumab padecen psoriasis y recibieron el tratamiento en tercera l\u00ednea o \nposterior \ufffd \nEl principal motivo de suspensi\u00f3n del mismo fue fallo primario seguido de fallo secundario.  \nNo se observaron diferencias significativas en la persistencia seg\u00fan patolog\u00eda y l\u00ednea de tratamiento.  \nSe necesitan estudios a largo plazo ya que la persistencia se podr\u00eda utilizar como criterio de decisi\u00f3n para posicionar \nixekizumab en el algoritmo terap\u00e9utico. Adem\u00e1s, ser\u00eda interesante realizar un estudio comparativo con f\u00e1rmacos que \ncomparten la misma diana (IL-17).161CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n956. FUNCIONES DE UNA COMISI\u00d3N DE ENFERMEDADES AUTOINMUNES DEL ADULTO Y EFECTO CL\u00cdNICO \nDE LOS TRATAMIENTOS AUTORIZADOS \nAUTORES\nFERN\u00c1NDEZ RUBIO, B; RODR\u00cdGUEZ RAMALLO, H; RODR\u00cdGUEZ P\u00c9REZ, A; GARC\u00cdA MORILLO, JS; LORA ESCOBAR, SJ; \nSANTOS RAMOS, B\nCOMPLEJO HOSPITALARIO REGIONAL VIRGEN DEL ROC\u00cdO. AV . MANUEL SIUROT , S/N SEVILLA. SEVILLA\nOBJETIVOS\nLas enfermedades inmunomediadas se caracterizan por su compleja etiolog\u00eda y abordaje y requieren de una intervenci\u00f3n \nmultidisciplinar. Se describe la actividad de una comisi\u00f3n de enfermedades autoinmunes del adulto (CEAA), as\u00ed como el \nefecto conseguido con los f\u00e1rmacos autorizados en la misma y su seguridad.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo y multidisciplinar realizado en un hospital de tercer nivel desde diciembre de 2020 a \nnoviembre de 2021\ufffd  \n \nLas funciones de la CEAA consistieron, por parte del m\u00e9dico solicitante, en la propuesta del f\u00e1rmaco a administrar en \nbase a la patolog\u00eda diagnosticada, a las caracter\u00edsticas individuales de cada paciente y a la evidencia cient\u00edfica disponible. \nA continuaci\u00f3n, el farmac\u00e9utico miembro de la comisi\u00f3n se encarg\u00f3 de la evaluaci\u00f3n cr\u00edtica de la evidencia asociada a \ntodos los f\u00e1rmacos solicitados y del establecimiento de un tiempo de seguimiento para comprobar la mejor\u00eda cl\u00ednica con \nel nuevo tratamiento seg\u00fan par\u00e1metros propios de la enfermedad en cuesti\u00f3n, para mantenerlo o modificarlo seg\u00fan \nresultados (efecto).  \n \nVariables recogidas: demogr\u00e1ficas (sexo y edad), patolog\u00eda, f\u00e1rmaco solicitado, tratamiento off label (s\u00ed/no), decisi\u00f3n \ntomada por la comisi\u00f3n, tiempo hasta la reevaluaci\u00f3n y consecuci\u00f3n del efecto cl\u00ednico (s\u00ed/no).  \n \nLos datos se recogieron de la historia cl\u00ednica y farmacoterap\u00e9utica (Diraya\u00ae) y del m\u00f3dulo de dispensaci\u00f3n individualizada \n(Athos Prisma\u00ae).\nRESULTADOS\n41 pacientes incluidos, 75,6% mujeres (n=31). La mediana de edad fue 49 (20-78) a\u00f1os.  \n \nLas patolog\u00edas diagnosticadas fueron uve\u00edtis (n=9), vasculitis (2 Takayasu, 1 Wegener, 1 poliangitis y 1 ANCA +), s\u00edndrome \nfebril peri\u00f3dico (2 Still, 1 fiebre mediterr\u00e1nea familiar, 1 s\u00edndrome peri\u00f3dico asociado a la criopirina y 1 fiebre de origen \ndesconocido), lupus (n=5), artritis \u00b1 psoriasis (n=4), hipertensi\u00f3n pulmonar arterial secundaria a esclerodermia (n=3), \nfibrosis pulmonar (n=2), miositis (n=2) y otras enfermedades raras de origen autoinmune (n=6).  \n \nLos f\u00e1rmacos solicitados fueron adalimumab (n=13), rituximab (n=8), otros inmunosupresores (n=5), anakinra (n=4), \nbelimumab (n=4), nintedanib (n=2), f\u00e1rmacos para la hipertensi\u00f3n pulmonar (n=3) y otros (n=2). El 63,4% de los \ntratamientos solicitados fueron off-label (n=26).  \n \nEn el 75,6% de los pacientes se aprob\u00f3 el tratamiento solicitado (n=31) y en el 24,4% restante (n=10), se propuso una \nalternativa terap\u00e9utica que fue consensuada en la comisi\u00f3n y autorizada. Los cambios fueron nintedanib por rituximab \n(n=2), belimumab por rituximab (n=2), rituximab por baricitinib (n=1) o por in fliximab (n=1), f\u00e1rmacos anti-interleucina-1 \npor ciclos de corticoides (n=1) o por metotrexato (n=1), tocilizumab por infliximab (n=1) y abatacept por inmunoglobulina \nG (n=1) . La mediana del tiempo de seguimiento propuesto fue de 3 (0,5-6) meses. \n \nEl 48,9% de los pacientes (n=20) presentaron efecto con el tratamiento, mientras que el 26,8% (n=11) restante, no. 7 \npacientes no llegaron a administrarse el tratamiento por diversas razones (17%), 2 no lo toleraron debido a reacciones \nadversas (4,9%) y 1 paciente fue exitus (2,4%).\nCONCLUSIONES\nDado el complejo abordaje de las enfermedades inmunomediadas, parece imprescindible la existencia de una comisi\u00f3n \nmultidisciplinar que asegure la administraci\u00f3n de la mejor terapia disponible y el seguimiento f\u00e1rmaco-cl\u00ednico del \npaciente. Adem\u00e1s, parece fundamental establecer, previo al inicio de las terapias autorizadas, par\u00e1metros de efectividad \ny tiempos de seguimiento adecuados para su reevaluaci\u00f3n.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n977. GRAVEDAD DE INFECCI\u00d3N POR SARS-COV2 E INFLUENCIA DE PSICOF\u00c1RMACOS EN POBLACI\u00d3N \nPSIQUI\u00c1TRICA \nAUTORES\nCOMELLA ANAYA, L; ECHEVERR\u00cdA ESNAL, D; DE ANTONIO CUSCO, M; ARDERIU FORMENT\u00cd, A; L\u00d3PEZ MULA, C; \nMIEDES ALIAGA, J; FERRANDEZ QUIRANTE, O; GRAU CERRATO, S\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA162OBJETIVOS\nLa pandemia SARS-CoV2 ha supuesto una crisis sanitaria, con m\u00e1s de 500 millones de casos seg\u00fan la John Hopkins \nUniversity. La informaci\u00f3n sobre el grado de afectaci\u00f3n en poblaci\u00f3n psiqui\u00e1trica es escasa. \nLos objetivos del estudio fueron describir la gravedad de los pacientes diagnosticados de SARS-CoV2 en un hospital \npsiqui\u00e1trico, y analizar una posible relaci\u00f3n entre la escala num\u00e9rica de gravedad de la OMS y los distintos grupos de \npsicof\u00e1rmacos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo, realizado en un centro monogr\u00e1fico de salud mental de 424 camas. Se \nseleccionaron pacientes ingresados y diagnosticados con infecci\u00f3n por SARS-CoV2 desde marzo hasta mayo de 2020. \nPar\u00e1metros registrados: demogr\u00e1ficos (edad, g\u00e9nero); patolog\u00eda psiqui\u00e1trica; \u00edndice de Charlson y comorbilidades; \nadquisici\u00f3n de la infecci\u00f3n (nosocomial/comunitaria); gravedad (escala num\u00e9rica de la OMS); sobreinfecci\u00f3n bacteriana \ny antibi\u00f3ticos; f\u00e1rmacos contra SARS-CoV2; psicof\u00e1rmacos prescritos para la patolog\u00eda psiqui\u00e1trica y mantenidos durante \nla infecci\u00f3n, clasificados seg\u00fan indicaci\u00f3n (depresi\u00f3n/ansiedad/psicosis/epilepsia/trastorno bipolar/Parkinson/Alzheimer/\nanticolin\u00e9rgico).  \nEstad\u00edstica: percentiles seg\u00fan escala num\u00e9rica de gravedad de la OMS; an\u00e1lisis Chi-cuadrado.\nRESULTADOS\nSe incluyeron un total de 49 pacientes, de los cuales 51% fueron varones, y 53,1% mayores de 65 a\u00f1os, con una edad \nmediana de 74 (57,0-81,5) a\u00f1os.  \nLas patolog\u00edas psiqui\u00e1tricas fueron: esquizofrenia (24,5%), demencia (20,4%), trastorno bipolar (4,1%), depresi\u00f3n mayor \n(8,2%) y deterioro cognitivo/funcional (20,4%).  \nLa puntuaci\u00f3n de Charlson media fue 4,082. El 20,4% presentaba asma o EPOC, el 57,1% hipertensi\u00f3n arterial o \ninsuficiencia card\u00edaca, y el 49% diabetes mellitus, dislipemia u obesidad.  \nEn el 77,6 % de los casos la infecci\u00f3n fue nosocomial, y comunitaria en el resto. Un 34% precis\u00f3 tratamiento antibi\u00f3tico \ny recibi\u00f3 al menos un f\u00e1rmaco de los considerados anti-SARS-CoV2 en el momento del estudio (lopinavir/ritonavir, \nhidroxicloroquina, azitromicina). No se diagnostic\u00f3 ninguna neumon\u00eda bilateral ni fue necesaria la derivaci\u00f3n a un hospital \nde agudos\ufffd  \nLos pacientes estudiados pertenecieron a una numeraci\u00f3n en la escala de OMS de 3 (71,4%, primer y segundo percentil), \n4 (24,5%, tercer percentil) y 8 (4,1%). La distribuci\u00f3n por percentiles descart\u00f3 a 2 pacientes con escala de OMS=8 por N \ninsuficiente, de modo que se incluy\u00f3 a los grupos con clasificaci\u00f3n 3 y 4 para el an\u00e1lisis estad\u00edstico comparativo.  \nLos antidepresivos estaban presentes en un 29,4% de pacientes en el grupo OMS=3 y un 58,3% en OMS=4 (P=0,181); \nlos antipsic\u00f3ticos en un 79,4% de pacientes en OMS=3 y un 50% en OMS=4 (P=0,07); los antiepil\u00e9pticos en un 29,4% en \nOMS=3 y un 16,7% en OMS=4 (P=0,612). Para el resto de psicof\u00e1rmacos no hubo diferencias de tendencia relevantes \nentre ambos grupos\ufffd\nCONCLUSIONES\nLa mayor\u00eda de los pacientes psiqui\u00e1tricos pertenecieron a escala de OMS=3, de gravedad leve. S\u00f3lo una minor\u00eda present\u00f3 \nsobreinfecci\u00f3n bacteriana, requiri\u00f3 antibi\u00f3tico y f\u00e1rmacos contra SARS-CoV2.  \nEn los pacientes clasificados como OMS=4 hubo m\u00e1s prevalencia de pauta antidepresiva, mientras que en OMS=3 hab\u00eda \nm\u00e1s tendencia de antipsic\u00f3ticos y antiepil\u00e9pticos.  \nHaber analizado pacientes s\u00f3lo de la primera ola descarta la influencia de haber comparado olas con variantes diferentes \na la \u201cwild type\u201d inicial, y distintos abordajes terap\u00e9uticos contra SARS-CoV2, que fueron modific\u00e1ndose durante la \nprimera parte de la pandemia\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n981. RESULTADOS EN SALUD EN EL TRATAMIENTO PROFIL\u00c1CTICO DE LA MIGRA\u00d1A CON ERENUMAB, \nFREMANEZUMAB Y GALCANEZUMAB \nAUTORES\nSOSA-PONS , A; SEGU\u00cd SOLANES, C; ALMENDROS-ABAD , N; CARDONA ROCA, L; CORONEL CORDERO, L; CANO \nALONSO, M; RUDI SOLA, N\nHOSPITAL GENERAL DE GRANOLLERS \ufffd AV\ufffd FRANCESC RIBAS, S/N GRANOLLERS \ufffd BARCELONA\nOBJETIVOS\nEvaluar resultados en salud de pacientes en tratamiento con inhibidores del p\u00e9ptido relacionado con el gen de la \ncalcitonina (CGRP) as\u00ed como, su efectividad y seguridad.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado entre julio 2020 y marzo 2022 en un hospital de segundo nivel. Se \nincluyeron todos los pacientes con migra\u00f1a cr\u00f3nica que iniciaron tratamiento profil\u00e1ctico con inhibidores de CGRP \n(erenumab, fremanezumab o galcanezumab) y tuvieron, al menos, una visita de atenci\u00f3n farmac\u00e9utica durante el per\u00edodo \nde estudio\ufffd  \nSe recogieron: datos demogr\u00e1ficos, f\u00e1rmaco recibido, discapacidad causada por la migra\u00f1a, calidad de vida al inicio del \ntratamiento y en las semanas (S) 12, 24 y 52, reducci\u00f3n del n\u00famero de d\u00edas de migra\u00f1as mensuales (DMM) tras iniciar \nel f\u00e1rmaco, efectos secundarios (ES) y visitas de seguimiento de atenci\u00f3n farmac\u00e9utica. An\u00e1lisis estad\u00edstico realizado con \nSTATA v.13. Los resultados se presentan con media y desviaci\u00f3n est\u00e1ndar (DE).  \nLa discapacidad causada por la migra\u00f1a se midi\u00f3 con la escala HIT-6 y la calidad de vida con el cuestionario EuroQoL-5D. 163Se consider\u00f3 un tratamiento como efectivo si reduc\u00eda \u226550% los DMM, \u226530% el valor de HIT-6 o hab\u00eda mejora en al menos \nun dominio del EuroQoL-5D. Los datos se obtuvieron de la historia cl\u00ednica electr\u00f3nica.\nRESULTADOS\nSe incluyeron 67 pacientes (49 (DE11) a\u00f1os, 93% mujeres). De estos, 66 recibieron fremanezumab, 8 erenumab, y 7 \ngalcanezumab. Doce pacientes utilizaron m\u00e1s de un inhibidor CGRP , de los cuales 2 recibieron los 3. Se realiz\u00f3 visita de \nseguimiento hasta la S12 al 100% de los pacientes, al 60% hasta S24 y al 12% hasta S52.  \nAl inicio del tratamiento presentaron una media de 18 (DE8) DMM y una media de HIT-6=70 (DE5). Un 57% de los \npacientes redujo, en la \u00faltima visita de seguimiento, \u226550% los DMM. En la S12 un 18% tuvo reducci\u00f3n \u226530% del HIT-6, en \nla S24 un 18% y en la S52 un 13%. Hubo mejor\u00eda de EuroQoL-5D en el 67% de los pacientes en la S12, en el 60% en S24 y \nen el 63% en S52\ufffd \nSe suspendi\u00f3 el tratamiento de 13 (19%) pacientes por: 7 fallo primario, 2 fallo secundario y 4 ES (2 por reacci\u00f3n en el \nlugar de inyecci\u00f3n, 1 por isquemia distal y 1 por tumefacci\u00f3n de falanges). Los ES m\u00e1s frecuentes, que ocurrieron en 11 \n(17%) pacientes, fueron: reacci\u00f3n en el lugar de inyecci\u00f3n (4), estre\u00f1imiento (3), cansancio (1), v\u00e9rtigo (1), tumefacci\u00f3n \nde falanges (1) e isquemia distal (1).\nCONCLUSIONES\nEl uso de inhibidores de CGRP produjo una disminuci\u00f3n del 50% de los DMM en m\u00e1s de la mitad de los pacientes. Esto \nse vio reflejado en una mejor\u00eda en la calidad de vida pero no as\u00ed en la discapacidad percibida por los pacientes. Para los \npacientes respondedores, la efectividad tiende a mantenerse en el tiempo.  \nLos ES que se produjeron fueron en su mayor\u00eda de car\u00e1cter leve, sobre todo reacci\u00f3n en el lugar de inyecci\u00f3n y \nestre\u00f1imiento\ufffd No obstante, se suspendi\u00f3 el tratamiento en 4 pacientes por ES graves\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1010. SEGUIMIENTO DE EFICACIA DE MEPOLIZUMAB EN ASMA GRAVE NO CONTROLADA \nAUTORES\nD\u00cdEZ VALLEJO, C; CASTELL\u00d3 N\u00d2RIA, \u00c0; NOGU\u00c9 PUJADAS, E; DORD\u00c0 BENITO, A; ARTIME RODR\u00cdGUEZ-HERMIDA, F; \nGARC\u00cdA RODICIO, S; LARREA URTARAN, X; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nAnalizar la eficacia de mepolizumab en el tratamiento del asma grave no controlada (AGNC) en pacientes con perfil \neosinof\u00edlico o mixto.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de 50 meses de duraci\u00f3n (enero 2018-febrero 2022) en un hospital de tercer nivel. \nSe recogieron datos demogr\u00e1ficos (sexo, edad) y cl\u00ednicos (al inicio y durante las visitas de seguimiento) de los pacientes \nque hab\u00edan realizado tratamiento con mepolizumab. Los par\u00e1metros cl\u00ednicos recogidos fueron: tratamiento biol\u00f3gico \nprevio, concentraci\u00f3n de IgE y recuento de eosin\u00f3filos basales, tratamiento con corticoides orales (CO) o inhalados (CI) \ndurante el \u00faltimo a\u00f1o, reducci\u00f3n de dosis de CO respecto al registro previo, puntuaci\u00f3n en Asthma Control Test (ACT) y \nexacerbaciones que requirieron aumento de dosis de CO y/o hospitalizaci\u00f3n.  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 con la prueba U de Mann-Whitney.\nRESULTADOS\nSe analizaron un total de 14 pacientes con una mediana de edad de 47 [14-75] a\u00f1os. El 65% fueron mujeres. 2/14 \npacientes hab\u00edan realizado tratamiento biol\u00f3gico previo con omalizumab. El tiempo medio de duraci\u00f3n de tratamiento \nfue de 26,8\u00b112,9 meses. Los valores medios basales de IgE y recuento de eosin\u00f3filos fueron de 388,9\u00b1569,9 UI/ml y \n495,0\u00b1288,7 c\u00e9lulas/\u00b5l, respectivamente. La puntuaci\u00f3n ACT al inicio del tratamiento fue de 16,5\u00b11,8 puntos.  \nDurante el a\u00f1o previo al inicio de tratamiento con mepolizumab, 6/14 (42,8%) hab\u00edan precisado tratamiento con CO y \n13/14 (92,8%) con CI. El n\u00famero medio de exacerbaciones que requirieron CO durante m\u00e1s de 3 d\u00edas fue de 2,4\u00b11,5. La \nmedia del n\u00famero de hospitalizaciones por exacerbaci\u00f3n asm\u00e1tica fue de 0,36\u00b10,45 [0-1].  \nA los 8 y 18 meses de tratamiento con mepolizumab, la puntuaci\u00f3n ACT fue de 20,7\u00b12,6 y 21,3\u00b13,2 puntos \nrespectivamente. A los 8 meses, no hubo casos de exacerbaciones con necesidad de CO durante m\u00e1s de 3 d\u00edas ni casos \nde hospitalizaci\u00f3n por exacerbaci\u00f3n asm\u00e1tica. A los 18 meses, la media del n\u00famero de exacerbaciones con necesidad \nde CO y n\u00famero de hospitalizaciones fue de 0,11\u00b10,33 [0-1] en ambos casos. Comparando los resultados obtenidos a \nlos 8 y a los 18 meses respecto a los valores basales, en todos los casos, excepto en el n\u00famero de hospitalizaciones por \nexacerbaci\u00f3n a los 18 meses, la diferencias fueron estad\u00edsticamente significativas (p < 0,05).  \nEn el periodo de estudio se realizaron un total de 55 visitas de seguimiento cl\u00ednico (cada 3-6 meses), en 20 de las cuales \nfue posible una reducci\u00f3n o parada de CO respecto la visita anterior \ufffd \nEn todos los pacientes el tratamiento fue bien tolerado\ufffd Dos pacientes abandonaron el tratamiento por decisi\u00f3n propia\ufffd\nCONCLUSIONES\nLos pacientes en tratamiento con mepolizumab mejoran el control del asma grave tanto en el n\u00famero de exacerbaciones \nasm\u00e1ticas como en la reducci\u00f3n del uso de CO y en la puntuaci\u00f3n de la escala ACT (\u226520).164CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1031. TRATAMIENTO BIOL\u00d3GICO DE RINOSINUSITIS CR\u00d3NICA CON P\u00d3LIPOS NASALES Y S\u00cdNTOMAS \nASOCIADOS EN PACIENTES CON ASMA GRAVE NO CONTROLADA \nAUTORES\nMERINO GARC\u00cdA, A; PEDREIRA BOUZAS, J; GARC\u00cdA GARC\u00cdA, C; MARI\u00d1O MART\u00cdNEZ, C; PUIVECINO MORENO, C; \nFERNANDEZ ROM\u00c1N, AB; GARC\u00cdA REBOLLEDO, EM; GARC\u00cdA GIL, M\nHOSPITAL DE FUENLABRADA \ufffd CAMINO DEL MOLINO, 2 FUENLABRADA \ufffd MADRID\nOBJETIVOS\nEvaluar la efectividad y seguridad del tratamiento con anticuerpos monoclonales en pacientes con asma grave \nno controlada (AGNC) y rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN), no controlados adecuadamente con \ncorticoterapia y/o cirug\u00eda.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo pre-post desde septiembre 2011 hasta marzo 2022. Se incluyeron pacientes \nmayores de 18 a\u00f1os diagnosticados de AGNC y RSCcPN, con al menos 6 meses de tratamiento biol\u00f3gico. La variable \nprincipal de efectividad fue la diferencia de medias pre y postratamiento en la escala de tama\u00f1o de p\u00f3lipos nasales\u2014\nnasal polyp score (NPS)\u2014y en la escala visual anal\u00f3gica (EVA) de s\u00edntomas: obstrucci\u00f3n y congesti\u00f3n nasal, olfato, \nrinorrea y presi\u00f3n facial. Otras variables recogidas fueron terapia biol\u00f3gica, fecha de inicio y duraci\u00f3n de tratamiento, \nuso de corticosteroides sist\u00e9micos y nasales concomitantes y necesidad de cirug\u00eda endosc\u00f3pica nasosinusal (CENS). Se \ndescribi\u00f3 la aparici\u00f3n de efectos adversos (EA) asociados al tratamiento. Los datos se obtuvieron consultando la historia \ncl\u00ednica electr\u00f3nica y las dispensaciones de los m\u00f3dulos inform\u00e1ticos. Se realiz\u00f3 una prueba T para muestras relacionadas \nmediante el estad\u00edstico SPSS\u00aev22.\nRESULTADOS\nSe incluyeron 22 pacientes, 50% mujeres de mediana de edad 55 a\u00f1os (32-86). Se excluy\u00f3 a un paciente por \u00e9xitus \nno asociado a AGNC. Diez pacientes iniciaron tratamiento con mepolizumab (48%), diez con omalizumab (48%) y uno \ncon reslizumab (4%). La duraci\u00f3n media de tratamiento fue 4,52\u00b13,06 a\u00f1os (0-10). La mayor\u00eda de pacientes precisaron \ncorticoterapia sist\u00e9mica (67%) y nasal (90%) como rescate durante el tratamiento biol\u00f3gico. En 13 pacientes (62%) se \nrealiz\u00f3 CENS pretratamiento biol\u00f3gico, tres (14%) durante o postratamiento y cinco (24%) nunca fueron operados. En el \nmomento del an\u00e1lisis, ocho pacientes (38%) continuaban con el mismo f\u00e1rmaco biol\u00f3gico inicial. Trece (62%) cambiaron \na otro f\u00e1rmaco biol\u00f3gico por falta de mejor\u00eda cl\u00ednica, corticodependencia o control inadecuado de la sintomatolog\u00eda \nasm\u00e1tica basal. De los que comenzaron con omalizumab, tres cambiaron a mepolizumab (23%), tres a benralizumab \n(23%) y uno a mepolizumab y despu\u00e9s a benralizumab (8%). De los que iniciaron con mepolizumab, uno cambi\u00f3 a \ndupilumab (8%), uno a benralizumab (8%), dos a reslizumab (15%), uno a benralizumab y despu\u00e9s con reslizumab \n(8%) y uno a reslizumab, despu\u00e9s a benralizumab y por \u00faltimo a reslizumab (8%). Las medias pre y postratamiento \npara NPS fueron 4,57\u00b11,60 vs 1,62\u00b11,28 [diferencia 2,95(IC95%:2,32-3,59; p < 0,05)]. Para EVA en obstrucci\u00f3n nasal \nfueron 7,05\u00b11,80 vs 4,10\u00b11,76 [diferencia 2,95(IC95%:1,95-3,95;p < 0,05)]; en congesti\u00f3n nasal 6,95\u00b11,94 vs 3,90\u00b11,18 \n[diferencia 3,05(IC95%:2,10-4;p < 0,05)], en olfato 5\u00b12,77 vs 5,52\u00b12.69 [diferencia 0,52(IC95%:0,97-0,08;p < 0,05), en \nrinorrea 6,43\u00b12,34 vs 4,19\u00b11,69 [diferencia 2,24(IC95%:1,44-3,04;p < 0,05)] y en presi\u00f3n facial 4,24\u00b12,62 vs 3\u00b11,41 \n[diferencia 1,24(IC95%:0,51-1,97;p < 0,05)]. Dos pacientes (10%) presentaron EA con benralizumab, uno refiri\u00f3 sensaci\u00f3n \nde hormigueo en lugar de inyecci\u00f3n y cefalea sin requerir cambio de terapia. Otro describi\u00f3 sudoraci\u00f3n, sofocos y \nn\u00e1useas provocando el cambio a reslizumab.\nCONCLUSIONES\nLa terapia biol\u00f3gica en pacientes con AGNC y RSCcPN, asociada a corticoterapia nasal y sist\u00e9mica de rescate, parece \nser efectiva reduciendo el tama\u00f1o de p\u00f3lipos nasales y s\u00edntomas asociados, con buen perfil de seguridad. Disponer de \ndistintas alternativas terap\u00e9uticas parece permitir individualizar el tratamiento y mantener una buena respuesta a lo largo \ndel tiempo.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1056. EVALUACI\u00d3N DE LA EFECTIVIDAD Y SEGURIDAD DE LOS INHIBIDORES DE LAS JANUS KINASAS EN \nARTRITIS REUMATOIDE \nAUTORES\nJULI\u00c1 LUNA, FJ; CORT\u00c9S FERN\u00c1NDEZ, R; DE LA CALLE RIAGUAS, B; CRIADO RUBIO, B; ALONSO SALMER\u00d3N, FJ; G\u00d3MEZ \nESPINOSA, P; LOMARES MANZANO, I; BERROCAL JAVATO, MA\nHOSPITAL NUESTRA SE\u00d1ORA DEL PRADO \ufffd CTRA \ufffd DE MADRID, KM \ufffd 114 TALAVERA DE LA REINA \ufffd TOLEDO\nOBJETIVOS\nBaricitinib, tofacitinib y upadacitinib son inhibidores reversibles de las janus quinasas (IJAK) indicados en artritis \nreumatoide (AR) con respuesta inadecuada a los f\u00e1rmacos modificadores de la enfermedad (FAMEs). El objetivo de este \nestudio es evaluar su efectividad y seguridad en el tratamiento de la AR en la pr\u00e1ctica cl\u00ednica\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital general (enero 2017- abril 2022) en pacientes con AR en tratamiento \ncon IJAK (tofacitinib, baricitinib y upadacitinib). Se recogieron variables: sexo, edad, duraci\u00f3n del tratamiento, f\u00e1rmacos \nbiol\u00f3gicos previos, n\u00famero de FAMEs concomitantes, posolog\u00eda, efectos adversos (EA) y motivo de suspensi\u00f3n.  165La efectividad se evalu\u00f3 a los 6 meses del inicio del tratamiento mediante el \u00edndice DAS28, herramienta para cuantificar el \ngrado de actividad en AR. Un valor inferior a 2,6 significa remisi\u00f3n de la AR, entre 2,6 y 3,2 actividad baja, entre 3.2 y 5.1 \nmoderada y valores superiores a 5.1 actividad alta .  \nLa seguridad se analiz\u00f3 con el registro de efectos adversos (EA) y suspensiones del tratamiento.  \nLos datos se obtuvieron del m\u00f3dulo de pacientes externos de Farmatools\u00ae e historia cl\u00ednica electr\u00f3nica\nRESULTADOS\nSe evaluaron 24 pacientes (79% mujeres), con edad media de 53 a\u00f1os (rango= 33-88). El 42% (n=10) estaba en \ntratamiento con baricitinib, el 37% (n=9) con tofacitinib y el 21% (n=5) con upadacitinib. La mediana de duraci\u00f3n \ndel tratamiento con baricitinib fue de 23 meses (rango=6-45), 16 meses (7-34) con tofacitinib y 10 meses (6-12) con \nupadacitinib.  \nLa mediana de tratamientos biol\u00f3gicos previos fue de 3 (0-8) y de FAMEs concomitantes de 2 (1-4). \nEl 8% (n=2) de los pacientes con baricitinib precis\u00f3 una reducci\u00f3n de dosis (4 a 2 mg ).  \nA los 6 meses, con baricitinib el 50% (n=5) de los pacientes presentaron remisi\u00f3n de la enfermedad, el 30% (n=3) \nactividad baja y el 20% (n=2) actividad moderada. Con tofacitinib, el 11% (n=1) present\u00f3 actividad baja, el 33% (n=3) \nactividad moderada y el 44% (n=4) actividad alta. Con upadacitinib, el 20% (n=1) present\u00f3 remisi\u00f3n de la enfermedad, el \n20% (n=1) actividad baja, el 40% (n=2) actividad moderada y el 40% (n=2) actividad alta.  \nSe suspendi\u00f3 baricitinib por motivo de ineficacia en el 20% (n=2) de los pacientes, en el 22% (n=2) con tofacitinib y en el \n20% (n=1) con upadacitib .  \nEn cuanto al perfil de seguridad, el 29% (n=7) present\u00f3 EA. Con baricitinib, el 8% (n=1) de los pacientes mostr\u00f3 erupci\u00f3n \ncut\u00e1nea y 8% (n=1) aumento de peso. Con tofacitinib, el 22% (n=2) present\u00f3 hipersensibilidad al f\u00e1rmaco, el 22% (n=2) \nhipertransaminasemia y el 11% (n=1) hiperalgesia. No se describieron EA con upadacitinib.\nCONCLUSIONES\nLos IJAK m\u00e1s prescritos fueron baricitinib y tofacitib. Upadacitinib fue el menos utilizado probablemente debido a su \nreciente comercializaci\u00f3n.  \nCon baricitinib la mitad de los pacientes presentaron remisi\u00f3n completa de la enfermedad, mientras que ning\u00fan paciente \nalcanz\u00f3 remisi\u00f3n completa por tofacitinib.  \nTofacitinib fue el IJAK peor tolerado causando EA en m\u00e1s de la mitad de los pacientes, siendo la reacci\u00f3n de \nhipersensibilidad y la elevaci\u00f3n de transaminasas los m\u00e1s frecuentes.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1067. EXPERIENCIA DE UTILIZACI\u00d3N DE TERAPIA BIOL\u00d3GICA DUAL EN EL TRATAMIENTO DE PACIENTES \nCON ENFERMEDAD INFLAMATORIA INTESTINAL \nAUTORES\nPORTA S\u00c1NCHEZ, A; ELBERDIN PAZOS, L; GONZ\u00c1LEZ CONDE, B; EST\u00c9VEZ PRIETO, E; DIZ-LOIS PALOMARES, MT; \nV\u00c1ZQUEZ L\u00d3PEZ, C; FEIJOO VILANOVA, P; MART\u00cdN HERRANZ, I\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nLa terapia dual con biol\u00f3gicos (TDB) con distinto mecanismo de acci\u00f3n se ha asociado a mejor\u00eda cl\u00ednica y endosc\u00f3pica en \npacientes seleccionados con enfermedad inflamatoria intestinal (EII) refractaria y fracaso a m\u00faltiples terapias biol\u00f3gicas \n(TB).  \nEl objetivo del estudio es evaluar la utilizaci\u00f3n de TDB en pacientes con EII, el perfil de efectividad y seguridad.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, multidisciplinar en adultos con EII refractarios a TB que han iniciado TDB en el \n\u00e1mbito de un hospital de tercer nivel. Se incluyeron pacientes con diagn\u00f3stico de EII a tratamiento con TDB durante \nal menos 3 meses. A partir de la historia cl\u00ednica informatizada se recogieron datos demogr\u00e1ficos, tratamiento previo, \nbiol\u00f3gicos combinados y posolog\u00eda, situaci\u00f3n cl\u00ednica que justific\u00f3 su utilizaci\u00f3n y biomarcadores de actividad (Prote\u00edna \nC reactiva+Calprotectina fecal). La utilizaci\u00f3n de TDB cont\u00f3 con la aprobaci\u00f3n del Comit\u00e9 de EII del hospital y el \nConsentimiento Informado del paciente.  \nLa efectividad se evalu\u00f3 a partir de la interpretaci\u00f3n del cl\u00ednico: mejor\u00eda de par\u00e1metros de inflamaci\u00f3n (respuesta parcial); \nresoluci\u00f3n de s\u00edntomas (remisi\u00f3n cl\u00ednica) o en base a criterios de respuesta radiol\u00f3gica/endosc\u00f3pica (si disponibles). Para \nanalizar la seguridad se recogieron los efectos adversos (EA) asociados al tratamiento y se evalu\u00f3 la inmunogenicidad por \ndeterminaci\u00f3n de niveles de anticuerpos anti-F\u00e1rmaco y concentraciones sangu\u00edneas de TB por el Servicio de Farmacia \n(inmunoensayos ELISA tipo s\u00e1ndwich en analizador Triturus\u00ae).\nRESULTADOS\nEn el periodo Enero/2020-Mayo/2022, cuatro pacientes (2 varones;edad:43-54 a\u00f1os) con EII (Crohn-3; Colitis Ulcerosa-1) \nhan iniciado terapia con adalimumab 160/80/40 mg/14d\u00edas en combinaci\u00f3n con Vedolizumab-IV (2 pacientes \n[1-Vedolizumab/28d\u00edas])/Ustekinumab-SC 90mg/8semanas(1paciente); y un paciente que inici\u00f3 Ustekinumab-IV+SC en \ncombinaci\u00f3n con Adalimumab/14d\u00edas. Los pacientes presentaban una larga evoluci\u00f3n de la enfermedad (media:17[13-24]\na\u00f1os) con fracaso a 3 biol\u00f3gicos previos y upadacitinib (1paciente). Co-morbilidades asociadas: espondiloartritis+asma \nbronquial (1); hidrosadenitis+eritema nodoso+psoriasis+artritis (1) y psoriasis (1). Se justific\u00f3 su utilizaci\u00f3n para evitar \ncirug\u00eda agresiva en 3 pacientes con extensa afectaci\u00f3n intestinal y en varios fragmentos y control de manifestaciones \nextraintestinales (hidrosadenitis y artritis) en un paciente con respuesta intestinal a Ustekinumab.  166Eficacia: \na)remisi\u00f3n cl\u00ednica en dos pacientes a tratamiento con Adalimumab+Ustekinumab (1-mejor\u00eda extra-intestinal a dosis \nest\u00e1ndar, 1-afectacion fragmentada).  \nb)respuesta parcial en paciente con alto riesgo de intestino corto con Adalimumab+Vedolizumab/28d\u00edas (con \nempeoramiento tras suspender 3 dosis de Adalimumab por cirug\u00eda dental; pendiente de valoraci\u00f3n tras intensificar a \n80mg/14d\u00edas).  \nc)no respuesta en un paciente con actividad severa que requiri\u00f3 colectom\u00eda total+ileostom\u00eda terminal tras 13 meses con \nVedolizumab/6 semanas+Adalimumab/semanal.  \nLa duraci\u00f3n media de la TDB fue 9(rango:5-13)meses. Se requiri\u00f3 intensificar la TDB en 3 pacientes.  \nEA comunicados: herpes z\u00f3ster y posteriormente sobreinfecci\u00f3n por Citomegalovirus+candidiasis esof\u00e1gica en un \npaciente con Vedolizumab/6semanas+Adalimumab/semanal y, en otro paciente tratado con Ustekinumab+Adalimumab, \nse comunic\u00f3 una reacci\u00f3n cut\u00e1nea pruriginosa leve tras inicio de Adalimumab y, posteriormente, infecci\u00f3n asintom\u00e1tica \npor SARS-Cov-2. No se detectaron anticuerpos anti-Adalimumab/anti-Ustekinumab.\nCONCLUSIONES\nA pesar de las opciones terap\u00e9uticas disponibles, hay pacientes con EII con necesidades no cubiertas en los que la terapia \nest\u00e1ndar no resulta \u00fatil. La TDB podr\u00eda ser una alternativa en pacientes con extensa actividad intestinal o en pacientes \ncon manifestaciones extra-intestinales con un perfil de seguridad aceptable.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1075. RESULTADOS DE LA IMPLANTACI\u00d3N DE UN PROGRAMA MULTIDISCIPLINAR DE MONITORIZACI\u00d3N \nTERAP\u00c9UTICA TEMPRANA PROACTIVA DE INFLIXIMAB EN ENFERMEDAD INFLAMATORIA INTESTINAL \nAUTORES\nRECAREY GERPE, V; S\u00c1NCHEZ HERN\u00c1NDEZ, JG; MU\u00d1OZ N\u00da\u00d1EZ, JF; P\u00c9REZ L\u00d3PEZ, R; GARC\u00cdA CASANUEVA, JC; OTERO \n, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nSe dispone de evidencia sobre la utilidad de la monitorizaci\u00f3n farmacocin\u00e9tica proactiva (TDMp) de las concentraciones \ns\u00e9ricas de infliximab (CSI) en fase de mantenimiento en pacientes con enfermedad inflamatoria intestinal (EII), pero \nexisten pocos estudios en fase de inducci\u00f3n. El objetivo del estudio fue analizar la utilidad de la TDMp de CSI durante la \nfase de inducci\u00f3n del tratamiento, tras la implantaci\u00f3n de un programa multidisciplinar de TDMp temprana en pacientes \ncon EII\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo y multidisciplinar de 4 a\u00f1os que incluy\u00f3 a los pacientes diagnosticados de EII moderada-\ngrave que iniciaron tratamiento con infliximab con las dosis indicadas en ficha t\u00e9cnica y seg\u00fan protocolo del centro. Se \ndeterminaron las CSI y los posibles anticuerpos (ATI) en la semana 2 y 6 de inducci\u00f3n y posteriormente en la semana 22, \nmediante una t\u00e9cnica de inmunoabsorci\u00f3n ligada a enzimas (ELISA). El estudio cont\u00f3 con la autorizaci\u00f3n del CEIm del \ncentro\ufffd  \nA partir de las CSI determinadas en semanas 2 y 6 se optimiz\u00f3 la dosis de infliximab para alcanzar una CSI > 5 \u00b5g/mL en \nsemana 22. Para ello se realiz\u00f3 una estimaci\u00f3n bayesiana utilizando el modelo farmacocin\u00e9tico poblacional desarrollado \npor S\u00e1nchez-Hern\u00e1ndez et al. Asimismo se estim\u00f3 cuales habr\u00edan sido las CSI de infliximab de seguir con las dosis \nhabituales de inducci\u00f3n de 5 mg/Kg.  \nSe determin\u00f3 la utilidad de la TDMp por el porcentaje de pacientes a los que se optimiz\u00f3 la dosis en la fase de inducci\u00f3n, \nlos pacientes con presencia de ATI y el porcentaje de pacientes que suspendieron el tratamiento por falta de respuesta \nprimaria. Se compararon las CSI alcanzadas en semana 22 tras la optimizaci\u00f3n de la dosis con las CSI que se habr\u00edan \nalcanzado de continuar con la dosis sin optimizar, mediante la t-student.\nRESULTADOS\nSe incluyeron 95 pacientes (44 mujeres) de los que 52 ten\u00edan enfermedad de Crohn y 43 colitis ulcerosa, con una mediana \n(rango) de edad de 44 (19-71) a\u00f1os. Diez iniciaron tratamiento con 10mg/Kg, 11 con 7,5 mg/Kg y 74 con 5 mg/Kg.  \nLa CSI media (DE) en la semana 2 fue de 22,4 (12,5) \u00b5g/mL y en la semana 6 de 16,2 (11,4) \u00b5g/mL. Solamente 4 (4,2%) \npacientes presentaron ATI\ufffd  \nSe optimiz\u00f3 la dosis a un total de 37 (38,9%) pacientes durante la inducci\u00f3n. Se observaron diferencias estad\u00edsticamente \nsignificativas entre las CSI que hubieran presentado los pacientes en semana 22 y las realmente alcanzadas en dicha \nsemana tras la optimizaci\u00f3n [2,3 (1,3)\u00b5g/mL vs 6,1 (1,8)\u00b5g/mL; p=0,002]  \nA lo largo del estudio se observ\u00f3 que 10 (9,5%) pacientes suspendieron el tratamiento por falta de respuesta primaria a \ninfliximab a pesar de la optimizaci\u00f3n y 5 (4,8%) por presencia de ATI, uno de ellos con reacci\u00f3n adversa infusional.\nCONCLUSIONES\nEn esta cohorte se observ\u00f3 que un elevado porcentaje de pacientes precisaron optimizar la dosis indicada en ficha \nt\u00e9cnica en la fase de inducci\u00f3n para llegar a alcanzar CSI terap\u00e9uticas en la fase de mantenimiento. La TDMp temprana \nde infliximab podr\u00eda ser una estrategia \u00fatil para conseguir una respuesta temprana al tratamiento y reducir la \ninmunogenicidad\ufffd167CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1087. RELACI\u00d3N DE LAS CONCENTRACIONES PLASM\u00c1TICAS DE OMALIZUMAB EN PACIENTES ASM\u00c1TICOS \nCON EL CONTROL DEL ASMA \nAUTORES\nMART\u00cdNEZ SU\u00c1REZ, A; CORDERO RAMOS, J; MART\u00cdN CASADO, L; ROMERO GONZ\u00c1LEZ, M; G\u00d3MEZ-BASTERO , A; \nMERINO BOH\u00d3RQUEZ, V\nHOSPITAL VIRGEN MACARENA \ufffd AV\ufffd DOCTOR FEDRIANI, 3 SEVILLA \ufffd SEVILLA\nOBJETIVOS\nOmalizumab es un anticuerpo monoclonal anti-IgE indicado en adultos, adolescentes y ni\u00f1os \u22656 a\u00f1os con asma al\u00e9rgica \nmoderada/grave no controlada. No hay estudios que determinen la relaci\u00f3n entre las concentraciones plasm\u00e1ticas de \nomalizumab (OMA) y la respuesta cl\u00ednica en pr\u00e1ctica cl\u00ednica. El objetivo del estudio es medir OMA en pacientes asm\u00e1ticos \ny determinar si los pacientes con mal control y buen control del asma presentan OMA diferentes y analizar si existe \ncorrelaci\u00f3n con: respuesta al f\u00e1rmaco seg\u00fan criterios cl\u00ednicos, peso y niveles de inmunoglobulina E al\u00e9rgeno-espec\u00edfica \n(IgE).\nMATERIALES Y M\u00c9TODOS\nEstudio experimental y prospectivo realizado desde enero de 2019 hasta diciembre de 2020. Se incluyeron pacientes \nen tratamiento > 6 meses con omalizumab y que a criterio cl\u00ednico se pudiesen beneficiar de la determinaci\u00f3n de OMA. \nLa respuesta cl\u00ednica se consider\u00f3 seg\u00fan los criterios de la Gu\u00eda Espa\u00f1ola para el Manejo del Asma: exacerbaciones \nmoderadas y graves, visitas a urgencias y hospitalizaciones en el ultimo a\u00f1o y el Test de Control del Asma (ACT) (asma \nbien controlada (\u226520 puntos), parcialmente controlada (19-16) o mal controlada (\u226415)). Se midi\u00f3 el Test de Adhesi\u00f3n a \nInhaladores (TAI) (buena adherencia (50 puntos), intermedia (49-46) o mala (\u226445)).  \nLas caracter\u00edsticas basales de los pacientes se obtuvieron de la historia cl\u00ednica electr\u00f3nica. OMA se cuantificaron mediante \nla t\u00e9cnica de inmunoensayo ELISA (SHIKARI\u00ae Q-OMA, Matriks Biotek). Las diferencias de OMA y la correlaci\u00f3n con las \ndiferentes variables (coeficiente Spearman) se analizaron mediante el software R (V.3.4.3).\nRESULTADOS\nSe obtuvieron 48 muestras correspondientes a 24 pacientes, 75% mujeres, 48 (Rango Intercuartilico (RI) 64-42,75) \na\u00f1os, 82 (RI 90-62) kg. En el momento de la determinaci\u00f3n presentaron el siguiente control del asma: 18,8% malo; \n20,8% parcial; 58,3% bueno y 2% sin poder determinar. 2 pacientes presentaron mala adherencia a inhaladores. 70,8% \nde los pacientes presentaron > 1 determinaci\u00f3n. 58,3% presentaron una variaci\u00f3n en OMA > 50%. OMA medio de los \npacientes fue 29,70\u00b18,27 mcg/ml\ufffd Los pacientes con parcial/buen control del asma presentaron OMA 33,8\u00b136,4 mcg/\nml y los pacientes con mal control del asma 19\u00b110 mcg/ml. Hubo diferencias estad\u00edsticamente significativas entre \nOMA de pacientes ACT \u226415 y pacientes ACT > 15 (p < 0,05). No se encontr\u00f3 correlaci\u00f3n entre OMA y la presentaci\u00f3n de \nexacerbaciones moderadas y graves, visitas a urgencias y hospitalizaciones en el \u00faltimo a\u00f1o, control del asma seg\u00fan el \nACT, peso y niveles de IgE. Un paciente con parcial control del asma (ACT=19) y OMA=11,7 mcg/ml (inferior a la media) \nse intensific\u00f3 el tratamiento y en 2 meses se logr\u00f3 OMA=52,54 mcg/mL, retirar corticoide oral cr\u00f3nico, no presentar \nexacerbaciones y \nbuen control del asma (ACT=21).\nCONCLUSIONES\nExiste variabilidad interindividual e intraindividual de OMA. Se encontraron diferencias significativas entre OMA de \nlos pacientes con mal y parcial/buen control. No se pudo establecer correlaci\u00f3n entre OMA y variables cl\u00ednicas. Seg\u00fan \nnuestro estudio podr\u00eda ser \u00fatil determinar OMA en pacientes con mal control del asma. Estudios con mayor n\u00famero de \npacientes son necesarios para confirmar estos datos, estudiar posible correlaci\u00f3n con variables cl\u00ednicas y determinar si al \nintensificar la terapia en pacientes con OMA bajos se puede controlar la enfermedad.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1107. OCRELIZUMAB EN ESCLEROSIS M\u00daLTIPLE, AN\u00c1LISIS DE EFICTIVIDAD Y SEGURIDAD POR \nINDICACIONES \nAUTORES\nDE FRUTOS DEL POZO, M; VICENTE GONZ\u00c1LEZ, B; REVILLA CUESTA, N; S\u00c1NCHEZ LUQUE, L; INFANTE CAMARERO, A; \nG\u00dcEMES GARC\u00cdA, M; BRIONES CUESTA, E; GUTI\u00c9RREZ FERN\u00c1NDEZ, I\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS\nOBJETIVOS\nEvaluar la efectividad y seguridad de Ocrelizumab en sus distintas indicaciones(Esclerosis M\u00faltiple Recurrente de alta \nactividad(EMR) y Esclerosis M\u00faltiple Primaria Progresiva(EMPP)).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo de los pacientes en tratamiento activo con Ocrelizumab desde su \ninclusi\u00f3n en la gu\u00eda farmacoterap\u00e9utica(enero-2019) hasta mayo-2022.  \n \nSe recogieron variables demogr\u00e1ficas y cl\u00ednicas a partir de la Historia Cl\u00ednica Electr\u00f3nica y del m\u00f3dulo de dispensaci\u00f3n \na pacientes ambulantes de Farmacia. Las variables fueron: fecha de nacimiento, sexo, fecha de inicio de Ocrelizumab, 168valores de Expanded Disability Status Scale(EDSS) al inicio del tratamiento y a los 6, 12 y 24 meses, aparici\u00f3n o no de \nbrotes(seg\u00fan cl\u00ednica) y de nuevas lesiones en resonancia magn\u00e9tica nuclear(RMN), l\u00ednea de tratamiento previo recibida y \nefectos adversos\ufffd  \n \nLa recogida de datos y el an\u00e1lisis estad\u00edstico se realiz\u00f3 con hoja de c\u00e1lculo Microsoft-Excel2010.\nRESULTADOS\nSe analizaron un total de 46 pacientes, 34(74%) diagnosticados de EMR y 12(26%) con EMPP .  \n \nDe los pacientes con EMR, el 61,8% fueron mujeres(n=21). Presentaron una mediana de edad de 43,3 a\u00f1os(21,2-59,5 \na\u00f1os) y un EDSS medio al inicio de 4,3(IC95% 3,6-4,9). La mediana de seguimien to fue de 21,5 meses(1,3-39,2 meses).  \nEl an\u00e1lisis de la diferencia entre el EDSS al inicio del tratamiento y el posterior fue: a los 6 meses (n=28), media del \ncambio: 0,0(IC95% -0,18-0,18 puntos de EDSS); a los 12 meses(n=25), 0,08(IC95% -0,31-0,47) y a los 24 meses(n=16), \n0,63(IC95% -0,16-1,41). Ninguno de los intervalos de confianza fueron estad\u00edsticamente significativos(incluyeron hip\u00f3tesis \nnula, diferencia=0). No se observaron nuevas lesiones en RMN ni brotes. \n \nEn cuanto a los tratamientos previos, 10 pacientes hab\u00edan recibido Fingolimod,7 Teriflunomida,5 Natalizumab,2 \nDimetilfumarato,2 Cladibrina,2 Glatir\u00e1mero,1 Alentuzumab,1 Siponimod y 1 Rituximab. Ocrelizumab fue primera l\u00ednea en \n3 pacientes con EMR de muy alta actividad.  \n \nDe los pacientes con EMPP , el 83,3% fueron mujeres(n=10). Presentaron una mediana de edad de 52,3 a\u00f1os(46,7-57 \na\u00f1os) y un EDSS medio al inicio de 4,4(IC95% 3,5-5,3). La mediana de seguimien to fue de 8,1 meses(1,3-38,8 meses).  \n \nEl an\u00e1lisis de la diferencia entre el EDSS fue: a los 6 meses(n=6), mediana del cambio: -0,25(rango -3,5-0,5 puntos de \nEDSS); a los 12 meses(n=5), -0,5(rango -5-0,5) y a los 24 meses(n=4),-0,25(rango -5-0,5).No se observaron nuevas lesiones \nen RMN ni brotes\ufffd \n \nNing\u00fan paciente hab\u00eda recibido tratamiento previo.  \n \nEn cuanto a la seguridad, el 28,3%(n=16)refirieron alg\u00fan efecto adverso, siendo la aparici\u00f3n de rash cut\u00e1neo el m\u00e1s \nfrecuente(n=10),seguido de reacciones infusionales(n=4).Cabe destacar la aparici\u00f3n de una neutropenia grave que \nrequiri\u00f3 ingreso.\nCONCLUSIONES\nEn el grupo de EMR, no podemos concluir que el uso de Ocrelizumab modifique el estado de discapacidad de los \npacientes, ya que el an\u00e1lisis de la diferencia de la media del EDSS no fue estad\u00edsticamente significativo. S\u00ed parece \nmantener el estado basal, incluso a los dos a\u00f1os y controlar la aparici\u00f3n de brotes y lesiones\ufffd  \n \nEn el grupo de EMPP , se observ\u00f3 un ligero descenso del EDSS no evaluable debido al tama\u00f1o muestral(la mitad de la \npoblaci\u00f3n no ha alcanzado la mediana de seguimiento).  \n \nLos datos de seguridad fueron similares a los reportados en otros estudios\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1124. LOS ANTICUERPOS FRENTE AL CGRP EN LA MIGRA\u00d1A EN PRIMERA L\u00cdNEA Y M\u00c1S ALL\u00c1: DATOS DE \nVIDA REAL \nAUTORES\nSANZ S\u00c1NCHEZ, C; CARRASCO PIERNAVIEJA, L; SANMARTIN FENOLLERA, P; ZHAN ZHOU, E; CASAS LIM\u00d3N, J; P\u00c9REZ \nENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nAnalizar la utilizaci\u00f3n del tratamiento anti-CGRP en pacientes con migra\u00f1a en distintos escenarios cl\u00ednicos de vida real en \nt\u00e9rminos de persistencia y motivos de suspensi\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio unic\u00e9ntrico observacional retrospectivo en pacientes con migra\u00f1a tratados con anti-CGRP entre diciembre/2019-\nabril/2022 con \u22651 valoraci\u00f3n neurol\u00f3gica postratamiento. Fue analizada la persistencia al tratamiento (PT) [tiempo \n(meses) desde el inicio hasta la discontinuaci\u00f3n (Kaplan-Meier)]. Se defini\u00f3 fracaso terap\u00e9utico como reducci\u00f3n < 50% del \nn\u00famero migra\u00f1as/mes(nMM). El an\u00e1lisis se realiz\u00f3 por l\u00ednea (L) de tratamiento recibida.  \nSe recogieron las variables edad, sexo, tratamientos previos y para cada l\u00ednea de tratamiento nMM basal y previa, fechas \nde inicio y discontinuaci\u00f3n y sus causas. El an\u00e1lisis estad\u00edstico se realiz\u00f3 con SPSS\u00aev20.0.\nRESULTADOS\nRecibieron anti-CGRP 125 pacientes diagnosticados de migra\u00f1a cr\u00f3nica(100%), siendo seleccionados 118: 83,9% \nmujeres, media de migra\u00f1as/mes (mMM) de 16,0\u00b17,0 que recibieron erenumab(40,7%), galcanezumab(41,5%) y \nfremanezumab(17,8%) en 1\u00aaL. El 100% recibieron \u22653 f\u00e1rmacos preventivos incluyendo OnabotulinumtoxinA. La mediana-169PT en 1\u00aaL fue 13,9meses (IC95% 11,6-16,2). El 43,9% alcanz\u00f3 los 16 meses y el 34,4% los 20 meses. El 47,5%(56/118) \ncontin\u00faan en tratamiento. Un 10,2%(12/118) finaliz\u00f3 por \u00e9xito terap\u00e9utico, de ellos 7 se trataron 1 a\u00f1o. El 39,0%(46/118) \nsuspendi\u00f3 por inefectividad, deseo gen\u00e9sico 1,7%(2/118) y, deseo paciente e hipersensibilidad 0,8%(1/118), \nrespectivamente.  \nSe estudiaron los anti-CGRP por mecanismo de acci\u00f3n en 1\u00aaL: frente al receptor(R) n=48 vs frente al ligando(Lig) n=70. Las \npoblaciones fueron comparables en sexo(p=0,310), edad(p=0,858) y nMM-basal(p=0,059). No hubo diferencias (p=0,574) \nde inefectividad (R=43,7% vs Lig=35,7%) ni en mediana-PT: R=12,6meses (IC95% 9,2-16,0) vs Lig=15,3 meses (IC95% 11,5-\n19,1) (p=0,715).  \nTras fracaso a 1\u00aaL (39,0%(46/118)) se realiz\u00f3 switch (2\u00aaL), analiz\u00e1ndose el 84,8%(39/46): edad media 60,0 \u00b112,0a\u00f1os, \n29,0% mujeres y 18,8 \u00b18,5mMM. El 51,3%(20/39) recibi\u00f3 erenumab, 41,0%(16/39) galcanezumab y 7,7%(3/39) \nfremanezumab. No hallamos diferencias entre mMM-basal-1\u00aaL(17,4\u00b17,8) y mMM-basal-2\u00aaL(18,8\u00b18,5), p=0,315. La \nmediana-PT fue 13,9meses (IC95% 6,6-21,3). El 56,4%(22/39) contin\u00faan en tratamiento y el 2,6%(1/39) finalizaron al a\u00f1o \npor efectividad. El 33,3%(13/39) suspendi\u00f3 por inefectividad y 2,6%(1/39) por falsa sospecha embarazo, deseo paciente y \np\u00e9rdida de seguimiento, respectivamente.  \nUn 30,8%(12/39) requiri\u00f3 switch (3\u00aaL), siendo valorable el 91,7%(11/12): edad media 51,0 \u00b113,9a\u00f1os, 63,6% mujeres y \nmMM 23,0 \u00b18,6. El 81,8%(9/11) recibi\u00f3 fremanezumab, y el 9,1%(1/11) galcanezumab y erenumab, respectivamente. No \nhallamos diferencias entre mMM-basal-2\u00aaL(22,2\u00b18,7) y mMM-basal-3\u00aaL(22,7\u00b18,2), p=0,792. La mediana-PT fue 8,4meses \n(IC95% 0,0-17,7). El 45,4%(5/11) suspendi\u00f3 por inefectividad y el 9,1%(1/11) por embarazo, el resto(5/11) contin\u00faan.  \nLos switches se iniciaron al mes de la \u00faltima dosis del anti-CGRP previo.  \nDe los 13 pacientes que discontinuaron por efectividad, 7 (1\u00aaL) y 1 (2\u00aaL) presentaron recurrencia. Todos fueron retratados \n(mismo anti-CGRP) sin suspensi\u00f3n al final de estudio.\nCONCLUSIONES\nLa mitad de los pacientes alcanzaron el a\u00f1o de tratamiento, siendo algunos m\u00e1s prolongados. Un tercio suspendieron \npor inefectividad, siendo la principal causa de interrupci\u00f3n. No hubo suspensiones por toxicidad, exceptuando un caso \nde hipersensibilidad. Los pacientes que discontinuaron por efectividad y presentaron recurrencia, fueron retratados. Se \nhallaron elevadas proporciones de rescates tras los fracasos. No se encontraron diferencias seg\u00fan mecanismo de acci\u00f3n. \nNuestros resultados contienen situaciones cl\u00ednicas, como fracasos y recurrencias, o duraciones \u00f3ptimas de tratamiento, \nasociadas a incertidumbre por falta de evidencia.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1130. EFECTIVIDAD Y SEGURIDAD DE DUPILUMAB A CORTO Y LARGO PLAZO: \u00bfSE CUMPLEN LOS \nOBJETIVOS TERAP\u00c9UTICOS? \nAUTORES\nLAFARGA LAPIEZA, V; FLOR GARC\u00cdA, A; CANALES UGARTE, S; FERN\u00c1NDEZ-BRAVO RODRIGO, J; PORTELA SOTELO, A; \nBARREDA HERN\u00c1NDEZ, D\nHOSPITAL GENERAL VIRGEN DE LA LUZ \ufffd HERMANDAD DONANTES DE SANGRE, 1 CUENCA \ufffd CUENCA\nOBJETIVOS\nEstudiar la efectividad, seguridad y adherencia al tratamiento con dupilumab a corto (16 semanas) y largo plazo (52 \nsemanas) en pacientes con dermatitis at\u00f3pica moderada-grave (DAMG) en un hospital de nivel-II.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo desde junio 2020 a enero 2022. Se incluyeron pacientes con DAMG que hab\u00edan iniciado tratamiento \ncon dupilumab cumpliendo con los criterios de financiaci\u00f3n y con al menos 16 semanas de tratamiento.  \nPara evaluar la efectividad se recogieron las variables: Eczema Area and Severity Index (EASI), Physician global assessment \n(PGA) y Body Surface Area (BSA) basales y en las semanas 16, 24 y 52 del Sistema de Informaci\u00f3n para determinar el Valor \nTerap\u00e9utico en la Pr\u00e1ctica Cl\u00ednica Real de los Medicamentos de Alto Impacto Sanitario y Econ\u00f3mico en el Sistema Nacional \nde Salud (VALTERMED). Se consideraron respondedores a corto plazo si presentaban reducci\u00f3n \u2265 50% del EASI inicial \n(EASI50) y reducci\u00f3n del PGA \u2265 2 en la semana 16 y a largo plazo si manten\u00edan esos valores en las semanas 24 y 52. \nPara evaluar la seguridad se analizaron los efectos adversos (EA) recogidos en las historias cl\u00ednicas (MambrinoXXI\u00ae). \nLa adherencia se calcul\u00f3 seg\u00fan el registro de dispensaciones del programa de dispensaci\u00f3n de pacientes externos \n(Farmatools\u00ae).\nRESULTADOS\nDe los 11 pacientes que iniciaron tratamiento, se incluyeron 10 en el estudio (9 hombres). Un paciente fue excluido \ndebido a su reciente inicio con dupilumab. La mediana de edad fue de 32[20-69] a\u00f1os y la de las variables basales fue: \nEASI= 25,5 [22-38], PGA= 3,5 [3-4] y BSA= 30 [20-70].  \nRespecto a la efectividad a corto plazo los resultados de las variables fueron: EASI=5 [0-25] y PGA=1 [0-3]. Alcanzaron el \nEASI50 9 pacientes (90%). El PGA se redujo 3 puntos en 6 pacientes (60%), 2 puntos en 3 pacientes (30%) y 0 puntos en 1 \npaciente (10%). Por tanto, se consideraron respondedores a corto plazo 9 pacientes (90%). \n evaluar la efectividad a largo plazo se excluyeron dos pacientes que no hab\u00edan alcanzado la semana 24 y el paciente \nno respondedor de la semana 16. El resultado de las variables en las semanas 24 y 52 fue: EASI=3[0-7], PGA=1[0-1] y \nEASI=3[0-5], PGA=1[0-1] respectivamente. Por tanto, el 100% de los pacientes mantienen su respuesta al tratamiento. Si \ntenemos en cuenta todos los pacientes que habr\u00edan llegado a la semana 52, la efectividad ser\u00eda del 85,7% (6/7).  \nAl final del estudio el tiempo medio de tratamiento fue 72 semanas conservando todos los pacientes una excelente \nrespuesta al mismo\ufffd  170Tres pacientes presentaron EA relacionados con dupilumab: xerosis cut\u00e1nea (n=1, 10%), reacci\u00f3n en el punto de inyecci\u00f3n \n(n=1, 10%) y molestias oculares (n=1, 10%). Todos ellos fueron considerados leves. \nLa adherencia global fue superior al 99%.\nCONCLUSIONES\nEl uso de dupilumab ha mostrado una elevada efectividad en la DAMG a corto y largo plazo manteni\u00e9ndose hasta la \nsemana 72 de tratamiento. Su uso se consider\u00f3 seguro con un perfil de EA leves, manteniendo buena adherencia. Es \nnecesario continuar con el estudio para ver c\u00f3mo se traduce, mediante escalas espec\u00edficas, dicha mejor\u00eda en la calidad de \nvida\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1135. IMPACTO ECON\u00d3MICO Y EN CALIDAD DE VIDA TRAS SWITCH DE ADALIMUMAB A ADALIMUMAB \nBIOSIMILAR EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL \nAUTORES\nESCRIGAS FERN\u00c1NDEZ, C; FERN\u00c1NDEZ-PACHECO , M; HERRERO , M; SAN ANDR\u00c9S CORRAL, C; \u00daBEDA RUIZ, B; \nCUERVO ESCRIBANO, K; GONZ\u00c1LEZ TRIGUEROS, C; URE\u00d1A TRIGUEROS, I\nHOSPITAL UNIVERSITARIO PR\u00cdNCIPE DE ASTURIAS. CTRA. ALCAL\u00c1-MECO, S/N ALCAL\u00c1 DE HENARES. MADRID\nOBJETIVOS\nConocer el impacto econ\u00f3mico que supondr\u00e1 el switch de adalimumab (ADA) a adalimumab biosimilar(ADAS) en un \nhospital de segundo nivel en un a\u00f1o en pacientes con enfermedad inflamatoria intestinal (EII). Evaluar el impacto en \ncalidad de vida a trav\u00e9s del grado de satisfacci\u00f3n en este grupo de pacientes.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo, llevado a cabo en pacientes con EII, en un periodo comprendido entre febrero-mayo \n2022. Se recogieron las siguientes variables: datos demogr\u00e1ficos(sexo y edad), diagn\u00f3stico, posolog\u00eda, y par\u00e1metros \nanal\u00edticos con el objetivo de analizar en un futuro la efectividad(calprotectina, niveles de ADA y niveles de anticuerpos \nADA). Se evalu\u00f3 el impacto econ\u00f3mico anual que supondr\u00e1 el cambio entre ADA y ADAS si los pacientes contin\u00faan con \nla misma pauta posol\u00f3gica. Para la evaluaci\u00f3n del impacto humano se elabor\u00f3 una encuesta simplificada tomando \ncomo referencia \u201cTreatment Satisfaction Questionnaire for Medication\u201d versi\u00f3n 1.4 en la que se analizaban cuatro \naspectos: molestias en el lugar de inyecci\u00f3n, reacciones adversas(RA) asociadas al nuevo f\u00e1rmaco, manejo de la pluma y \nsatisfacci\u00f3n global del cambio, valoradas del 1 al 5.\nRESULTADOS\nSe incluyeron 57 pacientes 50,88% (n=29) hombres, con una mediana de edad de 41 a\u00f1os[22-76]. Un 80,70% \npresentaban enfermedad de Crohn y un 13,90% colitis ulcerosa. Con relaci\u00f3n a la posolog\u00eda n=46 (80,70%) pacientes \nten\u00eda una pauta quincenal y n=11 (19,30%) pauta intensificada a semanal. Suponiendo que los pacientes continuaran un \na\u00f1o con esta pauta el impacto econ\u00f3mico ser\u00eda 339478,03\u20ac de ADA frente a 98438,00\u20ac de ADAS y 4992,32\u20ac/paciente-\na\u00f1o frente a 1447,62\u20ac/paciente-a\u00f1o de ADAS(pauta quincenal).  \nTras el an\u00e1lisis de la encuesta de satisfacci\u00f3n: un 68% afirm\u00f3 que no hab\u00eda sentido ninguna molestia en el lugar de la \ninyecci\u00f3n, un 16% y un 12% pocas o algunas y 2 pacientes habr\u00edan sufrido muchas y molestias excesivas respectivamente. \nUn 88% (n=44) de los pacientes no sufri\u00f3 ninguna RA, n=5 pacientes sufrieron alguna RA tipo cefalea, percibidas con ADA \ny un paciente sufri\u00f3 excesivas molestias no percibidas con ADA. En relaci\u00f3n con el manejo de la pluma el 50% y 44% de \nlos pacientes concluyeron que el manejo de la pluma era muy f\u00e1cil y f\u00e1cil respectivamente y n=3 pacientes algo f\u00e1cil m\u00e1s \ncompleja que ADA. La satisfacci\u00f3n global fue valorada con un 5 (muy satisfecho) en un 40% de los pacientes, con un 4 \n(satisfecho) en un 52%, y el 8% restante valor\u00f3 con 3, algo satisfecho(n=1), con un 2 algo insatisfecho(n=2) y un paciente \ncomo muy insatisfecho en relaci\u00f3n a una RA.\nCONCLUSIONES\nLos f\u00e1rmacos biosimilares generan competencia en el mercado con impacto positivo en la sostenibilidad del sistema \nsanitario. De esta manera, se consigue una mejor distribuci\u00f3n de los recursos pudiendo destinar parte a innovaci\u00f3n, \ndando oportunidades de tratamiento a pacientes que han fracasado a primeras l\u00edneas.  \nEl switch en nuestro Hospital supondr\u00e1 un fuerte impacto econ\u00f3mico, sin que haya repercutido en la satisfacci\u00f3n global \nde los pacientes con un 92% de los pacientes satisfechos o muy satisfechos. No se ha podido evaluar la efectividad, pero \nse han recogido los primeros datos para evaluarla a largo plazo.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1181. RESULTADOS DE EFECTIVIDAD EN VIDA REAL DEL TRATAMIENTO CON INHIBIDORES DE LA \nINTERLEUCINA 23 EN PACIENTES CON PSORIASIS MODERADA GRAVE. \nAUTORES\nAGUADO PAREDES, A; MART\u00cdNEZ SU\u00c1REZ, A; MO\u00d1INO DOMINGUEZ, L; BORREGO M\u00c1RQUEZ, E; ROMERO GONZ\u00c1LEZ, \nM; MART\u00cdN CASADO, L; MERINO BOH\u00d3RQUEZ, V\nHOSPITAL VIRGEN MACARENA \ufffd AV\ufffd DOCTOR FEDRIANI, 3 SEVILLA \ufffd SEVILLA171OBJETIVOS\nGuselkumab, tildrakizumab y risankizumab son anticuerpos monoclonales que inhiben selectivamente a la interleucina \n23 (anti IL-23) y est\u00e1n indicados para el tratamiento de la psoriasis en placas de moderada a grave. Hay pocos estudios \npublicados que eval\u00faen la eficacia de estos f\u00e1rmacos en la pr\u00e1ctica cl\u00ednica habitual.  \nEl objetivo de este estudio es evaluar la efectividad del tratamiento con anticuerpos monoclonales anti IL-23 en las \nsemanas 16, 24 y 52 en pacientes con psoriasis moderada-grave en la pr\u00e1ctica cl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, retrospectivo, realizado en un hospital de tercer nivel. Se incluyeron a todos los pacientes con \ndiagn\u00f3stico de psoriasis en placas en tratamiento con guselkumab, tildrakizumab y guselkumab desde el 1 de mayo de \n2019 hasta el 31 de diciembre de 2021.  \nLos datos se recogieron de la historia cl\u00ednica electr\u00f3nica. \nEl objetivo principal fue determinar la efectividad del tratamiento en las semanas 16, 24 y 52 medida mediante el \nporcentaje de pacientes que alcanzaron un PASI 75, 90 y 100, es decir, una reducci\u00f3n del 75%, 90% y 100% respecto del \nvalor basal y la reducci\u00f3n del PASI en dichas semanas.  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 con el programa IBM SPSS Statistics 25.0 mediante la prueba T de Student para muestras \napareadas\ufffd\nRESULTADOS\nSe incluyeron un total de 34 pacientes con 36 tratamientos: 19 con guselkumab, 14 con tildrakizumab y 3 con \nrisankizumab. La mediana de edad fue de 53 a\u00f1os (Rango Intercuart\u00edlico 62,25-44,50), 50% eran mujeres y 7 pacientes \n(20,6%) padec\u00edan artritis psori\u00e1sica. \nTodos los pacientes hab\u00edan sido tratados con terapia biol\u00f3gica antes de iniciar el tratamiento con un anti IL-23. 30 \npacientes (88,2%) hab\u00edan recibido tratamiento con un anti-TNF alfa, siendo adalimumab el m\u00e1s frecuente (76,5%); 12 \n(35,3%) con un anti IL-17; y 8 (23,5%) con un anti IL-12/23. La media de tratamientos biol\u00f3gicos previos por paciente fue \n2,15 \u00b1 1,52\ufffd  \nLa media del PASI basal (n=33) fue 9,71 \u00b1 8,2, a las 16 semanas (n=16) 3,49 \u00b1 4,99, a las 24 semanas (n=7) 3,6 \u00b1 8,05 y a \nlas 52 semanas (n=4) 0. Encontr\u00e1ndose diferencias estad\u00edsticamente significativas en todas las semanas (p < 0,05).  \nEn la semana 16 de tratamiento (n=21) el 66,7% de los casos alcanzaron el PASI 75; el 57,1% el PASI 90; y el 14,3% el PASI \n100\ufffd  \nEn la semana 24 (n=15) el 80% de los casos alcanzaron el PASI 75; el 53,3% el PASI 90; y el 33,3% el PASI 100.  \nEn la semana 52 (n=7) el 100% de los casos alcanzaron el PASI 75; el 71,4% el PASI 90; y el 42,8% el PASI 100.\nCONCLUSIONES\nEl tratamiento con guselkumab, tildrakizumab y risankizumab result\u00f3 ser efectivo en la pr\u00e1ctica cl\u00ednica real, la disminuci\u00f3n \ndel PASI respecto al basal fue estad\u00edsticamente significativa y el porcentaje de pacientes que alcanzan PASI 75, PASI 90 y \nPASI 100 aumenta conforme pasa el tiempo de tratamiento hasta la semana 52.  \nSon necesarios estudios con un mayor n\u00famero de pacientes para sacar conclusiones m\u00e1s s\u00f3lidas y poder posicionar a \nestos f\u00e1rmacos.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1193. PR\u00c1CTICA CLINICA REAL CON BELIMUMAB EN LUPUS ERITEMATOSO SIST\u00c9MICO EN UN HOSPITAL \nDE TERCER NIVEL \nAUTORES\nGARC\u00cdA SACRIST\u00c1N, AA; SANCHEZ-OCA\u00d1A MARTIN, N; YBA\u00d1EZ GARCIA, L; MOLINERO MU\u00d1OZ, M; ROSON SANCHEZ, \nE; PE\u00d1A PEDROSA, JA; LIRAS MEDINA, A; MARTINEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nBelimumab (BLM), es un anticuerpo monoclonal humano IgG1, que inhibe la actividad de BLyS soluble, con indicaci\u00f3n \nespec\u00edfica para el tratamiento de pacientes con lupus eritematoso sist\u00e9mico (LES) y respuesta inadecuada a tratamiento \nconvencional. Los datos sobre su uso proceden mayoritariamente de ensayos cl\u00ednicos aleatorizados (ECA), sin embargo, es \nde utilidad el an\u00e1lisis de la utilizaci\u00f3n de este medicamento biol\u00f3gico en pr\u00e1ctica cl\u00ednica habitual.  \n \nEl objetivo es conocer y evaluar las caracter\u00edsticas de los pacientes con LES en tratamiento con BLM, as\u00ed como su eficacia y \nseguridad\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, descriptivo y anal\u00edtico realizado en pacientes con diagn\u00f3stico de LES tratado con BLM desde el \na\u00f1o 2011 hasta la actualidad en un hospital de tercer nivel. Se recogieron los siguientes datos: Variables demogr\u00e1ficas: \nsexo y edad; variables de la enfermedad: tiempo de evoluci\u00f3n del LES (a\u00f1os) hasta inicio de tratamiento con BLM; \nmanifestaciones basales por las que se prescribe BLM; anal\u00edticas (antes del inicio del tratamiento con BLM y \u00faltima \nanal\u00edtica disponible): anticuerpos anti-ADN de doble cadena (anti-dsDNA); componentes 3 (c3) y 4 (c4) del complemento; \nfarmacol\u00f3gicas:, tiempo de tratamiento desde inicio (meses), suspensi\u00f3n y motivo, tratamiento concomitante, reducci\u00f3n \nde la utilizaci\u00f3n de corticoides; reacciones adversas (RA) a BLM descritas en los informes. Los datos se recogieron y \nanalizaron en una hoja de c\u00e1lculo, y se emplearon las pruebas t-Student de dos colas y Chi-cuadrado considerando un \u03b1 < \n0,05\ufffd172RESULTADOS\nSe incluyeron 13 pacientes (92,3% mujeres); edad media 41,5 a\u00f1os (26-69. El tiempo medio de evoluci\u00f3n de la \nenfermedad hasta que se inici\u00f3 BLM fue de 8 a\u00f1os y la duraci\u00f3n media del tratamiento fue de 31 meses. Las \nmanifestaciones cl\u00ednicas basales por las que se comenz\u00f3 el tratamiento con BLM fueron: 53,8% mucocut\u00e1neas, 69,2% \narticulares, 15,4% hematol\u00f3gicas y 15,4% renales.  \nEl tratamiento concomitante fue: 61,6% hidroxicloroquina, 84,6% inmunosupresores, 92,3% corticoides. 12 pacientes \ncontin\u00faan con el tratamiento. El motivo de la suspensi\u00f3n fue debido a deseo gestacional.  \nComparando los valores anal\u00edticos previo inicio del tratamiento y \u00faltima anal\u00edtica recogida, se observa una reducci\u00f3n \nestad\u00edsticamente significativa (\u03b1 < 0,05) de la utilizaci\u00f3n de corticoides de 10 mg/24 h. El valor anti-dsDNA disminuy\u00f3 de \n81,5 KIU/L a 16,7 KIU/L (\u03b1 < 0,05). En cuanto a los valores de C3 y C4, se observ\u00f3 un aumento de 19,5 mg/dl (\u03b1 > 0,05) y \n5,5 mg/dl (\u03b1 > 0,05) respectivamente. El 100% presentaron valores normalizados de C3 en su \u00faltima anal\u00edtica y el 84,6% \nen el caso de C4\ufffd  \nSe registraron los siguientes RA: 1 reacci\u00f3n infusional que consisti\u00f3 en cefalea, malestar y mareo y 2 infecciones de las \nv\u00edas respiratorias altas. En ninguno de los casos hubo interrupci\u00f3n del tratamiento.\nCONCLUSIONES\nNuestros datos replican lo observado en los ECA, reduciendo la necesidad de utilizaci\u00f3n de corticoides para el manejo \ndel LES, as\u00ed como los t\u00edtulos de anti-dsDNA. Se recoge una mejor\u00eda en los valores medios de C3 y C4 (\u03b1 > 0,05) con una \nnormalizaci\u00f3n de los valores en C3 en el 100% de los pacientes y del C4 en el 84,6%. \nTambi\u00e9n se confirma la seguridad del tratamiento a largo plazo con BLM en LES.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1194. EFECTIVIDAD Y SEGURIDAD DEL TRATAMIENTO CON INHIBIDORES DE LA JAK EN ARTRITIS \nREUMATOIDE EN PR\u00c1CTICA CL\u00cdNICA HABITUAL \nAUTORES\nALMENDROS- ABAD, N; SEGU\u00cd SOLANES, C; MORENO GIL, Q; FONT URGELLES, J; ORTIZ SANTAMAR\u00cdA, V; SALL\u00c9S \nLIZARZABURU, M; RUDI SOLA, N\nHOSPITAL GENERAL DE GRANOLLERS \ufffd AV\ufffd FRANCESC RIBAS, S/N GRANOLLERS \ufffd BARCELONA\nOBJETIVOS\nDeterminar la efectividad y seguridad del tratamiento con inhibidores de la JAK (iJAK) en pacientes con artritis reumatoide \n(AR) en pr\u00e1ctica cl\u00ednica habitual.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional y multic\u00e9ntrico en el que se incluyen todos los pacientes que han recibido \ntratamiento con iJAK (tofacitinib y baricitinib) para el manejo de la AR entre noviembre 2017 y agosto 2021. Variables \nrecogidas: demogr\u00e1ficas, f\u00e1rmaco iJAK, \u00edndices de la enfermedad (DAS28-VSG), f\u00e1rmacos biol\u00f3gicos modificadores de la \nenfermedad (FAMEb) previos, motivo de suspensi\u00f3n del f\u00e1rmaco y presencia y descripci\u00f3n de efectos adversos.  \nLa efectividad del tratamiento se evalu\u00f3 en funci\u00f3n del \u00edndice de actividad inflamatoria DAS28-VSG. Se consider\u00f3 que \nel paciente estaba en remisi\u00f3n si el DAS28-VSG < 2,6, y la respuesta se midi\u00f3 en base a los criterios de respuesta EULAR \n(buena/moderada/sin respuesta).  \nDatos obtenidos a trav\u00e9s de la historia cl\u00ednica del paciente y del programa de Farmacia de dispensaci\u00f3n ambulatoria.\nRESULTADOS\nSe incluyeron un total de 88 tratamientos, correspondientes a 78 pacientes. El 86% eran mujeres, edad media 56 a\u00f1os \n(28-77 a\u00f1os) y media de duraci\u00f3n de AR de 13,9 a\u00f1os (DE 8,1). El 37,8% fueron tratados con tofacitinib y el 62,2% con \nbaricitinib.  \nEl 73,3% hab\u00eda sido tratado con alg\u00fan FAMEb previamente (media de FAMEb previos 2), de los cu\u00e1les el 92% hab\u00eda \nrecibido anti-TNF. \nAl inicio del tratamiento, los pacientes presentaban un DAS28-VSG medio de 4,7 (DE 1,0) y se observ\u00f3 una reducci\u00f3n \ndel DAS28-VSG de 1,0 punto respecto al inicio (DE 1,6). La persistencia media fue de 17,2 meses (DE 12,2); 17,4 meses \n(DE 13,5) en el caso de tofacitinib y 17,1 meses (DE 11,5) de baricitinib. Al finalizar el estudio el 15,9% de los pacientes \nestaban en remisi\u00f3n, de los cuales el 42,9% no hab\u00eda recibido ning\u00fan FAMEb previo y el 28,6% hab\u00eda sido tratado con 1 \nFAMEb. Veintitr\u00e9s pacientes presentaron buena respuesta seg\u00fan criterios EULAR, siendo primera l\u00ednea el iJAK en el 43,5%. \nDe los 31 pacientes sin respuesta al tratamiento, el 58% hab\u00eda recibido 3 o m\u00e1s FAMEb.  \nEn cuanto a seguridad, 21 (23,9%) pacientes presentaron efectos adversos y en 13 (14,8%) casos provocaron la \nsuspensi\u00f3n del tratamiento con el iJAK, 5 en el primer mes (dolor abdominal [3], malestar general [1] y glositis [1]), y el \nresto a partir de los 3 meses (n\u00e1useas y v\u00f3mitos [3], malestar general [1] meningitis y tromboembolismo [1], edemas [1], \naumento de peso [1], infecciones [1]). Se suspendi\u00f3 el tratamiento con tofacitinib a 10 pacientes, de manera preventiva, \na ra\u00edz de la alerta de seguridad de la Agencia Espa\u00f1ola del Medicamento (AEMPS) que informaba de un incremento en la \nincidencia de eventos adversos cardiovasculares mayores y neoplasias malignas\ufffd\nCONCLUSIONES\nLos pacientes na\u00efve a FAMEb presentaron mejor respuesta en base a criterios EULAR con respecto a aquellos que \nya hab\u00edan recibido alguno previamente, y mayor porcentaje de ellos estaban en remisi\u00f3n cl\u00ednica. A pesar de que se \nsuspendieron tratamientos con iJAK por la aparici\u00f3n de efectos adversos, ninguno fue ocasionado por la alerta de \nseguridad de la AEMPS\ufffd173CLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1206. UTILIZACI\u00d3N DE PROPRANOLOL EN EL TRATAMIENTO DE LA SINTOMATOLOG\u00cdA PERIF\u00c9RICA DE \nLA ANSIEDAD \nAUTORES\nSALAZAR GONZ\u00c1LEZ, F; LONGONI MERINO, M; SEBASTI\u00c1N CARRASCO, C; IGLESIAS RODRIGO, M; MECA CASASNOVAS, \nN; NICOL\u00c1S PIC\u00d3, J\nHOSPITAL UNIVERSITARI MUTUA DE TERRASSA \ufffd PLAZA DOCTOR ROBERT 5 TERRASSA \ufffd BARCELONA\nOBJETIVOS\nAnalizar el tratamiento con propranolol (P) en pacientes psiqui\u00e1tricos que presentan sintomatolog\u00eda perif\u00e9rica de \nla ansiedad (SPA). Valorar los medicamentos que reciben para su tratamiento mental y que pueden empeorar la \nsintomatolog\u00eda perif\u00e9rica de la ansiedad.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de pacientes ingresados en una unidad de psiquiatr\u00eda de un hospital universitario de \n450 camas. Se incluyeron todos los pacientes ingresados en la unidad de psiquiatr\u00eda en el per\u00edodo julio 2020-diciembre \n2021 que recibieron P . De la historia cl\u00ednica obtenemos los siguientes datos: sexo, edad, diagn\u00f3stico. De la prescripci\u00f3n \nelectr\u00f3nica: dosis de P , duraci\u00f3n del tratamiento y resto de f\u00e1rmacos que pueden producir SPA (taquicardia o temblor): \nantidepresivos tric\u00edclicos (ADT), antipsic\u00f3ticos (AP): haloperidol, clorpromazina, levomepromazina, perfenazina, \naripiprazol, risperidona, paliperidona, y estabilizantes del \u00e1nimo (EA): carbonato de litio, \u00e1cido valproico. Se excluyeron \nlos pacientes que recibieron P para otras indicaciones.  \nSe llev\u00f3 a cabo un an\u00e1lisis estad\u00edstico descriptivo empleando medidas de tendencia central y dispersi\u00f3n para las variables \ncuantitativas (media y desviaci\u00f3n est\u00e1ndar), adem\u00e1s de frecuencias absolutas para las variables categ\u00f3ricas recogidas.\nRESULTADOS\nUn total de 29 pacientes fueron tratados con P durante el ingreso, de los que fueron excluidos dos pacientes. La media de \nedad fue 48 a\u00f1os (Desviaci\u00f3n Est\u00e1ndar: 15,3). El 70% eran mujeres. El 33,3% (9 pacientes) padec\u00eda trastorno depresivo, \n22,2% (6 pacientes) trastorno bipolar, 18,5% (5 pacientes) esquizofrenia, 14,8% (4 pacientes) trastorno ansioso depresivo \ny 11,2% (3 pacientes) otros diagn\u00f3sticos. La indicaci\u00f3n de temblor la tuvieron 23 pacientes (85%) y la de taquicardia 4 \npacientes (15%). Recibieron una dosis de 20 mg/d\u00eda 10 pacientes, de 40 mg/d\u00eda 8 pacientes, de 10 mg/d\u00eda 5 pacientes y \nde 30 mg/d\u00eda 4 pacientes. Como f\u00e1rmacos que empeoran la SPA, 12 pacientes recibieron ADT, 9 AP y 9 EA. Los pacientes \nque recibieron un f\u00e1rmaco que empeora la SPA fueron 14, los que recibieron dos 7, los que recibieron tres 1, los que \nrecibieron cuatro 1 y los pacientes que no recibieron ninguno 4.\nCONCLUSIONES\nTodos los pacientes recibieron propranolol en la indicaci\u00f3n terap\u00e9utica correcta. Los diagn\u00f3sticos con el componente \nde ansiedad estaban pr\u00e1cticamente en la totalidad de los pacientes. Las dosis utilizadas en todos los pacientes fueron \ninferiores a las indicadas en la ficha t\u00e9cnica  \nUn elevado n\u00famero de pacientes utilizan antidepresivos tric\u00edclicos, antipsic\u00f3ticos y estabilizantes del \u00e1nimo que pueden \nempeorar la sintomatolog\u00eda perif\u00e9rica de la ansiedad.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1209. EFICACIA DEL ADALIMUMAB EN EL TRATAMIENTO DE LAS UVE\u00cdTIS NO INFECCIOSAS REFRACTARIAS \nAUTORES\nBUSTO IGLESIAS, M; RODRIGUEZ FERN\u00c1NDEZ, CA; DE DOMINGO BAR\u00d3N, B; FERNANDEZ FERREIRO, A; ZARRA \nFERRO, I\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE SANTIAGO. CHOUPANA, S/N SANTIAGO DE COMPOSTELA. A CORU\u00d1A\nOBJETIVOS\nActualmente los corticoides e inmunomoduladores cl\u00e1sicos como el metotrexato, ciclosporina o micofenolato de \nmofetilo, contin\u00faan siendo el primer y segundo escal\u00f3n terap\u00e9utico en las uve\u00edtis no infecciosas (UNI), sin embargo, \nla introducci\u00f3n de nuevos medicamentos biol\u00f3gicos en el tratamiento de esta enfermedad ha supuesto una mejor\u00eda \nconsiderable en estos pacientes. El adalimumab (ADA) es el \u00fanico f\u00e1rmaco biol\u00f3gico con indicaci\u00f3n en el tratamiento \nde la UNI resistente a corticoides. El objetivo de este trabajo es estudiar la eficacia en pr\u00e1ctica cl\u00ednica real del ADA en el \ntratamiento de las las UNI refractarias\ufffd\nMATERIALES Y M\u00c9TODOS\nSe trata de un estudio observacional, retrospectivo, multic\u00e9ntrico y multidisciplinar, en el cual se incluyeron pacientes \nrefractarios a corticoides locales o sist\u00e9micos, que hayan iniciado ADA en los \u00faltimos 6 a\u00f1os para el tratamiento de UNI \n(panuve\u00edtis, uve\u00edtis anterior, intermedia o posterior) y que hayan permanecido a tratamiento con ADA al menos un a\u00f1o. El \nseguimiento de estos pacientes fue de un a\u00f1o tras el inicio de ADA. Durante el tiempo de seguimiento se monitorizaron \nlos siguientes par\u00e1metros de eficacia: la aparici\u00f3n de nuevos brotes, la reducci\u00f3n de la dosis de corticoides con respecto \na antes del inicio del adalimumab, la evoluci\u00f3n de los par\u00e1metros de inflamaci\u00f3n ocular (agudeza visual, celularidad \nen c\u00e1mara anterior, vitritis, edema macular, vasculitis\u2026), as\u00ed como la suspensi\u00f3n del tratamiento con ADA por falta de \nrespuesta. Para la recogida de datos se utiliz\u00f3 la historia cl\u00ednica electr\u00f3nica (IANUS) y los registros de dispensaci\u00f3n del \nprograma de prescripci\u00f3n electr\u00f3nica SILICON\ufffd174RESULTADOS\nSe incluyeron 19 pacientes con una media de edad de 45 (12-82) a\u00f1os. El 47% de los pacientes estudiados presentaban \npanuve\u00edtis (9/19), el 26% sufr\u00edan uve\u00edtis anterior (5/19), el 10% uve\u00edtis intermedia (2/19) y el 16% uve\u00edtis posterior \n(3/19). Un 39% de los pacientes presentaban enfermedad sist\u00e9mica asociada (7/19), y el 84 % (16/19) se encontraban \na tratamiento con corticoides sist\u00e9micos al inicio del tratamiento con ADA con una dosis media de 25 mg/d\u00eda de \nprednisona. Los resultados en las variables de eficacia fueron los siguientes: Las dosis medias de corticoides tras un a\u00f1o \nde tratamiento con ADA se redujeron a 5,9 mg/d\u00eda de prednisona. Los par\u00e1metros de inflamaci\u00f3n ocular mejoraron en \nel 79% de los pacientes (15/19), el 89% de los pacientes (17/19) se mantuvieron sin nuevos brotes durante el periodo \nde seguimiento. En los dos pacientes que sufrieron brotes de UNI durante el seguimiento, se realiz\u00f3 un cambio de \ntratamiento biol\u00f3gico\ufffd\nCONCLUSIONES\nEl ADA en nuestra cohorte de pacientes ha demostrado ser un f\u00e1rmaco eficaz como agente reductor de la dosis diaria de \ncorticoides, as\u00ed como en la limitaci\u00f3n del n\u00famero de brotes durante el seguimiento, y en la mejor\u00eda de los par\u00e1metros de \ninflamaci\u00f3n ocular en pacientes refractarios a corticoides locales o sist\u00e9micos y/o inmunomoduladores cl\u00e1sicos.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1220. EXPERIENCIA DE USO DE ANTICUERPOS MONOCLONALES CONTRA EL P\u00c9PTIDO RELACIONADO \nCON EL GEN DE LA CALCITONINA EN LA MIGRA\u00d1A. \nAUTORES\nMART\u00cdNEZ MARCOS, JM; S\u00c1NCHEZ CATALICIO, MDM; GARC\u00cdA MATILLAS, CN; F\u00c9RNANDEZ MART\u00cdNEZ, IM; MONTOYA \nEGEA, JM; MIRA SIRVENT , MC\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nEvaluar la efectividad de los anticuerpos monoclonales contra el p\u00e9ptido relacionado con el gen de la calcitonina (anti-\nCGRP) en la profilaxis de la migra\u00f1a en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de los pacientes en tratamiento con f\u00e1rmacos anti-CGRP hasta abril de 2022. Se \nexcluyeron aquellos que no alcanzaban los 3 meses de tratamiento. Los datos se obtuvieron del programa de gesti\u00f3n \nde farmacia y de la historia cl\u00ednica electr\u00f3nica. Las variables recogidas fueron: sexo, edad, tipo de migra\u00f1a, tratamiento \nprofil\u00e1ctico previo, tipo de anti-CGRP , tiempo de tratamiento, d\u00edas de migra\u00f1a al mes(DMM) al inicio y a los 3 meses, \ncambio de dosis, de anti-CGRP y suspensi\u00f3n del tratamiento. Para evaluar la efectividad se utiliz\u00f3 la reducci\u00f3n de los \nDMM a los 3 meses, consider\u00e1ndose efectivo cuando se reducen los DMM al menos en un 50% con respecto al inicio.\nRESULTADOS\nSe incluyeron 24 pacientes (22 mujeres) con una edad media de 50 a\u00f1os diagnosticados de migra\u00f1a, 8(33,33%) de \nmigra\u00f1a epis\u00f3dico (ME) y 16(66,67%) migra\u00f1a cr\u00f3nica (MC).Todos los pacientes hab\u00edan fracasado a 4 o m\u00e1s tratamientos \nprofil\u00e1cticos previos administrados durante al menos 3 meses, siendo uno de ellos toxina botul\u00ednica (100% MC, 37,5% \nME).  \nDe los 8 pacientes con ME, 6(75%) iniciaron erenumab (3 con 70 mg y 3 con 140 mg) y 2(25%) fremanezumab. La \nmediana de duraci\u00f3n del tratamiento fue de 9,3 meses (3,1-14). La mediana de DMM al inicio fue de 12(8-13) y a los 3 \nmeses de 3(2-10). En cuanto a la efectividad, 7(87,5%) pacientes disminuyeron los DMM en al menos un 50%. El paciente \nque no disminuy\u00f3 los DMM mejor\u00f3 en la intensidad de las crisis. Ning\u00fan paciente aument\u00f3 dosis, cambi\u00f3 ni suspendi\u00f3 el \ntratamiento\ufffd  \nDe los 16 pacientes con MC, 11(68,75%) iniciaron erenumab (6 con 70 mg y 5 con 140 mg), 4(25%) fremanezumab y \n1(6,25%) galcanezumab. La mediana de duraci\u00f3n del tratamiento fue de 11,9 meses (3-22,7). La mediana de DMM al \ninicio fue de 15(8-30) y a los 3 meses de 4(2-30). En cuanto a la efectividad, 14(85,71%) pacientes disminuyeron los \nDMM en al menos un 50%. 1 de los pacientes cambi\u00f3 de erenumab a fremanezumab siendo los DMM 20 y 20 por lo que \nsuspendi\u00f3 el tratamiento. Otro paciente suspendi\u00f3 galcanezumab por inefectividad siendo los DMM 30 y 30. 2 pacientes \naumentaron dosis de erenumab y pasaron de 9 a 2 y de 14 a 4, respectivamente.\nCONCLUSIONES\nEn general, el tratamiento con anti-CGRP fue efectivo siendo incluso superior a la de los ensayos pivotales. Esto \npodr\u00eda deberse a una sobrevaloraci\u00f3n de los resultados por la subjetividad de la variable (DMM) y la falta de terapias \nalternativas. En ME los resultados fueron ligeramente superiores a MC. El cambio de anti-CGRP no fue efectivo. Aumentar \nla dosis de erenumab mejor\u00f3 los DMM. La suspensi\u00f3n del tratamiento fue por inefectividad. Ser\u00eda interesante hacer un \nestudio a largo plazo para valorar la persistencia del tratamiento.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1222. EFECTIVIDAD Y SEGURIDAD DE GUSELKUMAB EN PACIENTES CON PSORIASIS MODERADA-GRAVE \nCONTROLADA CON USTEKINUMAB: ESTRATEGIA COSTE-EFECTIVIDAD. \nAUTORES\nCASTA\u00d1O AMORES, C; NIETO S\u00c1NCHEZ, MT; NIETO G\u00d3MEZ, P; MART\u00cdNEZ P\u00c9REZ, M\nHOSPITAL UNIVERSITARIO CLINICO SAN CECILIO \ufffd AVENIDA DE LA INVESTIGACION S/N GRANADA \ufffd GRANADA175OBJETIVOS\nAnalizar la efectividad, seguridad y ahorro econ\u00f3mico en pacientes con psoriasis moderada-grave actualmente \ncontrolados con ustekinumab tras una estrategia de cambio de tratamiento biol\u00f3gico a guselkumab\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, unic\u00e9ntrico en el que se analizaron variables de eficacia como la puntuaci\u00f3n en \nlas escalas BSA, PASI, PGI, EVA (picor), DLQA durante el tratamiento con ustekinumab y tras el cambio protocolizado a \nguselkumab a los 3 y 9 meses. Se calcul\u00f3 PASI-90 a los 9 meses tras el cambio a guselkumab en pacientes con un nivel de \nPASI > 0 durante el tratamiento con ustekinumab y se recogieron efectos adversos como medida de seguridad, variables \ndemogr\u00e1ficas, zonas de afectaci\u00f3n psori\u00e1sica y comorbilidades. Se calcul\u00f3 el coste/tratamiento/a\u00f1o por paciente sin dosis \nde carga\ufffd\nRESULTADOS\nSe incluyeron 28 pacientes, 12 mujeres y 16 hombres con mediana de edad de 51,5 a\u00f1os. Diez pacientes estaban en \ntratamiento con dosis de 90 mg de ustekinumab\ufffd Del total, 16 pacientes presentaban afectaci\u00f3n en el cuero cabelludo, \n9 afectaci\u00f3n ungueal, 3 palmo-plantar. Las comorbilidades eran: 6 pacientes con diabetes tipo II, 8 dislipemia, 5 \nhipertensi\u00f3n y 2 pacientes h\u00edgado graso. Los resultados de las escalas durante el tratamiento con ustekinumab fueron \n(mediana): BSA 1; PASI 0,8; PGA 1; EVA (picor) 0; DLQI 1. A los 3 y 9 meses del cambio a guselkumab: BSA 0; PASI 0; PGA \n0; EVA (picor) 0; DLQI 0. Se calcul\u00f3 PASI-90 a los 9 meses tras el cambio a guselkumab en 19 pacientes con PASI > 0 en \ntratamiento con ustekinumab: 17 pacientes (89,4%) alcanzaron el objetivo. Ning\u00fan paciente present\u00f3 efectos adversos. El \ncoste/a\u00f1o/paciente calculado es de 9.637,3 \u20ac y 9076,6 \u20ac para ustekinumab y guselkumab, con una diferencia de 560,7 \u20ac/\npaciente/a\u00f1o y diferencia global de 15.699,6 \u20ac para la cohorte de pacientes (n= 28).\nCONCLUSIONES\nEl cambio de tratamiento biol\u00f3gico en pacientes con psoriasis moderada-grave estabilizados con ustekinumab es una \nestrategia coste-efectiva con reducci\u00f3n en las escalas BSA, PASI, PGA y DLQI a los 3 y 9 meses. Adem\u00e1s, el cambio de \ntratamiento a guselkumab supone un menor coste de tratamiento al a\u00f1o por paciente, sin que reporte efectos adversos \nen la seguridad de los pacientes\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1281. DUPILUMAB EN DERMATITIS AT\u00d3PICA GRAVE: RESULTADOS DE UTILIZACI\u00d3N EN LA PR\u00c1CTICA \nCL\u00cdNICA \nAUTORES\nPAU PARRA, A; CARDONA PASCUAL, I; VANCELLS LUJAN, G; FLORENSA ROYO, E; LARROSA GARCIA, M; MARRERO \n\u00c1LVAREZ, P; GORGAS TORNER, MQ\nH. UNIVERSITARI MATERNOINFANTIL DE LA VALL D`HEBRON. PASSEIG VALL D\u00b4HEBRON 119-129 BARCELONA. \nBARCELONA\nOBJETIVOS\nLa dermatitis at\u00f3pica (DA) es una enfermedad cut\u00e1nea inflamatoria cr\u00f3nica, caracterizada por la presencia de prurito, \nlesiones eczematosas, xerosis y liquenificaci\u00f3n. Dupilumab es un anticuerpo monoclonal humano que bloquea el receptor \nde la interleukina 4 (IL-4R\u03b1) indicado en DA moderada-grave. El objetivo es evaluar la eficacia de dupilumab en DA grave \nen pacientes con indicaci\u00f3n seg\u00fan los criterios del protocolo farmacocl\u00ednico aprobado por la Comisi\u00f3n Permanente de \nFarmacia el 31/01/2020\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional que incluye los pacientes con DA que han iniciado dupilumab entre marzo \n2020 y septiembre 2021, con m\u00ednimo 16 semanas tratamiento, en un hospital de tercer nivel. Se recogen variables \nbiodemogr\u00e1ficas, farmacoterap\u00e9uticas (tratamientos previos y concomitantes, posolog\u00eda de dupilumab) y variables \ncl\u00ednicas: Eczema Area and Severity Score (EASI), Physician\u2019s Global Assessment (PGA), superficie corporal afectada (SCA), \nDermatology Life Quality Index (DLQI) y valoraci\u00f3n del prurito (escala 1-10). El seguimiento se realiza a las 16, 24 y 52 \nsemanas \u00b1 2 semanas de iniciar dupilumab (semana 0). Los datos se obtienen de la historia cl\u00ednica y del Registro de \nPacientes y Tratamientos (RPT) de CATSalut. Las variables continuas se expresan como medias \u00b1 desviaci\u00f3n est\u00e1ndar y las \nvariables categ\u00f3ricas como porcentajes (casos).\nRESULTADOS\nSe incluyeron 25 pacientes, 52% mujeres, diagnosticados de DA a los 19,7\u00b114,2 a\u00f1os. Todos cumplen los criterios de \nutilizaci\u00f3n de dupilumab en DA grave indicados en el protocolo farmacocl\u00ednico aprobado por la Comisi\u00f3n Permanente de \nFarmacia: \u226518a\u00f1os, EASI\u226521, PGA\u22653, SCA\u226510%, refractarios a medicaci\u00f3n t\u00f3pica, uso previo de ciclosporina (respuesta \ninsatisfactoria o contraindicaci\u00f3n) y candidatos a tratamiento sist\u00e9mico. La pauta de dupilumab es 600 mg en inducci\u00f3n \nseguido de 300 mg/14 d\u00edas en mantenimiento. Tratamientos previos a iniciar dupilumab en el 96%(24) de los pacientes: \nfototerapia 60%(15), azatioprina 44%(11), metotrexato 36%(9), micofenolato de mofetilo 12%(3) y otros 48%(12).  \nLa edad al inicio de dupilumab fue de 33,7\u00b111,5 a\u00f1os. Variables antes de iniciar dupilumab (semana 0): SCA 70,2\u00b121,4%, \nEASI 35,0\u00b110,9, PGA 3,8\u00b10,4, prurito 8,7\u00b11,1, DLQI 17,5\u00b15,4\ufffd  \nVariables semana 16 post-dupilumab (N=25): EASI 9,2\u00b14,4, PGA 1,1\u00b10,6, prurito 2,0\u00b11,5, DLQI 4,6\u00b13,3. Cambios respecto \na semana 0: reducci\u00f3n PGA\u22652 puntos 100%(25), reducci\u00f3n PGA\u22653 puntos 60%(15), reducci\u00f3n \u22657 puntos prurito 60%(15), \nreducci\u00f3n \u226550% EASI (EASI-50) 100%(25), reducci\u00f3n \u226575% EASI (EASI-75) 44%(11) y reducci\u00f3n \u226590% EASI (EASI-90) 16%(4).  176Variables semana 24 post-dupilumab (N=20): EASI 6,3\u00b12,8, PGA 0,85\u00b10,7, prurito 1,7\u00b11,4, DLQI 4,1\u00b13,4. Cambios respecto \na semana 0: reducci\u00f3n PGA\u22652 puntos 100%(20), reducci\u00f3n PGA\u22653 puntos 75%(15), reducci\u00f3n \u22657 puntos prurito 65%(13), \nEASI-50 100%(20), EASI-75 75%(15), EASI-90 30%(6). \nVariables semana 52 post-dupilumab (N=11): EASI 4,6\u00b11,8, PGA 0,7\u00b10,5, prurito 1,5\u00b11,2, DLQI 2,7\u00b12,1. Cambios respecto \na semana 0: reducci\u00f3n PGA\u22652 puntos 100%(11), reducci\u00f3n PGA\u22653 puntos 82%(9), reducci\u00f3n \u22657 puntos prurito 45%(5) \nEASI-50 100%(11), EASI-75 82%(9), EASI-90 55%(6). \nUna paciente suspende dupilumab por gestaci\u00f3n (semana 17) y otro por eosinofilia (semana 24).\nCONCLUSIONES\n- Dupilumab ha mostrado ser eficaz en el manejo de la DA grave, logrando un r\u00e1pido y prolongado control de la \nenfermedad, mejorando as\u00ed la calidad de vida de los pacientes. \n- Son necesarios m\u00e1s estudios que generen evidencia sobre la eficacia y seguridad a largo plazo.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1313. PROMS EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL Y TRATAMIENTO CON \nF\u00c1RMACOS BIOL\u00d3GICOS. \nAUTORES\nFERN\u00c1NDEZ CABALLERO, R; HENARES , A; MAYO , C; COLLADOS , V\nHOSPITAL INFANTA ELENA \ufffd AV\ufffd REYES CAT\u00d3LICOS, 21 VALDEMORO \ufffd MADRID\nOBJETIVOS\nLa implementaci\u00f3n de la salud digital ofrece herramientas \u00fatiles para mejorar la calidad de vida de los pacientes. El uso \nde los PROMs (patient-reported outcome measures) resulta de inter\u00e9s para medir el impacto de enfermedades cr\u00f3nicas \ncomo la enfermedad inflamatoria intestinal (EII) en la calidad de vida percibida desde la perspectiva del paciente.  \nEl objetivo del estudio fue medir la calidad de vida reportada por el paciente con EII tratado con f\u00e1rmacos biol\u00f3gicos \nen un hospital de segundo nivel. Adem\u00e1s se busc\u00f3 relaci\u00f3n entre calidad de vida, marcadores biol\u00f3gicos subrogados y \nniveles de f\u00e1rmaco.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, llevado a cabo entre mayo-2021/abril-2022. Se incluyeron pacientes con EII y \ntratamiento con f\u00e1rmacos biol\u00f3gicos que hab\u00edan respondido PROMs durante el tratamiento.  \nSe seleccion\u00f3 el cuestionario de calidad de vida IBDQ32 que fue enviado a trav\u00e9s de la historia cl\u00ednica electr\u00f3nica \ndisponible en el terminal m\u00f3vil del paciente (Portal del Paciente de Quironsalud \u00ae). IBDQ32 fue habilitado para pacientes \nseleccionados por el equipo m\u00e9dico en base a su capacitaci\u00f3n digital. Es un cuestionario validado en poblaci\u00f3n espa\u00f1ola \ncon 32 \u00edtems sobre 4 dimensiones que se valoran mediante una escala de Likert con una puntuaci\u00f3n entre 32 y 224: 32-\n95 baja, 96-159 moderada y 159-224 alta calidad de vida.  \nSe obtuvieron las siguientes variables sociodemogr\u00e1ficas, cl\u00ednicas y marcadores biol\u00f3gicos en EII (calprotectina fecal (CF), \nprote\u00edna C reactiva (PCR), alb\u00famina, hemoglobina) mediante la revisi\u00f3n de historias cl\u00ednicas.\nRESULTADOS\nRespondieron el cuestionario un total de 69 pacientes, de los cuales, 38 (18% hombres) estaban en tratamiento con \nf\u00e1rmacos biol\u00f3gicos (62 cuestionarios IBDQ32). La edad media (DE) de los pacientes incluidos fue de 44,9 (11,1) a\u00f1os.  \n6,5% de los cuestionarios (N=4) obtuvieron calidad de vida baja. Los pacientes que respondieron (N=4) estaban \nen tratamiento con: infliximab (n=2), ustekinumab (n=1) y adalimumab (n=1). El 75% de los pacientes ten\u00eda pauta \nintensificada de f\u00e1rmaco. Los valores medios de marcadores biol\u00f3gicos fueron: CF=63,3 (34,4), PCR=0,3 (0,2), \nalb\u00famina=4,6(0,3) y hemoglobina=14,9(0,1).  \n43,5% de los cuestionarios (N=27) obtuvieron calidad de vida moderada. Los pacientes que respondieron (N=15) estaban \nen tratamiento con: infliximab (n=7), ustekinumab (n=3), adalimumab 40 mg (n=3) y vedolizumab (n=2). Los valores \nmedios de marcadores biol\u00f3gicos fueron: CF=154,3(106,8), PCR=0,3(0,3), alb\u00famina=4,3(0,4) y hemoglobina=13,6(1,1).  \n50,0% de los cuestionarios (N=32) obtuvieron calidad de vida alta. Los pacientes que respondieron (N=23) estaban en \ntratamiento con: infliximab (n=11), ustekinumab (n=2), adalimumab 40 mg (n=9) y vedolizumab (n=1). Los valores medios \nde marcadores biol\u00f3gicos fueron: CF=78,8(14,7), PCR=0,5 (1,1), alb\u00famina=4,5(0,4) y hemoglobina=14,5(1,6).  \nEl 59,7% de los cuestionarios se correspond\u00edan con CFS dentro del margen terap\u00e9utico con una puntuaci\u00f3n media \nde IBDQ32 de 155(37). El 8% de los cuestionarios se correspond\u00edan con CFS fuera del margen terap\u00e9utico con una \npuntuaci\u00f3n media de IBDQ32 de 169(50).\nCONCLUSIONES\nEl 50% de los pacientes con EII en tratamiento con f\u00e1rmacos biol\u00f3gicos, refiere calidad de vida alta. \nEs indispensable conocer la percepci\u00f3n de la enfermedad por parte del paciente mediante cuestionarios de calidad \nde vida que apoyen las decisiones cl\u00ednicas, que no siempre se relacionar\u00e1n los marcadores biol\u00f3gicos de respuesta a \ntratamiento\ufffd177CLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n130. TRATAMIENTO T\u00d3PICO DE LAS ICTIOSIS CONG\u00c9NITAS: IMPACTO EN LA CALIDAD DE VIDA \nAUTORES\nGONZALEZ FREIRE, L; DAVILA POUSA, MC; BATALLA CEBEY , A; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA\nOBJETIVOS\nEvaluar el impacto en la calidad de vida del tratamiento t\u00f3pico de las ictiosis cong\u00e9nitas con f\u00f3rmulas magistrales (FM) \ndesarrolladas en el Servicio de Farmacia Hospitalaria (SFH): N-acetilciste\u00edna (NAC) 10% + Urea 5% + Aceite de Arg\u00e1n \ncrema O/W, NAC 10% + Urea 5% + Vaselina 20% crema manos/pies, NAC 10% + Urea 5% O/W loci\u00f3n capilar, Carbociste\u00edna \n10% + Urea 5% O/W, Glicerolado de almid\u00f3n y Tazaroteno 0,025% gel.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo de las caracter\u00edsticas de los pacientes diagnosticados de ictiosis cong\u00e9nitas que recibieron tratamiento \ncon las FM desarrolladas en el SFH. Estudio observacional prospectivo del impacto en la calidad de vida de dicho \ntratamiento\ufffd  \nBases de datos: historia cl\u00ednica electr\u00f3nica y aplicativo inform\u00e1tico de dispensaci\u00f3n a pacientes externos. \nVariables recogidas: edad, sexo, diagn\u00f3stico, FM dispensadas, dificultades en la aplicaci\u00f3n del tratamiento t\u00f3pico \ndispensado\ufffd  \nPara valorar la calidad de vida se realiz\u00f3 un cuestionario de calidad de vida DLQI antes del tratamiento y un cuestionario \nde calidad de vida DLQI despu\u00e9s del tratamiento. El impacto sobre la calidad de vida del tratamiento t\u00f3pico con las FM \ndesarrolladas en el SFH se evalu\u00f3 mediante la diferencia en la puntuaci\u00f3n del cuestionario DLQI antes y despu\u00e9s del \ntratamiento\ufffd  \nAn\u00e1lisis estad\u00edstico: prueba t-student. El programa utilizado fue el software IBM SPSS\u00ae Statistic versi\u00f3n 23.  \nEste estudio fue aprobado por el Comit\u00e9 \u00e9tico con el c\u00f3digo 2021/334.\nRESULTADOS\nSe incluyeron un total de 6 pacientes varones con una mediana de edad de 14,5 (5-60) a\u00f1os. El 33,3% de los pacientes \npresentaban diagn\u00f3stico de Ictiosis Vulgar (IV), el 50% Ictiosis Lamelar (IL) y el 16,7% Ictiosis Autos\u00f3mica Recesiva. \nEn cuanto a las FM recibidas, el 66,7% de los pacientes recibieron la FM de N-acetilciste\u00edna (NAC) 10% + Urea5% + Aceite \nde Arg\u00e1n crema O/W, 1 de los cuales precis\u00f3 cambio de FM por mal olor de la NAC. El 50% recibieron la FM de NAC10% + \nUrea5% + Vaselina 20% crema manos/pies, el 33,3% NAC10% + Urea5% O/W loci\u00f3n capilar, el 83,3% Carbociste\u00edna10% + \nUrea5% O/W de los cuales 2 manifestaron dificultad en la extensibilidad de la FM. Un 16,7% recibi\u00f3 la FM de Glicerolado \nde almid\u00f3n y un 16,7% Tazaroteno 0,025% gel. \nEn cuanto a la evaluaci\u00f3n de la calidad de vida, la media de puntuaci\u00f3n y desviaci\u00f3n est\u00e1ndar (DE) del cuestionario DLQI \nprevio al tratamiento fue de 10\u00b13,41 y del cuestionario DLQI posterior al tratamiento de 3,83\u00b13,71(p=0.013).  \nNo se observaron diferencias significativas en el impacto en calidad de vida entre los distintos tratamientos recibidos: \nDLQI NAC10% + Urea5% + Aceite de Arg\u00e1n crema O/W 3,5\u00b13(p=0,793), DLQI NAC10% + Urea5% + Vaselina20% crema \nmanos/pies 2\u00b10(p=0,454), DLQI NAC10% + Urea5% O/W loci\u00f3n capilar 3,67\u00b14,73(p=0,926), DLQI Carbociste\u00edna10% + \nUrea5% O/W 4,2\u00b14,02(p=0,644), DLQI Glicerolado de almid\u00f3n 2\u00b10(p=0,644) Y DLQI Tazaroteno 0,025% gel 9\u00b10(p=0,135).\nCONCLUSIONES\nEl tratamiento t\u00f3pico con las FM desarrolladas en el SFH ha demostrado una reducci\u00f3n significativa del impacto en \nla calidad de vida de los pacientes diagnosticados de ictiosis cong\u00e9nitas. Sin embargo, no se observaron diferencias \nsignificativas entre las diferentes alternativas terap\u00e9uticas elaboradas en el SFH.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n145. RESULTADOS EN SALUD DEL USO DE IDEBENONA EN NEUROPAT\u00cdAS \u00d3PTICAS MITOCONDRIALES \nAUTORES\nBEL\u00cdO AG\u00dcERA, B; ALONSO D\u00cdEZ, M; \u00c1LVAREZ LAVIN, M; CISNEROS CARPIO, M; VILA GALLEGO, C; VARA URRUCHUA, \nM; INCL\u00c1N CONDE, M; AGUIRREZABAL ARREDONDO, A\nHOSPITAL DE BASURTO \ufffd AV\ufffd MONTEVIDEO, 18 BILBAO \ufffd VIZCAYA\nOBJETIVOS\nConocer las caracter\u00edsticas de los pacientes en tratamiento con idebenona para neuropat\u00edas \u00f3pticas mitocondriales \n(NOM) y determinar la eficacia, seguridad y resultados en salud.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional que incluye todos los pacientes en tratamiento con idebenona para NOM identificados a trav\u00e9s del \naplicativo corporativo de prescripci\u00f3n.  \nSe recogieron de la historia cl\u00ednica electr\u00f3nica las variables: edad, sexo, diagn\u00f3stico de la enfermedad, dosis y duraci\u00f3n \ndel tratamiento\ufffd  \nPara la evaluaci\u00f3n de la eficacia y resultados cl\u00ednicos se utilizaron datos de estudios oftalmol\u00f3gicos: campo visual (CV) \ndeterminado seg\u00fan valores del Visual Field Index (VFI) o estudios del globo ocular, agudeza visual (AV), Tomograf\u00eda \u00d3ptica 178Computarizada (OCT) y el test Ishihara, y su variaci\u00f3n en el tiempo. La seguridad se determin\u00f3 por las reacciones adversas \ndescritas por los pacientes y/o aquellas que obligaron a suspender el tratamiento.\nRESULTADOS\nSe incluyeron 12 pacientes (58.3% hombres). La media de edad fue 42\u00b116 a\u00f1os. El diagn\u00f3stico del 41.7% fue neuropat\u00eda \n\u00f3ptica hereditaria de Leber (NOHL), y del 58.3% atrofia \u00f3ptica dominante (AOD) en un uso aprobado fuera de ficha \nt\u00e9cnica. Todos los casos fueron revisados por el Servicio de Farmacia y el comit\u00e9 multidisciplinar de enfermedades raras. \nLa duraci\u00f3n media de tratamiento fueron 11.8\u00b16.1 meses. La posolog\u00eda en pacientes adultos fue 300 mg cada 8 horas, y \nen pacientes pedi\u00e1tricos 150 mg cada 12 horas.  \nEn cuanto a la eficacia medida por mejor\u00eda de la AV, a los 3 meses tras el inicio el 72.7% de los pacientes mejoraron, el \n27.3% se mantuvieron y en ning\u00fan caso se vio disminuida. A los 6 meses, un 40% sigui\u00f3 mejorando, y al a\u00f1o, el mismo \nporcentaje mostr\u00f3 todav\u00eda mejor\u00eda, manteni\u00e9ndose estable el 60%.  \nLa OCT mostr\u00f3 estabilizaci\u00f3n en la capa de fibras en el 88.9% de los pacientes durante el tratamiento.  \nEl test Ishihara se realiz\u00f3 a 6 pacientes, de los cuales el 66.6% mostraron mejor\u00eda en alg\u00fan momento del tratamiento.  \nEn cuanto al CV, se dispone de datos en el tiempo de 9 pacientes. De ellos, un 77.8% mostr\u00f3 mejora o estabilizaci\u00f3n del \nCV a los 6 meses. De los 4 que han completado el a\u00f1o de tratamiento, s\u00f3lo en 1 ha habido empeoramiento.  \nUn paciente suspendi\u00f3 el tratamiento por no mejor\u00eda de la visi\u00f3n tras un a\u00f1o de terapia. En todos los casos el tratamiento \nfue bien tolerado sin reacciones adversas importantes\ufffd\nCONCLUSIONES\nLos pacientes en tratamiento con idebenona son en su mayor\u00eda adultos con diagn\u00f3stico de NOM confirmada \ngen\u00e9ticamente e importante p\u00e9rdida visual (pacientes con AOD con AV inferior a 0.7 y todos los pacientes que desarrollan \nla NOHL).  \nEn la mayor\u00eda se observa una mejor\u00eda en la visi\u00f3n durante los primeros meses de tratamiento, estabiliz\u00e1ndose esta \nmejor\u00eda conforme avanza el tiempo.  \nEl tratamiento con idebenona es bien tolerado en la mayor\u00eda de los pacientes y tiene pocas reacciones adversas.  \nEn nuestra cohorte la idebenona ha mostrado ser eficaz y segura, consiguiendo recuperaci\u00f3n o estabilizaci\u00f3n de la \nagudeza visual despu\u00e9s de 1 a\u00f1o de tratamiento, con los mejores resultados en los primeros meses.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n510. EFECTIVIDAD Y SEGURIDAD DE ELEXACAFTOR/TEZACAFTOR/IVACAFTOR EN EL TRATAMIENTO DE \nLA FIBROSIS QU\u00cdSTICA \nAUTORES\nRODR\u00cdGUEZ-MAR\u00cdN , M; MART\u00cdNEZ-BARROS , H; GUIJARRO-MART\u00cdNEZ , P; QUESADA-MU\u00d1OZ , L; RODR\u00cdGUEZ-\nSAGRADO , M\u00c1; \u00c1LVAREZ D\u00cdAZ, A; PARRO-MART\u00cdN , M\u00c1\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nAnalizar la efectividad y seguridad y describir los patrones de utilizaci\u00f3n en vida real de elexacaftor/tezacaftor/ivacaftor \nen el tratamiento de pacientes diagnosticados de fibrosis qu\u00edstica.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio longitudinal, retrospectivo y descriptivo que incluy\u00f3 a todos los pacientes mayores de 12 a\u00f1os \ndiagnosticados de fibrosis qu\u00edstica que iniciaron elexacaftor/tezacaftor/ivacaftor hasta el 31/01/2022 en un hospital de \ntercer nivel. Se recogieron las siguientes variables demogr\u00e1ficas y cl\u00ednicas: edad (variable cuantitativa discreta), sexo \n(variable cualitativa dicot\u00f3mica: var\u00f3n o mujer), genotipo de la prote\u00edna reguladora de la conductancia transmembrana \nde la fibrosis qu\u00edstica (CFTR) (variable cualitativa dicot\u00f3mica: homocigoto o heterocigoto. Entre los heterocigotos se \nregistrar\u00e1 el alelo de funci\u00f3n m\u00ednima implicado (variable cualitativa nominal)) y tratamiento previo con potenciadores \no modificadores de CFTR (variable cualitativa dicot\u00f3mica: s\u00ed o no). La variable de efectividad fue el cambio absoluto en \nel porcentaje de volumen espiratorio forzado en un segundo (ppVEF1) a la semana 12 con respecto al basal (variable \ncuantitativa continua). Los efectos adversos (EA) fueron recogidos (variable cualitativa dicot\u00f3mica: efecto adverso s\u00ed o no. \nEn caso de estar presente, se indicar\u00e1 el efecto adverso (variable cualitativa nominal)) y gradados de acuerdo con CTCAE \nv5.0 (Common Terminology Criteria for Adverse Events) (variable cualitativa ordinal: 1, 2, 3, 4 y 5).\nRESULTADOS\nSe identificaron un total de 23 pacientes que iniciaron elexacaftor/tezacaftor/ivacaftor en el per\u00edodo de estudio. La \nmediana de edad fue de 35 a\u00f1os (rango intercuartilico 23-51) y 52,2% eran varones. Nueve pacientes (39,1%) eran \nhomocigotos para la mutaci\u00f3n F508del. Entre los pacientes heterocigotos para la mutaci\u00f3n F508del, el alelo de funci\u00f3n \nm\u00ednima m\u00e1s frecuente fue F508del/G542X (seis, 42,9% de los heterocigotos). Quince (65,2%) de los pacientes estaban \nen tratamiento con potenciadores y modificadores de CFTR antes de iniciar elexacaftor/tezacaftor/ivacaftor. La mediana \nbasal de ppVEF1 fue de 63% (rango 30-119), que mejor\u00f3 a 74% (rango 32-127) a las 12 semanas. La mediana de cambio \ncon respecto al basal fue de 10 puntos porcentuales (rango 1-36). En pacientes homocigotos, la mediana de ppVEF1 basal \nfue de 66% (rango 37-119) y de 79% (58-117) a las 12 semanas, mediana de cambio de 10 puntos porcentuales (rango \n1-14). En pacientes heterocigotos, la ppVEF1 basal fue de 52% (rango 30-102) y de 54% (rango 32-122) a las 12 semanas, \nmediana de cambio de diez puntos porcentuales (rango 1-36). Cuatro (17,4%) de los pacientes padecieron un EA, \ntodos ellos de grado 1 o 2 de acuerdo con los CTCAE v5\ufffd0\ufffd Los EA descritos fueron: cefalea, prurito, infecci\u00f3n del tracto \nrespiratorio superior y fatiga.179CONCLUSIONES\nEn esta cohorte de vida real, elexacaftor/tezacaftor/ivacaftor mejora en 10 puntos porcentuales el ppVEF1.  \nA pesar del corto per\u00edodo de seguimiento, el perfil de seguridad de elexacaftor/tezacaftor/ivacaftor fue bueno, sin \nproducirse ning\u00fan EA grave. \nAproximadamente un tercio de los pacientes no recib\u00edan previamente tratamiento con moduladores o potenciadores del \nCFTR \ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n558. EVALUACI\u00d3N DE LA EFECTIVIDAD DE NINTEDANIB Y PIRFENIDONA EN FIBROSIS PULMONAR \nIDIOP\u00c1TICA \nAUTORES\nTEJADA MAR\u00cdN, D; RODR\u00cdGUEZ ESQU\u00cdROZ, A; LACALLE FABO, E; PRECIADO GOLDARACENA, J; PINO RAMOS, A; \nIRIGOYEN RODR\u00cdGUEZ, I; YERRO YANGUAS, A\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nNintedanib y pirfenidona son f\u00e1rmacos antifibr\u00f3ticos indicados en fibrosis pulmonar idiop\u00e1tica (FPI) de leve a \nmoderada. Se consideran equivalentes terap\u00e9uticos y la elecci\u00f3n entre ellos se basa en criterios de eficiencia, perfil de \ncomorbilidades y efectos adversos (EEAA). En nuestra comunidad se recomienda priorizar pacientes con capacidad vital \nforzada (CVF) 50-80% y prueba de difusi\u00f3n de mon\u00f3xido de carbono (DLCOc) 30-79%, as\u00ed como retirar tratamiento si \ndisminuye la CVF > 10% o la DLCOc > 15% durante en cualquier periodo de 12 meses como m\u00e1ximo.  \nEl objetivo de este estudio es evaluar la efectividad de estos f\u00e1rmacos en un hospital de tercer nivel a los 6 y 12 meses de \ninicio del tratamiento\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo. Se incluyeron pacientes diagnosticados de FPI en tratamiento con nintedanib y/o \npirfenidona entre junio 2015 y mayo 2022. \nSe recogieron datos sociodemogr\u00e1ficos (edad y sexo), cl\u00ednicos y de funci\u00f3n pulmonar: fecha de inicio/fin de tratamiento, \nmotivos de elecci\u00f3n, cambio/fin de tratamiento y persistencia. Para medir la efectividad del tratamiento se recogi\u00f3 la CVF \ny la DLCOc de la espirometr\u00eda, de forma basal y a los 6 y 12 meses, analiz\u00e1ndose las variaciones respecto al valor inicial. \nLos datos se recogieron de historia cl\u00ednica informatizada.\nRESULTADOS\nSe incluyeron 76 pacientes, 52 contin\u00faan en tratamiento activo, 15 exitus, 9 suspensiones de tratamiento. 74% hombres, \nedad media (rango) 70 a\u00f1os (40-83).  \nEl 61% de los pacientes inici\u00f3 con Nintedanib\ufffd Entre las causas de selecci\u00f3n a favor de nintedanib: deseo de exposici\u00f3n al \nsol, enfermedad hep\u00e1tica, tabaco y tendencia al estre\u00f1imiento. A favor de pirfenidona: toma de anticoagulantes orales, \nantecedentes de enfermedad cardiovascular, toma de otros f\u00e1rmacos que producen diarrea e insuficiencia renal.  \nLa CVF basal media fue del 77%(33-135%), aumentando del 68% en el a\u00f1o 2015 al 78% en el a\u00f1o 2022. El 67% dentro del \nrango de priorizaci\u00f3n.  \nLa DCLOc basal media fue del 53%(24-87%), estando el 89% de los pacientes dentro del rango recomendado.  \nA los 6 meses de tratamiento, hubo una diferencia relativa media de la CVF del +1.2% (+16% a -12%); en un 5% de los \npacientes > -10%. La variaci\u00f3n media del DLCOc fue de +4.0% (+55.7% a -26%); un 2% de los pacientes > -15%. \nA los 12 meses de tratamiento, CVF media fue de -3,6% (+15% a -51%), 22% con ca\u00edda > 10% y la DLCOc +3,2% (+49% a \n-20%), 11% con ca\u00edda > 15%.  \nLos motivos de las suspensiones definitivas de tratamiento fueron: Nintedanib: 5 por intolerancia gastrointestinal, 1 por \nreacci\u00f3n exantematosa; Pirfenidona: 1 por trasplante pulmonar, 1 intolerancia gastrointestinal y 1 astenia y malestar \ngeneral. Ninguno se suspendi\u00f3 por falta de efectividad.\nCONCLUSIONES\n- Es necesario reposicionar las indicaciones de los antifibr\u00f3ticos en FPI para adecuarse a la evidencia cient\u00edfica y las gu\u00edas \ndisponibles\ufffd  \n- Cada vez se inician los tratamientos antifibr\u00f3ticos con mejor funcionalismo pulmonar, como recomiendan las gu\u00edas.  \n- Las suspensiones de tratamiento en su mayor\u00eda son por EEAA. \n- Pirfenidona y Nintedanib son opciones igualmente coste efectivas, y la elecci\u00f3n entre uno u otro deber\u00eda basarse en CI, \nperfil de EEAA y preferencias del paciente.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n569. EVALUACI\u00d3N DE LA EFICACIA DEL TRATAMIENTO CON NUSINERSEN EN PACIENTES CON ATROFIA \nMUSCULAR ESPINAL. \nAUTORES\nGUZM\u00c1N CORDERO, C; MANCILLA MONTERO, E; APARICIO CASTELLANO, B; RUIZ LARA, LM\nHOSPITAL UNIVERSITARIO REINA SOFIA \ufffd AVENIDA MENENDEZ PIDAL S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA180OBJETIVOS\nEstudiar la eficacia del tratamiento de la atrofia muscular espinal (AME) con nusinersen en pacientes que sufren de AME \ntipo I, II o III en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio observacional retrospectivo que incluy\u00f3 a todos los pacientes, con independencia de su edad, que \nhan recibido nusinersen en nuestro hospital desde la comercializaci\u00f3n del f\u00e1rmaco y que llevasen en tratamiento como \nm\u00ednimo 12 meses.  \nLa evaluaci\u00f3n de la eficacia se realiz\u00f3 mediante la medici\u00f3n de escalas de funci\u00f3n motora de referencia en AME: HINE-2 y \nCHOP-INTEND en AME tipo I, y HFMSE y RULM en AME tipo II y III. Se consideraron pacientes no respondedores aquellos \ncon AME tipo I que no consegu\u00edan mejora en la escala HINE-2 o CHOP-INTEND al cabo de 12 y 18 meses de empezar la \nterapia; y aquellos con AME tipo II o III que no mejoraban en m\u00e1s de 3 puntos en la escala HFMSE ni m\u00e1s de 2 en RULM a \nlos dos a\u00f1os de tratamiento\ufffd\nRESULTADOS\nEl n\u00famero total de pacientes incluidos en el estudio fueron 11: cinco afectos de AME I y seis de AME II o III. Todos, \nexcepto dos, eran pacientes pedi\u00e1tricos.  \nLos resultados m\u00e1s satisfactorios se obtuvieron en los pacientes diagnosticados con AME tipo I, que ten\u00edan una edad \nmedia al comenzar el tratamiento de 6,4 meses. El 100% de los pacientes obtuvo resultados eficaces, aumentando la \npuntuaci\u00f3n en la escala HINE-2 en 8,20 puntos de media a los 12 meses de tratamiento (n=5) y en 14,25 puntos al cabo \nde 18 meses (n=4). La medici\u00f3n de la escala CHOP-INTEND fue tambi\u00e9n favorable: se aument\u00f3 la puntuaci\u00f3n una media \nde 28,60 puntos a los 12 meses y 30,50 puntos a los 18 meses\ufffd  \nEn el caso de los pacientes con AME tipo II o III, con una edad media al iniciar el tratamiento mucho mayor (21,33 a\u00f1os, \ndos adultos y cuatro ni\u00f1os), los resultados no fueron tan favorables. Las mediciones de las escalas en los seis pacientes \nmostraron un aumento medio en la escala HFMSE de 0,6 puntos, y de 1,17 en la escala RULM tras 2 a\u00f1os de tratamiento\ufffd \nSin embargo, el 50% de los tratamientos fueron considerados ineficaces debido a un aumento menor de 3 y 2 puntos \nen HFMSE y RULM, respectivamente. S\u00f3lo en uno de los pacientes no respondedores al tratamiento se produjo una \ndisminuci\u00f3n de puntuaci\u00f3n en ambas escalas\ufffd\nCONCLUSIONES\nLos resultados del estudio est\u00e1n en consonancia con los de los ensayos cl\u00ednicos, demostrando que el nusinersen presenta \nla m\u00e1xima eficacia en las etapas tempranas y m\u00e1s graves de la enfermedad, que es el caso de la AME I. Esto muestra la \nimportancia del diagn\u00f3stico y tratamiento precoz de la AME, pues el retraso al comenzar la terapia implica p\u00e9rdida de \neficacia del f\u00e1rmaco y un peor pron\u00f3stico.  \nEn el caso de AME II y III (formas menos graves), el nusinersen muestra una efectividad menor, pero la no existencia de \nalternativas en la actualidad aumenta el valor terap\u00e9utico de este f\u00e1rmaco.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n581. USO DE DEFIBROTIDE EN PACIENTES SOMETIDOS A TRASPLANTE DE PROGENITORES \nHEMATOPOY\u00c9TICOS \nAUTORES\nMATEO FOLGADO, E; GARC\u00cdA PASTOR, C; VALDELMILLOS CARB\u00d3, L; BERISA PRADO, S; BL\u00c1ZQUIZ IBERO, E; BARACE \nINDUR\u00c1IN, MC\nCLINICA UNIVERSITARIA DE NAVARRA \ufffd AV\ufffd PIO XII, 36 PAMPLONA/IRU\u00d1A \ufffd NAVARRA\nOBJETIVOS\nEl defibrotide es un medicamento hu\u00e9rfano indicado para el tratamiento de la enfermedad venooclusiva hep\u00e1tica (EVOH), \nen pacientes sometidos a trasplante de progenitores hematopoy\u00e9ticos (TPH). La EVOH grave sin tratamiento tiene una \nmortalidad > 80%. Este medicamento tambi\u00e9n se usa habitualmente como profilaxis de EVOH en pacientes con elevado \nriesgo\ufffd  \nEl objetivo del trabajo es estudiar la efectividad del tratamiento y profilaxis con defibrotide en nuestro centro.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de pacientes sometidos a TPH que recibieron defibrotide desde febrero de \n2006 hasta noviembre de 2021. Se recogieron de la historia cl\u00ednica electr\u00f3nica las siguientes variables: edad, g\u00e9nero, \ndiagn\u00f3stico principal, tipo de trasplante y acondicionamiento, factores de riesgo para el desarrollo de EVOH, d\u00eda de inicio \ny duraci\u00f3n de tratamiento, uso concomitante de corticoides, niveles de bilirrubina total inicial (Bti). Finalmente se revis\u00f3 \nel desarrollo y resoluci\u00f3n del EVOH\ufffd\nRESULTADOS\n24 pacientes fueron tratados, con edad media de 36 a\u00f1os (min-max:7-68), 8 pedi\u00e1tricos, siendo el 54% hombres. \nDiagn\u00f3sticos: Leucemia Linfoide Aguda-B (29%), Leucemia Mieloide Aguda (25%), Leucemia Linfoide Aguda-T (12,5%), \nS\u00edndrome mielodispl\u00e1sico (12,5%), Leucemia Mieloide Cr\u00f3nica (4%) y otros (17%). 2 trasplantes aut\u00f3logos y 22 alog\u00e9nicos \nhaploid\u00e9nticos (82% emparentados). El 87,5% de los acondicionamientos administrados fueron mieloablativos, el 8,3% \nde intensidad reducida y un 4,2% desconocido. Los factores de riesgo recogidos fueron: 8,3% era el 2\u00ba TPH, 4,2% recibi\u00f3 \ntratamiento previo con inotuzumab y 12,5% present\u00f3 sobrecarga f\u00e9rrica previa al desarrollo del EVOH.  \nEl 25% (n=6) recibi\u00f3 defibrotide como profilaxis del EVOH, comenzando el tratamiento entre los d\u00edas -7 a -4 del TPH \n, con una duraci\u00f3n media de 24 d\u00edas (17-35). El 75% (18) restante inici\u00f3 tratamiento tras el diagn\u00f3stico de EVOH en 181el d\u00eda promedio +61 post-TPH (11-251), con una duraci\u00f3n media de 14,5 d\u00edas (1-34). De ellos, el 66,7% (12) finaliz\u00f3 el \ntratamiento antes de 21 d\u00edas de tratamiento.  \nUn 41,7% de los pacientes recibi\u00f3 corticoterapia concomitante, con una duraci\u00f3n media de defibrotide de 20 d\u00edas. En los \npacientes en monoterapia con defibrotide, fue 15 d\u00edas.  \nEl rango de valores de la Bti fue 0,17-19,7 mg/dL, el 79,2% de los casos no tuvieron Bti > 2 mg/dL, uno de los criterios \ndiagn\u00f3sticos de EVOH. Del 20,8% de los pacientes restantes, un 75% fallecieron por causas relacionadas con EVOH.  \nTodos los pacientes que recibieron defibrotide como profilaxis (25% del total) no desarrollaron EVOH. De los pacientes \nen tratamiento (75%), el 72,1% resolvieron el EVOH, 5,6% se desconoce y el 22,3% fallecieron durante el tratamiento con \ndefibrotide, todos ellos por causas relacionadas con el EVOH.\nCONCLUSIONES\nEl uso de defibrotide como profilaxis en casos de riesgo y como tratamiento de EVOH es efectivo. Tres cuartas partes de \nlos pacientes con EVOH resolvieron el cuadro, con una duraci\u00f3n menor a 21 d\u00edas en la mayor\u00eda de los casos.  \nLa precocidad en el tratamiento con defibrotide, incluso antes de cumplir todos los criterios diagn\u00f3sticos de EVOH, se \nasocia a una buena resoluci\u00f3n del cuadro\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n587. USO DE CANNABIDIOL EN EL S\u00cdNDROME DE LENNOX-GASTAUT \nAUTORES\nRAMIS BARCEL\u00d3, MB; DEL R\u00cdO ORTEGA, P; FERN\u00c1NDEZ MART\u00cdNEZ, V; REY MONTALBAN, RL; G\u00d3MEZ G\u00d3MEZ, D; \nS\u00c1NCHEZ GUNDIN, J; ILLARO URANGA, A; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nEl s\u00edndrome de Lennox-Gastaut (SLG) es un s\u00edndrome poco definido que se asocia a convulsiones graves en la infancia \nnormalmente refractarias al tratamiento farmacol\u00f3gico. Recientemente se ha comercializado cannabidiol (CBD) para \nel tratamiento complementario de convulsiones asociadas con el SLG en conjunto con clobazam en pacientes mayores \nde dos a\u00f1os\ufffd CBD consigui\u00f3 en el ensayo pivotal GWPCARE4 una reducci\u00f3n del 43,9% en la frecuencia mensual de crisis \nconvulsivas. El objetivo de este estudio fue evaluar la efectividad y seguridad de CBD.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo que incluy\u00f3 a todos los pacientes externos con SLG en tratamiento con \ncannabidiol oral desde octubre del 2020 hasta marzo del 2022.  \nLos datos se extrajeron de la historia cl\u00ednica electr\u00f3nica y del programa de prescripci\u00f3n electr\u00f3nica asistida e incluyeron \nedad, sexo, posolog\u00eda, tratamiento previo, tratamiento concomitante con clobazam, n\u00famero de convulsiones mensuales \nprevias y posteriores al tratamiento con CBD (semanas 0, 6, 14 y actualidad) y efectos adversos asociados (EA).\nRESULTADOS\nSe incluyeron 3 pacientes de sexo masculino con una mediana de edad de 5 a\u00f1os (rango 5-13) en tratamiento con \ncannabidiol para el SLG. La media de f\u00e1rmacos antiepil\u00e9ticos previos al tratamiento con CBD fue de 2,6 (\u00b10,6).  \nAl inicio, todos los pacientes estaban en tratamiento concomitante con clobazam. En 2 pacientes la dosis inicial (2mg/kg/\nd\u00eda) fue inferior a la recomendada (5mg/kg/d\u00eda) aument\u00e1ndose hasta la dosis de mantenimiento habitual (10mg/kg/d\u00eda).  \nDurante el per\u00edodo de estudio, un paciente experiment\u00f3 somnolencia y dificultad motriz por lo que se procedi\u00f3 a la \nsuspensi\u00f3n del tratamiento y a la reintroducci\u00f3n del mismo a dosis reducida a los 3 meses (dosis de mantenimiento: \n4mg/kg/d\u00eda).  \nEn cuanto a la efectividad, en la semana 6 los pacientes experimentaron un reducci\u00f3n del 80%, 75% y 66,7% en el n\u00famero \nde convulsiones mensuales. En la semana 14 el primer paciente redujo la frecuencia de crisis respecto al inicio en un \n99,7%, el segundo paciente se mantuvo en una reducci\u00f3n del 75% (de menor duraci\u00f3n e intensidad) y el tercero sufri\u00f3 \nun repunte en el n\u00famero de crisis probablemente debido a la suspensi\u00f3n de CBD y reintroducci\u00f3n a dosis inferiores \n(reducci\u00f3n del 16,7% respecto la semana 0 y aumento del 50,0% respecto a la semana 6).  \nEn la actualidad los porcentajes de reducci\u00f3n de las convulsiones respecto al inicio son: 97,8% (semana 75), 75% \n(semana 17) y 100% (semana 78). Los datos del \u00faltimo paciente deben analizarse teniendo en cuenta su infradosificaci\u00f3n \ny la reciente implantaci\u00f3n de un dispositivo de estimulaci\u00f3n del nervio vago y al tratamiento con inmunoglobulinas \nintravenosas\ufffd\nCONCLUSIONES\nLa utilizaci\u00f3n de cannabidiol seg\u00fan la posolog\u00eda recomendada en ficha t\u00e9cnica permite reducir la frecuencia de las \nconvulsiones asociadas al s\u00edndrome de Lennox-Gastaut. Es necesario un mayor n\u00famero de pacientes para confirmar su \nefectividad. El tratamiento se asocia a la aparici\u00f3n de efectos adversos que pueden limitar su uso.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n648. EFECTIVIDAD Y SEGURIDAD DE RITUXIMAB EN EL TRATAMIENTO DE LA GLOMERULONEFRITIS \nREFRACTARIA, EXPERIENCIA DE UN HOSPITAL DE TERCER NIVEL. \nAUTORES\nTEJEDOR TEJADA, E; RODRIGUEZ GOICOECHEA, M; PORTILLO HARO, S; BRUGUERA TEIXIDOR, M\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA182OBJETIVOS\nLa nefropat\u00eda membranosa (NM) es la enfermedad glomerular primaria que con mayor frecuencia causa el s\u00edndrome \nnefr\u00f3tico en adultos. El rituximab se considera una terapia en pacientes a los que les han fallado los corticoides y los \ninmunosupresores. La importancia de controlar esta patolog\u00eda es evitar la insuficiencia renal y la necesidad de un \ntrasplante. Por ello, se pretende evaluar la efectividad y seguridad del rituximab en la glomerulonefritis refractaria a los \ntratamientos convencionales\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo y retrospectivo en un hospital de tercer nivel. Se seleccionaron pacientes diagnosticados de \nglomerulonefritis, previamente tratados con el r\u00e9gimen de Ponticelli (corticoides con ciclofosfamida) y otros \ninmunosupresores. Se recogieron las siguientes variables: edad, sexo, dosis acumulada y tipo de glomerulonefritis. Para \nevaluar la eficacia, se recogieron las siguientes variables antes y despu\u00e9s del tratamiento: creatinina, tasa de filtraci\u00f3n \nglomerular, alb\u00famina, relaci\u00f3n prote\u00ednas/creatinina en orina y antiPLA2R . Para evaluar la seguridad seg\u00fan la tolerancia \nal f\u00e1rmaco. Se utilizaron los siguientes programas: Silicon\u00a9 y Espoq\u00a9 de prescripci\u00f3n electr\u00f3nica, y SAP\u00a9 para la historia \ncl\u00ednica informatizada. Los datos se recogieron con Excel\u00a9 2010.\nRESULTADOS\nSe recogieron datos de 32 pacientes (31,25% mujeres). La mediana (rango) de edad fue de 58 (34-78) a\u00f1os. El periodo \nde estudio fue 2016-2021. La mayor\u00eda de los pacientes ten\u00edan una dosis acumulada de 2000 mg, aunque el 35% de \nlos pacientes requirieron dosis adicionales. Las principales diagnoticas fueron glomerulonefritis membranosa (85%), \nglomerulonefritis segmentaria focal (10%) y glomerulonefritis r\u00e1pidamente progresiva (5%). Los valores medios de \neficacia mejoraron ligeramente tras el tratamiento: la creatinina media disminuy\u00f3 0,65 mg/dL, la tasa de filtraci\u00f3n \nglomerular media mejor\u00f3 30ml/min, la alb\u00famina media aument\u00f3 0,5g/dL y la relaci\u00f3n prote\u00edna/creatinina disminuy\u00f3 \n1000mg/g. El anti-PLA2R s\u00f3lo se midi\u00f3 en 6 pacientes con una disminuci\u00f3n estad\u00edsticamente significativa (p < 0,001). En \ncuanto a la seguridad, no se produjeron acontecimientos adversos relacionados con el f\u00e1rmaco o su infusi\u00f3n.\nCONCLUSIONES\nRituximab ha demostrado su eficacia en pacientes con glomerulonefritis refractaria a los corticosteroides e \ninmunosupresores. Sin embargo, es necesario un seguimiento estrecho de los pacientes\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n663. TOCILIZUMAB EN ORBITOPAT\u00cdA TIROIDEA MODERADA O GRAVE: EST\u00c1NDAR DE TRATAMIENTO EN \nPACIENTES REFRACTARIOS \nAUTORES\nMAC\u00cdA RIVAS, L; \u00c1LVAREZ ASTEINZA, C; FERN\u00c1NDEZ LAGUNA, CL; MARAY MATEOS, I; DE LA FUENTE VILLAVERDE, I; \nOYAGUE L\u00d3PEZ, L; VELASCO ROCES, L; LOZANO BL\u00c1ZQUEZ, A\nHOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS \ufffd AVENIDA DE ROMA S/N OVIEDO \ufffd ASTURIAS\nOBJETIVOS\nAnalizar la efectividad y seguridad del uso fuera de ficha t\u00e9cnica de tocilizumab en orbitopat\u00eda tiroidea(OT)\nMATERIALES Y M\u00c9TODOS\nEstudio observacional,descriptivo y retrospectivo de los pacientes que iniciaron tratamiento con tocilizumab para \norbitopat\u00eda tiroidea con corticorrefractaridad o contraindicaci\u00f3n a corticoides en nuestro centro entre junio/2013 y \njulio/2021.La fecha de corte para la obtenci\u00f3n de los datos fue el 31/01/2022. \n \nDe la historia cl\u00ednica electr\u00f3nica se obtuvieron los datos antropom\u00e9tricos(edad, sexo),anal\u00edticos, prescripci\u00f3n de \ncorticoides,h\u00e1bito tab\u00e1quico y actividad de la enfermedad(escala Clinical activitiy score(CAS) expresada sobre 7 puntos).\nDel programa de gesti\u00f3n de preparaciones intravenosas se obtuvo la informaci\u00f3n sobre la posolog\u00eda y n\u00famero de dosis \nadministradas\ufffd  \n \nComo variable de eficacia se emple\u00f3 la variaci\u00f3n del valor de CAS respecto al basal. Las variables continuas se \npresentaron como mediana y rango intercuart\u00edlico;las categ\u00f3ricas como n\u00famero de observaciones y porcentaje.El an\u00e1lisis \nestad\u00edstico de los resultados se realiz\u00f3 empleando R4.0.0.\nRESULTADOS\nEn el periodo de estudio,24 pacientes(96% mujeres) iniciaron tratamiento con tocilizumab.La mediana de edad al \ninicio fue de 56 a\u00f1os(50-61).Ocho(33%) eran fumadores activos en el momento del inicio del tratamiento y cinco(21%) \nexfumadores.El 83% hab\u00edan recibido tratamiento previo con corticoides sist\u00e9micos sin mejor\u00eda de la OT. \n \nLa mediana del CAS basal fue de 4(3-4).En el desglose de cada par\u00e1metro del CAS,hubo una mayor incidencia de edema \npalpebral(20, 83%),hiperemia(19, 79%),quemosis(12, 50%) y dolor en reposo(11, 46%).  \n \nLa mediana de duraci\u00f3n de tratamiento fue de 6 meses,todos recibieron una dosis de tocilizumab de 8mg/kg cada 4 \nsemanas,con una mediana de 8 ciclos(4-12).  \n \nSe realiz\u00f3 seguimiento a 18(75%) pacientes, observ\u00e1ndose en el primer mes una reducci\u00f3n del valor de CAS en un \n83%(15) de los pacientes y un aumento en dos(11%).La reducci\u00f3n global de CAS fue del 50%(CAS 2/7 vs 4/7 basal).La 183efectividad evaluada a los tres meses(n=18),muestra una mejor\u00eda de CAS en el 94%(17) de los pacientes.La reducci\u00f3n \nglobal de CAS fue del 75%(1/7 a los 3 meses vs 4/7 basal).  \n \nTocilizumab fue efectivo reduciendo todos los par\u00e1metros CAS,observ\u00e1ndose una reducci\u00f3n a los 3 meses del 100% \ndel edema de car\u00fancula(presente en 1 paciente al inicio del tratamiento y en ninguno a los 3 meses),85% del eritema \npalpebral(9 vs 1),79% de la hiperemia(19 vs 3),78% la quemosis(12 vs 2),70% del dolor con el movimiento(9 vs 2),64% del \ndolor en reposo(11 vs 3) y 60% del edema palpebral(6 vs 20).  \n \nEn lo referente a la aparici\u00f3n de eventos adversos,se registr\u00f3 alteraci\u00f3n de las pruebas hep\u00e1ticas y de \ntriglic\u00e9ridos(1),neutropenia leve(1) y mareos y aftas en mucosa orofar\u00edngea(1);obligando a la suspensi\u00f3n del tratamiento \nen los dos primeros\ufffd\nCONCLUSIONES\nTocilizumab fuera de ficha t\u00e9cnica se ha convertido en un est\u00e1ndar de tratamiento de segunda l\u00ednea en pacientes con \nrefractariedad o contraindicaci\u00f3n a corticoides,ante ausencia de tratamientos autorizados.  \nUn porcentaje importante de los pacientes tratados obtienen una mejor\u00eda cl\u00ednica a los tres meses de tratamiento con una \nreducci\u00f3n de todos los par\u00e1metros del valor CAS.La baja prevalencia de la enfermedad dificulta la realizaci\u00f3n de estudios \nunic\u00e9ntricos con potencia estad\u00edstica suficiente. \nEl perfil de eventos adversos observados se corresponde con el descrito en la literatura para tocilizumab.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n685. EFECTIVIDAD Y SEGURIDAD DE TIOSULFATO S\u00d3DICO EN CALCIFILAXIS NO UR\u00c9MICA \nAUTORES\nCARDONA ROCA, L; BORR\u00c0S TRIAS, L; SEGU\u00cd SOLANES, C; MART\u00cd PELLUCH, C; SOLER SENDRA, A; RUDI SOLA, N\nHOSPITAL GENERAL DE GRANOLLERS \ufffd AV\ufffd FRANCESC RIBAS, S/N GRANOLLERS \ufffd BARCELONA\nOBJETIVOS\nObjetivo primario: evaluar la efectividad y la seguridad del tratamiento con tiosulfato s\u00f3dico (TS) en pacientes con \ncalcifilaxis no ur\u00e9mica (CNU). Objetivo secundario: analizar las medidas terap\u00e9uticas complementarias realizadas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital de segundo nivel. Se incluyeron todos los pacientes \ndiagnosticados de CNU que recibieron tratamiento con TS intravenoso entre 2013 y 2022.  \nVariables recogidas: datos demogr\u00e1ficos, posolog\u00eda de TS, n\u00famero de sesiones y semanas de tratamiento, estado de las \n\u00falceras post-tratamiento, reacciones adversas medicamentosas (RAM), otros tratamientos (bifosfonatos, cinacalcet), \nretirada de factores precipitantes (suplementos de vitamina D, antagonistas de la vitamina K, quelantes de fosfato de \nbase c\u00e1lcica).  \nLa recogida de datos se realiz\u00f3 a partir de la historia cl\u00ednica y prescripci\u00f3n electr\u00f3nica. Las variables cuantitativas se \nexpresaron como media, desviaci\u00f3n est\u00e1ndar (DE), mediana y rango intercuart\u00edlico (RIQ). El an\u00e1lisis estad\u00edstico se realiz\u00f3 a \ntrav\u00e9s del programa SAS (Statistical Analysis System) versi\u00f3n 9.4.  \nLa efectividad se evalu\u00f3 en funci\u00f3n del estado de las \u00falceras post-tratamiento seg\u00fan valoraci\u00f3n cl\u00ednica: resoluci\u00f3n, \nmejor\u00eda, estabilidad y deterioro. La seguridad se valor\u00f3 conforme a RAM documentadas en historia cl\u00ednica.\nRESULTADOS\nSe incluyeron 16 pacientes cauc\u00e1sicos (75% mujeres, 80 (DE 7,5) a\u00f1os) con diagn\u00f3stico de CNU tratados con TS \nintravenoso. El an\u00e1lisis de los datos sobre efectividad y seguridad se realiz\u00f3 en 14 pacientes, dos se excluyeron por \np\u00e9rdida de seguimiento.  \nLa posolog\u00eda de TS utilizada fue de 25 mg por v\u00eda intravenosa 3 veces por semana. La mediana de sesiones realizadas \npor paciente fue de 41 (RIQ 14-70) durante 14,7 (RIQ 5,7-21,9) semanas. Se realiz\u00f3 ajuste posol\u00f3gico en 2 pacientes por \nfragilidad o mala tolerancia\ufffd  \nLos resultados del estado de las \u00falceras post-tratamiento fueron: 50% resoluci\u00f3n, 29% mejor\u00eda, 14% estabilidad y 7% \ndeterioro\ufffd  \nLos 14 pacientes presentaron alguna RAM, observ\u00e1ndose 1,5 (DE 0,6) RAM por paciente. Todas ellas de gravedad leve \no moderada, sin provocar la suspensi\u00f3n del tratamiento\ufffd Se registraron las siguientes: 86% acidosis metab\u00f3lica, 29% \nn\u00e1useas y v\u00f3mitos, 21% hipernatremia, 14% sobrecarga de volumen.  \nTodos los pacientes recibieron curas t\u00f3picas realizadas por personal cualificado. Se iniciaron bifosfonatos en 4 pacientes \ny cinacalcet en 3 pacientes. Se retiraron suplementos de vitamina D en 6 de 10 pacientes, antagonistas de la vitamina \nK en 6 de 6 pacientes y quelantes de fosfato de base c\u00e1lcica en el \u00fanico paciente que estaba en tratamiento previo al \ndiagn\u00f3stico.\nCONCLUSIONES\nLa CNU es una enfermedad rara con un tratamiento de escasa evidencia cient\u00edfica. El TS intravenoso fue efectivo en la \nmayor\u00eda de los pacientes del estudio, con un perfil de seguridad aceptable. No se puede excluir la contribuci\u00f3n de otras \nmedidas terap\u00e9uticas administradas, mayoritariamente encaminadas a retirar medicaci\u00f3n precipitante. Es necesario \nseguir investigando para optimizar el tratamiento de esta entidad.184CLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n691. IMPACTO DE LOS MEDICAMENTOS HU\u00c9RFANOS EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nFERN\u00c1NDEZ VELA, J; GARC\u00cdA LAGUNAR, MH; MIRA SIRVENT , MC; MART\u00cdNEZ PENELLA, M; MONTOYA EGEA, JM; \nTAMBOLEO SANCHEZ, IJ\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nEvaluar el impacto econ\u00f3mico en medicamentos hu\u00e9rfanos (MH) dispensados desde el Servicio de Farmacia (SF) a \npacientes externos y ambulantes en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 los MH que han recibido la autorizaci\u00f3n de comercializaci\u00f3n por parte de \nla Uni\u00f3n Europea, dispensados para el tratamiento de enfermedades raras (ER) desde el SF en 2021.  \nLas variables registradas fueron f\u00e1rmaco, n\u00famero de pacientes con tratamiento activo, edad, sexo, patolog\u00eda, posolog\u00eda y \ncoste por envase\ufffd Se evalu\u00f3 el coste medio por paciente y mes y el impacto sobre el gasto anual del SF \ufffd \nSe analizaron los registros de dispensaci\u00f3n del programa inform\u00e1tico del SF (SAVAC\u00ae) y la historia cl\u00ednica electr\u00f3nica \n(Selene\u00ae).  \nSe excluyeron los tratamientos oncol\u00f3gicos por no tratarse de patolog\u00edas cr\u00f3nicas.\nRESULTADOS\nSe incluyeron 78 pacientes (60,26% varones y 39,74% mujeres, edad media: 55,21 \u00b1 20,89 a\u00f1os). Se clasificaron seg\u00fan el \nMH y la ER que padecen: Riociguat en hipertensi\u00f3n pulmonar cr\u00f3nica por tromboembolismo (4 pacientes); Pirfenidona \nen fibrosis pulmonar idiop\u00e1tica (24 pacientes); Macitentan en hipertensi\u00f3n arterial pulmonar (9 pacientes); \u00c1cido \ncarbagl\u00famico para el tratamiento de hiperamonemia (1 paciente) Fenilbutirato s\u00f3dico en el tratamiento de trastornos del \nciclo de la urea (4 pacientes); \u00c1cido quenodesoxic\u00f3lico para la xantomatosis cerebrotendinosa (2 pacientes); Isavuconazol \nen aspergillosis invasiva (1 paciente); Burosumab para el tratamiento de la hipofosfatemia ligada al cromosoma X (2 \npacientes); Cannabidiol tratamiento del Sindrome de Lennox Gastaut (2 pacientes); Icatibant en angioedema hereditario \n(2 pacientes); Migalastat para la enfermedad de Fabry (1 paciente); Miglustat para Niemman Pick (2 pacientes); \nVelaglucerasa \u03b1 en la enfermedad de Gaucher I (1 paciente); Imiglucerasa para la enfermedad de Gaucher (1 paciente); \nKetoconazol para el S\u00edndrome de Cushing (1 paciente); Obetic\u00f3lico en colangitis biliar primaria (5 pacientes); \u00c1cido \nc\u00f3lico para la falta de \u00e1cidos biliares end\u00f3genos (1 paciente); Eculizumab dos indicaciones: s\u00edndrome hemol\u00edtico at\u00edpico \n(4 pacientes) y hemoglobinuria parox\u00edstica nocturna (2 pacientes); Everolimus para el Angiolipoma renal (1 paciente); \nTolvaptan para el tratamiento de poliquistosis renal autos\u00f3mica dominante (7 pacientes). \nEl gasto global de los MH para ER no oncol\u00f3gicas dispensados por el SF es de: 4969,94 \u20ac/ paciente/mes. El porcentaje de \ngasto que representa este grupo de f\u00e1rmacos respecto al gasto anual del SF es de: 3,97%.\nCONCLUSIONES\nEl gasto en MH supone un porcentaje importante del gasto del SF en un n\u00famero muy peque\u00f1o de pacientes por lo que \nser\u00eda interesante buscar nuevas alternativas de financiaci\u00f3n o la participaci\u00f3n en un mayor n\u00famero de ensayos cl\u00ednicos.  \nEste tipo de ER son en muchos casos cr\u00f3nicas, de larga duraci\u00f3n y la tendencia es ascendente en el n\u00famero de pacientes \ny en el impacto econ\u00f3mico que ello supone.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n704. EFECTIVIDAD Y SEGURIDAD A LARGO PLAZO DE \u00c1CIDO OBETIC\u00d3LICO EN COLANGITIS BILIAR \nPRIMARIA \nAUTORES\nJIM\u00c9NEZ LE\u00d3N, C; BERTR\u00c1N DE LIS BARTOLOM\u00c9, B; GONZ\u00c1LEZ SEVILLA, M; HERN\u00c1NDEZ RAMOS, JA; GARC\u00cdA \nMU\u00d1OZ, C; MAYO OLVEIRA, F; GONZ\u00c1LEZ G\u00d3MEZ, \u00c1; FERRARI PIQUERO, JM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID\nOBJETIVOS\nEvaluar la efectividad respecto a la dosis y la seguridad del tratamiento con \u00e1cido obetic\u00f3lico (OCA) en pacientes \ndiagnosticados de colangitis biliar primaria (CBP) y/o s\u00edndrome overlap en un hospital de clase 5 seg\u00fan la clasificaci\u00f3n \ncluster \ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, longitudinal y retrospectivo, en el que se incluyeron todos los pacientes tratados con \nOCA desde marzo de 2018 en nuestro hospital.  \nLas variables recogidas fueron demogr\u00e1ficas (sexo, edad), cl\u00ednicas (diagn\u00f3stico, fecha inicio de tratamiento, cambio de \ndosis, niveles de fosfatasa alcalina (FA) y bilirrubina) y de seguridad (reacciones adversas y su gravedad).  \nLas herramientas de consulta fueron el programa de historia cl\u00ednica electr\u00f3nica y el m\u00f3dulo de dispensaci\u00f3n farmac\u00e9utica \na pacientes externos\ufffd \n \nPara evaluar la efectividad se seleccionaron pacientes con colangitis biliar primaria y/o s\u00edndrome overlap que presentaran \nal inicio de tratamiento cifras de FA 1,67 veces el l\u00edmite superior de normalidad (LSN) y que hubieran estado en 185tratamiento con OCA al menos 12 meses. Se consider\u00f3 respuesta al tratamiento alcanzar simult\u00e1neamente una FA < 1,67 \nx LSN, una bilirrubina total dentro de la normalidad y una disminuci\u00f3n de FA \u2265 15%. \n \nLa seguridad se evalu\u00f3 en pacientes que cumplieron al menos 6 meses de tratamiento.\nRESULTADOS\nSe recogieron datos de un total de 30 pacientes con una mediana de edad de 55 a\u00f1os (46-61). El 90% eran mujeres. \n \nPara evaluar la efectividad se tuvo en cuenta a 24 pacientes, 10 fueron tratados con 5 mg durante todo el estudio y en el \nresto (n=14) hubo que aumentar la dosis a 10 mg diarios por falta de respuesta bioqu\u00edmica.  \n \nRespecto a los pacientes que mantuvieron dosis de 5 mg (n=10), un 80% (n=8) alcanz\u00f3 respuesta a los 12 meses de \ntratamiento, de ellos 4 contin\u00faan en respuesta a los 24 meses y los otros 4 a\u00fan no han completado 24 meses de \ntratamiento\ufffd  \n \nDe los 14 pacientes que escalaron la dosis, 6 (42,86%) alcanzaron respuesta a los 12 meses. Adem\u00e1s 2 han completado \n24 meses de tratamiento y contin\u00faan en respuesta. Entre los 8 pacientes no respondedores al incremento de dosis, 5 \nsegu\u00edan sin responder a los 24 meses de tratamiento, 1 respondi\u00f3 a los 24 meses y 2 pacientes no hab\u00edan completado a\u00fan \n24 meses\ufffd  \n \nLa evaluaci\u00f3n de la seguridad incluy\u00f3 30 pacientes. En 13 personas (43,33%) se detectaron reacciones adversas. siendo la \nm\u00e1s frecuente el prurito 11 casos (84,6%).  \n \nTambi\u00e9n se notificaron casos de astenia (n=7), estre\u00f1imiento (n=1), taquicardia (n=1) e hiperpigmentaci\u00f3n cut\u00e1nea \n(n=2). Se registraron 2 casos de hepatotoxicidad que requirieron reducci\u00f3n de dosis y suspensi\u00f3n del tratamiento \nrespectivamente.\nCONCLUSIONES\nEn nuestra experiencia ser respondedor a una dosis de 5 mg es un posible factor predictivo de respuesta a largo plazo, \nmientras que el incremento de dosis no siempre conlleva una respuesta al tratamiento.  \nLas reacciones adversas detectadas coinciden con las descritas como m\u00e1s frecuentes en ficha t\u00e9cnica excepto la \nhiperpigmentaci\u00f3n cut\u00e1nea.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n760. EFICACIA Y SEGURIDAD DE ALPELISIB UTILIZADO FUERA DE INDICACI\u00d3N EN PACIENTES CON \nS\u00cdNDROMES DE SOBRECRECIMIENTO ASOCIADOS A PIK3CA. \nAUTORES\nGARCIA LOPEZ, L; COLLADA SANCHEZ, VL; BILBAO GOMEZ-MARTINO, C; TRIANA JUNCO, P; SOBRINO JIMENEZ, C; \nBLAZQUEZ RAMOS, N; ESCARIO GOMEZ, M; HERRERO AMBROSIO, A\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nAlpelisib es un inhibidor de fosfatidilinositol-3-cinasa (PI3K\u03b1) actualmente autorizado para el tratamiento del c\u00e1ncer de \nmama localmente avanzado o metast\u00e1sico con mutaci\u00f3n en PIK3CA en combinaci\u00f3n con fulvestrant.  \n \nLos s\u00edndromes de sobrecrecimiento relacionados con PIK3CA (PROS, del ingl\u00e9s PIK3CA-related overgrowth syndromes) \nengloban un grupo de enfermedades raras caracterizadas por malformaciones vasculares asociadas a sobrecrecimiento, \ncausadas por mutaciones som\u00e1ticas en PIK3CA. Actualmente su tratamiento es multidisciplinar pero carecen de opciones \nfarmacol\u00f3gicas que eviten la progresi\u00f3n y complicaciones asociadas. Esto ha llevado a la utilizaci\u00f3n de alpelisib en \npacientes PROS, en base a su diana terap\u00e9utica.  \n \nNuestro objetivo fue conocer la eficacia y seguridad de alpelisib en el tratamiento de pacientes con PROS.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo de 40 meses de duraci\u00f3n (enero 2019-abril 2022) realizado en un hospital de tercer \nnivel, de referencia para PROS\ufffd Se incluyeron todos los pacientes PROS en tratamiento con alpelisib durante al menos 6 \nmeses, excluyendo aquellos tratados dentro de ensayo cl\u00ednico.  \nUn equipo multidisciplinar de Cirug\u00eda Pl\u00e1stica Infantil y Farmacia Hospitalaria realiz\u00f3 el seguimiento de los pacientes \nmediante consulta presencial y revisi\u00f3n de historia cl\u00ednica. Las variables recogidas fueron: demogr\u00e1ficas, diagn\u00f3stico, \nfenotipo, genotipo, dosis de alpelisib inicial y variaciones, respuesta cl\u00ednica en base al criterio m\u00e9dico y efectos adversos.\nRESULTADOS\nSe incluyeron 33 pacientes (60,6% hombres) con media de edad al inicio de tratamiento de 13,0(DE 8,6) a\u00f1os. Todos \npresentaron variantes PIK3CA patog\u00e9nicas excepto un paciente con una variante de significado incierto.  \n \nDentro del espectro PROS, 7 pacientes presentaban lipomatosis (21%), 18 pacientes malformaciones vasculares difusas \n(54%) y 8 pacientes s\u00edndrome CLOVES (24%).  186El periodo de seguimiento medio fue 20,6(DE 9,5) meses. Ning\u00fan paciente sufri\u00f3 progresi\u00f3n de la enfermedad, \npresentando 43,3% respuesta completa, 36,7% respuesta parcial y 2,0% estabilizaci\u00f3n de la patolog\u00eda. Tres pacientes \ninterrumpieron tratamiento: uno por baja adherencia, otro por efectos adversos (alopecia y amenorrea) y otro por \neficacia insuficiente.  \n \nEl 63,6% de los pacientes present\u00f3 alg\u00fan efecto adverso. Los de mayor prevalencia fueron: diarrea(n=7), p\u00e9rdida \nde apetito/peso(n=6), alopecia(n=5), rash cut\u00e1neo(n=2) e hiperglucemia(n=2); siendo m\u00e1s frecuentes al inicio del \ntratamiento o tras aumento de dosis. En la mayor\u00eda de los casos estos efectos adversos fueron leves y autolimitados, \naunque en 8 pacientes fue necesario reducir dosis y 1 suspendi\u00f3 tratamiento.\nCONCLUSIONES\nEl descubrimiento de mutaciones en PIK3CA ha abierto la puerta a utilizar tratamientos dirigidos en los pacientes \ncon PROS, que pueden evitar la morbimortalidad y las secuelas de tratamientos quir\u00fargicos agresivos. Alpelisib, \nanteriormente utilizado como uso compasivo y actualmente como uso fuera de indicaci\u00f3n, supone una alternativa \nfarmacol\u00f3gica que detiene la progresi\u00f3n, mejorando la sintomatolog\u00eda de estos pacientes. \nAlpelisib en pacientes PROS presenta un perfil de seguridad tolerable y similar al reportado en sus ensayos cl\u00ednicos para \nc\u00e1ncer de mama. \nActualmente se est\u00e1 realizando un ensayo cl\u00ednico multic\u00e9ntrico internacional que podr\u00e1 confirmar estos resultados.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n831. EFECTIVIDAD Y SEGURIDAD DE DARVADSTROCEL EN LA PR\u00c1CTICA CL\u00cdNICA REAL \nAUTORES\nTORR\u00d3 GARC\u00cdA, L; GALINDO RUEDA, MDM; GIL ALMELA, J; D\u00cdAZ RAM\u00d3N, M; CANO MOLINA, J\u00c1; GOLNABI \nDOWLATSHAHI, F; MART\u00cdNEZ IB\u00c1NEZ, M\u00c1; VILLA CARPES, J\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nDarvadstrocel es una terapia avanzada a base de c\u00e9lulas madre expandidas alog\u00e9nicas humanas adultas de origen \nmesenquimal extra\u00eddas de tejido adiposo. Es un medicamento hu\u00e9rfano de origen espa\u00f1ol que dispone de protocolo \nfarmacocl\u00ednico en Valtermed (Sistema de Informaci\u00f3n del Valor Terap\u00e9utico de Medicamentos) y est\u00e1 sometido a un \nacuerdo de pago por resultados\ufffd  \n \nEl objetivo del estudio es evaluar la efectividad y seguridad de darvadstrocel en el tratamiento de las f\u00edstulas perianales \ncomplejas en pacientes adultos con enfermedad de Crohn (EC) luminal seg\u00fan protocolo farmacocl\u00ednico.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo realizado en un hospital de tercer nivel. Se incluyeron todos los pacientes que hab\u00edan \nrecibido una dosis \u00fanica de darvadstrocel de 120 millones de c\u00e9lulas desde mayo de 2021 hasta abril de 2022.  \n \nLas variables recogidas fueron: edad, sexo, \u00edndice de actividad de la EC (CDAI), supuraci\u00f3n en las \u00faltimas 6 semanas, tipo \nde f\u00edstula, n\u00ba de orificios internos (OI) y externos (OE), tratamiento previo para la enfermedad fistulizante, n\u00ba de OI y OE \ntratados y tratamiento concomitante\ufffd  \n \nLa efectividad se midi\u00f3 evaluando la remisi\u00f3n combinada a las 24 semanas, definida como el cierre cl\u00ednico de todas las \nf\u00edstulas tratadas y la ausencia de abscesos mayores de 2 cm confirmada mediante resonancia magn\u00e9tica.  \n \nLa seguridad se midi\u00f3 por la frecuencia de aparici\u00f3n de efectos adversos (EA) y la gravedad de los mismos.\nRESULTADOS\nSe trataron cuatro pacientes, con una mediana de edad de 39,5 a\u00f1os (22-48), tres mujeres y un hombre, todos ellos con \nun CDAI < 220 y con supuraci\u00f3n de las f\u00edstulas en las 6 semanas previas a la administraci\u00f3n de darvadstrocel. Tres de \ncuatro pacientes presentaban f\u00edstula transesfint\u00e9rica, y un paciente interesfint\u00e9rica. Dos pacientes presentaban dos OI y \nlos otros dos un OI. Tres pacientes presentaban dos OE, y un paciente un solo OE. Todos hab\u00edan sido sometidos al menos \na una cirug\u00eda previa de la fistula activa, y hab\u00edan recibido tratamiento previo con inmunosupresores y anti-TNF. \n \nA todos los pacientes se les trat\u00f3 un OI, a dos pacientes dos OE y a otros dos, un solo OE\ufffd  \n \nEn el momento de la administraci\u00f3n, todos estaban en tratamiento con un anti-TNF y uno de ellos adem\u00e1s, con un \ninmunosupresor \ufffd  \n \nTodos los pacientes alcanzaron la remisi\u00f3n combinada en la semana 24 tras la administraci\u00f3n del tratamiento y ninguno \nnotific\u00f3 alg\u00fan EA.\nCONCLUSIONES\nEn nuestro hospital, el tratamiento con darvadstrocel ha sido efectivo ya que todos los pacientes han alcanzado la \nremisi\u00f3n combinada a los seis meses de la administraci\u00f3n. Seg\u00fan el acuerdo de pago por resultados establecido, se 187ha procedido al pago \u00edntegro de esta terapia avanzada. Podemos considerar que ha sido un tratamiento seguro ya que \nnuestros pacientes no han presentado ning\u00fan EA hasta el momento. No obstante, ser\u00eda conveniente ampliar el n\u00famero \nde sujetos estudiados para afianzar estos resultados y ampliar el periodo de seguimiento para medir la duraci\u00f3n del \nefecto m\u00e1s all\u00e1 de los seis meses.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n857. EXPERIENCIA DE USO DE BUROSUMAB EN LA PR\u00c1CTICA CL\u00cdNICA EN EL RAQUITISMO \nHIPOFOSFAT\u00c9MICO LIGADO AL CROMOSOMA X \nAUTORES\nFERNANDEZ MART\u00cdNEZ, IM; GARC\u00cdA SIM\u00d3N, MS; GARC\u00cdA MATILLAS, CN; ASENSI CANT\u00d3, A; FERN\u00c1NDEZ VELA, J; \nCONESA NICOL\u00c1S, E\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nBurosumab es el primer f\u00e1rmaco dirigido para la hipofosfatemia ligada al cromosoma X (HLX), una enfermedad rara \nhereditaria que produce hipofosfatemia cr\u00f3nica, raquitismo y alteraciones \u00f3seas.  \nObjetivo: evaluar la efectividad y seguridad de burosumab en los pacientes con HLX tratados con el f\u00e1rmaco en un \nhospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo y observacional de pacientes tratados con burosumab desde febrero-2018 (inicio de su \ncomercializaci\u00f3n en Europa) hasta abril-2022 (tratamiento en Espa\u00f1a sujeto a las condiciones y objetivos seg\u00fan protocolo \nfarmacocl\u00ednico).  \nSe recogieron las siguientes variables de estudio de las historias cl\u00ednicas de los pacientes (Selene\u00ae) y del programa de \ndispensaci\u00f3n (Savac\u00ae): sexo, edad de diagn\u00f3stico (ED) de HLX, tratamientos previos, dosis recibidas, edad \u00f3sea, f\u00f3sforo \ns\u00e9rico (Pi), hormona paratiroidea (PTH), fosfatasa alcalina (FA), reabsorci\u00f3n tubular de fosfato (RTP), puntuaci\u00f3n de la \ngravedad del raquitismo (RSS) y de la impresi\u00f3n radiogr\u00e1fica global del cambio (RGI-C) basal y al a\u00f1o de tratamiento as\u00ed \ncomo efectos adversos (EA). La escala RSS (0 a 10) indica una mayor gravedad del raquitismo a mayor puntuaci\u00f3n; por el \ncontrario, la escala RGI-C (-3 a +3) eval\u00faa el cambio de las anomal\u00edas \u00f3seas siendo mayor la curaci\u00f3n a mayor puntuaci\u00f3n.\nRESULTADOS\nSe incluyeron 2 pacientes: una ni\u00f1a de 15 a\u00f1os (paciente-1) y un ni\u00f1o de 5 a\u00f1os (paciente-2) con una ED de HLX de 4 y 2 \na\u00f1os, respectivamente. \nAmbos pacientes hab\u00edan sido tratados con suplementos de sales de f\u00f3sforo y vitamina D previamente sin llegar a alcanzar \nvalores de Pi dentro del rango de referencia ajustado a la edad (RRAE).  \nPaciente-1:  \n-75 dosis recibidas (40 meses), iniciando con una dosis de 0,8 mg/kg, requiriendo dos aumentos progresivos de dosis por \nfalta de eficacia hasta alcanzar una dosis de mantenimiento de 1,2mg/kg (40mg) c/2 semanas.  \n-Datos anal\u00edticos: \n-Basales: P=1,8 [RRAE: 2,8-4,8 mg/dl]; PTH=192; FA=1173; RTP= < 77%. \n-Al a\u00f1o: P=2,9; PTH=69; FA=307; PTH=54,3; RTP=92%. \n-Escala RSS basal: 3,5 puntos; al a\u00f1o: 0,5.  \n-Escala RGI-C basal: -3 puntos; al a\u00f1o: +2.  \n-Edad \u00f3sea basal: 9 a\u00f1os; al a\u00f1o: 15 a\u00f1os.  \n \nPaciente-2:  \n-37 dosis recibidas (20 meses) iniciando a 0,8 mg/kg requiriendo un aumento de dosis inicial a 1,1mg/kg (20mg) c/2 \nsemanas manteniendo esta dosis hasta la fecha fin del estudio.  \n-Datos anal\u00edticos: \n-Basales: P=2,9 [RRAE: 3,7-5,6 mg/dl]; PTH=111; FA=692; PTH=36,8; RTP=76%. \n-Al a\u00f1o: P=3,7; PTH=28,7; FA=294; PTH=34,7; RTP=85%. \n-Escala RSS basal: 3,5 puntos; al a\u00f1o: 0,5.  \n-Escala RGI-C basal: -2 puntos; al a\u00f1o: +3.  \n-Edad \u00f3sea basal: 1 a\u00f1o; al a\u00f1o: 5 a\u00f1os.  \nEn cuanto a EA, no se registraron EA graves: dolor en la zona de administraci\u00f3n durante los primeros meses en el \npaciente-1, y un episodio de absceso dental en el paciente-2.\nCONCLUSIONES\nBurosumab ha mostrado ser una alternativa terap\u00e9utica efectiva en nuestros pacientes incrementando de forma \nsignificativa los niveles de Pi y de RTP , mostrando a su vez mejor\u00eda en t\u00e9rminos de gravedad del raquitismo (escala RSS) y \nde las anomal\u00edas \u00f3seas basales (escala RGI-C).  \nEn t\u00e9rminos de seguridad, burosumab ha mostrado un perfil aceptable de toxicidad y tolerancia.188CLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n883. EFECTIVIDAD Y SEGURIDAD DE ESTATINAS T\u00d3PICAS EN PACIENTES TRASTORNOS DE LA \nQUERATINIZACI\u00d3N \nAUTORES\nGUERRERO HURTADO, E; GARC\u00cdA ROBLES, A; CUELLAR MONREAL, MJ; CENTELLES ORIA, M; MONTE BOQUET , E; \nCRUZ SANCHEZ, A; VILA CLERIGUES, MN; POVEDA ANDRES, JL\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nLos queratinocitos son los encargados principales de controlar la permeabilidad de la piel y de ejercer de barrera \nf\u00edsica frente a agentes externos a nivel de estrato c\u00f3rneo. Adem\u00e1s de la influencia de la radiaci\u00f3n solar y una posible \nparticipaci\u00f3n inmunitaria, se ha observado la implicaci\u00f3n de la v\u00eda del mevalonato en la etiolog\u00eda de trastornos de la \nqueratinizaci\u00f3n como la poroqueratosis act\u00ednica superficial diseminada (PASD), debido a d\u00e9ficits enzim\u00e1ticos en dicha v\u00eda \nque provocan el ac\u00famulo de metabolitos t\u00f3xicos. El objetivo es la evaluaci\u00f3n de la adherencia, efectividad y seguridad de \nla emulsi\u00f3n oleosa en base acuosa de simvastatina 2%/colesterol 2% (S/C) en pacientes con diagn\u00f3stico de PASD.\nMATERIALES Y M\u00c9TODOS\n\u00c1mbito: Hospital terciario de 1000 camas. Dise\u00f1o: estudio observacional y retrospectivo. Periodo: Julio de 2020 a Mayo \nde 2022. Poblaci\u00f3n: pacientes con diagn\u00f3stico cl\u00ednico de PASD que iniciaron tratamiento con emulsi\u00f3n de S/C entre \njulio de 2020 y diciembre de 2021. Variables a estudio: edad, sexo, tratamientos previos, duraci\u00f3n del tratamiento, zona \ncorporal afectada, otras patolog\u00edas, pauta y efectividad (medida como la mejor\u00eda de los s\u00edntomas tras exploraci\u00f3n). La \nadherencia se estim\u00f3 seg\u00fan los registros de dispensaci\u00f3n de Farmacia.  \nVariables de seguridad: Frecuencia y gravedad de Reacciones Adversas (RA).  \nFuentes de datos: historia cl\u00ednica electr\u00f3nica y el programa de dispensaci\u00f3n ambulatoria.  \nLas variables cuantitativas se describieron como media e IC al 95% o mediana y rango intercuart\u00edlico (seg\u00fan la distribuci\u00f3n \nnormal o no de las variables).\nRESULTADOS\nSe incluyeron 7 pacientes. El 85,7% fueron mujeres. La edad media al inicio del tratamiento fue de 58,2 a\u00f1os (IC95%: \n48,1-68,5).  \nCon una mediana de seguimiento de 73,9 semanas (RIC: 24,5-88,3) la mediana de meses de tratamiento basada en el \nregistro de dispensaciones fue de 38,7 semanas (RIC: 0-44,7). La adherencia media fue del 60% (IC95%: 20,7-100,2).  \nLa distribuci\u00f3n de las lesiones en los distintos pacientes fue: Miembros superiores (MMSS), inferiores (MMII) y escote \n(N=3), MMSS, t\u00f3rax y escote (N=1), MMSS y MMII (N=1), MMSS (N=1) y MMII (N=1). \nTres pacientes presentaban una patolog\u00eda base de tipo autoinmune, mientras que otro era trasplantado renal con \ntratamiento inmunosupresor activo. El resto de pacientes no presentaban comorbilidades de inter\u00e9s. \nL\u00edneas previas empleadas a destacar: Calcipotriol (42,9 % de los pacientes), imiquimod (42,9%), fotoprotecci\u00f3n (28,6%) y \ndiclofenaco t\u00f3pico (28,6%). \nTras iniciar tratamiento con la emulsi\u00f3n de S/C en una pauta diaria cada 12 horas, las lesiones mejoraron en aspecto y \nsintomatolog\u00eda asociada (prurito), disminuyendo a su vez la superficie corporal afectada en un 71,4% de los pacientes, \nprincipalmente en zonas no expuestas a la radiaci\u00f3n solar. \nRA registradas: escozor en la zona de aplicaci\u00f3n (N=1) y eccema (N=1), provocando en el primer caso la interrupci\u00f3n de la \naplicaci\u00f3n en la zona afectada.\nCONCLUSIONES\nAunque la etiolog\u00eda de la PASD no se ha esclarecido del todo, el empleo de la emulsi\u00f3n de S/C muestra una mayor \nefectividad que las alternativas empleadas y un perfil de seguridad leve pero que puede condicionar la continuidad del \ntratamiento. Aun as\u00ed, la reducida muestra de estudio hace necesario llevar a cabo m\u00e1s estudios.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n886. EFECTIVIDAD Y SEGURIDAD DE ELEXACAFTOR/TEZACAFTOR/IVACAFTOR EN PACIENTES CON \nFIBROSIS QU\u00cdSTICA Y DETERIORO SEVERO DE LA FUNCI\u00d3N PULMONAR \nAUTORES\nDE BASAGOITI GORORDO, A; CASAS ARRATE, J; GOMEZ BONILLA, A; GOMEZ CRESPO, B; BARROSO CASTRO, J; LIGROS \nTORRES, M; CALLEJA BUENO, A; DE MIGUEL CASCON, M\nHOSPITAL DE CRUCES \ufffd PZA DE CRUCES, S/N \ufffd BARAKALDO \ufffd VIZCAYA\nOBJETIVOS\nAnalizar la efectividad y seguridad del tratamiento con elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) en pacientes \nadultos con fibrosis qu\u00edstica (FQ) con deterioro severo de la funci\u00f3n pulmonar.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluye pacientes con FQ que recibieron tratamiento con ELX/TEZ/IVA al \nmenos 48 semanas, a trav\u00e9s del programa de acceso previo a su comercializaci\u00f3n en Espa\u00f1a, para lo cual deb\u00edan no ser \ncandidatos a otros tratamientos comercializados moduladores del gen regulador de la conductancia transmembrana de \nla fibrosis qu\u00edstica(CFTR), tener un volumen espiratorio forzado en el primer segundo(FEV1) < 40% durante dos meses \ny/o estar en lista/evaluaci\u00f3n para trasplante pulmonar. Se recogen: edad, sexo, mutaciones, requerimiento de ox\u00edgeno 189domiciliario, y manifestaciones de FQ como diabetes mellitus(DM), insuficiencia pancre\u00e1tica, o infecci\u00f3n bronquial \ncr\u00f3nica(IBC).  \nLas variables de efectividad son: cambio de FEV1 en espirometr\u00eda respecto al basal, n\u00famero de exacerbaciones \npulmonares(EP) que requirieron ingreso y/o antibi\u00f3tico IV en el a\u00f1o previo y durante el estudio, cambio en el \u00edndice \nde masa corporal(IMC) respecto al basal, y test del sudor a las 24 semanas. En el an\u00e1lisis de seguridad se recogieron \nlos efectos adversos (EA) referidos por el paciente en la historia cl\u00ednica, par\u00e1metros anal\u00edticos de funci\u00f3n hep\u00e1tica y \nnecesidad de ajuste de dosis o suspensi\u00f3n del tratamiento.\nRESULTADOS\nSe incluyeron 6 pacientes con FQ (5 hombres) heterocigotos para la mutaci\u00f3n p.PheF508del y otra mutaci\u00f3n de funci\u00f3n \nm\u00ednima. La edad media fue 36 a\u00f1os(25-47) y el FEV1 medio basal 33% (26-38). T res pacientes sufren DM, 5 insuficiencia \npancre\u00e1tica, 2 antecedentes de hemoptisis con necesidad de embolizaci\u00f3n, 1 funci\u00f3n renal alterada (ClCr basal 49 \nml/min), 3 recib\u00edan \u00e1cido ursodeoxic\u00f3lico, 3 ox\u00edgeno domiciliario y todos ten\u00edan IBC (5 Pseudomonas aeruginosa, 3 \nStaphylococcus aureus MR y 1 Bordetella Bronchiseptica).  \nLa variaci\u00f3n media del FEV1 fue del 10% (0-24) y del 11% (4-19) a las 24 y 48 semanas. Todos los pacientes refirieron \nmejor\u00eda subjetiva desde el inicio en cuanto a capacidad pulmonar y s\u00edntomas como tos y disnea. De los 6 pacientes, 3 \ntuvieron EP el a\u00f1o previo y solo 1 present\u00f3 2 EP en el per\u00edodo de 48 semanas. Se realiz\u00f3 test del sudor a las 24 semanas \nen 5 pacientes con una disminuci\u00f3n media del cloro en sudor de 52 mmoles/L(40-64) respecto al del diagn\u00f3stico(78-123). \nEl IMC medio aument\u00f3 de 22 a 24 kg/m2 y, el incremento medio de peso fue de 4,4 kg\ufffd  \nEl tratamiento fue bien tolerado; dos pacientes refirieron EA leves al inicio: cefalea y dolor abdominal. En 2 pacientes se \nprodujeron elevaciones asintom\u00e1ticas de par\u00e1metros de funci\u00f3n hep\u00e1tica (alanina aminotransferasa y bilirrubina), que en \nning\u00fan caso requirieron ajuste de dosis ni suspensi\u00f3n de tratamiento.\nCONCLUSIONES\nA pesar de nuestro tama\u00f1o muestral; ELX/TEZ/IVA en pacientes con deterioro pulmonar severo secundario a FQ parece \nefectivo y seguro. Se trata de una poblaci\u00f3n pobremente representada en los ensayos cl\u00ednicos, en la que este tratamiento \nmejora la funci\u00f3n pulmonar y el estado nutricional y disminuye las EP graves, pudiendo retrasar e incluso eliminar la \nnecesidad de trasplante pulmonar \ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n891. ELEXACAFTOR/TEZACAFTOR/IVACAFTOR EN FIBROSIS QU\u00cdSTICA: RESULTADOS EN VIDA REAL EN \nUN HOSPITAL DE TERCER NIVEL \nAUTORES\nGUERRERO HURTADO, E; GARC\u00cdA ROBLES, A; MONTE BOQUET , E; CUELLAR MONREAL, MJ; CRUZ SANCHEZ, A; \nCENTELLES ORIA, M; FERN\u00c1NDEZ SANCHEZ, M; POVEDA ANDRES, JL\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nDescribir la efectividad, seguridad y adherencia al tratamiento modulador del regulador de conductancia transmembrana \nelexacaftor/tezacaftor/ivacaftor en pacientes con fibrosis qu\u00edstica (FQ).\nMATERIALES Y M\u00c9TODOS\n\u00c1mbito: Hospital terciario de 1000 camas. Dise\u00f1o: estudio observacional y retrospectivo. Periodo: Marzo de 2020 a Mayo \nde 2022. Poblaci\u00f3n: pacientes con FQ con al menos una mutaci\u00f3n F508DEL que iniciaron tratamiento con elexacaftor/\ntezacaftor/ivacaftor entre marzo de 2020 y octubre de 2021 y con una duraci\u00f3n m\u00ednima de 24 semanas. Variables a \nestudio: edad, sexo, mutaci\u00f3n, tratamientos moduladores previos, adherencia (medida por registros de dispensaci\u00f3n), \nduraci\u00f3n del tratamiento, volumen espirado forzado en el primer segundo (FEV1), cociente FEV1/FVC (Capacidad Vital \nForzada), Peso Corporal (PC), \u00cdndice de Masa Corporal (IMC), n\u00famero de exacerbaciones pulmonares (EP) y aislamientos \nbacterianos que requirieron hospitalizaci\u00f3n y/o antibioterapia intravenosa. Se evalu\u00f3 la situaci\u00f3n cl\u00ednica en las semanas \n-48, 0, +24, +48, +72 y +96 de tratamiento, tom\u00e1ndose como referencia temporal la semana 0 para las comparaciones.  \nVariables de seguridad: Frecuencia y gravedad de Reacciones Adversas (RA) medidas mediante CTCAE v5.0.  \nFuentes de datos: historia cl\u00ednica electr\u00f3nica y registro de dispensaci\u00f3n ambulatoria.  \nLas variables cuantitativas se describieron con media e IC al 95% o mediana y rango intercuart\u00edlico (seg\u00fan la distribuci\u00f3n \nnormal o no de las variables), y para la comparaci\u00f3n entre periodos se emple\u00f3 el test no param\u00e9trico de Wilcoxon (SPSS\u00ae)\nRESULTADOS\nSe incluy\u00f3 un total de 18 pacientes, 55,6% hombres, con una media de edad al inicio del tratamiento de 29,59 a\u00f1os \n(IC95%: 23,50-35,68). Un 22,2% (N=4) eran pacientes pedi\u00e1tricos. El 38,9% (N=7) eran homocigotos para la mutaci\u00f3n \nF508DEL. Ocho pacientes usaron otras terapias moduladoras previamente: tezacaftor/ivacaftor (N=7) y lumacaftor/\nivacaftor (N=1).  \nLa duraci\u00f3n media del tratamiento fue de 60,4 semanas (IC95%: 46,2-74,5). La adherencia media fue del 100,34% (IC95%: \n98,4-102,2).  \nLas medianas de las distintas variables en las semanas -48, 0, +24, +48, +72 y +96 fueron: \n-FEV1: 45% (RIC: 32,5-62,5), 38% (RIC: 33,5-59,15), 46% (RIC: 37,25-69,5), 47,5% (RIC: 37,5-67,5), 47% (RIC: 43-64,5), 46% \n(RIC: 41-77), con diferencias estad\u00edsticamente significativas en los per\u00edodos (-48-0), (0-24), (0-48) y (0-72).  \n-FEV1/FVC: 50,8 % (RIC: 43,8-67,7), 51,4% (RIC: 45,2-65,0), 53,5% (RIC:47,5-69,3), 51,2% (RIC: 48,3-65,6), 50,6% (RIC:48,2-\n58,3), 49,1% (RIC:45,6-58,5), sin diferencias estad\u00edsticamente significativas en ninguno de los per\u00edodos.  190-PC: 53,5 kg (RIC:42,3-57,3), 54,5 (RIC:40,7-59,0), 58 (RIC:48,7-62,5), 58,5 (RIC:45,6-61,8), 61,0 (RIC:53,5-69,5), 61,0 (RIC: \n59,0-66,0), con diferencias estad\u00edsticamente significativas en los per\u00edodos (0-24), (0-48) y (0-72).  \n-IMC: 19,7 (RIC:17,6-21,2), 20,1 (RIC:17,1-21,5), 21,5 (RIC:18,3-23,1), 21,6 (RIC:18,5-22,4), 23,0 (RIC:21,8-23,7), 22,8 (RIC: \n20,2-23,5), con diferencias estad\u00edsticamente significativas en los per\u00edodos (0-24), (0-48) y (0-72).  \nHubo 31 EP las 48 semanas previas al inicio del tratamiento, reduci\u00e9ndose a 3 durante las 48 semanas posteriores \n(mediana: 1,5 (RIC:0-3) y 0 (RIC:0-0) respectivamente (p < 0,05)). No se dio ning\u00fan otro episodio con posterioridad.  \nNo se registraron RA relacionadas con la medicaci\u00f3n\ufffd\nCONCLUSIONES\nLos resultados tras el inicio de elexacaftor/tezacaftor/ivacaftor muestran una mejora a nivel antropom\u00e9trico, cierta \nestabilidad en los par\u00e1metros respiratorios y una disminuci\u00f3n de las EP . Aun as\u00ed, la reducida muestra del estudio y el corto \nper\u00edodo de seguimiento hacen necesario llevar a cabo m\u00e1s estudios.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n971. ESTUDIO DE PERSISTENCIA Y TOXICIDAD A TRATAMIENTOS ANTIFIBR\u00d3TICOS EN FIBROSIS \nPULMONAR IDIOP\u00c1TICA \nAUTORES\nS\u00c1NCHEZ PASCUAL, B; SALVADOR LLANA, I; SOLLANO SANCHO, I; SANZ M\u00c1RQUEZ, S; GARRIDO PE\u00d1A, N; LINARES \nASENSIO, MJ; P\u00c9REZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nEvaluar la persistencia al tratamiento antifibr\u00f3tico (TAF) de primera l\u00ednea (pirfenidona o nintedanib) en pacientes con \nfibrosis pulmonar idiop\u00e1tica (FPI) analizando los motivos de suspensi\u00f3n y la toxicidad causada por los f\u00e1rmacos, as\u00ed como \nsu manejo y resoluci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico observacional retrospectivo que incluy\u00f3 todos los pacientes con FPI tratados con TAF en dos \nhospitales terciarios desde octubre 2014 hasta final de abril de 2022.  \nLos datos fueron obtenidos de la historia cl\u00ednica electr\u00f3nica y el m\u00f3dulo de pacientes externos recogi\u00e9ndose: sexo, \nedad, TAF, fecha de inicio, fecha y motivo de suspensi\u00f3n, aparici\u00f3n de toxicidad, tipo, manejo y resoluci\u00f3n. Se evalu\u00f3 \n\u00fanicamente el tratamiento en primera l\u00ednea. Los datos recogidos se analizaron a trav\u00e9s del programa estad\u00edstico SPSS\u00ae \nversi\u00f3n 17.0. Se emple\u00f3 la curva de supervivencia de Kaplan-Meier.\nRESULTADOS\nSe incluyeron 47 pacientes, 70,2%(33/47) hombres, mediana de edad 71,38 a\u00f1os (rango intercuart\u00edlico (RIC: 67,27-\n76,45)). El 36,2%(17/47) recibieron nintedanib y el 63,8%(30/47) pirfenidona.  \nLa mediana de persistencia global al TAF fue de 14,27 meses [IC 95% (9,18-19,35)], siendo para nintedanib de 17,1 \n[Intervalo de confianza (IC) 95% (0,09-34,1)] y de 14,26 [IC 95% (11,63-16,89)] para pirfenidona (LogRank, chi-cuadrado \np=0,671). \nEl 31,9 %(15/47) contin\u00faa en tratamiento a fecha de corte, el 68,1%(32/47) suspendieron. Los motivos de suspensi\u00f3n \nfueron: toxicidad 40,62%(13/32), fallecimiento 25%(8/32), falta de eficacia 18,75%(6/32), interacci\u00f3n con f\u00e1rmacos 6,25% \n(2/32) y otros motivos 6,25%(2/32). En un paciente no se conoce el motivo de suspensi\u00f3n.  \nEl 70% (21/30) de los pacientes con pirfenidona present\u00f3 toxicidad frente a un 93,33%(14/15) con nintedanib (2 de \nnintedanib sin registro de toxicidad). Se compar\u00f3 el riesgo de toxicidad con ambos TAF mediante test Chi cuadrado, \np=0,129. En pirfenidona el 53,3%(16/30) present\u00f3 toxicidad digestiva (p\u00e9rdida de peso 43,75%(7/16), diarrea \n37,5%(6/16), n\u00e1useas 37,5%(6/16) y p\u00e9rdida de apetito 31,35%(5/16)). Un 23,33%(7/30) presentaron toxicidad cut\u00e1nea: \nsarpullido/eczema en 57,14%(4/7) y picor 28,57%(2/7). 16,66%(5/30) present\u00f3 hepatotoxicidad, el 13,33%(4/30) \nmanifest\u00f3 astenia. Un 23,33%(7/30) presentaron otras toxicidades.  \nEn cuanto a nintedanib la toxicidad fue: digestiva 86,6%(13/15) (diarrea 61,53%(8/13), p\u00e9rdida de peso 46,15 \n%(6/13) y n\u00e1useas y v\u00f3mitos 38,46%(5/13)). Hasta un 33,33%(5/15) presentaron hepatotoxicidad destacando la \nhipertransaminemia en el 60% (3/5) de estos pacientes. Un 13,33% (2/15) toxicidad cut\u00e1nea y un 13,33%(2/15) otra \ntoxicidad\ufffd  \nRespecto al manejo: 45,7%(16/35) de los pacientes con toxicidad tuvieron que suspender, reiniciando 5 pacientes tras \nla resoluci\u00f3n (2 suspendieron por fallecimiento, 2 por toxicidad y 1 por falta de eficacia). 31,4%(11/35) redujeron dosis, \n28,57%(10/35) requirieron tratamiento farmacol\u00f3gico para resoluci\u00f3n (los f\u00e1rmacos m\u00e1s empleados fueron: loperamida \n25%(5/20), antihistam\u00ednicos 15%(3/20) y corticoides 15%(3/20)). El 17,14%(6/35) no requiri\u00f3 manejo.\nCONCLUSIONES\nLa persistencia al TAF es similar en nintedanib y pirfenidona, siendo el principal motivo de suspensi\u00f3n la toxicidad. Los \nTAF suponen un elevado riesgo de toxicidad, destacando la digestiva y hep\u00e1tica por nintedanib. La defunci\u00f3n fue la \nsegunda causa de suspensi\u00f3n. Teniendo en cuenta la toxicidad de estos f\u00e1rmacos, cabe destacar la importancia de la \nsuspensi\u00f3n del tratamiento cuando el riesgo supera el beneficio. El papel del farmac\u00e9utico es fundamental en la revisi\u00f3n \ndel tratamiento y la recomendaci\u00f3n de suspensi\u00f3n si procede\ufffd191CLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n972. MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE ECULIZUMAB EN PACIENTES CON S\u00cdNDROME \nHEMOL\u00cdTICO UR\u00c9MICO AT\u00cdPICO \nAUTORES\nSALVADOR GARRIDO, P\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nObjetivo: La monitorizaci\u00f3n farmacocin\u00e9tica de eculizumab (ECU) puede proporcionar la oportunidad para realizar su \npersonalizaci\u00f3n terap\u00e9utica en pacientes con S\u00edndrome Hemol\u00edtico Ur\u00e9mico At\u00edpico (SHUa). Los objetivos de nuestro \nestudio fueron determinar los niveles s\u00e9ricos m\u00ednimos de ECU (ECUm\u00edn) en pacientes con SHUa, y analizar, teniendo en \ncuenta la situaci\u00f3n cl\u00ednica del paciente, la posibilidad de realizar un ajuste posol\u00f3gico individualizado.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de todos los pacientes adultos con SHUa en los que se ha realizado la determinaci\u00f3n \nde las ECUm\u00edn.  \nTodos los pacientes han seguido el protocolo de administraci\u00f3n de la fase de mantenimiento establecido, excepto una \npaciente que por presentar hem\u00f3lisis est\u00e1 recibiendo 1500 mg/14 d\u00edas. Para valorar su respuesta cl\u00ednica se determinan \nlos par\u00e1metros cl\u00ednicos indicativos de anemia hemol\u00edtica (hemoglobina, haptoglobina y lactato deshidrogenasa), \ntrombocitopenia y funci\u00f3n renal, y la actividad hemol\u00edtica del complemento (CH50), as\u00ed como las ECUm\u00edn. Todos los \npacientes est\u00e1n vacunados y reciben profilaxis oral.  \nPara la determinaci\u00f3n de las ECUm\u00edn y de los anticuerpos anti-ECU se ha utilizado la t\u00e9cnica ELISA previamente \nvalidada, usando el kit KRIBIOLISATM ECU en el analizador ADLTISTM. ECUm\u00edn > 100 mcg/mL se asocian con un bloqueo \npr\u00e1cticamente completo del complemento.\nRESULTADOS\nLas ECUm\u00edn fueron determinadas en 12 pacientes (edad media: 56 a\u00f1os, rango: 26-72; peso medio: 65 kg, rango: 41-94), \n5/12 son mujeres y 8/12 son pacientes trasplantados renales en los que ECU se utiliza como profilaxis de recidiva por \nSHUa\ufffd  \nSe han realizado 98 determinaciones (rango: 2-14 por paciente), y los valores de ECUm\u00edn presentaban un valor medio \nde 328,27\u00b1 203,00 mcg/mL, y oscilaban entre 72,78 y 965,62 mcg/mL. No hubo un momento uniforme en la fase de \nmantenimiento para su determinaci\u00f3n en relaci\u00f3n al inicio de ECU (rango: 6-229 dosis). Los valores de ECUm\u00edn fueron > \n100 mcg/mL en todos los pacientes, para todas las determinaciones con el esquema establecido, excepto en la 7 dosis de \nmantenimiento en un paciente (72,78 mcg/mL). Los valores de ECUm\u00edn mostraron una gran variabilidad: > 200 mcg/mL \nen 13 determinaciones, > 300 en 25, > 400 en 19, > 500 en 5 y > 600 en 23.  \nTodos los pacientes han mostrado un control efectivo de la enfermedad, excepto una trasplantada renal que present\u00f3 \nrechazo humoral refractario al tratamiento.\nCONCLUSIONES\nNuestro estudio muestra que el esquema de administraci\u00f3n fijo establecido para ECU en pacientes con SHUa se asocia \ncon ECUm\u00edn altas en la mayor\u00eda de las determinaciones. As\u00ed, la utilizaci\u00f3n conjunta de la monitorizaci\u00f3n farmacocin\u00e9tica y \nfarmacodin\u00e1mica permitir\u00eda la optimizaci\u00f3n de su administraci\u00f3n, garantiz\u00e1ndose su coste/efectividad y seguridad.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n993. LANADELUMAB COMO PROFILAXIS A LARGO PLAZO EN EL ANGIOEDEMA HEREDITARIO: PRIMEROS \nRESULTADOS DE EFECTIVIDAD Y SEGURIDAD EN PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nESCARIO GOMEZ, M; GARCIA LOPEZ, L; PEREZ ROBLES, T; GARCIA-TREVIJANO CABETAS, M; AYLLON MORALES, M; \nCOLLADA SANCHEZ, VL; GONZALEZ FERNANDEZ, MA; HERRERO AMBROSIO, A\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nEl angioedema hereditario (AEH) es una enfermedad gen\u00e9tica caracterizada por la aparici\u00f3n de angioedema recurrente. \nEntre los distintos enfoques terap\u00e9uticos, la profilaxis a largo plazo (PLP) es una estrategia que se debe considerar en \naquellos pacientes en quienes la frecuencia o intensidad de los s\u00edntomas afectan a su calidad de vida, y tambi\u00e9n en \naquellos casos con m\u00e1s de un episodio agudo por mes. En Espa\u00f1a, hasta hace poco tiempo solo hab\u00eda un principio activo, \nel inhibidor C1 esterasa, con indicaci\u00f3n autorizada para la PLP , siendo lanadelumab el segundo f\u00e1rmaco con indicaci\u00f3n en \neste escenario. El objetivo del presente estudio es evaluar la eficacia y seguridad de lanadelumab como PLP en pacientes \ncon AEH\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo en el que se incluyeron todos los pacientes en tratamiento con lanadelumab, \ndurante un periodo m\u00ednimo de 4 meses, en un hospital de referencia de AEH. Se recogieron los siguientes datos de la \nhistoria cl\u00ednica electr\u00f3nica: edad, diagn\u00f3stico, fecha de inicio de tratamiento, tratamientos previos, posolog\u00eda, episodios \nde angioedema y efectos adversos. Para la evaluaci\u00f3n de la eficacia, se compar\u00f3 la media de episodios mensuales \n(tanto los que requirieron tratamiento como los que no) en los 4 meses previos y en los 4 meses posteriores al inicio de \ntratamiento con lanadelumab\ufffd192RESULTADOS\nSe incluyeron 5 pacientes; todos con diagn\u00f3stico de AEH tipo I. La edad media fue 48 a\u00f1os. Antes del inicio de \nlanadelumab, 2 pacientes estaban en tratamiento con icatibant a demanda, y 3 recib\u00edan PLP con inhibidor de C1 esterasa. \nCuatro pacientes iniciaron tratamiento con lanadelumab a la dosis establecida en ficha t\u00e9cnica (300 mg cada 15 d\u00edas); en \n1 de estos 3 pacientes se optimiz\u00f3 a la pauta mensual al tercer mes de tratamiento (300 mg cada 30 d\u00edas). Un paciente \ninici\u00f3 y mantuvo el tratamiento con la pauta mensual\ufffd  \nLa media de episodios mensuales fue de 2,25 antes del inicio de lanadelumab, y de 0,7 tras el mismo\ufffd Cuatro pacientes \nredujeron el n\u00famero de episodios mensuales, siendo la media de reducci\u00f3n de 1,55. Con respecto a los episodios que \nrequirieron tratamiento con icatibant o inhibidor C1 esterasa, se observ\u00f3 una reducci\u00f3n de 1,75 a 0,4 episodios al mes. \nEn un paciente se observ\u00f3 un incremento; de 2,25 a 3,25 en los episodios totales, y de 1,25 a 1,75 en los que requirieron \nrescate\ufffd \nEn relaci\u00f3n a la toxicidad, dos pacientes no experimentaron ning\u00fan efecto adverso, mientras que 3 pacientes reportaron \nastenia y reacci\u00f3n local en el lugar de inyecci\u00f3n\ufffd\nCONCLUSIONES\nEl n\u00famero de ataques mensuales de los pacientes con AEH en tratamiento profil\u00e1ctico con lanadelumab de nuestro \nestudio fue inferior a los experimentados con los tratamientos previos. El perfil de seguridad fue similar al reportado en el \nensayo cl\u00ednico pivotal.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n1033. PROFILAXIS DE MICROANGIOPAT\u00cdA TROMB\u00d3TICA CON ECULIZUMAB EN PACIENTES \nTRASPLANTADOS RENALES CON S\u00cdNDROME HEMOL\u00cdTICO UR\u00c9MICO AT\u00cdPICO \nAUTORES\nGIL ALMELA, J; DE LA CRUZ MURIE, P; TORR\u00d3 GARC\u00cdA, L; CANO MOLINA, J\u00c1; D\u00cdAZ RAM\u00d3N, M; GOLNABI DOWLATSHAHI, \nF; MART\u00cdNEZ IB\u00c1\u00d1EZ, M\u00c1; RAM\u00d3N P\u00c9REZ, M\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nEl s\u00edndrome hemol\u00edtico ur\u00e9mico at\u00edpico (SHUa) es una enfermedad gen\u00e9tica rara que cursa con anemia hemol\u00edtica \nmicroangiop\u00e1tica, trombopenia y afectaci\u00f3n renal. El da\u00f1o estructural caracter\u00edstico es una lesi\u00f3n endotelial que provoca \nun estado inflamatorio y protromb\u00f3tico conocido como microangiopat\u00eda tromb\u00f3tica (MAT).  \n \nAunque hist\u00f3ricamente el trasplante (Tx) renal no ha sido una buena opci\u00f3n para los pacientes con SHUa, el pron\u00f3stico ha \nmejorado con el uso profil\u00e1ctico de eculizumab.  \n \nEl objetivo del estudio es analizar la efectividad y seguridad de eculizumab como profilaxis de recidivas de MAT en \npacientes con SHUa sometidos a Tx renal durante el periodo de mayor riesgo de recurrencia postrasplante.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 todos los pacientes adultos con SHUa sometidos a Tx renal desde abril \nde 2018 hasta abril de 2022 en un hospital de tercer nivel, siguiendo el protocolo de profilaxis con eculizumab en Tx de \ndonante cad\u00e1ver: dosis inicial de 1200 mg el d\u00eda del Tx, continuando con 900 mg/7 d\u00edas desde el d\u00eda +1 y, a partir de la \nquinta semana, 1200 mg/14 d\u00edas. El periodo de seguimiento fue de 1 a\u00f1o postrasplante. Se recogieron: \n- Variables demogr\u00e1ficas: edad y sexo.  \n- Par\u00e1metros de funci\u00f3n renal: creatinina s\u00e9rica (Cr).  \n- Par\u00e1metros de hem\u00f3lisis: lactato deshidrogenasa (LDH) y hemoglobina (Hb).  \n- Recuento de plaquetas (PLT).  \nLos datos se obtuvieron de la historia cl\u00ednica electr\u00f3nica y se procesaron mediante Excel. \n \nLa evaluaci\u00f3n de la efectividad de eculizumab se bas\u00f3 en la mejor\u00eda de la funci\u00f3n renal (Cr\u22641,5 mg/dL) y en la respuesta \nhematol\u00f3gica: normalizaci\u00f3n del recuento de PLT (150-350 x1000/\u03bcL) y de los par\u00e1metros de hem\u00f3lisis (LDH: 135-\n214 U/L; Hb: 12,8-16,8 g/dL). La seguridad se midi\u00f3 por la aparici\u00f3n de reacciones adversas (RA) y la necesidad de \ndiscontinuaci\u00f3n del tratamiento.\nRESULTADOS\nSe incluyeron 5 pacientes (3 hombres, 2 mujeres) con una mediana de edad de 38 a\u00f1os (24-61).  \nLa evoluci\u00f3n de los par\u00e1metros cl\u00ednicos fue:  \n1) Previo Tx: Cr: 9,22\u00b13,65; Plaquetas: 166\u00b140; LDH: 274\u00b189; Hemoglobina: 9,7\u00b11,4.  \n2) 24h tras TX: Cr: 5,01\u00b13,05; Plaquetas: 153\u00b125; LDH: 221\u00b135; Hemoglobina: 9,4\u00b10,7.  \n3) 1 mes: Cr: 1,34\u00b10,34; Plaquetas: 221\u00b168; LDH: 214\u00b173; Hemoglobina: 11,9\u00b10,8.  \n4) 3 meses: Cr: 1,24\u00b10,44; Plaquetas: 187\u00b146; LDH: 205\u00b155; Hemoglobina: 13,7\u00b10,9.  \n5) 1 a\u00f1o: Cr: 1,2\u00b10,39; Plaquetas: 204\u00b160; LDH: 188\u00b137; Hemoglobina: 14,8\u00b11,8.  \n \nTras un a\u00f1o, se observaron las siguientes variaciones respecto a los valores previos al Tx: disminuci\u00f3n de Cr del 87%, \naumento de PLT del 23%, disminuci\u00f3n de LDH del 31% y aumento de Hb del 53%\ufffd En cuanto a la seguridad, no se observ\u00f3 \nninguna RA y ning\u00fan paciente tuvo que suspender el tratamiento.193CONCLUSIONES\nLos resultados indican que eculizumab mantiene la remisi\u00f3n de la MAT a largo plazo conservando la funci\u00f3n del injerto, \nobserv\u00e1ndose una importante mejor\u00eda en los par\u00e1metros de funci\u00f3n renal y de hem\u00f3lisis, adem\u00e1s del mantenimiento de \nla respuesta hematol\u00f3gica. \n \nNo obstante, existen interrogantes sobre la necesidad del uso indefinido de eculizumab, por lo que se necesitan m\u00e1s \nestudios para establecer conclusiones sobre la duraci\u00f3n del tratamiento tras la estabilizaci\u00f3n de los pacientes, m\u00e1s a\u00fan \nteniendo en cuenta su alto impacto econ\u00f3mico\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n1119. EFECTIVIDAD Y SEGURIDAD DE TEZACAFTOR/IVACAFTOR/ELEXACAFTOR EN LA PR\u00c1CTICA REAL \nAUTORES\nDIAZ RAMON, M; CANO MOLINA, JA; TORRO GARCIA, L; MARTINEZ IBA\u00d1EZ, MA; GIL ALMELA, J; VILLA CARPES, J; DE \nGOROSTIZA FRIAS, I; MANCEBO GONZALEZ, A\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nTezacaftor/ivacaftor/elexacaftor se encuentra incluido en el sistema de informaci\u00f3n VALTERMED del SNS para determinar \nel valor terap\u00e9utico en la pr\u00e1ctica cl\u00ednica real, y se incorpor\u00f3 a la gu\u00eda de nuestro hospital en diciembre de 2021 para \nel tratamiento de pacientes con fibrosis qu\u00edstica (FQ) con la mutaci\u00f3n F508del. El objetivo de este estudio es evaluar la \nefectividad y seguridad de tezacaftor/ivacaftor/elexacaftor en la pr\u00e1ctica cl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo realizado en un hospital de tercer nivel. Se incluyeron todos los pacientes en \ntratamiento con tezacaftor/ivacaftor/elexacaftor desde diciembre de 2021 a abril de 2022. \nLas variables recogidas al inicio, a las 4 semanas y a las 16 semanas fueron: volumen espiratorio forzado en el primer \nsegundo (FEV1), peso (kg), talla (cm), \u00edndice de masa corporal (IMC) y cantidad de cloro (Cl) en el sudor. Adem\u00e1s se \nrecogieron las variables de: sexo, edad, tipo de mutaci\u00f3n, duraci\u00f3n de tratamiento.  \nLa efectividad se evalu\u00f3 por: la mejora de la funci\u00f3n respiratoria, con el aumento de FEV1; la mejora de la funci\u00f3n \ndigestiva, con el aumento de peso e IMC; y la disminuci\u00f3n de Cl. La seguridad se evalu\u00f3 por la existencia de eventos \nadversos relacionados con el tratamiento\ufffd  \nLas fuentes de informaci\u00f3n utilizadas han sido el programa de prescripci\u00f3n electr\u00f3nica asistida y el programa de historia \ncl\u00ednica del hospital.\nRESULTADOS\nSe incluyeron 32 pacientes, con una mediana de edad de 22,2 a\u00f1os(12,2-69,7). El 59,37% eran hombres. La mediana de \nduraci\u00f3n de tratamiento con tezacaftor/ivacaftor/elexacaftor fue de 4,05 meses (1,4-4,5). El 62,5% eran homocigotos para \nla mutaci\u00f3n F508del, el 37,5% heterocigotos.  \nLa mediana de FEV1 basal fue 81,4%, el IMC basal 21,4 y la mediana de Cl en sudor 99,5mmol/l\ufffd  \nEn cuanto a los resultados de efectividad, a las 4 semanas del inicio de tratamiento, la mediana de FEV1 fue 97,75% (28,3-\n138), la mediana del IMC 21,87 y la cantidad de Cl de 60mmol/l (18-122). A las 16 semanas (n=15), la mediana de FEV1 \nera de 91,7% (55-138), la mediana de IMC 21,1 (18-,5-25,8).  \nRespecto a la seguridad, se registr\u00f3 un caso de dolor abdominal intenso, produciendo la interrupci\u00f3n del tratamiento \ndurante unos d\u00edas, reiniciando posteriormente a dosis crecientes y actualmente se encuentra con la dosis completa, 1 \ncaso de hipoglucemias post-pandriales y elevaci\u00f3n de enzimas hep\u00e1ticas en 6 pacientes, no elev\u00e1ndose por encima de 3 \nveces el l\u00edmite superior normal, por lo que no ha sido necesario suspender el tratamiento.\nCONCLUSIONES\nEl tratamiento con tezacaftor/ivacaftor/elexacaftor ha demostrado ser efectivo a las 4 semanas de seguimiento, ya que \nse produjo una mejor\u00eda en todos los par\u00e1metros evaluados, con un incremento medio en el FEV1 de 17,43% y en el IMC \nmedio de 0,52, as\u00ed como una disminuci\u00f3n media en el Cl en sudor de 33,26mmol/l. Esta mejor\u00eda se mantiene hasta la \nsemana 16 de tratamiento, de forma coherente con los resultados obtenidos en los ensayos cl\u00ednicos. El f\u00e1rmaco ha sido \nbien tolerado, siendo el aumento de las transaminasas hep\u00e1ticas el efecto m\u00e1s frecuente, sin embargo, ning\u00fan paciente \ntuvo que interrumpir el tratamiento por este motivo.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n1142. FORMULACION MAGISTRAL EN EL TRATAMIENTO DE LAS ENFERMEDADES RARAS \nAUTORES\nGARCIA QUEIRUGA, M; MARTINEZ ROCA, C; DEBEN TISCAR, E; YA\u00d1EZ GOMEZ, P; FEAL CORTIZAS, B; MARTIN \nHERRANZ, MI\nHOSPITAL UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nEl tratamiento de las enfermedades raras (EERR) contin\u00faa siendo un reto ya que existen necesidades terap\u00e9uticas sin \ncubrir debido a la no disponibilidad de medicamentos comercializados en muchos casos, siendo la Formulaci\u00f3n Magistral 194(FM) la \u00fanica alternativa en algunas EERR. La importancia de este tema se muestra en la disponibilidad de una plataforma \nonline de FM en EERR impulsada por la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH).  \nEl objetivo de este trabajo es describir qu\u00e9 FM est\u00e9riles se han elaborado en el Servicio de Farmacia de un hospital \nterciario para el tratamiento de EERR en el a\u00f1o 2021 e incluirlas en la plataforma de la SEFH\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Se incluy\u00f3 el 100% de FM elaboradas para el tratamiento de EERR en el a\u00f1o 2021. \nSe recogi\u00f3 el numero de pacientes, tipo y numero de FM elaboradas, as\u00ed como el motivo de su preparaci\u00f3n. Todas fueron \nincluidas en la plataforma online de FM en EERR de la SEFH\ufffd\nRESULTADOS\nEn el a\u00f1o 2021 se identificaron 21 EERR para las cuales se elaboraron un total de 25 FM diferentes. El n\u00famero de \nunidades de FM preparadas fue de 4949 para un total de 85 pacientes (58,2 unidades /paciente). Se describe para \ncada EERR (FM n\u00ba pacientes /n\u00ba unidades elaboradas): Abernethy malformaci\u00f3n (ursodiol suspensi\u00f3n oral 1/85); \nEsclerosis tuberosa (sirolimus pomada 2/125); Esofagitis eosinof\u00edlica (budesonida viscosa 10/535); S\u00edndrome Mc Cune \nAlbright (soluci\u00f3n oral fosfatos 1/218); Hemangioma infantil (timolol gel 20/304); Encefalopat\u00eda epil\u00e9ptica neonatal \n(piridoxal fosfato capsulas 2/100); Hiperinsulinismo cong\u00e9nito (diazoxido suspensi\u00f3n oral 1/1); Hiperplasia suprarrenal \ncong\u00e9nita (hidrocortisona suspensi\u00f3n oral 2/12), Hipertensi\u00f3n pulmonar (sildenafilo suspensi\u00f3n oral 5/77); Cardiopat\u00eda \ncong\u00e9nita infantil (capsulas acido acetilsaliciclico 10/2000; Enfermedad Kawasaki (capsulas acido acetilsaliciclico 2/400); \nMELAS (taurina sobres 1/387); Papilomatosis respiratoria (cidofovir intralesional 5/10 y fluorouracilo inhalaci\u00f3n 1/2); \nPoliquistosis renal (amlodipino suspensi\u00f3n oral 1/65; labetalol suspensi\u00f3n oral 1/29, enalaprilo suspensi\u00f3n oral 1/64 y \nclonidina suspensi\u00f3n oral 1/23); Raquitismo hipofosfat\u00e9mico (soluci\u00f3n oral fosfatos 2/218); Rendu-Osler (bevacizumab \nintralesional 4/8); glaucoma congenito primario (mitomicina colirio 1/12); Enfermedad.Wilson (suspensi\u00f3n oral Zinc \n2/14); Enfermedad hematol\u00f3gica pedi\u00e1trica (tioguanina suspensi\u00f3n oral 2/5 y mercaptopurina suspensi\u00f3n oral 4/154); \nCarcinoma plexos coroideos pediatr\u00eda (talidomida suspensi\u00f3n oral 1/17); S\u00edndrome de De Morsier (desmopresina \nsuspensi\u00f3n bucal 1/24 e Hidrocortisona suspensi\u00f3n oral 1/60). El motivo de prepararon fue en 17/25 casos la adaptaci\u00f3n \nde dosis para poblaci\u00f3n pedi\u00e1trica, en 5/25 la adaptaci\u00f3n a formula para via de administraci\u00f3n diferente y 3/25 casos \ncorresponden a principios activos no disponibles en presentaci\u00f3n comercial alguna.\nCONCLUSIONES\nSe pone de manifiesto el gran impacto de la Formulaci\u00f3n Magistral para la cobertura de necesidades terap\u00e9uticas \nen pacientes con EERR, que en nuestro caso ha permitido que 85 pacientes hayan podido disponer de una opci\u00f3n \nterap\u00e9utica. La plataforma online de FM en EERR de la SEFH permite compartir conocimiento entre los diferentes centros \ncon el fin de avanzar en el tratamiento de enfermedades poco prevalentes para las que existe informaci\u00f3n limitada.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n1208. EFECTIVIDAD Y SEGURIDAD DE IVACAFTOR TEZACAFTOR Y ELEXACAFTOR (KAFTRIO\u00ae) EN \nPACIENTES CON FIBROSIS QU\u00cdSTICA \nAUTORES\nROVIRA MEDINA, T; DEL ESTAL JIM\u00c9NEZ, J; L\u00d3PEZ GARC\u00cdA, B; ASENSIO DE LA CRUZ, O; OLIVER CERVELL\u00d3, M; DE \nCASTRO JULVE, M; REDONDO CAPAFONS, S; G\u00d3MEZ VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\nAnalizar la efectividad y seguridad de ivacaftor/tezacaftor/elexacaftor (Kaftrio\u00ae) en pacientes con fibrosis qu\u00edstica (FQ) en \nla pr\u00e1ctica cl\u00ednica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital universitario. Se incluyeron pacientes que hab\u00edan comenzado \ntratamiento con ivacaftor/tezacaftor/elexacaftor entre diciembre 2021 y marzo 2022. Se realiz\u00f3 un cuestionario telef\u00f3nico \no presencial a los pacientes y/o cuidadores\ufffd \nLa efectividad se evalu\u00f3 a partir del FEV1 previo al inicio del tratamiento y al mes de iniciarlo. Se registr\u00f3 el estado \ncomparativo de salud (mejor, peor o igual) respecto a antes del inicio, as\u00ed como el n\u00famero de exacerbaciones.  \n \nLa seguridad se evalu\u00f3 en base a la aparici\u00f3n de los efectos adversos m\u00e1s frecuentemente descritos en los ensayos \ncl\u00ednicos: infecciones (gripe/rinitis\u2026), trastornos metab\u00f3licos (hipoglucemia), del sistema nervioso (cefalea/mareos), del \no\u00eddo (dolor/taponamiento), respiratorios, tor\u00e1cicos y mediast\u00ednicos (congesti\u00f3n/rinorrea/sibilancias), gastrointestinales \n(diarrea/n\u00e1useas), dermatol\u00f3gicos (acn\u00e9/picor), y alteraciones de la mama (bulto/inflamaci\u00f3n/dolor). A los pacientes \npreviamente tratados con tezacaftor/ivacaftor, se pregunt\u00f3 por la mejor/peor tolerancia. Se registraron las bacterias \npresentes en el esputo de los pacientes antes de empezar, al primer y tercer mes de tratamiento.\nRESULTADOS\nSe incluyeron 16 pacientes, con una mediana de edad de 17,5 a\u00f1os (rango intercuart\u00edlico 4,5); 11(68,75%) eran hombres.  \n \nEl valor de FEV1 posterior al inicio se obtuvo en 13(81,25%) pacientes. El FEV1 mejor\u00f3 en 11(84,62%), empeorando en \nlos otros 2(15,38%). La mediana de mejora del FEV1 fue de 10,26% (media 13,68%). Quince (93,75%) pacientes indicaron \nmejor\u00eda con el nuevo tratamiento y 1(6,25%) se mantuvo igual. Ning\u00fan paciente tuvo exacerbaciones.  195Seis (37,5%) pacientes reportaron aparici\u00f3n de infecciones. De los 9(56,25%) que monitorizaron las glicemias, solamente \n1(11,11%) registr\u00f3 hipoglucemia tras el inicio, que pudo controlar ajustando la dosis de insulina. Solamente un paciente \n(6,25%) manifest\u00f3 efectos adversos del o\u00eddo (taponamiento). Cinco (31,25%) describieron efectos respiratorios, tor\u00e1cicos \ny mediast\u00ednicos. Tres (18,75%) pacientes experimentaron efectos gastrointestinales y otros 3, dermatol\u00f3gicos.  \nNing\u00fan paciente report\u00f3 cefalea o mareos ni alteraciones en la mama.  \nOnce pacientes (68,75%) presentaron bacterias pat\u00f3genas en esputo antes de iniciar. Tres (18,75%) no mostraron \nbacterias ni antes ni despu\u00e9s, y para 2(12,50%) de ellos no se han realizado determinaciones anal\u00edticas. Tras el inicio \nde ivacaftor/tezacaftor/elexacaftor, de los 11 pacientes en los que se hab\u00edan detectado bacterias, en 5(45,45%) \npermanecieron, en 3(27,27%) dejaron de detectarse, y en los otros 3(27,27%) no hay datos.  \nSiete pacientes (43,75%) hab\u00edan recibido previamente tezacaftor/ivacaftor; 2 de ellos (28,57%) no supieron comparar \ntolerancia, otros 2 toleraron mejor ivacaftor/tezacaftor/elexacaftor y 3(42,86%) no notaron diferencias.\nCONCLUSIONES\nIvacaftor/tezacaftor/elexacaftor ha demostrado beneficio cl\u00ednico y buena tolerancia en la muestra de pacientes con FQ, \ncon mejor\u00eda de la funci\u00f3n respiratoria y con un perfil de seguridad similar al reportado en ensayos cl\u00ednicos.  \nLas limitaciones del estudio son el peque\u00f1o tama\u00f1o muestral y tiempo de seguimiento, as\u00ed como la falta de datos \nanal\u00edticos que permitan evaluar la seguridad a nivel hepatobiliar.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n302. VALIDACI\u00d3N DE UNA ESCALA ACTUALIZADA PARA EVALUAR LA COMPLEJIDAD DE LOS ENSAYOS \nCL\u00cdNICOS EN UN SERVICIO DE FARMACIA \nAUTORES\nS\u00c1EZ FERN\u00c1NDEZ, EM; PE\u00d1A LORENZO, D; FURONES ARAUJO, D; SANTIAGO GALLEGO, B; JIM\u00c9NEZ CABRERA, S; \nOTERO L\u00d3PEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nLa creciente complejidad de los nuevos ensayos cl\u00ednicos (EC) supone un aumento de los recursos humanos y materiales \nnecesarios para gestionarlos en los servicios de farmacia, de acuerdo con las normas de buena pr\u00e1ctica cl\u00ednica. El objetivo \ndel estudio consisti\u00f3 en adaptar y validar una escala para evaluar la complejidad de los EC, ajustada a los requerimientos \nactuales exigidos a un servicio de farmacia\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional en el que se valor\u00f3 la complejidad de los EC abiertos en el servicio de farmacia desde \nenero-2015 hasta marzo-2022. Los datos se obtuvieron del programa de trazabilidad de EC. En primer lugar, a partir de \nla escala de complejidad publicada por Calvin-Lamas et al, se desarroll\u00f3 una escala actualizada compuesta inicialmente \npor 14 \u00edtems, considerando las actividades habituales llevadas a cabo en el \u00e1rea de EC. Se asign\u00f3 una puntuaci\u00f3n de 0 \na 3 puntos para valorar la complejidad de cada \u00edtem, seg\u00fan los recursos empleados para realizar dicha actividad y del \nriesgo asociado a la misma para el paciente o la integridad del EC. La puntuaci\u00f3n m\u00e1xima posible de complejidad de la \nescala fue de 49 puntos. Los \u00edtems incluidos inicialmente en la escala contemplaron: dise\u00f1o ciego/abierto, n\u00famero de \nprincipios activos, n\u00famero de presentaciones, m\u00e9todo de dispensaci\u00f3n, personal de farmacia implicado, uso de sistemas \ninteractivos*, modo de preparaci\u00f3n*, almacenamiento* (*\u00edtems con respuestas sumatorias), necesidad de material \nfungible espec\u00edfico, m\u00e9todo de aportaci\u00f3n de la medicaci\u00f3n, fase del estudio, incorporaci\u00f3n de anticuerpos de nueva \ngeneraci\u00f3n y/o terapia celular, n\u00famero de visitas con dispensaci\u00f3n/preparaci\u00f3n por ciclo de tratamiento y n\u00famero de \nramas del EC. En segundo lugar, se evalu\u00f3 la validez interna de la escala mediante el c\u00e1lculo del alfa de Cronbach, cuyo \nvalor \u2265 0,7 se considera aceptable por definici\u00f3n. Por \u00faltimo, se estim\u00f3 la complejidad de los EC con la escala validada. El \nan\u00e1lisis estad\u00edstico se realiz\u00f3 mediante el software SPSS\u00ae versi\u00f3n 25.\nRESULTADOS\nDe los 14 \u00edtems iniciales, se excluyeron 3 (dise\u00f1o ciego/abierto, m\u00e9todo de dispensaci\u00f3n y m\u00e9todo de aportaci\u00f3n de \nla medicaci\u00f3n) al obtenerse valores negativos de alfa de Cronbach, por lo que la escala final de valoraci\u00f3n incluy\u00f3 11 \n\u00edtems. La validez de esta escala final desarrollada mostr\u00f3 un valor global alfa de Cronbach de 0,741. Los \u00edtems con mayor \ncontribuci\u00f3n a esta escala resultaron ser: personal de farmacia implicado, modo de almacenamiento y necesidad de \nmaterial fungible espec\u00edfico. Se revis\u00f3 la complejidad de un total de 476 EC, de los que fueron excluidos 37 debido a \nla falta de informaci\u00f3n de alguno de los \u00edtems. En los 439 EC restantes en los que pudo ser valorada la complejidad, se \nobtuvo una mediana (rango) de 21 puntos (9-39).\nCONCLUSIONES\nSe ha adaptado y validado una escala de complejidad ajustada a los requerimientos de los EC actuales. Esta herramienta \npodr\u00eda ser de utilidad para valorar la complejidad de los EC en los servicios de farmacia y dimensionar los recursos \nnecesarios para gestionarlos de forma adecuada.196CLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n373. EVALUACI\u00d3N DEL GRADO DE SATISFACCI\u00d3N DE LOS PACIENTES EXTERNOS INCLUIDOS EN ENSAYOS \nCL\u00cdNICOS ATENDIDOS EN UNA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA \nAUTORES\nPINILLA LEBRERO, G; ARRIETA LOITEGUI, M; RANZ ORTEGA, P; AG\u00dc\u00cd CALLEJAS, AM; GONZ\u00c1LEZ ANDR\u00c9S, D; \nECHAVARRI DE MIGUEL, M; RIVA DE LA HOZ, B; POZAS DEL R\u00cdO, MT\nHOSPITAL INFANTIL UNIVERSITARIO NI\u00d1O JESUS. AV . MEN\u00c9NDEZ PELAYO, 65 MADRID. MADRID\nOBJETIVOS\nRealizar encuestas de satisfacci\u00f3n es una herramienta \u00fatil para conocer el grado de conformidad del paciente o familiares \ny ver las posibles oportunidades de mejora. \nEl objetivo fue analizar y valorar el grado de satisfacci\u00f3n de los pacientes externos incluidos en ensayos cl\u00ednicos de un \nhospital pedi\u00e1trico, que acudieron a la unidad de ensayos cl\u00ednicos del servicio de farmacia a recoger medicaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se realiz\u00f3 una encuesta de satisfacci\u00f3n voluntaria y an\u00f3nima a los pacientes \npedi\u00e1tricos o familiares que acudieron a recoger su medicaci\u00f3n de ensayo cl\u00ednico al servicio de farmacia durante enero y \nfebrero de 2022, para valorar la atenci\u00f3n farmac\u00e9utica recibida en el a\u00f1o 2021.  \n \nEsta encuesta consist\u00eda en 11 preguntas y un apartado libre para sugerencias. Los 11 \u00edtems fueron los siguientes:  \n1. Comodidad del horario de atenci\u00f3n del servicio de farmacia \n2\ufffd Tiempo de espera en ser atendido  \n3. El personal est\u00e1 correctamente identificado (con nombre y profesi\u00f3n)  \n4. Privacidad que siente donde se dispensa la medicaci\u00f3n  \n5. Disponibilidad del farmac\u00e9utico para consultar dudas respecto a la medicaci\u00f3n prescrita \n6. Satisfacci\u00f3n con las instrucciones recibidas para tomar los f\u00e1rmacos \n7\ufffd Explicaci\u00f3n de las reacciones adversas a medicamentos \n8. Explicaci\u00f3n de las pautas de medicaci\u00f3n (horario y c\u00f3mo tomar los medicamentos)  \n9. Amabilidad del farmac\u00e9utico \n10. Satisfacci\u00f3n con el trato global recibido  \n11. Satisfacci\u00f3n global con el servicio de farmacia \n \nCada pregunta se respondi\u00f3 utilizando la escala Likert, asign\u00e1ndoles una puntuaci\u00f3n entre 1 (muy mal) y 5 (muy bien).\nRESULTADOS\nSe cumplimentaron un total de 18 encuestas. Los \u00edtems mejor valorados fueron la amabilidad del farmac\u00e9utico (4,7/5), \nseguido de la correcta identificaci\u00f3n del personal, la privacidad a la hora de la dispensaci\u00f3n, la satisfacci\u00f3n con las \ninstrucciones recibidas y la satisfacci\u00f3n con el trato global recibido, recibiendo todas ellas una puntuaci\u00f3n media de 4,4/5.  \nLas siguientes puntuaciones fueron la comodidad del horario con un 4,33, seguido de las explicaciones de las pautas de \nmedicaci\u00f3n y la satisfacci\u00f3n global con el servicio de farmacia (4,2/5) y la disponibilidad para consultar dudas (4,1/5). Los \n\u00edtems con una menor puntuaci\u00f3n fueron la explicaci\u00f3n de las reacciones adversas a medicamentos (3,8/5) y el tiempo de \nespera en ser atendido (3,4/5).  \nEn el apartado de sugerencias, la petici\u00f3n m\u00e1s com\u00fan fue el poder reducir el tiempo en entregar la medicaci\u00f3n al \npaciente\ufffd\nCONCLUSIONES\nLa atenci\u00f3n farmac\u00e9utica al paciente externo pedi\u00e1trico incluido en ensayo cl\u00ednico es una funci\u00f3n del farmac\u00e9utico \nhospitalario clave a la hora de iniciar un tratamiento y realizar un seguimiento en cuanto a la entrega, toma y devoluci\u00f3n \nde la medicaci\u00f3n del ensayo correspondiente. De nuestro estudio, destacamos el grado de satisfacci\u00f3n general positivo, \naunque identificando puntos de mejora en cuanto al tiempo de espera para las siguientes consultas.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n614. SATISFACCI\u00d3N DEL PACIENTE AMBULATORIO CON EL \u00c1REA DE ENSAYOS CL\u00cdNICOS DE UN SERVICIO \nDE FARMACIA, EN HOSPITAL DE TERCER NIVEL \nAUTORES\nTEJEDOR TEJADA, E; MARTINEZ SANCHEZ, B; SUBIRANA BATLLE, C\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nUn ensayo cl\u00ednico es toda investigaci\u00f3n efectuada antes de aprobar un nuevo f\u00e1rmaco. La participaci\u00f3n es voluntaria y \nlos pacientes est\u00e1n sometidos a un control y monitorizaci\u00f3n constante. La preparaci\u00f3n y dispensaci\u00f3n desde el Servicio \nde Farmacia (SF) es m\u00e1s compleja a la pr\u00e1ctica convencional. Por ello, se pretende evaluar la opini\u00f3n de los pacientes \nambulatorios incluidos en un ensayo cl\u00ednico (EECC), a trav\u00e9s de una encuesta de satisfacci\u00f3n\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo de la satisfacci\u00f3n del paciente incluido en un EECC, sobre su la atenci\u00f3n recibida desde \nel SF. El periodo de recogida de la informaci\u00f3n fue marzo y abril 2022 (2 meses). El m\u00e9todo utilizado para la obtenci\u00f3n 197de la informaci\u00f3n fue a trav\u00e9s de una encuesta en papel. El paciente fue voluntario para realizar la encuesta y se respet\u00f3 \nla anonimizaci\u00f3n de las respuestas. En la encuesta se preguntaba sobre: la localizaci\u00f3n y el horario del SF, el tiempo de \nespera, atenci\u00f3n recibida y la medicaci\u00f3n de EECC. Se les solicit\u00f3 que indicaran una satisfacci\u00f3n global con el SF. Se evalu\u00f3 \nel grado de satisfacci\u00f3n con un resultado num\u00e9rico desde 1-10 (m\u00e1xima satisfacci\u00f3n). El proyecto cont\u00f3 con la aprobaci\u00f3n \ny supervisi\u00f3n del \u00e1rea de calidad.\nRESULTADOS\nDurante el periodo de recogida de datos, un total de 51 pacientes rellenaron la encuesta de satisfacci\u00f3n. Un paciente se \nneg\u00f3 a realizar el proyecto por alteraciones en la visi\u00f3n. El 57% de los pacientes fueron de sexo masculino. La franja de \nedad prevalente fue m\u00e1s 65 a\u00f1os en el 39,2% de los encuestados. Los resultados procedentes a la localizaci\u00f3n del servicio \nfue 8.8, con respecto al horario la media fue 9.3, el tiempo de espera 8.9, el espacio de la atenci\u00f3n fue evaluado con 8.8, \nla informaci\u00f3n de la atenci\u00f3n recibida 9.6 , el trato humano recibido 9.7 y la medicaci\u00f3n de EECC 9.5. En la satisfacci\u00f3n \ngeneral con el SF la nota fue 9\ufffd6\ufffd\nCONCLUSIONES\nEl funcionamiento del Servicio de Farmacia es altamente satisfactorio desde el punto de vista de los pacientes. Aspectos \ncomo el tiempo de espera o el lugar de la atenci\u00f3n se tendr\u00e1n en cuenta para favorecer la satisfacci\u00f3n del paciente \nambulatorio en un ensayo cl\u00ednico\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n642. CARACTER\u00cdSTICAS DE LOS ENSAYOS CL\u00cdNICOS CON MEDICAMENTOS INICIADOS EN \nONCOHEMATOLOG\u00cdA DURANTE EL 2021 \nAUTORES\nMART\u00cdNEZ-BARROS , H; LAVANDEIRA , M; D\u00cdAZ , \u00c1; PUEYO L\u00d3PEZ, C; POVEDA ESCOLAR, A; JIMENO AGUADO, S; \nCABELLO BRAVO, A; \u00c1LVAREZ D\u00cdAZ, A\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nDescribir las caracter\u00edsticas de los ensayos cl\u00ednicos (EECC) con medicamentos iniciados en oncohematolog\u00eda a lo largo del \na\u00f1o 2021 en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nSe incluyeron todos los EECC con intervenci\u00f3n con medicamentos para el tratamiento de patolog\u00edas oncohematol\u00f3gicas \ncuya visita de inicio hab\u00eda sido realizada entre el 1 de enero y el 31 de diciembre de 2021 en un hospital de tercer nivel. \nSe utilizaron las bases de datos del Registro Espa\u00f1ol de Ensayos Cl\u00ednicos y clinicaltrials.gov para recoger las siguientes \nvariables: Servicio, neoplasia, promotor, cobertura geogr\u00e1fica, fase cl\u00ednica de desarrollo, n\u00famero de pacientes que \nesperan reclutar a nivel global, control, aleatorizaci\u00f3n, ciego, y el tipo de variable principal: cl\u00ednica (supervivencia o \ncalidad de vida) o subrogada.\nRESULTADOS\nDurante 2021 se iniciaron en nuestro centro 71 EECC con intervenci\u00f3n con medicamentos en oncohematolog\u00eda, 59 \n(83,1%) de los cuales correspond\u00edan al Servicio de Oncolog\u00eda M\u00e9dica y 15 (21,1%) al c\u00e1ncer de mama, la neoplasia para \nla que se abrieron m\u00e1s EECC en el per\u00edodo estudiado. El promotor era la industria farmac\u00e9utica en 67 (94,4%). Todos los \nEECC iniciados eran internacionales y la mayor\u00eda (54,9%) de ellos era fase III. Globalmente, 39 (54,9%) de los EECC eran \ncontrolados y 34 (52,1%) eran aleatorizados. En cuanto al ciego, 47 (66,2%) eran abiertos, 1 (1,4%) ten\u00edan ciego simple \ny el resto (67,6%) eran doble o triple ciego. La variable principal era subrogada en 57 (80,3%) de los EECC, siendo la \nsupervivencia libre de progresi\u00f3n (SLP) la variable subrogada m\u00e1s frecuente (32,4% del total). Si atendemos al n\u00famero de \npacientes que se prev\u00e9 incluir globalmente en estos EECC, 22947 (78,9%) de los pacientes ser\u00e1n incluidos en un fase III. \nUn total de 21693 (74,6%) y 23630 (81,3%) pacientes entrar\u00e1n en un ensayo controlado y aleatorizado, respectivamente. \nGlobalmente, 13932 (47,9%), 490 (1,7%) y 14644 (50,4%) pertenecer\u00e1n a EECC con dise\u00f1o abierto, con ciego simple y con \nciego doble o triple. La variable principal ser\u00e1 subrogada para 22518 (77,5%) pacientes. Con respecto a los EECC fase III, \n32 (82,1%) eran controlados y 37 (94,9%) eran aleatorizados. Diecinueve (48,7%) ten\u00edan un dise\u00f1o abierto. La mayor\u00eda \nde los EECC fase III, 27 (69,2%), utilizaban variables subrogadas, siendo de nuevo la SLP la m\u00e1s habitual (18 EECC, 46,2%). \nNing\u00fan ensayo cl\u00ednico ten\u00eda la calidad de vida como variable principal.\nCONCLUSIONES\nAunque los EECC aleatorizados representan apenas la mitad de los EECC abiertos durante el per\u00edodo de estudio, \u00e9stos \nprev\u00e9n incluir a la extensa mayor\u00eda de pacientes.  \nCasi la mitad de los EECC fase III ten\u00edan un dise\u00f1o abierto, y la vasta mayor\u00eda utilizaban variables subrogadas como \nvariable principal\ufffd  \nNinguno de los EECC iniciados ten\u00eda la calidad de vida como variable principal.198CLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n786. EVALUACI\u00d3N DEL PROCESO DE CONSENTIMIENTO INFORMADO EN PACIENTES QUE PARTICIPAN \nEN ENSAYOS CL\u00cdNICOS CON MEDICAMENTOS \nAUTORES\nRUIZ DE HOYOS, M; VILLAMA\u00d1\u00c1N BUENO, E; FERNANDEZ DE UZQUIANO, E; G\u00d3MEZ SALCEDO, P; DEL R\u00cdO DURANGO, \nM; FR\u00cdAS INIESTA, J\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nEl objetivo del estudio es determinar c\u00f3mo se desarrolla el proceso de consentimiento informado (CI) en investigaci\u00f3n \ncl\u00ednica con medicamentos y si se ajusta a los requisitos regulatorios b\u00e1sicos. Adem\u00e1s, se pretende analizar la valoraci\u00f3n de \nlos participantes del proceso; describir los motivos para participar en un ensayo cl\u00ednico (EC); y conocer qu\u00e9 expectativas \nde beneficio y riesgo asociados a su participaci\u00f3n en el EC perciben los pacientes.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, transversal y descriptivo en un hospital de tercer nivel. Se incluyeron pacientes adultos que \nestaban participando en EC con medicamentos y que hab\u00edan firmado el formulario de CI en los \u00faltimos 30 d\u00edas. Para \nanalizar el proceso de CI se realiz\u00f3 una encuesta presencial a una muestra de pacientes que estaban participando en \nun EC para el que hab\u00edan dado su consentimiento. El periodo de selecci\u00f3n abarc\u00f3 1 a\u00f1o y se incluyeron todos aquellos \npacientes a los que fue posible acceder. Para la recogida de los datos se utiliz\u00f3 un cuestionario que fue desarrollado y \nvalidado por el equipo investigador, aprobado por el Comit\u00e9 de Innovaci\u00f3n del hospital y publicado.\nRESULTADOS\nSe incluyeron 159 pacientes, 50,9 % mujeres y con una edad media de 50,2\u00b118,5 a\u00f1os, que estaban participando en 72 \nensayos cl\u00ednicos con medicamentos diferentes. Todos los pacientes afirmaron haber recibido una hoja de informaci\u00f3n al \npaciente (HIP)durante el proceso de CI, haber firmado un formulario de CI y haber recibido una copia firmada del mismo. \nUn 96,2 % de los pacientes recibieron tambi\u00e9n informaci\u00f3n oral relativa al ensayo cl\u00ednico en el que participaban. Un \n39,6 % firm\u00f3 el formulario el mismo d\u00eda en que se les proporcion\u00f3 la informaci\u00f3n y un 14,6 % reconoci\u00f3 no haber le\u00eddo \nla HIP . Se detectaron dificultades con la lectura de estos documentos: 39,3 % de los participantes consideraba que eran \nexcesivamente largas y 45,2 % demasiado complejas. Estos aspectos fueron m\u00e1s se\u00f1alados entre aquellos de mayor edad \ny menor nivel educativo (p < 0,05).  \nSe observ\u00f3 un alto grado de satisfacci\u00f3n con el proceso de informaci\u00f3n, mostr\u00e1ndose satisfechos o muy satisfechos en un \n96,8 %. Los motivos principales para aceptar participar en el EC fueron: curaci\u00f3n (29%), mejor seguimiento y control de su \nenfermedad (21,9%), ayudar a futuros pacientes (14,8%), recomendaci\u00f3n del equipo m\u00e9dico (12,9 %), ayudar a mejorar \nen el conocimiento de la enfermedad (7,7%), acceso a nuevos f\u00e1rmacos (7,7%) y otros.  \nLos pacientes presentaron unas altas expectativas respecto al beneficio personal que pod\u00edan obtener, con una puntuaci\u00f3n \nmedia de 7,7 (DE=2,2) sobre 10, as\u00ed como una baja percepci\u00f3n del riesgo asociado, con una puntuaci\u00f3n media de 2,7 \n(DE=2,5) sobre 10. Un 23,4 % indic\u00f3 un riesgo igual a 0.\nCONCLUSIONES\nEl proceso de CI se ajust\u00f3 en su mayor\u00eda a los principales requisitos formales y recomendaciones pr\u00e1cticas establecidas \npor la regulaci\u00f3n, aunque se han detectado algunas dificultades. Las motivaciones m\u00e1s frecuentes para participar \nestuvieron relacionadas con la obtenci\u00f3n de beneficio personal, aunque los motivos altruistas estuvieron tambi\u00e9n \npresentes. Se observ\u00f3 una tendencia a sobrevalorar los beneficios asociados a la participaci\u00f3n e infraestimar los riesgos.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n790. AN\u00c1LISIS DEL NIVEL DE COMPRENSI\u00d3N QUE TIENEN LOS PACIENTES DE LOS PRINCIPALES ASPECTOS \nDE UN ENSAYO CL\u00cdNICO CON MEDICAMENTOS \nAUTORES\nRUIZ DE HOYOS, M; VILLAMA\u00d1AN BUENO, E; FERNANDEZ DE UZQUIANO, E; G\u00d3MEZ SALCEDO, P; DEL RIO DURANGO, \nM; FR\u00cdAS INIESTA, J\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nEl consentimiento informado (CI) es un proceso continuo de comunicaci\u00f3n entre investigador y paciente al que se \nle propone participar en un ensayo cl\u00ednico (EC). Un consentimiento solo ser\u00e1 v\u00e1lido si se garantiza que el potencial \nparticipante entiende la informaci\u00f3n suministrada. El objetivo del estudio es determinar la comprensi\u00f3n que tienen los \npacientes de los principales aspectos un EC con medicamentos y evaluar factores asociados a una mayor comprensi\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, transversal y descriptivo en un hospital de tercer nivel. Se incluyeron pacientes adultos que \nestaban participando en EC con medicamentos y que hab\u00edan firmado el formulario de CI en los \u00faltimos 30 d\u00edas. El periodo \nde selecci\u00f3n abarc\u00f3 1 a\u00f1o y se incluyeron todos aquellos pacientes a los que fue posible acceder a trav\u00e9s del servicio de \nfarmacia o de la unidad central de EC del centro. La recogida de datos se realiz\u00f3 mediante encuestas presenciales durante \nla visita de los pacientes al hospital. Para valorar la comprensi\u00f3n se utiliz\u00f3 el cuestionario Quality of Informed Consent \nQuestionnaire (QuIC), despu\u00e9s de su traducci\u00f3n, validaci\u00f3n y adaptaci\u00f3n al espa\u00f1ol. Se analiz\u00f3 la comprensi\u00f3n objetiva \n(grado de conocimiento real del EC en el que participan) y la comprensi\u00f3n subjetiva (percepci\u00f3n que tiene el paciente de 199su nivel de comprensi\u00f3n) siguiendo el sistema de puntuaci\u00f3n del QuIC. Para valorar factores asociados a la comprensi\u00f3n \nreal se realizaron an\u00e1lisis univariantes y multivariantes en los que se incluyeron variables relacionadas con: datos de \npacientes, caracter\u00edsticas del EC, desarrollo del proceso de CI, motivaciones para participar en EC y expectativas (beneficio \ny riesgo) que tiene el paciente del EC.\nRESULTADOS\nSe incluyeron 159 pacientes, 50,9% mujeres y con una edad media de 50,2\u00b118,5 a\u00f1os, que estaban participando en 72 EC \ncon medicamentos diferentes La comprensi\u00f3n objetiva media global fue de 71,3 (DE=11,1) sobre un m\u00e1ximo de 100. Las \nprincipales dificultades de comprensi\u00f3n surgieron en la identificaci\u00f3n de tratamientos y procedimientos experimentales, \nlos posibles beneficios para el paciente derivados de su participaci\u00f3n y los acontecimientos adversos y riesgos asumidos. \nLos pacientes valoraron el nivel de comprensi\u00f3n subjetiva que ten\u00edan en el momento de la firma del formulario de CI \ncon una puntuaci\u00f3n media global de 78,2 (DE=15,6) sobre 100. Encontramos una d\u00e9bil pero significativa asociaci\u00f3n (Rho \nSpearman=0,318; p < 0,001) entre la comprensi\u00f3n objetiva y subjetiva. Los siguientes factores se asociaron de forma \nsignificativa (p < 0,05) con una mayor comprensi\u00f3n objetiva: menor edad, mayor nivel educativo, lectura de las hojas de \ninformaci\u00f3n al paciente (HIP), firma tard\u00eda del CI, consulta de otras fuentes de informaci\u00f3n, valoraci\u00f3n positiva de la HIP , \nmayor grado de participaci\u00f3n en la toma de decisiones, mayor ansiedad para la toma de decisi\u00f3n y motivaci\u00f3n altruista \npara participar en el EC.\nCONCLUSIONES\nSe han detectado importantes carencias en la comprensi\u00f3n de aspectos fundamentales para tomar la decisi\u00f3n de \nparticipar. Las intervenciones dirigidas a fomentar un mayor di\u00e1logo con los pacientes, animar a la lectura de la HIP \ny promover que los pacientes dispongan de mayor tiempo para valorar las alternativas propuestas podr\u00edan ayudar a \nmejorar la calidad del CI.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n867. ERRORES DE PRESCRIPCI\u00d3N EN F\u00c1RMACOS ORALES DE ENSAYO CL\u00cdNICO \nAUTORES\nLAVANDEIRA P\u00c9REZ, M; MOLINA RUANO, \u00c1; MART\u00cdNEZ BARROS, H; CABELLO BRAVO, A; JIMENO AGUADO, S; POVEDA \nESCOLAR, A; PUEYO L\u00d3PEZ, C; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nActualmente, la prescripci\u00f3n de medicamentos intravenosos de Ensayos Cl\u00ednicos se realiza a trav\u00e9s del mismo programa \nque la medicaci\u00f3n comercial pero la prescripci\u00f3n de medicaci\u00f3n oral sigue haci\u00e9ndose en papel a trav\u00e9s de una receta \noficial del hospital.  \nPara que la prescripci\u00f3n de medicaci\u00f3n oral sea correcta, es necesario que se recojan todos los datos establecidos; fecha, \nc\u00f3digo de protocolo del ensayo cl\u00ednico, nombre del m\u00e9dico y firma, n\u00famero de paciente en el ensayo, medicamento, \ndosis, frecuencia y duraci\u00f3n\ufffd  \nEl continuo crecimiento del n\u00famero de ensayos cl\u00ednicos en el hospital, sobre todo en fases tempranas, hace que cada \nvez existan m\u00e1s f\u00e1rmacos nuevos con diferentes posolog\u00edas, aumentando exponencialmente el riesgo de errores en las \nprescripciones\ufffd  \nEl objetivo del estudio fue analizar los errores cometidos en la prescripci\u00f3n de medicamentos de ensayo cl\u00ednico de \nadministraci\u00f3n oral\ufffd\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio descriptivo retrospectivo donde se analizaron todas las recetas en papel de medicaci\u00f3n oral de \nensayos cl\u00ednicos desde el 21 de marzo al 21 de abril de 2022. Se recogieron las siguientes variables: c\u00f3digo del protocolo, \nservicio cl\u00ednico prescriptor, error o ausencia de datos en el nombre y firma del investigador principal, n\u00famero de paciente \nen el ensayo, f\u00e1rmaco, dosis, frecuencia y duraci\u00f3n.\nRESULTADOS\nSe analizaron un total de 331 recetas orales (15,8 recetas de media al d\u00eda). El 50,5% fueron del Servicio de Oncolog\u00eda \nM\u00e9dica, 11,7% Hematolog\u00eda, 9,5% Dermatolog\u00eda, 6,3% Enfermedades Infecciosas, 5,6% Cardiolog\u00eda y 16,4% de otros \nservicios\ufffd  \nEl 81,2% de las recetas no recog\u00edan todos los datos correctamente (el 89,3% fueron errores por ausencia de datos y el \n10,7% por errores de prescripci\u00f3n propiamente dichos). El 28,4% de las recetas incompletas conten\u00eda solamente un error, \nel 29,0% dos errores y el 23,8% tres errores o m\u00e1s. El error relativo por servicio fue: 100% Dermatolog\u00eda, Cardiolog\u00eda y \nEnfermedades Infecciosas, 89,1% Hematolog\u00eda y 66,8% Oncolog\u00eda.  \nEl error predominante fue en la duraci\u00f3n (74,9%) y en la frecuencia (40,5%) del tratamiento seguido por la dosis (24,8%), \nel f\u00e1rmaco (10,6%), la fecha (9,0%), nombre o firma del investigador principal (7,4%), n\u00famero del paciente (5,4%) y el \nc\u00f3digo del protocolo (0,3%).  \nTodos los errores fueron detectados por el farmac\u00e9utico. En ning\u00fan caso el error lleg\u00f3 al paciente.\nCONCLUSIONES\nSe han registrado un n\u00famero muy alto de errores en la receta oral de ensayos cl\u00ednicos. Los servicios que menos volumen \ntienen de ensayos cl\u00ednicos han sido los que han registrado m\u00e1s errores.  200El objetivo de la implantaci\u00f3n de la receta electr\u00f3nica en ensayos cl\u00ednicos ya se estableci\u00f3 como objetivo del Servicio de \nFarmacia. A la vista de los resultados y con la finalidad de evitar futuros errores en la dispensaci\u00f3n de medicaci\u00f3n oral \nde ensayos cl\u00ednicos, se va a llevar a cabo la implantaci\u00f3n definitiva de la receta electr\u00f3nica en estos pacientes. Se van a \nintroducir los datos en el programa de prescripci\u00f3n electr\u00f3nica para que el circuito sea el mismo que existe en pacientes \nexternos\ufffd\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n923. EVALUACI\u00d3N DEL AHORRO ECON\u00d3MICO EN MEDICACI\u00d3N DERIVADO DE LA PARTICIPACI\u00d3N EN \nENSAYOS CL\u00cdNICOS HEMATOL\u00d3GICOS EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nBOSCH , C; MIEDES , J; GARCIA , C; CONDE , D; GRAU , S; FERRANDEZ , O; ESPONA , M\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa participaci\u00f3n en los ensayos cl\u00ednicos (EC) constituye una oportunidad para los pacientes de acceder a nuevos \ntratamientos. El suministro de los medicamentos en investigaci\u00f3n por parte del promotor supone un ahorro para el \nhospital y el sistema sanitario. El objetivo de este estudio es evaluar los costes evitados en medicamentos de los EC del \nservicio de hematolog\u00eda (SH) por paciente y patolog\u00eda hematol\u00f3gica.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional, retrospectivo de los EC realizados por el SH entre enero de 2017 y abril del 2022 en \nun hospital terciario. Datos recogidos: identificaci\u00f3n EC (t\u00edtulo, c\u00f3digo de protocolo), promotor, fase, dise\u00f1o, patolog\u00eda \ny n\u00famero de pacientes. Para el an\u00e1lisis del coste evitado se tuvo en cuenta el n\u00famero de dispensaciones, n\u00famero de \nciclos, medicamentos dispensados, cantidad dispensada, duraci\u00f3n del tratamiento y los precios medios de adquisici\u00f3n. \nPatolog\u00edas incluidas: mieloma m\u00faltiple (MM), linfoma de Hodgkin (LH), linfoma folicular (LF), linfoma de c\u00e9lulas del \nmanto (LCM), linfoma mieloide agudo(LMA). Se defini\u00f3 el ahorro como el gasto econ\u00f3mico que hubiera ocasionado la \nprescripci\u00f3n de medicaci\u00f3n comercializada que deber\u00eda haber recibido el paciente incluido en EC seg\u00fan pr\u00e1ctica cl\u00ednica. \nPara el c\u00e1lculo del ahorro se revisaron los registros de dispensaciones y se realiz\u00f3 el sumatorio de los costes directos \nrelacionados con los tratamientos aportados por el promotor \ufffd Se calcul\u00f3 el coste medio evitado por EC, por paciente, \npatolog\u00eda y paciente/patolog\u00eda.\nRESULTADOS\nEl n\u00famero de EC en SH con pacientes durante el periodo de estudio fue de 6, 5(83,3%) EC de fase III y 1(16,6%) de \nfase II. El n\u00famero total de pacientes incluidos fue de 20 y el n\u00famero total de ciclos administrados 262, con una media \nde 8,3\u00b112,5 ciclos administrados/paciente. La distribuci\u00f3n de pacientes por patolog\u00eda fue: 1(5%) para MM, 8(40%) \nLH, 4(20%) LF, 5(25%) LCM, 2(10%) LMA. La industria farmac\u00e9utica fue el promotor en todos los ensayos evaluados. \nLa medicaci\u00f3n dispensada incluy\u00f3: 13 f\u00e1rmacos diferentes, destacando 85 viales de brentuximab(LH), 216 viales de \nrituximab(LCM, LF), 32 viales de bortezomib(MM), 48 viales de daratumumab(MM), 406 viales de azacitidina(LMA), \n924 c\u00e1psulas de lenalidomida(MM). El coste evitado global fue 712.397,8\u20ac. El coste medio evitado por EC fue 21.691,6\u20ac \n\u00b115490,9 \u20ac y el coste medio evitado por paciente 5.936,7 \u20ac \u00b15180,4\u20ac. El coste evitado por patolog\u00eda fue: 250.782,2\u20ac \npara mieloma m\u00faltiple, 219.626,2\u20ac linfoma de Hodgkin, 34.808,4\u20ac linfoma folicular, 65.183,7\u20ac linfoma de c\u00e9lulas del \nmanto, 34.552\u20ac linfoma mieloide agudo. El coste evitado por paciente/patolog\u00eda fue: 40.368,5\u20ac para mieloma m\u00faltiple, \n27.453,3\u20ac linfoma de Hodgkin, 8.202,1\u20ac para linfoma folicular, 34.931,8\u20ac linfoma de c\u00e9lulas del manto, y 17.261,1\u20ac para \nlinfoma mieloide agudo\ufffd\nCONCLUSIONES\n- La realizaci\u00f3n de los EC supone un ahorro importante por los costes evitados en medicamentos.  \n- El mieloma m\u00faltiple tratado con daratumumab, bortezomib y lenalidomida ha supuesto el ahorro m\u00e1s elevado en el \nentorno de los EC de hematolog\u00eda.  \n- A pesar del ahorro observado, deber\u00eda efectuarse un estudio una vez financiadas las mol\u00e9culas utilizadas para estimar el \nimpacto econ\u00f3mico real\ufffd\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n933. EVALUACI\u00d3N DE LA LEGIBILIDAD Y COMPRENSIBILIDAD DEL ETIQUETADO DE MEDICAMENTOS EN \nINVESTIGACI\u00d3N CL\u00cdNICA POR PACIENTES DE ENSAYOS CL\u00cdNICOS \nAUTORES\nFERN\u00c1NDEZ S\u00c1NCHEZ, M; BALLESTA LOPEZ, O; TORDERA BAVIERA, M; BENITO ZAZO, N; MELERO MORENO, MM; \nCRUZ SANCHEZ, A; FERRANDIS SALES, N; POVEDA ANDRES, JL\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEvaluar la legibilidad y comprensibilidad de las etiquetas de muestras de medicamentos en investigaci\u00f3n por parte de los \npacientes incluidos en ensayos cl\u00ednicos (EECC).\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una encuesta de ocho preguntas para evaluar el grado de facilidad de localizar informaci\u00f3n en las etiquetas de \nmedicaci\u00f3n en investigaci\u00f3n (dosis, v\u00eda de administraci\u00f3n, conservaci\u00f3n, caducidad, nombre del medicamento y del EC, 201legibilidad y comprensibilidad globales) en un hospital terciario. A cada respuesta correcta, se asignaron 4 puntos para un \ngrado de facilidad de \u201cmuy f\u00e1cil\u201d, 3 puntos \u201cf\u00e1cil\u201d, 2 puntos \u201cni f\u00e1cil ni dif\u00edcil\u201d, 1 punto \u201cdif\u00edcil\u201d y 0 puntos \u201cmuy dif\u00edcil\u201d. Si la \nrespuesta no era correcta, se asignaron 0 puntos y se registr\u00f3 como \u201cfallo\u201d \ufffd El grado de facilidad se midi\u00f3 en puntuaci\u00f3n \ntotal sobre 32 puntos. Adem\u00e1s, se recogieron datos referentes al EC: protocolo, promotor, n\u00famero de paciente en el EC, \nmuestra de investigaci\u00f3n y si se trataba de una primera dispensaci\u00f3n; y referentes a pacientes: edad y nivel de estudios \n(ESO/EGB, Bachiller/COU, FP , universitarios o sin estudios). Los datos se recogieron en una base de datos de Access\u00ae. Se \ncalcularon los estad\u00edsticos descriptivos para edad, moda de nivel de estudios, moda y porcentaje del grado de facilidad \npara cada pregunta y puntuaci\u00f3n total media. Asimismo, se analiz\u00f3 la influencia de la edad, nivel de estudios, primera \ndispensaci\u00f3n y promotor en la puntuaci\u00f3n total mediante ANOVA, Mann-Whitney y Kruskal-Wallis mediante SPSS\u00ae.\nRESULTADOS\nSe realizaron un total de 21 encuestas a 18 pacientes, de las cuales siete (33,3%) se realizaron durante una primera \ndispensaci\u00f3n. Se evaluaron las etiquetas de nueve medicamentos, englobados en un total de seis EECC y cinco \npromotores diferentes. La edad media fue 53,8 \u00b1 12,9 a\u00f1os (rango: 26-78 a\u00f1os) y la moda de nivel de estudios fue ESO/\nEGB. La moda del grado de facilidad por preguntas fue \u201cmuy f\u00e1cil/f\u00e1cil\u201d para la dosis y v\u00eda de administraci\u00f3n, \u201cmuy f\u00e1cil\u201d \npara la conservaci\u00f3n, \u201cmuy f\u00e1cil\u201d para la caducidad, \u201cf\u00e1cil\u201d para el nombre del medicamento y del EC y \u201cf\u00e1cil\u201d para la \nlegibilidad y comprensibilidad globales. La distribuci\u00f3n de frecuencias totales (n=168) fue: 44 \u201cmuy f\u00e1cil\u201d (26,2%), 51 \n\u201cf\u00e1cil\u201d (30,4%), 28 \u201cni f\u00e1cil ni dif\u00edcil\u201d (16,7%), 12 \u201cdif\u00edcil\u201d (7,1%), 11 \u201cmuy dif\u00edcil\u201d (6,5%) y 22 \u201cfallo\u201d (13,1%). La puntuaci\u00f3n \ntotal media fue de 18,9 \u00b1 6,5 puntos (59,1% sobre 32 puntos totales), y no se encontraron diferencias significativamente \nestad\u00edsticas en la puntuaci\u00f3n total entre subgrupos seg\u00fan las variables de edad, nivel de estudios, promotor o primera \ndispensaci\u00f3n\ufffd\nCONCLUSIONES\nEl grado de facilidad m\u00e1s frecuente contestado para la legibilidad y comprensibilidad de las etiquetas de muestras de \nEECC por los pacientes fue \u201cf\u00e1cil\u201d con un 30,4%, seguido de \u201cmuy f\u00e1cil\u201d con un 26,2%, y de \u201cfallo\u201d con un 13,1%. No \nse encontraron diferencias estad\u00edsticamente significativas en las puntuaciones totales seg\u00fan edad, nivel de estudios, \npromotor o primera dispensaci\u00f3n, probablemente debido al peque\u00f1o tama\u00f1o muestral.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; \nFARMACOECONOM\u00cdA\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n38. COMPARACI\u00d3N INDIRECTA DE NIVOLUMAB+IPILIMUMAB+QUIMIOTERAPIA FRENTE A \nPEMBROLIZUMAB+QUIMIOTERAPIA EN PRIMERA L\u00cdNEA DE C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO \nESCAMOSO ESTADIO IV \nAUTORES\nJIM\u00c9NEZ L\u00d3PEZ, Y; P\u00c9REZ CANO, E; SIERRA TORRES, MI; GARC\u00cdA G\u00d3MEZ, N\nCOMPLEJO HOSPITALARIO DE JA\u00c9N. AV . DEL EJ\u00c9RCITO ESPA\u00d1OL, 10 JA\u00c9N. JA\u00c9N\nOBJETIVOS\nEvaluar la eficacia comparada de nivolumab m\u00e1s ipilimumab y quimioterapia (QT) frente a pembrolizumab m\u00e1s QT en el \ntratamiento del c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) escamoso avanzado o metast\u00e1sico en primera l\u00ednea, a trav\u00e9s de \nuna comparaci\u00f3n indirecta (CI) empleando un comparador com\u00fan.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en Pubmed de los ensayos cl\u00ednicos fase III publicados que autorizan \nnivolumab+ipilimumab+QT y pembrolizumab+QT en primera l\u00ednea de CPNM estadio IV. Con estos datos se realiz\u00f3 una CI \nempleando el m\u00e9todo Bucher con la calculadora ITC (Indirect Treatment Comparisons) de la Canadian Agency for Health \nTechnology. La variable principal empleada en la CI fue la supervivencia global (SG).  \nEl valor delta (\u0394), es decir, m\u00e1xima diferencia cl\u00ednicamente irrelevante, se fij\u00f3 en 0,65 (y el inverso 1,53). Para ello se \nutiliz\u00f3 la gu\u00eda ``Escala de Magnitud de Beneficio Cl\u00ednico\u00b4\u00b4 de la Sociedad Europea de Oncolog\u00eda M\u00e9dica. Se observ\u00f3 \ngr\u00e1ficamente los resultados, comprobando si el intervalo de confianza (IC95%) estaba dentro del margen de equivalencia \n\u00b1\u0394 y, por \u00faltimo, se aplic\u00f3 la metodolog\u00eda de la Gu\u00eda ATE (alternativas terap\u00e9uticas equivalentes).\nRESULTADOS\nSe incluyeron dos ensayos cl\u00ednicos: CHECKMATE-9LA y KEYNOTE-407, donde se comparan nivolumab m\u00e1s ipilimumab \ncon 2 ciclos de QT y pembrolizumab con 4 ciclos de QT frente a QT, respectivamente. Las caracter\u00edsticas de los pacientes \ny el comparador eran similares (cisplatino/carboplatino m\u00e1s paclitaxel), adem\u00e1s de emplear ambos estudios la SG \ncomo variable principal de eficacia. Como limitaci\u00f3n en la CI nos encontramos con diferentes n\u00ba de ciclos de QT en los \nbrazos experimentales y que en KEYNOTE-407 los pacientes pod\u00edan recibir paclitaxel o nab-paclitaxel. Se acepta que el \ncomparador abarque diferentes esquemas de QT est\u00e1ndar, pues no se dispone de evidencia para considerar que uno sea \nsuperior a otro\ufffd  \nSe utilizaron los resultados de eficacia para SG del subgrupo de poblaci\u00f3n con histolog\u00eda escamosa del ensayo \nCHECKMATE-9LA, y los de la poblaci\u00f3n global (histolog\u00eda escamosa) del ensayo KEYNOTE-407. \nTras aplicar el m\u00e9todo Bucher obtenemos un valor de Hazard Ratio (HR) =1,02 (IC95%:0,65-1,59); p > 0,05. Por tanto, la \ndiferencia en SG no es estad\u00edsticamente significativa. 202Nos encontramos que este HR ajustado se aproxima al valor neutro y que los IC95% se encuentran, por un extremo, \ncoincidiendo con el \u0394 establecido (0,65) y por el otro, sobrepasando solo un peque\u00f1o porcentaje este margen de \nequivalencia.  \nFinalmente, no se aplic\u00f3 la terminolog\u00eda ATE ya que existen importantes diferencias de toxicidad y manejo de las terapias, \npues se emplea inmunoterapia combinada (nivolumab+ipilimumab) y un n\u00ba diferente de ciclos de QT en el ensayo \nCHECKMATE-9LA con respecto KEYNOTE-407.\nCONCLUSIONES\nEl resultado obtenido en la CI no es estad\u00edsticamente significativo (p > 0,05) y no se puede establecer que haya diferencias \nentre los esquemas de tratamiento comparados.  \nNo consideramos que sea adecuado aplicar la terminolog\u00eda ATE debido al diferente perfil de toxicidad y manejo de los \nf\u00e1rmacos.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n89. ANTIRETROVIRAL THERAPY OPTIMISATION STRATEGIES IN HUMAN IMMUNODEFICIENCY VIRUS \nINFECTED PATIENTS: A DECISIVE TASK FOR HOSPITAL PHARMACISTS \nAUTORES\nCHINCHILLA ALARC\u00d3N, T; DEL RIO VALENCIA, JC; LINARES ALARC\u00d3N, A; PARADAS PALOMO, JD; MU\u00d1OZ CASTILLO, I\nCOMPLEJO HOSPITALARIO REGIONAL CARLOS HAYA. AV . CARLOS HAYA, S/N M\u00c1LAGA. MALAGA\nOBJETIVOS\nAntiretroviral therapy (ART) for human immunodeficiency virus (HIV) causes a significant economic impact on health \nsystems worldwide. Simplification of ART improves adherence and comfort, and may prevent some adverse effects \ncaused by ART \n \nObjetives: To identify and propose patients who could benefit from ART simplification, from triple therapy to a two-drug \nregimen, dolutegravir/lamivudine (DTG/3TC), and to analyse the economic impact of this simplification.\nMATERIALES Y M\u00c9TODOS\nA prospective study was conducted in a tertiary hospital in March 2020. All HIV patients with active AR triple therapy ( > \n6-months) were included. Patients who were candidates for simplification had to meet the following criteria: treatment \nwith triple therapy for at least 6 months, absence of failure prior to another ART, plasma viral load (PVL) < 50-copies/\nml for at least 6 months, CD4 > 100-cells/\u03bcL and optimal adherence. Adherence was indirectly calculated by scoring the \ndays that treatment was collected on time; 95% score or more was considered optimal. Candidates were proposed to \ntheir doctor. The annual economic impact was evaluated by analysing laboratory sales prices in Spain and the number of \npatients who had a simplified ART.\nRESULTADOS\nSeventy-nine patients were transferred to receive the DTG+3TC combination in March 2020. Patients were aged 31\u201381 \nyears (median 55 years) and men were 53%. The previous PVL test was undetectable in 87% (n=69) of patients, and 10 \n(13%) patients had between 20-50 copies/mL) and CD4 cells was < 410-cel/\u00b5l in 4% (n=3). After 6 months of treatment, \nthe PVL test was undetectable in 84% (n=66) of patients, and 13 patients (16%) had between 20-50 copies/mL. The \nsimplification from triple therapy to a two-drug regimen gave a saving of \u20ac19,649.02/year/79 patients (\u20ac248.72/year/\npatient).\nCONCLUSIONES\nThe hospital pharmacist\u2019s role is fundamental in ensuring the correct use of these therapies and identifying patients \nwhose ART could be improved. The combination of DTG+3TC seemed to be an effective alternative to other ART when we \nre-evaluated patients after 6 months of treatment. The impact of simplifying ART contributes to economic sustainability \nof our Health System because resources are limited.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n121. ADECUACI\u00d3N DE PRESCRIPCIONES DE CICLOSILICATO DE ZIRCONIO-SODIO SEG\u00daN CONDICIONES \nDEL INFORME DE POSICIONAMIENTO TERAP\u00c9UTICO MEDIANTE MUESTREO PARA ACEPTACI\u00d3N DE \nLOTES \nAUTORES\nGARC\u00cdA GIM\u00c9NEZ, I; RODR\u00cdGUEZ JORGE, M; PEL\u00c1EZ BEJARANO, A; GRUTZMANCHER SA\u00cdZ, S\nHOSPITAL GENERAL JUAN RAM\u00d3N JIMENEZ. RONDA NORTE, S/N HUELVA. HUELVA\nOBJETIVOS\nDeterminar la adecuaci\u00f3n de las prescripciones de ciclosilicato de zirconio y sodio (CZS) a las condiciones establecidas en \nsu informe de posicionamiento terap\u00e9utico (IPT) de mayo de 2021.\nMATERIALES Y M\u00c9TODOS\nSe seleccionaron los pacientes con prescripci\u00f3n de CZS del a\u00f1o 2021 en toda la provincia. Se aplic\u00f3 la metodolog\u00eda de \nmuestreo para aceptaci\u00f3n de lotes para analizar la muestra con el objetivo de aceptar o rechazar la totalidad del lote. Se \nestableci\u00f3 un umbral de 60% como nivel l\u00edmite para definir mala calidad. Se estableci\u00f3 un riesgo alfa y beta del 5%. De 203tal forma, la muestra a analizar deb\u00eda ser de 19 pacientes, con un m\u00e1ximo de incumplimientos permitidos para aceptar el \nlote de 4. Se analizaron las prescripciones de 19 pacientes seleccionados de forma aleatoria y se evaluaron los siguientes \ncriterios: C1: Servicio prescriptor (Nefrolog\u00eda, Cardiolog\u00eda y Medicina Interna); C2: Enfermedad renal cr\u00f3nica (ERC) \navanzada o insuficiencia card\u00edaca (IC) grado III-IV seg\u00fan NYHA; C3: Hiperpotasemia leve a moderada (5,5 a 6,4 mmol/\nlitro); C4: En tratamiento con f\u00e1rmacos que act\u00faan en el sistema renina-angiotensina-aldosterona; C5: intolerancia o \nfracaso previo a resinas de intercambio i\u00f3nico\ufffd\nRESULTADOS\nEl n\u00famero de pacientes con prescripci\u00f3n de CZS fue de 40. De las 19 prescripciones seleccionadas, todas cumpl\u00edan C1 \n(36.8% de la unidad de Nefrolog\u00eda, 36.8% de Cardiolog\u00eda y 26.4% de Medicina Interna). \u00danicamente el 52.6% cumpl\u00eda C2 \n(31.6% con ERC avanzada y 21% con IC grado II-III). El 74.7% cumpl\u00edan C3, al igual que C4. El 64.3% cumpl\u00edan C4. En 17 \npacientes no se cumpl\u00edan las adecuaciones establecidas en el IPT. Con estos datos, por tanto, se rechaza la muestra.\nCONCLUSIONES\nLas prescripciones de CZS realizadas en el periodo de estudio no se ajustan a las condiciones establecidas en el IPT del \nmedicamento. Esta metodolog\u00eda, al requerir menor tama\u00f1o muestral, puede ser \u00fatil para monitorizar la calidad de las \nprescripciones de \u00e1reas o per\u00edodos de tiempo peque\u00f1os.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n225. COMPARACI\u00d3N INDIRECTA DE BARICITINIB, TOFACITINIB Y UPADACITINIB PARA EL TRATAMIENTO \nDE ARTRITIS REUMATOIDE EN EL PACIENTE RESISTENTE A TRATAMIENTOS BIOL\u00d3GICOS \nAUTORES\nSELVI SABATER, P; CASTA\u00d1EDA MACIAS, I; TOBARUELA SOTO, M; RAUSELL RAUSELL, V\nSERVICIOS CENTRALES - SERVICIO DE GESTI\u00d3N FARMAC\u00c9UTICA\nOBJETIVOS\nEstablecer si existen diferencias entre el criterio de la American College of Rheumatology (ACR) 20/50/70 entre los tres \ninhibidores de la Janus Activated Kinase (JAK) comercializados actualmente en Espa\u00f1a, en pacientes diagnosticados de \nartritis reumatoide y que sean resistentes a tratamientos con f\u00e1rmacos biol\u00f3gicos anti factor de necrosis tumoral (anti-\nTNF).\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda en Pubmed para identificar los ensayos cl\u00ednicos fase 3 en pacientes diagnosticados de artritis \nreumatoide que hubieran tenido una respuesta inadecuada a tratamientos biol\u00f3gicos anti-TNF y cuyo comparador fuera \nplacebo en tratamiento con baricitinib, tofacitinib o upadacitinib . Los ensayos deber\u00edan tener recogida la variable ACR \n20/50/70 en la semana 12\ufffd \nComo valor delta (m\u00e1xima diferencia entre tratamientos que se considera cl\u00ednicamente relevante) se establece un RR \nde 0,80 y 1,20, basado en la diferencia de respuesta de los inhibidores de JAK frente a otros tratamientos en diferentes \nensayos cl\u00ednicos.  \nSe realizaron comparaciones indirectas mediante el m\u00e9todo Bucher para comparar los tres f\u00e1rmacos y los distintos ACR \n20/50/70\ufffd\nRESULTADOS\nSe seleccionaron tres ensayos piv\u00f3tales (SELECT-BEYOND, RA-BEACON y ORAL-step) que cumpl\u00edan los criterios de \ninclusi\u00f3n, para upadacitinib, baricitinib y tofacitinib respectivamente. \nEn las siguientes l\u00edneas se expresa el riesgo relativo (RR) e intervalo de confianza (IC95%) de la comparaci\u00f3n indirecta para \nACR/20/50/70 en la semana 12\ufffd  \n \nUpadacitinib 30 mg vs Tofacitinib 10 mg: ACR 20 RR 0,99 (IC95% 0,64 a 1,55), ACR 50 RR 1,1 (IC95% 0,5 a 2,38), ACR 70 RR \n1,95 (IC95% 0,4 a 9,6).  \nUpadacitinib 30 mg vs Baricitinib 4 mg: ACR 20 RR 1,02 (IC95% 0,68 a 1,51), ACR 50 RR 1,18 (IC95% 0,57 a 2,41), ACR 70 \nRR 1,4 (IC95% 0,41 a 4,81).  \nTofacitinib 10 mg vs Baricitinib 4 mg: ACR 20 RR 1,02 (IC95% 0,65 a 1,59), ACR 50 RR 1,07 (IC95% 0,65 a 2,23), ACR 70 RR \n0,72 (IC95% 0,12 a 4,37).  \n*RR > 1 favorece al tratamiento de la derecha \n \nY para la dosis de Upadacitinib 15 mg y Tofacitinib 5mg el ACR 20:  \n \nUpadacitinib 15 mg vs Tofacitinib 5 mg: ACR 20 RR 0,77 (IC95% 0,49 a 1,21)  \nUpadacitinib 15 mg vs Baricitinib 4 mg: ACR 20 RR 0,88 (IC95% 0,06 a 1,28)  \nTofacitinib 5 mg vs Baricitinib 4 mg: ACR 20 RR 1,14 (IC95% 0,72 a 1,81)  \n*RR > 1 favorece al tratamiento de la derecha \n \nSeg\u00fan los criterios de la gu\u00eda Alternativa Terap\u00e9utica Equivalente las 3 comparaciones para ACR 20/50/70 se clasificar\u00edan \ncomo C \u201cPROBABLE EQUIVALENCIA CL\u00cdNICA. Este caso es dudoso, porque el intervalo de confianza sobrepasa el margen \nde equivalencia, pero no tenemos seguridad siquiera de que la diferencia exista (al ser estad\u00edsticamente no significativa)\u201d204CONCLUSIONES\nNo se encuentran diferencias estad\u00edsticamente significativas entre los tres inhibidores de JAK comparados para este perfil \nde pacientes, pudiendo considerarse \u201cprobablemente equivalentes terap\u00e9uticos\u201d. \n \nEs necesario disponer de estudios directos para poder establecer con mayor precisi\u00f3n si existen diferencias en cuanto \neficacia para los tres inhibidores de JAK\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n249. RESULTADOS EN SALUD DEL TRATAMIENTO DE LA DERMATITIS AT\u00d3PICA CON DUPILUMAB EN \nEDAD PEDI\u00c1TRICA \nAUTORES\nSALAZAR-SANTANDER , C; LATRE GORBE, C; GONZ\u00c1LEZ-ANLEO , C; BASELGA TORRES, E; PRAT TORRES, C; VICENTE \nVILLA, A; FONT I BARCEL\u00d3, A; FARR\u00c9 RIBA, R\nHOSPITAL SANT JOAN DE D\u00c9U BARCELONA\nOBJETIVOS\nEvaluar los resultados en salud del tratamiento con dupilumab de la dermatitis at\u00f3pica (DA) en edad pedi\u00e1trica seg\u00fan el \nprotocolo farmacocl\u00ednico (PF) y esquema de pago por resultados (EPR) aprobados en enero del 2020.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un an\u00e1lisis retrospectivo de los pacientes con tratamiento activo entre marzo del 2020 y febrero del 2022. \nDado que los criterios cl\u00ednicos de inicio del PF exclu\u00eda, hasta febrero del 2022, a todos los pacientes menores de 18 a\u00f1os, \nla valoraci\u00f3n del inicio del tratamiento en edad pedi\u00e1trica se gestion\u00f3 a trav\u00e9s de una Comisi\u00f3n de Medicamentos en \nSituaciones Especiales. La respuesta al tratamiento se evalu\u00f3 seg\u00fan las escalas EASI (eval\u00faa la intensidad y la extensi\u00f3n \nde las lesiones en una escala de 0 a 72 puntos) e IGA (escala de 0 a 4 puntos seg\u00fan eritema, exudado y p\u00e1pulas) a las 16, \n24 y 52 semanas del inicio del tratamiento, conforme a los criterios predefinidos en el PF y EPR. Se defini\u00f3 la respuesta \nal tratamiento como una reducci\u00f3n del EASI de, al menos, el 50%, y del IGA de 2 o m\u00e1s puntos respecto al valor basal. \nTambi\u00e9n se midieron otras escalas, como BSA (% superficie corporal afectada), VSA (valora intensidad del prurito de \nforma ascendente de 0 a 10) y DLQUI (valora el grado de afectaci\u00f3n de la DA a la calidad de vida, de 0 = nula afectaci\u00f3n a \n30 = m\u00e1xima afectaci\u00f3n).\nRESULTADOS\nUn total de 13 pacientes iniciaron tratamiento para la dermatitis at\u00f3pica moderada-grave con dupilumab entre marzo \ndel 2020 y febrero del 2022. Las dosis utilizadas fueron las especificadas en ficha t\u00e9cnica seg\u00fan rango de edad y peso. La \nmediana de edad fue de 12 a\u00f1os: 2 pacientes menores de 6 a\u00f1os, 4 entre 6 y 11 a\u00f1os, y 7 mayores de 12 a\u00f1os\ufffd El 100% de \nlos pacientes hab\u00eda recibido ciclosporina previamente y 12/13 pacientes hab\u00edan sido tratados tambi\u00e9n con metotrexate; \nel tratamiento previo de otro paciente inclu\u00eda tambi\u00e9n micofenolato de mofetilo y baricitinib. Los valores basales medios \nde EASI e IGA eran 31,41 y 3,85 puntos, respectivamente, caracter\u00edsticos de una DA grave. Los valores medios de estas \nvariables a las 16 semanas fueron 6,7 y 1, respectivamente, es decir, el 100% de los pacientes fueron respondedores y \nmantuvieron la respuesta a las 24 y 52 semanas del inicio del tratamiento, aunque 6 pacientes a\u00fan no hab\u00edan alcanzado \nlas 52 semanas de tratamiento. El BSA se redujo del 47% al inicio al 7% y 4% a las 16 y 24 semanas, respectivamente. La \nescala visual del prurito tambi\u00e9n mostr\u00f3 una reducci\u00f3n superior al 50%. Asimismo, la escala DLQUI revel\u00f3 una reducci\u00f3n \nde la afectaci\u00f3n de la DA a la calidad de vida de los pacientes del 75% a las 16 semanas. No hubo discontinuaciones del \ntratamiento por efectos adversos\ufffd\nCONCLUSIONES\nLos positivos resultados en salud de dupilumab para el tratamiento de la dermatitis at\u00f3pica grave est\u00e1n en l\u00ednea con los \nresultados de los ensayos cl\u00ednicos AD-1526 y AD-1652, tambi\u00e9n en lo que respecta al buen perfil de seguridad.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n307. COMPARACI\u00d3N INDIRECTA AJUSTADA ENTRE POMALIDOMIDA+BORTEZOMIB+DEXAMETASONA \nY DARATUMUMAB+BORTEZOMIB+DEXAMETASONA PARA EL TRATAMIENTO DEL MIELOMA M\u00daLTIPLE \nRECIDIVANTE/REFRACTARIO EN 2\u00aa L\u00cdNEA \nAUTORES\nMONTERO P\u00c9REZ, O; MARTINEZ BENAVIDES, J; IB\u00c1\u00d1EZ COLLADO, C; ORIOL ROCAFIGUERA, A; FONTANALS MART\u00cdNEZ, \nS; CLOPES ESTELA, A\nINSTITUTO CATAL\u00c1N DE ONCOLOG\u00cdA\nOBJETIVOS\nEn los \u00faltimos a\u00f1os se est\u00e1n generando grandes cambios en el tratamiento del mieloma m\u00faltiple, con nuevos esquemas \nen diferentes l\u00edneas de tratamiento. Y a su vez con grandes incertidumbres, entre ellas la no comparaci\u00f3n directa entre las \nopciones terap\u00e9uticas. En concreto en 2\u00aa l\u00ednea.  \nEspa\u00f1a actualmente dispone de 2 terapias financiadas que no contienen lenalidomida en MM recidivante/refractario \n(R/R): Pomalidomida+Bortezomib+Dexametasona (PVd) y Daratumumab+Bortezomib+Dexametasona (DVd).  \nEl objetivo del presente estudio es determinar si PVd y DVd pueden ser considerados alternativas terap\u00e9uticas 205equivalentes (ATE) a trav\u00e9s de una comparaci\u00f3n indirecta ajustada (CIA), en pacientes con MM R/R que han recibido 1 \nl\u00ednea previa.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en Pubmed de ensayos cl\u00ednicos aleatorizados (ECA), fase III, en la indicaci\u00f3n de MM \n2\u00aa l\u00ednea, con poblaci\u00f3n similar, misma variable principal y subgrupo de 2\u00aa l\u00ednea preespecificado, que pudieran permitir \nla comparaci\u00f3n entre DVd y PVd. La CIA se realiz\u00f3 mediante el m\u00e9todo de Butcher, usando la calculadora de la Canadian \nAgency for Health Technology Assessment. El valor delta se fij\u00f3 en 0,7 (y su inverso 1,43), tomando como referencia \nlos establecidos para el dise\u00f1o de los ECA incluidos, puesto que no est\u00e1 descrito un delta de referencia. Se emple\u00f3 la \ncalculadora de Shakespeare et als para calcular la probabilidad de que el intervalo de confianza del 95% (IC95%) excediera \nel margen delta. Para evaluar la relevancia cl\u00ednica de los resultados obtenidos se aplicaron los criterios descritos en la gu\u00eda \nATE\ufffd\nRESULTADOS\nSe incluyeron 2 ECA, fase III: CASTOR (DVd vs. Bortezomib+Dexametasona[Vd]) y OPTIMISMM (PVd vs. Vd). Para la CIA, \nse utiliz\u00f3 la variable principal de ambos estudios, la supervivencia libre de progresi\u00f3n (SLP). En el estudio CASTOR se \nadministr\u00f3 Vd durante 8 ciclos y en OPTIMISMM hasta toxicidad o progresi\u00f3n, pero dicha diferencia no tuvo repercusi\u00f3n \nen sus medianas de SLP (7,1 [6,2\u20137,9] meses y 7,1 [5,9\u20138,5] meses r espectivamente). En cuanto a la poblaci\u00f3n de \nlos estudios, era cl\u00ednicamente similar, siendo la diferencia m\u00e1s relevante la refractariedad a lenalidomida (29% de \nlos pacientes en CANDOR vs. 65% OPTIMISMM). Ambos estudios inclu\u00edan un subgrupo de pacientes en 2\u00ba l\u00ednea pre-\nespecificado y sus resultados en SLP , expresados como hazard ratio (HR) junto a su IC95% fueron los siguientes: CASTOR \n0,22 (0,15\u20130,32) y OPTIMISMM 0,54 (0,36\u20130,82). El resultado de la CIA de DVd vs. PVd fue de HR 0,41 (IC95% 0,23\u20130,71 \np < 0,05). Considerando el margen delta establecido, el IC95% obtenido en la CIA se encuentra fuera del margen de \nequivalencia casi en su totalidad (Shakespeare: la probabilidad de que el resultado estuviera por debajo del valor delta \nfue del 96,9%).\nCONCLUSIONES\nTeniendo en cuenta las incertidumbres inherentes a las comparaciones indirectas, seg\u00fan la gu\u00eda ATE, los datos obtenidos \nen SLP muestran que las diferencias encontradas entre los tripletes DVd y PVd en pacientes con MM R/R en 2\u00aa l\u00ednea son \nestad\u00edstica y cl\u00ednicamente relevantes, por lo que ambos esquemas no pueden considerarse ATE en esta poblaci\u00f3n.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n333. AN\u00c1LISIS DE LA IMPLANTACI\u00d3N DEL USO DEL FACTOR VIII DE VIDA MEDIA EXTENDIDA EN \nPACIENTES CON HEMOFILIA A SEVERA MODERADA. \nAUTORES\nBOO RODR\u00cdGUEZ, J; ROS OLASO, A; BERISTAIN ARAMENDI, I; ECEIZA D\u00cdEZ, A; GONZALEZ FERNANDEZ, T; LASA \nEGUIALDE, M; AGUIRRE ARRIZABALAGA, MA; MENDARTE BARRENETEXEA, LM\nHOSPITAL DONOSTIA-DONOSTIA OSPITALEA. P\u00ba DR. BEGUIRISTAIN, 109 DONOSTIA-SAN SEBASTI\u00c1N. GUIP\u00daZCOA\nOBJETIVOS\nEn 2019 se implant\u00f3 en nuestro hospital el uso del factor VIII de vida media extendida(FVIIILA) o efmoroctocog alfa, \nen contexto profil\u00e1ctico para pacientes con hemofilia A grave-moderada que hab\u00edan recibido previamente f\u00e1rmacos \nrecombinantes\ufffd \n \nEl objetivo es analizar los cambios tras la sustituci\u00f3n a FVIIILA a nivel posol\u00f3gico(unidades/kg/semana), a nivel \nfarmacocin\u00e9tico(niveles valle objetivo), a nivel cl\u00ednico(n\u00famero de eventos hemorr\u00e1gicos y n\u00famero de ingresos \nhospitalarios relacionados) y a nivel econ\u00f3mico(coste inicial vs coste actual) tras 3 a\u00f1os desde la implantaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio multidisciplinar retrospectivo que incluy\u00f3 pacientes diagnosticados de hemofilia A severa-moderada a los que se \nles aplic\u00f3 el cambio a FVIIILA desde 2019 hasta la actualidad.  \n \nSe recogieron las siguientes variables: demogr\u00e1ficas (sexo, edad), tipo de factor previo al cambio, pautas \nposol\u00f3gicas(unidades/kg/semana) en la implantaci\u00f3n y en la actualidad, los motivos por las que se modifican y si \ndesarrollan inhibidor frente al factor VIII.  \n \nSe calcul\u00f3:  \n- la mediana de eventos hemorr\u00e1gicos/paciente y el n\u00famero de ingresos relacionados/a\u00f1o antes y despu\u00e9s del cambio de \nfactor \ufffd \n- la mediana de niveles valle/paciente antes y despu\u00e9s del cambio de factor, siendo los objetivos en hemofilia grave (HG) \nentre 1-2% y en hemofilia moderada (HM) > 5%.  \n- la mediana de euros/semana/paciente desde la implantaci\u00f3n del cambio hasta la actualidad.  \n \nLos datos se obtuvieron de la historia cl\u00ednica electr\u00f3nica, del servicio de Hematolog\u00eda (secci\u00f3n de Hemostasia), registros \nde dispensaci\u00f3n del servicio de Farmacia y de la plataforma Wapps-Hemos.206RESULTADOS\n11 pacientes varones, edad media 28(2-73) con diagn\u00f3stico de Hemofilia A severa 8(72,7%), moderada 3(27,3%). Todos \nven\u00edan de tratamiento profil\u00e1ctico con factores de la coagulaci\u00f3n de vida media corta. 2(18%) desarrollaron inhibidor y \nhan tenido que suspender el tratamiento con el FVIIILA. \n \nDe los 9 que siguen en tratamiento con FVIIILA:  \n \n- La pauta media inicial fue de 95,8 UI/kg/semana (54-144,6) vi\u00e9ndose aumentada en la actualidad a 124,9 UI/kg/\nsemana (68-209). Los motivos por los que se increment\u00f3 la pauta fueron cl\u00ednicos (dolor y sangrado articular) y ajuste \nfarmacocin\u00e9tico.  \n- La mediana de niveles valle de factor VIII previo al cambio fue del 3%(1-12) y de 8%(5-17) en la actualidad. Se alcanz\u00f3 el \nobjetivo terap\u00e9utico en todos, seg\u00fan su grado severidad.  \n- La mediana de eventos hemorr\u00e1gicos/paciente previo al cambio fue de 5(1-8), siendo 2(1-3) en la actualidad.  \n- El n\u00famero de ingresos hospitalarios/a\u00f1o fue similar antes y despu\u00e9s del cambio siendo, 2 y 1 respectivamente por \nintervenci\u00f3n quir\u00fargica y traumatismo.  \n- La mediana de euros/semana/paciente al inicio del cambio fue de 2932(1955-5865), vi\u00e9ndose aumentada en la \nactualidad a 4399(1955-5865).\nCONCLUSIONES\nAunque nuestro tama\u00f1o de muestra no nos permite demostrar diferencias significativas, se observan niveles valle \nobjetivo m\u00e1s altos y estables tras el cambio de factor que se traduce en un mejor control de la enfermedad, con una \ndisminuci\u00f3n de eventos hemorr\u00e1gicos por paciente. Eso s\u00ed, vi\u00e9ndose incrementado el consumo de unidades y el coste por \npaciente\ufffd  \n \nEstos resultados sugieren un margen de mejora a la hora de optimizar los tratamientos, realizando un mayor n\u00famero de \ncontroles anal\u00edticos por paciente que permitan mejores ajustes farmacocin\u00e9ticos, disminuyendo el coste sin deteriorar/\nperjudicar su estado de salud.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n369. COMPARACI\u00d3N INDIRECTA AJUSTADA DE CEMIPLIMAB Y ATEZOLIZUMAB EN EL TRATAMIENTO DE \nPRIMERA L\u00cdNEA DEL C\u00c1NCER DE PULM\u00d3N METAST\u00c1SICO. \nAUTORES\nSALGUERO OLID, A; LOMARES MANZANO, I; JIM\u00c9NEZ DE-JUAN, C; MART\u00cdNEZ BAUTISTA, MJ\nHOSPITAL UNIVERSITARIO PUERTA DEL MAR \ufffd AVENIDA ANA DE VIYA 21 C\u00c1DIZ \ufffd C\u00c1DIZ\nOBJETIVOS\nConocer si cemiplimab y atezolizumab pueden ser declaradas alternativas terap\u00e9uticas equivalentes (ATE) en el \ntratamiento de primera l\u00ednea (1L) del c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) metast\u00e1sico en pacientes con alta \nexpresi\u00f3n del ligando 1 de muerte programada (PD-L1, \u226550%) sin aberraciones EGFR, ALK ni ROS1.\nMATERIALES Y M\u00c9TODOS\nCemiplimab est\u00e1 autorizado para el tratamiento de 1L de pacientes adultos con CPNM localmente avanzado que no son \ncandidatos a quimiorradiaci\u00f3n definitiva, o metast\u00e1sico, que expresan PD-L1\u226550%, con fecha de alta de financiaci\u00f3n del \n01/04/2022. Atezolizumab tambi\u00e9n est\u00e1 indicado y financiado para el tratamiento de 1L de pacientes adultos con CPNM \nmetast\u00e1sico que expresan PD-L1\u226550%. Hasta la aprobaci\u00f3n de los f\u00e1rmacos en cuesti\u00f3n, pembrolizumab era el \u00fanico \ninhibidor del punto de control inmunitario PD-1/PD-L1 que ten\u00eda autorizada esta indicaci\u00f3n en monoterapia.  \n \nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en MEDLINE-Pubmed de ensayos cl\u00ednicos aleatorizados (ECA), fase III, con  \npoblaci\u00f3n y duraci\u00f3n similares. A pesar de las dudas metodol\u00f3gicas de homogeneidad de los estudios pivotales, se realiz\u00f3 \nuna comparaci\u00f3n indirecta (CI) ajustada de cemiplimab y atezolizumab mediante el m\u00e9todo de Bucher con la calculadora \nExcel de Joaqu\u00edn Primo. Como variable principal se tomaron los resultados de supervivencia global (SG), por tratarse de \nuna variable final de relevancia cl\u00ednica. Tomamos como valor delta (\u0394), m\u00e1xima diferencia que consideramos cl\u00ednicamente \nirrelevante, el valor publicado en la Gu\u00eda ESMO-MCBS, HR=0,65, y se analizaron los resultados gr\u00e1ficamente, observando \nsi los intervalos de confianza (IC95%) se encontraban dentro del intervalo \u00b1\u0394. Para considerarlos ATE, se aplic\u00f3 la \nmetodolog\u00eda definida en la gu\u00eda del Grupo Hospitalario de Evaluaci\u00f3n de Medicamentos de Andaluc\u00eda (GHEMA).\nRESULTADOS\nSe incluyeron los datos de los ensayos cl\u00ednicos de cemiplimab y atezolizumab realizados frente a un comparador com\u00fan, \nquimioterapia basada en platino (est\u00e1ndar de tratamiento). Ambos estudios presentaron similitudes en cuanto a su \nmetodolog\u00eda, aunque los pacientes con alta expresi\u00f3n de PD-L1 incluidos en el estudio de atezolizumab fue menor (205 \nfrente a 563 en el de cemiplimab); adem\u00e1s, en este estudio se incluyeron solo pacientes con CPNM estad\u00edo IV (en el de \ncemiplimab adem\u00e1s, estad\u00edo IIIB y IIIC) y pacientes que nunca hab\u00edan fumado (a diferencia del de cemiplimab).  \n \nAplicando la metodolog\u00eda anteriormente descrita, se obtuvo un valor HR de cemiplimab frente a atezolizumab de 0,97 \n(IC95% 0,58-1,60, p=0,89284). Seg\u00fan la Gu\u00eda ATE, la eficacia comparada de cemiplimab y atezolizumab present\u00f3 un \nposicionamiento C (probable equivalencia cl\u00ednica). El IC95% sobrepas\u00f3 el margen de equivalencia, aunque solo una \npeque\u00f1a parte se encontraba fuera del mismo. Seg\u00fan el algoritmo, no podr\u00edan considerarse ATE debido a que un peor 207resultado supondr\u00eda un perjuicio grave/irreversible para el paciente. Se utiliz\u00f3 la calculadora de Shakespeare para \ncalcular la probabilidad de no sobrepasar el valor \u0394, que fue del 93,9% (muy alta probabilidad de considerar diferencias \ncl\u00ednicamente irrelevantes).\nCONCLUSIONES\nLas alternativas cemiplimab y atezolizumab presentan probable equivalencia cl\u00ednica, pero debido a que un peor \npron\u00f3stico supone un perjuicio grave/irreversible para el paciente y ante las dudas metodol\u00f3gicas de homogeneidad de \nlos estudios, se recomienda disponer de una comparaci\u00f3n directa o datos m\u00e1s maduros en pr\u00e1ctica cl\u00ednica.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n411. COMPARACI\u00d3N INDIRECTA AJUSTADA DE LA EFICACIA DE LOS INHIBIDORES DE JANUS QUINASAS \nPARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE \nAUTORES\nVALLEZ VALERO, L; GASO GAGO, I; GARRIDO ALEJOS, G; PLAZA DIAZ, A; MARTINEZ MOLINA, C; ROSICH MOYA, L; \nCOROMINAS MACIAS, H; MANGUES BAFALLUY , MA\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nValorar si la eficacia de los distintos inhibidores de Janus quinasas (iJAK) baricitinib, filgotinib, tofacitinib y upadacitinib \nes similar en el tratamiento de la artritis reumatoide (AR) en pacientes con respuesta inadecuada (RI) a f\u00e1rmacos \nantireum\u00e1ticos modificadores de la enfermedad biol\u00f3gicos (FAMEb), mediante una comparaci\u00f3n indirecta (CI) ajustada \nfrente a un comparador com\u00fan (placebo).\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda en pubmed para identificar los ensayos cl\u00ednicos aleatorizados (ECA) de filgotinib, baricitinib, \nupadacitinib y tofacitinib en AR.  \nSe seleccionaron los ECA que cumpl\u00edan los siguientes criterios: fase III, doble ciego, controlado con placebo, en pacientes \ncon AR moderada a grave con RI-FAMEb, que compararan un iJAK + FAME sint\u00e9tico convencional (FAMEsc) frente a \nplacebo + FAMMsc, con ACR20 (American College of Rheumatology-20) como variable principal y DAS28-PCR < 3,2 \n(Disease activity score) como variable secundaria, ambas evaluadas a las 12 semanas.  \nSe realiz\u00f3 una CI entre los distintos ECA aplicando el m\u00e9todo de Bucher con la calculadora de CI y mixtas elaborada por \nAurelio Tob\u00edas et al.  \nSe asumi\u00f3 un valor de delta (\u0394, m\u00e1xima diferencia cl\u00ednicamente irrelevante) de 8,5% y 4% para ACR20 y DAS28-PCR < 3,2, \nrespectivamente, calculado como la mitad de la reducci\u00f3n del riesgo absoluto (RAR) obtenida en el estudio que compara \ngolimumab versus placebo en pacientes con RI-FAMEb (NCT00299546).  \nSe compararon los distintos iJAK a las dosis autorizadas frente a upadacitinib, por ser el que mostr\u00f3 una RAR de mayor \nmagnitud frente a placebo en el ACR20. Para la consideraci\u00f3n de alternativas terap\u00e9uticas (ATE) se sigui\u00f3 la metodolog\u00eda \nde la gu\u00eda ATE elaborada por el Grupo Hospitalario de Evaluaci\u00f3n de Medicamentos de Andaluc\u00eda.\nRESULTADOS\nSe seleccionaron cuatro ECA (RA-BEACON, FINCH 2, ORAL STEP y SELECT-BEYOND), cuyas poblaciones presentaban \ncaracter\u00edsticas basales similares.  \nLa CI muestra que no hay diferencias estad\u00edsticamente significativas entre baricitinib y upadacitinib (RAR -7,75 [IC95% \n-21,75; 6,25], p=0,278) ni entre filgotinib y upadacitinib (RAR -0,93 [IC95% -15,54; 13,68], p=0,901) para ACR20. Sin \nembargo, tofacitinib parece presentar un peor perfil de eficacia que upadacitinib (RAR -18,73 [IC95% -33,64; -3,82] \np=0,0138). Respecto a la variable secundaria DAS28-PCR < 3,2, no se encontraron diferencias estad\u00edsticamente \nsignificativas para baricitinib (RAR -6,25 [IC95% -18,47; 5,97], p=0,316), filgotinib (-3,5 [IC95% -16,98; 9,98], p=0,611) ni \ntofacitinib (RAR -4,80 [IC95% -18,.02; 8,42], p=0,4768) frente a upadacitinib.  \nSeg\u00fan la gu\u00eda ATE, filgotinib y upadacitinib mostraron un posicionamiento tipo C, de probable equivalencia cl\u00ednica, sin \ndiferencias estad\u00edstica ni cl\u00ednicamente relevantes en las dos variables. Baricitinib, mostr\u00f3 un posicionamiento tipo E, no \nencontr\u00e1ndose diferencias estad\u00edsticamente significativas, pero s\u00ed posibles diferencias cl\u00ednicamente relevantes, a favor \nde upadacitinib (RAR > \u0394) en DAS28-PCR < 3,2. Por otro lado, tofacitinib mostr\u00f3 un posicionamiento tipo G porque las \ndiferencias frente a upadactinib fueron estad\u00edsitica y cl\u00ednicamente relevantes a favor de este.\nCONCLUSIONES\nEn base a los resultados obtenidos, filgotinib y upadacitinib podr\u00edan considerarse ATE en eficacia para el tratamiento de \nla AR. Baricitinib, en cambio, no puede considerarse ATE ya que podr\u00edan existir diferencias cl\u00ednicamente relevantes frente \na upadacitinib. Tofacitinib no se considera una ATE, ya que presenta diferencias estad\u00edstica y cl\u00ednicamente significativas \nfrente a upadacitinib en t\u00e9rminos de eficacia.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n420. DESCRIPCI\u00d3N Y EVALUACI\u00d3N DE LA PARTICIPACI\u00d3N DEL FARMAC\u00c9UTICO EN EL COMIT\u00c9 DE \nBIOL\u00d3GICOS DEL HOSPITAL \nAUTORES\nHIDALGO CABRERA, J; MART\u00cdNEZ-BROCAL OGAYAR, I; CUEVAS ASENCIO, I; REYES TORRES, I; FUENTES CAPARR\u00d3S, B\nHOSPITAL COMARCAL INFANTA MARGARITA \ufffd AV\ufffd DE G\u00d3NGORA, S/N CABRA \ufffd C\u00d3RDOBA208OBJETIVOS\nDescribir la participaci\u00f3n del farmac\u00e9utico como miembro del Comit\u00e9 de Biol\u00f3gicos y evaluar las intervenciones \nrealizadas durante la selecci\u00f3n del tratamiento y la adecuaci\u00f3n de la prescripci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional, retrospectivo de 40 meses de duraci\u00f3n (enero 2019-abril 2022) en el que se incluyeron \ntodos los pacientes para los que los Servicios de Digestivo, Dermatolog\u00eda y Reumatolog\u00eda solicitaron tratamiento con \nf\u00e1rmacos biol\u00f3gicos. Como fuentes de informaci\u00f3n se utilizaron las solicitudes enviadas por el prescriptor, actas de las \nreuniones y la aplicaci\u00f3n de farmacia de dispensaci\u00f3n de pacientes externos. Se analizaron las intervenciones realizadas \npor el farmac\u00e9utico siguiendo una clasificaci\u00f3n propia adaptada de la literatura. Las intervenciones se clasificaron en \ncuatro tipos: Necesidad/Efectividad (N), Adecuaci\u00f3n (A), Seguridad (S) y Eficiencia (E). Los subtipos incluidos fueron: N1 \n(Relaci\u00f3n indicaci\u00f3n/patolog\u00eda), N2 (Par\u00e1metros de valoraci\u00f3n de la efectividad), N3 (Valoraci\u00f3n de la adherencia), A1 \n(Comodidad del paciente), A2 (Ajuste posol\u00f3gico en situaciones especiales: pediatr\u00eda, Insuficiencia Hep\u00e1tica, Insuficiencia \nRenal\u2026), S1 (Toxicidad), S2 (Duplicidad), S3 (Riesgo de interacci\u00f3n), S4 (Par\u00e1metros de valoraci\u00f3n de efectos adversos), \nE1 (Adecuaci\u00f3n IPT/Ficha T\u00e9cnica), E2 (Adecuaci\u00f3n al protocolo interno del hospital). Las variables registradas: n\u00famero \nde reuniones, n\u00famero de pacientes evaluados, n\u00famero de solicitudes evaluadas, porcentaje de solicitudes aprobadas y \ndenegadas, n\u00famero de solicitudes urgentes no evaluadas, tipo y subtipos de intervenciones farmac\u00e9uticas.\nRESULTADOS\nEn las 30 veces que se reuni\u00f3 el comit\u00e9 se evaluaron 140 solicitudes correspondientes a 126 pacientes. De ellas se \naprobaron el 91,43% y se denegaron el 8,57%. As\u00ed mismo se inform\u00f3 al comit\u00e9 del inicio de 53 tratamientos de forma \nurgente previos a la reuni\u00f3n. El n\u00famero de intervenciones farmac\u00e9uticas fueron 145, intervini\u00e9ndose en el 48,7% de las \nsolicitudes y en el 53,07% de los pacientes evaluados, existiendo varias intervenciones por solicitud y habiendo sido todas \nellas aceptadas. En relaci\u00f3n al tipo de intervenci\u00f3n el 42,07% fueron del tipo E (n=61, siendo E1=10 y E2=51), 37,24% del \nN (n=54, siendo N1=14, N2=6 y N3=34), 16,55% del S (n=24, siendo S1=12, S3=2 y S4=10) y 4,14% del A (n=6, siendo A1=2 \ny A2=4).\nCONCLUSIONES\nEl papel del farmac\u00e9utico de hospital en el comit\u00e9 de biol\u00f3gicos se ha consolidado como un elemento clave en \nla selecci\u00f3n de tratamientos en \u00e1reas de gran impacto farmacoterap\u00e9utico. El cumplimiento de los protocolos \nestablecidos constituye una de las herramientas m\u00e1s importantes para un acceso de calidad, equitativo y sostenible a \nla farmacoterapia. Los resultados obtenidos sugieren que cuando el farmac\u00e9utico aporta informaci\u00f3n sobre adherencia \nal proceso de selecci\u00f3n, facilita las decisiones en relaci\u00f3n a las opciones terap\u00e9uticas de nuestros pacientes. Por \u00faltimo, \ndestacar que el elevado n\u00famero de solicitudes de urgencia que no pasaron de forma reglada por el comit\u00e9 se explica en \nel contexto de la pandemia de COVID-19, cuyas distintas olas retras\u00f3 o desconvoc\u00f3 reuniones previstas.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n432. EFICACIA COMPARADA DE ABROCITINIB, BARICITINIB Y UPADACITINIB EN COMBINACI\u00d3N CON \nCORTICOIDES T\u00d3PICOS PARA EL TRATAMIENTO DE LA DERMATITIS AT\u00d3PICA \nAUTORES\nCLARAMUNT GARC\u00cdA, R; S\u00c1NCHEZ CASANUEVA, T; MERINO ALMAZ\u00c1N, M; MU\u00d1OZ CID, CL; S\u00c1NCHEZ RUIZ, A\nHOSPITAL VIRGEN DE ALTAGRACIA \ufffd AVDA \ufffd D\ufffd EMILIANO GARC\u00cdA ROLD\u00c1N, 2 MANZANARES \ufffd CIUDAD REAL\nOBJETIVOS\nEstablecer, a trav\u00e9s de una comparaci\u00f3n indirecta (CI) frente a placebo, si abrocitinib, baricitinib y upadacitinib pueden \nconsiderarse alternativas equivalentes en eficacia para el tratamiento de la dermatitis at\u00f3pica, cuando se utilizan de \nmanera concomitante con corticoides t\u00f3picos.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda en Pubmed de los ensayos cl\u00ednicos (EC) pivotales de abrocitinib (200mg/24h, 100mg/24h), \nbaricitinib (2mg/24h, 4mg/24h) y upadacitinib (15mg/24h, 30mg/24h) para la dermatitis at\u00f3pica, en combinaci\u00f3n con \ncorticoides t\u00f3picos. Como variable principal para la comparaci\u00f3n se tomaron los resultados del EASI75 (Eczema Area and \nSeverity Index) en la semana 16 tras el inicio del tratamiento. Con los resultados del EASI75 (en %) se calcul\u00f3 el riesgo \nrelativo (RR) respecto a placebo. Finalmente, con estos valores se realiz\u00f3 una CI de estos f\u00e1rmacos mediante el m\u00e9todo \nde Bucher (calculadora ITC, Indirect Treatment Comparisons, de la Agencia Canadiense de Evaluaci\u00f3n de Tecnolog\u00edas \nSanitarias). Se compararon entre s\u00ed las dosis menores de los 3 f\u00e1rmacos (abrocitinib 100mg, baricitinib 2mg, upadacitinib \n15mg) y las dosis mayores entre ellas (abrocitinib 200mg, baricitinib 4mg, upadacitinib 30mg). Se analizaron los \nresultados, viendo si hab\u00eda diferencias estad\u00edsticamente significativas entre estos tres f\u00e1rmacos.\nRESULTADOS\nSe encontraron 3 EC, uno con cada f\u00e1rmaco, todos ellos frente a placebo como comparador com\u00fan. Todos los \nestudios presentaron una metodolog\u00eda similar (dise\u00f1o, caracter\u00edsticas de la poblaci\u00f3n a estudio, criterios de inclusi\u00f3n, \nvariable principal). Sin embargo, en el ensayo pivotal de upadacitinib se incluy\u00f3 a pacientes menores de 18 a\u00f1os \n(que corresponden al 12% del total), a diferencia de los otros ensayos que solo incluyeron a poblaci\u00f3n mayor de \nedad. Adem\u00e1s, el tama\u00f1o de la muestra difiere de unos EC a otros (el tama\u00f1o muestral del EC del upadacitinib es \naproximadamente tres veces mayor que el de baricitinib, mientras que el de abrocitinib se encuentra en una posici\u00f3n \nintermedia entre los otros dos). Finalmente se aceptaron estas limitaciones para la CI. Tras la aplicaci\u00f3n del m\u00e9todo 209Bucher, se obtuvieron los siguientes resultados: OR (abrocitinib 100 mg vs baricitinib 2mg) 0,95 [IC95% 0,58-1,57] p=0,85; \nOR (abrocitinib 100 mg vs upadacitinib 15mg) 1,25 [IC95% 0,88-1,77] p=0,21; OR (baricitinib 2mg vs upadacitinib 15mg) \n1,31 [IC95% 80,3-2,06] p=0,24; OR (abrocitinib 200 mg vs baricitinib 4mg) 0,9 [IC95%0,55-1,459] p=0,65; OR (abrocitinib \n200 mg vs upadacitinib 30mg) 1,26 [IC95%0,9-1,78] p=0,179; OR (baricitinib 4mg vs upadacitinib 30mg) 1,41 [IC95%0,9-\n2,19] p=0,129.\nCONCLUSIONES\nSeg\u00fan los resultados obtenidos, dado que no se han establecido diferencias estad\u00edsticamente significativas entre los \ndiferentes f\u00e1rmacos en cuanto a eficacia, la elecci\u00f3n de uno u otro para el tratamiento de la dermatitis at\u00f3pica deber\u00eda \nbasarse en criterios de seguridad y eficiencia. No obstante,  \nser\u00eda de especial inter\u00e9s disponer de una comparaci\u00f3n directa de estos f\u00e1rmacos para confirmar la equivalencia.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n437. CUANTIFICACI\u00d3N DEL VALOR SOCIAL QUE SUPONE LOGRAR UNA RESPUESTA COMPLETA EN LOS \nPACIENTES CON PSORIASIS EN PLACAS MODERADA-GRAVE EN ESPA\u00d1A. \nAUTORES\nMARAVILLA HERRERA, P; BALEA FILGUEIRAS, J; CARRASCOSA CARRILLO, JM; DELGADO S\u00c1NCHEZ, O; DOLZ \nSINISTERRA, F; HERRANZ PINTO, P; PUIG SANZ, L\nWEBER\nOBJETIVOS\nCuantificar el valor social que supondr\u00eda alcanzar una respuesta, seg\u00fan la variaci\u00f3n relativa del Psoriasis Area and Severity \nIndex - \u00cdndice de \u00c1rea y Severidad de Psoriasis (PASI), de PASI 90 o PASI 100, respecto a PASI 75, para pacientes con \npsoriasis en placas moderada-grave.\nMATERIALES Y M\u00c9TODOS\nSe desarroll\u00f3 un modelo econ\u00f3mico con un horizonte temporal de un a\u00f1o a partir de una revisi\u00f3n de literatura cient\u00edfica, \nun grupo de discusi\u00f3n con pacientes y un comit\u00e9 asesor multidisciplinar compuesto por representantes de los principales \ngrupos de inter\u00e9s con relaci\u00f3n a la psoriasis (dermatolog\u00eda, enfermer\u00eda, psicolog\u00eda, farmacia, gesti\u00f3n hospitalaria, \neconom\u00eda de la salud y pacientes). El modelo incluy\u00f3 4 \u00e1reas de an\u00e1lisis (calidad de vida, actividades de la vida diaria, \nproductividad laboral y gastos de bolsillo) y 3 escenarios (mejorar la respuesta de PASI 75 al PASI 90, de PASI 75 a \nPASI 100 y de PASI 90 a PASI 100). En primer lugar, se estim\u00f3 el coste o impacto econ\u00f3mico asociado a cada respuesta \n(PASI 75, PASI 90 y PASI 100) atribuyendo un coste a cada elemento identificado en cada una de las \u00e1reas de an\u00e1lisis. \nPosteriormente, se estim\u00f3 el valor social para cada escenario, entendiendo el valor social como el ahorro o la ganancia \nderivados de pasar de una respuesta determinada a otra superior. Dicho valor social contempl\u00f3 tanto aspectos tangibles \n(p. ej. disminuci\u00f3n en el consumo de recursos) como intangibles (p. ej. mejora en la calidad de vida). Por \u00faltimo, se \nincluy\u00f3 un an\u00e1lisis de sensibilidad para determinar la robustez del modelo. Los resultados se expresaron por paciente y \na\u00f1o en euros de 2021\ufffd\nRESULTADOS\nEl impacto econ\u00f3mico de alcanzar una respuesta PASI 100 (1.353 \u20ac) fue menor que el de alcanzar una respuesta PASI 90 \n(3.956 \u20ac) o PASI 75 (6.139 \u20ac). Por tanto, pasar de una respuesta PASI 75 a una respuesta PASI 90 o PASI 100 incrementar\u00eda \nel valor social en 2.183 \u20ac o 4.786 \u20ac, respectivamente. Si bien se observ\u00f3 el incremento del valor social con la mejora \nde la respuesta PASI en las 4 \u00e1reas de an\u00e1lisis, la mayor parte se debi\u00f3 a un menor impacto econ\u00f3mico por p\u00e9rdidas de \nproductividad laboral (73 % del valor social ganado al pasar de una respuesta PASI 75 a PASI 100), seguido de mejoras en \nla calidad de vida (15,1 %), mejoras en las actividades de la vida diaria (11,1 %) y reducciones en los gastos de bolsillo (0,7 \n%).\nCONCLUSIONES\nActualmente los avances terap\u00e9uticos permiten establecer las respuestas PASI 90 o PASI 100 como objetivos terap\u00e9uticos \nalternativos a la respuesta PASI 75, reduciendo el impacto econ\u00f3mico e incrementando el valor social.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n445. EVOLUCI\u00d3N Y RESULTADOS REPORTADOS TRAS EL INTERCAMBIO DE TRATAMIENTO DEL \nMEDICAMENTO DE REFERENCIA A BIOSIMILAR EN PACIENTES CON PATOLOG\u00cdA INFLAMATORIA \nAUTORES\nBELL\u00d3 CRESPO, M; MAESTRE FULLANA, MA; CRESP\u00cd MART\u00cdNEZ, L; QUI\u00d1ONES TORRES, JR; MANDILEGO GARC\u00cdA, A; \nCANO COLLADO, V; TRUJILLANO RUIZ, A; IGLESIAS IGLESIAS, AA\nFUNDACI\u00d3N HOSPITAL MANACOR. CRTA. MANACOR-ALCUDIA, S/N MANACOR. ILLES BALEARS\nOBJETIVOS\nAnalizar la evoluci\u00f3n de los pacientes, a nivel cl\u00ednico y sintomatol\u00f3gico, as\u00ed como el grado de satisfacci\u00f3n al tratamiento, \ntras el intercambio terap\u00e9utico del f\u00e1rmaco de referencia a un biosimilar.\nMATERIALES Y M\u00c9TODOS\nSe llev\u00f3 a cabo un estudio observacional descriptivo en pacientes, con patolog\u00edas inflamatorias reumatol\u00f3gicas, tratados \ncon f\u00e1rmacos biol\u00f3gicos de referencia, a los que se realiz\u00f3 un intercambio a la mol\u00e9cula biosimilar en un hospital de 210tercer nivel, desde septiembre 2021. Se analizaron datos de respuesta cl\u00ednica, teniendo en cuenta los marcadores \ninflamatorios de prote\u00edna C reactiva (PCR) y la velocidad de sedimentaci\u00f3n globular (VSG). En ambos casos, se obtuvo la \ninformaci\u00f3n tanto en el momento del cambio como a los 6 meses despu\u00e9s. Asimismo, se evalu\u00f3 la incidencia de recidiva y \nlos efectos adversos reportados tras el intercambio. Para determinar el grado de satisfacci\u00f3n ante el cambio los pacientesl \ncumplimentaron el cuestionariol \u201cTreatment Satisfaction Questionnaire for Medication\u201d (TSQM), tanto al inicio del \ncambio, referido al f\u00e1rmaco de referencia, como a los 6 meses, referido al biosimilar. Este est\u00e1 dividido a su vez en cuatro \npartes donde se valora: efectividad, efectos adversos, conveniencia y satisfacci\u00f3n global.\nRESULTADOS\nSe obtuvieron resultados de 18 pacientes, 55,5% hombres y con una mediana de edad de 52 a\u00f1os. Un 44,4% presentaban \ndiagn\u00f3stico de artritis reumatoide, 27,7% espondilitis anquilosante y 22,2% artritis psori\u00e1sica, todos ellos tratados con \nun f\u00e1rmaco de referencia anti-TNF\u03b1. La media de meses de tratamiento hasta el cambio a biosimilar fue de 51,3. En lo \nreferente a los valores anal\u00edticos, los valores medios de PCR al inicio de tratamiento con biosimilar fueron de 0,18 mg/\ndl frente a 0,24 mg/dl a los 6 meses de la introducci\u00f3n. Para VSG, los valores medios al inicio fueron de 6,9 mm/hora \nfrente a 9,1 mm/hora. La incidencia de recidiva de sintomatolog\u00eda se detect\u00f3 en un 16% pacientes, pero en ning\u00fan caso \nfue por aparici\u00f3n de reacciones adversas sino por falta de eficacia. En cuanto a los resultados del TSQM, se recogieron \nlas siguientes puntuaciones del f\u00e1rmaco de referencia frente a biosimilar: efectividad 85%vs53,6%, ausencia de efectos \nadversos 92,7%vs100%, conveniencia 86,8% vs70,1% satisfacci\u00f3n global 87,2% vs63%.\nCONCLUSIONES\nEl incremento progresivo de pacientes en tratamiento con biol\u00f3gicos, hace imprescindible la aplicaci\u00f3 de estrategia para \ngarantizar la sostenibilidad del sistema sanitario. La incorporaci\u00f3n de biosimilares en la pr\u00e1ctica asistencial es una de \nellas siendo necesaria la valoraci\u00f3n de su eficacia en programas de intercambio. El intercambio a biosimilar en nuestra \nserie de casos en vida real no parece tener un impacto significativo en los resultados cl\u00ednicos, tanto para marcadores \nproinflamatorios como incidencia de recidiva y efectos adversos, a corto plazo. Sin embargo, pese a que los pacientes \nalcanzan con ambos tratamientos control cl\u00ednico, la valoraci\u00f3n global en el cuestionario de satisfacci\u00f3n refleja una \ndisminuci\u00f3n en las puntuaciones de efectividad, conveniencia y satisfacci\u00f3n global. Esto refleja la importancia de medir \nvariables subjetivas reportadas por los pacientes y de darles valor en la toma de decisiones clinico-terap\u00e9uticas.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n604. AN\u00c1LISIS DE COSTE-EFECTIVIDAD DE DUPILUMAB EN EL TRATAMIENTO DE LA DERMATITIS AT\u00d3PICA \nEN NI\u00d1OS Y ADOLESCENTES EN ESPA\u00d1A \nAUTORES\nCALVO D\u00cdEZ, M\nNA\nOBJETIVOS\nLa dermatitis at\u00f3pica (DA) grave es una enfermedad de la piel, cr\u00f3nica, inflamatoria y limitante, que compromete de \nmanera significativa la calidad de vida del paciente. Dupilumab es la primera terapia biol\u00f3gica financiada en Espa\u00f1a para \nel tratamiento de la DA grave en pacientes a partir de los 6 a\u00f1os. En ni\u00f1os (6-11 a\u00f1os) es el \u00fanico tratamiento disponible \npara la DA grave. El objetivo del presente an\u00e1lisis fue estimar el ratio coste-efectividad incremental (RCEI) de dupilumab \nm\u00e1s el tratamiento de soporte, frente al tratamiento de soporte en ni\u00f1os y adolescentes con DA en Espa\u00f1a.\nMATERIALES Y M\u00c9TODOS\nSe utiliz\u00f3 un modelo de Markov adaptado al contexto Espa\u00f1ol para evaluar los efectos sobre la salud y los costes \nasociados seg\u00fan el manejo terap\u00e9utico de la DA. El modelo, con ciclos anuales, se estructur\u00f3 en 4 estados de salud: \u00e1rbol \nde decisi\u00f3n, dupilumab + tratamiento de soporte, tratamiento de soporte, y muerte. El \u00e1rbol de decisi\u00f3n represent\u00f3 el \ntratamiento a corto plazo y la respuesta cl\u00ednica inicial (a las 16 y 52 semanas), mientras que el resto de los estados de \nsalud consideraron la respuesta y el tratamiento de mantenimiento a largo plazo. En el primer a\u00f1o del an\u00e1lisis, el criterio \nde respuesta Eczema Area and Severity Index-75 (EASI-75) determin\u00f3 qu\u00e9 pacientes manten\u00edan el tratamiento con \ndupilumab en base a los ensayos cl\u00ednicos de dupilumab. Las respuestas a largo plazo se obtuvieron de la literatura y de la \nopini\u00f3n de expertos cl\u00ednicos. Asimismo, se utilizaron datos adicionales de los estudios de dupilumab para las utilidades, \nlos efectos adversos y la discontinuaci\u00f3n del tratamiento con dupilumab. La probabilidad de morir en los diferentes \nestados de salud se bas\u00f3 en el riesgo de muerte de la poblaci\u00f3n general Espa\u00f1ola ajustado por edad y g\u00e9nero. El an\u00e1lisis \nse realiz\u00f3 desde la perspectiva del Sistema Nacional de Salud (SNS) espa\u00f1ol, evaluando en el caso base s\u00f3lo los costes \nsanitarios directos (euros 2022) obtenidos de bases de datos nacionales y de la literatura. El horizonte temporal analizado \nfue toda la vida del paciente, considerando una tasa de descuento anual del 3% tanto para los costes como para los \nresultados en salud. Se realizaron an\u00e1lisis de sensibilidad determin\u00edsticos y probabil\u00edstico para evaluar la robustez de los \nresultados\ufffd\nRESULTADOS\nLos resultados del an\u00e1lisis mostraron que a\u00f1adir dupilumab al tratamiento de soporte en ni\u00f1os y adolescentes con DA \ngrave, proporcion\u00f3 +1,55 a\u00f1os de vida ajustados por calidad (AVAC) adicionales frente al tratamiento de soporte (18,95 \nAVAC vs. 17,40 AVAC), suponiendo un coste adicional de 37.555 \u20ac (89.229 \u20ac vs. 51.674 \u20ac). La raz\u00f3n de coste-efectividad \nincremental resultante fue de 24.262 \u20ac/AVAC, por debajo del umbral considerado actualmente en Espa\u00f1a como coste-\nefectivo. Los an\u00e1lisis de sensibilidad realizados confirmaron la robustez de los resultados del caso base.211CONCLUSIONES\nEste an\u00e1lisis demuestra que dupilumab combinado con el tratamiento de soporte es un r\u00e9gimen terap\u00e9utico coste-\nefectivo comparado con el tratamiento de soporte en el tratamiento de ni\u00f1os y adolescentes con DA para el SNS Espa\u00f1ol.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n727. OPTIMIZACI\u00d3N DE COSTES EN EL TRATAMIENTO CON NATALIZUMAB PARENTERAL \nAUTORES\nGONZ\u00c1LEZ TRIGUEROS, C; FERNANDEZ PACHECO GARCIA VALDECASAS, M; ESCRIGAS FERNANDEZ, C; SAN ANDR\u00c9S \nCORRAL, C; HERRERO FERNANDEZ, M; URE\u00d1A AGUILERA, I; AYUSO PERALTA, L; BALDOMINOS UTRILLA, G\nHOSPITAL UNIVERSITARIO PR\u00cdNCIPE DE ASTURIAS. CTRA. ALCAL\u00c1-MECO, S/N ALCAL\u00c1 DE HENARES. MADRID\nOBJETIVOS\nEn enero del 2022 se resolvi\u00f3 la resoluci\u00f3n de financiaci\u00f3n de la presentaci\u00f3n de natalizumab subcut\u00e1neo en jeringa \nprecargada. En nuestro centro se actualiz\u00f3 el protocolo de administraci\u00f3n consensuado con el Servicio de Neurolog\u00eda \ny Hospital de D\u00eda (HD), con el cambio de medicaci\u00f3n de natalizumab intravenoso a subcut\u00e1neo, con la finalidad de \noptimizar el tiempo en HD durante el tratamiento del mismo (150 minutos para la administraci\u00f3n intravenosa versus 30 \nminutos la subcut\u00e1nea).  \nEl objetivo del presente estudio es analizar la optimizaci\u00f3n de costes que ha supuesto el cambio de presentaci\u00f3n de \nnatalizumab intravenoso a natalizumab subcut\u00e1neo en un centro de segundo nivel\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de tres meses de duraci\u00f3n (febrero 2022-abril 2022) que incluy\u00f3 a todos los \npacientes con Esclerosis M\u00faltiple remitente recurrente en tratamiento con natalizumab parenteral.  \nSe extrajeron datos sobre el esquema de tratamiento en la historia cl\u00ednica electr\u00f3nica. Se registr\u00f3 el coste directo de \nadquisici\u00f3n de farmacia del programa de gesti\u00f3n econ\u00f3mica. Se calcularon los costes directos asociados al gasto en HD: \ncostes de personal, costes de funcionamiento, costes intermedios y costes estructurales\ufffd Los minutos totales de infusi\u00f3n \na cargo del servicio de neurolog\u00eda de natalizumab se calcularon como la suma de los minutos de cada paciente durante el \na\u00f1o 2021\ufffd El coste de administraci\u00f3n se calcul\u00f3 dividiendo el coste unitario total del a\u00f1o 2021 entre los minutos totales \nde infusi\u00f3n, expresando el resultado en \u20ac/min\nRESULTADOS\nSe incluy\u00f3 un total de 33 pacientes, 25 mujeres (75%) con una mediana de edad de 41 a\u00f1os (29-59). La moda de \nExpanded Disability Status Scale (EDSS) previo al cambio de tratamiento fue de 1.5. La dosis en todos los pacientes fue de \n300 mg, en el 33% cada seis semanas, en el 3% cada cinco semanas y en el 64% cada cuatro semanas\ufffd  \nEl coste de Natalizumab intravenoso por tratamiento fue de 1.376,54 \u20ac. Los costes desglosados son: gastos de adquisici\u00f3n \ndel vial de natalizumab de 300 mg: 1.302,28 \u20ac y del cloruro s\u00f3dico empleado para la diluci\u00f3n: 0,77 \u20ac. En cuanto a costes \ndirectos de HD se calcul\u00f3 para un coste unidad de 0,49 \u20ac/minuto en hospital de d\u00eda, suponiendo un total de 73,5 \u20ac por \ntratamiento para 150 minutos\ufffd  \nEl coste de natalizumab subcut\u00e1neo por tratamiento fue de 1.316,97 \u20ac. Los costes de adquisici\u00f3n fueron de 651,14 \u20ac \ncada jeringa de 150 mg, lo que supone un total de 1.302,27 \u20ac cada dosis. Los costes directos de HD fueron de 14,7 \u20ac por \ntratamiento, utilizando el coste unidad mencionado para 30 minutos.  \nSe han realizado un total de 81 tratamientos durante el periodo de estudio. El gasto total de natalizumab subcut\u00e1neo ha \nsido de 106.674,57\u20ac, mientras que el tratamiento intravenoso hubiera supuesto un coste de 111.499,74\u20ac. Esto supone un \nahorro de 4.825,17\u20ac, lo que supondr\u00e1 un ahorro anual de 19.300\u20ac en gastos directos de HD.\nCONCLUSIONES\nEl cambio de v\u00eda de administraci\u00f3n del natalizumab ha supuesto una reducci\u00f3n del coste asociado al tratamiento \nconsiderable, reduciendo los costes repercutidos a HD por parte del Servicio de Neurolog\u00eda.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n728. AN\u00c1LISIS DE UNA GESTI\u00d3N PROTOCOLIZADA DE LOS DESABASTECIMIENTOS DE MEDICAMENTOS \nY SUS CONSECUENCIAS CL\u00cdNICAS Y ECON\u00d3MICAS \nAUTORES\nMART\u00cdN RODR\u00cdGUEZ, M; L\u00d3PEZ M\u00c9NDEZ, P; BAJENARU , GT; FERN\u00c1NDEZ CEBRECOS, I; S\u00c1NCHEZ NAVARRO, IM; \nVILLARROYA PEIR\u00d3, E; NIETO M\u00c1RTIL, E; BALDOMINOS UTRILLA, G\nHOSPITAL UNIVERSITARIO PR\u00cdNCIPE DE ASTURIAS. CTRA. ALCAL\u00c1-MECO, S/N ALCAL\u00c1 DE HENARES. MADRID\nOBJETIVOS\nAnalizar la gesti\u00f3n de los desabastecimientos de medicamentos realizada por el Servicio de Farmacia, tras la elaboraci\u00f3n \nde un protocolo institucional, as\u00ed como sus implicaciones al paciente y el impacto econ\u00f3mico.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, prospectivo comprendido entre 01/01/2021 hasta 31/03/2022. Se incluyeron todos \nlos desabastecimientos ocurridos en el hospital en este periodo, excluyendo medicamentos del grupo terap\u00e9utico L.  \nRecursos materiales: m\u00f3dulo de Gesti\u00f3n de Farmacia, p\u00e1gina web del Centro de Informaci\u00f3n de Medicamentos \nAutorizados de la Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios, p\u00e1gina web de Medicamentos en \nSituaciones Especiales y tel\u00e9fonos de laboratorios.  212Datos registrados: medicamento desabastecido, fecha de detecci\u00f3n del problema de suministro, principio activo \n(p.a.), grupo terap\u00e9utico, alternativa (comercializada, f\u00f3rmula magistral (FM) o medicamento extranjero (ME)), \ninformaci\u00f3n escrita a servicios m\u00e9dicos y enfermer\u00eda, desabastecimientos que implicaron una restricci\u00f3n en su consumo, \nreabastecimientos, tiempo de desabastecimiento, precio neto unitario del medicamento desabastecido y su alternativa, \nconsumo mensual en el periodo de desabastecimiento, porcentaje del importe mensual de la alternativa con respecto al \nmedicamento desabastecido y problemas de seguridad detectados por personal sanitario y su alcance al paciente\ufffd\nRESULTADOS\nSe registraron 125 desabastecimientos, afectando a 111 especialidades y 93 p.a., lo que supone el 7,8% y el 12,2% del \ntotal de especialidades (n=1415) y p.a. (n=760) incluidos en la gu\u00eda farmacoterap\u00e9utica del hospital. En 9 medicamentos \ncesaron su comercializaci\u00f3n.  \nLa mediana de desabastecimientos/mes fue de 7 (RI: 4-11,5). La progresi\u00f3n trimestral de desabastecimientos fue de: 15 \n(enero-marzo 2021), 10 (abril-junio 2021), 32 (julio-septiembre 2021), 35 (octubre-diciembre 2021) y 33 (enero-marzo \n2022). La mediana del tiempo de desabastecimiento fue de 34 d\u00edas (RI: 18,25-70,75). \nLos 5 grupos terap\u00e9uticos m\u00e1s afectados fueron: N (15,3%), J (13,5%), B (12,6%), A (11,7%) y C (9,9%). En el 52,3% \nde las especialidades (n=58) no se dispon\u00eda de alternativa terap\u00e9utica con el mismo p.a., dosis y forma farmac\u00e9utica \ncomercializada en Espa\u00f1a. De estas, 12 (20,7%) supusieron la importaci\u00f3n de un ME y 7 (12,1%) la adquisici\u00f3n de una FM.  \nDe los 58 medicamentos sin alternativa id\u00e9ntica, se elaboraron y difundieron 49 (84,5%) notas informativas sobre el \ndesabastecimiento y la nueva especialidad adquirida.  \nEn 12 desabastecimientos se restringi\u00f3 su utilizaci\u00f3n en el hospital, reserv\u00e1ndolos para aquellas indicaciones sin \nalternativa. \nDe los desabastecimientos en los que se adquiere una alternativa (n=91), 37 supusieron un importe mensual superior \nal 25% con respecto al medicamento desabastecido (37.946,13 \u20ac), siendo las inmunoglobulinas las de mayor impacto \n(29.214,29 \u20ac). De estos, 8 fueron ME y 5 FM.  \nEn 16 medicamentos desabastecidos y sus alternativas se identificaron potenciales problemas de seguridad, de los cuales \n12 (75%) alcanzaron al paciente sin repercusi\u00f3n cl\u00ednica identificada.\nCONCLUSIONES\nSe observa un aumento progresivo en el n\u00famero de desabastecimientos, afectando a un porcentaje relevante de p.a. La \nmitad de ellos no dispon\u00edan de alternativa terap\u00e9utica comercializada, obligando a la adquisici\u00f3n de ME y FM con mayor \nimpacto econ\u00f3mico\ufffd  \nLa sistematizaci\u00f3n de la problem\u00e1tica de los desabastecimientos ha contribuido a mejorar el proceso de estos.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n748. EFECTIVIDAD Y SEGURIDAD DE UPADACITINIB EN LA PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nGARC\u00cdA MATILLAS, CN; GARC\u00cdA SIM\u00d3N, MS; FERN\u00c1NDEZ MART\u00cdNEZ, IM; MART\u00cdNEZ MARCOS, JM; FERN\u00c1NDEZ \nVELA, J; CONESA NICOL\u00c1S, E\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nEvaluar efectividad y seguridad de Upadacitinib en pacientes con artritis reumatoide y artritis psori\u00e1sica en un hospital de \ntercer nivel\ufffd\nMATERIALES Y M\u00c9TODOS\nSe trata de un estudio observacional retrospectivo en el que se incluyeron todos los pacientes tratados en nuestro centro \ncon Upadacitinib desde su comercializaci\u00f3n.  \nLos datos se obtuvieron del programa de dispensaci\u00f3n SAVAC\u00ae y de historia cl\u00ednica electr\u00f3nica Selene\u00ae. \nSe recogieron las siguientes variables: edad, sexo, diagn\u00f3stico cl\u00ednico, tratamientos previos, datos anal\u00edticos(prote\u00edna \nC reactiva(PCR) y velocidad de sedimentaci\u00f3n(VSG)), resultados de la escala Disease Activity Score-28(DAS-28) y del \ncuestionario Health Assessment Questionnaire(HAQ), reacciones adversas y motivo de la suspensi\u00f3n del tratamiento en \nel caso de que se haya producido.  \nLa efectividad se evalu\u00f3 en funci\u00f3n de los par\u00e1metros inflamatorios PCR, VSG, DAS-28 y HAQ al inicio de tratamiento y a \nlos 6 meses\ufffd La seguridad se valor\u00f3 mediante el registro de las reacciones adversas\ufffd  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 a trav\u00e9s del programa eSPSS v25.0\u00ae mostrando las variables continuas, como media y \ndesviaci\u00f3n est\u00e1ndar o mediana y rango intercuart\u00edlico en funci\u00f3n del ajuste de la normalidad, y las variables categ\u00f3ricas, \ncomo n\u00famero y frecuencia. Se estudiaron las diferencias en los valores anal\u00edticos, escala DAS-28 y cuestionario HAQ tras \nel tratamiento mediante la prueba estad\u00edstica de Wilcoxon para datos apareados.\nRESULTADOS\nSe incluyeron 23 pacientes(91,3% mujeres) con edad media de 60,48\u00b112,94 a\u00f1os. El 52%(n=12) recibi\u00f3 tofacitinib, \n34,78%(n=8) etanercept, 30,4%(n=7) abatacept, 21,7%(n=5) sarilumab, 17,39%(n=4)certolizumab, 17,39%(n=4) \nadalimumab, 13,04%(n=3) baricitinib, 4,35%(n=1) tocilizumab y 4,35%(n=1) ixekizumab .  \nEl 86,96%(n=20) presentaba artritis reumatoide y el 13,04%(n=3) artritis psori\u00e1sica. \nEn el estudio de efectividad la mediana de la PCR al inicio del tratamiento fue de 0,58 [1,06-0,06] mg/dL, disminuyendo a \nlos 6 meses a 0,21 [0,87-0,08] mg/dL(p=0,4). Por su parte, la mediana de VSG antes fue 19[27-9] mm/h, disminuyendo a \n16[26-10,75] en los 6 meses posteriores(p=0,84). En cuanto a la mediana del DAS-28 5,37 [6,37-4,07] y disminuye a 4,02 213[4,51-2,69] respectivamente(p=0,03). Con respecto a la puntuaci\u00f3n del cuestionario HAQ fue de 1,80 [2,3-1,22] y 1,24 \n[1,68-0,53] antes y en el seguimiento respectivamente(p=0,06). \nRespecto a la seguridad, el 37,5%(n=9) refirieron reacciones adversas: 2 pacientes manifiestan fatiga, 2 molestias \ngastrointestinales, 1 paciente present\u00f3 herpes, 1 urticaria y 1 edemas e infecciones de repetici\u00f3n.  \nEl 16,66%(n=4) suspendi\u00f3 el tratamiento por falta de eficacia y 12,5%(n=3) lo hizo por reacciones adversas. Actualmente \nel 71%(n=17) contin\u00faa con el tratamiento.\nCONCLUSIONES\nUn alto porcentaje(71%) de los pacientes refieren mejor\u00eda tras el tratamiento con Upadacitinib que se refleja a nivel \nanal\u00edtico con un descenso en la PCR y una reducci\u00f3n tanto en la puntuaci\u00f3n del cuestionario HAQ como, de forma \nsignificativa, en la escala empleada DAS-28. La ineficacia del tratamiento en nuestros pacientes es de 16,66%.  \nSe trata de un f\u00e1rmaco bien tolerado. Las reacciones adversas registradas han sido mayoritariamente leves y solo 3 \npacientes han tenido que suspender el tratamiento a consecuencia de ellas.  \nLa reciente comercializaci\u00f3n del Upadacitinib y los escasos resultados disponibles hacen necesarios m\u00e1s estudios para \nobtener datos m\u00e1s concluyentes, si bien, seg\u00fan nuestra experiencia se trata de un f\u00e1rmaco seguro y eficaz.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n757. RITUXIMAB EN EL TRATAMIENTO DE LAS GLOMERULONEFRITIS: EFECTIVIDAD Y SEGURIDAD. \nAUTORES\nGARC\u00cdA MATILLAS, CN; MARTINEZ PENELLA, M; FERN\u00c1NDEZ MART\u00cdNEZ, IM; GARCIA HERN\u00c1NDEZ, MA; NAVARRO \nPARRE\u00d1O, MJ; MARIN-BARNUEVO LARIOS, M\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nEl tratamiento est\u00e1ndar de las glomerulonefritis comprende el uso los corticoides en primera l\u00ednea y otros \ninmunosupresores utilizados en segunda l\u00ednea tales como: ciclofosfamida, micofenolato de mofetilo, tacrolimus, \nciclosporina y rituximab. En los \u00faltimos a\u00f1os, rituximab ha sido c onsiderado como un tratamiento potencial cada vez \nusado con m\u00e1s frecuencia ya que la respuesta inmune mediada por c\u00e9lulas B desempe\u00f1an un papel importante en las \nenfermedades autoinmunes que afectan al ri\u00f1\u00f3n.  \nEl objetivo de este estudio es evaluar la efectividad y seguridad del rituximab en el tratamiento de las glomerulonefritis.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo, en el que se incluyeron a todos los pacientes con enfermedades glomerulares \ntratados con rituximab en un hospital de tercer nivel desde febrero del 2015 hasta abril del 2022.  \nSe registraron las siguientes variables de estudio recogidas a trav\u00e9s de del programa de dispensaci\u00f3n (SAVAC\u00ae) y de \nhistoria cl\u00ednica electr\u00f3nica (Selene\u00ae): edad, sexo, diagn\u00f3stico, tratamientos previos, posolog\u00eda, n\u00famero de ciclos recibidos, \nvalores de creatinina, albuminuria y proteinuria previos y 12 meses despu\u00e9s del inicio del tratamiento, respuesta \nobtenida, reacciones adversas y causa de suspensi\u00f3n del tratamiento\ufffd  \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 a trav\u00e9s del programa eSPSS v25.0\u00ae mostrando las variables continuas, como media y \ndesviaci\u00f3n est\u00e1ndar o mediana y rango intercuart\u00edlico en funci\u00f3n del ajuste de la normalidad, y las variables categ\u00f3ricas, \ncomo n\u00famero y frecuencia. Se estudiaron las diferencias en los valores anal\u00edticos tras el tratamiento mediante la prueba \nestad\u00edstica de Wilcoxon para datos apareados.\nRESULTADOS\nSe incluyeron a 50 pacientes (60% hombres) con una edad media de 56,38\u00b119,21 a\u00f1os. El 74% (n=37) presentaba \nuna glomerulonefritis de tipo primaria y el 26% (n=13) secundaria. Dentro de las primarias destacan 18% (n=9) las \nglomerulonefritis proliferativas, seguidas de 16% (n=8) glomerulonefritis segmentarias; por su parte, en las secundarias \ndestacan un 10% (n=5) causada por lupus eritematosos sist\u00e9mico (nefritis l\u00fapica).  \nEn cuanto a los tratamientos previos a rituximab, el 92 de los pacientes (n=46) recibieron corticoides, el 24% (n=12) \nciclofosfamida, el 16% (n=8) azatioprina, el 12% (n=6) micofenolato y un 2% (n=1) eculizumab.  \nLa mediana de la magnitud de la reducci\u00f3n de la albumina fue de 70,8% [94,65-60,2] (p=0,007), de la creatinina s\u00e9rica de \n16,9 % [26,65-11,40] (p=0,018) y de la proteinuria 72,4% [90,75-59,35] (p=0,001).  \nEn la actualidad, el 48% (n=24) se encuentran estables, 15 pacientes (30%) en remisi\u00f3n completa, 12% (n=6) en remisi\u00f3n \nparcial, mientras que el 10% (n=5) no obtuvo respuesta. \nEn lo referente a la seguridad, se observaron reacciones adversas en cinco pacientes (10%), destacando: astenia, prurito, \nalergia a Rituximab, inmunosupresi\u00f3n, infecciones y trastornos de la memoria\ufffd\nCONCLUSIONES\nRituximab es una alternativa terap\u00e9utica v\u00e1lida en las glomerulonefritis primarias y secundarias que no responden a \ntratamientos utilizados en primera l\u00ednea permitiendo obtener respuestas completas o estabilidad de la enfermedad en \nun porcentaje significativo de pacientes. Adem\u00e1s, ha demostrado disminuir la creatinina s\u00e9rica, as\u00ed como la proteinuria y \nalbuminuria de forma significativa.  \nEn t\u00e9rminos de seguridad, rituximab ha mostrado un perfil aceptable de toxicidad y tolerancia en nuestros pacientes.214CLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n851. EFECTIVIDAD, SEGURIDAD Y COSTE DE LEVOSIMEND\u00c1N EN HOSPITAL DE D\u00cdA EN PACIENTES CON \nINSUFICIENCIA CARDIACA AVANZADA \nAUTORES\nDE CASTRO JULVE, M; FLORIT-SUREDA , M; OLIVER CERVELL\u00d3, M; RAMOS RODR\u00cdGUEZ, J; ROVIRA MEDINA, T; PINO \nGARC\u00cdA, J; ORTIZ RUIZ, L; G\u00d3MEZ-VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\n- Describir las caracter\u00edsticas de los pacientes con insuficiencia card\u00edaca (IC) avanzada que recibieron tratamiento con \nlevosimend\u00e1n en hospital de d\u00eda (HD) de Cardiolog\u00eda.  \n- Evaluar la efectividad y seguridad de levosimend\u00e1n en perfusi\u00f3n intermitente en estos pacientes.  \n- Calcular el ahorro econ\u00f3mico derivado de la optimizaci\u00f3n de viales de levosimend\u00e1n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital universitario de segundo nivel.  \nSe incluyeron todos los pacientes con IC avanzada que recibieron alguna dosis de levosimend\u00e1n en HD de Cardiolog\u00eda \nentre noviembre de 2018 y marzo de 2022, tras la puesta en marcha del protocolo de administraci\u00f3n intermitente: \nlevosimend\u00e1n 6,25mg durante 6 horas (velocidad ascendente seg\u00fan tolerancia) cada 15 d\u00edas. La elaboraci\u00f3n se realiza en \nFarmacia para optimizar viales.  \nVariables registradas: edad, sexo, comorbilidades; clase NYHA (New York Heart Association), fracci\u00f3n de eyecci\u00f3n \nventricular izquierda (FEVI) y p\u00e9ptido natriur\u00e9tico tipo B (NT-pro-BNP) antes de iniciar levosimend\u00e1n y tras la \u00faltima dosis; \nn\u00famero de ingresos por descompensaci\u00f3n cardiaca el a\u00f1o previo y posteriormente a la administraci\u00f3n de levosimend\u00e1n \n(a partir de la segunda dosis); n\u00famero de dosis administradas; mortalidad y efectos adversos.  \nEl coste se calcul\u00f3 teniendo en cuenta que de cada vial de levosimend\u00e1n se obtienen dos dosis.\nRESULTADOS\nSe incluyeron 23 pacientes; 20 (87%) hombres, edad media 72,5 (55-87) a\u00f1os. Comorbilidades: hipertensi\u00f3n 15 \n(65,2%), cardiopat\u00eda isqu\u00e9mica 15 (65,2%), fibrilaci\u00f3n auricular 14 (60,9%), dislipemia 19 (82,6%,) diabetes 13 (56,5%), \ninsuficiencia renal cr\u00f3nica 15 (65,2%); 19 (82,6%) pacientes presentaban \u2265 3 comorbilidades. Clase NYHA: clase III 13 \n(56,5%) pacientes, clase II 8 (34,8%), clase IV 2 (8,7%). FEVI media 28% (13-60%). NT-pro-BNP medio 11.110 pg/mL (884-\n55.196 pg/mL). Pacientes con \u22651 ingresos el a\u00f1o previo 18 (78,3%); media 1,3 ingresos/paciente.  \nDiez (43,5%) pacientes recibieron previamente levosimend\u00e1n en perfusi\u00f3n contin\u00faa estando hospitalizados. Media de \nadministraciones en HD 5,5 (1-19); 11 (47,8%) pacientes 6 o m\u00e1s dosis.  \nTras la \u00faltima dosis de cada paciente se observ\u00f3 mejor\u00eda de la clase NYHA en 7 (35%) pacientes, 7 (35%) se mantuvieron \nestables y 6 (30%) empeoraron. La FEVI mejor\u00f3 en 10 (50%) pacientes, 7 (35%) no mostraron diferencias y 3 (15%) \nempeoraron, siendo la FEVI media posterior de 31,1% (20-60%). El NT-pro-BNP mejor\u00f3 en 15 (75%) pacientes, con una \nmedia de 8.398 pg/mL (266-31.363 pg/mL). Pacientes con \u22651 ingresos durante y post-tratamiento 9 (45%); media 1 \ningreso/paciente. Fallecieron 6 (30%) pacientes.  \nEfectos adversos: hipotensi\u00f3n durante la administraci\u00f3n en 15 (65,2%) pacientes, 3 de los cuales discontinuaron el \ntratamiento en la primera dosis por este motivo, y se excluyeron del an\u00e1lisis posterior de efectividad; erupci\u00f3n cut\u00e1nea \nen 1 (4,3%) paciente. \nCoste te\u00f3rico del tratamiento sin optimizar viales 61.053 euros. Con la optimizaci\u00f3n se ahorr\u00f3 un 50% (30.526 euros) en \nel periodo estudiado\ufffd\nCONCLUSIONES\nEn nuestra muestra de pacientes con IC avanzada, el levosimend\u00e1n administrado de forma intermitente en HD parece \nmejorar los par\u00e1metros cl\u00ednicos y anal\u00edticos (clase NYHA, FEVI, NT-pro-BNP e ingresos), y presenta un perfil de seguridad \naceptable\ufffd  \nLa preparaci\u00f3n de levosimend\u00e1n en el servicio de Farmacia permite una reducci\u00f3n importante del coste del tratamiento.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1022. EVALUACI\u00d3N DEL USO DE FILGRASTIM EN EL TRATAMIENTO DE INFERTILIDAD DE CAUSA \nDESCONOCIDA EN PACIENTES CON RECEPTORES KIR TIPO INHIBIDOR. \nAUTORES\nANGUITA DOMINGO, D; JIM\u00c9NEZ LOZANO, I; DIELI CRIMI, R; JU\u00c1REZ GIM\u00c9NEZ, JC; G\u00d3MEZ GANDA, L; GARC\u00cdA PALOP , \nBM; FERN\u00c1NDEZ POLO, A\nH. UNIVERSITARI MATERNOINFANTIL DE LA VALL D`HEBRON. PASSEIG VALL D\u00b4HEBRON 119-129 BARCELONA. \nBARCELONA\nOBJETIVOS\nLas c\u00e9lulas NK del \u00fatero favorecen la angiog\u00e9nesis necesaria para el desarrollo placentario y la implantaci\u00f3n embrionaria. \nSu actividad es controlada por los genes de la familia receptora de inmunoglobulina KIR (killer cell immunoglobulin-like \nreceptor).  \nDiversos estudios han relacionado el haplotipo KIR materno AA (inhibidor) y un HLA-C2 fetal, con un elevado riesgo de \np\u00e9rdida del embarazo recurrente (PER), retraso en el crecimiento fetal y preeclampsia. Filgrastim parece ser efectivo en 215pacientes con antecedentes de PER con presencia de receptores KIR tipo inhibidor que van a realizar una transferencia \nembrionaria (TE).  \n \nEl objetivo fue evaluar la efectividad y seguridad de filgrastim en el tratamiento de infertilidad primaria asociada a la \npresencia de receptores KIR AA, en mujeres que van a realizar una TE.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional ambispectivo que incluye pacientes con PER de causa desconocida con receptores KIR AA que \nrecibieron filgrastim junto con TE en un hospital de tercer nivel entre septiembre 2019 y enero 2022. \n \nSe recogieron variables biodemogr\u00e1ficas (edad, KIR y HLA-C de la paciente y HLA-C de la pareja si estaba disponible), y de \ntratamiento (n\u00ba ciclos, respuesta y efectos adversos).  \n \nLa dosis de filgrastim fue 12 MU subcut\u00e1neo cada 72h comenzando 1h antes de la TE y continuando hasta la novena \nsemana de gestaci\u00f3n (SG) si beta-HCG positiva a las 2 semanas de la TE. Previo al inicio, las pacientes firmaron el \nconsentimiento informado.  \n \nLas variables continuas se expresan como medianas (rango) y las variables categ\u00f3ricas como n\u00famero de casos y las \ncorrespondientes frecuencias relativas.\nRESULTADOS\nSe incluyeron 28 pacientes con una mediana de 38,5 (31-46) a\u00f1os; 21 (75%) pacientes recibieron un \u00fanico ciclo, 5 (17,9%) \nrecibieron dos ciclos y 2 (7,1%) pacientes tres.  \n \nSe han producido 14 beta-HCG positiva en 13 pacientes (46,4%). 11 (39,2%) lograron la implantaci\u00f3n efectiva tras \nla primera TE con filgrastim. Una paciente obtuvo beta-HCG positiva con legrado posterior. Una paciente consigui\u00f3 \nimplantaci\u00f3n efectiva en la segunda TE tras una primera beta-HCG positiva con interrupci\u00f3n del embarazo a las 13+6 SG \npor feto con hallazgo ecogr\u00e1fico de anomal\u00edas faciales.  \n \nEn total 12 (42,9%) pacientes lograron una implantaci\u00f3n efectiva, en 9 (32,1%) pacientes se alcanz\u00f3 el parto a las 40 (36-\n40) SG y 2 (7,1%) siguen embarazadas en la actualidad de 30 y 33 SG. Se ha perdido el seguimiento de una paciente a las \n33 SG\ufffd  \nComo acontecimientos adversos se identific\u00f3 amenaza de parto inmaduro a las 22 SG que acab\u00f3 en parto a las 36 SG sin \nninguna otra incidencia y feto de bajo peso en una de las pacientes que contin\u00faa embarazada. No se identificaron efectos \nadversos asociados al tratamiento\ufffd\nCONCLUSIONES\nAproximadamente la mitad de nuestras pacientes, todas ellas con antecedentes de PER, han logrado la implantaci\u00f3n \nefectiva tras la administraci\u00f3n de filgrastim. Son necesarios m\u00e1s estudios que eval\u00faen la seguridad a largo plazo y la \nrelaci\u00f3n entre la efectividad y los distintos polimorfismos KIR y HLA-C.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1023. AN\u00c1LISIS DE MINIMIZACI\u00d3N DE COSTES ASOCIADO AL INTERCAMBIO A MEDICAMENTOS \nBIOSIMILARES ANTI-FACTOR DE NECROSIS TUMORAL \nAUTORES\nDEL POZO CARLAVILLA, C; SERNA SERRANO, B; LERMA GAUDE, V; GARC\u00cdA G\u00d3MEZ, C; ALDAZ FRANC\u00c9S, R; BERNARDO \nGUERRERO, F; VALLADOLID WALSH, A\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE ALBACETE. HERMANOS FALC\u00d3, S/N. ALBACETE. ALBACETE\nOBJETIVOS\nEn el 2021 la Gu\u00eda Farmacoterap\u00e9utica del centro contemplaba para cada mol\u00e9cula, un biosimilar (BS1) para inicios y \notro de referencia (REF) para continuaciones. Tras el Acuerdo Marco (AM) del SESCAM se licitaron otros biosimilares \nanti-factor de necrosis tumoral, de Etanercept y Adalimumab (BS2). Tras la adjudicaci\u00f3n, la Comisi\u00f3n de Farmacia y \nTerap\u00e9utica aprob\u00f3 el intercambio terap\u00e9utico (IT) de BS1 a BS2. El objetivo del estudio es estimar el ahorro econ\u00f3mico \nanual asociado al IT de los BS1 a los BS2 de Etanercept y Adalimumab y valorar el tiempo medio invertido por el \nfarmac\u00e9utico (TF) durante el proceso del IT.\nMATERIALES Y M\u00c9TODOS\nEstudio de minimizaci\u00f3n de costes donde se estim\u00f3 el ahorro econ\u00f3mico que supondr\u00eda la compra de las Unidades \nAdquiridas durante el a\u00f1o 2021(UA2021) de las plumas de Etanercept 50 mg y Adalimumab 40 mg, con los precios de los \nBS2 aprobados en el AM. Valorar el TF en la informaci\u00f3n, educaci\u00f3n y obtenci\u00f3n del consentimiento durante el IT. \nVariables: UA2021, Precio Medio por Unidad (PmU) de las plumas adquiridas por nuestro centro durante el 2021 \n(REF/BS1/BS2), Precio unitario de las plumas adjudicadas en el AM (PUBS2), coste asociado al TF (retribuci\u00f3n anual \nsin Seguridad Social), N\u00famero de pacientes susceptibles de IT, TF empleado en el IT. Fuentes: Farmatools\u00ae, Orden de \nRetribuciones 2022 de SESCAM y Excel\u00ae2007 (recogida de datos). Precios (descuentos e impuestos incluidos).216RESULTADOS\n- Adalimumab: 7.080 UA2021; 121,67\u20ac PmU; 34,84\u20ac PUBS2; Ahorro/unidad 86,83\u20ac; Ahorro/anual 614.756\u20ac.  \n- Etanercept: 4.108 UA2021; 120,36 \u20ac PmU; 56,06\u20ac PU BS2; Ahorro/unidad 64,3\u20ac; Ahorro/anual 264.144\u20ac.  \n- La retribuci\u00f3n del farmac\u00e9utico: 49.557\u20ac por 1.519 horas/a\u00f1o, (32,63\u20ac/hora).  \n- Los pacientes susceptibles de IT (31/12/2021): 248 pacientes; Coste asociado al TF: 2.023\u20ac.  \n- Ahorro total para el centro: 876.877\u20ac.\nCONCLUSIONES\nEl IT de los BS1 a los BS2 adjudicados por AM de las plumas de Etanercept 50 mg y Adalimumab 40 mg, permitir\u00eda un \nahorro en el gasto asociado.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1055. EVALUACI\u00d3N DE SOLICITUDES INDIVIDUALIZADAS DE MEDICAMENTOS DE ALTO IMPACTO Y \nMEDICAMENTOS EN SITUACIONES ESPECIALES EN UN HOSPITAL DE TERCER NIVEL. \nAUTORES\nMANCILLA MONTERO, E; RUIZ LARA, LM; PEREA PEREZ, A; RUIZ ARCA, G; HERN\u00c1NDEZ PARADA, J\nHOSPITAL REINA SOF\u00cdA \ufffd AV\ufffd MEN\u00c9NDEZ PIDAL, S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA\nOBJETIVOS\nEl objetivo de este estudio es analizar a lo largo de un hist\u00f3rico de cuatro a\u00f1os las solicitudes individualizadas de \nmedicamentos de alto impacto y de medicamentos en situaciones especiales (MSE) recibidas en un hospital de tercer \nnivel \ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo del periodo 2018-2021 , del que se evaluaron todas las solicitudes recibidas de \nmedicamentos de alto impacto sanitario y/o econ\u00f3mico y aquellas de MSE. Se excluy\u00f3 el a\u00f1o 2020 por no ser \nrepresentativo debido a la pandemia mundial por el SARS-COV-2. \nSe trata de medicamentos que la Comisi\u00f3n de Farmacia y Terap\u00e9utica ha acordado que sea el Servicio de Farmacia quien \nvalide la idoneidad del tratamiento\ufffd  \nLa evaluaci\u00f3n de las solicitudes, en funci\u00f3n del tipo que fuese, ten\u00eda en cuenta la situaci\u00f3n de financiaci\u00f3n, disponibilidad \nde IPT, criterios acordados en la Comisi\u00f3n de Farmacia, nivel de evidencia disponible, relevancia de resultados de eficacia \ny seguridad, alternativas y aplicabilidad externa al paciente.  \nLos datos utilizados fueron recogidos en un registro propio en el que se inclu\u00eda: servicio peticionario, m\u00e9dico solicitante, \npaciente, f\u00e1rmaco, indicaci\u00f3n, situaci\u00f3n administrativa, v\u00eda de comunicaci\u00f3n utilizada y resoluci\u00f3n. Estos datos se \nanalizaron mediante estad\u00edstica descriptiva.\nRESULTADOS\nDurante los tres a\u00f1os de estudio, (2018,2019 y 2021), se registraron un total de 850solicitudes: 169 en 2018, 277 en 2019 \ny 404 en 2021, lo que supone un incremento del 239% en estos tres a\u00f1os.  \nEl 70,7% de las solicitudes recibidas se concentran en oncolog\u00eda m\u00e9dica. Dentro de estas, las m\u00e1s frecuentes son aquellas \ndirigidas al c\u00e1ncer de pulm\u00f3n (34,7%) y de mama (19,9%). \nLos f\u00e1rmacos m\u00e1s solicitados fueron Atezolizumab (17,7%), Nivolumab (15,5%) Palbociclib (10,2%), Pembrolizumab \n(8,5%), trifluridina/tipiracilo (9,8%) y Ribociclib (4,7%) entre otros.  \n \nRespecto al tipo de solicitud, destacar que el 15% de los f\u00e1rmacos solicitados no dispon\u00edan a\u00fan de decisi\u00f3n de \nfinanciaci\u00f3n para la indicaci\u00f3n de tratamiento solicitada.  \n \nEl grado de acuerdo entre las solicitudes presentadas, seg\u00fan los criterios descritos fue: 87.1% (2018) 89.3% (2019) y \n92.5% (2021).\nCONCLUSIONES\nEl uso de medicamentos de alto impacto supone un gran reto para la sostenibilidad de nuestro Sistema Nacional de \nSalud. La evaluaci\u00f3n de medicamentos y validaci\u00f3n de los solicitudes de alto impacto e individualizadas es un actividad \ncl\u00ednica del farmac\u00e9utico de hospital con una carga de trabajo creciente y con impacto en la eficiencia de sistema de salud.  \nA lo largo de estos a\u00f1os, el grado de concordancia entre solicitudes y autorizaciones ha sido mayor, fruto del trabajo \nprevio para consensuar algoritmos de tratamiento e informes de las condiciones de financiaci\u00f3n y uso de las distintas \nalternativas terap\u00e9uticas.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1079. COMPARACI\u00d3N INDIRECTA AJUSTADA ENTRE ANTICUERPOS MONOCLONALES PARA EL \nTRATAMIENTO DE LA RINUSITIS CR\u00d3NICA CON POLIPOSIS NASAL \nAUTORES\nBARREIRO FERNANDEZ, EM; FENIX CABALLERO, S; SALMERON NAVAS, FJ; MORENO RAMOS, C; DOMINGUEZ \nSANTANA, CM\nHOSPITAL DE ESPECIALIDADES DE PUERTO REAL \ufffd CTRA \ufffd NACIONAL IV, KM \ufffd 665 PUERTO REAL \ufffd C\u00c1DIZ217OBJETIVOS\nEstablecer si omalizumab, dupilumab y mepolizumab pueden ser considerados alternativas terap\u00e9uticas equivales (ATE) \na trav\u00e9s de una comparaci\u00f3n indirecta ajustada (CIA), y un comparador com\u00fan, en pacientes con rinusitis cr\u00f3nica con \np\u00f3lipos nasales (RSCcPn) como tratamiento adicional a corticoides intranasales.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en Medline-Pubmed, utilizando la siguiente estrategia de b\u00fasqueda \u201csevere \nchronicrhinosinusitis with nasal polyps\u201d and \u201cmonoclonal antibody\u201d. Se seleccionaron ensayos cl\u00ednicos aleatorizados \n(ECA), fase III, que presentaran criterios de exclusi\u00f3n e inclusi\u00f3n, tiempo de estudio y variables medidas similares. La \nCIA se realiz\u00f3 a trav\u00e9s del m\u00e9todo Bucher, usando la calculadora de la Canadian Agency for Health Tecnology Assement \ny empleando placebo como comparador com\u00fan entre los tratamientos. Las variables seleccionadas para determinar la \nequivalencia fueron la media de la diferencia del cambio en el n\u00famero de p\u00f3lipos (DMP) y la diferencia de puntos en \nescalas equivalentes de s\u00edntomas de congesti\u00f3n nasal (DMC) tras 24 semanas de tratamiento. Se estableci\u00f3 como valor \ndelta una diferencia de -1,24 y +1,24 en DMP y -0.55 y +0.55 en DMC, tomando como referencia el valor establecido en \nel estudio LYBERTY NP SINUS-24. Para establecer el posicionamiento, se aplicaron los criterios de la gu\u00eda de alternativas \nterap\u00e9uticas equivalentes (gu\u00eda ATE) y se compar\u00f3 frente al de mejor resultado num\u00e9rico frente a placebo, dupilumab.\nRESULTADOS\nSe incluyeron 4 ECA, fase III, doble-ciego, aleatorizado, multic\u00e9ntricos: estudio LYBERTY NP SINUS-24(dupilumab), \nPOLIPY-1 y POLIPY-2 (omalizumab), SYNAPSE(mepolizumab). Las caracter\u00edsticas de los pacientes fueron: edad \u226518 a\u00f1os, \ndiagn\u00f3stico de RSCcPn, s\u00edntomas de congesti\u00f3n, n\u00famero m\u00ednimo de p\u00f3lipos de 5 a 8 (m\u00ednimo 2 en cada cavidad nasal), \ncongesti\u00f3n mayor o igual a moderada en las escalas DMC, cirug\u00eda previa desde m\u00e1s de 6 meses, fracaso a terapia con \ncorticoides inhalados. En todos los estudios el tratamiento control fue placebo. Los resultados de la media de la diferencia \ndel cambio en DMP , junto su IC95% fueron: dupilumab -2,06(IC95% -2,43; -1,69), omalizumab -0 ,86(IC95% -1,32;-0.41) y \nmepolizumab -1,5(IC95% -1,3;-0,9). El resultado obtenido de la CIA de mepolizumab frente dupilumab fue de -1,01(IC95% \n-1,40;-0,62; p < 0.001) y omalizumab frente dupilumab fue -1,2(IC95% -1,79;-0.61; p < 0.001). Los resultados de la media \nde la diferencia de DMC, junto su IC95% fueron: dupilumab -0.89 (IC95% -1,07; -0,71), omalizumab -0,52(-0,82; -0,22), \nmepolizumab -0,6 (IC95% -0,96;-0,36). El resultado obtenido de la CIA de mepolizumab frente dupilumab fue -0,29(IC95% \n-0,64; 0,06; p=0,104) y omalizumab frente dupilumab fue -0.37(IC95% -0,72;-0,02; p=0.038). A partir de la interpretaci\u00f3n \nde la gu\u00eda ATE, se obtiene en DMP un resultado de \u201cDiferencia probablemente irrelevante\u201d, por lo que pueden ser ATE \nsiempre que el fracaso no suponga un perjuicio grave/irreversible. Por otro lado, en el caso de DMC un resultado de \n\u201cDiferencia probablemente irrelevante\u201d en el caso de mepolizumab frente dupilumab y una \u201cProbable equivalencia \ncl\u00ednica\u201d en el caso de omalizumab frente dupilumab, pueden ser considerados ATE.\nCONCLUSIONES\nLos resultados obtenidos, junto a las posibles limitaciones de la CIA, muestran en ambas variables la posibilidad \nde considerar estos 3 tratamientos como alternativas terap\u00e9uticas equivalente en el tratamiento de RSCcPn como \ntratamiento adicional corticoides  \nintranasales\ufffd\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1152. EVALUACI\u00d3N DE LA EFICACIA Y SEGURIDAD DEL IMPLANTE INTRAV\u00cdTREO DE DEXAMETASONA EN \nEDEMA MACULAR EN UN HOSPITAL COMARCAL \nAUTORES\nFERRIS VILLANUEVA, E; GARABITO S\u00c1NCHEZ, MJ; CORRAL BAENA, S\nHOSPITAL SAN JUAN DE DIOS DE EL ALJARAFE. AVDA. SAN JUAN DE DIOS, S/N BORMUJOS. SEVILLA\nOBJETIVOS\nAnalizar la eficacia y seguridad del implante intrav\u00edtreo de dexametasona (IID) en edema macular tras la actualizaci\u00f3n del \nprotocolo de uso en un hospital comarcal.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluye a todos los pacientes que iniciaron tratamiento con IDD entre enero \n2020 y diciembre 2020 tras la actualizaci\u00f3n del protocolo de uso en nuestro hospital. Las indicaciones establecidas \nfueron: tratamiento de segunda l\u00ednea en Edema Macular Diab\u00e9tico (EMD) f\u00e1quicos en los que no se haya conseguido \nbuena respuesta al tratamiento tr\u00e1s dos dosis mensuales de antiangiog\u00e9nicos (AA), EMD pseudof\u00e1quicos y Edema \nMacular despu\u00e9s de una oclusi\u00f3n rama venosa retiniana (EMORVR) u Oclusi\u00f3n Venosa Retiniana Central (EMOVCR) \nsin biomarcadores inflamatorios (BI) en los que no se haya conseguido buena respuesta al tratamiento tras tres \ndosis mensuales de AA; y de primera l\u00ednea de tratamiento en uve\u00edtis no infecciosa. Tambi\u00e9n se indic\u00f3 como primera \nl\u00ednea en EMORVR, EMOVCR y EMD pseudof\u00e1quicos en pacientes con eventos cardiovasculares (CV) < 6 meses y \nEMD vitrectomizados. Como nueva indicaci\u00f3n de primera l\u00ednea se incorporan pacientes EMORVR, EMOVCR y EMD \npseudof\u00e1quicos o con cirug\u00eda de catarata prevista con presencia de BI. Para evaluar la eficacia se midi\u00f3 la agudeza visual \n(AV) y el grosor del edema mediante tomograf\u00eda de coherencia \u00f3ptica (OCT) en micras antes y despu\u00e9s del implante. Las \nvariables demogr\u00e1ficas recogidas fueron: sexo, edad, lateralidad e indicaci\u00f3n. An\u00e1lisis estad\u00edstico: test Wilcoxon para \ncomparar los valores de OCT y test de la t de Student para muestras emparejadas para la AV.218RESULTADOS\nSe trataron con IID a 37 pacientes\ufffd Se excluyeron del estudio a 7 pacientes por carecer de informaci\u00f3n tras la \nadministraci\u00f3n del IDI. Se analizaron en total a 30 pacientes (33 ojos) con edad media de 68 a\u00f1os, siendo 51,6 % varones. \nLos diagn\u00f3sticos fueron: 16 (53,3%) EMD, 3 (10%) EMORVR, 2 (6,66%) EMOVCR y 9 (30%) uve\u00edtis no infecciosa. De los \npacientes con EMD, 2 pacientes vitrectomizados y 1 paciente con eventos CV < 6 meses, fueron tratados como primera \nl\u00ednea de tratamiento. Con respecto a las nuevas indicaciones: 4 (13,3%) EMD con BI y 1 (3,33%) EMORVR con BI. La \nmedia para OCT pre-implante y post-implante fue de 404 (SD: 158) y 256 (SD:142) micras, respectivamente (p < 0,001). \nLa media de AV pre-implante y post-implante fue de 0,28 (SD: 0,19) y 0,39 (SD: 0,26), respectivamente (p < 0,001). Con \nrespecto a la respuesta, 3 (3,3%) pacientes fueron excluidos del protocolo al ser no respondedores. El 20% recidivaron \na los 4,5-5 meses. Respecto a las incidencias de eventos adversos, 3 (10%) presentaron hipertensi\u00f3n ocular y 1 (3,33%) \nendoftalmitis. No presentaron ninguna complicaci\u00f3n 26 (86,6%) pacientes.\nCONCLUSIONES\nLa principal indicaci\u00f3n ha sido EMD en pacientes refractarios a tratamiento previo con antiangiog\u00e9nicos. Se ha cumplido \nel protocolo en el 100% de los casos\ufffd La AV aument\u00f3 y OCT disminiy\u00f3 tras tratamiento con IDI, siendo las diferencias \nsignificativas en ambos casos. El IDI en nuestros pacientes ha presentado una eficacia y seguridad similar a la demostrada \nen ensayos cl\u00ednicos.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1158. DISE\u00d1O, IMPLANTACI\u00d3N E IMPACTO ECON\u00d3MICO DEL SWITCH DE INFLIXIMAB EN EL SERVICIO \nDE REUMATOLOG\u00cdA EN UN HOSPITAL MEDIANO. \nAUTORES\nJIM\u00c9NEZ MESEGUER, M; GARC\u00cdA MART\u00cdNEZ, S; SANTOS MENA, B; DOMINGUEZ GARC\u00cdA, A; SALAS PEREZ, JM; \nOROZCO CIFUENTES, I; RODRIGO LAMBAN, DJ; GARC\u00cdA D\u00cdAZ, B\nHOSPITAL SEVERO OCHOA \ufffd AV\ufffd DE ORELLANA, S/N LEGAN\u00c9S \ufffd MADRID\nOBJETIVOS\nDescribir las estrategias dise\u00f1adas por el servicio de farmacia junto con el servicio de reumatolog\u00eda para realizar el switch \nde infliximab (IFX) de referencia al biosimilar m\u00e1s eficiente y evaluar el impacto econ\u00f3mico del mismo.\nMATERIALES Y M\u00c9TODOS\n- Estudio descriptivo retrospectivo.  \n- Descripci\u00f3n del cronograma del dise\u00f1o e implantaci\u00f3n de las medidas consensuadas.  \n- Evaluaci\u00f3n econ\u00f3mica del intercambio: se compara el gasto por paciente e indicaci\u00f3n en la que se prescribe IFX en el \na\u00f1o 2020, previo al intercambio, con el de 2021, posterior al intercambio. As\u00ed como, el consumo global y el numero de \npacientes en tratamiento con IFX\ufffd\nRESULTADOS\nCronograma de dise\u00f1o e implantaci\u00f3n del switch: \n \n1. Enero 2021: Se plantea el objetivo de incrementar el uso del IFX m\u00e1s eficiente para contribuir a la sostenibilidad y \neficiencia del gasto farmac\u00e9utico.  \n2. Mayo 2021: Se identifica el proveedor m\u00e1s eficiente seg\u00fan Acuerdo Marco por Procedimiento Abierto elaborado por la \nComunidad Aut\u00f3noma\ufffd  \n3. Junio 2021: Se realiza una reuni\u00f3n con el servicio de Reumatolog\u00eda donde se comunica el resultado del concurso \np\u00fablico.  \n4. Septiembre 2021: Se tramitan los contratos con el proveedor m\u00e1s eficiente. \n5. Septiembre 2021: Se aprueba por la Comisi\u00f3n Farmacoterap\u00e9utica del hospital el uso del IFX m\u00e1s eficiente. \n6. Septiembre 2021: Se realiza una reuni\u00f3n con todos los facultativos y enfermeras de Reumatolog\u00eda donde se acuerda \nla intercambiabilidad de IFX, la elaboraci\u00f3n de un d\u00edptico informativo y la comunicaci\u00f3n de la decisi\u00f3n al paciente por el \nm\u00e9dico prescriptor. Se decide realizar la sustituci\u00f3n a todos los pacientes en su siguiente administraci\u00f3n.  \n7. Septiembre 2021: Se elabora un documento informativo para pacientes que contiene informaci\u00f3n cient\u00edfica que avala \nel uso de biosimilares e informaci\u00f3n econ\u00f3mica\ufffd \n8. Septiembre 2021: Cambio de las prescripciones de pacientes activos.  \n \nImpacto econ\u00f3mico: \nLa selecci\u00f3n del infliximab m\u00e1s eficiente caus\u00f3 la reducci\u00f3n en el coste ponderado de las patolog\u00edas atendidas por el \nServicio de Reumatolog\u00eda. El coste de tratamiento de artritis reumatoide (AR) fue de 2.036 \u20ac, en espondiloartropat\u00edas \n(ESART) fue de 3.123 \u20ac y en artritis psori\u00e1sica (ARPS) de 5. 633 \u20ac en el a\u00f1o 2020, a\u00f1o previo al intercambio. Se redujo el \ncoste en el a\u00f1o 2021, despu\u00e9s del intercambio, a 1.599 \u20ac para AR, 2.223 \u20ac para ESART y 3.231 \u20ac para ARPS. \nEl consumo global de reumatolog\u00eda se redujo de 132.132,55 \u20ac en 2020 a 92.945,21\u20ac en 2021, manteni\u00e9ndose estable en \nn\u00famero de pacientes: 35 en 2020 y 35 en 2021.\nCONCLUSIONES\nConsensuar las estrategias de intercambio de biol\u00f3gicos de referencia o biosimilares menos eficientes con el resto del \nequipo multidisciplinar, que atiende a los pacientes reumatol\u00f3gicos, permiti\u00f3 que todos los profesionales trasmitieran un \nmismo mensaje a los pacientes y se comprometieran con el uso eficiente de los recursos.219CLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1179. REVISI\u00d3N DEL USO DE INMUNOGLOBULINAS INESPEC\u00cdFICAS EN EL CONTEXTO DE \nDESABASTECIMIENTO MUNDIAL \nAUTORES\nNOGU\u00c9 PUJADAS, E; COMA PUNSET , M; D\u00cdEZ VALLEJO, C; VILA CURRIUS, M; CASTELL\u00d3 N\u00d2RIA, \u00c0; ARTIME RODR\u00cdGUEZ-\nHERMIDA, F; GARC\u00cdA RODICIO, S; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nRevisi\u00f3n de los tratamientos con inmunoglobulinas (IG) inespec\u00edficas en dos hospitales de referencia para poder optimizar \nel uso debido al desabastecimiento de estos hemoderivados.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de un a\u00f1o de duraci\u00f3n (abril 2021 \u2013 abril 2022) en dos hospitales de referencia con \ndirecci\u00f3n cl\u00ednica compartida. Se realiz\u00f3 una revisi\u00f3n de todos los tratamientos cr\u00f3nicos (pacientes ambulatorios) y agudos \n(pacientes ingresados) con IG, incluyendo datos demogr\u00e1ficos (edad, peso), indicaci\u00f3n, dosis y posibles alternativas. Se \nclasificaron en 4 categor\u00edas, seg\u00fan grado de evidencia cl\u00ednica: Grupo A - indicaciones incluidas en ficha t\u00e9cnica; Grupo B \n- indicaciones off-label, pero con grado de evidencia alto; Grupo C \u2013 indicaciones off-label con grado de evidencia d\u00e9bil o \nque se desaconseja su uso; Grado E \u2013 no clasificable en las anteriores categor\u00edas.  \nSe consensu\u00f3 con un equipo multidisciplinar (farmac\u00e9uticos, neur\u00f3logos, internistas, neum\u00f3logos, pediatras) las posibles \nalternativas y las pautas a seguir seg\u00fan disponibilidad del producto.\nRESULTADOS\nSe incluyeron un total de 68 pacientes, 38 ambulatorios y 30 ingresados\ufffd De los pacientes ambulatorios, la media de edad \nfue de 49 [10-88] a\u00f1os y el peso medio de 69 [32-97] kg. El 71,1% (n=27) de las indic aciones correspond\u00edan al grupo A \n(66,7% inmunodeficiencia (ID) primaria, 18,5% polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (CIDP), 7,4% miastenia \ngravis (MG), 3,7% p\u00farpura tromb\u00f3tica idiop\u00e1tica (PTI), 3,7% ID adquiridas); 7,9% (n=3) al grupo B (2/3 encefalitis, 1/3 ID \nadquirida); 10,5% (n=4) grupo C (3/4 ID primaria no espec\u00edfica, 1/4 ataxia) y 10,5% (n=4) grupo E (4/4 polimiositis). Solo \n2/38 pacientes estaban tratados con IG subcut\u00e1nea. El consumo total durante el per\u00edodo fue de 27840g. De los pacientes \ncon tratamiento agudo, 21/30 correspond\u00edan al grupo A (47,3% s\u00edndrome Guillan-Barr\u00e9 (SGB), 19,0% MG, 19,0% \nenfermedad de Kawasaki, 14,3% PTI), 2/30 grupo B (vasculitis y lupus eritematoso sist\u00e9mico) y 7/30 grupo E. El consumo \ntotal fue de 2777g. Todos los tratamientos estaban ajustados por peso y en el caso de obesos, por peso ajustado.  \nDespu\u00e9s de una revisi\u00f3n del stock y las especialidades disponibles en el mercado, se consensu\u00f3 con el equipo \nmultidisciplinar: utilizar tratamientos alternativos en los casos demostrados con la misma eficacia (por ejemplo, \nplasmaf\u00e9resis en SGB o rituximab en encefalitis); seguimiento exhaustivo del peso de los pacientes para valorar posibles \najustes de dosis; adquisici\u00f3n a trav\u00e9s de medicamentos en situaciones especiales de una nueva presentaci\u00f3n extranjera \nde IG intravenosa para inicios de tratamientos; reducci\u00f3n de tratamientos con indicaciones off-label.\nCONCLUSIONES\nLa revisi\u00f3n de los tratamientos y el manejo de esta situaci\u00f3n a trav\u00e9s del equipo multidisciplinar ha permitido \nestablecer unas pautas de actuaci\u00f3n consensuadas que han dado soporte en la toma de decisiones a la hora de \ninstaurar un tratamiento. La implementaci\u00f3n de estas pautas ha permitido optimizar el uso del IG en la situaci\u00f3n de \ndesabastecimiento actual\ufffd\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1221. IMPACTO DE LOS ACCESOS GESTIONADOS COMO HERRAMIENTA EN LA INCORPORACI\u00d3N \nSOSTENIBLE DE LA INNOVACI\u00d3N TERAP\u00c9UTICA \nAUTORES\nLIZANO GISPERT , E; ROIG IZQUIERDO, M; SABORIT CANALS, G; PASTOR FABREGAS, M; PONTES GARCIA, C\nSERVICIO CATAL\u00c1N DE LA SALUD\nOBJETIVOS\nAnalizar el impacto de los accesos gestionados vigentes en la incorporaci\u00f3n de la innovaci\u00f3n de medicamentos de \ndispensaci\u00f3n hospitalaria (MHDA) en los dos \u00faltimos a\u00f1os en Catalunya.\nMATERIALES Y M\u00c9TODOS\nA partir de un registro de datos cl\u00ednicos y de la facturaci\u00f3n de Catalunya se identificaron las innovaciones (nuevos \nmedicamentos [NM] o nuevas indicaciones [NI]) introducidas en la prestaci\u00f3n en los periodos 2019 - 2020 y 2020 - \n2021 (an\u00e1lisis de 2020 y de 2021, respectivamente), clasificadas por \u00e1rea terap\u00e9utica. Para los a\u00f1os 2020 y 2021 se \ncuantificaron los pacientes incluidos y los retornos econ\u00f3micos de todos los acuerdos de acceso gestionado (AG) vigentes \n(acuerdos de riesgo compartido financiero [ARCf] y esquemas de pago por resultados [EPR]), implementados por el \nSistema Nacional de Salud (SNS) y el Sistema Catal\u00e1n de Salud.\nRESULTADOS\nEn 2020 y 2021 se introdujeron 73 innovaciones (26 en oncolog\u00eda, 22 en enfermedades minoritarias, 13 en hematolog\u00eda, \n6 en neurolog\u00eda y 6 en otras \u00e1reas) que se utilizaron en 5.861 pacientes (2.426 para 2020 y 3.435 para 2021), con un gasto \npotencial de 74,4 millones de euros (M\u20ac) (47,8M\u20ac para 2020 y 26,6M\u20ac para 2021). 220Los 50 AG vigentes para MHDA en el periodo produjeron un retorno de 48,7M\u20ac en 8.493 pacientes. Los retornos \ncorrespondieron un 39% a hematolog\u00eda, 37% a minoritarias, 23% a oncolog\u00eda y 1% a otras \u00e1reas, para 12, 16, 19 y 1 \nmedicamentos, respectivamente. El 89% de los retornos fueron devoluciones por ARCf (33 acuerdos, 6.416 pacientes) \ny el 11% por EPR (17 acuerdos, 2.077 pacientes); 5 acuerdos inclu\u00edan tanto retornos por ARCf como EPR. El 13% (12 \nmedicamentos) del importe de las devoluciones de los ARCf y el 38% del importe de los EPR (8 medicamentos) fueron de \nacuerdos de \u00e1mbito auton\u00f3mico.  \n \nDe las 73 innovaciones analizadas, 34 fueron introducidas mediante AG, que generaron un retorno de 14M\u20ac, reduciendo \nel gasto en innovaci\u00f3n a 60,4M\u20ac y su impacto del 3% al 2,5% del gasto total en MHDA.\nCONCLUSIONES\nLas \u00e1reas de oncolog\u00eda y hematolog\u00eda suponen el mayor n\u00famero de innovaciones y tambi\u00e9n de AG durante 2020 y 2021. \nLos AG generan retornos relevantes, evidenciando las incertidumbres de impacto y/o resultados en el momento de la \nintroducci\u00f3n en el sistema, y disminuyen el elevado impacto econ\u00f3mico de la incorporaci\u00f3n de innovaciones\ufffd Los AG \nrepresentan herramientas \u00fatiles para gestionar la incertidumbre de la incorporaci\u00f3n de la innovaci\u00f3n terap\u00e9utica y a \nmejorar la sostenibilidad, generando un coste-oportunidad para sufragar el constante incremento del coste de MHDA. La \ngesti\u00f3n del gran n\u00famero de pacientes incluidos en los acuerdos implica costes asociados a la gesti\u00f3n de los AG, que no \nest\u00e1n cuantificados.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1252. USO RACIONAL DE ETELCALCETIDA EN HIPERPARATIROIDISMO SECUNDARIO EN PACIENTES EN \nHEMODI\u00c1LISIS \nAUTORES\nBAJENARU , GT; MART\u00cdN RODR\u00cdGUEZ, M; S\u00c1NCHEZ NAVARRO, IM; FERN\u00c1NDEZ CEBRECOS, I; L\u00d3PEZ M\u00c9NDEZ, P; \nURE\u00d1A AGUILAR, I; NIETO M\u00c1RTIL, E; BALDOMINOS UTRILLA, G\nHOSPITAL UNIVERSITARIO PR\u00cdNCIPE DE ASTURIAS. CTRA. ALCAL\u00c1-MECO, S/N ALCAL\u00c1 DE HENARES. MADRID\nOBJETIVOS\nLa etelcalcetida es un f\u00e1rmaco calcimim\u00e9tico que se introdujo en la gu\u00eda farmacoterap\u00e9utica del hospital como alternativa \nal cinacalcet, para mejorar la adherencia al tratamiento del hiperparatiroidismo (HPT) secundario en pacientes con \nterapia de reemplazo renal.  \nEn nuestro hospital, el uso de etelcalcetida supone m\u00e1s de un 60% del consumo total en la farmacoterapia de estos \npacientes, por lo que el objetivo del estudio es evaluar el uso de este f\u00e1rmaco, comprobando que se cumplan las \nrecomendaciones de ficha t\u00e9cnica (FT) e Informe de Posicionamiento Terap\u00e9utico (IPT) referidas al control anal\u00edtico de \ncalcio (Ca): [8,4-9,5 mg/dL] y paratohormona (PTH): [100-500 pg/mL]. Seg\u00fan recomendaci\u00f3n, los niveles de PTH deben \nmedirse al inicio y cada 1-3 meses durante el mantenimiento, y si la concentraci\u00f3n es < 100 pg/ml, la etelcalcetida debe \ninterrumpirse temporalmente\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de 9 meses de duraci\u00f3n (julio-2021 a marzo-2022). Se incluyen todos los pacientes \nen tratamiento con etelcalcetida por HPT secundario a enfermedad renal cr\u00f3nica en hemodi\u00e1lisis.  \nDatos recogidos: demogr\u00e1ficos (edad, sexo) y cl\u00ednicos (ajustes en la dosificaci\u00f3n en funci\u00f3n de niveles de PTH y calcio \ns\u00e9rico corregido).  \nRecursos materiales: m\u00f3dulo de dispensaci\u00f3n, historia cl\u00ednica electr\u00f3nica, FT disponibles en el Centro de Informaci\u00f3n \nOnline de Medicamentos Autorizados de la Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS) e IPT.\nRESULTADOS\nSe incluyen un total de 54 pacientes, 32 hombres (59%), media de edad 65 a\u00f1os (\u00b116,14). \nSe analiza la adecuaci\u00f3n de la prescripci\u00f3n al inicio seg\u00fan FT e IPT:  \n- Posolog\u00eda: 4/54 (7,4%) pacientes inician etelcalcetida seg\u00fan recomendaciones (5 mg tres veces/semana).  \n- Niveles de Ca: 16/54 (29,6%) pacientes est\u00e1n por debajo del l\u00edmite inferior y a pesar de ello inician etelcalcetida (inicio \nno recomendado por riesgo de prolongaci\u00f3n del segmento QT y arritmia ventricular).  \nSe analiza la adecuaci\u00f3n de la monitorizaci\u00f3n anal\u00edtica:  \n- A 2/54 (3,7%) de los pacientes no se les determinan niveles de Ca a las 4 semanas del inicio para el ajuste posol\u00f3gico, tal \ncomo se recomienda, y en 8/52 (15,4%) pacientes no se realiza ajuste de dosis a pesar de tener niveles de Ca por debajo \ndel l\u00edmite inferior. \n- Niveles de PTH al mes de inicio: En 13/54 (24%) pacientes no se determina la PTH al mes del inicio de tratamiento y en \n1/41 (2.4%) se suspende etelcalcetida por niveles muy inferiores al l\u00edmite inferior de normalidad.  \n- Niveles de PTH a los 3 meses: En 5/54 (9,3%) pacientes no se monitoriza y en 2/49 (4,1%) de los que s\u00ed, se suspende \netecalcetida por niveles bajos.\nCONCLUSIONES\nLa prescripci\u00f3n de etelcalcetida no se adec\u00faa a las recomendaciones de FT e IPT referidas a la dosis inicial y al ajuste \nposol\u00f3gico seg\u00fan control anal\u00edtico de Ca y PTH, con el consiguiente aumento de riesgo cardiovascular en esta poblaci\u00f3n.  \nDesde el Servicio de Farmacia, se crea un circuito de validaci\u00f3n farmac\u00e9utica mensual de todos los pacientes en \ntratamiento con etelcalcetida, para asegurar el cumplimiento de las recomendaciones, garantizar un uso racional del \nf\u00e1rmaco y aumentar la seguridad del paciente.221CLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1264. AN\u00c1LISIS DE EFECTIVIDAD Y SEGURIDAD DE OCRELIZUMAB: DATOS EN VIDA REAL \nAUTORES\nRICOY SANZ, I; MART\u00cdNEZ ALBALADEJO, P; LLOPIS SALVIA, P; POLO DUR\u00c1N, J; GIM\u00c9NEZ GINER, S; LLOPIS ALEMANY , \nA; PEREZ RODR\u00cdGUEZ, A; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEvaluar efectividad y seguridad del tratamiento con ocrelizumab en pacientes con esclerosis multiple (EM) en condiciones \nde pr\u00e1ctica cl\u00ednica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital general. Se incluyeron los pacientes que han recibido al menos una \ndosis de ocrelizumab desde su inclusi\u00f3n en la Gu\u00eda Farmacoterap\u00e9utica (03/2019).  \nVariables descriptivas: Edad, sexo, diagn\u00f3stico (Esclerosis M\u00faltiple Primaria Progresiva (EMPP) versus Esclerosis M\u00faltiple \nRemitente Recurrente (EMRR)), tiempo desde el diagn\u00f3stico hasta inicio de ocrelizumab, l\u00ednea terap\u00e9utica, raz\u00f3n del \ncambio, duraci\u00f3n del tratamiento con ocrelizumab (hasta fin del seguimiento 04/2022), n\u00famero de reca\u00eddas y grado \nde discapacidad funcional (Expanded Disability Status Scale (EDSS)) pre y post-ocrelizumab y, aparici\u00f3n durante el \ntratamiento de nuevas lesiones en la RMN\ufffd  \nVariables resultado-efectividad: pacientes libres de reca\u00edda, sin progresi\u00f3n de la discapacidad (sin aumento del valor \nEDSS) y libres de nuevas lesiones en la RMN.  \nVariables resultado-seguridad: retrasos en la administraci\u00f3n y efectos adversos (EA).  \nLas variables continuas se expresan como mediana (rango intercuart\u00edlico) y las categ\u00f3ricas como frecuencia (%).  \nSe analiz\u00f3 la variaci\u00f3n de reca\u00eddas y EDSS pre-post ocrelizumab mediante test chi cuadrado y Wilcoxon respectivamente. \nNivel de significaci\u00f3n estad\u00edstica p < 0,05 (programa estad\u00edstico R).\nRESULTADOS\nSe incluyeron 28 pacientes (68% mujeres) con 51,0 (11,8) a\u00f1os. El diagn\u00f3stico fue EMRR en 22 (79%) pacientes y EMPP en \n6 (21%), el tiempo hasta el inicio de ocrelizumab fue 14,2 (15,3) a\u00f1os.  \nRecibieron tratamiento con ocrelizumab en 1\u00aa l\u00ednea 6 (21%) pacientes (2 EMPP , 4 EMRR), 22 (79%) en 2\u00aa l\u00ednea y sucesivas \n(4 EMPP , 18 EMRR).  \nLa raz\u00f3n del cambio a ocrelizumab en 15 (54%) pacientes fue el fracaso terap\u00e9utico (progresi\u00f3n cl\u00ednica y/o radiol\u00f3gica), \nen 3 (14%) por EA y en 2 (9%) por seroconversi\u00f3n del virus JC en pacientes tratados previamente con natalizumab.  \nLa duraci\u00f3n del tratamiento con ocrelizumab hasta fin de seguimiento fue 2,5 (1,9) a\u00f1os (3,0 (4,0) ciclos).  \nEn el a\u00f1o previo al inicio de ocrelizumab la tasa de incidencia fue 6 reca\u00eddas por 10 pacientes-a\u00f1o y durante el \ntratamiento con ocrelizumab 1 reca\u00edda por 10 pacientes-a\u00f1o, 22 (78,6%) libres de reca\u00edda. Cuatro pacientes sufrieron una \nreca\u00edda en la primera mitad del primer a\u00f1o de tratamiento y 2 durante el tercer a\u00f1o (p = 0,01).  \nEl valor EDSS pre-ocrelizumab fue de 4,0 (2,4) y post 3,5 (1.9). Dieciocho pacientes (82%) mantienen o mejoran su grado \nde discapacidad (menor o igual EDSS) mientras que 4 (18%) empeoran (mayor EDSS) (p = 0,5).  \nDe los pacientes con RMN de control, 13 (87%) est\u00e1n libres de nuevas lesiones.  \nLos EA m\u00e1s frecuentes fueron: 7 (39%) infecciones (3 SARS-CoV2), 4 (22%) linfopenia, 4 (22%) cefalea y astenia y 3 (17%) \nreacciones infusionales (cut\u00e1neas e HTA). Se produjo retraso en la administraci\u00f3n (n=6) en 2 (22%) pacientes por SARS-\nCoV2 y en 4 (44%) por linfopenia. Ning\u00fan paciente finaliz\u00f3 el tratamiento durante el periodo de seguimiento.\nCONCLUSIONES\nEn los pacientes del estudio ocrelizumab disminuye el n\u00famero de brotes y mantiene el grado de discapacidad funcional \ndurante el tiempo de seguimiento. Los EA se ajustan a los observados en los ensayos cl\u00ednicos.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1265. IMPACTO EN LOS REINGRESOS POR INSUFICIENCIA CARDIACA CONGESTIVA TRAS LA \nINTRODUCCI\u00d3N DE DAPAGLIFOZINA EN LA GU\u00cdA FARMACOTERAP\u00c9UTICA DEL CENTRO \nAUTORES\nP\u00c9REZ MART\u00cdN, CY; BETANCOR GARC\u00cdA, T; \u00c1LVAREZ TOSCO, KI; PLASENCIA GARC\u00cdA, I; ESQUIVEL NEGR\u00cdN, J; SANTOS \nFAGUNDO, A; MERINO ALONSO, FJ\nCOMPLEJO HOSPITAL UNIVERSITARIO NTRA SRA DE CANDELARIA. CTRA. DEL ROSARIO, 145 SANTA CRUZ DE \nTENERIFE \ufffd SANTA CRUZ DE TENERIFE\nOBJETIVOS\nRecientemente se ha incorporado a la gu\u00eda farmacoterap\u00e9utica del hospital la Dapaglifozina (Dap) para el tratamiento de \nla Insuficiencia card\u00edaca congestiva cr\u00f3nica sintom\u00e1tica con fracci\u00f3n de eyecci\u00f3n disminuida. El objetivo del trabajo fue \ndescribir y comparar los pacientes que hab\u00edan iniciado el tratamiento con Dap durante el periodo de febrero a abril de \n2022 con aquellos que no llevaron Dap al alta y cu\u00e1ntos de ellos habr\u00edan sufrido un reingreso en el periodo de un mes \nposterior a ser dado de alta\ufffd\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda de aquellos pacientes que ten\u00edan Dap en su plan de tratamiento y se realiz\u00f3 una revisi\u00f3n de \nhistorias cl\u00ednicas de todos aquellos pacientes que reingresaron en el mes posterior debido a una descompensaci\u00f3n 222de su enfermedad card\u00edaca y se compar\u00f3 con una muestra de pacientes ingresados por el servicio de cardiolog\u00eda con \ninsuficiencia card\u00edaca congestiva que ingresaron y no estaban en tratamiento con Dap. Se realiz\u00f3 un an\u00e1lisis descriptivo a \ntrav\u00e9s de la media para las variables demogr\u00e1ficas num\u00e9ricas o el porcentaje para variables cualitativas como la diabetes \nmellitus tipo 2 (DM2), hipertensi\u00f3n arterial (HTA), enfermedad renal cr\u00f3nica (ERC) y la fracci\u00f3n de eyecci\u00f3n del ventr\u00edculo \nizquierdo (FEVI) disminuida (menos al 50%).  \nLa variable dependiente del estudio fue la presencia de reingreso en el mes siguiente al alta (dicot\u00f3mica).  \nLos an\u00e1lisis se realizaron mediante el programa estad\u00edstico SPSS/PC (versi\u00f3n 28.0 para Windows, SPSS, Inc, Chicago, IL).\nRESULTADOS\nSe incluyeron 149 pacientes con una media de edad de 69,1 [35-90], 64 de ellos ten\u00edan Dap en el plan de tratamiento al \nalta\ufffd  \nEl 47% de los pacientes presentaban DM2, el 30,2% ten\u00edan ERC y el 59,73% de los pacientes ten\u00edan FEVI disminuida.  \nPara nuestra muestra no se observaron diferencias significativas entre el grupo en tratamiento con Dap y el grupo que no \nlo llevaba. (p=0,107). No reingresaron m\u00e1s aquellos que no ten\u00edan pautado Dap.  \nTampoco encontramos relaci\u00f3n significativa entre aquellos que ten\u00edan HTA o ERC con los que reingresaron en el mes \nsiguiente\ufffd \nS\u00ed se encontr\u00f3 que aquellos que ten\u00edan DM2 ten\u00edan m\u00e1s probabilidad de reingresar (p=0,045).\nCONCLUSIONES\nSe observ\u00f3 que los pacientes que ingresaban con ICC y DM2 de manera concomitante ten\u00edan mayor probabilidad de sufrir \nun reingreso hospitalario en el mes posterior al alta. \nEn nuestro estudio no encontramos una disminuci\u00f3n de los reingresos en los pacientes que se encontraban en \ntratamiento con Dap, probablemente debido a la baja muestra que tenemos.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1269. EXPERIENCIA DE USO DE OMALIZUMAB EN EL TRATAMIENTO DE LA URTICARIA CR\u00d3NICA \nESPONT\u00c1NEA \nAUTORES\nPLA PAS\u00c1N, R; HUERTAS FERN\u00c1NDEZ, MJ; TUDELA TOM\u00c1S, J; CORALES PAZ, M; GANFORNINA ANDRADES, A\nHOSPITAL PUERTA DEL MAR \ufffd AV\ufffd ANA DE VIYA, 21 C\u00c1DIZ \ufffd C\u00c1DIZ\nOBJETIVOS\nEl objetivo del estudio fue evaluar la efectividad de omalizumab en la semana 12 (S12) y en la semana 24 (S24) en \npacientes diagnosticados de urticaria cr\u00f3nica espont\u00e1nea (UCE).\nMATERIALES Y M\u00c9TODOS\nOmalizumab est\u00e1 financiado para la UCE como tratamiento adicional en pacientes adultos y adolescentes (a partir de 12 \na\u00f1os) con respuesta inadecuada al tratamiento con antihistam\u00ednicos H1. La dosis recomendada es 300 mg v\u00eda subcut \u00e1nea \nde forma mensual\ufffd  \nEstudio descriptivo retrospectivo que incluy\u00f3 a pacientes diagnosticados de UCE que recibieron tratamiento con \nomalizumab, entre julio-2021 y diciembre-2021.  \nLos datos se obtuvieron de la historia cl\u00ednica digital y del m\u00f3dulo de dispensaci\u00f3n individualizada. Variables: edad, sexo, \ntratamientos previos, posolog\u00eda, efectividad S12, efectividad en la S24, intensificaci\u00f3n (aumento de dosis o disminuci\u00f3n \nde la frecuencia), y optimizaci\u00f3n (disminuci\u00f3n de dosis o aumento de la frecuencia) \nLa efectividad se evalu\u00f3 mediante la escala UCT (Urticarial Control Test) en las semanas 12 (S12) y 24 (S24), clasificando \na los pacientes en tres grupos: respuesta completa (RC) (UCT=16), buena respuesta (BR) (UCT=12-15) y mala respuesta \n(MR) (UCT < 12).\nRESULTADOS\nSe incluyeron 75 pacientes (edad media: 48+/-17 a\u00f1os; sexo: 62,8% mujeres) previamente tratados con antihistam\u00ednicos y \ncorticoides orales. El 49,3% (47/75) recibi\u00f3 anteriormente ciclosporina y el 13,3% (10/75) metotrexato.  \nEl 74,7% (56/75) recibieron la pauta de 300 mg/mensual, consiguiendo el 37,5% (21/56) RC en la S12 y en la S24. En el \n42,9% (9/21) se optimiz\u00f3 la dosis una vez alcanzada la S24.  \nEl 55,3% (31/56), consiguieron BR en la S12. De \u00e9stos, el 29% (9/31) alcanzaron RC en la S24, optimiz\u00e1ndose entonces el \n33,3% (3/9). El 67,7% (21/31) continu\u00f3 con BR a la S24, intensific\u00e1ndose el 28,6% (6/21). \nEl 7,4% (4/54), obtuvo MR en la S12, alcanzando el 75% (3/4) BR en la S24 e intensific\u00e1ndose y el 25% (1/4) \nmanteni\u00e9ndose con MR. \nEl 17,3% (13/75) recibieron tratamiento intensificado, alcanzando el 53,8% (7/13) RC,  \nel 30,8% (4/13) BR, y el 15,4% (2/13) MR en las S12 y S24.  \nEl 4% (6/75) de los pacientes recibieron tratamiento optimizado, alcanzando el 50% (3/6) BR en las S12 y S24, tras lo cual \nintensificaron nuevamente por falta de control de la enfermedad y el 50% (3/6) RC en las S12 y S24.\nCONCLUSIONES\nOmalizumab es un f\u00e1rmaco efectivo que podr\u00eda considerarse una opci\u00f3n de tratamiento adicional en pacientes con UCE \ncon respuesta inadecuada al tratamiento con antihistam\u00ednicos H1. El estudio demuestra la necesidad de la evaluaci\u00f3n de \nla efectividad durante el periodo de tratamiento, ya que un mejor ajuste posol\u00f3gico consigue tasas de respuesta mayores, \npermitiendo un mejor control de la enfermedad y la optimizaci\u00f3n de los recursos.223CLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1284. EVALUACI\u00d3N DE LOS COMPARADORES EMPLEADOS EN LOS ESTUDIOS PIVOTALES DE NUEVOS \nMEDICAMENTOS E INDICACIONES \nAUTORES\nALEGRE DEL REY , EJ; F\u00c9NIX CABALLERO, S; BARREIRO FERN\u00c1NDEZ, E; GIL SIERRA, MD; DOM\u00cdNGUEZ SANTANA, CM; \nMORA CORT\u00c9S, M; D\u00cdAZ NAVARRO, J; BORRERO RUBIO, JM\nHOSPITAL UNIVERSITARIO PUERTO REAL\nOBJETIVOS\nEn ocasiones, los estudios pivotales para aprobar nuevos medicamentos e indicaciones no emplean el comparador m\u00e1s \nadecuado o incluso carecen de dise\u00f1o comparativo. El objetivo es cuantificar la frecuencia de este problema analizando \nlos Informes de Posicionamiento Terap\u00e9utico (IPT) publicados por el Ministerio de Sanidad espa\u00f1ol.\nMATERIALES Y M\u00c9TODOS\nSe tom\u00f3 una muestra aleatoria del 50% de los IPT publicados entre 2013 y marzo de 2022, estratificada por grupos \nterap\u00e9uticos. Los comparadores se clasificaron en seis categor\u00edas: A-\u201cAdecuado\u201d, cuando era tratamiento est\u00e1ndar en \nel momento de aprobarse el nuevo f\u00e1rmaco/indicaci\u00f3n; B-\u201cInicialmente adecuado\u201d, cuando era tratamiento est\u00e1ndar al \niniciar el estudio pero qued\u00f3 posteriormente desbancado; C-\u201cSin comparador por causa \u00e9tica\u201d, caso de nuevas terapias \ncon buenos resultados iniciales para una patolog\u00eda grave sin tratamiento; D-\u201cSin comparador (estudio no controlado)\u201d \nexcluyendo la causa \u00e9tica; E-\u201cInadecuado\u201d, cuando no era tratamiento est\u00e1ndar y F-\u201cParcialmente sub\u00f3ptimo\u201d, cuando \nera est\u00e1ndar para parte de los pacientes incluidos pero no para otros.  \nLa variable principal fue la proporci\u00f3n de nuevos f\u00e1rmacos/indicaciones con comparaci\u00f3n aceptable (categor\u00edas A, B y \nC) o deficiente (el resto). Tambi\u00e9n se analiz\u00f3 la prevalencia de la enfermeded en los casos de ausencia del comparador \n(categor\u00eda D). Se estimaron resultados por a\u00f1o de publicaci\u00f3n del IPT y clasificaci\u00f3n ATC del medicamento.  \nLa informaci\u00f3n sobre comparadores, tratamiento est\u00e1ndar y prevalencia se extrajo de los IPTs analizados; en caso de \nduda se recurri\u00f3 al European Public Assessment Report (EPAR) u otras fuentes cient\u00edficas. Las fechas de aprobaci\u00f3n, inicio \ny fin de los estudios para diferenciar entre las categor\u00edas de \u201cinadecuado\u201d e \u201cinicialmente adecuado\u201d se extrajeron del \nEPAR y de la web clinicaltrials.gov. En caso de varias indicaciones en un IPT, se analiz\u00f3 la m\u00e1s prevalente. Cuando exist\u00edan \nvarios estudios con diferentes comparadores, se valor\u00f3 el comparador m\u00e1s adecuado.\nRESULTADOS\nSe analizaron 186 IPT con nuevos medicamentos o indicaciones. La comparaci\u00f3n se consider\u00f3 aceptable en un 73,7% \n(IC95 66,9-79,5) de los casos, siendo adecuado el comparador (categor\u00eda A) en el 66,1%, inicialmente adecuado (B) \nen el 5,4% y en el 2,2% se carec\u00eda de comparaci\u00f3n por causa \u00e9tica (C). El 26,3% restante (IC95 20,5-33,1) presentaban \ncomparaciones deficientes en el ensayo pivotal, ya fuera por comparador inadecuado (11,3%), parcialmente sub\u00f3ptimo \n(5,4%) o ausencia de un estudio comparativo excluyendo la justificaci\u00f3n \u00e9tica (9,7%). La proporci\u00f3n de comparaciones \naceptables oscil\u00f3 entre el 56% y el 75% anual, sin una tendencia apreciable a lo largo del tiempo. El grupo terap\u00e9utico \ncon m\u00e1s IPT fue el de antineopl\u00e1sicos (L01, N=72), con un 75,0% (IC95 63,9-83,6) de comparaciones aceptables. De los \nf\u00e1rmacos con estudio no controlado, el 58% (11/19) correspondi\u00f3 al tratamiento de enfermedades ultrarraras (menos de \n2 pacientes/100.000 habitantes).\nCONCLUSIONES\nAproximadamente uno de cada cuatro nuevos medicamentos o indicaciones carece de una comparaci\u00f3n suficiente en \nel momento de empezar a ser utilizado en la pr\u00e1ctica cl\u00ednica. La proporci\u00f3n no mejora a lo largo de los \u00faltimos 10 a\u00f1os. \nEn pocos casos, este problema podr\u00eda tener justificaci\u00f3n por tratarse de una enfermedad ultrarrara y la dificultad de \nencontrar pacientes para el estudio\ufffd\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1286. EVALUACI\u00d3N DE LA ADECUACI\u00d3N, EFECTIVIDAD Y SEGURIDAD DEL ANT\u00cdDOTO IDARUCIZUMAB \nEN REVERSI\u00d3N URGENTE DE ANTICOAGULACI\u00d3N EN UN HOSPITAL TERCIARIO. \nAUTORES\nRU\u00cdZ MART\u00cdNEZ, D; P\u00c9REZ RODR\u00cdGUEZ, A; ZAPATER GARC\u00cdA, A; LLOPIS ALEMANY , A; GIM\u00c9NEZ GINER, S; CAMPILLOS \nALONSO, P; CERC\u00d3S LLET\u00cd, AC; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEvaluar la adecuaci\u00f3n, efectividad y seguridad del ant\u00eddoto idarucizumab en los pacientes en tratamiento con dabigatr\u00e1n \ncuando es necesaria una reversi\u00f3n de sus efectos anticoagulantes en un hospital terciario.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional, retrospectivo desde enero de 2016 hasta abril de 2022. Se realiz\u00f3 una b\u00fasqueda en el \ngestor de historia cl\u00ednica electr\u00f3nica por prescripci\u00f3n de idarucizumab y se revisaron las historias cl\u00ednicas de los pacientes \ntratados\ufffd  \n \nSe recogieron datos de sexo, edad, filtrado glomerular estimado (CKD-EPI mL/min/1,73m2), indicaci\u00f3n y posolog\u00eda de \ndabigatr\u00e1n, tiempo desde la \u00faltima dosis dabigatr\u00e1n hasta administraci\u00f3n de idarucizumab, indicaci\u00f3n de idarucizumab, \nadecuaci\u00f3n a indicaci\u00f3n en ficha t\u00e9cnica, adecuaci\u00f3n a recomendaciones de uso seg\u00fan Comisi\u00f3n de Farmacia y 224Terap\u00e9utica (CFyT) ( < 12h desde \u00faltima dosis de anticoagulante o insuficiencia renal), n\u00famero de administraciones, \nvalores anal\u00edticos de hemostasia (TTPa, TT) pre y post administraci\u00f3n y tiempo hasta an\u00e1lisis de hemostasia, reinicio de \nanticoagulaci\u00f3n y tiempo hasta reinicio de terapia anticoagulante. \n \nLas variables con las que se evalu\u00f3 la efectividad fueron la recuperaci\u00f3n de la hemostasia (normalizaci\u00f3n de TTPa o TT), \nla recuperaci\u00f3n cl\u00ednica de la hemostasia, el tiempo hasta la recuperaci\u00f3n anal\u00edtica y/o cl\u00ednica notificada y la necesidad de \nmedidas complementarias hemost\u00e1ticas.  \n \nLa seguridad se evalu\u00f3 con el registro de reacciones adversas a la administraci\u00f3n\ufffd  \n \nLas variables categ\u00f3ricas se expresaron con frecuencias (%) y las cuantitativas con la mediana y el rango intercuart\u00edlico \n(RIQ).\nRESULTADOS\n17 pacientes (70,6%), edad 81 a\u00f1os [77-86,5] y filtrado glomerular estimado (CKD-EPI) de 50 ml/min/1,73m2 [37,5-75]. El \n100% compart\u00eda el diagn\u00f3stico de fibrilaci\u00f3n auricular como indicaci\u00f3n de dabigatr\u00e1n, 15 (88,2%) con dosis de 110 mg / \n12h y 2 (11,7%) 150 mg / 12h. El tiempo desde la \u00faltima dosis de an ticoagulante fue de 10h [6-12h].  \n \nLa indicaci\u00f3n de idarucizumab fue en 8 (47,1%) hemorragia no controlada y 9 (52,9%) cirug\u00eda o procedimiento urgente, \nsiendo ambas recogidas en ficha t\u00e9cnica. 16 pacientes (94,1%) cumplieron las recomendaciones de CFyT del hospital. \nTodos los pacientes recibieron una dosis \u00fanica de 5g de idarucizumab.  \n \nEl valor de TTPa pre administraci\u00f3n fue de 46,9 [40,8-64,3] y el post, medido en 13 pacientes, de 31,05 [24,3-33,95]. \nSe analiz\u00f3 la hemostasia post-administraci\u00f3n en 5h [4-30], 14 (82,3%) pacientes permanecieron en seguimiento en el \nhospital, 12 (70,5%) de los cuales reiniciaron la terapia anticoagulante (11 HBPM, 1 dabigatr\u00e1n) en un tiempo de 2 d\u00edas \n[1-4 d\u00edas].  \n \n16/17 pacientes (94,1%) mostraron signos cl\u00ednicos de recuperaci\u00f3n hemost\u00e1tica. En 13/17 (76,5%) se midi\u00f3 la hemostasia \npost-administraci\u00f3n observ\u00e1ndose una normalizaci\u00f3n del TTPa (TT en uno de los pacientes) en 10/13 (76,9%), con un \ntiempo hasta la recuperaci\u00f3n hemost\u00e1sica reportada de 5h [1,5-24]. Solo 3 (17,6%) pacientes requirieron administraci\u00f3n \nde concentrados de hemat\u00edes y 1 (5,8%) la transfusi\u00f3n de plasma fresco.  \n \nNinguno de los pacientes present\u00f3 reacciones adversas a la administraci\u00f3n\ufffd\nCONCLUSIONES\nEl ant\u00eddoto idarucizumab ha sido usado de acuerdo a indicaciones recogidas en ficha t\u00e9cnica y recomendaciones de \nCFyT. Ha conseguido resultados satisfactorios en cuanto a efectividad y seguridad en los pacientes en tratamiento con \ndabigatr\u00e1n que requirieron una reversi\u00f3n de sus efectos anticoagulantes en nuestro hospital.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1315. EXPERIENCIA DE USO DE FREMANEZUMAB EN EL TRATAMIENTO DE LA MIGRA\u00d1A CR\u00d3NICA Y \nEPIS\u00d3DICA \nAUTORES\nPLA PAS\u00c1N, R; MENGUIANO ROMERO, Y; S\u00c1NCHEZ LOB\u00d3N, I; RODR\u00cdGUEZ MORETA, C; TUDELA TOM\u00c1S, J\nHOSPITAL PUERTA DEL MAR \ufffd AV\ufffd ANA DE VIYA, 21 C\u00c1DIZ \ufffd C\u00c1DIZ\nOBJETIVOS\nEvaluar la efectividad y seguridad de fremanezumab en pacientes diagnosticados de migra\u00f1a cr\u00f3nica o epis\u00f3dica a los 3 \nmeses y a los 6 meses\nMATERIALES Y M\u00c9TODOS\nFremanezumab es un anticuerpo monoclonal humanizado (IgG2) que se une al p\u00e9ptido relacionado con el gen de la \ncalcitonina (CGRP). Est\u00e1 financiado en pacientes con 8 o m\u00e1s d\u00edas de migra\u00f1a/mes (migra\u00f1a epis\u00f3dica de alta frecuencia y \nen pacientes con migra\u00f1a cr\u00f3nica). La La dosis recomendada es de 225 mg de fremanezumab inyectado (v\u00eda subcut\u00e1nea) \nuna vez al mes (pauta mensual) \u00f3 675 mg cada tres meses (pauta trimestral).  \n \nSe realiz\u00f3 un estudio descriptivo retrospectivo que incluy\u00f3 a los pacientes diagnosticados de migra\u00f1a cr\u00f3nica o epis\u00f3dica \nque recibieron tratamiento con fremanezumab entre abril-2021 y abril-2022. Los criterios cl\u00ednicos requeridos para el \ninicio del tratamiento fueron: tres o m\u00e1s fracasos a tratamiento previos utilizados a dosis suficientes durante al menos 3 \nmeses, siendo uno de estos tratamientos toxina botul\u00ednica en el caso de migra\u00f1a cr\u00f3nica. \nLos datos se obtuvieron de la historia cl\u00ednica digital y del m\u00f3dulo de dispensaci\u00f3n individualizada. Se recogieron las \nsiguientes variables: sexo, edad, tipo de migra\u00f1a, tratamientos previos, eficacia a los 3 y a los 6 meses y reacciones \nadversas a la medicaci\u00f3n\ufffd  \nLa efectividad se evalu\u00f3 mediante la reducci\u00f3n en el n\u00famero e intensidad de las crisis. Se consideraron respondedores \naquellos pacientes que consiguieron una reducci\u00f3n de al menos el 50% a los 3 meses y que adem\u00e1s la manten\u00edan a los 6 \nmeses. La seguridad se valor\u00f3 mediante la aparici\u00f3n de efectos adversos (EA) graves225RESULTADOS\nSe incluyeron 49 pacientes diagnosticados de migra\u00f1a cr\u00f3nica o epis\u00f3dica (edad media: 46 +/-10 a\u00f1os; sexo: 83,7% \nmujeres); 4 fueron excluidos por no haber alcanzado los 6 meses de tratamiento. El 15,6% (7/45) fueron diagnosticados \nde migra\u00f1a epis\u00f3dica, frente al 84,4 % (38/45). Todos hab\u00edan sido tratados con al menos tres tratamientos previos. \nAdem\u00e1s el 10,2% (5/49) recibi\u00f3 tratamiento biol\u00f3gico con erenumab y el 2% (1/49) con galcanezumab.  \nEl 26,7% (12/45) no refirieron no notar mejor\u00eda en el n\u00famero ni la intensidad a los 3 meses, alcanzando el 8,3% (1/12) \nuna reducci\u00f3n de m\u00e1s del 50% a los 6 meses. De \u00e9stos, el 41,7 (5/12) realizaron un cambio de tratamiento a erenumab y \nel 8,3 (1/12) a galcanezumab  \nEl 11,% (5/45) de los pacientes lograron una reducci\u00f3n del 30% a los 3 meses, el 26,7% (12/45) lograron una reducci\u00f3n \nentre el 30-60%, y el 35,6% (16/45) una reducci\u00f3n superior al 60%. Esto se mantuvo a los 6 meses.  \nUn paciente manifest\u00f3 peque\u00f1os espasmos musculares desde que recibi\u00f3 el tratamiento, otro un incremento del \nestre\u00f1imiento y un tercer paciente inestabilidad y ptosis palpebral a las horas de la administraci\u00f3n.\nCONCLUSIONES\nFremanezumab es un f\u00e1rmaco efectivo que podr\u00eda considerarse una opci\u00f3n de tratamiento en pacientes con migra\u00f1a \ncr\u00f3nica y epis\u00f3dica. Su uso es seguro con un perfil de EA manejable.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n1317. AN\u00c1LISIS EN VIDA REAL DE LA EFICACIA DE NUEVOS TRATAMIENTOS COVID-19 EN UN HOSPITAL \nDE 3 NIVEL. \nAUTORES\nMART\u00cdN CASADO, L; ROMERO GONZ\u00c1LEZ, M; MARTIN FERN\u00c1NDEZ, N; SANDOVAL FERNANDEZ DEL CASTILLO, S; \nBELTR\u00c1N GARC\u00cdA, M\nCOMPLEJO HOSPITALARIO REGIONAL VIRGEN MACARENA. AV . DOCTOR FEDRIANI, 3 SEVILLA. SEVILLA\nOBJETIVOS\n1-Analizar la eficacia en vida real de los nuevos tratamientos disponibles para pacientes con Covid-19 -antivirales y \nanticuerpos monoclonales-.  \n2- Describir las caracter\u00edsticas de los pacientes en los que se ha prescrito este tipo de tratamientos y su adecuaci\u00f3n a los \ncriterios de priorizaci\u00f3n del Ministerio.\nMATERIALES Y M\u00c9TODOS\nSe defini\u00f3 tratamiento nuevo para Covid-19 (TNC): Molnupinavir, Remdesivir en pauta de 3 d\u00edas, Sotrovimab y Ronapreve. \nSe seleccionaron todos los pacientes con prescripci\u00f3n de alg\u00fan TNC en nuestra \u00e1rea sanitaria, desde 1 diciembre 2021 \nhasta 10 mayo 2022. El \u00e1rea sanitaria atiende a una poblaci\u00f3n de 481.296 pacientes. Se revisaron variables demogr\u00e1ficas, \ncl\u00ednicas y relacionadas con el tratamiento prescrito, as\u00ed como la evoluci\u00f3n de la infecci\u00f3n covid-19 hasta el final del \nestudio\ufffd  \nSe cre\u00f3 una base de datos en Excel para analizar los resultados. Las variables cualitativas se expresaron en porcentajes y \nlas cuantitativas en media y desviaci\u00f3n t\u00edpica.\nRESULTADOS\nSe analizaron un total de 44 pacientes con infecci\u00f3n covid-19, 61% hombres, con edad media de 62+-7, a los que se le \nprescribi\u00f3 alguno de los TNC: 33 pac (75%) con antivirales (17 con Molnupinavir y 16 con Remdesivir), 10 (22,7%) con \nAnticuerpos Monoclonales: 1 Ronapreve y 9 Sotrovimab y 1 (2%) con terapia combinada: Sotrovimab + Molnupinavir. \nLos pacientes en los que se prescribi\u00f3 alguno de estos f\u00e1rmacos estaban incluidos en los criterios de priorizaci\u00f3n de \nla AEMyPS: 37 (84%) en grupo 1, 3 en grupo 2 y 4 en grupo 3. Den tro del grupo 1 la indicaci\u00f3n m\u00e1s frecuente fue: 15 \n(40,5%) pacientes inmunocomprometidas por Transplante de \u00f3rgano s\u00f3lido y tratamiento inmunosupresor, 10 (27%) \ncon tratamiento activo con quimioterapia mielot\u00f3xica para enfermedades oncol\u00f3gicas o hematol\u00f3gicas, 9 (24%) con \ntratamiento inmunosupresor con nmunomoduladoires biol\u00f3gicos \u20135 con Anticuerpos monoclonales antiCD20, 2 con \ninhibidores de proliferaci\u00f3n de c\u00e9lulas B, 1 con Anticuerpos monoclonales antiCD52 y 1 con moduladores del receptor de \nla esfingosina-1-fosfato-, 3 en tratamiento sustitutivo renal (hemodi\u00e1lisis).  \nAl inicio del tratamiento, s\u00f3lo se detectaron 4 pacientes (9%) en situaci\u00f3n de gravedad e iniciaron todos tratamiento con \nSotrovimab, en 1 caso adem\u00e1s se a\u00f1adi\u00f3 tambi\u00e9n Molnupinavir. De estos, s\u00f3lo en 1 caso se produjo un \u00e9xitus. El resto de \nlos pacientes, 40 (91%), todos ten\u00eda una enfermedad leve-moderada y evolucionaron favorablemente. Si bien es verdad \nque los pacientes donde se inici\u00f3 el tratamiento con Sotrovimab en un 60% estaban en fase covid leve-moderado y los \nque iniciaron con Molnupinavir fue un 94%. Hay que tener en cuenta que la mediana de seguimiento fue de 2 meses (0-5 \nmeses).\nCONCLUSIONES\nLa eficacia en vida real de estos tratamientos observada en nuestros pacientes en relaci\u00f3n a mejor\u00eda cl\u00ednica y no \nnecesidad de hospitalizaci\u00f3n es superior a la descrita en ensayos cl\u00ednicos. Sin embargo hay que tener en cuenta el \npeque\u00f1o tama\u00f1o de muestra y el corto periodo de seguimiento en algunos pacientes.226CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n58. EFECTIVIDAD Y SEGURIDAD DE COLIRIO DE CICLOSPORINA EN VEH\u00cdCULO ACUOSO (L\u00c1GRIMAS \nARTIFICIALES) \nAUTORES\nBUSTELO PAZ, F; D\u00c1VILA POUSA, MC; BARCA DIEZ, C; PROUPIN CANTELAR, IC; FRANCO SANDAR, B; GONZ\u00c1LEZ \nFREIRE, L; BOULLOSA LALE, S; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA\nOBJETIVOS\nLa ciclosporina es utilizada por v\u00eda t\u00f3pica en oftalmolog\u00eda como tratamiento de la queratoconjuntivitis y del rechazo tras \nqueratoplastia. En Espa\u00f1a est\u00e1 comercializada al 0,1% (Ikervis\u00ae), mientras que concentraciones comprendidas entre \n0,25% y 2% deben elaborarse como f\u00f3rmula magistral\ufffd  \nInicialmente los colirios de ciclosporina se elaboraban a partir de la soluci\u00f3n comercial Sandimmun Neoral\u00ae en veh\u00edculos \noleosos, presentando problemas de intolerancia. Nuestro servicio elabora dicho colirio en veh\u00edculo acuoso seg\u00fan la \nf\u00f3rmula descrita por Fiscella RG et al\ufffd  \nEl objetivo del trabajo fue evaluar la efectividad y el perfil de tolerancia de esta formulaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo descriptivo que incluy\u00f3 todos los pacientes tratados con distintas concentraciones de Ciclosporina \ncolirio en el \u00e1rea sanitaria. Los colirios con concentraciones 0,05, 0,1, 0,25, 0,5 y 1% se elaboraron en el servicio de \nfarmacia con Sandimmun\u00ae ampollas 50mg/mL y alcohol polivinilico 1,4% (Liquifilm\u00ae) como veh\u00edculo.  \nPara la recogida de datos se utiliz\u00f3 el programa inform\u00e1tico de farmacotecnia (Pharmasuite\u00ae) y la revisi\u00f3n de la \nhistoria cl\u00ednica electr\u00f3nica (IANUS\u00ae). Las variables registradas fueron edad, sexo, dosis, duraci\u00f3n de tratamiento y uso \nconcomitante con corticoides. Las variables cuantitativas se expresaron como mediana y percentiles 25 y 75, mientras \nque las cualitativas se expresaron mediante porcentajes. \nLa efectividad se valor\u00f3 en funci\u00f3n de la continuidad del tratamiento en el per\u00edodo de estudio, la reducci\u00f3n paulatina de \ndosis y la posibilidad de monoterapia, abandonando el tratamiento con corticoides t\u00f3picos.  \nLa evaluaci\u00f3n de la seguridad se efectu\u00f3 mediante el registro de efectos adversos definidos como m\u00e1s comunes seg\u00fan \nficha t\u00e9cnica: dolor en lugar de instilaci\u00f3n, eritema palpebral y aumento del lagrimeo.\nRESULTADOS\nSe trataron un total de 8 pacientes (7 mujeres y un var\u00f3n). La mediana de edad fue 49 a\u00f1os (27-85). La mediana de \nduraci\u00f3n del tratamiento fue de 12,5 meses (6-29). Las indicaciones por las cuales se recibi\u00f3 el f\u00e1rmaco fueron profilaxis \ndel rechazo tras queratoplastia (2 pacientes) y queratoconjuntivitis v\u00edrica (6 pacientes). \nEntre los pacientes sometidos a queratoplastia, 1 contin\u00faa con ciclosporina al 1% mientras que el otro consigui\u00f3 reducir \ndosis hasta 0,1%. De los pacientes con queratoconjuntivitis v\u00edrica, 3 finalizaron tratamiento por buena evoluci\u00f3n cl\u00ednica, 2 \ncontin\u00faan actualmente con Ikervis\u00ae y 1 contin\u00faa con dosis al 1%.  \nLos 8 pacientes utilizaron concomitantemente colirios con corticoides y solo en uno de ellos se consigui\u00f3 suspender el \ntratamiento tras una pauta descendente de \u00e9stos.  \nNo se describieron reacciones adversas relevantes en 7 de los pacientes a estudio\ufffd En el paciente restante se describi\u00f3 un \nepisodio de picor relacionado con la ciclosporina con posterior remisi\u00f3n espont\u00e1nea.\nCONCLUSIONES\nLa reducci\u00f3n de dosis y la continuidad de tratamiento observada en el estudio parecen reflejar la efectividad cl\u00ednica \ndel colirio de ciclosporina en soluci\u00f3n acuosa. El tratamiento tambi\u00e9n se mostr\u00f3 seguro , dada la ausencia de eventos \nadversos en 7 de los pacientes y el car\u00e1cter leve de la reacci\u00f3n adversa documentada en el paciente restante.  \nSon necesarios futuros estudios prospectivos dirigidos a comparar el uso de ciclosporina + corticoides frente a corticoides \nen monoterapia, valorando una posible reducci\u00f3n en la dosis de \u00e9stos.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n78. ESTUDIO DE DISPERSI\u00d3N DE MEDICAMENTOS PELIGROSOS ORALES PARA ADMINISTRACI\u00d3N \nINMEDIATA \nAUTORES\nLIZONDO L\u00d3PEZ, T; GONZ\u00c1LEZ SU\u00c1REZ, S; TORRENT RODR\u00cdGUEZ, A; L\u00d3PEZ CABEZAS, C; FERN\u00c1NDEZ HERN\u00c1NDEZ, \nN; GEN\u00c9 SALLA, S; ESCOL\u00c0 RODR\u00cdGUEZ, A; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEn ocasiones es inevitable que el personal de enfermer\u00eda tenga que fraccionar o triturar medicamentos para facilitar \nla administraci\u00f3n por sonda o para pacientes con dificultades de degluci\u00f3n. Existe bibliograf\u00eda que recoge alternativas \na la trituraci\u00f3n de los medicamentos peligrosos (MP) orales. Entre estas alternativas se encuentra la dispersi\u00f3n del \ncomprimido o c\u00e1psula en agua dentro de una jeringa para su uso inmediato, utilizando equipos de protecci\u00f3n individual \n(EPIs) que garanticen la protecci\u00f3n del manipulador.  \n 227El objetivo del estudio es obtener informaci\u00f3n sobre la dispersi\u00f3n en agua de medicamentos peligrosos orales para \nfacilitar su administraci\u00f3n en pacientes con dificultades para la degluci\u00f3n o sonda nasog\u00e1strica, sin necesidad de triturar.\nMATERIALES Y M\u00c9TODOS\nSe revis\u00f3 la bibliograf\u00eda existente sobre alternativas a la trituraci\u00f3n de MP orales. Se identificaron 13 medicamentos con \ncriterios de MP incluidos en la gu\u00eda farmacoterap\u00e9utica del hospital, de los cuales no se encontr\u00f3 informaci\u00f3n sobre \ndispersi\u00f3n: cabozantinib 40 miligramos (mg), encorafenib 75mg, fingolimod 0,5mg, idelalisib 100mg, mifepristona 200mg, \nniraparib 100mg, noretisterona 10mg, raloxifeno 60mg, ribociclib 200mg, teriflunomida 14mg, tofacitinib 5mg, trametinib \n2mg y venetoclax 10mg. Todos se presentan en forma de comprimidos, excepto encorafenib, fingolimod y niraparib, que \nson c\u00e1psulas de gelatina dura. \nEl ensayo se realiz\u00f3 en el laboratorio de Farmacotecnia, utilizando EPIs y bajo cabina de filtraci\u00f3n de gases clase I \nCRUMA\u00ae. Los comprimidos sin triturar, o el contenido de las c\u00e1psulas, seg\u00fan el caso, se introdujeron en el cuerpo de una \njeringa de 20 mL con 10 mL de agua purificada a temperatura ambiente, agitando peri\u00f3dicamente durante un tiempo \nm\u00e1ximo de 10 minutos. Se consider\u00f3 el ensayo positivo para aquellos f\u00e1rmacos que se disgregaron completamente en las \ncondiciones de estudio, sin dejar grumos ni residuos en las paredes de la jeringa, generando una suspensi\u00f3n homog\u00e9nea.  \nEn el caso de los f\u00e1rmacos que no se dispersaron en las condiciones anteriormente descritas, se realiz\u00f3 un segundo \nensayo con agua tibia (45-50\u00baC).\nRESULTADOS\nDe los MP a estudio, 10 (83,33%) se dispersaron en menos de 10 minutos con 10 mL de agua purificada a temperatura \nambiente. Concretamente, cabozantinib, fingolimod, mifepristona, niraparib, noretisterona, teriflunomida y trametinib se \ndispersaron en menos de tres minutos, idelalisib y tofacitinib entre 3 y 5 minutos, y raloxifeno entre 5 y 10 minutos.  \nPor otra parte, ribociclib 200 mg se consigui\u00f3 dispersar correctamente en 10 mL de agua tibia, mientras que encorafenib \n75mg y venetoclax 10mg no se disgregaron adecuadamente en ninguna de las condiciones de estudio\ufffd\nCONCLUSIONES\nCabozantinib, fingolimod, idelalisib, mifepristona, niraparib, noretisterona, raloxifeno, teriflunomida, tofacitinib, \ntrametinib y venetoclax se dispersaron f\u00e1cilmente en agua a temperatura ambiente; para el ribociclib fue necesario \nutilizar agua tibia. En todos los casos se form\u00f3 una suspensi\u00f3n extempor\u00e1nea apta para su administraci\u00f3n inmediata. Con \nencorafenib y venetoclax el resultado no fue satisfactorio.  \n \nLa continua entrada en el mercado de nuevos f\u00e1rmacos considerados MP , hace necesaria una actualizaci\u00f3n peri\u00f3dica de \nla informaci\u00f3n sobre dispersi\u00f3n en agua para evitar la exposici\u00f3n innecesaria del personal de enfermer\u00eda.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n86. ENSAYO IN VITRO DE FORMACI\u00d3N DE UN FARMACOBEZOAR TRAS LA INGESTA MASIVA DE \nCOMPRIMIDOS DE \u00c1CIDO VALPROICO DE LIBERACI\u00d3N PROLONGADA \nAUTORES\nLIZONDO L\u00d3PEZ, T; SALGADO GARC\u00cdA, E; GONZ\u00c1LEZ SU\u00c1REZ, S; JULI\u00c1N PE\u00d1A, J; L\u00d3PEZ CABEZAS, C; RICO SANTANA, \nN; TORRENT RODR\u00cdGUEZ, A; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa sobreingesta de f\u00e1rmacos de liberaci\u00f3n prolongada se ha relacionado con la formaci\u00f3n de farmacobezoares \nestomacales, que pueden causar toxicidad retardada. Adem\u00e1s, en presencia de estos conglomerados, las sondas \nutilizadas habitualmente para la realizaci\u00f3n del lavado g\u00e1strico son ineficaces. \nEl objetivo de este estudio es evaluar mediante un ensayo in vitro la posible formaci\u00f3n y posterior desintegraci\u00f3n de un \nfarmacobezoar, a prop\u00f3sito de un caso de ingesta masiva de comprimidos de \u00e1cido valproico de liberaci\u00f3n retardada.\nMATERIALES Y M\u00c9TODOS\nEn el laboratorio de Farmacotecnia se prepar\u00f3 un fluido g\u00e1strico simulado (FGS) mezclando 2g de cloruro s\u00f3dico y 80mL \nde \u00e1cido clorh\u00eddrico 1M, disueltos en 1L de agua destilada, con un pH objetivo de 1,2. El FGS se verti\u00f3 en un recipiente \nde vidrio en agitaci\u00f3n magn\u00e9tica [30 revoluciones por minuto y 37\u00baC, durante 24h]. En \u00e9l se introdujo una malla de \npoli\u00e9ster con 47 comprimidos de liberaci\u00f3n prolongada de \u00e1cido valproico 500 mg (cantidad ingerida por la paciente) y \nse anud\u00f3 a una varilla de vidrio para asegurar la inmersi\u00f3n completa de los comprimidos. A los 30 minutos, 1h, 2h, 4h, \n8h, 12h y 24h se observ\u00f3 la formaci\u00f3n del conglomerado midiendo su tama\u00f1o, se comprob\u00f3 el pH de la soluci\u00f3n y se \ndetermin\u00f3 la concentraci\u00f3n de \u00e1cido valproico disuelto (inmunoensayo turbidim\u00e9trico, Atellica\u00ae Solution CH 930). Las \nconcentraciones obtenidas se compararon con las concentraciones s\u00e9ricas de \u00e1cido valproico medidas en la paciente \ndurante la intoxicaci\u00f3n\ufffd\nRESULTADOS\nEl FGS formulado result\u00f3 ser una soluci\u00f3n transparente con un pH entre 1-1,5. A partir de las 2h de inmersi\u00f3n de los \ncomprimidos en el FGS, se apreci\u00f3 la formaci\u00f3n de un farmacobezoar firme de 5x6 cm de tama\u00f1o, que permaneci\u00f3 \npr\u00e1cticamente constante durante todo el experimento, al igual que el pH de la soluci\u00f3n. Las concentraciones de \u00e1cido \nvalproico medidas en el FGS fueron: 381,5 \u00b5g/mL (30 min), 767,6 \u00b5g/mL (1h), 976,1 \u00b5g/mL (2h), 1136,4 \u00b5g/mL (4h), \n1131,4 \u00b5g/mL (8h), 1259 \u00b5g/mL (12h) y 1559,8 \u00b5g/mL (24h). Al comparar esta curva con las concentraciones plasm\u00e1ticas \nde \u00e1cido valproico halladas en la paciente, se observ\u00f3 que el pico m\u00e1ximo de la concentraci\u00f3n en sangre se dio a las 24h 228de la ingesta (656 \u00b5g/mL), que coincidi\u00f3 con el tiempo del pico m\u00e1ximo observado en el FGS. Hay que tener en cuenta \nque el tmax esperado para el \u00e1cido valproico de liberaci\u00f3n retardada es de 10-12h.\nCONCLUSIONES\nEste experimento ha permitido verificar la hip\u00f3tesis de formaci\u00f3n de un farmacobezoar tras la sobreingesta de \ncomprimidos de \u00e1cido valproico de liberaci\u00f3n retardada. El experimento tambi\u00e9n ha permitido comprobar que la \nformaci\u00f3n del farmacobezoar produce un retraso en la liberaci\u00f3n de \u00e1cido valproico, respecto a lo esperado para esta \nforma farmac\u00e9utica.  \nDesde el punto de vista de manejo toxicol\u00f3gico, es importante conocer qu\u00e9 formulaciones de f\u00e1rmacos pueden ocasionar \nla formaci\u00f3n de farmacobezoares, para valorar el m\u00e9todo de descontaminaci\u00f3n digestiva m\u00e1s adecuado, y prever el \ncomportamiento de las concentraciones s\u00e9ricas del f\u00e1rmaco.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n95. FORMULACI\u00d3N DE C\u00c1PSULAS PARA LA DESENSIBILIZACI\u00d3N A PROGEST\u00c1GENOS EN PACIENTES CON \nHIPERSENSIBILIDAD A PROGESTERONA END\u00d3GENA \nAUTORES\nTORRENT RODR\u00cdGUEZ, A; RIB\u00d3 GONZ\u00c1LEZ, P; LIZONDO L\u00d3PEZ, T; L\u00d3PEZ CABEZAS, C; GONZ\u00c1LEZ SU\u00c1REZ, S; ARANDA \nCORT\u00c9S, L; CASAS SAUCEDO, R; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa hipersensibilidad end\u00f3gena a progesterona puede originar reacciones dermatol\u00f3gicas coincidentes con la elevaci\u00f3n de \nniveles de progesterona la semana anterior a la menstruaci\u00f3n, con afectaci\u00f3n importante para la calidad de vida de las \npacientes que la padecen.  \nEl objetivo es describir el desarrollo y formulaci\u00f3n de un protocolo de desensibilizaci\u00f3n oral a desogestrel para una \npaciente con hipersensibilidad a progesterona end\u00f3gena.\nMATERIALES Y M\u00c9TODOS\nMujer de 40 a\u00f1os que, desde su tercer embarazo, presenta lesiones en forma de p\u00e1pulas eritematosas y algunas ves\u00edculas \nque dejan lesi\u00f3n residual coincidentes con el ciclo ov\u00e1rico. Las pruebas cut\u00e1neas a progesterona resultan positivas, por lo \nque se plantea de forma conjunta con ginecolog\u00eda la supresi\u00f3n de la ovulaci\u00f3n con progesterona sint\u00e9tica (desogestrel), \nprevia desensibilizaci\u00f3n.  \nEl servicio de Alergolog\u00eda propone a Farmacia la elaboraci\u00f3n de un protocolo de 11 d\u00edas de duraci\u00f3n, con una dosis inicial \nde 0,27 mcg, incrementando progresivamente hasta la dosis terap\u00e9utica de 75 mcg. Los 7 primeros d\u00edas la dosis diaria se \ndividi\u00f3 en dos tomas, seg\u00fan la siguiente pauta:  \nD\u00eda 1: 0,27 mcg (0,09 mcg + 0,18 mcg); D\u00eda 2: 1,08 mcg (0,18 mcg + 0,9 mcg); D\u00eda 3: 2,7 mcg (0,9 mcg + 1,8 mcg); D\u00eda 4: \n5,4 mcg (2,7 mcg + 2,7 mcg); D\u00eda 5, 6 y 7: 9,1 mcg (3,6 mcg + 5,5 mcg); D\u00eda 8: 18,4 mcg; D\u00eda 9 y 10: 37,5 mcg; D\u00eda 11: 75 \nmcg\ufffd\nRESULTADOS\nDebido a la insolubilidad del principio activo, el Servicio de Farmacia opt\u00f3 por la formulaci\u00f3n de c\u00e1psulas de cuatro \ndosis diferentes: 0,09 mcg, 0,9 mcg, 4,6 mcg y 37,5 mcg. Para resolver el problema de la dosificaci\u00f3n en las 3 dosis m\u00e1s \npeque\u00f1as, se prepararon tres diluciones madre de tres concentraciones distintas (0,009 mcgg/mg, 0,09 mcg/mg y 0,46 \nmcg/mg) a partir de comprimidos de desogestrel, que se trituraron y diluyeron con celulosa microcristalina, en diluci\u00f3n \ngeom\u00e9trica mezclando durante 20 minutos para asegurar homogeneizaci\u00f3n. Posteriormente, se dosificaron 10 mg de la \nmezcla correspondiente en cada c\u00e1psula para obtener las dosis deseadas.  \nLas c\u00e1psulas se elaboraron en cabina de filtraci\u00f3n de gases Cruma\u00ae clase I con equipos de protecci\u00f3n individual \nadecuados para la manipulaci\u00f3n de medicamentos peligrosos. Se realiz\u00f3 ensayo de uniformidad de masa como control de \nproducto final.  \nEl protocolo de desensibilizaci\u00f3n a desogestrel fue tolerado correctamente por la paciente, que finaliz\u00f3 la pauta sin \nmostrar nuevas lesiones cut\u00e1neas. La paciente ha continuado el tratamiento diario con desogestrel 75 mcg, que ha \npermitido eliminar la sintomatolog\u00eda derivada de los picos de progesterona durante el ciclo menstrual.\nCONCLUSIONES\nEl protocolo de desensibilizaci\u00f3n oral a desogestrel en c\u00e1psulas fue exitoso y permiti\u00f3 continuar con el tratamiento \nanovulatorio sin incidencias\ufffd  \nLa desensibilizaci\u00f3n a principios activos con dosis muy peque\u00f1as y baja solubilidad supone un reto para su formulaci\u00f3n en \nel servicio de Farmacia\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n110. REFORMULACI\u00d3N DE SIROLIMUS T\u00d3PICO: ESTABILIDAD QU\u00cdMICA, F\u00cdSICA Y MICROBIOL\u00d3GICA \nAUTORES\nCORTELL FUSTER, C; MART\u00cdNEZ G\u00d3MEZ, MA; CERC\u00d3S LLETI, AC; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nOptimizar la formulaci\u00f3n de sirolimus 0,4% para el tratamiento de los angiofibromas faciales en esclerosis tuberosa y \ndeterminar del periodo de validez (estabilidad f\u00edsica, qu\u00edmica y microbiol\u00f3gica) de las formulaciones propuestas.229MATERIALES Y M\u00c9TODOS\nSe prepararon 4 formulaciones de sirolimus 0,4%\ufffd  \nInstalaciones y equipo: CSB con EPI para el manipulador. \nEnvasado y conservaci\u00f3n: frasco 20g, temperatura 2-8\u00baC.  \n \na)Pomada: sirolimus 0,4%, transcutol-P 10%, lanolina 10%, manteca de karit\u00e9 20%, VitaminaE 1%, vaselina c.s.p. 20g.  \nb)Emulsi\u00f3n: sirolimus 0,4%, transcutol-P 10%, base de absorci\u00f3n W/O 20%, API c.s.p. 20 g  \nc)Gel: sirolimus 0,4%, transcutol-P 10%, hidroxipropilmetilcelulosa 2%, API c.s.p. 20g.  \nc)Liposomas: sirolimus 0,4%, transcutol-P 10%, soluci\u00f3n liposomal 25%, colesterol 0,1%, miristrato de isopropilo 10%, \npropilenglicol 10%, carbopol 2%, NaOH 10% c\ufffds\ufffdp\ufffd pH 7,5, API c\ufffds\ufffdp\ufffd 20g\ufffd  \n \n1. Estabilidad qu\u00edmica:  \nSe desarroll\u00f3 y valid\u00f3 un m\u00e9todo anal\u00edtico basado en la extracci\u00f3n l\u00edquido-l\u00edquido de sir\u00f3limus con solventes apolares y \nan\u00e1lisis mediante cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n con detecci\u00f3n ultravioleta/visible. Se determin\u00f3 el porcentaje \nde contenido de sir\u00f3limus remanente (%CR) para todas las formulaciones a t=0, 2, 14, 21, 28, 42 y 56 d\u00edas, y el T90, \ncuando %CR fue \u2264 90%.  \n \n2. Estabilidad f\u00edsica:  \nSe determin\u00f3 el pH con tiras reactivas a t=0 (Formulario Nacional, procedimiento normalizado de control de producto, \nPN/L/CP/001/00). \nSe evaluaron propiedades gal\u00e9nicas como uniformidad, extensibilidad, ausencia de cristales, ausencia de separaci\u00f3n \nde fases a t=0 d\u00edas seg\u00fan 3 niveles: nivel 1, el menos favorable y nivel 3, el m\u00e1s favorable (Gu\u00eda de buenas pr\u00e1cticas de \npreparaci\u00f3n de medicamentos en servicios de farmacia hospitalaria, 2014). \n \n3\ufffd Estabilidad microbiol\u00f3gica: \nSe sembraron e incubaron a 37\u00baC todas las formulaciones en agar sangre a t=28 y 56 d\u00edas.\nRESULTADOS\n1. Estabilidad qu\u00edmica: \nEl %CR a t=56 d\u00edas fue: pomada: 89,45 \u00b1 8,67; emulsi\u00f3n: 83,85 \u00b1 31,49; g el: 97,14 \u00b1 2,70; liposomas: 107,51 \u00b1 21,12.  \nEl T90 se alcanz\u00f3 durante el periodo de muestreo para las formulaciones pomada, emulsi\u00f3n y gel: T90=56, 14 y 21 d\u00edas, \nrespectivamente. \n \n2. Estabilidad f\u00edsica:  \na)Pomada: pH: 7.0; uniformidad, nivel 2; extensibilidad, nivel 1; ausencia de cristales, nivel 3; ausencia de separaciones \nde fases, nivel 3\ufffd  \nc)Emulsi\u00f3n: pH: 6.0; uniformidad, nivel 3; extensibilidad, nivel 2; ausencia de cristales, nivel 3; ausencia de separaciones \nde fases, nivel 1\ufffd \na)Gel: pH: 6.0; uniformidad, nivel 3; extensibilidad, nivel 3; ausencia de cristales, nivel 1; ausencia de separaciones de \nfases, nivel 3\ufffd \na)Liposomas: pH: 7.5; uniformidad, nivel 3; extensibilidad, nivel 3; ausencia de cristales, nivel 3; ausencia de separaciones \nde fases, nivel 3\ufffd \n \n2\ufffd Estabilidad microbiol\u00f3gica:  \nLos cultivos fueron negativos para las 4 formulaciones a t= 28 y 56 d\u00edas.\nCONCLUSIONES\n\u00danicamente la formulaci\u00f3n de liposomas mantuvo la estabilidad qu\u00edmica, f\u00edsica y microbiol\u00f3gica a lo largo del periodo de \nmuestreo. El periodo de validez para cada formulaci\u00f3n fue: pomada: 42 d\u00edas; emulsi\u00f3n: 7 d\u00edas; gel: 14 d\u00edas; liposomas: \n56 d\u00edas. Despu\u00e9s de la mejora gal\u00e9nica y la confirmaci\u00f3n de la idoneidad de los liposomas, se requieren m\u00e1s estudios \ndermocin\u00e9ticos y cl\u00ednicos para asegurar la efectividad, seguridad y satisfacci\u00f3n de los pacientes con la formulaci\u00f3n.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n152. IMPACTO DE LA FORMULACI\u00d3N MAGISTRAL SOBRE EL USO DE SONDAS PARA ADMINISTRACI\u00d3N \nENTERAL \nAUTORES\nMONCADA , AK; MART\u00cdNEZ SANTANA, V; CLOT SILLA, E; FIGUEIREDO ESCRIB\u00c1, C; FERN\u00c1NDEZ LASTRA, C; VIDAL \nSAMS\u00d3, J; MARI\u00d1O HERN\u00c1NDEZ, EL; MODAMIO CHARLES, P\nINSTITUT GUTTMANN \ufffd CAMI CAN RUTI, S/N BADALONA \ufffd BARCELONA\nOBJETIVOS\nAnalizar el impacto que tiene la elaboraci\u00f3n de f\u00f3rmulas magistrales l\u00edquidas (FML) sobre el uso sondas empleadas para \nla administraci\u00f3n enteral\ufffd230MATERIALES Y M\u00c9TODOS\nEstudio cuasi-experimental realizado en el Servicio de Farmacia de un hospital monogr\u00e1fico de neurorrehabilitaci\u00f3n. La \nelaboraci\u00f3n de FML se implement\u00f3 en 2021, de manera que en 2020 se dispensaban formas s\u00f3lidas para administraci\u00f3n \npor sonda. Se seleccionaron todos los pacientes ingresados en 2020 y 2021. Los pacientes sin prescripci\u00f3n m\u00e9dica fueron \nexcluidos del estudio\ufffd  \nSe registr\u00f3 la medicaci\u00f3n administrada por paciente y se analiz\u00f3 considerando la clasificaci\u00f3n cl\u00ednica de ingreso de los \npacientes (lesi\u00f3n medular (LM), da\u00f1o cerebral (DC), da\u00f1o cerebral no traum\u00e1tico (DCNT) / enfermedades progresivas (EP) \no secuelas de poliomielitis (P)) y unidad de hospitalizaci\u00f3n (UH). Los datos fueron analizados con el programa estad\u00edstico \nR versi\u00f3n 4.1.1. Los datos cualitativos se presentaron como frecuencias absolutas y porcentajes y los cuantitativos como \nmedia \u00b1 desviaci\u00f3n est\u00e1ndar. Se estableci\u00f3 significaci\u00f3n estad\u00edstica con p < 0,05. Se realiz\u00f3 la prueba de chi cuadrado para \nestablecer la relaci\u00f3n entre FML y sondas\ufffd\nRESULTADOS\nSe incluyeron 245 pacientes; 110 pacientes en 2020 y 135 en 2021, con una edad media de 45,1\u00b117,7 a\u00f1os y de \n44,6\u00b119,2 a\u00f1os, respectivamente. Seg\u00fan diagn\u00f3stico, 127 pacientes ingresaron por DCNT/EP , 76 por DC, 39 por LM, y 3 \npor P . La proporci\u00f3n hombre:mujer aproximada fue 3:1 (73% hombres).  \nSe dispensaron un total de 5928 medicamentos para administrar por sonda; 2605 en 2020 en forma s\u00f3lida vs\ufffd 3323 en \n2021 en forma l\u00edquida, con un consumo total de 273 sondas en 2020 vs. 325 en 2021 (p > 0,05). En funci\u00f3n de la UH se \nconsumieron: UH1, 529 vs. 339 medicamentos y 46 vs. 63 sondas, p < 0,05; UH2, 542 vs. 811 y 55 vs. 58, p > 0,05; UH4, \n566 vs. 1022 y 43 vs. 74, p > 0,05 y UH5, 543 vs. 855 y 100 vs. 92, p < 0,05, quir\u00f3fano 425 vs. 296 y 29 vs. 38, p < 0,05. \nSe administraron 570 vs. 302 medicamentos por sonda en LM, p < 0,05; 758 vs. 1130 en TCE, p < 0,05; 1255 vs. 1876 en \nDCNT, p < 0,05 y 22 vs. 15 en P , p=0,05.  \nLa implementaci\u00f3n de la formulaci\u00f3n magistral produjo un incremento en la administraci\u00f3n de f\u00e1rmacos por sonda en \npacientes con TCE y DCNT, mientras que en LM una disminuci\u00f3n. La intervenci\u00f3n supuso una disminuci\u00f3n significativa en \nel consumo de sondas en la UH5, pero no en la UH1 y quir\u00f3fano, por lo que se deber\u00eda estudiar la diferencia de pacientes \ny f\u00e1rmacos utilizados en cada UH.\nCONCLUSIONES\nNo se pudo demostrar que la elaboraci\u00f3n de FML tenga impacto sobre el consumo de sondas para administraci\u00f3n enteral; \nno se podr\u00eda inferir que la elaboraci\u00f3n magistral de formas l\u00edquidas optimice la administraci\u00f3n enteral de f\u00e1rmacos. \nSugerimos un estudio que contemple m\u00e1s aspectos que ayuden a esclarecer los diferentes resultados de las UHs.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n171. ESTABILIDAD F\u00cdSICO-QU\u00cdMICA DE UNA MEZCLA DE TRAMADOL, DEXKETOPROFENO Y METADONA \nEN DOS TIPOS DE INFUSORES ELASTOM\u00c9RICOS \nAUTORES\nL\u00d3PEZ CABEZAS, C; MARC\u00c9 BRIANS\u00d3, M; GONZ\u00c1LEZ SU\u00c1REZ, S; CEAMANOS RENOM, S; B\u00c1GUENA POLO, J; TORRENT \nRODR\u00cdGUEZ, A; BROTO PUIG, F; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEvaluar la compatibilidad f\u00edsicoqu\u00edmica a 14 d\u00edas de una mezcla para analgesia postoperatoria multimodal intravenosa en \ndos tipos diferentes de infusores elastom\u00e9ricos\nMATERIALES Y M\u00c9TODOS\nMezclas a estudio:  \nE1: Tramadol hidrocloruro 0,5mg/mL + Dexketoprofeno 1mg/mL + Metadona hidrocloruro 0,04mg/mL en suero \nfisiol\u00f3gico (SF), en elast\u00f3meros con reservorio de silicona (Autofuser 100 mL) \nE2: Tramadol hidrocloruro 0,4mg/mL + Dexketoprofeno 0,8mg/mL + Metadona hidrocloruro 0,04mg/mL en suero \nfisiol\u00f3gico (SF), en elast\u00f3meros con reservorio de poliisopropeno (Multirate Infusor Baxter LV 240 mL) \n \nSe prepararon 3 lotes de cada mezcla en cabina de flujo laminar a partir de los productos comercializados. Todas las \nmuestras se conservaron a temperatura ambiente (22-25\u00b0C) con bolsa fotoprotectora, y se testaron inmediatamente \ndespu\u00e9s de la preparaci\u00f3n (t0), y a las 24h, 7 y 14 d\u00edas postpreparaci\u00f3n.  \nSe estudiaron las siguientes variables: i) compatibilidad f\u00edsica: cambio de color y precipitaci\u00f3n (cualitativa), turbidez \n(cuantitativa, nefelometr\u00eda); ii) compatibilidad qu\u00edmica: pH (potenciometr\u00eda) y porcentaje de recuperaci\u00f3n de los \nf\u00e1rmacos en los tiempos estudiados (UHPLC-DAD, Acquity H UHPLC Class\u00ae).  \nPara el estudio cromatogr\u00e1fico se utilizaron dos m\u00e9todos UHPLC-DAD desarrollados y validados previamente en \nnuestras condiciones de laboratorio (coeficiente de variaci\u00f3n: CV < 1%; linealidad: 0,5-500mg/L (r2 > 0,999) con \nun l\u00edmite de detecci\u00f3n a 215nm entre 0,1-0,3mg/L). Se usaron dos columnas de fase reversa Acquity HSS-C18 \n(100mm\u00d72,1mm\u00d71,8\u00b5m) y Acquity BEH-C18 (100mm\u00d72,1mm\u00d71,7\u00b5m). Las c ondiciones cromatogr\u00e1ficas fueron: i) fase \nm\u00f3vil: acetonitrilo/agua en modo gradiente, ajustando el pH mediante una mezcla de \u00e1cido f\u00f3rmico/formiato de amonio \n(pH \u00e1cido) o formiato de amonio/amon\u00edaco (pH b\u00e1sico); ii) caudal: 0,025 mL/min; iii) volumen de inyecci\u00f3n: 2,0\u00b5L; iv) \n\u03bb=215nm. Se realiz\u00f3 degradaci\u00f3n forzada (HCl 1M,80\u00b0C; NaOH 1M,80\u00b0C; H2O2 15%,TA) para descartar interferencias con \nposibles productos de degradaci\u00f3n\ufffd231RESULTADOS\nEn las mezclas analizadas a las 24h, 7 y 14 d\u00edas postpreparaci\u00f3n no se observaron cambios de color, precipitaci\u00f3n o \nturbidez respecto t0. El pH permaneci\u00f3 estable durante la duraci\u00f3n del estudio, manteni\u00e9ndose en el intervalo 7,04-7,30 \npara todas las mezclas. Sin embargo, el estudio cromatogr\u00e1fico mostr\u00f3 un porcentaje de recuperaci\u00f3n a los 14 d\u00edas entre \n90-110% (96-107%) para tramadol y dexketoprofeno, pero para metadona el porcentaje de recuperaci\u00f3n oscilaba entre \n30-67%, siendo la p\u00e9rdida apreciable desde el inicio, y ligeramente m\u00e1s r\u00e1pida en el elast\u00f3mero E1 (% recuperaci\u00f3n \nt24h=57(E1) vs 67(E2)). En un estudio previo en que el contenedor eran bolsas de polipropileno de SF 100 mL no se \nobserv\u00f3 esta disminuci\u00f3n de la concentraci\u00f3n de metadona. Realizando extracciones con metanol de los elast\u00f3meros E1 \ny E2 se ha podido demostrar un fen\u00f3meno de adsorci\u00f3n a las paredes del recipiente, m\u00e1s acusado en E1 (concentraci\u00f3n \nmetadona: 0,020mg/mL(E1); 0,006mg/mL(E2)).\nCONCLUSIONES\nLa mezcla de tramadol y dexketoprofeno a las concentraciones descritas, en los dos elast\u00f3meros estudiados, se ha \nmostrado f\u00edsica y qu\u00edmicamente estable en las condiciones de estudio (14 d\u00edas a temperatura ambiente, en SF y \nprotegidas de la luz).  \nLa mezcla de tramadol, dexketoprofeno y metadona no es estable en las condiciones descritas en este estudio, debido a \nla adsorci\u00f3n de la metadona a las paredes del elast\u00f3mero; y por tanto, no se recomienda su uso en la pr\u00e1ctica cl\u00ednica.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n234. ESTABILIDAD MICROBIOL\u00d3GICA DE NITROPRUSIATO S\u00d3DICO 600 \u039cG/ML JERINGA \nINTRACAVERNOSA \nAUTORES\nGARC\u00cdA MART\u00cdN, E; BARRO ORDOV\u00c1S, JP; ANAYA GARC\u00cdA, J; SERRANO GARC\u00cdA, M; GARC\u00cdA DE SANTIAGO, B; \nPORTILLO HORCAJADA, L; GARC\u00cdA YUBERO, C; MART\u00cdNEZ HERN\u00c1NDEZ, A\nHOSPITAL INFANTA SOF\u00cdA \ufffd PASEO DE EUROPA, 34 SAN SEBASTI\u00c1N DE LOS REYES \ufffd MADRID\nOBJETIVOS\nEl nitroprusiato s\u00f3dico se utiliza para el tratamiento de la disfunci\u00f3n er\u00e9ctil tras prostatectom\u00eda radical refractaria al \ntratamiento con inhibidores PDE5 y/o intolerancia al tratamiento intracavernoso con pGE1 (erecciones dolorosas). El \nmecanismo de acci\u00f3n del f\u00e1rmaco se basa en la reducci\u00f3n del calcio intracelular y relajaci\u00f3n muscular.  \nLa finalidad del estudi\u00f3 fue establecer la estabilidad microbiol\u00f3gica a 26 semanas de jeringas de nitroprusiato s\u00f3dico \nintracavernosas (600 \u00b5g/ml) con el objetivo de ampliar el tiempo de almacenamiento.\nMATERIALES Y M\u00c9TODOS\nSe prepararon un total de 13 jeringas intracavernosas de nitroprusiato s\u00f3dico 600 \u00b5g/ml. Se acondicionaron en jeringas \nde 3ml luer-lock compuestas por polipropileno, polietileno y caucho sint\u00e9tico lubricado, no conten\u00edan pir\u00f3genos, l\u00e1tex, \nDEHP , PVC ni t\u00f3xicos\ufffd  \nLa elaboraci\u00f3n de la f\u00f3rmula se llev\u00f3 a cabo en cabina de flujo laminar horizontal. Como material de partida se emple\u00f3 \ncloruro s\u00f3dico 0,9% y nitroprusiato s\u00f3dico especialidad comercializada (Nitroprussiat Fides\u00ae 50 mg polvo y disolvente \npara soluci\u00f3n inyectable). Se conservan a temperatura ambiente y protegido de la luz (bolsa fotoprotectora). En estas \ncondiciones la estabilidad fue de 45 d\u00edas. Para su administraci\u00f3n se emplean aguja de 30G.  \nPara el estudio de estabilidad microbiol\u00f3gica se envi\u00f3 una muestra cada 2 semanas, hasta completar el per\u00edodo de 26 \nsemanas, al Servicio de Microbiolog\u00eda y se proces\u00f3 de la siguiente forma: se sembr\u00f3 en dos medios s\u00f3lidos: agar sangre \n(COS) y agar chocolate (PVX) y un medio l\u00edquido: caldo tioglicolato (TG). Se incubaron a 37\u00baC con atm\u00f3sfera de 5% de CO2 \ndurante 48 horas. La lectura de las placas a las 48 horas se consider\u00f3 negativa ante la ausencia de bacterias, mientras \nque el crecimiento en las placas conllev\u00f3 identificaci\u00f3n del microorganismo. Si el crecimiento tuvo lugar en el caldo TG se \nrealiz\u00f3 un subcultivo en placas de COS y PVX y se procedi\u00f3 como se ha detallado anteriormente.\nRESULTADOS\nEn el estudio microbiol\u00f3gico no se observ\u00f3 crecimiento microbiano en ninguna muestra analizada durante las 26 \nsemanas, por lo que todas las muestras cumplieron los criterios de aceptaci\u00f3n de calidad microbiol\u00f3gica para f\u00f3rmulas \nmagistrales est\u00e9riles hasta tiempo final.  \nTampoco se observaron cambios de aspecto durante el per\u00edodo analizado.\nCONCLUSIONES\nLas jeringas intracavernosas de nitroprusiato s\u00f3dico 600 \u00b5g/ml almacenadas a temperatura ambiente y protegidas de \nla luz durante 26 semanas fueron microbiol\u00f3gicamente estables. La limitaci\u00f3n de su uso vendr\u00e1 determinada por la \nestabilidad fisicoqu\u00edmica en este periodo.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n268. DESARROLLO GAL\u00c9NICO, EFECTIVIDAD Y SEGURIDAD DE GENTAMICINA SULFATO 0,5% F\u00d3RMULA \nMAGISTRAL T\u00d3PICA EN EL TRATAMIENTO DE LA ENFERMEDAD DE HAILEY-HAILEY . \nAUTORES\nGONZ\u00c1LEZ G\u00d3MEZ, \u00c1; ALONSO P\u00c9REZ, L; HERN\u00c1NDEZ RAMOS, JA; CASTRO FRONTI\u00d1\u00c1N, A; MAYO OLVEIRA, F; \nMONS\u00c1LVEZ HONRUBIA, V; FERRARI PIQUERO, JM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID232OBJETIVOS\nDise\u00f1ar y elaborar una f\u00f3rmula magistral de gentamicina sulfato para el tratamiento de una paciente con enfermedad de \nHailey-Hailey (EHH) que no respondi\u00f3 a otras terapias previas. Secundariamente, describir la efectividad y seguridad de la \nmisma\ufffd\nMATERIALES Y M\u00c9TODOS\nSe llev\u00f3 a cabo una b\u00fasqueda bibliogr\u00e1fica para evaluar las propiedades fisicoqu\u00edmicas de la gentamicina sulfato as\u00ed como \npara seleccionar la forma farmac\u00e9utica m\u00e1s adecuada para la paciente. La estabilidad de la f\u00f3rmula fue determinada \naplicando la matriz de riesgo incluida en la gu\u00eda de buenas pr\u00e1cticas de preparaci\u00f3n de medicamentos para servicios de \nfarmacia hospitalaria. Se evaluaron las propiedades gal\u00e9nicas tales como apariencia, extensibilidad, separaci\u00f3n de fases \ny caracter\u00edsticas organol\u00e9pticas de acuerdo al procedimiento normalizado de elaboraci\u00f3n de pomadas del Formulario \nNacional. La pomada se administr\u00f3 a la paciente con una posolog\u00eda de 1 aplicaci\u00f3n cada 12 horas y se hizo seguimiento \ndurante 6 meses con controles en el mes 1, 3 y 6\ufffd\nRESULTADOS\nLa gentamicina sulfato se presenta como un polvo blanco, higrosc\u00f3pico. Es soluble en agua e insoluble en alcohol \ny acetona. La paciente presentaba lesiones erosivas tipo fisura con halo eritematoso, algunas de ellas con costras \nhemorr\u00e1gicas superpuestas en todos los pliegues cut\u00e1neos. Por esta raz\u00f3n se eligi\u00f3 como forma farmac\u00e9utica una \npomada hidroabsorbente. El desarrollo gal\u00e9nico consisti\u00f3 en la diluci\u00f3n de 0,25 g de gentamicina sulfato en agua est\u00e9ril, \nque se vehiculiz\u00f3 con 3,75 g de lanolina. Posteriormente la lanolina se emulsion\u00f3 con vaselina filante hasta obtener \nun peso total de 50 g. La concentraci\u00f3n final de gentamicina sulfato fue del 0,5%. La preparaci\u00f3n fue almacenada a \ntemperatura ambiente y protegida de la luz, estableci\u00e9ndose una caducidad de 30 d\u00edas. En cuanto a la eficacia del \ntratamiento, se sigui\u00f3 la evoluci\u00f3n cl\u00ednica durante 6 meses. Tras 4 semanas de tratamiento se observ\u00f3 la resoluci\u00f3n \ntotal de las lesiones a nivel submamario y disminuci\u00f3n en el tama\u00f1o de las lesiones axilares, hueco antecubital y \nfosas popl\u00edpteas. En el tercer mes se observ\u00f3 la resoluci\u00f3n total de todas las lesiones, permitiendo reducir la dosis \nde apremilast que recib\u00eda de forma concomitante. A los 6 meses la respuesta cl\u00ednica se mantuvo y no se observaron \nreacciones adversas al tratamiento\ufffd\nCONCLUSIONES\nLa f\u00f3rmula magistral de gentamicina sulfato al 0,5% elaborada cumple con los criterios para su aplicaci\u00f3n por v\u00eda t\u00f3pica y \nes una alternativa favorable para el tratamiento de la EHH.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n340. AN\u00c1LISIS DE LAS COMPLICACIONES M\u00c1S FRECUENTES EN PACIENTES CON NUTRICI\u00d3N PARENTERAL \nDOMICILIARIA EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nRODR\u00cdGUEZ TIERNO, S; PINTOR RECUENCO, MDR; GUIJARRO MART\u00cdNEZ, P; P\u00c9REZ MEN\u00c9NDEZ-CONDE, C; G\u00d3MEZ \nDE SALAZAR L\u00d3PEZ DE SILANES, ME; VEGA PI\u00d1ERO, MB; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nAnalizar las complicaciones m\u00e1s frecuentes que sufren los pacientes con Nutrici\u00f3n Parenteral Domiciliaria (NPD), y \ndescribir el perfil de paciente incluido en este programa.\nMATERIALES Y M\u00c9TODOS\nEstudio longitudinal retrospectivo realizado en pacientes con NPD en un periodo de tres a\u00f1os (2019, 2020 y 2021) en \nun hospital de tercer nivel. Los datos se obtuvieron de la Historia Cl\u00ednica Electr\u00f3nica y del programa de prescripci\u00f3n de \nnutrici\u00f3n parenteral. Se revis\u00f3: sexo, edad, antecedentes m\u00e9dicos, motivo de inicio, complicaciones, reingresos tanto \nprogramados por la patolog\u00eda de base como urgentes no programados, tiempo con la NPD, suspensi\u00f3n temporal y/o \ndefinitiva de la NPD y motivo de dicha suspensi\u00f3n. Las variables cuantitativas se expresaron como media m\u00e1s desviaci\u00f3n \nt\u00edpica o mediana m\u00e1s rango intercuart\u00edlico (RIQ) y las variables cualitativas como porcentaje.\nRESULTADOS\nFueron estudiados 23 pacientes, 56% mujeres y 44% hombres. La media de edad fue de 55 a\u00f1os \u00b1 11. El 96% de los \npacientes presentaban patolog\u00eda oncol\u00f3gica, siendo m\u00e1s frecuentes los carcinomas de colon y g\u00e1stricos (22%). Solo un \npaciente presentaba como patolog\u00eda esclerosis peritoneal idiop\u00e1tica. El motivo de inicio de la NPD fue la carcinomatosis \nperitoneal en un 35% de los casos, seguido de oclusi\u00f3n intestinal y s\u00edndrome de intestino corto (17%).  \n \nUn 78% de los pacientes sufrieron complicaciones relacionadas con la NPD, siendo las m\u00e1s frecuentes: infecciones (61%), \nde las cuales 72% fueron bacteriemias asociadas a Staphylococcus epidermidis y 28% candidemias, seguidas de trastornos \nhematol\u00f3gicos (33%), como trombosis peri-cat\u00e9ter, trombosis venosa profunda y tromboembolismo pulmonar. Tambi\u00e9n \nse registraron molestias y enrojecimiento del punto de inserci\u00f3n del cat\u00e9ter (28%) y edemas e hinchaz\u00f3n (22%). En menor \nmedida se registr\u00f3 alg\u00fan caso de obstrucci\u00f3n de cat\u00e9ter, rotura de cat\u00e9ter y reacciones al\u00e9rgicas cut\u00e1neas (5%).  \n \nUn 70% de los pacientes ingresaron; de estos, solo un 8% programados por la patolog\u00eda de base. De los no programados, \nel 56% fue por causas relacionadas con la NPD \ufffd Un 52% de los pacientes sufrieron suspensi\u00f3n temporal de la NPD, de \nlos cuales en un 75% la causa fue una complicaci\u00f3n asociada a la misma, ya que hubo necesidad de retirada del cat\u00e9ter 233venoso por trombosis y/o infecci\u00f3n. La mediana de duraci\u00f3n de la NPD fue de 200 d\u00edas (RIQ 121-1226). El principal \nmotivo de suspensi\u00f3n de la NPD fue \u00e9xitus (56%). Un 35% de pacientes segu\u00edan en activo al terminar el periodo de \nestudio y solo dos pacientes (8%) suspendieron el tratamiento por recuperaci\u00f3n de la tolerancia oral.\nCONCLUSIONES\nLa mayor\u00eda de los pacientes incluidos dentro del programa de NPD son pacientes con patolog\u00eda oncol\u00f3gica asociada a \ncarcinomatosis peritoneal secundaria a su enfermedad\ufffd  \n \nUn alto porcentaje de pacientes con NPD sufre complicaciones, fundamentalmente infecciones y episodios de trombosis. \nLa mayor\u00eda est\u00e1n relacionadas con el cat\u00e9ter venoso central y muchas de ellas son causa de ingreso hospitalario, incluso \nde \u00e9xitus.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n355. DESARROLLO GALENICO DE UNA CREMA DE COLISTINA 0,1% PARA EL TRATAMIENTO TOPICO DE \nPSEUDOMONAS MULTIRRESISTENTES EN ULCERAS POR PRESION \nAUTORES\nPROUPIN CANTELAR, IC; DAVILA POUSA, MC; FRANCO SANDAR, B; BUSTELO PAZ, F; BARCA DIEZ, C; GONZALEZ \nFREIRE, L; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA\nOBJETIVOS\nEl tratamiento de las infecciones por Pseudomonas se ha visto influenciado por un gran incremento de bacterias \nmultirresistentes. Las escasas posibilidades terap\u00e9uticas junto con algunos problemas de suministro de f\u00e1rmacos, como el \nceftolozano-tazobactam, nos han llevado a buscar alternativas para el tratamiento de estas infecciones.  \nLa colistina es un polip\u00e9ptido c\u00edclico, perteneciente al grupo de las polimixinas, que act\u00faa da\u00f1ando la membrana \ncelular de bacterias aerobias Gram-negativas. Su administraci\u00f3n v\u00eda sist\u00e9mica requiere un aumento de dosis para lograr \nconcentraciones efectivas a nivel de \u00falceras, aumentando as\u00ed el riesgo de nefrotoxidad.  \nEl objetivo de este trabajo es desarrollar una f\u00f3rmula magistral (FM) de colistina t\u00f3pica para el tratamiento de infecciones \npor Pseudomonas multirresistentes en \u00falceras.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica para evaluar las propiedades fisicoqu\u00edmicas y organol\u00e9pticas de la colistina. \nSe revisaron las concentraciones descritas para su uso t\u00f3pico, seleccion\u00e1ndose colistina al 0,1% por sus numerosas \nreferencias en la literatura cient\u00edfica. \nPara el desarrollo gal\u00e9nico y validaci\u00f3n de la f\u00f3rmula, se realizaron ensayos y controles siguiendo el procedimiento de \nelaboraci\u00f3n de emulsiones del Formulario Nacional, evaluando los caracteres organol\u00e9pticos y determinando el signo de \nla emulsi\u00f3n seg\u00fan el procedimiento PN/L/FF/002/00. \nPara establecer el per\u00edodo de validez, se siguieron las recomendaciones de la \u201cGu\u00eda de buenas pr\u00e1cticas de preparaci\u00f3n \nde medicamentos en los servicios de farmacia hospitalaria\u201d.\nRESULTADOS\nSe seleccion\u00f3 la presentaci\u00f3n comercial parenteral de colistimetato de sodio 2 millones de unidades internacionales, \nequivalentes a 160 mg. El colistimetato de sodio es un polvo de color blanco a blanquecino soluble en agua, por lo \nque se adicion\u00f3 a la fase acuosa, reconstituyendo cada vial con 10 mL de agua est\u00e9ril. Se incluy\u00f3 Nipagin s\u00f3dico como \nconservante en la misma fase\ufffd \nPara la fase oleosa, se seleccion\u00f3 la base no i\u00f3nica Neo PCL O/W, empleada ampliamente en nuestro servicio por \nproporcionar emulsiones estables, f\u00e1cilmente extendibles y no oclusivas.  \nComo controles de calidad se estableci\u00f3 un control organol\u00e9ptico (crema consistente y uniforme de color blanco) y un \ncontrol de pH (5,5-6,5).  \nAplicando la matriz de riesgo de preparaciones no est\u00e9riles, se estableci\u00f3 una caducidad de 30 d\u00edas, durante la cual \nmantuvo sus propiedades fisicoqu\u00edmicas, permaneciendo estables sus caracter\u00edsticas organol\u00e9pticas y el signo de la \nemulsi\u00f3n\ufffd  \nLa composici\u00f3n final de la emulsi\u00f3n (100g) fue: Colistimetato de sodio (160mg), agua est\u00e9ril (75mL), Nipagin s\u00f3dico (0,1g) \ny Neo PCL O/W (25g).  \nLa FM se emple\u00f3 para el tratamiento de dos pacientes con aislamiento de Pseudomonas aeruginosa multirresistente \nen exudado de \u00falceras por presi\u00f3n. En ambos casos en los cultivos de control realizados a los 10 y 14 d\u00edas del inicio \ndel tratamiento, no se aisl\u00f3 ning\u00fan microorganismo pat\u00f3geno, demostrando as\u00ed su eficacia en el tratamiento de estas \ninfecciones\ufffd\nCONCLUSIONES\nLos resultados obtenidos plantean la crema de colistina 0,1% O/W como una alternativa terap\u00e9utica segura y eficaz en \nel manejo de las infecciones de \u00falceras causadas por Pseudomonas multirresistentes, logrando negativizar los cultivos \nmicrobiol\u00f3gicos. La FM desarrollada no present\u00f3 ning\u00fan problema de tolerancia y se mantuvo estable desde el punto de \nvista gal\u00e9nico durante el per\u00edodo de validez establecido.234CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n382. EXPERIENCIA DE EMPLEO DE \u00c1CIDOS GRASOS OMEGA-3 EN PACIENTES MENORES DE 3 MESES CON \nDA\u00d1O HEP\u00c1TICO ASOCIADO A FALLO INTESTINAL \nAUTORES\nWILHELMI ROCA, E; L\u00d3PEZ RAMOS, MG; VILLARONGA FLAQU\u00c9, M; IZQUIERDO RENAU, M; MEAVILLA OLIVAS, SM; \nPIERAS L\u00d3PEZ, \u00c1; M\u00cdNGUEZ RODR\u00cdGUEZ, B; DE LOS SANTOS DE PELEGR\u00cdN, MM\nHOSPITAL DE SANT JOAN DE D\u00c8U. PASSEIG SANT JOAN DE D\u00c9U, 2 ESPLUGUES DE LLOBREGAT . BARCELONA\nOBJETIVOS\nEvaluar la eficacia y seguridad de una emulsi\u00f3n lip\u00eddica exclusiva de \u00e1cidos grasos omega-3 (AG\u03c93) en la nutrici\u00f3n \nparenteral (NP) de pacientes menores de 3 meses con da\u00f1o hep\u00e1tico asociado a fallo intestinal\nMATERIALES Y M\u00c9TODOS\nEl da\u00f1o hep\u00e1tico asociado a fallo intestinal es una complicaci\u00f3n frecuente en ni\u00f1os que requieren nutrici\u00f3n parenteral \ndurante un periodo prolongado de tiempo, caracterizado principalmente por un cuadro colest\u00e1sico. El empleo de \nemulsiones lip\u00eddicas con elevado contenido en AG\u03c93 es una de las posibles estrategias para revertirla, junto con el ciclado \nde la NP , la reducci\u00f3n del aporte lip\u00eddico y/o el empleo de \u00e1cido ursodesoxic\u00f3lico.  \nEstudio observacional retrospectivo sobre el empleo de una emulsi\u00f3n lip\u00eddica exclusiva de AG\u03c93 (Omegaven\u00ae), sola \no asociada en proporciones variables con emulsi\u00f3n de \u00e1cidos grasos de soja/oliva/pescado, como parte de la NP en \nneonatos menores de 3 meses, en un hospital pedi\u00e1trico de tercer nivel, entre enero de 2017 y abril de 2022. Las \nvariables recogidas fueron: composici\u00f3n de NP , valores anal\u00edticos asociados a colestasis (bilirrubina directa (BD), \ngammaglutamiltransferasa (GGT), fosfatasa alcalina (FA)) y otros datos demogr\u00e1ficos.\nRESULTADOS\nSe incluyeron un total de 14 pacientes con colestasis confirmada anal\u00edticamente (BD \u2265 2 mg/mL, 12 pacientes) o \nalteraci\u00f3n de par\u00e1metros hep\u00e1ticos considerados indicadores de colestasis precoz como GGT y FA (2 pacientes).  \nLa mediana de edad gestacional al inicio de la NP fue de 30 semanas [24+5 - 40+1] y la edad mediana al inicio de la \nemulsi\u00f3n de AG\u03c93 de 39.5 d\u00edas de vida [7-96 ddv].  \nLas indicaciones de soporte con NP fueron: prematuridad (6), malformaciones cong\u00e9nitas del tracto gastrointestinal (5) y \nenterocolitis necrotizante con o sin perforaci\u00f3n (3).  \nAl inicio de tratamiento con AG\u03c93, los pacientes llevaban una mediana de 40.5 d\u00edas [2 \u2013 97] de NP . Recibieron AG\u03c93 \ndurante una mediana de 61 d\u00edas [2 - 181]. Las proporciones de las diferentes emulsiones lip\u00eddicas empleadas fueron \nvariables, y 8 pacientes llevaron aporte exclusivo con AG\u03c93 durante una mediana de 29 d\u00edas [3- 97])  \nEl 100% de los pacientes recibieron tratamiento con \u00e1cido ursodesoxic\u00f3lico, el 78,6% nutrici\u00f3n tr\u00f3fica, el 57,1% ciclado de \nNP , y 3 recibieron resincolestiramina a 200-250 mg/kg/d\u00eda.  \nLa mediana de bilirrubina directa al inicio del aporte de AG\u03c93 fue de 2,6 mg/mL[0,3 - 7,9] y al final de su empleo de 1,0 \nmg/mL [0,1 - 6,1]. Al finalizar el uso de AG\u03c93, 12 pacientes (85,7 %) mostraron mejor\u00eda/resoluci\u00f3n de la colestasis (BD < \n2 mg/mL). De los dos pacientes restantes, uno presentaba s\u00edndrome de Alagille (colestasis cr\u00f3nica) y en otro se resolvi\u00f3 la \ncolestasis en d\u00edas posteriores. \nLa mediana de d\u00edas con AG\u03c93 hasta la primera determinaci\u00f3n de BD < 2 mg/mL fue de 40 d\u00edas [2 - 156].  \nNo se detectaron efectos adversos al empleo de la emulsi\u00f3n lip\u00eddica exclusiva de AG\u03c93.\nCONCLUSIONES\n- Seg\u00fan nuestra experiencia, el uso de una emulsi\u00f3n lip\u00eddica exclusiva a base de \u00e1cidos grasos omega-3 revierte o mejora \nla colestasis hep\u00e1tica en pacientes menores de 3 meses que necesitan soporte con NP \n- El empleo de esta emulsi\u00f3n lip\u00eddica fue bien tolerado y no se detectaron efectos adversos\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n384. VALIDACI\u00d3N GAL\u00c9NICA DE UN SPRAY ORAL DE INDOMETACINA 0,25% COMO ALTERNATIVA \nTERAP\u00c9UTICA PARA MUCOSITIS \nAUTORES\nCARRILLO L\u00d3PEZ, V; PERELL\u00d3 ALOMAR, C; P\u00c9REZ ALMAGRO, MF; PADILLA CASTA\u00d1O, H; L\u00d3PEZ L\u00d3PEZ-CEPERO, M; \nDELGADO S\u00c1NCHEZ, O; RODR\u00cdGUEZ CAMPOS, E; GARCIA-CALVO GARC\u00cdA, J\nHOSPITAL SON ESPASES (ANTES SON DURETA). ANDREA DORIA, 55 PALMA DE MALLORCA. ILLES BALEARS\nOBJETIVOS\nLa mucositis es una inflamaci\u00f3n de la mucosa del tracto digestivo muy com\u00fan en pacientes oncohematologicos. El \ntratamiento habitual incluye opioides o antiinflamatorios no esteroideos (AINEs) en coadministraci\u00f3n de preparaciones \nalternativas con formulaciones t\u00f3picas que incluyen anest\u00e9sicos locales, antis\u00e9pticos y/o corticoides. En casos \nrefractarios, se requieren nuevas alternativas terap\u00e9uticas, como la indometacina t\u00f3pica, un AINE con experiencia de uso \nsist\u00e9mico en el control del dolor y enfermedades asociadas a inflamaci\u00f3n.  \nSe ensay\u00f3 la estabilidad gal\u00e9nica de una formulaci\u00f3n en spray oral de indometacina 0.25% seg\u00fan las directrices de la Real \nFarmacopea Espa\u00f1ola (RFE) y la Gu\u00eda de Buenas Pr\u00e1cticas de Preparaci\u00f3n de Medicamentos (GBPPM).\nMATERIALES Y M\u00c9TODOS\nTras una b\u00fasqueda bibliogr\u00e1fica se opt\u00f3 por validar una soluci\u00f3n de indometacina al 0,25% para administrar como spray \noral. Bas\u00e1ndonos en una formulaci\u00f3n descrita por Momo K. et al 2017 en Support Care Cancer , seleccionamos los 235productos nacionales disponibles que garantizaran la solubilizaci\u00f3n del principio activo, testamos los acondicionamientos \ndisponibles y establecimos el procedimiento de elaboraci\u00f3n acorde\ufffd  \nLa soluci\u00f3n final se formul\u00f3 a partir de indometacina en polvo y varias soluciones madre: KH2PO4 0.2M, NaOH 0.2M \ny tamp\u00f3n Sor\u00ebnsen (pH 7,4); que se decidi\u00f3 que fuera de elaboraci\u00f3n propia a partir de fosfato s\u00f3dico monob\u00e1sico \ndihidrato, fosfato s\u00f3dico dib\u00e1sico dodecahidrato y cloruro s\u00f3dico. Se comprob\u00f3 el pH de la soluci\u00f3n tamp\u00f3n antes del uso.  \nEn cuanto al acondicionamiento y la conservaci\u00f3n, escogimos frascos de vidrio opacos con atomizador con volumen de \ndosificaci\u00f3n de 0,20 ml para distribuir uniformemente la soluci\u00f3n sobre la mucosa oral.  \nLa soluci\u00f3n de indometacina final se prepar\u00f3 a partir de una soluci\u00f3n inicial de 35 ml 1:1 de KH2PO4 y NaOH para disolver \ncompletamente la indometacina. Posteriormente, se a\u00f1aden 18 ml de NaOH y se mide el pH, ajust\u00e1ndolo con KH2PO4 a \n7,4 y enrasando con agua destilada hasta 100 ml. La soluci\u00f3n se filtra por un tama\u00f1o de poro de 0.22 micras y se enrasa \ncon soluci\u00f3n Sor\u00ebnsen hasta 500ml. \nSe estableci\u00f3 conservaci\u00f3n en nevera (2-8\u00baC) en frasco de cristal topacio durante un periodo de 28 d\u00edas, seg\u00fan la \nbibliograf\u00eda y la GBPPM. Se realiz\u00f3 una validaci\u00f3n gal\u00e9nica los d\u00edas 1, 8, 15, 21 y 28. Los par\u00e1metros ensayados fueron: \nuniformidad de masa por pesada indirecta (por triplicado, siguiendo especificaciones de la RFE 2.9.40), caracter\u00edsticas \norganol\u00e9pticas (estabilidad del color por observaci\u00f3n directa en el envase final, la soluci\u00f3n madre y la porci\u00f3n desechada; \nolor y sabor tras agitaci\u00f3n y reposo de la soluci\u00f3n) y estabilidad fisicoqu\u00edmica por medici\u00f3n del pH.\nRESULTADOS\nDurante el periodo estudiado, se mantuvieron las caracter\u00edsticas organol\u00e9pticas y el pH (7.36\u00b10.08) en las formulaciones \ntesteadas\ufffd Se consigui\u00f3 una disoluci\u00f3n de indometacina para uso en mucosa oral: inolora, de color amarillento y \nligeramente amarga. Estas caracter\u00edsticas no variaron tras agitaci\u00f3n o reposo, ni entre los d\u00edas de ensayo. No se observ\u00f3 \nsedimentaci\u00f3n\ufffd  \nComprobamos la idoneidad del atomizador mediante el ensayo de uniformidad de masa (0.20mg \u00b10.005).\nCONCLUSIONES\nLa f\u00f3rmula dise\u00f1ada cumpli\u00f3 con los criterios de validaci\u00f3n gal\u00e9nica propuesta y puede considerarse como una nueva \nalternativa en el tratamiento mucositis.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n398. VALIDACI\u00d3N GAL\u00c9NICA DEL COLIRIO DE INTERFER\u00d3N ALFA-2B A PARTIR DE LA ESPECIALIDAD DE \nBIOFERON \nAUTORES\nGUIJARRO MART\u00cdNEZ, P; PEREZ MENENDEZ-CONDE, C; RODRIGUEZ MARIN, M; MENACHO ROM\u00c1N, M; RODRIGUEZ \nTIERNO, S; G\u00d3MEZ DE SALAZAR LOPEZ DE SILANES, ME; PINTOR RECUENCO, MDR; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nEl colirio de interfer\u00f3n alfa-2b se elaboraba a partir de la especialidad comercial de Intron A\u00ae para el tratamiento de \ncarcinoma intraepitelial y neoplasia conjuntival. Ante la retirada de comercializaci\u00f3n de dicha especialidad, nuestro \nServicio de Farmacia se vio obligado a utilizar para la preparaci\u00f3n del colirio la nueva especialidad comercial de interfer\u00f3n \nalfa importada por la Agencia del Medicamento:Bioferon\u00ae\ufffd  \nEl objetivo principal de este estudio es realizar la validaci\u00f3n gal\u00e9nica de un colirio de interfer\u00f3n alfa-2b de 1 MUI/ml \nformulado a partir de la especialidad de Bioferon\u00ae.  \nEl objetivo secundario es evaluar la tolerancia de los pacientes al colirio.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional en un hospital de tercer nivel. \nEl Procedimiento Normalizado de Trabajo (PNT) para la elaboraci\u00f3n del colirio de interfer\u00f3n alfa-2b se dise\u00f1\u00f3 partiendo \nde la formulaci\u00f3n descrita por el Grupo de Farmacotecnia de la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH), que \nutilizaba la especialidad de Intron A\u00ae para su elaboraci\u00f3n. Adaptamos dicha formulaci\u00f3n cambiando la especialidad de \nIntron A\u00ae por Bioferon\u00ae. Las condiciones de almacenamiento del colirio que se establecieron fueron: conservar en nevera \n(2-8\u00baC) protegido de la luz, asignando un caducidad de 30 d\u00edas y 7 d\u00edas una vez abierto.  \nSe consider\u00f3 como validaci\u00f3n gal\u00e9nica la verificaci\u00f3n y evaluaci\u00f3n de las propiedades gal\u00e9nicas de la preparaci\u00f3n en \nlas condiciones reales definidas desde el primer d\u00eda hasta la fecha de m\u00e1xima utilizaci\u00f3n asignada. La metodolog\u00eda \nutilizada fue la establecida por la gu\u00eda GERPAC \u201cMethodological guidelines for stability studies of hospital pharmaceutical \npreparations\u201d para la validaci\u00f3n de colirios. Se tomaron 3 muestras de 200 microlitros para cada tiempo de muestreo. \nLos tiempos de muestreo fueron a los 0, 7, 14, 21 y 30 d\u00edas. Los par\u00e1metros analizados en cada una de las muestras \nfueron esterilidad, aspecto, limpidez, pH, osmolaridad y color. El rango de valores de pH aceptado fue 3,5-10,5 medido \ncon pHmetro y osmolaridad 270-300mOsmol/L medido con osm\u00f3metro. El aspecto, color y limpidez se examinaron \nvisualmente y la esterilidad se estudi\u00f3 en un cultivo de aerobiosis durante 7 d\u00edas.  \nLa tolerancia al colirio se determin\u00f3 analizando la aparici\u00f3n de efectos adversos asociados al tratamiento. La informaci\u00f3n \nse obtuvo mediante la revisi\u00f3n de la historia cl\u00ednica y entrevistas a los pacientes realizadas por un farmac\u00e9utico en el \nmomento de la dispensaci\u00f3n\ufffd\nRESULTADOS\nSe analizaron un total de 15 muestras. \nLos resultados obtenidos en cada una de las muestras fueron:  236D\u00eda 0: osmolaridad 295,295,295mOsmol/L, pH 6,5  \nD\u00eda 7: osmolaridad 300,295,290mOsmol/L, pH 6,7  \nD\u00eda 14: osmolaridad 300,290,290mOsmol/L, pH 6,5  \nD\u00eda 21: osmolaridad 300,295,290mOsmol/L, pH 6.5 \nD\u00eda 30: osmolaridad 295,295,290mOsmol/L, pH 6.8 \nTodos los colirios eran l\u00edmpidos, incoloros y est\u00e9riles en cada una de las muestras tomadas.  \nEl n\u00famero de colirios elaborados en nuestro servicio para un total de 5 pacientes fue de 80. El 80%(4) tuvieron una buena \ntolerancia al colirio. Un paciente present\u00f3 escozor ocular en las sucesivas administraciones.\nCONCLUSIONES\nEl colirio de interfer\u00f3n alfa-2b cumple los criterios establecidos de validaci\u00f3n gal\u00e9nica de los par\u00e1metros estudiados.  \nLa tolerabilidad es adecuada en un 80% de pacientes\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n413. ESTANDARIZACION Y DESARROLLO GAL\u00c9NICO DE SUPLEMENTOS ORALES DE ELECTROLITOS PARA \nPEDIATRIA Y NEONATOLOGIA. \nAUTORES\nCORAZ\u00d3N VILLANUEVA, J; PUEBLA GARC\u00cdA, V; SANCHEZ-OCA\u00d1A MART\u00cdN, N; DE LA TORRE ORT\u00cdZ, M; YBA\u00d1EZ \nGARC\u00cdA, L; MOLINERO MU\u00d1OZ, M; MART\u00cdNEZ SESMERO, JM; ROS\u00d3N SANCHEZ, E\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nAnte la ausencia de formulaciones orales disponibles que llevan al uso de formas farmac\u00e9uticas inyectables, se busca \nestandarizar y definir los suplementos orales de electrolitos a utilizar en pediatr\u00eda y neonatolog\u00eda, proponiendo el \ndesarrollo gal\u00e9nico de f\u00f3rmulas magistrales (FM) de aquellos no disponibles.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una revisi\u00f3n bibliogr\u00e1fica para conocer requerimientos de l\u00edquidos y electrolitos en pediatr\u00eda y neonatolog\u00eda, las \nformulaciones disponibles y sobre aquellas que no exist\u00edan referencias bibliogr\u00e1ficas (cloruro pot\u00e1sico y cloruro s\u00f3dico) se \nrealiz\u00f3 un desarrollo y validaci\u00f3n gal\u00e9nica y la elaboraci\u00f3n de un protocolo normalizado de elaboraci\u00f3n (PNE).  \nPara establecer nivel de riesgo y caducidad de aquellas sin bibliograf\u00eda, se siguieron las recomendaciones de la Gu\u00eda de \nbuenas pr\u00e1cticas de preparaci\u00f3n de medicamentos de 2014 (GBPP).  \nLa validaci\u00f3n gal\u00e9nica se realiz\u00f3 conforme al Formulario Nacional: Evaluaci\u00f3n de caracter\u00edsticas organol\u00e9pticas (color, \nsabor, aspecto, homogeneidad) y control del pH (papel indicador) en los d\u00edas 0,7,14,21,30.\nRESULTADOS\nFM CALCIO carbonato 200mg/ml:  \n\u2022 Equivale a 80mg calcio elemento/ml y 4mEq Ca/ml  \n\u2022 Elaboraci\u00f3n 50ml: pesar 10g de carbonato c\u00e1lcico, 15ml de jarabe simple y cantidad suficiente de agua conservante sin \npropilenglicol\ufffd  \n\u2022 Suspensi\u00f3n homog\u00e9nea blanquecina con un pH de 7 y osmolaridad 1261mOsm/kg. Caducidad de 14 d\u00edas a 2-8\u00baC.  \n \nFM Fosfato 1mmol/ml (soluci\u00f3n Joulie):  \n\u2022 Equivale a 30mg de fosforo/ml y 95mg fosfato/ml  \n\u2022 Elaboraci\u00f3n 50ml: a\u00f1adir 2.725g \u00e1cido orto fosf\u00f3rico (85%), 9,375g de fosfato dis\u00f3dico y cantidad suficiente de agua \nconservante sin propilenglicol\ufffd  \n\u2022 Soluci\u00f3n transparente, pH pr\u00f3ximo a 5, osmolaridad 1725mOsm/kg y una caducidad de 30 d\u00edas.  \n \nFM SODIO cloruro 3,42mEq/ml (20%):  \n\u2022 Elaboraci\u00f3n 50ml: pesar 10 gramos de cloruro s\u00f3dico y diluir con cantidad suficiente de agua purificada.  \n\u2022 Soluci\u00f3n transparente con un pH pr\u00f3ximo a 5,5 y osmolaridad 6800mOsm/kg. Caducidad de 14 d\u00edas en refrigeraci\u00f3n \n(2-8\u00baC) y 8 d\u00edas una vez abierto.  \n \nFM POTASIO cloruro 2meq/ml: \n\u2022 Elaboraci\u00f3n 50ml: Pesar 7,5 gramos de cloruro pot\u00e1sico y diluir en agua purificada.  \n\u2022 Soluci\u00f3n transparente con un pH cercano a 5,5 y una osmolaridad de 5300mOsm/kg. Caducidad de 14 d\u00edas en \nrefrigeraci\u00f3n (2-8\u00baC) y 8 d\u00edas una vez abierto.  \n \nMAGNESIO, pidiolato (Actimag\u00ae 400mg/ml): \n\u2022 Equivale a 34,7 mg/ml y 2,84 mEq/ml de magnesio.  \n\u2022 Osmolaridad de 6786mOsm/kg, conservaci\u00f3n en refrigeraci\u00f3n (2-8\u00baC) una vez abierto.  \n \nDe aquellas formulaciones con alta osmolaridad, en funci\u00f3n de la edad del paciente se recomienda una diluci\u00f3n 1:2 o 1:4 \npara disminuir esta misma y evitar las complicaciones asociadas\ufffd237CONCLUSIONES\nLa suplementaci\u00f3n oral de los distintos electrolitos es una pr\u00e1ctica habitual para equilibrar y mantener niveles adecuados \nde estos mismos, la falta de presentaciones orales comerciales, que conllevan al uso de presentaciones inyectables, \nconcentraciones y sales diversas hacen que la unificaci\u00f3n, desarrollo y validaci\u00f3n gal\u00e9nica de formulaciones orales \npermitan una mejora en la seguridad en el manejo de estos f\u00e1rmacos.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n446. REFORMULACI\u00d3N DE IMIQUIMOD EN \u00d3VULOS VAGINALES PARA EL TRATAMIENTO DE CONDILOMAS \nPRODUCIDOS POR EL VIRUS DEL PAPILOMA HUMANO. \nAUTORES\nMAR\u00cdN ANDREU, Y; MART\u00cdNEZ MADRID, ME; SALAR VALVERDE, I; ALONSO HERREROS, JM; RU\u00cdZ RAMIREZ, JC; SOLER \nSOLER, MDM; ABELL\u00d3N RUIZ, J\nHOSPITAL LOS ARCOS. P\u00ba DE COL\u00d3N, 54 SAN JAVIER. MURCIA\nOBJETIVOS\nEl objetivo del estudio es dise\u00f1ar una f\u00f3rmula magistral de \u00f3vulos de imiquimod solicitada por ginecolog\u00eda para una \npaciente con condiloma recidivante y antecedentes de c\u00e1ncer de c\u00e9rvix.  \nEl imiquimod act\u00faa como modulador de la respuesta inmune estimulando la inducci\u00f3n de citoquinas. Se encuentra \ncomercializado como Aldara\u00ae, crema de imiquimod al 5%, para verrugas genitales externas.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en Medline utilizando como descriptores \u201cImiquimod\u201d y \u201cAdministration, \nIntravaginal\u201d. Se consultaron las bases de datos sobre formulaci\u00f3n de GUINAMA, ACOFAR, y SEFH, as\u00ed como la \nfarmacopea espa\u00f1ola, sobre el material y excipientes necesarios para la preparaci\u00f3n de \u00f3vulos vaginales\ufffd  \nLa disgregaci\u00f3n de los \u00f3vulos se comprob\u00f3 seg\u00fan el ensayo descrito en la Farmacopea Espa\u00f1ola (2\u00aaed, apartado 2.9.2).  \nSe emplearon moldes de \u00f3vulos desechables, y polietilenglicoles(PEGs) de calidad farmac\u00e9utica de GuinamaSLU, y ba\u00f1o \ntermostatizado Precisdig Selecta. \nPara asegurar la idoneidad del tipo y cantidad de excipiente a utilizar se procedi\u00f3 a calcular el factor de desplazamiento y \nel porcentaje de p\u00e9rdida de excipiente en el proceso de llenado de los \u00f3vulos.\nRESULTADOS\nSe encontr\u00f3 una \u00fanica referencia sobre la reformulaci\u00f3n de imiquimod en \u00f3vulos vaginales (P .Amor\u00f3s, et al; Imiquimod \novules for treatment of vaginal intraepithelial neoplasia. Hospital Clinic Barcelona, 41st ESCP ,2012) aunque sin un \nprocedimiento de elaboraci\u00f3n claramente definido. Como excipiente se seleccion\u00f3 una combinaci\u00f3n de PEGs que nos \nasegurasen la disgregaci\u00f3n del \u00f3vulo\ufffd  \nUna vez establecido el factor de desplazamiento (13.78) y el porcentaje de p\u00e9rdida (10%) se concret\u00f3 el siguiente \nprocedimiento para preparar 6 \u00f3vulos de 12\ufffd5 mg:  \n1. Lavar los moldes con agua jabonosa y desinfectarlos posteriormente con alcohol de 70\u00ba .  \n2. Fundir 47,7 g de PEG 400 y 31,8 g de PEG 4000 en un ba\u00f1o mar\u00eda a una temperatura de fusi\u00f3n aproximada de 70\u00baC.  \n3. Mezclar los PEGs y a\u00f1adir a ellos 1650 mg de crema Aldara\u00ae. \n4. Llenar los moldes, previamente lubricados con vaselina l\u00edquida, con la mezcla fundida.  \n5. Cerrar los moldes y dejar enfriar \nSe obtuvieron \u00f3vulos blancos, opacos y de consistencia semis\u00f3lida que se desagregaban a 37\u00baC. Se les asign\u00f3 un \nperiodo de validez de 6 meses seg\u00fan la matriz de riesgo de preparaciones no est\u00e9riles de la Gu\u00eda de Buenas Pr\u00e1cticas de \nPreparaci\u00f3n de Medicamentos en Servicios de Farmacia Hospitalaria (GBPP).  \nSe prepar\u00f3 informaci\u00f3n escrita para la paciente, as\u00ed como \u00f3vulos de demostraci\u00f3n fabricados con el mismo excipiente y \nazul de metileno (2%).  \nLa paciente de 39 a\u00f1os tratada previamente con terapias est\u00e1ndar, inici\u00f3 el tratamiento con \u00f3vulos de imiquimod, una \nvez por semana durante 6 semanas, siendo bien tolerados. Tras vaginoscopia a los 15 d\u00edas de finalizar el tratamiento, se \nobserv\u00f3 la desaparici\u00f3n de epitelio acetoblanco de la cara superior de cicatriz de colpotom\u00eda, indicando la eficacia inicial \ndel tratamiento\ufffd\nCONCLUSIONES\nLa elaboraci\u00f3n de \u00f3vulos de imiquimod con una mezcla de PEGs es una alternativa factible para administrar en pacientes \ncon serotipos de VPH de alto riesgo afectadas con lesiones vaginales intraepiteliales escamosas.  \nEl resultado de su utilizaci\u00f3n fue positivo, tal y como indica la serie de casos publicados anteriormente.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n459. EVALUACION DE LAS RECOMENDACIONES NUTRICIONALES EN PACIENTES CRITICOS: \nREFORMULANDO LA PRACTICA CLINICA \nAUTORES\nBODEGA AZUARA, J; BOS\u00d3 RIBELLES, V; CEBOLLA BELTR\u00c1N, T; PUPL\u00c1 BARTOLL, A; MATEU CAMPOS, ML; MENDOZA \nAGUILERA, M; VICENTE ESCRIG, E; FERRANDO PIQUERES, R\nHOSPITAL GENERAL DE CASTELL\u00d3 \ufffd AV\ufffd BENICASIM, S/N CASTELL\u00d3N DE LA PLANA/CASTELL\u00d3 DE LA PLANA \ufffd CASTELL\u00d3N238OBJETIVOS\nDentro del programa de calidad de nutrici\u00f3n del servicio de farmacia hospitalaria, tras la publicaci\u00f3n de las Gu\u00edas \nESPEN 2019, se realiz\u00f3 una auditor\u00eda para comprobar el cumplimiento de las mismas en pacientes cr\u00edticos con nutrici\u00f3n \nparenteral (NP), detect\u00e1ndose una desviaci\u00f3n en cuanto a las recomendaciones energ\u00e9ticas ( > 50% pacientes recib\u00edan \naportes superiores a los recomendados). Esto llev\u00f3 a una redefinici\u00f3n de las NP estandarizadas para adecuarse a las gu\u00edas \nque se implement\u00f3 en febrero de 2020. \nEl objetivo es analizar el cumplimento actual de las gu\u00edas y la utilidad de las auditor\u00edas peri\u00f3dicas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo (2020\u20132021) en medicina intensiva (UCI) de un hospital de tercer nivel. Las \nrecomendaciones evaluadas fueron: \n1. Iniciar nutrici\u00f3n parenteral total (NPT) cuando el ingreso en UCI supere las 48h y la v\u00eda oral o enteral est\u00e9n \ncontraindicadas\ufffd  \n2. Llevar a cabo un inicio progresivo alcanzando los requerimientos nutricionales totales (RN) en 3-7 d\u00edas.  \n3. El aporte de prote\u00ednas ser\u00e1 de 1,3g/kg/d\u00eda.  \n4\ufffd El aporte de glucosa no debe exceder la velocidad de infusi\u00f3n de 5mg/kg/minuto\ufffd  \n5. El aporte lip\u00eddico no debe exceder los 1,5g/kg/d\u00eda.  \n6. El aporte cal\u00f3rico debe ser de 20-25kcal/kg/d\u00eda alcanzados los RN.  \nSe incluyeron pacientes cr\u00edticos con NPT durante m\u00e1s de 48h. Se excluyeron pacientes con un filtrado glomerular < 30mL/\nmin y obesos (\u00edndice de masa corporal > 30kg/m2). Las variables estudiadas fueron: edad, sexo, diagn\u00f3stico, duraci\u00f3n de \nla NPT y aportes cal\u00f3ricos y de macronutrientes una vez alcanzados los RN. Estos datos se compararon con los obtenidos \npreviamente a la redefinici\u00f3n de los protocolos. Las variables cuantitativas se expresaron como mediana y rango \nintercuart\u00edlico y las cualitativas como porcentajes.\nRESULTADOS\nSe incluyeron 52 pacientes con una mediana de edad de 68,4 a\u00f1os (21,5-85,6), 30,8% mujeres. El diagn\u00f3stico de \nneoplasias digestivas se redujo a la mitad con respecto a 2019, afectando al 25,2% y al 50,0% de los pacientes \nrespectivamente. Apareci\u00f3 un nuevo diagn\u00f3stico: infecci\u00f3n respiratoria grave por SARS-CoV2 que afect\u00f3 al 19,8%.  \nEl inicio de NPT las primeras 24-48h se produjo en el 77,0% de los pacientes, similar a la evaluaci\u00f3n anterior (79,4%).  \nTodos los pacientes recibieron NPT progresiva, alcanzando RN los 3 d\u00edas posteriores al inicio en ambas evaluaciones. \nNing\u00fan paciente excedi\u00f3 la m\u00e1xima velocidad de infusi\u00f3n de glucosa [mediana 1,7mg/kg/min (0,8-2,3)], ni los aportes \nm\u00e1ximos diarios lip\u00eddicos recomendados [mediana 0,9g/kg/d\u00eda (0,4-1,1)], al igual que en la auditor\u00eda anterior, en la cual la \nmediana de velocidad de infusi\u00f3n de glucosa y de aportes lip\u00eddicos fueron 1,8mg/kg/min y 1,0g/kg/d\u00eda respectivamente. \nLa mediana de aportes proteicos diarios en 2019 fue 1,4g/kg/d\u00eda y tras la actualizaci\u00f3n de los protocolos fue 1,3g/kg/d\u00eda \n(1,0-2,0), ajust\u00e1ndose mejor a las recomendaciones. La mediana de aportes cal\u00f3ricos en 2019 fue 25,0kcal/kg/d\u00eda (siendo \n> 25kcal/kg/d\u00eda en el 50,4%) y en el estudio actual 22,5kcal/kg/d\u00eda (13,9-29,0) (siendo > 25kcal/kg/d\u00eda en el 21,2%), \noptimiz\u00e1ndose de acuerdo a las recomendaciones establecidas.\nCONCLUSIONES\nEl cumplimiento de las recomendaciones mejor\u00f3 tras la reformulaci\u00f3n de los protocolos. La evaluaci\u00f3n de la pr\u00e1ctica \ncl\u00ednica mediante auditor\u00edas peri\u00f3dicas permite conocer la situaci\u00f3n real y actualizar protocolos internos con el fin de \noptimizar la actividad asistencial.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n464. VALIDACI\u00d3N GAL\u00c9NICA DE DISTINTAS F\u00d3RMULAS MAGISTRALES DE COLIRIOS DE GANCICLOVIR \nAUTORES\nMART\u00cdNEZ L\u00d3PEZ, LM; P\u00c9REZ SU\u00c1REZ, A; TRELLES CAMPA, A; GRAND\u00cdO LEIVAS, L\nINSTITUTO OFTALMOLOGICO FERNANDEZ-VEGA. AVENIDA DTRES. FERNANDEZ VEGA 34 OVIEDO. ASTURIAS\nOBJETIVOS\nRealizar una validaci\u00f3n gal\u00e9nica de colirios de Ganciclovir a distintas concentraciones y distintos excipientes para el \ntratamiento de queratoconjuntivitis, endotelitis y uve\u00edtis por Citomegalovirus.\nMATERIALES Y M\u00c9TODOS\nSe realiza una b\u00fasqueda bibliogr\u00e1fica previa sobre las concentraciones necesarias y estudios de estabilidad de f\u00f3rmulas \nmagistrales (FM) publicadas de Ganciclovir. Se determinan las siguientes concentraciones: 0.15, 0.5, 1 y 2%. En base \na bibliograf\u00eda se utiliza como principio activo: Ganciclovir inyectable (Cymevene\u00ae) y como excipientes: Carb\u00f3mero \n(Viscotears\u00ae) para elaborar F1 al 0.15%, suero fisiol\u00f3gico 0.9% para elaborar F2 al 0.15%, F3 al 0.5%, F4 al 1% y F5 al 2%, \nagua para inyecci\u00f3n para la elaboraci\u00f3n de F6 al 2%. Se preparan 4 unidades por concentraci\u00f3n, utilizando un sistema \ncerrado para la diluci\u00f3n, esterilizaci\u00f3n por filtraci\u00f3n y se envasan en colirios de vidrio topacio. Se conservan entre 2-8\u00baC. \nSe realizan 3 determinaciones por colirio desde el d\u00eda 0 al d\u00eda 28, donde se eval\u00faa: pH, Osmolaridad (Osm), limpidez, \ncaracteres organol\u00e9pticos y esterilidad, y 1 estudio de citotoxicidad por colirio.\nRESULTADOS\nF1 se descarta el d\u00eda de la elaboraci\u00f3n, la manipulaci\u00f3n del carb\u00f3mero deriva en una FM viscosa que no permite la \nesterilizaci\u00f3n filtrante, ni la determinaci\u00f3n de los par\u00e1metros de estudio. Se contin\u00faa el estudio con el resto de FM. Los \nvalores de pH y Osmolaridad no se modifican de manera significativa durante todo el periodo de estudio. Todas las FM \npresentan una variabilidad y un coeficiente de variaci\u00f3n en torno al 1% durante el mes evaluado tanto para pH como para 239Osmolaridad (excepto F6 para Osmolaridad que, aun as\u00ed, es inferior al 5%): resultados de media de pH y Osm \u00b1 Desviaci\u00f3n \nest\u00e1ndar: F2 pH:9.86\u00b10.10/Osm:285.5\u00b12.63, F3 pH: 10.24\u00b10.06/Osm:287.5\u00b11.38, F4 pH:10.39\u00b10.06/Osm:288.5\u00b11.52, F5 \npH:10\ufffd6\u00b10\ufffd07/Osm:296\ufffd83\u00b11\ufffd72, F6pH:10\ufffd67\u00b10\ufffd07/Osm:129\u00b12\ufffd94\ufffd  \nTodas las FM presentan una Osmolaridad que coindice con las caracter\u00edsticas fisicoqu\u00edmicas de la l\u00e1grima, a excepci\u00f3n de \nF6 cuya Osmolaridad es inferior. Las soluciones de Ganciclovir son alcalinas no tamponadas, y se encuentran en el l\u00edmite \nsuperior de aceptaci\u00f3n de pH de las l\u00e1grimas. Debido a su alcalinidad sumada a su condici\u00f3n de medicamento citot\u00f3xico \nse decide llevar a cabo un estudio de citotoxicidad sobre epitelio corneal, concluyendo que ninguna es irritante para la \nsuperficie ocular ni genera toxicidad en el epitelio. No obstante, F5 Y F6 afectan a la integridad del efecto barrera epitelial.\nCONCLUSIONES\nLas FM elaboradas de distintas concentraciones de Ganciclovir diluido en Suero fisiol\u00f3gico no presentan variaciones \nsignificativas en todo el periodo de estudio en cuanto a pH y Osmolaridad, y mantienen limpidez y esterilidad en todo \nel proceso\ufffd Las formulaciones no son irritantes ni t\u00f3xicas para el epitelio\ufffd Las concentraciones elevadas pueden da\u00f1ar \nla integridad del efecto barrera epitelial, aunque dicho resultado no se puede relacionar con efectos adversos tras \naplicaciones puntuales, no se pueden descartar defectos epiteliales en administraciones cr\u00f3nicas\ufffd  \nSon necesarios m\u00e1s estudios de estabilidad y tolerancia. La ausencia de tratamientos comerciales para patolog\u00edas \noft\u00e1lmicas hace fundamental la labor de los servicios de Farmacia en la elaboraci\u00f3n de f\u00f3rmulas magistrales.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n478. OPTIMIZACI\u00d3N DE LA ELABORACI\u00d3N DE OMEPRAZOL 2 MG/ML SUSPENSI\u00d3N ORAL \nAUTORES\nPRIETO ROMAN, S; ALVARO ALONSO, EA; BARRUECO FERNANDEZ, N; IZQUIERDO GARCIA, E; CA\u00d1AMARES ORBIS, I; \nTEJEDOR PRADO, P; ESTEBAN CASADO, S; ESCOBAR RODRIGUEZ, I\nHOSPITAL INFANTA LEONOR \ufffd GRAN V\u00cdA DEL ESTE, 80 MADRID \ufffd MADRID\nOBJETIVOS\nEn la bibliograf\u00eda se describe originariamente una suspensi\u00f3n de omeprazol 2mg/ml a partir de bicarbonato s\u00f3dico 1M, a \nla que se atribuye un tiempo largo de elaboraci\u00f3n y una mala palatabilidad.  \nEl objetivo de este estudio es optimizar el proceso de elaboraci\u00f3n de omeprazol 2mg/ml suspensi\u00f3n oral para el \ntratamiento del reflujo gastroesof\u00e1gico en pediatr\u00eda, y realizar la validaci\u00f3n gal\u00e9nica correspondiente.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica y an\u00e1lisis de las formulaciones de omeprazol 2mg/ml encontradas. Se descartaron \nlas f\u00f3rmulas que inclu\u00edan excipientes de declaraci\u00f3n obligatoria no recomendados en pediatr\u00eda, y aquellas que requer\u00edan \nun tiempo largo de elaboraci\u00f3n. Se decidi\u00f3 elaborar omeprazol 2mg/ml suspensi\u00f3n a partir de omeprazol base en dos \nveh\u00edculos: bicarbonato s\u00f3dico 1M (FM-1) y Syrspend\u00ae SF-ALKA (FM-2) y, se aplicaron dos t\u00e9cnicas de agitaci\u00f3n: agitaci\u00f3n \nmagn\u00e9tica a 900 rpm (FM-1A y FM-2A) y agitaci\u00f3n a alta velocidad (batidora) a 15000-20000 rpm (FM-1B y FM-2B).  \nSe midi\u00f3 el tiempo total de elaboraci\u00f3n y el tiempo de agitaci\u00f3n. Todas las FM se conservaron en nevera y protegidas \nde la luz 14 d\u00edas. Para la validaci\u00f3n gal\u00e9nica se analizaron: aspecto, caracteres organol\u00e9pticos, tiempo de sedimentaci\u00f3n, \nredispersabilidad, homogeneidad, presencia de cristales y part\u00edculas extra\u00f1as mediante el visor de part\u00edculas KSR \nlighting\u00ae, y determinaci\u00f3n del pH en los d\u00edas 1,6,9,12 y 14.\nRESULTADOS\nEl tiempo total de elaboraci\u00f3n fue de 2h20min y 2h vs 1h30min y 54min para FM-1A y FM-1B vs FM-2A y FM-2B, \nrespectivamente. El tiempo de agitaci\u00f3n fue de 90min para FM-1A, y de 20min para FM-2B. La agitaci\u00f3n a alta velocidad \nde FM-1B form\u00f3 burbujas y favoreci\u00f3 el dep\u00f3sito de omeprazol en la superficie, que no cedi\u00f3 tras 90min y por tanto, \nesta f\u00f3rmula se rechaz\u00f3 y se elimin\u00f3 del estudio. Por otro lado, FM-2A present\u00f3 grumos que no cedieron tras 20min de \nagitaci\u00f3n magn\u00e9tica, necesitando la ayuda del pistilo del mortero para su incorporaci\u00f3n a la f\u00f3rmula durante 30min m\u00e1s \n(total: 50min de agitaci\u00f3n).  \nEn cuanto a la validaci\u00f3n gal\u00e9nica, el color de la suspensi\u00f3n FM-1A fue blanco-transparente y para FM-2A y FM-2B, \nblanco. FM-1A y FM-2B fueron totalmente homog\u00e9neas, mientras que en FM-2A se observaron peque\u00f1os grumos \naislados. Los caracteres organol\u00e9pticos de todas las suspensiones se mantuvieron constantes durante el tiempo de \nestudio, hallando diferencia entre el sabor amargo-salado desagradable de FM-1A frente al sabor dulce-salado de \nFM-2A y FM-2B. El tiempo de sedimentaci\u00f3n fue > 1min para todas ellas, se redispersaron f\u00e1cilmente y no se observ\u00f3 \ncrecimiento de cristales ni part\u00edculas extra\u00f1as. Por \u00faltimo, el pH fue 8,5 para FM-1A, y pH 8 para FM-2A y FM-2B. Todos \nlos par\u00e1metros estudiados se mantuvieron estables durante el tiempo de estudio.\nCONCLUSIONES\nLas suspensiones de omeprazol 2mg/ml elaboradas con Syrspend\u00ae SF-ALKA reducen en al menos un 50% el tiempo de \nelaboraci\u00f3n y ofrecen una mejor palatabilidad frente a las elaboradas con bicarbonato s\u00f3dico 1M. La incorporaci\u00f3n de \nun mecanismo de agitaci\u00f3n mec\u00e1nico a altas rpm a la elaboraci\u00f3n con Syrspend\u00ae SF-ALKA optimiza el proceso global de \nelaboraci\u00f3n al reducir el tiempo de agitaci\u00f3n y asegura la homogeneidad de la suspensi\u00f3n.240CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n486. EFECTIVIDAD Y SEGURIDAD DE LA TOXINA BOTUL\u00cdNICA EN PACIENTES CON HIPERTON\u00cdA DEL \nM\u00daSCULO CRICOFAR\u00cdNGEO \nAUTORES\nMARTIN TORRENTE, A; SANTOS IBA\u00d1EZ, A; IBARRONDO LARRAMENDI, I; PALACIOS ZABALZA, I; PERAL AGUIRREGOITIA, \nJ; COBAS BELSO, M; MIR\u00d3N ELORRIAGA, G; PALACIOS FILARDO, M\nHOSPITAL GALDAKAO-USANSOLO. BARRIO LABEAGA, S/N. GALDAKAO. VIZCAYA\nOBJETIVOS\nDesarrollar un circuito de preparaci\u00f3n y administraci\u00f3n de toxina botul\u00ednica en pacientes con hiperton\u00eda del m\u00fasculo \ncricofar\u00edngeo (acalasia cricofar\u00edngea) y evaluar la efectividad y seguridad en los pacientes tratados en un hospital \nterciario\ufffd\nMATERIALES Y M\u00c9TODOS\nLa hiperton\u00eda o acalasia cricofar\u00edngea es un trastorno motor esof\u00e1gico que consiste en la falta de relajaci\u00f3n del m\u00fasculo \ncricofar\u00edngeo, lo que provoca disfagia con regurgitaci\u00f3n y aspiraci\u00f3n. La inyecci\u00f3n de toxina botul\u00ednica permite relajar el \nm\u00fasculo cricofar\u00edngeo y mejorar la degluci\u00f3n. El uso de toxina botul\u00ednica en la acalasia cricofaringea se encuentra fuera \nde las indicaciones autorizadas en ficha t\u00e9cnica. \nJunto con el servicio de Otorrinolaringolog\u00eda (ORL) se desarroll\u00f3 un protocolo que fue aprobado por la Comisi\u00f3n de \nFarmacia y Terap\u00e9utica del hospital. Los pacientes candidatos a tratamiento seg\u00fan protocolo fueron informados y \notorgaron su consentimiento escrito. En el Servicio de Farmacia (SF) se dise\u00f1\u00f3 la Gu\u00eda de Elaboraci\u00f3n, Control y registro \nde la preparaci\u00f3n\ufffd  \nUna vez realizada la prescripci\u00f3n m\u00e9dica, se valida por parte del farmac\u00e9utico y se prepara la medicaci\u00f3n en jeringas de 1 \nmL con 50 ui cada una (concentraci\u00f3n 5 ui/0,1 ml), que se dispensan identificadas con los datos del paciente y n\u00famero de \nregistro de la preparaci\u00f3n. La medicaci\u00f3n se administra mediante inyecci\u00f3n percut\u00e1nea en el m\u00fasculo cricofar\u00edngeo con \ncontrol por electromiograf\u00eda.\nRESULTADOS\nEste circuito est\u00e1 implantado actualmente en el SF colaborando con el personal del servicio de ORL. En el periodo \ncomprendido entre el 24/9/2021 y el 10/5/2022 se trataron seg\u00fan protocolo 5 pacientes, todos ellos fueron hombres \nde edades entre 62 y 78 a\u00f1os. De los pacientes estudiados, 3 recibieron la toxina botul\u00ednica en el lado derecho y 2 en \nambos lados (derecho e izquierdo). A uno de los pacientes que recibi\u00f3 la toxina en ambos lados se le volvi\u00f3 a repetir la \ninfiltraci\u00f3n a los 7 meses en el lado derecho. La dosis finalmente administrada en todos los pacientes fue de 15 ui (0,3 \nml).  \nA las 2 semanas de la infiltraci\u00f3n de toxina se evaluaron los pacientes en la consulta de ORL y se comprob\u00f3 que 4 de los \npacientes refirieron tener una mejor\u00eda parcial en la degluci\u00f3n y solo 1 de ellos coment\u00f3 que no refer\u00eda mucha mejor\u00eda en \nla degluci\u00f3n de alimentos. Por otro lado, ning\u00fan paciente refiere haber tenido efectos adversos despu\u00e9s de la infiltraci\u00f3n \nde toxina botul\u00ednica.\nCONCLUSIONES\nLa implantaci\u00f3n del circuito ayuda a mejorar la seguridad en la preparaci\u00f3n y administraci\u00f3n de la toxina botul\u00ednica \nen la hiperton\u00eda del m\u00fasculo cricofar\u00edngeo. Analizando los resultados obtenidos en los pacientes que han recibido la \ntoxina botul\u00ednica, podemos concluir que el procedimiento es efectivo y seguro en dicha patolog\u00eda a pesar de que se haya \nadministrado en una poblaci\u00f3n reducida en nuestro hospital.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n496. ALGORITMO DE DECISI\u00d3N EN LA PRESCRIPCI\u00d3N DE NUTRICI\u00d3N ENTERAL EN NI\u00d1OS MAYORES DE \n1 A\u00d1O \nAUTORES\nSACANELLA ANGLES, I; BOADA HERN\u00c1NDEZ, P; MART\u00cdN MARQU\u00c9S, M; BAIXERAS MU\u00d1OZ, A; SANJU\u00c1N BELDA, A; \nSU\u00d1ER BARRIGA, H; JORNET MONTA\u00d1A, S; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA\nOBJETIVOS\nElaborar e implantar un algoritmo de soporte en la prescripci\u00f3n de nutrici\u00f3n enteral (NE) en ni\u00f1os mayores de 1 a\u00f1o.  \n \nEvaluar la adecuaci\u00f3n de este algoritmo de soporte post implantaci\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nPara la elaboraci\u00f3n del algoritmo, se reuni\u00f3 el servicio de Farmacia y Pediatr\u00eda para decidir qu\u00e9 nutriciones enterales eran \nnecesarias en ni\u00f1os mayores de 1 a\u00f1o. Los criterios que se tuvieron en cuenta fueron: indicaci\u00f3n, tipo de f\u00f3rmula, aporte \ncal\u00f3rico y si conten\u00edan o no fibra. Adem\u00e1s, se valoraron determinadas situaciones especiales.  \n \nSe trata de un estudio observacional y retrospectivo en pacientes > 1 a\u00f1o con las siguientes variables: sexo, edad, \npresencia de estancamiento ponderal e indicaci\u00f3n adecuada\ufffd  \n \nLa indicaci\u00f3n se clasific\u00f3 en 4 grupos seg\u00fan la tolerancia digestiva: normal (polim\u00e9ricas), leve (parcialmente hidrolizadas), \nmoderada (extensamente hidrolizadas) y grave (elementales).241RESULTADOS\nPara la elaboraci\u00f3n del algoritmo, se clasific\u00f3 seg\u00fan la tolerancia digestiva y el tipo de nutrici\u00f3n.  \n \nEn tolerancia normal se usaron f\u00f3rmulas polim\u00e9ricas normo e hipercal\u00f3ricas con o sin fibra; en intolerancia leve, \nse incluy\u00f3 el trastorno de motilidad y el trofismo intestinal, f\u00f3rmulas parcialmente hidrolizadas hipercal\u00f3ricas; en \nintolerancia moderada, que contempl\u00f3 la alergia a las prote\u00ednas de la leche de vaca (APLV), f\u00f3rmulas extensamente \nhidrolizadas hipercal\u00f3ricas (oligom\u00e9ricas/semielementales) y en intolerancia grave, se incluy\u00f3 el fracaso intestinal y el \npaso de nutrici\u00f3n parenteral a NE, f\u00f3rmulas elementales normocal\u00f3ricas (monom\u00e9ricas).  \n \nEn determinadas situaciones como el paciente cr\u00edtico, politraumatizado, destete dif\u00edcil e insuficiencia respiratoria se \nindicaron f\u00f3rmulas hipercal\u00f3ricas. En caso de pacientes con drogas adren\u00e9rgicas, malnutrici\u00f3n y ayuno prolongado ( > 7 \nd\u00edas) se decidieron f\u00f3rmulas oligom\u00e9ricas. \n \nEn el estudio, se incluyeron 35 pacientes (71% varones) con una edad media de 7 \u00b1 5 a\u00f1os. El 74% de los pacientes \npresentaron estancamiento ponderal. La tolerancia digestiva del 83% de los pacientes fue normal, el 14% present\u00f3 una \nintolerancia moderada (100% APLV) y el 3% grave. La indicaci\u00f3n de las f\u00f3rmulas de NE fue correcta en un 86%.\nCONCLUSIONES\nLa elaboraci\u00f3n de herramientas de soporte, como el algoritmo de decisi\u00f3n, facilita la prescripci\u00f3n de NE. Bas\u00e1ndonos en \neste estudio post implantaci\u00f3n, se ha observado una elevada tasa de adecuaci\u00f3n al algoritmo.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n497. VANCOMICINA EN EXCIPIENTE ADHESIVO PARA EL TRATAMIENTO DE LA COLITIS \nPSEUDOMEMBRANOSA \nAUTORES\nCANEDO CASTELO, M; COLLS GONZ\u00c0LEZ, M; SAB\u00c9 FERNANDEZ, N; SANTULARIO VERD\u00da, L; GARRIDO SANCHEZ, L; \nGONZALEZ CABALLERO, \u00cd; BADIA TAHULL, M; LEIVA BADOSA, E\nHOSPITAL UNIVERSITARI DE BELLVITGE. FEIXA LLARGA, S/N HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nOBJETIVOS\nLa colitis pseudomembranosa es una infecci\u00f3n del tracto gastrointestinal causada por Clostridium difficile (CD). Las gu\u00edas \ncl\u00ednicas recomiendan tratamiento adyuvante con enemas de vancomicina en casos graves, en pacientes con \u00edleo paralitico \no en aquellas situaciones en las que no sea posible el acceso del an tibi\u00f3tico oral a la zona afectada.  \nEl objetivo es describir una nueva formulaci\u00f3n de vancomicina en excipiente adhesivo oral (EAO) y evaluar su eficacia \npara el tratamiento de CD en un paciente con intolerancia a los enemas de vancomicina convencionales\ufffd\nMATERIALES Y M\u00c9TODOS\nEl Servicio de Enfermedades Infecciosas solicita al Servicio de Farmacia Hospitalaria la preparaci\u00f3n de una f\u00f3rmula de \nvancomicina rectal con menor volumen como alternativa a los enemas convencionales. Mediante revisi\u00f3n bibliogr\u00e1fica \n(dosificaci\u00f3n, propiedades f\u00edsico-qu\u00edmicas) se dise\u00f1a la f\u00f3rmula vancomicina 500 mg/15g en EAO tomando como \nreferencia la descontaminaci\u00f3n oral con antibi\u00f3ticos en EAO descrita por Bergmans et al. La efectividad de la preparaci\u00f3n \nse evalu\u00f3 valorando la respuesta cl\u00ednica, los resultados de los cultivos y los datos de la historia cl\u00ednica electr\u00f3nica.\nRESULTADOS\nElaboraci\u00f3n de la f\u00f3rmula: Composici\u00f3n (15g): vancomicina 500mg, parafina l\u00edquida 1 mL, EAO 14,5g. Modus operandi: \npesar y pulverizar la vancomicina en polvo en un mortero e incorporar la parafina l\u00edquida mezclando hasta formar \nuna pasta. Agregar el EAO en peque\u00f1as porciones mezclando hasta total homogenizaci\u00f3n. Se obtiene una mezcla de \nconsistencia untuosa y se envasa en jeringa de extremo romo. Conservaci\u00f3n: En nevera (entre 2 y 8\u00baC) y protegida de la \nluz. Estabilidad: 14 d\u00edas (plazo fijado en base a la matriz de preparaciones no est\u00e9riles de la Gu\u00eda de Buenas Pr\u00e1cticas de \nPreparaci\u00f3n de Medicamentos 2014). Las ventajas del EAO incluyen su acci\u00f3n protectora sobre las mucosas y la liberaci\u00f3n \nlenta del principio activo, permitiendo la aplicaci\u00f3n de una dosis total menor.  \nCaso cl\u00ednico: var\u00f3n de 52 a\u00f1os con diagn\u00f3stico de miocardiopat\u00eda por amiloidosis de cadenas ligeras secundaria \na mieloma m\u00faltiple. Recibi\u00f3 un trasplante cardiaco en julio del 2019 y como complicaciones inmediatas present\u00f3 \nperforaci\u00f3n col\u00f3nica secundaria a fecaloma requiriendo colostom\u00eda de descarga, \u00edleo paral\u00edtico y progresi\u00f3n de la \nenfermedad con afectaci\u00f3n intestinal, medular, cardiaca y renal.  \nDiez meses despu\u00e9s del trasplante ingresa debido a una infecci\u00f3n por CD. Se inicia tratamiento con metronidazol oral 500 \nmg/12h, vancomicina oral 125 mg/6h y enemas rectales de vancomicina 500mg/6h (diluci\u00f3n en 100 ml de NaCl 0.9%), \nque no fueron tolerados, presentando sangrado y dolor anal.  \nInicia el tratamiento con vancomicina 500mg/15g en EAO por v\u00eda rectal con c\u00e1nula a dosis de 500mg/24h durante 30 d\u00edas. \nSe finaliza el tratamiento con buena tolerancia y con negativizaci\u00f3n de los cultivos en heces.  \nEn un ingreso posterior con recidiva de CD se repite el mismo tratamiento, siendo de nuevo bien tolerado\ufffd\nCONCLUSIONES\nEl tratamiento rectal con vancomicina 500mg/15g en EAO result\u00f3 efectivo y bien tolerado, ofreciendo una alternativa \npara pacientes con colitis por CD que presenten intolerancia a los enemas convencionales debido a su elevado volumen.242CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n500. UTILIZACI\u00d3N DE COLIRIO DE INSULINA ELABORADO COMO FORMULACI\u00d3N MAGISTRAL EN EL \nTRATAMIENTO DE LA DESEPITELIZACI\u00d3N CORNEAL \nAUTORES\nSUBIRANA BATLLE, C; AGUILAR SALMER\u00d3N, R; ARTELLS DE JORGE, N; LARREA URTARAN, X; BRUGUERA TEIXIDOR, \nM; DORD\u00c0 BENITO, A; L\u00d3PEZ NOGUERA, Q; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nExiste evidencia cient\u00edfica de que la administraci\u00f3n t\u00f3pica de insulina favorece la reepitelizaci\u00f3n de la c\u00f3rnea en \nprocesos ulcerativos. No existe ninguna especialidad farmac\u00e9utica comercializada de insulina en presentaci\u00f3n colirio. A \ncontinuaci\u00f3n, se describe la utilizaci\u00f3n del colirio de insulina elaborado en un Servicio de Farmacia como formulaci\u00f3n \nmagistral para el tratamiento de procesos que cursen con desepitelizaci\u00f3n corneal.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo llevado a cabo en un hospital de referencia de provincia. Se evaluaron los pacientes \npara los que se prepar\u00f3 colirio de insulina como formulaci\u00f3n magistral desde septiembre de 2021 hasta marzo de 2022.  \nSe recogieron variables demogr\u00e1ficas (edad, sexo), antecedentes patol\u00f3gicos, diagn\u00f3stico, medicaci\u00f3n concomitante, \nevoluci\u00f3n del cuadro y duraci\u00f3n de tratamiento\ufffd  \nEl diagn\u00f3stico y el seguimiento de los pacientes se realiz\u00f3 mediante exploraci\u00f3n con biomicroscop\u00eda con l\u00e1mpara de \nhendidura y utilizando la t\u00e9cnica de tinci\u00f3n con fluoresce\u00edna. \nEl colirio de insulina fue elaborado en el Servicio de Farmacia del hospital seg\u00fan las recomendaciones de la Gu\u00eda de \nBuenas Pr\u00e1cticas de Preparaci\u00f3n de Medicamentos en Servicios de Farmacia Hospitalaria. El m\u00e9todo de elaboraci\u00f3n \nconsisti\u00f3 en la instilaci\u00f3n de 10 UI de insulina regular en un veh\u00edculo lubricante siguiendo las indicaciones descritas en la \nbibliograf\u00eda disponible. La dispensaci\u00f3n y el seguimiento de los pacientes durante el tratamiento se realiz\u00f3 en la consulta \nde atenci\u00f3n farmac\u00e9utica.\nRESULTADOS\nDurante el periodo de estudio, se elaboraron 34 preparaciones de colirio de insulina para un total de 21 pacientes: \n14 hombres (66,7%) y 7 mujeres (33,3%). La media de edad fue de 63 [40-99] a\u00f1os y en 7 casos estaban descritos \nantecedentes de patolog\u00eda diab\u00e9tica.  \n \nLa indicaci\u00f3n de la insulina t\u00f3pica fue el tratamiento de diferentes procesos que cursaban con desepitelizaci\u00f3n corneal. \nLos principales diagn\u00f3sticos fueron: queratitis herp\u00e9tica (6 pacientes, 28,6%), \u00falcera neurotr\u00f3fica (4 pacientes, 19%), \n\u00falcera corneal secundaria a traumatismo mec\u00e1nico (4 pacientes, 19%), causticaci\u00f3n ocular (3 pacientes, 14,3%), infecci\u00f3n \nbacteriana (2 pacientes, 9,5%) y otras queratitis ulcerativas (2 pacientes, 9,5%).  \n \nEl colirio fue prescrito con una pauta de administraci\u00f3n de 1 gota cada 6 o 8 horas y el tratamiento concomitante, \nprincipalmente, consisti\u00f3 en la administraci\u00f3n de lubricantes oculares, antibi\u00f3ticos, antiherp\u00e9ticos y/o corticosteroides.  \n \nEn el momento de la realizaci\u00f3n del estudio: 12 pacientes (57,1%) hab\u00edan finalizado el tratamiento, 8 (38,1%) segu\u00edan en \ntratamiento y 1 (4,8%) paciente no pudo ser evaluado por p\u00e9rdida de seguimiento. De los 12 pacientes con tratamiento \nfinalizado, 8 (66,7%) presentaron resoluci\u00f3n completa de la \u00falcera, 2 (16,7%) presentaron resoluci\u00f3n parcial y 2 (16,7%) \nno obtuvieron mejor\u00eda. La media de duraci\u00f3n del tratamiento fue de 1,5 [1-3] meses y en ning\u00fan caso se describieron \nefectos adversos relacionados con el f\u00e1rmaco.\nCONCLUSIONES\nLa utilizaci\u00f3n del colirio de insulina elaborado como f\u00f3rmula magistral podr\u00eda cubrir un vac\u00edo terap\u00e9utico en procesos de \ndesepitalizaci\u00f3n corneal. Los resultados preliminares en los pacientes tratados en nuestro hospital lo posicionan como \nuna alternativa eficaz y segura, aunque ser\u00e1 necesario realizar estudios posteriores para corroborar esta indicaci\u00f3n.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n504. \u00bfALTERNATIVAS AL COLIRIO DE INTERFERON ALFA 2B? A PROP\u00d3SITO DE UN CASO \nAUTORES\nBOADA HERNANDEZ, P; MART\u00cdN MARQU\u00c9S, M; BAIXERAS MU\u00d1OZ, A; SACANELLA ANGL\u00c8S, I; SANJU\u00c1N BELDA, A; \nSU\u00d1ER BARRIGA, H; ORTIZ VAQUERIZAS, D; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA\nOBJETIVOS\nDescribir la elaboraci\u00f3n y validaci\u00f3n gal\u00e9nica de inyecciones intrav\u00edtreas de interfer\u00f3n alfa 2b (INFa2b).  \nEvaluar la eficacia, seguridad y adherencia de las inyecciones intrav\u00edtreas en un paciente con carcinoma escamoso \nconjuntival (indicaci\u00f3n off-label).\nMATERIALES Y M\u00c9TODOS\nPaciente con carcinoma escamoso conjuntival de ojo derecho que inicia en agosto de 2021 tratamiento con colirio de \nINFa2b 1 MUI/mL. En las sucesivas consultas con el servicio de oftalmolog\u00eda se observ\u00f3 una recidiva tumoral debido \na una falta de adherencia al tratamiento con el colirio de interfer\u00f3n. Por este motivo, en diciembre 2021, se solicita al 243servicio de farmacia, la preparaci\u00f3n de inyecciones intrav\u00edtreas de interfer\u00f3n 3 MUI/0,5 mL para administraci\u00f3n semanal \ncon una duraci\u00f3n total de 8 semanas. Se encontr\u00f3 bibliograf\u00eda de experiencia limitada basada en un \u00fanico estudio de 14 \npacientes, donde se observ\u00f3 que la concentraci\u00f3n 3 MUI/0,5 mL fue segura y eficaz. El paciente firm\u00f3 el consentimiento \ninformado al ser indicaci\u00f3n off-label y se aprob\u00f3 por la comisi\u00f3n de farmacia del hospital.  \nEl f\u00e1rmaco fue adquirido a trav\u00e9s de medicamentos en situaciones especiales, para la preparaci\u00f3n del colirio de \ninterfer\u00f3n, y posteriormente para las intrav\u00edtreas. La dispensaci\u00f3n se realiz\u00f3 semanalmente desde el servicio de farmacia \ncomprob\u00e1ndose su adherencia.\nRESULTADOS\nPara la elaboraci\u00f3n, se revis\u00f3 que la especialidad estuviera exenta de excipientes t\u00f3xicos para uso oft\u00e1lmico. Las \ninyecciones intrav\u00edtreas de interfer\u00f3n se prepararon en el servicio de farmacia en condiciones as\u00e9pticas en Cabina de \nFlujo Laminar Horizontal (CFLH). Para cada intrav\u00edtrea, se diluy\u00f3 el vial de 5 MUI con su disolvente hasta conseguir una \nconcentraci\u00f3n de 3 MUI/0,5 mL. Se us\u00f3 filtro de 0,22 micras y se acondicion\u00f3 en jeringas de propiletileno libres de \nsilicona. Siguiendo la matriz de riesgo y seg\u00fan las Gu\u00edas de Buenas Pr\u00e1cticas, se asign\u00f3 un periodo de validez de 24 horas \nrefrigerado (2-8\u00baC) y protegido de la luz.  \nDespu\u00e9s de la administraci\u00f3n de 8 inyecciones se evidenci\u00f3 una remisi\u00f3n completa. En cuanto al perfil de seguridad, no \nse describi\u00f3 ninguna reacci\u00f3n adversa y la tolerancia fue buena hasta fin de tratamiento. El paciente fue adherente al \ntratamiento al 100%\ufffd\nCONCLUSIONES\nPara la validaci\u00f3n gal\u00e9nica de una nueva f\u00f3rmula magistral, los servicios de farmacia, deben valorar la estabilidad \nfisicoqu\u00edmica y microbiol\u00f3gica, para asegurar una adecuada preparaci\u00f3n.  \nLa elaboraci\u00f3n de una f\u00f3rmula magistral individualizada para este paciente permiti\u00f3 en una \u00fanica administraci\u00f3n \nsemanal, que el f\u00e1rmaco fuera eficaz, seguro y con una buena adherencia.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n514. DISE\u00d1O Y VALIDACI\u00d3N GAL\u00c9NICA DE UNA SUSPENSI\u00d3N OLEOSA ORAL DE CLOFAZIMINA PARA SU \nUSO EN PEDIATR\u00cdA \nAUTORES\nBOFILL ROIG, E; PERELL\u00d3 ALOMAR, C; PADILLA CASTA\u00d1O, H; LOPEZ LOPEZ-CEPERO, M\nHOSPITAL UNIVERSITARI SON ESPASES \ufffd CARRETERA VALLDEMOSSA 79 PALMA DE MALLORCA \ufffd ILLES BALEARS\nOBJETIVOS\nLa Clofazimina se encuentra disponible como medicaci\u00f3n extranjera en c\u00e1psulas blandas de 100 mg para el tratamiento \nde infecciones por micobacteria no tuberculosis en ni\u00f1os (uso fuera de ficha t\u00e9cnica), pero no existe una especialidad \nfarmac\u00e9utica comercializada que permita el ajuste de dosis en pediatr\u00eda.  \n \nEl objetivo es el dise\u00f1o y validaci\u00f3n gal\u00e9nica de una f\u00f3rmula oral l\u00edquida (FOL) de clofazimina como alternativa a la \nespecialidad comercial para pacientes pedi\u00e1tricos ante la dificultad para fraccionar la dosis de la c\u00e1psula blanda.\nMATERIALES Y M\u00c9TODOS\nPara dise\u00f1ar la FOL de clofazimina se realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica, encontrando solo una referencia de validaci\u00f3n \ngal\u00e9nica de una emulsi\u00f3n acuosa con triglic\u00e9ridos de cadena media (aceite MCT), edulcorante y polisorbato 80. Se \ndescart\u00f3 esta opci\u00f3n para evitar el uso de edulcorante y tensioactivo. Se tom\u00f3 como punto de partida la composici\u00f3n de \nla presentaci\u00f3n comercializada (suspensi\u00f3n oleosa a base de butilhidroxitolueno, \u00e1cido c\u00edtrico anhidr\u00edco, propilenglicol, \naceite de colza, lecitina de soja y mezcla de ceras vegetales) y la informaci\u00f3n proporcionada por el laboratorio fabricante \nen cuanto al peso dosificado en una c\u00e1psula blanda de 100 mg (300.0 mg \u00b1 2 %). Se valoraron dos tipos de veh\u00edculos \noleosos para suspender el contenido extra\u00eddo: aceite MCT y lecitina de soja. Adem\u00e1s, de la inclusi\u00f3n o no de antioxidante \n(alfa-tocoferol acetato). El desarrollo gal\u00e9nico y validaci\u00f3n se realiz\u00f3 siguiendo el procedimiento de elaboraci\u00f3n de \nsuspensiones acuosas del Formulario Nacional (PN/L/FF/002/00) y la matriz de riesgo incluida en la \u201cGu\u00eda de buenas \npr\u00e1cticas de preparaci\u00f3n de medicamentos en los servicios de farmacia hospitalaria\u201d, ya que no est\u00e1n descritos \nprocedimientos espec\u00edficos para suspensiones oleosas.\nRESULTADOS\nPara la elaboraci\u00f3n de 10 ml de una suspensi\u00f3n oleosa de clofazimina 10 mg/ml se requieren dos c\u00e1psulas blandas de \n100 mg para recuperar 300 mg de su contenido (riesgo medio). El veh\u00edculo seleccionado fue el aceite MCT al presentar \nmejores caracter\u00edsticas organol\u00e9pticas. Se establecieron 4 tiempos de an\u00e1lisis de las caracter\u00edsticas gal\u00e9nicas (color, \nolor, sabor, tiempo de sedimentaci\u00f3n, redispersabilidad, homogeneidad) a los 0, 4, 7 y 14 d\u00edas, y una conservaci\u00f3n a \n5\u00b12\u00baC, en frasco de cristal topacio. La suspensi\u00f3n oleosa es de color rojo anaranjado, inoloro y de sabor neutro, con \npart\u00edculas blancas en suspensi\u00f3n (procedentes de las ceras vegetales de la presentaci\u00f3n comercial). Tiene un tiempo de \nsedimentaci\u00f3n mayor a 10 minutos y no presenta problemas de redispersabilidad del precipitado ni de homogenizaci\u00f3n \nuna vez agitada. Se elabor\u00f3 tambi\u00e9n incorporando alfa-tocoferol acetato al 0,1% como antioxidante para comprobar \nsi influ\u00eda en los resultados. Ambas suspensiones mantuvieron las caracter\u00edsticas gal\u00e9nicas durante todo el periodo del \nestudio. No se ha observado el valor de \u00edndice de acidez ni el pH (al no presentar fase acuosa) que podr\u00edan aportar \ninformaci\u00f3n sobre su degradaci\u00f3n\ufffd244CONCLUSIONES\nLa elaboraci\u00f3n de clofazimina en FOL puede facilitar la administraci\u00f3n en pediatr\u00eda. Ambas suspensiones elaboradas \nmantienen las caracter\u00edsticas gal\u00e9nicas revisadas durante el per\u00edodo de observaci\u00f3n y en las condiciones de conservaci\u00f3n \nestablecidas\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n551. EFECTIVIDAD DE LA NUTRICI\u00d3N PARENTERAL INTRADI\u00c1LISIS EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nERDOZAIN SANCLEMENTE, S; IDOATE GRIJALBA, AI; PINO RAMOS, A; GO\u00d1I INDURAIN, N; PRECIADO GOLDARACENA, \nJ; DE MIGUEL GAZTELU, M; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nEvaluar el estado nutricional, realizar un seguimiento y verificar la efectividad de la nutrici\u00f3n parenteral intradi\u00e1lisis \n(NPID) en los pacientes de hemodi\u00e1lisis.\nMATERIALES Y M\u00c9TODOS\nPacientes desnutridos sometidos a hemodi\u00e1lisis cr\u00f3nica (HDC), en los que se administr\u00f3 NPID protocolizada. Se \nanalizaron par\u00e1metros antropom\u00e9tricos (sexo, edad, peso talla) as\u00ed como las comorbilidades (diabetes, alteraciones \ncardiovasculares(CV), hipertensi\u00f3n (HTA) y dislipemia). Se realiz\u00f3 seguimiento antes, durante (4 semanas post-inicio) y 2 \nmeses post-fin de la NPID, de los siguientes par\u00e1metros: alb\u00famina, prote\u00ednas totales, prealb\u00famina, linfocitos, transferrina, \ncreatinina, glucemia y triglic\u00e9ridos. Se eval\u00fao si fue preciso modificar la NPID estandarizada en el centro (glucosa: 120g, \namino\u00e1cidos: 42,5g, l\u00edpidos 50g y volumen: 1000mL).\nRESULTADOS\nSe han estudiado 60 pacientes con NPID desde Enero-2005 hasta Abril-2022 con edades comprendidas entre 40-89 \na\u00f1os (media 79), siendo el 70% hombres (n=42). Las comorbilidades m\u00e1s frecuentes fueron: diabetes 35% (n=21), HTA y \ndislipemia 27% (n=16) cada una y alteraciones CV 23% (n=14). El tiempo medio de nutrici\u00f3n fue de 92 d\u00edas (32-685).  \nDurante la NPID la prealb\u00famina aument\u00f3 de 16,68\u00b17,85 g a 17,72\u00b18,86 g. Los valores de alb\u00famina medios basales \n27,55\u00b15,97 g/L se incrementaron a 28,13\u00b17,07 g/L durante la NPID, alcanzando 29,03\u00b16,43 g/L en los dos meses post-\nNPID. Los valores de triglic\u00e9ridos se elevaron durante la NPID pasando de una mediana de 104(43-277) mg/dL a 115 (50-\n264) mg/dL. Los valores de creatinina aumentaron progresivamente antes, durante y en la post-NPID con valores medios \nde 4,13, 4,43 y 4,53 mg/dL respectivamente, sin superar en ning\u00fan momento el valor de 8 mg/dL en el cu\u00e1l la NPID \nest\u00e1 contraindicada seg\u00fan criterios ESPEN. Los linfocitos aumentaron progresivamente pero no de forma significativa \n(p=0,636). La transferrina antes de la NPID estaba mayoritariamente baja con una media de 114,89\u00b147,59 mg/dL, \ncorrespondiente a un 36,17% inferior al l\u00edmite de normalidad cifrado en 180 mg/dL. Durante la NPID, los valores de \ntransferrina aumentaron, alcanzando valores medios de 128,45\u00b136,81 mg/dL.  \nLa ingesta proteico-cal\u00f3rica fue de 1170 kcal, correspondiente al intervalo 13,45-26 kcal/kg/d\u00eda, siempre teniendo en \ncuenta que se trata de un aporte suplementario. Se necesit\u00f3 ajuste de macronutrientes en el 8,33% de los pacientes \n(n=5) y de micronutrientes en el 25% (n=15). \nLa glucemia en diab\u00e9ticos aument\u00f3 durante NPID pasando de 142\u00b131,21 mg/dL a 168,60\u00b167,82 mg/dL. La glucemia \nmedia durante la NPID en diab\u00e9ticos fue superior a no diab\u00e9ticos de forma significativa (168,60 vs 98,86 mg/dL; p=0,039). \nSe precis\u00f3 aporte de insulina en 11 pacientes (18,3%).\nCONCLUSIONES\n1. La NPID mejora par\u00e1metros nutricionales como la alb\u00famina, la prealb\u00famina y la transferrina, que son pron\u00f3sticos de \nmorbi-mortalidad.  \n2. Los valores de creatinina aumentan poco porque el grado de desnutrici\u00f3n es elevado y los valores iniciales son bajos.  \n3\ufffd Los valores alterados de glucemia y dislipemia van muy vinculados a las comorbilidades de los pacientes y pueden \ncontrolarse con el ajuste de la NPID estandarizada.  \n4.La NPID est\u00e1 indicada en estad\u00edos de desnutrici\u00f3n leve-moderados por lo que su efectividad est\u00e1 muy condicionada por \nel severo grado de desnutrici\u00f3n inicial de estos pacientes\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n555. ESTABILIDAD DE UNA SOLUCI\u00d3N DE MEROPENEM 50 MG/ML PARA EL TRATAMIENTO DE \nINFECCIONES OCULARES \nAUTORES\nMART\u00cdNEZ MADRID, ME; RU\u00cdZ RAM\u00cdREZ, JC; MAR\u00cdN ANDREU, Y; ALONSO HERREROS, JM; SALAR VALVERDE, I; SOLER \nSOLER, MDM; ABELL\u00d3N RU\u00cdZ, J\nHOSPITAL LOS ARCOS. P\u00ba DE COL\u00d3N, 54 SAN JAVIER. MURCIA\nOBJETIVOS\nEstudiar la estabilidad f\u00edsico-qu\u00edmica de un colirio de meropenem 50 mg/mL, para utilizarlo en infecciones oculares.\nMATERIALES Y M\u00c9TODOS\nSe prepararon dos formulaciones. Una con agua para inyecci\u00f3n (API) y otra con suero fisiol\u00f3gico. Se determin\u00f3 el pH y la \nosmolalidad de cada una\ufffd  245El estudio se realiz\u00f3 siguiendo las recomendaciones del International Council for Harmonisation of Technical \nRequirements for Pharmaceuticals for Human Use. Se formul\u00f3 un lote de colirio siguiendo las recomendaciones de \nla Gu\u00eda de Buenas Pr\u00e1cticas de Preparaci\u00f3n de Medicamentos en Servicios de Farmacia Hospitalaria. Las muestras se \nenvasaron en frascos de polietileno de baja densidad (Guinama, S.L.U.) y fueron congeladas a -20+2\u00baC. Las muestras \nfueron divididas en dos grupos: estabilidad congelado (GEC) y estabilidad refrigerado tras descongelaci\u00f3n (GER). Este \n\u00faltimo, simulando condiciones reales de uso.  \n \nEn el GEC se realizaron controles a tiempo cero. Luego, cada 7 d\u00edas, tras descongelaci\u00f3n de las muestras, midiendo la \nconcentraci\u00f3n y el pH del colirio de meropenem. Tambi\u00e9n, se revis\u00f3 visualmente el color y la limpidez de la soluci\u00f3n, la \npresencia de cristales y esterilidad\ufffd  \n \nEn el GER se realizaron controles a tiempo cero y tras descongelaci\u00f3n. Se procedi\u00f3 a la refrigeraci\u00f3n de las muestras \ndescongeladas realizando controles a los 3 y 7 d\u00edas. Cada d\u00eda se simul\u00f3 la administraci\u00f3n, dejando atemperar, dosificando \ndos gotas y retorn\u00e1ndolo al refrigerador. Los controles realizados fueron los mismos que en el grupo GEC.  \n \nLa concentraci\u00f3n de meropenem se midi\u00f3 por cromatograf\u00eda l\u00edquida de alta presi\u00f3n, validando la t\u00e9cnica anal\u00edtica. Se \nutiliz\u00f3 una fase m\u00f3vil de agua, acetonitrilo y metanol a 1 mL/min, una columna XBridge C18 y una longitud de onda de \n300 nm. El pH se midi\u00f3 utilizando pHmetro. La comprobaci\u00f3n del color y la limpidez se realiz\u00f3 por inspecci\u00f3n visual. Se \nevalu\u00f3 la presencia de cristales por microscop\u00eda \u00f3ptica y la esterilidad mediante controles microbiol\u00f3gicos.\nRESULTADOS\nSe seleccion\u00f3 la formulaci\u00f3n con 50 mg/mL de meropenem en API por su menor osmolalidad (362 miliosmoles), m\u00e1s \ncercana al fluido lacrimal.  \n \nEn el grupo GEC el porcentaje medio de recuperaci\u00f3n (%MR) en el d\u00eda 21, respecto de la concentraci\u00f3n inicial, fue del \n97,08% (IC95%:96,81-97,35%). El pH no cambi\u00f3 de manera significativa respecto al inicial (rango: 7,88-8,04). No hubo \ncambios en el color y limpidez de la soluci\u00f3n, ni formaci\u00f3n de cristales. El resultado del control microbiol\u00f3gico fue \nnegativo para el crecimiento de microorganismos.  \n \nEl %MR en el grupo GER a las 72 horas fue del 83,64% (IC95%:83,39-83,89%) y a los 7 d\u00edas del 66,57% (IC95%:66,33-\n66,81%). No hubo cambio significativo en el pH (rango:7,93-8,04). Se observ\u00f3 cambio de color que pas\u00f3 de transparente \na amarillo, siendo la intensidad mayor a los 7 d\u00edas respecto a las 72 h. Se observaron cristales longitudinales de escasa \nlongitud, a las 72 h y a los 7 d\u00edas. El resultado microbiol\u00f3gico fue negativo.\nCONCLUSIONES\nEl colirio de meropenem 50 mg/mL en API es fisco-qu\u00edmicamente estable congelado durante 21 d\u00edas. Sin embargo, no \nlo es refrigerado perdiendo m\u00e1s de un 10% de su concentraci\u00f3n inicial a las 72 h, cambiando de color y form\u00e1ndose \ncristales\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n556. FABRICACI\u00d3N DE FORMAS FARMAC\u00c9UTICAS SEMIS\u00d3LIDAS ESF\u00c9RICAS MEDIANTE UTILIZACI\u00d3N DE \nMOLDES DISE\u00d1ADOS POR IMPRESORA 3D PARA DIAGN\u00d3STICO DE DISFAGIA POR FLUOROSCOPIA \nAUTORES\nPUENTE IGLESIAS, M; CAJADE PASCUAL, F; VARELA REY , I; BUSTO IGLESIAS, M; GONZ\u00c1LEZ BARCIA, M; FERNANDEZ \nFERREIRO, A\nHOSPITAL CL\u00cdNICO UNIVERSITARIO DE SANTIAGO \ufffd CHOUPANA, S/N SANTIAGO DE COMPOSTELA \ufffd A CORU\u00d1A\nOBJETIVOS\nUno de los criterios diagn\u00f3sticos de disfagia es que el paciente no logre deglutir un compuesto de tama\u00f1o superior a 12 \nmm de di\u00e1metro. Para ello, se administran al paciente comprimidos de ese di\u00e1metro y se observa su progreso a trav\u00e9s \ndel paso gastrointestinal utilizando la videofluoroscopia. Sin embargo, la elaboraci\u00f3n de comprimidos requiere una \ncompleja infraestructura para administrarlos de forma segura en pacientes con esta patolog\u00eda, dado que deben presentar \nun determinado tama\u00f1o y consistencia. As\u00ed, su obtenci\u00f3n pasa a ser un factor limitante para la aplicaci\u00f3n de esta t\u00e9cnica \ndiagn\u00f3stica. \nEl objetivo del actual trabajo es mostrar la utilidad de la impresi\u00f3n 3D en el \u00e1rea de gal\u00e9nica para la elaboraci\u00f3n de \nequipamiento espec\u00edfico (moldes) que permitan obtener formas farmac\u00e9uticas semis\u00f3lidas gelatinosas adaptadas al \ntama\u00f1o que se requiera en funci\u00f3n de las demandas diagn\u00f3sticas en el campo de la videofluoroscopia.\nMATERIALES Y M\u00c9TODOS\nEstudio experimental prospectivo, multic\u00e9ntrico y multidisciplinar en el que se dise\u00f1a un molde con espacios esf\u00e9ricos \nutilizando para ello el software Fusion 360. Posteriormente, el dise\u00f1o se imprime utilizando una impresora 3D Artillery \nGenius utilizando \u00e1cido polil\u00e1ctico (PLA) de la marca FORMAKERS.  \nEl tama\u00f1o final obtenido de la cavidad para elaborar la forma farmac\u00e9utica esf\u00e9rica se determin\u00f3 mediante un calibre \ndigital modelo; HG00962A y marca; Parkside\ufffd  \nUna vez realizado el molde se han probado diferentes pol\u00edmeros para su relleno que permitiesen por una parte una \ntextura adecuada para la degluci\u00f3n en pacientes con disfagia y a su vez una disoluci\u00f3n inmediata con agua a 37\u00ba ante el \nhipot\u00e9tico caso de atragantamiento u obstrucci\u00f3n en diferentes partes del tracto gastrointestinal246RESULTADOS\nEl molde elaborado consta de dos partes que se unen mediante dos bisagras obteni\u00e9ndose un dispositivo que permite \nobtener 6 esferas con di\u00e1metros de 12 mm, el cual ha sido certificado con la medici\u00f3n mediante el calibre (se mostrar\u00e1n \nfotograf\u00edas en detalle).  \nEl llenado del dispositivo se realiza con una jeringa a trav\u00e9s de los orificios dise\u00f1ados en cada alveolo para realizar este \nprocedimiento. La soluci\u00f3n introducida debe estar en fase l\u00edquida en el momento de llenado y solidificarse a medida que \nse enfr\u00eda adquiriendo la forma esf\u00e9rica del molde, los excipientes que han mostrado mejores caracter\u00edsticas para ello han \nsido el agaragar y gelatina.\nCONCLUSIONES\nLa impresi\u00f3n tridimensional (3D) de medicamentos est\u00e1 en auge y ya existen diferentes publicaciones sobre su \nimplementaci\u00f3n, sin embargo, el potencial y versatilidad de la impresi\u00f3n 3D en el dise\u00f1o de material utilizado en \nla elaboraci\u00f3n de formulaciones magistral, puede representar un punto de inflexi\u00f3n en el desarrollo de nuevas \nformulaciones adaptadas a procedimientos diagn\u00f3sticos como el presente.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n590. ESTABILIDAD QU\u00cdMICA Y COMPATIBILIDAD F\u00cdSICA DE FUROSEMIDA EN CLORURO S\u00d3DICO 0,9% E \nHIPERT\u00d3NICO PARA EL TRATAMIENTO DE LA INSUFICIENCIA CARDIACA \nAUTORES\nMART\u00cdNEZ G\u00d3MEZ, MA; RICOY SANZ, I; MART\u00cdNEZ ALBALADEJO, P; GIM\u00c9NEZ GINER, S; LLOPIS ALEMANY , A; BRAVO \nCRESPO, C; POLO DUR\u00c1N, J; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nLa administraci\u00f3n de furosemida en combinaci\u00f3n con soluciones salinas hipert\u00f3nicas puede reportar beneficio cl\u00ednico \nen el manejo de la insuficiencia card\u00edaca congestiva avanzada. El objetivo es determinar la estabilidad qu\u00edmica y \ncompatibilidad f\u00edsica de furosemida a diferentes concentraciones en cloruro s\u00f3dico 0,9% y cloruro s\u00f3dico hipert\u00f3nico \n(1,5% y 3%) para el tratamiento de la insuficiencia card\u00edaca.\nMATERIALES Y M\u00c9TODOS\n- F\u00e1rmaco: Furosemida 250 mg/25mL, Sanofi-Aventis\u00ae (FUR)  \n- Veh\u00edculos: Cloruro s\u00f3dico 0,9% (S0,9%) y cloruro s\u00f3dico hipert\u00f3nico 1,5% (S1,5%) y 3% (S3%). \n- Envases: Viaflo\u00ae S0,9% 250mL, Baxter\u00ae.  \n- Conservaci\u00f3n: 48 h a 4,5\u00baC (N) o 23,4\u00baC (TA), con fotoprotecci\u00f3n.  \n- Mezclas: Se prepararon 18 mezclas por duplicado.  \n(i) FUR 1 mg/mL: M1, S0,9%-N; M2, S0,9%-TA; M3, S1,5%-N; M4, S1,5%-TA; M5, S3%-N; M6, S3%-TA. (ii) FUR 2,5 mg/mL: \nM7, S0,9%-N; M8, S0,9%-TA; M9, S1,5%-N; M10, S1,5%-TA; M11, S3%-N; M12, S3%-TA. (iii) FUR 5 mg/mL: M13, S0,9%-N; \nM14, S0,9%-TA; M15, S1,5%-N; M16, S1,5%-TA; M17, S3%-N; M18, S3%-TA. \n- Estabilidad qu\u00edmica: Se determin\u00f3 la concentraci\u00f3n de furosemida a diferentes tiempos mediante cromatograf\u00eda l\u00edquida \nde alta resoluci\u00f3n; se calcularon los porcentajes de concentraci\u00f3n remanente (%CR) y T90, cuando %CR fue \u226490%.  \n- Compatibilidad f\u00edsica: Se evalu\u00f3: a) variaci\u00f3n de color y aparici\u00f3n de precipitado, mediante inspecci\u00f3n visual \n(incompatibilidad: detecci\u00f3n de cambio); b) evaporaci\u00f3n, mediante gravimetr\u00eda (incompatibilidad: disminuci\u00f3n de \nvolumen > 5%); c) variaci\u00f3n de pH, mediante pH-metro y electrodo de vidrio (incompatibilidad: variaci\u00f3n pH > 5%).\nRESULTADOS\n- Estabilidad qu\u00edmica: %CR\u226590% en todas las mezclas durante 48 h excepto en M17, siendo T90, 8 h.  \n- Compatibilidad f\u00edsica: No hubo cambio de color ni evaporaci\u00f3n en las mezclas. Se observ\u00f3 precipitado en M17 a las 48 h. \nEl pH inicial de las mezclas fue: 7,1 para las mezclas con FUR 1 mg/mL, 7,6 para mezclas con FUR 2,5 mg/mL y 8,0 para las \nmezclas con FUR 5mg/mL. La variaci\u00f3n de pH fue \u22645% en todas las mezclas.\nCONCLUSIONES\nEl periodo de validez de mezclas de furosemida de concentraci\u00f3n 1 o 2,5 mg/mL en cloruro s\u00f3dico 0,9% o hipert\u00f3nico \n(1,5 o 3%) en Viaflo\u00ae a 23,4\u00baC o 4,5\u00baC con fotoprotecci\u00f3n es m\u00ednimo de 48 h. A la concentraci\u00f3n de 5 mg/mL, el periodo \nde validez en cloruro s\u00f3dico 0,9% o hipert\u00f3nico 1,5% en Viaflo\u00ae a 23,4\u00baC o 4,5\u00baC o bien en cloruro s\u00f3dico hipert\u00f3nico 3% \nen Viaflo\u00ae a 23,4\u00baC con fotoprotecci\u00f3n es m\u00ednino de 48 h, mientras que en cloruro s\u00f3dico hipert\u00f3nico 3% en Viaflo\u00ae a \n4,5\u00baC con fotoprotecci\u00f3n es de 8 h. La estabilidad qu\u00edmica y compatibilidad fisica de las mezclas de furosemida en cloruro \ns\u00f3dico hipert\u00f3nico (1,5% y 3%) permite su administraci\u00f3n simult\u00e1nea y avala la preparaci\u00f3n anticipada en la Unidad \nCentralizada de Terapia Parenteral de los Servicios de Farmacia.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n602. AN\u00c1LISIS DEL SOPORTE NUTRICIONAL DESDE UN ENFOQUE MULTIDISCIPLINAR EN PACIENTES \nCON ANOREXIA NERVIOSA \nAUTORES\nVALDEOLMILLOS CARB\u00d3, L; GARC\u00cdA PASTOR, C; MATEO FOLGADO, E; BARACE INDURAIN, MC; BLAZQUIZ IBERO, E; \nLACASA ARREGUI, C\nCLINICA UNIVERSITARIA DE NAVARRA \ufffd AV\ufffd PIO XII, 36 PAMPLONA/IRU\u00d1A \ufffd NAVARRA247OBJETIVOS\nLa anorexia nerviosa es una enfermedad psiqui\u00e1trica muy frecuente en pacientes j\u00f3venes. Esta enfermedad presenta \nalta variabilidad en su gravedad, condicionando diferentes abordajes terap\u00e9uticos y tratamientos cada vez m\u00e1s \nindividualizados. La restauraci\u00f3n del estado nutricional de manera progresiva es un primer paso en el tratamiento para la \nestabilizaci\u00f3n cl\u00ednica, evitando complicaciones a largo plazo.  \n \nEl objetivo del estudio es analizar la eficacia y la seguridad de la renutrici\u00f3n mixta v\u00eda oral y enteral.\nMATERIALES Y M\u00c9TODOS\nSe llev\u00f3 a cabo un estudio observacional, retrospectivo y unic\u00e9ntrico de pacientes ingresados para renutrici\u00f3n de octubre \nde 2018 a abril de 2022, en seguimiento por endocrinolog\u00eda, psiquiatr\u00eda, nutrici\u00f3n y farmacia. El an\u00e1lisis de las variables \nfue descriptivo expres\u00e1ndose como medias, medianas y porcentajes.  \n \nSe recogieron de la historia clinica electr\u00f3nica las siguientes variables: sexo, edad, \u00edndice de masa corporal (IMC), criterio \nGlobal Leadership iniciative on Malnutricion (GLIM), p\u00e9rdida de peso en los 6 meses previos al ingreso, tipo de nutrici\u00f3n \nenteral (NE) y su duraci\u00f3n, aporte nutricional mixto (kcal/kg/d\u00eda) los d\u00edas 1, 7, 14 y m\u00e1ximo alcanzado, la administraci\u00f3n \nde suplementos vitam\u00ednicos, ganancia de peso semanal (objetivo de 1 kg), desarrollo de s\u00edndrome de realimentaci\u00f3n (SR) \nseg\u00fan valores anal\u00edticos de electrolitos intracelulares y porcentaje de ganancia de peso final.\nRESULTADOS\nSe incluyeron 19 pacientes con diagn\u00f3stico anorexia nerviosa CIE-10 F50.0, siendo el 95 % mujeres con una mediana \nde edad e IMC al ingreso de 21 a\u00f1os (min/max: 14-58) y 14 kg/m2 (9,2-17,3) respectivamente. Todos los pacientes \npresentaron criterios GLIM de desnutrici\u00f3n severa, con un 23,8 % de p\u00e9rdida ponderal en los \u00faltimos 6 meses \ncondicionada por una reducci\u00f3n en la ingesta alimentaria\ufffd  \n \nDurante la renutrici\u00f3n mixta v\u00eda oral y enteral, el aporte nutricional promedio (kcal/kg/d\u00eda) el d\u00eda 1 fue de 27,9; el d\u00eda 7 \nde 44,2 y el d\u00eda 14 de 51,1, alcanzando un aporte m\u00e1ximo de 70,8 kcal/kg/d\u00eda. La composici\u00f3n de la NE en el 100% de los \npacientes fue normoproteica y en el 47 % hipercal\u00f3rica. \n \nLa duraci\u00f3n media del soporte nutricional con NE fue de 54,1 d\u00edas, obteni\u00e9ndose una ganancia de peso semanal de 1,05 \nKg. El incremento ponderal final fue de 25,1 % respecto al peso inicial, llegando a alcanzar un IMC al alta de 18,1 kg/m2. \nSe desarrollaron las siguientes alteraciones anal\u00edticas durante la renutrici\u00f3n (% pacientes): elevaci\u00f3n de ALT y AST \n(32 %), elevaci\u00f3n de FA (16%), elevaci\u00f3n ferritina (16%) y depleci\u00f3n de potasio, fosfato y magnesio (16%). El 79 % \nrecibieron suplementos vitam\u00ednicos siendo la gran mayor\u00eda vitamina B1 (93 %) y B6 (80 %). S\u00f3lo un 16 % de los pacientes \ndesarrollaron SR \ufffd\nCONCLUSIONES\nEl aporte cal\u00f3rico escalonado administrado mediante nutrici\u00f3n mixta consigui\u00f3 un progresivo aumento semanal de \npeso sin provocar SR en el 84 % de los pacientes\ufffd Cabe destacar la importancia del seguimiento por parte de farmacia y \ncolaboraci\u00f3n con el equipo de psiquiatr\u00eda, endocrinolog\u00eda y nutrici\u00f3n para el tratamiento individualizado de este tipo de \npaciente, consiguiendo la restauraci\u00f3n del estado nutricional\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n615. SOLUCI\u00d3N OFT\u00c1LMICA DE EDTA 2% EN QUERATOPAT\u00cdA C\u00c1LCICA EN BANDA \nAUTORES\nFUENTES IRIGOYEN, R; TORNERO TORRES, O; MATA DIAZ, E; TEJADA GONZ\u00c1LEZ, P; MONTEJANO HERVAS, P; MOR\u00c1N \nP\u00c9REZ, MA; C\u00c1CERES MOSQUETE, Y\nHOSPITAL CENTRAL DE LA CRUZ ROJA SAN JOS\u00c9 Y SANTA ADELA. AV . DE LA REINA VICTORIA, 22-26 MADRID. MADRID\nOBJETIVOS\nDescribir la efectividad y seguridad de la aplicaci\u00f3n una nueva formulaci\u00f3n de edetato dis\u00f3dico 2% soluci\u00f3n oft\u00e1lmica \n(EDTA2%) en dos pacientes afectados de queratopat\u00eda c\u00e1lcica en banda.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica para determinar la concentraci\u00f3n y formulaci\u00f3n m\u00e1s adecuada de la soluci\u00f3n \noft\u00e1lmica de EDTA como quelante de calcio en queratopat\u00eda as\u00ed como datos de eficacia y seguridad en esta patolog\u00eda. \nAdem\u00e1s, se siguieron las recomendaciones de la Gu\u00eda de Buenas Pr\u00e1cticas de Preparaci\u00f3n de Medicamentos en los \nServicios de Farmacia\ufffd  \nMet\u00f3dica de elaboraci\u00f3n:  \nEdetato dis\u00f3dico dihidratado 1,887 g  \nHidr\u00f3xido s\u00f3dico 1 N cs para pH entre 6,5-7,5  \nAgua est\u00e9ril para inyecci\u00f3n (API) csp 100 ml.  \n1. Pesar el EDTA en frasco est\u00e9ril en balanza de precisi\u00f3n. Cerrarlo y pasar a la cabina de flujo laminar horizontal de la sala \nlimpia con el resto de materias primas y utensilios previamente desinfectados\ufffd  \n2. Disolver el EDTA a\u00f1adiendo 60 ml de API en el mismo frasco est\u00e9ril.  \n3. Comprobar el pH, si es necesario a\u00f1adir hidr\u00f3xido s\u00f3dico para ajustarlo entre 6.5-7.5. \n4. Enrasar la soluci\u00f3n hasta 100 ml con API y mezclarla bien verti\u00e9ndola de nuevo en el frasco est\u00e9ril y agitando.  2485. Realizar doble filtraci\u00f3n con filtro esterilizante 0.22 mcm y envasar en frasco de colirio est\u00e9ril de pl\u00e1stico.  \nCaducidad: 14 d\u00edas refrigerado.  \nPara evaluar efectividad y seguridad en nuestros pacientes se les hizo seguimiento a trav\u00e9s de la historia cl\u00ednica \nelectr\u00f3nica desde el d\u00eda de la cirug\u00eda hasta 7 meses y 20 d\u00edas post cirug\u00eda respectivamente. Tambi\u00e9n se consult\u00f3 a la \noftalm\u00f3loga que oper\u00f3 a ambos pacientes.\nRESULTADOS\nLa t\u00e9cnica para tratar la queratopat\u00eda en ambos casos fue: desepitelizaci\u00f3n mec\u00e1nica del epitelio corneal que est\u00e1 sobre la \nzona de queratopat\u00eda en banda, aplicaci\u00f3n de EDTA2% en gotas con fresado de la superficie corneal hasta la desaparici\u00f3n \ndel dep\u00f3sito y colocaci\u00f3n de lente terap\u00e9utica. Tratamiento con colirio de tobramicina 3 mg/ml + dexametasona 1 mg/ml \ndurante al menos 7 d\u00edas.  \nPaciente 1: Var\u00f3n de 71 a\u00f1os. Desde el siguiente d\u00eda de la intervenci\u00f3n se objetiva cornea transparente consiguiendo la \nreepitelizaci\u00f3n corneal completa y retirada de lente terap\u00e9utica tras 25 d\u00edas. A los 7 meses de la cirug\u00eda se objetiva de \nnuevo queratopat\u00eda c\u00e1lcica en banda inferior. \nPaciente 2: Mujer de 81 a\u00f1os. Tras 7 d\u00edas de la intervenci\u00f3n se objetiva cornea transparente y reepitelizaci\u00f3n corneal \ncompleta con retirada de la lente y suspensi\u00f3n del tratamiento tobramicina + dexametasona. Se carece a\u00fan de resultados \na medio plazo.  \nAmbos pacientes tuvieron dolor, lagrimeo y visi\u00f3n borrosa hasta la reepitelizaci\u00f3n corneal.\nCONCLUSIONES\nEl EDTA2% es una formulaci\u00f3n sencilla, en la que se deben tener en cuenta las precauciones propias de las preparaciones \nest\u00e9riles partiendo de materias primas no est\u00e9riles. \nLos resultados de efectividad y seguridad en nuestros pacientes son acordes a la bibliograf\u00eda encontrada objetivando \nalta eficacia inmediata y recidiva tras 6 meses aproximadamente de la intervenci\u00f3n. Las molestias, producidas como \nconsecuencia de la desepitelizaci\u00f3n corneal m\u00e1s que por el EDTA2%, son normales, pero no graves y revierten tras la cura \ndel epitelio\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n635. USO DEL COLIRIO DE INSULINA EN DEFECTOS EPITELIALES CORNEALES PERSISTENTES A OTROS \nTRATAMIENTOS FARMACOL\u00d3GICOS \nAUTORES\nCAO VI\u00d1A, V; L\u00d3PEZ L\u00d3PEZ, MDP; PLAZA ARBEO, A; CONTRERAS COLLADO, R; GUTI\u00c9RREZ LUCENA, L; GARC\u00cdA \nG\u00d3MEZ, N\nCOMPLEJO HOSPITALARIO DE JA\u00c9N. AV . DEL EJ\u00c9RCITO ESPA\u00d1OL, 10 JA\u00c9N. JA\u00c9N\nOBJETIVOS\nEvaluar la eficacia y seguridad de la utilizaci\u00f3n del colirio de insulina como uso off-label para el tratamiento de defectos \nepiteliales corneales persistentes(DECP) de diferentes etiolog\u00edas. Estos DECP se incluyen dentro de un grupo heterog\u00e9neo \nde lesiones oculares, las cuales pueden ser de gravedad variable\ufffd Cuando los pacientes no responden al tratamiento, \nincluyendo incluso el trasplante corneal, se crea la necesidad de explorar otras alternativas. Algunos estudios refieren que \nlas erosiones epiteliales parecen responder favorablemente a la aplicaci\u00f3n de insulina t\u00f3pica\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo en un hospital de tercer nivel, donde se incluyeron pacientes tratados \ncon colirio de insulina, desde el 1 de Julio de 2021 hasta 30 abril de 2022. Las variables recogidas fueron las siguientes: \nsexo, edad, diagn\u00f3stico, tratamientos previos y concomitantes y datos relativos al tratamiento con colirio de insulina \n(concentraci\u00f3n, dosis, frecuencia de administraci\u00f3n, duraci\u00f3n tratamiento, efectividad y seguridad). Para la recogida \nde datos se revisaron las historias cl\u00ednicas de los pacientes y los protocolos de elaboraci\u00f3n del colirio como f\u00f3rmula \nmagistral\ufffd  \nLa respuesta al tratamiento fue evaluada por oftalmolog\u00eda mediante la observaci\u00f3n de la lesi\u00f3n corneal a trav\u00e9s del \nexamen de la fluoresce\u00edna, valor\u00e1ndose el estado de reepitelizaci\u00f3n de la c\u00f3rnea.\nRESULTADOS\nEn el estudio se incluyeron 11 pacientes con edades comprendidas entre 29 y 86 a\u00f1os, siendo la media de edad 59,3\ufffd \nDe ellos, 54,55% eran hombres y 45,45% mujeres. Los diagn\u00f3sticos fueron los siguientes: \u00falcera corneal neurotr\u00f3fica \n(n=2), \u00falcera corneal post cirug\u00eda (n=2), DEPC tras traumatismo perforante (n=2), queratitis herp\u00e9tica (n=1), \u00falcera por \nqueratopat\u00eda bullosa (n=1), queratitis severa tras cirug\u00eda de cataratas (n=1), defecto epitelial (n=1) e hidrops corneal con \nleucoma central (n=1). Del total, 3 hab\u00edan sido trasplantados de c\u00f3rnea. \nTodos los pacientes hab\u00edan recibido tratamientos orales y/o t\u00f3picos oft\u00e1lmicos previos y concomitantes al colirio de \ninsulina. Entre ellos encontramos: antibi\u00f3ticos, corticoides, AINEs, l\u00e1grimas artificiales, suero aut\u00f3logo, ciclosporina y \nciclop\u00e9jicos.  \nAl 81,82 % de los pacientes se le prescribi\u00f3 el colirio de insulina a la concentraci\u00f3n de 1UI/ml y al 18,18 %, 5UI/ml\ufffd La \ndosis y frecuencia de administraci\u00f3n fue de 1 gota 4 veces al d\u00eda en todos los casos. En el 36,36 % de los pacientes el \ntratamiento finaliz\u00f3 tras una duraci\u00f3n media de 2,25 meses, con resultados positivos. El 54,54% continuaron con el \ntratamiento tras finalizar el estudio (duraci\u00f3n media de 4 meses) y al 9% se le suspendi\u00f3 el tratamiento tras 10 d\u00edas por \nmala evoluci\u00f3n. No se reportaron efectos adversos en ning\u00fan caso.  249La preparaci\u00f3n del colirio se realiza en campana de flujo laminar horizontal(CFLH), diluyendo en Systane Ultra\u00ae, \ninsulina r\u00e1pida (Actrapid\u00ae) 10UI (0,1ml) y 50UI (0,5ml), para obtener concentraciones finales de 1UI/ml y 5UI/ml, \nrespectivamente.\nCONCLUSIONES\nEl uso del colirio de insulina, result\u00f3 ser efectivo y seguro en el tratamiento de los DECP refracta-rios a otros tratamientos \nen nuestra poblaci\u00f3n de estudio. Supone una herramienta sencilla, efi-ciente y segura, permitiendo la combinaci\u00f3n con \notras modalidades de tratamiento\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n670. AN\u00c1LISIS COMPARATIVO DE RECURSOS FARMAC\u00c9UTICOS DEDICADOS A ONCOLOG\u00cdA Y A \nNUTRICI\u00d3N \nAUTORES\nBERISTAIN ARAMENDI, I; VALLINAS HIDALGO, S; OLARIAGA SARASOLA, O; LEUNDA EIZMENDI, L; ROS OLASO, A; BOO \nRODRIGUEZ, J; BACHILLER CACHO, MP; RIPA CIAURRIZ, C\nHOSPITAL DONOSTIA-DONOSTIA OSPITALEA. P\u00ba DR. BEGUIRISTAIN, 109 DONOSTIA-SAN SEBASTI\u00c1N. GUIP\u00daZCOA\nOBJETIVOS\nAnalizar recursos farmac\u00e9uticos dedicados a oncolog\u00eda y nutrici\u00f3n en los Servicios de Farmacia de hospitales participantes \nen el estudio Onconutridos\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo. Datos obtenidos en los hospitales participantes en Onconutridos.  \n \nVariables: titularidad, tama\u00f1o, existencia unidad de nutrici\u00f3n, farmac\u00e9uticos dedicados a: oncolog\u00eda incluida la \nhematol\u00f3gica (OH), pacientes externos OH (PE-OH), ensayos cl\u00ednicos OH (EC-OH), nutrici\u00f3n; pacientes atendidos en: \nhospital de d\u00eda OH (HD-OH), consulta PE-OH; farmac\u00e9uticos con BPS (Board of Pharmacy Specialties) en: oncolog\u00eda, \nnutrici\u00f3n\ufffd\nRESULTADOS\nParticipan 85 hospitales, 81,18% p\u00fablicos, 11,76% privados, el resto mixto. El 22,62% tiene < 200 camas, el 47,62% 200-\n500, el 22,62% 500-1000, el 7,14% > 1000. El 71,76% tiene unidad de nutrici\u00f3n, en esos hospit ales el 59% tiene Comisi\u00f3n \nde Nutrici\u00f3n, el farmac\u00e9utico es miembro en todas.  \n \nTabla 1. Recursos farmac\u00e9uticos por Autonom\u00eda  \n \nAutonom\u00eda Hospital Farmac\u00e9uticos Pacientes  \nOH PE-OH EC-OH Nutrici\u00f3n HD-OH PE-OH \nAndaluc\u00eda 10 24 15 14 10 34.035 13.658 \nArag\u00f3n 3 9 5 1 9 9\ufffd186 1\ufffd337 \nAsturias 3 4,5 3 2 3 4\ufffd660 3\ufffd357  \nBaleares 3 5 3 4 3 13\ufffd089 892  \nCanarias 1 1 2 2 2 15\ufffd750 6\ufffd301 \nCantabria 1 6 2 2 2 14\ufffd500 1\ufffd838 \nCastilla la Mancha 4 6 5 2 5 1.905 799  \nCastilla y Le\u00f3n 8 19,5 14,5 8,5 11 13.332 4.885  \nCatalu\u00f1a 13 17,5 19 11 16 13\ufffd457 20\ufffd156  \nCom\ufffd Valenciana 12 22,5 17,5 9,5 16,5 45\ufffd158 6\ufffd136  \nEuskadi 7 20 11 10,5 11,3 27\ufffd310 28\ufffd861  \nGalicia 2 8 3,5 2 2,5 2\ufffd073 1\ufffd849  \nLa Rioja 1 2 1 1 1 800 700 \nMadrid 14 30 19,5 15 17 48\ufffd574 27\ufffd732  \nMurcia 1 2 1 2 1 6\ufffd250 0 \nNavarra 1 4 5 2 4 3\ufffd000 1\ufffd104  \n \n \nTabla 2. Farmac\u00e9uticos dedicados a oncohematolog\u00eda, nutrici\u00f3n. Formaci\u00f3n en BPS  \n \nAutonom\u00eda Farmac\u00e9uticos OH BPS Farmac\u00e9uticos nutrici\u00f3n BPS  \nAndaluc\u00eda 24 14 10 0  \nArag\u00f3n 9 1 9 0 \nAsturias 4,5 2 3 0 \nBaleares 5 1 3 0  \nCanarias 1 1 2 1 \nCantabria 6 3 2 0 \nCastilla la Mancha 6 1 5 1  250Castilla y Le\u00f3n 19,5 3 11 3 \nCatalu\u00f1a 17,5 8 16 6 \nComunidad Valenciana 22,5 2 16,5 2  \nEuskadi 20 5 11,3 4  \nGalicia 12 6 5,5 3 \nLa Rioja 2 0 1 0  \nMadrid 30 11 17 3 \nMurcia 2 0 1 0 \nNavarra 4 1 4 1 \nTotal 185 59 (31,89%) 117,3 24 (20,46%)\nCONCLUSIONES\nLa mayor\u00eda de los hospitales son p\u00fablicos, tienen 200-500 camas y unidad de nutrici\u00f3n. Madrid es la autonom\u00eda con m\u00e1s \nrecursos farmac\u00e9uticos en OH; en Canarias hay m\u00e1s en nutrici\u00f3n. La proporci\u00f3n de farmac\u00e9uticos con BPS en oncolog\u00eda \nes mayor que en nutrici\u00f3n, excepto en Castilla la Mancha, Castilla y Le\u00f3n, Comunidad Valenciana, Euskadi y Galicia, y en \nNavarra (misma proporci\u00f3n).\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n686. ESTUDIO DE PH Y OSMOLARIDAD DE LOS F\u00c1RMACOS EMPLEADOS EN EMERGENCIAS METAB\u00d3LICAS \nPARA SU ADMINISTRACI\u00d3N POR SONDA NASOG\u00c1STRICA Y POSTPIL\u00d3RICA. \nAUTORES\nFERN\u00c1NDEZ VELA, J; CHICA MARCHAL, AM; FERN\u00c1NDEZ MART\u00cdNEZ, I; MONTOYA EGEA, JM; ASENSI CANTO, A; \nTAMBOLEO S\u00c1NCHEZ, IJ\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\n1) Estudio de las condiciones de pH y osmolaridad (Osm) id\u00f3neas para la administraci\u00f3n por sonda nasog\u00e1strica (SNG) y \npostpil\u00f3rica de f\u00e1rmacos orales (FO) empleados en emergencias metab\u00f3licas (EM).  \n2) Adecuaci\u00f3n de los excipientes de los medicamentos empleados en EM.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo experimental: \n1) Selecci\u00f3n de los FO m\u00e1s empleados en EM.  \n2) Diluci\u00f3n de las formulaciones en 10 mL de: agua para inyectables (API), leche lactantes inicio y suero fisiol\u00f3gico (SF). \nPara las mediciones del pH se utiliza pHmetro marca: Mettler Toledo SevenMulti\u00ae y para la osmolaridad se emplea un \nosm\u00f3metro marca Osmomat 3000\u00ae\ufffd \n3) B\u00fasqueda de las condiciones \u00f3ptimas de absorci\u00f3n g\u00e1strica y postpil\u00f3rica y elaboraci\u00f3n de recomendaciones.\nRESULTADOS\nEn una EM el paciente puede sufrir disminuci\u00f3n del nivel de consciencia por lo que la v\u00eda oral no puede estar operativa. \nSe buscan alternativas pero la inadecuada administraci\u00f3n por sonda puede provocar malabsorci\u00f3n, disminuci\u00f3n de \neficacia, incluso obturaci\u00f3n. Tipos:  \n- Sonda postpil\u00f3rica (nasoyeyunal (SNY)) Osm recomendada 300-500 mOsm/L. pH intestinal b\u00e1sico, se absorben \nsustancias alcalinas\ufffd  \n- SNG admite mayor Osm hasta 600 mOsm/L. pH g\u00e1strico \u00e1cido, se absorben sustancias \u00e1cidas.  \nSe realizaron 88 determinaciones. pH y Osm de los disolventes empleados: A)API (pH=7,2; 188 mOsm/L); B)Leche \n(pH=6,7; 350 mOsm/L); C)Suero fisiol\u00f3gico (SF) (pH=4,5-7,0; 308 mOsm/L).  \nResultados e interpretaci\u00f3n:  \n- Fenilbutirato: Precipita, pH: sin diluir (SD)6,9; A)8,7; B)6,7; C)8,9. Osm: error de medici\u00f3n). No administrar por sonda por \nelevada viscosidad\ufffd  \n- Benzoato: pH: SD)8,8; A)8,5; B)6,7; C)8,4. Osm: SD)1739 mOsm/L; A)144 mOsm/L; B)411 mOsm/L; C)372 mOsm/L. \nAdministrar por SNY diluido en SF \ufffd  \n- \u00c1cido carbagl\u00famico: pH: A)2,9; B)4,4 C)2,8. Osm: A)43 mOsm/L; B)373 mOsm/L; C)320 mOsm/L. pH \u00e1cido, administrar \npor SNG en API\ufffd \n- Arginina 20%: pH: SD)5,9; A)6,2; B)6,4; C)6,2. Osm: SD)1339 mOsm/L; A)238 mOsm/L; B)506 mOsm/L; C)454 mOsm/L. \nDiluido en API y SF, administrar por SNG\ufffd \n- Arginina NM: pH: SD)4,7; A)4,9; B)6,2; C)4,9. Osm: SD: 1880 mOsm/L; A)350 mOsm/L; B)535 mOsm/L; C)588 mOsm/L. \npH m\u00e1s \u00e1cido que Arginina 20% favoreciendo su absorci\u00f3n por SNG diluido en API.  \n- Biotina: pH: A)8,6; B)6,6; C)8,4. Osm: A) 12 mOsm/L; B)330 mOsm/L; C)274 mOsm/L. No adminis trar por sonda.  \n- Carnitina: pH: SD)5,1; A)5,0; B)5,9; C)5,0. Osm: SD:2231 mOsm/L; A)155 mOsm/L; B)467 mOsm/L; C)458 mOsm/L. \nAdministrar por SNG\ufffd \n- Ubidecarenona: pH: SD)4,9; A)4,8; B)6,3; C)4,7. Osm: SD: 1327 mOsm/L; A)100 mOsm/L; B)426 mOsm/L; C)353 mOsm/L. \nAdministrar por SNG en API y SF. Contiene sorbitol, excipiente contraindicado en intolerancia hereditaria a la fructosa. A \naltas dosis produce diarrea osm\u00f3tica. \n- Dicloacetato: pH: SD)5,8; A)5,8; B)6,6; C)6,9. Osm: SD)1627 mOsm/L; A)155 mOsm/L; B)503 mOsm/L; C)606 mOsm/L. La \nOsm disminuye al diluirlo con mayor volumen de API, administraci\u00f3n por SNG\ufffd  251- Diaz\u00f3xido: pH: A)8,2; B)6,6; C)7,8. Osm: A)96mOsm/L; B)426mOsm/L; C)349mOsm/L. El pH limita su absorci\u00f3n por SNG. \nContiene lactosa, excipiente contraindicado en galactosemia.\nCONCLUSIONES\n1) El pH y Osm determinan la v\u00eda de absorci\u00f3n m\u00e1s adecuada para garantizar la m\u00e1xima absorci\u00f3n y evitar complicaciones \nque pongan en riesgo la vida del paciente. \n2) Este estudio nos ha permitido conocer las caracter\u00edsticas de cada f\u00e1rmaco para facilitar la administraci\u00f3n, evitar \nerrores, revisar los excipientes contraindicados para su administraci\u00f3n por SNG y asegurar la m\u00e1xima eficacia.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n705. DESARROLLO DE UNA SUSPENSI\u00d3N T\u00d3PICA DE SIMVASTATINA Y COLESTEROL PARA LA \nPOROQUERATOSIS ACT\u00cdNICA SUPERFICIAL DISEMINADA \nAUTORES\nGARC\u00cdA PASTOR, C; VALDEOLMILLOS CARB\u00d3, L; MATEO FOLGADO, E; BL\u00c1ZQUIZ IBERO, E; BARACE INDURAIN, MC; \nANTO\u00d1ANZAS P\u00c9REZ, J; LACASA ARREGUI, C\nCLINICA UNIVERSITARIA DE NAVARRA \ufffd AV\ufffd PIO XII, 36 PAMPLONA/IRU\u00d1A \ufffd NAVARRA\nOBJETIVOS\nLa poroqueratosis act\u00ednica superficial diseminada (PASD) es una enfermedad rara con herencia autos\u00f3mica dominante \nde la queratinizaci\u00f3n epid\u00e9rmica relacionada con la fotoexposici\u00f3n, con caracter\u00edsticas autoinflamatorias locales. En un \ntercio de los casos, la PASD est\u00e1 causada por mutaciones gen\u00e9ticas en la v\u00eda de la mevalonato quinasa, provocando una \ndeficiencia del colesterol, apoptosis de queratinocitos y acumulaci\u00f3n de metabolitos intermedios t\u00f3xicos.  \nEl tratamiento de la PASD es insuficiente y gran parte de los casos son refractarios. Recientes estudios apoyan un \ntratamiento dirigido a la v\u00eda de la patog\u00e9nesis. La combinaci\u00f3n de colesterol/estatina ha demostrado eficacia en otras \npatolog\u00edas con trastorno de la queratinizaci\u00f3n. La estatina inhibe la formaci\u00f3n de metabolitos proinflamatorios y la \nreposici\u00f3n del colesterol regula el desequilibrio de la bicapa lip\u00eddica. \nEl objetivo es elaborar una suspensi\u00f3n t\u00f3pica de simvastatina 2%-colesterol 2% y valorar la eficacia y seguridad en \npacientes con PASD \ufffd\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en PubMed del uso de una f\u00f3rmula t\u00f3pica de colesterol/estatina en el tratamiento \nde PASD, eligiendo la que m\u00e1s se adaptaba a nuestra necesidad. Se estableci\u00f3 una caducidad seg\u00fan la bibliograf\u00eda y \nla matriz de riesgo incluida en la Gu\u00eda de Buenas Pr\u00e1cticas de Preparaci\u00f3n de Medicamentos en Servicios de Farmacia \nHospitalaria (GBPPM).  \nDesde octubre de 2020 hasta enero de 2021 se trataron, previa tramitaci\u00f3n de uso fuera de ficha t\u00e9cnica a la direcci\u00f3n \nm\u00e9dica del hospital, pacientes con diagn\u00f3stico de PASD confirmado mediante biopsia cut\u00e1nea.  \nSe realiz\u00f3 el seguimiento de las lesiones cut\u00e1neas en las visitas a los 30, 60 y 90 d\u00edas del inicio de tratamiento, \ncomparando la iconograf\u00eda con el estado basal y se registraron los efectos adversos.\nRESULTADOS\nPara elaborar una suspensi\u00f3n de 50 ml de simvastatina 2%-colesterol 2% seguimos el siguiente modus operandi: triturar \n25 comprimidos de simvastatina 40 mg y tamizar; a\u00f1adir 1.000 mg de colesterol y homogeneizar; paralelamente, mezclar \n35 mL de propilenglicol con 15 mL de alcohol et\u00edlico 96\u00ba; adicionar la mezcla anterior a la de colesterol/simvastatina y \nhomogeneizar; envasar en un frasco de cristal topacio. Se estableci\u00f3 una caducidad conservado en frigor\u00edfico de 15 d\u00edas, \nconsiderando el riesgo medio de la preparaci\u00f3n seg\u00fan GBPPM y bibliograf\u00eda. Se obtuvo una suspensi\u00f3n homog\u00e9nea y \ntransl\u00facida de color blanquecino.  \n \nSe utiliz\u00f3 para tratar a 2 mujeres de 45 y 75 a\u00f1os y una madre e hija de 72 y 45 a\u00f1os. Se observ\u00f3 mejor\u00eda cl\u00ednica de las \nlesiones cut\u00e1neas en las 4 pacientes (100 %) durante los 90 d\u00edas de tratamiento.  \nEn la visita del d\u00eda 30, 2 pacientes (50 %) presentaron eritema como efecto adverso, una de ellas discontinu\u00f3 durante \nunas semanas hasta mejor\u00eda. Dicho efecto adverso no se observ\u00f3 durante el resto de visitas.\nCONCLUSIONES\nLa suspensi\u00f3n t\u00f3pica de simvastatina 2%-colesterol 2% elaborada por el \u00e1rea de farmacotecnia ha demostrado efectividad \nen el tratamiento de las lesiones epid\u00e9rmicas ocasionadas por PASD.  \nSe encontraron limitaciones en cuanto al reducido tiempo de seguimiento definido. Asimismo, se precisa una validaci\u00f3n \ngal\u00e9nica para asegurar las caracter\u00edsticas f\u00edsico-qu\u00edmicas y organol\u00e9pticas de la f\u00f3rmula elaborada hasta el periodo \nestablecido de caducidad\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n726. NUTRICI\u00d3N PARENTERAL TOTAL EN PACIENTE QUIR\u00daRGICO: ADECUACI\u00d3N A LAS GU\u00cdAS \nAUTORES\nPINO RAMOS, A; ERDOZAIN SANCLEMENTE, S; IDOATE GRIJALBA, AI; TEJADA MAR\u00cdN, D; FRES\u00c1N RESTITUTO, D; \nRODR\u00cdGUEZ ESQU\u00cdROZ, A; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA252OBJETIVOS\nEvaluar el empleo de nutrici\u00f3n parenteral total (NPT) en pacientes quir\u00fargicos en nuestro hospital respecto a los criterios \nde uso definidos en las gu\u00edas Early Career Faculty The European Society for Clinical Nutrition and Metabolism (ESPEN).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de pacientes quir\u00fargicos a los que se administr\u00f3 nutrici\u00f3n parenteral total post-\noperatoria (NPTP) estandarizada o individualizada. Se analizaron par\u00e1metros antropom\u00e9tricos (sexo, edad, peso talla), \ncomorbilidades (diabetes) y motivo de cirug\u00eda (c\u00e1ncer, oclusi\u00f3n no cancerosa e inflamaci\u00f3n intestinal entre otros). Se \ncompararon los aportes energ\u00e9ticos administrados con las recomendaciones descritas en las gu\u00edas ESPEN.\nRESULTADOS\n121 pacientes quir\u00fargicos que recibieron NPTP fueron analizados entre Junio-2021 y Marzo-2022. La mediana de edad \nfue 69 (17-94) a\u00f1os, siendo el 57,8% (n=70) hombres. El 62,8% (n=76) de las NPTP fueron individualizadas en funci\u00f3n de \nlos requerimientos de los pacientes. Un 76% (n=92) de los pacientes recibieron aporte cal\u00f3rico escalado en su NPTP , de \nlos cuales un 21,7% (n=20) requiri\u00f3 tiamina.  \nEl 29,8% (n=36) de las prescripciones fueron por oclusi\u00f3n no cancerosa, 41,3% (n=50) por oclusi\u00f3n cancerosa, 25,6% \n(n=31) por inflamaci\u00f3n intestinal y 3,3% (n=4) otras situaciones relacionadas con el compromiso de la v\u00eda digestiva.  \nLa duraci\u00f3n media fue de 13 (1-120) d\u00edas. Un total de 27,3% (n=33) de NPTP duraron menos de 7 d\u00edas y por tanto no se \najustan a las indicaciones de las gu\u00edas. Los motivos de suspensi\u00f3n fueron: inicio de tolerancia oral/enteral 64,5% (n=78), \n\u00e9xitus/limitaci\u00f3n del esfuerzo terap\u00e9utico 14,9% (n=18) y problemas relacionados con el cat\u00e9ter 20,6% (n=25).  \nUn 51,2% (n=62) de los pacientes no llegaron al 100% de los requerimientos cal\u00f3ricos totales calculados mediante la \nf\u00f3rmula de Harris-Benedict. Un 57,8% (n=70) de los pacientes recibieron menos de 25 kcal/kg/peso ideal de acuerdo a las \nrecomendaciones ESPEN\ufffd \nEl aporte medio de macronutrientes fue de 2,61, 0,82 y 1,41 g/kg para hidratos de carbono, l\u00edpidos y prote\u00ednas \nrespectivamente. Ninguno de los pacientes super\u00f3 los valores m\u00e1ximos recomendados. Un 64,5% (n= 78) de los pacientes \nrecibi\u00f3 NPTP baja en prote\u00ednas, l\u00edmite cifrado en 1,5 g/kg en las gu\u00edas. En cuanto al ratio kcal glucosa/l\u00edpido, un 34,7% \n(n=42) de los pacientes recibieron una ratio superior a 60/40, tendencia avalada por las gu\u00edas, pero un 8,3% (n=10) recibi\u00f3 \nuna ratio inferior a 50/50, alejada de las recomendaciones.  \n17 pacientes eran diab\u00e9ticos (14%); 11 de ellos (64,7%) recibieron NP con insulina. Otros 6 pacientes no-diab\u00e9ticos (4,9%) \nrecibieron NP con insulina por hiperglucemia secundaria al estr\u00e9s quir\u00fargico. Adem\u00e1s de la NPTP , un 4,1% (n=5) y un \n5,8% (n=7) de los pacientes recibieron NE y NP preoperatoria respectivamente, siendo de estos \u00faltimos el 71,4% (n=5) \npacientes oncol\u00f3gicos\ufffd\nCONCLUSIONES\nEl equipo multidisciplinar farmacia-nutrici\u00f3n se plantea como puntos de mejora en la pr\u00e1ctica diaria:  \n1. Valoraci\u00f3n beneficio-riesgo de la NPTP en pacientes cuya duraci\u00f3n pueda ser inferior a 7 d\u00edas.  \n2. Ajuste diario del aporte proteico-cal\u00f3rico a las necesidades individuales del paciente, evitando un aporte deficiente \nque pueda condicionar la recuperaci\u00f3n post-quir\u00fargica. \n3. Valorar el empleo de nutrici\u00f3n preoperatoria y escalado cal\u00f3rico progresivo tras cirug\u00eda en pacientes con grados de \ndesnutrici\u00f3n moderados-graves.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n732. FORMULACI\u00d3N DE CREMA DE COLESTEROL AL 2% Y SIMVASTATINA AL 2% EN EL TRATAMIENTO DE \nLA POROQUERATOSIS \nAUTORES\nLE\u00d3N MURCIANO, I; REAL PANISELLO, M; RODRIGUEZ SAMPER, MDC; MART\u00cdNEZ-CABALLERO MART\u00cdNEZ, D; S\u00c1EZ \nGARRIDO, M; COLOMER AGUILAR, C; BUJALD\u00d3N QUEREJETA, N; TALENS BOL\u00d3S, A\nHOSPITAL GENERAL DE ELDA-VIRGEN DE LA SALUD. CTRA. ELDA A SAX, S/N ELDA. ALICANTE\nOBJETIVOS\nLa poroqueratosis engloba un conjunto heterog\u00e9neo de trastornos de la queratinizaci\u00f3n subclasificados en base a la \napariencia cl\u00ednica. El fenotipo de la poroqueratosis refleja la deficiencia en el metabolismo de los productos finales de \nla v\u00eda del mevalonato, como es el colesterol, y el ac\u00famulo de metabolitos t\u00f3xicos sintetizados a lo largo de la ruta. La \nporoqueratosis se considera una condici\u00f3n premaligna con un ratio de transformaci\u00f3n a malignidad de 7,5%.  \nEl objetivo es evaluar la efectividad y seguridad de una f\u00f3rmula magistral (FM) t\u00f3pica de colesterol al 2% y simvastatina al \n2% para el tratamiento de la poroqueratosis.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica para recoger datos sobre la indicaci\u00f3n y la formulaci\u00f3n magistral de la crema que \nnos solicit\u00f3 el Servicio de Dermatolog\u00eda para estos pacientes.  \nPara realizar la f\u00f3rmula se estudi\u00f3 la estabilidad fisicoqu\u00edmica del colesterol y la simvastatina, as\u00ed como la compatibilidad \ncon los excipientes finalmente empleados para su elaboraci\u00f3n.  \nDurante 8-12 semanas se realiz\u00f3 un seguimiento de los pacientes para ver la evoluci\u00f3n de las lesiones y recoger los \nposibles efectos adversos\ufffd253RESULTADOS\nActualmente cuatro pacientes se encuentran en tratamiento con esta FM. Se trata de tres adultos (dos mujeres de 31 y \n52 a\u00f1os y un hombre de 83 a\u00f1os) y un ni\u00f1o (de 6 a\u00f1os).  \nAl cabo de 4 semanas tras el inicio del tratamiento se pudo observar un aclaramiento de las lesiones con disminuci\u00f3n del \neritema y la descamaci\u00f3n\ufffd  \nPor lo general, la crema fue bien tolerada con la excepci\u00f3n de un paciente que present\u00f3 rojez y picor alrededor de la zona \nde aplicaci\u00f3n, obligando a suspender el tratamiento\ufffd\nCONCLUSIONES\nLa crema de colesterol al 2% y simvastatina al 2% parece ser un tratamiento efectivo y bien tolerado en el tratamiento de \nla poroqueratosis a corto plazo (12 semanas) en la poblaci\u00f3n estudiada.  \nEs necesario continuar el seguimiento de estos pacientes para valorar la efectividad y seguridad del tratamiento a largo \nplazo.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n743. LACA DE U\u00d1AS DE ANFOTERICINA B AL 2% PARA ONICOMICOSIS RESISTENTE AL TRATAMIENTO \nHABITUAL \nAUTORES\nDE LA TORRE ORTIZ, M; PUEBLA GARCIA, V; FERNANDEZ RUIZ-MORON, A; CORAZON VILLANUEVA, J; SANCHEZ-\nOCA\u00d1A MARTIN, N; YBA\u00d1EZ GARCIA, L; MOLINERO MU\u00d1OZ, M; MARTINEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nDescribir el desarrollo de una f\u00f3rmula magistral (FM) de anfotericina B 2% (anfoB2%) para el tratamiento de onicomicosis.\nMATERIALES Y M\u00c9TODOS\nVar\u00f3n de 55 a\u00f1os en seguimiento desde hace ocho a\u00f1os por el Servicio de Dermatolog\u00eda (SD) por onicopat\u00eda en manos \ny pies. Inicialmente, se aisl\u00f3 Candida parapsilosis que fue tratada con itraconazol, terbinafina y amorolfina t\u00f3pica. \nTras el fracaso farmacol\u00f3gico y la ausencia de crecimiento de microorganismos en los posteriores cultivos, se trat\u00f3 \ncon metotrexato y con acitretina ante una posible onicopat\u00eda psori\u00e1sica. No mejor\u00f3. Ante la sospecha de onicomicosis \npersistente, el SD solicita al Servicio de Farmacia (SF) la elaboraci\u00f3n de una FM t\u00f3pica de anfoB2% como uso fuera de \nindicaci\u00f3n\ufffd  \nSe llev\u00f3 a cabo una b\u00fasqueda bibliogr\u00e1fica para conocer las propiedades fisicoqu\u00edmicas de la anfoB, los veh\u00edculos id\u00f3neos \npara elaborar una laca de u\u00f1as (LU) as\u00ed como la existencia de publicaciones cient\u00edficas de FM t\u00f3picas de anfoB2%. \nSe elaboraron 3 FM de anfoB2% con diferentes veh\u00edculos y/o concentraciones. Cada FM se dividi\u00f3 en dos envases \ntopacios de cristal espec\u00edficos para LU, conservando uno a temperatura ambiente (TA) y el otro en nevera (N). \nLa validaci\u00f3n gal\u00e9nica se estableci\u00f3 en 1 mes (controles d\u00edas 0, 7, 14, 30) y se siguieron los controles de calidad para \nf\u00f3rmulas t\u00f3picas especificados en el Formulario Nacional 3\u00baedici\u00f3n adapt\u00e1ndolos a LU:  \n-propiedades organol\u00e9pticas (aspecto visual)  \n-tiempo de secado: aplicando la LU sobre u\u00f1as sint\u00e9ticas. Tiempo \u00f3ptimo de secado < 6 min  \n-extensibilidad: aplicando sobre una cantidad de FM depositada en un portaobjetos, a intervalos de 1 min, el peso de: \notro portaobjetos, 1g, 2g y 5g. Se calcul\u00f3 la superficie del c\u00edrculo formado tras depositar cada peso.\nRESULTADOS\nLa anfoB es un polvo amarillo-naranja soluble en dimetilsulf\u00f3xido (DMSO) y propilenglicol. Conservaci\u00f3n protegida de la \nluz y en nevera o a temperatura ambiente. \nSe elaboraron tres FM de anfoB2%:  \n-FM1: anfoB 0,2g, propilenglicol 2 ml, base de LU 8 ml. \n-FM2: anfoB 0,2g, propilenglicol 3 ml, base de LU 7 ml. Se eligi\u00f3 una concentraci\u00f3n del 30% de propilenglicol para mejorar \nla disoluci\u00f3n de la anfotericina y para evitar la irritaci\u00f3n causada por su empleo a concentraciones mayores\ufffd \n-FM3: anfoB 0,2g, DMSO 30% 10 ml. \nCaracter\u00edsticas organol\u00e9pticas: fluidas, color amarillo. FM1: con part\u00edculas naranjas. FM2: homog\u00e9nea, sin part\u00edculas. \nFM3: totalmente l\u00edquida, con part\u00edculas naranjas.  \nTiempo de secado (min). FM1 TA y N: 5; FM2 TA: 5; FM2 N: 6. FM3 TA y N: no sec\u00f3.  \nExtensibilidad (cm2). Superficie media de los 4 pesos: FM1 TA y N: 4,49; FM2 TA: 6,79; FM2 N: 6,96.  \nFM3 se descart\u00f3 desde el d\u00eda 1 ya que sus caracter\u00edsticas gal\u00e9nicas no eran adecuadas.  \nSe eligi\u00f3 FM2 debido a la mejor solubilidad de la anfoB. No se observaron diferencias en cuanto a su conservaci\u00f3n.\nCONCLUSIONES\nCon el estudio y validaci\u00f3n gal\u00e9nica de la LU anfoB2%, se consigui\u00f3 elaborar la FM con las caracter\u00edsticas m\u00e1s adecuadas \npara el tratamiento de la onicomicosis\ufffd  \nEl farmac\u00e9utico colabor\u00f3 con el equipo m\u00e9dico en la elecci\u00f3n del tratamiento aportando una alternativa terap\u00e9utica ante \nla ineficacia de tratamientos previos.254CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n749. EVALUACI\u00d3N DE LOS EFECTOS DE LA FARMACOTERAPIA EN LA DISFAGIA Y ANOREXIA EN UNA \nPOBLACI\u00d3N ANCIANA. \nAUTORES\nTEJADA GONZ\u00c1LEZ, E; ARANDA RUBIO, Y; MARTINEZ ESCUDERO, M; FUENTES IRIGOYEN, R; MONTEJANO HERVAS, \nP; RUIZ-HUERTA GARC\u00cdA DE VIEDMA, C; TORNERO TORRES, O\nHOSPITAL CENTRAL DE LA CRUZ ROJA SAN JOS\u00c9 Y SANTA ADELA. AV . DE LA REINA VICTORIA, 22-26 MADRID. MADRID\nOBJETIVOS\nEvaluar los efectos de la farmacoterapia en la disfagia y anorexia en personas mayores\ufffd \n \nSe sabe que hay f\u00e1rmacos que pueden afectar a la degluci\u00f3n sobre todo de las personas mayores. Entre los factores que \npueden desencadenarla est\u00e1n los que producen sedaci\u00f3n, xerostom\u00eda, acci\u00f3n a nivel neuromuscular o los que lesionan la \nmucosa gastroesof\u00e1gica. Muchos f\u00e1rmacos tambi\u00e9n pueden producir anorexia\nMATERIALES Y M\u00c9TODOS\nEstudio observacional en una unidad de geriatr\u00eda de agudos entre diciembre de 2021 y febrero de 2022. Al ingreso del \npaciente se hace una valoraci\u00f3n de la disfagia mediante el test volumen viscosidad (MECV-V), p\u00e9rdida de apetito y estado \nnutricional con el mini nutritional assessment sort form, (MNA-SF). Se recoge la medicaci\u00f3n cr\u00f3nica prescrita previa al \ningreso y con la ayuda de la aplicaci\u00f3n Medynut\u00ae, se registran aquellos f\u00e1rmacos que tienen descrito entre sus efectos \nadversos, disfagia o anorexia. Se realiz\u00f3 un an\u00e1lisis descriptivo de la muestra y un an\u00e1lisis bivariante en b\u00fasqueda de \nasociaci\u00f3n entre f\u00e1rmacos y otros factores de riesgo y la disfagia/anorexia. Se utiliz\u00f3 el programa SPSS Statistics\u00ae 26.\nRESULTADOS\nSe incluyeron 97 pacientes, 69.07% mujeres y 30.92% varones. La edad media fue de 88.28 a\u00f1os. El \u00edndice de masa \ncorporal medio fue 25.19 (+-4.83), el MNA-SF medio fue 8.58 (+-2.59). El 61% de los pacientes presentaron alg\u00fan tipo de \ndisfagia (28.9 % disfagia tipo n\u00e9ctar, 16.5% miel y 15.5% pudding). El 56.7 % present\u00f3 p\u00e9rdida de apetito. En 33 pacientes \nse encontr\u00f3 disfagia y anorexia. La media de f\u00e1rmacos prescritos en la muestra fue de 9.22(+- 3.24). Se encontraron 50 \nmedicamentos prescritos con efectos adversos de disfagia/anorexia en Medynut\ufffd Se encontr\u00f3 asociaci\u00f3n entre disfagia \ny tener prescrito alg\u00fan f\u00e1rmaco con este efecto adverso (p=0.024), pero no se encontr\u00f3 con la anorexia (p= 0.48). \nTener un valor bajo de MNA-SF incrementa el riesgo de disfagia (p=0.003) y anorexia (p=0.002). Entre los f\u00e1rmacos m\u00e1s \nprescritos en pacientes con disfagia se encontraron: \u00e1cido acetil salic\u00edlico, quetiapina, risperidona, sertralina y levodopa. \nEn pacientes con anorexia fueron: trazodona, risperidona, acenocumarol, metformina, enalapril, calcifediol, levodopa, \ncitalopram. Se encontr\u00f3 asociaci\u00f3n entre el uso \u00e1cido acetil salic\u00edlico y disfagia a pudding (p=0.02); disfagia miel y \nquetiapina (p=0.033); risperidona y quetiapina con disfagia n\u00e9ctar (P= 0.064 y 0.065 respectivamente). No se encontr\u00f3 \nsignificaci\u00f3n estad\u00edstica con el resto de los f\u00e1rmacos analizados individualmente y la disfagia/anorexia.\nCONCLUSIONES\n-Medynut\u00ae ayuda a valorar los efectos adversos gastrointestinales de los f\u00e1rmacos prescritos.  \n-La poblaci\u00f3n evaluada estaba en riesgo de malnutrici\u00f3n o desnutrida como lo demuestra el  \nvalor medio del MNA-SF. \n-Tener prescrito alg\u00fan f\u00e1rmaco que produzca este efecto adverso puede incrementar o agravar la aparici\u00f3n de disfagia.  \n-Ser\u00eda necesario hacer estudios para confirmar estos datos y estudios de intervenci\u00f3n para evaluar si la modificaci\u00f3n del \ntratamiento mejora la disfagia o la anorexia.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n802. FORMULACI\u00d3N DE ALPURINOL CREMA COMO OPCI\u00d3N DE TRATAMIENTO EN LA ERITRODISESTESIA \nPALMOPLANTAR. A PROPOSITO DE UN CASO. \nAUTORES\nCORDERO RAMOS, J; MART\u00cdN CASADO, L; MART\u00cdNEZ SU\u00c1REZ, A; ROMERO GONZ\u00c1LEZ, M; BA\u00d1OS ROLD\u00c1N, \u00da\nHOSPITAL VIRGEN MACARENA \ufffd AV\ufffd DOCTOR FEDRIANI, 3 SEVILLA \ufffd SEVILLA\nOBJETIVOS\nEl alopurinol t\u00f3pico es una f\u00f3rmula magistral que se elabora a concentraciones del 3-7 % para el tratamiento de la \neritrodisestesia palmoplantar. Esta patolog\u00eda se caracteriza por la aparici\u00f3n de rojeces, descamaci\u00f3n, ampollas, \u00falceras, \ny prurito, en las palmas de las manos y plantas de los pies\ufffd Estas lesiones pueden evolucionar y ser ciertamente \nincapacitantes. Tambi\u00e9n puede existir sensaci\u00f3n de hormigueo y disestesia \nEl objetivo principal es describir la formulaci\u00f3n magistral de alopurinol 3% as\u00ed como valorar su impacto de la en la \neritrodisestesia palmoplantar y la calidad de vida del paciente\ufffd\nMATERIALES Y M\u00c9TODOS\nLa paciente a la que se le prescribi\u00f3 la formulaci\u00f3n fue una paciente con carcinoma de mama metast\u00e1sico que inici\u00f3 \ntratamiento con capecitabina tras progresi\u00f3n \u00f3sea y hep\u00e1tica a ribociclib y letrozol.  \nLa paciente inici\u00f3 el tratamiento con capecitabina en diciembre de 2020 a 1000mg/m2 cada 12 horas durante 14 d\u00edas. \nEn el tercer ciclo, debuta con eritrodistesia palmoplantar (EPP) grado 1 que empeora a grado 2-3 tras el 5\u00ba ciclo. Tras dos \nreducciones sucesivas del 20% de la pauta con capecitabina y tratamiento t\u00f3pico con urea, mantiene una EPP grado 2 y se \nplantea utilizar alopurinol t\u00f3pico 3%  255Para determinar el impacto de la utilizaci\u00f3n de alopurinol t\u00f3pico 3% se realiz\u00f3 un seguimiento prospectivo observacional \nde tres semanas de duraci\u00f3n. El alopurinol se administron en la zona de las lesiones c/8h. La variable principal fue la \nreducci\u00f3n de lesiones palmoplantares a las 3 semanas\ufffd Otras variables medidas fueron la calidad de vida del paciente \na trav\u00e9s del cuestionario Dermatology Life Quality Index (DLQI)(0-30) y escalas de valoraci\u00f3n anal\u00f3gicas(EVA)(0-10) de \ndolor, picor y descamaci\u00f3n\ufffd  \nPara valorar la seguridad se registraron los eventos adversos (EA) ocurridos durante el tratamiento.\nRESULTADOS\nLa f\u00f3rmula seleccionada:  \nAlopurinol \u2026\u2026\u2026\u2026\u2026\u2026...3g  \nVaselina l\u00edquida \u2026\u2026\u2026.2ml  \nNeoPCL O/W csp \u2026\u2026100g \n \nModus operandi: dispersion del alopurinol en la vaselina l\u00edquida e interponer en la base NeoPCL o/w \nSe observ\u00f3 inicialmente una reducci\u00f3n en la descamaci\u00f3n de las manos y los pies durante las primeras semanas de \ntratamiento (de 4 a 2 lesiones) pero se mantuvo el dolor y molestia a la presi\u00f3n en las plantas de los pies durante la \nprimera semana\ufffd \nEl DLQi disminuyo de 21 puntos a 14, observ\u00e1ndose una mejor\u00eda y los EVA de dolor, picor y descamaci\u00f3n, pasaron de 7; 7 \n;6 a 5; 6; 0 respectivamente. \n \n \nNo se observaron eventos adversos achacables al tratamiento con alopurinol durante las primeras semanas de \nseguimiento\nCONCLUSIONES\nEl tratamiento con alopurinol cerma 3% fue bien valorado por la paciente y parece ofrecer cierta mejor\u00eda en la EPP . \nSeguimiento a mayor plazo y en un mayor n\u00famero de pacientes ser\u00e1 necesario para valorar el impacto real de la \nformulaci\u00f3n\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n840. EFECTIVIDAD Y SEGURIDAD DE TIOSULFATO S\u00d3DICO INTRAVENOSO EN EL TRATAMIENTO DE LA \nCALCIFILAXIS \nAUTORES\nEIROA OSORO, M; GOENAGA ANSOLA, A; OYAGUE L\u00d3PEZ, L; MAC\u00cdA RIVAS, L; FERN\u00c1NDEZ LAGUNA, CL; DE LA FUENTE \nVILAVERDE, I; FERN\u00c1NDEZ LASTRAS, S; LOZANO BL\u00c1ZQUEZ, A\nHOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS \ufffd AVENIDA DE ROMA S/N OVIEDO \ufffd ASTURIAS\nOBJETIVOS\nLa calcifilaxis es un s\u00edndrome caracterizado por la ulceraci\u00f3n necr\u00f3tica de la piel por calcificaci\u00f3n de la media, fibrosis de \nla \u00edntima arteriolar y posterior isquemia cut\u00e1nea por trombosis. El tratamiento m\u00e1s aceptado es: control de los factores \npredisponentes y el uso fuera de ficha t\u00e9cnica de tiosulfato s\u00f3dico (TS) y pamidronato.  \nEl objetivo de este trabajo es analizar la efectividad y la seguridad de una f\u00f3rmula magistral (FM) de TS intravenoso en \npacientes diagnosticados de calcifilaxis.\nMATERIALES Y M\u00c9TODOS\nEstudio de cohorte \u00fanica, observacional, descriptivo y retrospectivo de los pacientes tratados con TS intravenoso entre \nenero de 2018 y abril de 2022 en un hospital de tercer nivel. Los pacientes se seleccionaron a partir de la historia cl\u00ednica \nelectr\u00f3nica y de la base de datos de elaboraci\u00f3n y dispensaci\u00f3n de FM\ufffd  \nLas variables recogidas fueron: edad, sexo, diagn\u00f3stico, confirmaci\u00f3n del diagn\u00f3stico por biopsia, patolog\u00edas de base, \ntratamiento concomitante con pamidronato, dosis y posolog\u00eda inicial de TS, duraci\u00f3n y motivo de finalizaci\u00f3n del \ntratamiento y reacciones adversas. Las variables continuas de expresan como mediana y rango intercuart\u00edlico.  \nLa efectividad (control del dolor y disminuci\u00f3n del tama\u00f1o de las lesiones cut\u00e1neas) se midi\u00f3 como una variable \ncualitativa de mejor\u00eda en funci\u00f3n de la impresi\u00f3n cl\u00ednica recogida en la historia cl\u00ednica electr\u00f3nica.\nRESULTADOS\nSe prescribi\u00f3 TS intravenoso a 13 pacientes (69,2% mujeres, n=9) diagnosticados de calcifilaxis con una mediana \nde edad de 75 a\u00f1os (65-81). En el 76,9% (n=10) de los casos, el diagn\u00f3stico fue confirmado mediante biopsia. Once \npacientes presentaban hipertensi\u00f3n arterial, 6 Diabetes Mellitus tipo 2 y 11 enfermedad renal cr\u00f3nica, estando 6 a \ntratamiento renal sustitutivo con hemodi\u00e1lisis. El 76,9% (n=10) de los pacientes fueron tratados concomitantemente con \npamidronato\ufffd  \nLas dosis iniciales de TS fueron: 12,5 g/48 h (2 pacientes), 12,5 g 3 veces/semana (5) y 25 g 3 veces/semana (5). En 7 \ncasos se aument\u00f3 la dosis por buena tolerancia inicial\ufffd  \nSiete pacientes presentaron reacciones adversas: alteraciones gastrointestinales (6), reacci\u00f3n al\u00e9rgica (1) y alteraci\u00f3n \nhidroelectrol\u00edtica (1). En 6 de estos pacientes se redujo la dosis y en uno de ellos se aument\u00f3 tambi\u00e9n el tiempo de \nadministraci\u00f3n. A un paciente se le redujo la dosis por recomendaci\u00f3n bibliogr\u00e1fica. \nLa duraci\u00f3n del tratamiento fue dispar: mediana de duraci\u00f3n de 27,5 d\u00edas (5-90). Los motivos de suspensi\u00f3n fueron: \nreacciones adversas (3), \u00e9xitus (3), amputaci\u00f3n del miembro (1), colocaci\u00f3n de stent (1), no voluntad de continuar el 256tratamiento (2) y recomendaci\u00f3n bibliogr\u00e1fica (1). Se perdi\u00f3 el seguimiento de un paciente a los sesenta d\u00edas por cambio \nde centro sanitario\ufffd  \nEn 7 pacientes se observ\u00f3 mejor\u00eda, consider\u00e1ndose mejor\u00eda importante en 3 y en 2 mejor\u00eda leve. En los dem\u00e1s casos no se \naprecia mejor\u00eda (2), no toleran tratamiento (2) o la duraci\u00f3n fue insuficiente (2).\nCONCLUSIONES\nEl TS es un tratamiento que parece mostrar una efectividad moderada en los pacientes con calcifilaxis. Sin embargo, \nproduce frecuentes reacciones adversas que en ocasiones no se pueden manejar con reducciones de dosis o aumentos \ndel tiempo de administraci\u00f3n y obligan a la suspensi\u00f3n del tratamiento.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n849. FORMULACI\u00d3N DE SUPOSITORIOS VAGINALES DE IMIQUIMOD PARA NEOPLASIA VAGINAL \nINTRAEPITELIAL POR VIRUS DEL PAPILOMA HUMANO: A PROP\u00d3SITO DE UN CASO \nAUTORES\nRODR\u00cdGUEZ RODR\u00cdGUEZ, A; GONZ\u00c1LEZ RODR\u00cdGUEZ, AM; RODR\u00cdGUEZ PEN\u00cdN, I\nCOMPLEJO HOSPITALARIO ARQUITECTO MARCIDE-PROF . NOVOA SANTOS. CTRA. DE SAN PEDRO DE LEIXA, S/N \nFERROL \ufffd A CORU\u00d1A\nOBJETIVOS\nDescripci\u00f3n de la elaboraci\u00f3n de una f\u00f3rmula magistral de supositorios vaginales de imiquimod y evaluaci\u00f3n de su \nseguridad\ufffd\nMATERIALES Y M\u00c9TODOS\nMujer de 40 a\u00f1os, inmunocomprometida, con antecedentes de Leucemia Mielobl\u00e1stica Aguda, a seguimiento desde \nel a\u00f1o 2014 por afectaci\u00f3n cervical, vaginal y vulvar. En 2017 es diagnosticada de Neoplasia Intraepitelial Vulvar (VIN) \ngrado III, condilomas vaginales y Neoplasia Intraepitelial Cervical (CIN) grado I en exocervix, (Virus Papiloma Humano \n(VPH) +), recibiendo vaporizaci\u00f3n con l\u00e1ser de CO2 eliminando el 70% de las lesiones. En 2020 vuelve a recaer con VIN \n(VPH +) someti\u00e9ndose a tumorectom\u00eda vulvar y complet\u00e1ndose tratamiento con imiquimod crema. Desde Junio de 2021 \npresenta Lesiones Escamosas de Bajo Grado (LSIL) en vagina bajo vigilancia con VPH persistente (\u00faltimo control 2022), \nsolicit\u00e1ndose por parte del Servicio de Ginecolog\u00eda la elaboraci\u00f3n de supositorios vaginales de imiquimod debido a \nintolerancia por parte de la paciente a las exploraciones con esp\u00e9culo que requiere la aplicaci\u00f3n de imiquimod en crema, \npermitiendo adem\u00e1s la autoaplicaci\u00f3n y disminuci\u00f3n en la frecuencia de administraci\u00f3n, evitando el desplazamiento al \nhospital.  \nEn base a la bibliograf\u00eda revisada y, previa autorizaci\u00f3n por la Direcci\u00f3n del Centro, se elaboran supositorios vaginales \nde Imiquimod 12,5 mg partiendo de materia prima y utilizando como excipiente una mezcla de polietilenglicol (PEG) \n400/4000 en proporci\u00f3n 60/40: imiquimod 0,0125 g, PEG 400 1,5 g y PEG 4000 1,0 g (Factor desplazamiento: 0,58). \nSe establece una caducidad de 3 meses, conserv\u00e1ndolos en nevera y protegidos de la luz. De cada lote formulado se \ncontrolan caracteres organol\u00e9pticos (color blanco, aspecto uniforme sin grietas) y uniformidad de peso (desviaci\u00f3n de \n\u00b15%). \nPara el seguimiento de la evoluci\u00f3n de la paciente y efectos adversos se recurre a la historia cl\u00ednica electr\u00f3nica.\nRESULTADOS\nLa paciente inicia tratamiento con supositorios vaginales el 24 Abril 2022 con pauta indicada de 1 aplicaci\u00f3n nocturna \nsemanal de un supositorio de imiquimod 12,5mg durante las 2 primeras semanas seguida de 1 aplicaci\u00f3n dos veces a la \nsemana (separaci\u00f3n 3 d\u00edas) durante 6 semanas (14 dosis totales). En caso de no tolerancia se indica disminuir la dosis a la \nmitad\ufffd  \nTras 3 semanas de tratamiento la paciente refiere una f\u00e1cil aplicaci\u00f3n sin expulsi\u00f3n en los d\u00edas posteriores adem\u00e1s de \nausencia de s\u00edntomas locales y sist\u00e9micos por lo que no resulta necesaria reducci\u00f3n de dosis.\nCONCLUSIONES\nEsta f\u00f3rmula podr\u00eda suponer una alternativa en casos de intolerancia a la aplicaci\u00f3n de crema de imiquimod comercial, \npermitiendo una mayor adherencia y autoaplicaci\u00f3n, con un bajo perfil de eventos adversos. Se precisa un mayor tiempo \nde seguimiento para confirmar su adecuaci\u00f3n y perfil de toxicidad.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n931. EFECTIVIDAD DE LA INSULINA T\u00d3PICA EN \u00daLCERAS NEUROTR\u00d3FICAS Y DEFECTOS DEL EPITELIO \nCORNEAL SIN RESPUESTA A OTROS ABORDAJES TERAP\u00c9UTICOS. \nAUTORES\nGARC\u00cdA CASTI\u00d1EIRA, C; BOCOS BAELO, A; MORALES TRIAD\u00d3, A; CARBONELL PUIG, M; CODINA JIM\u00c9NEZ, C; \nTERRICABRAS MAS, E; ESTRADA NIETO, L; QUI\u00d1ONES RIBAS, C\nHOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nOBJETIVOS\nDeterminar la efectividad del uso fuera de indicaci\u00f3n de la insulina t\u00f3pica en el tratamiento de pacientes con \u00falceras \nneurotr\u00f3ficas u otros defectos del epitelio corneal en los que hayan fracasado los abordajes terap\u00e9uticos previos.257MATERIALES Y M\u00c9TODOS\nEstudio observacional, longitudinal y prospectivo realizado por el servicio de farmacia (SF), en colaboraci\u00f3n con el servicio \nde oftalmolog\u00eda. Se incluyeron a todos los pacientes afectos de \u00falceras neurotr\u00f3ficas u otros defectos epiteliales de la \nc\u00f3rnea que iniciaron tratamiento con colirio de insulina entre julio de 2021 y abril de 2022.  \nLos pacientes fueron derivados desde oftalmolog\u00eda con una prescripci\u00f3n de colirio de insulina de 1 UI/ml, con una pauta \nde 1 gota cada 6 horas durante 4 semanas en el ojo afectado. En el SF se realiz\u00f3 la preparaci\u00f3n del colirio, a partir de \ninsulina soluble neutra de 100 UI/ml y suero fisiol\u00f3gico al 0,9%.  \nSe realiz\u00f3 una visita de atenci\u00f3n farmac\u00e9utica donde se dispensaron 4 colirios por paciente y se explicaron las \ncondiciones de conservaci\u00f3n: mantener entre 2 y 8\u00baC y desechar a los 7 d\u00edas de la apertura por riesgo de contaminaci\u00f3n \nmicrobiol\u00f3gica\ufffd \nTranscurridas las 4 semanas, los pacientes fueron citados en las consultas externas de oftalmolog\u00eda para valorar la \nevoluci\u00f3n de la lesi\u00f3n, as\u00ed como la continuaci\u00f3n del tratamiento. El par\u00e1metro determinante de la efectividad del \ntratamiento fue la medici\u00f3n del di\u00e1metro de la lesi\u00f3n corneal, expres\u00e1ndose la reducci\u00f3n del tama\u00f1o como variable \ndicot\u00f3mica (SI/NO).  \nAdem\u00e1s, mediante la historia cl\u00ednica se recogieron las siguientes variables demogr\u00e1ficas y cl\u00ednicas: edad, sexo, patolog\u00eda \ncausante de la afecci\u00f3n corneal y tratamientos previos para la misma\ufffd\nRESULTADOS\nSe evaluaron 19 pacientes (8 mujeres, 42,1 %), con una media de edad de 72 \u00b1 17 a\u00f1os. 10 pacientes (55,6%) fueron \ntratados en el ojo izquierdo; 8 (38,9%) en el derecho, y 1 (5,6%) en ambos ojos. Todos los pacientes hab\u00edan recibido \npreviamente terapias convencionales, sin obtener la respuesta esperada. De las patolog\u00edas estudiadas, la m\u00e1s frecuente \n(32% de los casos) fue la \u00falcera neurotr\u00f3fica secundaria a queratitis herp\u00e9tica. \nTras 4 semanas de tratamiento, se observ\u00f3 mejor\u00eda clara en 13 (68,4%) pacientes; en 2 (10,5%) no hubo mejor\u00eda \napreciable. En el 21% restante no pudo evaluarse la eficacia por ausencia de seguimiento posterior al inicio del \ntratamiento. En 9 pacientes (47,3% de los casos), se decidi\u00f3 continuar con el colirio transcurridas las 4 semanas por \nmejor\u00eda de la lesi\u00f3n corneal.  \nEn el grupo tratado por \u00falcera neurotr\u00f3fica secundaria a queratitis herp\u00e9tica, se observ\u00f3 mejor\u00eda tras el tratamiento en la \ntotalidad de los pacientes\ufffd\nCONCLUSIONES\nEl colirio de insulina parece ser efectivo para tratar \u00falceras neurotr\u00f3ficas por causas diversas, as\u00ed como otros defectos \ndel epitelio corneal, que no hayan respondido a otras alternativas terap\u00e9uticas. Su efecto reepitelizante se pone de \nmanifiesto en la reducci\u00f3n de tama\u00f1o de las \u00falceras tratadas.  \nNo obstante, los estudios existentes son limitados y con tama\u00f1os muestrales reducidos, por lo que el desarrollo de \nensayos cl\u00ednicos aleatorizados y estandarizados es necesario para establecer la pauta posol\u00f3gica y duraci\u00f3n id\u00f3nea del \ntratamiento\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n959. EVOLUCI\u00d3N DE LOS NIVELES PLASM\u00c1TICOS DE \u00c1CIDO \u00daRICO EN UNA COHORTE DE PACIENTES \nCON SOPORTE NUTRICIONAL PARENTERAL \nAUTORES\nR\u00cdO NO, L; MIEDES ALIAGA, J; MATEU DE ANTONIO, J\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEl objetivo del estudio fue analizar la evoluci\u00f3n de los niveles plasm\u00e1ticos de \u00e1cido \u00farico (AU) en pacientes con nutrici\u00f3n \nparenteral total (NPT) una semana despu\u00e9s de su inicio y su correlaci\u00f3n con los aportes de macronutrientes y otros \nmarcadores nutricionales\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en 2021 realizado en un hospital universitario terciario de 400 camas. \n \nCriterios de inclusi\u00f3n: pacientes con NPT al menos 5 d\u00edas, m\u00e1s de 18 a\u00f1os, IMC 18-35 Kg/m2, filtrado glomerular (FG-CKD-\nEPI) > 30 ml/min/1.73m2, sin dieta oral durante el per\u00edodo de estudio. Se excluyeron a pacientes con infecci\u00f3n Sars-CoV2.  \n \nDatos recogidos: demogr\u00e1ficos (edad, sexo) y cl\u00ednicos (IMC, \u00cdndice de comorbilidad de Charlson, MPM-III o \nprobabilidad de mortalidad al ingreso). Pacientes quir\u00fargicos y m\u00e9dicos. Indicaci\u00f3n de NPT. D\u00edas de NPT y estancia \nhospitalaria. Anal\u00edtica basal y a los 5-7 d\u00edas del inicio de NPT. Par\u00e1metros nutricionales: prote\u00ednas totales (PT), albumina \n(ALB), colesterol (COL), PCR y linfocitos (LINF). Macronutrientes y kcal totales recibidos en ese per\u00edodo. F\u00e1rmacos \nhiperuricemiantes potentes concomitantes (furosemida, tiazidas, tacrolimus, micofenolato, tolvaptan).  \n \nSe realiz\u00f3 el an\u00e1lisis estad\u00edstico mediante programa SPSS-v.25. Datos cuantitativos expresados como frecuencia y \ncualitativos como mediana (Q1-Q3). Se compararon los datos mediante el test de Wilcoxon para muestras relacionadas. \nCorrelaciones mediante el test de Spearman\ufffd258RESULTADOS\nSe incluyeron 46 pacientes, 26(56,5%) hombres con una edad de 71,5(56,0-80,5) a\u00f1os y un IMC de 24,2(21,7-27,5) kg/\nm2. Alta comorbilidad (Charlson \u2265 3), 10 (21,7%) pacientes, otros 10(21,7%) con MPM-III > 25% y 32 (69,6%) con riesgo \nnutricional elevado (NRS \u2265 3). Cuarenta (87%) eran pacientes quir\u00fargicos. La estancia hospitalaria fue de 17,0(14,0-26,0) \nd\u00edas y la duraci\u00f3n de NPT 9,0(7,0-12,3) d\u00edas. \n \nPrincipales indicaciones: 18(39,1%) complicaci\u00f3n postoperatoria, 10(21,7%) obstrucci\u00f3n del tracto digestivo y 8(17,4%) \nintolerancia a nutrici\u00f3n enteral/oral\ufffd  \n \nVariables cl\u00ednicas basales: FG-CKD-EPI 86,0 ml/min/1.73m2 (71,8-100,0); AU 3,9 mg/dL (3,0-5,4); PT 5,3 g/dL (5,0-5,9); \nALB 3,1 g/dL (2,7-3,6); COL 116,0 mg/dL (87,0- 142,5); Triglic\u00e9ridos 111,0 mg/dL (86,5-166,0); PCR 8,7 mg/dL (4,7-18,6); \nLINF 1,1 x103cel/mL (0,7-1,6).  \n \nEvoluci\u00f3n variables cl\u00ednicas a los 7 d\u00edas (valor 7 d\u00edas \u2013 valor basal): FG-CKD-EPI +10 ml/min/1.73m2 (1,5-24,5); PT +0,1 g/\ndL (-0,2-0,5); ALB +0,1 g/dL (-0,3-0,3); COL +4,5 mg/dL (-7,5-37,3); PCR -3,49 mg/dL (-7,8-0,0); LINF +0,1 x103cel/mL (-0,2-\n0,5). \n \nAportes nutricionales: prote\u00ednas 1,2 g/kg/d\u00eda (1,1-1,4), gl\u00facidos 1,9 g/kg/d\u00eda (1,7-2,4), l\u00edpidos 0,6 g/kg/d\u00eda (0,5-0,8) y 19,4 \nkcal Totales/kg/d\u00eda (16,9-19,4). \n \nF\u00e1rmacos hiperuricemiantes en 13(28,3%) pacientes. \n \nSe observaron diferencias entre el valor basal y a los 7 d\u00edas de AU (p < 0,001). El valor de AU disminuy\u00f3 una mediana de \n-1,73 (IC 95%: -2,2--1,2).  \n \nNo se correlacion\u00f3 la diferencia de AU a los 7 d\u00edas con la evoluci\u00f3n de los par\u00e1metros nutricionales ni con los \nmacronutrientes aportados. Tampoco hubo correlaci\u00f3n con los d\u00edas de NPT o la estancia hospitalaria.\nCONCLUSIONES\nDurante la NPT hubo una disminuci\u00f3n de los niveles de AU. No se ha observado una correlaci\u00f3n entre este descenso y \nlos aportes de macronutrientes ni con la evoluci\u00f3n de los marcadores nutricionales\ufffd El AU no se mostr\u00f3 como marcador \nnutricional en este estudio\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n986. VALIDACI\u00d3N DE UN M\u00c9TODO ESPECTROFOTOM\u00c9TRICO PARA EL CONTROL DE CALIDAD DE UN \nCOLIRIO DE MEDROXIPROGESTERONA 2% \nAUTORES\nYUSTE GUTIERREZ, AM; GARCIA SANCHEZ, S; MARTINEZ RODRIGUEZ, J; LAGUNAS CASADO, C; GRANDA LOBATO, P; \nSANCHEZ DE CASTRO, M; GONZALO SALADO, H; MONTENEGRO ALVAREZ DE TEJERA, P\nHOSPITAL CENTRAL DE LA DEFENSA GOMEZ ULLA. GLORIETA DEL EJ\u00c9RCITO, S/N. MADRID. MADRID\nOBJETIVOS\nValidaci\u00f3n de un m\u00e9todo espectrofotom\u00e9trico para la realizaci\u00f3n del control de calidad de un colirio de \nmedroxiprogesterona acetato 2%, preparado en nuestro hospital para el tratamiento de queratoconjuntivitis cicatricial, \nlesiones corneales, queratitis herp\u00e9ticas necrotizantes y procesos inflamatorios de la c\u00e1mara anterior.\nMATERIALES Y M\u00c9TODOS\nSe parti\u00f3 de medroxiprogesterona acetato (Fagron\u00ae) como materia prima. Se utiliz\u00f3 una balanza de precisi\u00f3n Precisa\u00ae \nXT220A (desviaci\u00f3n 0.0001g) y un espectrofot\u00f3metro Perkin Elmer\u00ae para el rango UV-visible, lambda 40.  \nEl m\u00e9todo se valid\u00f3 siguiendo los requerimientos de la ICH (Conferencia Internacional de Armonizaci\u00f3n). La \nmedroxiprogesterona acetato tiene un espectro caracter\u00edstico en la zona UV del espectro electromagn\u00e9tico, por lo que \npara determinar la especificidad se realiz\u00f3 un barrido de 300 a 200 nm.  \nPara obtener la recta de calibraci\u00f3n y estudiar la linealidad del m\u00e9todo se prepararon 5 concentraciones: 1,2mg/100ml; \n1,5 mg/100ml; 1,8 mg/100ml; 2mg/100ml, y 2,5mg/100ml. Se utiliz\u00f3 la prueba de ANOVA para comprobar la linealidad \ndel m\u00e9todo.  \nPara el estudio de precisi\u00f3n se utilizaron las tres diluciones de concentraciones intermedias. Se realizaron los an\u00e1lisis de \nrepetibilidad y de precisi\u00f3n intermedia, calcul\u00e1ndose los coeficientes de variaci\u00f3n (CV) de las medidas de absorbancia.  \nEl estudio de exactitud se realiz\u00f3 a partir de cinco series de las tres soluciones intermedias, para las que se calcul\u00f3 \nel porcentaje de recuperaci\u00f3n con respecto a la cantidad te\u00f3rica (100%). Se compararon las diferencias entre ambos \nporcentajes mediante la prueba t de Student-Fisher. Asimismo, se calcul\u00f3 el coeficiente de correlaci\u00f3n de Pearson entre \nel porcentaje te\u00f3rico y el porcentaje encontrado. Una p < 0,05 fue considerada estad\u00edsticamente significativa. El an\u00e1lisis \nestad\u00edstico se realiz\u00f3 mediante el programa SPSS\u00ae v25.\nRESULTADOS\nDurante el estudio de especificidad, el pico de absorci\u00f3n mejor delimitado coincidi\u00f3 con el m\u00e1ximo descrito en la \nbibliograf\u00eda (241 nm, A11 =426), por lo que se seleccion\u00f3 esta longitud de onda para las restantes determinaciones.  259La ecuaci\u00f3n de la recta de calibraci\u00f3n, obtenida mediante la relaci\u00f3n entre la concentraci\u00f3n y las medidas de absorbancia, \nfue \u201cy = 0,140 + 10,99x\u201d (r= 0,999, r2= 1). La ANOVA de la regresi\u00f3n tuvo una F-Snedecor = 1465,4 (p < 0,05), \ndemostrando la buena linealidad del m\u00e9todo.  \nLa precisi\u00f3n cumpli\u00f3 con las exigencias del m\u00e9todo (CV < 3%): CV de 0,29 % para la repetibilidad, y 0,48% para la precisi\u00f3n \nintermedia\ufffd \nEn el estudio de exactitud no se observaron diferencias estad\u00edsticamente significativas. Se obtuvo una t-Student-Fisher = \n-0,606 (p = 0,547) y un coeficiente de correlaci\u00f3n de Pearson r =1. La recuperaci\u00f3n media fue del 99,97% (SD 0,43).\nCONCLUSIONES\nSe ha puesto a punto un m\u00e9todo anal\u00edtico para el control de calidad de un colirio de medroxiprogesterona acetato. El \ncumplimiento de todos los criterios de aceptaci\u00f3n establecidos permiti\u00f3 demostrar la validez del m\u00e9todo. Este m\u00e9todo \nes r\u00e1pido, fiable en los par\u00e1metros exigidos y factible en las condiciones de la cl\u00ednica diaria, pudi\u00e9ndose adoptar como \ncontrol de calidad rutinario.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n996. PRUEBAS EPICUT\u00c1NEAS, INTRAEPID\u00c9RMICAS E INTRAD\u00c9RMICAS DE ALERGIA ELABORADAS EN UN \nSERVICIO DE FARMACIA \nAUTORES\nGARC\u00cdA CONTRERAS, S; FERRANDIS SALES, N; CRUZ S\u00c1NCHEZ, A; FERN\u00c1NDEZ S\u00c1NCHEZ, M; BELTR\u00c1N GARC\u00cdA, I; VILA \nCL\u00c9RIGUES, MN; L\u00d3PEZ BRIZ, E; POVEDA ANDR\u00c9S, JL\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nLos test cut\u00e1neos, (Pruebas Epicut\u00e1neas (EP), Prick e Intrad\u00e9rmicas (ID)), son de ayuda en determinar la causa de una \nreacci\u00f3n cut\u00e1nea. Con el fin de facilitar estudios comparativos es importante registrar correctamente la metodolog\u00eda \nseguida y deber\u00edan elaborarse de acuerdo a gu\u00edas comunes.  \nEl objetivo es describir y analizar cualitativamente los diferentes tipos de pruebas cut\u00e1neas elaboradas en un Servicio de \nFarmacia (SF).\nMATERIALES Y M\u00c9TODOS\nAn\u00e1lisis retrospectivo de los tipos de pruebas cut\u00e1neas elaboradas en el SF de un hospital de tercer nivel durante un \nperiodo de aproximadamente 5 a\u00f1os\ufffd  \nLas variables estudiadas son los tipos de formulaciones elaboradas, principio activo (PA) de partida (materia prima o \nespecialidad comercial) y forma farmac\u00e9utica (FF) en el \u00faltimo caso, veh\u00edculo utilizado y rango de concentraciones del PA \nen la formulaci\u00f3n final.\nRESULTADOS\nSe han elaborado un total de 170 formulaciones distintas con 144 PA diferentes, de las cuales un 89% fueron EP (151 con \n126 PA), un 3% PRICK (5 con 5 PA), un 4% ID (7 con 6 PA) y un 4% ID/Prick (7 con 7 PA).  \nEn cuanto a las EP , se parti\u00f3 de la especialidad comercial en un 76,8% y de materia prima en un 23,2% de los casos. \nCuando se parti\u00f3 de la especialidad, el 86,2% fueron FF orales s\u00f3lidas y el 13,8% parenterales. El veh\u00edculo de elecci\u00f3n \nfue vaselina en un 85,4% de las preparaciones y lanolina-vaselina en un 14,6%. Cuando se parti\u00f3 de una \u201cespecialidad \nfarmac\u00e9utica\u201d, un 55% de parches fueron al 30% del polvo de la misma y el resto (45%) a otras concentraciones. El rango \nde concentraciones de \u201cprincipio activo\u201d en los parches elaborados fue del 0,01% al 30%.  \nRespecto a las PRICK, se parti\u00f3 en un 83,3% de los casos de la especialidad y en un 16,7% de materia prima. Cuando se \nparti\u00f3 de la especialidad, se utilizaron viales en todos los casos excepto en uno en el que se utiliz\u00f3 una FF s\u00f3lida oral, \nsiendo el veh\u00edculo utilizado ClNa 0,9% o API. El rango de concentraciones de PA en las PRICK fue de 0,04mg/ml a 55mg/\nml\ufffd  \nEn las pruebas ID se parti\u00f3 en el 93% de los casos de formas parenterales y en un 7% de materia prima. Los diluyentes \nfueron mayoritariamente ClNa 0,9% o API. Los rangos de concentraciones fueron muy diferentes, realiz\u00e1ndose en muchos \ncasos diluciones seriadas a partir de la concentraci\u00f3n inicial.\nCONCLUSIONES\nExiste gran variabilidad en los test cut\u00e1neos solicitados al SF. En los tres tipos de formulaciones se parti\u00f3 \nmayoritariamente de una especialidad comercial, oral en mayor proporci\u00f3n en las pruebas EP y parenteral en las Prick e \nID. El veh\u00edculo depende de la solubilidad del PA y la v\u00eda de administraci\u00f3n, siendo principalmente lip\u00f3filo en las pruebas \nEP e hidr\u00f3filo en las dos restantes. Respecto al rango de concentraciones es muy amplio dependiendo del tipo de prueba \ny de la bibliograf\u00eda disponible.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n997. BIOIMPEDANCIA EL\u00c9CTRICA Y NUTRICI\u00d3N PARENTERAL \nAUTORES\nF\u00d3RNEAS SANGIL, A; APARICIO CARRE\u00d1O, C; FUERTES CAMPORRO, S; G\u00c1NDARA ANDE, A; D\u00cdAZ NAYA, L; RIESTRA \nFERN\u00c1NDEZ, M; SU\u00c1REZ-COALLA BANGO, C; AYASTUY RUIZ, A\nHOSPITAL DE CABUE\u00d1ES. LOS PRADOS, 395 GIJ\u00d3N. ASTURIAS260OBJETIVOS\nAnalizar la asociaci\u00f3n de la bioimpedancia el\u00e9ctrica corporal (BIA) con otros marcadores nutricionales tradicionales y \ncomo factor pron\u00f3stico de morbimortalidad.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo entre julio de 2021 y marzo de 2022 en el que se incluyeron los pacientes con nutrici\u00f3n \nparenteral (NP) a los cuales se les analiz\u00f3 la composici\u00f3n corporal mediante el m\u00e9todo no invasivo de BIA. \n \nLos pacientes a cargo del Servicio de Endocrinolog\u00eda deb\u00edan recibir m\u00e1s de siete d\u00edas de NP y disponer de al menos dos \nmediciones de BIA, representados por los componentes Resistencia (R- grado de hidrataci\u00f3n) y Reactancia (Xc- masa \ncelular), que permiten el c\u00e1lculo del \u00e1ngulo de fase (AF) como indicador de la integridad celular (asociado a mejor estado \nnutricional cuanto mayor AF). Mediante las variables R y Xc normalizadas por la altura (vectores R/H y Xc/H) se obtuvo la \nbioimpedancia vectorial (BIVA) que asociada a referencias poblacionales se destacan 4 cuadrantes para la monitorizaci\u00f3n \nde la composici\u00f3n corporal: con estado hidrataci\u00f3n disminuida (1-atletico y 2- delgado magro) o estado de hidrataci\u00f3n \naumentada (3-obeso y 4-caqu\u00e9ctico).  \n \nLas variables recogidas fueron: causa de ingreso, AF, cribado y/o valoraci\u00f3n nutricional mediante Malnutrition Universal \nScreening Tool (MUST) y criterios Global Leadership Initiative on Malnutrition (GLIM) respectivamente, cuadrantes, \nsexo, edad, \u00edndice de masa corporal (IMC), determinaci\u00f3n de alb\u00famina, comorbilidades, d\u00edas con NP , d\u00edas de estancia \nhospitalaria, complicaciones asociadas a la enfermedad, ingreso y/o fallecimiento en los 30 d\u00edas posteriores al alta.\nRESULTADOS\nSe incluyeron 13 pacientes de los que 6 (46,2%) ingresaron por causa infecciosa, 5 (38,5%) oncol\u00f3gica y 2 (15,3%) \ninflamatoria.  \n \nDe los pacientes analizados 4 (30,3%) ten\u00edan un AF \u2265 5 (5-6,3) estando 2 en riesgo de desnutrici\u00f3n y 2 con desnutrici\u00f3n \nmoderada-grave, divididos por cuadrantes 0-1-3-0, siendo 100% hombres con 63,75 a\u00f1os, IMC 29,9 y 31 g/dl de alb\u00famina \nmedia. De estos, 3 (75%) presentaban alguna comorbilidad. Recibieron 19 d\u00edas de media NP y la media de estancia \nhospitalaria fue de 30,5 d\u00edas. En 3 pacientes la segunda medici\u00f3n de AF fue igual o mayor al recibir soporte nutricional. En \n2 aparecieron complicaciones asociadas a la enfermedad\ufffd Ninguno reingres\u00f3 ni fue exitus\ufffd  \n \nLos 9 restantes (69,7%) presentaron un AF < 5 (3,1-4,6), estando 3 en riesgo de desnutrici\u00f3n y 6 con desnutrici\u00f3n \nmoderada-grave, cuadrantes 0-1-5-3, siendo 4 (44,4%) hombres con una media 67,4 a\u00f1os, IMC 26,1, alb\u00famina 24,4 g/\ndL y 8 (88%) con comorbilidades. Tuvieron una media de 27 d\u00edas con NP y 46,1 d\u00edas de media de estancia hospitalaria. En \n5 pacientes la segunda medici\u00f3n de AF fue igual o mayor al recibir soporte nutricional\ufffd En 7 aparecieron complicaciones \nasociadas a la enfermedad. Un paciente reingres\u00f3 en los 30 d\u00edas posteriores. Fueron exitus 3 (33,3%): 2 durante el ingreso \ny 1 en los 30 d\u00edas posteriores.\nCONCLUSIONES\nAunque son necesarios estudios con m\u00e1s pacientes, valores de AF < 5 se pueden asociar a una mayor desnutrici\u00f3n y \nmorbimortalidad\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1006. CARACTERIZACI\u00d3N FISICOQU\u00cdMICA Y DE ABSORCI\u00d3N GASTROINTESTINAL DE F\u00d3RMULAS ORALES \nL\u00cdQUIDAS DEL FORMULARIO NACIONAL PARA UNA ADMINISTRACI\u00d3N SEGURA POR SONDA ENTERAL. \nAUTORES\nRIOJA D\u00cdEZ, Y; GARC\u00cdA MORENO, FJ; PERN\u00cdA L\u00d3PEZ, MS; MONTERO ANT\u00d3N, MDP; MANRIQUE RODR\u00cdGUEZ, S; \nMART\u00cdNEZ FERN\u00c1NDEZ-LLAMAZARES, C; HERRANZ ALONSO, A; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nEl uso de f\u00f3rmulas magistrales tipificadas (FMT) l\u00edquidas recogidas en el Formulario Nacional (FN) es frecuente en el \n\u00e1mbito hospitalario, especialmente en pediatr\u00eda. Pese a que la elecci\u00f3n de formas l\u00edquidas facilita la administraci\u00f3n \nen pacientes portadores de sonda de alimentaci\u00f3n enteral, pueden aparecer efectos adversos como diarrea, v\u00f3mitos \no intolerancia GI adicional asociados a osmolaridad > 500 mOsm/L, pH < 3,5 y contenido en sorbitol elevado de estas \npreparaciones\ufffd  \nEl objetivo del presente trabajo es caracterizar las propiedades fisicoqu\u00edmicas de las FMT recogidas en el FN y \nsu absorci\u00f3n gastrointestinal para establecer unas instrucciones pr\u00e1cticas que incrementen la seguridad en su \nadministraci\u00f3n por sonda transpil\u00f3rica\ufffd\nMATERIALES Y M\u00c9TODOS\nSe escogieron 17 FMT recogidas en el FN y se realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica para establecer el sitio de absorci\u00f3n \ngastrointestinal de los f\u00e1rmacos formulados.  \n \nPara cada preparaci\u00f3n se determin\u00f3 experimentalmente el pH, osmolalidad y densidad. Adem\u00e1s, se revis\u00f3 el contenido \nen sorbitol a partir de las descripciones del FN. El pH se midi\u00f3 con un medidor de pH (Crison 2006, Hach Lange Espa\u00f1a, \nS.L.U., Espa\u00f1a). La osmolaridad se determin\u00f3 usando el aparato Micro Osm\u00f3metro Fiske Modelo 210 (John Morris 261Scientific Pty Ltd., Australia). Este aparato proporciona una medida de osmolalidad (mOsm/kg) que, multiplicado por \nla densidad de la soluci\u00f3n (g/ml) nos proporciona el dato de osmolaridad (mOsm /L). Para ello, se emplearon dos \ndens\u00edmetros Nah\u00edta de rangos 1000-1200 mg/ml y 1200-1400 mg/ml. Todas las medidas se realizaron por triplicado y en \nel caso de preparaciones de osmolalidad > 850 mOsm/kg se hizo una diluci\u00f3n 1:5 en agua previa a su an\u00e1lisis.\nRESULTADOS\nEn el 41,2% de los f\u00e1rmacos de las FMT (fenobarbital, furosemida, hidroclorotiazida y las 4 vitaminas del grupo B), \nse encontraron estudios que aseguraban una biodisponibilidad similar en administraci\u00f3n transpil\u00f3rica versus oral o \nuna absorci\u00f3n importante superada la porci\u00f3n proximal del intestino delgado. En \u00e1cido f\u00f3lico solo se contemplaba \nla administraci\u00f3n en duodeno, estando desaconsejada la administraci\u00f3n en yeyuno. En los f\u00e1rmacos restantes no se \nencontr\u00f3 bibliograf\u00eda que avalara ni contraindicara la administraci\u00f3n transpil\u00f3rica. \n \nSolo en el 11,8% de preparados (metadona y furosemida) las propiedades fisicoqu\u00edmicas eran \u00f3ptimas para su \nadministraci\u00f3n transpil\u00f3rica sin necesidad de diluir con agua. Se encontraron valores de pH < 3,5 en el 29,4% de \npreparaciones (captopril, enalapril, hidroclorotiazida, piridoxina y tiamina), lo que desaconseja la administraci\u00f3n \ntranspil\u00f3rica. En el 58,8% restante el valor de pH era adecuado para la administraci\u00f3n, pero presentaban osmolaridad > \n500. El 23,5% del total de FMT conten\u00edan adem\u00e1s sorbitol en concentraci\u00f3n > 200 mg/ml.\nCONCLUSIONES\nEn mayor\u00eda de principios activos estudiados la absorci\u00f3n gastrointestinal del f\u00e1rmaco no est\u00e1 suficientemente \ncaracterizada, lo que genera incertidumbre en la biodisponibilidad del mismo cuando se administra por sonda \ntranspil\u00f3rica\ufffd \nLa mayor\u00eda de FMT tienen una osmolaridad elevada por lo que es necesario una diluci\u00f3n previa, mientras que los valores \nde pH de algunas de ellas pueden ser un factor a\u00f1adido para el desarrollo de intolerancias digestivas.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1016. ESTRATEGIA DE OPTIMIZACI\u00d3N DEL FRACCIONAMIENTO DE EMICIZUMAB EN PEDIATR\u00cdA \nAUTORES\nD\u00cdAZ PERALES, R; YUNQUERA ROMERO, L; MART\u00cdN CLAVO, S; FERN\u00c1NDEZ MART\u00cdN, JM; SALDA\u00d1A SORIA, R; GALLEGO \nFERN\u00c1NDEZ, C\nHOSPITAL MATERNO INFANTIL \ufffd ARROYO DE LOS ANGELES, S/N M\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\nEmicizumab es un anticuerpo monoclonal humanizado indicado en la prevenci\u00f3n rutinaria del sangrado en pacientes \ncon hemofilia A con inhibidores del factor VIII y/o grave. Su posolog\u00eda var\u00eda en funci\u00f3n del peso y raramente se ajusta \na las presentaciones disponibles. Nuestro objetivo fue evaluar la eficiencia y seguridad de emicizumab en base al \nfraccionamiento del mismo\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo desarrollado en hospital de tercer nivel entre Febrero y Abril de \n2022 con pacientes pedi\u00e1tricos candidatos a individualizaci\u00f3n posol\u00f3gica de emicizumab. Se emple\u00f3 la Historia Cl\u00ednica \nDigital, el programa de farmacotecnia para la elaboraci\u00f3n y control y el programa de prescripci\u00f3n para la dispensaci\u00f3n \ny seguimiento. Se estableci\u00f3 un escenario A ficticio sin fraccionamiento y un escenario B real con fraccionamiento \ncentralizado en servicio de farmacia para el cual se programaron las preparaciones y administraciones de todos los \npacientes en los mismos d\u00edas. Se recopilaron datos: demogr\u00e1ficos, dosis, costes directos (viales, material y personal) \ny unidades relativas de valor (URV) de los procedimientos desarrollados (elaboraci\u00f3n de procedimiento normalizado \nde trabajo (PNT), elaboraci\u00f3n est\u00e9ril y dispensaci\u00f3n por reposici\u00f3n a paciente). Se compararon los datos de ambos \nescenarios. Se emple\u00f3 el precio de venta al p\u00fablico notificado con IVA (PVPiva) recopilado de una base de datos \nactualizada de medicamentos y el salario publicado por la resoluci\u00f3n m\u00e1s actualizada sobre retribuciones del personal \nde centros e instituciones sanitarias del sistema de salud de la comunidad aut\u00f3noma. Para el c\u00e1lculo de las URV se \nemple\u00f3 la estandarizaci\u00f3n del \u201cCat\u00e1logo de productos y facturaci\u00f3n, 2\u00baEd,2009\u201d. La seguridad se evalu\u00f3 con el n\u00famero de \nnotificaciones de reacciones adversas.\nRESULTADOS\nSe incluyeron 4 pacientes (100% varones; edad media: 3,55 a\u00f1os (1-6)). Uno de ellos en mantenimiento (60 mg \nquincenalmente) y el resto con comienzo de tratamiento en Febrero (40, 50 y 60 mg semanalmente (x4) y posteriormente \nquincenal). En el escenario A se utilizaron un total de 30 viales de 60 mg (150 mg/ml; 5.227,99\u20ac) con un coste de \n156.839,70\u20ac. El coste de personal fue de 18,79\u20ac y se alcanz\u00f3 un total de 19,98 URV. Se desaprovecharon 240 mg de \nemicizumab. Por otro lado, en el escenario B se emplearon un total de 22 viales con un coste total de 135.703,41\u20ac: 4 \nviales de 30 mg (30 mg/ml; 2.643,59\u20ac), 10 de 60 mg (150 mg/ml; 5.227,99\u20ac) y 8 de 105 mg (150 mg/ml; 9.106,15\u20ac). \nDebido al desarrollo de la actividad el coste de personal se increment\u00f3 a 423,7\u20ac con un total de 669,92 URV. Se consigui\u00f3 \nno desaprovechar nada de f\u00e1rmaco. En cuanto a seguridad no se recibi\u00f3 ninguna notificaci\u00f3n de seguridad.\nCONCLUSIONES\nEl fraccionamiento de emicizumab ha supuesto un ahorro trimestral en costes directos de 20.732,57\u20ac (13,22%) que \nextrapolado supondr\u00eda un ahorro anual de 82.930,28\u20ac. No obstante, el coste de personal y las URV alcanzaron un valor \nmuy superior debido a la elaboraci\u00f3n de los PNTs y a la elaboraci\u00f3n est\u00e9ril de las preparaciones. Sin embargo, como se ha \ndescrito, se trata de un procedimiento que permite velar por la seguridad as\u00ed como optimizar el gasto farmac\u00e9utico.262CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1029. BUDESONIDA VISCOSA: AN\u00c1LISIS DEL PERFIL DEL PACIENTE, EFECTIVIDAD Y SEGURIDAD EN EL \nTRATAMIENTO DE LA ESOFAGITIS EOSINOF\u00cdLICA \nAUTORES\nOYAGUE L\u00d3PEZ, L; GOENAGA ANSOLA, A; EIROA OSORO, M; MAC\u00cdA RIVAS, L; MARAY MATEOS, I; \u00c1LVAREZ ASTEINZA, \nC; FERN\u00c1NDEZ LAGUNA, CL; LOZANO BL\u00c1ZQUEZ, A\nHOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS \ufffd AVENIDA DE ROMA S/N OVIEDO \ufffd ASTURIAS\nOBJETIVOS\nAnalizar el perfil del paciente a tratamiento con la f\u00f3rmula magistral budesonida viscosa 0,5mg/ml suspensi\u00f3n oral (BVO), \nas\u00ed como su efectividad y seguridad, en pacientes con esofagitis eosinof\u00edlica (EEo) en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo donde se incluyeron todos los pacientes diagnosticados de EEo y \ntratados con BVO desde marzo de 2018 hasta abril de 2022. La recogida de datos se realiz\u00f3 mediante la historia cl\u00ednica \nelectr\u00f3nica y el programa inform\u00e1tico de formulaci\u00f3n magistral. Las variables recogidas fueron: sexo, edad, tratamiento \nprevio, manifestaciones cl\u00ednicas previas, antecedentes familiares, comorbilidades, fecha de diagn\u00f3stico e inicio de \ntratamiento, duraci\u00f3n de tratamiento, posolog\u00eda, tratamiento concomitante, citaciones en farmacia para recogida de \nmedicaci\u00f3n, hallazgos histol\u00f3gicos en gastroscopias, n\u00famero de eosin\u00f3filos por campo (Eo/CGA) en biopsias esof\u00e1gicas, \nmanifestaciones cl\u00ednicas tras tratamiento y efectos adversos. Las variables cuantitativas continuas se expresaron \ncomo mediana e intervalo intercuart\u00edlico. La adherencia se calcul\u00f3 mediante la frecuencia entre dispensaciones, \nconsider\u00e1ndose poco adherente cuando era superior a lo esperado en tres o m\u00e1s ocasiones o cuando as\u00ed se documentaba \nen la historia cl\u00ednica. La efectividad se determin\u00f3 valorando cambios histol\u00f3gicos, recuento de Eo/CGA y manifestaciones \ncl\u00ednicas y la seguridad valorando efectos adversos. El an\u00e1lisis estad\u00edstico de los datos se hizo con Microsoft Excel\u00ae.\nRESULTADOS\nSe incluyeron diez pacientes (80% varones) cuya mediana de edad al diagn\u00f3stico fue 27 a\u00f1os [17,5-42,5] y 32 a\u00f1os [20,5-\n45,5] al inicio de tratamiento. Todos ellos refractarios al tratamiento con inhibidores de la bomba de protones (IBP) en \nmonoterapia y 9 a dietas de exclusi\u00f3n y fluticasona deglutida. Previo al inicio con BVO 9 presentaron disfagia y 8 episodios \nde impactaci\u00f3n. Los antecedentes familiares al\u00e9rgicos (2) o asm\u00e1ticos (4) fueron los m\u00e1s comunes, mientras que 9 \npacientes eran al\u00e9rgicos y 5 asm\u00e1ticos.  \nLa mediana de tiempo transcurrido desde el diagn\u00f3stico hasta el comienzo con BVO fue 3 a\u00f1os y 4 meses [1,4-6,3] y la \nde duraci\u00f3n de tratamiento de 1 a\u00f1o [0,4-2], siendo tres pacientes de reciente inicio, quedando excluidos del an\u00e1lisis de \nefectividad y seguridad por carecer de datos de seguimiento.  \nTodos siguieron la pauta 1mg/12h, solamente 2 sufrieron una modificaci\u00f3n posterior, y 4 pacientes necesitaron \ntratamiento concomitante con IBP . La adherencia fue adecuada en 5 de ellos.  \nTodos presentaban alteraciones histol\u00f3gicas y > 15 Eo/CGA antes de iniciar tratamiento con BVO. Se observ\u00f3 mejor\u00eda \ncl\u00ednica en 6 pacientes, reducci\u00f3n en el n\u00famero de Eo/CGA en 5, siendo en dos de ellos completa, y mejor\u00eda histol\u00f3gica en \n4\ufffd \nEl 43% manifest\u00f3 efectos adversos; diarrea (2), dolor abdominal (1) y candidiasis esof\u00e1gicas (1).\nCONCLUSIONES\nEl perfil del paciente con EEo a tratamiento con BVO es hombre, joven, con comorbilidades y antecedentes de tipo \nal\u00e9rgico o asm\u00e1tico, refractario a otros tratamientos y con enfermedad de a\u00f1os de evoluci\u00f3n. La pauta habitual es \n1mg/12h, que suele requerir medicaci\u00f3n concomitante. El tratamiento con BVO se postula como una alternativa efectiva \ny segura en el manejo de EEo complicada, sin embargo, ser\u00eda necesaria mayor investigaci\u00f3n al respecto, que permita \nobtener resultados m\u00e1s consistentes que respalden los obtenidos en este estudio.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1041. ELABORACI\u00d3N DE DILUCIONES PARA EL ESTUDIO DE HIPERSENSIBILIDAD A VACUNAS ARNM \nFRENTE A SARS-COV-2 Y EVALUACI\u00d3N DE LA RESPUESTA. \nAUTORES\nGONZ\u00c1LEZ CABALLERO, \u00cd; SANTULARIO VERD\u00da, L; COLLS GONZ\u00c1LEZ, M; GARRIDO S\u00c1NCHEZ, L; DORDAL CULLA, MT; \nLLEONART BELLFILL, R; LEIVA BADOSA, E\nHOSPITAL UNIVERSITARI DE BELLVITGE. FEIXA LLARGA, S/N HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nOBJETIVOS\nLa incidencia de reacciones de hipersensibilidad (RHS) a las vacunas ARN mensajero (ARNm) frente a SARS-CoV2 \n(VacCOVID) es superior que para otras vacunas, considerando como agente causal alguno de sus excipientes. \nNuestro objetivo es describir la elaboraci\u00f3n de diluciones de polietilenglicol (PEG) y trometamol para el estudio de \npacientes con RHS administradas tras una primera dosis de VacCOVID y evaluar su respuesta\ufffd\nMATERIALES Y M\u00c9TODOS\nLos excipientes considerados potencialmente hipersensibilizantes de las vacunas ARNm BNT162b2 (Comirnaty\u00ae) y mRNA-\n1273 (Spikevax\u00ae) son PEG 2000 (en Comirnaty\u00ae) y Spikevax\u00ae) y trometamol (en Spikevax\u00ae).  \nEl protocolo definido por el Servicio de Alergolog\u00eda en pacientes con RHS tras la primera dosis VacCOVID, inclu\u00eda un \nprick test (PT) (1:1) con excedente de la vacuna. En caso de positividad, se aplicaban PT (1:1) de PEG3350 y trometamol 263(diluciones preparadas por el Servicio de Farmacia). Si las pruebas resultaban negativas se administraba, bajo \nconformidad del paciente, la segunda dosis VacCOVID con premedicaci\u00f3n: cetirizina 10mg. En caso de resultado positivo, \nse administraban diluciones de PEG de distinto PM y/o trometamol para evaluar la sensibilidad.  \nDatos recogidos: tipo de vacuna administrada, tipo de RHS y gravedad (seg\u00fan la clasificaci\u00f3n cl\u00ednica de reacciones \nadversas a f\u00e1rmacos con compromiso cut\u00e1neo por severidad), exposici\u00f3n previa a preparados con PEG 3350-4000 y \ntrometamol\ufffd\nRESULTADOS\nPara la elaboraci\u00f3n de diluciones de PEG, al no estar comercializado el PEG 2000 en Espa\u00f1a para su uso en PT se emple\u00f3 \notro PEG de elevado peso molecular (PM): Macrogol 3350, presente en soluciones evacuadoras. Para el trometamol \nse us\u00f3 la materia prima en polvo. En el Servicio de Farmacia se elaboraron bajo flujo laminar horizontal las soluciones \nmadre, preparadas con agua para inyectables, de PEG 3350 (500mg/mL) y trometamol (10mg/mL).  \nSe administr\u00f3 PT de diluciones a 9 pacientes, 2 hab\u00edan recibido Comirnaty\u00ae y 7 Spikevax\u00ae. Los vacunados con Comirnaty\u00ae \nno se hab\u00edan expuesto previamente a PEG sin embargo, ambos tuvieron reacciones leves post administraci\u00f3n de la \nvacuna. El PT de la vacuna y el de la diluci\u00f3n resultaron negativos. A ambos se les administr\u00f3 la segunda dosis de \nComirnaty\u00ae. El primero no present\u00f3 RHS mientras que el segundo hizo una RHS leve.  \nDe los 7 pacientes vacunados con Spikevax\u00ae, 3 hab\u00edan estado expuestos previamente a PEG en soluciones evacuantes y4 \na trometamol, en contrastes yodados, sin haber presentado incidencias. Tras la dosis de Spikevax\u00ae, 4 tuvieron reacciones \nleves, 2 moderadas y 1 paciente una reacci\u00f3n grave. Los resultados del PT con trometamol y PEG fueron negativos en \ntodos los casos. Se administr\u00f3 la segunda dosis de Spykevax\u00ae en todos los pacientes salvo en aquel que desarroll\u00f3 RHS \ngrave\ufffd De estos 6 pacientes, 4 no desarrollaron RHS y 2 mostraron una RHS leve\ufffd\nCONCLUSIONES\nLa elaboraci\u00f3n de diluciones con PEG 3350 procedente de soluciones evacuantes podr\u00eda ser una alternativa en ausencia \nde PEG 2000 comercial. En nuestro caso, la negatividad de los PT de excipientes no eximi\u00f3 de RHS post vacuna ARNm. Se \nrecomienda premedicar a pacientes con RHS a administraciones previas de la vacuna ARNm\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1054. AN\u00c1LISIS DESCRIPTIVO DE LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO DE \u00daLCERAS CORNEALES \nCON COLIRIO DE INSULINA 25 UI/ML \nAUTORES\nCAJADE PASCUAL, F; CASTRO BALADO, A; GARC\u00cdA QUINTANILLA, L; VARELA REY , I; ZARRA FERRO, I; MONDELO \nGARC\u00cdA, C; FERN\u00c1NDEZ FERREIRO, A; GONZ\u00c1LEZ BARCIA, M\nHOSPITAL CL\u00cdNICO UNIVERSITARIO DE SANTIAGO \ufffd CHOUPANA, S/N SANTIAGO DE COMPOSTELA \ufffd A CORU\u00d1A\nOBJETIVOS\nLa insulina es un factor anab\u00f3lico cuyo empleo se ha descrito en el tratamiento de \u00falceras corneales refractarias a otros \ntratamientos\ufffd El mecanismo de acci\u00f3n planteado es la regeneraci\u00f3n de plexos nerviosos corneales y la migraci\u00f3n de \nc\u00e9lulas epiteliales. Adem\u00e1s, el factor de crecimiento insul\u00ednico tipo 1 (IGF-1) es un modulador importante en la curaci\u00f3n \nde da\u00f1os en la c\u00f3rnea. El objetivo fue evaluar la eficacia y seguridad de colirios de insulina a concentraci\u00f3n de 25 UI/mL \nen pacientes con \u00falceras corneales refractarias.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y multic\u00e9ntrico desarrollado por un equipo multidisciplinar formado por \nfarmac\u00e9uticos y oftalm\u00f3logos. Se estudiaron los pacientes con \u00falceras corneales que recibieron tratamiento con colirios \nde insulina 25 UI/mL entre julio de 2021 y abril de 2022. La eficacia se evalu\u00f3 mediante la mejor\u00eda cl\u00ednica o epitelizaci\u00f3n \nde las \u00falceras observada por los oftalm\u00f3logos mediante tinci\u00f3n con fluoresce\u00edna tras 6 meses de tratamiento. La \nseguridad se evalu\u00f3 mediante la descripci\u00f3n de aparici\u00f3n de efectos adversos tras el inicio del tratamiento\ufffd\nRESULTADOS\nSe analizaron un total de 14 pacientes (57% hombres) que recib\u00edan el colirio con una posolog\u00eda de 1 gota entre 4 y 6 \nveces al d\u00eda en el ojo afectado. El oftalm\u00f3logo describi\u00f3 mejor\u00eda de la \u00falcera corneal en 10 pacientes (71%), y dentro de \nlos mismos, epitelizaci\u00f3n total con cese del tratamiento con colirios de insulina en un total de 5 pacientes (36%). En 3 \npacientes (19%) no se ha descrito mejor\u00eda y se ha discontinuado el tratamiento. No se registraron efectos adversos en \nninguno de los pacientes durante el periodo de evaluaci\u00f3n\ufffd\nCONCLUSIONES\nLa aplicaci\u00f3n de colirios de insulina a 25 UI/mL mostr\u00f3 un beneficio cl\u00ednico en la mayor\u00eda de pacientes con \u00falceras \ncorneales refractarias a otros tratamientos, adem\u00e1s de constituir un tratamiento seguro.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1058. VALORACI\u00d3N DEL RIESGO NUTRICIONAL DE PACIENTES CON INFECCION POR SARS-COV-2 \nINGRESADOS EN UNIDAD DE CUIDADOS INTENSIVOS \nAUTORES\nD\u00cdAZ SU\u00c1REZ, L; HU\u00c9LAMO MORUNO, C; VALLEJO B\u00c1EZ, A; BLANCO BERMEJO, C; DANI BEN ABDEL-LAH, L\nHOSPITAL VIRGEN DE LA VICTORIA \ufffd COLONIA DE STA INES, S/N M\u00c1LAGA \ufffd MALAGA264OBJETIVOS\nDescribir el riesgo nutricional, usando la escala de riesgo anal\u00edtico de desnutrici\u00f3n FILNUT (ERDF), de pacientes con \ninfecci\u00f3n por SARS-CoV-2 grave (ISARS-COV-2) y soporte nutricional por v\u00eda parenteral (SNP) ingresados en la unidad de \ncuidados intensivos (UCI) de un hospital de segundo nivel durante la \u201cquinta ola\u201d.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo coordinado con UCI de pacientes ingresados entre 01/07/2021 y 25/09/2021 en dicha \nUnidad por ISARS-COV-2 con SNP . Se registraron las siguientes variables a partir de la historia cl\u00ednica digital y aplicaci\u00f3n \nde gesti\u00f3n de dietas: edad, mediana estancia en UCI (MEUCI)(d\u00edas), vacunaci\u00f3n completa (VC)(si/no), ventilaci\u00f3n \nmec\u00e1nica(VM)(si/no), terapia de depuraci\u00f3n renal(TDR)(si/no),comorbilidades asociadas seg\u00fan informe de Ministerio de \nSanidad(si/no) del 28/10/2021 y motivo de alta (alta planta/exitus).  \nPara la valoraci\u00f3n nutricional, se ha empleado la ERDF (usando registros de prealb\u00famina, linfocitos y colesterol) para \ncalcular la puntuaci\u00f3n FILNUT al ingreso y alta de UCI. El riesgo de desnutrici\u00f3n seg\u00fan ERDF es:0 \u2013 1: sin riesgo; 2 \u2013 4: \nbajo; 5 \u2013 8: medio y 9 \u2013 12: alto.\nRESULTADOS\n44 pacientes incluidos; mediana de edad 61 a\u00f1os; Quince VC(31%); 42 VM(95%); 7 TDR(16%); Comorbilidades:12 \ndiabetes(27%), 12 hipertensi\u00f3n arterial(27%), 8 c\u00e1ncer(18%), 6 obesidad(14%), 6 enfermedad cardiovascular(14%), 4 \nenfermedad pulmonar cr\u00f3nica, 3 Insuficiencia renal cr\u00f3nica(7%), 3 enfermedad digestiva(7%) y ninguno con enfermedad \ncerebrovascular. Hubo 31 pacientes con 2 o m\u00e1s factores de riesgo(71%). Para la valoraci\u00f3n nutricional se incluyeron 28 \npacientes(64%). 16 fueron excluidos por falta de registros nutricionales para ERDF(36%). Riesgo de desnutrici\u00f3n:  \n\u2022 Bajo: 1 paciente; con VC; MEUCI 41 d\u00edas; VM; sin TDR; alta planta con mejor\u00eda de ERDF. \n \n\u2022 Medio: 9 pacientes(33%):  \n \n- 4 altas a planta(45%); MEUCI 24; 1 con VC(25%); 4 con VM(100%); ninguno con TDR; 4 con dos o m\u00e1s \ncomorbilidades(100%); 2 mejoran ERDF y no presentaban VC(50%).  \n \n- 5 exitus(55%); MEUCI 26; 1 con VC(20%); 5 con VM(100%); ninguno con TDR; 2 con dos o m\u00e1s comorbilidades(40%); \nninguno mejora ERDF. \n \n\u2022 Alto: 18 pacientes (64%):  \n \n- 7 altas a planta(39%): MEUCI 17; 5 con VC(71%); 6 con VM(85%); ninguno con TDR; 4 con dos o m\u00e1s \ncomorbilidades(57%); 5 mejoran ERDF(71%) de los cuales 4 presentaban VC(57%).  \n \n- 11 exitus(61%): MEUCI 27; 2 VC(18%); 11 VM(100%); 2 con TDR(18%); 7 con dos o m\u00e1s comorbilidades(63%); 5 mejoran \nERDF(45%) de los cuales 1 presentaba VC.\nCONCLUSIONES\nSe observa un elevado porcentaje de pacientes con ISARS-COV-2 ingresados en UCI durante \u201cla quinta ola\u201d con alto riesgo \nde desnutrici\u00f3n que podr\u00eda ser atribuible a las comorbilidades del paciente, situaci\u00f3n inflamatoria aguda y a s\u00edntomas \ngastrointestinales causados por la infecci\u00f3n. Por tanto, es importante la valoraci\u00f3n de riesgo nutricional al ingreso y \ndurante la estancia en UCI para un adecuado soporte nutricional de estos pacientes\ufffd  \nEn los pacientes con alto riesgo de desnutrici\u00f3n se observ\u00f3 un mayor porcentaje de exitus, y en este subgrupo: un \nporcentaje menor de mejor\u00eda de ERDF y tasa de VC, mayor MEUCI, VM y necesidad de TDR. Aunque son necesarios m\u00e1s \nestudios para profundizar en estos resultados.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1060. DISE\u00d1O Y VALIDACI\u00d3N GAL\u00c9NICA DE UNA NUEVA SUSPENSI\u00d3N ORAL DE AMIODARONA \nAUTORES\nDEL VALLE MORENO, P; \u00c1LVAREZ DEL VAYO BENITO, C\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nLa suspensi\u00f3n oral de Amiodarona 5mg/ml preparada seg\u00fan el estudio de estabilidad de Nahata (Ann Pharmacother \n1997), con frecuencia presenta problemas de homogeneidad tanto si se elabora a partir de comprimidos, como en el \nart\u00edculo original o a partir de principio activo.  \nAl tratarse de un f\u00e1rmaco de estrecho margen terap\u00e9utico, queremos dise\u00f1ar y validar una suspensi\u00f3n oral de \namiodarona homog\u00e9nea como paso previo al necesario estudio de estabilidad.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en Pubmed, bases de datos de formulaci\u00f3n magistral y de especialidades comerciales \nen el mercado internacional. Se estudiaron las caracter\u00edsticas fisicoqu\u00edmicas del principio activo. Se dise\u00f1aron y evaluaron \nnumerosas suspensiones; para el desarrollo de las f\u00f3rmulas se utiliz\u00f3 amiodarona clorhidrato (ClH) en polvo y excipientes \nsimples no comerciales. Se evalu\u00f3 y estableci\u00f3 el nivel de riesgo de la preparaci\u00f3n y su fecha de validez conforme a la Gu\u00eda \nde Buenas Pr\u00e1cticas de Preparaci\u00f3n (GBPP) (anexo 3). Se realiz\u00f3 la validaci\u00f3n gal\u00e9nica en cuanto a ausencia de turbidez y \nprecipitados, estabilidad de pH y control microbiol\u00f3gico dentro del periodo de validez.265RESULTADOS\nNo se encontr\u00f3 ninguna nueva referencia publicada con excipientes no comerciales en Pubmed ni en las bases de datos \nde formulaci\u00f3n magistral y tampoco ninguna especialidad extranjera. Se estableci\u00f3 conforme a la GBPP un nivel de riesgo \nmedio y un periodo de validez de 14 d\u00edas entre 2-8\u00baC.  \nLa primera suspensi\u00f3n se prepar\u00f3 a\u00f1adiendo polisorbato 80 a agua purificada y mezcl\u00e1ndolo posteriormente con la \namiodarona ClH. A esa mezcla se adicion\u00f3 agua purificada sin parar de agitar hasta un volumen final de 100 ml. La \nsegunda f\u00f3rmula se prepar\u00f3 utilizando adem\u00e1s glicerina y jarabe simple. Ambas suspensiones se dejaron en agitaci\u00f3n \ndurante al menos una hora en agitador Heidolph.  \nDe las dos suspensiones estudiadas, la segunda de ellas present\u00f3 problemas de resuspensi\u00f3n durante el periodo \nde validez, por lo que se descart\u00f3. La primera suspensi\u00f3n en estudio cumpli\u00f3 todos los par\u00e1metros fisicoqu\u00edmicos y \nmicrobiol\u00f3gicos durante el periodo de validez \nPara su empleo en lactantes, la cantidad de polisorbato 80 empleada en la formula seleccionada no supera la ingesta \ndiaria admitida para una dosis de mantenimiento de amiodarona de 5 mg/kg/d\u00eda.\nCONCLUSIONES\nUna suspensi\u00f3n oral de amiodarona 5 mg/ml homog\u00e9nea y transparente a partir del principio activo, polisorbato 80 y \nagua purificada fue dise\u00f1ada y validada gal\u00e9nicamente conforme a la GBPP como paso previo al estudio de su estabilidad.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1098. F\u00d3RMULA MAGISTRAL GEL GLUCOSA 40% EST\u00c9RIL PARA EL TRATAMIENTO DE HIPOGLUCEMIA EN \nNEONATOS Y RECI\u00c9N NACIDOS A T\u00c9RMINO \nAUTORES\nSALMER\u00d3N COBOS, AY; S\u00c1NCHEZ SUAREZ, MDM; MART\u00cdN ROLD\u00c1N, A; ARCHILLA AMAT , MI; MONTERO VILCHEZ, C\nHOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES \ufffd AV\ufffd DE LAS FUERZAS ARMADAS, 2 GRANADA \ufffd GRANADA\nOBJETIVOS\nElaboraci\u00f3n y validaci\u00f3n de una f\u00f3rmula magistral (FM) de glucosa al 40% forma farmac\u00e9utica gel sin conservantes para \ntratar las hipoglucemias tanto en reci\u00e9n nacidos a t\u00e9rmino como en neonatos.\nMATERIALES Y M\u00c9TODOS\nAnte la petici\u00f3n del equipo de pediatr\u00eda de elaborar una f\u00f3rmula magistral de glucosa exenta de conservantes, se \nrealiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en Pubmed y micromedex en relaci\u00f3n al uso de parabenes en neonatos y reci\u00e9n \nnacidos. Adem\u00e1s, tras no encontrar bibliograf\u00eda de una f\u00f3rmula de estas caracter\u00edsticas pero carente de conservantes, se \ndecidi\u00f3 crear la f\u00f3rmula desde el inicio. Bas\u00e1ndonos en manuales de elaboraci\u00f3n (c\u00f3mo \u201cHandbook of Pharmaceutical \nExcipients\u201d), se estudi\u00f3 sobre el manejo y compatibilidad de los componentes de la f\u00f3rmula como son la glucosa, \ncarboximetilcelulosa y agua destilada y as\u00ed garantizar una FM con las propiedades f\u00edsico-qu\u00edmicas y seguridad adecuadas. \nCon toda la informaci\u00f3n, se estableci\u00f3 un protocolo normalizado de trabajo (PNT).  \nEl modus operandi consisti\u00f3 en: pesar la carboximetilcelulosa s\u00f3dica (1,8 g) y a\u00f1adir a un vial de cristal topacio. \nSeguidamente, a\u00f1adir agua destilada( 8,8 mL) y cerrar herm\u00e9ticamente el vial con un tap\u00f3n de caucho y c\u00e1psula de aluminio \ndesgarrable. Una vez cerrado, autoclavar a 121\u00baC durante 20 min. A continuaci\u00f3n, en cabina de flujo laminar horizontal, \nse a\u00f1ade suero de glucosa 50% est\u00e9ril (40mL). El vial se deja reposar varios d\u00edas (alrededor de una semana) hasta obtener \nconsistencia y homogeneidad del gel y/o se puede introducir en el ba\u00f1o de ultrasonidos para agilizar el proceso. Finalmente, \nen campana de flujo horizontal para garantizar la esterilidad se cargan las jeringas orales con el gel (2,5 mL) para facilitar la \nadministraci\u00f3n oral de la f\u00f3rmula\ufffd En cuanto a los controles durante el proceso de elaboraci\u00f3n, se llevaron a cabo control \nde biocontaminaci\u00f3n de guantes y control de la esterilizaci\u00f3n del autoclave. Para verificar las caracter\u00edsticas del producto \nacabado se hicieron controles de calidad como control de esterilidad en botellas de hemocultivo (microbiolog\u00eda) o mediante \nsembrado en placa de agar-agar de una al\u00edcuota del gel una vez envasado en la jeringa oral.\nRESULTADOS\nInicialmente se obtuvo un vial con un gel transl\u00facido con la viscosidad apropiada, con una caducidad de 365 d\u00edas y cuya \nconservaci\u00f3n pod\u00eda ser tanto a temperatura ambiente como en el frigor\u00edfico. Una vez se carga el gel en las jeringas, \nse le da una caducidad de 180 d\u00edas y conservaci\u00f3n a 2-8\u00baC. Una vez abierta la jeringa, se le da una estabilidad de 24h. \nTodos los controles tanto del proceso de elaboraci\u00f3n como del producto acabado tuvieron resultados de no crecimiento \nmicrobiol\u00f3gico\nCONCLUSIONES\nEl gel de glucosa al 40% est\u00e9ril que se obtiene con esta f\u00f3rmula, se considera un tratamiento seguro para las \nhipoglucemias en neonatos. Desde la aprobaci\u00f3n de la f\u00f3rmula, no se han detectado efectos adversos. Adem\u00e1s, se \nconsidera una f\u00f3rmula sencilla de administrar, ya que se aplica en el interior de las mejillas, y econ\u00f3mica.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1115. ADECUACI\u00d3N DE LAS PRESCRIPCIONES DE NUTRICI\u00d3N PARENTERAL NEONATAL EN UN HOSPITAL \nDE TERCER NIVEL. \nAUTORES\nAPARICIO CASTELLANO, B; GUZM\u00c1N CORDERO, C; B\u00c1EZ GUTI\u00c9RREZ, N; PEREA P\u00c9REZ, \u00c1; RU\u00cdZ LARA, LM; MANCILLA \nMONTERO, E\nHOSPITAL UNIVERSITARIO REINA SOFIA \ufffd AVENIDA MENENDEZ PIDAL S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA266OBJETIVOS\nEn febrero de 2022 se elabor\u00f3 en el servicio de farmacia un checklist para la validaci\u00f3n farmac\u00e9utica de nutriciones \nparenterales de neonatos (NPN) basado en las principales gu\u00edas de referencia sobre prescripci\u00f3n, elaboraci\u00f3n y \nadministraci\u00f3n de NPN\ufffd \n \nEl objetivo de este estudio fue evaluar la adecuaci\u00f3n de las prescripciones de NPN, a trav\u00e9s de esta herramienta.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de las NPN prescritas de febrero a abril de 2022 en un hospital de tercer nivel. Para \nevaluar la adecuaci\u00f3n de las prescripciones se emple\u00f3 un checklist basado en las recomendaciones de las gu\u00edas NICE \n(2020), ASPEN (2019), ESPEN (2018) y SENPE (2017). \n \nEl checklist consta de 21 \u00edtems: Indicaci\u00f3n: < 31 semanas de gestaci\u00f3n o imposibilidad de v\u00eda enteral; Inicio: < 8 horas; \nEnerg\u00eda: 45-55 kcal/kg/d\u00eda (m\u00e1x. 120 kcal/kg/d\u00eda); Volumen total: 100-200 ml/kg/d\u00eda; Carbohidratos: 6-12 g/kg/d\u00eda \n(m\u00e1x.16-18 g/kg/d\u00eda); Amino\u00e1cidos: 1-2 g/kg/d\u00eda (m\u00e1x. 3 g/kg/d\u00eda); L\u00edpidos: 1-2 g/kg/d\u00eda (m\u00e1x. 4 g/kg/d\u00eda); Sodio: 2-5 \nmEq/kg/d\u00eda; Potasio: 2-5 mEq/kg/d\u00eda; Calcio: 0,8-3,5 mmol/kg/d\u00eda; Fosfato: 1- 2 mmol/kg/d\u00eda; Magnesio: 0,2-0,7 mg/\nkg/d\u00eda; Otros elementos traza: Zn, Cu, Mn, Se, Mo, Pb); Oligoelementos: 1ml/kg/d\u00eda; Vitaminas liposolubles: 4ml/kg/\nd\u00eda (m\u00e1x. 10 ml); Vitaminas hidrosolubles: 1ml/kg/d\u00eda (m\u00e1x. 3,7ml); Osmolaridad: < 900 mOs/l v\u00eda perif\u00e9rica; Presencia \nde medicamentos (insulina; heparina 0,5UI/kg); Duraci\u00f3n de la nutrici\u00f3n: tolerancia de 2/3 de los requerimientos \nenerg\u00e9ticos mediante nutrici\u00f3n enteral.\nRESULTADOS\nSe identificaron 26 neonatos que recibieron un total de 241 NPN durante el periodo de estudio.  \nLa mediana de nutriciones recibidas por paciente fue de 9 (rango 3-25).  \nLa indicaci\u00f3n y el inicio de la NPN fue correcta en el 100% y 73,1% de los pacientes\ufffd \nLos requerimientos de energ\u00eda y volumen fueron adecuados para el 98.3% y el 68,5%.  \nEl aporte de carbohidratos, l\u00edpidos y amino\u00e1cidos fueron correctos en el 99,6%, 99,2% y 61,4% de las prescripciones, \nrespectivamente. En el caso de los amino\u00e1cidos el 1.3% no alcanz\u00f3 el m\u00ednimo y un 37,3% super\u00f3 las cantidades \nrecomendadas\ufffd  \nLas cantidades de sodio, potasio, calcio, fosfato y magnesio cumplieron con las  \nrecomendaciones en un 49.4%, 7%, 47.7%, 32% y 75.5%, respectivamente. \nLos requerimientos de oligoelemento y vitaminas fueron adecuados en el 100% de los casos ya que se administran de \nforma protocolizada.  \nEl acceso venoso fue central en el 100%, siendo la osmolaridad de las NPN adecuada para la v\u00eda de administraci\u00f3n en \ntodos los casos\ufffd  \nNinguna nutrici\u00f3n fue adicionada con insulina y el 100% conten\u00edan heparina a dosis adecuada.  \nLa duraci\u00f3n de la nutrici\u00f3n fue adecuada en el 76\ufffd9% de los pacientes\ufffd \nNinguna de las NPN cumpli\u00f3 con los 21 \u00edtems; un 16,6% cumpli\u00f3 el 80% de los \u00edtems.\nCONCLUSIONES\nLas prescripciones de NPN no cumplieron con la mayor\u00eda de las recomendaciones del checklist. Los aportes de electrolitos \nfueron los principales causantes de esta inadecuaci\u00f3n, especialmente el potasio\ufffd Destaca un aumento en los valores de \nprote\u00ednas debido a que la mayor\u00eda de neonatos est\u00e1n en situaciones cr\u00edticas.  \nLa validaci\u00f3n farmac\u00e9utica de las NPN es esencial para alcanzar los requerimientos necesarios de los pacientes, \nespecialmente en una poblaci\u00f3n tan sensible como los neonatos, optimiz\u00e1ndose as\u00ed la eficacia y seguridad de estas.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1116. NUTRICI\u00d3N PARENTERAL ADITIVADA CON OCTRE\u00d3TIDO PARA EL TRATAMIENTO DE LA \nENFERMEDAD DE INJERTO CONTRA HU\u00c9SPED DIGESTIVA \nAUTORES\nGARC\u00cdA HERVALEJO, M; L\u00d3PEZ \u00c1LVAREZ, M; CONDE GONZ\u00c1LEZ, I; APARICIO PE\u00d1ACOBA, R; P\u00c9REZ L\u00d3PEZ, R; MART\u00cdN \nGUTI\u00c9RREZ, N; S\u00c1NCHEZ HERN\u00c1NDEZ, JG; OTERO L\u00d3PEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nEvaluar la utilidad de la nutrici\u00f3n parenteral aditivada con octre\u00f3tido (NPoctr). en pacientes hematol\u00f3gicos sometidos \na trasplante alog\u00e9nico (alo-TPH) que presentan enfermedad de injerto contra hu\u00e9sped (EICH) digestiva, para reducir el \nvolumen de deposiciones tras 5 y 10 d\u00edas de tratamiento.\nMATERIALES Y M\u00c9TODOS\nEstudio antes-despu\u00e9s, observacional, multidisciplinar y retrospectivo en un hospital general. El periodo de estudio \ncomprendi\u00f3 desde enero 2016 hasta abril de 2022. Se estudiaron los pacientes hematol\u00f3gicos sometidos a alo-TPH y \ndiagnosticados de EICH digestiva que ten\u00edan prescrita NPoctr. Las dosis de octre\u00f3tido se ajustaron diariamente en funci\u00f3n \ndel volumen de deposiciones\ufffd  \nSe recabaron de la historia cl\u00ednica electr\u00f3nica y del programa inform\u00e1tico de nutrici\u00f3n (Hospiwin\u00ae): sexo; fecha de \nnacimiento; diagn\u00f3stico; volumen (mL) de deposiciones 24 h previas al inicio (d\u00eda0) y 24 h previas al 6\u00ba d\u00eda (d\u00eda+5) y al 11\u00ba \nd\u00eda (d\u00eda+10) de tratamiento con NPoctr; composici\u00f3n de la NPoctr y fecha de inicio/fin de la misma.  267La variable principal fue el porcentaje de reducci\u00f3n del volumen de deposiciones en el d\u00eda+5 y el d\u00eda+10 de tratamiento, \ncon respecto al d\u00eda0, expresado mediante la mediana y rango intercuart\u00edlico (RIQ). Para el an\u00e1lisis de la significancia \nestad\u00edstica se realiz\u00f3 la prueba no param\u00e9trica de los rangos con signo de Wilcoxon mediante el programa SPSS\u00aev26.\nRESULTADOS\nEn el periodo de seguimiento considerado, se hab\u00eda prescrito NPoctr a un total de 36 pacientes (17 mujeres) sometidos a \nalo-TPH, con una mediana [rango] de edad de 54 a\u00f1os [20-69]. Los diagn\u00f3sticos de base fueron: leucemia mielobl\u00e1stica \naguda (n=18), linfoma no Hodgkin (n=5), leucemia linfobl\u00e1stica aguda (n=5), linfoma de Hodgkin (n=3), s\u00edndrome \nmielodispl\u00e1sico (n=4) y leucemia mielomonoc\u00edtica cr\u00f3nica (n=1). De estos 36 pacientes, hubo que excluir a 10 porque la \nduraci\u00f3n del tratamiento fue menor a 10 d\u00edas por motivos no relacionados con el tratamiento con octre\u00f3tido y a 2 por \nfalta de registro del volumen de deposiciones, por lo que el estudio finalmente incluy\u00f3 a 24 pacientes. \n \nDe los 24 pacientes analizados, en 14 (58%) se observ\u00f3 una disminuci\u00f3n del volumen de deposiciones en el d\u00eda+5, \nsiendo la mediana del porcentaje de reducci\u00f3n del 42,4% (RIQ: 20,2- 57,6). Estos pacientes recibieron una dosis media \nde octre\u00f3tido de 500 \u00b5g (RIQ: 400- 600). En el d\u00eda+10, 20 pacientes (83%) presentaron una disminuci\u00f3n del volumen de \ndeposiciones, con una mediana de reducci\u00f3n del 58,8% (RIQ: 45,4- 77,0). La dosis de octre\u00f3tido media fue de 500 \u00b5g \n(RIQ: 200- 750). La reducci\u00f3n del volumen de deposiciones en el d\u00eda+5 no fue estad\u00edsticamente significativa (p=0,211) \npero si lo fue en el d\u00eda+10 de tratamiento con NPoctr (p = 0,002).\nCONCLUSIONES\nEn esta cohorte limitada de pacientes hematol\u00f3gicos diagnosticados de EICH digestiva se redujo significativamente el \nvolumen de deposiciones tras 10 d\u00edas de tratamiento con nutrici\u00f3n parenteral aditivada con octre\u00f3tido. Ser\u00edan necesarios \nm\u00e1s estudios para determinar si la aditivaci\u00f3n de octre\u00f3tido en la nutrici\u00f3n parenteral resulta ser una buena estrategia \nterap\u00e9utica en este tipo de pacientes.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1139. FORMULACI\u00d3N T\u00d3PICA DE SIMVASTATINA 2% Y COLESTEROL 2% PARA EL TRATAMIENTO DE LA \nPOROQUERATOSIS. \nAUTORES\nOLIVER CERVELL\u00d3, M; DE CASTRO JULVE, M; ROVIRA MEDINA, T; ROMAN\u00cd DE GABRIEL, J; DEL ESTAL GIM\u00c9NEZ, J; \nL\u00d3PEZ GARC\u00cdA, B; PARRA BLANCA, A; G\u00d3MEZ VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\nLa poroqueratosis es un trastorno de la queratinizaci\u00f3n, que se asocia con mutaciones en la v\u00eda del mevalonato. La \ndeficiencia de colesterol y la acumulaci\u00f3n de metabolitos t\u00f3xicos en la piel se manifiesta en forma de placas asintom\u00e1ticas \no pruriginosas de bordes bien definidos, que podr\u00edan evolucionar a un carcinoma escamoso.  \n \nLos objetivos son:  \n\u2022 Desarrollar una f\u00f3rmula magistral (FM) t\u00f3pica de simvastatina 2% y colesterol 2%.  \n\u2022 Evaluar la efectividad y seguridad de esta formulaci\u00f3n para una paciente con Poroqueratosis de Mibelli que presenta \nlesiones cut\u00e1neas con riesgo de ulceraci\u00f3n en la extremidad inferior derecha.\nMATERIALES Y M\u00c9TODOS\nDermatolog\u00eda consult\u00f3 a Farmacia la posibilidad de preparar una formulaci\u00f3n t\u00f3pica de colesterol y un inhibidor de la \n3-hidroxi-3-metil-glutaril-CoA reductasa (HMGCR).  \nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica y se encontraron mayoritariamente formulaciones de lovastatina y colesterol a \nuna concentraci\u00f3n del 2% de cada principio activo (PA), y alguna de simvastatina y colesterol. Se decidi\u00f3 elaborar la \nf\u00f3rmula con simvastatina, por ser el inhibidor HMGCR disponible en el hospital. Se realiz\u00f3 la validaci\u00f3n gal\u00e9nica el d\u00eda \nde la elaboraci\u00f3n y mensualmente durante 3 meses. Se evaluaron las caracter\u00edsticas organol\u00e9pticas, extensibilidad, \nhomogeneidad y ausencia de exudaci\u00f3n.  \nSe valor\u00f3 la efectividad seg\u00fan datos de la historia cl\u00ednica y de las visitas de atenci\u00f3n farmac\u00e9utica.\nRESULTADOS\nInicialmente se dise\u00f1\u00f3 y elabor\u00f3 la siguiente FM con vaselina como veh\u00edculo:  \nSimvastatina\u20261g \nColesterol\u2026\u2026.1g  \nAceite de almendras dulces c\ufffds  \nVaselina c\ufffds\ufffdp 50g  \nModus operandi: triturar los comprimidos de simvastatina en el mortero hasta obtener un polvo fino. Tamizar hasta \ntama\u00f1o de gr\u00e1nulo uniforme. Pesar el colesterol y homogeneizar geom\u00e9tricamente con la simvastatina. A\u00f1adir el \naceite de almendras dulces suficiente para obtener una pasta uniforme. Finalmente, a\u00f1adir de forma geom\u00e9trica la \nvaselina removiendo hasta obtener una pasta homog\u00e9nea. El per\u00edodo de validez asignado inicialmente fue de 30 d\u00edas a \ntemperatura ambiente\ufffd  \nLa pomada present\u00f3 unas caracter\u00edsticas f\u00edsicas y organol\u00e9pticas adecuadas, color ros\u00e1ceo, untuosa y ligeramente \ngranulosa, que se mantuvieron durante toda la validaci\u00f3n gal\u00e9nica. \nSe produjo una mejora de la lesi\u00f3n cut\u00e1nea de la paciente tras un mes de tratamiento, aplicada dos veces al d\u00eda, aunque 268con irritaci\u00f3n secundaria en la zona aplicada, que dificult\u00f3 la adherencia al tratamiento. Se consigui\u00f3 la resoluci\u00f3n de la \nlesi\u00f3n a los 5 meses\ufffd  \nDebido a la textura granulosa, se opt\u00f3 por preparar una segunda formulaci\u00f3n en emulsi\u00f3n O/A con crema lanette, seg\u00fan \nbibliograf\u00eda encontrada posteriormente:  \nSimvastatina\u20261g \nColesterol\u2026\u2026.1g  \nPropilenglicol c\ufffds  \nCrema lanette c.s.p 50g \nModus operandi: Similar al anterior pero sustituyendo el aceite de almendras por propilenglicol y la vaselina por crema \nlanette.  \nLa crema present\u00f3 unas caracter\u00edsticas organol\u00e9pticas y f\u00edsicas adecuadas, color ros\u00e1ceo, sin part\u00edculas visibles al aplicarla \nsobre la piel y m\u00e1s f\u00e1cilmente extensible. Esta segunda f\u00f3rmula no se lleg\u00f3 a aplicar, por lo que no pudo valorarse su \ntolerabilidad\ufffd\nCONCLUSIONES\nLa formulaci\u00f3n de simvastatina 2% y colesterol 2% en vaselina result\u00f3 ser efectiva para la poroqueratosis en nuestra \npaciente, aunque no fue del todo bien tolerada.  \nAmbas formulaciones mantuvieron sus caracter\u00edsticas durante el periodo de estudio, presentando una mejor textura la \nformulada en crema lanette.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1175. ESTUDIO DE ESTABILIDAD FISICOQU\u00cdMICA DE UN COLIRIO DE CICLOSPORINA 0,5 MG/ML \nMEDIANTE CROMATOGRAF\u00cdA L\u00cdQUIDA DE ALTA RESOLUCI\u00d3N \nAUTORES\nGARC\u00cdA MORENO, FJ; YUSTE SOSA, I; PERN\u00cdA L\u00d3PEZ, MS; GONZ\u00c1LEZ BURGOS, EM; RIBED S\u00c1NCHEZ, A; HERRANZ \nALONSO, A; SANJURJO SA\u00c9Z, M; SERRANO L\u00d3PEZ, DR\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nLa ciclosporina t\u00f3pica oft\u00e1lmica se utiliza en diversas patolog\u00edas del ojo, como la enfermedad de ojo seco autoinmune, \nqueratoconjuntivitis vernal o tras trasplante de c\u00f3rnea. Se ha empleado a diversas concentraciones (0,5-20 mg/ml), \naunque solo hay presentaci\u00f3n comercial en formato monodosis a concentraci\u00f3n 1 mg/ml (Ikervis\u00ae).  \nObjetivo: evaluar la estabilidad fisicoqu\u00edmica de un colirio de ciclosporina 0,5 mg/ml en envases de vidrio topacio tipo III y \npolietileno de baja densidad (LDPE). Las condiciones de conservaci\u00f3n de las muestras de an\u00e1lisis fueron 5\u00b13\u00baC y 25\u00b12\u00baC.\nMATERIALES Y M\u00c9TODOS\nSe prepararon 3 lotes de la soluci\u00f3n en cabina de flujo laminar vertical por diluci\u00f3n de la presentaci\u00f3n parenteral \n(Sandimunn\u00ae) en suero fisiol\u00f3gico 0,9%. A partir de cada lote se prepararon al\u00edcuotas de 5 ml tanto en envase de vidrio \ncomo LDPE est\u00e9riles y se almacen\u00f3 un envase a T\u00aa ambiente y otro refrigerado para su an\u00e1lisis.  \nLa estabilidad se determin\u00f3 por medida de la concentraci\u00f3n remanente (mg/ml) de ciclosporina mediante cromatograf\u00eda \nl\u00edquida de alta resoluci\u00f3n (HPLC) acoplada a detector de absorci\u00f3n UV-visible. Las condiciones cromatogr\u00e1ficas \nfueron: fase estacionaria columna Thermo BDS Hypersil\u00ae C18 (250x4,6 mm, 5 \u03bcm), fase m\u00f3vil acetonitrilo/agua/\u00e1cido \nortofosf\u00f3rico (750/250/1 V:V:V) a flujo 2 ml/min, volumen de inyecci\u00f3n 20 \u03bcl, T\u00aa de la columna 25\u00baC y longitud de onda \nde absorci\u00f3n 210 nm. La recta de calibraci\u00f3n se obtuvo a partir de la preparaci\u00f3n de 6 est\u00e1ndares (L1-L6) en el rango de \nconcentraciones 6,25-500 \u03bcg/ml partiendo de Sandimunn\u00ae ampollas. A tiempos 0, 1, 3, 7, 10, 15, 21, 30, 45, 60 y 90 d\u00edas \ntras elaboraci\u00f3n, se extrajo un volumen de 150 \u03bcl de cada al\u00edcuota diluy\u00e9ndose con fase m\u00f3vil (1:1 V/V) para su an\u00e1lisis. \nLas muestras se inyectaron por triplicado en el m\u00f3dulo HPLC y se registraron altura de pico (H) y \u00e1rea bajo la curva (AUC) \nde cada se\u00f1al para establecer la concentraci\u00f3n de ciclosporina. Se consider\u00f3 cambio significativo variaciones de \u00b110%.  \nAdicionalmente se determin\u00f3 experimentalmente pH, osmolaridad y limpidez mediante visualizaci\u00f3n directa sobre \nfondos blanco y negro a t=0, 30, 60 y 90 d\u00edas.\nRESULTADOS\nEl m\u00e9todo mostr\u00f3 linealidad en el rango de concentraciones evaluado, con una recta de calibraci\u00f3n y=0,1979x+0,253 \n(siendo x=H) e y=0,5153x+2,7447 (siendo x=AUC), R2 > 0,999 en ambos casos. El tiempo de retenci\u00f3n fue 7\u00b10,2 min. La \nconcentraci\u00f3n remanente de principio activo se mantuvo por encima del 90% de la inicial a t=60 d\u00edas tanto a 25\u00baC como \nen refrigeraci\u00f3n y sin diferencias significativas entre tipo de envase, cayendo por debajo de 90% en todas las condiciones \ndel estudio a t=90 d\u00edas.  \nEl pH inicial de la soluci\u00f3n fue 6,09 y la osmolaridad 339 mOsm/l y permanecier on pr\u00e1cticamente invariables en todas las \ncondiciones estudiadas a lo largo del tiempo: \u00b10,15 y \u00b110 mOsm/l. No se detectaron cambios en la coloraci\u00f3n, turbidez ni \npart\u00edculas.\nCONCLUSIONES\nLa ciclosporina 0,5 mg/ml diluida en suero fisiol\u00f3gico presenta una estabilidad fisicoqu\u00edmica de al menos 60 d\u00edas, tanto a \n25\u00baC como refrigerada. El estudio permiti\u00f3 descartar procesos f\u00edsicos de adsorci\u00f3n a los recipientes del estudio (LDPE y \nvidrio), siendo ambos materiales v\u00e1lidos para almacenar la soluci\u00f3n.269CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1213. VALIDACI\u00d3N GAL\u00c9NICA DE UNA SUSPENSI\u00d3N DE BOSENT\u00c1N A PARTIR DE COMPRIMIDOS \nAUTORES\nRAM\u00d3N P\u00c9REZ, M; BOS\u00d3 RIBELLES, A; VILLA CARPES, J; D\u00cdAZ RAM\u00d3N, M; TORR\u00d3 GARC\u00cdA, L; GIL ALMELA, J; MART\u00cdNEZ \nIB\u00c1\u00d1EZ, M\u00c1; GOLNABI DOWLATSHAHI, F\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nDise\u00f1o y validaci\u00f3n de una suspensi\u00f3n oral de Bosent\u00e1n de concentraci\u00f3n 6,25mg/ml formulada en el servicio de \nfarmacia a partir de comprimidos y excipientes comerciales.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica en las distintas bases de datos que avalara la estabilidad f\u00edsico-qu\u00edmica de la \npreparaci\u00f3n. Se compararon los excipientes comercializados en Espa\u00f1a y disponibles en el hospital con los presentes en \nlas referencia bibliogr\u00e1ficas y se seleccionaron los equivalentes en su composici\u00f3n (ora plus\u00ae y ora Sweet\u00ae). \n \nLa suspensi\u00f3n se prepar\u00f3 triturando hasta polvo fino 5 comprimidos de 62.5 mg de bosent\u00e1n y se le a\u00f1adieron los \nexcipientes con una relaci\u00f3n 1:1 por adici\u00f3n geom\u00e9trica hasta un volumen final de 50 ml. Se mantuvo en agitaci\u00f3n \ndurante 30 minutos hasta obtener una soluci\u00f3n homog\u00e9nea (obteniendo una concentraci\u00f3n final de 6,25 mg/ml).  \n \nEl periodo de validez de la suspensi\u00f3n se determin\u00f3 seg\u00fan la Gu\u00eda de Buenas Pr\u00e1cticas de Preparaci\u00f3n de Medicamentos \nen Servicios de Farmacia Hospitalaria (GBPP , versi\u00f3n de 2014). Las suspensiones orales son preparaciones de riesgo \nmedio que requieren una validaci\u00f3n gal\u00e9nica obligatoria. Se procedi\u00f3 a realizar dicha validaci\u00f3n durante el periodo de \nvalidez asignado. Semanalmente, en los d\u00edas 1, 7, 14 y 28 se monitorizaban las caracter\u00edsticas organol\u00e9pticas (color, \nolor y sabor), el tiempo de sedimentaci\u00f3n, la redispersabilidad, la homogeneidad, la aparici\u00f3n de cristales y el pH de la \nsuspensi\u00f3n\ufffd\nRESULTADOS\nSe asign\u00f3 un periodo de validez de 30 d\u00edas al considerarse una FM oral l\u00edquida no est\u00e9ril, con estudios de estabilidad \nf\u00edsico-qu\u00edmica con conservantes y sin estudios de estabilidad microbiol\u00f3gica. \n \nEsta preparaci\u00f3n deber\u00eda conservarse en nevera entre 2-8\u00baC. \n \nEn el d\u00eda 1 la preparaci\u00f3n presentaba un color ligeramente rosa y un sabor y olor suave a cereza. El tiempo de \nsedimentaci\u00f3n correspondiente era superior a 1 minuto\ufffd Presentaba buena redispersabilidad tras agitaci\u00f3n suave, era \nhomog\u00e9neo a la vista y no mostraba presencia de cristales.  \n \nEl pH de la f\u00f3rmula se mantuvo entre 4 y 4,5\ufffd  \n \nA lo largo del periodo de estudio la FM no mostraba ninguna variaci\u00f3n destacable por lo que se mantuvo el periodo de \nvalidez asignado inicialmente.\nCONCLUSIONES\nLa elaboraci\u00f3n de suspensi\u00f3n oral de bosent\u00e1n a partir de comprimidos se puede considerar una alternativa v\u00e1lida para el \ntratamiento de la hipertensi\u00f3n pulmonar en poblaciones especiales como pediatr\u00eda y de esta forma poder administrar la \ndosis adecuada\ufffd  \n \nLa validaci\u00f3n gal\u00e9nica nos permite documentar que el proceso realizado en los par\u00e1metros establecidos ofrece resultados \nfiables.  \n \nLa FM presenta una adecuada estabilidad para su aplicaci\u00f3n en la pr\u00e1ctica cl\u00ednica, donde se deber\u00e1 estudiar si es \nfinalmente efectiva y segura.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1271. EFECTIVIDAD DE COLIRIO DE INSULINA EN DEFECTOS EPITELIALES CORNEALES PERSISTENTES \nREFRACTARIOS A TRATAMIENTO CONVENCIONAL \nAUTORES\nVILLA CARPES, J; BOS\u00d3 RIBELLES, A; LUCAS ELIO, G; VILLA CARPES, JA; RAM\u00d3N P\u00c9REZ, M; D\u00cdAZ RAM\u00d3N, M; CANO \nMOLINA, J\u00c1; GIL ALMELA, J\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nEvaluar la efectividad del colirio de insulina como una nueva opci\u00f3n terap\u00e9utica para el tratamiento de defectos \nepiteliales corneales persistentes (DEPs) refractarios a tratamiento convencional.270MATERIALES Y M\u00c9TODOS\nEl colirio de insulina se elabora en cabina de flujo laminar en la sala blanca del servicio de Farmacia a una concentraci\u00f3n \nde 1 UI/mL\ufffd  \nSe elabora a partir de insulina r\u00e1pida 100UI/mL diluida en suero fisiol\u00f3gico 0,9% y se envasa en frascos cuentagotas de \ncristal est\u00e9riles de 15 mL. El periodo de validez de la f\u00f3rmula es de 14 d\u00edas en nevera. \nLa administraci\u00f3n se realiza de manera t\u00f3pica con una pauta posol\u00f3gica de 4 aplicaciones/d\u00eda establecida por el Servicio \nde Oftalmolog\u00eda del hospital.  \n \nSe realiz\u00f3 un estudio observacional, retrospectivo, incluyendo todos los pacientes tratados con colirio de insulina como \ntratamiento adyuvante en DEPs, entre septiembre de 2020 y abril de 2022 en un hospital de tercer nivel.  \nSe recogieron variables demogr\u00e1ficas de edad y sexo, factores de riesgo (FR) de aparici\u00f3n y mal pron\u00f3stico de DEP \n(diabetes mellitus-2, ojo seco, uso de lentes de contacto, infecciones previas, trasplantes de c\u00f3rnea realizados), \ndiagn\u00f3stico principal, tratamiento previo recibido y duraci\u00f3n de tratamiento con colirio de insulina.  \n \nPara evaluar la efectividad del colirio de insulina, se midi\u00f3 el grado de respuesta al tratamiento tras su introducci\u00f3n \nobservando si hubo cicatrizaci\u00f3n completa o no de los defectos corneales mediante examen de biomicroscop\u00eda ocular.\nRESULTADOS\nSe incluyeron un total de 8 pacientes con una mediana de edad de 75 a\u00f1os (28-83), el 62,5% fueron mujeres. Los \ndiagn\u00f3sticos fueron: queratopat\u00eda bullosa pseudof\u00e1quica (n=1), queratopatia bullosa secundaria a distrofia corneal \nendotelial de Fuchs (n=1), queratoconjuntivitis herp\u00e9tica (n=1), queratoconjuntivitis seca asociada a blefaritis (n=1), \ns\u00edndrome de Sj\u00f6gren (n=1), \u00falcera ocular inmunol\u00f3gica (n=1) y \u00falceras corneales neurotr\u00f3ficas (n=2).  \nTodos los pacientes presentaron al menos uno de los FR asociados a la aparici\u00f3n y mal pron\u00f3stico de DEP . La presencia \nde infecciones previas y ojo seco fueron los m\u00e1s prevalentes (8), uso de lentes de contacto (6) y diabetes mellitus-2 (4). El \n75% de los pacientes (6) fueron intervenidos de trasplante de c\u00f3rnea, dos de ellos fueron retrasplantados.  \nLa mediana de tratamientos previos recibidos por paciente fue de 5: suero aut\u00f3logo (8), corticosteroides (8), l\u00e1grimas \nartificiales (8), pomada lubricante (8), recubrimiento con membrana amni\u00f3tica (6), antif\u00fangicos (3), antibi\u00f3ticos (2), \nantiv\u00edricos (1) e inmunosupresores (1). \nLa mediana de duraci\u00f3n del tratamiento con colirio de insulina fue de 2,6 meses (0,73-7,23).  \nEn cuanto a la respuesta al tratamiento, solamente en el 12,5% de los pacientes (1) se impresion\u00f3 en los ex\u00e1menes \noculares reepitelizaci\u00f3n corneal completa. En los 7 pacientes restantes se acab\u00f3 retirando el colirio por falta de respuesta.\nCONCLUSIONES\nSi bien el colirio de insulina ha demostrado su utilidad en series de casos con DEPs de peque\u00f1a extensi\u00f3n, en nuestro \nestudio, el colirio de insulina no ha ofrecido buenos resultados para el tratamiento de pacientes con DEPs avanzados que \nhan recibido varios tratamientos previos y con c\u00f3rneas pluripatol\u00f3gicas y antecedentes de queratoplastia.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1287. INSULINA T\u00d3PICA EN EL TRATAMIENTO DE DEFECTOS EPITELIALES OCULARES PERSISTENTES \nAUTORES\nNOVAJARQUE SALA, L; PINO RAMOS, A; LAMAS PILLO, A; MAGRO VAZQUEZ, C; GO\u00d1I INDURAIN, N; DE MIGUEL \nGAZTELU, M; FRESAN RESTITUTO, D\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDescribir la elaboraci\u00f3n de una f\u00f3rmula magistral de insulina t\u00f3pica ocular a una concentraci\u00f3n de 1UI/ml\ufffd Evaluar la \neficacia y seguridad del colirio de insulina como tratamiento off label en pacientes con defectos epiteliales persistentes \n(DEP) refractarios al tratamiento habitual.\nMATERIALES Y M\u00c9TODOS\nDesde el S\u00ba de Oftalmolog\u00eda se solicit\u00f3 el uso fuera de indicaci\u00f3n de colirio de insulina para el tratamiento de varios \npacientes con DEP refractarios a tratamientos convencionales\ufffd  \nEl colirio de insulina fue elaborado por el S\u00ba de Farmacia en cabina de flujo laminar horizontal. Para su preparaci\u00f3n \nse parti\u00f3 de insulina r\u00e1pida 100UI/mL (Actrapid \uf6da) y de soluci\u00f3n oft\u00e1lmica lubricante (Systane\uf6da), obteniendo una \nconcentraci\u00f3n final de 1UI/mL Se prepar\u00f3 en un frasco de cristal topacio con cuentagotas. Se le asign\u00f3 una caducidad de \n28 d\u00edas en nevera y 7 d\u00edas una vez abierto. La preparaci\u00f3n se realiz\u00f3 siguiendo la Gu\u00eda de Buenas Pr\u00e1cticas de Preparaci\u00f3n \nde Medicamentos. AEMPS (Junio 2014).  \nPara evaluar la eficacia y seguridad, se realiz\u00f3 un estudio retrospectivo observacional de los pacientes en tratamiento con \ncolirio de insulina desde octubre 2020 hasta mayo 2022.\nRESULTADOS\nSe evaluaron un total de 18 pacientes que recibieron tratamiento con colirio de insulina, de los cuales 9 fueron mujeres \ncon una edad media de 59 a\u00f1os\ufffd  \nLos 18 pacientes fueron diagnosticados de DEP de diferentes etiolog\u00eda: infecci\u00f3n v\u00edrica o bacteriana (n=2), cirug\u00eda \nocular previa (n=6), sequedad ocular grave (n=1), malposici\u00f3n palpebral (n=1), trastornos de sistema inmunol\u00f3gico con \nafectaci\u00f3n ocular(n=3), traumatismo ocular f\u00edsico o qu\u00edmico (n=5)  \nTodos los pacientes hab\u00edan recibido tratamiento convencional previo.  271La pauta utilizada con el colirio de insulina fue 1 gota cuatro veces al d\u00eda  \nEn cuanto a la eficacia, 9 pacientes presentaron una reepitelizaci\u00f3n total, 2 pacientes contin\u00faan en tratamiento y \nobjetivan una mejor\u00eda parcial y 7 pacientes no objetivaron mejor\u00eda alguna. La duraci\u00f3n media de curaci\u00f3n de la \u00falcera fue \nde 5,4 semanas\ufffd  \nNing\u00fan paciente sufri\u00f3 empeoramiento del DEP durante el tratamiento ni present\u00f3 recurrencia tras finalizar el mismo.  \nEl tratamiento fue bien tolerado y no se notificaron reacciones adversas.\nCONCLUSIONES\nLa elaboraci\u00f3n del colirio de insulina es un procedimiento de elaboraci\u00f3n sencillo, r\u00e1pido y econ\u00f3mico.  \nLa administraci\u00f3n del colirio de insulina 1UI/ml parece ser eficaz en el tratamiento del DEP refractario al tratamiento \nconvencional y con un buen perfil de seguridad.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS \nTECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n15. PRELIMINARY EVALUATION OF AN AUTOMATIZED INTERVENTION TO SWITCH ANTIBIOTICS FROM \nENDOVENOUS TO ORAL ROUTE \nAUTORES\nMURGADELLA SANCHO, A; COLOMA CONDE, A; GRACIA GARCIA, B; LOSA L\u00d3PEZ, L; PUEBLA VILLAESCUSA, A; \nHIDALGO ALBERT , E; S\u00c1NCHEZ , \u00d3\nHOSPITAL DE SANT JOAN DESPI MOISES BROGGI. AVENIDA JACINT VERDAGUER 90 SANT JOAN DESP\u00cd. BARCELONA\nOBJETIVOS\nOne of the most cost-effective and safe interventions of antimicrobial stewardship team (AMST) is the switch from \nintravenous to oral antibiotic therapy (SIVOR). The performance of this intervention consumes time and human \nresources\ufffd \nEvaluate the accordance of a SIVOR automatized recommendation proposed by the prescription program with the SIVOR \ncriteria of AMST \ufffd\nMATERIALES Y M\u00c9TODOS\nThe prescription program selected patients undergoing intravenous antibiotic treatment for more than 2 days with \nceftriaxone, amoxicillin/clavulanic acid, levofloxacin and linezolid. Based on predefined clinical stability criteria (corporal \ntemperature 36.0-37.5\u00baC, blood pressure > 120/60 mmHg, leukocytes 3.9-9.5 x 109 cells/L and tolerance to the oral \nroute), the program proposed SIVOR automatized recommendations.  \nIf a patient met 3 or 4 stability criteria, was marked in yellow or green respectively by the system and the program \nproposed the SIVOR recommendation.  \nIf a patient met less than 3 criteria, was marked in red. In that case, the program didn\u2019t propose the recommendation.  \nDuring May-June 2021 the AMST reviewed all recommendations performed by the program to assess the accordance \nwith AMST criteria.\nRESULTADOS\nDuring the study period there were 281 green and yellow marked treatments. 37 % (n=104) of the automatized \nrecommendations coincided with the AMST criteria and 63% (n=177) didn\u2019t coincide.  \nThe reasons for no coincidence were: 44% imminent finalization of treatment, 16% non-adequacy of oral route for the \ninfection source, 8% clinical impairment of the patient, 5 % pending microbiological results and 28 % no reason was \nregistred\ufffd\nCONCLUSIONES\nOnly a third of the SIVOR automatized recommendations coincided with those carried out by the AMST. Therefore the \nautomatic recommendations cannot be completely validated until some adjustments would be made.  \nThe most common reason for no coincidence was the imminent termination of treatment. The program should include \nthe variable duration of treatment to avoid an IVOR automatized intervention in those treatments. \nThe second reason was the infection source. It would be necessary to incorporate the indication of treatment during \nantibiotic prescription. In this way, this data could be incorporated in the algorithm decision of SIVOR automatized \nintervention.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n106. AN\u00c1LISIS DEL PRIMER A\u00d1O DE UN PROYECTO DE TELEFARMACIA ASOCIADO A RESULTADOS \nREPORTADOS POR LOS PACIENTES \nAUTORES\nMERCADAL ORFILA, G; BLASCO MASCARO, I; ROMERO DEL BARCO, R; LI\u00d1ANA GRANELL, C; CUBERO ALIAS, M; \nGOMEZ FRANCISCA, M; LLUCH TALTAVULL, J\nHOSPITAL MATEU ORFILA \ufffd RONDA MALB\u00daGER, 1 MAH\u00d3N \ufffd ILLES BALEARS272OBJETIVOS\nLa telefarmacia se ha erigido en una herramienta complementaria para conseguir una atenci\u00f3n farmac\u00e9utica \ncentrada en el seguimiento cl\u00ednico de los pacientes, la formaci\u00f3n , informaci\u00f3n, as\u00ed como la coordinaci\u00f3n del equipo \nasistencial, adecuado al nuevo contexto de asistencia sanitaria, como ayuda en la dispensaci\u00f3n o entrega informada de \nmedicamentos facilitando la accesibilidad a los mismos, sin perder de vista el objetivo final de mejorar los resultados en \nsalud y la seguridad de los pacientes\ufffd \nEn este contexto, pretendemos evaluar, los resultados del primer a\u00f1o de establecimiento de un proyecto global de \nasistencia con Telefarmacia, asociada al seguimiento cl\u00ednico mediante de resultados reportados por los pacientes \n(ePROMs) por via telem\u00e1tica\nMATERIALES Y M\u00c9TODOS\nSe incluyeron pacientes atendidos en consultas de Farmacia Hospitalaria de un Hospital , en el periodo Abril 2021 \u2013 Abril \nde 2022\ufffd\ufffd \nLa telefarmacia y el env\u00edo de cuestionarios se realiz\u00f3 por medio de una plataforma que permite el env\u00edo automatizado \ny programado de PROMs en 18 patolog\u00edas abordadas en las consultas de Farmacia Hospitalaria , as\u00ed como la recogida e \ninterpretaci\u00f3n de las respuestas\ufffd \nEvaluamos: n\u00famero de pacientes que se acogieron al programa, % de contestaci\u00f3n de los cuestionarios, evaluaci\u00f3n \ndel cuestionario de ansiedad/depresi\u00f3n(HADS), fatiga (FACIT) , productividad laboral( WRFQ) y efectos secundarios \nautoreportados  \nSe analizaron los resultados por medio de SPSS v28. Las variables continuas se resumir\u00e1n con media y desviaci\u00f3n t\u00edpica y \nlas variables categ\u00f3ricas se con frecuencias absolutas y relativas.\nRESULTADOS\nParticiparon 363 pacientes :  \n50,7% mujeres, 40,5% en la franja 31-50 a\u00f1os, eran pacientes procedentes de 31,7% reumatolog\u00eda, 19,2% VIH, 14,9% \nneurolog\u00eda, 13,77% dermatolog\u00eda, 13,6% digestivo, 6,83% otras \u00e1reas cl\u00ednicas. \nSe envi\u00f3 en un a\u00f1o 6.229 cuestionarios con el programa de seguimiento telem\u00e1tico asociado a ePROMs \nLa tasa de respuesta de los PROMs fue del 37,06%\ufffd \nDe los cuestionarios gen\u00e9ricos enviados, el an\u00e1lisis efectuado, permiti\u00f3 detectar:  \n1) En la esfera f\u00edsica, a nivel de fatiga medida con el cuestionario FACIT (Functional Assessment of Chronic Illness Therapy \n) , el 44,1% presentan fatiga moderada-severa \n \n2) En la esfera ps\u00edquica , el cuestionario HADS ( que eval\u00faa ansiedad y depresi\u00f3n) mostr\u00f3 que el 40,9% de los pacientes \npresentaban valores alterados  \n3) En cuanto a productividad laboral , el 35,3% presentaban alguna limitaci\u00f3n laboral evaluada por el cuestionario WRFQ ( \ncuestionario desempe\u00f1o del trabajo)  \n4) Los efectos secundarios autoreportados m\u00e1s frecuentes fueron: artromialgias (51,02%) , cefalea (46,9% ) molestias \ngastrointestinales( 30,6%), reacci\u00f3n en el lugar de inyecci\u00f3n(18,3%)  \nSe envi\u00f3 medicaci\u00f3n a domicilio al 4,3% de los pacientes, por su especial situaci\u00f3n de vulnerabilidad, y al centro de salud \nm\u00e1s cercano al 47,6% para ayudar a la conciliaci\u00f3n laboral-familiar. \nLa satisfacci\u00f3n con el programa de Telefarmacia asociado a ePROMs fue elevada (9,3 puntos sobre 10)\nCONCLUSIONES\nLa tasa de respuestas de ePROMS obtenidas est\u00e1 por debajo de las expectativas, por lo que habr\u00e1 que buscar estrategias \nde mejora (gamificaci\u00f3n, recordatorios\u2026)  \nDebemos prestar especial atenci\u00f3n a la esfera neuropsiqui\u00e1trica Y fatiga de los pacientes atendidos en consultas de \nFarmacia Hospitalaria\ufffd  \nLos pacientes est\u00e1n altamentes satisfechos con el modelo de Telefarmacia, complementario a la visita presencial.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n132. UTILIDAD DE LOS F\u00d3RUMS COMO FUENTE DE INFORMACI\u00d3N SOBRE LA SEGURIDAD DE LOS \nMEDICAMENTOS EN LA POBLACI\u00d3N PEDI\u00c1TRICA \nAUTORES\nVILIMELIS-PIULATS , I; P\u00c9REZ-RICART , A; JU\u00c1REZ-GIM\u00c9NEZ , JC; CALVO , A; SU\u00d1\u00c9 NEGRE, JM\nUNIVERSITAT DE BARCELONA\nOBJETIVOS\nEvaluar el potencial de f\u00f3rums para la detecci\u00f3n de reacciones adversas (RAM) y errores de medicaci\u00f3n (EM)\nMATERIALES Y M\u00c9TODOS\nEstudio observacional ambispectivo longitudinal durante enero-diciembre 2021. Se cre\u00f3 un software de miner\u00eda de datos \nusando la ontolog\u00eda de la Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios y la del diccionario de actividades \nM\u00e9dicas (MedDRA) para los principios activos (PA), para extraer RAMs y EM en pacientes pedi\u00e1tricos (0-18 a\u00f1os) en \natenci\u00f3n primaria. Se identific\u00f3 f\u00f3rums en \u201cGoogle\u201d mediante palabras clave (\u201cf\u00f3rums de padres\u201d, \u201cParent f\u00f3rums\u201d); con \npublicaciones p\u00fablicas, en ingl\u00e9s, espa\u00f1ol o catal\u00e1n y con permiso del administrador y usuarios. De los seleccionados, se \nextrajeron entradas hasta diciembre 2021.  \n 273Se excluyeron entradas duplicadas, dirigidas a adultos o exposici\u00f3n intra-utero (EIU), terapias no-farmacol\u00f3gicas, \nenlaces o noticias. De las RAM detectadas, se determin\u00f3 edad y \u00f3rgano afectado, medicamento seg\u00fan sistema de \nclasificaci\u00f3n anat\u00f3mica, gravedad seg\u00fan la Organizaci\u00f3n Mundial de la Salud, causalidad por el algoritmo de Liverpool \nCausality Assessment (LCAT) y frecuencia seg\u00fan ficha t\u00e9cnica (FT). Para EM, se determin\u00f3 usuario, tipo de error seg\u00fan \nla clasificaci\u00f3n de la American Society of Health-system Pharmacists y gravedad por National Coordinating Council for \nMedication Error Reporting and Prevention.\nRESULTADOS\nSe analizaron entradas de los forums mumnet.uk, socpetit.cat. De un total de 3375 posts, 727 (22%) mencionaban \nmedicamentos, excluy\u00e9ndose 94 entradas (13%) y encontr\u00e1ndose 161 (26%) RAM y 95 EM (15%). \n \nLas RAM ocurrieron mayormente en preescolares (78;48%), no report\u00e1ndose la edad en 8 (7%). PA mayoritarios: \nvacunas (57; 35%), antibacterianos sist\u00e9micos (34; 21%), antiinflamatorios/antirreum\u00e1ticos (12, 7%), anti\u00e1cidos (11, \n7%) y analg\u00e9sicos (11, 7%). \u00d3rganos mayormente afectados: gastrointestinal (41; 25%), alteraciones generales/lugar \nadministraci\u00f3n (32; 20%), piel (39, 18%), alteraciones psiqui\u00e1tricas (14, 9%) y sistema nervioso (8, 5%). Se encontraron \n21 (13%) RAM serias. 107 RAM (66%) ten\u00edan frecuencia no conocida en FT -de las cuales 33 (20%) no se encontraban \ndescritas- 3 (2%) fueron muy raras, 2 (1%) raras, 24 (15%) eran comunes, 14 (9%) poco frecuentes, 11 (7%) muy comunes. \nPor causalidad, 158 (98%) fueron posibles y 3 (2%) poco probables.  \n \nEM fueron por errores de prescripci\u00f3n (34; 36%), preparaci\u00f3n err\u00f3nea (2; 2%), omisi\u00f3n (3; 3%), medicamentos no \nprescritos (18; 19%), incumplimiento (15,16%), monitorizaci\u00f3n (17; 18%), t\u00e9cnica administraci\u00f3n (1; 1%), dosificaci\u00f3n \n(4; 4%) medicamento deteriorado (1;1%). La mayor\u00eda de los EM encontrados 73 (77%) llegaron al paciente: 69 (68%) sin \ncausar da\u00f1o, 3 (3%) no causaron da\u00f1o precisando monitorizaci\u00f3n y/o intervenci\u00f3n para comprobarlo y 1 (1%) caus\u00f3 da\u00f1o \ntemporal. Se detect\u00f3 14 (15%) EM que no llegaron al paciente y 8 (8%) fueron potenciales. Los EM fueron producidos \ntanto por PS (55; 58%) como cuidadores/familiares (40; 42%).\nCONCLUSIONES\nSe deduce que los f\u00f3rums en los que participan progenitores/cuidadores son una potencial fuente de datos de \nfarmacovigilancia. Se detectaron RAM, incluyendo graves, muy raras y no descritas en FT. EM que llegaron al paciente \ncausados por cuidadores y PS\ufffd Se dispuso informaci\u00f3n para aplicar LCAT \ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n239. AN\u00c1LISIS DE LOS DESABASTECIMIENTOS DE MEDICAMENTOS QUE REQUIEREN IMPORTACI\u00d3N Y \nDISPENSACI\u00d3N EN LOS SERVICIOS DE FARMACIA, EN UN \u00c1REA GEOGR\u00c1FICA. \nAUTORES\nYESTE G\u00d3MEZ, I; PALACIOS SOTO, M; ROIG CASTELLA, AM\nREGI\u00d3 SANIT\u00c0RIA DE GIRONA\nOBJETIVOS\nPrincipal: describir las caracter\u00edsticas de los desabastecimientos de medicamentos de dispensaci\u00f3n en oficina de \nfarmacia (OF), que requirieron importaci\u00f3n a trav\u00e9s del Servicio de Medicaci\u00f3n Extranjera (SME) entre 2016 y 2021 \ny fueron dispensados en los Servicios de Farmacia (SF) de 9 hospitales de un \u00e1rea geogr\u00e1fica, de 870.000 habitantes \naproximadamente\ufffd Secundario: conocer su impacto en los SF estudiados\ufffd\nMATERIALES Y M\u00c9TODOS\nSe analiz\u00f3 la facturaci\u00f3n anual de medicamentos de dispensaci\u00f3n en OF que fueron importados a trav\u00e9s del SME y \ndispensados en SF entre 2016 y 2021. Se cuantificaron los principios activos (p.a.) y pacientes afectados cada a\u00f1o. Se \nanalizaron cu\u00e1les fueron los p.a. y grupos ATC cuyo desabastecimiento afect\u00f3 a un mayor porcentaje de pacientes y la \nproporci\u00f3n de los mismos y del importe sobre el total de medicaci\u00f3n hospitalaria de dispensaci\u00f3n ambulatoria (MHDA) \nfacturada. Tambi\u00e9n se estudiaron los p.a. de dispensaci\u00f3n en OF en desabastecimiento, que el a\u00f1o 2021 fueron objeto de \ndispensaci\u00f3n hospitalaria.\nRESULTADOS\nLos desabastecimientos de medicamentos dispensados en OF que requirieron importaci\u00f3n a trav\u00e9s del SME y fueron \ndispensados en los 9 SF, afectaron de media a 274 pacientes/a\u00f1o durante el periodo estudiado (m\u00e1ximo 389 en 2016, \nm\u00ednimo 171 en 2017). Se realizaron una media de 1030 dispensaciones/a\u00f1o, m\u00e1ximo de 1297 en 2020. El n\u00famero de p.a. \nrecogidos en SF/a\u00f1o se mantuvo constante los 6 a\u00f1os (media 25; m\u00e1ximo 30 en 2020). La agrupaci\u00f3n ATC m\u00e1s afectada \nfue N (Sistema Nervioso) en 2016, 2019, 2020 y 2021, en 2017 fue A (Tracto alimentario y metabolismo) y en 2018, C \n(Sistema Cardiovascular).  \nEl a\u00f1o 2021 se dispensaron, en el conjunto de los 9 SF, un total de 23 p.a. importados por el SME, a 182 pacientes. \nLos p.a. m\u00e1s afectados fueron sucralfato (11,5%), \u00e1cido tranex\u00e1mico (11,5%) y metilergometrina(11,5%). Los grupos \nterap\u00e9uticos m\u00e1s afectados fueron N (Sistema nervioso, 22,5%) y A (Tracto alimentario y metabolismo, 22,0%).  \nLos p.a. dispensados en los hospitales, durante 2021, presentaron el siguiente comportamiento en las OF: 4 p.a. sin \ndispensaci\u00f3n, 4 p.a. disminuyeron respecto el a\u00f1o anterior y el resto sin cambios significativos.  \nImpacto SF: la media de dispensaciones anuales sobre el total de MHDA fue 0,50% (m\u00e1ximo 0,74% en 2016) y 0,71% en \npacientes\ufffd El impacto econ\u00f3mico anual en los a\u00f1os estudiados fue inferior al 0,03% de la facturaci\u00f3n\ufffd274CONCLUSIONES\nLos desabastecimientos de medicamentos dispensados en OF que requieren importaci\u00f3n por MSE y dispensaci\u00f3n en \nSF representan un esfuerzo a\u00f1adido en la gesti\u00f3n, dispensaci\u00f3n y atenci\u00f3n farmac\u00e9utica. Anualmente suponen un gran \nn\u00famero de dispensaciones y afectan a un n\u00famero considerable de pacientes, a pesar de que el impacto econ\u00f3mico queda \ndiluido en el global de la facturaci\u00f3n de MHDA \ufffd \nEl n\u00famero de p.a. afectados y de dispensaciones alcanz\u00f3 su m\u00e1ximo durante 2020, en el contexto pandemia, pero en \n2021 se observ\u00f3 una disminuci\u00f3n\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n306. EVOLUCI\u00d3N DEL GASTO ECON\u00d3MICO DURANTE LAS DIFERENTES OLEADAS DE LA PANDEMIA POR \nCOVID-19 EN UN HOSPITAL COMARCAL \nAUTORES\nMORA MORA, MA; CANTILLANA SU\u00c1REZ, MDG; ROLD\u00c1N GALNARES, M\nHOSPITAL COMARCAL SAN AGUST\u00cdN. AV . DE SAN CRISTOBAL, S/N LINARES. JA\u00c9N\nOBJETIVOS\nComparar el gasto farmac\u00e9utico por paciente COVID-19 ingresado en las diferentes oleadas de la pandemia por \ncoronavirus (COVID-19). Determinar qu\u00e9 grupos terap\u00e9uticos lideran el gasto y si la tendencia cambia con el avance de la \npandemia\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyeron los pacientes ingresados por COVID-19 en un hospital \ncomarcal desde Marzo-2020 hasta Enero-2022. Los variables recogidas fueron la edad y los medicamentos empleados \npara tratar la infecci\u00f3n por COVID-19. Se analiz\u00f3 el coste por paciente ingresado en cada una de las etapas de la \npandemia y, adem\u00e1s, el gasto global se desglos\u00f3 por grupo anat\u00f3mico, terap\u00e9utico, qu\u00edmico (grupo ATC). Los costes \nse calcularon en base al precio de venta libre de medicamentos (PVL). Los datos se recogieron de la historia cl\u00ednica \nelectr\u00f3nica y del programa inform\u00e1tico APD-ATHOS\u00ae.\nRESULTADOS\nSe incluyeron 985 pacientes, con una edad media de 65,3 \u00b1 16 a\u00f1os. De todos los pacientes, 97 (9,85%) fueron de la \nprimera ola, 292 (29,64%) de la segunda, 213 (21,63%) de la tercera, 165 (16,75%) de la cuarta, 91 (9,24%) de la quinta \ny 127 (12,89%) de la sexta ola. El coste por paciente ingresado fue de 550\u20ac en la primera ola, 398\u20ac en la segunda, \n467\u20ac en la tercera, 1.032\u20ac en la cuarta, 1.173\u20ac en la quinta y 465\u20ac en la sexta ola. Del total del gasto econ\u00f3mico de \nestos pacientes durante la pandemia (60.9537\u20ac), el mayor peso fue de los siguientes grupos: el B (sangre y \u00f3rganos \nhematopoyeticos, clasificaci\u00f3n ATC) supuso el 7%, principalmente por heparinas de bajo peso molecular; el grupo J \n(antiinfecciosos de uso sist\u00e9mico, clasificaci\u00f3n ATC) supuso un 26,16% del gasto total, donde los antiinfecciosos m\u00e1s \nconsumidos fueron ceftriaxona, lopinavir/ritonavir (a principios de la pandemia), piperacilina/tazobactam y remdesivir; y \nla mayor parte del consumo correspondi\u00f3 al grupo L (agentes antineopl\u00e1sicos e inmunomoduladores, clasificaci\u00f3n ATC) \ncon un 61,11% del gasto total, debido al uso de tocilizumab.\nCONCLUSIONES\nEl coste farmac\u00e9utico por paciente COVID-19 ingresado ha sufrido cambios a lo largo de la pandemia y ha sido mayor \nen la cuarta y quinta ola debi\u00e9ndose principalmente a un aumento del uso de tocilizumab y, en segundo lugar, de \nremdesivir. En la sexta ola se ha producido un descenso importante del coste por paciente COVID-19 ingresado debido \nal menor empleo de estos f\u00e1rmacos, probablemente por su menor gravedad puesto que una gran proporci\u00f3n de \npacientes ya estaban vacunados. Los grupos terap\u00e9uticos que lideran el gasto son los antiinfecciosos (grupo J) y los \ninmunomoduladores (grupo L), entre los que se encuentra el tocilizumab.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n410. EVALUACI\u00d3N DE IMPLEMENTACI\u00d3N DE UN PROGRAMA DE TELEFARMACIA EN PACIENTES VIH. \nAUTORES\nCASAS FERNANDEZ, X; VELEZ BLANCO, A; ORTEGA VAL\u00cdN, L; GUTIERREZ GUTIERREZ, E; LLAMAS LORENZANA, S; SAEZ \nVILLAFA\u00d1E, M; RODRIGUEZ FERNANDEZ, Z; ORTIZ DE URBINA, J\nCOMPLEJO ASISTENCIAL UNIVERSITARIO DE LE\u00d3N. ALTOS DE LA NAVA S/N LE\u00d3N. LE\u00d3N\nOBJETIVOS\nEl perfil de pacientes de VIH atendidos en las consultas de Farmacia Hospitalaria, est\u00e1 cambiando desde el punto de vista \nasistencial\ufffd  \nLos cambios de los \u00faltimos a\u00f1os dan lugar al nacimiento de la telefarmacia, que promueve una atenci\u00f3n sanitaria \ncontinuada y de calidad basada en las nuevas tecnolog\u00edas.  \nEl objetivo es determinar si un modelo de telefarmacia mejora la experiencia percibida y la adherencia del paciente VIH, \nfrente a un modelo tradicional\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo intervencionista (septiembre 2021 \u2013 abril 2022). Incluy\u00f3 24 pacientes VIH con \ntratamiento antirretroviral (TAR), mayores 18 a\u00f1os, en seguimiento por el farmac\u00e9utico, con acceso a tecnolog\u00edas y que \ndieron su consentimiento informado.  275El estudio se dividi\u00f3 en 2 etapas: T-4: previo a la instauraci\u00f3n de telefarmacia (septiembre-diciembre 2021). T+4: post \nimplantaci\u00f3n de telefermacia (enero-abril 2022)  \nLa captaci\u00f3n de pacientes se realiz\u00f3 en el per\u00edodo T-4, mediante consulta presencial donde se entregan 2 cuestionarios \npara valorar adherencia y experiencia percibida con la atenci\u00f3n farmac\u00e9utica. \nEn el per\u00edodo T+4, se realizaron consultas telem\u00e1ticas mensuales.  \nTras finalizar el estudio se envi\u00f3 por mensajer\u00eda de manera anonimizada, los mismos cuestionarios de adherencia y \nexperiencia percibida\ufffd  \nPara valorar adherencia se utiliz\u00f3 el cuestionario Simplified Medication Adherence Questionnaire SMAQ modificado. \nSe consider\u00f3 paciente adherente aquel con cumplimiento terap\u00e9utico igual o superior al 95%. El programa Spss\u00ae y \ntest McNemar, permiti\u00f3 identificar si existen diferencias en la adherencia en una misma poblaci\u00f3n antes y despu\u00e9s de \nintroducir un cambio\ufffd  \nPara valorar experiencia percibida por el paciente, se utiliz\u00f3 la escala Instrumento de Evaluaci\u00f3n de la eXperiencia del \nPaciente Cr\u00f3nico (IEXPAC), cuestionario de 15 \u00edtems con 11 preguntas globales y 4 condicionales. El programa Spss\u00ae y \ntest Wilcoxon, permiti\u00f3 valorar si hay diferencias en cuanto a la IEXPAC (global y condicional), en una misma poblaci\u00f3n \nrespecto antes y despu\u00e9s de introducir un programa de telefarmacia. \nSe recogieron otros datos de estratificaci\u00f3n: g\u00e9nero, edad, tiempo transcurrido desde el diagn\u00f3stico y numero de \ncomprimidos recibidos\ufffd\nRESULTADOS\nSe incluyeron 24 pacientes (100% varones), mediana de edad 53 a\u00f1os (31-72), el 91,67% realizaban una toma diaria de un \ncomprimido, mediana de evoluci\u00f3n de la enfermedad 17 a\u00f1os (0,5-33).  \nSe realiz\u00f3 un total de 4 consultas telem\u00e1ticas con cada uno de los pacientes. \nEl 100% de los pacientes se consideraron adherentes antes y despu\u00e9s de la implantaci\u00f3n de telefarmacia (p > 0,05).  \nIEXPAC global: (15 pacientes mejor resultado, 8 permanecieron igual y 1 paciente peor experiencia). IEXPAC condicional: \n(18 pacientes mejores resultados y 6 permanecieron igual). Se compar\u00f3 con test Wilcoxon los resultados de IEXPAC, antes \ny despu\u00e9s de instaurar la telefarmacia (p < 0,01).\nCONCLUSIONES\nLa instauraci\u00f3n de un programa de telefarmacia en pacientes VIH, no modific\u00f3 la adherencia, pero s\u00ed parece mejorar la \nexperiencia percibida de los pacientes en cuanto a la atenci\u00f3n farmac\u00e9utica.  \nLa telefarmacia, podr\u00eda ser una herramienta favorable para el control y seguimiento farmacoterap\u00e9utico de pacientes VIH.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n579. EL \u00c1RBOL DE LA FARMACIA HOSPITALARIA \nAUTORES\nMORALES PORTILLO, A; BARDOLL CUCALA, M; MIR CROS, M; RIUS PERERA, J; GILABERT SOTOCA, M; MANGUES \nBAFALLUY , I; MART\u00cdNEZ SOGUES, M; NEVOT BLANC, M\nHOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA \ufffd AVDA \ufffd ALCALDE ROVIRA ROURE, 80 LLEIDA \ufffd LLEIDA\nOBJETIVOS\nMedir el ahorro de papel generado por el trabajo sin papel en el \u00e1rea de preparaci\u00f3n de citost\u00e1ticos en un hospital de \nnivel 2\ufffd \nEstimar el impacto de este ahorro de papel sobre la tala de \u00e1rboles y la disminuci\u00f3n de la huella de carbono.\nMATERIALES Y M\u00c9TODOS\nEl \u00e1rea de preparaci\u00f3n de citost\u00e1ticos del Servicio de Farmacia cuenta con el programa de prescripci\u00f3n electr\u00f3nica, junto \ncon un m\u00f3dulo electr\u00f3nico de preparaci\u00f3n asistida.  \nEn abril de 2020 se pas\u00f3 a trabajar sin papel en el \u00e1rea de preparaci\u00f3n de citost\u00e1ticos.  \nSe extrajo el n\u00famero de pacientes con preparaci\u00f3n entre abril de 2020 y mayo de 2022 (24 meses) mediante el m\u00f3dulo \nde an\u00e1lisis y visualizaci\u00f3n de datos del programa de prescripci\u00f3n electr\u00f3nica. \nSe consider\u00f3 una hoja de papel por paciente, en base al protocolo previo de trabajo en el \u00e1rea. \nSe calcul\u00f3 el consumo en kg de papel en base a gramaje medio de 80 g, correspondiente a 5 g por hoja de papel.  \nEn base a datos de la Asociaci\u00f3n Espa\u00f1ola de Fabricantes de Pasta, Papel y Cart\u00f3n (AEFPC), se calcul\u00f3 el n\u00famero de \n\u00e1rboles no talados asumiendo un consumo medio de 2400 kg de madera, equivalentes a 17 \u00e1rboles, para la producci\u00f3n \nde una tonelada de papel\ufffd  \nSeg\u00fan datos de la AEFPC, se estim\u00f3 la huella de carbono asociada a la disminuci\u00f3n del consumo de papel mediante un \nfactor de 3,2 kg de CO2/kg de papel\ufffd\nRESULTADOS\nSe contabiliz\u00f3 un total de 51022 pacientes durante el periodo estudiado.  \nSe dejaron de usar 255,110 kg de papel. Se calcula que 4,34 \u00e1rboles dejaron de talarse gracias la al trabajo sin papel \ndurante el periodo de estudio\ufffd  \nLa disminuci\u00f3n de la huella de carbono gracias al trabajo sin papel fue de 816,352 kg/CO2.\nCONCLUSIONES\nEl trabajo sin papel en el \u00e1rea de preparaci\u00f3n de citost\u00e1ticos genera un beneficio medioambiental, evitando deforestaci\u00f3n \ny disminuyendo la huella de carbono asociada a nuestro trabajo.276CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n608. GESTI\u00d3N DE LOS INCIDENTES DE SUMINISTRO EN LA ADQUISICI\u00d3N DE MEDICAMENTOS E IMPACTO \nDE LAS ESTRATEGIAS DE ACTUACI\u00d3N \nAUTORES\nMART\u00cdN ZARAGOZA, L; V\u00c1ZQUEZ S\u00c1NCHEZ, R; RUBIO RUIZ, L; ROM\u00c1N PUENTE, MDM; BERNAL GARC\u00cdA, E; MOLINA \nGARC\u00cdA, T\nHOSPITAL UNIVERSITARIO DE GETAFE \ufffd CRTRA DE TOLEDO, KM \ufffd 12,5 GETAFE \ufffd MADRID\nOBJETIVOS\nLos desabastecimientos y suministros irregulares de medicamentos son una de las principales amenazas observadas \ndurante los \u00faltimos a\u00f1os en los Servicios de Farmacia de hospital, suponiendo la b\u00fasqueda de alternativas para poder \ncubrir las necesidades terap\u00e9uticas de los pacientes.  \nEl objetivo principal ha sido analizar los problemas de suministro, as\u00ed como determinar las principales l\u00edneas de acci\u00f3n \npara solventar el problema y el impacto que supone en el Servicio de Farmacia.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo, descriptivo, observacional en el que se han recogido los incidentes de suministros (IS) detectados en \nlos pedidos realizados desde enero 2022 hasta marzo de 2022. \nCada vez que un laboratorio nos informa de un IS se recogen las siguientes variables: tipo de IS, medicamento afectado, \nfecha inicio, fecha de fin, notificaci\u00f3n previa por la Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS), \nexistencias de alternativas, l\u00edneas de acci\u00f3n y su repercusi\u00f3n.  \nAdem\u00e1s, se ha incluido el precio de la presentaci\u00f3n que se estaba utilizando antes del IS y el precio de la alternativa, as\u00ed \ncomo las unidades que se han adquirido durante el periodo de duraci\u00f3n del mismo.\nRESULTADOS\nEn total se registraron 44 IS. El 65,9% no hab\u00edan sido publicados previamente por la AEMPS y el 33,3% de los restantes, \nfueron notificados por la AEMPS posteriormente a que se detectara el IS en el hospital.  \nLa media de duraci\u00f3n de los IS en nuestro centro fue de 52 d\u00edas hasta su resoluci\u00f3n por el laboratorio. No obstante, el \n43% de los desabastecimientos continuaban activos.  \nLos motivos de desabastecimiento fueron:  \n\u2022 En el 86% de los casos roturas de stock, de las cuales en el 60,6% se debe al cese temporal de suministro y en el 39,4% \nse debe a la existencia de un suministro controlado o restringido\ufffd  \n\u2022 En el 11% el motivo fue un retraso en la entrega del pedido.  \nAnte estos IS se plantearon distintas l\u00edneas de actuaci\u00f3n para solventarlos. En un 57% exist\u00eda la misma presentaci\u00f3n \ncomercializada por otro laboratorio espa\u00f1ol y en un 2% se adquiri\u00f3 como medicamento extranjero a trav\u00e9s de la \nplataforma de medicamentos en situaciones especiales\ufffd  \nEn un 23% de los casos se solucion\u00f3 la falta temporal del producto a trav\u00e9s de la gesti\u00f3n de pr\u00e9stamos entre hospitales, \nmientras que en un 18% supuso la b\u00fasqueda de alternativas terap\u00e9uticas equivalentes, as\u00ed como la puesta en marcha de \nacciones informativas y cambios log\u00edsticos intrahospitalarios.  \nLa adquisici\u00f3n de las alternativas ha supuesto un incremento de m\u00e1s de un 5% del importe en la compra de estos \nproductos\ufffd\nCONCLUSIONES\nLa rotura de stock y el suministro controlado son los principales motivos de los desabastecimientos que afectan a la \ncobertura de las necesidades terap\u00e9uticas de los pacientes. Adem\u00e1s, en la mayor\u00eda de los casos, la falta de informaci\u00f3n \nanticipada y la duraci\u00f3n indeterminada de los IS conllevan la implantaci\u00f3n de estrategias apresuradas de gesti\u00f3n log\u00edstica, \nplanificaci\u00f3n y comunicaci\u00f3n, adem\u00e1s, pueden suponer un incremento del importe de adquisiciones.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n617. DESARROLLO DE UN ESCRITORIO VIRTUAL COMO ENTORNO PERSONAL DE APRENDIZAJE EN UN \nSERVICIO DE FARMACIA \nAUTORES\nTEJEDOR TEJADA, E; RODRIGUEZ GOICOECHEA, M; CANO RODRIGUEZ, S; BRUGUERA TEIXIDOR, M\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEl uso de las herramientas digitales pertenecientes a la web 2.0 en el \u00e1mbito profesional del  \nfarmac\u00e9utico hospitalario ha aumentado en los \u00faltimos a\u00f1os.  \nLos escritorios digitales son sitios web gratuitos que permiten organizar de forma sencilla,  \npersonalizada y en una sola p\u00e1gina web los enlaces de inter\u00e9s del usuario  \nEl objetivo principal fue elaborar un escritorio digital Symbaloo\u00ae como herramienta de apoyo para un Servicio de \nFarmacia de Hospital que faciliten el acceso y la resoluci\u00f3n de consultas farmacoterap\u00e9uticas de una forma fiable y \neficiente.\nMATERIALES Y M\u00c9TODOS\nTras registrar una cuenta corporativa en Symbaloo\u00ae (www.Symbaloo.com), se cre\u00f3 un escritorio virtual con diferentes \nwebmix en funci\u00f3n de las \u00e1reas de la farmacia. Se a\u00f1adieron direcciones web recomendadas por el equipo farmac\u00e9utico 277del y que cumplieran alguno de los siguientes criterios de inclusi\u00f3n:  \n- Enlaces, documentos u otros recursos web presentes en la bibliograf\u00eda consultada o recomendadas por Instituciones \nSanitarias, Asociaciones Cient\u00edficas o Servicios de Farmacia Hospitalaria.  \n- Sitios web que cumplieran con las recomendaciones b\u00e1sicas de p\u00e1ginas web fiables de salud o tuvieran alg\u00fan sello de \ncalidad (Web M\u00e9dica Acreditada, Health On The Net Code o Web de Inter\u00e9s Sanitario).  \nLas p\u00e1ginas web a\u00f1adidas deb\u00edan estar en idioma castellano o ingl\u00e9s.  \nCada enlace se agrup\u00f3 en distintas zonas del escritorio virtual o webmix seg\u00fan el tipo de informaci\u00f3n que conten\u00eda, \notorg\u00e1ndole un color a cada categor\u00eda.  \nLa direcci\u00f3n web del escritorio se comparti\u00f3 por correo electr\u00f3nico con el resto de farmac\u00e9uticos del Servicio y \nposteriormente se hizo p\u00fablica tras una validaci\u00f3n conjunta de los enlaces.  \nLa aplicaci\u00f3n de Symbaloo para tel\u00e9fonos m\u00f3viles y tabletas permite el acceso al escritorio digital de forma inal\u00e1mbrica \ndesde cualquier lugar con acceso a internet.\nRESULTADOS\nEl escritorio virtual creado puede consultarse en la siguiente direcci\u00f3n web:  \nhttps://www.symbaloo.com/home/mix/13eOhK68gR \nA fecha de abril 2022 el n\u00famero total de enlaces a\u00f1adidos es de 160, siendo la distribuci\u00f3n por categor\u00edas la siguiente:  \n- Buscadores y metabuscadores de art\u00edculos cient\u00edficos e informaci\u00f3n farmacoterap\u00e9utica . \n- Documentos de consulta, calculadoras m\u00e9dicas y otros recursos web \u00fatiles para el desarrollo  \nde la actividad farmac\u00e9utica oncol\u00f3gica. \n- P\u00e1ginas web y documentos de consulta sobre seguridad, estabilidad, reconstituci\u00f3n,  \ndiluci\u00f3n, administraci\u00f3n e interacciones de medicamentos de car\u00e1cter oncol\u00f3gico.  \n- Webs oficiales de agencias, sociedades e instituciones cient\u00edficas de inter\u00e9s y Servicios de Farmacia hospitalaria.  \n- Bases de datos de medicamentos y situaciones especiales.  \n- Boletines Farmacoterap\u00e9uticos y Blogs sobre Medicamentos y Farmacoterapia.\nCONCLUSIONES\nSymbaloo\u00ae es una herramienta din\u00e1mica que facilita la gesti\u00f3n, clasificaci\u00f3n y almacenamiento de los contenidos web \nfarmacoterap\u00e9uticos m\u00e1s \u00fatiles para el equipo farmac\u00e9utico de un Hospital, pudiendo actuar adem\u00e1s como \u201cfiltro\u201d de \nla excesiva informaci\u00f3n sanitaria existente en internet. De esta manera la b\u00fasqueda y consulta de informaci\u00f3n se vuelve \nm\u00e1s sencilla, fiable y eficiente en t\u00e9rminos de optimizaci\u00f3n del tiempo.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n658. AN\u00c1LISIS DE LOS INDICADORES DE CONTINUIDAD ASISTENCIAL DEL CONTRATO PROGRAMA TRAS \nLA IMPLANTACI\u00d3N DE MEDIDAS FORMATIVAS Y DE SEGUIMIENTO \nAUTORES\nBARCIA MARTIN, MI; S\u00c1NCHEZ SUAREZ, S; AGUILAR GUISADO, C; GARC\u00cdA GIMENO, MM\nHOSPITAL DE EL ESCORIAL. CTRA. GUADARRAMA-S. LORENZO DE EL ESCORIAL, KM. 6,2 SAN LORENZO DE EL \nESCORIAL \ufffd MADRID\nOBJETIVOS\nAnalizar la evoluci\u00f3n de los Indicadores de Continuidad Asistencial (ICA) del Contrato Programa 2021 tras la implantaci\u00f3n \ndesde el Servicio de Farmacia de medidas formativas y de seguimiento de los mismos en los distintos servicios m\u00e9dicos \nimplicados\ufffd\nMATERIALES Y M\u00c9TODOS\nLa implantaci\u00f3n del M\u00f3dulo \u00danico de Prescripci\u00f3n en el \u00e1mbito hospitalario del Servicio Madrile\u00f1o de la Salud ha \nproducido un incremento del n\u00famero de prescripciones de receta por parte de los facultativos hospitalarios. Este \naumento, junto con el del gasto farmac\u00e9utico que resulta, conlleva realizar un buen seguimiento de las prescripciones \npara garantizar el uso adecuado y eficiente de los medicamentos m\u00e1s all\u00e1 del \u00e1mbito hospitalario. Como herramienta de \nayuda, es importante potenciar el buen cumplimiento de los ICA recogidos en el Contrato Programa\ufffd \nSe realiz\u00f3 un an\u00e1lisis por servicio del cumplimiento de los ICA del CP 2021 durante el periodo enero-agosto 2021. Se \nestablecieron sesiones formativas e informes individualizados por servicio y posteriormente, se analiz\u00f3 la evoluci\u00f3n de \npuntuaci\u00f3n desde el primer an\u00e1lisis respecto a la puntuaci\u00f3n final del periodo enero-diciembre 2021. Para ello de calcul\u00f3 \nel incremento porcentual de las puntuaciones de los mismos\ufffd  \nLos indicadores monitorizados fueron: Indicador-1, Porcentaje de envases de amoxicilina sin clavul\u00e1nico en pacientes \n15-65 a\u00f1os; Indicador-2, Prevalencia del uso de antibi\u00f3ticos en poblaci\u00f3n 15-65 a\u00f1os; Indicador-3, Porcentaje de \npacientes con fentanilo transmucoso sin opioide de base; Indicador-4, Prescripci\u00f3n de principios activos con Especialidad \nFarmac\u00e9utica Gen\u00e9rica; Indicador-5, Pacientes con insulina glargina, enoxaparina y teriparatida biosimilares. Para \ngarantizar un uso adecuado y eficiente de los medicamentos implicados, los indicadores 1, 4 y 5 deben tener una \ntendencia ascendente, el 2 tendencia descendente y el 3 debe ser 0\ufffd  \nEl cumplimiento de los indicadores se clasific\u00f3 en: alcanzado el umbral de excelencia (puntuaci\u00f3n obtenida por encima \ndel umbral de excelencia), cumplido (dentro del intervalo umbral de excelencia-l\u00edmite de valoraci\u00f3n) y no cumplido (fuera \ndel l\u00edmite de valoraci\u00f3n).278RESULTADOS\nDurante el primer periodo de an\u00e1lisis, se cumplieron los indicadores 1, 2, 4 y 5. Se incumpli\u00f3 el indicador 3.  \nSe imparti\u00f3 una sesi\u00f3n general formativa sobre los ICP . Se realizaron 9 sesiones informativas individualizadas con los \nservicios: Urolog\u00eda, Medicina Interna, Cirug\u00eda, Traumatolog\u00eda, Urgencias, Endocrino, Geriatr\u00eda, Anestesia y Oftalmolog\u00eda. \nSe realiz\u00f3 un informe individualizado para los servicios: Cardiolog\u00eda, Dermatolog\u00eda, Ginecolog\u00eda, Reumatolog\u00eda, \nHematolog\u00eda, Neumolog\u00eda y Otorrino.  \nAl finalizar el periodo de an\u00e1lisis: el indicador 4 alcanz\u00f3 el umbral de excelencia, se cumplieron los indicadores 1, 2 y 5 y \nse incumpli\u00f3 el indicador 3 debido a una prescripci\u00f3n no adecuada, subsanada posteriormente al periodo de estudio\ufffd  \nLos incrementos porcentuales obtenidos fueron: Indicador-1, +0,04%; Indicador-2, -10,22%; Indicador-3, 0%; Indicador-4, \n+4,30%; Indicador-5, +2,4%.\nCONCLUSIONES\nCon las medidas formativas establecidas, seg\u00fan los resultados obtenidos y en un breve periodo de tiempo, se observa \nuna tendencia a la mejora en todos los indicadores excepto en uno.  \nTanto los indicadores que monitorizan el uso eficiente y adecuado de la prescripci\u00f3n como el papel que desempe\u00f1a el \nfarmac\u00e9utico en el an\u00e1lisis, formaci\u00f3n y seguimiento de los mismos son fundamentales para contribuir a su cumplimiento \ny mejora.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n677. ANALISIS DE LA ACTIVIDAD DE UN SERVICIO DE FARMACIA DE UN HOSPITAL COMARCAL EN BASE \nA UNIDADES RELATIVAS DE VALOR \nAUTORES\nGARABITO S\u00c1NCHEZ, MJ; CORRAL BAENA, S; FERRIS VILLANUEVA, EM\nHOSPITAL SAN JUAN DE DIOS DE EL ALJARAFE. AVDA. SAN JUAN DE DIOS, S/N BORMUJOS. SEVILLA\nOBJETIVOS\nAnalizar y cuantificar la actividad del Servicio de Farmacia (SF) de un hospital comarcal a trav\u00e9s de Unidades Relativas de \nValor (URVs) del periodo 2017 a 2021.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo de la actividad del SF del per\u00edodo 2017-2021 mediante las URVs producidas para las \u00e1reas: Gesti\u00f3n \nlog\u00edstica (GL), dispensaci\u00f3n (D), elaboraci\u00f3n (E), gesti\u00f3n cl\u00ednica (GC) e investigaci\u00f3n/docencia (ID). Se calcul\u00f3 por a\u00f1o: \nUnidades producidas Totales, porcentaje de URVs por \u00e1rea, incremento interanual, \u00edndice de complejidad anual (ICA) \ndefinido como suma URVs/total unidades producidas, as\u00ed como el coste de URVs por a\u00f1o definido coste total del SF/ \nURVs\ufffd  \nLa definici\u00f3n del cat\u00e1logo de productos finales e intermedios, unidades de medida, formas de obtener cada dato y su \nvaloraci\u00f3n en URV se realiz\u00f3 por un grupo de trabajo formado por 3 farmac\u00e9uticas del servicio. Los datos se registran una \nbase de datos Excel\ufffd \nLos datos se procesaron mediante estad\u00edstica descriptiva con Microsoft Excell\u00ae 2010, las variables cuantitativas se \nexpresan como medianas (M) y cuartiles (Q1-Q3) y las cualitativas como porcentaje.  \nEl coste anual total del Servicio de Farmacia fue facilitado por la Direcci\u00f3n Financiera\ufffd Se incluyen gastos de personal, \ngasto de aprovisionamiento y otros gastos de explotaci\u00f3n\ufffd\nRESULTADOS\nEl total URVs de los a\u00f1os 2017 a 2021 fueron: 863.275, 871.750 (Q1), 919.722 (Q3), 875.951 (M) y 952.795 con un \nincremento interanual de 1%, 6%, -5% y 9%, respectivamente. El crecimiento global en URVs de los 5 a\u00f1os fue del \n10,4 %. El ICA fue de 1,7; 1,7; 1,7; 1,8 y 1,8 respectivamente. El coste anual por URV fue 0,44/0,43/0,43/0,47/0,49, \nrespectivamente, siendo la mediana 0,44 (0,43-0,47). El coste total del SF ha aumentado en 24% entre 2021 y 2017, \nsiendo la mediana de 394.620 \u20ac (379.401-411.910). La suma de URVs por cada \u00e1rea de actividad de mayor a menor y \nsu porcentaje respecto al total de URVs (4.483.494) fueron: 2.794.653 (62 %) D, 1.122.606 (25 %) GC; 410.201 (9 %) E, \n133.083 (3%) GL, 22.952 (1%) ID. Las medianas de cada \u00e1rea fueron: 557.707 (D), 219.497 (GC), 85.756 (E), 28.334 (GL) y \n4.816 (ID). Las \u00e1reas con crecimiento positivo fueron: GC (34 %), E (33 %), D (0,35 %) y con crecimiento negativo ID (-12,6 \n%) y GL (-13,4 %).\nCONCLUSIONES\nLas URVs producidas en los \u00faltimos 5 a\u00f1os han subido en 10,4%. El coste por URVs y ICA se han mantenido constante \nhasta 2020. El \u00e1rea que m\u00e1s ha crecido en los 5 a\u00f1os es la GC. En 2020, baj\u00f3 el total de URVs en todas las \u00e1reas excepto \nen la GC debido a la pandemia Covid. El \u00e1rea de ID es la menos desarrollada. Esta informaci\u00f3n ha sido \u00fatil para la gesti\u00f3n \nde Servicio y para poner de manifiesto a la Direcci\u00f3n el aumento continuo de la actividad y complejidad de Servicio de \nFarmacia\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n768. SILICON NEWS: CREANDO REDES CON 19 CENTROS HOSPITALARIOS \nAUTORES\nMARI\u00d1O FERN\u00c1NDEZ, C; GARAU GOMILA, G; AHMAD DIAZ, F; CALATAYUD BASSOLS, C; SALA PI\u00d1OL, F; \nSCHOENENBERGER ARNAIZ, JA\nCENTRO DE COMPETENCIA FUNCIONAL DEL INSTITUT CATAL\u00c0 DE LA SALUT279OBJETIVOS\nEvaluar el impacto y la satisfacci\u00f3n de los usuarios en relaci\u00f3n al proyecto Silicon News.\nMATERIALES Y M\u00c9TODOS\nEl proyecto Silicon News se inici\u00f3 en Noviembre de 2019 en el Centro de Competencia Funcional- Farmacia Hospitalaria \nubicado en el Centro Corporativo del Institut Catal\u00e0 de la Salut, equipo que proporciona soporte a 19 centros \nhospitalarios que utilizan el mismo sistema inform\u00e1tico para el manejo de medicamentos. La finalidad de este proyecto \nes difundir informaci\u00f3n relevante del aplicativo Silicon\u00ae, programa inform\u00e1tico donde se registra la prescripci\u00f3n \nelectr\u00f3nica asistida y se realiza el registro de la administraci\u00f3n de medicamentos y la gesti\u00f3n de los medicamentos, a nivel \nhospitalario.  \n \nConsiste en una infograf\u00eda mensual que se env\u00eda por correo electr\u00f3nico a los referentes del aplicativo Silicon del Servicio \nde Farmacia, y que tienen a su disposici\u00f3n en la plataforma Cercles\u00ae (repositorio de documentos de la Generalitat de \nCatalunya), para que hagan difusi\u00f3n en su centro. La comunicaci\u00f3n y la distribuci\u00f3n de la informaci\u00f3n es fundamental \npara la coordinaci\u00f3n de equipos interdisciplinares. \n \nSe presenta un estudio descriptivo y observacional realizado a trav\u00e9s de una encuesta enviada a los 19 centros \nhospitalarios. Cada centro ha enviado su respuesta, y si un centro tiene m\u00e1s de un referente s\u00f3lo se ha recibido una \nrespuesta en representaci\u00f3n del mismo. La encuesta est\u00e1 compuesta por 12 preguntas: 9 preguntas obligatorias tipo \nLikert (respuesta m\u00faltiple) y 3 opcionales tipo texto libre. La encuesta se ha enviado por correo electr\u00f3nico utilizando el \naplicativo Google Form. Los resultados se han tratado utilizando el mismo aplicativo y el programa inform\u00e1tico Excel.\nRESULTADOS\nHemos recibido respuesta de 13 centros hospitalarios. Todos conocen el proyecto y lo consideran una herramienta \nadecuada para transmitir informaci\u00f3n. Los temas tratados en Silicon News han parecido interesantes y han sido de \nutilidad, pero ning\u00fan centro ha propuesto nuevos temas. Todos los referentes con acceso la plataforma Cercles\u00ae han \naccedido a la documentaci\u00f3n a trav\u00e9s de esta v\u00eda. La mayor\u00eda han hecho difusi\u00f3n en su centro y la media del grado de \nsatisfacci\u00f3n general es 4,23 sobre 5, siendo 5 la m\u00e1xima satisfacci\u00f3n.\nCONCLUSIONES\nLos proyectos relacionados con la comunicaci\u00f3n de la informaci\u00f3n son indispensables para el trabajo de equipos \ninterdisciplinares. El proyecto Silicon News ha demostrado ser una herramienta \u00fatil que puede contribuir a mejorar la \ncoordinaci\u00f3n y comunicaci\u00f3n entre los 19 centros hospitalarios.Seguiremos fomentando este tipo de iniciativas para \ntransmitir la informaci\u00f3n y continuar trabajando en equipo.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n835. REVISI\u00d3N DE LA GESTI\u00d3N DE MEDICAMENTOS NO INCLUIDOS EN GU\u00cdA FARMACOTERAP\u00c9UTICA, \nCOMO MEJORA EN LA SELECCI\u00d3N Y ADQUISICI\u00d3N DE MEDICAMENTOS. \nAUTORES\nMONTERO SALGADO, B; SALAMANCA CASADO, A; G\u00d3MEZ S\u00c1NCHEZ, A; MIRANDA MAGA\u00d1A, M; TORTAJADA GOITIA, \nB\nCOMPLEJO HOSPITAL COSTA DEL SOL. CRTRA NACIONAL 340, KM. 187 MARBELLA. MALAGA\nOBJETIVOS\nDescribir los medicamentos no incluidos en la gu\u00eda farmacoterap\u00e9utica (MNIGFT) utilizados en nuestro centro y revisar \nsu utilidad terap\u00e9utica y frecuencia de uso, y determinar su propuesta de inclusi\u00f3n en la gu\u00eda farmacoterap\u00e9utica (GFT). \nAveriguar si existen presentaciones comerciales en formato monodosis de estos MNIGFT para mejorar la eficiencia del \nreacondicionamiento y de la dispensaci\u00f3n en dosis unitarias\ufffd\nMATERIALES Y M\u00c9TODOS\nSe registraron en base de datos Excel\u00ae los MNIGFT almacenados, con nombre, dosis, forma farmac\u00e9utica y grupo \nterap\u00e9utico.  \nSe determin\u00f3 la posibilidad de intercambio terap\u00e9utico \u00f3 si eran medicamentos VINE (valor intr\u00ednseco no elevado) en \nbase a las diferentes Gu\u00edas de Intercambio y Boletines Farmac\u00e9uticos publicados, y la frecuencia de prescripci\u00f3n a criterio \ndel farmac\u00e9utico que revisa la prescripci\u00f3n de los MNIGFT a diario.  \nLos medicamentos se dividieron en cuatro grupos: 1 - No adquirir, VINE; 2 - No adquirir, medicamento intercambiable; 3 - \nMantener, frecuencia baja; 4 \u2013 Mantener, frecuencia alta.  \nSe compararon las presentaciones comerciales adquiridas con las del listado \u201cNo reenvases por desconocimiento\u201d, \nse\u00f1alando cu\u00e1les dispon\u00edan de presentaci\u00f3n en formato monodosis.\nRESULTADOS\nSe registraron 178 MNIGFT, distribuidos seg\u00fan grupo terap\u00e9utico en antidepresivos (15%); antiepil\u00e9pticos (11%); \nantipsic\u00f3ticos (9%); antiparkinsonianos (7%); inmunosupresores (4%); inhibidores de la HMG-CoA reductasa (4%); agentes \nantiinflamatorios intestinales (3%); antagonistas de los receptores de angiotensina II (3%); otros preparados del coraz\u00f3n \n(3%); preparados contra el v\u00e9rtigo (3%); agentes relajantes musculares de acci\u00f3n central (2.5%); hormonas tiroideas \n(2.5%); antitromb\u00f3ticos (2.5%); otros (28%).  \n 280El 63,5% eran MNIGFT que deb\u00edan mantenerse durante el ingreso (grupos 3 y 4), siendo el 35,4% de uso poco frecuente \n(grupo 3) y el 28,1% muy frecuentes (grupo 4). El 36,5% de los MNIGFT no deber\u00eda haberse adquirido, ya que el 10,1% \neran VINE y el 26,4% eran intercambiables. De los MNIGFT que deben mantenerse (grupos 3 y 4), el 21,2% dispone de \npresentaci\u00f3n en monodosis\ufffd  \n \nSe determin\u00f3 que deb\u00eda proponerse para su inclusi\u00f3n en GFT el 14% de todos los MNIGFT utilizados, por ser \nmedicamentos que deb\u00edan mantenerse durante el ingreso y de uso muy frecuente, habi\u00e9ndose seleccionado aquellas \npresentaciones con dosis intermedias\ufffd\nCONCLUSIONES\nSon numerosos los MNIGFT que se utilizan en nuestro centro, siendo los m\u00e1s frecuentes aquellos destinados a trastornos \ndel sistema nervioso central, fundamentalmente antidepresivos, antiepil\u00e9pticos, antipsic\u00f3ticos y antiparkinsonianos, \npudiendo estar relacionado con la ausencia de Servicio de Psiquiatr\u00eda y Neurolog\u00eda en nuestro centro.  \nLa mayor\u00eda de los MNIGFT adquiridos son necesarios y se propondr\u00e1 a la Comisi\u00f3n de Farmacia la inclusi\u00f3n de aquellos \nde uso m\u00e1s frecuente. Sin embargo, m\u00e1s de un tercio de los MNIGFT deber\u00eda haber sido suspendido durante el ingreso o \nhaberse intercambiado por otro medicamento de la GFT. Adem\u00e1s, cerca de una cuarta parte de los MNIGFT necesarios, \nse puede adquirir en formato monodosis y no se estaba considerando. Todo esto viene a se\u00f1alar que la gesti\u00f3n de los \nMNIGFT a\u00fan es susceptible de mejora y la necesidad de una revisi\u00f3n sistem\u00e1tica y peri\u00f3dica del proceso para mejorar la \ncalidad en la selecci\u00f3n y adquisici\u00f3n de medicamentos.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n861. EVALUACION DE LAS CITAS DE PACIENTES EXTERNOS DE LA UNIDAD DE FARMACIA AMBULATORIA \nAUTORES\nMORA ATORRASAGASTI, O; IBARRA BARRUETA, O; IGLESIAS LAMBARRI, A; CALDERON RAMIREZ, L; RUIZ MORALES, \nC; LOPEZ PADRO, M; VIVANCO DE FRANCISCO, L; MARITN TORRENTE, A\nHOSPITAL GALDAKAO-USANSOLO. BARRIO LABEAGA, S/N. GALDAKAO. VIZCAYA\nOBJETIVOS\nLa citaci\u00f3n de los pacientes en la farmacia ambulatoria facilita la organizaci\u00f3n del trabajo, la disponibilidad de la \nmedicaci\u00f3n en la farmacia y evita las esperas innecesarias del paciente\ufffd \nEl objetivo de este trabajo fue evaluar la cumplimentaci\u00f3n de las citas de la farmacia ambulatoria por parte de los \npacientes que acuden al hospital a recoger medicaci\u00f3n y los motivos para acudir sin cita.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y transversal, de evaluaci\u00f3n de la cumplimentaci\u00f3n de las citas de las agendas de la \nfarmacia ambulatoria. Se recogieron datos en 43 d\u00edas, del 1 de febrero al 31 de marzo del 2022.  \nLos pacientes son citados en la aplicaci\u00f3n inform\u00e1tica del hospital en las agendas de la farmacia ambulatoria, tanto de \natenci\u00f3n farmac\u00e9utica como de dispensaci\u00f3n. La citaci\u00f3n incluye d\u00eda y hora para la recogida de medicaci\u00f3n.  \nDurante el estudio, las auxiliares de farmacia y las farmac\u00e9uticas registraron en un Excel los pacientes que acud\u00edan sin \ncita, el servicio de procedencia y el motivo que se clasific\u00f3 como inicio de tratamiento, reinicio de tratamiento, pacientes \ncon cita en d\u00eda diferente y otros motivos.\nRESULTADOS\nDurante el periodo de estudio acudieron al Servicio de Farmacia a recoger medicaci\u00f3n 3.743 pacientes de esto 418 (11%) \nno ten\u00edan cita.  \nLa mediana de pacientes citados por d\u00eda fue de 85 (IQR25-75 73-98) y de pacientes atendidos por d\u00eda fue de 84 (IQR25-\n75 77-93). Igualmente, la mediana de pacientes que acudieron sin cita por d\u00eda fue de 9 (IQR25-75 7-31) y la mediana de \ninasistencia por d\u00eda fue de 9 (IQR25-75 7-31).  \nLos principales servicios de procedencia de los pacientes sin cita fueron: 77 (18,4%) hematolog\u00eda, 63 (15,1%) infecciosas, \n58 (3,9%) oncolog\u00eda, 51 (12,2%) nefrolog\u00eda, 35 (8,4%) reumatolog\u00eda/medicina interna, 26 (6,2%) neumolog\u00eda y 20 (4,8%) \nneurolog\u00eda.  \nDe los 418 pacientes que acudieron al Servicio de Farmacia sin cita 216 (52%) acudieron en d\u00eda diferente a la cita prevista, \n157 (38%) eran pacientes nuevos en el servicio, a los que se les prescribi\u00f3 un nuevo tratamiento y 37 (9%) fueron reinicios \nde tratamiento\ufffd  \nDe los 194 pacientes que acudieron a iniciar o a reiniciar el tratamiento, los principales servicios de procedencia fueron: \n29 (14,9%) hematolog\u00eda, 29 (14,9%) oncolog\u00eda, 18 (9,3%) reumatolog\u00eda/medicina interna, 16 (8,2%) cirug\u00eda general, 15 \n(7,7%) neumolog\u00eda, 14 (7,2%) cardiolog\u00eda, 14 (7,2%) nefrolog\u00eda, 14 (7,2%) neurolog\u00eda, 11 (5,7%) hepatolog\u00eda, 8 (4,1%) \ndermatolog\u00eda y 8 (4,1%) infecciosas.\nCONCLUSIONES\nUn 11% de los pacientes acuden al Servicio de Farmacia sin cita, la mitad de ellos motivado por un inicio o reinicio de \ntratamiento. Esto plantea una educaci\u00f3n en aquellos pacientes que no acuden el d\u00eda indicado y a los servicios que env\u00edan \npacientes sin cita para iniciar o reiniciar \ufffd281CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n890. CONTROL DE CALIDAD EN EL REGISTRO DE LOS PROTOCOLOS DE ELABORACI\u00d3N EN MEZCLAS \nINTRAVENOSAS \nAUTORES\nTORRANO BELMONTE, P; FRUCTUOSO GONZ\u00c1LEZ, L; IBA\u00d1EZ CATURLA, J; PACHECO L\u00d3PEZ, P; CARVAJAL S\u00c1NCHEZ, \nM\u00c1; HERN\u00c1NDEZ S\u00c1NCHEZ, M; GUTIERREZ S\u00c1NCHEZ, JA; MANRESA RAM\u00d3N, N\nHOSPITAL J.M. MORALES MESEGUER. AV . MARQU\u00c9S DE LOS V\u00c9LEZ, S/N. MURCIA. MURCIA\nOBJETIVOS\nCuantificar y clasificar los errores en el registro de los procedimientos normalizados de trabajo (PNT) asociados a la \nelaboraci\u00f3n de las mezclas intravenosas (MIV) en sala blanca en funci\u00f3n del personal que interviene en cada proceso.\nMATERIALES Y M\u00c9TODOS\nSe trata de un estudio descriptivo retrospectivo en el que seleccion\u00f3 los 600 \u00faltimos PNT de MIV (durante el periodo de \n1 enero hasta 30 marzo del 2022) obtenidos a trav\u00e9s de la aplicaci\u00f3n inform\u00e1tica Farmis-Oncofarm\u00ae. Una vez validado \nel PNT por el farmac\u00e9utico/a, dichas preparaciones fueron elaboradas por enfermer\u00eda del Servicio de Farmacia (SF) en \nambiente est\u00e9ril y asistido por su t\u00e9cnico auxiliar. Antes de enviar la MIV a su destino, el coordinador/a de enfermer\u00eda de \nsala blanca realiza una \u201cdoble validaci\u00f3n\u201d, observando que el tipo/volumen y coloraci\u00f3n del suero sea correcto, purgado, \nausencia de part\u00edculas y adem\u00e1s, registra v\u00eda electr\u00f3nica el posible ahorro de vial.  \nSe elabor\u00f3 una base de datos en Excel\u00ae para la revisi\u00f3n manual de los PNT. Los \u00edtems analizados se dividieron en funci\u00f3n \nde la actividad que desempe\u00f1aba el personal:  \nT\u00e9cnico auxiliar de farmacia (TAF): su firma, n\u00famero de lote y caducidad de los componentes de la mezcla (si precisa \nacondicionamiento primario, sueroterapia y medicamento).  \nEnfermero/a elaborador/a: su firma, registro de posible ahorro de vial y anotaci\u00f3n de las posibles incidencias en la \nelaboraci\u00f3n\ufffd  \nCoordinador/a de enfermer\u00eda de la sala blanca: firma de \u201cdoble validaci\u00f3n\u201d.  \nFarmac\u00e9utico/a: firma tanto la validaci\u00f3n de la MIV como de las posibles correcciones.\nRESULTADOS\nEl 38.84% de las MIV fueron medicamentos peligrosos elaborados en cabina de flujo vertical (identific\u00e1ndose seg\u00fan el \ndocumento t\u00e9cnico del Instituto Nacional de Salud e Higiene en el Trabajo en: 12.16 % tipo 1, 12% tipo 2 y 13.6 % tipo 3). \nEl resto de mezclas se elaboraron en cabina de flujo laminar horizontal.  \nSe detect\u00f3 un total de 38.64 % errores, desglos\u00e1ndose en: 13.16% del TAF (12.5% sin firmar, 0.5% sin indicar caducidad \ndel f\u00e1rmaco y suero y 0.16% sin indicar n\u00famero de lote), el 12.16 % del enfermero/a elaborador (1.33% sin firmar y el \n10.83% donde no se registr\u00f3 ahorro de vial), el 12.16 % en coordinador/a de enfermer\u00eda de la sala blanca (todos ellos por \nfalta de firma de \u201cdoble validaci\u00f3n\u201d) y el 1.16% en farmac\u00e9utico/a (falta de firma rectificativa).\nCONCLUSIONES\nEste estudio ha puesto de manifiesto una gran carencia en la cumplimentaci\u00f3n de datos imprescindibles en los PNT \n(errores totales detectados 38.6%), adem\u00e1s de crear la necesidad de informatizaci\u00f3n en la sala blanca, que agilizar\u00eda este \nproceso\ufffd  \nGracias a este an\u00e1lisis, el \u00e1rea ha implantado una serie de medidas correctoras: \nReforzar la importancia del correcto registro de firmas en los PNT, puesto que refleja las responsabilidades que asume el \npersonal\ufffd  \nEstablecer un control de calidad retrospectivo de forma anual, bas\u00e1ndonos en el an\u00e1lisis previamente descrito.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n984. CREACI\u00d3N DE UNA AGENDA PARA LA ORGANIZACI\u00d3N DE LA ATENCI\u00d3N AL PACIENTE EXTERNO \nAUTORES\nDE\u00c1N BARAHONA, C; MART\u00cdNEZ RUIZ, E; CASARRUBIOS L\u00c1ZARO, GI; TARD\u00c1GUILA MOLINA, P; CODONAL DEMETRIO, \nA; CORRALES KRONHERT , S; BLANCO CRESPO, M; L\u00c1ZARO L\u00d3PEZ, A\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nObjetivos  \nEn los \u00faltimos a\u00f1os se ha incrementado la atenci\u00f3n al paciente a trav\u00e9s de las Tecnolog\u00edas de la Informaci\u00f3n y la \nComunicaci\u00f3n (TIC) en el \u00c1rea de Pacientes Externos, complementaria a la atenci\u00f3n presencial en las consultas de \nAtenci\u00f3n Farmac\u00e9utica (AF).  \n \nLos objetivos de este estudio fueron: \n- Implantar una agenda que facilitara la organizaci\u00f3n y el contacto de los pacientes con el Servicio de Farmacia (SF).  \n- Analizar los motivos por los que los pacientes contactaban con el SF y las intervenciones realizadas por el farmac\u00e9utico.\nMATERIALES Y M\u00c9TODOS\nSe contact\u00f3 con la coordinadora de Admisi\u00f3n, Archivos y Documentaci\u00f3n Cl\u00ednica para solicitar la creaci\u00f3n de una agenda \ndel SF exclusiva para AF telem\u00e1tica en la base de datos asistencial hospitalaria Mambrino XXI\u00ae.  \nUna vez creada, el auxiliar administrativo y/o los farmac\u00e9uticos del \u00e1rea registraban en esa agenda los contactos 282telem\u00e1ticos (llamadas, e-mail, whatsapp). Los farmac\u00e9uticos revisaban a diario dicha agenda garantizando el contacto con \nel paciente en un plazo de 24 horas.  \nSe realiz\u00f3 un estudio observacional retrospectivo analizando las intervenciones realizadas por el farmac\u00e9utico desde \njulio 2021 hasta octubre 2021. Las variables analizadas fueron: sexo y edad de los pacientes, n\u00famero y tipo de consultas, \nn\u00famero y tipo de intervenciones.\nRESULTADOS\nSe cre\u00f3 la agenda en junio 2021. Los pacientes que realizaron las consultas presentaban una mediana de edad de 57 a\u00f1os \n(RIC 41-75), 53% hombres. \nDurante el periodo de estudio se recibi\u00f3 una mediana de 12 consultas semanales (RIC 9-18). Se detect\u00f3 variabilidad en \nlas consultas recibidas en los meses analizados (45 consultas en julio, 17 en agosto, 76 en septiembre y 66 en octubre). El \n49% de las consultas fueron por problemas para recoger la medicaci\u00f3n, el 20% por necesidad de m\u00e1s medicaci\u00f3n, el 13% \npara consultar interacciones farmacol\u00f3gicas, el 6% por dudas en la administraci\u00f3n, el 5% por mala tolerancia al f\u00e1rmaco y \n7% otras consultas\ufffd  \nSe realizaron 208 intervenciones: seguimiento farmacoterap\u00e9utico y entrega informada de medicaci\u00f3n a domicilio (50%), \ncambio de cita programada (22%), revisi\u00f3n de interacciones farmacol\u00f3gicas (13%), monitorizaci\u00f3n de la tolerancia al \ntratamiento (6%), monitorizaci\u00f3n adherencia terap\u00e9utica (4%) y otras (5%).\nCONCLUSIONES\n- La creaci\u00f3n de esta agenda ha permitido crear un circuito para organizar la actividad asistencial telem\u00e1tica de las \nconsultas externas del Servicio de Farmacia y detectar/resolver problemas relacionados con la medicaci\u00f3n en el mismo \nd\u00eda. \n- La principal intervenci\u00f3n de consulta telem\u00e1tica en nuestra \u00e1rea es el seguimiento farmacoterap\u00e9utico con env\u00edo \nprogramado e informado de medicaci\u00f3n a domicilio\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1014. RESULTADOS DE ENCUESTA DE DIGITALIZACI\u00d3N EN LA UNIDAD DE PACIENTES EXTERNOS \nAUTORES\nMARTINEZ PUIG, P; NIEVAS BA\u00d1OS, AB; PEREA PEREZ, A; MANCILLA MONTERO, E; RUIZ LARA, LM\nHOSPITAL UNIVERSITARIO REINA SOFIA \ufffd AVENIDA MENENDEZ PIDAL S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA\nOBJETIVOS\nConocer el nivel de conocimiento en las tecnolog\u00edas de la informaci\u00f3n y c\u00f3mo las utilizan los usuarios que recogen \nmedicaci\u00f3n en la secci\u00f3n de pacientes externos\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio unic\u00e9ntrico, observacional, prospectivo. Se realiza una encuesta de forma aleatoria a usuarios (pacientes, \nfamiliares o cuidadores) que retiran medicaci\u00f3n en la unidad de Pacientes Externos en un hospital de tercer nivel de \nAndaluc\u00eda entre Septiembre-Octubre de 2021.  \nLa encuesta estaba constituida por 18 preguntas: una abierta (edad) y diecisiete cerradas, de las cuales una era \ndicot\u00f3mica; cuatro nominales; dos con opci\u00f3n m\u00faltiple y once escalas de Likert (Mucho-5-En absoluto-1).\nRESULTADOS\nSe realizaron 315 encuestas. El 51,8% fueron hombres (edad media 51 a\u00f1os). El usuario que cumpliment\u00f3 la encuesta \nfue principalmente el propio paciente (66,1%), seguido de familiares (31,9% ), y s\u00f3lo 2% cuidadores. En cuanto al nivel de \nestudios, la mayor\u00eda ten\u00eda estudios secundarios (42,1%), estudios superiores (28%), estudios primarios (24,8%) y el 5,1% \nno ten\u00edan estudios.  \nRespecto al uso de tecnolog\u00edas, encontramos que el 90,8% ten\u00edan tel\u00e9fono m\u00f3vil con acceso a internet, mientras que \ns\u00f3lo un 3,8% no ten\u00edan ning\u00fan tipo de recurso electr\u00f3nico. El 74,5% asegur\u00f3 utilizar habitualmente internet. En cuanto a \nlas herramientas digitales, la m\u00e1s utilizadas fue Whatsapp\u00ae (89,5%), seguido del correo electr\u00f3nico(81,6%), tambi\u00e9n las \naplicaciones de la Junta de Andaluc\u00eda: Salud Responde\u00ae (74%) seguida de ClicSalud+\u00ae (38,5%).  \nEntre los resultados de las escalas utilizadas para medir el grado de manejo de los usuarios: a la pregunta sobre si sab\u00edan \nc\u00f3mo encontrar fuentes de informaci\u00f3n sobre salud en internet hubo un 66,4% de los encuestados que respondieron \nmucho-bastante. Un 58% aseguraban saber c\u00f3mo utilizar la informaci\u00f3n que encontraban en internet (mucho-bastante). \nA su vez, un 58,8% afirm\u00f3 no estar seguro/no saber distinguir entre recursos de alta o baja calidad. El 62,5% no se \nencontraban seguros utilizando informaci\u00f3n de internet. \nEl 50,6% de los encuestados afirm\u00f3 preferir la atenci\u00f3n presencial y el 43,5% que le gustar\u00eda combinar la presencialidad \ncon la atenci\u00f3n telem\u00e1tica. La modalidad presencial es especialmente demandada entre mayores de 65 a\u00f1os (67%) y con \nmenos estudios (60% primarios-72% sin estudios).  \nEl 62,1% de los usuarios encontr\u00f3 muy \u00fatil que el Servicio de Farmacia realizara una aplicaci\u00f3n m\u00f3vil, especialmente \naquellos usuarios comprendidos en el grupo de edad entre 18-35 a\u00f1os. El 71% afirm\u00f3 que le gustar\u00eda que nos \ncomunic\u00e1ramos adicionalmente con ellos a trav\u00e9s de ella u otro medio digital. Les pareci\u00f3 \u00fatil que comparti\u00e9ramos \ninformaci\u00f3n de adherencia al tratamiento(57,8%), sobre resultados (65,8%) y sobre efectos adversos(71,4%) .\nCONCLUSIONES\nPodemos concluir que nuestra poblaci\u00f3n cuenta con usuarios que utilizan habitualmente los medios tecnol\u00f3gicos a su \nalcance. Que en su mayor\u00eda los utilizan para obtener informaci\u00f3n sobre salud, pero no se sienten del todo seguros con 283la calidad de esta informaci\u00f3n y est\u00e1n a favor de que el servicio de Farmacia les gu\u00ede en este aspecto, a trav\u00e9s de una \naplicaci\u00f3n digital\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1210. REFORMULANDO EL CIRCUITO TERAP\u00c9UTICO DE TOXINA BOTUL\u00cdNICA \nAUTORES\nGARCIA MARTINEZ, T; GRAS COLOMER, E; CEBRIAN ESCRIBANO, M; HERNANDEZ CARABAL, L; IGNAT , MA; CAJA \nCALVO, M; BELLVER MARTINEZ, M; PRATS ORTEGA, R\nHOSPITAL DE MANISES \ufffd AVDA \ufffd GENERALITAT VALENCIANA, 50 MANISES \ufffd VALENCIA\nOBJETIVOS\nImplantaci\u00f3n de un circuito de prescripci\u00f3n, validaci\u00f3n farmac\u00e9utica y dispensaci\u00f3n de toxina botul\u00ednica tipo A (TBA) \nmediante prescripci\u00f3n electr\u00f3nica asistida (PEA), adaptado a las indicaciones terap\u00e9uticas con el fin de facilitar la \nprescripci\u00f3n y dispensaci\u00f3n, as\u00ed como conseguir la trazabilidad total.\nMATERIALES Y M\u00c9TODOS\nEl proyecto se compuso de 2 fases: la primera fase consisti\u00f3 un an\u00e1lisis retrospectivo de los pacientes adultos \ncon prescripciones de TBA desde 1/1/2022 y el 30/4/2022\ufffd Se excluyeron todas las prescripciones del servicio de \nRehabilitaci\u00f3n, ya que se dispensan y administran en otro centro. Las variables recogidas de la historia cl\u00ednica fueron: \nedad, sexo, servicio prescriptor, indicaci\u00f3n, dosis y pauta de administraci\u00f3n. La segunda fase fue la constituci\u00f3n de un \ngrupo de trabajo multidisciplinar ( farmac\u00e9utico y m\u00e9dicos prescriptores) para: \n1) analizar el circuito vigente de prescripci\u00f3n: anotaci\u00f3n en historia cl\u00ednica y solicitud al Servicio de Farmacia mediante \nemail con la identificaci\u00f3n de paciente y unidades de TBA necesaria  \n2) dise\u00f1ar el nuevo circuito terap\u00e9utico completo, teniendo en cuenta la informaci\u00f3n recabada en la fase 1.\nRESULTADOS\nEn la fase 1 se incluyeron 186 pacientes, edad media 58 a\u00f1os (17 a 92), 81% mujeres. Los servicios prescriptores \nmayoritarios fueron Neurolog\u00eda 124 pacientes (66,7%) y Unidad del Dolor 42 pacientes (22,6%); el 10,7% restante \ncorrespondieron a 20 pacientes de otros servicios: Cirug\u00eda 5, Dermatolog\u00eda 6, Oftalmolog\u00eda 3, Otorrinolaringolog\u00eda 2 \ny Urolog\u00eda 4. Las indicaciones se ajustan a las autorizadas en ficha t\u00e9cnica en 123 pacientes (66%): blefaroespasmo 9, \ndiston\u00eda cervical 5, espasmo hemifacial 25, hiperhidrosis axilar 4, migra\u00f1a cr\u00f3nica 73 y vejiga hiperactiva 7; en todos los \ncasos se prescribi\u00f3 la posolog\u00eda autorizada en ficha t\u00e9cnica, con la excepci\u00f3n de diston\u00eda cervical donde las dosis fueron \nmayores en el 80% de los pacientes. Las indicaciones distintas de ficha t\u00e9cnica, utilizadas en 63 pacientes, fueron: diston\u00eda \n2, dolor miofascial 45, entropi\u00f3n 3, fisura anal 5, hiperhidrosis en manos 2, paraparesia 1, sialorrea 2 y temblor 3.  \nEn la fase 2, el circuito vigente de prescripci\u00f3n se redise\u00f1\u00f3 de forma que en la PEA se cre\u00f3 una solicitud medicamento \nasociado a un diagn\u00f3stico de los identificados en la fase 1, con las dosis recomendadas en cada indicaci\u00f3n. Para las \nindicaciones fuera de ficha t\u00e9cnica, se a\u00f1adi\u00f3, adem\u00e1s, la necesidad de incluir en la Historia Cl\u00ednica el consentimiento \ninformado por escrito. As\u00ed, queda registrada la dispensaci\u00f3n en la petici\u00f3n de la PEA desde el Servicio de Farmacia.\nCONCLUSIONES\nEn los \u00faltimos a\u00f1os se ha incrementado la utilizaci\u00f3n de TBA, tanto en indicaciones autorizadas como en situaciones \nespeciales, lo que ha dejado el circuito anterior ineficiente. Con este nuevo sistema, toda la informaci\u00f3n cl\u00ednica necesaria \nqueda asociada al paciente en la PEA, cubriendo las obligaciones legales referentes a prescripci\u00f3n, prescripci\u00f3n m\u00e9dica, \nvalidaci\u00f3n farmac\u00e9utica y dispensaci\u00f3n, tambi\u00e9n permite la explotaci\u00f3n de esta informaci\u00f3n mediante indicadores de \nactividad, as\u00ed como agilizar el proceso farmacoterap\u00e9utico y reducir la carga burocr\u00e1tica asociada al mismo.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1249. AN\u00c1LISIS MODAL DE FALLOS Y EFECTOS DE LA PREPARACI\u00d3N DE ANTINEOPL\u00c1SICOS MANUAL \nASISTIDA CON CONTROL GRAVIM\u00c9TRICO FRENTE A LA ROBOTIZADA \nAUTORES\nMART\u00cdNEZ ALBALADEJO, P; RICOY SANZ, I; S\u00c1NCHEZ GONZ\u00c1LEZ, JL; SAEZ BELL\u00d3, M; SENDRA GARC\u00cdA, A; AVENDA\u00d1O \nSERRANO, C; P\u00c9REZ LABA\u00d1A, F; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nDescribir y comparar dos sistemas de elaboraci\u00f3n de antineopl\u00e1sticos (preparaci\u00f3n manual asistida con control \ngravim\u00e9trico versus preparaci\u00f3n robotizada) mediante un An\u00e1lisis Modal de Fallos y Efectos (AMFE).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de tres meses de duraci\u00f3n realizado en un hospital terciario con un volumen anual de \npreparaciones de quimioterapia antineopl\u00e1sica de 38.133 (2021). \nSe compar\u00f3 el sistema de preparaci\u00f3n de quimioterapia manual asistido con control gravim\u00e9trico (elaboraci\u00f3n por \npersonal de enfermer\u00eda apoyado por un sistema electr\u00f3nico de soporte en la preparaci\u00f3n -m\u00f3dulo ePASE\u00ae, IMF S.L- que \npermite un control cualitativo y cuantitativo) frente a un sistema robotizado (elaboraci\u00f3n con robot -Kiro Oncology\u00ae, \nGrifols S.L). Se identificaron 3 sub-procesos diferentes para ambos m\u00e9todos: acondicionamiento, elaboraci\u00f3n y validaci\u00f3n \nt\u00e9cnica de la mezcla preparada.  284Para comparar ambos procesos se emple\u00f3 la metodolog\u00eda AMFE consistente en: a) creaci\u00f3n de un equipo de trabajo \nformado por profesionales relacionados con la preparaci\u00f3n de antineopl\u00e1sicos (tres farmac\u00e9uticos y dos enfermeros del \nServicio de Farmacia Hospitalaria); b) definici\u00f3n detallada de las fases de ambos procesos; c) identificaci\u00f3n de los modos \nde fallo (MF); d) c\u00e1lculo del N\u00famero de Prioridad de Riesgo (NPR), NPR=incidencia (1-5) x evitabilidad (1-5) x gravedad (1-\n5); e) obtenci\u00f3n de la mediana y el rango intercuart\u00edlico [RIQ] de los valores aportados por cada integrante del grupo.  \nSe calcul\u00f3 el porcentaje de reducci\u00f3n de MF y del NPR global y por sub-procesos. Las medianas de los NPR se compararon \nestad\u00edsticamente mediante la U de Mann-Whitney, analizando si exist\u00edan diferencias estad\u00edsticas (p < 0,05), con el \nprograma estad\u00edstico R-v4.2.0.\nRESULTADOS\nEn total, se identificaron 11 MF para el sistema manual y 12 MF para el robotizado, cuyos valores de NPR global fueron \n247[201-288] y 164[162-175] respectivamente. El proceso robotizado mostr\u00f3 un incremento global de MF de un 9,1% y \nuna reducci\u00f3n del NPR global del 33,6% (p=0,04). En el proceso manual, el MF con mayor NPR fue \u201comisi\u00f3n del control \ncuali-cuantitativo\u201d (NPR 40[20-45]) y en el proceso robotizado el \u201cerror en el etiquetado final\u201d (NPR 30[16-32]).  \n \nEn el an\u00e1lisis por subprocesos, los valores del NPR se redujeron en el sistema robotizado versus manual en un 71,1% en \nel acondicionamiento (NPR 51[40-53] y 24[22-32], p=0,01), un 29,7% en la elaboraci\u00f3n (NPR 118[91-120] y 83[80-95], \np=0,15), y un 7,7% en la validaci\u00f3n t\u00e9cnica del producto final preparado (NPR 78[76-107] y 72[60-73], p=0,09).\nCONCLUSIONES\nLa preparaci\u00f3n robotizada reduce, de manera estad\u00edsticamente significativa, el riesgo global de errores en el proceso de \npreparaci\u00f3n de quimioterapia antineopl\u00e1sica comparado con la preparaci\u00f3n manual asistida con control gravim\u00e9trico. El \nriesgo de error se reduce en todos los sub-procesos (acondicionamiento, elaboraci\u00f3n y validaci\u00f3n t\u00e9cnica final), pero s\u00f3lo \nde forma estad\u00edsticamente significativa en el sub-proceso de acondicionamiento. En consecuencia, el sistema robotizado \naporta una mejora en la seguridad de la preparaci\u00f3n de quimioterapia antineopl\u00e1sica.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1283. ATENCI\u00d3N FARMAC\u00c9UTICA AL PACIENTE AMBULATORIO MEDIANTE CONSULTAS TELEF\u00d3NICAS Y \nDISPENSACI\u00d3N DE LA MEDICACI\u00d3N A DOMICILIO. \u00bfQU\u00c9 OPINAN LOS PACIENTES? \nAUTORES\nVALDAZO MART\u00cdN, C; GUISASOLA RON, L; M\u00cdNGUEZ CABEZA, AC; ROSADO ANC\u00cdN, M; SANTAOLALLA S\u00c1NCHEZ, A; \nARENALES C\u00c1CERES, P; RISUE\u00d1O G\u00d3MEZ, B; MARTINEZ MARTINEZ, C\nHOSPITAL UNIVERSITARIO ARABA (SEDE TXAGORRITXU Y SEDE SANTIAGO). CALLE JOSE ACHOTEGUI, CALLE/KALEA \nS/N VITORIA-GASTEIZ. \u00c1LAVA\nOBJETIVOS\nEl objetivo de este trabajo es realizar una consulta an\u00f3nima a los pacientes ambulatorios atendidos por el Servicio de \nFarmacia de un hospital terciario sobre un nuevo circuito de atenci\u00f3n farmac\u00e9utica mediante consultas telef\u00f3nicas y \ndispensaci\u00f3n de la medicaci\u00f3n en el domicilio del paciente, para conocer su opini\u00f3n respecto al mismo e identificar \npuntos de mejora.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, realizado en septiembre de 2021, que incluy\u00f3 a todos los pacientes vivos que hab\u00edan sido \natendidos mediante el nuevo circuito\ufffd  \n \nSe desarroll\u00f3 una encuesta compuesta por un total de 17 preguntas; 5 con respuesta abierta y 12 cerrada\ufffd La encuesta \nredactada en castellano y en euskera, se envi\u00f3 a trav\u00e9s de correo postal al domicilio de los pacientes y se facilit\u00f3 un sobre \ncon franqueo concertado para la devoluci\u00f3n de las encuestas contestadas.\nRESULTADOS\nLa encuesta fue enviada a 180 pacientes, de los cuales contestaron 110 (61%). Respecto al total de respuestas destacan \nlos siguientes datos: \n \nEl 65,4% de los pacientes viv\u00edan en la ciudad y el 25,4% a una distancia mayor a 30 km.  \n \nRespecto al circuido de dispensaci\u00f3n el 97,0% consideraron que el respeto de la intimidad y trato de sus datos personales \nera bueno o muy bueno. El 90,0% consideraba que los horarios y tiempos de espera eran buenos o muy buenos. El \n94,0% consideraba que el procedimiento de env\u00edo y entrega de la medicaci\u00f3n en su domicilio como bueno o muy bueno. \nRespecto al proceso de entrega de la medicaci\u00f3n, se indicaron un total de 6 incidentes. Como aspectos a mejorar, los \npacientes sugirieron la dispensaci\u00f3n de la medicaci\u00f3n en horario de tarde, solicitar un documento identificativo del \npaciente al entregar la medicaci\u00f3n en el domicilio, concretar la hora exacta de entrega de la medicaci\u00f3n, una mejor \ngesti\u00f3n de la medicaci\u00f3n de nevera y la recogida de los contenedores de jeringuillas.  \n \nRespecto a la atenci\u00f3n farmac\u00e9utica, los pacientes indicaron que es igual (53,6%) o mejor (39,0%) que la presencial. El \n90,0% indic\u00f3 que la confianza en el consejo farmac\u00e9utico es buena o muy buena. El 97,2% consider\u00f3 que la disponibilidad \npara la escucha es buena o muy buena y que el respeto en el trato es bueno o muy bueno. Los pacientes no indicaron \nning\u00fan aspecto a mejorar directamente relacionado con la atenci\u00f3n farmac\u00e9utica.  285Como principales ventajas del nuevo circuito, los pacientes refirieron una mayor comodidad, evitar desplazamientos, \nevitar olvidos, evitar esperas, rapidez y eficacia, ahorrar tiempo y dinero en transporte y evitar riesgos de contagios. \nComo principales inconvenientes referidos figuraron el tiempo de espera al repartidor, no conocer el horario exacto de \nentrega, que no se entregue la medicaci\u00f3n por la tarde y la falta de atenci\u00f3n personal cara a cara con el farmac\u00e9utico.  \n \nLa satisfacci\u00f3n global con el servicio fue considerada por un 41,8% como buena y por un 53,6% como muy buena.\nCONCLUSIONES\nLa realizaci\u00f3n de la consulta ha permitido conocer la opini\u00f3n de los pacientes respecto al nuevo circuito establecido e \nidentificar puntos de mejora. La satisfacci\u00f3n de los pacientes con el nuevo circuito es elevado.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y \nFARMACOGEN\u00c9TICA\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n116. FRECUENCIA Y RELEVANCIA CL\u00cdNICA DE LAS VARIANTES DEL GEN DPYD EN PACIENTES CON \nTUMORES S\u00d3LIDOS \nAUTORES\nG\u00d3MEZ ZAMORA, M; DO PAZO OUBI\u00d1A, F\nHOSPITAL UNIVERSITARI SON ESPASES \ufffd CARRETERA VALLDEMOSSA 79 PALMA DE MALLORCA \ufffd ILLES BALEARS\nOBJETIVOS\nLas fluoropirimidinas son medicamentos contra el c\u00e1ncer que incluyen fluorouracilo (FU),capecitabina y tegafur.  \n \nA pesar de ser generalmente bien tolerados, aproximadamente un tercio de los pacientes presentan toxicidad grado 3-4.  \n \nEstudios previos han demostrado que los pacientes con deficiencia de la enzima dihidropirimidina deshidrogenasa (DPD) \ntienen mayor riesgo de desarrollar reacciones adversas graves como diarrea, mucositis o neutropenia.  \n \nEn caso de deficiencia en la actividad de DPD, se recomienda una reducci\u00f3n del 25-50% en la dosis inicial.  \n \nDesde septiembre de 2020, en nuestro centro se determinan cuatro variantes del gen DPYD para los pacientes candidatos \na ser tratados con fluoropirimidinas.  \n \nNuestro objetivo fue determinar la prevalencia de las variantes de p\u00e9rdida de funci\u00f3n en el gen DPYD en nuestra \npoblaci\u00f3n de referencia, as\u00ed como evaluar los resultados cl\u00ednicos de su implementaci\u00f3n en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional, retrospectivo y unic\u00e9ntrico. Se incluyeron los pacientes \u2265\u202f18 a\u00f1os diagnosticados \nde cualquier tipo de tumor a los que se hab\u00eda efectuado el genotipado del gen DPYD desde la implementaci\u00f3n de esta \ndeterminaci\u00f3n (septiembre de 2020) hasta enero de 2022. Los datos cl\u00ednicos se extrajeron de la historia cl\u00ednica. Las \nvariables recogidas fueron: sexo, edad, diagn\u00f3stico, si hab\u00edan iniciado o no el tratamiento antes de saber el resultado del \ngenotipado, reducci\u00f3n de dosis una vez conocido el resultado y grado de toxicidad en cualquiera de los ciclos.  \n \nSe genotiparon las variantes rs3918290 (c.1905+1G > A), rs55886062 (c.1679T > G), rs67376798 (c.2846A > T) y \nrs56038477 (c.1236G > A/HapB3)\nRESULTADOS\nSe incluyeron 188 pacientes. No se detectaron portadores en homocigosis, y la frecuencia de portadores en heterocigosis \nfue del 6,4% (12 pacientes). La variante m\u00e1s frecuente fue el rs56038477 (7 pacientes). La segunda variante fue el \nrs67376798 (3 pacientes), seguida del rs3918290 (2 pacientes). Ning\u00fan paciente present\u00f3 la variante rs55886062.  \n \nLa media de edad fue de 66 a\u00f1os, 7 pacientes eran hombres y el diagn\u00f3stico m\u00e1s com\u00fan fue c\u00e1ncer de colon (7 \npacientes).  \n \nDe los 12 pacientes, 5 iniciaron tratamiento sin reducci\u00f3n de dosis antes de tener el resultado del genotipo. Dos de ellos \ningresaron por toxicidad con mucositis grado III y plaquetopenia grado IV, y neutropenia grado IV, respectivamente. Los \notros tres presentaron toxicidades de grado I a III que no causaron ingreso.  \n \nOtros 5 pacientes empezaron con una reducci\u00f3n al 50%, y s\u00f3lo uno present\u00f3 toxicidad cut\u00e1nea grado III. De los otros \ncuatro, dos no tuvieron toxicidad y en los otros dos fue leve\ufffd  \n \nDos pacientes no llegaron a iniciar tratamiento\ufffd286CONCLUSIONES\nUn 6,4% de los pacientes en los que se realiz\u00f3 el genotipado de DPYD fueron portadores en heterocigosis.  \n \nLa frecuencia encontrada es similar a la de estudios previos, en los que se describe entre un 3 y 8% de portadores de \nalguna de estas variantes\ufffd  \n \nLos pacientes portadores presentaron una tendencia a mayor toxicidad en caso de iniciar tratamiento sin reducci\u00f3n de \ndosis\ufffd  \n \nEs necesario trabajar en colaboraci\u00f3n con genetistas, farmac\u00e9uticos hospitalarios y onc\u00f3logos.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n138. DESARROLLO DE UN MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE LITIO \nAUTORES\nDOM\u00cdNGUEZ GARC\u00cdA, A; SALCEDO MINGORRANZ, \u00c1L; OROZCO CIFUENTES, I; RODRIGO LAMB\u00c1N, DJ; JIM\u00c9NEZ \nMESEGUER, M; NOVO GONZ\u00c1LEZ, P; GARC\u00cdA MART\u00cdNEZ, S; GARC\u00cdA D\u00cdAZ, B\nHOSPITAL SEVERO OCHOA \ufffd AV\ufffd DE ORELLANA, S/N LEGAN\u00c9S \ufffd MADRID\nOBJETIVOS\n- Desarrollo de un modelo farmacocin\u00e9tico poblacional de litio  \n- Evaluar la influencia de las covariables recogidas en nuestro modelo poblacional: edad, sexo, peso y creatinina s\u00e9rica\nMATERIALES Y M\u00c9TODOS\nSe incluyeron 93 pacientes hospitalizados en un hospital de segundo nivel en tratamiento con litio y al menos una \nconcentraci\u00f3n de este medicamento entre 2018 y 2021. A partir de la historia cl\u00ednica y la prescripci\u00f3n electr\u00f3nicas \nse obtuvieron los valores del estudio: dosis y concentraci\u00f3n plasm\u00e1tica de litio, peso, sexo, creatinina y edad de los \npacientes\ufffd \nLos datos recogidos se analizaron mediante un programa de farmacocin\u00e9tica poblacional.  \nSe seleccion\u00f3 un modelo farmacocin\u00e9tico monocompartimental y se evaluaron con cuatro tipos de estimaci\u00f3n: primer \norden (FO), primer orden con interacci\u00f3n (FO+I), condicional de primer orden (FOCE) y condicional de primer orden con \ninteracci\u00f3n (FOCE+I).  \nPara decidir el modelo que mejor se ajustaba en nuestra poblaci\u00f3n se consider\u00f3 un descenso estad\u00edsticamente \nsignificativo del valor de la funci\u00f3n objetivo (OFV), el criterio de informaci\u00f3n de Akaike (AIC) y el criterio de informaci\u00f3n \nbayesiano (BIC).  \nPosteriormente se modificaron las estimas iniciales de los par\u00e1metros farmacocin\u00e9ticos poblacionales para centrar sus \nvalores y reducir el error relativo est\u00e1ndar: aclaramiento (Cl), volumen de distribuci\u00f3n (Vd) y constante de absorci\u00f3n (Ka). \nUna vez establecido el modelo b\u00e1sico, se analiz\u00f3 la influencia de las covariables recogidas (edad, sexo, peso y creatinina \ns\u00e9rica) para estimar el modelo poblacional definitivo.\nRESULTADOS\nLa poblaci\u00f3n estaba constituida por 43 (46,2%) hombres y 50 (53,8%) mujeres. La media de edad fue 47 a\u00f1os (19-82), el \npeso medio 75,2 Kg (46,4-133) y la creatinina s\u00e9rica media 0,94 mg/dL (0,47-2,64).  \nLas estimaciones FO y FO+I aportaron un OFV -157, AIC -143 y BIC -118. Con la estimaci\u00f3n FOCE se redujeron los 3 \npar\u00e1metros: OFV -248, AIC -234 y BIC -209, mientras que la estimaci\u00f3n FOCE+I disminuy\u00f3 a\u00fan m\u00e1s el OFV, AIC y BIC (-316, \n-302 y -277 respectivamente), por lo que fue el modelo b\u00e1sico seleccionado.  \nLos par\u00e1metros farmacocin\u00e9ticos de nuestro modelo poblacional b\u00e1sico y sus correspondientes datos de variabilidad \nfueron: \nCl = 1,23 L/h (4%), Vd = 35,4 L (26%), Ka = 0,293 1/h (fijada).  \nSe aplic\u00f3 una variabilidad interindividual exponencial en el Cl y el Vd, cuyos valores fueron 40,9% y 43,4% \nrespectivamente. La variabilidad residual fue 29,2%  \nSe analiz\u00f3 la influencia de las covariables edad, sexo, peso y creatinina s\u00e9rica, observando que ninguna de ellas influy\u00f3 de \nforma estad\u00edsticamente significativa en el OFV, AIC y BIC.\nCONCLUSIONES\n- El modelo monocompartimental con estimaci\u00f3n condicional de primer orden con interacci\u00f3n fue el que mejor se ajust\u00f3 \nen nuestra poblaci\u00f3n  \n- Aunque el modelo farmacocin\u00e9tico poblacional definitivo no incluy\u00f3 ninguna covariable, el sexo y el peso fueron las \ncaracter\u00edsticas con mayor influencia en nuestro modelo\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n181. DISE\u00d1O DE UN MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE VANCOMICINA EN PACIENTES \nOBESOS \nAUTORES\nMORONA M\u00cdNGUEZ, I; SALCEDO MINGOARRANZ, AL; SERNA ROMERO, O; GRANADA ECHEVERRIA, I; DEL CAMPO \nFIOCHI, O; MORIEL S\u00c1NCHEZ, C; CRUZ CRUZ, MT; GARC\u00cdA D\u00cdAZ, B\nHOSPITAL SEVERO OCHOA \ufffd AV\ufffd DE ORELLANA, S/N LEGAN\u00c9S \ufffd MADRID287OBJETIVOS\nDise\u00f1ar un modelo farmacocin\u00e9tico poblacional de vancomicina en pacientes obesos.  \nAnalizar la influencia de las covariables recogidas en nuestro modelo farmacocin\u00e9tico.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en el que se incluyeron 166 pacientes obesos (\u00edndice de masa corporal igual o superior a 30) en \ndos hospitales de segundo nivel entre 2010-2022. Todos los pacientes recibieron vancomicina intravenosa y ten\u00edan como \nm\u00ednimo una determinaci\u00f3n de concentraci\u00f3n plasm\u00e1tica. \nLas variables recogidas de la historia cl\u00ednica y la prescripci\u00f3n electr\u00f3nicas fueron: peso, talla, edad, sexo, pauta posol\u00f3gica \ny nivel de vancomicina, creatinina s\u00e9rica, albuminemia y tratamiento concomitante con antiinflamatorios no esteroideos \n(AINE), cefalosporinas, furosemida y penicilinas.  \nA partir de los datos recogidos se calcul\u00f3 el \u00edndice de masa corporal (IMC), la superficie corporal, el peso magro, ideal \ny ajustado y el aclaramiento de creatinina mediante las f\u00f3rmulas de Cockroft-Gault, CKD-EPI y Modified Diet Renal \nDisease-4 (MDRD4).  \nLos datos se analizaron mediante un programa farmacocin\u00e9tico para obtener los par\u00e1metros poblacionales aclaramiento \n(Cl) y volumen de distribuci\u00f3n (Vd).  \nSe analiz\u00f3 un modelo monocompartimental y cuatro tipos de estimaci\u00f3n: primer orden (FO), primer orden con \ninteracci\u00f3n (FO+I), condicional de primer orden (FOCE) y condicional de primer orden con interacci\u00f3n (FOCE+I). El modelo \nb\u00e1sico poblacional se seleccion\u00f3 teniendo en cuenta un descenso estad\u00edsticamente significativo en el valor de la funci\u00f3n \nobjetivo (OFV), el criterio de informaci\u00f3n de Akaike (AIC) y el criterio de informaci\u00f3n bayesiana (BIC).  \nUna vez establecido el modelo b\u00e1sico, se analiz\u00f3 la potencial influencia de las siguientes covariables: aclaramiento \ncalculado mediante Cockroft-Gault, CKD-EPI y MDRD4, creatinina s\u00e9rica, peso, IMC, peso ideal, edad, sexo, albuminemia y \ntratamiento concomitante con AINE, cefalosporinas, furosemida y penicilinas\ufffd\nRESULTADOS\nSe analizaron 166 pacientes (50% hombres) con 508 niveles, edad media 69 a\u00f1os (29-96), peso medio 89,9 Kg (62-155,8) \ne IMC medio 33,43 (30,1-59,4).  \nEl modelo farmacocin\u00e9tico poblacional que present\u00f3 un mejor ajuste fue el monocompartimental con estimaci\u00f3n \ncondicional de primer orden con interacci\u00f3n: OFV = 2525, AIC = 2535 y BIC = 2556. Se obtuvo un Cl poblacional de 3,61 \nL/h y un Vd de 148 L.  \nTras ensayar un modelo de error mixto (aditivo y proporcional) se observ\u00f3 que \u00fanicamente el error proporcional (24,1%) \ninfluy\u00f3 en la dispersi\u00f3n de los datos.  \nNinguna covariable tuvo influencia estad\u00edsticamente significativa en el Cl o en el Vd. Sin embargo, la influencia en el Vd \ndel aclaramiento calculado con MDRD4 mejor\u00f3 levemente el ajuste del modelo (dOFV = -9,2).\nCONCLUSIONES\nEl modelo monocompartimental con estimaci\u00f3n condicional de primer orden con interacci\u00f3n y error proporcional fue el \nque mejor se ajust\u00f3 en nuestros pacientes. \nA pesar de que ninguna covariable influy\u00f3 en el modelo de forma estad\u00edsticamente significativa, el aclaramiento de \ncreatinina calculado con MDRD4 mostr\u00f3 una tendencia en la bondad de ajuste.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n232. ASOCIACI\u00d3N ENTRE LA EFECTIVIDAD CL\u00cdNICA Y MICROBIOL\u00d3GICA DEL TRATAMIENTO CON \nVANCOMICINA Y LAS CONCENTRACIONES PLASM\u00c1TICAS EN PACIENTES NEONATOS \nAUTORES\nALONSO MORENO, M; MEJ\u00cdAS TRUEBA, M; CIUDAD GUTI\u00c9RREZ, P; HERRERA HIDALGO, L; GUTI\u00c9RREZ VALENCIA, A; \nGUISADO GIL, AB; GIL NAVARRO, MV\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nEl objetivo fue analizar las concentraciones m\u00ednimas s\u00e9ricas de vancomicina (Cmin) que lograron la efectividad cl\u00ednica y \nmicrobiol\u00f3gica en pacientes neonatos ingresados en la unidad de cuidados intensivos\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo y unic\u00e9ntrico, efectuado desde 2019 al 2021, donde se incluyeron pacientes neonatos \ny lactantes ( < 3 meses) en tratamiento con vancomicina intravenosa durante \u226572 horas de forma emp\u00edrica o dirigida con \n\u22651 Cmin documentada.  \n \nSe recogieron variables demogr\u00e1ficas (sexo, peso, edad), cl\u00ednicas y microbiol\u00f3gicas (enfermedad de base, tipo de \ninfecci\u00f3n, modalidad de tratamiento, pat\u00f3geno). La efectividad cl\u00ednica se evalu\u00f3 como la mejor\u00eda de los signos y \ns\u00edntomas de infecci\u00f3n, reducci\u00f3n de la fiebre, buen estado general y/o reducci\u00f3n franca de la prote\u00edna C reactiva; y la \nmicrobiol\u00f3gica, como la negativizaci\u00f3n de cultivos a las 48-72 horas del inicio y tras finalizar el tratamiento antibi\u00f3tico. Se \nmidieron las Cmin de vancomicina a las 48-72 h del inicio del tratamiento.  \nLos pacientes se clasificaron en dos grupos (favorable o desfavorable), seg\u00fan la evoluci\u00f3n cl\u00ednica inicial.  \n \nSe realiz\u00f3 una regresi\u00f3n log\u00edstica para predecir los factores asociados a la evoluci\u00f3n cl\u00ednica de los pacientes. Los an\u00e1lisis se \nrealizaron con el software estad\u00edstico R e IBM SPSS versi\u00f3n 28.288RESULTADOS\nUn total de 43 pacientes fueron incluidos en el estudio. 19 (44,2%) eran mujeres y 24 (55,8%) varones, con una mediana \nde peso de 1,94 (1,25-2,90) kg.  \n \nLa mediana de la edad gestacional, edad postnatal y edad postmenstrual fueron 30 (28-35) semanas, 14 (9-34) d\u00edas y 34 \n(30-39) semanas, respectivamente. \n \nEn cuanto a la enfermedad de base: 69,8 % eran prematuros con complicaciones, 14% con atresia o malformaci\u00f3n \nintestinal, 14% con atresia pulmonar, 4,7% con gastrosquisis, 2,3% bronquiolitis y 4,7% otras causas.  \n \nEl tratamiento con vancomicina se indic\u00f3 por: sepsis nosocomial (67,4%), bacteriemia nosocomial (9,3%), tromboflebitis \ns\u00e9ptica (4,7%), empeoramiento cl\u00ednico (4,7% ) y otros (14%).  \n \nEn cuanto a la modalidad de tratamiento el 90,7% fue dirigido, frente a un 9,3% emp\u00edrico. Los microorganismos \naislados fueron: S. epidermidis (71,8%), S. haemolyticus (12,8%), S. mitis (5,1%), S. hominis (5,1%), E. faecium (2,6%), S. \nepidermidis y S. hominis (2,6%).  \n \nLa evoluci\u00f3n cl\u00ednica inicial de los pacientes fue favorable en el 58,1% y desfavorable en el 41,9%. De estos \u00faltimos, \nfinalmente 13 se curaron, pero 5 pacientes siguieron presentando un curso desfavorable.  \n \nAunque la dosis inicial de vancomicina fue superior en el grupo favorable, esta diferencia no fue estad\u00edsticamente \nsignificativa [30 (20-33,45) mg/kg/d\u00eda vs. 21 (20-31,50) mg/kg/d\u00eda]. S\u00ed se apreciaron diferencias estad\u00edsticamente \nsignificativas en las Cmin de vancomicina entre el grupo favorable y desfavorable; 9,90 (RIQ: 7,30-13,40) \u00b5g/mL vs. \n6,15 (RIQ: 4,5-8,85) \u00b5g/mL (p=0,002), respectivamente. Este par\u00e1metro fue un buen predictor de la evoluci\u00f3n cl\u00ednica, \ndonde niveles \u22646,8 \u00b5g/mL se relacionaron con evoluci\u00f3n temprana desfavorable (p=0,001), causando 18,07 veces m\u00e1s \nprobabilidad de mala evoluci\u00f3n frente a aquellos que presentaban niveles superiores.\nCONCLUSIONES\nCmin de vancomicina > 6,8 \u00b5g/mL a las 48 horas del inicio del antibi\u00f3tico, parecen ser suficientes para lograr efectividad \ncl\u00ednica y microbiol\u00f3gica en neonatos.Es necesario futuros estudios con un tama\u00f1o muestral superior para poder afianzar \nlos resultados obtenidos\ufffd\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n379. AN\u00c1LISIS DEL GENOTIPADO DE POLIMORFISMOS DEL GEN DE LA DIHIDROPIRIMIDINA \nDESHIDROGENASA (DPD) ANTES DE LA ADMINISTRACI\u00d3N DE FLUOROPIRIMIDINAS \nAUTORES\nMELGAREJO ORTU\u00d1O, A; SANZ BAUTISTA, MP; APEZTEGUIA FERN\u00c1NDEZ, C; DE C\u00c1CERES VELASCO, C; AMOR GARCIA, \nMA; VIGIL RODRIGUEZ, A; BUENO MUI\u00d1O, C; MORENO DIAZ, R\nHOSPITAL INFANTA CRISTINA. AV . 9 DE JUNIO 2 PARLA. MADRID\nOBJETIVOS\nLa toxicidad de las fluoropirimidinas a menudo se ha relacionado con la deficiencia de la enzima DPD, que provoca \nel aumento de la vida media de estos f\u00e1rmacos. Es por tanto altamente recomendado determinar el genotipado de \npolimorfismos del gen DPYD antes de administrarlos. La deficiencia completa de la actividad de DPD es muy rara, \nestimada del 0,01% al 0,5% de individuos, la deficiencia parcial se ha estimado entre el 3% y el 8%.  \n \nLos objetivos del estudio incluyeron la descripci\u00f3n y frecuencia de los polimorfismos encontrados en el gen DPYD previo a \nla administraci\u00f3n de fluoropirimidinas en todos los tipos de tumores y las medidas realizadas ante la detecci\u00f3n del d\u00e9ficit \nde la enzima.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, multidisciplinar, en un hospital terciario, con la participaci\u00f3n de los Servicios de Farmacia, An\u00e1lisis \nCl\u00ednicos y Oncolog\u00eda, mediante la revisi\u00f3n de los resultados de la determinaci\u00f3n del genotipado de polimorfismos del gen \nDPYD. Se incluyeron a todos los pacientes oncol\u00f3gicos a los que se determin\u00f3 el genotipado en el per\u00edodo de junio 2020 \na diciembre 2021. Se analizaron cuatro variantes de DPYD: DPYD*2A, c.2846A > T, c.1679T > G y c.1236G > A (HapB3) y el \ngenotipo de 82 regiones polim\u00f3rficas del gen DPYD que relacionados con el nivel de actividad enzim\u00e1tica. Se registraron \nadem\u00e1s las siguientes variables relativas a los pacientes: sexo, edad, localizaci\u00f3n del tumor, fecha de realizaci\u00f3n del \ninforme, variante encontrada y grado de actividad enzim\u00e1tica (metabolizador pobre (0-0.5), metabolizador intermedio \n(1-1.5) y metabolizador normal (2).\nRESULTADOS\nSe realiz\u00f3 la determinaci\u00f3n a 150 pacientes, 56,7% mujeres, con una mediana de edad de 68,9 a\u00f1os (53,2-84,6). Las \nlocalizaciones tumorales fueron: colorrectal (48,7%), mama (22,7%), g\u00e1strico (8,7%), p\u00e1ncreas (8,7%), colangiocarcinoma \n(6%), cabeza y cuello (2,7%) y otras localizaciones (2,5%). Del total de pacientes, 15 (10%) presentaron alg\u00fan grado \nde deficiencia enzim\u00e1tica. 5 (30%) de los pacientes fueron metabolizadores con actividad enzim\u00e1tica 1,5, 8 (53%) con \nactividad enzim\u00e1tica 1, 1 (6%) con actividad 0,5 y 1 (6%) con actividad 0. Las variantes encontradas fueron: en 6 pacientes 289(40%) c.2846A > T, 3(20%) c.1129-5923C > G, 7(46,7%) c.1156G > T (*12), 1 (6,7%) c.1777G > A, 1(6,7%) c.1905+1G > A, \n1(6,7%) c.483+18G > A y 1(6,7%) c.1236G > A. 2 (13,3%) de los pacientes present\u00f3 ambos alelos con variantes mutadas. \n11 (73,3%) de los pacientes presentaron una variante, 3 (20%) presentaron 2 variantes y 1 (6,7%) presentaron 3 variantes \nafectadas. Siguiendo las gu\u00edas, a los pacientes metabolizadores intermedios se redujo la dosis de fluoropirimidinas un 50 \n% y en los pacientes metabolizadores pobres se evit\u00f3 el uso de este grupo de f\u00e1rmacos.\nCONCLUSIONES\nLos diagn\u00f3sticos principales fueron c\u00e1ncer de colon y mama debido al mayor uso de fluoropirimidinas en su abordaje \nterap\u00e9utico. Un 10 % de la poblaci\u00f3n estudiada present\u00f3 alg\u00fan grado de deficiencia enzim\u00e1tica seg\u00fan las variantes \nanalizadas, 8.6 % con deficiencia parcial y 1.3 % con deficiencia completa. Nuestra poblaci\u00f3n present\u00f3 una alta \nprevalencia de deficiencias en el gen DPYD en relaci\u00f3n a la bibliograf\u00eda descrita. Esta determinaci\u00f3n permiti\u00f3 el ajuste \nde dosis en estos f\u00e1rmacos, lo que supone un avance en t\u00e9rminos de seguridad permitiendo personalizar tratamientos, \nindividualizando dosis y evitando toxicidades.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n588. MODELIZACI\u00d3N FARMACOCIN\u00c9TICA POBLACIONAL DE FIBRIN\u00d3GENO EN PACIENTES CON \nHIPOFIBRINOGENEMIA ADQUIRIDA POR HEMORRAGIA GRAVE O CIRUG\u00cdA MAYOR. \nAUTORES\nAR\u00c9VALO BERNAB\u00c9, \u00c1G; COLOM CODINA, H; BLASI IB\u00c1\u00d1EZ, A; FERN\u00c1NDEZ ALARC\u00d3N, B; GUTI\u00c9RREZ RICO, RM; \nCENDR\u00d3S CARRERAS, JM; SABAT\u00c9 PES, A; MONTORO RONSANO, JB\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nEl fibrin\u00f3geno es un factor clave en la hemostasia. De su conversi\u00f3n a fibrina depende la formaci\u00f3n del co\u00e1gulo y su uso \nfarmacol\u00f3gico est\u00e1 indicado en el tratamiento y prevenci\u00f3n de la hemorragia. Su perfil farmacocin\u00e9tico est\u00e1 bien definido \nen pacientes con con afibrinogenemia cong\u00e9nita pero, sin embargo, se desconoce en pacientes con hipofibrinogenemia \nadquirida, en los que la generaci\u00f3n end\u00f3gena de fibrin\u00f3geno es significativa.  \nEl objetivo de este estudio es la modelizaci\u00f3n farmacocin\u00e9tica poblacional del fibrin\u00f3geno en pacientes con \nhipofibrinogenemia adquirida aguda -traumatismo grave- o cr\u00f3nica agudizada -pacientes cirr\u00f3ticos sometidos a trasplante \nhep\u00e1tico-.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional anal\u00edtico, retrospectivo, multic\u00e9ntrico. Se incluyeron aquellos pacientes con prescripci\u00f3n de \nfibrin\u00f3geno y diagn\u00f3stico de hemorragia grave traum\u00e1tica, o con cirrosis sometidos a trasplante de h\u00edgado, durante 2019.  \nLos datos biodemogr\u00e1ficos, anal\u00edticos (fibrin\u00f3geno en plasma, hematocrito, tiempo de Quick y TTPA), terap\u00e9uticos \n(dosis de fibrin\u00f3geno administradas) y cl\u00ednicos (diagn\u00f3stico) de los pacientes se extrajeron de los registros cl\u00ednicos \ninformatizados de cada centro participante. \nEl an\u00e1lisis farmacocin\u00e9tico poblacional se realiz\u00f3 mediante modelos no lineales de efectos mixtos (NONMEM7.4). Los \ndatos de concentraci\u00f3n-tiempo de fibrin\u00f3geno de nuestros pacientes se analizaron simult\u00e1neamente con datos de \npacientes con afibrinogenemia cong\u00e9nita procedentes de la literatura, utilizando el m\u00e9todo de estimaci\u00f3n condicional \nde primer orden con interacci\u00f3n. Se evaluaron los modelos de uno y dos compartimentos parametrizados en t\u00e9rminos \nde vol\u00famen de distribuci\u00f3n (V) y aclaramiento (CL). Para la modelizaci\u00f3n de la producci\u00f3n end\u00f3gena de fibrin\u00f3geno se \nutiliz\u00f3 un modelo de recambio. La variabilidad interindividual (VII) se evalu\u00f3 en todos los par\u00e1metros asumiendo una \ndistribuci\u00f3n logonormal. La influencia de las covariables cl\u00ednica y fisiol\u00f3gicamente m\u00e1s relevantes sobre los par\u00e1metros \nfarmacocin\u00e9ticos fue igualmente evaluada.\nRESULTADOS\nSe analizaron 428 valores concentraci\u00f3n-tiempo de 132 pacientes (172 de 86 con cirrosis; 161 de 14 con afibrinogenemia \ny 95 de 32 con hemorragia grave). El modelo de un compartimento con recambio end\u00f3geno es el que mejor describe la \nproducci\u00f3n end\u00f3gena y la disposici\u00f3n del fibrin\u00f3geno, seg\u00fan:  \ndAc/dt=Ksyn\u2022[1+C/(EC50+C)]-Kout\u2022Ac \nAc: fibrin\u00f3geno plasm\u00e1tico; Ksyn: constante de producci\u00f3n de orden cero (g/h); Kout: constante de eliminaci\u00f3n de orden \nuno (h-1)(CL/V); EC50: concentraci\u00f3n necesaria para alcanzar un 50% de producci\u00f3n m\u00e1xima.  \nEn el estado estacionario, la concentraci\u00f3n basal de fibrin\u00f3geno (Ao): Ksyn/Kout. Ksyn se fij\u00f3 en 0.1 (log valor/2) en \npacientes afibrinogen\u00e9micos. Para cirrosis y hemorragia grave se identificaron dos Ksyn distintas. Los valores finales de \nlos par\u00e1metros fueron (media, error est\u00e1ndar relativo): CL 0.0416 (7.91) L/h, V: 3.86 (5.07), Ksyn: 0.073 g/h (cirrosis) y \n0.106 g/h (hemorragia grave), EC50: 0.896 g/L. La VII se incluy\u00f3 en fibrin\u00f3geno basal, CL y V. El efecto del peso sobre V \nfue estad\u00edsticamente significativo, dando lugar a una reducci\u00f3n del 49% de la VII asociada a V. La variabilidad residual \nmodelizada con un error proporcional fue del 26.83%.\nCONCLUSIONES\nEl modelo monocompartimental con recambio end\u00f3geno es el que mejor describe la producci\u00f3n end\u00f3gena y la \ndisposici\u00f3n del fibrin\u00f3geno en pacientes con hipofibrinogenemia adquirida.  \nEste modelo permitir\u00e1 predecir la concentraci\u00f3n plasm\u00e1tica del f\u00e1rmaco y optimizar la dosis de fibrin\u00f3geno a administrar \na los pacientes con hipofibrinogenemia adquirida.290CLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n657. OPTIMIZACI\u00d3N POSOL\u00d3GICA DE LINEZOLID EN PACIENTES CR\u00cdTICOS \nAUTORES\nEGUES LUGEA, A; IRIGOYEN RODRIGUEZ, I; PRECIADO GOLDARACENA, J; LOBO PALANCO, J; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nCaracterizar la disposici\u00f3n de linezolid en pacientes cr\u00edticos y evaluar el impacto de la monitorizaci\u00f3n proactiva de las \nconcentraciones plasm\u00e1ticas del antibi\u00f3tico.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo que incluye pacientes ingresados en la unidad de pacientes cr\u00edticos (UCI), en tratamiento con linezolid \nendovenoso entre mayo 2021 y mayo 2022. Se registraron variables demogr\u00e1ficas, antropom\u00e9tricas, cl\u00ednicas, indicaci\u00f3n \ndel tratamiento y lugar de infecci\u00f3n. Los pacientes recibieron inicialmente la dosis est\u00e1ndar de 600mg cada 12h. Para \nla monitorizaci\u00f3n farmacocin\u00e9tica y posterior ajuste posol\u00f3gico se obtuvieron dos muestras de sangre, al menos 3 \nd\u00edas despu\u00e9s del inicio de tratamiento, una extra\u00edda 1h despu\u00e9s del fin de infusi\u00f3n (concentraci\u00f3n m\u00e1xima-Cmax) y \notra 30 minutos antes de la administraci\u00f3n de la dosis (concentraci\u00f3n m\u00ednima- Cmin). El objetivo farmacocin\u00e9tico-\nfarmacodin\u00e1mico (PK-PD) se defini\u00f3 como una concentraci\u00f3n valle entre 2 y 8 \u00b5g/mL, un tiempo por debajo de la \nconcentraci\u00f3n m\u00ednima inhibitoria (T > CMI) \u2265 85% del intervalo posol\u00f3gico y un \u00e1rea bajo la curva respecto a la CMI \n(ABC0-24/CMI) \u2265 80-120. Cuando no se dispon\u00eda del valor de CMI, esta se asumi\u00f3 en 2 \u00b5g/mL. La determinaci\u00f3n de \nlinezolid se realiz\u00f3 por t\u00e9cnica de inmunoensayo en ART TM.\nRESULTADOS\nSe incluyeron un total de 30 pacientes (50% hombres) con una media de edad de 61 a\u00f1os (rango 24-84 a\u00f1os). Ocho \npacientes (26,7%), recib\u00edan terapias continuas de reemplazo renal (TCRR) en el momento de la monitorizaci\u00f3n.  \nLinezolid se utiliz\u00f3 como tratamiento emp\u00edrico en el 63,3% de los casos. Las indicaciones de tratamiento mayoritarias \nfueron: infecci\u00f3n intraabdominal (13 pacientes) e infecci\u00f3n respiratoria (10 pacientes). Los par\u00e1metros farmacocin\u00e9ticos \ncalculados para linezolid en esta corte de pacientes fueron: volumen de distribuci\u00f3n (Vd) medio de 53,4 L\u00b1 25,7 y un \naclaramiento (CL) de 1,94mL*Kg/min (rango 0,81-6,10). La Cmin de linezolid fue inferior a 2 \u00b5g/mL en el 60% de los \npacientes, siendo menor a 0,75 \u00b5g/mL en el 27%. En dos pacientes la Cmin fue supraterap\u00e9utica (7%). Catorce pacientes \n(47%) cumpl\u00edan el objetivo PK/PD de 85% T > CMI y en 16 (53%), el ABC0-24/CMI fue superior a 80. \nEn ocho pacientes se increment\u00f3 la dosis a 600mg/8h y en 10 pacientes se modific\u00f3 la forma de administraci\u00f3n, \nutilizando la perfusi\u00f3n extendida en 3 horas como estrategia de optimizaci\u00f3n posol\u00f3gica. De los 18 pacientes que \nrequirieron modificaci\u00f3n de la pauta, pudo realizarse una segunda\nCONCLUSIONES\n\u2022 Los par\u00e1metros farmacocin\u00e9ticos de Linezolid presentan una elevada variabilidad interindivual.  \n\u2022 La dosificaci\u00f3n de est\u00e1ndar de linezolid 600mg cada 12h en pacientes cr\u00edticos conduce a concentraciones \ninfraterap\u00e9uticas en un porcentaje importante de pacientes. \n\u2022 La individualizaci\u00f3n posol\u00f3gica guiada por monitorizaci\u00f3n farmacocin\u00e9tica resulta una herramienta \u00fatil para conseguir \nconcentraciones en rango terap\u00e9utico.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n672. COMPARACI\u00d3N ENTRE PAUTA POSOL\u00d3GICA DE VANCOMICINA RECOMENDADA Y PAUTA NECESARIA \nPARA ALCANZAR OBJETIVOS TERAP\u00c9UTICOS EN UNA POBLACI\u00d3N DE NEONATOS \nAUTORES\nAGUILO LAFARGA, I; HERRANZ BAYO, E; P\u00c9REZ MORENO, M; PE\u00d1AS FERN\u00c1NDEZ, A; D\u00cdAZ-CALDERON HORCADA, CI; \nPERALES PASCUAL, J; CAZORLA PODEROSO, L; HUARTE LACUNZA, R\nHOSPITAL UNIVERSITARIO MIGUEL SERVET . P\u00ba DE ISABEL LA CAT\u00d3LICA, 1-3 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nLa vancomicina se usa con frecuencia en neonatos en los que su farmacocin\u00e9tica se ve modificada por cambios renales \ny por el volumen de distribuci\u00f3n. Nuestros objetivos fueron describir y evaluar a una muestra de neonatos tratados con \nvancomicina en pr\u00e1ctica cl\u00ednica real, comparando las pautas posol\u00f3gicas recomendadas por el protocolo del hospital con \nlas dosis y tiempo finalmente necesarios para alcanzar las concentraciones objetivo del f\u00e1rmaco.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo. Se incluyeron neonatos ( < 29 d\u00edas de edad) tratados con vancomicina, \nindependientemente de la indicaci\u00f3n, entre noviembre-2019 y diciembre-2021. Se excluyeron aquellos con una \u00fanica \ndeterminaci\u00f3n de niveles de vancomicina. Se recogieron datos demogr\u00e1ficos, cl\u00ednicos (as\u00ed como datos de toxicidad \npor vancomicina), microbiol\u00f3gicos, par\u00e1metros de laboratorio, concentraciones plasm\u00e1ticas y dosis diarias totales \nde vancomicina. La pauta posol\u00f3gica inicial recomendada seg\u00fan protocolo era: 10-15mg/kg/12-18h si < 29 semanas \nde gestaci\u00f3n (SG) y 10-15mg/kg/8-12h si 30-44 SG. El rango de vancomicina objetivo se consider\u00f3 10-20 mg/L. La \ncomparaci\u00f3n entre dosis del f\u00e1rmaco se analiz\u00f3 mediante la prueba Wilcoxon. El an\u00e1lisis de datos y estad\u00edstico se realiz\u00f3 \nmediante el software IBM\u00aeSPSS\u00aeStatistics v.25.291RESULTADOS\nSe incluyeron 108 pacientes (ni\u00f1as: 74,1%, edad cronol\u00f3gica mediana 1,6 (1,0-2,0) semanas). 25 ten\u00edan < 29 SG, 40 \nentre 30-36 SG y 43 entre 37-44 SG. El 57,4% con indicaci\u00f3n por infecci\u00f3n grave y 42,6% por infecci\u00f3n leve. El grado de \ncumplimiento del protocolo fue alto (93,5%) aunque tan solo el 26,9% logr\u00f3 concentraciones de vancomicina en rango \nobjetivo en la primera determinaci\u00f3n (20% de < 29 SG, 30% de 30-36 SG y 23,3% de 37-44 SG), estando la mayor\u00eda \n(71,3%) en rango infraterap\u00e9utico (80% de < 29SG, 62,5% de 30-36 SG y 74,4% de 37-44 SG). A pesar de iniciar con la \nposolog\u00eda recomendada, se requirieron 2 [0,8-4] d\u00edas y una dosis diaria de 32 [24,8-40] mg/kg/d\u00eda para alcanzar los \nniveles de vancomicina objetivo ( < 29s: 4 [2-5] d\u00edas y 24 [19-32] mg/kg/d\u00eda; 30-33 SG: 3,5 [2-4] d\u00edas y 30 [30-37,1] mg/\nkg/d\u00eda; 37-44 SG: 2 [1-4] d\u00edas y 36 [30-45] mg/kg/d\u00eda; p < 0.05 para las comparaciones entre dosis inicial y dosis final para \ntodos los grupos). Un 4,6% desarroll\u00f3 nefrotoxicidad y un 2,8% neutropenia por vancomicina durante el tratamiento. No \nse registraron casos de s\u00edndrome de hombre rojo.\nCONCLUSIONES\nEn nuestra muestra de neonatos de un hospital terciario y en pr\u00e1ctica cl\u00ednica real, las dosis recomendadas de vancomicina \nresultan insuficientes para lograr las concentraciones objetivo. Podr\u00eda ser necesario revisar los protocolos de posolog\u00eda \npara optimizar el tratamiento en esta poblaci\u00f3n que presenta ciertas particularidades en la cin\u00e9tica de la vancomicina.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n713. JUSTIFICACION DE LA MONITORIZACION FARMACOCINETICA DE LINEZOLID Y VORICONAZOL \nAUTORES\nS\u00c1EZ HORTELANO, JC; S\u00c1EZ VILLAFA\u00d1E, M; RODR\u00cdGUEZ FERN\u00c1NDEZ, Z; CAS\u00c1S FERN\u00c1NDEZ, X; V\u00c9LEZ BLANCO, A; DE \nCASTRO AVEDILLO, C; VELANDO PASCUAL, C; GARC\u00cdA GONZ\u00c1LEZ, D\nCOMPLEJO ASISTENCIAL UNIVERSITARIO DE LE\u00d3N. ALTOS DE LA NAVA S/N LE\u00d3N. LE\u00d3N\nOBJETIVOS\nLa monitorizaci\u00f3n de f\u00e1rmacos es una herramienta especialmente \u00fatil para el ajuste de dosis de f\u00e1rmacos con una \nrelaci\u00f3n respuesta cl\u00ednica y toxicidad dosis-dependiente y con estrecho margen terap\u00e9utico.  \nEl objetivo es comprobar si est\u00e1 justificada la monitorizaci\u00f3n de niveles plasm\u00e1ticos de linezolid y voriconazol tras la \nimplantaci\u00f3n en la cartera de servicios del \u00e1rea de farmacocin\u00e9tica.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional de 5 meses de duraci\u00f3n, realizado en un hospital de tercer nivel, que incluy\u00f3 \npacientes a los que, por recomendaci\u00f3n desde el Servicio de Farmacia, se les determinaron concentraciones plasm\u00e1ticas \nmediante la t\u00e9cnica anal\u00edtica de inmunoensayo enzim\u00e1tico homog\u00e9neo de linezolid y voriconazol.  \nSe recogieron las caracter\u00edsticas demogr\u00e1ficas (edad, sexo), datos anal\u00edticos (creatinina, filtrado glomerular por CKD-EPI, \nhemoglobina, recuento plaquetario, ALT, AST), posolog\u00eda, concentraci\u00f3n de f\u00e1rmaco, efectos adversos y valoraci\u00f3n de la \nrecomendaci\u00f3n posol\u00f3gica\ufffd \nCriterios de inclusi\u00f3n: Pacientes con determinaci\u00f3n de concentraciones m\u00ednimas en el estado de equilibrio de antibi\u00f3tico \n(al menos 3 d\u00edas de tratamiento, o 6 d\u00edas en caso de voriconazol si no se administr\u00f3 dosis de carga) \nCriterios de exclusi\u00f3n: Muestras extra\u00eddas en un periodo superior a 1 hora previo a la administraci\u00f3n de la siguiente dosis.  \nEl margen terap\u00e9utico considerado para linezolid fue 2-7 mcg/mL y para voriconazol 1-5,5 mcg/mL, en caso de profilaxis \n0,5-3 mcg/mL.  \nAn\u00e1lisis estad\u00edstico: Las variables categ\u00f3ricas se expresan como frecuencia y porcentaje. Las variables cuantitativas como \nmediana y rangos intercuart\u00edlicos.  \nSe analiz\u00f3 el porcentaje de pacientes que ten\u00edan concentraciones fuera del margen terap\u00e9utico, las reacciones adversas \nde los f\u00e1rmacos y el grado de aceptaci\u00f3n de las recomendaciones posol\u00f3gicas.\nRESULTADOS\nLinezolid: se incluyeron 26 pacientes, 23 hombres (88,5%), con una edad mediana de 64,5 [54-72] a\u00f1os. Se realizaron 33 \ndeterminaciones, de las cuales 11 (33,3%) estaban fuera del margen terap\u00e9utico: 8 (24,2%) supraterap\u00e9uticas y 3 (9,1%) \ninfraterap\u00e9uticas. Se recomend\u00f3 modificar la dosis en 11 casos, acept\u00e1ndose el cambio de posolog\u00eda en 10 de ellos \n(90,9%).  \nEn 8 pacientes (100%) que ten\u00edan concentraciones por encima del margen terap\u00e9utico se detect\u00f3 toxicidad hematol\u00f3gica \n(anemia y/o plaquetopenia). Sin embargo, en pacientes con concentraciones dentro o por debajo del margen terap\u00e9utico \nse detectaron en 6 (33,3%) casos de toxicidad.  \nVoriconazol: se incluyeron un total de 9 pacientes, 8 hombres (88,9%), con una edad mediana de 65 [64-73] a\u00f1os. Se \nrealizaron 12 determinaciones, de los cuales 8 (66,7%) fuera del margen terap\u00e9utico: 5 (41,7%) supraterap\u00e9uticas y 3 \n(25,0%) infraterap\u00e9uticos. Se recomend\u00f3 modificar la dosis en 8 casos, acept\u00e1ndose el cambio de posolog\u00eda en 7 (87,5%) \nocasiones\ufffd  \nEn 5 pacientes (100%) que ten\u00edan concentraciones por encima del margen terap\u00e9utico se detect\u00f3 toxicidad (elevaci\u00f3n \nde enzimas hep\u00e1ticas y/o alteraciones visuales). Sin embargo en pacientes con concentraciones dentro o por debajo del \nmargen terap\u00e9utico el porcentaje fue muy inferior 1 (25%).\nCONCLUSIONES\nUn elevado porcentaje de pacientes tiene concentraciones fuera del margen terap\u00e9utico que en muchos casos se ha \nasociado con reacciones adversas\ufffd Las recomendaciones posol\u00f3gicas tuvieron un alto grado de aceptaci\u00f3n\ufffd  \nSe identifica la necesidad de incorporar a la pr\u00e1ctica cl\u00ednica diaria la monitorizaci\u00f3n de linezolid y voriconazol.292CLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n742. DESARROLLO DE UN MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE ISAVUCONAZOL \nAUTORES\nAPARICIO PE\u00d1ACOBA, R; PAREJO MART\u00cdN, A; PE\u00d1A LORENZO, D; S\u00c1NCHEZ HERN\u00c1NDEZ, JG; REBOLLO D\u00cdAZ, N; \nZARZUELO CASTA\u00d1EDA, A; P\u00c9REZ BLANCO, JS; OTERO L\u00d3PEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nDesarrollar un modelo farmacocin\u00e9tico poblacional (PopPK) que describa el comportamiento de isavuconazol en la \nprofilaxis y tratamiento de las infecciones f\u00fangicas invasivas (IFI) y evaluar posibles factores que afecten a su dosificaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo y multidisciplinar realizado entre junio/2020 y enero/2022. Se incluyeron todos los pacientes adultos \nen tratamiento con isavuconazol oral e intravenoso con la pauta indicada en ficha t\u00e9cnica para profilaxis o tratamiento de \nIFI\ufffd El estudio cont\u00f3 con la aprobaci\u00f3n del CEIm\ufffd  \n \nSe recogieron datos demogr\u00e1ficos, de tratamiento, cl\u00ednicos y bioqu\u00edmicos [albumina s\u00e9rica (ALB), prote\u00ednas totales, \nfunci\u00f3n hep\u00e1tica (bilirrubina total, ALT, AST, FA y GGT), funci\u00f3n renal (aclaramiento de creatinina calculada por la f\u00f3rmula \nCKD-EPI) y hemograma (neutr\u00f3filos, plaquetas y hemoglobina)]. Las concentraciones s\u00e9ricas de isavuconazol fueron \ndeterminadas en estado de equilibrio estacionario, principalmente antes de la administraci\u00f3n y en algunos casos, cuando \nla administraci\u00f3n fue oral, tambi\u00e9n durante la fase de absorci\u00f3n Las muestras fueron analizadas mediante cromatograf\u00eda \nl\u00edquida de ultra-rendimiento (UPLC) acoplado a un detector ultravioleta. \n \nEl an\u00e1lisis PopPK se realiz\u00f3 aplicando una metodolog\u00eda f\u00e1rmaco-estad\u00edstica basada en modelos de efectos mixtos no \nlineales. El modelo se desarroll\u00f3 utilizando NONMEM v7.4 y el m\u00e9todo de estimaci\u00f3n condicional de primer orden con \niteraci\u00f3n (FOCEI). Los resultados, an\u00e1lisis estad\u00edsticos adicionales y representaciones gr\u00e1ficas fueron procesados mediante \nel software R v3.4. Se realizaron simulaciones determin\u00edsticas para evaluar el efecto de los factores identificados sobre la \nexposici\u00f3n al f\u00e1rmaco y su posible repercusi\u00f3n en la posolog\u00eda de isavuconazol.\nRESULTADOS\nSe incluyeron 21 pacientes (7 mujeres), pertenecientes al servicio de Hematolog\u00eda (13) y de la Unidad de Cuidados \nIntensivos (8), de los que 11 estaban en tratamiento por v\u00eda oral. La mediana (rango intercuat\u00edlico) de edad fue 58 (17) \na\u00f1os y el peso corporal total de 77 (17) kg. Se analizaron 65 muestras, de las que 39 fueron concentraciones m\u00ednimas. La \nconcentraci\u00f3n de isavuconazol m\u00ednima media (desviaci\u00f3n est\u00e1ndar) fue de 1,77 (1,62) \u00b5g/mL.  \n \nLa farmacocin\u00e9tica de isavuconazol se caracteriz\u00f3 mediante un modelo de un compartimento con absorci\u00f3n (oral) y \neliminaci\u00f3n de orden uno. La constante de absorci\u00f3n se fij\u00f3 en 22,6 1/h (seg\u00fan Cojutti et al. 2021). El volumen aparente \nde distribuci\u00f3n fue estimado en 219 L y el aclaramiento aparente (CL/F) seg\u00fan la siguiente ecuaci\u00f3n: \nCL/F (L/h) = 4,22*(SC/1,9)^2,1 *(ALB/2,9)^-0,9  \nDonde SC (superficie corporal) se expresa en m^2 y ALB en g/dL. La variabilidad interindividual (coeficiente de \nvariaci\u00f3n) del CL/F fue del 30,2% y la variabilidad residual del CL/F (proporcional y aditiva) fue del 20,2% y 0,83 \u00b5g/mL, \nrespectivamente. \nLas simulaciones mostraron que los pacientes con una SC mayor a 2 m^2 y concentraci\u00f3n de ALB inferior a 3 g/dL \nnecesitaban dosis superiores a las indicadas en ficha t\u00e9cnica para alcanzar concentraciones terap\u00e9uticas (1,5 \u00b5g/mL).\nCONCLUSIONES\nEl modelo PopPK desarrollado caracteriza adecuadamente el comportamiento cin\u00e9tico de isavuconazol e incluye la \nsuperficie corporal y la concentraci\u00f3n de alb\u00famina como factores que afectan a su aclaramiento. Los pacientes con \nuna superficie corporal elevada y con hipoalbuminemia podr\u00edan necesitar dosis mayores para alcanzar concentraciones \nterap\u00e9uticas.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n763. MONITORIZACION DE LAS CONCENTRACIONES PLASMATICAS DE VORICONAZOL EN PACIENTE \nCRITICO CON ASPERGILOSIS PULMONAR ASOCIADA A COVID-19 \nAUTORES\nDORD\u00c0 BENITO, A; LARREA URTARAN, X; GRATAC\u00d3S SANTANACH, L; ARTIME RODR\u00cdGUEZ-HERMIDA, F; VILA CURRIUS, \nM; RAMON RIGAU, N; BRUGUERA TEIXIDOR, M; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nEl aumento de mortalidad asociada a la aspergilosis pulmonar en pacientes cr\u00edticos con COVID-19 (CAPA) provoca que la \nindividualizaci\u00f3n de la terapia antif\u00fangica sea una prioridad. La monitorizaci\u00f3n de las concentraciones plasm\u00e1ticas (CP) de \nvoriconazol es indispensable en esta poblaci\u00f3n de pacientes.  \nLos objetivos de estudio son observar: a) si las dosis habituales de voriconazol proporcionan unas concentraciones \nm\u00ednimas (Cm\u00edn) adecuadas b) si las modificaciones de pauta realizadas en los pacientes con CP fuera de rango consiguen \nel objetivo terap\u00e9utico.293MATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico observacional retrospectivo que incluy\u00f3 a todos los pacientes cr\u00edticos con CAPA tratados con \nvoriconazol entre marzo 2021 y abril 2022. Se recogieron los siguientes datos: edad, sexo, fecha y hora de extracci\u00f3n \nde Cm\u00edn, Cm\u00edn, peso, talla, \u00edndice de masa corporal (IMC), peso real, peso ajustado (Paj), dosis de carga (Dc) y de \nmantenimiento (Dm). Se calcul\u00f3 la Dc y Dm por peso real y Paj.  \nSe realiz\u00f3 un an\u00e1lisis descriptivo de las variables cl\u00ednicas y demogr\u00e1ficas de los pacientes. Se consider\u00f3 como dosificaci\u00f3n \nde mantenimiento correcta, la indicada seg\u00fan ficha t\u00e9cnica 4mg/kg\u00b1 10%. \nSe calcul\u00f3 el porcentaje de pacientes que en la primera determinaci\u00f3n ten\u00edan una Cm\u00edn en rango terap\u00e9utico (RT) ( > \n1mcg/mL e < 5 mcg/mL) y el porcentaje de pacientes que los consigui\u00f3 despu\u00e9s de la modificaci\u00f3n de dosis.\nRESULTADOS\nSe incluyeron 14 pacientes, con una edad media de 61,8\u00b110,8 a\u00f1os, de los cuales un 35,7% (5) eran mujeres. El peso y la \ntalla media fue de 97,2\u00b116,4 kg y 169,1\u00b18,5 cm respectivamente, con un IMC medio de 33,3\u00b14,4 kg/cm2. El 92,9% (13) \nten\u00edan un IMC > 30 kg/cm2. \nLa media de Dc y Dm recibida por peso real fue de 6,0\u00b10.7 mg/kg y 4,0\u00b10,4 mg/kg respectivamente. En el caso de Paj \nfue de 7,3\u00b10,8 mg/kg y 5,1\u00b10,8 mg/kg. Un 14,3% (2) recibieron una Dm por peso real incorrecta seg\u00fan FT (en uno fue \nsuperior y en el otro inferior). \nUn 57,1% (8) obtuvieron una Cm\u00edn de voriconazol inicial correcta. Descartando los pacientes que no recibieron dosis \nadecuadas, un 58,3% (7) obtuvieron una Cm\u00edn en RT. \nDe los seis pacientes que ten\u00edan Cm\u00edn < 1mcg/mL, se realiz\u00f3 un ajuste posol\u00f3gico en cinco. En uno no se realiz\u00f3 por \ndiscontinuaci\u00f3n de tratamiento. En los que se realiz\u00f3 ajuste, se consigui\u00f3 que un 40,0% (2) tuvieran Cm\u00edn dentro RT. El \nporcentaje de aumento de dosis medio en estos pacientes fue del 37,1%.\nCONCLUSIONES\nAlrededor del 40% de los pacientes no consiguieron CP correctas con las dosis habituales de voriconazol. En ning\u00fan \npaciente del estudio se observaron CP supraterap\u00e9uticas, por ello, consideramos que se deber\u00eda dosificar inicialmente por \npeso real\ufffd  \nLa modificaci\u00f3n de pauta en los pacientes infradosificados no consigui\u00f3 alcanzar CP en RT en m\u00e1s de la mitad de los \npacientes. Despu\u00e9s de modificar la pauta, casi un 30% del total de pacientes continuaba con Cmin < 1mcg/mL. La \ndeterminaci\u00f3n de mutaciones en el CYP2C19 podr\u00eda ayudarnos a individualizar mejor el tratamiento en este grupo de \npacientes\ufffd\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n776. INFLUENCIA DE LA DOSIS DE CARGA EN LAS CONCENTRACIONES PLASM\u00c1TICAS DE VANCOMICINA \nEN PACIENTES CON HEMODI\u00c1LISIS CONVENCIONAL. \nAUTORES\nLARREA URTARAN, X; GRATAC\u00d3S SANTANACH, L; NOGU\u00c9 PUJADAS, E; BOIX I SOLER, L; MART\u00cdN ALEMANY , N; DORD\u00c0 \nBENITO, A; SUBIRANA BATLLE, C; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nLa vancomicina es el principal antibi\u00f3tico utilizado para el tratamiento de las infecciones causadas por Staphylococcus \nspp. en pacientes con enfermedad renal cr\u00f3nica en estadio V en tratamiento con hemodi\u00e1lisis.  \nLa mayor\u00eda de las gu\u00edas terap\u00e9uticas proponen una dosis de carga inicial seguida de una dosis de mantenimiento, sin \nembargo, no siempre se realiza.  \nEl objetivo es valorar como influye la dosis de carga (DC) en la concentraci\u00f3n plasm\u00e1tica de vancomicina pre-hemodi\u00e1lisis \n(CPVPH).\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional desde junio de 2020 hasta abril 2022. Se incluyeron pacientes de hemodi\u00e1lisis en \ntratamiento con vancomicina endovenosa a los que se les determin\u00f3 la CPVPH. Se establecieron 2 grupos: pacientes \ncon CPVPH < 10mcg/ml y con CPVPH > 10mcg/ml. Se recogieron datos demogr\u00e1ficos (edad, sexo, peso y talla) y cl\u00ednicos \n(dosis, diuresis residual y tipo de hemodi\u00e1lisis). Se excluyeron los pacientes a los que se les determin\u00f3 la CPVPH antes de \nla segunda dosis\ufffd  \nSe realiz\u00f3 un an\u00e1lisis descriptivo de las variables cl\u00ednicas y demogr\u00e1ficas de los dos grupos y se compararon mediante las \npruebas t-student o chi-cuadrado (X2). Se determin\u00f3 la influencia de la DC en la CPVPH mediante una X2.\nRESULTADOS\nSe incluyeron 32 pacientes\ufffd Se excluyeron 5 por determinar la CPVPH antes de la segunda dosis\ufffd  \nSe registraron CPVPH \u226510mcg/ml en 18 pacientes con una edad media de 60,4\u00b121,0 a\u00f1os, 33,3% mujeres, con un peso \nmedio de 74,7\u00b117,4 kg y un IMC 27,9\u00b17,5 kg/cm2. El 77,8% (n=14) recibieron una DC media de 15,1\u00b12,1 mg/kg y dosis de \nmantenimiento (DM) 11,9\u00b14,3 mg/kg. El 22,2% (n=4) no recibieron una DC y recibieron una DM media de 8,8\u00b10,3 mg/kg. \nEl 27,8% (n=5) presentaban diuresis residual. En el 27,8% (n=5) de los pacientes se utiliz\u00f3 hemodi\u00e1lisis de bajo flujo.  \nEn el grupo de CPVPH < 10mcg/ml (n= 9) la edad media fue de 63,7\u00b112,2 a\u00f1os, 33,3% mujeres, con un peso medio de \n76,6\u00b112,6kg y un IMC 27,9\u00b14,8 kg/cm2. El 33,3% (n=3) recibieron una DC media de 15,0\u00b10,4 mg/kg y DM 10,5\u00b14,3 mg/\nkg. 66,7% (n=6) no recibieron una DC y recibieron una DM media de 7,2\u00b12,2 mg/kg. El 55,6% (n=5) presentaban diuresis \nresidual. En todos los pacientes se utiliz\u00f3 hemodi\u00e1lisis de alto flujo o hemodi\u00e1lisis online.  294No existen diferencias estad\u00edsticamente significativas entre la edad (p= 0,670), el \u00edndice de masa corporal (p=0,997), y \nla DM (p=0,070) entre ambos grupos. Tampoco, hay relaci\u00f3n estad\u00edsticamente significativa entre la diuresis residual y la \nCPVPH (p=0,16) ni con el tipo de hemodi\u00e1lisis y la CPVPH (p=0,08).  \nHay relaci\u00f3n estad\u00edsticamente significativa en las CPVPH obtenidas en relaci\u00f3n con la administraci\u00f3n de una DC (p=0,024).\nCONCLUSIONES\nUn valor de CPVPH infraterap\u00e9utico est\u00e1 directamente relacionado con la no administraci\u00f3n de una dosis de carga. El \nestudio pone de manifiesto la necesidad de administrar una dosis de carga en los pacientes que realizan hemodi\u00e1lisis. \nSer\u00edan necesarios estudios prospectivos para evaluar otros factores que puedan influenciar en CPVPH.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n789. UTILIDAD DE LA MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE TEICOPLANINA DETERMINADA POR LA \nREDUCCI\u00d3N DE PRESCRIPCI\u00d3N DE AMIKACINA EN PACIENTES CON TRASPLANTE ALOG\u00c9NICO \nAUTORES\nL\u00d3PEZ \u00c1LVAREZ, M; GARC\u00cdA HERVALEJO, M; GARC\u00cdA CASANUEVA, JC; RECAREY GERPE, V; P\u00c9REZ L\u00d3PEZ, R; MORENO \nG\u00d3MEZ, \u00c1; S\u00c1NCHEZ HERN\u00c1NDEZ, JG; OTERO L\u00d3PEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nEl protocolo de prescripci\u00f3n de antibi\u00f3ticos en pacientes sometidos a trasplante alog\u00e9nico de progenitores \nhematopoy\u00e9ticos (alo-TPH) en nuestro centro contempla la prescripci\u00f3n escalonada de beta-lact\u00e1micos, glicop\u00e9ptidos y \namikacina\ufffd Concretamente, se a\u00f1ade amikacina si no se documenta aislamiento microbiol\u00f3gico y persisten picos febriles \na pesar de tratamiento concomitante con meropenem y teicoplanina. El objetivo de este estudio ha sido evaluar si la \nimplantaci\u00f3n de la monitorizaci\u00f3n farmacocin\u00e9tica y la optimizaci\u00f3n de la dosis de teicoplanina (teicoTDM) en pacientes \nsometidos a alo-TPH permite reducir la necesidad de prescribir amikacina.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional anal\u00edtico retrospectivo de cohortes en un hospital general que cuenta con un Servicio de \nHematolog\u00eda de referencia. Los datos corresponden a 2 per\u00edodos de tiempo, entre febrero 2019 y febrero 2020 antes de \nla implantaci\u00f3n de teicoTDM (no-teicoTDM), y entre febrero 2021 y febrero 2022 despu\u00e9s de la instauraci\u00f3n de teicoTDM \n(si-teicoTDM).  \nSe incluyeron los pacientes que estaban en tratamiento con teicoplanina durante el ingreso hospitalario en que fueron \nsometidos a alo-TPH. Se recopilaron los siguientes datos de la historia cl\u00ednica electr\u00f3nica y del programa de gesti\u00f3n de \nFarmacia: sexo, fecha de nacimiento, fecha de ingreso hospitalario, y si recibieron o no tratamiento con amikacina, que \nfue considerada la variable principal\ufffd  \nPara el c\u00e1lculo del tama\u00f1o muestral se accedi\u00f3 a la web clincalc.com presuponiendo una ocurrencia de la variable \nprincipal del 60% en no-teicoTDM y 20% en si-teicoTDM, con una probabilidad de error tipo-I \u03b1 de 0.05 y una potencia de \n90%. El tama\u00f1o muestral m\u00ednimo calculado fue de 58 pacientes. \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 en SPSSv26. Se estudi\u00f3 la Odds ratio (OR) con intervalos de confianza (IC95%) como factor \nprotector de la exposici\u00f3n a teicoTDM y se efectu\u00f3 un an\u00e1lisis de sensibilidad de la variable edad con modelo log\u00edstico \nbinario\ufffd\nRESULTADOS\nSe incluyeron un total de 60 pacientes: 30 controles de los que 13 eran mujeres con mediana [rango] de edad de 52 a\u00f1os \n[18-68] y 30 casos de los que 15 eran mujeres con edad de 60 a\u00f1os [23-71].  \nEn el grupo de no-teicoTDM se prescribi\u00f3 tratamiento con amikacina en 19 pacientes (63,3%) mientras que en el grupo \nde si-teicoTDM s\u00f3lo fue necesario prescribir amikacina en 4 pacientes (13,3%). Se calcul\u00f3 una OR si-teicoTDM versus \nno-teicoTDM de 0,089 (IC95% 0,025-0,323) para la variable principal si ocurrencia de tratamiento con amikacina. En el \nan\u00e1lisis de sensibilidad se encontr\u00f3 para la edad del paciente una OR de 0,963 (IC95% 0,927-1,000; p=0,05).\nCONCLUSIONES\nLa necesidad de utilizar amikacina se redujo en los pacientes en tratamiento con meropenem y teicoplanina, en los que se \nrealiz\u00f3 monitorizaci\u00f3n farmacocin\u00e9tica y ajuste de la dosis de teicoplanina. Por tanto, la monitorizaci\u00f3n farmac\u00e9utica de \nteicoplanina podr\u00eda mejorar la eficacia de este agente antimicrobiano y optimizar el uso de antiinfecciosos en pacientes \nsometidos a alo-TPH.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n794. EVALUACI\u00d3N DE LA DOSIFICACI\u00d3N DE LEVETIRACETAM EN PACIENTES CR\u00cdTICOS CON FUNCI\u00d3N \nRENAL NORMAL O AUMENTADA \nAUTORES\nFEIJOO VILANOVA, P; RAMUDO CELA, L; OUTEDA MAC\u00cdAS, M; ELBERD\u00cdN PAZOS, L; ALBI\u00d1ANA PEREZ, S; LUACES \nRODR\u00cdGUEZ, A; MART\u00cdN HERRANZ, I; MART\u00cdNEZ PRADEDA, A\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A295OBJETIVOS\nLevetiracetam es un antiepil\u00e9ptico muy utilizado en UCI, tanto en tratamiento como en profilaxis de convulsiones. Se \nexcreta principalmente inalterado en orina (66%) y las fichas t\u00e9cnicas AEMPS recomiendan ajuste de dosis cuando el \naclaramiento de creatinina (ClCr) es < 50 ml/min. El aclaramiento renal aumentado (ARA) es una condici\u00f3n frecuente en \npacientes cr\u00edticos que podr\u00eda alterar la farmacocin\u00e9tica de levetiracetam y para la que no existen recomendaciones de \ndosificaci\u00f3n espec\u00edficas. Este estudio tiene como objetivo evaluar la dosificaci\u00f3n de levetiracetam en pacientes cr\u00edticos \ncon ARA \ufffd\nMATERIALES Y M\u00c9TODOS\nLa determinaci\u00f3n de niveles valle se realiz\u00f3 en el servicio de farmacia mediante enzimoinmunoensayo (ARKTM \nLevetiracetam-Assay) en un analizador Alinity-CI\u00ae (Abbott\u00ae). Las dosis se ajustan para mantener los niveles de \nlevetiracetam dentro del rango terap\u00e9utico (12-46\u00b5g/ml) por consenso entre el farmac\u00e9utico y el m\u00e9dico intensivista. La \nfrecuencia de control de niveles se realiz\u00f3 bajo criterio cl\u00ednico con una periodicidad habitual de 48horas.  \nDise\u00f1o: estudio observacional retrospectivo que incluye pacientes cr\u00edticos adultos a tratamiento con levetiracetam y que \ningresan en la UCI de un hospital de tercer nivel entre noviembre de 2020 y abril de 2022. \nVariables cl\u00ednicas: se recogieron de la historia cl\u00ednica electr\u00f3nica: sexo, edad, diagn\u00f3stico de ingreso en UCI, concentraci\u00f3n \ns\u00e9rica de creatinina (Scr) y pauta de levetiracetam. Las concentraciones plasm\u00e1ticas (CP) de levetiracetam se \nnormalizaron por la dosis (CP/D), expres\u00e1ndose en mcg/ml/mg.  \nClasificaci\u00f3n de los pacientes: en funci\u00f3n del Clcr (f\u00f3rmula CKD-EPI) se dividieron las muestras en: \n- Clcr disminuido (ARD): < 50 ml/min  \n- Clcr normal (ARN): 50-130 ml/min  \n- Clcr aumentado (ARA): > 130 ml/min  \nAn\u00e1lisis descriptivo: variables continuas expresadas como medias\u00b1desviaci\u00f3n est\u00e1ndar y categ\u00f3ricas en porcentaje. \nAn\u00e1lisis estad\u00edstico: test de Shapiro Wilks como prueba de normalidad y para comparaci\u00f3n de los par\u00e1metros \nfarmacocin\u00e9ticos de los grupos el test de Kruskal-Wallis y Wilcoxon-Mann-Whitney. Se consider\u00f3 significativo (p < 0.05). \nAn\u00e1lisis estad\u00edstico realizado con programa R.\nRESULTADOS\nSe incluyeron 96 pacientes: 60 (63%) varones y edad media 57.0\u00b116.0 a\u00f1os. Los motivos de ingreso en UCI fueron: \n25% traumatismos craneoencef\u00e1licos graves, 21% estatus epil\u00e9ptico, 19% hemorragias subaracnoideas y 35% otras. \nSe tomaron 349 muestras con una mediana de 3 (1-17) muestras por paciente: un 17% correspondieron a pacientes \ncon ARA, 67% con ARN, y 16% con ARD, con unas edades medias de 39\ufffd85\u00b113\ufffd97, 59\ufffd38\u00b113\ufffd94 y 69\ufffd09\u00b19\ufffd14 a\u00f1os, \nrespectivamente. \nLos ratios CP/D fueron 0.0049\u00b10.0041 (ARA), 0.0071\u00b10.0043 (ARN) y 0.0183\u00b10.0136 (ARD) mcg/mL/mg. Los pacientes \ncon ARA necesitaron una dosis diaria media de 3025.00\u00b1997.56, mientras que en los otros grupos fue suficiente con dosis \nm\u00e1s bajas: 2710.30\u00b1813.90 (ARN) y 1812.50\u00b1796.65 mg (ARD).  \nLas diferencias en CP/D resultaron estad\u00edsticamente significativas tanto en la comparaci\u00f3n global (test Kruskal-Wallis; p < \n0.001) como en las comparaciones entre grupos (test Wilcoxon-Mann-Whitney; p < 0.001).\nCONCLUSIONES\nEn nuestro estudio, el ratio CP/D fue significativamente m\u00e1s bajo en pacientes con ARA que en aquellos con ARN. Por lo \ntanto, la presencia de ARA podr\u00eda conducir a una eliminaci\u00f3n m\u00e1s r\u00e1pida de levetiracetam, dando lugar a concentraciones \ninfraterap\u00e9uticas. El ARA definido como Clcr > 130 ml/min podr\u00eda ser un indicador que ayude a identificar pacientes con \nnecesidades de dosis m\u00e1s altas de levetiracetam.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n828. NIVELES DE DIGOXINA OBTENIDOS MEDIANTE UN MODELO MATEM\u00c1TICO \u00bfSE CORRELACIONAN \nCON LOS NIVELES OBTENIDOS MEDIANTE METODOS ANAL\u00cdTICOS? \nAUTORES\nQUEIPO GARC\u00cdA, E; REBOLLAR TORRES, E; PARIENTE JUNQUERA, A; FIJO PRIETO, A; BLANCO GARCIA, P; ALVAREZ \nGRANDE, B; MOLINA TORRES, N; LASALA HERN\u00c1NDEZ, E\nHOSPITAL NUESTRA SE\u00d1ORA DE GRACIA. RAM\u00d3N Y CAJAL, 60 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nAnalizar la capacidad predictiva de un modelo matem\u00e1tico (MM) dise\u00f1ado para calcular niveles de digoxina utilizando la \ndosis diaria prescrita, los datos antropom\u00e9tricos y los datos anal\u00edticos del paciente.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyen todos los pacientes ingresados en un hospital de primer nivel \nentre enero y diciembre de 2021 en tratamiento domiciliario con digoxina y con, al menos, una determinaci\u00f3n de nivel de \ndigoxina durante el ingreso\ufffd \n \nLas variables recogidas fueron: edad, sexo, talla, peso, pauta domiciliaria, creatinina s\u00e9rica, indicaci\u00f3n de uso: \ninsuficiencia cardiaca congestiva (ICC) o fibrilaci\u00f3n auricular (FA); presencia de ICC aguda, medicaci\u00f3n concomitante que \ninteracciona con digoxina, digoxinemia estimada mediante el MM y digoxinemia medida mediante m\u00e9todos anal\u00edticos \n(MA).  \n 296El MM utilizado est\u00e1 basado en el m\u00e9todo de Jelliffe y en las ecuaciones de Jusko y Koda-Kimble (disponible en https://\nglobalrph.com).  \n \nLa capacidad predictiva del MM se analiz\u00f3 comparando las digoxinemia estimadas por este m\u00e9todo con los niveles \nobtenidos por MA mediante el coeficiente de correlaci\u00f3n de Pearson y la diferencia de medias (d.m).  \nLos datos cl\u00ednicos de los pacientes fueron extra\u00eddos de la historia cl\u00ednica y el an\u00e1lisis de datos se realiz\u00f3 con el programa \nMicrosoft Excel\u00ae.\nRESULTADOS\nSe incluyeron 52 pacientes: 37 mujeres (71,15%); edad media: 86,98 a\u00f1os (SD:5,32); talla media: 155cm (SD:9,94); peso \nmedio: 69,41kg (SD:13,37). En el 55,78% de los pacientes (29/52) la indicaci\u00f3n de uso fue FA, en el 19,23% (10/52) ICC y \nen el 25% (13/52) ambas patolog\u00edas. 15 pacientes (28,87%) presentaron ICC aguda en el momento de la determinaci\u00f3n de \nlos niveles y 16 pacientes (30,77%) ten\u00edan prescrito alg\u00fan f\u00e1rmaco que interaccionaba con digoxina.  \n \nSe observ\u00f3 un grado de correlaci\u00f3n alto entre los niveles estimados por el MM y los obtenidos mediante MA r=0,81 (p < \n0.001). La d.m. fue 0.3 (SD:0,48).  \n \nSi se estratifican los resultados, en el caso de los pacientes que ten\u00edan prescrito alg\u00fan f\u00e1rmaco que interaccionaba \ncon digoxina, la d.m. fue de 0,6 (SD:0,57) y en los pacientes con ICC aguda fue de 0,39 (SD:0,59). Los pacientes que no \npresentaban ninguna de estas dos variables la d.m. fue de 0.16 (SD:0,4).\nCONCLUSIONES\n-Aunque el grado de correlaci\u00f3n entre los niveles estimados por el MM y los obtenidos mediante MA fue muy alto, la \nd.m. no es despreciable teniendo en cuenta el estrecho margen terap\u00e9utico de la digoxina, por lo que, aunque el MM no \npuede sustituir a los MA, s\u00ed puede ser \u00fatil para orientar en la dosificaci\u00f3n hasta que los MA est\u00e9n disponibles.  \n \n-El MM predice con m\u00e1s exactitud las concentraciones de digoxina cuando los pacientes no presentan ICC aguda ni tienen \nprescritos f\u00e1rmacos que interaccionan con la digoxina (la d.m. fue casi la mitad en este subgrupo de pacientes).\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n866. MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE MEROPENEM EN PLASMA Y L\u00cdQUIDO PERITONEAL EN \nUN PACIENTE CON PERITONITIS: A PROP\u00d3SITO DE UN CASO. \nAUTORES\nAGUADO PAREDES, A; RAM\u00cdREZ L\u00d3PEZ, M\u00c1; TIRADO P\u00c9REZ, MJ; MART\u00cdN BAEZ, IM; MART\u00cdNEZ ESCUDERO, A; AREST\u00c9 \nFOSALBA, NM; CALLEJA HERN\u00c1NDEZ, M\u00c1; MERINO BOH\u00d3RQUEZ, V\nHOSPITAL VIRGEN MACARENA \ufffd AV\ufffd DOCTOR FEDRIANI, 3 SEVILLA \ufffd SEVILLA\nOBJETIVOS\nLa administraci\u00f3n de meropenem intraperitoneal es una opci\u00f3n terap\u00e9utica adecuada para el tratamiento de peritonitis \ncausadas por Escherichia coli (E. Coli) productor de Betalactamasas de expectro extendido (BLEE). La monitorizaci\u00f3n \nde niveles de meropenem en el l\u00edquido peritoneal es una pr\u00e1ctica poco extendida, sin embargo, puede ser de utilidad \npara garantizar niveles \u00f3ptimos que ayuden a la resoluci\u00f3n de la infecci\u00f3n en base a par\u00e1metros Farmacocin\u00e9ticos-\nFarmacodin\u00e1micos (PK-PD).  \nEl objetivo es monitorizar las concentraciones de meropenem en el estado estacionario administrado por v\u00eda \nintraperitoneal en plasma y en l\u00edquido peritoneal en pacientes con peritonitis y analizar la consecuci\u00f3n del objetivo PK-\nPD\ufffd\nMATERIALES Y M\u00c9TODOS\nLos datos cl\u00ednicos y de laboratorio se extrajeron de la historia cl\u00ednica digitalizada del paciente y de la base de datos \nde prescripci\u00f3n de Farmacia. Se recogieron muestras de plasma y l\u00edquido peritoneal una vez alcanzado el estado \nestacionario, correspondientes al valle, previa a la administraci\u00f3n de la soluci\u00f3n para di\u00e1lisis peritoneal que contiene \nel f\u00e1rmaco, y a las 12 horas, es decir, al finalizar el intercambio peritoneal los d\u00edas 3, 7 y 10 de tratamiento. Las \nconcentraciones se determinaron mediante Cromatograf\u00eda L\u00edquida de Alta Resoluci\u00f3n asociada a detector ultravioleta \nde diodos en serie (HPLC-UV-DAD). El par\u00e1metro PK-PD propuesto para meropenem como predictor de eficacia fue fT > \n4xCMI\ufffd\nRESULTADOS\nPaciente diagnosticado de enfermedad renal cr\u00f3nica grado 5 secundaria a nefroangioesclerosis y  \nnefropat\u00eda intersticial cr\u00f3nica. Presenta peritonitis recurrente por E. coli multirresistente aislado en el cultivo de l\u00edquido \nperitoneal, siendo sensible (CMI\u22640,12 mg/L) a meropenem. Se administra una dosis de carga de 1 gramo por v\u00eda \nintravenosa, para continuar posteriormente con la pauta de 1 gramo al d\u00eda a\u00f1adido a las bolsas de soluci\u00f3n para di\u00e1lisis \nperitoneal de 12 h de duraci\u00f3n, posteriormente se hacen dos intercambios m\u00e1s cada 6 horas. Las extracciones de sangre \ny l\u00edquido se hacen tras el primer intercambio de 12 h (C12h) y se vuelven hacer tras el segundo intercambio de 6 horas \n(C6h). La media \u00b1 desviaci\u00f3n est\u00e1ndar de las concentraciones en el l\u00edquido peritoneal a C12h y a C6h fueron 24,72 \u00b1 5,13 \n\u00b5g/mL y 9,39 \u00b1 3,05 \u00b5g/mL respectivamente. \nLa media \u00b1 desviaci\u00f3n est\u00e1ndar de las concentraciones plasm\u00e1ticas a C12h y C6h fueron 12,37 \u00b1 0,63 \u00b5g/mL y 5,26 \u00b1 0,33 \n\u00b5g/mL respectivamente. Se estima una relaci\u00f3n aproximada de 2:1 l\u00edquido peritoneal/sangre y, por tanto, se alcanza el 297objetivo PK-PD definido. Los cultivos de control del l\u00edquido de di\u00e1lisis peritoneal realizados al mes y dos meses tras el \ninicio del tratamiento muestran la ausencia de crecimiento bacteriano, concluy\u00e9ndose la resoluci\u00f3n de la infecci\u00f3n.\nCONCLUSIONES\nLa monitorizaci\u00f3n farmacocin\u00e9tica en l\u00edquido de di\u00e1lisis peritoneal y sangre de un paciente con una peritonitis por \nE.coli multirresistente y en tratamiento con meropenem, garantiza la consecuci\u00f3n del objetivo PK-PD definido y es una \nherramienta \u00fatil que puede ayudar a la resoluci\u00f3n del cuadro infeccioso.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n874. COMPARACI\u00d3N DE UNA T\u00c9CNICA ELISA TRADICIONAL VERSUS UNA T\u00c9CNICA \u201cPOINT OF CARE\u201d EN \nLA DETERMINACI\u00d3N DE NIVELES DE INFLIXIMAB. \nAUTORES\nAGUADO PAREDES, A; TIRADO P\u00c9REZ, MJ; MART\u00cdNEZ ESCUDERO, A; VALD\u00c9S DELGADO, T; ARG\u00dcELLES ARIAS, F; \nCAUNEDO \u00c1LVAREZ, \u00c1; CALLEJA HERN\u00c1NDEZ, M\u00c1; MERINO BOH\u00d3RQUEZ, V\nHOSPITAL VIRGEN MACARENA \ufffd AV\ufffd DOCTOR FEDRIANI, 3 SEVILLA \ufffd SEVILLA\nOBJETIVOS\nLa t\u00e9cnica ELISA es la m\u00e1s utilizada para la determinaci\u00f3n de niveles de infliximab (IFX) en pacientes con enfermedad \ninflamatoria intestinal (EII), por ser sencilla y barata. Su principal limitaci\u00f3n es que precisan de un laboratorio \nespecializado y se han de acumular varias decenas de muestras para que el coste de cada determinaci\u00f3n sea m\u00e1s \neficiente, con el consiguiente retraso en la obtenci\u00f3n del resultado. El desarrollo de test r\u00e1pidos permite la obtenci\u00f3n de \nlos niveles en tiempos muy cortos (15 minutos) y, por tanto, actuar de forma inmediata en la optimizaci\u00f3n de la terapia \nbiol\u00f3gica\ufffd  \nEl objetivo de este estudio es comparar la t\u00e9cnica de referencia para cuantificaci\u00f3n de niveles IFX de tipo ELISA con una \nprueba r\u00e1pida, el test \u201cpoint of care (POC)\u201d.\nMATERIALES Y M\u00c9TODOS\nSe analizaron los niveles de IFX de 83 pacientes con EII que estaban en tratamiento de mantenimiento con IFX. Las \nmuestras se obtuvieron previas a la infusi\u00f3n de IFX (niveles valle) y fueron analizadas mediante ambos m\u00e9todos \nsiguiendo las instrucciones de cada fabricante. Para realizar el estudio mediante enzimoinmunoan\u00e1lisis (ELISA) se \nutilizaron los kits Promonitor\u00aeIFXv2, de Progenika Biopharma, Derio, Espa\u00f1a. Para el an\u00e1lisis r\u00e1pido (POC) se utiliz\u00f3 la \nt\u00e9cnica de Inmunocromatograf\u00eda de Flujo Lateral Quantum Blue\u00ae Infliximab (B\u00dcHLMANN Laboratories AG, Sch\u00f6nenbuch, \nSwitzerland).  \nLa comparaci\u00f3n cuantitativa de ambas t\u00e9cnicas se evalu\u00f3 con gr\u00e1ficos de Bland-Altman, la prueba t de Student y la recta \nde regresi\u00f3n para comprobar la concordancia entre ambas t\u00e9cnicas. Un valor p de < 0.05 se consider\u00f3 estad\u00edsticamente \nsignificativo. Los l\u00edmites de concordancia del 95% se calcularon utilizando la media \u00b1 1.96*SD. La correlaci\u00f3n se evalu\u00f3 \nmediante el coeficiente de correlaci\u00f3n de Pearson (r). Los an\u00e1lisis estad\u00edsticos fueron realizados con el paquete R\u00ae version \n4.1.2 (R Core Team, Viena, Austria).\nRESULTADOS\nLa mediana de la concentraci\u00f3n de IFX fue de 5.57 \u03bcg/mL (rango de medida 0.3-21.6 \u03bcg/mL) utilizando el test de \nELISA y 7.90 \u03bcg/mL (rango de medida 0.5-20 \u03bcg/mL) utilizando el test POC (Quantum Blue\u00ae). La correlaci\u00f3n de \nPearson para ambas fue alta (r=0.91, p < 0.001) y la recta de regresi\u00f3n y=0.94x+1.97, cuya pendiente de 0.94 indica \nuna buena concordancia entre ambas t\u00e9cnicas. La diferencia media entre test ELISA y test POC fue de -1.54 \u03bcg/mL \n(IC95%, -6.56-3.48) (p < 0.001). La gr\u00e1fica de Bland-Altman (no se muestra) indica que a concentraciones por encima \nde aproximadamente 10 \u03bcg/mL, el test r\u00e1pido (POC) sobreestima los valores de concentraci\u00f3n de IFX frente a la t\u00e9cnica \nELISA \ufffd\nCONCLUSIONES\nEl test r\u00e1pido (POC) Quantum Blue\u00ae para Infliximab muestra una correlaci\u00f3n y concordancia altas y unas diferencias \nm\u00ednimas aceptables en comparaci\u00f3n con los test de referencia ELISA, por lo que resultan fiables y presentan la ventaja de \nobtener resultados en muy pocos minutos\ufffd\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n888. IMPACTO CL\u00cdNICO DE LA INDIVIDUALIZACI\u00d3N DEL TRATAMIENTO CON FLUOROPIRIMIDINAS \nGUIADO POR ESTUDIO FARMACOGEN\u00c9TICO DEL GEN DPYD \nAUTORES\nFERN\u00c1NDEZ FRADEJAS, J; MOR\u00cdN RODR\u00cdGUEZ, M; DELGADO SILVEIRA, E; MORENO PELAYO, M\u00c1; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nLa presencia de determinados polimorfismos en el gen DPYD se asocia a d\u00e9ficit de actividad dihidropirimidina \ndeshidrogenasa (DPD) y un mayor riesgo de toxicidad severa durante el tratamiento con fluoropirimidinas \n(5-fluorouracilo, capecitabina, tegafur). En mayo de 2020, la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios \nrecomend\u00f3 la realizaci\u00f3n de pruebas de genotipo o fenotipo en pacientes candidatos a ser tratados con estos f\u00e1rmacos.  \n 298El objetivo del presente trabajo es evaluar 1) el impacto de la individualizaci\u00f3n del tratamiento con fluoropirimidinas \nguiado por estudio farmacogen\u00e9tico del gen DPYD en el desarrollo de toxicidad severa en pacientes con d\u00e9ficit de DPD y \n2) el grado de aceptaci\u00f3n de la recomendaci\u00f3n farmacoterap\u00e9utica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo en un hospital de tercer nivel. Se incluyeron todos los pacientes con estudio de \npolimorfismos en el gen DPYD desde la implantaci\u00f3n de la t\u00e9cnica en el centro (noviembre 2021-abril 2022). Se \nrecogieron las siguientes variables: edad, sexo, tipo de tumor, fluoropirimidina elegida, polimorfismo detectado, fenotipo \nDPD, recomendaci\u00f3n farmacoterap\u00e9utica, aceptaci\u00f3n de la recomendaci\u00f3n y toxicidad (tipo y grado seg\u00fan criterios CTCAE \n5.0). Esta informaci\u00f3n se obtuvo a partir de la historia cl\u00ednica electr\u00f3nica y el programa de gesti\u00f3n de laboratorio.  \n \nSe estudiaron los polimorfismos: c.1905+1G > A (DPYD*2A), c.1679T > G (DPYD*13), c.2846A > T y c.1129-5923C > G \na partir de muestra de sangre perif\u00e9rica mediante PCR a tiempo real con sondas fluorescentes y an\u00e1lisis de curvas de \nfusi\u00f3n. Los resultados y la recomendaci\u00f3n farmacoterap\u00e9utica fueron comunicados al equipo m\u00e9dico mediante un \ninforme integrado elaborado por el Servicio de Farmacia y el Servicio de Gen\u00e9tica del centro. Se monitoriz\u00f3 el desarrollo \nde toxicidad severa (grado 3 o superior) en los primeros 4 ciclos de tratamiento.\nRESULTADOS\nSe realiz\u00f3 el genotipado de DPYD en 180 pacientes (53,3% mujeres), con una edad mediana de 70 a\u00f1os (rango \nintercuart\u00edlico 60-79). Los tumores m\u00e1s frecuentes fueron: c\u00e1ncer de colon o recto (59,4%), g\u00e1strico (11,1%), p\u00e1ncreas \n(8,9%) y mama (6,6%). En el grupo de pacientes que iniciaron tratamiento, un 52,1% fueron tratados con capecitabina y \nun 47,9% con 5- fluorouracilo.  \n \nSe detectaron 5 pacientes (2,7%) con d\u00e9ficit parcial de DPD: 3 pacientes portadores de c.2846A > T en heterocigosis, \n1 portador de c.1129-5923C > G en homocigosis y un portador de C.1129-5923C > G en heterocigosis. No se encontr\u00f3 \nning\u00fan paciente con genotipo compatible con d\u00e9ficit absoluto de DPD. \n \nEn todos los casos se realiz\u00f3 informe farmacogen\u00e9tico. En el subgrupo de metabolizadores intermedios (d\u00e9ficit parcial) se \nrecomend\u00f3 una reducci\u00f3n de dosis inicial del 50% y posterior ajuste en funci\u00f3n de tolerancia y toxicidad experimentada. \nEsta recomendaci\u00f3n farmacoterap\u00e9utica fue aceptada en todos los casos. Durante el seguimiento, todos los pacientes \ncon d\u00e9ficit parcial DPD y dosis individualizada recibieron el tratamiento sin experimentar toxicidad severa.\nCONCLUSIONES\nLa individualizaci\u00f3n del tratamiento con fluoropirimidinas guiada por estudio farmacogen\u00e9tico del gen DPYD contribuye \na la prevenci\u00f3n de la toxicidad severa asociada al tratamiento en pacientes con d\u00e9ficit de DPD. Adicionalmente, esta \nintervenci\u00f3n tiene un elevado grado de aceptaci\u00f3n.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n895. DESARROLLO DE UN M\u00c9TODO DE DETERMINACI\u00d3N DE EXPRESI\u00d3N DEL GEN FLT3 NO MUTADO EN \nPACIENTES CON LEUCEMIA MIELOIDE AGUDA \nAUTORES\nSOLANA ALTABELLA, A; GIL ORTI, JV; MONTESINOS , P; SARGAS SIMARRO, C; POVEDA ANDR\u00c9S, JL; CANO FERRI, I; \nRODR\u00cdGUEZ VEIGA, R; BARRAG\u00c1N GONZ\u00c1LEZ, E\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEl gen FLT3 se localiza en el cromosoma 13q12 y codifica un receptor de membrana tirosin kinasa tipo III que se expresa \npreferentemente en c\u00e9lulas progenitoras hematopoy\u00e9ticas. Su activaci\u00f3n induce v\u00edas de se\u00f1alizaci\u00f3n celular que aumenta \nla supervivencia de las c\u00e9lulas leuc\u00e9micas. El aumento de la expresi\u00f3n del gen FLT3 puede inducir a una mayor resistencia \nde las c\u00e9lulas leuc\u00e9micas al tratamiento.  \nEl objetivo del estudio es desarrollar una t\u00e9cnica para determinar la expresi\u00f3n de FLT3 no mutado en pacientes con \nLeucemia Mieloide Aguda (LMA).\nMATERIALES Y M\u00c9TODOS\nLa t\u00e9cnica se fundamenta en la detecci\u00f3n cuantitativa del cDNA del mRNA de FLT3 mediante su medici\u00f3n por absorbancia. \nSe utiliz\u00f3 la detecci\u00f3n cuantitativa del cDNA del mRNA de ABL1 como control para comparar ambas expresiones. Para \nla detecci\u00f3n cuantitativa de la expresi\u00f3n de FLT3 se us\u00f3 el kit LightCycler FastStart DNA MasterPLUS HybProbe (Roche), \ncebadores y sonda TaqMan. Para que la muestra sea valorable debe tener el ciclo de crecimiento del gen control menor de 29.  \nLos cebadores utilizados para cuantificar la expresi\u00f3n de FLT3 han sido descritos previamente por Mekawy et al.1  \nForward: 5\u2019-TTTCACAGGACTTGGACAGAGATTT-3\u2019  \nReverse: 5\u2019-GAGTCCGGGTGTATCTGAACTTCT-3\u2019  \nProbe: 5\u2019-TCCAAATTCCAGCATGCCTGGTTCAAG-3\u2019  \nLos cebadores utilizados para cuantificar la expresi\u00f3n de ABL1 han sido descritos previamente por Gabert et al.2  \nForward: 5\u2019-TGGAGATAACACTCTAAGCATAACTAAAGGT-3\u2019  \nReverse: 5\u2019-GATGTAGTTGCTTGGGACCCA-3\u2019  \nProbe: 5\u2019-CCATTTTTGGTTTGGGCTTCACACCATT-3\u2019  \nLas variables cuantitativas est\u00e1n expresadas con la media y desviaci\u00f3n est\u00e1ndar(SD) y las categ\u00f3ricas en n\u00famero y \nfrecuencia(%).299RESULTADOS\nSe analiz\u00f3 58 muestras de m\u00e9dula \u00f3sea (MO) correspondientes a 53 pacientes diferentes (edad media de 58 a\u00f1os \n[SD:10], 60% hombres) con nuevo diagn\u00f3stico de LMA y tratados con un esquema de inducci\u00f3n IDA+ARA (3+7) con 4 \nconsolidaciones con citarabina a altas dosis. La mayor\u00eda de las muestras fueron extra\u00eddas en el momento del diagn\u00f3stico, \n5 tras la inducci\u00f3n y 2 tras la primera consolidaci\u00f3n\ufffd  \nAl diagn\u00f3stico la media de ciclos de la expresi\u00f3n de FLT3 fue de 21.0 (SD:2.0) ciclos y del gen control fue de 23.6 (SD:1.4) \nciclo. En la mayor\u00eda de muestras (n=52) la expresi\u00f3n de FLT3 era mayor que la de ABL, lo que sugiere un aumento de la \ns\u00edntesis de FLT3 en c\u00e9lulas leuc\u00e9micas. De las 6 muestras donde la expresi\u00f3n de FLT3 era menor a ABL, 4 eran en muestras \nde pacientes tras la inducci\u00f3n, lo podr\u00eda significar una disminuci\u00f3n de la expresi\u00f3n debida al tratamiento.\nCONCLUSIONES\nComo se preve\u00eda se mantiene estable la expresi\u00f3n del gen control, existiendo mayor variabilidad en la expresi\u00f3n de \nFLT3. Se ha validado la t\u00e9cnica de determinaci\u00f3n de expresi\u00f3n del gen que codifica FLT3 lo que permitir\u00e1 cuantificar la \nefectividad de los nuevos tratamientos desarrollados para esta nueva diana.  \nReferencias \n1Mekawy, MA, Eissa, DS, Hamza, MT, Hamed, GM & Youssef, MK. FLT3 receptor/CD135 expression by flow cytometry in \nacute myeloid leukemia: Relation to FLT3 gene mutations and mRNA transcripts. Egypt. J. Med. Hum. Genet. 19, 345\u2013351 \n(2018). \n2Gabert, J et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase \nchain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe Against Cancer Program. \nLeukemia 17, 2318\u20132357(2003).\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n942. AJUSTE DE LA CONCENTRACI\u00d3N PLASM\u00c1TICA DE LITIO EN TRES PROGRAMAS FARMACOCIN\u00c9TICOS \nAUTORES\nSOTO BASELGA, I; DOM\u00cdNGUEZ GARC\u00cdA, A; MORONA MINGUEZ, I; SALCEDO MINGOARRARNZ, AL; OROZCO \nCIFUENTES, I; RODRIGO LAMB\u00c1N, DJ; MORIEL S\u00c1NCHEZ, C; GARC\u00cdA D\u00cdAZ, B\nHOSPITAL SEVERO OCHOA \ufffd AV\ufffd DE ORELLANA, S/N LEGAN\u00c9S \ufffd MADRID\nOBJETIVOS\nAnalizar y comparar la precisi\u00f3n y la exactitud de tres modelos farmacocin\u00e9ticos en el ajuste de la concentraci\u00f3n \nplasm\u00e1tica de litio.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se analizaron los pacientes en tratamiento con litio que fueron \nmonitorizados entre enero y diciembre de 2021 en un hospital de segundo nivel. \nMediante la prescripci\u00f3n y la historia cl\u00ednica electr\u00f3nicas se recopilaron los datos demogr\u00e1ficos (sexo y edad), \nantropom\u00e9tricos (peso y talla) y bioqu\u00edmicos (litio y creatinina plasm\u00e1ticos).  \nSe introdujeron los datos de los pacientes en dos programas de farmacocin\u00e9tica individual (A y B) y se dise\u00f1\u00f3 un modelo \npoblacional propio a partir de 96 pacientes ingresados (C).  \nSe evalu\u00f3 la exactitud y la precisi\u00f3n de los tres modelos (A, B y C) mediante la teor\u00eda de los errores de predicci\u00f3n de \nSheiner y Beal: la exactitud se analiz\u00f3 con el error medio de predicci\u00f3n (EMP) y la precisi\u00f3n con el error medio absoluto \nde predicci\u00f3n (EAMP) y con la ra\u00edz cuadrada del error cuadr\u00e1tico medio de predicci\u00f3n (RECMP).\nRESULTADOS\nSe reclutaron 95 pacientes con 249 niveles plasm\u00e1ticos de litio. El 54.17% de los pacientes eran mujeres. Mediana de \nedad 48 a\u00f1os (37-54), mediana del peso 73 Kg (66-80,8) y mediana de la cr eatinina s\u00e9rica 0,88 mg/dL (0,75-0,99). \nEl programa farmacocin\u00e9tico A present\u00f3: EMP -0,02, EAMP 0,16 y RECMP 0,25.  \nEl programa farmacocin\u00e9tico B present\u00f3: EMP 0,04, EAMP 0,15 y RECMP 0.22. \nEl programa farmacocin\u00e9tico C present\u00f3: EMP -0,05, EAMP 0.15 y RECMP 0,23.\nCONCLUSIONES\nEl litio es un f\u00e1rmaco candidato a la monitorizaci\u00f3n farmacocin\u00e9tica ya que presenta una adecuada relaci\u00f3n entre su \nconcentraci\u00f3n plasm\u00e1tica y efecto terap\u00e9utico.  \nEl programa farmacocin\u00e9tico m\u00e1s exacto y preciso para estimar los niveles de litio en nuestra poblaci\u00f3n fue el modelo B, \nseguido del modelo C y por \u00faltimo del modelo A. \nEl software B a\u00fana precisi\u00f3n y exactitud por lo que ser\u00eda el de elecci\u00f3n para estimar los valores de litio en nuestra \npoblaci\u00f3n, consiguiendo as\u00ed una mayor seguridad y eficacia terap\u00e9utica.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n949. MONITORIZACI\u00d3N DE LA ACTIVIDAD DE LA ASPARRAGINASA PARA LA DETECCI\u00d3N DE PACIENTES \nPEDI\u00c1TRICOS INACTIVADORES \nAUTORES\nBARROSO CASTRO, J; LIGROS TORRES, M; MO\u00d1INO BL\u00c1ZQUEZ, B; DUQUE RODRIGUEZ, M; CALLEJA BUENO, A; \nANT\u00d3N MENDEZ, X; GIL LEMUS, M\nHOSPITAL DE CRUCES \ufffd PZA DE CRUCES, S/N \ufffd BARAKALDO \ufffd VIZCAYA300OBJETIVOS\nDetectar pacientes pedi\u00e1tricos que desarrollan fen\u00f3menos de inactivaci\u00f3n de la asparraginasa (inactivaci\u00f3n silente o \nhipersensibilidad) mediante la monitorizaci\u00f3n rutinaria de la actividad de la asparraginasa.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en el que se recogieron los valores obtenidos de actividad de la asparraginasa de todos los \npacientes pedi\u00e1tricos con Leucemia Linfobl\u00e1stica Aguda desde marzo de 2020 hasta marzo de 2022, tratados en nuestro \ncentro seg\u00fan el protocolo LAL/SEHOP-PETHEMA 2013 (Enmienda Versi\u00f3n 2.0 del 27/11/2016).\nRESULTADOS\nSe trataron 23 pacientes durante el periodo de estudio, de los cuales 13 fueron mujeres, con una media de edad de 7.1 \na\u00f1os (rango, 1 mes - 15 a\u00f1os). En funci\u00f3n de la fase del protocolo de tratamiento en la que se encontrase el paciente, se \nsacaron muestras para analizar la actividad el d\u00eda +7 y/o +14 post-administraci\u00f3n de la Escherichia coli L-asparraginasa \npegilada (Peg-asparraginasa). Se consideraron pacientes inactivadores aquellos que obtuvieron valores de actividad \ninferiores a 100 UI/L en el d\u00eda +7 y/o inferiores a 5 UI/L en cualquiera de las determinaciones. Para confirmar que \nse trataba de un paciente inactivador eran necesarias dos determinaciones diferentes con estos resultados. En caso \nde cumplir criterios de inactivaci\u00f3n, se cambi\u00f3 el tratamiento en sucesivas administraciones a Erwinia chrysanthemi \nL-asparraginasa (asparraginasa-Erwinia). 5 de los 23 pacientes (21.7%) fueron considerados inactivadores, de los cuales \n3 sufrieron, adem\u00e1s, alg\u00fan tipo de reacci\u00f3n de hipersensibilidad grado I-III, mientras que los 2 pacientes restantes no \npresentaron cl\u00ednica sugestiva hipersensibilidad. Se realiz\u00f3 el cambio de tratamiento a los 5 pacientes. Tras el cambio a \nasparraginasa-Erwinia, 4 pacientes obtuvieron valores de actividad adecuados, present\u00e1ndose el caso de 1 ni\u00f1o que \ntambi\u00e9n fue considerado inactivor a aparraginasa-Erwinia, objetiv\u00e1ndose con valores de actividad inferiores a 5 UI/L \nen determinaciones sucesivas a las 48 horas post-administraci\u00f3n. Cabe destacar que en este ni\u00f1o no se objetivaron \nreacciones de hipersensibilidad con ninguna de las dos presentaciones utilizadas de asparraginasa. Por \u00faltimo, en 4 \npacientes (80%) se detect\u00f3 la inactivaci\u00f3n a Peg-asparraginasa en fases iniciales del tratamiento (3 en inducci\u00f3n IA y 1 en \nla inducci\u00f3n de la reca\u00edda) y 1 paciente en fase de mantenimiento.\nCONCLUSIONES\nLa monitorizaci\u00f3n de la actividad de la asparraginasa de forma rutinaria permite detectar pacientes inactivadores \nde la asparraginasa, permitiendo el cambio a otro tratamiento con certeza e independiente de una reacci\u00f3n de \nhipersensibilidad. El control exhaustivo durante las fases iniciales del tratamiento podr\u00eda tener especial importancia, \naunque m\u00e1s estudios son necesarios para determinar si existe un mayor n\u00famero de inactivaciones en estas fases iniciales.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n952. MODELO FARMACOCIN\u00c9TICO POBLACIONAL DE PIPERACILINA-TAZOBACTAM EN PACIENTES \nCR\u00cdTICOS CON FUNCI\u00d3N RENAL CONSERVADA \nAUTORES\nMARTINEZ CASANOVA, J; COLOM , H; ESTEVE , E; MAISTERRA , K; TUBAU , F; COBO , S; SHAW , E; PADULL\u00c9S , A\nHOSPITAL UNIVERSITARI DE BELLVITGE. FEIXA LLARGA, S/N HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nOBJETIVOS\nPiperacilina-tazobactam (P/T) es uno de los antibi\u00f3ticos prescritos con mayor frecuencia en las unidades de cuidados \nintensivos. Los numerosos cambios fisiopatol\u00f3gicos y las terapias de soporte que reciben estos pacientes generan una \nelevada variabilidad inter e intra-individual en la exposici\u00f3n alcanzada y a su vez en la respuesta al tratamiento. Estudios \nprevios indican que este tipo de paciente se beneficiar\u00eda de dosis superiores de P/T para poder alcanzar el objetivo \nfarmacocin\u00e9tico/farmacodin\u00e1mico (PK/PD). \nEl objetivo fue desarrollar un modelo PK poblacional para caracterizar la PK de P/T administrado en perfusi\u00f3n continua \n(PC) en una poblaci\u00f3n de pacientes cr\u00edticos adultos con funci\u00f3n renal conservada.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional llevado a cabo en un hospital universitario de tercer nivel en el periodo Junio 2015- \nNoviembre 2018. Se incluyeron pacientes cr\u00edticos en tratamiento con P/T en PC seg\u00fan pr\u00e1ctica cl\u00ednica habitual y con \nfunci\u00f3n renal correcta (filtrado glomerular-FG Chronic Kidney Disease Epidemiology Collaboration - CKD-EPI > 60 ml/min). \nSe determinaron las concentraciones plasm\u00e1tica (Cp) de P/T total en dos ocasiones: despu\u00e9s de la dosis de carga (Cmax) y \nen estado de equilibrio estacionario (despu\u00e9s de 24h del inicio de la IC) (Css). Las Cp se midieron mediante cromatograf\u00eda \nl\u00edquida acoplada a espectrometr\u00eda de masas (UPLC/MS/MS). Se desarroll\u00f3 un modelo poblacional mediante la \naproximaci\u00f3n de modelos mixtos no lineales (NONMEM v7.4.3\u00ae).  \nDatos basales recogidos: demogr\u00e1ficos y cl\u00ednicos. El FG fue evaluado mediante el uso de distintas f\u00f3rmulas: CKD-EPI, \nCockcroft and Gault (CG) y Modification of Diet in Renal Disease (MDRD-4). Los datos num\u00e9ricos se muestran como \nmediana (Q1-Q3) y los categ\u00f3ricos como n (%).\nRESULTADOS\nSe incluyeron 115 pacientes (77 hombres (66,96 %)) y un total de 228 valores de Cp de P/T. Datos demogr\u00e1ficos: edad 65 \n(49,5-72) a\u00f1os; cauc\u00e1sicos 110 (95,65%); peso 74 (66-84,5) kg; IMC 26,45 (23,28-29,41) kg/m\u00b2. Datos cl\u00ednicos: FG CKD-\nEPI: 95,48 (85,72-113,53) mL/min/1.73 m2, CG: 112,3 (83,36-147,79) mL/min/m2, MDRD-4: 115,7 (88,15-145,75) mL/\nmin/1.73 m2; alb\u00famina s\u00e9rica 29 (26-33) g/L; pacientes neurocr\u00edticos 37 (32,17 %); portadores de drenaje 39 (33,91 %); \nventilados 67 (58,26 %) y tratados con drogas vasoactivas 48 (41,74%).  301El modelo que mejor describi\u00f3 el perfil de disposici\u00f3n de P/T fue un modelo bicompartimental con eliminaci\u00f3n de orden \nuno. El FG CKD-EPI redujo la variabilidad interindividual asociada al Cl en un 24.59% de forma estad\u00edstica y cl\u00ednicamente \nsignificativa. Dicha variable fue por tanto la \u00fanica covariable incluida en el modelo, su incremento se relaciona con un \naumento del Cl del f\u00e1rmaco.  \nLos par\u00e1metros PK finales fueron (estima inicial (varianza)): CL de PT 11.7\u00b7(FG/97.4) (siendo 97.4 la media de FG) (0.744) \nL/h, aclaramiento intercompartimental 4.81 (1.73) L/h, volumen de distribuci\u00f3n central 19.8 (2.00) L y perif\u00e9rico 51.1 \n(31.4) L.\nCONCLUSIONES\nSe desarroll\u00f3 un modelo PK poblacional de PT en que el FG CKD-EPI fue variable predictora del CL. El ajuste de dosis a \ntrav\u00e9s de esta variable permitir\u00e1 alcanzar exposiciones \u00f3ptimas.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n961. MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE AMINOGLUC\u00d3SIDOS EN CENTROS SOCIOSANITARIOS \nAUTORES\nP\u00c9REZ ROBRES, Y; SANZ RODR\u00cdGUEZ, SM; RUIZ MOLINA, F; MAR\u00cdN VENTURA, L; GARCIA-L\u00d3PEZ , L; HERN\u00c1NDEZ \nL\u00d3PEZ, A; RICO GUTI\u00c9RREZ, T; AMOR\u00d3S PAREDES, A\nHOSPITAL GENERAL DE SEGOVIA \ufffd CTRA \ufffd DE AVILA, S/N SEGOVIA \ufffd SEGOVIA\nOBJETIVOS\nLos aminogluc\u00f3sidos (gentamicina, amikacina y tobramicina) son una familia de antibi\u00f3ticos bactericidas que act\u00faan \nprincipalmente frente a infecciones causadas por bacterias Gram negativas.  \n \nLos objetivos fueron comparar la posolog\u00eda de aminogluc\u00f3sidos recomendada en las gu\u00edas de manejo antimicrobiano y \nNomograma Barnes-Jewish Hospital respecto a la ajustada tras monitorizaci\u00f3n farmacocin\u00e9tica y evaluar la efectividad y \nseguridad de estos tratamientos en dos centros sociosanitarios asociados a un hospital de segundo nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, realizado en dos centros sociosanitarios en el que se incluyeron todos los pacientes \ntratados con aminogluc\u00f3sidos en 2020 y 2021\ufffd  \n \nSe recogieron variables descriptivas (sexo, edad y peso) y propias de la enfermedad y el tratamiento (fecha de inicio y fin, \ndiagn\u00f3stico, microorganismo causante de la infecci\u00f3n, posolog\u00eda inicial y recomendada tras monitorizaci\u00f3n y creatinina \ninicial y final).  \n \nLa dosis de inicio se ajust\u00f3 a peso (3-5 mg/kg para gentamicina y tobramicina y 10-15 mg/kg para amikacina) y el \nintervalo posol\u00f3gico seg\u00fan el Nomograma de Barnes-Jewish Hospital. La monitorizaci\u00f3n farmacocin\u00e9tica se realiz\u00f3 no \nm\u00e1s tarde de la tercera dosis.  \n \nComo objetivos secundarios se analizaron la efectividad, entendi\u00e9ndose como resultado final de la intervenci\u00f3n sobre la \nsalud y la seguridad como toxicidad renal (incremento entre creatinina inicial y final \u22650.5 mg/dL o \u226550%).\nRESULTADOS\nSe analizaron 18 pacientes de los cuales 17/18 (94.4%) fueron mujeres, con una media de edad de 83.9 (\u00b112) a\u00f1os y 58.9 \n(\u00b111.6) kg de peso.  \n \nLa duraci\u00f3n de los tratamientos fue de 8.44 (\u00b12.3) d\u00edas. Se diagnosticaron infecciones del tracto urinario en el 77.8% \npacientes y \u00falceras cut\u00e1neas en 22.2%. Los microorganismos aislados fueron 50% Pseudomonas aeruginosa, 38.9% \nKlebsiella pneumoniae, 27\ufffd8% Proteus mirabilis y 22\ufffd2% otros pat\u00f3genos, con alta prevalencia de factores de resistencia: \n32% OXA-48 y 12% beta-lactamasas de espectro extendido. El 38.9% fueron infecciones mixtas.  \n \nSe prescribi\u00f3 amikacina a 8/18 pacientes, gentamicina a 8/18 y tobramicina a 2/18, a dosis de 13.5 (\u00b11.6) mg/kg, 3.8 (\u00b11) \nmg/kg y 3 mg/kg respectivamente. Las pautas iniciales fueron mayores a 24 horas en el 61.1% de los casos.  \n \nTras monitorizaci\u00f3n, en 12/18 pacientes (66.7%) la prescripci\u00f3n inicial difiri\u00f3 de la recomendaci\u00f3n requiriendo \nmodificaci\u00f3n de la dosis en 5/12 (41.7%) pacientes, de la pauta en 4/12 (33.3%) o de ambas en 3/12 (25%). La dosis diaria \nrequerida fue menor en 8/12 (66.7%) pacientes.  \n \nSe observ\u00f3 curaci\u00f3n cl\u00ednica en el 100% de los pacientes y deterioro de la funci\u00f3n renal en 1/18 (5.6%) paciente.\nCONCLUSIONES\nLos resultados del estudio indican que la monitorizaci\u00f3n farmacocin\u00e9tica de aminogluc\u00f3sidos es recomendable puesto \nque las pautas propuestas en las gu\u00edas no son adecuadas para la mayor\u00eda de estos pacientes, fr\u00e1giles, sintom\u00e1ticos y con \ndiagn\u00f3stico de pat\u00f3genos resistentes propios de los centros sociosanitarios.  \n \nEl uso de estos antiinfecciosos result\u00f3 ser efectivo y seguro ya que todos los pacientes se recuperaron de su proceso \npatol\u00f3gico y apenas se observ\u00f3 deterioro de la funci\u00f3n renal, no pudi\u00e9ndose descartar que esto se debiera a otras causas.302CLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n980. MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA PROACTIVA EN LA OPTIMIZACI\u00d3N DE LA ANTIBIOTERAPIA \nAUTORES\nJIMENEZ SIERRA JIMENEZ SIERRA, JJ; BELL\u00c9S MEDALL, MD; PUPL\u00c1 BARTOLL, A; GIL CANDELL, M; ESTEVE L\u00d3PEZ, V; \nGARC\u00cdA MU\u00d1OZ, S; BODEGA AZUARA, J; FERRANDO PIQUERES, R\nHOSPITAL GENERAL DE CASTELL\u00d3 \ufffd AV\ufffd BENICASIM, S/N CASTELL\u00d3N DE LA PLANA/CASTELL\u00d3 DE LA PLANA \ufffd CASTELL\u00d3N\nOBJETIVOS\nLa optimizaci\u00f3n de la antibioterapia seg\u00fan par\u00e1metros farmacocin\u00e9ticos y farmacodin\u00e1micos garantiza la mayor \nprobabilidad de alcanzar el \u00e9xito terap\u00e9utico y minimizar la toxicidad en el tratamiento antibi\u00f3tico. El objetivo de este \ntrabajo es contribuir a su consecuci\u00f3n a trav\u00e9s de la monitorizaci\u00f3n farmacocin\u00e9tica (TDM) proactiva desde el servicio de \nfarmacia, como integrante del programa de optimizaci\u00f3n en el uso de antimicrobianos (PROA) del hospital.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo realizado en un hospital de tercer nivel en el periodo de tiempo comprendido entre \nmarzo 2021 y marzo 2022. A partir de las solicitudes de monitorizaci\u00f3n farmacocin\u00e9tica (TDM) proactiva, la base \nde datos del PROA, el gestor de laboratorio de farmacocin\u00e9tica y la historia cl\u00ednica informatizada, se obtuvieron las \nsiguientes variables: identificaci\u00f3n del paciente candidato a optimizaci\u00f3n, fecha de solicitud de la TDM proactiva, grado \nde aceptaci\u00f3n de la TDM proactiva, fecha del informe farmacocin\u00e9tico, tipo de ajuste posol\u00f3gico realizado, grado de \naceptaci\u00f3n del informe farmacocin\u00e9tico, fecha de aceptaci\u00f3n de la recomendaci\u00f3n y motivo de no aceptaci\u00f3n.\nRESULTADOS\nSe realizaron un total de 251 solicitudes de TDM proactivas. El grado de aceptaci\u00f3n de la solicitud de TDM fue del 71% \n(n=178). Los antibi\u00f3ticos monitorizados fueron los siguientes: linezolid (47%), meropenem (24%), vancomicina (15%), \nvoriconazol (10%), amikacina (2%) y daptomicina (2%).  \nDe los 178 antibi\u00f3ticos que se monitorizaron, se recomend\u00f3 optimizaci\u00f3n posol\u00f3gica en un 62% (n=110), mantenimiento \nde la pauta posol\u00f3gica en un 32% (n=57), y en un 6% (n=11) no se lleg\u00f3 a realizar informe farmacocin\u00e9tico por suspensi\u00f3n \nde la antibioterapia. El perfil de los ajustes posol\u00f3gicos fue el siguiente; en un 56% (n=62) se indic\u00f3 reducir exposici\u00f3n, en \nun 27% (n=30) se recomend\u00f3 aumentar exposici\u00f3n y en un 16% (n=18) se propuso suspender el tratamiento.  \nEl grado de aceptaci\u00f3n de la recomendaci\u00f3n farmacocin\u00e9tica alcanz\u00f3 el 75,5% (n=83). Los motivos de no aceptaci\u00f3n \nfueron por; suspensi\u00f3n del tratamiento en el 19% (n=21) de los casos, y solo en un 5,5%(n=6) de los casos se mantuvo la \npauta posol\u00f3gica inicial no aceptando la recomendaci\u00f3n del informe farmacocin\u00e9tico.  \nDe las 83 recomendaciones aceptadas, la optimizaci\u00f3n posol\u00f3gica se instaur\u00f3 durante las primeras 24 horas, tras emisi\u00f3n \ndel informe farmacocin\u00e9tico, en el 85% (n=70) de los casos.  \nEl antibi\u00f3tico que requiri\u00f3 mayor optimizaci\u00f3n de dosis fue linezolid, en el 76% (n=64) de los pacientes. De estos, en el \n45% (n=38) de los informes farmacocin\u00e9ticos se recomend\u00f3 reducir exposici\u00f3n, en el 15% (n=12) aumentar exposici\u00f3n, y \nen el 16% (n=14) suspender tratamiento.\nCONCLUSIONES\nEn base a los datos obtenidos, hay que destacar la importancia de la TDM proactiva como intervenci\u00f3n para la mejora del \nuso de los antimicrobianos, ya que ha tenido un alto grado de aceptaci\u00f3n permitiendo optimizar la antibioterapia en m\u00e1s \nde la mitad de los pacientes monitorizados e instaur\u00e1ndose el cambio de pauta posol\u00f3gica en un tiempo de respuesta \n\u00f3ptimo.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1038. FARMACOCIN\u00c9TICA POBLACIONAL DE INFLIXIMAB EN PACIENTES CON ENFERMEDAD \nINFLAMATORIA INTESTINAL \nAUTORES\nGARC\u00cdA MART\u00cdNEZ, S; SALCEDO MINGORRANZ, \u00c1L; DEL R\u00cdO ORTEGA, P; ESCRIGAS FERN\u00c1NDEZ, C; LOZANO LLANO, \nC; AYLL\u00d3N MORALES, M; GARC\u00cdA D\u00cdAZ, B\nHOSPITAL SEVERO OCHOA \ufffd AV\ufffd DE ORELLANA, S/N LEGAN\u00c9S \ufffd MADRID\nOBJETIVOS\nDise\u00f1ar un modelo farmacocin\u00e9tico poblacional de infliximab en pacientes con enfermedad inflamatoria intestinal (colitis \nulcerosa o enfermedad de Crohn).  \nAnalizar la influencia de las covariables recogidas en nuestro modelo farmacocin\u00e9tico.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en el que se incluyeron 59 pacientes con enfermedad inflamatoria intestinal en un hospital de \nsegundo nivel entre 2016 y 2022. Todos los pacientes recibieron infliximab intravenoso y ten\u00edan como m\u00ednimo una \ndeterminaci\u00f3n de concentraci\u00f3n plasm\u00e1tica. \nLas variables recogidas de la historia cl\u00ednica y la prescripci\u00f3n electr\u00f3nica fueron: edad, sexo, peso, diagn\u00f3stico (colitis \nulcerosa o enfermedad de Crohn), creatinina s\u00e9rica, alb\u00famina, PCR, especialidad de infliximab (original o biosimilar) y \ntratamiento concomitante con inmunomoduladores (metotrexato, micofenolato de mofetilo, tacrolimus, azatioprina o \nciclosporina).  \nLos datos se analizaron mediante un programa farmacocin\u00e9tico para obtener los par\u00e1metros poblacionales: aclaramiento \n(Cl), volumen de distribuci\u00f3n central (Vc) y perif\u00e9rico (Vp), constante de velocidad de absorci\u00f3n (Ka) y aclaramiento 303intercompartimental (Q). En primer lugar, se analiz\u00f3 un modelo monocompartimental y cuatro tipos de estimaci\u00f3n: \nprimer orden (FO), primer orden con interacci\u00f3n (FO+I), condicional de primer orden (FOCE) y condicional de primer \norden con interacci\u00f3n (FOCE+I). Posteriormente se analiz\u00f3 la poblaci\u00f3n con un modelo bicompartimental.  \nSe seleccion\u00f3 el modelo poblacional teniendo en cuenta un descenso estad\u00edsticamente significativo en el valor de la \nfunci\u00f3n objetivo (OFV), el criterio de informaci\u00f3n bayesiana (BIC) y el criterio de informaci\u00f3n de Akaike (AIC). \nUna vez establecido el modelo b\u00e1sico se analiz\u00f3 la influencia de las siguientes covariables: edad, sexo, peso, creatinina \ns\u00e9rica, PCR y albuminemia.\nRESULTADOS\nSe analizaron 172 niveles de infliximab de 59 pacientes (49% mujeres). La edad media fue 53 a\u00f1os (24-81) y el peso \nmedio 74 kg (41-175). \nEl modelo farmacocin\u00e9tico poblacional que present\u00f3 un mejor ajuste fue el bicompartimental con estimaci\u00f3n condicional \nde primer orden con interacci\u00f3n: OFV: 544,751, BIC: 585,931, AIC: 560,751\ufffd  \nSe obtuvieron los siguientes par\u00e1metros poblacionales: Cl: 0,0064 L/h, Vc: 0,219 L, Vp: 3,42 L, Ka: 0,5 1/h (fijada) y Q: 409 \nL/h. La variabilidad interindividual en el aclaramiento fue del 20,1%, y en el volumen del 15%.  \nSe ensay\u00f3 un modelo de error mixto (aditivo y proporcional), observ\u00e1ndose que tanto el error proporcional (45,2%) como \nel aditivo (111,8%) influyeron en la dispersi\u00f3n de los datos.  \nNinguna de las covariables testeadas (edad, sexo, peso, creatinina s\u00e9rica, PCR y alb\u00famina) tuvo una influencia \nestad\u00edsticamente significativa en el modelo poblacional.\nCONCLUSIONES\nEl modelo farmacocin\u00e9tico poblacional que mejor se ajust\u00f3 a nuestros pacientes fue el modelo bicompartimental con \nestimaci\u00f3n condicional de primer orden con interacci\u00f3n, variabilidad interindividual exponencial en el aclaramiento y el \nvolumen de distribuci\u00f3n, y error proporcional y aditivo.  \nSe requerir\u00eda incorporar un mayor n\u00famero de pacientes al estudio y reevaluar la posible influencia de las covariables.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1049. INFLAMACI\u00d3N COMO FACTOR DE RIESGO EN LA INTOXICACI\u00d3N POR VORICONAZOL \nAUTORES\nPUPLA BARTOLL, A; BELL\u00c9S MEDALL, MD; BODEGA AZUARA, J; VICENTE ESCRIG, E; JIM\u00c9NEZ SIERRA, JJ; PUERTOLAS \nVAL, R; QUINTANA VARGAS, M; FERRANDO PIQUERES, R\nHOSPITAL GENERAL DE CASTELL\u00d3 \ufffd AV\ufffd BENICASIM, S/N CASTELL\u00d3N DE LA PLANA/CASTELL\u00d3 DE LA PLANA \ufffd CASTELL\u00d3N\nOBJETIVOS\nDurante el proceso inflamatorio, tanto los mediadores (interleucina 6) como el propio da\u00f1o tisular, pueden modificar el \naclaramiento de ciertos f\u00e1rmacos mediante la disminuci\u00f3n de la expresi\u00f3n g\u00e9nica de algunos complejos metabolizadores \ny transportadores. Entre estos f\u00e1rmacos se encuentra el voriconazol. El objetivo es determinar el riesgo de \nsobredosificaci\u00f3n en funci\u00f3n del valor de prote\u00edna C reactiva (PCR) de los pacientes tratados con este antif\u00fangico.\nMATERIALES Y M\u00c9TODOS\nSe recogieron todas las monitorizaciones de voriconazol administrado de forma intravenosa durante el periodo \nde abril/17 - abril/21 en un hospital terciario. Los criterios de inclusi\u00f3n fueron: pacientes en tratamiento con \nvoriconazol a dosis de 4 mg/Kg/12h (\u00b10,5 mg/kg/12h) sin tratamiento concomitante con inductores/inhibidores \npotentes (carbamacepina, fenito\u00edna, fenobarbital, rifampicina, inhibidores de la transcriptasa inversa no an\u00e1logos \nde los nucle\u00f3sidos e inhibidores de la proteasa) y con valores de alanina aminotransferasa (GPT) menores de 120 \nUI/L. La toma de muestras se realiz\u00f3 como m\u00ednimo a las 48h del inicio del tratamiento con dosis de choque en las \nprimeras 24h y siempre antes de administrar la dosis (Cmin). La concentraci\u00f3n de voriconazol se determin\u00f3 mediante \nenzimoinmunoensayo ARK\u00ae. \nSe calcul\u00f3 una curva Caracter\u00edstica Operativa del Receptor (ROC, en ingl\u00e9s) para definir un punto de corte de PCR que \npueda predecir la sobredosificaci\u00f3n. Para ello, se defini\u00f3 una Cmin > 4 mg/L como intoxicaci\u00f3n y se compar\u00f3 con el valor \nde PCR \ufffd \nSe realiz\u00f3 una regresi\u00f3n log\u00edstica binaria para establecer si la inflamaci\u00f3n es un factor de riesgo para la intoxicaci\u00f3n por \nvoriconazol. Se consider\u00f3 que exist\u00eda inflamaci\u00f3n si el valor de PCR era superior al punto de corte obtenido en la curva \nROC. El an\u00e1lisis estad\u00edstico se realiz\u00f3 mediante el software SPSS\u00ae.\nRESULTADOS\nSe recogieron 129 monitorizaciones de voriconazol. Se excluyeron 75 por no cumplir los criterios de dosificaci\u00f3n y 3 por \npresentar elevaci\u00f3n de la GPT. No se excluy\u00f3 ninguna por tratamiento concomitante con inductores/inhibidores potentes. \nEn total quedaron 51 determinaciones para el estudio. En la curva ROC se calcul\u00f3 una \u00e1rea bajo la curva de 0,733\u00b10,72(IC \n95%: 0,593-0,874). El \u00edndice de Youden fue de 0,507 y el punto de corte m\u00e1s adecuado para PCR fue de 61,5 mg/L \n(sensibilidad: 0,724 y especificidad: 0,783). En la regresi\u00f3n log\u00edstica binaria se obtuvo una odds ratio de 9,45 (IC 95%:2,62-\n34,07).\nCONCLUSIONES\nSeg\u00fan los datos obtenidos, presentar una PCR > 61,5 mg/L supone 9,45 veces m\u00e1s riesgo de desarrollar una intoxicaci\u00f3n \npor voriconazol con dosis de 4 mg/kg/12h (\u00b10,5 mg/kg/12h), en pacientes con buena funci\u00f3n hep\u00e1tica y sin tratamiento \nconcomitante con f\u00e1rmacos inductores/inhibidores potentes.304CLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1050. RESULTADOS DE UNA INTERVENCI\u00d3N FARMACOTERAP\u00c9UTICA REALIZADA EN PACIENTES \nANCIANOS EN TRATAMIENTO CR\u00d3NICO CON DIGOXINA \nAUTORES\nRECAREY GERPE, V; PE\u00d1A LORENZO, D; MARTIN GIL, M; GARC\u00cdA HERVALEJO, M; MORENO G\u00d3MEZ, \u00c1; RODR\u00cdGUEZ \nBARRUECO, C; HERN\u00c1NDEZ ARROYO, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nLa monitorizaci\u00f3n de digoxina permite establecer una pauta posol\u00f3gica individualizada y ajustada a las caracter\u00edsticas \nde los pacientes de edad avanzada. El objetivo del estudio fue analizar los resultados obtenidos tras una intervenci\u00f3n \nfarmac\u00e9utica realizada desde el Servicio de Farmacia de la Gerencia de atenci\u00f3n primaria en pacientes de edad avanzada \nen tratamiento con una dosis potencialmente inapropiada de digoxina\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo realizado entre febrero-2021 y abril-2022. Se incluyeron los pacientes \u226575 a\u00f1os del \n\u00e1rea de salud que se encontraban en tratamiento cr\u00f3nico con digoxina con una dosis prescrita, seg\u00fan el registro del plan \nfarmacoterap\u00e9utico, de 0,25 mg/d\u00eda todos los d\u00edas de la semana y que hab\u00edan recogido un envase de digoxina entre \nenero y febrero de 2021\ufffd  \n \nEn febrero-2021 se realiz\u00f3 una intervenci\u00f3n farmac\u00e9utica sobre la totalidad de estos pacientes, consistente en comunicar \na cada m\u00e9dico responsable los pacientes de su cupo para su revisi\u00f3n y valoraci\u00f3n de solicitud de monitorizaci\u00f3n \nfarmacocin\u00e9tica. Adem\u00e1s, se elabor\u00f3 y difundi\u00f3 una nota informativa sobre prevenci\u00f3n de errores de medicaci\u00f3n con \ndigoxina\ufffd  \n \nPosteriormente, en abril-2022 se seleccion\u00f3 a los pacientes \u226590 a\u00f1os, por ser considerados los de mayor riesgo, y se \nanalizaron los datos de aquellos que no dispon\u00edan de determinaci\u00f3n de concentraci\u00f3n plasm\u00e1tica (Cp) de digoxina en los \n\u00faltimos 2 a\u00f1os o esta era potencialmente t\u00f3xica ( > 1,2 ng/mL). Las variables registradas fueron: sexo, edad, diagn\u00f3stico, \nadherencia al tratamiento, filtrado glomerular (FG), pauta posol\u00f3gica real, solicitud de determinaci\u00f3n de la Cp de \ndigoxina tras la intervenci\u00f3n, Cp obtenida y modificaci\u00f3n de la pauta posol\u00f3gica en caso necesario tras la monitorizaci\u00f3n \nfarmacocin\u00e9tica.\nRESULTADOS\nSe realiz\u00f3 la intervenci\u00f3n farmac\u00e9utica inicial en 257 pacientes \u226575 a\u00f1os en tratamiento cr\u00f3nico con una dosis de digoxina \nde 0,25 mg/d\u00eda, de los que 67 pacientes eran \u226590 a\u00f1os.  \n \nPosteriormente, se seleccion\u00f3 a los 39 pacientes (18 mujeres) \u226590 a\u00f1os que cumplieron los criterios para el an\u00e1lisis \nde datos. La mediana (rango) de edad fue 92 (90-102) a\u00f1os. En cuanto al diagn\u00f3stico, 30 pacientes ten\u00edan fibrilaci\u00f3n \nauricular y 9 insuficiencia cardiaca. La adherencia media al tratamiento fue 88% ( < 80% en 7 pacientes); 14 pacientes \npresentaban un FG < 60 mL/min/1,73m2 (CKD-EPI).  \n \nSe hab\u00eda solicitado la monitorizaci\u00f3n de Cp de digoxina a 17 de los 39 pacientes analizados (43,6%), siendo la mediana \n(rango) de Cp de 0,98 (0,15-1,96) ng/mL. Ocho pacientes tomaban realmente una dosis inferior a la registrada en el plan \nfarmacoterap\u00e9utico. De los 9 pacientes que tomaban la dosis de digoxina registrada (0,25 mg/d\u00eda), 6 presentaron una Cp \nelevada o potencialmente t\u00f3xica con una mediana (rango) de 1,79 (1,07-1,96) ng/mL, siendo necesario reducir la dosis de \ndigoxina\ufffd\nCONCLUSIONES\nUn elevado porcentaje de pacientes de edad avanzada tienen prescritas dosis de digoxina potencialmente t\u00f3xicas para \nsu edad y funci\u00f3n renal y no se monitorizan las Cp. La intervenci\u00f3n farmac\u00e9utica realizada permiti\u00f3 identificar a los \npacientes con mayor riesgo de sufrir efectos adversos por digoxina y establecer una pauta posol\u00f3gica individualizada en \naquellos pacientes monitorizados.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1066. PACIENTES EN TRATAMIENTO CON ADALIMUMAB CON ENFERMEDAD INFLAMATORIA INTESTINAL, \n\u00bfINFLUYE EL INDICE DE MASA CORPORAL EN LAS CONCENTRACIONES? \nAUTORES\nHERRANZ MU\u00d1OZ, N; GARC\u00cdA GARC\u00cdA, S; SANZ MART\u00cdNEZ, MT; ALONSO MART\u00cdNEZ, C; GORGAS TORNER, MQ; \nMIARONS FONT , M\nH. UNIVERSITARI GENERAL DE LA VALL D\u2019HEBRON. PASSEIG VALL D\u2019HEBRON 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nEstudios observacionales describen la obesidad como un marcador de pron\u00f3stico negativo en pacientes con enfermedad \ninflamatoria intestinal (EII), relacion\u00e1ndose adem\u00e1s con peor respuesta a agentes biol\u00f3gicos.  \nEl objetivo principal es determinar si el \u00edndice de masa corporal (IMC) afecta al valor de las concentraciones s\u00e9ricas de \nadalimumab (ADA) tras su inicio en semanas 2, 6 y 14. El objetivo secundario es evaluar la efectividad de conseguir concen-\ntraciones dentro del margen terap\u00e9utico en semanas 6 y 14 al intensificar el tratamiento en semana 2, seg\u00fan el IMC.305MATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo desde octubre de 2019 a marzo de 2022. Incluye pacientes tratados con ADA con EII \ny concentraciones valle durante la inducci\u00f3n (semanas 2 y 6) y mantenimiento (semana 14).  \nSe recogieron variables demogr\u00e1ficas (edad, sexo) y caracter\u00edsticas antropom\u00e9tricas (peso, talla e IMC) al inicio del \ntratamiento con ADA, diagn\u00f3stico (enfermedad de Crohn (EC) o colitis ulcerosa (CU)), tratamiento inmunomodulador \n(IMM) concomitante y presencia de enfermedad perianal. Se recogi\u00f3 albumina y PCR en semana 2. Los pacientes se \nclasificaron seg\u00fan su IMC: normopeso < 25 kg/m2, sobrepeso 25\u201329 kg/m2 y obesidad > 30 kg/m2. \nSe registraron los pacientes con intensificaci\u00f3n de tratamiento, aumento de dosis o reducci\u00f3n de intervalo, por presentar \nconcentraciones < 10-15\u00b5g/ml en semanas 2 y/o 6.  \nSe realizaron pruebas estad\u00edsticas de Kolmogorov-Smirnov y Levene, y comparaci\u00f3n de variables continuas con an\u00e1lisis de \nvarianza (ANOVA). Se consider\u00f3 estad\u00edsticamente significativo un p-valor < 0,05. El an\u00e1lisis estad\u00edstico se realiz\u00f3 mediante \nSPSS v21\ufffd0\u00ae\ufffd\nRESULTADOS\nSe incluyeron 71 pacientes (N=37,52,11% hombres) con edad media al inicio del tratamiento de 41,03\u00b115,61 a\u00f1os y \ncon IMC < 25 (N=41,57,75%), IMC25\u201329 (N=23,32,39%) y IMC\u226530 (N=7, 9,86%). Tipo de EII: EC 73,24% y CU 26,76%. Un \n15,49% present\u00f3 afectaci\u00f3n perianal\ufffd  \nDel total, el 42,25% recibi\u00f3 tratamiento IMM concomitante, siendo azatioprina en un 83,33%. De los 40 (57,75%) \npacientes en monoterapia con ADA, 51,22% presentaban IMC < 25, 47,83% IMC25-29 y 57,14% IMC\u226530.  \nEn semana 2, la media de concentraciones fue 10,81\u00b14,60, 8,52\u00b12,45 y 7,94\u00b12,35 mcg/ml (p < 0,05) y se intensific\u00f3 la \nposolog\u00eda en 19,51%, 47,83% y 71,43% (p < 0,05) de los pacientes con IMC < 25, IMC25-29 y IMC\u226530, respectivamente. \nEl valor medio de albumina fue comparable en los 3 grupos, siendo 4,18\u00b10,37, 4,25\u00b10,37 y 4,01\u00b10,23 g/dl (p > 0,05); \nas\u00ed como la PCR 0,40\u00b10,62, 0,31\u00b10,29 y 0,27\u00b10,13 mg/dl (p > 0,05) en pacientes con IMC < 25, IMC25-29 y IMC\u226530, \nrespectivamente.  \nEn semana 6, se analizaron 47 pacientes (66,19%). La media de concentraciones fue 10,43\u00b14,79, 9,92\u00b13,74 y 5,77\u00b14,30 \nmcg/ml, (p > 0,05) y se intensific\u00f3 la pauta en un 48,28%, 40,00% y 66,67% de los pacientes (p > 0,05), respectivamente.  \nEn semana 14, se analizaron las concentraciones en 25 pacientes (35,21%), la media fue 10,54\u00b15,00, 8,22\u00b13,64 y \n9,46\u00b11,28 mcg/ml (p > 0,05).\nCONCLUSIONES\nLos pacientes con sobrepeso/obesidad alcanzan concentraciones de ADA significativamente inferiores en semana 2 en \nrelaci\u00f3n a la poblaci\u00f3n con normopeso requiriendo intensificaci\u00f3n del tratamiento para conseguir concentraciones en \nel margen terap\u00e9utico (no influyendo, a priori, ni alb\u00famina ni PCR). La estrategia proactiva de monitorizaci\u00f3n de ADA \ndurante la inducci\u00f3n permite conseguir concentraciones dentro del margen terap\u00e9utico de forma temprana (en las \nsemanas 6 y 14), independientemente del IMC.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1101. GENOTIPADO DPYD COMO GU\u00cdA PARA LA DOSIFICACI\u00d3N INDIVIDUALIZADA DE \nFLUOROPIRIMIDINAS EN PACIENTES ONCOL\u00d3GICOS. \nAUTORES\nRUIZ EL JERCHE, S; VIUDEZ MART\u00cdNEZ, A; RAM\u00cdREZ L\u00d3PEZ, AM; ESPADAS GARC\u00cdA, I; \u00c1LVAREZ N\u00da\u00d1EZ, L; D\u00cdAZ \nGONZ\u00c1LEZ, M; SELVA OTAOLAURRUCHI, J; BURGOS SAN JOS\u00c9, A\nHOSPITAL GENERAL UNIVERSITARIO DE ALICANTE \ufffd AV\ufffd PINTOR BAEZA, 12 ALICANTE/ALACANT \ufffd ALICANTE\nOBJETIVOS\nDeterminar el porcentaje de pacientes candidatos a tratamiento con fluoropirimidinas en los que se realiz\u00f3 genotipado \nde DPYD de forma previa al inicio del tratamiento. Describir la presencia de 4 polimorfismos gen\u00e9ticos del gen DPYD \n(DPYD*2A, DPYD*13, c.2846A > T, c.1236G > A ) en la poblaci\u00f3n estudiada.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo en el cual se incluyeron todos los pacientes oncol\u00f3gicos que iniciaron tratamiento \nde novo con fluoropirimidinas desde el 25 mayo 2021 hasta el 2 mayo 2022. Las variables recogidas fueron: sexo, edad, \ndiagn\u00f3stico, esquema terap\u00e9utico, indicaci\u00f3n, solicitud farmacog\u00e9netica, recomendaci\u00f3n de ajuste de dosis. Programas \nutilizados: FARMIS 3.0.11.40, Orion Cl\u00ednic 13.\nRESULTADOS\nEl n\u00famero de pacientes incluidos fue de 98. El porcentaje de hombres y mujeres fue de un 55%/45% respectivamente. \nLa mediana de edad de los pacientes fue de 66 a\u00f1os, rango de [34-85]. De ellos se realiz\u00f3 el genotipado de DPYD en \n77 pacientes (79%). La distribuci\u00f3n por diagn\u00f3sticos fue la siguiente: c\u00e1ncer colorrectal 66% (65), c\u00e1ncer de p\u00e1ncreas \n15% (15), c\u00e1ncer de est\u00f3mago 8% (8), c\u00e1ncer de es\u00f3fago 4% (4), c\u00e1ncer peritoneal 2% (2), c\u00e1ncer suprarrenal 1% (1), \nc\u00e1ncer duodeno 1% (1). Pacientes con diagn\u00f3stico sincr\u00f3nico de colon-p\u00e1ncreas 1% (1) y c\u00e1ncer gastroesof\u00e1gico 1% \n(1). Las fluoropirimidinas se utilizaron con indicaci\u00f3n adyuvante en 36 pacientes (37%), neoadyuvante en 25 (26%) y \nmetast\u00e1sica en 37 (38%). De todos ellos, se determin\u00f3 en 2 de los pacientes la existencia de mutaciones en el gen DPYD: \nun paciente portador en un alelo de la variante c.1236G > A y un paciente portador en un alelo de la variante c.2846A > \nT. Ambas variantes corresponden a un genotipo con funci\u00f3n reducida de la actividad de la enzima. En base al genotipo \nde estos pacientes, se aplic\u00f3 una escala de puntuaci\u00f3n (score) cuya suma representa la actividad total de la enzima que 306presentaba el paciente. Seg\u00fan este resultado los dos pacientes fueron asignados a un fenotipo metabolizador intermedio \ncon su consecuente riesgo de toxicidad grave o mortal. El manejo de estos pacientes se bas\u00f3 en iniciar con una dosis \ninicial al 50% de la dosis est\u00e1ndar de ficha t\u00e9cnica e incrementar gradualmente en siguientes ciclos si buena tolerancia o \ntolerancia aceptable. Actualmente, ambos pacientes se encuentran con dosis de fluoropirimidinas de un 75% y un 80% \nrespecto a la total y con buena tolerancia al tratamiento\ufffd\nCONCLUSIONES\nEn nuestro periodo de estudio, la prevalencia de dichas variantes al\u00e9licas en el gen correspondi\u00f3 a un grupo minoritario \nde la poblaci\u00f3n (2%). En la bibliograf\u00eda se hace referencia a que un 3-5% de la poblaci\u00f3n cauc\u00e1sica presenta una \ndeficiencia parcial en la actividad de la enzima.  \nA pesar de la poca prevalencia en la poblaci\u00f3n, la determinaci\u00f3n farmacogen\u00e9tica y el ajuste de dosis de las \nfluoropirimidinas en base a su fenotipo metabolizador podr\u00eda ayudarnos a prevenir la aparici\u00f3n de toxicidad \npotencialmente grave o mortal y mejorar la calidad de vida de estos pacientes.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1106. MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE LAMOTRIGINA Y LEVETIRACETAM EN MUJERES \nEMBARAZADAS \nAUTORES\nESTEVE L\u00d3PEZ, V; PUPL\u00c1 BARTOLL, \u00c1; BELL\u00c9S MEDALL, MD; GARC\u00cdA MU\u00d1OZ, S; MARIN DELGADO, D; BOS\u00d3 RIBELLES, \nV; JIM\u00c9NEZ SIERRA, JJ; FERRANDO PIQUERES, R\nHOSPITAL GENERAL DE CASTELL\u00d3 \ufffd AV\ufffd BENICASIM, S/N CASTELL\u00d3N DE LA PLANA/CASTELL\u00d3 DE LA PLANA \ufffd CASTELL\u00d3N\nOBJETIVOS\nEvaluar la utilidad de la monitorizaci\u00f3n farmacocin\u00e9tica (TDM) de los f\u00e1rmacos antiepil\u00e9pticos (FAE) de 2\u00aa generaci\u00f3n, \nlamotrigina (LTG) y levetiracetam (LEV) en mujeres gestantes.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo desde enero de 2019 hasta enero de 2022. Los criterios de inclusi\u00f3n fueron mujeres \nembarazadas diagnosticadas de epilepsia en tratamiento con LTG y LEV en monoterapia o biterapia, monitorizadas \ndurante el embarazo. Las concentraciones plasm\u00e1ticas de los FAEs fueron determinadas previo a la dosis (Cmin) y \nse analizaron mediante la t\u00e9cnica de enzimoinmunoensayo. No se incluyeron las determinaciones con sospecha de \nincumplimiento\ufffd  \nLa variable principal para el c\u00e1lculo de la eliminaci\u00f3n del f\u00e1rmaco fue el aclaramiento aparente (Clp/F) de cada FAE, como \ncociente entre dosis diaria (mg/d\u00eda) y Cmin (mg/L), se expres\u00f3 con la media acompa\u00f1ada de su desviaci\u00f3n est\u00e1ndar. Este \npar\u00e1metro se calcul\u00f3, para cada paciente en cada trimestre (T1, T2 y T3), antes (PRE) y despu\u00e9s del embarazo (POST). \nLos resultados obtenidos forman parte de una poblaci\u00f3n normal seg\u00fan el test de Saphiro-Wilk. Las variables secundarias \nfueron la variabilidad interindividual, expresada con el coeficiente de variaci\u00f3n (CV%), y el grado de aceptaci\u00f3n del \ninforme farmacocin\u00e9tico.\nRESULTADOS\nUn total de 57 muestras fueron analizadas en 12 pacientes con un ratio de 4.75 determinaciones por paciente. De estas, \n8 pacientes estaban en tratamiento con LGT y 4 con LEV \ufffd El 25% de las pacientes estaban con biterapia de LTG y LEV \ufffd En \nPRE el Clp/F fue 104.7 \u00b1 57.4 L/24h para LTG, y 106.7 \u00b1 46.5 L/24h para LEV. En T1 el Clp/F fue 270 \u00b1 170 L/24h para LTG, \ncon incremento de Clp/F > 250%, y 157.1 \u00b1 72.4 L/24h para LEV, con incremento de Clp/F > 140%. En T2 el Clp/F fue 435.5 \n\u00b1 286.7 L/24h para LTG, con incremento de Clp/F > 400%, y 249.3 \u00b1 124.1 L/24h para LEV, con incremento de Clp/F > \n230%. En T3 el Clp/F fue 370 \u00b1 185 L/24h para LTG, con incremento de Clp/F > 350%, y 243 \u00b1 121.3 L/24h para LEV, con \nincremento de Clp/F > 220%. En POST, el Clp/F fue 108.9 \u00b1 18.1 L/24h para LTG, y 101.5 \u00b1 12.5 L/24h para LEV, teniendo \nun Clp/F similar al PRE\ufffd La variabilidad interindividual para la LTG en PRE fue 42%, en T1 del 52%, en T2 del 72%, en T3 \ndel 48% y en POST del 28%\ufffd En cuanto a la variabilidad interindividual de LEV, en PRE fue 49%, en T1 del 34%, en T2 del \n39%, en T3 del 39% y en POST del 12%.El grado de aceptaci\u00f3n del informe farmacocin\u00e9tico fue 75%. Una paciente en \nmonoterapia con LTG sufri\u00f3 una crisis epil\u00e9ptica en T2, con un Cl/F de 808,1 L/24h, 1.85 veces superior a la media.\nCONCLUSIONES\nSeg\u00fan los resultados obtenidos, el Clp/F de LTG y LEV se ve incrementado en todos los trimestres del embarazo. \nAdem\u00e1s, se ha observado una elevada variabilidad interindividual, siendo mayor en la LTG durante T2. En este sentido, \nla individualizaci\u00f3n posol\u00f3gica mediante TDM es imprescindible en antiepil\u00e9pticos durante el embarazo. Se recomienda \nrealizar TDM al menos una vez en cada trimestre e inmediatamente tras el parto.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1117. ALTO RIESGO DE TOXICITAT HEMATOL\u00d3GICA EN PACIENTES CON SOBREEXPOSICI\u00d3N PLASM\u00c1TICA \nA LINEZOLID \nAUTORES\nARDERIU FORMENTI, A; PARERA PASCUAL, MM; LUQUE PARDOS, S; SORL\u00cd RED\u00d3, ML; HORCAJADA GALLEGO, JP; \nMONTERO , MM; MIEDES ALIAGA, J; GRAU CERRATO, S\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA307OBJETIVOS\nLa toxicidad m\u00e1s frecuente de linezolid es hematol\u00f3gica (TH) y se ha asociado a una exposici\u00f3n plasm\u00e1tica elevada. Los \nobjetivos fueron describir la prevalencia de TH al final del tratamiento en una cohorte de pacientes con niveles elevados y \nevaluar qu\u00e9 variable de exposici\u00f3n plasm\u00e1tica (Cmin,ss o AUC24h) predice mejor su aparici\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital terciario entre febrero 2013-marzo 2022 en una cohorte de pacientes \ncon niveles plasm\u00e1ticos elevados (Cmin,ss > 8 mg/L) dentro de un programa de TDM.  \nVariables recogidas: demogr\u00e1ficas, cl\u00ednicas, microbiol\u00f3gicas, farmacocin\u00e9ticas (PK) y TH. \nMuestras TDM: antes de la dosis (Cmin,ss) y 2h post-administraci\u00f3n a partir del 3r d\u00eda de tratamiento analizadas por \nHPLC. El AUC12h se estim\u00f3 mediante la ecuaci\u00f3n de Srinivas et al.  \nLa trombocitopenia se defini\u00f3 como reducci\u00f3n > 25% recuento plaquetas (RP) respecto al basal y/o como un RP al final \ndel tratamiento < 100.000 cel/ml y la anemia como disminuci\u00f3n de 2 puntos de Hb con respecto al basal sin otra causa \nque justificara el descenso.  \nAn\u00e1lisis estad\u00edstico: datos cualitativos como frecuencias (%) y cuantitativos como media (desviaci\u00f3n est\u00e1ndar). \nCorrelaciones entre variables cuantitativas: rho de Spearman y la capacidad predictiva de Cmin,ss y AUC24h en la \naparici\u00f3n de TH mediante curvas ROC\ufffd\nRESULTADOS\nSe monitorizaron 724 pacientes: 117(16,2%) presentaron niveles elevados. Datos demogr\u00e1ficos y cl\u00ednicos basales: \n72(61,5%) hombres, edad 69,5(12,0) a\u00f1os, 65(55,5%) cr\u00edticos; peso 72,4(16,9) kg, 27(23,1%) obesos; 83(70,9%) con \ninsuficiencia renal(IR), siendo en 36(43,4%) aguda; creatinina s\u00e9rica 2,3(2,0) mg/dL, filtrado glomerular estimado \n(CKDEPI) 48,9(35,9) ml/min/1,73m2, insuficiencia hep\u00e1tica 21(17,9%).  \nDatos de linezolid: terapia dirigida en 87(74,4%) pacientes, infecciones intraabdominales 33(28,2%) y respiratorias \n32(27,4%); microorganismos m\u00e1s prevalentes E.faecium 35(40,0%), SARM 17(19,5%) y S.epidermidis 12(13,8%); d\u00edas de \ntratamiento 11,6(10,0); 108(92,8%) con dosis inicial de 600 mg/12h y 9(7,7%) de 600 mg/8h.  \nDatos PK: Cmin,ss: 18,0(9,6)mg/L, AUC24h de 657,9(309,1)mg*h/L; 97(82,9%) con AUC24h > 400mg*h/L.  \nToxicidad: 73(62,4%) presentaron TH: 63,1% trombocitopenia, 23,9% anemia y 15,4% ambas.  \nSe observ\u00f3 una correlaci\u00f3n significativa negativa entre Cmin,ss y AUC24h con el RP final (ambas con una Rho Spearman \nde -0,260: p < 0,006), pero no as\u00ed con el valor final de Hb.  \nLa Cmin,ss y el AUC24h no fueron predictores de la aparici\u00f3n de anemia pero si de trombocitopenia (AUC curva ROC \n0,620(0,514-0,725), p=0,036 y de 0,620(0,515-0,726), p=0,035, par a Cmin,ss y AUC24h, respectivamente). Los puntos \nde corte con mejor sensibilidad y especificidad fueron una Cmin,ss > 15mg/L y AUC24h > 550mg*h/L. La mortalidad \nhospitalaria fue de 52(44,4%).\nCONCLUSIONES\nEl perfil de paciente con niveles elevados de linezolid presenta edad avanzada y IR basal.  \nM\u00e1s del 60 % de pacientes con sobreexposici\u00f3n presentaron toxicidad hematol\u00f3gica (siendo la trombocitopenia muchos \nm\u00e1s prevalente que la anemia), una frecuencia muchos m\u00e1s elevada a la descrita habitualmente  \nTanto la Cmin,ss como el AUC24h permiten predecir la trombocitopenia al final del tratamiento, hecho que sugiere que la \nmonitorizaci\u00f3n del valle es suficiente para evitar la aparici\u00f3n de TH.  \nEl TDM de linezolid con el fin de evitar a sobreexposici\u00f3n es esencial en pacientes ancianos con IR.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1156. MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE CONCENTRACIONES DE GENTAMICINA Y MEROPENEM \nEN L\u00cdQUIDO CEFALORRAQU\u00cdDEO EN UN PACIENTE PEDI\u00c1TRICO \nAUTORES\nWILHELMI ROCA, E; VILLARONGA FLAQU\u00c9, M; PIERAS L\u00d3PEZ, \u00c1; L\u00d3PEZ RAMOS, MG; FONT I BARCEL\u00d3, A; CASALD\u00c0LIGA \nTORRECILLAS, A; VELASCO ARNAIZ, E; FARR\u00c9 RIBA, R\nHOSPITAL DE SANT JOAN DE D\u00c8U. PASSEIG SANT JOAN DE D\u00c9U, 2 ESPLUGUES DE LLOBREGAT . BARCELONA\nOBJETIVOS\nDescribir el an\u00e1lisis de concentraciones de gentamicina y meropenem en l\u00edquido cefalorraqu\u00eddeo (LCR) de un paciente \npedi\u00e1trico con diagn\u00f3stico de ventriculitis por Klebsiella aerogenes.\nMATERIALES Y M\u00c9TODOS\nPaciente var\u00f3n de 12 a\u00f1os (47 kg, 157 cm) ingresado en unidad de cuidados intensivos pedi\u00e1tricos tras resecci\u00f3n parcial \nde un tumor de fosa posterior y colocaci\u00f3n de drenaje ventricular externo (DVE) por hidrocefalia secundaria, que a \nlos 10 d\u00edas presenta cl\u00ednica de hipertensi\u00f3n intracraneal y fiebre. Se extrae muestra de l\u00edquido cefalorraqu\u00eddeo (LCR) \nsugestiva de infecci\u00f3n bacteriana y se inicia cobertura emp\u00edrica con vancomicina y meropenem en infusi\u00f3n extendida. A \nlas 24h, por crecimiento en LCR de K.aerogenes, es diagnosticado de ventriculitis aguda, suspendi\u00e9ndose vancomicina e \ninici\u00e1ndose gentamicina interventricular e intravenosa.  \nSe administr\u00f3 gentamicina por v\u00eda intraventricular empleando la presentaci\u00f3n prediluida de Gentamicina Braun\u00ae 240 \nmg/80ml exenta de parabenos, con una pauta de 7,5 mg c/24h a trav\u00e9s del DVE durante 14 d\u00edas, y c/48h los 4 restantes, \npinzando la DVE 1 hora post-administraci\u00f3n. Para intentar retener la gentamicina en el compartimento ventricular, y \nevitar el paso hacia circulaci\u00f3n sist\u00e9mica, los 3 primeros d\u00edas se administr\u00f3 gentamicina endovenosa 2,5 mg/kg/8h.  \nSe administraron 2g c/6h de meropenem en infusi\u00f3n extendida (3 h) durante 6 semanas en total.308RESULTADOS\nSe determin\u00f3 la concentraci\u00f3n de gentamicina en muestra de LCR a las 12h y 24h posteriores a la primera dosis (22.26 \nmg/L y 6.08 mg/L), estim\u00e1ndose una Kel de 0.118 h\u00af\u00b9 y una semivida de eliminaci\u00f3n (t1/2) de 5.87 h. Se realiz\u00f3 una \nestimaci\u00f3n de concentraci\u00f3n m\u00e1xima de 65mg/L, empleando un modelo poblacional no desarrollado para muestras \nde LCR (software PKs Abbott), que se consider\u00f3 adecuado por ser superior a 20 veces la CMI de gentamicina del \nmicroorganismo ( < 2mg/L), y una concentraci\u00f3n m\u00ednima no t\u00f3xica ( < 20 mg/L). Se repitieron las determinaciones \nlos d\u00edas + 4 y + 13 de tratamiento, obteniendo valores de concentraci\u00f3n m\u00ednima (Cmin) de 11.13 mg/L y 4.3 mg/L, \nrespectivamente. \nSe determin\u00f3 la concentraci\u00f3n de meropenem en LCR a las 6h de una dosis por v\u00eda endovenosa los d\u00edas +1 y + 13, \nobteniendo valores de 5.8. y 5.6 mg/L, m\u00e1s de 4 veces superiores durante todo el intervalo a la CMI de meropenem del \nmicroorganismo ( < 0.125mg/L). A los 8 d\u00edas del inicio de la terapia dirigida, se obtuvo el primer cultivo de LCR negativo, \nsiguiendo negativos todos los cultivos posteriores, con buena evoluci\u00f3n cl\u00ednica. \nEl paciente no present\u00f3 ning\u00fan efecto adverso relacionado con el tratamiento antibi\u00f3tico.\nCONCLUSIONES\nLa administraci\u00f3n intratecal de gentamicina a la dosis escogida permiti\u00f3 la obtenci\u00f3n de concentraciones eficaces y \nseguras en l\u00edquido cefalorraqu\u00eddeo.  \nLa determinaci\u00f3n de concentraciones de meropenem en l\u00edquido cefalorraqu\u00eddeo permiti\u00f3 confirmar una exposici\u00f3n \ncorrecta al f\u00e1rmaco a la dosis y estrategia de administraci\u00f3n empleadas.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1163. ESTUDIO CIN\u00c9TICO DEL VORICONAZOL EN PACIENTES CON ECMO Y ASPERGILLOSIS PULMONAR \nAUTORES\nPADULL\u00c9S ZAMORA, A; LEIVA BADOSA, E; RONDA SERRAT , M; GUMUCIO SANGUINO, VD; RIGO BONNIN, R; COBO \nSACRIST\u00c1N, S; GONZ\u00c1LEZ CABALLERO, I; FUSET CABANES, MP\nHOSPITAL UNIVERSITARI DE BELLVITGE. FEIXA LLARGA, S/N HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nOBJETIVOS\nComparar las concentraciones predosis (Cmin) de voriconazol entre pacientes con y sin soporte de oxigenaci\u00f3n \nextracorp\u00f3reo (ECMO) y determinar si, en pacientes ECMO, la dosis est\u00e1ndar de 4 mg/kg de peso actual (PA) o peso \najustado (PAj) en pacientes con \u00edndice de masa corporal (IMC) \u2265 30 Kg/m2, es suficiente para alcanzar Cmin terap\u00e9uticas.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo en paciente cr\u00edtico tratado con voriconazol sist\u00e9mico en un hospital de tercer nivel. \nGrupo no-ECMO: pacientes sin soporte ECMO (noviembre 2012-mayo 2015) observacional sin ajuste de dosis seg\u00fan \nCmin. Grupo ECMO: pacientes con soporte ECMO vena-vena (diciembre 2020-enero 2022) con individualizaci\u00f3n de \ndosis para obtener Cmin objetivo de 1-5.5 mg/L. Se describieron las variables cuantitativas seg\u00fan su mediana y rango \nintercuart\u00edlico, y las cualitativas con n\u00famero y %. La dosis de voriconazol se calcular\u00e1 por PA si IMC < 30 o PAj si IMC\u226530 \nKg/m2\ufffd\nRESULTADOS\nGrupo ECMO: se incluyeron 8 pacientes con 28 Cmin (3 mujeres (37.5%), 58 a\u00f1os [57-60], PA 83 Kg [76-90] (n=3), PAj 67 \nKg [65-78] y IMC 30.2 Kg/m2 [28.4-30.9]). En el grupo ECMO el 60.7% de las Cmin eran < 1 mg/L. Los pacientes con Cmin \ninfraterap\u00e9uticas recibieron una dosis mediana de 3.34 mg/kg/12h [2.86-4.50], y en los que alcanzaron Cmin terap\u00e9uticas \nuna dosis mediana de 6.41 mg/kg/12h [6.19-6.44]. Grupo no-ECMO: se incluyeron 15 pacientes con 15 Cmin (6 mujeres \n(40%), 57 a\u00f1os [51-72], PA 70 Kg [61.5-75], PAj 62.2 Kg [59.1-70.6] y IMC 24.9 Kg/m2 [22.3-27.8]). Ning\u00fan paciente \npresent\u00f3 Cmin infraterap\u00e9uticas y la dosis mediana fue de 4mg/Kg/12 [3.9-4.6].\nCONCLUSIONES\nLa dosis de voriconazol requerida en pacientes con ECMO es superior a la recomendada en ficha t\u00e9cnica, y debido a \nla gran variabilidad interindividual del f\u00e1rmaco, la monitorizaci\u00f3n plasm\u00e1tica es indispensable para el alcanzar niveles \nterap\u00e9uticos.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1187. EFECTIVIDAD Y SEGURIDAD DE PEMBROLIZUMAB, PEMETREXED Y PLATINO EN PRIMERA L\u00cdNEA \nEN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO NO ESCAMOSO METAST\u00c1SICO \nAUTORES\nIBA\u00d1EZ CATURLA, J; TITOS ARCOS, JC; PACHECO L\u00d3PEZ, P; CARVAJAL S\u00c1NCHEZ, M\u00c1; FRUCTUOSO GONZ\u00c1LEZ, L; \nTORRANO BELMONTE, P; HERN\u00c1NDEZ S\u00c1NCHEZ, M; GUTI\u00c9RREZ S\u00c1NCHEZ, JA\nHOSPITAL J.M. MORALES MESEGUER. AV . MARQU\u00c9S DE LOS V\u00c9LEZ, S/N. MURCIA. MURCIA\nOBJETIVOS\nEl triplete de platino, pemetrexed y pembrolizumab est\u00e1 posicion\u00e1ndose como una de las opciones m\u00e1s beneficiosas \nen el tratamiento de pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) no escamoso metast\u00e1sico sin tratamiento \nprevio y ausencia de mutaciones para EGFR o ALK. El objetivo de este estudio es describir la efectividad y la seguridad en \nvida real de pembrolizumab en combinaci\u00f3n con pemetrexed y platino en estos pacientes en nuestro centro y compararlo \ncon los resultados del ensayo pivotal KEYNOTE-189.309MATERIALES Y M\u00c9TODOS\nEstudio descriptivo observacional retrospectivo de los pacientes con CPNM no escamoso en tratamiento con \npembrolizumab en combinaci\u00f3n con pemetrexed y platino en primera l\u00ednea desde enero de 2018 hasta abril de 2022. \nSe recogieron datos demogr\u00e1ficos (sexo, edad, y h\u00e1bito tab\u00e1quico), cl\u00ednicos (ECOG, histolog\u00eda, presencia de met\u00e1stasis \ncerebrales, mutaciones relevantes, puntuaci\u00f3n positiva combinada CPS de PDL-1) y relacionados con el tratamiento \n(respuesta, supervivencia libre de progresi\u00f3n (SLP), supervivencia global (SG), reacciones adversas (RA) y grado seg\u00fan \nCTCAE (Common Terminology Criteria for Adverse Event), einterrupci\u00f3n del tratamiento). Para la recogida de datos se \nutiliz\u00f3 el aplicativo Farmis-_Oncofarm\u00ae y la historia cl\u00ednica electr\u00f3nica Selene\u00ae, y para el trato estad\u00edstico Microsoft Excel y \nIBM SPSS\u00ae\ufffd\nRESULTADOS\nSe incluyeron 46 pacientes, 38 varones (83%), con una mediana de edad de 64 a\u00f1os (rango 39-77). El estado funcional \nECOG inicial fue de 0 en 13 pacientes (28%), 1 en 30 (65%) y 2 en 3 (6.5%). En cuanto al h\u00e1bito tab\u00e1quico, el 93% eran \nfumadores activos o exfumadores, presentando una mediana de consumo de 50 paquetes/a\u00f1o. 6 pacientes (13%) \npresentaban met\u00e1stasis cerebrales al momento del diagn\u00f3stico. La mayor\u00eda de los pacientes presentaban histolog\u00eda de \nadenocarcinoma (87%) siendo 5 en pacientes indeterminada (11%) y 1 de tipo mixto (2%). El CPS de PDL-1 fue menor de \n1 en un 60% y entre 1-50 en el resto de los pacientes.  \nLa mediana de seguimiento en el momento del estudio fue de 17,7 meses\ufffd En cuanto a tasas de respuesta, se detect\u00f3 \nen la primera revaluaci\u00f3n tras 3-6 ciclos respuesta al tratamiento (completa, muy buena respuesta parcial o respuesta \nparcial) en un 57% (24 pacientes), enfermedad estable 19% (8 pacientes) y progresi\u00f3n de la enfermedad en un 24% (10 \npacientes).  \nLa mediana de SLP fue 9,4 meses (rango 0.5-19.9) y la tasa estimada de SG a los 12 meses fue de un 60%, con una \nmediana de SG de 15,3 meses (rango 0.5-31).  \nSe objetiv\u00f3 RA de cualquier grado en 89% de los pacientes (G1 37%, G2 33%, G3 17%, G4 2%). Las m\u00e1s comunes fueron \nlas gastrointestinales (67%), seguidas de astenia (63%), dermatol\u00f3gicas (43%), hematol\u00f3gicas (24%), infecciones (15%), \nneurotoxicidad (15%), endocrinas (13%), hepatotoxicidad (13%) y pulmonares (7%).En 5 pacientes obligaron a la \nsuspensi\u00f3n definitiva del tratamiento (2 neumonitis, 2 hepatitis, 1 miopericarditis).\nCONCLUSIONES\nLos resultados concuerdan con los descritos en el ensayo KEYNOTE-189, encontr\u00e1ndose una mediana de SLP ligeramente \nsuperior (9.4 vs 8.8), una tasa de SG inferior (60% vs 69%) y una tolerancia aceptable con una incidencia de RA G3-4 \nmenor (20% vs 69%) en nuestros pacientes.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1192. FARMACOGEN\u00c9TICA DEL SIPONIMOD: IMPLEMENTACI\u00d3N DE RECOMENDACIONES \nINDIVIDUALIZADAS DE TRATAMIENTO CON SIPONIMOD BASADAS EN EL GENOTIPO CYP2C9 \nAUTORES\nNIETO S\u00c1NCHEZ, MT; MARTINEZ P\u00c9REZ, M; MOR\u00d3N ROMERO, R; D\u00cdAZ VILLAMAR\u00cdN, X; CABEZA BARRERA, J\nHOSPITAL SAN CECILIO \ufffd AV\ufffd DEL DOCTOR OLORIZ, 16 GRANADA \ufffd GRANADA\nOBJETIVOS\nSiponimod es el primer tratamiento indicado para pacientes adultos con esclerosis m\u00faltiple secundaria progresiva \n(EMSP). Los alelos CYP2C9*2 (430C > T; rs1799853) y el CYP2C9*3 (1075A > C; rs1057910), sin funci\u00f3n, se han relacionado \nsignificativamente con un menor metabolismo de siponimod por la enzima CYP2C9. La ficha t\u00e9cnica del medicamento \naprobada por la FDA y la EMA para este f\u00e1rmaco exigen que se analice a los pacientes para detectar el genotipo CYP2C9 \nantes de comenzar el tratamiento.  \nObjetivo: \nEl objetivo de este estudio es presentar la experiencia de implementaci\u00f3n de las recomendaciones terap\u00e9uticas \nbasadas en el genotipado de siponimod en un Servicio de Farmacia seg\u00fan las gu\u00edas cl\u00ednicas del grupo de trabajo de \nFarmacogen\u00e9tica Holandes (DPWG)\nMATERIALES Y M\u00c9TODOS\nRealizamos un an\u00e1lisis retrospectivo de todas las solicitudes en nuestro primer a\u00f1o de experiencia. Cada vez que a un \npaciente se le diagnostica EMSP y se le prescriba siponimod en nuestro hospital, los m\u00e9dicos pueden comunicarse con \nla unidad de Farmacogen\u00e9tica (PGx) realizando una solicitud electr\u00f3nica. Los pacientes reciben una cita para visitar la \nunidad de PGx dentro de las 24 horas posteriores a la prescripci\u00f3n del medicamento. Una vez que la unidad de PGx recibe \nal paciente, se le informa sobre la necesidad y utilidad del genotipado CYP2C9 antes de iniciar el tratamiento, y se les pide \nque firmen el consentimiento informado para las pruebas gen\u00e9ticas. Posteriormente una enfermera toma una muestra \nde saliva con 2-4 hisopos de algod\u00f3n esterilizados. Los datos de los pacientes y los ID de los hisopos se registran en una \nbase de datos cifrada a la que solo pueden acceder los farmac\u00e9uticos de la unidad PGx responsable de la notificaci\u00f3n de \nresultados. Finalmente, la unidad PGx env\u00eda la muestra de saliva anonimizada al laboratorio, elaborando posteriormente \nun informe con los resultados\ufffd\nRESULTADOS\nDesde Mayo 2021 hasta Mayo 2022 se solicit\u00f3 el genotipado de CYP2C9 a 24 pacientes. El tiempo promedio desde la \npetici\u00f3n hasta el informe fue de 3 d\u00edas. Un paciente (4%) presento una variante CYP2C9 *2/*3, fenotipo metabolizador \nintermedio, que necesito un 50% de la dosis de mantenimeinto y se le recomend\u00f3 evitar el uso de f\u00e1rmacos inductores 310del CYP3A4 y otro (4%) present\u00f3 una variante CYP2C9 3*/3*, fenotipo metabolizador pobre, que contraindica el \ntratamiento. Cinco pacientes (21%) presentaron un genotipo CYP2C9*1/*2, fenotipo metabolizador intermedio, pero que \nno requieren ajuste de dosis seg\u00fan las gu\u00edas DPWG.  \nNuestros resultados no difieren mucho de las frecuencias esperadas en poblaci\u00f3n cauc\u00e1sica, obteniendo *1*1,*1/*2, \n*2/*2,*1/*3,*2/*3 y *3/*3 en 71%, 21%, 0%, 0%, 4% y 4% de las mues tras, respectivamente. 2 pacientes (9 %) se \nbeneficiaron de las recomendaciones de dosis de siponimod derivados de su genotipo.\nCONCLUSIONES\nLa implementaci\u00f3n de las pruebas de PGx para el tratamiento de siponimod por el Servicio de Farmacia brinda un circuito \nf\u00e1cil y c\u00f3modo dentro de la practica cl\u00ednica habitual a trav\u00e9s de la colaboraci\u00f3n multidisciplinar, aportando un informe \nfarmacoterapuetico que da valor al proceso.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1251. UTILIDAD E IMPACTO DE LA MONITORIZACI\u00d3N FARMACOCIN\u00c9TICA DE VORICONAZOL EN \nPACIENTES PEDI\u00c1TRICOS \nAUTORES\nMO\u00d1INO DOM\u00cdNGUEZ, LM; TIRADO P\u00c9REZ, MJ; MART\u00cdNEZ ESCUDERO, A; AGUADO PAREDES, A; CALLEJA \nHERN\u00c1NDEZ, M\u00c1; MERINO BOH\u00d3RQUEZ, V\nHOSPITAL VIRGEN MACARENA \ufffd AV\ufffd DOCTOR FEDRIANI, 3 SEVILLA \ufffd SEVILLA\nOBJETIVOS\nEvaluar la utilidad y el impacto de la monitorizaci\u00f3n farmacocin\u00e9tica de voriconazol en pacientes pedi\u00e1tricos y explorar la \nvariabilidad farmacocin\u00e9tica en estos pacientes.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyeron todos los pacientes pedi\u00e1tricos en tratamiento con \nvoriconazol a los que se midieron las concentraciones plasm\u00e1ticas m\u00ednimas (Cmin) en el estado estacionario de este \nf\u00e1rmaco. Para medir las Cmin se emple\u00f3 cromatograf\u00eda l\u00edquida de alta presi\u00f3n (HPLC).  \nLos pacientes recibieron dosis intravenosas (IV) de 8 mg/kg cada 12 horas (con carga de 9mg/kg/12horas el primer d\u00eda) y \n9mg/kg v\u00eda oral de voriconazol.  \nSe recogieron variables sociodemogr\u00e1ficas, cl\u00ednicas, anal\u00edticas y cultivos microbiol\u00f3gicos. Se evaluaron las alteraciones en \nfunci\u00f3n hep\u00e1tica y renal durante el periodo de tratamiento, o cualquier reacci\u00f3n adversa atribuible a voriconazol.  \nPara realizar la recomendaci\u00f3n de ajuste posol\u00f3gico se consider\u00f3 el rango terap\u00e9utico entre 1.5-5.5\u00b5g/mL.  \nPara el an\u00e1lisis estad\u00edstico se us\u00f3 el coeficiente de correlaci\u00f3n de Spearman y U de Mann Whitney para pruebas no \nparam\u00e9tricas (software SPSS\u00ae). Se consider\u00f3 estad\u00edsticamente significativo p < 0,05.\nRESULTADOS\nSe evaluaron 13 pacientes, 61,5% mujeres (edad media 9\u00b14 a\u00f1os y peso medio 29,8\u00b111 kg). Los diagn\u00f3sticos principales \nfueron neoplasias hematol\u00f3gicas (69,2%,n=9) e inmunodeficiencias primarias (15,4%,n=2).  \nEn 69,2%(n=9) pacientes el tratamiento fue emp\u00edrico mientras que en 30,8%(n=4), dirigido.  \nEl principal foco de infecci\u00f3n fue el pulm\u00f3n (69,2%,n=9). El hongo aislado mayoritariamente fue Aspergillus spp \n(23%,n=3). \n30.8%(n=4) pacientes desarrollaron reacciones adversas atribuibles a voriconazol: 23%(n=3) hepatotoxicidad y 7,7%(n=1) \nreacci\u00f3n exantem\u00e1tica. Solo en un caso se relacion\u00f3 la hepatotoxicidad con niveles elevados de voriconazol (16,76\u00b5g/\nmL).  \nEn 76,9%(n=10) pacientes se midieron los niveles proactivamente, en 15,4%(n=2) por sospecha de hepatoxicidad y en \n7,7%(n=1) por toxicidad previa.  \nSe realizaron 44 determinaciones de Cmin con una mediana de 0,91\u00b5g/mL (RIC: 0,4-2,7). La Cmin inicial estuvo entre \n1,5-5,5\u00b5g/mL en 15,4%(n=2) pacientes; en 53,8%(n=7) fue infraterap\u00e9utica (2 de ellas indetectables) y en 30,8%(n=4) \nsupraterap\u00e9utica, llevando en un caso a la discontinuaci\u00f3n del f\u00e1rmaco. Se vio gran variabilidad en las Cmin entre los \npacientes (CV: 137%). \nNo se encontr\u00f3 relaci\u00f3n entre la Cmin inicial y la edad (p=0,98) y el peso (p=0,8) de los ni\u00f1os.  \nEl 30,8%(n=4) pacientes recibieron tratamiento oral y 69,2%(n=9) IV. La mediana inicial de la Cmin de los pacientes que \nrecibieron voriconazol IV fue 1,9\u00b5g/mL (RIC: 0,88-5,57) comparado con una mediana de 0,26\u00b5g/mL (RIC: 0-2,35) en oral \n(p=0,12)  \nSe realizaron 38 recomendaciones, un 60,5%(n=23) de aumento de dosis y 10.5%(n=4) de disminuci\u00f3n. Todas fueron \naceptadas\ufffd\nCONCLUSIONES\nEn este estudio se muestra la gran variabilidad farmacocin\u00e9tica de voriconazol en ni\u00f1os. Solo el 15,4% de los pacientes \nestaba en rango cuando se realiz\u00f3 la primera medici\u00f3n de niveles, demostr\u00e1ndose la necesidad de una monitorizaci\u00f3n \nproactiva en todos los pacientes pedi\u00e1tricos que reciban tratamiento con voriconazol.  \nEl 53,8% de los pacientes estuvieron infraterap\u00e9uticos, lo que aumentaba el riesgo de ineficacia terap\u00e9utica. \nLa administraci\u00f3n oral en pacientes pedi\u00e1tricos da lugar a concentraciones m\u00e1s bajas que la intravenosa, por tanto, es \nnecesaria la monitorizaci\u00f3n en caso de terapia secuencial.  \nEl peso y la edad de nuestra cohorte no ten\u00eda relaci\u00f3n con las Cmin de voriconazol.311CLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1255. FACTORES DE RIESGO ASOCIADOS AL DESARROLLO DE ANTICUERPOS ANTI-INFLIXIMAB EN \nENFERMEDAD INFLAMATORIA INTESTINAL. \nAUTORES\nBRETONES PEDRINACI, JI; RUBIO CALVO, D; HERRERA EXP\u00d3SITO, M; CANTO MANGANA, J; MARTOS ROSA, A; CASTRO \nVIDA, MA; MARTINEZ DE LA PLATA, JE\nCOMPLEJO HOSPITALARIO DE PONIENTE. CRTA. DE ALMERIMAR, S/N EJIDO, EL. ALMER\u00cdA\nOBJETIVOS\nAnalizar mediante datos epidemiol\u00f3gicos y monitorizaci\u00f3n farmacocin\u00e9tica de infliximab los principales factores de riesgo \nasociados al desarrollo de anticuerpos anti-f\u00e1rmaco (AAF) en enfermedad inflamatoria intestinal (EII) de la poblaci\u00f3n \nlocal\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital de segundo nivel en el que se incluyeron todos los pacientes con \nmonitorizaci\u00f3n farmacocin\u00e9tica en tratamiento con infliximab (IFX) intravenoso en EII durante un a\u00f1o. Se recogieron \ndatos de la historia cl\u00ednica digital: datos demogr\u00e1ficos y cl\u00ednicos (edad, sexo), EII (Enfermedad de Chrohn o colitis \nulcerosa), niveles de IFX y de AAF de las dos \u00faltimas determinaciones, (definiendo presencia de AAF como niveles > 1ug/\nmL), prote\u00edna C reactiva (PCR) y calprotectina fecal. Variables epidemiol\u00f3gicas: obesidad (definida IMC > 30), tabaquismo, \ntratamiento con inmunomodulador (azatioprina), enfermedad activa durante el periodo de estudio,(definida por datos \nendosc\u00f3picos, calprotectina fecal > 100ug/g y PCR > 1mg/dL), pacientes sin tratamiento previo con iTNF-alfa (na\u00efve \niTNF-alfa), pacientes incumplidores de la pauta,(definido como omisi\u00f3n de alguna dosis durante el periodo de estudio) y \npacientes con infecciones activas reportadas durante el periodo de estudio.\nRESULTADOS\nMuestra: 70 pacientes (61% hombres). Mediana edad: 39,5 [17-71]. Pacientes con E. Crohn: 47 (67%). Pacientes con \ncolitis ulcerosa: 23 (33%). Pacientes con AAF 11(15,71%). Pacientes obesos: 16 (22%). Fumadores: 19(27%). Pacientes \nen tratamiento con inmunomodulador: 30 (42%). Enfermedad activa: 16 (22%). Pacientes na\u00efve iTNF-alfa: 49 (70%). \nPacientes incumplidores de pauta: 16 (22%). Pacientes con infecci\u00f3n activa: 28(40%). \nAn\u00e1lisis estad\u00edstico factores de riesgo AAF: \u03c7\u00b2 Obesidad: 0,64 (p=0,41); \u03c7\u00b2Fumadores: 5,63 (p=0,03); Odds ratio \nfumadores: 4,95 IC95% (20.06-1,22); \u03c7\u00b2 tratamiento con inmunomodulador: 5,14 (p=0,02); Odds ratio tratamiento con \ninmunomodulador: 0,11 IC95%(0,45-0,03); \u03c7\u00b2 pacientes enfermedad activa 2,52 (p=0,17); \u03c7\u00b2 na\u00efve iTNF-alfa: 11,34 \n(p=0,01); Odds ratio na\u00efve iTNF-alfa: 0,10 IC95%(0,43-0,02); \u03c7\u00b2 incumplidores de pauta: 15,75(p=0,002); Odds ratio \nincumplidores de pauta: 2,15 IC95%(42,04-3,14); \u03c7\u00b2 pacientes infecciones activas: 7,39 (p=0,009) Odds ratio infecciones \nactivas: 6,15 IC95%(21,9-1,73).\nCONCLUSIONES\nLos datos sugieren asociaci\u00f3n estad\u00edsticamente significativa de desarrollar AAF en los pacientes fumadores, incumplidores \nde pauta y los que presentaron alguna infecci\u00f3n durante el periodo de estudio. Ser paciente na\u00efve iTNF-alfa y el \ntratamiento combo con inmunomodulador se muestran como factor protector de desarrollar AAF \ufffd La obesidad y \nenfermedad activa no han mostrado asociaci\u00f3n estad\u00edsticamente significativa (p > 0,05). Conocer los factores de riesgo \nasociados al desarrollo de AAF puede ser \u00fatil para evitar el fracaso terap\u00e9utico de IFX y desarrollar la mejor estrategia \npara optimizar la terapia como: potenciar la adherencia, reducir el tabaquismo y evitar las infecciones. Sin embargo, son \nnecesarios estudios con una muestra grande para conocer mas factores de riesgo y su magnitud\ufffd\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1259. COMPARACI\u00d3N DE LOS CRITERIOS PREDICTORES DE NEFROTOXICIDAD EN PACIENTES CON \nMONITORIZACI\u00d3N PLASM\u00c1TICA DE VANCOMICINA E IDENTIFICACI\u00d3N DE FACTORES DE RIESGO \nAUTORES\nARDERIU FORMENTI, A; LUQUE PARDOS, S; SORL\u00cd RED\u00d3, ML; BENITEZ-CANO MARTINEZ, A; DE ANTONIO CUSCO, M; \nBOSCH PEREZ, C; GRAU CERRATO, S; FERRANDEZ QUIRANTE, O\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa incidencia descrita de nefrotoxicidad por vancomicina es muy variable debido a que en los estudios se han incluido \ndiferentes tipos de pacientes y utilizado distintos criterios para su evaluaci\u00f3n. De hecho, la frecuencia real de esta \ntoxicidad contin\u00faa siendo un tema muy controvertido. \n \nLos objetivos fueron evaluar la nefrotoxicidad de vancomicina en pacientes con TDM comparando comparando los \ncriterios AKIN (KDIGO) y RIFLE e identificar los factores predictores.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital terciario durante el 2022. \n \nDatos recogidos: demogr\u00e1ficos, cl\u00ednicos (creatinina s\u00e9rica y filtrado glomerular estimado (CKD-EPI) basal y final del \ntratamiento (FGe) y farmacocin\u00e9ticos (PK): Cmin,ss/valle, Css y AUC24h. \n 312PK: valle/Cmin,ss y Cmax,ss (infusi\u00f3n intermitente) o en cualquier momento (continua)(Css) en varias ocasiones. AUC24h \nestimada por m\u00e9todos Bayesianos. Se calcul\u00f3 el promedio de Cmin,ss; Css y AUC24 de todas las determinaciones (la \ninicial y tras los distintos ajustes posol\u00f3gicos).  \n \nDefiniciones: PK/PD \u00f3ptimo: AUC/CMI: 400-600 L/mg*h y potencialmente nefrot\u00f3xico: Cmin,ss > 20 mg/L, seg\u00fan la gu\u00eda, \nCss > 25 mg/L o una AUC24h > 600 L/mg*h, considerando las nuevas gu\u00edas.  \n \nEstad\u00edstica: variables categ\u00f3ricas como frecuencias (%), cuantitativas como media (desviaci\u00f3n est\u00e1ndar). An\u00e1lisis \ncomparativo mediante test de Fisher y t de Student.\nRESULTADOS\nSe incluyeron 113 pacientes en el programa de TDM: 77 (68.1%) hombres, edad: 63,5 (14,0) a\u00f1os, peso: 78,7 (18,8) kg, \nIMC: 28,5 (6,5), 45 (39,8%) obesos, 43 (38,1%) cr\u00edticos. Creatinina inicial: 0,8 (0,4) mg/dL; creatinina final: 0,8 (0,7) mg/dL, \nFGe inicial: 90,4 (21,8) ml/min/1.73m2; FGe final: 94,1 (34,7) ml/min/1.73m2, %pacientes con FGe inicial < 60 ml/min: 16 \n(14,2%), edemas/anasarca: 18 (15,9%).  \n \nDatos de vancomicina: dosis inicial: 27,9 (9.5) mg/kg; intermitente: 71 (62,8%), continua: 42 (37,2%), duraci\u00f3n: 8,9 (6,1) \nd\u00edas. Microorganismos aislados: S.epidermidis 15 (29,4%), E. faecium 12 (23,5%) y SARM 8 (15,7%).  \n \nValores PK promedio: Cmin,ss 13,6 (6,2) y Css 20,6 (5,5) mg/L, AUC24h: 501,4 (136,8) mg*h/L, AUC: 400-600 mg*h/L: 52 \n(46,0%), Cmin > 20mg/L: 9(8.0%), Css > 25 mg/L: 9 (7,9%), AUC24h > 600 mg*h/L: 20 (17,7%).  \n \nNefrotoxicidad: 13 (11,5%) pacientes: 11 (9,7%) identificados seg\u00fan AKIN (todos AKIN-1) y 12 (10,6%) seg\u00fan RIFLE (9 Risk \ny 3 Injury). En 5 (38,5%) se suspendi\u00f3 el tratamiento.  \n \nEn el an\u00e1lisis multivariado predictor de nefrotoxicidad, la edad (OR: 1,072 (1,010-1,138), p=0,022), una creatinina s\u00e9rica \nbasal > 1 mg/L (OR: 5,094 (1,380-18,807),p=0,015) se identificaron como factores de riesgo y la infusi\u00f3n continua como \nuna tendencia a ser un factor protector (OR: 0,239 (0,044-1,302), p=0,098). La mortalidad hospitalaria fue de 9(8,0%).  \n \nNi la Cmin,ss ni la AUC24h se identificaron como factores predictores de nefrotoxicidad.\nCONCLUSIONES\nLa nefrotoxicidad asociada a vancomicina en pacientes incluidos en un programa de TDM fue del 11,5%, una incidencia \ninferior a la descrita en series anteriores\ufffd \n \nSe observa una elevada concordancia en los criterios AKIN y RIFLE para identificar la nefrotoxicidad.  \n \nUna mayor edad y creatinina s\u00e9rica al inicio del tratamiento son factores de riesgo para presentar nefrotoxicidad mientras \nque la infusi\u00f3n continua podr\u00eda reducir esta toxicidad.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1302. CARACTERIZACI\u00d3N FARMACOCIN\u00c9TICA DE RITUXIMAB EN PACIENTES CON ENFERMEDADES \nGLOMERULARES \nAUTORES\nLARROSA GARC\u00cdA, M; AGRAZ PAMPLONA, I; BURY MACIAS, RP; ANGUITA DOMINGO, D; SANZ MART\u00cdNEZ, MT; \nMONTORO RONSANO, JB; GORGAS TORNER, MQ; MARTINEZ GALLO, M\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nRituximab es un anticuerpo monoclonal anti-CD20 utilizado como indicaci\u00f3n no aprobada en las enfermedades renales \ncon afectaci\u00f3n glomerular, que habitualmente cursan con proteinuria. Las dosis utilizadas son extrapoladas de otras \nenfermedades como artritis reumatoide, pero no se ha definido la pauta \u00f3ptima en esta poblaci\u00f3n, que podr\u00eda sufrir una \nexcreci\u00f3n renal aberrante\ufffd  \nEl objetivo de este estudio es caracterizar las concentraciones de rituximab en plasma en los pacientes con enfermedades \nrenales y evaluar si existe una correlaci\u00f3n entre el aclaramiento de rituximab y la proteinuria\ufffd\nMATERIALES Y M\u00c9TODOS\nSe trata de un ensayo cl\u00ednico unic\u00e9ntrico de bajo nivel de intervenci\u00f3n aprobado por la Agencia Espa\u00f1ola del \nMedicamento (NEFRTX, c\u00f3digo EUDRACT 2020-000484-23). Se incluyeron pacientes tratados con rituximab a criterio \nm\u00e9dico tras aprobaci\u00f3n por la Comisi\u00f3n de Farmacia. La pauta utilizada fue 1g cada 15 d\u00edas, con premedicaci\u00f3n y \nadministraci\u00f3n de acuerdo a los protocolos del centro\ufffd  \nSe recogieron muestras de sangre y orina de 24 horas los d\u00edas 1 (post-rituximab), 7, 15 (pre y post-rituximab), 28 y 45. Se \ndetermin\u00f3 rituximab en suero utilizando ELISA (Lisa-Traker\u00ae-Rituximab, Theraradiag\u00ae).  \nSe realiz\u00f3 el an\u00e1lisis farmacocin\u00e9tico considerando un modelo monocompartimental mediante regresi\u00f3n no lineal con \nWinnolin\u00ae para obtener aclaramiento (Cl), vida media (t1/2), concentraci\u00f3n m\u00e1xima (Cmax) y volumen de distribuci\u00f3n \n(Vd).  313Se expresan los resultados cuantitativos como media\u00b1desviaci\u00f3n est\u00e1ndar. Se utiliz\u00f3 la regresi\u00f3n lineal para establecer \ncorrelaciones\ufffd\nRESULTADOS\nSe analizaron los resultados de 5 pacientes, 2 mujeres y 3 hombres, con edad media 68,8\u00b117,02 a\u00f1os de 72 a\u00f1os y \ndiagn\u00f3stico de glomerulopat\u00eda.  \nTodos los pacientes recibieron dosis de 1g, 2 pacientes recibieron una segunda dosis el d\u00eda 15.  \nTodos los pacientes presentaron proteinuria, con una media de 11.024\u00b114.624,91 mg en orina de 24h. El Cl medio fue \n0,676\u00b10,431 ml/h/kg, el Vd 222,35\u00b1140,52 mL/Kg y la Cmax 69,66\u00b126,14 mcg/mL y t1/2 269,66\u00b1 229,71 h (11 d\u00edas \naproximadamente). \nExiste una correlaci\u00f3n entre semivida de rituximab y logaritmo de la proteinuria (p=0,077).\nCONCLUSIONES\n- Los an\u00e1lisis preliminares del ensayo cl\u00ednico indican que rituximab presenta una vida media de 11 d\u00edas en los pacientes \nanalizados afectos de glomerulopat\u00eda con proteinuria, que es inferior a los 21-28 d\u00edas de vida media descritos para este \nf\u00e1rmaco en ficha t\u00e9cnica.  \n- Existe una correlaci\u00f3n entre vida media de rituximab y proteinuria. Es necesario aumentar el n\u00famero de pacientes \nanalizados para disponer de potencia suficiente para objetivar la significaic\u00f3n estad\u00edstica de esta correlaci\u00f3n.  \n- Los pacientes con s\u00edndrome nefr\u00f3tico podr\u00edan requerir dosis m\u00e1s elevadas para asegurar la efectividad del tratamiento \ncon rituximab\ufffd\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1308. EVALUACI\u00d3N DE RESULTADOS DE LA OPTIMIZACI\u00d3N FARMACOCIN\u00c9TICA Y FARMACODIN\u00c1MICA \n(PK/PD) DE DAPTOMICINA EN LA PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nGIM\u00c9NEZ GINER, S; LLOPIS ALEMANY , A; PORTA OLTRA, B; MART\u00cdNEZ G\u00d3MEZ, MA; BRAVO CRESPO, C; RUIZ \nMART\u00cdNEZ, D; RICOY SANZ, I; CLIMENTE MARTI, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEvaluar los resultados de la monitorizaci\u00f3n farmacocin\u00e9tica y la individualizaci\u00f3n posol\u00f3gica de daptomicina en la pr\u00e1ctica \ncl\u00ednica, en base al \u00edndice farmacocin\u00e9tico/farmacodin\u00e1mico (PK/PD) objetivo establecido de efectividad y seguridad del \ntratamiento\ufffd\nMATERIALES Y M\u00c9TODOS\nDise\u00f1o: estudio observacional retrospectivo en un hospital terciario.  \nPeriodo de estudio: 04/noviembre/2019 \u2013 30/abril/2022.  \nCriterios de inclusi\u00f3n: pacientes en tratamiento con daptomicina que cumplen criterios de monitorizaci\u00f3n (\u22656mg/kg/d\u00eda, \ncr\u00edtico, insuficiencia o reemplazo renal, hipoalbuminemia, obesidad, evoluci\u00f3n cl\u00ednica no \u00f3ptima).  \nCriterio de exclusi\u00f3n: toma de muestra incompleta, extracci\u00f3n previa 2\u00aa dosis.  \nVariables: datos demogr\u00e1ficos (edad; sexo; \u00edndice masa corporal (IMC)), renales (creatinina; reemplazo renal), infecciosos \n(tipo infecci\u00f3n; microorganismo; concentraci\u00f3n m\u00ednima inhibitoria (CMI)), farmacoterap\u00e9uticos (dosis/kg; intervalo), \nrespuesta cl\u00ednica (curaci\u00f3n cl\u00ednica con/sin erradicaci\u00f3n microbiol\u00f3gica; fallo tratamiento), mortalidad-30d\u00edas, seguridad \n(creatina fosfoquinasa (CPK) > 500UI/L), y de monitorizaci\u00f3n (n\u00ba monitorizaciones/paciente; hipoalbuminemia (alb\u00famina \n< 3,5g/dL); cumplimiento objetivo PK/PD; aceptaci\u00f3n recomendaci\u00f3n).  \nAn\u00e1lisis farmacocin\u00e9tico: se analizaron las concentraciones plasm\u00e1ticas (mg/L) pre-dosis (Cmin) y 30 minutos post-\ninfusi\u00f3n (Cpost), a partir de la 3\u00aa dosis de daptomicina, por cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC). Se calcul\u00f3 el \n\u00e1rea bajo la curva (AUC;mg\u00b7h/L) y la constante de eliminaci\u00f3n (Kel;horas-1) mediante el m\u00e9todo de Sawchuk-Zaske. Se \nconsider\u00f3 como objetivo PK/PD una relaci\u00f3n estimada AUC/CMI > 600-800 mg\u00b7h/L (efectividad), limitando CMI < 1 a 1, y \nuna Cmin < 24,3 mg/L (seguridad).  \nAn\u00e1lisis estad\u00edstico con R: media\u00b1desviaci\u00f3n est\u00e1ndar o mediana [rango intercuart\u00edlico] seg\u00fan normalidad (test \nde Shapiro-Wilk) para variables cuantitativas y frecuencias (%) para variables cualitativas; test Chi-cuadrado para \ncomparaci\u00f3n de la curaci\u00f3n cl\u00ednica seg\u00fan alcance del objetivo PK/PD.\nRESULTADOS\nSe realizaron 46 monitorizaciones de daptomicina correspondientes a 23 pacientes, con 1[1-2] monitorizaciones/\npaciente. La mediana de edad fue 74[62,5-78,5] a\u00f1os, 43,5% mujeres, IMC 25,8[23,4-28,5] kg/m2 (8,7% obesidad), 95,6% \ncon hipoalbuminemia. La mediana de creatinina fue 0,8[0,7-1,1] mg/dl, 5 pacientes (21,7%) con reemplazo renal y 3 \n(13,0%) con ClCr \u226430ml/min. El diagn\u00f3stico m\u00e1s frecuente fue bacteriemia (69,6%), y el microorganismo S.epidermidis \n(43,5%). Las pautas posol\u00f3gicas utilizadas se situaban entre 6-12mg/kg, con mediana de dosis 8[7-10] mg/kg, 69,6% cada \n24h. \nSe alcanz\u00f3 la curaci\u00f3n cl\u00ednica en el 65,2% (15/23) de los pacientes, en el 53,3% con erradicaci\u00f3n microbiol\u00f3gica y se \nprodujo fallo de tratamiento en el 34,8% (8/23) de los pacientes. La mortalidad a 30 d\u00edas fue del 26,1%.  \nEn el 63,0% de informes farmacocin\u00e9ticos se recomend\u00f3 cambio posol\u00f3gico: 24 reducci\u00f3n y 5 aumento de dosis. El grado \nde aceptaci\u00f3n fue 70,8% en las reducciones y 17,2% en los aumentos\ufffd  \nLa monitorizaci\u00f3n farmacocin\u00e9tica aument\u00f3 la proporci\u00f3n de pacientes que alcanzaban el cumplimiento de objetivo \nPK/PD de efectividad (73,9% a 86,9%) y seguridad (43,5% a 52,2%). La tasa de curaci\u00f3n cl\u00ednica no fue estad\u00edsticamente 314diferente en los pacientes que alcanzaron el objetivo PK/PD de efectividad (\u03c7\u00b2=0,4;p=0,5). El 13,0% elev\u00f3 CPK, ninguno \ncon debilidad o dolor muscular asociado\ufffd\nCONCLUSIONES\nLa monitorizaci\u00f3n farmacocin\u00e9tica de daptomicina ha permitido la individualizaci\u00f3n posol\u00f3gica en el 69% de los pacientes \ncon riesgo de toxicidad o fallo terap\u00e9utico, alcanzando los objetivos PK/PD de efectividad y seguridad en el 87% y 52% de \nlos pacientes, respectivamente. Existe una mayor tendencia a aceptar las recomendaciones relacionadas con la seguridad \ndel tratamiento\ufffd\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n1311. ESTUDIO COMPARATIVO DEL MANEJO FARMACOTERAP\u00c9UTICO DE LAS FLUOROPIRIMIDINAS \nTRAS LA IMPLANTACI\u00d3N DEL GENOTIPADO DPYD EN LA PR\u00c1CTICA CL\u00cdNICA ASISTENCIAL \nAUTORES\nBRAVO CRESPO, C; POLO DUR\u00c1N, J; PORTA OLTRA, B; GIM\u00c9NEZ GINER, S; MART\u00cdNEZ ALBALADEJO, P; RICOY SANZ, I; \nMAESTU MAIQUES, I; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nEvaluar el manejo farmacoterap\u00e9utico de las fluoropirimidinas en pacientes oncol\u00f3gicos tras la implantaci\u00f3n del \ngenotipado DPYD (GenDPYD) en la pr\u00e1ctica cl\u00ednica asistencial, as\u00ed como, su impacto cl\u00ednico en la toxicidad y sus \nconsecuencias\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio de cohortes comparativo, pre-post, unic\u00e9ntrico realizado en un hospital terciario en pacientes adultos con c\u00e1ncer \nen seguimiento por el Servicio de Oncolog\u00eda M\u00e9dica y tratados con fluoropirimidinas:  \n-Grupo estudio: cohorte con GenDPYD antes de iniciar tratamiento. Periodo: diciembre 2019-febrero 2022. \n-Grupo control: cohorte retrospectiva no GenDPYD representativa y aleatorizada. Periodo: enero-noviembre 2019.  \nVariables: biom\u00e9tricas (edad, sexo, estado funcional, activity-score DPYD), relacionadas con la enfermedad (diagn\u00f3stico, \nestad\u00edo) y el tratamiento (f\u00e1rmaco \u2013capecitabina/5-fluorouracilo-, intenci\u00f3n \u2013curativa/paliativa-).  \nPara la evaluaci\u00f3n del manejo farmacoterap\u00e9utico se analiz\u00f3 la dosis inicial (%), intensidad de dosis (%), n\u00famero de \nmodificaciones de dosis, aparici\u00f3n de toxicidad grado \u22653 (seg\u00fan Common Terminology Criteria for Adverse Events \u2013\nCTCAE- v.5.0.) (gastrointestinal, hematol\u00f3gica, dermatol\u00f3gica) y sus consecuencias (reducci\u00f3n de dosis, retraso de ciclo, \ningreso hospitalario y suspensi\u00f3n de tratamiento) durante los tres primeros ciclos de quimioterapia.  \nEstad\u00edstica: variables categ\u00f3ricas [frecuencia (%); chi-cuadrado o Fisher] y cuantitativas [media (\u00b1desviaci\u00f3n est\u00e1ndar); \nprueba t-Student]. Programa: R-Commander\u00ae v.4.0.5. (p < 0,05).\nRESULTADOS\nSe incluyeron 122 pacientes: 58(47,5%) en el grupo GenDPYD, de edad 68,5(\u00b111,7) a\u00f1os; 26(44,8%) hombres, 50(86,2%) \ncon estado funcional 0-1; y 64(52,5%) en el grupo control, de edad 69,5(\u00b1 10,0) a\u00f1os; 36(56,2%) hombres, 55(85,9%) \ncon estado funci\u00f3n 0-1. La distribuci\u00f3n por activity-score DPYD fue de: 2 (metabolizador normal) en 56(96,6%), 1-1.5 \n(intermedio) en 2(3,4%) y 0-0.5 (pobre) en 0(0,0%) pacientes genotipados. La intenci\u00f3n del tratamiento fue curativa en \n39(67,2%) vs. 35(54,7%) pacientes, y recibieron capecitabina 38(65,5%) vs. 40(62,5%) pacientes del grupo GenDPYD y \ncontrol, respectivamente. \nLos resultados evaluados del grupo GenDPYD vs. control fueron: dosis inicial \u226575% [46(77,6%) vs. 46(81,2%)], intensidad \nde dosis \u226575% [26(44,8%) vs. 34(53,1%)] y modificaciones de dosis \u22651 [8(13,8%) vs. 7(14,1%)]. Presentaron toxicidad \ngrado \u22653 11(19,0%) vs. 20(31,2%) pacientes: gastrointestinal [7(14,1%)] vs. [9(12,1%)], hematol\u00f3gica [4(6,9%)] vs. \n[10(15,2%)] y dermatol\u00f3gica [0(0,0%)] vs. [3(4,7%)]. Se produjeron consecuencias en 8(13,8%) vs. 19(29,7%) pacientes (p \n< 0,034): reducci\u00f3n de dosis [2(3,4%) vs. 7(10,9%)], retraso de ciclo [5(8,6%) vs. 13(20,3%)], ingreso hospitalario [2(3,4%) \nvs. 1(1,6%)] y suspensi\u00f3n del tratamiento [1(1,7%) vs. 1(1,6%)]. \nNo se encontraron diferencias estad\u00edsticamente significativas entre grupos en dosis inicial, intensidad de dosis y toxicidad.\nCONCLUSIONES\nLa implantaci\u00f3n del GenDPYD antes de iniciar tratamiento con fluoropirimidinas en la pr\u00e1ctica cl\u00ednica asistencial \nha permitido identificar un 3,4% de pacientes con riesgo de toxicidad severa. Sin embargo, no ha modificado \nsignificativamente el manejo farmacoterap\u00e9utico de las fluoropirimidinas en pacientes oncol\u00f3gicos. Al menos un 20% de \nlos pacientes reciben dosis iniciales inferiores al 75% de la dosis establecida en el esquema antineopl\u00e1sico. Esto evidencia \nla oportunidad de intensificar la exposici\u00f3n a fluoropirimidinas en los pacientes sin riesgo de toxicidad por d\u00e9ficit de la \nactividad DPYD, con especial inter\u00e9s en aquellos candidatos a recibir tratamiento con fluoropirimidinas con intenci\u00f3n \ncurativa. \nPor otro lado, los resultados obtenidos orientan a una menor proporci\u00f3n de toxicidad grado \u22653 , de retrasos de ciclo y de \nreducciones de dosis en el grupo GenDPYD \ufffd315CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n45. INTENSIDAD DE DOSIS DE PALBOCICLIB EN PACIENTES CON C\u00c1NCER DE MAMA METAST\u00c1SICO: 328 \nPACIENTES TRATADOS EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL \nAUTORES\nFORT CASAMARTINA, E; OTERO TORRES, S; PERNAS , S; LEZCANO RUBIO, C; SABAT\u00c9 FR\u00cdAS, N; BLEDA PEREZ, C; \nDELGADO MORILLO, O; FONTANALS MARTINEZ, S\nHOSPITAL DURAN Y REYNALS (INSTUTO CATALAN DE ONCOLOGIA)\nOBJETIVOS\nEl objetivo principal del estudio es cuantificar la intensidad de dosis real administrada de palbociclib en pacientes \ncon c\u00e1ncer de mama metast\u00e1sico RE+/HER2-negativo. Los objetivos secundarios son determinar si existen diferencias \nsignificativas en la intensidad de dosis recibida entre pacientes de edad mayor o menor de 75 a\u00f1os, as\u00ed como con la \ndosificaci\u00f3n inicial en mg/Kg.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, multic\u00e9ntrico en una instituci\u00f3n monogr\u00e1fica de c\u00e1ncer con 3 centros, en pacientes con c\u00e1ncer \nde mama met\u00e1stasico que iniciaron palbociclib como 1\u00aa o 2\u00aa linea de tratamiento entre Enero de 2018 \u2013 Octubre de \n2021. Se recogieron datos demogr\u00e1ficos (edad, peso y sexo) y del tratamiento con palbociclib del aplicativo digital de \nprescripci\u00f3n de quimioterapia. La intensidad de dosis (%) se define como la proporci\u00f3n de la dosis real (mg) recibida \nrespecto a la dosis total te\u00f3rica desde el inicio hasta la suspensi\u00f3n del tratamiento o fin de seguimiento. Para su c\u00e1lculo se \nrevis\u00f3 el registro de las dispensaciones/devoluciones de medicaci\u00f3n contrast\u00e1ndolo con la situaci\u00f3n ideal sin reducciones \nde dosis por toxicidad (es decir, 125mg c/21dias x ciclos de 28 d\u00edas). La comparaci\u00f3n entre grupos se analiz\u00f3 mediante la \nprueba param\u00e9trica T de Student no pareada para variables continuas.\nRESULTADOS\nSe incluyeron un total de 328 pacientes (324 mujeres y 4 hombres) que iniciaron tratamiento con palbociclib, con una \nmedia de edad de 64,2 a\u00f1os (29,7 \u2013 91,1) y 67,1Kg de peso medio (39 \u2013 132). El 76,5% de las pacien tes ten\u00edan menos \nde 75 a\u00f1os, con un peso medio inicial de 67Kg sin diferencias significativas entre ambos grupos de edad (P=0.771). El \n94,5% de las pacientes iniciaron tratamiento a dosis de 125 mg, con una dosificaci\u00f3n incial media de palbociclib por Kg \nde peso de 1,91mg/Kg (0,91 \u2013 3,2). La intensidad de dosis media realmente administrada durante todo el tratamiento \nfue del 83,4% (11,5% - 104,1%), y en 72 pacientes (21,9%) \u00e9sta fue inferior al 70% de la planificada inicialmente. No se \ndetectaron diferencias estad\u00edsticamente significativas en la intensidad de dosis entre pacientes menores y mayores de 75 \na\u00f1os (84,35% vs 80,4%;p=0.066) ni entre pacientes con dosificaci\u00f3n inicial inferior y superior a 1,91mg/Kg de peso (83,7% \nvs 83,1%; p=0.728). La duraci\u00f3n media del tratamiento fue de 404 d\u00edas (28 \u2013 1386) sin diferencias estad\u00edsticamente \nsignificativas entre las pacientes menores y mayores de 75 a\u00f1os (416 vs 363,7 d\u00edas; p=0.237).\nCONCLUSIONES\nLa toxicidad asociada a palbociclib obliga a disminuir la dosis en la pr\u00e1ctica cl\u00ednica diaria e implica una reducci\u00f3n de la \nintensidad de dosis administrada en nuestra poblaci\u00f3n. Palbociclib es un tratamiento que se utiliza a dosis fijas y no se \ndetectaron diferencias estad\u00edsticamente significativas entre la intensidad de dosis y el peso ni la edad. Son necesarios m\u00e1s \nestudios para cuantificar el impacto de estas reducciones de dosis en cuanto a eficacia, y un an\u00e1lisis multivariante para \ndeterminar los factores predictivos independientes que podr\u00edan estar asociados a una toxicidad temprana y que obligaran \na disminuir la dosis de palbociclib\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n61. EFICACIA Y SEGURIDAD DE IMATINIB EN ENFERMEDAD DE INJERTO CONTRA RECEPTOR \nAUTORES\nCUADROS MART\u00cdNEZ, CM; S\u00c1NCHEZ-MATAMOROS PIAZZA, MDV; MORALES GARC\u00cdA, \u00c1; L\u00d3PEZ MU\u00d1OZ, MJ\nHOSPITAL DE ESPECIALIDADES DE JEREZ DE LA FRONTERA. CTRA. DE CIRCUNVALACION, S/N JEREZ DE LA FRONTERA. \nC\u00c1DIZ\nOBJETIVOS\nEvaluar la eficacia y seguridad de Imatinib en pacientes con Enfermedad de Injerto Contra Receptor (EICR).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluye a todos los pacientes tratados con Imatinib para EICR hasta 30/04/22. \nPor medio de revisi\u00f3n de la Historia Cl\u00ednica y los registros de dispensaci\u00f3n se obtienen los siguientes datos: edad, sexo, \ntipo de TPH, tipo de EICR, tratamientos previos para EICR, tiempo hasta respuesta, respuesta total o parcial a Imatinib, \npresencia de eventos adversos (EA) y duraci\u00f3n del tratamiento con Imatinib.\nRESULTADOS\nReclutamos 7 pacientes, 5 hombres y 2 mujeres, con una edad media de 47.28 a\u00f1os [24-71 a\u00f1os]. Todos fueron \nreceptores de TPH alog\u00e9nico de Donante No Emparentado (DNE). El 100% de los pacientes desarrollaron EICR cr\u00f3nico \n(EICRc) cut\u00e1neo-mucoso, uno de ellos EICR hep\u00e1tico y otro pulmonar. Entre los tratamientos previos encontramos: \nsirolimus (71.43%), micofenolato de mofetilo (100%), pasta de triamcinolona (71.43%), metilprednisolona t\u00f3pica 316(71,43%), corticoides orales (71,43%), ciclosporina (14,28%), c\u00e9lulas mesenquimales (14.28%), rituximab (14.28%), \nfotoaf\u00e9resis (42,86%) y tacrolimus (28.57%). 1 paciente present\u00f3 respuesta a Imatinib en 1 semana; 2 pacientes en 2 \nsemanas; y el resto en 1 mes\ufffd El 71\ufffd43% de los pacientes presentan respuesta total, el resto parcial, siendo la mediana \nde tiempo de tratamiento 18 meses [10-57 meses]. 71.43% sufrieron EA: 3 pacientes de tipo gastrointestinal (nauseas, \ndiarrea, dispepsia y dolor abdominal), 2 trastornos oculares (edema palpebral, catarata y hemorragia conjuntival) y 1 \npaciente present\u00f3 cefaleas. Solo se tuvo que suspender el f\u00e1rmaco en 1 paciente por EA, otro lo abandon\u00f3 por decisi\u00f3n \npropia y el resto contin\u00faa en tratamiento a excepci\u00f3n de 1 \u00e9xitus (motivo de la muerte sin relaci\u00f3n con TPH).\nCONCLUSIONES\nImatinib constituye una alternativa eficaz en el tratamiento de EICR cr\u00f3nico y agudo refractario a otras l\u00edneas de \ntratamiento, sin embargo, numerosos pacientes desarrollan EA, de ah\u00ed que haya que valorar de forma individualizada la \nrelaci\u00f3n beneficio/riesgo del f\u00e1rmaco en esta patolog\u00eda.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n64. EFECTIVIDAD Y SEGURIDAD DE OSIMERTINIB EN PRIMERA Y SEGUNDA L\u00cdNEA EN PACIENTES \nDIAGNOTICADOS DE C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO EGFR+ \nAUTORES\nBOILLOS FERN\u00c1NDEZ, M; PERALTA ALVAREZ, J; TENA MESTRE, S; DE RIBA SOLER, M; BALSELLS VIVES, S; G\u00d3MEZ \nP\u00c9REZ, B; AMOROS REBOREDO, P; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nOsimertinib fue el primer inhibidor de la tirosina quinasa del receptor del factor de crecimiento epid\u00e9rmico (EGFR) de \ntercera generaci\u00f3n en recibir la aprobaci\u00f3n para pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (NSCLC) con mutaci\u00f3n \nde EGFR metast\u00e1sico que han adquirido la mutaci\u00f3n de resistencia EGFR T790M. Los ensayos cl\u00ednicos han demostrado la \neficacia de osimertinib en esta poblaci\u00f3n de pacientes pero los datos en pr\u00e1ctica cl\u00ednica real son a\u00fan limitados.  \nEl objetivo de este trabajo fue revisar la efectividad y seguridad de osimertinib en pacientes que presentaban c\u00e1ncer de \npulm\u00f3n no microc\u00edtico (CPMN) y mutaci\u00f3n en EGFR.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo sobre una cohorte de pacientes diagnosticados de CPNM con mutaci\u00f3n de EGFR, \ny con prescripci\u00f3n m\u00e9dica de Osimertinib v\u00eda oral en primera o sucesivas l\u00edneas de tratamiento, desde enero de 2017 \na junio de 2020, en un hospital universitario de tercer nivel. Para evaluar la efectividad del tratamiento se calcul\u00f3 la \nsupervivencia libre de progresi\u00f3n (SLP) y la supervivencia global (SG). Para evaluar la seguridad se registraron los efectos \nadversos y gravedad de los mismos. Para analizar la SLP se aplic\u00f3 el m\u00e9todo de Kaplan-Meier y para la SG a los 18 meses \nse revisaron los pacientes desde inicio del tratamiento con osimertinib. Los efectos adversos se registraron siguiendo los \nCriterios de Terminolog\u00eda Com\u00fan para Acontecimientos Adversos del National Cancer Institute (NCI-CTCAE v.5).  \nSe recogieron las siguientes variables: fecha de inicio del tratamiento, fecha de progresi\u00f3n de la enfermedad, toxicidad, \nfalta de beneficio, y fecha y motivo de suspensi\u00f3n.\nRESULTADOS\nSe incluyeron 38 pacientes (edad media: 65 a\u00f1os, rango: 44\u201390 a\u00f1os, 79% mujeres) que recibieron osimertinib 80 mg \nuna vez al d\u00eda hasta progresi\u00f3n, toxicidad inaceptable o discontinuaci\u00f3n (14 pacientes en primera l\u00ednea y 16 pacientes en \nsegunda l\u00ednea). La mediana estimada para la SLP en pacientes en primera l\u00ednea fue de 12,4 (IC95%: 5,1 \u2013 19,6) meses y \npara segunda l\u00ednea 16,1 (IC95%: 3,2 -29,0). La SG a los 18 meses fue del 79% (11/14) en los pacientes tratados en primera \nl\u00ednea y del 56% (9/16) en segunda l\u00ednea de tratamiento. Se registraron efectos adversos en el 97% de los pacientes \n(37/38), los m\u00e1s frecuentes fueron astenia (32%), rash (29%), diarrea (29%) y paroniquia (26%). El 66% de los efectos \nadversos presentados se catalogaron como grado 1, el 21% grado 2, el 7% grado 3 y el 1% grado 4\ufffd\nCONCLUSIONES\nOsimertinib ha mostrado en pr\u00e1ctica cl\u00ednica habitual una efectividad elevada en pacientes con CPMN, tanto en primera \ncomo segunda l\u00ednea. En nuestro estudio los resultados de SLP y SG han sido inferiores a los observados en los ensayos \ncl\u00ednicos de referencia y ser\u00e1n necesarios m\u00e1s estudios con un tama\u00f1o mayor de muestra para confirmar los resultados \nobtenidos. La toxicidad al tratamiento con osimertinib en nuestro centro ha sido por lo general bien tolerada a pesar de \nque se registraron efectos adversos en la mayor\u00eda de pacientes (97%; 66% grado 1).\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n82. EVALUACI\u00d3N DE LA EFICACIA, SEGURIDAD Y LA TOLERABILIDAD DE SORAFENIB EN PACIENTES CON \nCARCINOMA HEPATOCELULAR \nAUTORES\nNIEVAS BA\u00d1OS, AB; HERNANDEZ PARADA, J; PEREA PEREZ, A\nHOSPITAL REINA SOF\u00cdA \ufffd AV\ufffd MEN\u00c9NDEZ PIDAL, S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA\nOBJETIVOS\nEvaluar la eficacia, seguridad y tolerabilidad de sorafenib en pacientes diagnosticados de carcinoma hepatocelular (CHC) \nen estadios avanzados y/o pacientes que no eran candidatos a otras terapias previas por sus comorbilidades.317MATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y unic\u00e9ntrico realizado en un Hospital de tercer nivel desde enero de 2016 a abril \nde 2022 en el que se incluyeron los pacientes diagnosticados con CHC que iniciaron tratamiento con sorafenib. Las \nvariables observadas fueron: sexo, edad, ECOG, estadio del tumor al inicio de tratamiento (BCLC), tratamientos previos, \ncomorbilidades, funci\u00f3n hep\u00e1tica y duraci\u00f3n del tratamiento. Los pacientes que no recibieron al menos un mes de \ntratamiento fueron excluidos\ufffd  \nPara evaluar la eficacia del tratamiento se recogieron datos sobre la supervivencia global (SG) y la supervivencia libre de \nprogresi\u00f3n (SLP) seg\u00fan los criterios RECIST. Para analizar la seguridad se recogieron los efectos adversos y la tolerabilidad \ndurante el tratamiento con sorafenib. Los datos se obtuvieron de la Dominion\u00ae (programa de pacientes externos) y la \nhistoria cl\u00ednica DIraya \u00ae. Los datos fueron analizados estad\u00edsticamente con el programa Excel.\nRESULTADOS\nSe incluyeron 34 pacientes, siendo 88.6% hombres, con una mediana de edad de 68 a\u00f1os (54-83). Por no haber \nrecibido un m\u00ednimo de un mes de tratamiento con sorafenib, 4 pacientes fueron excluidos. La principal comorbilidad \nasociada fue cirrosis alcoh\u00f3lica (73.5%), seguida de v\u00edrica (28.5%), h\u00edgado graso (5%) y solo 1 paciente present\u00f3 cirrosis \npor metotrexato. El BCLC al inicio del tratamiento con sorafenib fue C(55.9%), A(17/6%), B(8.8%), siendo un 11,7% de \npacientes con un BCLC borderline entre B/C. La mayor\u00eda de los pacientes (73.5%) presentaban al inicio del tratamiento \nun ECOG de 0. Los tratamientos previos fueron; trasplante de h\u00edgado (11,7%), radioablaci\u00f3n con reca\u00edda y posterior \nquimiembolizaci\u00f3n (41,17% ) llegando a un 50 % de pacientes que no pudieron someterse a tratamiento previo al no \nser candidatos. La funci\u00f3n hep\u00e1tica general estaba compensada, grado A de child-Pugh (52.9%). Actualmente siguen en \ntratamiento 32\ufffd35% de los pacientes, siendo la duraci\u00f3n media de tratamiento con sorafenib de 15\ufffd2 meses\ufffd Hubo un \n55,88% de pacientes a los que hubo que reducir la dosis por la falta de tolerabilidad a los efectos adversos ocasionados \npor sorafenib. La principal raz\u00f3n de suspensi\u00f3n del tratamiento fue la intolerancia de estos efectos adversos, alcanzando \nun 20.5% de discontinuaci\u00f3n de la medicaci\u00f3n. Los efectos adversos que causaron la suspensi\u00f3n del tratamiento fueron: \ndiarrea(40%), astenia(26,7%) y s\u00edndrome mano-pie(26.7%) La eficacia se evalu\u00f3 en t\u00e9rminos de supervivencia siendo la \nmediana de supervivencia libre de progresi\u00f3n de de 7 meses (IC95%:7.6-20.4) y la media de la supervivencia global de 12 \nmeses (IC95%:2.9-NA).\nCONCLUSIONES\nSe observa que en la pr\u00e1ctica cl\u00ednica real los pacientes que toleran sorafenib se benefician de una mayor supervivencia \ntanto libre de progresi\u00f3n como global, siendo la supervivencia libre de progresi\u00f3n de 7 meses (IC95%:7.6-20.4) mientras \nque en el ensayo pivotal (Estudio SHARP) fue de 5.5 meses y la supervivencia global de 12 meses (IC95%:2.9-NA) vs 10.7 \nmeses\ufffd La intolerancia de los efectos adversos es la principal causa de reducci\u00f3n o cese de la medicaci\u00f3n\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n103. EXPERIENCIA MULTIDISCIPLINAR DEL TRATAMIENTO CON CISPLATINO INTRAPERIC\u00c1RDICO EN EL \nDERRAME PERIC\u00c1RDICO MALIGNO: EVALUACI\u00d3N DE EFICACIA, SEGURIDAD Y SUPERVIVENCIA \nAUTORES\nAMOROS REBOREDO, P; MU\u00d1OZ CARRILLO, FJ; PESANTEZ CORONEL, DS; REYES CABANILLAS, RM; CASTRO , P; \nMONGE ESCARTIN, I; REGUART ARANSAY , N; MARCO HERNANDEZ, J\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEl derrame peric\u00e1rdico maligno es una complicaci\u00f3n potencialmente grave de las neoplasias de \u00f3rgano s\u00f3lido. En algunos \ncentros se utiliza la instilaci\u00f3n intraperic\u00e1rdica de quimioterapia como tratamiento local para prevenir la recidiva del \nderrame, pero no existen gu\u00edas espec\u00edficas. El objetivo del estudio es describir la repercusi\u00f3n de la instilaci\u00f3n de cisplatino \nintraperic\u00e1rdico sobre la recurrencia del derrame peric\u00e1rdico maligno.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, unic\u00e9ntrico, multidisciplinar, basado en la revisi\u00f3n de historias cl\u00ednicas de pacientes \ntratados con cisplatino intraperic\u00e1rdico entre enero 2009 y diciembre 2021 en un hospital de tercer nivel. Se incluyeron \npacientes con derrame peric\u00e1rdico secundario a neoplasia de \u00f3rgano s\u00f3lido en quienes se realiz\u00f3 pericardiocentesis \ny colocaci\u00f3n de drenaje peric\u00e1rdico como procedimiento terap\u00e9utico que recibieron una o m\u00e1s dosis de cisplatino \nintraperic\u00e1rdico. Se excluyeron los pacientes en situaci\u00f3n de taponamiento peric\u00e1rdico por derrame peric\u00e1rdico maligno \nque no recibieron tratamiento con cisplatino intraperic\u00e1rdico.\nRESULTADOS\nSe incluyeron 37 pacientes (edad media diagn\u00f3stico derrame peric\u00e1rdico: 60 a\u00f1os, rango: 36-79 a\u00f1os, 54% hombres). \nEl 86,5% ten\u00edan met\u00e1stasis en el momento del diagn\u00f3stico del c\u00e1ncer, y derrame peric\u00e1rdico en un 43%. El origen m\u00e1s \nfrecuente del c\u00e1ncer fue el de pulm\u00f3n (86,5%), seguido del de mama (8%), siendo el adenocarcinoma la histolog\u00eda m\u00e1s \ncom\u00fan (73%). El 84% de los pacientes tomaba alg\u00fan medicamento concomitante (promedio: 5 principios activos, rango: \n0-12). El s\u00edntoma principal en el momento de la presentaci\u00f3n del derrame peric\u00e1rdico que requiri\u00f3 pericardiocentesis \nfue la disnea (73%). Se demostr\u00f3 derrame peric\u00e1rdico grave (con signos de taponamiento cl\u00ednico o ecocardiogr\u00e1fico) \npor ecocardiograf\u00eda en el 89% de los pacientes, siendo moderado en el 11% restante. Un 38% de los pacientes \ningresaron en la unidad de cuidados intensivos\ufffd Un 13,5% de los pacientes present\u00f3 complicaciones relacionadas con \nla pericardiocentesis, siendo la fibrilaci\u00f3n auricular la m\u00e1s frecuente (3 de cada 5). Se realizaron una mediana de 4 \ninstilaciones de 10 mg de cisplatino a trav\u00e9s del cat\u00e9ter peric\u00e1rdico (rango 1-5). Nueve pacientes (24,3%) experimentaron 318reacciones adversas relacionadas con la infusi\u00f3n de cisplatino, ocurriendo la mayor\u00eda de ellas (8 de 9) durante los \nprimeros 5 d\u00edas despu\u00e9s de la primera infusi\u00f3n: fibrilaci\u00f3n auricular (4), dolor tor\u00e1cico (3), taquicardia sinusal (1) y \nn\u00e1useas (1); ninguna de ellas puso en peligro la vida del paciente. La supervivencia media tras el diagn\u00f3stico de derrame \nperic\u00e1rdico maligno con necesidad de pericardiocentesis fue de 442 d\u00edas (SD:703). Solo 2 pacientes (5,4%) presentaron \nrecidiva del derrame peric\u00e1rdico durante el seguimiento, ambos en el primer mes tras la instilaci\u00f3n de cisplatino.\nCONCLUSIONES\nEl cisplatino intraperic\u00e1rdico parece ser un tratamiento seguro del derrame peric\u00e1rdico maligno, ya que los eventos \nadversos relacionados con la instilaci\u00f3n de quimioterapia ocurrieron solo en un 13,5% y 24,3% de los pacientes \nrespectivamente, ninguno de los cuales puso en peligro la vida. Solo un 5,4% de los pacientes present\u00f3 recurrencia del \nderrame peric\u00e1rdico, lo que sugiere que puede ser un tratamiento efectivo.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n117. EFECTIVIDAD Y SEGURIDAD DE LA INMUNOTERAPIA EN EL TRATAMIENTO DE PRIMERA L\u00cdNEA DEL \nC\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO NO ESCAMOSO \nAUTORES\nRODRIGUEZ PENIN, I; LOPEZ DE ULLIBARRI GALPARSORO, I; CERC\u00d3S LLETI, AC; AFONSO AFONSO, FJ; L\u00d3PEZ \nSANDOMINGO, L; VALCARCE PARDEIRO, N\nCOMPLEJO HOSPITALARIO ARQUITECTO MARCIDE-PROF . NOVOA SANTOS. CTRA. DE SAN PEDRO DE LEIXA, S/N \nFERROL \ufffd A CORU\u00d1A\nOBJETIVOS\nPembrolizumab en monoterapia y pembrolizumab combinado con quimioterapia (QT) (platino + pemetrexed) se \nconsideran primera l\u00ednea de tratamiento del c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) metast\u00e1sico no escamoso. Este \nestudio se llev\u00f3 a cabo para analizar datos de pr\u00e1ctica cl\u00ednica diaria.  \nObjetivos primarios: Analizar efectividad [respuesta, supervivencia libre de progresi\u00f3n (SLP) y supervivencia global (SG)] \ny efectos adversos inmunorrelacionados (EAir). Objetivos secundarios: analizar posibles diferencias de efectividad entre \nmonoterapia con inmunoterapia (IT) e inmuno-quimioterapia (IT-QT); investigar asociaci\u00f3n entre EAir y efectividad; \ninvestigar asociaci\u00f3n entre LIPI y efectividad; verificar adherencia a recomendaciones nacionales de tratamiento\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo en un hospital de segundo nivel. Se incluyeron todos los pacientes con \nCPNM localmente avanzado o metast\u00e1sico no escamoso que iniciaron IT desde octubre 2018 hasta abril 2021. De la \nhistoria cl\u00ednica electr\u00f3nica se recogieron datos demogr\u00e1ficos, histolog\u00eda, mutaciones target (EGFR, ALK, ROS1), PD-L1, \nh\u00e1bito tab\u00e1quico, ECOG y neutr\u00f3filos, leucocitos y LDH al inicio del tratamiento, efectividad y EAir. Del programa de \ngesti\u00f3n farmacoterap\u00e9utica se consultaron tratamientos oncol\u00f3gicos recibidos. Se analiz\u00f3 la respuesta seg\u00fan criterios \nRECIST, versi\u00f3n 1.1. y EAir seg\u00fan criterios NCI-CTCAE versi\u00f3n 5.0  \nSe obtuvieron estimaciones de Kaplan-Meier (KM) de las funciones de SLP y SG, construyendo intervalos de confianza \nal 95% (IC95%). Para SLP y SG, la hip\u00f3tesis de igualdad de Hazard rate entre grupos se contrast\u00f3 con el test de log-rank. \nMediante regresi\u00f3n de Cox univariante se calcularon estimaciones del Hazard ratio (HR). La asociaci\u00f3n entre la respuesta \ny otras variables se valor\u00f3 estimando el odds ratio (OR). El an\u00e1lisis estad\u00edstico se realiz\u00f3 con el programa R\nRESULTADOS\nSe incluyeron 54 pacientes, 20 tratados con pembrolizumab en monoterapia y 34 combinado con QT con una mediana \nde seguimiento de 10,91 meses (IC95% 8,80-20,37). La mediana de edad de la poblaci\u00f3n fue de 68 a\u00f1os, 81,5% varones, \n92,6% fumadores o exfumadores. Al inicio del tratamiento su ECOG fue: 0 (9,2%), 1 (77,8%), 2 (13%) y el LIPI: 0 (51,9%), \n1 (33,3%), 2 (14,8%). En la poblaci\u00f3n global, pembrolizumab en monoterapia y pembrolizumab-QT la mediana SLP fue de \n7,95 (IC95% 5,78-NE), 6,2 (IC95% 4,83-NE) y 8,57 (IC95% 5,78-NE) meses, r espectivamente; SG mediana: 24,84 (IC95% \n14,13-NE), no estimable (NE) y 24,84 (IC95% 9,56-NE) meses. La comparaci\u00f3n de efectividad seg\u00fan el tipo de tratamiento \nno alcanz\u00f3 diferencias estad\u00edsticamente significativas.  \nUn 29,6% de los pacientes presentaron EAir obteni\u00e9ndose diferencias estad\u00edsticamente significativas en efectividad a \nfavor de la poblaci\u00f3n que present\u00f3 EAir. Al comparar el \u00edndice LIPI no se obtuvieron diferencias significativas.  \nTodos los pacientes cumplieron los criterios para el tratamiento de primera l\u00ednea del adenocarcinoma de pulm\u00f3n.\nCONCLUSIONES\nLa efectividad y seguridad del tratamiento se aproxima a la obtenida en los ensayos pivotales. No se han encontrado \ndiferencias estad\u00edsticamente significativas de efectividad entre monoterapia con pembrolizumab frente a pembrolizumab-QT. \nLa aparici\u00f3n de EAir se asocia a una mayor efectividad. No hay evidencia concluyente de asociaci\u00f3n significativa entre LIPI y \nefectividad. La adherencia a los criterios de financiaci\u00f3n de tratamiento de primera l\u00ednea del CPNM no escamoso ha sido plena\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n119. EVENTOS ADVERSOS GRAVES DURANTE EL TRATAMIENTO CON NIVOLUMAB \nAUTORES\nGARC\u00cdA SOLER, JI; D\u00cdAZ CARRASCO, MS; ALONSO ROMERO, JL; RUIZ JIM\u00c9NEZ, MDM; VALDERREY PULIDO, M; ESPUNY \nMIR\u00d3, A\nHOSP . UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. MURCIA319OBJETIVOS\nDescribir la aparici\u00f3n de reacciones adversas graves asociadas al uso de nivolumab en monoterapia, en condiciones de \npr\u00e1ctica asistencial.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 a todos los pacientes con diagn\u00f3stico oncol\u00f3gico que iniciaron \ntratamiento con nivolumab en monoterapia en un hospital de tercer nivel entre 2015 y 2018. Las variables recogidas \nfueron sexo, edad, enfermedad oncol\u00f3gica y presencia de enfermedad autoinmune. Se analizaron la dosis, duraci\u00f3n de \ntratamiento, aparici\u00f3n de eventos adversos (EEAA) graves, tiempo que transcurri\u00f3 desde el inicio del tratamiento hasta \nla aparici\u00f3n del evento adverso (EA). Los EEAA fueron registrados y clasificados por sistemas seg\u00fan la clasificaci\u00f3n CTCAE \nv5.0 considerando graves aquellos de grado 4 o 5.\nRESULTADOS\nUn total de 193 pacientes iniciaron tratamiento con el f\u00e1rmaco, 148 de ellos fueron hombres (76,7%) y 26 presentaban \nalguna enfermedad autoinmune (13,5%). La edad media fue de 61,4\u00b111,0 a\u00f1os. El diagn\u00f3stico oncol\u00f3gico en estos \npacientes fue en 128 c\u00e1ncer de pulm\u00f3n no microc\u00edtico (66,3%), 21 c\u00e1ncer de c\u00e9lulas renales (10,9%), 20 melanoma \navanzado (10,4%), 12 c\u00e1ncer de cabeza y cuello (6,2%), 7 melanoma localizado (3,6%) y un paciente para los diagn\u00f3sticos \nde c\u00e1ncer de vejiga, canal anal, es\u00f3fago, est\u00f3mago y glioma (0,5% para cada uno). La mediana de duraci\u00f3n de tratamiento \nfue de 26,6 semanas [p25:10,0\u2013p75:63,0] y la de dosis recibida de 220,0 mg [p25:190,0\u2013p75:240,0]. Se produjeron un \ntotal de 41 EEAA graves en 35 pacientes (18,1%); 32 de grado 4 (78,0%) y 9 de grado 5 (22,0%). Los EEAA de grado 4 \nfueron: 8 alteraciones del metabolismo (25,0%), 7 alteraciones en pruebas anal\u00edticas y exploraciones complementarias \n(21,9%), 5 alteraciones respiratorias (15,6%), 4 cardiacas (12,5%), 3 neoplasias (9,4%), 2 alteraciones vasculares (6,3%) y \nuna alteraci\u00f3n general (3,1%), una gastrointestinal (3,1%) y una infecci\u00f3n (3,1%). Los EEAA de grado 5 se correspondieron \ncon 5 infecciones (55,6%), 2 alteraciones cardiacas (22,2%), una alteraci\u00f3n del sistema nervioso (11,1%) y una alteraci\u00f3n \nrespiratoria (11,1%). La mediana de tiempo transcurrido desde el inicio del tratamiento hasta su aparici\u00f3n fue de 50,0 \nsemanas (p25: 10,0\u2013p75:89,4).\nCONCLUSIONES\nUn porcentaje relevante de pacientes presenta EEAA graves durante el tratamiento con nivolumab. Los EEAA graves m\u00e1s \nfrecuentes son las alteraciones del metabolismo y en pruebas anal\u00edticas y exploraciones complementarias seguidas de \nlas infecciones y alteraciones cardiacas y respiratorias\ufffd Sin embargo, los EEAA responsables del exitus en estos pacientes \nfueron mayoritariamente las infecciones y las alteraciones cardiacas\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n122. ADMINISTRACI\u00d3N DE GLUCOCORTICOIDES Y SU IMPACTO EN LA EFECTIVIDAD DE LA \nINMUNOTERAPIA EN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO \nAUTORES\nGARC\u00cdA SOLER, JI; D\u00cdAZ CARRASCO, MS; ALONSO ROMERO, JL; CANO MOLINA, J\u00c1; LAORDEN CARRASCO, A; ESPUNY \nMIR\u00d3, A\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nAnalizar el impacto de la administraci\u00f3n de glucocorticoides en la efectividad, en t\u00e9rminos de supervivencia global (SG), \ndel tratamiento con un inhibidor del punto de control inmunitario (ICI) en pacientes diagnosticados de c\u00e1ncer de pulm\u00f3n \nno microc\u00edtico (CPNM) tratados en segunda l\u00ednea de tratamiento.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en pacientes diagnosticados de CPNM que comenzaron un tratamiento con un ICI \nen segunda l\u00ednea de tratamiento entre 2015 y 2018. Se analiz\u00f3 la edad, sexo, anticuerpo y duraci\u00f3n del tratamiento. \nEn cuanto a la enfermedad, se recogi\u00f3 la histolog\u00eda, estadio, valor de la escala ECOG, expresi\u00f3n de PD-L1, mutaci\u00f3n en \nEGFR y reordenamiento de ALK y ROS-1. El consumo de glucocorticoides; definido como la administraci\u00f3n de f\u00e1rmacos \ncon acci\u00f3n corticoide a dosis superiores a 10mg/d\u00eda de prednisona o equivalente, se evalu\u00f3 en los 30 d\u00edas previos y 30 \nd\u00edas posteriores al inicio del ICI. La SG se analiz\u00f3 mediante curvas de Kaplan-Meier y la influencia de la administraci\u00f3n de \nglucocorticoides en la SG a trav\u00e9s del modelo de regresi\u00f3n de Cox.\nRESULTADOS\nSe incluyeron un total de 99 pacientes con una media de edad de 63,9\u00b18,8 a\u00f1os; el 87,9% eran hombres. Los pacientes \nfueron tratados con nivolumab (79,8%), pembrolizumab (13,1%) y atezolizumab (7,1%) durante una mediana de 30,0 \nsemanas (p25:13,0-p75:22,0). La histolog\u00eda fue de tipo adenocarcinoma en 41 (41,4%), epidermoide en 49 (49,5%) e \nindiferenciado en 9 (9,1%). Catorce pacientes (14,1%) presentaban estadio IIIC y 85 (85,9%) estadio IV. El valor de la \nescala ECOG fue evaluado en 94 pacientes siendo de 0 en 8 pacientes (8,5%), 1 en 60 (63,8%), 2 en 23 (24,5%) y 3 en 3 \n(3,2%). En 25 pacientes se evalu\u00f3 la expresi\u00f3n de PD-L1 siendo: < 1,0% en 9 (36,0%), \u22651,0% y < 5,0% en 3 (12,0%), \u22655,0% \ny < 50,0% en 5 (20,0%) y \u226550,0% en 8 (32,0%). La mutaci\u00f3n de EGFR se determin\u00f3 en 42 pacientes; 1 (2,4%) presentaba la \nmutaci\u00f3n en EGFR. El reordenamiento de ALK y ROS-1 se determin\u00f3 en 35 y 13 pacientes, respectivamente, no habiendo \nning\u00fan paciente con estos reordenamientos.  320El consumo de glucocorticoides se puedo evaluar en 93 pacientes previo al inicio del ICI y en 97 de forma posterior, \nhabiendo 18 (19,4%) pacientes con consumo en los 30 d\u00edas previos y 21 (21,6%) con consumo en los 30 d\u00edas posteriores \nal inicio del ICI. La mediana de SG de estos pacientes fue de 13,1 meses (IC 95%:10,8\u201315,4), siendo el valor del HR del uso \nde glucocorticoides en los 30 d\u00edas previos al inicio del anti-PD-1 de 2,5 (IC95%:1,4\u20134,3); p < 0,001 y de 3,4 (IC95%:2,0\u2013\n5,9); p < 0,001 para su uso en los 30 d\u00edas tras el inicio.\nCONCLUSIONES\nEn los pacientes con CPNM que inician un ICI en segunda l\u00ednea de tratamiento, tanto el consumo de glucocorticoides \nen los 30 d\u00edas previos como en los 30 d\u00edas posteriores al inicio del tratamiento, ha presentado un impacto negativo en \nla SG. Este impacto ha sido de mayor magnitud cuando este consumo se ha producido en los 30 d\u00edas tras el inicio del \ntratamiento\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n128. EFICACIA Y SEGURIDAD DE OBINUTUZUMAB EN LA LEUCEMIA LINFOC\u00cdTICA CR\u00d3NICA EN LA \nPRACTICA CLINICA HABITUAL \nAUTORES\nNIEVAS BA\u00d1OS, AB; HERNANDEZ PARADA, J; APARICIO CASTELLANO, B\nHOSPITAL REINA SOF\u00cdA \ufffd AV\ufffd MEN\u00c9NDEZ PIDAL, S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA\nOBJETIVOS\nEl objetivo de este estudio fue analizar la eficacia y seguridad del tratamiento con obinutuzumab-clorambucilo en primera \nl\u00ednea en (LLC) en pacientes no aptos a la quimioterapia con fludarabina en la pr\u00e1ctica cl\u00ednica de un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio observacional, retrospectivo y descriptivo en pacientes diagnosticados de LLC no aptos a \nquimioterapia y tratados con obinutuzumab-clorambucilo entre abril de 2015 y abril de 2022. Las variables recogidas se \nobtuvieron de la historia cl\u00ednica electr\u00f3nica Diraya\u00ae y del programa de gesti\u00f3n de quimioterapia (FarmisOncofarm\u00ae): sexo, \nedad, estadio Rai / Binet, estudio mutacional, ciclos de obinutuzumab y duraci\u00f3n del tratamiento. La eficacia fue medida \nen t\u00e9rminos de tasa de respuesta y superviviencia; supervivencia libre de progresi\u00f3n (SLP) y la supervivencia global (SG) \nlos cuales se estimaron mediante el m\u00e9todo de Kaplan-Meier. La valoraci\u00f3n de la respuesta se hizo seg\u00fan los criterios \nde National Cancer Institute (NCI) catalogadas como: RC (respuesta completa), RP (respuesta parcial), EE (enfermedad \nestable) y P (progresi\u00f3n), para la que solo se tuvieron en cuenta los pacientes que hab\u00edan completado 6 ciclos. La \nseguridad se evalu\u00f3 seg\u00fan criterios del NCI \u201cCommon Terminology Criteria for Adverse Events\u201d (NCI-CTCAE-v3.0.). Los \ndatos se analizaron con el programa estad\u00edstico SPSS V.22.\nRESULTADOS\nSe incluyeron 35 pacientes (60% hombres), con una mediana de edad de 78 a\u00f1os (54-93) y diagnosticados de LLC. El \nestadio Rai/Binet al inicio del tratamiento m\u00e1s frecuente fue IIB(20%) y IV/C(17%). En cuanto al estado de las mutaciones, \nel 40.7% (n=11) presentaba la mutaci\u00f3n de la regi\u00f3n de la cadena pesada de la inmunoglobulina (IGHV), un 29.6% \ndelecci\u00f3n del 13q14 y un 7.4% mutaci\u00f3n en el gen 11q22. En el momento de nuestro estudio, 27 pacientes (77.1%) \nhab\u00edan completado los 6 ciclos. La eficacia fue medida con los datos obtenidos en supervivencia; la mediana de la SLP \nfue de 32 meses (IC95%, 20,5-43,5) y la media de SG fue de 67,6 meses (IC95%56.2-NA). La t asa de respuesta fue de: \nRC (n=12), RP (=10), EE(=4) y P(=2). En cuanto a la seguridad, 17 pacientes (48,5%) tuvieron una buena tolerancia al \ntratamiento, 4 pacientes (11,4%) tuvieron reacciones al\u00e9rgicas y 2 pacientes (5,7%) fueron refractarios al tratamiento. Los \nefectos adversos ocurrieron en un 40% de los pacientes tratados con obinutuzumab, los cuales fueron leves a moderados, \ndonde destacan astenia (n=3), gastrointestinales (n=3), hipotensi\u00f3n(n=2) y efectos hematol\u00f3gicos(n=2).\nCONCLUSIONES\nEste estudio sugiri\u00f3 que Obinutuzumab-clorambucilo tiene una mediana de la SLP ligeramente superior en la pr\u00e1ctica \ncl\u00ednica habitual a la del ensayo pivotal BO21004/ CLL11 (32vs26,7 meses) y una supervivencia global media de 67,6 \nmeses en el momento de extracci\u00f3n de los datos sin haber llegado a\u00fan a alcanzar la mediana. Se necesitan m\u00e1s estudios \npara confirmar estos resultados. La seguridad fue aceptable aunque hubo dos reacciones al\u00e9rgicas que motivaron la \nsuspensi\u00f3n del tratamiento\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n166. CIRUG\u00cdA CITORREDUCTORA SEGUIDA DE QUIMIOTERAPIA INTRAPERITONEAL HIPERT\u00c9RMICA EN \nEL TRATAMIENTO DE LA CARCINOMATOSIS PERITONEAL; EXPERIENCIA CL\u00cdNICA EN LA VIDA REAL. \nAUTORES\nROJAS ALBARR\u00c1N, A; RIVAS RODRIGUEZ, MD; GIL GARCIA, A; GRAGERA G\u00d3MEZ, M; REDONDO GAL\u00c1N, C; RANGEL \nMAYORAL, JF\nCOMPLEJO H. UNIVERSITARIO DE BADAJOZ. AV . DE ELVAS, S/N BADAJOZ. BADAJOZ\nOBJETIVOS\nLa carcinomatosis peritoneal (PC) es un tipo de c\u00e1ncer diseminado que afecta a la zona del peritoneo y las estructuras \nanat\u00f3micas adyacentes. En estos pacientes la eficacia de la quimioterapia sist\u00e9mica es limitada debido a la extensi\u00f3n de la \nenfermedad y a la poca vascularizaci\u00f3n, que dificulta el acceso. La cirug\u00eda citorreductora (CCR) seguida de quimioterapia 321intraperitoneal hipert\u00e9rmica (HIPEC) mejora la supervivencia en pacientes seleccionados, ya que permite alcanzar \nconcentraciones altas de f\u00e1rmaco en la zona peritoneal y abordar no solo la enfermedad macrosc\u00f3pica sino tambi\u00e9n \nla microsc\u00f3pica, responsable de recidivas. Adem\u00e1s, La asociaci\u00f3n de calor potencia el efecto terap\u00e9utico y provoca un \nefecto citot\u00f3xico directo\ufffd  \nEl objetivo de este estudio es analizar las caracter\u00edsticas de los pacientes sometidos a CCR seguida de HIPEC, estudiar las \ntoxicidades asociadas a dicha t\u00e9cnica y describir la experiencia cl\u00ednica.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo de los pacientes con diagn\u00f3stico de carcinomatosis peritoneal (CP) \nsometidos a CCR seguida de HIPEC entre 2019 y 2022. Se recogieron variables demogr\u00e1ficas, tipo de c\u00e1ncer, \u00edndice \nde carcinomatosis peritoneal (PCI), tratamiento previo, reg\u00edmenes utilizados, tiempo transcurrido desde la \u00faltima \nquimioterapia hasta la cirug\u00eda, estancia hospitalaria, necesidad de transfusi\u00f3n sangu\u00ednea y complicaciones. Los datos se \nobtuvieron de la historia cl\u00ednica electr\u00f3nica de los pacientes y Farmatools\u00ae.\nRESULTADOS\nSe incluyeron 70 pacientes; 78,5% (55) mujeres; 56 a\u00f1os fue la media de edad. El peso medio fue 69 Kg y 1,66 la \nsuperficie corporal media. 11 fue el PCI medio calculado. 57,1% (40) present\u00f3 CP de origen ov\u00e1rico; 25,7% (18) \ncolorrectal; 11,4% (8) apendicular; 5,7% (4) g\u00e1strico. 82,8% (58) recibi\u00f3 quimioterapia sist\u00e9mica previa; 5 semanas \nfue el tiempo medio desde el \u00faltimo ciclo de quimioterapia hasta el procedimiento; 42,8% (30) present\u00f3 intervenci\u00f3n \nquir\u00fargica previa relacionada con la enfermedad; 7,1% (5) recibi\u00f3 CCR seguida de HIPEC como primera l\u00ednea. Los \nreg\u00edmenes utilizados fueron: 51,4% (36) paclitaxel; 41,4% (29) mitomicina; 5,7% (4) cisplatino; 1,4% (1) combinaci\u00f3n de \ndoxorrubicina y cisplatino. Las HIPEC se administraron en un volumen de 2 Litros/ m\u00b2, con un rango de temperaturas de \n41-43 \u00b0C y en un tiempo de infusi\u00f3n de 60-90 minutos; 4,2% (3) redujo dosis y tiempo de infusi\u00f3n por toxicidad.  \nLa mediana de estancia hospitalaria fue 8 d\u00edas. 34.2% (24) precis\u00f3 transfusi\u00f3n sangu\u00ednea. 62,8% (44) present\u00f3 \ncomplicaciones; de \u00e9stas: 61,3% (27) toxicidad medular; 61,3% (27) infecciones; 52,7% (23) quir\u00fargicas; 52,7% (23) \ngastrointestinales; 27,2% (12) respiratorias; 18,1% (8) vasculares; 11,3% (5) renales; 9% (4) card\u00edacas; 6,8% (3) astenia y \n4,5% (2) neurol\u00f3gicas.  \n7,1% (5) ingres\u00f3 en Unidad de Cuidados Intensivos; 2,8% (2) fue \u00e9xitus durante el ingreso; no hubo mortalidad \nintraoperatoria\ufffd\nCONCLUSIONES\nLa mayor\u00eda de las toxicidades encontradas en este estudio son secundarias a complicaciones propias del procedimiento \nquir\u00fargico, siendo la HIPEC bien tolerada en dichos pacientes. Por tanto, con esta t\u00e9cnica es posible administrar \naltas dosis de quimioterapia intraperitoneal sin el desarrollo de toxicidades sist\u00e9micas directamente atribuibles a la \nquimioterapia. Aun as\u00ed son necesarios m\u00e1s estudios que permitan conocer las particularidades del procedimiento y los \nresultados obtenidos para mejorar la utilizaci\u00f3n y precisi\u00f3n de la t\u00e9cnica.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n197. PROGRAMA DE MEDICI\u00d3N DE RESULTADOS INFORMADOS POR EL PACIENTE (PROMS) CON \nHERRAMIENTA PROCTCAE EN PACIENTES CON LINFOMA EN TERAPIA INTRAVENOSA. \nAUTORES\nBARRERAS RUIZ, N; CASTILLO BAZ\u00c1N, E; RAMOS CILL\u00c1N, S; C\u00d3RDOBA MASCU\u00d1ANO, R; B\u00c9CARES MARTINEZ, J\nFUNDACI\u00d3N JIM\u00c9NEZ D\u00cdAZ-UTE. AV . DE LOS REYES CAT\u00d3LICOS, 2 MADRID. MADRID\nOBJETIVOS\nLa medida de los resultados reportados por los pacientes (PROMS) en la pr\u00e1ctica cl\u00ednica a\u00fan est\u00e1 por llegar. El reporte de \nlos s\u00edntomas por parte del paciente se ha propuesto como una fuente de datos adicional en la pr\u00e1ctica cl\u00ednica, pero las \nimplicaciones en el manejo m\u00e9dico del paciente todav\u00eda no se encuentran bien establecidas. Nuestra hip\u00f3tesis es que los \npacientes suscritos a este tipo de programas pueden beneficiarse de una autopercepci\u00f3n mejorada del estado de salud \npudiendo as\u00ed requerir un menor n\u00famero de visitas a urgencias as\u00ed como de ingresos hospitalarios permitiendo de esta \nmanera una reducci\u00f3n del coste de su tratamiento\ufffd\nMATERIALES Y M\u00c9TODOS\nSe incluyeron en nuestra investigaci\u00f3n pacientes con cualquier tipo de linfoma o leucemia linfoc\u00edtica cr\u00f3nica que \nnecesitaron tratamiento en nuestro centro hospitalario entre el 1 de enero de 2019 y el 31 de diciembre de 2020. \nSe ofreci\u00f3 la inclusi\u00f3n en el programa PROM a todos los pacientes que iniciaron tratamiento en 2020. Por tanto, los \npacientes que iniciaron tratamiento en 2019 y los que rechazaron la inclusi\u00f3n en el programa en 2020 forman parte de \nnuestro brazo control. El objetivo principal fue la b\u00fasqueda de una relaci\u00f3n entre la inclusi\u00f3n en el programa PROM y \nuna reducci\u00f3n en la tasa de visitas e ingresos hospitalarios en estos sujetos. Los criterios secundarios que se tuvieron en \ncuenta fueron una comparaci\u00f3n entre los s\u00edntomas y eventos adversos informados por los m\u00e9dicos y los informados por \nlos pacientes a trav\u00e9s de un formulario estandarizado, elaborado por el Instituto Nacional del C\u00e1ncer de estados unidos \n(PRO-CTCAETM) y validado en m\u00faltiples idiomas.\nRESULTADOS\nEl estudio incluy\u00f3 un total de 142 pacientes; de ellos 76 pacientes (53,5 %) se incluyeron en el programa PROM. Los \ndiagn\u00f3sticos m\u00e1s frecuentes fueron linfoma difuso de c\u00e9lulas B grandes (LDCBG), linfoma folicular (LF) y linfoma de \nHodgking (LH).  322Los pacientes incluidos en el programa PROMS experimentaron (EA) efectos adversos generales (64,5% frente a 84,8%; p \n< 0,05) e infecciosos (30,3% frente a 59,1% ; p < 0,05) con menos frecuencia que el grupo control. Tambi\u00e9n se encuentran \ndiferencias entre los EA informados por los m\u00e9dicos y los autoinformados por los pacientes. Los EA m\u00e1s notificados por \nlos facultativos fueron hematol\u00f3gicos (76,1 %), s\u00edntomas generales (73,9 %), gastrointestinales (59,9%) e infecciones \n(43,7%), mientras que los EA de mayor intensidad notificados por parte de los pacientes fueron principalmente s\u00edntomas \ngenerales (31,6 %), trastornos genitourinarios (23,7 %), neurol\u00f3gicos (15,8 %) y cut\u00e1neo (13,2%). Adem\u00e1s, la inclusi\u00f3n en \nel programa PROMS se asoci\u00f3 con un menor n\u00famero de visitas a urgencias, con 34,2 % de los pacientes frente a 60 % de \nlos pacientes no inscritos en el programa (p=0,003).\nCONCLUSIONES\nNuestro estudio permite establecer la relaci\u00f3n entre PROMs y los servicios sanitarios en pacientes con distintos tipos de \nlinfoma. Este programa podr\u00eda fomentar la mejora del cuidado por parte de profesionales de la salud de la calidad de vida \nde los pacientes. El objetivo de estudios futuros es la inclusi\u00f3n de pacientes que reciben terapias orales.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n214. ADECUACI\u00d3N DEL PROTOCOLO INTERNO LOCAL CON INHIBIDORES DE LA TIROSIN KINASA EN \nLEUCEMIA MIELOIDE CR\u00d3NICA \nAUTORES\nP\u00c9REZ REYES, S; GONZ\u00c1LEZ DE LA FUENTE, GA; CANTARELLI , L; GONZ\u00c1LEZ GARC\u00cdA, J; RAMOS SANTANA, E; GARC\u00cdA \nGIL, S; NAZCO CASARIEGO, GJ; GUTIERREZ NICOL\u00c1S, F\nCOMPLEJO HOSPITAL UNIVERSITARIO NTRA SRA DE CANDELARIA. CTRA. DEL ROSARIO, 145 SANTA CRUZ DE \nTENERIFE \ufffd SANTA CRUZ DE TENERIFE\nOBJETIVOS\nEn junio de 2018, tras la aparici\u00f3n de imatinib gen\u00e9rico, se aprob\u00f3 en nuestro Centro un protocolo de tratamiento en \nprimera l\u00ednea (1L) en leucemia mieloide cr\u00f3nica (LMC), con el objetivo de utilizar el inhibidor de tirosin kinasa (ITK) m\u00e1s \ncoste/eficaz en cada uno de los posibles escenarios. El objetivo del presente estudio es analizar la adecuaci\u00f3n a dicho \nprotocolo\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo de 46 meses de duraci\u00f3n (junio 2018-abril 2022) en el cual se incluyeron a todos los pacientes \ndiagnosticados de LMC a los cuales se les prescribi\u00f3 y dispens\u00f3 un ITK en 1L. Los datos de prescripci\u00f3n y consumo de \nmedicaci\u00f3n fueron extra\u00eddos del aplicativo inform\u00e1tico SAP\u00ae, as\u00ed como otras variables tales que: edad, sexo, fecha de \ninicio de tratamiento y tipo de ITK pautado. Las variables categ\u00f3ricas se expresaron como frecuencias y porcentajes. \nLa decisi\u00f3n de utilizar un ITK u otro se basaba en dos caracter\u00edsticas principales: la edad y el \u00edndice pron\u00f3stico SOKAL:  \n- Edad < 60 a\u00f1os: independientemente del SOKAL\u2192 ITK de 2\u00aa generaci\u00f3n (nilotinib).  \n- Edad 60-75 a\u00f1os: SOKAL bajo/intermedio\u2192 ITK de 1\u00aa generaci\u00f3n (imatinib).  \nSOKAL alto\u2192 ITK de 2\u00ba generaci\u00f3n (nilotinib o dasatinib).  \n- Edad > 75 a\u00f1os: independientemente del SOKAL\u2192 ITK de 1\u00aa generaci\u00f3n (imatinib).\nRESULTADOS\nEn el estudio han sido incluidos un total de 30 pacientes con una edad media de 69,6 a\u00f1os [33-91]. El 50% eran mujeres \n(n=15). El 76,6% (n=23) recibi\u00f3 tratamiento con imatinib, mientras que los 7 pacientes restantes iniciaron con nilotinib. \nNing\u00fan paciente recibi\u00f3 tratamiento de 1L con dasatinib.  \nEn el grupo de imatinib observamos que el 78,2% de casos (n=18) se ajustaba al protocolo, mientras que en el grupo de \nnilotinib, este porcentaje ascend\u00eda hasta el 85,7%.  \nPor tanto, en conjunto, se observ\u00f3 una adherencia al protocolo del 77%.\nCONCLUSIONES\nLa implantaci\u00f3n de protocolos locales de tratamiento son una buena herramienta para optimizar el uso de las diferentes \nalternativas de tratamiento, m\u00e1xime tras la aparici\u00f3n de medicamentos gen\u00e9ricos que disminuyen su coste de manera \nsignificativa. El seguimiento a la adecuaci\u00f3n del protocolo realizado por el Servicio de Farmacia ha permitido controlar \nel coste del tratamiento en 1L de la LMC y de esta manera garantizar que dichos f\u00e1rmacos se utilizan de la manera m\u00e1s \neficiente posible.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n238. EFECTIVIDAD Y SEGURIDAD DE BELANTAMAB MAFODOTINA EN PACIENTES CON MIELOMA \nM\u00daLTIPLE \nAUTORES\nPEREZ LAPIDO, M; ALCONADA CALLES, J; MARIN GORRICHO, R; ALFARO OLEA, A; SOILAN SACO, J; ITURBE HERAS, M; \nROA RUIZ, N; DELGADO GARCIA, J\nCOMPLEJO HOSPITALARIO SAN MILL\u00c1N-SAN PEDRO DE LA RIOJA. PIQUERAS 98 LOGRO\u00d1O. LA RIOJA\nOBJETIVOS\nEstudiar la efectividad y seguridad de belantamab mafodotina (BM) como monoterapia en el tratamiento de mieloma \nm\u00faltiple (MM) refractario tras tres o m\u00e1s terapias previas y comparar con la bibliograf\u00eda.323MATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo de pacientes tratados con BM desde julio 2021 hasta mayo 2022 en un hospital de \ntercer nivel. Se recogieron variables demogr\u00e1ficas (edad y sexo), estado funcional seg\u00fan Eastern Cooperative Oncology \nGroup (ECOG), tipo de mieloma, estadio seg\u00fan clasificaci\u00f3n Durie-Salmon, n\u00famero de l\u00edneas previas, n\u00famero de ciclos \ny posolog\u00eda de belantamab. La efectividad se evalu\u00f3 mediante la supervivencia global (SG). Para evaluar la seguridad se \nregistraron datos de toxicidad hematol\u00f3gica, hep\u00e1tica, infecciones y reacciones infusionales que se clasificaron seg\u00fan los \ncriterios Common Terminology Criteria for Adverse Events (CTCAE) versi\u00f3n 5.0, y de toxicidad ocular seg\u00fan ficha t\u00e9cnica \nde BM\ufffd \nSe extrajeron los datos de la historia cl\u00ednica electr\u00f3nica y el programa de gesti\u00f3n de quimioterapia.\nRESULTADOS\nSe incluyeron 3 pacientes, 2 de ellos mujeres, con media de edad 72 \u00b1 1,5 a\u00f1os. Dos pacientes ten\u00edan ECOG 0 al inicio del \ntratamiento, el otro ECOG 1. Los tipos de MM estudiados fueron un MM IgA lambda, un MM de cadena ligera lambda y \nun MM IgG lambda. Dos pacientes presentaban MM estadio III-A, el restante estadio II-A. \nLa mediana de l\u00edneas previas a BM fue de 4 (3-7). Se administraron una mediana de 5 ciclos (3-7) de BM. Todos los \npacientes iniciaron a dosis de 2,5mg/kg cada 3 semanas y todos experimentaron interrupciones del tratamiento y al \nmenos una reducci\u00f3n de dosis por efectos adversos\ufffd  \nLa mediana de SG observada para el periodo de seguimiento de 11 meses fue de 7 meses (6-11). Dos pacientes \nfallecieron durante el periodo de estudio, uno de ellos por neumon\u00eda y el otro por fallo multiorg\u00e1nico a causa de la \nenfermedad\ufffd \nTodos los pacientes presentaron efectos adversos. No se produjeron reacciones infusionales ni elevaci\u00f3n de \ntransaminasas. Dos pacientes presentaron plaquetopenia de grado 3. Un paciente present\u00f3 queratopat\u00eda grave, otro \nde grado moderado-grave y el otro de grado leve. Un paciente present\u00f3 neumon\u00eda grave. Dos pacientes requirieron \nreducci\u00f3n de dosis a 1,9mg/kg a partir del 2\u00ba ciclo por plaquetopenia y otro a partir del 6\u00ba ciclo por queratopat\u00eda. Un \npaciente experiment\u00f3 una segunda reducci\u00f3n de dosis a 1mg/kg a partir del 5\u00ba ciclo por queratopat\u00eda.\nCONCLUSIONES\nLa supervivencia global en nuestros pacientes fue escasa e inferior a la descrita en la bibliograf\u00eda. Sin embargo esto es \nprevisible al tratarse de pacientes refractarios a m\u00faltiples l\u00edneas de tratamiento. Dos pacientes fallecieron y otro contin\u00faa \nen tratamiento al momento de la fecha de corte del estudio.  \nEl 100% de los pacientes present\u00f3 efectos adversos y experiment\u00f3 al menos una reducci\u00f3n de dosis e interrupci\u00f3n del \ntratamiento. Las principales toxicidades fueron hematol\u00f3gicas (plaquetopenia) u oft\u00e1lmicas (queratitis), al igual que en \nlos estudios publicados (estudios DREAMM). \nEl escaso n\u00famero de pacientes estudiados en este trabajo supone una limitaci\u00f3n en los resultados, pero orienta hacia una \nmodesta efectividad de BM con importante toxicidad. Son necesarios m\u00e1s estudios con mayor tama\u00f1o muestral.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n244. ANALISIS DE EFICACIA Y SEGURIDAD DE LOS INHIBIDORES DE CICLINAS 4/6 EN CANCER DE MAMA \nMETASTASICO EN PRACTICA CLINICA HABITUAL \nAUTORES\nCHARQUES TRALLERO, V; MENDIOLA GARCIA, S; CASTRO SALINAS, P; RETAMERO DELGADO, A; SERRAIS BENAVENTE, \nJ; PARES MARIMON, RM; FERRANDEZ MARTI, D\nHOSPITAL D\u2019IGUALADA. AVDA. CATALUNYA, 1 IGUALADA. BARCELONA\nOBJETIVOS\nEl objetivo principal es analizar la eficacia y seguridad de los inhibidores de ciclinas CDK4/6 (palbociclib, ribociclib y \nabemaciclib) en pacientes con c\u00e1ncer de mama metast\u00e1sico o localmente avanzado positivo para el receptor hormonal \n(RH) y negativo para el receptor 2 del factor de crecimiento epid\u00e9rmico humano (HER2).\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en un hospital comarcal con un \u00e1rea de influencia de 110000 habitantes. Se incluyeron todos \nlos pacientes con c\u00e1ncer de mama metast\u00e1sico HER2 negativo y RH positivo que hab\u00edan recibido al menos un ciclo de \ntratamiento con un f\u00e1rmaco inhibidor de ciclinas CDK4/6 (palbociclib, ribociclib y abemaciclib) desde diciembre 2017 \nhasta mayo 2022.  \nLa recogida de datos se realiz\u00f3 a partir de los sistemas informatizados de prescripci\u00f3n electr\u00f3nica SAVAC y ESPOQ.  \nLas variables estudiadas fueron: datos demogr\u00e1ficos (sexo, edad), diagn\u00f3stico, fecha de inicio tratamiento, ECOG inicio \ny actual, n\u00famero de ciclos, respuesta cl\u00ednica en \u00faltimo seguimiento cl\u00ednico (criterios RECIST), reducci\u00f3n de dosis o \nsuspensi\u00f3n del tratamiento y sus motivos.  \nEstudio estad\u00edstico realizado con SPSS versi\u00f3n v22. Las variables cualitativas se describen con porcentaje y las \ncuantitativas con media y desviaci\u00f3n est\u00e1ndar.\nRESULTADOS\nSe incluyeron 32 pacientes (96.9% mujeres), con una edad media de 61.22 (\u00b111.5) a\u00f1os. Veinticinco (78.1%) pacientes \nfueron tratados con palbociclib, 6 (18.8%) pacientes con ribociclib y 1 (3.1%) paciente con abemaciclib. La duraci\u00f3n media \ndel tratamiento fue de 16 (\u00b114.7) meses. Actualmente est\u00e1n en tratamiento 9 (28.1%) pacientes. \nEn el grupo de palbociclib, 7 (28%) pacientes requirieron reducci\u00f3n de dosis (1a reducci\u00f3n 7 (28%) pacientes y 2\u00aa \nreducci\u00f3n 4 (16%) pacientes). Un (16.7%) paciente tuvo que reducir la dosis con ribociclib. Los efectos adversos que \nmotivaron la reducci\u00f3n de dosis fueron 71.4% neutropenia y 28.6% granulopenia.  324Respecto a la respuesta cl\u00ednica seg\u00fan los criterios RECIST del grupo de pacientes en tratamiento activo, 6 (66.7%) \npacientes se encuentran con enfermedad estable, y 3 (33.3%) con respuesta parcial.  \nDe los 23 (71.9%) pacientes que tuvieron que suspender el tratamiento, 19 (82.6%) fue por progresi\u00f3n enfermedad, 2 \n(8.7%) por toxicidad hematol\u00f3gica, 1 (4.3%) por mala adherencia a ra\u00edz de su enfermedad de Alzheimer de base y 1 (4.3%) \npor fatiga.  \nDiez (31.25%) pacientes fueron exitus, todos ellos con palbociclib.\nCONCLUSIONES\nEn los ensayos cl\u00ednicos se demostr\u00f3 que m\u00e1s de un tercio de los pacientes requirieron reducci\u00f3n de dosis con los \ninhibidores de las ciclinas CDK4/6. En nuestro estudio un 25% tuvo que reducir la dosis.  \nLa toxicidad m\u00e1s frecuente es la neutropenia, sin embargo es f\u00e1cilmente manejable con retrasos y reducci\u00f3n de dosis.  \nLa duraci\u00f3n media del tratamiento fue de 16 meses, similar a la media de supervivencia libre de progresi\u00f3n en los \nestudios cl\u00ednicos.  \nM\u00e1s del 80% de los pacientes que suspendieron el tratamiento fue por progresi\u00f3n de la enfermedad.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n274. LORLATINIB EN CANCER DE PULM\u00d3N NO MICROC\u00cdTICO: EXPERIENCIA EN LA PR\u00c1CTICA CL\u00cdNICA \nHABITUAL \nAUTORES\nGONZ\u00c1LEZ SEVILLA, M; ORTIZ PEREZ, S; BERTRAN DE LIS BARTOLOME, B; GONZALEZ GOMEZ, A; MAYO OLVEIRA, F; \nFERRARI PIQUERO, JM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID\nOBJETIVOS\nEvaluar la efectividad y seguridad de lorlatinib, inhibidor selectivo de las tirosinas quinasas ALK y oncog\u00e9n c-ros 1 (ROS1) \nen el tratamiento del c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyen todos los pacientes diagnosticados de CPNM, tratados con \nlorlatinib desde febrero 2017.  \nA trav\u00e9s de la historia cl\u00ednica electr\u00f3nica y del programa de dispensaci\u00f3n a pacientes externos se recogieron variables \ndemogr\u00e1ficas, cl\u00ednicas y farmacol\u00f3gicas: Sexo, edad, mutaci\u00f3n (ROS1 o ALK), localizaci\u00f3n de las met\u00e1stasis, l\u00edneas de \nquimioterapia previa y duraci\u00f3n del tratamiento.  \nPara evaluar la efectividad se analiz\u00f3 el grado de respuesta al tratamiento seg\u00fan criterios RECIST. La seguridad se evalu\u00f3 \nvalorando la aparici\u00f3n de efectos adversos, grado (seg\u00fan CTCAE) y manejo de los mismos.\nRESULTADOS\nSe incluyeron 12 pacientes, 7 de ellos varones, con una mediana de edad de 62 (48-85) a\u00f1os. Todos los pacientes fueron \ndiagnosticados de CPNM, de los cuales 8 (66,6 %) presentaron mutaci\u00f3n ROS1 y 4 (33,3%) mutaci\u00f3n ALK.  \n7 (58,3%) pacientes ten\u00edan met\u00e1stasis cerebrales, de los cuales 3 hab\u00edan recibido radioterapia previa al tratamiento con \nlorlatinib.  \nAl inicio del tratamiento con lorlatinib, todos los pacientes hab\u00edan recibido al menos una l\u00ednea de tratamiento. El 100% \nde los pacientes con CPNM ROS 1 hab\u00edan recibido tratamiento con crizotinib, mientras que el 100% de los pacientes con \nCPNM ALK se hab\u00edan tratado con alectinib.  \nLa mediana de la duraci\u00f3n del tratamiento fue de 8,8 meses (3,27-34,1). Al finalizar el periodo de estudio, 5 pacientes \nsegu\u00edan en tratamiento activo y 7 discontinuaron, todos debido a progresi\u00f3n de la enfermedad. \nLa tasa de respuesta global fue del 66,6% (alcanzando respuesta parcial (RP) como mejor resultado). Todos los pacientes \nque ten\u00edan met\u00e1stasis cerebrales obtuvieron RP . 4 (33,3%) pacientes mostraron estabilidad de la enfermedad.  \nEn cuanto a la seguridad, las toxicidades fueron hipercolesterolemia (n= 11; 5 grado II y 4 grado III), hipertrigliceridemia \n(n= 10; 4 grado II, 2 grado III y 1 grado IV). 8 pacientes requirieron iniciar tratamiento con estatinas y/o fibratos.  \nEn 5 pacientes se detectaron edemas en miembros inferiores (2 fueron tratados con furosemida) y 2 pacientes \ndesarrollaron neumonitis grado II que conllev\u00f3 a la interrupci\u00f3n temporal del tratamiento. En 3 pacientes fue necesario \nreducir la dosis de lorlatinib debido a la toxicidad.\nCONCLUSIONES\nLos resultados de efectividad obtenidos fueron mejores que los del ensayo pivotal, pero al tener un peque\u00f1o tama\u00f1o \nmuestral no pudimos analizar los subgrupos de mutaciones dado que en nuestro estudio se incluyeron pacientes con \nmutaci\u00f3n ROS1, indicaci\u00f3n fuera de ficha t\u00e9cnica actualmente. \nLorlatinib fue en general bien tolerado, si bien es cierto que casi todos los pacientes desarrollaron hipercolesterolemia e \nhipertrigliceridemia, en muchos casos de grado III-IV, requiriendo tratamiento para ello.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n281. EFECTIVIDAD Y SEGURIDAD DE SELUMETINIB EN PR\u00c1CTICA CL\u00cdNICA REAL \nAUTORES\nGONZ\u00c1LEZ SEVILLA, M; ARRIETA LOITEGUI, M; GONZ\u00c1LEZ G\u00d3MEZ, \u00c1; AG\u00dc\u00cd CALLEJAS, AM; MAYO OLVEIRA, F; GARC\u00cdA \nRODR\u00cdGUEZ, P; POZAS DEL R\u00cdO, M; FERRARI PIQUERO, JM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID325OBJETIVOS\nSelumetinib es un f\u00e1rmaco indicado para el tratamiento de pacientes pedi\u00e1tricos de 3 a\u00f1os en adelante con \nneurofibromatosis de tipo 1 (NF1) que presenten neurofibromas plexiformes (NP) sintom\u00e1ticos e inoperables.  \nEl objetivo de este estudio es evaluar la efectividad y seguridad de selumetinib en el tratamiento de NF1 en pr\u00e1ctica \ncl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y multic\u00e9ntrico en el que se incluyeron todos los pacientes tratados con selumetinib \nentre enero de 2020 y mayo de 2022\ufffd  \n \nA trav\u00e9s de la historia cl\u00ednica electr\u00f3nica y del programa de dispensaci\u00f3n a pacientes externos se recogieron variables \ndemogr\u00e1ficas, cl\u00ednicas y farmacol\u00f3gicas: sexo, edad, peso, superficie corporal, diagn\u00f3stico y tratamientos previos y/o \ncirug\u00edas, posolog\u00eda, duraci\u00f3n de tratamiento.  \n \nPara la evaluaci\u00f3n de la efectividad se analiz\u00f3 la respuesta al tratamiento mediante pruebas de imagen. La seguridad se \nevalu\u00f3 midiendo la aparici\u00f3n de efectos adversos (EA) y manejo de los mismos.\nRESULTADOS\nSe incluyeron 17 pacientes con una mediana de edad de 14,0 a\u00f1os (5,5-52,9), siendo el 52,9% varones (n=9). El \ndiagn\u00f3stico de todos ellos fue de NF1 con NP . El 64,7% (n=11) hab\u00eda sido operado previamente por NF1 y el 35,3%(n=6) \nno hab\u00eda recibido tratamiento ni cirug\u00eda de ning\u00fan tipo.\u202f  \n \nLa posolog\u00eda inicial fue de 25 mg/m2 seg\u00fan lo especificado en ficha t\u00e9cnica: 6%(n=1)\u202f10 mg/12h; 23,5%(n=4)\u202f20 mg/12h; \n17,6%(n=3)\u202f25 mg/12h; 23,5%(n=4)\u202f35 mg/12h; 11,8%(n=2)\u202f40 mg/12h y 17,6%(n=3)\u202f45 mg/12h.\u202f  \n \nLa mediana de seguimiento fue de 6,5 meses (1,8-23,9). En el momento de finalizar el estudio, el 88,2%(n=15) de los \npacientes segu\u00eda recibiendo tratamiento con selumetinib. Las dos suspensiones de tratamiento se debieron a toxicidad \nque no se control\u00f3 con disminuciones de dosis (elevaci\u00f3n de creatin kinasa (CK) y mialgias (6%,n=1) y situaci\u00f3n de final de \nvida (6%,n=1).\u202f  \n \nEn cuanto a la efectividad, el 80% (n=8) de los pacientes a los que se les realizaron pruebas de imagen mostr\u00f3 \nestabilidad, y el 20% (n=2) mostr\u00f3 una respuesta parcial con disminuciones del 30% y 50% del tama\u00f1o de las lesiones, \nrespectivamente. En 7 pacientes no se realizaron pruebas de imagen (1 por intolerancia a la prueba, y en 6 por inicio \nreciente del tratamiento).  \n \nLos EA relacionados con el tratamiento con selumetinib fueron: 58,8% rash cut\u00e1neo (n=10); 4,1% elevaci\u00f3n de la creatin \nkinasa (n=7); 23,5% paroniquia (n=4); 17,6% erupci\u00f3n acneiforme (n=3), prurito (n=3); aftas bucales (n=3); 11,8% \nelevaci\u00f3n de la amilasa (n=2); hipertransaminasemia (n=2); v\u00f3mitos (n=2); diarrea (n=2); dolor abdominal (n=1); aumento \nde peso (n=1); mialgias (n=1); edemas (n=1) y fiebre (n=1).  \n \nEl 6% de los pacientes (n=1) requiri\u00f3 2 reducciones de dosis debido a las mialgias con elevaci\u00f3n de CK, sin la resoluci\u00f3n \ndel EA. El 23,5% (n=4) requiri\u00f3 una reducci\u00f3n de dosis por rash, resolvi\u00e9ndose el EA en 2 de ellos. Adem\u00e1s, un paciente \nrequiere interrupciones temporales de selumetinib por episodios de fiebre.\nCONCLUSIONES\nSeg\u00fan nuestra experiencia, selumetinib es un f\u00e1rmaco con una efectividad moderada. El perfil de seguridad se \ncorresponde con el descrito en la literatura, siendo la mayor\u00eda de efectos adversos leves y manejables.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n287. EXPERIENCIA DE USO DE DAROLUTAMIDA EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA RESISTENTE \nA LA CASTRACI\u00d3N DE ALTO RIESGO \nAUTORES\nORTEGA , I; BEUNZA , M; CALVO , M; FRES\u00c1N , D; PINO , A; ERDOZ\u00c1IN , S; GO\u00d1I , N; SAROBE , M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nEvaluar la efectividad y seguridad obtenidas en vida real con darolutamida en pacientes diagnosticados de c\u00e1ncer de \npr\u00f3stata resistente a la castraci\u00f3n (CPRC) de alto riesgo.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital de tercer nivel. Se incluyeron todos los pacientes diagnosticados de \nCPRC de alto riesgo en tratamiento con darolutamida desde junio 2021 hasta abril 2022. Las variables registradas fueron: \nedad, tiempo transcurrido desde el diagn\u00f3stico de la enfermedad, tratamientos anteriores, ECOG al inicio y a los 3 meses, \nuso o no de opioides para el dolor y de \u00e1cido zoledr\u00f3nico y duraci\u00f3n del tratamiento. Todos los datos se obtuvieron a \npartir de la historia cl\u00ednica de los pacientes y del programa de dispensaci\u00f3n de la unidad de atenci\u00f3n farmac\u00e9utica a \npacientes externos\ufffd \nLa efectividad se evalu\u00f3 mediante los niveles de PSA al inicio y tras como m\u00ednimo 3 meses del comienzo del tratamiento 326con darolutamida, mediante la mejor respuesta objetiva al tratamiento (criterios RECIST), la supervivencia libre de \nprogresi\u00f3n (SLP) y la supervivencia global (SG).  \nPara evaluar la seguridad se registraron los efectos adversos y su gravedad seg\u00fan criterios CTCAE (Common Terminology \nCriteria for Adverse Events) del NCI (National Cancer Institute).\nRESULTADOS\nEntre junio 2021 y abril 2022, 8 pacientes con diagn\u00f3stico de CPRC de alto riesgo iniciaron tratamiento con darolutamida \na dosis de 600mg/12h. La mediana de edad fue de 81 a\u00f1os (69-88) y la mediana del tiempo transcurrido desde el \ndiagn\u00f3stico de la enfermedad fue de 79 meses (32-156). Todos los pacientes hab\u00edan recibido tratamiento previo de \ndeprivaci\u00f3n androg\u00e9nica y, adem\u00e1s, 2 de ellos hab\u00edan recibido tambi\u00e9n radioterapia. Todos los pacientes (100%) \nmantuvieron un ECOG entre 0 y 1. Ning\u00fan paciente tuvo que utilizar opiodes para el dolor y ninguno recibi\u00f3 tratamiento \ncon \u00e1cido zoledr\u00f3nico durante el periodo de estudio. La mediana de duraci\u00f3n del tratamiento fue de 7 meses (1-10). \nSe encontr\u00f3 una mediana de PSA al inicio del tratamiento de 12.2 ng/mL (1.4-53) y tras 3 meses como m\u00ednimo de \ntratamiento de 1.15 ng/mL (0.09-15). Se pudo evaluar la respuesta en 7 pacientes, observ\u00e1ndose en 6 (86%) enfermedad \nestable y en 1 (14%) respuesta completa. La mediana de SLP y SG no se alcanz\u00f3, aunque la SLP y la SG a los 6 meses fue \ndel 100% y 100% respectivamente. \nA nivel de seguridad, se observaron 5 eventos adversos de grado 1-2 en 4 pacientes: astenia (n=3) y anemia (n=1). No se \nprodujo ning\u00fan evento adverso de grado 3-4.\nCONCLUSIONES\nLos datos preliminares de este estudio en vida real sugieren que la efectividad de darolutamida para el tratamiento del \nCPRC de alto riesgo es buena. La mayor\u00eda de los eventos adversos recogidos fueron leves y acordes a los descritos en ficha \nt\u00e9cnica, por lo que su uso tambi\u00e9n se podr\u00eda considerar seguro. Sin embargo, hacen falta estudios con un mayor tama\u00f1o \nmuestral y tiempo de seguimiento que permitan corroborar los resultados obtenidos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n290. EFECTIVIDAD Y SEGURIDAD DE LETERMOVIR EN LA PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nMONTERO P\u00c9REZ, O; MART\u00cdNEZ BENAVIDES, J; OTERO TORRES, S; ESTEBAN GONZ\u00c1LEZ, J\u00c1; MU\u00d1OZ S\u00c1NCHEZ, C; \nMUSSETTI , A; FONTANALS MART\u00cdNEZ, S\nINSTITUTO CATAL\u00c1N DE ONCOLOG\u00cdA\nOBJETIVOS\nLetermovir es un medicamento hu\u00e9rfano indicado en profilaxis de reactivaci\u00f3n de citomegalovirus(CMV) en adultos \nseropositivos receptores de un trasplante alog\u00e9nico de c\u00e9lulas madre hematopoy\u00e9ticas, (en base al estudio pivotal \nde Marty et al.). En agosto 2021, se financi\u00f3 en Espa\u00f1a su uso restringido a la presencia de factor/es de alto riesgo de \nreactivaci\u00f3n de CMV. La Comisi\u00f3n Farmacoterap\u00e9utica del centro decidi\u00f3 su posicionamiento ligada a evaluaci\u00f3n de datos \nde vida real\ufffd \nUna de las variables del ensayo pivotal med\u00eda eficacia de letermovir como porcentaje de pacientes que iniciaban \nterapia anticipada con ganciclovir/valganciclovir seg\u00fan un umbral de carga s\u00e9rica de CMV determinado (151copias/mL). \nDicho umbral no est\u00e1 consensuado en pr\u00e1ctica cl\u00ednica habitual, y esto implica variabilidad al interpretar el beneficio de \nletermovir \ufffd \nEl objetivo del estudio fue analizar efectividad y seguridad de letermovir en un hospital monogr\u00e1fico onco/hematol\u00f3gico \ny comparar los resultados con el ensayo pivotal\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio multidisciplinar, observacional, retrospectivo que incluy\u00f3 pacientes con letermovir desde 01/08/2021 hasta \n01/04/2022. Variables: edad, sexo, factor riesgo de reactivaci\u00f3n CMV, \u00faltima carga CMV s\u00e9rica previa y durante \nletermovir, duraci\u00f3n tratamiento, terapia anticipada con ganciclovir/valganciclovir, enfermedad por CMV, ingreso por \nCMV, mortalidad en semana 14 y 24, y eventos adversos(EA). \nLos datos registrados se obtuvieron con la historia cl\u00ednica digital(SAP\u00ae) y el programa de prescripci\u00f3n electr\u00f3nica \nasistida(ESPOQ\u00ae).\nRESULTADOS\nSe incluyeron 12 pacientes (41,7% mujeres), con mediana edad 58(52-61) a\u00f1os. En cuanto al criterio de riesgo, 6(50%) \nten\u00edan donante haploid\u00e9ntico, 4(33,3%) donante no emparentado con al menos una discordancia en un locus HLA y \n2(16,7%) donante emparentado con al menos una discordancia en uno de los locus HLA. La carga viral previa al inicio de \nletermovir fue indetectable en 10(83,3%) pacientes, siendo de 51 y 181copias/\u00b5L en los 2 restantes.  \nEl tratamiento finaliz\u00f3 en 11(91,7%) pacientes, 2(18,2%) de ellos por exitus. La mediana de duraci\u00f3n del tratamiento \nfue de 93(69-100) d\u00edas. Solo 3(25%) pacientes presentaron carga de CMV s\u00e9rica durante el tratamiento (199, 303 \ny 1520copias/\u00b5L). Un \u00fanico paciente (8,3%) inici\u00f3 terapia anticipada con valganciclovir, un mes despu\u00e9s del fin de \nletermovir. Ning\u00fan paciente present\u00f3 enfermedad por CMV, ni requiri\u00f3 ingreso por CMV. La mortalidad fue evaluable \npara 11 y 10 pacientes en la semana 14 y 24, respectivamente, siendo del 18,2%(2 exitus) y 30%(3 exitus). Las muertes \nfueron debidas a shock s\u00e9ptico(2) y fallo multiorg\u00e1nico(1). Ning\u00fan paciente present\u00f3 EA atribuibles a letermovir.\nCONCLUSIONES\nLos datos obtenidos de nuestra poblaci\u00f3n en vida real sugieren que letermovir fue efectivo y seguro: la necesidad de \niniciar terapia anticipada fue escasa, ning\u00fan paciente desarroll\u00f3 enfermedad por CMV y no se presentaron EA asociados \nal f\u00e1rmaco.  327El porcentaje de pacientes que requiri\u00f3 terapia anticipada fue del 8,3% frente al 16% reportado en el brazo de letermovir \ndel estudio pivotal. Sin embargo, la mortalidad a la semana 24 fue 3 veces superior (30%) que en dicho estudio(10,2%). \nComo limitaciones, cabe destacar que el tama\u00f1o muestral de nuestro estudio y la variabilidad existente en el umbral de \ncarga s\u00e9rica de CMV para el inicio de terapia anticipada limitan la comparaci\u00f3n de los resultados obtenidos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n299. VALOR DEL RATIO NEUTR\u00d3FILO/LINFOCITO (NLR) COMO BIOMARCADOR PREDICTIVO EN \nINMUNOTERAPIA EN PACIENTES DE C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO \nAUTORES\nTOLEDO DAVIA, MA; LABRADOR AND\u00daJAR, N; TORRALBA FERN\u00c1NDEZ, L; JIM\u00c9NEZ M\u00c9NDEZ, C; BL\u00c1ZQUEZ ROMERO, \nC; MOYA G\u00d3MEZ, P\nCOMPLEJO HOSPITALARIO DE TOLEDO. AVDA. DE BARBER, 30 TOLEDO. TOLEDO\nOBJETIVOS\nEvaluar el papel del ratio Neutr\u00f3filo/linfoc\u00edtico (NLR) como biomarcador precoz de la respuesta al tratamiento con \ninmunoterapia. Analizar si los puntos de cortes m\u00e1s aceptados por la bibliograf\u00eda para NLR (3 y 5) muestran valor \npron\u00f3stico en nuestra cohorte.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo en hospital de tercer nivel en pacientes tratados con pembrolizumab. Se recogieron \nvariables demogr\u00e1ficas (sexo, edad), cl\u00ednicas (histolog\u00eda, ECOG, presencia de met\u00e1stasis en SNC y hep\u00e1ticas/\u00f3seas y fechas \nde inicio de tratamiento y progresi\u00f3n y/o \u00e9xitus) y variables hematol\u00f3gicas (recuento total de neutr\u00f3filos y linfocitos al \ninicio del tratamiento). An\u00e1lisis estad\u00edstico (programa SPSS v.25) para an\u00e1lisis de supervivencia por el m\u00e9todo de Kaplan-\nMeier y log Rank test como contraste de hip\u00f3tesis. Se realiz\u00f3 test de regresi\u00f3n de Cox para evaluar la asociaci\u00f3n entre \nvalor del NLR y la supervivencia\ufffd\nRESULTADOS\nResultaron un total de 74 pacientes tratados con pembrolizumab, 59 hombres y 14 mujeres con una mediana de edad \nde 65 [83-37] a\u00f1os. El 90% (66) con histolog\u00eda tipo adenocarcinoma y el 10% (7) tipo epidermoide, el 54% (40) de los \npacientes presentaron ECOG=0, 42% (31) ECOG=31 y un 2,7% (2) ECOG=2. El 16% (12) de los pacientes presentaron \nmet\u00e1stasis en SNC y el 29% (22) de los pacientes met\u00e1stasis hep\u00e1ticas y/u \u00f3seas. La mediana del recuento de neutr\u00f3filos \nfue de 5,45 [6,1-1,5] x109neut/L y la mediana del recuento de linfocitos fue de 1,45 [3,9-0,2] x109linf/L. En cuanto al NLR \nla mediana fue de 3,76 [9,6-0,52]. El n\u00famero de pacientes con NLR < 3 fue de 27, para NLR > 3 de 43 pacientes, para NLR \n< 5 41 pacientes y para NLR > 5 29 pacientes. \nResultados de supervivencia Kaplan-Meier:  \nPara el punto de corte NLR=3 los resultados en SLP fueron: 19,3 (12,1-26,2) IC95% meses (NLR < 3) vs. 11,24 (5,5-16,5) \nIC95% meses (NLR > 3) (p=0,05). En cuanto a SG se obtuvo una mediana de 25,9 (17,9-33,8) IC95% meses (NLR < 3) vs. \n20,1 (13,1-27,1) IC95% meses (NLR > 3) (p=0,107).  \nPara el punto de corte NLR=5 los resultados en SLP fueron: 16,1 (10,5-21,6) IC95% meses (NLR < 5) vs. 12,5 (5,1-19,9) \nIC95% meses (NLR > 5) (p=0,05). En cuanto a SG se obtuvo una mediana de 24,9 (18,5-31,3) IC95% meses (NLR < 5) vs. \n24,9 (18,5-31,3) IC95% meses (NLR > 5) (p=0,01).  \nMediante el test de regresi\u00f3n de Cox se obtuvo un HR=1,023 (p=0) para la SLP y un HR=1,028 (p=0,003) para la SG.\nCONCLUSIONES\nEl NLR parece ser \u00fatil para predecir la eficacia al tratamiento con pembrolizumab. A mayor valor de NLR parece obtenerse \nuna peor respuesta al tratamiento (HR=1,023 y 1,028). Ambos puntos de corte de NLR (3 y 5) obtienen resultados \ndiferentes en funci\u00f3n del valor de NLR en t\u00e9rminos de SLP y SG. Son necesarios m\u00e1s estudios para poder demostrar la \nasociaci\u00f3n entre el NLR y la supervivencia con los tratamientos de inmunoterapia y determinar qu\u00e9 punto de corte de \nNLR es el m\u00e1s \u00f3ptimo para cada poblaci\u00f3n.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n310. VALOR PREDICTIVO DEL INDICE DE MASA CORPORAL Y DE LA COMPOSICI\u00d3N CORPORAL EN LA \nRESPUESTA AL TRATAMIENTO CON INMUNOTERAPIA \nAUTORES\nTOLEDO DAVIA, MA; LABRADOR AND\u00daJAR, N; TORRALBA FERN\u00c1NDEZ, L; JIM\u00c9NEZ M\u00c9NDEZ, C; BL\u00c1ZQUEZ ROMERO, \nC; DOMINGUEZ BARAHONA, A; MOYA G\u00d3MEZ, P\nCOMPLEJO HOSPITALARIO DE TOLEDO. AVDA. DE BARBER, 30 TOLEDO. TOLEDO\nOBJETIVOS\nActualmente se postula que ciertos par\u00e1metros antropom\u00e9tricos pueden servir como biomarcadores predictivos en el \ntratamiento con inmunoterapia en pacientes con c\u00e1ncer. Nuestro objetivo es analizar la influencia del \u00edndice de masa \ncorporal (IMC) y la composici\u00f3n corporal (CC) en la respuesta al tratamiento con f\u00e1rmacos anti PD-L1 en pacientes con \nc\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM).328MATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo en un hospital de tercer nivel en pacientes tratados con pembrolizumab y \ndiagnosticados de CPNM. Se recogieron los datos demogr\u00e1ficos sexo y edad; talla, peso e histolog\u00eda; se calcul\u00f3 el IMC \n(kg/m2) y la CC mediante la f\u00f3rmula CUN-BAE (Estimador de adiposidad de la Cl\u00ednica Universitaria de Navarra). Se \nrevisaron las historias cl\u00ednicas de los pacientes y se recogieron las fechas desde el inicio del tratamiento hasta progresi\u00f3n \nde la enfermedad y/o \u00e9xitus por c\u00e1ncer. Se calcul\u00f3 la supervivencia libre de progresi\u00f3n (SLP) y supervivencia global (SG) \nmediante el m\u00e9todo de Kaplan-Meier y se realiz\u00f3 el log Rank test para comparar los resultados obtenidos. Tambi\u00e9n se \naplic\u00f3 el m\u00e9todo de regresi\u00f3n de Cox para evaluar la influencia del IMC y de la CC sobre la SLP y la SG. Los datos fueron \nprocesados mediante el programa inform\u00e1tico SPSS v.25.\nRESULTADOS\nResultaron un total de 74 pacientes tratados con pembrolizumab, 59 hombres y 14 mujeres con una mediana de edad de \n65 [83-37] a\u00f1os. El 90% (66) presentaban histolog\u00eda tipo adenocarcinoma y el 10% (7) tipo epidermoide; el IMC medio fue \nde 25,84 (SD 5,12), 34 pacientes con IMC normal (18,5-24,9), 25 pacientes con IMC medio-alto (25-25,9) y 11 pacientes \ncon IMC alto ( > 30). La media de CC fue de 20,24 (SD 4,35) y seg\u00fan este par\u00e1metro 48 pacientes presentaban CC normal ( \n< 20%), 11 pacientes sobrepeso (20-25%) y 11 pacientes con obesidad ( > 25%).  \nNo se encontraron diferencias estad\u00edsticamente significativas en la supervivencia calculada (ni en SLP ni en SG) para el \nIMC (p=0,368 en SG y p=0,14 en SLP)) ni para la CC (p=0,828 en SG y p=0,768 en SLP). El test de regresi\u00f3n de Cox no \nobtuvo significancia estad\u00edstica en ninguna de las variables a estudio (SLP y SG).\nCONCLUSIONES\nLos estudios publicados hasta ahora son confusos respecto al valor predictivo de par\u00e1metros antropom\u00e9tricos en la \neficacia al tratamiento con f\u00e1rmacos anti-PDL1. En nuestro estudio no se manifiesta influencia de estos par\u00e1metros sobre \nla eficacia de estos tratamientos. Son necesarios estudios espec\u00edficamente dise\u00f1ados que eval\u00faen el papel real del IMC y \nde la composici\u00f3n corporal como biomarcadores predictivos en los tratamientos con f\u00e1rmacos anti PD-L1.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n316. EFECTIVIDAD Y SEGURIDAD DE AVELUMAB COMO TRATAMIENTO DE MANTENIMIENTO EN \nPACIENTES CON CARCINOMA UROTELIAL LOCALMENTE AVANZADO O METAST\u00c1SICO \nAUTORES\nMORENO G\u00d3MEZ, \u00c1; LOZANO MEJORADA, R; JIM\u00c9NEZ CABRERA, S; MORENO G\u00d3MEZ, AM; S\u00c1EZ FERN\u00c1NDEZ, EM; \nOTERO L\u00d3PEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nLa quimioterapia basada en platino es el tratamiento est\u00e1ndar de primera l\u00ednea en pacientes con carcinoma urotelial \nlocalmente avanzado o metast\u00e1sico. Sin embargo, la supervivencia libre de progresi\u00f3n (SLP) y la supervivencia global \n(SG) se ve limitada por la resistencia de estos tumores a la quimioterapia. Avelumab es un anticuerpo monoclonal anti-\nPD-L1 recientemente financiado para el tratamiento de mantenimiento de primera l\u00ednea en pacientes con carcinoma \nurotelial localmente avanzado o metast\u00e1sico, libres de progresi\u00f3n tras recibir quimioterapia con platino, con tumores \nPD-L1 positivos, en base al incremento en SG y SLP mostrado. El objetivo de este estudio ha sido evaluar la efectividad y \nseguridad de avelumab en dicha indicaci\u00f3n, en los pacientes tratados hasta la fecha en nuestro centro.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo que incluy\u00f3 a los pacientes tratados con avelumab entre el 01/01/2021 \ny el 30/04/2022, en un hospital de cuarto nivel. \nSe registraron y analizaron variables relacionadas con el paciente (sexo, edad, ECOG e \u00edndice pronostico LIPI), el tumor \n(histolog\u00eda, localizaci\u00f3n del tumor y las met\u00e1stasis) y el tratamiento recibido (esquema de quimioterapia de inducci\u00f3n, \nn\u00famero de ciclos y respuesta obtenida, fecha de inicio y progresi\u00f3n con avelumab, n\u00famero de ciclos, fecha de exitus, \ny tipo y grado de las reacciones adversas observadas). Para estimar la SLP y la SG se emple\u00f3 el m\u00e9todo de an\u00e1lisis de \nKaplan-Meier mediante el softwareR v3.5.1.\nRESULTADOS\nSe incluyeron 8 pacientes, todos ellos con carcinoma urotelial en el tracto inferior, 5/8 (62,5%) de histolog\u00eda urotelial puro \ny los restantes con histolog\u00edas mixtas. El 75% eran hombres y la mediana (rango) de edad fue 72 (62-82) a\u00f1os. Al inicio del \ntratamiento con avelumab todos presentaban ECOG 0-1 y LIPI de buen pron\u00f3stico. En todos se identificaron met\u00e1stasis: \nen 6/8 (75%) viscerales y en 2/8 (25%) no viscerales; en ning\u00fan caso cerebrales.  \nComo quimioterapia de inducci\u00f3n 5/8 (62,5%) pacientes hab\u00edan recibido esquemas basados en platino-gemcitabina y 3/8 \n(37,5%) otros esquemas basados en platino. Tras la quimioterapia de inducci\u00f3n, 1 paciente alcanz\u00f3 respuesta completa, 4 \nparcial y 3 estabilizaci\u00f3n de enfermedad.  \nEn relaci\u00f3n a la efectividad del tratamiento con avelumab, en la fecha del an\u00e1lisis la mediana de ciclos recibidos fue de \n6,5 (3-16) ciclos/paciente. La mediana de SLP fue 4,6 meses (IC 95%, 4,1-NA), similar a la del ensayo pivotal NTC02603432 \nde 5,7 meses (IC 95%, 3,7-7,4). La mediana de SG no se hab\u00eda alc anzado.  \nRespecto a la seguridad, 7 (87,5%) pacientes presentaron reacciones adversas posiblemente relacionadas con el \ntratamiento: alteraciones de las pruebas de funci\u00f3n renal y hep\u00e1tica, trombocitopenia, hematuria, infecciones del tracto \nurinario o neumonitis. En 2 de ellos (25%) fueron de grado 3-4 y obligaron a la suspensi\u00f3n definitiva del tratamiento.329CONCLUSIONES\nAvelumab aport\u00f3 un beneficio en la SLP de los pacientes con carcinoma urotelial metast\u00e1sico PD-L1 positivos libre de \nprogresi\u00f3n tras quimioterapia basada en platino similar a la obtenida en el estudio pivotal. Aunque la toxicidad inmuno-\nrelacionada fue frecuente, la mayor parte de las reacciones adversas fueron grado 1-2 y no impidieron continuar el \ntratamiento\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n321. TOLERANCIA DE RIBOCICLIB FRENTE PALBOCICLIB EN CANCER DE MAMA MESTAST\u00c1SICO \nHORMONODEPENDIENTE HER2 NEGATIVO EN PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nOTERINO MOREIRA, I; L\u00d3PEZ GARC\u00cdA, \u00c1; HERRANZ MU\u00d1OZ, N; LOPEZ DELGADO, A; DIEZ FERN\u00c1NDEZ, R; ZHAN \nZHOU, E; MOLINA GARC\u00cdA, T; PEREZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nEvaluar la tolerabilidad de ribociclib frente palbociclib en c\u00e1ncer de mama metast\u00e1sico (CMm) hormonodependiente \nHER2 negativo.\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico observacional retrospectivo que incluy\u00f3 a mujeres que recibieron ribociclib o palbociclib m\u00e1s \ninhibidor hormonal como tratamiento de primera l\u00ednea de su CMm.  \nSe recogieron variables demogr\u00e1ficas, cl\u00ednicas y de toxicidad evaluada por criterios NCI-CTCAE v5.0. se\u00f1alando \nexpresamente si alg\u00fan efecto adverso (EA) era de grado > 1.  \nLa comparaci\u00f3n entre variables cuantitativas se realiz\u00f3 con la prueba U de Mann\u2013Whitney y las cualitativas con la prueba \nchi-cuadrado de Pearson/test exacto de Fisher.\nRESULTADOS\nSe incluyeron 56 pacientes, 32 en el grupo ribociclib con una mediana de edad 52,9 a\u00f1os (rango intercuart\u00edlico (RIC), 45,9-\n67,9) y 24 en el grupo palbociclib con una mediana de edad 61,6 a\u00f1os (RIC 51,0 -72,6). El ECOG al inicio del tratamiento \nfue 0 en el 21,9% y 1 en el 78,1%; y 54,2% y 45,8%, respectivamente. La mediana de ciclos fue 13 (RIC 6,2-23,5) con \nribociclib y 5,5 (RIC 4,0 \u2013 27,0) con palbociclib (p=0,471).  \nEn el grupo ribociclib fallecieron 18,8% de las pacientes, retrasaron ciclo de tratamiento 62,5%, redujeron dosis 56,3% \ny discontinuaron el 46,9% [10/15 por progresi\u00f3n y 5/15 por toxicidad: 2/5 toxicodermia, 2/5 hepatotoxicidad y 1/5 \nprolongaci\u00f3n de intervalo QT] frente al grupo palbociclib en el que fallecieron el 37,5% (p=0,117), retrasaron el ciclo \n45,8% (p=0,214), redujeron dosis 37,5% (p=0,165) y discontinuaron el 75,0% (p=0,034) [14/18 por progresi\u00f3n (p=0,373) y \n4/18 por toxicidad (p=0,609): 2/4 neutropenia, 1/4 toxicodermia, 1/4 astenia] \nEA hematol\u00f3gicos: en el grupo ribociclib apareci\u00f3 neutropenia en 23/32, siendo 18/23 grado 3, que supuso un retraso \nen el tratamiento en 17/32 pacientes y una reducci\u00f3n de la dosis a 14/32; frente a palbociclib, que apreci\u00f3 en 21/24 \n(p=0,158), siendo 11/21 grado 3, lo que supuso un retraso en 10/24 (p=0,074), reducci\u00f3n de dosis a 7/24 pacientes \n(p=0,068) y suspensi\u00f3n del tratamiento a 2/24 (p=0,221). En el grupo ribociclib apareci\u00f3 anemia en 4/32 casos v/s \n5/24 (p=0,475) siendo 1/5 grado 3. No hubo ning\u00fan caso de trombopenia con ribociclib y 3/24 en el tratamiento con \npalbociclib (p=0,731) con 1/3 grado 3.  \nEA no hematol\u00f3gicos ribociclib v/s palbociclib: astenia/fatiga 16/32 v/s 20/24 (p=0,010), infecciones 6/32 v/s 8/24 \n(p=0,212), mucositis 1/32 v/s 10/24 (p=0,000), artralgias/dolor muscular 17/32 (1/17 grado 2) v/s 16/24 (1/24 grado 3) \n(p=0,308), elevaci\u00f3n ALT/ASP 7/32 (3/7 grado 3) v/s 5/24 (p=0,925), dolor abdominal 6/32 v/s 12/24 (p=0,013), n\u00e1useas \n8/32 v/s 6/24 (2/6 grado 3) (p=0,204), diarrea 2/32 v/s 6/24 (3/6 grado 3) (p=0,050), estre\u00f1imiento 3/32 v/s 1/24 \n(p=0,422), picor 7/32 (1/7 grado 3) v/s 2/24 (1/2 grado 3) (p=0,160), alopecia 5/32 (1/5 grado 2) v/s 1/24 (p=0,177), \nsequedad ocular 4/32 v/s 2/24 (p=0,482), sequedad de piel 7/32 v/s 2/24 (p=0,160) y flatulencias 6/32 v/s 3/24 \n(p=0,529).\nCONCLUSIONES\nEl tratamiento con ribociclib y palbociclib sugiere un buen perfil de seguridad. En ambos, la toxicidad hematol\u00f3gica fue \nel EA m\u00e1s grave y frecuente (el resto fue com\u00fanmente de grado 1). Astenia/fatiga, mucositis, dolor abdominal y diarrea \naparece (con significaci\u00f3n estad\u00edstica) m\u00e1s frecuentemente en el tratamiento con palbociclib.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n338. EXPERIENCIA DE USO DE LUSPATERCEPT EN PACIENTES CON ANEMIA POR S\u00cdNDROME \nMIELODISPL\u00c1SICO CON P\u00c9RDIDA DE RESPUESTA A ERITROPOYETINA \nAUTORES\nRODR\u00cdGUEZ TIERNO, S; P\u00c9REZ MEN\u00c9NDEZ-CONDE, C; GUIJARRO MART\u00cdNEZ, P; PINTOR RECUENCO, MDR; G\u00d3MEZ \nDE SALAZAR L\u00d3PEZ DE SILANES, ME; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nEvaluar la efectividad y seguridad de luspatercept en la pr\u00e1ctica cl\u00ednica habitual en pacientes con S\u00edndrome \nMielodispl\u00e1sico con Sideroblastos en Anillo (SMD-SA) tratados en un hospital de tercer nivel.330MATERIALES Y M\u00c9TODOS\nSe llev\u00f3 a cabo un estudio descriptivo, longitudinal y retrospectivo, en el que se incluyeron todos los pacientes en \ntratamiento con luspatercept desde abril de 2021 hasta abril de 2022. Las variables recogidas fueron: sexo, edad, \nindicaci\u00f3n, tipo de displasia, presencia de trombocitosis, mutaci\u00f3n del gen SF3B1, dosis, n\u00famero de administraciones, \nefectividad, necesidad de transfusiones antes y durante el tratamiento, niveles de hemoglobina y reacciones \nadversas. El tratamiento se consider\u00f3 efectivo en aquellos pacientes que alcanzaron independencia de transfusiones \ncon concentrados de hemat\u00edes. En cuanto a la seguridad, se recogieron eventos adversos que aparecieron tras la \nadministraci\u00f3n de luspatercept. La informaci\u00f3n fue obtenida de la Historia Cl\u00ednica Electr\u00f3nica y del programa de \nprescripci\u00f3n oncol\u00f3gica. Los resultados se expresaron en t\u00e9rminos de media m\u00e1s desviaci\u00f3n est\u00e1ndar o mediana m\u00e1s \nrango intercuart\u00edlico (RIQ) para las variables cuantitativas y frecuencia absoluta para las variables cualitativas.\nRESULTADOS\nEn el estudio se incluyeron 6 pacientes, 5 hombres (83%) y 1 mujer (17%). La media de edad fue de 76a\u00f1os \u00b18. Todos \nellos estaban diagnosticados de SMD-SA con anemia refractaria a tratamiento con eritropoyetina. El 83% de los pacientes \npresentaban displasia unil\u00ednea y en un 67% se hall\u00f3 presencia de trombocitosis. Tambi\u00e9n un 67% presentaba la mutaci\u00f3n \ndel gen SF3B1\ufffd En todos los pacientes, la dosis prescrita al inicio del tratamiento fue de 1mg/kg cada 3 semanas, \nregistr\u00e1ndose 2 pacientes (33%) con subida de dosis hasta 1,33mg/kg cada 3 semanas y otros 2 (33%) con bajada de \ndosis a 0,8mg/kg cada 3 o 4 semanas, cumpliendo indicaciones de ficha t\u00e9cnica. La mediana de administraciones fue \nde 8(RIQ 5-14). Se observ\u00f3 una mejora en la necesidad de transfusiones; todos los pacientes precisaban recibir entre \n1 y 3 concentrados de hemat\u00edes mensuales antes de empezar el tratamiento y, tras el inicio, 5 de los pacientes (83%) \nalcanzaron independencia transfusional. En el paciente restante (17%), todav\u00eda no se ha observado mejor\u00eda cl\u00ednica, sigue \nnecesitando un concentrado mensual y se ha procedido a un aumento de dosis. Los valores de hemoglobina aumentaron \nen todos los pacientes tras la administraci\u00f3n de la primera dosis, increment\u00e1ndose m\u00e1s o manteni\u00e9ndose tras la \nadministraci\u00f3n de dosis sucesivas. Con respecto a la seguridad del f\u00e1rmaco, el 100% de los pacientes presentaron efectos \nadversos potencialmente asociados a luspatercept; los m\u00e1s frecuentes fueron fatiga y n\u00e1useas (50%), present\u00e1ndose \nen menor medida v\u00f3mitos, mareos y calambres musculares (17%). Estos efectos sucedieron tras la administraci\u00f3n de \nlas primeras dosis, reduci\u00e9ndose o no apareciendo con las siguientes. Ninguno de los pacientes requiri\u00f3 suspensi\u00f3n o \ninterrupci\u00f3n temporal del tratamiento\ufffd\nCONCLUSIONES\nLuspatercept consigue una mejora en la dependencia de transfusiones y de los valores de hemoglobina tras la \nadministraci\u00f3n de la primera dosis en condiciones de pr\u00e1ctica cl\u00ednica habitual. Muestra un buen perfil de seguridad y \ntolerabilidad; aunque se observan efectos adversos potencialmente asociados al mismo, son leves en la mayor parte de \nlos pacientes\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n358. ADHERENCIA Y CALIDAD DE VIDA EN PACIENTES CON LEUCEMIA LINFOC\u00cdTICA CR\u00d3NICA TRATADOS \nCON ANTINEOPL\u00c1SICOS ORALES. \nAUTORES\nOCHAGAV\u00cdA SUFRATEGUI, M; GIL LEMUS, M\u00c1; YA\u00d1EZ SAN SEGUNDO, L; AMADO DIAGO, CA; BARBADILLO \nVILLANUEVA, S; MART\u00cdNEZ CALLEJO, V; VILLACA\u00d1AS PALOMARES, MV; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nEvaluar la adherencia y la calidad de vida de los pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) tratados con \nantineopl\u00e1sicos orales. Comparar la adherencia y la calidad de vida seg\u00fan el f\u00e1rmaco recibido.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo prospectivo realizado de junio a noviembre de 2021 en un hospital de tercer nivel. Se incluyeron \npacientes con LLC, atendidos en la consulta de Farmacia Oncol\u00f3gica, tratados con antineopl\u00e1sicos orales desde al menos 6 \nmeses antes de la inclusi\u00f3n en el estudio. Se estim\u00f3 la adherencia mediante el cuestionario Morisky`s 8 item Medication \nAdherence Scale (MMAS-8) y el recuento de medicaci\u00f3n sobrante: se consideraron adherentes terap\u00e9uticos aquellos \npacientes cuya adherencia fue mayor o igual al 90%, seg\u00fan la evidencia disponible. Para evaluar la calidad de vida, se \nutilizaron los cuestionarios: EQ-5D-3L, Functional Assessment of Chronic Illness Therapy \u2013 Fatigue (FACIT-F) y EORTC \nQLQ-C30. Se programaron dos entrevistas telef\u00f3nicas: en el momento de la inclusi\u00f3n, para realizar los cuestionarios, \nobtener datos demogr\u00e1ficos y preguntar por el remanente de medicaci\u00f3n; y la segunda, a los 3 meses, para conocer el \nremanente de medicaci\u00f3n y calcular la tasa de adherencia. Se revis\u00f3 la historia cl\u00ednica electr\u00f3nica, recogi\u00e9ndose variables \ndemogr\u00e1ficas y cl\u00ednicas (comorbilidades seg\u00fan escala Cumulative Illness Rating Scale-Geriatric (CIRS-G)), deterioro \ncognitivo seg\u00fan Test de Pfeiffer, tratamiento farmacol\u00f3gico y efectos adversos seg\u00fan escala Common Terminology Criteria \nfor Adverse Events v5.0). El an\u00e1lisis estad\u00edstico se realiz\u00f3 con el programa SPSS\u00ae 25.0.\nRESULTADOS\nSe incluyeron 23 pacientes (100% de los candidatos): 15 hombres y 8 mujeres, con una media de 69,7 (\u00b1 8,02) a\u00f1os, con \npuntuaci\u00f3n media de 6,13 (\u00b1 4,14) en la escala CIRS-G y sin deterioro cognitivo en 18 pacientes, siendo moderado-leve \nen 5. La mediana de tratamientos concomitantes fue 5 (1-12) y de tratamientos previos para la LLC fue 1 (rango: 0-5). \nDieciocho pacientes estaban en tratamiento con ibrutinib y 5 con venetoclax, siendo la media de tiempo con ellos de 1,57 \n(\u00b1 0,98) a\u00f1os.  331Catorce pacientes no presentaban ning\u00fan efecto adverso (EA). Nueve presentaban EAs grado 1-2: hipertensi\u00f3n arterial (3 \npacientes), hematuria (2), mielotoxicidad (1), estre\u00f1imiento (1), y epistaxis y trastornos musculo esquel\u00e9ticos (1).  \nTodos los pacientes fueron adherentes seg\u00fan el recuento de medicaci\u00f3n, mientras que seg\u00fan el cuestionario MMAS-8, \n20 presentaron adherencia alta y 3 media. Los resultados del cuestionario EQ-5D-3L mostraron que todos los pacientes \neran aut\u00f3nomos para su cuidado personal y actividades cotidianas, el 70% no ten\u00edan problemas de movilidad, el \n78,3% no ten\u00eda ansiedad/depresi\u00f3n y el 56,5% presentaba alg\u00fan tipo de dolor. Seg\u00fan la escala FACIT-F, 18 pacientes \nno ten\u00edan fatiga, y 5 presentaron fatiga leve/moderada. Los resultados del cuestionario EORTC QLQ-C30 mostraron \nque los pacientes ten\u00edan un nivel funcional alto/saludable, una calidad de vida buena (66,5 puntos, rango: 58-83) y un \nbajo nivel de sintomatolog\u00eda. El an\u00e1lisis por subgrupos de tratamiento (ibrutinib vs venetoclax) no mostr\u00f3 diferencias \nestad\u00edsticamente significativas ni en la adherencia ni en la calidad de vida.\nCONCLUSIONES\nLos pacientes con LLC en tratamiento con ibrutinib o venetoclax presentan una elevada tasa de adherencia y refieren \ntener una buena calidad de vida\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n375. REAL WORLD SETTING OF OSIMERTINIB FOR NON SMALL CELL LUNG CANCER. \nAUTORES\nGARC\u00cdA PERALO, A; P\u00c9REZ AB\u00c1NADES, M; RUIZ GARC\u00cdA, S; CALVO GARC\u00cdA, A; \u00c1LVAREZ YUSTE, A; ESCUDERO \nS\u00c1NCHEZ, G; SANTOS SAN SEGUNDO, M; MORELL BALADR\u00d3N, A\nHOSPITAL UNIVERSITARIO DE LA PRINCESA \ufffd DIEGO DE LE\u00d3N, 62 MADRID \ufffd MADRID\nOBJETIVOS\nEuropean Medicines Agency (EMA) approved osimertinib for Non Small Cell Lung Cancer (NSCLC) with Epydermal Growth \nFactor Receptor (EGFR) mutations as first-line therapy or with T790M mutation.  \nTo evaluate effectiveness and safety of osimertinib in real-world setting.\nMATERIALES Y M\u00c9TODOS\nRetrospective study from May 2017 to September 2021. Patients in treatment with osimertinib at least 2 months were \nincluded\ufffd  \nData collected: age, sex, type of lung cancer, stage, EGFR and T790M mutations, previous treatment, treatment line, \ndosage, Eastern Cooperative Oncology Group (ECOG) performance status and Adverse Effects (AE). \nKaplan-Meier and Log-Rank tests were used for the statistical analysis.\nRESULTADOS\nTwenty-three patients with NSCLC were included: 95.65% (n=22) adenocarcinoma and 4.35% (n=1) large cell carcinoma. \n73.81% (n=17) were female. Mean age was 73.52 (12.45) years. All patients had EGFR mutations: 65.21% (n=15) exon \n19 deletion and 34.79% (n=8) exon 21 mutation. T790M mutation was identificated in 43.48% (n=10) patients. 82.61% \n(n=19) had metastasic NSCLC, 8.70% (n=2) stage 3, 4.35% (n=1) stage 2 and 4.35% (n=1) unknown.  \nOsimertinib was first-line therapy in 63.22% (n=15) patients. All patients started with 80 mg once daily. In 86.96% (n=20) \npatients the initial ECOG status was 0-1, 4.35% (n=1) 2-3 and 8.70% (n=2) unknown.  \nMedian Progression Free Survival (PFS) was 40.40 months (2.63-78.17). Median Overall Survival (OS) was not reached. \nThere were not statistical differences in OS/PFS according to sex, ECOG status, treatment line or T790M mutation.  \nAll grades AE were: 56.53% (n=13) diarrhea, 56.53% (n=13) cutaneous toxicity, 30.34% (n=7) paronychia, 26.10% (n=6) \nkeratitis, 21.74% (n=5) asthenia, 17.39% (n=4) stomatitis, 13.04% (n=3) gastric discomfort, 8.70% (n=2) dysgeusia, 4.35% \n(n=1) alopecia, 4.35% (n=1) nausea and vomiting and 4.35%(n=1) headache.  \nIn 21.74% (n=5) patients a dosage reduction (40 mg once daily) due to toxicity was requiered: 60% (n=3) diarrhea, 20% \n(n=1) keratitis and 20% (n=1) cutaneous toxicity.\nCONCLUSIONES\nOsimertinib demostrated to be effective. Median PFS was superior than AURA/FLAURA pivotals trials and it was not \ninfluenced by ECOG status or T790M mutation. The safety profile was similar to pivotals trials with a low rate of dosage \nreduction and none treatment interruption due to toxicity. Further research is needed to confirm these results.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n378. EFECTIVIDAD Y SEGURIDAD DE NIVOLUMAB EN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO \nAUTORES\nCODONAL DEMETRIO, A; CASARRUBIOS L\u00c1ZARO, GI; TARD\u00c1GUILA MOLINA, P; MART\u00cdNEZ RUIZ, E; DE\u00c1N BARAHONA, \nC; MENDOZA ACOSTA, I; DE JU\u00c1N-GARC\u00cdA TORRES, P; CHARA VELARDE, LE\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nNivolumab es un anticuerpo monoclonal humano de tipo IgG4 que se une al receptor PD-1 de los linfocitos T, \npotenciando la respuesta inmunitaria frente a las c\u00e9lulas tumorales.  \n \nEl objetivo del estudio fue evaluar la efectividad y seguridad de nivolumab en pacientes con c\u00e1ncer de pulm\u00f3n no \nmicroc\u00edtico metast\u00e1sico (CPNMm) en segunda l\u00ednea de tratamiento y sucesivas.332MATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyen todos los pacientes con CPNM que recibieron nivolumab a \ndosis de 3mg/Kg o dosis fija de 240 mg cada dos semanas desde agosto de 2015 hasta octubre de 2021 en un hospital \nde segundo nivel. Las variables recogidas fueron demogr\u00e1ficas y cl\u00ednicas: histolog\u00eda, h\u00e1bito tab\u00e1quico, estado funcional \n(ECOG), l\u00ednea de tratamiento, respuesta a quimioterapia previa y frecuencia de efectos adversos (EA). La efectividad se \nevalu\u00f3 mediante supervivencia global (SG), supervivencia libre de progresi\u00f3n (SLP), tasa de respuesta objetiva (TRO) \ny tasa de control de la enfermedad (TCE), calculadas mediante el estimador Kaplan-Meier con el programa estad\u00edstico \nSPSS\u00ae v.15.0. Se realiz\u00f3 an\u00e1lisis de subgrupos mediante regresi\u00f3n de Cox de histolog\u00eda, h\u00e1bito tab\u00e1quico, ECOG y \nrespuesta a quimioterapia previa.\nRESULTADOS\nSe incluyeron 65 pacientes (88 % hombres) con una mediana de edad al inicio de tratamiento de 67 a\u00f1os (RIC: 58-75). \nLa histolog\u00eda fue escamosa en el 40% de los pacientes. El h\u00e1bito tab\u00e1quico fue: ex fumadores (52%), fumadores (40%) y \nno fumadores (8%). El 54% present\u00f3 un ECOG 0-1. El 72% de los pacientes lo recibi\u00f3 en segunda l\u00ednea de tratamiento. La \nrespuesta a la quimioterapia previa fue completa (RC), parcial (RP) o enfermedad estable (EE) en el 77% de los pacientes.  \n \nLa mediana de SG y SLP fue de 5,3 meses IC95% (3,1-7,6) y 3,2 meses IC95% (1,8-4,5) r espectivamente. En el an\u00e1lisis \nde los diferentes subgrupos, la mediana de SG con IC95% fue: 4,6 meses (3,1-6,2) en el tipo histol\u00f3gico no escamoso y \n7,5 meses (4,5-10,6) en escamoso, p=0,5; 5,3 meses (2,6-7,9) en no fumadores, 7,4 meses (0,4-14,4) en ex fumadores/\nfumadores, p=0,2; 7,8 meses (3,6-12) ECOG 0-1, 3,2 meses (1,1-5,2) ECOG 2, p < 0,05; RC/RP/EE a quimioterapia previa \n6,7 meses (3,9-9,4), progresi\u00f3n de enfermedad 2,5 meses (1,1-3,9), p=0,2. Del total de pacientes reevaluados, la TRO fue \ndel 37%, mientras que la TCE fue del 50%.  \n \nLos EA m\u00e1s frecuentes fueron: astenia (37%), p\u00e9rdida de peso (19%), anemia (11%), neumonitis (8%), reacciones cut\u00e1neas \n(5%) y diarrea (5%), siendo de grado 1-2 en el 96% de los casos y grado 3-4 en el 4%.\nCONCLUSIONES\n- La mayor parte de los pacientes hab\u00edan recibido solo una l\u00ednea previa de tratamiento.  \n- La SG es mayor si el ECOG es 0-1 con diferencias estad\u00edsticamente significativas. \n- No hubo diferencias significativas seg\u00fan la histolog\u00eda, h\u00e1bito tab\u00e1quico ni la respuesta a la quimioterapia previa.  \n- La mayor parte de los efectos adversos fueron leves, siendo lo m\u00e1s frecuente la astenia, p\u00e9rdida de peso o anemia.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n395. EFICACIA DE LA VACUNACI\u00d3N FRENTE A COVID-19 EN PACIENTES CON PATOLOG\u00cdAS HEMATOL\u00d3GICAS \nEN TRATAMIENTO CON RITUXIMAB \nAUTORES\nGIL GARC\u00cdA, \u00c1; RIVAS RODRIGUEZ, MD; ROJAS ALBARR\u00c1N, A; GRAGERA G\u00d3MEZ, M; REDONGO GAL\u00c1N, C\nHOSPITAL INFANTA CRISTINA. AV . DE ELVAS, S/N BADAJOZ. BADAJOZ\nOBJETIVOS\nLas vacunas contra el Covid-19 han conseguido prevenir de una forma efectiva el desarrollo de la enfermedad grave, \naliviando la presi\u00f3n hospitalaria y la mortalidad asociada a la enfermedad. A\u00fan as\u00ed, hay ciertos grupos de pacientes, \nentre ellos los pacientes hematol\u00f3gicos en tratamiento con Rituximab. El objetivo del estudio es analizar la eficacia de las \nvacunas en este tipo de pacientes.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo de un hospital de tercer nivel de los pacientes con patolog\u00edas \nhematol\u00f3gicas que reciben o han recibido en los \u00faltimos 6 meses (Noviembre 2021 \u2013 Abril 2022) tratamiento con \nRituximab. Se recogieron variables demogr\u00e1ficas (sexo/edad), serolog\u00eda para IgG anti-Spike de SARS-CoV-2, patolog\u00eda \nhematol\u00f3gica, n\u00famero de dosis de vacunas administradas, fecha de \u00faltima administraci\u00f3n de dosis de vacuna, tiempo \nen tratamiento con Rituximab, dosis de Rituximab administradas, esquema de quimioterapia (QT) recibido, resultado \nde Prueba en Cadena de la Polimerasa (PCR) para la detecci\u00f3n de Covid-19 en alg\u00fan momento del tratamiento, \nrequerimiento de ingreso hospitalario, tasa de mortalidad. Los datos se obtuvieron de la historia cl\u00ednica del paciente \n(Jara\u00ae) y Farmatools\u00ae.\nRESULTADOS\nSe incluyeron 66 pacientes que cumpl\u00edan los criterios de tratamiento, quedando en \u00faltimo lugar 23 pacientes para \nanalizar ya que eran los que ten\u00edan una prueba serol\u00f3gica realizada recientemente. 14 (58,3%) eran hombres, 10 \nmujeres, con una media de edad de 67,8 (44-90) a\u00f1os. Los resultados de la serolog\u00eda: 20 fueron negativas (83,3%), 4 \npositivas, con niveles de anticuerpos de :22,80; 110; 133 y 171 UA/ml. Las patolog\u00edas hematol\u00f3gicas fueron: Linfoma \nfolicular 11 (45,8%) pacientes, linfoma B de c\u00e9lulas grandes 4 pacientes, Leucemia Linfoide Cr\u00f3nica (LLC) 2 pacientes, \nLinfoma bajo grado 2 pacientes, y Linfoma cut\u00e1neo, Macroglobulinemia de Waldestrom, Linfoma de la zona marginal, \nLinfoma de manto, s\u00edndrome linfoproliferativo, todos estos con 1 paciente cada uno. Las dosis de vacunas recibidas \nfueron: 8 recibieron 4 dosis, 12 recibieron 3 dosis, 3 recibieron 2 dosis y 1 no recibi\u00f3 ninguna, siendo 6 de ellas, despu\u00e9s \nde la \u00faltima dosis de Rituximab. La media de dosis de Rituximab r ecibida fue 10,8 dosis, con un tiempo medio de \ntratamiento de 14,5 meses. Los esquemas de QT utilizados fueron: 10 Rituximab-Bendamustina, 9 R-CHOP , 3 Rituximab \nen monoterapia y 1 Rituximab con Venetoclax\ufffd  \n5 pacientes tuvieron PCR positiva para SARS-CoV-2, 3 de ellos ingresaron y siendo \u00e9xitus uno de \u00e9stos.333CONCLUSIONES\nDado que los pacientes inmunocomprometidos fueron excluidos de los ensayos de las vacunas para el Covid-19, es crucial \nentender la eficacia de \u00e9stas en una poblaci\u00f3n de riesgo como son este tipo de pacientes. \nEn vista de los resultados obtenidos, la respuesta humoral frente a la vacunaci\u00f3n en pacientes que han recibido Rituximab \nrecientemente es nula en la mayor\u00eda de pacientes, y escasa en aquellos que logran desarrollar anticuerpos ( < 250 UA/ml \nen los 4 casos positivos).  \nCon estos datos y la continuidad por el momento de la pandemia, esta poblaci\u00f3n deber\u00eda recibir indicaciones espec\u00edficas, \nya que las recibidas por la poblaci\u00f3n general inmunocompetente y vacunada no son aplicables a ellos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n428. DESABASTECIMIENTO DE MITOMICINA: BUSCANDO LA OPORTUNIDAD \nAUTORES\nTORRES DEGAY\u00d3N, E; VICENTE S\u00c1NCHEZ, MP; FRANCO SERENO, MT; S\u00c1NCHEZ CADENA, AD; RODR\u00cdGUEZ MART\u00cdNEZ, \nM\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nEn diciembre de 2019 se produjo un desabastecimiento de mitomicina que condicion\u00f3 el tratamiento de los pacientes \ncon carcinoma urotelial de vejiga no m\u00fasculo invasivo de riesgo intermedio. En base a revisiones bibliogr\u00e1ficas y \nrecomendaciones cient\u00edficas se utiliz\u00f3 como alternativa epirubicina para las instilaciones intravesicales. El objetivo de este \nestudio es evaluar la efectividad y seguridad de mitomicina y epirubicina en este escenario, as\u00ed como cuantificar el coste \noportunidad generado a partir de esta estrategia.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo en el que se incluyeron pacientes diagnosticados de carcinoma urotelial \nde vejiga no m\u00fasculo invasivo de riesgo intermedio que iniciaron tratamiento con mitomicina entre 2018 y 2019 o \nepirubicina entre 2020 y 2021. Las variables recogidas fueron: sexo, edad, estadio al iniciar el tratamiento, fecha de inicio \ny fin del tratamiento, n\u00famero de ciclos recibidos, fecha de reca\u00edda, intervalo libre de progresi\u00f3n (ILE), supervivencia libre \nde enfermedad (SLE) a los 6, 12 y 18 meses, coste del tratamiento y toxicidades.  \nLos datos fueron obtenidos a trav\u00e9s de la historia cl\u00ednica y prescripci\u00f3n electr\u00f3nica. El an\u00e1lisis estad\u00edstico se realiz\u00f3 con el \nprograma SPSS Statistics utilizando la prueba Log-rank.\nRESULTADOS\nSe incluyeron 18 pacientes con mitomicina y 18 con epirubicina. La poblaci\u00f3n mayoritaria eran hombres (94,5% vs \n89%) con una mediana de edad al inicio del tratamiento de 69 y 70 a\u00f1os respectivamente. El 89% de los casos fueron \ndiagnosticados de un tumor no invasivo (Ta) y el 11% de un tumor superficial (T1), en ambos grupos, y recibieron una \nmedia de 13 ciclos con mitomicina y 11 ciclos con epirubicina\ufffd  \nAunque las medianas de ILE no se han alcanzado, comparando las curvas mediante la prueba Log-rank no se encontraron \ndiferencias estad\u00edsticamente significativas (p=0,664) entre ambos tratamientos. Tampoco se encontraron en las tasas \nde SLE: a los 6 meses (p=0,757) fue 94,4% en ambos, a los 12 meses (p=0,559) 83,3% c on mitomicina y 77,8% con \nepirubicina y a los 18 meses (p=0,460) 77,8% con mitomicina y 66,7% con epirubicina.  \nEl coste medio del tratamiento con mitomicina por paciente, antes del desabastecimiento, fue de 739,5 \u20ac, en el caso de \nepirubicina es de 211,1 \u20ac. Teniendo en cuenta que el coste actual del tratamiento con mitomicina ser\u00eda de 2085,5 \u20ac, el \ncoste oportunidad al utilizar epirubicina es de 1874,4 \u20ac por paciente. En los 2 a\u00f1os de utilizaci\u00f3n de epirubucina se ha \ngenerado un ahorro de 33.738,7 \u20ac. \nEn cuanto a la seguridad, en el 22,2% de los pacientes con mitomicina y en el 27,8% con epirubicina se registr\u00f3 alg\u00fan \nefecto adverso. Los m\u00e1s frecuentes fueron hematuria y disuria.\nCONCLUSIONES\nLas instilaciones de mitomicina y epirubicina han demostrado ser comparables tanto en efectividad como en seguridad.  \nEl presente estudio nos ha permitido posicionar la epirubicina como alternativa m\u00e1s eficiente en nuestro centro, \ngenerando un importante coste oportunidad en el tratamiento de esta patolog\u00eda.  \nNuestra experiencia pone de manifiesto que el papel del farmac\u00e9utico es de gran importancia a la hora de buscar y \nseleccionar alternativas terap\u00e9uticas eficaces, seguras y eficientes en situaciones de desabastecimiento.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n460. EFECTIVIDAD Y SEGURIDAD DE DURVALUMAB EN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO: \nEXPERIENCIA EN LA PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nCRIADO RUBIO, B; LOMARES MANZANO, I; JULI\u00c1 LUNA, FJ; ALONSO SALMER\u00d3N, FJ; DE LA CALLE RIAGUAS, B; CORT\u00c9S \nFERN\u00c1NDEZ, R; GONZ\u00c1LEZ JOGA, B; BERROCAL JAVATO, MA\nHOSPITAL NUESTRA SE\u00d1ORA DEL PRADO \ufffd CTRA \ufffd DE MADRID, KM \ufffd 114 TALAVERA DE LA REINA \ufffd TOLEDO\nOBJETIVOS\nDurvalumab es un anticuerpo monoclonal indicado en adultos con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) localmente \navanzado, no resecable, cuyos tumores expresan PD-L1 \u22651% y cuya enfermedad no haya presentado progresi\u00f3n despu\u00e9s 334de quimiorradioterapia basada en platino. En el ensayo PACIFIC, con una mediana de seguimiento (MS) de 14,5 meses, la \ntasa de supervivencia global (TSG) a los 24 meses fue del 66,3 % y la tasa de supervivencia libre de progresi\u00f3n (TSLP) a los \n12 y 18 meses fue del 55,7 % y 49,5 %\ufffd  \nEl objetivo del estudio es evaluar la efectividad y seguridad de Durvalumab en la pr\u00e1ctica cl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio observacional y retrospectivo del uso de Durvalumab en pacientes con CPNM. El periodo de estudio \nfue Enero-2018 hasta Mayo-2022. Se han empleado los programas inform\u00e1ticos Mambrino\u00ae y el m\u00f3dulo de gesti\u00f3n \nde pacientes ambulantes de Farmatools\u00ae para recoger las variables del estudio: demogr\u00e1ficas (sexo, edad), cl\u00ednicas \n(estadio, expresi\u00f3n de PD-L1, ECOG), de tratamiento (dosis, duraci\u00f3n del tratamiento, n\u00ba de ciclos y la MS del estudio). La \nefectividad se midi\u00f3 como la TSG a los 12 y 24 meses, y la TSLP a los 12 y 18 meses. La seguridad se valor\u00f3 mediante los \nefectos adversos (EA) notificados.\nRESULTADOS\nSe han analizado un total de 10 pacientes (50% mujeres), con una edad media de 67 a\u00f1os (55\u201372). El 100% de los \npacientes presentaban un diagn\u00f3stico de CPNM irresecable, el 60% histolog\u00eda epidermoide y 40% adenocarcinoma. \nTodos manifestaban un ECOG 0-1 y han recibido quimioterapia basada en platinos, 80% Carboplatino y 20% Cisplatino. \n7 pacientes presentaban expresi\u00f3n de PD-L1 > 1%, y en 3 no se midi\u00f3 por no ser requisito durante el uso compasivo. \nLa posolog\u00eda empleada fue Durvalumab 10 mg/kg cada 2 semanas durante 12 meses o hasta progresi\u00f3n/toxicidad \ninaceptable. La dosis media fue 755 mg (510\u20131000). La duraci\u00f3n media del tratamiento fueron 7,1 meses (1,5\u201312) y 14,5 \nciclos (4-24). 4 pacientes completaron 12 meses de tratamiento, un paciente continua el tratamiento a fecha del estudio, \nun paciente sufri\u00f3 progresi\u00f3n tumoral y 2 progresi\u00f3n a nivel metast\u00e1sico. Con una MS de 15, 7 meses, la TSG a los 12 y 24 \nmeses fue del 60% y 40% respectivamente. La TSLP a los 12 y 18 meses fue del 40% y 30% respectivamente. \nEn cuanto al perfil de seguridad en 2 pacientes notificaron rash cut\u00e1neo G1 y un paciente hipotiroidismo. En 2 pacientes \nse suspendi\u00f3 el tratamiento por toxicidad de grado 3, uno por neumonitis inmunomediada y otro por nefritis.\nCONCLUSIONES\nA pesar del peque\u00f1o tama\u00f1o muestral, en nuestra experiencia la TSG y la TSLP han sido ligeramente inferiores al \nensayo pivotal PACIFIC con una MS similar. La incidencia de EA G1-G2 ha sido escasa, sin embargo se han observado \ndos EA inmunomediados de G3 que han obligado a suspender el tratamiento. El uso de Durvalumab puede permitir la \nestabilizaci\u00f3n de la enfermedad en paciente con CPNM aunque el tratamiento con agentes de inmunoterapia requiere de \nuna estrecha vigilancia de los EA asociados.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n469. ACTIVIDAD DE TEBENTAFUSP EN EL TRATAMIENTO DEL MELANOMA UVEAL METAST\u00c1TICO: \nAN\u00c1LISIS RETROSPECTIVO DE LA EXPERIENCIA DE UN HOSPITAL MONOGR\u00c1FICO ONCOL\u00d3GICO \nAUTORES\nFERN\u00c1NDEZ OLIVEIRA, C; CA\u00d1IZARES PAZ, S; PORREDON ANTELO, C; REY SALIDO, M; FONTANALS MART\u00cdNEZ, S\nICO L\u2019HOSPITALET . AVDA. GRAN VIA, 2032,7 HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nOBJETIVOS\nTebentafusp es el primer tratamiento indicado en melanoma uveal irresecable o metast\u00e1sico (MUI/M) en pacientes con \nant\u00edgeno leucocitario humano A*02:01 (HLA A*02:01) positivo. Se trata de una prote\u00edna de fusi\u00f3n bioespec\u00edfica que \nforma una sinapsis inmunitaria entre linfocitos T y c\u00e9lulas cancer\u00edgenas, produciendo la lisis de las \u00faltimas. El objetivo de \neste trabajo es evaluar la respuesta obtenida y toxicidad de tebentafusp en este contexto.\nMATERIALES Y M\u00c9TODOS\nAn\u00e1lisis observacional retrospectivo de los pacientes con MUI/M tratados con tebentafusp desde su disponibilidad como \nmedicamento en situaciones especiales hasta el 10 de mayo de 2022. Se recogieron las caracter\u00edsticas demogr\u00e1ficas y \ncl\u00ednicas, las toxicidades y se evalu\u00f3 la respuesta, a los 2,5-3 meses y 6 meses del inicio, empleando criterios Response \nEvaluation Criteria In Solid Tumors (RECIST). Los datos fueron obtenidos de la Historia Cl\u00ednica Electr\u00f3nica y de la \nherramienta de soporte para la prescripci\u00f3n electr\u00f3nica de quimioterapia.\nRESULTADOS\nSe trataron un total de ocho pacientes (cinco mujeres), edad media 65,7 (rango 44-77) a\u00f1os y puntuaci\u00f3n en la escala \nEastern Cooperative Oncology Group al inicio de 0 en siete pacientes y 1 en uno. Presentaban met\u00e1stasis hep\u00e1ticas \nseis pacientes y subcut\u00e1neas dos; adem\u00e1s dos de ellos presentaban met\u00e1stasis pulmonares. En siete casos se trataba \nde la primera l\u00ednea en enfermedad avanzada; el caso restante hab\u00eda recibido previamente nivolumab en combinaci\u00f3n \nipilimumab hasta progresi\u00f3n. Recibieron una media de 6 (rango 1-13) ciclos de tebentafusp (20 mcg d\u00eda 1, 30 mcg \nd\u00eda 8, 68 mcg d\u00eda 15 y 68 mcg/semana a partir de entonces). La media de duraci\u00f3n del tratamiento fue 4,2 (rango \n8,7-0,2) meses. La respuesta a los 2,5-3 meses del inicio, fue estabilizaci\u00f3n de la enfermedad (EE) en tres pacientes y \npseudogrogresi\u00f3n/ptebentafusp en uno. Ning\u00fan paciente ha suspendido el tratamiento a la conclusi\u00f3n del estudio y \nen un caso, tras la primera dosis y el desarrollo de s\u00edndrome de liberaci\u00f3n de citoquinas (SLC) grado 3, el desenlace fue \nexitus. A la finalizaci\u00f3n del estudio, siete pacientes permanec\u00edan vivos, con una mediana de seguimiento de 3,5 meses. \nDos pacientes tuvieron SLC con la primera administraci\u00f3n que requiri\u00f3 manejo en la unidad de cr\u00edticos, siendo necesario \nel empleo de tocilizumab en un caso (exitus) y el retraso de la segunda dosis y ajuste posol\u00f3gico en el otro. Las reacciones \nadversas de cualquier grado m\u00e1s frecuentes reportadas fueron: rash 6/8, fiebre 4/8, hipotensi\u00f3n 3/8. La tolerancia \ndespu\u00e9s de las primeras 3 dosis fue buena en todos los casos.335CONCLUSIONES\nEl MUI/M es una enfermedad rara, con una SG al a\u00f1o de su diagn\u00f3stico del 50%. Tebentafusp representa una opci\u00f3n \nterap\u00e9utica \u00fanica en un escenario donde no exist\u00eda ning\u00fan tratamiento eficaz hasta el momento. A pesar de nuestro \nreducido tama\u00f1o muestral, el tratamiento ofrece resultados alentadores, donde ning\u00fan paciente ha tenido evidencia de \nprogresi\u00f3n definitiva a la finalizaci\u00f3n del estudio. En relaci\u00f3n a la seguridad, en la mayor\u00eda de los pacientes tras el primer \nciclo la tolerancia ha sido correcta, siendo necesaria la interrupci\u00f3n y ajuste de dosis en un \u00fanico caso.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n474. SEGURIDAD Y EFECTIVIDAD DE OLAPARIB EN MANTENIMIENTO EN PACIENTES CON C\u00c1NCER DE \nOVARIO TRATADAS PREVIAMENTE CON PLATINO EN RECA\u00cdDA \nAUTORES\nCHINCHILLA ALARC\u00d3N, T; PARADAS PALOMO, JD; FERN\u00c1NDEZ CUERVA, C; MART\u00cdN CLAVO, S; GALLEGO FERN\u00c1NDEZ, \nC\nCOMPLEJO HOSPITALARIO REGIONAL CARLOS HAYA. AV . CARLOS HAYA, S/N M\u00c1LAGA. MALAGA\nOBJETIVOS\nOlaparib es un inhibidor de la enzima poli adenosina 5\u00b4 difosfato ribosa polimerasa (PARP) que ha demostrado actividad \nantitumoral en pacientes con c\u00e1ncer de ovario seroso sensible al platino. Su administraci\u00f3n es v\u00eda oral.  \nEl objetivo del estudio fue evaluar la efectividad y seguridad de olaparib en mantenimiento en pacientes afectas de \nc\u00e1ncer de ovario en reca\u00edda con tratamiento basado en platino tratadas \nun hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 a todas las mujeres que recibieron terapia de mantenimiento con \nolaparib hasta mayo de 2021.  \nSe analizaron variables demogr\u00e1ficas (edad) y variables cl\u00ednicos: estadificaci\u00f3n, mutaci\u00f3n BCRA1/2, quimioterapia previa \ncon bevacizumab, respuesta cl\u00ednica parcial (RP) o completa (RC) tras quimioterapia basada en platino, reducci\u00f3n de dosis \ny eventos adversos (EA). \nLa efectividad se evalu\u00f3 mediante la supervivencia libre de progresi\u00f3n (SLP), definida como tiempo desde el inicio de \nolaparib hasta su cese por exitus, progresi\u00f3n o toxicidad inaceptable y supervivencia global (SG), definida como tiempo \ndesde inicio con olaparib hasta \u00e9xitus.  \nLos datos se obtuvieron de la historia cl\u00ednica electr\u00f3nica (HCE) y los an\u00e1lisis de SLP y SG se realizaron mediante el m\u00e9todo \nKaplan-Meier, con el programa estad\u00edstico SPSS/PC (V25.0).\nRESULTADOS\nVeinticinco pacientes fueron incluidas en el estudio, con una exclusi\u00f3n por p\u00e9rdida de seguimiento en el primer mes. \nLa mediana de edad de las pacientes fue 60 a\u00f1os (rango 40-80). Las pacientes presentaban enfermedad estad\u00edo III 96% \n(n=24) y estad\u00edo IV 4% (n=1). La mutaci\u00f3n BCRA1 fue detectada en el 36% (n=9), BCRA2 en 48% (n=12) y en 12% (n=4) \nambos (BCRA1/2). EL 48% recibi\u00f3 previamente quimioterapia con bevacizumab.  \nEl 40% (n=10) de las pacientes tuvo RP frente a platino, 48% (n=12) tuvieron RC y del 12% (n=3) no se dispone de \ninformaci\u00f3n en HCE\ufffd  \nLa mediana de tratamiento fue 18,5 meses\ufffd Respecto a la supervivencia: la mediana de SLP de nuestras pacientes fue de \n26,47 meses IC95% (17,56-35,37) y la mediana de SG de 48,93 meses IC95% (23,04-74,82).  \nEl 80% de las pacientes (n=20) presentaron EAs de cualquier grado. Los m\u00e1s frecuentes; n\u00e1useas y astenia (44%, n=11) , \nanemia y diarrea (36%, n=9) y dolor abdominal (20%, n=5). El 56% (n=14) precis\u00f3 modificaci\u00f3n de la dosis por toxicidad. \u2028\u2028\nCONCLUSIONES\nLos resultados de efectividad de nuestro estudio ponen de manifiesto que olaparib, en la pr\u00e1ctica real, produjo beneficio \ncl\u00ednico de las mujeres con c\u00e1ncer de ovario seroso de alto grado, recurrente y sensible a quimioterapia basada en platino. \nCabe destacar la diferencia en SLP de nuestra poblaci\u00f3n con la poblaci\u00f3n del Ensayo Cl\u00ednico SOLO2; 26,47 meses en \nnuestras pacientes vs. 19,1 meses en SOLO2 seg\u00fan la evaluaci\u00f3n del investigador. Este aumento en la SLP ha generado \nuna l\u00ednea de trabajo entre servicio de farmacia (SF) y servicio de onco-ginecolog\u00eda (SOG) para intentar conocer qu\u00e9 \ncaracter\u00edsticas diferenciales poseen nuestras pacientes. \nOlaparib presenta unos resultados en seguridad consistentes con los de la ficha t\u00e9cnica, con un manejo abordable, que \nrequiere un estrecho seguimiento y manejo multidisciplinar entre SF y SOG.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n488. TOXICIDAD DE DIFERENTES ESQUEMAS DE QUIMIOTERAPIA Y TRASTUZUMAB EN 645 PACIENTES \nCON ADENOCARCINOMA G\u00c1STRICO AVANZADO HER2-POSITIVO (HER2+) DEL REGISTRO AGAMENON-\nSEOM \nAUTORES\nMAC\u00cdA RIVAS, L; MART\u00cdNEZ TORR\u00d3N, A; ARIAS MART\u00cdNEZ, A; \u00c1LVAREZ MANCE\u00d1IDO, FJ; PIERAS L\u00d3PEZ, \u00c1; MATEOS \nRUEDA, L; CARBAJALES \u00c1LVAREZ, M; LOZANO BL\u00c1ZQUEZ, A\nHOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS \ufffd AVENIDA DE ROMA S/N OVIEDO \ufffd ASTURIAS336OBJETIVOS\nAnalizar la toxicidad de diferentes esquemas de tratamiento quimioter\u00e1pico empleados en el tratamiento del \nadenocarcinoma g\u00e1strico avanzado (AGA) HER2 positivo (HER2+) basados en platino (oxaliplatino o cisplatino) y \nfluoropirimidinas (5-fluorouracilo (5FU) o capecitabina) combinados con trastuzumab.\nMATERIALES Y M\u00c9TODOS\nSe incluyeron pacientes con adenocarcinoma gastroesof\u00e1gico avanzado HER2+ procedentes de un registro ambispectivo, \nnacional y multic\u00e9ntrico (34 centros) tratados en primera l\u00ednea con poliquimioterapia y trastuzumab entre 2008 y 2021.  \n \nLos esquemas de quimioterapia administrados fueron 5FU y cisplatino (FP), capecitabina y cisplatino (XP), 5FU y \noxaliplatino (FOLFOX) y capecitabina y oxaliplatino (CAPOX) asociados con trastuzumab (T).  \n \nLa toxicidad se clasific\u00f3 a trav\u00e9s de la escala de toxicidad Common Terminology Criteria for Adverse Events (CTCAE), \nconsider\u00e1ndose graves aquellos de grado 3-4.  \n \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 empleando R 4.0.5.\nRESULTADOS\nSe incluyeron un total de 645 pacientes. El efecto adverso m\u00e1s frecuente fue la astenia, 78% con XP-T y FOLFOX-T, 75% \ncon FP-T y 63% con CAPOX-T; seguidos por la anemia, neutropenia, diarrea y emesis.  \n \nRespecto a la toxicidad hematol\u00f3gica, la trombopenia se observ\u00f3 en mayor grado en los esquemas basados en \noxaliplatino (CAPOX-T 31%, FOLFOX-T 44%) respecto a los esquemas basados en cisplatino (XP-T 18%, FP-T 15%). La \nneutropenia fue similar con todos los esquemas empleados (XP-T 57%, FP-T 60%, CAPOX-T 37%, FOLFOX-T 63%).  \n \nLa neuropat\u00eda fue m\u00e1s frecuente con esquemas basados en oxaliplatino (CAPOX-T 74%, FOLFOX-T 74%) siendo rara la \ngrado 3-4 (CAPOX-T 1%, FOLFOX-T 9%). En los esquemas basados en cisplatino la neuropat\u00eda fue menos frecuente (XP-T \n31%, FP-T 17%) pero m\u00e1s pacientes presentaron toxicidad grado 3-4 (XP-T 4% y FP-T 5%).  \n \nLas trombosis fueron m\u00e1s frecuentes con esquemas basados en cisplatino (XP-T, 13% y FP-T 17%) respecto a los basados \nen oxaliplatino (CAPOX-T 4%, FOLFOX-T 11%).  \n \nLa alopecia fue mayor con esquemas basados en cisplatino (XP-T 26%, FP-T 27%) que con oxaliplatino (CAPOX-T 2%, \nFOLFOX-T 8%).  \n \nLos esquemas con capecitabina se asociaron con mayor incidencia de s\u00edndrome mano-pie (XP-T 44%, CAPOX-T 43% versus \nFOLFOX-T 19%, FP-T 10%).  \n \nLa toxicidad grave m\u00e1s frecuente fue la neutropenia. Los efectos adversos graves fueron diferentes seg\u00fan el r\u00e9gimen de \ntratamiento, siendo la diarrea m\u00e1s frecuente en la combinaci\u00f3n XP-T (11%), la estomatitis en FP-T (11%), astenia y emesis \nen CAPOX-T (7%) y neuropat\u00eda con FOLFOX-T (9%).  \n \nCasi una cuarta parte los pacientes tuvieron que ser hospitalizados debido a la toxicidad, 30% de los tratados con XP-T \nfrente a un 20-21% de los que recibieron CAPOX-T, FOLFOX-T o FP-T.  \nLas muertes t\u00f3xicas fueron muy infrecuentes, pero s\u00f3lo se dieron con los esquemas que contienen capecitabina (XP-T, 2% \nversus CAPOX-T, 1%).\nCONCLUSIONES\nEn esta serie multic\u00e9ntrica de pacientes con adenocarcinoma gastroesof\u00e1gico HER2+ que reciben quimioterapia y \ntrastuzumab se confirma diferente perfil de toxicidad seg\u00fan el esquema de quimioterapia lo que puede ayudar en la \nselecci\u00f3n del tratamiento\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n498. EFECTIVIDAD DE CARBOPLATINO ASOCIADO A TAXANO EN EL TRATAMIENTO NEOADYUVANTE DEL \nC\u00c1NCER DE MAMA TRIPLE NEGATIVO \nAUTORES\nTOLOSA MART\u00cdNEZ, C; COLOMA PERAL, R; GALLEGOS SANCHO, MI; P\u00c9REZ ROBRES, Y; SANZ RODR\u00cdGUEZ, SM; RICO \nGUTI\u00c9RREZ, T; RUIZ MOLINA, F\nHOSPITAL GENERAL DE SEGOVIA \ufffd CTRA \ufffd DE AVILA, S/N SEGOVIA \ufffd SEGOVIA\nOBJETIVOS\nEl objetivo fue describir la efectividad de la combinaci\u00f3n de carboplatino junto con taxano (CT) tras esquema basado \nen antraciclinas en el tratamiento neoadyuvante del c\u00e1ncer de mama triple negativo en condiciones de pr\u00e1ctica cl\u00ednica \nhabitual.337MATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, en el que se incluyeron a todos los pacientes que hab\u00edan recibido CT tras \nantraciclinas como tratamiento neoadyuvante del c\u00e1ncer de mama triple negativo entre mayo del 2014 y abril de 2022 en \nun hospital de segundo nivel. \nLas variables recogidas fueron sexo, edad, \u00edndice de masa corporal (IMC), menopausia, tama\u00f1o del tumor y ganglios \nafectados al diagn\u00f3stico (seg\u00fan clasificaci\u00f3n TNM), grado de proliferaci\u00f3n (ki67), grado de Nottingham, esquema de \ntratamiento, n\u00famero de ciclos e intensidad de dosis de la quimioterapia (QT), motivo de reducci\u00f3n de dosis o suspensi\u00f3n \ndel tratamiento con CT, respuesta al tratamiento previo a la cirug\u00eda y tipo de cirug\u00eda. Los datos se obtuvieron del \nprograma inform\u00e1tico de gesti\u00f3n de pacientes ambulantes y de la historia cl\u00ednica informatizada y se registraron en una \ntabla de Microsoft Excel\u00ae 2013.\nRESULTADOS\nEn el estudio se incluyeron 26 pacientes (100% mujeres). \nCon respecto a los datos demogr\u00e1ficos: la mediana de edad fue de 56.5 a\u00f1os (30-84); el 7.7% de las pacientes present\u00f3 \nun IMC (kg/m2) menor de 20, el 30.8% entre 20-25 y el 61.5% mayor de 25; el 19.2% mujeres premenop\u00e1usicas, el 73.1% \npostmenop\u00e1usicas y desconocido el 7.7%.  \nCon respecto a la cl\u00ednica: el tama\u00f1o del tumor en 69.2% de las pacientes fue T2, el 23.1% T3 y el 7.7% T4; la presencia de \nganglios afectados se clasificaron como N0 en el 42.3% de las pacientes, N1 el 42.3%, N2 el 3.8% y N3 el 11.6%; el 88.5% \nde las pacientes present\u00f3 ki67 > 20%, el 7.7% ki67 < 20% y en el 3.8% no hay datos; seg\u00fan el grado de Nottingham, el \n19.3% de las pacientes present\u00f3 G2, el 76.9% G3 y no se conoc\u00eda en el 3.8%.  \nEn cuanto al tratamiento QT: todas las pacientes fueron tratadas con antraciclinas, recibiendo el 57\ufffd7% antraciclina y \nciclofosfamida (AC) a dosis densas (DD), el 34.6% AC no DD y el 7.7% otros; el 84.6% recibi\u00f3 carboplatino (AUC2) con \npaclitaxel (80mg/m2) semanal, el 7.7% recibi\u00f3 carboplatino (AUC5) con paclitaxel (175mg/m2) trisemanal y el 7.7% \nrecibi\u00f3 carboplatino (AUC5) con docetaxel (75mg/m2) trisemanal; el 30.8% del total no pudo completar el tratamiento \ncon CT. El 15.6% necesit\u00f3 reducci\u00f3n de dosis del esquema CT. La toxicidad hematol\u00f3gica fue la causa de no recibir pauta \ncompleta o necesitar reducci\u00f3n de dosis\ufffd El 69\ufffd3% obtuvo respuesta completa, el 26\ufffd9% obtuvo respuesta parcial y se \ndesconoce la respuesta en el 3\ufffd8%\ufffd  \nCon respecto a la cirug\u00eda: el 69.2% se someti\u00f3 a cirug\u00eda conservadora mientras que en el 30.8% la cirug\u00eda fue radical. Fue \nnecesaria realizar linfadenectom\u00eda al 50.0% de las pacientes.\nCONCLUSIONES\nNuestros resultados muestran que la asociaci\u00f3n de carboplatino a la QT neoadyuvante en el tratamiento del c\u00e1ncer de \nmama triple negativo es efectiva para obtener respuesta completa en los pacientes, acorde con lo descrito en la literatura \ncient\u00edfica.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n521. AN\u00c1LISIS DEL PATR\u00d3N DE AUTORIZACI\u00d3N DE LOS TRATAMIENTOS FARMACOL\u00d3GICOS PARA EL \nMIELOMA M\u00daLTIPLE \nAUTORES\nGARRIDO ALEJOS, G; GAS\u00d3 GAGO, I; V\u00c1LLEZ VALERO, L; RIBA SOL\u00c9, M; MANGUES BAFALLUY , MA; PONTES GARC\u00cdA, \nC; FELIU RIBERA, A; VALLANO FERRAZ, A\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nAnalizar la evoluci\u00f3n temporal del patr\u00f3n de autorizaci\u00f3n de los tratamientos farmacol\u00f3gicos para el mieloma m\u00faltiple \n(MM) en Espa\u00f1a.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo en el que se identificaron los tratamientos farmacol\u00f3gicos para el MM con opini\u00f3n \npositiva del Comit\u00e9 de Medicamentos de Uso Humano (CHMP) mediante la consulta en la p\u00e1gina web de la Agencia \nEuropea del Medicamento (EMA) de los res\u00famenes (meeting highlights e informes mensuales), las agendas y las actas de \nlas reuniones del comit\u00e9 disponibles para los \u00faltimos 11 a\u00f1os (desde enero de 2011 hasta abril de 2022). Para identificar \ntratamientos autorizados antes de 2011 y tratamientos aprobados por v\u00eda no centralizada se realizaron b\u00fasquedas no \nsistem\u00e1ticas en las webs de la EMA y de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, respectivamente. \nSe excluyeron los inmunoestimulantes y los tratamientos basados en un agente quimioter\u00e1pico (QT) que no incluyen un \ninhibidor del proteasoma (PI), un inmunomodulador (IMiD) o un anticuerpo monoclonal (mAb), ya que no forman parte \nde los tratamientos utilizados en la actualidad. Para cada esquema de tratamiento se recogi\u00f3 la fecha de autorizaci\u00f3n, la \nl\u00ednea de tratamiento del MM en la que est\u00e1 indicado, el n\u00famero de f\u00e1rmacos que forman parte del tratamiento, la clase \nterap\u00e9utica de los f\u00e1rmacos y el tipo de autorizaci\u00f3n de los f\u00e1rmacos.\nRESULTADOS\nSe identificaron 39 tratamientos autorizados para el MM, de los que se excluyeron seis (un inmunoestimulante y cinco \nbasados en un QT) y se seleccionaron 33: tres (9,1%) autorizados entre 2005 y 2010, 10 (30,3%) entre 2011 y 2015, y 20 \n(60,6%) entre 2016 y abril de 2022. Todos los seleccionados fueron autorizados por v\u00eda centralizada. Cuatro tratamientos \n(12,1%) estaban indicados en primera l\u00ednea en pacientes candidatos a trasplante de progenitores hematopoy\u00e9ticos (TPH), \nsiete (21,2%) en primera l\u00ednea en pacientes no candidatos a TPH, 15 (45,5%) a partir de la segunda l\u00ednea de tratamiento, \ncuatro (12,1%) a partir de la tercera l\u00ednea, uno (3,0%) a partir de la cuarta l\u00ednea y dos (6,1%) a partir de la quinta l\u00ednea. 338Del total, cinco tratamientos (15,2%) eran monoterapias y 28 (84,8%) eran combinaciones de dos f\u00e1rmacos (ocho \ntratamientos, 24,2%), tres f\u00e1rmacos (18 tratamientos, 54,5%) o cuatro f\u00e1rmacos (dos tratamientos, 6,1%). Respecto a \nla clase terap\u00e9utica de los f\u00e1rmacos, 27 tratamientos (81,8%) inclu\u00edan un corticoide, 18 (54,5%) un PI, 17 (51,5%) un \nIMiD, 12 (36,4%) un mAb, cinco (15,2%) un QT, uno (3%) un inhibidor de la histona deacetilasa, uno (3%) un inhibidor de \nexportina y uno (3%) una terapia g\u00e9nica. Cinco f\u00e1rmacos recibieron una autorizaci\u00f3n condicional cuando se aprobaron: \ndaratumumab (mAb) e ixazomib (PI) en 2016, belantamab mafodotin (mAb) en 2020, y selinexor (inhibidor de exportina) \ne idecabtagen vicleucel (terapia g\u00e9nica) en 2021.\nCONCLUSIONES\nEl n\u00famero de tratamientos autorizados para el MM se ha duplicado aproximadamente cada 5 a\u00f1os. La mayor\u00eda se basan \nen la combinaci\u00f3n de tres f\u00e1rmacos y las indicaciones m\u00e1s frecuentes son la primera l\u00ednea en pacientes no candidatos a \nTPH y la segunda l\u00ednea. Los grupos terap\u00e9uticos m\u00e1s representados son los corticoides, los IMiD y los PI.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n533. AN\u00c1LISIS GEN\u00c9TICO PARA EVITAR TOXICIDADES: FLUOROPIRIMIDINAS Y EL GEN DE LA \nDIHIDROPIRIMIDINA DESHIDROGENASA. \nAUTORES\nLUQUE JIM\u00c9NEZ, M; ANGUITA MONTENEGRO, B; VICENTE S\u00c1NCHEZ, MP; NIETO SANDOVAL MART\u00cdN DE LA SIERRA, \nP; BUCES GONZ\u00c1LEZ, E; RODR\u00cdGUEZ MART\u00cdNEZ, M\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nEn mayo de 2020 la AEMPS (Agencia espa\u00f1ola del medicamento y productos sanitarios) public\u00f3 una nota de seguridad \nen la que se recomienda realizar la determinaci\u00f3n del gen de la dihidropirimidina deshidrogenasa (DPYD) a todos los \npacientes candidatos a tratamientos con fluoropirimidinas (5-fluorouracilo, capecitabina). A partir de ese momento se \nempez\u00f3 a implantar dicha determinaci\u00f3n en los diferentes hospitales de nuestro pa\u00eds. El objetivo de este estudio es \ndescribir las caracter\u00edsticas de nuestra poblaci\u00f3n en funci\u00f3n de su genotipo DPYD y evaluar el grado de cumplimiento de \nlas recomendaciones seg\u00fan el tipo de metabolizador.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Se incluyeron todos los pacientes a los que se les realiz\u00f3 el an\u00e1lisis genot\u00edpico \nDPYD desde su implementaci\u00f3n en noviembre 2020 hasta noviembre 2021. Se recogieron variables antropom\u00e9tricas, \nlocalizaci\u00f3n del tumor, variante DPYD (wilde type, DPYD*2A, DPYD*13, c.2846A > T, HapB3), tipo de alelos y de \nmetabolizador (normal, intermedio o pobre) y la decisi\u00f3n terap\u00e9utica tomada en base a los resultados: no iniciar \nfluoropirimidinas, reducci\u00f3n de dosis o no seguir las recomendaciones. El estudio obtuvo el dictamen favorable del \ncomit\u00e9 de \u00e9tica de investigaci\u00f3n con medicamentos del centro.\nRESULTADOS\nSe incluyeron 231 pacientes. El 38,8% (90) presentaban c\u00e1ncer de colon, 25,9% (60) recto, 12,5% (29) g\u00e1strico, 9,5% (22) \np\u00e1ncreas, 3,9% (9) biliar, 3% (7) pulm\u00f3n, 2,6% (6) es\u00f3fago y 3.9% (9) otros.  \n \nEl 93,5% (217) fueron wild type para DPYD, el 0.9% (2) presentaba DPYD*2A, 1,3% (3) c.2846A > T, 4,7% (11) HapB3 y \nninguno DPYD*13. El 100% alelos heterocigotos.  \n \nEl 5.6% (13) fueron metabolizadores intermedios, presentando un alelo con reducci\u00f3n de funci\u00f3n y otro normal y 0,4% (1) \nmetabolizador pobre, presentando dos variantes distintas con p\u00e9rdida de funci\u00f3n.  \n \nDe los 13 pacientes metabolizadores intermedios, 3 optaron por otras alternativas terap\u00e9uticas y 10 iniciaron \nfluoropirimidinas. El 90% de los que iniciaron fluoropirimidinas, cumplieron con las recomendaciones iniciando al 50% de \nla dosis correspondiente y el 10% inici\u00f3 al 100%, presentando toxicidad y finalizando tratamiento tras la primera dosis.\nCONCLUSIONES\nLa frecuencia al\u00e9lica de nuestra poblaci\u00f3n sigue un patr\u00f3n similar a la presentada en Europa, siendo la m\u00e1s frecuente \nla variante HapB3 (2.6-6.3% vs 4.33%). Est\u00e1 descrito que la variante *2A (1.6-1%) es m\u00e1s frecuente que la c.2846A > T \n(1.1-0.7%), sin embargo, en nuestro caso es a la inversa (0.87% vs 1,30%, respectivamente). La variante descrita como la \nmenos frecuente, DPYD*13, no fue detectada.  \nEn cuanto a tipo de metabolizadores, nuestra poblaci\u00f3n tambi\u00e9n est\u00e1 dentro de la media europea tanto de \nmetabolizadores intermedios (3-9% vs 5,56%) como de metabolizadores pobres (0.01-0.5% vs 0,43%). Existe un alto grado \nde cumplimiento de las recomendaciones, evitando iniciar a dosis completas en pacientes con reducci\u00f3n de funci\u00f3n DYPD \ny posibilidad aumentada de desarrollar toxicidades\ufffd  \nLa comprobaci\u00f3n de la realizaci\u00f3n de la prueba DPYD previo al inicio de fluoropirimidinas, as\u00ed como de la modificaci\u00f3n de \nla dosis en funci\u00f3n de su resultado debe formar parte de la validaci\u00f3n farmac\u00e9utica rutinaria para evitar el desarrollo de \ntoxicidades graves que condicionen retrasos o cambio de l\u00ednea comprometiendo su efectividad.339CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n534. ESTUDIO COMPARATIVO DE EFECTIVIDAD Y SEGURIDAD DE FOSAPREPITANT/ONDANSETRON/\nDEXAMETASONA Y NETUPITANT/PALONOSETRON/DEXAMETASONA EN LA PREVENCI\u00d3N DE N\u00c1USEAS \nY V\u00d3MITOS INDUCIDOS POR QUIMIOTERAPIA \nAUTORES\nIGLESIAS RODRIGO, M; MANZANEQUE , A; MOLAS , G; ALONSO , C; L\u00d3PEZ , L; NOGUERA , C; SEBASTI\u00c1N , C; NICOL\u00c1S \n, J\nHOSPITAL UNIVERSITARI MUTUA DE TERRASSA \ufffd PLAZA DOCTOR ROBERT 5 TERRASSA \ufffd BARCELONA\nOBJETIVOS\nComparar la efectividad y seguridad de fosaprepitant/ondansetron/dexametasona (FOSA-od) y netupitant/palonosetron/\ndexametasona (NEPA-d) en la prevenci\u00f3n de n\u00e1useas y v\u00f3mitos inducidos por quimioterapia (NAVIQ).\nMATERIALES Y M\u00c9TODOS\nEstudio de cohortes prospectivo en un hospital universitario de 450 camas. Se incluyeron todos los pacientes que \niniciaron tratamiento con esquemas considerados altamente emet\u00f3genos.  \n \nLa protecci\u00f3n antiem\u00e9tica se realiz\u00f3 con FOSA-od durante enero-febrero de 2022 y con NEPA-d en marzo-abril.  \nPara evaluar la efectividad del tratamiento antiem\u00e9tico se consider\u00f3 como variable principal el control total (no presencia \nde v\u00f3mitos y valor EVA para n\u00e1useas inferior a 5) de NAVIQ agudos y retardados, a las 24 horas (CT24) y a los 4 d\u00edas (CT4) \nrespectivamente. Como variables secundarias se consideraron: control de n\u00e1useas (escala EVA < 5) agudas (EVA24) y \nretardadas (EVA4), y necesidad de rescates con olanzapina.  \n \nLas variables recogidas v\u00eda telef\u00f3nica, por parte de la unidad de farmacia oncol\u00f3gica, fueron: demogr\u00e1ficas (edad/sexo); \ntratamiento antineopl\u00e1sico; antiem\u00e9tico (FOSA-od/NEPA-d); n\u00famero de v\u00f3mitos, EVA de n\u00e1useas y necesidad de rescates \ncon olanzapina, a las 24 horas y 4 d\u00edas del primer ciclo de quimioterapia, y efectos adversos asociados al esquema \nantiem\u00e9tico.  \nAdem\u00e1s, se realiz\u00f3 una valoraci\u00f3n del riesgo individual basal de NAVIQ, mediante el algoritmo Junker y Wieldman (alto \nriesgo/riesgo est\u00e1ndar).  \n \nLos resultados de las variables continuas se expresaron como media y desviaci\u00f3n est\u00e1ndar (DE), las variables categ\u00f3ricas \ncomo frecuencias y porcentajes. Para la comparaci\u00f3n de variables num\u00e9ricas, se utiliz\u00f3 la prueba t-Student o Mann-\nWitney. La asociaci\u00f3n entre variables cualitativas se estudi\u00f3 mediante el test Ji-cuadrado de Pearson o exacto de Fisher. \nSe consider\u00f3 estad\u00edsticamente significativo p < 0.05.\nRESULTADOS\nSe incluyeron 91 pacientes. Las caracter\u00edsticas basales para FOSA-od (n=48) y NEPA-d (n=43) fueron: edad (56,5 [DE:11,9] \nvs. 58,6 [DE: 12,5]); p=0,4083), sexo (68,8% mujeres vs. 69,8%; p=0,916) y alto riesgo NAVIQ (72,9% vs. 72,5%; p=0,930).  \nLos esquemas preescritos para el grupo FOSA-od y NEPA-d fueron respectivamente: antraciclinas+ciclofosfamida: 37,5% \nvs. 37,2%; carboplatino AUC \u22654: 37,5% vs. 34,9%, cisplatino 18,8% vs. 20,9%, carmustina: 4,2% vs. 4,7%, y dacarbazina: \n2,0% vs\ufffd 2,3%\ufffd \n \nPara FOSA-od vs. NEPA-d, se registr\u00f3: CT24 del 93,8% vs 93,0% (p=1,000), CT4 del 83,3% vs 86,1% (p=0,720); EVA24 del \n93,8% vs. el 95,4% (p=1.000) y EVA4 del 83,3% vs. 88,4% (p=0,493). \n \nLos pacientes del grupo FOSA-od vs. NEPA-d que requirieron rescates de olanzapina a las 24 horas y 4 d\u00edas fueron del \n12,5% vs. 4,65% (p=0,273) y 18,8% vs. 14,0% (p=0,538), respectivamente. \n \nLas principales toxicidades para FOSA-od vs. NEPA-d fueron: cefalea (60,4% vs. 53,5%; p=0,505), estre\u00f1imiento (39,58% \nvs. 25,58%; p=0,156), insomnio (39,6% vs. 14,0%; p=0,006), sofocos (39,6% vs. 7,0%; p=0,000) e inquietud (35,4% vs. \n2,3%; p=0,000).\nCONCLUSIONES\nNo se observaron diferencias estad\u00edsticamente significativas en las caracter\u00edsticas basales de los pacientes.  \n \nTodas las variables de efectividad comparadas no mostraron diferencias significativas, siendo ambos tratamientos \nantiem\u00e9ticos equivalentes en nuestra muestra. Sin embargo, se observ\u00f3 en el grupo de NEPA-d un menor porcentaje de \ninquietud, sofocos e insomnio, confirm\u00e1ndose una mayor seguridad para este esquema antiem\u00e9tico.  \n \nPor todo ello, el uso de NEPA-d es una alternativa adecuada a FOSA-d en la prevenci\u00f3n de NAVIQ en esquemas \nantineopl\u00e1sicos altamente emet\u00f3genos.340CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n536. ATENCI\u00d3N FARMAC\u00c9UTICA A PACIENTES EN EL CICLO 2 DE TRATAMIENTO ORAL EN UNA UNIDAD \nDE FARMACIA ONCOHEMATOL\u00d3GICA \nAUTORES\nCODINA-JIM\u00c9NEZ , C; LEZCANO RUBIO, C; ROMERO DOM\u00cdNGUEZ, R; V\u00c9LEZ PUIG, S; RODR\u00cdGUEZ-BERNUZ , C; VALLS \nS\u00c1NCHEZ, E; QUI\u00d1ONES RIBAS, C; MUNN\u00c9 GARCIA, M\nINSTITUT CATAL\u00c0 D\u2019ONCOLOGIA BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nOBJETIVOS\nRealizar una entrevista cl\u00ednica de seguimiento a los pacientes en el ciclo 2 de tratamiento oral oncohematol\u00f3gico y \ndeterminar si hay diferencias en la proporci\u00f3n de efectos adversos (EA) seg\u00fan edad y polifarmacia con el fin de evaluar la \nnecesidad de la implantaci\u00f3n de una visita de seguimiento adicional\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio transversal, observacional y prospectivo realizado durante los meses de marzo y abril de 2022 en una consulta \nde atenci\u00f3n farmac\u00e9utica oncohematol\u00f3gica de un hospital de tercer nivel. Se incluyeron todos los pacientes con \ntratamiento oral oncohematol\u00f3gico que acud\u00edan para la dispensaci\u00f3n del ciclo 2.  \nMediante la revisi\u00f3n de la historia cl\u00ednica se recogieron las siguientes variables: sexo, edad, patolog\u00eda, polifarmacia (\u2265 5 \nf\u00e1rmacos), \u00edndice de Charlson, soporte social y barrera idiom\u00e1tica. Con la entrevista cl\u00ednica personalizada al paciente se \nverific\u00f3 la adherencia y la comprensi\u00f3n de la pauta farmacol\u00f3gica preguntando el n\u00famero de comprimidos tomados y la \nforma de administraci\u00f3n. Se recogieron los EA y la omisi\u00f3n de alguna toma por dicha causa, inclusi\u00f3n de alguna nueva \nmedicaci\u00f3n, las consultas y/o visitas a urgencias y la causa, as\u00ed como la b\u00fasqueda de informaci\u00f3n relacionada con el \ntratamiento o falta de la misma que les gustar\u00eda haber recibido por parte del farmac\u00e9utico. Tambi\u00e9n, se recogieron las \nconsultas realizadas por parte del paciente. \nSe realiz\u00f3 el test chi-cuadrado para determinar las diferencias en la proporci\u00f3n de EA entre los pacientes con y sin \npolifarmacia y el test t-student para determinarlas seg\u00fan la edad.\nRESULTADOS\nSe incluyeron 49 pacientes (53% hombres) con una edad media de 65,2 \u00b1 12,4 a\u00f1os. El 65,3% de las patolog\u00edas eran \noncol\u00f3gicas, el 55,1% de los pacientes eran polimedicados y presentaban un \u00edndice de Charlson de 4,4 \u00b1 2,3. El 75% de los \npacientes vinieron acompa\u00f1ados y solamente 1 present\u00f3 barrera idiom\u00e1tica. \nDe la entrevista realizada solamente 1 paciente se tom\u00f3 incorrectamente la medicaci\u00f3n y 3 tuvieron alg\u00fan olvido. El \n71,4% present\u00f3 alg\u00fan efecto adverso durante el primer ciclo, los m\u00e1s frecuentes fueron: 48,6 % toxicidad gastrointestinal, \n40 % astenia y 22,9 % toxicidad cut\u00e1nea. El 20,4% de los pacientes ten\u00edan prescrita alguna medicaci\u00f3n nueva en el \u00faltimo \nmes, generalmente relacionada con el tratamiento de los EA. Necesitaron realizar alguna consulta extra el 18,4% de \nlos pacientes. Durante la entrevista farmac\u00e9utica de seguimiento se reforz\u00f3 la educaci\u00f3n sanitaria en el 26,5% de los \npacientes, principalmente relacionada con el manejo de toxicidades (18,4%) e interacciones (6,1%). La mayor\u00eda de los \npacientes estaban satisfechos de la informaci\u00f3n recibida en la visita de inicio.  \nNo se encontraron diferencias significativas en la proporci\u00f3n de EA entre los pacientes con y sin polifarmacia (p=0,276) ni \ntampoco con la edad (p=0,838).\nCONCLUSIONES\nLas visitas de seguimiento de los pacientes por parte del farmac\u00e9utico ayudan a reforzar la educaci\u00f3n sanitaria \nrelacionada con el manejo de toxicidades y pueden evitar interacciones de los medicamentos oncohematol\u00f3gicos. Ante \nla ausencia de diferencias en la proporci\u00f3n de EA seg\u00fan la edad y/o polifarmacia, ser\u00eda conveniente en la visita de inicio \nidentificar aquellos pacientes que m\u00e1s se podr\u00edan beneficiar de estas visitas.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n538. \u00bfINFLUYE LA REALIZACI\u00d3N DEL AN\u00c1LISIS DEL GEN DE LA DIHIDROPIRIMIDINA DESHIDROGENASA \nEN LA REDUCCI\u00d3N DE TOXICIDAD ASOCIADA A FLUOROPIRIMIDINAS? \nAUTORES\nLUQUE JIM\u00c9NEZ, M; ANGUITA MONTENEGRO, B; VICENTE S\u00c1NCHEZ, MP; NIETO SANDOVAL MART\u00cdN DE LA SIERRA, \nP; MAYO CANALEJO, B; ROMERA GARC\u00cdA, JM; RODR\u00cdGUEZ MART\u00cdNEZ, M\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nComparar la incidencia de eventos adversos y su gravedad en los pacientes tratados con fluoropirimidinas, antes y \ndespu\u00e9s de la implementaci\u00f3n del an\u00e1lisis del gen de la dihidropirimidina deshidrogenasa (DPYD).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional ambispectivo. Se incluyeron pacientes que iniciaron tratamiento basado en fluoropirimidinas \n(capecitabina o fluorouracilo) para tumores del tracto digestivo. Se incluyeron en el grupo control (GC) pacientes que \niniciaron tratamiento antes de la implantaci\u00f3n de an\u00e1lisis genotipico DPYD (noviembre 2019-octubre 2020) y grupo \ntratamiento (GT) a pacientes tratados despu\u00e9s la implantaci\u00f3n de dicha determinaci\u00f3n (noviembre 2020 octubre 2021). \nLas variables estudiadas fueron antropom\u00e9tricas, relacionadas con el tratamiento, an\u00e1lisis genot\u00edpico y toxicidades \ndesarrolladas seg\u00fan la clasificaci\u00f3n CTCAE v5. El estudio obtuvo el dictamen favorable del CEIm del centro y los pacientes \nfirmaron consentimiento informado previa inclusi\u00f3n en el mismo.341RESULTADOS\nSe incluyeron 258 pacientes; (GC:133 y GT:125). Eran hombres 66.9% del GC vs 70.4% en GT (p=0.547). Mediana de \nedad de 68 (\u00b110.984) del GC vs 69 (\u00b111.291) en GT (p=0.809). El 79.7% y el 83.2%, recibi\u00f3capecitabina en el GC y GT, \nrespectivamente (p=0.470). El 8% (10) de pacientes tuvo una variante DPYD con d\u00e9ficit de funci\u00f3n (0.8% DPYD*2\u00aa, \n1.6% c.2846 > T, 5.6% HapB3), todos ellos heterocigotios y metabolizadores intermedios. Aparecieron toxicidades \ngastrointestinales en el 69.2% de GC y el 67.2% de GT (p=0.734) y de tipo hematol\u00f3gico en el74.4% de GC y 71.24% en GT \n(p=0.522).Las toxicidades desarrolladas en el GC vs GT, fueron diarrea 38.3%vs37.3% (p=0.902), v\u00f3mitos 23.3%vs20.8% \n(p=0.627), na\u00faseas 27.1%vs27.2% (p=0.991), dolor abdominal 35.3%vs 20% (p=0.006), mucositis 9%vs4.9% (p=0.183), \neritrodisestesia palmoplantar (EPP) 13.5%vs16.8% (p=0.439), astenia 46.6%vs27.2% (p=0.001), cardiotoxicidad \n1.5%vs0.8% (p=0.598), neutropenia 24.1%vs24.8% (p=0.890), nefrotoxicidad 3%vs 11.2% (p=0.020), hepatotoxicidad \n15.8%vs17.6% (p=0.697), anemia 59.4%vs56.8%(p=0.552) y plaquetopenia 47.4%vs 41.6% (p=0.421). La toxicidades \ngraves (grado III-IV) fueron presentadas en un 27.8% del GC y 19.2% del GT, (p=0.103).\nCONCLUSIONES\nAmbos grupos son comparables no existiendo diferencias significativas en ninguna de las caracter\u00edsticas estudiadas. En \ncuanto a las toxicidades, de manera general, fueron menores num\u00e9ricamente en GT que en GC siendo dolor abdominal \ny astenia las que disminuyeron de manera m\u00e1s significativa. No obstante, se observ\u00f3 mayor toxicidad renal en el GT que \nen GC, aunque este hecho deber\u00eda correlacionarse con las caracter\u00edsticas renales basales de ambos grupos para sacar \nconclusiones\ufffd Con respecto a la gravedad de las reacciones adversas, la incidencia de toxicidades graves fue menor en el \nGT\ufffd \nEn nuestra experiencia, la implantaci\u00f3n de la determinaci\u00f3n gen\u00e9tica de DPYD ha supuesto una disminuci\u00f3n general \ntanto de la incidencia como de la gravedad de las reacciones adversas a fluoropirimidinas. Su protocolizaci\u00f3n, as\u00ed como la \nvalidaci\u00f3n farmac\u00e9utica de su realizaci\u00f3n previa al inicio del tratamiento y ajuste de dosis favorece la seguridad de estos \nf\u00e1rmacos en los pacientes oncol\u00f3gicos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n553. LETERMOVIR COMO PROFILAXIS DE LA INFECCI\u00d3N DE CITOMEGALOVIRUS EN PACIENTES \nSOMETIDOS A TRASPLANTE HEMATOPOY\u00c9TICO \nAUTORES\nBL\u00c1ZQUIZ IBERO, E; BARACE INDURAIN, MC; BERISA PRADO, S; GARC\u00cdA PASTOR, C; MATEO FOLGADO, E; \nVALDEOLMILLOS CARB\u00d3, L\nCLINICA UNIVERSITARIA DE NAVARRA \ufffd AV\ufffd PIO XII, 36 PAMPLONA/IRU\u00d1A \ufffd NAVARRA\nOBJETIVOS\nLetermovir es un medicamento aprobado para la prevenci\u00f3n de la reactivaci\u00f3n del citomegalovirus (CMV), en pacientes \nsometidos a trasplante de progenitores hematopoy\u00e9ticos (TPH), cuando el receptor es seropositivo para CMV. CMV afecta \nfrecuentemente a pacientes inmunodeprimidos. El objetivo de este estudio es determinar la efectividad y seguridad del \nletermovir en nuestro centro\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de pacientes sometidos a TPH desde enero de 2019 hasta marzo de 2022 en un \nhospital universitario.  \nSe recogieron de la historia cl\u00ednica electr\u00f3nica los siguientes datos: demogr\u00e1ficos, diagn\u00f3stico hematol\u00f3gico, d\u00eda de inicio \nde letermovir respecto al trasplante, dosis, duraci\u00f3n del tratamiento y adherencia, carga seriadas de control de CMV y \ntratamiento en caso de reactivaci\u00f3n, y seguimiento de la funci\u00f3n renal y hep\u00e1tica. \nPara el an\u00e1lisis de los datos, los pacientes se clasificaron en funci\u00f3n del d\u00eda de inicio de letermovir: grupo 1 cuando \niniciaron el d\u00eda 0 o 1, y grupo 2 para los que iniciaron m\u00e1s tarde. Se compararon los grupos mediante Stata/iC 12.0.\nRESULTADOS\nUn total de 8 pacientes recibieron letermovir, el 100% mujeres, con una edad media de 42 a\u00f1os (m\u00ednimo-m\u00e1ximo: 15-68). \nDe ellas, 2 pacientes fueron diagnosticadas de leucemia mieloide cr\u00f3nica, 2 con leucemia mieloide aguda, 2 pacientes con \nleucemia linfoide aguda, una con aplasia medular y una con linfoma linfobl\u00e1stico de c\u00e9lulas T. \nEl 50% (n=4) iniciaron el tratamiento entre el d\u00eda 0-1 de TPH (grupo 1), y el otro 50% iniciaron el d\u00eda promedio 12 (5-30) \n(grupo 2).  \nTodos recibieron dosis de 480 mg al d\u00eda, siendo la duraci\u00f3n media del tratamiento de 65 d\u00edas (9-114 d\u00edas), con buena \nadherencia al mismo.  \nDe los 4 pacientes del grupo 1, 3 tuvieron reactivaci\u00f3n a partir del d\u00eda +30 (30-50), y el otro paciente el d\u00eda +11. Todos los \npacientes del grupo 2 (4) reactivaron antes del d\u00eda +30 (11-18).  \nLa carga viral m\u00e1xima media detectada en el grupo 1 fue de 402 UI/mL (150-978), correspondiente al d\u00eda 46 (11-84); en el \ngrupo 2 fue de 2.860 UI/mL (150-8.530), correspondiente al d\u00eda 62 (15-121).  \nEl 50% de los pacientes (2 en cada grupo) requiri\u00f3 terapia anticipada por aumento de la carga viral, correspondiendo \nel inicio a los d\u00edas 84 y 137 para el grupo 1, y a los d\u00edas 15 y 70 para el grupo 2. Todos ellos recibieron, a dosis est\u00e1ndar \ny ajustado a funci\u00f3n renal, valganciclovir oral, excepto uno que recibi\u00f3 ganciclovir intravenoso, y la duraci\u00f3n media del \ntratamiento fue de 20 d\u00edas (11-29), no habiendo diferencias entre ambos grupos.  \nLas funciones renal y hep\u00e1tica se mantuvieron estables respecto a los valores basales en todos los pacientes durante el \ntratamiento con letermovir \ufffd342CONCLUSIONES\nTodos los pacientes tuvieron reactivaci\u00f3n de la carga de CMV, pero ninguno desarroll\u00f3 la enfermedad.  \nComenzar m\u00e1s tempranamente la profilaxis parece retrasar la reactivaci\u00f3n y alcanzar una menor carga viral m\u00e1xima, no \nencontr\u00e1ndose diferencias significativas, quiz\u00e1 por el n\u00famero limitado de pacientes.  \nLetermovir es un f\u00e1rmaco seguro, ya que ning\u00fan paciente experiment\u00f3 reacciones adversas relacionadas con su uso.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n557. EFECTIVIDAD Y SEGURIDAD CARDIOVASCULAR DE IBRUTINIB EN LEUCEMIA LINF\u00c1TICA CR\u00d3NICA: \nDATOS EN VIDA REAL. \nAUTORES\nPARADAS PALOMO, JD; DEL R\u00cdO VALENCIA, JC; ORTEGA DE LA CRUZ, C; IA\u00d1EZ ASPIZUA, AJ; MU\u00d1OZ CASTILLO, IM\nHOSPITAL GENERAL \ufffd AV\ufffd CARLOS HAYA, S/N M\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\nAn\u00e1lisis de la efectividad y seguridad cardiovascular de Ibrutinib en primera, segunda y posteriores l\u00edneas de tratamiento \nen pacientes con Leucemia Linfoide Cr\u00f3nica (LLC).\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo de la efectividad y seguridad cardiovascular (CV) de Ibrutinib en el \ntratamiento de la LLC en pacientes en seguimiento desde el servicio de farmacia, desde mayo 2015 hasta marzo 2022. \nVariables recogidas: demogr\u00e1ficas (sexo, edad), gen\u00e9ticas del(17p)/mutaci\u00f3n TP53, del(13q), del(11q), trisom\u00eda del \ncromosoma 12 y cl\u00ednicas (n\u00famero de l\u00edneas de tratamiento).  \nVariables estudiadas: mediana de tiempo de tratamiento; porcentaje de pacientes que descontin\u00faan el tratamiento \ny contin\u00faan vivos tras finalizar el estudio; efectividad mediante supervivencia global (SG) y supervivencia libre de \nprogresi\u00f3n (SLP) y seguridad CV mediante registro de hipertensi\u00f3n arterial (HTA), fibrilaci\u00f3n auricular (FA), taquicardia \nventricular (TV), hemorragias e Insuficiencia Card\u00edaca (IC) tras inicio de ibrutinib.  \nLos datos fueron obtenidos del programa de prescripci\u00f3n electr\u00f3nica a pacientes externos y de la historia cl\u00ednica \nelectr\u00f3nica\ufffd \nSe realiz\u00f3 estad\u00edstica descriptiva de las variables del estudio. El an\u00e1lisis de los datos se hizo mediante SSPS v20.\nRESULTADOS\nSe incluyeron 47 pacientes de los cuales el 68,1% (n=32) eran varones con una media de edad de 71,3 \u00b1 10,3 a\u00f1os y una \nmediana de tratamiento de 21 meses (2-71). De todos ellos, 57,4% (n=27) del (17p)/mutaci\u00f3n TP53, el 51,1% (n=24) del \n(13q), el 17% (n=8) del (11q) y el 23,4% (n=11) trisom\u00eda del cromosoma 12.  \nAl finalizar el estudio el 46,8% (n=22) hab\u00edan discontinuado el tratamiento y el 78,7% (n=37) continuaban vivos.  \nEl 42,5% (n=20) recibi\u00f3 Ibrutinib en primera l\u00ednea, el 29,8% (n=14) en segunda l\u00ednea, el 14,9% (n=7) en tercera l\u00ednea y \n12,8%% (n=6) en cuarta o posteriores l\u00edneas.  \nEn la poblaci\u00f3n global, la mediana de Supervivencia Libre de Progresi\u00f3n (mSLP) fue de 69,21 meses IC95% (15,26-123). \nNo se alcanz\u00f3 la SG y la SLP fue del 66,4% \u00b1 7,2% a los 19,3 meses.  \nEn primera y segunda l\u00ednea no se alcanz\u00f3 la SLP siendo del 75,8% a los 19,3 meses y del 76,2% a los 19,1 meses \nrespectivamente. \nEn tercera l\u00ednea la mSLP fue de 17,03 meses con un IC95% (11,05 - 23). A los 17 meses la SLP fue del 42,9% \u00b1 18,7%.  \nLos eventos CV m\u00e1s frecuentes fueron: HTA en el 14,8% (n=7), FA en el 10,6% (n=5), TV en el 8,5% (n=4), hemorragias en \nel 4,3% (n=2) e IC en el 4,3% (n=2).\nCONCLUSIONES\nEn nuestro estudio no se alcanza la mSLP en primera ni en segunda l\u00ednea, al igual que en otros estudios de pr\u00e1ctica cl\u00ednica \n(Ibrors). Sin embargo la SLP estimada a 19,3 meses del 66,4% es inferior a la de dicho estudio (SLP estimada a 24 meses \ndel 84,7%), pudiendo ser debida a nuestro menor tama\u00f1o muestral y a las diferencias de las caracter\u00edsticas basales de los \npacientes. El mayor porcentaje de eventos CV en nuestro estudio pudiera justificarse por dichas diferencias. El papel del \nfarmac\u00e9utico en el seguimiento farmacoterap\u00e9utico del paciente es fundamental para detectar posibles problemas de \nmedicaci\u00f3n y mejorar los resultados en salud.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n573. EFICACIA Y SEGURIDAD DE LA COMBINACI\u00d3N DE NIVOLUMAB E IPILIMUMAB EN MELANOMA \nUVEAL METAST\u00c1SICO. \nAUTORES\nGARC\u00cdA TREVIJANO CABETAS, M; HOYO MU\u00d1OZ, \u00c1; CASADO ABAD, G; S\u00c1NCHEZ-RUBIO FERR\u00c1NDEZ, L; HERRANZ \nMU\u00d1OZ, C; ESPINOSA ARRANZ, E; GONZ\u00c1LEZ DEL VALLE, L; HERRERO AMBROSIO, A\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nEl melanoma uveal es un tipo de melanoma maligno poco frecuente con muy mal pron\u00f3stico. La combinaci\u00f3n de \nnivolumab e ipilimumab ha demostrado un aumento de la supervivencia global (SG) de los pacientes con melanoma \nuveal metast\u00e1sico en dos ensayos fase II. El objetivo del estudio es analizar la eficacia y seguridad del uso de nivolumab \nen combinaci\u00f3n con ipilimumab en pacientes con melanoma uveal metast\u00e1sico en pr\u00e1ctica cl\u00ednica habitual.343MATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo realizado en un hospital de tercer nivel en el que se incluyeron todos los pacientes \ndiagnosticados de melanoma uveal metast\u00e1sico tratados entre enero de 2017 y abril de 2022 con la combinaci\u00f3n \nnivolumab e ipilimumab en primera l\u00ednea. Para la obtenci\u00f3n de los datos se utiliz\u00f3 la historia cl\u00ednica electr\u00f3nica y el \nprograma de prescripci\u00f3n electr\u00f3nica onco-hematol\u00f3gica. Las variables de eficacia analizadas fueron la SG, la respuesta al \ntratamiento y la duraci\u00f3n del tratamiento. Se llev\u00f3 a cabo el an\u00e1lisis de la SG con el m\u00e9todo de Kaplan-Meier. Tambi\u00e9n se \nrecogieron los efectos adversos\ufffd\nRESULTADOS\nSe incluyeron 18 pacientes; 11 de los cuales fueron hombres. La mediana de edad fue 63 a\u00f1os. Al inicio del tratamiento, \nla mayor\u00eda de los pacientes (94%) ten\u00eda un buen estado funcional (ECOG 0-1). El 83,3% de los pacientes presentaba \nmet\u00e1stasis hep\u00e1ticas y un 28% met\u00e1stasis tanto hep\u00e1ticas como extrahep\u00e1ticas, siendo pulm\u00f3n y hueso los sitios de \nmet\u00e1stasis extrahep\u00e1ticas m\u00e1s frecuentes.  \nLa mediana de seguimiento fue 14,5 meses (rango intercuart\u00edlico 6,3-27,5 meses). La mediana de duraci\u00f3n de tratamiento \nfue 18 semanas (rango 3-265 semanas). La tasa de respuesta objetiva fue 12,5%, siendo todas ellas respuestas parciales \ny un 31% de los pacientes alcanz\u00f3 enfermedad estable como mejor respuesta. En el momento de cierre del estudio, 10 \npacientes hab\u00edan fallecido. La mediana de SG fue 9,9 meses (IC 95% 1,9-17,7 meses) y la tasa de supervivencia al a\u00f1o fue \n45,5% (IC 95% 32,4-58,6%).  \nDe los 18 pacientes, 3 pacientes continuaban en tratamiento en el momento de cierre del estudio, mientras que 15 \npacientes lo hab\u00edan suspendido. Los motivos de suspensi\u00f3n de tratamiento fueron progresi\u00f3n (n=9) y toxicidad (n=6).  \nEl 83% de los pacientes experiment\u00f3 alg\u00fan efecto adverso relacionado con la inmunoterapia, siendo los m\u00e1s frecuentes \ndiarrea, toxicidad hep\u00e1tica, toxicidad cut\u00e1nea y astenia. Once pacientes (61%) requirieron corticoides sist\u00e9micos para el \nmanejo de los mismos. Seis pacientes (33%) tuvieron efectos adversos grade 3-4, y requiriendo todos ellos la suspensi\u00f3n \ndel tratamiento por toxicidad. Un paciente tuvo toxicidad renal inmunomediada que condujo al exitus.\nCONCLUSIONES\nLa SG de los pacientes con melanoma uveal metast\u00e1sico de nuestro estudio tratados con nivolumab en combinaci\u00f3n con \nipilimumab fue inferior a la reportada en los ensayos cl\u00ednicos. Sin embargo la tasa de supervivencia al a\u00f1o y el tiempo en \ntratamiento fue similar \ufffd  \nEl perfil de toxicidad fue tambi\u00e9n similar al reportado previamente para esta combinaci\u00f3n.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n576. AN\u00c1LISIS EN VIDA REAL DEL PERFIL DE SEGURIDAD DE IBRUTINIB \nAUTORES\nMART\u00cdNEZ PRADEDA, A; FERN\u00c1NDEZ GABRIEL, E; MATEOS SALVADOR, M; FEIJOO VILANOVA, P; LUACES RODR\u00cdGUEZ, \nA; ROTEA SALVO, S; MART\u00cdN HERRANZ, MI\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nIbrutinib, primer f\u00e1rmaco inhibidor de BTK, inhibe proliferaci\u00f3n y supervivencia del linfocito B y promueve su apoptosis. \nActualmente indicado (Agencia Europea del Medicamento) en leucemia linfoc\u00edtica cr\u00f3nica (LLC), linfoma no Hodgkin \n(LNH), y macroglobulinemia de Waldenstr\u00f6m (MW); posicion\u00e1ndose dentro de las primeras l\u00edneas en gu\u00edas cl\u00ednicas de \nreferencia\ufffd  \nEl objetivo es describir el perfil de seguridad de ibrutinib en vida real, analizando los efectos adversos, los cambios de \ndosis y las discontinuaciones asociadas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Se incluyeron el 100% de pacientes tratados con ibrutinib en nuestro centro. Se \nrecogieron variables demogr\u00e1ficas (sexo, edad), indicaci\u00f3n del tratamiento, n\u00famero de l\u00edneas previas, pauta posol\u00f3gica \ninicial, efectos adversos asociados a ibrutinib (EAi), reducciones de dosis, suspensiones temporales/definitivas y sus \ncausas\ufffd\nRESULTADOS\nEntre noviembre/16 y abril/22 118 pacientes (79 varones) recibieron ibrutinib. Edad media: 69 a\u00f1os (desviaci\u00f3n est\u00e1ndar \n9,5 a\u00f1os). Indicaci\u00f3n: 86/118 LLC, 25/118 LNH y 7/118 MW. Ibrutinib fue empleado en 41/118 pacientes en 1\u00aa l\u00ednea, en \n46/118 en 2\u00aa l\u00ednea y en 31/118 en tercera o posteriores. Dosis de inicio: 560 mg en 24/118 pacientes, 420 mg en 94/118, \n280 mg en 1/118 pacientes\ufffd En 117/118 en monoterapia y en 1/118 asociado a rituximab\ufffd  \nEl 89,8% (106/118) de pacientes experiment\u00f3 alg\u00fan Eai: En 63/118 (53,4%) pacientes no condicionaron modificaciones en \nel tratamiento (263 EAi: 58/263 infecciones\u00b1neutropenia, 31/263 trombocitopenias, 26/263 molestias g\u00e1stricas, 22/263 \nhipertensi\u00f3n arterial, 17/263 alteraciones hep\u00e1ticas, 15/263 mucositis, 13/263 sangrados, 13/263 edemas, 10/263 \ndiarrea, 7/263 alteraciones dermatol\u00f3gicas, 7/263 astenia, 6/263 artralgias, 5/263 dolor osteoarticular, 4/263 cefalea, \n4/263 onicoclasias, 4/263 hipogeusia, 21/263 otros Eai. En 12/118 pacientes (10%) los EAi condicionaron reducciones \nde dosis (5/12 por infecciones\u00b1neutropenia, 2/12 trombocitopenias, 2/12 diarrea, 1/12 artralgias, 1/12 mareos y 1/12 \nhiperbilirrubinemia). En 31/118 (26,3%) se suspendi\u00f3 el tratamiento por \u2265 1 Eai grave/inaceptable (8/31 hemorragias o \nsangrados graves, 8/31 infecciones\u00b1neutropenia, 6/31 diarreas, 5/31 fibrilaci\u00f3n auricular (FA), 3/31 hepatotoxicidad, 2/5 \ns\u00edndrome de lisis tumoral, 2/31 insuficiencia card\u00eda congestiva (ICC), 1/31 alteraciones psqui\u00e1tricas, 1/31 artralgias, 1/31 \ntrombopenia, 1/31 s\u00edncope, 1/31 exacerbaci\u00f3n parkinson, 1/31 insuficiencia renal aguda.  \nEl 42,3% (50/118) de los pacientes sufrieron eventos adversos hemorr\u00e1gicos (EAH): En el 86% (43/50) de los casos 344fueron leves y autolimitados, frente a un 14% (7/50) de pacientes que precisaron intervenci\u00f3n m\u00e9dica y suspensi\u00f3n del \ntratamiento. En 13 de estos casos, el paciente hab\u00eda recibido en alg\u00fan momento antiagregante, anticoagulante o ambos; \n5 pacientes que hab\u00eda recibido anticoagulaci\u00f3n y 13 antiagregaci\u00f3n no presentaron EAH. \nUn total de 17/118 pacientes presentaron eventos card\u00edacos: 10/17 ICC, 4/17 aparici\u00f3n de FA, 3/17 eventos isqu\u00e9micos y \n1/17 ICC con evento isqu\u00e9mico. Fue necesario suspender el tratamiento en 13/17 casos: 4/13 FA, 6/13 ICC, 2/13 eventes \nisqu\u00e9micos y 1/13 ICC con isquemia.\nCONCLUSIONES\nCasi el 90% de nuestros pacientes presentaron alg\u00fan Eai, mayoritariamente leves y manejables. Un tercio de pacientes \npresentaron toxicidades graves/potencialmente graves y que condicionaron la continuidad del tratamiento. Es \nimprescindible realizar una monitorizaci\u00f3n estrecha durante todo el tratamiento, y para ello, la atenci\u00f3n farmac\u00e9utica \ndebe ser una herramienta clave dentro del equipo multidisciplinar.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n584. CYTOKINE RELEASE SYNDROME IN HEMATOLOGICAL PATIENTS TREATED WITH TOCILIZUMAB \nAUTORES\nSERRANO-ALONSO , M; MOLINS CASTIELLA, E; MATEO FOLGADO, E; BLAZQUIZ IBERO, E\nCLINICA UNIVERSITARIA DE NAVARRA \ufffd AV\ufffd PIO XII, 36 PAMPLONA/IRU\u00d1A \ufffd NAVARRA\nOBJETIVOS\nThe aim of the study is to assess the effectiveness of tocilizumab in hematological patients with Cytokine Release \nSyndrome (CRS). Relationship between CRS severity and hematologic malignancies and targeted therapies will be also \nreviewed. \nCRS is a common and life-threatening toxicity directly related to new targeted therapies for hematological diseases. \nAlthough the optimal therapy for CRS remains unknown, tocilizumab has demonstrated success. \nOther toxicities related to new targeted therapies, such as Immune effector Cell Associated Neurotoxicity Syndrome \n(ICANS) and Macrophage Activation Syndrome (MAS), will be also studied.\nMATERIALES Y M\u00c9TODOS\nRetrospective cohort study in a single center. Cases of hematologic patients who received tocilizumab for CRS treatment \nfrom January 2019 to May 2022 were studied.  \nPatient demographics, hematological diagnosis and targeted therapy, CRS related symptoms and tocilizumab treatment \nwere collected from electronic patient files. CRS resolution after tocilizumab treatment was reviewed in order to evaluate \nthe effectiveness of therapy. \nCRS severity based on the American Society for Transplantation and Cellular Therapies (ASTCT) grading scale for CRS, was \ncompared between the groups of patients with different hematologic diagnosis and targeted therapies.  \nAlong with CRS, the development of ICANS (according to ASTCT criteria) and MAS were reviewed in all patients. \nComparisons between groups were analyzed with chi-square test.\nRESULTADOS\nA total of 53 patients received tocilizumab for CRS. Main hematological diagnosis were multiple myeloma (79,2 %), \nlymphoma (9,4 %) and acute myeloblastic leukemia (7,5 %). Targeted therapy consisted of CAR-T cells in 31 patients \n(58,5%), bispecific antibodies in 19 patients (35,8 %) and hematopoietic stem cell transplantation in 2 patients (3,8%).  \nTwenty two patients (41,5%) developed CRS grade 1, 26 patients (49,1%) grade 2 and 5 patients (9,4%) grade 3.  \nTocilizumab median (range) dose was 8,0 (5,1) mg/kg. Thirteen patients (22,6%) required more than one dose of \ntocilizumab for optimal CRS control. CRS resolution occurred in all patients. \nPatients who had received CAR-T cells as targeted therapy required more than one dose of tocilizumab more frequently \nthan patients in other treatment groups (41,9% vs. 0%, p < 0,01).  \nCRS was more severe in the group of patients with diagnosis of lymphoma, developing CRS grade 3 in 40,0% of patients vs. \n5,7% in the group of patients with multiple myeloma (p < 0,05) and 0% in the other groups (p < 0,05).  \nCRS severity was not associated with target therapy received. Nevertheless, in the group of patients treated with bispecific \nantibodies, 5 patients (26,3%) developed a second CRS episode, and 2 patients (10,5%) developed a third CRS episode.  \nSeven patients (13,2%) experienced ICANS and 5 patients (9,4%) experienced SAM, that were not associated with \ndiagnosis or targeted therapy group.\nCONCLUSIONES\nTocilizumab is an effective treatment in CRS after new targeted therapies in hematological patients. \nCRS related to CAR-T cell therapy frequently requires more than one dose of tocilizumab to ensure resolution.  \nSeverity of CRS seems to be higher in patients with diagnosis of lymphoma.  \nFurther studies are necessary to determine the optimal management of CRS in patients with hematological malignancies.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n589. RESULTADOS EN VIDA REAL DE DARATUMUMAB EN PACIENTES CON MIELOMA M\u00daLTIPLE EN \nRECA\u00cdDA/REFRACTARIO. \nAUTORES\nFERNANDEZ RIBEIRO, F; OLIVERA FERNANDEZ, R; GONZALEZ FREIRE, L; DIOS LOUREIRO, AM; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA345OBJETIVOS\nDaratumumab es una IgGk anti-CD38 que inhibe el crecimiento celular de las c\u00e9lulas CD38+ presentes en Mieloma \nM\u00faltiple en reca\u00edda/refractario (MMRR) mediante funciones efectoras de la inmunidad.  \nEvaluar la efectividad y seguridad de daratumumab en la pr\u00e1ctica cl\u00ednica habitual, comparando los resultados obtenidos \ncon los ensayos cl\u00ednicos pivotales (ECP) en MMRR.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional de los pacientes con MMRR tratados con daratumumab, en monoterapia o en \ncombinaci\u00f3n, desde enero de 2017 hasta diciembre de 2020.  \nSe realiz\u00f3 revisi\u00f3n de la historia cl\u00ednica electr\u00f3nica y de la prescripci\u00f3n electr\u00f3nica de quimioterapia en programa de \ngesti\u00f3n (Oncofarm\u00ae). An\u00e1lisis estad\u00edstico (SPSS\u00ae): para la valoraci\u00f3n por subgrupos seg\u00fan esquema terap\u00e9utico, se utiliz\u00f3 \nla funci\u00f3n Long RanK\ufffd  \nVariables: datos demogr\u00e1ficos, alteraciones citogen\u00e9ticas de alto riesgo (ACAR), supervivencia libre de progresi\u00f3n (SLP), \ntipo de respuesta (parcial-RP , completa-RC, m\u00ednima-RMIN), reacciones adversas (RAM).  \nSe llev\u00f3 a cabo una comparaci\u00f3n de la eficacia y seguridad obtenida con la publicada en los ECP .\nRESULTADOS\nDe un total de 45 pacientes, 30 recibieron daratumumab en el periodo de estudio\ufffd 15 pacientes fueron excluidos por no \ncumplir los criterios de inclusi\u00f3n. N\u00famero de pacientes seg\u00fan esquema: monoterapia 6; daratumumab-lenalidomida-\ndexametasona (DRd) 6; daratumumab-bortezomib-dexametasona (DVd) 15; daratumumab-pomalidomida-dexametasona \n(DPd) 1; daratumumab-bortezomib-melfalan-prednisona (DVMP) 1; daratumumab-carfilzomib-dexametasona (DKd) 1.  \nLa media de edad fue de 64,9 a\u00f1os (rango 45-80), mujeres (63,3%). 8 pacientes presentaban gammapat\u00eda monoclonal de \nsignificado incierto (GMSI) con un tiempo medio de progresi\u00f3n a MM de 77,88 meses (6,07 a\u00f1os) desde el diagn\u00f3stico de \nGMSI. El 63,6% present\u00f3 ACAR (ganancia 1q en 23,3%, t(4;14) en 16,66%, t(11;14) y reordenamiento IGH el 13,33%, del \n(17p) en 6,66% y t(14;16) en 3,33%).  \nEn los ECP la media de edad fue de 65 a\u00f1os y el porcentaje de ACAR fue < 25%. \nEfectividad: La mediana de SLP fue de 11,16 meses (IC95%, 6,4-15,9). Valoraci\u00f3n por subgrupos seg\u00fan esquema: mSLP: \nmonoterapia 11,03 meses; DRd 11,16 meses; DVd 14,60 meses\ufffd  \nLa RP se alcanz\u00f3 en un 66,66% (n=20) de los pacientes, RC en el 23,33 % (n=7), RMIN en el 10 % (n=3). \nEn los ECP la mediana de SLP no fue alcanzada en el intervalo de seguimiento, presentando mayoritariamente RP y RC \ncomo tipo de respuesta. \nToxicidad: Grado 1-2: 46,66% reacciones infusionales durante la primera administraci\u00f3n (RRP); 70% infecci\u00f3n respiratoria \ndel tracto superior (ITRS), presentando \u22653 eventos en el 16.66%. Grado 3: neutropenia (30%), trombopenia (23,3%), \nanemia (6,67%). \nLa media de RRP fue similar a la obtenida en los ECP . El porcentaje de reacciones adversas hematol\u00f3gicas y no \nhematol\u00f3gicas fue mejor en ECP .\nCONCLUSIONES\nLos resultados de efectividad y seguridad obtenidos en vida real son semejantes a los alcanzados en los ECP , a pesar de \nque nuestra cohorte incluye un mayor porcentaje de pacientes con citogen\u00e9tica al alto riesgo.  \nDaratumumab fue bien tolerado, siendo las ITRS y las RRP las reacciones adversas G1-2 m\u00e1s frecuentes.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n596. REAL-LIFE EXPERIENCE ON EFFECTIVENESS AND SAFETY OF ALPELISIB IN ADVANCED OR METASTATIC \nPIK3CA MUTATED BREAST CANCER \nAUTORES\nVALDEOLMILLOS CARB\u00d3, L; GARC\u00cdA PASTOR, C; MATEO FOLGADO, E; BLAZQUIZ IBERO, E; BARACE INDURAIN, MC; \nGIR\u00c1LDEZ QUIROGA, M\nCLINICA UNIVERSITARIA DE NAVARRA \ufffd AV\ufffd PIO XII, 36 PAMPLONA/IRU\u00d1A \ufffd NAVARRA\nOBJETIVOS\nCurrently, the ESMO guidelines recommend Alpelisib in combination with fulvestrant to be used in postmenopausal \npatients with advanced or metastatic luminal breast cancer, PIK3CA mutated, as second line treatment after an \nendocrine-based regimen. Alpelisib has shown further safety concerns that have led to warnings of this drug and dose \nreductions that may result in less drug efficacy than reported in clinical trials.  \nThe objective of this study is to assess the effectiveness and safety of Alpelisib treatment in patients with advanced or \nmetastatic breast cancer in clinical practice.\nMATERIALES Y M\u00c9TODOS\nThe observational study included patients with a diagnosis of advanced or metastatic breast cancer with the PIK3CA \nmutation, receiving Alpelisib from january 2020 to may 2022.  \nPatient\u00b4s baseline demographic and clinical characteristics were collected from the electronic medical record including \nage, gender and performance status scale according to the Eastern Cooperative Oncology Group (ECOG). The efficacy \nof Alpelisib was measured in terms of progression free survival (PFS), defined as the time from starting treatment to \nthe date of the first documented progression or death due to any cause. Safety profile of the treatment was assessed \nthrough the frequency of adverse reactions (AR) and severity according to CTCAE V5.0 (common terminology for adverse \nevents). Other data collected were dose reductions and reasons of Alpelisib withdrawal, in order to assess the treatment \ndiscontinuation rate.346RESULTADOS\nNine patients started treatment with Alpelisib during the study period. The median age was 64 years (range 51-79), all \nwomen. At baseline the ECOG was 0 for 22,2%, 1 for 66,6% and 2 for 11,1% and none carried a diagnosis of diabetes \nmellitus. Every patient was tested positive on the PIK3CA mutation, treated in combination with fulvestrant and received \nprior treatment with an aromatase inhibitor. \nThe median PFS was 6,18 months. During the study period 89 % (n=8) of the patients discontinued Alpelisib because of \ndisease progression and 11 % (n=1) deceased.  \nAll patients reported at least one AR, being the most common: hyperglycemia (66 %) being 29% grade 1, 43% grade 2, \n14 % grade 3 and 14% grade 4; rash (44%) including 67% grade 1 and 33% grade 2; asthenia (44%); diarrhea (33%); acute \nkidney injury (22%) and mucositis (11%). One patient was admitted to the hospital due to diabetic ketoacidosis (DKA) \ndespite concomitant treatment with metformin and Alpelisib dose was reduced to 250 mg at discharge. Another patient \nrequired a third dose reduction to 150 mg due to asthenia for better tolerability of the treatment. 77% of our patients did \nnot need a dose reduction.\nCONCLUSIONES\nIn our patients Alpelisib has shown similar PFS than described in the literature (6,18 months versus 7,3 months on the \nclinical trial). In addition, 1 patient (10%) reported DKA meaning that the frequency of this AR would be higher (0,7% in \nthe clinical trial).  \nAlpelisib is a promising drug, however it is still associated with significant adverse events and mandatory \npharmacovigilance is of special interest in our pharmacist daily practice.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n598. QUIMIOEMBOLIZACI\u00d3N TRANSARTERIAL CON MICROESFERAS PARA EL TRATAMIENTO DEL \nHEPATOCARCINOMA \nAUTORES\nRAMIS BARCEL\u00d3, MB; VILLACA\u00d1AS PALOMARES, MV; VALENCIA SOTO, CM; GARC\u00cdA-AVELLO FERN\u00c1NDEZ-CUETO, A; \nMART\u00cdNEZ CALLEJO, V; OCHAGAV\u00cdA SUFRATEGUI, M; REY MONTALBAN, RL; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nLa quimioembolizaci\u00f3n transarterial (TACE) es un procedimiento terap\u00e9utico de embolizaci\u00f3n para el tratamiento del \nhepatocarcinoma (CHC) no resecable. La TACE bloquea la vascularizaci\u00f3n tumoral y produce necrosis y reducci\u00f3n del \ntama\u00f1o tumoral, mejorando la calidad de vida y la supervivencia de los pacientes.  \nEl objetivo principal de este estudio fue evaluar la efectividad y seguridad de la TACE.  \nComo objetivo secundario se estableci\u00f3 describir el perfil de paciente que recibi\u00f3 tratamiento con microesferas de \ndoxorubicina para el CHC\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo que incluy\u00f3 a todos los pacientes diagnosticados de CHC tratados con \nmicroesferas de doxorubicina mediante TACE entre el 01/01/2017 y el 01/05/2022 en un hospital de tercer nivel.  \nLos datos se extrajeron de la historia cl\u00ednica electr\u00f3nica y del programa de prescripci\u00f3n electr\u00f3nica asistida e incluyeron \nedad, sexo, etiolog\u00eda, n\u00famero total de TACEs por paciente, n\u00famero de tratamientos sist\u00e9micos previos y complicaciones \ninmediatas de la TACE. Se utiliz\u00f3 el m\u00e9todo de Kaplan-Meier para estimar las variables de supervivencia libre de \nprogresi\u00f3n (SLP) y supervivencia global (SG) de los pacientes.\nRESULTADOS\nSe incluyeron 48 pacientes (43 hombres) con una media de edad de 68,2 a\u00f1os (\u00b1 9,1). Las etiolog\u00edas m\u00e1s comunes fueron: \nalcoholismo 56,3%, infecci\u00f3n por el virus de la hepatitis C (VHC) 13,0%, indeterminada 8,3%, combinaci\u00f3n de alcoholismo \ny VHC 6,3%, infecci\u00f3n por el virus de la hepatitis B 4,2%, combinaci\u00f3n de alcoholismo y hemocromatosis 4,2% y otras \ncausas 7,7%\ufffd \nSe realizaron un total de 104 TACE de las 107 previstas: 2 se cancelaron por dificultades en la administraci\u00f3n y 1 por \ndecisi\u00f3n del paciente\ufffd \nLa media de TACE por paciente fue 2,2 (\u00b11,2), con un 62,5% (30) de los pacientes con m\u00e1s de una quimioembolizaci\u00f3n.  \nEl tratamiento se recibi\u00f3 en primera l\u00ednea en todos los casos, salvo en 1, previamente tratado con sorafenib.  \nSe detectaron complicaciones inmediatas a la TACE en 5 pacientes (10%): crisis hipertensivas (2), fallo renal agudo (1), \nfiebre (1) y v\u00f3mitos acompa\u00f1ados de cuadro vasovagal (1).  \nLa mediana de SLP fue de 19 (IC 95% 14-24) meses y la mediana de SG de 34 (IC 95% 18-50) meses. En t otal, a fecha de \nfinalizaci\u00f3n del estudio, hab\u00edan progresado 26 pacientes (54,2%) y 19 hab\u00edan fallecido (39,6%).\nCONCLUSIONES\nNuestros datos muestran que la TACE es un procedimiento con buenos resultados de efectividad en un grupo de \npoblaci\u00f3n con escasas alternativas terap\u00e9uticas. La mayor parte de nuestros pacientes recibieron m\u00e1s de una TACE. Se \ntrata adem\u00e1s de una t\u00e9cnica segura, con una baja tasa de complicaciones inmediatas asociadas. En nuestra poblaci\u00f3n, el \nalcoholismo fue la etiolog\u00eda m\u00e1s frecuente de CHC.347CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n601. AN\u00c1LISIS DEL USO DE LA INMUNOTERAPIA ONCOL\u00d3GICA EN UNA COMUNIDAD AUT\u00d3NOMA \nAUTORES\nROSAS ESPINOZA, CR; ALONSO CASTRO, V; MAROTO GARC\u00cdA, E; GARC\u00cdA CEREZUELA, MD; ALIOTO , D; L\u00d3PEZ \nCENTENO, B; ARANGUREN OYARZ\u00c1BAL, A; CALVO ALC\u00c1NTARA, MJ\nSERVICIO MADRILE\u00d1O DE SALUD \ufffd AVENIDA DE MANUEL FRAGA IRIBARNE 2 MADRID \ufffd MADRID\nOBJETIVOS\nAnalizar el impacto de la incorporaci\u00f3n a la pr\u00e1ctica cl\u00ednica de la inmunoterapia oncol\u00f3gica en una Comunidad Aut\u00f3noma \n(CA).\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo del impacto de los f\u00e1rmacos inhibidores de punto de control inmunitario (ICI) de \naplicaci\u00f3n oncol\u00f3gica entre los a\u00f1os 2016 y 2021, inclusive, en una CA \ufffd  \nSe analiz\u00f3 la incorporaci\u00f3n de nuevos ICI y el impacto econ\u00f3mico de las adquisiciones hospitalarias, el estado de \nfinanciaci\u00f3n de sus indicaciones y la elaboraci\u00f3n de informes de posicionamiento terap\u00e9utico (IPT) para su evaluaci\u00f3n. \nSe excluyeron del an\u00e1lisis aquellas indicaciones sin solicitud de inclusi\u00f3n en la financiaci\u00f3n, y del an\u00e1lisis de pacientes a \naquellos hospitales de los cu\u00e1les no se dispon\u00eda registro de ellos.  \nFuente de datos: los datos referidos a la autorizaci\u00f3n, indicaciones e IPT, fueron obtenidos del portal web de la Agencia \nEspa\u00f1ola de Medicamentos y Productos Sanitarios. Los datos de pacientes y adquisiciones hospitalarias fueron recogidos \ndel sistema de informaci\u00f3n farmac\u00e9utica auton\u00f3mico. El estado de financiaci\u00f3n se recogi\u00f3 del Nomencl\u00e1tor Oficial de la \nPrestaci\u00f3n Farmac\u00e9utica del Sistema Nacional de Salud.\nRESULTADOS\nDurante el per\u00edodo de estudio, se autorizaron 4 f\u00e1rmacos y se estudiaron para su inclusi\u00f3n en financiaci\u00f3n 30 \nindicaciones, siendo un total de 7 f\u00e1rmacos y 38 indicaciones al final del per\u00edodo (media de 5,4 indicaciones por \nf\u00e1rmaco). Los f\u00e1rmacos con mayor n\u00famero de indicaciones evaluadas fueron pembrolizumab (31,6%), nivolumab \n(28,9%) y atezolizumab (21,1%). Se elaboraron 35 IPT para la evaluaci\u00f3n de la inclusi\u00f3n en la financiaci\u00f3n. Obtuvieron \nresoluci\u00f3n positiva de financiaci\u00f3n un 65,8% de las indicaciones evaluadas (dentro de ellas, un 44% con restricciones de \nfinanciaci\u00f3n).  \nLos pacientes en tratamiento aumentaron en todos los f\u00e1rmacos durante el per\u00edodo de estudio, siendo los que \npresentaron un aumento superior al 1.000% desde su inclusi\u00f3n en la financiaci\u00f3n: atezolizumab (7.140%), pembrolizumab \n(5.024%) y durvalumab (3.033%).  \nCuatro f\u00e1rmacos han presentado reducci\u00f3n del precio por miligramo de producto: pembrolizumab (44%), ipilimumab \n(32%), nivolumab (30%) y atezolizumab (15,4%). El resto mantuvieron el precio.  \nEn los 6 a\u00f1os de estudio, el impacto econ\u00f3mico total ha sido de 176.884.558,25\u20ac, con un incremento del 994,4% desde \n2016 a 2021. Los f\u00e1rmacos con mayor impacto fueron: pembrolizumab (43,1%), nivolumab (37,3%) y atezolizumab \n(10,8%).\nCONCLUSIONES\nEl acceso a la inmunoterapia en la Comunidad Aut\u00f3noma ha tenido un impacto muy relevante en los \u00faltimos a\u00f1os. El \naumento constante del n\u00famero de indicaciones ha supuesto un mayor n\u00famero de pacientes candidatos a tratamiento, lo \ncual implica la necesidad de centrar los esfuerzos en la correcta evaluaci\u00f3n y selecci\u00f3n de estos medicamentos, as\u00ed como \nen la negociaci\u00f3n de precios y modelos de financiaci\u00f3n que permitan mantener la sostenibilidad del sistema sanitario.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n621. AN\u00c1LISIS DEL USO Y EFECTIVIDAD DE GLUCARPIDASA EN EL TRATAMIENTO DE INTOXICACI\u00d3N POR \nMETOTREXATO A ALTAS DOSIS \nAUTORES\nPE\u00d1AS FERN\u00c1NDEZ, A; AGUST\u00cdN FERRANDEZ, MJ; BONA L\u00d3PEZ, C; DIAZ-CALDERON HORCADA, C; PERALES PASCUAL, \nJ; HERRANZ BAYO, E; AGUIL\u00d3 LAFARGA, I; L\u00d3PEZ P\u00c9REZ, A\nHOSPITAL UNIVERSITARIO MIGUEL SERVET . P\u00ba DE ISABEL LA CAT\u00d3LICA, 1-3 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nLa glucarpidasa es una enzima bacteriana recombinante que degrada el metotrexato (MTX) extracelular en metabolitos \ninactivos de eliminaci\u00f3n hep\u00e1tica. Proporciona una ruta alternativa para la eliminaci\u00f3n del f\u00e1rmaco en pacientes con \ndisfunci\u00f3n renal durante tratamientos con altas dosis de MTX\ufffd  \nEl objetivo de este estudio es analizar la efectividad y el manejo de la glucarpidasa en pacientes oncopedi\u00e1tricos \ndiagnosticados de toxicidad por MTX a concentraciones elevadas.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, retrospectivo (enero 2015 \u2013 mayo 2022) llevado a cabo en un hospital de tercer nivel. \nSe incluyeron pacientes del Servicio de Oncopediatr\u00eda en tratamiento con MTX a dosis altas (\u2265500 mg/m2 en infusi\u00f3n \nde 24 horas). Los datos recogidos se obtuvieron a partir de la Historia Cl\u00ednica Electr\u00f3nica y Modulab\u00a9 como programa \nde gesti\u00f3n de par\u00e1metros anal\u00edticos. Se recopilaron variables demogr\u00e1ficas (edad, sexo, superficie corporal) y cl\u00ednicas \n(diagn\u00f3stico principal, dosis total de MTX y de glucarpidasa pautados, concentraci\u00f3n de creatinina y de MTX en suero \ntras la infusi\u00f3n a las 24, 36, 48, 72 y 96 horas). La efectividad se evalu\u00f3 en funci\u00f3n de la reducci\u00f3n de la concentraci\u00f3n \nplasm\u00e1tica de MTX a las 96 horas tras administrar la glucarpidasa .348RESULTADOS\nLa glucarpidasa se us\u00f3 en 4 pacientes (el 100% fueron varones) cuya media de edad fue de 12 \u00b1 3,4 a\u00f1os y la superficie \ncorporal media 1,5 \u00b1 0,4 m2. El 75% de los pacientes ten\u00edan un diagn\u00f3stico de leucemia linf\u00e1tica aguda (LLA) (pauta \nseg\u00fan esquema de MTX de 5.000 mg/m2) y el 25% de osteosarcoma (pauta de MTX 12.000 mg/m2). De los pacientes \ndiagnosticados de LLA un 66,6% desarrollaron la intoxicaci\u00f3n en la fase de intensificaci\u00f3n de alto riesgo mientras que \nel otro 33,3% fue en la fase de consolidaci\u00f3n\ufffd La dosis media de MTX fue de 6\ufffd750 \u00b1 3\ufffd500 mg/m2\ufffd Todos los pacientes \nfueron tratados con bicarbonato para la alcalinizaci\u00f3n de orina e hiperhidratados antes y durante la quimioterapia, junto \ncon rescates de \u00e1cido fol\u00ednico. En el 50% de los pacientes se administr\u00f3 la glucarpidasa tras 36 horas desde la infusi\u00f3n \ncon unas concentraciones de MTX en plasma de 14,4 \u00b1 2,4 \u00b5mol/L. En otro 25% de los pacientes fue de 6,55 \u00b5mol/L a las \n42 horas y en el paciente restante a las 58 horas tuvo 4,78 \u00b5mol/L. La creatinina media previa al tratamiento fue de 0.5 \n\u00b1 0.3 mg/dL y posteriormente fue de 1.5\u00b1 0.6 m/dL, habiendo un aumento de creatinina de m\u00e1s del 100% el valor inicial \nen todos ellos. La dosis de glucarpidasa fue de 50 UI/kg en el 75% de los pacientes y 36.5 UI/kg en el resto. Despu\u00e9s de 4 \nd\u00edas tras la intoxicaci\u00f3n, la media de reducci\u00f3n de la concentraci\u00f3n de MTX en plasma fue del 96,6 \u00b10,3 %.\nCONCLUSIONES\nGlucarpidasa se considera un f\u00e1rmaco efectivo y bien tolerado en el manejo de la nefrotoxicidad inducida por altas dosis \nde MTX y su eliminaci\u00f3n tard\u00eda. Constituye una alternativa adecuada cuando el tratamiento con las medidas correctoras \nconvencionales como son el rescate con \u00e1cido fol\u00ednico, la hidrataci\u00f3n y alcalinizaci\u00f3n urinaria, no son suficientes.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n624. DOSIFICACI\u00d3N DE F\u00c1RMACOS ANTINEOPL\u00c1SICOS EN PACIENTES OBESOS \nAUTORES\nG\u00c1NDARA ANDE, A; FUERTES CAMPORRO, S; F\u00d3RNEAS SANGIL, A; APARICIO CARRE\u00d1O, C; PAMP\u00cdN S\u00c1NCHEZ, R; \nFERN\u00c1NDEZ GONZ\u00c1LEZ, A; MART\u00cdNEZ-M\u00daGICA BARBOSA, C; TERROBA ALONSO, PN\nHOSPITAL DE CABUE\u00d1ES. LOS PRADOS, 395 GIJ\u00d3N. ASTURIAS\nOBJETIVOS\nAnalizar la dosificaci\u00f3n de los antineopl\u00e1sicos en pacientes obesos y su grado de adecuaci\u00f3n a las recomendaciones \npublicadas por la \u201cAmerican Society of Clinical Oncology\u201d (ASCO) antes y despu\u00e9s de realizar una intervenci\u00f3n \nfarmac\u00e9utica.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo que incluy\u00f3 a todos los pacientes oncol\u00f3gicos con \u00edndice de masa corporal (IMC) \u2265 30 kg/m2, que \nrecibieron tratamiento antineopl\u00e1sico por v\u00eda parenteral.  \nA trav\u00e9s del programa de gesti\u00f3n de pacientes oncol\u00f3gicos se recogieron y analizaron las siguientes variables: edad, sexo, \ntalla, peso real y peso ideal ajustado, superficie corporal, IMC, Eastern Cooperative Oncology Group (ECOG), diagn\u00f3stico, \nantineopl\u00e1sico y dosis prescrita. Se calcul\u00f3 la dosis te\u00f3rica considerando el peso real de los pacientes, tal y como \nrecomiendan las gu\u00edas ASCO. Tambi\u00e9n se recogieron las reducciones de dosis por otras comorbilidades.  \nLos datos anteriormente descritos se analizaron durante el periodo comprendido entre diciembre de 2021 y febrero de \n2022. En marzo de 2022 se realiz\u00f3 una intervenci\u00f3n farmac\u00e9utica exponiendo al equipo m\u00e9dico las recomendaciones \npublicadas por la ASCO en 2021. En abril de 2022 se recogieron y analizaron de nuevo las prescripciones de \nantineopl\u00e1sicos para conocer el grado de aceptaci\u00f3n de la intervenci\u00f3n.\nRESULTADOS\nSe incluyeron 124 pacientes (68 mujeres) con una mediana de edad de 66 a\u00f1os y un IMC medio de 34 kg/m2. El 88% de \nlos pacientes presentaban un ECOG \u2264 1. Los diagn\u00f3sticos mayoritarios en la poblaci\u00f3n analizada fueron el tumor de mama \n(23,39%), el pulm\u00f3n no microc\u00edtico (18,55%), el de ovario (10,48%) y el de colon (9,68%). El n\u00famero de prescripciones \nrecogidas fue de 152\ufffd  \nEn el an\u00e1lisis realizado pre-intervenci\u00f3n, se encontr\u00f3 que el 33% de los antineopl\u00e1sicos prescritos en pacientes obesos se \ndosificaron por peso ideal ajustado.  \nAdem\u00e1s de la reducci\u00f3n de dosis producida por la utilizaci\u00f3n del peso ajustado, en un 37 % de los pacientes se redujo la \ndosis por presentar otras comorbilidades\ufffd  \nPor grupos de f\u00e1rmacos, se observ\u00f3 que los inhibidores del punto de control inmunitario se prescrib\u00edan a dosis fijas \ny/o completas. Sin embargo, un 35% de las terapias dirigidas como el bevacizumab o el cetuximab y un 43 % de la \nquimioterapia cl\u00e1sica se dosificaron utilizando el peso ideal ajustado.  \nLa diferencia entre la dosis prescrita y la te\u00f3rica supuso una reducci\u00f3n que oscilaba entre el 7% y el 22% en el caso de las \nterapias dirigidas y entre el 6% y el 25% en el caso de la quimioterapia cl\u00e1sica.  \nEn el an\u00e1lisis realizado post-intervenci\u00f3n farmac\u00e9utica se observ\u00f3 una reducci\u00f3n de las prescripciones calculadas seg\u00fan \npeso ideal ajustado de un 15%.\nCONCLUSIONES\nEl an\u00e1lisis de la dosificaci\u00f3n en pacientes obesos nos ha mostrado que el 33% de las prescripciones de antineopl\u00e1sicos \nse realizaban a peso ideal ajustado y por tanto no se adecuaban a las recomendaciones de las gu\u00edas ASCO. El trabajo \nconjunto del Servicio de Farmacia con el equipo m\u00e9dico ha permitido mejorar la prescripci\u00f3n en este grupo de pacientes.349CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n627. AN\u00c1LISIS DE LA INCIDENCIA DE EFECTOS ADVERSOS EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA \nRESISTENTE A LA CASTRACI\u00d3N METAST\u00c1SICO \nAUTORES\nMIR CROS, M; GILABERT SOTOCA, M; RIUS PERERA, J; BARDOLL CUCALA, M; MORALES PORTILLO, A; MANGUES \nBAFALLUY , I\nHOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA \ufffd AVDA \ufffd ALCALDE ROVIRA ROURE, 80 LLEIDA \ufffd LLEIDA\nOBJETIVOS\nDeterminar la incidencia de aparici\u00f3n de efectos adversos en pacientes diagnosticados de c\u00e1ncer de pr\u00f3stata resistente a \nla castraci\u00f3n metast\u00e1sico (CPRC M1) en tratamiento con abiraterona + prednisona o enzalutamida.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo que incluye pacientes diagnosticados de c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n \nmetast\u00e1sico que iniciaron tratamiento con abiraterona + prednisona o enzalutamida entre febrero 2016 y febrero 2022.  \nLas variables recogidas fueron: edad, fecha de inicio de tratamiento y aparici\u00f3n de efectos adversos (hipopotasemia, \nhipertensi\u00f3n, astenia, edemas, toxicidad neurol\u00f3gica, rash cut\u00e1neo y diarrea). Estos datos fueron recogidos de la historia \ncl\u00ednica informatizada.\nRESULTADOS\nSe evaluaron un total de 87 pacientes, de los cuales 46 fueron tratados con abiraterona + prednisona y 41 con \nenzalutamida. La media de edad fue de 78 (56 \u2013 91) a\u00f1os.  \nUn 82.6% y un 87.8% de los pacientes tratados con abiraterona + prednisona y enzalutamida, respetivamente, \npresentaron alg\u00fan efecto adverso durante el tratamiento.  \nLos efectos adversos m\u00e1s frecuentes en nuestros pacientes en tratamiento con abiraterona + prednisona y enzalutamida, \nrespectivamente, fueron: astenia (43,5% vs 53,7%), hipertensi\u00f3n (30,4 vs 22%), edemas (13% vs 19,5%), hipopotasemia \n(17,4% vs 0%), toxicidad neurol\u00f3gica (6,5% vs 7,3%), diarrea (6,5% vs 4,9%) y rash cut\u00e1neo (0% vs 2,4%). \nUn paciente discontinu\u00f3 el tratamiento con enzalutamida debido a la aparici\u00f3n de efectos adversos (espasmos \nmusculares).\nCONCLUSIONES\nEl tratamiento para el CPRC M1 con abiraterona + prednisona o enzalutamida se relaciona con una incidencia alta de \nefectos adversos\ufffd  \nSe observaron m\u00e1s efectos adversos en los pacientes tratados con enzalutamida en comparaci\u00f3n con abiraterona + \nprednisona\ufffd  \nLos efectos adversos m\u00e1s frecuentes en nuestros pacientes fueron astenia, hipertensi\u00f3n y edemas. S\u00f3lo un paciente \nfinaliz\u00f3 el tratamiento como consecuencia de los efectos adversos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n629. IMPACTO DEL CONSUMO DE ANTIBI\u00d3TICOS EN LA EFECTIVIDAD DE LA INMUNOTERAPIA. \nAUTORES\nG\u00c1NDARA ANDE, A; F\u00d3RNEAS SANGIL, A; APARICIO CARRE\u00d1O, C; FUERTES CAMPORRO, S; PAMP\u00cdN S\u00c1NCHEZ, R; \nRODR\u00cdGUEZ NEBREDA, S; TERROBA ALONSO, PN; MART\u00cdNEZ-M\u00daGICA BARBOSA, C\nHOSPITAL DE CABUE\u00d1ES. LOS PRADOS, 395 GIJ\u00d3N. ASTURIAS\nOBJETIVOS\nAnalizar el impacto del consumo de antibi\u00f3ticos en la efectividad de la inmunoterapia\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo que incluy\u00f3 a los pacientes que iniciaron inmunoterapia entre el 2014 y el 2021 \npara el tratamiento del c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) en estad\u00edo localmente avanzado o metast\u00e1sico. Se \nexcluyeron aquellos pacientes en los que no fue posible evaluar la respuesta. \nA trav\u00e9s del programa de gesti\u00f3n de pacientes oncol\u00f3gicos y de la historia cl\u00ednica electr\u00f3nica se recogieron y analizaron \nlas siguientes variables: edad, sexo, Eastern Cooperative Oncology Group (ECOG), histolog\u00eda, f\u00e1rmaco y duraci\u00f3n del \ntratamiento\ufffd  \nA partir de los datos extra\u00eddos de receta electr\u00f3nica se clasificaron a los pacientes en dos grupos: aquellos que hab\u00edan \nrecibido antibi\u00f3ticos por v\u00eda oral en los dos meses previos o dos meses posteriores al inicio de la inmunoterapia y los \npacientes que no recibieron antibi\u00f3ticos orales en ese periodo de tiempo.  \nLa efectividad se valor\u00f3 mediante la comparaci\u00f3n de la Supervivencia Libre de Progresi\u00f3n (SLP) y la Supervivencia Global \n(SG) entre los dos grupos de pacientes.\nRESULTADOS\nEl grupo que recibi\u00f3 antibi\u00f3ticos incluy\u00f3 55 pacientes (36 hombres) con una mediana de edad de 66 a\u00f1os. El 93% de los \npacientes presentaba un ECOG \u2264 1 al inicio del tratamiento. En cuanto a la histolog\u00eda, el 58% eran adenocarcinomas y el \n18% eran epidermoides. El 49% de los pacientes fueron tratados con pembrolizumab, el 31% con atezolizumab y el 20% \nrestante con nivolumab\ufffd  \nEl grupo que no recibi\u00f3 antibi\u00f3ticos durante el periodo ventana incluy\u00f3 89 pacientes (67 hombres) con una edad media \nde 66 a\u00f1os. El 98% de los pacientes presentaba un ECOG \u2264 1 al inicio del tratamiento. En cuanto a la histolog\u00eda, el 69% 350eran adenocarcinomas, el 28% eran epidermoides y el 3% restante era CPNM indiferenciado\ufffd El 45% de los pacientes \nfueron tratados con pembrolizumab, el 38% con atezolizumab y el 17% restante con nivolumab.  \nEl grupo de pacientes que recibi\u00f3 antibi\u00f3tico present\u00f3 una SLP de 3,6 meses (IC 95%; 3,36-6,12) y una SG de 11,64 \nmeses (IC95% 6,72-NA), mientras que el grupo de paciente que no recibi\u00f3 antibi\u00f3tico presento una SLP de 6 meses (IC \n95%; 4,56-9,12) y una SG de 17,16 meses (IC95% 13,8-21,48). Sin embar go, las diferencias encontradas no resultaron ser \nestad\u00edsticamente significativas (p=0,58) y (p=0,88), respectivamente.\nCONCLUSIONES\nEl uso de antibi\u00f3ticos por v\u00eda oral en los dos meses previos o posteriores al inicio de la inmunoterapia supone una \ndiferencia en la SLP y SG de los pacientes con CPNM, aunque esta no es estad\u00edsticamente significativa.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n640. EFECTIVIDAD Y SEGURIDAD DE AVELUMAB EN EL TRATAMIENTO DE MANTENIMIENTO DE PRIMERA \nL\u00cdNEA DEL CARCINOMA UROTERIAL LOCALMENTE AVANZADO O METAST\u00c1SICO \nAUTORES\nGEMENO L\u00d3PEZ, E; ESPADAS HERV\u00c1S, N; MART\u00cdN RUFO, M; MART\u00cdNEZ BARROS, H; FERN\u00c1NDEZ FRADEJAS, J; \nS\u00c1NCHEZ CUERVO, M; PUEYO L\u00d3PEZ, C; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nAnalizar la efectividad y seguridad de avelumab en el tratamiento de mantenimiento de primera l\u00ednea del carcinoma \nurotelial (CU) localmente avanzado o metast\u00e1sico.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital de tercer nivel, en el que se incluyeron todos los pacientes con \ncarcinoma urotelial (CU) localmente avanzado o metast\u00e1sico que hab\u00edan recibido avelumab de mantenimiento de primera \nl\u00ednea desde mayo de 2021 hasta abril de 2022.  \n \nSe recogieron las variables: sexo, edad, estado funcional (ECOG), n\u00famero de ciclos recibidos, supervivencia libre de \nprogresi\u00f3n (SLP), respuesta alcanzada, causa de finalizaci\u00f3n del tratamiento y reacciones adversas (RAM).  \nLos datos se recogieron de la historia cl\u00ednica electr\u00f3nica y el programa de prescripci\u00f3n electr\u00f3nica y se analizaron en \nExcel\u00ae\ufffd\nRESULTADOS\nSe incluyeron 13 pacientes (76.9% hombres) con una edad media de 74,5 \u00b1 8,9 a\u00f1os. El estado funcional de los pacientes \nantes de iniciar el tratamiento fue de ECOG 1 en el 92,3% de los pacientes y ECOG 0 en el resto\ufffd  \n \nLos pacientes recibieron mantenimiento con 800mg de avelumab cada 2 semanas\ufffd La media de ciclos recibida fue de \n10,8 \u00b1 4,6 meses\ufffd La mediana de SLP fue de 4,47 \u00b1 2,37 meses\ufffd La respuesta obtenida con el tratamiento fue enfermedad \nestable (EE) en el 53,5% de los pacientes, respuesta parcial (RP) en el 15,4%, respuesta completa (RC) en el 7,7% y \nprogresi\u00f3n de la enfermedad (PE) en el 23,1%. Discontinuaron el tratamiento 4 pacientes (30,8%). El motivo de la \ndiscontinuaci\u00f3n fue la PE en el 75% y RAM en el 25%.  \n \nEl 53,8% de los pacientes presentaron alguna RAM y solo uno de ellos present\u00f3 una \u00fanica RAM. La RAM m\u00e1s frecuente \nfue hipertiroidismo que apareci\u00f3 en 4 pacientes (57,1%), seguido de estre\u00f1imiento (28,6%, n=2), fiebre en las 24h tras \nadministraci\u00f3n del tratamiento (28,6%, n=2), y prurito (28,6%, n=2). Las RAM analizadas fueron todas G1 (72,2%) y G2 \n(27,8%). La media de tiempo de aparici\u00f3n fue de 42,1 \u00b1 38,3 d\u00edas\nCONCLUSIONES\nEl avelumab como tratamiento de mantenimiento en carcinoma urotelial avanzado o metast\u00e1sico ha demostrado ser \neficaz, manteniendo o mejorando la respuesta obtenida durante la inducci\u00f3n con quimioterapia en la mayor\u00eda de los \ncasos\ufffd  \n \nTambi\u00e9n ha demostrado ser un tratamiento seguro, que pese a la alta frecuencia de RAM \u00e9stas son en su mayor\u00eda leves y \nde f\u00e1cil manejo.  \n \nSon necesarios m\u00e1s estudios para obtener resultados m\u00e1s s\u00f3lidos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n644. NIVOLUMAB: \u00bfDIFERENCIA EN EFECTOS ADVERSOS ENTRE MUJERES Y HOMBRES? EXPERIENCIA \nEN PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nFERN\u00c1NDEZ-BRAVO RODRIGO, J; MARTIN NI\u00d1O, I; PORTELA SOTELO, A; MART\u00cdNEZ VALDIVIESO, L; LAFARGA LAPIEZA, \nV; BARREDA HERN\u00c1NDEZ, D\nHOSPITAL GENERAL VIRGEN DE LA LUZ \ufffd HERMANDAD DONANTES DE SANGRE, 1 CUENCA \ufffd CUENCA351OBJETIVOS\nDiferentes estudios muestran aumento de eventos adversos en mujeres frente a hombres tratados con inmunoterapia.  \n \nAnalizar y evaluar posibles diferencias en el perfil de seguridad de nivolumab entre mujeres y hombres.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo-anal\u00edtico retrospectivo desde su comercializaci\u00f3n (Enero\u00b416) hasta Diciembre\u00b421, en hospital-nivel-\nII. Se incluyeron pacientes con enfermedad neopl\u00e1sica localmente avanzada/metast\u00e1sica tratados con nivolumab en \nmonoterapia, diferenci\u00e1ndose por sexo (brazo-M: mujeres; brazo-H: hombres), excluy\u00e9ndose pacientes hematol\u00f3gicos.  \n \nSe utiliz\u00f3 para la recogida de datos: programa de gesti\u00f3n farmacoterap\u00e9utica oncol\u00f3gica (Farhos.v-5.3.3\u00ae) e historias \ncl\u00ednicas informatizadas (MambrinoXXI\u00ae). Adem\u00e1s, se consult\u00f3 las reacciones adversas (RAM) recogidas en ficha t\u00e9cnica \n(FT).  \n \nVariables evaluadas:  \n- Edad.  \n- Sexo.  \n- Tipo neoplasia.  \n- Intenci\u00f3n de tratamiento seg\u00fan enfermedad metast\u00e1sica vs adyuvante. \n- L\u00ednea de tratamiento.  \n- Pauta posol\u00f3gica. \n- N\u00famero ciclos, reducci\u00f3n y/o suspensi\u00f3n.  \n- Seguridad comparando grupos M-H; seg\u00fan:  \no N\u00famero y tipo de RAM/paciente descritas en evolutivo y/o notificadas con tarjeta amarilla para nivolumab.  \no Gravedad de RAM/paciente seg\u00fan criterios CTCAEv-5.0.  \no Frecuencia de RAM, analizando aquellas \u22655% incidencia en cada brazo.  \n \nAn\u00e1lisis estad\u00edstico: STATA\u00aev.16.0, comparando medias e intervalos de confianza (95%IC) para muestras no param\u00e9tricas \ncon test U de Mann-Whitney.\nRESULTADOS\nSe incluyeron 87 pacientes (66,7% H), con las siguientes caracter\u00edsticas basales (brazo-M vs brazo-H): \n \nMedia de edad: 70[50-91] vs67[40-96]a\u00f1os  \nTipos de neoplasia:  \na. Pulm\u00f3n no microc\u00edtico: 12vs28 \nb\ufffd Melanoma: 8vs12 \nc\ufffd Renal: 2vs5 \nd. Cabeza-cuello: 1vs9 \ne\ufffd Otros: 4vs6 \nTratamiento metast\u00e1sico: 29vs51  \na. L\u00ednea m\u00e1s prevalente: 2\u00aa (55vs47%) \nTratamiento adyuvante: 0vs7 \nN\u00famero medio de ciclos: 17vs13 \n \n \nPauta posol\u00f3gica: 3mg/kg/14d\u00edas(m\u00e1x:240mg), exceptuando administraciones puntuales por pandemia de 6mg/kg \n/28d\u00edas(m\u00e1x:480mg).  \n \n25 pacientes (64% H) interrumpieron tratamiento en alguna ocasi\u00f3n, 2H (8%) tuvieron una reducci\u00f3n (70 y 80%). \nFinalmente, por RAM y/o empeoramiento ECOG se suspendieron 16 tratamientos (62,5% H).  \n \nSe notificaron 8 tarjetas amarillas (87,5% H) por RAM grado-III, recogidas en FT como: \n \n- Frecuentes: neumonitis (2), neumon\u00eda, hepatitis aguda y cuadro febril intermitente con artritis y colitis ulcerosa.  \n- Poco frecuentes: nefritis autoinmune, miastenia gravis.  \n- No recogidas: leucemia linfobl\u00e1stica aguda-T.  \n \nEl an\u00e1lisis estad\u00edstico mostr\u00f3 las siguientes medias para brazo-M vs brazo-H: \n \n- N\u00ba RAM/paciente: 5,14(95%IC:3,59-6,69) vs4,55(95%IC:3,69-5,42); p=0,66  \n \n- Gravedad RAM/paciente:  \no Grado-I: 2,93(95%IC:2,12-3,74-) vs2,86(95%IC:2,25-3,47); p=0,69  \no Grado-II: 1,69(95%IC:0,96-2,42) vs1,38(1,00-1,76); p=0,59  \no Grado-III: 0,38(95%IC:0,10-0,65) vs0,21(95%IC:0,06-0,35); p=0,13  352- RAM \u22655% en alg\u00fan brazo: anemia, astenia, diarrea, dolor, disgeusia, eritema, hepatitis, hiperglucemia, hiporexia-\nanorexia, hipotiroidismo, incremento creatinina, infecci\u00f3n respiratoria, linfopenia, mucositis, n\u00e1useas, prurito, tos. Todas \nrecogidas en FT \ufffd \nS\u00f3lo se observ\u00f3 diferencias estad\u00edsticamente significativas en aparici\u00f3n de tos [M: 0,28(95%IC:0,08-0,48) vs H:0,08(0,01-\n0,16); p=0,04] y tendencia hacia hipotiroidismo [M:0,17(95%IC:0,03-0,32) vs H:0,07(95%IC:0-0,13); p=0,13] Por otro lado, \nmayor tendencia a incrementos de creatinina en H [M: 0,03(95%IC:0-0,11) vs H:0,16(95%IC:0,06-0,25); p=0,09]\nCONCLUSIONES\nEn nuestro estudio, cuyas principales limitaciones son, peque\u00f1o tama\u00f1o muestral, ser retrospectivo y brazos con \ncaracter\u00edsticas basales no homog\u00e9neas, se observa de forma estad\u00edsticamente significativa mayor aparici\u00f3n de tos en \nmujeres, as\u00ed como mayor predisposici\u00f3n a hipotiroidismo y RAM grado-III. Sin embargo, destaca la notificaci\u00f3n de 8 \ntarjetas amarillas, siendo 7 de hombres, incluyendo RAM no recogida en FT. \nLa actividad proactiva del farmac\u00e9utico hospitalario en materia de farmacovigilancia es clave para la evaluaci\u00f3n de la \nseguridad, especialmente en los f\u00e1rmacos de reciente introducci\u00f3n en la pr\u00e1ctica cl\u00ednica.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n659. FACTORES PREDICTIVOS DE RESPUESTA A QUIMIOTERAPIA COMBINADA CON TRASTUZUMAB EN \nPACIENTES CON C\u00c1NCER G\u00c1STRICO AVANZADO HER2 POSITIVO \nAUTORES\nMAC\u00cdA RIVAS, L; \u00c1LVAREZ MANCE\u00d1IDO, FJ; ARIAS MART\u00cdNEZ, A; MART\u00cdNEZ TORR\u00d3N, A; PIERAS L\u00d3PEZ, \u00c1; IGLESIAS \nP\u00c9REZ, C; CARBAJALES \u00c1LVAREZ, M; LOZANO BL\u00c1ZQUEZ, A\nHOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS \ufffd AVENIDA DE ROMA S/N OVIEDO \ufffd ASTURIAS\nOBJETIVOS\nDesarrollo de un modelo pron\u00f3stico de supervivencia basado en variables clinicopatol\u00f3gicas y de laboratorio en pacientes \ncon c\u00e1ncer g\u00e1strico avanzado HER2-positivo(HER2+) tratados con quimioterapia y trastuzumab con intenci\u00f3n paliativa\nMATERIALES Y M\u00c9TODOS\nSe incluyeron pacientes con adenocarcinoma gastroesof\u00e1gico avanzado HER2+ procedentes de un registro ambispectivo, \nnacional y multic\u00e9ntrico(34 centros) tratados con quimioterapia y trastuzumab entre 2008 y 2021.  \n \nLa identificaci\u00f3n de los predictores se realiz\u00f3 en base a la revisi\u00f3n de la literatura. Para limitar el sesgo de confusi\u00f3n, \nse eligieron 13 variables:localizaci\u00f3n del tumor primario (es\u00f3fago, uni\u00f3n gastroesof\u00e1gica o est\u00f3mago), carga tumoral, \nhaber sido sometido a cirug\u00eda previa, grado histol\u00f3gico, tipo histol\u00f3gico de Lauren, presencia de c\u00e9lulas en anillo \nde sello, intensidad de expresi\u00f3n de HER2 (inmunohistoqu\u00edmica 3 cruces(IHQ+3) o IHQ+2/fluorescence in situ \nhybridization(FISH)+), edad, estado general medido con la escala Eastern Cooperative Oncology Group(ECOG), esquema \nde quimioterapia, ratio neutr\u00f3filos/linfocitos(RNL), marcador CEA, y alb\u00famina.  \n \nAntes de construir el modelo, se realiz\u00f3 un Delta de Somers para conseguir conocer mejor la correlaci\u00f3n entre \nvariables. Para la construcci\u00f3n del modelo de supervivencia se escogi\u00f3 un modelo de tiempo de fallo acelerado (AFT) \ncon distribuci\u00f3n log-normal debido a la falta de proporcionalidad de las tasas de riesgo para las variables clave. Los \ncoeficientes exponenciados de este modelo se expresaron con ratios tiempo (TR). Si el TR es > 1, la variable ralentiza o \nprolonga el tiempo hasta el evento, mientras que un TR < 1 indica que es m\u00e1s probable que un evento ocurra antes. \n \nEl an\u00e1lisis estad\u00edstico se realiz\u00f3 empleando el software R4.0.5.\nRESULTADOS\nSe incluyeron un total de 645 pacientes. Tras una mediana de seguimiento de 62.8 meses(intervalo de \nconfianza(IC)95%,49.1-86.0), se detectaron 549 decesos con una mediana de supervivencia global de 14.0 \nmeses(IC95%,13.0-14.9).  \n \nLas variables que se relacionaron m\u00e1s estrechamente con supervivencia seg\u00fan el an\u00e1lisis Delta de Somers fueron la RNL, \nel ECOG, el subtipo de Lauren, el grado histol\u00f3gico, la carga tumoral, el tipo de expresi\u00f3n de HER2 y el CEA y los que \nmenos, el esquema de quimioterapia, la localizaci\u00f3n del tumor y la edad.  \n \nEl modelo pron\u00f3stico derivado se bas\u00f3 en las siguientes seis variables: RNL, ECOG-PS, tipo histol\u00f3gico de Lauren, nivel de \nsobreexpresi\u00f3n de HER2, grado histol\u00f3gico y carga tumoral. Las variables asociadas con peor pron\u00f3stico fueron: RNL 5.2 \nvs 2.1, TR= 0.81 (IC95%,0.71-0.93); ECOG 2 vs 1, 0.64 (0.52-0.80); Lauren difuso vs intestinal, 0.72 (0.55-0.95); HER2 IHQ \n+2/FISH+ vs IHQ +3, 0.82 (0.70-0.96); grado 3 vs 1, 0.92 (0.73-0.97) y carga tumoral muy alta vs baja, 0.86 (0.77-0.98). El \nmodelo, presentado como un nomograma, predice de forma significativa la supervivencia (prueba raz\u00f3n verosimilitud, \n\u03c72=128, grados de libertad=30, p-valor < 0.0001) y tiene un c-index de Harrell de 0.678.\nCONCLUSIONES\nSe han identificado diversas variables relacionadas con una mayor supervivencia en nuestra poblaci\u00f3n de estudio.  \nEl modelo pron\u00f3stico desarrollado se basa en seis variables cl\u00ednicopatol\u00f3gicas y de laboratorio accesibles y se ha \nrepresentado como un nomograma que predice la mediana de supervivencia y la probabilidad de supervivencia a \n1 o 2 a\u00f1os en pacientes con adenocarcinoma gastroesof\u00e1gico avanzado HER2+ candidatos a recibir quimioterapia y \ntrastuzumab.353CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n660. PERFIL DE EFECTIVIDAD Y TOXICIDAD DE ESQUEMAS DE PRIMERA L\u00cdNEA EN ADENOCARCINOMA \nGASTROESOF\u00c1GICO AVANZADO HER2 NEGATIVO. DATOS DE 1343 PACIENTES \nAUTORES\nMAC\u00cdA RIVAS, L; ARIAS MART\u00cdNEZ, A; \u00c1LVAREZ MANCE\u00d1IDO, FJ; PIERAS L\u00d3PEZ, \u00c1; MART\u00cdNEZ TORR\u00d3N, A; CONTRERAS \nTOLEDO, DC; CARBAJALES \u00c1LVAREZ, M; LOZANO BL\u00c1ZQUEZ, A\nHOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS \ufffd AVENIDA DE ROMA S/N OVIEDO \ufffd ASTURIAS\nOBJETIVOS\nDescribir la efectividad y toxicidad de los reg\u00edmenes est\u00e1ndar de quimioterapia en adenocarcinoma gastroesof\u00e1gico \navanzado para pacientes con neoplasia HER2 negativa (HER2-).\nMATERIALES Y M\u00c9TODOS\nSe incluyeron pacientes con adenocarcinoma gastroesof\u00e1gico avanzado HER2- diagnosticados entre 2008 y 2021 \nprocedentes de un registro ambispectivo, nacional y multic\u00e9ntrico (34 centros).  \n \nLos pacientes se trataron con quimioterapia basada en reg\u00edmenes est\u00e1ndar que inclu\u00edan un platino (cisplatino u \noxaliplatino) y una fluoropirimidina (5-fluouracilo (5FU) o capecitabina). Los grupos de esquemas terap\u00e9uticos evaluados \nfueron oxaliplatino asociado a 5FU (Oxalip5FU): FLO, FOLFOX6 y FUOX modificado; cisplatino asociado a 5FU (FP): FP3w y \nFP4w; oxaliplatino asociado a capecitabina (CAPOX); y cisplatino asociado a capecitabina (XP).  \n \nLa efectividad se midi\u00f3 como supervivencia calculada como el intervalo desde el inicio de la primera l\u00ednea de \nquimioterapia hasta la muerte por cualquier causa (global, SG) o hasta la progresi\u00f3n o la muerte (libre de progresi\u00f3n, \nSLP). La SLP y SG se analizaron mediante el m\u00e9todo de Kaplan-Meier y se compararon mediante el estad\u00edstico de Log-\nRank\ufffd \n \nLa toxicidad se clasific\u00f3 a trav\u00e9s de la escala de toxicidad Common Terminology Criteria for Adverse Events (CTCAE), y se \nrecogi\u00f3 la considerada significativa (grado 2 a 4). Para analizar su aparici\u00f3n en los diferentes grupos estudiados se utiliz\u00f3 \nel test estad\u00edstico de Chi2.  \n \nTodos los an\u00e1lisis estad\u00edsticos se realizaron con el programa STATA 14.2.\nRESULTADOS\nLa poblaci\u00f3n de estudio comprendi\u00f3 un total de 1343 pacientes, 66,49% (n= 893) varones con una mediana de edad \nal inicio de la quimioterapia de 65,69 a\u00f1os (20,16-89,42). La localizaci\u00f3n del tumor primario fue mayoritariamente en \nest\u00f3mago, un 78,48% (n=1054) de los pacientes, seguido de uni\u00f3n gastroesof\u00e1gica 11,39% (n= 153) y es\u00f3fago con un \n8,79% (n=118). \n \nPor orden de utilizaci\u00f3n, los grupos terap\u00e9uticos fueron Oxalip5FU en 518 (38,57 %), CAPOX en 466 (34,70 %) y XP en 252 \n(18,76%) y FP en 107 (7,97%). La mediana de SLP de la poblaci\u00f3n es tudiada fue de 6,53 meses (intervalo de confianza \n(IC) 95% 6,21-6,87) no obteni\u00e9ndose diferencias entre los grupos de tratamiento (p=0.070). Tampoco se obtuvieron \ndiferencias significativas en SG (p=0.2478) entre los grupos de tratamiento con una mediana global de 10,61 meses (IC \n95% 9,89-11,01).  \nEn cuanto a la tolerancia, un 19,94% (n= 249) de los pacientes requirieron ingreso hospitalario como consecuencia de un \nevento adverso. Las toxicidades grado 2-4 m\u00e1s habituales en esquemas con cisplatino fueron trombosis (FP3w 25%, FP4w \n9,47%), toxicidad renal (3,17% XP y 3,16% FP3w) y neutropenia (43,16% FP3w y 41,67% FP4w).  \n \nEn los esquemas con oxaliplatino destacaron la aparici\u00f3n de neuropat\u00eda (32,10% FOLFOX6 y 20,45% FUOXmodificado) y \ndiarrea (18,18% FUOXmodificado, 17,61% CAPOX y 15,84% FOLFOX6).\nCONCLUSIONES\nNuestro estudio muestra una efectividad similar entre los esquemas est\u00e1ndar utilizados en primera l\u00ednea de c\u00e1ncer \ng\u00e1strico avanzado.  \nEl perfil de toxicidad aqu\u00ed descrito para cada esquema puede ayudar a individualizar el tratamiento antineopl\u00e1sico.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n669. SEGUIMIENTO DE LA EFECTIVIDAD Y SEGURIDAD DEL USO DE NIVOLUMAB EN HEPATOCARCINOMA \nAVANZADO \nAUTORES\nFRAGA BUENO, E; RODR\u00cdGUEZ PEN\u00cdN, I\nCOMPLEXO HOSPITALARIO UNIVERSITARIO DE FERROL\nOBJETIVOS\nTras la progresi\u00f3n a sorafenib, nivolumab constituye una de las alternativas terap\u00e9uticas recogida en las gu\u00edas de pr\u00e1ctica \ncl\u00ednica para el tratamiento del hepatocarcinoma avanzado (indicaci\u00f3n no autorizada).  \n 354El objetivo principal es evaluar la efectividad y seguridad del uso de nivolumab en hepatocarcinoma avanzado, realizando \nun seguimiento a los primeros pacientes que iniciaron esta terapia en nuestra \u00e1rea sanitaria.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo en un hospital de segundo nivel. Se incluyeron todos los pacientes \ncon hepatocarcinoma avanzado que iniciaron tratamiento con nivolumab desde junio 2018 hasta abril 2021 (ambos \nincluidos). La fecha de corte para el seguimiento fue abril 2022 (incluido). Los inicios de tratamiento fueron gestionados a \ntrav\u00e9s de la plataforma corporativa de autorizaci\u00f3n de solicitudes especiales.  \n \nDe la historia cl\u00ednica electr\u00f3nica se recogieron datos demogr\u00e1ficos (sexo, edad), h\u00e1bito en\u00f3lico, infecci\u00f3n por VHB o \nVHC, Child-Pugh, presencia de cirrosis, estado funcional (PS) y efectividad y tolerancia del tratamiento con nivolumab. \nDe los programas de prescripci\u00f3n electr\u00f3nica se obtuvieron tratamientos oncol\u00f3gicos previos y ciclos administrados de \nnivolumab. La efectividad se evalu\u00f3 a partir de la mediana de supervivencia libre de progresi\u00f3n (SLP) y supervivencia \nglobal (SG). Para valorar la respuesta al tratamiento se aplicaron los criterios RECIST v.1.1. Para la valoraci\u00f3n de la \ntoxicidad se utilizaron los criterios del National Cancer Institute (CTCAE v.5.0).\nRESULTADOS\nEntre junio 2018 y abril 2021, iniciaron tratamiento con nivolumab 9 pacientes (8 hombres), con una mediana de edad \nde 77 a\u00f1os (RIQ: 71-81). Al inicio, 8 pacientes ten\u00edan un PS 1, 1 paciente PS 2. Cinco pacientes presentaban cirrosis. Seis \npacientes ten\u00edan Child-Pugh A, 1 paciente B, 2 desconocido. En cuanto al h\u00e1bito en\u00f3lico, 5 pacientes eran bebedores/\nexbebedores y 4 no bebedores. Un paciente infectado por VHB y otro por VHC. Todos hab\u00edan recibido tratamiento previo \ncon sorafenib, 1 regorafenib y 2 cabozantinib. En estadios iniciales, 2 pacientes fueron tratados con radiofrecuencia, 1 con \nquimioembolizaci\u00f3n y otro con ambas t\u00e9cnicas.  \n \nLa mediana de seguimiento fue de 472 d\u00edas (RIQ: 297-619), con una duraci\u00f3n media del tratamiento de 10,17 \u00b1 8 meses. \nLa mediana de ciclos fue de 16 (RIQ: 7-32). Tasa de control de la enfermedad: 5 pacientes (55,6%) respuesta parcial, 2 \npacientes (22,2%) enfermedad estable. La mediana de SLP fue de 10,9 meses (RIQ: 6,1-17,8) y la mediana de SG fue de \n15,7 meses (RIQ:9,9-20,6).  \n \nA la fecha de corte, 4 fueron \u00e9xitus, 2 continuaban con tratamiento activo, 2 en respuesta y sin tratamiento activo y 1 sin \ntratamiento por progresi\u00f3n\ufffd  \n \nSiete pacientes (77,8%) presentaron efectos adversos (EA) de cualquier grado, siendo la toxicidad hep\u00e1tica y la astenia \nlas m\u00e1s frecuentes. Toxicidad grado 3: colitis (1), nefropat\u00eda autoinmune (1). Toxicidad grado 2: neutropenia (1), \nhepatotoxicidad (2). Seis pacientes sufrieron retrasos en el tratamiento por toxicidad. A un paciente se le suspendi\u00f3 \nnivolumab por EA (colitis grado 3).\nCONCLUSIONES\nNuestros resultados de SG y SLP son superiores a los obtenidos en el CheckMate 040, aunque debido al peque\u00f1o tama\u00f1o \nmuestral no se pueden extraer conclusiones\ufffd  \n \nEl perfil de toxicidad coincide con el descrito en la bibliograf\u00eda.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n682. RESULTADOS SEROL\u00d3GICOS TRAS VACUNACI\u00d3N COVID-19 EN PACIENTES SOMETIDOS A \nTRASPLANTE AUT\u00d3LOGO DE PROGENITORES HEMATOPOY\u00c9TICOS \nAUTORES\nMORONA M\u00cdNGUEZ, I; POUSADA FONSECA, \u00c1B; MATEOS MATEOS, Y; GARRIDO PE\u00d1O, N; CALDER\u00d3N ACEDOS, C; \nMORIEL S\u00c1NCHEZ, C; S\u00c1NCHEZ G\u00d3MEZ, R; MART\u00cdNEZ HERN\u00c1NDEZ, J\nHOSPITAL UNIVERSITARIO DE M\u00d3STOLES. R\u00cdO J\u00daCAR, S/N M\u00d3STOLES. MADRID\nOBJETIVOS\nCuantificar los niveles de inmunoglobulinas G anti-spike de SARS-CoV-2 (IgG anti-S) alcanzados con la vacunaci\u00f3n en \npacientes que han recibido un trasplante aut\u00f3logo de progenitores hematopoy\u00e9ticos (TASPE).\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo en un hospital de segundo nivel en el que se incluyeron pacientes que hab\u00edan recibido \nun TASPE y posteriormente se les hab\u00eda determinado la serolog\u00eda de IgG anti-S una vez hab\u00edan sido vacunados de \nCOVID-19.  \n \nEn colaboraci\u00f3n con el servicio de Medicina Preventiva del hospital se recogieron las siguientes variables: sexo, edad al \nmomento del TASPE, infecci\u00f3n por SARS-CoV-2, momento de la infecci\u00f3n, n\u00famero de dosis recibidas de vacuna COVID-19, \nmarca, fecha de administraci\u00f3n, fecha de serolog\u00eda, valor de IgG anti-S y diagn\u00f3stico cl\u00ednico.  \n \nSe cuantificaron las IgG anti-S en el servicio de Microbiolog\u00eda mediante enzimoinmunoensayo de micropart\u00edculas \nquimioluminiscente (CMIA), en el cual se considera positivo un valor superior a 50 AU/mL.  \n 355Los criterios actuales para el uso de nuevas alternativas terap\u00e9uticas antivirales frente a la infecci\u00f3n por SARS-CoV-2 \nde la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (versi\u00f3n 3) incluyen a los pacientes receptores de \ntrasplante de progenitores hematopoy\u00e9ticos como grupo de riesgo. De acuerdo con estos criterios, se considera un nivel \nbajo de protecci\u00f3n a infecci\u00f3n por SARS-CoV-2 un t\u00edtulo inferior a 260 BAU/mL. Aplicando el factor de conversi\u00f3n de la \nOrganizaci\u00f3n Mundial de la Salud correspondiente a la t\u00e9cnica CMIA (0,142) definimos un valor umbral proporcionado \npor nuestro laboratorio de 1831 AU/mL para considerar a un paciente como protegido\ufffd\nRESULTADOS\nDiecisiete pacientes recibieron TASPE, 9 de ellos dispon\u00edan de un resultado IgG anti-S. Seis eran mujeres (66,7%), su \nmediana de edad en el momento del TASPE fue 63,8 a\u00f1os (RIQ 14,8). Todas las dosis administradas pertenecieron a la \nmisma marca de vacuna de \u00e1cido ribonucleico mensajero frente a COVID-19 con nucle\u00f3sidos modificados. La mediana de \ntiempo trascurrido entre la \u00faltima dosis recibida de la vacuna y la serolog\u00eda fue 5,5 meses (RIQ 2,1).  \n \nSeis pacientes (66,7%) presentaron cifras de IgG anti-S de protecci\u00f3n: 4 pacientes con valor superior a 40000 AU/mL \n(44,4%) tras 3 dosis de vacuna, 2 de ellos con diagn\u00f3stico de Linfoma No Hodgkin (LNH) y los 2 restantes de Mieloma \nM\u00faltiple (MM). El resto de los pacientes presentaron valores de 35023,5 AU/mL (11,1%) tras 3 dosis de vacuna con \ndiagn\u00f3stico de LNH y 8864 AU/mL (11,1%) tras 4 dosis de vacuna con diagn\u00f3stico de MM.  \n \nTres pacientes (33,3%) presentaron cifras de IgG anti-S de baja protecci\u00f3n: 1000,4 AU/mL (11,1%) tras 3 dosis de vacuna \ncon diagn\u00f3stico de MM, 416,1 AU/mL (11,1%) tras 3 dosis de vacuna con diagn\u00f3stico de MM y 321,1 AU/mL (11,1%) tras \n3 dosis de vacuna con diagn\u00f3stico de LNH.  \n \nDos pacientes (22,2%) fueron diagnosticados de COVID-19, 2,8 y 6,4 meses antes de la obtenci\u00f3n de la serolog\u00eda. Sus \nvalores de IgG anti-S fueron superiores a 40000 AU/mL y 35023,5 AU/mL, respectivamente.\nCONCLUSIONES\nA pesar de ser considerados como grupo de riesgo, todos los pacientes que recibieron TASPE presentaron cifras de IgG \nanti-S positivas y la mayor\u00eda de ellos alcanzaron niveles de protecci\u00f3n.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n687. TRAMETINIB EN PACIENTES PEDI\u00c1TRICOS CON GLIOMA DE BAJO GRADO: EXPERIENCIA DE 4 A\u00d1OS \nDE USO EN PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nPAU PARRA, A; OLIVERAS ARENAS, M; RENEDO MIR\u00d3, B; GROS SUB\u00cdAS, L; ANGUITA DOMINGO, D; S\u00c1NCHEZ SANCHO, \nP; CARRERAS SOLER, MJ; GORGAS TORNER, MQ\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLos tumores del sistema nervioso central son la segunda neoplasia infantil m\u00e1s frecuente y el tumor s\u00f3lido m\u00e1s com\u00fan \nen pediatr\u00eda; de estos, el 30-50% son gliomas de bajo grado (GBG). Trametinib es un inhibidor de MEK utilizado off-label \nen glioma pedi\u00e1trico, cuando existe duplicaci\u00f3n y translocaci\u00f3n de BRAF, aunque los datos de eficacia y seguridad son \nlimitados. El objetivo es describir nuestra experiencia de 4 a\u00f1os de uso de trametinib en GBG pedi\u00e1trico, en cuanto a \nrespuesta, duraci\u00f3n y efectos adversos\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional en pacientes pedi\u00e1tricos con GBG tratados con trametinib entre mayo 2018 y mayo \n2022, en un hospital terciario. La respuesta se evalu\u00f3 por resonancia magn\u00e9tica. Las variables demogr\u00e1ficas, anal\u00edticas \ny cl\u00ednicas se recogieron de la historia cl\u00ednica. Las variables continuas se expresan como medianas (rango) y las variables \ncateg\u00f3ricas como casos (porcentaje).\nRESULTADOS\nSe incluyeron 21 pacientes, 12(57,1%) ni\u00f1as, diagnosticados de GBG: 16(76,2%) astrocitoma piloc\u00edtico, 3(14,3%) \nastrocitoma pilomixoide y 2(9,5%) histolog\u00eda desconocida; 19(90,5%) con duplicaci\u00f3n y translocaci\u00f3n de BRAF y 3(14,3%) \nneurofibromatosis tipo 1. Previo a trametinib, se practic\u00f3 resecci\u00f3n tumoral en 15(71,4%), incompleta en todos, \n19(90,5%) recibieron quimioterapia (84,2% vincristina+carboplatino como 1\u00aa l\u00ednea) y 3(14,3%) radioterapia. Trametinib \nse inici\u00f3 tras progresi\u00f3n a 2(1-4) l\u00edneas, excepto en un paciente que fue como primera l\u00ednea. Tres recibieron bevacizumab \nconcomitantemente\ufffd  \n \nLa edad al iniciar trametinib fue 11,7(1,1-17,5) a\u00f1os; 4 ni\u00f1os < 6 a\u00f1os. La dosis inicial fue 0,025 mg/kg/24h en > 6 a\u00f1os y \n0,032 mg/kg/24h en menores. Diecinueve pacientes tomaron comprimidos a dosis de 0,25-2,0 mg/24h, representando \nuna desviaci\u00f3n en la dosis/kg de 7,5%(1,7-27,3) al ajustar a comprimidos o \u00bdcomprimido. Dos pacientes tomaron \nsoluci\u00f3n oral, como uso compasivo\ufffd  \n \nDieciocho(85,7%) pacientes fueron evaluados, objetiv\u00e1ndose estabilidad radiol\u00f3gica, como mejor respuesta, en \n16(88,9%), 1 con bevacizumab, y ausencia de respuesta en 2, en uno de los cuales trametinib se suspendi\u00f3 a los 7,7 \nmeses y el otro contin\u00faa por estabilidad cl\u00ednica. En dos pacientes se interrumpi\u00f3 por progresi\u00f3n tras 11 y 21 meses. En 1 \npaciente se suspendi\u00f3 trametinib transcurridos 2,5 a\u00f1os, reinici\u00e1ndose 3 meses despu\u00e9s por progresi\u00f3n.  356Todos los pacientes presentaron efectos adversos: toxicidad cut\u00e1nea 16(76,2%), hiperCKemia( > 400UI/L) 13(61,9%), \nparoniquia 11(52,4%), toxicidad gastrointestinal 10(47,6%), aftas bucales 4(19,0%), astenia 3(14,7%) y epistaxis 3(14,7%). \nSe interrumpi\u00f3 temporalmente trametinib por toxicidad en 11(52,4%), tras 41(10-306) d\u00edas, y definitivamente en 2(9,5%), \ntras 3 y 22 meses. Trece(61,9%) requirieron reducci\u00f3n de dosis, siendo la dosis tolerada de 0,021(0,008-0,029) mg/kg en > \n6 a\u00f1os y 0,024-0,030 mg/kg en < 6 a\u00f1os, suponiendo una variaci\u00f3n del 16,8%(1,3-68,2) respecto a la dosis recomendada. \nDieciseis(76,2%) contin\u00faan en tratamiento, con una duraci\u00f3n de 14,7(2,2-44,2) meses.\nCONCLUSIONES\n- Trametinib ha sido eficaz en detener la progresi\u00f3n del GBG en el 89% de nuestros pacientes, con estabilizaci\u00f3n de la \nenfermedad como mejor respuesta, mantenida en el tiempo.  \n- Todos los pacientes presentaron efectos adversos, requiriendo reducci\u00f3n de dosis y/o interrupci\u00f3n del tratamiento en \nm\u00e1s de la mitad y lo que posiblemente sea la causa de la respuesta limitada.  \n- Son necesarios ensayos cl\u00ednicos que aporten m\u00e1s evidencia sobre la eficacia y seguridad de trametinib en GBG en \npediatr\u00eda.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n692. USO DE AZACITIDINA EN UNA UNIDAD DE HOSPITALIZACI\u00d3N A DOMICILIO \nAUTORES\nCARDONA ROCA, L; PLANAS-GINER , A; CORONEL CORDERO, L; CANO ALONSO, M; SOSA-PONS , A; ALMENDROS-\nABAD , N; RUDI SOLA, N\nHOSPITAL GENERAL DE GRANOLLERS \ufffd AV\ufffd FRANCESC RIBAS, S/N GRANOLLERS \ufffd BARCELONA\nOBJETIVOS\nEvaluar efectividad y seguridad de azacitidina subcut\u00e1nea administrada en una unidad de Hospitalizaci\u00f3n a Domicilio \n(HAD).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital de segundo nivel. Se incluyeron los pacientes tratados con \nazacitidina en la unidad de HAD entre enero 2019 y marzo 2022. Se excluyeron aquellos que recibieron tratamiento \ndurante un periodo inferior a 2 meses\ufffd  \nVariables registradas: datos demogr\u00e1ficos, diagn\u00f3stico, clasificaci\u00f3n de riesgo seg\u00fan IPSS-R (Revised-International-\nPrognostic-Scoring-System) para s\u00edndromes mielodispl\u00e1sicos (SMD), l\u00ednea de tratamiento, posolog\u00eda, n\u00famero de ciclos \nrecibidos, porcentaje de ciclos administrados en HAD, evaluaci\u00f3n de respuesta hematol\u00f3gica, dependencia transfusional, \nsupervivencia libre de progresi\u00f3n (SLP), supervivencia global (SG), reacciones adversas medicamentosas (RAM) y ajustes \nposol\u00f3gicos\ufffd  \nEl registro de datos se realiz\u00f3 a partir de la historia cl\u00ednica (Savac\u00ae) y prescripci\u00f3n electr\u00f3nica (Farmis-Oncofarm\u00ae). Las \nvariables cuantitativas se expresaron como media, desviaci\u00f3n est\u00e1ndar (DE), mediana y rango intercuart\u00edlico (RIQ). El \nan\u00e1lisis estad\u00edstico se realiz\u00f3 a trav\u00e9s de Microsoft Excel\u00ae.  \nLa efectividad se midi\u00f3 a partir de evaluaci\u00f3n de respuesta seg\u00fan criterios IWS (International-Working-Group), reducci\u00f3n \ndel soporte transfusional, SLP y SG (pacientes vivos a los 2 a\u00f1os). La seguridad se evalu\u00f3 seg\u00fan RAM documentadas en la \nhistoria cl\u00ednica.\nRESULTADOS\nSe incluyeron 15 pacientes (60% hombres, 78 (DE 11) a\u00f1os), 80% diagnosticados de SMD (58% riesgo intermedio y 42% \nalto seg\u00fan IPSS-R), 13% leucemia mieloide aguda y 7% leucemia mielomonoc\u00edtica cr\u00f3nica. La l\u00ednea de tratamiento en la \nque se utiliz\u00f3 azacitidina fue: 40% en primera, 40% en segunda y 20% en tercera. Dos pacientes iniciaron el tratamiento \nen Hospital de D\u00eda Onco-Hematol\u00f3gico previamente a la implantaci\u00f3n del circuito en HAD. \nEl 80% de pacientes inici\u00f3 con posolog\u00eda est\u00e1ndar de 75 mg/m2 por v\u00eda subcut\u00e1nea durante 7 d\u00edas (5-0-2) cada 28 d\u00edas, el \n13% con reducci\u00f3n de frecuencia (5-0-0) y el 7% con reducci\u00f3n de dosis (50 mg/m2) y frecuencia (5-0-0). La mediana de \nciclos recibidos por paciente en total fue de 6 (RIQ 3-11), siendo el 94% (RIQ 75-100%) administrados en HAD. \nSe obtuvo estabilidad de enfermedad en el 60% de pacientes y respuesta completa/parcial en el 40%\ufffd Se observ\u00f3 \ndisminuci\u00f3n del soporte transfusional en 4 de 10 pacientes dependientes. La SLP media fue de 9,3 (DE 7) meses, teniendo \nen cuenta que cuatro no alcanzaron SLP . El 60% segu\u00edan vivos a los dos a\u00f1os, cuatro no hab\u00edan llegado al punto de corte \npara medir SG cuando finaliz\u00f3 el estudio.  \nUn 80% present\u00f3 RAM durante el tratamiento. Se identificaron 10 pacientes con toxicidad hematol\u00f3gica (anemia, \nleucopenia y/o plaquetopenia), cinco con toxicidad gastrointestinal (n\u00e1useas-v\u00f3mitos, dolor abdominal), dos con \nmucositis y dos con inflamaci\u00f3n local. En un 80% de pacientes se realiz\u00f3 ajuste posol\u00f3gico por toxicidad (73% reducci\u00f3n \ndosis y 27% reducci\u00f3n frecuencia).\nCONCLUSIONES\nEl tratamiento con azacitidina en HAD fue efectivo en la mayor\u00eda de pacientes seg\u00fan respuesta hematol\u00f3gica, reducci\u00f3n \ntransfusional y SG. La SLP observada fue inferior a la descrita en los ensayos pivotales. Se consider\u00f3 un f\u00e1rmaco con un \nperfil de seguridad aceptable para su administraci\u00f3n en HAD.357CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n696. EVALUACI\u00d3N DEL EFECTO PREVENTIVO DE LA CREMA DE VITAMINA E-ALANTO\u00cdNA EN EL \nDESARROLLO DE ERITRODISESTESIA PALMO-PLANTAR POR CAPECITABINA. \nAUTORES\nVARELA REY , I; TOURIS LORES, M; CASTRO BALADO, A; GARC\u00cdA QUINTANILLA, L; LOPEZ MONTERO, E; GONZ\u00c1LEZ \nBARCIA, M; BERNARDEZ FERRAN, B; ZARRA FERRO, I\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE SANTIAGO. CHOUPANA, S/N SANTIAGO DE COMPOSTELA. A CORU\u00d1A\nOBJETIVOS\nLa eritrodisestesia palmo-plantar (EPP) es un efecto adverso frecuente en la poblaci\u00f3n a tratamiento con capecitabina \nque puede limitar la calidad de vida y comprometer la continuaci\u00f3n del tratamiento quimioter\u00e1pico. El mecanismo exacto \npor el cual se desarrolla este efecto adverso se desconoce\ufffd Desde el Servicio de Farmacia, se prepara crema de vitamina \nE-alanto\u00edna (VitE-A) como f\u00f3rmula magistral para su prevenci\u00f3n o tratamiento. El objetivo de este trabajo es evaluar si el \ntratamiento preventivo con VitE-A iniciada al mismo tiempo que la capecitabina previene o retrasa la aparici\u00f3n de EPP \ngrado 2 durante los 3 primeros meses de tratamiento\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo de los pacientes con c\u00e1ncer de mama a tratamiento con capecitabina desde Enero \ndel 2021 a Marzo del 2022. Se recogieron datos demogr\u00e1ficos (edad, sexo) y cl\u00ednicos (diagn\u00f3stico, fecha de inicio y fin de \ncapecitabina, fecha de inicio de tratamiento con VitE-A y fecha de aparici\u00f3n de EPP grado 2).  \nSe eval\u00fao el efecto preventivo del uso de la VitE-A en el retraso de la aparici\u00f3n de EPP grado 2 durante los 3 primeros \nmeses de tratamiento con capecitabina. Para ello, se clasific\u00f3 a las pacientes en dos grupos en funci\u00f3n de si hab\u00edan \nrecibido VitE-A al inicio del tratamiento con capecitabina o no.  \nLas intervenciones cl\u00ednicas se realizaron de acuerdo con la practica cl\u00ednica habitual. Los datos de dispensaciones realizadas \na cada paciente se obtuvieron del programa de prescripci\u00f3n electr\u00f3nica Silicon\u00ae y los datos demogr\u00e1ficos, el subtipo de \npatolog\u00eda y los datos cl\u00ednicos se recogieron del programa de historia cl\u00ednica electr\u00f3nica IANUS\u00ae.  \nPara el an\u00e1lisis de datos se utiliz\u00f3 el paquete estad\u00edstico SPSS-Statistics V.26 (IBM Inc. Armonk, NY , USA).\nRESULTADOS\nSe estudiaron un total de 48 mujeres con una media de edad de 60,2 (rango: 29-88) a\u00f1os al inicio del tratamiento con \ncapecitabina. 16 pacientes (39,6%) fueron diagnosticadas de c\u00e1ncer de mama triple negativo, 3 (6,25%) HER2 positivo, 8 \n(16,6%) luminal A y 18 (37,5%) luminal B. La mediana de la duraci\u00f3n del tratamiento con capecitabina fue de 5,9 meses. \nLa mediana hasta la aparici\u00f3n del evento fue de 6,9 meses.  \n10 pacientes (20,8%) presentaron EPP grado 2 durante los 3 primeros meses de tratamiento y 38 (79,1%) la presentaron \ncon posterioridad. De las 10 pacientes que presentaron EPP grado 2 durante los 3 primeros meses, el 70% hab\u00edan recibido \nVitE-A desde el inicio y el 30% restante no. Se observ\u00f3, aunque sin significaci\u00f3n estad\u00edstica, un retraso en la aparici\u00f3n del \nevento en las pacientes que llevaron VitE-A desde el inicio (2,3 vs 1,4 meses; p=0,42).\nCONCLUSIONES\nLa EPP es un efecto adverso habitual con el tratamiento con capecitabina para la cual todav\u00eda no hay ning\u00fan tratamiento \nefectivo. El uso de VitE-A de forma preventiva parece retrasar la aparici\u00f3n del evento en aquellas pacientes que lo \ndesarrollan de forma temprana. Ser\u00eda interesante ampliar este estudio de forma prospectiva y teniendo en cuenta el \nestudio del polimorfismo gen\u00e9tico de la dihidropirimidina deshidrogenasa y la intensidad de dosis de capecitabina.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n703. REGORAFENIB Y TRIFLURIDINA/TIPIRACILO EN EL C\u00c1NCER COLORRECTAL METAST\u00c1SICO: \nEFECTIVIDAD EN VIDA REAL \nAUTORES\nALONSO CASTRO, V; L\u00d3PEZ CENTENO, B; MORALES IRALA, D; MAROTO GARC\u00cdA, E; ROSAS ESPINOZA, C; GARC\u00cdA \nCEREZUELA, MD; ARANGUREN OYARZ\u00c1BAL, A; CALVO ALC\u00c1NTARA, MJ\nSUBDIRECCI\u00d3N GENERAL DE FARMACIA Y PRODUCTOS SANITARIOS \ufffd SERVICIO MADRILE\u00d1O DE SALUD \ufffd\nOBJETIVOS\nAnalizar la efectividad del tratamiento con regorafenib y trifluridina/tipiracilo (TAS-102) en pacientes con c\u00e1ncer \ncolorrectal metast\u00e1sico (CCRm) en la pr\u00e1ctica cl\u00ednica de los hospitales de un Servicio de Salud (SS).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo de los pacientes con CCRm que inician tratamiento con regorafenib y TAS-102 en los \nhospitales de un SS durante el 1 enero de 2019 y 31 de octubre de 2021.  \nEn un grupo de trabajo multidisciplinar formado por onc\u00f3logos y farmac\u00e9uticos de distintos hospitales junto con \nfarmac\u00e9uticos e inform\u00e1ticos de servicios centrales del SS, se ha desarrollado un registro institucional y obligatorio de \npacientes con CCRm que inician tratamiento con regorafenib y TAS-102, con el objetivo de monitorizar la efectividad de \nestos f\u00e1rmacos, con una magnitud de beneficio cl\u00ednico 1-2 seg\u00fan la escala ESMO-MCBS.  \nVariables principales del registro: edad, sexo, escala ECOG al inicio, localizaci\u00f3n del tumor primario, n\u00famero de \u00f3rganos \nafectados metast\u00e1sicos, presencia de met\u00e1stasis hep\u00e1ticas y cerebrales, estado mutacional RAS/BRAF, n\u00famero de l\u00edneas \nprevias de tratamiento, variables de seguimiento (dosis prescrita, tipo de respuesta, efectos adversos), fecha y motivo de \nsuspensi\u00f3n, fecha de exitus.358RESULTADOS\nSe registraron 661 pacientes en tratamiento con TAS-102 y 180 con regorafenib. La edad media para cada uno de los \ngrupos de tratamiento fue de 70 y 68 a\u00f1os respectivamente. \nTAS-102: 60,8% hombres, 99,4% ECOG 0-1 (0,6% ECOG2), media de 3,4 l\u00edneas de tratamiento previas, 58,6% y 2,4% \npresentaron mutaci\u00f3n RAS y BRAF respectivamente, 6,1% hab\u00edan recibido regorafenib previamente. \nRegorafenib: 55,6% hombres, 100% ECOG 0-1, media de 4,2 l\u00edneas de tratamiento previas, 66,7% y 1,7% presentaron \nmutaci\u00f3n RAS y BRAF respectivamente, 58,9% hab\u00edan recibido TAS-102 previamente. \nEl resto de caracter\u00edsticas basales se encuentran balanceadas en ambos grupos: 74,7% localizaci\u00f3n del tumor primario \nen colon izquierdo, 34,2% presentaron 3 o m\u00e1s \u00f3rganos afectados metast\u00e1sicos, 66,0% met\u00e1stasis hep\u00e1ticas y 2,1% \nmet\u00e1stasis SNS.  \nSe excluyeron del an\u00e1lisis de efectividad, los pacientes que no ten\u00edan ning\u00fan dato de seguimiento a fecha de cierre del \nregistro (31 de enero de 2022): 8,0% TAS-102 y 6,1% regorafenib.  \nTras 25 meses de seguimiento, el 36,0% de los pacientes con TAS-102 y el 24,9% con regorafenib no ten\u00edan registrada \nfecha de exitus. La mediana de supervivencia global (SG) para TAS-102 fue de 7,3 meses (IC95% 6,6-7,9) y de 6,2 meses \n(IC95% 6,2-7,8) para regorafenib.  \nEl 92,9% de pacientes con TAS-102 y el 92,3% con regorafenib suspendieron tratamiento por: \n- TAS-102: 80,0% progresi\u00f3n, 2,8% toxicidad, 2,1% toxicidad/progresi\u00f3n, 8,0% exitus, 1,9% abandono de tratamiento y \n5,1% otros o desconocido\ufffd  \n- Regorafenib: 66,7% progresi\u00f3n, 16,7% toxicidad, 2,6% toxicidad/progresi\u00f3n, 7,1% exitus, 0,6% abandono de tratamiento \ny 6,4% otros o desconocido\ufffd\nCONCLUSIONES\nEl registro centralizado de resultados en salud es una herramienta eficaz para evaluar la efectividad de los tratamientos \nen la pr\u00e1ctica cl\u00ednica. \nEn nuestro estudio, se observa una SG similar para ambos tratamientos y acorde a la descrita en sus ensayos pivotales \n(TAS-102-RECOURSE:SG 7,1 meses y Regorafenib-CORRECT:6,4 meses). La mayor\u00eda de los pacientes suspendieron \ntratamiento por progresi\u00f3n de la enfermedad, observ\u00e1ndose una mayor tasa de suspensi\u00f3n por toxicidad con regorafenib \nrespecto a TAS-102.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n709. EVALUAR LA EFECTIVIDAD DEL DOBLE BLOQUEO ANTIHER2 CON TRASTUZUMAB+PERTUZUMAB+\nQUIMIOTERAPIA EN LA NEOADYUVANCIA DEL C\u00c1NCER DE MAMA. \nAUTORES\nBRADY GARC\u00cdA, A; NIGORRA CARO, M; P\u00c9REZ DE AMEZAGA TOM\u00c1S, L; MONSERRAT MONSERRAT , MV; MOREG\u00d3 \nSOLER, MA; PARERA PASCUAL, MM; CRESP\u00cd CIFRE, MA; VILANOVA BOLT\u00d3, M\nHOSPITAL SON LLATZER \ufffd CTRA \ufffd MANACOR, KM \ufffd4 PALMA DE MALLORCA \ufffd ILLES BALEARS\nOBJETIVOS\nEvaluar la efectividad del doble bloqueo antiHER2 con trastuzumab+pertuzumab+quimioterapia en la neoadyuvancia del \nc\u00e1ncer de mama.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo en el que se incluyeron todas las pacientes con el receptor 2 del factor de \ncrecimiento epid\u00e9rmico humano (HER-2) positivo tratadas con trastuzumab+pertuzumab en neoadyuvancia de c\u00e1ncer de \nmama en un hospital de segundo nivel, desde Mayo de 2016 hasta Mayo de 2022. \nVariables: edad, afectaci\u00f3n ganglionar al diagn\u00f3stico, receptores hormonales (RH), Ki-67, Eastern Cooperative \nOncology Group (ECOG) al inicio de tratamiento, esquema de neoadyuvancia y adyuvancia, tipo de cirug\u00eda, respuesta \nanatomopatol\u00f3gica tras la cirug\u00eda y fecha y tipo de reca\u00eddas. La efectividad se evalu\u00f3 mediante la tasa de respuestas \npatol\u00f3gicas completas y el tiempo hasta la reca\u00edda.  \nEstos datos fueron recogidos a trav\u00e9s del programa Farmis_Oncofarm\u00ae y de la historia cl\u00ednica, con el programa \nHPHCISv \ufffd3\ufffd8\ufffd\nRESULTADOS\nSe incluyeron 50 mujeres, con una mediana de edad de 53 a\u00f1os (30-78). Un 92% de pacientes presentaron un ECOG 0 al \ndiagn\u00f3stico, el resto ECOG 1. El 34,0% presentaron RH negativos. El Ki-67 fue > 14% (considerado \u00edndice de proliferaci\u00f3n \nelevado) en el 88,0% de las pacientes. Veintiocho (56,0%) pacientes presentaron afectaci\u00f3n ganglionar. \nCuarenta (80,0%) pacientes recibieron el esquema antraciclinas+ciclofosfamida seguido de \ntaxanos+trastuzumab+pertuzumab (27,5% docetaxel, el resto (72,5%) paclitaxel). Nueve (18,0%) pacientes no recibieron \nantraciclinas, ocho de \u00e9stas siguieron el esquema TPCH (docetaxel+carboplatino+trastuzumab+pertuzumab) y una recibi\u00f3 \nel esquema paclitaxel+trastuzumab+pertuzumab. Una (2%) paciente cambi\u00f3 de TPCH a AC por mala tolerancia, seguido \nde paclitaxel+trastuzumab+pertuzumab.  \nTras la neoadyuvancia, hubo un 40% de respuestas parciales (pRP), un 54% de respuestas completas (pRC) y un 6% (3) de \npacientes pendientes de cirug\u00eda a fecha de corte de datos.  \nSe practicaron 20 (40%) tumorectom\u00edas y 27 (54%) mastectom\u00edas.  \nEn cuanto a la adyuvancia, 39 pacientes recibieron trastuzumab en monoterapia, 4 recibieron trastuzumab+pertuzumab, \n3 pacientes recibieron trastuzumab-emtansina. Cuatro pacientes no hab\u00edan iniciado adyuvancia a fecha de corte de datos. 359Recibieron radioterapia 32(64%) pacientes y hormonoterapia todas aquellas con RH positivos.  \nLa mediana de seguimiento fue de 30,5 meses. En este per\u00edodo, 5 (10%) pacientes tuvieron una reca\u00edda de la \nenfermedad, cuatro de ellas a distancia, y una local, a los 7,9 - 22,8 - 25,2 - 40,2 y 46,7 meses. De las cinco pacientes, \ncuatro hab\u00edan obtenido pRP , y una pRC. La paciente con pRC, present\u00f3 una reca\u00edda \u00f3sea \u00fanica que se irradi\u00f3 en dosis \n\u00fanica, continuado con anastrazol, sin evidencia de m\u00e1s lesiones metast\u00e1sicas en la fecha de corte de datos.  \nEn cuanto al tratamiento en la reca\u00edda del resto de pacientes, 2 recibieron docetaxel-trastuzumab-pertuzumab seguido de \ntrastuzumab-pertuzumab-hormonoterapia de mantenimiento, una paciente trastuzumab-emtansina y a una paciente se \nle perdi\u00f3 el seguimiento\ufffd\nCONCLUSIONES\nLos resultados obtenidos reflejan la importancia de obtener una respuesta patol\u00f3gica completa y el beneficio del doble \nbloqueo antiHER-2, y est\u00e1n en l\u00ednea con los publicados en el estudio de D\u00edaz-Redondo T et al. (2019) -39% pRP vs 61% \npRC- que eval\u00faa la neoadyuvancia con trastuzumab+pertuzumab en la pr\u00e1ctica cl\u00ednica habitual.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n729. ESTUDIO DE INCIDENCIA DE ERRORES Y TIEMPOS DE PREPARACI\u00d3N DE MEZCLAS \nONCOHEMATOLOGICAS EN EL \u00c1REA DE ELABORACI\u00d3N DE UN HOSPITAL \nAUTORES\nBELTR\u00c1N GARC\u00cdA, I; PERETTO , S; CATAL\u00c1 MALLOR, \u00c1; BORRELL GARC\u00cdA, C; ALBERT MARI, A; ESCOBAR CAVA, P; \nL\u00d3PEZ BRIZ, E; POVEDA ANDR\u00c9S, JL\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nLa carga asistencial en las \u00e1reas de elaboraci\u00f3n oncohematol\u00f3gica esta continuamente incrementado en n\u00famero de \npreparaciones. Con motivo de conocer la situaci\u00f3n actual, se plante\u00f3 analizar las preparaciones para comprobar su \ncalidad, para as\u00ed cuantificar y clasificar los errores de preparaci\u00f3n(EP) y tiempos de elaboraci\u00f3n, e identificar puntos de \nmejora.\nMATERIALES Y M\u00c9TODOS\nSe analizaron las preparaciones elaboradas en una sola cabina durante 10 d\u00edas en horario de ma\u00f1ana laborable mediante \nun observador externo. Las preparaciones se diferenciaron en tipos de medicamentos quimioter\u00e1picos(QT), anticuerpos \nmonoclonales(AC) y f\u00e1rmacos de soporte(S). Se registraron para cada preparaci\u00f3n: fecha, n\u00famero identificativo de \npreparaci\u00f3n, n\u00famero de paciente, medicamento, tipo de medicamento, tipo de preparaci\u00f3n(bolsa/jeringa/bolsa EVA/\nfrasco de vac\u00edo), grado de complejidad de la preparaci\u00f3n (baja: vial listo para cargar en dispositivo de administraci\u00f3n; \nmedia: vial liofilizado o con ajuste csp.; elevada: ajuste veh\u00edculo, filtraci\u00f3n, 2 jeringas, bolsa EVA, calentamiento o \nsolvente espec\u00edfico), t\u00e9cnica de preparaci\u00f3n abierta/cerrada, n\u00famero, tipo y gravedad de EP(desviaciones del protocolo, \nerrores en: t\u00e9cnica, dosificaci\u00f3n, veh\u00edculo, jeringa, medicamento, etiquetado y caducidad), enfermera elaboradora y su \nexperiencia en elaboraci\u00f3n, profesional que detecta EP y si ser\u00eda detectable sin observador externo, franja horaria(8-\n11:59h/12-15h) y tiempo de elaboraci\u00f3n(desde la revisi\u00f3n de la hoja de preparaci\u00f3n y componentes por enfermera \nelaboradora hasta la firma de la hoja de preparaci\u00f3n). Se excluyeron las preparaciones con m\u00e1s de un principio activo y \nlas preparaciones en bombas elastom\u00e9ricas. La ciclofosfamida se considera como vial listo para su uso por reconstituirse \npor stock\ufffd\nRESULTADOS\nSe obtuvieron 423 preparaciones de 238 pacientes, 295 QT, 75 AC y 53 S\ufffd La proporci\u00f3n de preparaciones en bolsa, \njeringa, bolsa EVA y frasco de vac\u00edo fueron, respectivamente, 72,4%, 26,5%, 0,9% y 0,2%. El 51,8% fueron de complejidad \nbaja, el 27,9% de complejidad elevada y 20,3% de complejidad media. El 63,4% se prepararon mediante t\u00e9cnica cerrada. \nSe detectaron 95 EP en 84 preparaciones, 69,5%(66) fueron desviaciones del protocolo y errores en: t\u00e9cnica 7,4%(7), \ndosificaci\u00f3n 6,3%(6), veh\u00edculo 6,3%(6), selecci\u00f3n de jeringa 5,3%(5), selecci\u00f3n de medicamento 2,1%(2), etiquetado \n2,1%(2) y caducidad 1,0%(1). Ning\u00fan EP alcanz\u00f3 al paciente. El 8,4%(8) se clasificaron como posibles EP graves por \nlas posibles consecuencias que tendr\u00eda sobre el paciente. De las EP recogidos, 13 no hubiesen sido detectados sin \nobservador externo, de los cuales 2 podr\u00edan haber sido graves relacionados con la dosificaci\u00f3n. Fueron detectados en un \n71,6%(68) por enfermer\u00eda, experiencia media en elaboraci\u00f3n 67,1 (DS 57,5) meses, 25%(21) por observador y el resto por \nla coordinadora. Respecto a los errores por franja horaria, hubo mayor incidencia de 8-11:59h(64/95) de forma uniforme \ntodos los d\u00edas, especialmente mi\u00e9rcoles(15) y jueves(19), quiz\u00e1s por mayor volumen de trabajo. Los tiempos medios de \nelaboraci\u00f3n fueron respectivamente de menor a mayor complejidad de la preparaci\u00f3n y comparando jeringa/bolsa(EP) \n00:02:21(8)/00:03:16(33), 00:02:52(11)/00:05:25(5) y 00:02:34(0)/00:06:17(38).\nCONCLUSIONES\nEn nuestro medio, la incidencia de EP(76,1%) est\u00e1 ligada a la franja horaria 8-11h. La incidencia de EP graves no \ndetectables(2,1%) pone de manifiesto que son necesarios sistemas de seguridad que garanticen la calidad de las \npreparaciones dentro de la cabina para que sean detectables por la coordinadora.360CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n737. EFICACIA Y SEGURIDAD EN VIDA REAL DE DURVALUMAB COMO TERAPIA DE CONSOLIDACI\u00d3N EN \nC\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO ESTADIO III \nAUTORES\nCASTA\u00d1O RODR\u00cdGUEZ, B; CERC\u00d3S LLET\u00cd, AC; BAYONA ANT\u00d3N, C; VICENTE GONZ\u00c1LEZ, B; DE FRUTOS DEL POZO, M; \nS\u00c1NCHEZ LUQUE, L; INFANTE CAMARERO, A; REVILLA CUESTA, N\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS\nOBJETIVOS\nEvaluar la eficacia y seguridad de durvalumab en vida real, como terapia de consolidaci\u00f3n, en pacientes con c\u00e1ncer de \npulm\u00f3n no microc\u00edtico (CPNM) estadio III, as\u00ed como analizar el consumo de antibi\u00f3ticos y el \u00edndice inmunol\u00f3gico del \npulm\u00f3n (LIPI) como predictores de respuesta.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo de los pacientes tratados con durvalumab en un hospital desde junio-2018 a \njulio-2021. La eficacia se evalu\u00f3 mediante supervivencia libre de progresi\u00f3n (SLP por confirmaci\u00f3n radiol\u00f3gica) y global \n(SG), y las tasas de respuestas globales (TRG) y de control de la enfermedad (TCE), seg\u00fan criterios RECISTv1.1. El an\u00e1lisis \nde supervivencia se realiz\u00f3 mediante Kaplan-Meier y el de subgrupos mediante test Long-rank univariante (SPSS\u00ae). La \nseguridad se analiz\u00f3 mediante el perfil de efectos adversos (criterios CTCAEv5.0), discontinuaciones y suspensiones \nde durvalumab. El consumo de antibi\u00f3ticos se evalu\u00f3 en los 30 d\u00edas previos al inicio y/o durante el tratamiento con \ndurvalumab. El \u00edndice LIPI se estim\u00f3 a partir de LDH y la ratio neutr\u00f3filos/(leucocitos-neutr\u00f3filos).Fuentes de informaci\u00f3n: \nhistoria cl\u00ednica, programas de citost\u00e1ticos y an\u00e1lisis cl\u00ednicos.\nRESULTADOS\nSe revisaron 23 pacientes (44% programa uso especial), con una mediana de 63 a\u00f1os (49-78), varones (65%), tabaco \n(91%), alcohol (61%), ECOG (0-1:95%, 2:5%), con m\u00faltiple comorbilidad, estadio (IIIA: 31%, IIIB:48%, IIIC:17%), histolog\u00eda \n(epidermoide:44%, no-epidermoide:39%), EGFR (nativo:48%, desconocido:52%), PD-L1 (\u22651%:52%, < 1%:22%, \u226525%:30%, \n< 25%:44%, desconocido:26%). 22 pacientes recibieron quimioterapia-radioterapia concomitante basada en platino y 1 \nsecuencial, alcanzado respuesta completa (n=3), parcial (n=18) y estable (n=2). La mediana de ciclos de quimioterapia \nfue 4 (4-7) y la dosis de radioterapia: 66Gy. La mediana de tiempo entre fin de radioterapia-inicio de durvalumab fue \n77 d\u00edas (18-196), la mediana de duraci\u00f3n de durvalumab:11 meses (4-31) y de ciclos: 24 (8-55). El 48% de los pacientes \ncompletaron el tratamiento con durvalumab, 30% progresaron bajo tratamiento, 5% interrumpi\u00f3 por intolerancia, y 17% \npermanecen en tratamiento activo a fecha fin de estudio. Con una mediana de seguimiento de 16,2 meses (4,3-36,1), la \nmediana de SLP fue: 14,8 meses (IC95%, 7,2-22,5), la tasa de SG a 25 meses:74%, la TRG:15% (RC:0/RP:3) y la TCE:85% \n(RP:3/EE:14). El an\u00e1lisis de subgrupos no mostr\u00f3 correlaci\u00f3n significativa con ninguna variable analizada. Los pacientes se \nclasificaron en buen pron\u00f3stico (LIPI:0;n=13), intermedio (LIPI:1;n=9) e indeterminado (n=1), observ\u00e1ndose una tendencia \nfavorable en SLP en el primer subgrupo (p=0,226). El 78% de los pacientes consumi\u00f3 antibi\u00f3ticos, observ\u00e1ndose una \ntendencia favorable en SLP en el subgrupo no consumidor (p=0,336). Todos los pacientes experimentaron alg\u00fan tipo de \ntoxicidad (grado-1:63%, grado-2:34%, grado-3:3%), registr\u00e1ndose 5 interrupciones y una suspensi\u00f3n.\nCONCLUSIONES\nLa poblaci\u00f3n de este estudio presenta unas caracter\u00edsticas cl\u00ednico-demogr\u00e1ficas peores que la del ensayo pivotal PACIFIC. \nA pesar de ello, durvalumab proporciona un importante beneficio cl\u00ednico, con toxicidad aceptable y manejable. No es \nposible establecer una correlaci\u00f3n significativa con ninguna de las variables analizadas, posiblemente debido al bajo \ntama\u00f1o muestral y la falta de estratificaci\u00f3n. El valor predictivo del LIPI no ha podido ser explorado por la ausencia de \npacientes con mal pron\u00f3stico. El consumo de antibi\u00f3ticos es muy elevado y sugiere una peor supervivencia, que deber\u00eda \nser confirmada en estudios formales.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n744. RESULTADOS INICIALES DE APALUTAMIDA EN C\u00c1NCER DE PR\u00d3STATA HORMONOSENSIBLE \nMETAST\u00c1SICO \nAUTORES\nFERN\u00c1NDEZ VARELA, AM; L\u00d3PEZ SANDOMINGO, L; VALCARCE PARDEIRO, N; RODR\u00cdGUEZ PEN\u00cdN, I\nCOMPLEJO HOSPITALARIO ARQUITECTO MARCIDE-PROF . NOVOA SANTOS. CTRA. DE SAN PEDRO DE LEIXA, S/N \nFERROL \ufffd A CORU\u00d1A\nOBJETIVOS\nDescribir los datos iniciales de evoluci\u00f3n de PSA, respuesta y seguridad, en pr\u00e1ctica cl\u00ednica real, con el uso de apalutamida \nen c\u00e1ncer de pr\u00f3stata hormonosensible metast\u00e1sico (CPHSM).\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional, retrospectivo de todos los pacientes con CPHSM revisados en el Comit\u00e9 de Tumores \nde Urolog\u00eda de un hospital de segundo nivel, en los que se decide iniciar tratamiento con apalutamida asociada a terapia \nde deprivaci\u00f3n androg\u00e9nica (TDA) desde el 09/04/2021 hasta el 23/04/2022. \nDe la historia cl\u00ednica electr\u00f3nica y programa de dispensaci\u00f3n a pacientes externos se recogieron: variables demogr\u00e1ficas \n(edad), estado funcional (ECOG), diagn\u00f3stico, Gleason y PSA al diagn\u00f3stico, terapias previas, met\u00e1stasis, duraci\u00f3n del 361tratamiento, volumen de enfermedad (CHAARTED), cin\u00e9tica del PSA, respuesta y tolerabilidad.  \nSe valor\u00f3 la cin\u00e9tica del PSA (al mes, 3 meses, 6 meses y 12 meses) por subgrupos seg\u00fan volumen de enfermedad \n(CHAARTED) y las respuestas bioqu\u00edmica (progresi\u00f3n seg\u00fan PCWG2), radiol\u00f3gica y cl\u00ednica (deterioro cl\u00ednico/\u00e9xitus).  \nSe evalu\u00f3 la seguridad seg\u00fan criterios NCI-CTCAE v5.0.\nRESULTADOS\nSe incluyeron 22 pacientes. Mediana de edad: 72 a\u00f1os (RIQ: 68,5-77). Diez pacientes ECOG-0, nueve ECOG 1 y tres ECOG \n2. Mediana de Gleason al diagn\u00f3stico: 7 (RIQ: 7-8) y de PSA: 7,81 (RIQ: 1,22-99,91).  \nSeis pacientes fueron metast\u00e1sicos de debut, el resto hab\u00eda recibido previamente tratamiento quir\u00fargico (n=12) y/o \nradioterapia (n=7). Tres pacientes (13,63%) eran M1a, 17 (73,91%) M1b y 2 (9,09%) M1c. Diez (45,45%) eran de alto \nvolumen seg\u00fan CHAARTED y 12 (54,54%) de bajo volumen. La mediana de duraci\u00f3n del tratamiento en nuestra serie fue \nde 163 d\u00edas (RIQ: 85,75-329).  \nEn 21 pacientes se evalu\u00f3 la evoluci\u00f3n del PSA. En alto volumen (n=10): al mes (n=10): 90% pacientes reducci\u00f3n PSA > \n50% y 80% > 90%, tres meses (n=9): 88,89% reducci\u00f3n PSA > 50% y 66,67% > 90%, seis meses (n=7): 85,71% reducci\u00f3n \nPSA > 50% y 57,14% > 90% y doce meses (n=2): todos reducci\u00f3n PSA > 90 %. En bajo volumen (n=11): al mes (n=11): \ntodos los pacientes reducci\u00f3n PSA > 50% y 72,72% > 90%, tres meses (n=9): todos reducci\u00f3n PSA > 50% y 88,8% > 90%, \nseis meses (n=5): todos reducci\u00f3n PSA > 50% y 80% > 90% y doce meses (n=4): todos reducci\u00f3n PSA > 50% y 75% > 90 %.  \nTres pacientes presentaron progresi\u00f3n cl\u00ednica y bioqu\u00edmica, dos tambi\u00e9n progresi\u00f3n radiol\u00f3gica y uno de ellos fue exitus.  \nEl 81,82% de los pacientes experimentaron efectos adversos (EAs). Dos pacientes (9,09%) EAs grado 3 o superior (rash, \nlesiones cut\u00e1neas, dolor \u00f3seo) y dieciocho (81,82%) EAs grados 1-2 (10 fatiga, 6 sofocos, 3 reacciones cut\u00e1neas, 3 \nhipertensi\u00f3n, 2 hipotiroidismo, 2 alteraci\u00f3n perfil lip\u00eddico). Reducci\u00f3n de dosis en dos pacientes (1 fatiga, 1 reacci\u00f3n \ncut\u00e1nea).  \nA la finalizaci\u00f3n del estudio, en 4 pacientes se hab\u00eda suspendido el tratamiento (2 progresi\u00f3n, 1EAs, 1EAs m\u00e1s progresi\u00f3n).\nCONCLUSIONES\n-A pesar de las limitaciones de nuestro estudio en cuanto a tiempo de seguimiento y tama\u00f1o muestral observamos una \nrespuesta favorable al uso de apalutamida en CPHSM\ufffd  \n-En los dos subgrupos estudiados destaca un r\u00e1pido y marcado descenso de PSA.  \n-El perfil de seguridad es superponible al del ensayo pivotal.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n746. TOXICIDAD HEMATOL\u00d3GICA DE DARATUMUMAB SEG\u00daN ADMINISTRACI\u00d3N INTRAVENOSA O \nSUBCUTANEA \nAUTORES\nHERRERA CARRANZA, S; ZAMORANO M\u00c9NDEZ, P; SALVADOR LLANA, I; S\u00c1NCHEZ PASCUAL, B; TORO CHICO, P; P\u00c9REZ \nENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nEvaluar la aparici\u00f3n de toxicidad hematol\u00f3gica en los pacientes tratados con daratumumab, analizando la incidencia de \nneutropenia y plaquetopenia en funci\u00f3n de la v\u00eda de administraci\u00f3n intravenosa(IV) o subcut\u00e1nea(SC).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo en un hospital de tercer nivel en el que se incluy\u00f3 a todos los pacientes tratados \ncon daratumumab desde su inclusi\u00f3n en marzo 2017 y que han recibido al menos un ciclo hasta abril 2022. Se recogieron \nlas siguientes variables: sexo, edad, esquema de tratamiento, fechas de inicio/fin, motivo de suspensi\u00f3n, administraci\u00f3n \nintravenosa o subcut\u00e1nea, dosis hasta primera citopenia, dosis hasta primera citopenia grave (seg\u00fan clasificaci\u00f3n \nCTCAEv5) y suspensi\u00f3n asociada, valores m\u00ednimos de neutr\u00f3filos y plaquetas y soporte con G-CSF. Para la recogida de \ndatos se utiliz\u00f3 la historia cl\u00ednica electr\u00f3nica y el m\u00f3dulo de pacientes ambulantes de farmacia. El an\u00e1lisis estad\u00edstico se \nrealiz\u00f3 mediante Stata MP v16.1.\nRESULTADOS\nSe analizaron 33 pacientes(57,6%(19/33) mujeres, mediana 74 a\u00f1os(Rango Intercuart\u00edlico(RIQ):66-77,25)). La mediana \nde dosis recibidas es 18(8,75-29,25). 16 pacientes recibieron daratumumab por v\u00eda intravenosa, 16 por v\u00eda subcut\u00e1nea \ny 1 paciente comenz\u00f3 IV y paso a SC. Los esquemas fueron monoterapia 36,4%(12/33) y 63,6%(21/33) en combinaci\u00f3n: \nlenalidomida/dexametasona (DRd) 33,3%(11/33), bortezomib/melfal\u00e1n/prednisona (DVMP) 9,1%(3/33), bortezomib/\nciclofosfamida/dexametasona (esquema Andromeda) 9,1%(3/33), bortezomib/dexametasona (DVd) 6,1%(2/33) y \nbortezomib/lenalidomida/dexametasona (DVRd) 6,1%(2/33). Actualmente hay 48,5%(16/33) pacientes activos y \n51,5%(17/33) suspensiones siendo 58,8%(10/17) por progresi\u00f3n, 17,6%(3/17) exitus, 17,6%(3/17) trasplante y 5,9%(1/17) \nnueva neoplasia\ufffd  \nLa proporci\u00f3n de pacientes con neutropenia en el grupo de administraci\u00f3n IV fue 64,7%(11/17) y en administraci\u00f3n \nSC 76,5%(13/17), p=0,452; alcanz\u00e1ndose a las 2(RIQ:1-2) y 2(RIQ:2-3) dosis de mediana, respectivamente. El grado \nalcanzado en administraci\u00f3n IV fue G1 11,8%(2/17), G2 23,5%(4/17), G3 17,6%(3/17) y G4 11,8%(2/17); las neutropenias \ngraves(G3-4) se alcanzaron a las 3 dosis(RIQ:2-4) de mediana. El grado alcanzado con administraci\u00f3n SC fue G1 \n17,6%(3/17), G2 29,4%(5/17), G3 17,6%(3/17) y G4 11,8%(2/17); las neutr openias graves(G3-4) se alcanzaron a las 3 \ndosis(3-10) de mediana.  \nEl 83,3%(20/24) de los pacientes con neutropenia precisaron rescate con filgrastim con una mediana de 11 dosis (RIQ:5,25-36241,75). 20,0%(2/10) de las neutropenias graves conllevaron retraso de administraci\u00f3n y ninguna suspensi\u00f3n.  \nLa proporci\u00f3n de pacientes con plaquetopenia en el grupo de administraci\u00f3n IV fue 47,1%(8/17) y en administraci\u00f3n \nSC 64,7%(11/17), p=0,300; alcanz\u00e1ndose a las 2(RIQ:1-5,5) y 3(RIQ:2-7) dosis de mediana, respectivamente. En \nadministraci\u00f3n IV el grado alcanzado fue G1 23,5%(4/17), G2 17,6%(3/17) y G3 5,9%(1/17 a las 16 dosis). En pacientes \ncon administraci\u00f3n SC el grado alcanzado fue G1 47,1%(8/17), G2 11,8%(2/17) y G3 5,9%(1/17 a las 2 dosis). \nSeg\u00fan esquemas, la neutropenia se present\u00f3 en el 58,3%(7/12) de pacientes en monoterapia y en el 81,0%(17/21) de \npacientes en combinaci\u00f3n, p=0,247. La plaquetopenia se present\u00f3 en el 66,7%(8/12) de pacientes en monoterapia y en \n52,4%(11/21) de pacientes en combinaci\u00f3n, p=0,350.\nCONCLUSIONES\nLa toxicidad hematol\u00f3gica, neutropenia y trombocitopenia, aparece en las primeras dosis desde el inicio del tratamiento, \nno encontrando diferencias atribuibles a la v\u00eda de administraci\u00f3n de daratumumab.  \nEl retraso de administraci\u00f3n y la suspensi\u00f3n debidos a toxicidad hematol\u00f3gica grave fueron m\u00ednimos.  \nEn este an\u00e1lisis, la toxicidad hematol\u00f3gica no difiere entre esquemas en monoterapia o combinaci\u00f3n.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n766. EXPERIENCIA DE USO DE NIRAPARIB EN EL TRATAMIENTO DE MANTENIMIENTO DEL C\u00c1NCER DE \nOVARIO DE ALTO GRADO EN RECA\u00cdDA. \nAUTORES\nCORRALES PAZ, M; L\u00d3PEZ-SANTAMARIA DONOSO, J; PLA PAS\u00c1N, R; MENGUIANO ROMERO, Y; TUDELA TOM\u00c1S, J\nHOSPITAL PUERTA DEL MAR \ufffd AV\ufffd ANA DE VIYA, 21 C\u00c1DIZ \ufffd C\u00c1DIZ\nOBJETIVOS\nDescribir la experiencia de uso (efectividad y seguridad) de niraparib como tratamiento de mantenimiento en el c\u00e1ncer \nde ovario epitelial seroso y de las trompas de Falopio de alto grado, recidivado y sensible a quimioterapia (QT) con \nplatino. El c\u00e1ncer de ovario es la causa de muerte m\u00e1s frecuente entre las neoplasias ginecol\u00f3gicas y el riesgo de recidiva \nen mujeres con enfermedad avanzada es muy alto. Actualmente niraparib est\u00e1 aprobado y financiado en Espa\u00f1a para \nel mantenimiento tras reca\u00edda de la enfermedad al menos pasados 6 meses del pen\u00faltimo tratamiento con platino y en \nrespuesta parcial/completa al \u00faltimo esquema con platino.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio descriptivo retrospectivo en el que se incluyeron pacientes con c\u00e1ncer de ovario epitelial seroso y \nde las trompas de Falopio de alto grado, tratadas con niraparib desde junio 2018-febrero 2022 . Las variables recogidas \nfueron: edad, estado funcional (ECOG), estado mutacional BRCA, tratamientos previos y posteriores, dosis y duraci\u00f3n \nde tratamiento con niraparib, as\u00ed como efectos adversos y tolerancia al f\u00e1rmaco. Los datos fueron obtenidos del \nprograma de prescripci\u00f3n Athos-Prisma\u00ae y de la Historia Cl\u00ednica de Andaluc\u00eda (DAE\u00ae). La efectividad se evalu\u00f3 mediante \nla supervivencia libre de progresi\u00f3n (SLP) y la supervivencia global (SG). La seguridad se valor\u00f3 mediante la aparici\u00f3n de \nefectos adversos (EA) graves seg\u00fan cristerios RECIST v.1.1 y reducciones de dosis/interrupci\u00f3n del tratamiento.\nRESULTADOS\nFueron incluidas 9 mujeres con una media de edad de 61\u00b113 a\u00f1os, con diagn\u00f3stico de c\u00e1ncer de ovario epitelial \nseroso de alto grado estad\u00edo avanzado (8) y de las trompas de falopio de alto grado (1) con un ECOG 0-1. Ninguna \npresent\u00f3 mutaci\u00f3n para el gen BRCA.Todas hab\u00edan recibido al menos dos esquemas de tratamiento con platino, siendo \nprincipalmente el esquema carboplatino/paclitaxel. La dosis se paut\u00f3 en base al peso de la paciente, iniciando 7 pacientes \nniraparib a 200 mg/d\u00eda y 2 niraparib a 300 mg/d\u00eda. El 66,7% (6) de las pacientes necesitaron reducir la dosis por EA \ngraves (interrumpiendo el tratamiento antes de reiniciar a dosis reducida), principalmente hematol\u00f3gicos.Las reacciones \nadversas registradas fueron: astenia (5), n\u00e1useas (4), plaquetopenia (4),estre\u00f1imiento (3), anemia (3), disgeusia (3), \nneutropenia (2), diarrea (1), v\u00f3mitos (1), todas ellas fueron de grado 1-2; algunos EA de grado 3 (neutropenia (1), anemia \n(1), cefalea (1) y plaquetopenia (1) obligaron a reducir la dosis).  \nCon una mediana de seguimiento de 19 meses (6-30), 6 pacientes progresaron, obteniendo una mediana de SLP 3,75 \nmeses (1-NA) y de las cuales 3 fallecieron a pesar de ser tratadas con posteriores l\u00edneas de tratamiento. El resto (3), \ncontin\u00faan en tratamiento en la actualidad.\nCONCLUSIONES\nEn nuestro estudio, la mediana de SLP result\u00f3 ser inferior a la obtenida en los ensayos cl\u00ednicos y la SG no fue alcanzada, \naunque esto puede ser debido a que nuestro tama\u00f1o de muestra es peque\u00f1o.Los EA detectados fueron similares a los \ndescritos en la bibliograf\u00eda, destacando la astenia y los EA hematol\u00f3gicos como los m\u00e1s frecuente entre los pacientes.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n769. EVALUACI\u00d3N DEL TRATAMIENTO ADYUVANTE CON INMUNOTERAPIA EN PACIENTES CON \nMELANOMA DE ALTO RIESGO \nAUTORES\nFERN\u00c1NDEZ MART\u00cdNEZ, IM; MART\u00cdNEZ PENELLA, M; GARC\u00cdA MATILLAS, CN; MART\u00cdNEZ MARCOS, JM; TAMBOLEO \nSANCHEZ, IJ; MIRA SIRVENT , MC\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA363OBJETIVOS\nEvaluar la seguridad y la efectividad de los agentes inhibidores de puntos de control (anti-PD-1), espec\u00edficamente \npembrolizumab y nivolumab, como tratamiento adyuvante en pacientes con melanoma (estadios III y IV resecables) tras \nresecci\u00f3n quir\u00fargica completa y alto riesgo de recidiva.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional de pacientes diagnosticados de melanoma maligno que recibieron tratamiento \nadyuvante con pembrolizumab o nivolumab desde marzo-2018 hasta abril-2022. Al inicio del periodo de estudio la \nindicaci\u00f3n se encontraba pendiente de financiaci\u00f3n para ambos f\u00e1rmacos, por lo que muchos fueron evaluados por la \nComisi\u00f3n Regional de Farmacia\ufffd  \nSe recogieron las siguientes variables de estudio a trav\u00e9s de las historias cl\u00ednicas (Selene\u00ae) y del programa de prescripci\u00f3n \nelectr\u00f3nica (Farmis-Oncofarm\u00ae): edad, sexo, estadio, mutaci\u00f3n gen BRAF, inmunoterapia, ciclos recibidos, progresi\u00f3n \nde la enfermedad (PE), intervalo libre de enfermedad (ILE), supervivencia libre de progresi\u00f3n (SLP), supervivencia global \n(SG) y efectos adversos (EA). El an\u00e1lisis estad\u00edstico se realiz\u00f3 a trav\u00e9s del programa eSPSS v25.0\u00ae mostrando las variables \ncontinuas, como media y desviaci\u00f3n est\u00e1ndar o mediana y rango intercuart\u00edlico en funci\u00f3n del ajuste de normalidad y las \nvariables categ\u00f3ricas, como n\u00famero y frecuencia.\nRESULTADOS\nSe analizaron un total de 21 pacientes (14 varones) con una edad media de 62,2\u00b12,8 a\u00f1os, de los cuales el 38,1% \npresentaban un estadio IV de la enfermedad, el 33,3% IIIB, el 14,3% % IIIA y el 14,3% IIIC\ufffd El gen BRAF se encontraba \nmutado en 3 pacientes (14,3%). La media de seguimiento de los pacientes fue de 26,8\u00b115,7 meses: diez pacientes(47,6%) \nfueron tratados con nivolumab, mientras que once(52,4%) recibieron pembrolizumab seg\u00fan pautas posol\u00f3gicas \nindicadas en ficha t\u00e9cnica. Del total de pacientes, trece (61,9%) completaron el a\u00f1o de tratamiento adyuvante con \nuna mediana de ILE de 30 [17-43] meses hasta la fecha fin del estudio; seis (28,6%) suspendieron el tratamiento por \nEA; y dos (9,5%) continuaban en tratamiento. Tres pacientes (14,2%) presentaron PE (n=2 tratados con nivolumab ; \nn=1 con pembrolizumab) con una mediana de ILE de 12 [9-13] meses, habiendo completado el a\u00f1o de tratamiento \ndos de ellos. En el momento del an\u00e1lisis no se pudo obtener la mediana de SLP y SG ya que no se hab\u00edan alcanzado las \nmedianas requeridas. El 66,5 % de los pacientes present\u00f3 al menos un EA secundario a la inmunoterapia, siendo los de \nmayor relevancia y consecuencia de la interrupci\u00f3n de \u00e9sta: fracaso renal agudo (n=2), nefritis tubulointesticial (n=2), \nhipotiroidismo (n=2), poliartralgias (n=2), hipofisitis (n=1), colitis autoinmune (n=1), insuficiencia cardiaca (n=1), astenia \ninvalidante (n=2) y diarrea grado 1 (n=1); requiriendo tres de ellos ingreso hospitalario para tratar la sintomatolog\u00eda.\nCONCLUSIONES\nLa terapia adyuvante con pembrolizumab o nivolumab presenta un beneficio cl\u00ednico significativo en t\u00e9rmicos de ILE en los \npacientes estudiados a pesar de mostrar un perfil de toxicidad no despreciable. Sin embargo, todav\u00eda no se ha alcanzado \nla SLP ni la SG en nuestros pacientes a fin de comparar los resultados con el ensayo pivotal debido a la inmadurez de \nlos datos. Por ello, se requiere un seguimiento a m\u00e1s largo plazo para determinar la efectividad real del tratamiento \nadyuvante del melanoma\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n778. EXPERIENCIA DE USO DE APALUTAMIDA EN EL TRATAMIENTO DEL C\u00c1NCER DE PR\u00d3STATA \nHORMONOSENSIBLE METAST\u00c1SICO. \nAUTORES\nCORRALES PAZ, M; ROMERO HERN\u00c1NDEZ, I; L\u00d3PEZ-SANTAMARIA DONOSO, J; S\u00c1NCHEZ LOB\u00d3N, I; MENGUIANO \nROMERO, Y\nHOSPITAL PUERTA DEL MAR \ufffd AV\ufffd ANA DE VIYA, 21 C\u00c1DIZ \ufffd C\u00c1DIZ\nOBJETIVOS\nDescribir la experiencia de uso de apalutamida en el tratamiento del c\u00e1ncer de pr\u00f3stata hormonosensible metast\u00e1sico. \nEl c\u00e1ncer de pr\u00f3stata es el tumor maligno urogenital m\u00e1s frecuente en varones europeos. En la actualidad las opciones \nde tratamiento en c\u00e1ncer de pr\u00f3stata hormonosensible metast\u00e1sico (CPHSm) van m\u00e1s all\u00e1 de la terapia de privaci\u00f3n \nandrog\u00e9nica (TDA) sola. Uno de los \u00faltimos tratamientos aprobados en este tipo de tumor es la apalutamida y nuestro \nobjetivo es analizar los resultados de efectividad y seguridad en la pr\u00e1ctica cl\u00ednica en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio descriptivo retrospectivo en el que se incluyeron pacientes con c\u00e1ncer de pr\u00f3stata hormonosensible \nmetast\u00e1sico tratados con apalutamida durante 2021, y con al menos tres meses de seguimiento. Las variables recogidas \nfueron: edad, estado funcional (ECOG), niveles de ant\u00edgeno prost\u00e1tico espec\u00edfico (PSA) y puntuaci\u00f3n de Gleason al inicio \ndel tratamiento, localizaci\u00f3n de met\u00e1stasis, tratamientos previos, dosis y duraci\u00f3n de tratamiento con apalutamida, as\u00ed \ncomo efectos adversos y tolerancia al f\u00e1rmaco. Los datos fueron obtenidos del programa de prescripci\u00f3n Athos-Prisma\u00ae y \nde la Historia Cl\u00ednica de Andaluc\u00eda (DAE\u00ae). \nLa efectividad se evalu\u00f3 mediante la supervivencia libre de progresi\u00f3n (SLP) y la supervivencia global (SG). La seguridad se \nvalor\u00f3 mediante la aparici\u00f3n de efectos adversos (EA) graves y reducciones de dosis/interrupci\u00f3n del tratamiento.\nRESULTADOS\nFueron incluidos 12 hombres con una media de edad de 74\u00b18 a\u00f1os, con diagn\u00f3stico de c\u00e1ncer de pr\u00f3stata \nhormonosensible metastasico y ECOG 0-1. Ten\u00edan una mediana de PSA 13.87ng/ml (4.26-313 ng/ml) y puntuaci\u00f3n de \nGleason de 8 (6-10).  364Dos pacientes no hab\u00edan recibido tratamiento previo, 9 hab\u00edan sido tratados con hormonoterapia y uno con \nquimioterapia basada en carboplatino+etoposido+docetaxel. Todos los pacientes presentaban met\u00e1stasis \u00f3seas, tres de \nellos ganglionares, dos de los cuales, adem\u00e1s, presentaban met\u00e1stasis pulmonares. Todos iniciaron a dosis completa de \n240 mg/d\u00eda de apalutamida, aunque tres de ellos necesitaron reducci\u00f3n de dosis posteriormente por efectos adversos \n(dos tuvieron que interrumpir el tratamiento antes de reiniciar a dosis reducida).  \nLas reacciones adversas registradas fueron: astenia (7), mareos (1), sofocos (4), s\u00edncope (1), hipertensi\u00f3n (1), cefalea (1), \nmialgias (1), artralgias (2), n\u00e1useas (2), prurito (1) y descamaci\u00f3n (1), todas ellas fueron de grado 1-2; s\u00f3lo un paciente \nsufri\u00f3 rash cut\u00e1neo grado 3.  \nA fecha fin del estudio dos pacientes han progresado: uno al mes de iniciar tratamiento, pasando a cuidados paliativos, y \notro a los 8 meses, tratado posteriormente con docetaxel. El resto de pacientes contin\u00faa en tratamiento con una mediana \nde 7 meses y 27 d\u00edas (184-318 d\u00edas).\nCONCLUSIONES\nLa mediana de SLP y SG no fue alcanzada en nuestro estudio, por lo que es necesario ampliar el tiempo de seguimiento \ny el tama\u00f1o muestral para confirmar la efectividad y seguridad del tratamiento con apalutamida. Los efectos adversos \ndetectados fueron similares a los descritos en la bibliograf\u00eda, destacando la astenia como el efecto adverso m\u00e1s frecuente \nentre los pacientes\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n798. ESTUDIO EN VIDA REAL DE TRIFLURIDINA/TIPIRACILO EN PACIENTES CON C\u00c1NCER COLORRECTAL \nMETAST\u00c1SICO \nAUTORES\nROLD\u00c1N GALNARES, M; ARTACHO CRIADO, SM; ROBUSTILLO CORT\u00c9S, MDLA; M\u00c1RQUEZ SAAVEDRA, E\nHOSPITAL NUESTRA SE\u00d1ORA DE VALME. CTRA. C\u00c1DIZ-BELLAVISTA, KM. 548,9 SEVILLA. SEVILLA\nOBJETIVOS\nEvaluar efectividad y seguridad de Trifluridina/Tipiracilo (TAS-102) en pacientes con c\u00e1ncer colorrectal metast\u00e1sico \n(CCRm) y revisar si el cumplimiento de los criterios de Tabernero et al. impacta en la efectividad del tratamiento.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyeron pacientes con diagn\u00f3stico de CCRm tratados con TAS-102 \nentre junio-2016/abril-2022 en un hospital de especialidades. Se excluyeron aquellos en ensayos cl\u00ednicos. Variables \nrecogidas: sexo, edad, ECOG, localizaci\u00f3n de la enfermedad, mutaci\u00f3n RAS, haber recibido \u22652 l\u00edneas de quimioterapia \nprevias (si/no), cumplimiento de los criterios de Tabernero et al. y motivo de suspensi\u00f3n del tratamiento. Variables \nevaluadas: supervivencia libre de progresi\u00f3n (SLP), supervivencia global (SG) y reacciones adversas (RA). Se cumpl\u00edan los \ncriterios de Tabernero et al. si: carga tumoral baja ( < 3 localizaciones metast\u00e1sicas) y tiempo desde el diagn\u00f3stico de la \nenfermedad metast\u00e1sica hasta el inicio del tratamiento \u226518 meses. Fuentes de informaci\u00f3n: historia cl\u00ednica electr\u00f3nica \ny programa de dispensaci\u00f3n a pacientes externos. La SLP y la SG se estimaron a trav\u00e9s del m\u00e9todo Kaplan-Meier, \ncompar\u00e1ndose con el test Log-Rank. Procesamiento de datos: programa estad\u00edstico SPSS\u00aev.25.0.\nRESULTADOS\nSe incluyeron 27 pacientes, 51,9% mujeres (n=14), con mediana de edad de 73 a\u00f1os (Rango:49-80). El 88,9% (n=24) \npresent\u00f3 ECOG 0-1. En el 74,1% (n=20) la localizaci\u00f3n de la enfermedad fue colon frente al 25,9% (n=7) en recto. El \n51,9% (n=14) present\u00f3 RAS mutado. Todos hab\u00edan recibido al menos dos l\u00edneas de quimioterapia previas. El motivo de \nsuspensi\u00f3n del tratamiento fue progresi\u00f3n/\u00e9xitus en el 74,1% (n=20), toxicidad en un 11,1% (n=3) y deterioro cl\u00ednico en \notro 11,1% (n=3). En uno de los casos no se estableci\u00f3 el motivo. El 77,8% de los pacientes (n=21) cumpli\u00f3 los criterios \nde Tabernero et al., 4 pacientes (14,8%) no lo cumplieron por presentar \u22653 localizaciones metast\u00e1sicas y 2 (7,4%) por \nno haber transcurrido \u226518 meses desde el diagn\u00f3stico de la enfermedad metast\u00e1sica. A fecha de recogida de datos \n(abril 2022), solo 1 paciente segu\u00eda en tratamiento. La mediana de SLP fue de 2,8 meses (IC95%:2,5-3,1) y la de SG 7,6 \n(IC95%:6,4-8,7). La mediana de SG en aquellos que cumpl\u00edan los crit erios de Tabernero et al. fue 8,1 meses frente a \nuna mediana de 5,6 en los que no los cumpl\u00edan, no alcanzando la significaci\u00f3n estad\u00edstica (p > 0,05). Con respecto a la \ntoxicidad, presentaron RA de cualquier grado el 85,2% de los pacientes (n=23) y RA de grado 3-4, el 33,3% (n=9). Se \ndescribi\u00f3 toxicidad hematol\u00f3gica en el 51,9% (n=14), siendo neutropenia lo m\u00e1s caracter\u00edstico (48,1%, n=13), seguido de \ntoxicidad gastrointestinal en el 40,7% (n=11).\nCONCLUSIONES\nLa efectividad de TAS-102 es limitada. Los efectos adversos presentados coinciden con los descritos en ficha t\u00e9cnica y \nsu incidencia es algo inferior a la detallada en el ensayo cl\u00ednico pivotal. La mayor\u00eda de los pacientes cumpli\u00f3 los criterios \nde Tabernero et al., siendo este grupo el que mayor SG present\u00f3 sin mostrar diferencias estad\u00edsticamente significativas, \npudiendo estar esto relacionado con el bajo tama\u00f1o muestral.365CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n805. PERFIL DE SEGURIDAD DE PEGASPARGASA EN UNA COHORTE DE PACIENTES EN UN HOSPITAL DE \nTERCER NIVEL \nAUTORES\nESCOL\u00c0 RODR\u00cdGUEZ, A; MONGE ESCART\u00cdN, I; RUIZ BOY , S; MAT\u00c9 ARBAIZA, P; ALBANELL FERN\u00c1NDEZ, M; LIZONDO \nL\u00d3PEZ, T; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa pegaspargasa es una formulaci\u00f3n pegilada que produce una depleci\u00f3n m\u00e1s sostenida de la asparagina, presentando \nmenos reacciones de hipersensibilidad que la asparaginasa nativa de E.Coli. Algunos estudios han asociado su empleo \na un mejor pron\u00f3stico en la leucemia aguda linfobl\u00e1stica (LAL) del adulto, lo que ha supuesto su posicionamiento como \ntratamiento de primera l\u00ednea.  \n \nEl objetivo del estudio fue analizar el perfil de seguridad de pegaspargasa y evaluar la asociaci\u00f3n entre caracter\u00edsticas \nbasales y presencia de toxicidad\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital de tercer nivel. Se incluyeron pacientes con: LAL (esquema basado en \nel protocolo PETHEMA) o con otras neoplasias hematol\u00f3gicas (tratamiento con pegaspargasa Fuera de Indicaci\u00f3n), entre \nenero/2016-marzo/2022. \n \nLos pacientes iniciaban pegaspargasa a dosis matizadas si presentaban, de forma basal, factores de riesgo definidos en \nprotocolo PETHEMA: edad > 50 a\u00f1os, \u00edndice de masa corporal (IMC) > 30Kg/m2 o alteraciones hep\u00e1ticas.  \n \nSe recogieron datos demogr\u00e1ficos y par\u00e1metros referentes a toxicidad secundaria al f\u00e1rmaco seg\u00fan criterios CTCAE \n(Common Terminology Criteria for Adverse Events) v.5. Se evalu\u00f3 la asociaci\u00f3n entre sexo, edad \u226540 a\u00f1os, IMC\u226525Kg/m2 \ny tipo de neoplasia con presencia de toxicidad (de cualquier grado y grado 3-4) mediante la prueba exacta de Fisher.\nRESULTADOS\nSe incluyeron 33 pacientes, (15 mujeres, 45,5%), con una mediana de edad de 34 (26-44) a\u00f1os. Diecis\u00e9is fueron \ndiagnosticados de LAL-B, 10 de LAL-T, 4 de linfoma linfobl\u00e1stico T y 3 presentaban otras patolog\u00edas.  \n \nSe detectaron 33 reacciones adversas de cualquier grado relacionadas con pegaspargasa en 22 (66,7%) pacientes: 13 \n(39,4%) presentaron hepatotoxicidad, 12 (36,4%) hipertrigliceridemia, 3 (9,1%) reacciones de hipersensibilidad, 2 (6,1%) \nhiperamonemia, 1 (3,0%) trombosis, 1 (3,0%) pancreatitis y 1 (3,0%) hiperfibrinogenemia. Quince (45,5%) pacientes \npresentaron 16 toxicidades de grado 3-4: 10 (30,3%) desarrollaron hipertrigliceridemia, 5 (15,2%) hepatotoxicidad y 1 \n(3,0%) hipersensibilidad.  \n \nOnce (33,3%) pacientes requirieron reducci\u00f3n de dosis. Se disminuy\u00f3 la dosis en una media de 36,7\u00b114,4% con respecto \nla dosis inicial. Las causas fueron: hepatotoxicidad (30,3%), hipertrigliceridemia (15,2%), hiperamonemia (6,1%), \npancreatitis (3,0%) e hiperfibrinogenemia (3,0%). \n \nCinco (15,2%) pacientes precisaron interrupci\u00f3n del tratamiento; principalmente por hepatotoxicidad (12,1%), \nhipertrigliceridemia (6,1%) e hiperamonemia (3,0%).  \n \nDos (6,1%) pacientes discontinuaron tratamiento por reacci\u00f3n de hipersensibilidad pese a la reducci\u00f3n dosis o \ninterrupci\u00f3n del tratamiento. Ambos requirieron tratamiento sist\u00e9mico con corticoides y antihistam\u00ednicos. Adem\u00e1s, uno \nde ellos present\u00f3 numerosas toxicidades\ufffd  \n \nNo se identific\u00f3 asociaci\u00f3n entre sexo, edad, IMC y diagn\u00f3stico y toxicidad (cualquier grado o grado 3-4), aunque se \nobserv\u00f3 una tendencia entre IMC \u226525Kg/m2 y toxicidad de cualquier grado (p=0,054).\nCONCLUSIONES\nPegaspargasa, aun siendo menos inmunog\u00e9nico que asparaginasa nativa, presenta un perfil de seguridad bajo, con casi \nla mitad de pacientes presentando reacciones adversas grado 3-4. Las toxicidades m\u00e1s frecuentes son hepatotoxicidad e \nhipertrigliceridemia. Reducir la dosis o interrumpir el tratamiento son estrategias generalmente \u00fatiles para controlar la \ntoxicidad\ufffd  \n \nSe observa una tendencia entre el peso elevado, incluyendo el sobrepeso y la presencia de toxicidad a pegaspargasa\ufffd A \nfalta de confirmaci\u00f3n, podr\u00eda llevar a plantear un ajuste de dosis inicial en pacientes con sobrepeso y no \u00fanicamente en \naquellos con obesidad, como ya se especifica en protocolo PETHEMA.366CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n832. AN\u00c1LISIS DE LA EFECTIVIDAD DE LOS INHIBIDORES DE TIROSINA QUINASA A DOSIS REDUCIDAS EN \nPACIENTES CON LEUCEMIA MIELOIDE CR\u00d3NICA \nAUTORES\nALARC\u00d3N PAYER, C; S\u00c1NCHEZ SU\u00c1REZ, MDM; MART\u00cdN ROLD\u00c1N, A; ARCHILLA AMAT , MI; JIM\u00c9NEZ MORALES, A\nHOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES \ufffd AV\ufffd DE LAS FUERZAS ARMADAS, 2 GRANADA \ufffd GRANADA\nOBJETIVOS\nAnalizar las causas de reducci\u00f3n de dosis de los inhibidores de tirosina quinasa (ITK) y evaluar como impactan estas \nreducciones en la respuesta citogen\u00e9tica y molecular de los pacientes con Leucemia Mieloide Cr\u00f3nica en fase cr\u00f3nica \n(LMC-FC).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de todos los pacientes con LMC-FC que hayan estado en tratamiento con imatinib, \nnilotinib o dasatinib a dosis reducidas desde Enero de 2011 hasta Marzo de 2022 en un hospital de tercer nivel. Las \nvariables recogidas fueron: sexo, edad, diagn\u00f3stico, comorbilidades y tratamiento/s previo/s. Para cada ITK se recogi\u00f3 \nla fecha de inicio, duraci\u00f3n, suspensi\u00f3n (s\u00ed/no), causa de la suspensi\u00f3n y duraci\u00f3n de la misma, reducci\u00f3n de dosis (s\u00ed/\nno), causa y duraci\u00f3n. Para evaluar la respuesta se registr\u00f3 si se obtuvo respuesta citogen\u00e9tica (RC) y molecular (RM), \nas\u00ed como el mes a la que se alcanz\u00f3 desde el inicio, tipo de respuesta alcanzada (RM completa, RM5, RM4.5 y RM4), si la \nreducci\u00f3n de dosis se realizaba tras alcanzar la RM o no, si se produc\u00eda p\u00e9rdida de respuesta y mes en que se produc\u00eda.\nRESULTADOS\nSe analizaron un total de 68 pacientes con reducci\u00f3n de dosis o suspensi\u00f3n. Mediana de edad de 65 a\u00f1os (rango \nintercuart\u00edlico 50-80), con una mediana de 10 a\u00f1os desde el diagn\u00f3stico (rango intercuart\u00edlico 6-14). El 50,1% no \npresentaban antecedentes y dentro de las comorbilidades al diagn\u00f3stico se destac\u00f3 la hipertensi\u00f3n arterial (23,1%) y \ndiabetes(16%). El 92,6% recibi\u00f3 previamente hidroxicarbamida y 3 pacientes citarabina e interfer\u00f3n. Como primera l\u00ednea \nde ITK hubo 40 pacientes con imatinib, 17 nilotinib y 13 dasatinib con unas medianas de duraci\u00f3n de tratamiento de \n58, 59 y 43 meses respectivamente. Entre los pacientes con imatinib se realizaron 30 suspensiones de tratamiento ( 1 \nvoluntaria, 17 por efectos adversos, 12 por no alcanzar/p\u00e9rdida de respuesta) y 12 reducciones de dosis. Entre los efectos \nadversos (EA) destacaron: toxicidad hematol\u00f3gica (5), edemas (3) y toxicodermia (2). Entre los pacientes con Nilotinib \nhubo 6 suspensiones (3 EA, 2 voluntaria, 1 por no alcanzar/p\u00e9rdida de respuesta) y 14 reducciones de dosis. Entre los \npacientes con dasatinib hubo 6 suspensiones (4 EA, 2 voluntaria, 1 no respuesta) y 5 reducciones de dosis.  \nEl 86,7% de los pacientes alcanz\u00f3 la RC (mediana 3,5 meses). 33 pacientes (48%) alcanzaron una RM superior a 4 log y 19 \nde ellos (57,5%) ten\u00edan reducci\u00f3n de dosis. Del total, 12 pacientes perdieron la RM (mediana mes 21,5) y s\u00f3lo 5 pacientes \nten\u00edan dosis reducidas.  \nA los pacientes en 2\u00aa l\u00ednea: Imatinib (4), nilotinib (18), dasatinib (16), se redujeron la dosis a 12 de ellos con una mediana \nde duraci\u00f3n de tratamiento de 34, 98 y 36 meses respectivamente. Un 53% alcanz\u00f3 una RM superior a 4 log.\nCONCLUSIONES\nLa suspensi\u00f3n temporal o la reducci\u00f3n de dosis de los ITK pueden alcanzar y mantener una RM superior a 4 log en un \nelevado porcentaje de los pacientes, por lo que en caso de toxicidad una reducci\u00f3n de dosis ser\u00eda mejor opci\u00f3n que \nrealizar un cambio de ITK.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n833. EFECTIVIDAD Y SEGURIDAD DE DURVALUMAB EN C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO \nAUTORES\nTORR\u00d3 GARC\u00cdA, L; GIL ALMELA, J; D\u00cdAZ RAM\u00d3N, M; CANO MOLINA, J\u00c1; GOLNABI DOWLATSHAHI, F; VILLA CARPES, \nJ; OLMOS JIM\u00c9NEZ, R; D\u00cdAZ CARRASCO, MS\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nEvaluar la efectividad y seguridad de durvalumab en mantenimiento tras quimiorradioterapia previa en pacientes con \nc\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) localmente avanzado, no resecable.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo realizado en un hospital de tercer nivel. Se incluyeron todos los pacientes con \ndiagn\u00f3stico de CPNM localmente avanzado no resecable, que iniciaron tratamiento con durvalumab entre enero de 2020 \ny marzo de 2022.  \n \nLas variables recogidas fueron: edad, sexo, ECOG, historia de tabaquismo, estadio, histolog\u00eda, expresi\u00f3n de PD-L1, \ntratamiento previo, respuesta tras quimiorradioterapia de acuerdo con los RECIST versi\u00f3n 1.1. Para evaluar la efectividad \nse utiliz\u00f3 la variable supervivencia libre de progresi\u00f3n (SLP) y supervivencia global (SG) aplicando el m\u00e9todo de Kaplan-\nMeier. La seguridad se evalu\u00f3 analizando la toxicidad, para ello se registraron los eventos adversos (EA) y su gravedad \nseg\u00fan los criterios CTCAE (Common Terminology Criteria for Adverse Events v5.0). Para el an\u00e1lisis estad\u00edstico se utiliz\u00f3 el \nprograma estad\u00edstico SPSS v25.0\u00ae.367RESULTADOS\nSe analizaron 17 pacientes, con una mediana de edad de 65 a\u00f1os (40-76), el 88,2% eran hombres, todos los pacientes con \nun ECOG entre 0-1. El 52,9% eran fumadores activos, el 41,2% exfumadores y el 5,9% no fumadores. Respecto al estadio, \nel 41,2% presentaba estadio IIIA, el 41,2% al IIIB y el 17,6% al IIIC. En cuanto a la histolog\u00eda, el 52,9% fue CPNM escamoso, \ny el 47,1% CPNM no escamoso. En todos los pacientes se observ\u00f3 un nivel de expresi\u00f3n de PD-L1 \u22651%.  \n \nEl 100% de los pacientes recibieron quimioterapia basada en un doblete de platino, de los cuales el 82,4% recibieron \nradioterapia concomitante y el 17,6% secuencial. Adem\u00e1s, el 88,2% recibi\u00f3 quimioterapia de inducci\u00f3n adicional, antes \nde la quimiorradioterapia definitva. La tasa de respuesta completa tras la quimiorradioterapia fue del 5,9% y de respuesta \nparcial del 94,1%\ufffd  \n \nCon una mediana de seguimiento de 12 meses (4,5-23), la mediana de SLP estimada fue de 11,53 meses IC95% (6,29-\n16,8). La mediana de SG fue de 15,57 meses IC95% (8,09-23,04 meses).  \n \nEl 64,7% de los pacientes present\u00f3 un EA de cualquier grado, y un \u00fanico paciente sufri\u00f3 un evento de grado 3 (astenia) \nsiendo causa de suspensi\u00f3n del tratamiento; ning\u00fan paciente present\u00f3 eventos de grado 4 \u00f3 5. Se observaron 20 EA de \ngrado 1-2 en 11 pacientes: rash cut\u00e1neo(4), astenia(3), neumonitis(3), diarrea(2), hipertransaminemia(2), mucositis(2), \nxerostom\u00eda(2), hipotiroidismo(1), prurito(1). Dos de los 3 casos de neumonitis requirieron ingreso hospitalario para \ntratamiento de la sintomatolog\u00eda, siendo causa de suspensi\u00f3n del tratamiento. El resto de EA se trataron de forma \nambulatoria\ufffd\nCONCLUSIONES\nEn t\u00e9rminos de efectividad, a pesar de que las caracter\u00edsticas de los pacientes no eran de mayor riesgo que los del \nestudio, la mediana de SLP y SG fueron inferiores a las del ensayo PACIFIC (SLP 17,2 meses y SG no alcanzada). Estas \ndiferencias podr\u00edan explicarse dado el menor tiempo de seguimiento de los pacientes en nuestro estudio as\u00ed como por el \nn\u00famero limitado de pacientes incluidos.  \n \nEn cuanto a la seguridad, el perfil de eventos adversos fue similar al descrito en el ensayo pivotal, predominando la \ntoxicidad dermatol\u00f3gica, astenia y neumonitis.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n837. EFECTIVIDAD Y SEGURIDAD DE TRASTUZUMAB EMTANSINA EN SEGUNDA L\u00cdNEA EN C\u00c1NCER DE \nMAMA METAST\u00c1SICO HER2 POSITIVO \nAUTORES\nTORR\u00d3 GARC\u00cdA, L; GIL ALMELA, J; CANO MOLINA, J\u00c1; D\u00cdAZ RAM\u00d3N, M; MART\u00cdNEZ IB\u00c1\u00d1EZ, M\u00c1; RAM\u00d3N P\u00c9REZ, M; \nOLMOS JIM\u00c9NEZ, R; D\u00cdAZ CARRASCO, MS\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nEvaluar la efectividad y seguridad de trastuzumab emtansina (T-DM1) en segunda l\u00ednea en mujeres con c\u00e1ncer de mama \nmetast\u00e1sico (CMM) Her2+.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo realizado en un hospital de tercer nivel. Se incluyeron todas las pacientes con \ndiagn\u00f3stico de CMM Her2+ que iniciaron tratamiento con T-DM1 entre enero de 2017 y abril de 2022. \n \nLas variables recogidas fueron: edad, ECOG al inicio del tratamiento, FEVI, expresi\u00f3n de receptores hormonales, \ntratamiento previo para enfermedad localizada y metast\u00e1sica. Para evaluar la efectividad se utiliz\u00f3 la variable \nsupervivencia libre de progresi\u00f3n (SLP) y supervivencia global (SG) aplicando el m\u00e9todo de Kaplan-Meier. La seguridad \nse evalu\u00f3 analizando la toxicidad, para ello se registraron los eventos adversos (EA) y su gravedad seg\u00fan los criterios \nCTCAE (Common Terminology Criteria for Adverse Events v5.0). Los datos se obtuvieron del programa de prescripci\u00f3n \nelectr\u00f3nica y de la historia cl\u00ednica electr\u00f3nica. Para el an\u00e1lisis estad\u00edstico se utiliz\u00f3 el programa estad\u00edstico SPSS v25.0\u00ae.\nRESULTADOS\nSe analizaron 19 pacientes, todas mujeres, con una mediana de edad de 52 a\u00f1os (32-75). Al inicio del tratamiento el \n26,4% presentaba un ECOG de 0, el 36,8% ECOG 1 y el otro 36,8% ECOG 2. El FEVI era > 50% en 18 de las 19 pacientes y el \n79% presentaban receptores hormonales positivos.  \n \nEl 58% de las pacientes recibieron quimioterapia (QMT) previa para enfermedad localizada, y todas las pacientes \nrecibieron QMT previa para enfermedad met\u00e1stasica, el 89,5% basada en un taxano m\u00e1s trastuzumab y pertuzumab, y el \n10,5% solamente basada en taxano y trastuzumab.  \n \nEn el momento de corte, el 89,5% de las pacientes hab\u00eda interrumpido el tratamiento, siendo la mediana de SLP de 8,53 \nmeses IC95% (5,41\u201311,67). La mediana de SG fue de 24,2 meses IC95% (14,67-33,73). La pr obabilidad de SG a 1 a\u00f1o fue \ndel 73% y la probabilidad de SG a 2 a\u00f1os fue del 55,6%\ufffd  368Respecto a la seguridad, el 79% de las pacientes presentaron al menos un EA de cualquier grado. Se observaron 24 EA \nde grado 1-2 en 12 pacientes: transaminitis(5), n\u00e1useas y v\u00f3mitos(3), neuropat\u00eda(3), astenia(3), trombopenia(2), cut\u00e1nea \n(2), artralgias(1), epistaxis(1), hepatotoxicidad(1), ungueal(1), hiporexia(1), xeroftalmia(1). Tres de las 19 pacientes \npresentaron alg\u00fan evento grado 3 que conllev\u00f3 el retraso en la administraci\u00f3n del tratamiento: trombopenia(1), \nneutropenia(1) y astenia(1). Una paciente present\u00f3 un EA grado 4 (neuropat\u00eda) siendo causa de suspensi\u00f3n del \ntratamiento\ufffd Todos los EA fueron tratados de forma ambulatoria\ufffd\nCONCLUSIONES\nEn condiciones de pr\u00e1ctica asistencial, la efectividad, en t\u00e9rminos de mediana de SLP , SG y probabilidad de SG a 1 y 2 \na\u00f1os, fue ligeramente inferior a la descrita en el ensayo cl\u00ednico pivotal \u201cEMILIA\u201d. Estas diferencias podr\u00edan explicarse por \nla diferencia en las poblaciones incluidas, ya que en el ensayo pivotal se incluyeron a pacientes en tratamiento con T-DM1 \ntanto en primera l\u00ednea como en segunda, y en nuestro estudio \u00fanicamente a pacientes en segunda l\u00ednea.  \n \nEn cuanto a la seguridad, el perfil de eventos adversos fue similar al descrito en el ensayo, predominando la transaminitis, \nn\u00e1useas y v\u00f3mitos y astenia.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n915. INFUSI\u00d3N DE LINFOCITOS T VIRUS ESPEC\u00cdFICOS: TRATAMIENTO DE INFECCIONES EN EL POST-\nALOTRASPLANTE DE PROGENITORES HEMATOPOY\u00c9TICOS EN PEDIATR\u00cdA \nAUTORES\nANGUITA DOMINGO, D; PAU PARRA, A; FERN\u00c1NDEZ SOJO, J; MEDINA BORONAT , L; ALONSO GARC\u00cdA, L; D\u00cdAZ DE \nHEREDIA RUBIO, MC; RENEDO MIR\u00d3, B; ALONSO MART\u00cdNEZ, C\nH. UNIVERSITARI GENERAL DE LA VALL D\u2019HEBRON. PASSEIG VALL D\u2019HEBRON 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLos pacientes sometidos a alo-trasplante de progenitores hematopoy\u00e9ticos (alo-TPH) presentan un estado de \ninmunosupresi\u00f3n que favorece la reactivaci\u00f3n de infecciones oportunistas virales como citomegalovirus (CMV), virus \nEpstein-Barr (VEB) y adenovirus (ADV).  \n \nLos linfocitos T virus espec\u00edficos (LTVE), medicamentos de terapia avanzada (MTA), constituyen una alternativa \ninmunoterap\u00e9utica en los pacientes que no responden a la terapia antiviral convencional.  \n \nEl objetivo de este estudio es evaluar la eficacia de los LTVE en pacientes pedi\u00e1tricos, describiendo sus caracter\u00edsticas y \nevoluci\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyen pacientes pedi\u00e1tricos que recibieron LTVE para el tratamiento \nde infecciones por ADV, VEB y CMV tras haberse sometido a alo-TPH desde enero 2016 hasta septiembre 2021, en un \nhospital de tercer nivel. \n \nSe recogieron variables demogr\u00e1ficas, cl\u00ednicas (patolog\u00eda de base, tipo de trasplante), farmacol\u00f3gicas (tratamientos \nantivirales previos, profilaxis utilizada) y de tratamiento (dosis y respuesta).  \n \nLos LTVE fueron fabricados por el proceso IFN-CSS en CliniMACS\u00ae en el Banco de Sangre y Tejidos de Catalu\u00f1a con \nCertificado de conformidad-Buenas Pr\u00e1cticas de Fabricaci\u00f3n n\u00baES/0021/18(PEI-18-143) y se gestionaron como MTA. \n \nLa dosis de LTVE fue de 0,01-5 x 10E4 linfocitos T espec\u00edficos productores de INFg/peso del paciente (kg).  \n \nTodos los tratamientos de LTVE requirieron consentimiento informado, informe cl\u00ednico, informe t\u00e9cnico favorable \ndel Servicio de Farmacia, aprobaci\u00f3n de la Direcci\u00f3n del Hospital y autorizaci\u00f3n previa de la Agencia Espa\u00f1ola de \nMedicamentos y Productos Sanitarios (AEMPS).  \n \nEl tratamiento se consider\u00f3 efectivo tras la resoluci\u00f3n de la infecci\u00f3n (3 PCR negativas consecutivas).  \n \nLas variables continuas se expresan como medianas (rango) y las variables categ\u00f3ricas como n\u00famero de casos (%).\nRESULTADOS\nSe incluyeron diez pacientes (67% mujeres), con una mediana de 11 (0-18) a\u00f1os. Las enfermedades de base fueron: \nleucemia linfobl\u00e1stica aguda (3), aplasia (2), anemia de Fanconi (1), trastorno gen\u00e9tico (2) e inmunodeficiencia (2). Todos \nlos donantes de LTVE fueron no emparentados excepto uno\ufffd  \n \nLas infecciones fueron causadas por CMV (2), ADV (6), CMV+ADV (1) y EBV (1). El 80% de los pacientes recibi\u00f3 1 infusi\u00f3n \nde LTVE y el 20% requiri\u00f3 2 infusiones.  \n \nLas indicaciones para LTVE fueron falta de respuesta (70%) y contraindicaci\u00f3n a f\u00e1rmacos antivirales por toxicidad renal o \nhematol\u00f3gica inaceptable para el paciente (30%).  369El 70% de los pacientes recibi\u00f3 un \u00fanico tratamiento antiviral previo, mientras que el 30% recibi\u00f3 2 tratamientos \nantivirales previos con una duraci\u00f3n media de 111,6 (2-487) d\u00edas.  \n \nLa mediana de dosis de LTVE infundida fue 6,68E2 (2,28E2 - 4,92E4) linfocitos T espec\u00edficos/kg. Los LTVE se infundieron \n5,3 (0,8\u20139,0) meses despu\u00e9s del alo-TPH.  \n \nLa eficacia se logr\u00f3 en 5 (50%) pacientes que recibieron LTVE contra ADV (resoluci\u00f3n de infecci\u00f3n en 25 (6 \u2013 54) d\u00edas).  \n \nEn cuanto a la toxicidad, ning\u00fan paciente report\u00f3 efectos adversos durante o despu\u00e9s de la infusi\u00f3n. Ning\u00fan paciente \ntuvo EICH debido a la infusi\u00f3n\ufffd\nCONCLUSIONES\nLos LTVE fueron efectivos en la mitad de los nuestros pacientes. Este MTA supone una terapia prometedora; sin embargo, \nse necesitan m\u00e1s estudios para aclarar la efectividad y definir los efectos secundarios a largo plazo en la poblaci\u00f3n \npedi\u00e1trica.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n964. IMPACTO DE LOS INHIBIDORES DE LA BOMBA DE PROTONES EN LA SUPERVIVENCIA LIBRE DE \nPROGRESI\u00d3N EN EL TRATAMIENTO CON PALBOCICLIB. \nAUTORES\nTOUR\u00cdS LORES, M; UBEDA RUIZ, B; VARELA REY , I; CASTRO BALADO, A; GARC\u00cdA QUINTANILLA, L; L\u00d3PEZ MONTERO, \nE; BERN\u00c1RDEZ FERR\u00c1N, B; ZARRA FERRO, I\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE SANTIAGO. CHOUPANA, S/N SANTIAGO DE COMPOSTELA. A CORU\u00d1A\nOBJETIVOS\nEl uso de inhibidores de la bomba de protones (IPB) en pacientes oncol\u00f3gicos es una pr\u00e1ctica habitual para mitigar los \nefectos adversos gastrointestinales. En aquellos antineopl\u00e1sicos orales cuya absorci\u00f3n depende del pH g\u00e1strico, el uso de \nIBP puede limitar la absorci\u00f3n de los mismo, y por ende, su eficacia. El objetivo de este estudio es evaluar el impacto del \nuso de IBP en aquellos pacientes a tratamiento con palbociclib en la supervivencia libre de progresi\u00f3n (SLP).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo donde se revisaron aquellos pacientes diagnosticados de c\u00e1ncer de mama \nmetast\u00e1sico con receptores hormonales positivos y HER2 negativo, entre enero de 2018 y enero de 2021 y a tratamiento \nen primera l\u00ednea con palbociclib a dosis plenas, en los que no hubo ni retrasos ni reducciones de dosis. Los pacientes se \ndividieron en dos grupos, los no concomitantes, en los que no se usaba el IBP durante el tratamiento con palbociclib, \ny los concomitantes, en los que el uso del IBP se solapaba como m\u00ednimo dos tercios de la duraci\u00f3n del tratamiento \ncon palbociclib. Las intervenciones cl\u00ednicas se realizaron de acuerdo con la pr\u00e1ctica cl\u00ednica habitual. Los datos de \ndispensaciones realizadas a cada paciente se obtuvieron del programa de prescripci\u00f3n electr\u00f3nica de Farmacia (Silicon\u00ae) \ny las caracter\u00edsticas demogr\u00e1ficas, el tipo de IBP pautado y el subtipo histol\u00f3gico, de la historia electr\u00f3nica (Ianus\u00ae). Para \nel an\u00e1lisis de datos se utiliz\u00f3 el paquete estad\u00edstico SPSS-Statistics V.26 (IBM Inc., Armonk, NY , USA)\nRESULTADOS\nSe analizaron 39 pacientes con una media de edad de 61,6 a\u00f1os (37-83), 26 (66,7 %) pacientes se incluyeron en el grupo \nde concomitantes y 13 (33,3 %) en el de no concomitantes. El subtipo patol\u00f3gico en 14 (35,9%) de los pacientes fue \nluminal A, en 23 (59,0 %) luminal B y en 2 (5,1 %) desconocido. Ten\u00edan met\u00e1stasis viscerales 18 (46,2 %) de los pacientes y \nno viscerales 21 (23,8 %). En 24 (61,5 %) de los pacientes el palbociclib se combin\u00f3 con letrozol en el escenario hormono-\nsensible y 15 (38,5 %) con fulvestrant en el escenario hormo-resistente. 33 (84,6 %) de los pacientes ten\u00edan un ECOG-PS \n0-1 y 6 (15,4 %) un ECOG-PS \u2265 2. El IBP m\u00e1s prescrito fue el omeprazol. Aquellos pacientes que concomitaban el IBP con el \npalbociclib tuvieron una SLP m\u00e1s corta que aquellos que no lo hac\u00edan (10,9 meses frente no alcanzada; p= 0,043).\nCONCLUSIONES\nEl uso de IBP para paliar las molestias digestivas en aquellas pacientes diagnosticadas de c\u00e1ncer de mama con receptores \nhormonales positivos y HER2 negativo y a tratamiento con palbociclib a dosis plenas, puede tener efecto negativo \nen la supervivencia libre de progresi\u00f3n. Se debe de ser cauto a la hora de prescribir este tipo de f\u00e1rmacos de forma \nconcomitante con el palbociclib, y si es posible suspender su uso durante el tratamiento. Son necesarios m\u00e1s estudios \nque respalden esta hip\u00f3tesis.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n989. RESULTADOS EN VIDA REAL DE TRABECTEDINA PARA SARCOMAS AVANZADOS DE PARTES BLANDAS. \nM\u00c1S ALL\u00c1 DEL LIPOSARCOMA Y LEIOMIOSARCOMA. \nAUTORES\nHERRERO BERMEJO, S; GONZ\u00c1LEZ-HABA PE\u00d1A, E; REVUELTA HERRERO, JL; S\u00c1NCHEZ FRESNEDA, MN; G\u00d3MEZ \nCOSTAS, D; VICENTE VALOR, J; HERRANZ ALONSO, A; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID370OBJETIVOS\nConocer la eficacia, en t\u00e9rminos de supervivencia libre de progresi\u00f3n y supervivencia global, y la seguridad de la \ntrabectedina cuando se emplea en el tratamiento de sarcomas avanzados de partes blandas de subtipos diferentes a \nliposarcoma y leiomiosarcoma\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio unic\u00e9ntrico, observacional, retrospectivo en el que se analizan los resultados de 35 pacientes con sarcomas de \npartes blandas de subtipos diferentes a liposarcoma y leiomiosarcoma tratados con trabectedina entre los a\u00f1os 2014 \ny 2022. Para el an\u00e1lisis estad\u00edstico de la supervivencia libre de progresi\u00f3n y la supervivencia global se ha empleado el \nsoftware de STATA 16.  \nLos efectos adversos se han recogido teniendo en cuenta la definici\u00f3n de grado 3 o grado 4 marcada por los \u201cCommon \nTerminology Criteria for Adverse Events\u201d (CTCAE) versi\u00f3n 5.0\nRESULTADOS\nLa mediana de edad de los 35 pacientes al inicio del tratamiento con trabectedina fue de 54,7 a\u00f1os (rango 23,2-79,0 \na\u00f1os). El subtipo histol\u00f3gico m\u00e1s frecuente fue el sarcoma sinovial (31,4%), seguido del sarcoma pleom\u00f3rfico (17,1%). \nLos pacientes recibieron una mediana de 4 ciclos, (rango: 1-25 ciclos) principalmente como tratamiento de enfermedad \nmetast\u00e1sica en tercera l\u00ednea (40%) o en segunda (37,1%). La mediana de supervivencia libre de progresi\u00f3n fue de 3,45 \nmeses (IC95%: 2,20 - 5,98 meses), mientras que la mediana de supervivencia global fue de 12,65 meses (IC95%: 4,47 \u2013 \n19,38 meses). La tasa de control de la enfermedad fue del 37,1%, mientras que la tasa de respuesta objetiva fue tan solo \ndel 11,4%\ufffd \nLos principales efectos adversos de grado 3/4 detectados fueron neutropenia (40%), seguido de trombocitopenia (17,1%) \ny de anemia (14,3%). Ning\u00fan paciente suspendi\u00f3 el tratamiento a causa de los efectos adversos. No hubo muertes \nrelacionadas con el tratamiento\ufffd\nCONCLUSIONES\nLos resultados sugieren que la trabectedina es un tratamiento activo \u00fanicamente en algunos sarcomas de partes blandas \ncon histolog\u00eda diferente a liposarcoma y ieiomiosarcoma en estad\u00edos avanzados metast\u00e1sicos, con un perfil de efectos \nadversos tolerable. Son necesarios estudios capaces de identificar otros subtipos de sarcomas de partes blandas que se \npuedan beneficiar del uso de trabectedina.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n994. TOXICIDAD DE LA INMUNOTERAPIA EN LA PR\u00c1CTICA CL\u00cdNICA EN MELANOMA METAST\u00c1SICO \nAUTORES\nDE LA FUENTE VILLAVERDE, I; MART\u00cdNEZ TORR\u00d3N, A; FERN\u00c1NDEZ LASTRAS, S; \u00c1LVAREZ ASTEINZA, C; MAC\u00cdA RIVAS, \nL; OYAGUE L\u00d3PEZ, L; LOZANO BL\u00c1ZQUEZ, A\nHOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS \ufffd AVENIDA DE ROMA S/N OVIEDO \ufffd ASTURIAS\nOBJETIVOS\nAnalizar la toxicidad de la inmunoterapia en la pr\u00e1ctica cl\u00ednica real en pacientes con melanoma metast\u00e1sico.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo de todos los pacientes diagnosticados de melanoma metast\u00e1sico que \niniciaron tratamiento con inmunoterapia (pembrolizumab, nivolumab, nivolumab-ipilimumab) en nuestro centro entre \nenero 2018 y marzo 2022. \n \nSe obtuvieron de la historia cl\u00ednica electr\u00f3nica las siguientes variables: sexo, edad, efectos adversos y motivo de \nsuspensi\u00f3n del tratamiento. Del programa onco-hematol\u00f3gico de prescripci\u00f3n electr\u00f3nica se obtuvieron los siguientes \ndatos: tipo de anticuerpo monoclonal y fecha de inicio y fin del tratamiento. La toxicidad se evalu\u00f3 seg\u00fan los criterios \nCTCAE v5 (Common Terminology Criteria for Adverse Events) del NCI (National Cancer Institute).\nRESULTADOS\nDurante el periodo de estudio iniciaron tratamiento con inmunoterapia 52 pacientes (53,9% hombres), con una mediana \nde edad de 66 a\u00f1os (11-89). El 21,2% (11) recibieron tratamiento con m\u00e1s de un anticuerpo monoclonal. El 44,2% (23) \nfueron tratados con pembrolizumab, el 57,7 % (30) con nivolumab y el 21,2 % (11) con nivolumab-ipilimumab.  \n \nEntre los pacientes tratados con pembrolizumab, el 82,6% (19) presentaron toxicidad atribuible a inmunoterapia, siendo \nlos efectos adversos m\u00e1s comunes: astenia (11), prurito (8), artralgia (3), hipotiroidismo (3) y neumonitis (3). El 26,1% (6) \nrequirieron aplazamiento de dosis por toxicidad y el 13% (3) suspensi\u00f3n definitiva del tratamiento por toxicidad grave: 1 \npor debut de diabetes mellitus, 1 por neumonitis y 1 por reacci\u00f3n cut\u00e1nea. \n \nEntre los pacientes tratados con nivolumab, el 70% (21) presentaron toxicidad atribuible a inmunoterapia, siendo \nlos efectos adversos m\u00e1s comunes: prurito (10), astenia (7), artralgia (7) e hipopigmentaci\u00f3n cut\u00e1nea (4). El 20% (6) \nrequirieron aplazamiento de dosis por toxicidad y el 13,3% (4) suspensi\u00f3n definitiva del tratamiento por toxicidad grave: 1 \npor nefritis, 1 por neumonitis, 1 por neuropat\u00eda y 1 por polimialgia.  \n \nEntre los pacientes tratados con nivolumab-ipilimumab, el 54,5% (6) presentaron toxicidad atribuible a inmunoterapia, \nsiendo el prurito (3) la m\u00e1s frecuente. El 27,3% (3) requirieron aplazamiento de dosis por toxicidad y el 18,2% (2) 371suspensi\u00f3n definitiva del tratamiento por toxicidad grave: 1 por uve\u00edtis y 1 por alteraci\u00f3n de la funci\u00f3n hep\u00e1tica. \n \nEntre los pacientes que recibieron una o m\u00e1s l\u00edneas de inmunoterapia, el 76,9% (40) sufrieron alg\u00fan tipo de toxicidad, \nsiendo las m\u00e1s frecuentes: toxicidad cut\u00e1nea (26), malestar general (20), alteraciones del sistema m\u00fasculo-esquel\u00e9tico \n(11), alteraciones endocrinas (6) y toxicidad gastrointestinal (6). En el 26,9% (14) se retras\u00f3 alguna dosis por toxicidad y \nen el 17,3% (9) se suspendi\u00f3 el tratamiento por toxicidad grave.\nCONCLUSIONES\nNuestra experiencia en la pr\u00e1ctica cl\u00ednica real muestra que los anticuerpos monoclonales estudiados presentan un perfil \nde seguridad favorable y una toxicidad menor a la descrita en estudios pivotales. Los efectos adversos observados est\u00e1n \ndescritos en ficha t\u00e9cnica. \n \nLa inmunoterapia se posiciona en las primeras l\u00edneas del tratamiento del melanoma metast\u00e1sico. Su amplio uso \ncontribuye a la importancia de analizar su seguridad en la pr\u00e1ctica cl\u00ednica diaria.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1009. BELANTAMAB MAFODOTINA EN MIELOMA MULTIPLE: SEGURIDAD Y EFECTIVIDAD \nAUTORES\nPERALES PASCUAL, J; MERCHANTE ANDREU, M; LOPEZ PEREZ, A; HERRANZ BAYO, E; AGUILO LAFARGA, I; PE\u00d1AS \nFERNANDEZ, A; D\u00cdAZ-CALDER\u00d3N HORCADA, CI\nHOSPITAL UNIVERSITARIO MIGUEL SERVET . P\u00ba DE ISABEL LA CAT\u00d3LICA, 1-3 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nEvaluar la efectividad y la seguridad de belantamab mafodotina en monoterapia en el tratamiento de mieloma m\u00faltiple \nen reca\u00edda/refractario (MMr/r) en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Criterios de inclusi\u00f3n: Pacientes mayores de 18 a\u00f1os que iniciaron tratamiento con \nbelantamab desde julio 2020 a abril 2022.  \nVariables de estudio: ECOG, edad, sexo, peso, a\u00f1os desde el diagn\u00f3stico, tipo de MM, estadio, n\u00famero de ciclos, n\u00famero \nde l\u00edneas previas, posolog\u00eda, porcentaje de pacientes que precisaron una reducci\u00f3n de dosis, interrupci\u00f3n del tratamiento \ny efectos adversos. La efectividad se valor\u00f3 mediante el tiempo de progresi\u00f3n y la seguridad de acuerdo a los criterios \nCommon Terminology Criteria for Adverse eventes. Fuente de datos: Historia cl\u00ednica electr\u00f3nica y programa inform\u00e1tico \nOncowin\u00ae. An\u00e1lisis estad\u00edstico: programa Excell\u00ae.\nRESULTADOS\nSe incluyeron 8 pacientes (3 hombres, edad media 71,5 [54-82] a\u00f1os, peso medio 74 [56-83] Kg). Siete de ellos \npresentaban MM IgG y 1 IgA. Al diagn\u00f3stico 3 pacientes presentaban estadio III-B y 5 estadio III-A, 4 con ECOG-1 y 4 con \nECOG-2. La mediana de a\u00f1os desde el diagn\u00f3stico al inicio de tratamiento con belantamb fueron 5,5. Un paciente inici\u00f3 \nbelantamab en s\u00e9ptima l\u00ednea, 3 en quinta , 3 en cuarta, 1 en tercera y 1 en s\u00e9ptima. La mediana de ciclos recibidos fueron \n4 [1 - 24].  \nSe observaron microquistes o queratopat\u00eda grave en 2 de los pacientes, moderada en 2 pacientes y leve en 3. \u00danicamente \nun paciente desarroll\u00f3 na\u00faseas/v\u00f3mitos. Un paciente present\u00f3 ligera elevaci\u00f3n de las cifras de ALT y 7 de AST (en todos \nlos casos < 1,5LSN). Dos pacientes presentaron trombocitopenia en G3, 3 pacientes en G2, y 3 pacientes en G1. No se \nreportaron eventos de grado 4 o 5\ufffd  \nEl 100% de los pacientes iniciaron tratamiento a 2,5mg/kg, 3 de ellos precisaron disminuci\u00f3n de dosis a 1,9mg/kg, y \n1 de ellos a 1,3mg/kg. Uno de los pacientes tuvo reducci\u00f3n de dosis por trombocitopenia (G3) y 3 discontinuaron el \ntratamiento reduciendo dosis en la reanudaci\u00f3n por toxicidad ocular \ufffd \n\u00danicamente dos de los ocho pacientes han progresado al tratamiento con Belantamab (mediana de tiempo de progresi\u00f3n \n1,5 meses), los 6 pacientes restantes contin\u00faan en tratamiento (actualmente los pacientes presentan duraciones de \ntratamiento de: 25,4 meses, 8,5 meses, 7,2 meses dos pacientes, 6,2 meses y 2,2meses respectivamente).\nCONCLUSIONES\nTodos los pacientes presentaron alg\u00fan efecto adverso descrito en ficha t\u00e9cnica siendo \u00fanicamente necesario discontinuar \no disminuir dosis por toxicidad ocular o trombocitopenia\ufffd  \nEn el ensayo Fase-II DREAMM-2 se report\u00f3 una mediana de SLP de 2.8 meses, para los dos pacientes que progresaron, \nel tiempo de progresi\u00f3n fue inferior. En el momento del an\u00e1lisis, cinco pacientes (62.5%) han superado ampliamente ese \ntiempo.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1017. IMPLEMENTACI\u00d3N DEL GENOTIPADO DE UGT ANTICIPADO EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nPERALES PASCUAL, J; LARRODE LECI\u00d1ENA, I; AGUST\u00cdN FERRANDEZ, MJ; CAZORLA PODEROSO, L; P\u00c9REZ MORENO, \nM; HERRANZ BAYO, E\nHOSPITAL UNIVERSITARIO MIGUEL SERVET . P\u00ba DE ISABEL LA CAT\u00d3LICA, 1-3 ZARAGOZA. ZARAGOZA372OBJETIVOS\nEn Octubre de 2021 se implement\u00f3 la determinaci\u00f3n del gen uridindifosfatoglucuronosiltransferasa 1A1 (UGT1A1), que \ncodifica para la enzima uridinodifosfatoglucuronosil transferasa, enzima fundamental en el metabolismo del irinotec\u00e1n y \nnal-irinotecan.  \nEl objetivo de este trabajo es evaluar el impacto de la implementaci\u00f3n de la farmacogen\u00e9tica del gen UGT en un hospital \nde tercer nivel\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se analizan los resultados tras la implementaci\u00f3n del genot\u00edpado del gen \nUGT1A1; se analiza la presencia de polimorfismos en la regi\u00f3n promotora del gen. El paciente puede presentar reducci\u00f3n \nde la actividad enzim\u00e1tica presentando polimorfismo en heterocigosis (*1*28) o en homocigosis (*28*28).  \nDatos recogidos: sexo, edad, patolog\u00eda, estadio, intenci\u00f3n de tratamiento, polimorfismo, porcentaje de pacientes con \nreducci\u00f3n de dosis y toxicidad. Los datos se analizaron con el programa inform\u00e1tico Excel\u00ae.\nRESULTADOS\nDe octubre 2021 a abril 2022 se ha realizado el genotipado de UGT a 60 pacientes, 35 (57%) hombres (mediana de edad \nde 67 a\u00f1os [33-87]). Los c\u00e1nceres que padecen un mayor porcentaje de pacientes son: p\u00e1ncreas 26,6% (16/60), g\u00e1strico \n26,6% (16/60), esof\u00e1gico 16,6% (10/60), colon 13,3% (8/60) y hep\u00e1tico 6,7% (4/6). La mayor\u00eda en estadios IV 64,9% \n(37/57) o III 28,1% (16/57). Un 21,1% (12/57) de pacientes reciben tratamiento con intenci\u00f3n neoadyuvante, 15,8% \n(9/57) adyuvante y 64,9%(37/57) paliativa (se desconoce el estadio y la intenci\u00f3n de tratamiento de 3 pacientes).  \nUn 51,7% (31/60) de los pacientes presentan el alelo UGT1A1 *1/*1, el 36,6% (22/60) el alelo UGT1A1 *1/*28 y el \n11,6% (7/60) el alelo UGT1A1 *28/*28. El 71,4% (5/7) de los pacientes homocigotos 28*28 no iniciaron tratamiento con \nirinotecan tras el genotipado. El 28,6% (2/7) restante hab\u00edan iniciado tratamiento con irinotecan previo al genotipado \ndesarrollando toxicidad hematol\u00f3gica (neutropenia, trombocitopenia y/o anemia) y requiriendo reducci\u00f3n de dosis \n(reducci\u00f3n del 33% y del 30%). El 4,5% (1/22) de los pacientes heterocigotos *1/*28 y el 3,2% (1/31) de los pacientes \nque presentaban el alelo UGT1A1 *1/*1 iniciaron tratamiento con irinotecan tras el genotipado sin requerir reducci\u00f3n de \ndosis posterior, el resto de pacientes actualmente a\u00fan no han iniciado tratamiento.\nCONCLUSIONES\nLa implantaci\u00f3n de farmacogen\u00e9tica mediante un protocolo multidisciplinar, permite personalizar la dosis del paciente, \nlo que se traduce en una disminuci\u00f3n de la toxicidad en pacientes candidatos a tratamiento con irinotecan. Los pacientes \nportadores del polimorfismo UGT1A1*28/*28 si hubiesen sido genotipados previamente al inicio del tratamiento \nprobablemente hubiesen experimentado buena tolerancia a la dosis ajustada desde la primera dosis.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1030. EXPERIENCIA DE USO DE NIVOLUMAB EN PACIENTES CON LINFOMA DE HODGKIN CL\u00c1SICO EN \nRECA\u00cdDA O REFRACTARIOS EN UN HOSPITAL ONCOHEMATOL\u00d3GICO \nAUTORES\nPORREDON ANTELO, C; MU\u00d1OZ S\u00c1NCHEZ, C; ESTEBAN GONZ\u00c1LEZ, J\u00c1; MART\u00cdNEZ BENAVIDES, J; MONTERO P\u00c9REZ, \nO; FONTANALS MART\u00cdNEZ, S\nICO L\u2019HOSPITALET . AVDA. GRAN VIA, 2032,7 HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nOBJETIVOS\nEn Espa\u00f1a, nivolumab tiene la indicaci\u00f3n aprobada y financiada para el tratamiento en monoterapia de pacientes adultos \ncon linfoma de Hodgkin cl\u00e1sico en reca\u00edda o refractarios (LHc R/R) despu\u00e9s de trasplante aut\u00f3logo de progenitores \nhematopoy\u00e9ticos (autoTPH) y de tratamiento con brentuximab vedotina (BV).  \nEl objetivo es comparar el grado de adecuaci\u00f3n existente entre la pr\u00e1ctica cl\u00ednica y la indicaci\u00f3n aprobada y financiada en \nel estado espa\u00f1ol y a su vez evaluar la efectividad en nuestra poblaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, retrospectivo de pacientes con LHc R/R tratados con nivolumab en un centro monogr\u00e1fico \noncohematol\u00f3gico, entre septiembre de 2015 y abril de 2022. Se revisaron las historias cl\u00ednicas informatizadas, la \nherramienta de prescripci\u00f3n electr\u00f3nica de tratamientos oncohematol\u00f3gicos y la base de datos de medicamentos \nespeciales del centro\ufffd  \nDatos recopilados: edad, sexo, l\u00edneas terap\u00e9uticas recibidas (incluyendo autoTPH o trasplante alog\u00e9nico de progenitores \nhematopoy\u00e9ticos (aloTPH)), respuesta a nivolumab, duraci\u00f3n de la respuesta y motivo de discontinuaci\u00f3n del \ntratamiento\ufffd\nRESULTADOS\nOcho pacientes diagnosticados de LHc R/R recibieron nivolumab en monoterapia con una mediana de edad de 54 a\u00f1os \n(34-62), el 50% eran mujeres y la mediana de l\u00edneas terap\u00e9uticas previas fue de 4 (3-5).  \nRespecto al trasplante de progenitores hematopoy\u00e9ticos (TPH), 2 pacientes recibieron TPH previo a nivolumab (uno \nautoTPH y aloTPH y otro aloTPH); 2 pacientes recibieron TPH despu\u00e9s de nivolumab (uno autoTPH y otro aloTPH); el resto \nde los pacientes (4/8) no recibi\u00f3 ning\u00fan TPH. Todos los pacientes recibieron BV previo a nivolumab (4 en monoterapia y 4 \nen combinaci\u00f3n con quimioterapia).  \nLa mediana de duraci\u00f3n de la respuesta con nivolumab fue de 9,3 meses (6,6-11). El 50% de los pacientes en el momento \nde la revisi\u00f3n continuaban en tratamiento manteniendo una respuesta parcial medida mediante PET/TC, destacando 373un paciente en tratamiento durante 79 meses y despu\u00e9s de 9 l\u00edneas terap\u00e9uticas previas (incluyendo un autoTPH y un \naloTPH). 4 pacientes discontinuaron el tratamiento con nivolumab: 2 para recibir un TPH (uno autoTPH y otro aloTPH) \ny 2 por progresi\u00f3n. Ning\u00fan paciente interrumpi\u00f3 el tratamiento por efectos adversos. Los 2 pacientes que recibieron \nnivolumab previo a un TPH segu\u00edan en respuesta completa mediante PET/TC despu\u00e9s de 6 y 38 meses del TPH.  \nEn nuestro centro, ninguno de los 8 pacientes con LHc R/R tratados con nivolumab present\u00f3 una situaci\u00f3n cl\u00ednica que \nse ajustara a la indicaci\u00f3n aprobada para el f\u00e1rmaco, trat\u00e1ndose de indicaciones fuera de ficha t\u00e9cnica (FFT). Todos los \ntratamientos se realizaron previa autorizaci\u00f3n del centro, en contexto de medicamentos especiales.\nCONCLUSIONES\nLos hallazgos del estudio indican que la situaci\u00f3n cl\u00ednica de nuestros pacientes no se adecu\u00f3 a la indicaci\u00f3n aprobada del \nf\u00e1rmaco. No obstante, los resultados de efectividad obtenidos en la muestra evaluada se consideran positivos, si bien es \nnecesario el seguimiento de los resultados obtenidos. Por lo tanto, nivolumab podr\u00eda plantearse como opci\u00f3n terap\u00e9utica \nFFT en casos muy seleccionados de poblaci\u00f3n politratada y con pocas o nulas opciones terap\u00e9uticas.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1035. EFECTIVIDAD Y SEGURIDAD DE TRASTUZUMAB-EMTANSINA EN SEGUNDA L\u00cdNEA DE C\u00c1NCER DE \nMAMA METAST\u00c1SICO TRAS PRIMERA LINEA CON DOBLE BLOQUEO HER-2. \nAUTORES\nESPINA LOZANO, JM; ARTACHO CRIADO, S; JIM\u00c9NEZ GAL\u00c1N, R; GALV\u00c1N BANQUERI, M; RODR\u00cdGUEZ DE LA BORBOLLA \nARTACHO, M; ROLD\u00c1N GALNARES, M; M\u00c1RQUEZ SAAVEDRA, E\nHOSPITAL NUESTRA SE\u00d1ORA DE VALME. CTRA. C\u00c1DIZ-BELLAVISTA, KM. 548,9 SEVILLA. SEVILLA\nOBJETIVOS\nEvaluar la efectividad y seguridad de la utilizaci\u00f3n de trastuzumab-emtansina (TDM-1) en pacientes con c\u00e1ncer de mama \nmetast\u00e1sico en segunda l\u00ednea de tratamiento.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, multic\u00e9ntrico y multidisciplinar en el que se incluyeron todos los pacientes tratados \ncon trastuzumab-emtansina en segunda l\u00ednea de tratamiento del c\u00e1ncer de mama metast\u00e1sico.  \nSe recogieron de la historia cl\u00ednica las siguientes variables: edad, variables cl\u00ednicas al inicio del tratamiento [pre/\npostmenop\u00e1usicas, puntuaci\u00f3n en la escala Eastern Cooperative Oncology Group (ECOG)], patol\u00f3gicas [debut \nmetast\u00e1sico, localizaci\u00f3n de las met\u00e1stasis, estado de los receptores hormonales (RH), \u00edndice de proliferaci\u00f3n celular (Ki-\n67)] y l\u00edneas anteriores y posteriores de tratamiento recibidas.  \nLas variables de efectividad fueron: tasa de respuesta objetiva (TRO), duraci\u00f3n de la respuesta global, supervivencia libre \nde progresi\u00f3n (SLP) y supervivencia global (SG). Las variables de seguridad fueron: porcentaje de pacientes con efectos \nadversos (EA) y con EA grado 3-4, seg\u00fan criterios Common Terminology Criteria for Adverse Events 5.0 y porcentaje de \npacientes con reducci\u00f3n de dosis por toxicidad. Para calcular SLP y SG se aplic\u00f3 el m\u00e9todo de Kaplan-Meier.\nRESULTADOS\nSe incluyeron 34 mujeres, con una mediana de edad de 59 a\u00f1os (RIC=50-70), siendo un 82,4% postmenop\u00e1usicas. El \n85,2% de las pacientes presentaron un ECOG 0-1 al inicio del tratamiento.  \nEl 41,2% de las pacientes presentaban enfermedad metast\u00e1sica al diagn\u00f3stico. Las principales localizaciones metast\u00e1sicas \nfueron: hep\u00e1tica (55,0%), \u00f3sea (41,2%), pulmonar (38,2%) y ganglionar (32,4%).Un 64,7% de las pacientes presentaron \nRH positivos y un 71,4% presentaban un \u00edndice de proliferaci\u00f3n celular elevado (ki-67 > 20%). El 44,1% de las pacientes \nrecibieron bloqueo HER2 con trastuzumab en adyuvancia. El 88,2% recibi\u00f3 doble bloqueo HER2-con pertuzumab + \ntrastuzumab como quimioterapia en primera l\u00ednea de enfermedad metast\u00e1sica previo a TDM-1 frente al 11,8% que \nrecibi\u00f3 bloqueo simple (trastuzumab o lapatinib asociado a la quimioterapia). Un 64,7% de las pacientes recibieron al \nmenos 1 l\u00ednea posterior de tratamiento [mediana: 1; rango: 0-8].  \nLa TRO fue del 23,5% (8,8% respuesta completa y 14,7% respuesta parcial), un 44,1% presentaron enfermedad estable y \nun 29,4% progresi\u00f3n de la enfermedad\ufffd \nA fecha de corte del an\u00e1lisis (abril 2022), con una mediana de seguimiento de 38 meses, el 85,3% de las pacientes hab\u00edan \nprogresado al tratamiento con TDM-1 y el 44,1% de las pacientes hab\u00edan fallecido. Las medianas de SLP y SG obtenidas \nfueron de 7,1 meses (IC 95% 4,4-9,9) y 45,5 meses (IC 95% 24,2-66,8), respectivamente.  \nEl 73,5% presentaron EA grado 1-2, mientras que s\u00f3lo se report\u00f3 un caso de toxicidad grado 3 (trombopenia). Los EA m\u00e1s \nfrecuentes fueron: astenia (50,0%), toxicidad hematol\u00f3gica (11,7%), n\u00e1useas (5,9%), diarrea (5,9%) y mucositis (8,8%). La \ndosis de TDM-1 tuvo que ser reducida por toxicidad en un 5,9% de las pacientes.\nCONCLUSIONES\nEl tratamiento con trastuzumab-emtansina en segunda l\u00ednea de c\u00e1ncer de mama metast\u00e1sico tras una primera l\u00ednea \ncon doble bloqueo HER2 presenta similares resultados de efectividad a los del ensayo pivotal, teniendo en cuenta que \nnuestros pacientes difieren de la poblaci\u00f3n del ensayo, la cual hab\u00eda recibido simple bloqueo HER2. Los efectos adversos \nfueron los esperados para este f\u00e1rmaco.374CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1051. EFECTIVIDAD Y SEGURIDAD DE PALBOCICLIB EN C\u00c1NCER DE MAMA METAST\u00c1SICO O LOCALMENTE \nAVANZADO \nAUTORES\n\u00c1LVAREZ CRIADO, J; GARC\u00cdA-TREVIJANO CABETAS, M; HERRERO AMBROSIO, A\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nEvaluar la efectividad y seguridad de palbociclib en pacientes con c\u00e1ncer de mama localmente avanzado o metast\u00e1sico \n(CMM) en pr\u00e1ctica cl\u00ednica habitual.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, descriptivo de todas las pacientes con c\u00e1ncer de mama metast\u00e1sico (CMM) tratadas \ncon palbociclib entre enero 2016 y diciembre 2021. Los datos se obtuvieron a trav\u00e9s de la historia cl\u00ednica electr\u00f3nica, \nm\u00f3dulo de dispensaci\u00f3n a pacientes externos y de prescripci\u00f3n de tratamientos oncol\u00f3gicos\ufffd Se recogieron variables \ndemogr\u00e1ficas como y cl\u00ednicas: edad, estado menop\u00e1usico, estado funcional seg\u00fan la escala Eastern Cooperative Oncology \nGroup (ECOG), n\u00famero de met\u00e1stasis y tratamiento hormonal asociado. Para medir la efectividad, se utiliz\u00f3 tasa de \nsupervivencia libre de progresi\u00f3n al a\u00f1o y segundo a\u00f1o de tratamiento\ufffd Para evaluar la seguridad se registr\u00f3 la toxicidad \nG3-G4 asociada al tratamiento, usando como referencia la clasificaci\u00f3n Common Terminology Criteria for Adverse Events \n(CTCAE V5.0). Adem\u00e1s, se recogieron las reducciones de dosis derivadas de la toxicidad.\nRESULTADOS\nSe incluyeron 174 pacientes que recibieron palbociclib durante el per\u00edodo de estudio. La mediana de edad fue de 62 \na\u00f1os (RIC 53-73); la mayor\u00eda (84%) postmenop\u00e1usicas. El n\u00famero medio de met\u00e1stasis fue 1,82 (DE \u00b1 0,92). El 74% hab\u00eda \nrecibido hormonoterapia previa: 43% letrozol, 42% tamoxifeno, 14% anastrozol y 1% exemestano. En relaci\u00f3n al ECOG al \ninicio del tratamiento: el 39% presentaban ECOG 0, 49% ECOG 1, 10% ECOG 2 Y 1% ECOG 3\ufffd El tratamiento concomitante \nhormonal fue letrozol en el 52% de las pacientes, fulvestrant en el 44% y exemestano en el 4%.  \nEn cuanto a la efectividad, la tasa supervivencia libre de progresi\u00f3n al a\u00f1o fue del 59,7%, mientras que al segundo a\u00f1o \neste porcentaje descendi\u00f3 a un 20,8%. En el momento del an\u00e1lisis, 55 (32%) pacientes hab\u00edan fallecido. La mediana de \nseguimiento fue de 20,01 meses\ufffd  \nEn el momento de corte del estudio, 67 pacientes continuaban en tratamiento, mientras que 107 lo hab\u00edan suspendido. \nLos motivos de suspensi\u00f3n de tratamiento fueron progresi\u00f3n (n=84) y toxicidad (n=23), destacando 44% por toxicidad \nhematol\u00f3gica, 22 % gastrointestinal, 10% hep\u00e1tica. Un 37,62% de las pacientes precis\u00f3 reducciones de dosis al nivel -1, \nprincipalmente por neutropenia (84%), y hasta 43% de los que hab\u00edan requerido una reducci\u00f3n, necesitaron una segunda \nreducci\u00f3n adicional. En cuanto a la toxicidad hematol\u00f3gica y hep\u00e1tica, el 22% de las pacientes present\u00f3 leucopenia G3-4, \n56% neutropenia G3-4, 4% anemia G3-4, 3% trombocitopenia G3-4 y 4% aumento de AST y ALT G3-4.\nCONCLUSIONES\nLa tasa de supervivencia libre de met\u00e1stasis al a\u00f1o y a los dos a\u00f1os de las pacientes con CMM de nuestro estudio tratadas \ncon palbociclib fue similar a la reportada en los ensayos cl\u00ednicos.  \nEl perfil de toxicidad de palbociclib tambi\u00e9n fue similar al reportado previamente, siendo manejable con reducciones de \ndosis en un porcentaje de pacientes semejante al de los ensayos cl\u00ednicos pivotales.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1063. TOXICIDAD AUTO-INFORMADA POR LAS PACIENTES (PRO-CTCAE) EN TRATAMIENTO CON \nINHIBIDORES DE CICLINAS EN C\u00c1NCER DE MAMA METAST\u00c1SICO \nAUTORES\nOTERINO MOREIRA, I; SANMARTIN FENOLLERA, P; ZHAN ZHOU, E; P\u00c9REZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nDescribir resultados de toxicidad auto-informada (Patient Reported Outcome, PRO) de palbociclib y ribociclib en c\u00e1ncer \nde mama metast\u00e1sico.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo de intervenci\u00f3n realizado entre Junio 2019- Junio 2021. El farmac\u00e9utico proporcion\u00f3 a las pacientes \ntratadas con palbociclib/ ribociclib un cuestionario PRO (elaborado seg\u00fan criterios PRO-CTCAE Item Library v1.0) \nque define los efectos adversos (EA) en forma de preguntas al paciente que describen la frecuencia, gravedad y/o \ninterferencia con las actividades diarias.  \n \nSe analizaron 13 EA (definidos en la ficha t\u00e9cnica) en 24 preguntas. Las respuestas se reportaron en una escala de tipo \nsumativo de cinco puntos de Likert (0-4). Se incluyeron adem\u00e1s dos preguntas extra\u00eddas del cuestionario de calidad \nde vida EORTC QLQ-C30 v.3 y un espacio de escritura libre para aquellos s\u00edntomas que la paciente quisiera informar \nlibremente\ufffd \n \nLa literatura aporta una toxicidad similar para palbociclib y ribociclib de modo que para el objetivo de este trabajo se \nanalizaron conjuntamente.375RESULTADOS\nSe incluyeron 40 mujeres con una mediana de edad de 55 a\u00f1os (Rango Intercuart\u00edlico, RIC 48-71), de las que 23 recibieron \npalbociclib y 17 ribociclib. La mediana de l\u00ednea paliativa fue 1 (RIC 1-2) y la mediana del ciclo en la que se entreg\u00f3 el \ncuestionario 14 (RIC 10-20).  \n \nEl dolor muscular fue el EA m\u00e1s informado (89,5%), seguido de astenia/fatiga (84,2%), sequedad de piel (83,8%), \nartralgias (81,6%), sofocos (76,3%), lagrimeo (58,3%), visi\u00f3n borrosa (50,0%), ca\u00edda del pelo (48,6%), diarrea (35,1%), \ndisminuci\u00f3n apetito (29,7%), n\u00e1useas (28,9%), sarpullido (13,5%) y v\u00f3mitos (8,1%). El 44,8% report\u00f3 otro EA, en su \nmayor\u00eda relacionado con el aparato digestivo (p\u00e9rdida del gusto, gases, reflujo, aftas, dolor de est\u00f3mago).  \n \nEl dolor muscular, los sofocos, las artralgias, las n\u00e1useas y la diarrea suced\u00edan con una frecuencia \u22653 puntos en la escala \nLikert (a menudo/casi siempre) en el 44,7%, 39,5%, 36,8%, 7,9% y 5,4% de las pacientes, respectivamente  \n \nLos siguientes EA aparecieron con una intensidad \u22653 puntos en la escala Likert (intensa/muy intensa): dolor muscular en \nel 36,8% de las pacientes, sofocos en el 31,6%, artralgias en el 23,7%, sequedad de piel en el 18,9%, lagrimeo en el 18,9%, \nastenia/fatiga en el 15,8%, visi\u00f3n borrosa en el 8,3%, alopecia en el 8,1%, disminuci\u00f3n apetito en el 2,7% y n\u00e1useas en el \n2,6% de las pacientes\ufffd \n \nEn cuanto al grado de interferencia con las actividades diarias, la astenia/fatiga, lagrimeo, visi\u00f3n borrosa, artralgias, dolor \nmuscular y disminuci\u00f3n apetito fueron reportados con \u22653 puntos en la escala Likert (mucho/much\u00edsimo) por el 75,0%, \n13,9%, 11,1%, 10,5%, 7,9% y 2,7% de las pacientes, respectivamente. \n \nEl 73,0% de las pacientes afirm\u00f3 que su salud general y calidad de vida era buena/muy buena.\nCONCLUSIONES\nEl dolor muscular, los sofocos y las artralgias fueron los EA que aparecieron con mayor frecuencia y tambi\u00e9n los m\u00e1s \nintensos, aunque para la mayor\u00eda de las pacientes el grado de interferencia con las actividades diarias fue bajo.  \n \nLos autoinformes PRO-CTCAE proporcionan informaci\u00f3n complementaria a las evaluaciones de seguridad de los cl\u00ednicos \n(CTCAE), favoreciendo la detecci\u00f3n precoz y manejo de los EA.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1071. EFECTIVIDAD DE PALBOCICLIB CON TRATAMIENTO HORMONAL VS TRATAMIENTO HORMONAL \nEN PRIMERA L\u00cdNEA EN C\u00c1NCER DE MAMA AVANZADO O METAST\u00c1SICO (HR+/HER2-) \nAUTORES\nABDELKADER MART\u00cdN, L; JIM\u00c9NEZ GAL\u00c1N, R; PRADO MEL, E; FERN\u00c1NDEZ GONZ\u00c1LEZ, M; VEGA COCA, MD; FLORES \nMORENO, S\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nPalbociclib con tratamiento hormonal (TH) es actualmente el tratamiento de elecci\u00f3n en pacientes con c\u00e1ncer de mama \navanzado (CMA) con receptor hormonal positivo y HER-2 negativo (HR+/HER2-) no tratadas previamente, en base a los \nresultados en t\u00e9rminos de supervivencia libre de progresi\u00f3n (SLP), fundamentalmente, del ensayo cl\u00ednico aleatorizado \npivotal PALOMA-2. Si bien, se desconoce la eficacia en t\u00e9rminos de supervivencia global (SG), especialmente en la \npr\u00e1ctica cl\u00ednica habitual en nuestro entorno.  \nEl objetivo de este estudio es valorar la efectividad de palbociclib en primera l\u00ednea de tratamiento en enfermedad \nlocalmente avanzada o metast\u00e1sica en combinaci\u00f3n con TH (letrozol o fulvestrant) vs TH en base a la experiencia en \npr\u00e1ctica cl\u00ednica habitual.\nMATERIALES Y M\u00c9TODOS\nSe llev\u00f3 a cabo un estudio retrospectivo de pacientes con CMA RH+/HER2-, en tratamiento de primera l\u00ednea con \npalbociclib con TH vs TH, entre junio 2016 y abril 2022. Variables sociodemogr\u00e1ficas, cl\u00ednicas y de laboratorio fueron \nrecogidos de las historias cl\u00ednicas electr\u00f3nicas y registro de laboratorio. La efectividad se valor\u00f3 mediante las variables \nSLP y SG. El an\u00e1lisis estad\u00edstico se llev\u00f3 a cabo con el software SPSS v.18. Se realiz\u00f3 un an\u00e1lisis de supervivencia a trav\u00e9s \ndel m\u00e9todo de Kaplan-Meier, y la prueba de Mantel-Haenszel (test de logrank) para estimar la mediana de SLP y SG. Se \nrealiz\u00f3 un an\u00e1lisis multivariante a trav\u00e9s de regresi\u00f3n log\u00edstica de Cox para estimar la tasa de riesgos proporcionales (HR) \npara SLP y SG, ajustada por posibles variables confundidoras del efecto.\nRESULTADOS\nUn total de 116 pacientes cumplieron los criterios de inclusi\u00f3n. La mediana de edad (\u00b1DE) fue de 55,3 (\u00b112,7). El 8,8% \npresent\u00f3 ECOG \u22652. El 45,8% debut\u00f3 s\u00f3lo con met\u00e1stasis \u00f3seas y el 27,4% s\u00f3lo con met\u00e1stasis viscerales. El 92,2 % \npresent\u00f3 < 3 met\u00e1stasis al diagn\u00f3stico. El 39,5% de las pacientes recibieron palbociclib con letrozol, 37,8% palbociclib \ncon fulvestrant, 9,2% letrozol, 5,9% fulvestrant, 4,2% anastrozol y el 1,8% otros TH. La mediana de PFS fue de 36 \nmeses (IC95%: 22,8-49,2) en las pacientes en tratamiento con palbociclib con TH vs 15 meses IC95% (8.1-21.9) en las \nque recibieron TH en monoterapia. La mediana de SG fue de 51 meses (IC95%:37,3-64,7) vs. 30 meses (IC95%:12-48), \nrespectivamente. La HR en t\u00e9rminos de SLP fue de 0,4 (IC95%: 0,257-0,789) y de 0,51 para la SG (IC95%: 0,265-0,987). El \n65,6% de las pacientes con palbociclib con TH desarrollaron neutropenia grado 3-4.376CONCLUSIONES\nPalbociclib con TH versus TH en primera l\u00ednea de tratamiento, en pacientes con c\u00e1ncer de mama avanzado HR+/HER2- \nmejora la SLE y la SG, en pr\u00e1ctica cl\u00ednica habitual. Otros estudios que comparen la eficacia entre los distintos inhibidores \nde ciclina disponibles en el mercado ser\u00edan deseables para optimizar la toma de decisiones.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1085. EFICACIA DEL TRATAMIENTO DE ABIRATERONA CON PREDNISONA Y ENZALUTAMIDA EN \nPACIENTES CON C\u00c1NCER DE PR\u00d3STATA RESISTENTE A LA CASTACI\u00d3N METAST\u00c1SICO \nAUTORES\nRIUS PERERA, J; MIR CROS, M; GILABERT SOTOCA, M; MANGUES BAFALLUY , I; MURATA YONAMINE, EP; MIRA FLORES, \nMJ; SCHOENENBERGER ARNAIZ, JA\nHOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA \ufffd AVDA \ufffd ALCALDE ROVIRA ROURE, 80 LLEIDA \ufffd LLEIDA\nOBJETIVOS\nEvaluaci\u00f3n de la eficacia de abiraterona con prednisona versus enzalutamida en pacientes diagnosticados de c\u00e1ncer de \npr\u00f3stata resistente a la castraci\u00f3n (CPRC) metast\u00e1sico en los cuales la quimioterapia no est\u00e1 a\u00fan cl\u00ednicamente indicada.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 pacientes tratados como m\u00ednimo con dos ciclos de abiraterona o \nenzalutamida entre febrero 2016 - 2022. Las variables recogidas fueron: edad, fecha de inicio de tratamiento, fecha de \nprogresi\u00f3n y fecha de exitus, valores de PSA al inicio, a los 6 y a los 12 meses. Estos datos se recogieron de la historia \ncl\u00ednica informatizada.  \nComo variable principal se evalu\u00f3 la eficacia en t\u00e9rminos de supervivencia libre de progresi\u00f3n (SLP) y supervivencia global \n(SG).  \nLa EMA aprob\u00f3 la indicaci\u00f3n de abiraterona en CPRC M1 pre docetaxel seg\u00fan los resultados del ensayo cl\u00ednico fase III COU \nAA-302 de 1088 pacientes y enzalutamida seg\u00fan los resultados del ensayo cl\u00ednico fase III PREVAIL en fase de extensi\u00f3n de \n1717 pacientes. Se evidenci\u00f3 una mediana de SLP de 16.5 meses con una HR 0.52 (IC95%, 0.45-0.61) p < 0.0001 y 20.0 \nmeses con una HR 0.32 (IC95%, 0.28-0.36) p < 0.0001 respectivamente y SG de 34,7 meses con una HR 0.81 (IC95% 0.70-\n0.93) p=0.0033 y 35.3 meses con una HR 0.77 (IC95% 0.67-0.88) p < 0.0002, respectivamente. \nComo variables secundarias se analiz\u00f3: \n- diferencias en SLP y SG entre ambos tratamientos en los pacientes tratados en nuestro centro calculado mediante \nKaplan Meier  \n- disminuci\u00f3n de PSA > 50% a los 6 meses y a los 12 meses de inicio de tratamiento.\nRESULTADOS\nSe incluyeron 87 pacientes, de los cuales 46 fueron tratados con abiraterona m\u00e1s prednisona y 41 con enzalutamida. La \nmedia de edad fue de 78 (56 \u2013 91) a\u00f1os.  \nLa mediana de SLP de nuestros pacientes tratados con abiraterona m\u00e1s prednisona fue de 14.1 meses y la mediana de SG \nde 25\ufffd5 meses, en comparaci\u00f3n con la mediana de SLP de 18\ufffd8 meses y SG de 27\ufffd6 meses de los pacientes tratados con \nenzalutamida.  \nLos resultados de la comparaci\u00f3n entre abiraterona m\u00e1s prednisona y de enzalutamida fueron: SLP (IC95% 0.54-21.62) \np=0.832 y SG (IC95% 0.76-22.86) p=0.3244  \nUn 34.8% de los pacientes tratados con abiraterona m\u00e1s prednisona consiguieron una disminuci\u00f3n de PSA > 50% a los \n6 meses de inicio de tratamiento en comparaci\u00f3n con el 63.4% de los tratados con enzalutamida. A los 12 meses de \ninicio de tratamiento, un 32.6% y un 41.5% de los pacientes tratados con abiraterona m\u00e1s prednisona y enzalutamida, \nrespectivamente, alcanzaron una disminuci\u00f3n de PSA > 50%.\nCONCLUSIONES\nLa SLP y la SG de los pacientes tratados en nuestro centro, es inferior a la reportada en los ensayos cl\u00ednicos pivotales.  \nNo existen diferencias significativas entre los pacientes analizados tratados con abiraterona m\u00e1s prednisona o \nenzalutamida respecto a SLP y SG, aunque los valores sean superiores con enzalutamida.  \nLa disminuci\u00f3n de m\u00e1s del 50% en el valor de PSA es mayor a los 6 meses que a los 12 meses, siendo esta disminuci\u00f3n \nm\u00e1s pronunciada en el caso de los pacientes tratados con enzalutamida.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1092. EFECTIVIDAD DE ERIBULINA EN C\u00c1NCER DE MAMA METAST\u00c1SICO. RESULTADOS EN LA PR\u00c1CTICA \nCLINICA REAL. \nAUTORES\nROMERA GARC\u00cdA, JM; MAYO CANALEJO, B; VICENTE SANCHEZ, MP; RODRIGUEZ MARTINEZ, M\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nEribulina est\u00e1 indicada en el tratamiento de pacientes adultos con c\u00e1ncer de mama localmente avanzado o metast\u00e1sico \n(CMm) tras, al menos, un r\u00e9gimen de quimioterapia (QT) que incluya una antraciclina y un taxano. Adem\u00e1s, su Informe \nde Posicionamiento Terap\u00e9utico (IPT) a\u00f1ade que deben haber recibido capecitabina en este escenario. El objetivo de este \nestudio fue evaluar la efectividad de eribulina para esta indicaci\u00f3n en la pr\u00e1ctica cl\u00ednica real.377MATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, retrospectivo en el que se incluyeron pacientes con CMm tratados con eribulina \n(agosto 2014-mayo 2022). Variables: edad, sexo, diagn\u00f3stico, adyuvancia o neoadyuvancia, localizaci\u00f3n de met\u00e1stasis, \nexpresi\u00f3n de HER-2 y receptores hormonales (RH), QT previa y duraci\u00f3n. La efectividad se determin\u00f3 mediante \nsupervivencia libre de progresi\u00f3n (SLP) y supervivencia global (SG).  \nLos datos fueron obtenidos de la historia cl\u00ednica informatizada (Mambrino XXI\u00ae) y prescripci\u00f3n electr\u00f3nica (Farmis_\nOncofarm\u00ae). El an\u00e1lisis estad\u00edstico se realiz\u00f3 con el programa SPSS Statistics\u00aev23 utilizando la prueba de Long-Rank.\nRESULTADOS\nSe recopil\u00f3 un total de 46 pacientes, todas mujeres, con edad media de 57 a\u00f1os. El diagn\u00f3stico fue carcinoma ductal \ninfiltrante en el 80,4%, siendo el resto carcinoma lobulillar infiltrante. Un 73,9% de las pacientes recibi\u00f3 QT adyuvante \ny el 26,1% neoadyuvante. En cuanto a localizaci\u00f3n de met\u00e1stasis, el 60,9% fueron viscerales (47,8% hep\u00e1ticas, 34,8% \npulmonares, 17,4% cerebrales) y el 39,1% restante fueron \u00f3seas. La expresi\u00f3n HER-2 fue negativa en el 82,6%, positiva en \nel 8,7% y desconocida en un 8,7%; en cuanto a RH, el 71,5% fue positiva y en el restante negativa. Un 95,6% recibi\u00f3 QT \nprevia con taxanos, el 89,1% antraciclinas y el 58,7% capecitabina\ufffd  \nLa duraci\u00f3n media del tratamiento fue de 5,6 meses\ufffd El 93,5% de los pacientes progres\u00f3, con una mediana de SLP de 5,6 \nmeses (rango 0,93-32,27) y un 76% falleci\u00f3, con una mediana de SG de 8,9 meses (rango 0,9-74,8).  \nNo hubo diferencias significativas (p > 0,05) en cuanto a SG y SLP al estudiar las variables met\u00e1stasis viscerales, HER-2 \npositivo, y toma previa de capecitabina.  \nPor el contrario, si se obtuvieron diferencias estad\u00edsticamente significativas en SG y SLP en cuanto a n\u00famero de met\u00e1stasis \n(p=0,026 y p=0,001 respectivamente) y expresi\u00f3n RH positivo (p=0,023 y p=0,027).\nCONCLUSIONES\nEn la pr\u00e1ctica cl\u00ednica real, eribulina ha demostrado una SLP ligeramente favorable respecto a su ensayo pivotal (5,6 vs. 3,6 \nmeses) pero una SG inferior (8,9 vs. 13,2 meses). \nComo era de esperar, las pacientes con mayor n\u00famero de met\u00e1stasis obtuvieron resultados m\u00e1s pobres en cuanto a \nsupervivencia. Adem\u00e1s, cabe destacar que la variable RH positiva resulta estad\u00edsticamente significativa en cuanto a \nefectividad, pero estamos ante una muestra muy modesta como para poder afirmar que este subgrupo se beneficie m\u00e1s \nde este f\u00e1rmaco.  \nTampoco hubo diferencias estad\u00edsticamente significativas en cuanto a efectividad respecto a la toma previa de \ncapecitabina, lo cual apoya los resultados del IPT que posicionan este f\u00e1rmaco como alternativa terap\u00e9utica \nrecomendando su uso previo y relegando el uso de eribulina a l\u00edneas posteriores.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1094. INHIBIDORES DE QUINASAS DEPENDIENTES DE CICLINAS EN C\u00c1NCER DE MAMA: PERSISTENCIA \nAL TRATAMIENTO \nAUTORES\nRODR\u00cdGUEZ JORGE, M; GUZM\u00c1N RAMOS, MI; ROBUSTILLO CORT\u00c9S, MDLA\nCOMPLEJO HOSPITALARIO DE ESPECIALIDADES JUAN RAM\u00d3N JIMENEZ. RONDA NORTE, S/N HUELVA. HUELVA\nOBJETIVOS\nEl c\u00e1ncer de mama es el m\u00e1s frecuente en la poblaci\u00f3n femenina a nivel mundial y la primera causa de muerte por c\u00e1ncer. \nCasi el 70% son de tipo luminal, expresando receptores hormonales. Palbociclib, ribociclib y abemaciclib son potentes \ninhibidores de las quinasas dependientes de ciclinas 4 y 6, estando indicados en el tratamiento del c\u00e1ncer de mama \nlocalmente avanzado o metast\u00e1sico con receptor hormonal positivo.  \nEl objetivo fue evaluar la persistencia al tratamiento de los diferentes inhibidores de quinasas dependientes de ciclinas, \ncon la finalidad de ver si existen diferencias entre ellos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyeron los pacientes en tratamiento con palbociclib, ribociclib y \nabemaciclib desde octubre de 2020 hasta abril de 2022.  \nSe recogieron las variables sexo y edad, estado menop\u00e1usico al diagn\u00f3stico, enfermedad metast\u00e1sica de inicio, \nhormonoterapia concomitante, as\u00ed como quimioterapia y hormonoterapia previa, n\u00famero de ciclos recibidos, tiempo \nhasta la discontinuaci\u00f3n del tratamiento y causa de este a trav\u00e9s del programa Athos y de la historia digital Diraya. \nSe estableci\u00f3 la persistencia como n\u00famero de meses de utilizaci\u00f3n continua de la medicaci\u00f3n. La evoluci\u00f3n de la \npersistencia se obtuvo mediante las curvas de Kaplan-Meier a trav\u00e9s del programa IBM SPSS Statistics 26.\nRESULTADOS\nSe incluyeron 99 pacientes, con una mediana de edad de 59 a\u00f1os (RIC: 51-69), siendo el 98% mujeres. El 83,8% \neran pacientes menop\u00e1usicas al diagn\u00f3stico, y el 32,3% ten\u00edan enfermedad metast\u00e1sica al diagn\u00f3stico. El 46,5% (46 \npacientes) estaban en tratamiento con palbociclib, el 26,3% (26 pacientes) con abemaciclib, y el 27,3% (27 pacientes) con \nribociclib. Un 54,5% de los pacientes recibieron quimioterapia previa, y un 70,7% recibieron hormonoterapia. Respecto \nal tratamiento hormonal concomitante al inhibidor de quinasas dependiente de ciclinas: el 62,6% fueron tratados con \nletrozol, el 31,3% con fulvestrant, el 3% con anastrozol, el 2% no recibieron hormonoterapia concomitante, y el 1% recibi\u00f3 \nexemestano\ufffd  \nEl 56,6% de los pacientes continuaban en tratamiento al finalizar el periodo de estudio, el 26,3% hab\u00eda abandonado por \nprogresi\u00f3n de la enfermedad, y el 17,2% lo hizo por toxicidad.  378La mediana de ciclos completados por la poblaci\u00f3n de estudio fue de 8 (RIC: 4-18), con una mediana de persistencia al \ntratamiento de 8,63 meses (IC95%: 5,62-11,64).  \nDel porcentaje de pacientes que continuaban en tratamiento, la mediana de persistencia fue de 15,6 meses (IC95%: \n10,70-20,54).  \nRespecto a la mediana de persistencia en la poblaci\u00f3n que finaliz\u00f3 el tratamiento, esta fue de 21,10 meses (IC95%: \n13,71-28,50). Si diferenciamos seg\u00fan los distintos f\u00e1rmacos nos da una mediana de 21 meses para palbociclib (IC95%: \n16,9-25,10), de 21,10 meses para abemaciclib (IC95%: 0-45), y de 28,27 meses para ribociclib (IC95%: 1,8-54,74); no hubo \ndiferencias estad\u00edsticamente significativas entre la persistencia de todos ellos (X2= 0,457, p=0,796).\nCONCLUSIONES\nDebido a que no existen diferencias significativas en la persistencia al tratamiento de cada uno de los f\u00e1rmacos en nuestra \npoblaci\u00f3n, se constata el uso de los tres f\u00e1rmacos como equivalentes terap\u00e9uticos en el c\u00e1ncer de mama localmente \navanzado o metast\u00e1sico con receptores hormonales positivos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1104. EFECTIVIDAD Y SEGURIDAD DEL ESQUEMA VRD EN PACIENTES CON MIELOMA M\u00daLTIPLE \nCANDIDATOS A TRASPLANTE \nAUTORES\nDIAZ RAMON, M; CANO MOLINA, JA; GOLNABI DOWLATSHAHI, F; RAMON PEREZ, M; ESPUNY MIRO, A; DIAZ \nCARRASCO, MS\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nEvaluar la efectividad y seguridad del esquema VRd (bortezomib-lenalidomida-dexametasona) como tratamiento de \ninducci\u00f3n (fuera de ficha t\u00e9cnica) seguido de trasplante aut\u00f3logo de progenitores hematopoy\u00e9ticos (TASPE) en pacientes \ncon mieloma m\u00faltiple (MM).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, incluyendo todos los pacientes diagnosticados de MM candidatos a TASPE tratados \ncon el esquema VRd, entre noviembre de 2020 y abril de 2022, en un hospital de tercer nivel. Variables recogidas: sexo, \nedad, tipo de MM, estadio inicial R-ISS, componente monoclonal (CM), c\u00e9lulas plasm\u00e1ticas (CP) clonales en m\u00e9dula \n\u00f3sea (MO), presencia de insuficiencia renal (IR)(ClCr < 40ml/min), lesiones \u00f3seas o plasmocitoma al diagn\u00f3stico, ciclos \nadministrados y recepci\u00f3n del primer y segundo TASPE en t\u00e1ndem. La efectividad se evalu\u00f3 mediante la tasa de respuesta \npost-inducci\u00f3n y post-TASPE. La seguridad se evalu\u00f3 mediante el registro de eventos adversos (EA) y su gravedad seg\u00fan \nlos criterios CTCAE v5.0 y las reducciones de dosis realizadas.\nRESULTADOS\nSe analizaron 16 pacientes, con una mediana de edad de 58 a\u00f1os (29-68), el 76,92% eran hombres. El tipo de MM fue: \n43,75% IgG, 31,25% BJ, 18,75% IgA y 6,25% no secretor. El estadio; 37,5% estadioI, 43,75% estadioII, y 18,75 % estadioIII. \nAl diagn\u00f3stico, 8 pacientes presentaban CM en suero, con una mediana de 3,35mg/dl(1,07-5,77). Todos los pacientes \npresentaban > 10% de CP en MO, 56,25% lesiones \u00f3seas, 25% plasmocitoma y 18,75% IR. Con una mediana de seguimiento \nde 12,4 meses(1,03-17,3), 4 pacientes han completado la inducci\u00f3n y TASPE en t\u00e1ndem, 6 pacientes la inducci\u00f3n y un TASPE, \n3 pacientes se encuentran en la inducci\u00f3n. Un paciente ha progresado tras la inducci\u00f3n y 3 pacientes la han interrumpido por \nprogresi\u00f3n, aparici\u00f3n de un nuevo tumor y toxicidad. La mediana de ciclos de VRd recibidos fue de 6(1-6). La tasa de respuesta \nglobal tras la inducci\u00f3n(n=11), fue del 87,5%, obteni\u00e9ndose:RC 27,27%, MBRP 27,27%, RP 36,37% y progresi\u00f3n 9%. Los \npacientes que no hab\u00edan completado aun la inducci\u00f3n presentan una RC, una MBRP y EE. La tasa de respuesta tras el primer \nTASPE(n=10) fue de 60% RC, 20% MBRP y 20% RP; tras el segundo TASPE(n=4) fue de 50% RC, 25% MBRP y 25% RP . El 80% de \nlos pacientes mantuvo, tras el TASPE, la respuesta obtenida tras la inducci\u00f3n\ufffd Un 20% pas\u00f3 de MBRP a RC y de RP a RC\ufffd   \nOcurrieron EA de cualquier grado en el 75% de los pacientes, con una media de 1,25 EA/paciente. Los EA de grado 3-4 \nocurrieron en un 25% de los pacientes: neuropat\u00eda(n=3) y rash(n=2) g3 y neumonitis g4(n=1). Bortezomib se suspendi\u00f3 \nen dos pacientes: neumonitis g4 y neuropat\u00eda g3. Dos pacientes precisaron reducci\u00f3n de dosis por neuropat\u00eda g3. \nLenalidomida se suspendi\u00f3 en un paciente por rash g3 y en otro paciente se redujo la dosis.\nCONCLUSIONES\nLos resultados preliminares obtenidos en vida real, en t\u00e9rminos de tasa de respuesta, parecen similares a los obtenidos \nen el ensayo PETHEMA/GEM2012, siendo el perfil de pacientes tratados similar al incluido en el estudio. El perfil de EA \nfue similar al descrito en el ensayo. Destaca por su gravedad un caso de neumonitis grado 4.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1114. EVALUACI\u00d3N CL\u00cdNICA Y ECON\u00d3MICA DE LA IMPLANTACI\u00d3N DE UN PROTOCOLO DE REGIMEN \nPOSOL\u00d3GICO DE PEMBROLIZUMAB POR PESO CORPORAL \nAUTORES\nGRAS COLOMER, E; GARCIA MARTINEZ, T; BELLVER MART\u00cdNEZ, M; CAJA CALVO, M; FERRANDIS RODRIGUEZ, P; \nPRATS ORTEGA, R\nHOSPITAL DE MANISES \ufffd AVDA \ufffd GENERALITAT VALENCIANA, 50 MANISES \ufffd VALENCIA379OBJETIVOS\nDeterminar el impacto cl\u00ednico y econ\u00f3mico del uso de pembrolizumab en el r\u00e9gimen de dosis por kg de peso versus dosis \nfija.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que se incluyeron pacientes desde 2018 a 2021 en tratamiento con pembrolizumab \nen un hospital comarcal. En 2019 la Comisi\u00f3n de Farmacia y terap\u00e9utica, en base a la evidencia cient\u00edfica disponible y el \npotencial ahorro econ\u00f3mico, estableci\u00f3 que se podr\u00eda utilizar la dosificaci\u00f3n por kg de peso si resulta conveniente.  \nLos pacientes se asignaron a la cohorte A-dosis fijas en tratamiento con pembrolizumab (200mg) y cohorte B-dosificaci\u00f3n \npor kg de peso en tratamiento con pembrolizumab (2mg/kg peso).  \nLas variables cl\u00ednicas se recogieron de la historia cl\u00ednica electr\u00f3nica: sexo, edad, diagn\u00f3stico, esquema tratamiento y \nl\u00ednea, ciclos recibidos, motivo de discontinuaci\u00f3n. Se evalu\u00f3 la eficacia mediante el tiempo medio desde el inicio del \ntratamiento hasta la progresi\u00f3n objetiva del tumor, y su significaci\u00f3n estad\u00edstica. \nVariables econ\u00f3micas: se recogieron los costes de las dos cohortes a trav\u00e9s de los costes imputados en el programa de \ngesti\u00f3n del hospital. El impacto presupuestario se calcul\u00f3 mediante la diferencia de costes entre la cohorte de dosis fija vs \ndosificaci\u00f3n/peso, y los costes medios por ciclo en 2021.\nRESULTADOS\nSe incluyeron 52 pacientes. En la cohorte A: 25 pacientes, edad media 64 a\u00f1os, 80% hombres y diagn\u00f3sticos neoplasia \npulm\u00f3n 84%, vejiga 12%, melanoma 1%. Respecto al esquema de tratamiento: 13 pacientes con pembrolizumab+cisplati\nno+pemetrexed, 12 pacientes con pembrolizumab en monoterapia. EL 16% de los pacientes discontinuaron por toxicidad \ny 80% por progresi\u00f3n. En la Cohorte B: 27 pacientes, edad media 63 a\u00f1os, 56% hombres y diagn\u00f3sticos 78% neoplasia de \npulm\u00f3n, 4% melanoma, 1% ORL. Respecto al esquema de tratamiento: 13 pacientes con pembrolizumab+cisplatino+pem\netrexed, 13 pacientes con pembrolizumab en monoterapia, y 1 pacientes con pembrolizumab+carboplatino+fluorouracilo. \nEL 7% de los pacientes discontinuaron por toxicidad y 81% por progresi\u00f3n. El tiempo medio hasta la progresi\u00f3n del tumor \nen la Cohorte A fue 2,1 meses (RIQ 0,7 a 6 meses) y en la cohorte B fue 2,1 meses (RIQ 1,5 a 4,6 meses), por lo que no se \nobservaron diferencias significativas.  \nLa dosis media en la Cohorte A fue 200mg y en la cohorte B 128mg. El coste de tratamiento por ciclo en la cohorte A fue \n2.684\u20ac frente a 2.076\u20ac de cohorteB, lo que supuso un ahorro en 2021 de 71.744\u20ac.\nCONCLUSIONES\nNo se observaron diferencias significativas en el tiempo medio hasta la progresi\u00f3n en la dosis fija frente a la dosis por kg \nde peso de pembrolizumab, mientras que el impacto econ\u00f3mico supuso un ahorro de 71.744\u20ac en la dosis por kg de peso \nen 27 pacientes en 2021. Tras estos resultados, confirmamos que la dosificaci\u00f3n de pembrolizumab por Kg de peso es la \nalternativa m\u00e1s coste-efectiva.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1131. DESCRIPCI\u00d3N Y AN\u00c1LISIS DE LOS MOTIVOS DE RETRASO EN LA ADMINISTRACI\u00d3N DE \nTRATAMIENTOS ANTINEOPL\u00c1SICOS INTRAVENOSOS \nAUTORES\nMART\u00cdNEZ ALBALADEJO, P; RICOY SANZ, I; S\u00c1NCHEZ GONZ\u00c1LEZ, JL; SENDRA GARC\u00cdA, A; BRAVO CRESPO, C; POLO \nDUR\u00c1N, J; MAESTU MAIQUES, I; CLIMENTE MART\u00cd, M\nHOSPITAL UNIVERSITARIO DR \ufffd PESET \ufffd AV\ufffd GASPAR AGUILAR, 90 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nDescribir los motivos m\u00e1s frecuentes de retraso en la administraci\u00f3n de quimioterapia antineopl\u00e1sica intravenosa y \nanalizar cu\u00e1les son las caracter\u00edsticas que m\u00e1s influyen en ellos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo (28/02/22 \u2013 03/04/22) realizado en un hospital terciario. Se incluyeron pacientes \noncohematol\u00f3gicos tratados con quimioterapia intravenosa que experimentaran un retraso inter-ciclo de > 5 d\u00edas. Se \nexcluyeron aquellos pacientes que fueron exitus durante el estudio.  \nLas fuentes de informaci\u00f3n consultadas fueron la historia cl\u00ednica electr\u00f3nica (OrionClinic\u00ae) y Farmis-Oncofarm\u00ae. Las \nvariables recogidas fueron: (1) relacionadas con el paciente (edad, sexo, Performance Status (PS), diagn\u00f3stico); (2) \nrelacionadas con el tratamiento (n\u00famero de ciclo y periodicidad); (3) relacionadas con el retraso (d\u00edas de retraso, \nmodificaci\u00f3n de esquema).  \nSe definieron tres motivos de retraso: voluntario (d\u00edas festivos, petici\u00f3n del paciente), mal estado general (MEG) del \npaciente y toxicidad de la quimioterapia. Se realiz\u00f3 un an\u00e1lisis descriptivo de los motivos y caracter\u00edsticas de dichos \nretrasos expresando las variables continuas como media\u00b1desviaci\u00f3n est\u00e1ndar y las categ\u00f3ricas como frecuencias. Se \ncorrelacion\u00f3 el motivo de retraso con el PS, diagn\u00f3stico y n\u00famero de ciclo; analizando si exist\u00edan diferencias estad\u00edsticas \n(p < 0,05) mediante el test Chi-cuadrado (programa estad\u00edstico R-v4.2.0.).\nRESULTADOS\nSe incluyeron en el estudio 136 pacientes (51,5% mujeres) con una media de edad de 66,1\u00b111,6 a\u00f1os, cuyas \ncaracter\u00edsticas m\u00e1s frecuentes fueron diagn\u00f3stico de c\u00e1ncer de pulm\u00f3n (16,7%), PS1 (55,7%) y segundo ciclo de \nquimioterapia (14,0%). La media de d\u00edas de retraso fue 10,3\u00b17,6 d\u00edas: 92(67,6%) pacientes sufrieron una semana \nde retraso, 21(15,4%) dos semanas, 12(8,8%) tres o m\u00e1s y en 11(7,7%) pacientes se suspendi\u00f3 definitivamente el 380tratamiento. Tras el retraso, 21(14,7%) pacientes sufrieron una modificaci\u00f3n del esquema farmacoterap\u00e9utico: 12(57,1%) \nreducci\u00f3n de dosis, 6(28,6%) aumento de la periodicidad de administraci\u00f3n, 2(9,5%) retirada de uno de los f\u00e1rmacos y \n1(4,8%) adici\u00f3n de un tratamiento de soporte. \nEntre los motivos de retraso, el m\u00e1s frecuente fue la toxicidad por quimioterapia en 61(45,6%) pacientes, seguido de MEG \nen 39(28,7%) y retraso voluntario en 35(25,7%).  \nPor PS, el principal motivo de retraso fue la toxicidad en pacientes con PS0 13/28(46,4%) y PS1 34/69(49,2%), mientras \nque fue el MEG en pacientes con PS2 13/25(52,0%) (p=0,03).  \nPor diagn\u00f3stico, el principal motivo de retraso fue el voluntario en pacientes con c\u00e1ncer colo-rectal 8/18(44,4%) y de \nmama 9/21(42,8%), mientras que fue la toxicidad por quimioterapia en c\u00e1ncer de pulm\u00f3n 9/22(54,5%) (p=0,02).  \nPor n\u00famero de ciclo, entre los ciclos 1-5 y 6-10, la toxicidad fue el motivo m\u00e1s frecuente en 38/72(52,8%) y 14/30(46,7%) \npacientes respectivamente. Cuando se recibieron > 10 ciclos, el retraso voluntario fue el m\u00e1s habitual con 17/34(50,0%) \npacientes (p=0,005).\nCONCLUSIONES\nEl retraso en la administraci\u00f3n de quimioterapia es en este caso fundamentalmente debido a la toxicidad del tratamiento, \ncuya consecuencia m\u00e1s frecuente es la demora en la administraci\u00f3n.  \nLos retrasos por toxicidad son m\u00e1s frecuentes en pacientes con PS0-1, en tratamiento por c\u00e1ncer de pulm\u00f3n y entre los \nciclos 1-10, mientras que los retrasos voluntarios son m\u00e1s frecuentes en pacientes en tratamiento por c\u00e1ncer colo-rectal, \nmama o con m\u00e1s de 10 ciclos recibidos de quimioterapia antineopl\u00e1sica.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1151. EVALUACI\u00d3N DE EFECTIVIDAD Y SEGURIDAD DE CAPLACIZUMAB EN EL TRATAMIENTO DE LA \nP\u00daRPURA TROMBOCITOP\u00c9NICA TROMB\u00d3TICA ADQUIRIDA \nAUTORES\nGARCIA GARCIA, S; ALONSO MARTINEZ, C; VALCARCEL FERREIRAS, D; GUERRA GONZALEZ, M; JUAREZ GIMENEZ, JC; \nFARRIOLS DANES, A; CARRERAS SOLER, MJ; JIMENEZ BALAREZO, M\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nCaplacizumab es un nanoanticuerpo bivalente humanizado que act\u00faa sobre el dominio A1 del factor Von Willebrand \nindicado en el tratamiento de la p\u00farpura trombocitop\u00e9nica tromb\u00f3tica (PTT).  \nEl objetivo del estudio es evaluar la efectividad y la seguridad de caplacizumab en el tratamiento de la PTT en la pr\u00e1ctica \ncl\u00ednica real.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluye pacientes con PTT tratados con caplacizumab y tratamiento est\u00e1ndar \ndesde enero de 2018 a diciembre de 2020. Se evaluaron dos grupos de pacientes, el grupo control (gC) recibi\u00f3 \ntratamiento est\u00e1ndar: recambio plasm\u00e1tico terap\u00e9utico (RPT) y corticosteroides; y el grupo de caplacizumab (gCPL) \nrecibi\u00f3: caplacizumab 10 mg intravenoso (dosis \u00fanica) seguido de caplacizumab 10 mg/24h por v\u00eda subcut\u00e1nea asociado \nal tratamiento est\u00e1ndar. Se a\u00f1adi\u00f3 rituximab en caso de enfermedad grave (presencia de s\u00edntomas neurol\u00f3gicos graves) o \nfalta de respuesta\ufffd \n \nSe recogieron de la historia cl\u00ednica datos demogr\u00e1ficos, anal\u00edticos (hemoglobina (Hb), recuento plaquetario, creatinina, \nactividad de ADAMTS13 y auto-anticuerpos anti-ADAMTS13), cl\u00ednicos (tiempo hasta la normalizaci\u00f3n del recuento \nplaquetario, muerte relacionada con la PTT o recurrencia de PTT) y efectos adversos del f\u00e1rmaco.\nRESULTADOS\nSe incluyeron 17 pacientes. Las caracter\u00edsticas demogr\u00e1ficas, anal\u00edticas y cl\u00ednicas se describen en la siguiente tabla:  \ngCPL* gC \nEdad (a\u00f1os) 44,8 (25,7-56,6) 41,0 a\u00f1os (33,0-52,0)  \nSexo (mujeres) 7/8 (87,5%) 6/9(67,0%)  \nRecuento plaquetario (x109/L) 30(8-77) 12(7-18)  \nHemoglobina (g/dL) 8,1(5,9-9,4) 8,3(6,6-9,2)  \nCreatinina (mg/d) 0,89(0,44-1,47) 0,85(0,81-1,37)  \nHospitalizaci\u00f3n (d\u00edas) 12,5 (11-23) -  \nEmbarazo, n(%) 2/8 (25,0%) - \nS\u00edntomas neurol\u00f3gicos 3/8 (37,5%) 6/9 (66,7%)  \nSangrado mucocut\u00e1neo 6/8 (75,0%) 2/9 (22,2%)  \n \n*gCPL incluye pacientes de nuevo diagn\u00f3stico, excepto dos recurrencias.  \n \nEn el gCPL, caplacizumab se inici\u00f3 tras una mediana de 2,5 d\u00edas (1-9) tras el diagn\u00f3stico de PTT, administr\u00e1ndose durante \nuna mediana de 38 d\u00edas (13-59). Se precis\u00f3 una mediana de 11,5 RPT (2-17) y corticoides durante 68,5 d\u00edas (20-98). \nSolamente 2/8 (25,0%) pacientes precisaron la administraci\u00f3n de rituximab. La mediana de tiempo hasta la normalizaci\u00f3n \ndel recuento plaquetario fue 2 d\u00edas (1-5). La actividad de ADAMTS-13 fue del 19%(0-50) el d\u00eda 8 y 22%(0-89) el d\u00eda 30; y el \ninhibidor anti-ADAMTS-13 fue de 25,3 (16-112,2) UI/L al diagn\u00f3stico, 0 (0-78,5) UI/L al d\u00eda 8 y 0 (0-16,9) UI/L al d\u00eda 22.  381Con una mediana de seguimiento de 11,4 meses (4,3-23,2), 6/8 (75%) pacientes eliminaron el inhibidor anti-ADAMTS-13; \nlos dos pacientes con inhibidor positivo est\u00e1n en remisi\u00f3n cl\u00ednica con actividad ADAMTS-13 de 33 y 100%. Solamente \nexisti\u00f3 un caso de reca\u00edda a los 8,7 meses. No se informaron eventos adversos, excepto un eritema cut\u00e1neo que remiti\u00f3 \ndespu\u00e9s de suspender el f\u00e1rmaco.  \n \nEn el gC, con una mediana de seguimiento de 51,8 meses, se observaron 4/9 (44,4%) casos refractarios, 3/9 (33,3%) \nexacerbaciones y 1/9 (11,1%) reca\u00edda. Requirieron administraci\u00f3n de rituximab 8/9 (88,9%) pacientes y de vincristina 4/9 \n(44,4%), como tercera l\u00ednea de tratamiento.\nCONCLUSIONES\nNuestra experiencia, corrobora la efectividad y seguridad de caplacizumab. El a\u00f1adir el f\u00e1rmaco a la primera l\u00ednea de \ntratamiento de la PTT aporta menor tasa de refractariedad y recurrencia, por ende menor necesidad de otras l\u00edneas de \ninmunosupresi\u00f3n como rituximab o vincristina.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1170. DETECCI\u00d3N Y CONTROL DE N\u00c1USEAS NO RELACIONADAS DIRECTAMENTE CON EL TRATAMIENTO \nQUIMIOTER\u00c1PICO. \nAUTORES\nBLANCO RIVAS, M; GALLEGO GALISTEO, M; MARQUEZ FERNANDEZ, E; CAMPOS DAVILA, E; VILLA RUBIO, J\nHOSPITAL DE LA L\u00cdNEA DE LA CONCEPCI\u00d3N. AV . MEN\u00c9NDEZ Y PELAYO, 103 L\u00cdNEA DE LA CONCEPCI\u00d3N (LA). C\u00c1DIZ\nOBJETIVOS\nUno de los efectos adversos gastrointestinales m\u00e1s frecuentes del tratamiento quimioter\u00e1pico (TQT), son las n\u00e1useas y \nv\u00f3mitos. Sin embargo, existen casos en los que estos s\u00edntomas pueden aparecer como resultado de un estre\u00f1imiento \nprolongado o por reflujo gastroesof\u00e1gico.  \nEl objetivo de este estudio es describir el proceso de detecci\u00f3n de la causa de las n\u00e1useas en la consulta de atenci\u00f3n \nfarmac\u00e9utica oncohematol\u00f3gicas (CAFOH) y las medidas de intervenci\u00f3n farmac\u00e9uticas para su control.\nMATERIALES Y M\u00c9TODOS\nDesde septiembre 2020 hasta abril 2022, se entrevistaron a todos aquellos pacientes que acudieron a la consulta de \nAFOH por su tratamiento antiem\u00e9tico.  \nPara describir el procedimiento de detecci\u00f3n e intervenci\u00f3n de nauseas indirectas postquimioterap\u00e9uticas se estudiaron \nlas siguientes variables recogidas durante la entrevista cl\u00ednica al paciente y/o cuidador: sexo, edad, poder emet\u00f3geno del \nTQT, terapia antiem\u00e9tica basal, ausencia de control de nauseas con tratamiento antiem\u00e9tico intensificado, antecedentes \nde disfunci\u00f3n gastrointestinal (reflujo gastroesof\u00e1gico, gastritis, etc.), mejor\u00eda de nauseas con o sin alimentos, \ncorticoterapia y terapia con anti\u00e1cidos.\nRESULTADOS\nEn la CAFOH fueron atendidos en el periodo de estudio a 288 pacientes, de los cuales el 20,83% (60) presentaron n\u00e1useas \nrelacionadas indirectamente por estre\u00f1imiento prolongado o reflujo gastroesof\u00e1gico.  \nEn estos casos, al profundizar en la entrevista cl\u00ednica con el paciente/cuidador, refer\u00edan dolor estomacal agudo y n\u00e1useas \nno seca con reflujo g\u00e1strico. Estos s\u00edntomas se acentuaban con el est\u00f3mago vac\u00edo y mejoraba tras la ingesta de alg\u00fan \nalimento\ufffd  \nEl tratamiento antiem\u00e9tico base del todos los pacientes eran corticoesteroides, en concreto dexametasona en pauta \ndescendente durante varios d\u00edas (40 mg repartidos en 10 dosis en una pauta descendente de 5 d\u00edas tras el tratamiento \nquimioter\u00e1pico). Seg\u00fan ficha t\u00e9cnica, los efectos adversos gastrointestinales de estos pueden ser: Dispepsia, distensi\u00f3n \nabdominal, flatulencia, n\u00e1useas o v\u00f3mitos que a dosis altas puede llegar a \u00falceras g\u00e1stricas con perforaci\u00f3n y hemorragia, \npancreatitis aguda, esofagitis ulcerativa. Es por ello que, el tratamiento antiem\u00e9tico dispensado incluy\u00f3 un inhibidor de la \nbomba de protones para su prevenci\u00f3n, siendo en alg\u00fan caso insuficiente como en pacientes con antecedentes de hernia \nde hiato o reflujo gastroesof\u00e1gico.  \nLa alta incidencia de n\u00e1useas indirectas supuso la definici\u00f3n de las siguientes medidas de intervenci\u00f3n:  \n1. Reducir la dosis de corticoesteroides como posible causa de las alteraciones gastrointestinales descritas. \n2. Reducir la dosis de 5-HT3 como posible causa del estre\u00f1imiento prolongado.  \n3\ufffd Estudiar la posibilidad de control de nauseas con la toma de un alimento saludable\ufffd  \n4. Aumentar el uso de procin\u00e9ticos en caso de nauseas por reflujo gastroesof\u00e1gico.  \n5. En caso de que las medidas anteriores fueran insuficientes, derivar al Servicio de Oncolog\u00eda o Hematolog\u00eda para \nreevaluaci\u00f3n de su terapia antiem\u00e9tica de forma conjunta con el farmac\u00e9utico.\nCONCLUSIONES\nUna entrevista cl\u00ednica adecuada en la CAFOH y la detecci\u00f3n precoz de nauseas indirectas por el tratamiento \nquimioterap\u00e9utico nos ayuda a adecuar la terapia antiem\u00e9tica m\u00e1s beneficiosas para los pacientes. \nEl trabajo colaborativo entre los servicios de Farmacia, Oncolog\u00eda y Hematolog\u00eda permite un abordaje integral de la \nterapia antiem\u00e9tica y con ello un mejor control de los s\u00edntomas propios de la quimioterapia.382CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1172. EVALUACI\u00d3N DE EFECTIVIDAD Y SEGURIDAD DE RUXOLITINIB EN LA ENFERMEDAD DE INJERTO \nCONTRA RECEPTOR CR\u00d3NICA. \nAUTORES\nGARCIA GARCIA, S; ALONSO MARTINEZ, C; ORTI PASCUAL, G; VALDIVIA VADELL, C; RIVERA SANCHEZ, L; MONTORO \nRONSANO, JB; CARRERAS SOLER, MJ; FOX , ML\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLa enfermedad de injerto contra receptor (EICR) es una complicaci\u00f3n del trasplante alog\u00e9nico de progenitores \nhematopoy\u00e9ticos (aloTPH) que afecta al 30-70% de los pacientes, aumentando su morbimortalidad. La EICR cr\u00f3nica \n(EICRc) acontece > 100 d\u00edas post-aloTPH. Un 50% de los pacientes son refractarios al tratamiento de primera l\u00ednea con \ncorticoesteroides y requieren alternativas farmacol\u00f3gicas.  \n \nEl objetivo del estudio es evaluar la efectividad y seguridad de ruxolitinib como tratamiento de segunda l\u00ednea o \nposteriores de la cEICR corticorresistente, y comparar la respuesta global en pr\u00e1ctica cl\u00ednica real con la obtenida en \nensayos cl\u00ednicos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, unic\u00e9ntrico en pacientes adultos ( > 18 a\u00f1os) con diagn\u00f3stico de cEICR \ncorticorresistente que recibieron tratamiento con ruxolitinib. Se recogieron variables demogr\u00e1ficas, cl\u00ednicas (diagn\u00f3stico, \ntipo donante, compatibilidad inmunol\u00f3gica), terap\u00e9uticas y anal\u00edticas. La efectividad se evalu\u00f3 mediante el an\u00e1lisis de \nla proporci\u00f3n de pacientes con respuesta objetiva (parcial/completa), el tiempo hasta la progresi\u00f3n y supervivencia. La \nseguridad se evalu\u00f3 como la incidencia de efectos adversos graves (CTCAE v.5).  \nSe realiz\u00f3 estad\u00edstica descriptiva para datos continuos. Distribuci\u00f3n de frecuencias para variables categ\u00f3ricas (SPSS v.18).\nRESULTADOS\nSe incluyeron 30 pacientes, 54,7\u00b114,3 a\u00f1os. Catorce (46,7%) fueron mujeres. Recibieron tratamiento con ruxolitinib \nentre enero de 2015 y diciembre de 2021. Enfermedades hematol\u00f3gicas m\u00e1s frecuentes, n (%): LMA 9 (30%), LDCGB 5 \n(16,7%), MM 4 (13,3%). Tipo de donante, n (%): DE 11 (36,7%), DNE 17 (56,7%), SCU 1 (3,3%) y desconocido 1 (3,3%). \nCompatibilidad inmunol\u00f3gica, n (%): 10/10 en 24 (80,0%), 9/10 en 4 (13,3%) y desconocida en 2 (6,7%). Diagn\u00f3stico \ndel cEICR 884 (120-4420) d\u00edas post-aloTPH. Localizaciones cEICR m\u00e1s frecuentes, n (%): cut\u00e1nea 25 (83,3%), ocular 15 \n(50,0%), hep\u00e1tica 12 (40,0%), tracto gastrointestinal 12 (40,0%) y pulmonar 11 (36,7%).  \n \nEl n\u00famero de f\u00e1rmacos previos a ruxolitinib fueron 2,3 (1,4), siendo los m\u00e1s comunes rapamicina en 25 (83,3%) pacientes, \nmetoxaleno 16 (53,3%), micofenolato de mofetilo 8 (26,7%) y tacrolimus 7 (20,0%). Seguimiento medio de los pacientes: \n33,7 (20,1) meses.  \n \nRuxolitinib se inici\u00f3 675,5 (187,0-4420,0) d\u00edas post-aloTPH. La dosis m\u00e1xima fue 20 mg/d\u00eda en 23 (76,7%) pacientes, \n30 mg/d\u00eda en 3 (10%), 40 mg/d\u00eda en 1 (3,3%), 10 mg/d\u00eda en 2 (6,7%) y 15 mg/d\u00eda en 1 (3,3%). Se objetiv\u00f3 respuesta a \nruxolitinib en 27 (90%) pacientes, tiempo de respuesta 44,8 (3,4-189,7) semanas. En concreto, 20 (66,7%) pacientes \nalcanzaron respuesta parcial y 7 (23,3%) respuesta completa. A las 24 semanas se observ\u00f3 una tasa de respuesta global \ndel 44,4%, resultado similar a la tasa de respuesta global del 49,7% a las 24 semanas de los ensayos cl\u00ednicos. Se objetiv\u00f3 \nprogresi\u00f3n de cEICR tras la finalizaci\u00f3n de ruxolitinib en 13 (43,3%) pacientes.  \n \nSufrieron aparici\u00f3n de efectos adversos 7 (23,3%) pacientes, siendo los m\u00e1s frecuentes anemia grado 2-3 (13,3%) y \nplaquetopenia grado 3 (10,0%). Fueron exitus 7 (23,3%) pacientes: 3 (10,0%) por causas relacionadas con la EICR, 3 \n(10,0%) por neumon\u00eda secundaria a COVID-19 y 1 (3,3%) por pancreatitis aguda grave.\nCONCLUSIONES\nRuxolitinib es una opci\u00f3n de tratamiento efectiva y segura de la cEICR corticorresistente. Los datos obtenidos en vida real \nfueron comparables a los obtenidos en ensayos cl\u00ednicos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1177. EFECTIVIDAD Y ADHERENCIA DE PALBOCICLIB EN EL TRATAMIENTO DE PRIMERA L\u00cdNEA DE \nC\u00c1NCER DE MAMA METAST\u00c1SICO \nAUTORES\nMART\u00cdNEZ-BARROS , H; S\u00c1NCHEZ CUERVO, M; MART\u00cdNEZ J\u00c1\u00d1EZ, N; \u00c1LVAREZ D\u00cdAZ, A\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nEvaluar la efectividad y adherencia en la pr\u00e1ctica cl\u00ednica del tratamiento con palbociclib en primera l\u00ednea de c\u00e1ncer de \nmama metast\u00e1sico (CMM) o localmente avanzado, positivo para receptores hormonales (RH) y negativo para el receptor \n2 del factor de crecimiento epid\u00e9rmico humano (HER2).383MATERIALES Y M\u00c9TODOS\nEstudio observacional, longitudinal y descriptivo que incluy\u00f3 a todas las mujeres adultas con CMM o localmente avanzado \nRH+ y HER2-negativo que iniciaron tratamiento de primera l\u00ednea con palbociclib en un hospital de tercer nivel, entre \nenero de 2018 y agosto de 2019. El seguimiento se realiz\u00f3 hasta el 31/10/2021, fecha de corte de la recogida de datos. \nSe recogieron las siguientes variables: supervivencia libre de progresi\u00f3n (SLP), definida como el tiempo desde la primera \ndosis de palbociclib hasta progresi\u00f3n de la enfermedad seg\u00fan los criterios RECIST v1.1 o muerte; supervivencia global, \nexpresada como proporci\u00f3n (%) de pacientes vivas dos a\u00f1os tras el inicio de palbociclib; tasa de beneficio cl\u00ednico (TBC), \ndefinida como la proporci\u00f3n de los sujetos con respuesta completa o parcial o enfermedad estable prolongada \u2265 24 \nsemanas; intensidad de dosis relativa (IDR), definida como la proporci\u00f3n entre la dosis realmente administrada en el \nper\u00edodo de tratamiento -asumiendo que la paciente toma el 100% de las dosis dispensadas- y la dosis est\u00e1ndar (125 mg \ndurante tres semanas seguido de una semana de descanso); adherencia medida como porcentaje de d\u00edas cubiertos (PDC), \ndefinido como la proporci\u00f3n entre n\u00famero de d\u00edas de medicaci\u00f3n dispensados/n\u00famero de d\u00edas entre dispensaciones. Se \nutiliz\u00f3 el m\u00e9todo de Kaplan Meier para estimar la curva de SLP . Se realiz\u00f3 una comparaci\u00f3n gr\u00e1fica entre la curva de SLP \nobtenida en nuestra cohorte y las del PALOMA-2. Los datos fueron recogidos y gestionados utilizando REDCAP (Research \nElectronic Data Capture) a trav\u00e9s de la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (www.sefh.es). Se utiliz\u00f3 SPSS \nStatistics versi\u00f3n 26 para el an\u00e1lisis de los datos.\nRESULTADOS\nSe identificaron un total de 51 mujeres que iniciaron palbociclib para el tratamiento en primera l\u00ednea para el CMM o \nlocalmente avanzado RH+ y HER2-negativo en el en el per\u00edodo de estudio, con una mediana de seguimiento de 21,7 \nmeses (rango intercuart\u00edlico (RIC) 8,6-29,35) para la SLP . La SLP obtenida fue de 27,4 meses (Intervalo de confianza (IC) \ndel 95%: 15,5-35,5), comparado con 27,6 meses (IC95%: 22,4\u201230,3) en el PALOMA-2. Se obtuvo una tasa de supervivencia \na los dos a\u00f1os de inicio de tratamiento con palbociclib del 88% (IC95%: 79 \u2013 97). La TBC fue del 82% (IC95%: 72 \u2013 93). La \nIDR fue de 80% (RIC 73,7-93,9%). La PDC fue del 99,4% (RIC 98,1 \u2013 100).\nCONCLUSIONES\nLos resultados de este trabajo apoyan que el beneficio del tratamiento con palbociclib en primera l\u00ednea de tratamiento \ndel CMM o localmente avanzado RH+ y HER2-negativo, demostrado en el ensayo PALOMA-2, se traslada a la pr\u00e1ctica \ncl\u00ednica habitual.  \nLa adherencia al tratamiento con palbociclib durante el per\u00edodo estudiado fue buena.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1190. EVALUACI\u00d3N DE LA EFECTIVIDAD, SEGURIDAD Y ADHERENCIA EN PACIENTES TRATADAS CON \nTUCATINIB EN UN HOSPITAL TERCIARIO \nAUTORES\nBOLEA LACUEVA, A; \u00c1LVAREZ N\u00da\u00d1EZ, L; RUIZ EL JERCHE, S; BELTR\u00c1 PIC\u00d3, I; CLIMENT BALLESTER, S; FUSTER RUIZ DE \nAPODACA, R; PASCUAL CARRASCO, \u00c1; POLACHE VENGUD, J\nHOSPITAL GENERAL UNIVERSITARIO DE ALICANTE \ufffd AV\ufffd PINTOR BAEZA, 12 ALICANTE/ALACANT \ufffd ALICANTE\nOBJETIVOS\nEvaluar la efectividad, seguridad y adherencia de tucatinib en combinaci\u00f3n con trastuzumab y capecitabina para el \ntratamiento de pacientes con c\u00e1ncer de mama HER2+, localmente avanzado o metast\u00e1sico, con al menos dos l\u00edneas de \ntratamiento previos antiHER2+.\nMATERIALES Y M\u00c9TODOS\nDise\u00f1o: estudio observacional prospectivo realizado desde junio de 2021 hasta abril de 2022, incluyendo las pacientes \ntratadas con tucatinib (disponibilidad del f\u00e1rmaco por uso compasivo) en combinaci\u00f3n con trastuzumab y capecitabina \natendidas en la Unidad de Atenci\u00f3n Farmac\u00e9utica a Pacientes Externos (UFPE) en un hospital terciario.  \nVariables recogidas: edad, diagn\u00f3stico, presencia y localizaci\u00f3n de la met\u00e1stasis (cerebral o no), n\u00famero de l\u00edneas de \ntratamiento previas, tratamiento, duraci\u00f3n (dosis inicial, reducci\u00f3n de dosis, n\u00famero de ciclos) y motivo de la suspensi\u00f3n \n(por toxicidad y/o por progresi\u00f3n de la enfermedad), reacciones adversas medicamentosas y adherencia al f\u00e1rmaco.  \nFuentes de informaci\u00f3n: revisi\u00f3n de la historia cl\u00ednica electr\u00f3nica (Abucasis\u00ae) y registros de dispensaci\u00f3n en UFPE.  \nEfectividad: supervivencia libre de progresi\u00f3n (SLP).  \nSeguridad: reacciones adversas medicamentosas\ufffd  \nAdherencia: c\u00e1lculo de la Tasa de Posesi\u00f3n de la Medicaci\u00f3n (MPR) definida como (n\u00famero de unidades totales \ndispensadas/n\u00famero de unidades totales te\u00f3ricas prescritas) x100. Se consider\u00f3 buena adherencia a una MPR\u226590%.\nRESULTADOS\nSe incluyeron 5 mujeres diagnosticadas de c\u00e1ncer de mama HER2+ (dos ductales, dos luminales y una sin datos), con \nuna media de edad de 51 a\u00f1os (36-60). Tres ten\u00edan receptores estrog\u00e9nicos positivos (60%) y ninguna receptores de \nprogesterona positivos. Al inicio del tratamiento, todas ten\u00edan met\u00e1stasis (en el 80% a nivel cerebral).  \nSe utiliz\u00f3 como tercera l\u00ednea en dos pacientes (40%), como cuarta l\u00ednea en una paciente (20%) y como quinta l\u00ednea en dos \npacientes (40%).  \nTodas iniciaron con dosis completa de 300mg/12h, y solo una requiri\u00f3 reducci\u00f3n de dosis a 250mg/12h tras el primer \nciclo debido a reacciones adversas por tucatinib.  \nLa duraci\u00f3n del tratamiento fue de una mediana de 7 ciclos (2-10): 1 paciente 2 ciclos, 1 paciente 3 ciclos, 1 paciente 7 \nciclos, 1 paciente 8 ciclos y 1 paciente 10 ciclos. Al finalizar el estudio una paciente (20%) continuaba en tratamiento. La 384causa de la interrupci\u00f3n fue progresi\u00f3n de la enfermedad en tres de las pacientes (60%) y reacciones adversas en una \npaciente (20%). La SLP fue de una mediana de 5 meses (2,1-7): 1 paciente 2,1 meses, 1 paciente 5 meses y 1 paciente 7 \nmeses\ufffd \nLas reacciones adversas notificadas fueron diarrea (40%), v\u00f3mitos (20%), dispepsia (20%), astenia (20%), mialgia (20%) y \nencefalopat\u00eda leve (20%). La reacci\u00f3n adversa m\u00e1s frecuente fueron las n\u00e1useas (60%). Ninguna present\u00f3 hepatotoxicidad \no toxicidad hematol\u00f3gica. Dos pacientes no tuvieron reacciones adversas.  \nEl 100% de las pacientes tuvieron una buena adherencia al tratamiento.\nCONCLUSIONES\nLa SLP fue menor a la obtenida en el ensayo pivotal (5,3 frente a 7,8 meses), pero este estudio tiene limitaciones en \ncuanto a tama\u00f1o muestral y duraci\u00f3n\ufffd  \nSe observ\u00f3 una mayor incidencia de n\u00e1useas y menor de diarrea en las pacientes respecto al ensayo pivotal.  \nLa adherencia al tratamiento con tucatinib fue elevada (100 %).\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1191. PERFIL DE SEGURIDAD DEL TRATAMIENTO CON APALUTAMIDA EN PACIENTES CON C\u00c1NCER DE \nPR\u00d3STATA \nAUTORES\nGUZM\u00c1N RAMOS, MI; BARRIGA RODR\u00cdGUEZ, P; ALVARADO FERN\u00c1NDEZ, MD; SUAREZ CASILLAS, P; RODR\u00cdGUEZ \nJORGE, M\nHOSPITAL GENERAL JUAN RAM\u00d3N JIMENEZ. RONDA NORTE, S/N HUELVA. HUELVA\nOBJETIVOS\nAnalizar el perfil de seguridad del tratamiento con apalutamida en pacientes con c\u00e1ncer de pr\u00f3stata (CP).\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico observacional retrospectivo en el que se incluyeron aquellos pacientes con CP que recibieron \ntratamiento con apalutamida entre marzo de 2021 y marzo de 2022 en dos hospitales de tercer nivel. Se excluyeron \npacientes en ensayos cl\u00ednicos.  \nLas variables recogidas fueron: edad, sexo, indicaci\u00f3n (CP hormono sensible metast\u00e1sico (CPHSm) o CP resistente a la \ncastraci\u00f3n no metast\u00e1sico (CPRCnm)), eventos adversos (EA), reducci\u00f3n de dosis, interrupci\u00f3n temporal, suspensi\u00f3n \ndefinitiva del tratamiento. Los datos se obtuvieron a trav\u00e9s del programa corporativo ATHOS\u00ae y de la Historia cl\u00ednica \nDIRAYA\u00ae. En el an\u00e1lisis estad\u00edstico realizado las variables cuantitativas se describieron en tablas de frecuencias y medidas \nde tendencia central. Se emple\u00f3 el programa estad\u00edstico IBM SPSS 20.0.\nRESULTADOS\nSe incluyeron 51 pacientes con una mediana de edad de 77 (RIQ: 69-81) a\u00f1os. La indicaci\u00f3n fue CPHSm en el 62,7% \n(32) de los casos y CPRCnm en el 37,3% (19). El 76,5% de los pacientes presentaron alg\u00fan EA durante el tratamiento \ncon apalutamida, destacando que el 41,2% sufrieron trastornos de la piel y tejido subcut\u00e1neo (erupci\u00f3n cut\u00e1nea y/o \nprurito), el 37,3% trastornos vasculares (sofocos y/o hipertensi\u00f3n), el 25,5% astenia, el 15,7% toxicidad gastrointestinal \n(diarrea, dispepsia, dolor abdominal y/o n\u00e1useas) y el 9,8% trastornos card\u00edacos (dolor tor\u00e1cico y/o taquicardia). Otros \nEA que se detectaron fueron disminuci\u00f3n de peso en el 7,8%; p\u00e9rdida de apetito y alteraci\u00f3n de la micci\u00f3n en el 5,9%; \nhipotiroidismo, disgeusia, piernas inquietas, artralgias y cefaleas en el 3,9%; edemas en miembros inferiores, ca\u00eddas y \ndisnea en el 2%. La presencia de toxicidad produjo reducciones de dosis en 8 (15,7%) pacientes (75% trastornos de la piel \ny 25% trastornos card\u00edacos) y suspensiones temporales del tratamiento en 11 (21,6%) pacientes (72,7% trastornos de la \npiel, 18,2% trastornos card\u00edacos y 9% dispepsia). A fecha de an\u00e1lisis, el 23,5% (12) de los pacientes hab\u00edan finalizado el \ntratamiento, el 19,6% (10) por toxicidad (60% trastornos de la piel, 30% trastornos card\u00edacos y 10% piernas inquietas), y el \n3,9% (2) por progresi\u00f3n. El 76,5% (39) continuaban en tratamiento.\nCONCLUSIONES\nEl tratamiento con apalutamida di\u00f3 lugar a toxicidad en la mayor\u00eda de pacientes, siendo los trastornos de la piel (erupci\u00f3n \ncut\u00e1nea y/o prurito) la principal causa de reducci\u00f3n de dosis, suspensi\u00f3n temporal y finalizaci\u00f3n del tratamiento. En \nmuchos de los pacientes \u00e9sta toxicidad fue leve y reversible.  \nDebido al corto periodo de tiempo desde la publicaci\u00f3n del informe de posicionamiento terap\u00e9utico (IPT) del f\u00e1rmaco \n(marzo 2021 en CPHSm y octubre 2021 CPRCnm) ser\u00eda interesante continuar el seguimiento de estos pacientes para \nanalizar los resultados de seguridad a m\u00e1s largo plazo.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1207. IMPACTO ECON\u00d3MICO DEL ESQUEMA AZACITIDINA-VENETOCLAX EN LMA \nAUTORES\nJOY CARMONA, P; VI\u00d1A ROMERO, MM; L\u00d3PEZ MARTIN, A; P\u00c9REZ MART\u00cdN, CY; GONZ\u00c1LEZ GARC\u00cdA, I; SANTOS \nFAGUNDO, A; P\u00c9REZ REYES, S; MERINO ALONSO, FJ\nHOSPITAL NUESTRA SE\u00d1ORA DE CANDELARIA \ufffd CTRA \ufffd DEL ROSARIO, 145 SANTA CRUZ DE TENERIFE \ufffd SANTA CRUZ DE \nTENERIFE385OBJETIVOS\nEn los pacientes diagnosticados de Leucemia Mieloide Aguda (LMA) y que no son candidatos a quimioterapia intensiva, \nla opci\u00f3n de tratamiento preferente (a la espera de financiaci\u00f3n) es la combinaci\u00f3n azacitidina-venetoclax (AZA-V). En \nlos casos en los que se requiere de profilaxis antif\u00fangica se emplea el posaconazol, f\u00e1rmaco que interacciona con el \nmetabolismo del venetoclax y que conlleva una reducci\u00f3n del 75% del mismo.  \nEl objetivo del presente estudio ha consistido en analizar el impacto econ\u00f3mico que supondr\u00e1 el esquema de tratamiento \n(AZA-V) considerando la profilaxis con posaconazol en los pacientes diagnosticados de LMA.\nMATERIALES Y M\u00c9TODOS\nPara estimar el n\u00famero de pacientes, as\u00ed como la proporci\u00f3n de pacientes con profilaxis antif\u00fangica, se analizaron \naquellos con diagn\u00f3stico de LMA no candidatos a quimioterapia intensiva de los \u00faltimos 14 meses. Los datos de los \npacientes, adem\u00e1s de los datos de profilaxis antif\u00fangica fueron obtenidos del aplicativo inform\u00e1tico Farmatools y DRAGO \nAE\u00ae\ufffd \nSe realiz\u00f3 un an\u00e1lisis de minimizaci\u00f3n de costes en el que se compararon los pacientes con profilaxis frente a los que no la \nllevan en un periodo de 9,8 meses que es la supervivencia libre de enfermedad (SLE) seg\u00fan el ensayo pivotal.\nRESULTADOS\nDesde febrero de 2021 hasta la actualidad, 18 pacientes han iniciado tratamiento con azacitidina. De todos ellos, 7 \nhan suspendido el tratamiento por diversas razones: 5 exitus, 1 renuncia voluntaria y 1 cambio de tratamiento (ensayo \ncl\u00ednico).  \nDe los pacientes que actualmente contin\u00faan con azacitidina, 3 se encuentran en tratamiento combinado con venetoclax.  \nEl 88,9% del total de pacientes iniciaron profilaxis con posaconazol. En estos casos, el mantenimiento de venetoclax se \nrealizar\u00eda con dosis de 100 mg en lugar de 400 mg.  \nEl coste del tratamiento con venetoclax a los 9,8 meses en aquellos pacientes sin profilaxis con posaconazol es de 32.000 \n\u20ac por paciente, frente a los 8.000 \u20ac de los pacientes con profilaxis antif\u00fangica, lo que supondr\u00eda un ahorro del 75,0% \n(24.000 \u20ac) por paciente a los 9,8 meses de tratamiento. En nuestra poblaci\u00f3n, 8 pacientes requerir\u00edan esta disminuci\u00f3n de \ndosis lo cual supondr\u00eda un ahorro final de 192.000 \u20ac.\nCONCLUSIONES\nA la hora de realizar un an\u00e1lisis de costes del esquema AZA-V, se debe tener en cuenta que la mayor\u00eda de los pacientes \ncon LMA (88,9% en nuestra poblaci\u00f3n) requieren de profilaxis f\u00fangica con posaconazol, lo que conlleva una disminuci\u00f3n \nde la dosis de mantenimiento de venetoclax y con ello una reducci\u00f3n en el coste del 75%\ufffd\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1216. COMPARACI\u00d3N DE LA TOXICIDAD AUTO-INFORMADA (PRO-CTCAE) DE PALBOCICLIB/RIBOCICLIB \nPARA C\u00c1NCER DE MAMA CON LA RECOGIDA POR EL CL\u00cdNICO (ESCALA CTCAE) \nAUTORES\nOTERINO MOREIRA, I; ZHAN ZHOU, E; SANMART\u00cdN FENOLLERA, P; P\u00c9REZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nComparar la toxicidad auto-informada (Patient Reported Outcome, PRO) de palbociclib y ribociclib en c\u00e1ncer de mama \nmetast\u00e1sico (CMm) con la escala de medici\u00f3n de toxicidad CTCAE (Common Terminology Criteria for Adverse Events).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional ambispectivo con periodo de seguimiento Noviembre 2017- Junio 2021. Se proporcion\u00f3 un \ncuestionario PRO, elaborado seg\u00fan criterios PRO-CTCAE Item Library v1.0, a las pacientes con CMm tratadas con \npalbociclib/ribociclib que cuantificaba la frecuencia, intensidad e interferencia de los EA preguntados en una escala Likert \nde tipo sumativo de 0-4 puntos.  \n \nSe recopilaron de la historia cl\u00ednica variables demogr\u00e1ficas, cl\u00ednicas y de seguridad percibida por el onc\u00f3logo seg\u00fan la \nescala CTCAE v5.0. Se excluyeron los EA hematol\u00f3gicos/bioqu\u00edmicos.  \n \nLa literatura aporta un perfil de toxicidad similar para palbociclib y ribociclib de modo que para el objetivo de este trabajo \nse analizaron conjuntamente.\nRESULTADOS\nSe incluyeron 40 mujeres con una mediana de edad de 54,6 a\u00f1os (Rango intercuart\u00edlico (RIQ) 47,8- 71,2) de las que 23 \nrecibi\u00f3 palbociclib y 17 ribociclib. La mediana de l\u00ednea paliativa fue 1 (RIC 1-2) y la mediana de seguimiento 25,23 meses \n(RIQ 12,43-35,25).  \n \nLa frecuencia de EA estimada onc\u00f3logo versus la reportada paciente fueron las siguientes: mialgia/artralgia 64,6% v/s \n92,1%; fatiga 62,5% v/s 84,2%; n\u00e1useas 27,1% v/s 28,9%; diarrea 14,6% v/s 35,1%; piel seca 18,8% v/s 83,8%; sofocos \n18,75% v/s 76,3%; ojos llorosos 12,5% v/s 58,3%; erupci\u00f3n m\u00e1culo-papular 13,5% v/s 16,7%; alopecia 12,5% v/s \n48,6%; anorexia 10,4% v/s 29,7%; v\u00f3mitos 8,1% v/s 12,5%; y visi\u00f3n borrosa 0,0% v/s 50,0%. El cl\u00ednico detect\u00f3 molestias \nabdominales (31,3%), aftas (18,8%), estre\u00f1imiento (8,3%) y epistaxis (8,3%) que no aparec\u00edan en los cuestionarios \npredefinidos. Estos EA tambi\u00e9n fueron informados por las pacientes en el espacio de escritura libre, aunque con \nfrecuencia menor: 10,0%, 2,5%, 5,0% y 2,5%, respectivamente. 386El 42,9% de la diarrea fue grado (G) CTCAE de 3, erupci\u00f3n m\u00e1culo-papular 25,0% G3, alopecia 16,7% G2, n\u00e1useas 15,4% \nG3, artralgias/dolor muscular 6,5% G3\ufffd El resto de EA fueron de G1\ufffd  \n \nSeg\u00fan los auto-informes el dolor muscular, los sofocos, las artralgias, las n\u00e1useas y la diarrea suced\u00edan a menudo/casi \nsiempre (\u22653 puntos) en el 44,7%, 39,5%, 36,8%, 7,9% y 5,4% de las pacientes. \n \nLa intensidad fue intensa/muy intensa (\u22653 puntos) para el dolor muscular en el 36,8% de las pacientes, sofocos en el \n31,6%, artralgias en el 23,7%, sequedad de piel en el 18,9%, lagrimeo en el 18,9%, astenia/fatiga en el 15,8%, visi\u00f3n \nborrosa en el 8,3%, alopecia en el 8,1%, disminuci\u00f3n apetito en el 2,7% y n\u00e1useas en el 2,6% de las pacientes. \n \nLa interferencia con las actividades diarias la astenia/fatiga, lagrimeo, visi\u00f3n borrosa, artralgias, dolor muscular y \ndisminuci\u00f3n apetito fueron reportados como mucho/much\u00edsimo (\u22653 puntos) por el 75,0%, 13,9%, 11,1%, 10,5%, 7,9% y \n2,7% de las pacientes, respectivamente.\nCONCLUSIONES\nLas frecuencias de los EA aumentan cuando se pregunta expl\u00edcitamente por cada EA (PRO-CTCAE). La evaluaci\u00f3n CTCAE \ninfravalora la gravedad con la que los pacientes perciben los EA. \n \nLos autoinformes PRO-CTCAE proporcionan informaci\u00f3n diferente y complementaria de toxicidad en comparaci\u00f3n con la \nobservada por los m\u00e9dicos (CTCAE).\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1219. BENEFICIO CL\u00cdNICO DE F\u00c1RMACOS ONCOL\u00d3GICOS CON INFORMES DE POSICIONAMIENTO \nTERAPEUTICO Y DECISION DE FINANCIACION EN ESPA\u00d1A EN EL PERIODO 2013-2021 \nAUTORES\nLAFUENTE GONZALEZ, M\nAGENCIA ESPA\u00d1OLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS\nOBJETIVOS\nAnalizar el beneficio cl\u00ednico con la Escala de Magnitud de Beneficio Cl\u00ednico de la Sociedad Europea de Oncolog\u00eda M\u00e9dica \n(ESMO-MCBS) de medicamentos oncol\u00f3gicos con Informe de Posicionamiento Terap\u00e9utico (IPT) publicado por la Agencia \nEspa\u00f1ola de Medicamentos (AEMPS) y la decisi\u00f3n de financiaci\u00f3n por el Sistema Nacional de Salud.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo de medicamentos oncol\u00f3gicos con IPT publicado en el periodo de 2013-\n2021 y con informaci\u00f3n en el buscador de la informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos en \nEspa\u00f1a (BIFIMED) del Nomenclator de enero de 2022.  \nLas variables recogidas fueron: principio activo seg\u00fan el Sistema de Clasificaci\u00f3n Anat\u00f3mica Terap\u00e9utica, Qu\u00edmica \n(clasificaci\u00f3n ATC), indicaci\u00f3n autorizada, tipo y caracter\u00edsticas del ensayo cl\u00ednico pivotal, beneficio cl\u00ednico utilizando la \nescala ESMO-MCBS v1.1. para tumores s\u00f3lidos e informaci\u00f3n sobre financiaci\u00f3n en Espa\u00f1a.  \nLa escala ESMO-MCBS clasifica los f\u00e1rmacos con intenci\u00f3n curativa en las categor\u00edas A, B o C, siendo el grado A de mayor \nbeneficio cl\u00ednico, mientras que los f\u00e1rmacos con intenci\u00f3n paliativa, se clasifican en categor\u00edas num\u00e9ricas, de 1 a 5, de \nmenor a mayor beneficio cl\u00ednico.  \nPara la recogida y registro de los datos, el an\u00e1lisis estad\u00edstico se utiliz\u00f3 la base de datos Microsoft Office Excel\u00ae 2007. Se \nrealiz\u00f3 un an\u00e1lisis descriptivo de las variables y frecuencias absolutas.\nRESULTADOS\nEntre 2013 y 2021 la AEMPS public\u00f3 92 IPT de f\u00e1rmacos oncol\u00f3gicos de 52 principios activos para 112 indicaciones en \n19 tipos de tumores. La decisi\u00f3n de la Comisi\u00f3n Interministerial de Precios de Medicamentos sobre financiaci\u00f3n fueron: \nde las 112 indicaciones oncol\u00f3gicas evaluadas en el periodo de estudio, 59 (52,7%) fueron financiadas, 22 (19,6%) \nfinanciadas con restricciones, 26 (23,2%) no financiadas, 4 (3,6%) hab\u00edan sido retirados, anulados o revocada la solicitud \nde comercializaci\u00f3n y una (0,9%) hab\u00eda sido financiada pero fue baja por no comercializar. El c\u00e1ncer de pulm\u00f3n fue la \nindicaci\u00f3n con mayor n\u00famero de IPT con 29 (25,9%), seguido del c\u00e1ncer de mama 17 (15,2%), melanoma 16 (14,3%) y \nc\u00e1ncer de pr\u00f3stata 12 (10,7%). El subgrupo terap\u00e9utico de la clasificaci\u00f3n ATC con mayor n\u00famero de principios activos fue \nL01E (inhibidores de la proteinquinasa).  \nDe las 112 indicaciones oncol\u00f3gicas evaluadas, usando la escala ESMO-MCBS, 50,9% (57/112) ten\u00edan un beneficio cl\u00ednico \nsustancial o relevante (puntuaci\u00f3n A para tumores curativos y puntuaciones 4 y 5 para tratamientos paliativos) y 42,9% \n(48/112) beneficio cl\u00ednico no relevante (puntuaci\u00f3n C en terapias curativas y puntuaciones 1, 2 y 3 para terapias no \ncurativas). En 7 (6,2%) no se dispuso de informaci\u00f3n. Los ensayos cl\u00ednicos pivotales fueron mayoritariamente de fase III \n(82,1%) y las variables primarias m\u00e1s frecuentemente asociadas con las indicaciones financiadas fueron la supervivencia \nlibre de progresi\u00f3n (42,1%) y la supervivencia global (26,3%).\nCONCLUSIONES\nAunque este estudio no encontr\u00f3 relaci\u00f3n entre la magnitud del beneficio cl\u00ednico evaluada con la escala ESMO-MCBS \nv.1.1 y la decisi\u00f3n de financiaci\u00f3n, los resultados muestran su utilidad. Se financiaron mayor n\u00famero de f\u00e1rmacos con \nbeneficio cl\u00ednico relevante que con beneficio no relevante. Los IPT son una herramienta \u00fatil para el posicionamiento de \nun nuevo medicamento y la decisi\u00f3n de financiaci\u00f3n.387CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1224. COMPARACI\u00d3N DE CRITERIOS DE DOSIFICACI\u00d3N DE ANTINEOPL\u00c1SICOS EN REG\u00cdMENES DE \nACONDICIONAMIENTO PREVIO AL TRASPLANTE DE PROGENITORES HEMATOPOY\u00c9TICOS EN PACIENTES \nOBESOS \nAUTORES\nPERETTO , S; POLO MONTANERO, P; ALBERT MAR\u00cd, A; BORRELL GARC\u00cdA, C; ESCOBAR CAVA, P; L\u00d3PEZ BRIZ, E; POVEDA \nANDR\u00c9S, JL\nHOSPITAL UNIVERSITARIO LA FE \ufffd AV\ufffd CAMPANAR, 21 VALENCIA \ufffd VALENCIA\nOBJETIVOS\nComparar la dosis prescrita de antineopl\u00e1sicos en reg\u00edmenes de acondicionamiento previos al trasplante de progenitores \nhematopoy\u00e9ticos (TPH) en pacientes adultos obesos, seg\u00fan criterios propios del hospital y recomendaciones de \ndosificaci\u00f3n propuestas por la American Society for Blood and Marrow Transplantation (ASBMT).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo en pacientes adultos obesos (IMC\u226530) sometidos a TPH con esquemas de \nacondicionamiento en un hospital terciario de enero de 2019 a septiembre de 2021.  \nSe recogieron las variables talla, peso real (PR), edad, sexo, \u00edndice de masa corporal (IMC), superficie corporal (SC), \npeso ideal (PI), peso dosificaci\u00f3n (PD, utilizado en el c\u00e1lculo de dosis), dosis prescrita para cada antineopl\u00e1sico del \nesquema de acondicionamiento. La SC se calcula en base al peso de dosificaci\u00f3n (PD). Se han comparado dosis para cada \nantineopl\u00e1sico:  \nA) Dosis prescrita utilizando criterios propios del hospital: PD=PI del receptor; si PR-PI > 25%PI utilizar peso ideal ajustado \n(PIA), PD=PIA40 (PIA40= PI + 0.4*(PR-PI). Se aplica a todos los f\u00e1rmacos que componen el esquema.  \nB) Dosis calculada por peso o SC basado en PD seg\u00fan criterios recomendados por la ASBMT diferente para cada f\u00e1rmaco: \nbusulf\u00e1n [Kg;PD=PIA25; PIA25= PI + 0.25*(PR-PI)]; carboplatino (SC;PD=PR); carmustina (SC; si PR > 120%PI\u2192PD=PIA25); \nciclofosfamida (kg; si PR > 120%PI\u2192PD=PIA25); citarabina (SC;PD=PR); etop\u00f3sido (SC;PD=PR); fludarabina (SC;PD=PR); \nmelfal\u00e1n (SC;PD=PR); timoglobulina (kg;PD=PR).  \nSe excluy\u00f3 tiotepa del an\u00e1lisis por el m\u00e9todo de c\u00e1lculo de dosis (por Kg en nuestros esquemas y por SC seg\u00fan \nrecomendaciones ASBMT).\nRESULTADOS\nSe incluyeron 63 pacientes obesos (62.5% hombres) con IMC\u226530. La mediana de edad fue de 58 a\u00f1os (rango 23-71); y la \nmediana del IMC de 32 Kg/m2 (rango 30-49.1). Se compararon las dosis de 579 mezclas de antineopl\u00e1sicos.  \nLas variaciones medias seg\u00fan f\u00e1rmaco (en pacientes obesos) fueron (valor e IC95%):  \nbusulf\u00e1n 1,92% (1,41-2,43%); carboplatino 0%; carmustina 0,77% (0,03-1,51%); ciclofosfamida 1,29% (0,70-1,88%); \ncitarabina 4,3% (3,96-4,64%); etop\u00f3sido 3,98% (3,65-4,31%); fludarabina 3,95% (3,70-4,20%); melfal\u00e1n 5,19% (4,75-\n5,63%); timoglobulina 5,11% (3,46-6,76%).\nCONCLUSIONES\nComparando con las recomendaciones de la ASBMT, el porcentaje de desviaci\u00f3n de todos los f\u00e1rmacos est\u00e1 por debajo \ndel 5%, excepto melfal\u00e1n y timoglobulina ( < 7%), por lo que se considera que no presentan diferencias significativas en la \ndosificaci\u00f3n prescrita seg\u00fan nuestros criterios y los de la ASBMT.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1242. ADECUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE ANTIEM\u00c9TICOS EN F\u00c1RMACOS ANTINEOPL\u00c1SICOS POR \nV\u00cdA ORAL \nAUTORES\nHENARES L\u00d3PEZ, A; FERN\u00c1NDEZ CABALLERO, R; COLLADOS ARROYO, V; MAYO L\u00d3PEZ, C\nHOSPITAL INFANTA ELENA \ufffd AV\ufffd REYES CAT\u00d3LICOS, 21 VALDEMORO \ufffd MADRID\nOBJETIVOS\nLas \u00faltimas actualizaciones de gu\u00edas sobre antiemesis de la American Society of Clinical Oncology (ASCO) en 2020 \ny National Comprehensive Cancer Network (NCCN) en 2021 cambiaron la clasificaci\u00f3n del grado emet\u00f3geno de \nquimioterapia por v\u00eda oral pasando de 4 niveles de riesgo (alto, moderado, bajo y m\u00ednimo) a dos (alto/moderado y bajo/\nm\u00ednimo).  \nEl objetivo de nuestro estudio es analizar la adecuaci\u00f3n a las nuevas gu\u00edas de las prescripciones de antiem\u00e9ticos a \npacientes en tratamiento con f\u00e1rmacos antineopl\u00e1sicos orales que acuden a la consulta de Farmacia.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo de los pacientes en tratamiento con quimioterapia oral que acudieron a la Farmacia de \nun hospital de segundo nivel entre el 04/04/2022 y el 12/05/2022.  \nA partir de la historia cl\u00ednica electr\u00f3nica y de la entrevista con el paciente se obtuvieron las variables: edad, sexo, f\u00e1rmaco, \nd\u00edas con n\u00e1useas y/o v\u00f3mitos desde la \u00faltima cita con Farmacia, grado de n\u00e1useas/v\u00f3mitos, presencia/ausencia de \nantiem\u00e9ticos prescritos en la receta electr\u00f3nica (RE) y necesidad de tomar antiem\u00e9ticos profil\u00e1cticos o de rescate.388RESULTADOS\nSe realizaron 86 dispensaciones a 63 pacientes (33 hombres) y de \u00e9stos, 55 recibieron antineopl\u00e1sicos de riesgo bajo/\nm\u00ednimo: acalabrutinib(n=1), alectinib(n=3), cabozantinib(n=1), capecitabina(n=6), dasatinib(n=2), ibrutinib(n=7), \nimatinib(n=5), lenalidomida(n=8), neratinib(n=1), nilotinib(n=1), osimertinib(n=2), palbociclib(n=3), pomalidomida(n=1), \nribociclib(n=3), sorafenib(n=2), sunitinib(n=3), temozolomida(n=3), trifluridina/tipiracilo(n=2), y vandetanib(n=1). Ocho \npacientes recibieron f\u00e1rmacos o esquemas de riesgo moderado/alto: niraparib (n=1) y capecitabina+oxaliplatino, XELOX \n(n=7).  \nDe los 55 pacientes del grupo de riesgo bajo/m\u00ednimo, 31 (56%) ten\u00edan alg\u00fan antiem\u00e9tico en su RE: ondansetron(n=14), \nmetoclopramida(n=15) y ondansetron+metoclopramida(n=1). Cinco pacientes del grupo (60% hombres) con una edad \nmedia de 76.3 (\u00b16.76) a\u00f1os tuvieron n\u00e1useas (3 con capecitabina, 1 con trifluridina/tipiracilo y 1 con ibrutinib) una \nmediana de 3 d\u00edas (1-15). De ellos, s\u00f3lo 1 tom\u00f3 metoclopramida de rescate. El grado de n\u00e1useas vari\u00f3 de grado 1-3.  \nUn paciente tom\u00f3 ondansetron como profilaxis antiem\u00e9tica los 5 d\u00edas de tratamiento con temozolomida sin presentar \nn\u00e1useas ni v\u00f3mitos.  \nDe los 8 pacientes del grupo de riesgo alto/moderado, 7 (7,5%) ten\u00edan ondansetron en su RE. Tres pacientes (100% \nhombres) con una edad media de 58(\u00b115.1) a\u00f1os tuvieron n\u00e1useas con el esquema XELOX una mediana de 3 d\u00edas (3-4). \nS\u00f3lo 2 tomaron ondansetron tras un episodio de n\u00e1useas. El grado de n\u00e1useas vari\u00f3 entre 1-2.\nCONCLUSIONES\nA pesar de tratarse de una poblaci\u00f3n peque\u00f1a y no poder obtener resultados concluyentes, se demuestra que existe \ngran variabilidad en las prescripciones de antiem\u00e9ticos. Cuando se prescribieron en el grupo de riesgo bajo/m\u00ednimo se \nadecuaron a las gu\u00edas (antagonistas 5-HT3 o metoclopramida), pero no en el caso del grupo de riesgo moderado/alto, en \nel que estar\u00eda recomendado utilizar al menos un antagonista 5-HT3 combinado con dexametasona.  \nLa reagrupaci\u00f3n de 4 a 2 grupos de riesgo hace dif\u00edcil predecir qu\u00e9 profilaxis se debe utilizar. Las gu\u00edas tampoco hacen \nalusi\u00f3n a la posolog\u00eda de los antiem\u00e9ticos en el caso de f\u00e1rmacos antitumorales orales, los cuales se toman diariamente o \ndurante varias semanas seguidas\ufffd  \nSer\u00eda necesaria una revisi\u00f3n m\u00e1s exhaustiva por parte de las sociedades cient\u00edficas centr\u00e1ndose en estos f\u00e1rmacos para \nevitar la variabilidad en la prescripci\u00f3n y unificar criterios.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1282. EFECTOS ADVERSOS INMUNOMEDIADOS ASOCIADOS A LOS INHIBIDORES DE CHECKPOINTS \nAUTORES\nMART\u00cdN RUFO, M; MART\u00cdNEZ BARROS, H; FERN\u00c1NDEZ FRADEJAS, J; ESPADAS HERV\u00c1S, N; GEMENO L\u00d3PEZ, E; \nS\u00c1NCHEZ CUERVO, M; PUEYO L\u00d3PEZ, C; \u00c1LVAREZ D\u00cdAZ, A\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nCada vez son m\u00e1s los inhibidores de checkpoints (ICI) que se utilizan como alternativa terap\u00e9utica en diferentes tipos de \nc\u00e1ncer. Sin embargo, el desequilibro inmunol\u00f3gico producido puede dar lugar a la aparici\u00f3n de m\u00faltiples efectos adversos \ninmunomediados (EAir). El objetivo de este estudio es analizar los EAir asociados a ICIs, su momento de aparici\u00f3n y \nmanejo.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y descriptivo realizado en un hospital de tercer nivel entre enero y diciembre de \n2021. Se incluyeron todos los pacientes que iniciaron tratamiento con un ICI. Se recogieron las siguientes variables: sexo, \nedad, diagn\u00f3stico, ICI, EAir [frecuencia (%) con respecto al global de la muestra], momento de aparici\u00f3n (semanas) y \nmanejo (farmacol\u00f3gico, necesidad de interrupci\u00f3n temporal o permanente). Los datos se recogieron a partir de la historia \ncl\u00ednica electr\u00f3nica y del programa de prescripci\u00f3n electr\u00f3nica del hospital y se analizaron en la base de datos Excel\u00ae.\nRESULTADOS\nSe incluyeron 201 pacientes (68,2% hombres), mediana de edad 69 (rango intercuart\u00edlico: 60-75) y en tratamiento \ncon: pembrolizumab (34,3%), nivolumab (20,9%), atezolizumab (17,4%), ipilimumab+nivolumab (12,4%), avelumab \n(5,5%), durvalumab (5,5%) y cemiplimab (4,0%). Las principales neoplasias fueron c\u00e1ncer de pulm\u00f3n no microc\u00edtico \n(31,8%), melanoma (14,9%), urotelial (14,4%), renal (10,4%), cabeza y cuello (8,5%) y hep\u00e1tico (6,0%). Se produjeron \nun total de 109 EAir en 83 pacientes (41,3%), de los cuales 20 (9,9%) presentaron m\u00e1s de un tipo. Los EAir descritos \nfueron afectaci\u00f3n cut\u00e1nea (13,9% prurito; 4,5% exantemas y 0,5% psoriasis), diarrea (7,5%), nefritis (7,5%), afectaci\u00f3n \ntiroidea (4,0% hipotiroidismo y 1,0% hipertiroidismo), neumonitis (4,5%), hepatotoxicidad (4,0%), trombopenia (1,5%) \ny miastenia gravis (1%). Hubo casos aislados (1 paciente) de miocarditis, miositis y vasculitis. De acuerdo al ICI prescrito, \nla proporci\u00f3n de EAir fue: 72,7% durvalumab; 69,23% ipilimumab+nivolumab; 61,5% avelumab; 42,7% pembrolizumab; \n39,1% nivolumab; 37,5% cemiplimab; 25,0% atezolizumab. El 65,1% de los EAir aparecieron en las primeras 12 semanas, \nde los cuales el 33,9% entre las semanas 0 y 4 destacando la afectaci\u00f3n cut\u00e1nea (9,2%) y la diarrea (6,5%). El manejo de \nlos EAir se realiz\u00f3 principalmente con corticoides sist\u00e9micos en el 53,2%, antihistam\u00ednicos y/o corticoides t\u00f3picos 16,5% \n(casos de afectaci\u00f3n cut\u00e1nea), levotiroxina 7,4% (hipotiroidismo) y el 19,8% no requiri\u00f3 manejo. El 15,4% de los pacientes \ninterrumpi\u00f3 definitivamente el ICI debido a los EAir y el 9,9% lo interrumpi\u00f3 temporalmente.\nCONCLUSIONES\nEn nuestro estudio, la toxicidad inmunomediada asociada a los ICIs afecta a casi la mitad de los pacientes, predominando \nla afectaci\u00f3n cut\u00e1nea y la diarrea.  389Los EAir se han descrito con mayor frecuencia en pacientes en tratamiento con durvalumab y la combinaci\u00f3n \nipilimumab+nivolumab.  \nLa tercera parte de los EAir se ha manifestado en el primer mes de tratamiento.  \nEn la mayor parte de los casos el manejo se realiza con corticoides y no implica la suspensi\u00f3n del tratamiento.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS \nV\u00cdRICAS Y VIH)\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n71. AN\u00c1LISIS DE LA EFECTIVIDAD Y FACTORES DE RIESGO DE MORTALIDAD RELACIONADOS CON EL USO \nDE TIGECICLINA \nAUTORES\nBARRANTES GONZ\u00c1LEZ, M; GRAU CERRATO, S; CONDE EST\u00c9VEZ, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEvaluar la efectividad y factores de riesgo de mortalidad relacionados con el uso de tigeciclina.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional de febrero de 2007 a febrero de 2013 en un hospital universitario de tercer nivel \n(431 camas, 18 de UCI). Se incluyeron todos los pacientes ingresados, mayores de 18 a\u00f1os, a los que se les administr\u00f3 al \nmenos una dosis de tigeciclina.  \n \nDatos recogidos: demogr\u00e1ficos; cl\u00ednicos (unidad de hospitalizaci\u00f3n, \u00edndice de Charlson agrupado, gravedad mediante la \npuntuaci\u00f3n del Simplified Acute Physiology Score (SAPS II); relacionados con la infecci\u00f3n (foco, mono/polimicrobiana, \ncomunitaria/nosocomial); microbiol\u00f3gicos (cultivos, microrganismos aislados, evoluci\u00f3n y flora emergente); relacionados \ncon el tratamiento (tiempo hasta la prescripci\u00f3n, duraci\u00f3n del tratamiento, primera elecci\u00f3n, rescate, emp\u00edrico o dirigido, \ntratamiento previo y concomitante, cumplimiento de la pauta posol\u00f3gica y de las indicaciones aprobadas); evoluci\u00f3n \n(favorable o fracaso terap\u00e9utico), mortalidad cruda y a los 30 d\u00edas.  \n \nSe realiz\u00f3 un an\u00e1lisis independiente de efectividad y mortalidad: an\u00e1lisis bivariado con la prueba de chi cuadrado y test \nexacto de Fischer para variables categ\u00f3ricas y t student para las cuantitativas. Posteriormente se realiz\u00f3 una regresi\u00f3n \nlog\u00edstica multivariante. Los coeficientes de regresi\u00f3n log\u00edstica se utilizaron para estimar la raz\u00f3n de las ventajas (Odds \nRatio (OR) o raz\u00f3n de odds) de cada variable independiente del modelo. Se estableci\u00f3 como significaci\u00f3n estad\u00edstica una \np < 0,05.\nRESULTADOS\nSe incluyeron un total de 524 pacientes. Se produjo evoluci\u00f3n favorable en 264 pacientes (50,4%).Tras la realizaci\u00f3n del \nan\u00e1lisis multivariante, las variables consideradas como factores de riesgo independientes de evoluci\u00f3n favorable fueron \n[OR (IC95%; p)]: SAPS II < 34 al inicio de tigeciclina: 0,385 (0,237-0,623; p < 0,001), ausencia de bacteriemia: 0,578 (0,332-\n1,008; p=0,054), ausencia de infecci\u00f3n por enterobacterias BLEE: 0,241 (0,099-0,590; p= 0,002), ausencia de infecci\u00f3n por \nS. maltophilia: 0,164 (0,042-0,641; p=0,009), tratamiento con tigeciclina superior a 7 d\u00edas: 3,261 (2,040-5,215; p < 0,001), \nausencia de uso de antimicrobianos previos: 0,472 (0,283-0,788; p= 0,004), no persistencia microbiol\u00f3gica: 0,133 (0,068-\n0,259; p < 0,001) y no aparici\u00f3n de flora emergente: 0,281 (0,166-0,476; p < 0,001). Mortalidad cruda: 113 pacientes \n(21,6%). Casi la totalidad de las defunciones se produjeron a los 30 d\u00edas o menos de iniciar el tratamiento: 95 (18,1%). Las \n\u00fanicas variables consideradas como factores de riesgo independientes de mortalidad a los 30 d\u00edas fueron [OR (IC 95%; \np)]: SAPS II al ingreso > 30: 1,995 (1,036- 3,841; p=0,039); SAPS II al iniciar tratamiento con tigeciclina > 30: 5,084 (2,374-\n10,887; p < 0,001), paciente cr\u00edtico: 3,946 (2,214-7,033; p < 0,001), infecci\u00f3n nosocomial: 2,228 (1,068-4,649; p=0,033), \ninfecci\u00f3n por enterobacterias BLEE: 2,657 (1,045-6,752; p=0,040); infecci\u00f3n por S. maltophillia: 3,484 (1,246-9,740; 0,017) \ny persistencia microbiol\u00f3gica: 3,347 (1,802-6,219; p < 0,001). La Infecci\u00f3n de piel y tejidos blandos (IPTB) se consider\u00f3 \ncomo variable relacionada con la supervivencia a los 30 d\u00edas o menos: 0,340 (0,157-0,736; p= 0,006).\nCONCLUSIONES\nSe produjo evoluci\u00f3n favorable en casi la mitad de los pacientes tratados con tigeciclina. La mortalidad fue casi del 22%, \nsiendo la IPTB la \u00fanica variable relacionada con la supervivencia a los 30 d\u00edas o menos.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n73. AN\u00c1LISIS DESCRIPTIVO DE UNA COHORTE DE PACIENTES TRATADOS CON TIGECICLINA \nAUTORES\nBARRANTES GONZ\u00c1LEZ, M; GRAU CERRATO, S; CONDE EST\u00c9VEZ, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nDescribir las caracter\u00edsticas de una cohorte de pacientes tratados con tigeciclina.390MATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional (febrero 2007-febrero 2013) en un hospital universitario de tercer nivel (431 camas, 18 \nde UCI). Aprobado por el CEIC. Pacientes incluidos: mayores de 18 a\u00f1os con al menos una dosis de tigeciclina.  \n \nDatos recogidos: demogr\u00e1ficos; cl\u00ednicos (unidad de hospitalizaci\u00f3n, \u00edndice de Charlson agrupado, gravedad mediante la \npuntuaci\u00f3n del Simplified Acute Physiology Score (SAPS-II); de la infecci\u00f3n (foco, mono/polimicrobiana, comunitaria/\nnosocomial); microbiol\u00f3gicos (cultivos, microrganismos aislados, evoluci\u00f3n y flora emergente); del tratamiento (tiempo \nhasta la prescripci\u00f3n, duraci\u00f3n del tratamiento, primera elecci\u00f3n, emp\u00edrico o dirigido, tratamiento previo y concomitante, \ncumplimiento de la pauta posol\u00f3gica y de las indicaciones aprobadas); evoluci\u00f3n cl\u00ednica, mortalidad cruda, a los 30 y 60 \nd\u00edas.  \n \nEstad\u00edstica descriptiva: se calcularon las frecuencias para las variables categ\u00f3ricas, las medias e intervalos de confianza \npara las cuantitativas continuas con distribuci\u00f3n param\u00e9trica, y las medianas y sus percentiles en caso de distribuci\u00f3n no \nparam\u00e9trica.\nRESULTADOS\nTotal pacientes incluidos: 524\ufffd  \n \nCaracter\u00edsticas cl\u00ednicas [n (%)]: 287 (55) hombres; edad media [m (\u00b1SD)] 64 (\u00b116,13) a\u00f1os; 197 (37,6) \u00edndice Charlson 0; \nSAPS-II (m (\u00b1SD)): 30 (\u00b111,85) al ingreso y 30,9 (\u00b112,90) al iniciar tratamiento; cirug\u00eda previa o durante el tratamiento: 299 \n(59); cr\u00edticos: 134 (25); estancia hospitalaria [md (p25-p75)]: 23 (11-44) d\u00edas y de 6 (0-23) desde la infecci\u00f3n hasta iniciar \ntratamiento; al\u00e9rgicos a penicilina: 194 (37).  \n \nCaracter\u00edsticas microbiol\u00f3gicas [n (%)]: focos de infecci\u00f3n mayoritario: infecci\u00f3n piel y tejidos blandos (IPTB) 190 (36) e \nintraabdominal (IIA) 184 (35); foco \u00fanico: 269 (51,3); nosocomial: 293 (56); monomicrobiana: 204 (39); microorganismos \naislados m\u00e1s frecuentes: 82 (15) E. coli y 57 (10.9) Streptococcus spp.; bacteriemia: 99 (19); flora emergente: 129 (24,6) \nuna vez iniciado el tratamiento, siendo los microorganismos m\u00e1s frecuentes: 46 (8,8) P . aeruginosa y 42 (8) Candida spp..  \n \nCaracter\u00edsticas del tratamiento (n (%)): dosis de carga: 411 (78,4); dosis superior (100 mg/12h): 25 (4,8) y en 7 (1,3) \nla frecuencia incorrecta; indicaciones aprobadas EMA: 372 (71); duraci\u00f3n tratamiento [md (p25-p75)]: 6 (3-11) d\u00edas; \ndirigido: 167 (31,9); uso de antimicrobianos previos: 383 (73,1), con una md [(p25-p75)] de 2 (0-3) antimicrobianos \nutilizados durante 6 (0-23) d\u00edas, siendo los m\u00e1s frecuentes: 188 (35,9) penicilinas, 157 (30) quinolonas y 152 (29) \ncarbapen\u00e9micos. Terapia combinada: 284 (54,2), siendo los m\u00e1s frecuentes aminogluc\u00f3sidos: 76 (14,5); quinolonas: 62 \n(11,8) y carbapen\u00e9micos: 51 (9,7).  \n \nEvoluci\u00f3n de los pacientes [n (%)]: favorable: 264 (50,4); erradicaci\u00f3n microbiol\u00f3gica 84 (16) y 110 (21) persistencia. Un \ntotal de 113 (21,6) pacientes fallecieron, de los cuales 95 (18,1) a los 30 d\u00edas o antes y 106 (20,2) a los 60 d\u00edas o antes.\nCONCLUSIONES\nLa mayor\u00eda de pacientes en tratamiento con tigeciclina fueron hombres de < 65 a\u00f1os, con IPTB o IIA. Se utiliz\u00f3 \nprincipalmente como tratamiento emp\u00edrico, de rescate y combinado. La evoluci\u00f3n fue favorable en el 50% de los \npacientes y la mortalidad fue del 22%\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n75. IMPACTO EN EL CONSUMO DE TIGECICLINA TRAS LA EMISI\u00d3N DE ALERTAS DE SEGURIDAD E \nIMPLEMENTACI\u00d3N DEL PROGRAMA OPTIMIZACI\u00d3N DE ANTIBI\u00d3TICOS \nAUTORES\nBARRANTES GONZ\u00c1LEZ, M; GRAU CERRATO, S; CONDE EST\u00c9VEZ, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa FDA (Food and Drug Administration), en 2010 y 2013, y la EMA (European Medicines Agency) en el 2011, emitieron \nadvertencias de seguridad sobre un mayor riesgo de mortalidad con tigeciclina en comparaci\u00f3n con otros antibi\u00f3ticos. \nEl objetivo fue cuantificar la evoluci\u00f3n temporal de consumo y prescripci\u00f3n de tigeciclina despu\u00e9s de la emisi\u00f3n de la \nprimera alerta FDA y tras la implementaci\u00f3n de un Programa de Optimizaci\u00f3n del Uso de Antibi\u00f3ticos (PROA).\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo observacional (febrero 2007-febrero 2013) en un hospital universitario de tercer nivel (431 camas, \n18 de UCI). Aprobado por el CEIC. Pacientes incluidos: mayores de 18 a\u00f1os con al menos una dosis de tigeciclina. Datos \nrecogidos: total prescripciones y consumo evaluado mediante DDD/100 estancias-d\u00eda (DDD/100e-d\u00eda). Se calcul\u00f3 el \ntama\u00f1o de muestra necesario para estimar una disminuci\u00f3n en el uso como m\u00e1ximo del 80% (confianza del 95% y un \nerror m\u00e1ximo de \u00b15%). Se dise\u00f1\u00f3 un modelo de regresi\u00f3n lineal segmentada para series de tiempo interrumpido (STI):  \n \nYt = \u03b20 + \u03b21Tiempo t + \u03b22 intervenci\u00f3n 1 Tt + \u03b23 tiempo despu\u00e9s de la intervenci\u00f3n 1 Tt + \u03b24 intervenci\u00f3n 2 Tt + \u03b25 \ntiempo despu\u00e9s de la intervenci\u00f3n 2 Tt + et  \n 391Siendo:  \n \nYt: tasa de consumo medio; \u03b20: nivel basal; \u03b21Tiempo t: tendencia de consumo mensual previo a la alerta FDA; \u03b22 \nintervenci\u00f3n 1 Tt: cambio en el nivel de consumo mensual tras alerta FDA; \u03b23 tiempo despu\u00e9s de la intervenci\u00f3n 1 \nTt: cambio en la tendencia de consumo mensual tras alerta FDA; \u03b24 intervenci\u00f3n 2 Tt: cambio en el nivel de consumo \nmensual tras PROA; \u03b25 tiempo despu\u00e9s de la intervenci\u00f3n 2 Tt: cambio en la tendencia de consumo mensual tras PROA; \nEt: Error a tiempo t, variabilidad aleatoria.  \n \nSe calcul\u00f3 la proporci\u00f3n de disminuci\u00f3n de consumo en cada per\u00edodo y se consider\u00f3 un valor de p < 0,05 como \nestad\u00edsticamente significativo (ES).\nRESULTADOS\nMuestra m\u00ednima calculada: 246 pacientes. Total pacientes incluidos: 524.  \n \nPrescripciones 2007-2013: 43; 93; 155; 129; 65; 42 y 2.  \n \nAn\u00e1lisis de consumo STI: Yt = 0,271 \u03b20 + 0,029 \u03b21 (p < 0,001) - 0,562 \u03b22 (p=0,053) + 0,031 \u03b23 (p=0,575) - 0,831 \u03b24 \n(p=0,010) + 0,004 \u03b25 (p=0,815).  \n \nPreviamente a la alerta, las DDD/100e-d\u00eda aumentaron a un ritmo mensual de 0,029. Tras la primera alerta, se observ\u00f3 \nun descenso de -0,562 en el nivel de consumo y la tendencia de consumo mensual creci\u00f3 a un ritmo de 0,031. Tras la \nimplementaci\u00f3n PROA, se observ\u00f3 un descenso del nivel de -0,831 y un aumento de consumo mensual de 0,004.  \n \nSe calcul\u00f3 una disminuci\u00f3n en el consumo del 35,9% (p=0,053) tras la primera alerta de la FDA y del 67,3% (p=0,010) tras \nla instauraci\u00f3n del PROA \ufffd\nCONCLUSIONES\nSe observ\u00f3 una disminuci\u00f3n significativa del consumo de tigeciclina (35,9%) post-alerta FDA, siendo m\u00e1s significativa \n(67,3%) post-PROA. El equipo PROA demostr\u00f3 ser fundamental para una mejor adecuaci\u00f3n de las prescripciones.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n136. VARIACI\u00d3N DEL GASTO FARMACEUTICO COMO CONSECUENCIA DE LA RETIRADA DE CEFTOLOZANO/\nTAZOBACTAM \nAUTORES\nSOLIS OLIVARES, J; GARRIDO PE\u00d1O, N; SOTO BASELGA, I; SOLLANO SANCHO, I; MORONA M\u00cdNGUEZ, I; POUSADA \nFONSECA, AB; MATEOS MATEOS, Y; MORIEL S\u00c1NCHEZ, C\nHOSPITAL UNIVERSITARIO DE M\u00d3STOLES. R\u00cdO J\u00daCAR, S/N M\u00d3STOLES. MADRID\nOBJETIVOS\nEvaluar y comparar el posible aumento o disminuci\u00f3n del gasto farmac\u00e9utico como consecuencia de la retirada de \nCeftolozano/tazobactam en diciembre de 2020, hasta su restauraci\u00f3n de suministro.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo en un hospital de segundo nivel. Se elabor\u00f3 una base de datos con todos aquellos \npacientes que recibieron ceftazidima/avibactam en el periodo comprendido entre diciembre de 2020 hasta enero \ndel 2022. Incluy\u00f3 el sexo, edad, servicio m\u00e9dico, d\u00edas desde ingreso hasta inicio de tratamiento, d\u00edas en tratamiento, \npatolog\u00eda de base, indicaci\u00f3n y desenlace. Fueron excluidos todos aquellos pacientes cuyo tratamiento con ceftazidima/\navibactam fue dirigido a una bacteria no sensible a ceftolozano/tazobactam. Para el precio de ambos medicamentos, se \nutiliz\u00f3 el precio notificado, el IVA del 4% y el descuento oficial aplicado del 7,5%. Para la determinaci\u00f3n del coste total por \npaciente se comprob\u00f3 aquellas dosis dispensadas y administradas a los pacientes seg\u00fan el registro del M\u00f3dulo Unidosis \nde Farmatools\u00ae y la Historia Cl\u00ednica Electr\u00f3nica Selene\u00ae.\nRESULTADOS\nDurante el periodo de estudio, fueron tratados en nuestro centro 30 pacientes con ceftazidima/avibactam. De los cuales 2 \nde ellos fueron excluidos por presentar un microorganismo con resistencia intr\u00ednseca al ceftolozano/tazobactam. Fueron \nincluidos 28 pacientes (60% hombres, edad media 68 a\u00f1os, DE 11). Los servicios prescriptores fueron Medicina Intensiva \n(71%), Medicina Interna (14%), Traumatolog\u00eda (7%), Hematolog\u00eda (4%) y Urolog\u00eda (4%). La mediana de d\u00edas desde el \ningreso hasta que se instaur\u00f3 el tratamiento con ceftazidima/avibactam fue de 19,78 d\u00edas (DE 17,66) y la mediana de \ntiempo de tratamiento fue de 7 d\u00edas (DE 16,8). El microorganismo aislado fue en un 25% Pseudomona aeruginosa, 18% \nKlebsiella pneumoniae, 18% Enterobacter cloacae y 11% Escherichia coli. Un 29% fue tratado de forma emp\u00edrica por \nempeoramiento cl\u00ednico, anal\u00edtico y situaci\u00f3n epidemiol\u00f3gica bacteriana de la unidad, sin aislamiento microbiol\u00f3gico. 2 de \nlos pacientes presentaron bacterias tambi\u00e9n resistentes a ceftazidima/avibactam, uno de los pacientes falleci\u00f3. 9 de los \n29 pacientes fallecieron durante el ingreso hospitalario.  \nEl gasto total de ceftazidima/avibactam durante todo el periodo fue de 758 viales, lo que supone un total de 80.628\u20ac. El \ngasto equivalente en ceftolozano/tazobactam habr\u00eda sido de 46.768\u20ac. Esto supone un gasto extra de 33.859\u20ac.392CONCLUSIONES\nLa retirada de ceftolozano/tazobactam supuso una perdida muy importante en el escaso arsenal terap\u00e9utico para \nel tratamiento de microorganismos gram negativos multiresistentes, que tuvo que ser suplido con otros f\u00e1rmacos y \ncombinaciones. En nuestro caso adem\u00e1s dos pacientes obtuvieron en sus cultivos microorganismos que solo eran \nsensibles a ceftolozano/tazobactam, por lo que el efecto de la retirada fue mayor en esos casos. Sobre esto hay que \na\u00f1adir el aspecto econ\u00f3mico, que como hemos podido destacar supuso un aumento importante del gasto farmac\u00e9utico. \nComo desventaja cabe destacar las caracter\u00edsticas de conservaci\u00f3n del ceftolozano/tazobactam, ya que es un \nmedicamento de conservaci\u00f3n en frio\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n179. APLICACI\u00d3N DE NUEVOS INDICADORES EN LA MONITORIZACI\u00d3N DEL USO DE ANTIMICROBIANOS \nEN CUIDADOS INTENSIVOS \nAUTORES\nRODR\u00cdGUEZ CAMPOS, E; GUISADO GIL, AB; FERN\u00c1NDEZ RUBIO, B; HERRERA HIDALGO, L; ADRIAENSENS P\u00c9REZ, M; \nFERN\u00c1NDEZ DELGADO, E; ALDAB\u00d3 PALL\u00c1S, T; GIL NAVARRO, MV\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nSe han propuesto nuevos indicadores sobre el uso de antimicrobianos basados en el consumo (Guti\u00e9rrez-Urb\u00f3n et al., \n2019). El objetivo es aplicar los indicadores m\u00e1s relevantes para una Unidad de Cuidados Intensivos (UCI), monitorizar \nsu evoluci\u00f3n y analizar su utilidad para establecer nuevas estrategias en el programa de optimizaci\u00f3n de uso de \nantimicrobianos (PROA) del centro.\nMATERIALES Y M\u00c9TODOS\nUn equipo formado por farmac\u00e9uticos hospitalarios y m\u00e9dicos intensivistas miembros del equipo PROA de un hospital de \ntercer nivel seleccionaron aquellos indicadores de mayor inter\u00e9s para la UCI.  \n \nPara el c\u00e1lculo de los indicadores, fue necesario obtener la dosis diaria definida (DDD) por 100 estancias, globalmente \ny de cada antimicrobiano, durante los a\u00f1os 2019, 2020 y 2021, a partir del programa de prescripci\u00f3n electr\u00f3nica Athos-\nPRISMA\u00ae\ufffd\nRESULTADOS\nLos indicadores seleccionados de cada a\u00f1o se expresan en la siguiente tabla: \n \nTRIMESTRE (T) DDD/100 estancias  \nMACR/FQ SAMS/SAMR AC/PTZ Diversificaci\u00f3n de betalact\u00e1micos antipseudom\u00f3nicos FLUC/EQ \nPTZ CEFA PA CARBA PA  \n1T 2019 0,07 0,70 1,12 14,21 7,50 10,85 2,44  \n2T 2019 0,03 0,83 1,03 14,41 12,27 14,61 3,37  \n3T 2019 0,01 0,67 0,95 13,71 9,68 16,17 5,05  \n4T 2019 0,12 0,80 0,97 15,45 8,92 8,34 2,73  \n1T 2020 0,09 0,87 0,70 18,19 8,12 10,39 3,64  \n2T 2020 0,24 0,76 1,05 14,04 6,59 16,76 1,57  \n3T 2020 0,11 1,05 0,84 18,80 9,31 15,69 4,17  \n4T 2020 0,03 1,18 0,75 17,74 12,24 19,49 1,29  \n1T 2021 0,17 1,03 0,57 23,53 13,70 20,26 1,52  \n2T 2021 0,15 1,15 0,95 16,50 12,27 18,09 2,29  \n3T 2021 0,16 1,07 1,03 15,65 13,95 19,57 1,90  \n4T 2021 0,05 0,86 0,96 17,80 13,80 14,79 3,71  \nAbreviaciones: MAC/FQ, ratio macrolidos intravenosos/fluorquinolonas respiratorias; SAMS/SAMR, ratio agentes \nanti-Staphylococcus aureus sensible a meticilina/agentes anti-Staphylococcus aureus resistente a meticilina; AC/\nPTZ, ratio amoxicilina-clavul\u00e1nico/piperacilina-tazobactam; PTZ, piperacilina-tazobactam; CEFA PA; cefalosporinas \nantipseudom\u00f3nicas; CARBA PA, carbapen\u00e9micos antipseudom\u00f3nicos; FLUC/EQ, ratio fluconazol/equinocandinas.  \n \nSe observa un incremento progresivo del consumo de macr\u00f3lidos frente a fluorquinolonas respiratorias, en l\u00ednea con \nel cambio de protocolos de tratamiento, priorizando el uso de azitromicina frente a quinolonas en la combinaci\u00f3n con \nceftriaxona en neumon\u00eda comunitaria grave. Tambi\u00e9n aumentaron los agentes anti-SAMS frente a agentes anti-SAMR en \nrelaci\u00f3n con la baja prevalencia de SAMR en nuestro centro. La diversificaci\u00f3n de betalact\u00e1micos antipseudom\u00f3nicos fue \nmuy elevada a lo largo de los tres a\u00f1os. Sin embargo, aument\u00f3 notablemente el uso de piperacilina-tazobactam frente a \namoxicilina-clavul\u00e1nico y el uso de equinocandinas fue variable, con incrementos en algunos trimestres.\nCONCLUSIONES\nLos nuevos indicadores permiten conocer la calidad del uso de antimicrobianos en la UCI, aportando m\u00e1s informaci\u00f3n \nque el an\u00e1lisis individual de las DDD/100 estancias de cada antimicrobiano. Su aplicaci\u00f3n ha llevado a la detecci\u00f3n de \nproblemas potenciales en el uso de los antimicrobianos, lo que facilita la implantaci\u00f3n de acciones de mejora dirigidas en \nestas unidades\ufffd393CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n180. PROFILAXIS PRE-EXPOSICI\u00d3N DE PACIENTES VIH: SEGUIMIENTO FARMACOTERAP\u00c9UTICO EN \nPR\u00c1CTICA HABITUAL \nAUTORES\nGONZALEZ FREIRE, L; MARTINEZ MARTINEZ, L; BARCA DIEZ, C; PROUPIN CANTELAR, IC; BUSTELO PAZ, F; FRANCO \nSANDAR, B; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA\nOBJETIVOS\nEvaluar la efectividad, seguridad y adherencia del tratamiento antirretroviral para pacientes seronegativos que reciben \nprofilaxis preexposici\u00f3n (PrEP) con emtricitabina/tenofovir (FTC/TDF), mediante monitorizaci\u00f3n farmacoterap\u00e9utica en \npr\u00e1ctica farmac\u00e9utica habitual.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de 15 pacientes que iniciaron tratamiento con FTC/TDF desde la comercializaci\u00f3n y \npuesta en mercado para PrEP (diciembre 2019 - noviembre 2021). El tiempo de seguimiento de cada tratamiento fue 12 \nmeses\ufffd \nLas variables utilizadas en el estudio (edad, sexo, cribados serol\u00f3gicos, creatinina s\u00e9rica, fosfatemia y RA) se recogieron de \nla historia cl\u00ednica electr\u00f3nica y el aplicativo electr\u00f3nico de dispensaci\u00f3n de medicamentos a pacientes externos. \nPara la valoraci\u00f3n de la efectividad se realizaron cribados serol\u00f3gicos de VIH cada 3 meses desde el inicio de tratamiento \nde cada paciente\ufffd \nLa toxicidad renal se evalu\u00f3 mediante las determinaciones de creatinina s\u00e9rica y fosfatemia al inicio de tratamiento, a los \n3, 6 y 12 meses\ufffd  \nPara la monitorizaci\u00f3n de la adherencia se utiliz\u00f3 una escala visual anal\u00f3gica (EVA) y se cotej\u00f3 con el porcentaje de \nposesi\u00f3n a 12 meses, calculado como el n\u00famero total de unidades dispensadas partido del n\u00famero de unidades totales \nte\u00f3ricas prescritas en ese intervalo de tiempo multiplicado por 100.  \nEl an\u00e1lisis estad\u00edstico se llev\u00f3 a cabo mediante la prueba t-student expresando los resultados como media \u00b1 desviaci\u00f3n \nest\u00e1ndar. Se consider\u00f3 un nivel de significancia estad\u00edstica p < 0,05. El programa utilizado fue el software IBM SPSS\u00ae \nStatistic versi\u00f3n 23.\nRESULTADOS\nDel total de 15 pacientes estudiados, 14 (93,3%) eran hombres y 1 (6,7%) transexual. La mediana de edad fue de 34 (26-\n55) a\u00f1os.  \nEl 100% de los cribados serol\u00f3gicos realizados resultaron negativos para VIH.  \nNo se encontraron diferencias estad\u00edsticamente significativas en la creatinina s\u00e9rica al inicio 0,86\u00b10,13; a los 3 meses \n0,90\u00b10,13 (p=0,387); a los 6 meses 0,90\u00b10,12 (p=0,469) y a los 12 meses de tr atamiento 0,91\u00b10,13 (p=0,390).  \nLa fosfatemia fue de 3,61\u00b10,62 al inicio del tratamiento; 3,74\u00b10,71 (p=0,626) a los 3 meses; 3,84\u00b10,67 (p=0,408) a los 6 \nmeses y 3,56\u00b10,91 (p=0,885) a los 12 meses, resultando sin diferencias estad\u00edsticamente significativas.  \nNo se detectaron RA al tratamiento con FTC/TDF en ninguno de los pacientes\ufffd \nLa adherencia media resultante en funci\u00f3n de la EVA fue de 97,86\u00b13,93%. El resultado del porcentaje de posesi\u00f3n fue de \n91,11\u00b19,99%\ufffd\nCONCLUSIONES\nEn nuestro estudio los tratamientos PrEP de VIH fueron efectivos atendiendo a los cribados serol\u00f3gicos realizados.  \nAsimismo, se puede considerar que el tratamiento PrEP es seguro, al no detectarse RA ni objetivarse toxicidad renal en \nlos controles realizados.  \nLa adherencia observada muestra una alta tasa de cumplimiento terap\u00e9utico por parte de los pacientes.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n198. HIPERPOTASEMIA POR COTRIMOXAZOL: ALGUNOS ASPECTOS A TENER EN CUENTA DURANTE LA \nVALIDACI\u00d3N. \nAUTORES\nMURGADELLA SANCHO, A; GRACIA GARCIA, B; PUEBLA VILLAESCUSA, A; LOSA L\u00d3PEZ, L; BARRERA PUIGDOLLERS, \nMT; HIDALGO ALBERT , E\nHOSPITAL DE SANT JOAN DESPI MOISES BROGGI. AVENIDA JACINT VERDAGUER 90 SANT JOAN DESP\u00cd. BARCELONA\nOBJETIVOS\nLa hiperpotasemia es una reacci\u00f3n adversa descrita asociada al uso de cotrimoxazol. Los objetivos de nuestro estudio \nson: \n- Evaluar la incidencia de hiperpotasemia en pacientes hospitalizados en tratamiento con cotrimoxazol.  \n- Evaluar si existen diferencias, en cuanto a presencia de insuficiencia renal cr\u00f3nica (IRC) y prescripci\u00f3n de f\u00e1rmacos \nconcomitantes que causen hiperpotasemia (FH), entre los pacientes que desarrollan hiperpotasemia y los que no.\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico (2 centros de nivel II), observacional y retrospectivo en el que se incluy\u00f3 a todos los pacientes \nhospitalizados que recibieron cotrimoxazol durante m\u00e1s de 3 d\u00edas durante su ingreso a lo largo del 2021.  \nVariables recogidas: Edad, sexo, d\u00edas de estancia hospitalaria, indicaci\u00f3n del tratamiento, presencia de IRC, presencia de 394FH, incidencia de hiperpotasemia y repercusi\u00f3n cl\u00ednica de la misma.  \nLos FH estudiados fueron: IECAs, ARAII, beta-bloqueantes, digoxina, litio, inhibidores de la calcineurina, AINEs, \nespironolactona, Eplerenona y suplementos de potasio\ufffd  \nLas variables cuantitativas se expresaron en forma de mediana con su rango intercuart\u00edlico y las variables cualitativas en \nforma de proporci\u00f3n. La comparaci\u00f3n de proporciones se analiz\u00f3 mediante el test \u03c72. Para el an\u00e1lisis estad\u00edstico se utiliz\u00f3 \nel SPSS versi\u00f3n 26\ufffd\nRESULTADOS\nSe incluyeron en el estudio 137 pacientes, de los cuales el 68% (n=93) fueron hombres. La mediana de edad fue de 71 \na\u00f1os [57,0-82,5] y la mediana de la estancia hospitalaria fue de 16 d\u00edas [10,0-27,0].  \nLas indicaciones de cotrimoxazol fueron: infecci\u00f3n del tracto urinario (29%), profilaxis Pneumocystis jiroveccii (20%), \ninfecci\u00f3n respiratoria (19%), Infecci\u00f3n Osteoarticular (14%), infecci\u00f3n de piel y partes blandas (13%) y otras (5%).  \n \nLa incidencia de hiperpotasemia fue del 21% en los pacientes tratados con cotrimoxazol (n=29). En todos los casos, \u00e9sta \nfue leve (Potasio < 6 mmol/L) y sin repercusi\u00f3n cl\u00ednica. \nSe compar\u00f3 la proporci\u00f3n de pacientes con FH entre el grupo que desarroll\u00f3 hiperpotasemia y el que no (69% vs 55%, \nrespectivamente), no encontr\u00e1ndose diferencias estad\u00edsticamente significativas (\u03c72, p=0.165).  \nTambi\u00e9n se compar\u00f3 la proporci\u00f3n de pacientes con IRC entre ambos grupos (75% vs 57%, respectivamente). Aunque \nla proporci\u00f3n de IRC fue casi 20 puntos mayor en el grupo con hiperpotasemia, esta diferencia no fue estad\u00edsticamente \nsignificativa (\u03c72, p=0.058).\nCONCLUSIONES\n- En nuestro estudio, la incidencia de hiperpotasemia en pacientes hospitalizados tratados con cotrimoxazol fue \nrelativamente frecuente, pero leve y sin repercusi\u00f3n cl\u00ednica. Por lo tanto, consideramos que no requiere de una \nmonitorizaci\u00f3n intensificada durante la validaci\u00f3n farmac\u00e9utica. \n- En nuestra poblaci\u00f3n, ni los FH ni la IRC se asociaron a mayor incidencia de hiperpotasemia, desde el punto de vista \nestad\u00edstico. Sin embargo, en el caso de la IRC dado que la magnitud de la diferencia es relevante desde el punto de vista \ncl\u00ednico, deber\u00eda estudiarse en un mayor n\u00famero de pacientes antes de descartar la asociaci\u00f3n.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n223. USO DE SOTROVIMAB EN PACIENTES CON COVID-19: RESULTADOS INICIALES EN VIDA REAL \nAUTORES\nRODR\u00cdGUEZ ESQU\u00cdROZ, A; TEJADA MAR\u00cdN, D; CAPDEVILLA BASTONS, F; DE LA RIVA BOHIGAS, R; ERDOZAIN \nCLEMENTE, S; INDURAIN GO\u00d1I, N; LAMAS PILLO, A; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDescribir los resultados iniciales de eficacia y seguridad del uso de sotrovimab en pacientes con COVID-19 en riesgo de \nprogresi\u00f3n a COVID grave\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en el que se incluyeron todos los pacientes tratados con sotrovimab entre septiembre 2021 y marzo \n2022, tanto hospitalizados como ambulatorios. Se recogieron datos demogr\u00e1ficos (edad y sexo), n\u00famero de d\u00edas de \ns\u00edntomas previos al tratamiento, variante del virus, anticuerpos postvacunales, y uso de corticoides concomitantes.  \nSe recogi\u00f3 la tasa de requerimiento de ox\u00edgeno de alto flujo (OAF) o ventilaci\u00f3n mec\u00e1nica (VM), reingreso, ingreso en UCI \no muerte a los 30 d\u00edas tras la administraci\u00f3n de sotrovimab y la tasa de reacciones adversas tras la administraci\u00f3n del \nf\u00e1rmaco.\nRESULTADOS\nRecibieron sotrovimab 34 pacientes: 32 (94.1%) hospitalizados y 2 (5.9%) de manera ambulatoria. La edad media fue \nde 60,4\u00b115,2 a\u00f1os, 35% mujeres. Veinticinco (59,5%) pacientes presentaban la variante \u00f3micron, un paciente (2,9%) \nla variante india y en el resto (23,5%) se desconoc\u00eda. El tiempo medio de evoluci\u00f3n de s\u00edntomas fue de 21\u00b118.4 d\u00edas. \nTan solo un paciente presentaba anticuerpos post-vacunales positivos, siendo el resto negativos (n=32, 94.1%), o no \ndeterminados (n=1). Un 82% de los pacientes recibi\u00f3 tratamiento con corticoides concomitantes. \nAl inicio del tratamiento, 10 pacientes (29,4%) requirieron ox\u00edgeno de bajo flujo (OBF), un paciente (2.9%) OAF, \notro (2.9%) ventilaci\u00f3n mec\u00e1nica invasiva, y el resto (64.7%) no requer\u00edan soporte respiratorio. Hasta el d\u00eda 30 post-\ntratamiento, se produjo el fallecimiento de 1 paciente (2.9%), otro (2.9%) requer\u00eda OAF, 3 (8.8%) OBF y el resto (85.3%) \nno requer\u00edan soporte respiratorio complementario. Adem\u00e1s, 2 (5.9%) pacientes requirieron ingreso en UCI y 8 (23.5%) \nrequirieron reingreso hospitalario tras el alta. \nCon respecto a seguridad, 7 pacientes (20%) sufrieron reacciones infusionales durante su administraci\u00f3n. Uno de \nellos requiri\u00f3 un aumento de los aportes de ox\u00edgeno, mientras que en el resto de los casos fue suficiente con soporte \nfarmacol\u00f3gico\ufffd En todos los casos, el cuadro se resolvi\u00f3\ufffd\nCONCLUSIONES\nSotrovimab es una alternativa al tratamiento de la enfermedad COVID-19 en pacientes de alto riesgo de progresi\u00f3n a \nenfermedad grave. La poblaci\u00f3n de nuestro estudio difiere considerablemente de la incluida en el ensayo COMET-ICE. En \nnuestros pacientes se obtienen peores resultados de eficacia que los presentados en dicho ensayo.  \nEn referencia a los efectos adversos, existe una proporci\u00f3n relevante de pacientes que desarrolla reacciones relacionadas \ncon la infusi\u00f3n, aunque todas fueron resueltas.395CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n226. USO DE TOCILIZUMAB DE FORMA PRECOZ EN EL TRATAMIENTO DE PACIENTES CON NEUMON\u00cdA \nGRAVE POR COVID-19 EN UN HOSPITAL COMARCAL. \nAUTORES\nCORRAL BAENA, S; GARABITO S\u00c1NCHEZ, M; FERRIS VILLANUEVA, E\nHOSPITAL SAN JUAN DE DIOS DE EL ALJARAFE. AVDA. SAN JUAN DE DIOS, S/N BORMUJOS. SEVILLA\nOBJETIVOS\nAnalizar el uso de Tocilizumab (TZC) de forma precoz, previo al inicio de la ventilaci\u00f3n mec\u00e1nica, en pacientes \nhospitalizados por neumon\u00eda grave por COVID-19 y su influencia en la evoluci\u00f3n y pron\u00f3stico de los pacientes.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo. Se incluyen los pacientes hospitalizados con diagn\u00f3stico confirmado de neumon\u00eda \ngrave por COVID-19 que recibieron TCZ de marzo 2020 a mayo 2021. Las variables registradas fueron: sexo, edad, \ncomorbilidad previa, d\u00edas desde inicio de s\u00edntomas hasta administraci\u00f3n de TCZ y tipo de soporte ventilatorio en el \nmomento de la administraci\u00f3n de TZC. Los resultados se analizaron seg\u00fan si los pacientes hab\u00edan recibido TZC de forma \nprecoz (Tp), previo al inicio de la ventilaci\u00f3n mec\u00e1nica no invasiva (VMNI) o gafas nasales de alto flujo (ONAF) o de forma \ntard\u00eda (Tt); estando ya con dicho soporte respiratorio. La evoluci\u00f3n cl\u00ednica se evalu\u00f3 mediante los cambios en la necesidad \nde oxigenoterapia a los 14 d\u00edas de la administraci\u00f3n de TCZ, d\u00edas de ingreso hospitalario, necesidad de ingreso en UCI y \nmortalidad. Los datos se obtuvieron a partir de la historia cl\u00ednica digital y se procesaron mediante estad\u00edstica descriptiva \ncon Microsoft Excell\u00ae 2010, las variables cuantitativas se expresan como medianas y cuartiles (Q1-Q3) y las cualitativas \ncomo porcentaje\nRESULTADOS\nSe incluyeron 48 pacientes, 20 (42%) en el Tp y 28 (58%) en el Tt. En cuanto a las caracter\u00edsticas de los pacientes: 12 (60%) \nhombres, mediana de edad 59 (16-78) a\u00f1os en el Tp y 21 (75%) hombres, mediada de edad 63 (43-88) en el Tt. El 90% de \nlos pacientes en el Tp y el 86% en el Tt, presentaban patolog\u00edas previas siendo hipertensi\u00f3n arterial y dislipemias las m\u00e1s \nfrecuentes\ufffd \nLa mediana de d\u00edas desde el inicio de los s\u00edntomas hasta la administraci\u00f3n de TZC fue de 9 (2-13) d\u00edas en el Tp y 10 (2-35) \nen el Tt\ufffd El soporte respiratorio de los pacientes en el momento de la administraci\u00f3n en el Tp fue: 10% gafas nasales, 35% \nmascarilla reservorio, 55% mascarilla efecto venturi y en el Tt: 28% VMNI y 68% ONAF \ufffd  \nA los 14 d\u00edas de la administraci\u00f3n de TCZ, en el Tp: 2 pacientes (10%) estaban sin soporte; 11 (55%) desescalaron y 7 \n(35%) progresaron en el soporte respiratorio; sin precisar ninguno de ellos intubaci\u00f3n orotraqueal (IOT). Requirieron \ningreso en UCI 6 pacientes (30%) y no hubo exitus. La mediana de d\u00edas de ingreso fue 15,5 (5-28) d\u00edas.  \nEn el Tt: 11 pacientes (37%) desescalaron y 16 (57%) progresaron en el soporte respiratorio, 7 de ellos necesitaron IOT. \nRequirieron ingreso en UCI 20 pacientes (71%) y 12 (57%) fueron exitus. La mediana de d\u00edas de ingreso fue de 17(3-57) \nd\u00edas.\nCONCLUSIONES\nEl uso de TCZ en estadios m\u00e1s precoces de la enfermedad mejoro la evoluci\u00f3n y el pron\u00f3stico de los pacientes, \ndisminuyendo el porcentaje de pacientes que ingresaron en Uci, progresaron en el soporte respiratorio (incluyendo la \nIOT) as\u00ed como la mortalidad y los d\u00edas de ingreso hospitalario.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n235. AN\u00c1LISIS DE EFECTIVIDAD Y VALOR PREDICTIVO POSITIVO DE ALERTAS PROA EN UNA HERRAMIENTA \nDE AYUDA A LA PRESCRIPCI\u00d3N DE ANTIMICROBIANOS \nAUTORES\nAMOR GARC\u00cdA, M\u00c1; DE C\u00c1CERES VELASCO, C; MORENO D\u00cdAZ, R; MATILLA GARC\u00cdA, E; RODR\u00cdGUEZ VARGAS, B; \nAPEZTEGUIA FERN\u00c1NDEZ, CA; MELGAREJO ORTU\u00d1O, A; BAUTISTA SANZ, MDP\nHOSPITAL INFANTA CRISTINA. AV . 9 DE JUNIO 2 PARLA. MADRID\nOBJETIVOS\nLas herramientas de ayuda a la prescripci\u00f3n (HAP) son utilizadas en el entorno de trabajo de los programas de \noptimizaci\u00f3n de antibi\u00f3ticos (PROA) para la generaci\u00f3n de alertas que sirven como fuente de recomendaciones e \nintervenciones. Para potenciar esta metodolog\u00eda, es necesario discriminar qu\u00e9 alertas son m\u00e1s \u00fatiles para la rutina diaria.  \nEl objetivo de este estudio es evaluar el uso de alertas generadas en una HAP asociada al PROA mediante el an\u00e1lisis de \nefectividad y valor predictivo positivo (VPP) de las mismas en un hospital de primer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo.  \nSe incluyeron todas las alertas PROA generadas en la HAP de nuestro hospital durante 6 meses, desde el 01/11/2021 \nal 30/04/2022. Las alertas incluidas en la HAP fueron: 1-duraci\u00f3n de tratamiento antimicrobiano intravenoso \u22657 d\u00edas, \n2-terapia secuencial (antimicrobiano intravenoso con buena biodisponibilidad \u22653 d\u00edas), 3-ajuste de antibi\u00f3tico en paciente \ncon insuficiencia renal, 4-ausencia de monitorizaci\u00f3n de antimicrobianos de margen estrecho, 5-inicios de tratamientos \nantimicrobianos restringidos y 6-tratamientos de alto impacto ecol\u00f3gico (TAE) (carbapen\u00e9micos, piperacilina-tazobactam, \ndaptomicina, linezolid, tigeciclina y ceftazidima-avibactam) con duraci\u00f3n \u22653 d\u00edas. Se registraron el n\u00famero total de \nalertas, pacientes con alerta, antimicrobiano implicado, alertas por servicio y n\u00famero de alertas por tipo.  396La efectividad de las alertas se calcul\u00f3 como ratio entre alertas que requieren actuaci\u00f3n PROA y el total de alertas. El VPP \nse calcul\u00f3 como ratio entre recomendaciones y el total de alertas. Se registr\u00f3 el n\u00famero y grado de aceptaci\u00f3n (%) de las \nrecomendaciones. Ambos se calcularon globalmente y por tipo.\nRESULTADOS\nSe incluyeron 1.685 alertas para 658 pacientes. Los antimicrobianos m\u00e1s frecuentemente implicados fueron: 26,0% \npiperacilina-tazobactam (438/1.684), 12,1% meropenem (204/1.684), 11,9% linezolid (201/1.684), 7,2% levofloxacino \n(121/1.684) y 6,6% ceftriaxona (111/1.684). Por servicio, los m\u00e1s implicados fueron: medicina interna (50,6%; 852/1.684), \ncirug\u00eda general (13,0%; 219/1.684), oncolog\u00eda m\u00e9dica (7,5%; 126/1.684), digestivo (6,4%; 108/1.684), traumatolog\u00eda \n(4,9%; 83/1.684), urolog\u00eda (3,4%; 57/1.684) y geriatr\u00eda (3,2%; 54/1.684). Respecto al total de alertas, la m\u00e1s frecuente fue \nla alerta 1 (29,8%), seguido de la 6 (27,6%), 3 (18,2%), 2 (12,3%), 5 (7,6%) y 4 (4,5%).  \nLa efectividad global de las alertas PROA fue de 0,15, con un VPP de 0,09. Por tipo de alerta, la efectividad global fue \nde 0,10 (tipo 1), 0,22 (tipo 2), 0,09 (tipo 3), 0,23 (tipo 4), 0,10 (tipo 5) y 0,22 (tipo 6). El VPP c alculado fue de 0,06 (tipo \n1), 0,20 (tipo 2), 0,08 (tipo 3), 0,15 (tipo 4), 0,05 (tipo 5) y 0,09 (tipo 6). Se r egistraron un total de 157 intervenciones \nasociadas a alerta en el per\u00edodo indicado, con un grado de aceptaci\u00f3n del 71,3% (112/157).\nCONCLUSIONES\nLas alertas PROA generadas m\u00e1s frecuentes fueron las relacionadas con tratamientos antimicrobianos intravenosos con \nduraci\u00f3n \u22657 d\u00edas, TAE con duraci\u00f3n \u22653 d\u00edas y ajuste de dosis de antimicrobiano en pacientes con insuficiencia renal. Sin \nembargo, las que generan m\u00e1s recomendaciones son terapia secuencial antibi\u00f3tica y monitorizaci\u00f3n de antibi\u00f3ticos \nde estrecho margen terap\u00e9utico, seguidas de TAE \u2265 3 d\u00edas. Es necesario una evaluaci\u00f3n individualizada por centro para \nseleccionar aquellas alertas con mayor efectividad.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n288. AN\u00c1LISIS DEL CONSUMO DE ANTIBI\u00d3TICOS SEG\u00daN LA CLASIFICACI\u00d3N AWARE (ACCES, WATCH \nAND REVERSE) EN UN HOSPITAL PEDI\u00c1TRICO DE TERCER NIVEL \nAUTORES\nFERN\u00c1NDEZ-POLO , A; PUERTAS SANJUAN, A; MELENDO , S; MENDOZA-PALOMAR , N; LARROSA , N; GORGAS , MQ; \nSOLER-PALACIN , P\nH. UNIVERSITARI MATERNOINFANTIL DE LA VALL D`HEBRON. PASSEIG VALL D\u00b4HEBRON 119-129 BARCELONA. \nBARCELONA\nOBJETIVOS\nEn 2017, la Organizaci\u00f3n Mundial de la Salud (OMS) desarroll\u00f3 la clasificaci\u00f3n AWaRe en la que los antibi\u00f3ticos se \nordenan en tres categor\u00edas: Access (acceso libre), Watch (uso controlado) y Reserve (uso reservado). En base a esta \nclasificaci\u00f3n, se ha propuesto la creaci\u00f3n de un indicador universal que permita comparar los resultados de uso adecuado \nde los antibi\u00f3ticos a nivel global con una recomendaci\u00f3n para los antibi\u00f3ticos de la categor\u00eda Access de al menos el 60%; \nesta recomendaci\u00f3n es general, no limitada a un escenario hospitalario y menos pedi\u00e1trico. El objetivo principal del \nestudio fue conocer el consumo de antibi\u00f3ticos en un hospital pedi\u00e1trico de tercer nivel en base a la clasificaci\u00f3n AWaR, \ncomo indicador cualitativo de la utilizaci\u00f3n de los antibi\u00f3ticos en un programa de optimizaci\u00f3n de antimicrobianos (PROA) \nespec\u00edfico para pediatr\u00eda.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo unic\u00e9ntrico. Se incluyeron el consumo de los antibacterianos de uso sist\u00e9mico (J01) de todos \nlos pacientes pedi\u00e1tricos (0-18 a\u00f1os) ingresados en nuestro centro. Se evaluaron las unidades de hospitalizaci\u00f3n de \nespecialidades m\u00e9dicas y quir\u00fargicas y las unidades de cuidados intensivos pedi\u00e1trica (UCI-P) y neonatal (UCI-N), desde \nenero de 2015 hasta diciembre de 2019. El an\u00e1lisis de tendencia del consumo se calcul\u00f3 en base a los d\u00edas de tratamiento \n(DOT) ponderados por la actividad asistencial expresada en estancias calculada como pacientes-d\u00eda (PD), siendo el \nindicador para la monitorizaci\u00f3n de la tendencia del consumo los DOT/100PD. Los antibi\u00f3ticos se clasificaron seg\u00fan las \ndefiniciones de la clasificaci\u00f3n AWaRe publicada en 2019 y se codificaron mediante c\u00f3digo de colores de un sem\u00e1foro \npara facilitar la visualizaci\u00f3n en la evoluci\u00f3n. Los datos del an\u00e1lisis AWaRe se describieron como la proporci\u00f3n (%) de cada \ncategor\u00eda.\nRESULTADOS\nEn el periodo de estudio la media de estancias anuales fue de 59.523 (DE 2.514). La distribuci\u00f3n del porcentaje \nde utilizaci\u00f3n de los distintos antibi\u00f3ticos seg\u00fan la clasificaci\u00f3n AWaRe se mantuvo estable: los antibi\u00f3ticos Access \nrepresentaron el 43,1% del consumo total, los antibi\u00f3ticos Watch el 54,5% y los Reserve en torno al 2% entre 2015-2018 \ny con un aumento puntual (4%) en 2019. El mayor uso de antibi\u00f3ticos Access fue en las unidades quir\u00fargicas (63,4%) \ny la UCI-N (58,9%), y menor en las unidades m\u00e9dicas (36,2%) y UCI-P (30,1%). Los antibi\u00f3ticos Reserve se utilizaron \nprincipalmente en las unidades de especialidades m\u00e9dicas con un 3,8% del uso de antibi\u00f3ticos. El principal antibi\u00f3tico \nReserve fue la colistina en pacientes afectos de fibrosis qu\u00edstica con exacerbaci\u00f3n respiratoria.\nCONCLUSIONES\nEl consumo de antibi\u00f3ticos mayoritario correspondi\u00f3 a los grupos Access y Watch, sin cambios relevantes durante el \nperiodo de estudio. Destaca el consumo m\u00ednimo de antibi\u00f3ticos Reserve focalizado en los pacientes con fibrosis qu\u00edstica. \nEs preciso seguir implantando en nuestro centro, acciones enfocadas a aumentar la utilizaci\u00f3n de antibi\u00f3ticos Access as\u00ed \ncomo, disminuir la utilizaci\u00f3n de antibi\u00f3ticos del grupo Watch, seg\u00fan lo recomendado por la OMS. Es importante destacar 397el inter\u00e9s de la clasificaci\u00f3n AWaRe para comparar la utilizaci\u00f3n de los antibi\u00f3ticos entre centros pedi\u00e1tricos en relaci\u00f3n a \nsu complejidad y establecer puntos de corte recomendados.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n318. MACHINE LEARNING Y EVALUACI\u00d3N DE FACTORES ASOCIADOS CON LA FALTA DE EFICACIA AL \nTRATAMIENTO CON TOCILIZUMAB EN PACIENTES CON SARS-COV-2 \nAUTORES\nZARAGOZ\u00c1 GONZ\u00c1LEZ, M; RAM\u00d3N ALBERT , A; MILARA PAYA, J; DEL R\u00cdO SAN CRIST\u00d3BAL, R; GONZ\u00c1LEZ FITENI, M; \nBETORET VILAR, M; OLIVES CASASNOVAS, R; BLASCO SEGURA, P\nCONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA \ufffd AV\ufffd TRES CRUCES, S/N VALENCIA \ufffd VALENCIA\nOBJETIVOS\nAplicaci\u00f3n de t\u00e9cnicas de Machine Learning (ML) en un amplio conjunto de datos \u201cbig data\u201d para determinar variables \nque puedan predecir la falta de eficacia del tratamiento con tocilizumab en pacientes con SARS-CoV-2.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional de cohortes retrospectivo de un solo centro. Se incluyeron 67 pacientes ingresados en un hospital \nterciario con SARS-CoV-2 confirmada microbiol\u00f3gicamente mediante el ensayo de reacci\u00f3n en cadena de la polimerasa \ncon transcriptasa inversa (RT-PCR) de un hisopo nasofar\u00edngeo entre el 10 de marzo y el 16 de septiembre de 2020. Se \nrecogieron 41 variables demogr\u00e1ficas, cl\u00ednicas y anal\u00edticas.  \nSe utilizaron diferentes m\u00e9todos de ML supervisados: K-Nearest Neighbours (KNN), Decision Tree (DT), Gaussian Na\u00efve \nBayes (GNB), Support Vector Machine (SVM) y eXtreme Gradient Boosting (XGB) para ver las variables que tienen un \nmayor peso en predecir la falta de eficacia al tratamiento con tocilizumab, medida como incremento de la mortalidad y \ncomo aumento del n\u00famero de d\u00edas de estancia hospitalaria.\nRESULTADOS\nDe los diferentes m\u00e9todos supervisados de ML, el que ofrec\u00eda una mejor precisi\u00f3n equilibrada, sensibilidad, especificidad, \nprecisi\u00f3n y AUC para predecir el peso de las variables, fue XGB. Las m\u00e9tricas obtenidas en la mortalidad para el \nclasificador XGB fueron: PE(%) de 94,69, sensibilidad de 94,78, especificidad de 94,59, precisi\u00f3n de 93,99 y \u00e1rea bajo la \ncurva (AUC) de 0,94. Para la estancia hospitalaria, los valores fueron: PE(%) de 93,49, sensibilidad de 93,58, especificidad \nde 93,39, precisi\u00f3n de 92,81 y AUC de 0,93. Aplicando este m\u00e9todo, se puede observar que las variables con mayor \ninfluencia en la falta de eficacia del tratamiento con tocilizumab, en cuanto a la mortalidad, fueron: la ferritina, la lactato \ndeshidrogenasa (LDH), las transaminasas (alanina transaminasa (ALT) y la aspartato transaminasa (AST)) y el \u00edndice \nPAFI (PaO2/FiO2), lo que sugiere que a mayor valor de estas variables menor eficacia de tocilizumab. Por otro lado, las \nvariables con mayor peso en la predicci\u00f3n del aumento del n\u00famero de d\u00edas de estancia hospitalaria son la ferritina y las \ntransaminasas. Ninguno de los tratamientos farmacol\u00f3gicos concomitantes tuvo peso en la predicci\u00f3n de eficacia de \ntocilizumab.\nCONCLUSIONES\nEl m\u00e9todo de ML que mejor predice el peso de nuestras variables para determinar la eficacia al tratamiento con \ntocilizumab es XGB. Este m\u00e9todo ofrece los valores m\u00e1s altos en todas las m\u00e9tricas de inter\u00e9s. Las variables que mayor \npeso tienen para influir en la eficacia al tratamiento con tocilizumab (reducci\u00f3n de mortalidad y estancia hospitalaria) \nson la ferritina y las transaminasas. La LDH y el \u00edndice PAFI se asocian a peor resultado en mortalidad con el uso de \ntocilizumab.  \nEl ML es un m\u00e9todo \u00f3ptimo para evaluar una elevada cantidad de datos (\u201cbig data\u201d) de forma agrupada y r\u00e1pida. \nActualmente no existen estudios que analicen variables de eficacia de tocilizumab en pacientes COVID-19 positivo.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n322. VANCOMICINA ORAL PARA EL TRATAMIENTO DE LAS INFECCIONES POR CLOSTRIDIOIDES DIFFICILE: \nEFECTIVIDAD Y SEGURIDAD \nAUTORES\nCRESPO RODR\u00cdGUEZ, E; BECERRA INGERTO, L; GARC\u00cdA LASTRA, S; PLANO S\u00c1NCHEZ, AI; ZAPICO GARC\u00cdA, I; GONZ\u00c1LEZ \nS\u00c1NCHEZ, N; MART\u00cdN CARRO, C\nHOSPITAL SAN AGUST\u00cdN \ufffd CAMINO DE HEROS, 6 AVIL\u00c9S \ufffd ASTURIAS\nOBJETIVOS\nAnalizar la efectividad y seguridad de la suspensi\u00f3n oral de vancomicina 50 mg/mL (SOV) en pacientes con infecci\u00f3n por \nClostridioides difficile (ICD) sintom\u00e1tica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo. Se identificaron los pacientes con ICD tratados con la SOV entre junio \nde 2021 y mayo de 2022. Se recogieron variables demogr\u00e1ficas, como la edad y el sexo, y cl\u00ednicas: gravedad de la ICD \nevaluada seg\u00fan los criterios de la Infectious Diseases Society of America (IDSA) 2021, antecedentes de ICD, tratamiento \nantibi\u00f3tico en los 3 meses previos, duraci\u00f3n del tratamiento y de los s\u00edntomas, n\u00famero de deposiciones y estado de las \nmismas al principio y al final del tratamiento y aparici\u00f3n de recurrencias.  \nPara evaluar la efectividad se utiliz\u00f3 la reducci\u00f3n en el n\u00famero de deposiciones diarias y la ausencia de recurrencias. Se \nregistraron los efectos adversos para evaluar la seguridad\ufffd398RESULTADOS\nSe incluyeron 48 pacientes, de los cuales 29 eran mujeres (60.4%). La mediana de edad fue de 79 a\u00f1os.  \nEn cuanto a la gravedad de la ICD, el 39.6% de los pacientes cumpl\u00edan criterios de enfermedad severa no complicada. \nEl 60.4% restante presentaba enfermedad leve-moderada. 3 pacientes presentaban antecedentes de ICD, de los cuales \ndos fueron tratados con la SOV previamente. El 60.4% hab\u00eda recibido antibioterapia en los 3 meses previos: 72.4% \nbetalact\u00e1micos, 20.7% quinolonas y 6.9% otros.  \nEl tiempo de tratamiento fue igual o inferior a 8 d\u00edas en un 12.5% de los pacientes, mayor de 11 d\u00edas en un 25.0% y entre \n9 y 11 d\u00edas en un 62.5% de los pacientes. El tiempo de tratamiento no fue el recomendado seg\u00fan los criterios de gravedad \nen un 35.4% de los pacientes. La mediana de resoluci\u00f3n de los s\u00edntomas fue de 3 d\u00edas desde el inicio del tratamiento. \nAntes de iniciar el tratamiento, la mediana de deposiciones diarias era de 5 y al final del tratamiento \u00e9stas disminuyeron a \n1. En el 95.8% de los casos, las heces pasaron de estado l\u00edquido a forme una vez completado el tratamiento.  \nUn total de 13 pacientes presentaron recurrencias, de los cuales 9 fueron tratados de nuevo con la SOV, 2 con \nfidaxomicina, 1 con la SOV en una primera recurrencia y con fidaxomicina en la segunda y otro paciente fue tratado con \nvancomicina y bezlotoxumab en la primera recurrencia. La mediana de seguimiento de los pacientes despu\u00e9s de finalizar \nel tratamiento fue de 140 d\u00edas. No se registraron efectos adversos (EA) relacionados con la toma de la SOV.\nCONCLUSIONES\nLa suspensi\u00f3n oral de vancomicina result\u00f3 efectiva al reducir significativamente el n\u00famero de deposiciones diarias y \nprevenir las recurrencias, con una tasa de curaci\u00f3n del 73.0%. Se demostr\u00f3 que el perfil de seguridad fue favorable, ya \nque no se registraron efectos adversos en ninguno de los pacientes.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n325. EXPERIENCIA USO DE ANTICUERPOS MONOCLONALES FRENTE AL COVID-19 EN LA PR\u00c1CTICA \nCL\u00cdNICA EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nGRACIA , R; ARENERE , M; ALLENDE , MA; BONAGA , B; GOMEZ , P; ALC\u00c1CERA , MA; VARELA , I; SALVADOR , T\nHOSPITAL CL\u00cdNICO UNIVERSITARIO LOZANO BLESA. SAN JUAN BOSCO, 15 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nEvaluar el uso y la efectividad de anticuerpos monoclonales neutralizantes (mAB) para el tratamiento de pacientes con \nCOVID-19 en la pr\u00e1ctica cl\u00ednica en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyeron pacientes que recibieron tratamiento con mAB frente al \nCOVID-19 desde Octubre 2021 hasta Abril 2022.  \nSe incluyeron pacientes que cumplieron los criterios de alto riesgo seg\u00fan el protocolo de la Agencia Espa\u00f1ola de \nMedicamentos y Productos Sanitarios (AEMPS) y el protocolo auton\u00f3mico de Uso Racional del Medicamento y Productos \nSanitarios  \nSe analizaron: variables demogr\u00e1ficas (media de edad, sexo);mAB; variables cl\u00ednicas: condiciones de alto riesgo, factores \nde riesgo, n\u00famero dosis de vacuna frente al COVID-19, serolog\u00eda de IgG anti-SARS-CoV2, cepa, mediana d\u00edas desde \ninicio de s\u00edntomas, dispositivo de oxigenoterapia, lugar de administraci\u00f3n y medicaci\u00f3n concomitante contra el COVID \nadministrada durante el proceso\ufffd  \nPara valorar la efectividad se determinaron los d\u00edas de estancia hospitalaria y la mortalidad hasta el d\u00eda 29 desde la \nadministraci\u00f3n del f\u00e1rmaco.\nRESULTADOS\n31 pacientes, edad media de 66,5\u00b111,8 a\u00f1os, 58% varones. Se administr\u00f3 sotrovimab al 70,97%(n=22) de los pacientes, \ncasirivimab/indevimab 16,13%(n=5) y regdanviamb 12,90%(n=4).  \nLas condiciones de alto riesgo del 45,2%(n=14) fueron tratamiento inmunosupresor con un f\u00e1rmaco anti-CD20 o \nbelimumab, 29,1%(n=9) pacientes inmunocomprometidos en tratamiento, 16,1%(n=5) trasplantados de \u00f3rgano s\u00f3lido, \n3,20%(n=1) trasplante de \u00f3rgano hematopoy\u00e9tico, 3,20%(n=1) s\u00edndrome de Down de m\u00e1s de 40 a\u00f1os y 3,20%(n=1) \npacientes en tratamiento con CAR-T. Factores de riesgo: enfermedad renal cr\u00f3nica(n=8), diabetes(n=7), enfermedad \npulmonar cr\u00f3nica(n=7), obesidad(n=6), enfermedad cardiaca cr\u00f3nica(n=5), enfermedad hep\u00e1tica cr\u00f3nica(n=3), \nenfermedad neurol\u00f3gica cr\u00f3nica(n=2).  \nLa cobertura vacunal frente al COVID-19 fue completa en 15 pacientes (3 dosis), 13 recibieron dos dosis, 1 recibi\u00f3 \nuna dosis y 2 no recibieron ninguna. Todas serolog\u00edas IgG anti-SARS-CoV fueron negativas. La cepa fue omicron en \n51,6%(n=16) de los pacientes, no omicron en 16,1%(n=5) y no se test\u00f3 en 32,3% (n=10). La mediana de d\u00edas desde el \ninicio de los s\u00edntomas fue de 7(2-20) d\u00edas.  \nDispositivo de oxigenoterapia: gafas nasales 32,3%(n=10), alto flujo 22,6%(n=7) y 25,8%(n=8) no llevaba soporte de \nox\u00edgeno. El lugar de administraci\u00f3n fue en planta 80,6%(n=25), UCI 9,7%(n=3) y urgencias 9,7%(n=3). El 74,2%(n=23) de \nlos pacientes recibieron tratamiento con remdesivir (15 de ellos en combinaci\u00f3n con corticoides, 2 con baricitinib, 1 con \ntocilizumab y 1 con molnupiravir), 16,1%(n= 5) no recibieron m\u00e1s tratamientos y 9,7% (n=3)otros.  \nLa mediana de n\u00famero de d\u00edas de estancia hospitalaria fue de 11(0-49). 8 pacientes fallecieron en los 29 d\u00edas posteriores \na la administraci\u00f3n del mAB\ufffd399CONCLUSIONES\nNuestra experiencia cl\u00ednica con el uso de mAB frente al COVID-19 ha sido principalmente en pacientes \ninmunodeprimidos, destacando aquellos en tratamiento con f\u00e1rmacos anti-CD20 que no hab\u00edan hecho IgG anti-SARS-\nCoV y con enfermedad leve-moderada, puesto que la mayor\u00eda llevaban como dispositivo de oxigenoterapia gafas \nnasales(32,3%) o no llevaban(25,8%) y casi todos los tratamientos se han administrado en pacientes hospitalizados \nen planta. La cepa predominante en nuestra zona epidemiol\u00f3gica, ha sido la omicron. Conocer la efectividad de estas \nterapias todav\u00eda es un gran reto, ya que es necesario realizar m\u00e1s estudios en condiciones de vida real.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n339. PROFILAXIS ANTIBI\u00d3TICA QUIR\u00daRGICA: UNA ASIGNATURA PENDIENTE \nAUTORES\nMAYO CANALEJO, B; ROMERA GARC\u00cdA, JM; FRANCO SERENO, MT; P\u00c9REZ SERRANO, R; RODR\u00cdGUEZ MART\u00cdNEZ, M\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nUna adecuada profilaxis antibi\u00f3tica es la principal medida de prevenci\u00f3n de infecciones de lugar quir\u00fargico. Por contra, \nsu duraci\u00f3n excesiva puede provocar un aumento de efectos adversos e infecciones. Adem\u00e1s, el uso apropiado de los \nantibi\u00f3ticos es crucial para reducir la aparici\u00f3n de resistencias, problema actual y relevante en nuestro medio. Durante \noctubre-noviembre/2019 se realiz\u00f3 un estudio para conocer el grado de adecuaci\u00f3n de la profilaxis antibi\u00f3tica pautada en \nservicios quir\u00fargicos del hospital al actual protocolo local consensuado en la Comisi\u00f3n de Infecciones, Pol\u00edtica Antibi\u00f3tica \ny Profilaxis publicado en mayo/2017, notific\u00e1ndose posteriormente los resultados a dichos servicios. El objetivo del nuevo \nestudio es comparar el grado de adecuaci\u00f3n actual utilizando la misma metodolog\u00eda.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo durante marzo-abril/2022 en un hospital terciario, estableciendo un plan de \nrevisi\u00f3n diario seg\u00fan servicio quir\u00fargico: traumatolog\u00eda (lunes), ginecolog\u00eda (martes), cirug\u00eda maxilofacial (CMF), \notorrinolaringolog\u00eda y urolog\u00eda (mi\u00e9rcoles), y cirug\u00eda general y digestivo (CGD), neurocirug\u00eda, y angiolog\u00eda y cirug\u00eda \nvascular (ACV) (viernes). Mediante revisi\u00f3n de la prescripci\u00f3n electr\u00f3nica (Farmatools\u00ae) e historia cl\u00ednica informatizada \n(MambrinoXXI\u00ae) se recogieron los siguientes datos: servicio, cirug\u00eda, antibi\u00f3tico, posolog\u00eda, duraci\u00f3n y alergias. La \nprescripci\u00f3n se consider\u00f3 correcta si los tres par\u00e1metros, antibi\u00f3tico, posolog\u00eda y duraci\u00f3n, eran correctos. Criterios de \ninclusi\u00f3n: pacientes ingresados en servicios quir\u00fargicos durante un postoperatorio. Criterios de exclusi\u00f3n: pacientes \ncon tratamiento antibi\u00f3tico previo a la cirug\u00eda, cirug\u00edas sin ingreso y embarazadas con tratamiento profil\u00e1ctico para \nestreptococo B\ufffd\nRESULTADOS\nSe incluyeron 320 pacientes (261 en 2019). Los servicios mayoritarios fueron nuevamente CGD (28,7%) y traumatolog\u00eda \n(22,5%). La profilaxis fue inapropiada en 204 cirug\u00edas (63,7% vs. 67,8% en 2019): antibi\u00f3tico inapropiado 17,2% (24,1%), \nposolog\u00eda inapropiada 41,2% (21,8%), duraci\u00f3n inapropiada 55% (57,3%). El mayor porcentaje de error se observ\u00f3 en \nla duraci\u00f3n, excesiva en 156 cirug\u00edas (88,6% vs. 91%) y demasiado corta en 20 (11,4% vs. 9%). Los servicios que m\u00e1s la \nprolongaron fueron CMF 100% (85,7%), otorrinolaringolog\u00eda 84,2% (88,9%) y traumatolog\u00eda 77,8% (73%). La distribuci\u00f3n \nde servicios quir\u00fargicos, de menor a mayor tasa de error, fue: neurocirug\u00eda 43,2% (71,4%), CGD 43,5% (51,5%), \nginecolog\u00eda 45,4% (54,5%), ACV 68,2% (60%), traumatolog\u00eda 77,8% (73,5%), otorrinolaringolog\u00eda 94,7% (100%), urolog\u00eda \n94,7% (100%), y CMF 100% (88,9%).\nCONCLUSIONES\nEl grado de adecuaci\u00f3n al protocolo ha variado levemente, observ\u00e1ndose cierta mejor\u00eda en aspectos como las tasas de \nprofilaxis global o duraci\u00f3n inapropiada, y cierto empeoramiento en la tasa de posolog\u00eda incorrecta. Con ello, se plantean \namplias \u00e1reas de mejora, siendo nuevamente la duraci\u00f3n excesiva el principal problema detectado. Como limitaciones del \nestudio, no se recogieron datos de infecciones o colonizaciones previas que podr\u00edan justificar prescripciones antibi\u00f3ticas \nal margen del protocolo, ni se ha evaluado la hora de administraci\u00f3n o si excepcionalmente existi\u00f3 necesidad de \nsegunda dosis profil\u00e1ctica. Posibles estrategias de ayuda a la mejora de resultados: 1) Actualizaci\u00f3n del protocolo para \nincorporar nuevas evidencias desde su publicaci\u00f3n 2) Intervenci\u00f3n del equipo PROA (Programa de Optimizaci\u00f3n de Uso \nde Antimicrobianos) como unidad clave de abordaje multidisciplinar en el control y adecuaci\u00f3n de la profilaxis antibi\u00f3tica \nquir\u00fargica 3) Plan peri\u00f3dico de formaci\u00f3n y difusi\u00f3n del protocolo a profesionales sanitarios de servicios quir\u00fargicos.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n343. BEZLOTOXUMAB: AN\u00c1LISIS DE EFECTIVIDAD Y SEGURIDAD \nAUTORES\nHERN\u00c1NDEZ RAMOS, JA; CARO TELLER, JM; ORTIZ P\u00c9REZ, S; BRUNI MONTERO, M\u00c1; GONZ\u00c1LEZ G\u00d3MEZ, \u00c1; MAYO \nOLVEIRA, F; FERRARI PIQUERO, JM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID\nOBJETIVOS\nDesde la comercializaci\u00f3n de bezlotoxumab en prevenci\u00f3n secundaria para recurrencias de infecci\u00f3n por Clostridioides \ndifficile (rICD), se han publicado escasos estudios sobre su efectividad y seguridad en la pr\u00e1ctica cl\u00ednica. \nEl objetivo principal del estudio es analizar la efectividad en todos los pacientes que recibieron bezlotoxumab en nuestro 400hospital. Fueron objetivos secundarios:  \nAnalizar la efectividad en funci\u00f3n del tratamiento anticlostridial y en subgrupos de alto riesgo de nueva recurrencia.  \nEvaluar la seguridad a corto-medio plazo.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en un hospital de grupo 5 seg\u00fan la clasificaci\u00f3n cl\u00faster que incluy\u00f3 todos los \npacientes tratados con bezlotoxumab desde enero de 2019 hasta junio de 2021.  \nSe utilizaron los programas de historia cl\u00ednica electr\u00f3nica de atenci\u00f3n primaria y hospitalaria para registrar el tratamiento \nfarmacol\u00f3gico y la evoluci\u00f3n cl\u00ednica de los pacientes. El periodo de seguimiento abarc\u00f3 las 12 semanas siguientes a la \nadministraci\u00f3n de bezlotoxumab.  \nLa efectividad se analiz\u00f3 a partir de tasas de rICD y la seguridad se evalu\u00f3 mediante descripci\u00f3n de los eventos adversos \ndetectados\ufffd  \nPara el an\u00e1lisis de efectividad por subgrupos se defini\u00f3 la poblaci\u00f3n de alto riesgo de rICD como pacientes con edad > \n65 a\u00f1os en tratamiento simult\u00e1neo con un inhibidor de la bomba de protones (IBP), recurrencia previa, enfermedad \ninflamatoria intestinal (EII), cirrosis hep\u00e1tica, enfermedad renal cr\u00f3nica grave o inmunosupresi\u00f3n (inmunodeficiencias \nprimarias, infecci\u00f3n por VIH con < 200 c\u00e9lulas CD4+/\u00b5L, trasplante de progenitores hematopoy\u00e9ticos o de \u00f3rgano s\u00f3lido, \ntratamiento inmunomodulador o quimioterapia concomitante).\nRESULTADOS\nSe incluyeron 53 pacientes con una mediana de edad de 67 a\u00f1os (60 \u2013 80) de los cuales 28 (52,8%) eran mujeres. 32 \npacientes (60,4%) estaban inmunodeprimidos, 22 (41,5%) ten\u00edan un aclaramiento de creatinina < 60 mL/min/1,73 m2, \n11 (20,8%) estaban diagnosticados de EII y 6 (11,3%) de cirrosis hep\u00e1tica. Se detectaron 13 (24,5%) episodios de primera \ninfecci\u00f3n, 17 (32,1%) de primera recurrencia, 13 (24,5%) de segunda recurrencia y 10 (18,9%) de tercera recurrencia o \nposterior. Hubo 11 pacientes (20,8%) sin tratamiento antiulceroso cr\u00f3nico, 10 (18,9%) recib\u00edan un antagonista H2 y 31 \n(58,5%) tomaban un IBP . De estos \u00faltimos, 17 (32,1% del total) ten\u00edan edad > 65 a\u00f1os.  \nLos reg\u00edmenes de tratamiento anticlostridial inclu\u00edan vancomicina en 34 casos (64,1%), fidaxomicina en 18 casos (34,0%) \no ambas en 1 caso (1,9%).  \nEn total, 6 pacientes (11,3%) sufrieron una rICD durante el periodo de seguimiento. No hubo diferencias estad\u00edsticamente \nsignificativas en el an\u00e1lisis de subgrupos de alto riesgo de recurrencia. La efectividad de la combinaci\u00f3n con vancomicina \nversus fidaxomicina tampoco mostr\u00f3 diferencias estad\u00edsticamente significativas.  \nEntre los 11 pacientes con antecedente de insuficiencia cardiaca (IC), 2 sufrieron una exacerbaci\u00f3n durante el \nseguimiento. Un paciente sin historia previa de IC desarroll\u00f3 un episodio de IC congestiva el d\u00eda posterior a la \nadministraci\u00f3n de bezlotoxumab. No se identificaron otros eventos adversos.\nCONCLUSIONES\nEn nuestros pacientes, bezlotoxumab ha mostrado menor tasa de rICD respecto de los ensayos pivotales, sin haberse \ndemostrado que su asociaci\u00f3n con fidaxomicina sea superior que con vancomicina. A pesar de que es bien tolerado, ser\u00eda \nconveniente utilizarlo con precauci\u00f3n en pacientes con riesgo de desarrollar IC congestiva.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n363. \u00bfINFLUYE LA VACUNACI\u00d3N FRENTE AL COVID-19 EN LA NECESIDAD DE USAR LOS TRATAMIENTOS \nM\u00c1S FRECUENTEMENTE EMPLEADOS PARA ESTA INFECCI\u00d3N? \nAUTORES\nORTIZ LATORRE, JL; CANTILLANA SU\u00c1REZ, MDG; ROBUSTILLO CORT\u00c9S, MDLA; ROLD\u00c1N GALNARES, M\nHOSPITAL COMARCAL SAN AGUST\u00cdN. AV . DE SAN CRISTOBAL, S/N LINARES. JA\u00c9N\nOBJETIVOS\nAnalizar y cuantificar la necesidad de uso de los medicamentos m\u00e1s empleados en la pr\u00e1ctica cl\u00ednica habitual para el \ntratamiento de la infecci\u00f3n por COVID-19, en funci\u00f3n del estado de vacunaci\u00f3n de los pacientes con necesidad de ingreso \nhospitalario.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en el que se incluyeron los pacientes con PCR positiva para SARS-CoV-2 que fueron ingresados \nen un hospital comarcal entre agosto-2020 y marzo-2022 (correspondientes al per\u00edodo entre segunda y sexta ola de la \npandemia). Fueron excluidos los pacientes de la primera ola (marzo-julio 2020) debido a la gran variabilidad y falta de \nconsenso en los tratamientos utilizados.  \nSe recogieron datos demogr\u00e1ficos (sexo, edad), pauta de vacunaci\u00f3n recibida, tiempo de hospitalizaci\u00f3n, necesidad \nde ingreso en UCI y desenlace del ingreso (alta/\u00e9xitus). Se diferenci\u00f3 entre pacientes no vacunados y vacunados con al \nmenos una dosis o pauta completa (dos/tres dosis en funci\u00f3n del calendario de vacunaci\u00f3n).  \nSe analizaron los medicamentos considerados de elecci\u00f3n seg\u00fan los protocolos de actuaci\u00f3n del centro para la infecci\u00f3n \npor COVID-19 (tocilizumab, remdesevir, baricitinib, dexametasona y azitromicina). La variable principal fue analizar la \nfrecuencia de uso de estos f\u00e1rmacos en funci\u00f3n de la vacunaci\u00f3n recibida por los pacientes.  \nLos datos fueron recogidos del programa de prescripci\u00f3n electr\u00f3nica ATHOS-Prisma\u00ae y de la historia cl\u00ednica electr\u00f3nica. \nPara el an\u00e1lisis estad\u00edstico se compararon las variables cualitativas mediante la prueba chi-cuadrado de Pearson, \nconsider\u00e1ndose estad\u00edsticamente significativos valores de p < 0,05.401RESULTADOS\nSe incluyeron 962 pacientes (59,6% hombres) con mediana de edad de 66 a\u00f1os (RIQ:55-79). El 76,6% no estaban \nvacunados en el momento del ingreso, mientras que de los pacientes que s\u00ed hab\u00edan recibido alguna dosis (23,4%) ten\u00edan \npauta completa un 80%. La mediana de tiempo de ingreso fue de 10 d\u00edas (RIQ:7-16). El 7% del total de pacientes requiri\u00f3 \ningreso en UCI y un 20,7% fue \u00e9xitus. En cuanto al uso de medicamentos empleados: el 89,6% recibi\u00f3 dexametasona, \n33,1% tocilizumab, 14,7% remdesivir, 8,3% baricitinib y 7,1% azitromicina.  \nEn el an\u00e1lisis entre el uso de f\u00e1rmacos y la vacunaci\u00f3n (s\u00ed/no) se observaron diferencias estad\u00edsticamente significativas en \nel uso de dexametasona, azitromicina, tocilizumab y remdesivir. La diferencia observada fue de: tres veces m\u00e1s riesgo de \nuso de dexametasona en no vacunados (IC 95%= 1,92-4,52; p=0,00); tres veces m\u00e1s riesgo de uso de azitromicina en no \nvacunados (IC95%= 1,43-7,87; p=0,03) y dos veces y media m\u00e1s de riesgo de uso de tocilizumab en no vacunados (IC95%= \n1,84-3,91; p=0,00). Sin embargo se observ\u00f3 que hab\u00eda dos veces m\u00e1s riesgo de uso de remdesivir en vacunados frente a \nno vacunados (IC95% =1,17-2,56; p=0,05). No se observ\u00f3 diferencia significativa con el uso de baricitinib (p=0,83).\nCONCLUSIONES\nEl hecho de tener cobertura vacunal frente al COVID-19 parece mostrar una disminuci\u00f3n en la necesidad de recibir la \nmayor\u00eda de tratamientos de uso habitual en la pr\u00e1ctica cl\u00ednica, a excepci\u00f3n de remdesivir, seg\u00fan los datos obtenidos. \nPara poder extrapolar estos resultados ser\u00eda necesaria la unanimidad en la forma de uso de estos tratamientos en los \ndiferentes centros y realizar estudios con un mayor n\u00famero de pacientes vacunados.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n365. RESULTADOS DE LA IMPLEMENTACI\u00d3N DE LA PROFILAXIS PRE-EXPOSICI\u00d3N AL VIH EN UN HOSPITAL \nDE TERCER NIVEL \nAUTORES\nLUACES RODR\u00cdGUEZ, A; GIM\u00c9NEZ ARUFE, V; FEIJOO VILANOVA, P; MART\u00cdNEZ PRADEDA, A; ROTEA SALVO, S; \nMARGUSINO FRAMI\u00d1\u00c1N, L; MART\u00cdN HERRANZ, I; CID SILVA, P\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nEvaluaci\u00f3n de la seguridad, efectividad y adherencia a la combinaci\u00f3n de emtricitabina y tenofovir disoproxil fumarato \n(FTC/TDF) en el programa Profilaxis Pre-Exposici\u00f3n al VIH (PrEP-VIH) en una poblaci\u00f3n con riesgo de infecci\u00f3n por VIH de \nun \u00e1rea sanitaria de m\u00e1s de 500.000 habitantes.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional en personas incluidas en el programa PrEP-VIH desde marzo de 2020 hasta abril de \n2022. Los criterios de exclusi\u00f3n, excepto para el an\u00e1lisis de seguridad, fueron permanecer menos de 24 semanas en el \nprograma PrEP-VIH. Los datos se obtuvieron a trav\u00e9s de la historia cl\u00ednica electr\u00f3nica y el programa de dispensaci\u00f3n de \nfarmacia a pacientes externos\ufffd \nLas variables analizadas fueron: datos epidemiol\u00f3gicos, serolog\u00edas de control del VIH, niveles de creatinina y de f\u00f3sforo \ns\u00e9rico basales y a las 24 semanas, reacciones adversas medicamentosas (RAMs), enfermedades de transmisi\u00f3n sexual \n(ETS) diagnosticadas tras el inicio de la PrEP-VIH, adherencia terap\u00e9utica y vacunaci\u00f3n para poblaciones de riesgo.  \nLa seguridad se evalu\u00f3 a trav\u00e9s de las RAMs detectadas en anal\u00edticas o comunicadas por el usuario, la efectividad seg\u00fan \nlos resultados de las serolog\u00edas VIH y la adherencia a trav\u00e9s del registro de dispensaci\u00f3n en farmacia. El an\u00e1lisis estad\u00edstico \nfue realizado con R-statistics.\nRESULTADOS\nSe incluyeron en el estudio 79 personas usuarias de la PrEP-VIH, 97.5% hombres y 2.5% mujeres transg\u00e9nero, con una \nedad media de 37\ufffd3 \u00b1 8\ufffd21 a\u00f1os\ufffd  \nDurante el seguimiento, 43.0% de los usuarios presentaron RAMs: trastornos gastrointestinales (61.8%), cefaleas (11,8%), \nfatiga (5.9%), gastrointestinales junto a cefaleas (5.9%), gastrointestinales junto a fatiga (5,9%) y otras (8.7%); la mayor\u00eda \ndurante las primeras cuatro semanas de tratamiento\ufffd Cuatro usuarios abandonaron el programa debido a reacciones \ngastrointestinales y uno por mareos graves.  \nLos valores de creatinina basales y a las 24 semanas no mostraron diferencias estad\u00edsticamente significativas (0.92 \u00b1 0.12 \nmg/dL vs 0.91 \u00b1 0.12 mg/dL, p = 0.7). Los valores de f\u00f3sforo s\u00e9rico basales y a las 24 semanas fueron 3.45 \u00b1 0.64 mg/dL y \n3.82 \u00b1 0.58 mg/dL, respectivamente (p < 0.01).  \nNing\u00fan usuario de PrEP-VIH present\u00f3 serolog\u00eda VIH positiva durante el seguimiento. Sin embargo, el 27.8% de los usuarios \ndesarrollaron ETS desde el inicio (Neisseria gonorrhoeae (68.2%), Chlamydia trachomatis (31.8%) y Treponema pallidum \n(31.8%)).  \nLa adherencia a la PrEP-VIH fue del 100% en el 58.2% de los usuarios, del 90-99% en el 21,5% y menor del 90% en el \n20.3%. 16 usuarios abandonaron el seguimiento y no se dispone de serolog\u00eda posterior. Una persona tuvo que abandonar \npor incompatibilidad con el tratamiento quimioter\u00e1pico.  \nEn el 49.4% de los usuarios se logr\u00f3 la vacunaci\u00f3n por ser poblaci\u00f3n de riesgo tras el inicio de la PrEP-VIH: 87.2% frente al \nVPH, 38\ufffd5% frente al VHA y 28\ufffd2% frente al VHB\ufffd\nCONCLUSIONES\nLos usuarios de PrEP presentaron durante el seguimiento RAMs conocidas y limitadas en el tiempo, confirmando la \nseguridad de la PrEP-VIH. En el 100% de los casos las serolog\u00edas del VIH se mantuvieron negativas, demostrando una \neficacia de la profilaxis durante el tiempo a estudio. Destaca el alto porcentaje de usuarios con adherencia inferior al 90% \ny los abandonos sin comunicaci\u00f3n previa\ufffd402CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n374. FACTORES DE RIESGO PARA EL DESARROLLO DE ASPERGILOSIS PULMONAR EN PACIENTES CON \nINFECCI\u00d3N POR COVID-19 \nAUTORES\nCORRAL ALAEJOS, \u00c1; JIM\u00c9NEZ CASAUS, J; FERN\u00c1NDEZ CA\u00d1ABATE, S; ALONSO CASTA\u00d1\u00c9, D; GIL NAVARRO, I; L\u00d3PEZ \nMESTANZA, IC; BREZMES VALDIVIESO, MF; GIL VALI\u00d1O, C\nCOMPLEJO ASISTENCIAL DE ZAMORA. AVDA. REQUEJO, 35 ZAMORA. ZAMORA\nOBJETIVOS\nLa aspergilosis pulmonar invasiva asociada a coronavirus (CAPA) es una complicaci\u00f3n infecciosa relativamente frecuente \nen pacientes con infecci\u00f3n por COVID-19 que puede conllevar una elevada mortalidad. El objetivo del trabajo ha sido la \nevaluaci\u00f3n de los posibles factores de riesgo que puedan favorecer la infecci\u00f3n por CAPA.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo observacional de dos a\u00f1os de duraci\u00f3n (marzo 2020 \u2013 marzo 2022), en el que se registraron los \npacientes con infecci\u00f3n por COVID-19 confirmada mediante reacci\u00f3n en cadena de la polimerasa (PCR), y diagn\u00f3stico de \nCAPA en un hospital de segundo nivel.  \nSe registraron datos demogr\u00e1ficos (edad, sexo, e \u00edndice de masa corporal (IMC)), tiempo entre el diagn\u00f3stico de COVID-19 \ny CAPA, especie de aspergillus y tipo de muestra en la que se aisl\u00f3, servicio cl\u00ednico, tratamiento y desenlace (curaci\u00f3n/\n\u00e9xitus).  \nLos factores de riesgo evaluados fueron: comorbilidades del paciente, inmunodepresi\u00f3n previa (trasplante de \u00f3rgano \ns\u00f3lido, hematopoy\u00e9tico, neoplasia, infecci\u00f3n por VIH, tratamiento biol\u00f3gico\u2026) tratamiento con corticoides y/o \ntratamiento inmunomodulador (tocilizumab/baricitinib\u2026) para el COVID, duraci\u00f3n de ingreso.\nRESULTADOS\nSe registraron un total de 22 pacientes diagnosticados de aspergilosis pulmonar y COVID-19. La mediana [rango] de edad \nde los pacientes fue de 66 [58-86] a\u00f1os, de los cuales un 63,6% fueron mujeres. La media (+DS) de IMC fue de 29,4 + 5,1. \nEl tiempo medio (+DS) entre el diagn\u00f3stico de COVID y CAPA fue de 16,4 + 12,1 d\u00edas. Las especies de aspergillus aisladas \nfueron A. fumigatus (n=15), A. niger (n=1) y otras especies (n=6), aisladas en lavado bronco-alveolar (n=18) y esputo \n(n=4). El 86,4% de los pacientes requiri\u00f3 ingreso en la unidad de cuidados intensivos. 17 pacientes fueron tratados con \nvoriconazol, 3 con isavuconazol y el \u00faltimo con la combinaci\u00f3n de voriconazol y anfotericina B liposomal. Uno de los \npacientes no fue tratado al considerarse colonizaci\u00f3n en esputo. Finalmente, el 59,1% de los pacientes falleci\u00f3.  \nEn un 90,1% se encontr\u00f3 alg\u00fan factor de riesgo para el desarrollo de CAPA. En el registro de las comorbilidades destac\u00f3 \nla obesidad (n=17), hipertensi\u00f3n arterial (n=12), diabetes mellitus (n=8), y asma/EPOC (n=5). 11 pacientes presentaban \ninmunosupresi\u00f3n previa: neoplasia onco-hematol\u00f3gica (n=5), tratamiento biol\u00f3gico (n=5) y trasplante de \u00f3rgano s\u00f3lido \n(n=1).  \nEl 100% de los pacientes fueron tratados para la infecci\u00f3n por COVID-19 con dexametasona seg\u00fan posolog\u00eda del ensayo \nRecovery. El 72,7% de los pacientes recibi\u00f3 alg\u00fan tipo de inmunomodulador: 12 pacientes recibieron tocilizumab (con una \nmedia de dos dosis por paciente), y 12 pacientes recibieron baricitinib. 7 de ellos recibieron ambos tratamientos de forma \nsecuencial\ufffd\nCONCLUSIONES\nLa elevada tasa de mortalidad en pacientes con CAPA encontrada, crea la necesidad de un diagn\u00f3stico precoz para la \ninstauraci\u00f3n temprana de un tratamiento adecuado. Los principales factores de riesgo identificados para el desarrollo de \nCAPA han sido la obesidad, hipertensi\u00f3n arterial, diabetes mellitus, e inmunosupresi\u00f3n.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n376. EFECTO A LARGO PLAZO DE TOCILIZUMAB SOBRE MORTALIDAD, TASA DE REINGRESO, PERSISTENCIA \nDE S\u00cdNTOMAS Y FUNCI\u00d3N PULMONAR EN PACIENTES SARS-COV-2 \nAUTORES\nCARDONA PASCUAL, I; BERLANA MARTIN, D; MONTORO RONSANO, JB\nH. UNIVERSITARI GENERAL DE LA VALL D\u2019HEBRON. PASSEIG VALL D\u2019HEBRON 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLa pandemia por SARS-CoV-2 ha presentado tasas de hospitalizaci\u00f3n y \u00e9xitus muy elevadas, especialmente en la primera \nola. La b\u00fasqueda de un tratamiento eficaz para las formas m\u00e1s graves ha sido una constante, siendo tocilizumab junto con \ndexametasona, y remdesivir los \u00fanicos f\u00e1rmacos evaluados ampliamente en el paciente hospitalizado grave.  \nActualmente, aunque la mortalidad intrahospitalaria ha disminuido, la rehospitalizaci\u00f3n y la mortalidad post-alta son \nsignificativas y es evidente la existencia de un s\u00edndrome post-COVID, con variedad de s\u00edntomas y \u00f3rganos afectados.  \nEl objetivo de este estudio es evaluar el efecto a largo plazo de tocilizumab sobre mortalidad, tasa de reingreso, \npersistencia de s\u00edntomas, funci\u00f3n pulmonar (FP) y capacidad de esfuerzo f\u00edsico (CEF) en pacientes SARS-CoV-2 graves-\nmoderados\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, anal\u00edtico, retrospectivo de los registros cl\u00ednicos de pacientes con SARS-CoV2 dados de alta de un \nhospital de tercer nivel entre Marzo-Abril 2020, comparando su evoluci\u00f3n seg\u00fan recibieran tocilizumab o no. Estudio \naprobado por el CEIM del centro\ufffd  403Los endpoints primarios fueron la muerte por cualquier causa y el reingreso por cualquier s\u00edntoma relacionado con \nCOVID-19. Objetivos secundarios fueron la FP , la evoluci\u00f3n de la CEF durante el primer a\u00f1o tras el alta y la asociaci\u00f3n \nentre \u00e9stos y los endpoints primarios.  \n \nEl an\u00e1lisis de las variable principal y las secundarias se realiz\u00f3 mediante tests ANOVA, Kruskal\u2013Wallis, o chi-cuadrado, \nseg\u00fan la variable. Los datos basales de tratados y no tratados se compararon mediante los tests t-Student o Mann\u2013\nWhitney, para variables continuas, y el test chi-cuadrado \u2013test exacto de Fisher, si proced\u00eda-. El dise\u00f1o estad\u00edstico del \nestudio incluy\u00f3 metodolog\u00eda de emparejamiento por propensity-score (PS), para eliminar la influencia de factores \npotenciales de confusi\u00f3n entre los pacientes tratados y no tratados. El an\u00e1lisis estad\u00edstico se realiz\u00f3 con Stata, versi\u00f3n 14 \n(Stata Corp., TX, USA), fijando la significaci\u00f3n estad\u00edstica en p < 0.05.\nRESULTADOS\nDe 439 pacientes supervivientes dados de alta tras infecci\u00f3n por SARS-CoV-2, 38 no pudieron ser seguidos por \nimposibilidad de contacto o falta de informaci\u00f3n\ufffd 405 pacientes se incluyeron en el seguimiento de mortalidad, y 390 en \nla aparici\u00f3n s\u00edntomas relacionados con COVID-19 y evoluci\u00f3n de la FP y CEF.  \nLa mortalidad global total tras alta fue del 1.0% (n = 4). La mortalidad al a\u00f1o de seguimiento ajustada por PS no mostr\u00f3 \nasociaci\u00f3n entre el uso de tocilizumab o no (HR = 2.05, 95% CI: 0.21\u201319.98). Tampoco mostr\u00f3 diferencias la aparici\u00f3n \nde cualquier s\u00edntoma relacionado con COVID-19 a los 12 meses ajustada por PS (OR= 1.01 95%CI 0.57-1.79). No se \nobservaron diferencias en la FP (OR= 1.02, 95%CI 0.62-1.68) ni en la evoluci\u00f3n de la CEF (OR= 0.88, 95%CI 0.50-1.58).\nCONCLUSIONES\nAjustando las covariables por un modelo de PS, no se observan diferencias en mortalidad, reingreso, persistencia de \ns\u00edntomas, FP o CEF en los pacientes con SARS-CoV-2 grave-moderado seg\u00fan sean tratados o no con tocilizumab.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n383. AN\u00c1LISIS DEL TRATAMIENTO EMP\u00cdRICO DE LAS INFECCIONES URINARIAS EN UN CENTRO \nSOCIOSANITARIO. \nAUTORES\nCARRASCO FONS, N; TABARES COLLAZO, Y; SANCHEZ ROSALES, J; D\u00cdAZ-MUNI\u00d3 MERODIO, E; CASASIN EDO, T\nHOSPITAL DE VILADECANS \ufffd AV GAV\u00c0, 38 VILADECANS \ufffd BARCELONA\nOBJETIVOS\nAnalizar las prescripciones emp\u00edricas iniciadas ante una sospecha de infecci\u00f3n del tracto urinario (ITU) en un centro \nsociosanitario\ufffd  \nDetectar puntos de mejora para optimizar el tratamiento antibi\u00f3tico.  \nAn\u00e1lisis de la sintomatolog\u00eda que conlleva un diagn\u00f3stico de ITU y comparar si se hubiera iniciado aplicando un diagrama \npara toma de decisiones para instaurar un tratamiento emp\u00edrico en sospecha de ITU en ancianos, de publicaci\u00f3n reciente.\nMATERIALES Y M\u00c9TODOS\nDurante un per\u00edodo de 2 meses se recogieron los tratamientos emp\u00edricos iniciados por una sospecha de ITU. Se registr\u00f3: \nn\u00famero de historia, edad, unidad, g\u00e9nero, si era portador de sonda vesical, antibi\u00f3tico, duraci\u00f3n, recogida de urinocultivo \ny resultado de \u00e9ste, sintomatolog\u00eda que motiv\u00f3 la sospecha de ITU. \nA posteriori, con la sintomatolog\u00eda reportada se compar\u00f3 si aplicando el diagrama de toma de decisiones, los \ntratamientos se hubieran iniciado en primera instancia o bien se hubieran reconsiderado de manera diferida.\nRESULTADOS\nDurante el periodo estudiado se iniciaron 35 tratamientos . De \u00e9stos, 12 fueron en varones y 23 en mujeres. La media de \nedad fue de 85 a\u00f1os. La mayor\u00eda, (16), institucionalizados en r\u00e9gimen de residencia asistida , 13 en convalecencia, 4 en \nlarga estancia y 2 en cuidados paliativos. \u00danicamente un 8% de los casos eran portadores de sonda vesical. En la mayor\u00eda \nde los casos se curs\u00f3 urinocultivo (28/35). En todos los casos, antes de iniciar tratamiento se realiz\u00f3 una tira reactiva de \norina. El antibi\u00f3tico m\u00e1s empleado fue la fosfomicina ( 27), seguido de cefuroxima (5), ciprofloxacino (2) y piperacilina/\ntazobactam (1) \nDe los cultivos de orina realizados, 4 fueron negativos, 3 contaminados.  \nEl tratamiento fue adecuado a la sensibilidad del microorganismo en 15 de los 28 cultivos (53%), \u00fanicamente en 7 (25%) \nno fue adecuado\ufffd  \n\u00danicamente se iniciaron tratamientos ante s\u00edntomas urinarios en 7 casos; los 28 restantes, iniciados por s\u00edntomas \ninespec\u00edficos (agitaci\u00f3n, cambio del estado del paciente, desorientaci\u00f3n\u2026) de los cuales presenciaron fiebre 9 de ellos. \nDado que estos signos y s\u00edntomas podr\u00edan tener otra causa en poblaci\u00f3n de edad avanzada y se conoce que la prevalencia \nde bacteriuria asintom\u00e1tica es elevada en paciente anciano institucionalizado, a posteriori, se decidi\u00f3 revisar un diagrama \nde decisiones para instaurar tratamiento emp\u00edrico en ancianos, resultando que en 19 de los 35 casos, se hubiera diferido \nel inicio antibi\u00f3tico y no se hubiera instaurado en primera instancia.\nCONCLUSIONES\nLa mayor\u00eda de los tratamientos emp\u00edricos iniciados fueron en mujeres, institucionalizadas en r\u00e9gimen de residencia \nasistida. En la mayor\u00eda de casos se emple\u00f3 fosfomicina trometamol, antibi\u00f3tico recomendado en las gu\u00edas locales. De los \ncasos con resultados de urinocultivo positivos, el 69% fueron adecuados a la sensibilidad del microrganismo.  \nEn la mayor\u00eda de casos (80%), los s\u00edntomas que motivaron el tratamiento fueron inespec\u00edficos Al aplicar el diagrama, 404se concluy\u00f3 que en la mayor\u00eda de los casos (54%), se hubiera podido diferir el tratamiento antibi\u00f3tico. Con estos datos \npodemos concluir que hay un cierto margen de mejora para disminuir el n\u00famero de tratamientos emp\u00edricos, pudiendo \ncontribuir de este modo a una disminuci\u00f3n de consumo de antibi\u00f3ticos y aparici\u00f3n de resistencias derivado de \u00e9ste.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n401. EXPERIENCIA DE USO EN VIDA REAL DE SOTROVIMAB PARA EL TRATAMIENTO DE LA INFECCI\u00d3N \nPOR SARS-COV2. \nAUTORES\nCORAZ\u00d3N VILLANUEVA, J; MANZANO LORENZO, R; TALL\u00d3N MARTINEZ, JC; PE\u00d1A PEDROSA, JA; MART\u00cdNEZ SESMERO, \nJM; SANCHEZ-OCA\u00d1A MART\u00cdN, N; MOLINERO MU\u00d1OZ, M; YBA\u00d1EZ GARC\u00cdA, L\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nSotrovimab es un anticuerpo monoclonal aprobado como una nueva alternativa terap\u00e9utica para el tratamiento del \nCOVID-19. El objetivo es describir la evoluci\u00f3n cl\u00ednica y el perfil de los pacientes que han recibido Sotrovimab, as\u00ed como \nanalizar su seguridad en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo realizado entre agosto 2021 y marzo de 2022. Se incluyeron el 100% \nde pacientes con enfermedad COVID-19 positiva (confirmada mediante diagn\u00f3stico microbiol\u00f3gico) a los que se les \nadministr\u00f3 sotrovimab previa aprobaci\u00f3n de forma individualizada por la Agencia Espa\u00f1ola del medicamento y productos \nsanitarios (AEMPS), seg\u00fan los criterios de priorizaci\u00f3n establecidos en cada momento.  \n \nLas variables de estudio se obtuvieron a trav\u00e9s de la historia cl\u00ednica y programa de prescripci\u00f3n electr\u00f3nica. Se \nrecogieron como variables principales: caracter\u00edsticas demogr\u00e1ficas (edad, sexo); gravedad de la sintomatolog\u00eda previa \na recibir sotrovimab: leve o moderada-grave seg\u00fan criterios de la Organizaci\u00f3n mundial de la salud (OMS); progresi\u00f3n a \noxigenoterapia (bajo o alto flujo), resoluci\u00f3n cl\u00ednica (recuperaci\u00f3n, UCI, exitus) y perfil de seguridad. Variables secundarias \nregistradas fueron: comorbilidades, d\u00edas de s\u00edntomas, pauta vacunal y d\u00edas de hospitalizaci\u00f3n tras la administraci\u00f3n.\nRESULTADOS\nSe incluyeron un total de 14 pacientes, 57% hombres, con una media de edad de 70\u00b17,6 a\u00f1os, todos con m\u00e1s de una \ncomorbilidad registrada, el 71% eran trasplantados renales con inmunosupresores y otro 20% estaba en tratamiento \ncon rituximab\ufffd El 93% de los pacientes se encontraban con la pauta vacunal completa en el momento de la solicitud y \npresentaban una serolog\u00eda negativa para SARS-CoV2 IgG anti RBD ( < 50UA/ml). El 71% de los pacientes ten\u00edan menos \nde 5 d\u00edas de cl\u00ednica cuando recibieron el anticuerpo y el resto menos de 10 d\u00edas a excepci\u00f3n de un caso de COVID-19 \npersistente\ufffd \n \nDos de los ocho pacientes con sintomatolog\u00eda leve requirieron ingreso hospitalario por empeoramiento, con una media \nde 10 d\u00edas de estancia. Ninguno de ellos progres\u00f3 a oxigenoterapia y todos evolucionaron favorablemente, recibiendo el \nalta hospitalaria.  \n \nTodos los pacientes con sintomatolog\u00eda grave-moderada requirieron ingreso hospitalario con una media de 11,83\u00b14,75 \nd\u00edas y se encontraban con oxigenoterapia en el momento de la administraci\u00f3n. El 83.3% con oxigenoterapia de bajo \nflujo y de este grupo, m\u00e1s de la mitad progres\u00f3 a oxigenoterapia de alto flujo. Aunque todos los moderados-graves \neran candidatos a UCI/UCRI, solo la mitad de ellos requirieron ingreso en esta, de estos 2 fueron exitus, uno contin\u00faa \ningresado en el momento del estudio y otro recibi\u00f3 el alta\ufffd En total, de los 6 pacientes el 50% recibieron el alta y un 33% \nexitus\ufffd  \n \nNo se identificaron ninguna de las reacciones adversas descritas en ficha t\u00e9cnica: hipersensibilidad, reacciones en la \nperfusi\u00f3n y anafilaxia.\nCONCLUSIONES\nSotrovimab presenta un buen perfil de seguridad y aunque no podemos atribuir dichos resultados \u00fanica y exclusivamente \na dicho f\u00e1rmaco y se necesitan m\u00e1s estudios, los datos obtenidos muestran una alta tasa de resoluci\u00f3n cl\u00ednica favorable, \nprincipalmente en pacientes con sintomatolog\u00eda leve, en concordancia con la indicaci\u00f3n en ficha t\u00e9cnica. Por lo que \npuede ser considerado como una alternativa efectiva para evitar la progresi\u00f3n a COVID-19 grave.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n404. ADECUACI\u00d3N, SEGURIDAD Y EFECTIVIDAD DE LA PROFILAXIS PRE-EXPOSICI\u00d3N AL VIH Y \nCARACTERIZACI\u00d3N DE LAS ENFERMEDADES DE TRANSMISI\u00d3N SEXUAL REPORTADAS \nAUTORES\nSEBASTI\u00c1N CARRASCO, C; PARDO PASTOR, J; SALAZAR GONZ\u00c1LEZ, F; IGLESIAS RODRIGO, M; MECA CASASNOVAS, \nN; NICOL\u00c1S PIC\u00d3, J\nHOSPITAL UNIVERSITARIO M\u00daTUA DE TERRASSA \ufffd PL\ufffd DOCTOR ROBERT , 5 TERRASSA \ufffd BARCELONA405OBJETIVOS\nDescribir el perfil del paciente incluido en el programa de profilaxis pre-exposici\u00f3n (PrEP) al VIH, evaluar la efectividad y \nseguridad del tratamiento, y estudiar la incidencia de las enfermedades de transmisi\u00f3n sexual (ETS) reportadas durante la \nPrEP \ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que se llev\u00f3 a cabo en un hospital universitario de tercer nivel entre enero de 2020 y \nabril de 2022\ufffd  \nSe incluyeron todos los pacientes que iniciaron la PrEP durante el per\u00edodo de estudio. Para la caracterizaci\u00f3n de \nla poblaci\u00f3n se recogieron las siguientes variables: demogr\u00e1ficas, filtrado glomerular estimado (FGe), usuarios de \n\u201cchemsex\u201d, uso previo de profilaxis de post-exposici\u00f3n (PPE) al VIH y antecedentes de ETS. Tambi\u00e9n se revisaron los \ncriterios de inicio de PrEP , uso de pauta fija o intermitente y d\u00edas de tratamiento. Para evaluar la efectividad y seguridad, \nse recogi\u00f3 la incidencia de infecci\u00f3n por VIH, efectos adversos (EAs) presentados; tambi\u00e9n discontinuaciones de \ntratamiento y motivos de retirada. Por \u00faltimo, se recogieron las ETS reportadas durante la PrEP .  \nSe extrajeron los datos de la historia cl\u00ednica del programa inform\u00e1tico HCIS\u00ae.  \nSe realiz\u00f3 un an\u00e1lisis estad\u00edstico descriptivo con medidas de tendencia central y dispersi\u00f3n para las variables cuantitativas \ny frecuencias absolutas para las variables categ\u00f3ricas\ufffd\nRESULTADOS\nSe obtuvo una muestra de 165 pacientes, de los cuales 162 (98,18%) fueron hombres que ten\u00edan sexo con hombres \n(HsH). La edad media fue de 37\u00b110 a\u00f1os, y el FGe medio de 103,97\u00b116,33 ml/min. De la poblaci\u00f3n estudiada, 42 (25,45%) \npacientes refirieron ser usuarios de \u201cchemsex\u201d y 36 (21,82%) hab\u00edan realizado al menos una vez PPE. La incidencia de \nantecedentes de ETS fue de 136 en total, distribuidos en 92 (55,80%) pacientes, siendo la m\u00e1s com\u00fan la producida por \nTreponema pallidum, con un total de 46 (33,82%). \n \nTodos los pacientes (100%) cumpl\u00edan los criterios de inicio de PrEP , 162 (98,18%) iniciaron a pauta fija y 3 (1,82%) \npacientes pauta intermitente. La media de duraci\u00f3n del tratamiento fue de 247\u00b1175 d\u00edas.  \n \nEn cuanto a efectividad y seguridad, todos los pacientes (100%) mantuvieron serolog\u00edas negativas de VIH. Presentaron \nalteraciones gastrointestinales (diarrea, v\u00f3mitos, molestias g\u00e1stricas y/o dolor abdominal) 16 (9,70%) pacientes, y 1 \n(0,61%) present\u00f3 rash cut\u00e1neo.  \nSe observ\u00f3 que 37 (22,42%) pacientes abandonaron el tratamiento: 32 (19,39%) por decisi\u00f3n del paciente, 3 (1,82%) por \nEAs relacionados con la PrEP y 2 (1,21%) por traslado a otro centro.  \nSe registraron 80 ETS durante la PrEP en un total de 41 (24,85%) pacientes, la m\u00e1s prevalente fue la producida por \nNeisseria gonorrhoeae, con 36 (45,00 %) episodios. De media hubo una disminuci\u00f3n de un 58,82% de ETS detectadas \nantes y despu\u00e9s del inicio de PrEP .\nCONCLUSIONES\nLos pacientes incluidos en el programa PrEP se adecuaron a la normativa vigente y la mayor\u00eda eran hombres que tienen \nsexo con hombres. \nLa efectividad de la PrEP frente a infecci\u00f3n por VIH fue total y los efectos secundarios mayoritarios fueron las alteraciones \ngastrointestinales.  \nLas ETS m\u00e1s detectada durante el tratamiento fue Neisseria gonorrhoeae. Ser\u00eda importante continuar fomentando el uso \ndel preservativo para reducir la aparici\u00f3n de ETS en esta poblaci\u00f3n.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n436. SEGUIMIENTO FARMACOTERAP\u00c9UTICO MULTIDISCIPLINAR AL PACIENTE EN TRATAMIENTO \nANTIVIRAL CONTRA LA HEPATITIS C \nAUTORES\nIBARRA GARC\u00cdA, E; P\u00c9REZ D\u00cdEZ, E; BUSTOS MART\u00cdNEZ, M; VALLINAS HIDALGO, S; DE JUAN ARROYO, A; PRIETO \nELORDUI, J\nURDULIZ OSPITALEA \ufffd CALLE GOIETA KALEA 32 URDULIZ \ufffd VIZCAYA\nOBJETIVOS\nDescribir el procedimiento de seguimiento farmacoterap\u00e9utico multidisciplinar realizado a los pacientes con hepatitis C \n(VHC) en tratamiento con antivirales de acci\u00f3n directa en un hospital comarcal.  \nEvaluar la efectividad y seguridad de sofosbuvir/velpatasvir en estos pacientes.\nMATERIALES Y M\u00c9TODOS\nSofosbuvir/velpatasvir es el antiviral de acci\u00f3n directa de uso mayoritario en nuestra organizaci\u00f3n sanitaria, tanto en \npacientes sin cirrosis como con cirrosis compensada y descompensada (este \u00faltimo caso en combinaci\u00f3n con ribavirina), \npor su perfil pangenot\u00edpico.  \nEn nuestro centro el m\u00e9dico responsable realiza cada solicitud de tratamiento antiviral VHC de manera individualizada \na trav\u00e9s de la historia cl\u00ednica electr\u00f3nica (HCE). La farmac\u00e9utica responsable verifica que el paciente cumple criterios \nde inicio de tratamiento y revisa la HCE del paciente para corroborar la adecuaci\u00f3n del mismo\ufffd En caso de detectar \ninteracciones farmacol\u00f3gicas, las comunica y ofrece una recomendaci\u00f3n\ufffd  406Una vez iniciado el tratamiento, se realizan dispensaciones mensuales, buscando mejor seguimiento de la tolerancia y \nadherencia al tratamiento.  \nTodos los datos recogidos se incluyen en la HCE, lo cual permite su extracci\u00f3n posterior: interacciones farmacol\u00f3gicas y \nefectos adversos, adherencia y efectividad (respuesta viral sostenida -RVS- a las 12 semanas y a los 12 meses).\nRESULTADOS\nDesde febrero de 2020 hasta marzo de 2022, 62 pacientes fueron tratados con sofosbuvir/velpatasvir (12 semanas) en \nnuestro hospital.  \nLos pacientes ten\u00edan una mediana de edad de 58 a\u00f1os (rango: 38-90), el 62% eran hombres y el 38% mujeres. No se \ndetect\u00f3 ninguna coinfecci\u00f3n VIH/VHC y s\u00f3lo un 6% eran retratamientos. El 64% de los pacientes eran genotipos G1 y G2.  \nSe detectaron, previo al inicio del tratamiento, 24 potenciales interacciones farmacol\u00f3gicas con tratamientos cr\u00f3nicos\ufffd \nLos f\u00e1rmacos implicados fueron inhibidores de la bomba de protones (37%), estatinas (12%), antiepil\u00e9pticos (5%) y \nanalg\u00e9sicos (21%), entre otros (26%). Las interacciones supusieron la suspensi\u00f3n del tratamiento cr\u00f3nico en el 33% de los \ncasos, un cambio de f\u00e1rmaco en el 33% y la modificaci\u00f3n de la hora de administraci\u00f3n en el 33% restante.  \nEl 19% de los pacientes notificaron alg\u00fan efecto adverso (principalmente cefalea y astenia), todos leves y autolimitados, y \ns\u00f3lo hubo una suspensi\u00f3n de tratamiento por este motivo.  \nLa adherencia, calculada seg\u00fan los registros de dispensaci\u00f3n electr\u00f3nica, fue del 100% en todos los pacientes, al igual que \nla efectividad, alcanz\u00e1ndose RVS indetectable a las 12 semanas en todos pacientes tratados y RVS indetectable a los 12 \nmeses en todos los pacientes de los que se dispone de esta informaci\u00f3n. Ning\u00fan paciente ha requerido retratamiento.\nCONCLUSIONES\nEl procedimiento multidisciplinar establecido fomenta la comunicaci\u00f3n con los m\u00e9dicos responsables y mejora el \nseguimiento cl\u00ednico del paciente, lo cual redunda en una mejora de la calidad asistencial. Seg\u00fan nuestra experiencia, \nsofosbuvir/velpatasvir es un f\u00e1rmaco seguro y efectivo en el tratamiento de la infecci\u00f3n por el virus VHC, siendo muy bien \ntolerado por los pacientes y alcanzando tasas de erradicaci\u00f3n del virus del 100%.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n499. DATOS EN VIDA REAL DEL USO DE NIRMATRELVIR/RITONAVIR PARA LA ENFERMEDAD POR COVID-19 \nAUTORES\nECHEVERR\u00cdA GORRITI, A; ALZUETA IST\u00daRIZ, N; CAPDEVILA BASTONS, F; ALDAVE COBOS, P; GARC\u00cdA GONZALEZ, P; \nSANZ \u00c1LVAREZ, L; FERN\u00c1NDEZ GONZ\u00c1LEZ, J; L\u00d3PEZ ANDR\u00c9S, A\nSERVICIO NAVARRO DE SALUD- OSASUNBIDEA\nOBJETIVOS\nEvaluar los datos en vida real de los pacientes tratados con nirmatrelvir/ritonavir para la infecci\u00f3n por SARS-CoV-2 en una \ncomunidad aut\u00f3noma\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de pacientes tratados con nirmatrelvir/ritonavir. \nCriterios de inclusi\u00f3n: pacientes tratados con nirmatrelvir/ritonavir entre el 04/04/2022 y el 10/05/2022\ufffd  \nLas variables recogidas fueron: sexo, edad, criterio de priorizaci\u00f3n, n\u00famero de vacunas recibidas para la COVID-19, fecha \nde inicio de s\u00edntomas, fecha de inicio de nirmatrelvir/ritonavir, funci\u00f3n hep\u00e1tica y renal e interacciones relevantes. Las \nvariables de efectividad fueron: fecha de hospitalizaci\u00f3n y muerte por cualquier causa. Para analizar la seguridad se \nrecogieron datos sobre efectos adversos notificados en historia cl\u00ednica. Los datos fueron extra\u00eddos de los programas de \nprescripci\u00f3n electr\u00f3nica y de la historia cl\u00ednica.\nRESULTADOS\nSe incluyeron 27 pacientes, 16 mujeres, con una edad media de 66,4 \u00b1 0,6 a\u00f1os. Todos los pacientes tuvieron diagn\u00f3stico \nconfirmado de infecci\u00f3n por SARS-CoV-2 y pertenec\u00edan al grupo 1 de priorizaci\u00f3n seg\u00fan el documento de \u201cCriterios para \nvalorar la administraci\u00f3n de las nuevas alternativas terap\u00e9uticas antivirales frente a la infecci\u00f3n por SARS-CoV-2 (versi\u00f3n \n3)\u201d. \nTodos los pacientes estaban vacunados frente a la COVID-19: 16 con tres dosis, 2 con cuatro y 1 con dos.  \nEl promedio de tiempo transcurrido desde el inicio de los s\u00edntomas hasta el inicio del tratamiento fue de 2,4 d\u00edas, y en 25 \nde ellos se inici\u00f3 el tratamiento dentro de los cinco d\u00edas posteriores al inicio de s\u00edntomas.  \nEn todos los casos la duraci\u00f3n del tratamiento fue de 5 d\u00edas, 24 pacientes recibieron 300 mg de nirmatrelvir y 100 mg de \nritonavir cada 12 horas, mientras que tres pacientes requirieron ajuste de dosis por insuficiencia renal. Ning\u00fan paciente \npresentaba alteraci\u00f3n de la funci\u00f3n hep\u00e1tica. \nDos pacientes requirieron hospitalizaci\u00f3n y ning\u00fan paciente falleci\u00f3 por COVID-19 durante este periodo.  \nLa mediana de tiempo de seguimiento fue de 17 d\u00edas.  \nLa incidencia de reacciones adversas fue superior a la del ensayo cl\u00ednico. Se notificaron reacciones adversas en el 18,5% \nde los pacientes: diarrea (2), malestar g\u00e1strico (2), cefalea (1) y v\u00f3mitos (3).  \nEn 1/3 de los pacientes el farmac\u00e9utico detect\u00f3 interacciones relevantes con diversos f\u00e1rmacos: atorvastatina, zolpidem, \namlodipino, simvastatina, tacr\u00f3limus, metamizol, trazodona, fentanilo, rosuvastatina, fesoterodina, digoxina, clonazepam \ny sacubitrilo/valsartan. En seis pacientes fue necesario interrumpir el tratamiento con estatinas, en dos monitorizar la \ntensi\u00f3n arterial y en otro monitorizar niveles de tacr\u00f3limus.407CONCLUSIONES\nEl perfil de paciente tratado en vida real difiere considerablemente de la poblaci\u00f3n incluida en el ensayo cl\u00ednico EPIC-\nHR. Nuestros pacientes ten\u00edan una edad media mayor (66 vs 44 a\u00f1os), toda la poblaci\u00f3n estaba vacunada, la variante \nmayoritaria era BA.2, se aplicaron distintos criterios de \u201calto riesgo\u201d y nuestro seguimiento fue menor (17 vs 28 d\u00edas).  \nEl uso de nirmatrelvir/ritonavir en la vida real ha mostrado ser menos eficaz (mayor tasa de hospitalizaci\u00f3n) y seguro \n(mayor incidencia de reacciones adversas) en los pacientes seleccionados respecto al ensayo.  \nLa validaci\u00f3n por el farmac\u00e9utico ha permitido el ajuste de dosis y la detecci\u00f3n de interacciones evitando posibles \ntoxicidades\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n517. ESTUDIO DESCRIPTIVO DE LA BACTERIEMIA ASOCIADA A CAT\u00c9TER EN UN HOSPITAL DE SEGUNDO \nNIVEL EN 2021 \nAUTORES\nPUEBLA VILLAESCUSA, A; MURGADELLA SANCHO, A; LOSA L\u00d3PEZ, L; GRACIA GARC\u00cdA, B; HIDALGO ALBERT , E\nHOSPITAL DE SANT JOAN DESPI MOISES BROGGI. AVENIDA JACINT VERDAGUER 90 SANT JOAN DESP\u00cd. BARCELONA\nOBJETIVOS\nConocer las caracter\u00edsticas cl\u00ednicas y microbiol\u00f3gicas de los pacientes que desarrollaron bacteriemias relacionadas con \ncat\u00e9ter (BRC) en un hospital de segundo nivel en 2021.  \nEvaluar la adecuaci\u00f3n de los tratamientos antibi\u00f3ticos emp\u00edricos a los resultados microbiol\u00f3gicos obtenidos.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional en el que se incluyeron adultos ingresados en nuestro centro en 2021 con \ndiagn\u00f3stico confirmado de BRC.  \nSe registraron los siguientes datos: edad, sexo, comorbilidades m\u00e1s prevalentes ( > 10%), \u00edndice de comorbilidad de \nCharlson (ICC), diagn\u00f3stico SARS-CoV-2, \u00e1rea hospitalaria, d\u00edas de estancia hospitalaria (EH), tipo de cat\u00e9ter: cat\u00e9ter \nvenoso central (CVC), cat\u00e9ter central de inserci\u00f3n perif\u00e9rica (CVIP), cat\u00e9ter venoso perif\u00e9rico (CVP), agentes etiol\u00f3gicos, \nadecuaci\u00f3n del tratamiento emp\u00edrico y mortalidad.  \nLas variables cuantitativas se calcularon media y desviaci\u00f3n est\u00e1ndar (DE), y de las variables cualitativas se calcularon \nporcentajes. El an\u00e1lisis de los datos se realiz\u00f3 con Excel\u00ae.\nRESULTADOS\nMuestra: 35 pacientes, el 69% fueron hombres. \nEdad media: 66,6 a\u00f1os (DE=15,58). El 57% fueron > 70 a\u00f1os. S\u00f3lo el 6% fueron < 40 a\u00f1os.  \nComorbilidades: hipertensi\u00f3n (57%), insuficiencia renal (40%), dislipemias (40%), obesidad con IMC > 30 (34%); diabetes \n(23%); cardiopat\u00edas (31%); antecedentes de ictus (11%); hiperuricemia (11%); tumores (23%).  \nICC medio: 4,97 (DE=3,09).  \nSARS-CoV-2: 20 (57%) PCR+. \n\u00c1rea hospitalaria: \u00e1reas m\u00e9dicas (48%), unidad de vigilancia intensiva (46%) y \u00e1reas quir\u00fargicas (6%).  \nEH media: 47,9 d\u00edas (DE=38,2).  \nTipos de cat\u00e9ter: CVC (51%), CVIP (26%) y CVP (23%).  \nAgentes etiol\u00f3gicos: Grupo Klebsiella/Serratia/Enterobacter (28,6%); Staphylococcus aureus (23,8%); Staphylococcus \nepidermis (21,4%); Enterococcus (11,9%); CoNS (4,8%); grupo Escherichia coli (2,4%); Pseudomonas (2,4%); Otras Gram\u2013 \n(2,4%); Candida (2,4%).  \nMortalidad: 10 (29%) pacientes fueron \u00e9xitus, de los que 5 fallecieron por SARS-CoV-2. La edad media de los fallecidos fue \nde 70,6 a\u00f1os (DE=10,8). \nAdecuaci\u00f3n del tratamiento emp\u00edrico: 33 (94%) de los tratamientos fueron adecuados, es decir cubr\u00edan el agente causal \nde la BCR. Sin embargo, 5 de ellos ten\u00edan un espectro antimicrobiano mayor al recomendado en nuestras gu\u00edas locales. \nSolamente en 2 (6%) tratamientos la cobertura inicial no fue adecuada y requirieron de un cambio antibi\u00f3tico.\nCONCLUSIONES\nNuestros pacientes tuvieron una edad avanzada y un alto \u00edndice de comorbilidad, as\u00ed como una alta tasa de CVC. \nPresentaron una alta tasa de ingreso en UCI y una larga EH\ufffd Es destacable la elevada proporci\u00f3n del grupo Klebsiella/\nSerratia/Enterobacter (Gram-) como agente implicado en las bacteriemias de nuestro estudio.  \nLos tratamientos emp\u00edricos iniciados fueron adecuados en un alto porcentaje, poniendo de manifiesto la importancia de \nla creaci\u00f3n de gu\u00edas adaptadas a la epidemiolog\u00eda local.  \nSer\u00eda necesario comparar nuestros resultados con otros a\u00f1os para ver las consecuencias reales del efecto de la pandemia \nSARS-CoV-2, tanto en las caracter\u00edsticas cl\u00ednicas de los pacientes, como en el desarrollo y cambio de la microbiota a nivel \nhospitalario.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n552. SARS-COV-2 INFECTIONS AND HOSPITALIZATIONS AMONG PEOPLE AGED \u226560 YEARS, BY \nVACCINATION STATUS IN A TERTIARY HOSPITAL \nAUTORES\nDEL RIO VALENCIA, JC; TAMAYO BERMEJO, R; ORTEGA DE LA CRUZ, C; MU\u00d1OZ CASTILLO, IM\nCOMPLEJO HOSPITALARIO REGIONAL CARLOS HAYA. AV . CARLOS HAYA, S/N M\u00c1LAGA. MALAGA408OBJETIVOS\nCOVID-19 vaccines fully approved or currently authorized for use through Emergency Use Authorization from the \nEuropean Medicine Agency are critical tools for controlling the COVID-19 pandemic; however, even with highly effective \nvaccines, a proportion of fully vaccinated persons will become infected with SARS-CoV-2, the virus that causes COVID-19. \nThe objective of this work has been to estimate the effectiveness of the COVID-19 vaccines about hospital and ICU \nadmissions and mortality in people aged \u2265 60 years.\nMATERIALES Y M\u00c9TODOS\nObservational, retrospective study was carried out during the month of July in 2021. We took at random the patients \ninfected by COVID-19, older than 60 years, and admitted to an infectious ward of our hospital. Patient data were taken \nfrom clinical records. Outcomes collected: Demographic variables: age and sex and clinical variables: admission days, fully \nvaccinated and unvaccinated with Pfizer-BioNTech, Moderna, Oxford-AstraZeneca or Janssen vaccines, admitted to ICU \nand death. Statistical analysis was performed using SPSS Statistics V.17. Categorical variables are shown as percentages \nand quantitative variables as mean (\u00b1 SD).\nRESULTADOS\nEighty-five patients were included in this study, 40 of them were unvaccinated and 45 fully vaccinated. \nUnvaccinated group: Median age was 73.70 \u00b1 10.17 years-old and 45.50% were men. Admission days mean 15.27 \u00b1 7,84; \n25% (10) of patients were admitted to ICU and 35% of them (14) died.  \nFully vaccinated: Median age was 76.48 \u00b1 9.21 years-old and 51.11% were men. Admission days mean 12.73 \u00b1 9.26; \n9.11% of patients were admitted to ICU and 26.66% (12) of them died.  \nAs to mortality, fully vaccinated group had an absolute risk reduction of 8.33% (CI95%: -11.30 -27.97) (p > 0.05) and a \nrelative risk of 0.76 (CI95%: 0.40 - 1.45) (p > 0.05) with respect to unvaccinated group.  \nThere were statistically significant differences between the unvaccinated group and fully vaccinated as to admission days \nto a ward (p < 0.05, Mann-Whitney test).  \nAs to ICU admission, fully vaccinated group had an absolute risk reduction of 16.11% (CI95%: 0.32 - 31.90), (p < 0.05) and \na relative risk of 0.36 (CI95%: 0.12 - 1.05) with respect to unvaccinated group. The number-needed-to-treat (NNT) was 6 \n(CI95%: 3.14 - 308.05).\nCONCLUSIONES\nFully vaccinated people had a lower mortality rate, fewer admission days and less admission rate to ICU. It would be very \ninteresting to do a serologic study of vaccinated patients to know the immunologic status of them and find out why the \npercentage of death is considerable in this group.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n575. CONSULTA MULTIDISCIPLINAR DE INFECCIONES DE TRANSMISI\u00d3N SEXUAL: ESTUDIO DESCRIPTIVO \nDE PACIENTES TRATADOS CON PROFILAXIS PRE-EXPOSICI\u00d3N A VIH \nAUTORES\nP\u00c9REZ F\u00c1CILA, A; PROY VEGA, B; PATI\u00d1O ORTEGA, HD; NAVARRO CAMACHO, C; GONZ\u00c1LEZ ESCRIBANO, MC; SAIZ \nMOLINA, JJ\nHOSPITAL GENERAL LA MANCHA CENTRO. AVENIDA DE LA CONSTITUCI\u00d3N, 3 ALC\u00c1ZAR DE SAN JUAN. CIUDAD REAL\nOBJETIVOS\nLa profilaxis pre-exposici\u00f3n (PrEP) es una estrategia de prevenci\u00f3n de infecci\u00f3n por VIH basada en administrar \nconcomitantemente emtricitabina y tenofovir disoproxilo. Objetivo: describir el perfil de pacientes que inician \ntratamiento con PrEP atendidos en una consulta multidisciplinar de infecciones de transmisi\u00f3n sexual (ITS).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo, en pacientes que iniciaron PrEP frente a infecci\u00f3n por VIH (diciembre \n2019-abril 2022) en una consulta multidisciplinar de ITS. La actividad del farmac\u00e9utico respondi\u00f3 a adecuar la \nprescripci\u00f3n a las condiciones de financiaci\u00f3n establecidas.  \n \nVariables recogidas: sexo, edad, procedencia (Espa\u00f1a/extranjero), nivel de estudios (b\u00e1sicos/secundarios/universitarios), \npareja estable, pareja portadora de VIH, n\u00famero de parejas sexuales durante el \u00faltimo a\u00f1o ( < 10/10-20/ > 20), empleo \nde apps de citas y/o participaci\u00f3n en saunas sexuales (si/no), uso de protecci\u00f3n (nunca/casi nunca/casi siempre/siempre), \nconsumo de drogas y tipo durante el acto sexual, consumo de alcohol durante el acto sexual, vacunaci\u00f3n frente a virus \nhepatitis VHA, VHB y papilomavirus, realizaci\u00f3n de pruebas de detecci\u00f3n de ITS y fecha de realizaci\u00f3n de \u00faltima prueba ( \n< 1 a\u00f1o/\u22651 a\u00f1o), presencia y tipo de ITS previas y durante la PrEP y; empleo de profilaxis post-exposici\u00f3n (PEP) a VIH.  \n \nFuentes de informaci\u00f3n consultadas: Historia Cl\u00ednica Electr\u00f3nica y entrevista con el paciente. Los datos fueron registrados \nen una base de datos Acces\u00ae\ufffd\nRESULTADOS\nEl tratamiento con PrEP se inici\u00f3 y registr\u00f3 en 28 pacientes (39,14\u00b110,11 a\u00f1os de media; 100% hombres; 96,43% \nprocedencia espa\u00f1ola). Nivel de estudios (b\u00e1sicos: 3; secundarios: 15; universitarios: 10). 19 pacientes no ten\u00edan pareja \nestable; 2 pacientes ten\u00edan pareja portadora de VIH y; n\u00famero de parejas sexuales en el \u00faltimo a\u00f1o ( < 10: 4; 10-20: 24; > \n20:1). 26 pacientes emplearon apps de citas y/o participaron en saunas sexuales. Uso de protecci\u00f3n (nunca: 8; casi nunca: 4092; casi siempre: 17; siempre: 1); 9 pacientes consum\u00edan drogas durante el acto sexual (popper: 8; \u00e9xtasis: 2; viagra: 1) y; 7 \npacientes consum\u00edan alcohol durante el acto sexual.  \n \nPrevio al inicio de PrEP , 19 pacientes presentaron vacunaci\u00f3n frente a VHA, 25 frente a VHB y 6 frente a papilomavirus\ufffd \n27 pacientes presentaron pruebas de detecci\u00f3n de ITS (19: < 1 a\u00f1o previo a la consulta). 22 pacientes presentaron ITS \nprevias al inicio de PrEP , por orden de frecuencia fueron: s\u00edfilis (7), uretritis inespec\u00edfica (6), gonorrea (6), pediculosis (4), \ninfecci\u00f3n por papilomavirus (3) y uretritis por Haemophilus parainfluenzae (1). Durante la PrEP , 7 pacientes desarrollaron \nuna ITS (3: gonorrea; 3: s\u00edfilis; 1: herpes) y un paciente desarroll\u00f3 m\u00faltiples ITS (gonorrea y papilomavirus). 8 pacientes \nrecibieron PEP a VIH\ufffd\nCONCLUSIONES\nLa poblaci\u00f3n que inicia tratamiento con PrEP se caracteriza por presentar un nivel de estudios intermedio-alto, otras ITS \nprevias y m\u00faltiples parejas sexuales con conductas de riesgo. Es por esto, la presencia de una consulta multidisciplinar de \nITS puede ser \u00fatil para mejorar la calidad de la atenci\u00f3n sanitaria y la salud sexual de la poblaci\u00f3n, as\u00ed como permitir un \nmanejo adecuado de las ITS.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n618. EVALUACI\u00d3N DEL TRATAMIENTO PROFIL\u00c1CTICO PREEXPOSICI\u00d3N AL VIH EN UN HOSPITAL DE \nSEGUNDO NIVEL \nAUTORES\nMIR CROS, M; MORALES PORTILLO, A; CANO MARRON, SM; TORRES BONDIA, FI; BARDOLL CUCALA, M; SANTOS \nRODRIGUEZ, C; MART\u00cdNEZ CASTRO, B; TABERNER BONASTRE, P\nHOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA \ufffd AVDA \ufffd ALCALDE ROVIRA ROURE, 80 LLEIDA \ufffd LLEIDA\nOBJETIVOS\nEvaluar la efectividad y seguridad, as\u00ed como la adherencia y satisfacci\u00f3n del paciente en el tratamiento profil\u00e1ctico \npreexposici\u00f3n (PrEP) al VIH con emtricitabina/tenofovir disoproxilo en un hospital de segundo nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo retrospectivo de los pacientes que iniciaron PrEP al VIH con emtricitabina/tenofovir disoproxilo entre \nfebrero 2020 y enero 2022\ufffd \nLas variables recogidas fueron: edad, sexo, indicaciones de la profilaxis, infecci\u00f3n de transmisi\u00f3n sexual (ITS) previa y \nposterior al tratamiento y microorganismos causantes de estas infecciones, motivos de discontinuaci\u00f3n del tratamiento, \nadherencia y efectos adversos. Los datos fueron recogidos de la historia cl\u00ednica informatizada.  \nSe ofreci\u00f3 a los pacientes la realizaci\u00f3n de la encuesta TQSM de satisfacci\u00f3n con el tratamiento. Consideramos alto grado \nde satisfacci\u00f3n respuestas de \u201cSatisfecho\u201d, \u201cMuy satisfecho\u201d y \u201cSumamente satisfecho\u201d, y facilidad las respuestas \u201cF\u00e1cil\u201d, \n\u201cMuy f\u00e1cil\u201d y \u201cSumamente f\u00e1cil\u201d.\nRESULTADOS\nSe incluyeron 45 pacientes, 95,5% hombres, con edad media de 36,7 (23 \u2013 67) a\u00f1os. Las indicaciones de PrEP m\u00e1s \nprevalentes fueron: > 10 parejas sexuales diferentes en el \u00faltimo a\u00f1o (62,2%), sexo anal sin preservativo en el \u00faltimo \na\u00f1o (44,4%) y al menos una ITS bacteriana en el \u00faltimo a\u00f1o (24,4%). El 35,6% de los pacientes presentaban m\u00e1s de una \nindicaci\u00f3n de profilaxis.  \nUn 55,6% de los pacientes hab\u00edan presentado una ITS previa al inicio de la PrEP y un 37,8% la present\u00f3 despu\u00e9s. Las ITS \nm\u00e1s frecuentes fueron causadas por Treponema pallidum (36,4%), Neisseria gonorrea (31,8%), Clamidia trachomatis \n(22,7%), y Mycoplasma genitalium (9,1%).  \nLa adherencia al tratamiento fue del 100%.  \nS\u00f3lo un 4,4% manifest\u00f3 p\u00e9rdida de seguimiento al tratamiento. Ning\u00fan paciente discontinu\u00f3 la PrEP por presentar \nserolog\u00edas positivas para el VIH.  \nUn 13,3% de los pacientes manifest\u00f3 efectos adversos a emtricitabina/tenofovir disoproxilo, siendo problemas \nintestinales, mareos, cefalea y elevaci\u00f3n de las transaminasas.  \nDe los 45 pacientes, 20 (44,4%) realizaron la encuesta TQSM de forma an\u00f3nima.  \nLa mayor\u00eda mostr\u00f3 un alto grado de satisfacci\u00f3n respecto a la capacidad del medicamento para prevenir o tratar \nsu condici\u00f3n (85%) y el tiempo que demora en empezar a hacer efecto (90%), mostrando el 100% un alto grado de \nsatisfacci\u00f3n respecto a su medicamento.  \nDos pacientes (10%) presentaron efectos adversos, siendo \u00e9stos muy poco o nada relevantes para su estado de salud \nf\u00edsico, capacidad mental o satisfacci\u00f3n general con el medicamento.  \nLa mayor\u00eda tuvo facilidad para usar/tomar el medicamento (90%), mientras que el 100% consider\u00f3 f\u00e1cil planear las tomas. \nEl 60% consideraron el tratamiento \u201cSumamente pr\u00e1ctico\u201d, el 30% lo consideraron \u201cMuy pr\u00e1ctico\u201d y, el 10%, pr\u00e1ctico.  \nLa mayor\u00eda report\u00f3 mucha (45%) o absoluta (45%) confianza en que el medicamento era bueno para ellos, mostr\u00e1ndose \nmuy (35%) o totalmente (60%) convencidos con que las ventajas superaban las desventajas.\nCONCLUSIONES\nLa PrEP para al VIH es un tratamiento efectivo en pacientes con elevado riesgo de infecci\u00f3n.  \nLos pacientes conocen la importancia de la adherencia al tratamiento para obtener el beneficio de \u00e9ste. \nEs un tratamiento muy bien tolerado, con un porcentaje bajo de efectos adversos siendo estos leves. \nEl grado de satisfacci\u00f3n de nuestros pacientes con la PrEP es muy elevado.410CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n628. AN\u00c1LISIS DE LA UTILIZACI\u00d3N Y EFECTIVIDAD DE FIDAXOMICINA EN INFECCI\u00d3N POR CLOSTRIDIOIDES \nDIFFICILE EN UNA COHORTE DE PR\u00c1CTICA CL\u00cdNICA REAL \nAUTORES\nGARC\u00cdA LLORET , P; CANTUDO CUENCA, MD; ROLD\u00c1N GALNARES, M\nCOMPLEJO HOSPITALARIO DE ESPECIALIDADES VIRGEN DE VALME. CTRA. DE C\u00c1DIZ, KM. 548,9 SEVILLA. SEVILLA\nOBJETIVOS\nAnalizar la efectividad de fidaxomicina as\u00ed como las condiciones de utilizaci\u00f3n para el tratamiento de la infecci\u00f3n por \nClostridioides difficile (ICD).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y unic\u00e9ntrico en el que se incluyeron pacientes en tratamiento con fidaxomicina \npara ICD desde 1 de abril 2014 hasta 30 marzo 2022 en un hospital de especialidades. Se recogieron las siguientes \nvariables: edad, sexo, inmunosupresi\u00f3n, terapia antibi\u00f3tica concomitante, episodio de ICD. Para evaluar la efectividad \nse utiliz\u00f3: \u00edndice de curaci\u00f3n cl\u00ednica definido como resoluci\u00f3n de la diarrea sin sintomatolog\u00eda tras fin de tratamiento, \n\u00edndice de recurrencia tras ocho semanas de la finalizaci\u00f3n del tratamiento, \u00edndice de curaci\u00f3n global (curaci\u00f3n cl\u00ednica sin \nrecurrencia), mejor\u00eda a los 5 d\u00edas de tratamiento y tiempo hasta resoluci\u00f3n de la diarrea. Los datos se obtuvieron de la \nhistoria cl\u00ednica digitalizada. Las variables cuantitativas se describieron mediante mediana y rango intercuart\u00edlico (RIQ) y las \ncateg\u00f3ricas mediante frecuencia y porcentaje.\nRESULTADOS\nSe incluyeron 45 episodios de ICD grave tratados con fidaxomicina en 39 pacientes (59% mujeres) con edad mediana de \n80 a\u00f1os (RIQ: 69-88), siendo el 87% mayores de 65 a\u00f1os. En el 29% de los casos, los pacientes estaban inmunodeprimidos \ny el 24% recibieron concomitantemente antibi\u00f3ticos intravenosos. En el 38% de los casos, fidaxomicina se utiliz\u00f3 en \nprimer episodio de ICD \ufffd En el resto de episodios para el tratamiento de la infecci\u00f3n recurrente: primera, segunda, tercera \ny cuarta recidiva en el 33%, 15%, 9% y 4%, respectivamente. El uso de fidaxomicina en primer episodio fue en el 82% de \nlos casos por fracaso al tratamiento con vancomicina, en el 12% por alto riesgo de recurrencia y en el 6% por alergia a \nvancomicina y fracaso a metronidazol. Se obtuvo un \u00edndice de curaci\u00f3n cl\u00ednica del 83% (34/41 episodios, no valorable en \n4 casos por \u00e9xitus), un \u00edndice de recurrencia tras 8 semanas del 32% (9/28 episodios, no valorable en 17 casos por \u00e9xitus) \ny un \u00edndice de curaci\u00f3n global del 64% (18/28 episodios). Los pacientes mejoraron tras 5 d\u00edas de tratamiento en el 80% \nde los casos, siendo la mediana de d\u00edas de resoluci\u00f3n de la diarrea de 7,5 (RIQ: 5,0-11,5). Todos los pacientes tratados en \nprimer episodio de ICD con fidaxomicina presentaron criterios de alto riesgo de recurrencia, obteni\u00e9ndose en este grupo \nun \u00edndice de recurrencia a las 8 semanas del 46% (5/11 episodios, no valorable en 6 casos por \u00e9xitus).\nCONCLUSIONES\nNuestros datos sugieren un \u00edndice de curaci\u00f3n cl\u00ednica, recurrencia y curaci\u00f3n global menos favorable que la mostrada \nen ensayo cl\u00ednico pivotal aunque debemos resaltar que fidaxomicina se utiliz\u00f3 principalmente para tratamiento de la \ninfecci\u00f3n recurrente. Estos datos deber\u00edan interpretarse con cautela debido al tama\u00f1o muestral. El motivo de uso en \nprimer episodio es fundamentalmente por fracaso a vancomicina\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n634. IMPACTO DE LA RESISTENCIA A F\u00c1RMACOS ANTIMICROBIANOS EN LA ESTANCIA/ MORTALIDAD \nHOSPITALARIA A PARTIR DEL CONJUNTO MINIMO B\u00c1SICO DE DATOS. \nAUTORES\nOTERINO MOREIRA, I; L\u00d3PEZ DELGADO, \u00c1; LORENZO MART\u00cdNEZ, SF; MORALES CATAL\u00c1N, MDC; TEJEDOR ALONSO, \nM\u00c1; LOSA GARC\u00cdA, JE; P\u00c9REZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nDeterminar el impacto de la resistencia a f\u00e1rmacos antimicrobianos en la estancia y mortalidad hospitalaria en pacientes \nhospitalizados.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo de caso-control que incluy\u00f3 a todos los episodios de hospitalizaci\u00f3n de pacientes mayores de 17 \na\u00f1os dados de alta durante el periodo 2017-2019 en un hospital terciario utilizando el Conjunto M\u00ednimo B\u00e1sico de Datos \n(CMBD).  \nSe excluy\u00f3 la categor\u00eda diagn\u00f3stica mayor (CDM) 14: embarazo, parto y puerperio, por no considerarla representativa del \nobjetivo del estudio.  \nLos casos se definieron como cualquier hospitalizaci\u00f3n de pacientes que contiene como diagn\u00f3stico secundario en \nel CMBD los c\u00f3digos Z16.1 \u201cresistencia a antibi\u00f3ticos \u03b2-lact\u00e1micos\u201d y Z16.2 \u201cresistencia a otros antibi\u00f3ticos\u201d de la \nClasificaci\u00f3n Internacional de Enfermedades 10, versi\u00f3n espa\u00f1ola (CIE-10-ES). Los controles se seleccionaron de una \nmuestra aleatoria de hospitalizaciones exentas de dichos c\u00f3digos.  \nLas medianas se compararon mediante test Mann\u2013Whitney\u2013Wilcoxon y las proporciones por Chi-2. Se construyeron \ndos modelos de regresi\u00f3n multivariante que estudiaron la influencia de la resistencia a antimicrobianos en la estancia \n(modelo lineal generalizado) o mortalidad hospitalaria (regresi\u00f3n log\u00edstica multinomial), usando como covariales edad e \n\u00edndice de comorbilidad de Charlson (ICC)411RESULTADOS\nEl n\u00famero de hospitalizaciones durante 2017-2019 fue 54672. De ellos 653 episodios se definieron como casos \n(1,19%) y 2612 se seleccionaron como grupo control. Los pacientes con registro de resistencia a antimicrobianos eran \nsignificativamente m\u00e1s mayores, con una mediana de 80 a\u00f1os (RIC: 71\u201387) versus 72 a\u00f1os (RIC: 57-80), p > |z| < 0,001. La \nproporci\u00f3n de mujeres en el grupo resistencia a antimicrobianos fue del 47,78% y en el grupo control 46,36%, p=0,516. \nLa mediana del ICC fue 2 (RIC: 1-4) para los casos de resistencia a antimicrobianos y 1 (RIC: 0-3) en los controles, p > |z| < \n0,001\ufffd  \nLas principales CDM en el grupo con resistencia a antimicrobianos fueron: enfermedades ri\u00f1\u00f3n/v\u00edas urinarias (35,07%), \ntrastornos del aparato respiratorio (16,39%) y enfermedades infecciosas (12,25%); y para el grupo control fue: trastornos \ndel aparato respiratorio (14,93%), digestivo (14,28%), circulatorio (13,9%) y sistema musculoesquel\u00e9tico/tejido conectivo \n(11,91%). \nLa mediana de la estancia hospitalaria en el grupo con resistencia a antimicrobianos fue 9,88 d\u00edas (RIC: 5,28-17,86) y \n4,21 d\u00edas (RIC: 1,93-7,38) para el grupo control, p > |z| < 0,001. El 8,88% de los episodios del grupo con resistencia a \nantimicrobianos fue \u00e9xitus v/s el 3,45% del grupo control, p > |z| < 0,001.  \nEl modelo lineal general multivariante demostr\u00f3 que los pacientes con resistencia a antimicrobianos se asociaban a una \nmayor estancia hospitalaria: IRR=2,22 (IC95% 1,98-2,50), p > |z| < 0,001. As\u00ed mismo, la comorbilidad fue un factor que \naument\u00f3 la estancia hospitalaria: IRR=1,19 (IC95% 1,14-1,24), p > |z| < 0,001.  \nPor su parte, el modelo de regresi\u00f3n log\u00edstica multinomial para la mortalidad demostr\u00f3 un aumento significativo de la \nmortalidad en pacientes resistentes a los antimicrobianos: OR=1,93 (IC95% 1,35-2,73), p > |z| < 0,001. En dicho modelo, \nla edad y la comorbilidad tambi\u00e9n se asociaron con mayor riesgo de muerte (p > |z| < 0,001).\nCONCLUSIONES\nLas hospitalizaciones de pacientes con infecciones por bacterias resistentes a f\u00e1rmacos antimicrobianos se asociaron con \nmayor estancia y mortalidad hospitalaria. En consecuencia, programas de optimizaci\u00f3n y uso racional de antimicrobianos \n(PROA) son necesarios no s\u00f3lo durante la infecci\u00f3n sino para proteger la salud futura de los pacientes.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n641. POLIFARMACIA Y PATRONES DE POLIFARMACIA EN UNA COHORTE DE PACIENTES VIH \nAUTORES\nCASAS ARRATE, J; ANTON MENDEZ, X; DE BASAGOITI \u00b4GORORDO, A; GUIO CARRI\u00d3N, L; BLANCO VIDAL, MJ; DUQUE \nRODRIGUEZ, M; BARROSO CASTRO, J; LIGROS TORRES, M\nHOSPITAL DE CRUCES \ufffd PZA DE CRUCES, S/N \ufffd BARAKALDO \ufffd VIZCAYA\nOBJETIVOS\nEvaluar la prevalencia de Polifarmacia, tipo y patrones de Polifarmacia (PP) de los pacientes VIH+ con tratamiento \nantirretroviral (TAR) seguidos en consultas externas de la farmacia hospitalaria. Adicionalmente, analizar la adherencia o \nno adherencia al tratamiento concomitante (NAC).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional unic\u00e9ntrico transversal en el que se analiza la medicaci\u00f3n concomitante prescrita como \u201cactiva\u201d, \n\u201ccr\u00f3nica\u201d y con \u201cAdherencia > 0%\u201d en el programa de prescripci\u00f3n electr\u00f3nica de la historia cl\u00ednica de los pacientes en \nTAR a 03/01/2022\ufffd  \nSe clasifica a los pacientes con Polifarmacia si tienen prescritos 6 o m\u00e1s principios activos (ppaa) concomitantes TAR \nincluido y el tipo de polifarmacia: Polifarmacia (6-10), P . Mayor (\u226511) o P . extrema (\u226521). \nSe determina la presencia de PP si tienen \u22653 ppaa prescritos seg\u00fan enfermedad a tratar en patr\u00f3n: cardiovascular \n(CV), depresi\u00f3n-ansiedad, enfermedad pulmonar obstructiva cr\u00f3nica, teniendo en cuenta los 3 primeros niveles de la \nclasificaci\u00f3n ATC y patr\u00f3n mixto en caso de que se cumpla ese criterio en varios de los patrones.  \nLa adherencia se eval\u00faa con el registro de dispensaciones de los 8 meses previos en el programa de prescripci\u00f3n \nelectr\u00f3nica y se considera al paciente NAC si la adherencia promedio a su tratamiento concomitante es < 90%.\nRESULTADOS\nSe incluyen 947 pacientes (67% hombres) con mediana (IQR) de edad de 54 a\u00f1os (46-59), 65,5% de los cuales > 50 a\u00f1os. \nEl TAR es triple en 64,5% de los pacientes, doble en 34,4%, 0,7% monoterapia y 0,4% cu\u00e1druple.  \nEl 38,6% tiene polifarmacia: 25,9% de 6-10ppaa, 12,1% P . mayor y 0,8% (8) P . extrema. La mediana (IQR) de \nmedicamentos concomitantes es 1 (0-4) y el 49% toman \u2265 2 ppaa de forma concomitante. \nEn el 63,5% de pacientes que toman alg\u00fan medicamento adem\u00e1s del TAR se detecta NAC.  \nEl 28% del total de los pacientes tiene alg\u00fan ppaa perteneciente al grupo de Psicof\u00e1rmacos (N05-N06-N07), 22% para \ntratamiento de dislipemia (C10) y 20% para sistema CV y antihipertensivos (C01-C09), 13,8% Antiulcerosos y anti\u00e1cidos \n(A02), 8,7% enfermedades respiratorias cr\u00f3nicas (R03), 5,8% para la diabetes mellitus (A10).  \nUn 20,4% (193) de los pacientes cumple criterio de PP: 10,1% Cardiovascular; 6,2% depresi\u00f3n-ansiedad; 1,8% enfermedad \nPulmonar y 2,2% patr\u00f3n mixto. Del total de los pacientes con alg\u00fan patr\u00f3n, el 49,7% es CV, 30,6% depresi\u00f3n-ansiedad, \n8,8% enfermedad pulmonar y 10,9% patr\u00f3n mixto\ufffd\nCONCLUSIONES\nLa presencia de polifarmacia es elevada en la poblaci\u00f3n VIH+ atendida en nuestro hospital. El PP mas frecuente es el \ncardiovascular y depresi\u00f3n-ansiedad. Los resultados obtenidos son consistentes con otras publicaciones como el estudio \nPOINT (Feb-2017), a pesar de las limitaciones de la comparaci\u00f3n, teniendo una poblaci\u00f3n m\u00e1s envejecida (media 54 vs 49 412a\u00f1os) y considerando la edad como factor asociado a mayor polifarmacia. \nLa NAC es elevada, aunque su determinaci\u00f3n s\u00f3lo mediante los registros de dispensaci\u00f3n, as\u00ed como no conocer el grado \nde actualizaci\u00f3n de las prescripciones, supone una limitaci\u00f3n para la obtenci\u00f3n de conclusiones.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n674. ESTUDIO DE UTILIZACI\u00d3N DE SOTROVIMAB EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nITURBE HERAS, M; ROA RUIZ, N; LERALTA GONZALEZ, C; SANZ ALONSO, V; DELGADO GARCIA, J; DROZDZ VERGARA, \nA; PEREZ LAPIDO, M; SAINZ DE ROZAS APARICIO, C\nHOSPITAL SAN PEDRO. CTRA. DE PIQUERAS, 98 LOGRO\u00d1O. LA RIOJA\nOBJETIVOS\nSotrovimab es un anticuerpo monoclonal indicado en el tratamiento de la COVID19 en adultos y adolescentes que no \nrequieren ox\u00edgeno suplementario y que tienen un mayor riesgo de progresar a estadios m\u00e1s graves del COVID-19.  \nEl objetivo de este estudio es describir la utilizaci\u00f3n de sotrovimab en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo y observacional en un hospital de tercer nivel en pacientes que recibieron sotrovimab entre \ndiciembre 2021 y abril 2022\ufffd \nSe obtuvieron los pacientes a trav\u00e9s del programa inform\u00e1tico de validaci\u00f3n y se recogieron las siguientes variables de la \nhistoria cl\u00ednica electr\u00f3nica: variables demogr\u00e1ficas (edad y sexo), fechas de inicio de s\u00edntomas, de ingreso, de diagn\u00f3stico, \nde administraci\u00f3n del anticuerpo monoclonal y de alta, patolog\u00eda de base, situaci\u00f3n respecto a vacunaci\u00f3n COVID-19, \nresultado de serolog\u00eda SARS-CoV2 inmunoglobulinas totales, cumplimiento de criterios de priorizaci\u00f3n, tratamiento con \nremdesivir y tocilizumab, ingreso en unidad de medicina intensiva (UMI), fallecimiento y fecha y motivo del mismo.\nRESULTADOS\nSe incluyeron un total de 16 pacientes, 63% mujeres, cuya mediana de edad fue 68,5 a\u00f1os (RIC 56,3-75,0). Las patolog\u00edas \nde base de los pacientes que recibieron el tratamiento fueron: linfoma en 5 pacientes (31%), trasplante de \u00f3rgano s\u00f3lido \nen 4 pacientes (25%) c\u00e1ncer de mama en 2 pacientes (13%), artritis reumatoide en 2 pacientes (13%), insuficiencia renal y \nhemodi\u00e1lisis en 2 pacientes (13%) y mielitis transversa en un paciente (6%). \n10 de estos pacientes (63%) cumpl\u00eda con los criterios de priorizaci\u00f3n establecidos por el ministerio.  \nEl 94% presentaba serolog\u00eda negativa para SARS-CoV2 inmunoglobulinas totales.  \nTodos los pacientes estaban vacunados: 1 paciente (6%) con 4 dosis, 10 pacientes (63%) con 3 dosis y 5 pacientes (31%) \ncon 2 dosis\ufffd  \nDe los 16 pacientes, 11 (69%) recibieron tambi\u00e9n al menos un ciclo de tratamiento con remdesivir. Solamente 1 paciente \n(6%) recibi\u00f3 adem\u00e1s tratamiento con tocilizumab.  \nLa fecha de administraci\u00f3n del tratamiento con sotrovimab fue de una mediana de 5 d\u00edas (RIC 2,0-8,0) tras la fecha de \ninicio de s\u00edntomas, 2 d\u00edas (RIC 1,0-7,3) tras la fecha de diagn\u00f3stico de la infecci\u00f3n y 1,5 d\u00edas (RIC 1,0-10,0) tras el ingreso \nhospitalario. Los pacientes recibieron el alta hospitalaria 6 d\u00edas (RIC 3,0-17,8) despu\u00e9s de la administraci\u00f3n del anticuerpo \nmonoclonal\ufffd  \nRespecto a la evoluci\u00f3n de los pacientes, 2 pacientes (13%) ingresaron en UMI tras la administraci\u00f3n de sotrovimab y 4 \npacientes (25%) fallecieron, de modo que en 3 de ellos (75%) el desenlace pudo atribuirse a la infecci\u00f3n por COVID-19. \nEstas muertes sucedieron en el d\u00eda 29,5 (RIC 21,5-101,3) tras el tratamiento con sotrovimab.\nCONCLUSIONES\nEl tratamiento con sotrovimab se administr\u00f3 mayoritariamente a pacientes que cumpl\u00edan con los criterios de priorizaci\u00f3n \nestablecidos. La mayor\u00eda de pacientes que recibieron sotrovimab tambi\u00e9n recibieron remdesivir para el tratamiento de la \ninfecci\u00f3n por SARS-CoV2. Un 25% de los pacientes murieron pese a recibir el tratamiento.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n675. EFECTIVIDAD, SEGURIDAD Y ADHERENCIA DE LA PROFILAXIS PREEXPOSICI\u00d3N AL VIH \nAUTORES\nMONTOYA EGEA, JM; GARC\u00cdA LAGUNAR, MH; GARC\u00cdA MATILLAS, CN; FERN\u00c1NDEZ MART\u00cdNEZ, IM; MART\u00cdNEZ \nMARCOS, JM; MIRA SIRVENT , MC\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nAnalizar la efectividad, seguridad y adherencia de la profilaxis preexposici\u00f3n al VIH (PrEP) en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de todos aquellos pacientes a los que se les dispens\u00f3 desde el Servicio de Farmacia \nal menos una dosis de PrEP (emtricitabina/tenofovir disoproxilo) desde junio del 2020 a abril del 2022. Para analizar la \nefectividad del tratamiento se comprobaron los resultados de las serolog\u00edas posteriores de control de todos los pacientes \npara detectar si alg\u00fan paciente hab\u00eda contra\u00eddo la infecci\u00f3n.  \n \nPara analizar la seguridad se entrevistaron a todos los pacientes en las consultas de Atenci\u00f3n Farmac\u00e9utica a Pacientes \nExternos del Servicio de Farmacia para conocer si alguno hab\u00eda tenido una reacci\u00f3n adversa medicamentosa (RAM), 413adem\u00e1s, debido a que el tenofovir disoproxilo puede producir fallo e insuficiencia renal, se examinaron las anal\u00edticas de \ntodos los pacientes para detectar si se hab\u00edan producido cambios en la funci\u00f3n renal desde el comienzo del tratamiento.  \n \nPor \u00faltimo, para analizar la adherencia, se revisaron todas las dispensaciones realizadas con el programa inform\u00e1tico de \ngesti\u00f3n farmac\u00e9utica SAVAC\u00a9 y se calcul\u00f3 la raz\u00f3n de posesi\u00f3n de la medicaci\u00f3n (RPM: d\u00edas cubiertos con la medicaci\u00f3n \ndispensada/d\u00edas con la medicaci\u00f3n prescrita x 100). \n \nLas variables recogidas en el estudio fueron: sexo, edad, duraci\u00f3n del tratamiento, aclaramiento de creatinina (calculado \ncon la ecuaci\u00f3n CKD-EPI), n\u00famero de dosis dispensadas e infecciones de transmisi\u00f3n sexual (ITS) previas y posteriores al \ninicio de la PrEP \ufffd\nRESULTADOS\nEn el estudio se incluyeron 17 pacientes con una mediana de edad de 38 a\u00f1os (IQR: 29-42 a\u00f1os), de los que el 82% (n=14) \neran varones. A fecha de corte del estudio (mayo del 2022) la mediana de la duraci\u00f3n del tratamiento era de 3,91 meses \n(IQR: 1,64-8,61 meses).  \n \nLa efectividad del tratamiento fue del 100%, ya que en ning\u00fan paciente se obtuvo una serolog\u00eda positiva de VIH en los \ncontroles posteriores al inicio de la PrEP . Respecto a la seguridad, ning\u00fan paciente notific\u00f3 una RAM ni se apreciaron \ncambios en la funci\u00f3n renal. Un paciente abandon\u00f3 el tratamiento por decisi\u00f3n propia y cuatro pacientes dejaron de \nrecoger el tratamiento en nuestro hospital con la consiguiente p\u00e9rdida de seguimiento.  \n \nEl 88% de los pacientes ten\u00eda una ITS previa; pero s\u00f3lo en un paciente se diagnostic\u00f3 una ITS posterior al inicio de la PrEP . \nLa adherencia fue muy buena (RPM: 100%) en dos tercios de los pacientes, aceptable (RPM: 90%-100%) en el 14% y muy \nmala (RPM < 65%) en el 20% restante.\nCONCLUSIONES\nLa efectividad y seguridad de la PrEP en nuestros pacientes ha sido muy buena, aunque es cierto que la principal \nlimitaci\u00f3n del estudio es el corto tiempo de seguimiento; por lo que se necesitan realizar estudios posteriores que avalen \nestos resultados a m\u00e1s largo plazo.  \n \nLa adherencia del tratamiento es superior al 90% en la mayor\u00eda de pacientes, aunque se ha detectado un grupo de \npacientes que abandonaron la terapia o cuya adherencia no era la adecuada y que se podr\u00edan beneficiar de planes de \nacci\u00f3n personalizados enfocados a mejorar la adherencia.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n681. EVALUACI\u00d3N DE LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON ANAKINRA EN PACIENTES \nCON NEUMONIA SARS-COV 2 \nAUTORES\nL\u00d3PEZ S\u00c1NCHEZ, P; FERRER SOLER, FM; M\u00c1RQUEZ NIEVES, JJ\nHOSPITAL GENERAL DE TOMELLOSO \ufffd VEREDA DE SOCU\u00c9LLAMOS, S/N TOMELLOSO \ufffd CIUDAD REAL\nOBJETIVOS\nAnakinra es un antagonista del receptor de interleuquina-1 (IL-1) que bloquea la actividad biol\u00f3gica de la IL-1, la cual se \nencuentra aumentada ante est\u00edmulos inflamatorios, incluyendo la tormenta de citoquinas en pacientes con enfermedad \npor coronavirus 2019 (COVID19) .  \n \nEn el momento del estudio, el tratamiento de la COVID19 con Anakinra no est\u00e1 recogido en ficha t\u00e9cnica. Los objetivos \nson analizar los perfiles de efectividad y seguridad de Anakinra en pacientes ingresados con neumon\u00eda por SARS-CoV2 en \nesta indicaci\u00f3n\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de marzo 2020-diciembre 2021 en un hospital de tercer nivel. Aunque su pauta e \nindicaci\u00f3n ha ido variando, desde abril de 2020 se incluy\u00f3 en el protocolo COVID19 para pacientes con IL6 < 40 mcg/\nml, a dosis de 100 mg IV c/6h durante 7-10 d\u00edas, siempre en pacientes ingresados con claros indicios de tormenta de \ncitoquinas.  \n \nDatos recogidos: edad, sexo, d\u00edas de evoluci\u00f3n al ingreso, ingreso en UCI, vacunaci\u00f3n COVID-19, f\u00e1rmacos concomitantes \npara COVID19 (bolos de corticoides, remdesivir, doxiciclina con acetilciste\u00edna, plasma hiperinmune), desenlace (exitus), \ndatos anal\u00edticos basales al ingreso (ferritina, GOT, GPT, LDH, Prote\u00edna C reactiva, d\u00edmero D, plaquetas) y transaminasas \npost-tratamiento con Anakinra. \n \nPara evaluar la eficacia, se cuantificaron los fallecimientos y los ingresos UCI, analizando posibles correlaciones. Respecto \na seguridad, se evalu\u00f3 el aumento de transaminasas frente a los datos basales y la aparici\u00f3n de otras complicaciones \ndescritas con Anakinra, como reacciones al\u00e9rgicas. Los datos fueron analizados con SPSSv.10 realizando el an\u00e1lisis \ndescriptivo de los valores, y utilizando el estad\u00edstico Chi-cuadrado para variables categ\u00f3ricas.414RESULTADOS\nSe incluyeron 53 pacientes, 72% hombres y 28% mujeres con edad media 65 a\u00f1os (52-78), que recibieron Anakinra \ndurante una mediana de tiempo de 5 d\u00edas (1-15). La estancia mediana en el hospital fue de 12 d\u00edas (2-65).  \n \nDe los 53 pacientes, el 24% fueron ingresados en UCI y fallecieron el 30%. Se relacion\u00f3 estad\u00edsticamente que los pacientes \ncon m\u00e1s d\u00edas de s\u00edntomas COVID19 eran los que iban a UCI (p=0,007) y que los fallecimientos en aquellos que ingresaron \nen UCI fueron significativamente mayores (p=0.003).  \n \nNo se encontr\u00f3 asociaci\u00f3n significativa entre sexo, edad, vacunaci\u00f3n, n\u00famero de ola o uso concomitante de f\u00e1rmacos \npara COVID19 y el ingreso en UCI o exitus\ufffd  \n \nRespecto a seguridad, 35 pacientes presentaron una GOT/GPT > 40U/L tras recibir Anakinra frente a 29 basal, lo que \nsupuso un incremento del 12%, existiendo una correlaci\u00f3n entre alteraci\u00f3n hep\u00e1tica-edad (p=0,019), especialmente en el \ngrupo de 60-75 a\u00f1os. Un paciente suspendi\u00f3 el f\u00e1rmaco por empeoramiento hep\u00e1tico, y otro requiri\u00f3 ajuste de dosis. No \nse encontraron otras complicaciones relacionadas con Anakinra\ufffd\nCONCLUSIONES\nHemos observado una relaci\u00f3n entre el uso precoz y dirigido de Anakinra en pacientes COVID19 con mal pron\u00f3stico y la \nreducci\u00f3n de ingresos UCI, y su mortalidad asociada. Hubo una clara tendencia de asociaci\u00f3n edad-exitus, aunque no fue \nestad\u00edsticamente significativa, probablemente porque la muestra es peque\u00f1a. En general el f\u00e1rmaco es bien tolerado, \naunque observamos mayor deterioro de la funci\u00f3n hep\u00e1tica en pacientes mayores de 60 a\u00f1os.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n699. EFECTIVIDAD DE DOLUTEGRAVIR/LAMIVUDINA FRENTE A DOLUTEGRAVIR/ ABACAVIR/ \nLAMIVUDINA EN UNA COHORTE REAL DE PACIENTES NAIVE CON VIH-1. \nAUTORES\nMENDOZA ACOSTA, I; L\u00c1ZARO L\u00d3PEZ, A; CORRALES KROHNERT , S; HORTA HERN\u00c1NDEZ, AM; TORRALBA GONZ\u00c1LEZ \nDE SUSO, M\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nDolutegravir/lamivudina (2-DR) ha sido la primera terapia antirretroviral dual incluida como est\u00e1ndar de tratamiento para \npacientes na\u00efve. Aunque su eficacia y seguridad frente a triple terapia (3-DR) ha sido demostrada (estudio GEMINI), los \ndatos de vida real son escasos\ufffd  \nEl objetivo de este estudio es analizar la efectividad, seguridad y durabilidad de 2-DR frente a 3-DR con dolutegravir/\nabacavir/lamivudina en una cohorte real de pacientes na\u00efve con VIH-1.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional ambispectivo en pacientes con VIH-1 na\u00efve tratados con 2-DR o 3-DR en un \u00e1rea de salud desde \njulio de 2018 hasta enero de 2022. El estudio fue aprobado por el comit\u00e9 de \u00e9tica e investigaci\u00f3n del hospital y registrado \nen la Agencia Espa\u00f1ola del Medicamento\ufffd  \nSe midi\u00f3 la efectividad a las 24, 48, 72 y 96 semanas mediante el porcentaje de pacientes con carga viral (CV) < 50 y 200 \ncopias/ml con un dise\u00f1o de no inferioridad. Se estableci\u00f3 un valor delta del 12% (m\u00e1xima diferencia aceptable como \ncriterio cl\u00ednico de no inferioridad). Se calcul\u00f3 la incidencia de efectos adversos (EA) y la durabilidad del tratamiento \nmediante regresi\u00f3n de Cox. El an\u00e1lisis se realiz\u00f3 mediante Stata 15.0.\nRESULTADOS\nSe incluyeron 67 pacientes de los cuales el 40,3% estaban en tratamiento con 2-DR. La mediana de edad fue de 35 (28-50) \na\u00f1os en 2-DR y 43 (34-52) a\u00f1os en 3-DR (p=0,36). El porcentaje de varones fue 74% y 78% respectivamente (p=0,31). La \nmediana de logCV basal fue 4,5 (4,1-5) y 4,8 (4,3-5,4) (p=0,09).  \nEn la semana 24, el porcentaje de pacientes con CV < 50 copias/ml del grupo con DT fue del 70,8% frente al 70% en el \ngrupo con TT (diferencia: 0,8% [IC95% -23,7% a 25,3%]). El porcentaje de pacientes con CV < 200 copias/ml fue de 91,7% \nen el grupo de DT y 86,7% en el de TT (diferencia: 5% [IC95% -11,4% a 21,4%]). En la semana 48, el 66,6% de pacientes \ncon DT presentaron CV < 50 copias/ml frente al 81,2% con TT (diferencia: -15% [IC95% -46% a 16%]).  \nEl 100% de pacientes con DT presentaban CV < 50 copias/ml en la semana 72, frente al 75% del grupo TT (diferencia: \n25% [IC95% 0,05% a 49,5%]). En la semana 96, el 100% de pacientes con DT presentaban CV < 50 copias/ml frente al 91% \nde TT (diferencia: 9,1% [IC95% -7,9% a 26,1%]). Solo un paciente con 2-DR presento fracaso virol\u00f3gico relacionado con \nfalta de adherencia. El 18,5% de pacientes con 2-DR presento alg\u00fan EA frente al 23% de 3-DR, p=0,65. El porcentaje de \npacientes que suspendieron el tratamiento por un motivo distinto de simplificaci\u00f3n fue de 15% en DT frente a 40% en TT \n(p=0,027). No se observan diferencias significativas en la durabilidad del tratamiento entre ambos grupos (HR:0,37 [IC95% \n0,1 a 1,7; p=0,15]).\nCONCLUSIONES\nSe observa la no inferioridad en pacientes na\u00efve a las 24 semanas (para una CV < 200 copias/ml), y a las 72 y 96 semanas \n(para una CV < 50 copias/ml). DT muestra un menor porcentaje de EA aunque sin diferencias significativas. Se observa \nmayor riesgo de suspensi\u00f3n de tratamiento en el grupo de TT y durabilidad similar en ambos tratamientos\ufffd415CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n719. PERFIL DE USUARIOS DE LA PROFILAXIS PREEXPOSICI\u00d3N AL VIH EN UNA CONSULTA MONOGR\u00c1FICA \nAUTORES\nFERN\u00c1NDEZ PI\u00d1EIRO, N; GONZ\u00c1LEZ P\u00c9REZ, C; PE\u00d1A PEDROSA, JA; YBA\u00d1EZ GARC\u00cdA, L; RODR\u00cdGUEZ CABEZAS, M\u00c1; \nDEL ROMERO GUERRERO, J; MART\u00cdNEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nDescribir el perfil de usuarios atendidos en una consulta monogr\u00e1fica de atenci\u00f3n farmac\u00e9utica (AF) a usuarios de \nProfilaxis preexposici\u00f3n al VIH (PrEP) durante los dos primeros a\u00f1os desde su implantaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo, de usuarios del programa PrEP que recibieron AF desde el 20 de enero \nde 2020 hasta el 19 de enero de 2022.  \nSe incluyeron personas VIH negativas que cumplieran los criterios del Ministerio de Sanidad para la indicaci\u00f3n de la PrEP \ne incluidos en el registro informatizado de usuarios de PrEP . Se excluyeron los usuarios con serolog\u00eda positiva del VIH, \ninfecci\u00f3n aguda por virus de hepatitis B, tasa de filtrado glomerular inferior a 60 ml/min u otras contraindicaciones para \nla toma de Tenofovir disoproxil/Emtricitabina\ufffd  \nVariables: Edad, sexo, origen, porcentaje de uso del preservativo, n\u00famero parejas sexuales al mes, Infecciones de \nTransmisi\u00f3n Sexual (ITS), uso de drogas recreativas, tratamientos concomitantes, fitoterapia y suplementaci\u00f3n deportiva.\nRESULTADOS\nSe incluyeron 2256 usuarios, mediana de edad 35 a\u00f1os, rango 18-74. Seg\u00fan las regiones de origen, el 61,39% proced\u00edan \nde Espa\u00f1a, el 28,68% de Latinoam\u00e9rica, el 5,81% de Europa occidental, el 1,20% de Europa oriental y el 2,92% de otras \nregiones\ufffd  \nCumpl\u00edan los siguientes criterios principales de indicaci\u00f3n: 3 (0,13%) mujeres que ejerc\u00edan prostituci\u00f3n con bajo uso del \npreservativo, 2231 (98,89%) hombres que tienen sexo con hombres (HSH), 19 (0,84%) transexuales, 2 (0,09%) usuario \nde drogas inyectadas y 1 (0,04%) mujer cisexual, que refirieron un uso no habitual del preservativo. Los \u00faltimos cuatro \ngrupos deb\u00edan cumplir tambi\u00e9n con al menos dos de los siguientes criterios secundarios en el \u00faltimo a\u00f1o: m\u00e1s de 10 \nparejas sexuales diferentes: 2208 (98,87%); pr\u00e1ctica de sexo anal/vaginal sin preservativo: 2189 (97,03%); uso de drogas \nrelacionado con el mantenimiento de relaciones sexuales sin preservativo: 1475 (65,38%); al menos una ITS bacteriana: \n1064 (47,16%) y administraci\u00f3n de profilaxis postexposici\u00f3n en varias ocasiones: 240 (9,93%).  \nEn cuanto al uso del preservativo, el 26,06% afirm\u00f3 usarlo en menos del 25% de ocasiones, el 12,85% entre un 25 y 49%, \nel 35,77% lo us\u00f3 entre el 50 y 75% de ocasiones y el 25,04% lo us\u00f3 en m\u00e1s del 75% de relaciones. El n\u00famero de parejas \nsexuales al mes por cada usuario fue: menor de 5 en el 41,04% de usuarios, entre 6 y 10 en el 27,79%, entre 11 y 20 para \nel 19,64% y mayor de 20 en el 11,17% de usuarios\ufffd  \nEl 50,84% de usuarios usaba alg\u00fan tratamiento concomitante, el 43,53% alguna suplementaci\u00f3n deportiva, el 19,10% \nfitoterapia y el 68,22% consumi\u00f3 drogas en los meses previos a la visita basal. El 33.95% fue diagnosticado de alguna ITS \nen el cribado inicial\ufffd\nCONCLUSIONES\nEl perfil mayoritario del usuario de PrEP es un HSH de 35 a\u00f1os, de origen espa\u00f1ol, que cumple criterios por elevado \nn\u00famero de parejas sexuales al a\u00f1o, bajo uso del preservativo y uso de drogas asociado al sexo.  \nLa indicaci\u00f3n de la PrEP a usuarios de drogas y personas cisexuales se incluy\u00f3 con posterioridad (en diciembre de 2021). \nHabr\u00e1 que hacer an\u00e1lisis posteriores para determinar su impacto real.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n722. BEZLOTOXUMAB EN PREVENCI\u00d3N DE RECURRENCIAS DE INFECCI\u00d3N POR CLOSTRIDIOIDES \nDIFFICILE \nAUTORES\nPATIER RUIZ, I; ALONSO ZAZO, FJ; MOLINA GARCIA, T\nHOSPITAL UNIVERSITARIO DE GETAFE \ufffd CRTRA DE TOLEDO, KM \ufffd 12,5 GETAFE \ufffd MADRID\nOBJETIVOS\nAnalizar la utilizaci\u00f3n de bezlotoxumab en nuestro centro y evaluar la efectividad en la prevenci\u00f3n de recurrencias en \npacientes con infecci\u00f3n por Clostridioides difficile (CID).\nMATERIALES Y M\u00c9TODOS\nSe trata de un estudio observacional y retrospectivo, llevado a cabo entre noviembre/2019 y febrero/2022. Se incluyeron \npacientes con diagn\u00f3stico de CID en tratamiento con bezlotoxumab.  \nSe registraron una serie de variables: demogr\u00e1ficas (sexo, edad); factores de riesgo para el desarrollo de CID (tratamiento \ncon antibioterapia, inhibidores de la bomba de protones (IBP), pacientes institucionalizados); factores de riesgo \nde recurrencia (inmunosupresi\u00f3n, edad > 65 a\u00f1os, antibioterapia concomitante, episodio en 6 meses previos de \nCID, tratamiento quimioter\u00e1pico activo, ausencia de mejor\u00eda cl\u00ednica tras 5 d\u00edas de tratamiento y presencia de cepas \nhipervirulentas); los principales criterios de gravedad (leucocitosis > 15*109/mL, creatinina s\u00e9rica > 1.5 mg/dl o incremento \ndel 50% con respecto a la basal, alb\u00famina < 3mg/dl y colitis pseudomembranosa o engrosamiento de la pared col\u00f3nica) y \nla escala Zar (Edad > 60 a\u00f1os, fiebre > 38.5\u00baC, alb\u00famina < 2.5 mg/dl, leucocitos > 15*109/mL, colitis pseudomembranosa 416en colonoscopia, estancia en UCI). As\u00ed mismo, se registraron los tratamientos previos para CID recibidos y tipo de episodio \nde CID. Para evaluar la eficacia, se realiz\u00f3 un seguimiento de recurrencia de CID a la semana 8 y 12.\nRESULTADOS\nFueron incluidos 32 pacientes en el estudio, con una mediana en edad (a\u00f1os) de 78.3 (70.7-84.9); siendo el 62% varones. \nComo antecedentes para el desarrollo de CID, el 100% hab\u00eda recibido antibioterapia en los 3 meses previos, siendo \nlos betalact\u00e1micos el grupo mayoritario (81%). El 97% recib\u00edan tratamiento concomitante con IBP y el 28% estaba \ninstitucionalizado.  \nEl 100% de las CID presentaban alg\u00fan criterio de recurrencia, el 38% ten\u00edan 2 o m\u00e1s criterios de gravedad y el 28% \npuntuaba 2 o m\u00e1s en la escala Zar. Se detectaron un 22% de cepas hipervirulentas, siendo en su totalidad del tipo \nbinaria. Bezlotoxumab se utiliz\u00f3 en el 65% de casos de 1er episodio de CID, el 22% en 1\u00aa recurrencia y 13% en 2\u00aa o mayor \nrecurrencia. Vancomicina se utiliz\u00f3 concomitantemente en el 66% de los casos mientras que fidaxomicina en el 34% \nrestante\ufffd \nCon respecto a la eficacia, solo se pudo realizar seguimiento completo a 12 semanas a 22 pacientes (68.7%), 9 fallecieron \ny 1 no fue realizable por cambio de domicilio. \u00danicamente hubo una recurrencia (1/22; 4.5%) y fue antes de la semana 8.\nCONCLUSIONES\nEn nuestra experiencia, bezlotoxumab disminuye marcadamente la aparici\u00f3n de recurrencias en CID cuando su utilizaci\u00f3n \nse realiza en pacientes con criterios de recurrencia y principalmente en el primer episodio de CID.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n730. REMDESIDIVIR EN PACIENTES CON NEUMON\u00cdA POR COVID-19: UTILIZACI\u00d3N Y AN\u00c1LISIS DE \nFACTORES PREDICTORES DE RECUPERACI\u00d3N \nAUTORES\nRUIZ DE HOYOS, M; LARRUBIA MARFIL, Y; PORTILLO HORCAJADA, L; GARCIA DE SANTIAGO, B; L\u00d3PEZ ASPIROZ, E; \nGARCIA YUBERO, C; LLORENTE GUTIERREZ, J; MARTINEZ HERN\u00c1NDEZ, A\nHOSPITAL INFANTA SOF\u00cdA \ufffd PASEO DE EUROPA, 34 SAN SEBASTI\u00c1N DE LOS REYES \ufffd MADRID\nOBJETIVOS\nDescribir la utilizaci\u00f3n y efectividad del tratamiento con remdesivir en una cohorte de pacientes diagnosticados de \nneumon\u00eda por SARS-CoV-2. Adem\u00e1s, se pretende conocer factores asociados a una mayor recuperaci\u00f3n en pacientes que \nhan recibido remdesivir.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo en adultos, no vacunados, hospitalizados con neumon\u00eda confirmada por SARS-\nCoV-2 y que recibieron remdesvir durante el ingreso. Se incluyeron todos los pacientes que hab\u00edan recibido la primera \ndosis de remdesivir dentro de un periodo de estudio de 4 meses en un hospital universitario de nivel 2. Se recogieron \ndatos relativos a: caracter\u00edsticas demogr\u00e1ficas y cl\u00ednicas; tratamientos previos; criterios de utilizaci\u00f3n de remdesivir, \nreacciones adversas, complicaciones y evoluci\u00f3n de la enfermedad (recuperaci\u00f3n, ingreso UCI, exitus) como medida de \nefectividad del tratamiento durante un periodo de seguimiento de 28 d\u00edas. La recuperaci\u00f3n se defini\u00f3 como el primer d\u00eda \nen el que el paciente se inclu\u00eda en categor\u00edas 1 (no hospitalizado) o 2 (hospitalizado sin ox\u00edgeno suplementario) de una \nescala 6 puntos. Se analiz\u00f3 la asociaci\u00f3n la probabilidad de recuperaci\u00f3n y las variables analizadas mediante modelos \nlineales generalizados. Se construyeron modelos multivariantes mediante regresiones binomiales log\u00edsticas para analizar \nfactores predictores de la probabilidad de recuperaci\u00f3n\ufffd\nRESULTADOS\n104 pacientes (54,8% mujeres), con una edad media 61,8\u00b11,7 a\u00f1os recibieron remdesivir durante el periodo de \nestudio. La mayor\u00eda eran de raza blanca (97%) y origen espa\u00f1ol (67,3%). Un 71,2% presentaban comorbilidad, siendo \nlas patolog\u00edas m\u00e1s frecuentes la hipertensi\u00f3n (44,2%), dislipemia (31,7%) y diabetes mellitus (19,2%). Un 43,2% estaba \nen tratamiento previo con f\u00e1rmacos biol\u00f3gicos, un 26,9% con IECAs/ARA-2 y un 2,9% con inmunosupresores. Los \ntratamientos concomitantes para la COVID-19 m\u00e1s frecuentes fueron los corticoides (96,1%) y el tocilizumab (38,5%). \nEn un 54,8% fue necesario tratamiento antibi\u00f3tico por coinfecci\u00f3n bacteriana. Se inici\u00f3 remdesivir despu\u00e9s de 6,3\u00b10,3 \nd\u00edas desde inicio de s\u00edntomas y transcurrido un tiempo medio de hospitalizaci\u00f3n de 1,8\u00b10,2 d\u00edas. En 21 casos se \nsuspendi\u00f3 el remdesivir antes del d\u00eda 5 de tratamiento, principalmente debido a ingreso en UCI (36,8%) o a mejor\u00eda y alta \nhospitalaria (31,6%). S\u00f3lo en 5 pacientes se suspendi\u00f3 por reacci\u00f3n adversa al tratamiento (alteraciones hep\u00e1ticas). Se \nprodujo recuperaci\u00f3n en un 83,2% de los casos, ingreso en UCI en 12,6% y exitus en 13,6%. Observamos una asociaci\u00f3n \nestad\u00edsticamente significativa (p < 0,05) entre la probabilidad de recuperaci\u00f3n y las variables: edad, comorbilidades \n(especialmente hipertensi\u00f3n arterial), coinfecci\u00f3n bacteriana e incremento en el recuento linfocitario. El mejor \nmodelo predictor de la probabilidad de recuperaci\u00f3n incluy\u00f3 \u00fanicamente las variables edad y coinfecci\u00f3n bacteriana, \ncontribuyendo ambas significativamente al modelo (p < 9.46x10-3). El valor de R2 de McFadden fue de 0,23. Se observ\u00f3 \nuna mayor probabilidad de ingreso en UCI en pacientes con coinfecci\u00f3n bacteriana (p < 1x10-5) y en aquellos que recib\u00edan \nf\u00e1rmacos biol\u00f3gicos como tratamiento previo (p=1x10-4).\nCONCLUSIONES\nLa mayor\u00eda de los pacientes tratados con remdesivir se recuperaron y mostraron buena tolerancia al tratamiento. Los \nsiguientes factores se asociaron de forma significativa a una mayor probabilidad de recuperaci\u00f3n en estos pacientes: \nmenor edad, ausencia de hipertensi\u00f3n, incremento en recuento linfocitario y ausencia de coinfecci\u00f3n bacteriana.417CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n741. OPTIMIZACI\u00d3N DEL USO DE ANTIMICROBIANOS EN LA UNIDAD DE MEDICINA INTENSIVA: \nCUESTI\u00d3N DE EQUIPO. \nAUTORES\nSAINZ DE ROZAS APARICIO, C; SANZ FRANCO, M; SORIA BLANCO, LM; MAC\u00cdAS PASCUAL, M; GALLARDO ANCIANO, J; \nROA RUIZ, N; DELGADO GARC\u00cdA, J; P\u00c9REZ LAPIDO, M\nHOSPITAL SAN PEDRO. CTRA. DE PIQUERAS, 98 LOGRO\u00d1O. LA RIOJA\nOBJETIVOS\nPor su estado de extrema gravedad, los pacientes ingresados en unidades de cr\u00edticos precisan tratamientos que \naseguren el control de la infecci\u00f3n desde su inicio. A su vez es necesario un exhaustivo control de los microorganismos \nmultiresistentes, que complican exponencialmente el manejo de estos pacientes. \nCon el objetivo de optimizar el uso de los antimicrobianos en la Unidad de Medicina Intensiva (UMI) se form\u00f3 un grupo \nde trabajo compuesto por integrantes del equipoPROA y m\u00e9dicos intensivistas, que analiz\u00f3 el estado de situaci\u00f3n del \nconsumo de antibi\u00f3ticos y el perfil de resistencias de la Unidad. En este trabajo se describen las actuaciones realizadas \npara ello\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo pre-post intervenci\u00f3n, en el que se analizaron los datos de consumo de antimicrobianos pre y post \nintervenci\u00f3n, la sensibilidad de partida de los microorganismos implicados, las alternativas de tratamiento antibi\u00f3tico en \npacientes cr\u00edticos y las estancias.  \nSe seleccionaron las entidades nosol\u00f3gicas prioritarias, seleccionando los antimicrobianos m\u00e1s eficaces y que ejercieran \nmenor presi\u00f3n en el desarrollo de las resistencias\ufffd  \nEl estudio se realiz\u00f3 en la Unidad de Medicina Intensiva del hospital, entre enero y diciembre de 2021.  \nLos datos se trataron con Microsoft Excel.\nRESULTADOS\n-Media de estancias en 2021: 815 (SD 273) \n-Entidades nosol\u00f3gicas seleccionadas para analizar: Neumon\u00eda y Candidemia/Candidiasis invasiva. \n-Intervenci\u00f3n: se elaboraron 2 protocolos:  \n\u2022 Tratamiento de la Neumon\u00eda intrahospitalaria/Neumon\u00eda asociada a ventilaci\u00f3n mec\u00e1nica, en el que se priorizaba \nVancomicina frente a Linezolid, y establec\u00edan alternativas terap\u00e9utica prioritaria para reducir el uso de carbapenems. \n \n\u2022 Tratamiento de la candidemia y candidiasis invasiva en pacientes no-neutrop\u00e9nicos en UMI, en el que se establecieron \nlas condiciones de uso correcto de las equinocandinas, evitando tratar a pacientes colonizados en el tracto respiratorio.  \n-Media de DDD/100 estancias y d\u00eda antes y despu\u00e9s de la intervenci\u00f3n:  \n\u2022 Linezolid antes: 16.9 (SD 5.3), despu\u00e9s: 8.5 (SD 2.9)  \n\u2022 Vancomicina antes: 24.8 (SD 10.5), despu\u00e9s: 18.1 (SD 5.2)  \n \n\u2022 Meropenem antes: 26.5 (SD 4.1), despu\u00e9s: 18.4 (SD 4.1)  \n\u2022 Cefepime antes: 4.9 (SD 2.8), despu\u00e9s: 9.2 (SD 6.7)  \n \n\u2022 Caspofungina: antes: 18.8 (SD 3.5), despu\u00e9s: 8.8 (SD 2.4)\nCONCLUSIONES\n- La elaboraci\u00f3n de protocolos de tratamiento consensuados parece haber sido una medida eficaz para mejorar la \nutilizaci\u00f3n de los antibi\u00f3ticos en la UMI.  \n- El trabajo conjunto del equipo PROA con los especialistas de la Unidad cl\u00ednica implicada en las acciones de mejora es \nesencial para traducir las decisiones te\u00f3ricas en pr\u00e1ctica real.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n751. INFLUENCIA DE LA INFECCI\u00d3N POR SARS-COV2 EN EL USO DE CEFTAZIDIMA-AVIBACTAM EN EL \nPACIENTE CR\u00cdTICO \nAUTORES\nMAYO OLVEIRA, F; CARO TELLER, JM; ORTIZ P\u00c9REZ, S; JIM\u00c9NEZ LE\u00d3N, C; GONZ\u00c1LEZ G\u00d3MEZ, \u00c1; FERRARI PIQUERO, \nJM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID\nOBJETIVOS\n\u2022 Establecer si existe un patr\u00f3n de uso diferente de ceftazidima-avibactam en pacientes cr\u00edticos con infecci\u00f3n por SARS-\nCoV2 frente a los pacientes no infectados\ufffd  \n\u2022 Determinar la mortalidad de los pacientes a los 28 d\u00edas del inicio del antimicrobiano.  \n\u2022 Describir los microorganismos m\u00e1s frecuentemente aislados en pacientes cr\u00edticos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, unic\u00e9ntrico y de cohortes. Se incluyeron 89 pacientes que estuvieron ingresados en las unidades \nde Medicina Intensiva y que recibieron tratamiento con ceftazidima-avibactam en el periodo comprendido entre marzo 418de 2020 y septiembre de 2021. A trav\u00e9s de la Historia Cl\u00ednica Electr\u00f3nica integrada con la prescripci\u00f3n electr\u00f3nica asistida, \nse recogieron variables demogr\u00e1ficas (edad, sexo), microbiol\u00f3gicas (colonizaci\u00f3n, aislamientos), farmacol\u00f3gicas (duraci\u00f3n \nde tratamiento, antimicrobianos empleados en sinergia) y cl\u00ednicas (mortalidad, tiempo de estancia hospitalaria).\nRESULTADOS\nSe incluyeron 89 pacientes, de los cuales el 85,39% fueron hombres, con una media de edad de 53,31 \u00b1 17,04 a\u00f1os. \nDe ellos, el 55% (n=49) present\u00f3 infecci\u00f3n por Sars-CoV2. La mediana de tiempo que permanecieron ingresados en \nel hospital fue de 45 d\u00edas (Rango=261) y la mediana de estancia en UCI fue de 40 d\u00edas (Rango=265). La mediana de \npermanencia en UCI fue de 46 d\u00edas (Rango=130) en infectados por SARS CoV2 y de 34 d\u00edas (Rango=265) en pacientes sin \nesta infecci\u00f3n. Los pacientes estuvieron en tratamiento con ceftazidima-avibactam durante una mediana de tiempo de 8 \nd\u00edas (Rango=38); fue de 7 d\u00edas (Rango=26) en pacientes COVID y de 11 d\u00edas (Rango=38) en pacientes no COVID. El 41,57% \n(n=37) comenzaron el tratamiento de forma emp\u00edrica. La proporci\u00f3n de inicios emp\u00edricos en pacientes COVID fue del 0,43 \ny en pacientes no COVID, del 0,4, no habiendo diferencias estad\u00edsticamente significativas entre el inicio de forma emp\u00edrica \nseg\u00fan el estado de diagn\u00f3stico de COVID19 (p=0,7856). \n \nAl 52,8% (n=47) se les prescribi\u00f3 aztreonam conjuntamente por su efecto sin\u00e9rgico. De estos, \u00fanicamente el 36,2% hab\u00eda \ncomenzado tratamiento emp\u00edrico con ceftazidima-avibactam.  \n \nEl 43,8% (n=39) estaban colonizados por alguna bacteria multirresistente (BMR): el 50% (n=20) de los pacientes \nsin diagn\u00f3stico COVID-19 y el 38% (n=19) de los pacientes con COVID-19, pero no se encontraron diferencias \nestad\u00edsticamente significativas entre el nivel de colonizaci\u00f3n de ambos grupos (p=0,1446). De los microorganismos \naislados, el m\u00e1s frecuente fue K. pneumoniae (59,4%), del cual el 68% era productor de carbapenemasas. La segunda \nbacteria m\u00e1s frecuente fue P . aeruginosa (17%). Tambi\u00e9n se aislaron E. cloacae (6,25%) E. faecalis (4,7%), E. coli (3,13%), \nE. faecium (3,13%) o A. baumannii (1,54%).  \n \nDel total de pacientes, el 41,57% (n=37) falleci\u00f3. De ellos, un 56,76% (n=21) ten\u00eda infecci\u00f3n por SARS-CoV2. El 81% [69-93] \nde los mismos falleci\u00f3 en un periodo inferior a 28 d\u00edas de haber iniciado ceftazidima-avibactam. De ellos, el 56,8% [40,8-\n72,8] estaba infectado por SARS-CoV2.\nCONCLUSIONES\nDe acuerdo con nuestra experiencia, la infecci\u00f3n por SARS CoV2 no influy\u00f3 en el patr\u00f3n de uso de ceftazidima-avibactam. \nLa mortalidad de los pacientes tratados con este f\u00e1rmaco fue del 41,57%. \nEl microorganismo m\u00e1s frecuentemente aislado fue K. pneumoniae.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n753. EVALUACI\u00d3N DE LA EFECTIVIDAD SEGURIDAD Y ADHERENCIA DE LA PROFILAXIS PREEXPOSICION \nAL VIH-1 \nAUTORES\nRUIZ MOLINA, F; MAR\u00cdN VENTURA, L; TOLOSA MART\u00cdNEZ, C; HERN\u00c1NDEZ L\u00d3PEZ, A; P\u00c9REZ ROBRES, Y; GARC\u00cdA-\nL\u00d3PEZ , L; COLOMA PERAL, R; RICO GUTI\u00c9RREZ, T\nHOSPITAL GENERAL DE SEGOVIA \ufffd CTRA \ufffd DE AVILA, S/N SEGOVIA \ufffd SEGOVIA\nOBJETIVOS\nEvaluar la efectividad y seguridad del tratamiento con emtricitabina/tenofovir disoproxil para la profilaxis preexposici\u00f3n \n(PrEP) al VIH-1, as\u00ed como la adherencia terap\u00e9utica de los pacientes, en un hospital general de segundo nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo donde se incluyeron todos los pacientes que iniciaron tratamiento con emtricitabina/\ntenofovir disoproxil para la PrEP al VIH-1 desde noviembre de 2021 hasta abril de 2022. Los datos se obtuvieron a partir \ndel m\u00f3dulo inform\u00e1tico de gesti\u00f3n de pacientes externos y de la historia cl\u00ednica informatizada.  \n \nLas variables recogidas fueron: sexo, edad, criterios de inicio, duraci\u00f3n del tratamiento, interacciones e infecciones de \ntransmisi\u00f3n sexual (ITS) durante el tratamiento. La efectividad se evalu\u00f3 mediante los resultados de las serolog\u00edas VIH-1 \nde control. La seguridad se evalu\u00f3 a por las reacciones adversas detectadas y la evoluci\u00f3n de la funci\u00f3n renal seg\u00fan la \nf\u00f3rmula Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). La adherencia se calcul\u00f3 a partir del cuestionario \nSMAQ y la tasa de posesi\u00f3n de medicaci\u00f3n, considerando que el paciente es adherente si es superior al 95%. Los \npacientes fueron evaluados cada tres meses\ufffd\nRESULTADOS\nSe incluyeron 12 pacientes, todos ellos varones, con una media de edad de 35,9 \u00b1 7,8 a\u00f1os. Todos los pacientes cumpl\u00edan \nlos siguiente criterios de inclusi\u00f3n: hombres que mantienen sexo con hombres, m\u00e1s de 10 parejas diferentes en el \u00faltimo \na\u00f1o y padecer ITS en el \u00faltimo a\u00f1o siendo las m\u00e1s comunes por Treponema pallidum y Ureaplasma urealyticum/parvum. \nLa duraci\u00f3n media de tratamiento fue de 6,4 \u00b1 1,1 meses. Ning\u00fan paciente present\u00f3 interacciones. El 2/12 (16,7%) de los \npacientes contrajeron una ITS posterior al inicio del tratamiento.  \nEn cuanto a la efectividad, la totalidad de los pacientes se mantuvieron con serolog\u00edas negativas para el VIH-1 durante el \ntratamiento\ufffd  \nRespecto a la seguridad, un paciente present\u00f3 reacciones adversas a nivel cut\u00e1neo que supuso la interrupci\u00f3n del \ntratamiento. Ning\u00fan paciente present\u00f3 alteraciones de la funci\u00f3n renal.  419Seg\u00fan el cuestionario SMAQ, el 33,3% de pacientes se consideraron adherentes. Seg\u00fan la tasa de posesi\u00f3n de \nmedicaci\u00f3n, el 83,3% de pacientes eran adherentes.\nCONCLUSIONES\nEmtricitabina/tenofovir disoproxilo es un f\u00e1rmaco efectivo y seguro para la PrEP al VIH-1 en nuestros pacientes. La \nadherencia en nuestro centro seg\u00fan la tasa de posesi\u00f3n de medicaci\u00f3n ha sido elevada, destacando la discrepancia con \nlos resultados obtenidos en el cuestionario SMAQ. Se considera necesaria la elaboraci\u00f3n de un cuestionario espec\u00edfico \npara valorar la adherencia de la PrEp. Se deber\u00eda insistir en la recomendaci\u00f3n del uso de preservativo en nuestra \npoblaci\u00f3n para prevenir otras ITS\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n761. EVALUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE SULFAMETOXAZOL-TRIMETOPRIMA Y OPTIMIZACI\u00d3N \nPOSOL\u00d3GICA EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nINCLAN CONDE, M; DOMINGUEZ MENENDEZ, JA; VILA GALLEGO, C; BELIO AG\u00dcERA, B; FERRERO BENEITEZ, OL; \nVIDAL GARCIA, M; AZKORRA KAMIRUAGA, A; AGUIRREZABAL ARREDONDO, AV\nHOSPITAL DE BASURTO \ufffd AV\ufffd MONTEVIDEO, 18 BILBAO \ufffd VIZCAYA\nOBJETIVOS\n- Revisar las prescripciones de sulfametoxazol-trimetoprima (STX-TMP) y su adecuaci\u00f3n posol\u00f3gica.  \n- Cuantificar y analizar las intervenciones realizadas y evaluar el grado de aceptaci\u00f3n de las mismas.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo descriptivo desde septiembre de 2021 a enero de 2022 (5 meses de duraci\u00f3n). Se consider\u00f3 la \nnecesidad de la revisi\u00f3n exhaustiva de los tratamientos con STX-TMP , tras la detecci\u00f3n en varias ocasiones de pautas \nincorrectas (debido a confusi\u00f3n de dosis referenciadas y/o no adecuaci\u00f3n de dosis a microorganismo o gravedad de la \ninfecci\u00f3n).  \nDe forma diaria se analizaron los nuevos tratamientos con dicho antibi\u00f3tico, a trav\u00e9s del programa de prescripci\u00f3n \nelectr\u00f3nica e historia cl\u00ednica, recogiendo las variables del paciente, indicaci\u00f3n de tratamiento y microorganismo \nresponsable de la infecci\u00f3n, en el caso de confirmaci\u00f3n microbiol\u00f3gica. Posteriormente se evalu\u00f3 la adecuaci\u00f3n de dosis e \nintervalo terap\u00e9utico, siguiendo las recomendaciones de tratamiento de Ficha t\u00e9cnica, UpToDate\u00ae, Micromedex\u00ae, y Gu\u00edas \nde terap\u00e9utica antimicrobiana Mensa J. 2021 y Sanford 2021.  \nEn el caso de discrepancia entre indicaci\u00f3n y posolog\u00eda pautada y recomendada, se notific\u00f3 al facultativo responsable \nla recomendaci\u00f3n por v\u00eda telef\u00f3nica, adem\u00e1s de al equipo del programa de optimizaci\u00f3n de antimicrobianos (PROA) del \ncentro. Por \u00faltimo, se registr\u00f3 el grado de aceptaci\u00f3n de dichas intervenciones.\nRESULTADOS\nSe revisaron 69 prescripciones de 65 pacientes, 55% hombres, mediana de edad 66 a\u00f1os (54,75-79). Las unidades de \ningreso fueron: infecciosas (15/69), reanimaci\u00f3n (11/69), respiratorio (10/69), cardiolog\u00eda (4/69), cirug\u00eda general (4/69), \ndigestivo (3/69), hematolog\u00eda (3/69), medicina interna (3/69), urolog\u00eda (3/69), otorrinolaringolog\u00eda (3/69) y varios \n(10/69). \nLas indicaciones de los tratamientos fueron: 23 tratamientos profil\u00e1cticos, 5 tratamientos emp\u00edricos y 41 dirigidos. \nLos tratamientos dirigidos seg\u00fan diagn\u00f3stico cl\u00ednico fueron: infecci\u00f3n respiratoria 22, urinaria 10, herida quir\u00fargica \n2, bacteriemia 2, y varios 5. Seg\u00fan microorganismo: Stenotrophomona maltophila 14, Pneumocystis jirovecii 6, \nStaphylococcus aureus resistente a meticilina 6, Escherichia coli 6, Klebsiella pneumoniae 3, Acinetobacter baumanii 2, \nSerratia marcescens 2, Toxoplasma gondii 1 y Enterobacter cloacae mas Proteus mirabilis 1.  \nSe detectaron 18 prescripciones inadecuadas (26%). 13 fueron dosis inadecuadas en relaci\u00f3n con el diagn\u00f3stico \nmicrobiol\u00f3gico (10 correspond\u00edan a pacientes con infecci\u00f3n por Stenotrophomona maltophila), 3 errores de conciliaci\u00f3n \ndel tratamiento domiciliario profil\u00e1ctico y 2 fueron ajustes de dosis por aclaramiento estimado menor a 30 ml/min. Se \naceptaron 17 intervenciones (94%).\nCONCLUSIONES\nDurante el estudio se detect\u00f3 un alto porcentaje de discrepancias entre la prescripci\u00f3n y posolog\u00edas recomendadas, \nespecialmente en el caso de infecci\u00f3n por Stenotrophomonas maltophila, la cual requiere una mayor exposici\u00f3n al \nf\u00e1rmaco. La revisi\u00f3n de dichas infecciones, as\u00ed como las prescripciones de STX-TMP , podr\u00edan considerarse un objetivo a \nvalorar dentro del PROA \ufffd \nLa intervenci\u00f3n del farmac\u00e9utico hospitalario, con un alto grado de aceptaci\u00f3n, es necesaria para una correcta \noptimizaci\u00f3n del tratamiento con STX-TMP .\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n788. USO DE MEDICACI\u00d3N PSIQUIATRICA E INTERACCIONES FARMACOL\u00d3GICAS EN PACIENTES CON \nINFECCI\u00d3N POR VHC TRATADOS CON ANTIVIRALES DE ACCI\u00d3N DIRECTA PANGENOT\u00cdPICOS \nAUTORES\nMORILLO VERDUGO, R; TURNES V\u00c1ZQUEZ, J; GARC\u00cdA HEROLA, A; M\u00c9NDEZ PERTUZ, M; DE \u00c1LVARO P\u00c9REZ, C; \nHERN\u00c1NDEZ L\u00d3PEZ, C; SICRAS MAINAR, A\nCOMPLEJO HOSPITALARIO DE ESPECIALIDADES VIRGEN DE VALME. CTRA. DE C\u00c1DIZ, KM. 548,9 SEVILLA. SEVILLA420OBJETIVOS\nAnalizar la presencia y gravedad de las interacciones farmacol\u00f3gicas de pacientes con antipsic\u00f3ticos tratados con \nAntivirales de Acci\u00f3n Directa Pangenot\u00edpicos en una cohorte de vida real.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional multicentrico y multidisciplianr de caracter retrospectivo, empleando la base de datos BIG-PAC \n(Atrys Health), en pacientes HCV tratados entre enero-2017 y diciembre-2020 con AADp, Sofosbuvir/Velpatasvir [SOF/\nVEL] y Glecaprevir/Pibrentasvir [GLE/PIB].  \nSe incluyeron pacientes: (i) \u226518 a\u00f1os, (ii) con \u22652 EMR (electronic medical records) en la base de datos al menos 12 meses \nantes de la fecha \u00edndice, (iii) estar en el programa de prescripci\u00f3n (\u2265 1 prescripci\u00f3n durante el periodo de seguimiento), y \n(iv) pacientes con seguimiento regular (\u22651 EMR durante el periodo de tratamiento con AAD). Se excluyeron los pacientes \ntrasladados a otros centros, desplazados, fuera del \u00e1rea o institucionalizados permanentemente. \nSe recogieron variables demogr\u00e1ficas: edad, sexo; cl\u00ednicas: grado de fibrosis, presencia de adicciones o abuso de \nsustancias; farmacoterap\u00e9uticas; y efectos adversos. tipo de antiviral directo prescrito y presencia o no de comedicaci\u00f3n \npsiqui\u00e1trica empleada.  \nLas posibles interacciones entre la medicaci\u00f3n concomitante y los antivirales se evaluaron utilizando la base de datos de \nla Universidad de Liverpool\ufffd  \nSe utilizaron intervalos de confianza (IC) del 95% para estimar los par\u00e1metros poblacionales. Para los an\u00e1lisis se utiliz\u00f3 el \nsoftware estad\u00edstico IBM/SPSS. Los valores de p < 0,05 se consideraron estad\u00edsticamente significativos.\nRESULTADOS\nSe incluyeron un total de 1620 pacientes; (edad mediana: 54 a\u00f1os; 61% hombres; 32,4% F3/4). El 61% (985 pacientes) \npresentaban adicciones o abuso de sustancias, mientras que el resto (635 pacientes) eran poblaci\u00f3n general (sin \nadicciones /sin abuso sustancias).  \nLos f\u00e1rmacos m\u00e1s prescritos pertenec\u00edan al sistema nervioso SN (35,8%), siendo los psicol\u00e9pticos (N05) los f\u00e1rmacos m\u00e1s \nprescritos de este grupo (40% de todas las prescripciones del SN), y dentro de estos la quetiapina fue la m\u00e1s prescrita. \nEl 12% (187/1620) de la poblaci\u00f3n total se encontraba en tratamiento con antipsic\u00f3ticos (N05A), eran m\u00e1s j\u00f3venes y \npresentaban mayor grado de fibrosis F3/F4 que la poblaci\u00f3n total [mediana de edad: 53 a\u00f1os; hombres: 59%; F3/4: 44%]. \nDe estos, el 75% (140/187) pertenec\u00eda a poblaci\u00f3n con adicciones o abuso de sustancias, mientras que el 25% (47/187) \nrestante pertenec\u00eda a la poblaci\u00f3n general; p < 0.001.  \nAdem\u00e1s, 14% (140/985) del total de pacientes con adicciones o abuso de sustancias ten\u00edan prescripci\u00f3n de antipsic\u00f3ticos, \nsiendo este porcentaje inferior en la poblaci\u00f3n general, 7% (47/635); p < 0.001 \nEn t\u00e9rminos de interacciones, el 28% (53/187) de los pacientes con antipsic\u00f3ticos presentaban riesgo de IFs con los AADs, \nsiendo el porcentaje num\u00e9ricamente mayor en los pacientes con adicciones o abuso de sustancias, 30% (42/140) vs. 23% \n(11/47) en la poblaci\u00f3n general. p=0.336.  \nSe reportaron 2 efectos adversos, uno con quetiapina (dando lugar a discontinuaci\u00f3n del AADp) y otro con paliperidona, \nambos en el grupo tratado con GLE/PIB. No se report\u00f3 ning\u00fan efecto adverso en el grupo tratado con SOF/VEL.\nCONCLUSIONES\nEn pacientes con hepatitis C y en tratamiento con antipsic\u00f3ticos la presencia de interacciones potenciales es elevada, \nrequiriendo un abordaje integral de su seguimiento para llevar a cabo una optimizaci\u00f3n de la terapia prescrita.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n792. EFECTIVIDAD, SEGURIDAD Y AHORRO POR D\u00cdAS DE HOSPITALIZACI\u00d3N EVITADOS CON \nDALBAVANCINA EN INDICACIONES NO INCLUIDAS EN FICHA T\u00c9CNICA \nAUTORES\nROLD\u00c1N GALNARES, M; LAO DOM\u00cdNGUEZ, F\u00c1; CANTUDO CUENCA, MD\nHOSPITAL NUESTRA SE\u00d1ORA DE VALME. CTRA. C\u00c1DIZ-BELLAVISTA, KM. 548,9 SEVILLA. SEVILLA\nOBJETIVOS\nEvaluar efectividad y seguridad de dalbavancina en indicaciones no incluidas en ficha t\u00e9cnica, as\u00ed como estimar el ahorro \nen costes indirectos por d\u00edas de hospitalizaci\u00f3n evitados.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y unic\u00e9ntrico en el que se incluyeron pacientes adultos con infecciones \nbacterianas que recibieron tratamiento con dalbavancina durante el ingreso y/o de forma ambulatoria en un hospital \nde especialidades desde junio-2019 hasta febrero-2022. Los datos se obtuvieron de la historia cl\u00ednica electr\u00f3nica y el \nprograma de prescripci\u00f3n electr\u00f3nica. Variables recogidas: edad, sexo, alergia a antibi\u00f3ticos, indicaci\u00f3n, agente etiol\u00f3gico, \nmotivo de prescripci\u00f3n, pauta posol\u00f3gica, n\u00famero de dosis administradas, d\u00edas de tratamiento, reca\u00edda a los 30 d\u00edas de \nfinalizar el tratamiento, curaci\u00f3n cl\u00ednica (seg\u00fan criterio m\u00e9dico) y/o microbiol\u00f3gica y efectos adversos.  \nLos d\u00edas de hospitalizaci\u00f3n evitados se consideraron como los d\u00edas de tratamiento ambulatorio con dalbavancina. El \nahorro estimado por d\u00eda de hospitalizaci\u00f3n evitado posteriormente se determin\u00f3 mediante datos de costes hospitalarios \ndel Ministerio de Sanidad (2019), al cual se le restaron los costes del tratamiento IVA incluido y los asociados a su \nadministraci\u00f3n ambulatoria\ufffd\nRESULTADOS\nSe incluyeron 13 pacientes (9 hombres) con mediana de edad de 74 a\u00f1os (RIQ:69-79). Solo un paciente mostr\u00f3 alergia a \nantibi\u00f3ticos (penicilinas).  421Las infecciones detectadas fueron infecciones osteoarticulares (n=4; 30,8%), infecciones prot\u00e9sicas (n=4; 30,8%), \nendocarditis de v\u00e1lvula nativa (n=3; 23,1%) y bacteriemia complicada (n=2; 15,4%). Los microorganismos aislados \nfueron Enterococcus faecalis (n=4; 26,6%), estafilococos coagulasa negativos (n=4; 26,6%), Staphylococcus aureus \nmeticilin sensible (n=3; 20%), Staphylococcus aureus meticilin resistente (n=1; 6%), Streptococcus spp. (n=1, 6%) y \nCorynebacterium striatum (n=1; 6%). Tres infecciones fueron polimicrobianas, en un caso con un gram negativo. En una \nde las infecciones no se lleg\u00f3 a aislar el microorganismo causante\ufffd  \nEl principal motivo de prescripci\u00f3n fue alta hospitalaria (n=10; 76.9%) seguido de fracaso al tratamiento previo (n=1; \n7,7%), alergias e interacciones (n=1; 7,7%) y mal cumplimiento terap\u00e9utico (n=1; 7,7%). Las pautas posol\u00f3gicas empleadas \nfueron 1.000mg dosis de carga + 500mg semanales (n=4, 30,7%), 1.500mg dosis \u00fanica (n=3; 23%), 1.500mg dosis de carga \n+ 1.000mg semanales (n=1; 7,7%), otras (n=5; 38,4%). La mediana de dosis administradas fue 3 (RIQ:2-4) y la mediana \nde duraci\u00f3n de tratamiento 28 d\u00edas (RIQ:21-49). Al final del tratamiento todos presentaron curaci\u00f3n cl\u00ednica y cultivos \nnegativos. S\u00f3lo un paciente present\u00f3 reca\u00edda, en este caso a las 20 semanas. El 23% (n=3) present\u00f3 efectos adversos \nleves: febr\u00edcula, temblor generalizado y visi\u00f3n borrosa.  \nEn cuanto al an\u00e1lisis de costes, el uso de dalbavancina evit\u00f3 394 d\u00edas de estancia hospitalaria (30 d\u00edas de media/paciente). \nSeg\u00fan un coste de estancia hospitalaria de 492\u20ac/d\u00eda, el coste evitado fue 193.848\u20ac. Restando los costes debidos al \nf\u00e1rmaco (447,33\u20ac/vial) y los asociados a su administraci\u00f3n ambulatoria (196,01\u20ac/d\u00eda) el ahorro estimado result\u00f3 ser de \n151.090,63\u20ac.\nCONCLUSIONES\nDalbavancina fue un tratamiento efectivo y seguro en el abordaje de infecciones por microorganismos gram positivos. \nEl principal motivo de su prescripci\u00f3n fue el seguimiento ambulatorio, lo cual evit\u00f3 un gran n\u00famero de d\u00edas de ingreso \nhospitalario y los costes asociados.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n793. \u00bfLA COVID-19 HA IMPACTADO SOLAMENTE A NIVEL INTRAHOSPITALARIO?: CAMBIOS EN EL PERFIL \nDE LOS PACIENTES CON TRATAMIENTO ANTIBI\u00d3TICO DOMICILIARIO ENDOVENOSO \nAUTORES\nORTONOBES ROIG, S; MUJAL MART\u00cdNEZ, A; DE CASTRO JULVE, M; AVIL\u00c9S G\u00d3MEZ, E; MAY\u00c9 P\u00c9REZ, I; RIBAS OB\u00d3N, L; \nGONZ\u00c1LEZ S\u00c1NCHEZ, A; G\u00d3MEZ-VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\n- Analizar la evoluci\u00f3n de ingresos en la Unidad de Hospitalizaci\u00f3n a Domicilio con Tratamiento Antibi\u00f3tico Domiciliario \nEndovenoso (TADE) antes y despu\u00e9s del inicio de la pandemia por COVID-19.  \n- Comparar las caracter\u00edsticas de los pacientes con TADE de 2021 con una cohorte pre-pand\u00e9mica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital universitario con TADE mediante dispositivos elastom\u00e9ricos \nelaborados en el Servicio de Farmacia. Se incluyeron todos los pacientes con TADE desde 2017, analizados por trimestres \na partir del promedio semanal, excluyendo el segundo trimestre de 2020 por la afectaci\u00f3n de la primera ola de COVID-19. \nSe us\u00f3 el a\u00f1o 2019 como cohorte pre-pand\u00e9mica para comparar con 2021. Variables registradas: sociodemogr\u00e1ficas, \ncaracter\u00edsticas del TADE (indicaci\u00f3n, antibi\u00f3tico, duraci\u00f3n), elast\u00f3meros elaborados y destino al finalizar TADE. Variables \ncuantitativas expresadas como mediana (rango intercuartil); variables cualitativas como valor relativo. An\u00e1lisis estad\u00edstico \nde la evoluci\u00f3n mediante regresi\u00f3n lineal simple (coeficiente de regresi\u00f3n; IC95%; R2), comparaciones variables \ncuantitativas prueba de Mann-Whitney-Wilcoxon; test de Chi-cuadrado para cualitativas.\nRESULTADOS\nEl promedio semanal de pacientes con TADE desde el primer trimestre de 2017 hasta el primer trimestre de 2020 fue de \n13,9 (13,1-15,9) vs 18,7 (15,2-23,5) desde el tercer trimestre de 2020 hasta final de 2021, p=0,023. En el primer periodo \nel promedio de pacientes semanales se mantuvo estable (-0,14; IC95% -0,55-0,26; 0,05); mientras en el segundo, hubo \nun crecimiento significativo (2,24; IC95% 1,30-3,17; 0,92). El n\u00famero de elast\u00f3meros elaborados evolucion\u00f3 de forma \nsimilar: (-14,68; IC95% -55,03-25,68; 0,06) vs (175,63; IC95% 24,37-326,90; 0,72).  \nComparaci\u00f3n de pacientes con TADE 2019 (268; 45,3%) vs 2021 (324; 57,7%): edad 67 (52-78) a\u00f1os vs 72 (59-80) p=0,002; \nmujeres 33,9% vs 38,6% p=0,245. Indicaciones: infecciones urinarias 21,6% vs 32,1% p=0,005; infecciones pulmonares \n32,1% vs 14,2% p < 0,001; bacteriemia 14,6% vs 15,1% p=0,846; infecciones intraabdominales 10,5% vs 12,4% p=0,471; \ninfecciones piel/partes blandas 6,7% vs 12,7% p=0,016; infecciones osteoarticulares 9,3% vs 5,6% p=0,078; endocarditis \n0,75% vs 3,7% p=0,018; otras infecciones 4,5 % vs 4,3% p=0,926. Antibi\u00f3ticos mayoritarios: ertapenem 35,7% vs 38,9% \np=0,339; ceftriaxona 13,4% vs 14,8% p=0,631; meropenem 10,5% vs 12,9% p=0,345; piperacilina/tazobactam 5,6% vs \n12,9% p=0,002; ceftazidima 8,6% vs 5,3% p=0,108. Promedio semanal de pacientes con monoterapia 13,0 (11-15,5) vs \n19,5 (17-23) p < 0,0001 y con biterapia 1 (0-1,5) vs 1 (1-2) p=0,021. Duraci\u00f3n TADE 13 (8-17,5) d\u00edas vs 12 (8-19) p=0,751. \nPacientes con necesidad de re-ingreso en agudos/sociosanitario y/o derivaci\u00f3n a urgencias por cualquier causa: 18 (6,7%) \nvs 49 (15,1%) p=0,001.\nCONCLUSIONES\n- Tras la primera ola de la pandemia por COVID-19 han incrementado significativamente los pacientes con TADE y el \nn\u00famero de elast\u00f3mero elaborados.  \n- Las infecciones urinarias sin alternativa de antibi\u00f3tico oral han aumentado, pero tambi\u00e9n los pacientes con infecciones \ngraves como la endocarditis y con biterapia.  422- Los protocolos TADE no han variado en cuanto a duraci\u00f3n o selecci\u00f3n de antibi\u00f3tico, aunque s\u00ed se observa una mayor \nprescripci\u00f3n de piperacilina/tazobactam, manteni\u00e9ndose estable el uso de carbapen\u00e9micos.  \n- Los pacientes de 2021 requirieron de m\u00e1s re-ingresos y/o derivaciones a urgencias. La causa podr\u00eda ser una mayor edad \ny complejidad del TADE comparando con la cohorte pre-pand\u00e9mica.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n799. ESTUDIO DE UTILIZACI\u00d3N, EFECTIVIDAD Y SEGURIDAD DE CASIRIVIMAB/IMDEVIMAB EN EL \nTRATAMIENTO DEL COVID-19 \nAUTORES\nGIL ALMELA, J; MU\u00d1OZ GARC\u00cdA, I; TORR\u00d3 GARC\u00cdA, L; CANO MOLINA, J\u00c1; D\u00cdAZ RAM\u00d3N, M; GOLNABI DOWLATSHAHI, \nF; MART\u00cdNEZ IB\u00c1\u00d1EZ, M\u00c1; VILLA CARPES, J\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nCasirivimab e imdevimab (CSR/IMD) son dos anticuerpos (Ac) monoclonales utilizados para el tratamiento del COVID-19 \n(variante no \u00f3micron) en pacientes que tienen alto riesgo (AR) de progresar a enfermedad grave. \nEl objetivo del estudio es describir el perfil de pacientes tratados con CSR/IMD, evaluar la adecuaci\u00f3n a los criterios de \npriorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) y analizar la efectividad y seguridad \ndel f\u00e1rmaco.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo donde se incluyeron todos los pacientes tratados con CSR/IMD desde diciembre \nde 2021 hasta febrero de 2022 en un hospital de tercer nivel. Se recogieron variables demogr\u00e1ficas, fecha de inicio de \ns\u00edntomas, factores de riesgo (FR), pauta de vacunaci\u00f3n, t\u00edtulo de Ac y variante del virus.  \nSe evalu\u00f3 la adecuaci\u00f3n a los criterios de priorizaci\u00f3n de la AEMPS, diferenciando dos perfiles:  \n- Grupo A: Paciente de AR no hospitalizado con enfermedad leve-moderada y periodo sintom\u00e1tico \u22647 d\u00edas. Dosis \u00fanica: \nCSR/IMD 600 mg/600 mg\ufffd \n- Grupo B: Paciente de AR hospitalizado por COVID-19 grave o cr\u00edtico con infecci\u00f3n por variante diferente de \u00f3micron y \nserolog\u00eda negativa para SARS-CoV-2. Dosis \u00fanica: CSR/IMD 1200 mg/1200 mg. \nLa variable de efectividad fue hospitalizaci\u00f3n relacionada con COVID-19 o muerte por cualquier causa hasta el d\u00eda 29. \nLa variable de seguridad fue la aparici\u00f3n de reacciones adversas (RA). Los datos se obtuvieron de la historia cl\u00ednica \nelectr\u00f3nica y se procesaron mediante Excel\ufffd\nRESULTADOS\nSe registraron 13 pacientes (7 hombres, 6 mujeres), con una mediana de edad de 55 a\u00f1os (38-74). En todos ellos, el \ntiempo transcurrido desde el inicio de s\u00edntomas hasta la administraci\u00f3n del f\u00e1rmaco fue \u22647 d\u00edas. Las caracter\u00edsticas de los \npacientes por grupos fueron:  \n- Grupo A: 11 pacientes (85%), 9 con trasplante (Tx) renal, 1 con Tx hep\u00e1tico y 1 con mieloma m\u00faltiple. 3 pacientes no \nvacunados y 7 con serolog\u00eda negativa.  \n- Grupo B: 2 pacientes (15%), 1 con Tx renal y 1 con fibrosis qu\u00edstica (FQ) y doble Tx renal y hep\u00e1tico. Ambos pacientes \npresentaron pauta de vacunaci\u00f3n completa y serolog\u00eda negativa, y la variante del virus fue diferente de \u00f3micron. \nConcomitantemente con CSR/IMD, fueron tratados con remdesivir y dexametasona\ufffd  \nEn cuanto a la efectividad, ning\u00fan paciente muri\u00f3 ni reingres\u00f3 tras el alta. En relaci\u00f3n con la seguridad, no se observ\u00f3 \nninguna RA tras la administraci\u00f3n, excepto en un paciente del grupo A con Tx renal y Ac muy elevados (10.547 UA/mL), \nque present\u00f3 fiebre y descenso de la saturaci\u00f3n de ox\u00edgeno hasta el 92%, por lo que se mantuvo ingresado.\nCONCLUSIONES\nTodos los pacientes cumplieron los criterios de priorizaci\u00f3n de la AEMPS.  \nCon estos datos, como conclu\u00eda el estudio pivotal COV-2067, CSR/IMD ha demostrado ser una alternativa terap\u00e9utica \nefectiva y segura para evitar que pacientes con AR progresen a COVID-19 grave. Sin embargo, debido a las incertidumbres \nsobre la eficacia reducida de CSR/IMD frente a la variante \u00f3micron, predominante en Espa\u00f1a actualmente, ser\u00eda necesario \nrealizar estudios frente a nuevas variantes para establecer el lugar que ocupa dentro de las estrategias terap\u00e9uticas \npotenciales para la infecci\u00f3n por el virus SARS-CoV-2.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n812. UTILIZACION DE ANFOTERICINA B DEOXICOLATO INTRAVESICAL EN INFECCIONES POR CANDIDA \nEN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nINFANTE CAMARERO, A; VICENTE GONZALEZ, B; DE FRUTOS DEL POZO, M; SANCHEZ LUQUE, L; BRIONES CUESTA, E; \nMACHIN MORON, MA; GUEMES GARCIA, M; GUTIERREZ FERNANDEZ, I\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS423OBJETIVOS\nAnfotericina B es un antif\u00fangico de amplio espectro y su forma deoxicolato ha ca\u00eddo en desuso debido a su mayor \ntoxicidad sist\u00e9mica, siendo sustituido por las formulaciones lip\u00eddica o liposomal. Sin embargo, la literatura recoge el uso \nde anfotericina B deoxicolato en irrigaciones locales como terapia combinada, habi\u00e9ndose demostrado ser segura y bien \ntolerada\ufffd  \nEl objetivo de nuestro estudio fue analizar la efectividad y seguridad del tratamiento con anfotericina B deoxicolato por \nv\u00eda intravesical (ABDi) en nuestro hospital.\nMATERIALES Y M\u00c9TODOS\nAn\u00e1lisis observacional y retrospectivo de los pacientes en tratamiento con ABDi (50 mg/L administrado en instilaciones \nintravesicales de 200-300 mL) durante el periodo abril 2018-abril 2022. Se recogieron datos demogr\u00e1ficos (sexo, edad), \nservicio cl\u00ednico, indicaci\u00f3n, duraci\u00f3n del tratamiento, antif\u00fangicos previos y resultados de cultivos microbiol\u00f3gicos (al \ninicio y al final del tratamiento). La efectividad se defini\u00f3 como: resultados de cultivos negativos tras al menos 5 d\u00edas de \ntratamiento con ABDi as\u00ed como evoluci\u00f3n favorable del paciente [afebril las \u00faltimas 72 horas y disminuci\u00f3n reactantes de \nfase aguda (RFA)]. La seguridad se evalu\u00f3 observando los eventos adversos registrados en la historia cl\u00ednica.  \nLa recogida de datos se llev\u00f3 a cabo revisando la historia cl\u00ednica electr\u00f3nica y las dispensaciones realizadas a trav\u00e9s del \nprograma espec\u00edfico de Farmacia.\nRESULTADOS\nSe incluyeron un total de 19 pacientes (63,2% hombres) con una mediana de edad de 70 a\u00f1os(42-87). Los pacientes \npertenec\u00edan a los siguientes servicios cl\u00ednicos:15 Unidad de Cuidados Intensivos, 2 Urolog\u00eda y 2 Medicina Interna. \nIndicaci\u00f3n: 6 Candidiasis diseminada, 13 Candiduria. La mediana de duraci\u00f3n del tratamiento con ABDi fue de 6 d\u00edas (1-\n27), el 26,3%(5) pacientes lo recibieron concomitante con anfotericina B liposomal IV. \nEl 42,1%(8) de los pacientes no hab\u00eda recibido tratamiento previo con otros antif\u00fangicos mientras que el 26,3%(5) \nhab\u00eda estado en tratamiento con caspofungina, 31,6%(6) con fluconazol y el 5,3%(1) con voriconazol. Microorganismos \nresponsables: 6 Candida parapsilosis, 10 Candida glabrata, 1 Candida dubliniensis, 1 Candida guilliermondii, 1 Candida \nalbicans\ufffd  \nResultados de los cultivos tras al menos 5 d\u00edas con ABDi: 42,1% (8) negativos; 10,5%(2) positivos; 47,4%(9) no realizaron \ncultivos de control, de los cuales, 3 evolucionaron favorablemente, 3 fallecieron y otros 3 desarrollaron par\u00e1metros de \ninfecci\u00f3n (fiebre y elevaci\u00f3n de RFA). \nEn referencia a la seguridad, el 57,9%(11) de los pacientes no tuvieron ning\u00fan evento adverso. Sin embargo, 5 pacientes \npresentaron alteraciones en el ionograma (hipopotasemia e hipomagnesemia), 1 paciente describi\u00f3 dolor vesical con la \ninfusi\u00f3n del f\u00e1rmaco, 1 desarroll\u00f3 fallo renal y otro present\u00f3 reacci\u00f3n cut\u00e1nea y v\u00f3mitos que requirieron la suspensi\u00f3n \ndel tratamiento\ufffd\nCONCLUSIONES\nEl perfil del paciente tratado es el de un individuo cl\u00ednicamente complejo teniendo en cuenta el servicio prescriptor \nmayoritario, la unidad de cuidados intensivos. En casi la mitad de los pacientes no se realiz\u00f3 un cultivo de control \nposterior al tratamiento con ABDi. La v\u00eda de administraci\u00f3n intravesical puede suponer un menor riesgo de eventos \nadversos que la v\u00eda intravenosa, sin embargo, podr\u00eda ser necesario monitorizar la funci\u00f3n renal as\u00ed como realizar \nionograma de manera peri\u00f3dica\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n825. HOSPITALIZACI\u00d3N A DOMICILIO: EVOLUCI\u00d3N DE UN PROGRAMA DE TRATAMIENTO ANTIBI\u00d3TICO \nDOMICILIARIO ENDOVENOSO (2020-2022) \nAUTORES\nAYESTAR\u00c1N ALTUNA, A; FIERRO BANZO, J; MONTES CASAS, M; GARCIA PORTA, R; OLIVER SINTES, C; SANTILLANA \nMONTAL, M\nHOSPITAL DE BARCELONA \ufffd AV\ufffd DIAGONAL, 656 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nDescribir el tratamiento antibi\u00f3tico endovenoso administrado en r\u00e9gimen de hospitalizaci\u00f3n a domicilio (TADE), las \ncaracter\u00edsticas de los pacientes que reciben dicho tratamiento y los d\u00edas/costes evitados de hospitalizaci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo desarrollado en un hospital de tercer nivel de 273 camas, que dispone de una Unidad \nde Hospitalizaci\u00f3n a Domicilio con una importante actividad TADE. Se han incluido todos los pacientes tratados con TADE \ndurante el periodo enero 2020-abril 2022.  \nLas variables registradas fueron: datos demogr\u00e1ficos, localizaci\u00f3n de la infecci\u00f3n, microorganismo, tipo de antibi\u00f3tico y \nduraci\u00f3n del tratamiento. Para la valoraci\u00f3n econ\u00f3mica: coste por d\u00edas de hospitalizaci\u00f3n evitados.\nRESULTADOS\nSe han incluido un total de 205 pacientes: 81 en 2020; 87 en 2021 y 37 en 2022. Edad mediana: 81(rango 38-102) en \n2020; 78 (rango 30-102) en 2021 y 87 (rango 69-95) en 2022. Sexo (hombres): 56% en 2020; 52% 2021 y 57% hombres en \n2022\ufffd \nLugar de la Infecci\u00f3n: urinario (32% en 2020, 32% en 2021 y 43% en 2022), respiratorio (19% en 2020, 9% en 2021 y 22% \nen 2022), bacteriemia (15% en 2020, 23% en 2021 y 11% en 2022), osteoarticular (9% en 2020, 12% en 2021 y 0% en \n2022) y otros (25% en 2020, 24% en 2021 y 24% en 2022).  424Antibi\u00f3tico: ertapenem (31% en 2020, 36% en 2021 y 35% en 2022); piperacilina-tazobactam (28% en 2020, 38% en 2021 \ny 27% en 2022), ceftriaxona (23% en 2020, 11% en 2021 y 14 % en 2022) y otros (18% en 2020, 15% en 2021 y 24% en \n2022). \nMicroorganismo: germen con alg\u00fan mecanismo de resistencia (28% en 2020, 29% en 2021 y 19% en 2022), bacilos gram \n(-) (12% en 2020, 11% en 2021 y 14% en 2022), polimicrobiano (7% en 2020, 16% en 2021 y 8% en 2022), P . aeruginosa \n(2% en 2020, 6% en 2021 y 0% en 2022), sin aislamiento (30% en 2020, 20% en 2021 y 33% 2022) y otros (21% en 2020, \n18% en 2021 y 26% en 2022).  \nDuraci\u00f3n mediana TADE: 10 (rango 1-66) en 2020; 10 (rango 1-34) en 2021 y 7 (rango 1-29) en 2022. \nLos d\u00edas totales que se han evitado de hospitalizaci\u00f3n han sido 1.931 (826 en 2020, 849 en 2021 y 256 en 2022) y el coste \ntotal evitado (se ha considerado tambi\u00e9n el coste de los dispositivos de infusi\u00f3n elastom\u00e9rico utilizados en domicilio) \n645.375,70 \u20ac (276.122,70 \u20ac en 2020, 283.362,50 \u20ac en 2021 y 85.890,50 \u20ac en 2022).\nCONCLUSIONES\nSe observa una tendencia hacia un aumento en el n\u00famero de pacientes que se incluyen en el programa TADE. Permite \nadministrar antibi\u00f3ticos en pacientes con microorganismos que presentan alg\u00fan mecanismo de resistencia, en situaciones \nde estabilidad cl\u00ednica, contribuye a evitar la necesidad de aislamiento en las plantas de hospitalizaci\u00f3n y ahorra d\u00edas de \nestancia hospitalaria.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n826. EVALUACI\u00d3N DE LA PRESCRIPCI\u00d3N DE ANTIBI\u00d3TICOS AL ALTA EN PACIENTES CON INFECCI\u00d3N \nRESPIRATORIA EN EL SERVICIO DE URGENCIAS \nAUTORES\nSAN ANDRES CORRAL, C; SANTOLAYA PERRIN, R; UBEDA RUIZ, B; GALLUR MARTINEZ, AM; GIN\u00c9S PALOMARES, A; \nGONZ\u00c1LEZ TRIGUEROS, C; ESCRIGAS FERN\u00c1NDEZ, C; CUERVO ESCRIBANO, K\nHOSPITAL UNIVERSITARIO PR\u00cdNCIPE DE ASTURIAS. CTRA. ALCAL\u00c1-MECO, S/N ALCAL\u00c1 DE HENARES. MADRID\nOBJETIVOS\nAnalizar la prescripci\u00f3n de antibi\u00f3ticos al alta en el Servicio de Urgencias en pacientes con infecci\u00f3n respiratoria para \nidentificar puntos de mejora en la utilizaci\u00f3n de antibi\u00f3ticos y priorizar las estrategias de Programa de Optimizaci\u00f3n de \nUso de Antibi\u00f3ticos (PROA)\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo donde se incluyen los pacientes dados de alta desde el 28/03/2022 al 03/04/2022 en \nel Servicio de Urgencias con infecci\u00f3n respiratoria\ufffd Los datos se recopilan de los informes de alta y la receta electr\u00f3nica\ufffd \nLas variables recogidas son: edad, diagn\u00f3stico, tratamiento, fecha de inicio y de fin de tratamiento al alta, edad y factores \nde riesgo como tabaquismo, enfermedad cardiopulmonar, diabetes mellitus, enfermedad renal, alcoholismo, malignidad \ny EPOC\ufffd Las variables de valoraci\u00f3n son: indicaci\u00f3n, selecci\u00f3n y duraci\u00f3n de tratamiento adecuado acorde a los protocolos \ndel Hospital y Gu\u00eda PRAN (Plan Nacional frente a la Resistencia de Antibi\u00f3ticos), prescripci\u00f3n en receta electr\u00f3nica \ncorrecta, dosis correcta y presencia de interacciones\ufffd  \nLa indicaci\u00f3n se considera incorrecta cuando se emplea un antibi\u00f3tico no estando indicado la terapia antimicrobiana \nseg\u00fan las Gu\u00edas.  \nPara valorar la selecci\u00f3n adecuada se incluyen s\u00f3lo los pacientes que tienen indicaci\u00f3n de antibi\u00f3tico. Se considera \nadecuado cuando se ha utilizado el tratamiento de primera elecci\u00f3n o esta justificado cl\u00ednicamente la utilizaci\u00f3n del \nsegundo por alergia o tratamiento previo con la primera elecci\u00f3n\ufffd  \nLa duraci\u00f3n de tratamiento se considera correcta si se ajusta a las recomendaciones de PRAN, que en Infecci\u00f3n \nrespiratoria no neum\u00f3nica, neumon\u00eda y bronquitis complicada no debe superar los 5 d\u00edas.\nRESULTADOS\nDe 85 pacientes, se analizan 56 que acuden a Urgencias con infecci\u00f3n respiratoria y no ingresan. La distribuci\u00f3n de los \ndiagn\u00f3sticos es: Infecci\u00f3n respiratoria no neum\u00f3nica 36 (64,3%), Neumon\u00eda 9 (16,1%), Bronquitis 7 (12,5%), Infecci\u00f3n \nCOVID-19 3 (5,4%), Infecci\u00f3n Gripe A 1 (1,8%) \nEn el an\u00e1lisis de indicaci\u00f3n, de 56 pacientes incluidos, 34 no requieren antibi\u00f3tico, de los cuales en 28 no se prescribe, por \ntanto, se considera un porcentaje de adecuaci\u00f3n de indicaci\u00f3n en un 82,3%  \nEn cuanto a la selecci\u00f3n, se eval\u00faan 16 pacientes. Se considera adecuada en 25%. En el resto, o bien se utiliza el \nantibi\u00f3tico de segunda elecci\u00f3n sin estar justificado (25%) o se utilizan otros antibi\u00f3ticos (50%) como: amoxicilina/\nclavul\u00e1nico o levofloxacino siendo lo indicado amoxicilina (31,25%); o cefditoreno siendo lo indicado amoxicilina/\nclavul\u00e1nico (18,75%),  \nPara la evaluaci\u00f3n de la duraci\u00f3n de tratamiento, se incluyen los 22 pacientes que reciben antibi\u00f3tico al alta. Solo en \n13,6% se considera correcta\ufffd \nLa duraci\u00f3n media fue de 7 d\u00edas.  \nEn la actualizaci\u00f3n de prescripci\u00f3n al alta, uno de los pacientes presenta discrepancias y no tiene receta electr\u00f3nica \n(4,5%). \nNing\u00fan paciente presenta interacciones medicamentosas.\nCONCLUSIONES\nLa indicaci\u00f3n de utilizaci\u00f3n de antibi\u00f3ticos es correcta en un porcentaje elevado, no se prescribe a la mayor\u00eda de \npacientes que no requiere antibi\u00f3tico.  425Por otro lado, se identifican como puntos de mejora prioritarios: la duraci\u00f3n de tratamiento, ya que la mayor\u00eda de \npacientes reciben tratamiento m\u00e1s prolongados de lo recomendado por las Gu\u00edas; y la selecci\u00f3n de medicamentos, por la \nutilizaci\u00f3n de amoxicilina sin clavul\u00e1nico cuando est\u00e1 indicado seg\u00fan protocolo.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n830. ESTUDIO DE UTILIZACI\u00d3N, EFECTIVIDAD Y SEGURIDAD DE CEFIDEROCOL EN VIDA REAL \nAUTORES\nMARCOS FENDIAN, A; ALBANELL , M; TUSET , M; PITART , C; CASTRO , P; SORIANO , A; MARTINEZ , JA; SOY , D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nCefiderocol es una nueva cefalosporina sider\u00f3fora dise\u00f1ada para tratar infecciones por microorganismos gramnegativos \naerobios en adultos con opciones terap\u00e9uticas limitadas. En la actualidad se obtiene tras aprobaci\u00f3n previa por la Agencia \nEspa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). El objetivo del estudio es evaluar la experiencia del uso de \ncefiderocol en pacientes con infecciones multirresistentes en un hospital universitario de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo. Se incluyeron pacientes tratados con cefiderocol durante m\u00e1s de 72h entre Julio \n2021-Mayo 2022. Los datos se expresan como mediana (rango intercuart\u00edlico). Se recogieron variables demogr\u00e1ficas \n(sexo, edad y unidad de ingreso hospitalario), cl\u00ednicas y anal\u00edticas (foco de infecci\u00f3n, exposici\u00f3n a antibi\u00f3ticos en \nlos 14 d\u00edas previos a la infecci\u00f3n, microorganismos causales y antibiograma, determinaci\u00f3n de prote\u00edna C reactiva, \nprocalcitonina, leucocitos y fiebre al inicio [D0], cuarto d\u00eda [D+4] y final del tratamiento [Dfin], presencia de sepsis/\nshock s\u00e9ptico, intubaci\u00f3n orotraqueal [IoT], terapia de sustituci\u00f3n renal, oxigenaci\u00f3n por membrana extracorp\u00f3rea \n[ECMO], valores en las escalas Acute Physiology And Chronic Health Evaluation II [APACHE II] y Sequential Organ Failure \nAssessment [SOFA] al ingreso para pacientes cr\u00edticos y r\u00e9gimen de tratamiento de la infecci\u00f3n), y de efectividad y \nseguridad (curaci\u00f3n/mejor\u00eda cl\u00ednica y curaci\u00f3n microbiol\u00f3gica a los 7 d\u00edas de Dfin, desarrollo de resistencia a cefiderocol, \nmortalidad a 14 d\u00edas de Dfin y efectos adversos [EA] relacionados con el f\u00e1rmaco).\nRESULTADOS\nSe incluyeron 8 pacientes, 7 (87,5%) de ellos hombres, de edad mediana 60,5 (43,0-70,0) a\u00f1os. Siete pacientes eran \ncr\u00edticos (APACHE II 16 [13-17], SOFA 6 [4-8], 5 (62,5%) bajo IoT y 1 (12,5%) ECMO. Las infecciones tratadas fueron \nneumon\u00eda asociada a ventilaci\u00f3n mec\u00e1nica en 4 (50%) casos, 1 (12,5%) infecci\u00f3n relacionada con el cat\u00e9ter, 1 (12,5%) \nbacteriemia, 1 (12,5%) infecci\u00f3n de piel y partes blandas, y 1 (12,5%) peritonitis bacteriana espont\u00e1nea del cirr\u00f3tico. \nCinco pacientes (62,5%) presentaban sepsis y dos (25%) shock s\u00e9ptico. Todos los pacientes hab\u00edan recibido beta-\nlact\u00e1micos antipseudom\u00f3nicos previos. Los microorganismos implicados fueron Pseudomonas aeruginosa en 6 (75%) \ncasos, Escherichia coli en 1 (12,5%) y Acinetobacter baumannii en 1 (12,5%). El 37,5% fueron polimicrobianas. La dosis \nde cefiderocol fue 2g cada 8h en 7 (87,5%) pacientes y uno recibi\u00f3 8g en perfusi\u00f3n cont\u00ednua. Siete pacientes recibieron \ntratamiento combinado. Tras el inicio de cefiderocol, 5 (62,5%) pacientes presentaron reducci\u00f3n de reactantes de fase \naguda. Hubo curaci\u00f3n/mejor\u00eda cl\u00ednica en todos los casos y curaci\u00f3n microbiol\u00f3gica en 6 (75%). Ning\u00fan paciente hab\u00eda \nfallecido a los 14 d\u00edas. Tras una mediana de seguimiento de 95 [51-180] d\u00edas, 2 (25%) pacientes presentaron reca\u00edda \ncl\u00ednica/microbiol\u00f3gica y 3 (37,5%) fallecieron. Los dos pacientes que recayeron desarrollaron resistencia a cefiderocol. \nNing\u00fan paciente present\u00f3 EA relacionados.\nCONCLUSIONES\nCefiderocol es una opci\u00f3n terap\u00e9utica efectiva para el tratamiento de infecciones nosocomiales graves causadas \npor microorganismos multirresistentes. No obstante, una cuarta parte de los enfermos presentaron reca\u00edda cl\u00ednica y \nmicrobiol\u00f3gica asociada al desarrollo de resistencia\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n838. EVALUACI\u00d3N DEL TRATAMIENTO CON REMDESIVIR EN PACIENTES INGRESADOS DURANTE LA \nSEXTA OLA DE LA PANDEMIA COVID-19 \nAUTORES\nZAMORANO M\u00c9NDEZ, P; \u00c1LVAREZ ATIENZA, S; MART\u00cdN DE ROSALES CABRERA, AM; MARTINEZ SIM\u00d3N, JJ; S\u00c1NCHEZ \nCANO, JG; MART\u00cdN GARC\u00cdA, DJ; WU YANG, AY; PEREZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nEvaluar el impacto del tratamiento con remdesivir en la estancia hospitalaria y la mortalidad del paciente ingresado por \nCOVID-19 durante la sexta ola de la pandemia\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo caso-control de pacientes adultos ingresados por infecci\u00f3n por SARS-COV-2, desde el 10 de \ndiciembre de 2021 al 10 de marzo de 2022 en un hospital de tercer nivel. Se compararon los pacientes tratados con \nremdesivir (casos) obtenidos del sistema de informaci\u00f3n de farmacia frente a los no tratados (controles) seleccionados de \nforma aleatoria a partir del CMBD del hospital.  \nSe revisaron las historias cl\u00ednicas recogiendo datos demogr\u00e1ficos y cl\u00ednicos: edad, sexo, patolog\u00edas concomitantes \nasociadas al \u00edndice de comorbilidad de Charlson (IC), neumon\u00eda en el diagn\u00f3stico COVID-19 y estado de vacunaci\u00f3n. Se 426definieron como variables de resultado la estancia hospitalaria y el n\u00famero de muertes durante el ingreso.  \nLas variables cuantitativas se compararon mediante la prueba U de Mann Whitney, previo an\u00e1lisis de normalidad. Las \nvariables cualitativas se expresaron mediante proporciones compar\u00e1ndose con la prueba Ji-cuadrado.  \nPara valorar influencia del remdesivir en la estancia y las muertes, se aplic\u00f3 un an\u00e1lisis multivariante, ajustado por las \ncovariables con significaci\u00f3n estad\u00edstica (p < 0,05). El an\u00e1lisis estad\u00edstico se realiz\u00f3 con STATA-MP17.0\nRESULTADOS\nEl n\u00famero de ingresos hospitalarios por infecci\u00f3n por SARS-COV-2 durante el periodo de estudio fue 395. De ellos 60 \npacientes recibieron al menos una dosis de remdesivir, y 60 pacientes se seleccionaron aleatoriamente como control (1:1)  \nLa mediana de edad fue en los casos 76 a\u00f1os (RIC=18) y en los controles 78 a\u00f1os (RIC=28), p > |z|= 0,68. La proporci\u00f3n \nde varones en el grupo tratado fue 66,7% y en el grupo control 50% (p=0,064). La mediana del IC fue 6 (RIC:4) en el \ngrupo tratado y 5 (RIC:4) en el grupo control p > |z|=0.104. El IC en los casos result\u00f3 ser superior en las puntuaciones \nm\u00e1s altas 7-10 (46,66%) frente a los controles 7-10 (26,67%) (p < 0,05). El 85% de los casos presentaron un estado de \nvacunaci\u00f3n completo frente al 73,33% de los controles (p=0,116). La neumon\u00eda en el diagn\u00f3stico de infecci\u00f3n COVID-19 \nfue significativamente superior en los casos (71,67%) frente a los controles (41,67%), (p < 0,05). \nLa mediana de la estancia hospitalaria en el grupo tratado fue 11 d\u00edas (RIC=16,5) y 7 d\u00edas (RIC=8,5) en el grupo no tratado \ncon remdesivir \ufffd Se obtuvo un 21,67% de muertes en la poblaci\u00f3n tratada con remdesivir frente a un 18,33% en los no \ntratados (p=0,648).  \nEl an\u00e1lisis de regresi\u00f3n multivariante incluyendo las covariables significativas demostr\u00f3 que el tratamiento con remdesivir \nse asociaba con una prolongaci\u00f3n de la estancia hospitalaria OR 2.93 (IC 95% 1,43-5,97) as\u00ed como el \u00edndice Charlson OR \n1,34 (IC 95% 1,04-1,72). Respecto a la mortalidad intrahospitalaria, el an\u00e1lisis de regresi\u00f3n multivariante no demostr\u00f3 \nasociaci\u00f3n con el tratamiento con remdesivir OR 1,96 [IC 95% 0,82-4,68].\nCONCLUSIONES\nEn pacientes ingresados por infecci\u00f3n por SARS-COV-2 el tratamiento con remdesivir se asoci\u00f3 a un aumento de la \nestancia hospitalaria, sin embargo, no se encontraron diferencias en cuanto a mortalidad intrahospitalaria entre los \npacientes tratados con remdesivir y los no tratados\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n868. EFECTIVIDAD Y SEGURIDAD DEL USO OFF-LABEL DE DAPTOMICINA EN POBLACI\u00d3N NEONATAL: \nAN\u00c1LISIS DE SERIES DE CASOS \nAUTORES\nALONSO MORENO, M; MEJ\u00cdAS TRUEBA, M; GUISADO GIL, AB; HERRERA HIDALGO, L; GIL NAVARRO, MV; GUTIERREZ \nVALENCIA, A; JIMENEZ , F; GOYCOCHEA VALDIVIA, WA\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nEvaluar la efectividad y seguridad de daptomicina para el tratamiento de infecciones por estafilococos coagulasa \nnegativos (ECN) resistentes a meticilina en poblaci\u00f3n neonatal.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo y unic\u00e9ntrico, efectuado desde el 01/2019 al 12/2021 en la Unidad de Cuidados \nIntensivos Neonatales de un hospital de tercer nivel. Se incluyeron pacientes neonatos, en tratamiento con daptomicina \nintravenosa en monoterapia o tratamiento combinado, durante \u226572 horas de forma dirigida.  \nSe recogieron variables demogr\u00e1ficas (sexo, peso, edad), cl\u00ednicas y microbiol\u00f3gicas (enfermedad de base, tipo de \ninfecci\u00f3n, pat\u00f3geno), r\u00e9gimen posol\u00f3gico, tratamiento antibi\u00f3tico previo, dosis y motivo de cambio.  \nLa efectividad cl\u00ednica se evalu\u00f3 como la mejor\u00eda de los signos y s\u00edntomas de infecci\u00f3n (resoluci\u00f3n de la fiebre, \nnormalizaci\u00f3n de alteraciones cl\u00ednicas a su estado basal y reducci\u00f3n la prote\u00edna C (PCR) reactiva a par\u00e1metros normales); \ny la efectividad microbiol\u00f3gica, como la negativizaci\u00f3n del hemocultivo. Para evaluar la seguridad, se registraron los \nefectos adversos (EA).\nRESULTADOS\nSe incluyeron en el estudio 3 pacientes prematuros con sepsis por ECN quienes hab\u00edan recibido tratamiento previo con \nvancomicina con una dosis inicial de 10mg/kg/12h y posterior individualizaci\u00f3n seg\u00fan niveles plasm\u00e1ticos, alcanzando \nniveles objetivo (10-20mg/L). El cambio de tratamiento a daptomicina en todos ellos fue por inefectividad cl\u00ednica y \nmicrobiol\u00f3gica\ufffd \n \n- Paciente 1: var\u00f3n prematuro de 26 semanas de edad gestacional (EG) y 14 d\u00edas de vida con un peso de 748 gramos, \ndiagnosticado de sepsis nosocomial por Staphylococcus epidermidis relacionada a cat\u00e9ter central. Se realiza cambio de \nvancomicina tras 9 d\u00edas de tratamiento ineficaz. Se administra daptomicina 6mg/kg/12h durante 6 d\u00edas. Se confirma \nefectividad microbiol\u00f3gica a las 48 horas. El tratamiento es descontinuado al presentar el paciente eosinofilia y fiebre \nsin aumento de PCR, EA no confirmado su relaci\u00f3n con el f\u00e1rmaco. Completa tratamiento con linezolid alcanzando cura \ncl\u00ednica tras 16 d\u00edas.  \n \n- Paciente 2: mujer prematura de 28 semanas de EG y 7 d\u00edas de vida con un peso de 1,047 kg, diagnosticada de infecci\u00f3n \nrelacionada con cat\u00e9ter por Staphylococcus epidermidis. Se realiza cambio de vancomicina tras 10 d\u00edas de tratamiento \nineficaz. Se administra daptomicina 6mg/kg/12h durante 10 d\u00edas. Se consigue tanto efectividad microbiol\u00f3gica como \ncl\u00ednica a las 48 horas sin EA registrados.  427- Paciente 3: mujer prematura de 30 semanas de EG y 30 d\u00edas de vida con un peso de 1,526 kg, diagnosticada de \ntromboflebitis s\u00e9ptica por Staphylococcus hominis. Se realiza cambio de vancomicina tras 15 d\u00edas de tratamiento ineficaz. \nSe administra daptomicina 6mg/kg/12h durante 10 d\u00edas. Se consigue efectividad microbiol\u00f3gica a las 48 horas y cl\u00ednica a \nlas 72 horas sin EA registrados.\nCONCLUSIONES\nDaptomicina se postula como una opci\u00f3n terap\u00e9utica en neonatos que han fracasado al tratamiento con vancomicina \nen infecciones por ECN. Se precisan ensayos cl\u00ednicos aleatorizados en este grupo etario y recopilaci\u00f3n de su uso off-label \nen un mayor n\u00famero de pacientes, para definir la efectividad y seguridad as\u00ed como las dosis id\u00f3neas e intervalos de \nadministraci\u00f3n\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n881. IMPACTO DEL TRATAMIENTO CR\u00d3NICO CON F\u00c1RMACOS ANTI-CD20 EN LA EVOLUCI\u00d3N CL\u00cdNICA DE \nLOS PACIENTES CON INFECCION POR SARS-COV-2 \nAUTORES\nCARRASCO PIERNAVIEJA, L; HERRERA CARRANZA, S; TORO CHICO, P; SIERRA TORRES, G; S\u00c1NCHEZ CANO, JG; DE \nPABLO ESTEBAN, A; VELASCO ARRIBAS, M; P\u00c9REZ ENCINAS, M\nHOSPITAL UNIVERSITARIO FUNDACI\u00d3N ALCORC\u00d3N \ufffd BUDAPEST , 1 ALCORC\u00d3N \ufffd MADRID\nOBJETIVOS\nDescribir la incidencia y evoluci\u00f3n de la infecci\u00f3n por SARS-CoV-2 en pacientes en tratamiento con f\u00e1rmacos anti-CD20.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo que incluy\u00f3 todos los pacientes que recibieron al menos 1 dosis de f\u00e1rmacos \nanti-CD20 (rituximab/ocrelizumab) entre septiembre/2019-septiembre/2021 en un hospital terciario. El tiempo de \nseguimiento fue hasta marzo 2022. \nLas variables recogidas fueron: edad, sexo, factores de riesgo (hipertensi\u00f3n arterial(HTA), dislipemia(DL), diabetes \nmellitus(DM), obesidad, tabaquismo, s\u00edndrome de apnea obstructiva del sue\u00f1o(SAOS), CPAP basal, enfermedad \ncoronaria (EC), enfermedad renal cr\u00f3nica(ERC), enfermedad cerebro-vascular(ECV), enfermedad pulmonar obstructiva \ncr\u00f3nica(EPOC), hepatopat\u00eda cr\u00f3nica(HP) y neoplasia activa(NA)), vacunaci\u00f3n frente a SARS-CoV-2, f\u00e1rmaco anti-CD20, \ntratamientos concomitantes y servicio prescriptor \ufffd  \nSe consider\u00f3 COVID-19 confirmado a los pacientes que presentaron prueba antig\u00e9nica o PCR positiva. Se definieron \n5 grupos en funci\u00f3n de la gravedad (asintom\u00e1tica, leve, moderada, grave y cr\u00edtica). Se registr\u00f3 sintomatolog\u00eda, \ncomplicaciones (sobreinfecci\u00f3n bacteriana y s\u00edndrome de distr\u00e9s respiratorio del adulto (SDRA)), ingreso en Unidad de \nCuidados Cr\u00edticos (UCI), tratamientos espec\u00edficos para COVID-19, persistencia de infecci\u00f3n ( > 1 mes) y exitus.  \n \nPara la recogida de datos se consult\u00f3 la historia cl\u00ednica electr\u00f3nica y el m\u00f3dulo de pacientes ambulantes de farmacia y el \nan\u00e1lisis estad\u00edstico se realiz\u00f3 con SPSS\u00ae.\nRESULTADOS\nSe incluyeron 182 pacientes con una mediana edad de 65,8a\u00f1os (rango intercuart\u00edlico: 50,1-77,7), 51,1% mujeres. Los \nfactores de riesgo que presentaron son: 46,7% HTA, 40,7% DL, 29,7% NA, 20,9% ERC, 16,5% obesidad, 15,9% DM, < 10% \nSAOS, CPAP basal, EC, ECV, EPOC y HP \ufffd El 20,3% eran fumadores y el 7,2% exfumadores\ufffd  \nEl 82,5% recibieron rituximab, el 15,9% ocrelizumab y el 1,6% ambos. As\u00ed mismo, el 32,9% recib\u00eda tratamiento \nconcomitante con corticoides, inmunosupresores o ambos. Los servicios prescriptores fueron: hematolog\u00eda(37,9%), \nneurolog\u00eda(24,7%), nefrolog\u00eda(23,6%), reumatolog\u00eda(7,7%), medicina interna(3,9%) y dermatolog\u00eda(2,2%).  \nRespecto a la vacunaci\u00f3n, el 90,7%(165/182) recibieron al menos 1 dosis y, de estos, el 86,1%(142/165) recibieron 3 o \nm\u00e1s dosis. El 33,9% no seroconvirti\u00f3 tras la vacunaci\u00f3n, el 28,5% seroconvirti\u00f3 y en un 37,6% no se determin\u00f3 serolog\u00eda.  \nEl 24,7%(45/182) fue diagnosticado de COVID-19 con la siguiente distribuci\u00f3n de gravedad: 26,7% asintom\u00e1tico, \n20,0% leve, 11,1% moderada, 22,2% grave y 20% cr\u00edtico. El 80% recibi\u00f3 rituximab y el 20% ocrelizumab. Requirieron \ningreso aquellos que presentaron infecci\u00f3n moderada a cr\u00edtica (25/45), con infiltrados pulmonares en el 92% de los \npacientes. Las manifestaciones cl\u00ednicas m\u00e1s frecuentes fueron: tos(68%), disnea(56%), fiebre(52%), astenia(52%) y \nartromialgias(24%). El 28%(7/25) present\u00f3 sobreinfecci\u00f3n bacteriana, el 12,0%(3/25) SDRA y un 20,0%(5/25) requiri\u00f3 \ningreso en UCI. Los tratamientos espec\u00edficos empleados fueron: corticoides(68%), remdesivir(28%), tocilizumab(16%), \nplasma hiperinmune(16%), sotrovimab(12%) y otros (hidroxicloroquina/lopinavir/interferones) (24%). En el 15,5%(7/25) \nla viremia fue persistente. El 20%(5/25) de los pacientes fallecieron debido a la infecci\u00f3n por SARS-CoV-2.\nCONCLUSIONES\nEn nuestro estudio uno de cada cuatro pacientes tratados con anti-CD20 de forma cr\u00f3nica presentaron infecci\u00f3n \npor SARS-COV-2, con evoluci\u00f3n cl\u00ednica compleja, requiriendo ingreso en torno a la mitad de ellos y desarrollando \ncomplicaciones que requieren ingreso en UCI. Comparando con el informe n\u00ba127 de la situaci\u00f3n de COVID-19 en Espa\u00f1a \n(Instituto de Salud Carlos III), nuestro subgrupo presenta un mayor porcentaje de ingreso en UCI y una mayor letalidad \nque la poblaci\u00f3n general.428CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n914. TRATAMIENTO CON MOLNUPIRAVIR DE LA INFECCI\u00d3N POR SARS-COV2 EN PACIENTES \nINMUNODEPRIMIDOS \nAUTORES\nJUANBELTZ ZURBANO, R; SIGNES FORT , B; PINO RAMOS, A; MAGRO V\u00c1ZQUEZ, C; ERDOZAIN SANCLEMENTE, S; GO\u00d1I \nINDUR\u00c1IN, N; SAN MIGUEL ELCANO, R; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDescribir la experiencia de tratamiento de la infecci\u00f3n por SARS-CoV2 con el antiviral molnupiravir en pacientes \ninmunodeprimidos de alto riesgo\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo de los pacientes con PCR positiva para SARS-CoV2 que recibieron tratamiento con molnupiravir en \nuna Comunidad Aut\u00f3noma. En la historia cl\u00ednica informatizada se recogieron las comorbilidades, el estado de vacunaci\u00f3n \nfrente a SARS-CoV2, la sintomatolog\u00eda y Ct (tiempo de ciclado) asociada a la enfermedad COVID-19, los tratamientos \nespec\u00edficos recibidos frente a la misma, as\u00ed como tratamientos antimicrobianos frente a posibles co-infecciones. Se \ncompararon los par\u00e1metros cl\u00ednico-anal\u00edticos anteriores y posteriores al tratamiento con molnupiravir.\nRESULTADOS\nCinco pacientes (4 hematol\u00f3gicos y 1 trasplantado renal) recibieron tratamiento con molnupiravir entre los meses de \nmarzo y abril de 2022, con edades comprendidas entre 55-80 a\u00f1os (media=68), siendo el 60% (n=3) mujeres. Todos los \npacientes presentaban un estado de inmunosupresi\u00f3n, de origen humoral y/o relacionado con la quimioterapia (n=4) \ny secundario a ciclosporina (n=1). Las comorbilidades m\u00e1s prevalentes fueron insuficiencia renal (n=4), hipertensi\u00f3n \n(n=3) y diabetes mellitus tipo II (n=3). Los s\u00edntomas m\u00e1s frecuentes fueron fiebre (80%), tos y astenia (60%). Todos los \npacientes hab\u00edan recibido pauta completa de vacunaci\u00f3n, con anticuerpos post-vacunales negativos en cuatro casos, \ntratados con sotrovimab. Molnupiravir se inici\u00f3 m\u00e1s de dos meses despu\u00e9s del primer diagn\u00f3stico de COVID-19 en tres \npacientes, que hab\u00edan desarrollado neumon\u00eda tras episodios de reactivaci\u00f3n de la infecci\u00f3n, con reingresos hospitalarios, \ntratamiento con corticoides y remdesivir. Previo al inicio de molnupiravir el rango de Ct era 10,87-17,38. El f\u00e1rmaco fue \nbien tolerado con un \u00fanico caso de diarrea como efecto adverso, sin observarse alteraciones anal\u00edticas tras el inicio del \nantiviral. La evoluci\u00f3n cl\u00ednica de los pacientes fue variable, siendo favorable en los dos casos tratados ambulatoriamente. \nSin embargo, dos pacientes fallecieron con complicaciones durante el ingreso, colitis y probable neumonitis por \nreactivaci\u00f3n de citomegalovirus y Aspergillus fumigatus, y otro caso por progresi\u00f3n de amiloidosis primaria y reactivaci\u00f3n \nde una coinfecci\u00f3n de Mycobacterium abscessus. El quinto paciente se encuentra ingresado en la actualidad, habiendo \ndesarrollado fibrosis pulmonar y probable neumon\u00eda organizativa como complicaci\u00f3n de la COVID-19.\nCONCLUSIONES\nLa fase viral de la infecci\u00f3n por SARS-CoV2 en pacientes inmunodeprimidos es m\u00e1s prolongada que en el paciente \nno inmunocomprometido, por lo que el empleo de antivirales a largo plazo parece justificado en estos casos. Las \ncomplicaciones asociadas a la enfermedad de base comprometieron el pron\u00f3stico de la COVID-19, si bien el tratamiento \ncon molnupiravir fue seguro. La realizaci\u00f3n de ensayos cl\u00ednicos comparativos entre diferentes antivirales contribuir\u00eda a \noptimizar el tratamiento en estos pacientes de alto riesgo.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n932. APLICACI\u00d3N DE UN PROTOCOLO DE ADMINISTRACI\u00d3N DE ANTIBI\u00d3TICOS \u0392-LACT\u00c1MICOS EN \nPACIENTES AL\u00c9RGICOS \nAUTORES\nFUERTES CAMPORRO, S; GANDARA ANDE, A; F\u00d3RNEAS SANGIL, A; APARICIO CARRE\u00d1O, C; MARTINEZ-MUJICA \nBARBOSA, C; FERN\u00c1NDEZ GONZ\u00c1LEZ, A; PAMP\u00cdN S\u00c1NCHEZ, R; MODRO\u00d1O RIA\u00d1O, G\nHOSPITAL DE CABUE\u00d1ES. LOS PRADOS, 395 GIJ\u00d3N. ASTURIAS\nOBJETIVOS\nConocer los resultados tras la puesta en marcha de un protocolo de administraci\u00f3n de antibi\u00f3ticos \u03b2-lact\u00e1micos en \npacientes con alertas de alergia a \u03b2-lact\u00e1micos en la historia digital.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, retrospectivo, de la administraci\u00f3n de antibi\u00f3ticos \u03b2-lact\u00e1micos en pacientes al\u00e9rgicos, \nsiguiendo el protocolo implantado en un hospital de tercer nivel entre Junio de 2020 y Mayo de2022. \nDe acuerdo con las recomendaciones, realiza en primer lugar pruebas cut\u00e1neas (prick-test e intradermorreacci\u00f3n) y \nposteriormente prueba de exposici\u00f3n controlada (3 bolsas de concentraci\u00f3n creciente). Si el paciente es positivo en \ncualquiera de las pruebas cut\u00e1neas o en la exposici\u00f3n controlada, se procede a la desensibilizaci\u00f3n (8-12 pasos con \nconcentraciones crecientes de antibi\u00f3tico).  \nSe recogen las siguientes variables independientes: edad, sexo, antibi\u00f3tico solicitado, alergia confirmada, y en caso \ncontrario motivo de sospecha de alergia. Como variables dependientes: resultados de prick-test, intradermorreacci\u00f3n y \nexposici\u00f3n controlada, desensibilizaciones hechas y su resultado.429RESULTADOS\nSe localizaron 25 pacientes, 3 fueron descartados por imposibilidad de acceder a su historia digital (resultados de pruebas \ncut\u00e1neas y exposici\u00f3n controlada negativos) y se descart\u00f3 un paciente con alerta de alergia al que se le administr\u00f3 \nmeropenem sin aplicar el protocolo (sin ninguna incidencia). Se incluyeron 21 pacientes a los que se les aplic\u00f3 el \nprotocolo, tratados con Ceftarolina (1), Ceftriaxona (1), Ertapenem (4), Meropenem (14) y Piperacilina/tazobactam (1).  \nLa mediana de edad fue de 74 a\u00f1os [36-88] y 12 de ellos fueron mujeres. La distribuci\u00f3n temporal de los casos fue en \naumento (2020: n=2, 2021: n=5, 2022 n=14).  \nLa descripci\u00f3n m\u00e1s frecuente de la alergia fue \u201cpenicilinas sensibles penicilinasa\u201d (7).  \nEn cuanto a la confirmaci\u00f3n de las alergias, 1 paciente ten\u00eda pruebas cut\u00e1neas confirmatorias; 8 pacientes refer\u00edan \nsintomatolog\u00eda asociada al tratamiento (edemas, angioedema, alteraciones dermatol\u00f3gicas, disnea, v\u00f3mitos); 12 \npacientes sin informaci\u00f3n en su historia cl\u00ednica que justifique la alerta de alergia.  \nLos 20 pacientes a los que se les hicieron pruebas cut\u00e1neas obtuvieron resultado negativo en la prueba prick-test, uno \nde ellos result\u00f3 positivo en la intradermorreacci\u00f3n. Se realizaron 19 pruebas de exposici\u00f3n controlada, 18 pacientes \ncompletaron las tres bolsas sin incidencias y uno tuvo un episodio de hipotensi\u00f3n que hizo que se detuviera la \nadministraci\u00f3n y se descartara usar ese antibi\u00f3tico. Se realizaron dos desensibilizaciones, una para el paciente con \npruebas confirmatorias y otra como consecuencia del resultado positivo en la intradermorreacci\u00f3n. En ambos casos se \ncomplet\u00f3 el procedimiento sin incidencias\ufffd\nCONCLUSIONES\nLa puesta en marcha del protocolo nos ha permitido confirmar que las alertas de alergias recogidas en la historia \ncl\u00ednica condicionan la elecci\u00f3n del tratamiento m\u00e1s adecuado y en la mayor\u00eda de los casos no existe una confirmaci\u00f3n \ndiagn\u00f3stica de alergia (1 caso confirmado de 21 en este estudio). Una alerta no confirmada puede condicionar la curaci\u00f3n \ndel paciente. Por ello, es necesario disponer de un diagn\u00f3stico inequ\u00edvoco de alergia a antibi\u00f3ticos y de un procedimiento \npor el que se modifique la alerta con los resultados de las pruebas de alergia realizadas.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n979. MANEJO DE TUBERCULOSIS MULTIRESISTENTE: A PROP\u00d3SITO DE UN CASO \nAUTORES\nDE MIGUEL GAZTELU, M; PRECIADO GOLDARACENA, J; GO\u00d1I INDURAIN, N; NOVAJARQUE SALA, L; ELIZONDO \nARMENDARIZ, J; DE LA RIVA BOHIGAS, R; PINO RAMOS, A; ERDOZAIN SANCLEMENTE, S\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDescribir un caso de tuberculosis multirresistente (MDR) y su tratamiento\nMATERIALES Y M\u00c9TODOS\nSe trata de un paciente de 29 a\u00f1os, natural de Marruecos, que ingresa por invaginaci\u00f3n intestinal, objetiv\u00e1ndose en \nradiograf\u00eda torax infiltrado cavitado en l\u00f3bulo superior izquierdo por lo que se solicita baciloscopia de esputo. Se aisla \nMycobacterium tuberculosis, con resistencia a dos f\u00e1rmacos de primera l\u00ednea (isoniacida y rifampicina) y es considerado \nun caso de tuberculosis extremadamente resistente. Adem\u00e1s, presenta resistencia a quinolonas y linezolid.\nRESULTADOS\nEl tratamiento de primera l\u00ednea de la MDR, seg\u00fan las recomendaciones de la Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda \nTor\u00e1cica (SEPAR) y la OMS vigentes, debe dar prioridad a pautas orales acortadas (9 meses) que incluyan bedaquilina \ndurante los seis primeros, junto con fluoquinolonas, linezolid y clofazimina, en lugar de otros esquemas que son menos \neficaces, m\u00e1s t\u00f3xicos y m\u00e1s prolongados.  \nTras consultar con experto de referencia a nivel nacional e internacional se solicita a farmacia el siguiente tratamiento: \nBedaquilina: 4 comprimidos diarios, en una sola toma matutina, 14 d\u00edas. Despu\u00e9s, reducir a 2 comprimidos tres d\u00edas por \nsemana; Delamanid 50 mg: dos comprimidos cada 12 horas; Cicloserina 250 mg: 3 comprimidos/d\u00eda; Protionamida 250 \nmg: 3 comprimidos/d\u00eda y Clofazimina: 100 mg/d\u00eda. Adem\u00e1s, se asocia meropenem 1,5 gramos cada 12 horas.  \nDesde el servicio de farmacia, se tramitan Bedaquilina, Cicloserina, Clofazimina y Protionamida como medicaci\u00f3n \nextranjera. Bedaquilina, adem\u00e1s, tiene resoluci\u00f3n de no financiaci\u00f3n, por lo que se solicita a la Agencia Espa\u00f1ola del \nMedicamento la excepcionalidad del caso al ser un bacil\u00edfero potencial y suponer un problema de salud p\u00fablica. Adem\u00e1s, \nse solicita la conformidad de la Subdirecci\u00f3n de Farmacia y Prestaciones que por motivos de salud p\u00fablica lo autorizan.  \nClofacilina es un medicamento esencial de la OMS para lupus por lo que se manda un informe al laboratorio para su \nconformidad, que autorizan.  \nDelamanid est\u00e1 incluido en el registro del plan de gesti\u00f3n de riesgos.  \nTras dos meses de tratamiento, la baciloscopia es negativa y el cultivo del lavado broncoalveolar (BAL) es negativo.  \nEl tratamiento es bien tolerado excepto por elevaci\u00f3n de los niveles de transaminasas hasta valores de alanina transferasa \n(ALT) superiores a 500 UI/L. Dada la buena evoluci\u00f3n cl\u00ednica y tras consultar con el experto de referencia, se recomienda \nla suspensi\u00f3n del tratamiento completo durante 5-14 d\u00edas hasta valores inferiores de ALT de 80 UI/L. El f\u00e1rmaco m\u00e1s \nprobable de causar esta hepatitis es protionamida.  \nUna vez que los valores de las enzimas hep\u00e1ticas est\u00e9n en rango terap\u00e9utico, la recomendaci\u00f3n es iniciar levofloxacino, \ncicloserina y clofazimina. A los 3 d\u00edas, repetir anal\u00edtica y reiniciar bedaquilina y delamanid.430CONCLUSIONES\nA pesar de que las resistencias en TB complican el tratamiento, siguiendo las recomendaciones se pueden conseguir tasas \naceptables de curaci\u00f3n en la gran mayor\u00eda de los enfermos. \nLos esquemas de tratamiento, requieren la colaboraci\u00f3n farmac\u00e9utica tanto en la adquisici\u00f3n de f\u00e1rmacos como en la \nrevisi\u00f3n de las pautas\ufffd  \nLa prioridad principal seguir\u00e1 siendo dar tratamiento adecuado a todos los pacientes con TB sensible y conseguir una \nbuena adherencia para evitar el desarrollo de resistencias.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n987. BITERAPIA EN EL PACIENTE NA\u00cfVE: ESTUDIO DE EFECTIVIDAD DE LA COMBINACI\u00d3N DOLUTEGRAVIR-\nLAMIVUDINA \nAUTORES\nESCARIO G\u00d3MEZ, M; GARC\u00cdA L\u00d3PEZ, L; JIMENEZ NACHER, I; HOYO MU\u00d1OZ, A; AYLLON MORALES, M; COLLADA \nSANCHEZ, VL; GARCIA-TREVIJANO CABETAS, M; HERRERO AMBROSIO, A\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nEl tratamiento del VIH ha experimentado importantes cambios en los \u00faltimos a\u00f1os. La publicaci\u00f3n de los estudios GEMINI \nen noviembre de 2018 supuso un importante cambio en el manejo del paciente naive, al demostrar la no-inferioridad de \nla combinaci\u00f3n dolutegravir (DTG) + lamivudina (3TC) con respecto a la triple terapia con DTG + 3TC + tenofovir disoproxil \nfumarato. Por primera vez una combinaci\u00f3n de dos f\u00e1rmacos se convirti\u00f3 en un est\u00e1ndar de tratamiento. El objetivo del \npresente estudio es evaluar la eficacia de la doble terapia con DTG+3TC en la pr\u00e1ctica cl\u00ednica real, con datos a 48 semanas.\nMATERIALES Y M\u00c9TODOS\nSe incluyeron todos los pacientes que iniciaron tratamiento antirretroviral (TAR) entre enero del 2019 y diciembre del \n2020. Se recogieron los siguientes datos demogr\u00e1ficos y caracter\u00edsticas basales: edad, sexo, fecha de diagn\u00f3stico, fecha de \ninicio de tratamiento, TAR inicial, TAR en la semana 48, estadio de la enfermedad, recuento de CD4 y carga viral (CV) en la \nvisita de inicio y en las sucesivas visitas de seguimiento, hasta la semana 48.\nRESULTADOS\nDe los 108 pacientes que iniciaron TAR, 37 (34,25%) lo hicieron con doble terapia, todos con la combinaci\u00f3n DTG+3TC. \nHubo una p\u00e9rdida de seguimiento. De los 36 pacientes en tratamiento con DTG+3TC que completaron el seguimiento, el \n91,7% (33/36) continuaban con el mismo tratamiento en la semana 48. Los motivos de cambio de TAR de los 3 pacientes \nrestantes fueron los siguientes: uno fue incluido en un ensayo cl\u00ednico y dos cambiaron a otra combinaci\u00f3n de f\u00e1rmacos \n(uno por intolerancia a DTG, y otro por diagn\u00f3stico posterior de tuberculosis).  \nEn la semana 48, el 96,96% (32/33) de los pacientes que continuaron con el TAR inicial manten\u00edan una CV < 50, y de estos, \nel 87,5% (28/32) una CV < 20. Solo se observ\u00f3 un paciente que no alcanz\u00f3 respuesta virol\u00f3gica, definida como CV > 50 en \nla semana 48. De los pacientes para los cuales se dispon\u00eda de CV en la semana 4, la mayor\u00eda presentaba una CV < 50. Del \nsubgrupo de pacientes con CV basal > 100000 copias/mL, la mayor\u00eda (87,5%) manten\u00eda una CV < 50 en la semana 48.  \nEstos resultados muestran que la efectividad de la doble terapia con DTG+3TC es comparable a la observada en los \nestudios pivotales (GEMINI-1 y GEMINI-2). En los ensayos cl\u00ednicos, la proporci\u00f3n de pacientes del grupo de DTG+3TC \ncon CV < 50 en la semana 48 (variable principal) fue del 92%, y en nuestro estudio, esa proporci\u00f3n alcanz\u00f3 un 96,7%. \nLa proporci\u00f3n de pacientes con CV < 50 en la semana 4 tambi\u00e9n fue superior en nuestro estudio (87,5% vs 70%). Cabe \ndestacar que en nuestro estudio, no se incluyeron pacientes con un recuento de linfocitos CD4 < 200, en los cuales se \nobserv\u00f3 menor eficacia en los estudios GEMINI. Por su parte, y en l\u00ednea con lo observado en los ensayos cl\u00ednicos, la \neficacia se mantiene en el subgrupo de pacientes con CV > 100000 copias/mL.\nCONCLUSIONES\nLa doble terapia con DTG+3TC es una alternativa con alta eficacia en el tratamiento del VIH en pacientes na\u00efve, \ncomparable a la observada en los ensayos cl\u00ednicos.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1001. AN\u00c1LISIS COMPARATIVO DE LAS BITERAPIAS BASADAS EN DOLUTEGRAVIR EN PACIENTES QUE \nVIVEN CON INFECCI\u00d3N POR VIH EN PR\u00c1CTICA CLINICA REAL \nAUTORES\nLAO DOM\u00cdNGUEZ, F\u00c1; GARC\u00cdA LLORET , P; CONTRERAS MAC\u00cdAS, E; MONTES AND\u00daJAR, M; ROLD\u00c1N GALNARES, M; \nMORILLO VERDUGO, R\nHOSPITAL NUESTRA SE\u00d1ORA DE VALME. CTRA. C\u00c1DIZ-BELLAVISTA, KM. 548,9 SEVILLA. SEVILLA\nOBJETIVOS\nAnalizar la persistencia y las causas de discontinuaci\u00f3n del tratamiento antirretroviral basado en biterapias que incluyen \ndolutegravir en pacientes que viven con infecci\u00f3n por VIH en una cohorte de un hospital general de especialidades.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y unic\u00e9ntrico en el que se incluyeron todos los pacientes que iniciaron tratamiento \ncon alguna de las biterapias disponibles (dolutegravir+lamivudina o dolutegravir+rilpivirina) y acudieron a consulta 431de farmacia de un hospital de especialidades hasta el 15 de abril de 2022. Los criterios de exclusi\u00f3n fueron: pacientes \nmenores de 18 a\u00f1os y pacientes incluidos en ensayos cl\u00ednicos durante el periodo de an\u00e1lisis.  \nSe recogieron variables demogr\u00e1ficas: edad, sexo y farmacoterap\u00e9uticas: fecha de inicio y fin de tratamiento con biterapia \ny causa de discontinuaci\u00f3n. Se analiz\u00f3 la persistencia con dolutegravir+lamivudina o dolutegravir+rilpivirina a las 24, 48 y \n72 semanas desde el inicio de tratamiento (datos detallados de manera acumulada).  \nLa persistencia se calcul\u00f3 mediante la prueba t dependiente para muestras apareadas curvas de supervivencia por el \nm\u00e9todo de Kaplan-Meier y la significancia estad\u00edstica por la prueba Log-Rank, mediante el programa IBM SPSS\u00ae v.25.\nRESULTADOS\nSe incluyeron un total de 267 pacientes (190 en tratamiento con dolutegravir+lamivudina y 77 con \ndolutegravir+rilpivirina). La edad mediana de los pacientes fue 53 a\u00f1os (RIQ: 44-58), siendo el 85,4% hombres (n=228). \nLa duraci\u00f3n mediana de tratamiento para dolutegravir+lamivudina fue de 91 semanas (RIQ: 75-99) mientras que con \ndolutegravir+rilpivirina fue de 120 semanas (RIQ: 82-144).  \nEl porcentaje de discontinuaci\u00f3n de dolutegravir+lamivudina y dolutegravir+rilpivirina fue del 1,6% vs 3,9% \nrespectivamente en la semana 24 (p=0,265); 2,2% vs 3,9% en la semana 48 (p=0,254) y 3,0% vs 8,1% en la semana 72 \n(p=0,253). A fecha de fin de seguimiento continuaban tratamiento con dolutegravir+lamivudina 180 pacientes (94,7%) \ny con dolutegravir+rilpirivirina 70 pacientes (90,9%); se perdi\u00f3 seguimiento de 5 vs 1 pacientes y 26 vs 3 pacientes no \nhab\u00edan alcanzado la semana 72 de tratamiento, respectivamente. \nEl tiempo medio hasta la discontinuaci\u00f3n fue 36,2\u00b10,9 semanas (24,3\u00b10,5 vs 35,9\u00b11,2 para dolutegravir+lamivudina y \ndolutegravir+rilpivirina, respectivamente). No se encontraron diferencias estad\u00edsticamente significativas en el tiempo \nhasta la discontinuaci\u00f3n a las 24 (p=0,375), 48 (p=0,626) y a las 72 semanas (p=0,262).  \nEntre los pacientes que discontinuaron tratamiento con dolutegravir+rilpivirina (n=8), las causas fueron: 37,5% (n=3) \npor optimizaci\u00f3n, 25% (n=2) por reacci\u00f3n adversa, 25% (n=2) por exitus y 12,5% (n=1) por fallo virol\u00f3gico. En el caso de \ndolutegravir+lamivudina (n=6), las causas de discontinuaci\u00f3n fueron: 50,0% por fallo virol\u00f3gico (n=3), 33,3% por reacci\u00f3n \nadversa (n=2) y 16,7% por exitus (n=1).\nCONCLUSIONES\nNo se observaron diferencias significativas en la persistencia de los reg\u00edmenes antirretrovirales de biterapias basados \nen dolutegravir a lo largo del tiempo. El fallo virol\u00f3gico y la optimizaci\u00f3n fueron las causas de discontinuaci\u00f3n m\u00e1s \nprevalentes para dolutegravir-lamivudina y dolutegravir-rilpivirina respectivamente en la poblaci\u00f3n de estudio.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1003. EFECTIVIDAD Y SEGURIDAD DE LA BITERAPIA CON DOLUTEGRAVIR/LAMIVUDINA EN PACIENTES \nCON VIH PRETRATADOS, VIROL\u00d3GICAMENTE SUPRIMIDOS \nAUTORES\nMART\u00cdN CARRO, C; GARC\u00cdA LASTRA, S; CRESPO RODR\u00cdGUEZ, E; P\u00c9REZ DOM\u00cdNGUEZ, N; PLANO S\u00c1NCHEZ, AI; ZAPICO \nGARC\u00cdA, I; GONZ\u00c1LEZ S\u00c1NCHEZ, N; BECERRA INGERTO, L\nHOSPITAL SAN AGUST\u00cdN \ufffd CAMINO DE HEROS, 6 AVIL\u00c9S \ufffd ASTURIAS\nOBJETIVOS\nEvaluar la efectividad y seguridad del cambio a biterapia con dolutegravir (DTG)/lamivudina (3TC) en pacientes con VIH \npretratados, virol\u00f3gicamente suprimidos (carga viral plasm\u00e1tica (CVP) < 50 copias/mL).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, prospectivo, que incluy\u00f3 todos los pacientes con VIH que cambiaron de tratamiento antirretroviral \n(TAR) basado en tres o m\u00e1s principios activos a biterapia con DTG/3TC entre julio de 2020 y enero de 2022, en nuestro \ncentro. Todos los pacientes seleccionados para realizar el cambio presentaban buena adherencia al TAR y CVP suprimida \ndurante al menos 6 meses\ufffd \nSe revis\u00f3 la historia cl\u00ednica y se recogieron las variables: sexo, edad, tiempo desde el diagn\u00f3stico, tiempo en TAR, nadir de \nlinfocitos CD4, TAR previos y motivo de cambio; CVP , CD4 y niveles plasm\u00e1ticos de colesterol-LDL (cLDL) y creatinina (Crp) \nprevios al cambio y tras 12, 24 y 48 semanas; reacciones adversas y suspensi\u00f3n de tratamiento en cualquier momento del \nestudio\ufffd  \nLas variables para evaluar la efectividad fueron: %pacientes con CVP < 50 copias/mL, %pacientes con repunte virol\u00f3gico \n(RV) y variaci\u00f3n de CD4 (c\u00e9lulas/\u03bcL) respecto al valor basal. La efectividad se defini\u00f3 como mantenimiento de la supresi\u00f3n \nvirol\u00f3gica\ufffd \nLas variables para evaluar la seguridad fueron: variaci\u00f3n de cLDL (mg/dL) y Crp (mg/dL) respecto al valor basal, reacciones \nadversas y suspensi\u00f3n de tratamiento\ufffd  \nLas variables cuantitativas se expresaron como media (\u00b1 desviaci\u00f3n est\u00e1ndar) o mediana [rango intercuart\u00edlico] seg\u00fan \nsiguieran una distribuci\u00f3n normal o no normal, respectivamente. Los datos se analizaron utilizando el software estad\u00edstico \nR\u00ae\ufffd\nRESULTADOS\nSe incluyeron 48 pacientes con las siguientes caracter\u00edsticas: 70,83% varones, 49,52 (\u00b113,27) a\u00f1os de edad, 13 [5,50-\n23,50] a\u00f1os desde el diagn\u00f3stico, 11 [4-20,50] a\u00f1os en TAR, nadir de CD4 de 281 [197-373] c\u00e9lulas/\u03bcL y 2 [1-4] l\u00edneas \nde tratamiento previas. El 62,50% de los pacientes recib\u00eda TAR con 1 inhibidor de la integrasa (INI)+2 inhibidores de la \ntranscriptasa inversa an\u00e1logos de nucle\u00f3sidos (ITIAN). En el 91,67% de los casos el cambio fue proactivo y los motivos \nfueron: simplificaci\u00f3n (75%), toxicidad (10,42%), comorbilidades (8,33%) e interacciones (8,33%). Los valores basales de 432CD4, cLDL y Crp fueron 747,50 [567,50-1025,25], 109,53 (\u00b133,43) y 0,98 (\u00b10,17), respectivamente. \nTras 48 semanas de tratamiento (n=42) el 95,5% de los pacientes presentaba CVP < 50 copias/mL.  \nDos pacientes presentaron \u201cblip\u201d aislado (CVP 50-1000 copias/mL, con valor previo y posterior < 50 copias/mL). Otros dos \npacientes tuvieron RV que motiv\u00f3 la suspensi\u00f3n de la biterapia, retomando el TAR previo.  \nEl recuento de CD4 tras 12, 24 y 48 semanas fue 814,50 [567,50-1086,50], 767 [599-1058] y 806 [658-1221], \nrespectivamente. No se observaron diferencias estad\u00edsticamente significativas (p > 0,05).  \nEl cLDL tras 12, 24 y 48 semanas fue 112,63 (\u00b133,40), 105,78 (\u00b135,60) y 107,61 (\u00b132,60), respectivamente, y la Crp 1 (\u00b10,19), \n0,99 (\u00b10,16) y 1,02 (\u00b10,14). No se observaron diferencias estad\u00edsticamente significativas (p > 0,05).  \nDos pacientes sufrieron reacci\u00f3n adversa (exantema pruriginoso; cefalea, mareo, palpitaciones) que motiv\u00f3 la suspensi\u00f3n \ndel tratamiento\ufffd\nCONCLUSIONES\nLa simplificaci\u00f3n del TAR a biterapia con DTG/3TC parece una estrategia efectiva y segura en pacientes con VIH \npretratados, virol\u00f3gicamente suprimidos. No obstante, ser\u00eda conveniente realizar estudios con mayor tama\u00f1o muestral y \nmayor tiempo de seguimiento.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1026. AN\u00c1LISIS GLOBAL Y POR SUBGRUPOS DE LA EFECTIVIDAD Y SEGURIDAD DE BEZLOTOXUMAB \nAUTORES\nFERN\u00c1NDEZ RUBIO, B; CIUDAD GUTI\u00c9RREZ, P; GUISADO GIL, AB; HERRERA HIDALGO, L; MOLINA GIL-BERMEJO, J; \nRODR\u00cdGUEZ HERN\u00c1NDEZ, MJ; GIL NAVARRO, MV\nCOMPLEJO HOSPITALARIO REGIONAL VIRGEN DEL ROC\u00cdO. AV . MANUEL SIUROT , S/N SEVILLA. SEVILLA\nOBJETIVOS\nAnalizar la efectividad y seguridad de bezlotoxumab, indicado para la prevenci\u00f3n de la recurrencia de la infecci\u00f3n por \nClostridioides difficile (ICD) en adultos, estratificando los resultados seg\u00fan los subgrupos analizados en los ensayos \ncl\u00ednicos pivotales que dieron lugar a la aprobaci\u00f3n del anticuerpo monoclonal.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo que incluy\u00f3 a todos los pacientes tratados con bezlotoxumab en un hospital de \ntercer nivel hasta febrero de 2022. \nCaracter\u00edsticas basales recogidas: sexo, edad, factores de riesgo para la recurrencia de la ICD (edad \u2265 65 a\u00f1os, episodios \nprevios de ICD, inmunosupresi\u00f3n y criterios de ICD severa seg\u00fan la puntuaci\u00f3n de ZAR) y f\u00e1rmaco empleado para tratar el \nbrote de ICD \ufffd \nComo variable de efectividad se recogi\u00f3 la proporci\u00f3n de pacientes con cura cl\u00ednica sostenida (CCS), definida como la cura \ncl\u00ednica inicial junto con la no recurrencia a lo largo de 12 semanas de seguimiento. La variable de efectividad se estratific\u00f3 \nen diferentes subgrupos (edad \u2265 65 a\u00f1os, episodios previos de ICD en los \u00faltimos 6 meses, inmunosupresi\u00f3n, criterios de \nICD severa seg\u00fan la puntuaci\u00f3n de ZAR y f\u00e1rmaco empleado para tratar la ICD).  \nLa variable de seguridad fue el n\u00famero de eventos adversos sufridos durante las 24 horas posteriores a la infusi\u00f3n de \nbezlotoxumab.  \nLos datos se recogieron de la historia cl\u00ednica y farmacoterap\u00e9utica (Diraya\u00ae) y del m\u00f3dulo de prescripci\u00f3n electr\u00f3nica \nintrahospitalaria (Athos\u00ae prisma).\nRESULTADOS\n41 pacientes incluidos (66,7% mujeres), mediana de edad 61 (16-88) a\u00f1os.  \n \nEl 41,5% de los pacientes ten\u00edan \u2265 65 a\u00f1os, el 31,7% tuvo al menos un episodio de ICD en los 6 meses previos, y el 4,8% al \nmenos 2 episodios de ICD en alg\u00fan momento. El 73,2% de los pacientes eran inmunodeprimidos. El 68,3% ten\u00eda criterios \nde ICD severa. El 75,6% de los pacientes utiliz\u00f3 vancomicina en monoterapia para tratar el brote, el 17% vancomicina junto \na metronidazol, el 4,9% fidaxomicina y el 2,5% metronidazol. Con esta terapia, el 73,2% de los pacientes alcanzaron la \ncura cl\u00ednica del episodio de ICD, mientras que el 26,8% requirieron otras terapias para alcanzar la curaci\u00f3n inicial (19,5% \nfidaxomicina, 2,4% vancomicina y 4,9% trasplante fecal).  \nLa CCS se alcanz\u00f3 en el 68,2% de los pacientes. Por subgrupos, la CCS la lograron el 75% de los pacientes con edad \u2265 65 \na\u00f1os, el 69,2% con episodios de ICD en los \u00faltimos 6 meses, el 75% de pacientes con inmunosupresi\u00f3n y el 61,9% con \ncriterios de ICD severa. Seg\u00fan el f\u00e1rmaco empleado para tratar la ICD, la CCS fue alcanzada en el 77,4% de pacientes \ntratados con vancomicina en monoterapia, el 100% de los tratados con vancomicina y metronidazol, el 100% de los \ntratados con fidaxomicina y el 57,1% de los que recibieron metronidazol en monoterapia.  \nEn t\u00e9rminos de seguridad, no se registraron eventos adversos.\nCONCLUSIONES\nBezlotoxumab ha demostrado ser un f\u00e1rmaco efectivo y seguro en nuestra cohorte de pacientes. Sin embargo, el an\u00e1lisis \nde subgrupos parece indicar que los pacientes con episodios recientes de ICD, con criterios de gravedad y tratados \nexclusivamente con metronidazol se benefician en menor medida del anticuerpo monoclonal.433CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1072. TRATAMIENTO EMP\u00cdRICO EN PACIENTES CON NEUMON\u00cdA EN EL SERVICIO DE URGENCIAS: \nADECUACI\u00d3N A LAS GU\u00cdAS DE TERAP\u00c9UTICA ANTIMICROBIANA \nAUTORES\nFERN\u00c1NDEZ-VILLACA\u00d1AS FERN\u00c1NDEZ, P; ORTIZ FERN\u00c1NDEZ, P; MART\u00cdNEZ SOTO, AM; PASTOR MOND\u00c9JAR, C; \nCABALLERO REQUEJO, C; ALEGR\u00cdA SAMPER, R; URBIETA SANZ, E\nHOSPITAL GENERAL UNIVERSITARIO REINA SOFIA. AV . INTENDENTE JORGE PALACIOS, 1 MURCIA. MURCIA\nOBJETIVOS\nLa Neumon\u00eda Adquirida en la Comunidad (NAC) es una de las principales causas de ingreso hospitalario a trav\u00e9s de los \nServicios de Urgencias (SU), cuyo abordaje es se basa en el inicio precoz de tratamiento antimicrobiano (TA) de forma \nemp\u00edrica. El objetivo de nuestro estudio fue evaluar la adecuaci\u00f3n del TA prescrito en el SU a la Gu\u00eda de Terap\u00e9utica \nAntimicrobiana (GTA).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital de referencia de \u00e1rea que atiende a una poblaci\u00f3n de \n200.000 habitantes, entre los meses de octubre a diciembre de 2021. Se incluyeron todos los pacientes que ingresaron a \ntrav\u00e9s del SU con diagn\u00f3stico de neumon\u00eda producida por un organismo no especificado (J18) del C\u00f3digo Internacional de \nEnfermedades 10\u00aa Revisi\u00f3n (CIE-10-ES), y con prescripci\u00f3n de TA. Los datos se extrajeron del Conjunto M\u00ednimo B\u00e1sico de \nDatos (CMBD), del programa de historia cl\u00ednica y del programa de prescripci\u00f3n electr\u00f3nica.  \nLa variable principal del estudio fue la adecuaci\u00f3n a la GTA del tratamiento prescrito en el SU \ufffd Ser recogieron asimismo \nvariables: sociodemogr\u00e1ficas (sexo y edad), cl\u00ednicas (gravedad de la NAC (seg\u00fan estala PSI o CURB-65), antimicrobianos \nprescritos, comorbilidades, factores de riesgo de infecci\u00f3n por SARM y/o Pseudomonas). Para comprobar la asociaci\u00f3n \nentre las variables categ\u00f3ricas, se utiliz\u00f3 el estad\u00edstico Chi-cuadrado de Pearson, con el paquete estad\u00edstico SPSS\u00ae.\nRESULTADOS\nSe incluyeron 149 pacientes, siendo el 52,3% hombres, con una media de edad de 72,5 \u00b125,2 a\u00f1os. El 72,5% ten\u00eda m\u00e1s de \n65 a\u00f1os, y el 84,6% presentaba alguna comorbilidad. La gravedad de la neumon\u00eda fue clasificada como moderada (clase \nIII-IV escala PSI o CURB-65\u22652) en el 90,6% de los casos. El 29,5% ten\u00edan factores de riesgo para Pseudomonas y el 1,3% \npara SARM\ufffd \nEl antibi\u00f3tico m\u00e1s prescrito fue ceftriaxona (35,2% de las prescripciones), seguido de azitromicina (26,5%) y levofloxacino \n(13,1%). \nLa adecuaci\u00f3n del TA a la GTA fue del 46,3% (69 de los 149 pacientes). La principal causa de no adecuaci\u00f3n fue la \nprescripci\u00f3n incompleta (58,75%), seguido de TA no recogida en la GTA (20%) y uso de TA de espectro mayor del \nnecesario (13,8%). Se adecuan m\u00e1s a la GTA los pacientes con neumon\u00eda moderada (95,7% vs 86,3%; p=0,05) que \naquellos que presentan neumon\u00eda leve (2,9% vs 6.3%; p > 0,05) o grave (1,4% vs 7,5%; p > 0,05). Los pacientes con \ncomorbilidades se adecuan menos a la GTA (78,3% vs 90,0%; p < 0,05), al igual que los que presentan factores de riesgo \nfrente a P . aeruginosa (7,2% vs 48,8%; p < 0,05).\nCONCLUSIONES\nLos resultados de nuestro estudio ponen de manifiesto una baja adherencia a la GTA vigente en el centro. Las NAC fueron \nm\u00e1s frecuentes en poblaci\u00f3n de mayor edad, y con comorbilidades. Esta \u00faltima fue un factor asociado a una menor \nadecuaci\u00f3n a la GTA, as\u00ed como presentar factores de riesgo de infecci\u00f3n por Pseudomonas, por lo que esta constituir\u00eda la \npoblaci\u00f3n prioritaria para realizar una intervenci\u00f3n de mejora en la prescripci\u00f3n antimicrobiana.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1074. PERFUSION CONTINUA VS PERFUSION INTERMITENTE DE LA VANCOMICINA EN UNA COHORTE \nDE PACIENTES PEDI\u00c1TRICOS \nAUTORES\nALONSO MORENO, M; HERRERA HIDALGO, L; GIL NAVARRO, MV; GOYCOCHEA VALDIVIA, WA\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nEl objetivo fue comparar la efectividad y la seguridad de la perfusi\u00f3n continua de vancomicina (PCV) frente a la \nintermitente (PIV) en una cohorte de pacientes pedi\u00e1tricos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrosprospectivo y unic\u00e9ntrico, efectuado desde 2017 al 2020, donde se incluyeron pacientes \npedi\u00e1tricos (1 mes - 17 a\u00f1os) en tratamiento con vancomicina intravenosa durante \u226572 horas de forma emp\u00edrica o \ndirigida\ufffd  \nLos pacientes se clasificaron en dos grupos (PCV y PIV) seg\u00fan el m\u00e9todo de administraci\u00f3n.  \nSe recogieron variables demogr\u00e1ficas (sexo, peso, edad), cl\u00ednicas y microbiol\u00f3gicas (tipo de infecci\u00f3n, muestra \nmicrobiol\u00f3gica, pat\u00f3geno, modalidad de tratamiento). La efectividad cl\u00ednica se evalu\u00f3 como la mejor\u00eda de los signos \ny s\u00edntomas de infecci\u00f3n, reducci\u00f3n de la fiebre, buen estado general y reducci\u00f3n franca de la prote\u00edna C reactiva; y la \nmicrobiol\u00f3gica, como la negativizaci\u00f3n de cultivos a las 48-72 horas del inicio. Para la seguridad se registraron los efectos \nadversos\ufffd  \nLos an\u00e1lisis se realizaron con el software estad\u00edstico R e IBM SPSS versi\u00f3n 28.434RESULTADOS\nUn total de 81 pacientes fueron incluidos en el estudio: 41 en el grupo de PIV y 40 en PCV. 26 (32,1%) eran mujeres y 55 \n(67,9%) varones, sin diferencias significativas en ambos grupos (p=0,381).  \nLos pacientes del grupo PCV eran significativamente m\u00e1s j\u00f3venes (2 a\u00f1os frente a 7 a\u00f1os, p = 0,036) y, por tanto, con \nmenor peso en comparaci\u00f3n con el grupo PIV (12 kg frente a 21,5 kg, p= 0,040).  \nLos s\u00edndromes infecciosos fueron diferentes entre los grupos con diferencias significativas (p=0,041). Infecciones del \nsistema nervioso central fue el m\u00e1s frecuente en ambos, pero con un mayor porcentaje en el grupo PCV en comparaci\u00f3n \ncon el grupo PIV (57,5% para PCV vs 21,9% para PIV) y en concordancia, la muestra microbiol\u00f3gica fue diferente entre \nlos grupos con diferencias significativas (p=0,004). La sangre fue la muestra m\u00e1s frecuente en el grupo PIV (43,9%) y el \nl\u00edquido cefalorraqu\u00eddeo en el grupo PCV (47,5%).  \nEl pat\u00f3geno aislado m\u00e1s frecuente en ambos grupos fue Staphylococcus epidermidis (17% para la PIV y 35% para la PCV; \np=0,409).  \nEl tratamiento con vancomicina fue emp\u00edrico en el 51,85% de los casos y dirigido en el 48,15%, sin diferencias por tipo de \nperfusi\u00f3n (p=0,439).  \nLa efectividad cl\u00ednica y microbiol\u00f3gica no mostr\u00f3 diferencias significativas seg\u00fan el tipo de perfusi\u00f3n; sin embargo, las \nproporciones de efectividad fueron del 70,73% para el grupo de PIV y del 82,50% para el de PCV, lo que indica una \ndiferencia de 11,77% m\u00e1s de efectividad en PCV. \nUn paciente present\u00f3 nefrotoxicidad en el grupo PCV \ufffd En este paciente, la vancomicina se administr\u00f3 de forma \nconcomitante con otros f\u00e1rmacos nefrot\u00f3xicos y fue reversible cuando se suspendi\u00f3 el tratamiento con vancomicina.\nCONCLUSIONES\nEl mejor m\u00e9todo de administraci\u00f3n de este antibi\u00f3tico en la poblaci\u00f3n pedi\u00e1trica sugiere ventajas cl\u00ednicas para la PCV. \nEs necesario realizar m\u00e1s investigaciones, preferiblemente ensayos cl\u00ednicos aleatorizados que comparen la infusi\u00f3n \nintermitente con la continua en cuanto a efectividad y resultados de toxicidad ya que actualmente la evidencia de la PCV \nen esta poblaci\u00f3n es muy limitada\ufffd\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1077. EXPERIENCIA CL\u00cdNICA CON EL USO DE DALBAVANCINA \nAUTORES\nFERN\u00c1NDEZ FRAGA, F; MART\u00cdNEZ N\u00da\u00d1EZ, ME; HERRANZ MU\u00d1OZ, N; RUBIO RUIZ, L; MART\u00cdN ZARAGOZA, L; G\u00d3MEZ \nBERMEJO, M; MOLINA GARC\u00cdA, T\nHOSPITAL UNIVERSITARIO DE GETAFE \ufffd CRTRA DE TOLEDO, KM \ufffd 12,5 GETAFE \ufffd MADRID\nOBJETIVOS\nEl tratamiento de las infecciones por Gram positivos(G+) supone un reto asistencial por su complejidad, resistencias \nantibi\u00f3ticas y en ocasiones por la duraci\u00f3n del cuadro. En este contexto, se establecen como objetivos: describir la \nexperiencia de uso y analizar la efectividad de la dalbavancina en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, restrospectivo, longitudinal y observacional. Se incluyeron todos los pacientes con al menos una \nadministraci\u00f3n de dalbavancina desde mayo 2016 hasta abril 2022. Los datos fueron recogidos de la historia cl\u00ednica y \nprescripci\u00f3n electr\u00f3nica hospitalarios.  \nLas variables basales del paciente y del episodio recogidas fueron: sexo; edad del paciente al inicio del tratamiento; foco \nde infecci\u00f3n; resultado microbiol\u00f3gico de la muestra diagn\u00f3stica correspondiente; la antibioterapia previa(90 d\u00edas antes) \ny su duraci\u00f3n y si se trat\u00f3 de infecci\u00f3n polimicrobiana\ufffd  \nLos datos recogidos de la antibioterapia con dalbavancina fueron: duraci\u00f3n del tratamiento; prescripci\u00f3n de tratamiento \nantibi\u00f3tico concomitante y el motivo de inicio clasificado como: favorecer el alta hospitalaria precoz(AP), fallo al \ntratamiento previo(FTP), resistencia antibi\u00f3tica del microorganismo(RM) aislado, alergia(AL), toxicidad(TX) o mala \nadherencia(MA) a otros antibi\u00f3ticos posibles u otras causas(OC).  \nComo variable de efectividad a los 90 d\u00edas tras la \u00faltima administraci\u00f3n de dalbavancina se defini\u00f3 el fracaso terap\u00e9utico \ncon una variable combinada de: reingreso hospitalario < 30 d\u00edas, necesidad de antibioterapia diferente de rescate, nuevo \nciclo de dalbavancina o muerte asociada a la infecci\u00f3n\ufffd\nRESULTADOS\nSe analizaron un total de 43 episodios en 38 pacientes(63% hombres) con una mediana de edad de 71 a\u00f1os(RIC:62 \u2013 80).  \nLos focos de infecci\u00f3n m\u00e1s frecuentes fueron la infecci\u00f3n de pr\u00f3tesis aguda (IPA) (28,95%), espondilodiscitis(26,32%) \ne infecci\u00f3n de la v\u00eda biliar e intraabdominal (10,53% cada una). Otros focos tratados fueron la, endocarditis Infecciosa, \nbacteriemia asociada a cat\u00e9ter, osteomielitis y artritis s\u00e9ptica y otras(7,89% cada una) y la infecci\u00f3n de piel y partes \nblandas(2,63%). Los microorganismos m\u00e1s frecuentemente aislados fueron S. epidermidis(44,74%), S. aureus(28,95%) y E. \nfaecalis(7,89%). En un 10,53% no hubo aislamiento microbiol\u00f3gico. El 28,95% de las infecciones fueron polimicrobianas.  \nEn un 73,68% de los episodios se administr\u00f3 antibioterapia previa frente G+ con al menos uno de los siguientes f\u00e1rmacos: \nlinezolid, vancomicina o daptomicina con una mediana de duraci\u00f3n de 21 d\u00edas(RIC:16 \u2013 35,5).  \nEl motivo de inicio de dalbavancina fue: AP 73,68%; FTP 23,68%; TX y RM 10,53% cada una y OC 7,89%. La mediana de \nduraci\u00f3n del antibi\u00f3tico fue de 22 d\u00edas(RIC:7,5 \u2013 52,5). En un 39,47% de los episodios se prescribi\u00f3 terapia concomitante, \nsiendo la rifampicina el f\u00e1rmaco m\u00e1s empleado(73,33%).  \nLa tasa de fracaso terap\u00e9utico fue del 42,11%. El reingreso hospitalario fue el principal motivo(68,75%), seguido de un \n56,25% de episodios en los que se precis\u00f3 terapia antibi\u00f3tica de rescate diferente y un 6,25% en los que se administr\u00f3 un \nnuevo ciclo de dalbavancina. Tres pacientes fallecieron(18,75%).435CONCLUSIONES\nEn nuestro centro se ha utilizado la dalbavancina para el tratamiento de diferentes infecciones siendo la IPA la m\u00e1s \nfrecuente. Esta se muestra especialmente efectiva en este tipo de infecciones en las que la duraci\u00f3n de la antibioterapia \nes prolongada, posibilitando acortar estancias hospitalarias.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1093. PRESCRIPCI\u00d3N DE F\u00c1RMACOS QUE PROLONGAN EL INTERVALO QT EN PACIENTES MAYORES DE \n50 A\u00d1OS CON VIH \nAUTORES\nDE LA CALLE RIAGUAS, B; BRICE\u00d1O CASADO, MDP; CORTES FERN\u00c1NDEZ, R; LOMARES MANZANO, I; G\u00d3MEZ \nESPINOSA, P; JULI\u00c1 LUNA, FJ; CRIADO RUBIO, B; ALONSO SALMER\u00d3N, F\nHOSPITAL NUESTRA SE\u00d1ORA DEL PRADO \ufffd CTRA \ufffd DE MADRID, KM \ufffd 114 TALAVERA DE LA REINA \ufffd TOLEDO\nOBJETIVOS\nAnalizar la tendencia de prescripci\u00f3n de f\u00e1rmacos que prolongan el intervalo QT (FQT) en pacientes mayores de 50 a\u00f1os \ncon infecci\u00f3n por virus de la inmunodeficiencia humana (VIH), identificar los f\u00e1rmacos m\u00e1s implicados y evaluar los \nfactores de riesgo (FR) asociados.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo y transversal en un hospital general (abril 2022) en pacientes mayores de 50 a\u00f1os con VIH. Se \nrecogieron: datos demogr\u00e1ficos (sexo y edad), tratamiento antirretroviral (TAR): dos an\u00e1logos inhibidores de transcriptasa \ninversa m\u00e1s inhibidor de integrasa (2ITIAN+INI), dos an\u00e1logos inhibidores de transcriptasa inversa m\u00e1s inhibidor \nde proteasa (2ITIAN+IP/p), r\u00e9gimen con biterapia u otras pautas; n\u00famero y FQT prescritos, y FR que potencian la \nprolongaci\u00f3n del QT: patolog\u00eda cardiovascular, patolog\u00eda tiroidea, insuficiencia renal, insuficiencia hep\u00e1tica y alteraci\u00f3n \nelectrol\u00edtica.  \nLa identificaci\u00f3n de FQT se realiz\u00f3 en base al listado elaborado por el Arizona Center for Education and Research on \nTerapeutics (AZCERT), d\u00f3nde se clasifican en tres grupos, seg\u00fan el nivel de evidencia de prolongaci\u00f3n del QT y riesgo de \nproducir torsade de pointes (TdP): \n\u2022 Riesgo definido de TdP (RD): F\u00e1rmacos que alargan el intervalo QT con riesgo de causar TdP . \n\u2022 Riesgo posible de TdP (RP): F\u00e1rmacos que pueden causar prolongaci\u00f3n del intervalo QT, sin evidencias suficientes de \nriesgo de causar TdP \ufffd  \n\u2022 Riesgo condicional de TdP (RC): F\u00e1rmacos que alargan el intervalo QT y aumentan el riesgo de TdP en determinadas \ncircunstancias\ufffd  \nLos datos se obtuvieron del m\u00f3dulo de dispensaci\u00f3n a pacientes externos de Farmatools\u00ae e historia cl\u00ednica electr\u00f3nica.\nRESULTADOS\nSe evaluaron 55 pacientes (61,8% hombres) con edad media de 59 (rango 51-87) a\u00f1os. El 32,7% (n=18) recib\u00eda 2ITIAN+INI, \nel 21,8% (n=12) 2ITIAN+IP/p, el 32,7% (n=18) r\u00e9gimen con biterapia y el 12,8% restante (n=7) otras pautas.  \nEl 78,2% (n=43) llevaba prescrito al menos un FQT: el 41,9% (n=18) uno, el 23,2% (n=10) dos, y el 34,9% (n=15) m\u00e1s de \ndos. Se encontraron 90 FQT: 15,6% (14) con RD; 20% (18) con RP y 64,4% (58) con RC.  \nLos principales f\u00e1rmacos prescitos con RD fueron: clorpromazina (35,7%), escitalopram (28,6%) y haloperidol (14,3%); \ncon RP: mirabegr\u00f3n (22,2%), mirtazapina (16,7%) y aripiprazol (16,7%); y con RC: omeprazol (34,5%), trazodona (15,5%) y \nfurosemida (8,6%).  \nEn cuanto a los FR asociados, el 83,6% (n=46) de los pacientes presentaba al menos un FR: el 41,3% (n=19) uno y el 58,7% \n(n=27) m\u00e1s de uno. El 65,6% (n=36) presentaba patolog\u00eda cardiovascular, el 12,7% (n=7) patolog\u00eda tiroidea, el 34,5% \n(n=19) insuficiencia renal, el 3,6% (n=2) insuficiencia hep\u00e1tica y el 32,7% (n=18) alteraci\u00f3n electrol\u00edtica.\nCONCLUSIONES\nLa tendencia de prescripci\u00f3n de FQT fue alta (m\u00e1s del 75% de pacientes). Un 16% de los FQT ten\u00edan RD de TdP . Los \nf\u00e1rmacos m\u00e1s implicados por grupos terap\u00e9uticos fueron antipsic\u00f3ticos, antidepresivos, inhibidores de la bomba de \nprotones, antiespasm\u00f3dicos urinarios y diur\u00e9ticos. La mayor\u00eda de pacientes presentaban al menos un FR de prolongaci\u00f3n \ndel intervalo QT. Ser\u00eda necesaria una validaci\u00f3n exhaustiva de estos f\u00e1rmacos por el farmac\u00e9utico y crear equipos \nmultidisciplinares para disminuir la prescripci\u00f3n de los mismos, especialmente en pacientes con FR.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1112. AN\u00c1LISIS DE EFECTIVIDAD Y SEGURIDAD DE SOTROVIMAB EN PACIENTES AFECTADOS POR SARS-\nCOV-2 \nAUTORES\nVILLA CARPES, J; MU\u00d1OZ GARC\u00cdA, I; RAM\u00d3N P\u00c9REZ, M; D\u00cdAZ RAM\u00d3N, M; TORR\u00d3 GARC\u00cdA, L; GIL ALMELA, J; GOLNABI \nDOWLATSHAHI, F; MART\u00cdNEZ IB\u00c1\u00d1EZ, M\u00c1\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nSotrovimab es un anticuerpo monoclonal indicado para el tratamiento de la enfermedad por coronavirus 2019 \n(COVID-19) en pacientes que no requieren ox\u00edgeno suplementario y que tienen un mayor riesgo de progresar a COVID-19 436grave. La dosis recomendada es de 500 mg por v\u00eda intravenosa en perfusi\u00f3n \u00fanica. \nEl objetivo de nuestro estudio es valorar la adecuaci\u00f3n a los criterios de priorizaci\u00f3n para la administraci\u00f3n de los nuevos \nanticuerpos y analizar la efectividad y seguridad de sotrovimab en pacientes con COVID-19.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio observacional retrospectivo incluyendo todos los pacientes que recibieron sotrovimab desde \nenero-2022 hasta marzo-2022 en un hospital de tercer nivel. \n \nSe recogieron variables de edad y sexo, diagn\u00f3stico principal, comorbilidades, pauta de vacunaci\u00f3n, serolog\u00eda, tipo de \nvariante descrita del SARS-CoV-2, necesidad de ox\u00edgeno durante el ingreso, tiempo en d\u00edas desde el inicio de s\u00edntomas \nhasta la administraci\u00f3n del f\u00e1rmaco y otros tratamientos para la COVID-19 administrados en concomitancia durante el \ningreso\ufffd \nLa efectividad se midi\u00f3 por la necesidad de hospitalizaci\u00f3n durante > 24 horas por cualquier causa o muerte (hasta 29 \nd\u00edas despu\u00e9s). La seguridad se midi\u00f3 por las reacciones adversas tras la administraci\u00f3n del f\u00e1rmaco.  \n \nEl Servicio de Farmacia se bas\u00f3 en los criterios de priorizaci\u00f3n para el uso del f\u00e1rmaco de la Agencia Espa\u00f1ola de \nMedicamentos y Productos Sanitarios (AEMPS) en base al riesgo de progresi\u00f3n a enfermedad grave.\nRESULTADOS\nSe incluyeron un total de 17 pacientes (47% mujeres) con una mediana de edad de 59 a\u00f1os [rango 20 - 74]. El diagn\u00f3stico \nprincipal fue: trasplante renal (10), trasplante hepatorrenal (2), trasplante pulmonar (2), trasplante card\u00edaco (1) y \npacientes en tratamiento con quimioterapia activa (2). Como comorbilidades, presentaron: hipertensi\u00f3n arterial (82%), \ndislipemia (70,5%), enfermedad renal cr\u00f3nica (47%), diabetes mellitus-2 (41,2%) y Enfermedad Pulmonar Obstructiva \nCr\u00f3nica (EPOC) (17,6%).  \n \nDel total de paciente, 14 hab\u00edan recibido pauta completa de vacunaci\u00f3n, 2 con dos dosis y un paciente no recibi\u00f3 ninguna \ndosis. La serolog\u00eda fue negativa para 10 (58,8%) pacientes. La variante \u00f3micron se confirm\u00f3 en 11 (64,7%) pacientes. \n \nNing\u00fan paciente precis\u00f3 suplementaci\u00f3n de ox\u00edgeno durante el ingreso, excepto, los 3 pacientes con EPOC que \nprecisaban oxigenoterapia previa por su enfermedad basal\ufffd  \n \nSotrovimab fue administrado dentro de los primeros 5 d\u00edas despu\u00e9s del inicio de s\u00edntomas en todos los pacientes. El 88% \n(15) de los pacientes recibieron tambi\u00e9n profilaxis con remdesivir durante 3 d\u00edas.  \n \nNo hubo necesidad de hospitalizaci\u00f3n > 24 horas y se registr\u00f3 un fallecimiento por causa desconocida.  \n \nNo se notific\u00f3 ninguna reacci\u00f3n adversa tras la administraci\u00f3n del f\u00e1rmaco.\nCONCLUSIONES\nLos pacientes que han recibido sotrovimab corresponden con un perfil de riesgo de progresi\u00f3n a enfermedad grave. \n \nRespecto a la efectividad, nuestros resultados muestran un caso de muerte, un porcentaje superior al obtenido para la \nvariable principal en el ensayo COMET-ICE, teniendo adem\u00e1s en cuenta que los pacientes incluidos en este ensayo eran \nno vacunados\ufffd  \n \nSotrovimab muestra un buen perfil de seguridad.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1141. \u00bfES ADECUADO EL TRATAMIENTO DE LA INFECCI\u00d3N POR CLOSTRIDIOIDES DIFFICILE EN NUESTRO \nHOSPITAL? \nAUTORES\nJIM\u00c9NEZ M\u00c9NDEZ, C; BL\u00c1ZQUEZ ROMERO, C; TOLEDO DAVIA, MA; TORRALBA FERN\u00c1NDEZ, L; L\u00d3PEZ \u00c1LVAREZ, R; \nDOM\u00cdNGUEZ BARAHONA, A; FERN\u00c1NDEZ AR\u00c9VALO, M; MOYA G\u00d3MEZ, P\nHOSPITAL UNIVERSITARIO DE TOLEDO\nOBJETIVOS\nEn 2019 se realiz\u00f3 un protocolo sobre el manejo de Clostridioides difficile en el hospital. Tras 3 a\u00f1os, se decide analizar \nel manejo de esta enfermedad en pacientes hospitalizados evaluando tanto el grado de adecuaci\u00f3n a dicho protocolo, \ncomo el grado de aceptaci\u00f3n de las intervenciones realizadas desde el servicio de Farmacia para la correcta adecuaci\u00f3n al \nmismo\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y prospectivo de 6 meses de duraci\u00f3n (Noviembre 2021\u2013Mayo 2022) en el que se registraron todos \nlos pacientes hospitalizados con una prescripci\u00f3n para el tratamiento de la infecci\u00f3n por C.difficile.  \nSe recogieron las siguientes variables: sexo, edad, servicio m\u00e9dico, tipo de episodio, tratamiento prescrito, duraci\u00f3n, valor \nGDH, toxina y si el tratamiento era emp\u00edrico o dirigido. Adem\u00e1s, se registr\u00f3 el n\u00famero y tipo de intervenci\u00f3n realizada \n(oral/escrita/ambas) y si se adecuaba o no al protocolo del hospital.  437Para ello se utiliz\u00f3 el programa de prescripci\u00f3n electr\u00f3nica (Farmatools\u00ae) y la historia cl\u00ednica informatizada (Mambrino \nXXI\u00ae). Los datos se trataron en una hoja Excel\u00ae, y se utiliz\u00f3 el programa estad\u00edstico STATA-MP-16.0 para los resultados.\nRESULTADOS\nSe analizaron 81 pacientes, 44 mujeres (54,32%). La mediana de edad fue de 71 a\u00f1os (RIQ=65-79). El servicio m\u00e9dico \ncon m\u00e1s casos de C.difficile fue Medicina Interna con un 47,37%, seguido del Servicio de Digestivo (10,53%), Nefrolog\u00eda \n(9,47%) y otros (32,63%).  \nEn total se registraron 155 episodios, lo que supone 1,91 episodios/paciente. La distribuci\u00f3n seg\u00fan la tipolog\u00eda del \nepisodio fue: 59,73% primer episodio, 18,12% primera recidiva, 14,77% reca\u00edda, 4,03% primer episodio fulminante y \n3,36% segunda recidiva\ufffd \nLa vancomicina se utiliz\u00f3 en el 55,48% de los casos, seguida de fidaxomicina (19,35%), vancomicina (pulsada) (13,55%), \nmetronidazol (7,74%), vancomicina+metronidazol (1,94%), vancomicina rectal (1,29%), y Bezlotoxumab (0,65%). \nLa duraci\u00f3n de tratamiento tuvo una mediana de 9 d\u00edas (RIQ=7-10).  \nDe todos los episodios, se obtuvo valor de la GDH en 143, resultando positiva en 137 ocasiones (95,8%) y la toxina se \nrecogi\u00f3 en 138 episodios, siendo positiva en 136 ocasiones (98,55%). Del total de episodios, el 88,39% (137) fue dirigido.  \nLa adecuaci\u00f3n del tratamiento solo se pudo recoger en 153 episodios, resultando un 21,57% (33) no adecuados. \nLas causas de no adecuaci\u00f3n fueron: elecci\u00f3n del f\u00e1rmaco inadecuado y duraci\u00f3n del tiempo de tratamiento. De los \n33 tratamientos que no se adecuaban al protocolo, se pudo intervenir en 17 (51,5%) de las cuales solo 1 se realiz\u00f3 \n\u00fanicamente por v\u00eda telef\u00f3nica (5,88%), 9 se realizaron de forma escrita (52,94%) y 7 se realizaron de forma tanto escrita \ncomo con contacto telef\u00f3nico con el m\u00e9dico prescriptor (41,18%). De todas las intervenciones 13 fueron aceptadas \n(76,47%) y 4 no fueron aceptadas (23,53%).\nCONCLUSIONES\nEn general, el tratamiento de la infecci\u00f3n por C.difficile se realiza correctamente en nuestro hospital. Sin embargo, se \ndetectaron prescripciones que no se adecuaban al protocolo. En aquellas en las que se pudo realizar una intervenci\u00f3n, \nesta fue en un gran porcentaje aceptada, llevando a un manejo adecuado de esta enfermedad.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1153. \u00bfC\u00d3MO AFECTA LA MAYOR COMPLEJIDAD DE LOS PACIENTES AL TRATAMIENTO ANTIBI\u00d3TICO \nDOMICILIARIO ENDOVENOSO? \nAUTORES\nORTONOBES ROIG, S; MUJAL MART\u00cdNEZ, A; DE CASTRO JULVE, M; MEJIA DIAZ, J; HERN\u00c1NDEZ-\u00c1VILA , M; JIM\u00c9NEZ \nP\u00c9REZ, R; GONZ\u00c1LEZ-SEQUERO , V; G\u00d3MEZ-VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\n- Comparar la actividad y las caracter\u00edsticas de ingresos en la Unidad de Hospitalizaci\u00f3n a Domicilio (HAD) con Tratamiento \nAntibi\u00f3tico Domiciliario Endovenoso (TADE) del 2021 con una cohorte anterior.  \n- Analizar los pacientes que requirieron de re-ingreso y/o derivaci\u00f3n a urgencias por cualquier causa en 2021.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de todos los episodios TADE mediante dispositivos elastom\u00e9ricos elaborados en el \nServicio de Farmacia (SF). Se us\u00f3 el a\u00f1o 2019 como cohorte comparativa con 2021. Variables registradas: actividad HAD, \nelast\u00f3meros elaborados SF, sociodemogr\u00e1ficas, caracter\u00edsticas del TADE (indicaci\u00f3n, antibi\u00f3tico, frecuencia, duraci\u00f3n) \ny destino al alta. Variables cuantitativas expresadas con mediana (rango intercuartil); variables cualitativas con valor \nrelativo. An\u00e1lisis estad\u00edstico mediante prueba Mann-Whitney-Wilcoxon para variables cuantitativas; test Chi-cuadrado \npara cualitativas.\nRESULTADOS\nActividad HAD/SF 2019 vs 2021: ingresos UHD con TADE 25,6% vs 37,6% p < 0,0001; promedio semanal de pacientes con \nTADE 14 (12-16,5) vs 20,5 (18-24) p < 0,0001; n\u00famero de elast\u00f3meros elaborados semanalmente 113 (91-141,5) vs 216 \n(174-252,5) p < 0,001; n\u00famero anual de elast\u00f3meros elaborados 6251 vs 10996.  \nComparaci\u00f3n de pacientes totales con TADE 2019 (268; 45,3%) vs 2021 (324; 57,7%): edad 67 (52-78) a\u00f1os vs 72 (59-\n80) p=0,002; mujeres 33,9% vs 38,6% p=0,245. Indicaciones: infecciones urinarias 21,6% vs 32,1% p=0,005; infecciones \npulmonares 32,1% vs 14,2% p < 0,001; bacteriemia 14,6% vs 15,1% p=0,846; infecciones intraabdominales 10,5% vs \n12,4% p=0,471; infecciones piel y partes blandas 6,7% vs 12,7% p=0,016; infecciones osteoarticulares 9,3% vs 5,6% \np=0,078; endocarditis 0,75% vs 3,7% p=0,018; otras infecciones 4,5 % vs 4,3% p=0,926. Antibi\u00f3ticos mayoritarios: \nertapenem 35,7% vs 38,9% p=0,339; ceftriaxona 13,4% vs 14,8% p=0,631; meropenem 10,5% vs 12,9% p=0,345; \npiperacilina/tazobactam 5,6% vs 12,9% p=0,002; ceftazidima 8,6% vs 5,3% p=0,108. Promedio semanal de pacientes con \nmonoterapia 13,0 (11-15,5) vs 19,5 (17-23) p < 0,0001 y con biterapia 1 (0-1,5) vs 1 (1-2) p=0,021. N\u00famero de pacientes \ncon TADE c/24h 10 (8-11) vs 11 (9,5-13) p=0,011; c/12h 1 (0-2) vs 1 (1-2) p=0,700; c/8h 2,5 (2-5) vs 7 (6-8) p < 0,0001; \nperfusi\u00f3n continua 24h 0 (0-0) vs 3 (1,5-4) p < 0,0001. Duraci\u00f3n TADE 13 (8-17,5) d\u00edas vs 12 (8-19) p=0,751. Pacientes con \nnecesidad de re-ingreso en agudos/sociosanitario y/o derivaci\u00f3n a urgencias por cualquier causa: 18 (6,7%) vs 49 (15,1%) \np=0,001. No se encontraron diferencias estad\u00edsticamente significativas en ninguna de las variables asociadas al TADE \n(edad, sexo, tipo de infecci\u00f3n, antibi\u00f3tico TADE o duraci\u00f3n) entre estos dos grupos. Tampoco se encontraron diferencias \nen la comparaci\u00f3n de pacientes con necesidad de re-ingreso (49; 15,1%) vs no re-ingreso (275; 84,8%) en 2021.438CONCLUSIONES\n- En 2021 ha habido un incremento significativo en el n\u00famero de pacientes con TADE que ha conllevado en un incremento \nen la actividad de la HAD y en la elaboraci\u00f3n de elast\u00f3meros en el SF.  \n- Los pacientes candidatos a TADE en 2021 fueron mayores, con mayor proporci\u00f3n de infecciones urinarias e infecciones \ngraves como endocarditis, y esto ha comportado un mayor uso de biterapia, perfusiones continua y TADE complejo.  \n- El incremento de pacientes que re-ingresaron y/o acudieron a urgencias por cualquier causa en el 2021 no parece estar \nrelacionado con variables sociodemogr\u00e1ficas, tipo de infecci\u00f3n ni TADE seleccionado.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1166. AN\u00c1LISIS DEL USO EN VIDA REAL DE TOCILIZUMAB Y BARICITINIB EN PACIENTES CON NEUMON\u00cdA \nCOVID-19 \nAUTORES\nPEDREIRA BOUZAS, J; PUIVECINO MORENO, C; GARC\u00cdA GIL, M\nHOSPITAL DE FUENLABRADA \ufffd CAMINO DEL MOLINO, 2 FUENLABRADA \ufffd MADRID\nOBJETIVOS\nDurante la pandemia COVID-19 fue habitual el uso de tocilizumab y baricitinib fuera de indicaci\u00f3n. Ambos se emplearon \nen pacientes similares seg\u00fan ensayos como el RECOVERY . Sin embargo ser\u00eda de inter\u00e9s conocer si existen diferencias en \nel perfil de los pacientes que recibieron estos tratamientos en un hospital de segundo nivel y su efectividad. El objetivo \nde este an\u00e1lisis es conocer el perfil y la evoluci\u00f3n de los pacientes que recibieron tocilizumab y baricitinib para tratar la \nneumon\u00eda por COVID-19 en una cohorte de un hospital de segundo nivel.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo donde se seleccionaron todos los pacientes que ingresaron por neumon\u00eda COVID-19 \nque recibieron tocilizumab o baricitinib durante el per\u00edodo entre 01/01/2021 y 01/01/2022.Fueron excluidos los \npacientes que recibieron ambos f\u00e1rmacos o remdesivir.Las variables de estudio para conocer el perfil de pacientes \nfueron: demogr\u00e1ficas(sexo,edad,IMC); antecedentes cl\u00ednicos(hipertensi\u00f3n,diabetes,dislipemia,EPOC,oxigenoterapia \ndomiciliaria, vacunaci\u00f3n COVID); neumon\u00eda COVID-19(uni/bilateral); farmacoterapia COVID-19(oxigenoterapia alto flujo \ndurante el ingreso, corticoides).Las variables de efectividad analizadas fueron:tasa de mortalidad a los 28 d\u00edas, d\u00edas hasta \nexitus y tiempo de estancia hospitalaria.Las variables cuantitativas se expresan como medias aritm\u00e9ticas(desviaci\u00f3n \nest\u00e1ndar[DE]) o mediana(rango intercuart\u00edlico[RIC]).Para la recogida de datos se emple\u00f3 una herramienta de inteligencia \nartificial desarrollada por el hospital que se nutre de la Historia Cl\u00ednica Electr\u00f3nica y de los programas de registro de datos \nhospitalarios.El an\u00e1lisis estad\u00edstico se realiz\u00f3 con el SPSSv.26\u00ae.\nRESULTADOS\nSe seleccionaron 412 pacientes de los cuales 376 recibieron tocilizumab y 36 baricitinib.En el grupo de tocilizumab hubo \nun 60,9%(229/376) de hombres con una media de edad de 63,6 a\u00f1os(DE=15,6) e IMC medio de 31,6 kg/m2(DE=18,2). \nComorbilidades en este grupo:51,3%(193/376) hipertensi\u00f3n, 22,3%(84/376) diabetes, 38,3%(144/376) dislipemia y 6,9% \n(26/376) EPOC.El 3,2%(12/376) recib\u00eda oxigenoterapia domiciliaria y el 65,2%(245/376) hab\u00edan recibido al menos una \ndosis de vacuna contra el SARS-CoV2.El 84,6%(318/376) ten\u00eda neumon\u00eda de tipo bilateral.En cuanto a la terapia durante \nel ingreso:Un 13,6%(51/376) requiri\u00f3 oxigenoterapia alto flujo y el 99,7%(375/376) recibieron corticoides.Con respecto \nal grupo baricitinib, hubo un 50,0%(18/36) de varones con una media de edad de 56,6 a\u00f1os(DE=11,7) e IMC medio de \n29,4 kg/m2(DE=6,3).Comorbilidades en este grupo:30,6%(11/36) hipertensi\u00f3n, 25,0%(9/36) diabetes, 41,7%(15/36) \ndislipemia y no hubo ning\u00fan paciente con EPOC ni que recibiera oxigenoterapia domiciliaria.El 61,1%(22/36) ten\u00eda \nal menos una dosis de vacuna contra el SARS-CoV2 administrada.El 66,7%(24/36) ten\u00eda neumon\u00eda de tipo bilateral.\nDurante el ingreso:Ninguno requiri\u00f3 oxigenoterapia alto flujo, el 88,9%(32/36) recibieron corticoides.Con respecto a la \nevoluci\u00f3n de los pacientes:Tasa de mortalidad a los 28 d\u00edas 14,4%(54/376) vs 0%(0/36); mediana de d\u00edas hasta \u00e9xitus \n12,5 d\u00edas(RIC=5-26) vs 0;mediana de estancia hospitalaria 9,5 d\u00edas(RIC=6-18) vs 5 d\u00edas(RIC=3-6) para los pacientes que \nrecibieron tocilizumab y baricitinib, respectivamente.\nCONCLUSIONES\nPese a que los grupos de tratamiento con baricitinib y tocilizumab no eran comparables num\u00e9ricamente, parece que los \npacientes tratados con tocilizumab presentaban m\u00e1s factores de riesgo para un peor desenlace por neumon\u00eda COVID19 \n(IMC superior,hipertensi\u00f3n y EPOC previos).Esto se podr\u00eda traducir en una mayor mortalidad y estancia hospitalaria \ncon respecto a baricitinib, y no tratarse de un peor resultado asociado al f\u00e1rmaco.Parece que fue priorizado el uso de \ntocilizumab frente a baricitinib en pacientes con peor pron\u00f3stico.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1204. EFECTIVIDAD Y SEGURIDAD DEL PASO PRECOZ DE LA ANTIBIOTERAPIA A V\u00cdA ORAL EN \nNEUMOLOG\u00cdA: AN\u00c1LISIS DE PROPENSIONES \nAUTORES\nECHEVERR\u00cdA ESNAL, D; RODR\u00cdGUEZ ALARC\u00d3N, A; DOM\u00cdNGUEZ \u00c1LVAREZ, M; AUS\u00cdN HERRERO, MP; BALCELLS , E; \nG\u00d3MEZ-ZORRILLA , S; HORCAJADA , JP; GRAU CERRATO, S\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA439OBJETIVOS\nLa terapia antibi\u00f3tica secuencial de v\u00eda intravenosa a oral se ha asociado a numerosos beneficios. Dicha estrategia no \nha sido estudiada en el caso de pacientes con patolog\u00eda pulmonar cuya resoluci\u00f3n tard\u00eda de la insuficiencia respiratoria \npodr\u00eda retrasar el paso del tratamiento a v\u00eda oral.  \n \nEl objetivo fue evaluar la efectividad y seguridad del paso precoz de la antibioterapia a v\u00eda oral en el servicio de \nneumolog\u00eda.\nMATERIALES Y M\u00c9TODOS\nEstudio cuasiexperimental antes-despu\u00e9s en un hospital universitario de tercer nivel. \n \nEl protocolo fue instaurado por el equipo PROA en febrero del 2018 mediante educaci\u00f3n a los neum\u00f3logos. Se \nrecomend\u00f3 el paso a v\u00eda oral siguiendo los criterios de estabilidad cl\u00ednica previamente establecidos.  \n \nCriterio de inclusi\u00f3n: tratamiento antibi\u00f3tico intravenoso potencialmente modificable a v\u00eda oral en el momento del \ningreso en neumolog\u00eda. El grupo pre comprende los pacientes entre diciembre 2015-febrero 2018, mientras que el post \nlos ingresados a partir de marzo 2018. \n \nDatos expresados en media (desviaci\u00f3n est\u00e1ndar) y frecuencias absolutas. An\u00e1lisis de propensi\u00f3n ajustando por edad, \nhipertensi\u00f3n pulmonar, sexo y fibrosis pulmonar. Se realizaron pruebas no param\u00e9tricas para la estancia hospitalaria y se \nexpres\u00f3 en mediana (Q1-Q3).\nRESULTADOS\nSe incluyeron 286 pacientes (181 grupo post, 105 grupo pre). Edad 69,9 (12,7) a\u00f1os, mujeres 40,6%. SAPSII 28,8 (8,1), \nFEV1 48,5 (19,1). No se observaron diferencias entre grupos en la edad, SAPSII ni comorbilidades, incluyendo la gravedad \nde EPOC\ufffd  \n \nPrincipales focos de infecci\u00f3n: neumon\u00eda (18,7% vs. 18,0%, [CURB-65 2 vs. 1, P=0,290]), exacerbaci\u00f3n de EPOC (51,4% vs. \n60,0%, p=0,351), broncoaspiraci\u00f3n (11,2% vs. 14%, P=0,120).  \n \nAntibi\u00f3ticos empleados: 62,2% beta-lact\u00e1micos, 32,1% fluoroquinolonas, 2,1% clindamicina, sin diferencias entre los \ngrupos\ufffd  \n \nEn el grupo post 5,5% de los pacientes se encontraban en semicr\u00edticos. La modalidad ventilatoria fue: sin oxigenoterapia \n27,1%, gafas nasales 37,6%, ventimask 37,6%, ventilaci\u00f3n mec\u00e1nica no invasiva 1,7%. \n \nLa estancia hospitalaria fue inferior tras la implementaci\u00f3n del protocolo: 8 (6-13) vs. 10 (7-15) d\u00edas (P=0,120), as\u00ed como \nlos d\u00edas de v\u00eda intravenosa: 8,3 (4,9) vs. 12,3 (19,1) d\u00edas (P=0,007), d\u00edas hasta v\u00eda oral: 3,6 (2,3) vs. 5,3 (2,9) d\u00edas (P=0,000), \ny la duraci\u00f3n total de tratamiento: 7,7 (4,1) vs. 10,1 (4,2) d\u00edas (P=0,000). No hubo diferencias ni en la mortalidad a los \n7 d\u00edas (0 vs 1%, P=0,671), 30 d\u00edas (0 vs 1%, P=0,671), reingreso al mes (24,9% vs. 21,0%, P=0,452) ni curaci\u00f3n cl\u00ednica al \nfinalizar el tratamiento (91,7% vs. 89,6%, P=0,609). Los motivos de fallo cl\u00ednico fueron: sobreinfecci\u00f3n (11,1% vs. 40,0%, \nP=0,165), tratamiento emp\u00edrico inadecuado (77,8% vs. 60,0%, P=0,211) y fallo tras paso v\u00eda oral (11,1% vs. 0, P=0,240). \nSin diferencias en la incidencia de tromboflebitis, bacteriemias de cat\u00e9ter o toxicidad gastrointestinal.\nCONCLUSIONES\nA pesar de no alcanzar la significancia estad\u00edstica, probablemente por falta de potencia estad\u00edstica, se observ\u00f3 una \nreducci\u00f3n de la estancia hospitalaria de dos d\u00edas.  \n \nEl paso precoz a v\u00eda oral fue seguro sin observar un aumento de los efectos adversos o una peor evoluci\u00f3n cl\u00ednica.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1212. EVALUACI\u00d3N DE LAS INTERVENCIONES PROA EN VALIDACI\u00d3N FARMAC\u00c9UTICA VERSUS LAS \nREALIZADAS POR UN PROA MULTIDISCIPLINAR Y SU GRADO DE ACEPTACI\u00d3N \nAUTORES\nGARC\u00cdA PARICIO, R; P\u00c9REZ NAVARRO, MC; PASCUAL ARCE, B; MURO PEREA, N; FENOLLOSA MART\u00cdNEZ, A; DE LA \nCRUZ UBACH, S\nHOSPITAL MUNICIPAL DE BADALONA \ufffd VIA AUGUSTA, 9 BADALONA \ufffd BARCELONA\nOBJETIVOS\nLos Programas de Optimizaci\u00f3n de Antimicrobianos (PROA) est\u00e1n orientados a mejorar los resultados cl\u00ednicos de \nlos pacientes con infecciones mejorando la utilizaci\u00f3n de los antimicrobianos con la adecuaci\u00f3n del tratamiento, \nminimizando sus efectos adversos, la aparici\u00f3n de resistencias y seleccionando tratamientos m\u00e1s coste-efectivos. \nObjetivos: \n \n-Cuantificar y tipificar las intervenciones PROA relizadas diariamente por el farmac\u00e9utico (PROAFARM) y las efectuadas en \nrevisi\u00f3n semanal por un grupo PROA multidisciplinar (GPROA) en un hospital de agudos (HA) y un centro sociosanitario \n(CSS).  \n-Comparar el tipo de intervenci\u00f3n realizada seg\u00fan el asesor que efect\u00faa la recomendaci\u00f3n y su grado de aceptaci\u00f3n.440MATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo de las intervenciones de optimizaci\u00f3n de antimicrobianos realizadas desde \nPROAFARM en la validaci\u00f3n farmac\u00e9utica diaria mediante un sistema de prescripci\u00f3n electr\u00f3nica y las efectuadas \nmediante revisi\u00f3n semanal por el GPROA (internista, microbi\u00f3loga y farmac\u00e9utico) en un HA y en un CSS de julio-21 a \nmarzo-22.  \n \nVariables recogidas: demogr\u00e1ficas; n\u00baintervenciones total y por centro; n\u00baintervenciones total/asesor(PROAFARM o \nGPROA); n\u00ba intervenciones/asesor y centro; n\u00ba total intervenciones seg\u00fan tipo y asesor; % aceptaci\u00f3n (excepto en \nintervenci\u00f3n seguimiento tratamiento/validaci\u00f3n).Datos cuantitativos se expresan en mediana (rango intercuartil (IQR)) o \nporcentaje(%).\nRESULTADOS\n-Demogr\u00e1ficos: 240(53,7%) hombres; edad: 81(70-87) a\u00f1os. \n \n-Se realizaron 870 intervenciones: 489(56.2%) HA y 381(43,8%) en CSS. \n \n-N\u00ba intervenciones total/asesor: 446(51,3%)PROAFARM-vs-424(48,7%)GPROA.  \n \n-N\u00ba intervenciones/asesor y centro: CSS: 181(47,5%)PROAFARM y 200(52,5%)GPROA; HA: 265(54,2%) PROAFARM y \n224(45,8%) GPROA. \n \n-N\u00ba total intervenciones seg\u00fan tipo y asesor; grado aceptaci\u00f3n:  \n \nAjuste insuficiencia renal: 81(9.3%): 76(93,8%)PROAFARM y 5(6,2%)GPROA; aceptadas: 71,1%PROAFARM-vs-80%GPROA.  \n \nCambio antibi\u00f3tico: 68(7,8%): 35(51,5%)PROAFARM y 33(48,5%)GPROA; aceptadas: 82,9%PROAFARM-vs-90,9%GPROA. \n \nCambio/retirada por reacci\u00f3n adversa(RAM): 3(0,3%): 1(33,3%)PROAFARM y 2(66,7%)GPROA; aceptadas: 100,0% en \nambos grupos\ufffd  \n \nRevisi\u00f3n etiqueta alergia: 23(2,6%): 16(69,6%)PROAFARM y 7(30,4%)GPROA; aceptadas: 68,8%PROAFARM-vs-\n71,4%GPROA \ufffd \n \nDesetiquetado alergia: 11(1,3%): 9(81,8%)PROAFARM y 2(18,2%)GPROA; aceptadas: 100,0% en ambos grupos.  \n \nDesescalado: 44(5,1%): 6(13,6%)PROAFARM y 38(86,4%)GPROA; aceptadas: 83,3%PROAFARM-vs-84,2%GPROA. \n \nIndicaci\u00f3n inicio antibi\u00f3tico: 19(2,2%): 8(42,1%)PROAFARM y 11(57,9%)GPROA; aceptadas: 100,0%PROAFARM-vs-\n90,9%GPROA \ufffd \n \nModificaci\u00f3n dosis: 118(13,6%): 101(85,6%)PROAFARM y 17(14,4%)GPROA; aceptadas: 88,1%PROAFARM-vs-\n100,0%GPROA \ufffd \n \nModificaci\u00f3n duraci\u00f3n: 67 (7,7%): 32(47,8%)PROAFARM y 35(52,2%)GPROA; aceptadas: 96,9%PROAFARM-vs-\n88,6%GPROA \ufffd \n \nModificaci\u00f3n frecuencia: 28(3,2%): 23(82,1%)PROAFARM y 5(17,9%)GPROA; aceptadas: 87,0%PROAFARM-vs-\n80,0%GPROA \ufffd \n \nRetirar antibi\u00f3tico: 106(12,2%): 37(34,9%)PROAFARM y 69(65,1%)GPROA; aceptadas: 94,6%PROAFARM-vs-81,2%GPROA. \n \nSeguimiento tratamiento/validaci\u00f3n: 251(28,9%):67(26,7%)PROAFARM y 184(73,3%)GPROA. \n \nTerapia secuencial: 26(3,0%): 10(38,5%)PROAFARM y 16(61,5%)GPROA; aceptadas: 90,0%PROAFARM-vs-68,8%GPROA. \n \nFarmacocin\u00e9tica (exclusivamente PROAFARM): 25(2,9%): aceptadas:96,0%.\nCONCLUSIONES\n-Las intervenciones PROAFARM representaron m\u00e1s de la mitad en el periodo estudiado, suponiendo m\u00e1s del 80% de \nlos ajustes por insuficiencia renal, modificaci\u00f3n de dosis, frecuencia y desetiquetado de alergia. Mientras que en m\u00e1s \nde un 60% de los casos el GPROA realiz\u00f3 el desescalado, seguimiento del tratamiento, retirada del antibi\u00f3tico y terapia \nsecuencial\ufffd  \n \n-El grado de aceptaci\u00f3n global de las intervenciones es \u226570%. Se observ\u00f3 una aceptaci\u00f3n entre 10-20% superior en la \nrecomendaci\u00f3n de modificaci\u00f3n de dosis para el GPROA y en la retirada de antibi\u00f3tico para el PROAFARM. En el caso de la \nterapia secuencial, el PROAFARM obtuvo un 20% m\u00e1s de aceptaci\u00f3n. En el resto de intervenciones la diferencia es inferior \nal 10%\ufffd 441-Agregando las 4 intervenciones mayoritarias del PROAFARM y el GPROA se alcanz\u00f3 pr\u00e1cticamente el 60% de las \nintervenciones realizadas, por lo que una evaluaci\u00f3n multidisciplinar permite abordar un mayor n\u00famero de aspectos para \nla optimizaci\u00f3n de la terapia antimicrobiana.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1235. ANEMIA HEMOL\u00cdTICA INDUCIDA POR CEFTRIAXONA: A PROPOSITO DE UN CASO \nAUTORES\nDEL R\u00cfO GUTI\u00c9RREZ, JM; PUERTAS SANJUAN, A; PAU PARRA, A; GRACIA MOYA, A; MONTORO RONSANO, B; GORGAS \nTORNER, MQ\nH. UNIVERSITARI GENERAL DE LA VALL D\u2019HEBRON. PASSEIG VALL D\u2019HEBRON 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLa anemia hemol\u00edtica inducida por f\u00e1rmacos (AHIF) es un efecto adverso muy raro pero potencialmente mortal. Aunque \nno est\u00e1n del todo esclarecidos los mecanismos por los cuales se produce este evento, si se sabe que el principal implicado \nes el sistema inmune: los f\u00e1rmacos inducen la formaci\u00f3n de anticuerpos (IgG o IgM) que act\u00faan sobre la membrana \ncelular de los eritrocitos, produciendo una lisis celular directa o una lisis indirecta mediante el secuestro espl\u00e9nico.  \n \nLos principales f\u00e1rmacos sospechosos de inducir una AHIF son, entre otros, las sulfamidas, la nitrofuranto\u00edna, el \ndiclofenaco o las cefalosporinas. Debido a que se trata de un evento muy extraodinario, la evidencia sobre la incidencia, \ndiagn\u00f3stico y manejo de la AHIF es a\u00fan escasa.  \n \nEl objetivo del estudio fue la descripci\u00f3n del caso de una paciente que desarrollo AHIF tras la administraci\u00f3n de una dosis \nde ceftriaxona y su evoluci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nSe trata de una paciente de 23 a\u00f1os que ingres\u00f3 con diagn\u00f3stico de endocarditis infecciosa. Como antecentes de inter\u00e9s, \npadece de cardiopat\u00eda cong\u00e9nita cian\u00f3tica compleja, presencia de dextrocardia, comunicaci\u00f3n intraventricular estenosis \nde la v\u00e1lvula pulmonar e ictus cardioemb\u00f3lico.  \n \nComo tratamiento antiinfeccioso se prescribi\u00f3 ceftriaxona 2 gramos cada 24 horas. \n \nSe presenta el caso de una paciente que desarroll\u00f3 anemia hemol\u00edtica tras la administraci\u00f3n de una dosis de ceftriaxona.\nRESULTADOS\nA las cinco horas de la administraci\u00f3n de la primera dosis de ceftriaxona, la paciente present\u00f3 fatiga, debilidad y mareos. \nAnte este cuadro cl\u00ednico, se decidi\u00f3 realizar una anal\u00edtica de urgencia, donde se observ\u00f3 un descenso de la hemoglobina a \n3,8 g/dl, un aumento de la LDH a m\u00e1s de 600 UI/L y un descenso de la haptoglobina plasm\u00e1tica a indetectable.  \n \nSe orient\u00f3 el diagn\u00f3stico como una anemia hemol\u00edtica aguda. Se decidi\u00f3 terminar el tratamiento con ceftriaxona ante la \nsospecha de ser el responsable del evento y se inici\u00f3 tratamiento con ampicilina. Se monitoriz\u00f3 a la paciente de manera \nconstante, se realizaron varias tandas de transfusiones sangu\u00edneas diarias y se inici\u00f3 corticoterapia con metilprednisolona \n80 mg cada 24 horas durante cuatro d\u00edas. A los seis d\u00edas de ingreso la paciente remont\u00f3 hasta alcanzar una hemoglobina \nde 10,6 g/dl. Ante la mejor\u00eda cl\u00ednica y estabilidad, se le da el alta hospitalaria tras diez d\u00edas de ingreso. \n \nSe supuso que el responsable de la anemia hemol\u00edtica fue la ceftriaxona. Este diagn\u00f3stico fue confirmado mediante \nel cultivo de suero sangu\u00edneo junto al antibi\u00f3tico, detect\u00e1ndose anticuerpos anti-ceftriaxona y la formaci\u00f3n de \ninmunocomplejos con los eritrocitos de la paciente.\nCONCLUSIONES\nLa AHIF es un evento raro pero que puede llegar a ser de gran gravedad. En este caso, el manejo de la paciente consisti\u00f3 \nen la retirada del f\u00e1rmaco sospechoso de provocar la AHIF, transfusiones sangu\u00edneas y corticoterapia. Pese a no ser un \ntratamiento espec\u00edfico, result\u00f3 ser eficaz. Dado que la AHIF puede confundirse con una anemia hemol\u00edtica de origen \nprimario, es recomendable confirmar el diagn\u00f3stico mediante la detecci\u00f3n de inmunocomplejos y de anticuerpos anti-\nfarmaco mediante el cultivo del f\u00e1rmaco junto a suero sangu\u00edneo del paciente.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1244. AN\u00c1LISIS DE LA EFECTIVIDAD DEL SWITCH A BITERAPIA BASADA EN DOLUTEGRAVIR/RILPIVIRINA \nEN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nGUTI\u00c9RREZ FERN\u00c1NDEZ, I; DE FRUTOS DEL POZO, M; VICENTE GONZALEZ, B; ARN\u00c1IZ D\u00cdEZ, S; ESPINOSA G\u00d3MEZ, MP; \nMACH\u00cdN MORON, M\u00c1; G\u00dcEMES GARC\u00cdA, M; BRIONES CUESTA, E\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS442OBJETIVOS\nDolutegravir/rilpivirina (DTG/RPV) est\u00e1 indicado en pacientes infectados por VIH-1, virol\u00f3gicamente suprimidos (carga \nviral(CV) indetectable(CVI): < 50 copias/ml) en una pauta antirretroviral estable de \u22656meses sin antecedentes de fracaso \nvirol\u00f3gico(FV) y sin resistencias a cualquier inhibidor de la transcriptasa inversa no nucle\u00f3sido o inhibidor de la integrasa. \nObjetivo: evaluar la efectividad del switch a biterapia basada en DTG/RPV en pacientes diagnosticados de VIH frente al \ntratamiento previo con triple terapia antirretroviral estable (TTAE) en un hospital terciario.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo, retrospectivo de pacientes VIH+ en tratamiento con triple terapia, que pasaron a \nbiterapia con DTG/RPV durante el periodo de estudio (mayo2019-diciembre2021).  \nCriterios de inclusi\u00f3n: recogida de DTG/RPV en la consulta de pacientes externos (PE) de farmacia, TTAT estable previa \ndurante \u22656meses.  \nCriterios de exclusi\u00f3n: DTG/RPV \u22646meses dentro del periodo estudio, no disponibilidad de datos anal\u00edticos [CV y linfocitos \nCD4+(LCD4)] previos y/o posteriores al switch, recoger antirretrovirales asociados a DTG/RPV. \nSe recogieron variables a partir de la historia cl\u00ednica electr\u00f3nica, programa de laboratorio y m\u00f3dulo de dispensaci\u00f3n a \nPE: fecha de nacimiento, sexo, TTAE previa\u22656meses, fecha de inicio biterapia, LCD4+ (cel/\u03bcL) y CV (copias/ml) (\u00faltima \nanal\u00edtica previa al switch y posteriores). Se define FV: > 50 copias/ml en 2 determinaciones consecutivas, separadas por \n2-4 semanas. Se analiz\u00f3 el control inmunol\u00f3gico (LCD4+ > 300 c\u00e9lulas/\u03bcL) y virol\u00f3gico antes y despu\u00e9s del switch con \nMicrosoft Excel.\nRESULTADOS\n137 pacientes recogieron DTG/RPV durante el periodo de estudio con TTAE estable previa \u22656meses. Se excluyeron 5 \npacientes por biterapia \u22646 meses y 10 por no disponer de datos anal\u00edticos: antes y despu\u00e9s del switch en 1 paciente \ny despu\u00e9s del switch en 9 (3 de ellos adem\u00e1s tomaban otro f\u00e1rmaco asociado a DTG/RPV). Ninguno present\u00f3 FV, se \nobservaron BLIPS (CV=50-500 copias/ml) aislados en 8 pacientes (6 previos y 2 posteriores al switch. En 1 caso con 2 \ndeterminaciones aisladas > 30.000 copias por abandonos del tratamiento recuperando CVI en < 4 semanas tras insistir en \nla adherencia).  \nDe los 122 pacientes a estudio, el 77,05% eran hombres con una edad media de 50,05 a\u00f1os (IC95% 48,06-52,03a\u00f1os). \nLa media de duraci\u00f3n de la biterapia durante el periodo de estudio fue 24,43 meses (IC95% 23,41-25,46meses). En el \nan\u00e1lisis previo al switch se observaron datos de LCD4 con una media de 818,53 cel/\u03bcL (IC95% 748,77-888,29 cel/\u03bcL) y \ncontrol virol\u00f3gico=100%. Los datos observados tras el cambio fueron: media de LCD4 805,12 cel/\u03bcL (IC95% 745,90-864,35 \ncel/\u03bcL) y control virol\u00f3gico=100%. La diferencia de medias fue 13,40 cel/\u03bcL (IC95% -0,05-13,35 cel/\u03bcL), p-valor=0.257 \n(mediante prueba t Student para datos apareados). Estos valores indican que no hay diferencias estad\u00edsticamente \nsignificativas ya que el IC95% incluye el valor cero y p > 0.05. Por tanto, el control inmunol\u00f3gico y virol\u00f3gico se mantiene \ntras el cambio a DTG/RPV \ufffd\nCONCLUSIONES\nLa estrategia de simplificaci\u00f3n del tratamiento antirretroviral a un r\u00e9gimen dual de mantenimiento basado en DTG/RPV \nno presenta diferencias en cuanto a efectividad en comparaci\u00f3n a pautas de tres f\u00e1rmacos. La biterapia es una opci\u00f3n \npara aquellos pacientes que quieran simplificar su r\u00e9gimen actual manteniendo la eficacia.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1247. ESTUDIO SOBRE EFECTOS ADVERSOS DE LA ANTIBIOTERAPIA INHALADA EN PACIENTES CON \nENFERMEDAD PULMONAR OBSTRUCTIVA CR\u00d3NICA Y/O BRONQUIECTASIAS \nAUTORES\nSALAZAR GONZ\u00c1LEZ, F; CASTELLS LAO, G; COUSO , A; IGLESIAS RODRIGO, M; SEBASTI\u00c1N CARRASCO, C; MECA \nCASASNOVAS, N; NICOL\u00c1S PIC\u00d3, J\nHOSPITAL UNIVERSITARI MUTUA DE TERRASSA \ufffd PLAZA DOCTOR ROBERT 5 TERRASSA \ufffd BARCELONA\nOBJETIVOS\nDeterminar la prevalencia de efectos adversos (EA) que propiciaron la discontinuaci\u00f3n del tratamiento con antibioterapia \ninhalada en pacientes con EPOC y/o bronquiectasias con infecci\u00f3n bronquial cr\u00f3nica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional unicentrico retrospectivo realizado en un hospital universitario de 450 camas. Se incluyeron los \npacientes desde febrero de 2011 hasta mayo de 2022, con diagn\u00f3stico de EPOC y/o bronquiectasias con infecci\u00f3n cr\u00f3nica \npor Pseudomonas aeruginosa, Stenotrophomonas maltophilia o Escherichia coli y que fueron tratados con Colistina o \nTobramicina inhalada.  \nLas variables recogidas fueron edad, sexo, enfermedad de base, f\u00e1rmaco prescrito, posolog\u00eda, fecha inicio y fin de \ntratamiento, motivo de discontinuaci\u00f3n del tratamiento, fecha cultivo de esputo previo inicio del tratamiento y fecha de \nla primera negativizaci\u00f3n del cultivo del esputo.  \nLa variable principal fue el porcentaje de pacientes que discontinuaron el tratamiento por presentar un EA. Se realiz\u00f3 un \nan\u00e1lisis descriptivo de las variables y un an\u00e1lisis de supervivencia mediante curvas Kaplan Meier\nRESULTADOS\nSe incluyeron 192 pacientes, de los cuales 126 eran hombres (65.62%), entre las enfermedades de base de la poblaci\u00f3n \nestudiada se observ\u00f3 que 68 pacientes (35,42%) padec\u00edan EPOC, 62 (32,29%) bronquiectasias y el resto la combinaci\u00f3n \nde ambos\ufffd  443Entre los antibi\u00f3ticos m\u00e1s empleados destacaron: Bramitob\u00ae con 59 pacientes tratados (30.73%), Colistina 1M UI EFG \n41 pacientes (21.35%), Colistina 2M UI EFG 34 pacientes (17.71%), Promixin\u00ae 34 pacientes (17.71%), Colobreathe\u00ae 19 \npacientes (9.90%). El microrganismo aislado en el cultivo del esputo que llev\u00f3 al inicio del tratamiento fue Pseudomonas \naeruginosa en 186 pacientes (96.88%). \n151 pacientes discontinuaron el tratamiento de los cuales 98 fueron por EA, siendo los m\u00e1s frecuentes: Disnea en 54 \npacientes (55.10%) y broncoespasmo en 31 pacientes (31.63%). \nSe observ\u00f3 c\u00f3mo en 33 pacientes (55.93%) del total de tratados con Bramitob\u00ae se registraron EA que llevaron a su \ndiscontinuaci\u00f3n, en aquellos con Colistina 2M UI EFG fueron 17 pacientes (50%) los que discontinuaron por alg\u00fan EA, con \nPromixin\u00ae discontinuaron por EA 15 pacientes (44,11%), distintos EA llevaron a 18 pacientes (43.90%) en tratamiento con \nColistina 1M UI EFG, mientras que 8 pacientes (42.1%) con Colobreathe\u00ae lo suspendieron por EA. \nLa media de d\u00edas hasta la aparici\u00f3n de EA que llevo a la finalizaci\u00f3n del tratamiento fue de 388.41 d\u00edas con Colistina 2M \nUI EFG, 251.76 d\u00edas con Bramitob\u00ae, 222.22 d\u00edas con Colistina 1M UI EFG, 209.73 d\u00edas con Promixin\u00ae y 58.87 d\u00edas con \nColobreathe\u00ae.\nCONCLUSIONES\nGran cantidad de pacientes discontinuaron la antibioterapia inhalada por EA, siendo aquellos de car\u00e1cter respiratorio \nlos m\u00e1s mayoritarios. Tanto el Bramitob\u00ae como la Colistina 2M UI EFG fueron los f\u00e1rmacos con mayor porcentaje de \ndiscontinuaci\u00f3n. Colobreathe\u00ae fue el f\u00e1rmaco con menor tiempo hasta la aparici\u00f3n de EA con respecto a los dem\u00e1s \nf\u00e1rmacos. Este hecho confirma que la inhalaci\u00f3n de antibi\u00f3ticos con polvo seco puede propiciar una aparici\u00f3n de EA m\u00e1s \nprematura respecto a los nebulizados.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n1254. COMPARACI\u00d3N DEL PATR\u00d3N DE RESISTENCIAS ANTIMICROBIANAS DE UN CENTRO \nSOCIOSANITARIO Y SU HOSPITAL DE REFERENCIA. \nAUTORES\nFRUCTUOSO GONZ\u00c1LEZ, L; ALONSO DOMINGUEZ, T; HU\u00c9SCAR PASCUAL, MD; TORRANO BELMONTE, P; GUTI\u00c9RREZ \nSANCHEZ, JA; HERNANDEZ SANCHEZ, M; CARVAJAL SANCHEZ, M\u00c1; PACHECO LOPEZ, P\nHOSPITAL J.M. MORALES MESEGUER. AV . MARQU\u00c9S DE LOS V\u00c9LEZ, S/N. MURCIA. MURCIA\nOBJETIVOS\nComparar la distribuci\u00f3n y el patr\u00f3n de resistencia antimicrobiano de los microorganismos causantes de infecciones \nurinarias en un centro sociosanitario con el de su hospital de referencia.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo, descriptivo en el que a trav\u00e9s del programa del laboratorio de microbiolog\u00eda \nse revisaron los microorganismos aislados en los cultivos urinarios as\u00ed como su patr\u00f3n de resistencia en el centro \nsociosanitario, en el hospital durante el a\u00f1o 2021.\nRESULTADOS\nDe los 34.630 urocultivos realizados en el hospital en 2021, 10.329 fueron positivos. Se encuentran institucionalizados \n110 pacientes en la residencia con una media de edad fue de 84 a\u00f1os, siendo el 76% mujeres. Se incluyeron en el estudio \nun total de 54 pacientes del centro sociosanitario, con sospecha de infecci\u00f3n urinaria, y se presentaron un total de 32 \nurocultivos positivos de 23 pacientes diferentes, presentando por tanto el 21% infecciones de repetici\u00f3n. Dieron positivo \npara 8 microorganismos: Escherichia coli (35.5%), Klebsiella pneumoniae (25.81%), Enterococcus faecalis (16.13%), \nProvidencia stuartii (9.7%), Enterococcus avium (3.2%), Proteus mirabilis (3.2%), Pseudomonas aeruginosa (3.2%), \nMorganella morganii (3.2%).  \n \nEn cuanto a las distribuciones de los microorganismo, al comparar los datos obtenidos en el a\u00f1o 2021 con los del hospital \nen este \u00faltimo, de los 2223 urocultivos positivos para estos microorganismos la distribuci\u00f3n es la siguiente: E. coli (51%), \nseguido de E. faecalis (18.5%), Klebsiella pneumoniae (13.7%), Proteus mirabilis (6.4%), Pseudomonas aeruginosa (6.4%), \nMorganella morganii (2.3); Providencia stuartii (0.7%).  \n \nEn lo relativo a las resistencias, se analizaron y compararon los 2 microorganismo principales:  \nDe los urocultivos E.coli en el centro sociosanitario, el 18% presenta beta lactamasas de espectro extendido (frente al \n5% en el hospital), el 54% eran resistentes a la fluoroquinolona ciprofloxacino (frente al 21%) , otro 9% eran resistentes \na fosfomicina (frente al 4%), 36% resistentes a cotrimoxazol (22%), el 54% eran resistentes a penicilinas (igual que en el \nhospital) y el 27% eran resistentes a penicilinas con un inhibidor de beta lactamasas (amoxicilina/clavulanico),frente a \nsolo el 12\ufffd7%\ufffd  \nPara Klebsiella pneumoniae en el centro sociosanitario: 9% presenta beta lactamasas de espectro extendido (frente a un \n7.8% en el hospital), el 75% eran resistentes a fluoroquinolonas (frente al 11.8%), el 75% eran resistentes a fosfomicina \n(frente al 65%), 37.5% resistentes a cotrimoxazol (frente al 12.8%), el 25% eran resistentes a penicilinas con un inhibidor \nde beta lactamasas (frente al 20%).\nCONCLUSIONES\nLos patrones de resistencia de ambos centros sanitarios var\u00edan considerablemente. A destacar la diferencia de resistencia \nen el caso de E. coli a fluoro quinolonas, ya que m\u00e1s del 50% de las cepas son resistentes a este f\u00e1rmaco por su uso en \nel centro sociosanitario y menos del 25% lo son en el hospital. Al igual que para Klebsiella pneumoniae, de un 11.8% de 444resistencia a fluoro quinolonas, en el centro sociosanitario observamos hasta un 75% de resistencia. Estos resultados \nincitan a tomar medidas para mejorar el patr\u00f3n de resistencias en los centros sociosanitarios, teniendo los farmac\u00e9uticos \nhospitalarios herramientas disponibles a su alcance para llevarlas a cabo.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n90. EXPERIENCIA DE LA UTILIZACI\u00d3N DE LONOCTOCOG ALFA EN LA PROFILAXIS DEL SANGRADO \nPERIOPERATORIO EN PACIENTES CON HEMOFILIA A \nAUTORES\nJU\u00c1REZ GIM\u00c9NEZ, JC; BEN\u00cdTEZ HIDALGO, O\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nEl manejo perioperatorio del paciente con Hemofilia A, requiere ajustar los niveles de Factor VIII (FVIII) conforme al \ntipo de cirug\u00eda y el nivel de factor necesario para impedir hemorragias y favorecer la cicatrizaci\u00f3n adecuada de la herida \nquir\u00fargica. El objetivo principal del presente trabajo es mostrar la experiencia de utilizaci\u00f3n en vida real de lonoctocog \nalfa, un FVIII recombinante de tercera generaci\u00f3n sin dominio B, en una poblaci\u00f3n de pacientes con Hemofilia A \nsometidos a diferentes tipos de cirug\u00eda.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo, abierto y unic\u00e9ntrico en el que se incluyeron los pacientes Hemof\u00edlicos tipo A sometidos a cirug\u00eda \ndurante el a\u00f1o 2021 y que fueron tratados con lonoctocog alfa durante todo el perioperatorio. Para cada paciente se \nrecopilaron los datos antropom\u00f3rficos (peso y edad), gravedad de la hemofilia, tipo de cirug\u00eda, tipo de perfusi\u00f3n, numero \nde dosis y unidades totales administradas previas, y numero de dosis administradas post cirug\u00eda, unidades totales \nadministradas y eficacia hemost\u00e1tica evaluada en 4 grados (mala, moderada, buena y excelente). Tambi\u00e9n se realiz\u00f3 \nun estudio de minimizaci\u00f3n de costes comparando con otros FVIII recombinantes de tercera generaci\u00f3n de vida media \nextendida (EHL) y plasm\u00e1tico.\nRESULTADOS\nSe incluyeron7 pacientes adultos (Hemofilia A leve y una paciente portadora de hemofilia con niveles bajos de FVIIII de \nmediana de edad 59 a\u00f1os (7-81) y mediana de peso 66kg (22.2-90 ), some tidos a 9 cirug\u00edas, con la siguiente distribuci\u00f3n: \nuna cirug\u00eda card\u00edaca (qu\u00edntuple bypass coronario), cuatro cirug\u00edas ortop\u00e9dicas ( 3 Hallux valgus y una reparaci\u00f3n de \nligamento colateral cubital) y cuatro cirug\u00edas menores (1 timpanoplastia; 1 vasectom\u00eda y 2 hernias inguinales). Todas las \nadministraciones previas y durante la cirug\u00eda se realizaron mediante un bolus intravenoso, y solo se administr\u00f3 una sola \ndosis previa. El paciente con cirug\u00eda card\u00edaca fue el que present\u00f3 un mayor n\u00famero de unidades totales consumidas, \nhasta 21000 UI, con 15 dosis postquir\u00fargicas y una eficacia hemost\u00e1tica excelente. En las cirug\u00edas ortop\u00e9dicas se \nconsumi\u00f3 una media de 4375 UI +/- 1875 UI, necesitando una dosis postquirurgica en 3, siendo la eficacia hemost\u00e1tica \nexcelente en todas ellas. Respecto a las cirug\u00edas menores, se consumi\u00f3 una media de 5375 UI +/- 1625 UI, necesitando \nuna media de 2,5 dosis postquirugicas, siendo la eficacia hemost\u00e1tica clasificada como excelente en 3, y como buena en \nuna de ellas. En el an\u00e1lisis global de minimizaci\u00f3n de costes de todas las cirug\u00edas, present\u00f3 una media de ahorro de 2600 \n\u20ac respecto a la utilizaci\u00f3n de un FVIII EHL y una media de ahorro de 1200 \u20ac respecto a la utilizaci\u00f3n de un FVIII plasm\u00e1tico.\nCONCLUSIONES\nEn nuestra poblaci\u00f3n de pacientes sometidos a cirug\u00eda, lonoctocog alfa mostr\u00f3 una excelente eficacia hemost\u00e1tica en la \ngran mayor\u00eda de las cirug\u00edas evaluadas con un coste inferior a las alternativas potenciales.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n191. EFICIENCIA DEL AJUSTE FARMACOCIN\u00c9TICO INDIVIDUALIZADO FRENTE A DOSIFICACI\u00d3N \nCONVENCIONAL DE DOS CONCENTRADOS DE FIX DE VIDA MEDIA EXTENDIDA. \nAUTORES\nJU\u00c1REZ GIM\u00c9NEZ, JC; BEN\u00cdTEZ HIDALGO, O; ROMERO GARRIDO, JA; MATEOS SALILLAS, C; GONZ\u00c1LEZ PI\u00d1EIRO, S; \nMONTORO RONSANO, JB\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLos concentrados de factor IX recombinantes (rFIX) de vida media extendida (VME), pueden mejorar la eficiencia del \ntratamiento y profilaxis de la Hemofilia B (HB) gracias al aumento del intervalo terap\u00e9utico y la optimizaci\u00f3n de la dosis. El \nobjetivo es comparar la eficiencia del tratamiento, en dos concentrados de rFIX VME, obtenida utilizando un ajuste de los \npar\u00e1metros farmacocin\u00e9ticos mediante un modelo poblacional y un modelo monocompartimental individual de regresi\u00f3n \nlineal, frente a la dosificaci\u00f3n convencional (DC).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, multic\u00e9ntrico, prospectivo desde enero de 2021 a marzo de 2022. Pacientes con HB grave tratados \nen tres unidades de Hemofilia y aprobado por los distintos CEIMs. Se incluyeron pacientes que hab\u00edan recibido un rFIX \nVME del tipo FIX unido a alb\u00famina (rFIX- FP) o FIX unido a un fragmento cristalizable de IgG (rFIXFc). Se registr\u00f3 la pauta 445de DC y el nivel valle sostenido, basada en las recomendaciones de las fichas t\u00e9cnicas. Las concentraciones de rFXI se \ndeterminaron por primera etapa de la coagulaci\u00f3n. Los datos se introdujeron en el programa poblacional WAPPS-HEMO \ny un programa basado en el c\u00e1lculo monocompartimental. Para cada modelo y preparado, se realiz\u00f3 una estimaci\u00f3n \ndel tiempo de cobertura para alcanzar 0,05 UI/mL de FIX. El an\u00e1lisis estad\u00edstico se realiz\u00f3 el test t-Student-Fisher, de \ncomparaci\u00f3n de medias\ufffd\nRESULTADOS\nSe incluyeron un total de 15 pacientes. Nueve pacientes tratados con rFIX-FP con una media de 60 kg y 33 a\u00f1os. \nSeis pacientes tratados con rFIXFc con una media de 86 kg y 49 a\u00f1os. La pauta de DC media era 3222 UI (SD, 1716) \ncada 11,9 d\u00edas (SD, 4,4) para rFIX-FP y de 4333 UI (SD, 606) cada 14,0 d\u00edas (SD, 0,0) para rFIXFc . El intervalo de \ndosificaci\u00f3n individualizado, para una actividad m\u00ednima de 0,05 UI/dL, respetando la dosis prescrita, aplicando modelo \nmonocompartimental, fue: 13,6 d\u00edas (SD, 5,1), -1,8 d\u00edas (SD, 5,9) frente a DC, 240 UI/d\u00eda (SD, 136,1), para rFIX-FP (p=0,40), \ny de 8,6 d\u00edas (SD, 1,2), +5,4 d\u00edas (SD, 1,2) frente a DC, 508 UI/d\u00eda (SD, 65,6), para rFIXFc, (p < 0,001); aplicando WAPPS- \nHEMO, fue: 15,0 d\u00edas (SD, 5,1), -3,1 d\u00edas (SD, 5,3) frente a DC, 217 UI/d\u00eda (SD, 114,7), para rFIX-FP (p=0,12), y de 10,2 d\u00edas \n(SD, 2,5), +3,8 d\u00edas (SD, 2,5) frente a DC, 449,7 UI/d\u00eda (SD, 129,1), para rFIXFc, (p=0,012).\nCONCLUSIONES\nLa eficiencia del tratamiento con rFIX VME mediante un ajuste PK individualizado frente a la dosificaci\u00f3n convencional \n(DC) es significativamente superior. Seg\u00fan el concentrado de rFIX, las necesidades son distintas para una actividad m\u00ednima \nde 0,05 UI/dL: 217 \u2013 240 UI/d\u00eda para rFIX-FP , o 449 \u2013 508 UI/d\u00eda para rFIXFc, seg\u00fan el modelo PK empleado, poblacional o \nmonocompartimental individual.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n230. EVALUACI\u00d3N Y COMPARACI\u00d3N DEL PERFIL FARMACOCIN\u00c9TICO DE DOS CONCENTRADOS DE FIX DE \nVIDA MEDIA EXTENDIDA EN PACIENTES CON HEMOFILIA B \nAUTORES\nJU\u00c1REZ GIM\u00c9NEZ, JC; BEN\u00cdTEZ HIDALGO, O; ROMERO GARRIDO, JA; MATEOS SALILLAS, C; GONZ\u00c1LEZ PI\u00d1EIRO, S; \nBRUNO MONTORO, J\nH. UNIVERSITARI MATERNOINFANTIL DE LA VALL D`HEBRON. PASSEIG VALL D\u00b4HEBRON 119-129 BARCELONA. \nBARCELONA\nOBJETIVOS\nEn la actualidad se dispone de varios preparados de factor IX recombinantes (rFIX) de vida media extendida (VME) para \nla profilaxis de la Hemofilia B (HB). Seg\u00fan los datos de sus fichas t\u00e9cnicas, los par\u00e1metros farmacocin\u00e9ticos (PK) son \ndiferentes, por lo que las dosis y intervalos tambi\u00e9n pueden diferenciarse. El objetivo del presente trabajo es evaluar y \ncomparar los PK de dos concentrados de rFIX VME comercializados en nuestro medio, en una poblaci\u00f3n de pacientes con \nHB grave, en condiciones pragm\u00e1ticas o vida real utilizando un modelo poblacional y un modelo monocompartimental de \nregresi\u00f3n lineal\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio, multic\u00e9ntrico, observacional y prospectivo, de enero del a\u00f1o 2021 a marzo del a\u00f1o 2022, aprobado por el \nCEIM de cada centro. Se incluyeron pacientes con HB grave que hab\u00edan recibido un rFIX VME del tipo: FIX unido a \nalb\u00famina (rFIX- FP) o un FIX unido a un fragmento cristalizable de IgG (rFIXFc). Se extrajeron un m\u00ednimo de tres muestras \na diferentes tiempos por paciente tras la administraci\u00f3n de una dosis seg\u00fan las pautas de las fichas t\u00e9cnicas de cada \npreparado en una perfusi\u00f3n IV de 5 minutos. Las concentraciones de rFXI se determinaron mediante una t\u00e9cnica \ncoagulativa en primera etapa. Se registraron las variables demogr\u00e1ficas y terap\u00e9uticas. Los datos obtenidos se procesaron \npor separado; mediante el programa poblacional WAPPS-HEMO y el programa de c\u00e1lculo monocompartimental. Los PK \nque se determinaron para cada concentrado con cada modelo fueron: constante de eliminaci\u00f3n (Ke; h-1), volumen de \ndistribuci\u00f3n (Vd; mL/kg), aclaramiento (Cl; mL/h/Kg) y vida media de eliminaci\u00f3n (t 1/2, h). El an\u00e1lisis estad\u00edstico se realiz\u00f3 \nel test t-Student-Fisher, de comparaci\u00f3n de medias entre los dos rFIX VME y los diferentes modelos.\nRESULTADOS\nSe incluyeron un total de 15 pacientes. Nueve pacientes tratados con rFIX-FP con una media de 60 kg y 33 a\u00f1os. Seis \npacientes tratados con rFIXFc con una media de 86 kg y 49 a\u00f1os. La media de puntos actividad-tiempo por paciente 3,4 \ny 3,2, respectivamente. Utilizando el modelo poblacional de WAPPS- HEMO los valores obtenidos de los PK, para rFIX- FP \nfrente a rFIXFc, fueron: Ke (h-1)= 0,0054 vs 0,0048 (p=0,338); Vd (mL/kg) =108,81 vs 217,41 (p < 0,001); Cl (mL/h/Kg)= \n0,229 vs 0,120 (p=0,331) y t 1/2 (h)= 135,7 vs 148,6 (p=0,428). Utilizando el modelo monocompartimental los valores de \nlos PK de rFIX- FP frente a rFIXFc fueron: Ke (h-1)= 0,008 vs 0,0278 (p=0,203); Vd (mL/kg) =117,29 vs 161,63 (p=0,123); Cl \n(mL/h/Kg)= 0,906 vs 1,59 (p=0,014) y t 1/2 (h)= 91,4 vs 71,9 (p=0,05).\nCONCLUSIONES\nLos preparados rFIX-FP y rFIXFc presentan diferencias significativas en los par\u00e1metros Cl y t \u00bd, cuando se eval\u00faan \nmediante el modelo monocompartimental, mostrando una t 1/2 superior para rFIX- FP; 91 h frente a 71,9 h de FIXFc. \nLa evaluaci\u00f3n mediante el modelo poblacional no ofrece diferencias entre ambos preparados para ninguno de los \npar\u00e1metros analizados.446CLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n330. AJUSTE FARMACOCIN\u00c9TICO EN PACIENTES CON HEMOFILIA B DE CONCENTRADOS DE FIX DE VIDA \nMEDIA EXTENDIDA MEDIANTE DIFERENTES MODELOS. \nAUTORES\nJU\u00c1REZ GIM\u00c9NEZ, JC; BEN\u00cdTEZ HIDALGO, O; ROMERO GARRIDO, JA; MATEOS SALILLAS, C; GONZ\u00c1LEZ PI\u00d1EIRO, S; \nMONTORO RONSANO, JB\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLa monitorizaci\u00f3n farmacocin\u00e9tica de los concentrados de factor IX recombinantes (rFIX) de vida media extendida \n(VME) es fundamental para optimizar la dosis, evitar los hemartros y favorecer intervalos de administraci\u00f3n amplios. La \nevidencia del perfil farmacocin\u00e9tico (PK) de estos f\u00e1rmacos es escasa debido a la baja prevalencia de la Hemofilia B (HB). \nEl objetivo del presente trabajo es calcular el PK de dos concentrados de rFIX VME que se obtiene utilizando un modelo \npoblacional y un modelo monocompartimental de regresi\u00f3n lineal, adem\u00e1s de comparar los resultados de cada modelo \npara cada preparado de forma individual\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, multic\u00e9ntrico, prospectivo, de enero de 2021 a marzo de 2022, en pacientes con HB grave tratados \nen tres unidades de Hemofilia diferentes, y aprobado por los distintos CEIMs. Se incluyeron pacientes que hab\u00edan recibido \nun rFIX VME del tipo FIX unido a alb\u00famina (rFIX- FP) o FIX unido a un fragmento cristalizable de IgG (rFIXFc). Para cada \npaciente se obtuvieron un m\u00ednimo de dos muestras a diferentes tiempos tras la administraci\u00f3n de una dosis basada en las \nrecomendaciones des las fichas t\u00e9cnicas y en una perfusi\u00f3n IV de 5 minutos. Las concentraciones de rFXI se determinaron \nmediante una t\u00e9cnica coagulativa en primera etapa. Tambi\u00e9n se registraron las variables demogr\u00e1ficas del tipo, edad y \npeso. Los datos obtenidos se introdujeron en el programa poblacional WAPPS-HEMO y un programa basado en el c\u00e1lculo \nmonocompartimental. Los par\u00e1metros farmacocin\u00e9ticos que se determinaron para cada concentrado con cada modelo \nfueron: constante de eliminaci\u00f3n (Ke; h-1), volumen de distribuci\u00f3n (Vd; mL/kg), aclaramiento (Cl; mL/h/Kg) y vida media \nde eliminaci\u00f3n (t 1/2,; h). El an\u00e1lisis estad\u00edstico se realiz\u00f3 el test t-Student-Fisher, de comparaci\u00f3n de medias.\nRESULTADOS\nSe incluyeron un total de 15 pacientes. Nueve pacientes tratados con rFIX-FP con una media de 60 kg y 33 a\u00f1os. Seis \npacientes tratados con rFIXFc con una media de 86 kg y 49 a\u00f1os. La media de puntos actividad-tiempo por paciente 3,4 \ny 3,2, respectivamente. Para rFIX-FP , los par\u00e1metros obtenidos con modelo monocompartimental frente WAPPS- HEMO \nfue: Ke (h-1)= 0,008 vs 0,005 (p=0,002); Vd (mL/kg) =117,29 vs 108,81(p=0,442); Cl (mL/h/Kg)= 0,906 vs 0,229 (p=0,001) y \nt 1/2 (h)= 91,4 vs 135,7 (p=0,002). Igualmente, Para rFIXFc, los resultados, comparando ambos m\u00e9todos fueron: Ke (h-1)= \n0,0278 vs 0,005 (p=0,001); Vd (mL/kg) =161,63 vs 217,41(p=0,041); Cl (mL/h/Kg)= 1,59 vs 0,12 (p=0,001) y t 1/2 (h)= 71,9 \nvs 148,6 (p=0,001).\nCONCLUSIONES\nSe observan diferencias estad\u00edsticamente significativas seg\u00fan el modelo utilizado en los diferentes par\u00e1metros \nfarmacocin\u00e9ticos, para cada f\u00e1rmaco. Para ambos preparados las diferencias se muestran en la Ke, el Cl y la t 1/2, y para \nrFIXFc las diferencias se muestran tambi\u00e9n para el Vd. Son necesarios m\u00e1s estudios que permitan establecer el modelo \nm\u00e1s adecuado para establecer el PK de cada preparado.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n364. AN\u00c1LISIS DE NIVELES S\u00c9RICOS DE VANCOMICINA EN UNA UNIDAD DE CUIDADOS INTENSIVOS \nNEONATALES \nAUTORES\nJIM\u00c9NEZ N\u00da\u00d1EZ, C; RUANO ENCINAR, M; AYLL\u00d3N MORALES, M; ESCARIO G\u00d3MEZ, M; COLLADA S\u00c1NCHEZ, VL; \nG\u00d3MEZ L\u00d3PEZ, L; HERRERO AMBROSIO, A\nHOSPITAL UNIVERSITARIO LA PAZ. P\u00ba DE LA CASTELLANA, 261 MADRID. MADRID\nOBJETIVOS\nAnalizar la correlaci\u00f3n entre la dosificaci\u00f3n y los niveles de vancomicina en la Unidad de Cuidados Intensivos Neonatales \n(UCIN) y evaluar la idoneidad del protocolo de dosificaci\u00f3n de la Unidad\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se obtuvieron de la Historia Cl\u00ednica Electr\u00f3nica entre los meses de febrero-\nabril de la UCIN, los niveles de vancomicina obtenidos, los datos de laboratorio de an\u00e1lisis cl\u00ednicos, la prescripci\u00f3n \nelectr\u00f3nica y los datos de edad post-menstrual (EPM).  \nSe consideraron valores dentro de rango terap\u00e9utico aquellos en funci\u00f3n del objetivo buscado en el tratamiento: entre \n10 y 15 mg/dl para infecciones moderadas y entre 15 y 20 mg/dl para infecciones graves o sepsis. La dosificaci\u00f3n de \nvancomicina en la UCIN es 15 mg/kg y la frecuencia de administraci\u00f3n est\u00e1 establecida por protocolo en funci\u00f3n de la \nEPM: < 29 semanas c/24h, 30-35 semanas c/12h y > 35 semanas c/8h.\nRESULTADOS\nDurante el periodo de estudio se solicitaron un total de 78 niveles s\u00e9ricos de vancomicina, de 29 pacientes distintos.  \nDe los 78 valores obtenidos, 38 se encontraron entre 10-15 mg/dl, requiriendo uno de ellos disminuci\u00f3n del intervalo 447posol\u00f3gico por sepsis. De los 10 niveles obtenidos por encima de 15 mg/dl, 2 se consideraron en rango de 15-20 mg/dl \npor sepsis, y 8 supraterap\u00e9uticos que precisaron disminuir dosis. Por debajo de 10 mg/dl se obtuvieron 31 niveles. Por lo \ntanto, se consider\u00f3 en rango terap\u00e9utico 40 de los valores obtenidos (51,28%), 8 en rango de toxicidad (10,2%) y 31 en \nrango infraterap\u00e9utico 31 (39,7%).  \nCinco de los 8 valores por encima del margen de toxicidad se atribuyeron a una paciente en tratamiento con ECMO \n(depuraci\u00f3n extracorp\u00f3rea) y otro coincidi\u00f3 con un aumento de creatinina s\u00e9rica del paciente por disminuci\u00f3n de la \ndiuresis\ufffd  \nLa distribuci\u00f3n por EPM y por pauta de inicio de tratamiento seg\u00fan protocolo fue:  \n- 4 pacientes (14%) de EPM < 29 semanas, y pauta de 15 mg/kg/24h. Todos ellos con valores infraterap\u00e9uticos al inicio \nque hubo que aumentar a cada 12h para conseguir niveles en rango \n- 7 pacientes (24%) de EPM entre 30 y 35 semanas, y pauta de 15 mg/kg/12h. De \u00e9stos, s\u00f3lo dos (28%) consiguieron \nniveles en rango al inicio de tratamiento, el resto precis\u00f3 de modificaci\u00f3n de frecuencia a cada 8 o cada 6h.  \n- 18 pacientes (62%) de EPM > 35 semanas, y pauta de 15 mg/kg/8h. De estos, el 39% comenz\u00f3 el tratamiento en rango \nterap\u00e9utico, el 16% en rango por encima de 15 mg/dl y se alarg\u00f3 intervalo a cada 12h y el 45% en rango infraterap\u00e9utico \nque requirieron disminuci\u00f3n del intervalo.\nCONCLUSIONES\nExiste una elevada variabilidad interindividual en los niveles s\u00e9ricos de vancomicina en el paciente neonatal, que se ve \nafectada tambi\u00e9n por el uso de dispositivos (ECMO), y precisa de una estrecha monitorizaci\u00f3n farmacocin\u00e9tica para \nobtener niveles en rango terap\u00e9utico y evitar toxicidad.  \nEs necesario adaptar los protocolos vigentes de dosificaci\u00f3n, siguiendo las gu\u00edas y recomendaciones de las sociedades \ncient\u00edficas y los valores obtenidos en vida real en la propia Unidad, especialmente en pacientes de EPM < 29 semanas.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n387. USO DE MODULADORES DEL CFTR EN PEDIATR\u00cdA \nAUTORES\nD\u00cdAZ PERALES, R; FERN\u00c1NDEZ MART\u00cdN, JM; YUNQUERA ROMERO, L; MART\u00cdN CLAVO, S; GALLEGO FERN\u00c1NDEZ, C\nHOSPITAL MATERNO INFANTIL \ufffd ARROYO DE LOS ANGELES, S/N M\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\nLos f\u00e1rmacos moduladores del CFTR (cystic fibrosis transmembrane conductance regulator) est\u00e1n indicados en fibrosis \nqu\u00edstica (FQ) al tratarse de la diana mutada en esta patolog\u00eda. Nuestro objetivo fue evaluar la efectividad, seguridad y \nadherencia de dichos f\u00e1rmacos en poblaci\u00f3n pedi\u00e1trica.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo, observacional y descriptivo en hospital de tercer nivel con pacientes pedi\u00e1tricos de FQ con \nmoduladores del CFTR desde Febrero 2020 a Enero 2021. Se revisaron historias cl\u00ednicas mediante Historia Cl\u00ednica Digital \ny registro de dispensaciones del programa de dispensaci\u00f3n a pacientes externos. Los pacientes se agruparon seg\u00fan \ntratamiento en grupos A (ivacaftor/lumacaftor) y B (ivacaftor/tezacaftor). Datos recogidos: demogr\u00e1ficos, tipo mutaci\u00f3n \ny seguimiento en semanas 0, 24, 48 y 72 de variables cl\u00ednicas respiratorias (porcentaje predicho del volumen espiratorio \nforzado en un segundo (pFEV1%), n\u00famero exacerbaciones pulmonares (EP) con hospitalizaci\u00f3n o antibi\u00f3tico IV) y estatus \nnutricional y desarrollo (\u00edndice masa corporal (IMC)). Respuesta cl\u00ednica: no reducci\u00f3n superior al 5% del pFEV1% en \nal menos 2 de las 3 mediciones recopiladas. Se analiz\u00f3 la notificaci\u00f3n de reacciones adversas (RA) y el abandono por \ntoxicidad de los excluidos del estudio para evaluar seguridad. Adherencia: medida porcentaje de medicaci\u00f3n dispensada \ndel total prescrita. Los datos se analizaron mediante estad\u00edstica descriptiva.\nRESULTADOS\nSe incluyeron once pacientes (64% varones; edad media: 11,73 a\u00f1os (6-16)). Tres (edad media: 7 a\u00f1os) en el grupo A y \nocho (edad media: 12 a\u00f1os) en el B. Todos portadores homocigotos de mutaci\u00f3n F508del. Media pFEV1% basal (semana \n0): 71,67% (\u00b124,8%) en grupo A y 77,38% (\u00b112,5%) en grupo B. Mediana EP: 1 en los 12 meses pr evios en ambos grupos. \nIMC medio: 15,1 (\u00b11,6) y 18,9 (\u00b12.4). Grupo A present\u00f3 variaci\u00f3n del pFEV1% de +6%, +7% y +8,6% y el B de +3,6%, \n+1,6% y -0,6%, a las 24, 48 y 72 semanas respectivamente desde inicio del tratamiento. La mediana de EP se redujo a 0 \na las 72 semanas y se increment\u00f3 el IMC medio hasta 16,34 (+8%) y 19,98 (+5,6%) en los grupos A y B respectivamente. \nTanto a las 24 como a las 48 semanas todos los pacientes fueron respondedores al tratamiento\ufffd A las 72 semanas 3 \npacientes (27,3%) del grupo B fueron clasificados como no respondedores. No se notific\u00f3 ninguna RA y s\u00f3lo un paciente \nfue excluido del estudio por toxicidad con tratamiento < 72 semanas (5% del total de pacientes del hospital tratados con \nestos f\u00e1rmacos). El grado de adherencia medio fue del 99,9% para el grupo A y 97,4% para el B.\nCONCLUSIONES\nEl incremento de pFEV1% refleja efectividad superior en el brazo con ivacaftor/lumacaftor aunque no es significativo dado \nel bajo n\u00famero de pacientes. \nCasi 3/4 partes de los pacientes (72,7%) mantuvieron efectividad durante las 72 semanas de seguimiento: todos los \ntratados con ivacaftor/lumacaftor y el 62,5% con ivacaftor/tezacaftor.  \nSon f\u00e1rmacos con un buen perfil de seguridad y tolerancia, con baja tasa de abandono por toxicidad.  \nA pesar de tratarse de tratamientos cr\u00f3nicos y complejos con numerosas recomendaciones nutricionales espec\u00edficas \npresentaron un alto grado de adherencia.448CLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n595. ADECUACI\u00d3N DEL USO DE INMUNOGLOBULINAS INESPEC\u00cdFICAS INTRAVENOSAS EN PEDIATR\u00cdA \nAUTORES\nRIVA DE LA HOZ, B; ITURGOYEN FUENTES, DP; ECH\u00c1VARRI DE MIGUEL, M; AG\u00dc\u00cd CALLEJAS, AM; GONZ\u00c1LEZ ANDR\u00c9S, \nD; RANZ ORTEGA, P; ARRIETA LOITEGUI, M; POZAS DEL R\u00cdO, MT\nHOSPITAL INFANTIL UNIVERSITARIO NI\u00d1O JESUS. AV . MEN\u00c9NDEZ PELAYO, 65 MADRID. MADRID\nOBJETIVOS\nTras la comunicaci\u00f3n del desabastecimiento mundial de inmunoglobulinas inespec\u00edficas intravenosas (IgIV), el \nServicio Madrile\u00f1o de Salud (SERMAS) public\u00f3 en noviembre de 2021 el documento \u201cCriterios para el uso racional de \ninmunoglubulinas\u201d para la priorizaci\u00f3n de su uso. El objetivo de este estudio es describir el grado de adecuaci\u00f3n a los \nmismos\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo que incluy\u00f3 a todos los pacientes tratados con IgIV en un hospital \npedi\u00e1trico entre diciembre de 2021 y abril de 2022. \nLas variables recogidas fueron: edad, sexo, servicio prescriptor e indicaci\u00f3n\ufffd Los datos se recogieron de los registros de los \nprogramas inform\u00e1ticos de dispensaci\u00f3n del Servicio de Farmacia y de prescripci\u00f3n electr\u00f3nica del centro.  \nSe revisaron las indicaciones de las distintas marcas de IgIV disponibles en el hospital y se clasificaron en funci\u00f3n del \ngrado de evidencia y de urgencia vital seg\u00fan los \u201cCriterios para el uso racional de inmunoglobulinas\u201d publicado por el \nSERMAS\ufffd\nRESULTADOS\nDurante el periodo de estudio recibieron al menos una administraci\u00f3n de IgIV 53 pacientes con una edad media de 10 \na\u00f1os (0-22), de los cuales el 53% eran varones.  \nEl principal servicio prescriptor fue Oncolog\u00eda M\u00e9dica (22 pacientes), seguido de Neurolog\u00eda (18) y Pediatr\u00eda general (8). \nEl resto de servicios fueron: Reumatolog\u00eda (2), Cuidados Paliativos (1), Endocrino (1) y Neumolog\u00eda (1). El 43% de las \nindicaciones no estaban autorizadas en ficha t\u00e9cnica.  \nLa mayor\u00eda de las IgIV (24) se prescribieron como tratamiento sustitutivo, siendo la hipogammaglobulinemia \ntras trasplante de progenitores hematopoy\u00e9ticos la principal indicaci\u00f3n (17). Las otras indicaciones fueron \nhipogammaglobulinemia secundaria (3), aplasia tras CART (2), inmunodeficiencia combinada (1) y s\u00edndrome de \ninmunodeficiencia (1). Como tratamiento inmunomodulador, autorizado en ficha t\u00e9cnica, las inmunoglobulinas se usaron \nen el s\u00edndrome de Kawasaki (4), trombocitopenia inmune (2) y polineuropat\u00eda desmielinizante (2). El resto de indicaciones \nfueron epilepsia refractaria (3), opsoclonus-mioclonus (3), encefalitis (2), primer episodio desmielinizante (2), s\u00edndrome \ndel shock t\u00f3xico (1), dermatomiositis (1), narcolepsia refractaria (1), paniculitis lipoatr\u00f3fica generalizada (1), s\u00edndrome \nde Rassmusen (1), trastorno desintegrativo (1), encefalomielitis recurrente (1), neuritis \u00f3ptica (1), s\u00edndrome inflamatorio \nmultisist\u00e9mico pedi\u00e1trico (1), mielitis (1) y hemosiderosis pulmonar (1).  \nSiguiendo los \u201cCriterios para el uso racional de inmunoglobulinas\u201d, el 36% de las indicaciones se encontraban fuera de \nlas recogidas en dicho documento. El 60% de los pacientes (32) se encontraban ante una situaci\u00f3n considerada como de \nurgencia vital grado 1, de los cuales 20 contaban con un grado de evidencia Ib, 8 con un grado de evidencia Ia, 3 con un \ngrado de evidencia III y 1 con un grado de evidencia IIb. Los 2 pacientes restantes se clasificaron como de urgencia vital \ngrado 2(1), con grados de evidencia Ia y III.\nCONCLUSIONES\nLa mayor\u00eda de las indicaciones para las que se utilizan las IgIV en nuestro hospital est\u00e1n autorizadas en ficha t\u00e9cnica y se \nadec\u00faan a las \u00faltimas recomendaciones publicadas por el SERMAS.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n651. USO DE ECULIZUMAB PARA LA MICROANGIOPAT\u00cdA TROMB\u00d3TICA EN PACIENTES PEDI\u00c1TRICOS. \nAUTORES\nFONT BARCEL\u00d3, A; SANCHEZ CELMA, M; ARROJO SUAREZ, J; MADRID ARIS, A; CASALDAGILA TORRECILLAS, A; \nWILLHELMI ROCA, E; FARR\u00c9 RIBA, R\nHOSPITAL DE SANT JOAN DE D\u00c8U. PASSEIG SANT JOAN DE D\u00c9U, 2 ESPLUGUES DE LLOBREGAT . BARCELONA\nOBJETIVOS\nEvaluar y describir el uso de eculizumab en pacientes pedi\u00e1tricos con microangiopat\u00eda tromb\u00f3tica (MAT) secundaria a \ntrasplante o alteraci\u00f3n gen\u00e9tica del complemento.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo y observacional incluyendo pacientes diagnosticados de MAT tratados con eculizumab entre 2009 y \n2021 en un hospital pedi\u00e1trico terciario.  \nMediante la historia cl\u00ednica se recogieron las siguientes variables: edad, sexo, tratamientos previos, alteraciones al debut \ny respuesta al tratamiento (al mes y a los seis meses).  \nLa evaluaci\u00f3n de la respuesta se bas\u00f3 en la recuperaci\u00f3n hematol\u00f3gica, con resoluci\u00f3n de la anemia hemol\u00edtica (niveles \nde lactato deshidrogenasa (LDH) normales y ausencia de esquistocitos) adem\u00e1s de plaquetas en rango. Tambi\u00e9n se evalu\u00f3 \nla mejora de la funci\u00f3n renal (FR) con normalizaci\u00f3n de los valores de tensi\u00f3n arterial (TA), creatinina s\u00e9rica y proteinuria \nnegativa.449RESULTADOS\nSe administr\u00f3 eculizumab en 13 pacientes, de los cuales 2 fueron excluidos por falta de datos. Los 11 pacientes incluidos \n(3 mujeres) debutaron a una mediana de edad de 5 a\u00f1os (0.5 - 18).  \nDel total de pacientes, 6 sufrieron una MAT secundaria a trasplante, todos ellos en tratamiento con inmunosupresores \n(ciclosporina o tacrolimus) considerados factor de riesgo. De los 6 pacientes, 5 no presentaron mejor\u00eda hematol\u00f3gica ni \nrenal (3/5 fallecieron antes de evaluar la respuesta y 2/5 precisaron plasmaf\u00e9resis por empeoramiento de la FR). En 1/5, \nal mes de tratamiento, se observ\u00f3 una resoluci\u00f3n de la anemia hemol\u00edtica con plaquetas normales, escasos esquistocitos \ny recuperaci\u00f3n de la FR. A los 6 meses, present\u00f3 recuperaci\u00f3n completa pudi\u00e9ndose retirar el tratamiento.  \nEl resto de pacientes (5/11) se diagnosticaron de MAT secundaria a s\u00edndrome ur\u00e9mico-hemol\u00edtico at\u00edpico (SHUa) y 2/5 \nfuerontratados previamente con plasmaf\u00e9resis.  \nAl debut, todos los pacientes presentaban alteraci\u00f3n renal con proteinuria, con 2/5 requiriendo hemodi\u00e1lisis, y 3/5 \nsufrian hipertensi\u00f3n. Todos presentaron anemia hemol\u00edtica con plaquetopenia, aumento de LDH y presencia de \nesquistocitos. Al mes de tratamiento con eculizumab, la anemia hemol\u00edtica se resolvi\u00f3 en 3/5 pacientes mientras que \nen el resto persist\u00edan esquistocitos. Al mes, la FR mejor\u00f3 significativamente en todos los pacientes con una creatinina \npr\u00f3xima a los valores normales y proteinuria negativa; sin embargo la TA precis\u00f3 control con antihipertensivos. A los 6 \nmeses se reevalu\u00f3 la FR y hematol\u00f3gica en 4/5 pacientes, en el otro paciente se suspendi\u00f3 el tratamiento por buena \nrespuesta. En 3/4 se observ\u00f3 tendencia a la normalizaci\u00f3n de la creatinina y TA de mejor control que permiti\u00f3 reducci\u00f3n \nde dosis o retirada de antihipertensivos. Se consigui\u00f3 una respuesta hematol\u00f3gica completa en todos los pacientes.  \nA 2/5 pacientes se suspendi\u00f3 el tratamiento por estabilidad y presencia de mutaci\u00f3n de bajo riesgo. No obstante, \nrecayeron requiriendo reinicio del tratamiento.\nCONCLUSIONES\n- Eculizumab presenta buenos resultados en los pacientes de nuestro estudio con MAT secundaria a SHUa, consiguiendo \nrecuperaci\u00f3n hematol\u00f3gica y renal.  \n- Los pacientes estudiados con MAT secundaria a trasplante presentan una peor evoluci\u00f3n, concordante con \ndatos previamente publicados, por presentar un mecanismo fisiopatol\u00f3gico distinto y ser pacientes con mayores \ncomorbilidades\ufffd  \n- En nuestro estudio se pude observar que la recuperaci\u00f3n hematol\u00f3gica es m\u00e1s precoz que la renal.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n661. EFECTIVIDAD A LARGO PLAZO DE LUMACAFTOR-IVACAFTOR EN PACIENTES CON FIBROSIS QU\u00cdSTICA \nAUTORES\nP\u00c9REZ-PERI\u00c1\u00d1EZ ORRILLO, L; FERN\u00c1NDEZ MART\u00cdNEZ, V; FERN\u00c1NDEZ MART\u00cdNEZ, C; RAMIS BARCEL\u00d3, MB; G\u00d3MEZ \nG\u00d3MEZ, D; S\u00c1NCHEZ GUNDIN, J; ILLARO URANGA, A; VALERO DOM\u00cdNGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nLumacaftor-ivacaftor es un f\u00e1rmaco indicado en el tratamiento de pacientes con fibrosis qu\u00edstica (FQ), mayores de 6 a\u00f1os, \nhomocig\u00f3ticos para la mutaci\u00f3n F508del en el gen regulador de la conductancia transmembrana de la fibrosis qu\u00edstica \n(CFTR). El objetivo de este estudio fue evaluar la efectividad a largo plazo de lumacaftor-ivacaftor (LUM/IVA) y compararla \ncon la evidencia cient\u00edfica.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo que incluy\u00f3 a los pacientes en tratamiento con LUM/IVA. De la \nhistoria cl\u00ednica y del Sistema de Informaci\u00f3n para determinar el Valor Terap\u00e9utico en la Pr\u00e1ctica Cl\u00ednica Real de los \nMedicamentos de Alto Impacto Sanitario y Econ\u00f3mico en el SNS (VALTERMED) se extrajeron los datos demogr\u00e1ficos (sexo, \nedad) y las variables de efectividad (\u00edndice de masa corporal (IMC), volumen espiratorio forzado en un segundo (VEF1), \nexacerbaciones pulmonares (EP) y hospitalizaciones.  \nSe evalu\u00f3 la progresi\u00f3n del VEF1 y el IMC al a\u00f1o (52 semanas) y a los dos a\u00f1os (104 semanas) de tratamiento, as\u00ed como la \naparici\u00f3n de EP u hospitalizaciones durante todo el periodo de estudio (2 a\u00f1os). Los resultados obtenidos se compararon \ncon los de la semana 96 del ensayo cl\u00ednico de extensi\u00f3n (semana 120 de tratamiento) (Estudio 110; NCT:03125395).\nRESULTADOS\nSe incluyeron 5 pacientes (3 ni\u00f1as) cuya edad media fue de 10\u00b12 a\u00f1os.  \nEl valor medio del VEF1 al inicio del tratamiento fue de 89,3\u00b110,1% y ascendi\u00f3 a 96,0\u00b14,6% en la semana 52 (cambio \nabsoluto medio del 6,8\u00b19,6%). En este periodo, 2 pacientes mejoraron notablemente su VEF1, 1 se mantuvo y 2 \nempeoraron ligeramente\ufffd \nSin embargo, las cifras del VEF1 al segundo a\u00f1o de tratamiento se redujeron: 1 paciente mantuvo la mejor\u00eda, otro \nretrocedi\u00f3 al valor basal y otros 2 empeoraron notablemente. Adem\u00e1s, un paciente no respondedor con cifras en \ndescenso interrumpi\u00f3 el tratamiento en la semana 54. Todo ello se tradujo en un descenso medio del 3,7\u00b112,7% respecto \nal inicio (valor medio de VEF1 85,6\u00b14,6%).  \nNo se registraron EP ni ingresos hospitalarios en el periodo de estudio.  \nEl valor medio del IMC, que fue de 17,0\u00b12,6Kg/m2 al inicio del tratamiento, aument\u00f3 hasta 17,0\u00b12,2Kg/m2 al a\u00f1o y hasta \n19,0\u00b14,7Kg/m2 al 2\u00ba a\u00f1o. El cambio absoluto medio en IMC fue de 0,04\u00b10,9Kg/m2 y 2,0\u00b12,1Kg/m2 respectivamente. \nTodos los valores se categorizaron como IMC de bajo peso.  \nLa evoluci\u00f3n descendente del VEF1 observada en el segundo a\u00f1o de seguimiento de nuestros pacientes contrasta con el \naumento medio del 3,1% (IC95%: 1,0-5,1) obtenido en la semana 96 del estudio de extensi\u00f3n. Sin embargo, el cambio 450observado en el IMC de los pacientes en la semana 96 de dicho estudio (+1,8kg/m\u00b2; IC95%: 1,6-2,0), se asemeja al valor \nobtenido en nuestro estudio\ufffd\nCONCLUSIONES\nLa mejor\u00eda obtenida en el VEF1 con el tratamiento de LUM/IVA durante el primer a\u00f1o no se mantiene a los 2 a\u00f1os de \ntratamiento, a diferencia del ensayo cl\u00ednico pivotal. En cambio, s\u00ed que se obtienen datos similares de eficacia y efectividad \nen t\u00e9rminos de ganancia del IMC. Son necesarios estudios con mayor n\u00famero de pacientes para valorar el impacto de \neste tratamiento en la vida real\ufffd\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n679. ESTANDARIZACI\u00d3N Y CARACTERIZACI\u00d3N DE LA TERAPIA INTRAVENOSA EN PEDIATR\u00cdA \nAUTORES\nTALADRIZ SENDER, I; GARC\u00cdA MORENO, FJ; MART\u00cdNEZ FERN\u00c1NDEZ-LLAMAZARES, C; MANRIQUE RODRIGUEZ, S; \nPERN\u00cdA L\u00d3PEZ, MS; HERRANZ ALONSO, A; SANJURJO SAEZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nLa v\u00eda de administraci\u00f3n intravenosa juega un papel fundamental en los pacientes pedi\u00e1tricos, sin embargo; no est\u00e1 \nexenta de riesgos. Reducir la variabilidad de las preparaciones y conocer la naturaleza de las mismas, aporta valor en la \nselecci\u00f3n del tipo de acceso vascular m\u00e1s adecuado y seguro para cada paciente. \n \nLos objetivos fueron: estandarizar las concentraciones de los f\u00e1rmacos de administraci\u00f3n intravenosa m\u00e1s habituales en \npacientes pedi\u00e1tricos y caracterizar las diluciones seg\u00fan su osmolaridad, pH y naturaleza vesicante para poder seleccionar \nel tipo de acceso vascular m\u00e1s adecuado para cada paciente.\nMATERIALES Y M\u00c9TODOS\nEstudio anal\u00edtico, experimental llevado a cabo en tres etapas:  \n1. Selecci\u00f3n de f\u00e1rmacos y concentraciones: se elabor\u00f3 una propuesta que inclu\u00eda f\u00e1rmacos de administraci\u00f3n \nintravenosa en perfusi\u00f3n continua(PC) o intermitente(PI) m\u00e1s habitualmente empleados en pacientes pedi\u00e1tricos. Para \ncada f\u00e1rmaco se propusieron varias concentraciones.  \n2. Estandarizaci\u00f3n: se constituy\u00f3 un panel formado por 13 intensivistas pedi\u00e1tricos, 6 anestesistas, 11 enfermeras y 13 \nfarmac\u00e9uticos hospitalarios. El consenso de concentraciones se realiz\u00f3 mediante metodolog\u00eda Delphi de doble ronda \ndonde participaron los miembros del grupo multidisciplinar. Los profesionales deb\u00edan seleccionar para cada f\u00e1rmaco, las \nconcentraciones que consideraban necesarias para abordar las posibles situaciones cl\u00ednicas de un paciente. El umbral de \nconsenso se estableci\u00f3 en 70%, las concentraciones que no lo alcanzaron en primera ronda, fueron sometidas a segunda ronda.  \n3. Caracterizaci\u00f3n: Se determinaron osmolaridad y pH en suero fisiol\u00f3gico 0,9% y suero glucosado 5%. Se utiliz\u00f3 \nosm\u00f3metro (Fiske Model 210 Micro Osmometer) para medir la osmolalidad de cada disoluci\u00f3n(mOsm/Kg). La \nosmolaridad(mOsm/L), se obtuvo multiplicando la osmolalidad por la densidad obtenida de cada mezcla(g/mL) \nseg\u00fan el m\u00e9todo del picn\u00f3metro calibrado a 25\u00baC con agua bidestilada. De cada concentraci\u00f3n se realizaron tres \ndeterminaciones de osmolalidad y pH (pH metro Crision Model 2006). Los resultados se expresaron como la media de \ntres determinaciones\u00b1desviaci\u00f3n est\u00e1ndar.  \nCada f\u00e1rmaco con su respectiva mezcla, se clasific\u00f3 como riesgo alto(Grupo 1): vesicante, osmolaridad > 600 mOsm/L, pH \n< 4 o > 9), riesgo moderado(Grupo 2): osmolaridad 450\u2013600 mOsm/L, pH 4\u20135 o 7.5\u20139, bajo riesgo(Grupo 3): osmolaridad \n< 450 mOsm/L, pH 5\u20137.5.\nRESULTADOS\nSe parti\u00f3 de una lista de 102 f\u00e1rmacos y 192 posibles concentraciones. Tras la primera ronda, se consensuaron 132 \nconcentraciones de 101 f\u00e1rmacos y en la segunda ronda, 28 concentraciones. Finalmente, se incluyeron 101 f\u00e1rmacos \n(44 en PC y 59 en PI) y 160 concentraciones, que supon\u00edan teniendo en cuenta el diluyente compatible para cada f\u00e1rmaco \n285 mezclas.  \nSeg\u00fan la naturaleza de cada f\u00e1rmaco:  \n\u2022Grupo1: 128 Mezclas (44,9%) correspondientes a 35 f\u00e1rmacos(21 de administraci\u00f3n en PC y 14 en PI).  \n\u2022Grupo2: 87 Mezclas (30,5%) correspondientes a 45 f\u00e1rmacos(32 de administraci\u00f3n en PI y 13 en PC) \n\u2022Grupo3: 70 Mezclas (24,5%) correspondientes a 36 f\u00e1rmacos(24 de administraci\u00f3n en PI y 12 en PC).\nCONCLUSIONES\nLa estandarizaci\u00f3n es una medida factible que permite reducir la variabilidad de preparaciones en la poblaci\u00f3n pedi\u00e1trica. \nCabe destacar que casi la mitad de las mezclas intravenosas eran vesicantes, con osmolaridad > 600 mOsm/L y/o pH < 4 o \n> 9; en este tipo de terapia es esencial la elecci\u00f3n del cat\u00e9ter m\u00e1s adecuado para evitar el da\u00f1o vascular\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n752. USO DE TOFACITINIB EN PACIENTES PEDI\u00c1TRICOS CON DIAGN\u00d3STICO DE ALOPECIA AREATA \nAUTORES\nCASALD\u00c0LIGA TORRECILLAS, A; FONT BARCEL\u00d3, A; GONZ\u00c1LEZ ANDR\u00c9S, D; AG\u00dc\u00cd CALLEJAS, AM; GONZ\u00c1LEZ-ANLEO \nL\u00d3PEZ, C; LATRE GORBE, C; GARC\u00cdA RODR\u00cdGUEZ, MDP; POZAS DEL R\u00cdO, MT\nHOSPITAL DE SANT JOAN DE D\u00c8U. PASSEIG SANT JOAN DE D\u00c9U, 2 ESPLUGUES DE LLOBREGAT . BARCELONA451OBJETIVOS\nEvaluar la eficacia y seguridad de tofacitinib en la indicaci\u00f3n de alopecia areata en poblaci\u00f3n pedi\u00e1trica en dos hospitales \nmonogr\u00e1ficos de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nDise\u00f1o observacional, multic\u00e9ntrico y retrospectivo, entre diciembre 2018 y abril 2022. La variable principal fue la \nrepoblaci\u00f3n capilar (parcial (RP), total (RT), sin repoblaci\u00f3n (SR)) del cuero cabelludo (CC), cejas y pesta\u00f1as a las 12 y \n24 semanas de tratamiento. Se recogieron otras variables a partir de las historias cl\u00ednicas y programas de dispensaci\u00f3n \nambulatoria: edad, sexo, tipo de alopecia, edad de debut, duraci\u00f3n de enfermedad, tratamientos previos, par\u00e1metros \nanal\u00edticos (perfil lip\u00eddico, Quantifer\u00f3n y neutr\u00f3filos), efectos adversos y adherencia.\nRESULTADOS\nSe estudiaron 15 pacientes (8 mujeres) con una mediana de edad de 14 a\u00f1os (IC:12,0-14,8) y edad debut de la alopecia a \nlos 11 a\u00f1os (IC:8,2-11,8). La dosis inicial de tofacitinib fue de 5mg/12h, inici\u00e1ndose 3,8\u00b13,3 a\u00f1os de media desde el debut.  \n \nEntre los tratamientos previos m\u00e1s frecuentes se encontraban; t\u00f3picos: glucocorticoides (60%), antralinas (20%), \nanticalcineur\u00ednicos (13.3%) y retinoides (6,67%) y orales: glucocorticoides (100%) y metotrexato (33%).  \n \nPrevio al inicio del tratamiento, 5/7 pacientes con alopecia universal presentaban p\u00e9rdida total de pelo y 2/7 parcial. A las \n12 semanas, en el primer grupo se observ\u00f3: RP de CC en 4/5 y RT en 1/5; RP de cejas en 3/5 y SR en 2/5; RT de pesta\u00f1as \nen 1/5, RP en 1/5 y SR en 3/5. En el segundo, se observ\u00f3 RP de CC en los dos pacientes, RT de cejas en 1/2 y no hubo \nrespuesta en pesta\u00f1as. A las 24 semanas, no se evidenciaron cambios en CC, \u00fanicamente 1 paciente con p\u00e9rdida total \npresent\u00f3 RT de cejas y otro con respuesta insuficiente aument\u00f3 la dosis a 15mg/d\u00eda. Los pacientes con p\u00e9rdida parcial \npresentaron RP de pesta\u00f1as\ufffd  \n \nEn alopecia total (2/3 p\u00e9rdida grave y 1/3 parcial), a las 12 semanas s\u00f3lo son evaluables los pacientes con p\u00e9rdida grave, \npresentando una RP de CC\ufffd A las 24 semanas, se observ\u00f3 RT de CC en 1/2 y RP en 1/2\ufffd  \n \nEn alopecia areata en placas m\u00faltiples, a las 12 semanas, de 4/5 pacientes, en 2 se observ\u00f3 RT y en 2 RP . A las 24 semanas \nde 3 pacientes evaluables, en 1 hay RC y en 2 RP .  \n \nEn cuanto a seguridad, 5/15 han presentado alg\u00fan efecto adverso: eritema en CC, cefaleas, molestias gastrointestinales, \nletargia, infecci\u00f3n respiratoria e hipertensi\u00f3n.  \n \nUn paciente present\u00f3 neutropenia leve en la semana 12, normaliz\u00e1ndose en la semana 24. La prueba Quantifer\u00f3n \nfue realizada en todos los pacientes previo al inicio, menos en un caso que se realiz\u00f3 a las 4 semanas. No se hallaron \nalteraciones en el perfil lip\u00eddico.  \n \nLa adherencia global al tratamiento por registro de dispensaciones fue de un 94,3%.\nCONCLUSIONES\nSe ha observado buena respuesta al tratamiento consiguiendo una respuesta total o parcial en todos los tipos de \nalopecia\ufffd  \n \nNo se han registrado efectos adversos con repercusi\u00f3n cl\u00ednicas ni alteraciones anal\u00edticas.  \n \nTofacitinib ha demostrado en nuestra muestra ser un tratamiento seguro y efectivo para pacientes pedi\u00e1tricos con \ndiagn\u00f3stico de alopecia.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n976. INDIVIDUALIZACI\u00d3N DE LOS TRATAMIENTOS EN HEMOFILIA. INTERVENCI\u00d3N DEL FARMAC\u00c9UTICO \nHOSPITALARIO. \nAUTORES\nD\u00cdAZ D\u00cdAZ, CL; JOY CARMONA, P; OCA\u00d1A G\u00d3MEZ, M\u00c1; R\u00cdOS DE PAZ, M; DE DIOS GARC\u00cdA, D; SANTOS FAGUNDO, A; \nGONZ\u00c1LEZ GARC\u00cdA, I; MERINO ALONSO, J\nHOSPITAL NUESTRA SE\u00d1ORA DE CANDELARIA \ufffd CTRA \ufffd DEL ROSARIO, 145 SANTA CRUZ DE TENERIFE \ufffd SANTA CRUZ DE \nTENERIFE\nOBJETIVOS\nDescribir la incorporaci\u00f3n de la farmacocin\u00e9tica poblacional (PKp) en los tratamientos de hemofilia A (HA) en nuestro \nhospital.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y descriptivo desde enero 2019 hasta el momento.  \nSe seleccionaron pacientes con Hemofilia A grave en tratamiento con terapia sustitutiva en r\u00e9gimen de profilaxis y \nque acuden a consulta de coagulopat\u00edas por otra causa. A estos pacientes se les propone la obtenci\u00f3n de la curva \nfarmacocin\u00e9tica y par\u00e1metros farmacocin\u00e9ticos personalizados con s\u00f3lo tres muestras de sangre. 452El m\u00e9todo de laboratorio utilizado para la determinaci\u00f3n de actividad de Factor VIII (FVIII) ha sido el cromog\u00e9nico.  \nLa evaluaci\u00f3n farmacocin\u00e9tica se obtuvo a trav\u00e9s de WAPPS-Hemo, portal dirigido por la Universidad McMaster, red \ninternacional con m\u00e1s de 600 centros asociados, que ha permitido tener modelos poblacionales para todas las edades y \nlos distintos concentrados de factores.\nRESULTADOS\nLa poblaci\u00f3n hemof\u00edlica de nuestro hospital es de 43 pacientes con HA con una media de edad de 30,5 a\u00f1os (1-66) y 19 \npacientes con Hemofilia B (HB) con una media de edad de 43,4 a\u00f1os (13-75).  \nEl 50% tienen tratamiento con terapia sustitutiva en r\u00e9gimen de profilaxis. De ellos, al 64% se les ha podido realizar \nla curva personalizada y obtener los par\u00e1metros farmacocin\u00e9ticos con su concentrado de factor. El resto no ten\u00eda \ndisponibilidad para poder realizar las anal\u00edticas necesarias por distintos motivos.  \nTras realizar este an\u00e1lisis, se beneficiaron de un mayor ajuste de tratamiento el 65% de los pacientes monitorizados, \nlos cambios se hicieron en las dosis y/o frecuencias de administraci\u00f3n seg\u00fan las necesidades de cada uno. El resto de \npacientes no precisaron ajuste y continuaron con el r\u00e9gimen anterior. El cambio que m\u00e1s satisface a los pacientes es el \nespaciamiento de las administraciones\ufffd\nCONCLUSIONES\nEl comportamiento de los concentrados de factores de coagulaci\u00f3n, al igual que otros tratamientos, tiene una gran \nvariabilidad interindividual. El mantenimiento de una concentraci\u00f3n plasm\u00e1tica m\u00ednima es primordial para prevenir \nsangrados. La implicaci\u00f3n del servicio de farmacia ha permitido la incorporaci\u00f3n de la PKp como herramienta \ncomplementaria para la personalizaci\u00f3n de los tratamientos , permitiendo un mayor ajuste de las dosis necesarias en la \nprofilaxis en HA grave.  \nEl farmac\u00e9utico especialista juega un papel fundamental en coordinaci\u00f3n con el servicio de hematolog\u00eda, aportando, \nno solo la atenci\u00f3n farmac\u00e9utica personalizada al paciente, sino tambi\u00e9n realizando el ajuste de dosis adecuado lo que \nrepercutir\u00e1 directamente en la eficacia terap\u00e9utica y en la mejora de la calidad de vida.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n1008. EXPERIENCIA DE USO DE LA PAUTA SNAP DE N-ACETILCISTE\u00cdNA EN INTOXICACI\u00d3N POR \nPARACETAMOL EN PEDIATR\u00cdA \nAUTORES\nCASALD\u00c0LIGA TORRECILLAS, A; L\u00d3PEZ RAMOS, MG; MART\u00cdNEZ S\u00c1NCHEZ, L; WILHELMI ROCA, E; SALAZAR \nVALDEBENITO, C; DUERO ADRADOS, M\nHOSPITAL DE SANT JOAN DE D\u00c8U. PASSEIG SANT JOAN DE D\u00c9U, 2 ESPLUGUES DE LLOBREGAT . BARCELONA\nOBJETIVOS\nEvaluar la implementaci\u00f3n de la pauta SNAP (Scottish and Newcastle Acetylcysteine Protocol) de N-acetilciste\u00edna (NAC) en \nun servicio de urgencias pedi\u00e1trico.\nMATERIALES Y M\u00c9TODOS\nEn el tratamiento de una sobreingesta de paracetamol, la pauta SNAP administra en 12h (100mg/kg en 2h, 200mg/kg en \n10h) la misma dosis de NAC que la pauta cl\u00e1sica de 21h, y ha demostrado en pacientes adultos una eficacia equiparable a \nla pauta cl\u00e1sica y menor incidencia de reacciones al\u00e9rgicas. \nEstudio observacional retrospectivo, donde se incluyeron pacientes < 18 a\u00f1os a los que se administr\u00f3 NAC tras una \nsobreingesta de paracetamol entre noviembre-2020 y marzo-2022. Se recogieron variables de eficacia (hepatotoxicidad) y \nseguridad (efectos adversos e incidentes), variables demogr\u00e1ficas y sobre las circunstancias de la intoxicaci\u00f3n (edad, sexo, \ncausa de la ingesta y asociaci\u00f3n a otros f\u00e1rmacos). Se excluyeron los pacientes que ya hab\u00edan iniciado la administraci\u00f3n de \nNAC en otros centros\ufffd  \nSe evalu\u00f3 la hepatotoxicidad seg\u00fan el consenso sobre hipertransaminasemia en pediatr\u00eda (leve si < 5 \u00d7 l\u00edmite superior \nde normalidad (LSN); moderada=5-10\u00d7LSN; muy elevada si > 10\u00d7LSN), se consideraron efectos adversos las reacciones \nal\u00e9rgicas que requirieron tratamiento y la alteraci\u00f3n aislada de la coagulaci\u00f3n (INR > 1,3 o TP < 60%), que es un conocido \nefecto asociado a la administraci\u00f3n de NAC\ufffd\nRESULTADOS\nSe evaluaron 37 casos, correspondientes a 34 pacientes, con edad mediana 15 a\u00f1os [0-17], 86,5% mujeres. 36 de los \ncasos ten\u00edan intenci\u00f3n autol\u00edtica y 1 error de dosificaci\u00f3n. En 15 de ellos la ingesta estaba asociada a antiinflamatorios \nno esteroideos y en 2 a m\u00faltiples f\u00e1rmacos. La dosis mediana de paracetamol ingerida fue de 16g [0,5-40] equivalentes a \n250mg/kg [86-741]. La mediana de tiempo desde la ingesta fue de 9h [0,5-33].  \nEn todos los casos se emple\u00f3 pauta SNAP: 4 s\u00f3lo recibieron una dosis de NAC, 17 (46%) recibieron pauta completa de 12h \ny 16 (43%) necesitaron m\u00e1s administraciones por persistencia de concentraci\u00f3n plasm\u00e1tica de paracetamol detectable \ny/o alteraciones anal\u00edticas (10 de ellos una tercera dosis, y 6 cuatro dosis o m\u00e1s).  \nAl evaluar la eficacia, 11 pacientes presentaron hepatotoxicidad: 3 muy elevada, 2 moderada y 6 leve. La cifra m\u00e1xima \nde ALT fue 2447 UI/L. En ning\u00fan caso se produjo fallo hep\u00e1tico agudo, y controles en d\u00edas posteriores mostraron la \nresoluci\u00f3n\ufffd  \nEn cuanto a seguridad, se produjo una reacci\u00f3n al\u00e9rgica cut\u00e1nea no anafil\u00e1ctica resuelta con antihistam\u00ednicos, y se \ndetectaron alteraciones aisladas en la coagulaci\u00f3n en 16 casos\ufffd En 9 de ellos el INR aument\u00f3 por encima de 1,4, con un \nm\u00e1ximo de 1,87, y en todos se resolvi\u00f3 sin repercusi\u00f3n cl\u00ednica. Se detect\u00f3 un error en el volumen de diluci\u00f3n de NAC sin \nconsecuencias cl\u00ednicas y un error en la prescripci\u00f3n que no lleg\u00f3 al paciente.  \nLa evoluci\u00f3n en todos los casos fue satisfactoria.453CONCLUSIONES\nLa pauta SNAP permite acortar la duraci\u00f3n del tratamiento con respecto a la pauta cl\u00e1sica, en un 46% de los casos el \ntratamiento con NAC finaliz\u00f3 en 12h.  \nEs frecuente la prolongaci\u00f3n del INR, sin repercusi\u00f3n cl\u00ednica. \nLa pauta SNAP se ha utilizado en pacientes pedi\u00e1tricos de manera efectiva, resolviendo las posibles complicaciones \nasociadas y sin efectos adversos relevantes\ufffd\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n1019. DISE\u00d1O DE UNA HERRAMIENTA INFORM\u00c1TICA PARA DETERMINAR LA OSMOLALIDAD DE LAS \nFORMAS FARMAC\u00c9UTICAS L\u00cdQUIDAS ORALES EN RECI\u00c9N NACIDOS PRET\u00c9RMINO. \nAUTORES\nVIUDEZ MART\u00cdNEZ, A; MATEO GARC\u00cdA, M; MART\u00cdNEZ FERN\u00c1NDEZ, B; BOLEA LACUEVA, A; RAM\u00cdREZ L\u00d3PEZ, A; RUIZ \nEL JERCHE, S; S\u00c1NCHEZ ZAPLANA, H; CLIMENT GRANA, E\nHOSPITAL GENERAL UNIVERSITARIO DE ALICANTE \ufffd AV\ufffd PINTOR BAEZA, 12 ALICANTE/ALACANT \ufffd ALICANTE\nOBJETIVOS\nDise\u00f1ar una herramienta inform\u00e1tica de apoyo a la prescripci\u00f3n de formas farmac\u00e9uticas l\u00edquidas orales en reci\u00e9n nacidos \npret\u00e9rmino, basada en los valores m\u00e1ximos de osmolalidad recomendados (500 mOsm/kg H2O), para disminuir el riesgo \nde enterocolitis necrotizante.\nMATERIALES Y M\u00c9TODOS\nSe identificaron los medicamentos l\u00edquidos orales utilizados en una unidad de cuidados intensivos (UCI) neonatal, \nclasific\u00e1ndolos en f\u00f3rmula magistral (n=15) o presentaci\u00f3n comercial (n=13). Se elabor\u00f3 una tabla identificativa en la que \nse especificaron criterios de correcta conservaci\u00f3n (temperatura y fotoprotecci\u00f3n), as\u00ed como la osmolalidad (mOsm/kg \nH2O) de los mismos y de los veh\u00edculos empleados como diluyentes (leche materna, leche materna fortificada y f\u00f3rmula \ncomercial).  \nLa determinaci\u00f3n de la osmolalidad se realiz\u00f3 mediante doble medici\u00f3n con un osm\u00f3metro basado en descenso \ncriosc\u00f3pico (Advanced Instruments, TECIL\u00ae). El sistema se configur\u00f3 con una calibraci\u00f3n a 3 puntos (50, 850 y 2000 \nmOsm/Kg). Las muestras que superaron los 2000 mOsm/Kg fueron diluidas con agua para inyectables y su osmolalidad \nfue calculada posteriormente\ufffd \nEl dise\u00f1o de la herramienta inform\u00e1tica se llev\u00f3 a cabo utilizando el software de hojas de c\u00e1lculo corporativo (Excel\u00ae, \nMicrosoft).\nRESULTADOS\nUn total de 13 f\u00f3rmulas magistrales (87%) y 12 preparados comerciales (92%) presentaron una osmolalidad superior a \n500 mOsm/kg H2O. Los veh\u00edculos empleados como diluyente mostraron valores inferiores: leche materna (286 mOsm/kg \nH2O), leche materna fortificada (387 mOsm/kg H2O) y f\u00f3rmula comercial (294 mOsm/kg H2O).  \nCon los datos obtenidos se dise\u00f1aron tablas de datos en las que se registran los par\u00e1metros de osmolalidad medidos y las \ncaracter\u00edsticas del medicamento. Asimismo, se elaboraron tablas din\u00e1micas en las que aparecen datos identificativos del \npaciente y del tratamiento: peso (kg), f\u00e1rmaco prescrito, dosis (mg/kg), cantidad de ingesta oral permitida por toma (ml/\nkg) y diluyente. Mediante f\u00f3rmulas de c\u00e1lculo que incluyen el volumen y diluyente se obtiene el valor de osmolalidad. La \nalerta m\u00e1xima se fijo en 500 mOsm/kg H2O.\nCONCLUSIONES\nEl dise\u00f1o de una herramienta inform\u00e1tica para el c\u00e1lculo de la osmolalidad resultante tras la diluci\u00f3n de formas \nfarmac\u00e9uticas l\u00edquidas orales en una UCI neonatal aumenta la seguridad en la administraci\u00f3n de los tratamientos. Esta \nmedida permitir\u00e1 disminuir el riesgo de enterocolitis necrotizante en reci\u00e9n nacidos pret\u00e9rmino.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n1097. ESTUDIO DE UTILIZACI\u00d3N DE DEFIBROTIDE EN PEDIATR\u00cdA Y CUMPLIMIENTO DE UNA NUEVA \nESCALA DIAGN\u00d3STICA DEL S\u00cdNDROME OCLUSIVO SINUSOIDAL \nAUTORES\nRUIZ BRIONES, P; TALADRIZ SENDER, I; NARRILLOS MORAZA, A; MART\u00cdNEZ FERN\u00c1NDEZ-LLAMAZARES, C; MANRIQUE \nRODR\u00cdGUEZ, S; VICENTE VALOR, J; HERRANZ ALONSO, A; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nLa Sociedad Europea de Trasplante de Sangre y M\u00e9dula (EBMT por sus siglas en ingl\u00e9s), emiti\u00f3 en 2018 una nueva gu\u00eda \npara el diagn\u00f3stico del S\u00edndrome Oclusivo Sinusoidal (SOS) en pacientes pedi\u00e1tricos sometidos a trasplante de m\u00e9dula \n\u00f3sea. Este hecho, sumado a la aparici\u00f3n de nueva evidencia en el uso de defibrotide en profilaxis del SOS, produjeron un \naumento considerable de la utilizaci\u00f3n y, por ende, del gasto realizado en este f\u00e1rmaco en nuestro centro. El objetivo del \ntrabajo es evaluar las condiciones de utilizaci\u00f3n de defibrotide en pacientes pedi\u00e1tricos desde 2018 hasta 2021, as\u00ed como \nel cumplimiento de los criterios diagn\u00f3sticos para pediatr\u00eda seg\u00fan la EBMT\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, descriptivo y retrospectivo. Desde enero de 2018 hasta diciembre de 2021 en un hospital de tercer \nnivel. Se incluyeron todos los pacientes pedi\u00e1tricos a los que se administr\u00f3 defibrotide durante el periodo del estudio y 454se realiz\u00f3 un seguimiento hasta al menos el d\u00eda +100 postrasplante, en caso de haber sido trasplantados. Se recogieron \nvariables demogr\u00e1ficas, duraci\u00f3n y pauta de defibrotide, motivo de uso (profilaxis o tratamiento), par\u00e1metros anal\u00edticos \nen el periodo peri-administraci\u00f3n, y coste del tratamiento. Los datos se obtuvieron de historia cl\u00ednica y prescripci\u00f3n \nelectr\u00f3nicas. Las variables se estudiaron mediante an\u00e1lisis estad\u00edstico descriptivo\nRESULTADOS\nSe obtuvieron datos de 17 pacientes, que supusieron 21 episodios en los que fue necesario el uso de defibrotide. Los \npacientes ten\u00edan una edad mediana de 9,9 a\u00f1os (0,2-18,4 a\u00f1os) al inicio del tratamiento con defibrotide. El 76,5% de \nlos pacientes eran mujeres. La media de los d\u00edas en tratamiento fue de 26,5 (Rango Intercuartil (RIC)=17,0-32,0 d\u00edas), \nmientras que para la profilaxis fue de 33,4 d\u00edas (RIC=24,3-35,8 d\u00edas). En 13 de los 21 (57,1%) episodios, defibrotide se \nutiliz\u00f3 como tratamiento de SOS, mientras que el resto de episodios (42,9%) fueron profilaxis. Todos los pacientes que \nnecesitaron tratamiento para el SOS cumpl\u00edan al menos dos de los criterios EBMT. La trombocitopenia refractaria a \ntransfusi\u00f3n (92,3%) y el aumento progresivo de bilirrubina (61,5%) fueron los motivos m\u00e1s frecuentes en el estudio para \nel diagn\u00f3stico del SOS siguiendo los criterios EBMT. S\u00f3lo dos pacientes ten\u00edan niveles de billirubina superiores a 2mg/dl \nen el inicio del tratamiento con defibrotide. Los motivos de su uso como profilaxis del SOS fueron uso de gemtuzumab en \ntres episodios, uno por uso de inotuzumab, dos en prevenci\u00f3n en segundos trasplantes tras episodios previos de SOS y un \ncaso de hepatitis C y necesidad de trasplante de m\u00e9dula\nCONCLUSIONES\nEl manejo y, por tanto, el reconocimiento temprano del SOS, han demostrado ser uno de los condicionantes del \npron\u00f3stico de esta grave complicaci\u00f3n en pacientes trasplantados de m\u00e9dula. La mayor prevalencia del SOS en ni\u00f1os y sus \ncaracter\u00edsticas (anicteria, variaciones frecuentes en el peso y dif\u00edcil medici\u00f3n, etc.) influyen claramente a ello. En nuestro \ncentro, todos los pacientes que recibieron defibrotide como tratamiento del SOS cumpl\u00edan los criterios EBMT para su uso. \nEl uso de defibrotide como profilaxis en nuestro centro es cada vez creciente, y ser\u00e1 necesario protocolizar esta indicaci\u00f3n \ncon el fin de su racionalizaci\u00f3n\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n1234. VALIDACI\u00d3N DE LAS DOSIS DIARIAS DEFINIDAS DE ANTIMICROBIANOS EN POBLACI\u00d3N \nPEDI\u00c1TRICA. FASE II DEL PROYECTO KIDDDS. \nAUTORES\nMONTECATINE ALONSO, E; GIL NAVARRO, MV; VILLANUEVA BUENO, C; CHAVARRI GIL, E; MART\u00cdNEZ FERN\u00c1NDEZ-\nLLAMAZARES, C; DOLZ BUBI, E; GUTIERREZ URB\u00d3N, JM; \u00c1LVAREZ DEL VAYO BENITO, C\nHOSPITAL VIRGEN DEL ROC\u00cdO \ufffd AV\ufffd MANUEL SIUROT , S/N SEVILLA \ufffd SEVILLA\nOBJETIVOS\nValidar la herramienta dise\u00f1ada en la fase I del proyecto KiDDDs, cuya finalidad es medir las dosis diarias definidas (DDD) \nde antimicrobianos en pediatr\u00eda para su uso en Programas de Optimizaci\u00f3n de Uso de Antimicrobianos pedi\u00e1tricos.\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico, observacional y retrospectivo en el que se recogieron las prescripciones de antimicrobianos en las \nunidades de pediatr\u00eda de 7 hospitales de tercer nivel durante los a\u00f1os 2017 y 2018. \nLas variables recogidas fueron: unidad cl\u00ednica del ingreso, sexo, edad, peso, antimicrobiano, v\u00eda de administraci\u00f3n y dosis \nde antimicrobiano al d\u00eda prescrita. Se consideraron aquellos antimicrobianos incluidos en la fase I del proyecto KiDDDs.  \nA partir de los datos recogidos, se obtuvo la dosis por kg/d\u00eda de cada una de las prescripciones. Se calcul\u00f3 la mediana de \nlas dosis reales prescritas y se compar\u00f3 con la dosis de antimicrobianos consensuada mediante el M\u00e9todo Delphi en la \nfase I del proyecto\ufffd\nRESULTADOS\nSe recogieron 4780 prescripciones de 44 antimicrobianos (29 intravenosos y 15 orales). En el an\u00e1lisis estad\u00edstico se \nobserv\u00f3 que, en los administrados por v\u00eda intravenosa, no hubo diferencia estad\u00edsticamente significativa entre las \nmedianas de dosis en el 100% de los carbapenemes [imipenem/cilastatina (N=86), meropenem (N=132)], 80% de las \npenicilinas [amoxicilina/clavul\u00e1nico (N=866), amoxicilina (N=45), ampicilina (N=143), cloxacilina (N=65), piperacilina/\ntazobactam (N=133)], 66.67% de los aminogluc\u00f3sidos [amikacina (N=64), gentamicina (N=454), tobramicina (N=22)], \nde antimic\u00f3ticos [anfotericina B liposomal (N=49), fluconazol (N=38), micafungina (N=45)] y de otros antibacterianos \n[(daptomicina (N=4), linezolid (N=11), metronidazol (N=395)], 50% de los glucop\u00e9ptidos [teicoplanina (N=119), \nvancomicina (N=168)] y 33,33% de las cefalosporinas [cefazolina (N=401), cefepima (N=187), cefotaxima (N=255), \nceftazidima (N=66), ceftriaxona (N=161), cefuroxima (N=66)] y de macr\u00f3lidos/lincosamidas [azitromicina (N=15), \nclindamicina (N=54), eritromicina (N=26)].  \nEn los administrados por v\u00eda oral, no hubo diferencia estad\u00edsticamente significativa en el 66.67% de los macr\u00f3lidos \n[azitromicina (N=75), claritromicina (N=23), eritromicina (N=24)] y de otros antibacterianos (fosfomicina (N=9), linezolid \n(N=7), metronidazol (N=25)], 33,33% de las cefalosporinas [cefadroxilo (N=4), cefixima (N=28), cefuroxima (N=41)] y de \npenicilinas [amoxicilina/clavul\u00e1nico (N=133), amoxicilina (N=107), cloxacilina (N=5)], tampoco hubo diferencias en la \nmediana de dosis de fluconazol (N=83).\nCONCLUSIONES\nLa estandarizaci\u00f3n de las DDD del grupo de antimicrobianos en poblaci\u00f3n pedi\u00e1trica supondr\u00eda la creaci\u00f3n de una \nherramienta de medida del consumo de antimicrobianos, que ya ha demostrado su utilidad en poblaci\u00f3n adulta en los \nPROA \ufffd 455En este estudio, la mayor\u00eda de las dosis prescritas coincidieron con los valores de las dosis te\u00f3ricas consensuadas, \ndemostrando la validez de esta herramienta. No obstante, existen algunos grupos terap\u00e9uticos, como betalact\u00e1micos, en \nlos que no se han obtenido los resultados esperados. Por tanto, ser\u00eda interesante proponer m\u00e1s estudios multic\u00e9ntricos \ninternacionales que permitieran ampliar la muestra y estandarizar la herramienta a nivel internacional.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n1258. IDENTIFICACI\u00d3N DE \u00c1REAS DE MEJORA PARA LA OPTIMIZACI\u00d3N DE TRATAMIENTOS CON \nINMUNOGLOBULINAS \nAUTORES\nP\u00c9REZ-RICART , A; SOL\u00cdS DIEZ, G; TURU PEDROLA, M; PUIG SOLER, R; RODR\u00cdGUEZ DARRIBA, M; VENTURA ORRIOLS, \nE; COMA FUST\u00c9, A; PONTES GARC\u00cdA, C\nSERVICIO CATAL\u00c1N DE LA SALUD\nOBJETIVOS\nCuantificar el cambio en una serie de indicadores relacionados con la utilizaci\u00f3n de inmunoglobulinas (IgG) despu\u00e9s \nde una intervenci\u00f3n para la optimizaci\u00f3n de su uso seg\u00fan objetivo terap\u00e9utico, en un contexto de desabastecimiento \nprolongado\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo longitudinal basado en registros, del a\u00f1o 2020 (pre-intervenci\u00f3n), al a\u00f1o 2021 (intervenci\u00f3n) con \npoblaci\u00f3n de estudio de 7.739.758 habitantes (2021). \nPara cada objetivo terap\u00e9utico (terapia de reposici\u00f3n a s\u00edndromes de inmunodeficiencia primaria (SIP), Terapia de \nreposici\u00f3n a s\u00edndromes de inmunodeficiencia secundaria (SID), inmunomodulaci\u00f3n, terapia asociada a trasplante, otras \npatolog\u00edas e indicaciones no clasificables (NC) se analiz\u00f3: n\u00famero de pacientes, adecuaci\u00f3n de la indicaci\u00f3n terap\u00e9utica \n(IT), dosis mensual estimada (g/Kg), consumo anual estimado por paciente (g), coste anual estimado por paciente (\u20ac) para \nlos dos per\u00edodos, diferencia de medias (DM) para cada indicador. \nLos datos cl\u00ednicos fueron obtenidos de un registro centralizado que cumplimentan los hospitales y los datos econ\u00f3micos \ndel registro de facturaci\u00f3n. Se realiz\u00f3 una revisi\u00f3n de la evidencia de las indicaciones terap\u00e9uticas (IT) en base a gu\u00edas de \npr\u00e1ctica cl\u00ednica, clasific\u00e1ndolas en: rol terap\u00e9utico establecido (RTE), rol terap\u00e9utico en desarrollo (RTD), uso terap\u00e9utico \nexcepcional o sin evidencia (UTE) y no clasificable.\nRESULTADOS\nEn 2021 se registraron 1.956 pacientes ambulatorios con prescripci\u00f3n de IgG. Seg\u00fan la clasificaci\u00f3n de la evidencia \nestablecida, 1.480 (75,66%) tratamientos fueron prescritos para un RTE, 224 (12,17%) tratamientos para RTD, 93 (4,66%) \ntratamientos para UTE y 157 (8,1%) tratamientos no pudieron ser clasificados por falta de informaci\u00f3n.  \nEn 2021, la media (desviaci\u00f3n est\u00e1ndar [DE]) de la dosis mensual de IgGs fue de 0,57 (0,3) g/Kg en SIP , 0,54 (0,51) g/Kg en \nSID, 1,68 (0,69) g/Kg en inmunomodulaci\u00f3n, 1,69 (1,06) g/Kg en otras patolog\u00edas y 1,41 (1,02) g/Kg en NC.  \nEl consumo medio anual estimado por paciente (g) en 2021 fue estad\u00edsticamente inferior al del 2020 (DM: \u221247; IC 95% \n\u221262,28; \u221231,72; p = 0,03). Adem\u00e1s, el coste medio anual estimado por paciente (\u20ac) en 2021 tambi\u00e9n fue inferior al de \n2020 (DM: \u20131.492; IC 95%, \u20132.132,12; \u2013851,88; p = 0,027).  \nPor objetivo terap\u00e9utico, el consumo medio anual estimado por paciente (g) en SIP disminuy\u00f3 estad\u00edsticamente en 2021 \n(DM: \u221228; IC 95%: \u221240,71; \u221215,29; p = 0,037), y la dosis media mensual por pacien te (g/Kg) (DM: \u22120,05; IC 95%: = 0,003). \nEl consumo medio anual estimado por paciente (g) para otras patolog\u00edas, principalmente por miastenia gravis, tambi\u00e9n \nfue estad\u00edsticamente inferior en 2021 (DM: \u221248; IC 95%: \u221281,81; \u221214,19; p = 0,029). Por el contrario, no se observ\u00f3 \nun descenso significativo para SID (DM: \u221225; IC 95%: \u221243,59; \u22126,41; p > 0) ni inmunomodulaci\u00f3n (DM: \u221281; IC95%: \n\u2212132.69;\u221229.31; p = 0.1).\nCONCLUSIONES\nLos datos muestran un alto porcentaje de adecuaci\u00f3n terap\u00e9utica. Las medidas para la optimizaci\u00f3n del uso han surgido \nefecto, aunque de manera desigual seg\u00fan el objetivo terap\u00e9utico. Se observa un mayor descenso de los indicadores \npropuestos en las terapias de reposici\u00f3n, por contra en la inmunomodulaci\u00f3n el cambio es menor o aumenta, sugiriendo \nun \u00e1rea de mejora para la optimizaci\u00f3n en este objetivo terap\u00e9utico.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N \nASISTENCIAL\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n50. EVALUACI\u00d3N DE LA EXPERIENCIA DE LOS PACIENTES CON LA ATENCI\u00d3N COORDINADA Y CENTRADA \nEN LA PERSONA \nAUTORES\nMERCADAL ORFILA, G; VENTAYOL BOSCH, P; GOMEZ LOBON, A; MAESTRE FULLANA, MA; SERRANO LOPEZ DE LAS \nHAZAS, J; MATEU AMENGUAL, F; LLUCH TALTAVULL, J; IGLESIAS SERRANO, MC\nHOSPITAL MATEU ORFILA \ufffd RONDA MALB\u00daGER, 1 MAH\u00d3N \ufffd ILLES BALEARS456OBJETIVOS\nEn el contexto de la medicina basada en valor, cada vez se enfatiza m\u00e1s en la medici\u00f3n de la experiencia de los pacientes \ncon la atenci\u00f3n sanitaria como un mecanismo para la mejora de la calidad, la efectividad cl\u00ednica y la atenci\u00f3n del paciente, \nas\u00ed como la seguridad de la atenci\u00f3n.  \nLa atenci\u00f3n coordinada centrada en la persona (P3C) es la conjunci\u00f3n de dos constructos: atenci\u00f3n centrada en la \npersona y coordinaci\u00f3n de la atenci\u00f3n\ufffd  \nExiste un cuestionario validado para evaluar dicha atenci\u00f3n: el \u201cperson-centred coordinated care experience \nquestionnaire\u201d (P3CEQ).  \nEl objetivo del estudio es evaluar la experiencia percibida por el paciente que acude a consultas externas de farmacia \nhospitalaria, por medio del cuestionario P3CEQ (puntuaci\u00f3n global 0-30 mejor), que eval\u00faa estas dos esferas: \n- la atenci\u00f3n centrada en la persona (puntuaciones 0-24 mejor)  \n- la atenci\u00f3n coordinada (puntuaciones 0-15 mejor)  \ncon el fin de analizar las demandas de los pacientes y mejorar la comunicaci\u00f3n y coordinaci\u00f3n profesional-pacientes.\nMATERIALES Y M\u00c9TODOS\nSe incluyeron pacientes atendidos en las consultas externas de Farmacia Hospitalaria de 4 hospitales p\u00fablicos de una \ncomunidad aut\u00f3noma, en el periodo Enero \u2013 Abril de 2022.  \nEl cuestionario se envi\u00f3 basalmente por medio de una plataforma telem\u00e1tica que permite el env\u00edo automatizado y \nprogramado\ufffd  \nSe analizaron los resultados por medio de SPSS v28. Las variables continuas se resumir\u00e1n con media y desviaci\u00f3n t\u00edpica y \nlas variables categ\u00f3ricas con frecuencias absolutas y relativas.  \nPara estudiar las diferencias entre las medidas de las variables continuas se utilizar\u00e1 una prueba de t-Student y para \nevaluar la independencia de los efectos encontrados en el an\u00e1lisis bivariante se realizar\u00e1 una regresi\u00f3n lineal.\nRESULTADOS\nDe 472 pacientes a los que se envi\u00f3 el cuestionario, contestaron 217 (44,38%). \nEl 44,6% estaba en la franja 31-50 a\u00f1os, 55,1% % mujeres, 39,6% en primera l\u00ednea de tratamiento.  \nLos pacientes acud\u00edan a recoger medicaci\u00f3n procedente de consultas de reumatolog\u00eda (37,9%), dermatolog\u00eda (18,4%), \ndigestivo (15,8%), neurolog\u00eda (14,8%), VIH (10,7%), oncolog\u00eda (5,9%), neumolog\u00eda (1,8%).  \nLa puntuaci\u00f3n media obtenida del cuestionario P3CEQ, fue de 19,82 + 6,6 . De la subescala centrada en la persona 17,66+ \n5,5 y de la subescala centrada en la coordinaci\u00f3n asistencial 6,6 + 3,3 . \nEl an\u00e1lisis univariante mostr\u00f3 :  \n-peores puntuaciones de forma estad\u00edsticamente significativa en mujeres (24,43 +8,5) vs hombres (27,3 +8,2) p=0,005 y \nen fumadores (23,25 +9,5) vs no fumadores (28,65+7,8), p < 0,05, y sin significaci\u00f3n estad\u00edstica en parados laboralmente \n(24,16 +8,8) vs ocupados (25,51 +8,9) p=0,276, y en los que ten\u00edan educaci\u00f3n primaria o inferior (23,94 +7,7) vs estudios \nsuperiores (26,43+ 7,2), P=0,078  \nLa regresi\u00f3n lineal, incluy\u00f3 en el modelo como factores que influ\u00edan en el score global del P3CEQ: g\u00e9nero, fumar y la \nsituaci\u00f3n laboral\ufffd En cambio el nivel de estudios no entr\u00f3 en el modelo\ufffd\nCONCLUSIONES\nNuestros hallazgos apuntan a una peor experiencia con la atenci\u00f3n coordinada y centrada en la persona por parte \nde las mujeres, fumadores y parados , como tambi\u00e9n apunta un estudio neerland\u00e9s reciente (Rijken M et al Health \nExpectations. 2022;1\u201312), lo cual nos apunta los items que debemos mejorar.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n57. DOSE BANDING DE MEZCLAS INTRAVENOSAS DE 5-FLUOROURACILO, OXALIPLATINO, PACLITAXEL Y \nGEMCITABINA: IMPLANTACI\u00d3N Y EVALUACI\u00d3N DE LA EFICIENCIA Y SEGURIDAD \nAUTORES\nBUSTELO PAZ, F; FERN\u00c1NDEZ RIBEIRO, MF; OLIVERA FERN\u00c1NDEZ, R; BARCA DIEZ, C; PROUPIN CANTELAR, IC; \nBOULLOSA LALE, S; GONZ\u00c1LEZ FREIRE, L; CRESPO DIZ, C\nCOMPLEJO HOSPITALARIO DE PONTEVEDRA. MOURENTE PONTEVEDRA. PONTEVEDRA\nOBJETIVOS\nImplantar un sistema de DB y analizar el impacto en la eficicencia y seguridad de los pacientes a tratamiento intravenoso \ncon bombas elastom\u00e9ricas de 5-fluorouracilo(5FU) y soluciones de Oxaliplatino, Paclitaxel y Gemcitabina.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo de 5 meses de duraci\u00f3n con 147 pacientes a tratamiento antineopl\u00e1sico: 44 con 5FU, 28 con \nOxaliplatino, 36 con Paclitaxel y 39 con Gemcitabina. El 5FU se prepar\u00f3 en bomba elastom\u00e9rica (Autofuser UFSC-2) y el \nresto de f\u00e1rmacos diluidos en NaCl 0,9% en bolsa de Pl\u00e1stico Freeflex\u00ae. \nSe establecieron dos grupos de pacientes para cada f\u00e1rmaco en funci\u00f3n de las dosis calculadas de manera te\u00f3rica dada \nsu superficie corporal: P1, dosis superiores y P2, dosis inferiores. El rango de dosis se estableci\u00f3 con una variabilidad del \n\u00b15%\ufffd \nPara medir la eficiencia se utilizaron: n\u00famero elaboraciones, n\u00famero preparaciones caducadas y porcentaje viales \nahorrados.  \nLa seguridad se midi\u00f3 comparando valores de leucocitos (5FU) y neutr\u00f3filos (Oxaliplatino, Paclitaxel y Gemcitabina) en el \nd\u00eda anterior a la administraci\u00f3n de los f\u00e1rmacos frente a valores previos a la siguiente dosis.  457La significaci\u00f3n estad\u00edstica se valor\u00f3 mediante prueba t de Student y el test de Wilcoxon para muestras apareada. La \nnormalidad se estudi\u00f3 con la prueba de Shapiro Wilks. Se considera resultado favorable la no significancia estad\u00edstica.\nRESULTADOS\nSe estandarizaron 6 dosis para 5FU, Oxaliplatino y Paclitaxel que cubren el 93,6%, 100% y 72% de los tratamientos \nrespectivamente. De Gemcitabina se estandarizaron 7 dosis cubriendo al 97,5%.  \nSe elaboraron 412 mezclas 5FU, 312 Oxaliplatino, 431 Paclitaxel y 372 Gemcitabina. Caducaron el 6,3%, 15,6%, 4,4% y \n11,8% respectivamente. El aprovechamiento de viales supuso un ahorro del 23,41% para 5FU, 32,2% para Oxaliplatino, \n52,6% para Paclitaxel y 22,2% para Gemcitabina\ufffd  \nNo hubo diferencias estad\u00edsticamente significativas entre los niveles de leucocitos y neutr\u00f3filos en ninguno de los \ndos grupos de cada f\u00e1rmaco [(5FU: p= 0,99 y p=0,57), (Oxaliplatino: p= 0,71 y p=0,57), (Paclitaxel: p= 0,90 y p=0,26), \n(Gemcitabina: p= 0,32 y p=1).\nCONCLUSIONES\nLa dificultad de implantaci\u00f3n del proceso fue m\u00ednima y el proceso se mostr\u00f3 eficiente tras la realizaci\u00f3n de ajustes de \nstocks en los casos de Oxaliplatino y Gemcitabina El DB no comprometi\u00f3 la seguridad cl\u00ednica de los pacientes respecto a la \ntoxicidad hematol\u00f3gica evaluada. Por todo ello, se revela como una t\u00e9cnica coste-eficiente a considerar.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n101. EFICACIA Y SEGURIDAD DE CLADRIBINA EN ESCLEROSIS M\u00daLTIPLE: \u00bfQU\u00c9 OBSERVAMOS M\u00c1S ALL\u00c1 \nDE LOS 2 A\u00d1OS? \nAUTORES\nCAS\u00c1S FERN\u00c1NDEZ, X; VELEZ BLANCO, A; ORTEGA VALIN, L; RODRIGUEZ FERNANDEZ, Z; LLAMAS LORENZANA, S; \nSAEZ HORTELANO, JC; DE CASTRO AVEDILLO, C; VARELA FERNANDEZ, R\nCOMPLEJO ASISTENCIAL UNIVERSITARIO DE LE\u00d3N. ALTOS DE LA NAVA S/N LE\u00d3N. LE\u00d3N\nOBJETIVOS\nLa esclerosis m\u00faltiple (EM) es una enfermedad inflamatoria y desmielinizante de SNC. Cladribina es una nueva estrategia \nsusceptible de modificar la evoluci\u00f3n de la enfermedad.  \nEl objetivo es evaluar eficacia y seguridad de cladribina en pacientes con EM, en tiempo real, tras superar los 2 a\u00f1os de \ntratamiento\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo. Incluy\u00f3 pacientes con esclerosis m\u00faltiple remitente recurrente (EMRR) tratados con \ncladribina a dosis acumulada de 3,7 mg/kg durante 96 semanas repartida en 1,75 mg/kg/a\u00f1o.  \nLos datos fueron recogidos de la historia del paciente y del m\u00f3dulo de externos. Se analizaron las variables: edad, a\u00f1os \nde evoluci\u00f3n de la enfermedad, n\u00famero de brotes tras inicio del tratamiento, valores EDSS (inicio/fin) del tratamiento, \ntratamientos modificadores previos, reacciones adversas (RA), semanas de seguimiento, tiempo que tardan en aparecer \nreca\u00eddas y existencia de progresi\u00f3n radiol\u00f3gica tras finalizar tratamiento.  \nSe analiz\u00f3 eficacia y seguridad en tiempo real, m\u00e1s all\u00e1 de 96 semanas y se compar\u00f3 con los resultados obtenidos con el \nensayo CLARITY \ufffd \nSe consideraron marcadores de eficacia: ausencia de brotes y de actividad radiol\u00f3gica y de seguridad: aparici\u00f3n de RA.\nRESULTADOS\nSe incluyeron 30 pacientes, el 83% mujeres (n=25), mediana de edad 40 (26-72) a\u00f1os, mediana de a\u00f1os de evoluci\u00f3n de \nla enfermedad 14 (2-28).  \nEl 10% (n=3) aumentaron el valor de EDSS en al menos 1 punto, el resto lo mantuvo.  \nEl 80% recibieron tratamientos previos a cladribina: (INF \u03b2: n=15; dimetilfumarato: n=11; Acetato glatiramero: n=7; \nteriflunomida: n=6 y fingolimod: n=1), frente al 66% del CLARITY . \nEl 93% (n=28) completaron 96 semanas de tratamiento, s\u00f3lo 2 lo suspendieron. En 3 pacientes, se administr\u00f3 un tercer \nciclo por persistencia de brotes. La mediana de seguimiento fue de 108 (48-164) semanas. \nEficacia: El 53% sufrieron nuevos brotes (n=16), vs 20,3% del ensayo pivotal. En el 46% (n=14) se observ\u00f3 enfermedad \nactiva en resonancia magn\u00e9tica. La mediana de aparici\u00f3n de reca\u00eddas tras iniciar el tratamiento fue de 16 (12-39) meses. \nSeguridad: El % de RA fue: (33% linfopenia grados 3 y 4: n=10 vs 20-25% en CLARITY; 26% astenia: n= 8; 16% n\u00e1useas \ny v\u00f3mitos: n=5; 13% infecciones: n= 4; 10% erupci\u00f3n cut\u00e1nea: n=3; 6% herpes z\u00f3ster: n=2 y 3% alopecia: n=1). Por \nlinfopenia severa 2 pacientes suspendieron tratamiento y en 4 se retras\u00f3 la administraci\u00f3n del mismo\ufffd\nCONCLUSIONES\nLa mayor\u00eda de RA fueron esperables y bien toleradas, s\u00f3lo 2 casos requirieron la suspensi\u00f3n del tratamiento.  \nLa eficacia de cladribina con dosis acumulada de 3,7 mg/kg, repartida en 2 a\u00f1os result\u00f3 ser menor a la obtenida en el \nensayo CLARITY en relaci\u00f3n al porcentaje de aparici\u00f3n de brotes (53%).  \nLa observaci\u00f3n directa de eficacia y seguridad m\u00e1s all\u00e1 de las 96 semanas, podr\u00eda ayudar a definir la necesidad de utilizar \ncladribina en m\u00e1s de 2 ciclos, en aquellos pacientes donde persiste enfermedad activa y presenten buena tolerancia.  \nLa atenci\u00f3n farmac\u00e9utica en pacientes tratados con nuevas terapias a medio y largo plazo, permite conocer los resultados \nen la pr\u00e1ctica real, detectar y abordar RA y facilitar la toma de decisiones terap\u00e9uticas en pacientes complejos.458CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n124. INCORPORACI\u00d3N DEL FARMAC\u00c9UTICO A UNA CONSULTA M\u00c9DICA DE ATENCI\u00d3N AL PACIENTE VIH \nAUTORES\nMARTINEZ RUIZ, E; TARDAGUILA MOLINA, P; CODONAL DEMETRIO, A; DEAN BARAHONA, C; CORRALES KROHNERT , \nS; CARRASCO CORRAL, T; LAZARO LOPEZ, A; HORTA HERNANDEZ, AM\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nLa atenci\u00f3n multidisciplinar que requiere el paciente VIH, hace imprescindible la colaboraci\u00f3n del farmac\u00e9utico. La \npresencia del mismo en la consulta de medicina interna de atenci\u00f3n al paciente VIH (CMI-VIH), permite optimizar \u201cin situ\u201d \nla farmacoterapia\ufffd  \nLos objetivos del estudio fueron: \n- Evaluar el impacto de la presencia del farmac\u00e9utico en la CMI-VIH analizando los problemas relacionados con \nmedicamentos (PRM) y los resultados negativos asociados a la medicaci\u00f3n (RNM) detectados.  \n- Analizar las intervenciones farmac\u00e9uticas.\nMATERIALES Y M\u00c9TODOS\nSe realiz\u00f3 un estudio prospectivo-descriptivo entre enero-abril de 2022. Durante este per\u00edodo, el farmac\u00e9utico realizaba \nuna revisi\u00f3n de la historia farmacoterap\u00e9utica de cada paciente detectando posibles discrepancias y a continuaci\u00f3n, \npasaba consulta conjuntamente con el facultativo de medicina interna, dispensando la medicaci\u00f3n en la CIM-VIH.  \nVariables recogidas: demogr\u00e1ficas, tratamiento antirretroviral (TAR), adherencia al TAR en el \u00faltimo a\u00f1o (seg\u00fan registro \nde dispensaciones y entrevista con el paciente), PRM y RNM detectados (seg\u00fan el Tercer Consenso de Granada), \nintervenciones farmac\u00e9uticas para resolverlos, as\u00ed como otras intervenciones realizadas.\nRESULTADOS\nDe 102 pacientes a los que se dispens\u00f3 la medicaci\u00f3n en consulta, se realizaron intervenciones en 56 (80% hombres) con \nuna mediana de edad de 53 a\u00f1os (RIC: 43-59).  \nEl 46% estaba en tratamiento con dolutegravir/lamivudina, 27% con tenofovir alafenamida/emtricitabina/bictegravir, 7% \ncon abacavir/lamivudina/dolutegravir y 20% con otras pautas. El 91% tuvo una adherencia al TAR > 90%. \nSe detectaron 32 PRM en la medicaci\u00f3n concomitante. Los principales fueron: 27% PRM 13 (problema de salud \ninsuficientemente tratado), 27% PRM 9 (incumplimiento), 10% PRM 10 (interacciones), 10% PRM 12 (probabilidad de \nefectos adversos), 10% PRM 5 (dosis, pauta y/o duraci\u00f3n inadecuada) y 16% otros.  \nLos principales RNM fueron: 40% N1 (problema de salud no tratado), 27% N2 (efecto de medicamento innecesario), 13% \nE1 (inefectividad no cuantitativa), 10% S1 (inseguridad no cuantitativa) y un 10% otros.  \nLas intervenciones realizadas sobre los PRM fueron: 27% a\u00f1adir medicamento, 27% promover adherencia al tratamiento, \n23% retirar medicamento, 13% sustituir medicamento y 10% otras.  \nAdem\u00e1s, se realizaron 25 intervenciones sobre h\u00e1bitos de vida cardiosaludables y relacionadas con el cambio de TAR. Un \n41% relacionadas con el abandono del tabaco, un 30% con recomendaciones diet\u00e9ticas, un 7% con aumento de actividad \nf\u00edsica y un 15% con simplificaci\u00f3n del TAR de triple a doble terapia.\nCONCLUSIONES\n- La presencia de un farmac\u00e9utico integrado en el equipo de atenci\u00f3n al paciente VIH, permite detectar en el momento \nun n\u00famero elevado de PRM causantes de RNM y optimizar la farmacoterapia.  \n- La necesidad del seguimiento individualizado multidimensional del paciente VIH, hace necesaria la incorporaci\u00f3n del \nenfoque del riesgo cardiovascular como parte del seguimiento integral de estos pacientes. \n- Con la dispensaci\u00f3n \u201cin situ\u201d en la CMI-VIH se evita que el paciente se desplace hasta el servicio de farmacia. \n- Esta medida, ha sido muy bien aceptada tanto por el personal sanitario como por los pacientes, plante\u00e1ndose en el \nfuturo la incorporaci\u00f3n de una consulta de atenci\u00f3n farmac\u00e9utica pr\u00f3xima a la CMI-VIH.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n165. APLICACI\u00d3N DE UN PROTOCOLO CL\u00cdNICO DE PRESCRIPCI\u00d3N DE INMUNOGLOBULINAS \nINTRAVENOSAS: EVIDENCIA DE USO Y CONSUMO \nAUTORES\nVARELA FERN\u00c1NDEZ, R; S\u00c1EZ HORTELANO, JC; DE CASTRO AVEDILLO, C; CASAS FERN\u00c1NDEZ, X; V\u00c9LEZ BLANCO, A; \nRODR\u00cdGUEZ FERN\u00c1NDEZ, Z; GUTI\u00c9RREZ GUTI\u00c9RREZ, E; ORTIZ DE URBINA GONZ\u00c1LEZ, JJ\nCOMPLEJO ASISTENCIAL UNIVERSITARIO DE LE\u00d3N. ALTOS DE LA NAVA S/N LE\u00d3N. LE\u00d3N\nOBJETIVOS\nEvaluaci\u00f3n del uso de Ig inespec\u00edficas seg\u00fan la evidencia cl\u00ednica disponible en un hospital de tercer nivel tras \nimplementaci\u00f3n de un protocolo cl\u00ednico para garantizar una prescripci\u00f3n coherente con la evidencia disponible.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en dos periodos diferentes, en un intervalo de tiempo de un a\u00f1o (enero-diciembre de \n2018 vs enero-diciembre de 2021), en el que se incluyeron todos los pacientes que recibieron Ig inespec\u00edficas por v\u00eda IV. \nLas variables incluidas en el estudio fueron edad, sexo, indicaci\u00f3n (grupos A, B y C), duraci\u00f3n (tratamiento corto o largo) \ny servicio cl\u00ednico, utilizando como referencia las Gu\u00eda Cl\u00ednicas de Uso de Inmunoglobulinas publicadas por la Sociedad \nEspa\u00f1ola de Farmacia Hospitalaria (SEFH).459RESULTADOS\nSe incluyeron 207 pacientes del a\u00f1o 2018 (52.17% varones) y 235 pacientes del a\u00f1o 2021 (44.11% varones), cuya \nmediana de edad era de 52 (16-92) y 54 a\u00f1os (19-91), respectivamente. En 2018, 104 pacientes (50.24%) recibieron Ig \npara las indicaciones enumeradas en ficha t\u00e9cnica mientras que, en 2021, 144 pacientes (61.27%) recibieron Ig con las \nmismas indicaciones. De los tratamientos off-label, 60 correspondieron al Grupo A (58.25%), 27 al B (22.33%) y 20 al C \n(19,42%) durante el a\u00f1o 2018 mientras que, en el a\u00f1o 2021, 66 tratamientos correspondieron al Grupo A (72.53%), 16 \nal B (17.58%) y 9 al C (9.89%). Los Servicios Cl\u00ednicos implicados fueron: Neurolog\u00eda (118 vs 152 pacientes), Hematolog\u00eda \n(39 vs 48), Neumolog\u00eda (20 vs 14), Reumatolog\u00eda (16 vs 10), Medicina Interna (14 vs 8), Cuidados Intensivos (0 vs 2) y \nDigestivo (0 vs 1). Todos los pacientes de la categor\u00eda B correspond\u00edan a Neurolog\u00eda (14 vs 10), Hematolog\u00eda (8 vs 6), \nReumatolog\u00eda (4 vs 2) y Medicina Interna (1 vs 0). Todos los pacientes de la categor\u00eda C correspond\u00edan a Neurolog\u00eda (15 vs \n6), Hematolog\u00eda (3 vs 2) y Reumatolog\u00eda (2 vs 1).\nCONCLUSIONES\nAproximadamente, el 50% de las indicaciones en las que se utilizando las inmunoglobulinas no figuraban en la ficha \nt\u00e9cnica del medicamento. En 2018, el 41.42% de los pacientes recibi\u00f3 Ig para indicaciones con evidencia de uso \nlimitada o incluso no recomendadas, mientras que en 2021 tan s\u00f3lo el 27.47% de los pacientes se encontraron en \nla misma situaci\u00f3n. La implementaci\u00f3n del protocolo cl\u00ednico permiti\u00f3 optimizar el uso de las administraciones de \ninmunoglobulinas, aumentando el n\u00famero de prescripciones en base a sus indicaciones, tras aplicaci\u00f3n de criterios de \nselecci\u00f3n y eficacia en base a la evidencia disponible para la optimizaci\u00f3n de su uso.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n257. FARMACOVIGILANCIA DE VACUNAS COVID-19 DESDE EL INICIO DEL PER\u00cdODO DE VACUNACI\u00d3N A \nNIVEL DE UN CENTRO DE FARMACOVIGILANCIA AUTON\u00d3MICO. \nAUTORES\nP\u00c9REZ ALMAGRO, MF; P\u00c9REZ PONT , J; M\u00c9NDEZ SASTRE, AG; DUR\u00c1N ABAD, M; CARRILLO L\u00d3PEZ, V\nHOSPITAL UNIVERSITARI SON ESPASES \ufffd CARRETERA VALLDEMOSSA 79 PALMA DE MALLORCA \ufffd ILLES BALEARS\nOBJETIVOS\nEl Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso Humano (SEFV-H), integrado por los Centros \nAuton\u00f3micos de Farmacovigilancia y coordinado por la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios \n(AEMPS), valora de forma continua las sospechas de reacciones adversas a Medicamentos (RAM) notificadas en Espa\u00f1a, \nincluyendo las vacunas\ufffd  \nHasta el 6 de marzo de 2022, se han administrado en Espa\u00f1a 99.455.472 dosis de vacunas frente a la COVID-19, \nhabi\u00e9ndose registrado 64.427 notificaciones de acontecimientos adversos. Los acontecimientos notificados con m\u00e1s \nfrecuencia siguen siendo los trastornos generales (fiebre y dolor en la zona de vacunaci\u00f3n), del sistema nervioso (cefalea \ny mareos) y del sistema musculoesquel\u00e9tico (mialgia y artralgia).  \nEl objetivo es mostrar los datos de farmacovigilancia de vacunas en las Baleares durante el per\u00edodo de vacunaci\u00f3n contra \nla Covid-19.\nMATERIALES Y M\u00c9TODOS\nAn\u00e1lisis descriptivo de las RA de vacunaci\u00f3n contra la COVID-19 de Baleares explotados de una herramienta din\u00e1mica de \nMicrosoft, PowerBI, desde el 27 de diciembre de 2020 hasta el 22 de marzo de 2022. Los datos han sido extra\u00eddos desde \nel centro de Farmacovigilancia de las Islas Baleares\ufffd \nLas variables medidas son: notificaciones totales, por vacuna, por notificador y tipo de centro, tipo de gravedad y listado \nde RA por vacuna\ufffd  \nVacunas incluidas en el an\u00e1lisis: Comirnaty, Spikevax, Vaxzevria y Janssen.\nRESULTADOS\nEn 2021, se notificaron un total de 4.293 RAM, se observ\u00f3 un aumento de notificaci\u00f3n del 340% respecto a la media de \nlos 4 a\u00f1os anteriores, 1\ufffd264\ufffd  \nEl n\u00famero de notificaciones correspondientes a vacunas COVID-19 fueron 3.660, 18 en menores de 12 a\u00f1os, 5 pirexias, 4 \ncefaleas y 3 graves, anafilaxis, epilepsia y cefalea + diplop\u00eda. 2.633 (72%) registradas por profesional sanitario (m\u00e9dicos, \nenfermeros, farmac\u00e9uticos, fisioterapeutas y pod\u00f3logos) y 1.025 (28%) no sanitario. Centros hospitalarios 921 (35%) y \nextrahospitalarios 1.712 (65%).  \nNotificaciones por vacuna: Comirnaty 1.809, Spikevax 903, Vaxzevria 863 y Janssen 85. \n3.281 (90%) notificaciones fueron no graves, 379 (10%) graves. \nNotificaciones no graves por System Organ Class (SOC) y Preferred Term (PT): Trastornos generales 2490 (Pirexia 1556, \nescalofr\u00edos 477, malestar 421, fatiga 382), Sistema nervioso 1.642 (cefalea 1241, na\u00faseas 344), musculoesquel\u00e9ticas \n1.258 (mialgia 578, artralgia 263).  \n180 notificaciones graves seg\u00fan la lista Important Medical Event, 22 s\u00edncope, 16 embolia pulmonar, 15 miocarditis, 8 \npar\u00e1lisis facial y 7 angioedema.  \nLos 3 PT m\u00e1s frecuentes por vacuna son: Comirnaty: pirexia 674, cefalea 536 y mialgia 264; Spikevax: pirexia 396, cefalea \n308 y escalofr\u00edos 128; Vaxzevria: pirexia 459, cefalea 374, mialgia 187; Janssen: pirexia 27, cefalea 23 y fatiga 11.\nCONCLUSIONES\nLos datos no se pueden considerar RA debidas a vacunas ni son v\u00e1lidos para calcular la frecuencia de aparici\u00f3n. El an\u00e1lisis \nde las notificaciones proporciona \u201cse\u00f1ales\u201d que eval\u00faan las agencias.  460Se observa un incremento significativo en la actividad de la FV auton\u00f3mica y nacional, causado por el impacto de la \nvacunaci\u00f3n masiva\ufffd \nLa mayor parte de notificaciones se realizaron desde centros extrahospitalarios.  \nSe observa relaci\u00f3n entre las RAM notificadas con la incidencia descrita en ficha t\u00e9cnica. \nEs importante seguir notificando todas las RAM para fomentar el uso seguro del medicamento.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n265. ESTUDIO DE LOS FACTORES DE RIESGO DE HEMORRAGIAS DIGESTIVAS EN PACIENTES QUE ACUDEN \nAL SERVICIO DE URGENCIAS \nAUTORES\nS\u00c1NCHEZ ARAG\u00d3N, S; DE TEMPLE PLA, M; ESTEBAN GONZ\u00c1LEZ, C; S\u00c1NCHEZ DORREGO, L; GALOFR\u00c9 MESTRE, L; \nMONTOLIU ALC\u00d3N, P; FLORIT SUREDA, M; GONZ\u00c1LEZ VALDIVIESO, J\nHOSPITAL UNIVERSITARI SAGRAT COR \ufffd VILADOMAT , 288 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nAnalizar los factores de riesgo de los pacientes atendidos en el servicio de urgencias por hemorragias digestivas (HD) \ncomo principal motivo de consulta.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional y retrospectivo realizado en un hospital de segundo nivel durante un a\u00f1o (enero-diciembre del \n2021). Se incluyeron todos los pacientes mayores de 18 a\u00f1os ingresados con diagn\u00f3stico de HD (altas y bajas).  \nLas variables analizadas fueron: edad; sexo; antecedentes de ingesta habitual de alcohol y tabaco; antecedentes \ndigestivos (\u00falcera, esofagitis/gastritis, varices, neoplasia, angiodisplasia de colon, diverticulosis, HD previa, hemorroides/\nfisura rectal, hernia hiatal, p\u00f3lipos y otras patolog\u00edas gastrointestinales); tratamientos farmacol\u00f3gicos potencialmente \ngastrolesivos (antiinflamatorios no esteroideos (AINEs), anticoagulantes orales, heparina de bajo peso molecular (HBPM), \nantiagregantes orales, corticoides y antidepresivos); comorbilidades (hipertensi\u00f3n, diabetes e inmunosupresi\u00f3n); \ninestabilidad hemodin\u00e1mica (sepsis); requerimiento de transfusi\u00f3n sangu\u00ednea.  \nSe estim\u00f3 la medida de asociaci\u00f3n entre los factores de riesgo (antecedentes, comorbilidades y medicaci\u00f3n) y las HD de \nrepetici\u00f3n y tambi\u00e9n con el requerimiento de transfusi\u00f3n (gravedad de la HD) a partir de la raz\u00f3n de odds (OR), as\u00ed como \nel c\u00e1lculo de su intervalo de confianza (IC95%). El valor de la significaci\u00f3n estad\u00edstica fue para un valor p < 0,05 a partir de \nc\u00e1lculo del \u03c7\u00b2 de Pearson. Para llevar a cabo dichos c\u00e1lculos se utiliz\u00f3 SPSS\u00ae_v.20.\nRESULTADOS\nSe incluyeron 99 pacientes, de los cuales un 48,5% eran mujeres, con una edad media de 79,9 a\u00f1os (IC95%: 77,3-82,7). El \n26,5% y el 45% ten\u00edan antecedentes de ingesta habitual de alcohol y tabaco, respectivamente. El 77% eran hipertensos, el \n30% diab\u00e9ticos y un 5% presentaban inmunosupresi\u00f3n. El 55% ten\u00edan 2 o m\u00e1s antecedentes digestivos y el 20% ninguno, \nsiendo el de mayor prevalencia la diverticulosis (46%). El 24% de los pacientes ingresaron con HD de repetici\u00f3n. Un 11% \nllevaban prescrito AINEs, un 37% anticoagulantes (43% acenocumarol y 32% apixaban), un 32% antiagregantes (78% \u00e1cido \nacetilsalic\u00edlico), un 5% corticoides y un 25% antidepresivos (60% inhibidores selectivos de la recaptaci\u00f3n de serotonina).  \nEl 8% de los pacientes presentaron inestabilidad hemodin\u00e1mica durante el ingreso y el 43% requirieron transfusi\u00f3n \nsangu\u00ednea.  \nSe observaron medidas de asociaci\u00f3n estad\u00edsticamente significativas para HD de repetici\u00f3n y los siguientes factores de \nriesgo: pacientes con antecedentes de consumo de alcohol y en tratamiento con antidepresivos (OR=10,1; IC95%: 1,1-\n102,0) y pacientes con m\u00e1s de un antecedente digestivo (OR=30,9; IC95%: 4,0-241,0).  \nAs\u00edmismo, se observaron medidas de asociaci\u00f3n estad\u00edsticamente significativas para requerimiento de transfusi\u00f3n y los \nsiguientes factores de riesgo: pacientes con HD de repetici\u00f3n (OR=2,8; IC95%: 1,1-7,2), antecedente de \u00falcera digestiva \n(OR=3,9; IC95%: 1,1-13,6) y pacientes con antecedentes de consumo de alcohol y en tratamiento con antiagregantes \n(OR=5,4; IC95%: 1,1-27,5).\nCONCLUSIONES\nLos pacientes que acudieron al servicio de urgencias por HD son mayoritariamente pacientes de edad avanzada con \nantecedentes digestivos y comorbilidades asociadas. La presencia de antecedentes digestivos, as\u00ed como la asociaci\u00f3n de \nconsumo de alcohol y tratamiento con antidepresivos, aumentan el riesgo de HD reiteradas. Adem\u00e1s, la presencia de HD \nde repetici\u00f3n, antecedentes de \u00falcera digestiva, as\u00ed como consumo concomitante de alcohol y antiagregantes, aumentan \nel riesgo de requerir transfusi\u00f3n sangu\u00ednea en los pacientes hospitalizados con HD.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n279. TRATAMIENTO CON UREA EN LA HIPONATREMIA DEBIDA AL S\u00cdNDROME DE SECRECI\u00d3N INADECUADA \nDE HORMONA ANTIDIUR\u00c9TICA \nAUTORES\nGARC\u00cdA LASTRA, S; BECERRA INGERTO, L; CRESPO RODR\u00cdGUEZ, E; GARC\u00cdA LEDO, S; PRADO ALONSO, N; PLANO \nS\u00c1NCHEZ, AI; GONZ\u00c1LEZ S\u00c1NCHEZ, N; MART\u00cdN CARRO, C\nHOSPITAL SAN AGUST\u00cdN \ufffd CAMINO DE HEROS, 6 AVIL\u00c9S \ufffd ASTURIAS\nOBJETIVOS\nEvaluar la efectividad y seguridad de urea oral como tratamiento de la hiponatremia asociada al s\u00edndrome de secreci\u00f3n \ninadecuada de hormona antidiur\u00e9tica (SIADH).461MATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo de los pacientes a tratamiento con urea para la hiponatremia secundaria a SIADH \ndesde julio de 2018 hasta abril de 2022.  \n \nPara medir la efectividad se evaluaron los niveles de sodio al ingreso y al alta. Otras variables recogidas en el estudio \nfueron: edad, sexo, niveles de urea, tratamiento al alta, dosis de urea, duraci\u00f3n del tratamiento, ingresos posteriores por \nhiponatremia y efectos adversos. Adem\u00e1s, se realiz\u00f3 una revisi\u00f3n del diagn\u00f3stico y etiolog\u00eda del SIADH.  \n \nEl grado de hiponatremia se clasific\u00f3 como leve (130-135 mmol Na/L), moderada (125-129 mmol Na/L) y grave ( < 125 \nmmol Na/L).  \n \nLos datos se recogieron a trav\u00e9s de la historia cl\u00ednica electr\u00f3nica.\nRESULTADOS\nSe incluyeron un total de 39 pacientes, el 51.3% (n=20) mujeres, con una mediana de edad de 82 a\u00f1os.  \n \nAl ingreso, la mediana de los niveles de sodio fue 123 mmol/L, mientras que al alta fue 132 mmol/L. El grado de \nhiponatremia al ingreso fue leve en un 5.1% (n=2) de los pacientes, moderada en un 64.1% (n=25) y grave en un 30.8% \n(n=12). En la anal\u00edtica realizada al alta, de los 39 de pacientes, el 41% (16) padec\u00eda hiponatremia leve, el 35.9% (14) \nmoderada, el 15.4% (6) normal y de el 7.7% (3) no se determinaron los niveles de sodio. La mediana de los niveles de \nurea durante el ingreso fue 28 mg/dL, y al alta fue 50 mg/dL\ufffd  \n \nEl tratamiento al alta fue en un 10.3% (n=4) urea oral, en un 64.1% (n=25) urea y retirada de f\u00e1rmacos asociados a \nhiponatremia, en un 23.1% (n=9) urea y restricci\u00f3n h\u00eddrica y por \u00faltimo en un 2.5% (n=1) urea, retirada de f\u00e1rmacos \nasociados a hiponatremia y restricci\u00f3n h\u00eddrica. La dosis prescrita de urea fue en un 66,7% (n=26) de 15 g al d\u00eda, en un \n17,9% (n=7) de 30 g al d\u00eda, en un 10,3% (n=4) de 15 g cada 48 horas y en un 5,1% (n=2) de 45 g al d\u00eda. El tratamiento se \nmantuvo durante una mediana de 4 meses\ufffd  \n \nUn 10.3 % (n=4) de los pacientes ingresaron de nuevo debido a hiponatremia y solo uno de ellos notific\u00f3 mala tolerancia \nal f\u00e1rmaco por molestias gastrointestinales.  \n \nLa etiolog\u00eda del SIADH fue farmacol\u00f3gica en un 46% (n=18), paraneopl\u00e1sica en un 18% (n=7), multifactorial en el 15% \n(n=6) e idiop\u00e1tica en un 21% (n=8) de los pacientes. En los pacientes con SIADH de etiolog\u00eda farmacol\u00f3gica, un 45% (n=8) \nfue causado por diur\u00e9ticos, un 33% (n=6) por antidepresivos y un 22% (n=4) por antiepil\u00e9pticos.\nCONCLUSIONES\nLa urea oral parece ser una alternativa efectiva y de bajo coste en el tratamiento de la hiponatremia secundaria a SIADH. \nProduce un aumento gradual de los niveles de sodio s\u00e9rico evitando el riesgo de producir hipernatremia debido a la \ncorrecci\u00f3n excesivamente r\u00e1pida que pueden producir los antagonistas selectivos de los receptores de vasopresina V2.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n283. DESCRIPCI\u00d3N DEL USO DE F\u00c1RMACOS ANTICOLIN\u00c9RGICOS EN PACIENTES GERI\u00c1TRICOS \nINSTITUCIONALIZADOS \nAUTORES\nARRANZ , N; ROVIRA , M; SOTOCA , JM; ESPIER , M; SOY , D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nMedir la prevalencia de f\u00e1rmacos con actividad anticolin\u00e9rgica prescritos en pacientes geri\u00e1tricos institucionalizados \ny calcular su carga anticolin\u00e9rgica. Determinar cu\u00e1les son los principios activos (PA) con actividad anticolin\u00e9rgica m\u00e1s \nprescritos y si se prescriben en situaci\u00f3n de deterioro cognitivo/demencia.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo en personas mayores institucionalizadas en una residencia urbana. Se estudiaron los pacientes \nque se encontraban ingresados en la residencia en diciembre de 2021. Las variables se recogieron a trav\u00e9s del programa \ninform\u00e1tico del centro de atenci\u00f3n primaria que atiende la residencia y fueron: edad, sexo, diagn\u00f3stico: demencia/\ndeterioro cognitivo; tipo de demencia, ca\u00eddas en el \u00faltimo a\u00f1o, tratamiento concomitante con inhibidores de la \nacetilcolinesterasa (IACE), n\u00famero de PA prescritos, n\u00famero y descripci\u00f3n de los PA anticolin\u00e9rgicos prescritos, grupo \nde morbilidad ajustada (GMA), probabilidad de reingreso, las escalas cl\u00ednicas de evaluaci\u00f3n: del estado funcional del \npaciente (Barthel y Lawton-Brody) y del deterioro cognitivo (Pfeiffer) y situaci\u00f3n de paciente cr\u00f3nico complejo (PCC).\nRESULTADOS\nSe analizaron 92 pacientes con una media de edad de 86,9 (DE 7,5) a\u00f1os y un 73,9% mujeres. Un 80,4 % de los residentes \nten\u00eda prescrito uno o m\u00e1s PA anticolin\u00e9rgicos, de los cuales un 67,6% presentaba diagn\u00f3stico de deterioro cognitivo/\ndemencia (22,8% deterioro cognitivo, 29,8% Alzheimer, 15,8% senilidad, 12,3% demencia vascular, 10,5% Parkinson y \n8,8% demencia no especificada) y un 10% de ellos recib\u00eda tratamiento concomitante con IACE. Un 16% de los pacientes \ntratados con PA anticolin\u00e9rgicos present\u00f3 una ca\u00edda en el \u00faltimo a\u00f1o, como m\u00ednimo.  462La media de PA/paciente fue de 7,7 (DE 3,9) y de PA anticolin\u00e9rgicos/paciente de 1,6 (DE 1,2) con una media de carga \nanticolin\u00e9rgica seg\u00fan la escala Drug Burden Index (DBI) de 1 (DE 0,6) (carga alta). Un 13,4% de los pacientes presentaba \ncarga anticolin\u00e9rgica baja (DBI < 0,5), un 35,1% media (DBI 0,5-0,99), un 46,3% alta (DBI \u22651) y un 5,2% muy alta (DBI \n\u22652). Los f\u00e1rmacos anticolin\u00e9rgicos m\u00e1s prescritos fueron quetiapina (22,1% de total de PA anticolin\u00e9rgicos prescritos), \nlorazepam (15%), citalopram (10%), trazodona (8,6%), seguidos de pregabilina (4,6%), tramadol (4,6%), risperidona (4,6%) \ny sertralina (4,6%). Se observa una mayor prescripci\u00f3n de quetiapina en detrimento de las benzodiazepinas.  \nLa mediana [rango intercuartil] de GMA fue de 3 [2;4] (complejidad cl\u00ednica moderada), de la probabilidad de reingreso \nfue de 5,4% [1; 28,3] y de la puntuaci\u00f3n de las escalas cl\u00ednicas: Barthel 60 [25; 80] (registrada en el 46,7% de los \npacientes), Lawton-Brody 2 [0; 4] (registrada en el 16,3% de los pacientes) y Pfeiffer 5,5 [2; 9] (registrada en el 48,9% de \nlos pacientes). Seg\u00fan las escalas los pacientes presentaban una demencia moderada-importante y un deterioro cognitivo \nmoderado\ufffd Un 58,7%de los pacientes presentaba situaci\u00f3n de PCC\ufffd\nCONCLUSIONES\nLa polifarmacia y la prescripci\u00f3n de PA anticolin\u00e9rgicos es elevada en la residencia geri\u00e1trica evaluada, incluso en \npacientes con demencia/deterioro cognitivo, situaci\u00f3n en la que se recomienda evitar su uso. Es necesaria la optimizaci\u00f3n \nfarmacoterap\u00e9utica de estas prescripciones por un equipo cl\u00ednico multidisciplinar para disminuir la carga anticolin\u00e9rgica \nen estos pacientes\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n292. EVALUACI\u00d3N DE LA SEGURIDAD DE NATALIZUMAB EN ESCLEROSIS M\u00daLTIPLE REMITENTE-\nRECURRENTE \nAUTORES\nGUILL\u00c9N MART\u00cdNEZ, O; GONZ\u00c1LEZ FERN\u00c1NDEZ, A; RODR\u00cdGUEZ MOROTE, M; MORANTE HERN\u00c1NDEZ, M; MURCIA \nL\u00d3PEZ, AC; NAVARRO RUIZ, A\nHOSPITAL GENERAL DE ELCHE \ufffd CAM\u00cd DE L\u00b4AMAZARA, 11 ELCHE/ELX \ufffd ALICANTE\nOBJETIVOS\nNatalizumab (Tysabri\u00ae) es un anticuerpo humanizado recombinante anti-\u03b14-integrina indicado como tratamiento \nmodificador de la enfermedad en monoterapia en adultos con esclerosis m\u00faltiple remitente-recurrente (EMRR) muy \nactiva. Se encuentra asociado a un incremento del riesgo de desarrollar leucoencefalopat\u00eda multifocal progresiva (LMP), \nenfermedad desmielinizante que afecta a la sustancia blanca subcortical del sistema nervioso central, causada por el \nvirus John Cunningham (VJC), siendo factores de riesgo la presencia de anticuerpos frente al virus JC, una duraci\u00f3n \nde tratamiento > 2 a\u00f1os y el uso previo de inmunosupresores. El objetivo es evaluar la seguridad en la pr\u00e1ctica cl\u00ednica \nhabitual de natalizumab en pacientes con EMRR muy activa.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital general de tercer nivel. Se incluyeron todos los pacientes con \nEMMR en tratamiento con natalizumab entre abril de 2012 y abril de 2022. Se recogieron variables demogr\u00e1ficas (sexo, \nedad), cl\u00ednicas (determinaci\u00f3n de anticuerpos VJC antes del inicio del tratamiento y cada 6 meses, resonancia magn\u00e9tica \n(RNM) cerebral realizada al menos en los tres \u00faltimos meses anteriores al inicio del tratamiento y posteriormente cada 6 \nmeses), farmacoterap\u00e9uticas (duraci\u00f3n del tratamiento, uso previo de tratamiento inmunosupresor, otros tratamientos \nprevios para EMRR) y de toxicidad (signos y s\u00edntomas de disfunci\u00f3n neurol\u00f3gica). Los datos se extrajeron de los programas \ninform\u00e1ticos OrionClinic12\u00ae, Abucasis\u00ae y Oncofarm\u00ae.\nRESULTADOS\nSe detectaron 11 pacientes durante el periodo de estudio, 3 hombres y 8 mujeres con una media de edad de 30\u00b116a\u00f1os \ny 42\u00b112a\u00f1os, respectivamente. Antes del inicio del tratamiento con natalizumab, el 100% de los pacientes present\u00f3 \nun resultado negativo en la determinaci\u00f3n de anticuerpos VJC y dispon\u00edan de una RMN cerebral reciente. Durante \nel tratamiento, se realizaron RMN cada 6 meses sin observarse cambios significativos. Diez pacientes contin\u00faan con \nserolog\u00eda negativa VJC y en 1 paciente se ha objetivado serolog\u00eda positiva VJC tras 1 a\u00f1o de tratamiento. En cuanto a \nlas variables farmacoterap\u00e9uticas, actualmente 6 pacientes (55%) se encuentran en tratamiento con natalizumab > 2 \na\u00f1os, 4 pacientes (36%) < 2 a\u00f1os y en tan solo 1 paciente se suspendi\u00f3 el tratamiento con natalizumab tras 7 a\u00f1os y se \ninici\u00f3 ocrelizumab debido a progresi\u00f3n de la enfermedad. El 100% de los pacientes hab\u00edan sido tratados previamente \ncon tratamiento inmunosupresor (corticoesteroides) y 8 de ellos (73%) hab\u00edan recibido previamente otro tratamiento \nmodificador de la enfermedad. En cuanto a la toxicidad, ninguno de los pacientes present\u00f3 signos y s\u00edntomas de \ndisfunci\u00f3n neurol\u00f3gica alarmantes, solo 2 de ellos refirieron presentar en alguna ocasi\u00f3n p\u00e9rdidas de memoria \nespor\u00e1dicas.\nCONCLUSIONES\nDe los pacientes estudiados, m\u00e1s de la mitad de ellos se encuentra en tratamiento con natalizumab > 2 a\u00f1os sin \ndesarrollar LMP y solo en uno de ellos se objetiv\u00f3 serolog\u00eda positiva VJC con un resultado < 0.9 (riesgo de LMP bajo), por \nlo que se ha decidido continuaci\u00f3n del tratamiento con evaluaciones peri\u00f3dicas de serolog\u00eda y RMN. Tras estos resultados \ny la ausencia de toxicidad se puede objetivar la seguridad del tratamiento con natalizumab en pacientes con EMRR en la \npr\u00e1ctica cl\u00ednica habitual.463CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n335. SATISFACCI\u00d3N PERCIBIDA POR LOS PACIENTES: COMPARACI\u00d3N ENTRE DOS MODELOS DE ATENCI\u00d3N \nFARMAC\u00c9UTICA \nAUTORES\nPRADO MONTES, P; ALFONS\u00cdN LARA, M; COU\u00d1AGO FERN\u00c1NDEZ, M; GAYOSO REY , M; L\u00d3PEZ L\u00d3PEZ, A; \u00c1LVAREZ \nPAYERO, M; RODR\u00cdGUEZ LORENZO, D; MART\u00cdNEZ L\u00d3PEZ DE CASTRO, N\nHOSPITAL \u00c1LVARO CUNQUEIRO \ufffd ESTRADA DE CLARA CAMPOAMOR, 341 VIGO \ufffd PONTEVEDRA\nOBJETIVOS\nComparar la satisfacci\u00f3n de los pacientes entre el modelo de atenci\u00f3n farmac\u00e9utica (AF) convencional con dispensaci\u00f3n \npresencial en la consulta externa (CE) y la telefarmacia (TF) combinada con entrega informada de medicaci\u00f3n y/o \nnutrici\u00f3n en un punto de recogida (PR).\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, transversal y descriptivo en un hospital universitario de 1200 camas en el que se realiz\u00f3 una \nencuesta de satisfacci\u00f3n electr\u00f3nica a los pacientes de la Unidad de Atenci\u00f3n Farmac\u00e9utica a Pacientes Externos (UFPE).  \nSe incluyeron aquellos pacientes atendidos en la UFPE en enero 2022, suscritos al sistema de notificaci\u00f3n por m\u00f3vil del \nServicio de Salud y que contestaron voluntariamente la encuesta. Se envi\u00f3 al tel\u00e9fono m\u00f3vil registrado en la ficha de los \npacientes un enlace a la encuesta, indicando su car\u00e1cter voluntario y an\u00f3nimo.  \nLa entrega informada de medicaci\u00f3n y/o nutrici\u00f3n se realiz\u00f3 a trav\u00e9s de dos PR en el exterior del hospital, a los que los \npacientes acced\u00edan directamente en su propio veh\u00edculo tras una consulta de AF telef\u00f3nica con el farmac\u00e9utico.  \nLa encuesta de satisfacci\u00f3n, confeccionada con el programa Typeform, incluy\u00f3 variables sociodemogr\u00e1ficas y 7 atributos \nrelacionados con la calidad del proceso de AF recibida en el \u00faltimo a\u00f1o valorados con una escala tipo Likert (1=peor \nvaloraci\u00f3n; 5=mejor). Los datos fueron analizados con el programa estad\u00edstico SPSS (vs.22).\nRESULTADOS\nSe recibieron 1483 respuestas. Se excluyeron aquellas repetidas e incompletas, consider\u00e1ndose v\u00e1lidas 1289 (44,1% AF-\nCE y 55,9% TF-PR). El 87% de las respuestas (n=1122) corresponden a pacientes, el 10,2% (n=132) a cuidadores o tutores \nlegales, y el 2,8% (n=35) a \u201cotros\u201d. El 54,5% (n=703) fueron mujeres, edad media: 51,4 a\u00f1os\u571f13,37\ufffd  \nLa satisfacci\u00f3n en cuanto al tiempo dedicado por el farmac\u00e9utico fue mayor en el modelo de AF-CE presencial respecto a \nla TF-PR (4,01\u571f1,13 y 3,77 \u571f1,25, p < 0,001).  \nNo se hallaron diferencias estad\u00edsticamente significativas entre la AF-CE y TF-PR en la resoluci\u00f3n de dudas (4,33 \u571f0,95 y \n4,37\u571f0,96, p=0,16), la confidencialidad (4,40 \u571f0,94 y 4,44 \u571f0,94, p=0,12), el trato recibido (4,49 \u571f0,86 y 4,53 \u571f0,83, \np=0,18), el tiempo de espera hasta ser atendido (3,99 \u571f1,13 y 3,95 \u571f1,14, p= 0,39), la se\u00f1alizaci\u00f3n y carteles para llegar \n(3,97\u571f1,14 y 3,94 \u571f1,14, p=0,47) y la valoraci\u00f3n del horario de atenci\u00f3n (4,16\u571f1,05 y 4,16 \u571f1,05, p= 0,91).\nCONCLUSIONES\nLa satisfacci\u00f3n de los pacientes con la AF a trav\u00e9s de telefarmacia con entrega en PR fue similar a la obtenida con la \natenci\u00f3n presencial en CE. Sin embargo, los pacientes perciben una dedicaci\u00f3n menor del farmac\u00e9utico. El Servicio \nde Farmacia debe mejorar y establecer estrategias que igualen la calidad de la atenci\u00f3n prestada a trav\u00e9s de ambos \nmodelos\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n475. \u00bfSABEN LOS PACIENTES C\u00d3MO ELIMINAR CORRECTAMENTE LOS RESIDUOS QUE GENERAN SUS \nMEDICAMENTOS PARENTERALES DE DISPENSACI\u00d3N HOSPITAL\u00c0RIA? \nAUTORES\nPENA VILLANUEVA, P; GONZALEZ MARTINEZ, J; CANSADO JUSTICIA, A; MARTINEZ SOLER, C; GUERRERO GARCIA, L; \nTEYS MUSACH, D; TORRES DE LA TORRE, V; HEREDIA CANO, ME\nHOSPITAL COMARCAL SANT JAUME DE CALELLA. SANT JAUME, 209-217 CALELLA. BARCELONA\nOBJETIVOS\n\u2022 Calcular el porcentaje de pacientes que realiza la eliminaci\u00f3n de residuos relacionada con medicamentos parenterales \nde dispensaci\u00f3n hospitalaria de manera correcta.  \n\u2022 Analizar donde eliminan los pacientes los residuos de la medicaci\u00f3n parenteral.\nMATERIALES Y M\u00c9TODOS\nEstudio multic\u00e9ntrico prospectivo abierto sin grupo control realizado en dos hospitales comarcales de un misma \nCorporaci\u00f3n Sanitaria que atiende a una poblaci\u00f3n de 195.000 habitantes.  \nSe incluy\u00f3 a todos los pacientes que acudieron a la consulta de atenci\u00f3n farmac\u00e9utica del Servicio de Farmacia \nentre el 11-3-22 y el 11-5-22 a recoger medicaci\u00f3n de administraci\u00f3n parenteral. Se excluyeron a aquellos que no se \nadministrasen la medicaci\u00f3n en su domicilio o que no diesen su consentimiento informado.  \nSe dise\u00f1\u00f3 un cuestionario que inclu\u00eda una sola pregunta \u201c\u00bfC\u00f3mo elimina usted los siguientes residuos?\u201d con las siguientes \nopciones: en basura normal, en punto SIGRE, en Punto Limpio, en Centro de Atenci\u00f3n Primaria (CAP), en Hospital y Otras \nopciones. Seg\u00fan el medicamento parenteral dispensado, el paciente podr\u00eda generar los siguientes residuos: jeringa o \npluma usada y tapada, jeringa o pluma usada y no tapada, cartucho de medicamento usado, vial de medicamento usado \ny agujas usadas.  464Se registr\u00f3 en una hoja excel el n\u00famero de historia del paciente, edad, medicaci\u00f3n parenteral dispensada, tipo de residuo \ngenerado, forma de eliminaci\u00f3n del residuo y si es v\u00e1lida la forma de eliminaci\u00f3n.  \nSe consider\u00f3 como una eliminaci\u00f3n v\u00e1lida la eliminaci\u00f3n de jeringas/plumas tapados, viales y cartuchos en el SIGRE, CAPs \ny Hospitales. Tambi\u00e9n se consider\u00f3 como una eliminaci\u00f3n v\u00e1lida la eliminaci\u00f3n de agujas y jeringas/plumas no tapadas en \nel Punto Limpio, CAPs y Hospitales\ufffd El resto de posibilidades se consideraron incorrectas\ufffd\nRESULTADOS\nSe reclutaron 96 pacientes durante el periodo de estudio, los cuales respondieron a un total de 100 encuestas\ufffd Eran \n43 mujeres y 53 hombres, con una media de edad de 50 a\u00f1os (rango de 18-89). El 63% de los residuos generados se \neliminaron incorrectamente\ufffd  \nEl 90% de los residuos se trataban de jeringas y plumas de medicaci\u00f3n subcut\u00e1nea, 2% cartuchos, 4% viales y 4% agujas. \nLa mayor parte de los residuos (54%) se eliminaron sin proteger en la basura normal, un 21% lo hicieron en el SIGRE, el \n12% lo hicieron en el Punto Limpio, el 5% fueron entregados en el hospital, el 5% en el CAP y un 3% se desecharon por \notras v\u00edas.\nCONCLUSIONES\nUn alto porcentaje de los pacientes eliminaron incorrectamente los residuos generados tras la administraci\u00f3n de su \nmedicaci\u00f3n parenteral de dispensaci\u00f3n hospitalaria, principalmente tir\u00e1ndolos a la basura normal. Esto evidencia \nuna clara necesidad de concienciaci\u00f3n de los pacientes en este sentido, no solo con el objetivo de evitar pinchazos \naccidentales a nivel de la gesti\u00f3n de residuos urbanos, sino tambi\u00e9n de proteger el medio ambiente que nos rodea.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n483. USO DE ATROPINA, EFEDRINA Y FENILEFRINA EN QUIR\u00d3FANO Y AN\u00c1LISIS DEL IMPACTO ECON\u00d3MICO \nAL SUSTITUIR SUS PRESENTACIONES POR JERINGAS PRECARGADAS. \nAUTORES\nBARCEL\u00d3 SANS\u00d3, F; PRATS RIERA, M; BOFILL ROIG, E; LUQUE MESA, JA\nHOSPITAL CAN MISSES \ufffd CORONA, S/N EIVISSA \ufffd ILLES BALEARS\nOBJETIVOS\nAnalizar el modo de preparaci\u00f3n de atropina, efedrina y fenilefrina en quir\u00f3fano, contabilizar el n\u00famero de ampollas \nde atropina y efedrina cargadas desechadas y cu\u00e1l ser\u00eda el impacto econ\u00f3mico te\u00f3rico que supondr\u00eda el cambio de \npresentaci\u00f3n de ampolla a jeringa precargada para ambos f\u00e1rmacos.  \n \nComo objetivo secundario, conocer si existe beneficio econ\u00f3mico al sustituir la presentaci\u00f3n de fenilefrina en soluci\u00f3n \npor la jeringa precargada.\nMATERIALES Y M\u00c9TODOS\nSe solicit\u00f3 al personal m\u00e9dico de anestesia y al personal de enfermer\u00eda que conservaran las jeringas cargadas de efedrina \ny atropina no utilizadas al final de d\u00eda para su posterior recogida por parte del Servicio de Farmacia. Se ha considerado un \nprimer periodo de recogida de 3 de diciembre de 2021 a 9 de febrero de 2022\ufffd  \n \nPara analizar el impacto econ\u00f3mico se ha tenido en cuenta tanto el coste de cada f\u00e1rmaco como el coste del material \nfungible (jeringa, aguja de carga, etiqueta identificativa, suero para diluir).  \n \nEn la pr\u00e1ctica cl\u00ednica de nuestro hospital, fenilefrina no se carga de rutina en jeringa de manera preventiva por lo que no \ntenemos registro de recogida de este f\u00e1rmaco, pero si hemos obtenido datos de consumo.\nRESULTADOS\nDurante el per\u00edodo de estudio se han contabilizado un total de 97 jeringas cargadas no utilizadas de atropina y 52 \nde efedrina. Teniendo en cuenta que el consumo de atropina y efedrina durante el mismo per\u00edodo fue de 236 y 219 \nunidades, respectivamente, se calcula un desecho del 40 % para atropina y del 24 % para efedrina. El consumo de \nfenilefrina fue de 27 unidades\ufffd  \n \nDurante el an\u00e1lisis se observa una falta de estandarizaci\u00f3n en la preparaci\u00f3n de atropina. Se detectan hasta tres \nconcentraciones distintas (atropina 1 mg/mL, atropina 0,1 mg/mL y atropina 0,2 mg/mL). En relaci\u00f3n a la preparaci\u00f3n de \nefedrina, todas las jeringas recuperadas se han preparado de manera unificada a una concentraci\u00f3n de 5 mg/mL.\nCONCLUSIONES\nEn nuestro \u00e1mbito, la implantaci\u00f3n de jeringas precargadas de efedrina supondr\u00eda un nulo incremento de coste al evitarse \nel gasto del consumo preventivo y en el caso de atropina la sustituci\u00f3n de ampolla por jeringa precargada representar\u00eda \nun incremento de unos 3000 euros anuales, teniendo en cuenta que la sustituci\u00f3n solo se plantear\u00eda en el \u00e1rea quir\u00fargica. \nLa adquisici\u00f3n de las jeringas precargadas de atropina estar\u00eda justificada con el objetivo de incrementar la seguridad del \npaciente ya que se evitar\u00eda el uso de distintas concentraciones y formas de preparaci\u00f3n.  \n \nPor otro lado, la sustituci\u00f3n de la presentaci\u00f3n de fenilefrina en bolsa por las jeringas precargadas supondr\u00eda un ahorro de \naproximadamente 4000 euros anuales, adem\u00e1s de incrementar la seguridad para la pr\u00e1ctica asistencial.465CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n492. EVALUACI\u00d3N DEL SISTEMA DE UTILIZACI\u00d3N DE MEDICAMENTOS EN UN SERVICIO DE MEDICINA \nINTENSIVA Y DEFINICI\u00d3N DE ESTRATEGIAS DE MEJORA \nAUTORES\nBRUGUERA TEIXIDOR, M; P\u00c9REZ PLASENCIA, A; VILA CURRIUS, M; ORTIZ BALLUJERA, P; SAMPER SANCHEZ, N; TORO \nBLANCH, C; ORT\u00cd JUAN, C; DORD\u00c0 BENITO, A\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nEvaluar el sistema de utilizaci\u00f3n de medicamentos en un servicio de Medicina Intensiva (SMI), detectar puntos d\u00e9biles y \ndefinir acciones de mejora a implementar.\nMATERIALES Y M\u00c9TODOS\n- Creaci\u00f3n de un equipo multidisciplinar  \n- Aplicaci\u00f3n del cuestionario de autoevaluaci\u00f3n de utilizaci\u00f3n de medicamentos en los SMI elaborado por el ISMP-Espa\u00f1a, \nel Grupo de trabajo FarMIC de la Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH) y la Sociedad Espa\u00f1ola de Medicina \nIntensiva, Cr\u00edtica y Unidades Coronarias (SEMICYUC)  \n- Comparaci\u00f3n de los resultados obtenidos con los de otros SMI y detecci\u00f3n de puntos d\u00e9biles  \n- Definici\u00f3n e implantaci\u00f3n de acciones de mejora\nRESULTADOS\nEn mayo de 2021 se cre\u00f3 un grupo multidisciplinar formado por m\u00e9dicos intensivistas, enfermeras, farmac\u00e9uticos, \nresponsables de prevenci\u00f3n de errores y de la direcci\u00f3n del centro. Se aplic\u00f3 el cuestionario del ISMP obteniendo una \npuntuaci\u00f3n global total de 51,56%, ligeramente superior a la puntuaci\u00f3n media obtenida por otros 40 SMI que hab\u00edan \ncumplimentado el cuestionario en dicha fecha (49,2%). Los bloques con mejor puntuaci\u00f3n respecto la media fueron los \nde informaci\u00f3n de los pacientes y medicamentos, comunicaci\u00f3n de las prescripciones e incorporaci\u00f3n de farmac\u00e9uticos \n(claves I, II y III). Los de peor puntuaci\u00f3n fueron los relacionados con formaci\u00f3n del personal, educaci\u00f3n a pacientes/\nfamiliares y programas de calidad y gesti\u00f3n de riesgos (claves VIII, IX y X).  \n \nSe definieron las siguientes 14 acciones de mejora, de las cuales ya se han implementado las 7 primeras: \n \n1. Realizar un estudio de errores de prescripci\u00f3n en el SMI  \n2. Almacenar los bloqueantes neuromusculares separados del resto de medicaci\u00f3n, etiquetados con la advertencia: \n\u201cParalizante respiratorio\u201d  \n3. Realizar una sesi\u00f3n anual sobre errores de medicaci\u00f3n (EM) a enfermeros y m\u00e9dicos del SMI  \n4. Introducir en el tr\u00edptico para familiares la recomendaci\u00f3n de preguntar a los profesionales sanitarios cualquier duda \nsobre los medicamentos prescritos \n5. Definir e implementar un sistema de diferenciaci\u00f3n y almacenamiento de medicamentos similares \n6. Asegurar los descansos establecidos de m\u00e9dicos y farmac\u00e9uticos \n7. Constituir un equipo multidisciplinar del SMI que revise peri\u00f3dicamente los EM notificados e implementar acciones de \nmejora.  \n8. Adecuar la dotaci\u00f3n del personal m\u00e9dico a las necesidades actuales  \n9. Asegurar que el personal est\u00e1 cualificado para trabajar en los SMI  \n10. Incluir en el programa de acogida (residentes, enfermer\u00eda) ejemplos de errores de medicaci\u00f3n en el centro.  \n11. Definir la formaci\u00f3n inicial y continuada en EM.  \n12. Definir un sistema de formaci\u00f3n continuada para exponer al personal los errores que se producen en el servicio.  \n13. Potenciar la notificaci\u00f3n de EM en el SMI.  \n14. Realizar el cuestionario SMI cada 2 a\u00f1os.\nCONCLUSIONES\nLa situaci\u00f3n basal del sistema de utilizaci\u00f3n de medicamentos en nuestro SMI es ligeramente superior a la de los otros \nSMI. La aplicaci\u00f3n del cuestionario del ISMP es una herramienta \u00fatil para detectar puntos d\u00e9biles y definir acciones para \nmejorar la seguridad en el uso de medicamentos en los SMI.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n494. SEGURIDAD EN VIDA REAL DEL TRATAMIENTO CON TOFACITINIB: A PROP\u00d3SITO DE UNA ALERTA. \nAUTORES\nG\u00d3MEZ LLUCH, MT; FOBELO LOZANO, MJ; GALV\u00c1N BANQUERI, M; GABELLA BAZAROT , E; GUTI\u00c9RREZ PIZARRAYA, A; \nM\u00c1RQUEZ SAAVEDRA, E\nCOMPLEJO HOSPITALARIO DE ESPECIALIDADES VIRGEN DE VALME. CTRA. DE C\u00c1DIZ, KM. 548,9 SEVILLA. SEVILLA\nOBJETIVOS\nEn Julio 2021, la AEMPS public\u00f3 una alerta de seguridad relacionada con el iJAK tofacitinib tras los resultados del estudio \nORAL-Surveillance (Disponible en: https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/\nseguridad-1/2021-seguridad-1/xeljanz-tofacitinib-nuevas-precauciones-de-uso/).  466Objetivo principal: analizar la presencia de cualquier evento adverso (EA) y la posible relaci\u00f3n de EAs cardiovasculares \nmayores y neoplasias malignas con el perfil de paciente con mayor riesgo de desarrollarlos establecido en la alerta. \nObjetivo secundario: analizar el motivo de suspensi\u00f3n y examinar si tras la alerta ha disminuido el n\u00famero de pacientes \nde riesgo en tratamiento\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y retrospectivo de los pacientes tratados con tofacitinib hasta mayo de 2022 en un \nhospital de especialidades.  \nVariables: sexo, edad al inicio, patolog\u00eda y dosis, duraci\u00f3n del tratamiento, motivo de suspensi\u00f3n y EAs. \nSe analizaron los antecedentes para ver si los pacientes se consideraban con perfil de riesgo aumentado para el desarrollo \nde EA seg\u00fan la alerta. Este perfil de riesgo se defini\u00f3 como: presencia de alg\u00fan factor de riesgo cardiovascular (FRC) (edad \nsuperior a 65 a\u00f1os, fumador/exfumador, hipertensi\u00f3n, diabetes, hiperlipidemia, obesidad y enfermedad coronaria) o con \nfactores de riesgo para el desarrollo de neoplasias (FRN) (edad superior a 65 a\u00f1os y/o fumador/exfumador).  \nLos datos se obtuvieron de la historia cl\u00ednica y Farmatools\u00ae.  \nLas variables discretas se expresaron como frecuencia y las continuas como medianas y rangos. La hip\u00f3tesis de \nindependencia se estudi\u00f3 mediante la prueba de Chi-cuadrado o exacta de Fisher en el caso de variables categ\u00f3ricas y \ncon la prueba T o U de Mann-Whitney, para las variables cualitativas. Los c\u00e1lculos se realizaron mediante SPSS v25.0 y se \ntom\u00f3 un valor de p < 0,05 como estad\u00edsticamente significativo.\nRESULTADOS\nSe incluyeron 77 pacientes, 69% mujeres, con una edad mediana al inicio del tratamiento de 53 a\u00f1os (17-76). \nDiagn\u00f3sticos: 74 % artritis reumatoide,19,5% artritis psori\u00e1sica,3,9% colitis ulcerosa (dosis de 10mg) y el 2,6% espondilitis \nanquilosante. Mediana de duraci\u00f3n del tratamiento: 308 d\u00edas (28-1652).  \nEl 79,2% de los tratamientos fueron suspendidos: 42,9% por inefectividad, 20,8% por EA, y 10,4% por ambos motivos. En \nun 5,2% la suspensi\u00f3n fue debida al considerar al paciente de alto riesgo tras la alerta\ufffd \nEl 74% fueron considerados de alto riesgo: 19,5% mayores de 65 a\u00f1os, 42,9% fumador/exfumador, 55,8% FRC, 57,1% \nFRN\ufffd \nEl 37,7% del total desarrollaron EAs (herpes z\u00f3ster y cefalea los m\u00e1s comunes), siendo graves un 2,6% (TEP y FARVR).  \nAl analizar la posible asociaci\u00f3n entre una situaci\u00f3n basal de riesgo y el desarrollo de EAs de cualquier tipo, no se \nobservaron diferencias estad\u00edsticamente significativas en la ocurrencia de los mismos entre pacientes de riesgo y el resto. \nTras la alerta los pacientes de riesgo pasaron del 75% al 67%\ufffd\nCONCLUSIONES\nSe observa un alto porcentaje de suspensiones del f\u00e1rmaco, aunque la mayor\u00eda debido a inefectividad y no a EAs graves. \nLos EAs no se relacionan con el perfil de riesgo del paciente, no obstante, la muestra es limitada para observar estos \nacontecimientos. Se requieren m\u00e1s estudios a largo plazo de los f\u00e1rmacos iJAK, y ver si estos EAs corresponden a un \nefecto de clase de los iJAK.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n522. SEGURIDAD EN VIDA REAL DEL TRATAMIENTO CON IVACAFTOR/TEZACAFTOR/ELEXACAFTOR \nAUTORES\nGARCIA-PALOP , B; FERN\u00c1NDEZ-POLO , A; G\u00d3MEZ-GANDA , L; VANCELLS-LUJ\u00c1N , P; PUERTAS-SANJUAN , A; TRAVERSI \n, L; \u00c1LVAREZ-FERN\u00c1NDEZ , A; GORGAS-TORNER , MQ\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nEl acceso de los pacientes con fibrosis qu\u00edstica (FQ) a f\u00e1rmacos moduladores de CFTR (cystic fibrosis transmembrane \nconductance regulator) ha modificado el curso de esta enfermedad. En diciembre de 2021 se comercializ\u00f3 en Espa\u00f1a la \ntriple terapia con ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX). Los datos sobre su seguridad disponibles hasta la fecha \nindican que un n\u00famero elevado de pacientes presentan alguna reacci\u00f3n adversa (RAM), en su mayor\u00eda leve-moderada.  \n \nEl objetivo del estudio es describir la incidencia de RAM y su manejo cl\u00ednico en una cohorte de pacientes adultos FQ \ntratados con IVA/TEZ/ELX\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en un hospital de tercer nivel. Se incluyeron pacientes con FQ \u226518 a\u00f1os que \niniciaron tratamiento con IVA/TEZ/ELX entre diciembre de 2021 y marzo de 2022 seg\u00fan indicaci\u00f3n de ficha t\u00e9cnica. Se \nexcluyeron aquellos pacientes que hab\u00edan recibido IVA/TEZ/ELX previamente (ensayo cl\u00ednico o managed acces program) \no sin registro m\u00e9dico de seguimiento disponible. A partir de la historia cl\u00ednica informatizada, se recogieron variables \nbiodemogr\u00e1ficas y estudio gen\u00e9tico, as\u00ed como RAM reportadas y su manejo e impacto en el tratamiento con IVA/TEZ/ELX. \nEn el caso de las reacciones cut\u00e1neas, se evalu\u00f3 la distribuci\u00f3n por sexo, edad y toma de anticonceptivos hormonales.\nRESULTADOS\nSe incluyeron 86 pacientes (49% mujeres) con una edad mediana de 29,6 (23,2 \u2013 36,9) a\u00f1os; 50 pacientes eran \nheterocigotos para la mutaci\u00f3n F508del. Hab\u00edan recibido tratamiento previo con otros moduladores de CFTR: 45 \npacientes IVA/ELX y una paciente IVA \ufffd \n 467Un total de 27 (31%) pacientes presentaron 39 RAM, s\u00f3lo 5 de ellos presentaron 2 o m\u00e1s RAM. Las RAM m\u00e1s frecuentes \nfueron 13 (33%) gastrointestinales, 8 (21%) cut\u00e1neas 4 (10%) reproductor/ mama y 3 (8%) hepatobiliares. Se identific\u00f3 \nuna epididimitis posiblemente relacionada con el tratamiento. Las RAM se catalogaron como leve, moderada o severa \nen 24 (62%), 11 (28%) \u00f3 4 (10%) casos respectivamente. No se observaron eventos amenazantes para la vida o que \nprovocaran la muerte\ufffd \n \nRespecto a los pacientes que presentaron RAM cut\u00e1neas, 5 (63%) fueron mujeres, con una edad mediana de 30,9 (26,8 \u2013 \n32,7) a\u00f1os y una de ellas refiri\u00f3 tomar anticonceptivos hormonales.  \n \nLa aparici\u00f3n de RAM motiv\u00f3 la modificaci\u00f3n del tratamiento en 7 (26%) de los pacientes. De \u00e9stos, 2 lo interrumpieron \ntemporalmente y lo reintrodujeron a dosis completas, 3 disminuyeron la dosis a d\u00edas alternos y 2 realizaron pauta de \ndesensibilizaci\u00f3n. Una de estas pacientes interrumpi\u00f3 el tratamiento definitivamente tras la aparici\u00f3n de una RAM severa \ndurante la pauta de desensibilizaci\u00f3n.\nCONCLUSIONES\nLa tasa de RAM en nuestra cohorte no fue superior a la reportada en los ensayos cl\u00ednicos, aunque destac\u00f3 una incidencia \nsuperior en RAM gastrointestinales (33%) y cut\u00e1neas (21%). No obstante, se necesitan estudios a largo plazo para \nconfirmar estos resultados. Adem\u00e1s, el estudio ha permitido identificar una posible RAM no registrada en los ensayos \ncl\u00ednicos (epididimitis). La mayor\u00eda de pacientes que interrumpieron el tratamiento por una RAM lo pudieron reiniciar. Se \nrequieren estudios m\u00e1s amplios para confirmar la eficacia de las pautas de desensibilizaci\u00f3n en los pacientes que han \npresentado RAM severas a IVA/TEZ/ELX\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n539. CUESTIONARIO DE AUTOEVALUACI\u00d3N DE SEGURIDAD DE UTILIZACI\u00d3N MEDICAMENTOS EN \nHOSPITALES. HERRAMIENTA PARA AN\u00c1LISIS DE RESULTADOS Y DEFINIR ESTRATEGIAS DE MEJORA. \nAUTORES\nMARTINEZ BERNABE, EM; BESALU VIVES, S; GARCIA FLORES, A; CASAS GRIMALDOS, A; GARCIA MU\u00d1OZ, E; LASC _, \nAR; RIBAS DUOCASTELLA, M; SOLANES JIMENEZ, A\nHOSPITAL COMARCAL SANT JAUME DE CALELLA. SANT JAUME, 209-217 CALELLA. BARCELONA\nOBJETIVOS\nComparar los resultados del cuestionario de autoevaluaci\u00f3n de la Seguridad de Utilizaci\u00f3n de Medicamentos en \nHospitales en dos ediciones consecutivas 2019-2021.  \nEstablecer los objetivos a trabajar por la Comisi\u00f3n de Uso Seguro del Medicamento, a partir de los resultados\nMATERIALES Y M\u00c9TODOS\nEstudio realizado en una organizaci\u00f3n sanitaria con todos los niveles asistenciales, dos hospitales de agudos, tres equipos \nde atenci\u00f3n primaria y tres centros sociosanitarios\ufffd  \nLa Comisi\u00f3n del Uso Seguro del Medicamento (CUSM) es una comisi\u00f3n multidisciplinar e interniveles, formada \npor m\u00e9dicos y enfermeras de los distintos \u00e1mbitos asistenciales, farmac\u00e9uticos y t\u00e9cnico de farmacia. Se re\u00fane \nbimensualmente para analizar las notificaciones recibidas a trav\u00e9s de la herramienta de notificaci\u00f3n voluntaria de errores \nde medicaci\u00f3n y establecer acciones de mejora. \nEl Cuestionario de Autoevaluaci\u00f3n de la Seguridad del Sistema de Utilizaci\u00f3n de los Medicamentos en los Hospitales es \nuna herramienta proactiva de mejora de la seguridad desarrollada por el Institute for Safe Medication Practices (ISMP) \nen Estados Unidos, adaptada por el Instituto para el Uso Seguro de Medicamentos en Espa\u00f1a (2007), con una segunda \nversi\u00f3n actualizada en 2018. Est\u00e1 estructurado en 10 apartados correspondientes a elementos clave que m\u00e1s inciden en \nla seguridad del sistema de utilizaci\u00f3n de medicamentos. \u00c9stos contienen uno o m\u00e1s criterios esenciales y cada criterio, \nincluye varios \u00edtems de evaluaci\u00f3n que representan pr\u00e1cticas destinadas a prevenir errores de medicaci\u00f3n. El cuestionario \ncontiene un total de 265 \u00edtems. \nBianualmente desde 2007, se resuelve el cuestionario de autoevaluaci\u00f3n ISMP por el equipo multidisciplinar. \nPreviamente los miembros de la CUSM responden individualmente el cuestionario. Las respuestas se consens\u00faan durante \ndos reuniones de dos horas. Posteriormente se introducen los datos en la aplicaci\u00f3n inform\u00e1tica online. Los resultados \nse comparan con la edici\u00f3n anterior y se analizan por parte del equipo multidisciplinar para detectar oportunidades de \nmejora, a partir de las cuales se consensuar\u00e1n los objetivos bianuales de \u00e1mbito hospitalario de la CUSM.\nRESULTADOS\nSe comparan los resultados obtenidos en dos ediciones consecutivas, 2019 y 2021.  \nSe obtuvo una mejora significativa en la puntuaci\u00f3n total del cuestionario 2021 respecto a 2019 de 9,6 % o puntos \nporcentuales (IC 95% 6,3 - 13). Se obtuvieron mejoras significativas de los elementos clave 2-Informaci\u00f3n de \nmedicamentos: 16,5% (IC 95% 7,9-25,1) 3- Comunicaci\u00f3n de las prescripciones: 16,3% (IC 95% 4-28,6), 8. Competencia y \nformaci\u00f3n del personal: 15,3% (IC 95% 2,1-28,5) y 9. Programas de calidad y gesti\u00f3n de riesgos: 10,2% (IC 95% 2,9-17,5).  \nEl resto de elementos tambi\u00e9n experimentaron mejoras, aunque \u00e9stas no fueron significativas. Ning\u00fan elemento clave \nobtuvo peor resultado respecto a la edici\u00f3n 2019\ufffd  \nA partir de los elementos que no experimentaron mejoras significativas, se establecieron los objetivos de \u00e1mbito \nhospitalario de la CUSM468CONCLUSIONES\nEl cuestionario ISMP es una herramienta \u00fatil para la evaluaci\u00f3n de la seguridad en la utilizaci\u00f3n de los medicamentos en \nlos hospitales. Permite identificar oportunidades de mejora, establecer estrategias de seguridad y realizar el seguimiento \nde las medidas implementadas\ufffd  \nCumplimentar peri\u00f3dicamente el cuestionario ISMP deber\u00eda formar parte de las actividades de mejora continua de la \nseguridad de los medicamentos en los hospitales.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n563. EVALUACI\u00d3N DE LA CALIDAD DE VIDA DE LOS PACIENTES CON TROMBOCITOPENIA INMUNE \nPRIMARIA ATENDIDOS EN LA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA \nAUTORES\nPARRO MART\u00cdN, M\u00c1; MORENO JIM\u00c9NEZ, G; MONTERO LLORENTE, B; V\u00c9LEZ D\u00cdAZ-PALLAR\u00c9S, M; GRAMAGE CARO, T; \nRODR\u00cdGUEZ SAGRADO, M\u00c1; RODR\u00cdGUEZ MAR\u00cdN, M; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nEvaluar la calidad de vida de los pacientes con trombicitopenia inmune primaria(PTI) atendidos en la consulta de atenci\u00f3n \nfarmac\u00e9utica. Analizar si existen diferencias entre los pacientes que recogen la medicaci\u00f3n de forma presencial y aquellos \na los que se les dispensa en el domicilio.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional prospectivo en un hospital de tercer nivel en el que se incluyeron todos los pacientes con PTI en \ntratamiento con eltrombopag y romiplostim a 1 marzo 2022.  \n \nSe utiliz\u00f3 el cuestionario de calidad de vida SF36 validado al espa\u00f1ol. El cuestionario fue realizado telef\u00f3nicamente \npor farmac\u00e9uticos de la unidad de pacientes externos. Los datos cl\u00ednicos (edad,sexo) se obtuvieron del programa de \ndispensaci\u00f3n a pacientes externos\ufffd  \n \nPara el an\u00e1lisis estad\u00edstico se utiliz\u00f3 media y desviaci\u00f3n t\u00edpica en distribuciones sim\u00e9tricas y mediana y rango \nintercuart\u00edlico para no sim\u00e9tricas. Un valor de p < 0,05 fue considerado como significativo.\nRESULTADOS\nSe incluyeron 35 pacientes con una media de edad de 64,8 a\u00f1os \u00b116,2, siendo el 51,4% hombres. No se pudo realizar el \ncuestionario a 5 pacientes por imposibilidad de contacto tras 3 intentos telef\u00f3nicos.  \n \nLa funci\u00f3n con mayor porcentaje y por lo tanto la mejor valorada, fue la funci\u00f3n social con 78,7%, seguido del rol f\u00edsico \ncon 74,2% y la salud mental con 72,9%. La m\u00e1s baja fue la salud general con 53,8%, seguida de la transici\u00f3n de salud y la \nvitalidad, con un 59,2 y 64,5% respectivamente.  \n \nEn cuanto al sexo, las mujeres presentaron porcentajes mayores en el rol emocional y la salud mental con un 94,8 y \n79,1% respectivamente, frente a 74,5 y 68,2% en hombres. Sin embargo, en el rol f\u00edsico y el dolor, el porcentaje fue \nmayor en hombres, con 77,9 y 72,6% respectivamente, frente al 69,2 y 65,2% en mujeres. Las diferencias no fueron \nestad\u00edsticamente significativas (p > 0,05).  \n \nCon respecto a las diferencias entre los pacientes que recogen la medicaci\u00f3n en persona y los que se le dispensa a \ndomicilio, se observ\u00f3 una gran diferencia en cuanto a la funci\u00f3n f\u00edsica y la vitalidad siendo 91,9 y 71,9% respectivamente \nen los que recogen en persona y 56,5 y 58,8% en los de dispensaci\u00f3n domiciliaria. La diferencia en la funci\u00f3n f\u00edsica result\u00f3 \nestad\u00edsticamente significativa (p=0,00).  \n \nEn cuanto al medicamento utilizado, los pacientes con eltrombopag presentaron una funci\u00f3n f\u00edsica mejor con 76,0%, \nfrente al 60,0% de los pacientes con romiplostim. Sin embargo, la transici\u00f3n en salud fue mejor en pacientes tratados \ncon romiplostim con 66,7%, frente al 56,2% de pacientes con eltrombopag. Las diferencias no fueron estad\u00edsticamente \nsignificativas (p > 0,05).\nCONCLUSIONES\nLa evaluaci\u00f3n de la calidad de vida en nuestra serie de pacientes confirma el deterioro en distintas dimensiones, \nparticularmente en las \u00e1reas de salud general, transici\u00f3n de salud y vitalidad.  \n \nLas mujeres muestran m\u00e1s deterioro en el rol f\u00edsico, sin embargo, presentan un mejor rol emocional que los hombres.  \n \nLa dispensaci\u00f3n de medicaci\u00f3n a domicilio es una iniciativa de mejora asistencial, con impacto favorable en pacientes con \nPTI con peor perfil en la funci\u00f3n f\u00edsica y vitalidad.  \n \nNo existen diferencias estad\u00edsticamente significativas entre los pacientes tratados con eltrombopag y romiplostim.469CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n650. ANALISIS Y DESCRIPCI\u00d3N DE LAS NOTIFICACIONES DE ERRORES DE MEDICACION EN UN HOSPITAL \nCOMARCAL \nAUTORES\nSANCHEZ SUAREZ, S; BARCIA MARTIN, MI; AGUILAR GUISADO, C; GARCIA GIMENO, M\nHOSPITAL DE EL ESCORIAL. CTRA. GUADARRAMA-S. LORENZO DE EL ESCORIAL, KM. 6,2 SAN LORENZO DE EL \nESCORIAL \ufffd MADRID\nOBJETIVOS\nDescribir y analizar las notificaciones realizadas por errores de medicaci\u00f3n (EM) en un hospital comarcal durante 3 a\u00f1os a \ntrav\u00e9s de la plataforma establecida por el Servicio Madrile\u00f1o de la Salud denominada CISEMadrid.\nMATERIALES Y M\u00c9TODOS\nEl farmac\u00e9utico es miembro de la Unidad Funcional de Gesti\u00f3n de Riesgos del hospital y participa en el an\u00e1lisis y \nvaloraci\u00f3n de los incidentes de seguridad notificados por el personal sanitario, as\u00ed como en la implementaci\u00f3n de \nmedidas que se acuerden y que sean necesarias establecer para evitar la ocurrencia de los mismos.  \nEstudio observacional retrospectivo de EM notificados durante el periodo 2019-2021.  \nSe registr\u00f3 el total de EM ocurridos frente al total de incidentes de seguridad notificados en el hospital, el servicio que \nnotifica, tipo, la causa, lugar, numero de EM analizados, herramientas empleadas en el an\u00e1lisis y las medidas establecidas \na fin de evitarlos.\nRESULTADOS\nSe notificaron 147 EM a CISEMadrid que correspondieron a un 38,68% frente al total de incidentes de seguridad \nnotificados en el hospital 233 (61,31%). \nLos servicios cl\u00ednicos y los EM notificados fueron: 85 Farmacia Hospitalaria, 31 Medicina Interna, 18 Urgencias, 7 \nPediatr\u00eda, 3 Anestesia y 1 Medicina Intensiva, Oftalmolog\u00eda y Obstetricia y Ginecolog\u00eda.  \nEntre los tipos de EM m\u00e1s frecuentes ocurridos se encuentran con un 34,01% la selecci\u00f3n inapropiada del medicamento, \n31,97% error en la dosis por omisi\u00f3n o incorrecta y un 7,48% duplicidad de medicamentos o utilizaci\u00f3n de medicamentos \ninnecesarios\ufffd  \nEntre las causas de EM m\u00e1s frecuentes notificados se encuentran : 38,78% por falta de cumplimiento de los \nprocedimientos de trabajo establecidos , 19,05% por falta de conocimiento y formaci\u00f3n , 7,48% debido a la presentaci\u00f3n \nde la especialidad farmac\u00e9utica que da lugar a confusi\u00f3n , 6,8% lapsus/despiste y problemas en equipos y dispositivos de \ndispensaci\u00f3n/preparaci\u00f3n/administraci\u00f3n y 4,76% por falta o fallo del procedimiento de conciliaci\u00f3n de la medicaci\u00f3n al \ningreso,  \nEl lugar donde ocurri\u00f3 el EM: el 62,59% en la unidad de hospitalizaci\u00f3n ,23,13% en urgencias, 8,84% en el servicio \nde farmacia, 2,72% en consultas externas, 1,36% en hospital de d\u00eda y 0,68% en el domicilio del paciente y 0,68% en \nquir\u00f3fano.  \nTras una valoraci\u00f3n inicial se analizaron 123EM (83,67%), de los cuales 69 (56,1%) se realiz\u00f3 mediante un an\u00e1lisis \nagrupado estableciendo unas medidas definidas comunes para todos y 53 (43,9%) an\u00e1lisis individual empleando las \nsiguientes herramientas: 19EM con entrevistas, 17 por grupos de discusi\u00f3n, 10 con discusi\u00f3n de casos, 4 con an\u00e1lisis de \ncausa ra\u00edz, 2 revisi\u00f3n de historias cl\u00ednicas y 1 a trav\u00e9s de otras herramientas.  \nLas medidas mayoritarias tomadas fueron: formaci\u00f3n del profesional en el manejo de la prescripci\u00f3n electr\u00f3nica (PE), \ncreaci\u00f3n de protocolos de utilizaci\u00f3n para dispositivos y medicamentos, cambio de especialidades para evitar confusi\u00f3n \npor isoaparencia e incidir en la conciliaci\u00f3n\ufffd\nCONCLUSIONES\nLa mayor\u00eda de los EM son identificados por el servicio de farmacia originados sobre todo por el desconocimiento y \nformaci\u00f3n en la PE\ufffd  \nEl an\u00e1lisis nos ha permitido identificar los EM y establecer medidas para evitar y prevenir que ocurran de nuevo, \nasimismo garantizar durante el proceso de prescripci\u00f3n, la seguridad del paciente.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n671. EFECTOS ADVERSOS DE LA VACUNACI\u00d3N ANTI-MENINGOC\u00d3CICA B EN PACIENTES PREMATUROS \nAUTORES\nJUANBELTZ ZURBANO, R; CASTRO QUIROGA, A; SIERRA COLOMINA, G; JORDA SIRERA, N; URRIZA YEREGUI, L; \nERDOZAIN SANCLEMENTE, S; GO\u00d1I INDUR\u00c1IN, N; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDescribir tres casos de apneas graves en pacientes prematuros tras la administraci\u00f3n de la primera dosis de vacuna frente \nal meningococo B, a los 2-3 meses de edad cronol\u00f3gica, en una Unidad Neonatal.\nMATERIALES Y M\u00c9TODOS\nSe analizan en historia cl\u00ednica informatizada los antecedentes perinatales (edad gestacional, peso al nacimiento, \nenfermedad de membrana hialina, grado de displasia broncopulmonar, edad gestacional corregida el d\u00eda de \nvacunaci\u00f3n), el estado respiratorio basal previo a la vacunaci\u00f3n, en las 72 horas posteriores, y soporte requerido ante el \nempeoramiento cl\u00ednico.470RESULTADOS\nTres reci\u00e9n nacidos prematuros (26+2, 26+4, 28+5 semanas EG) con extremado bajo peso al nacimiento, enfermedad \nde membrana hialina leve-moderada y displasia broncopulmonar grado II que ha requerido tratamiento (corticoide, \nnutrici\u00f3n hipercal\u00f3rica, restricci\u00f3n de l\u00edquidos y diur\u00e9ticos). El primer paciente recibe la primera dosis de vacuna \nantimeningoc\u00f3cica B a los tres meses de edad (39+1 EGC), sin premedicaci\u00f3n con paracetamol. Se hab\u00eda retirado el \nox\u00edgeno a alto flujo (OAF) hac\u00eda 8 d\u00edas y ten\u00eda planificada el alta a domicilio al d\u00eda siguiente. A las 10 horas de recibir la \nvacuna realiza episodio de desaturaci\u00f3n (70%) con bradicardia profunda y polipnea. Se administra ox\u00edgeno indirecto \ncon mejor\u00eda inicial, pero realiza nuevamente dos episodios de desaturaci\u00f3n con hipoton\u00eda y decaimiento. Se inicia OAF \na 4 lpm precisando FiO2 hasta 0.3. La gasometr\u00eda mostraba acidosis respiratoria que normaliza a las 24 horas y se retira \nel OAF. Se descarta empeoramiento por infecci\u00f3n y recibe el alta 6 d\u00edas despu\u00e9s de la vacunaci\u00f3n. El segundo caso es \nvacunado a los 2 meses de edad (35+4 EGC) junto a vacuna hexavalente, neumoc\u00f3cica y rotavirus, premedicando con \nparacetamol (una dosis pre y dos dosis post-vacuna). Llevaba 17 d\u00edas con soporte OAF 4 lpm, que requiere aumento a \n5 lpm por desaturaci\u00f3n y bradicardia a las 20 horas de las vacunas. Realiza apneas intensas que requieren est\u00edmulo y \naumento FiO2 hasta 40%, por lo que recibe cafe\u00edna a dosis de choque (10 mg/Kg). El soporte con ox\u00edgeno se puedo retirar \n9 d\u00edas despu\u00e9s. El tercer paciente se vacun\u00f3 asimismo a los 2 meses de edad (37+3 EGC) premedicando con paracetamol. \nSe encontraba sin soporte respiratorio desde hac\u00eda 5 d\u00edas, pero se recuper\u00f3 OAF a 3 lpm por distr\u00e9s, hipoxemia y apneas \nen el contexto de vacunaci\u00f3n. Se pudo retirar a las 10 horas con buena tolerancia. Los tres casos fueron notificados al \nSistema Espa\u00f1ol de Farmacovigilancia\ufffd\nCONCLUSIONES\nLa \u00faltima actualizaci\u00f3n del calendario de vacunaci\u00f3n recomienda adelantar la vacuna frente a meningococo B a los dos \nmeses de edad. Debido a que las apneas son un efecto adverso ya descrito, y por el riesgo de gravedad en pacientes \nprematuros, parece aconsejable la premedicaci\u00f3n con paracetamol y monitorizaci\u00f3n estrecha en estos casos. La \nrealizaci\u00f3n de estudios contribuir\u00eda a decidir el momento \u00f3ptimo de vacunaci\u00f3n en estos pacientes.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n673. ESTUDIO DE DISTRIBUCI\u00d3N E IDENTIFICACI\u00d3N DE LOS MEDICAMENTOS DE ALTO RIESGO EN \nSISTEMAS AUTOMATIZADOS DE DISPENSACI\u00d3N DE MEDICAMENTOS \nAUTORES\nMONTOYA EGEA, JM; FERN\u00c1NDEZ-LOBATO , B; ASENSI CANT\u00d3, A; MART\u00cdNEZ MARCOS, JM; FERN\u00c1NDEZ VELA, J; \nMIRA SIRVENT , MC\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nEstudiar la distribuci\u00f3n de los medicamentos de alto riesgo (M.A.R.) en los sistemas automatizados de dispensaci\u00f3n \n(PYXIS\u00ae) de nuestro hospital, con el fin de proceder a una correcta identificaci\u00f3n de los mismos.\nMATERIALES Y M\u00c9TODOS\nAn\u00e1lisis de la distribuci\u00f3n de todos los M.A.R. ubicados en los PYXIS\u00ae. Para ello, se han obtenido listados con la ubicaci\u00f3n \nde todos los medicamentos de cada PYXIS\u00ae y se han comparado con el listado de M.A.R. de la Gu\u00eda Farmacoterap\u00e9utica \nelaborado seg\u00fan los criterios publicados por el ISMP (Institute for Safe Medication Practice).  \n \nTras el an\u00e1lisis de la distribuci\u00f3n de los M.A.R., se han identificado mediante una infograf\u00eda todas las ubicaciones de los \nPYXIS\u00ae en las que se encontrase alguno de estos medicamentos.\nRESULTADOS\nSe han analizado 17 PYXIS\u00ae, y del total de 137 M.A.R. incluidos en la Gu\u00eda Farmacoterap\u00e9utica del hospital, 72 se \nencuentran ubicados en alg\u00fan PYXIS\u00ae.  \n \nLa media de M.A.R. por PYXIS\u00ae es de 39,41 [14-55]. Los PYXIS\u00ae d\u00f3nde se encuentran ubicados m\u00e1s M.A.R. son los de la \nUCI 2 (n=55), UCI 1 (n=54) y UCI 3 y Reanimaci\u00f3n (con n=53 ambos). Por el lado contrario, d\u00f3nde se encuentran menos \nM.A.R. es en los PYXIS\u00ae de Hospital de D\u00eda M\u00e9dico (n=14), Neonatos (n=22) y Urgencias Pedi\u00e1tricas (n=26).  \n \nDe media, el porcentaje de M.A.R. respecto al total de medicamentos ubicados en los PYXIS\u00ae es del 24,94%. Los PYXIS\u00ae \ncon una mayor proporci\u00f3n de M.A.R son el de Hemodin\u00e1mica (44,71%), UCI 4 (32,83%) y Hospital de D\u00eda Quir\u00fargico \n(30,22%). Por otra parte, los PYXIS\u00ae con un menor porcentaje de M.A.R. son los de Hospital de D\u00eda M\u00e9dico (14,00%), \nUrgencias BOXES (18,99%) y Urgencias Observaci\u00f3n (18,97%).  \n \nLos M.A.R. m\u00e1s com\u00fanmente ubicados en los PYXIS\u00ae son morfina ampollas 10 mg/mL 1 mL (en todos los PYXIS\u00ae), \nfentanilo ampollas 0,15 mg 3 mL parenteral (en 15 de los 17 PYXIS\u00ae) y bromuro de rocuronio ampollas 50 mg 5 mL (en 15 \nde los 17 PYXIS\u00ae).  \n \nEn total se han identificado con infograf\u00edas 740 ubicaciones.\nCONCLUSIONES\nLa identificaci\u00f3n de las ubicaciones donde se encuentran los M.A.R. mediante infograf\u00edas es un proceso que aporta \nseguridad al paciente y reduce los errores de medicaci\u00f3n\ufffd  471Esta iniciativa ayuda a los t\u00e9cnicos de farmacia en la reposici\u00f3n de los PYXIS\u00ae, alert\u00e1ndolos y concienci\u00e1ndolos de \nlos mayores riesgos que se podr\u00edan derivar de un equ\u00edvoco con estos medicamentos durante el desempe\u00f1o de esta \nlabor. Adem\u00e1s, contribuye a minimizar los errores en la administraci\u00f3n de los M.A.R., al poner un especial \u00e9nfasis en \nla ubicaci\u00f3n de los mismos, que advierta al personal de enfermer\u00eda de la exhaustiva atenci\u00f3n con la que se tiene que \nproceder durante la administraci\u00f3n de estos medicamentos\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n714. REACCIONES INFUSIONALES DE F\u00c1RMACOS ADMINISTRADOS EN HOSPITAL DE D\u00cdA \nAUTORES\nBRADY GARC\u00cdA, A; NIGORRA CARO, M; MOREG\u00d3 SOLER, MA; P\u00c9REZ DE AMEZAGA TOM\u00c1S, L; PARERA PASCUAL, MM; \nCRESP\u00cd CIFRE, MA; OLIVER NOGUERA, A; VILANOVA BOLT\u00d3, M\nHOSPITAL SON LLATZER \ufffd CTRA \ufffd MANACOR, KM \ufffd4 PALMA DE MALLORCA \ufffd ILLES BALEARS\nOBJETIVOS\nCuantificar el n\u00famero y el tipo de Reacciones Infusionales(RI) relacionadas con la administraci\u00f3n de tratamientos en el \nHospital De D\u00eda(HDD) en el a\u00f1o 2021 y describir su manejo. Hacer una comparaci\u00f3n con las RI de los dos a\u00f1os anteriores.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo descriptivo en un hospital de segundo nivel. \nVariables: sexo, f\u00e1rmaco responsable de la RI, ciclo de tratamiento en el que se produjo, tipo de RI y manejo posterior. \nLas RI se categorizaron en: cut\u00e1neas, card\u00edacas, gastrointestinales, generales(fiebre y dolor), neurol\u00f3gicas, oculares, \nrespiratorias y mixtas (combinaci\u00f3n de una o m\u00e1s de las anteriores). \nLas RI que se produjeron m\u00e1s de una vez en un mismo paciente se contabilizaron como 1 RI.  \nLos datos se obtuvieron a trav\u00e9s del programa Farmis_Oncofarm\u00ae. La informaci\u00f3n fue contrastada con la historia cl\u00ednica \ncon el programa HPHCISv \ufffd3\ufffd8\ufffd\nRESULTADOS\nDurante el a\u00f1o 2021 se administraron un total de 15.875 f\u00e1rmacos en un total de 1.977 pacientes en HDD. Se produjeron \nRI en 48(2,4%) pacientes, 75% mujeres. \nLos f\u00e1rmacos implicados fueron 14: oxaliplatino(20;41,6%), rituximab(10;20,8%), hierro carboximaltosa(3;6,2%), \ninfliximab(3;6,2%), paclitaxel(2;4,1%), Inmunoglobulina humana, Carboplatino, Nivolumab, Tiragolumab, Tocilizumab, \nAtezolizumab, Cisplatino, Trastuzumab y Anfotericina B.  \nOxaliplatino provoc\u00f3 RI en el 13% de los pacientes a los que se administr\u00f3, rituximab en el 8,7%, hierro carboximaltosa en \nel 0,6%, infliximab en el 2,6% y paclitaxel en el 2%.  \nEl esquema de quimioterapia con mayor incidencia de RI fue el FOLFOX (10;20,8%), seguido de XELOX (7;14,5%), ambos \ncon oxaliplatino.  \nEn cuanto al momento en el que acontecieron las RI, el 56,2%(27) lo hicieron en el primer ciclo, y un 22,9% en el \nsegundo(11). El resto se produjeron entre el ciclo 2 y 10.  \nLas RI m\u00e1s comunes fueron las cut\u00e1neas(14; 29,1 %) y las mixtas(11;22,9%), seguidas de las generales(8;16,6%), \nneurol\u00f3gicas (7;14,5%), respiratorias(6;12,5%) y gastrointestinales(2;4,1%). \nEn siete(14,5%) ocasiones el f\u00e1rmaco que produjo la RI fue suspendido, obligando a un cambio de tratamiento. En el resto \nse pudo continuar con el tratamiento ajustando la velocidad de infusi\u00f3n. Una RI (mixta) a tocilizumab requiri\u00f3 el ingreso \ninmediato del paciente en la unidad de semicr\u00edticos.  \nLa incidencia de RI a oxaliplatino(13%) es similar a la reportada en las fichas t\u00e9cnicas( > 10%) y Micromedex(1-12%), y es \ncomparable a la reportada en los a\u00f1os 2019 y 2020 en este centro (18% y 13,4%, respectivamente). \n \nPor otro lado, la incidencia de RI a rituximab(8,7%) fue menor a la esperable (77% seg\u00fan ficha t\u00e9cnica, 10% graves), y \nalgo menor a la de los a\u00f1os 2019 y 2020 en este centro (11,1% y 14,6%, respectivamente). En 2021 el biosimilar utilizado \nfue diferente al de los dos a\u00f1os anteriores, no pudi\u00e9ndose relacionar un cambio en la incidencia de RI con rituximab a un \ncambio de marca\ufffd\nCONCLUSIONES\nEl n\u00famero de RI no se desv\u00eda de lo esperable, ni se ha observado un cambio de incidencia respecto a los dos a\u00f1os \nanteriores\ufffd \nLa mayor\u00eda de las RI no fueron graves y se resolvieron mediante la administraci\u00f3n de medicaci\u00f3n de rescate habitual y \najustando la velocidad, pudiendo continuar con el tratamiento.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n720. ESTUDIO DE UTILIZACI\u00d3N DE ANTIDEPRESIVOS DURANTE LA PANDEMIA DE COVID-19 EN LA \nREGI\u00d3N DE MURCIA \nAUTORES\nMART\u00cdNEZ IB\u00c1\u00d1EZ, M\u00c1; GOLNABI DOWLATSHAHI, F; GIL ALMELA, J; TORRO GARC\u00cdA, L; D\u00cdAZ RAM\u00d3N, M; CANO \nMOLINA, J\u00c1; RAM\u00d3N P\u00c9REZ, M; GALINDO RUEDA, MDM\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA472OBJETIVOS\nAnalizar el impacto de la pandemia sobre el consumo de f\u00e1rmacos antidepresivos en un \u00e1rea de salud.\nMATERIALES Y M\u00c9TODOS\nPara hacer este an\u00e1lisis retrospectivo y descriptivo, se ha analizado el consumo en receta m\u00e9dica de todos los f\u00e1rmacos \nantidepresivos del grupo terap\u00e9utico N06A de la clasificaci\u00f3n ATC durante los a\u00f1os 2019- 2020-2021, en un \u00e1rea sanitaria \nque atiende a una poblaci\u00f3n de 260.000 habitantes. Se calcularon las dosis diarias definidas (DDD) dispensadas y la dosis \nhabitante/d\u00eda (DHD). Se analiz\u00f3 el f\u00e1rmaco antidepresivo utilizado, el consumo por edad, sexo y la evoluci\u00f3n del consumo \ninteranual. Los datos fueron extra\u00eddos de la base de datos de consumo farmac\u00e9utico del servicio auton\u00f3mico de salud.\nRESULTADOS\nEn 2019 se dispensaron 8.391.844 de DDD de f\u00e1rmacos antidepresivos del ATC N06A (DHD =88,4), en 2020 fueron \ndispensadas 9.104.058 de DDD (DHD =95,9) y en 2021, 10.058.014 de DDD (DHD =105,9). Es to supone un crecimiento del \nconsumo total de antidepresivos entre 2019-20 y 2020-21 del 8,5 % y de 10,5%, respectivamente (el crecimiento entre \n2019 y 2021 fue de 19,8%). Este crecimiento continuo se hace evidente al observar que el mes de mayor consumo del \nperiodo estudiado fue diciembre de 2021, con 892.435 DDD dispensadas (DHD = 110).  \nAnalizando el consumo por sexos, las mujeres consumieron un 158 % m\u00e1s respecto a los hombres de media durante los \ntres a\u00f1os de an\u00e1lisis (6.536.900 frente a 2.531.945 DDD/a\u00f1o, respectivamente). Por edades, la franja de edad con mayor \nconsumo, por encima de las 150.000 DDD/a\u00f1o, se sit\u00faa entre los 42 a 77 a\u00f1os siendo el pico m\u00e1ximo de consumo los 57 \na\u00f1os de edad (243.530 DDD/a\u00f1o).  \nLos antidepresivos m\u00e1s consumidos en 2021 han sido sertralina, (DHD=27), escitalopram (DHD = 18) y fluoxetina (DHD \n=9,6). Estos tres f\u00e1rmacos suponen el 52% de todo el consumo de antidepresivos.\nCONCLUSIONES\n1. Durante los a\u00f1os de la pandemia del COVID-19, se ha producido un incremento significativo del consumo de \nantidepresivos del grupo N06A en nuestra \u00e1rea de salud  \n2. Las mujeres de mediana edad, son la franja de poblaci\u00f3n con mayor consumo de antidepresivos en la poblaci\u00f3n \nestudiada\ufffd  \n3. Sertralina, escitalopram y fluoxetina son los f\u00e1rmacos m\u00e1s prescritos por los m\u00e9dicos de atenci\u00f3n primaria de nuestra \n\u00e1rea sanitaria \n4. Las condiciones de la pandemia han propiciado que haya un aumento en el consumo de psicof\u00e1rmacos, relacionado \nposiblemente con variables de g\u00e9nero y clase social.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n738. SATISFACCI\u00d3N PERCIBIDA POR EL PERSONAL DEL SERVICIO DE FARMACIA COMO M\u00c9TODO DE \nMEJORA DE LA CALIDAD \nAUTORES\nFERN\u00c1NDEZ MART\u00cdNEZ, I; P\u00c9REZ P\u00c9REZ, I; GARC\u00cdA MATILLAS, C; ASENSI CANT\u00d3, A; FERN\u00c1NDEZ VELA, J; TAMBOLEO \nS\u00c1NCHEZ, I\nHOSPITAL GENERAL UNIVERSITARIO SANTA LUCIA. CALLE MEZQUITA (PARAJE LOS ARCOS) S/N CARTAGENA. MURCIA\nOBJETIVOS\nEvaluar el grado de satisfacci\u00f3n del personal del servicio farmacia (SF) con el objetivo de actuar en la mejora de las \ncondiciones en que se desarrolla.\nMATERIALES Y M\u00c9TODOS\nSe enviaron encuestas de satisfacci\u00f3n de forma an\u00f3nima (formulario online) a todo el personal del SF formado por \n76 trabajadores, de los cuales, el 19.7% (n=15) eran personal de enfermer\u00eda; el 47.4% (n=36) t\u00e9cnicos; el 5.3% (n=4) \nceladores; el 3.9% (n=3) administrativos; el 14.5% (n=11) farmac\u00e9uticos adjuntos y el 9.2%% (n=7) farmac\u00e9uticos internos \nresidentes (FIR). Las encuestas constaban de once preguntas divididas en 6 bloques referentes a las condiciones de \ntrabajo (3 preguntas), formaci\u00f3n (2 preguntas), valoraci\u00f3n y reconocimiento (1 pregunta), participaci\u00f3n (1 pregunta), \norganizaci\u00f3n (2 preguntas) y comunicaci\u00f3n interna (2 preguntas). En cada pregunta, los trabajadores deb\u00edan indicar la \npuntuaci\u00f3n en base a 5 niveles: 1\ufffd Muy mal; 2\ufffd Mal; 3\ufffd Normal; 4\ufffd Bien; 5\ufffd Muy bien\ufffd Los resultados se transformaron en \nescala de 0-10. Se estudiaron las respuestas seg\u00fan cada grupo profesional.\nRESULTADOS\nSe obtuvieron un total de 33 respuestas (tasa de respuesta (TR): 43.4%). Respecto a las condiciones f\u00edsicas y ambientales, \nla puntuaci\u00f3n obtenida fue de 6,8; sobre las condiciones de seguridad 6,6 y sobre los recursos disponibles de 6,3\ufffd La \npuntuaci\u00f3n media de la satisfacci\u00f3n con la formaci\u00f3n recibida fue de 4,2, con una segunda pregunta abierta en la se \nrecogieron comentarios destacando la falta de formaci\u00f3n continuada. Sobre la valoraci\u00f3n y reconocimiento se obtuvo \nuna puntuaci\u00f3n media de 4,3 y la la participaci\u00f3n (facilidad para aportar sugerencias) obtuvo una puntuaci\u00f3n de 5,9. El \napartado de organizaci\u00f3n y coordinaci\u00f3n dentro del SF fue valorado con una puntuaci\u00f3n media de 4,5, y la comunicaci\u00f3n \ninterna con una puntuaci\u00f3n de 4,9\ufffd  \nLa TR por grupo profesional fue, por orden decreciente, del 66,6% en el personal administrativo, 47,2% t\u00e9cnicos, 45,6% \nfacultativos, 28,6% FIR, 20% enfermeros y 0% celadores. En cuanto a los bloques mejor y peor valorados, los resultados \nfueron homog\u00e9neos y coincidentes entre los diferentes grupos profesionales del SF. \nEl grado de satisfacci\u00f3n medio en todas las respuestas de las personas que trabajan en el SF fue de 5,3\u00b10,9.473CONCLUSIONES\nEl aspecto mejor valorado por el personal del SF fue las condiciones de trabajo y seguridad, seguido de la facilidad para \nparticipar y aportar sugerencias e ideas dentro del servicio. Las dimensiones peor valoradas fueron la formaci\u00f3n continua \ny la valoraci\u00f3n y reconocimiento del trabajo realizado.  \nLos resultados de esta encuesta nos proporcionan una informaci\u00f3n \u00fatil para detectar puntos de mejora dentro del SF con \nel fin de mejorar la satisfacci\u00f3n del personal de farmacia y la calidad del servicio prestado. Como acci\u00f3n de mejora se ha \npropuesto el establecimiento de un programa interno de formaci\u00f3n continuada que permita una actualizaci\u00f3n sistem\u00e1tica \nde los conocimientos en procedimientos de las diferentes \u00e1reas del SF.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n747. EVALUACI\u00d3N DE LA SEGURIDAD DEL ETIQUETADO Y ENVASADO DE LOS MEDICAMENTOS DE ALTO \nRIESGO DISPONIBLES EN UN HOSPITAL \nAUTORES\nAPARICIO PE\u00d1ACOBA, R; GARC\u00cdA CASANUEVA, JC; MART\u00cdN GUTI\u00c9RREZ, N; MART\u00cdN MU\u00d1OZ, MR; L\u00d3PEZ \u00c1LVAREZ, \nM; OTERO L\u00d3PEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA\nOBJETIVOS\nUn etiquetado inapropiado o un envasado de apariencia similar son causas frecuentes de errores de medicaci\u00f3n, \nparticularmente en los procesos de dispensaci\u00f3n y administraci\u00f3n. Cuando estos errores involucran a medicamentos de \nalto riesgo (MAR) las consecuencias para los pacientes pueden ser graves.  \nEl Consejo de Europa, el Institute for Safe Medication Practices (ISMP) y otros organismos han emitido recomendaciones \ndirigidas a garantizar la seguridad del etiquetado de los medicamentos. El objetivo de este trabajo ha sido evaluar la \nadecuaci\u00f3n del etiquetado y envasado de los MAR disponibles en nuestro hospital a dichas recomendaciones.\nMATERIALES Y M\u00c9TODOS\nSe evaluaron las presentaciones de MAR disponibles en nuestro centro a 1/3/2022, a excepci\u00f3n de contrastes \nradiol\u00f3gicos, anest\u00e9sicos inhalados, y soluciones de di\u00e1lisis y de nutrici\u00f3n parenteral. Se analiz\u00f3 el acondicionamiento \nprimario en todas las presentaciones y el embalaje s\u00f3lo en aquellas dispensadas con el mismo. Para evaluar el etiquetado \ny envasado se elabor\u00f3 un cuestionario con 19 apartados para las presentaciones inyectables y 11 apartados para las \norales, a partir de las recomendaciones del Consejo de Europa, del ISMP , del International Medication Safety Network \ny de la National Patient Safety Agency. Los aspectos que se incluyeron fueron legilibilidad y presentaci\u00f3n de elementos \ncr\u00edticos en el etiquetado, expresi\u00f3n de la composici\u00f3n cuantitativa, indicaci\u00f3n de la v\u00eda, presentaci\u00f3n en unidosis, \ninclusi\u00f3n de c\u00f3digo de barras y similitud con otras presentaciones\ufffd\nRESULTADOS\nSe evaluaron 279 presentaciones de 178 medicamentos, de las que 176 eran inyectables, 99 orales y 4 t\u00f3picos. Un 49% \nfueron citost\u00e1ticos y 12% opioides.  \nEn el acondicionamiento primario de los 176 inyectables evaluados, las desviaciones con respecto a las recomendaciones \nm\u00e1s frecuentemente detectadas fueron: expresi\u00f3n inapropiada de la dosis en inyectables en soluci\u00f3n (39%), ausencia de \nc\u00f3digo de barras (39%), presencia de informaci\u00f3n innecesaria (33%) y presentaci\u00f3n de los elementos cr\u00edticos no adecuada \n(13%). Un 23% de las ampollas estaban serigrafiadas. Un 87,5% de los medicamentos destinados s\u00f3lo a la v\u00eda epidural no \nindicaban de forma destacada dicha v\u00eda.  \nLas desviaciones m\u00e1s frecuentes encontradas en las presentaciones en las que se evalu\u00f3 el embalaje fueron: expresi\u00f3n \ninapropiada de la dosis en inyectables en soluci\u00f3n (21%), presentaci\u00f3n de los elementos cr\u00edticos no adecuada (9%) e \nindicaci\u00f3n de la v\u00eda de administraci\u00f3n de forma no adecuada (9%).  \nEn el acondicionamiento primario de las 99 presentaciones orales evaluadas las desviaciones m\u00e1s frecuentes fueron: \nausencia de c\u00f3digo de barras (86%), ausencia de presentaci\u00f3n en dosis unitarias (47%), similitud con otras presentaciones \ndel mismo laboratorio (42%) y lote/caducidad no visibles (31%).\nCONCLUSIONES\nEl etiquetado y envasado de los MAR disponibles en nuestro centro no se adecua a los requisitos de seguridad \nrecomendados por organizaciones expertas, a pesar de que se efect\u00faa una evaluaci\u00f3n cuando se seleccionan las \npresentaciones a adquirir para el hospital. Ser\u00eda necesario que dichos requisitos se incorporaran en los marcos \nnormativos, particularmente la inclusi\u00f3n del c\u00f3digo de barras, y se estableciera un procedimiento exhaustivo de revisi\u00f3n \ndel etiquetado y envasado de los medicamentos antes de su autorizaci\u00f3n.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n803. CALIDAD DE VIDA, ACTIVIDAD F\u00cdSICA Y FATIGA EN PACIENTES CON C\u00c1NCER DE MAMA EN \nTRATAMIENTO CON ANTINEOPL\u00c1SICOS ORALES \nAUTORES\nCONDE GONZ\u00c1LEZ, I; GARC\u00cdA HERVALEJO, M; VALVERDE MERINO, MP; MART\u00cdN CILLERO, MT; FERN\u00c1NDEZ \nDOM\u00cdNGUEZ, E; S\u00c1NCHEZ HERN\u00c1NDEZ, JG; OTERO L\u00d3PEZ, MJ\nHOSPITAL UNIVERSITARIO DE SALAMANCA. P\u00ba DE SAN VICENTE, 58-182 SALAMANCA. SALAMANCA474OBJETIVOS\nEvaluar mediante cuestionarios de resultados percibidos por los pacientes (PRO) la calidad de vida, actividad f\u00edsica y fatiga \nen mujeres con c\u00e1ncer de mama tratadas con antineopl\u00e1sicos orales y detectar \u00e1reas de intervenci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEstudio descriptivo y prospectivo realizado del 15 de marzo al 30 de abril de 2022 en pacientes con c\u00e1ncer de mama \nmenores de 80 a\u00f1os en tratamiento con antineopl\u00e1sicos orales que recogen dicha medicaci\u00f3n en el Servicio de Farmacia.  \nLos datos recogidos de la historia cl\u00ednica informatizada fueron: datos demogr\u00e1ficos, cl\u00ednicos y tipo de medicamento \nutilizado. Para medir las diferentes variables se utilizaron los cuestionarios de PRO: EORTC-QLQ-C30 (calidad de vida en \nescalas global, funcional y sintom\u00e1tica, siendo la mejor puntuaci\u00f3n para la escala global y funcional de 100, y para la \nescala de s\u00edntomas de 0), IPAQ (actividad f\u00edsica en MET y categorizada en leve/moderada/intensa) y PERFORM (siendo \n1=no fatiga y 5=fatiga extrema).  \nSe analiz\u00f3 la asociaci\u00f3n entre actividad f\u00edsica y calidad de vida del paciente, mediante an\u00e1lisis ANOVA (Rv4) y entre \nactividad f\u00edsica y fatiga mediante test chi-cuadrado.\nRESULTADOS\nAceptaron participar 23 pacientes de 68 posibles, debido al tiempo requerido para la cumplimentaci\u00f3n de los \ncuestionarios. Presentaban una mediana (rango) de edad de 56 (40-72) a\u00f1os. La mayor\u00eda eran mujeres postmenop\u00e1usicas \n(69,5%) y un 50% presentaban obesidad o sobrepeso seg\u00fan su IMC. En cuanto a las variables cl\u00ednicas, la mediana del \ntiempo desde el diagn\u00f3stico fue de 12,5 a\u00f1os (2-28), el 91% se hab\u00eda sometido a cirug\u00eda y el 82,6% utilizaba inhibidores \nde ciclinas\ufffd  \n \nRespecto a la calidad de vida, la mediana de la puntuaci\u00f3n de salud global fue 58,7 (0-100), la de la escala funcional 71,1 \n(21,4-97,8) y la de la escala de s\u00edntomas 20,5 (2,6-56,4). La esfera funcional de mejor puntuaci\u00f3n fue la del rol y la peor \nla emocional. Dentro de la escala sintom\u00e1tica, la mejor puntuaci\u00f3n fue para la dificultad econ\u00f3mica y la peor para el \ninsomnio\ufffd  \n \nUn 82,6% refiri\u00f3 realizar alg\u00fan tipo de actividad f\u00edsica. Seg\u00fan el IPAQ, 7 alcanzaron un nivel de actividad f\u00edsica intensa \n(30,4%), 12 moderada (52,2%) y s\u00f3lo 4 (17,4%) actividad baja/inactividad. Para 8 (42%) de las 19 pacientes con actividad \nf\u00edsica, la \u00fanica actividad era caminar.  \n \nEn cuanto a la fatiga, seg\u00fan el cuestionario PERFORM, 8 pacientes (34,8%) presentaban fatiga moderada y 3 (13,0%) \ngrave. La mediana de puntuaci\u00f3n del cuestionario fue de 3,6 (1,4-5).  \nSe encontr\u00f3 asociaci\u00f3n estad\u00edsticamente significativa entre la actividad f\u00edsica y dos de las subescalas de calidad de \nvida: global (p=0,016) y funcional (p=0,027). Cuando se compar\u00f3 actividad f\u00edsica y fatiga, no se observ\u00f3 asociaci\u00f3n \nestad\u00edsticamente significativa.\nCONCLUSIONES\nConocer los resultados percibidos por los pacientes nos permite detectar \u00e1reas de mejora en la atenci\u00f3n farmac\u00e9utica de \nnuestros pacientes con c\u00e1ncer de mama. Los resultados del cuestionario EORT-QLQ-30 nos indican como posibles \u00e1reas \nde intervenci\u00f3n la salud emocional y la higiene del sue\u00f1o. Las pacientes con actividad f\u00edsica moderada o intensa informan \nde una mejor calidad de vida, por lo que tambi\u00e9n deber\u00edan incluirse intervenciones dirigidas al ejercicio.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n822. ADECUACI\u00d3N DE LA CLASIFICACI\u00d3N DE LA PHARMACEUTICAL-CARE-NETWORK-EUROPE A LOS \nPROBLEMAS RELACIONADOS CON LA MEDICACI\u00d3N EN EL \u00c1REA DE PACIENTES EXTERNOS \nAUTORES\nALBALAT TORRES, A; COLOMINAS-GONZ\u00c1LEZ , E; CARBALLO MART\u00cdNEZ, N; ANTONIO-CUSCO , MD; FERN\u00c1NDEZ-\nSALA , X; NAVARRETE-ROUCO , E; FERR\u00c1NDEZ , O; GRAU , S\nHOSPITAL DEL MAR \ufffd PASSEIG MAR\u00cdTIM DE LA BARCELONETA, 25 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa atenci\u00f3n farmac\u00e9utica al paciente externo ha experimentado un importante desarrollo en los \u00faltimos a\u00f1os. Una de \nlas actividades principales es la prevenci\u00f3n y resoluci\u00f3n de problemas relacionados con la medicaci\u00f3n (PRM). A pesar \nde que existen diversas clasificaciones de las intervenciones farmac\u00e9uticas, una de las m\u00e1s aceptadas es la desarrollada \npor la Pharmaceutical Care Network Europe (PCNE). El objetivo del estudio es describir las intervenciones farmac\u00e9uticas \nrealizadas ante la detecci\u00f3n de PRM y evaluar la adecuaci\u00f3n de esta actividad a la clasificaci\u00f3n de la PCNE.\nMATERIALES Y M\u00c9TODOS\nEstudio prospectivo llevado a cabo en el \u00e1rea de pacientes externos de un hospital universitario de tercer nivel. Se \nrecogieron las intervenciones farmac\u00e9uticas realizadas ante la detecci\u00f3n de PRM potenciales o manifiestos entre junio \n2021 y marzo 2022. Datos recogidos: f\u00e1rmaco/s implicado/s, servicio prescriptor, PRM e intervenci\u00f3n farmac\u00e9utica \nrealizada. En marzo de 2022 se clasificaron dichas intervenciones conforme la clasificaci\u00f3n PCNE.\nRESULTADOS\nSe realizaron un total de 376 intervenciones durante el periodo de estudio.  \nLos f\u00e1rmacos mayoritariamente implicados fueron: darbepoetina 75 (20,0%), adalimumab biosimilar 43 (11,4%) y \ncinacalcet 37 (9,8%). 475Servicios m\u00e1s frecuentemente implicados: nefrolog\u00eda 115 (30,6%), reumatolog\u00eda 54 (14,4%), dermatolog\u00eda 41 (11,0%), \nmedicina interna/infecciosas 34 (9,0%), digestivo 33 (8,8%) y neurolog\u00eda 30 (8,0%).  \nLos PRM m\u00e1s frecuentes fueron: C6.2 \u201cerror de prescripci\u00f3n por falta de informaci\u00f3n\u201d 188 (50,0%), C8.1 \u201cotra causa\u201d 86 \n(22,9%) y C1.3 \u201ccombinaci\u00f3n inapropiada de f\u00e1rmacos o f\u00e1rmacos y alimento\u201d 17 (4,5%).  \nLas intervenciones m\u00e1s frecuentes fueron: I1.1 \u201cse informa al prescriptor\u201d 242 (64,4%), I1.3 \u201cintervenci\u00f3n propuesta \naprobada por el prescriptor\u201d 61 (16,2%) y I3.2 \u201ccambio de la dosis por\u2026\u201d 28 (7,4%). En 81 (22,15%) intervenciones, el \nPRM se clasific\u00f3 como \u201cotras causas\u201d dado que no se pudo realizar ninguna adaptaci\u00f3n a las incluidas en la clasificaci\u00f3n \nPCNE. De estas 81 intervenciones, 66 (81,5%) fueron causadas por faltas de adherencia a las visitas m\u00e9dicas y p\u00e9rdidas de \nseguimiento al tratamiento\ufffd\nCONCLUSIONES\nEl PRM identificado con m\u00e1s frecuencia fue \u201cerror de prescripci\u00f3n por falta de informaci\u00f3n\u201d seguido de \u201cotra causa\u201d y \n\u201ccombinaci\u00f3n inapropiada de f\u00e1rmacos o f\u00e1rmacos y alimentos\u201d.  \nLa intervenci\u00f3n mayoritariamente realizada fue la de \u201cse informa al prescriptor\u201d, lo que resalta la importancia de \nestablecer un adecuado circuito de coordinaci\u00f3n entre todos los miembros del equipo asistencial multidisciplinar. \nDentro de categor\u00eda \u201cotra causa\u201d, se incluyeron principalmente p\u00e9rdidas de seguimiento y falta de adherencia a las visitas \nm\u00e9dicas, que pone de manifiesto la necesidad de adaptaci\u00f3n de las clasificaciones m\u00e1s extendidas o el dise\u00f1o de nuevas \nclasificaciones adaptadas al \u00e1rea de pacientes externos.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n910. VACUNAS FRENTE A LA COVID-19: PERFIL DE SEGURIDAD TRAS UN A\u00d1O DE SEGUIMIENTO \nAUTORES\nFERN\u00c1NDEZ VARELA, AM; GRANERO L\u00d3PEZ, M; RODR\u00cdGUEZ PEN\u00cdN, I\nCOMPLEJO HOSPITALARIO ARQUITECTO MARCIDE-PROF . NOVOA SANTOS. CTRA. DE SAN PEDRO DE LEIXA, S/N \nFERROL \ufffd A CORU\u00d1A\nOBJETIVOS\nEl desarrollo de vacunas frente a la COVID-19 (2 de ARN mensajero [ARNm] y 2 de vector viral no replicante [VVNR]) \nresult\u00f3 imprescindible para hacer frente al virus durante el a\u00f1o 2021. Su administraci\u00f3n no estuvo exenta de reacciones \nadversas (RAs) que fue necesario notificar al Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso Humano \n(SEFV-H) al tratarse de f\u00e1rmacos sujetos a seguimiento adicional.  \nEl objetivo de este trabajo es describir el perfil de RAs de vacunas frente a la COVID-19 notificadas en nuestra poblaci\u00f3n \nde pacientes frente al total de RAs\ufffd\nMATERIALES Y M\u00c9TODOS\nEstudio observacional descriptivo retrospectivo (enero-diciembre 2021) de las RAs por vacunas frente a la COVID-19 \ndetectadas en un hospital de segundo nivel que atiende a 175.172 tarjetas sanitarias.  \nLa detecci\u00f3n se efectu\u00f3 a trav\u00e9s del Sistema de Codificaci\u00f3n del Centro al Alta del Paciente Ingresado (SIAC) y por \nnotificaci\u00f3n espont\u00e1nea, previo aviso del profesional sanitario que detect\u00f3 la RA.  \nDatos obtenidos de la historia cl\u00ednica electr\u00f3nica: demogr\u00e1ficos (edad, sexo); historia previa de COVID; gravedad de RAs \n(leve, moderada, grave, mortal); vacuna: tipo (ARNm, VVNR), dosis responsable de la RA.\nRESULTADOS\nEn el a\u00f1o 2021, se recogieron y notificaron 36 RAs a las vacunas frente a la COVID-19 (2 moderadas, 33 graves y 1 mortal), \nde las 654 RAs detectadas (600 SIAC, 54 notificaci\u00f3n espont\u00e1nea), en 29 pacientes (mediana de edad: 61 [Rango: 21-93] \na\u00f1os; 51,72 % mujeres). Dos pacientes tuvieron infecci\u00f3n previa por coronavirus, experimentando ambos RAs graves. \nCon la primera dosis se produjeron 8 RAs (4 ARNm, 4 VVNR), 18 con la segunda (15 ARNm, 3 VVNR) y 10 con la tercera (7 \nARNm, 3 VVNR). \nLas RAs detectadas fueron: \n- 10 RAs por SIAC: 9 RAs con vacuna RNAm [graves: 1 cefalea, 1 debilidad generalizada, 1 fiebre, 1 s\u00edncope, 1 \nmiopericarditis, 1 parestesias, 1 herpes zoster, 1 hemiparesia derecha; moderadas: 1 dolor epig\u00e1strico]. Una RA con \nvacuna VVNR: oligoartritis grave. \n- 26 RAs por notificaci\u00f3n espont\u00e1nea: 17 RAs con vacuna ARNm [graves: 1 anemia hemol\u00edtica, 1 hiperpotasemia t\u00f3xica, 1 \nparada cardiorrespiratoria no mortal, 2 trombosis venosas profundas, 1 accidente cerebrovascular isqu\u00e9mico, 1 herpes \nz\u00f3ster, 1 miocarditis, 1 insuficiencia card\u00edaca, 1 infarto agudo de miocardio sin elevaci\u00f3n de ST (IAMCEST), 1 adenopat\u00eda, \n1 cefalea, 4 tromboembolismos pulmonares (TEP); mortales: 1 TEP]. Nueve RAs con vacuna VVNR [graves: 1 s\u00edndrome de \nGuillain Barr\u00e9, 1 nefritis, 2 miocarditis, 1 IAMCEST, 2 vasculitis, 1TEP; moderadas: 1 exantema cut\u00e1neo cervical]. \nEl 48,14% de las RAs detectadas por notificaci\u00f3n espont\u00e1nea pertenecen a vacunas frente a la COVID-19.\nCONCLUSIONES\nEn nuestra poblaci\u00f3n, las RAs a vacunas frente a la COVID-19 se produjeron mayoritariamente tras la 2\u00aa dosis. Las vacunas \ncon mayor n\u00famero de notificaciones fueron las de ARNm, resultando una de ellas mortal.  \nAproximadamente, la mitad de las RAs detectadas por notificaci\u00f3n espont\u00e1nea pertenecen a dichas vacunas, lo que \nrefleja la alta implicaci\u00f3n del profesional sanitario en la ampliaci\u00f3n de su perfil de seguridad.476CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n969. RELACI\u00d3N ENTRE INFECCI\u00d3N POR COVID-19 Y EFECTOS ADVERSOS A LA VACUNA FRENTE AL SARS-\nCOV-2 EN PR\u00c1CTICA REAL \nAUTORES\nARNAIZ DIEZ, S; SANTIAGO GALLEGO, B; VICENTE GONZ\u00c1LEZ, B; DE FRUTOS DEL POZO, M; ESPEJA MARTINEZ, AM; \nIZQUIERDO ACOSTA, L; \u00c1LAMO GONZ\u00c1LEZ, O; UBEIRA IGLESIAS, M\nHOSPITAL UNIVERSITARIO DE BURGOS (COMPLEJO ASISTENCIAL UNIVER. DE BURGOS). AVENIDA ISLAS BALEARES \nS/N BURGOS \ufffd BURGOS\nOBJETIVOS\nDescribir la relaci\u00f3n entre los efectos adversos tras la primera o segunda dosis de vacuna contra la COVID-19 y haber \npasado infecci\u00f3n por coronavirus\ufffd\nMATERIALES Y M\u00c9TODOS\nDurante el mes de junio de 2021, se realiz\u00f3 un estudio observacional descriptivo transversal, basado en una encuesta \nan\u00f3nima, sobre los efectos adversos relacionados con la vacuna contra la COVID-19, dirigida a profesionales sanitarios \nespa\u00f1oles a trav\u00e9s de Google Forms\u00ae. La encuesta consta de 14 preguntas estructuradas en 3 partes: a) Datos \ndemogr\u00e1ficos y si se hab\u00eda sufrido COVID-19 con prueba confirmatoria (PCR o Test de ant\u00edgenos). b) Si se hab\u00eda recibido \nvacuna. c) Efectos adversos: Se diferenci\u00f3 si se produjeron con la primera dosis de vacuna y/o la segunda dosis. La \ninformaci\u00f3n recogida se analiz\u00f3 con Excel\u00ae 2018.\nRESULTADOS\nSe incluyeron en el estudio un total de 314 profesionales sanitarios, de los cuales 273 (86%) fueron mujeres. La edad \nmedia fue de 42,74 a\u00f1os (IC 41,56-43,92). Todos los participantes recibieron al menos una dosis de vacuna, 17 (5,41%) \nrecibieron una dosis y 297 (94,58%) la pauta completa seg\u00fan las recomendaciones (dos dosis en el momento del estudio).  \nPasaron la infecci\u00f3n por COVID-19, 52 (16,56%) participantes, de ellos 10 (58,82%) hab\u00edan recibido solo una dosis y 42 \n(14,14%) pauta completa.  \nDel total de participantes, (N=314), 200 (63,69%) refirieron alg\u00fan efecto adverso a la primera dosis, frente a 212 (67,51%) \nque lo hicieron a la segunda dosis (PR 1,06, IC95% 0,95- 1,19). Respondieron haber presentado alg\u00fan efecto adverso con \nambas dosis 155 (49,36%) participantes, 45 (14,33%) solo tuvieron efectos tras la primera dosis y 57 (18,15%) \u00fanicamente \ntras la administraci\u00f3n de la segunda dosis\ufffd  \nSe observ\u00f3 que tras la primera dosis de vacuna, el porcentaje de participantes que tuvieron test COVID-19 positivo que \npresentaron efectos adversos fue de 73,1% (N=52) frente a un 61,2% (N=262) en los que no sufrieron COVID-19 (PR 1,18, \nIC95% 0,98-1,43). Por otro lado se observ\u00f3 que el porcentaje de efectos adversos observados tras la segunda dosis en \nparticipantes que pasaron COVID-19 fue de 57,7% (N=30) frente a un 69,5% (N=182) en los que no (PR 0,83, IC95% 0,65-\n1,06).\nCONCLUSIONES\nCon nuestros resultados, no se observa estad\u00edsticamente un aumento significativo del porcentaje de participantes que \nsufre efectos adversos con la segunda respecto a la primera dosis, se puede decir que el n\u00famero de participantes que \npresent\u00f3 efectos adversos a la primera dosis fue igual al de la segunda dosis\ufffd  \nSeg\u00fan nuestros datos no hay diferencias en cuanto al porcentaje de efectos adversos tras la administraci\u00f3n de la primera \no segunda dosis de vacuna en participantes con o sin antecedentes de haber pasado la COVID-19.  \nUna de las limitaciones que encontramos al realizar nuestro estudio es que la muestra se reduce \u00fanicamente a poblaci\u00f3n \nactiva dentro del sector sanitario, por lo que ser\u00edan necesarios m\u00e1s datos en mayores de 65 a\u00f1os o menores de 16. Este \nestudio muestra la relevancia de la Farmacovigilancia pues a trav\u00e9s de ella se identifican, cuantifican, eval\u00faan y previenen \nlos riesgos del uso de los medicamentos una vez comercializados.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1000. AN\u00c1LISIS Y ADECUACI\u00d3N DE TRATAMIENTOS EN PACIENTES UROL\u00d3GICOS CON INSUFICIENCIA \nRENAL EN COLABORACI\u00d3N CON EL SERVICIO DE NEFROLOG\u00cdA \nAUTORES\nGONZ\u00c1LEZ BARTOLOM\u00c9, J; TENA ALEJANDRE, P; DUQUE AGUILAR, JJ; ALMANCHEL RIVADENEYRA, A; CABA \nHERN\u00c1NDEZ, C; FERN\u00c1NEZ LIS\u00d3N, LC\nCOMPLEJO HOSPITALARIO DE C\u00c1CERES. AV .PABLO NARANJO, S/N C\u00c1CERES. C\u00c1CERES\nOBJETIVOS\nAnalizar las intervenciones farmac\u00e9uticas realizadas a los pacientes con insuficiencia renal del Servicio de Urolog\u00eda en \ncolaboraci\u00f3n con el Servicio de Nefrolog\u00eda.\nMATERIALES Y M\u00c9TODOS\nEstudio transversal, observacional y descriptivo llevado a cabo entre 01/01/2017 y 20/04/2022. La base de pacientes \na analizar se obtiene a trav\u00e9s de una herramienta a cargo del Servicio de Nefrolog\u00eda que obtiene alertas de pacientes \ningresados con deterioro renal (FG < 60mL/min/1.73m2). Se realiza un an\u00e1lisis de datos exhaustivo a trav\u00e9s de la base de \ndatos del complejo hospitalario y la historia cl\u00ednica electr\u00f3nica. En el estudio, se incluyen datos de: edad, sexo, tasa de \nfiltraci\u00f3n glomerular, tratamiento prescrito, intervenciones, grado de aceptaci\u00f3n de las mismas y resultado.477RESULTADOS\nEn el periodo de estudio se analizaron un total de 1139 pacientes en el Servicio de Urolog\u00eda con una tasa de filtraci\u00f3n \nglomerular inferior a 60mL/min/1\ufffd73m2\ufffd  \nSe realizaron un total de 191 intervenciones, de las cuales 135 (70,68%) fueron aceptadas, correspondiendo a \nmodificaciones en la pauta o intervalo posol\u00f3gico o bien recomendaciones de suspensi\u00f3n de tratamientos; 34 (17,80%) \nfueron rechazadas por el equipo m\u00e9dico encargado y, por \u00faltimo; 22 (11,52%) corresponden a altas o exitus en los \npacientes analizados.  \nDesde un abordaje farmacol\u00f3gico, se pueden dividir las 191 intervenciones realizadas en 130 (68,06%) correspondientes \na tratamientos antibi\u00f3ticos, 42 (21,99%) al grupo de AINEs y, el resto, 19 (9,95%) correspondientes a otros grupos \nterap\u00e9uticos variados.  \nDe las intervenciones ejecutadas en los tratamientos antibi\u00f3ticos (130), fueron aceptadas 94 (72,30%), suponiendo una \nmodificaci\u00f3n de la dosificaci\u00f3n o ampliaci\u00f3n del intervalo de administraci\u00f3n de los tratamientos pautados. En cuanto a las \nsugerencias rechazadas, supusieron 25 (19,24%) y 11 (8,46%) fueron altas/exitus.  \nSobre el grupo AINEs, de un total de 42 intervenciones, 27 (64.29%) fueron aceptadas, 7 (16.66%) rechazadas y, las 8 \n(19.05%) restantes fueron altas/exitus.  \nEl resto de intervenciones (19) correspond\u00edan a diversos grupos terap\u00e9uticos, encontr\u00e1ndonos con que 14 (73,68%) \nfueron aceptadas, 2 (10,53%) rechazadas y 3 (15,79%) altas/exitus.\nCONCLUSIONES\nEste tipo de programa multidisciplinar de optimizaci\u00f3n de tratamientos en pacientes con insuficiencia renal nos garantiza \nunos mejores resultados en t\u00e9rminos de salud, permitiendo optimizar los tratamientos y aportar una mayor seguridad, \nminimizando as\u00ed los efectos adversos y el riesgo de toxicidad. Adem\u00e1s, teniendo en cuenta el n\u00famero de intervenciones \naceptadas, se puede observar \nc\u00f3mo se promueve y reconoce la importancia de la figura del farmac\u00e9utico hospitalario en el \u00e1mbito sanitario a la hora de \ntomar decisiones en relaci\u00f3n a tratamientos farmacol\u00f3gicos\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1027. ANALISIS Y ADECUACION MULTIDISCIPLINAR DE TRATAMIENTOS EN PACIENTES CON \nINSUFICIENCIA RENAL DE LOS SERVICIOS DE CIRUGIA GENERAL, VASCULAR Y ANESTESIOLOGIA. \nAUTORES\nGONZ\u00c1LEZ BARTOLOM\u00c9, J; TENA ALEJANDRE, P; DUQUE AGUILAR, JJ; ALMANCHEL RIVADENEYRA, A; CABA \nHERN\u00c1NDEZ, C; FERN\u00c1NDEZ LIS\u00d3N, LC\nCOMPLEJO HOSPITALARIO DE C\u00c1CERES. AV .PABLO NARANJO, S/N C\u00c1CERES. C\u00c1CERES\nOBJETIVOS\nAnalizar las intervenciones farmac\u00e9uticas realizadas en los pacientes con insuficiencia renal del Servicio de Cirug\u00eda \nGeneral, Cirug\u00eda Vascular y Anestesiolog\u00eda en colaboraci\u00f3n con el Servicio de Nefrolog\u00eda.\nMATERIALES Y M\u00c9TODOS\nEstudio transversal, observacional y descriptivo llevado a cabo entre 01/01/2017 y 03/05/2022. La base de pacientes \na analizar se obtiene a trav\u00e9s de una herramienta a cargo del Servicio de Nefrolog\u00eda que obtiene alertas de pacientes \ningresados con deterioro renal (FG < 60mL/min/1.73m2). Se realiza un an\u00e1lisis de datos exhaustivo a trav\u00e9s de la base de \ndatos del complejo hospitalario y la historia cl\u00ednica electr\u00f3nica. En el estudio, se incluyen datos de: edad, sexo, tasa de \nfiltraci\u00f3n glomerular, tratamiento prescrito, intervenciones y grado de aceptaci\u00f3n de las mismas y resultado.\nRESULTADOS\nEn el periodo de estudio se analizaron un total de 1245 pacientes en los Servicios de Cirug\u00eda General (557), Cirug\u00eda \nVascular (316) y Anestesiolog\u00eda (372) con una tasa de filtraci\u00f3n glomerular inferior a 60mL/min/1.73m2.  \nSe realizaron un total de 216 intervenciones, de las cuales 162 (75,00%) fueron aceptadas, correspondiendo a \nmodificaciones en la pauta o intervalo posol\u00f3gico o bien recomendaciones de suspensi\u00f3n de tratamientos; 44 (20,37%) \nfueron rechazadas por el equipo m\u00e9dico encargado y, por \u00faltimo; 10 (4,63%) corresponden a altas o exitus en los \npacientes analizados.  \nDesde un abordaje farmacol\u00f3gico, se pueden dividir las 216 intervenciones realizadas en 153 (70,83%) correspondientes \na tratamientos antibi\u00f3ticos, 49 (22,69%) al grupo de AINEs y, el resto, 14 (6,48%) correspondientes a otros grupos \nterap\u00e9uticos variados.  \nDe las intervenciones ejecutadas en los tratamientos antibi\u00f3ticos (153), fueron aceptadas 119 (77,78%), suponiendo una \nmodificaci\u00f3n de la dosificaci\u00f3n o ampliaci\u00f3n del intervalo de administraci\u00f3n de los tratamientos pautados. En cuanto a las \nsugerencias rechazadas, supusieron 29 (18,95%) y 5 (3,27%) fueron altas/exitus.  \nSobre el grupo de AINEs, de un total de 49 intervenciones; 33 (67,35%) fueron aceptadas, 11 (22,45%) rechazadas y, las 5 \n(10,20%) restantes fueron altas/exitus.  \nEl resto de intervenciones (14) correspond\u00edan a diversos grupos terap\u00e9uticos, encontr\u00e1ndonos con que 10 (71,43%) \nfueron aceptadas y 4 (28,57%) rechazadas.\nCONCLUSIONES\nEl gran n\u00famero de intervenciones aceptadas puede visualizar la importancia de la figura del farmac\u00e9utico hospitalario \nen el \u00e1mbito sanitario a la hora de tomar decisiones en relaci\u00f3n a tratamientos farmacol\u00f3gicos. Adem\u00e1s, este tipo \nde abordaje multidisciplinar, nos garantiza una optimizaci\u00f3n e incremento de la seguridad en pacientes en situaci\u00f3n 478de insuficiencia renal, aportando mejores resultados en t\u00e9rminos de salud, as\u00ed como una minimizaci\u00f3n de los efectos \nadversos y el riesgo de toxicidad\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1105. TERAPIA RADIONUCL\u00cdDICA DE RECEPTORES PEPT\u00cdDICOS. EVALUACI\u00d3N DE LA SEGURIDAD DE \n[177LU]LU-OXODOTREOTIDA EN TUMORES NEUROENDOCRINOS EN LA PR\u00c1CTICA CL\u00cdNICA HABITUAL. \nAUTORES\nFRANCO MONTERROSO, CG; HERN\u00c1NDEZ FRUCTUOSO, M\u00c0; REY S\u00c1NCHEZ, L; PASCUAL PASCUAL, V; SANTOS \nMONTERO, B; GORGAS TORNER, MQ\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLa terapia radionucl\u00eddica de receptores pept\u00eddicos (PRRT) est\u00e1 indicada para el tratamiento de tumores neuroendocrinos \ngastroenteropancre\u00e1ticos (TNE-GEP) positivos al receptor de somatostatina. El prop\u00f3sito de este estudio es evaluar los \nefectos adversos (EA) asociados al tratamiento durante y despu\u00e9s de la administraci\u00f3n del radiof\u00e1rmaco, [177Lu]Lu-\noxodotreotida. con el objetivo de incorporar un sistema de farmacovigilancia en nuestra Unidad de Radiofarmacia.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo entre junio de 2016 y abril 2022 en el que se incluyeron los pacientes tratados con \n[177Lu]Lu-oxodotreotida (protocolo est\u00e1ndar de 4 ciclos de 7,4GBq cada 8 semanas). La administraci\u00f3n de [177Lu]\nLu-oxodotreotida se realiz\u00f3 mediante bomba de infusi\u00f3n intravenosa aproximadamente en 30 minutos. Para reducir la \ndosis absorbida en el ri\u00f1\u00f3n se administr\u00f3 una soluci\u00f3n de amino\u00e1cidos cati\u00f3nicos (f\u00f3rmula magistral al 2,5% lisina + 2,5% \narginina 1,5L preparada en el Servicio de Farmacia de nuestro Hospital) mediante infusi\u00f3n lenta durante 6h, comenzando \n30minutos antes de la inyecci\u00f3n del radiof\u00e1rmaco. Se registraron los EA para cada paciente durante y despu\u00e9s de cada \nadministraci\u00f3n y entre ciclos en una base de datos interna de la unidad. Las variables evaluadas fueron: n\u00famero de \npacientes, edad, sexo, tipo de TNE-GEP , pauta recibida, y EA al tratamiento.\nRESULTADOS\nSe incluyeron un total de 73 pacientes (50 hombres y 23 mujeres, media de edad 60,2\u00b113,9). 46 pacientes (63%) \nrecibieron la pauta completa. 57 pacientes ten\u00edan TNE localizados en el sistema digestivo (24 p\u00e1ncreas, 18 intestinal, \n13 ileal, 1 duodenal, 1 recto). 14 pacientes recibieron tratamiento autorizado por la comisi\u00f3n farmacoterap\u00e9utica del \nhospital para la utilizaci\u00f3n del radiof\u00e1rmaco por indicaci\u00f3n fuera de ficha t\u00e9cnica (8 TNE de pulm\u00f3n, 3 paragangliomas, \n1 feocromocitoma, 1 meningioma y 1 TNE t\u00edmico). 2 pacientes ten\u00edan TNE de origen desconocido. 21 pacientes (28,8%) \nno completaron el tratamiento: 12 por progresi\u00f3n de la enfermedad, 6 por toxicidad hematol\u00f3gica severa, y 2 por \nmuerte. 1 paciente suspendi\u00f3 el tratamiento por voluntad propia. 6 pacientes (8,2%) est\u00e1n actualmente en tratamiento \ny monitorizaci\u00f3n. 23 pacientes (31,5%) registraron EA durante y despu\u00e9s de la administraci\u00f3n siendo los m\u00e1s comunes: \nn\u00e1useas y v\u00f3mitos (relacionadas con la soluci\u00f3n de amino\u00e1cidos), enrojecimiento facial, sofocaci\u00f3n, mareos, dolor \ngastrointestinal y cefalea. Todos ellos cedieron 5 minutos tras la administraci\u00f3n. Los EA registrados entre ciclos fueron: \nastenia y fatiga (55,1%), diarrea (13%), n\u00e1useas y v\u00f3mitos (13%), alopecia (11,6%), dolor abdominal (11,6%), p\u00e9rdida de \npeso (7,2%), dolor osteoarticular (5,8%), disminuci\u00f3n del apetito (4,3%), esteatorrea (2,9%) y fiebre (1,4%). 26 pacientes \n(35,6%) desarrollaron toxicidad hematol\u00f3gica (linfopenia, trombocitopenia y neutropenia). No se detectaron reacciones \nadversas no previstas\ufffd\nCONCLUSIONES\nLos EA leves y agudos de [177Lu]Lu-oxodotreotida fueron principalmente relacionados con la soluci\u00f3n de amino\u00e1cidos \ny fueron bien tolerados. Los EA subagudos se relacionaron con la radioactividad (dosis absorbida en m\u00e9dula \u00f3sea) y casi \ntodos fueron reversibles. A pesar de los EA observados, el tratamiento es generalmente bien tolerado por la mayor\u00eda de \nlos pacientes. Todos los EAs estaban descritos en Ficha T\u00e9cnica. La farmacovigilancia activa (registro y notificaci\u00f3n de EAs) \ncontribuye a un mayor conocimiento del perfil de seguridad de las nuevas terapias con radiof\u00e1rmacos.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1120. IMPACTO DE UN PROGRAMA DE FORMACI\u00d3N DE T\u00c9CNICOS DE FARMACIA PARA ELABORACI\u00d3N \nDE PREPARADOS EST\u00c9RILES EN CABINA DE FLUJO LAMINAR \nAUTORES\nBARBADILLO VILLANUEVA, S; GOMEZ GOMEZ, D; COL\u00d3N LOPEZ DE DICASTILLO, A; VALERO RODRIGUEZ, M\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nSe detect\u00f3 la necesidad de elaborar un plan formativo que supliera la carencia de competencias relacionadas con el \ntrabajo en los Servicios de Farmacia de Hospital (SFH) del grado medio de los T\u00e9cnicos de Farmacia (TF), especialmente en \ncuanto a elaboraci\u00f3n de preparados est\u00e9riles. \nEl objetivo es describir el contenido, desarrollo y resultados de este programa formativo.\nMATERIALES Y M\u00c9TODOS\nSe organiz\u00f3 un curso con 3 m\u00f3dulos online (18h), compuestos por material te\u00f3rico escrito y audiovisual que reforzaba los \nconceptos te\u00f3ricos. Fue desarrollado e impartido por el Jefe de Servicio del SFH en colaboraci\u00f3n con tres farmac\u00e9uticos 479especializados en t\u00e9cnicas de elaboraci\u00f3n de medicamentos. Se dirigi\u00f3 a todos los TF de los SFH de la Comunidad \nAut\u00f3noma\ufffd  \nEl contenido de los m\u00f3dulos fue:  \n1) Introducci\u00f3n al \u00e1rea est\u00e9ril en un SFH  \n2) Elaboraci\u00f3n de preparados est\u00e9riles \n3) Medicamentos y controles de calidad  \nEl material audiovisual cubr\u00eda 8 temas:  \n1) Higiene manos, vestimenta y manejo del material para la elaboraci\u00f3n de los preparados est\u00e9riles \n2) Elaboraci\u00f3n de colirio en cabina de flujo laminar horizontal \n3) Elaboraci\u00f3n de mezcla intravenosa de neonatos \n4) Elaboraci\u00f3n de mezcla intravenosa en cabina de flujo laminar horizontal \n5) Elaboraci\u00f3n de mezcla intravenosa en cabina de flujo laminar vertical \n6) Elaboraci\u00f3n de nutrici\u00f3n parenteral de adulto \n7) Elaboraci\u00f3n de nutrici\u00f3n parenteral neonatos \n8) Realizaci\u00f3n de c\u00e1lculos  \nLa evaluaci\u00f3n de la adquisici\u00f3n de conocimientos se realiz\u00f3 mediante una prueba test general, previa a la realizaci\u00f3n del \ncurso (prueba pre), una prueba test de evaluaci\u00f3n de cada m\u00f3dulo y la repetici\u00f3n del mismo test general al finalizar el \ncurso (prueba post). Los test se calificaron sobre un total de 10 puntos y en cada m\u00f3dulo, si se obten\u00eda una puntuaci\u00f3n \nmenor a 5 exist\u00eda un examen de recuperaci\u00f3n.  \nSe evalu\u00f3 el porcentaje de participaci\u00f3n de los profesionales en plantilla, las calificaciones de la prueba pre y post, las \ncalificaciones de cada m\u00f3dulo, y los resultados de la encuesta de satisfacci\u00f3n de los alumnos.\nRESULTADOS\n74 de los 88 TF en plantilla realizaron el curso (84.09% de participaci\u00f3n). Las notas medias obtenidas fueron 7,48 (prueba \npre), 8,79 (m\u00f3dulo 1), 8,90 (m\u00f3dulo 2), 8,48 (m\u00f3dulo 3) y 8,71 (prueba post).  \nEn cuanto a los conocimientos previos, destacar que todos los alumnos con una nota inferior a 5 puntos (6 alumnos), \nlograron una puntuaci\u00f3n mayor a 5 en la prueba post. La nota m\u00e1s baja de las pruebas post fue un 5.  \nNing\u00fan alumno suspendi\u00f3 las pruebas de m\u00f3dulo.  \nLa satisfacci\u00f3n global de los alumnos fue de 9,40 puntos.\nCONCLUSIONES\nLos TF part\u00edan de un alto nivel de conocimientos, como refleja la nota de la prueba pre, en parte porque muchos de ellos \nllevaban tiempo trabajando en el SFH. Aun as\u00ed, la realizaci\u00f3n del curso logr\u00f3 mejorarlo. El porcentaje de participaci\u00f3n y \nlas notas obtenidas son un indicativo de la implicaci\u00f3n de este colectivo. La satisfacci\u00f3n de los alumnos es notable, lo que \nalienta a realizar nuevos programas formativos que combinen estos formatos escritos y audiovisuales. El impacto de esta \nformaci\u00f3n ser\u00eda mayor si se realizara en el momento en que el TF se incorpora al SFH.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1165. SOFTWARE PARA LA MEJORA EN LA SEGURIDAD Y TRAZABILIDAD DE TRATAMIENTOS \nONCOHEMATOLOGICOS \nAUTORES\nPLANAS GINER, A; CARDONA ROCA, L; CORONEL CORDERO, LE; SOSA PONS, A; ALMENDROS ABAD, N; VINALLONGA \nBLAS, N; MORENTE VICENTE, A; RUDI SOLA, N\nHOSPITAL GENERAL DE GRANOLLERS \ufffd AV\ufffd FRANCESC RIBAS, S/N GRANOLLERS \ufffd BARCELONA\nOBJETIVOS\nValidar si la utilizaci\u00f3n de un software para administraci\u00f3n segura de citost\u00e1ticos (Oncosafety\u00ae) mejora la seguridad y la \ntrazabilidad en la administraci\u00f3n de los tratamientos oncohematol\u00f3gicos.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo realizado en el hospital de d\u00eda Oncohematol\u00f3gico de un hospital general de segundo \nnivel desde septiembre de 2020 hasta abril de 2022. Se incluyeron los pacientes que recibieron quimioterapia en el \nHospital de d\u00eda mediante el programa Oncosafety\u00ae. \nSe dise\u00f1\u00f3 una base de datos registrando las variables: n\u00famero de pacientes, tratamientos y mezclas administradas, \nerrores evitados por medicaci\u00f3n incorrecta, desviaciones de dosis, efectos adversos, extravasaciones, flujos no \nrecomendados, presiones no recomendadas, tratamientos administrados sin asistente de seguridad y tiempos de \nadministraci\u00f3n\ufffd  \nPara evaluar la seguridad se utiliz\u00f3 el n\u00famero de errores de administraci\u00f3n evitados por selecci\u00f3n de medicaci\u00f3n \nincorrecta\ufffd\nRESULTADOS\nDurante el periodo de estudio se administraron 11.645 tratamientos con Oncosafety\u00ae (554 sin asistente de seguridad) \nen un total de 1.489 pacientes. Estos tratamientos sumaron 51.213 mezclas administradas (34% citost\u00e1ticos, 42% \nmedicamentos de soporte y 23% diluyentes).  \nLa dosis administrada se desvi\u00f3 de la prescrita en 954 mezclas (1,8%). Se super\u00f3 el nivel de presi\u00f3n recomendado en \n1.214 mezclas (2,3%). En 1.251 ocasiones se evitaron errores de administraci\u00f3n por selecci\u00f3n de medicaci\u00f3n incorrecta \n(f\u00e1rmaco por f\u00e1rmaco).  480Se registraron un total de 63 efectos adversos (0,2% del total de f\u00e1rmacos administrados), 23 extravasaciones (0,1% de \ncitost\u00e1ticos administrados) y 167 mezclas administradas a flujos no recomendados en el protocolo (0,4% de f\u00e1rmacos).  \nLos tiempos de administraci\u00f3n reales se ajustaron a los te\u00f3ricos en el 69,4% de los tratamientos de corta duraci\u00f3n (5-120 \nminutos), un 80,2% en los de duraci\u00f3n media (120-240 minutos) y un 59,4% en los de larga duraci\u00f3n (240-1000 minutos).\nCONCLUSIONES\nOncosafety\u00ae es una herramienta que permite mejorar la seguridad y la calidad en la administraci\u00f3n de los tratamientos \noncohematol\u00f3gicos, reduciendo los errores y garantizando la trazabilidad de todo el proceso. Su funci\u00f3n permite \nadministrar el medicamento correcto, al paciente correcto, en la dosis correcta, de la manera correcta y en el momento \nadecuado\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1180. GESTI\u00d3N DE RIESGO EN EL USO DE TERAPIAS BIOL\u00d3GICAS, INMUNOSUPRESORAS E \nINMUNOMODULADORAS EN REFERENCIA AL ESTADO INMUNO-INFECCIOSO DEL PACIENTE. \nAUTORES\nZAYAS SORIANO, M; BONETE SANCHEZ, M; PONS MARTINEZ, L; MARTINEZ LAZCANO, T; PLANELLES DE CASTRO, M; \nGONZALEZ LOPEZ, A; MOLINA MARTINEZ, M; AZNAR SALIENTE, T\nHOSPITAL UNIVERSITARIO SAN JUAN DE ALICANTE. CTRA. ALICANTE-VALENCIA S/N SANT JOAN DALACANT . ALICANTE\nOBJETIVOS\nDebido al amplio uso de terapias biol\u00f3gicas, inmunosupresoras e inmunomoduladoras(BII) en distintas enfermedades, \nse ha observado un aumento de riesgo asociado a su uso: reactivaci\u00f3n de pat\u00f3genos latentes, empeoramiento de \ninfecciones cr\u00f3nicas asintom\u00e1ticas y posibles infecciones de novo.  \n \nEl objetivo del trabajo es medir la adecuaci\u00f3n de las prescripciones a las recomendaciones de ficha t\u00e9cnica (FT) en \nrelaci\u00f3n al estado inmuno-infeccioso del paciente, previo al tratamiento con terapias BII centradas en actualizaci\u00f3n \ndel calendario vacunal(CV), realizaci\u00f3n de serolog\u00eda de virus de la hepatitis B(VHB) y determinaci\u00f3n de tuberculosis \nlatente(TL), seg\u00fan requerimientos del f\u00e1rmaco prescrito.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y unicentrico que incluy\u00f3 a pacientes adultos que iniciaron tratamiento entre \n01/01/21 y 31/03/22 con f\u00e1rmacos BII prescritos en nuestro centro y dispensados en la unidad de pacientes externos u \nhospital de d\u00eda.  \n \nSe revisaron las FT de los f\u00e1rmacos BII recogidos y se clasificaron seg\u00fan necesidad de actualizaci\u00f3n de CV, realizaci\u00f3n de \nserolog\u00eda VHB o determinaci\u00f3n de TL previa al inicio del tratamiento. Posteriormente se realiz\u00f3 revisi\u00f3n de la historia \ncl\u00ednica para comprobar el cumplimiento de las recomendaciones.  \n \nSe recogieron variables demogr\u00e1ficas (edad y sexo), f\u00e1rmaco prescrito, servicio prescriptor y fecha de inicio del \ntratamiento\ufffd La variable principal fue la adecuaci\u00f3n de las prescripciones a las recomendaciones de FT \ufffd \n \nSe definieron 3 grados de adecuaci\u00f3n: Totalmente adecuado(TA), cuando hubo un cumplimiento total de las \nrecomendaciones, parcialmente adecuado(PA) si solo se cumplieron algunas de las recomendaciones y no adecuado(NA), \nsi no se tuvo en cuenta ninguna recomendaci\u00f3n\ufffd  \n \nSe utiliz\u00f3 estad\u00edstica descriptiva con media, desviaci\u00f3n est\u00e1ndar y frecuencias.\nRESULTADOS\nSe analizaron un total de 360 pacientes; el 55,3% fueron mujeres y la media de edad fue de 60,3\u00b116 a\u00f1os. El an\u00e1lisis \nde la frecuencia de prescripci\u00f3n por servicio fue: oncolog\u00eda m\u00e9dica(103), hematolog\u00eda(93), medicina digestiva(45), \nreumatolog\u00eda(41), dermatolog\u00eda(38), urolog\u00eda(35), neurolog\u00eda(8), oftalmolog\u00eda(6), medicina interna(4), cardiolog\u00eda(1), \nmedicina intensiva(2).  \n \nEl 43,3% de los tratamientos se consideraron TA, el 13,6% PA y el 43,1% NA \ufffd \n \nLos servicios con mayor grado de TA fueron: oftalmolog\u00eda, medicina interna, medicina digestiva y reumatolog\u00eda. Los de \nmayor porcentaje de NA fueron: urolog\u00eda, oncolog\u00eda m\u00e9dica y hematolog\u00eda.  \nRespecto a los principios activos adalimumab, cladribina, infliximab fueron los que mayor porcentaje de AT presentaron. \nLos que menos se adecuaron a las condiciones de FT fueron BCG, irinotecan y pomalidomida.  \n \nA fin de mejorar los resultados obtenidos, se motiv\u00f3 la creaci\u00f3n e implantaci\u00f3n de un protocolo multidisciplinar que \ninclu\u00eda un check list de los f\u00e1rmacos que requieren evaluaci\u00f3n inmuno-infecciosa previa a la prescripci\u00f3n y un circuito \nde actuaci\u00f3n. La implantaci\u00f3n del protocolo se realiz\u00f3 en el servicio de farmacia, en los servicios m\u00e9dicos del hospital \ny en los comit\u00e9s de biol\u00f3gicos, haciendo hincapi\u00e9 en los servicios y f\u00e1rmacos que presentaron peor adaptaci\u00f3n a las \nrecomendaciones seg\u00fan el estudio realizado.481CONCLUSIONES\nA pesar del amplio conocimiento y recomendaciones expresas acerca de la reactivaci\u00f3n de determinadas enfermedades \ncon el uso de f\u00e1rmacos BII, los resultados muestran que la adecuaci\u00f3n a las recomendaciones es < 50%, por lo que se han \npuesto en marcha estrategias de mejora.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1195. SWITCH DE HORMONA DEL CRECIMIENTO RECOMBINANTE ORIGINAL AL BIOSIMILAR \nAUTORES\nSACANELLA ANGL\u00c8S, I; JORNET MONTA\u00d1A, S; MART\u00cdN MARQU\u00c9S, M; BOADA HERN\u00c1NDEZ, P; SANJU\u00c1N BELDA, A; \nSU\u00d1ER BARRIGA, H; PLO SECO, I; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA\nOBJETIVOS\nAnalizar todos los pacientes pedi\u00e1tricos con prescripciones activas de hormona del crecimiento recombinante (GHr) con \nla finalidad de identificar aquellos casos candidatos a ser cambiados al f\u00e1rmaco biosimilar. \nEvaluar los pacientes a los que se les hizo el cambio para comprobar que la respuesta terap\u00e9utica fue adecuada.\nMATERIALES Y M\u00c9TODOS\nEstudio observacional, retrospectivo y unic\u00e9ntrico en el que se evaluaron todas las prescripciones activas de hormona del \ncrecimiento de distintas marcas comerciales durante el a\u00f1o 2021. Otros par\u00e1metros analizados fueron: edad, indicaci\u00f3n, \ndisconformidad con el dispositivo de administraci\u00f3n por parte de padres o tutores y el mantenimiento de la respuesta \nterap\u00e9utica.  \nSe confirm\u00f3 con la historia cl\u00ednica la respuesta al tratamiento y la no aparici\u00f3n de efectos adversos, par\u00e1metro que \ntambi\u00e9n se registr\u00f3 en las consultas externas de atenci\u00f3n farmac\u00e9utica. \nLos f\u00e1rmacos estudiados fueron Omnitrope\u24c7 (biosimilar), Humatrope\u24c7, Norditropin \u24c7, Saizen\u24c7 y Genotonorm\u24c7 (NO \nbiosimilares).\nRESULTADOS\nLa media de edad de los pacientes fue de 12 \u00b1 2 a\u00f1os\ufffd El total de pacientes con prescripci\u00f3n de la GHr fue de 48, de los \ncu\u00e1les un 52,1% ya ten\u00edan prescrita la somatropina biosimilar y se analiz\u00f3 el potencial switch al biosimilar del 47,9% \nrestante. Dentro de estos, un total de 12 prescripciones no se pudieron cambiar al biosimilar por distintas razones: 1 \npaciente con Humatrope\u24c7 (\u00fanico con indicaci\u00f3n en la alteraci\u00f3n del gen SHOX), 3 pacientes con Norditropin Simplexx\u24c7 \n(\u00fanico con indicaci\u00f3n en el s\u00edndrome de Noonan) y 8 con Saizen\u24c7 (\u00fanico con autoinyector EasyPod \u24c7 que permite la \nmonitorizaci\u00f3n de la adherencia).  \nDe los 11 pacientes con Genotonorm \u24c7, 5 eran adolescentes. En este grupo de pacientes se decidi\u00f3 no promover ning\u00fan \ncambio debido a su pr\u00f3xima finalizaci\u00f3n del tratamiento. Sin embargo, en los 6 pacientes con una edad menor de 12 a\u00f1os \ns\u00ed se consigui\u00f3 hacer el switch (54,5%).  \nEn la totalidad de los pacientes se mantuvo la respuesta terap\u00e9utica. El 100% de los pacientes estudiados en tratamiento \ncon la GHr tuvieron un diagn\u00f3stico confirmatorio de d\u00e9ficit de la hormona del crecimiento.  \nUn 16,6% mostraron rechazo al nuevo dispositivo utilizado y propusieron volver al anterior. Sin embargo, tras unos \nmeses de utilizaci\u00f3n y visitas sucesivas con el servicio de Farmacia se reforz\u00f3 la educaci\u00f3n sanitaria logrando el cambio al \nbiosimilar \ufffd  \nAcorde a lo escrito en la historia cl\u00ednica y en las consultas externas, ning\u00fan paciente refiri\u00f3 eventos adversos.  \nFinalmente, con los cambios realizados, se obtuvo un total de 64,5% de prescripciones de hormona del crecimiento \nbiosimilar \ufffd\nCONCLUSIONES\nEl farmac\u00e9utico hospitalario tiene un rol fundamental en promover la utilizaci\u00f3n de mol\u00e9culas biosimilares en los \ntratamientos. Con este estudio se pudo evaluar a los pacientes con hormona del crecimiento original y se logr\u00f3 \ncambiar un porcentaje destacable de esas prescripciones al f\u00e1rmaco biosimilar. As\u00ed pues, estos datos refuerzan la \nintercambiabilidad entre el biol\u00f3gico original y el biosimilar sin comprometer la eficacia ni la seguridad.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1257. AN\u00c1LISIS DE LOS PACIENTES EN TRATAMIENTO CON TOFACITINIB: APLICANDO NUEVAS \nPRECAUCIONES DE USO. \nAUTORES\nG\u00d3MEZ DELGADO, M; GONZ\u00c1LEZ PADILLA, M; L\u00d3PEZ ESCOZ, R; S\u00c1NCHEZ Y\u00c1\u00d1EZ, E; MOYA CARMONA, I\nCOMPLEJO HOSPITALARIO DE ESPECIALIDADES VIRGEN DE LA VICTORIA. CAMPUS UNIVERSITARIO TEATINOS, S/N \nM\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\n- Describir las caracter\u00edsticas de los pacientes que est\u00e1n en tratamiento con tofacitinib desde julio de 2021.  \n- Identificar a los pacientes con un mayor riesgo de eventos adversos en los que se desaconseja el uso de tofacitinib seg\u00fan \nla alerta MUH(FV),10/2021 de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios(AEMPS).  \n- Informar/aplicar de las nuevas precauciones de uso emitidas por la AEMPS en dicha alerta y evaluar el impacto de la \nintervenci\u00f3n\ufffd482MATERIALES Y M\u00c9TODOS\nEstudio observacional retrospectivo en el que se incluyeron todos los pacientes en tratamiento con tofacitinib desde \njulio de 2021 hasta la actualidad. Las variables recogidas fueron: edad (y si eran mayores de 65 a\u00f1os), sexo, tabaquismo \nsi/no, antecedentes de diabetes o enfermedad coronaria (EC). Son factores que aumentan el riesgo cardiovascular o \nde neoplasia y contraindican el uso de tofacitinib. Los datos han sido recogidos de la historia cl\u00ednica y del programa de \nprescripci\u00f3n electr\u00f3nica\ufffd \nSe comunic\u00f3 por v\u00eda telef\u00f3nica a los m\u00e9dicos prescriptores los pacientes que se encontraban en tratamiento con \ntofacitinib a pesar de presentar factores de riesgo, ofreci\u00e9ndoles otras alternativas terap\u00e9uticas.\nRESULTADOS\nFueron incluidos 43 pacientes en tratamiento con tofacitinib, 30% hombres, con una edad media de 53 a\u00f1os (17-78). 10 \npacientes ten\u00edan prescrito tofacitinib por colitis ulcerosa y 33 por artritis reumatoide.  \nSe detectaron 19 pacientes con factores de riesgo: 21% (4) eran mayores de 65 a\u00f1os, 21% (4) fumaban, 10,5% (2) \npadec\u00edan EC y 47,4% (9) ten\u00edan dos o m\u00e1s factores de riesgo (hombre, > 65 a\u00f1os, tabaquismo, diabetes, EC).  \nEn el momento de esta revisi\u00f3n 7 de ellos ya hab\u00edan descontinuado el tratamiento con tofacitinib. Se realizaron 12 \nnotificaciones a los especialistas. Tras las cuales 3 (25%) prescripciones de tofacitinib se suspendieron y 9 (75%) se \nmantuvieron: 5 por asumir bajo riesgo de efectos adversos, 1 por no tener otra alternativa terap\u00e9utica y 3 se encuentran \nen reevaluaci\u00f3n\ufffd\nCONCLUSIONES\nTras la publicaci\u00f3n por la AEMPS de la alerta MUH(FV),10/2021 decidimos hacer una revisi\u00f3n de los pacientes que \nestaban en tratamiento con tofacitinib para poder identificar si estaban afectados con un mayor riesgo de seguridad.  \nEn nuestro centro se han encontrado pacientes con factores de riesgo que predisponen a una mayor incidencia de \neventos adversos cardiovasculares y de neoplasias malignas, lo que contraindica que reciban tratamiento con tofacitinib. \nComo medida de seguridad la mitad de los pacientes han tenido una modificaci\u00f3n de su tratamiento en el periodo del \nestudio, sustituyendo tofacitinib por otra alternativa eficaz y m\u00e1s segura. \nA ra\u00edz de esta revisi\u00f3n, el Servicio de Farmacia ha informado a los especialistas de los servicios de Digestivo y de \nReumatolog\u00eda sobre la alerta de seguridad del tofacitinib, lo que ha motivado un cambio en las prescripciones, de manera \nque no reporten un riesgo de seguridad para el paciente. El conocimiento de la nota de seguridad permite evaluar las \ncaracter\u00edsticas de los pacientes antes de iniciar el tratamiento con tofacitinib, en consecuencia en la actualidad no se \ninicia el tratamiento si el paciente presenta factores de riesgo\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1272. NUEVA ALERTA DE SEGURIDAD DE TOFACITINIB: AN\u00c1LISIS DE LOS PACIENTES EN RIESGO. \nAUTORES\nALCAL\u00c1 SOTO, A; V\u00c1ZQUEZ REAL, M; L\u00d3PEZ MU\u00d1OZ, MJ; CUADROS MART\u00cdNEZ, CM; SIERRA S\u00c1NCHEZ, JF\nHOSPITAL DE ESPECIALIDADES DE JEREZ DE LA FRONTERA. CTRA. DE CIRCUNVALACION, S/N JEREZ DE LA FRONTERA. \nC\u00c1DIZ\nOBJETIVOS\nEn julio de 2021 la AEMPS public\u00f3 una nota de seguridad de tofacitinib, por presentar un incremento del riesgo de \nacontecimientos adversos cardiovasculares mayores y de neoplasias malignas en comparaci\u00f3n con inhibidores del factor \nde necrosis tumoral alfa: \u201clos pacientes > 65 a\u00f1os, pacientes fumadores o exfumadores y aquellos que presenten factores \nde riesgo cardiovascular adicionales o para el desarrollo de neoplasias, no deber\u00e1n recibir tratamiento con tofacitinib \na menos que no pueda utilizarse otra alternativa terap\u00e9utica\u201d. El objetivo es detectar los pacientes con tofacitinib en \nriesgo de estar afectados por la alerta, comunicar a los prescriptores los pacientes en riesgo y ofrecer una alternativa \nterap\u00e9utica basada en eficacia, seguridad y coste.\nMATERIALES Y M\u00c9TODOS\nEn julio-2021, se revisaron las historias cl\u00ednicas de los pacientes con tofacitinib y desde entonces, se revis\u00f3, previo al inicio \ndel tratamiento con tofacitinib, que los pacientes no estuvieran afectados por la alerta. Se obtuvieron los siguientes datos \nde la Historia Cl\u00ednica: edad, sexo, prescriptor m\u00e9dico, enfermedad cardiovascular, factores de riesgo cardiovasculares \nadicionales y neoplasias. Se consideraron factores de riesgo: > 65 a\u00f1os, factores de riesgo cardiovascular y c\u00e1ncer. Se \ncomunic\u00f3 a los prescriptores los pacientes en tratamiento con tofacitinib y aquellos pacientes considerados en riesgo. \nSe revis\u00f3 el historial farmacoterap\u00e9utico previo para proponer un cambio de tratamiento basado en eficacia, seguridad y \ncoste \ufffd\nRESULTADOS\nEn julio 2021 hab\u00eda 36 pacientes con tofacitinib. 28 eran mujeres (73%), la media de edad fue 51,6 a\u00f1os. 17 pacientes \nten\u00edan Artritis reumatoide, 13 Artritis psori\u00e1sica, 4 colitis ulcerosa y 2 Alopecia areata. Hab\u00eda 10 pacientes en riesgo: \n6 pacientes ten\u00edan m\u00e1s de 65 a\u00f1os y 5 pacientes ten\u00edan factores de riesgo cardiovasculares adicionales o evento \ncardiovascular previo. Ninguno ten\u00eda diagn\u00f3stico de c\u00e1ncer. \nDesde el Servicio de Farmacia, se propuso a los prescriptores el cambio de tratamiento a los 10 pacientes afectados por \nla alerta y la comunicaci\u00f3n del riesgo a los mismos. Se cambi\u00f3 el tratamiento a 3 pacientes por opciones m\u00e1s eficientes: \netanercept biosimilar, rituximab biosimilar y filgotinib; 1 paciente ha abandonado el tratamiento por decisi\u00f3n propia tras \nser informado de los riesgos; 1 paciente se suspendi\u00f3 el tratamiento por ingreso por insuficiencia card\u00edaca y otro por \nefecto adverso; 4 pacientes decidieron continuar con el tratamiento asumiendo los riesgos. Todo se hizo constar en la \nHistoria Cl\u00ednica. 483De julio 2021 a mayo 2022, han iniciado 5 pacientes (2 Artritis psori\u00e1sica, 1 Artritis reumatoide, 1 Artritis y Alopecia \nareata, y 1 alopecia areata), todos ellos sin factores de riesgo. Una paciente con Artritis reumatoide se solicit\u00f3, pero \nestaba afectada por la alerta (edad > 65 y antecedente de c\u00e1ncer de mama), por lo que se propuso una alternativa \nterap\u00e9utica: filgotinib.\nCONCLUSIONES\nM\u00e1s de uno de cada cuatro pacientes en tratamiento con tofacitinib estaban afectados por la alerta de seguridad: \nconsiderados como poblaci\u00f3n en riesgo de sufrir eventos cardiovasculares mayores o neoplasias. Este estudio permiti\u00f3 \ndetectar los pacientes en riesgo y comunicarlo a los prescriptores, ofreci\u00e9ndoles una alternativa terap\u00e9utica basada en \neficacia, seguridad y costes. Destaca el Servicio de Farmacia como garante de la seguridad del paciente.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1274. PATIENT REPORTED OUTCOMES EN PACIENTES CON ASMA GRAVE EN TRATAMIENTO CON \nF\u00c1RMACOS BIOL\u00d3GICOS \nAUTORES\nMART\u00cdNEZ BARROS, H; MU\u00d1OZ GARC\u00cdA, M; RIVERA MARCOS, MB; S\u00c1NCHEZ CU\u00c9LLAR, S; GONZ\u00c1LEZ DE OLANO, D; \nSANTAMAR\u00cdA GADEA, A; ANTOL\u00cdN AM\u00c9RIGO, D; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nEvaluar la calidad de vida de los pacientes con asma grave en tratamiento con f\u00e1rmacos biol\u00f3gicos a trav\u00e9s de patient \nreported outcomes measures (PROM) y su correlaci\u00f3n con las comorbilidades asociadas al asma, control asm\u00e1tico o \nadherencia.\nMATERIALES Y M\u00c9TODOS\nEstudio transversal descriptivo realizado entre abril-mayo 2022 en un hospital de tercer nivel. Se incluyeron pacientes \nadultos con asma grave en tratamiento activo con f\u00e1rmaco biol\u00f3gico durante al menos un a\u00f1o que otorgaron \nconsentimiento informado.  \nSe revis\u00f3 la historia cl\u00ednica electr\u00f3nica para obtener las siguientes variables demogr\u00e1ficas y cl\u00ednicas: \n\u2022 Sexo, edad \n\u2022 N\u00famero de comorbilidades asociadas al asma  \n\u2022 FEV1, FEV/FVC \n\u2022 N\u00famero de exacerbaciones, visitas a urgencias y hospitalizaciones por asma en a\u00f1o previo \n\u2022 Ciclo corticoides a\u00f1o previo, corticoides orales prescritos (s\u00ed/no)  \n\u2022 Puntuaci\u00f3n de ACT (asthma control test) y TAI (test adherencia a inhaladores) \nSe realiz\u00f3 una entrevista telef\u00f3nica para registrar los siguientes PROM: \nCuestionarios de calidad de vida:  \n\u2022 Mini-AQLQ (asthma-quality-of-life-questionnaire-versi\u00f3n-reducida)  \n\u2022 EQ5D-5L (EVA: Escala-visual-anal\u00f3gica incluida)  \nCuestionario de control de s\u00edntomas: \n\u2022 Escala MRC (medical research council) de disnea  \nCuestionario de adherencia: \n\u2022 Morisky Green, se consider\u00f3 adherente si cumpl\u00eda \u00e9ste y TAI \nLas variables cuantitativas fueron expresadas como media m\u00e1s desviaci\u00f3n t\u00edpica en distribuciones sim\u00e9tricas y mediana e \nintervalo intercuart\u00edlico para no sim\u00e9tricas.  \nSe realiz\u00f3 t student para calcular asociaci\u00f3n entre calidad de vida, seg\u00fan EQ5D-5L y cuatro esferas del miniAQLQ, y \nvariables categ\u00f3ricas. Para variables cuantitativas se us\u00f3 el test de correlaci\u00f3n de Spearman,. p < 0,05 fue considerado \nsignificativo.\nRESULTADOS\nSe identificaron 55 pacientes que cumpl\u00edan criterios de inclusi\u00f3n, se localiz\u00f3 a 38 que accedieron a participar. La mediana \nde edad fue 65 a\u00f1os(56-70) y el 60,5%(23) eran mujeres. La media de comorbilidades relacionadas con el asma fue \n2,4(DE=0,280). El % de FEV1 y FEV/FVC medio fue 76,3 (DE=3,16) y 69(DE=1,63), respectivamente. La mediana mini-\nAQLQ fue 6,2(5,8-7) en la esfera de s\u00edntomas, 6,12 (5,5-6,75) en actividades, 7(5,33-7) en emocional y 5(4,33-6,33) en \nambiental, mientras que la mediana para el EQ5D-5L fue de 0,924(0,818-1). El 73,7% (28) refiri\u00f3 una puntuaci\u00f3n \u2264 1 \nen la escala MRC-disnea. La mediana de EVA fue 70 (60-85). El 52,6% (20) de los pacientes se consider\u00f3 adherente. Se \ndetect\u00f3 asociaci\u00f3n positiva moderada entre la puntuaci\u00f3n del ACT y EQ5D-5L (coeficiente de correlaci\u00f3n de Spearman, \n(rs[37]=0,4938,p=0,0019) y mini-AQLQ de las esferas sintom\u00e1tica (rs[37] < 0,6757,p < 0,001), actividad (rs[37]=0,6200,p \n< 0,001) y emocional (rs[37]=0,6472,p < 0,001). Se encontr\u00f3 correlaci\u00f3n moderada negativa entre disnea y EQ5D-5L \n(rs[38]=-0,6566,p < 0,001) y las esfera sintom\u00e1tica (rs[38]=-0,5303,p < 0,001), actividad (rs[38]=-0,04769,p=0,025) y \nemocional (rs[38]=-0,4998,p=0,014) de miniAQLQ. Se detect\u00f3 asociaci\u00f3n moderada negativa entre prescripci\u00f3n de \ncorticoides y EQ5D-5L (rs[38]=-0,4619,p=0,035) y esfera emocional de miniAQLQ (rs[38]=-0,4310,p=0,0112).\nCONCLUSIONES\nLos pacientes con asma grave tratados con f\u00e1rmaco biol\u00f3gico presentan una buena calidad de vida seg\u00fan cuestionarios \nespec\u00edficos de asma, destacando la esfera emocional, y cuestionarios generales utilizados como PROM.  484Se encontr\u00f3 asociaci\u00f3n moderada positiva entre puntuaci\u00f3n del ACT y EQ5D-5L y los datos reportados en 3 esferas de \nminiAQLQ y moderada negativa entre la prescripci\u00f3n de corticoides con EQ5D-5L y esfera emocional.  \nNo se observ\u00f3 relaci\u00f3n entre adherencia y calidad de vida, aunque es necesario desarrollar medidas que aumenten el \nporcentaje de pacientes adherentes.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1293. RELEVANCIA CL\u00cdNICA DE LA INTERACCI\u00d3N FARMACOL\u00d3GICA ENTRE MIRTAZAPINA Y LINEZOLID. \nAUTORES\nALABORT AYLLON, H; DROZDZ , A; TEBAR , E; COLLADO , JM; DEL POZO , C; SERNA , B; SANCHEZ , JL\nHOSPITAL GENERAL DE ALBACETE \ufffd HERMANOS FALC\u00d3, S/N \ufffd ALBACETE \ufffd ALBACETE\nOBJETIVOS\nDescribir la relevancia cl\u00ednica de la interacci\u00f3n entre mirtazapina y linezolid y compararla en la pr\u00e1ctica hospitalaria frente \na la relevancia establecida en diferentes bases de datos\ufffd\nMATERIALES Y M\u00c9TODOS\nSe realiza un estudio retrospectivo observacional en el cual son elegidos como pacientes candidatos todos aquellos que \nhayan sido tratados con mirtazapina y linezolid de manera conjunta. Al presentar linezolid una biodisponibilidad cercana \nal 100%, no se diferencia entre las especialidades intravenosas u orales\ufffd  \nSe cruzaron los datos de pacientes hospitalizados que hab\u00edan sido tratados con mirtazapina y linezolid durante los a\u00f1os \n2018, 2019 y 2020. Se obtuvo un total de 2777 pacientes, los cuales hab\u00edan recibido mirtazapina o linezolid. De estos, 95 \nhab\u00edan llevado los dos tratamientos y solo 64 llevaron los tratamientos de forma simult\u00e1nea. Finalmente, se dividieron los \npacientes en dos grupos: aquellos que llevaron durante el ingreso dosis de mirtazapina de 15mg, 38 pacientes y los que \nllevaron 30 mg, 26 pacientes\ufffd \nLa explotaci\u00f3n de datos cl\u00ednicos se realiz\u00f3 mediante revisi\u00f3n de historias cl\u00ednicas electr\u00f3nicas (Mambrino XXI\u00ae) y el \nsoftware de gesti\u00f3n farmac\u00e9utica (Farmatools).  \nLas bases de datos consultadas son: Drugs\u00ae, Lexicomp\u00ae, Micromedex\u00ae y ficha t\u00e9cnica.\nRESULTADOS\nEn las bases de datos consultadas est\u00e1 reflejada la interacci\u00f3n entre linezolid y mirtazapina. Adem\u00e1s, est\u00e1n de acuerdo \nen contraindicar la administraci\u00f3n concomitante. Esta interacci\u00f3n puede originar s\u00edndrome serotonin\u00e9rgico, afecci\u00f3n \ndel sistema nervioso central, caracterizada por un aumento de serotonina en las sinapsis. Debida principalmente a la \npotenciaci\u00f3n en la inhibici\u00f3n de la recaptaci\u00f3n de serotonina.  \nRevisando las historias cl\u00ednicas de estos pacientes se obtuvo que: la edad media de la poblaci\u00f3n estudiada fue de \n66\u00b17 a\u00f1os, la duraci\u00f3n media de la coadministraci\u00f3n de los medicamentos fue de 5 d\u00edas y la duraci\u00f3n media de la \nhospitalizaci\u00f3n de estos pacientes fue de 13 d\u00edas. Un 35% (22) de los pacientes detuvo de forma temprana la combinaci\u00f3n \nde estas terapias, los principales motivos fueron: Un 55% (12) por intervenciones farmac\u00e9uticas en las que se \nrecomendaba su suspensi\u00f3n, un 40% (9) por decisi\u00f3n m\u00e9dica y un 5% (1) por muerte de los pacientes, que no resolvieron \nla infecci\u00f3n\ufffd  \nEn cuanto a s\u00edndromes serotonin\u00e9rgicos no se observaron diferencias entre el grupo de 15mg y de 30mg, no se detect\u00f3 \nning\u00fan caso confirmado: se observaron ligeros aumentos de la temperatura, por mal control de la infecci\u00f3n, aumentos \nde presi\u00f3n, agitaci\u00f3n o temblor, pero ninguno de ellos cumpli\u00f3 ning\u00fan criterio de Hunter: Hiperton\u00eda muscular, Clonus \nespont\u00e1neo Temblor m\u00e1s hiperreflexia o Clono ocular o inducible, adem\u00e1s de agitaci\u00f3n, diaforesis o temperatura > 38\u00b0 C.\nCONCLUSIONES\nEn nuestra poblaci\u00f3n de estudio no observamos ning\u00fan caso de s\u00edndrome serotonin\u00e9rgico. La combinaci\u00f3n en ambiente \nhospitalario result\u00f3 segura para los pacientes, los cuales estuvieron bajo monitorizaci\u00f3n. Son necesarios m\u00e1s estudios con \nmayor n\u00famero de muestra para confirmar estas conclusiones. Es deber del farmac\u00e9utico informar de la posibilidad de \neste tipo de interacciones para que se tomen las medidas oportunas.486COMUNICACIONES OPERATIVAS\nCLASIFICACI\u00d3N: ADHERENCIA\nCLASIFICACI\u00d3N: ADHERENCIA\n229. IMPLANTACI\u00d3N DE UN CIRCUITO PARA LA PRESCRIPCI\u00d3N, DISPENSACI\u00d3N Y ADMINISTRACI\u00d3N \nAMBULATORIA DE BUPRENORFINA INYECTABLE DE LIBERACI\u00d3N PROLONGADA \nAUTORES\nALDAVE COBOS, P; S\u00c1NCHEZ RUIZ DE GORDOA, M; DOM\u00cdNGUEZ ORTIZ, MD; ULACIA EPELDE, L\nCENTRO PSICOGERI\u00c1TRICO SAN FRANCISCO JAVIER\nOBJETIVOS\nDescribir la experiencia en la implantaci\u00f3n de un circuito de prescripci\u00f3n, dispensaci\u00f3n y administraci\u00f3n ambulatoria de \nbuprenorfina inyectable de liberaci\u00f3n prolongada (ILP).\nMEJORAS ESPERADAS\nAumentar la adherencia de los pacientes en tratamiento de la dependencia a opioides con buprenorfina sublingual. \nProtocolizar los criterios para iniciar tratamiento con buprenorfina ILP .\nDISE\u00d1O CIRCUITO Y ETAPAS\nFormaci\u00f3n de un equipo multidisciplinar con representaci\u00f3n de los servicios de Psiquiatr\u00eda, Medicina General, Farmacia y \nEnfermer\u00eda. Elaboraci\u00f3n de un nuevo protocolo de prescripci\u00f3n, dispensaci\u00f3n y administraci\u00f3n de buprenorfina ILP . \n \n-Establecer los criterios de prescripci\u00f3n de buprenorfina ILP (seg\u00fan condiciones de financiaci\u00f3n): pacientes en \ntratamiento con buprenorfina/naloxona sublingual que presentan problemas de adherencia al tratamiento o no est\u00e1n \nadecuadamente estabilizados.  \n-El psiquiatra prescribe a los pacientes candidatos la buprenorfina ILP en el programa inform\u00e1tico. Aparece por defecto \ncomo \u201cNo Dispensable en Farmacia (NDF)\u201d y una ventana en la que el psiquiatra debe indicar si se trata de un paciente no \nestabilizado o con problemas de adherencia a buprenorfina/naloxona.  \n-El psiquiatra solicita al Servicio de Farmacia, a trav\u00e9s de un formulario online, el tratamiento para cada paciente. \n-El farmac\u00e9utico comprueba que el paciente cumple los criterios establecidos y valida la prescripci\u00f3n. A continuaci\u00f3n, \ncataloga la buprenorfina ILP en el botiqu\u00edn del Centro de Salud Mental (CSM) correspondiente para que el f\u00e1rmaco pueda \nser solicitado por la v\u00eda habitual.  \n-El pedido de buprenorfina ILP se realizar\u00e1 la semana previa a la administraci\u00f3n del f\u00e1rmaco, con el objetivo de no \nacumular stock en los CSM. Adem\u00e1s, debe ser registrada la administraci\u00f3n en el programa inform\u00e1tico.  \n-El Servicio de Farmacia registra todos los pacientes en tratamiento con buprenorfina ILP as\u00ed como los datos necesarios \npara llevar a cabo la dispensaci\u00f3n (CSM, dosis y frecuencia de administraci\u00f3n, fecha de \u00faltima dispensaci\u00f3n y de \nadministraciones registradas por enfermer\u00eda).\nIMPLANTACI\u00d3N\nSe inici\u00f3 en mayo de 2021\ufffd\nRESULTADOS\nDesde mayo de 2021 hasta abril de 2022, 4 pacientes (3 mujeres y 1 hombre) han iniciado tratamiento con buprenorfina \nILP . La media de edad es de 48,75 \u00b1 13,67 a\u00f1os y la duraci\u00f3n media de tratamiento ha sido de 43,6 \u00b1 2,85 semanas. Se \nhan administrado todas las dosis correspondientes a los 4 pacientes, lo que supone una adherencia total al tratamiento.  \nDestacar la comodidad para el paciente, al que se administra la medicaci\u00f3n en el CSM sin tener que recogerla \npreviamente en ning\u00fan Servicio de Farmacia.\nLIMITACIONES\nEl registro y actualizaci\u00f3n de las dispensaciones en farmacia conlleva una carga de trabajo adicional que actualmente es \nasumible por el peque\u00f1o n\u00famero de pacientes.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nCircuito aplicable a todos los servicios de Farmacia que env\u00edan buprenorfina ILP a los CSM, por tratarse de un f\u00e1rmaco de \nuso hospitalario.\nCLASIFICACI\u00d3N: ADHERENCIA\n1295. DISE\u00d1O, IMPLANTACI\u00d3N Y RESULTADOS PRELIMINARES DE UN PROTOCOLO PARA IDENTIFICAR Y \nMEJORAR LA ADHERENCIA EN PACIENTES CON TERAPIA ANTIRRETROVIRAL. \nAUTORES\nD\u00cdAZ SU\u00c1REZ, L; L\u00d3PEZ ESCOZ, R; S\u00c1NCHEZ Y\u00c1\u00d1EZ, E; MOYA CARMONA, I\nHOSPITAL VIRGEN DE LA VICTORIA \ufffd COLONIA DE STA INES, S/N M\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\nDescribir el dise\u00f1o, implantaci\u00f3n y resultados preliminares del protocolo para identificar pacientes VIH no adherentes al trata-\nmiento antirretroviral(TAR) y mejorar la adherencia al mismo mediante estrategias de atenci\u00f3n farmac\u00e9utica(AF).487MEJORAS ESPERADAS\nMejorar la adherencia al TAR, ya que la falta de esta sigue siendo la principal causa de fracaso terap\u00e9utico en esta \npoblaci\u00f3n\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nEl protocolo fue elaborado por un equipo multidisciplinar siguiendo las recomendaciones del Plan Nacional del SIDA, \nSEFH y GESIDA. La revisi\u00f3n de los resultados se realiz\u00f3 revisando la historia cl\u00ednica electr\u00f3nica de los pacientes. \nPara el dise\u00f1o del protocolo fueron necesarias tres reuniones del equipo multidisciplinar. Se definieron los factores de \nriesgo(FR) de mala adherencia y las intervenciones farmac\u00e9uticas(IF) a realizar. Etapas:  \n1.Identificaci\u00f3n de pacientes no adherentes por: personal t\u00e9cnico, m\u00e9dico y/o farmac\u00e9utico mediante registros de \ndispensaci\u00f3n, antecedentes de abandono voluntario o por la presencia de FR de mala adherencia.  \n2.Se registrar\u00e1n en el momento de inclusi\u00f3n del paciente y en visitas de seguimiento: carga viral(CV), CD4, TAR prescrito, \npresencia de polimedicaci\u00f3n, \u00edndice de complejidad del tratamiento, presencia de pluripatolog\u00eda, nivel CMO, tasa \nde posesi\u00f3n de la medicaci\u00f3n, cuestionarios SMAQ(TAR), Morinsky-Green(tratamiento domiciliario),los FR de mala \nadherencia e IFs planteadas.  \n3.Seguimiento farmacoterap\u00e9utico: La AF(presencial, telefarmacia, telefarmacia+presencial)y la frecuencia de la misma es \nindividualizada en funci\u00f3n de las caracter\u00edsticas del paciente basadas en la estratificaci\u00f3n de pacientes seg\u00fan modelo CMO.  \n4.El paciente se considerar\u00e1 adherente cuando alcance CV indetectable y sea adherente seg\u00fan SMAQ y Morinsky-Green y \nadquiera compromiso e implicaci\u00f3n con su estado de salud y tratamiento(paciente activado-cuestionario PAM).\nIMPLANTACI\u00d3N\nDiciembre 2021\nRESULTADOS\nHasta Abril 2022 se han incluido 39 pacientes. En el momento de la inclusi\u00f3n, la CV media(n=25)era de 1469 copias y CD4 \nmedios(n=25)181,14 pacientes no ten\u00edan anal\u00edtica reciente en el momento de la inclusi\u00f3n en el programa. Un23% son \npolimedicados, el 31% son pluripatol\u00f3gicos, CMO1:21%, CMO2:56%, CMO3:23%, el62% ten\u00edan una tasa de posesi\u00f3n de \nmedicaci\u00f3n menor del 90%\ufffd  \nProfesionales que identifican a los pacientes: m\u00e9dico12%, farmac\u00e9utico56%, t\u00e9cnico de farmacia32%. Los FR de \nmala adherencia fueron: problemas de accesibilidad al centro sanitario12%(3), consumo activo de drogas28%(7), \nconsumo de alcohol 20%(5), baja percepci\u00f3n autoeficacia 16%(4), ausencia de soporte social/familiar 20%(5) , nivel \nsocioecon\u00f3mico 36%(9), bajo nivel de educaci\u00f3n 28%(7), temor efectos adversos (EA)12%(3), comorbilidad psiqui\u00e1trica \n16%(4), desconocimiento sobre la enfermedad 4%(1), edades extremas 8%(2), hostilidad hacia los profesionales 4%(1), \nintrusividad en el estilo de vida 24%(6), vivienda inestable 8%(2).  \nEn cuanto a las IFs, se realiz\u00f3 en todos los pacientes: educaci\u00f3n sobre VIH, TAR y adherencia; motivaci\u00f3n(activaci\u00f3n) del \npaciente, planificaci\u00f3n de las sucesivas visitas, negociaci\u00f3n y consenso del plan farmacoterap\u00e9utico con el paciente y \nrevisi\u00f3n de posibles interacciones. Otras IFs realizadas: soporte emocional/conductual mediante una red comunitaria o \nde entidades no gubernamentales, consejo sobre el manejo de EA y propuesta de cambio de TAR. \nTipo de seguimiento farmacoterap\u00e9utico: presencial11%, telefarmacia16%, telefarmacia+presencial73%. Un15% de \npacientes(6) se consideran actualmente adherentes al tratamiento, a un5%(2) se le ha perdido el seguimiento y el resto \nsigue incluido en el programa\ufffd\nLIMITACIONES\nBajo n\u00famero de muestra.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl protocolo desarrollado es adaptable a cualquier otro servicio de farmacia.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n209. IMPLANTACI\u00d3N DE UNA TELECONSULTA DE PRE-INGRESO EN PACIENTES CON CIRUG\u00cdA VASCULAR \nPROGRAMADA \nAUTORES\nBLANCO DORADO, S; VARELA REY , I; ESTEBAN CARTELLE, H; SEMPERE SERRANO, P; CAJADE PASCUAL, F; ZARRA \nFERRO, I\nCOMPLEJO HOSPITALARIO UNIVERSITARIO DE SANTIAGO. CHOUPANA, S/N SANTIAGO DE COMPOSTELA. A CORU\u00d1A\nOBJETIVOS\nLos errores con medicamentos representan una de las principales causas de incidentes y eventos adversos (EA) durante \nel periodo perioperatorio. El correcto manejo de la medicaci\u00f3n cr\u00f3nica adquiere un papel relevante en la prevenci\u00f3n de \nestos errores. El objetivo de este proyecto fue implantar una consulta telef\u00f3nica farmac\u00e9utica de pre-ingreso en pacientes \ncon cirug\u00eda vascular (CV) programada.\nMEJORAS ESPERADAS\nCon esta consulta se pretende evitar errores de medicaci\u00f3n en el perioperatorio, EA asociados y en \u00faltima instancia evitar \nla cancelaci\u00f3n de la cirug\u00eda por motivos relacionados con la medicaci\u00f3n cr\u00f3nica del paciente. Se pretende mejorar la \ncalidad asistencial y el uso seguro de medicamentos\ufffd488DISE\u00d1O CIRCUITO Y ETAPAS\nSe trata de un programa prospectivo, multidisciplinar e integral dise\u00f1ado en colaboraci\u00f3n con el Servicio de CV. Se \nconsideraron pacientes candidatos todos aquellos con una cirug\u00eda programada con ingreso hospitalario.  \n1\ufffd Revisi\u00f3n diaria de ingresos programados\ufffd Los pacientes son citados en la agenda electr\u00f3nica de Consultas Externas con \nuna semana de antelaci\u00f3n\ufffd  \n2. Consulta telef\u00f3nica Farmac\u00e9utica:  \n1. Entrevista farmacoterap\u00e9utica:  \ni\ufffd Revisi\u00f3n de alergias  \nii. Revisi\u00f3n de medicaci\u00f3n domiciliaria, terapias alternativas, medicaci\u00f3n de dispensaci\u00f3n hospitalaria o sin receta.  \niii. Revisi\u00f3n de manejo de anticoagulaci\u00f3n y antiagregaci\u00f3n  \n2. Registrar en la historia cl\u00ednica la consulta con el listado de medicaci\u00f3n domiciliaria revisado y recomendaciones con \nrespecto al manejo periquir\u00fargico de la medicaci\u00f3n.\nIMPLANTACI\u00d3N\n1. Desarrollo del proyecto y aprobaci\u00f3n del CEIC (diciembre 2020-enero 2021). \n2. Difusi\u00f3n del proyecto entre personal m\u00e9dico y enfermer\u00eda del Servicio de CV y Farmacia (Enero 2021). \n3. Inicio del proyecto e inclusi\u00f3n de pacientes: Febrero 2021-actualidad  \n4. An\u00e1lisis de los resultados y difusi\u00f3n: Mayo 2022\nRESULTADOS\nEn abril de 2022 se han realizado 55 consultas telef\u00f3nicas de pre-ingreso. La mayor\u00eda fueron hombres (80%). La edad \nmedia fue 71 a\u00f1os (48-89). El 17% de los pacientes consultados presentaron alguna alergia (betalactamicos, medios de \ncontraste, y AAS fueron las m\u00e1s habituales). La duraci\u00f3n media del ingreso fue de 6,9 d\u00edas. Con respecto a la medicaci\u00f3n \ncr\u00f3nica de los pacientes, el promedio de medicamentos por paciente fue de 8,73 (2-18), con un alto porcentaje de \nmedicamentos cr\u00f3nicos de alto riesgo: hipoglucemiantes (58,5%), heparinas o anticoagulantes orales ( 51,2%), opi\u00e1ceos \n(19,5%)e insulinas (14.6%). Se repas\u00f3 el manejo de la anticoagulaci\u00f3n y antiagregaci\u00f3n en los pacientes tratados con \nanticoagulantes (29,1%) y antiagregantes distintos a AAS (29,1%) . Se revis\u00f3 la necesidad de dosis de estr\u00e9s de corticoides \nen los pacientes tratados de forma cr\u00f3nica (5,5%). Se comprob\u00f3 que el paciente tenia claro las indicaciones relacionadas \ncon el manejo de anticoagulaci\u00f3n/antiagregaci\u00f3n. Se dej\u00f3 registrada la consulta en la historia cl\u00ednica del paciente. Desde \nel inicio del proyecto no se cancel\u00f3 ninguna cirug\u00eda programada por motivos relacionados con la medicaci\u00f3n del paciente.\nLIMITACIONES\nNecesidad de recursos personales para realizar la consulta telem\u00e1tica.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste proyecto es extensible a cualquier Servicio de Farmacia con disponibilidad de recursos y que persiga objetivos de \ncontinuidad asistencial y uso seguro de medicamentos.\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n324. IMPLANTACI\u00d3N DE LA ATENCI\u00d3N FARMAC\u00c9UTICA EN UNA UNIDAD DE HOSPITALIZACI\u00d3N A \nDOMICILIO PEDI\u00c1TRICA \nAUTORES\nRANZ ORTEGA, P; AG\u00daNDEZ REIGOSA, B; CABRERA L\u00d3PEZ, I; GONZALEZ ANDR\u00c9S, D; AG\u00dc\u00cd CALLEJAS, AM; POZAS DEL \nRIO, M; ONTENIENTE GONZ\u00c1LEZ, A\nHOSPITAL INFANTIL UNIVERSITARIO NI\u00d1O JESUS. AV . MEN\u00c9NDEZ PELAYO, 65 MADRID. MADRID\nOBJETIVOS\n\u2022 Optimizar el manejo farmacoterap\u00e9utico \n\u2022 Minimizar los posibles errores de medicaci\u00f3n (EM) derivados de la prescripci\u00f3n y la administraci\u00f3n en el domicilio  \n\u2022 Educaci\u00f3n sanitaria para el uso adecuado de medicamentos dirigida al paciente, cuidador y profesionales sanitarios \n\u2022 Optimizar recursos econ\u00f3micos y personales\nMEJORAS ESPERADAS\n\u2022 Impacto cl\u00ednico: uso eficiente y seguro del medicamento en el domicilio  \n\u2022 Impacto econ\u00f3mico: evitar visitas sanitarias injustificadas por estabilidad limitante de mezclas intravenosas\nDISE\u00d1O CIRCUITO Y ETAPAS\nEstudio retrospectivo y descriptivo. Proyecto iniciado en octubre de 2020, y se analizan los \u00faltimos 12 meses de actividad.  \n \nEn una primera fase se implant\u00f3 el programa Atenci\u00f3n farmac\u00e9utica b\u00e1sica para todos los pacientes ingresados en la \nUnidad de Hospitalizaci\u00f3n a Domicilio (UHAD), que consist\u00eda en:  \n\u2022 Seguimiento diario farmacoterap\u00e9utico del paciente y participaci\u00f3n en las sesiones multidisciplinares (enfermer\u00eda, \npediatras y infect\u00f3loga pedi\u00e1trica) \n\u2022 Conciliaci\u00f3n del tratamiento cr\u00f3nico \n\u2022 Validaci\u00f3n farmac\u00e9utica \n\u2022 Especificar en la prescripci\u00f3n electr\u00f3nica recomendaciones en el manejo de la medicaci\u00f3n relacionados con la \npreparaci\u00f3n, administraci\u00f3n, conservaci\u00f3n, caducidad o manipulaci\u00f3n del f\u00e1rmaco en el paciente pedi\u00e1trico 489\u2022 An\u00e1lisis de los EM  \n\u2022 Redise\u00f1ar los diferentes circuitos de dispensaci\u00f3n  \n\u2022 Elaboraci\u00f3n centralizada de mezclas intravenosas en el Servicio de Farmacia con el objetivo de aumentar la seguridad y \nla estabilidad microbiol\u00f3gica en: inmunodeprimidos, bacteriemias asociadas a cat\u00e9ter o pacientes con estabilidad cl\u00ednica \nque no requieren diariamente de visitas sanitarias.  \n \nEn una segunda fase, se ha desarrollado el programa de Atenci\u00f3n farmac\u00e9utica avanzada, centrada en el paciente, \nespecialmente aquel con alta complejidad farmacol\u00f3gica.Actualmente est\u00e1 en fase piloto. Consiste en:  \n \n\u2022 Dise\u00f1o de la aplicaci\u00f3n Access HOMED\u00ae para la elaboraci\u00f3n de un Informe Farmacoterap\u00e9utico Personalizado (IFP) \nque contiene: prescripci\u00f3n farmacol\u00f3gica y recomendaciones para la preparaci\u00f3n, administraci\u00f3n, conservaci\u00f3n, \nmanipulaci\u00f3n, eliminaci\u00f3n, y adquisici\u00f3n en situaciones especiales  \n\u2022 Repasar los aspectos m\u00e1s importantes del IFP con el cuidador principal o paciente al inicio y tras cada actualizaci\u00f3n  \n\u2022 Monitorizar la adherencia \n\u2022 Educaci\u00f3n sanitaria: \n- Tr\u00edpticos de informaci\u00f3n sobre la preparaci\u00f3n de medicamentos que requieren de su preparaci\u00f3n en el momento por \nestabilidad reducida  \n- Hojas de informaci\u00f3n farmacoterap\u00e9utica sobre los medicamentos m\u00e1s relevantes\nIMPLANTACI\u00d3N\nSe inici\u00f3 en octubre 2020,aunque el registro electr\u00f3nico de las intervenciones farmac\u00e9uticas no se implant\u00f3 hasta abril \n2021\nRESULTADOS\nSe revisaron 586 pacientes y se realizaron 147 IF(25%).Durante la conciliaci\u00f3n del tratamiento cr\u00f3nico, se realizaron 1.5 \nIF/paciente. Alto grado de aceptaci\u00f3n (82%)  \n \nLas m\u00e1s relevantes estaban relacionadas con la efectividad (44%), seguidas de las realizadas durante la conciliaci\u00f3n (20%), \nseguridad (16%), monitorizaci\u00f3n farmacocin\u00e9tica (13% y educaci\u00f3n sanitaria (7%).  \n \nCasi el 71% fueron significativas y muy significativas (11%),fundamentalmente relacionadas con la indicaci\u00f3n (66,7%) y \npertenec\u00edan al grupo ATC: J (60%). \n \nDurante este periodo se han elaborado en el Servicio de Farmacia 1968 mezclas,evitando 783 d\u00edas de desplazamiento al \npersonal de enfermer\u00eda,teniendo en cuenta su coste/hora, ha supuesto un ahorro econ\u00f3mico de 6849\u20ac.\nLIMITACIONES\n\u2022 Infranotificaci\u00f3n de las IF,por las dificultades t\u00e9cnicas en su registro \n\u2022 Ahorro econ\u00f3mico de las mezclas:no se han podido excluir las visitas justificadas ni se han incluido gastos de \ndesplazamiento\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa aplicaci\u00f3n HOMED\u00ae es aplicable a cualquier SF que desee elaborar informes farmacoterap\u00e9utico personalizados.El \nproyecto es aplicable a cualquier hospital con Unidad de Hospitalizaci\u00f3n a Domicilio\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n416. IMPLANTACI\u00d3N DE UNA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA PREVIA A LA ADMINISTRACI\u00d3N \nDE CILGAVIMAB/TIXAGEVIMAB \nAUTORES\nDOMINGUEZ GUERRA, M; BRANDARIZ NU\u00d1EZ, D; FEIJOO VILANOVA, P; LUACES , A; MARTIN HERRANZ, MI\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nDise\u00f1ar e implantar un programa de atenci\u00f3n farmac\u00e9utica previo al proceso farmacoterap\u00e9utico de utilizaci\u00f3n de \nCILGAVIMAB/TIXAGEVIMAB/(C-T).\nMEJORAS ESPERADAS\n- Garantizar la correcta selecci\u00f3n de pacientes candidatos a recibir C-T, de acuerdo con el orden de prioridades \nestablecido por la AEMPS\ufffd  \n- Reforzar la informaci\u00f3n que recibe el paciente sobre C-T. \n- Evitar posibles efectos adversos derivados de la administraci\u00f3n del mismo\nDISE\u00d1O CIRCUITO Y ETAPAS\nFruto de la necesidad generada tras la autorizaci\u00f3n de C-T, como medicamento en situaciones especiales, se instaura \nuna consulta presencial destinada a la atenci\u00f3n farmac\u00e9utica de pacientes que van a recibir este tratamiento. Para poder \nllevar a cabo esta actividad se obtienen los recursos humanos y materiales necesarios, incluido un espacio para una \nconsulta presencial donde se ubica el farmac\u00e9utico.  490* Dise\u00f1o circuito de atenci\u00f3n al paciente y etapas: \n- Servicio de Farmacia Hospitalaria(SFH):  \n\u2022 Recibir la agenda de citaci\u00f3n con los pacientes candidatos a recibir C-T, dos d\u00edas antes de la fecha prevista para la \nadministraci\u00f3n\ufffd  \n\u2022 Emitir la solicitud de dosis de C-T a trav\u00e9s del coordinador de vacunaci\u00f3n COVID-19; dirigida a la Direcci\u00f3n General de \nSalud P\u00fablica  \ny al SFH del propio hospital para la dispensaci\u00f3n.  \n -Consulta enfermer\u00eda Medicina Preventiva (EMP):  \n\u2022 Realizar test ant\u00edgenos previo a la administraci\u00f3n del tratamiento \n\u2022 Entregar el documento de consentimiento informado para la administraci\u00f3n de C-T  \n  - Consulta atenci\u00f3n farmac\u00e9utica: \n\u2022 Comprobar la indicaci\u00f3n del tratamiento en los pacientes seleccionados\ufffd  \n\u2022 Entrevistar al paciente: historial de alergias medicamentosas, antecedentes de enfermedad cardiovascular, tratamiento \nactivo con  \nanticoagulantes y cifra de plaquetas.  \n\u2022 Explicar el tratamiento: mecanismo de acci\u00f3n, administraci\u00f3n y principales efectos adversos\ufffd  \n\u2022 Registrar la informaci\u00f3n en la H\u00aaCl\u00aa del paciente siguiendo la metodolog\u00eda SOAP  \n- Consulta EMP:  \n\u2022 Administrar tratamiento y vigilar al paciente durante los 30 minutos siguientes\ufffd\nIMPLANTACI\u00d3N\nLa implantaci\u00f3n se llev\u00f3 a cabo el 07/04/2022, con la administraci\u00f3n de la primera dosis de C-T en nuestro hospital, \nsiguiendo las recomendaciones de la Comisi\u00f3n de Salud P\u00fablica para seleccionar los pacientes candidatos.\nRESULTADOS\nDesde el 07/04/2022 hasta el 07/05/2022 se atendieron a un total de 48 pacientes (20 mujeres). El 50% eran receptores \nde trasplante de \u00f3rgano s\u00f3lido con tratamiento inmunosupresor;el 41.67% hab\u00eda recibido tratamiento con rituximab en \nlos 3-6 meses previos a la primovacunaci\u00f3n; el 2.08% presentaba alg\u00fan tipo de inmunodeficiencia primaria y el 6.25% \neran pacientes con riesgo muy alto de enfermedad grave tras infecci\u00f3n por SARS-CoV-2 en tratamiento con terapias \ninmunosupresoras. Se detect\u00f3 un total de 7 pacientes con plaquetopenia y/o anticoagulados, advirtiendo a enfermer\u00eda \nde la necesidad de adoptar medidas de prevenci\u00f3n para la administraci\u00f3n, debido al mayor riesgo de sangrado. A fecha \ndel 08/05/2022 ninguno de los pacientes hab\u00eda tenido que acudir a urgencias por efectos adversos relacionados con \nel tratamiento. Obtuvimos el consentimiento informado de todos los pacientes para realizar estudios retrospectivos \nrelacionados con C-T en el SFH.\nLIMITACIONES\nEl periodo de an\u00e1lisis y el n\u00famero de pacientes incluidos, dada la reciente autorizaci\u00f3n del medicamento.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a cualquier SFH que pueda coordinar su actividad con el Servicio de Medicina Preventiva para la administraci\u00f3n \nde C-T\nCLASIFICACI\u00d3N: ATENCI\u00d3N FARMAC\u00c9UTICA EN \u00c1REAS M\u00c9DICAS Y QUIR\u00daRGICAS\n785. SEGUIMIENTO MULTIDISCIPLINAR DEL PACIENTE CON MIGRA\u00d1A TRATADO CON ANTICUERPOS \nMONOCLONALES ANTI-CGRP . DESCRIPCI\u00d3N, EVALUACI\u00d3N Y REDISE\u00d1O DEL PROCESO. GESTI\u00d3N \nEXPECTATIVAS. \nAUTORES\nPEREZ RECHE, C; MAS SALA, N; ALONSO CASTELL, P; CANO LOPEZ, M; RAMOS PRADA, M; BRAVO MONTERO, I; SALA \nVILAJOSANA, N\nHOSPITAL DE SANT JOAN DE D\u00c9U. DR. JOAN SOLER, 1-3 MANRESA. BARCELONA\nOBJETIVOS\nDescribir, evaluar y redise\u00f1ar el proceso asistencial del manejo del paciente con migra\u00f1a tratado con anticuerpos \nmonoclonales anti-CGRP con la finalidad de optimizar y mejorar el seguimiento y tratamiento del paciente en un hospital \nuniversitario\ufffd\nMEJORAS ESPERADAS\nObtener datos en vida real de efectividad y tolerabilidad para evaluar si el f\u00e1rmaco elegido como primera opci\u00f3n cubre \ncon las expectativas esperadas o es necesario incorporar otros anticuerpos monoclonales anti-CGRP (AMC anti-CGRP) que \naporten un valor a\u00f1adido en el manejo de estos pacientes. \nAdecuar los tempos de las visitas multidisciplinares de seguimiento propuestas para optimizar la toma de decisiones \nreferente a la respuesta y tolerabilidad al tratamiento y las acciones a realizar.\nDISE\u00d1O CIRCUITO Y ETAPAS\n1. Revisi\u00f3n de la evidencia cient\u00edfica disponible de estos f\u00e1rmacos.  \n2. Evaluaci\u00f3n de la mejor alternativa terap\u00e9utica para iniciar el manejo migra\u00f1a refractaria \n3. Introducci\u00f3n en Gu\u00eda farmacoterap\u00e9utica (GFT) un AMC anti-CGRP .  4914. Dise\u00f1o seguimiento multidisciplinar:  \n- Visita m\u00e9dica (VM) inicial: valoraci\u00f3n pacientes candidatos seg\u00fan dictamen del CatSalut y registro de variables basales \n(media  \nmigra\u00f1as/mes, riesgo cardiovascular,escala discapacidad \u201cHIT\u201d, tratamientos profil\u00e1cticos)  \n- Visita farmac\u00e9utica(VF) inicial: Explicaci\u00f3n tratamiento, dosis y pauta. Manejo efectos adversos y autoadministraci\u00f3n. \nRefuerzo de  \nadherencia. Cumplimentaci\u00f3n adecuada del diario de cefaleas.  \n- VF seguimiento mes 1: registro n\u00famero migra\u00f1as seg\u00fan diario. Valoraci\u00f3n y registro de tolerabilidad.  \n- VM seguimiento mes 3-6-12: valorar seguir el tratamiento actual, stop o switch.  \n5. Gesti\u00f3n de las expectativas terap\u00e9uticas seg\u00fan resultados obtenidos.  \n- Valoraci\u00f3n de incluir otros AMC anti-CGRP en GFT.  \n- Posicionamiento de estos mediante algoritmo de decisi\u00f3n.  \n7. Evaluaci\u00f3n circuito del seguimiento multidisciplinar y redise\u00f1o.\nIMPLANTACI\u00d3N\n1. Introducci\u00f3n de Galcanezumab en GFT. \n2. Creaci\u00f3n de una agenda m\u00e9dica y una farmac\u00e9utica \u201cAMC anti-CGRP\u201d semanal  \n3\ufffd Selecci\u00f3n de pacientes candidatos al tratamiento \n4\ufffd Inicio seguimiento del paciente con las visitas establecidas  \n5. Valoraci\u00f3n multidisciplinar y toma de decisiones seg\u00fan respuesta y tolerabilidad  \n6. Reevaluaci\u00f3n de inclusi\u00f3n en GFT otros AMC anti-CGRP seg\u00fan resultados.  \n7. Introducci\u00f3n de fremanezumab y erenumab; dise\u00f1o del correspondiente algoritmo de decisi\u00f3n del arsenal terap\u00e9utico \ndisponible\ufffd\nRESULTADOS\nDesde diciembre 2020 hasta actualidad han iniciado tratamiento 86pacientes, 5hombres (6%) y 81mujeres (94%), edad \nmedia 47\ufffd  \nEl primer tratamiento incluido en GFT mostr\u00f3 buen perfil de seguridad y tolerabilidad. El efecto adverso leve m\u00e1s \nfrecuente observado fue estre\u00f1imiento\ufffd  \nSe ha observado que en un subgrupo de pacientes la efectividad no ocurre de forma inmediata (primer mes), si no \ngradual consiguiendo respuesta en mes 3\ufffd  \nNo han respondido 6pacientes (7%) y 1paciente present\u00f3 un efecto adverso importante requiriendo switch.  \nTras observaci\u00f3n de estos resultados: \n- se decide incluir en GFT los AMC anti-CGRP disponibles: fremanezumab (diferente posolog\u00eda y seguridad) y erenumab \n(diana  \nterap\u00e9utica diferente). \n- la VF mes 1 no ha aportado valor a\u00f1adido en el seguimiento del paciente debido al buen perfil de seguridad de estos \nf\u00e1rmacos y la  \nrespuesta retardada observada. Esto ha permitido optimizaci\u00f3n de las visitas siendo el actual modelo:Visitas iniciales \nVM+VF,  \nseguimiento VF 3mes y VM 6-12mes.\nLIMITACIONES\nNo se ha detectado una limitaci\u00f3n destacable, si se dispone de los suficientes recursos.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a cualquier Servicio de Farmacia que realice atenci\u00f3n farmac\u00e9utica del tratamiento AMC anti-CGRP .\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n248. PROGRAMA DE CONCILIACI\u00d3N DE LA MEDICACI\u00d3N AL ALTA HOSPITALARIA A PERSONAS \nINSTITUCIONALIZADAS EN CENTROS SOCIOSANITARIOS \nAUTORES\nMARTIARENA AYESTARAN, A; MART\u00cdNEZ ARRECHEA, S; BARRAL JUEZ, I; LANDA ALBERDI, J; D\u00cdAZ BURUMENDI, I; \nBACHILLER CACHO, MP\nHOSPITAL DONOSTIA-DONOSTIA OSPITALEA. P\u00ba DR. BEGUIRISTAIN, 109 DONOSTIA-SAN SEBASTI\u00c1N. GUIP\u00daZCOA\nOBJETIVOS\nEl cambio de legislaci\u00f3n de Servicios de Farmacia (SF) y Dep\u00f3sitos de Medicamentos (DM) en residencias para personas \nmayores ha modificado su modelo de funcionamiento. Los DM de 25 centros de 2 Organizaciones Sanitarias Integradas \nhan pasado a estar vinculados al SF del hospital de referencia de la red p\u00fablica. Este cambio contempla la realizaci\u00f3n de \nAtenci\u00f3n Farmac\u00e9utica que, entre otras actividades, implica realizar conciliaci\u00f3n de la medicaci\u00f3n (CM) en las transiciones \nasistenciales. Se trata de implantar un programa de CM de pacientes dados de alta del hospital cuyo destino es un centro \nsociosanitario (CSS) vinculado al SF.492MEJORAS ESPERADAS\nMejorar, con la intervenci\u00f3n del farmac\u00e9utico especialista (FE), la informaci\u00f3n farmacoterap\u00e9utica recogida en el informe \nde alta, favoreciendo la comunicaci\u00f3n entre farmacia, CSS y servicios m\u00e9dicos hospitalarios.  \nFomentar la actualizaci\u00f3n del tratamiento en el programa de prescripci\u00f3n electr\u00f3nica en el momento del alta.\nDISE\u00d1O CIRCUITO Y ETAPAS\nInclusi\u00f3n en la pr\u00e1ctica cl\u00ednica diaria de un programa de CM de pacientes dados de alta del hospital con un ingreso \nsuperior a 24 horas y cuyo destino es un CSS. Se hace una prueba piloto de 2 meses en un CSS y despu\u00e9s se extiende al \nresto\ufffd  \nDiariamente el FE revisa el listado de ingresos en el hospital de pacientes procedentes de los CSS. Adem\u00e1s, \nsemanalmente, la unidad de traslados del hospital env\u00eda el listado de altas a CSS previstas. El FE:  \n- revisa el tratamiento activo (prescripciones cr\u00f3nicas, agudas y a demanda) para detectar discrepancias entre la \nmedicaci\u00f3n prescrita y la recogida en el informe de alta\ufffd \n- comunica y resuelve las discrepancias justificadas no documentadas y las no justificadas (DNJ) con el m\u00e9dico de atenci\u00f3n \nhospitalaria.  \n- registra la actividad y redacta un informe de conciliaci\u00f3n en la historia cl\u00ednica electr\u00f3nica del paciente.  \n- comunica el informe de conciliaci\u00f3n al personal m\u00e9dico de la residencia.\nIMPLANTACI\u00d3N\nEn una primera fase se realizan reuniones informativas al personal m\u00e9dico y de enfermer\u00eda de los CSS, as\u00ed como \nal personal m\u00e9dico de los servicios implicados. Se realiza una prueba piloto en un CSS de junio a agosto de 2021. \nComprobada la factibilidad, se ampl\u00eda al resto de CSS.\nRESULTADOS\nHasta mayo 2022 se han incluido en el programa de conciliaci\u00f3n 233 pacientes que corresponden a 270 altas \nhospitalarias. El n\u00ba medio de medicamentos conciliados por alta hospitalaria es 10,8. Se han detectado 188 discrepancias \nque requieren aclaraci\u00f3n, de las que 95 (50,5%) son DNJ. De \u00e9stas, las m\u00e1s frecuentes son: omisi\u00f3n de medicamento 28 \n(29,5%), duraci\u00f3n diferente 21 (22,1%), frecuencia diferente 15 (15,8%) y dosis diferente 13 (13,7%).\nLIMITACIONES\nObtener respuesta del m\u00e9dico hospitalario a las intervenciones de discrepancias detectadas en el momento del alta del \npaciente a la residencia\ufffd  \nFalta de conocimiento del funcionamiento, por parte del prescriptor, del circuito de prescripci\u00f3n-dispensaci\u00f3n \nautomatizada y, por tanto, de la relevancia y repercusiones de la no actualizaci\u00f3n de la prescripci\u00f3n electr\u00f3nica.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nA todos los SF que trabajen de forma directa con CSS y que dispongan de programa de prescripci\u00f3n e historia cl\u00ednica \nelectr\u00f3nica implantada en todos los niveles asistenciales, incluido los CSS\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n282. INTEGRACI\u00d3N DE UN FARMAC\u00c9UTICO EN LOS EQUIPOS DE ATENCI\u00d3N PRIMARIA \nAUTORES\nCAMPABADAL PRATS, C; SALOM GARRIGUES, C; CONDE GINER, S; CASTILLO PALOMARES, L; MARCO BAS, N; \nBEJARANO ROMERO, F; CANADELL VILARRASA, L\nHOSPITAL UNIVERSITARI JOAN XXIII DE TARRAGONA. DOCTOR MALLAFR\u00c9 GUASCH, 4 TARRAGONA. TARRAGONA\nOBJETIVOS\nIntegrar la figura del Farmac\u00e9utico cl\u00ednico como miembro del Equipo de Atenci\u00f3n Primaria (EAP)\nMEJORAS ESPERADAS\nAdecuaci\u00f3n de los tratamientos en criterios de seguridad, eficacia y eficiencia traducidos en resultados en salud para el \npaciente\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O: \nRevisi\u00f3n integral del plan farmacoterap\u00e9utico de los pacientes asignados a m\u00e9dicos de familia. Se prioriza la revisi\u00f3n en \naquellos pacientes con alertas de seguridad e indicaci\u00f3n inadecuada del f\u00e1rmaco en base a los indicadores de calidad de \nla prescripci\u00f3n institucionales.  \nLas propuestas realizadas son valoradas junto con el m\u00e9dico y posteriormente registradas en la historia cl\u00ednica del \npaciente\ufffd  \nEl m\u00e9dico es el responsable de informar al paciente de los motivos de los cambios realizados en el plan \nfarmacoterp\u00e9utico.  \nSe incluyen todos los pacientes asignados a cada m\u00e9dico sin restricci\u00f3n.  \nCIRCUITO Y ETAPAS: \n1. Aprobaci\u00f3n del proyecto por el Comit\u00e9 Ejecutivo de la Direcci\u00f3n de Atenci\u00f3n Primaria.  \n2\ufffd Aprobaci\u00f3n del proyecto por los directores de los EAP  \n3. Selecci\u00f3n de los equipos participantes en el proyecto piloto \n4. Presentaci\u00f3n del proyecto a los facultativos en los EAPs participantes  \n5. Organizaci\u00f3n de las reuniones con cada facultativo, adapt\u00e1ndose el farmac\u00e9utico a cada equipo participante493IMPLANTACI\u00d3N\nParticipan en el proyecto piloto 3 EAPs, el proyecto se inicia con fecha 18/03/2022, se presentan resultados hasta \n1/05/2022\ufffd  \nCada EAP se organiza de distinta forma:  \nEAP 1: viernes de 8:00 a 10:30 con agenda cerrada por parte de los m\u00e9dicos \nEAP 2: viernes de 11:00 a 15:00 sin agenda cerrada por parte de los m\u00e9dicos. Comunicaci\u00f3n v\u00eda chat para programar cita \nEAP 3: se asiste 4 d\u00edas/ semana de 8:00 a 11:00 con agenda cerrada por parte de los m\u00e9dicos\nRESULTADOS\nSe han realizado 395 revisiones de tratamiento de 338 pacientes (1.17 intervenciones por paciente).  \nEstas revisiones corresponden con indicadores de selecci\u00f3n de f\u00e1rmacos (61.01%), indicadores de seguridad (27.87%) y \nconsultas terap\u00e9uticas (11.14%) \nLos principales grupos terap\u00e9uticos intervenidos han sido antidiab\u00e9ticos orales (32.4%), hipolipemiantes (23.8%), \nantidepresivos (10.63%), AINE (10.13%), antiresortivos (4.81%), antihipertensivos (4.05%), otros (8.35%).  \nEl grado de aceptaci\u00f3n de las propuestas fue de un 97\ufffd42% y el grado de implementaci\u00f3n del 55\ufffd56%\ufffd El grado de \nimplementaci\u00f3n corresponde casi en su totalidad a la implementaci\u00f3n en el momento de realizar la propuesta, pasados 3 \nmeses se revisar\u00e1n aquellas propuestas en las que se ha considerado la necesidad de realizar pruebas complementarias o \ncomentar el cambio previamente con el paciente\ufffd  \nLas propuestas realizadas fueron suspender f\u00e1rmaco (59.28%), cambiar por equivalente terap\u00e9utico (20.62%), cambiar \npor otra mol\u00e9cula (7.99%), pedir control anal\u00edtico (5.41%), intensificar posolog\u00eda (3.61%), otras (3.09%)\nLIMITACIONES\nNo se disponen de resultados de indicadores sobre el efecto del proyecto en la Calidad de la prescripci\u00f3n e indicadores de \nseguridad. Los indicadores est\u00e1n definidos pero no se dispone de ellos debido a que el proyecto se acaba de iniciar y los \nindicadores se publican en diferido\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste proyecto aplica a todos los Servicios de Farmacia con la Atenci\u00f3n primaria integrada\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n352. EVALUACI\u00d3N DEL GRADO DE DESNUTRICI\u00d3N DE LOS USUARIOS DE CENTROS SOCIOSANITARIOS \nCON SERVICIO DE FARMACIA \nAUTORES\nGO\u00d1I ZAMARBIDE, O; ROS BERNAOLA, G; ROJO GARC\u00cdA, A; PELLEJERO JIMENEZ, R; AC\u00cdN GERIC\u00d3, T; SANZ ALVAREZ, \nL; ECHEVERR\u00cdA GORRITI, A; GARC\u00cdA GONZ\u00c1LEZ, P\nSERVICIO NAVARRO DE SALUD OSASUNBIDEA\nOBJETIVOS\nEl RD 1030/2006 donde se establecen los requisitos para la financiaci\u00f3n de los productos para nutrici\u00f3n enteral \ndomiciliaria, indica las condiciones y patolog\u00edas subsidiarias de financiaci\u00f3n, pero sin valorar el grado de desnutrici\u00f3n \ndel paciente. En nuestra comunidad, consideramos necesario establecer unos criterios objetivos para poder evaluar la \neficacia del tratamiento de soporte nutricional peri\u00f3dicamente para evitar que se utilice de forma indefinida y garantizar \nas\u00ed su utilizaci\u00f3n eficiente.\nMEJORAS ESPERADAS\nConocer el grado de desnutrici\u00f3n de los usuarios con soporte nutricional al inicio del tratamiento y pasados 6 meses \n(periodo m\u00e1ximo de autorizaci\u00f3n), nos permitir\u00e1 justificar y reevaluar la continuaci\u00f3n o no del tratamiento, si se solicita \nuna renovaci\u00f3n del mismo\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nUn grupo de trabajo formado por m\u00e9dicos y farmac\u00e9uticos tanto del \u00e1mbito p\u00fablico como privado trabaj\u00f3 durante los \nmeses de octubre-diciembre de 2021 en el establecimiento de los criterios de valoraci\u00f3n de la desnutrici\u00f3n.  \nEstos criterios son:  \nPorcentaje de p\u00e9rdida de peso en los \u00faltimos 3 meses ( < 5% 1 punto; 5-10% 2 puntos y > 10% 3 puntos). Concentraci\u00f3n \nde alb\u00famina s\u00e9rica (g/dl) (3,01-3,49 1 punto; 2,50-3,00 2 puntos y < 2,50 3 puntos). IMC < 75 a\u00f1os (21-23 0,5 puntos; \n18,5-20,9 1 punto y < 18,5 1,5 puntos). IMC \u226575 a\u00f1os (21-23 1 punto; 18,5-20,9 2 puntos y < 18,5 3 puntos). Per\u00edmetro \ndel brazo (cm) si no es posible valorar la p\u00e9rdida de peso en los \u00faltimos 3 meses (23-25 1 punto; 21-23,5 2 puntos y < 21 3 \npuntos).  \nLa prescripci\u00f3n de un tratamiento nutricional debe justificarse con un informe m\u00e9dico que incluya la patolog\u00eda subsidiaria \ny la puntuaci\u00f3n correspondiente. Si la puntuaci\u00f3n es \u22653 (desnutrici\u00f3n moderada-severa), se autoriza durante un m\u00e1ximo \nde 6 meses. Si se solicita una renovaci\u00f3n, se remitir\u00e1 un nuevo informe que demuestre que concurren nuevamente los \ncriterios necesarios\ufffd\nIMPLANTACI\u00d3N\nEsta informaci\u00f3n se comunic\u00f3 a todos los profesionales m\u00e9dicos y se hizo efectiva el 11 de enero de 2022 para todos los \npacientes de nuestra comunidad (institucionalizados o no).494RESULTADOS\nLos resultados obtenidos son exclusivamente referidos a los usuarios de centros sociosanitarios privados con Servicio de \nFarmacia durante los 4 meses posteriores a su puesta en marcha. Se han recibido un total de 106 informes. La puntuaci\u00f3n \nmedia por paciente fue de 4,20. La justificaci\u00f3n es una combinaci\u00f3n de los 3 criterios (% de p\u00e9rdida de peso, alb\u00famina \ns\u00e9rica e IMC) en un 71% de los informes, un 25% se justifican en base a dos criterios y solo en un 4% de los casos existe \nun \u00fanico criterio de justificaci\u00f3n. Solo el 11% de ellos recogen el per\u00edmetro del brazo en lugar de la p\u00e9rdida de peso.  \nLos criterios de p\u00e9rdida de peso, alb\u00famina s\u00e9rica e IMC son referidos de manera equiparable por una media del 85% de \nlos informes\ufffd \nSe espera que, conforme se reciban informes de continuaci\u00f3n de tratamiento, podamos valorar objetivamente el efecto \nde los dietoter\u00e1picos en los datos cl\u00ednicos de los pacientes.\nLIMITACIONES\nNo tiene\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEsta valoraci\u00f3n nutricional puede aplicarse a cualquier usuario que resida en un centro de larga estancia para evaluar la \neficacia del soporte nutricional.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n570. REVISI\u00d3N Y ADECUACI\u00d3N DE LA MEDICACI\u00d3N EN PACIENTES HOSPITALIZADOS A CONSECUENCIA \nDE UNA CA\u00cdDA. \nAUTORES\nMEDIAVILLA GARC\u00cdA, MM; LARRABEITI ETXEBARRIA, A; BLANCO GARC\u00cdA, C; QUINTANA BASTERRA, A; ARENALES \nC\u00c1CERES, P; L\u00d3PEZ DE TORRE QUEREJAZU, A; CUMBRAOS S\u00c1NCHEZ, MJ; MART\u00cdNEZ GARC\u00cdA, MD\nHOSPITAL UNIVERSITARIO ARABA (SEDE TXAGORRITXU Y SEDE SANTIAGO). CALLE JOSE ACHOTEGUI, CALLE/KALEA \nS/N VITORIA-GASTEIZ. \u00c1LAVA\nOBJETIVOS\nDise\u00f1ar e implementar un circuito para revisar y adecuar la medicaci\u00f3n de pacientes que ingresan en el hospital tras \nsufrir una ca\u00edda.\nMEJORAS ESPERADAS\nLas ca\u00eddas en las personas mayores son un importante problema de salud p\u00fablica debido a su alta prevalencia, las \nlesiones que provocan y los costes asociados a las mismas. Sus causas son a menudo multifactoriales, siendo el uso \nde f\u00e1rmacos que aumentan el riesgo de ca\u00eddas (Fall Risk Increasing Drugs, FRIDs) una de las m\u00e1s destacadas. Con esta \niniciativa se espera reducir las prescripciones de FRIDs entre las personas con riesgo de ca\u00eddas.\nDISE\u00d1O CIRCUITO Y ETAPAS\nLa Unidad de Gesti\u00f3n Sanitaria del Hospital env\u00eda diariamente un listado de los ingresos hospitalarios relacionados con \nca\u00eddas al Servicio de Farmacia (SF), donde se revisa la medicaci\u00f3n de esos pacientes y se identifican los FRIDs. Adem\u00e1s, \nse consulta la Historia Cl\u00ednica Electr\u00f3nica (HCE) para considerar si la medicaci\u00f3n tuvo relaci\u00f3n con esas ca\u00eddas. Cuando \nla medicaci\u00f3n de los pacientes es susceptible de ser optimizada, el SF contacta con el m\u00e9dico referente para proponer \nlas modificaciones terap\u00e9uticas correspondientes. Esta comunicaci\u00f3n farmac\u00e9utica-m\u00e9dico se realiza durante el periodo \nde hospitalizaci\u00f3n en el caso de ingresos a cargo de Medicina Interna (sesiones semanales conjuntas), y mediante \u201ccita \nadministrativa\u201d al M\u00e9dico de Atenci\u00f3n Primaria (MAP) cuando los pacientes ingresan a cargo de otros Servicios Cl\u00ednicos. \nEn estos casos, el MAP eval\u00faa a posteriori un informe de revisi\u00f3n de la medicaci\u00f3n adjuntado por el SF en la HCE de cada \npaciente\ufffd\nIMPLANTACI\u00d3N\nEntre el 1 de mayo de 2021 y el 1 de mayo 2022, 467 pacientes ingresaron en el hospital a consecuencia de una ca\u00edda. \nSe excluyeron 48 pacientes institucionalizados (manejo por su propio equipo cl\u00ednico), 18 pacientes que hab\u00edan ca\u00eddo en \ncontexto de enolismo o abuso de drogas, 19 pacientes en situaci\u00f3n de \u00faltimos d\u00edas o \u00e9xitus tras el ingreso, 7 pacientes \ncon ca\u00eddas por accidentes y 5 pacientes procedentes de otras organizaciones sanitarias (no aplicable nuestro circuito). Se \nrevis\u00f3 finalmente la medicaci\u00f3n de 370 pacientes.\nRESULTADOS\nSe identific\u00f3 un promedio de 2,43 FRIDs por paciente y se realizaron 115 intervenciones. El 48% de las propuestas fueron \ndeprescripciones de FRIDs, el 46% reducciones de dosis y las restantes fueron sugerencias de cambio de medicamento\ufffd \nPr\u00f3ximamente evaluaremos el impacto de nuestra pr\u00e1ctica implementada en t\u00e9rminos de intervenciones aceptadas, \nreducci\u00f3n de resultados negativos asociados a la medicaci\u00f3n y reducci\u00f3n de reingresos hospitalarios.\nLIMITACIONES\nExiste falta de consenso en el listado de f\u00e1rmacos considerados FRIDs, y a pesar de haber tratado de unificar criterios, \nresulta inevitable cierta variabilidad en las revisiones de la medicaci\u00f3n de los pacientes y recomendaciones realizadas por \nlas diferentes farmac\u00e9uticas participantes en el circuito.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nConsideramos que esta iniciativa aporta valor, ya que, puede ser reproducible en otros SF y beneficiosa para el cuidado \nde la salud de los pacientes. La revisi\u00f3n de la medicaci\u00f3n conduce a la identificaci\u00f3n no s\u00f3lo de la prescripci\u00f3n de FRIDs, 495sino tambi\u00e9n de diferentes problemas relacionados con los medicamentos: infra o sobredosificaciones, duplicidades, \nmedicamentos inapropiados en pacientes de edad avanzada, etc.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n813. ATENCION FARMAC\u00c9UTICA HOSPITALARIA A PERSONAS MAYORES QUE VIVEN EN RESIDENCIAS \n\u00bfUN OBJETIVO POSIBLE? \nAUTORES\nESTEBAN-CASADO , S; SUCH-D\u00cdAZ , A; TEJEDOR-PRADO , P; LOZANO-ROSIQUE , I; BRA\u00d1AS-BAZT\u00c1N , F; ESCOBAR-\nRODR\u00cdGUEZ , I\nHOSPITAL INFANTA LEONOR \ufffd GRAN V\u00cdA DEL ESTE, 80 MADRID \ufffd MADRID\nOBJETIVOS\nDescribir el circuito de atenci\u00f3n farmac\u00e9utica (AF) al paciente anciano como parte del proceso de atenci\u00f3n sanitaria \na personas mayores que viven en residencia (PASPMVR) creado por el Servicio de Geriatr\u00eda (SG) en un hospital de \ncomplejidad intermedia.\nMEJORAS ESPERADAS\nOptimizaci\u00f3n de los tratamientos farmacogeri\u00e1tricos de los pacientes ancianos.  \nIntegraci\u00f3n del farmac\u00e9utico en el equipo multidisciplinar del PASPMVR.\nDISE\u00d1O CIRCUITO Y ETAPAS\nComo consecuencia de la primera ola de la pandemia por SARS-CoV-2, los Servicios de Geriatr\u00eda y Farmacia establecieron \nuna relaci\u00f3n de colaboraci\u00f3n con los centros sociosanitarios (CSS) de nuestra \u00e1rea asistencial. Fruto de esta colaboraci\u00f3n, \nel SG cre\u00f3 el PASPMVR en el que participan facultativos y personal de enfermer\u00eda de especialidades como geriatr\u00eda, \nfarmacia, urgencias, medicina interna, hospitalizaci\u00f3n a domicilio, entre otros.  \nPara la identificaci\u00f3n de los pacientes que acuden al Servicio de Urgencias hospitalarias (SUH) derivados desde su CSS, \nse cre\u00f3 una marca identificativa en historia cl\u00ednica electr\u00f3nica (HCE) que tambi\u00e9n permite la localizaci\u00f3n de los pacientes \nmediante informes parametrizados.  \nAdem\u00e1s, se consensu\u00f3 con los CSS la necesidad de enviar un informe con los antecedentes del paciente, su tratamiento \nhabitual y el motivo de derivaci\u00f3n con cada paciente derivado al SUH.  \nPosteriormente, el Servicio de Farmacia (SF), SG y SUH consensuaron la necesidad de la revisi\u00f3n de la terapia \nfarmacogeri\u00e1trica de los pacientes derivados al SUH por un farmac\u00e9utico.  \n \nCIRCUITO y ETAPAS \nTodos los d\u00edas laborables, un farmac\u00e9utico localiza a los pacientes derivados del CSS en las \u00faltimas 24-72h mediante los \ninformes parametrizados. Aquellos pacientes que contin\u00faan en el hospital son candidatos a AF. \nEn este proceso, el farmac\u00e9utico consulta el informe de derivaci\u00f3n de la residencia y realiza una revisi\u00f3n de los \ntratamientos cr\u00f3nicos y agudos, bas\u00e1ndose en la aplicaci\u00f3n de criterios de mejora en la farmacoterapia del paciente \nanciano (criterios START/STOPP , criterios Beers y gu\u00eda farmacogeri\u00e1trica de la consejer\u00eda de sanidad; principalmente). \nPor \u00faltimo, si considera necesarias modificaciones en el tratamiento agudo o cr\u00f3nico, comunica sus recomendaciones a \ntrav\u00e9s del evolutivo en HCE con una nomenclatura identificativa del PASPMVR; indicando la residencia de procedencia del \npaciente y el tratamiento habitual recogido del informe de residencia.\nIMPLANTACI\u00d3N\nJunio2020: Creaci\u00f3n del PASPMVR \nDiciembre2020: Creaci\u00f3n de marca identificativa e informes parametrizados en HCE.  \nMayo2021: Inicio del circuito de AF a la persona mayor que vive en residencia.\nRESULTADOS\nDurante el per\u00edodo Mayo-Diciembre 2021, se revisaron 3431 tratamientos cr\u00f3nicos en 378 asistencias al SUH de 254 \npacientes diferentes derivados por los 8 CSS del \u00e1rea asistencial.  \nEl proceso de AF dio lugar a 735 intervenciones farmac\u00e9uticas, de las cuales fueron aceptadas el 52,4%. De ellas, el 60,2% \nfueron sobre el tratamiento agudo y el 50,6% sobre el tratamiento cr\u00f3nico\ufffd\nLIMITACIONES\n-Actividad s\u00f3lo llevada a cabo en d\u00edas laborables y en turno de ma\u00f1ana.  \n-Dificultad para conocer el tratamiento cr\u00f3nico a trav\u00e9s de la prescripci\u00f3n de receta electr\u00f3nica, lo que hace \nimprescindible el informe de residencia\ufffd  \n-Dado el alto n\u00famero de anotaciones en HCE, en ocasiones las recomendaciones farmac\u00e9uticas no son visualizadas por el \nm\u00e9dico responsable.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a todos los SF que tengan una adecuada coordinaci\u00f3n con SG.496CLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n958. INTEGRACI\u00d3N DEL FARMAC\u00c9UTICO EN LA UNIDAD DE HOSPITALIZACI\u00d3N DE GERIATR\u00cdA. \nAUTORES\nMART\u00cdN ALCALDE, E; CARRASCO CORRAL, T; HORTA HERN\u00c1NDEZ, AM\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nIntegraci\u00f3n del farmac\u00e9utico en la unidad de hospitalizaci\u00f3n de geriatr\u00eda. Participaci\u00f3n activa en la asistencia del paciente \ningresado, cooperando con el m\u00e9dico en la toma de decisiones sobre el tratamiento, validaci\u00f3n farmac\u00e9utica, resoluci\u00f3n \nde consultas, conciliaci\u00f3n de la medicaci\u00f3n al ingreso y alta y adecuaci\u00f3n farmacoterap\u00e9utica.\nMEJORAS ESPERADAS\nMejorar la seguridad y la calidad asistencial, disminuyendo la incidencia de problemas relacionados con los \nmedicamentos durante la hospitalizaci\u00f3n. Reducir los errores de conciliaci\u00f3n durante las transiciones asistenciales y \nadecuar la farmacoterapia a la situaci\u00f3n funcional del paciente durante el ingreso\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nEn 2019 se llev\u00f3 a cabo un proyecto piloto de conciliaci\u00f3n de la medicaci\u00f3n al ingreso y al alta en los pacientes ingresados \nen la unidad de hospitalizaci\u00f3n de Geriatr\u00eda. Tras el an\u00e1lisis de los resultados se consensu\u00f3 con el Servicio de Geriatr\u00eda \n(SG) la integraci\u00f3n del farmac\u00e9utico en la unidad de hospitalizaci\u00f3n con los objetivos espec\u00edficos de realizar la conciliaci\u00f3n \nal ingreso y al alta y colaborar en la adecuaci\u00f3n farmacoterap\u00e9utica del tratamiento cr\u00f3nico de los pacientes. \nCIRCUITO Y ETAPAS: \n- Proyecto piloto de conciliaci\u00f3n durante seis meses en el a\u00f1o 2019. Durante dicho proyecto el farmac\u00e9utico realizaba la \nconciliaci\u00f3n de los pacientes ingresados procedentes de domicilio, que el SG solicitaba mediante interconsulta. En dicho \nperiodo s\u00f3lo se solicit\u00f3 realizar la conciliaci\u00f3n en el 20% del total de ingresos procedentes de domicilio. Se expusieron \nlos resultados al SG mostrando la incidencia de discrepancias y errores de conciliaci\u00f3n y la importancia de promover esta \nactividad.  \n- Integraci\u00f3n del farmac\u00e9utico en la unidad de hospitalizaci\u00f3n. Actividades: Asistencia diaria en el pase de guardia, \nconciliaci\u00f3n de la medicaci\u00f3n al ingreso de todos los pacientes procedentes de domicilio, elaboraci\u00f3n y registro de \nla historia farmacoterap\u00e9utica completa del paciente en la historia cl\u00ednica electr\u00f3nica, revisi\u00f3n y validaci\u00f3n de los \ntratamientos, monitorizaci\u00f3n farmacocin\u00e9tica de f\u00e1rmacos: digoxina y vancomicina, resoluci\u00f3n de consultas, conciliaci\u00f3n \nal alta de los pacientes que el geriatra solicite, adecuaci\u00f3n stock unidad de geriatr\u00eda, elaboraci\u00f3n gu\u00eda de administraci\u00f3n \nde f\u00e1rmacos intravenosos, participaci\u00f3n en protocolos, sesiones cl\u00ednicas.\nIMPLANTACI\u00d3N\nIniciado en 2020, pero se tuvo que interrumpir tras el inicio de la pandemia COVID. Se reanud\u00f3 completamente desde \nenero 2021\ufffd\nRESULTADOS\nDesde 2021 se han conciliado al ingreso 798 pacientes. Mediana de edad: 90 RIC(86-92), 82% con dependencia \nparcial o leve, 74% sin deterioro cognitivo. Mediana de f\u00e1rmacos cr\u00f3nicos: 9 RIC(7-12). En el 49% de los pacientes se \nencontraron discrepancias de conciliaci\u00f3n: 38% por omisi\u00f3n, 33% comisi\u00f3n, 27% dosis o frecuencia diferente\ufffd En el 67% \nde pacientes se han realizado recomendaciones de adecuaci\u00f3n farmacoterap\u00e9utica (842 intervenciones) con un grado de \naceptaci\u00f3n del 80%: 38% suspensi\u00f3n de tratamiento, 25% inicio de tratamiento, 23% cambio de dosis o frecuencia, 14% \nmonitorizaciones de f\u00e1rmacos. Conciliaci\u00f3n al alta (elaboraci\u00f3n mapa horario y educaci\u00f3n paciente): 32% de pacientes.\nLIMITACIONES\nLa elevada carga asistencial, dificulta la planificaci\u00f3n con tiempo de las altas por lo que el porcentaje de conciliaciones al \nalta es bajo.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEs aplicable a otros servicios de farmacia\ufffd\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1042. LAZOS DESDE LA URGENCIA, HOSPITALIZACI\u00d3N HASTA LA ATENCI\u00d3N PRIMARIA: CIRCUITO DE \nCOLABORACI\u00d3N Y COMUNICACI\u00d3N ENTRE DISTINTOS \u00c1MBITOS ASISTENCIALES \nAUTORES\nHIJAZI VEGA, M; IBA\u00d1EZ HERAS, N; HERRANZ MU\u00d1OZ, N; ONTENIENTE GONZ\u00c1LEZ, A; PEL\u00c1EZ AGUDO, M; RAM\u00d3N \nGARCIA, JM; LUQUE GALAN, J; MOLINA GARCIA, T\nHOSPITAL UNIVERSITARIO DE GETAFE \ufffd CRTRA DE TOLEDO, KM \ufffd 12,5 GETAFE \ufffd MADRID\nOBJETIVOS\nEstablecer un circuito en colaboraci\u00f3n con Atenci\u00f3n Primaria(AP)para la revisi\u00f3n y optimizaci\u00f3n farmacoterap\u00e9utica de \nlos pacientes desde el ingreso en Urgencias hasta el alta hospitalaria y posterior seguimiento por AP con el fin de mejorar \nla calidad asistencial y garantizar la seguridad del paciente durante los tr\u00e1nsitos asistenciales.497MEJORAS ESPERADAS\n- Mejorar la comunicaci\u00f3n relacionada con el tratamiento farmacol\u00f3gico entre AP y el Hospital mediante un circuito \u00e1gil y \neficiente. \n- Mejorar la conciliaci\u00f3n del tratamiento en los puntos cr\u00edticos durante los cambios asistenciales.  \n- Fomentar la participaci\u00f3n del paciente y/o familiares mediante entrevista cl\u00ednica cuando sea posible.  \n- Minimizar de errores de medicaci\u00f3n mediante la detecci\u00f3n precoz y comunicaci\u00f3n de los mismos.\nDISE\u00d1O CIRCUITO Y ETAPAS\nUna de las funciones del farmac\u00e9utico en Urgencias es la revisi\u00f3n farmacoterap\u00e9utica de los pacientes tanto del \ntratamiento que controla el proceso agudo que motiva su ingreso hospitalario como de la medicaci\u00f3n cr\u00f3nica habitual. \nSin embargo, las discrepancias relacionadas con patolog\u00edas c\u00f3nicas, fundamentalmente en seguimiento por el M\u00e9dico \nde Familia (MF), no siempre eran valoradas. Por ello, surge la necesidad de establecer un circuito de comunicaci\u00f3n \ny coordinaci\u00f3n con AP a trav\u00e9s de los farmac\u00e9uticos de AP(FAP), quienes participan en la revisi\u00f3n y dirigen las \nrecomendaciones finales a los MF implicados.  \n \nEste proyecto se acota a pacientes con antiagregantes y/o anticoagulantes que ingresan en el Hospital desde Urgencias \npor su complejidad y alto riesgo de generar errores de medicaci\u00f3n. Se establece un plan de optimizaci\u00f3n y revisi\u00f3n \nfarmacoterap\u00e9utica adem\u00e1s de crear una base de datos(BBDD) para el registro y seguimiento durante su ingreso y un \ncanal de comunicaci\u00f3n seguro para compartir la informaci\u00f3n entre ambos \u00e1mbitos asistenciales.  \n \nEtapas: \n- Elaboraci\u00f3n de un procedimiento normalizado de trabajo que defina el circuito y aprobaci\u00f3n del mismo por la Comisi\u00f3n \nde Continuidad Asistencial.  \n \n- Creaci\u00f3n de BBDD para el cribado, registro y seguimiento durante el ingreso. \n \n- Creaci\u00f3n de un canal seguro de comunicaci\u00f3n a trav\u00e9s de Teams con la informaci\u00f3n compartida  \n \nCircuito: \n1- Cribado diario de pacientes en Urgencias \n2- Revisi\u00f3n farmacoterap\u00e9utica integral y entrevista cl\u00ednica  \n3- Comunicaci\u00f3n con el m\u00e9dico responsable y registro estructurado en H\u00aaCl\u00ednica: \n\u2022 Motivo de visita a Urgencias \n\u2022 Antecedentes destacados con medicaci\u00f3n asociada  \n\u2022 Discrepancias encontradas \n\u2022 Recomendaciones emitidas  \n4- Volcado de datos a la BBDD  \n5- Comunicaci\u00f3n al alta hospitalaria de las discrepancias no valoradas durante el ingreso al FAP  \n6- Revisi\u00f3n adicional del FAP y transmisi\u00f3n del informe final al MF  \n7- Feedback final del MF a trav\u00e9s del FAP\nIMPLANTACI\u00d3N\nInicio del proyecto: noviembre-2021\nRESULTADOS\nDesde la implantaci\u00f3n hace 6 meses, se han revisado un total de 358 pacientes donde 62%(222 pacientes) requirieron al \nmenos una intervenci\u00f3n. El total de discrepancias encontradas fueron 422 (1.9 intervenciones/paciente). El 80.8% de las \nintervenciones fueron evaluadas durante la hospitalizaci\u00f3n, mientras que el 18.9% correspondientes a 59 pacientes, se \ntrasladaron a AP para su revisi\u00f3n\ufffd\nLIMITACIONES\nCribado de pacientes en Urgencias se realiza una vez al d\u00eda\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable en todos los Servicios de Farmacia con presencia f\u00edsica del farmac\u00e9utico en Urgencias y posibilidad de \ncomunicaci\u00f3n con facultativos de referencia en AP\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1091. PROGRAMA DE COORDINACI\u00d3N ASISTENCIAL PARA LA MEJORA DE LA FARMACOTERAPIA EN EL \nPACIENTE MAYOR POLIMEDICADO \nAUTORES\nMOLINERO MU\u00d1OZ, M; FERN\u00c1NDEZ RUIZ-MOR\u00d3N, A; TALL\u00d3N MART\u00cdNEZ, JC; YB\u00c1\u00d1EZ GARC\u00cdA, L; S\u00c1NCHEZ-OCA\u00d1A \nMARTIN, N; DE LA TORRE ORTIZ, M; CORAZ\u00d3N VILLANUEVA, J; MART\u00cdNEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID498OBJETIVOS\nEstablecer un circuito de conciliaci\u00f3n y revisi\u00f3n de medicaci\u00f3n en el paciente mayor polimedicado en una Unidad de \nCorta Estancia, actuando de manera coordinada farmac\u00e9uticos de Atenci\u00f3n Primaria (FAP) y farmac\u00e9uticos de Atenci\u00f3n \nEspecializada (FAE).\nMEJORAS ESPERADAS\n\u2022Optimizaci\u00f3n del tratamiento mediante validaci\u00f3n, detecci\u00f3n y resoluci\u00f3n de problemas relacionados con la medicaci\u00f3n \n(PRM). \n\u2022Fomento del uso racional de medicamentos logrando un impacto en la eficiencia del sistema. \n\u2022Mayor satisfacci\u00f3n del paciente gracias a la actualizaci\u00f3n del tratamiento sin actuar de intermediario en el flujo de \ninformaci\u00f3n entre niveles asistenciales\ufffd  \n\u2022Aumento de la coordinaci\u00f3n entre FAP y FAE, trabajando en un entorno carente de niveles asistenciales estancos.\nDISE\u00d1O CIRCUITO Y ETAPAS\nCreaci\u00f3n de un canal seguro de comunicaci\u00f3n para que FAP y FAE de manera conjunta tomen decisiones sobre la \nfarmacoterapia del paciente, realizando intervenciones farmac\u00e9uticas (IF) al m\u00e9dico de Atenci\u00f3n Primaria (MAP).  \nETAPAS: \n1\ufffdConciliaci\u00f3n de la medicaci\u00f3n por el FAE mediante entrevista con paciente/familiar e informaci\u00f3n disponible \n(prescripci\u00f3n en MUP con registro de dispensaciones, informes de alta o consultas en historia cl\u00ednica del hospital, \ncomentarios del MAP en HORUS)  \n2.Revisi\u00f3n y validaci\u00f3n de la medicaci\u00f3n cr\u00f3nica por el FAE, comprobando previamente si existe alg\u00fan informe de revisi\u00f3n \nde la farmacoterapia emitido por FAP . \n3.Detecci\u00f3n de medicamentos potencialmente inapropiados (MPI) en el tratamiento cr\u00f3nico y/o PRM. \n4.Registro del paciente y los PPI y/o PRM detectados en una tabla compartida en red con FAP .  \n5.An\u00e1lisis de la medicaci\u00f3n cr\u00f3nica por el FAP y revisi\u00f3n de las intervenciones realizadas por FAE. Elaboraci\u00f3n del informe \nde revisi\u00f3n (IR) y env\u00edo del mismo al MAP a trav\u00e9s de APMadrid y al FAE a trav\u00e9s del canal.  \n6.Verificaci\u00f3n en MUP de la aceptaci\u00f3n o no de la intervenci\u00f3n. Registro.\nIMPLANTACI\u00d3N\nAnte la necesidad de hacer llegar al m\u00e9dico de AP las IF relacionadas con la medicaci\u00f3n cr\u00f3nica de los pacientes, se \nrealizaron reuniones en 1er trimestre del a\u00f1o 2020 entre FAE y FAP , inici\u00e1ndose en 06/2020 este proyecto, que contin\u00faa \nvigente\ufffd\nRESULTADOS\nDesde la implantaci\u00f3n hasta 03/2022 los FAE han realizado IF en 74 pacientes. La mediana de edad de los pacientes con \nintervenci\u00f3n fue 83 y la media de medicamentos prescritos/paciente en MUP fue 13. El n\u00famero medio de IF/paciente \ndetectadas es 1,3. Se realizaron cambios en el 50% de los pacientes en los que se envi\u00f3 un IR. El n\u00famero total de IF \nrealizadas fue 106, con una aceptaci\u00f3n del 42,4%. Las IF m\u00e1s frecuentes fueron las relacionadas con duplicidad (25%), uso \nde MPI (18.8%), prescripci\u00f3n de medicamentos sin indicaci\u00f3n clara (18.8%) y aquellas relacionadas con pauta posol\u00f3gica \nincorrecta (12.2%).\nLIMITACIONES\nLa sobrecarga asistencial en la especialidad de Medicina de Familia y Comunitaria resulta un obst\u00e1culo a la hora de dar \nrespuesta a las recomendaciones emitidas por los farmac\u00e9uticos. La v\u00eda de comunicaci\u00f3n al MAP dificulta conocer el \nmotivo de la no aceptaci\u00f3n de las intervenciones por el MAP .\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl proceso es f\u00e1cilmente replicable en otros Servicios de Farmacia y responde a la necesidad de realizar un seguimiento \nfarmacoterap\u00e9utico en el paciente mayor polimedicado.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n1185. INTERVENCI\u00d3N FARMAC\u00c9UTICA PARA LA MEJORA DE LA PRESCRIPCI\u00d3N EN PACIENTES \nPOLIMEDICADOS A TRAV\u00c9S DE UN APLICATIVO WEB \nAUTORES\nV\u00c1ZQUEZ REAL, M; ALCAL\u00c1 SOTO, \u00c1; CUADROS MART\u00cdNEZ, CM; L\u00d3PEZ MU\u00d1OZ, MJ; RUIZ P\u00c9REZ, DS; SIERRA \nS\u00c1NCHEZ, JF\nHOSPITAL DE ESPECIALIDADES DE JEREZ DE LA FRONTERA. CTRA. DE CIRCUNVALACION, S/N JEREZ DE LA FRONTERA. \nC\u00c1DIZ\nOBJETIVOS\nA diario pasan por las consultas externas multitud de pacientes considerados polimedicados. En su gran mayor\u00eda, no s\u00f3lo \nno se modifica el tratamiento o no se quitan f\u00e1rmacos, sino que habitualmente acaban con m\u00e1s f\u00e1rmacos prescritos.  \nEl objetivo es medir el efecto de la revisi\u00f3n del tratamiento mediante ciertos criterios de priorizaci\u00f3n por parte del \nfarmac\u00e9utico con la revisi\u00f3n posterior del m\u00e9dico.\nMEJORAS ESPERADAS\nEntre las mejoras esperadas se encuentran la disminuci\u00f3n del n\u00famero de f\u00e1rmacos por pacientes as\u00ed como en el n\u00famero \nde f\u00e1rmacos considerados de riesgo que conforman el \u00edndice de inadecuaci\u00f3n (IIn) (definido en Dise\u00f1o).499DISE\u00d1O CIRCUITO Y ETAPAS\nSe elabor\u00f3 un aplicativo web (VIGIA) en el que es posible visualizar los pacientes polimedicados (con m\u00e1s de 15 \nmedicamentos activos) que acuden a consultas externas del hospital, as\u00ed como su tratamiento, desde el cual el \nfarmac\u00e9utico hospitalario puede revisar el tratamiento y hacer comentarios al m\u00e9dico. Se priorizaba su revisi\u00f3n en base \na IIn de elaboraci\u00f3n propia, asignando una puntuaci\u00f3n seg\u00fan la presencia en el tratamiento o no de criterios de riesgo: \na) duplicidades (1 punto), b) medicamentos de bajo valor terap\u00e9utico (1 punto), c) medicamentos que alargan el QT (0,5 \npuntos), d) cascadas terap\u00e9uticas (0,5 puntos) y e) carga anticolin\u00e9rgica (0,5 puntos).  \n \nEtapas: \n1. Elaboraci\u00f3n del aplicativo web e integraci\u00f3n en los sistemas inform\u00e1ticos del hospital.  \n2. Instalaci\u00f3n en los equipos de los m\u00e9dicos que habitualmente pasan consulta. \n3. Revisi\u00f3n de los pacientes que acuden a consultas (m\u00ednimo el d\u00eda previo de su consulta).  \n4\ufffd Medici\u00f3n de resultados\ufffd\nIMPLANTACI\u00d3N\nPara la implantaci\u00f3n, se elabor\u00f3 una sesi\u00f3n cl\u00ednica a los servicios m\u00e9dicos en los que se iba a iniciar la herramienta web, \ninicialmente Reumatolog\u00eda, con recordatorios peri\u00f3dicos para que consultaran la herramienta.\nRESULTADOS\nEn un periodo de dos meses (de 15 de octubre a 15 de diciembre de 2021), tras la revisi\u00f3n de 52 pacientes, se consigui\u00f3 \nreducir la media del IIn un 21,13% (de 2,13 a 1,68). La media del n\u00famero de medicamentos por paciente se redujo un \n1,6% (de 18,4 a 18,13). En datos netos, tras 72 recomendaciones reportadas (de retirada o modificaci\u00f3n del tratamiento), \nse retiraron 31 medicamentos y se a\u00f1adieron 17.\nLIMITACIONES\nLa falta de tiempo de los profesionales puede suponer una limitaci\u00f3n a la utilidad de la herramienta. Por otro lado existe \ncierta incertidumbre sobre si los cambios se han realizado por recomendaci\u00f3n o por situaci\u00f3n cl\u00ednica.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa dificultad principal de la aplicabilidad radica en la propia herramienta web, pero ser\u00eda implantable un procedimiento \nde revisi\u00f3n de los pacientes polimedicados que pasan por consultas externas, con revisi\u00f3n priorizada en base a \ndeterminados criterios de riesgo y con recomendaciones espec\u00edficas.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n240. ACTUALIZACI\u00d3N DE UN MANUAL DE ESTANDARIZACI\u00d3N DE PERFUSIONES DE MEDICAMENTOS DE \nALTO RIESGO Y CREACI\u00d3N DE NOMOGRAMAS DE ADMINISTRACI\u00d3N \nAUTORES\nSANCHEZ NAVARRO, IM; ZAZU VIVES, M; PINTADO DELGADO, MDC; FERNANDEZ ARBERAS, N; BALDOMINOS \nUTRILLA, G\nHOSPITAL UNIVERSITARIO PR\u00cdNCIPE DE ASTURIAS. CTRA. ALCAL\u00c1-MECO, S/N ALCAL\u00c1 DE HENARES. MADRID\nOBJETIVOS\n- Actualizaci\u00f3n de un manual de estandarizaci\u00f3n de soluciones, a una concentraci\u00f3n \u00fanica, para Medicamentos de \nAlto Riesgo (MAR) y otros de Estrecho Margen Terap\u00e9utico (EMT), que entra como estrategia prioritaria definida por el \nMinisterio de Sanidad y Consumo para mejorar la seguridad de los MAR. \n- Mejorar la difusi\u00f3n del manual.  \n- Creaci\u00f3n de nomogramas de dosificaci\u00f3n, diluci\u00f3n y administraci\u00f3n de las 13 perfusiones estandarizadas m\u00e1s utilizadas \nen la Unidad de Cuidados Intensivos (UCI).\nMEJORAS ESPERADAS\nAumentar la seguridad de la prescripci\u00f3n y administraci\u00f3n de los MAR y de EMT, evitando en lo posible la variabilidad \nindividual, sobre todo en circunstancias de urgencia\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O:  \nActualizaci\u00f3n del manual: se organiza un equipo multidisciplinar de intensivistas y farmac\u00e9uticos, que revisa y selecciona \nperfusiones de MAT o EMT de uso habitual en el hospital, que no constan en el manual antiguo.  \nSe ordena alfab\u00e9ticamente por principio activo y se recogen las siguientes caracter\u00edsticas:  \n- Presentaciones farmac\u00e9uticas \n- Perfusi\u00f3n estandarizada: dosis de principio activo, volumen de disolvente y concentraci\u00f3n de la soluci\u00f3n.  \n- Dosis de carga, dosis de mantenimiento y flujo de administrar en bomba para un peso de 70Kg.  \n- Observaciones durante la administraci\u00f3n.  \n- Utilizaci\u00f3n de sistemas de administraci\u00f3n de fotoprotecci\u00f3n y libre de cloruro de polivinilo para las perfusiones \nfotosensibles o de alta adsorci\u00f3n\ufffd  500Desde el Servicio de Farmacia, se dise\u00f1an nomogramas de dosificaci\u00f3n, diluci\u00f3n y administraci\u00f3n de las 13 perfusiones \nestandarizadas m\u00e1s habituales de UCI que recogen:  \n- Presentaci\u00f3n farmac\u00e9utica.  \n- Velocidad de infusi\u00f3n (ml/h) en funci\u00f3n del peso (kg) y de la dosis (mg/kg/h).  \n- Perfusi\u00f3n estandarizada.  \n- Observaciones durante la administraci\u00f3n.  \nCIRCUITO Y ETAPAS: \nEn cuanto al manual de perfusiones:  \n- Reuni\u00f3n del equipo multidisciplinar que revisa bibliograf\u00eda y actualiza e introduce 17 nuevas perfusiones.  \n- Inclusi\u00f3n de la informaci\u00f3n y creaci\u00f3n de protocolos de las perfusiones en la aplicaci\u00f3n de la Historia Cl\u00ednica Electr\u00f3nica \nHCIS\u00ae\ufffd  \n- Inclusi\u00f3n del manual en una aplicaci\u00f3n inform\u00e1tica, para uso desde dispositivos electr\u00f3nicos, para mejorar su difusi\u00f3n.  \nEn cuanto a los nomogramas: se calculan todas las velocidades de infusi\u00f3n en funci\u00f3n del peso (de 30 kg a 120 kg) y de la \ndosis (rango de menor a mayor dosis indicada).\nIMPLANTACI\u00d3N\n- El equipo multidisciplinar contacta con los Servicios implicados en las perfusiones del manual y acuerda cual ser\u00e1 la \nperfusi\u00f3n \u00fanica. \n- Actualizaci\u00f3n del Manual y difusi\u00f3n mediante una aplicaci\u00f3n inform\u00e1tica.  \n- Creaci\u00f3n de los nomogramas de dosificaci\u00f3n, diluci\u00f3n y administraci\u00f3n de perfusiones estandarizadas, consensuadas \ncon el equipo de intensivistas.\nRESULTADOS\n- Manual con 61 perfusiones de MAR y otras de EMT.  \n- Nomograma de dosificaci\u00f3n, diluci\u00f3n y administraci\u00f3n de las 13 perfusiones estandarizadas m\u00e1s utilizadas en UCI.  \n- Aplicaci\u00f3n inform\u00e1tica con el manual.\nLIMITACIONES\nVariabilidad de concentraciones en la literatura y en la pr\u00e1ctica cl\u00ednica, que dificultan la selecci\u00f3n de una \u00fanica.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEstas recomendaciones pueden ser implementadas en otros Servicios de Farmacia y unificar las concentraciones de \nsoluciones de medicamentos de alto riesgo, aumentando as\u00ed la seguridad en la pr\u00e1ctica cl\u00ednica asistencial.\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n739. APLICACI\u00d3N DE UN SISTEMA DE TRIAJE FARMAC\u00c9UTICO EN EL SERVICIO DE URGENCIAS \nAUTORES\nRAMOS RODR\u00cdGUEZ, J; GOZALO ESTEVE, I; SOLER BLANCO, N; ORTONOBES ROIG, S; G\u00d3MEZ VALENT , M; ROVIRA \nMEDINA, T; OLIVER CERVELL\u00d3, M; FERN\u00c1NDEZ MOLINA, S\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\nPriorizar la atenci\u00f3n farmac\u00e9utica (AF) en pacientes que acuden al Servicio de Urgencias (SU) con alto riesgo de \nproblemas relacionados con la medicaci\u00f3n (PRM).\nMEJORAS ESPERADAS\nOptimizar el tratamiento farmacol\u00f3gico de la manera m\u00e1s precoz posible en pacientes con alto riesgo de PRM.\nDISE\u00d1O CIRCUITO Y ETAPAS\nEstudio experimental, prospectivo, en el cual se identificaban pacientes con alto riesgo de PRM a trav\u00e9s del cumplimiento \nde alguna de las siguientes variables (Journal of Pharmacy Practice and Research (2019) 49, 570\u2013584 doi: 10.1002/\njppr.1627):  \n \n- asistencia al SU debido a un mal uso de f\u00e1rmaco \n- combinaci\u00f3n de edad mayor de 70 a\u00f1os, uso habitual de 5 o m\u00e1s f\u00e1rmacos y 3 o m\u00e1s patolog\u00edas cr\u00f3nicas  \n- solicitud de AF por parte de un profesional sanitario, paciente o cuidador  \n- posibilidad de prescripci\u00f3n de f\u00e1rmacos de alto riesgo en situaciones cr\u00edticas (trombolisis, sepsis, ant\u00eddotos, bloqueantes \nneuromusculares, etc) \n- probabilidad de ingreso en cualquier unidad de hospitalizaci\u00f3n  \n \nA primera hora de la ma\u00f1ana (8:00), se realizaba la extracci\u00f3n de un listado con el total de Pacientes Censados (PC) en el \nSU y reparto de pacientes entre 4 farmac\u00e9uticos en funci\u00f3n de su \u00e1rea de competencia. Se registraba el n\u00famero total de \nPC, n\u00famero de Pacientes con Solicitud de Ingreso (PSI) y servicio de ingreso potencial (SIP).  \n \nAl finalizar la jornada laboral (15:00), se registr\u00f3 el total de pacientes que recibieron AF. Dicha documentaci\u00f3n se realiz\u00f3 \nen una base de datos EXCEL durante el mes de Marzo de 2022 (Lunes - Viernes 8:00 - 15:00).501IMPLANTACI\u00d3N\nAplicaci\u00f3n de este sistema de triaje farmac\u00e9utico utilizando como variables la posibilidad de prescripci\u00f3n de f\u00e1rmacos de \nalto riesgo en situaciones cr\u00edticas y la probabilidad de ingreso en unidades hospitalizaci\u00f3n.\nRESULTADOS\nLa media de PC fue de 118 (74-157) de los cuales 68 (58%) eran PSI. Se realiz\u00f3 AF en el 84% de los PSI (58) y del 100% \nen el caso de pacientes con posibilidad de prescripci\u00f3n de f\u00e1rmacos de alto riesgo en situaciones cr\u00edticas (C\u00f3digo Ictus 8, \nC\u00f3digo Paciente Politraumatizado 9 y C\u00f3digo Infarto 2).\nLIMITACIONES\nLas \u00fanicas variables disponibles que se utilizaron para la identificaci\u00f3n y priorizaci\u00f3n a trav\u00e9s del sistema de triaje fueron \nla solicitud de ingreso y la posibilidad de prescripci\u00f3n de f\u00e1rmacos de alto riesgo en situaciones cr\u00edticas. El resto de \nvariables no estaban disponibles para aplicarlas por limitaciones inform\u00e1ticas en el momento de extraer el listado de \npacientes\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa identificaci\u00f3n de pacientes con alto riesgo de PRM a partir de las variables disponibles nos ha permitido priorizar la AF \nen determinados pacientes con alto riesgo de PRM, llegando a un 84% de AF en PSI y del 100% en situaciones cr\u00edticas. \nOptimizar el sistema de triaje farmac\u00e9utico identificando el resto de variables con la ayuda del triaje de enfermer\u00eda en el \nSU nos permitir\u00eda detectar de manera m\u00e1s \u00e1gil y precisa pacientes con alto riesgo de PRM, con el consencuente beneficio \nen la atenci\u00f3n sanitaria\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n717. IMPLEMENTACI\u00d3N DE LA MONITORIZACI\u00d3N DE NIVELES PLASM\u00c1TICOS DE ARIPIPRAZOL, \nPALIPERIDONA Y RISPERIDONA EN UNIDADES DE HOSPITALIZACI\u00d3N PSIQUI\u00c1TRICA Y SALUD MENTAL \nAUTORES\nRAMUDO CELA, L; Y\u00c1\u00d1EZ RUBAL, JC; OUTEDA MAC\u00cdAS, M; ELBERDIN PAZOS, L; MART\u00cdN HERRANZ, MI\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\n-Evaluar la operatividad y factibilidad del proceso de determinaci\u00f3n los niveles plasm\u00e1ticos (TDM) para aripiprazol, \npaliperidona y risperidona\ufffd  \n-Determinar la utilidad de la TDM para la toma de decisi\u00f3n terap\u00e9utica.\nMEJORAS ESPERADAS\n-Implementar un proceso asistencial que mejore la farmacoterapia con antipsic\u00f3ticos.  \n-Consolidar el papel de los farmac\u00e9uticos hospitalarios como profesionales de referencia en farmacocin\u00e9tica y propiciar la \ncolaboraci\u00f3n activa con los servicios de psiquiatr\u00eda.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe elabor\u00f3 un protocolo asistencial presentado a direcci\u00f3n m\u00e9dica con los criterios de inclusi\u00f3n de pacientes: (1) \nreacciones adversas, (2) respuesta parcial o incompleta, (3) sospecha de incumplimiento (4) utilizaci\u00f3n de dosis altas. \nEl desarrollo del proyecto se dividi\u00f3 en 3 etapas: (1) adquisici\u00f3n de recursos: reactivos y equipamiento y definici\u00f3n \nde circuito y etapas (2) puesta a punto de la t\u00e9cnica, validaci\u00f3n de la matriz (plasma vs suero) y validaci\u00f3n externa de \nresultado con t\u00e9cnica alternativa (3) Despliegue asistencial.  \n \nCircuito y Etapas: \n(1) Psiquiatra: solicitud electr\u00f3nica de TDM en pacientes que cumplen los criterios de inclusi\u00f3n. (2) Enfermer\u00eda: \nextracci\u00f3n de la muestra previo a la dosis o transcurridas al menos 12 horas para administraci\u00f3n nocturna, (3) T\u00e9cnico de \nlaboratorio: determinaci\u00f3n de niveles. (4) Farmac\u00e9utico: validaci\u00f3n e informe farmacocin\u00e9tico.\nIMPLANTACI\u00d3N\nDesarrollo del proyecto se inici\u00f3 en abril 2021 y se aprob\u00f3 en junio 2021. La etapa 1 concluy\u00f3 en septiembre 2021, la \netapa 2 en noviembre 2021 y el despliegue asistencial se inici\u00f3 en diciembre 2021\ufffd\nRESULTADOS\n-Recursos: Reactivos y controles MyCare Psychiatry (MyCare\u00ae) adaptados al equipo Aliniti-CI\u00ae (Abbott\u00ae) para risperidona \ntotal (risperidona+paliperidona) y aripiprazol total (aripiprazol+dehidroarpipiprazol). Gesti\u00f3n de muestras, resultados e \ninformes con Openlab\u00ae (Nexius-IT\u00ae).  \n \n-Validaci\u00f3n de la matriz: los valores en suero fueron un 4,98% y 3,88% superiores frente a plasma para risperidona total y \npara aripiprazol total respectivamente. Las matrices se consideraron equivalentes (diferencias < 5%).  \n \n-Validaci\u00f3n externa del resultado: risperidona total mostr\u00f3 una variaci\u00f3n absoluta frente a HPLC del 9,83%, considerada \naceptable ( < 10%). Para aripiprazol total se realiz\u00f3 una validaci\u00f3n cualitativa basada en el rango terap\u00e9utico porque el \nlaboratorio externo no proporcion\u00f3 los valores del metabolito\ufffd La concordancia fue del 100%\ufffd  502-Demogr\u00e1ficos: 20 pacientes, 10 mujeres (50%), edad media 45,6 a\u00f1os. \n \n-Tratamientos: 6(30%) risperidona oral + paliperidona mensual y 1(5%), 4(20%) aripiprazol oral, 4 (20%) paliperidona \ntrimestral, 3(15%) risperidona oral, 1(5%) aripiprazol mensual, 1(5%) risperidona bisemanal, risperidona oral + \npaliperidona trimestral. 15(75%) con politerapia antipsic\u00f3tica. \n \n-Criterios de inclusi\u00f3n: 7(35%) RAMs, 6(30%) respuesta parcial/incompleta, 4(20%) dosis altas, 2(10%) adherencia, 1(5%) \nNo especificado.  \n \n-Resultados: 9 (45%) niveles dentro del rango terap\u00e9utico, 10(50%) superior y 1(5%) inferior al rango. 8(40%) muestras \nincorrectas no realizadas previo a la dosis.  \n \n-Utilidad: 16 (60%) de los resultados motivaron un cambio prescriptivo: 4 (20%) cambio de antipsic\u00f3tico, 4(20%) \nreducci\u00f3n de dosis, 4 (20%) aumento de dosis.\nLIMITACIONES\nPrograma limitado a aripiprazol, risperidona y paliperidona. No se recogieron datos respuesta y sintomatolog\u00eda cl\u00ednica con \ninstrumentos estandarizados.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nServicios de farmacia con unidades de farmacocin\u00e9tica.\nCLASIFICACI\u00d3N: ENFERMEDADES INMUNOMEDIADAS Y NEURO-PSIQUI\u00c1TRICAS\n1069. CONSTITUCI\u00d3N DE COMIT\u00c9 MULTIDISCIPLINAR DE ASMA \nAUTORES\nSAIZ MOLINA, JJ; NOTARIO DONGIL, C; GONZ\u00c1LEZ ESCRIBANO, MDC; P\u00c9REZ F\u00c1CILA, A; ANDR\u00c9S NAVARRO, N; \nALA\u00d1\u00d3N PARDO, MDM\nHOSPITAL GENERAL LA MANCHA CENTRO. AVENIDA DE LA CONSTITUCI\u00d3N, 3 ALC\u00c1ZAR DE SAN JUAN. CIUDAD REAL\nOBJETIVOS\nEstablecer un comit\u00e9 multidisciplinar de asma entre los servicios de alergias, neumolog\u00eda y farmacia hospitalaria.\nMEJORAS ESPERADAS\n1- Adecuaci\u00f3n del tratamiento de forma individualizada en funci\u00f3n de la evoluci\u00f3n de la enfermedad y respuesta al \ntratamiento\ufffd  \n2- Sentar las bases para la elaboraci\u00f3n de un protocolo farmacocl\u00ednico.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe realiz\u00f3 la constituci\u00f3n del comit\u00e9 multidisciplinar con la participaci\u00f3n de dos neum\u00f3logos, dos alerg\u00f3logos y tres \nfarmac\u00e9uticos hospitalarios del centro. La labor principal de dicho comit\u00e9 fue adecuar los tratamientos (f\u00e1rmacos \nbiol\u00f3gicos) en funci\u00f3n de las caracter\u00edsticas de cada paciente. \n \nCircuito y Etapas: \n1- Establecimiento de n\u00famero de reuniones: se acordaron 12 sesiones anuales a las que deb\u00eda, como m\u00ednimo, un \nrepresentante de cada servicio\ufffd  \n2- Revisi\u00f3n de pacientes en tratamiento activo: se elabor\u00f3 una base de datos para recoger todas las variables en relaci\u00f3n \na los pacientes con asma eosinof\u00edlica grave y asma al\u00e9rgica en tratamiento con f\u00e1rmacos biol\u00f3gicos.  \n3- Inicios de tratamiento: Se acuerda la puesta en com\u00fan de los inicios de tratamiento, consensu\u00e1ndolo en funci\u00f3n de las \ncaracter\u00edsticas del paciente. \n4- Revisi\u00f3n de nuevos tratamientos disponibles, nuevas autorizaciones y actualizaciones de las principales gu\u00edas de \npr\u00e1ctica cl\u00ednica. \n5- Elaboraci\u00f3n de un protocolo de uso para unificar y facilitar la prescripci\u00f3n.\nIMPLANTACI\u00d3N\nLa actividad se implant\u00f3 en noviembre de 2021.\nRESULTADOS\nDesde su implantaci\u00f3n, se revisaron 56 pacientes en tratamiento con alguno de los f\u00e1rmacos biol\u00f3gicos para el asma, \ncon una mediana de edad de 56,5 a\u00f1os (7-78). El 50% fueron diagnosticados de asma al\u00e9rgica, 39% asma eosinof\u00edlica, \n10% asma intr\u00ednseca y 1% s\u00edndrome Churg-Strauss. El 50% estaban siendo tratados con omalizumab. El 45% y 5% con \nmepolizumab y benralizumab, respectivamente. En cuanto a la reducci\u00f3n de corticoides sist\u00e9micos, el 84% de pacientes \nen tratamiento con mepolizumab, el 71% con omalizumab y 67% con benralizumab, lo redujeron. Sin embargo, el 39 % \nde pacientes con omalizumab, 40% de pacientes con mepolizumab y 67% de pacientes con benralizumab presentaron \nalguna crisis asm\u00e1tica.  \nLa IgE se redujo en el 72% de pacientes con mepolizumab, 66% con benralizumab y 43 % con omalizumab. La capacidad \npulmonar se evalu\u00f3 analizando el volumen espirado m\u00e1ximo en el primer segundo de la espiraci\u00f3n forzada (FEV1), \ndefiniendo como mejor\u00eda de la enfermedad un aumento en la FEV1 control con respecto a la inicial. El 100% de pacientes \ncon benralizumab, 68% con mepolizumab y 29 % con omalizumab presentaron mejor\u00eda de este par\u00e1metro. En el 50353% de los pacientes con omalizumab no se realiz\u00f3 seguimiento mediante espirometr\u00eda. La mayor\u00eda de los pacientes \npresentaron buena tolerancia y poca toxicidad al tratamiento\ufffd Solamente 1 paciente suspendi\u00f3 tratamiento por toxicidad \n(parestesias). Finalmente, se discontin\u00fao el tratamiento en el 9% por mala efectividad.\nLIMITACIONES\nHasta la elaboraci\u00f3n de un protocolo de uso, es necesario consensuar el f\u00e1rmaco que m\u00e1s se adec\u00faa al paciente, lo cual \npuede retrasar el acceso temprano a cada tratamiento\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl proyecto se puede aplicar a cualquier hospital que presente un servicio de neumolog\u00eda y alergias, adem\u00e1s de servicio \nde farmacia\ufffd\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n922. EPILEPSIA REFRACTARIA EN S\u00cdNDROME LENNOX-GASTAUT: NUEVOS RETOS CON LA ATENCI\u00d3N \nFARMAC\u00c9UTICA AL PACIENTE EXTERNO PEDIATRICO \nAUTORES\nTALADRIZ SENDER, I; RUIZ BRIONES, P; MARTINEZ FERNANDEZ-LLAMAZARES, C; MANRIQUE RODRIGUEZ, S; \nHERRANZ ALONSO, A; SANJURJO SAEZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nEl cannabidiol es un medicamento hu\u00e9rfano indicado en crisis asociadas al S\u00edndrome Lennox-Gastaut en pacientes > \n2 a\u00f1os. Antes se adquir\u00eda como medicamento extranjero, el 1/09/2021 se comercializ\u00f3 en Espa\u00f1a con condiciones de \nfinanciaci\u00f3n restringidas. Son pacientes del nivel-1 de estratificaci\u00f3n del paciente cr\u00f3nico pedi\u00e1trico de la SEFH, que \npueden verse beneficiados de una atenci\u00f3n farmac\u00e9utica adaptada.  \nLos objetivos son: desarrollar e implantar una lista de verificaci\u00f3n de validaci\u00f3n farmac\u00e9utica del tratamiento con \ncannabidiol v\u00eda oral en pacientes pedi\u00e1tricos diagnosticados de epilepsia refractaria con S\u00edndrome de Lennox-Gastaut en \nla consulta de pacientes externos\ufffd\nMEJORAS ESPERADAS\nAumento de la seguridad y calidad de la atenci\u00f3n farmac\u00e9utica a los pacientes en tratamiento con cannabidiol. Permite \ndetectar eventos adversos potenciales e intervenir de manera precoz colaborando con neuropediatras.\nDISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O  \nSe dise\u00f1aron dos listas de verificaci\u00f3n: Check-list-1(inicios de tratamiento) y Check-list-2(seguimientos). Se consultaron \ndistintos documentos: ficha t\u00e9cnica cannabidiol(Epidyolex\u00ae), ensayos cl\u00ednicos GWPCARE3 y GWPCARE4, modelo de \nselecci\u00f3n y atenci\u00f3n farmac\u00e9utica de pacientes cr\u00f3nicos pedi\u00e1tricos de la SEFH.  \nLos check-list son cumplimentados por farmac\u00e9utico con informaci\u00f3n proporcionada en historia cl\u00ednica electr\u00f3nica y \nentrevista con familiar. La periodicidad de las consultas es cada mes hasta alcanzar dosis de mantenimiento, despu\u00e9s c/2 \nmeses. Las intervenciones realizadas en la consulta son consensuadas con neuropediatria.  \nCheck-list-1: \nVariables del paciente: demogr\u00e1ficas, diagn\u00f3stico principal, n\u00famero crisis ca\u00edda/d\u00eda, comorbilidades, antiepil\u00e9pticos \nconcomitantes, antiepil\u00e9pticos ensayados previamente, niveles antiepil\u00e9pticos y otros f\u00e1rmacos monitorizables( < 1 mes).  \nVariables cannabidiol: Indicaci\u00f3n financiada(si no, justificaci\u00f3n), dosis inicial por kilogramo de peso. Aspectos relacionados \ncon tolerancia: descartar alergia al aceite de s\u00e9samo, perfil hepatobiliar (niveles de transaminasas[ALT y AST], GGT y \nbilirrubina en determinaci\u00f3n < 1mes), nivel basal somnolencia y/o cansancio, trastornos gastrointestinales(diarrea/\nv\u00f3mitos), alteraciones apetito. Interacciones farmacol\u00f3gicas relevantes cl\u00ednicamente. \nCheck-list-2: \nConciliaci\u00f3n, niveles de f\u00e1rmacos concomitantes, cambios de peso, dosis actual de cannabidiol, variables de eficacia: \ndisminuci\u00f3n del n\u00famero y/o duraci\u00f3n crisis de ca\u00edda, perfil-hepatobiliar, aspectos relacionados con tolerancia y \nadherencia al tratamiento.  \nETAPAS \n1.Solicitud del f\u00e1rmaco por neurolog\u00eda-pedi\u00e1trica con informe cl\u00ednico.  \n2.Revisi\u00f3n de historia m\u00e9dica previa consulta inicio de tratamiento y verificaci\u00f3n de informaci\u00f3n disponible mediante \nCheck-list-1. \n3.Si no cumple criterios de la validaci\u00f3n se contacta con el m\u00e9dico prescriptor para comentar el caso.  \n4.Consulta de inicio de tratamiento con paciente y cuidador principal y se termina de cumplimentar el check-list-1. \n5.Realizaci\u00f3n se consultas sucesivas utilizando check-list-2.\nIMPLANTACI\u00d3N\nLa lista de verificaci\u00f3n se implant\u00f3 con el primer paciente tratado en julio de 2020.504RESULTADOS\n(01/07/2020-14/05/2022)  \nSe han realizado 4 inicios de tratamiento y 21 consultas de seguimiento.  \nSe registraron: \n- 10 Intervenciones en las consultas de inicio: 8 interacciones(4 con \u00e1cido valproico, 2 con clobazam, 1 con inhibidor de \nmTOR, 1 con inhibidores de citocromo-CYP450) y 2 indicaciones no financiadas sin justificar. \n- 8 Intervenciones en las consultas de seguimiento: 5 derivaciones a consulta de neurolog\u00eda por: reacci\u00f3n adversa grave, \nfalta de seguimiento de perfil hepatobiliar, dosis incorrecta y alteraci\u00f3n de niveles de f\u00e1rmaco concomitante; 3 de \neducaci\u00f3n sanitaria y falta de adherencia.\nLIMITACIONES\nLa poblaci\u00f3n a tratar es baja. Se requieren m\u00e1s pacientes para validar la herramienta.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nExportable a otros Servicios en los que se dispense cannabidiol.\nCLASIFICACI\u00d3N: ENFERMEDADES RARAS Y MEDICAMENTOS HU\u00c9RFANOS\n1076. TERAPIA GENICA EN EL PACIENTE PEDIATRICO CON ATROFIA MEDULAR ESPINAL: ATENCION \nFARMACEUTICA Y GARANTIA DE CALIDAD \nAUTORES\nJIM\u00c9NEZ LOZANO, I; PARRAM\u00d3N TEIXID\u00d3, CJ; ALONSO MART\u00cdNEZ, C; COSTA COMELLAS, L; CLEMENTE BAUTISTA, S; \nRODR\u00cdGUEZ SOTO, A; CABA\u00d1AS POY , MJ; GORGAS TORNER, MQ\nHOSPITAL UNIVERSITARI VALL D\u2019HEBRON. PS VALL D\u2019HEBRON, 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nDise\u00f1o e implementaci\u00f3n del circuito de gesti\u00f3n y atenci\u00f3n farmac\u00e9utica de la terapia g\u00e9nica (TG) con el medicamento de \nterapia avanzada onasemnogen abeparvovec en pacientes pedi\u00e1tricos con atrofia medular espinal (AME).\nMEJORAS ESPERADAS\nEl dise\u00f1o y estandarizaci\u00f3n de todos los procedimientos permitir\u00e1 garantizar la calidad, seguridad y eficacia de la TG con \nonasemnogen abeparvovec y futuras TGs en el paciente pedi\u00e1trico.\nDISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O  \nEl Servicio de Farmacia, junto con el Servicio de Neurolog\u00eda pedi\u00e1trica y el equipo de Enfermer\u00eda referente, coordinaron \nla puesta a punto de la TG, as\u00ed como la elaboraci\u00f3n de Procedimientos Normalizados de Trabajo (PNT), check-lists, e \ninformaci\u00f3n para el paciente\ufffd \nCIRCUITO Y ETAPAS \n1. Evaluaci\u00f3n del paciente y revisi\u00f3n de los criterios de acceso al tratamiento. Confirmaci\u00f3n de los requisitos para su \nfinanciaci\u00f3n por parte del organismo de prestaciones sanitarias p\u00fablicas correspondiente.. \n2. Revisi\u00f3n de la normativa, directrices e instrucciones de gesti\u00f3n de la TG y todos los procesos de minimizaci\u00f3n del riesgo \ntanto para el paciente, como para los profesionales implicados en su manipulaci\u00f3n\ufffd  \n3. Verificaci\u00f3n con el laboratorio farmac\u00e9utico de las precauciones de manipulaci\u00f3n, la compatibilidad de materiales y \nfungibles con la TG, y adaptaci\u00f3n del nivel de peligrosidad al entorno cl\u00ednico.  \n4. Coordinaci\u00f3n con el equipo de enfermer\u00eda del acondicionamiento de la TG y tipo de sistemas cerrados y alargaderas, \npara asegurar la m\u00ednima manipulaci\u00f3n a pie de cama. \n5. Elaboraci\u00f3n de los PNTs para la recepci\u00f3n, preparaci\u00f3n, administraci\u00f3n, eliminaci\u00f3n de desechos, gesti\u00f3n de derrame o \nexposici\u00f3n accidental y extravasaci\u00f3n\ufffd Asegurar la disponibilidad de la medicaci\u00f3n de rescate\ufffd \n6. Informatizaci\u00f3n y validaci\u00f3n del tratamiento y medicamentos concomitantes.  \n7. Garantizar la correcta capacitaci\u00f3n del personal t\u00e9cnico que prepara la TG. \n8. Dise\u00f1o de un diario de paciente para el registro de la medicaci\u00f3n concomitante necesaria (antiem\u00e9ticos, corticoides) y \nlos efectos adversos acontecidos\ufffd\nIMPLANTACI\u00d3N\nImplantaci\u00f3n desde agosto de 2021\ufffd\nRESULTADOS\nDesde la implementaci\u00f3n del circuito: \n- Se han tratado dos pacientes con onasemnogen abeparvovec: un ni\u00f1o de 2 meses y una ni\u00f1a de 4 meses.  \n- Se han realizado 4 reuniones multidisciplinares para la puesta en com\u00fan de los procedimientos acordados y una reuni\u00f3n \ncon el laboratorio farmac\u00e9utico.  \n- No se ha registrado ning\u00fan incidente en ning\u00fan punto del proceso de recepci\u00f3n, conservaci\u00f3n, preparaci\u00f3n, \ndispensaci\u00f3n y administraci\u00f3n\ufffd  \n- Se ha realizado el seguimiento cl\u00ednico de los pacientes y registro de sus efectos adversos: ambos pacientes presentaron \nv\u00f3mitos los siguientes d\u00edas post infusi\u00f3n y un paciente present\u00f3 elevaci\u00f3n de las enzimas hep\u00e1ticas y trombocitopenia.\nLIMITACIONES\nLa falta de regulaci\u00f3n espec\u00edfica para el manejo de las TGs en el \u00e1mbito cl\u00ednico conlleva la necesidad de adaptaci\u00f3n en \ncada centro de todos los circuitos para garantizar la calidad y seguridad de la TG.505APLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEs aplicable a cualquier Servicio de Farmacia que deba implementar procedimientos de gesti\u00f3n, manipulaci\u00f3n y atenci\u00f3n \nfarmac\u00e9utica con medicamentos de terapia avanzada como la TG onasemnogen abeparvovec .\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n43. MEJORA DE LA CALIDAD EN EL MANEJO DE MEDICAMENTOS EN INVESTIGACI\u00d3N: ADAPTACI\u00d3N AL \nAUMENTO Y COMPLEJIDAD DE ENSAYOS CL\u00cdNICOS \nAUTORES\nAMOR\u00d3S REBOREDO, P; G\u00d3MEZ P\u00c9REZ, B; PERALTA ALVAREZ, J; TENA MESTRE, S; BOILLOS FERN\u00c1NDEZ, M; DE RIBA \nSOLER, M; BALSELLS VIVES, S; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nEn los \u00faltimos a\u00f1os los ensayos cl\u00ednicos han aumentado en n\u00famero y complejidad debido a distintos factores, como el \nincremento de ensayos en fases tempranas y la aparici\u00f3n de nuevos medicamentos con requerimientos especiales. El \nobjetivo de este estudio es describir los cambios realizados en un servicio de farmacia de un hospital de tercer nivel \nteniendo en cuenta estos aspectos\ufffd\nMEJORAS ESPERADAS\nReducir el riesgo de error en los procedimientos, facilitar la organizaci\u00f3n del \u00e1rea y aumentar la calidad en el manejo de \nmedicamentos en investigaci\u00f3n (MI).\nDISE\u00d1O CIRCUITO Y ETAPAS\nProyecto de cambio con relaci\u00f3n a MI teniendo en cuenta las necesidades internas y externas\ufffd \nAn\u00e1lisis de las debilidades, fortalezas, amenazas y oportunidades (DAFO) por parte de farmac\u00e9uticas especialistas del \nservicio de farmacia\ufffd \nAn\u00e1lisis de los problemas en referencia a la preparaci\u00f3n en cabinas seg\u00fan metodolog\u00eda Lean a trav\u00e9s de un grupo de \ntrabajo de t\u00e9cnicos de farmacia y farmac\u00e9uticas.  \nRevisi\u00f3n de las necesidades en la manipulaci\u00f3n de MI\ufffd  \nDetecci\u00f3n de medicamentos auxiliares para tratar reacciones adversas a MI\ufffd\nIMPLANTACI\u00d3N\nA partir de los datos obtenidos: (i) se increment\u00f3 la plantilla de profesionales permitiendo la integraci\u00f3n de las \nfarmac\u00e9uticas en los equipos cl\u00ednicos, referenciando farmac\u00e9utica por patolog\u00eda y facilitando la coordinaci\u00f3n; (ii) \nse aument\u00f3 el n\u00famero de equipos de refrigeraci\u00f3n; (iii) se redact\u00f3 un procedimiento de manejo de medicamentos \npeligrosos y se revisaron las preparaciones de medicamentos que contienen organismos modificados gen\u00e9ticamente; (iv) \nse identific\u00f3 tocilizumab como principal medicamento auxiliar para tratar reacciones adversas a MI.  \nEn relaci\u00f3n con la preparaci\u00f3n, se plantearon 16 acciones (ej: actualizaci\u00f3n de la estandarizaci\u00f3n de las fichas de \nelaboraci\u00f3n, priorizaci\u00f3n del listado de preparaciones diaria por horas de entrega, adquisici\u00f3n de un carro para viales \na preparar, reorganizaci\u00f3n seg\u00fan flujo de proceso, etc.). Se han incluido los MI en una aplicaci\u00f3n de trazabilidad de \npreparaciones\ufffd\nRESULTADOS\nSe ha reorganizado el equipo y aumentado el n\u00famero de profesionales. Se ha reducido la exposici\u00f3n a medicamentos \npeligrosos redactando un procedimiento de trabajo espec\u00edfico, y se ha aumentado la calidad de los procesos a trav\u00e9s \nde la estandarizaci\u00f3n. Se han mejorado aspectos en la preparaci\u00f3n de MI, por ejemplo, los que afectan a organismos \nmodificados gen\u00e9ticamente y el uso de una aplicaci\u00f3n de trazabilidad de los preparados. Se han adecuado los circuitos de \ndispensaci\u00f3n de medicamentos auxiliares en situaci\u00f3n de emergencia\ufffd\nLIMITACIONES\nLas infraestructuras siguen sin modificarse. Las necesidades de los clientes externos a menudo requieren de una \nnegociaci\u00f3n\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa mejora de la calidad y de la seguridad es necesaria y posible mediante el trabajo en equipo para adaptar los servicios \nde farmacia a los nuevos retos que presentan los ensayos cl\u00ednicos. Este proyecto es solo el inicio de uno mucho mayor, \npero ya en esta fase temprana puede ayudar a otros servicios de farmacia que gestionen medicamentos en investigaci\u00f3n.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n164. CREACI\u00d3N DE UNA SALA BLANCA Y ESTANDARIZACI\u00d3N DE PNTS PARA LA FABRICACI\u00d3N DE \nMEDICAMENTOS EN UNA UNIDAD DE INVESTIGACI\u00d3N CL\u00cdNICA. \nAUTORES\nDEL R\u00cdO SAN CRIST\u00d3BAL, R; ZARAGOZ\u00c1 GONZALEZ, M; MILARA PAYA, J\nCONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA \ufffd AV\ufffd TRES CRUCES, S/N VALENCIA \ufffd VALENCIA506OBJETIVOS\nDocumentar la creaci\u00f3n de una sala blanca acorde a la normativa europea vigente, para la fabricaci\u00f3n de medicamentos \nen una Unidad de Investigaci\u00f3n Cl\u00ednica (UIC) que permita el desarrollo de Ensayos Cl\u00ednicos (EC) en fases tempranas (fase \nI-II).\nMEJORAS ESPERADAS\nLa fabricaci\u00f3n de medicamentos en el contexto de los EC requiere medidas de control excepcionales. Actualmente la \nmayor\u00eda de UICs posee instalaciones adecuadas para la manipulaci\u00f3n, pero no para la fabricaci\u00f3n de medicamentos, \nlo que limita la realizaci\u00f3n de EC en fases tempranas. Con la creaci\u00f3n de esta sala blanca conseguimos dar soporte a la \ninvestigaci\u00f3n cl\u00ednica llevada a cabo en ensayos cl\u00ednicos fase I-II.\nDISE\u00d1O CIRCUITO Y ETAPAS\n1)Construcci\u00f3n y dotaci\u00f3n con el equipo material de una sala blanca para la fabricaci\u00f3n de medicamentos acorde a las \nNormas de Correcta Fabricaci\u00f3n (NCF) de medicamentos en investigaci\u00f3n de uso humano publicadas por la Comisi\u00f3n \nEuropea (CE) y a la normativa ISO 14644 con los siguientes recintos: \n-Sala de entrada con clasificaci\u00f3n D. \n-Sala de clasificaci\u00f3n C, almac\u00e9n de material fungible est\u00e9ril y fluidoterapia.  \n-Sala de clasificaci\u00f3n C, vestuario donde el personal de trabajo se viste con los equipos de protecci\u00f3n individual.  \n-Sala de fabricaci\u00f3n de medicamentos no peligrosos de clasificaci\u00f3n B, dotada de una campana de flujo laminar horizontal \ncon calidad de aire clasificaci\u00f3n A. \n-Sala de fabricaci\u00f3n de medicamentos citost\u00e1ticos de clasificaci\u00f3n B, dotada de una campana de flujo laminar vertical con \ncalidad de aire clasificaci\u00f3n A. \nCada una de las puertas de acceso est\u00e1 enclavada con la siguiente y cuenta con una diferencia de presi\u00f3n con la anterior \nde un m\u00ednimo de -10 pascales.  \n \n2)Redacci\u00f3n de Procedimientos Normalizados de Trabajo (PNTs) de todos los procesos relativos al trabajo en la sala \nblanca y su mantenimiento\ufffd  \n \n3)Formaci\u00f3n del personal implicado en cualquier etapa del proceso de fabricaci\u00f3n de medicamentos, personal de \nlimpieza y mantenimiento, seg\u00fan las gu\u00edas de Buena Pr\u00e1ctica Cl\u00ednica (ICH E6).  \n \n4)Determinaci\u00f3n de los controles peri\u00f3dicos relativos al n\u00famero de part\u00edculas, flujo de aire, temperatura ambiente y \ncontaminaci\u00f3n microbiol\u00f3gica, de acuerdo a la normativa ISO 14644.\nIMPLANTACI\u00d3N\n-Validaci\u00f3n de las salas blancas mediante certificaci\u00f3n ENAC \n-Autorizaci\u00f3n para la fabricaci\u00f3n de medicamentos por la DGFyP de la Comunidad Aut\u00f3noma competente, como \nrepresentante delegado de la AEMPS\ufffd\nRESULTADOS\nDotaci\u00f3n de la UIC con una sala blanca homologada para la fabricaci\u00f3n de medicamentos en EC fase I-II. Su creaci\u00f3n \nha permitido el desarrollo de EC de relevancia cl\u00ednica nacional e internacional en las \u00e1reas de onco-hematolog\u00eda, \ndermatolog\u00eda, oftalmolog\u00eda y enfermedades digestivas y una mayor implicaci\u00f3n del farmac\u00e9utico hospitalario en la \ninvestigaci\u00f3n cl\u00ednica en fases tempranas.\nLIMITACIONES\nLa construcci\u00f3n de la sala blanca y la redacci\u00f3n de los PNTs de trabajo se han realizado seg\u00fan lo establecido en la \nnormativa vigente, en caso de modificaci\u00f3n de la misma deben actualizarse tanto las instalaciones como los PNTs de \ntrabajo para asegurar la calidad y seguridad de todos los procesos.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nNuestra experiencia sirve de apoyo para cualquier UIC que se plantee su acreditaci\u00f3n para la fabricaci\u00f3n de \nmedicamentos para ensayos cl\u00ednicos en fases tempranas.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n447. DIGITALIZACI\u00d3N DE PROCEDIMIENTOS ADMINISTRATIVOS DEL \u00c1REA DE ENSAYOS CL\u00cdNICOS DEL \nSERVICIO DE FARMACIA \nAUTORES\nHERNANDO LLORENTE, G; G\u00d3MEZ CASTILLO, JJ; GONZ\u00c1LEZ P\u00c9REZ, C; HIDALGO COLLAZOS, P; LUENGO MOLERO, CG; \nDE LA SANT\u00cdSIMA TRINIDAD MAQUEDA, A; S\u00c1NCHEZ OCA\u00d1A, N; MART\u00cdNEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nImplantar un sistema interactivo de gesti\u00f3n de citas y la creaci\u00f3n de un repositorio de informaci\u00f3n en red para mejorar la \neficiencia de la Unidad de Ensayos Cl\u00ednicos (EECC) de un Hospital de tercer nivel.507MEJORAS ESPERADAS\nConseguir una gesti\u00f3n de citas m\u00e1s eficiente, coordinada y din\u00e1mica, mejorando la organizaci\u00f3n del d\u00eda a d\u00eda en la \natenci\u00f3n a monitores\ufffd \nFacilitar la obtenci\u00f3n y transferencia de informaci\u00f3n administrativa requerida por los monitores antes y durante el \ndesarrollo de los EECC, optimizando la gesti\u00f3n y eficiencia del \u00e1rea.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe dise\u00f1a un gestor de citas a trav\u00e9s de un enlace web con informaci\u00f3n de los d\u00edas y horarios disponibles para reserva \nseg\u00fan el tipo de visita.  \nA su vez, en la p\u00e1gina de reserva de citas se incluye un v\u00ednculo que redirecciona a un repositorio digital donde se incluye \ninformaci\u00f3n de acceso libre para los monitores. Se proporciona hist\u00f3rico de registros de temperatura, certificados de \ncalibraci\u00f3n de las sondas de temperatura, Curriculum Vitae y Certificado de Buenas Pr\u00e1cticas del personal de la unidad \nprevio obtenci\u00f3n de su consentimiento, procedimiento y certificado de destrucci\u00f3n de medicamentos de investigaci\u00f3n, \nlistado de materiales fungibles y el documento de informaci\u00f3n a promotores y monitores acerca de nuestros \nprocedimientos de trabajo.  \nPara el gestor de agenda digital se determina el n\u00famero y tipo de citas que se podr\u00e1n reservar: visita de pre-estudio/\nselecci\u00f3n, visita de inicio, visita de monitorizaci\u00f3n y visita de cierre, definiendo los campos del formulario de solicitud \nimprescindibles que ayudar\u00e1n a preparar la visita del ensayo con antelaci\u00f3n: promotor, c\u00f3digo, servicio/s cl\u00ednico/s \nimplicado/s, investigador principal y datos de contacto del monitor. \nPara el repositorio digital se realiza una revisi\u00f3n de las peticiones de documentaci\u00f3n m\u00e1s demandadas por los monitores.\nIMPLANTACI\u00d3N\nEl gestor de citas fue implantado en junio 2019 y el repositorio digital en agosto 2021. La informaci\u00f3n se ha difundido a \nlos monitores para su conocimiento y es accesible mediante un c\u00f3digo QR disponible en la sala de monitorizaci\u00f3n.\nRESULTADOS\nSe ha reducido dr\u00e1sticamente la cantidad de solicitudes de documentaci\u00f3n, optimizando el tiempo en gestiones \nadministrativas pudiendo destinarse a actividades con mayor valor cl\u00ednico.  \nEl 100% de los monitores valoran como \u201cmuy satisfecho\u201d la implantaci\u00f3n del repositorio digital.  \nLa agenda digital permiti\u00f3 una mejor organizaci\u00f3n de las visitas. Desde su implantaci\u00f3n se realizaron 2.964 reservas, con \nuna media de 82 reservas/mes\ufffd\nLIMITACIONES\nComo limitaci\u00f3n, ser\u00eda conveniente recoger el compromiso de los monitores para que la informaci\u00f3n compartida s\u00f3lo se \nutilice en el contexto de ese Ensayo Cl\u00ednico.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAmbas herramientas no han tenido coste para el servicio de Farmacia, siendo personalizables y f\u00e1cilmente implantables \nen hospitales con requerimientos similares.  \nEl acceso al repositorio es relativamente restringido ya que hay que disponer del enlace, pero no requiere registrarse, lo \nque evita la gesti\u00f3n de credenciales, necesarias con otros programas. Esto es relevante debido al gran volumen de EECC \ngestionados y a la alta rotaci\u00f3n de monitores.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n505. MEJORAS EN LA REVISI\u00d3N DE LA MEDICACI\u00d3N DOMICILIARIA EN EL PER\u00cdODO DE SCREENING DE \nPACIENTES CANDIDATOS A ENSAYO CL\u00cdNICO \nAUTORES\nP\u00c9REZ QUIR\u00d3S, M\u00c1; ALCALDE RODRIGO, M; L\u00d3PEZ SISAMON, D; GASS\u00d3 MASANA, M; MUNN\u00c9 GARC\u00cdA, M; ROMERO \nDOM\u00cdNGUEZ, R; LEZCANO RUBIO, C\nINSTITUT CATAL\u00c0 D\u2019ONCOLOGIA BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nOBJETIVOS\nRevisar en 2021, durante la etapa de screening, la medicaci\u00f3n domiciliaria en un mayor n\u00famero de pacientes candidatos \na ensayo cl\u00ednico que en 2020 y, concretamente, la de pacientes de ensayos de fase I\nMEJORAS ESPERADAS\nDetectar criterios de exclusi\u00f3n relacionados con la medicaci\u00f3n habitual e interacciones antes de que el paciente comience \nel ensayo cl\u00ednico y realizar las intervenciones farmac\u00e9uticas oportunas, entre ellas, prevenir efectos adversos relacionados \ncon la medicaci\u00f3n\nDISE\u00d1O CIRCUITO Y ETAPAS\nElaboraci\u00f3n de un circuito de revisi\u00f3n para todos los pacientes de fase I y los pacientes con medicaci\u00f3n oral de fases II, III \ny IV candidatos a ensayo cl\u00ednico.  \n \n1) Los coordinadores de ensayo informan al equipo multidisciplinar (enfermer\u00eda, investigador principal (IP) y farmacia) \nde la programaci\u00f3n de los pacientes citados para screening a trav\u00e9s de correo electr\u00f3nico. 2) El IP registra durante la \nentrevista de screening la medicaci\u00f3n domiciliaria de los pacientes en la historia cl\u00ednica. 3) El farmac\u00e9utico revisa esta \nmedicaci\u00f3n con los protocolos de ensayo actualizados e informa de las interacciones y criterios de exclusi\u00f3n detectados a \nlos facultativos. 4) Se discuten las posibles intervenciones entre las partes y se procede a la toma de decisiones508IMPLANTACI\u00d3N\nSe dise\u00f1a el circuito en diciembre de 2020 y se revisa la medicaci\u00f3n domiciliaria en los pacientes desde enero de 2021 en \nadelante\nRESULTADOS\nDurante 2021 se realiza la revisi\u00f3n de la medicaci\u00f3n habitual en 163 pacientes, 91 de ellos hombres. La media de edad de \nlos pacientes es de 65,61 a\u00f1os\ufffd \nEn 2020 se realiza la revisi\u00f3n de la medicaci\u00f3n habitual en 125 pacientes. En 2020 se hab\u00edan revisado 19 pacientes de fase \nI frente a los 56 de fase I en 2021\ufffd \nDel resto, en 2021, 8 de ellos son pacientes de fase 0, 31 de fase II, 2 de fase II/III, 65 de fase III y 1 de fase IV \ufffd \n \nDe los ensayos cl\u00ednicos estudiados, 79 son de hematologia; principalmente de mieloma m\u00faltiple, linfoma no Hodgkin y \ns\u00edndrome mielodispl\u00e1sico. El resto son de oncolog\u00eda; sobre todo de m\u00e1ma, pulm\u00f3n y tumores s\u00f3lidos.  \n \nSe realizan 54 intervenciones farmac\u00e9uticas. En 23 de ellas se suspende o cambia alg\u00fan f\u00e1rmaco por ser criterio de \nexclusi\u00f3n (15 por uso de corticoides, 10 por interacciones relevantes y 3 por posible alargamiento de onda QT). En 2 \nde los pacientes no se pudo suspender y fueron fallo de screening (en los 2 casos carbamazepina). En 20 de ellas se \nrecomienda la monitorizaci\u00f3n del paciente (13 por interacciones relevantes y 7 por posible alargamiento de onda QT). El \nresto son recomendaciones varias para prevenci\u00f3n de otros posibles efectos adversos\ufffd  \n \nEn total se detectan 23 interacciones\ufffd\nLIMITACIONES\nA d\u00eda de hoy se prioriza la revisi\u00f3n de medicaci\u00f3n a todos los pacientes de fase I y pacientes de ensayos con medicaci\u00f3n \noral de otras fases, aunque el objetivo es que progresivamente y con un mayor n\u00famero de recursos se pueda realizar la \nrevisi\u00f3n en todos los pacientes\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste circuito de trabajo coordinado entre distintos equipos multidisciplinares se puede adaptar a cualquier Servicio de \nFarmacia\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; \nFARMACOECONOM\u00cdA\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n16. ALGORITMOS DE TRATAMIENTOS BASADOS EN POSICIONAMIENTO Y FINANCIACI\u00d3N COMO \nHERRAMIENTA DE APOYO A LA PRESCRIPCI\u00d3N Y VALIDACI\u00d3N ONCOHEMATOL\u00d3GICA \nAUTORES\nMONTECATINE ALONSO, E; SIERRA TORRES, MI; CARRASCO GOMARIZ, M; C\u00c1RDENAS ARANZANA, MJ; ISLA TEJERA, \nB\nHOSPITAL REINA SOF\u00cdA \ufffd AV\ufffd MEN\u00c9NDEZ PIDAL, S/N C\u00d3RDOBA \ufffd C\u00d3RDOBA\nOBJETIVOS\nDesarrollar una herramienta que, abogando por un uso racional del medicamento, facilite la toma de decisiones en el \n\u00e1rea de selecci\u00f3n de medicamentos, disminuyendo la variabilidad en la pr\u00e1ctica cl\u00ednica.\nMEJORAS ESPERADAS\nLas patolog\u00edas oncohematol\u00f3gicas suponen uno de los mayores retos a los que se enfrenta el farmac\u00e9utico en el \u00e1mbito \nde la selecci\u00f3n de medicamentos, tanto por la amplia variabilidad y complejidad de los tratamientos y patolog\u00edas, \ncomo por el contexto de situaci\u00f3n de financiaci\u00f3n en Espa\u00f1a. Por ello, esperamos que esta herramienta sirva de apoyo \ntanto para la validaci\u00f3n en el \u00e1rea de selecci\u00f3n del servicio de farmacia como para la prescripci\u00f3n en los servicios \noncohematol\u00f3gicos.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe dise\u00f1an algoritmos que contemplan el arsenal terap\u00e9utico disponible para las distintas enfermedades \noncohematol\u00f3gicas. Se posicionan los reg\u00edmenes terap\u00e9uticos seg\u00fan criterios de eficacia, conclusiones de IPTs y situaci\u00f3n \nde financiaci\u00f3n en un formato accesible y sencillo de actualizar. \n \nEtapas: \n \n1. Se acuerda con los servicios de oncolog\u00eda y hematolog\u00eda los algoritmos a elaborar, priorizando aquellos con mayor \narsenal terap\u00e9utico y carga asistencial.  \n \n2. Se realiza una b\u00fasqueda bibliogr\u00e1fica en las principales bases de datos (Embase, Medline, UptoDate), se seleccionan las \ngu\u00edas de pr\u00e1ctica cl\u00ednica m\u00e1s relevantes (ESMO, SEOM, ASCO y NCCN) y se establece la situaci\u00f3n de financiaci\u00f3n a trav\u00e9s \nde los IPTs, BIFIMED, Ficha T\u00e9cnica y EPAR de la EMA. 5093. Con la informaci\u00f3n obtenida se elabora el algoritmo. Se estratifican las indicaciones de cada r\u00e9gimen terap\u00e9utico en \nfunci\u00f3n de su situaci\u00f3n de financiaci\u00f3n utilizando 5 niveles crom\u00e1ticos: \n \n- Rojo: No financiado.  \n- Naranja: Propuesta negativa de financiaci\u00f3n.  \n- Gris: No incluido en Ficha T\u00e9cnica. \n- Amarillo: Pendiente de financiaci\u00f3n.  \n- Verde: Incluido en Gu\u00eda Farmacoterap\u00e9utica. \n \n4. Se a\u00f1aden dos anexos que recogen:  \n \n- Criterios de dosificaci\u00f3n y posolog\u00eda. Si fuera relevante, se incluyen los ajustes recomendados en insuficiencia renal y \nhep\u00e1tica. \n \n- Coste del tratamiento seg\u00fan la duraci\u00f3n en el ensayo cl\u00ednico pivotal y variables cl\u00ednicas, y la magnitud del beneficio \ncl\u00ednico de los reg\u00edmenes terap\u00e9uticos seg\u00fan la escala ESMO-MCBS.  \n \n6. Se env\u00eda el documento a la unidad cl\u00ednica implicada para su revisi\u00f3n y se discuten las discrepancias.  \n \n7. El algoritmo se actualiza mensualmente teniendo en cuenta la publicaci\u00f3n de nuevos IPT, actas de CIPM, nomencl\u00e1tor y \ndecisiones favorables del CHMP \ufffd\nIMPLANTACI\u00d3N\nAnte una solicitud individualizada de un tratamiento, el farmac\u00e9utico sit\u00faa al paciente seg\u00fan su historial cl\u00ednico en una \nde las ramas del algoritmo, y de forma r\u00e1pida y sencilla, es posible conocer qu\u00e9 tratamiento le corresponder\u00eda y en qu\u00e9 \nsituaci\u00f3n de financiaci\u00f3n se encuentra.\nRESULTADOS\nDesde marzo de 2020 se han creado algoritmos para 7 patolog\u00edas: c\u00e1ncer de mama, pulm\u00f3n, colon, ovario, pr\u00f3stata, \nmelanoma y leucemia linfoc\u00edtica cr\u00f3nica. \n \nLos algoritmos se construyen atendiendo al estad\u00edo de la enfermedad y el manejo de los pacientes en funci\u00f3n de las \nrecomendaciones de gu\u00edas de pr\u00e1ctica cl\u00ednica (subtipo histol\u00f3gico, biomarcadores relacionados con f\u00e1rmacos, etc).\nLIMITACIONES\nAumento de la carga de trabajo al requerir actualizaciones frecuentes.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nModelo exportable a otros hospitales. Permitir\u00eda disminuir la variabilidad de la pr\u00e1ctica cl\u00ednica en el uso de medicamentos \nen nuestro pa\u00eds.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n46. NORMALIZACI\u00d3N DE LA GESTI\u00d3N DE LOS MEDICAMENTOS EN SITUACIONES ESPECIALES \nAUTORES\nBA\u00d1UELOS MARTINEZ, S; SOTOCA MOMBLONA, JM; MONGE ESCARTIN, I; RUIZ BOY , S; MATE ARBAIZA, P; CASTELL\u00c0 \nKASTNER, M; TORRENT RODRIGUEZ, A; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nNormalizar la gesti\u00f3n de los medicamentos en situaciones especiales (usos compasivos, medicamentos extranjeros y \nusos fuera de las indicaciones autorizadas) en un hospital universitario de tercer nivel, a trav\u00e9s de una Subcomisi\u00f3n de \nMedicamentos en Situaciones Especiales (SCMSE).\nMEJORAS ESPERADAS\nEvaluar las solicitudes de los medicamentos en situaciones especiales garantizando su utilizaci\u00f3n en base a unos criterios \ncl\u00ednicos consensuados y homog\u00e9neos asegurando el seguimiento de los resultados cl\u00ednicos obtenidos.  \nRecomendar la protocolizaci\u00f3n de aquellos medicamentos en situaciones especiales que en base a datos de eficacia, \nseguridad y coste favorables se pueden autorizar directamente sin necesidad de una evaluaci\u00f3n individual. Mantener \nestos protocolos en revisi\u00f3n peri\u00f3dica\ufffd \nRealizar un seguimiento trimestral para valorar la eficacia de los tratamientos, as\u00ed como su coste econ\u00f3mico.\nDISE\u00d1O CIRCUITO Y ETAPAS\nCreaci\u00f3n de un procedimiento normalizado de trabajo.  \nFormaci\u00f3n del equipo de evaluadores (farmac\u00e9uticos y farmac\u00f3logos) miembros de la SCMSE, junto con los \nrepresentantes de Oncolog\u00eda, Hematolog\u00eda, Enfermedades Infecciosas, Dermatolog\u00eda, Urolog\u00eda y Anatom\u00eda Patol\u00f3gica.  \nCreaci\u00f3n de una \u00fanica direcci\u00f3n de correo electr\u00f3nico y una p\u00e1gina en la intranet del Hospital para consultar el \nfuncionamiento, las solicitudes y las actas de las reuniones\ufffd  \n 510Se establecieron dos circuitos: \n \n1. Circuito para m\u00e9dicos solicitantes:  \n \n\u2022 Cumplimentar la plantilla de solicitud:  \n \no Datos del solicitante y del paciente  \no Historia cl\u00ednica. \no Datos del tratamiento que se solicita: indicaci\u00f3n, justificaci\u00f3n, dosis, duraci\u00f3n, coste/mensual, tratamientos previos,  \nalternativas, tipo de seguimiento y bibliograf\u00eda.  \no Firmas de la Direcci\u00f3n del Servicio solicitante\ufffd \n\u2003 \n2\ufffd Circuito para los miembros de la SCMSE:  \n \n\u2022 La SCMSE gestiona las solicitudes recibidas a trav\u00e9s de su direcci\u00f3n de correo electr\u00f3nico.  \n \no Se asigna un evaluador: farmac\u00e9utico o farmac\u00f3logo cl\u00ednico que realiza un informe y emite una conclusi\u00f3n provisional.  \no Se celebra una reuni\u00f3n semanal donde se revisan los casos individualmente\ufffd \n\u2663 El m\u00e9dico solicitante puede ser convocado a la reuni\u00f3n para explicar los motivos y ampliar la informaci\u00f3n.  \no Se env\u00edan las resoluciones, positivas o negativas, de las solicitudes.  \n\u2663 En caso de medicamentos de extranjeros o de uso compasivo se env\u00edan los informes al Servicio de Farmacia para \nsolicitar  \nla autorizaci\u00f3n a la AEMPS (Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios).\nIMPLANTACI\u00d3N\nPuesta en marcha en enero de 2021, sustituyendo al anterior circuito en papel que se demoraba varias semanas al \nrequerir firmas.\nRESULTADOS\nSe evaluaron un total de 490 solicitudes de medicamentos en situaciones especiales en el a\u00f1o 2021, de las cuales:  \n \n\u2022 Aprobadas: 472 (91%) \no Extranjeros: 43 \no Indicaci\u00f3n no aprobada en ficha t\u00e9cnica: 268  \no No-gu\u00eda: 18 \no Uso compasivo: 119  \n \n\u2022 Denegadas: 42 (9%) \n \nLas especialidades m\u00e9dicas m\u00e1s solicitantes fueron Oncohematolog\u00eda (45%) y Medicina Interna/Dermatolog\u00eda (35%).  \n \nDel total de solicitudes se realiz\u00f3 un seguimiento trimestral, 96 finalizaron prematuramente debido a:  \n \no 73 ineficacia del tratamiento \no 20 efectos adversos  \no 2 exitus  \no 1 traslado de centro\nLIMITACIONES\nEn los tratamientos urgentes el procedimiento dificulta el cumplimiento de plazos y deben valorarse en otro \nprocedimiento diferente\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa normalizaci\u00f3n del circuito de gesti\u00f3n de medicamentos en situaciones especiales es f\u00e1cilmente aplicable considerando \nel trabajo en equipo de personal sanitario asistencial y administrativo del Hospital.\nCLASIFICACI\u00d3N: EVALUACI\u00d3N Y SELECCI\u00d3N DE MEDICAMENTOS; FARMACOECONOM\u00cdA\n262. PROGRAMA INTEGRAL DE GESTI\u00d3N DE USO DE INMUNOGLOBULINAS INTRAVENOSAS \nAUTORES\nRODR\u00cdGUEZ QUESADA, PP; GARC\u00cdA MU\u00d1OZ, C; CARO TELLER, JM; ORTIZ P\u00c9REZ, S; GONZ\u00c1LEZ G\u00d3MEZ, \u00c1; MAYO \nOLVEIRA, F; FERRARI PIQUERO, JM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID\nOBJETIVOS\nEvaluar el impacto de la implantaci\u00f3n de un programa integral de gesti\u00f3n del uso de inmunoglobulinas intravenosas \n(PROIg).511MEJORAS ESPERADAS\n1.-Registro actualizado de pacientes tratados con inmunoglobulinas intravenosas (IGIV).  \n2.-Priorizaci\u00f3n de IGIV en indicaciones con mayor nivel de evidencia seg\u00fan Protocolo local de uso racional de IGIV \n(PLURIG). \n3.-Control de inicios de IGIV y priorizaci\u00f3n seg\u00fan PLURIG. \n4.-Aumento de la solicitud de usos en situaciones especiales (USE) de IGIV. \n5.-Disminuci\u00f3n del consumo de IGIV en indicaciones con menor nivel de evidencia.\nDISE\u00d1O CIRCUITO Y ETAPAS\nCreaci\u00f3n del PROIg basado en 5 pilares:  \n1.-Elaboraci\u00f3n de PLURIG. \n2.-Validaci\u00f3n de inicios de tratamiento seg\u00fan indicaciones priorizadas en PLURIG. \n3.-Revisi\u00f3n integral de tratamientos activos.  \n4.-Previsi\u00f3n semanal de pacientes. \n5.-Dispensaci\u00f3n diaria individualizada por paciente desde el Servicio de Farmacia. \n \nFases:  \nFase 0:  \nEnero 2018: se revisaron todos los pacientes en tratamiento con IGIV (indicaciones, dosis y frecuencias de \nadministraci\u00f3n).  \nOctubre 2018: se puso en marcha un Grupo de Trabajo multidisciplinar sobre Uso Racional de Inmunoglobulinas, \nque trabaj\u00f3 hasta mayo 2019 en la revisi\u00f3n de indicaciones con mayor evidencia, con el fin de elaborar un PLURIG, \nestratificado las indicaciones en tres niveles de evidencia: alto (INEA), medio (INEM) y bajo (INEB).  \nFase I:  \nJunio 2019: se revis\u00f3 la adecuaci\u00f3n de todas las prescripciones activas al contenido del PLURIG, realizando intervenciones \nen aquellos pacientes con INEM o INEB (modificaciones posol\u00f3gicas o de frecuencia de administraci\u00f3n en INEM y \nvaloraci\u00f3n de suspensi\u00f3n de tratamientos en INEB con bajo beneficio cl\u00ednico para el paciente). \nFase II:  \nEnero 2021: se implement\u00f3 la dispensaci\u00f3n diaria por paciente desde el Servicio de Farmacia y se promovi\u00f3 el uso de \nalternativas a IGIV, restringi\u00e9ndose su uso s\u00f3lo a INEA e INEM.\nIMPLANTACI\u00d3N\nEl PROIg se inici\u00f3 en junio 2019.\nRESULTADOS\nEntre 2017-2021, el n\u00famero de pacientes en tratamiento con IGIV se ha incrementado en nuestro centro un 33,47% (251 \nvs 335). La evoluci\u00f3n en la adecuaci\u00f3n de uso de las IGIV al PLURIG ha mejorado, con un incremento del 14,55% (64,94% \nvs 74,39%) en INEA y una disminuci\u00f3n del 83,88% (15,14% vs 2,44%) en INEB.  \nAsimismo, se ha conseguido mantener en este per\u00edodo el n\u00famero de inicios de tratamiento con IGIV (174 vs 174), \nconsiguiendo una mejora en la adecuaci\u00f3n al PLURIG de dichos inicios con un incremento del 34,58% (64,37% vs 86,63%) \nen INEA y una disminuci\u00f3n del 86,23% (64,37% vs 86,63%) en INEB.  \nEn este per\u00edodo tambi\u00e9n se ha incrementado el n\u00famero de tramitaciones de USE de IGIV 1.222,31% (4,84% vs 64,00%), \nlogrando un incremento del 700,00% (7,5% vs 60,00%) en INEM y del 100,00% (0.,00% vs 80,00%) en INEB.  \nFinalmente, el consumo de IGIV/paciente/a\u00f1o, se redujo durante dicho periodo en un 12,13% (325,48 g/paciente/a\u00f1o vs \n285,99 g/paciente/a\u00f1o).\nLIMITACIONES\nLa principal limitaci\u00f3n del proyecto ha sido la coincidencia en tiempo con la pandemia COVID-19.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nNuestro programa de gesti\u00f3n puede ser puesto en marcha en cualquier centro de disponga de historia cl\u00ednica electr\u00f3nica \ny prescripci\u00f3n electr\u00f3nica tanto en hospitalizaci\u00f3n como en ambulantes.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n297. IMPLANTACI\u00d3N DE UN PROTOCOLO DE MEDICI\u00d3N DEL GASTO ENERG\u00c9TICO EN REPOSO A TRAV\u00c9S \nDE CALORIMETR\u00cdA INDIRECTA EN PACIENTE CR\u00cdTICO. \nAUTORES\nPRECIADO GOLDARACENA, J; IRIGOYEN RODRIGUEZ, I; EG\u00dcES LUGEA, A; ALDUNATE CALVO, S; DE MIGUEL GAZTELU, \nM; PINO RAMOS, A; GO\u00d1I INDURAIN, N; SAROBE CARRICAS, MT\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDescribir el dise\u00f1o, elaboraci\u00f3n e implantaci\u00f3n de un protocolo de medici\u00f3n del gasto energ\u00e9tico en reposo (GER) \nmediante calorimetr\u00eda indirecta (CI) en pacientes cr\u00edticos con el fin de ajustar su tratamiento nutricional de forma \nindividualizada.512MEJORAS ESPERADAS\n\u2022 Medici\u00f3n precisa del GER frente a la estimaci\u00f3n mediante ecuaciones predictivas, las cuales son m\u00e1s imprecisas y \nconllevan un riesgo significativo de infra y/o sobrenutrici\u00f3n.  \n\u2022 Ajuste individualizado del tratamiento nutricional y reevaluaci\u00f3n de sus requerimientos nutricionales seg\u00fan su \nevoluci\u00f3n\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe dise\u00f1\u00f3 un protocolo de medici\u00f3n del GER a trav\u00e9s de CI en el paciente critico por un grupo de trabajo, recogiendo:  \n\u2022 Indicaciones de la prueba, especificando los pacientes candidatos (ingresado en Unidad de Cuidados Intensivos, \nsometido a ventilaci\u00f3n mec\u00e1nica con una FiO2 < 0,8 y un Vt > 200 ml).  \n\u2022 Contraindicaciones: pacientes sometidos a terapia ECMO, tratamiento con gases anest\u00e9sicos o presencia de fugas \na\u00e9reas o f\u00edstulas.  \n\u2022 Requisitos previos de preparaci\u00f3n del personal sanitario y del paciente. \n\u2022 Materiales a emplear \ufffd \n\u2022 Configuraci\u00f3n del calor\u00edmetro.  \n\u2022 Momento adecuado para realizar la medici\u00f3n.  \n\u2022 Duraci\u00f3n de la medida\ufffd  \n\u2022 Criterios para la recogida e interpretaci\u00f3n de los resultados, teniendo en cuenta el estado fisiopatol\u00f3gico del paciente al \nmomento de realizar la medici\u00f3n y los medicamentos recibidos.  \n\u2022 Condiciones de validez de la prueba.  \nCircuito y etapas: \n1.Creaci\u00f3n de un equipo multidisciplinar integrado por intensivistas, personal de enfermer\u00eda y Farmacia.2. Revisi\u00f3n \nbibliogr\u00e1fica de la evidencia actual que sustenta el uso de la CI y de las perspectivas futuras en cuidados cr\u00edticos. 3. \nParticipaci\u00f3n en actividades de formaci\u00f3n impartidas por expertos en el empleo de CI para el equipo multidisciplinar. 4. \nElaboraci\u00f3n del protocolo por parte del equipo multidisciplinar. 5. Realizaci\u00f3n de la CI e interpretaci\u00f3n de datos y ajuste \ndel aporte nutricional individualizado de acuerdo con la evoluci\u00f3n cl\u00ednica.\nIMPLANTACI\u00d3N\nEn diciembre de 2021 comienza la elaboraci\u00f3n del protocolo y una vez finalizado, la realizaci\u00f3n de CI durante 3 meses \ncomo pruebas piloto\ufffd\nRESULTADOS\nTras la implantaci\u00f3n del protocolo se realizaron CI en 15 pacientes seg\u00fan las condiciones establecidas en el protocolo con \nel objetivo de determinar sus requerimientos energ\u00e9ticos y ajustar su tratamiento nutricional establecido previamente \nmediante ecuaciones predictivas basadas en el peso. Se observ\u00f3 que el 60% (n=9) requer\u00edan un ajuste de su tratamiento \nnutricional al encontrarse con aportes que no se ajustaban a los resultados obtenidos mediante CI. Cuatro pacientes \n(27%) se encontraban en situaci\u00f3n de infranutrici\u00f3n y en cinco (33%) en sobrealimentaci\u00f3n, condiciones que en la \nbibliograf\u00eda se han asociado a resultados adversos en el paciente cr\u00edtico.\nLIMITACIONES\nRequiere disponibilidad del aparato en el hospital, un elevado grado de implicaci\u00f3n de los profesionales, as\u00ed como unas \ncondiciones del paciente espec\u00edficas. No existe un consenso sobre la realizaci\u00f3n de la CI, por lo que no se han definido \nest\u00e1ndares de duraci\u00f3n de la prueba, ni frecuencia de repetici\u00f3n de la misma.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEs aplicable a cualquier Servicio de Farmacia de hospitales que dispongan de calor\u00edmetro, resultando una herramienta \n\u00fatil, confiable y accesible en la que el farmac\u00e9utico juega un papel clave para optimizar el manejo nutricional de los \npacientes en estado cr\u00edtico.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n354. ESTANDARIZACI\u00d3N DE DOSIS PRECARGADAS DE METOTREXATO PARA ADMINISTRACI\u00d3N \nINSTRAMUSCULAR EN GESTACI\u00d3N ECT\u00d3PICA \nAUTORES\nCASALD\u00c0LIGA TORRECILLAS, A; GAVRUS ION, D; CATAL\u00c0 FOGUET , JM; L\u00d3PEZ RAMOS, MG; BOSSACOMA BUSQUETS, \nF; VILLARONGA FLAQU\u00c9, M\nHOSPITAL DE SANT JOAN DE D\u00c8U. PASSEIG SANT JOAN DE D\u00c9U, 2 ESPLUGUES DE LLOBREGAT . BARCELONA\nOBJETIVOS\nAumentar la seguridad en la administraci\u00f3n de dosis de metotrexato intramuscular (IM) en el caso de gestaciones \nect\u00f3picas en la unidad de Urgencias Gineco-Obst\u00e9tricas de un hospital de tercer nivel, evitando la manipulaci\u00f3n del \nf\u00e1rmaco por el personal administrador.\nMEJORAS ESPERADAS\nGarantizar la manipulaci\u00f3n en condiciones seguras de un f\u00e1rmaco citost\u00e1tico (medicamento peligroso tipo 1 seg\u00fan \nclasificaci\u00f3n NIOSH), eliminando el riesgo de manipulaci\u00f3n in situ en condiciones no adecuadas.  \nDisminuir/evitar incidencias de seguridad asociadas a la administraci\u00f3n de metotrexate IM\ufffd513DISE\u00d1O CIRCUITO Y ETAPAS\nDe acuerdo con las dosis de metotrexate IM descritas en el protocolo actualizado del centro para los distintos tipos de \ngestaci\u00f3n ect\u00f3pica (1mg/kg/dosis), se seleccionaron 4 dosis est\u00e1ndar que permiten cubrir las necesidades de todas \npacientes, seg\u00fan su peso: 65mg/2,6mL, 75mg/3mL, 85mg/3,4mL y 95mg/3,8mL (la dosis administrada es la m\u00e1s pr\u00f3xima \nal peso de la paciente). Estas dosis excluyen pacientes con IMC extremos ( < 18 y > 35), as\u00ed como las dosis sucesivas en \ncaso de requerir dosis m\u00faltiples, en cuyo caso se preparan dosis individualizadas.  \n \nSe estableci\u00f3 un circuito de preparaci\u00f3n en el Servicio de Farmacia (cabina de flujo laminar vertical), distribuci\u00f3n y \nreposici\u00f3n de estas jeringas precargadas de metotrexate puro 25mg/mL, en caso de uso y/o caducidad (que establecimos \nen 28 d\u00edas). Se defini\u00f3 el espacio de almacenaje seguro y correctamente identificado en el Servicio de Urgencias Gineco-\nObst\u00e9tricas, se redactaron los procedimientos correspondientes y se realiz\u00f3 difusi\u00f3n y formaci\u00f3n a todo el personal \nimplicado\ufffd\nIMPLANTACI\u00d3N\nEl nuevo circuito se puso en marcha en marzo 2018, eliminando la presencia de viales de metotrexate en la unidad de \nenfermer\u00eda. Se realiz\u00f3 un control prospectivo de las incidencias asociadas.\nRESULTADOS\nDesde su implantaci\u00f3n en marzo 2018 hasta abril 2022, se han elaborado en el Servicio de Farmacia 264 jeringas \nprecargadas de metotrexate para uso IM en gestaci\u00f3n ect\u00f3pica. Durante este periodo se han empleado para su \nadministraci\u00f3n 91 de estas jeringas (13 de 65mg, 22 de 75mg, 36 de 85mg y 20 de 95mg). No se ha declarado en este \nperiodo ning\u00fan incidente de seguridad relacionado con la manipulaci\u00f3n de metotrexate en esta unidad. Todas las \npacientes que han necesitado administraci\u00f3n de metotrexate IM han tenido la dosis disponible, no habi\u00e9ndose detectado \nfallos en el circuito establecido de reposici\u00f3n y caducidad\ufffd\nLIMITACIONES\nLa cantidad de jeringas precargadas elaboradas es superior a las empleadas, con la caducidad establecida en la \nactualidad\ufffd  \nActualmente ninguno de los pasos del circuito se encuentra automatizado, dependiendo de la comunicaci\u00f3n verbal de \nempleo de las dosis y revisi\u00f3n de las caducidades\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nConsideramos que el circuito es aplicable a cualquier otro Servicio de Farmacia que sea responsable de una unidad de \nUrgencias gineco-obst\u00e9tricas, ya que se trata de un tratamiento de urgencia que puede ser necesario administrar fuera \ndel horario de apertura del Servicio de farmacia. Se trata de un f\u00e1rmaco citot\u00f3xico, cuya manipulaci\u00f3n debe garantizarse \nen condiciones adecuadas, y su elevada estabilidad permite su almacenamiento\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n433. ADMINISTRACI\u00d3N SEGURA DE MEDICAMENTOS POR DISPOSITIVOS PARA ALIMENTACION ENTERAL \nAUTORES\nMARTIN BLAS, C; L\u00d3PEZ GARC\u00cdA, \u00c1; G\u00d3MEZ BERMEJO, M; CARMONA JU\u00c1REZ, L; ALC\u00c1NTARA PRADO, A; V\u00c1ZQUEZ \nS\u00c1NCHEZ, R; MOLINA GARC\u00cdA, T\nHOSPITAL UNIVERSITARIO DE GETAFE \ufffd CRTRA DE TOLEDO, KM \ufffd 12,5 GETAFE \ufffd MADRID\nOBJETIVOS\nLa recomendaci\u00f3n m\u00e1s frecuente para proceder a la administraci\u00f3n de los medicamentos por dispositivos de \nalimentaci\u00f3n enteral (DAE) es triturar y dispersar en agua. Sin embargo, existen determinados f\u00e1rmacos que por sus \ncaracter\u00edsticas fisicoqu\u00edmicas, por presentar incompatibilidad o interacciones con DAE o la propia nutrici\u00f3n enteral (NE) \nno debe seguirse esta recomendaci\u00f3n. El objetivo es determinar los f\u00e1rmacos, que son prescritos con mayor frecuencia, \nque presentan alguna incompatibilidad/interacci\u00f3n en la administraci\u00f3n por DAE y/o con la NE y estandarizar unas \nrecomendaciones en el programa de prescripci\u00f3n electr\u00f3nica (PPE).\nMEJORAS ESPERADAS\nMejorar la adecuaci\u00f3n de la administraci\u00f3n de medicamentos por DAE a las recomendaciones vigentes. Con la revisi\u00f3n \nproactiva y la estandarizaci\u00f3n de alertas, favorecer una administraci\u00f3n segura de los medicamentos.\nDISE\u00d1O CIRCUITO Y ETAPAS\n1. Estudio piloto y revisi\u00f3n bibliogr\u00e1fica \nEstudio transversal de prescripci\u00f3n de medicamentos administrados por DAE en pacientes con NE\ufffd Las variables \nrecogidas fueron: demogr\u00e1ficas (sexo, edad), relativas a la NE (DAE, tipo de NE, modalidad de infusi\u00f3n), relativas a los \nmedicamentos (principio activo (PA), forma farmac\u00e9utica, clasificaci\u00f3n de medicamento peligroso (MP), administraci\u00f3n \ncon/sin alimentos, compatibilidad con DAE y con la NE y recomendaci\u00f3n para la administraci\u00f3n). Los datos se obtuvieron \na trav\u00e9s del PPE. Se consult\u00f3 bibliograf\u00eda espec\u00edfica sobre recomendaciones de administraci\u00f3n por DAE, fichas t\u00e9cnicas \n(CIMA) y la base de datos INFOMEP . \n2. Creaci\u00f3n localizador para revisi\u00f3n activa de pacientes con DAE. \n3. Creaci\u00f3n de alertas estandarizadas de ayuda a la administraci\u00f3n en PPE.514IMPLANTACI\u00d3N\nEl estudio piloto se realiz\u00f3 en febrero-abril de 2022. Simult\u00e1neamente, se estandarizaron las recomendaciones y con el \nlocalizador se realiza revisi\u00f3n proactiva diaria.\nRESULTADOS\nSe analizaron 260 l\u00edneas de tratamiento en 72 pacientes (73,7a\u00f1os de media y 38,4% mujeres) con 3,6 PA/paciente de \nmedia. La frecuencia de utilizaci\u00f3n de DAE fue: sonda nasog\u00e1strica (69,62%), gastrostom\u00eda (27,69%) y sonda nasoyeyunal \n(2,69 %). El 65,38% de los pacientes ten\u00edan la NE de manera continua, siendo el restante en tomas.  \nSe han revisado un total de 97 PA diferentes para administraci\u00f3n por DAE. En un 5,38% de f\u00e1rmacos prescritos para \nadministraci\u00f3n por DAE no se encontr\u00f3 bibliograf\u00eda con especificaciones concretas. Se solicit\u00f3 informaci\u00f3n al laboratorio \npara 3 PA. La incompatibilidad de los medicamentos con la NE y la contraindicaci\u00f3n de su administraci\u00f3n por DAE son \nlos problemas m\u00e1s habituales. En el 5% se contraindicaba la administraci\u00f3n por DAE pero exist\u00edan recomendaciones \nde utilizaci\u00f3n de una alterativa. El 20,38% no eran compatibles con la NE. En el 25% de los casos la NE estaba pautada \nde forma continua. Un 2,69% fueron MP . S\u00f3lo uno era grupo 1 y se acondicion\u00f3 en cabina de seguridad biol\u00f3gica. Para \nel resto, se recomend\u00f3 la utilizaci\u00f3n de formulaciones l\u00edquidas como alternativa y equipos de protecci\u00f3n individual \nnecesarios\ufffd  \nAproximadamente un 30% de los f\u00e1rmacos prescritos requer\u00edan de recomendaciones espec\u00edficas para su administraci\u00f3n. \nSe han estandarizado recomendaciones espec\u00edficas de administraci\u00f3n en PPE para los m\u00e1s frecuentes.\nLIMITACIONES\nInformaci\u00f3n limitada en medicamentos nuevos\ufffd  \nLa administraci\u00f3n continua de NE puede comprometer la administraci\u00f3n de algunos PA.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a todos los servicios de farmacia\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n448. IMPLANTACI\u00d3N DE UNA CONSULTA DE SEGUIMIENTO NUTRICIONAL SEMANAL EN PACIENTES CON \nPSORIASIS MODERADA-GRAVE CON SOBREPESO EN TRATAMIENTO CON F\u00c1RMACOS BIOL\u00d3GICOS. \nAUTORES\nBELL\u00d3 CRESPO, M; MAESTRE FULLANA, MA; MANDILEGO GARCIA, A; CANO COLLADO, V; TRUJILLANO RUIZ, A; \nIGLESIAS IGLESIAS, AA; LLODR\u00c1 ORTOLA, V\nFUNDACI\u00d3N HOSPITAL MANACOR. CRTA. MANACOR-ALCUDIA, S/N MANACOR. ILLES BALEARS\nOBJETIVOS\nDescribir la implantaci\u00f3n de una consulta de seguimiento nutricional semanal en pacientes con psoriasis moderada-\ngrave, en tratamiento con f\u00e1rmacos biol\u00f3gicos (factor de necrosis tumoral alfa (TNF-alfa), la interleucina 17 (IL17) y la \ninterleucina 23 (IL23)), y con un \u00cdndice de Masa Corporal superior a 25.\nMEJORAS ESPERADAS\nLa psoriasis es una enfermedad inflamatoria cr\u00f3nica inmunomediada de la piel directamente asociada con la obesidad. \nAmbas condiciones se retroalimentan al compartir v\u00edas antinflamatorias, como TNF-alfa, IL17 e IL23. Con la consulta \nnutricional de seguimiento semanal se pretende obtener una reducci\u00f3n del peso de los pacientes, de entre el 5-10% \ndel peso inicial, con la intenci\u00f3n de influir positiva y directamente tanto en su enfermedad como en la respuesta al \ntratamiento, suponiendo un impacto positivo en la calidad de vida de los pacientes.\nDISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O  \nPara la puesta en marcha, se cre\u00f3 un equipo de trabajo multidisciplinar formado por farmac\u00e9uticos hospitalarios \nespecialistas en nutrici\u00f3n cl\u00ednica, m\u00e9dicos y enfermeras del Servicio de Dermatolog\u00eda. Se consensu\u00f3 un protocolo de \nseguimiento con las variables a medir. Se elaboraron dietas ajustadas e infograf\u00edas para la valoraci\u00f3n nutricional, en \naspectos como raciones, hidrataci\u00f3n y h\u00e1bitos de vida saludables.  \n \n \nCIRCUITO Y ETAPAS \nSe form\u00f3 un equipo integrado por tres farmac\u00e9uticas, dos de ellas especialistas en nutrici\u00f3n cl\u00ednica, el jefe de servicio \ndel \u00e1rea de dermatolog\u00eda y una enfermera de consultas de dermatolog\u00eda. Se realiz\u00f3 una revisi\u00f3n bibliogr\u00e1fica de la \nevidencia cient\u00edfica sobre la relaci\u00f3n entre psoriasis y sobrepeso y obesidad. Se elabor\u00f3 un protocolo con la metodolog\u00eda \ndel proyecto a desarrollar. Se prepar\u00f3 el material a utilizar en la consulta de seguimiento. Por \u00faltimo, se contact\u00f3 \ntelef\u00f3nicamente con los pacientes que cumpl\u00edan los criterios de inclusi\u00f3n y, a aquellos que accedieron a participar, se les \ncit\u00f3 en una agenda del Servicio de Farmacia de seguimiento nutricional\ufffd\nIMPLANTACI\u00d3N\nEl protocolo del proyecto se revis\u00f3 y consensu\u00f3 entre los participantes del grupo multidisciplinar y fue aprobado tanto \npor la Comisi\u00f3n de Investigaci\u00f3n del Hospital y el Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n de las Islas Baleares.515RESULTADOS\nSe cre\u00f3 un protocolo de estudio observacional de seguimiento de pacientes que, al ser presentado a la Direcci\u00f3n del \nHospital, se consigui\u00f3 la creaci\u00f3n de una agenda y de un espacio f\u00edsico para el desarrollo del estudio. Se reclutaron a un \ntotal de 40 pacientes\ufffd\nLIMITACIONES\nLa implantaci\u00f3n de este Proyecto requiere de un elevado grado de implicaci\u00f3n de los profesionales y pacientes por lo que \nes imprescindible desarrollar una estrategia de comunicaci\u00f3n, participaci\u00f3n y reconocimiento atractiva y pertinente.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa medida implantada sirve como puerta para el desarrollo de un estudio observacional que puede contribuir en la \nmejora de la calidad de vida y de la evoluci\u00f3n de la enfermedad en pacientes con psoriasis y sobrepeso, por lo que puede \nser f\u00e1cilmente exportable a otros Servicios de Farmacia.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1171. ACTUALIZACI\u00d3N DEL PROCEDIMIENTO DE NUTRICI\u00d3N PARENTERAL DOMICILIARIA \nAUTORES\nL\u00d3PEZ P\u00c9REZ, A; PERALES PASCUAL, J; DIAZ DE CALDER\u00d3N HORCADA, C; PE\u00d1AS FERN\u00c1NDEZ, A; AGUILO LAFARGA, \nI; HERRANZ BAYO, E; SERRANO VICENTE, C\nHOSPITAL UNIVERSITARIO MIGUEL SERVET . P\u00ba DE ISABEL LA CAT\u00d3LICA, 1-3 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nLa Nutrici\u00f3n Parenteral Domiciliaria (NPD) es una modalidad de soporte nutricional que se administra en el domicilio del \npaciente utilizando una v\u00eda de acceso central. El objetivo principal es describir el procedimiento actual de la formulaci\u00f3n \nde NPD, incluyendo su prescripci\u00f3n, validaci\u00f3n, preparaci\u00f3n y dispensaci\u00f3n\ufffd\nMEJORAS ESPERADAS\n- Estandarizaci\u00f3n del proceso para aumentar seguridad.  \n- Mejora de calidad de vida de los pacientes, evit\u00e1ndose desplazamientos y permanencias innecesarias en el hospital.  \n- Incremento en la formaci\u00f3n de pacientes/familiares para facilitar el manejo de NPD. \n- Mayor disponibilidad de camas hospitalarias/disminuci\u00f3n de costes.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe cont\u00f3 con un equipo compuesto por m\u00e9dicos y farmac\u00e9uticos expertos en nutrici\u00f3n y enfermeras con experiencia \neducadora\ufffd \nCircuito y Etapas: \n- Identificaci\u00f3n de paciente con nutrici\u00f3n parenteral hospitalaria con criterios de inclusi\u00f3n en el programa de educaci\u00f3n \nde NPD \ufffd \n- Informaci\u00f3n/formaci\u00f3n al paciente/cuidador sobre manejo y mantenimiento de NPD por parte de la enfermera de \nnutrici\u00f3n. La formaci\u00f3n se distribuir\u00e1 en varias sesiones que se prolongar\u00e1n hasta confirmar plena autonom\u00eda en la \nt\u00e9cnica con independencia y seguridad.  \n- Prescripci\u00f3n m\u00e9dica de la NPD e informaci\u00f3n al Servicio de Farmacia (SF).  \n- Desde SF, validaci\u00f3n e inclusi\u00f3n del paciente en el programa. \n- Enfermer\u00eda de nutrici\u00f3n contacta con atenci\u00f3n primaria para informar del alta, resolver dudas y garantizar la continuidad \nde cuidados que pueda requerir el paciente. \n- Tras el alta, la NPD y el material necesario para su administraci\u00f3n se suministrar\u00e1n desde el SF. El facultativo del \u00e1rea de \nnutrici\u00f3n fija las citas con el paciente y le informa de la necesidad de mantener una v\u00eda de comunicaci\u00f3n disponible, bien \nsea correo electr\u00f3nico o tel\u00e9fono.  \n- Semanalmente el paciente/cuidador se pone en contacto con el SF para realizar la petici\u00f3n de material.\nIMPLANTACI\u00d3N\nEl protocolo fue aprobado en febrero de 2020 y su implantaci\u00f3n fue inmediata\ufffd\nRESULTADOS\n11 pacientes (7/11 mujeres) han requerido NPD durante los 2 \u00faltimos a\u00f1os, siendo 6 de ellos ni\u00f1os. La edad media de los \nadultos al inicio de la NPD fue de 48,6 \u00b1 23,14 a\u00f1os\ufffd  \n4/5 pacientes adultos eran oncol\u00f3gicos y se incluyeron en el programa por intolerancia a nutrici\u00f3n enteral y episodios de \noclusi\u00f3n intestinal secundarios a progresi\u00f3n tumoral. El paciente adulto restante padec\u00eda s\u00edndrome del intestino corto, al \nigual que los ni\u00f1os. En 2/6 ni\u00f1os se ha conseguido suspender totalmente la NPD tras observarse mejor\u00eda y tolerancia oral.  \nActualmente contin\u00faan en tratamiento domiciliario 4/11 pacientes, todos ellos ni\u00f1os. Todos sus cuidadores mantienen \ncontacto semanal/mensual con enfermer\u00eda y con SF.  \nDesde la implantaci\u00f3n se han preparado un total 1.856 NPD.\nLIMITACIONES\nFalta de datos previos a la implantaci\u00f3n del protocolo y de indicadores para evaluar la mejor\u00eda del proceso.516APLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEn los \u00faltimos a\u00f1os el conocimiento de que hospitalizar a un paciente implica aislarlo de su entorno social, ha llevado \nal desarrollo de un n\u00famero mayor de modalidades de tratamientos ambulatorios. Por ello, la NPD ha cobrado un \nimportante inter\u00e9s en los \u00faltimos a\u00f1os, convirti\u00e9ndose en una pr\u00e1ctica habitual del soporte nutricional\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1198. REVISI\u00d3N DEL PLAZO DE VALIDEZ DE F\u00d3RMULAS ORALES L\u00cdQUIDAS ELABORADAS POR UN \nSERVICIO DE FARMACIA TRAS APERTURA DE ENVASES MULTIDOSIS \nAUTORES\nGARC\u00cdA MORENO, FJ; PERN\u00cdA L\u00d3PEZ, MS; MANRIQUE RODR\u00cdGUEZ, S; TALADRIZ SENDER, I; MONTERO ANT\u00d3N, MP; \nROMERO JIM\u00c9NEZ, R; HERRANZ ALONSO, A; SANJURJO SA\u00c9Z, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nAsignar un tiempo de uso tras apertura de envase para f\u00f3rmulas orales l\u00edquidas (FOL) elaboradas por un Servicio de \nFarmacia Hospitalaria (SFH) e incorporar la informaci\u00f3n al etiquetado.\nMEJORAS ESPERADAS\nAportar seguridad en el empleo de estas preparaciones, reduciendo el riesgo de crecimiento microbiano por encima de \nvalores admitidos en Farmacopeas y de degradaci\u00f3n del principio activo y excipientes.\nDISE\u00d1O CIRCUITO Y ETAPAS\nB\u00fasqueda bibliogr\u00e1fica de estudios de estabilidad disponibles para las FOL elaboradas y revisi\u00f3n de la composici\u00f3n de las \nmismas, especialmente de los conservantes. Para asignar plazos de validez se consideraron las indicaciones de la Gu\u00eda de \nBuenas Pr\u00e1cticas de Preparaci\u00f3n de Medicamentos en Servicios de Farmacia Hospitalaria y del Grupo de Farmacotecnia \n(Bolet\u00edn vol. 9 N\u00ba1, 2021). Se consider\u00f3 que la concentraci\u00f3n de conservantes era relevante cuando la suma de \nconcentraciones de todos ellos (parabenos, sorbato pot\u00e1sico, benzoato y \u00e1cido benzoico) superaba el 0,1%. \n \nSe part\u00eda de un etiquetado en el que constaba \u00fanicamente fecha de caducidad seg\u00fan los datos de estabilidad \nfisicoqu\u00edmica disponibles en el momento de su primera elaboraci\u00f3n por el SFH. En ausencia de datos, antes de \ncomenzar a elaborar el preparado se realizaba una validaci\u00f3n gal\u00e9nica, limit\u00e1ndose la caducidad a 14 d\u00edas, o menor si \nel procedimiento constataba una alteraci\u00f3n de las propiedades antes de ese plazo. Para actualizar esta informaci\u00f3n, se \nsiguieron los siguientes pasos: \n1-Revisi\u00f3n bibliogr\u00e1fica estudios de estabilidad (Pubmed\u00ae, Embase\u00ae, Stabilis 4.0) y de la composici\u00f3n de las FOL \nelaboradas\ufffd  \n2-Aplicaci\u00f3n de criterios para asignaci\u00f3n de vida \u00fatil tras apertura de envase. \n3-Incorporaci\u00f3n del dato obtenido en el etiquetado, en el apartado de informaci\u00f3n para enfermer\u00eda del programa de \nPrescripci\u00f3n Electr\u00f3nica (ficha de producto) y en tr\u00edpticos informativos dirigidos a pacientes.\nIMPLANTACI\u00d3N\nEn abril 2022 se hab\u00eda actualizado la informaci\u00f3n en el 100% de FOL elaboradas.\nRESULTADOS\nDel total de 61 FOL elaboradas, 14 (23,0%) no ten\u00edan estudios referenciados de estabilidad fisicoqu\u00edmica o esta no \nsuperaba las dos semanas. En 3/14 de estas preparaciones se limit\u00f3 el plazo de validez tras apertura de 14 a 8 d\u00edas por \ncarecer de conservantes, manteni\u00e9ndose inalterado en los restantes. \n \nEn 47 preparaciones (77,0%) exist\u00eda respaldo de estudios de estabilidad que permit\u00edan asignar una caducidad de entre \n28 y 90 d\u00edas. De ellas 6 carec\u00edan de conservantes, limitando el plazo de validez tras apertura a 14 d\u00edas si se almacenaban \nrefrigeradas (2) y a 8 d\u00edas para conservaci\u00f3n a temperatura ambiente (4). Las 41 restantes contaban con conservantes, \nde las cuales 7 ten\u00edan una caducidad de 28-30 d\u00edas que se manten\u00eda invariable tras apertura y 34 una caducidad superior, \nacort\u00e1ndose a 30 d\u00edas.\nLIMITACIONES\n-La elaboraci\u00f3n en atm\u00f3sfera no controlada modificar\u00eda los plazos de validez descritos.  \n-Principios activos y excipientes altamente sensibles a exposici\u00f3n a condiciones ambientales por oxidaci\u00f3n u otros \nprocesos degradativos podr\u00edan necesitar una limitaci\u00f3n del tiempo de uso del envase abierto a\u00fan mayor.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable en cualquier Servicio de Farmacia. La metodolog\u00eda aplicada puede ser v\u00e1lida tanto para f\u00f3rmulas magistrales \ncomo FOL comerciales que no aporten esta informaci\u00f3n, ya que el Real Decreto 175/2003 no la considera indispensable \nen el etiquetado.517CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS \nTECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n79. AUTOMATIZACI\u00d3N DE LA ELABORACI\u00d3N DE ANTINEOPL\u00c1SICOS. EXPERIENCIA EN UN HOSPITAL DE \nTERCER NIVEL. \nAUTORES\nVALENCIA SOTO, CM; VILLACA\u00d1AS PALOMARES, MV; GARC\u00cdA-AVELLO FERN\u00c1NDEZ-CUETO, A; BARBADILLO \nVILLANUEVA, S; MART\u00cdNEZ CALLEJO, V; OCHAGAV\u00cdA SUFRATEGUI, M; RAMIS BARCEL\u00d3, MB; VALERO DOM\u00cdNGUEZ, \nM\nHOSPITAL UNIVERSITARIO MARQU\u00c9S DE VALDECILLA \ufffd AV\ufffd DE VALDECILLA, S/N SANTANDER \ufffd CANTABRIA\nOBJETIVOS\nIncrementar la seguridad y optimizar el proceso de elaboraci\u00f3n de f\u00e1rmacos antineopl\u00e1sicos en un \u00e1rea de Farmacia \nOncol\u00f3gica\ufffd\nMEJORAS ESPERADAS\nEl uso de sistemas de reconocimiento y el control gravim\u00e9trico garantizan la trazabilidad y aumentan la exactitud en la \nelaboraci\u00f3n, mejorando la seguridad del paciente.  \nAdem\u00e1s, la incorporaci\u00f3n de sistemas robotizados minimiza la exposici\u00f3n a f\u00e1rmacos citot\u00f3xicos, contribuyendo a una \nmayor seguridad del trabajador.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe instal\u00f3 el sistema APOTECA en las salas blancas del \u00e1rea de Farmacia Oncol\u00f3gica. Esto incluy\u00f3 el software de gesti\u00f3n \n(APOTECAmanager), los sistemas para elaboraci\u00f3n semiautomatizada incorporados a las cabinas de flujo vertical \n(APOTECAps) y el sistema automatizado (APOTECAchemo).  \nSe realiz\u00f3 un an\u00e1lisis retrospectivo del proceso de implementaci\u00f3n y los resultados obtenidos.  \n \nSe dise\u00f1\u00f3 un flujo de trabajo:  \n1\u00ba Periodo de puesta a punto (noviembre 2020-abril 2021):  \n-Integraci\u00f3n de APOTECA con el sistema de prescripci\u00f3n electr\u00f3nica asistida propio del hospital (PEA).  \n-Configuraci\u00f3n y parametrizaci\u00f3n de los f\u00e1rmacos en el software de gesti\u00f3n.  \n-An\u00e1lisis de f\u00e1rmacos y condiciones de elaboraci\u00f3n.  \nSe seleccionaron los f\u00e1rmacos susceptibles de elaboraci\u00f3n en APOTECA, excluyendo determinados f\u00e1rmacos por \nparticularidades en la elaboraci\u00f3n, problemas en la integraci\u00f3n o uso muy puntual.  \nSe estableci\u00f3 un error m\u00e1ximo tolerado en la elaboraci\u00f3n de \u00b15% para considerar v\u00e1lidas las preparaciones.  \n2\u00ba Periodo de utilizaci\u00f3n:  \n-Formaci\u00f3n (mayo-julio 2021). Se estableci\u00f3 un calendario de formaci\u00f3n en el manejo de la plataforma para \nfarmac\u00e9uticos y t\u00e9cnicos de farmacia. Se trabaj\u00f3 en paralelo de forma manual, con incorporaci\u00f3n progresiva de la \nelaboraci\u00f3n mediante APOTECA \ufffd  \n-Producci\u00f3n real con APOTECA (julio 2021-abril 2022). Durante esta fase, se mantuvieron actividades de formaci\u00f3n y \nconfiguraci\u00f3n de nuevos f\u00e1rmacos.\nIMPLANTACI\u00d3N\nSe llev\u00f3 a cabo entre noviembre de 2020 y julio 2021.\nRESULTADOS\nSe analiz\u00f3 la actividad de 41 semanas (julio 2021-abril 2022). Se excluyeron fines de semana y festivos, as\u00ed como \npreparaciones correspondientes a ensayos cl\u00ednicos.  \nDurante el periodo evaluado, se elaboraron un total de 23.506 mezclas (122 diarias) en Farmacia Oncol\u00f3gica, de las \ncuales 19.735 (103 diarias) se realizaron en APOTECA, lo cual supuso un 84% de la producci\u00f3n.  \nDesglosado por dispositivos, 7.434 preparaciones (39 diarias) se elaboraron en el sistema robotizado APOTECAchemo, y \n12.301 (64 diarias) en APOTECAps.  \nLos 5 f\u00e1rmacos m\u00e1s frecuentemente preparados en el sistema robotizado fueron paclitaxel, carboplatino, oxalipatino, \ncisplatino y ciclofosfamida, que supusieron un 52% de la producci\u00f3n total del dispositivo. La media de error en \nAPOTECAchemo fue de 1,11 (\u00b10,94)%.  \nEtop\u00f3sido, fosaprepitant, azacitidina, fluorouracilo y pembrolizumab fueron los m\u00e1s habitualmente elaborados en \nAPOTECAps (30% de la producci\u00f3n). La media de error en APOTECAps fue 1,54 (\u00b11,37)%.\nLIMITACIONES\nTras las fases iniciales, el uso de APOTECA requiere tiempo y recursos. Se necesita un farmac\u00e9utico disponible para:  \n\u2022Resoluci\u00f3n de incidencias en el manejo de los sistemas, ya sea de forma aut\u00f3noma o a trav\u00e9s del personal t\u00e9cnico \nresponsable de APOTECA \ufffd \n\u2022Configuraci\u00f3n de nuevas presentaciones por los frecuentes desabastecimientos de f\u00e1rmacos.  \n\u2022Coordinar y organizar el flujo de trabajo para optimizar la producci\u00f3n.518APLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a Servicios de Farmacia que valoren la incorporaci\u00f3n de esta tecnolog\u00eda.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n163. DESARROLLO DE UNA APLICACI\u00d3N M\u00d3VIL PARA ADMINISTRACI\u00d3N DE MEDICAMENTOS EN \nPACIENTES CON DISFAGIA \nAUTORES\nDELGADO SILVEIRA, E; HIDALGO CORREAS, FJ; \u00c1LVARO ALONSO, EA; BEOBIDE TELLER\u00cdA, I; BRAVO JOS\u00c9, P; CASAJ\u00daS \nLAGRANJA, MP; LLANOS GARC\u00cdA, MT; SAAVEDRA QUIR\u00d3S, V\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\nDesarrollar una aplicaci\u00f3n m\u00f3vil (App), en formato gu\u00eda, para consultar la administraci\u00f3n adecuada y segura de \nmedicamentos en pacientes con disfagia\ufffd\nMEJORAS ESPERADAS\nDisponer de una App para dispositivos m\u00f3viles, de f\u00e1cil manejo, con recomendaciones necesarias y actualizadas para \nla administraci\u00f3n de medicamentos en disfagia y que permita adecuar las diferentes formas farmac\u00e9uticas de los \nmedicamentos a las necesidades reales de los pacientes, sin por ello disminuir la efectividad y seguridad.\nDISE\u00d1O CIRCUITO Y ETAPAS\nDise\u00f1o:  \nLa App recoge recomendaciones sobre la administraci\u00f3n de medicamentos en disfagia. Se cre\u00f3 un grupo de trabajo de \nfarmac\u00e9uticos especialistas que trabajan en diferentes \u00e1mbitos de la asistencia sanitaria (grupo investigador). Se clasific\u00f3 \na los f\u00e1rmacos siguiendo la clasificaci\u00f3n ATC, especificando para cada forma farmac\u00e9utica las recomendaciones seg\u00fan \nla evidencia. Se contrat\u00f3 a una empresa dise\u00f1adora de App. La recogida de informaci\u00f3n se realiz\u00f3 en una base de datos \ncreada en REDCAP \ufffd \n \nCircuito y etapas: \n\u25cf Revisi\u00f3n bibliogr\u00e1fica: revisi\u00f3n de la evidencia disponible en diferentes bases de datos, p\u00e1ginas web, empleando \ndiferentes estrategias de b\u00fasqueda y t\u00e9rminos MeSH relacionados con disfagia.  \n\u25cf Selecci\u00f3n de los medicamentos a revisar.  \n\u25cf Elaboraci\u00f3n de contenidos: Se pidi\u00f3 colaboraci\u00f3n a los farmac\u00e9uticos adheridos a los grupos de trabajo, se \ndistribuyeron los medicamentos a revisar, revisando, extrayendo y estructurando la informaci\u00f3n\ufffd  \n\u25cf Desarrollo App: dos fases: (1) desarrollo del dise\u00f1o de la App (se crearon varios prototipos, el seleccionado se revis\u00f3 y \nvalid\u00f3), (2) revisi\u00f3n y unificaci\u00f3n de los contenidos adapt\u00e1ndolos a la misma.  \n\u25cf Prueba de la App: el contenido fue entregado a la empresa, que activ\u00f3 una primera versi\u00f3n beta, y que fue revisado \ntanto su contenido como su dise\u00f1o\ufffd  \n\u25cf Etapa de actualizaci\u00f3n de contenidos.\nIMPLANTACI\u00d3N\nSe ha implantado la primera versi\u00f3n en 2022. Esta App seguir\u00e1 actualiz\u00e1ndose con medicamentos no incluidos en la \nprimera versi\u00f3n y de las nuevas evidencias sobre manipulaci\u00f3n de medicamentos que se vayan publicando.\nRESULTADOS\nSe ha dise\u00f1ado una App que contiene 477 principios activos.  \n- Informaci\u00f3n general: info disfagia, info app, enlaces a p\u00e1ginas web. \n- Buscador de medicamentos por principio activo y nombre comercial.  \n- Gu\u00eda de contenidos de cada principio activo: subgrupo terap\u00e9utico (clasificaci\u00f3n ATC), formas farmac\u00e9uticas \ncomercializadas y f\u00f3rmulas magistrales, peligrosidad, formas farmac\u00e9uticas manipulables para administrar en disfagia con \nrecomendaciones espec\u00edficas, recomendaciones de administraci\u00f3n con espesantes, soporte nutricional oral y alimentos, \ndescripci\u00f3n de elaboraci\u00f3n de la f\u00f3rmula magistral (en caso de disponibilidad), excipientes de declaraci\u00f3n obligatoria, \nreferencias bibliogr\u00e1ficas y fecha de revisi\u00f3n.\nLIMITACIONES\n- Existe poca evidencia acerca de la manipulaci\u00f3n de algunos medicamentos y su combinaci\u00f3n con espesantes. \n- Inicialmente se ha dise\u00f1ado para profesionales sanitarios. En fases posteriores se destinar\u00e1 a pacientes y cuidadores.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa App permitir\u00e1 a los farmac\u00e9uticos disponer, en dispositivos m\u00f3viles, de informaci\u00f3n veraz y de instrucciones sencillas \npara la manipulaci\u00f3n de medicamentos en disfagia. Facilitar\u00e1, de forma r\u00e1pida y \u00e1gil, la toma de decisiones en el manejo \nde la medicaci\u00f3n en estos pacientes\ufffd519CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n233. PROFESIONALIZACI\u00d3N DEL USO DE REDES SOCIALES EN UN SERVICIO DE FARMACIA HOSPITALARIA \nAUTORES\nMONTERO PASTOR, B; IZQUIERDO GARC\u00cdA, E; \u00c1LVARO ALONSO, EA; SANTIAGO P\u00c9REZ, A; DE AGUST\u00cdN SIERRA, L; \nCA\u00d1AMARES ORBIS, I; SUCH D\u00cdAZ, A; ESCOBAR RODR\u00cdGUEZ, I\nHOSPITAL INFANTA LEONOR \ufffd GRAN V\u00cdA DEL ESTE, 80 MADRID \ufffd MADRID\nOBJETIVOS\nDescribir el desarrollo e implantaci\u00f3n de un plan de Community Management (CM) para la gesti\u00f3n de las redes sociales \n(RRSS) de un Servicio de Farmacia Hospitalaria (SFH).\nMEJORAS ESPERADAS\nCon este plan se pretende potenciar la visibilidad del SFH en el entorno digital, obtener informaci\u00f3n cient\u00edfica de inter\u00e9s \npara la pr\u00e1ctica diaria de los profesionales del SFH, difundir contenido cient\u00edfico propio y proporcionar informaci\u00f3n de \ncalidad sobre medicamentos y salud a pacientes y poblaci\u00f3n general\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\n1. Definici\u00f3n de los objetivos del plan de CM: benchmarking y promoci\u00f3n de las actividades y logros del SFH, difusi\u00f3n de \ncontenido cient\u00edfico a profesionales sanitarios y atenci\u00f3n farmac\u00e9utica y formaci\u00f3n a pacientes y poblaci\u00f3n general.  \n2. An\u00e1lisis de la audiencia potencial y selecci\u00f3n de RRSS en las que se busca presencia (Twitter\u00ae e Instagram\u00ae). \n3. Creaci\u00f3n de una imagen de marca: nombre de usuario, logotipo y colores de marca. \n4. Selecci\u00f3n y creaci\u00f3n de contenidos a compartir: en coordinaci\u00f3n con las diferentes \u00e1reas del SFH, se selecciona \nun tema principal sobre el que se va a elaborar contenido (infograf\u00edas, hilos de Twitter, publicaciones o reels -videos \ncortos- en Instagram). Semanalmente, se realiza un an\u00e1lisis de los perfiles seguidos y a seguir por el SFH y se revisan los \ncontenidos publicados por los mismos\ufffd  \n5. Programaci\u00f3n de la difusi\u00f3n de contenidos: una vez al mes, se publica contenido de elaboraci\u00f3n propia. \nSemanalmente, se revisa y comparte contenido generado por otros perfiles y se recopila para la elaboraci\u00f3n de boletines \nde difusi\u00f3n interna en el SFH (herramienta Revue\u00ae).  \n6. An\u00e1lisis de las m\u00e9tricas obtenidas y redefinici\u00f3n de la selecci\u00f3n de contenidos en funci\u00f3n de las mismas.\nIMPLANTACI\u00d3N\nDesde mayo de 2021 el SFH dispone de un perfil en Twitter e Instagram que utiliza para la obtenci\u00f3n de informaci\u00f3n \ncient\u00edfica y la difusi\u00f3n de contenido propio.\nRESULTADOS\nEn Twitter, el SFH cuenta con 330 seguidores. Se han publicado 87 tuits originales con una tasa de interacci\u00f3n media \ndel 4,0%. En Instagram, el n\u00famero de seguidores es de 369, se han realizado 47 publicaciones, con una media de 15 \ninteracciones por publicaci\u00f3n\ufffd  \nSe han elaborado 8 infograf\u00edas y 6 reels relacionados con formaci\u00f3n sanitaria especializada, vacunaci\u00f3n COVID-19, \npatolog\u00edas v\u00edricas y oncohematolog\u00eda, destinadas tanto a profesionales sanitarios como a pacientes y poblaci\u00f3n general.\nLIMITACIONES\nLa implantaci\u00f3n de un plan de CM en un SFH requiere un coordinador con un perfil dual, ya que es necesario disponer \ntanto de conocimientos sobre el uso de RRSS como de conocimientos cient\u00edfico-sanitarios para la selecci\u00f3n de \ninformaci\u00f3n y el desarrollo de contenidos propios. Por otra parte, esta actividad requiere dedicaci\u00f3n y seguimiento \ncontinuado, aunque el uso de herramientas para su gesti\u00f3n como Hootsuite\u00ae o Metricool\u00ae permiten su optimizaci\u00f3n.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nExiste un elevado n\u00famero de SFH que disponen de cuenta en Twitter\u00ae y algunos de ellos tambi\u00e9n disponen de perfil en \nInstagram\u00ae. La profesionalizaci\u00f3n del uso de RRSS mediante la implantaci\u00f3n de un plan de CM permite definir objetivos \nespec\u00edficos para las RRSS del SFH y optimizar el modo en el que se adquiere y comparte informaci\u00f3n.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n243. REFORM\u00daLATE DE FORMA SOSTENIBLE EN LA IDENTIFICACI\u00d3N DE F\u00c1RMACOS: REETIQUETAR EN \nLUGAR DE REENVASAR \nAUTORES\nGARCIA MARTINEZ, D; MARTINEZ CAMACHO, M; CAZORLA MARTINEZ, MJ; LOPEZ DOLADO, E; RODRIGUEZ JIMENEZ, \nE; RUEDA NAHARRO, A; GARCIA MARCO, D\nHOSPITAL GERI\u00c1TRICO VIRGEN DEL VALLE \ufffd CTRA \ufffd DE COBISA, S/N \ufffd TOLEDO \ufffd TOLEDO\nOBJETIVOS\nMejorar la sostenibilidad ambiental reformulando el proceso de reacondicionamiento de medicamentos en dosis \nunitarias\ufffd\nMEJORAS ESPERADAS\nDisminuir la contaminaci\u00f3n ambiental reduciendo el material empleado en el reacondicionamiento: pl\u00e1stico, aluminio y \ncalco\ufffd520DISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O  \nSe realiz\u00f3 un estudio comparativo analizando la contaminaci\u00f3n generada en el proceso de reetiquetado frente al \nproceso de reenvasado\ufffd Para ello se compararon el reacondicionamiento de tres medicamentos diferentes\ufffd Para \nreenvasar se emple\u00f3 una m\u00e1quina reenvasadora de f\u00e1rmacos, marca Automed\u00ae modelo FASTPAK-TABLETOP UP507; \ncinta de impresora, papel blanco, opalina y calco negro. Para reetiquetar se utiliz\u00f3 el programa \u201cDale color a tu Dosis \nUnitaria\u201d\u00ae, un ordenador Fujitsu Siemens Computers\u00ae Pentium\u00ae 4 CPU 3.00GHz 2,79GHz, 1,00 GB de RAM (Windows XP \nProfessional), una impresora EPSON XP-442 \u00ae, Toner EPSON\u00ae negro, cian, yellow y margenta, etiquetas autoadhesivas \nblancas APLI\u00ae\ufffd \nCIRCUITO Y ETAPAS \nSe procedi\u00f3 a reenvasar y reetiquetar 100 comprimidos de tres \nmedicamentos diferentes y para obtener el dato del peso en gramos del residuo generado se pesaron tanto las etiquetas \nempleadas como cada unidad de envase generado en el reenvasado. Adem\u00e1s, para medir el espacio, se obtuvo la \nsuperficie que ocupaba cada residuo midiendo cada producto final en cm2, as\u00ed como del material que se desech\u00f3 durante \nel proceso\ufffd\nIMPLANTACI\u00d3N\nEl hospital ya dispon\u00eda de una m\u00e1quina de reenvasado de medicamentos. El proyecto de reetiquetado se implanta al mes \nde disponer de los recursos necesarios para desarrollar el reetiquetado, con una breve formaci\u00f3n al personal del \u00e1rea del \nprograma \u201cDale color a tu Dosis Unitaria\u201d\u00ae\ufffd\nRESULTADOS\nLa media del peso del residuo generado en 100 comprimidos fue de 5,95 g en el reetiquetado frente a 81,27 g en el \nreenvasado, ahorrando un 92,68% de desecho de material. En cuanto a la superficie, se redujo en un 93,82 % con el \nreetiquetado, siendo de 7769,52 cm2 frente a 480 cm2.  \nDel 01 de Enero al 31 de Diciembre de 2021 se reetiquetaron en el servicio de Farmacia 163.216 formas farmac\u00e9uticas \ns\u00f3lidas. Realizando una estimaci\u00f3n, el residuo del etiquetado ocup\u00f3 78,34 m2, frente a 1268,11 m2 del reenvasado, por \nlo que se ha evitado una superficie de material de 1268,11 m2. Si dispusi\u00e9ramos el material del reenvasado en l\u00ednea recta \nocupar\u00eda 21,54 km. El peso del residuo generado en el reenvasado fue de 132,64 Kg frente a 9,71 Kg del reetiquetado \n(reduci\u00e9ndose 92,68%). Se ha ahorrado al medio ambiente 122,93 Kg de residuo.\nLIMITACIONES\nEl proceso de reenvasado no se puede sustituir totalmente por el reetiquetado. Por un lado, hay pacientes que precisan \nde dosis peque\u00f1as de f\u00e1rmacos que no est\u00e1n comercializadas, requiriendo del fraccionamiento. Por otra parte, es \nnecesario reenvasar los medicamentos que no est\u00e1n emblistados.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEs aplicable en los servicios de farmacia para su dispensaci\u00f3n tanto a Hospitales como a Centros Sociosanitarios ya que \nlos recursos necesarios suponen menor coste econ\u00f3mico que el reenvasado tradicional.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n334. DISE\u00d1O, DESARROLLO E IMPLEMENTACI\u00d3N DE LA TELEFARMACIA EN UN HOSPITAL DE TERCER \nNIVEL. \nAUTORES\nFRESQUET MOLINA, R; GRACIA PIQUER, R; GIMENO GRACIA, M; SALVADOR GOMEZ, T; PASCUAL MARTINEZ, O; \nVINUESA HERNANDO, JM; SOPENA CARRERA, L; MERCHAN FLORES, A\nHOSPITAL CL\u00cdNICO UNIVERSITARIO LOZANO BLESA. SAN JUAN BOSCO, 15 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nDise\u00f1ar un programa de dispensaci\u00f3n y atenci\u00f3n farmac\u00e9utica con telefarmacia a pacientes del \u00e1rea rural, desde el \nServicio de Farmacia (SF) de un hospital de tercer nivel.\nMEJORAS ESPERADAS\nDisminuci\u00f3n del tiempo empleado por el paciente en la recogida de medicaci\u00f3n hospitalaria manteniendo la calidad de la \natenci\u00f3n farmac\u00e9utica. \nEvitar desplazamientos en pacientes vulnerables por motivos sociales, patol\u00f3gicos o dificultad en el desplazamiento.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe realiz\u00f3 un procedimiento normalizado de trabajo (PNT) definiendo las tareas de cada profesional sanitario. Se \nseleccionaron pacientes de una zona rural con centro m\u00e9dico de especialidades (CME).  \nINFORMACI\u00d3N AL PACIENTE DE LA TELEFARMACIA \n\u2022 Explicaci\u00f3n al paciente del objetivo y circuito de coordinaci\u00f3n. Firma del consentimiento informado.  \n\u2022 Previa a la dispensaci\u00f3n se realiza la teleconsulta por telef\u00f3no.  \n\u2022 Env\u00edo de f\u00e1rmacos al CME el tercer martes de cada mes.  \n\u2022 Dispensaci\u00f3n al paciente o persona autorizada por un t\u00e9cnico de farmacia (TAF) del CME el tercer jueves de cada mes. \nTELECONSULTA  \n\u2022 Se dispensa para un mes o dos, seg\u00fan la situaci\u00f3n del paciente.  \n\u2022 Se confirma el servicio en la empresa log\u00edstica detallando medicamento, unidades, lote y caducidad. La medicaci\u00f3n se 521dispensa tambi\u00e9n en el programa de pacientes externos del SF.  \n\u2022 El TAF acondiciona la medicaci\u00f3n por paciente y en en cajas seg\u00fan termol\u00e1biles o no.  \nENV\u00cdO DE MEDICACI\u00d3N \n\u2022 Antes del env\u00edo se comprueba que cada caja contiene un term\u00f3metro que hace trazabilidad de la temperatura hasta su \nllegada al destino en CME.  \n\u2022 El TAF comprueba que la medicaci\u00f3n llega en buen estado y la temperatura es correcta. Y env\u00eda las temperaturas por \ncorreo electr\u00f3nico al SF y a la empresa externa\ufffd\nIMPLANTACI\u00d3N\nLa implantaci\u00f3n requiri\u00f3 un cambio en la forma de trabajar de farmac\u00e9uticos y TAF. As\u00ed como una inversi\u00f3n econ\u00f3mica \ndestinada a la empresa log\u00edstica externa encargada de llevar la medicaci\u00f3n y al mantenimiento de la aplicaci\u00f3n \ninform\u00e1tica. \nTodo el personal implicado requiri\u00f3 una formaci\u00f3n espec\u00edfica de circuitos y programas inform\u00e1ticos.\nRESULTADOS\nDe media se ha dispensado a 44 pacientes/mes en 2020 y 50 pacientes/mes en 2021, representan el 2,3% del total de \npacientes en dispensaci\u00f3n en pacientes externos\ufffd  \nLa satisfacci\u00f3n medida a trav\u00e9s de una encuesta fue del 97%. La encuesta se realiz\u00f3 a 70 pacientes, con una edad media \nde 51,5\u00b117,8 a\u00f1os; 57,1% hombres. 82,5% viv\u00eda en la misma ciudad que el CME y 7,5% poblaciones cercanas. 68,6% \nf\u00e1rmacos biol\u00f3gicos, 7,1% f\u00e1rmacos para la esclerosis m\u00faltiple, 5,7% antibacterianos, 4,3% hormona de crecimiento, 2,8% \nantirretrovirales y 11,5% otros.\nLIMITACIONES\nEl tiempo invertido en cada paciente es superior al que se invierte en la consulta de atenci\u00f3n farmacia presencial, debido \na la labor log\u00edstica y la duplicidad de tareas en los sistemas inform\u00e1ticos al no estar integrados.  \nPacientes con dificultades cognitivas o con problemas en el manejo de dispositivos m\u00f3viles.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\n.Este sistema se puede aplicar en todos los SF tengan como objetivo implantar la telefarmacia como medida alternativa \nla atenci\u00f3n farmac\u00e9utica presencial. Especialmente en aquellos hospitales con un elevado volumen de pacientes de \u00e1reas \nrurales y tienen problemas en los desplazamientos.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n409. EXPERIENCIA DE LIDERAZGO EN LA GESTI\u00d3N Y OPTIMIZACI\u00d3N DE TERAPIAS DE ALTO IMPACTO \nAUTORES\nORTEGA ARMI\u00d1ANA, AM; SANCHO ART\u00c9S, A; VALCUENDE ROSIQUE, A; COLOM MORENO, RM; CEBRIAN LARA, L; \nS\u00c1NCHEZ ALCARAZ, A\nHOSPITAL UNIVERSITARIO DE LA RIBERA \ufffd CRTRA CORBERA, KM \ufffd 1 ALZIRA \ufffd VALENCIA\nOBJETIVOS\n1) Optimizar el proceso de gesti\u00f3n de tratamientos de alto impacto (TAI) por el Comit\u00e9. \n2) Promover la optimizaci\u00f3n terap\u00e9utica, tomando como base la evidencia cient\u00edfica y resultados en salud, para lograr \nmayor seguridad y eficiencia.\nMEJORAS ESPERADAS\n1) Mejorar la gesti\u00f3n del tiempo, mediante reducci\u00f3n del n\u00ba solicitudes que requieren evaluaci\u00f3n por el Comit\u00e9. \n2) Optimizar la terap\u00e9utica, mediante protocolos de tratamiento (PT) consensuados para lograr menor variabilidad en \npr\u00e1ctica cl\u00ednica y elecci\u00f3n entre alternativas basada en eficiencia.\nDISE\u00d1O CIRCUITO Y ETAPAS\n1) Revisi\u00f3n de debilidades del circuito. Circuito: las solicitudes de inicio/cambio requer\u00edan ser presentadas por el \nsolicitante en la reuni\u00f3n semanal del Comit\u00e9, representado por Direcci\u00f3n M\u00e9dica (DM) y Servicio de Farmacia (SF). \nDebilidades: elevado n\u00ba de solicitudes que requer\u00edan evaluaci\u00f3n, deficiente gesti\u00f3n del tiempo, escasa consideraci\u00f3n de \neficiencia, variabilidad en pr\u00e1ctica cl\u00ednica y escasa orientaci\u00f3n a evaluaci\u00f3n de resultados.  \n2) Propuesta de mejoras: actualizaci\u00f3n del procedimiento de gesti\u00f3n, instauraci\u00f3n de PT (tras ello, si la solicitud cumple \nlos criterios definidos, se considera ordinaria y se evita la presencia del solicitante en la reuni\u00f3n), actualizaci\u00f3n de costes y \nde PT en lo referente a eficiencia y evaluaci\u00f3n de resultados.  \n3) Puesta en marcha. Se acuerda mantener el Comit\u00e9 con actualizaci\u00f3n de procedimientos, y conformar grupos \nde trabajo espec\u00edficos. Se han conformado dos Unidades Funcionales (UF) para la gesti\u00f3n de terapias biol\u00f3gicas y \noncohematol\u00f3gicas, representadas por DM, SF y Servicios Cl\u00ednicos implicados. Las UF consensuan los PT de mayor \neficiencia y conveniencia para los pacientes que se toman como referencia en la valoraci\u00f3n de las solicitudes de \ntratamiento\ufffd\nIMPLANTACI\u00d3N\nLa implantaci\u00f3n ha requerido un periodo de 6 meses. Ha implicado actitud de liderazgo por el SF y DM para generar un \ncambio en la cultura organizativa, crear un clima de confianza y un sentimiento de equipo y orgullo de pertenencia que \nfavorezca tanto al profesional como al paciente.522RESULTADOS\n1) Instauraci\u00f3n de PT consensuados por las UF y basados en eficiencia.  \n2) Revisi\u00f3n de procesos relacionados con la optimizaci\u00f3n terap\u00e9utica, como la monitorizaci\u00f3n de biol\u00f3gicos.  \n3) Puesta en com\u00fan de proyectos de evaluaci\u00f3n de resultados.  \n4) Promoci\u00f3n del uso de biosimilares: aumento en la penetraci\u00f3n en 2021 (57,7%) respecto a 2020 (37,5 %).  \n5) Promoci\u00f3n del uso de terapias eficientes: indicador de eficiencia TAI en 2021 (3,42) superior a la media de los \nhospitales de la Comunidad Valenciana (2,97).  \n6) Reducci\u00f3n del n\u00ba de solicitudes que requieren evaluaci\u00f3n por el Comit\u00e9: Primer trimestre 2020 (previo al cambio): \n303 solicitudes evaluadas. Primer trimestre 2022 (posterior al cambio): 309 solicitudes recibidas, de las cuales 30 han \nrequerido evaluaci\u00f3n por el Comit\u00e9: 12 fuera de ficha t\u00e9cnica, 6 fuera de gu\u00eda farmacoterap\u00e9utica, 3 no financiados, \n3 usos compasivos y 1 cambio por reacci\u00f3n adversa no documentada\ufffd Respecto a las decisiones tomadas, constan 16 \naprobaciones, 7 aprobaciones temporales sujetas a revisi\u00f3n, 3 denegaciones y 4 cambios a alternativa m\u00e1s eficiente.\nLIMITACIONES\nResistencia al trabajo en equipo y/o dedicaci\u00f3n de tiempo a la evaluaci\u00f3n de resultados.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a cualquier centro con profesionales con motivaci\u00f3n, capacidad de liderazgo y trabajo en equipo.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n511. DESARROLLO DE UNA APLICACI\u00d3N M\u00d3VIL DE MAPEO DE LAS MOCHILAS DE URGENCIA \nAUTORES\nAC\u00cdN GERIC\u00d3, MT; GARC\u00cdA GIMENO, \u00cd; GARC\u00cdA GONZ\u00c1LEZ, P; FALCONE LANAS, F; SANZ ALV\u00c1REZ, L; FERN\u00c1NDEZ \nGONZ\u00c1LEZ, J; GARJ\u00d3N PARRA, J\nSUBDIRECCI\u00d3N DE FARMACIA Y PRESTACIONES. SERVICIO NAVARRO DE SALUD - OSASUNBIDEA\nOBJETIVOS\nPara lograr cubrir de la manera m\u00e1s eficiente posible la atenci\u00f3n prehospitalaria de urgencia, dentro del proyecto de \nhomogeneizaci\u00f3n de la medicaci\u00f3n y material sanitario de las mochilas del personal que cubre la urgencia desde los \ncentros de salud (CS), ambulancias de soporte vital b\u00e1sico (ASVB) y ambulancias de soporte vital avanzado (ASVA), se \nincluye su ubicaci\u00f3n adecuada en los distintos departamentos de los que consta la mochila de urgencias.\nMEJORAS ESPERADAS\nSe espera facilitar la r\u00e1pida localizaci\u00f3n de los medicamentos (M) y material sanitario (MS) en las mochilas de urgencia, \nas\u00ed como su estado de stock en tiempo real. \nDisponer de esta informaci\u00f3n en una aplicaci\u00f3n informatizada proporcionar\u00eda una imagen visual para una localizaci\u00f3n \nr\u00e1pida del M y MS, reduciendo la posibilidad de error, facilitando y agilizando la asistencia, lo que es crucial en situaciones \nde urgencia, especialmente tiempo-dependientes. \nAdem\u00e1s, se podr\u00edan retirar los formatos en papel u otros formatos que impliquen su instalaci\u00f3n en ordenadores fijos o \nport\u00e1tiles con la sobrecarga de peso que supone en un desplazamiento de urgencia.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe desarrolla una aplicaci\u00f3n m\u00f3vil por medio de la cual se podr\u00e1n localizar los M y MS del que se dispone en las mochilas \nde urgencia ubicadas en los CS, ASVB y ASVA \ufffd \nLos M y MS se pueden buscar tanto por sistema de voz como por escritura. La aplicaci\u00f3n muestra su ubicaci\u00f3n en la \nmochila, as\u00ed como la dosis de carga y otros archivos de texto de los protocolos de actuaci\u00f3n seg\u00fan el tipo de urgencia.  \nCircuito y etapas: \n1\u00ba. Se pacta el inventario de M y MS incluidos en la mochila de urgencias.  \n2\u00ba. Se incluye en la aplicaci\u00f3n el inventario de las mochilas basado en el sistema de identificaci\u00f3n mediante \nradiofrecuencia RFID para reducir el tiempo que tarda el personal sanitario en realizar la b\u00fasqueda, su reposici\u00f3n y dejar \nla mochila disponible para la pr\u00f3xima urgencia.  \n3\u00ba. La aplicaci\u00f3n se presenta a los centros implicados para valorar su viabilidad y puesta en funcionamiento.\nIMPLANTACI\u00d3N\nHasta la fecha, se ha desarrollado un prototipo de la aplicaci\u00f3n, en colaboraci\u00f3n con la Escuela de Ingenier\u00eda de \nTelecomunicaci\u00f3n de la Universidad P\u00fablica de la comunidad.\nRESULTADOS\nSe ha presentado como Trabajo de Fin de Grado y se proyecta un estudio piloto de su viabilidad y utilidad en la pr\u00e1ctica \nasistencial, con el fin de expandir esta aplicaci\u00f3n a la sistem\u00e1tica habitual.\nLIMITACIONES\nLa falta de integraci\u00f3n de la aplicaci\u00f3n en el sistema de gesti\u00f3n de stocks MM-SAP dificulta la detecci\u00f3n de fallos de stock \ny registro de caducidades. Requiere de su implementaci\u00f3n en los sistemas inform\u00e1ticos y para ello otorgar a este proyecto \nuna prioridad en su desarrollo\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl desarrollo de esta aplicaci\u00f3n es aplicable en cualquier servicio de farmacia que cuente con dispensaci\u00f3n de \nmedicamentos a los servicios de urgencias\ufffd523CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n512. CIRCUITO DE PRESCRIPCI\u00d3N, VALIDACI\u00d3N Y DISPENSACI\u00d3N DE NIRMATRELVIR/RITONAVIR \n(PAXLOVID\u00ae) PARA LA INFECCI\u00d3N POR SARS-COV-2: COORDINANDO NIVELES ASISTENCIALES \nAUTORES\nGARC\u00cdA GONZ\u00c1LEZ, P; TIRAPU NICOL\u00c1S, B; SANZ \u00c1LVAREZ, L; P\u00cdO AS\u00cdN, M; ECHEVERR\u00cdA GORRITI, A; FERN\u00c1NDEZ \nGONZ\u00c1LEZ, J; GARJ\u00d3N PARRA, J; SAROBE CARRICAS, M\nSERVICIO NAVARRO DE SALUD - OSASUNBIDEA\nOBJETIVOS\nDise\u00f1ar e implementar un circuito de prescripci\u00f3n, validaci\u00f3n y dispensaci\u00f3n de nirmatrelvir/ritonavir en una comunidad \naut\u00f3noma (CA), siguiendo los criterios establecidos por la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios \n(AEMPS).\nMEJORAS ESPERADAS\nGarantizar la validaci\u00f3n por un farmac\u00e9utico especialista en farmacia hospitalaria.  \nFacilitar la accesibilidad a todos los pacientes candidatos al tratamiento en los distintos niveles asistenciales.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe centraliz\u00f3 el almacenamiento de nirmatrelvir/ritonavir en una distribuidora de la CA, a la que tienen acceso diario \nOficinas de Farmacia (OF) y Servicios de Farmacia Hospitalaria (SFH).  \n \nSe establecieron dos circuitos:  \nCircuito 1: Dispensaci\u00f3n en OF:  \nAtenci\u00f3n primaria (AP) y atenci\u00f3n especializada (AE) prescriben en el sistema de receta electr\u00f3nica de la CA. Se a\u00f1adi\u00f3 \nla condici\u00f3n de visado para autorizar la dispensaci\u00f3n mediante validaci\u00f3n farmac\u00e9utica. Esta validaci\u00f3n se realiza \nhabitualmente en AP y, fuera de su horario, en los SFH. Todas las prescripciones se validan en un plazo < 12 horas. \nLa prescripci\u00f3n puede ser aceptada, denegada o quedar pendiente de informaci\u00f3n. La aceptaci\u00f3n genera un mensaje al \ntel\u00e9fono del paciente indic\u00e1ndole que puede solicitar el tratamiento en la OF. En el caso de que se deniegue, el mensaje \nrecomienda ponerse en contacto con el m\u00e9dico prescriptor. \n \nCircuito 2: Dispensaci\u00f3n en SFH:  \nPara los pacientes ingresados se prescribe en la historia cl\u00ednica informatizada del centro hospitalario, se valida por los \nfarmac\u00e9uticos de los SFH y se dispensa en el circuito de dosis unitarias.  \nLos pacientes atendidos en el hospital de d\u00eda, consultas externas y urgencias hospitalarias pueden recoger el \nmedicamento en las unidades de atenci\u00f3n a pacientes externos de los SFH o pueden incorporarse al circuito 1 seg\u00fan \nnecesidad o preferencia del paciente\ufffd \n \nEtapas:  \nSe dise\u00f1\u00f3 el circuito en colaboraci\u00f3n con los distintos profesionales implicados, farmac\u00e9uticos y m\u00e9dicos de AP y AE. \nSe incluyeron las contraindicaciones e interacciones relevantes en el sistema de ayuda a la prescripci\u00f3n electr\u00f3nica\ufffd \nEste sistema permite bloquear la prescripci\u00f3n en caso de contraindicaci\u00f3n absoluta y mostrar alertas a los prescriptores \ninformando de las interacciones m\u00e1s relevantes. \nSe recomend\u00f3 contactar antes de la prescripci\u00f3n con el farmac\u00e9utico responsable de la validaci\u00f3n.  \nSe habilit\u00f3 el visado obligatorio para la prescripci\u00f3n por receta electr\u00f3nica y se dio acceso y formaci\u00f3n a todos los \nfarmac\u00e9uticos especialistas que participan en la validaci\u00f3n.  \nSe desarroll\u00f3 el env\u00edo de mensajes autom\u00e1ticos al paciente tras la aceptaci\u00f3n/denegaci\u00f3n del visado.\nIMPLANTACI\u00d3N\nEl circuito entr\u00f3 en vigor el 04/04/2022\ufffd\nRESULTADOS\nDesde el 04/04/2022 hasta el 13/05/2022 se realizaron 31 prescripciones de nirmatrelvir/ritonavir, 23 en el sistema de \nreceta electr\u00f3nica (circuito 1) y 8 en historia cl\u00ednica informatizada (circuito 2).  \nSe autoriz\u00f3 el tratamiento de 27 pacientes de alto riesgo y se deneg\u00f3 en cuatro que no cumpl\u00edan los criterios establecidos \npor la AEMPS\ufffd\nLIMITACIONES\nLa implantaci\u00f3n de este circuito ha exigido un elevado grado de coordinaci\u00f3n y comunicaci\u00f3n fluida entre todas las partes \nimplicadas, as\u00ed como disponer de herramientas de gesti\u00f3n compartidas.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl sistema es aplicable a otras CCAA que se planteen facilitar el acceso a este tratamiento garantizando la validaci\u00f3n por \nparte de un farmac\u00e9utico especialista en farmacia hospitalaria.524CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n715. IMPLANTACI\u00d3N DE UNA APLICACI\u00d3N EN LOS SISTEMAS AUTOM\u00c1TICOS DE DISPENSACI\u00d3N QUE \nPERMITE GESTIONAR LA TOTALIDAD DE PRESCRIPCIONTES ACTIVAS. \nAUTORES\nRIVERA RUIZ, M; S\u00c1NCHEZ CERVI\u00d1O, AC; CALVO SALVADOR, M; L\u00d3PEZ ESTEBAN, L; COCA CRESPO, J; ALCAR\u00c1Z L\u00d3PEZ, \nJI; LOZANO LLANO, C; S\u00c1NCHEZ GUERRERO, A\nHOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA. JOAQU\u00cdN RODR\u00cdGO, 2 MAJADAHONDA. MADRID\nOBJETIVOS\nDescribir la implantaci\u00f3n de una nueva funcionalidad inform\u00e1tica en los sistemas autom\u00e1ticos de dispensaci\u00f3n (SAD) que \npermite optimizar la dispensaci\u00f3n de medicaci\u00f3n a las unidades de hospitalizaci\u00f3n (UH) al gestionar los SAD todos los \nmedicamentos con prescripci\u00f3n activa, en un hospital de tercer nivel.\nMEJORAS ESPERADAS\n- Aumento de la disponibilidad de medicamentos gestionados por los SAD. \n- Reducci\u00f3n del n\u00famero de peticiones de medicaci\u00f3n por fuera de turno al Servicio de Farmacia (SF).  \n- Eliminaci\u00f3n del tiempo de entrega de f\u00e1rmacos desde el SF a las UH, mejorando el cumplimiento terap\u00e9utico.\nDISE\u00d1O CIRCUITO Y ETAPAS\nEstudio observacional, descriptivo, prospectivo. Periodo de 2 meses dividido en dos fases: pre-implantaci\u00f3n (Enero 2022) \ny post-implantaci\u00f3n (Marzo 2022). Se seleccionaron los SAD de 13 UH (350 camas).  \nInicialmente se realiz\u00f3 una prueba piloto en una de las UH. Posteriormente se extendi\u00f3 al resto. Se dise\u00f1aron rutas de \nreposici\u00f3n espec\u00edficas para cada SAD. \nSe compar\u00f3 en ambos periodos el uso de los SAD mediante el aumento del n\u00famero de referencias y las dispensaciones \nrealizadas desde \u00e9ste por el personal de enfermer\u00eda de las UH, as\u00ed como el n\u00famero de peticiones por fuera de turno al SF. \n \nEscenario 1: L\u00ednea de prescripci\u00f3n electr\u00f3nica de medicaci\u00f3n activa.  \nLa nueva funcionalidad implantada:  \n1. Detecta qu\u00e9 f\u00e1rmacos necesita la UH y no se encuentran gestionados dentro del SAD.  \n2. Calcula la reposici\u00f3n de los art\u00edculos para cubrir las necesidades de la prescripci\u00f3n m\u00e9dica en funci\u00f3n de la posolog\u00eda \ndurante un tiempo establecido.  \n3. Genera una orden de preparaci\u00f3n de dichos f\u00e1rmacos al almac\u00e9n del SF. \n4. Asigna ubicaci\u00f3n para que el t\u00e9cnico de farmacia reponga estos f\u00e1rmacos en el SAD permitiendo su disponibilidad en la \nUH\ufffd \nDe esta forma, toda la medicaci\u00f3n del paciente es gestionada por el SAD de la UH.  \nEscenario 2: L\u00ednea de prescripci\u00f3n electr\u00f3nica de medicaci\u00f3n suspendida.  \nLa nueva funcionalidad, autom\u00e1ticamente, realiza el proceso inverso para gestionar la retirada de los f\u00e1rmacos que no \nvan a ser utilizados en la UH, ser devueltos al SF y liberar ubicaciones dentro del SAD para futuras prescripciones que se \nrealicen\ufffd\nIMPLANTACI\u00d3N\nSe instal\u00f3 la aplicaci\u00f3n a lo largo de 3 semanas de marzo de 2022 en los SAD de 13 UH.\nRESULTADOS\nTras la implantaci\u00f3n se observ\u00f3 un incremento del n\u00famero de dispensaciones y unidades dispensadas desde los SAD \nde un 17% (711) y 19% (23.007), respectivamente. Tambi\u00e9n se produjo una reducci\u00f3n del n\u00famero de peticiones y \nunidades demandadas por parte de enfermer\u00eda al SF de un 34% y un 60%, respectivamente. Desde la implementaci\u00f3n se \nincrement\u00f3 el n\u00famero de referencias incluidas en los SAD en un 11% (61).  \nEstos datos evidencian un incremento de automatizaci\u00f3n del \u00e1rea de dispensaci\u00f3n a paciente ingresado.  \nPr\u00f3ximamente, se analizar\u00e1 la mejora del cumplimiento terap\u00e9utico tras la implantaci\u00f3n de esta aplicaci\u00f3n en los SAD.\nLIMITACIONES\n- Adquisici\u00f3n no gratuita de la aplicaci\u00f3n.  \n- Exclusividad de instalaci\u00f3n en una \u00fanica marca comercial de SAD.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa funcionalidad es aplicable a todas las UH que dispongan de SAD ligado a prescripci\u00f3n electr\u00f3nica y que no almacenen \nla totalidad de f\u00e1rmacos con prescripci\u00f3n activa.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n721. OPTIMIZACI\u00d3N DE LOS SISTEMAS AUTOMATIZADOS DE DISPENSACI\u00d3N (SAD): CREACI\u00d3N DE UNA \nHERRAMIENTA PARA SU AGILIZACI\u00d3N Y SISTEMATIZACI\u00d3N. \nAUTORES\nALCARAZ L\u00d3PEZ, JI; LOZANO LLANO, C; COCA CRESPO, J; S\u00c1NCHEZ CERVI\u00d1O, AC; RIVERA RUIZ, M; DE SANTIAGO \nALVAREZ, R; CALVO SALVADOR, M; S\u00c1NCHEZ GUERRERO, A\nHOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA. JOAQU\u00cdN RODR\u00cdGO, 2 MAJADAHONDA. MADRID525OBJETIVOS\nAgilizar la optimizaci\u00f3n de la gesti\u00f3n de medicamentos incluidos en los sistemas automatizados de dispensaci\u00f3n (SAD)\nMEJORAS ESPERADAS\nDise\u00f1ar un circuito de optimizaci\u00f3n que permita que el SAD pueda ser actualizado de manera continua para que incluya \nlas referencias m\u00e1s consumidas en las unidades de hospitalizaci\u00f3n (UH).\nDISE\u00d1O CIRCUITO Y ETAPAS\nEl dise\u00f1o del circuito requiri\u00f3 previamente la creaci\u00f3n de una base de datos de Access\u00ae, la revisi\u00f3n de los stocks de \nbotiqu\u00edn de las UH, as\u00ed como sus consumos de medicaci\u00f3n. Toda esta informaci\u00f3n recopilada fue incluida en la base de \ndatos\ufffd  \n \nLa base de datos opera cruzando el stock de botiqu\u00edn y la medicaci\u00f3n prescrita pero no incluida en el SAD, dando como \nresultado un listado con aquellos medicamentos prescritos que no se encuentran disponibles en la unidad, y que han sido \nconsumidos m\u00e1s de 20 veces durante los \u00faltimos 6 meses, para valorar su inclusi\u00f3n en el SAD. \nEl circuito de optimizaci\u00f3n se desarrolla de la siguiente manera: \nInicialmente, se analizan los medicamentos incluidos en los SAD, con menos de 20 dispensaciones en los \u00faltimos 6 meses, \ny se valora la modificaci\u00f3n de su parametrizaci\u00f3n o retirada del mismo.  \n \nTras el proceso de retirada y ajuste, a partir de los listados elaborados con la base de datos creada, se obtiene una \nselecci\u00f3n de medicamentos candidatos a incluir en el SAD. Estos medicamentos son analizados por el farmac\u00e9utico \ndecidiendo finalmente cu\u00e1les ser\u00e1n incluidos en los SAD. \n \nLos listados analizados son entregados a los t\u00e9cnicos para su asignaci\u00f3n f\u00edsica o retirada del SAD, este proceso se realiza \ntres veces por semana\ufffd\nIMPLANTACI\u00d3N\nEl proyecto de optimizaci\u00f3n se llev\u00f3 a t\u00e9rmino entre mayo de 2020 y marzo de 2021, en 10 (UH) con 23 camas cada una.\nRESULTADOS\nDurante el periodo del proyecto se han llevado a cabo 2.268 modificaciones de art\u00edculos en los SAD, lo que supone un \nincremento del 81% respecto al mismo periodo del a\u00f1o anterior \ufffd \n \nTras la puesta en marcha del circuito las peticiones de medicaci\u00f3n por parte de las UH se han visto reducidas en un 27,9% \nrespecto al a\u00f1o anterior \ufffd\nLIMITACIONES\nEste proyecto tiene en cuenta los consumos en los \u00faltimos 6 meses, por lo que aquellos f\u00e1rmacos de nueva inclusi\u00f3n \ndeben ser valorados de manera independiente. A ello hay que a\u00f1adir que en algunos casos no se podr\u00e1n incluir nuevos \nart\u00edculos al disponer de un espacio l\u00edmite.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl proyecto utiliza datos proporcionados por la plataforma de gesti\u00f3n para saber los consumos, y cruza los mismos con \nlas prescripciones realizadas, por lo que puede ser aplicable a cualquier servicio de farmacia cuyo hospital cuente con \nprescripci\u00f3n electr\u00f3nica\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n810. CREACI\u00d3N DE UNA UNIDAD DE CONDUCTAS ADICTIVAS DEPENDIENTE DEL SERVICIO DE FARMACIA \nDE UN HOSPITAL DE TERCER NIVEL. \nAUTORES\nCARVAJAL SANCHEZ, MA; LACRUZ GUZMAN, D; PACHECO LOPEZ, P; IBA\u00d1EZ CATURLA, J; FRUCTUOSO GONZALEZ, L; \nTORRANO BELMONTE, P; HERNANDEZ SANCHEZ, M; GUTIERREZ SANCHEZ, JA\nHOSPITAL J.M. MORALES MESEGUER. AV . MARQU\u00c9S DE LOS V\u00c9LEZ, S/N. MURCIA. MURCIA\nOBJETIVOS\nDescribir la creaci\u00f3n de una Unidad de Conductas Adictivas (UCA) dependiente del Servicio de Farmacia Hospitalaria \n(SFH) de nuestra \u00e1rea de Salud y la elaboraci\u00f3n del procedimiento de prescripci\u00f3n, validaci\u00f3n y dispensaci\u00f3n de \nmedicaci\u00f3n\ufffd\nMEJORAS ESPERADAS\nElevar la calidad asistencial de los pacientes atenidos en la UCA (pacientes en tratamiento para las adicciones): Conseguir \nuna asistencia sanitaria (AS) lo m\u00e1s integrada posible gracias a una mayor accesibilidad y una mejor coordinaci\u00f3n entre \nprofesionales\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nEn el circuito participan trabajadores de:  \n- SFH: cinco farmac\u00e9uticos (Farmacotecnia, Estupefacientes, Atenci\u00f3n Primaria y Gesti\u00f3n), dos enfermeros, dos t\u00e9cnicos \nde farmacia, un auxiliar administrativo y un celador. \n- UCA: un m\u00e9dico, una enfermera, una psic\u00f3loga. 526Se realizaron cuatro reuniones para informar sobre la creaci\u00f3n de la unidad, las necesidades de personal y de recursos \nmateriales, la implantaci\u00f3n del programa de prescripci\u00f3n electr\u00f3nica asistida (PPEA) y de dispensaci\u00f3n, elaboraci\u00f3n de \nprotocolos y formaci\u00f3n del personal\ufffd  \n \nEl m\u00e9dico de la UCA eval\u00faa individualmente a cada paciente y decide si cumple los criterios necesarios para ser \nincluido en el Programa. Tras la prescripci\u00f3n m\u00e9dica en el PPEA el farmac\u00e9utico valida el tratamiento y la enfermera \nrealiza la dispensaci\u00f3n. La historia cl\u00ednica queda registrada de forma electr\u00f3nica, a disposici\u00f3n de los profesionales \nsanitarios responsables del paciente. Adem\u00e1s, se ha creado un pacto de medicaci\u00f3n para que la enfermera de la UCA \nrealice el pedido de medicamentos y f\u00f3rmulas magistrales inform\u00e1ticamente. Si en el pedido se solicitan psic\u00f3tropos o \nestupefacientes, se deben enviar los vales correspondientes firmados por el m\u00e9dico.  \n \nEl \u00fanico estupefaciente incluido en su pacto es la soluci\u00f3n de metadona que se elabora en la sala blanca del SFH. Esta \npreparaci\u00f3n se somete a control anal\u00edtico y microbiol\u00f3gico por la Consejer\u00eda de Sanidad y el Servicio de Microbiolog\u00eda, \nrespectivamente.\nIMPLANTACI\u00d3N\nOctubre 2021: actualizaci\u00f3n del Programa de Adicciones y creaci\u00f3n de la UCA.  \n \nNoviembre \u2013 diciembre 2021: el SFH realiza las siguientes actividades: \n- An\u00e1lisis y adaptaci\u00f3n de la Gu\u00eda farmacoterap\u00e9utica a sus necesidades.  \n- Establecimiento de los procedimientos prescripci\u00f3n, validaci\u00f3n y dispensaci\u00f3n de medicaci\u00f3n, elaboraci\u00f3n de soluci\u00f3n \nde metadona, cronograma y procedimiento de comunicaci\u00f3n entre la UCA y el SFH\ufffd  \n- Dise\u00f1o de los documentos necesarios para la actividad, talonario y libro de estupefacientes. \n- Creaci\u00f3n inform\u00e1tica de un pacto de medicaci\u00f3n y adaptaci\u00f3n del PPEA. \n- Visita a la UCA, comprobaci\u00f3n de recursos materiales, implantaci\u00f3n de los programas inform\u00e1ticos y formaci\u00f3n de sus \ntrabajadores.\nRESULTADOS\nDe enero a abril se han elaborado 67 litros de metadona, realizado 14 env\u00edos de medicaci\u00f3n y validado un total de 83 \nprescripciones de 63 pacientes\ufffd \nEl SFH se ha situado como un referente de la UCA, mejorando la comunicaci\u00f3n entre niveles asistenciales y resolviendo \nlas dudas consultadas en el d\u00eda a d\u00eda. Tambi\u00e9n se han informatizado las historias cl\u00ednicas y los tratamientos de los \npacientes atendidos en la UCA, estando disponibles para los profesionales sanitarios y favoreciendo el abordaje \nmultidisciplinar de estas patolog\u00edas.\nLIMITACIONES\nDisponibilidad de una sala blanca, plantilla y recursos materiales correspondientes.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nSe trata de un circuito aplicable a los hospitales que cumplan los requisitos mencionados.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n859. IMPLANTACI\u00d3N DE LA SALUD M\u00d3VIL EN LA ATENCI\u00d3N DEL PACIENTE RECEPTOR DE TRASPLANTE \nALOG\u00c9NICO DE PROGENITORES HEMATOPOY\u00c9TICOS \nAUTORES\nDE DIOS L\u00d3PEZ, A; MORENO MART\u00cdNEZ, ME; RIBA SOL\u00c9, M; MEZA BURGOS, CP; GARC\u00cdA CADENAS, I; ASO FERRERAS, \nMO; MANGUES BAFALLUY , MA; GOMIS PASTOR, M\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLos pacientes receptores de un trasplante alog\u00e9nico de progenitores hematopoy\u00e9ticos (aloTPH) sufren complicaciones \nm\u00e9dicas y psico-sociales a corto y largo plazo pudiendo afectar a su calidad de vida y al consumo de recursos sanitarios.  \nEl proyecto eMedula tiene como objetivo el redise\u00f1o de la ruta asistencial e incorporaci\u00f3n de una herramienta de salud \nm\u00f3vil (EMMASalud) en el manejo ambulatorio multidisciplinar de los pacientes aloTPH.\nMEJORAS ESPERADAS\nHumanizaci\u00f3n de la atenci\u00f3n mediante un programa sostenible e integral que permita:  \n\uf8fc Facilitar la resoluci\u00f3n de dudas sobre farmacoterapia, manejo de s\u00edntomas y efectos adversos  \n\uf8fc Realizar una intervenci\u00f3n anticipada gracias al seguimiento de los resultados y experiencias reportados por los \npacientes (PROMs/PREMs).  \n\uf8fc Mejorar la informaci\u00f3n y comunicaci\u00f3n, as\u00ed como la experiencia del paciente.\nDISE\u00d1O CIRCUITO Y ETAPAS\nEstudio piloto prospectivo no aleatorizado para implementar la herramienta EMMASalud (app y web de seguimiento del \npaciente oncohematol\u00f3gico) en la ruta asistencial de pacientes aloTPH.  \n \n1. Contextualizaci\u00f3n y dise\u00f1o de la herramienta a partir de una base tecnol\u00f3gica ya integrada en la pr\u00e1ctica cl\u00ednica \n(mHeart). Se realizaron grupos focales con pacientes y profesionales sanitarios.  5272. Desarrollo tecnol\u00f3gico para incorporar mejoras propuestas en base al punto anterior. \n3. Creaci\u00f3n del equipo multidisciplinar: farmac\u00e9uticas coordinadoras de salud digital, farmac\u00e9uticas especializadas en \nonco-hematolog\u00eda, hemat\u00f3logos, enfermera gestora de casos, nutricionistas y psic\u00f3loga. \n4. Realizaci\u00f3n de testeo (alfa y beta) de EMMASalud con pacientes y profesionales contando con la colaboraci\u00f3n del \nServicio de farmacia de otro Hospital terciario espa\u00f1ol\ufffd  \n5. Definici\u00f3n de la nueva ruta asistencial con el equipo multidisciplinar: pacientes candidatos, condiciones de la inclusi\u00f3n, \nselecci\u00f3n de PREMs y PROMs\ufffd  \n6. Coordinaci\u00f3n del equipo interdisciplinar: canales de comunicaci\u00f3n, periodicidad de reuniones, repartici\u00f3n de tareas y \nresponsabilidades\ufffd  \n7. Formaci\u00f3n de los profesionales para el manejo de EMMASalud.  \n8\ufffd Estudio piloto: inclusi\u00f3n, formaci\u00f3n y seguimiento de pacientes\ufffd \n9\ufffd Evaluaci\u00f3n y difusi\u00f3n de resultados\ufffd\nIMPLANTACI\u00d3N\nEl proyecto se inici\u00f3 en 2018 en fase de contextualizaci\u00f3n. En 2020 se llevaron a cabo los grupos focales y la incorporaci\u00f3n \nde los cambios tecnol\u00f3gicos. En octubre 2021 se inici\u00f3 el estudio piloto de viabilidad de la herramienta con un mes de \nperiodo de inclusi\u00f3n y dos meses de seguimiento\ufffd  \nEn 06/2022 iniciar\u00e1 el ensayo cl\u00ednico aleatorizado.\nRESULTADOS\nSe cuenta con resultados preliminares del estudio piloto: se incluyeron 28 pacientes, 18(64,3%)varones con edad media \nde 54,4(rango 26-75)a\u00f1os. La mitad(14) se encontraban entre el d\u00eda + 30 y +365 post-TPH), el resto presentaba EICR \nrefractario\ufffd  \nDurante el periodo de estudio, 12(42,9%) pacientes distintos registraron 49 efectos adversos(EA), siendo el m\u00e1s frecuente \nrash/erupci\u00f3n cut\u00e1nea(n=12, 24,5%).  \nSe recibieron 205 mensajes, los m\u00e1s frecuentes (20,9%) dudas respecto la medicaci\u00f3n.  \nEl 100% de los pacientes utiliz\u00f3 la aplicaci\u00f3n y el 96,4%(27) realiz\u00f3 los cuestionarios propuestos.\nLIMITACIONES\n- Inherentes tecnolog\u00eda: capacidad de empoderamiento digital, disponibilidad de dispositivo compatible.  \n- Inherentes al estudio piloto: muestra reducida, periodo de seguimiento corto.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl modelo asistencial es implantable en centros que persigan incorporar la telefarmacia en equipos interdisciplinares \nque atienden poblaciones altamente complejas. El \u00e9xito radica en la organizaci\u00f3n y coordinaci\u00f3n del equipo, as\u00ed como en \nla implicaci\u00f3n de sus miembros. Los farmac\u00e9uticos disponemos de habilidades y capacidades para impulsar proyectos \ninnovadores en las instituciones sanitarias.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n887. PROCEDIMIENTO PARA LA INTERCAMBIABILIDAD DE MEDICAMENTOS BIOL\u00d3GICOS: \nSOSTENIBILIDAD DEL SISTEMA DE SALUD CASTELLANO MANCHEGO. \nAUTORES\nCEBRI\u00c1N CARRASCOSA, C; PALACIOS MOYA, E; LUC\u00cdA AREAS DEL AGUILA, V; VILA TORRES, E; FRANCO SERENO, MT; \nRODR\u00cdGUEZ MART\u00cdNEZ, M\nHOSPITAL GENERAL DE CIUDAD REAL \ufffd TOMELLOSO S/N CIUDAD REAL \ufffd CIUDAD REAL\nOBJETIVOS\nDescribir el procedimiento para intercambiar los medicamentos biol\u00f3gicos (MB) (adalimumab ADA, etanercept ETA, \ninfliximab IFX y rituximab RTX) en cumplimiento del acuerdo marco (AM) de suministro de medicamentos biosimilares \n(BS) del sistema de salud de Castilla-La Mancha (SESCAM).\nMEJORAS ESPERADAS\nMejorar la eficiencia y acceso a la innovaci\u00f3n en pacientes tratados con MB.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe consensu\u00f3 un procedimiento con los servicios m\u00e9dicos (SM) (dermatolog\u00eda, digestivo y reumatolog\u00eda) aprobado por la \nComisi\u00f3n de Farmacia y Terap\u00e9utica (CFT) para el intercambio simult\u00e1neo de todos los pacientes en tratamiento con MB \nal BS adjudicado por AM (BSAM) en un hospital de tercer nivel a trav\u00e9s de la prescripci\u00f3n electr\u00f3nica (PE) validada previa \na la dispensaci\u00f3n\ufffd  \n \n1. Aprobaci\u00f3n por la CFT del posicionamiento en materia de intercambiabilidad de BS en el hospital de acuerdo con el AM \nque inclu\u00eda lotes de estos medicamentos para patolog\u00edas digestivas, reumatol\u00f3gicas y dermatol\u00f3gicas.  \n2. Consenso con los SM del intercambio al BSAM a trav\u00e9s de la PE con validaci\u00f3n m\u00e9dica previa a la dispensaci\u00f3n.  \n3. Establecimiento de un circuito para valoraci\u00f3n de adquisiciones al margen del contrato basado y seguimiento \nfarmacoterap\u00e9utico en pacientes con p\u00e9rdida de efectividad o reacciones adversas tras el intercambio.  \n4\ufffd Intercambiabilidad en pacientes con PE de MB en el programa Farmatools\u00ae\ufffd  \n5. Semanalmente se inform\u00f3 a los SM que pacientes citados en las agendas, de consulta de pacientes externos (CPEX) y \nhospital de d\u00eda m\u00e9dico quir\u00fargico (HDMD), ten\u00edan pendiente la validaci\u00f3n m\u00e9dica del BSAM trascrita previamente por el \nfarmac\u00e9utico.  5286. Validaci\u00f3n farmac\u00e9utica, y dispensaci\u00f3n tras informar al paciente con apoyo de una hoja informativa consensuada con \nDM\ufffd  \n7. Seguimiento de resultados en las consultas sucesivas m\u00e9dica y farmac\u00e9utica.\nIMPLANTACI\u00d3N\nEn enero de 2022 se inici\u00f3 la dispensaci\u00f3n de BSAM a pacientes que los ten\u00edan prescritos y validados; se complet\u00f3 el \nintercambio en abril, de acuerdo con la dispensaci\u00f3n CPEX y periodicidad de administraci\u00f3n en HDMQ\ufffd\nRESULTADOS\nUn total de 671 pacientes estaban en tratamiento con ADA (398), ETA (146), IFX (104) y RTX (23).  \nSe realiz\u00f3 intercambio a BSAM en 70,34% (66,33%, 80,82%, 84,62%, 17,39%), respectivamente. La distribuci\u00f3n por SM \nfue: reumatolog\u00eda (55,14%), digestivo (32,10%), dermatolog\u00eda (10,08%), y otros (2,67%). \nNo fueron susceptibles del intercambio 196 pacientes por iniciar con BSAM (86), cambiar a otro medicamento (54), \nsuspender MB (24), tener pendiente el intercambio (17) y p\u00e9rdida de seguimiento (15).  \nAl dispensar, 36 pacientes no ten\u00edan PE de BSAM. \nSe solicit\u00f3 a CFT la adquisici\u00f3n de MB previo al intercambio en 9 pacientes, por sospecha de reacciones adversas (ADA 3, \nETA 2, IFX 2) y empeoramiento (ADA 2); tres pacientes volvieron al MB previo; se reevalu\u00f3 la respuesta al tratamiento en \n3, se realiz\u00f3 interconsulta a alergolog\u00eda en 2 y un paciente mantuvo el tratamiento.\nLIMITACIONES\n1\ufffd Desacuerdo de los prescriptores con la intercambiabilidad ocasionando incidencias en la dispensaci\u00f3n\ufffd  \n2. Dificultad para establecer relaci\u00f3n entre intercambiabilidad de BS y p\u00e9rdida de efectividad o aparici\u00f3n de efectos \nadversos\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste procedimiento es aplicable a otros hospitales con AM auton\u00f3micos que incluyan BS apoyado en acuerdos de CFT, \nincrementando la penetraci\u00f3n de BS\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n911. DISMINUCI\u00d3N DE LOS ERRORES DE MEDICACI\u00d3N RELACIONADOS CON LA INTRODUCCI\u00d3N DE \nNUEVAS PRESENTACIONES DE F\u00c1RMACOS MEDIANTE LA METODOLOG\u00cdA LEAN A3 \nAUTORES\nALBA ARANDA, G; VILA BUND\u00d3, A; PALACIOS LUPIA\u00d1EZ, C; DELM\u00c0S CAMACHO, G\nHOSPITAL RESID\u00c8NCIA SANT CAMIL - CONSORCI SANITARI DEL GARRAF . RONDA SANT CAMIL, S/N SANT PERE DE \nRIBES \ufffd BARCELONA\nOBJETIVOS\nDisminuir los errores relacionados con la introducci\u00f3n de nuevas presentaciones de medicamentos en el Servicio de \nFarmacia: medicaci\u00f3n extranjera, cambios de presentaci\u00f3n o nuevos medicamentos en gu\u00eda.\nMEJORAS ESPERADAS\n- Disminuir los errores de medicaci\u00f3n relacionados con la introducci\u00f3n de nuevas presentaciones de medicamentos  \n- Mejorar el circuito de la introducci\u00f3n de nuevas presentaciones de medicamentos \n- Mejorar la difusi\u00f3n de la informaci\u00f3n relacionada con la introducci\u00f3n de nuevas presentaciones de medicamentos\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe us\u00f3 la herramienta A3 de metodolog\u00eda Lean para la resoluci\u00f3n de problemas.  \nEtapas y circuito: \n- Formaci\u00f3n del grupo de trabajo: 3 farmac\u00e9uticas, 1 administrativa de compras y 1 t\u00e9cnico de calidad  \n- Formaci\u00f3n en metodolog\u00eda A3  \n- Se plante\u00f3 el objetivo del proyecto, se analizaron los errores detectados y se dibuj\u00f3 el mapa de proceso actual (Value \nStream Map) identificando todos los problemas, se busc\u00f3 la causa ra\u00edz de los problemas detectados y se propusieron \ncontramedidas para corregir o prevenir estos problemas  \n- De todas las medidas propuestas se eligi\u00f3 el dise\u00f1o de un documento \u201ccheck list\u201d que deb\u00eda aplicar la administrativa \nde compras en el momento de recepci\u00f3n de todas las nuevas presentaciones de f\u00e1rmacos. Este documento contiene \nla siguiente informaci\u00f3n: todos los \u00edtems que se deben revisar (principio activo, dosis, concentraci\u00f3n/volumen, \nconservaci\u00f3n, identificaci\u00f3n, tama\u00f1o del envase y si est\u00e1 en unidosis), adem\u00e1s de qu\u00e9 acciones derivadas hay que realizar \ny quien lo hace. Tambi\u00e9n se recoge c\u00f3mo se difunde toda la informaci\u00f3n (colgando los documentos en una pizarra y/o \nenviando un mail con el documento \u201ccheck list\u201d).  \n- Dise\u00f1o del nuevo circuito que deben seguir estos f\u00e1rmacos\nIMPLANTACI\u00d3N\nSe explic\u00f3 el nuevo circuito de introducci\u00f3n de nuevos f\u00e1rmacos a todo el servicio y c\u00f3mo se har\u00eda la difusi\u00f3n de la \ninformaci\u00f3n\ufffd\nRESULTADOS\nDesde mayo 2021 a febrero 2022 se han realizado 42 documentos \u201ccheck list\u201d: 9 debidos a cambios de presentaci\u00f3n, 14 a \nla introducci\u00f3n de nuevos medicamentos en la gu\u00eda y 19 a medicaci\u00f3n extranjera.  529Todos los documentos \u201ccheck list\u201d se han colgado en una pizarra durante un mes para difundir la informaci\u00f3n a todo el \nServicio de Farmacia. Tambi\u00e9n se ha difundido toda la informaci\u00f3n por mail. Los documentos validados se han registrado \npara control de calidad y trazabilidad.  \nDespu\u00e9s de la implantaci\u00f3n no se ha detectado ning\u00fan error de medicaci\u00f3n relacionado con la introducci\u00f3n de nuevas \npresentaciones de f\u00e1rmacos en el Servicio de Farmacia.\nLIMITACIONES\nEl administrativo de compras tiene una tarea extra al tener que hacer el \u201ccheck list\u201d de todas las nuevas presentaciones \nde medicamentos\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa implantaci\u00f3n estandarizada de un documento \u201ccheck list\u201d en cada uno de los medicamentos introducidos es una \nmetodolog\u00eda \u00fatil, de bajo coste y f\u00e1cil de implantar en cualquier servicio de farmacia, que aporta seguridad y trazabilidad.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n925. CENTRALIZACI\u00d3N DE LA PREPARACI\u00d3N DE F\u00c1RMACOS EST\u00c9RILES DE DOS HOSPITALES COMARCALES \nAUTORES\nALBA ARANDA, G; CALAFELL BRULL, Y; POLA ROBLES, N; PAG\u00c9S RAVENT\u00d3S, E; PIC\u00d3N RAFOLS, E; FARRERAS POCH, S\nHOSPITAL RESID\u00c8NCIA SANT CAMIL - CONSORCI SANITARI DEL GARRAF . RONDA SANT CAMIL, S/N SANT PERE DE \nRIBES \ufffd BARCELONA\nOBJETIVOS\nDescribir y evaluar el proceso de unificaci\u00f3n y centralizaci\u00f3n de la preparaci\u00f3n de medicamentos est\u00e9riles de dos \nhospitales comarcales, que distan 22 km, en uno de ellos.\nMEJORAS ESPERADAS\n- Optimizar los recursos trabajando de manera m\u00e1s segura y eficaz \n- Asegurar la calidad de las preparaciones  \n- Unificar la forma de trabajar de los dos centros tanto en el Servicio de Farmacia como en Hospital de D\u00eda\nDISE\u00d1O CIRCUITO Y ETAPAS\nEn el dise\u00f1o de circuitos y organizaci\u00f3n de las tareas se utilizaron las siguientes herramientas Lean: A3, 5S, gesti\u00f3n visual y \nVSM (Value Stream Map). \n \nEsta reorganizaci\u00f3n supuso diferentes etapas previas a la implantaci\u00f3n:  \n- Dise\u00f1o y construcci\u00f3n de una nueva sala blanca \n- Actualizaci\u00f3n del protocolo de preparaci\u00f3n de medicamentos est\u00e9riles \n- Dise\u00f1o del circuito de transporte de f\u00e1rmacos entre los dos hospitales \n- Unificaci\u00f3n del personal de los dos hospitales (3 t\u00e9cnicos de farmacia) \n- Nueva organizaci\u00f3n de las funciones de los t\u00e9cnicos y horarios de preparaci\u00f3n  \n- Coordinaci\u00f3n transversal con enfermeras y m\u00e9dicos de hospital de d\u00eda para ajustar horarios de prescripci\u00f3n y \nadministraci\u00f3n  \n- Comunicaci\u00f3n a la direcci\u00f3n de los nuevos circuitos \n- Formaci\u00f3n del personal\nIMPLANTACI\u00d3N\nEn enero de 2021 se implantaron los nuevos circuitos y nueva organizaci\u00f3n. Durante 3 meses se centraliz\u00f3 en un \nhospital mientras se realizaban las obras en el otro. Finalmente se empez\u00f3 a trabajar en la nueva sala blanca revisando y \nadaptando los circuitos dise\u00f1ados\ufffd  \nPara evaluar el correcto funcionamiento de los circuitos se midieron los siguientes indicadores: retrasos en la llegada del \ntransporte, incidencias en Hospital de D\u00eda y errores en la preparaci\u00f3n.\nRESULTADOS\nDurante el a\u00f1o 2021 se hicieron 15.497 preparaciones est\u00e9riles: 9 % nutriciones parenterales, 43 % citost\u00e1ticos y 48 % \notras preparaciones est\u00e9riles. Se fabricaron un 75 % m\u00e1s de preparaciones que el a\u00f1o anterior, aumentando las horas de \npersonal un 20 %\ufffd Parte de estas preparaciones fueron debidas al aumento de ingresos de pacientes con COVID \ufffd \nNo se incrementaron desplazamientos ni tiempo de espera de pacientes. Se produjo \u00fanicamente un retraso significativo \nen la entrega del tratamiento por motivos log\u00edsticos que provoc\u00f3 la administraci\u00f3n en otro d\u00eda.  \nSe detectaron 2 errores en la preparaci\u00f3n que no llegaron al paciente. \nSe notificaron 10 incidencias por parte de enfermer\u00eda de los dos Hospitales de D\u00eda que se analizaron y solucionaron de \nforma conjunta.\nLIMITACIONES\nLa principal limitaci\u00f3n de este proyecto ha sido que las aplicaciones inform\u00e1ticas no estaban integradas.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nReorganizaci\u00f3n aplicable a hospitales que no est\u00e9n separados muchos km ya que no ser\u00eda viable para preparaciones que \nse confirman y administran el mismo d\u00eda. El hecho de que los 2 hospitales tuvieran la misma direcci\u00f3n tambi\u00e9n facilit\u00f3 la \nimplantaci\u00f3n del proyecto\ufffd530CLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1015. IMPLEMENTACI\u00d3N DE UN SISTEMA DE DISPENSACI\u00d3N DE MEDICAMENTOS EN UNA RESIDENCIA \nSOCIOSANITARIA GUIADA POR UN PROGRAMA DE BIG DATA \nAUTORES\nFRESQUET MOLINA, R; ALLENDE BANDRES, MA; GRACIA PIQUER, R; FRUTOS PEREZ-SURIO, A; GIMENO BALLESTER, \nV; PRIETO LARA, EA; SALVADOR GOMEZ, T; SOPENA CARRERA, L\nHOSPITAL CL\u00cdNICO UNIVERSITARIO LOZANO BLESA. SAN JUAN BOSCO, 15 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nEl sistema cl\u00e1sico de dispensaci\u00f3n de medicamentos a residencias sociosanitarias en nuestro hospital se ha venido \nrealizando mediante un sistema de pedidos por reposici\u00f3n de stock de botiqu\u00edn.  \nEl objetivo de este proyecto es describir el impacto de la implementaci\u00f3n de un sistema de prescripci\u00f3n electr\u00f3nica con \nposterior dispensaci\u00f3n de medicamentos utilizando un sistema de BIG DATA (KNIME) en una residencia sociosanitaria.\nMEJORAS ESPERADAS\nOptimizaci\u00f3n de la farmacoterapia a trav\u00e9s de la validaci\u00f3n de las prescripciones electr\u00f3nicas. \nDisminuci\u00f3n del gasto farmac\u00e9utico de la residencia. El pedido generado por KNIME a partir de la prescripci\u00f3n electr\u00f3nica \nes m\u00e1s preciso que la petici\u00f3n de stock generada a demanda por las enfermeras de las residencias.\nDISE\u00d1O CIRCUITO Y ETAPAS\nProyecto piloto desarrollado en una residencia sociosanitaria de 100 camas dependiente de un hospital de tercer nivel. El \nproyecto se llev\u00f3 a cabo en dos fases: Primero se puso en marcha el sistema de prescripci\u00f3n electr\u00f3nica y en una segunda \nfase se desarroll\u00f3 un modelo de gesti\u00f3n de datos dentro del programa de BIG DATA KNIME.  \nKNIME es una herramienta que ayuda a crear plataformas de Data Science de manera sencilla e intuitiva, mediante el \ntrabajo con nodos a partir de m\u00faltiples fuentes de datos.  \nCircuito y Etapas \nPrimera fase: Implantaci\u00f3n prescripci\u00f3n electr\u00f3nica \n1-Reuniones del equipo multidisciplinar formado farmac\u00e9uticos, t\u00e9cnicos de farmacia, enfermeras y m\u00e9dico de la \nresidencia\ufffd  \n2- Implantaci\u00f3n de la prescripci\u00f3n electr\u00f3nica: Puesta en marcha del programa de prescripci\u00f3n electr\u00f3nica, formaci\u00f3n del \npersonal de la residencia y transcripci\u00f3n de ordenes m\u00e9dicas.  \nSegunda fase: Desarrollo del modelo de gesti\u00f3n de an\u00e1lisis de datos en programa KNIME  \n1. Dise\u00f1o de un modelo anal\u00edtico de gesti\u00f3n de datos dentro de la plataforma KNIME con el objetivo de obtener un listado \nmensual del consumo de la residencia generado a partir de las prescripciones electr\u00f3nicas. \n2\ufffd Para ello, se introducen 3 listados en el programa KNIME: listado de ofertas, listado de inventario y listado de consumo \ndel programa de prescripci\u00f3n electr\u00f3nica. Con estas bases de datos el programa genera un pedido que distingue entre la \nmedicaci\u00f3n que se dispensar\u00e1 desde el hospital y la que se suministrar\u00e1 a trav\u00e9s de los laboratorios directamente. \n3\ufffd Revisi\u00f3n de los pedidos por personal de la residencia y de farmacia y posterior preparaci\u00f3n\nIMPLANTACI\u00d3N\nEste proyecto se implant\u00f3 en mayo de 2021\ufffd\nRESULTADOS\nEl gasto farmac\u00e9utico en 2018 fue de 88385 euros, en 2019 de 89249 euros, en 2020 de 75900 euros y en 2021 de 39964 \neuros\ufffd La reducci\u00f3n del gasto fue de un 54,7% respecto a 2018, 55 % respecto a 2019 y del 47% respecto a 2020\ufffd\nLIMITACIONES\nEl proyecto requiere de conocimientos inform\u00e1ticos avanzados para el dise\u00f1o y desarrollo del modelo de an\u00e1lisis en la \nplataforma KNIME adaptado a la residencia\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nDados los buenos resultados obtenidos, se pretende aplicar este sistema al resto de las residencias sociosanitarias del \nServicio de Farmacia\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1125. IMPLANTACI\u00d3N DE UN MODELO DE TELEFARMACIA EN COLABORACI\u00d3N CON LA FARMACIA \nCOMUNITARIA EN UN HOSPITAL DE TERCER NIVEL \nAUTORES\nGONZ\u00c1LEZ FERN\u00c1NDEZ, A; GUILL\u00c9N MART\u00cdNEZ, O; LUCAS MAYOL, MJ; GARC\u00cdA MONSALVE, A; PERAL BALLESTER, L; \nNAVARRO RU\u00cdZ, A\nHOSPITAL GENERAL DE ELCHE \ufffd CAM\u00cd DE L\u00b4AMAZARA, 11 ELCHE/ELX \ufffd ALICANTE\nOBJETIVOS\nImplementar el circuito de dispensaci\u00f3n de medicaci\u00f3n desde las unidades de Servicio de Atenci\u00f3n Farmac\u00e9utica (AF) a \npacientes externos (PEX) en colaboraci\u00f3n con la Farmacia Comunitaria.\nMEJORAS ESPERADAS\nGarantizar una atenci\u00f3n farmac\u00e9utica de calidad apoy\u00e1ndose en la atenci\u00f3n farmac\u00e9utica telem\u00e1tica, mejorar el acceso \nde los pacientes a la medicaci\u00f3n e incrementar su satisfacci\u00f3n con la asistencia prestada.531DISE\u00d1O CIRCUITO Y ETAPAS\nComo consecuencia del desarrollo del plan asistencial de atenci\u00f3n farmac\u00e9utica telem\u00e1tica (PAt) en las unidades de \natenci\u00f3n farmac\u00e9utica a pacientes externos (UFPE) de los hospitales de nuestra comunidad, se dise\u00f1\u00f3 un circuito de \ndispensaci\u00f3n de medicaci\u00f3n en proximidad en colaboraci\u00f3n con el Colegio Oficial de Farmac\u00e9uticos (COF) de nuestra \ncomunidad y las oficinas de farmacia comunitarias (OF) que voluntariamente acceden a participar.  \nEl circuito est\u00e1 constituido por 7 fases:  \n1) Selecci\u00f3n de los pacientes candidatos a la modalidad de dispensaci\u00f3n en proximidad bas\u00e1ndose en criterios de \npriorizaci\u00f3n (situaci\u00f3n cl\u00ednica estable, adherencia adecuada, dificultad de desplazamiento a la UFPE entre otros).  \n2) Autorizaci\u00f3n para participar e indicaci\u00f3n de la oficina de Farmacia Comunitaria de elecci\u00f3n por parte del paciente.  \n3) Previo a cada dispensaci\u00f3n, se contacta telef\u00f3nicamente con el paciente/cuidador para realizar una consulta de AF y \nseguimiento de la adherencia, as\u00ed como resoluci\u00f3n de dudas del nuevo servicio ofrecido.  \n5) Registra la dispensaci\u00f3n en la plataforma de distribuci\u00f3n de medicamentos hospitalarios del MICOF (Muy Ilustre \nColegio Oficial de Farmac\u00e9uticos de Valencia), al que tienen acceso tanto las oficinas de Farmacia como el personal de \nreparto\ufffd  \n6) Se realizan dos env\u00edos semanales y se prepara la medicaci\u00f3n de los pacientes programados para m\u00e1ximo dos meses de \ntratamiento (Orden SND/293/2020) teniendo en cuenta las condiciones de conservaci\u00f3n de cada especialidad.  \n7) Recogida de la medicaci\u00f3n en la UFPE por parte de la empresa log\u00edstica y entrega al paciente en la OF. En el momento \nde la entrega de la medicaci\u00f3n, el paciente firma un \u201crecib\u00ed\u201d para que quede constancia de la recepci\u00f3n y la OF registra su \nentrega en la plataforma, de forma que queda cerrado el circuito.\nIMPLANTACI\u00d3N\nEl circuito se implant\u00f3 en Junio de 2021.\nRESULTADOS\nUn total de 151/2252 (6.7%) pacientes se han incluido hasta el momento en la modalidad de dispensaci\u00f3n en proximidad, \n56.7% mujeres con una edad media de 64 (0-99) a\u00f1os. Se han realizado un total de 632 env\u00edos. Las principales patolog\u00edas \ndentro de esta modalidad fueron: enfermedades reumatol\u00f3gicas(20,5%) cardiovasculares(15,2%), enfermedades \nneurol\u00f3gicas(9,2%), c\u00e1ncer(8,6%), enfermedades infecciosas(7,2%), hematol\u00f3gicas(5,9%), enfermedades inflamatorias \nintestinales(3,9%) y otras como metabolopat\u00edas, oftalmol\u00f3gicas y alergias(7,9%). Desglosado por patolog\u00eda, el porcentaje \nde pacientes adheridos al programa de dispensaci\u00f3n en proximidad ha sido: enfermedades reumatol\u00f3gicas(15%), \nenfermedades cardiovasculares(11,8%), infecciosas(8,2%), neurol\u00f3gicas(5,8%), intestinales(5,4), c\u00e1ncer(4,7%).\nLIMITACIONES\nRequiere una reorganizaci\u00f3n del proceso de dispensaci\u00f3n de medicamentos a PEX y disponibilidad de recursos humanos \ne infraestructuras\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste modelo es aplicable y extrapolable a otros Servicios de Farmacia Hospitalaria\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1306. TELETRABAJO EN FARMACIA HOSPITALARIA, \u00bfPOSIBILIDAD O REALIDAD? \nAUTORES\nELVIRO LLOR\u00c9NS, M; MONFORTE GASQUE, P; OCHOA BALLESTEROS, N; AINAGA L\u00d3PEZ, C; GUTI\u00c9RREZ VALENCIA, M; \nL\u00c1ZARO GALLARDO, EM\nCL\u00cdNICA NUESTRA SE\u00d1ORA DEL PILAR. P\u00ba DE RUISE\u00d1ORES, 20 ZARAGOZA. ZARAGOZA\nOBJETIVOS\nContinuar con la apertura y correcto funcionamiento del Servicio de Farmacia (SF) en un hospital privado, y evitar as\u00ed su \nconversi\u00f3n en dep\u00f3sito de medicamentos ante la falta de farmac\u00e9uticos especialistas en Farmacia Hospitalaria (FH).\nMEJORAS ESPERADAS\n1. Mantener activo un SF propio, permitiendo dar continuidad a las actividades propias del servicio: adquisici\u00f3n, custodia, \noptimizaci\u00f3n y dispensaci\u00f3n de medicamentos y productos sanitarios (PS), atenci\u00f3n farmac\u00e9utica (AF), informaci\u00f3n del \nmedicamento, dosis unitaria, dispensaci\u00f3n a pacientes externos, etc\ufffd  \n2. Mejorar y optimizar recursos, racionalizar su consumo y reducir el gasto hospitalario.  \n3. Aportar calidad y seguridad a la atenci\u00f3n sanitaria a trav\u00e9s de la integraci\u00f3n del FH en el equipo multidisciplinar del \ncentro\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nLa situaci\u00f3n de inestabilidad y dificultad para encontrar un FH y responsable del servicio hace peligrar la continuidad \ndel SF. Por ello, se plante\u00f3 un modelo de contrataci\u00f3n del FH a distancia, para llevar a cabo su jornada laboral de forma \ncombinada: presencial y teletrabajo.  \n1. Previsi\u00f3n del personal necesario y estimaci\u00f3n de la periodicidad de visitas presenciales del FH.  \n2. Contrataci\u00f3n del farmac\u00e9utico responsable del SF. Realizar\u00e1 al menos una visita semanal al centro (dos, si necesidad), \ncompletando su jornada con teletrabajo.  \n3. Contrataci\u00f3n de un t\u00e9cnico de farmacia (TF) presencial a jornada completa, que estar\u00e1 en comunicaci\u00f3n permanente \ncon el farmac\u00e9utico.  \n4. An\u00e1lisis de procesos y m\u00e9todos de trabajo del centro.  5325. Detecci\u00f3n de las necesidades prioritarias e implantaci\u00f3n de mejoras centradas en optimizar tiempo, recursos y espacio.  \n6. Evaluaci\u00f3n y balance de los resultados obtenidos tras un a\u00f1o de trabajo.\nIMPLANTACI\u00d3N\nEn octubre 2020 se puso en marcha esta propuesta de trabajo. La farmac\u00e9utica comenz\u00f3 sus visitas semanales y trabaj\u00f3 \nconjuntamente con el TF distribuyendo las tareas semanales, y con Supervisoras, Direcci\u00f3n M\u00e9dica y Gerencia definiendo \nnecesidades y prioridades de intervenci\u00f3n\ufffd  \nPara habilitar el teletrabajo, se llev\u00f3 a cabo el aprovisionamiento de los medios inform\u00e1ticos y de comunicaci\u00f3n \nnecesarios\ufffd\nRESULTADOS\n- \u00c9xito en el objetivo primario: mantener activo y funcional el SF.  \n- Actividad anual: 48 visitas presenciales del FH  \no Control de stocks y optimizaci\u00f3n de almacenes.  \no Implantaci\u00f3n de dosis unitaria, y revisi\u00f3n de medicaci\u00f3n al ingreso/alta\ufffd \no AF a 98 pacientes ambulatorios\ufffd  \no Integraci\u00f3n del FH en el equipo multidisciplinar asistencial.  \no Reuniones presenciales con mandos intermedios\ufffd \no Atenci\u00f3n a la industria farmac\u00e9utica. \n- Jornadas de teletrabajo:  \no Gesti\u00f3n econ\u00f3mica: pedidos a proveedores, revisi\u00f3n de facturas y resoluci\u00f3n de incidencias.  \no Elaboraci\u00f3n de procedimientos normalizados de trabajo.  \no Pactos de consumo y botiquines de unidades cl\u00ednico-quir\u00fargicas.  \no Validaci\u00f3n unidosis e intercambio terap\u00e9utico.  \no AF, informaci\u00f3n y respuesta a consultas\ufffd  \n- Gesti\u00f3n y optimizaci\u00f3n de recursos (2021 vs 2020):  \no Reducci\u00f3n consumo: 20% medicamentos, 5% PS, 8% global\ufffd  \no Reducci\u00f3n gasto: 23% medicamentos\ufffd\nLIMITACIONES\nEs necesario establecer m\u00e9todos eficientes de telecomunicaci\u00f3n, as\u00ed como una buena previsi\u00f3n y organizaci\u00f3n del \ntiempo. Tambi\u00e9n el tiempo y la distancia de traslado al hospital desde la zona de teletrabajo, podr\u00eda suponer una \nlimitaci\u00f3n\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste modelo podr\u00eda ser aplicable a hospitales privados de peque\u00f1o tama\u00f1o en los que existe dificultad para conseguir \nun FH de forma estable y continua, una alternativa a valorar antes del cierre del SF y su conversi\u00f3n en dep\u00f3sito de \nmedicamentos\ufffd\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y \nFARMACOGEN\u00c9TICA\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n543. IMPLEMENTACI\u00d3N DEL GENOTIPADO DEL CYP3A5 PARA EL AJUSTE DE LA DOSIS INICIAL DE \nTACROLIMUS EN PACIENTES TRASPLANTADO CARDIACOS \nAUTORES\nRIERA ARMENGOL, P; DE DIOS L\u00d3PEZ, A; BERNAL NOGUERA, S; ROJAS RODR\u00cdGUEZ, E; L\u00d3PEZ L\u00d3PEZ, L; MIRABET \nP\u00c9REZ, S; MANGUES BAFALLUY , M; GOMIS PASTOR, M\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa supervivencia tras el trasplante de \u00f3rgano s\u00f3lido (TOS) ha aumentado en las \u00faltimas d\u00e9cadas gracias, entre \notros factores, a la optimizaci\u00f3n de la terapia antirechazo. Tacrolimus es un inmunosupresor ampliamente usado \npara la profilaxis del rechazo, siendo el CYP3A5 una de las enzimas m\u00e1s implicadas en su metabolismo. El Clinical \nPharmacogenetics Implementation Consortium (CPIC) recomienda genotipar el CYP3A5 antes de iniciar el tratamiento y \naumentar la dosis inicial 1,5-2 veces en pacientes metabolizadores normales e intermedios. El objetivo de este proyecto \nfue implementar el genotipado del CYP3A5 en las pruebas previas al trasplante cardiaco para individualizar la dosis inicial \nde tacrolimus siguiendo las recomendaciones del CPIC\ufffd\nMEJORAS ESPERADAS\n\u2022 Implementar intervenciones de valor que permitan una mayor optimizaci\u00f3n del tratamiento farmacol\u00f3gico en el campo \ndel TOS\ufffd  \n\u2022 Acortar el tiempo necesario para alcanzar concentraciones de tacrolimus en rango terap\u00e9utico en pacientes \nmetabolizadores del CYP3A5 normales e intermedios tras el trasplante card\u00edaco.533DISE\u00d1O CIRCUITO Y ETAPAS\nImplementaci\u00f3n de una nueva pr\u00e1ctica asistencial multidisciplinar promovida desde el Servicio de Farmacia. Se identific\u00f3 \nla capacidad metabolizadora del CYP3A5 como un posible factor de variabilidad en los d\u00edas necesarios para llegar a \nrango terap\u00e9utico de tacrolimus despu\u00e9s del trasplante card\u00edaco. Se plante\u00f3 a los Servicios de Cardiolog\u00eda y Gen\u00e9tica la \nutilidad cl\u00ednica de genotipar el CYP3A5 antes de iniciar el tratamiento. Se llevaron a cabo reuniones multidisciplinares \npara establecer los requerimientos necesarios y consensuar procedimientos. Se consensu\u00f3 la dosis inicial del f\u00e1rmaco en \nfunci\u00f3n del genotipo y recomendaci\u00f3n de las gu\u00edas CPIC.  \n \nLa solicitud del genotipado del CYP3A5 se a\u00f1ade a las pruebas realizadas al receptor en el momento de inclusi\u00f3n a la lista \nde trasplante. Para ello, durante la entrevista de atenci\u00f3n farmac\u00e9utica que se realiza a los pacientes en lista de trasplante \nse incluye: la informaci\u00f3n al paciente, firma de consentimiento informado y petici\u00f3n de la solicitud de genotipado. \nRealizada la extracci\u00f3n, desde el Servicio de Gen\u00e9tica se extrae el ADN de una muestra de sangre perif\u00e9rica y se \ndeterminan los alelos de p\u00e9rdida de funci\u00f3n del CYP3A5 (*3, *6 y *7) por PCR a tiempo real mediante sondas Taqman\u00ae. \nEn pacientes metabolizadores normales e intermedios se inicia el tacrolimus a una dosis el doble de la est\u00e1ndar. Los \nfarmac\u00e9uticos cl\u00ednicos reflejan en la historia cl\u00ednica del paciente dicha recomendaci\u00f3n y monitorizan su implementaci\u00f3n y \nadecuaci\u00f3n tras el trasplante\ufffd\nIMPLANTACI\u00d3N\nLos primeros an\u00e1lisis se realizaron en julio de 2020, con la implicaci\u00f3n de los Servicios de Farmacia, Cardiolog\u00eda y \nGen\u00e9tica.\nRESULTADOS\nSe han genotipado 18 pacientes. Trece de ellos (72%) presentaron el genotipo *3/*3. Los cinco pacientes restantes (18%) \npresentaron el genotipo *1/*3. No se ha hallado ning\u00fan paciente con el genotipo *1/*1 ni portador de alguno de los \notros alelos de p\u00e9rdida de funci\u00f3n (*6 o *7).\nLIMITACIONES\nTama\u00f1o muestral limitado debido al n\u00famero de trasplantes card\u00edacos que se efect\u00faan anualmente en el centro (15-18/\na\u00f1o).\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEsta pr\u00e1ctica es aplicable a otros Servicios de Farmacia que cuenten con farmac\u00e9uticos de TOS y formados en \nfarmacogen\u00e9tica. Esta nueva pr\u00e1ctica puede servir de soporte para su implementaci\u00f3n en otros centros de trasplante.\nCLASIFICACI\u00d3N: MEDICINA DE PRECISI\u00d3N: FARMACOCIN\u00c9TICA Y FARMACOGEN\u00c9TICA\n548. IMPLEMENTACI\u00d3N DE ESTUDIOS FARMACOGEN\u00c9TICOS EN PSIQUIATR\u00cdA PARA LA OPTIMIZACI\u00d3N \nDEL TRATAMIENTO CON PSICOF\u00c1RMACOS \nAUTORES\nRIERA ARMENGOL, P; BERNAL NOGUERA, S; ROJAS RODR\u00cdGUEZ, E; D\u00cdAZ P\u00c9REZ, A; P\u00c9REZ BLANCO, J; CORRIPIO \nCOLLADO, I; MANGUES BAFALLUY , M; G\u00c1MEZ LECHUGA, M\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa respuesta farmacol\u00f3gica a los psicof\u00e1rmacos es extremadamente variable. En el caso de los antidepresivos, el 20-30% \nde los pacientes no muestran una respuesta significativa a dosis terap\u00e9uticas, mientras que un 30-50% de los pacientes \nno responden de forma \u00f3ptima a los neurol\u00e9pticos y/o desarrollan efectos adversos que pueden ser graves y duraderos.  \n \nEl objetivo de este proyecto multidisciplinar fue implementar la medicina personalizada mediante estudios \nfarmacogen\u00e9ticos para identificar las causas de refractariedad o intolerancia al tratamiento con neurol\u00e9pticos o \nantidepresivos en la pr\u00e1ctica cl\u00ednica.\nMEJORAS ESPERADAS\nOptimizar el tratamiento con f\u00e1rmacos neurol\u00e9pticos y antidepresivos tras identificar las causas de inefectividad o \ntoxicidad al tratamiento recibido\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nLa implementaci\u00f3n de los estudios farmacogen\u00e9ticos en psiquiatr\u00eda se realiz\u00f3 a trav\u00e9s de la coordinaci\u00f3n de los Servicios \nde Psiquiatr\u00eda, Gen\u00e9tica y Farmacia. Se analiz\u00f3 la bibliograf\u00eda existente para decidir y consensuar los genes de mayor \nrelevancia para el objetivo planteado, que fueron el CYP1A2, CYP2D6, CYP2C19, CYP2C9, 5-HTT y HTR2A. Los tres \nservicios trabajan de forma coordinada, siendo los psiquiatras los responsables del reclutamiento, los genetistas los \nresponsables de la realizaci\u00f3n del estudio gen\u00e9tico y los farmac\u00e9uticos los encargados de su interpretaci\u00f3n cl\u00ednica.  \n \nLos psiquiatras seleccionan los pacientes candidatos a estudio farmacogen\u00e9tico. El Servicio de Farmacia, tras analizar el \nmotivo de estudio, determina en cada caso los genes de inter\u00e9s considerando la farmacocin\u00e9tica y farmacodinamia de \nlos f\u00e1rmacos implicados. Tras extraerse el ADN de una muestra de sangre perif\u00e9rica, el Servicio de Gen\u00e9tica determina las \nvariantes gen\u00e9ticas acordadas y el n\u00famero de copias del CYP2D6 mediante PCR a tiempo real utilizando sondas Taqman\u00ae. \nLos farmac\u00e9uticos realizan la interpretaci\u00f3n cl\u00ednica del resultado, que se deja registrada en la historia cl\u00ednica de cada \npaciente\ufffd534IMPLANTACI\u00d3N\nLos primeros an\u00e1lisis se realizaron en enero de 2021. Se cre\u00f3 una prueba gen\u00e9tica espec\u00edfica para que los psiquiatras \npudieran solicitar el an\u00e1lisis farmacogen\u00e9tico con facilidad.\nRESULTADOS\nHasta el momento actual, se han genotipado 10 pacientes. En un 30% de los casos, el estudio farmacogen\u00e9tico \npermiti\u00f3 entender las causas de refractariedad o mala tolerancia al tratamiento recibido. En concreto, fue el caso \nde una paciente metabolizadora intermedia del CYP2D6 que presentaba mala tolerancia a risperidona y olanzapina, \nel caso de una paciente metabolizadora ultrarr\u00e1pida del CYP1A2 sin respuesta a olanzapina y el caso de un paciente \nmetabolizador ultrarr\u00e1pido del CYP1A2 con altos requerimientos de clozapina. En el 70% de los casos restantes, el estudio \nfarmacogen\u00e9tico no permiti\u00f3 dilucidar la causa de la falta de efectividad/ mala tolerancia al tratamiento recibido.\nLIMITACIONES\nEl tama\u00f1o muestral es relativamente peque\u00f1o debido al bajo n\u00famero de pacientes estudiado hasta el momento.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste proyecto es aplicable a otros Servicios de Farmacia hospitalarios con farmac\u00e9uticos formados en farmacogen\u00e9tica y \npsiquiatr\u00eda.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n664. COMUNIDAD VIRTUAL PARA EL APOYO INTEGRAL A PACIENTES CON C\u00c1NCER DE MAMA. \nAUTORES\nVILLANUEVA BUENO, C; ESCUDERO VILAPLANA, VD; COLLADO BORRELL, R; REVUELTA HERRERO, JL; GARC\u00cdA \nRAMIREZ, M; GONZALEZ-HABA PE\u00d1A, E; OCHOA ARNEDO, C; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nOBJETIVOS\nDise\u00f1ar, implementar y coordinar una comunidad virtual de apoyo integral a las pacientes diagnosticadas de c\u00e1ncer de \nmama (CM).\nMEJORAS ESPERADAS\nGarantizar una atenci\u00f3n integral para pacientes con CM y mejorar la calidad de la atenci\u00f3n percibida de las pacientes \nmediante una mayor interconectividad, acceso a informaci\u00f3n y comunicaci\u00f3n con los profesionales sanitarios y otras \npacientes con CM\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nDise\u00f1o:  \nNuestra comunidad virtual es un entorno seguro, donde las pacientes interact\u00faan de forma as\u00edncrona y an\u00f3nima entre \ns\u00ed. Permite una interacci\u00f3n dual: paciente-profesional sanitario para resoluci\u00f3n instant\u00e1nea de dudas y paciente-paciente \npara compartir experiencias, informaci\u00f3n y apoyarse. \nEl acceso a la comunidad se realiza desde una app m\u00f3vil o p\u00e1gina web y est\u00e1 estructurada en 7 grupos de conversaci\u00f3n: \nestilos de vida, tratamientos, imagen corporal y sexualidad, respuesta emocional, relaciones interpersonales, cambios \ndespu\u00e9s del c\u00e1ncer y cuestiones laborares y recursos sociales, incluyendo 33 temas de conversaci\u00f3n diferentes. Adem\u00e1s, \ncada tema dispone de numerosos recursos formativos (art\u00edculos, videos\u2026).  \nCircuito y etapas: \n-Marzo 2020: creaci\u00f3n del grupo de trabajo multidisciplinar (5 farmac\u00e9uticos especialistas en Oncohematolog\u00eda, 4 \nonc\u00f3logos y 2 psico-onc\u00f3logas y 1 enfermera gestora de casos)  \n-Abril 2020-mayo 2020: desarrollo de la plataforma y sus contenidos  \n-Junio 2020: definici\u00f3n del circuito de atenci\u00f3n integral a trav\u00e9s de la comunidad  \n-Junio 2020-mayo 2022: inclusi\u00f3n de pacientes \n-Junio 2021-agosto 2021: integraci\u00f3n de Google Analytics \n-Junio 2022-julio 2022: evaluaci\u00f3n del impacto\nIMPLANTACI\u00d3N\nLas pacientes son incluidas en cualquiera de las consultas de los profesionales implicados. Los criterios de inclusi\u00f3n son: \n(1) paciente mayor de 18 a\u00f1os que padezca CM este o no en tratamiento activo, (2) disponibilidad de Smartphone o \nposibilidad de acceso a internet\ufffd \nTras instalarse la app y ser registradas con un pseud\u00f3nimo, pueden interactuar en cualquiera de los temas de \nconversaci\u00f3n\ufffd  \nActualmente se est\u00e1 evaluando el impacto mediante patient-reported outcomes measures (PROMs) que se env\u00edan \ncada 3 meses: MOS (Cuestionario de Apoyo social), PCL-5 (Estr\u00e9s post-traum\u00e1tico), HAD (Ansiedad y Depresi\u00f3n), PTGI \n(Crecimiento post-traum\u00e1tico), EQ-5D (Calidad de vida). Empoderamiento: herramienta de Uden-Kraan; Encuesta de \nsatisfacci\u00f3n e Indicadores de usabilidad con Google Analytics.535RESULTADOS\n90 pacientes incluidas, mediana de edad de 53,8 a\u00f1os (37-81). 80 (90,0%) pacientes en tratamiento activo, y 64(71,1%) \ncon enfermedad metast\u00e1sica. En cuanto al tratamiento, 51(56,7%) fueron tratadas con antineopl\u00e1sicos orales, y \n29(32,2%) recibieron quimioterapia intravenosa. Se han enviado 563 mensajes (80,4% entre pacientes, 19,6% profesional \nsanitario-paciente). Las categor\u00edas m\u00e1s utilizadas fueron: tratamientos (190 mensajes) y estilos de vida (141 mensajes). El \n30,0% han participado activamente en la comunidad.\nLIMITACIONES\nBarreras tecnol\u00f3gicas derivadas del uso de nuevas tecnolog\u00edas: facilitamos el acceso a la comunidad mediante la app o v\u00eda \nweb para una atenci\u00f3n equitativa adaptada por paciente. \nProblemas \u00e9ticos: Las pacientes tratan temas personales y, aunque utilizan pseud\u00f3nimos, los profesionales sanitarios \ndeben cumplir estrictamente los principios de confidencialidad.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa comunidad virtual est\u00e1 desarrollada para que sea f\u00e1cilmente adaptable a cualquier patolog\u00eda y a cualquier entorno.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1070. AN\u00c1LISIS DE LOS RESULTADOS TRAS LA IMPLANTACI\u00d3N DE UN CIRCUITO DE ADMINISTRACI\u00d3N \nDE TRATAMIENTOS ONCO-HEMATOL\u00d3GICOS EN PAUTA DE DESENSIBILIZACI\u00d3N \nAUTORES\nROS OLASO, A; BERISTAIN ARAMENDI, I; BOO RODRIGUEZ, J; GONZALEZ FERNANDEZ, T; ECEIZA DIEZ, A; ULACIA \nEPELDE, L; LIZEAGA CUNDIN, G; GARCIA DE ANDOIN BARANDIARAN, MJ\nHOSPITAL DONOSTIA-DONOSTIA OSPITALEA. P\u00ba DR. BEGUIRISTAIN, 109 DONOSTIA-SAN SEBASTI\u00c1N. GUIP\u00daZCOA\nOBJETIVOS\nDescribir la experiencia y analizar los resultados de la implantaci\u00f3n de un circuito de administraci\u00f3n de agentes \nantineopl\u00e1sicos mediante la t\u00e9cnica de desensibilizaci\u00f3n.\nMEJORAS ESPERADAS\nLa administraci\u00f3n segura en pauta de desensibilizaci\u00f3n de la terapia antineopl\u00e1sica imprescindible, a pacientes que \npreviamente han presentado reacci\u00f3n de hipersensibilidad al medicamento.  \nLa pauta de desensibilizaci\u00f3n permite inducir una situaci\u00f3n de tolerancia temporal a un medicamento responsable de una \nreacci\u00f3n de hipersensibilidad, partiendo de una dosis sub\u00f3ptima e incrementandola progresivamente hasta alcanzar la \ndosis terap\u00e9utica adecuada para el paciente.\nDISE\u00d1O CIRCUITO Y ETAPAS\nCreaci\u00f3n de un circuito coordinado entre los servicios de Alergolog\u00eda, Hematolog\u00eda, Oncolog\u00eda y Farmacia. El servicio \nde Farmacia es responsable de la elaboraci\u00f3n de protocolos y preparaci\u00f3n de las mezclas de medicamentos para los \npacientes onco-hematol\u00f3gicos.  \n-Cuando se detecta un episodio sugestivo de reacci\u00f3n de hipersensibilidad en la administraci\u00f3n de un agente \nantineopl\u00e1sico, el onc\u00f3logo o hemat\u00f3logo responsable del paciente valora si ese medicamento es indispensable y hay \notra alternativa terap\u00e9utica valida.  \n-Si el medicamento se considera indispensable, se realiza una interconsulta no presencial (CNP) a Alergolog\u00eda.  \n-El alerg\u00f3logo, valora la necesidad de realizar pruebas cut\u00e1neas para la confirmaci\u00f3n de la reacci\u00f3n de hipersensibilidad y \nla indicaci\u00f3n de la desensibilizaci\u00f3n.  \n-En caso de indicar la desensibilizaci\u00f3n, el alerg\u00f3logo realiza una CNP a farmacia indicando la pauta de desensibilizaci\u00f3n \na seguir: n\u00famero de diluciones del medicamento a preparar y ritmos de administraci\u00f3n de cada bolsa. La premedicaci\u00f3n \nqueda a cargo de alergolog\u00eda.  \n- El farmac\u00e9utico elabora el protocolo de desensibilizaci\u00f3n predefinido para el agente antineopl\u00e1sico, garantizando su \nestabilidad y seguridad y crea el esquema en el programa corporativo de prescripci\u00f3n de antineopl\u00e1sicos (Onkobide\u00ae).  \n-El m\u00e9dico responsable, programa el tratamiento y el farmac\u00e9utico verifica la correcta prescripci\u00f3n del esquema de \ndesensibilizaci\u00f3n.  \n-El d\u00eda de la administraci\u00f3n, se preparan en la cabina de flujo laminar vertical las bolsas de los antineopl\u00e1sicos con las \ndistintas diluciones: se env\u00eda primero \u00fanicamente, la mezcla m\u00e1s diluida y una vez iniciada la administraci\u00f3n, se env\u00edan las \nsiguientes para evitar errores y empezar la administraci\u00f3n con la bolsa m\u00e1s diluida.  \n-El paciente ingresa en el hospital para la administraci\u00f3n del tratamiento bien, en planta de hospitalizaci\u00f3n o bien, en \nCuidados Intensivos si Alergolog\u00eda lo estima oportuno.\nIMPLANTACI\u00d3N\nSe inici\u00f3 en marzo 2019.\nRESULTADOS\nDesde marzo 2019 hasta mayo 2022, se incluyeron 41 pacientes en el circuito, 19 de hematolog\u00eda y 22 de oncolog\u00eda. \nSe administraron 154 procedimientos de desensibilizaci\u00f3n: 55 oxaliplatino, 42 brentuximab vedotin, 23 rituximab, 19 \npaclitaxel, 8 dacarbazina, 6 carboplatino y 1 fluorouracilo.  \nSe consigui\u00f3 administrar el medicamento mediante la t\u00e9cnica de desensibilizaci\u00f3n a todos los pacientes excepto a uno \nque tuvo reacci\u00f3n de hipersensibilidad grave al oxaliplatino con la pauta de desensibilizaci\u00f3n y se suspendi\u00f3.  \nUn paciente con hipersensibilidad a dacarbazina preciso la administraci\u00f3n de omalizumab de manera profil\u00e1ctica.536LIMITACIONES\n- Requiere personal especializado  \n- Medidas de seguridad espec\u00edficas \n- Pr\u00e1ctica realizada un \u00fanico d\u00eda a la semana\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nCircuito aplicable a todos los servicios de Farmacia que preparen tratamientos quimioterapicos para pacientes onco-\nhematol\u00f3gicos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1081. DISPENSACI\u00d3N DE LA PREMEDICACI\u00d3N DE LOS ESQUEMAS CON DARATUMUMAB SUBCUT\u00c1NEO \nEN LA CONSULTA DE ATENCI\u00d3N FARMAC\u00c9UTICA. \nAUTORES\nREDONDO CAPAFONS, S; SORIANO GUTIERREZ, L; MAYORAL REGALADO, R; ORTIZ RUIZ, L; QUINTANA , S; ROVIRA \nMEDINA, T; G\u00d3MEZ VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA\nOBJETIVOS\n-Implementar un nuevo circuito de dispensaci\u00f3n en la consulta de atenci\u00f3n farmac\u00e9utica (CAF) de premedicaci\u00f3n y \ncorticoides orales (PyCO) utilizados en los esquemas quimioter\u00e1picos que contienen daratumumab subcut\u00e1neo para el \ntratamiento del mieloma m\u00faltiple.  \n-Analizar la satisfacci\u00f3n de los pacientes asociada al nuevo circuito.\nMEJORAS ESPERADAS\nLa dispensaci\u00f3n del n\u00famero exacto de comprimidos de PyCO en la CAF rotulados con la fecha de la toma deber\u00eda facilitar \nel cumplimiento y aumentar adherencia a las pautas de los esquemas con daratumumab, disminuyendo los errores y \naumentando la satisfacci\u00f3n de los pacientes.\nDISE\u00d1O CIRCUITO Y ETAPAS\nLa premedicaci\u00f3n consiste en un comprimido de paracetamol 1g, dexclorfeniramina 2mg, dexametasona 40mg el d\u00eda de \nla administraci\u00f3n de daratumumab y montelukast 10mg el d\u00eda antes y el d\u00eda mismo de la administraci\u00f3n, as\u00ed como los \ncorticoides utilizados durante el ciclo de tratamiento.  \nDe forma habitual, los pacientes en tratamiento con daratumumab recogen en las oficinas de farmacia (OF) la PyCO \ndonde se dispensa envases enteros de cada f\u00e1rmaco.  \nDebido a la complejidad de los protocolos con daratumumab y la detecci\u00f3n de errores en la toma de la medicaci\u00f3n, se \nacord\u00f3 entre el servicio de farmacia y hematolog\u00eda que se dispensar\u00eda dicha medicaci\u00f3n desde la CAF en unidosis con la \nfecha de administraci\u00f3n.  \n \n-Revisi\u00f3n de informaci\u00f3n sobre la premedicaci\u00f3n de daratumumab subcut\u00e1neo.  \n-Reuni\u00f3n de consenso entre hematolog\u00eda y farmacia para decidir el contenido del kit.  \n-Informaci\u00f3n de implantaci\u00f3n del nuevo circuito.  \n-Puesta en marcha en la CAF. \n-Realizaci\u00f3n encuesta de satisfacci\u00f3n a los pacientes.\nIMPLANTACI\u00d3N\nCuando el paciente finaliza la visita m\u00e9dica, el paciente acude a la CAF donde tras la validaci\u00f3n del esquema por el \nfarmac\u00e9utico/a, se le dispensa el kit de PyCO. Se individualiza seg\u00fan el protocolo y ciclo de tratamiento, marcando el d\u00eda \nde la toma de cada f\u00e1rmaco.  \nTras un a\u00f1o de la implementaci\u00f3n de este circuito, se llev\u00f3 a cabo un estudio transversal para conocer el grado de \nsatisfacci\u00f3n de los pacientes. El proyecto dispone de la aprobaci\u00f3n del CEIm del centro.  \nEl cuestionario se ofreci\u00f3 a los pacientes en el momento de recogida de PyCO en la CAF. \nEl cuestionario punt\u00faa del 1 al 10 la satisfacci\u00f3n, siendo 1 nada satisfecho y 10 muy satisfecho. \nPara poder comparar la satisfacci\u00f3n entre los dos \u00e1mbitos de dispensaci\u00f3n, el cuestionario incluye preguntas referentes a \nla recogida previa en la OF y en la CAF \ufffd\nRESULTADOS\nSe han dispensado 101 kits de PyCO correspondientes a 27 pacientes. El 56%% fueron hombres; mediana de edad 76 \na\u00f1os (54-85). El esquema m\u00e1s frecuente implicado fue daratumumab-bortezomib-melfalan-prednisona en un 40,7%.  \nOnce pacientes respondieron el cuestionario de satisfacci\u00f3n.  \nLa media de puntuaci\u00f3n de satisfacci\u00f3n fue de: 9,3 en CAF y 6,3 en OF sobre el circuito; 9,4 en CAF y 6,1 en OF respecto \na la explicaci\u00f3n recibida; 9,1 en CAF y 7 en OF sobre la comodidad; 9,2 en CAF y 7 en OF sobre conocimiento de la \nmedicaci\u00f3n\ufffd  \nSe observaron diferencias estad\u00edsticamente significativas p= 0,003 a favor de la dispensaci\u00f3n en la CAF.\nLIMITACIONES\nReducido tama\u00f1o muestral\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a la totalidad de hospitales.537CLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1226. IMPACTO DE UNA APLICACI\u00d3N M\u00d3VIL EN EL CONTROL DE LA ADHERENCIA AL TRATAMIENTO Y EN \nLA COMUNICACI\u00d3N PACIENTE-FARMAC\u00c9UTICO HOSPITALARIO \nAUTORES\nL\u00d3PEZ BRUNS\u00d3, M; QUER MARGALL, N; FORT CASAMARTINA, E; LEZCANO RUBIO, C; ALCALDE RODRIGO, M; \nFONTANALS MARTINEZ, S; IB\u00c1\u00d1EZ COLLADO, C; CLOP\u00c9S ESTELA, A\nICO GIRONA. AVDA FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nLas aplicaciones (app) m\u00f3viles pueden conectar y mejorar el seguimiento farmacoterap\u00e9utico, la comunicaci\u00f3n, la \nadherencia y el manejo de los efectos secundarios.  \n \nEl objetivo principal de este estudio piloto es determinar la adherencia a la medicaci\u00f3n para el tratamiento de la leucemia \nmieloide cr\u00f3nica (LMC) a trav\u00e9s de los registros inform\u00e1ticos de dispensaci\u00f3n durante los primeros 6 meses de utilizaci\u00f3n \nde la app en comparaci\u00f3n con los 6 meses antes de la inclusi\u00f3n del estudio\ufffd  \n \nLos objetivos secundarios fueron analizar (1) adherencia a trav\u00e9s del cuestionario ARMS-E (2) satisfacci\u00f3n y la usabilidad \nde la app de los pacientes (3) impacto de la app en la comunicaci\u00f3n paciente-farmac\u00e9utico.\nMEJORAS ESPERADAS\nMejorar la atenci\u00f3n farmac\u00e9utica de los pacientes de LMC en tratamiento con inhibidores de la tirosinquinasa (ITK).\nDISE\u00d1O CIRCUITO Y ETAPAS\nEstudio observacional que consta de una fase de control (FC) (seguimiento previo a la inclusi\u00f3n en el estudio) y una fase \nde intervenci\u00f3n (FI) (app). Se identificaron los pacientes en tratamiento activo con ITK durante 6 meses o m\u00e1s. Se analizan \nlos datos 6 meses antes de la inclusi\u00f3n del estudio, a los 6 y a los 12 meses posteriores\ufffd \n \nLa adherencia se ha determinado mediante dos m\u00e9todos: registros dispensaci\u00f3n y cuestionario ARMS-e (12-48 mejor-\npeor adherencia). La usabilidad (0-100) y la satisfacci\u00f3n de la plataforma (0-10) se evaluaron mediante dos cuestionarios \na los 6 y 12 meses\ufffd \n \n1. Creaci\u00f3n de un equipo multidisciplinar (hemat\u00f3logos, farmac\u00e9uticos y psiconc\u00f3logos)  \n2. Desarrollo protocolo y aprobaci\u00f3n por Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica del Hospital.  \n3. Definici\u00f3n circuitos \n4\ufffd Inclusi\u00f3n de pacientes\nIMPLANTACI\u00d3N\nEnero 2021. Actualmente en curso (duraci\u00f3n del estudio: 2 a\u00f1os).\nRESULTADOS\nSe incluyeron 38 pacientes, 32 evaluables (4 rechazaron a posteriori y 2 discontinuaron el ITK). Se describe resultados a \nlos 6 meses de seguimiento\ufffd  \n \nCaracter\u00edsticas demogr\u00e1ficas y cl\u00ednicas: Edad media 53 a\u00f1os (29-76), hombres 69%, ECOG (0): 100%. Factores pron\u00f3sticos: \nSokal (alto-intermedio-bajo) 11%-11%-78%. Respuesta \u00f3ptima seg\u00fan criterio de ELN: 100%. N\u00famero de tratamientos \nprevios: 1 ITK 13 (41%), 2 ITKS 15 (47%), \u22653 ITKs (12%). ITK y pacientes iniciales en la app: Imatinib (12), dasatinib \n(7), nilotinib (13). Tiempo medio desde el diagn\u00f3stico e inicio del ITK actual: 7.8 a\u00f1os y 60 meses (3-204 meses) \nrespectivamente. Pluripatolog\u00eda (S\u00ed): 25%, polimedicaci\u00f3n (S\u00ed): 14%.  \n \nAdherencia FC y FI: 96.2% (DE=14.7) y 98.8% (DE=2.9) respectivamente (p=0.98).  \n \nResultados de los cuestionarios FI: Tasa de realizaci\u00f3n de los cuestionarios ARMS-e, usabilidad y satisfacci\u00f3n en la FI \nfueron de 43.5%, 50% y 46,8% respectivamente. La media de los cuestionarios ARMS-e: 14 (DE=2.18), usabilidad: 73.9 \n(DE: 15.9) y satisfacci\u00f3n: 7.8 (DE=1.9).  \n \nUn 56,3% de los pacientes han enviado mensajes a trav\u00e9s de la app (mayoritariamente consulta de interacciones y de \ntoxicidades).\nLIMITACIONES\nPoblaci\u00f3n de estudio con baja participaci\u00f3n en la usabilidad de la app al tratarse de pacientes con una media de tiempo \ncon el ITK 5 a\u00f1os. Con estos resultados, se podr\u00eda ofrecer la plataforma a pacientes en el inicio de tratamiento, con mayor \nnecesidad de soporte farmac\u00e9utico.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste proyecto de salud digital es aplicable a otros servicios de farmacia para complementar y mejorar la atenci\u00f3n \nfarmac\u00e9utica.538CLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS \nV\u00cdRICAS Y VIH)\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n170. CIRCUITO TRATAMIENTOS FRENTE A COVID-19 EN PACIENTE HOSPITALIZADO EN UN HOSPITAL DE \nTERCER NIVEL \nAUTORES\nMANZANO LORENZO, R; TALLON MARTINEZ, JC; FERNANDEZ RUIZ-MORON, A; CORAZON VILLANUEVA, J; YBA\u00d1EZ \nGARCIA, L; MOLINERO MU\u00d1OZ, M; SANCHEZ-OCA\u00d1A MARTIN, N; MARTINEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nMejorar la calidad asistencial a pacientes COVID-19 realizando una mejor trazabilidad de los tratamientos.\nMEJORAS ESPERADAS\nAsegurar que los pacientes tratados cumplen los criterios de priorizaci\u00f3n de los tratamientos y no presentan ninguna \ncontraindicaci\u00f3n\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nDebido a la continua actualizaci\u00f3n de indicaciones de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios y de \nla Comunidad de Madrid, se han realizado las siguientes acciones: actualizaci\u00f3n de protocolos, informaci\u00f3n a los m\u00e9dicos \nde las modificaciones continuas en las condiciones de uso, generaci\u00f3n y actualizaci\u00f3n de protocolos en el programa de \nprescripci\u00f3n electr\u00f3nica asistida (PEA), validaci\u00f3n de tratamientos, registro de dispensaci\u00f3n y recepci\u00f3n de medicamentos \ny generaci\u00f3n de bases de datos de seguimiento con registro de duraci\u00f3n de tratamiento, reacciones adversas, motivos de \nsuspensi\u00f3n y evoluci\u00f3n de los casos\ufffd  \nEl circuito se inici\u00f3 en marzo-2020 con el inicio de la pandemia y se ha ido modificando seg\u00fan disponibilidad de los \nf\u00e1rmacos: \n1. Circuito remdesivir: reuniones con los m\u00e9dicos para la creaci\u00f3n y actualizaci\u00f3n de los protocolos de uso en el \nhospital, generaci\u00f3n de protocolo en el programa de PEA, seguimiento de dispensaci\u00f3n y creaci\u00f3n de base de datos de \nseguimiento\ufffd  \n2. Circuito tocilizumab: reuniones con los m\u00e9dicos para la creaci\u00f3n y actualizaci\u00f3n de los protocolos de uso en el hospital, \ngeneraci\u00f3n de protocolo en el programa de PEA, seguimiento de dispensaci\u00f3n\ufffd  \n3. Circuito sotrovimab en paciente ingresado: reuni\u00f3n con m\u00e9dicos responsables de estos pacientes para comunicarles las \nindicaciones de uso y establecimiento de circuito de comunicaci\u00f3n entre m\u00e9dicos solicitantes y farmacia, seguimiento de \ndispensaci\u00f3n y creaci\u00f3n de base de datos de seguimiento\ufffd\nIMPLANTACI\u00d3N\nLos circuitos se implantaron de manera \u00e1gil desde el momento en que estos f\u00e1rmacos estuvieron disponibles. Se crearon \nprotocolos para cada f\u00e1rmaco en el programa de prescripci\u00f3n electr\u00f3nica, con las dosis y duraci\u00f3n de los tratamientos. \nDe manera paralela el prescriptor comunicaba el caso al Servicio de Farmacia (SF) para realizar una evaluaci\u00f3n conjunta \nde la indicaci\u00f3n de uso y de posibles contraindicaciones. Si se cumpl\u00edan todos los criterios la medicaci\u00f3n era enviada \ny la enfermera comunicaba telef\u00f3nicamente al SF su recepci\u00f3n\ufffd Si durante el seguimiento del paciente desde el SF se \ndetectaba la suspensi\u00f3n del f\u00e1rmaco, se registraban las causas y se solicitaba a enfermer\u00eda la devoluci\u00f3n del tratamiento \nsobrante\ufffd\nRESULTADOS\nDesde el inicio de la pandemia y hasta el 26/04/22 se han tratado en el hospital un total de 636 pacientes con remdesivir, \n300 con tocilizumab y 14 con sotrovimab. Consiguiendo generar un circuito \u00e1gil que ha permitido que los pacientes que \ncumpl\u00edan criterios de acceso a estos f\u00e1rmacos los hayan podido recibir en el menor tiempo posible, realizando adem\u00e1s \nuna estrecha monitorizaci\u00f3n de posibles efectos adversos.\nLIMITACIONES\nLa elevada rotaci\u00f3n del personal sobre todo en el \u00e1rea de urgencias, la falta de integraci\u00f3n entre los distintos programas \nde prescripci\u00f3n disponibles en el hospital, as\u00ed como la sobrecarga de trabajo de los profesionales han hecho necesaria la \nadaptaci\u00f3n continua del circuito para su mejor funcionamiento.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl programa es aplicable a todos los hospitales que atiendan pacientes con infecci\u00f3n por SARS-CoV-2.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n808. OPTIMIZACI\u00d3N DEL CIRCUITO DE ELABORACI\u00d3N Y SEGUIMIENTO DE SELLADOS CON ANTIBI\u00d3TICOS \nPARA LAS INFECCIONES DE CAT\u00c9TER VENOSO CENTRAL \nAUTORES\nORTONOBES ROIG, S; DE CASTRO JULVE, M; GASCH BLASI, O; BADIA-CEBADA , L; ALGUACIL GUILL\u00c9N, M; GOMILA \nGRANGE, A; MARR\u00d3N PUIGDUETA, A; G\u00d3MEZ-VALENT , M\nHOSPITAL DE SABADELL \ufffd PARC TAUL\u00cd, S/N SABADELL \ufffd BARCELONA539OBJETIVOS\nOptimizar y homogeneizar el tratamiento conservador de infecciones de cat\u00e9ter venoso central (ICVC) mediante la \npreparaci\u00f3n centralizada de los sellados de antibi\u00f3ticos en el Servicio de Farmacia (SF).\nMEJORAS ESPERADAS\n- Garantizar la estabilidad fisicoqu\u00edmica e incrementar la estabilidad microbiol\u00f3gica de los sellados de antibi\u00f3ticos.  \n- Instaurar un seguimiento de los pacientes con sellado para ICVC.\nDISE\u00d1O CIRCUITO Y ETAPAS\nProtocolizaci\u00f3n e implementaci\u00f3n de la elaboraci\u00f3n de sellados de antibi\u00f3ticos por ICVC en las cabinas de flujo laminar \ndel SF \ufffd  \n \n1\u00ba Actualizaci\u00f3n de la gu\u00eda institucional sobre manejo de pacientes con ICVC, incluyendo los sellados de antibi\u00f3tico m\u00e1s \nfrecuentes a utilizar en funci\u00f3n del microorganismo. Se consensu\u00f3 que la elaboraci\u00f3n de todos los sellados se realizar\u00eda \nen el SF \ufffd  \n2\u00ba Revisi\u00f3n bibliogr\u00e1fica sobre estabilidad, compatibilidad y concentraci\u00f3n m\u00e1s apropiada de los diferentes antibi\u00f3ticos \ncon heparina. Creaci\u00f3n y/o actualizaci\u00f3n de los protocolos de elaboraci\u00f3n.  \n3\u00ba Identificaci\u00f3n de los pacientes con ICVC durante las reuniones diarias entre Servicios de Microbiolog\u00eda/Infecciosas/\nFarmacia donde se reportan hemocultivos positivos (perif\u00e9ricos y/o cat\u00e9ter) y tiempo diferencial de positividad. \nPrescripci\u00f3n y validaci\u00f3n del sellado de antibi\u00f3tico m\u00e1s adecuado.  \n4\u00ba Elaboraci\u00f3n del sellado en el SF, adecuando volumen final y concentraci\u00f3n de heparina seg\u00fan el tipo de cat\u00e9ter venoso \ncentral (CVC).  \n5\u00ba Seguimiento cl\u00ednico de la evoluci\u00f3n de la ICVC.\nIMPLANTACI\u00d3N\nA partir de la actualizaci\u00f3n de la gu\u00eda institucional en 2019, todos los sellados prescritos para el manejo de ICVC se han \nelaborado en el SF \ufffd\nRESULTADOS\nSe realizaron 33 sellados de CVC en 25 pacientes (cinco pacientes tuvieron 2 episodios de ICVC y un paciente, 4). Mediana \nde edad 60,9 (RIQ 47,2-71,3) a\u00f1os; 66,7% mujeres. En 18 episodios, el CVC afectado fue un Port-a-Cath\u00ae, 16 de ellos para \nadministraci\u00f3n de quimioterapia. En 9 episodios, los CVC sellados fueron cat\u00e9teres tunelizados para hemodi\u00e1lisis cr\u00f3nica \n(8 yugulares, 1 femoral). Los 6 restantes fueron tipo Hickman\u00ae, para administrar nutrici\u00f3n parenteral domiciliaria. Se \npudo identificar el microorganismo causante en 29 episodios, siendo aislados en hemocultivo en 28, mientras que en 1 \nepisodio la muestra microbiol\u00f3gica positiva fue un exsudado. En 27 episodios se aisl\u00f3 un \u00fanico microorganismo, y hubo \n2 ICVC polimicrobianas. Se aislaron 13 (40,6%) estafilococos coagulasa-negativa y 12 (37,5%) bacilos Gram-negativo, de \nlos cuales 6 (54,5%) fueron enterobacterias. Se aislaron 4 (12,5%) bacilos Gram-positivo, 2 (6,3%) Enterococcus faecium y \n1 (3,1%) Staphylococcus aureus cloxacilina-S. Los antibi\u00f3ticos de sellado fueron: vancomicina 5mg/mL 66,7%; amikacina \n2mg/mL 12,1%; ceftazidima 5mg/mL 9,1%; ciprofoxacino 200mcg/mL 9,1% y cefazolina 5mg/mL 3,0%; formulados \ncon heparina s\u00f3dica. La duraci\u00f3n media fue de 13,2 (DS\u00b14,9) d\u00edas; el 72,7% de ellos renovados diariamente y el 63,6% \nadministrados ambulatoriamente. Todas las ICVC recibieron tambi\u00e9n antibi\u00f3tico sist\u00e9mico con una duraci\u00f3n de 13,7 \n(DS\u00b15,3) d\u00edas: 30,3% con vancomicina/teicoplanina; 27,3% cefalosporinas; 12,1% penicilinas; 12,1% daptomicina; 9,1% \nertapenem; 6,1% dalbavancina y 3,0% levofloxacino. Se consigui\u00f3 conservar el CVC en 26 (78,9%) episodios, siendo \nnecesaria su retirada en 7 (21,2%). Ning\u00fan paciente falleci\u00f3 30 d\u00edas despu\u00e9s del sellado.\nLIMITACIONES\nDisponibilidad de escasos datos de estabilidad de sellados de algunos antibi\u00f3ticos con heparina.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste circuito se puede aplicar en cualquier SF con pacientes con ICVC.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n845. IMPLANTACI\u00d3N DE LA PRESCRIPCI\u00d3N ELECTR\u00d3NICA ASISTIDA CON ALGORITMOS DE DECISI\u00d3N \nPARA LOS PROTOCOLOS DE PROFILAXIS ANTIBI\u00d3TICA EN CIRUG\u00cdA \nAUTORES\nSALA VILAJOSANA, N; BALET DUAT , MA; CERVERA MUDARRA, S; MARZA L\u00cdDIA, M; SEGARRA PERRAMON, T; P\u00c9REZ \nVIDAL, R\nHOSPITAL DE SANT JOAN DE D\u00c9U. DR. JOAN SOLER, 1-3 MANRESA. BARCELONA\nOBJETIVOS\nImplantar la prescripci\u00f3n electr\u00f3nica asistida con algoritmos de decisi\u00f3n para los protocolos de profilaxis antibi\u00f3tica en \ncirug\u00eda con integraci\u00f3n electr\u00f3nica de la dispensaci\u00f3n y su administraci\u00f3n.\nMEJORAS ESPERADAS\nLa profilaxis antibi\u00f3tica en cirug\u00eda es una de las principales medidas para prevenir la infecci\u00f3n de localizaci\u00f3n quir\u00fargica.  \nCon este proyecto se espera mejorar el cumplimiento de los protocolos tanto por lo que refiere al antibi\u00f3tico indicado, \ndosis, horario y tiempo de administraci\u00f3n como a su registro en la historia cl\u00ednica.540DISE\u00d1O CIRCUITO Y ETAPAS\nA partir de la disponibilidad de:  \na) Protocolo de profilaxis antibi\u00f3tica en cirug\u00eda en permanente actualizaci\u00f3n por la Comisi\u00f3n de Infecciones.  \nb) Aplicativo dentro del programa de gesti\u00f3n integrada de medicamentos para poder configurar protocolos con \nalgoritmos de decisi\u00f3n de f\u00e1cil visualizaci\u00f3n. Este aplicativo permite automatizar la prescripci\u00f3n del tratamiento despu\u00e9s \nde responder a las sucesivas preguntas que se van formulando.  \nSe cre\u00f3 un grupo de trabajo multidisciplinar para integrar el Protocolo de profilaxis antibi\u00f3tica perioperatoria vigente en \nel hospital dentro del programa de gesti\u00f3n integrada del medicamento.  \nEl grupo multidisciplinar dise\u00f1\u00f3 los algoritmos de decisi\u00f3n para cada uno de los procedimientos de cirug\u00eda candidatos a \nprofilaxis antibi\u00f3tica. \nEstos algoritmos contemplan: edad del paciente, presencia o no de insuficiencia renal, alergia a familias de antibi\u00f3ticos, \nfactores de riesgo de endocarditis y otras caracter\u00edsticas espec\u00edficas para cada situaci\u00f3n detalladas todas ellas en el \nprotocolo vigente en el hospital. Al prescribir el protocolo de la cirug\u00eda/procedimiento correspondiente se formula una \npregunta con las respuestas posibles a seleccionar, ante cada respuesta se formulan nuevas preguntas hasta llegar al \ntratamiento que le corresponde. Permite retroceder en cada paso y visualizar el tratamiento resultante. \nLas etapas fueron: \nElaboraci\u00f3n de los algoritmos e introducci\u00f3n en el aplicativo \nPrueba piloto en preproducci\u00f3n  \nImplantaci\u00f3n parcial en un tipo de intervenci\u00f3n quir\u00fargica \nExtensi\u00f3n progresiva a todas las intervenciones/procedimientos quir\u00fargicos con indicaci\u00f3n de profilaxis antibi\u00f3tica \nSucesivas actualizaciones y desarrollos\nIMPLANTACI\u00d3N\nSe inici\u00f3 en enero 2017 y se implant\u00f3 progresivamente durante el mismo a\u00f1o\ufffd\nRESULTADOS\nLa totalidad de los protocolos que figuran en la Gu\u00eda del hospital (25) disponen de prescripci\u00f3n electr\u00f3nica asistida con \nalgoritmos de decisi\u00f3n y desde 2017 hasta la actualidad se ha prescrito en 20.288 pacientes. \nLa valoraci\u00f3n ha sido muy positiva por todos los profesionales y ha incrementado substancialmente la adherencia al \nprotocolo vigente de profilaxis antibi\u00f3tica, aportando a la vez una gran mejora del registro de la profilaxis antibi\u00f3tica en la \nhistoria cl\u00ednica del paciente.\nLIMITACIONES\nSolamente puede aplicarse en paciente ingresado\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa prescripci\u00f3n asistida con algoritmos de decisi\u00f3n es aplicable en Servicios de Farmacia que dispongan de programas de \nprescripci\u00f3n que permitan un desarrollo similar.\nCLASIFICACI\u00d3N: PATOLOG\u00cdA INFECCIOSA (ANTIBIOTICOTERAPIA, HEPATOPAT\u00cdAS V\u00cdRICAS Y VIH)\n846. DISE\u00d1O E IMPLANTACI\u00d3N DE PRESCRIPCI\u00d3N ELECTR\u00d3NICA ASISTIDA CON ALGORITMOS DE \nDECISI\u00d3N PARA DESESCALADA SEG\u00daN MALDI-TOF EN EL TRATAMIENTO DE BACTERIEMAS. \nAUTORES\nBALET DUAT , MA; ISERN GL\u00d2RIA, T; FLOR P\u00c9REZ, A; CATALAN G\u00d3MEZ, I; GARC\u00cdA P\u00c9REZ, D; CERVERA MUDARRA, S; \nSALA VILAJOSANA, N; P\u00c9REZ VIDAL, R\nHOSPITAL DE SANT JOAN DE D\u00c9U. DR. JOAN SOLER, 1-3 MANRESA. BARCELONA\nOBJETIVOS\nImplantar la prescripci\u00f3n electr\u00f3nica asistida con algoritmos de decisi\u00f3n para desescalada r\u00e1pida del tratamiento \nantibi\u00f3tico emp\u00edrico en las bacteriemias seg\u00fan el resultado de MALDI-TOF.\nMEJORAS ESPERADAS\nLa espectrometr\u00eda de masas MALDI-TOF, junto con t\u00e9cnicas de determinaci\u00f3n r\u00e1pida de resistencias proporcionan un gran \navance para la identificaci\u00f3n precoz del microorganismo y la optimizaci\u00f3n temprana del tratamiento antibi\u00f3tico, con gran \nimpacto sobre la morbimortalidad\ufffd  \nCon este proyecto se espera facilitar la rapidez en el tratamiento dirigido de las bacteriemias tras el resultado MALDI-TOF \ny la adherencia a la gu\u00eda antibioticoterapia dirigida de bacteriemias del hospital.\nDISE\u00d1O CIRCUITO Y ETAPAS\nEl grupo de trabajo multidisciplinar PROA del hospital elabor\u00f3 la Gu\u00eda de tratamiento antibi\u00f3tico dirigido de la \nbacteriemia. A continuaci\u00f3n, se propuso la elaboraci\u00f3n de algoritmos de decisi\u00f3n para ayuda en la prescripci\u00f3n \nelectr\u00f3nica\ufffd \nSe dispon\u00eda de un programa de gesti\u00f3n integrada de medicamentos con un aplicativo para poder configurar protocolos \ncon algoritmos de decisi\u00f3n de f\u00e1cil visualizaci\u00f3n. Este aplicativo permite automatizar la prescripci\u00f3n del tratamiento \ndespu\u00e9s de responder a las sucesivas preguntas que se van formulando.  \nSe dise\u00f1aron los algoritmos de decisi\u00f3n para cada uno de los microorganismos que contemplan: alergias, gravedad de \nla infecci\u00f3n, sospecha de endocarditis, presencia de inmunodepresi\u00f3n, riesgo de infecci\u00f3n polimicrobiana, resistencias \ny otras caracter\u00edsticas espec\u00edficas para cada situaci\u00f3n siguiendo la Gu\u00eda del hospital de antibioticoterapia dirigida de la \nbacteriemia\ufffd 541Al prescribir el protocolo del microorganismo correspondiente se formula una pregunta con las respuestas posibles a \nseleccionar, ante cada respuesta se formulan nuevas preguntas hasta llegar al tratamiento adecuado. Permite retroceder \nen cada paso y visualizar el tratamiento resultante. Por defecto se automatiza primera dosis inmediata, que puede ser \nmodificada si se considera oportuno. As\u00ed mismo, la prescripci\u00f3n est\u00e1 integrada con la dispensaci\u00f3n por unidosis o por \nsistemas de dispensaci\u00f3n automatizada y con el registro de administraci\u00f3n por enfermer\u00eda.  \n \nLas etapas fueron: \nElaboraci\u00f3n e introducci\u00f3n en el aplicativo de los algoritmos y de los tratamientos.  \nPrueba piloto en preproducci\u00f3n\ufffd  \nActivaci\u00f3n del aplicativo para todos los facultativos.\nIMPLANTACI\u00d3N\nSe inici\u00f3 e implant\u00f3 en diciembre 2021\nRESULTADOS\nSe han creado 15 protocolos para los diferentes microorganismos siguiendo la Gu\u00eda de tratamiento dirigido de la \nbacteriemia: Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus anginosus, \notros estreptococcus, Staphylococcus aureus, Satphlococcus coagulasa negativos, Enterococcus faeclis, Enterococcus \nfaecium, cocos Gram positivos anaerobios, Neisseria meningitidis, Listeria, Clostridium, Haemophilus, Salmonella, \nEscherichia coli, Klebsiella, Proteus mirabilis, otros Preteus, Enterobacter o Citrobacter, Serratia, Enterobacterias \nproductoras de carbapenemasa, Pseudomonas aeruginosa, bacilos Gram negativos.  \nDesde su implantaci\u00f3n hasta la actualidad se ha activado en 23 pacientes. \nLa valoraci\u00f3n ha sido muy positiva por todos los profesionales.\nLIMITACIONES\nSolamente puede aplicarse cuando el paciente ya ha ingresado.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa prescripci\u00f3n asistida con algoritmos de decisi\u00f3n es aplicable en Servicios de Farmacia que dispongan de programas de \nprescripci\u00f3n que permitan un desarrollo similar.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n852. INMUNOGLOBULINAS HUMANAS: ESTRATEGIA PARA FOMENTAR EL USO EFICIENTE DE LOS \nRECURSOS. \nAUTORES\nGARC\u00cdA CEREZUELA, MD; ALONSO CASTRO, V; L\u00d3PEZ CENTENO, B; MAROTO GARC\u00cdA, E; ALIOTO , D; ROSAS ESPINOZA, \nC; ARANGUREN OYARZ\u00c1BAL, A; CALVO ALC\u00c1NTARA, MJ\nSERVICIO MADRILE\u00d1O DE SALUD \ufffd AVENIDA DE MANUEL FRAGA IRIBARNE 2 MADRID \ufffd MADRID\nOBJETIVOS\nEl uso de inmunoglobulinas (Igs) se ha convertido en una opci\u00f3n terap\u00e9utica en diversas indicaciones cl\u00ednicas, como \nprocesos autoinmunes e inflamatorios agudos, y tanto en indicaciones autorizadas como no autorizadas. Esto ha \nsupuesto un aumento progresivo de su utilizaci\u00f3n en los \u00faltimos a\u00f1os.  \nEl Servicio de Salud (SS) suministra a los hospitales de forma centralizada productos hemoderivados (entre ellos, \nIgs) obtenidos del fraccionamiento industrial del plasma procedente de donaciones altruistas de ciudadanos de la \nComunidad, mediante la tramitaci\u00f3n de contratos de suministro con la empresa fraccionadora\ufffd  \nEl aumento de la demanda de Igs, sumado a un suministro limitado, que se ha visto mermado en los \u00faltimos a\u00f1os, ha \nprovocado problemas de suministro\ufffd  \nLos objetivos de la estrategia fueron: elaborar un documento de criterios de utilizaci\u00f3n de Igs, estimar las necesidades de \nIgs del SS para garantizar el tratamiento de los pacientes prioritarios ante situaciones de problemas de desabastecimiento \ny conocer el grado de autosuficiencia a trav\u00e9s del proceso de fraccionamiento.\nMEJORAS ESPERADAS\nMejorar la eficiencia en la utilizaci\u00f3n de Igs en un SS y garantizar el acceso a los pacientes prioritarios ante problemas de \nabastecimiento\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nCreaci\u00f3n de un grupo de trabajo multidisciplinar para definir las l\u00edneas estrat\u00e9gicas.  \nLa estrategia se dividi\u00f3 en dos fases:  \nEn la primera fase, el grupo de trabajo elabor\u00f3 un documento de criterios de utilizaci\u00f3n de Igs, en que se priorizaron 42 \nindicaciones terap\u00e9uticas indic\u00e1ndose, en base a la evidencia disponible: criterios de selecci\u00f3n, evaluaci\u00f3n, seguimiento, \nposolog\u00eda y grado de evidencia. El objetivo era seleccionar las indicaciones y situaciones cl\u00ednicas para las que, la utilizaci\u00f3n \nde Igs era de urgencia vital, con el objetivo de poder garantizar tratamiento a estos pacientes.  \nEn la segunda fase, se realiz\u00f3 un estudio descriptivo del uso real de Igs en los hospitales mediante un formulario remitido \na los Servicios de Farmacia Hospitalaria\ufffd  542Las variables solicitadas fueron: n\u00famero de pacientes tratados en las indicaciones especificadas, consumo (gramos (g)/\na\u00f1o) y presentaci\u00f3n comercial utilizada para cada indicaci\u00f3n.\nIMPLANTACI\u00d3N\nEn octubre de 2021 se public\u00f3 el documento. En noviembre se remiti\u00f3 el formulario a los SFH. En diciembre se desarroll\u00f3 \nuna jornada multidisciplinar para la difusi\u00f3n a los profesionales del trabajo realizado.\nRESULTADOS\nEl n\u00famero de pacientes en tratamiento con Igs fueron 1.931, con 756.662 g/a\u00f1o. El 93% de estos g corresponden a \nindicaciones priorizadas en el documento.  \nDado que la demanda supera el abastecimiento, es necesario establecer una estrategia para fomentar el uso racional Igs \nen los hospitales y potenciar la obtenci\u00f3n de plasma de donaciones para incrementar su producci\u00f3n y la autosuficiencia \nen la Comunidad\ufffd\nLIMITACIONES\nEl fraccionamiento de plasma cubre el 38,7% de las necesidades estimadas por los SFH, teniendo que cubrir el resto \nde la necesidad mediante la adquisici\u00f3n directa. Las necesidades de Igs del SS son 61,3% superiores a la capacidad de \nsuministro por el procedimiento de fraccionamiento del plasma\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl documento publicado es de aplicaci\u00f3n en todos los hospitales del SS para garantizar una equidad en el acceso al \ntratamiento a los pacientes prioritarios\ufffd\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n920. IMPLANTACI\u00d3N DE PR\u00c1CTICAS SEGURAS DE UTILIZACI\u00d3N DE MEDICAMENTOS EN LA URGENCIA \nPEDI\u00c1TRICA. \nAUTORES\nSOLLANO SANCHO, I; GARRIDO PE\u00d1O, N; CHINCHILLA LANGEBER, S; MORONA MINGUEZ, I; SOTO BASELGA, I; \nGONZ\u00c1LEZ GARC\u00cdA, I; VILLARES , M; MORIEL S\u00c1NCHEZ, C\nHOSPITAL UNIVERSITARIO DE M\u00d3STOLES. R\u00cdO J\u00daCAR, S/N M\u00d3STOLES. MADRID\nOBJETIVOS\nImplantar medidas para la correcta identificaci\u00f3n, almacenamiento, dispensaci\u00f3n, prescripci\u00f3n, preparaci\u00f3n y \nadministraci\u00f3n de medicamentos en el box vital de urgencias pedi\u00e1tricas (BVUP).\nMEJORAS ESPERADAS\nDisminuir los posibles errores potencialmente graves asociados a la utilizaci\u00f3n de f\u00e1rmacos en la poblaci\u00f3n pedi\u00e1trica.\nDISE\u00d1O CIRCUITO Y ETAPAS\nCon la aparici\u00f3n de los cuadros de S\u00edndrome Inflamatorio Multisist\u00e9mico en ni\u00f1os en marzo-abril de 2020, el Servicio \nde Pediatr\u00eda contact\u00f3 con el Servicio de Farmacia por la necesidad de revisar los f\u00e1rmacos disponibles en el BVUP . \nDebido a la vulnerabilidad de la poblaci\u00f3n pedi\u00e1trica, las posibles consecuencias de una incorrecta manipulaci\u00f3n de \nmedicamentos, la presencia de Medicamentos de Alto Riesgo (MAR) y las situaciones cr\u00edticas de estr\u00e9s que predisponen a \nerrores, se identific\u00f3 la necesidad de implantar medidas de seguridad en el uso de medicamentos en el BVUP . \n1. Creaci\u00f3n de un equipo multidisciplinar (pediatr\u00eda, farmacia y enfermer\u00eda).  \n2. Revisi\u00f3n bibliogr \u00e1fica (bases de datos, fichas t \u00e9cnicas, gu\u00edas farmacoterap\u00e9uticas y protocolos) de los medicamentos \nm\u00e1s frecuentemente utilizados en el BVUP .  \n3. Elaboraci\u00f3n de la lista de f\u00e1rmacos necesarios en el BVUP . \n4. Selecci\u00f3n de las presentaciones (las de menor concentraci\u00f3n).  \n5. Reubicaci\u00f3n de medicamentos que no se emplean en situaciones de urgencia fuera del BVUP . \n6. Identificaci\u00f3n (etiquetado amarillo y combinaci\u00f3n de may\u00fasculas y min\u00fasculas de los MAR) y almacenamiento correcto \n(con fotoprotecci\u00f3n y en nevera) de los medicamentos.  \n7. Creaci\u00f3n de carteles informativos sobre la importancia de la correcta manipulaci\u00f3n de los medicamentos.  \n8. Elaboraci\u00f3n de una calculadora pedi\u00e1 trica: Excel de perfusiones intravenosas estandarizadas y medicaci\u00f3n urgente \n(parada cardiorrespiratoria, intubaci\u00f3n, sedoanalgesia, cardioversi\u00f3n) que, al introducir el peso del paciente, calcula las \ndosis y velocidad de administraci\u00f3n\ufffd  \n9. Elaboraci\u00f3n de una tabla de f \u00e1rmacos con la informaci\u00f3n: presentaci\u00f3n (mg/forma farmac\u00e9utica), dosis/cc, dosis/kg, \ndiluci\u00f3n, comentarios, v\u00eda perif\u00e9rica/central. Se identificaron los MAR, incompatibilidades, fotosensibilidad, refrigeraci\u00f3n \ny tiempo de administraci\u00f3n.\nIMPLANTACI\u00d3N\nEn mayo de 2020 se cre\u00f3 el grupo multidisciplinar, en septiembre de 2020 se elabor\u00f3 la lista de f\u00e1rmacos y en diciembre \nde 2020 se distribuyeron, organizaron y etiquetaron los medicamentos. En abril de 2021 se valid\u00f3 el Excel de perfusiones. \nEn febrero de 2022 se valid\u00f3 y public\u00f3 la tabla de medicaci\u00f3n\ufffd\nRESULTADOS\nSe a\u00f1adieron a la tabla 31 principios activos, un 18 (58%) eran MAR, 12 (38,7%) deb\u00edan administrarse lentamente, 10 \n(32,3%) fotosensibles y 4 (12,9%) termol\u00e1biles. Todos se pod\u00edan administrar por v\u00eda perif\u00e9rica, excepto el salbutamol que \nera el \u00fanico de administraci\u00f3n inhalada, pero en 14 (45,2%) de ellos se incluyeron especificaciones para su administraci\u00f3n 543por dicha v\u00eda. Seg\u00fan la clasificaci\u00f3n ATC, los f\u00e1rmacos pertenec\u00edan a los siguientes grupos: 2 (6,5%) al A, 4 (12,9%) al B, 5 \n(16,1%) al C, 2 (6,5%) al H, 3 (9,7%) al M, 11 (35,5%) al N, 2 (6,5%) al R, 2 (6,5%) al V.\nLIMITACIONES\nNo se pudieron realizar cambios visibles y viables hasta finalizar la pandemia por SARS-CoV-2.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEstas pr\u00e1cticas son aplicables a otros Servicios de Farmacia y Pediatr\u00eda para mejorar la seguridad del paciente pedi\u00e1 trico.\nCLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n995. ESTRATEGIA PARA LA OPTIMIZACI\u00d3N DEL USO DE INMUNOGLOBULINA IV \nAUTORES\nTIRAPU NICOL\u00c1S, B; MART\u00cdNEZ ITURRIAGA, S; JARNE BETR\u00c1N, V; ARTEAGA MAZUELAS, M; ASTIZ LIZARRAGA, R; \nSAROBE CARRICAS, M; AB\u00cdNZANO GUILL\u00c9N, M; DE LA RIVA BOHIGAS, R\nHOSPITAL GARC\u00cdA ORCOYEN \ufffd SANTA SORIA, 22 ESTELLA/LIZARRA \ufffd NAVARRA\nOBJETIVOS\nRacionalizar el consumo de Inmunoglobulina IV (IgIV) en un hospital comarcal, debido a su limitada disponibilidad actual \ny elevado coste\ufffd\nMEJORAS ESPERADAS\nDisminuir el consumo de IgIV, optimizando las dosis y priorizando su utilizaci\u00f3n en aquellas patolog\u00edas con mayor grado \nde evidencia\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe trabaj\u00f3 conjuntamente entre el Servicio de Medicina Interna, de Hematolog\u00eda y Farmacia Hospitalaria como \nprincipales profesionales sanitarios implicados en los tratamientos con IgIV, para actuar a varios niveles dentro del \nhospital: Revisi\u00f3n de los tratamientos y sus indicaciones, optimizaci\u00f3n de la dosis de los tratamientos y actividades de \nformaci\u00f3n y divulgaci\u00f3n a nivel del centro hospitalario.  \n1\ufffd Se revisaron los tratamientos actuales en base a un documento de consenso de indicaciones de uso de IgIV, elaborado \npor el hospital de referencia de la misma Comunidad Aut\u00f3noma, que contiene las patolog\u00edas en las que estar\u00eda indicado \nel tratamiento con IgIV con su grado de evidencia y los casos en que se priorizar\u00eda la plasmaf\u00e9resis por ser m\u00e1s eficiente.  \n2. Se optimizaron las dosis e intervalo de dosificaci\u00f3n en los tratamientos de reposici\u00f3n de los s\u00edndromes de \ninmunodeficiencia primaria, de manera que se alcanzara el nivel de IgG preinfusi\u00f3n m\u00ednimo que permitiera el adecuado \ncontrol cl\u00ednico del paciente. Se valor\u00f3 tambi\u00e9n el uso de Inmunoglobulinas subcut\u00e1neas (IgSC) de forma individualizada \nen casos de intolerancia a IgIV o por motivos de conveniencia.  \n3. Se distribuy\u00f3 el documento de consenso de indicaciones de uso de IgIV a los Servicios m\u00e9dicos prescriptores y se llev\u00f3 \na cabo una sesi\u00f3n de formaci\u00f3n para todo el personal sanitario del centro\ufffd  \n4. Se analizaron los datos de consumo de los \u00faltimos 5 a\u00f1os.\nIMPLANTACI\u00d3N\nPrimer trimestre de 2021\nRESULTADOS\nConsumos:  \n2021 es el a\u00f1o de menor consumo de los \u00faltimos 5. El consumo se redujo un 20% respecto al a\u00f1o anterior a pesar de \ntratar un paciente m\u00e1s.  \n2017: 3930 g (3790 g de IgIV en 9 pacientes y 140 g de Ig sc en 1 paciente) \n2018: 4290 g (3650 g de IgIV en 9 pacientes y 640 g de Ig sc en 1 paciente) \n2019: 4705 g (4005 g de IgIV en 10 pacientes y 700 g de Ig sc en 1 paciente) \n2020: 4005 g (2965 g de IgIV en 7 pacientes y 1040 g de Ig sc en 2 pacientes) \n2021: 3210 g (2200 g de IgIV en 8 pacientes y 1010 g de Ig sc en 2 pacientes) \n \nIndicaciones:  \nDurante el a\u00f1o 2021 se trataron 10 pacientes, todos ellos en indicaciones donde las IgIV son la primera opci\u00f3n de \ntratamiento\ufffd  \nInmunodeficiencia com\u00fan variable primaria: 6 pacientes \nInmunodeficiencia secundaria a enfermedad hematol\u00f3gica: 2 pacientes \nNeuropat\u00eda motora multifocal: 1 paciente  \nP\u00farpura trombocitop\u00e9nica idiop\u00e1tica: 1 paciente\nLIMITACIONES\nRequiere colaboraci\u00f3n y disponibilidad de diferentes profesionales sanitarios que en ocasiones es dif\u00edcil de conseguir, \nsobre todo en centros peque\u00f1os con menor n\u00famero de facultativos.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEs aplicable a otros centros que se planteen analizar y reevaluar la utilizaci\u00f3n de IgIV para lograr un empleo \u00f3ptimo de las \nmismas\ufffd544CLASIFICACI\u00d3N: PEDIATR\u00cdA Y HEMODERIVADOS\n998. REVISI\u00d3N DE LA COMPATIBILIDAD DE F\u00c1RMACOS DE ADMINISTRACI\u00d3N INTRAVENOSA EN \nNEONATOLOG\u00cdA E INCORPORACI\u00d3N A LA PR\u00c1CTICA CL\u00cdNICA \nAUTORES\nCANALES SIGUERO, MD; MART\u00cdNEZ DE LA TORRE, F; GARC\u00cdA MU\u00d1OZ, C; OLMOS AMBEL, L; S M ALQDWAH , M; \nN\u00da\u00d1EZ L\u00d3PEZ, I; MAYO OLVEIRA, F; FERRARI PIQUERO, JM\nHOSPITAL UNIVERSITARIO 12 DE OCTUBRE \ufffd AV\ufffd DE C\u00d3RDOBA, S/N MADRID \ufffd MADRID\nOBJETIVOS\nDurante los primeros d\u00edas de vida, los neonatos prematuros reciben para su alimentaci\u00f3n nutrici\u00f3n parenteral total. \nAdem\u00e1s, puede ser necesaria la administraci\u00f3n de antibi\u00f3ticos, vasopresores y otros f\u00e1rmacos. Un problema importante \nen esta poblaci\u00f3n es la limitaci\u00f3n de los accesos venosos y el limitado calibre de los mismos, teniendo \u00fanicamente en \nmuchas ocasiones una v\u00eda en la vena umbilical para administrar toda la medicaci\u00f3n necesaria.  \nEl objetivo de este estudio es revisar la pr\u00e1ctica de administraci\u00f3n de medicamentos en los primeros d\u00edas de vida, \ncomprobando la compatibilidad para la administraci\u00f3n en \u201cY\u201d de todos los f\u00e1rmacos usados en la Unidad de Cuidados \nIntensivos Neonatales (UCIN) de nuestro hospital, as\u00ed como la compatibilidad con la nutrici\u00f3n parenteral, e incorporarlo \nen la pr\u00e1ctica cl\u00ednica con la finalidad de que la administraci\u00f3n sea lo m\u00e1s segura posible.\nMEJORAS ESPERADAS\nAumentar la seguridad en la administraci\u00f3n de medicamentos en Neonatolog\u00eda. Poner a disposici\u00f3n de enfermer\u00eda \ninformaci\u00f3n actualizada sobre administraci\u00f3n intravenosa de medicamentos en Neonatolog\u00eda y en el programa de \nprescripci\u00f3n electr\u00f3nica\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe seleccionaron todos los f\u00e1rmacos administrados por v\u00eda intravenosa en la UCIN en un Hospital de clase 5. Se realiz\u00f3 \nuna revisi\u00f3n bibliograf\u00eda en PubMed\u00ae con las palabras clave \u201cY compatibility\u201d \u201cnewborn\u201d y los nombres de los f\u00e1rmacos \ncorrespondientes. Se revisaron las fichas t\u00e9cnicas y se comprobaron todos los f\u00e1rmacos en su monograf\u00eda de la base de \ndatos Trissel\u00ae. Se clasificaron los f\u00e1rmacos en tres categor\u00edas: compatible, incompatible o compatibilidad variable en \nfunci\u00f3n del diluyente y la concentraci\u00f3n\ufffd  \nRevisi\u00f3n bibliogr\u00e1fica. Elaboraci\u00f3n de tabla resumen de forma gr\u00e1fica. Impresi\u00f3n y difusi\u00f3n en UCIN con educaci\u00f3n a \nenfermer\u00eda por parte del farmac\u00e9utico responsable de Neonatolog\u00eda. Introducci\u00f3n de la informaci\u00f3n en el programa de \nprescripci\u00f3n electr\u00f3nica de la UCIN y en los protocolos de la Unidad\ufffd\nIMPLANTACI\u00d3N\nSe distribuy\u00f3 la informaci\u00f3n a enfermer\u00eda mediante una sesi\u00f3n por parte del farmac\u00e9utico responsable de Neonatolog\u00eda, \nse introdujo la tabla de compatibilidades en los protocolos de administraci\u00f3n de la UCIN.\nRESULTADOS\nSe analizaron un total de 80 medicamentos que son administrados por v\u00eda intravenosa de forma habitual en la UCIN. \nRespecto a la compatibilidad con la nutrici\u00f3n parenteral, se encontr\u00f3 que 33 f\u00e1rmacos son compatibles con la misma, \n7 incompatibles (Aciclovir, albumina, amikacina, ceftriaxona, esomeprazol, fenobarbital, ganciclovir), 2 variable y en el \nresto, 38, no exist\u00edan de compatibilidad. Adem\u00e1s, se incluy\u00f3 esta informaci\u00f3n en la prescripci\u00f3n m\u00e9dica electr\u00f3nica de \nestos f\u00e1rmacos.  \nEn cuanto a la compatibilidad entre dos f\u00e1rmacos, se encontr\u00f3 que hab\u00eda 1094 compatibilidades, 276 incompatibilidades, \n206 mezclas con una compatibilidad variable y 1544 mezclas en las que no hab\u00eda informaci\u00f3n sobre la compatibilidad de \nla mezcla.\nLIMITACIONES\nEscasa informaci\u00f3n publicada. Se ha localizado aproximadamente informaci\u00f3n sobre la mitad de los f\u00e1rmacos estudiados. \nEs necesario realizar m\u00e1s estudios de compatibilidad de los f\u00e1rmacos habitualmente empleados en Neonatolog\u00eda para \ngarantizar la seguridad en la administraci\u00f3n intravenosa de medicamentos.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa tabla resumen de compatibilidad puede compartirse con otros servicios de Neonatolog\u00eda, as\u00ed como la base de datos \npara prescripci\u00f3n electr\u00f3nica en UCIN\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N \nASISTENCIAL\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n76. IMPLANTACI\u00d3N DE UN PROCEDIMIENTO PARA LA MANIPULACI\u00d3N SEGURA DE MEDICAMENTOS \nPELIGROSOS EN UN HOSPITAL PSIQUIATRICO \nAUTORES\nVELASCO COSTA, J; PE\u00d1ALVER GONZALEZ, JM; ROBLES BLAZQUEZ, EM; SANCHEZ MARTINEZ, R; MARTINEZ DE \nGUZMAN, M\nHOSPITAL PSIQUI\u00c1TRICO ROMAN ALBERCA. LORCA, 58 (EL PALMAR) MURCIA. MURCIA545OBJETIVOS\nMuchos estudios han confirmado que la mayor exposici\u00f3n a medicamentos peligrosos (MP) se produce durante su \npreparaci\u00f3n antes de la administraci\u00f3n, ya que para conseguir las dosis individualizadas por paciente se reconstituyen y/o \ndiluyen los f\u00e1rmacos concentrados o se manipulan los f\u00e1rmacos s\u00f3lidos fraccionables.  \n \nLos objetivos de este estudio son:  \n- Identificar los MP existentes en nuestro hospital psiqui\u00e1trico.  \n- Implantar un procedimiento de manejo de acuerdo a las recomendaciones y normativa vigente.\nMEJORAS ESPERADAS\n- Establecer pr\u00e1cticas seguras en la manipulaci\u00f3n de medicamentos peligrosos que eviten o minimicen la exposici\u00f3n de \nlos trabajadores del centro.\nDISE\u00d1O CIRCUITO Y ETAPAS\nEstudio observacional, descriptivo y longitudinal de implantaci\u00f3n en los 6 \u00faltimos meses de 2021.  \n \n1\ufffd Dise\u00f1o:  \n- Grupo de trabajo: 2 especialistas en Farmacia Hospitalaria, 1 t\u00e9cnico en Prevenci\u00f3n de Riesgos Laborales, 3 supervisores \nde enfermer\u00eda y Direcci\u00f3n m\u00e9dica. \n- Elaboraci\u00f3n cronograma trabajo.  \n \n2\ufffd Desarrollo y etapas: \n- Reuniones mensuales.  \n- B\u00fasqueda bibliogr\u00e1fica e identificaci\u00f3n de f\u00e1rmacos disponibles en sus distintas formas farmac\u00e9uticas para evitar su \nmanipulaci\u00f3n\ufffd  \n- Revisi\u00f3n de la manipulaci\u00f3n medicamentos en pacientes con dificultad o negativa para la degluci\u00f3n.  \n- Elaboraci\u00f3n del procedimiento.\nIMPLANTACI\u00d3N\n3\ufffd Implantaci\u00f3n:  \n- Plan de formaci\u00f3n dise\u00f1ado para todos los profesionales implicados en la manipulaci\u00f3n de medicamentos peligrosos.  \n- Difusi\u00f3n del protocolo a todo el personal implicado.  \nEl procedimiento queda completamente implantado y en funcionamiento garantizando la seguridad de trabajadores y \nusuarios al minimizar la exposici\u00f3n siguiendo pr\u00e1cticas seguras.\nRESULTADOS\nSe identificaron 11 MP en el hospital: 5 de ellos pertenecientes a la lista 1 (Carbamazepina, Espironolactona, \nOxcarbazepina, Fenito\u00edna y Medroxiprogesterona) y 6 del grupo 3 (Acenocumarol, Clonazepam, Paroxetina, Topiramato, \nValproico y Ziprasidona). Estos se identificaron adecuadamente en su acondicionamiento de reenvasado.  \nSe elabor\u00f3 una tabla con recomendaciones para sustituir un medicamento peligroso por otro comercializado ya en \ncaso de requerir manipulaci\u00f3n, y las recomendaciones de acondicionamiento en farmacia y de administraci\u00f3n de forma \nespec\u00edfica para cada uno.  \nPara los MP orales que precisaban manipulaci\u00f3n se implantaron diferentes estrategias consistentes en: adaptaci\u00f3n y \nadquisici\u00f3n de otras formas farmac\u00e9uticas en el centro (comprimidos dispersables, soluciones y suspensiones, f\u00f3rmulas \nmagistrales), t\u00e9cnica de dispersi\u00f3n de comprimidos en jeringa y adquisici\u00f3n de sistemas cerrados sencillos para la \nmanipulaci\u00f3n adem\u00e1s de los equipos de protecci\u00f3n individual (EPIs).  \nSe detall\u00f3 tambi\u00e9n el sistema de gesti\u00f3n de los residuos; as\u00ed, los residuos que contengan restos de MP de los grupos 2 y 3 \n(frascos, ampollas, viales, jeringas,...) se eliminar\u00e1n en el contenedor azul de residuos peligrosos. Y los EPIs utilizados para \nla administraci\u00f3n de MP se eliminar\u00e1n en el contenedor verde de residuos sanitarios no espec\u00edficos, salvo contaminaci\u00f3n \nevidente (salpicadura, derrame, etc.).\nLIMITACIONES\nComo principal limitaci\u00f3n, este procedimiento debe revisarse de forma continua y peri\u00f3dica, especialmente cuando \nse incluyan otros medicamentos peligrosos a la gu\u00eda del hospital que impliquen una reorganizaci\u00f3n tanto del stock en \nfarmacia como de las normas de protecci\u00f3n del personal\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a todos los Servicios de Farmacia en los que se utilicen medicamentos peligrosos.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n87. IMPLEMENTACI\u00d3N DE PROTOCOLOS DE PRESCRIPCI\u00d3N ELECTR\u00d3NICA EN EL PACIENTE \nTRASPLANTADO RENAL \nAUTORES\nCHINCHILLA ALARC\u00d3N, T; FERNANDEZ CUERVA, C; PARADAS PALOMO, JD; MU\u00d1OZ CASTILLO, I\nCOMPLEJO HOSPITALARIO REGIONAL CARLOS HAYA. AV . CARLOS HAYA, S/N M\u00c1LAGA. MALAGA\nOBJETIVOS\nElaboraci\u00f3n de protocolos de tratamiento de los pacientes con trasplante renal de cad\u00e1ver en el programa de \nprescripci\u00f3n electr\u00f3nica (PE).546MEJORAS ESPERADAS\n-Estandarizar el tratamiento para las distintas posibilidades cl\u00ednicas del paciente:  \n\u2022 Bajo riesgo inmunol\u00f3gico con funci\u00f3n renal inmediata \n\u2022 Bajo riesgo inmunol\u00f3gico que se prev\u00e9 funci\u00f3n renal inmediata pero que no lo es en las primeras 24 horas.  \n\u2022 Alto riesgo inmunol\u00f3gico \n\u2022 Funci\u00f3n retrasada del injerto (FRI)  \n-Aumentar la Seguridad del Paciente, actuando de forma menos variable ante las distintas opciones cl\u00ednicas del paciente \ntrasplantado\ufffd  \n-Fomentar un uso seguro y responsable del medicamento.  \n-Incorporar al itinerario formativo de los Farmac\u00e9uticos Internos Residentes (FIR) una rotaci\u00f3n en el Servicio de Nefrolog\u00eda \nen la unidad de trasplantes\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O  \nTras la implantaci\u00f3n de la PE y validaci\u00f3n farmac\u00e9utica en el Servicio de Nefrolog\u00eda, se detectaron errores y variabilidad \nen la prescripci\u00f3n de la inmunosupresi\u00f3n en pacientes trasplantados. Se form\u00f3 un equipo multidisciplinar (Farmacia-\nNefrolog\u00eda) para la revisi\u00f3n de protocolos de tratamiento para pacientes trasplantados y su creaci\u00f3n en el sistema de \nprescripci\u00f3n electr\u00f3nica\ufffd  \n \nCIRCUITO Y ETAPAS  \n1. Creaci\u00f3n de equipo multidisciplinar entre ambos servicios para establecer los f\u00e1rmacos inmunosupresores y las dosis \nm\u00e1s frecuentes empleados.  \n2. Revisi\u00f3n bibliogr\u00e1fica y creaci\u00f3n de los protocolos de tratamiento.  \n\u2022 Paciente con bajo riesgo inmunol\u00f3gico con funci\u00f3n renal inmediata. \n\u2022 Paciente con bajo riesgo inmunol\u00f3gico que se prev\u00e9 funci\u00f3n renal inmediata pero que no lo es en las primeras 24 horas \ntras la cirug\u00eda (ausencia diuresis inmediata o sospecha de una necrosis tubular aguda).  \n\u2022 Alto riesgo inmunol\u00f3gico definido como hiperinmunizados (Panel Reactive Antibody (PRA) mayor de 50 % en los \n6 \u00faltimos meses), retrasplante, p\u00e9rdida del injerto previo por causa inmunol\u00f3gica en los 6 primeros meses, pruebas \ncruzadas previas positivas (m\u00e1s de 2 en los \u00faltimos 12 meses), raza negra. \n\u2022 Paciente con alto riesgo inmunol\u00f3gico y FRI: Donantes con criterios expandidos, donante en asistolia, tiempo de \nisquemia fr\u00eda prolongado ( > 20 horas), donante con deterioro agudo de la funci\u00f3n renal, puntuaci\u00f3n histol\u00f3gica > 3. \n3. Validaci\u00f3n conjunta de los protocolos creados.  \n4\ufffd Creaci\u00f3n por de los protocolos en la PE por el Servicio de Farmacia\ufffd \n5. Presentaci\u00f3n al Servicio de Nefrolog\u00eda de los diferentes protocolos establecidos en la PE.  \n6. Puesta en marcha del uso de la prescripci\u00f3n estandarizada.\nIMPLANTACI\u00d3N\nEn enero de 2022 se ha iniciado la colaboraci\u00f3n entre los dos servicios, presentando los protocolos de PE en abril 2022.\nRESULTADOS\n- Dise\u00f1o de cuatro protocolos de tratamiento.  \n- Revisi\u00f3n de las fichas t\u00e9cnicas de los principales f\u00e1rmacos intravenosos usados en trasplante renal para estandarizar la \ndiluci\u00f3n y velocidad de infusi\u00f3n\ufffd  \n- Revisi\u00f3n de las fichas t\u00e9cnicas de los principales f\u00e1rmacos orales para estandarizar las horas de administraci\u00f3n y \nconcomitancia o no con otros f\u00e1rmacos y/o alimentos.  \n- Incorporaci\u00f3n de los principales f\u00e1rmacos para la profilaxis de los pacientes reci\u00e9n trasplantados.  \n- Se prev\u00e9 protocolizar todos los trasplantes de donante vivo.\nLIMITACIONES\nSe trata de un circuito din\u00e1mico en fase de desarrollo y mejora continuos.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste modelo es aplicable en todos los hospitales con Servicio de Nefrolog\u00eda.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n192. ELABORACION DE UNA GUIA PARA LA ADMINISTRACION DE MEDICAMENTOS POR V\u00cdA SUBCUTANEA \nAUTORES\nDE LA RIVA BOHIGAS, R; ALDAVE COBOS, P; FERNANDEZ GONZALEZ, J; EGU\u00c9S LUGEA, A; DE MIGUEL GAZTELU, M; \nPRECIADO GOLDARACENA, J; RODRIGUEZ ESQUIROZ, A; SAROBE CARRICAS, M\nCOMPLEJO HOSPITALARIO DE NAVARRA. CALLE IRUNLARREA 3 - PAMPLONA/IRU\u00d1A. NAVARRA\nOBJETIVOS\nDisponer de una herramienta de consulta para la administraci\u00f3n de f\u00e1rmacos por v\u00eda subcut\u00e1nea ya que resulta una \nalternativa muy utilizada a la v\u00eda oral, intramuscular y/o endovenosa cuando estas no se consideran adecuadas para el \npaciente. La v\u00eda subcut\u00e1nea es ampliamente utilizada en cuidados paliativos para la administraci\u00f3n de medicamentos, \nbien en forma de bolo, perfusi\u00f3n intermitente o infusi\u00f3n continua.547MEJORAS ESPERADAS\nDisponer de una herramienta de ayuda para la administraci\u00f3n de f\u00e1rmacos por v\u00eda subcut\u00e1nea de forma eficaz y segura. \nReducir las complicaciones de la administraci\u00f3n de medicamentos por v\u00eda subcut\u00e1nea. \nDisminuir la incidencia de errores de administraci\u00f3n\nDISE\u00d1O CIRCUITO Y ETAPAS\nDISE\u00d1O  \nSe recogieron todos los f\u00e1rmacos susceptibles de administrar por v\u00eda subcut\u00e1nea incluidos en la Gu\u00eda Farmacoterap\u00e9utica \ndel hospital.  \nLa gu\u00eda incluye tres tablas diferentes: una con los medicamentos que se pueden administrar por v\u00eda subcut\u00e1nea, otra \nespec\u00edfica de antibi\u00f3ticos y otra de f\u00e1rmacos cuya administraci\u00f3n est\u00e1 contraindicada por v\u00eda subcut\u00e1nea.  \n \nCIRCUITO Y ETAPAS \n1. Se seleccionaron todos los f\u00e1rmacos susceptibles de administrar por v\u00eda subcut\u00e1nea en base a los siguientes criterios: \nv\u00eda de administraci\u00f3n parenteral, subcut\u00e1nea e intramuscular. \n2. De esta primera selecci\u00f3n, se excluyeron los f\u00e1rmacos que cumpl\u00edan los siguientes criterios: administraci\u00f3n por v\u00eda \nsubcut\u00e1nea y dispensaci\u00f3n hospitalaria, citost\u00e1ticos, f\u00e1rmacos para el tratamiento de enfermedades metab\u00f3licas, \nvacunas, inmunoglobulinas, terapia hormonal e insulinas.  \n3. Se llev\u00f3 a cabo una revisi\u00f3n bibliogr\u00e1fica de los f\u00e1rmacos seleccionados que no cumpl\u00edan los criterios de exclusi\u00f3n \nmediante consulta de fichas t\u00e9cnicas, gu\u00edas, art\u00edculos y bases de datos (Uptodate y Micromedex).\nIMPLANTACI\u00d3N\nSe ha implantado la Gu\u00eda subcut\u00e1nea en todo el hospital como consulta para la administraci\u00f3n de medicamentos por v\u00eda \nsubcut\u00e1nea\nRESULTADOS\nSe seleccionaron un total de 967 f\u00e1rmacos susceptibles de administrar por v\u00eda subcut\u00e1nea. De esta primera selecci\u00f3n, \nfueron finalmente revisados 132 (13,6%) f\u00e1rmacos.  \nTras la revisi\u00f3n, 51 f\u00e1rmacos se pod\u00edan administrar por v\u00eda subcut\u00e1nea y los 81 restantes estaban contraindicados para \nesta v\u00eda de administraci\u00f3n. En cuanto a los antibi\u00f3ticos, \u00fanicamente 7 se pod\u00edan administrar por v\u00eda subcut\u00e1nea.\nLIMITACIONES\nDificultad de acceso a informaci\u00f3n sobre la administraci\u00f3n de f\u00e1rmacos por esta v\u00eda.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa elaboraci\u00f3n de gu\u00edas para la administraci\u00f3n subcut\u00e1nea de f\u00e1rmacos resulta de gran importancia en los Servicios de \nfarmacia ya que es una alternativa muy \u00fatil cuando la administraci\u00f3n por otras v\u00edas no es adecuada.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n193. IMPLANTACI\u00d3N DE UNA ESTRATEGIA MULTIDISCIPLINAR PARA LA OPTIMIZACI\u00d3N DEL USO DE \nPSICOF\u00c1RMACOS EN UN CENTRO PENITENCIARIO \nAUTORES\nFERN\u00c1NDEZ L\u00d3PEZ DE VICU\u00d1A, EM; NOGALES GARC\u00cdA, M; VELASCO GARCIA, R; LABORDE ZUFIAURRE, M; ANTIA \nOZCARIZ, P; SANTAOLALLA SANCHEZ, A; ROSADO ANCIN, M; LOPEZ DE ARCAUTE TRINCADO, A\nCENTRO PENITENCIARIO ARABA\nOBJETIVOS\nDescribir el desarrollo e implantaci\u00f3n de un programa multidisciplinar de optimizaci\u00f3n del uso de psicof\u00e1rmacos en un \ncentro penitenciario (CP) basado en la deprescripci\u00f3n de f\u00e1rmacos en base a su potencial de abuso. Analizar el impacto \nde esta medida\ufffd\nMEJORAS ESPERADAS\nReducci\u00f3n del abuso/mal uso de psicof\u00e1rmacos prescritos en el CP \nEstandarizaci\u00f3n de la deprescripci\u00f3n en la pr\u00e1ctica cl\u00ednica diaria.\nDISE\u00d1O CIRCUITO Y ETAPAS\nDise\u00f1o  \nEn octubre de 2020 un auto judicial decreta la inclusi\u00f3n en tratamiento directamente observado (TDO) de todos aquellos \npacientes del CP en tratamiento con psicof\u00e1rmacos. A pesar de ello, sigue habiendo abuso/mal uso de psicof\u00e1rmacos \nprescritos, lo cual genera la necesidad de abordar esta problem\u00e1tica desde un punto de vista transversal.  \nCircuito y etapas \nCreaci\u00f3n de un equipo multidisciplinar (Atenci\u00f3n Primaria (AP), Salud Mental (SM) y Farmacia) para analizar la situaci\u00f3n \nactual y plantear la estrategia a seguir \ufffd Se estructura en fases:  \n1. Identificar los psicof\u00e1rmacos con mayor potencial de abuso y riesgo en caso de intoxicaci\u00f3n. Se utiliza la Gu\u00eda Safer \nPrescribing In Prisons 2019, que clasifica a los f\u00e1rmacos por colores (sem\u00e1foro) en funci\u00f3n de su idoneidad de uso dentro \nde prisi\u00f3n. Por consenso, se decide actuar prioritariamente sobre pregabalina, gabapentina, amitriptilina y mirtazapina.  \n 5482. Verificar, para los f\u00e1rmacos elegidos, si hay pautas en el CP con dosis diaria igual o superior a la m\u00e1xima recomendada \nen ficha t\u00e9cnica (600 mg para pregabalina, 2400mg gabapentina, 150mg amitriptilina, 45mg mirtazapina), sin entrar a \nvalorar la indicaci\u00f3n\ufffd  \n \n3. Se establecen las pautas de deprescripci\u00f3n y los f\u00e1rmacos para manejar ansiedad/insomnio de rebote. Se redacta \nun documento de consenso y se presenta en una jornada en el CP , remarcando la importancia de la participaci\u00f3n del \npaciente en el proceso\ufffd  \n \n4. Farmacia realiza una monitorizaci\u00f3n semanal mediante consultas autom\u00e1ticas al programa de prescripci\u00f3n.\nIMPLANTACI\u00d3N\nLa actividad se inici\u00f3 el 11/11/2021. Hay nuevas fases en desarrollo: Interacciones que incrementen el riesgo elevaci\u00f3n \ndel intervalo QT, pacientes que toman 2 o m\u00e1s benzodiacepinas simult\u00e1neamente, psicof\u00e1rmacos pautados fuera de \nindicaci\u00f3n\ufffd\nRESULTADOS\nAntes (11/11/2021). Total internos: 718. De ellos 45 con pregabalina, 39 gabapentina, 26 amitriptilina y 44 mirtazapina. \nN\u00ba pacientes con dosis \u2265 m\u00e1xima: pregabalina (7), gabapentina (4), amitriptilina (2) y mirtazapina (2). Dosis diaria media \npor paciente (mg): pregabalina (18,5), gabapentina (48,6), amitriptilina (2,7) y mirtazapina (1,3).  \n \nDespu\u00e9s (11/04/2022). Total internos: 731. De ellos, 32 con pregabalina, 23 gabapentina, 17 amitriptilina y 31 \nmirtazapina. Esto supone reducciones del 30,1%, 42,1%, 35,8% y 30,8% respectivamente. N\u00ba pacientes con dosis \u2265 \nm\u00e1xima: pregabalina (5), gabapentina (3), amitriptilina (2) y mirtazapina (0), se reduce 29,8%, 26,3%, 1,77% y 100% \nrespectivamente. Dosis diaria media por paciente (mg): pregabalina (13,89), gabapentina (31,3), amitriptilina (1,4) y \nmirtazapina (0,9). Se reduce la dosis por paciente en 26,5%, 36,7%, 49% y 32% respectivamente.\nLIMITACIONES\nAlta movilidad de internos entre prisiones dificulta el desarrollo del programa. \nEs necesaria mayor coordinaci\u00f3n entre equipos de AP y SM.  \nNo disponemos de una Gu\u00eda adaptada a nuestro pa\u00eds \u2013 entorno.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nA cualquier centro penitenciario con equipos de AP , SM y Farmacia.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n423. HUMANIZACION DEL AREA DE PACIENTES EXTERNOS: DESARROLLO Y ANALISIS DE UN \nPROCEDIMIENTO DE DISPENSACION MEDIANTE LA COORDINACION ENTRE NIVELES ASISTENCIALES \nAUTORES\nMART\u00cdNEZ-BROCAL OGAYAR, I; HIDALGO CABRERA, J; CUEVAS ASENCIO, I; REYES TORRES, I; FUENTES CAPARR\u00d3S, B\nHOSPITAL COMARCAL INFANTA MARGARITA \ufffd AV\ufffd DE G\u00d3NGORA, S/N CABRA \ufffd C\u00d3RDOBA\nOBJETIVOS\nDescribir la puesta en marcha de un circuito de dispensaci\u00f3n de pacientes externos mediante la coordinaci\u00f3n de Atenci\u00f3n \nprimaria y Hospitalaria. Analizar el perfil de pacientes que utilizaron este medio.\nMEJORAS ESPERADAS\nLa comunicaci\u00f3n entre niveles asistenciales en un entorno rural donde la poblaci\u00f3n se encuentra dispersa y alejada del \nhospital, se considera un elemento clave de Humanizaci\u00f3n del Sistema Sanitario. Promover el uso de circuitos alternativos \nde dispensaci\u00f3n de medicamentos, constituye una oportunidad para mejorar la adherencia, en casos de dif\u00edcil acceso al \nhospital.\nDISE\u00d1O CIRCUITO Y ETAPAS\nEl circuito se desarroll\u00f3 en un \u00c1rea de Gesti\u00f3n Sanitaria (AGS) ante las dificultades de movilidad para los pacientes en el \ncontexto de la pandemia COVID19\ufffd  \nSe consensu\u00f3 una v\u00eda de comunicaci\u00f3n entre los enfermeros gestores de casos y el \u00e1rea de Pacientes Externos del \nHospital, mediante correo electr\u00f3nico corporativo.  \nLos pacientes que necesitaban medicaci\u00f3n y no pod\u00edan acudir al hospital, solicitaban a su centro de salud este servicio, \ndonde se valoraba la idoneidad de utilizar esta v\u00eda de dispensaci\u00f3n. Adem\u00e1s, se hac\u00eda una valoraci\u00f3n por parte del \nFarmac\u00e9utico seg\u00fan tipo de paciente y caracter\u00edsticas de la medicaci\u00f3n solicitada.  \nDiariamente un farmac\u00e9utico validaba los tratamientos y los preparaba de forma adecuada para su distribuci\u00f3n mediante \nlos circuitos de transporte interniveles. Las incidencias eran subsanadas con el responsable de gestionar el caso en el \ncentro de salud y con el paciente directamente si era necesario \nSe hizo un registro en Excel de las dispensaciones realizadas por esta v\u00eda entre los meses de enero de 2021 hasta abril \nde 2022, registrando: Fecha de dispensaci\u00f3n, Numero de historia, km de distancia al hospital, f\u00e1rmaco y necesidad de \nrefrigeraci\u00f3n, patolog\u00eda del paciente y especialidad m\u00e9dica.549IMPLANTACI\u00d3N\nEl proceso se inici\u00f3 en abril de 2020, el registro de datos se inici\u00f3 en enero de 2021. El proyecto se puso en marcha en un \nAGS de 4.310,57 Km2, dividida en 13 Zonas B\u00e1sicas de Salud, 21 Consultorios Locales y 10 consultorios auxiliares.\nRESULTADOS\nSe realizaron 1.396 dispensaciones a trav\u00e9s de este circuito, (10,31 % del total de dispensaciones a pacientes externos). \nUsaron este circuito 123 pacientes de 18 Localidades diferentes, 51Km de distancia la m\u00e1s lejana y 12Km la m\u00e1s cercana \nal hospital.  \nEl 45% de las dispensaciones eran de f\u00e1rmacos termol\u00e1biles. Los f\u00e1rmacos que se enviaron con mayor frecuencia fueron: \nAdalimumab (10,34%), Tenofovir (9,91%) y Fumarato de Dimetilo (7,76%). Existiendo una gran variabilidad entre el resto \nde f\u00e1rmacos enviados. Las patolog\u00edas m\u00e1s atendidas fueron Esclerosis M\u00faltiple (14,80% de dispensaciones) y patolog\u00edas \nreum\u00e1ticas en tratamiento con biol\u00f3gico (10,76%).\nLIMITACIONES\nConsideramos que el car\u00e1cter proactivo de este circuito es una limitaci\u00f3n, ya que los propios pacientes son los que \nsolicitan este servicio, podr\u00eda considerarse estudiar los resultados obtenidos y ofrecer este servicio a pacientes que por su \nvulnerabilidad podr\u00edan beneficiarse de este circuito.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nPodr\u00eda aplicarse en hospitales que abarquen una poblaci\u00f3n geogr\u00e1ficamente dispersa.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n430. IMPLEMENTACION DE UN PROTOCOLO DE ANALGESIA MEDIANTE LA ELABORACION DE UNA \nMEZCLA INTRAVENOSA TERNARIA DE ANALGESIA CONTROLADA POR PACIENTE \nAUTORES\nCORAZ\u00d3N VILLANUEVA, J; CORAZ\u00d3N VILLANUEVA, J; PUEBLA GARC\u00cdA, V; V\u00cdLCHEZ LARA, MJ; MOLINERO MU\u00d1OZ, M; \nDE LA TORRE ORT\u00cdZ, M; YBA\u00d1EZ GARC\u00cdA, L; MART\u00cdNEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nEstablecer un circuito seguro de prescripci\u00f3n, elaboraci\u00f3n, dispensaci\u00f3n y administraci\u00f3n de una mezcla ternaria de \ntramadol, dexketoprofeno y haloperidol (TDH), para la administraci\u00f3n intravenosa en bomba de analgesia controlada por \nel paciente (PCA), en colaboraci\u00f3n con la Unidad del dolor Agudo (UDA) en un hospital de tercer nivel.\nMEJORAS ESPERADAS\n-Mejorar el control del dolor agudo postcirug\u00eda mediante la sustituci\u00f3n de elast\u00f3meros por bombas PCA, en donde el \npaciente puede controlar el dolor a demanda, ajust\u00e1ndose as\u00ed a sus propias necesidades.  \n-Evitar errores de sobredosificaci\u00f3n la creaci\u00f3n de protocolos con dosis diarias variables en funci\u00f3n de la velocidad de \ninfusi\u00f3n y de n\u00famero de rescates m\u00e1ximos totales.  \n-Minimizar riesgos atribuidos a la manipulaci\u00f3n de medicamentos de alto riesgo en unidades de hospitalizaci\u00f3n en un \nentorno no controlado, como la unidad de recuperaci\u00f3n postanest\u00e9sica (URPA). \n-Asegurar la estabilidad fisicoqu\u00edmica y microbiol\u00f3gica de las mezclas analg\u00e9sicas con m\u00e1s de dos componentes.\nDISE\u00d1O CIRCUITO Y ETAPAS\nCreaci\u00f3n de un grupo de trabajo con la UDA para establecer un protocolo de analgesia postcirug\u00eda en la URPA.  \n \n1) Revisi\u00f3n bibliogr\u00e1fica de la compatibilidad y estabilidad de los componentes de la mezcla ternaria (tramadol, \ndexketoprofeno y ondansetr\u00f3n) utilizada hasta ese momento en la URPA.  \n2) Propuesta de sustituci\u00f3n por una mezcla ternaria con TDH con estudios publicados de estabilidad fisicoqu\u00edmicos en \nbombas PCA \ufffd \n3) Estandarizaci\u00f3n de protocolo: Dosis diarias variables en funci\u00f3n de requerimientos mediante dos velocidades \ninfusionales estandarizadas, n\u00famero de rescates y tiempo recomendado de infusi\u00f3n (24-48 horas).  \n4) Parametrizaci\u00f3n del protocolo en las bombas PCA y en los sistemas de prescripci\u00f3n del hospital.  \n5) Sesiones formativas para implementar el protocolo a Servicio de Anestesiolog\u00eda.  \n6) Elaboraci\u00f3n de un protocolo normalizado de elaboraci\u00f3n.  \n7) An\u00e1lisis del nivel de riesgo con el modelo propuesto por la Gu\u00eda de Buenas Pr\u00e1cticas de Elaboraci\u00f3n de medicamentos, \nestableciendo condiciones de conservaci\u00f3n, plazos de validez y controles seguridad  \n8) Puesta a punto del circuito de dispensaci\u00f3n y trazabilidad.\nIMPLANTACI\u00d3N\nEl periodo de implantaci\u00f3n se inici\u00f3 en Agosto de 2021\ufffd\nRESULTADOS\nElaboraci\u00f3n centralizada de la mezcla analg\u00e9sica:  \n\u2022 Composici\u00f3n: tramadol 600mg + dexketoprofeno 300mg + haloperidol 5mg. Diluyente: Cloruro s\u00f3dico 0,9%. \n\u2022 Caducidad: 14 d\u00edas conservado entre 2-8\u00baC y protegido de la luz.  \n\u2022 Control de seguridad se realiza un control gravim\u00e9trico de las bolsas preparadas. Se desechan si hay una desviaci\u00f3n del \n3%\ufffd  550\u2022 Prescripci\u00f3n: Tras el traslado a URPA, el anestesi\u00f3logo prescribe el protocolo en el programa electr\u00f3nico eligiendo \nseleccionando dosis estandarizadas en funci\u00f3n de velocidad de infusi\u00f3n (en 48 horas): 1,3 mL/h (2 rescates hora) o 1,7 \nmL/h (2 rescates hora).  \n \nEl almacenamiento se comparte con un stock m\u00ednimo en URPA y servicio de farmacia, y tras la administraci\u00f3n existe una \ntrazabilidad manual en URPA de lote administrado por paciente.  \nDesde la implementaci\u00f3n de este circuito se han elaborado y dispensado 360 mezclas analg\u00e9sicas. No se ha notificado \nninguna incidencia en relaci\u00f3n\ufffd\nLIMITACIONES\nAlta Carga de trabajo y/o falta recursos humanos del personal de servicio de farmacia. \nDificultad de asegurar la trazabilidad y dispensaci\u00f3n individualizada por paciente, al existir stock en la URPA.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nHospitales donde en la pr\u00e1ctica habitual se elaboren mezclas intravenosas en las unidades de hospitalizaci\u00f3n.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n643. IMPLANTACI\u00d3N DE UN PROCEDIMIENTO DE IDENTIFICACI\u00d3N Y MANIPULACI\u00d3N SEGURA DE \nMEDICAMENTOS BIOPELIGROSOS EN UN HOSPITAL DE MEDIA ESTANCIA \nAUTORES\nLAR\u00cdA CAMPA\u00d1A, C; S\u00c1NCHEZ GREGORIO, ML; CANDENAS TORRES, Y\nHOSPITAL GUADARRAMA \ufffd PASEO DEL MOLINO DEL REY , 2 \ufffd GUADARRAMA \ufffd MADRID\nOBJETIVOS\nDise\u00f1ar e implantar un procedimiento para la identificaci\u00f3n y manipulaci\u00f3n seguras de medicamentos biopeligrosos (MB) \nen un hospital de media estancia, desde su prescripci\u00f3n hasta su administraci\u00f3n, en base a los documentos del Instituto \nNacional de Seguridad e Higiene en el Trabajo (INSHT) y el National Institute for Occupational Safety and Health (NIOSH).\nMEJORAS ESPERADAS\nManipulaci\u00f3n e identificaci\u00f3n seguras de MB.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe constituy\u00f3 un comit\u00e9 multidisciplinar (Prevenci\u00f3n de riesgos laborales, Direcci\u00f3n-Gerencia, enfermer\u00eda, m\u00e9dicos, \nfarmac\u00e9utico hospitalario) para evaluar la situaci\u00f3n del hospital y determinar los puntos clave en los que trabajar. \n \nSe definieron las siguientes l\u00edneas de trabajo:  \n- Identificar y clasificar los MB disponibles.  \n- Definir un adecuado m\u00e9todo de identificaci\u00f3n, reenvasado y reetiquetado.  \n- Incorporar informaci\u00f3n sobre preparaci\u00f3n y manipulaci\u00f3n de MB en las bases de datos (programa de gesti\u00f3n \nfarmac\u00e9utica, de prescripci\u00f3n electr\u00f3nica y administraci\u00f3n de enfermer\u00eda \u2013PIPM-\u2026).  \n- Equipos de protecci\u00f3n individual (EPI) y dispositivos de seguridad para manipulaci\u00f3n de MB.  \n- Sesiones formativas al personal sanitario.\nIMPLANTACI\u00d3N\nEl procedimiento se desarroll\u00f3 en 2020-2021.\nRESULTADOS\nSe identificaron 39 MB en la Gu\u00eda Farmacoterap\u00e9utica (GFT) del hospital, de los cuales 9 (23,1%) pertenec\u00edan al grupo 1 \n(G1), 13 (33,3%) al grupo 2 (G2) y 17 (43,6%) al grupo 3 (G3).  \nTodos los MB en forma de comprimido/c\u00e1psula fueron reenvasados/reetiquetados utilizando un c\u00f3digo de colores \npara su adecuada identificaci\u00f3n: color azul para G1 y G2, y verde para el G3. El color naranja se reserv\u00f3 para aquellos \nmedicamentos que no fueran biopeligrosos y requiriesen de reenvasado/reetiquetado. Se incluyeron los datos: principio \nactivo, nombre comercial, excipientes de declaraci\u00f3n obligatoria, c\u00f3digo nacional, fecha de caducidad, fecha de envasado, \nlote y, en el caso de los MB, grupo de riesgo al que pertenec\u00edan. Para ello, se adquiri\u00f3 un dispositivo de reenvasado \nmanual, as\u00ed como el software para elaborar las etiquetas identificativas. \nLos MB acondicionados en forma de viales/ampollas/sobres fueron identificados con un adhesivo del color \ncorrespondiente en cada caso\ufffd  \nA lo largo del a\u00f1o, se reenvasaron 13.203 unidades de MB: 4,2% (560) pertenec\u00edan al G1, 27,4% (3617) al G2 y 68,4% \n(9026) al G3. Se adquiri\u00f3 una campana de flujo laminar vertical para la manipulaci\u00f3n y fraccionamiento de MB en el SF \ny se elaboraron dos nuevos Procedimientos Normalizados de Trabajo sobre manejo y limpieza de los nuevos equipos, \nadem\u00e1s de impartir 3 sesiones formativas.  \nSe incluyeron recomendaciones sobre manipulaci\u00f3n y administraci\u00f3n de MB en las bases de datos del SF, as\u00ed como en el \nPIPM, para que tanto m\u00e9dicos prescriptores como personal de enfermer\u00eda visualizaran dicha informaci\u00f3n.  \nSe adquirieron 4 dispositivos para pulverizar/triturar MB en las unidades cl\u00ednicas (administraci\u00f3n por sonda, problemas \nde degluci\u00f3n\u2026) y bolsas zip, ajustables a jeringas de administraci\u00f3n oral, para la diluci\u00f3n y administraci\u00f3n de estos \nmedicamentos, y se impartieron 4 sesiones formativas sobre clasificaci\u00f3n de MB y empleo de EPI.551LIMITACIONES\n- Aunque se han fraccionado MB para obtener dosis no comercializadas, a\u00fan es necesario optimizar la GFT elaborando \nf\u00f3rmulas magistrales e incluyendo nuevas especialidades y formas farmac\u00e9uticas. \n- Revisar y adaptar el circuito particular de la medicaci\u00f3n aportada por los pacientes.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nAplicable a todos los hospitales.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n678. OPTIMIZACI\u00d3N DEL CIRCUITO DE ESTUPEFACIENTES APLICANDO EL SISTEMA DE GESTI\u00d3N DE \nCALIDAD \nAUTORES\nGARC\u00cdA CASTI\u00d1EIRA, C; BOCOS BAELO, A; LAGUNA M\u00c1RMOL, L; TERRICABRAS MAS, E; ESTRADA NIETO, L; VALLS \nS\u00c1NCHEZ, E; AULET LUCAS, S; RIBAS QUI\u00d1ONES, C\nHOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nOBJETIVOS\nUtilizar el sistema de gesti\u00f3n de calidad del Servicio de Farmacia (SF) para optimizar el circuito de prescripci\u00f3n y \ndispensaci\u00f3n de estupefacientes en las unidades de hospitalizaci\u00f3n que dispongan del programa de prescripci\u00f3n \nelectr\u00f3nica (PE).\nMEJORAS ESPERADAS\n- Disminuir el n\u00famero de recetas de estupefacientes en formato papel que llegan al SF  \n- Eliminar posibles fuentes de error en la gesti\u00f3n del stock \n- Simplificar el circuito de petici\u00f3n/dispensaci\u00f3n de estupefacientes \n- Asegurar una trazabilidad completa de la medicaci\u00f3n en todos los procesos del circuito\nDISE\u00d1O CIRCUITO Y ETAPAS\nEn el an\u00e1lisis de debilidades, amenazas, fortalezas y oportunidades (DAFO) realizado en el SF durante el a\u00f1o 2021, una de \nlas debilidades identificadas fue un sistema de gesti\u00f3n de estupefacientes poco eficaz.  \nPara estudiar y solventar la debilidad detectada, se estableci\u00f3 como uno de los objetivos de calidad el a\u00f1o la optimizaci\u00f3n \ndel circuito de estupefacientes en las unidades de enfermer\u00eda que dispusiesen del programa de PE . \nSe eligi\u00f3 y adapt\u00f3 a la gesti\u00f3n de estupefacientes el sistema de introducci\u00f3n r\u00e1pida de medicaci\u00f3n por enfermer\u00eda (IRMP)\ndisponible en el programa de PE. El sistema IRMP , adaptado a estupefacientes, permite que prescripci\u00f3n, solicitud y \ndispensaci\u00f3n se realicen a nombre de paciente a trav\u00e9s de una plataforma \u00fanica. Adem\u00e1s, identifica al profesional \nimplicado, y registra autom\u00e1ticamente los datos necesarios para cubrir el libro electr\u00f3nico de estupefacientes.  \nLos pasos a seguir para la consecuci\u00f3n del objetivo se plasmaron en el documento de planificaci\u00f3n de cambios asociado \nal objetivo de calidad.  \nETAPAS \n1. Creaci\u00f3n de un equipo multidisciplinar integrado por el SF y los supervisores de enfermer\u00eda (SE) de las unidades \nimplicadas\ufffd  \n2. Optimizaci\u00f3n del stock de estupefacientes en las unidades de enfermer\u00eda (UE) con PE.  \n3. Formaci\u00f3n y autorizaci\u00f3n de acceso al sistema de IRMP de estupefacientes a todos los SE.  \n4. Creaci\u00f3n de un protocolo de trabajo.  \n5. Realizaci\u00f3n de encuesta de satisfacci\u00f3n.\nIMPLANTACI\u00d3N\nEl nuevo circuito de trabajo se puso en marcha progresivamente, iniciando en noviembre de 2021, y finalizando en abril \nde 2022 con la implantaci\u00f3n en las 14 unidades con PE\ufffd\nRESULTADOS\nPara evaluar el objetivo de calidad, se realiz\u00f3 una encuesta a los SE de las 14 unidades implicadas. Se tom\u00f3 como escala \nun valor num\u00e9rico del 0 (valoraci\u00f3n negativa) al 5 (valoraci\u00f3n positiva), y se consider\u00f3 mejor\u00eda una puntuaci\u00f3n igual o \nsuperior a 4\ufffd Los resultados medios obtenidos fueron:  \n- El 100% de los encuestados consideraron que se hab\u00eda optimizado el tiempo invertido en el circuito, y que hab\u00eda \naumentado la seguridad en la dispensaci\u00f3n de estupefacientes\ufffd  \n- El 77\u20198% consideraron que hab\u00eda mejorado la trazabilidad y que hab\u00eda disminuido el n\u00famero de errores.  \nReducci\u00f3n en un 70% del n\u00famero de recetas de estupefacientes en formato papel.\nLIMITACIONES\n- Susceptibilidad de errores inform\u00e1ticos \n- Sistema de gesti\u00f3n aplicable \u00fanicamente a unidades de hospitalizaci\u00f3n con sistema de PE.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\n- El sistema de gesti\u00f3n de estupefacientes es aplicable a cualquier SF interesado en optimizar la trazabilidad y control del \ncircuito de estupefacientes que disponga de programa de PE.552CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n774. IMPROVING ONCOLOGY PATIENT JOURNEY USING LEAN METHODOLOGY \nAUTORES\nJORGE , A; ESCADA , T; DUARTE , A; CORTES , P; PRATA , J; CORTES , R\nOBJETIVOS\nThe aim of this study was to analyze the patient\u00b4s journey in an oncology center of a Portuguese private hospital, to \ndecrease patient\u2019s waiting time and eliminate non-value-added process steps, using Lean methodology.\nMEJORAS ESPERADAS\nThis project aimed to reduce the lead-time of treatments by 15%, reduce by 80% the number of patients with more than \none hour of waiting time and dematerialize 90% of medical prescriptions. These were defined as indicators.\nDISE\u00d1O CIRCUITO Y ETAPAS\nA value stream map was created and observation grids were filled in, in order to calculate the real times of all stages \nof the process and identify bottlenecks. Surveys were applied to the entire team involved in the patient circuit to help \nidentify priorities for action.  \nThis study was conducted on patients that had their labs and doctor\u2019s appointment done previously of the treatment day. \nThe complexity of the patient circuit led to the definition of the time between the call to pharmacy confirming the \npatient\u2019s eligibility to treatment and the end of the chemotherapy administration as the priority point of intervention. \nExpected times were defined per cycle. \nA dashboard was built to monitor the indicators and an internal audit checklist was prepared for quarterly application.\nIMPLANTACI\u00d3N\nIt was conducted a descriptive and retrospective study from January 2021 to September 2021. From October 2021 \nto February 2022, it was performed an observational descriptive study, in which it was measured the lead-time from \nadmission to discharge in the oncology ward.  \nSimultaneously all oncology treatment prescriptions were revised and updated. \nThroughout the study development and implementation, other improvement opportunities were identified, qualified as \nquick wins, so they were immediately implemented. The Pharmacy department adjusted their opening hours, in order \nto go along with the Oncology Center operating period. There were also implemented changes in the treatment delivery \nform the Pharmacy and the invoicing processes.\nRESULTADOS\nIn January 2021 the lead-time from admission to discharge was 330 minutes. At an intermediate check point (September \n2021) it was 221 minutes and by February 2022 it had decreased to 193 minutes (42%). \nAll medical prescriptions are currently electronic, while initially 51% were manual.  \nThe number of patients with more than one hour of waiting time was reduced by more than 80%.\nLIMITACIONES\nOne of the main limitations of this study is that the process times were manually measured. We are currently working \nwith the Information Technology team on creating these process indicators and for them to be accessible.  \nBecause the study was focused on a specific type of patient, we cannot ensure that we improved all of the patient\u2019s \njourney at the Oncology Center.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nIt is intended to extend the study to patients who have lab and doctor\u2019s appointments on treatment day, and measure \nthe impact of the changes on their lead-time as well.  \nThis project is applicable to every Pharmacy department, as long as a multidisciplinary team is created and the staff is \ntrained and motivated to improve the patient journey.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n780. IMPLANTACI\u00d3N DE LA METODOLOG\u00cdA NOT TO DO EN UN SERVICIO DE FARMACIA HOSPITALARIA \nAUTORES\nMATEOS SALVADOR, M; MART\u00cdNEZ PRADEDA, A; MARGUSINO FRAMI\u00d1\u00c1N, L; CALV\u00cdN LAMAS, M; FEAL CORTIZAS, B; \nGONZ\u00c1LEZ PI\u00d1EIRO, S; MART\u00cdN HERRANZ, I\nCOMPLEXO HOSPITALARIO UNIVERSITARIO A CORU\u00d1A. XUBIAS DE ARRIBA, 84 CORU\u00d1A (A). A CORU\u00d1A\nOBJETIVOS\nEstablecer un circuito de implantaci\u00f3n de metodolog\u00eda Not To Do (o dejar de hacer) para optimizar actividades/acciones/\nprocesos\ufffd\nMEJORAS ESPERADAS\n-Evitar actividades/acciones/procesos que no aportan valor, para centrarse en las que s\u00ed lo hacen.  \n-Liberar capacidad y, por tanto, aportar m\u00e1s servicios y m\u00e1s valor con los mismos recursos.  \n-Organizaci\u00f3n basada en el paciente. \n \nEn definitiva, mejorar la calidad de la atenci\u00f3n farmac\u00e9utica prestada y la satisfacci\u00f3n del paciente.553DISE\u00d1O CIRCUITO Y ETAPAS\nSe identific\u00f3 la necesidad de desarrollar un circuito que pudiera aumentar la eficiencia, optimizar tiempo, planificar con \nantelaci\u00f3n tareas, delegar funciones para ser m\u00e1s productivo y descartar actividades que no a\u00f1adan valor. 7 etapas para \nla implantaci\u00f3n:  \n \n1.Formar un grupo de trabajo Not To Do.  \n \n2.Solicitar la colaboraci\u00f3n de los farmac\u00e9uticos para proponer aspectos que consideraban que hab\u00eda que \u201cdejar de hacer\u201d \no modificar para mejorar procesos dentro de su secci\u00f3n o del servicio.  \n \n3\ufffdRecoger las propuestas en una base de datos\ufffd  \n \n4.Priorizar las propuestas recibidas utilizando la matriz de Eisenhower. Seg\u00fan la importancia y la urgencia de la acci\u00f3n se \nestablecieron cuatro prioridades: 1-hacer de inmediato 2-planificar 3-delegar 4-eliminar. \n \n5.Crear de una ficha/formulario Not To Do para el planteamiento y resoluci\u00f3n de cada propuesta con distintos apartados: \n\u00e1rea de aplicaci\u00f3n, personal implicado, situaci\u00f3n inicial, plan de acci\u00f3n, facilidad de implantaci\u00f3n, impacto de la mejora...\nEsta ficha/formulario est\u00e1 basada en el A3, una herramienta \u201cLean Management\u201d mediante la cual se aplica el m\u00e9todo \nPDCA(Plan-Do-Check-Act): planificar-realizar-comprobar-ajustar. A trav\u00e9s de ella se presenta, de forma estandarizada y en \nuna \u00fanica hoja de tama\u00f1o A3 (de ah\u00ed su nombre), toda la informaci\u00f3n necesaria para el planteamiento y resoluci\u00f3n de un \nproblema\ufffd  \n \n6.Convocar reuniones de manera peri\u00f3dica para analizar cada situaci\u00f3n y plantear un plan de acci\u00f3n.  \n \n7.Aplicar medicadas acordadas y continuar el ciclo PDCA.\nIMPLANTACI\u00d3N\nEn noviembre del 2021 se inici\u00f3 un proceso para implantar la metodolog\u00eda Not To Do.\nRESULTADOS\nSe recogieron 50 propuestas distribuidas en 7 \u00e1reas: coordinaci\u00f3n log\u00edstica(22), atenci\u00f3n farmac\u00e9utica(13), \nfarmacotecnia/citost\u00e1ticos(9), farmacocin\u00e9tica(1), ensayos cl\u00ednicos(2), informaci\u00f3n de medicamentos(1), humanizaci\u00f3n(2). \nPrioridad: 44% delegar, 32% eliminar, 24% planificar. Desde diciembre 2021 a abril 2022: 7 reuniones del grupo de \ntrabajo, 7 propuestas tratadas (5-coordinaci\u00f3n log\u00edstica, 1-atenci\u00f3n farmac\u00e9utica, 1-farmacotecnia/citost\u00e1ticos), 5 fichas \nNot To Do completadas\ufffd  \n \nEjemplos Not To Do/plan de acci\u00f3n:  \n-Homologaci\u00f3n de recetas no urgentes de pacientes derivados de consulta externa que acuden al Servicio de Farmacia \nsin cita/Realizaci\u00f3n de una infograf\u00eda para los pacientes del circuito de homologaci\u00f3n desde el Servicio de Farmacia previa \ncita u homologaci\u00f3n desde Atenci\u00f3n Primaria.  \n-El farmac\u00e9utico realiza cambios y crea c\u00f3digos de medicamentos/Delegar en un TEF la gesti\u00f3n de c\u00f3digos en el aplicativo.\nLIMITACIONES\nRequiere un elevado grado de implicaci\u00f3n del grupo de trabajo, tanto en la implantaci\u00f3n del circuito, como en la \nplanificaci\u00f3n y el seguimiento de las medidas acordadas.  \nLa delegaci\u00f3n de funciones est\u00e1 limitada por la disponibilidad y aceptaci\u00f3n de las personas en las que se decide delegar el \ntrabajo.  \nOtra limitaci\u00f3n es la evaluaci\u00f3n del programa mediante alg\u00fan indicador.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLa sencillez del circuito lo convierte en una metodolog\u00eda de f\u00e1cil aplicaci\u00f3n e implantaci\u00f3n en cualquier servicio de \nfarmacia\ufffd\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1136. INCORPORACI\u00d3N DEL VISADO DE PRESCRIPCIONES A LA CARTERA DE SERVICIOS DE FARMACIA: \nAN\u00c1LISIS DE LA PRESCRIPCI\u00d3N DE ANTICOAGULANTES ORALES DIRECTOS \nAUTORES\nAGUILAR DEL VALLE, E; G\u00d3MEZ DELGADO, M; MART\u00cdNEZ CASANOVA, N; DANI BEN ABDEL-LAH, L; MOYA CARMONA, \nI\nCOMPLEJO HOSPITALARIO DE ESPECIALIDADES VIRGEN DE LA VICTORIA. CAMPUS UNIVERSITARIO TEATINOS, S/N \nM\u00c1LAGA \ufffd MALAGA\nOBJETIVOS\n- Describir el procedimiento de incorporaci\u00f3n de la unidad de visados al Servicio de Farmacia de un hospital de \nespecialidades\ufffd  \n- Analizar las intervenciones farmac\u00e9uticas realizadas en la prescripci\u00f3n de ACODs (anticoagulantes orales directos) 554orientadas a mejorar el uso racional mediante el cumplimiento del IPT (informe de posicionamiento) publicado en 2016; \nas\u00ed como las intervenciones realizadas sobre problemas relacionados con dicha medicaci\u00f3n (PRM).\nMEJORAS ESPERADAS\n- Integrar las actividades de la unidad de visado en nuestra cartera de servicios agilizando el proceso de visado de \nprescripciones para que el paciente no tenga que esperar m\u00e1s de 24 horas para retirar el medicamento de la oficina de \nfarmacia\ufffd \n- Detectar PRM en el momento de la prescripci\u00f3n para subsanarlos y evitar resultados negativos de la medicaci\u00f3n.  \n- Establecer un circuito comunicativo entre la unidad de visados y los m\u00e9dicos prescriptores. \n- Concienciar a los prescriptores de la existencia y el obligado cumplimiento de la legislaci\u00f3n vigente sobre los \nmedicamentos\ufffd\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe fijaron plazos para el inicio de la actividad, se revis\u00f3 la legislaci\u00f3n vigente, los protocolos asistenciales del centro y los \nrealizados por servicios centrales de la comunidad aut\u00f3noma y se recopil\u00f3 la documentaci\u00f3n. Se dise\u00f1\u00f3 un procedimiento \npara consultar los PRM m\u00e1s comunes relacionados con ACOD, entre otros.  \n \nEtapas: \n1. Realizaci\u00f3n de sesiones formativas.  \n2\ufffd Designaci\u00f3n de profesionales implicados del Servicio de Farmacia y los servicios prescriptores de medicamentos \nsujetos a visado, entre ellos los ACOD. \n3. Puesta en marcha del circuito: revisi\u00f3n diaria de las prescripciones m\u00e9dicas, con visado o denegaci\u00f3n, detecci\u00f3n de \nPRM, comunicaci\u00f3n v\u00eda email al jefe del servicio prescriptor en caso de duda/discrepancia.  \n4. Establecimiento de tiempos de respuesta, clasificando las prescripciones en dos grupos: comunicaci\u00f3n inmediata (por \nejemplo ACOD) o comunicaci\u00f3n en 48 horas.\nIMPLANTACI\u00d3N\nSe present\u00f3 el proyecto en el Servicio de Farmacia para una validaci\u00f3n interna del circuito y a la direcci\u00f3n del centro para \nvalidaci\u00f3n externa. Tras su aprobaci\u00f3n se inici\u00f3 la actividad en septiembre de 2021 con las sesiones formativas en los \nservicios prescriptores\ufffd\nRESULTADOS\nDesde diciembre de 2021 se incorpor\u00f3 el visado de medicamentos a la cartera de servicios design\u00e1ndose un farmac\u00e9utico \ncoordinador y responsable del visado por la ma\u00f1ana y manteniendo la continuidad asistencial del visado por el resto de \nfarmac\u00e9uticos en la tarde. \n \nSe denegaron 75 prescripciones de ACOD: 41 (54,6%) prescritos en TVP/TEP , 30 (40%) por un valor igual a 0 o 1 en \nla escala CHA2DS2-VASc, 2 (2,6%) por diagn\u00f3stico de flutter y 2 (2,6%) por no tener informe de visado asociado. Se \nrealizaron 9 intervenciones por errores en la posolog\u00eda.  \n \nSe ha observado una disminuci\u00f3n de denegaci\u00f3n de prescripciones de ACOD tras la implantaci\u00f3n, probablemente debida \na la difusi\u00f3n de las indicaciones financiadas y a una mayor adaptaci\u00f3n a estas por parte de los facultativos prescriptores.\nLIMITACIONES\nLa comunicaci\u00f3n v\u00eda email es poco eficiente en t\u00e9rminos de tiempo por lo que se est\u00e1 trabajando para que las incidencias \nlleguen inmediatamente al prescriptor sin tener que realizar notificaciones manuales v\u00eda email.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nPuede aplicarse si incorporan la gesti\u00f3n del visado de prescripciones m\u00e9dicas.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1143. IMPLANTACI\u00d3N DE UN PROTOCOLO DE MANEJO SEGURO DE MEDICAMENTOS DE ALTO RIESGO Y \nPELIGROSOS EN UN CENTRO DE ATENCI\u00d3N INTERMEDIA \nAUTORES\nMIRALLES ALBORS, P; MONTERO CONDE, M; ALONSO CASTELL, P; FUSTER MALDONADO, E; CRUSELLAS PUBILL, E; \nC\u00c1NOVAS MONTERO, C; ANTONELL BOIXADER, I; GRAELL L\u00d3PEZ, S\nHOSPITAL DE SANT ANDREU \ufffd REMEI DE DALT , 3 MANRESA \ufffd BARCELONA\nOBJETIVOS\nImplantar un protocolo para el manejo Medicamentos de Alto Riesgo (MAR) y Medicamentos Peligrosos (MP) en un \ncentro de atenci\u00f3n intermedia de 155 camas, que permita incrementar la seguridad del paciente y de los profesionales \nsanitarios que los manipulan.\nMEJORAS ESPERADAS\nEstablecer pr\u00e1cticas laborales de acuerdo con la normativa vigente que incrementen la seguridad en el uso de estos \nmedicamentos\ufffd  \nMinimizar los riesgos para los pacientes asociados a los posibles errores que pueden ocurrir con los MAR.  \nPrevenir la potencial toxicidad que los MP representan para la salud de los profesionales sanitarios que los manipulan.555DISE\u00d1O CIRCUITO Y ETAPAS\n1. Constituci\u00f3n del grupo de trabajo. Formado por: 1 auxiliar de farmacia, la responsable de prevenci\u00f3n de riesgos \nlaborales (PRL), la delegada de PRL, la coordinadora de enfermer\u00eda, 1 farmac\u00e9utica, y la directora del centro.  \n2. Reuniones realizadas: 4.  \n3. Revisi\u00f3n de la normativa y bibliograf\u00eda relacionada.  \n4. Elaboraci\u00f3n de la lista de MAR y MP incluidos en la gu\u00eda farmacoterap\u00e9utica del centro.  \n5\ufffd Dise\u00f1o de:  \n- Etiquetas identificativas para las ubicaciones del almac\u00e9n de la Farmacia y las dosis unitarias. De color rojo para los MAR, \namarillo para los MP y lila para aquellos que cumplen con ambas condiciones.  \n- Iconos y mensajes informativos para el programa de prescripci\u00f3n.  \n6. Informatizaci\u00f3n del plan de administraci\u00f3n de enfermer\u00eda (Kardex).  \n7\ufffd Redacci\u00f3n del protocolo\ufffd  \n8. Elaboraci\u00f3n de una infograf\u00eda que incluye: las etiquetas identificativas, alertas de las consecuencias de un mal uso, las \nmedidas que debe tomar el trabajador para su manipulaci\u00f3n y equipos de protecci\u00f3n individual (EPI).  \n10. Preparaci\u00f3n de la sesi\u00f3n formativa para todos los trabajadores del centro.\nIMPLANTACI\u00d3N\n1. Identificaci\u00f3n de los MAR y MP mediante etiquetas de color en el almac\u00e9n de farmacia y en las dosis unitarias.  \n2. Personalizaci\u00f3n del programa inform\u00e1tico con iconos y mensajes informativos visibles en las pantallas del plan \nfarmacol\u00f3gico y de administraci\u00f3n de enfermer\u00eda.  \n3\ufffd Publicaci\u00f3n del protocolo\ufffd  \n4. Sesi\u00f3n formativa dirigida a todos los profesionales del centro.  \n5. Difusi\u00f3n de la infograf\u00eda a las diferentes unidades de hospitalizaci\u00f3n.\nRESULTADOS\nSe dispone de un protocolo de manejo seguro de medicamentos de alto riesgo y medicamentos peligrosos.  \nEntre febrero y abril de 2022, se han etiquetado 16.722 dosis unitarias y se han dispensado 12.275 MAR y 2.673 MP . \nSuponen un 4,6% y 1% del total de las dispensaciones realizadas.  \nLos MAR m\u00e1s prescritos son: insulina, morfina y midazolam. Y los MP: espironolactona, finasteride y clonazepam.\nLIMITACIONES\nLa etiqueta identificativa no siempre est\u00e1 presente en el momento de la administraci\u00f3n. Depende del tama\u00f1o del envase \nprimario del f\u00e1rmaco y de si es el mismo profesional el que lo administra que el que lo prepara.  \nEst\u00e1 pendiente la realizaci\u00f3n de una encuesta a todos los profesionales implicados en la manipulaci\u00f3n de los MAR Y MP \npara evaluar el impacto de las intervenciones y poder mejorar las limitaciones encontradas.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nSe puede aplicar en aquellos Servicios de Farmacia en los que el programa de prescripci\u00f3n y administraci\u00f3n permita \ncambios en su configuraci\u00f3n y se disponga de personal suficiente para el etiquetado.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1157. APLICACI\u00d3N DE LA METODOLOG\u00cdA LEAN A UNA UNIDAD MULTIDISCIPLINAR DE ASMA GRAVE \nAUTORES\nMU\u00d1OZ GARC\u00cdA, M; MART\u00cdNEZ BARROS, H; ANTOL\u00cdN AM\u00c9RIGO, D; BLITZ CASTRO, E; GONZ\u00c1LEZ DE OLANO, D; \nS\u00c1NCHEZ CU\u00c9LLAR, S; DE LOS SANTOS GRANADOS, G; \u00c1LVAREZ D\u00cdAZ, AM\nHOSPITAL UNIVERSITARIO RAM\u00d3N Y CAJAL. CTRA. DE COLMENAR VIEJO, KM. 9,1 MADRID. MADRID\nOBJETIVOS\n- Mejorar la organizaci\u00f3n de una unidad multidisciplinar de asma grave (UMAG). \n- Identificar procesos estrat\u00e9gicos clave y de apoyo para aumentar la calidad del servicio de la UMAG.\nMEJORAS ESPERADAS\n\u2022 Aumentar de forma transversal la calidad asistencial de los procesos: obtener mejoras en comunicaci\u00f3n, innovaci\u00f3n, \nvisibilidad, creaci\u00f3n de equipo y trabajo de forma multidisciplinar real que repercutan en los pacientes.  \n\u2022 Simplificar y estandarizar procesos: detectar y eliminar duplicidades.\nDISE\u00d1O CIRCUITO Y ETAPAS\nProyecto realizado en 3 sesiones de trabajo de 3 h cada una entre septiembre-noviembre 2021 en un hospital de tercer \nnivel\ufffd \nSe cre\u00f3 un grupo de trabajo con la implicaci\u00f3n activa de profesionales de los diferentes Servicios de la UMAG \n(Alergolog\u00eda, Farmacia Hospitalaria, Neumolog\u00eda, Otorrinolaringolog\u00eda, Pediatr\u00eda).  \nLas sesiones fueron conducidas por una empresa externa con amplia experiencia en metodolog\u00eda Lean. Se establecieron \nelementos y criterios de organizaci\u00f3n y oportunidades de mejora.  \nSe utilizaron las siguientes herramientas:  \n\u2022 Encuesta personal a todos los profesionales del grupo de trabajo para dise\u00f1ar la geograf\u00eda de la unidad basada en el \nliderazgo cognitivo.  \n\u2022 Mapa de flujo de valor: analiza el viaje del paciente con asma grave y todas las acciones que se realizan en la UMAG, \nnecesarias e innecesarias\ufffd 556Se realizaron las siguientes fases:  \n1. Dise\u00f1o de la geograf\u00eda de la unidad.  \n2. Identificaci\u00f3n y entendimiento: Se dise\u00f1\u00f3 un mapa de flujo de valor. Se incluy\u00f3 la intervenci\u00f3n de los profesionales, \npruebas solicitadas, aspectos relacionados con la medicaci\u00f3n y flujo de informaci\u00f3n. Se identificaron procesos clave. \n3. An\u00e1lisis y mejora de los procesos: Se dise\u00f1\u00f3 el circuito ideal del paciente y se detectaron duplicidades y retrasos en \nalgunos procesos asistenciales. Se analizaron causas y se dise\u00f1\u00f3 un plan de acciones para ponerles soluci\u00f3n.  \n4\ufffd Difusi\u00f3n de los resultados a los profesionales para poder complementarlo con su visi\u00f3n\ufffd\nIMPLANTACI\u00d3N\nLas acciones seleccionadas se encuentran en fase de implantaci\u00f3n seg\u00fan un cronograma establecido. Se realizar\u00e1 un \nseguimiento anual de las mismas\ufffd\nRESULTADOS\nSe identificaron los siguientes procesos clave: proporcionar atenci\u00f3n integral al paciente de alta complejidad, al paciente \nmal controlado y/o no adherente, al paciente controlado y al paciente pedi\u00e1trico, transici\u00f3n entre paciente joven y \nadulto, aspectos relacionados con f\u00e1rmacos, investigaci\u00f3n y docencia.  \nSe detectaron 10 acciones de mejora: 1.Criterios de derivaci\u00f3n monogr\u00e1fica, 2.Estandarizaci\u00f3n de pruebas a la llegada del \npaciente a la UMAG, 3.Check list de actuaci\u00f3n, 4.Plantilla com\u00fan consensuada para el informe m\u00e9dico, 5.Integraci\u00f3n de la \ninformaci\u00f3n de Farmacia en la historia cl\u00ednica de la UMAG, 6.Creaci\u00f3n de una agenda com\u00fan de la UMAG, 7.Identificaci\u00f3n \nde la prestaci\u00f3n Asma Grave por Admisi\u00f3n, 8.Algoritmo de decisi\u00f3n terap\u00e9utica, 9.Estandarizaci\u00f3n del seguimiento de \nrespuesta al tratamiento y evaluaci\u00f3n de desescalada terap\u00e9utica y 10.Revisi\u00f3n y consenso de informaci\u00f3n entregada al \npaciente\ufffd\nLIMITACIONES\nLas soluciones encontradas responden a necesidades de la UMAG en el momento de realizaci\u00f3n de los talleres. No todas \nlas medidas son aplicables a corto plazo por insuficiencia de recursos.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nLos procesos clave y las acciones de mejora identificadas pueden servir a otras UMAG. Asimismo, muchas de las acciones \nplanteadas pueden utilizarse en el seno de otros grupos de trabajo multidisciplinares.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1164. ELABORACI\u00d3N DE MATERIAL AUDIOVISUAL PARA PACIENTES SOMETIDAS A TECNICAS DE \nREPRODUCCI\u00d3N ASISTIDA \nAUTORES\nCASARRUBIOS L\u00c1ZARO, GI; DE\u00c1N BARAHONA, C; MART\u00cdNEZ RU\u00cdZ, E; L\u00c1ZARO L\u00d3PEZ, A; P\u00c9REZ BARTOLOM\u00c9, A; \nGONZ\u00c1LEZ YELA, C; BENITO MEN\u00c9NDEZ, G; HORTA HERN\u00c1NDEZ, AM\nHOSPITAL UNIVERSITARIO DE GUADALAJARA. DONANTES DE SANGRE, S/N. GUADALAJARA. GUADALAJARA\nOBJETIVOS\nEn las t\u00e9cnicas de reproducci\u00f3n asistida (TRA) se utilizan combinaciones de f\u00e1rmacos para la estimulaci\u00f3n folicular \ncontrolada y posterior ovulaci\u00f3n. La variabilidad en el tipo de f\u00e1rmacos, la posolog\u00eda y la autoadministraci\u00f3n en domicilio, \nunido a la carga emocional, hacen que estas TRA sean complejas para las pacientes.  \nDesde 1/9/2005 en esta comunidad los medicamentos para TRA se dispensan en los Servicios de Farmacia Hospitalaria \n(SFH).  \nObjetivos: \n- Averiguar el conocimiento previo de las pacientes antes de acudir al SFH.  \n- Elaborar material audiovisual (MA) espec\u00edfico de TRA.  \n- Conocer la utilidad del MA generado.\nMEJORAS ESPERADAS\n- Facilitar la comprensi\u00f3n del tratamiento: posolog\u00eda, f\u00e1rmacos, conservaci\u00f3n, v\u00eda de administraci\u00f3n.  \n- Mejorar la administraci\u00f3n.  \n- Reducir errores de medicaci\u00f3n asociados a la administraci\u00f3n.  \n- Obtener MA de todos los f\u00e1rmacos de TRA. \n- Disminuir las consultas telef\u00f3nicas/presenciales por dudas relacionadas con TRA. \n- Mejorar la Atenci\u00f3n Farmac\u00e9utica (AF) a pacientes de TRA.\nDISE\u00d1O CIRCUITO Y ETAPAS\nTodas las pacientes en TRA recib\u00edan informaci\u00f3n oral y escrita del tratamiento en el SFH. Para apoyar esta informaci\u00f3n, se \ndecidi\u00f3 elaborar MA explicando el manejo y la administraci\u00f3n de cada f\u00e1rmaco. El MA fue editado por el Departamento \nde Comunicaci\u00f3n del Hospital (DCH). El Servicio de Ginecolog\u00eda valid\u00f3 el MA.  \nEtapas: \n1. Identificar el problema: necesidad de proporcionar informaci\u00f3n complementaria.  \n2\ufffd Obtener recursos materiales\ufffd \n3. Planificar/dise\u00f1ar contenido del MA.  \n4\ufffd Elaborar MA \ufffd \n5. Validar contenido por S\u00ba Ginecolog\u00eda.  5576. Editar contenido gr\u00e1fico por DCH.  \n7. Subir MA generado al canal de Youtube del hospital y obtener link divulgativo.  \n8. Difundir MA a cada paciente que inicia TRA en la consulta de AF. \n9. Realizar encuestas telem\u00e1ticas para averiguar el conocimiento previo de las pacientes antes de acudir al SFH y el grado \nde satisfacci\u00f3n con el MA.\nIMPLANTACI\u00d3N\nEl MA se elabor\u00f3 en enero-2022. El link del MA y la encuesta telem\u00e1tica se enviaron por correo electr\u00f3nico a las pacientes \natendidas en el SFH por inicio o cambio de TRA desde enero-2022 hasta la actualidad.\nRESULTADOS\nSe elaboraron 6 v\u00eddeos, cada uno correspondiente a un f\u00e1rmaco: an\u00e1logo hormona liberadora de las gonadotropinas \n(GnRH), antagonista GnRH, hormona fol\u00edculo estimulante (FSH) recombinante, FSH urinaria con disolvente en ampolla, \nFSH urinaria con disolvente en jeringa, gonadotropina cori\u00f3nica humana (HCG). \nDesde su elaboraci\u00f3n, el MA se ha entregado a 59 pacientes. 34% respondieron la encuesta, mediana de edad 34 a\u00f1os \n(RIC31-37). 85% utilizaban el espa\u00f1ol como idioma habitual, 90% utilizaban internet para resolver dudas m\u00e9dicas, 75% \nno estaban familiarizadas con la v\u00eda subcut\u00e1nea, 65% no dispon\u00eda de informaci\u00f3n relacionada con el tratamiento antes de \nacudir al SFH\ufffd 90% se autoadministraron la medicaci\u00f3n\ufffd  \nTodas visualizaron el MA: 40% alg\u00fan v\u00eddeo; 60% todos. 100% consideraron de utilidad los v\u00eddeos proporcionados.\nLIMITACIONES\n- MA identificado por principio activo, esto puede ser una dificultad a\u00f1adida para las pacientes. \n- La encuesta no es obligatoria, por lo que las pacientes se pueden olvidar hacerla.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste modelo es aplicable a otros SFH. Gracias al MA elaborado, las pacientes tienen un mejor conocimiento del \ntratamiento, incluso aquellas en las que hab\u00eda una barrera idiom\u00e1tica.559COMUNICACIONES DE T\u00c9CNICOS\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n458. RELACI\u00d3N ENTRE MEDICACI\u00d3N TRITURADA Y DISFAGIA EN UN CENTRO DE ESTANCIAS TEMPORALES \nAUTORES\nJURADO FIOL, C; CANSINO PIC\u00d3N, C; YBEAS ZAMORA, X; MENA CARMONA, D\nSERVEIS RESIDENCIALS D\u2019ESTADES TEMPORALS I RESPIR\nOBJETIVOS\nConocer las necesidades de medicaci\u00f3n triturada de las personas usuarias y su relaci\u00f3n con el diagn\u00f3stico de disfagia en \nun centro residencial de estancias temporales de personas dependientes para el descanso del cuidador principal (Serveis \nResidencials d\u2019Estades Temporals i RESPIR, Diputaci\u00f3 de Barcelona).\nMATERIALES Y M\u00c9TODOS\nEn nuestro centro, el diagn\u00f3stico de disfagia se realiza mediante la valoraci\u00f3n y realizaci\u00f3n del cuestionario \u201cEating \nassesment tool-10 (EAT-10)\u201d y para clasificarla se utiliza el \u201cM\u00e9todo de exploraci\u00f3n cl\u00ednica volumen viscosidad (MECVV)\u201d \npor el servicio de logopedia previa consulta por parte de enfermer\u00eda, lo cual queda registrado en el sistema inform\u00e1tico. \nLa necesidad de medicaci\u00f3n triturada se solicita a farmacia por parte de enfermer\u00eda o por el equipo m\u00e9dico.  \nPara conocer la prevalencia y el subtipo de disfagia se extraer\u00e1 la informaci\u00f3n de las personas usuarias ingresados \ndurante el a\u00f1o 2019 de la base de datos del centro. Para conocer la necesidad y la cantidad de medicaci\u00f3n triturada se \nexplotar\u00e1n los datos de los listados de preparaci\u00f3n de triturados del citado a\u00f1o.\nRESULTADOS\nEn el a\u00f1o 2019 se realizaron 2.047 ingresos en el centro correspondiendo a 1.387 personas \u00fanicas (\u22481,5 ingresos/\npersona). El 70% de los ingresos fue de g\u00e9nero femenino y la media de edad fue de 88,3 a\u00f1os.  \nPresentaron disfagia 367 personas (26,5%), con una edad media de 90 a\u00f1os y un porcentaje de mujeres de 65,4%. De \nestos, presentaron disfagia a l\u00edquidos 276 personas (75,2%), 10 personas a s\u00f3lidos (2,7%) y 81 a ambos (22,1%).  \nEn todo el periodo descrito se tritur\u00f3 la medicaci\u00f3n a 394 personas con un total de 96.844 formas farmac\u00e9uticas \ntrituradas en el periodo de un a\u00f1o. Esto representa una media de 265 formas farmac\u00e9uticas diarias.  \nDe las personas usuarias a las que se tritur\u00f3 la medicaci\u00f3n, el 44,7% fue por disfagia y el resto fue por otros motivos. El \n52% de las personas con disfagia no necesit\u00f3 medicaci\u00f3n triturada\ufffd\nCONCLUSIONES\nDe las personas del centro en 2019, El 26,4% de la poblaci\u00f3n present\u00f3 diagn\u00f3stico de disfagia, lo que conlleva, entre otras \ncosas, una dificultad a la hora de la administraci\u00f3n de la medicaci\u00f3n.  \nSe tritur\u00f3 la medicaci\u00f3n al 28,4% de las personas ingresadas, de las cuales el 55,3% no tuvieron diagn\u00f3stico de disfagia.  \nLa trituraci\u00f3n de la medicaci\u00f3n centralizada por parte de los t\u00e9cnicos de farmacia es una tarea fundamental que conlleva \nuna mejora en la atenci\u00f3n a la persona usuaria y en los circuitos asistenciales del centro. En futuras fases del proyecto, se \nprev\u00e9 realizar un estudio con un dise\u00f1o experimental para conocer el ahorro en la carga de trabajo de enfermer\u00eda. Esto \nser\u00eda gracias a la trituraci\u00f3n de la medicaci\u00f3n de una manera centralizada en el servicio de farmacia hospitalaria por los \nt\u00e9cnicos.\nCLASIFICACI\u00d3N: CRONICIDAD Y CONTINUIDAD ASISTENCIAL\n847. TRATAMIENTO FARMACOL\u00d3GICO DE LOS PACIENTES CON ENFERMEDAD DE ALZHEIMER EN \nCATALU\u00d1A DURANTE EL PER\u00cdODO DE LA PANDEMIA DE COVID-19 \nAUTORES\nUMBRIA VIVANCOS, M; EXP\u00d3SITO LOSADA, J\u00c1; OBACH CORTADELLAS, M; PRAT CASANOVAS, A; PONTES GARC\u00cdA, C; \nVALLANO FERRAZ, A\nSERVEI CATAL\u00c0 DE LA SALUT\nOBJETIVOS\nDescribir la evoluci\u00f3n del tratamiento espec\u00edfico antidemencia de los pacientes con Enfermedad de Alzheimer (EA) en \nCatalu\u00f1a en el per\u00edodo de la pandemia de COVID-19.\nMATERIALES Y M\u00c9TODOS\nEstudio longitudinal prospectivo. La poblaci\u00f3n del estudio fueron todos pacientes tratados con medicamentos espec\u00edficos \npara la EA en Catalu\u00f1a en un per\u00edodo de tres a\u00f1os (2019 a 2021). La fuente de datos fue el Registro de Pacientes \nTratados con Enfermedad de Alzheimer, y el Fichero de Reembolso Farmac\u00e9utico del Servicio Catal\u00e1n de la Salud, y \nlos datos poblacionales del Instituto de Estad\u00edstica de Catalu\u00f1a (Idescat). Se recogieron datos sobre las caracter\u00edsticas \ndemogr\u00e1ficas y la mortalidad de los pacientes, el inicio del tratamiento, continuaci\u00f3n e interrupci\u00f3n del tratamiento de \nlos medicamentos antidemencia, y el gasto total de estos medicamentos.560RESULTADOS\nEn el per\u00edodo de estudio 51.350 pacientes (67% mujeres) recibieron un tratamiento para la EA en 2019, 47.608 pacientes \n(67% mujeres) en 2020, y 49.242 pacientes (67% mujeres) en 2021. Se estim\u00f3 una prevalencia de tratamiento de \n673,9/100\ufffd000 en 2019, de 616,5/100\ufffd000 en 2020, y de 636,2/100\ufffd000 en 2021\ufffd La proporci\u00f3n de pacientes tratados \naument\u00f3 con la edad, siendo el 77% mayores de 74 a\u00f1os en 2019, 77% en 2020 y 76% en 2021\ufffd  \nIniciaron un tratamiento 9.040 pacientes (17,6% del total anual) en 2019, 6.692 pacientes (14%) en 2020, y 9.756 \npacientes (19,8%) en 2021. Se interrumpi\u00f3 el tratamiento en 7.878 pacientes (15% del total) en 2019, 10.652 pacientes \n(22% del total) en 2020, y 8.202 pacientes (17% del total) en 2021. El motivo de la interrupci\u00f3n fue la defunci\u00f3n en 2.674 \npacientes (34% de las interrupciones) en 2019, 6.587 pacientes (62$ de las interrupciones) en 2020 y 4.568 pacientes \n(56% de las interrupciones) en 2021.  \nLos pacientes fueron tratados con f\u00e1rmacos inhibidores de la enzima acetilcolinesterasa, principalmente como \nmonoterapia (88% en 2019, 89% en 2020, y 90% en 2021). El donepezilo fue el f\u00e1rmaco m\u00e1s utilizado en 2019 (41%), \n2020 (42%) y 2021 (44%). El gasto de medicamentos espec\u00edficos de la EA fue de 34 millones de euros en 2019 (2,1% del \npresupuesto global de medicamentos con recepta), 32,4 millones de euros en 2020 (2%), y 32,3 millones de euros en \n2021 (1,9%).\nCONCLUSIONES\nDurante la pandemia por COVID-19 se ha observado una disminuci\u00f3n de tratamientos con f\u00e1rmacos antidemencia y \nun mayor n\u00famero de interrupciones del tratamiento con estos medicamentos como consecuencia del aumento de la \nmortalidad de los pacientes tratados. Aunque la efectividad de los medicamentos de la demencia es incierta, todav\u00eda \nrepresenta un gasto relevante dentro del presupuesto general\ufffd Un seguimiento del uso y de los resultados de salud en \nla poblaci\u00f3n con EA tratada puede ayudar a reevaluar el lugar en la priorizaci\u00f3n de estos tratamientos y del gasto que \ngeneran\ufffd\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\nCLASIFICACI\u00d3N: CUIDADOS CR\u00cdTICOS Y URGENCIAS\n84. ESTUDIO DE LA COMPATIBILIDAD F\u00cdSICA DE F\u00c1RMACOS ADMINISTRADOS EN Y EN UNA UNIDAD DE \nPACIENTES CR\u00cdTICOS ADULTOS. \nAUTORES\nBERTROL\u00cd BERGAD\u00c0, N; DOM\u00c9NECH MORAL, L; JIM\u00c9NEZ LOZANO, I\nH. UNIVERSITARI GENERAL DE LA VALL D\u2019HEBRON. PASSEIG VALL D\u2019HEBRON 119-129 BARCELONA. BARCELONA\nOBJETIVOS\nLa incompatibilidad entre dos f\u00e1rmacos ocurre cuando se producen entre ellos reacciones f\u00edsicas y/o qu\u00edmicas que \npueden afectar a la seguridad y/o efectividad en la terapia. Dicha incompatibilidad provoca una parte de los errores de \nadministraci\u00f3n de f\u00e1rmacos por v\u00eda IV.  \nEl objetivo del presente trabajo fue determinar las compatibilidades en Y de las preparaciones de f\u00e1rmacos \nhabitualmente utilizadas en una Unidad de Cuidados Cr\u00edticos Adultos de un Hospital Terciario y su posterior difusi\u00f3n en \nuna tabla para su uso en la pr\u00e1ctica diaria\nMATERIALES Y M\u00c9TODOS\nEn una primera fase se recogieron los principales f\u00e1rmacos utilizados en la Unidad, sus concentraciones y diluyentes \nestablecidos. Se realiz\u00f3 una b\u00fasqueda de datos de compatibilidad en Y para cada par de f\u00e1rmacos en Micromedex\u00ae. \nSe aceptaron los resultados de los estudios en los que la concentraci\u00f3n y disolvente ensayados coincidieron con los de \nnuestra Unidad \u00f3 \u00e9sta estaba dentro de un intervalo ensayado. Se consideraron resultados \u201cno recomendables\u201d aquellos \ncuyos datos proven\u00edan de ensayos con concentraciones y/o disolventes diferentes. \nA continuaci\u00f3n, con los resultados anteriores, se evalu\u00f3 la compatibilidad f\u00edsica de diferentes mezclas no ensayadas en \nla literatura mediante control visual por dos personas (fondo blanco y oscuro), turbidimetr\u00eda (nefel\u00f3metro HI 98713, \nHanna Instruments) y pH (pH\u00edmetro Testo 206 pH3) a distintos tiempos (t0, t60, t180 i t24 h) para las siguientes mezclas. \nSe estudiaron: Lidoca\u00edna-Ketamina (L-K), Ketamina-Dexmedetomidina (K-D), y Lidoca\u00edna-Dexmedetomidina (L-D) y \nNoradrenalina-Vasopresisna (N-V). Se consider\u00f3 incompatible la aparici\u00f3n de turbidez, part\u00edculas visibles, formaci\u00f3n de \ngas o cambio de color; un aumento de 0,5 unidades de turbidez nefelom\u00e9trica (UTN) y/o una variaci\u00f3n de pH superior a 1 \nunidad respecto a los f\u00e1rmacos por separado y el control basal de la mezcla.\nRESULTADOS\nSe incluyeron un total de 28 f\u00e1rmacos y se revisaron 378 combinaciones posibles.  \nSe encontraron 124 (38,1%) combinaciones no estudiadas y 173 (45,8%) combinaciones no recomendadas, de \u00e9stas 162 \n(42,72%) por un cambio en la concentraci\u00f3n y 11 (2,91%) en el diluyente; 38 combinaciones resultaron compatibles y 43 \nno compatibles.  \nEn cuanto a las combinaciones analizadas de L-K, K-D, L-D y N-V, no hubo variaciones relevantes significativas en los \nvalores de turbidez y pH a lo largo de las 24 h del ensayo para las cuatro combinaciones de f\u00e1rmacos estudiadas.  \nTras elaborar la tabla se consider\u00f3 que furosemida, heparina s\u00f3dica, insulina, pantoprazol y las aminas vasoactivas deb\u00edan \nadministrarse por luz \u00fanica como norma general para evitar incompatibilidades y otros problemas relacionados con la \nmedicaci\u00f3n\ufffd561CONCLUSIONES\nSe requieren estudios de compatibilidad para la mayor\u00eda de los f\u00e1rmacos a las concentraciones utilizadas en la pr\u00e1ctica \ncl\u00ednica.  \nLas cuatro combinaciones ensayadas son f\u00edsicamente compatibles, pero su estabilidad qu\u00edmica deber\u00eda ser estudiada \nmediante otros m\u00e9todos.  \nLa tabla de compatibilidad es una herramienta muy \u00fatil para el personal de enfermer\u00eda especialmente en los casos en que \nse tiene que actuar con urgencia.\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\nCLASIFICACI\u00d3N: ENSAYOS CL\u00cdNICOS\n451. FORMULARIO DE REGISTRO DE RETORNO A PROMOTOR DE MEDICACI\u00d3N DE ENSAYO CL\u00cdNICO \nAUTORES\nGARCIA DEU, G; RODRIGUEZ ROJAS, J; FARR\u00c9 CABRERIZO, N; BAD\u00c0S MORENO, M; LOZANO ANDREU, T; GONZALEZ \nLAGUNA, M; MIQUEL ZURITA, ME; PERAYRE BADIA, M\nICO L\u2019HOSPITALET . AVDA. GRAN VIA, 2032,7 HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nOBJETIVOS\nEl proceso de retorno a promotor (RP) de medicaci\u00f3n de Ensayo Cl\u00ednico (EC) en la Unidad de EC (UEC) del Servicio de \nfarmacia (SF) requiere una serie de pasos previos antes de la recogida del env\u00edo de medicaci\u00f3n.  \nLa gran cantidad de EC abiertos en el centro y la creciente cantidad de devoluciones, hacen primordial un registro de \ncontrol de todas las salidas de medicaci\u00f3n de la unidad de EC del SF \ufffd \nEste control hace posible conocer r\u00e1pidamente algunas de las caracter\u00edsticas generales del env\u00edo como es la ubicaci\u00f3n y si \nel paquete sigue o no en el centro.\nMEJORAS ESPERADAS\nPoder localizar en todo momento donde est\u00e1 ubicada la medicaci\u00f3n a devolver (dependiendo de sus condiciones \nde almacenamiento), destino de la caja, fecha de recogida e identificaci\u00f3n de la empresa transportista, evitando as\u00ed \ncualquier p\u00e9rdida una vez sale del SF evitando errores entre EC.\nDISE\u00d1O CIRCUITO Y ETAPAS\nSe dise\u00f1a un formulario de registro de RP (FRRP) donde se recogen todos los datos caracter\u00edsticos del env\u00edo, y unas \netiquetas identificativas con un ID que enlazan la caja de RP con su correspondiente certificado de RP (CRP) y con el FRRP . \nCampos del FRRP:  \nDatos a rellenar el d\u00eda de la preparaci\u00f3n: Id cajas, cantidad de cajas, c\u00f3digo de EC, fecha de preparaci\u00f3n, identificaci\u00f3n de \nquien prepara la caja (nombre, apellidos y firma), destino, ubicaci\u00f3n (temperatura ambiente, nevera o congelador)  \nDatos a rellenar el d\u00eda de la recogida: fecha de recogida, mensajero que recoge la caja (nombre, apellidos, n\u00ba trabajador y \nfirma), empresa de transporte. \nObservaciones/Incidencias\ufffd  \nEn el proceso de RP se realizan las siguientes etapas: solicitud de retorno/devoluci\u00f3n de medicaci\u00f3n, autorizaci\u00f3n por \nparte del promotor/monitor, retirada de la medicaci\u00f3n del stock del programa de gesti\u00f3n de la UEC, generaci\u00f3n del \nCRP , comprobaci\u00f3n que la medicaci\u00f3n retirada coincide con CRP , preparaci\u00f3n de la caja con la medicaci\u00f3n a devolver, \nidentificaci\u00f3n de la caja con la etiqueta Id, cumplimentaci\u00f3n de los campos de preparaci\u00f3n del FRRP el d\u00eda de la \nrealizaci\u00f3n, cumplimentaci\u00f3n de los campos de recogida del FRRP el d\u00eda que el transportista se lleva la caja.\nIMPLANTACI\u00d3N\nA finales de 2019 se realiz\u00f3 un an\u00e1lisis conjunto por parte del equipo de EC para dise\u00f1ar un registro de control y \nseguimiento de los env\u00edos de medicaci\u00f3n con RP que, finalmente, se implement\u00f3 en enero de 2020.\nRESULTADOS\nEn 2020 se registraron un total de 65 env\u00edos de medicaci\u00f3n con RP . En 2021 se realizaron 99 env\u00edos y durante el primer \ncuatrimestre de 2022 se registraron 30\ufffd  \nEl crecimiento anual de los env\u00edos con RP hace necesaria la aplicaci\u00f3n de un sistema de control que permita conocer el \nestado de las salidas de medicaci\u00f3n del SF, para as\u00ed evitar errores, agilizar el proceso de RP y mejorar tanto la trazabilidad \ndel env\u00edo como el traspaso de informaci\u00f3n entre miembros del equipo.\nLIMITACIONES\nPosibles errores derivados del registro manual\ufffd\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEste control puede ser aplicable a cualquier \u00e1rea de la farmacia cumplimentando una tabla para documentar cualquier \nsalida del SF y tener constancia de la trazabilidad del proceso.562CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n94. IMPORTANCIA DEL T\u00c9CNICO DE FARMACIA EN EL CIRCUITO DE VALIDACI\u00d3N DE NUTRICI\u00d3N \nPARENTERAL: CONTROL DE CALIDAD GRAVIM\u00c9TRICO. \nAUTORES\nS\u00c1NCHEZ-OCA\u00d1A MART\u00cdN, N; CISNEROS DE LA IGLESIA, L; APARICIO CARMENA, A; ESTEBAN AGUADO, L; ESTRELLA \nMIRA, M; LORIGA LOSADA, R; ALB\u00c1S TRICAS, M; MART\u00cdNEZ SESMERO, JM\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nLa nutrici\u00f3n parenteral (NP) se considera una preparaci\u00f3n de alto riesgo ya que se combinan en su elaboraci\u00f3n hasta 40 \ncomponentes distintos. La elaboraci\u00f3n manual, adem\u00e1s, entra\u00f1a riesgos relacionados con el proceso como p\u00e9rdida de \nesterilidad, generaci\u00f3n de precipitados de fosfato c\u00e1lcico, aditivaci\u00f3n err\u00f3nea de los vol\u00famenes de componentes, etc.  \n \nPor ello, deben realizarse controles de calidad tales como inspecci\u00f3n visual, determinaci\u00f3n microbiol\u00f3gica, anal\u00edtica y \ngravim\u00e9trica sobre el producto terminado con el fin de asegurar la calidad y seguridad.  \n \nEl objetivo de esta comunicaci\u00f3n es destacar la importancia del equipo t\u00e9cnico en un servicio farmacia, en cuanto al \nproceso de validaci\u00f3n de NP en un hospital de tercer nivel, determinando cu\u00e1ntas tuvieron que ser repetidas tras no \npasar el control de calidad gravim\u00e9trico en el per\u00edodo de un a\u00f1o.\nMATERIALES Y M\u00c9TODOS\nSe llev\u00f3 a cabo una b\u00fasqueda del total de NP que se hab\u00edan elaborado en el per\u00edodo de abril de 2021 a abril de 2022 \ntanto para pacientes adultos como para pedi\u00e1tricos o neonatos en la aplicaci\u00f3n inform\u00e1tica cl\u00ednica para la elaboraci\u00f3n de \nNP Kabisoft\u00ae.  \nDel total de NP , se eliminaron aquellas que son presentaciones comerciales tricamerales \u201cready to use\u201d, que no son \nobjeto del control de calidad gravim\u00e9trico.  \nSe estableci\u00f3 un margen de error para la pesada en el control gravim\u00e9trico de \u00b15% en el caso de NP para pacientes \nadultos y del \u00b13% para pacientes pedi\u00e1tricos o neonatos en base a la bibliograf\u00eda consultada.  \nEl equipo t\u00e9cnico de farmacia, llev\u00f3 a cabo la pesada de todas las NP individualizadas, en balanza electr\u00f3nica de precisi\u00f3n \ncon sensibilidad de 1g y capacidad de pesado desde 100 g hasta 4.000g, previa tara con la bolsa vac\u00eda correspondiente. \nPosteriormente, registraron los datos correspondientes al peso te\u00f3rico y al peso real en una hoja Excel para su validaci\u00f3n \n(mediante la f\u00f3rmula: peso real-peso te\u00f3rico/peso te\u00f3rico*100), y en el caso de que alguna NP quedara fuera de los \nm\u00e1rgenes de error, lo notificaban al farmac\u00e9utico correspondiente.  \nSi la NP deb\u00eda repetirse, quedaba constancia en la hoja Excel y se proced\u00eda a repetir el control de calidad en la misma.\nRESULTADOS\nDe abril de 2021 a abril de 2022 se elaboraron 6\ufffd637 NP , de las cuales 5\ufffd482 fueron para pacientes adultos y 1\ufffd155 para \npacientes pedi\u00e1tricos.  \nDe las de adulto, se eliminaron 520 presentaciones comerciales tricamerales de NP que no eran objeto del control de \ncalidad\ufffd  \nPor tanto, el n\u00famero total de NP pesadas para el control gravim\u00e9trico fue de 6.117 (4.962 de adultos y 1.155 de \npedi\u00e1tricos)  \nDe las mismas, hubo que repetir por no cumplir el margen de error, 19 correspondientes a pacientes adultos (0,38%) y 0 a \npacientes pedi\u00e1tricos o neonatos (0%).\nCONCLUSIONES\nLa labor del equipo t\u00e9cnico en farmacia y su participaci\u00f3n en los circuitos de calidad, es de vital importancia para \ngarantizar la seguridad en la preparaci\u00f3n de mezclas intravenosas.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n162. DISPENSACI\u00d3N SEGURA Y TRAZABILIDAD ELECTR\u00d3NICA DE F\u00d3RMULAS MAGISTRALES A PACIENTES \nEXTERNOS EN UN HOSPITAL \nAUTORES\nALBAS TRICAS, M; CISNEROS DE LA IGLESIA, L; LORIGA LOSADA, R; PUEBLA GARCIA, V; TALLON MARTINEZ, JC; \nCORAZON VILLANUEVA, J; MOLINA MU\u00d1OZ, P\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nCreaci\u00f3n de un circuito de dispensaci\u00f3n segura de f\u00f3rmulas magistrales que incluya un registro electr\u00f3nico de trazabilidad \nde lote y caducidad para pacientes externos en un hospital de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nSe emplea el m\u00f3dulo de Mezclas de la aplicaci\u00f3n inform\u00e1tica Farmatools para registrar todas aquellas f\u00f3rmulas \nmagistrales (FM) que vayan a ser elaboradas en el \u00e1rea de Farmacotecnia del Servicio de Farmacia. Cada FM que vaya a 563ser elaborada contar\u00e1 con los siguientes datos, que quedar\u00e1n debidamente registrados en la aplicaci\u00f3n:  \nN\u00ba de Registro: corresponde con el n\u00ba de albar\u00e1n que otorga el programa al generar la mezcla.  \nLote: se asignar\u00e1n los n\u00fameros del d\u00eda en curso, seguidos del mes y el a\u00f1o (Formato XXMMYYYY)  \nCaducidad: se introducir\u00e1 la fecha correspondiente a cada f\u00f3rmula.  \nDesde el m\u00f3dulo de Gesti\u00f3n Econ\u00f3mica, se imprimir\u00e1n etiquetas identificativas capaces de ser reconocidas de forma \ninequ\u00edvoca por los dispositivos de dispensaci\u00f3n segura (pistolas de dispensaci\u00f3n).  \nLa dispensaci\u00f3n se realiza desde el m\u00f3dulo de Pacientes Externos. Para cada dispensaci\u00f3n, adem\u00e1s, se debe indicar el lote \ny la caducidad de cada FM dispensada, quedando un registro electr\u00f3nico de la trazabilidad.\nRESULTADOS\nDurante el a\u00f1o 2021 se han realizado 6164 dispensaciones de 59 FM diferentes para un total de 1223 pacientes. \nUn 68% de las dispensaciones (4191) han sido FM oftalmol\u00f3gicas, destacando el colirio de insulina de 1 U/mL, con un \n9,1% (561) del total de dispensaciones, y el colirio de insulina de 5 U/mL, con un 9.34% (576) del total de dispensaciones.  \nDe las FM orales, destacan las c\u00e1psulas de tolvapt\u00e1n de 3.75 mg, 7.5 mg y 15 mg, que en conjunto suponen un 10.71% \n(660) de las dispensaciones.  \nGracias al sistema de dispensaci\u00f3n segura no se han producido errores de dispensaci\u00f3n, y en todas las dispensaciones ha \nquedado registrada de forma electr\u00f3nica la trazabilidad de lote y caducidad de cada FM dispensada.\nCONCLUSIONES\nEl elevado n\u00famero de dispensaciones de FM junto con los requerimientos legales de trazabilidad requeridos en su \ndispensaci\u00f3n, hacen imprescindible la creaci\u00f3n de un circuito informatizado de dispensaci\u00f3n y trazabilidad, que permita \nreducir al m\u00ednimo los errores de dispensaci\u00f3n, pues la elaboraci\u00f3n de una FM es siempre individuada.  \nNuestro circuito de dispensaci\u00f3n permite tener un acceso inmediato a toda la informaci\u00f3n: fecha de dispensaci\u00f3n, \nt\u00e9cnico de farmacia que la ha realizado, previsi\u00f3n de vuelta del paciente y lote y caducidad de la FM dispensada.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n252. DISE\u00d1O E IMPLEMENTACI\u00d3N DE UN PLAN DE FORMACI\u00d3N PARA ESTUDIANTES DE T\u00c9CNICO DE \nGRADO SUPERIOR EN EL \u00c1REA DE PREPARACI\u00d3N \nAUTORES\nREY VECINO, P; MART\u00cdNEZ PUJOL, G; RODRIGUEZ JIMENEZ, M; CASANOVAS NAVARRO, M; GONZALEZ MORAGA, M; \nROMERO CHOMBA, VA; PELEGRIN CRUZ, R; JUANES BORREGO, E\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nDise\u00f1ar e implementar un plan de formaci\u00f3n te\u00f3rico-pr\u00e1ctico de elaboraci\u00f3n de medicamentos para estudiantes de \nt\u00e9cnico de grado superior, que realizan la asignatura de pr\u00e1cticas en el servicio de farmacia hospitalaria.\nMEJORAS ESPERADAS\nAdquisici\u00f3n de un mayor grado de conocimientos te\u00f3ricos sobre la normativa vigente y su aplicaci\u00f3n.  \nCapacitaci\u00f3n de los estudiantes para la elaboraci\u00f3n de medicamentos en servicios de farmacia hospitalaria.\nDISE\u00d1O CIRCUITO Y ETAPAS\nDise\u00f1o:  \n1. Se form\u00f3 un equipo docente compuesto por el supervisor t\u00e9cnico, farmac\u00e9uticos del \u00e1rea y liderado, por t\u00e9cnicos \nsuperiores de farmacia\ufffd  \n2. Se dise\u00f1\u00f3 un programa adaptado al n\u00famero de horas lectivas, estableciendo un periodo m\u00ednimo de una semana de \nformaci\u00f3n te\u00f3rica y tres de pr\u00e1cticas. \nComo refuerzo de las actividades realizadas, se crearon cuestionarios de evaluaci\u00f3n.  \n3. Se redact\u00f3 una encuesta de motivaci\u00f3n personal y satisfacci\u00f3n, para valorar el paso del alumno por la secci\u00f3n.  \n \nCircuito y Etapas: \nPARTE TE\u00d3RICA \n1. Formaci\u00f3n inicial sobre el trabajo realizado en un \u00e1rea de preparaci\u00f3n.  \n2. Lectura de procedimientos normalizados de trabajo (PNTs)  \n- Higiene del personal  \n- Lavado higi\u00e9nico de manos  \n- Colocaci\u00f3n de guantes est\u00e9riles \n- Limpieza y desinfecci\u00f3n de las cabinas de preparaci\u00f3n de productos est\u00e9riles  \n- Preparados est\u00e9riles peligrosos. Trabajo en cabina de seguridad biol\u00f3gica \n- Actuaci\u00f3n en derrames de medicamentos peligrosos  \n- Preparaci\u00f3n de nutriciones parenterales en adultos  \n- Elaboraci\u00f3n de preparados no est\u00e9riles  \n3. Realizaci\u00f3n de un cuestionario de evaluaci\u00f3n.  \nPARTE PR\u00c1CTICA \n1. Simulaci\u00f3n pr\u00e1ctica que consiste en la elaboraci\u00f3n de una forma l\u00edquida oral y un preparado en el \u00e1rea est\u00e9ril. Se \nevalu\u00f3 el cumplimiento de las normas de vestuario e higiene del personal, la capacidad de compresi\u00f3n de la gu\u00eda de \nelaboraci\u00f3n as\u00ed como la gesti\u00f3n de recursos disponibles y el resultado final de la preparaci\u00f3n.  5642. Rotaci\u00f3n adaptada al perfil del alumno seg\u00fan los resultados de la simulaci\u00f3n:  \n- Gesti\u00f3n y preparaci\u00f3n de medicamentos citost\u00e1ticos  \n- Nutrici\u00f3n parenteral y mezcla endovenosas  \n- Preparados no est\u00e9riles \n3. Encuesta de motivaci\u00f3n personal y satisfacci\u00f3n\nIMPLANTACI\u00d3N\nOctubre-Noviembre 2021 dise\u00f1o del plan de formaci\u00f3n. Diciembre 2021 implementaci\u00f3n en estudiantes\nRESULTADOS\nTres estudiantes realizaron el nuevo plan de formaci\u00f3n.  \nTodos terminaron las pr\u00e1cticas con evaluaci\u00f3n positiva en conocimientos te\u00f3ricos.  \nDos de ellos finalizaron la rotaci\u00f3n con alto grado de capacitaci\u00f3n para la preparaci\u00f3n de medicamentos \nLos datos recogidos en las encuestas han permitido una mejora continua del plan de formaci\u00f3n.\nLIMITACIONES\nEl bajo n\u00famero de personas que han realizado el plan formativo, debido a su reciente implementaci\u00f3n.\nAPLICABILIDAD A OTROS SERVICIOS DE FARMACIA\nEl plan de formaci\u00f3n puede ser aplicado en cualquier servicio de farmacia que sea receptor de estudiantes de grado \nsuperior \ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n467. DISE\u00d1O Y ELABORACI\u00d3N DE FLUCITOSINA 15,5% CREMA PARA EL TRATAMIENTO DE VULVOVAGINITIS. \nAUTORES\nL\u00d3PEZ MORALES, S; PINTO MART\u00cdNEZ, J; ROM\u00c1N MERCH\u00c1N, S; \u00c1LVARO ALONSO, EA; BARRUECO FERN\u00c1NDEZ, N; \nESCOBAR RODR\u00cdGUEZ, I\nHOSPITAL INFANTA LEONOR \ufffd GRAN V\u00cdA DEL ESTE, 80 MADRID \ufffd MADRID\nOBJETIVOS\nDescribir el proceso de elaboraci\u00f3n y mejora gal\u00e9nica de una crema de flucitosina 15,5% para el tratamiento t\u00f3pico de \nvulvovaginitis por Candida no-albicans.\nMATERIALES Y M\u00c9TODOS\nSe elabor\u00f3 una crema de flucitosina 15,5% (FM1) a partir de comprimidos de flucitosina 500mg (Ancotil\u00ae500mg), un \nhumectante (glicerina) y un veh\u00edculo W/O siguiendo el procedimiento normalizado de trabajo (PNT) del Servicio de \nFarmacia (SF) resultando en la rotura del signo de la emulsi\u00f3n y rechazo de la elaboraci\u00f3n.  \nAl suceder esto, se realizaron dos pruebas denomidas FM2 y FM3 para comprobar las posibles incompatibilidades de los \ncomponentes de la f\u00f3rmula:  \nSe mezcl\u00f3 \u2153 de la glicerina con la base W/O con \u00e9xito y posteriormente se a\u00f1adi\u00f3 1 comprimido de flucitosina sin \nobservar cambio en la emulsi\u00f3n (FM2). Por tanto, se volvi\u00f3 a elaborar la crema de flucitosina 15,5% pero con \u2153 de la \nglicerina utilizando las cantidades indicadas el PNT (FM3) Aun as\u00ed, se rompi\u00f3 el signo de emulsi\u00f3n de nuevo.  \nSe revisa el PNT de elaboraci\u00f3n y la bibliograf\u00eda en la que se basan y se realiza una nueva b\u00fasqueda bibliogr\u00e1fica de otra \nf\u00f3rmula de flucitosina v\u00eda vaginal, encontr\u00e1ndonos una formulaci\u00f3n que empleaba el K-Y\u00ae gel lubricante vaginal (FM4) .  \nTodas las f\u00f3rmulas se elaboraron seg\u00fan bibliograf\u00eda y siguiendo las Gu\u00edas de Buenas Pr\u00e1cticas de elaboraci\u00f3n (GBP) \nen CSB-I por la peligrosidad de la Flucitosina, teniendo en cuenta la matriz de riesgo de las preparaciones no est\u00e9riles \nquedando como resultado final el conjunto CCCACA para los 6 criterios.\nRESULTADOS\nFM1 fue una crema blanca, opaca, con separaci\u00f3n de fases W/O debido a la rotura del signo de la emulsi\u00f3n\ufffd  \nFM2 fue una crema blanca, opaca, con ausencia de grumos y cristales con aspecto homog\u00e9neo. \nFM3 inicialmente fue una crema blanca y opaca pero al integrar la flucitosina a la base se volvi\u00f3 a romper el signo de la \nemulsi\u00f3n\ufffd  \nFM4 fue un gel blanco cremoso, homog\u00e9neo, de consistencia densa y el\u00e1stica en el que no hab\u00eda presencia de cristales ni \ngrumos\ufffd Con este resultado, la preparaci\u00f3n pas\u00f3 el control de calidad y se procedi\u00f3 a la dispensaci\u00f3n al paciente\ufffd \nTras el an\u00e1lisis de los resultados y la revisi\u00f3n de la bibliograf\u00eda, se detect\u00f3 un cambio de marca de la base W/O con alguna \ndiferencia en su composici\u00f3n con respecto a las bases usadas anteriormente para las elaboraciones previas\ufffd  \nLa paciente fue tratada con la FM4 durante 21 d\u00edas con buena tolerancia, sin efectos adversos, con mejor\u00eda de la \nsintomatolog\u00eda cl\u00ednica.\nCONCLUSIONES\nNo se puede realizar un cambio de marca comercial de bases para cremas sin verificar la composici\u00f3n de \u00e9stas, porque \npueden resultar en una rotura de emulsi\u00f3n o cualquier otro efecto en la calidad del preparado.  \nGracias a los cambios y mejoras gal\u00e9nicas implementadas, se ha conseguido dar con una f\u00f3rmula magistral de \ncaracter\u00edsticas adecuadas y calidad necesarias para su aplicaci\u00f3n en nuestra paciente. Ello ha permitido tratar a la \npaciente con \u00e9xito y subsanar en resultado inicial no satisfactorio.565CLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n482. RELEVANCIA DE LA VALIDACI\u00d3N GAL\u00c9NICA DE F\u00d3RMULAS MAGISTRALES CON DISTINTOS \nPRINCIPIOS ACTIVOS DE PARTIDA \nAUTORES\nTRELLES CAMPA, A; P\u00c9REZ SU\u00c1REZ, A; GRAND\u00cdO LEIVAS, L; MART\u00cdNEZ L\u00d3PEZ, LM\nINSTITUTO OFTALMOLOGICO FERNANDEZ-VEGA. AVENIDA DTRES. FERNANDEZ VEGA 34 OVIEDO. ASTURIAS\nOBJETIVOS\nRealizar una validaci\u00f3n gal\u00e9nica con distintas presentaciones del principio activo utilizado para elaborar la f\u00f3rmula \nmagistral (FM) Povidona 0.3% - Tetraca\u00edna 0.25% colirio, para el tratamiento de la conjuntivitis v\u00edrica.\nMATERIALES Y M\u00c9TODOS\nSe elaboran dos lotes de cinco unidades cada uno de la f\u00f3rmula magistral de povidona 0.3% - tetraca\u00edna 0.25% colirio \ncon distintos principios activos de partida. En el primer lote (F1) se utiliza Povidona Yodada 10% soluci\u00f3n 50 mL de Kern \nPharma\u00ae como principio activo mientras que en el segundo lote (F2) se utiliza Betadine 10% soluci\u00f3n 50mL de Meda \nPharma\u00ae, el resto de componentes se mantienen iguales. Se realiz\u00f3 un estudio de un mes de duraci\u00f3n, desde el d\u00eda 0 al \nd\u00eda 28, en el que semanalmente se realiza una medici\u00f3n de pH, Osmolaridad (Osm), esterilidad, limpidez y revisi\u00f3n de \ncaracteres organol\u00e9pticos. Se realizaron fotograf\u00edas de las FM.\nRESULTADOS\nSe obtienen los siguientes resultados de media \u00b1 desviaci\u00f3n est\u00e1ndar en cuanto a pH y Osmolaridad: F1 pH: 5.25\u00b10.95, \nOsm 249\u00b12\ufffd45 versus F2 pH 4\ufffd6\u00b10\ufffd41, Osm 250\ufffd6\u00b11\ufffd96  \nSe observan diferencias entre las dos FM en cu\u00e1nto a pH y caracteres organol\u00e9pticos en el periodo de estudio. F1 \nexperimenta una variabilidad de pH del 32.7% y coeficiente de variaci\u00f3n de 14.93% al d\u00eda 21 mientras que F2 sufre \nuna disminuci\u00f3n del 0.8% con coeficiente de variaci\u00f3n de 5.88%. Al d\u00eda 28 se observa una diferencia de variabilidad \ny coeficiente de variaci\u00f3n de 33.5% - 15.35% para F1 versus 20.4% - 8.5% para F2. En cuanto a los caracteres \norganol\u00e9pticos, a partir del d\u00eda 14 para F1 se comienza a observar una degradaci\u00f3n del color, mientras que dicha \ndegradaci\u00f3n empieza a observarse en F2 a partir del d\u00eda 21. La Osmolaridad, limpidez y esterilidad se mantienen estables \nen todo el proceso de evaluaci\u00f3n para las dos f\u00f3rmulas\ufffd\nCONCLUSIONES\n- La elaboraci\u00f3n de las FM a partir de Betadine\u00ae o Povidona Yodada de Kern pharma\u00ae provoca una variaci\u00f3n en la \nestabilidad de la f\u00f3rmula reflejada en una variabilidad superior al 5% en el pH y una degradaci\u00f3n del color temprana.  \n- La validaci\u00f3n gal\u00e9nica de las f\u00f3rmulas magistrales permiten detectar diferencias de estabilidad de las mismas partiendo \nde distintos componentes. La modificaci\u00f3n de la presentaci\u00f3n del principio activo utilizado en la elaboraci\u00f3n de una \nFM implica la necesidad de realizar una validaci\u00f3n gal\u00e9nica para verificar si se mantienen o modifican los valores de \nestabilidad de la f\u00f3rmula\ufffd  \n- Son necesarios m\u00e1s estudios de estabilidad para poder establecer un per\u00edodo de validez de estas FM.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n490. VALIDACI\u00d3N GAL\u00c9NICA DE COLIRIO DE VANCOMICINA 50MG/ML EN CONGELADOR \nAUTORES\nTRELLES CAMPA, A; P\u00c9REZ SU\u00c1REZ, A; GRAND\u00cdO LEIVAS, L; MART\u00cdNEZ L\u00d3PEZ, LM\nINSTITUTO OFTALMOLOGICO FERNANDEZ-VEGA. AVENIDA DTRES. FERNANDEZ VEGA 34 OVIEDO. ASTURIAS\nOBJETIVOS\nRealizar la validaci\u00f3n gal\u00e9nica de la F\u00f3rmula Magistral de Vancomicina 50mg/ml colirio diluido en soluci\u00f3n salina \nbalanceada como excipiente, conservada en congelador durante un periodo de un mes, con el fin de determinar su \nestabilidad f\u00edsico-qu\u00edmica, para su uso en el tratamiento de queratitis y endoftalmitis bacterianas sensibles a este \nantibi\u00f3tico.\nMATERIALES Y M\u00c9TODOS\nSe elabora un lote de cinco colirios de Vancomicina 50 mg/ml colirio. Se utiliza como principio activo de partida \nVancomicina en polvo de Guinama\u00ae y se diluye con 20 ml de BSS\u00ae de Alcon Healthcare para obtener la concentraci\u00f3n \nindicada. Posteriormente se realiza doble filtraci\u00f3n esterilizante y se envasa en al\u00edcuotas de 4 ml en colirios est\u00e9riles de \npolietileno de baja densidad. Se conserva entre -15 y -25\u00baC en congelador. Desde el d\u00eda 0 hasta el d\u00eda 28, se realiza un \nestudio de estabilidad en el que semanalmente se miden los siguientes par\u00e1metros: pH y Osmolaridad (Osm), limpidez y \nesterilidad. Se tomaron fotograf\u00edas para los caracteres organol\u00e9pticos.\nRESULTADOS\nResultados de pH y Osmolaridad expresados en media \u00b1 desviaci\u00f3n est\u00e1ndar: pH 5.42 \u00b1 0.09 y Osm 327.5 \u00b1 2.58. Se \nobtiene una variabilidad del pH de 3.7% con un coeficiente de variaci\u00f3n de 1.66% y de Osmolaridad de 2.2% y 0.79% \nrespectivamente durante el periodo de estudio.  \nLas preparaciones cumplen con las exigencias tecnol\u00f3gicas directamente relacionadas con las caracter\u00edsticas \nfisicoqu\u00edmicas de la l\u00e1grima seg\u00fan pH y Osm. Adem\u00e1s la soluci\u00f3n se mantiene l\u00edmpida y est\u00e9ril en todo el proceso y no se \nmodifican los caracteres organol\u00e9pticos.566CONCLUSIONES\nEl colirio de Vancomicina 50mg/ml diluido en BSS\u00ae no presenta variaci\u00f3n significativa en ninguno de los par\u00e1metros \nanalizados durante el per\u00edodo de estudio de 28 d\u00edas tras la conservaci\u00f3n del mismo en congelador. Los resultados son \nconsistentes y similares a la bibliograf\u00eda publicada para esta FM con diversos componentes de partida y distintas condiciones \nde conservaci\u00f3n. Son necesarios m\u00e1s estudios de estabilidad para determinar el per\u00edodo de validez de esta FM.\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n530. INDIVIDUALIZACI\u00d3N DE DOSIS DE ENOXAPARINA 20MG/ML JERINGAS EN NEONATOS Y LACTANTES \nAUTORES\nGAVRUS ION, D; CATAL\u00c0 FOGUET , JM; CASALD\u00c0LIGA TORRECILLAS, A; L\u00d3PEZ RAMOS, MG; BOSSACOMA BUSQUETS, \nF; VILLARONGA FLAQU\u00c9, M\nHOSPITAL DE SANT JOAN DE D\u00c8U. PASSEIG SANT JOAN DE D\u00c9U, 2 ESPLUGUES DE LLOBREGAT . BARCELONA\nOBJETIVOS\nDescribir nuestra experiencia en la preparaci\u00f3n de dosis individualizadas de enoxaparina diluida 20mg/mL en pacientes \npedi\u00e1tricos con dosis inferiores a 10mg, en un hospital pedi\u00e1trico de tercer nivel.\nMATERIALES Y M\u00c9TODOS\nLas presentaciones comerciales de enoxaparina en jeringas precargadas de concentraci\u00f3n 100mg/mL dificultan la \nadministraci\u00f3n de las dosis necesarias en neonatos y lactantes, ya que suponen vol\u00famenes muy inferiores a los \nmarcados en la jeringa. La enoxaparina es un f\u00e1rmaco de alto riesgo, cuyo efecto anticoagulante debe ser monitorizado \npara garantizar su seguridad y eficacia, y en el que peque\u00f1as variaciones en el volumen administrado pueden tener \nimplicaciones de relevancia cl\u00ednica. Se ha descrito la estabilidad de enoxaparina s\u00f3dica diluida a 20mg/mL en agua \ndurante 14 d\u00edas, preparada en en condiciones de esterilidad en cabina de flujo laminar horizontal. El procedimiento \nimplementado en nuestro servicio en noviembre de 2021 consiste en la preparaci\u00f3n de las dosis inferiores a 10mg de \nforma individualizada a esta concentraci\u00f3n, cargadas en jeringas sin volumen muerto y con la aguja de administraci\u00f3n \nsubcut\u00e1nea puesta para evitar infradosificaci\u00f3n asociada a los vol\u00famenes muertos.  \nSe han revisado retrospectivamente todas las preparaciones de enoxaparina 20mg/mL en jeringa individualizada \nelaboradas entre noviembre de 2021 y mayo de 2022, recogiendo indicaci\u00f3n y duraci\u00f3n de tratamiento, dosis/volumen, y \nunidades preparadas\ufffd\nRESULTADOS\nDesde su implantaci\u00f3n en noviembre de 2021 se han preparado un total de 502 jeringas individualizadas para un total de \n14 pacientes (7 con indicaci\u00f3n profil\u00e1ctica y 7 como tratamiento de trombosis).  \nEn el caso de los pacientes con indicaci\u00f3n profil\u00e1ctica, la mediana de unidades preparadas por paciente fue de 6 jeringas \n[rango 1-101], con una dosis mediana de 8mg [2-9], equivalentes a un volumen de 0,4mL [0,1-0,45] de la diluci\u00f3n.  \nEn el caso de los pacientes con indicaci\u00f3n de tratamiento, la mediana de unidades preparadas por paciente fue de 23 \njeringas [10-183], con una dosis mediana de 2,8mg [1-9], equivalentes a un volumen de 0,14mL [0,05-0,45] de la diluci\u00f3n.  \nTodos los pacientes en que se realizaron controles de coagulaci\u00f3n mediante medida de factor X activado, mantuvieron \nniveles estables y proporcionales a las modificaciones de dosis. No se detectaron durante este periodo valores de factor X \nactivado an\u00f3malos (indetectables o demasiado elevados).\nCONCLUSIONES\nLa elaboraci\u00f3n de jeringas individualizadas de enoxaparina en del servicio de farmacia ha permitido una mejor \ndosificaci\u00f3n y una mayor estabilidad en la anticoagulaci\u00f3n de neonatos y lactantes. \nNo se ha detectado durante el periodo de implantaci\u00f3n ning\u00fan incidente de seguridad relacionado con este f\u00e1rmaco de \nriesgo\ufffd\nCLASIFICACI\u00d3N: FARMACOTECNIA Y NUTRICI\u00d3N\n1103. CREACI\u00d3N DE UNA BASE DE DATOS EN \u00c1REA DE FARMACOTECNIA PARA LA GESTION E IMPRESION \nDE CITAS DE F\u00d3RMULAS MAGISTRALES \nAUTORES\nALBAS TRICAS, M; PUEBLA GARCIA, V; CISNEROS DE LA IGLESIA, L; LORIGA LOSADA, R; TALLON MARTINEZ, JC; \nCORAZON VILLANUEVA, J; SANCHEZ-OCA\u00d1A MARTIN, N; MOLINA MU\u00d1OZ, P\nHOSPITAL CL\u00cdNICO SAN CARLOS \ufffd PROF \ufffd MART\u00cdN LAGOS, S/N MADRID \ufffd MADRID\nOBJETIVOS\nDescribir la creaci\u00f3n de una base de datos en el \u00e1rea de Farmacotecnia para la gesti\u00f3n e impresi\u00f3n de citas de f\u00f3rmulas \nmagistrales individualizadas (FMI) previa a la dispensaci\u00f3n de pacientes no ingresados.\nMATERIALES Y M\u00c9TODOS\nSe emplea una hoja de c\u00e1lculo Excel para la creaci\u00f3n de una base de datos. Se recogen los siguientes campos en las \ncolumnas: fecha programada de recogida, n\u00famero de historia, apellidos y nombre de paciente, n\u00famero de tel\u00e9fono, \nf\u00f3rmula magistral, unidades dispensadas, frecuencia de recogida en d\u00edas, tipo de dispensaci\u00f3n, observaciones e \nincidencias y fecha de pr\u00f3xima recogida  \nSe categoriza la frecuencia de recogida en 7,14,28 y 56 d\u00edas y el tipo de dispensaci\u00f3n en: Nuevo, programado, confirmado, \nsuspendido, no necesario elaborar-hay medicaci\u00f3n de Stock. 567Para la impresi\u00f3n de cita, se desarrolla una etiqueta estandarizada que va adherida al embalaje externo de cada f\u00f3rmula. \nEn esta etiqueta va impresa la fecha de pr\u00f3xima elaboraci\u00f3n tel\u00e9fono de contacto para el cambio de cita de siguiente \nelaboraci\u00f3n. Para el dise\u00f1o de la etiqueta-cita se emplea una hoja de c\u00e1lculo estandarizada en donde se autocompleta la \npropuesta de fecha de pr\u00f3xima vuelta mediante la conexi\u00f3n con la base de datos original.  \nCada d\u00eda, se imprime la relaci\u00f3n de pacientes a los que es necesario elaborar una FM. Una vez elaborados, se modifica \nel tipo de dispensaci\u00f3n a confirmada y autom\u00e1ticamente el campo de fecha de pr\u00f3xima recogida se autocompleta, \ngener\u00e1ndose una nueva l\u00ednea con la fecha posterior programada de recogida en funci\u00f3n de la frecuencia de recogida. \nCada FM, antes de dispensar ir\u00e1 identificada con: etiqueta de dispensaci\u00f3n segura por c\u00f3digo de barras, etiqueta con \ncondiciones espec\u00edficas de conservaci\u00f3n y etiqueta-cita con fecha de pr\u00f3xima recogida.\nRESULTADOS\nDurante el a\u00f1o 2021, un total de 1223 pacientes, el 10% de todos los pacientes externos, se les elabor\u00f3 y dispens\u00f3 \nalguna FMI. Se han realizado un total de 6164 dispensaciones de 59 FMI diferentes. El 68% de las dispensaciones fueron \npreparados oft\u00e1lmicos, el 24% formulas l\u00edquidas orales y el 8% t\u00f3picas.  \nEl 91% de pacientes acudieron a recoger su tratamiento en los d\u00edas indicados en la etiqueta-cita. Hubo un 6% de \npacientes que acudieron en d\u00edas posteriores a la cita programada y un 3% que no acudieron a por su medicaci\u00f3n, debido \na la suspensi\u00f3n o cambio de tratamiento\ufffd\nCONCLUSIONES\nLa creaci\u00f3n de una base de datos ha permitido optimizar el tiempo destinado a la organizaci\u00f3n diaria de la carga \nde trabajo en el \u00e1rea de farmacotecnia y minimizar los tiempos de espera de los pacientes a la hora de recoger su \nmedicaci\u00f3n\ufffd  \nPermite hacer un control y seguimiento por paciente con observaciones e incidencias ocurridas.  \nDe manera indirecta, con la creaci\u00f3n de la base de datos, hemos fomentado la adherencia de los pacientes a su \ntratamiento facilit\u00e1ndoles su recogida y teniendo una comunicaci\u00f3n m\u00e1s directa.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; \nPRODUCTOS SANITARIOS\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n200. SEGUIMIENTO DE LAS PREPARACIONES ELABORADAS EN EL SERVICIO DE FARMACIA A TRAV\u00c9S DE \nUNA APLICACI\u00d3N PARA DISPOSITIVOS M\u00d3VILES. \nAUTORES\nMAR\u00cdN ROMERO, AM; MART\u00cdN DEL PUEYO, AM; GONZ\u00c1LEZ SU\u00c1REZ, S; BOILLOS FERN\u00c1NDEZ, M; P\u00c9REZ GONZ\u00c1LEZ, \nS; PE\u00d1A HINOJOSA, P; L\u00d3PEZ CABEZAS, MDC; SOY MUNER, D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nLa trazabilidad del proceso de elaboraci\u00f3n de preparaciones est\u00e9riles est\u00e1 garantizada en nuestro centro; sin embargo, \nel seguimiento de las preparaciones durante la dispensaci\u00f3n se realiza \u00fanicamente a trav\u00e9s de registros manuales. La \nmultitud de preparaciones, destinos y casu\u00edsticas provoca un elevado n\u00famero de incidencias.  \nEl objetivo es el dise\u00f1o e implementaci\u00f3n de una aplicaci\u00f3n para dispositivos m\u00f3viles (App) para facilitar el seguimiento \n(\u201ctracking\u201d) de las preparaciones elaboradas en el servicio de Farmacia.\nMATERIALES Y M\u00c9TODOS\n1. Se cre\u00f3 un equipo de trabajo multidisciplinar, que inclu\u00eda un t\u00e9cnico del \u00e1rea, para definir los requisitos a cumplir por \nel aplicativo inform\u00e1tico, los f\u00e1rmacos susceptibles de entrar en el sistema y los circuitos de entrega seg\u00fan necesidades y \ncasu\u00edsticas de cada uno de los destinos.  \n2. Desarrollo de la aplicaci\u00f3n por parte del proveedor e integraci\u00f3n con los programas inform\u00e1ticos implicados en la \nprescripci\u00f3n/validaci\u00f3n\ufffd  \n3. Creaci\u00f3n de c\u00f3digos QR de identificaci\u00f3n y ubicaci\u00f3n de los puntos de entrega de forma consensuada con el personal \nde enfermer\u00eda.  \n4\ufffd Formaci\u00f3n del personal implicado en el uso de la aplicaci\u00f3n\ufffd  \n5\ufffd Prueba piloto en una unidad, y posteriormente, extensi\u00f3n al resto de unidades\ufffd  \n6. Seguimiento de incidencias y opini\u00f3n de los usuarios con el que desarrollar mejoras de la aplicaci\u00f3n.\nRESULTADOS\nLa aplicaci\u00f3n dise\u00f1ada incluye: informaci\u00f3n de paciente, f\u00e1rmaco, destino, d\u00eda y hora de administraci\u00f3n, personal \nimplicado y estado de la preparaci\u00f3n (pendiente de preparar, preparado, en tr\u00e1nsito, entregado) indicado a trav\u00e9s de un \nc\u00f3digo de colores a modo de sem\u00e1foro. Todos los usuarios pueden consultar en cualquier momento, a tiempo real, el \nestado de la preparaci\u00f3n a trav\u00e9s del m\u00f3vil u ordenador. Los cambios de estado se realizan a trav\u00e9s del escaneado del QR \nincorporado en la etiqueta del producto y en la ubicaci\u00f3n final.  \nEn esta fase se incorporaron las preparaciones est\u00e9riles elaboradas en Farmacia, citost\u00e1ticos (incluyendo los ensayos \ncl\u00ednicos) y nutriciones parenterales.  \nEl t\u00e9cnico colabor\u00f3 activamente tanto en la ubicaci\u00f3n de los puntos de entrega como en la formaci\u00f3n del personal y \nseguimiento de incidencias\ufffd  568Hasta el momento, se han incluido diez plantas de hospitalizaci\u00f3n, todos los hospitales de d\u00eda y dos sedes externas.  \nTras la implantaci\u00f3n, se ha observado una disminuci\u00f3n de reclamaciones, del tiempo empleado en la resoluci\u00f3n de las \nmismas y de la repetici\u00f3n de preparaciones por extrav\u00edo.  \nLos usuarios se muestran satisfechos con la aplicaci\u00f3n y consideran que los beneficios superan ampliamente el tiempo \ninvertido en la lectura de los c\u00f3digos. Adem\u00e1s, la explotaci\u00f3n de los datos registrados en la aplicaci\u00f3n permite el \nseguimiento pormenorizado de los horarios de preparaci\u00f3n, entrega y administraci\u00f3n, como posible herramienta \nde mejora de la organizaci\u00f3n del trabajo. En este momento a\u00fan no ha sido posible eliminar totalmente los registros \nmanuales a la espera de completar la implantaci\u00f3n del sistema\ufffd\nCONCLUSIONES\nLa aplicaci\u00f3n dise\u00f1ada permite realizar el \u201ctracking\u201d de las preparaciones de una manera intuitiva y sencilla unificando \nen un solo registro las preparaciones procesadas con distintos programas inform\u00e1ticos. La contribuci\u00f3n del t\u00e9cnico de \nFarmacia en el proceso ha sido fundamental para el \u00e9xito del proyecto.\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n1240. OPTIMIZACI\u00d3N DEL TIEMPO Y MEJORA DE LA SEGURIDAD TRAS CLASIFICAR POR PRINCIPIO \nACTIVO LOS MEDICAMENTOS ANTINEOPL\u00c1SICOS EN LA SALA BLANCA \nAUTORES\nGARAY MARTINEZ, A; ALVAREZ MORENO, MC; PEREZ ANDREU, L; ALVAREZ MORENO, IM; GUIRAO PEREZ, AJ; VERA \nMOALES, A; RAMON PEREZ, M; VILLA CARPES, J\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA\nOBJETIVOS\nEn el \u00c1rea de Farmacia Oncol\u00f3gica, dentro de la sala blanca, los medicamentos antineopl\u00e1sicos estaban clasificados \npor marca comercial, dando como resultado un incremento del tiempo en su localizaci\u00f3n. El objetivo del estudio fue \nreducir el tiempo que requiere un T\u00e9cnico de Farmacia (TF) en familiarizarse con la disposici\u00f3n y localizaci\u00f3n de los \nmedicamentos, as\u00ed como contribuir a una mejora de la seguridad en la preparaci\u00f3n de los medicamentos antineopl\u00e1sicos, \nal cambiar su disposici\u00f3n por orden alfab\u00e9tico y principio activo.\nMATERIALES Y M\u00c9TODOS\nEn el Servicio de Farmacia de un Hospital de Tercer Nivel Asistencial, se llev\u00f3 a cabo un cambio en la clasificaci\u00f3n de \nlos medicamentos antineopl\u00e1sicos de marca comercial a principio activo. Para ello, tras la obtenci\u00f3n de la hoja de \ninventario de ubicaciones proporcionada por el administrativo, se procedi\u00f3 al vaciado de las cajoneras mediante la ayuda \nde los carros situados en el interior de la sala blanca, se retir\u00f3 el etiquetado por marca comercial de las cajoneras y se \netiquetaron por principio activo, posteriormente se llev\u00f3 a cabo la colocaci\u00f3n de los medicamentos en orden alfab\u00e9tico \ny se actualiz\u00f3 las ubicaciones en la hoja de inventario. Tras finalizar, se comunic\u00f3 a todo el personal sanitario que tiene \nacceso a esta \u00e1rea la nueva disposici\u00f3n de los medicamentos antineopl\u00e1sicos de temperatura ambiente. La denominaci\u00f3n \nde los medicamentos termol\u00e1biles no se modific\u00f3 debido a que ya estaban ordenados por orden alfab\u00e9tico y principio \nactivo.\nRESULTADOS\nTras finalizar la reubicaci\u00f3n de los medicamentos, se observ\u00f3 un mayor rendimiento del equipo encargado del \u00e1rea de \nantineopl\u00e1sicos, reduci\u00e9ndose el tiempo de b\u00fasqueda de los mismos. Por otro lado, se facilit\u00f3 el aprendizaje de los TF \nreci\u00e9n incorporados, ya que en la hoja de preparaci\u00f3n del tratamiento antineopl\u00e1sico del paciente viene la denominaci\u00f3n \ndel medicamento en principio activo y su marca comercial.\nCONCLUSIONES\nEl \u00e1rea de preparaci\u00f3n de medicamentos antineopl\u00e1sicos dentro la sala blanca del servicio de farmacia, requiere de la \nformaci\u00f3n continuada del equipo multidisciplinar que lo compone, as\u00ed como la optimizaci\u00f3n de recursos tan importantes \ncomo el tiempo. En este estudio se demuestra la importancia de la implantaci\u00f3n de las nuevas medidas, que favorecen el \nbuen funcionamiento y desarrollo de los distintos protocolos normalizados de trabajo implantados en este servicio.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n422. EL ROL DEL T\u00c9CNICO DE FARMACIA EN UNA UNIDAD DE PACIENTES EXTERNOS ONCOHEMATOL\u00d3GICOS \nAUTORES\nVELEZ PUIG, S; BOTELLO GARC\u00cdA, A; MART\u00cdNEZ VIZCA\u00cdNO, C; ROSA LE\u00d3N, B; TERCEROS CHUNGARA, J; CODINA-\nJIM\u00c9NEZ , C; LEZCANO RUBIO, C; MUNN\u00c9 GARCIA, M\nINSTITUT CATAL\u00c0 D\u2019ONCOLOGIA BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nOBJETIVOS\nEvaluaci\u00f3n del papel desarrollado por parte del t\u00e9cnico de farmacia (TF) en una consulta de atenci\u00f3n farmac\u00e9utica \noncohematol\u00f3gica con programaci\u00f3n de pacientes, mediante el registro del tipo de llamadas realizadas y recibidas a los \npacientes y/o cuidadores y la evaluaci\u00f3n de las mismas\ufffd569MATERIALES Y M\u00c9TODOS\nEstudio descriptivo, observacional y prospectivo de las tareas del TF realizado durante los meses de febrero y marzo de \n2022 en una consulta de pacientes externos oncohematol\u00f3gicos de un hospital universitario de tercer nivel.  \nSe elabor\u00f3 una base de datos Excel\u00ae para recoger la informaci\u00f3n relativa a las consultas telef\u00f3nicas recibidas y/o \nrealizadas. Las variables recogidas fueron: tipo de consulta (recibida o realizada proactivamente), motivo de la consulta, \ndatos demogr\u00e1ficos (edad, sexo). Se registr\u00f3 el n\u00famero de dispensaciones de medicaci\u00f3n as\u00ed como el n\u00famero de \npacientes atendidos durante el per\u00edodo del estudio.  \nEn relaci\u00f3n a las consultas recibidas se evalu\u00f3 el nivel de resoluci\u00f3n de la consulta en base a la necesidad de trasladar la \nmisma al farmac\u00e9utico responsable del \u00e1rea.\nRESULTADOS\nDurante el per\u00edodo de estudio se realizaron un total de 2269 dispensaciones de medicaci\u00f3n en un total de 491 pacientes. \nLos pacientes ten\u00edan una edad media de 61,6 \u00b1 14,5 a\u00f1os, siendo el 53,4% mujeres.  \nSe recibieron 99 llamadas telef\u00f3nicas por parte del paciente y/o cuidador y se realizaron 90 llamadas por parte del \nt\u00e9cnico.  \nDe las 99 llamadas recibidas, el 83,8% fueron solucionadas en el momento por parte del t\u00e9cnico de farmacia, el 16,2% \ntuvieron que ser derivadas por requerir atenci\u00f3n farmac\u00e9utica. De las 83 consultas solucionadas inmediatamente, el 88% \nestaban relacionadas con la agenda de programaci\u00f3n de farmacia y el 12% con la gesti\u00f3n de la medicaci\u00f3n.  \nDe las 90 llamadas realizadas, el 63,3% se realizaron a pacientes que no acudieron a la cita programada de farmacia, el \n21,1% fueron para informar sobre cambios en la programaci\u00f3n de la visita y el 15,6% otras gestiones relacionadas con la \nmedicaci\u00f3n (env\u00edo a domicilio y/o falta de estoc).\nCONCLUSIONES\nEl TF en una unidad de farmacia oncohematol\u00f3gica permite solucionar las consultas realizadas por los pacientes y/o \ncuidadores en m\u00e1s del 80% de las situaciones encontradas.  \nMediante la realizaci\u00f3n de llamadas telef\u00f3nicas proactivamente, el TF contribuye a evitar posibles problemas \nrelacionados con la medicaci\u00f3n y es fundamental para asegurar la continuidad de los tratamientos.\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n1007. DESENSIBILIZACI\u00d3N DE CITOST\u00c1TICOS EN BOLSA \u00daNICA: AN\u00c1LISIS DEL IMPACTO EN EL TIEMPO \nDE ELABORACI\u00d3N. \nAUTORES\nRIVERO , E; LESTA , C; V\u00c1ZQUEZ , M; MAR\u00cdN , AM; MONGE , I; RUIZ , S; MAT\u00c9 , P; SOY , D\nHOSPITAL CLINIC I PROVINCIAL DE BARCELONA \ufffd VILLARROEL, 170 BARCELONA \ufffd BARCELONA\nOBJETIVOS\nDe forma consensuada con los servicios de Alergolog\u00eda y Oncolog\u00eda del hospital se decidi\u00f3 modificar la pr\u00e1ctica cl\u00ednica \nhabitual de preparaci\u00f3n de tratamientos de desensibilizaci\u00f3n de citost\u00e1ticos de tres bolsas (m\u00e9todo A) a bolsa \u00fanica \n(m\u00e9todo B).  \nEl objetivo del estudio fue comparar el tiempo empleado por el t\u00e9cnico en la preparaci\u00f3n con los dos m\u00e9todos \nespecificados.\nMATERIALES Y M\u00c9TODOS\nEstudio retrospectivo unic\u00e9ntrico en el que se incluyeron las preparaciones en pauta de desensibilizaci\u00f3n de citost\u00e1ticos \ndurante los tres primeros meses de 2022 tras la implantaci\u00f3n del m\u00e9todo B.  \nCon el m\u00e9todo A las preparaciones para desensibilizaci\u00f3n de citost\u00e1ticos se elaboraban en tres bolsas de concentraci\u00f3n \ncreciente que, a excepci\u00f3n de la de mayor concentraci\u00f3n, se administraban parcialmente a los pacientes. Con el nuevo \nprotocolo la dosis creciente se consigue modulando la velocidad de la perfusi\u00f3n, por lo que la preparaci\u00f3n se reduce a \nuna \u00fanica bolsa que se administra en su totalidad.  \nSe diferenci\u00f3 entre f\u00e1rmacos reconstituidos (tipo 1) vs f\u00e1rmacos liofilizados (tipo 2).  \nSe calcul\u00f3 la media de tiempo de preparaci\u00f3n en tres tratamientos de cada tipo. Con esta estimaci\u00f3n, se compar\u00f3 el \ntiempo empleado para la elaboraci\u00f3n de las preparaciones con cada uno de los m\u00e9todos. Todas las preparaciones se \nelaboraron en cabina de seguridad biol\u00f3gica, siguiendo t\u00e9cnica as\u00e9ptica y purgado con medicamento.\nRESULTADOS\nDurante el per\u00edodo evaluado se elaboraron 66 tratamientos en pauta de desensibilizaci\u00f3n: 49 de tipo 1 y 17 de tipo 2.  \nEn el m\u00e9todo A, el tiempo medio de preparaci\u00f3n calculado fue de 8,88 minutos y de 16,11 minutos para los f\u00e1rmacos de \ntipo 1 y 2, respectivamente. Con el m\u00e9todo B, el tiempo medio de preparaci\u00f3n calculado fue de 4,29 minutos y de 10,50 \nminutos para los f\u00e1rmacos de tipo 1 y 2, respectivamente.\nCONCLUSIONES\nLa preparaci\u00f3n de desensibilizaciones a citost\u00e1ticos en bolsa \u00fanica ha supuesto una reducci\u00f3n del 51,72% en el \ntiempo empleado por el t\u00e9cnico en el caso de f\u00e1rmacos reconstituidos y de un 34,86% en los liofilizados. El cambio de \nprocedimiento implica tambi\u00e9n una reducci\u00f3n del material fungible utilizado y del residuo generado, as\u00ed como una mayor \nfacilidad a la hora de administraci\u00f3n por parte de enfermer\u00eda.  \nDado el elevado n\u00famero de desensibilizaciones que se preparan, esta nueva t\u00e9cnica permite aumentar el rendimiento del \n\u00e1rea de Farmacotecnia.570CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N \nASISTENCIAL\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n466. IMPLICACI\u00d3N DEL T\u00c9CNICO EN LA GESTI\u00d3N DE MEDICAMENTOS CADUCADOS EN EL SERVICIO DE \nFARMACIA \nAUTORES\nHUERGA STANGEL, N; BRUGUERA TEIXIDOR, M; P\u00c9REZ PLASENCIA, A; NOGU\u00c9 PUJADAS, E; SALGADO ROPERO, Y; \nGONZALEZ RODRIGUEZ, C; SUBIRANA BATLLE, C; SACREST G\u00dcELL, R\nHOSPITAL UNIVERSITARI DR. JOSEP TRUETA DE GIRONA. AV . FRAN\u00c7A, S/N GIRONA. GIRONA\nOBJETIVOS\nDescribir el sistema de gesti\u00f3n de medicamentos caducados en el Servicio de Farmacia (SF) realizado por el personal \nt\u00e9cnico y seguimiento del proceso mediante indicadores.\nMATERIALES Y M\u00c9TODOS\n- Dise\u00f1o e implantaci\u00f3n de un nuevo sistema de control de caducidades en el SF  \n- Definici\u00f3n y seguimiento de indicadores de proceso dentro del sistema de gesti\u00f3n de calidad del SF (ISO 9001:2015)\nRESULTADOS\nEn noviembre de 2020 se defini\u00f3 una nueva instrucci\u00f3n para el control de caducidades en el SF. El t\u00e9cnico responsable de \nesta actividad elabora mensualmente un listado de medicamentos a revisar a partir de tres fuentes:  \n- Una hoja de datos elaborada manualmente durante el inventario anual del SF donde se registra la fecha de caducidad \nde los medicamentos en los que se encontraron unidades que caducaban durante el a\u00f1o siguiente y que incluye c\u00f3digo \nnacional, descripci\u00f3n, ubicaci\u00f3n y precio unitario  \n- Una extracci\u00f3n de los datos del programa de adquisiciones que permite seleccionar los medicamentos comprados desde \nel \u00faltimo inventario y que tienen como fecha de caducidad informada el mes en curso \n- Un listado de medicamentos reenvasados en el SF con caducidad distinta a la original  \nUna vez fusionados los tres listados, el t\u00e9cnico realiza la revisi\u00f3n f\u00edsica de estos f\u00e1rmacos, retirando y registrando las \nunidades caducadas si las hay. Tambi\u00e9n incluye manualmente los medicamentos caducados detectados por cualquier otro \nprofesional del SF fuera del mes en curso. Posteriormente, el t\u00e9cnico y el farmac\u00e9utico referente se re\u00fanen para revisarlo, \ndecidir conjuntamente las acciones pertinentes (comprar, ajustar m\u00e1ximos o m\u00ednimos, solicitar la inclusi\u00f3n o retirada en \nla Gu\u00eda Farmacoterap\u00e9utica, etc) y valorar la solicitud de abono por parte del laboratorio farmac\u00e9utico.  \nPara realizar el seguimiento del proceso se definieron como indicadores mensuales el n\u00famero total de medicamentos \nrevisados, el n\u00famero de especialidades con alguna unidad caducada, los medicamentos caducados detectados fuera del \nmes en curso y el importe total (exceptuando los ant\u00eddotos, f\u00e1rmacos con poco margen para poder aplicar acciones de \nmejora en su gesti\u00f3n).  \nDe enero de 2021 a marzo de 2022 se revis\u00f3 una media de 79 medicamentos/mes [27-117], que supone un 86% menos \nque si se hubiesen utilizado \u00fanicamente los datos del programa de gesti\u00f3n de compras (516 medicamentos/mes). El \nn\u00famero de especialidades caducadas fue de 28 al mes [8-39], que supone el 35% de los medicamentos revisados. Se \ndetect\u00f3 una media de 3,5 medicamentos caducados fuera del mes en curso\ufffd El importe medio fue de 1912 euros/mes \n(1592 euros/mes sin tener en cuenta los medicamentos espec\u00edficos comprados en el inicio de la pandemia por COVID-19).\nCONCLUSIONES\nEl actual sistema de gesti\u00f3n de caducados en el SF permite detectar de manera \u00f3ptima los medicamentos que caducan y \nretirarlos antes de ser dispensados. La labor del t\u00e9cnico de farmacia es indispensable para poder realizar este circuito de \nmanera adecuada hasta que no se disponga de una tecnolog\u00eda m\u00e1s eficiente. El seguimiento del proceso con indicadores, \nen el marco del sistema de gesti\u00f3n de calidad, permite detectar posibles desviaciones y aplicar acciones correctivas en \n\u00e9ste u otros procesos relacionados.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n559. SATISFACCI\u00d3N PERCIBIDA POR LOS PACIENTES EXTERNOS EN LA UNIDAD DE PACIENTES EXTERNOS \nDEL SERVICIO DE FARMACIA DE DOS HOSPITALES. \nAUTORES\nALVAREZ EXPOSITO, L; PEREZ RELUCIO, D; SEIJO LOPEZ, A; MOLERA FARRE, S; GIMENEZ BOROS, A; JORQUERA \nCAMPA\u00d1A, K; LAORDEN MARTINEZ, C; SOLIS RODRIGUEZ, A\nHOSPITAL COMARCAL DE BLANES \ufffd CRTRA CALA DE SANT FRANCES, 5 BLANES \ufffd GIRONA\nOBJETIVOS\nConocer el grado de satisfacci\u00f3n de pacientes atendidos en la unidad de pacientes externos (UPE) del Servicio de \nFarmacia (SF) de dos hospitales e identificar aspectos de mejora.\nMATERIALES Y M\u00c9TODOS\nEstudio transversal de 3 semanas de duraci\u00f3n (25 abril-13 mayo de 2022) realizado en dos hospitales comarcales \npertenecientes a una misma organizaci\u00f3n sanitaria, que atiende a una poblaci\u00f3n de 195.000 habitantes.  571El hospital A est\u00e1 ubicado en el centro de una poblaci\u00f3n, con horario de atenci\u00f3n UPE de 8-19 h. El hospital B est\u00e1 \nubicado en las afueras de otra poblaci\u00f3n, con horario de atenci\u00f3n UPE de 8-17:30. Ambos hospitales comparten \nprotocolos y procedimientos en la UPE del SF \ufffd \nSe dise\u00f1\u00f3 una encuesta de 8 preguntas cerradas con formato tipo Likert con 5 respuestas posibles (rango 1-5): \nlocalizaci\u00f3n-acceso, confort sala de espera, tiempo de espera, trato recibido, informaci\u00f3n sobre tratamiento, \nconfidencialidad, confort en la consulta y horario de atenci\u00f3n. El cuestionario contiene tambi\u00e9n una escala de valoraci\u00f3n \nglobal del SF (rango 1-10) y un espacio libre para comentarios o sugerencias.  \nSe ofreci\u00f3 rellenar la encuesta de forma voluntaria y an\u00f3nima a los pacientes que acudieron al Servicio de Farmacia los \nd\u00edas laborables durante el periodo de estudio. Las encuestas eran depositadas por los pacientes en un buz\u00f3n espec\u00edfico. \nPara el an\u00e1lisis se incluyeron las encuestas con m\u00ednimo de 75% de respuestas y/o que incluyeran la valoraci\u00f3n global del \nSF. Los resultados obtenidos se expresaron como media y desviaci\u00f3n est\u00e1ndar.\nRESULTADOS\nHospital A \nRecibieron la encuesta 73 pacientes, tasa de respuesta 79,45%. 64% eran mujeres y la media de edad 54,94 \u00b1 13,61 a\u00f1os.  \nEl aspecto mejor valorado fue el trato recibido por el personal (4,86 \u00b10,35), seguido de la informaci\u00f3n proporcionada \nsobre el tratamiento (4,79\u00b10,41) y el tiempo de espera para ser atendido (4,64\u00b10\u201961). Los aspectos peor valorados fueron \nel confort en la zona de espera (3,12\u00b11,39) y la localizaci\u00f3n-acceso (3,47\u00b11,21). El grado de satisfacci\u00f3n global fue de \n8,77\u00b11,12\ufffd  \nSe recogieron 15 comentarios/sugerencias: 7 agradecimientos al personal, 7 quejas sobre la zona de espera y 1 \ncomentario sobre la zona de aparcamiento.  \n \nHospital B  \nRecibieron la encuesta 124 pacientes, tasa de respuesta 86,29%. 58% eran hombres y la media de edad 54,46 \u00b1 14,50 \na\u00f1os\ufffd  \nEl aspecto mejor valorado fue el trato recibido por el personal (4,75 \u00b10,46), seguido de la confidencialidad durante la \nvisita (4,59\u00b10\u201959) y la informaci\u00f3n proporcionada sobre el tratamiento (4,57\u00b10\u201968). Aspectos menos valorados fueron \nel confort en la zona de espera (4,37\u00b10,58) y la localizaci\u00f3n-acceso (4,37\u00b10,67). El grado de satisfacci\u00f3n global de los \npacientes fue de 9,33\u00b10\u201996.  \nSe recogieron 15 comentarios/sugerencias, 11 agradecimientos al personal, 2 comentarios sobre la accesibilidad y zona \nde aparcamiento, 1 comentario sobre dispensaci\u00f3n de medicamento en fr\u00edo sin nevera.\nCONCLUSIONES\nLa realizaci\u00f3n de encuestas de satisfacci\u00f3n a pacientes externos permite detectar aspectos de mejora.  \nLa puntuaci\u00f3n global obtenida es satisfactoria, sobretodo en cuanto a calidad de la atenci\u00f3n percibida por el paciente e \ninformaci\u00f3n recibida sobre el tratamiento, pero existe margen de mejora en cuanto a accesibilidad y confort de la zona de espera.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1238. ACCESOS VASCULARES Y ADMINISTRACI\u00d3N DE MEDICAMENTOS DURANTE EL INGRESO \nHOSPITALARIO \nAUTORES\nGARC\u00cdA LLOPIS, P; GOMIS BALDOV\u00cd, S; HERN\u00c0NDEZ LORENTE, E; M\u00c1\u00d1EZ GUARINOS, MS; GIMENO TORTOSA, E; \nGADEA SENENT , A\nHOSPITAL UNIVERSITARIO DE LA RIBERA \ufffd CRTRA CORBERA, KM \ufffd 1 ALZIRA \ufffd VALENCIA\nOBJETIVOS\nSe estima que m\u00e1s del 80% de los pacientes hospitalizados recibe terapia intravenosa, pudiendo administrarse a trav\u00e9s \nde diferentes dispositivos de acceso vascular. En la selecci\u00f3n del mismo influyen la facilidad de colocaci\u00f3n y posibles \ncomplicaciones asociadas (el acceso vascular perif\u00e9rico presenta un balance beneficio/riesgo m\u00e1s favorable) y las \ncaracter\u00edsticas del f\u00e1rmaco. Las recomendaciones para la selecci\u00f3n de la v\u00eda de administraci\u00f3n, contemplan la v\u00eda midline \ny central (CVC, PICC, RVC) para los medicamentos con riesgo alto de producir da\u00f1o tisular y algunos de riesgo moderado, \ndejando la v\u00eda perif\u00e9rica para parte de los de riesgo moderado y los de riesgo bajo.  \n \nEl objetivo del presente estudio es evaluar la idoneidad de los accesos vasculares utilizados para administrar \nmedicamentos durante el ingreso hospitalario.\nMATERIALES Y M\u00c9TODOS\nSe realiza un corte transversal que incluye a todos los pacientes adultos hospitalizados, excepto la unidad de cr\u00edticos y la \nsala COVID. Se registran los accesos vasculares canalizados en cada paciente y la medicaci\u00f3n administrada. Se consultan \nen la bibliograf\u00eda los datos de osmolaridad, ph y caracter\u00edsticas vesicantes de las diluciones administradas, as\u00ed como el \nalgoritmo de selecci\u00f3n de acceso vascular publicado por Manrique-Rodr\u00edguez et al. Los datos se registran y analizan con \nla hoja de c\u00e1lculo Excel.\nRESULTADOS\nSe incluyen 148 pacientes en el estudio, a los que se les administran 487 medicamentos por v\u00eda intravenosa (43 \ndiferentes). Se registran 4 tipos de accesos vasculares utilizados en la administraci\u00f3n de medicamentos: CVP (Cat\u00e9ter \nVenoso Perif\u00e9rico), CVC (Cat\u00e9ter Venoso Central), PICC (CVC de Inserci\u00f3n Perif\u00e9rica) y RVC (Reservorio Venoso Central). Se 572obtienen 10 medicamentos de alto riesgo, 23 de riesgo moderado y 10 de bajo riesgo.  \nDe las 80 diluciones de medicamentos de riesgo alto administrados, la mayor\u00eda de ellos (81%) lo hicieron por un CVP; el \n11% por un PICC y el 8% por un CVC. Las 188 administraciones de riesgo moderado fueron hechas mayoritariamente por \nun CVP (73%); por un PICC un 15%; mediante CVC un 10% y por RVC un 1%. De estas, solo 12 pertenecen a f\u00e1rmacos para \nlos que se recomiende un acceso midline o central. Los 219 medicamentos de bajo riesgo se administraron por CVP en un \n79%; por PICC un 15%; por CVC un 6% y por RVC un 1%\ufffd\nCONCLUSIONES\nLa pr\u00e1ctica cl\u00ednica durante la hospitalizaci\u00f3n contempla la administraci\u00f3n por v\u00eda perif\u00e9rica de un alto porcentaje (81%) de \nlas diluciones de medicamentos clasificadas como de alto riesgo de da\u00f1o tisular. Seg\u00fan el trabajo de Manrique-Rodr\u00edguez \net al, estos medicamentos deber\u00edan ser administrados preferentemente mediante cat\u00e9teres midline o centrales, por \ntanto, es necesario promover la utilizaci\u00f3n de estos dispositivos, m\u00e1s a\u00fan cuando en ninguno de los pacientes registrados \nse ha colocado una v\u00eda de tipo midline, claramente infrautilizada.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1256. ASSESSING SYRINGE ACCURACY: REDUCING DOSE ERRORS AND INCREASING SAFETY \nAUTORES\nSOBREIRA GON\u00c7ALVES, R; RATO CORREIA, R; CORREIA PIRES, H; FELISMINO GORDICHO, S; LAVRADOR PEREIRA, C; \nSOBREIRA FERNANDES, A; SOUSA NUNES, A; DUARTE BENTO, A\nOBJETIVOS\nAssessing syringes accuracy in comparison with theoretical volume delivered, by determining the associated error when \nmeasuring the same volume in syringes with different capacities, quantifying the associated error of measurements with \ntwo syringes (to ensure the exact scale) versus with a single syringe (scale reading by approximation), and assessing the \ndead space volume retained in the syringe and needle.\nMATERIALES Y M\u00c9TODOS\nFour different methods were designed. Method I to assess measurement variability between syringes (1mL measured \nin 1mL, 3mL, 5mL, 10mL and 20mL syringes; 3mL measured in 3mL, 5mL, 10mL and 20mL syringes; 5mL measured in \n5mL, 10mL and 20mL syringes; 9mL measured in 10mL and 20mL syringes). Method II to assess measurement variability \nbetween using a single syringe versus two syringes (1,7mL measured in a 3mL syringe versus 1,7mL measured in two \ndifferent 1mL syringes; 4,3mL measured in a 5mL syringe versus 4,3mL measured in 5mL + 1mL syringes; 9,9mL measured \nin a 10mL syringe versus 9,9mL measured in 10mL + 1mL syringes). Method III to assess the dead volume in syringes \n(1mL measured in a 1mL syringe; 5 mL measured in a 5mL syringe; 9mL measured in a 20 mL syringe). Method IV to \nassess the dead volume in needles with different gauge (19G, 20G and 21G, 40, 40 and 25mm long respectively). Two \ndifferent operators performed 30 measurements for each procedure using distilled water. The volumes measured were \nthen gravimetrically assessed in a calibrated analytical balance and converted to volume using water density at 20\u00b0C. \nMeasurement volume error was calculated to perform group comparison within each method.\nRESULTADOS\nMethod I showed that the error increases as the difference between the target volume and the syringe capacity increases \n(e.g. the volume error varied, respectively, for 1mL: 6,03% (1mL syringe) - 26,03% (20mL syringe) and for 9mL: -0,14% \n(10mL syringe) - 1,53% (20mL syringe)). Method II suggested that using a single measurement is associated with a \nlower error (e.g. for the 1,7mL measurement the error was 2,88% with one syringe and 7,12% with two syringes; when \nmeasuring 4,3mL in one syringe the error was -0,84% and 1,51% when using two syringes; for the 9,9mL measurement no \nsignificative differences were observed). Method III and IV revealed that the error associated with the addition of dead \nvolume via air flush is significantly higher for syringes with lower capacity (e.g. 44,91% when measuring 0,1mL in a 1mL \nsyringe) and for needles with lower gauge (e.g. the retained volume was 0,069mL for the 19G needle and 0,053mL for a \n21G needle).\nCONCLUSIONES\nThe results suggested that to minimize the error associated with the syringe choice, the operators should select syringes \nwith volume capacity closer to the target volume and, whenever possible, use a single measurement, particularly for \nsyringes of 5mL and under. These results are aligned with Erstad, A. et al (2006) and Jordan, M et al (2021). To avoid \nexcess volume delivery, the air flush technique should not be used, as it carries a considerable error, particularly \nsignificant for volumes under 1mL.\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n1261. EL T\u00c9CNICO DE FARMACIA EN EL REENVASADO \nAUTORES\nMARTINEZ MORENO, A; BOSO RIBELLES, A; ALVAREZ MORENO, MC; PEREZ ANDREU, L; GUIRAO PEREZ, AJ; NAVARRO \nSAEZ, R; RAMON PEREZ, M; GARAY MARTINEZ, A\nHOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA. CTRA. MADRID-CARTAGENA, S/N. (EL PALMAR) MURCIA. \nMURCIA573OBJETIVOS\nEl reenvasado de medicamentos es el procedimiento por el cual se acondiciona un medicamento para que pueda ser \nadministrado al paciente a la dosis prescrita, permitiendo una completa identificaci\u00f3n y sin necesidad de manipulaci\u00f3n. \nDe esta manera, contin\u00faa la trazabilidad permitiendo establecer circuitos de control de calidad y garantizar la seguridad.  \nLos T\u00e9cnicos de Farmacia (TF) son los encargados de realizar las tareas de reenvasado, seg\u00fan los Procedimientos \nNormalizados de Trabajo (PNT) establecidos en el servicio. Nuestro objetivo es estudiar el grado de satisfacci\u00f3n en el \nservicio de Farmacia Hospitalaria (FH), en relaci\u00f3n con el  \nmanejo de las m\u00e1quinas de reenvasado de s\u00f3lidos por los TF, mediante una encuesta de satisfacci\u00f3n.\nMATERIALES Y M\u00c9TODOS\nEl material utilizado para este estudio se obtuvo mediante la revisi\u00f3n del PNT del \u00e1rea de reenvasado y manuales propios \ndel fabricante. Disponemos de dos m\u00e1quinas reenvasadoras automatizadas: \n1.Reenvasadora 1: Automatiza el cortado del bl\u00edster y reenvasado, el TF introduce manualmente los bl\u00edsteres, el lote y la \ncaducidad\ufffd  \n2.Reenvasadora 2: \u00danicamente reenvasa, el TF debe cortar el bl\u00edster o realizar las fracciones, introducir los datos \nmanualmente, as\u00ed como colocar el medicamento ya cortado o en fracciones, en la l\u00ednea de reenvasado.  \nSe realiz\u00f3 un estudio observacional, descriptivo y transversal. Se elabor\u00f3 una encuesta de satisfacci\u00f3n sobre la actividad \ndel TF en el \u00e1rea de reenvasado mediante una aplicaci\u00f3n inform\u00e1tica compartida v\u00eda telef\u00f3nica durante una semana, \nrecogi\u00e9ndose las siguientes variables: \n1.Valoraci\u00f3n de las m\u00e1quinas de reenvasado.  \n2.Incidencias de la m\u00e1quina reenvasadora 1. \n3.Incidencias de la m\u00e1quina reenvasadora 2. \n4. Facilidad de uso de las m\u00e1quinas de reenvasado.  \n5. Satisfacci\u00f3n con el resultado del reenvasado.  \n6. Seguridad percibida por el TF en el uso de las m\u00e1quinas de reenvasado.\nRESULTADOS\nTras las encuestas realizadas y analizadas por la aplicaci\u00f3n telef\u00f3nica, respondieron 7 TF y los resultados fueron: \n1.El 14,3% valora muy bien las m\u00e1quinas de reenvasado,el 42,9% las valora bien y el 42,9% las valora regular. \n2.El 28,6% afirma que la m\u00e1quina reenvasadora 2 suele tener incidencias, el 14,3% afirma que no suele tener incidencias \ny el 57,1% afirma en ocasiones tiene incidencias.  \n3.El 14,3% afirma que la m\u00e1quina reenvasadora 1 suele tener incidencias, el 28,6% afirma que no suele tener incidencias \ny el 57,1% afirma en ocasiones tiene incidencias.  \n4.El 100% indica que es f\u00e1cil utilizar las reenvasadoras automatizadas.  \n5.El 100% demuestran estar satisfechos con los resultados del reenvasado.  \n6.El 85,7% admite seguridad al trabajar con estas m\u00e1quinas, frente al 14,3% que no le da seguridad.\nCONCLUSIONES\nEn relaci\u00f3n con la encuesta realizada podemos concluir que las m\u00e1quinas de reenvasado ayudan en el trabajo diario,  \naunque ser\u00eda necesario un repaso de las incidencias producidas. De esta forma, se tendr\u00eda una mejora en la actividad  \ndiaria, as\u00ed como un aumento en la satisfacci\u00f3n del TF en el uso de estas m\u00e1quinas automatizadas.  \nAdem\u00e1s, en la encuesta podemos ver que la mayor\u00eda de los usuarios admiten que las m\u00e1quinas de reenvasado son  \nnecesarias en la tarea diaria y aportan grandes beneficios en el resultado final, tanto en las dosis unitarias como en \nlas fracciones\ufffd575PROYECTOS I+I\nCLASIFICACI\u00d3N: ADHERENCIA\nCLASIFICACI\u00d3N: ADHERENCIA\n586. PROGRAMA DE ATENCI\u00d3N FARMAC\u00c9UTICA PARA MEJORAR LA ADHERENCIA AL TRATAMIENTO \nINMUNOSUPRESOR EN PACIENTES TRASPLANTADOS RENALES \nAUTORES\nESTOPI\u00d1\u00c1 ANTOL\u00cd, M; MELILLI MELILLI, E; D\u00cdAZ JURADO, MI; FAV\u00c0 BUCH, A; MANONELLES MONTERO, A; CANEDO \nCASTELO, M; BAD\u00cdA TAHULL, MB; PADULL\u00c9S ZAMORA, A\nHOSPITAL UNIVERSITARI DE BELLVITGE. FEIXA LLARGA, S/N HOSPITALET DE LLOBREGAT (L\u2019). BARCELONA\nRESUMEN\nIntroducci\u00f3n: En los pacientes receptores de un trasplante renal (TR), la adherencia al tratamiento inmunosupresor es \ncrucial para prevenir el rechazo, p\u00e9rdida del injerto y la morbilidad adicional. Otros factores de riesgo incluir\u00edan, una \ninadecuada inmunosupresi\u00f3n, elevada variabilidad intrapaciente (cuantificada mediante el coeficiente de variaci\u00f3n (CV)) \ny la formaci\u00f3n de anticuerpos espec\u00edficos del donante de novo.  \nExisten diferentes m\u00e9todos para evaluar la adherencia al tratamiento, desde m\u00e9todos indirectos como, recuento diario de \npastillas, cuestionarios y entrevistas con el paciente, hasta m\u00e9todos directos, como, observaci\u00f3n directa de la toma de la \nmedicaci\u00f3n, an\u00e1lisis de biomarcadores y de concentraciones s\u00e9ricas de los f\u00e1rmacos inmunosupresores. \nOBJETIVOS\nPrincipal: Evaluar el impacto de la implementaci\u00f3n de un programa de atenci\u00f3n farmac\u00e9utica ambulatoria en pacientes \nTR de novo sobre el CV de las concentraciones predosis de tacrolimus durante los primeros 6 meses postTR \ufffd  \nSecundarios: 1) Determinar la adherencia a los 6 meses postTR mediante cuestionario BAASIS\u00ae; 2) Detectar pacientes \ncon errores en el seguimiento del tratamiento precozmente y 3) Cuantificar las tasas de rechazo y el n\u00famero de ingresos \ndurante los primeros 6 meses postTR \ufffd  \n \nAPLICABILIDAD Y UTILIDAD DE LOS RESULTADOS\nMejorar el CV de las concentraciones de inmunosupresores y el cumplimiento terap\u00e9utico seg\u00fan cuestionario BAASIS\u00ae, \nas\u00ed como, la detecci\u00f3n prematura de pacientes con errores en la toma de medicaci\u00f3n.  \n \nDISE\u00d1O Y M\u00c9TODO\nEstudio prospectivo, unic\u00e9ntrico, pre post-intervenci\u00f3n (ratio 2:1) en pacientes TR de novo en un hospital de tercer nivel, \ncon casi 200 TR anuales. La visita se realiza dentro de la primera semana despu\u00e9s del alta postTR, que se engloba dentro \ndel manejo integral postTR. En la visita se refuerza el esquema y objetivo del tratamiento, as\u00ed como posibles efectos \nadversos e interacciones con f\u00e1rmacos y plantas medicinales. Se podr\u00e1n realizar visitas extras si el paciente lo requiere. A \nlos 6 meses postTR se realizar\u00e1 el cuestionario BAASIS\u00ae. El grupo control ser\u00e1n los pacientes TR de novo en el a\u00f1o previo \na la implantaci\u00f3n del programa (sin cuestionario BAASIS\u00ae realizado).  \n \nCALENDARIO PREVISTO\nInicio de las visitas a pacientes: enero de 2022, sin fecha de finalizaci\u00f3n prevista.  \nSeguimiento de los pacientes visitados durante el a\u00f1o 2022 \nInicio y finalizaci\u00f3n de la recogida de datos: enero 2022-junio 2023  \n \nLIMITACIONES Y POSIBLES SESGOS\nEs necesario el compromiso del paciente para efectuar correctamente el tratamiento inmunosupresor. Para el c\u00e1lculo de \nCV, se asumir\u00e1n concentraciones pre-dosis de tacrolimus a no ser que se especifique en el curso cl\u00ednico.  \n \nPROBLEMAS \u00c9TICOS: \nNinguno  \n \nORGANIZACI\u00d3N DEL ESTUDIO: \nPrimera visita a la semana del alta postTR en Farmacia (comunicaci\u00f3n con equipo de la unidad de TR) \u25ca Visitas extras \nseg\u00fan paciente \u25ca Cuestionario BAASIS\u00ae a los 6 meses.  \n \nPRESUPUESTO: \nAn\u00e1lisis, extracci\u00f3n y recogida de datos: 4.000 \u20ac. Publicaci\u00f3n en una revista internacional Open Access: 2.000 \u20ac. \nPendiente de financiaci\u00f3n.  \n \nBIBLIOGRAF\u00cdA:  \n- Kuypers DRJ. From Nonadherence to Adherence. Transplantation 2020;104:1330\u20131340.  \n- Lieb M. Accuracy and concordance of measurement methods to assess nonadherence after renal transplantation\u2013a \nprospective study. Nephrology 2020;21:114.  576- Neuberger JM. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver \nTransplant Recipient. Transplantation2017;101:S1\u2013S56.\nTWEET RESUMEN\nPrograma de #atenci\u00f3n farmac\u00e9utica para mejorar la #adherencia al tratamiento #inmunosupresor en pacientes \n#trasplantados renales\ufffd\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS;  \nPRODUCTOS SANITARIOS\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n824. TRANSFORMACI\u00d3N DIGITAL DE LA GU\u00cdA FARMACOTERAP\u00c9UTICA MEDIANTE EL DESARROLLO DE \nUN AGENTE CONVERSACIONAL BASADO EN LA INTELIGENCIA ARTIFICIAL. \nAUTORES\nBOCOS BAELO, A; GARC\u00cdA CASTI\u00d1EIRA, C; P\u00c9REZ RICART , A; CODINA JIMENEZ, C; QUI\u00d1ONES RIBAS, C\nHOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nRESUMEN\nLa inteligencia artificial (IA) constituye un recurso \u00fatil, c\u00f3modo y sencillo para incorporar a la pr\u00e1ctica cl\u00ednica recursos \nya existentes cuyo formato dificulta el manejo y la accesibilidad. As\u00ed, se propone la transformaci\u00f3n digital de la Gu\u00eda \nFarmacoterap\u00e9utica (GFT), ya que se detecta una infrautilizaci\u00f3n de la misma con dudas reiterativas.  \n \nOBJETIVOS  \nDise\u00f1ar una herramienta de IA en formato bot conversacional (ChatBot) que facilite el acceso a la GFT para mejorar su \nusabilidad y agilizar su consulta. \n \nAPLICABILIDAD Y UTILIDAD  \nProyecto aplicable a todo el personal hospitalario involucrado en el circuito del medicamento: prescripci\u00f3n, dispensaci\u00f3n \ny administraci\u00f3n. Posteriormente, ser\u00eda adaptable a las GFT de otros centros hospitalarios.  \nEl desarrollo de esta herramienta permitir\u00e1 incrementar la eficiencia, la calidad y la seguridad en la utilizaci\u00f3n de \nmedicamentos en el entorno hospitalario.  \n \nDISE\u00d1O Y M\u00c9TODO  \nDise\u00f1o de ChatBot en formato escrito y aplicaci\u00f3n m\u00f3vil con registro de usuario, de acceso off-line y actualizaciones \non-line peri\u00f3dicas. El ChatBot generar\u00e1 una serie de preguntas, con respuesta cerrada, en las que el usuario tendr\u00e1 que \nseleccionar el principio activo (PA) o grupo terap\u00e9utico que desee consultar, as\u00ed como la v\u00eda de administraci\u00f3n deseada.  \nLa herramienta proporcionar\u00e1 informaci\u00f3n sobre la disponibilidad en GFT del PA consultado, las especificaciones \ndel mismo (nombre comercial, dosis y forma farmac\u00e9utica) y condiciones especiales de dispensaci\u00f3n, adquisici\u00f3n y \nfinanciaci\u00f3n, como: medicaci\u00f3n en situaci\u00f3n especial, medicaci\u00f3n aprobada para indicaciones espec\u00edficas, medicaci\u00f3n \npeligrosa, de preparaci\u00f3n en sala blanca, medicaci\u00f3n no sustituible y extranjera. Adem\u00e1s, proporcionar\u00e1 un acceso \ndirecto a la documentaci\u00f3n necesaria para realizar los tr\u00e1mites pertinentes en caso de solicitudes fuera de indicaci\u00f3n, \nincorporaciones a la GFT, etc\ufffd  \nSe crear\u00e1 una base de datos propia que recoja la informaci\u00f3n relativa a la GFT, equivalentes terap\u00e9uticos y dem\u00e1s \nespecificaciones descritas. Para los PA, se utilizar\u00e1 la ontolog\u00eda de la Agencia Espa\u00f1ola del Medicamento (AEMPS). Las \nactualizaciones sobre abastecimiento se volcar\u00e1n peri\u00f3dicamente de la AEMPS.  \n \nCALENDARIO  \n- 1\u00aa etapa: creaci\u00f3n de la base de datos (5 meses) \n- 2\u00aa etapa: desarrollo de la aplicaci\u00f3n (4 meses)  \n- 3\u00aa etapa: prueba piloto por parte del Servicio de Farmacia (2 meses)  \n- 4\u00aa etapa: correcci\u00f3n de errores (1 mes) \n- 5\u00aa etapa: implantaci\u00f3n en todos los servicios del hospital \n \nLIMITACIONES  \nPuesto que la autorizaci\u00f3n y comercializaci\u00f3n de medicamentos, as\u00ed como la inclusi\u00f3n/exclusi\u00f3n en GFT, est\u00e1n sometidas \na constantes modificaciones, la base de datos requerir\u00e1 de una actualizaci\u00f3n peri\u00f3dica.  \n \nPROBLEMAS \u00c9TICOS  \nLa aplicaci\u00f3n no recoge datos personales de pacientes. A los usuarios registrados se aplicar\u00e1 la Ley Org\u00e1nica 3/2018, de 5 \nde diciembre, de Protecci\u00f3n de Datos Personales y garant\u00eda de los derechos digitales.  \n \nORGANIZACI\u00d3N DEL ESTUDIO:  \n1\u00aa Etapa: farmac\u00e9uticos adjuntos y residentes involucrados en la actualizaci\u00f3n de la GFT y de los equivalentes \nterap\u00e9uticos.  5772\u00aa Etapa: personal de la unidad de transformaci\u00f3n digital del hospital \n3\u00aa Etapa: personal del servicio de farmacia \n4\u00aa etapa: personal 1\u00aa y 2\u00aa etapa.  \n \nPRESUPUESTO  \n25000\u20ac  \n \nBIBLIOGRAF\u00cdA  \nNadarzynski T, Miles O, Cowie A, Ridge D. Acceptability of artificial intelligence (AI)-led chatbot services in healthcare: A \nmixed-methods study. Digit Heal [Internet]. 2019 Jan 21;5:205520761987180 Available from: http://journals.sagepub.\ncom/doi/10\ufffd1177/2055207619871808\nTWEET RESUMEN\nTransformaci\u00f3n digital de la Gu\u00eda Farmacoterap\u00e9utica mediante el desarrollo de un agente conversacional basado en la \ninteligencia artificial\nCLASIFICACI\u00d3N: GESTI\u00d3N Y DESARROLLO ORGANIZATIVO; NUEVAS TECNOLOG\u00cdAS; PRODUCTOS SANITARIOS\n811. MAPA DEL MEDICAMENTO: INCORPORACI\u00d3N DE UNA HERRAMIENTA INTELIGENTE A LA VALI -\nDACI\u00d3N FARMAC\u00c9UTICA \nAUTORES\nMARTIN VAL, A; ARIAS MARTINEZ, A; VILARI\u00d1O SEIJAS, A; LAGUNA MARMOL, L; GARC\u00cdA CASTI\u00d1EIRA, C; BOCOS \nBAELA, A; BOSCH PELIGERO, MT; QUI\u00d1ONES RIBAS, C\nHOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA. CT . CANYET , S/N BADALONA. BARCELONA\nRESUMEN\nT\u00edtulo: Mapa del Medicamento: incorporaci\u00f3n de una herramienta inteligente a la validaci\u00f3n farmac\u00e9utica \n \nINTRODUCCI\u00d3N  \nLas organizaciones sanitarias consideran la seguridad en el uso de medicamentos un objetivo clave y la implantaci\u00f3n \nde estrategias que promuevan la prevenci\u00f3n de los errores de medicaci\u00f3n (EM) una prioridad. (1-3) Entre las \nrecomendaciones emitidas se encuentra la incorporaci\u00f3n de tecnolog\u00edas de la informaci\u00f3n que mejoren los actuales \nsistemas de soporte a la decisi\u00f3n cl\u00ednica. \n \nOBJETIVOS  \n- Crear un Mapa del Medicamento: sistema capaz de integrar diferentes datos cl\u00ednicos y generar alertas.  \n- Estandarizar la validaci\u00f3n farmac\u00e9utica de calidad promoviendo la seguridad en el uso de medicamentos.  \n- Evaluar el impacto tras su implantaci\u00f3n.  \n- Compartir la herramienta con los equipos asistenciales.  \n \nAPLICABILIDAD Y UTILIDAD DE LOS RESULTADOS  \nSe espera que la metodolog\u00eda presentada permita la creaci\u00f3n de una herramienta inteligente que se incorpore a la \npr\u00e1ctica cl\u00ednica, mejorando la seguridad del paciente gracias a la prevenci\u00f3n de EM.  \n \nDISE\u00d1O Y M\u00c9TODO  \n1. Creaci\u00f3n del grupo de trabajo entre Sistemas de la Informaci\u00f3n y el servicio de Farmacia, con el asesoramiento de \nm\u00e9dicos y enfermer\u00eda.  \n2. Definici\u00f3n de las alertas de validaci\u00f3n a parametrizar. \n3\ufffd Desarrollo y dise\u00f1o del Mapa del Medicamento\ufffd  \n4. Validaci\u00f3n de la herramienta en una unidad piloto.  \n5. Formaci\u00f3n al resto del equipo y ampliaci\u00f3n al resto unidades.  \n6. Evaluaci\u00f3n del impacto mediante el an\u00e1lisis de intervenciones farmac\u00e9uticas realizadas antes y tras su implantaci\u00f3n.  \n7. Colaboraci\u00f3n en la actualizaci\u00f3n y mantenimiento del sistema. \n \nCALENDARIO PREVISTO  \n1. Creaci\u00f3n del grupo de trabajo: abril de 2022.  \n2. Definici\u00f3n de las alertas de validaci\u00f3n a parametrizar: abril a julio de 2022.  \n3. Desarrollo y dise\u00f1o de la herramienta: julio a noviembre de 2022.  \n4\ufffd Validaci\u00f3n en unidad piloto: noviembre y diciembre de 2022\ufffd  \n5. Formaci\u00f3n al resto del equipo y ampliaci\u00f3n de la implantaci\u00f3n: enero 2023. \n6\ufffd Evaluaci\u00f3n del impacto: noviembre de 2022 a noviembre de 2023\ufffd  \n \nLIMITACIONES Y POSIBLES SESGOS  \nExistencia de diferentes sistemas de prescripci\u00f3n electr\u00f3nica\ufffd \nIntegraciones entre sistemas de informaci\u00f3n\ufffd  \nAplicabilidad de la ontolog\u00eda a los sistemas de informaci\u00f3n y herramienta a desarrollar. \n 578PROBLEMAS \u00c9TICOS  \nNo se contemplan\ufffd  \n \nORGANIZACI\u00d3N DEL ESTUDIO  \nA los farmac\u00e9uticos responsables del proyecto se les asignan las tareas de definici\u00f3n, conjuntamente con los \nfarmac\u00e9uticos referentes de \u00e1rea y asesor\u00eda de m\u00e9dicos y enfermer\u00eda, de las alertas de validaci\u00f3n a parametrizar; \nprogramaci\u00f3n de reuniones con Sistemas de la Informaci\u00f3n para acordar el dise\u00f1o de la herramienta; validaci\u00f3n en \nunidad piloto; formaci\u00f3n y ampliaci\u00f3n de la implantaci\u00f3n al resto de unidades del hospital; evaluaci\u00f3n de resultados; \nactualizaci\u00f3n y mantenimiento de la herramienta. \nSistemas de Informaci\u00f3n asume el desarrollo de la herramienta y la integraci\u00f3n de los diferentes datos cl\u00ednicos que \npermiten generar alertas por combinaci\u00f3n de los par\u00e1metros definidos (ej. alerta f\u00e1rmaco-resultado anal\u00edtico); soporte \na la validaci\u00f3n de la herramienta en unidad piloto; evaluaci\u00f3n de resultados tras la implantaci\u00f3n; actualizaci\u00f3n y \nmantenimiento de la herramienta. \n \nPRESUPUESTO  \nSe estima que el desarrollo del proyecto tendr\u00e1 un impacto econ\u00f3mico de 6.600 euros como resultado del tiempo \ninvertido en cada etapa.\nTWEET RESUMEN\nMapa del medicamento: herramienta inteligente para estandarizar la validaci\u00f3n farmac\u00e9utica y promover el uso seguro \nde medicamentos\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\nCLASIFICACI\u00d3N: ONCOHEMATOLOG\u00cdA\n438. PROYECTO QUAD: IMPLANTACI\u00d3N DE UN PROGRAMA DE ADMINISTRACI\u00d3N DE QUIMIOTERAPIA \nA DOMICILIO EN PACIENTES HEMATOL\u00d3GICOS CON SISTEMA DE TRAZABILIDAD \nAUTORES\nMANZANEQUE , A; VILLALOBOS , MT; MUNTA\u00d1OLA , A; L\u00d3PEZ , L; MOLAS , G; NICOL\u00c1S , J; MART\u00cd , JM\nHOSPITAL UNIVERSITARI MUTUA DE TERRASSA \ufffd PLAZA DOCTOR ROBERT 5 TERRASSA \ufffd BARCELONA\nRESUMEN\nIntroducci\u00f3n: con la aparici\u00f3n de nuevos f\u00e1rmacos para el tratamiento de neoplasias hematol\u00f3gicas, cada vez son m\u00e1s los \npacientes que deben desplazarse al hospital de d\u00eda (HD) para recibir tratamiento.  \nEn este contexto, se dispone de varias experiencias reportadas en el \u00e1mbito domiciliario, tanto de administraci\u00f3n de \nquimioterapia, como de seguimiento de pacientes hematol\u00f3gicos agudos demostrando la seguridad y coste-efectividad \nde esta modalidad (Ver bibliograf\u00eda:1,2). \n \nOBJETIVOS  \n\u2663 Mejorar la calidad de vida y satisfacci\u00f3n de los pacientes \n\u2663 Evitar desplazamientos en el hospital y posibles complicaciones derivadas de la estancia en los centros sanitarios  \n\u2663 Descargar a los cuidadores que les acompa\u00f1an en HD  \n\u2663 Mejorar la adherencia al tratamiento \n \nParalelamente, se dise\u00f1ar\u00e1 y validar\u00e1 un aplicativo (Oncosafety HomeCare) de trazabilidad a tiempo real, que se \nincorporar\u00e1 al circuito de administraci\u00f3n domiciliario dise\u00f1ado espec\u00edficamente para este proyecto.  \n \nAPLICABILIDAD\nEl programa QuaD con Oncosafety-HC, permite la implantaci\u00f3n de la administraci\u00f3n de quimioterapia a domicilio \nasegurando la trazabilidad del proceso.  \n \nUTILIDAD DE LOS RESULTADOS\nEl proyecto permitir\u00e1 a pacientes con neoplasias hematol\u00f3gicas recibir la quimioterapia en su domicilio con la misma \nseguridad que lo har\u00eda en el hospital mejorando la calidad de vida del paciente.  \nLa administraci\u00f3n mediante Oncosafety-HC permite conocer el estado de la administraci\u00f3n a tiempo real, pudiendo \ndetectar as\u00ed cualquier incidencia durante el proceso.  \n \nDISE\u00d1O\nSe realizar\u00e1 un estudio descriptivo, en el que se medir\u00e1n variables relacionadas con: tipo de tratamiento administrado \n(f\u00e1rmaco y v\u00eda de administraci\u00f3n), incidencias durante la administraci\u00f3n, incidencias relacionadas con el aplicativo \nOncosafety-HC, grado de satisfacci\u00f3n del paciente, escalas de calidad de vida (EORTC QLQ-C30, EQ-5D-5L), y costes \nasociados\ufffd579M\u00c9TODO\nSe cre\u00f3 un equipo multidisiciplinar (hematolog\u00eda, enfermer\u00eda y farmacia). Se elabor\u00f3 un plan de ejecuci\u00f3n de las fases \ndel proyecto, dise\u00f1o de circuitos de actuaci\u00f3n, y an\u00e1lisis de recursos necesarios. Se establecieron criterios de inclusi\u00f3n \nespec\u00edficos (basados en caracter\u00edsticas de: paciente, f\u00e1rmaco y esquema) para cada fase.  \n \nCALENDARIO  \nFase 1: f\u00e1rmacos orales con necesidad de monitorizaci\u00f3n espec\u00edfica y parenterales v\u00eda subcut\u00e1nea (Octubre 2021-Octubre \n2022) \nFase 2: incorporaci\u00f3n de f\u00e1rmacos intravenosos con tiempo de infusi\u00f3n \u2264 30 minutos. (Noviembre 2022-Abril 2023)  \nFase 3: incorporaci\u00f3n de f\u00e1rmacos intravenosos con tiempo de administraci\u00f3n > 30 minutos. (Abril 2023-Setiembre 2023)  \nFase 4: incorporaci\u00f3n de seguimiento de la fase de aplasia en auto-trasplantes de progenitores hematopoy\u00e9ticos y \nleucemias agudas en domicilio (Octubre 2023)  \nEl aplicativo Oncosafety-HC se dise\u00f1\u00f3 durante el 2021, y se est\u00e1 usando en nuestro centro desde marzo de 2022. \n \nLIMITACIONES\nSe requiere una adaptaci\u00f3n previa del programa de prescripci\u00f3n y administraci\u00f3n de quimioterapias para implantar \nla metodolog\u00eda de trabajo mediante Oncosafety-HC. En nuestro centro ya se dispon\u00eda de Oncosafety (integrado con el \naplicativo Farmis_Oncofarm) en la administraci\u00f3n de tratamientos en HD, por lo que la implantaci\u00f3n de Oncosafety-HC, \nha sido relativamente sencilla.  \n \nPRESUPUESTO\nActualmente, con un presupuesto aproximado de 20.000\u20ac, se han realizado 332 administraciones (67,8% con Oncosafety-\nHC) a domicilio (13 pacientes). \n \nProblemas \u00e9ticos: se dispone un sistema inform\u00e1tico de protecci\u00f3n de datos personales y el proyecto dispone de la \nconformidad del comit\u00e9 de \u00e9tica del centro.  \n \nBIBLIOGRAF\u00cdA  \nhttp://doi.org/10.22585/hospdomic.v4i1.98 \nhttps://doi.org/10.1016/j.critrevonc.2018.03.011\nTWEET RESUMEN\nLos pacientes hematol\u00f3gicos se benefician de la administraci\u00f3n con trazabilidad de quimioterapia a domicilio\nIMAGEN O GR\u00c1FICO DEL PROYECTO\n580CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N \nASISTENCIAL\nCLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n144. IMPLEMENTACI\u00d3N DE UNA HERRAMIENTA DE SALUD M\u00d3VIL PARA EL SEGUIMIENTO FARMACO -\nTERAP\u00c9UTICO DE LOS PACIENTES CON C\u00c1NCER COLORRECTAL EN TRATAMIENTO QUIMIOTER\u00c1PICO \nAUTORES\nRIERA ARMENGOL, P; PAG\u00c8S PUIGDEMONT , N; MASIP TORN\u00c9, M; DE DIOS L\u00d3PEZ, A; RIBA SOL\u00c9, M; RAM\u00cdREZ L\u00d3PEZ, \nL; MART\u00cdN CULLELL, B; P\u00c1EZ L\u00d3PEZ-BRAVO, D\nHOSPITAL DE LA SANTA CREU I SANT PAU \ufffd SANT ANTONI MARIA CLARET , 167 BARCELONA \ufffd BARCELONA\nRESUMEN\nINTRODUCCI\u00d3N \nLos pacientes con c\u00e1ncer colorrectal (CCR) tratados con quimioterapia suelen presentar efectos adversos (EA) que afectan \na su calidad de vida, por lo que es preciso un manejo r\u00e1pido y adecuado (1). La detecci\u00f3n precoz de estos EA mediante \nsalud m\u00f3vil puede disminuir la gravedad de los mismos y el n\u00famero de visitas a Hospital de D\u00eda/Urgencias (2).  \nPor otro lado, el mantenimiento de la calidad de vida es uno de los objetivos en el paciente oncol\u00f3gico y es un aspecto \nmuy valorado por los propios pacientes\ufffd \n \nOBJETIVOS  \n1) Implementar una App/plataforma de salud digital (EMMASalud) para el seguimiento multidisciplinar telem\u00e1tico en \npacientes con CCR en tratamiento quimioter\u00e1pico.  \n2) Empoderar al paciente y/o cuidador para el registro proactivo de las toxicidades (Patient-Reported Outcomes, PROs).  \n3) Potenciar la interacci\u00f3n con el profesional sanitario (m\u00e9dico-farmac\u00e9utico-enfermera) a trav\u00e9s de eConsultas sobre EA, \ninteracciones y pauta terap\u00e9utica. \n4) Mejorar la experiencia del paciente, valorada mediante cuestionarios de calidad de vida y satisfacci\u00f3n. De ese modo, se \npretende adaptar e individualizar la asistencia sanitaria a las necesidades del paciente.  \n \nAPLICABILIDAD Y UTILIDAD DE LOS RESULTADOS  \nEMMASalud permite mejorar el registro de los PROs en relaci\u00f3n a las toxicidades farmacol\u00f3gicas y otros aspectos \nrelacionados con la calidad de vida, al realizarse por parte del propio paciente y/o cuidador de forma prospectiva. Esto \nconlleva una detecci\u00f3n y abordaje m\u00e1s precoces de las toxicidades.  \n \nDISE\u00d1O Y M\u00c9TODO  \nEn 2021 se adapt\u00f3 EMMASalud a las caracter\u00edsticas y necesidades de los pacientes con CCR. La plataforma incorpora los \nsiguientes cuestionarios: ansiedad y depresi\u00f3n (HADS), calidad de vida (EORTC) y adherencia terap\u00e9utica (Morisky-Green) \npara los pacientes que reciben esquemas con capecitabina. En cuanto a los EA, se incluyeron aquellos caracter\u00edsticos de \nlos esquemas terap\u00e9uticos habituales en CCR.  \nPara determinar si esta herramienta es efectiva, se comparar\u00e1n los resultados de toxicidad obtenidos con una cohorte \nhist\u00f3rica equivalente.  \n \nCALENDARIO PREVISTO  \nLa implementaci\u00f3n de esta herramienta se inici\u00f3 en 01/2022 con el objetivo de que, si los resultados son favorables, \nquede implementada en la ruta asistencial de los pacientes con CCR. \n \nLIMITACIONES Y POSIBLES SESGOS  \nAlgunos pacientes, ya sea por barrera idiom\u00e1tica o tecnol\u00f3gica, pueden quedar excluidos de recibir esta intervenci\u00f3n, lo \nque podr\u00eda suponer un sesgo de selecci\u00f3n.  \n \nPROBLEMAS \u00c9TICOS  \nEl proyecto fue aprobado por el Comit\u00e9 \u00c9tico del Hospital (2021).  \n \nORGANIZACI\u00d3N DEL ESTUDIO  \nEl onc\u00f3logo, en la visita pre-tratamiento, propone al paciente el uso de EMMASalud. A continuaci\u00f3n, la enfermera gestora \nde casos activa la plataforma y explica su funcionamiento al paciente. Posteriormente, los farmac\u00e9uticos programan \ny revisan los cuestionarios. El equipo m\u00e9dico y enfermer\u00eda revisan los autocontroles y los efectos adversos/s\u00edntomas \nnotificados por los pacientes. Cada miembro del equipo resuelve las dudas enviadas por los pacientes mediante la \nmensajer\u00eda. El equipo de farmacia resuelve consultas sobre la medicaci\u00f3n e interacciones, y realiza intervenciones para \nfomentar la adherencia en pacientes con tratamiento quimioter\u00e1pico oral.  \n \nPRESUPUESTO  \nProyecto financiado por: FIS (PI21/01913) y AI-FEFH.  \n 581BIBLIOGRAF\u00cdA  \n1. Lapinsky E et al. Curr Oncol Rep 2019; 21(9):81.  \n2. Basch E et al. J Clin Oncol 2016; 34(6):557 -65.\nTWEET RESUMEN\nImplementaci\u00f3n pionera en Espa\u00f1a de una herramienta de salud m\u00f3vil (EMMASalud) para el seguimiento \nfarmacoterap\u00e9utico en c\u00e1ncer colorrectal\nIMAGEN O GR\u00c1FICO DEL PROYECTO\n582CLASIFICACI\u00d3N: SEGURIDAD, GESTI\u00d3N DEL RIESGO, CALIDAD Y HUMANIZACI\u00d3N ASISTENCIAL\n541. ELABORACI\u00d3N CENTRALIZADA EN EL SERVICIO DE FARMACIA Y EVALUACI\u00d3N DEL USO DE PLASMA \nRICO EN PLAQUETAS EN PATOLOG\u00cdAS MUSCULOESQUEL\u00c9TICAS. \nAUTORES\nFERRIS VILLANUEVA, M; GARCIA MORENO, FJ; GIM\u00c9NEZ MANZORRO, \u00c1; PERN\u00cdA L\u00d3PEZ, S; RIBED S\u00c1NCHEZ, A; \nESCUDERO VILAPLANA, V; HERRANZ ALONSO, A; SANJURJO S\u00c1EZ, M\nHOSPITAL GENERAL UNIVERSITARIO GREGORIO MARA\u00d1\u00d3N \ufffd DR ESQUERDO, 46 MADRID \ufffd MADRID\nRESUMEN\nINTRODUCCI\u00d3N\nEn los \u00faltimos a\u00f1os, el plasma rico en plaquetas (PRP) ha despertado gran inter\u00e9s como herramienta terap\u00e9utica por sus \npropiedades reparadoras de tejidos con bajo aporte sangu\u00edneo (cart\u00edlago, tendones, ligamentos, etc). El PRP es plasma \naut\u00f3logo con una concentraci\u00f3n de plaquetas superior al nivel basal que, tras su desgranulaci\u00f3n, libera factores de \ncrecimiento y citoquinas, disminuyendo la inflamaci\u00f3n tisular y aumentando su vascularizaci\u00f3n.  \nPese a tratarse de un medicamento de uso humano, su elaboraci\u00f3n no est\u00e1 centralizada en los Servicios de Farmacia, \ngenerando incertidumbre sobre la calidad y trazabilidad del proceso. Existe controversia sobre su eficacia y los estudios \nque respaldan su uso son considerados de baja calidad. Adem\u00e1s, suele usarse ajeno a las Comisiones de Farmacia y sin los \nprocedimientos de evaluaci\u00f3n de otros medicamentos\ufffd  \n \nOBJETIVOS  \n1. Desarrollar un procedimiento de elaboraci\u00f3n centralizada de PRP en un Servicio de Farmacia. \n2. Evaluar la efectividad y seguridad del uso de PRP en las indicaciones de gonartrosis y ciertas entesopat\u00edas a partir de \nevaluaci\u00f3n de resultados en salud (PROs), t\u00e9cnicas de imagen y tiempo hasta precisar intervenci\u00f3n quir\u00fargica (IQ).  \n \nAPLICABILIDAD Y UTILIDAD DE LOS RESULTADOS:  \nAl tratarse de una elaboraci\u00f3n mediante t\u00e9cnica cerrada, es aplicable a todos los Servicios de Farmacia. La centralizaci\u00f3n \ndel proceso definir\u00e1 el papel del Servicio de Farmacia como piedra angular en la elaboraci\u00f3n, control de calidad y \ntrazabilidad del preparado.  \nLos resultados obtenidos aportar\u00e1n evidencia sobre efectividad y seguridad del uso de PRP en las patolog\u00edas \nseleccionadas\ufffd  \n \nDISE\u00d1O Y M\u00c9TODO  \nEstudio observacional prospectivo sobre el uso de PRP en gonartrosis y entesopat\u00edas (epicondilitis, tendinopat\u00eda del \nsupraespinoso, tendinopat\u00eda aqu\u00edlea y fasciopat\u00eda plantar) con limitadas opciones terap\u00e9uticas previas a IQ.  \nVariable principal: Capacidad funcional y calidad de vida del paciente medido a trav\u00e9s de PROs adaptados seg\u00fan \npatolog\u00eda: \u00edndice WOMAC [osteoartritis], QUICK DASH [entesopat\u00edas de extremidades superiores], FAAM [entesopat\u00eda de \ntobillo y pie]).  \nVariables secundarias: Evaluaci\u00f3n del dolor mediante Escala Visual Num\u00e9rica [EVN], regeneraci\u00f3n tisular evaluada por \necograf\u00eda y tiempo transcurrido hasta precisar IQ comparado con aquellos pacientes con situaci\u00f3n cl\u00ednica similar y que no \nreciben PRP \ufffd \nLas variables ser\u00e1n recogidas los meses 0, 3 y 12.  \nSe registrar\u00e1n los efectos adversos asociados al tratamiento  \n \nCALENDARIO PREVISTO  \nEnero 2022\u2013mayo 2022: Protocolizaci\u00f3n de prescripci\u00f3n, elaboraci\u00f3n, dispensaci\u00f3n y seguimiento.  \nJunio 2022\u2013junio 2023: Selecci\u00f3n de pacientes, elaboraci\u00f3n y tratamiento.  \nJunio 2022\u2013junio 2024: Seguimiento de efectividad y seguridad.  \nJunio 2024-agosto 2024: An\u00e1lisis y procesamiento de datos.  \nSeptiembre 2024\u2013diciembre 2024: Comunicaci\u00f3n y publicaci\u00f3n de resultados.  \n \nLIMITACIONES Y POSIBLES SESGOS  \nLa no aleatorizaci\u00f3n de pacientes. \n \nPROBLEMAS \u00c9TICOS  \nSe solicitar\u00e1 aprobaci\u00f3n del Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n con medicamentos (CEIm) y se obtendr\u00e1 el \nconsentimiento informado del paciente antes de iniciar el tratamiento.  \n \nORGANIZACI\u00d3N DEL ESTUDIO  \nServicios de Farmacia y Rehabilitaci\u00f3n.  \n \nPRESUPUESTO  \nCoste anual estimado asociado al consumo de kits de PRP: 15.682 \u20ac. \n 583BIBLIOGRAF\u00cdA  \n1. https://www.aemps.gob.es/medicamentosUsoHumano/medSituacionesEspeciales/docs/PRP-AEMPS-DEF-mayo13.\npdf?x40511  \n2. Moreno R, et al. T\u00e9cnicas de obtenci\u00f3n del plasma rico en plaquetas y su empleo en terap\u00e9utica osteoinductora. Farm \nHosp. 2015;39(3): 130-136.\nTWEET RESUMEN\nEl Servicio de Farmacia como piedra angular en elaboraci\u00f3n centralizada y evaluaci\u00f3n de #PRP en patolog\u00edas \nmusculoesquel\u00e9ticas #Reform\u00falate\nIMAGEN O GR\u00c1FICO DEL PROYECTO\n585CASOS CL\u00cdNICOS\nBEVACIZUMAB EN SCHWANNOMATOSIS FAMILIAR  \nINTRODUCCI\u00d3N  \nLa Schwannomatosis es una polineoplasia de nervio perif\u00e9rico. Reconocida como cl\u00ednica y \ngen\u00e9ticamente distinto de la neurofibromatosis tipo 1 (NF1) y la neurofibromatosis tipo 2 \n(NF2) por primera vez a finales de la d\u00e9cada de los noventa. 1  \nUna de cada 40.000 personas en todo el mundo desarrolla schwannomatosis. Es un \ntrastorno gen\u00e9tico raro, la persona que lo padece genera tumores no cancerosos \n(benignos) , llamados  schwannomas , que  conduce a la formaci\u00f3n de m\u00faltiples schwannomas \nno cut\u00e1neos en los nervios perif\u00e9ricos, las ra\u00edces espinales y los nervios craneales. Las \nmutaciones de la l\u00ednea germinal en el gen supresor de tumores SMARCB1  est\u00e1n presentes \nhast a en el 50% de los casos familiares y en una peque\u00f1a proporci\u00f3n de los casos \nespor\u00e1dicos. 2  \nEl dolor cr\u00f3nico es muy com\u00fan en pacientes con schwannomatosis y afecta \naproximadamente a dos tercios de los pacientes. La etiolog\u00eda del dolor suele ser compleja, \ncon una mezcla de caracter\u00edsticas neurop\u00e1ticas y nociceptivas. Los factores de riesgo para el \ndolor no est\u00e1n bien caracterizados. El tama\u00f1o, la ubicaci\u00f3n y el n\u00famero de tumores no se \ncorrelacionan bien con la morbilidad relacionada con el dolor. 3 Sin embargo, el volumen \ntotal del tumor se correlacion\u00f3 con un aumento de las puntuaciones de dolor en un \nestudio. 4 Algunos pacientes experimentan dolor que no parece correlacionarse con tumores \nespec\u00edficos y puede ser de naturaleza difusa. El dolor puede  ser dif\u00edcil de controlar \nm\u00e9dicamente y puede volverse incapacitante . La resecci\u00f3n debe reservarse para tumores \nsintom\u00e1ticos o cuando exista amenaza de causar compresi\u00f3n de la m\u00e9dula espinal. 3 586El tratamiento de pacientes con schwannomatosis es principalmen te sintom\u00e1tico. \nActualmente, no existen terapias m\u00e9dicas establecidas que se dirijan a la enfermedad \nsubyacente. Siempre que sea posible, los pacientes deben ser atendidos por un equipo \nmultidisciplinario con experiencia en el cuidado de pacientes con neur ofibromatosis.  \nDESCRIPCI\u00d3N DEL CASO:  \nVar\u00f3n de 42 a\u00f1os, con antecedentes familiares: hermano y padre fallecidos a los 35 a\u00f1os \npor schwannomatosis.  \n Diagnosticado de Schwannomatosis familiar con paraparesia progresiva y disfunci\u00f3n \nesfinteriana, asociada a co la de caballo, paresia de miembros superiores (ra\u00edces C8 -T1) \ncr\u00f3nica. Reflujo vesicorrenal derecho grado III, disfunci\u00f3n vesicouretral tipo vejiga \nneurog\u00e9nica motoneurona superior (NMS). Hiperactividad neurog\u00e9nica del detrusor, \ninsuficiencia contr\u00e1ctil. Di vert\u00edculo uretral. Se le realiz\u00f3 adenoidectom\u00eda en la infancia.  \nIntervenciones:  \n\u2022 En 2001 de neurofibroma cervical C1 -C4. \n\u2022 En 2003 de neurofibroma de rama muscular del nervio ci\u00e1tico derecho, confirmado \nschwannoma por anatom\u00eda patol\u00f3gica (AP).  \n\u2022 En 2004 de lesi\u00f3n expansiva intracraneal y de musculatura paravertebral (AP de \ntumor maligno de nervio perif\u00e9rico, neurofibroma maligno).  \n\u2022 En 2009 por un tumor orbitario derecho (AP de tumor maligno de vaina  nerviosa \nperif\u00e9rica ). Resaltar la malignidad de ambos tumores (2004 y 2009) , debido a lo \ninusual que resulta  en est a enfermedad .  587En 2011 se le realiza un estudio gen\u00e9tico, donde se identifica la variante patog\u00e9nica:  \nc.207_208dupTA (p.Lys70lle fs X16) en el gen SMARCB I. \nDesde el diagn\u00f3stico el paciente presenta m\u00faltiples schwannomas, de los cuales,  se van \nresecando aquellos que por el tama\u00f1 o o la localizaci\u00f3n van ocasionando cl\u00ednica neurol\u00f3gica \no dolor . Hasta que en junio de 2021 cuando acude a consulta de medicina interna , presenta \nun empeoramiento generalizado de las les iones , con aum ento del dolor especialmente a \nnivel de miembros inferiores (MMII) , se realiza  resonancia magn\u00e9tica (RM) de columna \ndorsal con/sin contraste, con firmando  la progresi\u00f3n  a trav\u00e9s  de m\u00faltiples im\u00e1genes \ncompatibles con schwannomas  a nivel cervical, dorsal y lumbar . Ante  la progresi\u00f3n y  el \naumento del dolor, se propone abordaje multidisciplinar para valorar las opciones de \ntratamiento para el paciente. Adem\u00e1s, s e comenta el caso con la unidad de Facomatosis del \nICO, en conjunto con ellos , se toma la decisi\u00f3n de solicit ar Bevacizumab.  \nDesde el servicio de oncolog\u00eda se ponen en contacto con el servicio de farmacia hospitalaria \n(SFH), informando de la situaci\u00f3n cl\u00ednica del paciente, al no existir un  tratamiento m\u00e9dico \npara dicho tumor, tras revisi\u00f3n bibliogr\u00e1fica, se concluye que la monoterapia con \nbevacizumab podr\u00eda ser la mejor opci\u00f3n terap\u00e9utica, fundamentado en la evidencia \ndemostrada por bevacizumab en el tratamiento del schwannoma vestibular pr ogresivo en la \nNF2 .(5,6,7,8,9,10,11,12,13)  \nEn base a la creencia de que el crecimiento de los tumores depende de la formaci\u00f3n de \nnuevos vasos sangu\u00edneos a partir del sistema vascular (angiog\u00e9nesis y vasculog\u00e9nesis). \nRegulada a trav\u00e9s de sustancias qu\u00edmicas , entre ellas el \u201cfactor de crecimiento endotelial \nvascular\u201d (VEGF en ingl\u00e9s) que estimula la proliferaci\u00f3n, desplazamiento y supervivencia de 588los vasos sangu\u00edneos. El VEGF es una prote\u00edna presente en nuestro organismo y tambi\u00e9n es \nproducida por los tumore s, por lo que es un objetivo para las terapias antic\u00e1ncer. 14 \nBevacizumab es un anticuerpo monoclonal que se une a VEGF, factor clave de la \nvasculog\u00e9nesis y la angiog\u00e9nesis, inhibiendo as\u00ed la uni\u00f3n de \u00e9ste a sus receptores Flt \u20111 \n(VEGFR\u20111) y KDR (VEGFR \u20112), situados en la superficie de las c\u00e9lulas endoteliales. \nNeutralizando la actividad biol\u00f3gica del VEGF produciendo una regresi\u00f3n de la \nvascularizaci\u00f3n de los tumores, normalizando la vasculatura residual del tumor e inhibe la \nneovascularizaci\u00f3n tumoral, inhib iendo as\u00ed el crecimiento del tumor. 15 \nDesde SFH se solicita el uso off label del bevacizumab, ya que no dispone de esta indicaci\u00f3n. \nRecibiendo aprobaci\u00f3n por parte de la comisi\u00f3n de la comunidad e inici\u00e1ndose tratamiento \ncon bevacizumab (21/05/22). Esquema de tratamiento: BEVACIZUMAB 7.5mg/kg cada 2 \nsemanas (Peso 59kg, dosis 440 mg), hasta ciclo 16 (18/01/22) donde se pasa a esquema \nBEVACIZUMAB 7.5mg/kg cada 3 semanas con el fin de conseguir una mayor comodidad para \nel paciente .16 \nDurante  el tratamiento, eventos adversos registrados: leve proteinuria (grado I) desde \n5\u00baciclo que mantiene hasta 11\u00ba ciclo, tras 4 -5 ciclos mantiene de forma ocasional sensaci\u00f3n \nde calambres y hormigueo en ambos MMII , 2 episodios aislados d e taquicardia \nsupraventricular (julio 2021 y abril 2022) documentados a trav\u00e9s de electrocardiograma \n(ECG). Episodios ocasionales de epitaxis (desde el ciclo 14 al 16). Todos resueltos, sin \nnecesidad de reducci\u00f3n de dosis.  \nA continuaci\u00f3n, se muestra una g r\u00e1fica de la evoluci\u00f3n del proteinograma del paciente \ndurante el tratamiento con bevacizumab (normalidad: 0 -150 miligramos/24 horas):  589 \n \nRelevancias cl\u00ednicas dur ante tratamiento: A partir 8\u00ba ciclo leve mejor\u00eda cl\u00ednica al levantarse.  \nTras 13 ciclo, refiere remisi\u00f3n del dolor lumbar cr\u00f3nico que aquejaba previamente, aunque \nmantiene dolor fluctuante irradiado de ambas regiones inguinales hacia MMII, sobre el que \nrefiere mejor\u00eda al acudir a 20\u00ba ciclo (en tratamiento con tramadol 75mg cada 8 horas y \npregabalina 75 mg cada 12 horas).  \nEn noviembre de 2021 se solicita nueva RM de columna completa para reevaluar, de cara a \najustar dosis bevacizumab. En la que se describe l igero aumento de tama\u00f1o \n(aproximadamente del 20%) de los neurofibromas -schwannomas localizados en regi\u00f3n \norbital derecha. Por otro lado, aparici\u00f3n de imagen nodular de 6x7 mm compatible con \nneurofibroma del V par craneal I. En el resto del estudio se infor ma de estabilidad \nmorfol\u00f3gica de las lesiones, algunas de ellas se describen con contenido qu\u00edstico -\nhemorr\u00e1gico.  \nAnte la ausencia de alternativas terap\u00e9uticas  y un perfil riesgo -beneficio favorable,  con una  \nmejor\u00eda  cl\u00ednica por disminuci\u00f3n del dolor, especialmente en piernas y caderas,  se decide \nmantener tratamiento  con bevacizumab . \nValor promedio m\u00f3vil  \nL\u00edmite  de normalidad  590Actualmente el paciente ha recibido un total de 21 ciclos, tras los cuales, se pu ede \nconsiderar que se ha conseguido una estabilizaci\u00f3n de la enfermedad  y una mejor\u00eda  cl\u00ednica , \ncon disminuci\u00f3n del dolor , especialmente en piernas y caderas . Mantiene remisi\u00f3n de dolor \nlumbar cr\u00f3nico  y mejor\u00eda de dolor fluctuante en ambos MMII controlado con tramadol (75 \nmg cada 8 horas) junto a pregabalina (75mg cada 12 horas).  \nTampoco presenta toxicidades relevantes , salvo leve astenia los d\u00edas posteriores al ciclo. TA \ncontrolada, en torno a 120/80 -70, sin sangrados objetivos.  \nDISCUSI\u00d3N Y APORTACION FARMAC\u00c9UTICA \nEn el caso cl\u00ednico anteriormente descrito, el farmac\u00e9utico ejerce un papel clave en la \ntramitaci\u00f3n de uso off label del bevacizumab, manejo y ajuste de dosis  del mismo, \nelaboraci\u00f3n en la unidad de mezclas intravenosas y productos est\u00e9riles del SFH, as\u00ed como \nrecomendaciones de estabilidad, manipulaci\u00f3n y administraci\u00f3n. Adem\u00e1s de seguimiento de \npaciente, a trav\u00e9s de la comunicaci\u00f3n con el onc\u00f3logo. Cabe resalta r la importancia de un \nabordaje multidisciplinar debido a la complejidad y caracter\u00edsticas de la enfermedad.  \nDebido a la propia naturaleza de la enfermedad y a la elevada carga tumoral, es dif\u00edcil \nevaluar la respuesta al f\u00e1rmaco, pero dada la complejidad d e la misma, y la limitaci\u00f3n de \ntratamiento, a pesar de que el mecanismo patol\u00f3gico no est\u00e1 totalmente definido, lo que \nparece evidente, es que la inclusi\u00f3n de bevacizumab en el tratamiento, aportar beneficio \ncl\u00ednico al paciente, estabilizando y/o retrasand o la progresi\u00f3n de la enfermedad, as\u00ed como \nmejorando su calidad de vida.  \nBIBLI OGRAF\u00cdA : 5911. MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and \npathologic study. Neurology 1996; 46:1072.  \n2. J W C Reinders , P J Koehler  Familial  schwannomatosis, a new entity distinct from \nneurofibromatosis type 1 and 2. Ned Tijdschr Geneeskd 2007 Aug 25;151(34):1891 -5. \n3. M MacCollin , E A Chiocca , D G Evans , J M Friedman , R Horvitz , D Jaramillo , M Lev , V F \nMautner , M Niimura , S R Plotkin , C N Sang , A Stemmer -Rachamimov , E S Roach.  \nDiagnostic criteria for schwannomatosis. 2005 Jun 14;64(11):1838 -45. \n4. Justin T Jordan , Miriam J Smith , James A Walker , Serkan Erdin , Michael E Talkowski , \nVanessa L Merker , Vijaya Ramesh , Wenli Cai , Gordon J Harris , Miriam A Bredella , Marlon \nSeijo , Alessandra Suuberg , James F Gusella , Scott  R Plotkin.  Pain correlates with germline \nmutation in schwannomatosis. 2018 Feb;97(5):e9717.  \n5. Morris KA, Golding JF, Axon PR, et al. Bevacizumab in Neurofibromatosis type 2 (NF2) \nrelated vestibular schwannomas: a nationally coordinated approach to delive ry and \nprospective evaluation. Neuro -Oncology Practice 2016.  \n6. Mautner VF, Nguyen R, Kutta  H, et al. Bevacizumab induces regression of vestibular \nschwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010; 12:14.  \n7. Plotkin SR, Stemmer- Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after \nbevacizumab in patients with neurofib romatosis type 2. N Engl J Med 2009; 361:358.  \n8. Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular \nschwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol \nNeurotol 2012; 33:1046.  \n9. Hochart A, Gaillard V, Baroncini M, et al. Bevacizumab decreases vestibular \nschwannomas growth rate in children and teenagers with neurofibromatosis type 2. J \nNeurooncol 2015; 124:229.  59210. Blakeley JO, Ye X, Duda DG, et al. Efficacy and Biomarker Study of Bevacizumab for \nHearing Los s Resulting From Neurofibromatosis Type 2 -Associated Vestibular \nSchwannomas. J Clin Oncol 2016; 34:1669.  \n11. Sverak P, Adams ME, Haines SJ, et al. Bevacizumab for Hearing Preservation in \nNeurofibromatosis Type 2: Emphasis on Patient -Reported Outcomes and Toxic ities. \nOtolaryngol Head Neck Surg 2019; 160:526.  \n12. Li KL, Djoukhadar I, Zhu X, et al. Vascular biomarkers derived from dynamic contrast -\nenhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in \ntype 2 neurofibromatosis. Neuro Oncol 2016; 18:275.  \n13. Lu VM, Ravindran K, Graffeo CS, et al. Efficacy and safety of bevacizumab for vestibular \nschwannoma in neurofibromatosis type 2: a systematic review and meta -analysis of \ntreatment outcomes. J Neurooncol 2019; 144:239.  \n14. Kazazi -Hyseni F, Beijnen  JH, Schellens JHM. Bevacizumab. The Oncologist. \n2010;15(8):819 -825. doi:10.1634/theoncologist.2009 -0317  \n15. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios.  https:/ /www.aemps.gob.es  \n16. Plotkin SR, Duda DG, Muzikansky A, et al. Multicenter, Prospective, Phase II and \nBiomarker Study of High -Dose Bevacizumab as Induction Therapy in Patients With \nNeurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Onco l 2019; \n37:3446.  \n \n 593Rubio Alo nso L, G ea Navarrete S, Gonz\u00e1lez Mateo A, Soler Company E.  \nAdecuaci\u00f3n  farmacoterap\u00e9utica en paciente anciano polimedicado en urgencias  \nIntroducci\u00f3n  \nLa adecuaci\u00f3n farmacoterap\u00e9utica  es el proceso de revisi\u00f3n cl\u00ednica de la medicaci\u00f3n. \nSe valoran si los criterios que determinan qu\u00e9 f\u00e1rmaco es el m\u00e1s eficaz y seguro para \nun paciente en situaciones ideales, se adapta a su situaci\u00f3n real. Un medicamento se \nconsidera adecua do cuando existen evidencias para su empleo en una indicaci\u00f3n \nconcreta, es bien tolerado por el paciente y es coste -efectivo.  \nLa falta de adecuaci\u00f3n terap\u00e9utica es un problema f recuente en la pr\u00e1ctica cl\u00ednica que  \nva de la mano de repercusiones cl\u00ednicas im portantes como deterioro de salud y calidad \nde vida del paciente, aumento de ingr esos hospitalarios y aumento de mortalidad.  \nEstas repercusiones cl\u00ednicas son mucho m\u00e1s notables en pacientes mayores de 65 a\u00f1os \ncon m\u00faltiples patolog\u00edas. Esta es una situaci\u00f3n que se trad uce, en general, en una \npolifarmacia dif\u00edcil de manejar y susceptible de numerosos errores y problemas \nrelacionados con los medicamentos (PRM). \nPor todo esto es conveniente implementar intervenciones que permitan mejorar la \nadecuaci\u00f3n de los tratamientos. En los centros hospitalarios es clave llevar a cabo la \nrevisi\u00f3n farmacoterap\u00e9utica en el Servicio de Urgencias, ya que, normalmente es la \nprimera parada de un cambio en el proceso asistencial de los pacientes.  \nDescripci\u00f3n del caso  (presentaci\u00f3n cl\u00ednica y evoluci\u00f3n).  \nLa protagonista de este caso cl\u00ednico es una mujer de 85 a\u00f1os institucionalizada en una \nresidencia sin deterioro cognitivo.  594Como antecedentes de salud destacan: arritmia cardiaca por fibrilaci\u00f3n auricular, \nhipertensi\u00f3n arterial, dislipemia, ane mia macroc\u00edtica, osteopen ia/osteoporosis y \nenfermedad pulmonar intersticial difusa (EPID).  \nLa medicaci\u00f3n habitual de la paciente se recoge en la siguiente tabla:  \nPrincipio activo  Dosis  Posolog\u00eda  \nCalcio carbonato + colecalciferol  1000 mg/880 UI  1/24 horas  \n\u00c1cido ibandr\u00f3nico  150 mg  Mensual  \nEnalapril  5 mg  1/24 horas  \nSimvastatina  20 mg  1/24 horas  \nAcenocumarol  1 mg  Seg\u00fan hematolog\u00eda  \nCianocobalamina + \u00e1cido f\u00f3lico  2/400 mcg  1/24 horas  \nOmeprazol  20 mg  1/24 horas  \nCarmelosa s\u00f3dica  10 mg/ml  1 monodosis/24 horas  \nBromuro de ipratropio  20 mcg  2 pulsaciones/8 horas  \nBisoprolol  2.5 mg  1/24 horas  \nAmiodarona  200 mg  1/24 horas  \nFurosemida  40 mg  1/24 horas  \nTabla1: medicaci\u00f3n habitual de la paciente  \nLa paciente fue trasladada al Servicio de Urgencias en Soporte Vital B\u00e1sico por fiebre, \nsensaci\u00f3n de debilidad, disnea y n\u00e1useas sin v\u00f3mitos.  \nEn la primera exploraci\u00f3n f\u00edsica la paciente presentaba fiebre (38,8\u00baC), tensi\u00f3n arterial \n(TA) de 67/39 mmHg y sa turaci\u00f3n de oxigeno del 99% con soporte de gafas nasales a 5952L/minuto. No presentaba edemas de miembros inferiores ni disminuci\u00f3n de la \ndiuresis.  \nEn la auscultaci\u00f3n card\u00edaca se detectaron tono s arr\u00edtmicos sin soplos y en la \nauscultaci\u00f3n pulmonar crepitantes  basales.  \nComo pruebas complementarias se realizaron una radiograf\u00eda de t\u00f3rax, en la que se \nobserv\u00f3 un patr\u00f3n t\u00edpico de neumon\u00eda derecha y un electrocardiograma en el que se \nconfirm\u00f3 la arritmia cardiaca que ya presentaba la paciente.  \nAdem\u00e1s se le realiz \u00f3 una anal\u00edtica. C abe desta car del hemograma una Hb de 10,20 g/dl \n(tiene un diagn\u00f3stico previo de su M\u00e9dico de Atenci\u00f3n Primaria (MAP) de anemia \nmacroc\u00edtica) y de la bioqu\u00edmica una hiponatremia (Na 129 mEq/l), el Prp BNP -NT \nelevado (3.529 pg/ml) y la prote \u00edna C reactiva elevada (104,9 mg/dl). \nTras la exploraci\u00f3n y las pruebas realizadas se diagnostica en urgencias de neumon\u00eda \nderecha. Se decide el ingreso en el Servicio de Neumolog\u00eda.  \nAl ingreso en planta se ampli\u00f3 el estudio con un ecocardio donde se vio d errame \nperic\u00e1rdico ligero de aspecto cr\u00f3nico sin compromiso hemodin\u00e1mico y con una \ngasometr\u00eda en la que destaca un CO 2 total de 29,00 mmol/L y pO 2 de 66,60 mmHg.  \nLas cifras de tensi\u00f3n arterial fueron remontando  en las siguientes 36 h  hasta alcanzar \nvalores  en rango (71/39, 73/46, 88/54, 107/70 y 101/50).  \nEn el hemograma de seguimiento, la Hb se mantuvo en valores acordes a la anemia \nmacroc\u00edtica (10,7 g/dl). En la bioqu\u00edmica el Na aument\u00f3 a 133  mEq/l y  el Prp BNP -NT \ncontinu\u00f3  siendo elevado ( 1.818 pg /ml, 7.213 pg/ml y 4.884 pg/ml). La prote\u00edna C \ndescendi\u00f3 significativamente a 25.9 mg/l en la anal\u00edtica previa al alta.  596Tambi\u00e9n se realiz\u00f3 una gasometr\u00eda adicional donde se observ\u00f3 un CO 2 total de 36.50 \nmmol/L y un pO 2 de 69,00 mmHg.  \nAnte la mejor\u00eda cl\u00ednica y anal\u00edtica de la paciente, sin hipercapnia y con SO 2 del 95% con \nsoporte de gafas nasales a 1L/ minuto  se decide dar el alta a la paciente con control en \nconsultas externas de neumolog\u00eda.  \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica  \nAnte un caso de pacient e anciano polimedicado que ingresa en urgencias se debe \nrealizar una primera revisi\u00f3n farmacoterap\u00e9utica  siempre que sea posible en presencia \ndel paciente y/o cuidador , ya que ser\u00e1 el punto de partida para el seguimiento y \nvalidaci\u00f3n terap\u00e9utica posterior. Tambi\u00e9n esta revisi\u00f3n es clave para recomendar \najustes de trat amiento al alta. Tras la revisi\u00f3n del historial farmacoterap\u00e9utico, realizar \nuna entrevista con un familiar de la paciente y consultar la historia cl\u00ednica ambulatoria \ny la de urgencia s; por parte de farmacia se realiz\u00f3 el informe de revisi\u00f3n \nfarmacoterap\u00e9u tica. En el informe de se registr\u00f3 la siguiente informaci\u00f3n de forma \nresumida:  \nSe han generado 8 discrepancias justificadas por la interrupci\u00f3n de los tratamientos \npara la s siguientes patolog\u00edas : \n- Osteopenia/osteoporosis con \u00e1cido ibandr\u00f3nico  (pauta mensual  y no disponible \nen la Gu\u00eda Farmacoterap\u00e9utica)  + calcio carbonato/colecalciferol. No fue \nnecesario el tratamiento para el manejo de la paciente en urgencias.  \n- Anemia macroc\u00edtica con cianocobalamina + \u00e1cido f\u00f3lico. No fue necesario el \ntratamiento para el ma nejo de la paciente en urgencias. Se reiniciar\u00e1 la pauta al \nalta con valoraci\u00f3n por su MAP.  597- Dislipemia con simvastatina por no ser necesario el tratamiento para el manejo \nde la paciente en urgencias. Adem\u00e1s se obtiene un buen control lip\u00eddico en la \n\u00faltima anal\u00edtica y el f\u00e1rmaco puede interaccionar con amiodarona. De cara al \nalta y en la pr\u00f3xima visita con su MAP recomendamos no pautar dosis \nsuperiores a 20 mg/d\u00eda de simvastatina o valorar el intercambio por otras \nestatinas que no se metabolicen por el CYP3A 4 como pravastatina 40 mg o \npitavastatina 2 mg para evitar la interacci\u00f3n.  \n- Hipertensi\u00f3n arterial con enalapril + furosemida ante paciente con TA bajas \ndurante su estancia en observaci\u00f3n. Valorar ajuste de antihipertensivos por su \nMAP.  \n- Tratamiento con omepr azol ya que no cumple ninguna indicaci\u00f3n.  \nEl manejo de la arritmia cardiaca con bisoprolol + amiodarona + acenocumarol no \ngener\u00f3 discrepancias por lo que se continu\u00f3 el tratamiento en urgenci as y se paut\u00f3 en \nel ingreso en N eumolog\u00eda. Durante su estancia e n planta, Cardiolog\u00eda propuso el \ncambio de tratamiento de amiodarona a digoxina dada la comorbilidad de EPID. \nGracias a un trabajo multidisciplinar con este servicio se llev\u00f3 a cabo la monitorizaci\u00f3n \nfarmacocin\u00e9tica del f\u00e1rmaco para pautar al alta la posol og\u00eda \u00f3ptima para la paciente.  \nPor \u00faltimo para el manejo del episodio agudo se paut\u00f3 antibioterapia emp\u00edrica para el \ndiagn\u00f3stico de neumon\u00eda con levofloxacino 500 mg/d\u00eda, sin requerir ajuste de dosis \npor funci\u00f3n renal y ceftriax ona 2 g/d\u00eda. En planta mantuv ieron la  antibioterapia hasta \nmejor\u00eda cl\u00ednica de la pa ciente y cultivos de secreciones  bronquiales negativos.  \nPor otro lado los signos y s\u00edntomas que presenta la paciente al ingreso, como \nsensaci\u00f3n de debilidad o disnea, y los par\u00e1metros anal\u00edticos, como la hiponatremia, 598pod\u00edan estar asociados a un mal control del tratamiento habitual. Al revisar la \nfarmacoterapia de la paciente desde el ingreso al alta se detectaron posibles \nProblemas Relacionados con Medicamentos (PRM). Los PRM detectados fueron \nhiponatr emia/hipotensi\u00f3n y toxicidad pulmonar. Se evaluaron mediante el m\u00e9todo \nSOAP.  \n1. Hiponatremia/hipotensi\u00f3n  \nSubjetivos: Debilidad y aumento de la disnea.  \nObjetivos: Na plasm\u00e1tico de 129 mEq/l y TA de 67/39mmHq.  \nAn\u00e1lisis: la hiponatremia cr\u00f3nica se define como una concentraci\u00f3n de sodio \ns\u00e9rico<135mmol/L durante m\u00e1s de 48 horas. Es importante excluir el diagn\u00f3stico de \nhiponatremia hipergluc\u00e9mica, midiendo la glucemia. Adem\u00e1s se deber\u00eda estudiar la \nosmolaridad y la concentraci\u00f3n de Na en orina para establecer  las causas de la \nhiponatremia hipot\u00f3nica. Los s\u00edntomas m\u00e1s comunes de la hiponatremia son n\u00e1useas \nsin v\u00f3mitos, confusi\u00f3n y dolor de cabeza. Los valores normales de tensi\u00f3n arterial son \n120/80 mmHg o ligeramente inferiores y se puede considerar TA baja con  cifras de \n90/60 mmHg. Los s\u00edntomas m\u00e1s comunes son mareos, debilidad, desmayos y piel fr\u00eda y \nsudorosa.  \nTras revisar la medicaci\u00f3n cr\u00f3nica de la paciente se identific\u00f3 como posible causa de la \nhiponatremia el tratamiento cr\u00f3nico con furosemida, enalapril u omeprazol. Uno de \nlos efectos adversos m\u00e1s frecuentes asociados al uso de diur\u00e9ticos es la hiponatremia. \nAunque se produce con m\u00e1s frecuencia por el tratamiento con tiazidas, la furosemida \nproduce este efecto adverso de forma frecuente. La hiponatremia p or enalapril y 599omeprazol son reacciones adversas raras.  La TA baja se relacion\u00f3 con su tratamiento \nhabitual con furosemida y enalapril.  \nSe recomend\u00f3 interrumpir el tratamiento con el diur\u00e9tico y el IECA si la paciente segu\u00eda \npresentando cifras bajas de TA.  Se propuso valorar un manejo alternativo, \nsimplificando el tratamiento a un diur\u00e9tico, seg\u00fan la cl\u00ednica de la paciente.  \nTras interrumpir el tratamiento con furosemida y enalapril el Na plasm\u00e1tico remont\u00f3 \nligeramente en la siguiente anal\u00edtica a las 24 hor as (Na: 133 mEq/l) y tambi\u00e9n las cifras \nde TA en las siguientes 36 horas (71/39, 68/44, 70/44, 73/46, 88/54, 84/48, 107/70, \n85/47 y 101/50 mmHq).  \n2. Toxicidad pulmonar  \nSubjetivos : aumento de la disnea \nObjetivos: patr\u00f3n de fibrosis pulmonar con bronquiectasias  de peque\u00f1o calibre por \ntracci\u00f3n y m\u00faltiples tractos fibrosos perif\u00e9ricos distribuidos por ambos pulmones.  \nAn\u00e1lisis: la paciente fue diagnosticada de EPID en 2017, una patolog\u00eda que se \ncaracteriza por el engrosamiento de los tabiques alveolares, proliferaci\u00f3n de \nfibroblastos, dep\u00f3sito de col\u00e1geno y fibrosis pulmonar.  \nDe la medicaci\u00f3n cr\u00f3nica de la paciente, la amiodarona  se ha asociado con toxicidad \npulmonar y es el efecto adverso m\u00e1s limitante para su uso. Tras consultar con el \nm\u00e9dico se lleg\u00f3 a la conclusi\u00f3n de que el riesgo de empeoramiento de la EPID \nsuperaba al beneficio del tratamiento con amiodarona por lo que se d ecidi\u00f3 suspender \nel tratamiento con este f\u00e1rmaco y controlar la FA con digoxina, con una dosis de inicio \nde 0,125 mg cada 24 horas. Se recomend\u00f3 realizar la determinaci\u00f3n del f\u00e1rmaco en 600sangre a los 10 d\u00edas de iniciar el tratamiento, una vez alcanzado el e stado estacionario \n(no disponemos del valor en el momento de redactar el caso cl\u00ednico).  \n \nBibliograf\u00eda.  \n- Adecuaci\u00f3n farmacoterap\u00e9utica. Recomendaciones. Servicio de Salud de \nCastilla -La Mancha (SESCAM 2019).  \n- C. Gal\u00e1n -Retamal, R. Garrido -Fern\u00e1ndez, S. Fern\u00e1ndezEsp\u00ednola y V. Padilla -\nMar\u00edn.  Seguimiento del paciente anciano polimedicado en un \u00e1rea de salud. \nFarm Hosp. 2010;34(6):265 -270 \n- Spasovski G., Vanholder R., Allolio B., Annane D., Ball S., Bichet D., Decaux G. et \nal. Gu\u00eda de la pr\u00e1ctica cl\u00ednica sobre  el diagn\u00f3stico y tratamiento de la \nhiponatremia. Nefrolog\u00eda 2017;37(4):370 -380.  \n- Procter L. Hipotensi\u00f3n arterial (Hipotensi\u00f3n). Manual MSD. Nov. 2020.  \n- Ficha t\u00e9cnica furosemida. CIMA  \n- Lee J. generalidades sobre la enfermedad pulmonar intersticial. Manua MSD.  \nSep 2019. Disponible en: https://www.msdmanuals.com/es -\nes/professional/tr astornos -pulmonares/enfermedades -pulmonares-\nintersticiales/generalidades -sobre -la-enfermedad -pulmonar -intersticial . \n- Bordas J., Flores M.A., Mart\u00ednez C. Neumonitis por amiodarona. Rev Esp Geriatr \nGerontol. 2005;40(5): 323 -4. \n 601Desensibilizaci\u00f3n a dasatinib como alternativa en paciente con leucemia mieloide \ncr\u00f3nica tras intolerancia a otros tratamientos  \nIntroducci\u00f3n  \nLa Leucemia Mieloide Cr\u00f3nica (LMC) es un s\u00edndrome mieloproliferativo cr\u00f3nico \ninducido por la translocaci\u00f3n rec\u00edproca de los brazos largos de los cromosomas 9 y 22. \nEl cromosoma resultante es conocido como Philadelfia (Ph+), que da origen al oncogen \nBCR-ABL . Este gen codifica para una oncoprote\u00edna con actividad tirosina qui nasa,  \nresponsable de la patogenia y desarrollo de la LMC debido a su implicaci\u00f3n en la \nleucog\u00e9nesis1. \nPara determinar la elecci\u00f3n del tratamiento para esta patolog\u00eda se tiene que tener en \ncuenta:  fase de la enfermedad,  historia del paciente, respuesta a tratamientos \nrecibidos previamente y disponibilidad de donante para un trasplante de progenitores \nhematopoy\u00e9ticos. Actualmente, los inhibidores de tirosina quinasa (ITK) forman parte \nde la primera l\u00ednea de tratamiento y han relegado a un segundo plano a los agentes \nquimioterap\u00e9uticos como hidroxiurea, interfer\u00f3n alfa o citarabina 1,2. \nLos ITK indicados para LMC inhiben la actividad de la prote\u00edna BCR-ABL. Imatinib fue el \nprimer ITK indicado en LMC, mientras que dasatinib, bosutinib y nilotinib, son de \nsegunda generaci\u00f3n y ponatinib, forma parte de los de tercera generaci\u00f3n3. \nAunque e l perfil de seguridad var \u00eda seg\u00fan el f\u00e1rmaco, en todos ellos se han descrito \ncon frecuencia  reacciones adversas (RA) de aparici\u00f3n aguda como n\u00e1useas, miopat\u00edas, \nerupciones cut\u00e1neas, diarrea y cansancio. Tambi\u00e9n presentan reacciones \nhematol\u00f3gicas (principalmente mielosupresi\u00f3n) que suelen aparecer en fases m\u00e1s \navanzadas de la enfermedad. Imatinib se asocia m\u00e1s con dolores musculares, cefalea y 602edemas; dasatinib con derrame pleural e hipertensi\u00f3n pulmonar; bosutinib puede \nalterar la funci\u00f3n hep\u00e1tica y se relaciona con aparici\u00f3n de erupciones cut\u00e1neas; \nnilotinib se relaciona con patolog\u00edas cardiovasculares,  prolongaci\u00f3n del intervalo QT e \nhiperglucemias; y ponatinib con  alteraciones hep\u00e1ticas y pancreatitis4. \nLas RA cut\u00e1neas pueden aparecer  debido  a tratamiento con ITK, siendo en algunos \ncasos su nivel de gravedad dosis dependiente. Sin embargo, si la erupci\u00f3n cut\u00e1nea \naparece de forma temprana podr\u00edan estar interviniendo mecanismos de \nhipersensibilidad5. En estos casos, si la reacci\u00f3n implica una discontinuaci\u00f3n del \ntratamiento y no existe la posibilidad de sustituir el f\u00e1rmaco por una alternativa de \nigual eficacia o superior , podr\u00eda estar indicado realizar una desensibilizaci\u00f3n6. \nPara diagnosticar una reacci\u00f3n de hipersensibilidad a un f\u00e1rmaco oral, se realizan \npruebas cut\u00e1neas intraepid\u00e9 rmicas (prick test) para determinar si el f\u00e1rmaco \ninteracciona con receptores IgE presentes en los mastocitos cut\u00e1neos del paciente. \nEstas pruebas est\u00e1n indicadas cuando se sospecha una reacci\u00f3n de hipersensibilidad \nde tipo I. Un resultado positivo en los primero s 15-20 minutos favorece el diagn\u00f3stico \nde este tipo de hipersensibilidad; no obstante, un resultado negativo no excluye la \nalergia al f\u00e1rmaco, ya que puede tratarse de un falso negativo, o bien que se trate de \nun mecanismo no-IgE mediado7. \nCon la finalidad de evitar resultados falsos negativos en las pruebas cut\u00e1neas, se \nrealizan pruebas in vitro,  como el test de activaci\u00f3n de bas\u00f3filos (TAB). Este test \npermite detectar  por citometr\u00eda de flujo marcadores de activaci\u00f3n en la superficie de \nlos bas\u00f3filos,  como CD63 o CD203, cuando est\u00e9  en contacto con el f\u00e1rmaco en estudio \n8. 603 \nDescripci\u00f3n del caso cl\u00ednico  \nVar\u00f3n de 53 a\u00f1os, sin alergias medicamentosas conocidas y con antecedentes \npatol\u00f3gicos previos de cardiopat\u00eda isqu\u00e9mica, fue diagnosticado en diciembre de 2019 \nde LMC de bajo riesgo,  por lo que inici\u00f3  tratamiento de primera l\u00ednea con\u202fimatinib\u202f400 \nmg al d\u00eda.  \nEl primer mes de tratamiento,  el paciente toler \u00f3 bien el f\u00e1rmaco y el hemograma \nreflej\u00f3 una buena respuesta hematol\u00f3gica, confirm\u00e1ndose posteriormente en la visita \nde control en marzo de 2020. Hasta entonces, la \u00fanica RA que hab\u00eda manifestado el \npacie nte fue un edema palpebral,  que se decidi\u00f3 tratar \u00fanicamente con diur\u00e9tico.  \nEn las siguientes visitas de control el paciente sigui\u00f3 tolerando correctamente el \ntratamiento y se situ\u00f3 en Respuesta Molecular Mayor , por presentar una relaci\u00f3n BCR-\nABL/ABL inferior al 0,1%.  \nEl paciente  hab\u00eda manifestado desde  el inicio del tratamiento la sensaci\u00f3n de notar la \npiel de las manos m\u00e1s fr\u00e1gil, teniendo erosiones con facilidad. El servicio de \nDermatolog\u00eda valor\u00f3 las lesiones,  diagnostic\u00e1ndose  pseudoporfiria inducida por \nimatinib,  por lo que  se decid i\u00f3 suspender el tratamiento.  \nDesde entonces, el paciente mostr\u00f3 un empeoramiento cl\u00ednico de la LMC,  por ello se \ndecide iniciar  tratamiento con dasatinib 100 mg cada 24 horas.  \nInmediatamente despu\u00e9s de la primera toma de\u202fdasatinib, el paciente avis\u00f3 \ntelef\u00f3nicamente al equipo cl\u00ednico al presentar un cuadro de\u202feritema\u202fcut\u00e1neo \ngeneralizado con importante cefalea. En consecuencia,  se suspend i\u00f3 el tratamiento, \nderivando el caso al Servicio de  Alergolog\u00eda  para ser valorado.  604Se realizaron pruebas cut\u00e1neas y test de activaci\u00f3n de bas\u00f3filos (TAB) para dasatinib y \nbosutinib. Para dasatinib las pruebas cut\u00e1neas resultaron negativas y el TAB positivo, \nmientras que todas las pruebas fueron negativas para bosutinib.  \nTras los resultados del estudio alergol\u00f3gico, y dada la necesidad de seguir tratando la \nLMC del paciente , se decide iniciar  tratamiento con\u202fbosutinib\u202f500 mg cada 24 \nhoras, \u202fhaciendo un seguimiento estrecho del paciente para detectar la aparici\u00f3n de \nalguna reacci\u00f3n cruzada.\u202f  \nDesafortunadamente, el paciente no toler\u00f3 correctamente el tratamiento con \nbosutinib (ni a dosis normales ni reducidas), manifestando malestar, n\u00e1useas y v\u00f3mitos \nincapacitantes.  Debido a que la reacci\u00f3n presentada con dasatinib era sugestiva de \nuna hipersensibilidad de tipo 1 o IgE mediada,  se solicit\u00f3 a Farmacia la elaboraci\u00f3n de \nuna pauta de desensibilizaci\u00f3n a dasatinib. \nSe propuso realizar una desensibilizaci\u00f3n r\u00e1pida en 10 pasos hasta alcanzar \nprogresivamente la dosis de 50 mg de dasatinib. Cada dosis se administrar\u00eda en un \nintervalo de 30 minutos,  monitorizando en cada paso posibles reacciones de \nhipersensibilidad que pudiera mostrar el paciente. \nPara llevar a cabo el protocolo de desensibilizaci\u00f3n propuesto, e l Servicio de Farmacia \nformul\u00f3 una suspensi\u00f3n oral de dasatinib a partir de los comprimidos, utilizando como \nveh\u00edculo jarabe simple y agua purificada. Para ello se prepar\u00f3 la suspensi\u00f3n a  dos \nconcentraciones diferentes:  0,1 mg/mL (suspensi\u00f3n  A) y 1 mg/mL (suspensi\u00f3n B)  y se \nenvasaron las diferentes dosis en jeringas individuales. Se adjuntaron las instrucciones \nde administraci\u00f3n para enfermer\u00eda. Todas las operaciones se realizaron en cabina de \nseguridad clase I con las medidas de protecci\u00f3n adecuadas para el manejo de \nmedicamentos peligrosos. En la tabla 1 se representa como se consigui\u00f3 abarcar cada 605dosis de dasatinib establecida seg\u00fan el protocolo de la desensibilizaci\u00f3n, hasta llegar al \nd\u00eda 9 que se combin\u00f3 la administraci\u00f3n de un comprimido de 20 mg con 5 mL de la \nsuspensi\u00f3n B.  \nPaso Tipo de suspensi\u00f3n  Volumen  Dosis  Dosis Acumulada \n1 A (0,1mg/ml) 0,5 mL 0,05 mg 0,05 mg \n2 A (0,1mg/ml) 1,5 mL 0,15 mg 0,20 mg \n3 A (0,1mg/ml) 3,5 mL 0,35 mg 0,55 mg \n4 B (1mg/mL) 0,75 mL 0,75 mg 1,3 mg \n5 B (1mg/mL) 1,5 mL 1,5 mg 2,8 mg \n6 B (1mg/mL) 3 mL 3 mg 5,8 mg \n7 B (1mg/mL) 6 mL  6 mg 11,8 mg \n8 B (1mg/mL) 12,5 mL 12,5 mg 24,3 mg \n9 B (1mg/mL)1 5 mL1 25 mg 49,3 mg \n10   50 mg2 99,3 mg \nTabla 1.  Protocolo de desensibilizaci\u00f3n a dasatinib. 1En la 9\u00aa dosis se combin\u00f3 la \nadministraci\u00f3n de la suspensi\u00f3n B con un comprimido de 20mg de Dasatinib. 2En el \u00faltimo \npaso de la desensibilizaci\u00f3n se administr\u00f3 un comprimido de 50mg de dasatinib.  \nLa pauta de desensibilizaci\u00f3n result\u00f3 satisfactoria, pudiend o alcanzar la dosis \nterap\u00e9utica para el paciente sin presentar RA.\u202f  \nActualmente (mayo de 2022) el paciente contin\u00faa en tratamiento con dasatinib 50 mg \ncada 24 h. \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica  \nLos ITK son un pilar fundamental en el abordaje terap\u00e9utico de la LMC y uno de los \nmayores retos es el manejo de la toxicidad que estos presentan.  Por ello, es de vital \nimportancia disponer de un equipo multidisciplinar donde el farmac\u00e9utico ejerce un \nrol clave, para poder determinar el perfil de segur idad del f\u00e1rmaco y aportar \nalternativas terap\u00e9uticas acorde con los pacientes. Los ITK se dispensan en la consulta \nde pacientes externos, all\u00ed se hace una atenci\u00f3n farmac\u00e9utica  al paciente  inform ando \nde los posibles efectos adversos que pueden presentar, lo que puede ayudar al 606paciente a familiarizarse con el tratamiento y a detectar precozmente si presenta \nalguno de ellos.  \nInicialmente se diagnostic\u00f3 al paciente  de una pseudoporfiria asociada a imatinib, una \nRA cut\u00e1nea muy poco frecuente y con pocos casos descritos en literatura. En Mart\u00ednez \nMera et al.9 se recomienda en casos de pseudoporfiria asociada a este f\u00e1rmaco \nmodificar el tratamiento a dasatinib o nilotinib,  por no haber casos descritos de \nfragilidad cut\u00e1nea para e stos f\u00e1rmacos. En este caso, finalmente  se opt\u00f3 por dasatinib \ndebido a las RA cardiovasculares que presenta nilotinib (contraindicado en este caso \npor antecedente de cardiopat\u00eda isqu\u00e9mica en el paciente)10. \nAl administrarse por primera vez dasatinib, el paciente desarroll\u00f3 r\u00e1pidamente una \nerupci\u00f3n generalizada, la cual detect\u00f3 y notific\u00f3 precozmente . Esta al valorase se \norient\u00f3 como hipersensibilidad de tipo I. Por ello, se le realizaron pruebas \nintraepid\u00e9rmicas y TAB para dasatinib y bosutinib. Al resultar el TAB positivo para \ndasatinib y negativo para bosutinib, Alergolog\u00eda  recomend\u00f3 iniciar tratamiento con \nbosutinib, y en caso de fracasar, valorar desensibilizaci\u00f3n a dasatinib. Mediante la \ndesensibilizaci\u00f3n se pretende conseguir  generar una tolerancia temporal al f\u00e1rmaco. \nFinalmente, el paciente presenta RA en contexto de tratamiento con bosutinib,  pero , \ndado que en el estudio alergol\u00f3gico realizado con bosutinib no se objetivan resultados \nsugestivos de tratarse de una reacci\u00f3n de hipersensibilidad IgE mediada, se decide \noptar por una desensibilizaci\u00f3n con dasatinib.  \nDesde el punto de vista gal\u00e9nico, las desensibilizaciones suponen un reto dado que \nmuchas veces la bibliograf\u00eda es escasa. En este caso se realiz\u00f3 una b\u00fasqueda \nbibliogr\u00e1fica y \u00fanicamente hab\u00eda descrito un protocolo de desensibilizaci\u00f3n a dasatinib 607en pacientes pedi\u00e1tricos. El equipo propuso ajustar la pauta descrita en el art\u00edculo a la \npoblaci\u00f3n adulta11, formulando dos suspensiones a distinta concentraci\u00f3n. \nEn conclusi\u00f3n, en este caso se refleja el manejo de un paciente con LMC intolerante a \ndiferentes ITK al que se realiz\u00f3 una desensibilizaci\u00f3n exitosa a dasatinib. Este tipo de \nprocedimientos se deben contemplar  para pacientes sin opciones terap\u00e9uticas de igual \no superior eficacia al tratamiento al cual han presentado una reacci\u00f3n sugestiva de \nalergia, siempre tras validar el diagn\u00f3stico mediante un estudio alergol\u00f3gico adecuado. \nPor \u00faltimo, debido a la frecuencia de aparici\u00f3n de  RA asociadas a estos tipos de \ntratamientos, consideramos que la coordinaci\u00f3n de un equipo multidisciplinar  entre \nfarmacia, onco-hematolog\u00eda y alergolog\u00eda puede permit ir una detecci\u00f3n precoz y un \ncorrecto manejo de este tipo de  reacciones. \nReferencias bibliogr\u00e1ficas  \n1.  Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, \ntherapy and monitoring. American Journal of Hematology. 2020;95(6):691 -709.  \n2.  Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of \nconcepts and management recommendations of European LeukemiaNet. \nJournal of Clinical Oncology. 2009;27(35):6041 -6051.  \n3.  A Schiffer C, Ehab A. Overview of the treatment of chronic myeloid leukemia. \nwww.uptodate.com.  \n4.  Rea D. Management of adverse events associated with tyrosine kinase inhibitors \nin chronic myeloid leukemia. Annals of Hematology. 2015;94(S2):149 -158.  6085.  Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: A review of \nadverse cutaneous reactions with emphasis on our clinical experience. Journal \nof the European Academy of Dermatology and Venereology . 2013;27(12):1471 -\n1480.  \n6.  Castells M, Solensky R. Rapid drug desensitization for immediate \nhypersensitivity reactions. www.uptodate.com. \n7.  Dykewicz MS, Lam JK. Drug Hypersensitivity Reactions. Medical Clinics of North \nAmerica. 2020;104(1):109 -128.  \n8.  Kleine -Tebbe J, Erdmann S, Knol EF, MacGlashan DW, Poulsen LK, Gibbs BF. \nDiagnostic tests based on human basophils: Potentials, pitfalls and perspectives. \nInternational Archives of Allergy and Immunology . 2006;141(1):79 -90.  \n9.  Martinez-Mera C, Capusan TM, Herrero-Moyano M, Urqu\u00eda Renke A, Steegmann \nOlmedillas JL, de Argila D. Imatinib-induced pseudoporphyria . Clinical and \nExperimental Dermatology. 2018;43(4):463 -466.  \n10.  Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor \u2013Associated Cardiovascular \nToxicity in Chronic Myeloid Leukemia. Journal of Clinical Oncology. \n2015;33(35):4210 -4218.  \n11.  Betul Karaatmaca M, Selin Aytac M, Umit Murat Sahiner M, Bulent Enis Sekerel \nM, Ozge Soyer M. Successful oral desensitization with dasatinib in delayed \ncutaneous hypersensitivity reactions. Ann Allergy Asthma Immunol 123 .  \n  609TROMBOSIS VENOSA PROFUNDA EN USUARIO DE DROGA POR V\u00cdA PARENTERAL CON \nTUBERCULOSIS -VIH \nIntroducci\u00f3n  \nLa tuberculosis (TB) asociada a la infecci\u00f3n por VIH es uno de los mayores proble mas de \nsalud a nivel mundial1. El riesgo anual de TB entre personas con VIH  con infecci\u00f3n \ntuberculosa latente , sin tratamiento antirretroviral (TAR) , es del 3 -16% por a\u00f1o, lo que \nsupone aproximadamente el mismo riesgo de desarrollar TB a lo largo de toda la v ida de \npersonas no infectadas por VIH .2 Su incidencia es mayor a medida que aumenta la \ninmunodepresi\u00f3n, pero a diferencia de otras infecciones oportunistas la TB puede \nocurrir en cualquier paciente infectado por VIH con independencia de su cifra de \nlinfoci tos CD4+.3,4 Por todo ello, la TB, pese a ser una enfermedad prevenible y curable, \ncontin\u00faa siendo uno de los principales problemas de salud en pacientes infectados por \nVIH. En general, el tratamiento de la TB en adultos infectados por VIH es muy similar a l \nde los adultos sin infecci\u00f3n por VIH, aunque en aquellos  debemos abordar  las posibles \ninteracciones farmacol\u00f3gicas y el momento \u00f3ptimo para iniciar el TAR en pacientes que \nno lo recib\u00edan previamente.5 \nPor otro lado, usuarios de droga por v\u00eda parenteral (UDVP)  diagnosticados de VIH, son \nel grupo poblacional de mayor prevalencia para el desarrollo de complicaciones \narteriales y venosas, asociadas frecuentemente a infecci\u00f3n . El amplio espectro de \nafectaci\u00f3n vascular obliga a que los m\u00e9todos diagn\u00f3sticos y l as posibilidades \nterap\u00e9uticas sean individualizadas.6 \n \n 610Descripci\u00f3n del caso  \nPaciente de 55 a\u00f1os con los siguientes antecedentes personales:  \nUDVP habi\u00e9ndose inyectado en todas las venas accesibles, incl uso femorales. Fumador \nde m\u00e1s de un paquete al d\u00eda sin ingesta de alcohol. Permaneci\u00f3  en prisi\u00f3n m\u00e1s de 20 \na\u00f1os. Sali\u00f3 hace varios a\u00f1os y desde entonces , estuvo  viviendo  en la calle. Actualmente \nreside en una pensi\u00f3n que le abona los Servicios Sociales.   \nCom o problemas cr\u00f3nicos de salud presenta ba: infecci\u00f3n por  VIH diagnosticad a en 1986  \nsin TAR actual  y TB pulmonar durante su estancia en prisi\u00f3n. Su medicaci\u00f3n h abitual e ra \nmetadona 80mg/24h y a lprazolam 1mg/24h en la noche . \nIngres\u00f3  en planta de Enfermedades In fecciosas , durante mi rotaci\u00f3n cl\u00ednica , por \ndesnutrici\u00f3n severa con sensaci\u00f3n febril y tos desde 2 -3 meses  de evoluci\u00f3n  sin \nexpectoraci\u00f3n importante. Tras la sospecha cl\u00ednic a-radiol\u00f3gica de enfermedad  \ntuberculosa diseminada, se realiz\u00f3  una anal\u00edtica completa y se recog i\u00f3 una muestra de \nesputo con los siguientes resultados:  \n \nANALITICA   \n- Hemograma : Hemoglobina 13.2g/L, \nLeucocitos 6560 a costa de neutr\u00f3filos (93.4%) con \n310 linfocitos,  \nPlaquetas 233000   \n- Bioqu\u00edmica : Glucosa 79, Urea 98, \nCrea tinina  0.76, Prote\u00ednas totales 6.1 g/dl, perfil \nhep\u00e1tico con valores discretamente aumentados, \nNa 131 mEq/L, K 4.4 mEq/L, P 3.9 mg/dL, Ca 8.3 \nmg/dL PCR 43.3   INMUNOFENOTIPO:    \n- Linfocitos CD3 (recuento) 251.00 x 1/L   \n- Linfocitos CD3 (porcentaje) 84.7 %   \n- Linfocit os CD3+CD4+ (recuento) 45.00 x 1/L   \n- Linfocitos CD3+CD4+ (porcentaje) 15.3 %   \n- Linfocitos CD3+CD8+ (recuento) 196.00 x 1/L  \n- Linfocitos CD3+CD8+ (porcentaje) 66.0 %   \n- Recuento de linfocitos 301.00 x 1/L   \nCARGA VIRAL   \n- Virus de la hepatitis C , cuantificacion ARN: \n11300000 UI/mL   \n- Virus inmunodeficiencia humana  1 cuantif ARN:  \n1720000 copias/mL   Muestra: Esputo    \n- ADN Mycobacterium tuberculosis complex: Se \ndetecta M. tuberculosis complex sensible a \nrifampicina.   611 \nD\u00eda +2, tras la confirmaci\u00f3n del diagn\u00f3stico microbiol\u00f3gico de la tuberculosis, com enz\u00f3  \ncon tratamiento antituberculos o (antiTB) con rifampicina , isoniazida y pirazinamida \n(Rifater\u00ae) 5 comprimidos/24h. Posteriormente, se revis\u00f3 el  historial de TAR, y se \ncomprob\u00f3  que la \u00faltima dispensaci\u00f3n en la consulta de Farmacia de Pacientes Externos \nfue en 2012 con Efavirenz,Tenofovir y Emtricitabina. Desde entonces, el paciente no \nhab\u00eda asistido a  la consulta de Enfermedades infecciosas ni a la consulta de pac ientes \nexternos  de Farmacia . Inici\u00f3 tratamiento dos semanas despu\u00e9s del inicio con \ntratamiento antiTB con 1 comprimido de Triumeq\u00ae (Abacavir, lamivudina y dolutegravir) \ncada 24h + 1 comprimido de T ivicay\u00ae (dolutegravir) cada 24h . En d\u00edas posteriores, el \npaciente emp ez\u00f3 a tener dificultades para moverse, con p\u00e9rdida del tono muscular y \ncon escasa ingesta alimentaria. Tra s exploraci\u00f3n f\u00edsica, se observ\u00f3  edemas en miembros \ninferiores, sospech\u00e1ndose  el diagn\u00f3stico de trombosis venosa profunda (TVP), \nconfirmado con una ecograf \u00eda-d\u00f3ppler el d\u00eda +7. Por esta raz\u00f3n se inici\u00f3 tratamiento \nanticoagulante con rivaroxab\u00e1n 15 mg dos veces al d\u00eda . El paciente fue evolucionando \nfavorablemente con aumento del apetito, sin dificultades a la deambulaci\u00f3n con \nevidente disminuci\u00f3n de edema y s in sensaci\u00f3n disneica. El d\u00eda +23, tras baciloscopia \nnegativa y tras contacto con Trabajo Social, el paciente fue dado de alta con medicaci\u00f3n \npara el tratamiento de VIH, TB, TVP y metadona hasta cubrir necesidades por su centro \nde drogodependencia. El trat amiento para la TB se revis\u00f3 que estuviera correctamente \nprescrito en la tarjeta sanitaria . \n \n 612 \nDiscusi\u00f3n  y aportaci\u00f3n farmac\u00e9utica  \nTanto el VIH como la TB, son dos enfermedades que requieren un seguimiento estrecho \ny un abordaje farmacoterap\u00e9utico complejo, por lo que es necesario un equipo \nmultidisciplinar, del que forma parte el farmac\u00e9utico. Se han desarrollado tres aspectos \nimportantes en este caso cl\u00ednico: elecci\u00f3n de f\u00e1rmacos para el tratamiento de la TB, VIH \ny TVP teniendo en cuenta las inter acciones farmacol\u00f3gicas y las caracter\u00edsticas cl\u00ednicas y \nsocio -demogr\u00e1ficas del paciente.  \nTratamiento TB y VIH  \nTras la confirmaci\u00f3n del diagn\u00f3stico microbiol\u00f3gico de la tuberculosis, com enz\u00f3  con \ntratamiento antiTB  con rifampicina ,isoniazida y pirazinamida (Rifater\u00ae)  con una dosis de  \n5 comprimidos/24h  ya que el paciente pesaba 51 kg. Posteriormente, se revis\u00f3  historial \ndel TAR confirmando una falta de adherencia al TAR durante muchos a\u00f1os y \ncorrelacion\u00e1ndose con la alta carga viral del VIH. La introducci\u00f3n d el TAR en un paciente \nque recibe tratamiento anti TB debe valorarse individualmente atendiendo al estado \ninmunol\u00f3gico y con el objetivo de evitar interacciones entre los tratamientos. Seg\u00fan las \ngu\u00edas GESIDA7, el momento \u00f3ptimo de iniciar el TAR depende de l a cifra de linfocitos \nCD4+ en sangre. En nuestro caso, el  paciente ten\u00eda un cifra <50 c\u00e9lulas/mL  por lo que se \nrecomend\u00f3 iniciar TAR a las dos semanas del inicio del tratamiento antiTB , tras \ncomprobar su tolerancia . Los f\u00e1rmacos de elecci\u00f3n en este tipo de  pacientes (TB con \ninfecci\u00f3n por el VIH) son dos inhibidores de la transcriptasa inversa an\u00e1logos de \nnucle\u00f3sidos  (ITIAN) y efavirenz , inhibidor de la transcriptasa inversa no nucle\u00f3sido \n(ITINN).7 Sin embargo, en paciente s con TAR previo administrado de forma irregular , 613como es el caso de este paciente,  pueden existir archivadas mutaciones que se destapen \ntras exposici\u00f3n a efavirenz. Se consensu\u00f3 con  el cl\u00ednico , por lo tanto,  iniciar tratamiento \ndolutegravir, un inhibidor de la integrasa (INI) ya que tien e una mejor tolerancia y \neficacia que el efavirenz  al no conocerse mutaciones existentes.  \nLa administraci\u00f3n conjunta de rifampicina y dolutegravir disminuye las concentraciones \nde manera significativa de  dolutegravir  debido a que la rifampicina  induce su \nmetabolismo mediante las enzimas UGT1A1 y CYP3A .8 El ensayo cl\u00ednico INSPIRING  \nrecoge una  soluci\u00f3n aument ando la dosis de dolutegravir  a 50mg  cada 12 horas hasta \ndos s emanas tras finalizar antiTB , obteniendo muy buenos resultados para ambas \npatolog\u00edas .9 El tratamiento, por tanto, fue 1 comprimido de Triumeq\u00ae (Abacavir, \nlamivudina y dolutegravir) por la ma\u00f1ana  + 1 comprimido de Tivicay\u00ae (dolutegravir) a \nlas 12 horas , para evitar la disminuci\u00f3n de la concentraci\u00f3n de dolutegravir por la \ninteracci\u00f3n con rifa mpicina.  \nTratamiento TVP  \nEn el caso de nuestro paciente, era un paciente VIH drogodependiente con \nadministraci\u00f3n por v\u00eda parenteral en todas las venas accesibles durante muchos a\u00f1os \ndiagnosticado de TVP durante el ingreso. Por lo tanto, nuestro paciente presentaba \ndificultades par a canalizar un acceso venoso y utilizar heparina por v\u00eda intravenosa para \nel tratamiento de TVP. Por otro lado, la heparina por v\u00eda subcut\u00e1nea tampoco era una \nbuena opci\u00f3n ya que se trataba de un paciente caqu\u00e9ctico con escaso  tejido subcut\u00e1neo \nabdominal. Adem\u00e1s, la v\u00eda subcut\u00e1nea de cara al alta, requiere una autonom\u00eda del \npaciente que podr\u00eda fomentar su adicci\u00f3n por v\u00eda parenteral  y un mayor riesgo de \nincumplimiento terap\u00e9utico . Antes de iniciar tratamiento con un anticoagulante por v\u00eda 614oral, fue necesari o comprobar interacciones con la medicaci\u00f3n para el VIH y TB. La \nrifampicina es un inductor del citocromo P450 2C9 mientras que el acenocumarol es un \nanticoagulante que se metaboliza por este mismo citocromo.10 Por lo tanto, la \nrifampicina puede acelerar su metabolismo y disminuir su actividad anticoagulante.10 Al \nser una interacci\u00f3n de tipo grave, se debe evitar su uso concomitante. Debido a lo \nanteriormente mencionado, exist\u00edan dos alternativas: modificar tratamiento antiTB con \nuna pauta sin rifampacina , por  ejemplo, con  quinolonas , lo que obligar\u00eda a prolongar el \ntratamiento antiTB o inicar tratamiento con nuevos anticoagual antes orales (NACO). En \nnuestro caso, analizando a nuestro paciente  y sus antecedentes (p aciente mal \nadherente a tratamientos previos) , optamos por la segunda opci\u00f3n. E l anticoagulante \nde elecci\u00f3n en nuestro caso fue rivaroxab\u00e1n. Los NACO  como el rivaroxab\u00e1n tienen \nindicaci\u00f3n autorizada para el tratamiento de la TVP.11 Sin embargo, en Andaluc\u00eda, no \ntiene indicaci\u00f3n de visado, lo cual tendr\u00ed a que ser autofinanciable por el propio paciente \ncuando saliera del hospital. Al ser un paciente a cargo de Trabajo Social, sin recursos \necon\u00f3micos, el caso fue enviado a la comisi\u00f3n de trombosis para que pudiera ser \ndispensado por el hospital de manera ex cepcional durante el tiempo requerido para el \ntratamiento de la TVP: 15 mg dos veces al d\u00eda, durante las tres primeras semanas, \nseguida de 20 mg una vez al d\u00eda durante al menos 3 meses.11 En nuestro hospital \n\u00fanicamente se dispensa NACO para pacientes con fib rilaci\u00f3n auricular que tienen \nprevista una cardioversi\u00f3n o ablaci\u00f3n.  \nEl proceso del manejo farmacoterap\u00e9utico compete en gran medida al farmac\u00e9utico \nhospitalario, ya que debido a sus conocimientos en farmacoterapia y al contacto directo \ncon el equipo m\u00e9dic o es capaz de adaptar de forma eficiente el tratamiento del paciente \na las necesidades y particularidades de cada ingreso hospitalario. Este paciente, al ser 615paciente VIH, tendr\u00e1 un seguimiento por el farmac\u00e9utico en la consulta de pacientes \nexternos fomen tando la adherencia al tratamiento para evitar futuras complicaciones \nvasculares e infecciones a fin de conseguir resultados que mejoren su calidad de vida.  \nBibliograf\u00eda  \n1. World Health Organization. Global tuberculosis report 2017. Ginebra (Suiza); \n2017.  URL: http://www.who.int/tb/publications/global_report/en/ (Acceso 2 de \nMayo de 20 22) \n2. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A \nprospective study of the risk of tuberculosis among intravenous drug users with \nhuman immuno deficiency virus infection. N Eng l J Med. 1989; 320: 545 \u2013550  \n3. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. \nRelationship of the manifestations of tuberculosis to CD4 cell counts in patients \nwith human immunodeficiency virus infection.  Am Rev Respir  Dis. 1993; 148: \n1292\u2013 1297.  \n4. Post F, Wood R, Pillay G. Pulmonary tuberculosis in HIV infection: Radiographic \nappearance is related to CD4+ T -lymphocyte count. Tuber Lung Dis. 1995; 76: \n518\u2013 521.  \n5. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers \nfor Disease Control and Prevention/Infectious Diseases Society of America \nClinical Practice Guidelines: Treatment of Drug -Susceptible Tuberculosis. Clin \nInfect Dis 2016; 63: e147  6166. Bravo -Ruiz, E., Vega -de C\u00e9niga, M., Izagirr e-Loro\u00f1o, M, et al. Complicaciones \nvasculares secundarias a la administraci\u00f3n parenteral de drogas de abuso. \nAngiolog\u00eda . 2008 , 60(3), 199 -20 \n7. Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento \nantirretroviral en adultos infectados por el viru s de la inmunodefciencia humana . \nActualizaci\u00f3n 2020. PANEL DE EXPERTOS DE GeSIDA Y PL AN NACIONAL SOBRE EL SIDA . \n8. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, \nand pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice \ndaily with rifampin or once daily with rifabutin: results of a phase 1 study among \nhealthy subjects. J Acquir Immune Defic Syndr. 2013 Jan; 62(1):21 -7.  \n9. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. \nInternational study of patients with HIV on rifam picin ING study group. \nDolutegravir -based antiretroviral therapy for patients coinfected with \ntuberculosis and Human Immunodeficiency Virus: A multicenter, \nnoncomparative, open -label, randomized trial. Clin Infect Dis. 2020 Feb; \n70(4):549- 556.  \n10. Lexicomp Drug Interactions. https://www.upt odate.com/drug -interactions/#di -\ndocumen t  \n11. Ficha t\u00e9cnic a Rivaroxaban. Agencia Espa\u00f1ola de Medicamentos y productos \nsanitarios. CIMA . Consultado  2 de Mayo  de 2022 . Disponible en: \nhttps://cima.aemps.es/cima/pdfs/es/ft/84007/FT_84007.pdf   617ELABORACI\u00d3N DE UNA F\u00d3RMULA MAGISTRAL DE TIOSULFATO S\u00d3DICO \nINTRALESIONAL PARA EL TRATAMIENTO DE CALCINOSIS CUTIS  \n \nINTRODUCCI\u00d3N  \nLa calcinosis cutis  (CC) es un trastorno que se define como el dep\u00f3sito de sales \ninsolubles de calcio en la piel y en los tejidos blandos  (1,2). Seg\u00fan la etiopatogenia y los \nniveles s\u00e9ricos de calcio y fosfato, se clasifica en cinco tipos que incluyen la CC \ndistr\u00f3fica, metast \u00e1sica, idiop\u00e1tica, iatrog\u00e9nica y calcifilaxis.  La calcificaci\u00f3n distr\u00f3fica \nconstituye el tipo m\u00e1s frecuente y aparece principalmente en enfermedades \nautoinmunes del tejido conectivo.   En cuanto al tratamiento, s e cuenta  tanto con \nopciones farmacol\u00f3gicas como  no farmacol\u00f3gicas,  pero con una  amplia  variabilidad de \nresultados. Por este motivo, el tratamiento de la CC supone un reto terap\u00e9utico. El \npresente caso trata de una paciente diagnosticada de CC que se trat\u00f3 con tiosulfato \ns\u00f3dico intralesional y que result\u00f3 eficaz y seguro.  \nDESCRIPCI\u00d3N DEL CASO   \nSe trata de una paciente femenina cauc\u00e1sica de 72 a\u00f1os. Como antecedentes \npatol\u00f3gicos destaca enfermedad mixta del tejido conectivo (EMTC) de 8 a\u00f1os de \nevoluci\u00f3n, en tratamiento con met otrexato 10 mg/semana en forma de inyecciones \nsubcut\u00e1neas junto con \u00e1cido f\u00f3lico oral 5 mg/semana, de rescate, azatioprina oral 50 \nmg/d\u00eda y prednisona 5 mg y 2.5 mg en d\u00edas alternos. La paciente tambi\u00e9n toma de \nmanera habitual enalapril 20 mg/d\u00eda e hidrocl orotiazida 50 mg/d\u00eda para el tratamiento \nde la hipertensi\u00f3n arterial.   \n \nEn enero del 2021, acude a la \nconsulta de dermatolog\u00eda por \naparici\u00f3n de unas lesiones en \nambos brazos.  Debido a los \nantecedentes m\u00e9dicos y al \naspecto de las lesiones, el \nservicio de dermatolog\u00eda \nsospecha de posibles \ncalcificaciones.   \n \nAnte una paciente con  sospecha de calcificaciones se recomienda realizar una serie de \nestudios anal\u00edticos y pruebas de imagen que permita n orientar el tipo de calcificaci\u00f3n y \nacercarnos a su etiolog\u00eda.  \nLa paciente es valorada a trav\u00e9s de la realizaci\u00f3n de las siguientes pruebas \ncomplementarias:   Figura 1: Imagen de las lesiones en brazo izquierdo.  \n \n618Anal\u00edtica sangu\u00ednea : \n\u2713 Perfil renal  y un metabolismo fosfo -c\u00e1lcico sin alteraciones  y factor reumatoide \n(FR) negativo.  \n\u2713 Pruebas de anticuerpos  negativas para anticuerpos antinucleares ( ANA ) y anti-\nRo, pero positivas para anticuerpos anti -RNP  (presentes en la mayor\u00eda de los \npacientes  con EMTC ).  \n \nPruebas de imagen : (para orient ar causa etiol\u00f3gica ) \n \n\u2713 Se realiza una radiograf\u00eda  de las extremidades superiores donde se observan \nunas im\u00e1genes radiopacas de densidad que evidencian la presencia de calcio en \ntejido blando en ambos antebrazos.   \n\u2713 Se realiza una ecograf\u00eda  cut\u00e1nea de la s lesiones ya que permite determinar el \ngrosor y la presencia de inflamaci\u00f3n asociada. La ecograf\u00eda permite medir las \nlesiones con precisi\u00f3n, adem\u00e1s de ser una t\u00e9cnica preferible por no ser invasiva \ny no irradia a la paciente. En las im\u00e1genes ecogr\u00e1ficas s e observan, en codo \nizquierdo, dos calcificaciones en hipodermis de 5,6 x 5 mm de di\u00e1metro \nsuperior (longitudinal). Son hiperecoicas y presentan sombra ac\u00fastica posterior \n(caracter\u00edstico de las calcificaciones). En el codo derecho, se observan m\u00faltiples \npeque\u00f1as calcificaciones, la m\u00e1s grande de 2 mm.  \n \nAnte los resultados de las pruebas de imagen que demuestran la presencia de \ncalcificaciones en hipodermis, la presencia de una enfermedad autoinmune asociada y \nla evidencia de un metabolismo fosfo -c\u00e1lcico sin  alteraciones, la paciente es \ndiagnosticada finalmente de calcinosis cutis distr\u00f3fica.   \n \nEn este contexto, el servicio de dermatolog\u00eda decide iniciar un tratamiento con \ndiltiazem comprimidos orales 30mg/24h y diltiazem 2% gel t\u00f3pico cada 8h, que no \nresulta  efectivo.  \n \nSe decide entonces , en reuni\u00f3n multidisciplinar formada por el Servicio de \nDermatolog\u00eda y la farmac\u00e9utica  respons able  de farmacotecnia, probar una alternativa \ne iniciar tratamiento con una f\u00f3rmula magistral de  tiosulfato s\u00f3dico (TSS) 250 mg/ml  \nintralesional  de administraci\u00f3n mensual.    \n \nLa paciente da su consentimiento  informado y se le explica los posibles efectos \nadversos  m\u00e1s frecuentes  (infecci\u00f3n y dolor local) de la terapia.   \nSe mantiene el tratamiento concomitante con diltiazem 30mg/24h.  \nDespu\u00e9s del diagn\u00f3stico de la patolog\u00eda en enero del 2021, la paciente recibe la \nprimera dosis de TSS el 17 de marzo del 2021. Se aplica una dosis d e 1 ml por cm2. \nDebido a que la inyecci\u00f3n intralesional suele ser dolorosa, ya que el tiosulfato s\u00f3dico \nes altamente hipert\u00f3nico, se inyecta previamente anestesia local (lidoca\u00edna 1%).   \nLa primera dosis de tratamiento resulta ser efectiva y bien tolerada y  se decide \ncontinuar con una segunda sesi\u00f3n en abril del 2021.    \nNo presenta en ning\u00fan momento un efecto adverso no deseado.  \nLa paciente recibe un total de 6 sesiones, finalizando el tratamiento en septiembre del \n2021.  619Durante los meses que dura el tratam iento, se realiza un seguimiento ecogr\u00e1fico que \nmuestra una p\u00e9rdida de consistencia de las lesiones del tejido. A  pesar de  no \nproducirse  una remisi\u00f3n completa , se objetiva  una mejor\u00eda cl\u00ednica en cuanto a  que el \ntama\u00f1o de las lesiones disminuye despu\u00e9s del tratamiento , acompa\u00f1ado de una \nreducci\u00f3n del dolor y de las molestias con  el consiguiente beneficio en cuanto a  salud y \ncalidad de vida de la paciente.   \n \n \n \nFigura 2: Evoluci\u00f3n de las lesiones antes y despu\u00e9s del tratamiento  con tiosulfato s\u00f3dico.  \n \nDISCUSI\u00d3N  Y APORTACI\u00d3N FARMAC\u00c9UTICA  \nLa CC distr\u00f3fica  constituye el tipo m\u00e1s frecuente de CC. Los niveles de calcio y f\u00f3sforo \nen suero son normales. Aparece secundaria a un da\u00f1o o alteraci\u00f3n del col\u00e1geno, \nelastina o grasa subcut\u00e1nea  (1,2).   El da\u00f1o tisular, hipoxia o hipovascularizaci\u00f3n \npromueven un microambiente propenso a la calc ificaci\u00f3n. Se produce la liberaci\u00f3n de \nprote\u00ednas fijadoras de fosfato desde las c\u00e9lulas necr\u00f3ticas, que van a captar fosfato \nfavoreciendo la calcificaci\u00f3n. Estos dep\u00f3sitos de calcio se localizan normalmente en las \nregiones periarticulares de los codos y la s rodillas, en el dorso de las manos, cuero \ncabelludo, zona preauricular y cuello.  Se asocia a m\u00faltiples enfermedades \nautoinmunes (principalmente esclerosis sist\u00e9mica, dermatomiositis y lupus \neritematoso), enfermedades hereditarias del tejido conectivo, ne oplasias cut\u00e1neas, \npaniculitis e infecciones.  Suele presentarse de manera progresiva y asintom\u00e1tica.  \nEl manejo terap\u00e9utico  de la CC es complejo y debe ser individualizado. No existen \ngrandes ensayos cl\u00ednicos controlados sobre las distintas alternativas te rap\u00e9uticas. La \neficacia de los diferentes tratamientos depende de publicaciones sobre casos aislados \no peque\u00f1as series de casos ( 4,5,6). El tratamiento de la calcinosis incluye tres \nestrategias: \n6201. Medidas generales : reducir factores de hipoxia y favorecer el  flujo sangu\u00edneo \nevitando traumatismos, tabaquismo, estr\u00e9s o exposici\u00f3n al fr\u00edo. Manejar el \ndolor y favorecer la curaci\u00f3n de las heridas, incluyendo tratamiento antibi\u00f3tico \nsi fuera necesario.  \n2. Tratamiento farmacol\u00f3gico : inmunog lobulinas, minociclina, ceftriaxona, \nwarfarina, corticoides, anti -TNF alfa, colchicina , diltiazem, probenecid, \nhidr\u00f3xido de aluminio, bifosfonatos, tiosulfato s\u00f3dico.   \n3. Tratamiento no farmacol\u00f3gico : litotricia extr acorp\u00f3rea, extirpaci\u00f3n quir\u00fargica, \nl\u00e1ser de CO2.   \nEl tiosulfato s\u00f3dico  es una sal inorg\u00e1nica cuyo mecanismo de acci\u00f3n es multifactorial. \nSe basa en la capacidad de formar complejos solubles con muchos metales y minerales \n(en esta patolog\u00eda act\u00faa como quelante de calcio), adem\u00e1s de un posible efecto \nvasodilatador, antioxidant e y directamente inhibidor del proceso de calcificaci\u00f3n  (7). \nLa \u00fanica indicaci\u00f3n de la soluci\u00f3n inyectable de tiosulfato s\u00f3dico que aparece en ficha \nt\u00e9cnica es para el tratamiento de la intoxicaci\u00f3n aguda con cianuro. Por tanto, para el \ntratamiento de la c alcinosis cutis, la administraci\u00f3n de tiosulfato s\u00f3dico es una medida \noff-label  basada en el reporte de algunos casos cl\u00ednicos publicados.  La v\u00eda intralesional \nsuele ser de bajo riesgo y un m\u00e9todo de liberaci\u00f3n del principio activo que penetra \nm\u00e1s profunda mente que la simple administraci\u00f3n t\u00f3pica, mientras estamos evitando a \nla vez, los posibles efectos secundarios de la distribuci\u00f3n sist\u00e9mica. La \u00fanica limitaci\u00f3n \nen la administraci\u00f3n intralesional del TSS es el dolor en el momento de la inyecci\u00f3n, \nque se p uede solventar con uso de anest\u00e9sico t\u00f3pico como lidoca\u00edna.    \nEn febrero del 2021, el servicio de Dermatolog\u00eda del hospital contacta con el \u00e1rea de \nfarmacotecnia del Servicio de Farmacia para la  elabora ci\u00f3n de la  f\u00f3rmula magistral  \n(FM)  de tiosulfato s \u00f3dico 250 mg/ml  en jeringa  de 5ml.  \n \nLa farmac\u00e9utica de l \u00e1rea de farmacotecnia  valid a la indicaci\u00f3n y justificaci\u00f3n de la FM . \nPor ser la primera vez que se elaboraba dicha FM, se crea un nuevo  procedimiento \nnormalizado de trabajo (PNT) . Para ello,  realiz a una b\u00fasqueda bibliogr\u00e1fica  (7,8,9) para \nrecopilar toda la evidencia cient\u00edfica publicada disponible y que permita conocer la \ndosis correcta, el modus operandi  adecuad o y la estabilidad fisicoqu\u00edmica y \nmicrobiol\u00f3gica del producto final.  Todo ello con el prin cipal objetivo de garantizar la \nseguridad del paciente y la eficacia del tratamiento.   Se encuentran pocos casos \nreportados de uso del TSS a nivel local, para el tratamiento de la calcinosis cutis \ndistr\u00f3fica, pero los casos publicados muestran una mejor\u00eda y efectividad que alienta a \nvalidar el uso off-label  del tiosulfato s\u00f3dico intralesional  (4,5,6).   \n \nElaboraci\u00f3n de la f\u00f3rmu la magistral:  \n \nSe trabaja en cabina de flujo laminar horizontal , para garantizar  la esterilidad de la \nf\u00f3rmula ya que la administraci\u00f3n es intralesional.  \n \nComo material necesario para la elaboraci\u00f3n y acondicionamiento  constan: vaso s de \nprecipitados , vidrio de reloj  y esp\u00e1tula previamente esterilizados , filtro de 0,22 \u00b5m, \nbalanza , tiras de determinaci\u00f3n del pH, jeringa de 5 ml y de 10 ml, aguja  y tap\u00f3n de \nsellado. 621\nEl modus operandi consiste en: \n1) Pesar la cantidad de  tiosulfato s\u00f3dico pentahidratado  (1,25 gr. ) en el vaso de \nprecipitados esterilizado.  \n2) Disolver el TTS en  5 ml de agua para preparaciones inyectables  (API) hasta obtener \nuna soluci\u00f3n transparente y homog\u00e9nea.  \n3) Es importante determinar el pH que debe estar entre 6 -9,5 y de lo contrario ajustar  \ncon HCl o NaOH seg\u00fan el caso.  \n4) Realizar doble filtraci\u00f3n con un filtro de 0,22 micras. *Esta doble filtraci\u00f3n se realiza \nsiempre que la formulaci\u00f3n final sea est\u00e9ril, pero se parte de una materia prima que \nno lo es (8).  \n5) Pasar la soluci\u00f3n doblemente filtrada a la jeringa final  de 5 ml.  \n6) Cerrar con tap\u00f3n,  sella r en bolsa est\u00e9ril  y etiquetar.  \n \nSe obtiene una  soluci\u00f3n final que es est\u00e9ril, incolora y transparente .  \nEn cuanto a la conservaci\u00f3n de la FM, s eg\u00fan la matriz de riesgos  de la Gu\u00eda de Buenas \npr\u00e1cticas ( 8) y la bibliograf\u00eda consultada  (9), se decide dar una caducidad de 9 d\u00edas en \nnevera  (2-8\u00baC)  y conservar protegido de la luz. Sin embargo, se prepara el producto el \nmismo d\u00eda de la citaci\u00f3n del paciente en la consulta de dermatolog\u00eda  para confirmar su  \nasistencia y minimizar los posibles riesgos  de contaminaci\u00f3n microbiol\u00f3gica .  \n \nFinalmente, se dispensa al servicio de dermatolog\u00eda en una bolsa opaca protegido de la \nluz y debidamente etiquetado .  \n \nDurante el per\u00edodo que dura el tratamiento, se realiza un seguimiento de la evoluci\u00f3n \ncl\u00ednica del paciente en las sucesivas visitas a la consulta de dermatolog\u00eda y se observa \nque la administraci\u00f3n intralesional de tiosulfato s\u00f3dico es eficaz y segura, resu ltando \nen una mejor\u00eda de las lesiones cut\u00e1neas por CC tras solo 6 sesiones de tratamiento.  Figura 3 : Procedimiento de elaboraci\u00f3n de la FM.  \n1: Material necesario, 2: Pesado de la materia prima, 3: Determinaci\u00f3n del pH, 4: Validaci\u00f3n del \npH=6 -7, 5: Doble filtraci\u00f3n con filtro 0.22 micras, 6: Producto final sin etiquetar.  622Este caso evidencia la utilidad de la formulaci\u00f3n en el tratamiento de enfermedades \npara las que no se dispone de preparados farmac\u00e9uticos espec\u00edficos. Resuelve \nsituaciones terap\u00e9uticas personalizadas en cuanto a dosis, formas farmac\u00e9uticas, \nveh\u00edculos o adaptaci\u00f3n del medicamento a la cl\u00ednica concreta del paciente.  \n \nEl conocimiento cient\u00edfico en el \u00e1mbito de la farmacotecnia junto con el trabajo \nmultidi sciplinar ha permitido conseguir una terapia ajustada a las caracter\u00edsticas de la \npaciente, basada en la terapia individualizada, con la consecuente mejor\u00eda de su \npatolog\u00eda y la ausencia de efectos adversos de inter\u00e9s.  \n \n \nBIBLIOGRAF\u00cdA  \n \n1. Jim\u00e9nez -Gallo D, Ossor io-Garc\u00eda L, Linares -Barrios M. Calcinosis Cutis and \ncalciphylaxis. Actas Dermo -Sifiliogr\u00e1ficas. 2015 Dec;106(10):785 -94.  \n2. Valenzuela A, Chung L. Calcinosis: pathophysiology and management. Curr Opin \nRheumatol. 2015 nov;27(6):542 -8. \n3. Howard RM, Smith GP. Treatment of calcinosis cutis with sodium thiosulfate \ntherapy. J Am Acad Dermatol. 2020 nov;83(5):1518 -1520. doi: \n10.1016/j.jaad.2020.06.996. Epub 2020 Jul 2. PMID: 32622148.  \n4. Strazzula L., Nigwekar S.U., Steele D. Intralesional sodium  thiosulfate for \nthetreatment of calciphylaxis. JAMA Dermatol. 2013;149(8):946 \u2013949.  \n5. Baumgartner -Nielsen J., Olesen A.B. Treatment of skin calcifications with intra -\nlesional injection of sodium thiosulphate: a case series. Acta Derm Venereol. \n2016;96(2):257 \u2013 258.  \n6. Traineau H et al. Treatment of calcinosis cutis in systemic sclerosis and \ndermatomyositis: A review of the literature. J Am Acad Dermatol. 2020 \nfeb;82(2):317 -325 \n7. Jose Carlos de Miguel Bouzas, Eva Castro Tub\u00edo, Luc\u00eda Villamayor Blanco. \nTiosulfato s\u00f3 dico a bajas dosis en el tratamiento de la arteriolopat\u00eda ur\u00e9mica \ncalcificante.  Farmacia Hospitalaria, 2017; 41(5):638- 639. \n8. Gu\u00eda de buenas pr\u00e1cticas de preparaci\u00f3n de medicamentos en servicios de \nfarmacia hospitalaria (junio 2014), (GBPP). Ministerio de Sanidad, Servicios \nsociales  e Igualdad. \nhttp://www.msssi.gob.es/profesionales/farmacia/pdf/GuiaBPP3.pdf  \n9. G\u00f3mez Pe\u00f1a C, Garc\u00eda Fern\u00e1ndez C, Ru\u00edz Fuentes S, Bleda Ru starazo S, \nFernandez Lopez C, Medarde Caballero C. Elaboraci\u00f3n de tiosulfato s\u00f3dico al \n25% para el tratamiento de calcifilaxis intradi\u00e1lisis en enfermerdad renal. A \nprop\u00f3sito de un caso. Libro de comunicaciones cient\u00edficas del 57 Congreso de la \nSociedad Es pa\u00f1ola de Farmacia Hospitalaria.  623EXPERIENCIA DE USO DE ETANERCEPT COMO FUERA DE INDICACI\u00d3N EN NECR\u00d3LISIS\nEPID\u00c9RMICA T\u00d3XICA EN UN HOSPITAL DE TERCER NIVEL\nINTRODUCCI\u00d3N \nLa Necr\u00f3lisis Epid\u00e9rmica T\u00f3xica (NET) es una reacci\u00f3n mucocut\u00e1nea muy grave y\nproco frecuente que se puede desencadenar como efecto  adverso (EA)  a distintos\nf\u00e1rmacos. Es considerada la reacci\u00f3n secundaria a medicamentos m\u00e1s grave dentro del\nespectro de las reacciones mucocutaneas. \nSe trata de una enfermedad rara, con una incidencia de 2 a 13 casos por mill\u00f3n\nde  habitantes.  Los  principales  f\u00e1rmacos  asociados  a  NET  son  los  antiepil\u00e9pticos\narom\u00e1ticos  (carbamazepina,  fenito\u00edna,  fenobarbital),  algunos  antibi\u00f3ticos\n(sulfametoxazol, -lact\u00e1micos, quinolonas), el alopurinol y los antirretrovirales (abacavir,\nnevirapina) (Dreyer et al., 2021).\nSe caracteriza por la separaci\u00f3n de las uniones dermicoepid\u00e9rmicas, necrosis y\ndesprendimiento  de  la  epidermis  en  m\u00e1s  del  30%  de  la  superficie  corporal  y  la\nafectaci\u00f3n de las mucosas. Tiene una alta mortalidad (alrededor del 25-30%), siendo la\nsepsis la principal causa de muerte en estos pacientes  (Dreyer et al., 2021).\nLos par\u00e1metros para evaluar la gravedad del NET, son la escala de Mortalidad en\nla  Necr\u00f3lisis  Epid\u00e9rmica  T\u00f3xica  (SCORTEN)  y  el  porcentaje  de  superficie  corporal\nafectada. La escala SCORTEN consiste en un sistema de puntuaci\u00f3n elaborado para\ncalcular la probabilidad de fallecimiento de los enfermos afectados por NET mediante\nel an\u00e1lisis de 7 factores de riesgo independientes: edad > 40 a\u00f1os, frecuencia cardiaca\nmayor a 120/min, presencia de neoplasia s\u00f3lida o hematol\u00f3gica, superficie corporal624descamada >10%, urea plasm\u00e1tica > 60mg/dL, bicarbonato plasm\u00e1tico < 20 mEq/L y\nglucemia > 255 mg/dL (Bastuji-Garin et al., 2000).\nEl  manejo  de  la  enfermedad  se  basa  principalmente  en  la  suspensi\u00f3n  del\nf\u00e1rmaco  sospechoso,  as\u00ed  como  el  abordaje  multidisciplinar  tanto  en  planta  de\nhospitalizaci\u00f3n  como  en  la  UCI  (Unidad  de  Cuidados  Intensivos).  En  cuanto  al\ntratamiento  farmacol\u00f3gico,  los  tratamientos  sist\u00e9micos  empleados  basan  su\nmecanismo de acci\u00f3n en la supresi\u00f3n y la limitaci\u00f3n de la respuesta inflamatoria e\nincluyen: glucocorticoides, ciclosporina, inmunoglobulina humana intravenosa (IgIV) y\nanticuerpos monoclonales contra el factor de necrosis tumoral (TNF) alfa (etanercept)\n(Barrera-Ochoa et al., 2022).\nA continuaci\u00f3n, se describen 3 casos (Tabla 1) de pacientes con NET ingresados\nen un hospital de tercer nivel tratados con etanercept.\nDESCRIPCI\u00d3N DE LOS CASOS CL\u00cdNICOS\nCaso 1\nVar\u00f3n de 82 a\u00f1os con antecedentes de hipertensi\u00f3n arterial (HTA), hiperplasia\nbenigna de pr\u00f3stata, s\u00edndrome de hiperreactividad bronquial, neumon\u00eda basal en 2008,\npoliartritis,  s\u00edndrome  metab\u00f3lico,  fibrilaci\u00f3n  auricular  y  polineuropat\u00eda  sensitivo-\nmotora de predominio axonal y sensitivo . Como medicaci\u00f3n habitual en domicilio toma\ntramadol/paracetamol. Acude a urgencias por un cuadro de 2 d\u00edas de evoluci\u00f3n de\ndeposiciones  l\u00edquidas  sin  productos patol\u00f3gicos  (>10  veces al d\u00eda)  acompa\u00f1ado  de\nn a \u00fa s e a s y v \u00f3 m i t o s ( > 5 v e c e s a l d \u00ed a ) . I n g r e s a e n p l a n t a e i n i c i a t r a t a m i e n t o c o n\nmetronidazol y ceftriaxona. Se realiza una colonoscopia en la que se observa edema,\neritema, con mucosa erosionada de forma continua, y friabilidad y sangrado al roce625instrumental en toda la longitud del colon explorado, incluido el recto. No se observan\n\u00e1reas de necrosis. Se establece pancolitis infecciosa como diagn\u00f3stico principal.  Tras 5\nd\u00edas  con  tratamiento  antibi\u00f3tico,  aparecen  en  la  piel  maculas  eritematosas  de\npredominio troncular con alguna \u00e1rea erosionada escasa, afectaci\u00f3n mucosa oral y\nlabial  y  despegamiento  cut\u00e1nea  palmo-plantar  doloroso  en  bloque  sin  eritema  ni\nlesiones subyacentes. No afectaci\u00f3n ocular aparente. As\u00ed mismo, en las \u00faltimas 48\nhoras presenta franco empeoramiento de la funci\u00f3n renal y marcado empeoramiento\nde la funci\u00f3n hep\u00e1tica. \nEn este contexto, el paciente ingresa en UCI con sospecha de NET, presentado lesiones\nmucosas, cut\u00e1neas y orales compatibles con toxicodermia tipo Stevens-Johnson. Se\nrealiza interconsulta a Dermatolog\u00eda, que suspende toda la medicaci\u00f3n que no sea\nestrictamente  necesaria  e  inicia  una  pauta  de  metilprednisolona  80mg/24h.\nequivalentes de prednisona de 0.75-1 mg/kg. Ante la progresi\u00f3n de las lesiones y el\naumento  progresivo  de  los  despegamientos  cut\u00e1neos,  se  solicit\u00f3  al  Servicio  de\nFarmacia  el tratamiento con inmunoglobulinas intravenosas ( Ig IV) a dosis de 3g/kg en\nuna dosis \u00fanica como uso fuera de indicaci\u00f3n. A las 24 horas de su administraci\u00f3n,\ndebido a la persistencia de las lesiones y a la r\u00e1pida progresi\u00f3n se solicit\u00f3 tambi\u00e9n el\nuso fuera de indicaci\u00f3n de etanercept 50 mg como dosis \u00fanica, que fue administrado a\nlos 7 d\u00edas tras el inicio de los s\u00edntomas.\nEl paciente evolucion\u00f3 favorablemente con una reepitelizaci\u00f3n completa de las\nlesiones cut\u00e1neas y buena tolerancia a etanercept, por lo que fue dado de alta de la\nUCI a los 5 d\u00edas. En la actualidad sigue ingresado en planta por diagn\u00f3stico de pancolitis\ntras 6 meses desde NET.626Caso 2\nVar\u00f3n  de 64 a\u00f1os  con antecedentes m\u00e9dicos de HTA, dislipemia, neumon\u00eda\nCOVID  en  2020  con  tromboemolismo  pulmonar  (TEP)  post-COVID,  coxartrosis,\nosteonecrosis de cabeza de f\u00e9mur derecho e intervenida de mucocele labial superior\nen  2021.  Como  medicaci\u00f3n  habitual  en  domicilio  toma  rosuvastatina,  omeprazol,\namlodipino, calcio/colecalcifediol, \u00e1cido alendronico y tramadol/paracetamol .\nAcude a urgencias por aparici\u00f3n desde hace 5 d\u00edas de edema y erosi\u00f3n genital,\nlesiones cut\u00e1neas y linguales eritemasotas. Como \u00fanico factor asociado, hace 9 d\u00edas\nhab\u00eda empezado tratamiento con trimeptoprim/sulfametoxazol por hallazgo de SARM\n(Staphylococcus  aureus  meticilin  resietente).  A  la  exploraci\u00f3n  presenta  lesiones\nmaculares  eritematosas  muy  numerosas  en  tronco  anterior,  espalda,  cara  y  zona\nproximal de extremidades y boca con erosiones amplias de la lengua y sensaci\u00f3n de\ndisfagia,  que  afectaban  al  20%  de  la  superficie  corporal.  Presentan  denudaci\u00f3n  al\nraspado (Nikolsky positivo) y un \u00edndice SCORTEN de 2%. \nSe diagnostica al paciente de NET y se inicia tratamiento con metilprednisolona\n100mg/24h.  A los 6 d\u00edas  desde  el inicio  de  los  s\u00edntomas  se  solicita al  Servicio  de\nFarmacia el uso fuera de indicaci\u00f3n de una dosis \u00fanica de etanercept 50 mg. Tras la\nadministraci\u00f3n,  se observa unaevoluci\u00f3n  favorable  tras  su administraci\u00f3n,  con una\nreepitalizaci\u00f3n de las lesiones. El paciente presenta buena tolerancia al tratamiento y\nfinalmente es dado de alta a los 14 d\u00edas tras la administraci\u00f3n de etanercept. \nCaso 3627Var\u00f3n de 60 a\u00f1os con antecedentes m\u00e9dicos de HTA y asma bronquial. Como\nmedicaci\u00f3n  habitual  en  domicilio  se  administra  dipropionato  de  beclometasona  +\nfumarato de formoterol inhalado. Acude a urgencias por presentar erupci\u00f3n cut\u00e1nea\npruriginosa y dolorosa de dos d\u00edas de evoluci\u00f3n. Refiere consumo de paracetamol y\ntetraciclinas 3 d\u00edas previos a la aparici\u00f3n de las lesiones.\nIngresa en planta y a la exploraci\u00f3n f\u00edsica se aprecia afectaci\u00f3n mucosa, genital\ny  cut\u00e1nea,  con  lesiones  eritematosas,  edematosas,  erosionadas  y  dolorosas  a  la\npalpaci\u00f3n  en  espalda,  tronco,  flancos  abdominales,  cara  interna  de  muslos,\nextremidades, manos y pies, as\u00ed como afectaci\u00f3n ocular y despegamiento del glande. El\npaciente presenta una superficie afectada del 4%, \u00edndice de SCORTEN de 1% y Nikolsky\npositivo.\nAnte  la  sospecha  diagn\u00f3stica  de  NET  por  paracetamol  o  tetracilinas,  se\nsuspenden  ambos  f\u00e1rmacos  y  se  solicita tratamiento  como  fuera de indicaci\u00f3n  de\netanercept 50 mg en dosis \u00fanica en combinaci\u00f3n con corticoides y antibi\u00f3ticos t\u00f3picos.\nObserv\u00e1ndose, tras la administraci\u00f3n del tratamiento, una evoluci\u00f3n favorable con una\nbuena tolerancia, siendo dado de alta a los 11 d\u00edas. \nTodos  los  casos  fueron  reportados  como  sospechas  de  reacci\u00f3n  adversa  al\nSistema Espa\u00f1ol de farmacovigilancia.\nCaso 1 Caso 2 Caso 3\nEdad (a\u00f1os) 82 64 60\nF\u00e1rmaco Metronidazol/\nceftriaxonaSulfametoxazol/tri\nmetoprimParacetamol/tetraciclin\nas\nSuperficie corporal\nafectada (%)No datos 20% 4%\n\u00cdndice SCORTEN No datos 2% 1%\nNikolsky Negativo Positivo Positivo628Evoluci\u00f3n  tras\netanercept (d\u00edas)ingresado  por\npancolitis14 11\nCara Si Si No\nExtremidades Si SI Si\nTronco No Si Si\nDorso No Si Si\nMucosa\nbucofar\u00edngeaSi Si Si\nMucosa anal No No No\nMucosa ocular No No Si\nMucosa genital No Si Si\nEstancia  en  UCI\n(d\u00edas)5 No No\nCorticoterapia\npreviaSI SI SI (combinada)\nIgIV previas SI No No\nTabla 1.  Resumen casos de NET en tratamiento con etanercept.\nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA\nLa  NET  se  suele  presentar  como  un  exantema  eritematoso  sim\u00e9trico,\nconfluente, iniciado en cara y tronco, con extensi\u00f3n r\u00e1pida al resto del tronco y partes\nproximales de las extremidades. Tiene lugar tambi\u00e9n desprendimiento de la epidermis\nlaminar y/o ampolloso, con una importante \u00e1rea de la piel desepitelizada. Las lesiones\nampollosas  t\u00edpicas  son  fl\u00e1cidas  y  se  extienden  con  la presi\u00f3n  superficial  (signo  de\nNikolsky positivo) (Frantz et al., 2021).\nEl  diagn\u00f3stico  de  NET  es  fundamentalmente  cl\u00ednico.  Se  realizan  biopsias\ncut\u00e1neas, aunque no son espec\u00edficas. Para el tratamiento, lo principal es la suspensi\u00f3n\nde  los  f\u00e1rmacos  causales  sospechosos.  En  cuanto  al  tratamiento  sist\u00e9mico\nfarmacol\u00f3gico,  no  existe  un  algoritmo  bien  establecido  puesto  que  la  evidencia\ncient\u00edfica del tratamiento curativo de la NET es escasa. 629En los tres pacientes descritos, se solicit\u00f3 etanercept 50mg en dosis \u00fanica como\nuso fuera de indicaci\u00f3n, aprobado en todos ellos por la Comisi\u00f3n de Farmacia. Las otras\nalternativas consideradas fueron: IgIV (administradas en el caso 1), corticoides (, que se\nadministrados en los tres pacientes como primera l\u00ednea) y ciclosporina (que finalmente\nno  es  seleccionado  por  sus  efectos  adversos  potenciales,  como  son  la  HTA  y/o\ninsuficiencia renal en pacientes predispuestos (Paradisi et al., 2014).\nEn todos los pacientes se realizaron simult\u00e1neamente curas con cremas con\ncorticoides y antibi\u00f3ticos. \u00danicamente un paciente desarroll\u00f3 NET durante el ingreso\nhospitalario, siendo el \u00fanico que precis\u00f3 estancia en UCI. \nAunque  el  tratamiento  con  etanercept  carece  del  respaldo  de  un  ensayo\ncontrolado aleatorizado, al igual que el resto de tratamientos utilizados actualmente\npara  NET,  los  casos  reportados  destacan  un  beneficio  en  la  progresi\u00f3n  de  la\nenfermedad y mejora en el tiempo de reepitelizaci\u00f3n. \nEn nuestra experiencia, el tratamiento de la NET con etanercept result\u00f3 seguro\ny efectivo. En los tres casos presentados se observ\u00f3 reepitalizaci\u00f3n de las lesiones y\ncura de las mismas. \nBIBLIOGRAF\u00cdA\n1.Fernandez Carmona A., D\u00edaz Redondo A., Olivencia Pe\u00f1a L., et al. Tratamiento de necr\u00f3lisis epid\u00e9rmica\nt\u00f3xica con ciclosporina A. Med Intensiva. 2011;35(7):442-445\n2.  Barrera-Ochoa  C.A.,  Marioni-Manr\u00edquez  S.,  Cort\u00e1zar-Azuaje  A.M.,  et  al.  Tratamiento  con\ninmunoglobulina  intravenosa  y  esteroides  sist\u00e9micos  en  pacientes  con  necr\u00f3lisis  epid\u00e9rmica  t\u00f3xica:\nExperiencia en un hospital en Ciudad de M\u00e9xico, Actas Dermo-Sifiliogr\u00e1ficas. 2022.113(3):294-299.6303.  Quintana-Sancho A., Rubio-Lombrana M., Guergue D\u00edaz-de-Cerio O., et al. S\u00edndrome de Stevens-\nJohnson y necr\u00f3lisis epid\u00e9rmica t\u00f3xica. Actualizaci\u00f3n en el manejo terap\u00e9utico. Actas Dermosifiliogr\n2016;107:247-8.\n4. Schneider JA. Cohen PR. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review\nwith a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.  Adv\nTher (2017) 34:1235\u20131244.\n5. Paradisi A ., Abeni D ., Bergamo F ., et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad\nDermatol. 2014 Aug;71(2):278-83. \n6. Dreyer S.D., Torres J., Stoddard M., et al. Efficacy of Etanercept in the Treatment of Stevens-Johnson\nSyndrome and Toxic Epidermal Necrolysis. Cutis. 2021 Jun;107(6):E22-E28.\n7. Frantz R., Huang S., Are A., et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review\nof Diagnosis and Management. Medicina (Kaunas). 2021 Aug 28;57(9):895.\n8.  Bastuji-Garin  S,  Bertocchi  M,  Roujeau  JC,  et  al.:  SCORTEN:  a  severity  of  illness  Score  for  Toxic\nEphdermal Necrolysis. J Invest Dermatol 2000;115:149-153631Autores:  LC Fernandes, B Pimentel, J Cotrina Luque , P Raimundo, M Capoulas, A \nMessias, C Santos . \n \nT\u00edtulo:  Ceftazidima -avibactam en infecci\u00f3n del sistema nervioso central por \nEnterobacter cloacae : a prop\u00f3sito de un caso.  \n \nIntroducci\u00f3n: \nLas infecciones del sistema nerv ioso central (SNC) causadas por bacte rias Gram  negativ o \nmulti rresistentes son  dif\u00edcil es de tratar debido  a la penetraci\u00f3n limitada de los \nantibi\u00f3ticos en el  SNC.1 \nCeftazidima -avibactam es un a cefalosporina de 3\u00aa generaci\u00f3n  que combina cef tazidima \ny un  inhibidor  de beta -lactamasa s con actividad  contra bacterias  Gram  negativo \nmultir resistentes. Ceftazidima inhibe  la s\u00edntesis del peptidoglicano de la  pared celular \nbacteriana cuando se une a las prote\u00ednas de uni\u00f3n de penicilinas (PLPs), lo que conlleva \na lisis y muerte celular bacteriana. Avibactam es un inhibidor de las beta -lactamasas, no \nbeta -lactamico, que act\u00faa  mediante formaci\u00f3n de una uni\u00f3n covalente con la enzima \nque es estable frente a la hidr\u00f3lisis. Avibactam aument\u00f3 la potencia y expandi\u00f3 el \nespectro de inhibici\u00f3n de las beta -lactamasas de clase A y C comparado con los restantes \nAmpC y carbapenemasas , expa ndiendo as\u00ed el espectro  de actividad de la ceftazidima y \nque incluye gran parte de Enterobacterias  y Pseudomonas aerugin osa resistentes a \nceftazidima y carbapenem s.  \nAvibactam no inhibe l as enzimas beta -lactamasa s de clas e B (metalo -beta -lactamasas) y \nno e s capaz de inhibir muchas de las enzimas de clase D .2 632Un r\u00e9gime n posol\u00f3gico de 2,5 g de ceft azidima -avibactam administrado cada 8 horas  \ncomo una perfusi\u00f3n intravenosa de 2 horas en pacientes con funci\u00f3n renal normal (con \najuste de dosis en caso de aclaramiento de creatinina calculado menor de 30 ml/min ) \ndemostr\u00f3 no inferioridad estad\u00edstica comparado con carbapenems en estudios de fase \nIII relativos al tratamientos de infecciones intra -abdominales complicadas, infecciones \ncomplicadas del tracto urina rio y neumon\u00eda  nosocomial, incluyendo infecciones a \nbacterias Gram  negativ o no sensibles a ceftazidima.3 \nSin embargo, no se encuentran disponibles en la literatura  datos cl\u00ednicos y/o anal\u00edticos  \nreferentes a la penetraci\u00f3n de ceftazidima -avibactam  en el  SNC. 4 \nAqui, describimos un caso de meningitis causada por Enterobacter cloacae  \nmulti rresistente tratada  con \u00e9xito con  monoterapia con  ceftazidima -avibactam.  \n \nDescripci\u00f3n del caso  \nVar\u00f3n de 27 a\u00f1os sin antecedentes cl\u00ednicos, victima de accidente de tr\u00e1fico en Senegal. \nAdmitido en hospital local, donde fue realizado craneotom\u00eda  descompresora  iniciando \nemp\u00edricamente vancomicina y meropenem por herida abierta y sospecha de meningitis, \ncon identificaci\u00f3n de bacteriemia por Staphylococcus hominis  y Enterobacter  cloacae  \n(sin test de sensibilidad antibi\u00f3tica ).  Fue  transferido en el dia 9 de ingreso  para el \nservicio de medicina intensiva de nuestro hospital , manteniendo terap\u00e9utica \nantimicr obiana con vancomicina en perfusi\u00f3n continua (niveles de vancomicina \nobjetivos 25 -30 mg/L) y meropenem 2g cada 8  horas . Fue admitida inicialmente \nmeningitis nosocomial, con aislamiento posterior en liquido cefalorraqu\u00eddeo obtenido \npor punci\u00f3n y craniectom\u00eda de una estirpe de Enterobacter  cloacae  multi rresistente \npero sensible a meropenem. Efectuados drenaje quir\u00fargico y ext racci\u00f3n de muestra 633\u00f3sea en el d\u00eda 12 de ingreso. A pesar de la mejor\u00eda cl\u00ednica, el paciente evolucion\u00f3 con \nepilepsia y colestasis refractarias. Ante esto, pasados 16 d\u00edas de t erap\u00e9utica con \nmeropenem se decidi\u00f3  substituir por ceftazidima -avibactam  2,5g cada 8 horas , \nmanteniendo durante 7 semanas por focos cerebrales sin ventriculitis. Fue r ealizada \ncraneopat\u00eda con pr\u00f3tesis en el d\u00eda 80 de ingreso y el paciente fue transferido para unidad \nde neuro -rehabilitaci\u00f3n en el d\u00eda 101 de ingreso, sin ocurrencias .  \n \nDiscusi\u00f3n y aporta ci\u00f3n  farmac\u00e9utica : \nAnte la necesidad de encontrar una alternativa al meropenem para el tratamiento de la \ninfecci\u00f3n del sistem a nervioso (donde fue aislado microorganismo  multir resistente ), \nhubo la necesidad de, en conjunto con el equipo m\u00e9dico, revisar la bibliograf\u00eda existente \nen lo que respecta a la utilizaci\u00f3n de ceftazidima -avibactam en este  contexto. Nos \ndeparamos con escas ez de informaci\u00f3n cl\u00ednica disponible relativamente a la utilizaci\u00f3n \nde este antibi\u00f3tico pero con algunas series de casos con resultados favorables en el \ntratamiento de infecciones del SNS con microorganismos multi rresistentes.  \nPara m\u00e1s all\u00e1 de esto, los farmac\u00e9uticos intervenimos tambi\u00e9n en la optimizaci\u00f3n de la \neficacia del antibi\u00f3tico desde el punto de vista del tiempo de perfusi\u00f3n recomendado (2 \nhoras ), par\u00e1metro de  vital  importancia dado que se trata de un antibi\u00f3tico tiempo \ndepe ndiente.   \nTeniendo en cuenta que se trata de un antibi\u00f3tico de reserva y de una utilizaci\u00f3n  \noff-label  del mismo , se recogi\u00f3 una justificaci\u00f3n m\u00e9dica del f\u00e1rmaco extra -formulario \nhospitalario.  \nA pesar de la escasez de serie de casos publicados5,6 de casos  publicados destacamos el \ntratamiento con buenos resultados de esta infecci\u00f3n recurriendo a este antibi\u00f3tico.   634Bibliografia:  \n1. Samuel S, Edwards NJ, Rojas LJ, Rudin SD, Marshall SH, De Cicco I, Bo nomo RA, Arias \nC, Tran TT. Ceftazidime -Avibactam for the Treatment of Post -Neurosurgical Meningitis \nCaused by a Klebsiella pneumoniae carbapenemase (KPC) -Producing Klebsiella \npneumoniae . Open Forum Infectious Diseases, Volume 3, Issue suppl_1, December \n2016, 1182 . \n2. Zasowski EJ, Ry bak JM, Rybak MJ. The \u03b2-Lactams Strike Back: Ceftazidime -Avibactam. \nPharmacotherapy. 2015 Aug;35(8):755 -70. doi: 10.1002/phar.1622. PMID: 26289307; \nPMCID: PMC4545577.  \n3. Sy SKB, Zhuang L, Sy S, Derendorf H. Clinical Pharmacokinetics and Pharmacodynamics \nof Ceftazidime -Avibactam Combination: A Model -Informed Strategy for its Clinical \nDevelopment. Clin Pharmacokinet. 2019 May;58(5):545 -564. doi: 10.1007/s40262 -018-\n0705 -y. PMID: 30097887.  \n4. Yasmin  M, Hanrahan  J, Marshall  S, Lodise  TP, Chen  L, Perez  F, Kreiswirth  B, Bonomo  \nRA, Using Therapeutic Drug Monitoring to Treat KPC -Producing  Klebsiella  \npneumoniae  Central Nervous System Infection With Ceftazidime/Avibactam,  Open  \nForum  Infectious  Diseases , Volume 7, Issue 9, September 2020, ofaa349 .  \n5. Lagac\u00e9- Wiens P, Walkty A, Karlowsky JA. Ceftazidime -avibactam: an evidence -based \nreview of its pharmacology and potential use in the treatment of Gram -negative \nbacterial infections. Core Evid. 2014 Jan 24;9:13 -25. doi: 10.2147/CE.S40698. PMID: \n24493994; PM CID: PMC3908787.  \n6. Pektezel MY, Isikay I, Gocmen R, Inkaya AC. Carbapenem -resistant Klebsiella \npneumoniae meningitis and abscess treated with ceftazidime -avibactam. Enferm Infecc 635Microbiol Clin (Engl Ed). 2021 Apr 12:S0213 -005X(21)00083 -5. English, Spanis h. doi: \n10.1016/j.eimc.2021.03.014. Epub ahead of print. PMID: 33858707.  636Introducci\u00f3n \nLas fluoropirimidinas, principalmente 5-Fluorouracilo (5-Fu) y capecitabina, \nconstituyen la base del tratamiento quimioter\u00e1pico de los tumores gastrointestinales. \nEntre los efectos adversos m\u00e1s frecuentemente descr itos para estos f\u00e1rmacos \nencontramos la toxicidad hematol\u00f3gica, gastrointest inal y cardiaca (1). \nLa incidencia de toxicidad card\u00edaca asociada a fluo ropirimidinas reportada est\u00e1 entre 1 \ny 35% (2,3). Una mayor incidencia se asocia con la administraci\u00f3n del 5-Fu en infusi\u00f3n \ncontinua, presencia previa de enfermedad cardiaca, insuficiencia renal, radioterapia \ntor\u00e1cica previa y el uso de otros f\u00e1rmacos cardiot\u00f3 xicos (3,4). \nEl s\u00edntoma cardiol\u00f3gico m\u00e1s frecuente es la angina,  en relaci\u00f3n a vasoespasmo \ncoronario. Otras presentaciones incluyen arritmias,  pericarditis, miocarditis, \ninsuficiencia cardiaca e incluso la muerte. \nEl manejo de estos pacientes requiere un abordaje m ultidisciplinar e individualizado, \nya que la tasa de recurrencia de la toxicidad cardi aca si se reinicia la fluoropirimidina es \nde hasta el 90% y, en un 13%, con consecuencias fatales (muerte s\u00fabita). \nSe describe el caso de un paciente que present\u00f3 dol or tor\u00e1cico tras el primer ciclo de \nquimioterapia con fluoropirimidinas y en el que se pudo reiniciar con \u00e9xito el \ntratamiento. \nDescripci\u00f3n \nHombre de 33 a\u00f1os sin alergias medicamentosas conoc idas y con antecedente de \nhipertensi\u00f3n tratada con valsartan/hidroclorotiazida. No tiene h\u00e1bitos t\u00f3xicos, as\u00ed \ncomo tampoco antecedentes familiares relevantes. 637Se diagnostica de adenocarcinoma de p\u00e1ncreas periam pular pT3N0M0 tratado con \nduodenopancretectom\u00eda radical (cirug\u00eda R0 con invas i\u00f3n perineural). \nInicia tratamiento adyuvante seg\u00fan esquema FOLFIRIN OX (oxaliplatino 85 mg/m2 d\u00eda 1, \nirinotecan 150 mg/m2 d\u00eda 1, folinato 400 mg/m2 d\u00eda 1 e infusi\u00f3n continua de 5-\nfluorouracilo 2400 mg/m2 d\u00eda 1 a pasar en 46 horas). Ciclos cada 14 d\u00edas. \nAcude al hospital el d\u00eda de la retirada del infusor  de 5-Fu del primer ciclo refiriendo \nvarios episodios de dolor tor\u00e1cico opresivo irradia do a la espalda, de 5 minutos de \nduraci\u00f3n, que lo despertaron la noche anterior. Se retira el infusor, se administran 2 \npulsaciones de nitroglicerina sublingual, \u00e1cido ace tilsalic\u00edlico 300 mg y se deriva a \nurgencias para valoraci\u00f3n por cardiolog\u00eda. \nEn urgencias se realizan las siguientes pruebas: \n- Troponinas: 9.24 pg/mL, 10.55 pg/mL, 16.9 pg/mL y 1 2,9 pg/mL (valores \nnormales 0-14 pg/mL). \n- Electrocardiograma (ECG): ritmo sinusal a 60 lpm, P R normal, QRS estrecho, \nsignos de repolarizaci\u00f3n precoz y ondas T picudas V 3-V6. \n- Ecocardiograma: ventr\u00edculo izquierdo con fracci\u00f3n d e eyecci\u00f3n preservada, sin \nevidencia de segmentarismos, ni valvulopat\u00edas significativas ni derrame. \n- AngioTC de aorta: ausencia de signos de patolog\u00eda a \u00f3rtica aguda. \n- Radiograf\u00eda de t\u00f3rax: normal. \nSe deja al paciente monitorizado 24 horas con pauta  de nitroglicerina si se repite el \ndolor tor\u00e1cico. Dada la estabilidad hemodin\u00e1mica de l paciente y la normalidad de las \npruebas de da\u00f1o mioc\u00e1rdico se decide darle el alta con normas de reconsulta, con el \ndiagn\u00f3stico de dolor tor\u00e1cico probablemente secunda rio a fluoropirimidinas.  638Se cambia el tratamiento antihipertensivo a nifedipino oros 30 mg/12h, dado su efecto \nvasodilatador. \nSe solicita un TAC coronario para realizar de forma ambulatoria que descarta \nenfermedad coronaria ateroscler\u00f3tica. \nCon el diagn\u00f3stico de posible vasoespasmo por 5-Fu y, de acuerdo con el servicio de \ncardiolog\u00eda, se decide administrar el segundo ciclo  con el paciente ingresado y \nadaptando el esquema de quimioterapia a la bibliograf\u00eda publicada (8). \nSe contacta con el servicio de farmacia para modificar el esquema de quimioterapia, \nsustituyendo la infusi\u00f3n continua de 5-Fu por bolus . El esquema propuesto fue: \noxaliplatino 85 mg/m2 d\u00eda 1, irinotecan 150 mg/m2 d\u00eda 1, folinato 500 mg/m2 d\u00edas 1 y 8 \nbolus de 5-fluorouracilo 500 mg/m2 d\u00edas 1 y 8, ciclos de 14 d\u00edas. \nEn la tabla 1 se detalla el esquema propuesto y las  diferencias con el esquema original \nF\u00c1RMACOS FOLIRINOX ESTANDAR FOLFIRINOX ADAPTADO \nOxaliplatino 85 mg/m2 d\u00eda 1 85 mg/m2 d\u00eda 1  \nIrinotecan 150 mg/m2 d\u00eda 1 150 mg/m2 d\u00eda 1  \nFolinato 400 mg/m2 d\u00eda 1 500 mg/m2 d\u00eda s 1 y 8 \n5-fu 2400 mg/m2 en bomba de 46 h 500 mg/m2 en bolus d\u00edas 1 y 8  \nTabla 1: diferencias entre el esquema FOLFIRINOX original y el adaptado para nuestro \npaciente. \nAdem\u00e1s, se prescribe pre y post-tratamiento con ant agonistas del calcio y nitratos \nseg\u00fan el siguiente esquema: 639- Cuatro horas antes de recibir el bolus de 5-Fu toma r nifedipino oros 30 mg y \nmononitrato de isosorbide 30 mg. \n- Una hora antes de recibir el bolus de 5-Fu tomar di ltiazem 30 mg. \n- Doce horas despu\u00e9s de recibir el bolus de 5-Fu toma r nifedipino oros 30 mg y \nmononitrato de isosorbide 30 mg. \n- A partir de las 24 horas de recibir el bolus de 5-F u puede seguir con su pauta \nhabitual de nifedipino oros 30 mg/12h. \nF\u00c1RMACO   HORAS RESPECTO LA ADMINISTRACI\u00d3N DEL BOLUS DE 5-FU \n-4 -3 -2 -1 0 +1 +2 +3 +4 +5 +6 +7 +8 +9 +10 +11 +12 \nBolus de 5-Fu     X              \nNifedipino 30 mg \nOROS X                 X  \nMononitrato de \nisosorbide 30 mg X                 X  \nDiltiazem 30 mg    X              \nTabla 2: esquema de pre y post tratamiento con nitr atos y antagonistas del calcio \nSe administra el bolus de 5-Fu con seguimiento estr echo por parte de cardiolog\u00eda y \ncontroles diarios de ECG. El paciente no presenta n ing\u00fan episodio de dolor tor\u00e1cico y, \nal d\u00eda siguiente de la administraci\u00f3n de la QT, se le da el alta para seguir controles \nambulatorios. \nSe programa el C2D8 para realizarse en hospital de d\u00eda, con la misma pre y post \nmedicaci\u00f3n que se administr\u00f3 durante el ingreso. \nEl paciente acude a consultas externas de oncolog\u00eda  para C3. Se consensua con \ncardiolog\u00eda volver a prescribir el esquema original de FOLFIRINOX junto a la pre y post 640medicaci\u00f3n con nitratos y antagonistas del calcio, dada ausencia de dolor tor\u00e1cico en \nel ciclo previo. El objetivo de este cambio es opti mizar la dosis del 5-Fu, ya que con el \nesquema adaptado \u00e9sta era aproximadamente un 50% in ferior. \nSe administran 2 ciclos de FOLFIRINOX est\u00e1ndar con pre y post tratamiento, pero el \npaciente vuelve a presentar episodios de dolor angi noso coincidiendo con la \nadministraci\u00f3n del infusor (4-5 episodios al d\u00eda de  5-10 minutos de duraci\u00f3n). \nSiguiendo la recomendaci\u00f3n de cardiolog\u00eda, se decid e volver a prescribir el FOLFIRINOX \nadaptado (con el bolus de 5-Fu en lugar de la infus i\u00f3n continua). \nEl paciente sigue tratamiento seg\u00fan este esquema si n repetir dolor tor\u00e1cico hasta \ncompletar 8 ciclos. \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica \nEl manejo de la toxicidad cardiaca por 5-Fu es comp lejo, d\u00f3nde las decisiones de \ncontinuar o no el tratamiento deben ser tomada de forma multidisciplinar y centradas \nen el paciente. En la literatura se encuentran desc ritas varias estrategias con \nresultados dispares (5-10). \nUna posible estrategia de manejo es cambiar el esqu ema de tratamiento a otro que no \ncontenga la fluoropirimidina. Se debe valorar el paciente, su estado general y la \nintenci\u00f3n de tratamiento (curativo vs paliativo). E n nuestro paciente se decidi\u00f3 seguir \ncon el esquema prescrito ya que FOLFIRINOX demostr\u00f3 ser superior a gemcitabina en \nel ensayo pivotal (11), con una supervivencia libre  de progresi\u00f3n de 21.6 meses en el \ngrupo FOLFIRINOX frente a 12,8 meses en el grupo ge mcitabina (HR 0.58, p <0.0001) y \nuna supervivencia global de 54.4 meses en el grupo FOLFIRINOX frente a 35 meses en \nel grupo gemcitabina (HR 0.64, p=0.003). Adem\u00e1s, se  trataba de un paciente joven con 641muy buen estado general (ECOG 0) y con intenci\u00f3n de  tratamiento curativo, por lo que \nse pod\u00eda beneficiar de seguir el tratamiento. \nExiste experiencia publicada de retratamiento con fluoropirimidinas en pacientes que \nhayan presentado toxicidad cardiaca. Dado que la incidencia de cardiotoxicidad se \nasocia m\u00e1s a la infusi\u00f3n continua de 5-Fu que a su administraci\u00f3n en bolus, las \nestrategias propuestas consisten en cambiar la forma de administraci\u00f3n del 5-Fu en el \nesquema de quimioterapia. \nEn las series de casos publicados, se presentan may oritariamente casos de pacientes \ncon c\u00e1ncer de colon tratados con los esquemas FOLFO X, XELOX y capecitabina en \nmonoterapia. En los pacientes tratados con FOLFOX, \u00e9ste se cambi\u00f3 al esquema FLOX, \nque incluye la administraci\u00f3n del 5-Fu en bolus en lugar de en infusi\u00f3n continua (tabla \n3). En estos estudios tambi\u00e9n se administraba a los  pacientes tratamiento con \nantagonistas del calcio y nitratos antes y despu\u00e9s del 5-Fu. Con esta estrategia los \npacientes pudieron seguir con los tratamientos pres critos sin recurrencia de la \ntoxicidad cardiaca. \nF\u00c1RMACOS FOLFOX FLOX \nOxaliplatino 85 mg/m2 d\u00eda 1 85 mg/m2 d\u00eda 1  \nFolinato 400 mg/m2 d\u00eda 1 500 mg/m2 d\u00eda s 1 y 8 \n5-fu 400 mg/m2 en bolus d\u00eda 1 500 mg/m2 en bolus d\u00edas 1 y 8  \n2400 mg/m2 en bomba de 46 h d\u00eda 1 \nTabla 3: diferencias entre los esquemas FOLFOX y FL OX (12) \nNo existen datos publicados de toxicidad cardiaca c on el esquema FOLFIRINOX, por lo \nque, cuando se nos contact\u00f3 des del servicio de onc olog\u00eda para adaptar el esquema de 642quimioterapia, se hizo una analog\u00eda de los cambios del esquema FOLFOX respecto al \nFLOX, para adaptarlos al FOLFIRINOX. Se cambi\u00f3 la i nfusi\u00f3n continua de 5-Fu por el \nbolus, modificando la periodicidad a los d\u00edas 1 y 8  del ciclo y ajustando la dosis del \nfolinato, mientras que el resto de f\u00e1rmacos del esq uema (oxaliplatino e irinotecan) no \nsufrieron cambios (tabla 1). \nEn cuanto a la pre y post medicaci\u00f3n con nitratos y  antagonistas del calcio, desde el \nservicio de farmacia, se hizo educaci\u00f3n al paciente  sobre cuando deber\u00eda tomarlo, \nteniendo en cuenta la programaci\u00f3n el tratamiento e n hospital de d\u00eda y los f\u00e1rmacos \nprevios al 5-Fu (tabla 2). \nSiguiendo estas recomendaciones, el paciente pudo s eguir con su tratamiento de \nquimioterapia sin recurrencia de la toxicidad cardi aca. \nBibliograf\u00eda \n1. Fichas t\u00e9cnicas 5-Fluorouracilo y capecitabina. Dis ponibles en: \nhttps://cima.aemps.es/cima/publico/home.html  (acceso 11/05/22) \n2. Sara JD et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol \n2018;10:1-18. \n3. Polk A et al. Cardiotoxicity in cancer patients tre ated with 5-fluorouracil or \ncapecitabine: a systematic review of incidence, man ifestation and predisposing \nfactors. Cancer Treat Rev 2013;39:974-984 \n4. Zafar A, et al. The incidence, risk factors and out comes with 5-fluorouracil-\nassociated coronary vasospasm. JACC: CardioOncol 20 21;3:101-109 \n5. Cianci G et al. Prophylactic options in patients with 5-fluorouracil-associated \ncardiotoxicity. Br J Cancer 2003;88:1507-1509. 6436. Chakrabarti S et al. Bolus 5-Fluorouracil (5-Fu) in  combination with oxaliplatin is \nsafe and well tolerated in patients who experienced coronary vasospasm with \ninfusional 5-Fu or capecitabine. Clin Colorectal Ca ncer 2019;18:52-57. \n7. Clasen SC et al. Fluoropyrimidine-induced cardiac t oxicity: challenging the \ncurrent paradigm. J Gastrointest Oncol 2017;8:970-9 79. \n8. Padegimas A et al. How to diagnose and manage patie nts with \nfluoropyrimidine-induced chest pain. JACC: CardioOn col 2020;17:650-654. \n9. Desai A et al. 5-Fluorouracil rechallenge after car diotoxicity. Am J Case Rep \n2020;21:e924446. \n10.  Zafar A et al. The efficacy and safety of cardio-protective therapy in patients \nwith 5-Fu (fluorouracil)-associated coronary vasosp asm. PLoS ONE \n2022;17:e0265767. \n11.  Conroy T et al. FOLFIRINOX or gemcitabine as adjuva nt therapy for pancreatic \ncancer. N Engl J Med 2018;379:2395-2406 \n12.  Sharif S et al. FOLFOX and FLOX regimens for the ad juvant treatment of \nresected stage II and III colon cancer. Cancer Inve st 2008;26:956-63. 644INTRODUCCI\u00d3N  \nEl tratamiento  con inhibidores del punto de control inmunitario (IPCi) dirigidos  contra \nel ant\u00edgeno 4 asociado a linfocitos T citot\u00f3xicos (CTLA4) como ipilimumab y el  receptor \nde muerte programada -1 (PD -1) como nivolumab , se han posicionado como una piedra \nangular en el tratamiento de determinadas neoplasias  como el melanoma . Sin \nembargo, el uso de IPCi puede conducir a una activaci\u00f3n inespec\u00edfica del sistema \ninmunitario. Esto ha dado lugar a un grupo particular de efecto s secundarios  \ndiferentes de los producidos por la quimioterapia tradicional, llamados efectos \nadversos inmunomediados (EAi), y que requieren  un manejo espec\u00edfico. Diversos \nensayos cl\u00ednicos han demostrado que los EAi ocurren hasta en un 65% de los pacientes  \nen tratamiento con IPCi y que cualquier \u00f3rgano o tejido puede verse afectado . \nEn cuanto a la afectaci\u00f3n hep\u00e1tica por los IPCi, s u incidencia, inicio y gravedad var\u00edan \nampliamente, dependiendo del tipo de tumor, as\u00ed como de la dosis, la duraci\u00f3n y \nprincipalmente de si se administran en monoterapia o junto a otro IPCi. En pacientes \ncon melanoma tratados con  nivolumab e ipilimumab  en combinaci\u00f3n , esta toxicidad \naparece en un 29,5% de los pacientes, incluyendo eventos de grado 2, 3 y 4  en el \n6,7%, 15,4% y 1,8% de los caso s, respectivamente. El tiempo medio hasta la aparici\u00f3n \nes de  1,5 (rango:0,0 \u201330,1) meses, mientras que el tiempo medi o para la resoluci\u00f3n se \nestima en 1,27 (rango: 0,03 -26,73) meses. Cl\u00ednicamente  suele manifestarse con \nelevaci\u00f3n asintom\u00e1tica de las transaminasas o la bilirrubina, aunque en ocasiones esto \nse acompa\u00f1a de s\u00edntomas sist\u00e9micos como fiebre o malestar. El mecan ismo \nfisiopatol\u00f3gico no se conoce con exactitud, pero parece que los IPC i inducen la \ninfiltraci\u00f3n hep\u00e1tica por linfocitos T activados  que desencadenan el da\u00f1o tisular .  645El caso desarrollado a continuaci\u00f3n es una muestra del abordaje terap\u00e9utico y \nevoluci\u00f3n  cl\u00ednica de un paciente que pre sent a distintos EAi asociados al tratamiento \ncon nivolumab e ipilimumab, entre los cuales destaca una hepatitis grave.  \nDESCRIPCI\u00d3N DEL CASO  \nHombre de 62 a\u00f1os con antecedentes m\u00e9di cos de hipercolesterolemia  no tratada y \ndiagn\u00f3stico oncol\u00f3gico de melanoma infiltrante  en cuero cabelludo  en 2019. Se realiz\u00f3 \nex\u00e9resis  quir\u00fargica y biopsia selectiva del ganglio centinela , pT2b  N1a estad\u00edo IIIB  BRAF \nmutado . El estudio de extensi\u00f3n fue negativo. Inici\u00f3 tratamiento adyuvante  con \nterapia dirigida (dabrafen ib y trametinib ) en otro centro, suspendido  en el ciclo 3  por \ntoxicidad (transaminitis  grado 2  y fiebre  grado 1 ). Present\u00f3  3 reca\u00eddas de la \nenfermedad a nivel cervical. Las dos primeras se abordaron de forma quir\u00fargica con \nlinfadenectom\u00eda cervical izquierda y ex\u00e9resis de la tumoraci\u00f3n. Sin embargo , en el TAC \nde extensi\u00f3n de la tercera , se observaro n adenopat\u00edas supraclavicula res y lesiones en \nbazo  suges tivas de met\u00e1stasis de melanoma , estad\u00edo IV M1c.  \nInici\u00f3  primera l\u00ednea de tratamiento p ara enfermedad  avanzada  con nivolumab  1 mg/kg \ne ipilimumab  3 mg/kg i ntravenoso  (IV) cada 3 semanas . Las enzimas hep\u00e1tic as en ese \nmomento  se encontraban dentro del rango de normalidad. Tras dos ciclos, a cudi\u00f3 a \nurgencias por s\u00edndrome constitucional y fiebre sin focalidad infecciosa . Ingres\u00f3 del 12 \nal 17/12/2021  con diagn\u00f3stico de  tiroiditis, hipofisitis y  hepatitis grado 3 . El paciente \nmanten\u00eda buen  estado general, salvo  ictericia, coluria y prurito, en contexto de \nhiperbilirrubinemia. Se descartaron otras etiolog\u00edas  y dada la coexistencia de las 3 \npatolog\u00edas tras tratamiento  reciente  con inmunoterapia , se orient\u00f3 como una toxicidad \ninmu nomediada grado 3, por lo que s e interrumpi\u00f3 la inmunoterapia de forma 646permanente y se inici\u00f3 metilprednisolona  (MP)  1 mg/kg /d\u00eda  IV. En cuanto a  la \ntoxicidad endocrina se trat\u00f3  con metimazol, propranolol  durante la fase hipertiroidea  \ny levotiroxina  posteriormente por el hipotiroidismo  secundario , con buena evoluci\u00f3n y \nsin complicaciones asociadas . El prurito  se manej\u00f3 con  hidroxicina  y dexclorfeniramina . \nNo se inici\u00f3 ning\u00fan otro tratamiento activo para el melanoma pues se objetiv\u00f3 \nrespuesta completa  de las lesiones metast\u00e1sicas en prueba de imagen.  \nBuena respuesta inicial a  MP, por lo que se inici\u00f3  descenso progresivo de la dosis. S in \nembargo, e n enero de 2022  present\u00f3  empeoramiento del perfil hep\u00e1tico , motivo por \nel que reingres\u00f3 . Adem\u00e1s, fue COVID positivo. Se aument\u00f3  MP a 1,5  mg/kg /d\u00eda  IV, y \ntras 48 horas sin respuesta, se asoci\u00f3  micofenolato de mofetilo (MMF)  1000 mg/12 \nhoras  v\u00eda oral (VO) . Se realiz\u00f3 biopsia hep\u00e1tica con resultado confirmatorio de \nhepatitis aguda con infiltrado inflamatorio de predominio linfocitario T . El paciente \ncontinu \u00f3 con empeoramiento hep\u00e1tico progresivo , decidi\u00e9ndose administrar 3 bolus \nIV de MP 1000 mg /d\u00eda  y continuar con MP 2 mg/kg /d\u00eda  IV. No hubo  mejor\u00eda,  y dada la \nrefractariedad al tratamiento, se administr\u00f3 tocilizumab 400 mg  IV. Tras  mejor\u00eda  de la \ntransaminitis , fue dado de alta  con prednisona  (Pd) 2 mg/kg/d\u00eda  VO y MMF  1000 \nmg/12h  VO. Sin embargo, en  anal\u00edtica de control a los 7 d\u00edas  se apreci\u00f3  nueva \nelevaci\u00f3n de marcadores hep\u00e1ticos, por lo que se administr\u00f3 una segunda dosis de \ntocilizumab 400 mg  IV. En este caso, hubo nula respuesta al tratamiento  y se decidi\u00f3 \niniciar  fotoaf\u00e9resis extracorp\u00f3rea  (FE). Aunque  se objetiv\u00f3 cierta mejor\u00eda que motiv\u00f3 \nla reducci\u00f3n de MMF a 500 mg/12 horas  VO, los marcadores hep\u00e1ticos empeoraron \npoco despu\u00e9s  y se a soci\u00f3 tacrolimus  (TK) 1,5 mg/12  horas  VO. Continu\u00f3 siendo \nrefractario al tratamiento , repiti\u00e9ndose biopsia hep\u00e1tica con resultado de Vanishing 647Bile Duct Syndrome (VBDS) ; se decidi\u00f3 suspender MMF y TK  y continuar con Pd 2 \nmg/kg/d\u00eda  VO, FE e iniciar  recambio s plasm\u00e1tico s (RP)  cada 48 horas, con reposici\u00f3n \nde inmunoglobulinas  (Ig) IV cada 2 RP. Ante estabilidad de los marcadores hep\u00e1tic os \ntras 6 RP,  se inici\u00f3 pauta descendente progresiva de  Pd.  \nActualmente y por empeoramiento del patr\u00f3n de colestasis y de la bilirrubinemia con \ntransaminasas estables, el paciente se encuentra recibiendo una nueva tanda de RP, \nsin mejor\u00eda significativa, y continua con  pauta descendente de Pd. \nA continuaci\u00f3n,  se expone gr\u00e1ficamente  la evoluci\u00f3n de los par\u00e1metros anal\u00edticos \nhep\u00e1ticos  desde el inicio de nivolumab e ipilimumab, as\u00ed como  la secuencia temporal  \nde los tratamiento s prescritos  para la hepatotoxicidad secundaria a  inmunoterapia : \n \nTratamiento: 1. Segundo ciclo nivolumab e ipilimumab. 2. MP 1 mg/kg/d\u00eda. 3. MP 1,5 mg/kg/d\u00eda. 4. MP 1,5 mg/kg/d\u00eda + MMF \n1000 mg/12 h. 5. Bolus MP 1000 mg/d\u00eda x 3 d\u00edas  + MMF 1000 mg/12h . 6. Tocilizumab  400 mg  + MP 2 mg/kg/d\u00eda + MMF 1000 \nmg/12h. 7. Pd 2 mg/kg/d\u00eda +  MMF 1000 mg/12h . 8. Segunda dosis t ocilizumab 400 mg  + Pd 2 mg/kg/d\u00eda + MMF 1000 mg/12h . 9. \nFE + Pd 2 mg/kg/d\u00eda  + MMF 1000 mg/12h . 10. FE + Pd 2 mg/kg/d\u00eda +  MMF 500 mg/12h . 11. TK 1,5 mg/12h + FE + Pd 2 mg/kg/d\u00eda +  \nMMF  500 mg/12 h 12. RP + reposici\u00f3n inmunoglobulinas  + Pd en pauta descendente.  \nTratamiento  Fecha  AST U/L  \nLSN: 40  \n ALT U/L  \nLSN:40  GGT U/L  \nLSN: 40  FA U/L  \nLSN:116  Bil total \nmg/dL  \nLSN: 1,2  \n1 7/12/2021  18 25 27 104 0,7 \n2 12/12/2021  162 203 60 92 1 \n3 11/1/2022  246 627 474 212 5,6 \n4 14/1/2022  265 726 530 224 9 648 \n \n \n \n \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA  \nLas aportaciones realizadas por los farmac\u00e9uticos del \u00e1rea de farmacia \nonco hematol\u00f3gica  fueron:  \n1. Gesti\u00f3n de la solicitud de tratamiento con nivolumab e ipilimumab para \nmelanoma metast\u00e1tico a las autoridades sanitarias de la comunidad aut\u00f3noma.  \nPara iniciar el tratamiento de nivolumab e ipilimumab para melanoma  \nmetast\u00e1sico en nuestra comunidad, el m\u00e9d ico debe cumplimentar un \nformulario y un  informe basal del paciente . La solicitud de tratamiento es \nremitida a la autoridad competente por el servicio de farmacia, quien tambi\u00e9n \nse encarga del registro de los datos para evaluar resultados en salud, en caso  \nde que el tratamiento sea autorizado.   \n2. Validaci\u00f3n de la prescripci\u00f3n m\u00e9dica  y elaboraci\u00f3n del tratamiento de \nnivolumab e ipilimumab.  Desde el \u00e1rea de far macia onco hematol\u00f3gica , se \nrevisa la indicaci\u00f3n y los par\u00e1metro s de la historia cl\u00ednica que pueda n requerir \nintervenci\u00f3n. Se valida cl\u00ednica y gal\u00e9nicamente la prescripci\u00f3n y se ordena su \npreparaci\u00f3n.  \n3. Revisi\u00f3n de l tratamiento de  la hepatotoxicidad derivada de la combinaci\u00f3n \nnivolumab e ipilimumab . No existe evidencia consistente para guiar el manejo \nde esta toxicidad y las recomendaciones actuales se basan en el consenso de la 5 18/1/2022  359 857 502 266 17,2  \n6 21/1/2022  344 881 479 252 15,9  \n7 10/2/2022  133 403 541 127 15,8  \n8 15/2/2022  195 636 840 180 23,1  \n9 21/2/2022  231 767 979 182 21,4  \n10 28/2/2022  184 769 1087  166 21,1  \n11 5/3/22  260 847 1186  169 22,6  \n12 16/3/22  208 767 1145  170 20,3  649Sociedad Europea de Oncolog\u00eda M\u00e9dica, Sociedad Estadounidense de \nOncolog\u00eda Cl\u00ednica y las gu\u00edas NCCN. Todas ellas coinciden en que los dos ejes \nprincipales son la interrupci\u00f3n temp oral o permanente de los IPCi y el inicio de \nterapia inmunosupresora con corticosteroides. Sin embargo, si la hepatitis \ninmunomediada es refractaria a esteroides o requiere m\u00e1s inmunosupresi\u00f3n \npara ser resuelta, las opciones de tratamiento alternativas no est\u00e1n claramente \ndefinidas. Las decisiones se basan en un abordaje farmacol\u00f3gico an\u00e1logo a \notros trastornos autoinmunes, series de casos  y caracter\u00edsticas individuales del \npaciente.  \nAnte la refractariedad d el paciente, se valoraron  alternativas con el onc\u00f3log o \nresponsable: infliximab , contraindicado en insuficiencia  hep\u00e1tica;  TK, evidencia \nlimitada basada en series de casos ; RP, desestimados  inicialmente  por paciente \nCOVID positivo e Ig antitimoc\u00edtica , desestimada por elevada toxicidad  asociada . \n4. Revisi\u00f3n de la evidencia del uso de tocilizumab en toxicidad inmunomediada y \nelaboraci\u00f3n de informe para su uso fuera de indicaci\u00f3n. Se trata de un uso \nfuera de ficha t\u00e9cnica  y no contemplado en las gu\u00edas de consenso  para esta \nindicaci\u00f3n . Por este motivo, fue re querida  la redacci\u00f3n de un informe de \nevaluaci\u00f3n para exponer ante la Subcomisi\u00f3n de Medicamentos en Situaciones \nEspeciales  del hospital  la evidencia disponible, resultados publicados en cuanto \na eficacia y seguridad y el c\u00e1lculo del coste. El tratamiento fue aprobado de \nforma urgente y sujeto a seguimiento cl\u00ednico estrecho . \n5. Asesoramiento al equipo m\u00e9dico  para el manejo posol\u00f3gic o de  TK, f\u00e1rmaco \npoco frecuente  en oncolog\u00eda . Se revis\u00f3 la limitada bibliograf\u00eda disponible  y se \nrecomend\u00f3 una posolog\u00eda de 1,5 mg/12 horas  VO y posterior ajuste con 650monitorizaci\u00f3n farmacocin\u00e9tica,  para unas concentraciones sangu\u00edneas \nobjetivo de 8 -10 ng/mL. En cuanto a la administraci\u00f3n,  se recomend\u00f3 tomarlo \nen ayunas y separarlo 2 horas del resto de medicamentos concomitantes para \nasegurar  su absorci\u00f3n. Adem\u00e1s, se indic\u00f3 iniciar suplementos de magnesio VO \npara prevenir una posible hipomagnesemia asociada al f\u00e1rmaco.  \nEn cuanto a la monito rizaci\u00f3n farmacocin\u00e9tica,  y por  la semivida del f\u00e1rmaco  \nrelativamente larga  (23-46 horas ), se recomend\u00f3  extracci\u00f3n de niveles \nplasm\u00e1ticos  tras 2 semanas  desde el inicio del tratamiento , una vez alcanzado \nel estado de equilibrio. El paciente alcanz\u00f3 concent raciones  objetivo con esa \npauta  (8,7 ng/mL) , pero el tratamiento se suspend i\u00f3 por ineficacia  en la mejora \nde los par\u00e1metros hep\u00e1ticos y por su marcado car\u00e1cter hepatot\u00f3xico . \n6. Propuesta de desprescripci\u00f3n de f\u00e1rmacos hepatot\u00f3xicos por posible \ncontribuci\u00f3n al  VBDS: interrupci\u00f3n de cotrimoxazol, antitiroideos, MMF y TK.  \nLa hepatitis inmunomediada suele resolverse en 4 -6 semanas con tratamiento \napropiado. De no resolverse se deben considerar otras posibles casusas. En el caso \nexpuesto, tras haber descartado otras  etiolog\u00edas y tras  5 meses  desde el inicio del \ncuadro , no se ha alcanzado la resoluci\u00f3n de la toxicidad poniendo de manifiesto la \nnecesidad de identificar nuevos agentes o medicas terap\u00e9uticas eficaces en este \ncontexto. Las gu\u00edas tera p\u00e9uticas disponib les no definen un manejo espec\u00edfico de la \ntoxicidad hep\u00e1tica inmunomediada tras dos l\u00edneas de tratamiento basadas en \ncorticoides y MMF de jando en manos de los cl\u00ednicos  la elecci\u00f3n de la terapia \nfarmacol\u00f3gica.  Por este motivo, se considera de especial impo rtancia la investigaci\u00f3n y \npublicaci\u00f3n de datos en vida real en este \u00e1rea  para poder alcanzar un consenso en el \nabordaje de la toxicidad inmunomediada.  651En este sentido, hay que recalcar la importancia del farmac\u00e9utico en el equipo \nmultidisciplinar del pac iente oncohematol\u00f3gico , como elemento clave en la toma de \ndecisiones de abordaje f armacol\u00f3gico cuando  la evidencia disponible es limitada . \nBIBLIOGRAF\u00cdA  \nHaanen J, Carbonnel F  et al. Management of toxicities from immunotherapy: ESMO \nClinical Practice Guideli nes for diagnosis, treatment and follow up. Annals of Oncology \n28 (Supplement 4): i119 -i142, 2017.  \nThompson J et al. \u201cManagement of immunotherapy -related toxicities . NCCN \nGuidelines version 1.202 2. \nStroud CR et al. Tocilizumab for the management of immune mediated adverse events \nsecondary to PD -1 blockade. J Oncol Pharm Pract. 2019;25:551 -557.  \nDimitrou F et al. Interleukin -6 blockade for prophylaxis and management of immune -\nrelated adverse events in cancer immunotherapy. Eur J Cancer 157 (2021): 214 -224 \nCampochiaro C et al. Tocilizumab for the treatment of immune -related adverse events: \na systematic literature review and a multicentre case series. Eur J Intern Med.  \nZiogas DC, Aikaterini G et al. When steroids are not enough in immune -related \nhepatitis: current clinical challenges discussed on the basis of a case report. Journal for \nImmunoTherapy of Cancer. 2020;8:e001322.  \nBeardslee T, Draper A et al. Tacrolimus for the treatment of immune -related adve rse \neffects refractory to systemic steroids and anti -tumor necrosisalpha therapy. J Oncol \nPharm Practice 2019, Vol 25(5) 1275 -1281.  652\t\nABORDAJE\t TERAP\u00c9UTICO\t DE\t UNA\t PACIENTE\t EMBARAZADA\t DIAGNOSTICADA\t DE\t\nLEUCEMIA\tMIELOIDE\tAGUDA:\tA\tPROP\u00d3SITO\tDE\tUN\tCASO\t\n\t\nINTRODUCCI\u00d3N\t\nEl\tc\u00e1ncer\tcomplica\taproximadamente\t1\tde\tcada\t1.000\tembarazos,\trepresentando\tlas\t\nneoplasias\thematol\u00f3gicas\tcomo\tgrupo\tel\t18%\t -\t25%\tde\tlas\tmalignidades\tque\tcomplican\t\nel\tembarazo\t(1).\t\t\nLas\tleucemias\tagudas\tson\tde\tdif\u00edcil\tmanejo\ten\tla\tgravidez\t por\tlo\tque \tsu\ttratamiento\tdebe\t\niniciarse\t inmediatamente\t para\t no\t perjudicar\t el\t pron\u00f3stico\t materno;\t este\t tipo\t de\t\nneoplasias\ten\tuna\tpaciente\tembarazada\tsupone\tun\taumento\tdel\triesgo\tde\taborto,\t\nmortalidad\t fetal\t y\t perinatal,\t adem\u00e1s\t de\t restricci\u00f3n\t del\t crecimiento\t fetal\t y\t parto\t\npret\u00e9rmino\tespont\u00e1neo\ten\tun\t40%\t -\t50%\tde\tlas\tpacientes\t(1)(2).\t La\tLeucemia\tMieloide\t\nAguda\t(LMA)\tpuede\tgenerar\ten\tla\tembarazada\tleucocitosis,\ttrombosis\ty\tcoagulopat\u00eda,\t\nagravadas\tpor\tla\tgestaci\u00f3n,\tpor\tlo\tque\tposponer\tel\ttratamiento\thasta\tel\tpostparto\tpuede\t\ntener\tgrandes\trepercusiones\tsobre\tla\tpaciente\t(2).\t\nEn\teste\tcontexto\tde\tinminente\tabordaje\tterap\u00e9utico,\tes\timportante\ttener\ten\tcuent a\tque\t\ncon\tel\ttratamiento\tse\tpretende \tfavorecer\tuna\tremisi\u00f3n\tprolongada\tde\tla\tenfermedad\ten\t\nla\tpaciente,\tcon\tuna\ttoxicidad\tm\u00ednima\tpara\tel\tfeto\t(1).\tEs\tnecesario,\tpor\ttanto,\tadaptar\t\nesquemas\t quimioter\u00e1picos\t teniendo\t en\t cuenta\t el\t desarrollo\t fetal,\t sin\t que\t est as\t\nmodificaciones\t supongan\t un\t detrimento\t en\t el\t manejo\t de\t la\t evoluci\u00f3n\t de\t la\t\nneoplasia(2).Esta\t problem\u00e1tica\t requiere\t de\t la\t intervenci\u00f3n\t de\t un\t equipo\t\nmultidisciplinar,\t que\t permita\t abordar\t la\t patolog\u00eda,\t tratamiento\t y\t comorbilidades,\t\nadem\u00e1s\tde\tla\teducaci\u00f3n\tal\t paciente\tsobre\tsu\tdiagn\u00f3stico\ty\tpron\u00f3stico\t(3). \tPor\totro\tlado,\t\nla\tinterpretaci\u00f3n\tde\tla\tliteratura\tm\u00e9dica\tque\tsoporte\testas\tdecisiones\t es\tcompleja, \tya\t653\t\nque\tlos\tdatos\tdisponibles\tprovienen\tde\tseries\tpeque\u00f1as\ty\tretrospectivas\to\tde\treportes\t\nde\tcasos;\tpor\tlo\tque \tla\tverdadera\tincidencia\ty\tcurso\tdel\tembarazo\ty\tla\tleucemia\tson\t\ndesconocidos\t(1)(2). \t\nDESCRIPCI\u00d3N\tDEL\tCASO\t(Presentaci\u00f3n\tcl\u00ednica\ty\tevoluci\u00f3n) \t\nPresentaci\u00f3n\tcl\u00ednica: \t\nMujer,\t35\ta\u00f1os,\tgestante\tde\t23\tsemanas\tque\tingresa\t a\tfinales\tde\tabril\tde\t2021\t por\t\nsospecha\tde\t leucemia\t aguda\ttras\tanal\u00edtica\tcon\tleucosis\ty\tbicitopenia\t(anemia\tsevera\ty\t\ntrombopenia\tmoderada),\tastenia\ty\tdebilidad\tgeneralizada\tde\tdos\tsemanas\tde\tevoluci\u00f3n\t\ny\tgingivorragia.\t Se\trealiza\taspirado\tde\tm\u00e9dula\t\u00f3sea\tconfirmando\tel\tdiagn\u00f3stico\tde \tLMA.\t\t\nSe\t presenta\t la\t situaci\u00f3n\t de\t embarazo\t concomitante\t a\t leucemia,\t ante\t un\t comit\u00e9\t\nmultidisplinar\t que\t comprend\u00eda\t diferentes\t servicios\t (Neonatolog\u00eda,\t Ginecolog\u00eda,\t\nHematolog\u00eda\ty\tFarmacia),\tplanteando\tel\triesgo-beneficio\tde\tiniciar\tquimioterapia\tcon\t\nfinalidad\tcurativa\tque\tfuese \tm\u00ednimamente \tinvasiva\tpara\tel\tfeto.\t\t\nTodos\tlos\t f\u00e1rmacos\templeados\tfueron\tconsensuados\tcon\tel\t Servicio\tde\tFarmacia\td\u00f3nde\t\nse\testudi\u00f3\t su\tseguridad\tdurante\tel\tembarazo\t seg\u00fan\tla\t clasificaci\u00f3n\tterat\u00f3gena\tde\t\nf\u00e1rmacos\t de\tla\tFDA\t(Categor\u00eda\tA,\tB,\t C,\tD\t\u00f3\tX)\ty\tse\trealiz\u00f3\testudio\tde\tinteracciones\tde\tlos\t\nf\u00e1rmacos\templeados.\tLas\tcategor\u00edas\tde\tteratogenia\tde\tla\tFDA\tde\tlos\tf\u00e1rmacos\trevisados\t\nse\tdesglosan\ten\tla\ttabla\t1.\t\t\nCATEGOR\u00cdA\tTERATOG\u00c9NICA\t F\u00c1RMACOS \t\nA\t Piridoxina,\t\u00c1cido\tf\u00f3lico\t\nB\t Anfotericina\t B\t liposomal,\t Ondansetr\u00f3n,\t\nParacetamol\t\nC\t Trimetoprim/Sulfametoxazol,\tAlopurinol,\t\nDexametasona,\tBetametasona.\t\nD\t Daunorrubicina,\tCitarabina,\t\t654\t\nX\t No\tse\templearon\tf\u00e1rmacos\t\nCategor\u00eda\tA :\tNo\texiste\t riesgo\tpara\tel\tfeto\tdurante\tel\tprimer\ttrimestre\ty\tla\tposibilidad\t\nde\tda\u00f1o\tfetal\taparece\tremota.\t\nCategor\u00eda\tB :\tEn\testudios\tbien\tcontrolados\tcon\tmujeres\tgestantes\tno\tse\tha\tdemostrado\t\nriesgo\tfetal.\t\nCategor\u00eda\tC :\tLos\testudios\ten\tanimales\than\tdemostrado\tque\tel\tme dicamento\tejerce\t\nefectos\t teratog\u00e9nicos\t o\t embriocidas,\t pero,\t no\t existen\t estudios\t controlados\t con\t\nmujeres\to\tno\tse\tdispone\tde\testudios\tni\ten\tanimales\tni\ten\tmujeres.\t\nCategor\u00eda\tD :\tExiste\tevidencia\tpositiva\tde\triesgo\tfetal\ten\thumanos,\tpero,\ten\tciertos\t\ncasos,\t\tlos\tbeneficios\tpueden\thacer\tel\tmedicamento\taceptable\ta\tpesar\tde\tsus\triesgos.\t\nCategor\u00eda\tX :\tLos\testudios\ten\tanimales\to\ten\thumanos\than\tdemostrado\tanormalidades\t\nfetales\ty\tel\triesgo\tsupera\tclaramente\tcualquier\tposible\tbeneficio.\t\nTabla\t1.\tF\u00e1rmacos\templeados\ty\tclasificaci\u00f3n\tterat\u00f3gena\tde\tla\tFDA. \t\n(elaboraci\u00f3n\tpropia)\t\nEvoluci\u00f3n\tdel\tcaso: \t\nUna\tsemana\tantes\tde\tcomenzar\tel\ttratamiento\tquimioter\u00e1pico\tse\tinici\u00f3\tla\t maduraci\u00f3n\t\npulmonar\tfetal.\tEsta\tse\tpuede\trealizar\tcon\tbetametasona\tintramuscular\t(12\t mg/24h,\t2\t\ndosis)\to\tdexametasona\tendovenosa\t(6\tmg/12h,\t4\tdosis).\tComo\tambos\tcorticoides\t\npertenecen\ta\tla\tclase\tC,\tse\tinform\u00f3\ty\taconsej\u00f3\tdesde\tel\tservicio\tde\tfarmacia\tuna\t\nmaduraci\u00f3n\tcon\tbetametasona\tcon\tel\tobjetivo\tde\tdisminuir\tel\ttiempo\tde\texposici\u00f3n\ta\t\nestos\tf\u00e1rmacos.\t\nLa\tadministraci\u00f3n\tde\tquimioterapia\t se\tinici\u00f3\tel\td\u00eda\t07\tde\tmayo\tde\t2021.\t El\tesquema\t\ncl\u00e1sico\tde\tinducci\u00f3n\t en\tel\tabordaje\tde\tLMA;\t Ida\t+\tAra-C\t(3\t+\t7),\t incluye\tidarubicina\ta\t\ndosis\tde\t12\tmg/m \u00b2/d\u00eda\tIV\tlos\td\u00edas\t1\ta\t3\t+\t citarabina\ta\tdosis\t200\tmg/m\u00b2/d\u00eda\tIV\ten\tperfusi\u00f3n\t\ncontinua\tlos\td\u00edas\t1\ta\t7\t(4).\tSin\tembargo,\tfue\tnecesario\tadaptarlo\ta\tla\tsituaci\u00f3n\tde\tla\t\npaciente.\tAs\u00ed,\tlas\trecomendaciones\tde\tLa\tGu\u00eda\tde\tla\tSociedad\tBrit\u00e1nica\tde\tHematolog\u00eda\t\npara\t el\t manejo\t de\t LMA\t en\t embarazadas\t (2015)\t indican\t un\t esquema\t modificado:\t\ndaunorrubicina\t60\tmg/m\u00b2/d\tIV\tlos\td\u00edas\t1,\t3\ty\t5\ty\tcitarabina\t100\tmg/m\u00b2/cada\t12\th\tIV\tlos\t\nd\u00edas\t1\ta\t10\t(5).\tSe\tconsideraron\tadecuadas\testas\tmodificaciones\tdel\tprotocolo\t3+7:\t655\t\ndaunorrubicina\tsustituy\u00f3\ta\tidarubicina\tya\tque\tla\tsegunda\t es\tm\u00e1s\tliposoluble\ty\tatraviesa\t\nf\u00e1cilmente\tla\tplacenta,\t pudiendo\tafectar\tal\tfeto\t(5).\tRespecto\ta\tla\tcitarabina,\tla\tdosis\t\ntotal\tdiaria\tse\tmantuvo,\tpuesto\tque\ttiene\t menor\triesgo\tde\tmalformaci\u00f3n\tcong\u00e9nita\ten\t\nel\tsegundo\ty\ttercer\ttrimestre .\t\nSe\tllev\u00f3\ta\tcabo\tun\tseguimiento\tfarmacoterap\u00e9utico\tdurante\tla\tadministraci\u00f3n\tasociado\t\na\t las\t principales\t reacciones\t adversas\t y/o\t complicaciones\t que\t pudieran\t aparecer\t\nasociadas\tal\ttratamiento\tquimioter\u00e1pico.\t\nLa\tprofilaxis\t infecciosa\t se\t realiz\u00f3\t con\t trimetoprim/sulfametoxazol\t y\t anfotericina\t B\t\nliposomal\t en\t lugar\t de\t quinolonas\t y\t azoles.\t Estos\t \u00faltimos,\t presentan\t un\t riesgo\t\nteratog\u00e9nico\tmayor\tque\tel\tasociado\ta\ttrimetorpin/sulfametoxazol\ty\tanfotericina\tB,\tpor\t\nlo\tque\tse\tconsideran\tuna\tbuena\topci\u00f3n\tterap\u00e9utica\ten\tnuestra\tpaciente.\tAdem\u00e1s,\tcomo\t\nmedicaci\u00f3n\tcoadyuvante\ttambi\u00e9n\tse\temple\u00f3\tpara\tla\tprofilaxis\tdel\ts\u00edndrome\tde\tlisis\t\ntumoral,\t v\u00f3mitos\t y\t s\u00edndrome\t mano -pie:\t alopurinol,\t ondansetr\u00f3n\t y\t piridoxina\t\nrespectivamente,\tse\tasoci\u00f3,\tadem\u00e1s,\tcolirio\tde\tdexametasona\tlos\td\u00edas\tde\tadministraci\u00f3n\t\nde\tla\tcitarabina\tpara\tpr evenir\tla\tconjuntivitis\tasociada\ta\testa\ty,\tpor\t\u00faltimo,\t\u00e1cido\tf\u00f3lico\t\npara\tprevenci\u00f3n\tde\tdefectos\tdel\ttubo\tneural.\t\nLa\tfunci\u00f3n\trenal\ty\thep\u00e1tica\t se\tmantuvo\tconservada\ten\ttodo\tmomento\tno\trequiriendo\t\najuste\tde\tdosis\tpor\tinsuficiencia\trenal\to\thep\u00e1tica.\t\nLa\tgestante\tpresent\u00f3\tuna\tevoluci\u00f3n\tde\tla\tgestaci\u00f3n\tnormal\ty\testrecho\tseguimiento\tfetal\t\nmediante\t monitorizaci\u00f3n\t y\t ecograf\u00eda\t (que\t permiti\u00f3\t descartar\t toxicidad\t card\u00edaca\t\ninducida\tpor\tantraciclinas).\tNo\tse\treportaron\tproblemas\tde\talteraci\u00f3n\tfetal\ty\ten\tjunio\tde\t\n2021\t(semana\t29\tde\tgestaci\u00f3n)\tante\tla\treducci\u00f3n\tconsiderable\tde\tlas\tcomplicaciones\tpor\t\nprematuridad\ty\ttras\tla\trecuperaci\u00f3n\themoperif\u00e9rica\tde\tla\tpaciente\tse\tprogram\u00f3\tel\tparto\t\npor\tces\u00e1rea,\tel\td\u00eda\t9\tde\tjunio\t(d\u00eda\t+\t33\tinicio\tde\tquimioterapia),\tsin\tincidencias.\tTras\tla\t656\t\nces\u00e1rea,\tla\tpaciente\tevolucion\u00f3\tfavorablemente,\t no\tpresent\u00f3\tsangrado\tanormal,\ttuvo\t\nuna\t excelente\t cicatrizaci\u00f3n,\t recibi\u00f3\t 4\t d\u00edas\t de\t profilaxis\t con\t cefazolina\t y\t ante\t la\t\nrecuperaci\u00f3n\themoperif\u00e9rica\tfue\tdada\tde\talta\tcon\tamoxicilina -clavul\u00e1nico\toral.\t Los\t\nsiguientes\tciclos\tde\tquimioterapia\ty\tel\ttrasplante\tde\tprecursores\thematopoy\u00e9ticos\tde\t\ndonante\temparentado\tfueron\trealizados\tsiguiendo\tprotocolos\thabituales\tdel\tcentro.\t\nPor\totro\tlado,\tel\tneonato\tingres\u00f3\ten\tla\tUnidad\tde\tNeonatolog\u00eda\tpor\tprematuridad\t\npresentando\ts\u00edndrome\tde\tdistr\u00e9s\trespiratorio,\tausencia\tde\tcl\u00ednica\tinfecciosa,\tecograf\u00eda\t\ncerebral\t normal,\t se\t mantuvo\t hemodin\u00e1micamente\t estable,\t hemograma\t con\t\nneutropenia\tfinalmente\tresuelta\ty\tsin\talteraci\u00f3n\tdel\tresto\tde\tl\u00edneas\tcelulares.\t\nDISCUSI\u00d3N\t \t\nSe\tevidencia\tla\timportancia\tde\tcomunicar\tlos\tcasos\tde\tneoplasias\thematol\u00f3gicas\tdurante\t\nel\tembarazo\tpara\tincrementar\tlos\tconocimientos\ta\tla\tcomunidad\tm\u00e9dica\tdebido\ta\tla\trara\t\nasociaci\u00f3n\tentre\testas\tpatolog\u00edas\ty\tla\tgestaci\u00f3n;\ty\ta\tlas\tdificultades\ten\tcuanto\ta\tsu\t\nmanejo.\tDestacar\ttambi\u00e9n\t la\timportancia\tde\tla\tfigura\tdel\tfarmac\u00e9utico\tcomo\texperto\t\ndel\t medicamento\t en\t situaciones\t de\t especial\t importancia\t como\t es\t este\t caso\t para\t\nasegurar\tuna\tcorrecta\tfarmacoterapia\tdel\tpaciente\toptimizando\tel\tuso\tde\taquellos\t\nf\u00e1rmacos\tque\tpermitan\tconseguir\tuna\t m\u00e1xima\tefectividad\ta\tla\tvez\tque\tminimizan\tlos\t\nposibles\tefectos\tadversos\t(seguridad)\tmediante\tun\testudio\texhaustivo\tde\tlos\tmismos\t\n(teratogenicidad,\tfarmacocin\u00e9tica,\tetc.).\t\nAportaci\u00f3n\tfarmac\u00e9utica: \t\n1-\tB\u00fasqueda\tbibliogr\u00e1fica\tde\tcasos\tsimilares\tcon\tLMA\ten\t pacientes\tembara zadas.\tEl\td\u00eda\t\n01/05/2021\t se\t realiz\u00f3\t una\t b\u00fasqueda\t bibliogr\u00e1fica\t en\t PUBMED\t con\t los\t Mesh:\t\n\u201c((((leukaemia)\tAND\t(acute))\tAND\t(myeloid))\tAND\t(treatment))\tAND\t(pregnant))))\u201d,\t\nencontrando\t28\tresultados\tacotando\tla\tb\u00fasqueda\ta\t10\ta\u00f1os\tanteriores.\tTras\tla\trevisi\u00f3n\t657\t\nde\tlos\tregistros\tse\tseleccionan\t3\tart\u00edculos\tque\tincluyen\tinformaci\u00f3n\tsobre\tel\tmanejo\tde\t\nla\tmujer\tembarazada\tdiagnosticada\tde\tLMA.\t\t\nEn\tprimer\tlugar,\tLa\tGu\u00eda\tde\tla\tSociedad\tBrit\u00e1nica\tde\tHematolog\u00eda\tpara\tel\tmanejo\tde\tLMA\t\nen\tembarazadas\t(2015)\trealiza\tun\tan\u00e1lisis\tdel\tesquema\tterap\u00e9utico\ty\tde\tla\ttoxicidad\tde\t\nla\tquimioterapia,\tque\tha\tservido\tde\tbase\tpara\tel\tmanejo\tde\tla\tpaciente\t(5).\tLa\timagen\t1\t\nresume\tel\tesquema\tde\ttratamiento\tpropuesto\ten\tla\tgu\u00eda\ty\tque\tla\tpaciente\tfinalmente\t\nrecibi\u00f3.\t La\t serie\t de\t casos\t publicados\t por\t Saleh\t et\t al.\t (2014)\t (6),\t revisa\t pacientes\t\nembarazadas\tdiagnosticadas\tde,\tde\tlas\tque\t15\tfueron\tde\tLMA.\tEl\tesquema\tseleccionado\t\npara\tel\ttratamiento\tquimioterap\u00e9utico\tde\tlas\tembarazadas\tcon\tLMA\tfue\ten\ttodos\tlos\t\ncasos\tcon\tdaunorubicina\t+\tcitarabina,\tigual\tque\tel\tutilizado\tcon\tnuestra\tpaciente.\t En\tel\t\nart\u00edculo\tde\trevisi\u00f3n\t de\tThomas\tet\tal.\t(2014),\tse\tconcluye\tque\tembarazadas\ten\t2\u00bay3\u00ba\t\ntrimestre,\tel\tuso\tde\tidarrubicina\test\u00e1\tcontraindicado\tpor\tsu\tmayor\tliposolubilidad\ty\t\ncapacidad\t de\t atravesar\t la\t barrera\t placentaria,\t por\t lo\t que\t propone\t su\t cambio\t a\t\ndoxorrubicina\tpara\tterapia\tcombinada\tcon\tcitarabina\t(2).\t\t\n\t\nImagen\t1 .\tEsquema\tde\ttratamiento\ten\tpacientes\tembarazadas\t\ndiagnosticadas\tde\tLMA\t(b).\t(elaboraci\u00f3n\tpropia) \t\n\t\n658\t\n2-\tRevisi\u00f3n\t de\t los\t f\u00e1rmacos\t usados\t y\t su\t clasificaci\u00f3n\t terat\u00f3gena\t seg\u00fan\t la\t FDA.\tSe\t\nrealiz\u00f3\t una\t b\u00fasqueda\t de\t los\t posibles\t f\u00e1rmacos\t usados\t durante\t los\t ciclos\t de\t\nquimioterapia\ty\tse\tclasific\u00f3\tseg\u00fan\tcategor\u00eda\tFDA\tpara\tpoder\ttomar\tdecisiones\tcl\u00ednicas\t\n(tabla\t1).\t\t\nDe\tlos\tf\u00e1rmacos\tconsultados,\tse\tsustituyeron\tdos\tusados\ten\tla\tpr\u00e1ctica\tcl\u00ednica\thabitual\t\npara\tminimizar\tlos\tefectos\tterat\u00f3genos:\tIdarubicina\tpor\tdaunorubina\ty\tazoles\tpor\t\nanfotericina\tB.\t\n3-\tRevisi\u00f3n\tde\tlas\tprincipales\tinteracciones\tde\tlos\tf\u00e1rmacos\tusados.\t\nNo\t se\t detectaron\t interacciones\t farmacol\u00f3gicas\t potencialmente\t importantes\t que\t\nrequirieran\tmodificaciones\tde\tla\tterapia\tfarmacol\u00f3gica\tpor\tlo\tque\tcon\tla\tmonitorizaci\u00f3n\t\nde\tla\tpaciente\tfue\tsuficiente.\t\n4-\tMonitorizaci\u00f3n\testrecha\tde\tfunci\u00f3n\trenal\ty\thep\u00e1tica\ten\tcaso\tde\tnecesitar\tajustes\tde\t\nposolog\u00eda.\t\nLa\tpaciente\tse\tmantuvo\tdurante\ttodo\tel\tingreso\ty\tadministraci\u00f3n\tde\tlos\tciclos\tcon\tuna\t\nfunci\u00f3n\thep\u00e1tica\testable\ty\tdentro\tde\tlos\tpar\u00e1metros\tde\tnormalidad\ty\tuna\tfunci\u00f3n\trenal\t\ncon\tun\taclaramiento\tde\tla\tcreatinina\tsiempre\t>90\tml/min,\tpor\tlo\tque\tno\tfue\tne cesario\t\nel\tajuste\tde\tdosis\tde\tninguno\tde\tlos\tf\u00e1rmacos\tusados\tdurante\tel\tciclo\tde\tquimioterapia\t\ny\tprofilaxis\tde\tla\tmisma.\t\nConclusi\u00f3n :\t\t\nEl\tabordaje\tde\tuna\tgestante\tdiagnosticada\tde\tLMA\ten\tnuestro\tcentro\tha\tsupuesto\tun\t\nreto\tpara\ttodo\tel\tequipo\tasistencial.\t La\tpaciente\trecibi\u00f3\tun\tciclo\tdel\tesquema\tmodificado\t\npara\tembarazadas\trealizar\tla\tces\u00e1rea\tprogramada,\tsin\tefectos\tadversos\tdestacables\tpara\t\nla\tpaciente\tni\tterat\u00f3genos\tpara\tel\tneonato.\tSe\ttrata\tde\tun\tcaso\tque \tpone\tde\tmanifiesto\t659\t\nla\timportancia\tde\tcontar\tcon\tequipos\tde\ttrabajo\tmultidisciplinares\tpara\tconsensuar\t\nintervenciones\ty\tllevar\ta\tcabo\tel\tseguimiento\tde\tla\tpaciente.\t \t\nBIBLIOGRAF\u00cdA\t\n1. Urdaneta\tMachado\tJ,\tBen\u00edtez\tB,\tBaabel\tZambrano\tN,\tValbuena\tG.\tLeucemia\t\nmieloide\taguda\tdurante\tel\tembarazo:\tReporte\tde\tun\tcaso.\tRe vista\tobstetricia\ty\t\nginecolog\u00eda\tde\tVenezuela\t2013\tMar\t1,;73(1):65-71\t\n2. Thomas\tX.\tAcute\tmyeloid\tleukemia\tin\tthe\tpregnant\tpatient.\tEuropean\tjournal\tof\t\nhaematology\t2015\tAug;95(2):124-136. \t\n3. Patel\tSJ,\tAjebo\tG,\tKota\tV,\tGuddati\tAK.\tAnalysis\tof\toutcomes\tin\thospitalized\t\npregnant\tpatients\twith\tacute\tmyeloid\tleukemia.\t American\tjournal\tof\tblood\t\nresearch\t2020\tJan\t1,;10(4):68-75.\t\n4. Recomendaciones\t para\t el\t tratamiento\t de\t primera\t l\u00ednea\t de\t la\t leucemia\t\nmielobl\u00e1stica\taguda\tNPM1\tpositivo\ten\tpacientes\tde\tedad\tmenor\to\tigual\ta\t65\ta\u00f1os\t\ncandidatos\ta\tquimioterapia\tintensiva.\tGrupo\tPETHEMA.\tProtocolo\tLMA-NPM1-\n17\t\t\t\n5. Ali\tS,\tJones\tGL,\tCulligan\tDJ,\tMarsden\tPJ,\tRussell\tN,\tEmbleton\tND,\tet\tal.\tGuidelines\t\nfor\tthe\tdiagnosis\tand\tmanagement\tof\tacute\tmyeloid\tleukaemia\tin\tpregnancy.\t\nBritish\tjournal\tof\thaematology\t2015\tAug;170(4):487-495.\t\n6. Saleh\tAJM,\tAlhejazi\tA,\tAhmed\tSO,\tAl\tMohareb\tF,\tAlSharif\tF,\tAlZahrani\tH,\tet\tal.\t\nLeukemia\tduring\tpregnancy:\tLong\tterm\tfollow\tup\tof\t32\tcases\tfrom\ta\tsingle\t\ninstitution.\tHematology/Oncology\tand\tStem\tCell\tTherapy\t2014;7(2):63-68.\t660OPTIMIZACI\u00d3N DEL TRATAMIENTO DE LA ENFERMEDAD DE CROHN EN PACIENTES \nPEDI\u00c1TRICOS  \nGonz \u00e1lez Andr\u00e9s D, Pedraza Nieto L, Garc\u00eda Rodr\u00edguez MP, Agu\u00ed Callejas  AM, Riva de la \nHoz B, Echavarri de Miguel M, Arrieta Loitegui M,  Pozas del R\u00edo MT  \nIntroducci\u00f3n  \nEl tratamiento de la enfermedad de Crohn (EC) en pediatr\u00eda var\u00eda en funci\u00f3n de la \ngravedad de la enfermedad. Cuando es leve, se realiza una inducci\u00f3n con nutrici\u00f3n \nenteral exclusiva (NEE) con/sin glucocorticoides, seguido de un mantenimiento c on \nmetotrexato y/o tiopurinas. Cuando la enfermedad es grave, o la enfermedad leve no \nse consigue controlar con el mantenimiento, se realiza una inducci\u00f3n con f\u00e1rmacos \nanti-TNF con/sin inmunomoduladores  que se contin\u00faan en el mantenimiento . El \nseguimiento se realiza mediante evaluaci\u00f3n de s\u00edntomas cl\u00ednicos , marcadores \nanal\u00edticos de evoluci\u00f3n de la enfermedad y la medici\u00f3n de niveles plasm\u00e1ticos de \nf\u00e1rmaco y de anticuerpos anti -f\u00e1rmaco (ADA) ; ante niveles  altos o normales de \nf\u00e1rmaco si el paciente no responde al tratamiento, independientemente del valor de \nADA, ser\u00e1 necesario cambiar de diana terap\u00e9utica . Tanto si se trata de una \nenfermedad leve como grave, es muy importante monitorizar la desnutrici\u00f3n en estos \npacientes (niveles sangu\u00edneos de vitamina  D, alb\u00famina, hierro, etc.)  y, valorar a\u00f1adir \nuna dieta de exclusi\u00f3n de la enfermedad de Crohn (CDED) . Esta dieta se caracteriza por \nser libre de lactosa, az\u00facares a\u00f1adidos, alimentos procesados y, baja en  carnes magra s \ny en grasas  saturadas4. \nDescripci\u00f3n del caso  661Se trata de  un ni\u00f1o de 2 a\u00f1os , 12,4kg de peso y 84cm de estatura, en seguimiento por \nel Servicio de Digestivo  (SD) con diagn\u00f3stico de EC desde los 12 meses de edad  \n(Clasificaci\u00f3n Paris : A1aL2L4bB1G0 ).  \nAntecedentes familiares de inter\u00e9s :  \n- Padre: diagnosticad o de EC a los 16 a\u00f1os en tratamiento con adalimumab, psoriasis, \ncarcinoma basocelular facial (extirpado) y artritis secundaria.  \n- Abuela paterna con EC, en tratamiento con azatioprina.  \n- No antecedentes de carcinoma colorrectal.  \nEvoluci\u00f3 n: \nLa enfermedad debut\u00f3 en abril de 2021  con un cuadro  leve y se trat\u00f3 seg\u00fan la gu\u00eda \n\u201cECCO -ESPGHAN1 de la Enfermedad de Crohn en pacientes pedi\u00e1tricos \u201d: una inducci\u00f3n \ncon NEE ( Modulen IBD: dieta polim\u00e9rica normocal\u00f3rica) y prednisolona v\u00eda oral (VO) \n(2mg/kg/d\u00eda), seguido de un mantenimiento con azatioprina VO (2,7 mg/kg/d\u00eda), \nobteniendo una adecuada respuesta al tratamiento.  \nEn agosto de 2021, acude a urgencias por empeoramiento del estado cl\u00ednico (tiene \nunas 7 deposiciones diarreicas con sangre en to das ellas, adem\u00e1s de algunas nocturnas \nque le dificultan el sue\u00f1o) , y en el an\u00e1lisis de sangre  destaca n los siguientes \npar\u00e1metros : calprotectina  2430 mcg/g , hemoglobina 9,5 g/dl, hemat\u00edes 3,53 \nmillones/ \u00b5l. El SD debido al empeoramiento cl\u00ednico del paciente  decide suspender el \ntratamiento con azatioprina e iniciar infliximab con pauta de inducci\u00f3n directamente  \nintensificada a 10 mg/kg/dosis  dada la gravedad de la cl\u00ednica  y la edad del paciente \n(semanas 0, 2, 6 y posteriormente c ada 8 semanas). Antes de llegar a la tercera 662administraci\u00f3n, el paciente empeora cl\u00ednicamente por lo que se adelanta la dosis de la \nsemana 6 a la semana 4 . El paciente se mantiene controlado unos d\u00edas  (3 deposiciones, \ncalprotectina: 504 mcg/g, hemoglobina 8,1 g/dl, hemat\u00edes 2,75  millones/\u00b5l ). Dos \nsemanas m\u00e1s tarde  el pacien te vuelve a empeorar (hasta  14 deposiciones al d\u00eda todas \ncon sangre , calprotectina: 2976  mcg/g, hemoglobina 9,6 g/dl, hemat\u00edes 3,81 \nmillones/ \u00b5l) llegando a precisar hospitalizaci\u00f3n . Al in greso, inicia tratamiento con \nmetilprednisolona intravenosa ( IV) (1 mg/kg/d\u00eda)  y CDED. A nte la sospecha de no estar \nobteniendo niveles terap\u00e9uticos , se solicitan niveles  y se decide intensifica r \nnuevamente  el tratamiento con infliximab , adelantando la infusi\u00f3n y aumentando  a \n15mg/kg/dosis cada 2 semanas.  \nA pesar de la intensificaci\u00f3n llevada a cabo, los niveles obtenidos de infliximab en la \nsemana 6 y 10 son 2,79 mcg/mL y 4 mcg/mL respectivamente. Ambos por debajo del \nmargen terap\u00e9utico ( >5 mcg/mL).  Esto a\u00f1adido a la falta de respuesta cl\u00ednica (mismo \nn\u00famero de deposiciones y calprotectina: 3491 mcg/g), hace que el SD solicite \nintensificar el tratamiento a 20 mg/kg/dosis, aportando bibliograf\u00eda de pacientes \npedi\u00e1tricos en los que se ha lle gado a utilizar esta pauta semanalmente5.  \nEn base a los niveles plasm\u00e1ticos de infliximab y respaldados por la bibliograf\u00eda \npreviamente mencionada, se tramita la solicitud del tratamiento a Direcci\u00f3n M\u00e9dica \ndel hospital, siendo aprobado e iniciado el trat amiento ese mismo d\u00eda . \nEn las semanas posteriores y tras una administraci\u00f3n quincenal y otra semanal  el \npaciente se mantiene en 7 deposiciones al d\u00eda  (calprotectina 3094 mcg/g, hemoglobina \n9,9 g/dl, hemat\u00edes 3,73 millones/ \u00b5l), detect\u00e1ndose unos niveles de infliximab (> 22,5 \nmcg/ml) y de ADA (0,5 1) supra terap\u00e9uticos.  663Quince d\u00edas m\u00e1s tarde , el paciente vuelve a empeorar (hasta 20 deposiciones al d\u00eda \ntodas con sangre , calprotectina: 3136 mcg/g , 25-hidroxi- vitamina D 6,9 ng/ml, \nalb\u00famina 2,5 g/dl, hemoglobina 6,8 g/dl, hemat\u00edes 2,49  millones/ \u00b5l). Por todo ello, se \nle realiza una tra nsfusi\u00f3n de hemat\u00edes, suplementaci\u00f3n con colecalciferol VO  (1000 UI \ncada 24 horas) , hierro IV  (6mg/kg/dosis),  y alb\u00fami na IV (0,5g/kg/dosis).  \nDe nuevo las concentraciones  plasm\u00e1ticas de f\u00e1rmaco se manten\u00edan en niveles \nsupraterap\u00e9uticos (> 22,5 mcg/ml) y ADA (< 0,1), por lo que al paciente se le clasifica \ncomo  refractario a los anti -TNF.  \n \nGr\u00e1fica 1.  Niveles de Infliximab y ADA.  \nDada la gravedad  del caso, e l SD contacta con el Servicio de Farmacia ( SF) para valora r \nposibles alternativas, planteando incluso utilizar una terapia combinada de biol\u00f3gicos. \nTras evaluar el caso en el grupo interdisciplinar de Enfermeda d Inflamatoria Intestinal \n(EII), en el que participa el SF, se consens\u00faa iniciar ustekinumab (con monitorizaci\u00f3n de \nniveles plasm\u00e1ticos) y en caso de fallo al mismo , vedolizumab en monoterapia.  Se \nsolicita tratamiento con ustekinumab, para lo cual se trami ta a Direcci\u00f3n M\u00e9dica, ya \n664que se trata de  un fuera de indicaci\u00f3n  (solo autorizado para  adultos). Una vez \nautorizado , se inicia ustekinumab a 6 mg/kg/dosis en inducci\u00f3n con intenci\u00f3n de pasar \na 3mg/kg s ubcut\u00e1neo  (SC) en mantenimiento.  \nAdem\u00e1s,  para tratar una posible disbiosis del paciente2, el SD decide iniciar un cocktail \nantibacteriano VO junto con probi\u00f3tico ( L. salivarius ) durante 14 d\u00edas . Este cocktail \nconsiste en: ciprofloxacino (20 mg/kg/d\u00eda) , vancomicina  (40mg/kg/d\u00eda) , metronidazol \n(15mg/kg/d\u00eda)  y amoxicilina (50 mg/kg/d\u00eda).  \nEn las semanas posteriores el paciente mejora de nuevo ligeramente (7 deposiciones, \ncalprotectina: 2 93 mcg/g , 25-hidroxi -vitamina D 27,5 ng/ml, alb\u00famina 4,1 g/dl, \nhemoglobina 12,2  g/dl, hemat\u00edes 3,87  millones/ \u00b5l). Sin embargo, esta mejor\u00eda se va \nperdiendo con el tiempo, con brote antes de la siguiente dosis. De nuevo, el SD \ncontacta con el SF y se acuerda aument ar la frecuencia de administraci\u00f3n y que el \nmantenimiento se haga por v\u00eda IV en lugar de SC (previo nuevo tr\u00e1mite de autorizaci\u00f3n \npor Direcci\u00f3n M\u00e9dica)  \nRecibe la segunda dosis de ustekinumab (10 mg/kg/dosis)  a las 3 semanas con buena \nrespuesta , obteni\u00e9ndos e niveles de ustekinumab: 4,28 mcg/ml, y ADA: 0,11 . En cuanto \na la disbiosis del paciente, se obtiene respuesta parcial al cocktail antibacteriano, por \nlo que se le retira la NEE y se va de alta al domicilio con pauta de usteki numab mensual \na 10 mg/kg/dosi s.  \nDebido a la r\u00e1pida evoluci\u00f3n de  la enfermedad, el SD plantea n dudas de si el paciente \npuede tener una colitis ulcerosa, por lo que se decide  a\u00f1adir al tratamiento m esalazina \nenema 1 g/d\u00eda  y mesalazina VO 1 g/d\u00eda , antes de pasar a l\u00edneas de tratamiento m\u00e1s 665complejas . El pacie nte est\u00e1 estable hasta la fecha con la pauta combinada de \nustekinumab mensual y mesalazina  diaria . \n \n \nGr\u00e1fica 2 . Evoluci\u00f3n del paciente en funci\u00f3n de los par\u00e1metros cl\u00ednicos  y tratamiento.  \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica  \nLa EC es una enfermedad digestiva con m\u00faltiples opciones de tratamiento que \nrequiere un abordaje multidisciplinar. El tratamiento se hace a\u00fan m\u00e1s complejo en \npacientes pedi\u00e1tricos en los que la cin\u00e9tica de los f\u00e1rmacos es muy diferente al \npaciente adulto y en los que la mayor parte del arsenal terap\u00e9utico no tiene indicaci\u00f3n.  \nNo disponer de servicio de farmacocin\u00e9tica con capacidad para medir niveles de \nf\u00e1rmacos de forma \u00e1gil en el propio centro es una barrera en la toma de decisiones en \npacientes que requieren un cambio urgente.  \n666La integraci\u00f3n del farmac\u00e9utico en el equipo mul tidiciplinar de EII y su formaci\u00f3n en \nlos tratamientos frente a enfermedades inmunomediadas es clave para la optimizaci\u00f3n \nde estos f\u00e1rmacos biol\u00f3gicos.  \nBibliograf\u00eda  \n1. van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL et al. The \nMedical Ma nagement of Paediatric Crohn's Disease: an ECCO -ESPGHAN Guideline \nUpdate. J Crohns Colitis. 2020 Oct 7:jjaa161. doi: 10.1093/ecco -jcc/jjaa161. Epub \nahead of print. PMID: 33026087.  \n2. Turner D, Bishai J, Reshef L, Abitbol G, Focht G, Marcus D et al. Antibio tic Cocktail for \nPediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized \nControlled Trial. Inflamm Bowel Dis. 2020 Oct 23;26(11):1733 -1742. doi: \n10.1093/ibd/izz298. PMID: 31833543.  \n3. Bischoff S. C., Escher J., H\u00e9buterne X., K\u0142\u0119k S., Krznaric Z., Schneider S. et al. (2020). \nESPEN practical guideline: Clinical nutrition in inflammatory bowel disease. Clinical \nNutrition, 39(3), 632 \u2013653. https://doi.org/10.1016/j.clnu.2019.11.002  \n4. Sigall -Boneh R, Pfeffer -Gik T, Segal I, Zangen T, Boaz M, Levine A. Partial enteral \nnutrition with a Crohn's disease exclusion diet is effective for induction of remission in \nchildren and young adults with Crohn's disease. Inflamm Bowel Dis. 2014 \nAug;20 (8):1353 -60. doi: 10.1097/MIB.0000000000000110. PMID: 24983973.  \n5. Assa A, Dorfman L, Shouval DS, Shamir R, Cohen S. Therapeutic Drug Monitoring -\nguided High -dose Infliximab for Infantile -onset Inflammatory Bowel Disease: A Case 667Series. J Pediatr Gastroente rol Nutr. 2020 Oct;71(4):516 -520. doi: \n10.1097/MPG.0000000000002832. PMID: 32639454.  668Introducci\u00f3n\nLafibrosis qu\u00edstica(FQ)eslaenfermedad hereditaria autos\u00f3mic arecesiv am\u00e1s com\u00fan en\npoblaci\u00f3n cauc\u00e1sica.Est\u00e1causada por mutaciones enelgenregulador delaconduct ancia\ntransmembr ana, que codific auna prote\u00edna regulador aCFTR .CFTR act\u00faa como uncanal de\nclorur oque transport aiones atrav\u00e9sdelamembr ana apicaldelasc\u00e9lulas epiteliales de\ntodo elcuerpo ,perotiene otrasfunciones, incluida lasecreci\u00f3n debicarbona toyla\ninhibici\u00f3n del transport edesodio ,que son import antesparalafisiopa tolog\u00eda dela\ndeficiencia y dis funci\u00f3n de CFTR . (1, 2)\nHastalafecha sehan descrit om\u00e1s de2000 mutaciones enestegen, aunque sesabe que\nmenos de150 soncausan tesdeenfermedad. Lamutaci\u00f3n pat\u00f3gena m\u00e1s com\u00fan esF508del .\nAproximadamen teel90%delospacien tesconFQpresen tanalmenos una copia deesta\nmutaci\u00f3n  y el 50 % son homocig otos.(3)\nApesar deseruna enfermedad monog \u00e9nicatiene granvariabilidad fenot\u00edpic a,como se\ndemues traenelamplio abanic odegravedad delaenfermedad observado enpacien tescon\nelmismo genotipo. Elfenotipo deFQsecaracterizaporenfermedad pulmonar progresiva,\ninsuficiencia pancr e\u00e1ticaexocrina que result aen malab sorci\u00f3n gastrointestinal,\nanormalidades intestinales que result anendesnutrici\u00f3n, retraso enelcrecimien toyotras\nmanif estaciones, incluy endo sinusitis y diabe tes.\nEltratamien todelaFQescr\u00f3nic o,incluy egrann\u00famer odef\u00e1rmac os,diferentesv\u00edas de\nadminis traci\u00f3n ymodific aciones habituales enelmismo. Cons tadebroncodila tador es,\ncortic oides, salino hipert \u00f3nic o,dornasa alfa,antibi\u00f3tic ossist\u00e9mic osynebuliz ados,\nantif\u00fangic os,enzimas pancr e\u00e1ticas,vitaminas liposolubles yaveces f\u00e1rmac osparatratarla669depr esi\u00f3n yansiedad. Adem\u00e1s, enlos\u00faltimos a\u00f1os sehan a\u00f1adido los modulador esde\nCFTR, que han represen tado unavance import anteeneltratamien todelaFQporque se\ndirig enalaproducci\u00f3n ofunci\u00f3n delaprote\u00edna CFTR mutanteenlugardesusconsecuencias\nposterior es.(4) Estoaumen talaprobabilidad deinteracciones farmac ol\u00f3gic as,sobr etodo\nparalosf\u00e1rmac osque semetaboliz anv\u00edacitocromo P450 (CYP450). Acontinuaci\u00f3n se\ndescriben dos c asos similar es, c on dif erente actuaci\u00f3n por part e del Ser vicio de F armacia.\nDescripci\u00f3n del c aso\nSepresen tandos casos cl\u00ednic ossimilar es,depacien tesmujer esde20(pacien te1)y26a\u00f1os\ndeedad (pacien te2)diagnos ticadas alosdos meses deedad deFQ(homocig osis F508del),\nambas c on a fectaci\u00f3n pulmonar e insuficiencia pancr e\u00e1tica.\nLapacien te1,recib\u00eda tratamien toconantibi\u00f3tic osnebuliz ados (aztr eonam-lisina cada 8hy\ntobramicina 300 mgcada 12h ameses alternos), soluci\u00f3n hipert \u00f3nic aparanebuliz aci\u00f3n,\ndornasa alfa,enzimas pancr e\u00e1ticas, vitaminas liposolubles ybudesonida/f ormot erol\ninhalado ,tezacaftor/iv acaftoradosis de100/150mg porlama\u00f1ana eivacaftor150 mgpor\nla noche.\nEnuncultiv odeesput orutinario sedetectalapresencia deAspergillus (adem\u00e1s de\nPseudomonas) porloque sedecide desde elservicio deneumolog\u00eda iniciar tratamien tocon\nvoriconaz oladosis de200mg cada 12h,monit orizando niveles delf\u00e1rmac oyevoluci\u00f3n de\nenzimas hep\u00e1 ticas.Trasdos semanas detratamien toconvoriconaz olselerealiz auna\nanal\u00edtic aalapacien teenlaque seobservauna elevaci\u00f3n delastransaminasas ylafosfatasa\nalcalina por encima delosvaloresnormales (VN) (FA219 UI/L ,VN: 40-126, GGT111 UI/L\nVN: 1-43, GPT48UI/L VN:4-40). Los niveles def\u00e1rmac oseencuen tranenelrango\nterap\u00e9utic odeseado (3,71 ug/mL,rangoterap\u00e9utic o:1-5.5). Debido alamejor\u00eda delacl\u00ednic a670respir atoria desde elinicio deltratamien toconvoriconaz ol,yaunque lapacien tepresen taba\nmoles tias g\u00e1stricas, sedecide man tener dicho tratamien toaexpensas desuspender\ntezacaftor/iv acaftordemaner aprovisional conelobje tivodenormaliz arlosvaloresde\nenzimas hep\u00e1 ticas.Seleprescribi\u00f3 pantoprazolparalasmoles tias g\u00e1stricas. Trasuna\nsemana, lapacien tesuspende por sucuen taeltratamien toconvoriconaz oldebido ala\nepig astralgia, que noremit eapesar del tratamien toconinhibidor esdelabomba de\nprotones. Seman tiene lasuspensi\u00f3n devoriconaz olytezacaftor/iv acaftor.Unmes despu\u00e9s\nenlaanal\u00edtic asehan normaliz ado lasenzimas hep\u00e1 ticas.Actualmen te,lapacien tese\nencuen traen tratamien tocon tezacafotr/iv acaftor/elexacaftor tras suspensi\u00f3n de\ntezacaftor/iv acaftor por f alta de e ficacia.\nLapacien te2,presen taba adem\u00e1s hipertr ansaminasemia fluctuan teloque oblig aa\ncontroles anal\u00edtic osm\u00e1s frecuen tes.Adem\u00e1s deennues trocentro,tambi\u00e9n seocupaban de\nsuseguimien toenelhospit aldereferencia paratrasplan tes.Seencontraba atratamien to\ncontezacaftor/iv acaftoradosis de 100/150mg por lama\u00f1ana eivacaftor150 mgporla\nnoche, tobramicina 300mg inhalada cada 12h ameses alternos, sulfame toxazol/trime toprim\n160mg /800mg v\u00edaorallunes, mi\u00e9r coles yviernes ,soluci\u00f3n hipert \u00f3nic aparanebuliz aci\u00f3n,\ndornasa alfa,enzimas pancr e\u00e1ticas, vitaminas liposolubles, tiotr opio inhalado ,y\nvilan terol/flutic asona inhalado. Trasvarios episodios de hemop tisis, aislamien tode\nAsper gillus encultiv odeesput oyhallaz goenimag endeTCcompa tible conasper gilloma en\nl\u00f3bulo superior izquier do,sedecide iniciar tratamien toconvoriconaz ol200mg cada 12h.Se\nsuspende tezacaftor/iv acaftorparaevitarlainteracci\u00f3n. Trasmes ymedio detratamien to\nconvoriconaz ol,yantevaloresdeenzimas hep\u00e1 ticasnormales enlasanal\u00edtic asseindic a\nreintroducir tezacaftor/iv acaftoradosis reducida. Mes ymedio m\u00e1s tarde,sedetectaenla\nconsult adefarmacia que lapacien tehab\u00eda reintroducido tezacaftor/iv acaftoradosis plenas,671por loque seavisa alservicio deneumolog\u00eda paracorregir laposolog\u00eda. Los valoresde\nenzimas hep\u00e1 ticasseencontraban dentrodelanormalidad, salvodiscr etoaumen todeGGT\n(49UI/L). Lapacien teactualmen teseencuen traenlistadeesper adetrasplan tepulmonar\nycontin\u00faa sutratamien tocontezacaftor/iv acaftor100/150mg eivacaftor150 mguna vezal\nd\u00eda en d\u00edas alt ernos, suspendiendo la dosis nocturna.\nDiscusi\u00f3n y aport aci\u00f3n f armac\u00e9utic a\nUna granpropor ci\u00f3n delasinteracciones entref\u00e1rmac oscl\u00ednic amen terelevantesest\u00e1n\nrelacionadas conelmetabolismo porpartedelasenzimas delCYP450, ym\u00e1s del90% dela\noxidaci\u00f3n def\u00e1rmac osseatribuy easeis deellas: CYP1AS, 2C9, 2C19, 2D6, 2E1 Y3A4.\nCYP3A4, CYP2C9 YCYP2C19 son responsables deunn\u00famer oimport antedeinteracciones\nrelevantes en el tr atamien to de la F Q. (5)\nLos datosinvitro indic anque ivacaftorytezacaftorsemetaboliz anprincipalmen tepor\nCYP3A4 yCYP3A5, yque tezacaftorposee adem\u00e1s una v\u00edasecundaria minorit aria de\nmetaboliz aci\u00f3n median teglucur onidaci\u00f3n directa.Los inhibidor esdeCYP3A4 relevantes\nparamuchos pacien tesdeFQincluy enlosantif\u00fangic osdetipo azol(itraconaz ol,ketoconaz ol,\nposac onaz ol,voriconaz ol\u2026), yaque son losf\u00e1rmac osm\u00e1s com\u00fanmen teutiliz ados enel\ntratamien to de la asper gillosis.  (5, 6, 7, 8)\nEnunestudio farmac ocin\u00e9 ticolaadminis traci\u00f3n deitraconaz ol(200 mgdosveces ald\u00edaen\n2dosis, seguido de200 mgald\u00eda) juntocontezacaftor/iv acaftor(25mg/50mguna vezal\nd\u00eda) produjo unaumen toenelAUCylaCma xdetezacaftor4,0y2,8veces, respectiv amen te.\nElAUCylaCma xdeivacaftoraumen taron15,6 y8,6veces ,respectiv amen te.(7)Enestudios672adicionales devolun tarios sanos ypacien tesconFQ,ritonavir(100 mgdos veces ald\u00eda)\naumen t\u00f3elAUCylaCma xdeivacaftor(150 mgendosis \u00fanica)de10a11veces yde2,2a\n2,3veces, respectiv amen te,ylaclaritr omicina aumen t\u00f3elAUCylaCma xdeivacaftorde3,4\na 3,6 v eces y de 1,6 a 2 v eces, r espectiv amen te. (9)\nElaumen todeAUCdeivacaftorytezacaftor/iv acaftorencoadminis traci\u00f3n coninhibidor es\npotentesdelCYP3A puede redundar enuna mayortoxicidad delosf\u00e1rmac os,que enlos\ncasos que nos ocupan se vio r eflejada en el aumen to de las enzimas hep\u00e1 ticas.\nPortanto,enadminis traci\u00f3n concomit anteconinhibidor esdeCYP3A moder ados opotentes,\nsedebe ajustarladosis detezacaftor/iv acaftoreivacaftor.Seg\u00fan laficha t\u00e9cnic ade\nSymkevi\u00ae, ylaplataforma Lexicomp\u00ae deUptoDate\u00aeenpacien tesde12om\u00e1s a\u00f1os deedad\natratamien toconinhibidor espotentesdeCYP3A ,como elvoriconaz ol,elajustededosis\ndeber\u00eda hacer sedelasiguien temaner a:uncomprimido detezacaftor/iv acaftor100/150mg\npor lama\u00f1ana dos veces por semana conunintervalode3-4 d\u00edas aproximadamen te,y\nninguna dosis por la noche.  (5)\nEnambas pacien tesserevis\u00f3 elinicio detratamien to,selespropor cion\u00f3 informaci\u00f3n acer ca\ndelmismo eindic aciones sobr elaforma deadminis traci\u00f3n (espaciar aproximadamen te12\nhorasladosis delama\u00f1ana detazacaftor/iv acaftor100/150 mgyladelanoche deivacaftor\n150 mg,adminis trarjuntoconalimen tosque contengangrasas\u2026). Enese momen tose\ndesc art\u00f3lapresencia deinteracciones. Sinembar go,duranteelseguimien todelaprimer a\npacien tenosedetect\u00f3lainteracci\u00f3n enelmomen todelaprescripci\u00f3n devoriconaz ol,\nmien trasque enelsegundo caso,pese ahaber seefectuado una reducci\u00f3n dedosis por\npartedelm\u00e9dic o,lapacien tecontinu\u00f3 tomando eltratamien toadosis plenas. Elerrorfue673detectado enlaconsult adefarmacia cuando lapacien tesolicit \u00f3sumedic aci\u00f3n habitual, y\nfue c omunic ado a su m\u00e9dic o par a proceder al ajus te de dosis.\nDebido alapandemia porcovid-19, elseguimien todelospacien tesconFQ(consider ados de\nriesg o)empe z\u00f3aefectuar sev\u00edatelefarmacia paraevitarsuexposici\u00f3n enlassalas deesper a\ndelhospit al.Lospacien tesautogestionan sumedic aci\u00f3n, acuden alhospit alenhorario de\ntardeyrecogenlamedic aci\u00f3n que ellos mismos solicit anmedian tecorreoelectr \u00f3nic o,\nrevisada yprepar ada porlama\u00f1ana porelfarmac\u00e9utic oresponsable delaconsult aexterna.\nEste cir cuito hiz o m\u00e1s dif\u00edcil la de tecci\u00f3n de la in teracci\u00f3n en ambos c asos.\nLos pacien tesdeFQson pacien tespolimedic ados ydegrancomplejidad por elelevado\nn\u00famer odemedic amen tosque reciben, los cambios frecuen tesdetratamien to,las\ndiferentesv\u00edas deadminis traci\u00f3n yestarsome tidos atransiciones asistenciales. Peseaque\nsetratadepacien tesj\u00f3venes, conbuen nivelsociocultur al,habituados alapolimedic aci\u00f3n y\nque autogestionan demaner amuy eficien tesutratamien to,precisan igualmen teun\nseguimien toexhaus tivodelmismo ydeloscambios que en\u00e9lseproducen decaraaevitar\nposibles erroresdemedic aci\u00f3n ointeracciones que puedan afectarnegativamen teala\neficacia y/oseguridad desutratamien to.Como refuerz o,sevanaincluir lasinteracciones\ndelosmodulador esCFTR enelprograma inform\u00e1 ticodeprescripci\u00f3n ydispensaci\u00f3n\nSilicon\u00ae (versi\u00f3n 11.4.8) paraque senotifiquen como alert aenelmomen todela\nprescripci\u00f3n, tantoenpacien tesingresados como ambula torios. Enelcasodeltratamien to\nconazoles, enelque existeuna granvariabilidad farmac ocin\u00e9 ticaintereintraindividual en\nlospacien tesconFQ,esinteresan telamonit orizaci\u00f3n deniveles plasm\u00e1 ticosparareducir el\nriesg odeaparici\u00f3n deresistencias micr obianas yprevenir lahepa totoxicidad (que se674presen taenun25% delospacien tes)as\u00edcomo realiz aranal\u00edtic asdeenzimas hep\u00e1 ticas\nperi\u00f3dic amen te par a de tectarla. (8)\nBibliograf\u00eda\n1.Ratjen F,D\u00f6ring G.Cysticfibrosis. Lance t.2003 Feb22;361(9358):681-9. doi:\n10.1016/S0140-6736(03)12567-6. PMID: 12606185.,\n2.Ratjen F,Bell SC,RoweSM, Goss CH,Quit tner AL,Bush A.Cysticfibrosis. NatRevDis\nPrimer s. 2015 Ma y 14;1:15010.\n3.BoyleMP,DeBoeck K.Anewerainthetreatmen tofcysticfibrosis: correction ofthe\nunderlying CFTR de fect. Lance t Respir Med. 2013 Apr;1(2):158-63.\n4.DavisPB.Ther apyforcysticfibrosis--the end ofthebeginning? NEngl JMed. 2011\nNov 3;365(18):1734-5.\n5.Jordan CL,Noah TL,Henr yMM. Ther apeutic challeng esposed bycritic aldrug-drug\ninteractions in cy stic fibr osis. P edia tr Pulmonol. 2016 Oct;51(S44):S61-S70.\n6.Ficha t\u00e9cnic a de Symkevi\u00ae disponible en:\nhttps://cima.aemp s.es/ cima/doch tml/ft/1181306001/FT_1181306001.h tml\n7.GargV,Shen J,LiC,AgarwalS,Gebr eA,Robertson S,Huang J,Han L,Jiang L,Stephan\nK,Wang LT,Lekstrom-Himes J.Pharmac okine ticand Drug-Drug Interaction Profiles of\nthe Combina tion of T ezacaftor/Iv acaftor. Clin T ransl Sci. 2019 Ma y;12(3):267-275.\n8.VanderMeer R,Touw DJ,Heijerman HGM. Prevention ofdrug-r elatedcomplic ations\nin cy stic fibr osis. Curr Opin Pulm Med. 2019 No v;25(6):666-673\n9.Vander Meer R,Wilms EB,Sturm R,Heijerman HGM. Pharmac okine ticinteractions\nbetween ivacaftorand cytochr ome P450 3A4 inhibit orsinpeople with cysticfibrosis\nand health y controls [published online Ma y 15, 2021]. J Cy st Fibr os.675INTERVENCI\u00d3N FARMAC\u00c9UTICA EN LA DETECCI\u00d3N DE TRASTORNOS CARD\u00cdACOS \nSECUNDARIOS A ADALIMUMAB  \n \nINTRODUCCI\u00d3N  \nAdalimumab es un anticuerpo monoclonal humanizado con actividad espec\u00edfica frente \nal factor de necrosis tumoral (TNF -alfa) , autorizado, entre otras indicaciones , en el \ntratamiento de la psoriasis en placas cr\u00f3nica de moderada a grave en pacientes adultos \nque sean candidatos para tratamiento sist\u00e9mico . Entre las reacciones adversas ( RAM ) \nma\u0301s frecuentemente notificadas se encuentran las  infecciones, las reacciones en el lugar \nde inyecci o\u0301n, la cefalea y el dolor m u\u0301sculo -esquel e\u0301tico. Tambi\u00e9n se han detectad o RAM \ngraves tales como sepsis, tuberculosis, reactivaci\u00f3n de tumores y del virus de la hepatitis \nB as\u00ed como  pancitopenia, anemia apl\u00e1sica, lupus y s\u00edndrome de Stevens -Johnson1.   \nEn relaci\u00f3n con la ap arici\u00f3n de efectos adversos de tipo cardiaco , la taquicardia est\u00e1 \ncategorizada como frecuente , el infarto de miocardio, la arritmia y la insuficiencia \ncard\u00edaca congestiva como poco frecuentes y el paro card\u00edaco como raro . En la pr\u00e1ctica \ncl\u00ednica real se han descrito casos de alteraciones  card\u00edacas  (ej: taquiarritmia ventricular \ncon reversi\u00f3n total ) en pacientes sin otros f\u00e1rmacos cardiot\u00f3xicos tras periodos  de \ntratamiento con adalimumab2. Incluso, algunas bases de datos pertenecientes a \ninstituciones reguladoras lo clasifican entre los f\u00e1rmacos a los que m\u00e1s se asocian las \narritmias distintas de la prolongaci\u00f3n de l intervalo QT3.   \nA nivel vascular, se ha observado en trabajos publicados una mayor incidencia de \nhipertensi\u00f3n arterial (HTA)  en enfermos con artritis reumatoide  tratado s con este \nf\u00e1rmaco anti-TNF-alfa4.  676Adalimumab est\u00e1 contraindicado en i nsuficiencia cardiaca moderada a grave (NYHA \nclases III/IV) . \nA continuaci\u00f3n , se describe el caso de un paciente t ratado con adalimumab  que \ndesarrolla fibrilaci\u00f3n auricular.   \n \nDESCRIPCI \u00d3N DEL CASO  \nVar\u00f3n de 58 a\u00f1os  en seguimiento por Dermatolog\u00eda con diagn\u00f3stico de psoriasis guttata  \ny fracaso a diversos tratamientos previos, entre los que se incluyen la fototerapia \nultravioleta B (UVB) y la combinaci\u00f3n t\u00f3pica de calcipotriol y betametasona. \nPosteriormente se recurre a la  ciclosporina por v\u00eda oral en pauta inicial de 2,5mg/kg/d\u00eda5 \nen dos dosis diarias (100mg cada 12h) , pero el paciente manifiesta HTA (RAM frecuente) \ntras 3 meses de tratamiento , lo que provoca la reducci\u00f3n de dosis a 100mg diarios.  Al 4\u00ba \nmes, refiere parestesias  (RAM frecuente)  en las extremidades y en la consulta de \nReumatolog\u00eda se le diagnostica de polineuropat\u00eda mixta secundaria a ciclosporina ; se \nsuspende el f\u00e1rmaco inmediatamente.  Tras  la reevaluaci\u00f3n cl\u00ednica  en Dermatolog\u00eda, se \ndecide iniciar metotrexato (20 mg semanales v\u00eda oral) m\u00e1s \u00e1cido f\u00f3lico (1 comprimido \nde 5 mg el d\u00eda posterior al metotrexat o), lo cual deriva en aparici\u00f3n de  intolerancia \ng\u00e1strica (RAM gastrointestinales muy frecuentes)6.     \nA partir de este momento , y cumpliendo con el algoritmo de tratamiento de la psoriasis  \naprobado en el centro , el paciente se considera candidato a terapia sist\u00e9mica biol\u00f3gica . \nSe prescribe , desde Dermatolog\u00eda , adalimumab seg\u00fan la posolog\u00eda recomendada en la \nficha t\u00e9cnica para psor iasis: dosis inicial de 80 mg administrada por v\u00eda subcut\u00e1nea, \nseguida de 40 mg administrados por v\u00eda subcut\u00e1nea en semanas alternas comenzando 677una semana despu\u00e9s de la dosis inicial.  A los 8 meses de iniciar el tratamiento, debido a \nla buena situaci\u00f3n cl\u00ed nica, se propone una pauta extendida para optimizar el uso del \nf\u00e1rmaco biol\u00f3gico ; el paciente  recibe , durante 2 meses m\u00e1s , dosis de 40mg cada 3 \nsemanas . \nTranscurrido este tiempo, acude  a una nueva consulta de dispensaci\u00f3n ambulatoria en \nel Servicio de Farmacia Hospitalaria para llevar a cabo un seguimiento del tratamiento y \nrecibir su medicaci\u00f3n. En la entrevista con el farmac\u00e9utico , refiere taquicardias e HTA \ndescontrolada que asocia al  adalimumab y comenta que tiene un reciente diagn\u00f3stico \nde arritmia por su m\u00e9dico de atenci\u00f3n primaria . Desde Farmacia se verifica y se confirma \nel diagn\u00f3stico de fibrilaci\u00f3n auricular manifestada en forma de mareo  e inestabilidad \ndurante la pr\u00e1ctica depor tiva, sin pres\u00edncope s, palpitaciones, disnea ni dolor tor\u00e1cico. \nAnte estos hallazgos, se descartan otros posibles f\u00e1rmacos cardiot\u00f3xicos y se revisa el \nperfil de seguridad del f\u00e1rmaco  biol\u00f3gico , estando descritas la  taquicardia y las arritmia s \ncomo RAM frecuente s y poco frecuente s, respectivamente.  Adem\u00e1s, se establece \ncontacto con el m\u00e9dico especialista en Dermatolog\u00eda para informar y tomar una decisi\u00f3n \nconjunta  acerca  del tratamiento del paciente. De esta manera, Dermatolog\u00eda opta por \nsuspender el tratamiento y procede a la derivaci\u00f3n a consultas de Cardiolog\u00eda, a la \nespera de una pr\u00f3xima visita en la que considerar la b\u00fasqueda de una nueva alternativa \nterap\u00e9utica para la psoriasis.  \nEn las siguientes semanas, y ya en la consulta de Cardiolog\u00eda, se le practica al paciente \nuna cardioversi\u00f3n con \u00e9xito para revertir su fibrilaci\u00f3n auricular. Desde entontes, hace \nvida normal, se muestra asintom\u00e1tico y sin cl\u00ednica asociada.  678En cuanto a la psoriasis, se decidi\u00f3 permanecer sin tratamiento sist\u00e9mico durante  un \ntiempo y controlar con tratamiento t\u00f3pico. A los 10 meses de esta interrupci\u00f3n \ntemporal, y tras sufrir un brote  en codos , espalda, piernas  y zona  inguinal , se decidi\u00f3 \niniciar tildrakizumab .  \n \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA \nEntre las diferentes actividades desarrolladas en la consulta farmac\u00e9utica , se facilita \ninformaci\u00f3n sobre los medicamentos desde el momento en que se inicia el tratamiento \ny se pretende que el paciente tome conciencia sobre la importancia de ser part\u00edcipe de \nla vigi lancia de su  evoluci\u00f3n con el f\u00e1rmaco y de comunicar al farmac\u00e9utico cualquier \nduda relativa a su medicaci\u00f3n. Esto,  junto con la accesibilidad que muestra  el \nfarmac\u00e9utico hospitalario, permite una comunicaci\u00f3n fluida tanto de forma presencial \nen la consult a como v\u00eda telef\u00f3nica. En consecuencia, se produce la anticipaci\u00f3n de \nintervenciones que ayudan tanto a prevenir  riesgos y da\u00f1os evitables,  como  a optimizar \nla efectividad de la terapia.   \nEn este caso cl\u00ednico, que involucra a un paciente de dif\u00edcil manejo con mala tolerancia a \ndiversos f\u00e1rmacos, cobran vital importancia los siguientes  aspectos : \n\u2022 Adecuada entrevista farmac\u00e9utica para  la detecci\u00f3n de RAM . \n\u2022 Papel  del farmac\u00e9utico hospitalario como experto del medicamento  y como \nnexo com\u00fan entre los distintos especialistas m\u00e9dicos.  \n\u2022 Importancia de las consultas de Farmacia Hospitalaria , debido  a su mayor \nperiodicidad respecto a las  consultas  m\u00e9dicas, en el seguimien to del paciente , 679en la evaluaci\u00f3n de la efectividad  del medicamento y en la detecci\u00f3n de \nproblemas de seguridad relacionados (especialmente aquellos poco frecuentes) . \n\u2022 Accesibilidad  del farmac\u00e9utico hospitalario como profesional sanitario de \nreferencia en materia farmacol\u00f3gica . \n \nBIBLIOGRAF\u00cdA  \n \n1 Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha t\u00e9cnica \nHyrimoz  40mg soluci\u00f3n inyectable en pluma precargada \u00ae   \nhttps://cima.aemps.es/cima/dochtml/ft /1181286001/FT_1181286001.html  \n \n2 Eder,  P., Lykowska -Szuber , L., Krela -Kazmierczak , I., Stawczyk -Eder , K., Linke , K. (2013). \nVentricular Tachyarrhythmia After Adalimumab Therapy In A Patient With Crohn's \nDisease . AGEB Journal, 76 . \n3 Moreland -Head, L. N., Coons, J. C., Seybert, A. L., Gray, M. P., & Kane -Gill, S. L. (2021). \nUse of Disproportionality Analysis to Identify Previously Unknown Drug -Associated \nCauses of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event  \nReporting System (FAERS) Database. Journal of cardiovascular pharmacology and \ntherapeutics, 26(4), 341 \u2013348.  \n \n4 Zhao, Q., Hong, D., Zhang, Y., Sang, Y., Yang, Z., & Zhang, X. (2015). Association \nbetween anti -TNF therapy for rheumatoid arthritis and hyperte nsion: a meta -analysis \nof randomized controlled trials. Medicine, 94(14), e731.   \n \n5 Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha t\u00e9cnica \nSandimmun Neoral  100mg c\u00e1psulas blandas \u00ae   \nhttps://cima.aemps.es/cima/dochtml/ft/60320/FT_60320.html  \n \n6 Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha t\u00e9cnica \nMetotrexato Wyeth 2,5 mg comprimidos\u00ae   \nhttps://cima.aemps.es/cima/dochtml/ft/40698/FT_40698.html  \n 680INTRODUCCI\u00d3N \nLa leucemia linfoc\u00edtica cr\u00f3nica (LLC) se caracteriza por una proliferaci\u00f3n clonal de c\u00e9lulas \nB maduras en m\u00e9dula \u00f3sea, sangre perif\u00e9rica y \u00f3rganos linfoides. El desarrollo del \ninhibidor de  la tirosin-kinasa de Bruton (BTK) ibrutinib supuso  un gran avance en el \nabordaje de la LLC y otras neoplasias de c\u00e9lulas B. La diana terap\u00e9utica de ibrutinib es la \nBTK, una kinasa de la familia TEC no receptora encargada de transducir se\u00f1ales del \nreceptor de c\u00e9lulas B (BCR) y otros receptores de superficie, tanto en linfocitos B \nnormales como malignos, induciendo proliferaci\u00f3n celular1. A pesar de ello, existe falta \nde selectividad de ibrutinib por la BTK, inhibiendo a otras tirosin-kinasas. Ello deriva en \nla aparici\u00f3n de efectos off target que, en determinadas ocasiones, obligan a reducir \ndosis o suspender el tratamiento. Las toxicidades dermatol\u00f3gicas se encuentran entre \nlas m\u00e1s comunes de ibrutinib, debido a la inhibici\u00f3n del receptor de factor de \ncrecimiento epid\u00e9rmico (EGFR). Estas reacciones dermatol\u00f3gicas son de intensidad leve -\nmoderada en la mayor\u00eda de casos, siendo f\u00e1cilmente manejables. Con frecuencia \naparecen alteraciones de u\u00f1as y cabello, infecciones cut\u00e1neas oportunistas, foliculitis y \notro tipo de erupciones. Tambi\u00e9n pueden aparecer paniculitis, ulceraciones de tipo aftas \ncon estomatitis, dermatosis neutrof\u00edlica, edema perif\u00e9rico y agrietamiento de la piel2.  \nPor otro lado, el inicio de ibrutinib conlleva a la prescripci\u00f3n en cascada de terapia anti-\ninfecciosa profil\u00e1ctica. A su vez, estos tratamientos no est\u00e1n exentos de reacciones \nadversas medicamentosas dermatol\u00f3gicas. En concreto, para \nsulfametoxazol/trimetoprim y aciclovir se encuentran descritos,  en sus respectivas \nfichas t\u00e9cnicas, de manera frecuente la aparici\u00f3n de erupciones cut\u00e1neas. Se han \nnotificado casos de reacciones de hipersensibilidad al medicamento con eosinofilia y 681s\u00edntomas sist\u00e9micos (DRES S), s\u00edndrome de Stevens-Johnson y necr\u00f3lisis epid\u00e9rmica \nt\u00f3xica; este \u00faltimo de elevada mortalidad. En caso de aparici\u00f3n, tanto \nsulfametoxazol/trimetoprim como  aciclovir  deben suspenderse inmediatamente3. \nA continuaci\u00f3n, presentamos el caso de una paciente diagnosticada de LLC, que tras \niniciar ibrutinib desarrolla una reacci\u00f3n t\u00f3xico-cut\u00e1nea grave ocasionada por m\u00faltiples \nf\u00e1rmacos, siendo un escenario cl\u00ednico poco frecuente. El Servicio de Farmacia ejerce un \npapel clave  en la toma de decisiones formando parte del equipo multidisciplinar . \nDESCRIPCI\u00d3N DEL CASO \nSe trata de una mujer de 61 a\u00f1os,  sin alergias medicamentosas notificadas, \ndiagnosticada en 2018 de LLC-B estadio 0B de Rai y Binet, con IGHV no hipermutado, \nTP53 no mutado, deleci\u00f3n heterocigota 13q14 positiva y del17p negativa. Su patolog\u00eda \nde base y tratamiento farmacol\u00f3gico se describen en la Tabla 1.  El 9 de febrero de 2022, \ntras 4 a\u00f1os de vigilancia activa, inici\u00f3 tratamiento con ibrutinib 420mg/d\u00eda por \nduplicaci\u00f3n de poblaci\u00f3n linfocitaria en los \u00faltimos 6 meses, hepatomegalia y \nesplenomegalia, con afectaci\u00f3n adenop\u00e1tica extensa. Tratamiento adicional: sulfato \nferroso 80mg/d\u00eda, trimetoprim/sulfametoxazol 160/800mg/12 horas los lunes, \nmi\u00e9rcoles y viernes y aciclovir 800mg/d\u00eda.  En la Consulta de Dispensaci\u00f3n de Pacientes \nExternos del Servicio de Farmacia, una vez revisada la indicaci\u00f3n y cualquier par\u00e1metro \nque pudiera requerir ajuste posol\u00f3gico, se valid\u00f3 la prescripci\u00f3n procediendo a la \ndispensaci\u00f3n.  \n \n 682Tabla 1. Tratamiento farmacol\u00f3gico domiciliario del paciente  \nAntecentes Fecha \ninicio  Principio \nactivo Dosis  Frecuencia V\u00eda \nDiabetes mellitus tipo II  2018 Repaglinida 1mg Cada 12 \nhoras Oral \nHipotirodismo  2018 Levotiroxina  100mcg Diario Oral \nHipovitaminosis D  2019 Hidroferol  0,266mg Cada 2 \nsemanas Oral \n \nEl 25 de febrero , la paciente acudi\u00f3 al Servicio de Urgencias Hospitalarias por erupci\u00f3n \ncut\u00e1nea extensa y pruriginosa . Es por esto,  se suspendi\u00f3  sulfametoxazol/trimetoprim y \naciclovir , inici\u00e1ndose tratamiento con prednisona oral 50mg/d \u00eda y dexclorfeniramina \n2mg/8 horas. La paciente acudi\u00f3 de nuevo el 5 de marzo debido a refractariedad al \ntratamiento, fiebre , prurito generalizado y exacerbaci\u00f3n de lesiones : microp\u00e1pulas \nfoliculares dispersas en tronco, p\u00e1pulas planas liquenoides hiperpigmentadas viol\u00e1ceas \nlumbares, pliegues axilares y zona genital y afectaci\u00f3n de mucosa s (costra hem\u00e1tica en \nbermell\u00f3n con imposibilidad de abrir la boca, mucosa peridontal erosionada, \nmembr anas blanquecinas, eritema en cara interna de labios) (Figura 1).  \n \nFigura 1. Afectaci\u00f3n lumbar (izquierda) y mucosas (derecha) \n683Se decid i\u00f3 ingresar a cargo del Servicio de Hematolog\u00eda, precisando interconsulta al \nServicio de Dermatolog\u00eda y al Servicio de Alergia. Datos anal\u00edticos de inter\u00e9s: \nhemoglobina 8,9g/dL, leucocitos 356,4x10\u00b3 c\u00e9lulas/\u00b5L, linfocitos 347,6x10\u00b3 c\u00e9lulas/\u00b5L. \nAl ingreso se suspendi\u00f3 ibrutinib, inici\u00e1ndose metilprednisolona 100mg/ 12 horas y \nceftriaxona 2g/d\u00eda. El 9 de marzo, se aisl\u00f3 E.faecalis en urocultivo, modificando la \nantibioterapia a gentamicina 240mg/d\u00eda por exacerbaci\u00f3n de prurito coincidiendo con  \nla administraci\u00f3n de \u00df-lact\u00e1micos. De acuerdo con el Servicio de Alergia,  se decidi\u00f3 no \nrealizar estudio alergol\u00f3gico por administraci\u00f3n concomitante de corticoides y \nantihistam\u00ednicos-H1.  \nSe realiz\u00f3 una b\u00fasqueda bibliogr\u00e1fica junto al Servicio de Dermatolog\u00eda, estableciendo  \nibrutinib, aciclovir y/o sulfametoxazol/trimetoprim como posibles agentes \ndesencadenantes de  la reacci\u00f3n adversa. El Servicio de Dermatolog\u00eda indic\u00f3 la aplicaci\u00f3n \nde vaselina filante est\u00e9ril varias veces al d\u00eda en zona labial, crema hidratante en todo el \ncuerpo, metilprednisolona aceponato crema 1mg/g en zonas de mayor afectaci\u00f3n \ncut\u00e1nea c/12 horas y \u00e1cido fus\u00eddico pomada 20mg/g c/12 horas en pliegue axilar \nizquierdo. El 12 de marzo se inici\u00f3 descenso de corticoides a ritmo de 10mg de \nmetilprednisolona/12 horas cada 2 d\u00edas. El 18 de marzo se a\u00f1adi\u00f3 al tratamiento un \nspray secante sobre \u00e1reas genital y axilar, junto con una f\u00f3rmula magistral elaborada \npor el Servicio de Farmacia de triamcinolona 0,2%.  El 22 de marzo se administr\u00f3 \nciclofosfamida 400mg/m2 para reducir linfocitosis previa  a eventual inicio de \ntratamiento con venetoclax.  El d\u00eda 30 de marzo se prepararon enjuagues con agua \noxigenada (1:10) y se pautaron colutorios de \u00e1cido hialur\u00f3nico y se aument\u00f3 dosis de  \ncorticoides sist\u00e9micos (bolo: 500mg de metilprednisolona; seguido de 120mg/12 horas) , \ndebido a escasa respuesta de lesiones orales. De manera conjunta,  se inici\u00f3 tratamiento 684con: 1) valganciclovir 450mg/12 horas por PCR positiva a citomegalovirus que debi\u00f3 \nsuspenderse a los 10 d\u00edas por rash  y; 2) fluconazol como profilaxis antif\u00fangica, que debi\u00f3 \nrotarse a anidulafungina, en consenso con el Servicio de F armacia, por alteraci\u00f3n \nhep\u00e1tica (GOT: 129 UI/L; GPT: 132 UI/L; GGT: 2264 UI/L, fosfatasa alcalina: 660 UI/L). \nJunto a ello, se realiz\u00f3 interconsulta al Servicio de Endocrinolog\u00eda quien decidi\u00f3, ante \ndesnutrici\u00f3n por incapacidad de cumplir requerimientos energ\u00e9ticos, iniciar \nsuplementos orales hiperproteicos espec\u00edficos de diabetes, acompa\u00f1ados de tiamina y \nf\u00f3sforo profil\u00e1cticos frente a s\u00edndrome de realimentaci\u00f3n. El 4 de abril, se decidi\u00f3 junto \nal Servicio de Farmacia, iniciar nutrici\u00f3n parenteral (NP)  central debido a la imposibilidad \nde colocaci\u00f3n de sonda nasog\u00e1strica por lesiones orales graves e insuficiente ingesta de \ncalor\u00edas v\u00eda oral. Por este motivo, se realiz\u00f3 una estrategia mixta de NP y suplementos \norales, manteni\u00e9ndose la NP hasta el d\u00eda 22 de abril, debido a la posibilidad de cubrir \nrequerimientos nutricionales v\u00eda oral. \nEl 9 de abril, la paciente present\u00f3 de nuevo fiebre, inici \u00e1ndose amoxicilina-clavul\u00e1nico \n875/125mg/8horas que debi\u00f3 rotarse a clindamicina 600mg/8 horas por prurito. Tras \naislamiento de P.aeruginosa en cultivo bucal, se paut\u00f3 amikacina 1g/d\u00eda y ceftazidima \n2g/8 horas. La paciente present\u00f3 rash  cut\u00e1neo decidi\u00e9ndose  suspender antibioterapia \nel 17 de abril. El 22 de abril se aisl\u00f3 S.epidermidis en cat\u00e9ter venoso central (CVC) y \nsangre perif\u00e9rica, se inici\u00f3 vancomicina 1g/12 horas y se retir\u00f3 el CVC con cultivo de  \npunta negativo. Ante eritema y edema facial al inicio de vancomicina, el equipo del \nPrograma de Optimizaci\u00f3n de uso de Antimicrobianos (PROA) en consens o con el \nServicio de Alergia, decidi\u00f3 iniciar  ciprofloxacino 400mg/12 horas y fosfomicina  4g/8 \nhoras, en lugar de vancomicina. La paciente present\u00f3 una nueva reacci\u00f3n cut\u00e1nea a nivel \nfacial, suspendi\u00e9ndose  de nuevo  la antibioterapia. El 22 de abril se traslad\u00f3 a la paciente 685a la Unidad de Quemados de un hospital de tercer nivel debido a persistencia de \nafectaci\u00f3n cut\u00e1nea (45% seg\u00fan regla de Wallace ), ocular, bucal y genital con signo de \nNikolsky positivo (Figura 2). \n \nFigura 2. Signo de Nikolsky positivo \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA \n1.- Atenci\u00f3n farmac\u00e9utica previa al inicio de ibrutinib : La validaci\u00f3n farmac\u00e9utica de la \nterapia antineopl\u00e1sica oral en la paciente conllev\u00f3 a la realizaci\u00f3n de una  consulta de \natenci\u00f3n farmac\u00e9utica onco-hematol\u00f3gica, proporcionando informaci\u00f3n relativa a l os \nobjetivos terap\u00e9uticos, correcta administraci\u00f3n, efectos adversos y manejo de los \nmismos, as\u00ed como interacciones con tratamientos domiciliarios y de fitoterapia. D urante \nla entrevista, la paciente hizo referencia a un consumo regular de zumo de pomelo y una \ngran cantidad de productos de herborister\u00eda e infusiones: t\u00e9 verde, tila, manzanilla, \nhierba buena, hierba luisa, diente de le\u00f3n, hibisco y suplemento de aloe vera. En la Tabla \n2 se recogen las recomendaciones establecidas, en base a la informaci\u00f3n obtenida en la \nFicha T\u00e9cnica de ibrutinib3 y en la base de datos Memorial Sloan Kettering Cancer Center \n- Integrative medicine4. \n686Tabla 2. Efecto farmacocin\u00e9tico y recomendaci\u00f3n acerca de los productos consumidos \nProductos  Efecto farmacocin \u00e9tico Recomendaciones \nZumo de pomelo Inhibici\u00f3n CYP3A4: incremento de la \nexposici\u00f3n a ibrutinib (AUC y Cm\u00e1x) en \naproximadamente 2 y 4 veces. No tomar zumo de \npomelo.  \nT\u00e9 verde  (Green \ntea) Inhibici\u00f3n CYP3A4: afecta a la \nconcentraci\u00f3n intracelular de ibrutinib. No tomar t\u00e9 verde. \nTila (Linden) No se encontr\u00f3 informaci\u00f3n. No fue posible \nconfirmar su seguridad. \nManzanilla \n(Chamomile ) Inhibici\u00f3n CYP3A4 in vitro: afecta la \nconcentraci\u00f3n intracelular de ibrutinib.  No tomar manzanilla. \nHierbabuena \n(Peppermint) Inhibici\u00f3n del CYP3A4: afecta a la \nconcentraci\u00f3n intracelular de ibrutinib.  No tomar hierbabuena. \nHierba luisa  \n(Lemon verbena) No se encontr\u00f3 informaci\u00f3n. No es posible confirmar \nsu seguridad. \nDiente de le\u00f3n \n(Lion\u00b4s tooth) Inhibici\u00f3n del CYP3A4 en modelos \nanimales e in vitro: afecta a la \nconcentraci\u00f3n intracelular de ibrutinib. No tomar diente de \nle\u00f3n. \nHibisco  (Hibiscus) No se encontr\u00f3 informaci\u00f3n. No fue posible \nconfirmar su seguridad. \nAloe vera Inhibici\u00f3n del CYP3A4: afecta a la \nconcentraci\u00f3n intracelular de ibrutinib.  No tomar Aloe vera. \n \n2.- Integraci\u00f3n del farmac\u00e9utico hospitalario en el equipo multidisciplinar : El caso \ncl\u00ednico que se presenta es muy complejo, poniendo de manifiesto la polivalencia del \nfarmac\u00e9utico hospitalario no solo en la colaboraci\u00f3n para la b\u00fasqueda de los diferentes \nagentes implicados en la reacci\u00f3n t\u00f3xico-cut\u00e1nea. El farmac\u00e9utico hospitalario jug\u00f3 un \npapel clave relevante en: 1) aspecto nutricional con la sele cci\u00f3n conjunta al Servicio de \nEndocrinolog\u00eda y validaci\u00f3n de una nutrici\u00f3n artificial que permitiera llegar a unos \naportes energ\u00e9tico-proteicos adecuados para cubrir el gasto energ\u00e9tico; 2) participaci\u00f3n \nactiva en el equipo PROA implic\u00e1ndose en la selecci\u00f3n de la antibioterapia m\u00e1s eficiente, \nteniendo en cuenta el contexto de una paciente con sensibilidad incrementada a \nf\u00e1rmacos as\u00ed como alteraci\u00f3n hep\u00e1tica; 3) validaci\u00f3n y elaboraci\u00f3n o adquisici\u00f3n de \ndiferentes productos de aplicaci\u00f3n cut\u00e1nea tras la recomendaci\u00f3n por el Servicio de 687Dermatolog\u00eda y; 4) validaci\u00f3n del tratamiento quimioter\u00e1pico administrado durante el \ningreso, as\u00ed como colaboraci\u00f3n con el Servicio de Hematolog\u00eda en el planteamiento de \nun tratamiento futuro frente a la LLC en el contexto de intolerancia a ibrutinib, pudiendo \nrepetirse un tratamiento de primera l\u00ednea, en este caso con obinutuzumab+venetoclax, \nsiendo un tratamiento financiado5 y recogido en las principales gu\u00edas de pr\u00e1ctica cl\u00ednica \n(European Society for Medical Oncology6 y National Comprehensive Cancer Network7). \nBIBLIOGRAF\u00cdA \n1.  Gordon MJ, Danilov AV. The evolving role of Bruton\u2019s tyrosine kinase inhibitors in \nchronic lymphocytic leukemia. Therapeutic Advances in Hematology. 2021; \n12:204062072198958.  \n2.  Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Dermatological \nToxicities of Bruton\u2019s Tyrosine Kinase Inhibitors. Am J Clin Dermatol.  \n2020;21(6):799-812.  \n3.  Fichas T\u00e9cnicas de los Medicamentos [Internet]. Disponible en: \nhttps://cima.aemps.es/cima/publico/home.html \n4.  Memorial Sloan Kettering Cancer Center - Integrative medicine [Internet]. \nDisponible en: https://www.mskcc.org/cancer-care/diagnosis-\ntreatment/symptom-management/integrative -medicine/herbs/search \n5.  BIFIMED: Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los \nmedicamentos [Internet]. Disponible en: \nhttps://www.sanidad.gob.es/profesionales/medicamentos.do  \n6.  Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et  al. Chronic \nlymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment \nand follow-up. Annals of Oncology. 2021;32(1):23-33.  \n7.  Chronic lymphocytic leukaemia / Small Lymp hocytic Lymphoma - Version 2.2022 \n[Internet]. NCCN; 2022. Disponible en: \nhttps://www.nccn.org/professionals/physician_gls/pdf/cll.pdf \n \n 688Necr\u00f3lisis epid\u00e9rmica t\u00f3xica secundaria  a f\u00e1rmacos antipal\u00fadicos  \nIntroducci\u00f3n  \nLa necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET)  o s\u00edndrome de Lyell  es una reacci\u00f3n mucocut\u00e1nea \ngrave de tipo inmunol\u00f3gico que se caracteriza por necrosis epid\u00e9rmica extensa y \ndespegamiento cut\u00e1neo . Presenta una  incidencia estimada de 0,4 -1,4 casos por mill\u00f3n \nde habitantes/ a\u00f1o y una tasa de mortalidad de entre el 25% al 70% (1) , por lo que se \nconsidera  el tipo de reacci\u00f3n adversa cut\u00e1nea grave (RACG) con mayor \nmorbimortalidad asociada.  \nEl factor etiol\u00f3gico m\u00e1s com\u00fan es el  farmacol\u00f3gico , siendo el alopurinol, los \nantibi\u00f3ticos (especialmente sulfonamidas y penicilinas), los antiinflamatorios no \nesteroideos (AINES) y los antiepil\u00e9pticos (carbamazepina, fenobarbital y fenito\u00edna), los \nf\u00e1rmaco s m\u00e1s frecuentemente asociados  (1-3).  \nEl tratamiento consiste  en la interrupci\u00f3n inmediata del f\u00e1rmaco responsable y en  la \naplicaci\u00f3n de  medidas de soporte  vital  dado el alto riesgo de sepsis y p\u00e9rdida de la \nhomeostasis cut\u00e1nea . Adem\u00e1s, es habitual el uso de tratamientos complementarios  \npara controlar la respuesta inflamatoria.  Destacan en la literatura: f\u00e1rmacos \ninmunomoduladores (corticoides,  inmunoglobulinas  (IGIV) , ciclosporina  y agentes \ncontra el factor de necrosis tum oral al fa, como etanercept) , as\u00ed como  t\u00e9cnicas que \nfavorecen la eliminaci\u00f3n del f\u00e1rmaco desencadenante (di\u00e1lisis y plasmaf\u00e9resis). No \nobstante, la evidencia de estos estudios es todav\u00eda insuficiente y controvertida (4,5) , \nsiendo la combinaci\u00f3n de corticoides con IGIV la \u00fanica alternativa que demostr\u00f3 de \nforma significativa  reducir la mortalidad en un metaan\u00e1lisis reciente (6).  \n 689Descripci\u00f3n del caso  \nHombre de 55 a\u00f1os, sin alergias medicamentosas ni h\u00e1bitos t\u00f3xicos conocidos. No \npresenta antecedentes patol\u00f3gicos de  inter\u00e9s ni toma mediaci\u00f3n  de forma  habitual. Se \ntrata de un paciente que realiza viajes recurrentes a \u00c1frica por motivos laborales.  \nEl paciente realiz\u00f3 un viaje reciente a Ben\u00edn, que tuvo una duraci\u00f3n aproximada de un \nmes. En este viaje se le paut\u00f3 la pr ofilaxis antipal\u00fadica oral con atova quona \n250mg/ proguanil 100mg, el cual  inici\u00f3 dos d\u00edas antes de viajar. Al cuarto d\u00eda de \ntratamiento  (d\u00eda +2 del viaje ), el paciente decidi\u00f3 suspender el tratamiento por mala \ntolerancia gastrointestinal. Dos d\u00edas m\u00e1s tarde  (d\u00eda +4 ), el pacient e inici\u00f3 una pauta \nprofil\u00e1ctica con sulfadoxina 500mg/ pirimetamina 25mg  (3 comprimidos /24h  durante \n21 d\u00edas ). Al d\u00eda +25, en una anal\u00edtica de control laboral previa a su regreso, se detect\u00f3 \npaludismo residual, por lo que se inici\u00f3 tratamiento antipal\u00fadico oral con \nsulfametoxipirazina 500mg/ artesunato 200mg/ pirimetamina 25mg  (1 comprimido /24h  \ndurante 3 d\u00edas ). A las 24 horas, el paciente present\u00f3 un cuadro de prurito e irritaci\u00f3n \ncut\u00e1n ea por lo que se modific\u00f3 su tratamiento antimal\u00e1rico  por artemeter \n20mg/ lumefantrina 120mg. Al d\u00eda siguiente  (d\u00eda + 27), el paciente sigui\u00f3 con prurito y \npresent\u00f3 empeoramiento cl\u00ednico con  aparici \u00f3n de  placas eritematosas en tronco y \nconjuntivitis, por lo que se decidi \u00f3 suspender dicho f\u00e1rmaco.  \nEn el  d\u00eda +28, el paciente viaj\u00f3 de nuevo a Espa\u00f1a  y, dos d\u00edas m\u00e1s tarde, acudi\u00f3 a \nurgencias por empeoramiento sintom\u00e1tico . En Urgencias, estaba consciente y \norientado , febril e hipertenso. En la exploraci\u00f3n f\u00edsica destacaba la presencia de \nm\u00e1culas eritematosas confluentes y de centro parduzco, en forma de dianas at\u00edpicas, \ncon afectaci\u00f3n del 45% de la superficie corporal . Adem\u00e1s, presentaba  \u00e1reas de 690despegamiento epid\u00e9rmico  con formaci\u00f3n de ves\u00edculas fl\u00e1cidas a nivel pectoral  y signo \nde Nikolsky positivo . A nivel mucoso, destacaba la presencia de erosiones labiales con \nformaci\u00f3n de costras, enantema perianal, hiperemia conjuntival  y \u00falceras bien \ndelimitadas a nivel del glande  (Figu ra 1a -c). El SCORTEN ( Score of Toxic Epidermal \nNecrosis ) al ingreso era de 2. Se orient\u00f3 el cuadro como una NET y se deriv\u00f3 a la unidad \nde cuidados intensivos (UCI) para vigilancia estrecha . Dada la presencia de fiebre y la \nelevaci\u00f3n de reactantes de fase aguda ( prote\u00edna C reactiva (7,72mg/dL) y \nprocalcitonina (0 ,8 ng/mL) ) se extrajeron cultivos y se inici\u00f3 antib ioticoterapia  \nintravenosa  emp\u00edrica con ceftriaxona (1g/12h) y clindamicina (600mg/8h).  Al tratarse \nde un paciente que hab\u00eda estado recientemente e n una zona rural de Ben\u00edn, tambi\u00e9n \nse solicitaron: microfilarias en sangre, serolog\u00eda de Stongyloides  y frotis de gota gruesa \npara malaria. Se inici\u00f3 tratamiento intravenoso con IGIV a dosis de 0,5g/kg/d\u00eda durante \n4 d\u00edas y metilprednisolona a dosis de 1mg/ kg/d\u00eda durante 7 d\u00edas.  \nEl equipo m\u00e9dico se puso en contacto con el farmac\u00e9utico para estudiar el caso y \nrevisar que f\u00e1rmaco podr\u00eda ser el responsable del cuadro cl\u00ednico. Se revis aron  los \ntratamientos que hab\u00eda recibido el paciente y se objetiv\u00f3  una probable  correlaci\u00f3n \ncausal con la sulfadoxina/pirimetamina , por temporalidad ( 1-3 semanas tras inicio del \nf\u00e1rmaco) y mayor asociaci\u00f3n a f\u00e1rmaco s del grupo sulfamidas . Posteriormente, se \ncorrobor\u00f3 con la prueba  de proliferaci\u00f3n linfocitaria que fue positi va para  sulfadoxina. \nEn la entrevista cl\u00ednica con el paciente, se  detect\u00f3 que hab\u00eda tomado una dosis 21 \nveces superior a la indicada en profilaxis. Se revisaron los potenciales efectos adversos \nde la sobreexposici\u00f3n a  dicho f\u00e1rmaco  y se recomend\u00f3 la administraci\u00f3n de folinato \nc\u00e1lcico  endovenoso . Se valoraron alternativas para la eliminaci\u00f3n plasm\u00e1tica del \nf\u00e1rmaco , como  la plasmaf\u00e9resis o la hemodi\u00e1lisis, descart\u00e1ndose  la realizaci\u00f3n de 691hemodi\u00e1lisis debido a l bajo rendimiento de la t\u00e9c nica para la eliminaci\u00f3n de \nsulfadoxina/pirimetamina  (9). Se plane\u00f3  realizar plasmaf\u00e9resis en caso de evoluci\u00f3n \ndesfavorable  y de no responder al tratamiento con corticoides e IGIV .  \nPara las lesiones mucocut\u00e1neas se realizaron curas t\u00f3picas diarias , lavados con suero \nfisiol\u00f3gico 0,9% seguido s de fomentos de Goulard en genitales , y permanganato \npot\u00e1sico 3% en \u00e1re as denudadas. Se aplic\u00f3 fusidato de sodio  en crema en lesiones \ngenitales y en labios, y vaselina l\u00edquida est\u00e9ril en \u00e1reas no denudadas pero necr\u00f3ticas. \nFinalmente, se cubrieron to das las \u00e1reas ero sionadas con ap\u00f3sitos de b \u00e1lsamo de Per\u00fa  \ny aceite de ricino . El enan tema perioral fue tratado con la f\u00f3rmula magistral de \nsoluci\u00f3n para mucositis y dieta l\u00edquida. Adem\u00e1s, se llev\u00f3 a cabo un estricto c ontrol del \ndolor en las curas, con paracetamol, diazepam, morfina y fentanilo seg\u00fan tolerancia \ndel paciente.  A nivel ocular, se trat\u00f3 la hiperemia conjuntival con colirios \nantinflamatorios (colirio de prednisona al 1% (1 gota/4h)) y antibi\u00f3ticos (ofloxaci no al \n0,3% (1 gota/8h)).  \nPasados 6 d\u00edas del ingreso , el paciente present\u00f3 una evoluci\u00f3n favorable sin progresi\u00f3n \nde la necrosis cut\u00e1nea e inicio de focos de reepitelizaci\u00f3n . Los cultivos microbiol\u00f3gicos  \nfueron negativos,  as\u00ed como la determinaci\u00f3n de  microfilarias en sangre, la serolog\u00eda de \nStrongyloides  y el frotis de gota gruesa para malaria. El tratamiento antibi\u00f3tico se \nmantuvo hasta completar un total de 7 d\u00edas.  \nA los 12 d\u00edas de ingreso, el paciente pudo ser trasladado a la sala de dermatolog\u00eda c on \nuna completa reepitelizaci\u00f3n cut\u00e1nea, mejor\u00eda de las lesiones en mucosa oral y genital, \ny disminuci\u00f3n de la fotofobia y la quemosis ocular. A los 14 d\u00edas fue dado de alta 692continuando el tratamiento con  corticoides orales en pauta descendente, colirios \nantibi\u00f3ticos , antinflamatorios y curas cut\u00e1neas.  \nEn el momento actual,  pasados 4 meses del cuadro cl\u00ednico, el paciente se encuentra \nasintom\u00e1tico , sin xerosis ni lesiones inflamatorias. Presenta m\u00faltiples m\u00e1culas  \nhiperpigmentadas coalescentes en tronco y extremidades , sin  lesiones a niv el de la \nmucosa oral (Figuras 1d -f). A nivel ocular, continua en tratamiento de la hiperemia \nconjuntival.  \n \n \n \n \n \n \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica  \nLa NET es una reacci\u00f3n mucocut\u00e1 nea grave que requiere un estricto control cl\u00ednico y \nfarmacoterap\u00e9u tico. Aunque en la literatura se encuentran series de casos y estudios \nobservacionales con diferentes tratamientos espec\u00edficos para este cuadro, la evidencia \nes todav\u00eda insuficiente , siendo la terapia combinada de corticoesteroides e IGIV  la que \nmayor evidencia posee en la reducci\u00f3n de la mortalidad.  El manejo de la NET se basa \nen identificar y suspender de forma precoz el f\u00e1rmaco  causal , y en aplicar medidas de \nsoporte para mantener la estabilidad hemodin\u00e1mica del paciente y prevenir \nFigura  1a-c. Necr\u00f3lisis epid\u00e9rmica t\u00f3xica s ecundaria a antimal\u00e1ricos. Exantema  macular confluente eritem ato-parduzco con \nafectaci\u00f3n del 45%  de la superficie cut\u00e1nea, con \u00e1reas de despegamiento cut\u00e1neo y presencia de ves\u00edculas fl\u00e1cidas. A nivel oral, se \nobservan erosiones superficiales con formaci\u00f3n de costras. Figura 1d -f. Evoluci\u00f3n  tras 4 meses. Resoluci\u00f3n de lesiones inflamatorias \nsin signos de necrosis epid\u00e9rmica, con importante presencia de hiperpigmentaci\u00f3n postinflamatoria residual.  a b c \nd e f 693complicaciones (4,5).  La ciclosporina y el etanercept son tratamientos alternativos, de \nevidencia a\u00fan limitada (6). \nEn el caso que nos ocupa, se evaluaron los f\u00e1rmacos tomados por el paciente y se \nseleccionaron aquellos susceptibles de  causar esta patolog\u00eda. Al tratarse de una \nreacci\u00f3n que suele aparecer durante los 7 -21 d\u00edas posteriores al inicio del f\u00e1rmaco \ndesencadenante (3), se analiz\u00f3 el tiempo transcurrido des de la toma de \u00e9stos hasta la \naparici\u00f3n de los s\u00edntomas. Se estableci\u00f3 una correlaci\u00f3n entre la administraci\u00f3n de \nsulfadoxina/pirimetamina entre los d\u00edas +4 y +2 4 y la aparici\u00f3n de lesiones d\u00e9rmicas \nsugestivas de NET el d\u00eda +25, es decir, 21 d\u00edas tras el  inicio del tratamient o. Se descart\u00f3 \nla sulfametoxipirazina como agente causal ya que el paciente \u00fanicamente hab\u00eda \ntomado una dosis el d\u00eda antes del inicio de los  de los primeros s\u00edntomas.   \nLa sulfadoxina/pirimetamia contiene u na sulfonamida, reportada como uno de los  \nf\u00e1rmacos asociados con mayor frecuencia a esta reacci\u00f3n mucocut\u00e1nea (2,3, 7). Este \ncuadro se ha observado con mayor prevalencia en pacientes que recibieron dosis \nm\u00faltiples -genera lmente utilizadas en profilaxis - siendo  menor esta asociaci\u00f3n en los \nque recibieron dosis \u00fanicas utilizadas en el tratamiento de la malaria ( 8).  \nA pesar de tratarse de una reacci\u00f3n idiosincr\u00e1tica no dependiente de la dosis, en el \npaciente se evidenci\u00f3 que la exposici\u00f3n al f\u00e1rmaco hab\u00eda sido 21 veces superior a las \ndosis indicadas en prof ilaxis. Asimismo, se revisaron los principales efectos adversos \ndel f\u00e1rmaco implicado . Tanto la sul fadoxina como la pirime tamina son antagonistas del \n\u00e1cido f\u00f3lico y pueden causar mielotoxicidad, especialmente la pirimetamina. Para  \nevitar este efecto advers o se recomend\u00f3 tratar al paciente con folinato c\u00e1lcico 694endovenoso con dosis de 15mg al d\u00eda ( 9). El paciente no present\u00f3 signos de \nmielotoxicidad bajo este tratamiento.  \nLa eliminaci\u00f3n  del f\u00e1rmaco causante mediante di\u00e1lisis  es otra opci\u00f3n de tratamiento \npara facilitar su eliminaci\u00f3n.  Las caracter\u00edsticas farmacol\u00f3gicas que determinan la \neliminaci\u00f3n mediante esta t\u00e9cnica son: hidrosolubilidad, baja uni\u00f3n a prote\u00ednas \nplasm\u00e1ticas (UPP) y peso molecular  peque\u00f1o . En nuestro caso, se descart\u00f3 ya que \ntanto su lfadoxina como pirimetamina presen tan una UPP cercana al 90%  (9). De la \nmisma manera, se evalu\u00f3 alternativamente la realizaci\u00f3n de plasmaf\u00e9resis,  por haber \nsido descrita esta  t\u00e9cnica como  beneficiosa en  los pacientes refractarios al tratamiento \nde soporte y a la terapia sist\u00e9mica con corticoides (1,2). Sin embargo, dada la \nevoluci\u00f3n favorable del paciente dicho procedimiento finalmente no fue necesario . \nPor \u00faltimo, e l empleo de  ciclosporina , que tambi\u00e9n  se ha descrito como una \nalternativa para el tratamiento de la NET  (2,5) , se descart\u00f3 debido a su potencial \ntoxicidad hematol\u00f3gica.  El paciente descrito recibi\u00f3 tratamiento intravenoso con \nmetilprednisolona  a dosis de 1mg/kg/ d\u00eda e IGIV a dosis de 0, 5g/kg/ d\u00eda durante 4 d\u00edas , y \ntratamiento t\u00f3pico de las lesiones mucocut\u00e1neas, resultando en una evoluci\u00f3n \nfavorable.   \nAl alta, s e le indic\u00f3  al paciente la necesidad de evitar el medicamento responsable , as\u00ed \ncomo  mol\u00e9culas con estructura  bioqu\u00edmica  similar por posibles reacciones cruzadas , \nespecialmente entre las sulfonamidas antibi\u00f3ticas (7).  \nFinalmente, cabe destacar el papel del farmac\u00e9utico hospitalario como miembro del \nequipo multidisciplinar que atendi\u00f3 este caso, aportando soluciones, revis ando el \ntratamiento  y las t\u00e9cnicas de eliminaci\u00f3n del f\u00e1rmaco causante .  695Bibliograf\u00eda  \n1. Nunes JM, Santareno S, Guerreiro L, Margalho AF. Lyell's Syndrome and \nAntimalarials: A Case Report and Clinical Review. J Glob Infect Dis. 2017 Jan -\nMar;9(1):23 -30.  \n2. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens -\nJohnson syndrome and toxic epidermal necrolysis. F1000Research. 202 0;9:1 -12. \n3. Bolognia JL, Schaffer JV, Duncan KO, Ko CJ . Dermatology Essentials. 2nd ed. Vol. 1. \nElsevier; 2021. 149 \u2013158 p.  \n4. Estrella -Alonso A, Aramburu JA, Gonz\u00e1lez -Ruiz MY, Cachafeiro L, S\u00e1nchez MS, Lo-\nrente JA. Necrolisis epid\u00e9rmica t\u00f3xica: un paradigma de enfermedad cr\u00edtica. Rev \nBras Ter Intensiva. 2017 Oct 1;29(4):499 \u2013508.  \n5. Gilbert M, Scherrer LA. Efficacy and safety of cyclosporine in Stevens -Johnson syn-\ndrome and toxic epidermal necrolysis. Dermatol Ther. 2019 Jan 1;32(1):1 -6. \n6. Tsai TY, Huang IH, Chao YC, Li H, Hsieh TS, Wang HH, et al. Treating toxic epidermal \nnecrolysis with systemic immunomodulating therapies: A systematic review and \nnetwork meta -analysis. J Am Acad Dermatol. 2021 Feb 1;84(2):390 \u20137. \n7. Dibbern DA, Montanaro A. Al lergies to sulfonamide antibiotics and sulfur -\ncontaining drugs. Ann Allergy Asthma Immunol. 2008;100(2):91 \u2013101.  \n8. St\u00fcrchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous \nadverse reactions to Fansidar? Drug Saf. 1993;8(2):160 \u20138. \n9. Product Information: Fansidar(R) pyrimethamine/sulfadoxine. Roche Laboratories, \nNutley, NJ, 1996.  696\n 1 ABORDAJE DE LA INTOXICACI\u00d3N POR M ETOTREXATO DESDE EL PUNTO DE VISTA DE \nLA FARMACOCIN\u00c9TICA \nINTRODUCCI\u00d3N \nEl metotrexato (MTX) es un an\u00e1logo estructural del \u00e1cido f\u00f3lico que act\u00faa inhibiendo \ncompetitivamente la enzima dihidrofolato reductasa (DHFR), la cual participa en la \nformaci\u00f3n del \u00e1cido fol\u00ednico que es necesario para la formaci\u00f3n del nucle\u00f3sido timidina, \nrequerido para la s\u00edntesis de ADN, ARN, timidilatos y prote\u00ednas1. \nEntre el 70-90% del MTX se elimina por v\u00eda renal. Las toxicidades m\u00e1s frecuentes de MTX \nson pulmonar, hep\u00e1tica, hematol\u00f3gica y renal. En caso de fallo renal agudo, el \nmetotrexato se mantiene m\u00e1s tiempo en el organismo, aumentando su potencial efecto \nt\u00f3xico sobre otros \u00f3rganos. Cuando se utiliza a dosis altas (\u2265 500 mg/m2) se recomienda \nla monitorizaci\u00f3n de las concentraciones s\u00e9ricas de MTX. El objetivo de la monitorizaci\u00f3n \nes ajustar  la dosis de \u00e1cido fol\u00ednico necesaria para reducir la incidencia de efectos \nadversos2.  \nExisten dos f\u00e1rmacos de rescate para ayudar a la eliminaci\u00f3n del MTX: \u00e1cido fol\u00ednico  y \nglucarpidasa ; siendo el primero el de elecci\u00f3n y el segundo al que se recurre en caso de \nintoxicaciones graves debido a su elevado coste y  dificultad de adquisici\u00f3n.  \nEl \u00e1cido fol\u00ednico , tambi\u00e9n conocido como leucovorina  o factor citrovorum , es un \nan\u00e1logo del \u00e1cido f\u00f3lico que compite con e l MTX por la entrada en la c\u00e9lula, ya que \ncomparten el mismo transportador, por lo que act\u00faa eliminando el MTX a nivel \nintracelular . Adem\u00e1s, tambi\u00e9n repone el dep\u00f3sito de folato reducido necesario para la \ns\u00edntesis de ADN, ARN y prote\u00ednas3. Su forma habitual de comercializaci\u00f3n es el folinato \nc\u00e1lcico.  697\n 2 La glucarpidasa  es una carboxipeptidasa que metaboliza el MTX en \u00e1cido \ndiaminopteroico (DAMPA) y glutamato, pero  tambi\u00e9n va a metabolizar  al \u00e1cido fol\u00ednico \nen su principal metabolito 5-metiltetrahidrofolato, por lo que hay que dejar un espacio \nde tiempo de 2 a 4 horas entre la administraci\u00f3n de  \u00e9ste  y la glucarpidasa. A diferencia \ndel \u00e1cido fol\u00ednico, act\u00faa eliminando s\u00f3lo el MTX extracelular, por eso despu\u00e9s de su \nadministraci\u00f3n, hay que continuar con la pauta de \u00e1cido fol\u00ednico, para que termine de \neliminar el MTX que pueda quedar dentro de la c\u00e9lula. La administraci\u00f3n de una dosis \n\u00fanica de 50 UI/Kg IV disminuye los niveles de MTX en el 98% en los primeros 30 \nminutos4,5. \nAdem\u00e1s, se dispone  de sales biliares,  carb\u00f3n activado y re sincolestiramina , que tiene n \npor objeto secuestrar en el lumen gastrointestinal el MTX procedente del ciclo \nenterohep\u00e1tico, para, de este modo, incrementar el aclaramiento total del MTX. \n \u00c1cido fol\u00ednico  Glucarpidasa  \nMecanismo de acci\u00f3n  An\u00e1logo \u00e1cido f\u00f3lico.  \nCompite con el MTX por la \nentrada a la c\u00e9lula. Acci\u00f3n \na nivel intracelular. Metaboliza el MTX en \nDAMPA + glutamato. \nAcci\u00f3n a nivel extracelular. \nV\u00eda de administraci\u00f3n  IV, IM, oral (nunca IT) IV \nInicio terapia de rescate  36 h desde el inicio  36-48h desde el inicio  \nDosis  De 15 mg/m2 a 100 \nmg/m2 c ada 6h 50 UI/kg dosis \u00fanica \nTabla 1. Diferencias entre \u00e1cido fol\u00ednico y glucarpidasa. 698\n 3 DESCRIPCI\u00d3N DEL CASO:  \nSe trata de un v ar\u00f3n de 56 a\u00f1os, 78 kg y 172 cm, que acudi\u00f3 a urgencias por presentar \ncl\u00ednica inespec\u00edfica de debilidad generalizada, torpeza con ambas manos y trastorno de \nla marcha de dos semanas de evoluci\u00f3n. Tambi\u00e9n refiri\u00f3 a nivel cognitivo episodios  de \ndesorientaci\u00f3n puntuales y mayor enlentecimiento de pensamiento y habla. Se le realiz\u00f3 \nun TAC toraco-abdomino-p\u00e9lvico  y se observa ron n\u00f3dulos pulmonares y hep\u00e1ticos junto \ncon una masa adrenal izquierda sugestivos de met\u00e1stasis. Todos los hallazgos llevaron \nal diagn\u00f3stico de  Linfoma difuso de c\u00e9lulas grandes B (LDCGB).  \nRespecto a los antecedentes cl\u00ednicos , el paciente refiri\u00f3 Enfermedad Pulmonar \nObstructiva Cr\u00f3nica (EPOC) e infecci\u00f3n por  Virus de la Hepatitis C (VHC) tratado con \nInterfer\u00f3n en los 90. Se le realiz\u00f3 una serolog\u00eda siendo \u00e9sta positiva para VHC. D ada la \nausencia de fibrosis significativa y la toxicidad de los f\u00e1rmacos presentes en los \nesquemas de  linfoma, se decidi\u00f3 dar tratamiento primero para el linfoma (4 meses de \nduraci\u00f3n) e iniciar tratamiento para el VHC tras finalizar la quimioterapia, llevando a \ncabo controles estrictos de transaminasas y carga viral mensual. Tambi\u00e9n se le realiz\u00f3 la \nprueba del quantiferon,  siendo \u00e9st a positiva, por lo que se inici\u00f3 la profilaxis de \ntuberculosis con isoniazida  durante 9 meses.  \nPara el tratamiento del linfoma el paciente recibi\u00f3 el esquema R -CHOP y MTX a altas \ndosis (MTX AD). El esquema R-CHOP consta de 6 ciclos con la siguiente  combinaci\u00f3n de \nf\u00e1rmacos:  Rituximab 375 mg/m2, Ciclofosfamida 750 mg/m2, Doxorubicina  50 mg/m2, \nVincristina 1,4 mg/m2 y Prednisona  10 mg/d\u00eda. El MTX AD consta de 3 ciclos  de MTX a \ndosis de 1,5 g/m2 (5500 mg en el caso del paciente) en perfusi\u00f3n continua durante  24h.  699\n 4 Tras la administraci\u00f3n de los ciclos de MTX se monitoriz\u00f3 la eliminaci\u00f3n del f\u00e1rmaco en \nsangre y se realizaron los correspondientes rescates con \u00e1cido fol\u00ednico, comenzando por \ndosis de 60 mg/m2 hasta dosis de 15 mg/m2 seg\u00fan la velocidad de eliminaci\u00f3n.   \nEn los dos primeros ciclos la eliminaci\u00f3n suced i\u00f3 de manera adecuada,  pero tras la \nadministraci\u00f3n del tercer ciclo de MTX AD, el paciente debut\u00f3 con un cuadro de  fallo \nrenal agudo. El f\u00e1rmaco se eliminaba muy lentamente y, a pesar de los rescates con \n\u00e1cido fol\u00ednico, fue necesario recurrir a la administraci\u00f3n de una dosis de glucarpidasa .  \nEn ese tercer ciclo de MTX AD, la infusi\u00f3n comenz\u00f3 tras conseguir alcalinizaci\u00f3n del pH \nen orina  y finaliz\u00f3 a las 24h sin complicacione s inmediatas. A las 36h post-inicio de la \ninfusi\u00f3n de MTX se objetiv \u00f3 en la anal\u00edtica deterioro de la funci\u00f3n renal con un aumento \nde la creatinina de 0,87 mg/dL a 1,96 mg/dL. Los niveles de MTX se encontraban \nelevados (>3mcM/L) por lo que se mantuvieron  los rescates con \u00e1cido fol\u00ednico a dosis de \n30 mg/m2 cada 6h y se ajust\u00f3 la fluidoterapia. Mientras,  se le realiz\u00f3 al paciente un \nestrecho control farmacocin\u00e9tico cada 12 horas, as\u00ed como  del pH urinario y funci\u00f3n  \nrenal.  \nEn el d\u00eda +3, por persistencia del deterioro de la funci\u00f3n renal y niveles elevados de MTX, \nse aument\u00f3 la dosis de \u00e1cido fol\u00ednico a 100 mg/m2 cada 6h y, se le administr\u00f3 una dosis \n\u00fanica de glucarpidasa  de 3000 UI (Voraxaze \u00ae), dejando pasar 4 horas horas entre la \nadministraci\u00f3n de \u00e1cido fol\u00ednico y glucarpidasa, tanto antes como despu\u00e9s de la \nadministraci\u00f3n de esta \u00faltima cuando se vuelve a reanudar la pauta con \u00e1cido fol\u00ednico.  \nCon la administraci\u00f3n de glucarpidasa, se observ \u00f3 un ligero aumento de la Cp de MTX \nen las determinaciones realizadas en las 48 horas posteriores, pero despu\u00e9 s se consigu i\u00f3 \nun descenso r\u00e1pido de los niveles de MTX. Se administr\u00f3 tambi\u00e9n una dosis de 700\n 5 rasburicasa  por hiperuricemia .  Se consult\u00f3 con nefrolog\u00eda que descart\u00f3 fracaso renal \npor necrosis tubular aguda y ajust\u00f3 la fluidoterapia.  \nEn los d\u00edas posteriores se mantuvieron los  rescates con leucovorina 15 mg/m\u00b2 cada 3h \ndado que la eliminaci\u00f3n de MTX continu\u00f3 siendo muy lenta y adem\u00e1s se a\u00f1ad i\u00f3 \nresinc olestiramina 4g cada 6h. \nEn el d\u00eda +15, la funci\u00f3n renal comenz\u00f3 a mejorar con un descenso de la creatinina desde \n3,3 mg/dL hasta 1,89 mg/dL. Finalmente elimin\u00f3 totalmente todo el MTX 18 d\u00edas \ndespu\u00e9s del inicio de la infusi\u00f3n, siendo la Cp de 0,01 mcM/L. \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA:  \nEl seguimient o del paciente  desde el Servicio de Farmacia (SF) y las recomendaciones se \nrealizaron siguiendo el PNT elaborado y revisado en febrero de 2022 por el SF, en \ncolaboraci\u00f3n con el Serv icio de Hematolog\u00eda. Dicho PNT se basa e n el protocolo LAL-\nAR/2011 del grupo PETHEMA.  \n1. Revisi\u00f3n y seguimiento  farmac\u00e9utic o: \nEl farmac\u00e9utico valid\u00f3 que las condiciones previas, durante  y tras la administraci\u00f3n del \nMTX  fueron las adecuadas. Estas fueron : \n- Hidrataci\u00f3n y alcalinizaci\u00f3n de la orina: es necesario asegurar que el paciente \nmantiene una buena hidrataci\u00f3n y alcalinizaci\u00f3n urinaria. Desde las 12 hora s \nantes de la infusi\u00f3n de MTX hasta la finalizaci\u00f3n del tratamiento de rescate , se \nadministraron 3000 mL/m2 y d\u00eda, a repartir entre suero glucosalino y suero \nbicarbonatado a fin de mantener un pH en orina mayor a 7,5 antes, durante y al \nmenos 48h despu\u00e9s de la infusi\u00f3n.  701\n 6 - Control diario de creatinina, bilirrubina, GOT y GPT: junto con la monitorizaci\u00f3n \nde la concentraci\u00f3n plasm\u00e1tica (Cp) del f\u00e1rmaco,  la creatinina es un \ndeterminante importante en el proceso de eliminaci\u00f3n de MTX.  \n2. Monitorizaci\u00f3n de MTX: \nEl proceso de monitorizaci\u00f3n es crucial para establecer la terapia de  rescate con \u00e1cido \nfol\u00ednico  y/o glucarpidasa. Esta monitorizaci\u00f3n comenz\u00f3 a las 36 horas post-inicio de la \ninfusi\u00f3n y finaliz\u00f3 cuando la Cp de MTX se encontraba por debajo de 0, 25 mcM/L.  \nSe recomienda un m\u00e9todo de cromatograf\u00eda de alta eficacia (HPLC) para medir las \nconcentraciones de MTX tras la administraci\u00f3n de glucarpidasa. Los inmunoan\u00e1lisis \nactuales son poco fiables para muestras recolectadas tras la administraci\u00f3n de \nglucarpidasa debido a que el DAMPA, un metabolito activo de MTX que se forma \ndespu\u00e9s de la administraci\u00f3n de glucarpidasa, interfiere con la medici\u00f3n de la \nconcentraci\u00f3n de MTX. Esta interferencia resulta en una sobrevaloraci\u00f3n de la \nconcentraci\u00f3n de MTX. El efecto de la interferencia DAMPA disminuye con el tiempo a \nmedida que se elimina el DAMPA4. No obstante,  en la pr\u00e1ctica real son pocos los SF que \ndisponen de esta t\u00e9cnica, siendo la de inmunoan\u00e1lisis la que se utiliz\u00f3 para medir la \nconcentraci\u00f3n del f\u00e1rmaco. Esto explica el ligero aumento que se observ\u00f3 al medir la Cp \nde MTX tras la administraci\u00f3n de la glucarpidasa.  \n3. Adquisici\u00f3n y validaci\u00f3n farmac\u00e9utica de la glucarpidasa : \nDado el riesgo probable de intoxicaci\u00f3n cuando se da MTX a altas dosis, se dispone de \nun protocolo para la gesti\u00f3n de glucarpidasa, ya que se trata de un medicamento \nextranjero que se ha de tramitar  a trav\u00e9s de  la plataforma de \u201cGesti\u00f3n de Medicamentos 702\n 7 en Siuaciones Especiales\u201d de la AEMPS, por  lo que fue necesaria la realizaci\u00f3n de un \npr\u00e9stamo para disponer del f \u00e1rmaco en el momento. Este protocolo incluye los criterios \nde inicio de t ratamiento; estos son:  Cp de MTX > 30 mcM/L en las 36-48h post-inicio, \nincremento de la creatinina s\u00e9rica en m\u00e1s de un 100% en 24h tras la administraci\u00f3n del \nMTX y que no hayan pasado m\u00e1s de 48h desde el inicio de la infusi\u00f3n, pues teniendo en \ncuenta que la glucarpidasa act\u00faa e liminando en MTX extracelular,  cuanto m\u00e1s temprana \nsea la intervenci\u00f3n, mayor ser\u00e1 el beneficio.  \nEn conclusi\u00f3n, la disponibilidad de una unidad de farmacocin\u00e9tica cl\u00ednica en los \nhospitales donde se administra MTX a altas dosis es necesario para garantizar una \natenci\u00f3n continuada a los pacientes en colaboraci\u00f3n con el equipo de  hemat\u00f3logos y de \nenferme r\u00eda, permitiendo la detecci\u00f3n temprana de las intoxicaciones por MTX. Lo que  \nse traduce en unos resultados \u00f3ptimos, en el menor tiempo posible y sin secuelas para \nel paciente.  \nBIBLIOGRAF\u00cdA: \n1. Metotrexato. Ficha t\u00e9 cnica  del medicamento. Agencia Espa\u00f1ola del Medicamento \ny Productos Sanitarios.  Disponible en:  \nhttps://cima.aemps.es/cima/publico/home.html  \n2. LaCasce A. Therapeutic use and toxicity of high-dose methotrexate. UpToDate \n2019. Disponible en: https://www.uptodate.com/contents/therapeutic-use -and-\ntoxicity -of- high -dose -methotrexate.  \n3. Folinato c\u00e1lcico. Ficha t\u00e9cnica del medicamento. Agencia Espa\u00f1ola del \nMedicamento y Productos Sanitarios. Disponible en: \nhttps://cima.aemps.es/cima/publico/home.html 703\n 8 4. Voraxace\u00ae. Ficha t\u00e9cnica del medicamento. Agencia Espa\u00f1ola del Medicamento y \nProductos Sanitarios. Gesti\u00f3n de Medicamentos en Situaciones Especiales. \nDisponible en: https://mse.aemps.es/mse (fecha de consulta: 05/2022)  \n5. P\u00e1gina web \u201cRed de Ant\u00eddotos\u201d: Disponible en: https://redantidotos.org/  \n 704ACTUACI\u00d3N DEL FARMAC\u00c9UTICO EN LA INTERACCI\u00d3N DE COLIRIOS PARA EL \nTRATAMIENTO DE LA ENDOFTALMITIS INFECCIOSA.  \nAUTORES:  Zamorano M\u00e9ndez P,  Mart\u00edn de Rosales Cabrera AM , Herrera Carranza S, \nS\u00e1nchez Pascual B, Salvador Llana I, P\u00e9rez Encinas M.  \nINTRODUCCI\u00d3N  \nLa endoftalmitis  se define como afecci\u00f3n inflamatoria del ojo desencadenada por la \nentrada de microorganismos al interior del globo ocular  \u00b9. La gravedad y la evoluci\u00f3n  \ncl\u00ednica est\u00e1 relacionada con la virulencia y el in\u00f3culo de bacterias infecciosas, el tiempo \nhasta el diagn\u00f3stico y el estado inmunitario del paciente. Es clave un diagn\u00f3stico cl\u00ednico \nprecoz y actuaci\u00f3n  inmediat a por lo que se recurre en primera instancia a el tratamiento \nemp\u00edrico basado en vancomicina y ceftazidima en formulaci\u00f3n intrav\u00edtrea o t\u00f3pica \n(colirio )2. Ambos antimicrobianos no cuentan con formas farmac\u00e9uticas comercializadas \npara su administraci\u00f3n por v\u00eda ocular, por ello la actuaci\u00f3n del servicio de farmacia es \nclave en el abordaje terap\u00e9utico de la patolog\u00eda.  \nDESCRIPCI\u00d3N DEL CASO  \nMujer de 74 a\u00f1os que acude al servicio de Urgencias M\u00e9dicas del hospital por presentar  \nescozor, lagrimeo y sensaci\u00f3n de cuerpo extra\u00f1o en el ojo i zquierdo de  dos d\u00edas  de \nevoluci\u00f3n (26/10/2021 ). Comunica que ha realizado lavados con agua del grifo de sus \nlentes de contacto en d\u00edas previos y no presenta lega\u00f1as.  \nComo antecedentes personales destaca ser portadora de lentes de contacto. No \npresenta reacciones al\u00e9rgicas a  medicamentos conocidas , ni acontecimiento s m\u00e9dico s \nprevio s relevante s. 705Se le realiz a una exploraci\u00f3n por parte del servicio de oftalmolog\u00eda , presen tando una \nagudeza visual con correcci\u00f3n en el ojo izquierdo (ojo afectado) de 0, 05 (la previa era de \n0,3). En la  biomicroscopia se observ a edema corneal central, abundantes pliegues en la \nmembrana de Descemet y queratitis punteada superficial difusa. La presi\u00f3n intraocular \nresult a ser de 14mmHg [VN: 10 -20 mmHg].  Adem\u00e1s, se solicita  una muestra de raspado \ncorneal para su an\u00e1lisis microbiol\u00f3gi co. \nTras  la exploraci\u00f3n el juicio cl\u00ednico es de  una queratitis disciforme herp\u00e9tica en OI.  \nComo plan terap\u00e9utico se opta por colocar a la paciente una lente de contacto \nterap\u00e9utica (LDCT) y se le prescribe:  \n\u27a2 VIA OCULAR  TOPICA : \n- Colirio ciclopl\u00e9jico cada 8 h oras  \n- Colirio de tobramicina ( Tobra bact\u00ae) cada 8 horas.  \n- Colirio de dexamentasona ( Maxidex\u00ae ) cada 8 horas.  \n- L\u00e1grimas artificiales Systane\u00ae para hidrataci\u00f3n ocular cada 3 horas.  \n\u27a2 VIA ORAL:  \n- Valaciclovir de 1 G. ( Valtrex \u00ae) cada  8 horas.  \n- Analgesia oral, si precisa .  \n \nLa paciente a pesar de la medicaci\u00f3n comercial pautada  presenta en d\u00edas posteriores un  \nagravamiento  de su sintomatolog\u00eda . \nSe le realiza de nuevo una exploraci\u00f3n oftalmol\u00f3gica y en esta ocasi\u00f3n presenta \namaurosis en el ojo afectado. En la biomicroscopia se observa endoftalmitis secundaria \na absceso corneal, con hipopion que ocupa el cuarto inferior.  \nEstablecido el diagn\u00f3stico  cl\u00ednico  de endoftalmitis aguda,  la actuaci\u00f3n fue de urgencia , \ndebido a que en estos casos el pron\u00f3stico visual final  puede cambiar en funci\u00f3n de la \nrapidez de actuaci\u00f3n.  706Por ello, el servicio de oftalmolog\u00eda solicita  al servicio de farmacia del hospital \ninyecciones intrav\u00edtreas de vancomicina y ceftazidima, para realizar su administraci\u00f3n a \nla mayor brevedad posible.  \nEl servicio de farmacia cuenta con un stock siempre disponible de jeringas  intrav\u00edtreas \nde urgencia de ceftazidima y vancomicina  preparadas en jeringas listas para su \nadministraci\u00f3n , para  urgencias  en el tratamiento emp\u00edrico de endoftalmitis5. La \npreparaci\u00f3n se realiza en condiciones de asepsia en una cabina de flujo laminar \nhorizontal en sala blanca,  envas\u00e1ndose en una bolsa est\u00e9ri l correctamente etiquetada \nen la parte externa, siguiendo la normativa que marca la Gu\u00eda de buenas pr\u00e1cticas de \npreparaci\u00f3n de medicamentos en servicios de farmacia hospitalaria ( GBPP)3. \nPara completar el tratamiento emp\u00edrico , dado la gravedad del cuadro , se completa la \nprescripci\u00f3n con  colirios reforzados de ambos antibi\u00f3ti cos (vancomicina y ceftazidima).  \nLa paciente, por tanto, fue derivada a farmacia para la dispensaci\u00f3n de las formulaciones \npautadas.  \nEl servicio de farmacia tiene una consulta  de atenci\u00f3 n individualizada para pacientes con \ntratamientos  y f\u00f3rmulas magistrales  elaborados por el \u00e1rea de farmacotecnia, donde \npacientes con preparados oft\u00e1lmicos como e l del caso, realizan sus visitas de inicio de \nmedicaci\u00f3n, as\u00ed como sus visitas sucesivas de seguimiento.  En la dispensaci\u00f3n , el \nfarmac\u00e9utico que entrevista al paciente incluye informaci\u00f3n para su correcta \nadministraci\u00f3n  y conservaci\u00f3n, en especial en estos pacientes con esquemas \nposol\u00f3gicos complejos de administraci\u00f3n cada hora de di stintos colirios . Se inform\u00f3 \nsobre  la forma de aplicaci\u00f3n, tiempo de espera entre colirios, posibles efectos adversos \ny compatibilidades. La informaci\u00f3n se entrega por escrito pero la entrevista es crucial \npara este tipo de pacientes en estas situaciones a gudas que tienen poca capacidad de 707visi\u00f3n.  En la siguiente tabla  1 se explica el tratamiento pautado,  as\u00ed como su frecuencia \nde administraci\u00f3n.   \n  \nTRATAMIENTO  POSOLOG\u00cdA  \nVIA OCULAR  \nColirio reforzado de Vancomicina  50mg/mL  1 gota cada media hora durante el d\u00eda.  \n1 gota cada hora durante la noche  \nColirio reforzado de Ceftazidima  100mg/mL  1 gota cada media hora durante el d\u00eda.  \n1 gota cada hora durante la noche  \nColirio Moxifloxacino 5mg/ml (Vigamox\u00ae)  1 gota cada 1 hora hasta revisi\u00f3n  \nColirio ciclopl\u00e9jico  Cada 4 horas  \nVIA ORAL  \nLevofloxacino 500mg  1 comprimido cada 24 horas durante 14 \nd\u00edas \nValaciclovir 1G  Cada 12 horas. (Ya pautado, acabar envase)  \nIbuprofeno 400mg  Cada 12 horas  \nTabla 1: Plan terap\u00e9utico  \nEn el caso de nuestra paciente, en la visita de inicio se realiz a la dispensaci\u00f3n de los dos \ncolirios reforzados, se le ense\u00f1 a cual es la forma \u00f3ptima para su administraci\u00f3n y se hace \nespecial menci\u00f3n a la importancia de separar ambos colirios en un tiempo de al menos \nmedia hor a, por la posibilidad de formaci\u00f3n de precipitados  que tienen ambos principios \nactivos (vancomicina y ceftazidima), descrita en bibliograf\u00eda4. \nEn visitas de seguimiento  posteriores, la paciente nos informa que presenta  mala \ntolerancia del colirio reforzado  de vancomicina 50mg/mL .  \nDesde el servicio de farmacia se realiza una entrevista  a la paciente y nos refiere  que \ntras la  administra ci\u00f3n de  los colirios reforzados , el colirio de vancomicina  le provoca  un \ndolor intenso que le irradia hacia la cabeza y le aparecen peque\u00f1os  gr\u00e1nulos \nblanquecinos que nos muestra en la visita .  \nTomamos la decisi\u00f3n de comprobar in situ, si la preparaci\u00f3n estuviera por alg\u00fan motivo \nen mal estado y vemos que la misma se muestr a l\u00edmpida a la vista y con apariencia \norganol\u00e9ptica correcta. A continuaci\u00f3n, decidimos juntar ambos colirios  para ver el 708aspecto de l precipitado  (conocida la interacci\u00f3n de ambos principios activos4) en un \nmismo recipiente. Se adjunta foto  (imagen 1) con los precipitados .  \n \nImagen  1: Precipitados: interacci\u00f3n colirios de vancomicina y ceftazidima.  \nEl aspecto de los precipitados fue el mismo que el que presentaba la paciente en la \nsuperficie ocular.  \nAl descartarse el posible error de formulaci\u00f3n y confirmar se la interacci\u00f3n ya conocida \npor la bibliograf\u00eda4. Se c omprueba  si la paciente  se administra de forma adecuada los \ncolirios, tal y como explicamos  en la visita de inicio. La paciente nos refiere que separa \nmedia hora los  colirios  cuando los administra . Continuamos nuestra entrevista  para \ntratar de conocer el origen del problema  y nos percatamos  que la paciente deb e tener \nel conducto nasolagrimal obstruido,  ya que nos refiere ausencia de sabor tras la \nadministraci\u00f3n de cualquier colirio. Esta obstrucci\u00f3n justificar\u00eda  el contacto de ambas \nformulaciones y la aparici\u00f3n de la interacci\u00f3n con ocida, por el incremento de tiempo de \npermanencia de ambas formulaciones en la superficie ocular.  \nTras conocer el origen del problema de tolerancia de la paciente, se informa \ndebidamente al servicio de oftalmolog\u00eda.  Se valora la posible retirada del colir io de \nvancomicina,  pero se desestima, por los resultados  obtenidos en d\u00edas previos  del cultivo \ndel raspado corneal , realizado en la primera visita. Se adjunta imagen de antibiograma \n(imagen 2). Al presentar absceso corneal  se prefiere mantener el colirio de ceftazidima \npor incrementar el espectro antimicrobiano.   \n709 \nImagen 1:Antibiograma  \nFinalmente, ambos servicios  acordaron como mejor opci\u00f3n dentro de las propuestas , \nintercalar la administraci\u00f3 n de otro colirio con el fin de arrastrar  la formulaci\u00f3n  anterior \ny generar  que ambos colirios no coincid ieran  en el espacio ocular.  \nLa nueva formulaci\u00f3n que se utiliz\u00f3 para este fin fue el  colirio de medroxiprogesterona \nindicado para el alivio de la inflamaci\u00f3n local . Se anexa tabla 2 con nuevo plan \nterap\u00e9utico .  \n \nEl servicio de farmacia obtuvo de una farmacia formuladora externa este nuevo colirio. \nLa paciente continu \u00f3 con citas frecuentes por parte del servicio de oftalmolo g\u00eda y \nfarmacia donde se comprob\u00f3 su correcta evoluci\u00f3n, la buena tolerancia de las \nformulaciones  y se le asegur \u00f3 la dispensaci\u00f3n de todas las preparaciones, comprobando \nla correcta adherencia y administraci\u00f3n en cada una de sus visitas.  \nTRATAMIENTO  POSOLOG\u00cdA  OBSERVACIONES  \nVIA OCULAR  \nColirio reforzado de \nVancomicina 50mg/mL  1 gota cada 8 horas. Primero en administrarse  \nColirio reforzado de Ceftazidima \n100mg/mL  1 gota cada 8 horas. Administrar el \u00faltimo, tras el \ncolirio de medroxiprogesterona  \nColirio Medroxiprogesterona  1 gota cada 8 horas.  Intercalado entre los AB  \nLagrima artificial, Hyloparin\u00ae  1 gota cada 4 horas   \nColirio Moxifloxacino 5mg/Ml \n(Vigamox\u00ae)  1 gota cada 4 horas.  \nColirio ciclopl\u00e9jico  1 gota cada 4 horas.   \nColirio Neomicina / Polimixina B \n/ Dexametasona (Maxitrol\u00ae)  1 gota cada 8 horas.  \nLagrimas artificiales, Systane \ncomplete\u00ae  Hasta cuatro veces al d\u00eda.   \nVIA ORAL  \nDoxiciclina 100mg  1 comprimido cada 12 horas   \nTabla 2: Plan terap\u00e9utico  710Finalmente, tras v arios ajustes y cambios posol\u00f3gicos del plan terap\u00e9utico, el 7 de enero \nde 2022, tras tres meses en tratamiento antimicrobiano se realiza la retirada de los \ncolirios reforzados, al haberse resuelto la endoftalmitis bacteriana.  \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA  \n La patolog\u00eda ocular, cuenta con un gran vac\u00edo terap\u00e9utico que trata de solventarse \nmediante manipulaci\u00f3n, reformulaci\u00f3n o adaptaci\u00f3n a la v\u00eda ocular de formas \nfarmac\u00e9uticas fabricadas para su administraci\u00f3n por otras v\u00edas. Formas avaladas por El \nReal Decreto 1015/2009, que regula la disponibilidad de medicamentos en situaciones \nespeciales . La farmacia hospitalaria desempe\u00f1a un papel esencial en la fabricaci\u00f3n de \nformulaci\u00f3n magistral oft\u00e1lmica.  En el caso expuesto, el servicio de farmacia de nuestro \nhospital tuvo que formular  varias preparaciones por no disponerse en el mercado de \nninguna alte rnativa v\u00e1lida para el tratamiento de la paciente. Se adjunta  tabla 3  con las \nformulaciones que se realizaron.  \n Formulaci\u00f3n  Composici\u00f3n  Acondiciona -\nmiento  Matriz de riesgo \nmicrobiol\u00f3gico  Caducidad  \nColirio reforzado \nde vancomicina \n50mg/ml  Vancomicina 500mg: \n1vial.  \n \nFRASCO \nBEXEN  AAACCA  \nPreparaci\u00f3n de riesgo \nmedio.  9 d\u00edas / \nfrigor\u00edfico (2 \n\u02daC \u2013 8 \u02daC) 45 \nd\u00edas en \ncongelador \n(\u2264 -20 \u02daC)  Meinsol agua: 5mL  \n \nCol Liquifilm: 5mL  \nColirio reforzado \nde ceftazidima \n100mg/ml  Ceftazidima 1g: 1 vial  \nSoluci\u00f3n BSS: 5mL  \nMeinsol agua: 5mL  \nIntrav\u00edtrea de \nVancomicina 1 \nMG/0,1ML  Vancomicina 500mg: 1 \nvial JERINGA DE \nINSULINA.  \n \nBOLSA EST\u00c9RIL  ACACAA  \nPreparaci\u00f3n de riesgo \nmedio.  9 d\u00edas / \nfrigor\u00edfico (2 \n\u02daC \u2013 8 \u02daC) 45 \nd\u00edas en \ncongelador \n(\u2264 -20 \u02daC)  Meinsol agua: 20mL  \nintrav\u00edtrea de \nCeftazidima \n2,25MG/0,1ML  Ceftazidima 1g: 1 vial.  \nMeinsol agua: 20mL  \n     \nTabla 2: Formulaciones  711Una atenci\u00f3n farmac\u00e9utica personalizada y centrada en el paciente  es crucial , puesto \nque, la gravedad y la urgencia de las patolog\u00edas oft\u00e1lmica s oculares obliga a utilizar \nconcentraciones de antibi\u00f3tico de varios \u00f3rdenes de magnitud y posolog\u00edas frecuentes \nque dificultan la adherencia.  La necesidad de este servicio queda reflejada en el caso, la \npaciente nos visit\u00f3 un total de ocho veces,  detect\u00e1 ndose en una de estas visitas y \nsolucion\u00e1ndose  el problema  de interacci\u00f3n   \nFinalmente, el caso cl\u00ednico muestra la importancia del trabajo multidisciplinar y la \nnecesidad de colaboraci\u00f3n entre el servicio de oftalmolog\u00eda y farmacia. La complejidad \nde la pat olog\u00eda infecciosa requiere tanto de conocimientos cl\u00ednicos como gal\u00e9nicos para \nla elaboraci\u00f3n de la mayor\u00eda del arsenal terap\u00e9utico. Adem\u00e1s,  necesita de un \nseguimiento estrecho del paciente por ambas partes donde asegurar la concreta \nevoluci\u00f3n cl\u00ednica  del paciente .  \nBIBLIOGRAF\u00cdA:  \n1. Ferreiro AF. Formulaci\u00f3n magistral en oft\u00e1lmica infecciosa. SEFH.; 2019.  \n2. \u201cENDOFTALMITIS INFECCIOSA\u201d. Gu\u00edas de Pr\u00e1ctica Cl\u00ednica de la SERV\u201d. Disponible en \nwww.serv.es Copyright \u00a9 2011, Sociedad Espa\u00f1ola de Retina y V\u00edtreo.  \n3. Sani tarios P. Ministerio de sanidad, servicios sociales e igualdad direcci\u00f3n general de \ncartera b\u00e1sica de servicios del SNS y farmacia. Gob.es. Disponible en: \nhttps://www.sanida d.gob.es/profesionales/farmacia/pdf/GuiaBPP3.pdf  \n4. Trissel LA, Gilbert DL. Concentration dependen decy of vanconmycin  hydrochloride \ncompatibility with beta antibiotics during simulated Y -site administration.Hosp \nPharm.1998; 33:1515 -22. \n 712 \n7131 \n Introducci\u00f3 n \nExisten diferentes tipos de cirug\u00eda a la hora de trat ar un c\u00e1ncer de p\u00e1ncreas. La  t\u00e9cnica  \nm\u00e1s extendida es la duodenopancreatectom\u00eda  o Whipple , la operaci\u00f3n m\u00e1s com\u00fan \npara extirpar un c\u00e1ncer en la cabeza del p\u00e1ncreas. No obstante, hay pacientes con \nestad ios m\u00e1s avanzados  de la  enferm edad, en los que la cirug\u00eda de elecci\u00f3n es la  \npancreatect om\u00eda total.  \nEn esta operaci\u00f3n se extrae el p\u00e1ncreas por completo, la ves\u00edcula biliar, parte del \nest\u00f3mago e intestino delgado,  y el bazo. Es poco fre cuente porque presenta una \nelevada morbilidad .  \nCuando el p\u00e1ncreas se extirpa por completo, los pacientes carecen de las  c\u00e9lulas de los \nislotes de Langerhans , predominantes en la cola del p\u00e1ncreas , y responsabl es de la  \nfunci\u00f3n pancre\u00e1tica endocrina: La producci\u00f3n  de insulina y otras hormona s que \nayudan a mantener adecuados los niveles de glucosa  en sangr e. En consecuencia, \npueden presentar  diabetes  de dif\u00edcil contro l y depend iente  de insulina.  \nAdem\u00e1s , tambi\u00e9n necesita r\u00e1n suplem entos de  enzimas pancre\u00e1ticas para ayudar  a \ndigerir ciertos ali mentos. E n la cabeza del p\u00e1ncreas, se p roducen y liberan enzimas que \nintervienen en la digesti\u00f3n , entre ellas la amilasa, lipasa y proteasa, que constituyen la \nfunci\u00f3n pancre\u00e1tica exocrina.  Una insuficiencia pancre\u00e1tica exocrina tambi\u00e9n puede \nocasionar diarrea, gras as en heces (esteatorrea) y p\u00e9rdida de peso por mala absorci\u00f3n.  7142 \n Por tanto, tras la pancreatectom\u00eda  total se deber\u00e1 tratar la insuficiencia pancre\u00e1tica , \ntanto endocrin a como exocrina , y recomendar una dieta y suplementos  que puedan  \nser tolerad os por el nuevo aparato digestivo.  \nDescripci\u00f3 n del caso  \nPaciente de sexo femenino, de 57 a\u00f1os de edad , sin reacciones adversas \nmedicamentosas  ni alergias conocidas . Antecedentes personales : Hipertiroidismo \nautoinmune en tratamiento con carbimazol. Fumadora de 5 -6 cigarros al d\u00eda. \nAntecedentes familiares : Padre f allecido de linfoma no Hodgkin y m adre fallecida por  \ninsuficiencia re nal.  \nIngres\u00f3 e n febrero de 2022  en el  hospital por dolor abdominal, coluria, acolia, e \nictericia. Se realiz \u00f3 ecoendoscopia que reflej \u00f3 engrosamiento del col\u00e9doco distal.   Se \ndiagnostic\u00f3  de probable colangiocarcinoma , confirmado  con biopsia. El tumor  se \nextend\u00eda por todo el p\u00e1ncreas y la paciente fue sometida a pancreatectom\u00eda total , con \ncolecistectom\u00eda (extirpaci\u00f3n de la ves\u00edcula biliar), esplenectom\u00eda (extirpaci\u00f3n del bazo), \nextirpaci\u00f3n de parte del est\u00f3mago y duodeno, y dos anastomosis , bilioyeyunal y \ngastroyeyunal, por colangiocarcinoma.  \nTras la cirug\u00eda, e l Servicio de Farmacia  se encarg\u00f3 del seguimien to de la paciente. Se \ninici\u00f3 n utrici\u00f3n pare nteral total central  (NPT) ajusta da a sus necesidades energ\u00e9ticas  \ncon la f\u00f3rmula de Harris Benedic t. Su objeti vo con  65 kg de peso y 158 cm de altura  fue \nde 177 2 kcal al d\u00eda de gasto energ\u00e9tico total (GET), por tanto 27,2 kcal/kg/d\u00eda. Las \nnecesidades proteicas , con un grado de estr\u00e9s moderado de 2 correspondiente a \ncirug\u00eda mayor abdominal (1,7 g ramos  de prote\u00ednas/kg/d\u00eda), fueron  110 gramos de 7153 \n prote\u00ednas al d\u00eda . La NPT s e inici \u00f3 a la mitad de sus requerimientos para evitar el \ns\u00edndrome d e realimentaci\u00f3n , cuadro cl\u00ednico que engloba las alteraciones metab\u00f3licas \nque aparecen cuando a pacientes desnutridos, que se han mantenido  durante un \ntiempo en ayuno o semiayuno, se les inicia r\u00e1pidamente el soporte nutricional con \nelevados aportes de agua y  macronutrientes sin el apropiado refuerzo de  \nmicronutrientes . \nSe eligi\u00f3 la  nutrici\u00f3n parenteral central de tipo Smofkaviben Extra N itr\u00f3geno , debido a \nsu mayor contenido en amino\u00e1cidos, y su menor contenido en glucosa, en \ncomparaci\u00f3n con la nutrici\u00f3n parenteral Smofkaviben Central . Tras unos d\u00edas, se inici\u00f3 \ndieta pro gresi va, l\u00edquid a, semi  l\u00edqui da y blanda , a la vez que se redu jo la NPT a la mitad \nde los requerimientos nutricionales seg\u00fan la paciente fue tolerando  la dieta oral.  \nEn primer lugar, como se ha mencionado en la introd ucci\u00f3n, la extirpaci\u00f3n total del \np\u00e1ncreas ocasiona un d\u00e9ficit de insulina e hiperglucemia . Por tanto , es necesario el \ntratamiento con  insulina , que evitar\u00e1 descompensaciones metab\u00f3licas y el \nagravamiento de la desnutrici\u00f3n.  \nLa pauta de la paciente fue la siguiente:  Insulina  glargi na Lantus Solostar 100 u/ml  \n(pluma precargada de 3 ml ), 12 unidades subcut\u00e1neas antes de la cena , con \nautocontroles de glucemia capilar antes de desayuno, comida y cena.  En caso de  \nglucemias  mayores de 240 mg/d l, aumentar insulina Lantus 2 unidades al d\u00eda cada 2 \nd\u00edas.   Insulina  glulisina  Apidra Solostar 100 u/ml  (pluma precargada de 3 ml ), con \ncontroles de glucemia antes del desayuno, comida y cena, siguiendo las pautas : 7164 \n  \nPor otra parte, desde el Servicio de Farmacia s e recomend\u00f3 la toma de  prep arados \ncomerciales de enzimas pancre\u00e1ticas  amila sa-lipasa  (Kreon ), las cuales se toman con \nlos alimentos y ayudan a digerirlos y  asimilar sus nutrientes. La dosis necesaria por \ncomida var\u00eda entre 25000 -80000 UI de lipasa y la mitad de dosis individual en las \ncomidas ligeras . La pauta de  la paciente fue una c\u00e1psula de Kreon (25000 UI  de lipasa, \n18000 UI de Amilasa, 1000 UI de Proteasa) en cada comida principal.  \nTambi\u00e9n se explic\u00f3 a la paciente  los s\u00edntomas de alarma a nivel gastrointestinal : \nDiarrea, esteatorrea, meteorismo (distensi\u00f3n abdominal, gases) y  p\u00e9rdida de peso, \nasociados a la insuficien cia pancre\u00e1tica exocrina.  \nEn caso de diarrea, se limitar \u00e1 el consumo de alimentos ricos en fibra insoluble y que \nocasionen flatulencias. A dem\u00e1s de a umentar la ingesta de l\u00edquido para evitar \ndeshidrataci\u00f3n , y fraccionar las ingestas para facilitar  la tolerancia.  \n7175 \n Se incidi\u00f3  en la importan cia del an\u00e1lisis de las heces, que pueden  mostrar  alimentos \nparcialmente digeridos, lo que significa que no se asimila una proporci\u00f3n de lo \ningerido . O si las heces son flotantes, lo que indica  la presencia de grasa en estas.  \nAl alta se realizaron las siguientes recomendaciones diet\u00e9ticas para evitar \ncomplicaciones:  \nUna fuente de  grasa adecuada es el  aceite rico en triglic\u00e9ridos de cadena media (MCT) , \nque f acilita la absorci\u00f3n de l\u00edpidos, y el organismo puede asimilarlo  sin necesidad de \nsecreci\u00f3n pancre\u00e1tica , mejorando el aporte cal\u00f3rico . Se puede usar crudo, como ali\u00f1o, \npara saltear o a sar en el horno (160 -180\u00b0C  m\u00e1ximo) y tomar hasta 50 -60 ml al d\u00eda. No \ndebe usarse para fre\u00edr, ya que se oxida a altas temperaturas.  \nEs im portante saber  que las grasas vegetales crudas (aceite de oliva) se toleran mejor \nque las fritas . Por tanto, se priorizar\u00e1 el  aceite de oliva o girasol, no en grandes \ncantidades . \nSe deber\u00e1 e liminar de la dieta  alimentos con contenido graso elevado como l\u00e1cteos \nazucarados, carnes grasas, v\u00edsceras y \u00f3rganos, embutidos, productos de pasteler\u00eda o \nmanufacturados y salsas preparadas. Como sustituto podr\u00e1 consumir l\u00e1cteos \ndesnatados, carnes magras, pescado blanco, mol uscos y crust\u00e1ceos . \nEn cuanto a la ingesta de carbohidratos, el objetivo ser\u00e1 evitar la desnutrici\u00f3n y las \nhipoglucemias. Se recomend\u00f3 repartir los alimentos ricos en carbohidratos de forma \nuniforme en el d\u00eda, aumentando el n\u00famero de tomas.  Esta medida tambi\u00e9n es \u00fatil en \ncaso de n\u00e1useas o distensi\u00f3n abdominal, pues las tomas peque\u00f1as y repetidas (6 -7 \nveces al d\u00eda) se toleran mejor que las ingestas m\u00e1s copiosas.  7186 \n Los carbohidratos complejos tardan m\u00e1s en convertirse en glucosa  y ser asimilados por \nel organismo.  As\u00ed, no aumentan  los niveles de az\u00facar en sangre tan r\u00e1pidamente, como  \nocurre con  los carbohidratos simples. Por ell o, la dieta incluir \u00e1 carbohidratos \ncomplejos, como pan, patata, arroz, pasta, y si se puede, preferiblemente integrales. \nAs\u00ed como evitar az\u00facares simples si  se presentan s\u00edntomas de intolerancia a la glucosa \no evacuaci\u00f3n g\u00e1strica r\u00e1pida (s\u00edndrome de dumping).  \nEs imp rescindible  que la introducci\u00f3n de cada alimento sea por separado , para as\u00ed \npoder reconocer l a tolerancia o no al mism o; Y en caso de no tolerar, volver a probar \nunas semanas despu\u00e9s.  \nPor \u00faltimo, s e realiz aron diferentes  recomendaci ones en cuanto a  suplemen taci\u00f3n.  \nEn caso de no llegar a ingerir los requerimientos cal\u00f3ricos necesarios con la dieta , o \ndarse la situaci\u00f3n de desnutrici\u00f3n o posibilidad de la misma, ser\u00e1 necesaria la \nsuplementaci\u00f3n  con nutrici\u00f3n enteral. Es preciso comprobar su  tolerancia antes de dar \nel alta , para as\u00ed  realizar una pauta  adecuada y  realista .  \nLa paciente no toler\u00f3  estos supl ementos , pero l a nutrici\u00f3n enteral de elecci\u00f3n en el \ncaso de post operatorio de pancreatectom\u00eda total son las llamadas dietas pept\u00eddicas \n(Survimed ). Son f \u00f3rmulas donde el aporte nitrogenado es en for ma de oligop\u00e9ptidos, \nlos hidratos de carbono son hidrolizados de almid\u00f3n de ma\u00edz, y las grasas suelen ser \ngrasas vegetales y triglic\u00e9ridos de cadena media. Tambi\u00e9n tienen una osmolaridad m\u00e1s \nelevada que las dietas polim\u00e9ricas  y contribuyen al reposo pancre \u00e1tico.  \nSe detall\u00f3 a la paciente  la importancia de monitorizar los ni veles de vitaminas \nliposolubles (A, D, K, E), ya que no se absorben adecuadamente al no digerir bien las \ngrasas, y, en ausencia de \u00e1cidos biliares, una  fracci\u00f3n significativa de estas puede 7197 \n absorberse y salir del intestino con la sangre portal . Y, por tanto, podr\u00edan ser \nnecesarios  suplementos  vitam\u00ednicos . \nFina lmente, t ambi\u00e9n se destac\u00f3  la importancia de  monitorizar peri\u00f3dicamente \nmicronutrientes  cuyo lugar de absorci\u00f3n es predominantemente el duodeno, que ha \nsufrido una alteraci\u00f3n anat\u00f3 mica y  funcional al resecar  parte del mismo , como el \nhierro, calcio y \u00e1cido f\u00f3lico . Su absorci\u00f3n puede ser  insuficiente o deficitaria , y deber\u00e1 \ntomar suplement os para suplir estas carencias . \nDiscusi\u00f3n  y aportaci\u00f3n farmac\u00e9utica  \nLa cirug\u00eda de pancreatectom\u00eda  total requiere de m\u00faltiples tratamientos  y cuidados , \ntanto medicamentosos como nutricionales, para abordar  las complicaciones  derivadas \nde esta intervenci \u00f3n. Es importante concienciar al paciente de que se trata de un \nproceso de adaptaci\u00f3n a largo plazo, en el que finalmente se podr\u00e1 lograr una \nadecuada tolerancia , siempre que se sigan las indicaciones que se han descrito , tanto \nal in greso como al alta , por parte del farmac\u00e9utico y farmac\u00e9 utico - nutricionista .  \nEstas actuaciones  ponen en valor  la vital  funci\u00f3n de estas figuras en equipos \nasistenciales  hospitalarios . \nBibliograf \u00eda \nProtocolo de Nutrici\u00f3n Parenteral del Servicio de Farmacia  de la  Cl\u00ednica HLA \nVistahermosa, Alicante , Espa\u00f1a . \nGu\u00eda pr\u00e1ctica de  Nutri ci\u00f3n Artificial del Servicio de Farmacia  del Hospital Universitario \nSan Juan de Alicante, Alic ante, Espa\u00f1a.  7208 \n Perlas de conocimiento en nutrici \u00f3n cl\u00ednica: F\u00f3rmulas p ara el c\u00e1lculo de los \nrequerimientos nut ricionales del Servicio de Farmacia  del Hospital de D\u00e9nia  Marina  \nSalud  \nPerlas de conocimiento en nutrici \u00f3n cl\u00ednica: Transformaci\u00f3n de las  necesi dades \nnutricionales en una  f\u00f3rmula de nutrici\u00f3n parenteral  del \u00e1rea de Nutrici\u00f3n de  la Cl\u00ednica \nHLA Vistahermosa, Alicante , Espa\u00f1a . \nThe american cancer society . <https://www.cancer.org/es/cancer/cancer -de-\npancreas/tratamiento/cirugia.html >. [Consulta : 30 de m arzo  de 2022 ]. \nMorbimortalidad de la resecci\u00f3n pancre\u00e1tica  (2013), vol. 91, 10, p. 651-658. Revista de \ncirug\u00eda espa\u00f1ola.  Pontevedra.  [Consulta:   28 de m arzo  de 2022 ]. \n \n 721Optimizaci \u00f3n posol \u00f3gica de In fliximab guiada por \nmonitorizaci\u00f3n farmaco cin\u00e9tica en paciente con \nenfermedad de Crohn \nAutores: Serna Romero O, Buend\u00eda Bravo S, Gastalver Mart\u00edn C, Capilla Montes C, \nIglesias Bola\u00f1os AM, Cruz Cruz T.   \nINTRODUCCI\u00d3N  \nEl Infliximab (IFX) es un anticuerpo monoclonal quim\u00e9rico humano que inhibe e l factor \nde necrosis tumoral alfa (TNF alfa). Se caracteriza por ser una mol\u00e9cula grande e hidr\u00f3fila \nde distribuci\u00f3n predominantemente dentro del compartimento vascular. Las v\u00edas de \neliminaci\u00f3n no se han caracterizado y su semivida de eliminaci\u00f3n es larga, \naproximadamente de 13 d\u00edas (1). \nA pesar de posicionarse como un f\u00e1rmaco bien tolerado y seguro, existe una elevada \nvariabilidad inter e intraindividual de las concentraciones plasm\u00e1ticas del f\u00e1rmaco tras \nla administraci\u00f3n de dosis est\u00e1ndar. Esta variabilidad permite que a dosis est\u00e1ndar se \npuedan producir reacciones adversas al f\u00e1rmaco en algunos individuos (niveles \nsupraterap\u00e9uticos) o falta de eficacia al tratamiento (niveles infraterap\u00e9uticos).  \nAunque la causa de la presencia de concentraciones subterap\u00e9uticas del f\u00e1rmaco suele \nser multifactorial, existen variables conocidas que afectan a la farmacocin\u00e9tica de los \nanti-TNF alfa. Entre ellas se e ncuentran los mecanismos de inmunogenicidad, es decir, \nel desarrollo de anticuerpos contra IFX. La aparici\u00f3n de anticuerpos anti-f\u00e1rmaco se ha \nrelacionado con la aceleraci\u00f3n del aclaramiento plasm\u00e1tico del f\u00e1rmaco, disminuyendo \nsus concentraciones s\u00e9ricas y su efecto terap\u00e9utico (2). 722Existen tambi\u00e9n otros factores que influyen en el aclaramiento de IFX como la carga \ninflamatoria, la extensi\u00f3n y gravedad de la enfermedad, el nivel de alb\u00famina  y el peso . \nUna prote\u00edna C reactiva (PCR) alta, un \u00edndice de masa corporal elevado y un nivel de \nalb\u00famina baja se han asociado con aumento del aclaramiento del f\u00e1rmaco. Adem\u00e1s, la \nadministraci\u00f3n de inmunosupresores como azatioprina o metotrexato, pueden \naumentar las concentraciones del IFX, disminuyendo la formaci\u00f3n de los anticuerpos o \nel aclaramiento del f\u00e1rmaco (3).  \nPor todo lo anterior, la falta de respuesta primaria (paciente no responde a la terapia de \ninducci\u00f3n) o la p\u00e9rdida de respuesta secundaria (pierde la respuesta inicial con el \ntiempo) a IFX representa un desaf\u00edo en muchos pacientes. \nEn EC, debido a esta variabilidad de las concentraciones plasm\u00e1ticas, hasta un 40% de \nlos pacientes con una respuesta inicial luego experimentan una p\u00e9rdida secundaria de \nla respuesta que requiere un aumento de la dosis o un cambio a otro antagonista del \nTNF alfa para recuperar la respuesta (4). En este sentido, la introducci\u00f3n de modelos \nfarmacocin\u00e9ticos predictivos ayudar\u00eda a la correcta interpretaci\u00f3n de concentraciones \ns\u00e9ric as y la individualizaci\u00f3n posol\u00f3gica.  \nEl intervalo terap\u00e9utico de IFX todav\u00eda no est\u00e1 claramente establecido. Sin embargo, \nseg\u00fan los estudios publicados, en EC el intervalo terap\u00e9utico objetivo es de 3-7 mcg/ml \nen mantenimiento,  aunque este puede variar seg\u00fan el ensayo utilizado y el fenotipo de \nla enfermedad (5). En el caso de Adalimumab, el intervalo terap\u00e9utico para obtener \nrespues ta cl\u00ednica en mantenimiento es de 5 -10 mcg/ml (5).  \nPresentamos un caso cl\u00ednico de un paciente con concentraciones plasm\u00e1ticas \ninfraterap\u00e9uticas y persistencia de la cl\u00ednica intestinal de la Enfermedad de Crohn. Tras 723ajuste posol\u00f3gico de IFX guiado por monitorizaci\u00f3n farmacocin\u00e9tica, recuper\u00f3 niveles \nplasm\u00e1ticos con la consiguiente mejor\u00eda cl\u00ednica.  \nDESCRIPCI \u00d3N DEL CASO  \nSe trata de una mujer de 49 a\u00f1os diagnosticada de enfermedad de Crohn ileal \nestenosante  de debut en 2013 mediante entero-resonancia magn\u00e9tica. Desde 2013 se \nencuentra en tratamiento con Azatioprina (125 mg al d\u00eda). \nEn junio de 2014, debido a un aumento en la actividad se a\u00f1adi\u00f3 Adalimumab (inducci\u00f3n \nde 160 mg d\u00eda 1, 80 mg d\u00eda 14 y posteriormente mantenimiento con 40 mg en semanas \nalternas). Se mantuvo estable hasta febrero  del 2021 cuando ingres\u00f3 por i nfecci\u00f3n de \norina y se detect\u00f3 por tomograf\u00eda computarizada (TC) afectaci\u00f3n de \u00edleon distal-terminal \nen relaci\u00f3n con edema submucoso y realce mucoso, siendo tratada con ceftriaxona y \ncorticoterapia con respuesta cl\u00ednica favorable.  \nSe realiz\u00f3 control posti ngreso con colonoscopia y ecograf\u00eda intestinal que mostraron \npersistencia de actividad a pesar de tratamiento.  S\u00f3lo se realiz\u00f3 una determinaci\u00f3n de \nlas concentraciones plasm\u00e1ticas de Adalimumab el 15/02/2021 obteniendo niveles \ninfraterap\u00e9uticos (3.7 mcg/l) y anticuerpos negativos. \nAnte estos hallazgos se decidi\u00f3 cambio de biol\u00f3gico.   \nEl abril de 2021 tras completar estudio preanti-TNF  alfa,  se inici\u00f3 tratamiento con \nInfliximab intravenoso en combinaci\u00f3n con Azatioprina (IFX 5 mg/kg administrados en \nsemanas 0-2-6 y posteriormente cada 8 semanas).  En septiembre del 2021 en TC se \nidentific\u00f3 mayor engrosamiento mural  que indic\u00f3 persistencia de actividad. Los niveles \nde IFX fueron infraterap\u00e9uticos (1.43 mcg/ml) y anticuerpos anti-IFX negativos, por lo \nque se intensific\u00f3 IFX a 10mg/kg cada 8 semanas. 724En la visita de enero del 2022 se observ\u00f3 empeoramiento cl\u00ednico, mayor actividad en \nanal\u00edtica y pruebas de imagen. De nuevo, los niveles de IFX fueron subterap\u00e9uticos (3.7 \nmcg/ml). Se paut\u00f3 ciclo de corticoides orales con antibioterapia por dudosa colecci\u00f3n \nincipiente (Ciprofloxacino + Metronidazol) y profilaxis con Trimetroprima / \nsulfametoxazol.  \nGracias al tratamiento se observ\u00f3 mejor\u00eda de la diarrea, pero persisti\u00f3 el dolor \nabdominal, la pirosis y la acidez ocasional. Por todo esto, se plante\u00f3 cambio de diana \nterap\u00e9utica.  \n \nTabla 1. Resumen  de las dosis de Infliximab administradas y seguimiento de los par\u00e1metros anal\u00edticos.  \n \nLa unidad de farmacocin\u00e9tica cl\u00ednica del Servicio de Farmacia fue creada en el a\u00f1o 2021, \nsiendo incorporada la monitorizaci\u00f3n farmacocin\u00e9tica del Infliximab en el a\u00f1o 2022. Por \nlo tanto, desde Farmacia se recomend\u00f3 monitorizaci\u00f3n farmacocin\u00e9tica de Infliximab \ncon el objetivo de aumentar niveles y respuesta cl\u00ednica, antes de buscar otras \nalternativas. La \u00faltima determinaci\u00f3n de los niveles plasm\u00e1ticos de IFX fueron el \n72514/01/2022 (3.7 mcg/ml). En la anal\u00edtica destaca una Calprotectina fecal elevada de \n1968 \u00b5g/g y PCR de 1.8 mg/dL.  \nTras los resultados de las concentraciones plasm\u00e1ticas de Infliximab se realiz\u00f3 el an\u00e1lisis \nfarmacocin\u00e9tico utilizando la estimaci\u00f3n bayesiana y obteniendo los siguientes \npar\u00e1metros farmacocin\u00e9ticos individuales del paciente:  \n\u2022 Volumen de distribuci\u00f3n central: 52 ml/kg y perif\u00e9rico: 13.7 ml/kg . \n\u2022 Aclaramiento total: 4.77 ml/kg/d\u00eda y Semivida de eliminaci\u00f3n: 11.81 d\u00edas. \nLa estimaci\u00f3n bayesiana de par\u00e1metros farmacocin\u00e9ticos se realiz\u00f3 con un software \nfarmacocin\u00e9tico y se utiliz\u00f3 el modelo poblacional Fasanmade el al. 2011 (6).  \nTras la estimaci\u00f3n de par\u00e1metros farmacocin\u00e9ticos individuales y simulaci\u00f3n de \ndiferentes pautas posol\u00f3gicas, se recomend\u00f3 intensificar dosis reduciendo el intervalo \nposol\u00f3gico a cada 5 semanas y dosis de 8mg/kg: Infliximab 456 mg/5 semanas. La \nconcentraci\u00f3n plasm\u00e1tica valle estimada en el estado estacionario fue de: 9 mcg/ml.  \n \n726Gr\u00e1fico 1. Simulaci\u00f3n de las dosis administradas de IFX, de las concentraciones plasm\u00e1ticas obt enidas \n(representadas con un punto) y de la nueva pauta posol\u00f3gica de 456 mg cada 5 semanas. La l\u00ednea \ndiscontinua representa la concentraci\u00f3n de 9 mcg/ml.  \n \nDesde Digestivo aceptaron la nueva pauta posol\u00f3gica, iniciando el 04/03/2022 con 456 \nmg (8 mg/kg) ca da 5 semanas.  \nTras un mes, el paciente refer\u00eda mejor\u00eda cl\u00ednica sin dolor abdominal, ni diarreas. En \ncontrol anal\u00edtico destac\u00f3 una reducci\u00f3n del 93,3% de la calprotectina,  de 1968 \u00b5g/g a \n120.2 \u00b5g/g . Los niveles de IFX el d\u00eda 8/04/2022 fueron de 9.5 mcg/ml y el paciente \nmanten\u00eda buen estado general. Se decidi\u00f3 mantener misma pauta posol\u00f3gica y obtener \nnivel valle  en la pr\u00f3xima administraci\u00f3n. \nDISCUSI \u00d3N Y APORTACI \u00d3N FARMAC \u00c9UTICA  \nEl \u00e1rea de farmacocin\u00e9tica cl\u00ednica del servicio de Farmacia nos permite utilizar nuevos \nm\u00e9todos de dosificaci\u00f3n basados en el ajuste individualizado de la dosis, lo que supone \nuna herramienta m\u00e1s precisa para la consecuci\u00f3n del objetivo farmacol\u00f3gico.  \nLa monitorizaci\u00f3n farmacocin\u00e9tica de Infliximab ha surgido como una herramienta \u00fatil \npara realizar un abordaje m\u00e1s personalizado de la posolog\u00eda del paciente, evitando \nreacciones adversas y optimizando tratamientos (7). El farmac\u00e9utico contribuye a la \nindividualizaci\u00f3n posol\u00f3gica en base a principios farmacocin\u00e9ticos y farmacodin\u00e1micos \n(modelos poblacionales optimizados), pudiendo llevar a cabo la simulaci\u00f3n y predicci\u00f3n \nbayesiana del comportamiento cin\u00e9tico del f\u00e1rmaco (8).  \nEn el caso cl\u00ednico presentado, el paciente no ha desarrollado anticuerpos anti-f\u00e1rmaco y \nes susceptible de monitorizaci\u00f3n farmacocin\u00e9tica para aumentar sus nive les plasm\u00e1ticos \ny conseguir el efecto terap\u00e9utico deseado. En este caso, se han ahorrado costes al evitar 727cambio de tratamiento y se ha mejorado el estado de salud del paciente optimizando \nInfliximab y reservando otros tratamientos posibles para futuros fallos terap\u00e9uticos. \nActualmente en nuestro hospital se realiza una monitorizaci\u00f3n reactiva de Infliximab \n(cuando hay p\u00e9rdida de respuesta) pudiendo identificar mecanismos para guiar las \ndecisiones terap\u00e9uticas ante falta de respuesta (9). El caso cl\u00ednico presentado muestra \nsu utilidad para Infliximab en pacientes con enfermedad de Crohn.  Por otro lado, ser\u00eda \ninteresante introducir tambi\u00e9n una monitorizaci\u00f3n proactiva de Infliximab, \ncontribuyendo a la identificaci\u00f3n temprana de fallos terap\u00e9uticos y su etiolog\u00eda, incluso \nantes de la manifestaci\u00f3n de los s\u00edntomas cl\u00ednicos (10). Tambi\u00e9n en el caso de pacientes \ncon una buena respuesta y concentraciones plasm\u00e1ticas elevadas, se podr\u00eda optimizar \nla dosis mediante monitorizaci\u00f3n facilitando el desescalado terap\u00e9utico y, por lo tanto, \nminimizando costes.  \nTodo ello pone de manifiesto la necesidad de la individualizaci\u00f3n posol\u00f3gica de \nInfliximab y la incorporaci\u00f3n en la cartera de servicios de la unidad de farmacocin\u00e9tica \ncl\u00ednica. \nBIBLIOGRAF \u00cdA \n1. Agencia espa\u00f1ola del me dicamento. Ficha t\u00e9cnica Infliximab. \n2. CASTEELE, Niels Vande, et al. The relationship between infliximab concentrations, \nantibodies to infliximab and disease activity in Crohn's disease. Gut, 2015, vol. 64, \nno 10, p. 1539 -1545. 7283. SANTACANA -JUNCOSA, Eug\u00e8nia, et al. Individualizaci\u00f3n de la terapia con infliximab: \nmonitorizaci\u00f3n farmacocin\u00e9tica. Farmacia Hospitalaria, 2015, vol. 39, no 1, p. 59 -60. \n4. ZHANG, Qi Wei, et al. Loss of response to scheduled infliximab therapy for Crohn's \ndisease in adults: A systematic review and meta-analysis. Journal of Digestive \nDiseases , 2019, vol. 20, no 2, p. 65 -72. \n5. PAPAMICHAEL, Konstantinos; CHEIFETZ, Adam S. Therapeutic drug monitoring in \ninflammatory bowel disease: for every patient and every drug?. Current Opinion in \nGastroenterology, 2019, vol. 35, no 4, p. 302 -310. \n6. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic \nproperties of Infliximab in children and adults with Crohn's disesase: a retrospective \nanalysis of data from 2 phase III clinical trials. Clin Ther 2011;33(7):946-62.  \n7. ELBERD\u00cdN PAZOS, L., et al. La monitorizaci\u00f3n farmacocin\u00e9tica como nueva \nherramienta para individualizar la terapia anti-TNF.  Farmacia Hospitalaria, 2014, vol. \n38, no 2, p. 83 -85. \n8. CALVO, M. V., et al. 2.12. Farmacocin\u00e9tica cl\u00ednica. \n9. CHEIFETZ, Adam S., et al. A comprehensive l iterature review and expert consensus \nstatement on therapeutic drug monitoring of biologics in inflammatory bowel \ndisease. The American journal of gastroenterology, 2021, vol. 116, no 10, p. 2014 -\n2025.  \n10. BALLESTA -L\u00d3PEZ, Octavio, et al. Monitorizaci\u00f3n farmacocin\u00e9tica proactiva y an\u00e1lisis \nfarmacogen\u00e9tico en la enfermedad inflamatoria intestinal: Revisi\u00f3n \nsistem\u00e1tica. FARMACIA HOSPITALARIA , 2021, vol. 45, no 07, p. 56 -63. 729- 1 - \n ATENCI\u00d3N FARMAC\u00c9UTICA EN ASPERGILLOSIS PULMONAR E INFECCI\u00d3N POR SARS -\nCoV- 2 EN PACIENTE A TRATAMIENTO CON IBRUTINIB . \n \n1. Introducci\u00f3n \nSe describe el caso de un paciente con leucemia linf\u00e1tica cr\u00f3nica a tratamiento con \nibrutinib y hepatitis B cr\u00f3nica a tratamiento con entecavir que ingresa en la unidad de \nenfermedad infecciosas por neumon\u00eda bilateral por SARS -CoV-2 grave. La evaluaci\u00f3n fu e \ndesfavorable, presentando durante los 3 meses de ingreso varias complicaciones entre \nlas que destaca una aspergilosis pulmonar y una reactivaci\u00f3n de citomegalovirus. Por \nello, necesita el soporte del servicio de farmacia en m\u00faltiples ocasiones, destacand o los \ntr\u00e1mites de solicitud de medicamentos, recomendaciones de dosis de antif\u00fangicos, \ninformaci\u00f3n sobre la correcta administraci\u00f3n de medicamentos y conciliaci\u00f3n \nfarmacoterap\u00e9utica en las transiciones asistenciales.  \n \n2. Descripci\u00f3n del caso (incluyendo la pr esentaci\u00f3n cl\u00ednica y su evoluci\u00f3n)  \nSe trata de un paciente var\u00f3n de 68 a\u00f1os y 80 kg de peso diagnosticado en 2013 de \nleucemia linf\u00e1tica cr\u00f3nica a tratamiento en 7\u00aa l\u00ednea con ibrutinib. Presenta tambi\u00e9n \nhipogammaglobulinemia a tratamiento  sustitutivo  con in munoglobulinas mensuales \nsustitutivas desde 2020, infecci\u00f3n cr\u00f3nica por hepatitis B a tratamiento con entecavir, \nhernia de hiato e hipercolesterolemia.  \nTratamiento habitual al ingreso: cotrimoxazol/trimetoprim 800/160 mg c/12h \nlunes y viernes, entecavir 0, 5 mg c/24h, ibrutinib 420 mg c/24h, \ninmunoglobulinas IV c/28 d\u00edas, lormetazepam 1 mg c/24h, paracetamol e \nibuprofeno si dolor.  730- 2 - \n El paciente ingresa  en la unidad de infecciosas por neumon\u00eda bilateral por SARS -CoV-2 \nde 15 d\u00edas de evoluci\u00f3n y sospecha de sobreinfecci\u00f3n bacteriana por lo que se inicia \ntratamiento con dexametasona 20 mg c/24h y antibioterapia de amplio espectro \n(meropenem 1g c/8h y Linezo lid 600 mg c/12h). Se inicia tambi\u00e9n remdesivir 200 mg iv \nde carga seguidos de 100 mg /d\u00eda de mantenimiento y se solicita sotrovimab 500  mg iv \ncomo dosis \u00fanica  a la Agencia Espa\u00f1ola del Medicamento, consigui\u00e9ndose la aprobaci\u00f3n . \nA d\u00eda +10 de ingreso se det ecta galactomanano en lavado broncoalveolar ( BAL). La \nsituaci\u00f3n cl\u00ednica del paciente empeora y es trasladado a la Unidad de Cuidados \nIntensivos (el d\u00eda + 10 de ingreso) por insuficiencia respiratoria, con los diagn\u00f3sticos de \nneumon\u00eda bilateral por SARS -CoV-2 y aspergilosis pulmonar invasiva. Ante esta \nsituaci\u00f3n, se decide finalmente no administrar sotrovimab. Se desescala antibioterapia \na ceftriaxona 2g/24h y azitromicina 500 mg c/24h (PCR en BAL positiva para \nHaemophilus influenzae ) y se inicia tratamiento con voriconazol 480 mg (6 mg/kg) c/12h \nel d\u00eda 1 y 300 mg (4 mg/kg) c/12h de mantenimiento. A d\u00eda +2 de inicio de tratamiento \nantif\u00fangico con voriconazol, se asocia anidulafungina 100 mg c/24h con el objetivo de \nllevar a cabo una doble terapia antif\u00fangica en paciente de alto riesgo de mala evoluci\u00f3n. \nSe suspende tratamiento con ibrutinib debido a la relaci\u00f3n de este f\u00e1rmaco con el \ndesarrollo de enfermedades f\u00fangicas. Se mantiene tratamiento con dexametasona 20 \nmg c/24h, comenzando a descender dosis de corti coides 3 d\u00edas m\u00e1s tarde. Se mantiene \nprofilaxis con cotrimoxazol/trimetoprim 800/160 mg c/12h lunes y viernes y tratamiento \ncon entecavir 0,5 mg c/24h.  \n \n\u2022 Problema farmacoterap\u00e9utico:   \nAl ingreso el paciente presenta cl\u00ednica subjetiva de infecci\u00f3n respiratoria con disfon\u00eda, 731- 3 - \n disnea, fiebre, escalofr\u00edos, taquipnea y obnubilaci\u00f3n.  \nAl ingreso el paciente presenta los siguientes datos objetivos:  \n- Anal\u00edtica al ingreso:  Hb 11,4 g/dl, Plaquetas 98000/\u00b5l , Neutr\u00f3filos 78600/\u00b5l, \nfibrin\u00f3geno 593 mg/dl, Glucosa  195 mg/dl, Urea 55 mg/dl, Creatinina 0,7 mg/dl, GOT 26 \nUI/L, GPT 25 UI/L, GGT 56 UI/L, FA 42 UI/L, Alb\u00famina 2.1, PCR 17 mg/dl , LDH 410 U/L , \nFerritina >1000 ng/ml . \n- Pruebas de imagen al ingreso:  pulm\u00f3n blanco difuso, infiltrados pulmonares \nsubpleurales.     \nDurante el ingreso, el paciente presenta los siguientes cultivos microbiol\u00f3gicos \npositivos:  \no PCR SARS -CoV-2 (d\u00eda -15 de ingreso): positiva  \no Esputo (d\u00eda +10 de ingreso): Aspergillus fumigatus  \no BAL (d\u00eda +10 de ingreso): Galactomanano positivo \u2192 Negativiza 1 2 d\u00edas m\u00e1s \ntarde.  \no Suero (d\u00eda +19 de ingreso): Galactomamano positivo \u2192 Negativiza 12 d\u00edas m\u00e1s \ntarde.  \no Urocultivo(UC) (d\u00eda +37 de ingreso): Enterococcus faecium  \no Punta cat\u00e9ter (d\u00eda +37 de ingreso): Staphylococcus epidermidis  \no BAL (d\u00eda +38 de ingreso): citomegalovirus positivo  \no Suero (d\u00eda +43 de ingreso): citomegalovirus positivo  \n \nCon los datos cl\u00ednicos, microbiol\u00f3gicos y las pruebas de imagen; el paciente es \ndiagnosticado de infecci\u00f3n por SARS -CoV-2 de 15 d\u00edas de evoluci\u00f3n con sobreinfecci\u00f3n \nbacteriana v s neumonitis con signos claros de inflamaci\u00f3n (PCR 17 mg/dl, LDH 410 U/L, 732- 4 - \n ferritina >1000 ng/ml) y aspergilosis pulmonar invasiva tras el galactomanano positivo.  \nLa aspergilosis pulmonar es una complicaci\u00f3n relativamente frecuente en pacientes con \nneumon\u00eda  bilateral por SARS -CoV-2 que ingresan en UCI y que contribuye a  un aumento \nde la mortalidad (1). Por otro lado, se han notificado casos de infecciones f\u00fangicas \ninvasivas en pacientes a tratamiento con ibrutinib, en muchos casos con desenlace \nmortal (2,3). Por lo tanto, la aparici\u00f3n de la aspergilosis en este paciente pudo estar \nmotivada por esas dos principales causas: la infecci\u00f3n primaria por SARS -CoV-2 y el \ntratamiento con ibrutinib.  \n \n\u2022 Tratamiento : El tratamiento inicial de este paciente se basa principalmente en el \nabordaje de la infecci\u00f3n v\u00edrica junto con la posible sobreinfecci\u00f3n bacteriana vs \nneumonitis secundaria y el tratamiento de la aspergilosis pulmonar invasiva.  \no Neumon\u00eda SARS- CoV-2 con sospec ha de sobreinfecci\u00f3n bacteriana: \nremdesivir, sotrovimab, corticoides, antibioterapia dirigida  (ceftriaxona, \nazitromicina).  \no Aspergilosis pulmonar invasiva : El tratamiento de primera l\u00ednea en la \naspergil osis pulmonar invasiva son los azoles, pudiendo combinarse con \nequinocandinas en casos graves, como es el descrito en este caso cl\u00ednico.  \nEl plan farmacol\u00f3gico llevado a cabo en este paciente fue el siguiente:  \n\u2022 Manejo r\u00e1pido de la infecci\u00f3n por SARS -CoV- 2 y solicitud de sotrovimab a la \nAEMPS:  se solicita el f\u00e1rmaco a\u00fan sin cumplir estrictamente los criterios de \npriorizaci\u00f3n de riesgo de la AEMPS (a fecha de 20/01/2022) debido a que se \nconsidera un paciente inmunodeprimido (patolog\u00eda hematol\u00f3gica a tratamiento  \ncon ibrutinib e hipogammaglobulinemia secundaria) de alto riesgo que podr\u00eda 733- 5 - \n beneficiarse del tratamiento.  \n\u2022 PK/PD voriconazol, monitorizaci\u00f3n estrecha de eficacia y toxicidad y manejo de \nla interacci\u00f3n con corticoides:  Debido a sospecha de aspergilosis pulm onar vs \nneumonitis por SARS -CoV-2, el paciente inicia tratamiento con voriconazol pero \nno se suspenden los corticoides hasta 4 d\u00edas m\u00e1s tarde. Tras la suspensi\u00f3n de \ndexametasona se observa un claro aumento de los niveles de voriconazol \nllegando a niveles t \u00f3xicos de 7,6 ng/ml a d\u00eda +14 de tratamiento a pesar de \nreducirse la dosis a d\u00eda +12. Debido a que el paciente no presentaba efectos \nadversos y la anal\u00edtica era normal, se decidi\u00f3 reducir la dosis un 25% (de 300 mg \nc/12h a 250 mg c/12h y despu\u00e9s a 200 mg c /12h). A d\u00eda + 14  de tratamiento , \ndebido a la no mejor\u00eda cl\u00ednica y la presencia de inflamaci\u00f3n subjetiva de \nneumonitis, se decide introducir de nuevo corticoides (metilprednisolona 40 mg \nc/24h). Adem\u00e1s, el paciente presenta alteraci\u00f3n de las transaminasas por lo que \nse d ecide, de manera multidisciplinar, reducir dosis de voriconazol a 150 mg \nc/12h (50% de la dosis inicial) (4). A d\u00eda +17 de tratamiento se observa un claro \ndescenso de los niveles de voriconazol (2 ng/ml),  por lo que se aumenta la dosis \na 250 mg c/12h. Sin embargo, los niveles de voriconazol contin\u00faan bajando, \nllegando a ser de 0,3 ng/ml a d\u00eda +20 de tratamiento. En este momento, se decide \ncambio a isavuconazol dada su menor interacci\u00f3n con corticoides y su  \nfarmacocin\u00e9tica m\u00e1s lineal (ver Figura 1).  734- 6 - \n Figura 1: Evaluaci\u00f3n de la interacci\u00f3n voricanozol -corticoides.  \n \n\u2022 Suspensi\u00f3n de ibrutinib y comunicaci\u00f3n de RAM:  ante la sospecha de \naspergilosis pulmonar y la posible relaci\u00f3n de esta con el tratamiento con \nibrutinib, se suspende y se comunica reacci\u00f3n adversa.  \n\u2022 Recomendaciones de manejo de antimicrobianos:  \no Adici\u00f3n de anidulafungina al tratamiento antif\u00fangico con v oriconazol \npara llevar a cabo doble terapia en paciente de alto riesgo y niveles de \nvoriconazol no estables.  \no Monitorizaci\u00f3n de voriconazol y cambio a isavuconazol para mejor \ncontrol de interacciones, asegurando eficacia y menor toxicidad.  \no Inicio de tratami ento con ganciclovir 5 mg/kg c/12h durante 21 d\u00edas \ndebido a la reactivaci\u00f3n de CMV a d\u00eda +38 de ingreso.  \no Tratamiento de ITU por Enterococcus faecium  con vancomicina ajustada \nseg\u00fan niveles durante tratamiento corto de 5 d\u00edas.  \n735- 7 - \n o Recomendaci\u00f3n de no tratar tras  el positivo en punta de cat\u00e9ter por \nStaphylococus epidermidis  debido a sospecha de contaminaci\u00f3n.  \n \nA pesar de las m\u00faltiples complicaciones que desarroll\u00f3 el paciente durante su ingreso, \nel paciente evolucion\u00f3 favorablemente, consiguiendo suspenderse el is avuconazol a d\u00eda \n+76 de ingreso (tras 46 d\u00edas de tratamiento con isavuconazol y 66 d\u00edas de tratamiento \nantif\u00fangico total). Tras valoraci\u00f3n multidisplinar, se decide reiniciar el ibrutinib a d\u00eda +80 \nde ingreso. El paciente es dado de alta con su medicaci\u00f3n habitual tras 3 meses de \ningreso.  \n \n3. Discusi\u00f3n y aportaci\u00f3n farmac\u00e9utica  \nSe presenta un caso complejo en el que el papel del farmac\u00e9utico resulta esencial para \nun correcto manejo de los f\u00e1rmacos e imprescindible para la toma de decisiones cl\u00ednicas.  \nPor un lado, es destacable el papel que tiene en la resoluci\u00f3n r\u00e1pida del tr\u00e1mi te de \nsolicitud de medicamentos en situaciones especiales  con la solicitud individualizada de \nsotrovimab en un paciente de alto riesgo. Por otro lado, resulta esencial la detecci\u00f3n, \ninterpretaci\u00f3n y comunicaci\u00f3n de la aspergilosis como posible  reacci\u00f3n adv ersa  a \nibrutinib.  \nAdem\u00e1s, durante toda la estancia hospitalaria de este paciente, el farmac\u00e9utico \ndesemp e\u00f1a un papel activo en el manejo de los antimicrobianos , tanto en la \nrecomendaci\u00f3n de la posolog\u00eda al inicio como en monitorizaci\u00f3n cl\u00ednica y \nfarmacocin \u00e9tica y la duraci\u00f3n de los tratamientos. Destacar que el paciente fue seguido \nestrechamente por el grupo PROA  espec\u00edfico de la Unidad de Cuidados Intensivos, del \nque forma parte una farmac\u00e9utica hospitalaria.  736- 8 - \n Es un caso en el que se aprecia claramente la interacci\u00f3n entre azoles y corticoides  y su \nimportante repercusi\u00f3n cl\u00ednica.  \nEs importante tambi\u00e9n el papel del farmac\u00e9utico en la conciliaci\u00f3n del tratamiento  en \nlos m\u00faltiples traslados  del paciente desde la unidad de infecciosas a la unidad de cr\u00edticos, \nfacilitando el seguimiento del paciente y evitando errores de medicaci\u00f3n . \n \n4. Bibliograf\u00eda  \n1.  Kariyawasam RM, Dingle TC, Kula BE, Vandermeer B, Sligl WI, Schwartz IS. \nDefining COVID -19 a ssociated pulmonary aspergillosis: systematic review and meta -\nanalysis. Clinical Microbiology and Infection [Internet]. 10 de febrero de 2022 [citado 5 \nde abril de 2022]; Disponible en: \nhttps://www.sciencedirect.com/science/article/pii/S1198743X22000519  \n2.  Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, et  al. Incidence and \nassociated risk factors for invasive fungal infections and other serious infections in \npatients on ibrutinib. J Infect Chemother. diciembre de 2021;27(12):1700 -5.  \n3.  FICHA TECNICA IMBRUVICA 140 MG CAPSULAS DURAS [Internet]. [citado 5 de \nabril de 2022]. Disponible en: \nhttps://cima.aemps.es/cima/dochtml/ft/114945001/FT_114945001.html  \n4.  Chau MM, Daveson K, Alffenaar J -WC, Gwee A, Ho SA, Marriott DJE, et  al. \nConsensus guide lines for optimising antifungal drug delivery and monitoring to avoid \ntoxicity and improve outcomes in patients with haematological malignancy and \nhaemopoietic stem cell transplant recipients, 2021. Intern Med J. noviembre de 2021;51 \nSuppl 7:37 -66.  \n 737TRATAMIENTO DEL S\u00cdNDROME HEMOL\u00cdTICO UR\u00c9MICO AT\u00cdPICO EN PACIENTE COVID -19 \nPOSITIVO  \nIntroducci\u00f3n  \nEl s\u00edndrome hemol\u00edtico ur\u00e9mico (SHU) es una entidad cl\u00ednica caracterizada por la tr\u00edada \nanemia hemol\u00edtica no inmune, trombocitopenia e insuficiencia renal aguda, donde las \nlesiones subyacentes est\u00e1n mediadas por un proceso de microangiopat\u00eda tromb\u00f3tica (MAT) \nsist\u00e9mica.  \nLa clasificaci\u00f3n actual distingue entre:  \n\u25cf SHU t\u00edpico (90% de los casos) causado por infecciones, sobre todo las asociadas a la \ntoxina Shiga en  infecciones por Escherichia coli (E.coli) , aunque tambi\u00e9n puede \nasociarse a otros g\u00e9rmenes productores de verotoxina.  \n\u25cf SHU at\u00edpico (10% de los casos) consecuencia de una desregulaci\u00f3n de la v\u00eda alternativa \ndel sistema del complemento sobre las superficies celulares.  \nEn este caso trataremos el SHU at\u00edpico, entidad cr\u00f3nica considerada una enfermedad muy \nrara.  \nEn los \u00faltimos a\u00f1os, se ha establecido el papel que desempe\u00f1a el sistema del complemento \nen la inducci\u00f3n de da\u00f1o endotelial, mediante la caracterizaci\u00f3n  de m\u00faltiples mutaciones y \npolimorfismos en los genes que codifican determinados factores del complemento.  \nEl inicio de la cl\u00ednica suele ser abrupto, aunque en aproximadamente el 20 % de los pacientes \npuede ser progresivo (semanas o incluso meses). Los niv eles altos de lactato deshidrogenasa \n(LDH), los niveles indetectables de haptoglobina y la presencia de esquistocitos confirman la \npresencia de hem\u00f3lisis intravascular. Es frecuente observar hematuria, proteinuria y/o 738fracaso renal agudo (con o sin oligoan uria). Adem\u00e1s, la presencia de hipertensi\u00f3n arterial, por \nsobrecarga de volumen o por lesi\u00f3n vascular, tambi\u00e9n es frecuente.  \nA pesar de que las tasas de recuperaci\u00f3n hematol\u00f3gica y renal eran en general inferiores al \n50 % y la mortalidad elevada, durante a \u00f1os, el \u00fanico tratamiento disponible para el SHU \nat\u00edpico ha sido la terapia plasm\u00e1tica. Esto ha cambiado desde la aprobaci\u00f3n en 2011 por parte \nde la EMA y la AEMPS de eculizumab para el tratamiento de esta patolog\u00eda. Se trata de un \nanticuerpo monoclonal hu manizado que act\u00faa inhibiendo la activaci\u00f3n de la prote\u00edna C5 del \ncomplemento que ha mejorado sustancialmente el manejo y el pron\u00f3stico de estos pacientes.  \n \nDescripci\u00f3n del caso  \nPaciente var\u00f3n de 28 a\u00f1os de edad sin tratamiento cr\u00f3nico domiciliario que acude a urgencias \nel d\u00eda 28 de enero de 2022 con cuadro de v\u00f3mitos, diarrea y anuria de 48 horas de evoluci\u00f3n. \nRefiere haber recibido la tercera dosis de la vacuna COVID -19 cuatro d\u00edas antes . Pocas horas \ndespu\u00e9s de la administraci\u00f3n, comienza con los sigui entes  s\u00edntomas: fiebre, n\u00e1useas, v\u00f3mitos \ny diarrea.  \nEntre sus antecedentes destacan neumon\u00eda por Streptococcus pneumoniae  a los 16 meses de \nedad y dos ingresos durante su infancia por  SHU, uno a los 3 a\u00f1os de edad y otro a los 11 \na\u00f1os, en los cuales fue t ratado con plasma fresco. En ninguno de los dos ingresos lleg\u00f3 a \nprecisar di\u00e1lisis.  \nA su llegada a urgencias se encuentra afebril, con una presi\u00f3n arterial de 159/94 mmHg y sin \nninguna alteraci\u00f3n neurol\u00f3gica. Se sonda y se extrae una m\u00ednima cantidad de or ina col\u00farica y \nse realiza, adem\u00e1s, test de ant\u00edgeno COVID -19, que resulta positivo. A nivel anal\u00edtico presenta \nuna hemoglobina pr\u00f3xima a la normalidad, trombocitopenia y marcadores de funci\u00f3n renal \n(creatinina, urea) elevados. Adem\u00e1s, se pide un frotis de sangre perif\u00e9rica donde se observa 739la presencia de esquistocitos y, aunque se trata de obtener el valor de LDH, resulta imposible \ndebido a la hem\u00f3lisis de la muestra.  \nAnte sus antecedentes personales y los hallazgos de fracaso renal agudo, trombocitopenia y \ndem\u00e1s datos anal\u00edticos se diagnostica de  MAT  (sospecha de brote de SHU causado por la \ninfecci\u00f3n /vacuna COVID -19), insuficiencia renal aguda secundaria, infecci\u00f3n por COVID -19 e \nhipertensi\u00f3n, la cual mantiene pr\u00e1cticamente a lo largo de todo el ingreso.   \nSe ingresa al paciente y se inicia hemodi\u00e1lisis urgente , previa transfusi\u00f3n de un pool de \nplaquetas. Adem\u00e1s, se extraen una bater\u00eda de pruebas de estudio entre las que se \nencuentran: muestra para medir la actividad de ADAMS13,  coprocultivo y toxina para \ndescartar la presencia de E. coli  en heces. Ante la sospecha de SHU este mismo d\u00eda se solicita \ntratamiento con eculizumab al servicio de farmacia.  \nAl d\u00eda siguiente, el paciente contin\u00faa en anuria y se lleva a cabo una segunda sesi\u00f3n de \nhemodi\u00e1lisis. A nivel anal\u00edtico se obtiene el valor de la LDH y los resultados de la actividad de \nADAMS13 (resultado normal, 69%). Adem\u00e1s, el examen preliminar de heces descarta \nverotoxina de E. coli , por lo que el paciente recibe, este mismo d\u00eda, la primera dosis de \neculizumab  900 mg sin incidencias. Las siguientes dosis las recibi\u00f3 los d\u00edas 4, 11 y 18 de febrero  \nsiguiendo la pauta de inicio habitual del medicamento . \nEl seguimiento anal\u00edtico del paciente a lo largo del ingreso (Ver T abla 1)  nos permite observar \nc\u00f3mo con el paso de los d\u00edas la hemoglobina y las plaquetas se van estabilizando y tanto los \nmarcadores de hem\u00f3lisis como los de funci\u00f3n renal disminuyen. Adem\u00e1s, se observa un \naumento de la tasa de filtraci\u00f3n glomerular y de la diure sis del paciente,  que incluso  llega a \npresentar poliuria los \u00faltimos d\u00edas de ingreso.  \nFinalmente, el paciente acude a su \u00faltima sesi\u00f3n de hemodi\u00e1lisis el d\u00eda 16 de febrero y recibe \nel alta dos d\u00edas m\u00e1s tarde, tras recibir la cuarta dosis de eculizumab. En ese momento, el 740paciente presentaba un filtrado glomerular pr\u00f3ximo a los 30 mL/min estimado mediante la \nf\u00f3rmula de Cockroft -Gault . \nA partir del alta el paciente es seguido en consultas externas de nefrolog\u00eda y comienza a acudir \na hospital de d\u00eda para recibir la administraci\u00f3n quincenal de eculizumab 1200 mg. En la \nrevisi\u00f3n del d\u00eda 24 de marzo, tras seis dosis de eculizumab, se conside ra que el brote de SHU \nest\u00e1 inactivo y que el paciente se ha recuperado \u00edntegramente del mismo (filtrado mayor de \n90 ml/min). Los datos anal\u00edticos de este mismo d\u00eda tambi\u00e9n se reflejan en la tabla 1.  \nActualmente el paciente est\u00e1 pendiente del estudio gen\u00e9t ico.  \n \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica.  \nExisten dos entidades cl\u00ednicas caracterizadas por lesiones de MAT primaria, de causa y base \nfisiopatol\u00f3gica diferente: la p\u00farpura trombocitop\u00e9nica  tromb\u00f3tica  (PTT) y el SHU. Ante un \ncuadro cl\u00ednico sugestivo de MAT, el diagn\u00f3stico deber\u00e1 orientarse hacia SHU at\u00edpico si la \nprueba de toxina Shiga es negativa, la actividad plasm\u00e1tica de ADAMTS13 > 5 % (considerada \nnormal) y se descartan formas secundarias de SHU. Este es el caso de nuestro paciente, el \ncual presentaba la tr\u00edada t\u00edpica de SHU, coprocultivo y toxina negativos para E. coli  y una \nactividad normal de ADAMTS13 (69%).  \nEl papel del farmac\u00e9utico estuvo presente durante todo el proceso de tratamiento del \npaciente. Nos encargamos tanto de la log\u00edstica como de la validaci\u00f3n farmac\u00e9utica durante la \nterapia con eculizumab intravenoso.  \nDesde el servicio de farmacia se revisaron las condiciones necesarias para el inicio del \ntratamiento. Antes de iniciar el tratami ento, los pacientes con SHU at\u00edpico deben vacunarse \nde acuerdo con las recomendaciones vigentes  frente a infecciones meningoc\u00f3cicas al menos \n2 semanas antes de la administraci\u00f3n del f\u00e1rmaco, a menos que el riesgo de retrasar el 741tratamiento sea superior al riesgo de desarrollar una infecci\u00f3n meningoc\u00f3cica. En este caso, \nal ser un tratamiento urgente, la vacunaci\u00f3n se ha iniciado durante el ingreso , tras haber \nrecibido ya dos dosis de eculizumab.  \nDesde el servicio de farmacia se le ha enviado al m\u00e9dico respon sable del paciente el \ndocumento que es necesario cubrir para la compra y distribuci\u00f3n del f\u00e1rmaco, en el cual se \nconfirma por escrito que el paciente ha recibido o recibir\u00e1 vacunaci\u00f3n meningoc\u00f3 cica y/o \nprofilaxis antibi\u00f3tica. Una vez cubierto, enviamos ese  documento al laboratorio para poder \ncontinuar con la compra del f\u00e1rmaco.   \nDurante el ingreso, cada d\u00eda se ha revisado la evoluci\u00f3n anal\u00edtica del paciente, prestando \nespecial atenci\u00f3n al hemograma y a la funci\u00f3n renal. Cuando el paciente empieza a acudir a  \nhospital de d\u00eda, realizamos atenci\u00f3n farmac\u00e9utica explicando, inicialmente, en qu\u00e9 consiste \nla infusi\u00f3n del f\u00e1rmaco y sus principales efectos adversos, as\u00ed como otras recomendaciones.  \nEn la actualidad, validamos el tratamiento que se administra en hospit al de d\u00eda y seguimos \nofreciendo atenci\u00f3n farmac\u00e9utica  con el fin de solucionar cualquier duda sobre su \ntratamiento o reconocer cualquier efecto adverso producido por el mismo.  \n \n \n \n \n \n \n \n 742 \nFECHA  Hb \n(g/dL)  PLAQUETAS  \n(miles/ m.c)  LDH \n(U/L)  HAPTOGLOBINA  \n(mg/ dL) ESQUISTOCITOS  \n(%) CREATININA  \n(mg/dL)  UREA  \n(mg/dL)  PROTEINURIA \n(mg/mL)  DIURESIS  \n(mL)  \n28/02/22  13.7  27.000  \u2014 \u2014 5-8 13.13  229 \u2014 \u2014 \n29/02/22  11.1  26.000  3842  \u2014 5-6 11.42  182 \u2014 50 \n30/01/22  9.2 18.000  \u2014 \u2014 \u2014 10.55  149 \u2014 0 \n31/01/22  7.7 29.000  3792  <8  6 12.59  209 29.998  25 \n01/02/22  9.1 27.000  3614  <8  >10 9.67  146 \u2014 50 \n02/02/22  7.9 92.000  2172  \u2014 <10 12.16  168 \u2014 60 \n03/02/22  9.5 168.000  1468  <8  \u2014 8.26  86 22.414  85 \n04/02/22  8.8 221.000  1112  \u2014 \u2014 10.56  107 10.625  60 \n05/02/22  8.4 246.000  827 \u2014 \u2014 9.13  63 \u2014 20 \n06/02/22  9.0 311.000  \u2014 \u2014 \u2014 11.62  80 \u2014 90 \n07/02/22  8.6 379.000  667 116  3 12.87  106 4.491  90 \n08/02/22  8.9 451.000  \u2014 \u2014 \u2014 10.43  75 \u2014 20 \n09/02/22  8.0 487.000  489 185  2-6 11.55  100 \u2014 160 \n10/02/22  \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 500 \n11/02/22  8.5 572.000  \u2014 \u2014 \u2014 10.03  93 \u2014 930 74312/02/22  \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 1820  \n13/02/22  \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 3800  \n14/02/22  8.6 450.000  341 \u2014 \u2014 7.67  104 \u2014 3100  \n15/02/22  \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 2600  \n16/02/22  8.0 369.000  298 226  2-3 3.87  81 107 3000  \n17/02/22  8.5 325.000  \u2014 \u2014 \u2014 2.79  65 121 2000  \n24/03/22  11.6  212.000  176 \u2014 \u2014 0.74  36 \u2014 \u2014 \n \nTabla 1 . Seguimiento anal\u00edtico del paciente a lo largo del brote de SHU.744Bibliograf\u00eda  \n1. Soliris\u00ae 300 mg concentrado para soluci\u00f3n para perfusi\u00f3n (Eculizumab). Ficha T\u00e9cnica. \nhttps://www.ema.europa.eu/en/documents/product -information/soliris -epar -\nproduct -information_en.pdf  \n2. Sep\u00falveda Rodrigo A., Tagle Rodrigo, Jara Aq uiles. S\u00edndrome hemol\u00edtico ur\u00e9mico \nat\u00edpico. Rev. m\u00e9d. Chile  [Internet]. 2018  Jun [citado  2022  Mayo  10]; 146(6): 770 -779.  \n3. Campistol, Josep M., et al. \"Actualizaci\u00f3n en s\u00edndrome hemol\u00edtico ur\u00e9mico at\u00edpico: \ndiagn\u00f3stico y tratamiento. Documento de consenso.\"  Nefrolog\u00eda (Madrid)  35.5 \n(2015): 421 -447.  \n4. Trimarchi H, Gianserra R, Lampo M, Monkowski M, Lodolo J. Eculizumab, SARS -CoV-2 \nand atypical hemolytic uremic syndrome . Clin Kidney J . 2020 Sep 27;13(5):739 -741.  \n 745PROTEINOSIS ALVEOLAR PULMONAR  AUTOINMUNE  REFRACTARIA AL \nLAVADO PULMONAR TOTAL : APLICACI\u00d3N DEL SARGRAMOSTIM  \n \nINTRODUCCI\u00d3N  \nLa p roteinosis alveolar pulmonar (PAP) es una enfermedad rara caracterizada por una \nacumulaci\u00f3n de material lipoprotein\u00e1ceo del surfactante en los alveolos y bronquiolos \nterminales, debido a una disminuci\u00f3n de su aclaramiento por parte de los macr\u00f3fagos \nalveolares, provocando una alteraci\u00f3n en el intercambio gaseoso y pudiendo causar \ninsuficiencia respiratoria p rogresiva. Las principales causas de esta disfunci\u00f3n son el \nd\u00e9ficit de actividad del factor estimulante de colonias de granulocitos -macr\u00f3fagos (GM -\nCSF) o las alteraciones en el receptor del G M-CSF, por lo que la  maduraci\u00f3n de los \nmacr\u00f3fagos alveolares se v e comprometida.  El GM -CSF es crucial en el desarrollo y \nmaduraci\u00f3n de los macr\u00f3fagos  alveolares, implicados en funciones metab\u00f3licas e \ninmunol\u00f3gicas.  Respecto a la etiolog\u00eda de la enfermedad, el 90% de las PAP son de origen \nautoinmune, debido a la aparici\u00f3 n de anticuerpos anti GM -CSF que bloquean la \nmaduraci\u00f3n del macr\u00f3fago (PAP autoinmune o idiop\u00e1tica). Tambi\u00e9n puede deberse a \nmutaciones en los genes que codifican las prote\u00ednas del surfactante o las cadenas del \nreceptor del GM -CSF (PAP hereditaria) y , en u n 5-10% de los casos , la disfunci\u00f3n \nmacrof\u00e1gica alveolar es secundaria  (PAP secundaria)  a la exposici\u00f3n a toxinas y algunos \nmetales , trastornos hematol\u00f3gicos  (linfomas, mielomas) , enfermedades autoinmunes, \ninmunodeficiencias,  infecciones por Pneumocystis o Nocardia , as\u00ed como la exposici\u00f3n a \ndeterminados f\u00e1rmac os (busulf\u00e1 n, micofenolato de mofetilo, dasatinib o  imatinib, entre \notros) . 746La enfermedad se manifie sta entre los 30 -60 a\u00f1os , siendo m\u00e1s frecuente en hombres \nque en mujeres (ratio 2:1),  con una cl\u00ednica muy variada, desde pacientes asintom\u00e1ticos \nhasta paciente en  situaci\u00f3n de insuficiencia respiratoria grave. En caso de presentar \nsintomatolog\u00eda, los  s\u00edntomas  son inespec\u00edficos, siendo los m\u00e1s comunes la disnea, fatiga, \np\u00e9rdida de peso, artralgias y una mayor susceptibilidad a  infecciones  causadas  por \nagentes como Nocardia  y algunas micobacterias . Este mayor riesgo de infecciones  es \ndebido a la presencia de macr\u00f3fa gos inmaduros, implicados  en la inmunidad.  \nEn cuanto al diagn\u00f3stico, se debe tener en cuenta la cl\u00ednica del paciente, las pruebas \nradiol\u00f3gicas (principalmente radiograf\u00eda o TAC de t\u00f3rax ), las pruebas de funci\u00f3n \nrespiratoria ( capacidad de difusi\u00f3n de mon\u00f3x ido de carbono [ DLCO ], capacidad vital \nforzada [ CVF] y presi\u00f3n parcial de ox\u00edgeno [P O2]), algunos biomarcadores relacionado s, \naunque inespec\u00edficos, como la lactato deshidrogenasa (LDH, incrementada en el 80% de \nlos pacientes), y resulta indispensable la realizaci\u00f3n de fibrobroncoscopia, para poder \nevaluar el aspecto del lavado bronco alveolar (BAL), caracterizado  por su aspecto \nblanquecino, y poder realizar una biopsia transbronquial de confirmaci\u00f3n.  Debe \ndeterminarse la presencia de anti cuerpos frente al GM -CSF en sangre o BAL, para \nconfirmar el car\u00e1cter  autoinmune de la enfermedad, aunque la concentraci\u00f3n de estos \nno se correlaciona con la severidad de la enfermedad. 1,2 \nRespecto al abordaje terap\u00e9utico, no hay unas gu\u00edas de consenso int ernacionales sobre \nel tratamiento de la PAP, por lo que, convencionalmente, las decisiones terap\u00e9uticas \nest\u00e1n basadas en la gravedad y el tipo de PAP. En pacientes con PAP asintom\u00e1ticas o con \nla funci\u00f3n pulmonar preservada -ligeramente reducida, acostumbra a realizarse una 747monitorizaci\u00f3n peri\u00f3dica (cl\u00ednica, funci\u00f3n respiratoria, biomarcadores y pruebas de \nimagen), sin instaurar tratamiento.  \nEn el caso de presentar sintomatolog\u00eda, con la funci\u00f3n pulmonar disminuida de forma \nmoderada o severa , sin remisi\u00f3n y, una vez descartadas otras causas, la terapia  de \nelecci\u00f3n es el lavado pulmonar total (LPT) , realizado bajo anestesia general y \nnormalmente en soporte con circulaci\u00f3n con membrana extracorp\u00f3rea (ECMO) . \nDurante la realizaci\u00f3n del LPT, se evidenci a la presencia de material lipoprotein \u00e1ceo, \nconsecuencia de una disminuci\u00f3n de la degradaci\u00f3n del surfactante (90% fosfol\u00edpidos y \n10% prote\u00ednas ). El LPT ha demostrado mejorar de forma significativa la oxigenaci\u00f3n y le \nfunci\u00f3n pulmonar, con una larga duraci \u00f3n de la respuesta, por lo que en pacientes con \nrecurrencias podr\u00eda repetirse y/o a\u00f1adir otra terapia.3 Entre las  terapias indicadas en el \ntratamiento de la PAP, se encuentran  los factores estimulantes de colonias de \ngranulocitos  recombinante s, como sargra mostim y morgramostim, de aplicaci\u00f3n  en PAP \nautoinmune, administrado v\u00eda subcut\u00e1nea o nebulizada . Al restaurar la funcionalidad de \neste factor, los macr\u00f3fagos son funcionales y pueden contribuir en la degradaci\u00f3n del \nsurfactante pulmonar . El uso de estos f actores ha mostrado resultados muy positivos en \ncuando a la mejora de la funci\u00f3n pulmonar,  aunque las pautas de tratamiento no est\u00e1n \nclaramente definidas.4-6 Otras terapias como rituximab, plasmaf\u00e9resis o el trasplante de \nprogenitores hematopoy\u00e9ticos, pre sentan una evidencia mucho m\u00e1s limitada y se \nencuentran todav\u00eda en fase de investigaci\u00f3n.1 \nPRESENTACI\u00d3N DEL CASO  \nHombre de 51 a\u00f1os, sin alergias medicamentos conocidas y exfumador desde hace m\u00e1s \nde 2 a\u00f1os, que presenta como antecedentes  m\u00e9dicos de inter\u00e9s una neumopat\u00eda 748intersticial no espec\u00edfica (NINE), con requerimiento de oxigenoterapia domiciliaria de \nrescate y saturaciones habituales en torno al 95%, as\u00ed como nocardiosis pulmo nar \ndiagnosticada 2 meses antes, en un paciente bajo trat amiento corticoideo cr\u00f3nico  \n(factor de riesgo de nocardiosis)  y diabetes mellitus corticoidea. Su tratamiento habitual \nconsiste en: dipropionato de beclometasona/formoterol 100/6 mcg 2 inhalaciones/12 \nhoras, bromuro de ipratropio 20 mcg/inh 2 inhalaciones/6 horas, metformina 850 \nmg/24  horas, prednisona 30 mg/24  horas  (pauta descendente), cotrimoxazol 1600 \nmg/320 mg /12 h oras  y salbutamol 100 mcg/inh (rescate).  \nEl paciente acude a Urgencias por cuadro disneico, tos y mareos. Se encuentra \nhemodin\u00e1micamente estable, afebril, ligeramente cian\u00f3tico y taqui pn\u00e9ico, destacando \ndisnea y desaturaci\u00f3n hasta 85% a aire ambiente.  A la exploraci\u00f3n presenta crepitantes \nbilaterales, con una gasometr\u00eda arterial en la que destaca hipoxemia (pO2 56 mm Hg) y \nligero  aumento de lactatos (2.3 mmol/L).  En la anal\u00edtica no se observa leucocitosis ni \nelevaci\u00f3n de reactantes de fase aguda y la radiograf\u00eda de t\u00f3rax muestra patr\u00f3n \nintersticial con progresi\u00f3n de infiltrado bilateral respecto a previas. En este contexto, \npresen ta deterioro respiratorio, por lo que requiere ingreso en la Unidad de Cuidados \nIntensivos (UCI) por insuficiencia respiratoria hipox\u00e9mica cr\u00f3nica reagudizada.  \nEn el TAC tor\u00e1cico realizado, poco sugestivo de proceso infeccioso, se observan m\u00faltiples \nlesion es pulmonares bilaterales  cavitadas  de aspecto consolidativo, y el lavado \nbroncoalve olar muestra un aspecto blanquinoso, por lo que se orienta como una posible \nPAP (primera posibilidad en el diagn\u00f3stico diferencial). En previsi\u00f3n de la necesidad de \nrealizar lavados pulmonares y, debido al deterioro progresivo de la oxigenaci\u00f3n, se \ndecide iniciar soporte con oxig enaci\u00f3n con ECMO  veno -venosa (VV) como puente a \nconfirmar el diagn\u00f3stico y plantear una estrategia de tratamiento. Dado que se 749encuentra pendiente de evaluaci\u00f3n de su patolog\u00eda de base, se indica corticoterapia \nemp\u00edrica 1mg/kg/24h junto a antibioterapia em p\u00edrica de infecci\u00f3n respiratoria, a la \nespera de los resultados microbiol\u00f3gicos.   \nEl BAL muestra aspecto macrosc\u00f3pico compatible con PAP (aspecto \u201clechoso \u201d) y la \ntinci\u00f3n  de Periodic Acid -Schiff  (PAS) resulta positiva, por lo que se confirma la sospecha \ndiagn\u00f3stica y se decide realizar LPT. El LPT se realiza con el paciente en apnea y bajo \nsoporte con ECMO VV, instilando  un total de 16 litros de cloruro s\u00f3dico  0.9% por cada \npulm\u00f3n, constatando aclaramiento y disminuci\u00f3n de la densidad de este.  A pesar de la \nrealizaci\u00f3n de LPT, presenta empeoramiento global progresivo con necesidad de \nsoporte hemodin\u00e1mico y requerimientos de oxigenoterapia en aumento. Se realiza un \nsegundo LPT bajo soporte con ECMO y se administran 5 dosis de inmunoglobulinas \ninespec\u00edficas (0, 5 g/kg/d\u00eda durante 5 d\u00edas), sin buena respuesta.  Se indica la \ndeterminaci\u00f3n de anticuerpos anti -GM-CSF, que resultan positivos (anticuerpos anti -\nGM-CSF de 28 U/mL \u2013 valor de corte <5  U/mL ), lo que confirma el car\u00e1cter primario de \nla enfermedad.  Dada la refractariedad al LPT, tratamiento de elecci\u00f3n en la PAP, es \nnecesario plantear otras estrategias terap\u00e9uticas. Una de las opciones propuestas, \nseg\u00fan la evidencia publicada, es realizar plas maf\u00e9resis y administrar rituximab, lo que \nimplicar\u00eda asociar profilaxis antiinfecciosa y realizar una estrecha monitorizaci\u00f3n, puesto \nque se trata de un paciente con antecedente de nocardiosis y otras infecciones activas \nen ese momento. Los corticoides tam poco ser\u00edan de elecci\u00f3n en este caso, adem\u00e1s de \nla escasa evidencia a favor de su uso en PAP.  \nSe valora, junto al equipo m\u00e9dico, la administraci\u00f3n de factor estimulante de colonias \nde granulocitos -macr\u00f3fagos (GM -CSF). Sargramostim (Leukine\u00ae) es un factor d e \nestimulaci\u00f3n de las colonias de granulocitos -macr\u00f3fa gos recombinante humano (GM -750CSF-rhu) que induce la divisi\u00f3n de c\u00e9lulas progenitoras parcialmente comprometidas, \nas\u00ed como su diferenciaci\u00f3n a las v\u00edas de los granulocitos -macr\u00f3fagos (comprenden \nneutr\u00f3fil os, monocitos/macr\u00f3fagos y c\u00e9lulas dendr\u00edticas de origen mieloide). Adem\u00e1s, \ntambi\u00e9n es capaz de activar a granulocitos y macr\u00f3fagos maduros.  Se ha descrito su uso \ncomo tratamiento de la PAP en pacientes refractarios a la terapia est\u00e1ndar de LPT con \nsoluci\u00f3 n salina, mediante su administraci\u00f3n subcut\u00e1nea o nebulizada. En este contexto, \ndada la escasez de alternativas terap\u00e9uticas, se elabora un informe individualizado que \njustifique su uso en nuestro paciente, autoriz\u00e1ndose  el tratamiento tras la evaluaci\u00f3n \npor parte de la Comisi\u00f3n de Evaluaci\u00f3n de Tratamientos en Situaciones Especiales de \nUso (CATSEU). Adem\u00e1s, se tramit a la solicitud de autorizaci\u00f3n del  medicamento \nextranjero a la AEMPS, al ser un medicamento no comercializado en Espa\u00f1a.  \nSe decid e iniciar la administraci\u00f3n de sargramostim v\u00eda subcut\u00e1nea debido a la situaci\u00f3n \nde inestabilidad del paciente, siguiendo una pauta de 125 mcg/12h, con el objetivo de \ncontinuar posteriormente el tratamiento v\u00eda nebulizada, cuando presente una evoluci\u00f3n \ncl\u00ednica favorable. Tras 2 semanas de tratamiento v\u00eda subcut\u00e1nea, se cambia la \nadministraci\u00f3n a v\u00eda nebulizada, siguiendo con la pauta de 125 mcg/12h. En el Servicio \nde Farmacia, a partir del vial de Leukine\u00ae de 250 mcg, tras reconstituci\u00f3n y diluci\u00f3n, \nelabora mos las preparaciones de dosis unitarias para la administraci\u00f3n nebulizada \ndurante el ingreso, que deben almacenarse en nevera y tienen una estabilidad de 7 d\u00edas  \nseg\u00fan la matriz de riesgos. Manteniendo esta  pauta nebulizada de 125 mcg/12h, el \npaciente tole ra correctamente el tratamiento y se ha evidenciado una clara mejor\u00eda \ncl\u00ednica  y radiol\u00f3gica  desde el inicio de sargramostim, pudiendo ser dado de alta de UCI \na la planta de hospitalizaci\u00f3n  y posteriormente a domicilio . Adem\u00e1s de la marcada \nmejor\u00eda cl\u00ednica asociada a la administraci\u00f3n de sargramostim, queda resulta la infecci\u00f3n 751por Nocardia . Se realiza educaci\u00f3n sanitaria para la autoadministraci\u00f3n en domicilio de \nsargramostim, resolviendo las dudas referentes a la preparaci\u00f3n  de la soluci\u00f3n para \nnebulizar  y otros aspectos de su tratamiento.   \nLas pautas de utilizaci\u00f3n de sargramostim descritas en los diferentes trabajos publicados \nvar\u00edan en cuanto a dosis y duraci\u00f3n del tratamiento. En nuestro paciente, tras \npresentarlo en el Comit\u00e9 de Enfermedades Pulmonares Intersticiales, se acuerda \ncompletar al menos 24 semanas de tratamiento c on GM -CSF 125 mcg/12h, \nadministrado de forma continua. En caso de no presentar evoluci\u00f3n del todo favorable  \ncon este tratamiento , se plantea la posibilidad de un trasplante bipulmonar.  \n \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA  \nDado que la PAP es una enfermedad rara sin un manejo farmacoterap\u00e9utico claramente \nestablecido, es indispensable una revisi\u00f3n de la evidencia sobre las terapias disponibles. \nEn la situaci\u00f3n de nuestro paciente, no es recomendable el uso de terapias como \nrituximab, debido a las infecciones recie ntes, lo que motivo la b\u00fasqueda de otras \nalternativas de tratamiento. Consideramos la posibilidad de sargramostim en base a \nestudios recientes publicados sobre su utilizaci\u00f3n5,6, as\u00ed como otros factores \nestimulantes de granulocitos4, en el manejo de la PAP autoinmune. Adem\u00e1s, el \nsargramostim nebulizado ofrece la posibilidad de continuar con el tratamiento \nfarmacol\u00f3gico en domicilio, aunque el elevado coste y su adquisici\u00f3n como \nmedicamento extranjero pueden suponer una limitaci\u00f3n para  su utilizaci\u00f3n . No est\u00e1 \nclara la duraci\u00f3n ni el tipo de pauta (continua frente a pauta con descansos) \u00f3ptim os de \nla terapia con sargramostim, lo que requiere estudios que aporten mayor evidencia.  752Tal y como se ha descrito en la literatura, existe una cier ta relaci\u00f3n entre la proteinosis \nalveolar y las infecciones por  pat\u00f3genos como  Nocardia, lo que podr\u00eda explicar la \npresencia asociada de ambas patolog\u00edas en nuestro paciente . \nPor nuestra parte, como farmac\u00e9uticos,  participamos activamente, junto al equipo \nm\u00e9dico responsable, en el manejo farmacoterap\u00e9utico  del paciente. Adem\u00e1s,  \nrealizamos un seguimiento de la eficacia y seguridad del tratamiento y llevaremos a cabo \nla dispensaci\u00f3n de este  desde la Unidad de Atenci\u00f3 n a Paciente Externos, as\u00ed como la \natenci\u00f3n farmac\u00e9utica que pueda requerir a  lo largo de todo el tratamiento.  \n \nBIBLIOGRAF\u00cdA  \n1. Kumar A, Abdelmala k B, Inoue Y, Culver  DA. Pulmonary alveolar proteinosis in adults:  \npathophysiology and clinical approach.  Lancet Respir Med. 2018;6(7):554 -65.  \n2. Griese M. Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective. \nPediatrics. 2017;140(2):e20170610.   \n3. Antoniu SA, Rajnoveanu R, Grigore M, Antohe  I. Pharmacotherapy options in \npulmonary alveolar proteinosis.  Expert Opin Pharmacother.  2020;21(11):1359 -1366.  \n4. Trapnell BC, Inoue Y, Bonella F, Morgan C, Jouneau S, Bendstrup E . Inhaled \nMolgramostim  Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J \nMed. 2020;383(17):1635 -1644.  \n5. Campo I, Mariani F, Paracchini E,  Kadija, Zorzetto ZM, Tinelli C, et al. Inhaled \nsargramostim and whole lung lavage as therapy of autoimmune pulmonary alveolar \nproteinosis (aPAP). European Respiratory Journal 2016 ;48:PA3870;  \n6. Tanner LM, Kurko J, Tringham M, Aho H, Mykk\u00e4nen J, N\u00e4nt\u00f6 -Salonen K, et al. Inhaled \nSargramostim  Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric \nProtein Intolerance. JIMD Rep.  2017;34:97 -104.  753 Hipofosfatemia  grave  tras administraci\u00f3n de hierro carboximaltosa  endovenoso. \nAutores: Arranz -Pasqual N1, Torrent -Rodr\u00edguez  A1, Miana -Mena MT1, L\u00f3pez -Su\u00f1\u00e9 E1, \nCorominas -Garc\u00eda N1, Soy -Muner D1. \n1Servicio de Farmacia. Hospital Cl\u00ednic de Barcelona  \nIntroducci\u00f3n  \nLa introducci\u00f3n del preparado de hierro carboximaltosa  (HCM)  ha supuesto un avance \nimportante en la terapia endovenosa  (EV) de hierro ya que permite una correcci\u00f3n r\u00e1pida y \ntotal del d\u00e9ficit de hierro administrando \u00fanicamente una o dos dosis del f\u00e1rmaco1.  \nSeg\u00fan ficha t\u00e9cnica, el preparado EV de HCM est\u00e1 indicado en el tratamiento del d\u00e9ficit de \nhierro cuando es refractario a los preparados orales o estos no se pueden administrar y \ncuando hay una necesidad cl\u00ednica de reponer el d\u00e9ficit de hierro r\u00e1pidamente2.  \nEl HCM  se presenta en forma de soluci\u00f3n coloidal que permite la liberaci\u00f3n controlada de \nhierro para que se pueda unir de forma correcta a la transferrina y a la ferritina. La \nestabilidad del complejo de hierro con la carboximaltosa permite que se puedan adminis trar \naltas dosis de hierro (1000mg) de forma r\u00e1pida (15 minutos)3. Esta caracter\u00edstica permite \nadministrar el HCM  en dosis espaciadas en el tiempo , lo que es adecuado  para pacientes \nque acuden a hospital de d\u00eda, mientras otras formas de hierro EV como el  hierro sacarosa, \nrequieren de una administraci\u00f3n diaria y suele utilizarse en  pacientes ingresados.  \nLa dosis individual de HCM  se determina en funci\u00f3n d el nivel de hemoglobina y peso del \npaciente, no pudiendo superar la dosis de 1000 mg de hierro a la semana. Para valorar la \neficacia del tratamiento , a las cuatro semanas de la  \u00faltima dosi s se realizar\u00e1 una \ndeterminaci\u00f3n de  hemoglobina3. 754Un problema de los  preparados EV de hierro es la aparici\u00f3n de reacciones de \nhipersensibilidad. Los preparados de HCM,  gracias a su mecanismo de liberaci\u00f3n gradual y a \nsu menor frecuencia de administraci\u00f3n , tienen una menor incidencia de este tipo de \nreacciones que los preparados de hierro sacarosa, por lo que ser\u00eda la opci\u00f3n EV m\u00e1s segura \npara pacientes m\u00e1s susceptibles a presentar reacciones al\u00e9rgicas2,3. \nOtras reacciones adversas frecuentes ocasionadas tras la administraci\u00f3n de HCM fueron \nn\u00e1useas, reacciones en el lugar de inyecci\u00f3n, hipofosfatemia, cefalea, rubefacci\u00f3n, mareos e \nhipertensi\u00f3n2,3. La hipofosfatemia se ha descrito principalmente con HCM y no con otras \nformas de hierro EV.  \nA continuaci\u00f3n, presentamos el caso cl\u00ednico de un paciente que desarroll\u00f3 hipofosfatemia \ngrave  (1,0 mg/dL) tras la administraci\u00f3n de HCM  para el tratamiento de una anemia \nnormoc\u00edtica post cardiotom\u00eda .  \nCaso cl\u00ednico  \nPaciente var\u00f3n de 66 a\u00f1os, peso 69 kg  y altura 170 cm , sin alergias medicamentosas \nconocidas, que presenta como antecedentes patol\u00f3gicos de inter\u00e9s asma laboral por \nexposici\u00f3n a goma ar\u00e1biga y mucopolisacaridasa e hipertensi\u00f3n pulmonar tromboemb\u00f3lica  \ncr\u00f3nica , complicada con dos episodios de t romboembolismo pulmonar .  El 29 noviembre de \n2021 el paciente ingresa de forma electiva para tromboendarter ectom\u00eda  pulmonar y tras \nestar ingresado unos d\u00edas en la unidad de cuidados intensivos para monitorizaci\u00f3n, puede \nser trasladado a la planta de hospit alizaci\u00f3n y dado de alta dos semanas despu\u00e9s de la \nintervenci\u00f3n.  755Quince d\u00edas despu\u00e9s el paciente consulta en urgencias por dolor tor\u00e1cico de 3 d\u00edas de \nevoluci\u00f3n acompa\u00f1ado de fiebre y edemas en las extremidades inferiores. El cuadro se \norienta como pericarditis post cardiotom\u00eda y se diagnostica anemia normoc\u00edtica hipocr \u00f3mica \n(con hemoglobina ( Hb) de 8,9 g/ dL). El paciente es dado de alta a domicilio con furosemida \n40 mg al d\u00eda por v\u00eda oral (VO), hasta la visita con su neum\u00f3logo de referencia, colchicina 0,5 \nmg al d\u00eda VO durante 6 semanas e ibuprofeno 600 mg cada 8 horas VO durante dos semanas \no hasta remisi\u00f3n del dolor . Se programa en hospital de d\u00eda (HD) la administraci\u00f3n de dos \ndosis de  1000 mg de  HCM  separadas entre s\u00ed una semana.  \nEl paciente acude a HD  (4/1/22), presenta Hb 8,1 g/dL  y se administra n 1000 mg de HCM .  A \nlos 7 d\u00edas , el paciente vuelve a HD para la administraci\u00f3n de la segunda dosis y refiere \nsensaci\u00f3n de mareo, cansancio , incapacidad para caminar m\u00e1s de 100 metros  y taquicardia \nque inicialmente se asocia a la anemia del paciente . Se rea liza un electrocardiograma que \npresenta QT alargado y ondas T negativas precordiales derechas.  Se le solicita una anal\u00edtica \nurgente que muestra  potasio (K) 3,2 mEq/L  (Valores de referencia ( VR): 3,5 -5,5 mEq/L), \ncalcio (Ca) de 8,3 mg/dL (V R 8,5-10,5 mg/dL)  y f\u00f3sforo (P) de 1 ,0 mg/dL  (VR 2,3-4,3 mg/dL), \ndiagnostic\u00e1ndose hipofosfatemia grave . Se administran 20 mmol de fosfato monopot\u00e1sico  \n(FMK ) y 9 mEq de gluconato c\u00e1lcico, adem\u00e1s de la dosis de 1000 mg de  HCM.  Se solicita  \ncontrol anal\u00edtico en HD  para el d\u00eda  siguiente.  \nEl 12/1/22 presenta Ca normalizado (8,90 mg/dL ) y un leve aumento de los niveles de P (1,4 \nmg/dL), que contin\u00faan por debajo de rango , por lo que se administra n 20 mmol de FMK . Al \nd\u00eda siguiente se cita en HD,  contin\u00faa con hipofosfatemia grave (1,3 mg/dL), por lo que se \nadministran  50 mmol  de FMK  y se decide ingresar al paciente en sala  de hospitalizaci\u00f3n  para \nmonitorizaci\u00f3n. Posterior a la administraci\u00f3n de FMK, se realiza un electrocardiograma que 756es normal y se realiza interconsulta a nefrolog\u00eda para determinar la causa de la \nhipofosfatemia,  teniendo como principal orientaci\u00f3n diagn\u00f3stica efecto adverso de HCM. \nDesde nefrolog\u00eda se descartan las principales  causas de hipofosfa temia (enol ismo , \ndesnutrici\u00f3n, diabetes mellitus descompensada, alcalosis respiratoria) y solicitan una \nanal\u00edtica de perfil  tiroid eo, cortisol, parathormona, equilibrio \u00e1cido -base y vitamina D, \npresentando  todos valores normales .      \nTras cuatro d\u00edas  de ingreso, se aprecia  mejor\u00eda en la sintomatolog\u00eda cl\u00ednica del paciente y \nconcentraci\u00f3n s\u00e9rica de P  1,9 mg/dL,  por lo que  se decide alta a domicilio  (17/1/22) , sin \nsuplemento externo de FMK y realizar  seguimiento en HD. El 26/1/22 persiste la \nhipofosfate mia grave (1,3 mg/dL ), por lo que se le administra n 30mmol de FMK . Se le \nprograma un nuevo control a los dos d\u00edas , mostrando niveles de P bajos (1,9 mg/dL ). Se \nadministra una dosis de 60mmol de FMK y se decide iniciar tratamiento  oral con de 1 sobre \nal d\u00eda de fosfato s\u00f3dico  monohidrato  (3,56 g). A pesar del tratamiento oral, en la visita a HD \n10 d\u00edas despu\u00e9s , sigue presentando unos niveles de P de 2 ,0 mg/dL, por lo que se aumenta \nla pauta de fosfato s\u00f3dico  (FNM)  a 2 sobres al d\u00eda.  \nFinalmente, un mes des pu\u00e9s de iniciar la terapia con fosfato s\u00f3dico VO, el paciente presenta \nunos niveles de P de 3,5 mg/dL y mejor\u00eda  de la sintomatolog\u00eda. Se decide dejar la pauta de 1 \nsobre de fosfato s\u00f3dico con control anal\u00edtico peri\u00f3dico . Un mes y medio despu\u00e9s, en la \n\u00faltima anal\u00edtica realizada, el P ya presenta una concentraci\u00f3n s\u00e9rica de 4,5 mg/dL y la Hb se \nmantiene a 16,1 g/ dL, par\u00e1metros que se acompa\u00f1an tambi\u00e9n de mejor\u00eda cl\u00ednica (el \npaciente puede caminar  m\u00e1s de 1000 metros ).  Con estos resultados  anal\u00edticos  y la cl\u00ednica \ndel paciente se considera que tanto la hipofosfatemia c omo la anemia est\u00e1n resueltas.  757La evoluci\u00f3n de la concentraci\u00f3n s\u00e9rica de P y de Hb en funci\u00f3n del tratamiento recibido se \nresumen en la Figura 1 .  \nFigura 1: Evoluci\u00f3n de los niveles s\u00e9ricos de P y Hb en funci\u00f3n del tratamiento recibido.  \n \nHb: hemoglobina, HCM: hierrocarboximaltosa, FMK: fosfato monopot\u00e1sico, FNM: fosfato s\u00f3dico monohidrato  \n(sobres 3,56 g) , P: f\u00f3sforo  \nDiscusi\u00f3n  \nLa hipofosfatemia es un trastorno electrol\u00edtico que se caracteriza por una concentraci\u00f3n \ns\u00e9rica de P por debajo de 3 ,0 mg/dL.  En princip io, los s\u00edntomas son inespec\u00edficos (n\u00e1useas, \nmialgias, astenia) pudiendo llegar en la hipofosfatemia grave a afectaci\u00f3n neurol\u00f3gica grave \n(letargia, confusi\u00f3n, convulsiones, par\u00e1lisis ascendente), rabdomiolisis, arritmias y hem\u00f3lisis.   \nEn la tabla 1  se clasifica la hipofosfatemia en funci\u00f3n de su gravedad4.   \nTabla 1: Clasificaci\u00f3n hipofosfatemia en funci\u00f3n de los niveles s\u00e9ricos de P.  \n \n758Clasificaci\u00f3n de la hipofosfatemia  \nLeve  2,3 \u2013 2,7 mg/dL  \nModerada  1,5 \u2013 2,3 mg/dL  \nGrave  < 1,5 mg/dL  \n \nCuando el paciente present\u00f3 hipofosfatemia grave tras la primera administraci\u00f3n de HCM , \nel equipo m\u00e9dico responsable contact\u00f3 con las farmac\u00e9uticas de referencia del \u00e1rea para \nconsultar si el HCM  podr\u00eda ser la causa de la hipofosfatemia y para optimizar  su manejo .  \nA pesar de que la hipofosfatemia es un efecto adverso poco conocido del HCM , se \nencuentra descrit a en la ficha t\u00e9cnica c omo u na reacci\u00f3n adversa frecuente (afectaci\u00f3n: \n1/10  a 1/100 personas)  y tambi\u00e9n consta como efecto adverso , aunqu e de frecuencia \ndesconocida, ya que solo se ha observado despu\u00e9s de la comercializaci\u00f3n, la osteomalacia \nhipofosfat\u00e9mica2. Las instituciones sanitarias del Reino Unido  publica ron una alerta de \nseguridad  a finales de noviembre del 2020  donde se informaba de que la administraci\u00f3n de \nHCM se hab\u00eda asociado con casos comunes de hipofosfatemia y que en casos graves se \nhab\u00eda llegado a producir osteomalacia  hipofosfat\u00e9mica5. Desde el Servicio de Farmacia se \nrealiz\u00f3 la notificaci\u00f3n de la reacci\u00f3n adversa al centro auton\u00f3mico de farmacovigilancia \nmediante la tarjeta amarilla.  \nEn estos casos la hipofosfatemia es debida a que el HCM aumenta los niveles del factor de \ncrecimiento de fibroblastos 23 (FGF23) inhi biendo la enzima responsable de su degradaci\u00f3n. \nEL FGF23 es secretado a nivel \u00f3seo y aumenta la excreci\u00f3n urinaria del P al inhibir el \ncotransportador de sodio potasio.  La hi pofosfatemia suele aparecer en tre 2 -5 semanas \ndespu\u00e9s de la administraci\u00f3n6.  759Este tipo de reacci\u00f3n adversa es m\u00e1s relevante en pacientes que presentan una mayor \nsusceptibilidad a la hipofosfatemia, por lo que es importante identificar la presencia de los  \nposibles factores de riesgo de desarrollarla como : d\u00e9ficit de vitamina D, malabs orci\u00f3n de \ncalcio y fosfato, hipoparatiroidismo secundario, enfermedad inflamatoria intestinal y \nosteoporosis5.  \nEn cuanto al tratamiento  de la hipofosfatemia aguda con depleci\u00f3n de P se recomienda su \nsuplementaci\u00f3n ex\u00f3gena . En los casos leves se recomienda la v\u00eda  oral por presenta r menor \nriesgo de complicaciones que la v\u00eda EV (hipocalcemia, arritmias e insuficiencia renal aguda ), \naunque es menos eficaz . En los casos m\u00e1s graves o refractarios se utiliza  v\u00eda EV  que corrige \nla hipofosfatemia m\u00e1s r\u00e1pidament e4. En este caso, dado que el paciente presentaba \nsintomatolog\u00eda se opt\u00f3 por la v\u00eda EV. Desde el Servicio de Farmacia revisamos la dosis \ncorrecta de FMK, siendo esta  de 0,25 y 0,50 mmol/kg de FMK , hasta una m\u00e1ximo de 80 \nmmol  al d\u00eda  y desde enfermer\u00eda nos consultaron su forma de administraci\u00f3n (diluir dos \nampollas en un suero fisiol\u00f3gico de 250ml y pasar en 2 horas)7. Debido a que el paciente \ncuando dejaba de recibir cargas de FMK EV no consegu\u00eda mantener la concentraci\u00f3n s\u00e9rica \nde P en rango , desde farmacia se recomend\u00f3 a\u00f1adir al tratamiento P por VO . Se busc\u00f3 la \npresentaci\u00f3n comercializada m\u00e1s adecuada  (fosfato s\u00f3dico NM)  y la dosis recomendada8.  \nEn conclusi\u00f3n, la hipofosfatemia debida a la administraci\u00f3n de HCM es un efecto ad verso \nfrecuente y que  puede llegar a resultar grave. Por ello, es importante determinar los niveles \ns\u00e9ricos de P antes de la administraci\u00f3n  del f\u00e1rmaco  y controlarlos durante un tiempo \ndespu\u00e9s de la administraci\u00f3n, sobre todo en aquellos pacientes que deben recibir m\u00faltiples \ndosis o presentan factores de riesgo para desarrollar hipofosfatemia.  \n 760Bibliograf\u00eda  \n1.  Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron \ndeficiency with intravenous ferric carboxymaltose or iron isomaltoside \u2014a systematic \nreview and meta\u2010analysis. British Journal of Clinical Pharmacology . 2021;87(5):2256-  \n2.  Ficha t\u00e9cnica Ferinject 50 mg/mL Soluci\u00f3n i nyectable y para perfusi\u00f3n.  Centro \nInformaci\u00f3n de Medicamentos. Agencia Espa\u00f1ola del Medicamento y Productos \nSanitarios.    \n3.  Scott LJ. Ferric Carboxymaltose: A Review in Iron Deficiency. Drugs . 2018;78(4):479 -\n493.   \n4.  Brown KA, Dickerson  RN, Morgan LM, Alexander KH, Minard G, Brown RO. A new \ngraduated dosing regimen for phosphorus replacement in patients receiving nutrition \nsupport. JPEN J Parenter Enteral Nutr. 2006 May -Jun;30(3):209 -14.  \n5.  Ferric carboxymaltose (Ferinject): risk of sy mptomatic hypophosphataemia leading to \nosteomalacia and fractures.  Medicines and Healthcare products Regulatory Agency.  \n6.  Efe O, Garc\u00eda JDC, Mount DB, Sheridan AM. Refractory hypophosphatemia following \nferric carboxymaltose administration. CEN Case Repor ts. 2021;10(4):473 -475.  \n7.  Ficha t\u00e9cnica f osfato dipot\u00e1sico 1M Fresenius Kabi 174,2 mg/ml concentrado para \nsoluci\u00f3n para perfusi\u00f3n.  Centro Informaci\u00f3n de Medicamentos. Agencia Espa\u00f1ola del \nProductos Sanitarios.  \n8.  Ficha t\u00e9cnica Fosfato NM 3,56 g. Polvo para soluci\u00f3n oral.  Centro Informaci\u00f3n de \nMedicamentos. Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios.   761 \n APLASIA MEDULAR SECUNDARIA A F\u00c1RMAC OS EN UN PACIENTE  PEDI\u00c1TRICO  CON \nENCEFALITIS AUTOINMUNE  \nIntroducci\u00f3n  \nLa aplasia medular (AM) es un s\u00edndrome cl\u00ednico caracterizado por una desaparici\u00f3n total \no parcial de precursores hematopoy\u00e9ticos en la medula \u00f3sea, ocasionando una \npancitopenia.  \nLa AM se puede clasificar en cong\u00e9nita, o  m\u00e1s frecuentemente, adquirida. Sin embargo, \nhasta en el 80% de los casos no es posible identificar la causa.  La AM causada por \nf\u00e1rmacos es una reacci\u00f3n a dversa grave y poco frecuente. Entre l os medicamentos m\u00e1s \nimplicados se encuentran  inmunosupresores, antiepil\u00e9pticos, anti depresivos y \nantiinflamatorios .  \nA continuaci\u00f3n, se presenta el  caso de un paciente con una encefalopat\u00eda autoinmune \nque desar rolla una AM , probablemente f\u00e1rmaco -inducida,  durante su ingreso . \nDescripci\u00f3n del caso  \nPaciente var\u00f3n de 12 a\u00f1os y 60 kg de peso  con antecedentes de vit\u00edligo, leve \ndiscapacidad intelectual y epilepsia en tratamiento con levetiracetam.  \nIngresa en enero de 2022  por crisis conv ulsivas. Se realiza punci\u00f3n lumbar (PL)  y \nresonancia magn\u00e9tica nuclear (RMN) cerebral que orienta el cuadro a una encefalitis \nautoinmune/inflamatoria . Se inician bolos de metilprednisolona 1 g durante 3 d\u00edas con \nclara mejor\u00eda cl\u00ednica por lo que es dado de alta.  762 \n Diez d\u00edas m\u00e1s tarde,  el paciente consulta por empeoramiento de las crisis  y cuadro de \nv\u00f3mitos. Ante la t\u00f3rpida evoluci\u00f3n , se decide ingreso en UCI pedi\u00e1trica donde se inicia  \ntratamiento con perampanel, fenobarbital, \u00e1cido valproico, lacosamida y brivaracetam \na dosis terap\u00e9uticas, sin respuesta cl\u00ednica,  por lo que se induce el  coma barbit\u00farico . \nSe realiza es tudio diagn\u00f3stico de epilepsi a refractaria con PL , biopsia  cerebral y estudio \nmetab\u00f3lico. Dado el antecedente de probable etiolog\u00eda autoinmune/ inflamatoria se \nreinician bolos de corticoides y se introduce dieta cetog\u00e9nica.  \nEl resultado de la biopsia sugiere una encefalitis autoin mune (enfermedad de \nRasmus sen), por lo que se inicia p lasmaf\u00e9resis y rituximab a dosis de 375mg/m2 semanal \ndurante 4 semanas. Dos d\u00edas m\u00e1s tarde, el paciente presenta pico febril de 39\u00baC y \naumento de  reactantes de fase aguda  (RFA) (prote\u00edna C reactiva, velocidad de \nsedimentaci\u00f3n globular  y procalcitonina). Se realiza  RMN  cerebral en la que se objetiva  \ncolecci\u00f3n intracraneal en la regi\u00f3n de  la biopsia , por lo que se inicia antibioterapia \nemp\u00edrica con v ancom icina (12mg/kg/6h) y meropenem (30mg/kg/8h).  Tambi\u00e9n se inicia \nfluconazol  (200mg/24 h) tras aislarse Candida  albicans  en cat\u00e9ter venoso central (CVC).  \nTras la estabilizaci\u00f3n y  buena evoluci\u00f3n del paciente, s e decide traslado  a planta el 09/03 \ncon 4 f\u00e1 rmacos antiepil\u00e9pticos v\u00eda oral : perampanel  (12mg/24h) , fenobarbital  \n(150mg/12h) , lacosamida  (200mg/12h)  y bri varacetam  (100mg/12h), dieta cetog\u00e9 nica y \ntratamiento antibi\u00f3tico hasta completar 6 semanas .  \nDesde su llegada a planta, e l paciente persiste con picos febriles y en la anal\u00edtica del \n14/03 aparecen  alteraciones en el hemograma: anemia normoc\u00edtica  (8,4 g/dL) , \nleucopenia  (2,2 mil/mm3) y linfopenia  (0,3 mil/mm3) con ferritina elevada  (25517 ug/L) , \nhipertrigliceridemia  (542 mg/dL ) y transaminasas e n ascenso (ALT: 138 UI/L y AST: 178 763 \n UI/L) ( Ver Gr\u00e1fico 1 ). Ante estos hallazgos, se orienta en un primer momento hacia un \nprobable  s\u00edndrome hemofagoc\u00edtico (SHF)  secundario a  f\u00e1rmacos o a  virus herpes simple \ntipo 1 (VHS -1) tras result ar p ositiva la PCR para  VHS-1 en frotis de mucosa bucal. \nParalelamente, el paciente presenta  dolor epig\u00e1strico intenso mal controlado a pesar de \ntratamiento con inhibidor de la bomba de protones. En una primera instancia se \nsospech\u00f3 de una causa mec\u00e1nica por l a sonda nasog\u00e1strica, pero posteriormente , tras \nrealizaci\u00f3n de endoscopia gastroesof\u00e1gica y biopsia , se diagnostic\u00f3 de una infecci\u00f3n por \nVHS-1 y Candida  albicans , por lo qu e se inici\u00f3 tratamiento con aciclovir  IV (800mg/8h), \nmicafungina (150mg/ 24h) y gammaglobulinas para optimizar el ma nejo de la infecci\u00f3n \nherp\u00e9tica. Adem\u00e1s, se inicia profilaxis con cotrimoxazol ( 600 mg de sulfametoxazol cada \n12h 3 d\u00edas a la semana ).  \nEl d\u00eda 29/03 en la anal\u00edtica se acent\u00faa la  trombocitopenia  (83 mil/mm3) y la neutropenia \n(0,2 mil/mm3) sin recuperaci\u00f3n del  resto de par\u00e1me tros hematol\u00f3gicos, por  lo que se \ninici\u00f3  tratamiento con factor estimulante de colonias  de granulocitos ( filgrastim) SC a \ndosis de 300  mg durante 5 d\u00edas . Se le realiz \u00f3 PCR para  COVID -19 ante con tacto positivo \nde un familiar, que result \u00f3 positiva  tambi\u00e9n en nuestro paciente , por lo que se  inici\u00f3 \ntratamiento con remdesivir 200 mg el primer d\u00eda seguido de 100 mg/d\u00eda durante 4 d\u00edas.  \nAl valorar los posibles desencadenantes de la AM y descartar la caus a infecciosa , se \norient \u00f3 c\u00f3mo  hip\u00f3tesis m\u00e1s probable la toxicidad farmacol\u00f3gica. Se revisaron los \nf\u00e1rmacos que recibi\u00f3 el paciente, recogi endo  las fechas de inicio y fin de los tratamientos  \ny se relacionaron con la evoluci\u00f3n de los par\u00e1metros hematol\u00f3gicos ( Ver Gr\u00e1fico 1 ). \nTras analizar los potenciales f\u00e1rmacos implicados en la toxicidad, se atribuy\u00f3 \nprincipalmente al uso concomitante de vancomicina, meropenem y micafungina por lo 764 \n que s e hiz o ajuste de todo el tratamiento del paciente con el fin de conseguir \nnormalizaci\u00f3n de cifras de los diferentes par\u00e1metros hematol\u00f3gicos . El paciente es dado \nde alta a domicilio el d\u00eda 29/04 tras haberse resuelto los problemas infecciosos, \nhematol\u00f3gicos  y con un mejor control de las crisis.  \n \nGr\u00e1fico 1. Evoluci\u00f3n de par\u00e1metros hematol\u00f3gicos y tratamientos entre 12 /03-25/04  \n765 \n Discusi\u00f3n y aportaci\u00f3n farmac\u00e9utica  \nEl rol del farmac\u00e9utico estuvo integrado en el equipo multidisciplinar durante todo el  \nproceso asistencial del paciente  y a continuaci\u00f3n,  se exponen l as principales  \naportaciones realizadas : \n\u2022 Aplasia medular farmacol\u00f3gica  \nEl paciente fue valorado en conjunto en reuniones multidisciplinares organizadas de \nforma semanal con diferentes especialidades (pediatr\u00eda, neurolog\u00eda, inmunolog\u00eda, \ninfectolog\u00eda, hematolog\u00eda y farmacia), donde finalmente se concluy\u00f3 que la hip\u00f3tesis \nm\u00e1s probable de la AM fue la toxicidad farmacol\u00f3gica. De sde farmacia, se realiz\u00f3 una \nrevisi\u00f3n exhaustiva de todos los f\u00e1rmacos que recibi\u00f3 el paciente durante toda su \nestancia en el hospital al momento de manifestarse la toxicidad, as\u00ed como los efectos \nadversos tanto agudos como tard\u00edos de los medicamentos.  \nTras revisar bibliograf\u00eda sobre los diferentes antiepil\u00e9pticos, se concluy\u00f3 que estos no \nparecieron estar relacionados con la aparici\u00f3n de AM,  adem\u00e1s, ya hab\u00edan pasado \naproximadamente dos meses desde el inicio de estos tratamientos sin manifestar \ntoxicidad pr evia.  \nAl revisar los antibi\u00f3ticos que recib\u00eda y que recibi\u00f3, se pud ieron  relacionar algunos de \nellos con alteraciones en el recuento de c\u00e9lulas sangu\u00edneas. Existe evidencia cient\u00edfica \nen revisiones, casos cl\u00ednicos publicados y las fichas t\u00e9cnicas respectiv as donde se ha \npodido relacionar con esta complicaci\u00f3n a meropenem, vancomicina y micafungina.  \nEn cuanto a meropenem y vancomicina, las alteraciones en el hemograma se consideran \npoco frecuentes. Sin embargo, se han notificado casos de pancitopenia produci da hasta 766 \n dos semanas despu\u00e9s del inicio de estos tratamientos. En este paciente, la \nantibioterapia hab\u00eda sido iniciada aproximadamente dos semanas antes del desarrollo \nde la AM.  \nEn el caso de micafungina, est\u00e1n documentadas como reacciones adversas frecue ntes: \nanemia, neutropenia, leucopenia y trombocitopenia (estos efectos adversos persisten \ndurante una mediana de 13 d\u00edas tras la suspensi\u00f3n del f\u00e1rmaco). Adem\u00e1s, se ha descrito \nque la proporci\u00f3n de pacientes que presentan estos efectos adversos es mayor en  \npacientes pedi\u00e1tricos que en adultos.  \nSe transmiti\u00f3 la informaci\u00f3n recogida en relaci\u00f3n a estos efectos adversos a los \ndiferentes equipos implicados, realiz\u00e1ndose ajustes en el tratamiento. En concreto, se \ncambi\u00f3 micafungina por posaconazol por considera rse que este \u00faltimo presenta menor \nriesgo de AM  sin riesgo de interacci\u00f3n farmacol\u00f3gica con su tratamiento de base . \nMeropenem se rot\u00f3 a ciprofloxacino  por la misma raz\u00f3n. Respecto a vancomicina, se \ndecidi\u00f3 mantener el tratamiento hasta completar  la duraci\u00f3n prevista, por la necesidad \nde controlar el empiema secundario a la biopsia cerebral.  \nPor otra parte, en cuanto  a remd esivir , desde su introducci\u00f3n se produ jo una evidente \ntrombocitopenia , que,  aunque en ficha t\u00e9cnica  no se contem pla, no habr\u00eda datos \nsuficientes  para descartarla debido a su corto  recorrido en  la pr \u00e1ctica cl\u00ednica .  \nEl paciente present\u00f3 una linfopenia muy marcada, consecuencia del tratamiento  para \nsu enfermedad autoinmune. Respecto a l rituximab , se descart\u00f3 la as ociaci\u00f3n con la AM, \nya que se trata de un anticuerpo que se une espec\u00edficamente a la prote\u00edna CD20  \nexpresada \u00fanicamente en la superficie de los linfocitos B, por lo que no pod\u00edan verse \nafectadas el resto de l\u00edneas celulares  sangu\u00edneas.  767 \n \u2022 Revisi\u00f3n  de potenci ales i nteracciones farmacol\u00f3gicas  \nEl complejo  y variado tratamiento m\u00e9dico  que recibi\u00f3 el paciente, y que incluy\u00f3 \ninductores e inhibidores enzim\u00e1ticos, present\u00f3 m\u00faltiples modificaciones durante e l \ningreso . Se buscaron  interacciones en diferentes bases de datos farmacol\u00f3gicas cada  vez \nque se a\u00f1ad\u00eda alg\u00fan nuevo f\u00e1rmaco , sin detectarse ninguna interacci\u00f3n que haya \nobligado a suspender o modificar el tratamiento.  \n\u2022 Excipientes en dieta cetog\u00e9 nica  (DC)  \nPara evitar romper la e ficacia de la DC se recomienda utilizar medicamentos que no \ncontengan excipientes que aporten carbohidratos, como el almid\u00f3n, sacarosa, lactosa, \nentre otros. Se revisaron los excipientes de l os medicamentos que recib i\u00f3 y en los casos \nen que fue posible se sustituyeron  por alternativas  libres de excipientes en cuesti\u00f3n . Sin \nembargo,  esta estrategia a los pocos d\u00edas fue retirada por falta de eficacia.  \n\u2022 Monitorizaci\u00f3n farmacocin\u00e9tica  \nEl paciente recibi\u00f3 terapia antibi\u00f3tica emp\u00edrica para tratar el empiema cere bral con \nvancomicina y meropenem a dosis m\u00e1ximas , siguiendo el protocolo del hospital para la \ninfecci\u00f3n del s istema nervioso central.  Con el fin de asegurar  la efectividad del \ntratamiento y limitar los efectos adversos  de la vancomicina , se realiz\u00f3  la monitorizaci\u00f3n \nestrecha de los niveles plasm\u00e1ticos mediante el programa PKS .  La concentraci\u00f3n \nplasm\u00e1tica m\u00ednima deseada para cubrir sistema nervioso central deb i\u00f3 estar siempre \nentre 1 5-20 mg/L , comprobando en todo momento la funci\u00f3n renal del paciente.  \nEn cuanto al tratamiento anticomicial, para asegurar la eficacia , fueron monitorizados \ntambi\u00e9n fenobarbital  y \u00e1cido valproico.  En relaci\u00f3n al fenobarbital , se consider\u00f3 como 768 \n rango terap\u00e9utico \u00f3ptimo  una concentraci\u00f3n plasm\u00e1tica entre 15 -40 \u00b5g/mL. En el caso \ndel \u00e1cido valproico , los niveles plasm\u00e1ticos fueron ajustados  en funci\u00f3n de la alb\u00famina \ns\u00e9rica y el rango \u00f3ptimo se consid er\u00f3 entre 50 -125 \u00b5g/mL. Es importante tenerlo en \ncuenta ya que es un f\u00e1rma co que se une en elevado porcentaje a prote\u00ednas plasm\u00e1ticas \ny solo la fracci\u00f3n libre del f\u00e1rmaco es la responsable del efecto farmacol\u00f3gico.  \nEl caso cl\u00ednico presentado es complejo por tratarse de un paciente con un dif\u00edcil manejo \nm\u00e9dico, inmunocomprometid o y polimedicado .  En dicho contexto realiz\u00f3 una AM  que,  \nhabi\u00e9ndose  descartado causas infecciosas, se orient\u00f3 como farmacol\u00f3gica . No fue \nposible realizar el algoritmo de Naranjo para poder atribuir la toxicidad a un f\u00e1rmaco en \nconcreto por la situaci\u00f3n de gravedad en que se encontraba el paciente, no obstante, la \nrecuperaci\u00f3n a nivel hematol\u00f3gico fue evidente tras la retirada de meropenem y \nmicafungina , apoyando esta idea . Todas las decisiones fueron tomadas siempre de \nforma multidisciplinar y la integraci\u00f3n del farmac\u00e9utico se mantuvo y fue fundamental \na lo largo de toda la estancia hospitalaria.  \nBibliograf\u00eda  \n1. Bruniera FR, Ferreira FM, et al . The use of vancomycin with its therapeutic and \nadverse effects: a review. Eur Rev Med Pharmacol  Sci. 2015 Feb;19(4):694 -700.  \n2. Mitta A, Curtis BR,  et al . Drug -induced thrombocytopenia: 2019 Update of clinical \nand laboratory data. Am J Hematol . 2019 Mar;  94(3 ): E76-E78.  \n3. Hussain K, Salat MS, et al. Meropenem -induced pancytopenia in a preterm \nneonate: a case report. J Med Case Rep . 2021 Jan 29;  15(1):25.  \n4. Rubio PM, Riesco S. Pancitopenia: valoraci\u00f3n cl\u00ednica y diagn\u00f3stica. Anales de \nPediatr\u00eda Continuada , 2012, vol. 10, no 4, p. 217 -221.  769Farmac ovigilancia y uso segur o capma tinib en c \u00e1ncer de pulm\u00f3n no micr oc\u00edtic o\nIntroducci\u00f3n\nElc\u00e1ncer depulm\u00f3n represen taelsegundo c\u00e1ncer m\u00e1s com\u00fan enincidencia, trat\u00e1ndose\nadem\u00e1s deuna delasprimer ascausas demuert eporc\u00e1ncer ,conuna super vivencia alos5\na\u00f1os deun15% [1]. Elc\u00e1ncer depulm\u00f3n nomicr oc\u00edtic o(CPNM) eselsubtipo m\u00e1s\nfrecuen te,represen tando el84% detodos losdiagn\u00f3s ticosdec\u00e1ncer depulm\u00f3n [2]. La\nmayor\u00eda delospacien tespresen tanenfermedad localmen teavanzada ometast\u00e1sicaenel\nmomen todel diagn\u00f3s tico.Laquimiot erapia (QT)hasido elest\u00e1ndar detratamien toen\ncontextopalia tivodeestospacien tes[3],hastalaaparici\u00f3n enlas\u00faltimas d\u00e9cadas denuevas\ndianas terap\u00e9utic as[4]olosinhibidor esdelospuntosdecontrolinmunit ario (ICI), que han\ncambiado dr\u00e1sticamen teelabor daje terap\u00e9utic odel CPNM. Estasnuevasterapias han\nlogrado unmejor controldeloss\u00edntomas delaenfermedad, mejor estasas derespues tay\nuna mejor atantodesuper vivencia libredeprogresi\u00f3n (SLP) como desuper vivencia global\n(SG) de los pacien tes con respect o a tr atamien tos convencionales c omo la Q T.\nDescripci\u00f3n del c aso\nAnamnesis y an teceden tes per sonales\nPacien temujer de70a\u00f1os, que esfumador apasiv adesde hace m\u00e1s de20a\u00f1os ehipert ensa\natratamien toconolmesart \u00e1n/hidr oclor otiazida, sinotrosanteceden tespersonales de\ninter\u00e9syconun\u00cdndice deComorbilidad deCharlson de0puntos.Acude enjulio 2021 en\nvarias ocasiones alServicio deUrgencias por uncuadr odedolor deespalda, trasla\nrealiz aci\u00f3n deuna radiogr af\u00edadet\u00f3raxsehalla una lesi\u00f3n pulmonar ,por loque seinicia\nestudio a tr av\u00e9s del cir cuito asis tencial de v\u00eda r \u00e1pida de c \u00e1ncer de pulm\u00f3n.770Diagn\u00f3s tico\nSerealiz auntomogr af\u00edacomput arizada (TC)enelque sedescribe una neoplasia pulmonar\nenestadio T4N2M0. Acude aconsult adeoncolog\u00eda paraconocer result ados, momen toen\nelque refierecl\u00ednic adeparestesias enextremidades inferior es,porloque antesospecha de\ncompr esi\u00f3n medular ingresaenNeur ocirug\u00eda paracomple tarestudio einicio detratamien to.\nSe realiz a resonancia magn\u00e9 tica de columna urgente, visualiz \u00e1ndose una\nfractur a-aplas tamien todelcuerpo vertebraldeT2conretropulsi\u00f3n hacia elcanal raqu\u00eddeo ,\ncondiagn\u00f3s ticodecompr esi\u00f3n medular inicia radiot erapia deforma urgentesobr eD2\nadminis trando 20Gysen5fracciones. Secomple tanestudios yserealiz abroncoscopia con\ntoma debiop sia, siendo elresult ado deAnatom\u00eda Patol\u00f3gic adeunAdenoc arcinoma\npulmonar invasivopobr emen tediferenciado. Aprincipios deagostode2021 setraslada la\npacien teaOncolog\u00eda, yserealiz aeldiagn\u00f3s ticofinal deadenoc arcinoma depulm\u00f3n estadio\nIVpormet\u00e1stasis \u00f3seas, conomisi\u00f3n delex\u00f3n14enlatransici\u00f3n mesenquima tosa-epit elial\n(MET) y PD-L1 de un 80%.\nEvoluci\u00f3n\nDuranteelingreso presen tasobr einfecci\u00f3n delamasa pulmonar ,concavitaci\u00f3n e\ninsuficiencia respir atoria, que result aenlaamput aci\u00f3n delbronquio principal izquier do.\nAdem\u00e1s lapacien tepresen t\u00f3otrascomplic aciones: dosneumon\u00edas, bact eriemia porE.coli,y\nun tromboembolismo pulmonar subsegmen tario en l\u00f3bulo inferior derecho ,que\nprolong aronelingreso yretrasaronelinicio deltratamien to.Una vezresuelt oslosprocesos\nagudos, latercerasemana deseptiembr e,sedecide iniciar tratamien todirigido con\ncapma tinib enuso expandido (adosis est\u00e1ndar de400 mgcada 12h) ,enbase alamutaci\u00f3n771MET ex\u00f3n14.Trascasitresmeses deingresosedecide altadelapacien teconelServicio de\nHospit alizaci\u00f3n a Domicilio y el siguien te tratamien to:\n-Ox\u00edgeno domiciliario por g afas nasales a 3 lpm.\n-Code\u00edna si pr ecisa por t os.\n-Diaz epam 5 mg por la noche.\n-Enoxaparina 80 mg c ada 24h.\n-Fentanilo par che tr ansd\u00e9rmic o cada 72 hor as.\n-Fentanilo 200 mcg c omprimido sublingual en c aso de dolor (m\u00e1 ximo c ada 4 hor as).\n-Lactulosa 10 g un sobr e desa yuno , comida y cena.\n-Metoclopr amida jar abe 10 ml desa yuno , comida y cena.\n-Omepr azol 20 mg c \u00e1psula al desa yuno.\n-Paracetamol 1 gr amo desa yuno , comida y cena.\n-Capma tinib 400 mg c ada 12 hor as.\nSeguimien to de la r espues ta y t oxicidad del tr atamien to onc ol\u00f3gic o\nLarespues taesevaluada enuna primer aTCrealiz ada duranteelingreso alascuatro\nsemanas delinicio detratamien to(19/10/2022), observ\u00e1ndose respues taparcialanivelde\ntumor primario yganglionar ,condudas deuna lesi\u00f3n ocupan tedeespacio hep\u00e1 ticode10\nmm. Traselalta,secitaparaseguimien toambula torio porpartedeOncolog\u00eda M\u00e9dic a.Se\nrealiz auna segunda TCdeevaluaci\u00f3n endiciembr econrespues taparcial, por loque se\nman tiene tratamien toconCapma tinib adosis de400 mgcada 12h. Sinembar go,trasesta\nconsult a,seproduce unerrorenlacomunic aci\u00f3n conlapacien tecuyareper cusi\u00f3n esla\nreducci\u00f3n delapaut adeCapma tinib a400 mgcada 24h. Esteerrorhasido propiciado porla\nduplicidad delaprescripci\u00f3n del tratamien tooncol\u00f3gic o:deforma electr \u00f3nic ayen772prescripci\u00f3n enpapel, siendo laprescripci\u00f3n electr \u00f3nic aconcordanteconlahistoria cl\u00ednic a\n(400 mgcada 12h), mien trasque laprescripci\u00f3n enpapel fueuna dosis menor (400 mgcada\n24h). Elerrorencadena, favorecido porlafaltadeconocimien todelmedic amen toalserde\nuso expandido ,provoc\u00f3que ladosis recibida por lapacien tenofuese laadecuada.\nParalelamen te,enlasanal\u00edtic asdecontrolsedetectaunaumen toprogresivodelosniveles\ndecreatinina s\u00e9ric a(Figura1),obteniendo enmarz ode2022 unpicode1,67 mg/dl,\nmomen toenelque sedecide suspender tempor almen teeltratamien toconCapma tinib.\nTraslanormaliz aci\u00f3n delosniveles decreatinina, sedecide reiniciar adosis de300 mgcada\n12h. Enlaconsult adeFarmacia sedetectaque lapacien teestaba adminis trando lapaut a\nerr\u00f3nea (400 mgcada 24h; enlugardecada 12h), porloque senotific aalonc\u00f3log oyuna\nvezaclar ado conlapacien tesedecide iniciar adosis de200 mgcada 12h (recibiendo la\npacien tesolamen teuna toma nocturna de300 mg). Lapacien tecontin\u00faa actualmen tecon\nla paut a de 200 mg c ada 12h, c on controles peri\u00f3dic os  de la funci\u00f3n r enal.\nFigura1.Dosis totaldiaria decapma tinib, paut aposol\u00f3gic ayevoluci\u00f3n delosniveles de\ncreatinina s\u00e9ric a.773Discusi\u00f3n y aport aci\u00f3n f armac\u00e9utic a\nEnprimer lugarelfarmac\u00e9utic oevalu\u00f3 laindic aci\u00f3n deltratamien toconcapma tinib enesta\npacien te,yaque esunmedic amen tosinaprobaci\u00f3n porpartedelaAgencia Europea del\nMedic amen to(EMA). Hasido aprobado por laFood and Drug Adminis tration (FDA)con\nindic aci\u00f3n eneltratamien todepacien tesadult osconCPNM metast\u00e1sicocuyostumor es\npresen tanuna mutaci\u00f3n queconduce alaomisi\u00f3n delex\u00f3n14enlaMET,detectadaporuna\nprueba aprobada porlaFDAenbase alestudio GEOMETR YMono-1 [5].Capma tinib esun\ninhibidor delacinasa que sedirig eaMET,incluida lavarian temutanteproducida porla\nomisi\u00f3n delex\u00f3n14.Laomisi\u00f3n delex\u00f3n14deMET dalugaraunaprote\u00edna alaquelefalta\nundominio regulador quereduce suregulaci\u00f3n negativa,loqueconduce aunaumen todela\nse\u00f1aliz aci\u00f3n deMET [5]. Sesolicit aeltratamien toconcapma tinib enbase asuuso\nexpandido. Laalterna tivaterap\u00e9utic aenestapacien teser\u00eda pembr olizumab (PD-L1 del\n80%), peroseprefiri\u00f3 lautiliz aci\u00f3n decapma tinib porseruntratamien tomolecular dirigido\nyunperfil deefectosadversosfavorable. Nosedetectaroninteracciones conlamedic aci\u00f3n\n774domiciliaria activ a(evaluadas por IBM Micr omede x\u00aeyLexicomp\u00ae) ylafunci\u00f3n renal y\nhep\u00e1 tica fuer on normales al inicio del tr atamien to.\nEnestecaso,elfarmac\u00e9utic ohasido claveparadetectarelerrorinstaurado enlapaut a\nposol\u00f3gic a,previniendo as\u00edmayortoxicidad alevitarunaumen todedosis trasladetecci\u00f3n\ndelaumen todecreatinina yhaciendo una propues tadedisminuci\u00f3n deladosis, nodescrit a\nenlasrecomendaciones delaficha t\u00e9cnic a,as\u00edcomo unseguimien todelatoxicidad renal\npor capma tinib. Seg\u00fan lasrecomendaciones delfabric anteparaCrCl\u226530 mL/minut onose\nrecomienda ajustededosis yparaCrCl <30 mL/minut onohayajustesdedosis previstos[6].\nSinembar go,s\u00edque secontemplan reducciones dedosis progresivasdelniveldedosis de\ncapma tinib en caso de reacciones adversas. Los acontecimien tos adversos m\u00e1s\nfrecuen temen tenotific ados enrelaci\u00f3n coneltratamien toconcapma tinib fueronedema\nperif \u00e9rico,n\u00e1useas, v\u00f3mit osyaumen todelniveldecreatinina ensangr e[5]. Laprimer a\nreducci\u00f3n deladosis son 300 mgdos veces ald\u00edaylasegunda 200 mgdosveces ald\u00eda. Siel\npacien teno puede tolerar200 mg dos veces ald\u00eda serecomienda suspender\npermanen temen teelcapma tinib [6].Basamos larecomendaci\u00f3n enelajustededosis endos\npar\u00e1me tros:ladosis realque estaba tomando elpacien teyelgrado delainsuficiencia renal\ngener ada porestadosis, seg\u00fan losCriterios deTerminolog\u00eda deEventosAdversosversi\u00f3n 5.0\n[7]. Clasific amos lareacci\u00f3n adversacomo grado dos, por serelaumen todecreatinina\nmayora1,5veces elumbr alsuperior denormalidad. Teniendo encuen taque estatoxicidad\nfuecausada conuna dosis yareducida (400 mgcada 24h), recomendamos una paut ade200\nmgcada 12h. Adem\u00e1s, senotific \u00f3lareacci\u00f3n adversayelerrorenlaadminis traci\u00f3n del\nmedic amen toalSistema Espa\u00f1ol deFarmac ovigilancia deMedic amen tosdeUso Humano y\nalSistema deNotific aci\u00f3n yAprendiz ajeparalaSeguridad del Pacien te(SiNASP). Para\npromo vereluso segur odecapma tinib seinstaur\u00f3elsistema dedosis por defectoenla775prescripci\u00f3n electr \u00f3nic a,por loque sepropone lapaut aposol\u00f3gic aest\u00e1ndar alrealiz arla\nprescripci\u00f3n.\nConclusi\u00f3n\nElfarmac\u00e9utic osehaencargado delaevaluaci\u00f3n del medic amen to,revisi\u00f3n delas\ninteracciones medic amen tosas, detecci\u00f3n deunerrordemedic aci\u00f3n, seguimien todela\ntoxicidad deuna reacci\u00f3n adversa,propues tadeunajusteenlapaut aposol\u00f3gic ay\npromoci\u00f3n del uso segur odel medic amen toatrav\u00e9sde las notific aciones de\nfarmac ovigilancia.\nBibliograf\u00eda\n1.- Hospit al Univ ersitario Clinic de Barcelona. Avaliable online:\nhttps://w ww.clinicbar celona.or g/asistencia/ enfermedades/ cancer -de-pulmon/ evolucion-de-\nla-en fermedad (accesed on 4 Ma y 2022).\n2.-Majem, M.;Juan, O.;Insa, A.;Reguart, N.;Trigo,J.M.; Carcereny,E.;Garc\u00eda-Campelo ,R.;\nGarc\u00eda, Y.;Guir ado,M.; Provencio ,M.SEOM Clinic alGuidelines forthe Treatmen tof\nNon-Small Cell Lung Cancer (2018). ClinTranslOncol2019 ,21, 3\u201317,\ndoi:10.1007/ s12094-018-1978-1.\n3.-Molina, J.R.;Yang,P.;Cassivi, S.D.;Schild, S.E.; Adjei, A.A.Non-Small Cell Lung Cancer:\nEpidemiology ,Risk Factors,Treatmen t,and Survivorship.MayoClinicProceedings2008 ,83,\n584\u2013594, doi:10.4065/83.5.584.7764.-Berge,E.M.; Doebele, R.C.TargetedTher apies inNon-Small Cell Lung Cancer: Emer ging\nOncogene TargetsFollowing theSuccess ofEpidermal GrowthFactorRecep tor.Seminars in\nOncology2014 , 41, 110\u2013125, doi:10.1053/j.seminonc ol.2013.12.006.\n5.-Wolf,J.;Seto,T.;Han, J.-Y.;Reguart, N.;Garon,E.B.; Groen, H.J.M.; Tan,D.S.W.;Hida, T.;de\nJong e,M.; Orlo v,S.V.;etal.Capma tinib inMET Exon14\u2013Mut atedorMET -Amplified\nNon\u2013Small-Cell Lung Cancer .NEnglJMed2020 ,383, 944\u2013957,\ndoi:10.1056/NEJMoa2002787.\n6.-Highligh tof prescribing informa tion TABRE CTATM (capma tinib). Available on:\nhttps://w ww.accessda ta.fda.gov/drugsa tfda_docs/label/2020/213591s000lbl.pdf (accessed\non 4 Ma y 2022).\n7.-Common Terminology Criteria forAdverseEvents(CTCAE) Version 5.0. Available on:\nhttps://ctep.cancer .gov/pr otocolde velopmen t/electr onic_applic ations/docs/ ctcae_v5_quick\n_reference_8.5x11.pdf (accessed on 4 Ma y 2022).777SOPORTE NUTRICIONAL EN PACIENTE CON NECR \u00d3LISIS EPID\u00c9RMICA T\u00d3XICA  \nINTRODUCCI\u00d3N  \nLa necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET) o s\u00ed ndrome de Lyell es una reacci\u00f3n de \nhipersensiblidad mucocut\u00e1nea , mayoritariamente secundaria a f\u00e1rmacos . Se trata de \nuna reacci\u00f3n de tipo inmunol\u00f3gico en la que se produce la activaci\u00f3n de los linfocitos T \nCD8 y de las c\u00e9lulas Natural Killer . Esta activaci \u00f3n da lugar a la apoptosis de los \nqueratinocitos produciendo la consiguiente separaci\u00f3n de epidermis -dermis, formaci\u00f3n \nde ampollas y descamaci\u00f3n.  \nEl protocolo a seguir en el manejo de los pacientes con NET es en primer lugar \ndeterminar la etiolog\u00eda  y si es debida a  un f\u00e1rmaco suspender lo. Posteriormente se \neval\u00faa de forma multidisciplinar la gravedad de las lesiones d\u00e9rmicas,  lesiones  mucosas \n(orofar\u00edngea , rectal, genital y ocular)  y se solicitan las pruebas complementarias de \nlaboratorio as\u00ed como una biopsia de piel , todo ello es fundamental para establecer el \ndiagn\u00f3stico , pron\u00f3stico y tratamiento . \nLos paciente s con NET son considerados pacientes cr\u00edticos y su tratamiento es  similar al \nde un paciente gran quemado  (GQ) . Su manejo  engloba : \n- El cuidado d e las lesiones . \n- La resucitaci\u00f3n  con fluidoterapia que resulta fundamental para compensar las p\u00e9rdidas \nd\u00e9rmicas y la maldistribuci\u00f3n h\u00eddrica que se p roduce en estos pacientes y se asocia con \nisquemia renal y gastrointestinal.  \n- El control del dolor  asociado a las curas . 778- El soporte nutricional es muy importante  ya estos pacientes presentan un alto riesgo \nde desnutrici\u00f3n  debido al incremento de sus necesidades energ\u00e9ticas .  \n- La prevenci\u00f3n de infecciones mediante protocolo de descontaminaci\u00f3n digest iva y la \ntoma de muestras de cultivos de vigilancia durante el ingreso . \n- El tratamiento inmunosupresor con ciclosporina que ha demostrado ser el tratamiento \nfarmacol\u00f3gico con mayor eficacia y seguridad , act\u00faa retrasando la progresi\u00f3n de la NET .  \nRespecto al soporte nutricional no existen recomendaciones para los pacientes con NET \npor lo que su manejo se podr\u00eda asimilar al de los pacientes GQ. Resulta fundamental \niniciar la nutrici\u00f3n de forma precoz ya que son pacientes con un importante \nhipermetabolismo e hipercatabolismo  y la desnutrici\u00f3n se asocia con peor cicatrizaci\u00f3n, \nmayor riesgo de infecciones y disfunci\u00f3n multiorg\u00e1nica . La v\u00eda de administraci\u00f3n \nrecomendada es la enteral ya que ejerce un efecto protector de las funciones inmunes, \nmetab\u00f3licas, gastrointestinales  (efecto tr\u00f3fico) y se asocia con un descenso de \nmorbilidad infecciosa . En pacientes con nutrici\u00f3n enteral (NE) contraindicada o que no \nalcancen el objetivo cal\u00f3rico -proteico v\u00eda enteral al cuarto d\u00eda de inicio del tratamiento  \nnutricional se recomienda  la nutrici\u00f3n parenteral (NP).   \nEn los pacientes GQ l as gu\u00edas  de las sociedad es espa\u00f1ola, europea y americana de \nnutrici\u00f3n  recomiendan dietas hipercal\u00f3ricas, hiperproteicas y bajas en grasas . La \ncalorimetr\u00eda indirecta es el m\u00e9tod o m\u00e1s preciso para determinar el requerimiento \ncal\u00f3rico.  No todos los hospitales disponen de calor\u00edmetros por lo que es frecuente \nutilizar ecuaciones  predictivas  adaptadas al paciente GQ como la ecuaci\u00f3n de Toronto o \na la ecuaci\u00f3n de Curreri (figura 1 ). \n \n25-30 kcal/kg/d\u00eda+(30 -40 kcal x (%)SCTQ)                                                                                                                          \nKilocalor\u00edas (kcal)    kilogramos (kg)   porcentaje (%)   Superficie corporal total quemada (SCTQ)  \n \n Figura 1: Ecuaci\u00f3n de Curreri  779Respecto al aporte de macro  y micronutrientes :  \nLos hidratos de carb ono (HC) son la principal fuente energ\u00eda en el paciente GQ y se  \nrecomienda aportar entre 4 -5gramos (g)/kg/d\u00eda. En paciente cr\u00edtico , cuando los aportes \nson por v\u00eda parenteral, la recomendaci\u00f3n es de no superar 3,5g/kg/d\u00eda, monitorizando \nla glucemia y llevando a cabo un correcto manejo  con insulina , para evitar \ncomplicaciones como  peor cicatrizaci\u00f3n y mayor riesgo de infecciones. Se recomienda \nmantener el valor de glucemia por debajo de 180 mg/decilitros( dL) y si es posible \npr\u00f3ximo a 150 mg/d L iniciando  tratamiento con insulina cuando la glucemia supere \n150mg/d L. \nLa dieta debe ser hiperproteica recomend\u00e1ndose al menos  un aporte proteico de 2-2,5 \ng/kg/d\u00eda lo que supone el 20 -25% del aporte cal\u00f3rico total, a mayor superficie corporal \ntotal quemada ( SCTQ)  mayor aporte proteico, la relaci\u00f3n entre kcal no proteicas y g de \nnitr\u00f3geno (N) debe ser 80 -100:1.  \nEn cuanto al aporte lip\u00eddico se recomienda una dieta baja en grasas, el 15 -18% del aporte \ncal\u00f3rico total. Un bajo aporte de l\u00edpidos se asocia  con mayor apro vechamiento de las \nprote\u00ednas,  menos complicaciones y reducci\u00f3n de la estancia hospitalaria.  \nEl aporte de micronutrientes (vitaminas y oligoelementos) es importante para evitar la \noxidaci\u00f3n y evitar las p\u00e9rdidas que se producen a trav\u00e9s de las lesiones . \nDESCRIPCI\u00d3N DEL CASO  \nMujer de 75 a\u00f1os que en el momento del ingreso tiene un peso de  70 kg y una altura de \n1,68  metros  de altura . Presenta  como antecedentes : hipertensi\u00f3n arterial, cardiopat\u00eda 780hipertensiva, Diabetes Mellitus tipo II (DMII), inf ecciones del tracto urinario (ITU) de \nrepetici\u00f3n y obesidad m\u00f3rbida.  \nIngresa  por sospecha de ITU , se pauta  ceftriaxona 2g intravenosa ( IV) y 24 horas \ndespu\u00e9s , tras haber recibido dos dosis , la paciente desarrolla lesiones tipo diana en el \ntronco  que se tra tan co n metilprednisolona . Se suspende el tratamiento con ceftriaxona \ny se cambia por ciprofloxacino. Ante la sospecha  de NET secundaria a ceftriaxona y \nempeoramiento de las lesiones se decide traslado a la Unidad de  GQ.  \nEl manejo  de los pacientes GQ se lleva a cabo por un equipo multidisciplinar  compuesto \npor los Servicios  de Cuidados Intensivos (UCI), Cirug\u00eda Pl\u00e1stica, Dermatolog\u00eda, \nGinecolog\u00eda y Oftalmolog\u00eda.  El soporte nutricional de estos pacientes es competencia del \nequipo de  nutrici\u00f3n en el que participa activamente el farmac\u00e9utico  responsable del \n\u00e1rea de nutrici\u00f3n.  \nAl ingreso en la Unidad de GQ l a paciente presenta el 34% SCQT con mayor afectaci\u00f3n \nen tronco y nalgas  y sin afectaci\u00f3n oft\u00e1lmica  ni ginecol\u00f3gica . Se encuentra \nhemodin\u00e1micamente estable en fase de reanimaci\u00f3n con fluidoterapia . Se inicia \ntratamiento con ciclosporina IV  a dosis de 1mg/kg/d\u00eda cada 24h dividida en dos dosis . El \nfiltrado glomerular (FG) es de 4 4,7 mililitros/minuto (m L/min) .   \nA nivel digestivo y nutricional se inicia protocolo de NE pero la paciente se autorretira la \nsonda y adem\u00e1s presenta glucemias elevadas de dif\u00edcil control con insulin a. Respecto a \nla evoluci\u00f3n nutricional durante el ingres o (figura 2). E l primer d\u00eda de ingreso se inicia \nprotocolo de NE, se coloca la sonda en dos ocasiones pero la paciente se la autorretira \npor lo que se mantiene con dieta oral (dieta t\u00farmix sin sal para diab\u00e9ticos) durante la \nprimera semana, la paciente pre senta falta de apetito y la dieta oral no cubre sus  781requerimientos calorico -prot\u00e9 icos (se aportaban  en torn o 500kcal ). El d\u00eda 8 de ingreso \nlos intensivistas solicitan al Servicio de Farmacia el dise\u00f1o y la elaboraci\u00f3n de la NP \ncomplementaria que se mantendr\u00e1 durante 22 d\u00edas. Asociado a la NP aparecen \ncomplicaciones de colestasis y candi demia. D ebido a la colestasis y siguiendo las \nrecomendaci ones del Servicio de F armacia, se inicia NE que es bien tolerada y pasados \nocho d\u00edas se reintroduce dieta oral.   \n \n \nLa paciente permanece ingresada durante 38 d\u00edas en la Unidad de GQ en seguimiento \npor el equipo multidisciplinar mencionado. A destacar durante su ingreso las infecciones \nque desarrolla : ITU y bacteriemia que se resuelven con antibioterapia y la candidiasis \nsecundaria a l cat\u00e9ter venoso central (CVC) de la NP , la candidiasis aunque se trata con \nfluconazol es persistente y adem\u00e1s se observa afectaci\u00f3n ocular con c oriorretinitis.   \nLa paciente al ingreso presenta insuficiencia renal aguda (IRA) de origen prerrenal . \nDurante  la estancia hospitalaria el FG se reduce de 45 m L/min  a 15 mL/min , y esto es \ndebido al efecto nefrot\u00f3xico de la ciclosporina  por lo que se decide reducir  \nprogresivamente la dosis hasta suspenderla. No obstante, el FG se recupera \nprogresivamente ya que el efecto nefrot\u00f3xico de la ciclosporina es reversible.  \nFigura 2  \n 782DISCUSI\u00d3N Y APORTACI\u00d3N FARMACE\u00daTICA . \nEn nuestro Servicio de Farmacia , los farmac\u00e9uticos del  \u00e1rea de nutrici\u00f3n son los \nresponsable s del dise\u00f1o individualizado de  la NP de los pacientes cr\u00edtico s. En los \npacientes GQ hemodin\u00e1micamente estables se recomienda iniciar el soporte nutricional \ndurante las 6 -12 primeras horas.  En esta pac iente , la dieta ora l no cubr\u00eda el 60% de los \nrequerimientos , y la v\u00eda enteral no era posible ya que la paciente se retiraba  la sonda. \nSiguiendo las recomendaciones , el soporte nutricional complementario  deber\u00eda  haberse \nrealizado de forma m\u00e1s precoz , al menos, desde los primeros d\u00edas que se  detectan \ningestas insuficientes.  Fue en el octavo d\u00eda de ingreso cuando se inici\u00f3  una NP \ncomplementaria . Los  valores  de prealb\u00famina que presentaba la paciente  en ese \nmomento  eran de 3,5 mg/ dL. No se debe evaluar como dato aislado puesto que en \npaciente cr\u00edtico estos valores se ven alterados por aumento de otros reactantes de fase \naguda. La medici\u00f3n seriada de la misma  nos puede orientar sobre la evoluci\u00f3n del \nestado nutricio nal.  \nEn primer lugar , lo que hicimos fue calcular los requerimientos cal \u00f3rico-proteicos  \naplicando la f\u00f3rmula de Curreri  (figura 1 ), el peso de la paciente era  de 70kg y \npresentaba el 34% de la SCTQ por lo que calculamos un objetivo de  requerimientos \ncal\u00f3ricos de 2770kcal  (39,5kcal/kg) .  \nSe inici\u00f3 NP con un aporte cal\u00f3rico de 15kcal/kg, con el fin de evitar el s\u00edndrome de \nrealimentaci\u00f3n . Progresivamente se fueron aumentando los aportes  hasta llegar a un \nm\u00e1ximo  de 28,5 kcal/kg (2000K cal). No fue posible incrementar los aportes hasta el \nobjetivo cal\u00f3rico -prote ico establecido , ya que el aporte de HC, l\u00edpidos y prote\u00ednas estaba 783limitado al tratarse de una paciente diab\u00e9tica , con IR y ligera colestasis.  Se aport\u00f3 un \nm\u00e1ximo de 200  g de HC y una media diaria de 60  g de l\u00edpidos.  \nEn cuanto a las  prote\u00ednas , aunque las  gu\u00edas recomiendan en el paciente GQ dietas \nhiperproteicas , en esta paciente debido a la IR se limit\u00f3 el aporte proteico  a un m\u00e1ximo \n1,5g/kg/d\u00eda lo que suponen 16,9g de N . Adem\u00e1s se administraron  vitaminas y \noligoelementos a d\u00edas alternos para evitar la acumulaci\u00f3n a nivel renal . \nSe administr\u00f3 NP  durante 22 d\u00edas.  D iariamente se ajustaba el contenido de la misma en \nfunci\u00f3n  de los par\u00e1metros  anal\u00edtic os, la funci\u00f3n renal y la evoluci\u00f3n de la paciente. A \ndestacar la evoluci\u00f3n favorable de los valores  de prealb\u00famina, que  en los \u00faltimos d\u00edas \nde NP se encontraban en rango  (20-40 mg/dl)  con un valor  de 26,6  mg/dL.  \nLa paciente desarroll\u00f3 colestasis, un efecto adverso estrechamente relacion ado con el \nuso prolongado de NP.  Se siguieron varias estrategias: evitar la sobrealimentaci\u00f3n \nproporcionando un aporte equilibrado de nutrientes , recomendar el inicio de NE  precoz  \n(aunque no pudo ser hasta el d\u00eda  22 de ingreso)  y seleccionar una NE normocal\u00f3rica, \nhiperproteica y con fibra soluble . Se prioriz\u00f3 el aporte de fibra soluble frente al aporte \ncal\u00f3rico ya que en el momento de inicio de la NE la paciente presentaba diarrea. La dieta \nenteral se asoci\u00f3 a pr ocin\u00e9ticos y fue bien tolerada. P asados 8 d\u00edas , la paciente inici\u00f3 \ndieta oral con buena tolerancia.  \nAdem\u00e1s del abordaje nutricional  y la validaci\u00f3n farmacoterap\u00e9utica, el Servicio de \nFarmacia  report\u00f3 la sospecha de reacci\u00f3n ad versa a medicamentos (RAM) al Sistema  \nNacional de Farmacovigilancia como probable s\u00edndrome de Lyell causado por \nceftriaxona.  784Un estado nutricional adecuado se ha relaciona do con una evoluci\u00f3n cl\u00ednica m\u00e1s \nfavorable del paciente con NET , as\u00ed como con la prevenci\u00f3n de las complicaciones \nasociadas a la desnutrici\u00f3n . Es por ello que la  participaci\u00f3n del farmac\u00e9utico , como \nresponsable del soporte nutricional , es fundamental en los equipos multidiscipl inares \nde manejo del paciente quemado . \nBIBLIOGRAF\u00cdA  \n-Consenso SEMICYUC -SENPE Recomendaciones para el soporte nutricional y metab\u00f3lico  \nespecializado del paciente cr\u00edtico (2011).  Medicina Intensiva,  35. \n-Rousseau, A. F., Losser, M. R., Ichai, C., &amp; Berger, M. M. (2013). ESPEN endorsed  \nrecommendations: Nut ritional therapy in major burns.  Clinical Nutrition,  32(4), \n497\u2013 502. https ://doi.org/10.1016/j.clnu.2013.02.012  \n-ASPEN Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediat ric \nPatients. (2002).  Journal of Parenteral and Enteral Nutrition,  26(1_suppl), 88SA -90SA. \nhttps://doi.org/10.1177/0148607102026001011  \n-Whitney A High. Stevens -Johnson syndrome and toxic epidermal  necrolysis: \nManagement, prognosis, and long -term sequelae. \nhttps://www.uptodate.com/contents/stevens -johnson -syndrome -and-toxic -\nepidermal -necrolysis- pathogenesis -clinical -manifestations -and-diagnosis  \n 785INTRODUCCI\u00d3N \nEl osteosarcoma es un tumor \u00f3seo maligno que se diagnostica con m\u00e1s frecuencia entre \nlos 10 y los 30 a\u00f1os, principalmente en adolescentes.  \nLa mayor\u00eda de los protocolos de tratamiento utilizados actualmente para el \nosteosarcoma se basan en una combinaci\u00f3n de doxorrubicina, cisplatino, metotrexato \na altas dosis (HDMTX) y/o ifosfamida, de los cuales el metotrexato (MTX) parece ser uno \nde los f\u00e1rmacos m\u00e1s activos(1). \nLa nefrotoxicidad inducida por HDMTX es una emergencia m\u00e9dica ampliamente \ndescrita, ya que la excreci\u00f3n renal de MTX se retrasa aumentando la exposici\u00f3n al \nf\u00e1rmaco, que mantenida en el tiempo puede ser muy perjudicial. Por ello, es  necesario \nuna rigurosa monitorizaci\u00f3n de la evoluci\u00f3n de la concentraci\u00f3n plasm\u00e1tica de MTX \nhasta completar su eliminaci\u00f3n, lo que permite ir adecuando el rescate con folinato \nc\u00e1lcico o leucovorin (LV) a las concentraciones observadas. Si el rescate adecuado se \nretrasa m\u00e1s de 42-48h de exposici\u00f3n al MTX, su citotoxicidad puede ser irreversible.  \nEl r\u00e9gimen de HDMTX para osteosarcoma (8-12 g/m2 durante 4 horas), tiene una mayor \nincidencia de insuficiencia renal aguda (IRA),  y por ello mayor riesgo de intoxicaci\u00f3n por \nMTX. La toxicidad depende de la concentraci\u00f3n de MTX en sangre y del tiempo de \nexposici\u00f3n al f\u00e1rmaco. \nSe presenta un caso de un paciente de 19 a\u00f1os diagnosticado recientemente de \nosteosarcoma, que sufri\u00f3 una intoxicaci\u00f3n muy severa por MXT alcanzando \nconcentraciones 5 veces por encima del nivel normal, que se resolvi\u00f3 \u00fanicamente c on la \nadministraci\u00f3n de folinato c\u00e1lcico y tratamiento de soporte, sin necesidad de \nadministrar glucarpidasa,  a pesar de cumplir el criterio de uso indicado en el documento \nde consenso publicado en 2018(2) y la ficha t\u00e9cnica. 786DESCRIPCI\u00d3N DEL CASO \nVar\u00f3n de 19 a\u00f1os de edad remitido desde un hospital comarcal por dolor en la rodilla \nderecha desde mayo de 2021 sin antecedentes traum\u00e1ticos previos. En la biopsia \nrealizada en el centro, se observ\u00f3 proliferaci\u00f3n neopl\u00e1sica de intensa atipia nuclear e \ninmu nofenotipo sugestivo de sarcoma convencional, y el TAC de t\u00f3rax/pelvis reflej\u00f3 \nmicron\u00f3dulos pulmonares de aspecto inespec\u00edfico y lesiones hep\u00e1ticas hipodensas \nmilim\u00e9tricas que pued\u00edan corresponderse con quistes, aunque no fueron  \ncompletamente caracterizables en dicho estudio.  \nEn diciembre de 2021 se diagnostic\u00f3 de osteosarcoma en la regi\u00f3n proximal de la tibia \nderecha, estad\u00edo T2N0Mx (dudosas pulmonares), y se decidi\u00f3 iniciar tratamiento con \nquimioterapia neoadyuvante seg\u00fan esquema MAP (Figura 1) y posterior cirug\u00eda. Este \nesquema est\u00e1 considerado como tratamiento est\u00e1ndar en ni\u00f1os y adultos j\u00f3venes y se \nha utilizado como brazo control en los principales ensayos aleatorizados dise\u00f1ados en \nla \u00faltima d\u00e9cada(3). \nEl paciente no presenta antecedentes m\u00e9dicos/quir\u00fargicos de inter\u00e9s ni alergias \nmedicamentosas. \nFigura 1. Esquema MAP de tratamiento. A. Redondo et al. Osteosarcoma del adulto. \nGu\u00eda de buena pr\u00e1ctica cl\u00ednica(3) \n \n \n \n787El paciente comenz\u00f3 este tratamiento en enero de 2021 (semana 1), recibiendo \nCisplatino 100 mg,  50% de la dosis (D1) y Adriamicina 50 mg (D1 y D2)  en infusi\u00f3n \ncontinua. Como \u00fanica sintomatolog\u00eda present\u00f3 s\u00edndrome em\u00e9tico grado II (G2) que \ncedi\u00f3 con antie m\u00e9ticos y dolor en miembro inferior derecho controlado con analgesia, \npor lo que recibi\u00f3 el alta al tercer d\u00eda del ingreso. \nEn febrero de 2021 se administr\u00f3 el 1\u00ba ciclo de HDMXT (semana 4), 12g/m2 en 4 horas \n(D21) por protocolo, pero c\u00f3mo la superficie corporal era de 1,98m2 se administr\u00f3 la \ndosis m\u00e1xima,  20g (10g/m2), que se infundi\u00f3 en 4,5 horas. 12 horas antes de iniciar la \ninfusi\u00f3n de MTX, comenz\u00f3 la prehidrataci\u00f3n con 1000ml/6h (2L/m2/d\u00eda) de suero \nglucosalino, a\u00f1adiendo en cada suero de 1000ml, 50 ml de bicarbonato 1M,  10 mEq de \nCLK y media ampolla de furosemida,  para alcalinizar la orina (el riesgo de nefrotoxicidad \ninducida por MTX se incrementa cuando la orina es \u00e1cida porque disminuye su \nsolubilidad) y se vigil\u00f3 estrechamente el pH urinario para procurar mantenerlo \u22657 hasta \nla finalizaci\u00f3n del rescate(4) . La extracci\u00f3n de muestras se realiz\u00f3  siguiendo el protocolo \nde monitorizaci\u00f3n de MTX del centro, en tubos con  EDTA como anticoagulante,  que se \nanalizaron por quimioluminiscencia (CMIA) en un architect ci4100.  La estimaci\u00f3n de los \npar\u00e1metros farmacocin\u00e9ticos se realiz\u00f3 con un modelo poblacional bicompartimental \nimplementado en el programa Abbottbase PKSystem (PKS) (Abbott Laboratorios \nDiagnostic divisi\u00f3n). \nAl finalizar la infusi\u00f3n de MTX, a las 4,5 horas, se alcanz\u00f3 una Cmax de 1494,91\u00b5M \n(objetivo: Cmax:>1000\u00b5M), muy pr\u00f3xima al valor t\u00f3xico (Cmax:>1500\u00b5M), \nposteriormente la concentraci\u00f3n descendi\u00f3 m\u00e1s lentamente (semivida \u03b1=4,24 horas, \nvalor normal <3,5 horas), probablemente porque el pH uri nario baj\u00f3 a valores de 6 en \nvarias ocasiones durante las primeras 14 horas post-infusi\u00f3n (Tabla 1). Con las muestras 788obtenidas a las  4,5 h, 7,42h y 18,42h desde el inicio de la infusi\u00f3n y un algoritmo \nbayesiano se predijo la concentraci\u00f3n de MTX a las 24 horas, que se estim\u00f3 en un valor \npor encima de 50\u00b5M (riesgo de toxicidad: C 24h>10 \u00b5M), mas de 5 veces el valor de \nreferencia,  por lo que se  recomend\u00f3 iniciar el rescate con 500mg/m2/3h (1000mg/3h) \nde LV, un incremento muy considerable respecto al rescat e est\u00e1ndar de 15mg/m2/6h. \nDe este modo, el paciente recibi\u00f3 a tiempo, a las 24 desde el inicio de la infusi\u00f3n, el \nrescate que le correspond\u00eda al nivel de esa hora, antes de conocer el resultado anal\u00edtico \nde esa muestra. C\u00f3mo el folinato c\u00e1lcico solo neutraliza la acci\u00f3n del MTX, pero no \ninfluye en su eliminaci\u00f3n, en el informe de farmacocin\u00e9tica tambi\u00e9n se recomend\u00f3 \naumentar la hidrataci\u00f3n a 6L/d\u00eda para forzar la diuresis, e iniciar tratamiento con \ncolestiramina 3g/6h, con leche o zumos de frutas fr\u00edos, para interrumpir el ciclo \nenterohep\u00e1tico del MTX y aumentar su aclaramiento total.  \nTabla 1. Valores de pH urinario desde las 6 horas antes hasta las 48 horas despu\u00e9s de \niniciar la infusi\u00f3n de MTX.   \n \n08/02/2022 09/02/2022 10/02/2022 \npH=5 (7:00h) \npH=8 (9:30h) \npH= 7,5 (11:30)  \npH= 6 (17:00h) \npH= 7,5 (19:00h) \npH=6 (24:00h) pH= 7-7,5 (2:30h) \npH= 6,5-7 (6:30h) \npH= 7,5 (7:45h) \npH=9 (12:00h) \npH= 9 (16:00h) \npH= 9 (20:00h) pH= 7-7,5 (4:00h) \npH= 6 (8:30h) \npH= 9 (12:00h) \npH= 9 (16:00h) \npH= 9 (20:00h) \n \n \nSimult\u00e1neamente a la 1\u00ba dosis de LV, se extrajo la muestra de las 24 horas desde inicio \nde la infusi\u00f3n y se confirm\u00f3 que la concentraci\u00f3n realmente estaba >50 \u00b5M, en 61,60 \n\u00b5M, por lo que se recomend\u00f3 continuar con 500mg/m2/3h de LV, una dosis m\u00e1s (27 \nhoras) y a partir de las 30 horas con 500mg/m2/6h (30, 36 y 42 horas). \nAl d\u00eda siguiente, con las medidas de soporte implantadas, la concentraci\u00f3n plasm\u00e1tica \nde MTX a las 42 horas hab\u00eda descendido h asta 4,82\u00b5M, lo que nos permiti\u00f3 reducir el 789rescate a  75mg/m2/6h, 2 dosis (a las 48 y 54 horas) y 50mg/m2/6h, 2 dosis m\u00e1s (a las 60 \ny 66 horas). El d\u00eda +3, la concentraci\u00f3n a las 66 horas fu\u00e9 de 0.98\u00b5M y se recomend\u00f3 \nreducir la dosis de LV a 15mg/m2/6h (rescate est\u00e1ndar) desde las 72 horas hasta las 138 \nhoras (d\u00eda +6). Posteriormente, cuando se confirm\u00f3 que la concentraci\u00f3n de MTX hab\u00eda \ndescendido a  0.14\u00b5M a las 138 horas, se plante\u00f3 al cl\u00ednico la posibilidad de dar el alta \nal paciente y continuar con el rescate por v \u00eda oral de forma ambulatoria, con \n7.5mg/m2/12h hasta las 174 horas (2 dosis m\u00e1s y suspender), porque se estim\u00f3 que 12 \nhoras despu\u00e9s de la \u00faltima dosis de LV, a las 186 horas, la concentraci\u00f3n de MTX habr\u00eda \ndescendido por debajo del valor citot\u00f3xico (<0.05\u00b5M) (Figura 2) \n \nFigura 2. Evoluci\u00f3n de la concentraci\u00f3n de MTX (\u00b5M) en un paciente con osteosarcoma \nque recibi\u00f3 10g/m2 (20g) en 4.5 horas.  \n \n \n \nLa evoluci\u00f3n cl\u00ednica del paciente fue favorable, la creatinina s\u00e9rica que se hab\u00eda elevado \na 1,31 mg/dl el d\u00eda +2,  se normaliz\u00f3 al alta. No present\u00f3 mucositis, ni neutropenia, y \ncomo \u00fanico signo de toxicidad las enzimas h\u00e9p\u00e1ticas se elevaron el d\u00eda + 1 3, AST=197    \n790UI y ALT=352UI, toxicidad grado III (G3), aunque la toxicidad hep\u00e1tica no se ha podido \nrelacionar con la concentraci\u00f3n plasm\u00e1tica de MTX. \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA \nLa evoluci\u00f3n de la concentraci\u00f3n plasm\u00e1tica de MXT se considera el mejor valor \npredictivo de su toxicidad, por lo que su monitorizaci\u00f3n farmacocin\u00e9tica (TDM) es una \npr\u00e1ctica habitual y necesaria para identificar precozmente los pacientes que presentan \nun retraso en la eliminaci\u00f3n del MTX y que requerir\u00e1n un incremento del rescate.  \nLa estimaci\u00f3n de los par\u00e1metros farmacocin\u00e9ticos individuales en este enfermo \nmediante la aplicaci\u00f3n del m\u00e9todo bayesiano permiti\u00f3 estimar la concentraci\u00f3n de MTX \nen el momento de iniciar el rescate, a las 24 horas desde el inicio de la infusi\u00f3n, de modo \nque el paciente pudo recibir el rescate que le correspond\u00eda a ese nivel (rescate \nadecuado) a tiempo, sin esperar al an\u00e1lisis de esa muestra, lo que supondr\u00eda   un retraso \nen la correcci\u00f3n del rescate de 3 -6 horas.   En casos de intoxicaci\u00f3n severa, la rapidez en \nel establecimiento del rescate adecuado resulta decisiva para evitar una toxicidad que \nen algunos casos puede ser letal. Un valor de concentraci\u00f3n >10\u00b5M a las 24 horas se ha \nrelacionado con mayor riesgo de toxicidad si el paciente recibe solo el rescate est\u00e1ndar. \nLa dosis de LV depende de la concentraci\u00f3n de MTX a esa hora y la predicci\u00f3n de ese \nnivel de forma precisa es fundamental para administrar al paciente la dosis de LV \nadecuada, ni una dosis insuficiente que no pudiera evitar la toxicidad, ni tampoco una \ndosis excesiva que pudiera reducir la eficacia del MTX  porque tambi\u00e9n es importante \nno sobrerescatar al paciente. \nEn este caso, el farmac\u00e9utico responsable del \u00e1rea de farmacocin\u00e9tica, juega un papel \nindispensable, al programar un protocolo  de monitorizaci\u00f3n de MTX, donde establece \nlos tiempos \u00f3ptimos de muestreo, realiza el an\u00e1lisis de las muestras, permitiendo una 791mayor flexibilidad y agilidad en el proceso (el an\u00e1lisis y la interpretaci\u00f3n del resultado la \nrealiza el mismo servicio), y establece la pauta m\u00e1s adecuada de LV para cada enfermo, \nmediante la aplicaci\u00f3n de un m\u00e9todo robusto, como es el ajuste de la dosis por m\u00e9todos \nbayesianos, adem\u00e1s tambi\u00e9n propone las medidas de soporte necesarias para mejor ar \nla eliminaci\u00f3n del f\u00e1rmaco.  \nOtro punto cr\u00edtico de la monitorizaci\u00f3n es estimar el momento adecuado para \nsuspender el rescate, sobretodo cuando se advierte un retraso en la eliminaci\u00f3n del MTX \nporque es importante confirmar antes de finalizar el rescate que ya no quedan \nconcentraciones citot\u00f3xicas en sangre. El farmac\u00e9utico puede valorar la posibilidad de \ncontinuar el rescate de forma ambulatoria estableciendo el n\u00famero de dosis de LV \nnecesarias de modo que el ingre so del paciente no se prolongue de forma innecesaria   \nFinalmente , seg\u00fan las recientes publicaciones, este paciente podr\u00eda haber sido \ncandidato al uso de glucarpidasa (una concentraci\u00f3n a las 24 horas >50\u00b5M, cuando se \nadministra el MTX en infusi\u00f3n de 4 horas), pero en este caso se opt\u00f3 por mantener un \nrescate con folinato c\u00e1lcico a dosis elevadas acordes a su concentraci\u00f3n en sangre, \nporque la experiencia de nuestro centro nos demuestra, que concentraciones a las 24 \nhoras <100\u00b5M puede ser rescatadas \u00fanicame nte con LV. \nLa glucarpidasa esta indicada en casos de intoxicaci\u00f3n muy severa por MTX, sobretodo \ncuando se produce una IRA. Esta enzima hidroliza la mol\u00e9cula de MTX y consigue reducir \nen un 95 -98% la concentraci\u00f3n de MTX en sangre en unos minutos despu\u00e9s de su \nadministraci\u00f3n, pero no est\u00e1 exenta de inconvenientes. Adem\u00e1s de su precio elevado \n(el coste de tratamiento para este enfermo hubiera sido de 91180 Euros), su principal \ndesventaja es que no puede penetrar en la c\u00e9lula por lo que solo elimina  el MTX del \nplasma, mientras que el MTX del interior de la c\u00e9lula, que es el MTX activo, sigue 792actuando. Este es el motivo por el que el LV sigue siendo necesario para el rescate \nintracelular del ciclo de los folatos. \nSer\u00eda necesario una revisi\u00f3n de las gu\u00edas de manejo de intoxicaci\u00f3n severa de MTX, de \nla evidencia disponible y del tratamiento recomendado en cada caso. Por problemas \n\u00e9ticos no es posible realizar ensayos cl\u00ednicos que demuestren la efectividad de la \nglucarpidasa frente al tratamiento est\u00e1ndar  de referencia, el folinato calcico, por lo que \nes muy importante difundir los casos individuales de intoxicaci\u00f3n severa que puedan \naportar informaci\u00f3n sobre su manejo \u00f3ptimo. \n \nBIBLIOGRAF\u00cdA \n1.  van Dalen EC, van As JW, de Camargo B. Methotrexate for high -grade osteosarcoma in \nchildren and young adults. Cochrane Database of Systematic Reviews [Internet]. 2011 \nMay 11 [cited 2022 Apr 26];(5). Available from: \nhttps://doi.wiley.com/10.1002/14651858.CD006325.pub3  \n2.  Ramsey LB, Balis FM, O\u2019Brien MM, Schmiegelow K, Pauley JL, Bleyer A, et al. Consensus \nGuideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced \nAcute Kidney Injury and Delayed Methotrexate Clearance. The Oncologist. 2018 Jan \n1;23(1):52\u201361.  \n3.  Redondo A, Bra\u00f1a A, Bagu\u00e9 S, Pousa AL, Garc\u00eda X, Muro D, et al. Oncology Translational \nClinical OSTEOSARCOMA DEL ADULTO Gu\u00eda de buena pr\u00e1ctica cl\u00ednica Official publication \nof: Asociaci\u00f3n Espa\u00f1ola de Investigaci\u00f3n sobre el C\u00e1ncer.  \n4.  Luis de Francisco \u00c1M, Mac\u00eda M, Alonso F, Garc\u00eda P, G uti\u00e9rrez E, Fernando Quintana L, \net al. Efectos renales adversos del actual tratamiento del c\u00e1ncer. Vol. 11, N NefroPlus. \n2019.  \n5.  Widemann BC, Schwartz S, Jayaprakash N, Christensen R, Pui CH, Chauhan N, et al. \nEfficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury \nafter high-dose methotrexate therapy. Pharmacotherapy. 2014;34(5):427\u201339. \n \n 793OPTIMIZACI\u00d3N DE LA DOSIFICACI\u00d3N DE ANTIMICROBIANOS EN UN PACIENTE \nPEDI\u00c1TRICO EN CIRCULACI\u00d3N CON MEMBRANA EXTRACORP\u00d3REA  MEDIANTE \nMONITORIZACI\u00d3N FARMACOCIN\u00c9TICA   \n \nINTRODUCCI\u00d3N  \n \nLas alteraciones fisiol\u00f3gicas descritas en los pacientes cr\u00edticos, como el s\u00edndrome de \nrespuesta inflamatoria sist\u00e9mica (SRIS), la hipoalbuminemia, el s\u00edndrome de fuga capilar, \nla hipoperfusi\u00f3n (fluidoterapia intensiva y vasopresores) y la disfunci\u00f3n org\u00e1n ica \n(hep\u00e1tica y/o renal), pueden comportar alteraciones en la farmacocin\u00e9tica (PK) y \nfarmacodinamia (PD) de los antimicrobianos. Adem\u00e1s, el soporte con t\u00e9cnicas \nextracorp\u00f3reas, como la oxigenaci\u00f3n con membrana extracorp\u00f3rea ( ECMO ), indicada en \nfallo respir atorio y/o cardiaco refractario, puede comportar variaciones PK adicionales.1,2 \nLa adsorci\u00f3n de los f\u00e1rmacos a la superficie del circuito ECMO es uno de los fen\u00f3menos \nque puede modificar  los par\u00e1metros PK, pudiendo provocar un incremento del volumen \nde distribuci\u00f3n ( Vd) y una disminuci\u00f3n de las concentraciones plasm\u00e1ticas (Cp). La \nadsorci\u00f3n est\u00e1 condicionada por factores del circuito y por las propiedades fisicoqu\u00edmicas \ndel f\u00e1rmaco, especialmente la lipofilia y el grado de uni\u00f3n a prote\u00ednas plasm\u00e1ticas (UPP).  \nOtro fen\u00f3meno descrito en los pacientes con ECMO es la hemodiluci\u00f3n, especia lmente \nen pacientes pedi\u00e1tricos, debido a la utilizaci\u00f3n de soluciones de cebado del circuito para \nsustituir el volumen de sangre extra\u00eddo del organismo durante la oxigenaci\u00f3n. Los \nf\u00e1rmacos hidr\u00f3filos, como los antibi\u00f3ticos \u03b2 -lact\u00e1micos, y con bajo Vd (< 1 L/kg) son los \nque presentan mayor afectaci\u00f3n por esta hemodiluci\u00f3n.3  \nIsavuconazol (IVZ) es un antif\u00fangico triaz\u00f3lico de amplio espectro, inhibidor de la \nlanosterol  14-alfa-desmetilasa, implicada en la s\u00edntesis de ergosterol f\u00fangico, activo 794frente a Candida spp ., Cryptococcus spp ., hongos dim\u00f3rficos, Aspergillus spp . y mucorales. \nPor su elevada semivida ( \u2248 110 horas), se recomienda administrar dosis de carga, en \nadul tos IVZ base 200 mg cada 8 horas durante las primeras 48 horas (6 administraciones \nen total), seguido de una pauta de mantenimiento de  200 mg/24h, tanto v\u00eda oral (VO) \ncomo intravenosa (IV) .4 No tiene indicaci\u00f3n autorizada en pediatr\u00eda, por lo que la \ndosifi caci\u00f3n en esta poblaci\u00f3n no est\u00e1 claramente defin ida. En base a un estudio  en el \nque se eval\u00faa la eficacia, seguridad y farmacocin\u00e9tica de IVZ en pediatr\u00eda, se propone la \ndosificaci\u00f3n de IVZ base 5,38 mg/kg/24h (m\u00e1ximo 200 mg/24 h), tras las 6 dosis de carga  \n(5,38 mg/kg/8h) .5 A pesar de que no existe  consenso sobre la necesidad de monitorizar \nlas concentraciones plasm\u00e1ticas de IVZ , podr\u00eda resultar de utilidad en  pacientes con \nECMO, especialmente paci entes pedi\u00e1tricos.  Por su elevada lipofilia  (coeficiente de \npartici\u00f3n octanol/agua [log P] 3 ,4-4) y alta UPP (>  99%), IVZ es un f\u00e1rmaco candidato a \npresentar adsorci\u00f3n al circuito ECMO, tal y como se ha descrito en un caso publicado en \nel que se objetivan concentraciones post -oxigenador inferiores a las concentraciones \nsist\u00e9micas del paciente.6 En otro  estudio PK en pacientes adultos con infecci\u00f3n f\u00fangica \ninvasiva (IFI ), se observaron Cp de IVZ inferiores  en los pacientes con ECMO.7  Adem\u00e1s, el \nmargen terap\u00e9utico no est\u00e1 claramente  definido, con una importante variaci\u00f3n en las Cp  \npre-dosis  objetivo publicadas en diferentes trabajos , evidenci\u00e1ndose una importante \nvariabilidad intra e interindividual.8 Teniendo en cuenta el agente causal, dado que las \nconcentraciones  in vitro  de IVZ necesarias para inhibir las diferentes especies \nde Aspergillus  y Mucorales  son heterog\u00e9neas , as\u00ed como la localizaci\u00f3n y gravedad de la \ninfecci\u00f3n, se han considerado d iversos  m\u00e1rgenes terap\u00e9utico s, comprendido s entre 2 -10 \n\u00b5g/mL5,9. En el protocolo de monitorizaci\u00f3n de antimicrobianos de nuestro centro se ha \npropuesto como rango terap\u00e9utico en profilaxis 2.5 -5 \u00b5g/mL  y en IFI 2.5 -10 \u00b5g/mL . 795Por otro lado, l os \u03b2-lact\u00e1micos son antibi\u00f3ticos con actividad tiempo dependiente, por lo \nque el \u00edndice PK/PD que mejor se correlaciona con resultados de eficacia cl\u00ednica es el \nporcentaje de tiempo (T) del intervalo entre dos dosis durante el cual la concentraci\u00f3n de \nantibi\u00f3tico libre ( f) (no UPP),  permanece por encima de la concentraci\u00f3n m\u00ednima \ninhibitoria (CMI), % fT>CMI. En base a los resultados cl\u00ednicos de varios estudios en \npacientes cr\u00edticos, se considera que el 100 %\u0192T>CMI podr\u00eda establecerse como un objetivo \nm\u00ednimo de eficacia cl\u00ednica. Otros estudios y revisiones de expertos plantean como \nobjetivo terap\u00e9utico una fCmin al menos 4 veces la CMI (100 %\u0192 T> 4x CMI). Adem\u00e1s, se \ndebe tener en cuenta la penetraci\u00f3n del antibi\u00f3tico en el lugar de la infecci\u00f3n, para \ngarantizar concentraciones terap\u00e9uticas y la eficacia del mismo. \nCeftazidima -avibactam (CAZ -AVI) incluye la combinaci\u00f3n de ceftazidima, cefalosporina de \n3\u00aa generaci\u00f3n con acci\u00f3n bactericida principalmente frente a bacterias gram -negativas, y \navibactam, inhibidor irreversible de \u00df -lactamasas,  incluyendo  las de clase A y C de \nA m b l e r ,  a s \u00ed  c o m o  a l g u n a s  d e l  g r u p o  D  ( O X A ) ,  c o m o  l a s  \u03b2 -lactamasas de espectro \nextendido (BLEE)  y carbapenemasas tipo KPC y OXA -48. La  posolog\u00eda recomendada es \n2 g/0.5 g cada 8h en adultos, 50  mg/12 ,5 mg/kg cada 8h en pacientes de \n6 meses - 18 a\u00f1os y 40  mg/10  mg/kg cada 8h en <6 meses (no se ha establecido la \nseguridad y eficacia en pacientes pedi\u00e1tricos <3 meses) .11  \nDado que es un  f\u00e1rmaco hidr\u00f3filo (log P= - 1,2) y con baja UPP  (<30%) , se espera que la \nadsorci\u00f3n al sistema ECMO sea  m\u00ednima, a pesar de que existe poca evidencia. Aunque no \nse han realizado estudios PK/PD de CAZ -AVI en pacientes con ECMO, la posolog\u00eda \nrecomendada es an\u00e1loga a la rec omendada en pacientes sin ECMO.12 \n 796DESCRIPCI\u00d3N DEL CASO  \nSe trata de un paciente de 4 a\u00f1os diagnosticado de hemangiomatosis capilar pulmonar, \nmotivo por el requi ere un trasplante bipulmonar, con m\u00faltiples complicaciones \ninfecciosas postoperatorias. A los 8 meses del trasplante, ingresa por un cuadro de \nhemoptisis asociado a insuficiencia re spiratoria hipox\u00e9mica, consecuencia de una \nestenosis bronquial derecha y una traqueobronquitis por Aspergillus flavus complex \n(resistente a amfotericina B, sensible a triazoles, como IVZ, y equinocandinas). Se inicia \ntratamiento con IVZ IV  5,4 mg/kg/d\u00eda, previa administraci\u00f3n de 6 dosis de carga (5 ,4 \nmg/kg/8h), manteni\u00e9ndose como profilaxis secundaria tras negativizaci\u00f3n de cultivos. \nDurante el ingreso presenta un empeoramiento respiratorio progresivo, cl\u00ednico y \nradiol\u00f3gico, lo que precipita su ingreso en la Unidad de Cuidados Intensivos pedi\u00e1tricos \n(UCI -P) y su inclusi\u00f3n en lista para retrasplante pulmonar, requiriendo ECMO  como \nterapia puente. Dado que la dosificaci\u00f3n de IVZ en pediatr\u00eda no e st\u00e1 claramente \nestablecida y las posibles alteracione s PK asociadas  al soporte ECMO , se  decide \nmonitorizar las concentraciones de IVZ , con el objetivo de optimizar la terapia \nantif\u00fangica .  \nTal y como se observa en la Figura 1, las concentraciones plasm\u00e1ticas se determina n \nprincipalmente mientras el paciente est \u00e1 en ECMO, lo que puede  contribuir a la necesidad \nde utilizaci\u00f3n de dosis m\u00e1s elevadas  de IVZ para alcanzar las concentraciones objetivo . \nAs\u00ed, l a dosis diaria requerida  de IVZ  se va incrementando seg\u00fan el valor de las Cp, hasta \nuna dosis m\u00e1xima de 19.1 mg/kg, correspondiente a m\u00e1s de 3 veces la dosis recomendada \nen pediatr\u00eda. En este contexto, se lleva a cabo una monitorizaci\u00f3n estrecha de las Cp de \nIVZ (valores de Cp de 1,4 \u2013 6,5 \u00b5g/mL), especialmente tras las modificaciones de dosis , sin \nevidenciarse  concentraciones t\u00f3xicas asociadas a  los incrementos progresivos  de dosis. 797Durante la profilaxis  con IVZ, no se objetiv a reinfecci\u00f3n f\u00fangic a, toxicidad  ni interacciones \nfarmacol\u00f3gicas que p uedan afectar a la exposici\u00f3n de IVZ.  \n \nFigura 1 . Gr\u00e1fica con las concentraciones plasm\u00e1ticas pre -dosis de IVZ, expresadas  en \u00b5g/mL, \nrespecto a la dosis de IVZ v\u00eda intravenosa ( mg/kg/ 24h) y el tiempo  (d\u00edas) .  \nOtra de las complicaciones infecciosas que presenta el paciente durante este ingreso es \nuna infecci\u00f3n respiratoria por Pseudomonas aeruginosa multirresistente, por lo que se \ndecide  iniciar tratamiento con CAZ-AVI (CMI 4 \u00b5g/mL) , a la dosis recomendada de  50 \nmg/10 mg/kg/8h, administra do en 2 horas.  Dado el potencial , aunque no muy descrito  \nimpacto de la ECMO en la PK de f\u00e1rmacos hidr\u00f3filos, como CAZ -AVI, como consecuencia \nde la hemodiluci\u00f3n, especialmente en ni\u00f1os, se decide monitoriza r tambi\u00e9n las Cp del \nantibi\u00f3tico.  En nuestro centro se determina la concentraci\u00f3n de ceftazidima  (CAZ) , por lo \nque se establece el objetivo de fCmin \u2265  4xCMI en base a esta, considerando \nconcentraciones t\u00f3xicas  de CAZ cuando la  Cmin>80 \u00b5g/mL.10 Tras alcanzar el estado \nestacionario , se determina la Cp pre -dosis (Cmin) de CAZ, obteni\u00e9ndose una Cmin  total \nde 8,17 \u00b5g/mL, lo que corr esponde a una fCmin  de 7 ,35 \u00b5g/mL, considerando  una UPP \ndel 10%.11 Puesto que la Cp no alcanza el objetivo terap\u00e9utico  de fCmin \u2265 4xCMI  (16 \n798\u00b5g/mL ), y tambi\u00e9n teniendo en cuenta que la  penetraci\u00f3n estimada en pulm\u00f3n es del \n30%  11,13, se plantean dos opciones para optimizar la terapia: incrementar la dosis o \naumentar el tiempo de administraci\u00f3n, considerando la posibilidad de administrar lo en \ninfusi\u00f3n continua. Finalmente, se decid e incrementar la dosis a 70mg /14mg  /kg/8h y \nrealizar una nueva determinaci\u00f3n a las 24h, que finalmente no es posible obtener debido \na que el paciente es exitus  en contexto de un hematoma intracraneal con evoluci\u00f3n a \nmuerte encef\u00e1lica.  \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA  \nEn este paciente  pedi\u00e1trico con ECMO , la utilizaci\u00f3n de dosis est\u00e1ndares de IVZ y CAZ -AVI \nno permit i\u00f3 alcanzar concentraciones terap\u00e9uticas, por lo que fue necesario optimizar la \ndosificaci\u00f3n  guiad a por monitorizaci\u00f3n PK . En rela ci\u00f3n al IVZ, la monitorizaci\u00f3n PK  \ncontinuada permit i\u00f3 realizar ajustes progresivos de la do sis, logrando concentraciones \ndentro del margen terap\u00e9utico objetivo. S in embargo, no fue posible evaluar el impacto \ndel incremento de dosis de CAZ -AVI en las concentraciones plasm\u00e1ticas, debido al \ndesenlace fatal. Como farmac\u00e9uticos, colaboramos  con el equipo m\u00e9dico responsable , \nincluyendo intensivistas e infect\u00f3logos pedi\u00e1tricos,  en el seguimiento y optimizaci\u00f3n del \ntratamiento antimicrobiano .  \nEn conclusi\u00f3n, resulta de utilidad monitorizar las concentraciones plasm\u00e1ticas de los \nantimicrobianos en pacientes pedi\u00e1tricos con ECMO, especialmente aquellos f\u00e1rmacos \nsin indicaci\u00f3n aprobada  en pediatr\u00eda , como IVZ,  permitiendo guiar en los ajustes de do sis, \ncon el objetivo de aumentar la eficacia y limitar los efectos adversos.  Adem\u00e1s, es \nnecesario  realizar nuevos estudios para establecer la dosificaci\u00f3n de IVZ en pediatr\u00eda. \nSer\u00eda de utilidad el  desarrollo de modelos PK poblacionales en pacientes pedi\u00e1tricos con 799ECMO, con un papel esencial del farmac\u00e9utico, lo que permitir\u00eda  predecir la exp osici\u00f3n \nde los antimicrobianos y podr\u00eda suponer un  soporte a la prescripci\u00f3n de los mismos,  tanto  \npara  la correcta selecci\u00f3n de la dosis inicial  como en los posteriores ajustes posol\u00f3gicos .  \nBIBLIOGRAF\u00cdA  \n1. Phe K, Heil EL, Tam VH. Optimizing pharmacokinetics -pharmacodynamics of \nantimicrobial management in patients with sepsis: A review. J Infect Dis. \n2021;222(Suppl 2):S132 \u201341. \n2. Cheng V, Abdul -Aziz MH, Roberts JA, Shekar K. Optimizing drug dosing in patients \nreceiving extracorporeal m embrane oxygenation. J Thorac Dis. 2018;10(Suppl \n5):S629 \u201341. \n3. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients \nreceiving extracorporeal mem brane oxygenation. J Crit Care. 2012;27(6):741.e9 -\n741.e18.  \n4. Ellsworth M, Ostrosky -Zeich ner L. Isavuconazole: Mechanism of Action, Clinical \nEfficacy, and Resistance. J Fungi (Basel). 2020;6(4):324.   \n5. Arrieta AC, Neely M, Day JC, Rheingold SR, Sue PK, Muller WJ, et al. Safety, \nTolerability, and Population Pharmacokinetics of Intravenous and Oral \nIsavuconazonium Sulfate in Pediatric Patients. Antimicrob Agents Chemother. \n2021;65(8):e0029021.  \n6. Zhao Y, Seelhammer TG, Barreto EF, Wilson JW. Altered Pharmacokinetics and Dosin g \nof Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane \nOxygenation. Pharmacotherapy. 2020;40(1):89 -95.  8007. Zurl C, Waller M, Schwameis F, Muhr T, Bauer N, Zollner -Schwetz I. Isavuconazole \nTreatment in a Mixed Patient Cohort with Invasi ve Fungal Infections: Outcome, \nTolerability and Clinical Implications of Isavuconazole Plasma Concentrations. J Fungi \n(Basel). 2020;6(2):90.  \n8. Risum M, Vestergaard MB, Weinreich UM, Helleberg M, Vissing NH, J\u00f8rgensen R. \nTherapeutic Drug Monitoring of Isavuc onazole: Serum Concentration Variability and \nSuccess Rates for Reaching Target in Comparison with Voriconazole. Antibiotics \n(Basel). 2021;10(5):487.  \n9. Furfaro E, Signori A, Di Grazia C, Dominietto  A, Raiola AM, Aquino S. Serial monitoring \nof isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob \nChemother. 2019;74(8):2341 -2346.  \n10. Guilhaumou R, Benaboud S, Bennis Y, Dahyot -Fizelier C, Dailly E, Gandia P, et al. \nOptimization of t he treatment with beta -lactam antibiotics in critically ill patients. Crit \nCare. 2019;23(1):104.  \n11.  Ficha T\u00e9cnica Zavicefta\u00ae (ceftazidima -avibactam). Disponible en: \nhttps:// cima.aemps.es/cima/dochtml/ft/1161109001/FT_1161109001.html  \n12. Hinojosa P\u00e9rez R , Herr uzo Avil\u00e9s A, Herrera Hidalgo L , Gil L, Cabello V, De la Cerda F, \net al. Ajustes en pacientes especiales: T\u00e9cnica contin\u00faa de reemplazo renal (TRRC), \nTerapia de depuraci\u00f3n extracorp\u00f3rea (TDE) y Oxigenador de membrana \nextracorp\u00f3rea (ECMO). Gu\u00eda PRIOAM; 2019.  \n13. Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, Das S. Phase 1 study assessing \nthe steady -state concentration of ceftazidime and avibactam in plasma and epithelial \nlining fluid following two dosing regimens. J  Antimicrob Chemother. \n2015;70(10):2 862-9. 801TITULACI\u00d3N DE SELEXIPAG EN PACIENTE CON HIPERTENSI\u00d3N ARTERIAL \nPULMONAR  \nINTRODUCCI\u00d3N : \nLa hipertensi\u00f3n arterial pulmonar  (HAP)  es una enfermedad rara,  progresiva, de dif\u00edcil \nmanejo.  La prevalencia es de 1,5 casos po r 100.000 habitantes, es m\u00e1s frecuente en \nmujeres y la media de edad en el momento de su diagn\u00f3stico es de aproximadamente \n45 a\u00f1os, seg\u00fan el Registro Espa\u00f1ol de Hipertensi\u00f3n Arterial Pulmonar  (REHAP) . Los \npacientes con esta enfermedad presentan un mal pron \u00f3stico a corto -medio plazo si no \nse realiza una intervenci\u00f3n terap\u00e9utica, con una supervivencia estimada de 2,8 a\u00f1os .  \nLa HAP pertenece al grupo 1 en la clasificaci\u00f3n de la HP, que  se define como un trastorno \nfisiopatol\u00f3gico y hemodin\u00e1mico caracterizado  por el aumento de la presi\u00f3n arterial \npulmonar media (PAPm) \u226520mm Hg, medida por cateterismo card\u00edaco derecho. Las \nprincipales manifestaciones son disnea, fatiga, dolor tor\u00e1cico, s\u00edncope, palpitaciones y \nedema perif\u00e9rico. Tambi\u00e9n puede n aparecer ingurgita ci\u00f3n yugular y reflujo hepato -\nyugular . \nLa HP se clasifica en cinco clases o categor\u00edas,  seg\u00fan el proceso cl\u00ednico predominante \n(dentro de cada grupo se pueden encontrar diferentes causas) :  \n- Grupo 1. HAP .  \n- Grupo  2: HP debido a cardiopat\u00eda izquierda.  \n- Grupo 3:  HP debida a enfermedad pulmonar/hipoxemia . \n- Grupo 4: HP tromboemb\u00f3lica cr\u00f3nica  (HPTE)  y otras obstrucciones de las \narterias pulmonares . 802- Grupo 5: HP de mecanismo no establecido y/o multifactorial . \nLa HAP se diferencia de otros tipos de hipertensi\u00f3n pulmonar  porque existe afectaci\u00f3n \nexclusiva del \u00e1rbol arterial pulmonar, con un incremento  de la resistencia vascular \npulmonar (RVP) que lleva  a la insuficiencia ventricular derecha y , finalmente,  la muerte. \nEl aumento en la RVP parece estar relacionado con diferentes mecanismos, que incluyen \nvasoconstricci\u00f3n, remodelado proliferativo y obstructivo de la pared vascular pulmonar, \ninflamaci\u00f3n y trombosis. Puede deberse a diferentes causas: idiop\u00e1tica , hereditaria, \ndebida a t\u00f3xicos, o asociada a otras patolog\u00eda, como la hipertensi\u00f3n portal.  \nLa HAP es de dif\u00edcil manejo, como se ha comentado previamente , aunque  este manejo  \nha ido evolucionando en complejidad y evidencia. La terapia b\u00e1sica para la HAP se centra  \nen rehabilitaci\u00f3n y entrenamiento bajo supervisi\u00f3n, as\u00ed como el empleo de \noxigenoterapia, diur\u00e9ticos y tratamientos anticoagulantes. En cuanto al tratamiento \nfarmacol\u00f3gico espec\u00edfico, el tratamiento vasodilatador pulmonar es la primera l\u00ednea en \npacientes con HAP. Los principales grupos de f\u00e1rmacos empleados son aquellos que \nact\u00faan sobre la v\u00eda de la endotelina -1, ambrisent\u00e1n, bosent\u00e1n y macitent\u00e1n; los \nf\u00e1rmacos de la v\u00eda del \u00f3xido n\u00edtrico (NO) y GMP -c\u00edclico, que son los inhibidores de la \nfosfodiester asa, sildenafilo y tadalafilo , y los estimuladores de la guanilciclasa soluble, \nel riociguat ( la \u00fanica indicaci\u00f3n aprobada es la HPTE) . El \u00faltimo grupo empleado es el de \naquellos f\u00e1rmacos que act\u00faan sobre la v\u00eda de la prostaciclina. Aqu\u00ed se encuentran el \nepoprostenol, iloprost, teprostinil y el selexipag . Este \u00faltimo es  un agonista del receptor \nde la prostaciclina, administrado v\u00eda oral, a diferencia de los otros f\u00e1rmacos de su grupo.  \nA pesar de s u c\u00f3moda v\u00eda de administraci\u00f3n , ha aparecido reciente mente una alerta \nemitida por la Agen cia Espa\u00f1o la de Medicamentos y Productos Sanitarios (A EMPS) que 803manifiesta la importancia de la participaci\u00f3n del farmac \u00e9utico en la titulaci\u00f3n de este \nmedicamento.  \nEn la actualidad, la experiencia con terapia de combina ci\u00f3n est\u00e1 aumenta ndo. Se \nrecomienda que esta se inicie cuando no se alcancen los objetivos del tratamiento, \nalcanzar una clase funcional II seg\u00fan la New York Heart Association (NYHA) y una casi \nnormalizaci\u00f3n del \u00edndice card\u00edaco , el p\u00e9ptido natriur\u00e9tico cerebral  (BNP) y el pro-BNP . A \nfin de conseguir estos objetivos y mejorar la calidad de vida de los pacientes con HAP, la \nasistencia por un equipo multidisciplinar en la que el servicio de neumolog\u00eda est\u00e9 \ncoordinado con los farmac\u00e9uticos del hospital, adem\u00e1s de otros profesio nales de la \nsalud, es fundamental.  \nDESCRIPCI\u00d3N DEL CASO : \nMujer de 72 a\u00f1os con hipertensi\u00f3n arterial, Diabetes Mellitus tipo II \ninsulinodependiente, fibrilaci\u00f3n auricular y trasplantada de h\u00edgado por cirrosis por virus \nde la hepatitis B (VHB) y virus de la hepatitis C (VHC) el 25/09/2002. Tuvo una recidiva \nde hepatitis C en el injerto, carcinoma basocelular en nariz en dos ocasiones e \ninsuficiencia renal postrasplante. Durante esta \u00e9poca la paciente p resent\u00f3 hipertensi\u00f3n \npulmonar secundaria a hipertensi\u00f3n portal que se trat\u00f3 con sildenafilo e iloprost. Tras \nmejor\u00eda, la paciente fue dada de alta en 2010. No se tienen datos de los tratamientos de \nla paciente hasta 2011, \u00fanicamente los datos que los m\u00e9dic os especialistas han reflejado \nen la historia cl\u00ednica de la paciente en informes posteriores.  \nEn enero de 2020, la paciente acude a realizarse una ecocardiograf\u00eda, donde se detectan \nalteraciones sugerentes de hipertensi\u00f3n pulmonar severa y derrame peric\u00e1r dico. Es \nderivada desde cardiolog\u00eda al servicio de neumolog\u00eda. La paciente refiere presentar 804disnea de esfuerzo progresiva, que llega a interferir con sus actividades cotidianas. Tiene \ntendencia a edematizaci\u00f3n de piernas y no presenta s\u00edncopes.  \nLa pacien te es diagnosticada de hipertensi\u00f3n pulmonar de probable origen \nportopulmonar, con una clase funcional III -IV.  \nEn agosto de 2020, se le realiza cateterismo card\u00edaco derecho, donde se observa una \nPAPm de 47mm Hg  y una PAP sist\u00f3lica (PAPs) de 60mm Hg . En la  anal\u00edtica destacan los \nvalores elevados de pro -BNP (4430pg/ml, siendo lo normal valores menores a \n300pg/ml).  \nEn diciembre de 2020, la paciente inicia tratamiento con sildenafilo, 20mg cada 8 horas. \nEn ecocardiograma realizado a finales de marzo de 2021, se observa un derrame \nperic\u00e1rdico circunferencial severo e hipertensi\u00f3n pulmonar severa (PAPm=70mm Hg ; \nPAPs=75mm Hg ), por lo que se inicia terapia combinada con macitent\u00e1n, 10mg cada 24 \nhoras. En junio de 2021 se aumenta la dosis de sildenafilo a 40mg cada  8 horas por no \nestar bien controlada.  \nEn noviembre de 2021, la paciente acude a revisi\u00f3n, donde se mantiene en una clase \nfuncional III, sin conseguir los objetivos de la terapia doble combinada, por lo que se \nsolicita a farmacia el empleo de selexipag , para iniciar la triple terapia combinada.  \nLa paciente inicia titulaci\u00f3n de selexipag el 02/12/2021 seg\u00fan indica ficha t\u00e9cnica, \naumentando las dosis de selexipag 200mg en cada dosis semanalmente , iniciando \nsiempre el aumento en la dosis nocturna. En la tabla  1 se presenta la titulaci\u00f3n completa \ndel f\u00e1rmaco.  805El 09/02/2022 finaliza la titulaci\u00f3n de selexipag, alcanz\u00e1ndose dosis plenas (1600mg \ncada 12 horas), sin efectos secundarios. El 16/03/2022 se reduce la dosis de sildenafilo \na 20mg cada 8 horas.  \nLa \u00faltima  consulta con neumolog\u00eda se realiza el 27/04/2022, tras una ecocardiograf\u00eda \nrealizada el 22/04/2022. En ella se observa que la paciente mantiene el derrame \nperic\u00e1rdico, ya presente  en las anteriores pruebas. Muestra  hipertensi\u00f3n pulmonar \nmoderada (PAPs=50m m Hg, no se determina la PAPm) , en clase funcional II -III, aunque \nel pro -BNP se mantiene elevado (3240pg/ml). Sin embargo, seg\u00fan los criterios de la \nneum\u00f3loga existe un riesgo bajo de progresi\u00f3n de los s\u00edntomas.  \nEl tratamiento actual de la paciente se especifica en la tabla 2.  \nTabla 1.  \nDosis de \nselexipag  Comprimidos por \ndosis  Fecha de inicio  Fecha de fin  \n200mg cada 12h  1 comprimido \n(comp.) de 200mg  02/12/2021  09/12/2021  \n400mg cada 12h  2 comp. de 200mg  09/12/2021  16/12/2021  \n600mg cada 12h  3 comp. de 200mg  16/12/2021  27/12/2021  \n800mg cada 12h  1 comp. de 800mg  27/12/2021  05/01/2022  \n1000mg cada 12h  1 comp. de 800mg y \n1 comp. De 200mg  05/01/2022  12/01/2022  \n1200mg cada 12h  1 comp. de 800mg y \n2 comp. De 200mg  12/01/2022  19/01/2022  8061400mg cada 12h  1 comp. de 1400mg  19/01/2022  02/02/2022  \n1600mg cada 12h  1 comp. de 1400mg \ny 1 comp de 200mg  02/02/2022  14/02/2022  \n  \n \n \nTabla 2.  \nF\u00e1rmaco  Dosis  F\u00e1rmaco  Dosis  \nSildenafilo 20mg \ncomp. *  20mg cada 8h  Bisoprolol 5mg  5mg cada 24h  \nMacitentan 10mg \ncomp. *  10mg cada 24h  Ramipril 2,5mg  2,5mg cada 24h  \nSelexipag 1600mg \ncomp. *  1600mg cada 12h  Atorvastatina 10mg  10mg cada 24h  \nEntecavir 0,5mg *  0,5mg cada 24h  Warfarina 5mg  10mg cada 24h \nEverolimus 0,5mg  0,5mg cada 12h  Insulina Glargina \n100UI/ml  20UI cada 24h  \nIgantibe 200UI/ml \n(IG anti VHB)  1 inyectable cada \n90 d\u00edas  Sitagliptina 50mg/ \nMetformina 1000mg  1 compr. Cada \n12h 807Espironolactona \n100mg  100mg cada 24h  Alopurinol 100mg  100mg cada 24h  \nFurosemida 40mg  40mg cada 24h  Hierro  (II) ferroglicina \n567,7mg  1 compr. Cada \n24h \nBisoprolol 2,5 mg  2,5mg cada 24h  Lormetazepam  2mg  2mg cada 24h.  \n*Medicaci\u00f3n recogida en consultas externas de farmacia hospitalaria.  \n \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA : \nLa hipertensi\u00f3n pulmonar  requiere  de un equipo m\u00e9dico multidisciplinar muy \nespecializado, pues se requiere un arsenal terap\u00e9utico importante para su tratamiento. \nDurante el proceso de titulaci\u00f3n del selexipag, tanto la neum\u00f3loga en cargada del caso, \ncomo las farmac\u00e9uticas del \u00e1rea de pacientes externos, contactamos con la paciente \nsemanalmente. El marido de la paciente recog\u00eda la s dosis . Esta s visitas  se emplea ban \npara hacer un correcto seguimi ento farmacoterap \u00e9utico y prevenir posibles error es de \nmedicaci\u00f3n. La informaci \u00f3n se le entr egaba oral y por escrita, para el registro de las dosis \nadministra das, y la farmac\u00e9utica com probaba la compresi\u00f3n p or parte de  la paciente y \nsu ma rido mediante mecanis mos de feedback.  La paciente , adem \u00e1s, se comunicaba con \nlos profesionales sanitarios v\u00eda telef\u00f3nica siempre que lo precisara. Gracias a esto se \npudo ajustar, adem\u00e1s, la dosis de furosemida, de 60mg a 40mg en la ma\u00f1ana, ya que la \npaciente, tras haber iniciado tratamiento con selexipag , desarroll\u00f3 enuresis nocturna.  \nTambi \u00e9n se estudi aron las posibles interacciones de los f\u00e1rmacos de la paciente 808polimedicada y se recomend \u00f3 un control  estrecho  de los niveles del INR , debido a la \ninteracci\u00f3n de la warfarina  con el selexipa g, por riesgo aumentado de sangrado.   \nEste caso cl\u00ednico pone de manifiesto la necesidad de subespecializaci\u00f3n del farmac\u00e9utico \ny la comunicaci\u00f3n con el equipo multidisciplinar , as\u00ed como una atenci\u00f3n farmac\u00e9utica \ncentrada en el paciente.  \nBIBLIOGRAF\u00cdA : \n1. Registro REHAP , \nhttps://www.separ.es/node /1559#:~:text=Habitualmente%2C%20esta%20enfe\nrm edad%20afecta%20a,cada%20100.000%20habitantes%20y%20a%C3%B1o.  \n2. James R. Klinger, C. Gregory Elliott, Deborah J. Levine et al. Therapy for \nPulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline  and \nExpert Panel Report, Chest, Volume 155, Issue 3, 2019,Pages 565 -586,ISSN 0012 - \n3692, https://doi.org/10.1016/j.chest.2018.11.030 .  \n3. Condon DF, Nickel NP, Anderson R et al. The 6th World Symposium on Pulmonary \nHypertension: what\u2019s old is new [version 1;  peer review: 3 approved]. \nF1000Research 2019, 8(F1000 Faculty Rev):888 \n(https://doi.org/10.12688/f1000research.18811.1 )  \n4. Joan Albert Barber\u00e0, Antonio Rom\u00e1n, Miguel \u00c1ngel G\u00f3mez -S\u00e1nchez et al., Gu\u00eda \nde diagn\u00f3stico y tratamiento de la hipertensi\u00f3n pulmonar: resumen de \nrecomendaciones, Archivos de Bronconeumolog\u00eda, Volume 54, Issue 4, 2018, \nPages 205 -215, ISSN 0300 -2896, https://doi.org/10.1016/j.arbres.2017.11.014  \n \n 809TERAPIA ANTICOAGULANTE EN PACIENTES DE EDAD AVANZADA CON FIBRILACI\u00d3N \nAURICULAR EN TRATAMIENTO CON IBRUTINIB: OPTIMIZACI\u00d3N DE \nTRATAMIENTO DESDE URGENCIAS  \nINTRODUCCI\u00d3N :  \nEl avance de las t\u00e9cnicas diagn\u00f3sticas y el desarrollo de mejores tratamientos onco -\nhematol\u00f3gicos en las \u00faltimas d\u00e9cadas ha aumentado la supervivencia de los pacientes \ncon c\u00e1ncer, lo que conlleva un incremento de sus comorbilidades asociadas y mayor \ncomplejidad en el manejo de su tratamiento farmacol\u00f3gico1. Es bien descrito que los \npacie ntes longevos est\u00e1n m\u00e1s expuestos a sufrir errores de medicaci\u00f3n (EM) con peores \nconsecuencias por los cambios fisiol\u00f3gicos inherentes a la edad, la presencia de \ncomorbilidades, polifarmacia, prescripciones en cascada, interacciones farmacol\u00f3gicas, \nmalnutr ici\u00f3n y caquexia  2. Por todo ello, es necesario un abordaje multidisciplinar para \nel beneficio y mejora de la calidad de vida del paciente oncohematol\u00f3gico adulto mayor.  \nUno de los puntos cr\u00edticos son las transiciones asistenciales, donde resulta esencial \nrealizar una adecuada revisi\u00f3n y conciliaci\u00f3n farmacoterap\u00e9utica de estos pacientes. Las \nUrgencias Hospitalarias por su distinta naturaleza respecto a otros servicios cl\u00ednicos hace \nque sea un escenario m\u00e1s propicio para la ocurrencia de EM. Por tanto, las diferentes \nestrategias implementadas en el Servicio de Urgencias para mejorar la calidad \nasistencial y garantizar la seguridad del paciente son una prioridad. Cada vez m\u00e1 s \nhospitales apuestan por la presencia f\u00edsica del farmac\u00e9utico hospitalario en los equipos \nde Urgencias. Una de sus funciones principales es la revisi\u00f3n farmacoterap\u00e9utica integral \ny la conciliaci\u00f3n del tratamiento cr\u00f3nico habitual.   \nDESCRIPCI\u00d3N DEL CASO:  \nMujer de 89 a\u00f1os que acude al Servicio de Urgencias  por dolor costal izquierdo de inicio \ns\u00fabito no opresivo en reposo  de una hora de evoluci\u00f3n  que se intensifica con 810movimientos respiratorios  asociado a disnea . La situaci\u00f3n basal de la paciente \npreviamente era: independiente para las actividades de la vida diaria  (\u00edndice Barthel \n100), sin deterioro cogniti vo (escala  Pfeiffer 0 ) y una puntuaci\u00f3n de 3 de fragilidad en \nescala FRAIL . A la exploraci\u00f3n f\u00edsica destaca l a aparici\u00f3n de edemas con f\u00f3vea hasta las \nrodillas  y tensiones arterial es sist\u00f3lica/ diast\u00f3lica de 163/53 mmHg . En el ECG se \nevidencia Fibrilaci\u00f3n Auricular  (FA) a 90 latidos/ min ya conocido y  en la anal\u00edtica resaltan \nvalores de  Pro-p\u00e9ptido natriur\u00e9tico  cerebral  (NT-proBNP)  de 2214 pg/ml y  PCR 151 mg/L \nsin leucocitosis ni neutrofilia y D -d\u00edmero de 3 . Adem\u00e1s, el s istem\u00e1tico y sedimento de \norina  es compatible con  una posible infecci\u00f3n del tracto urinario  (ITU) . Se realiza \nangiograf\u00eda por tomograf\u00eda computarizada que no muestra signos de tromboembolismo \npulmonar, pero s e objetiva derrame pleural bilateral. Por tanto, parece tratarse del \nprimer episodio de insuficiencia cardiaca  con fracci\u00f3n de eyecci\u00f3n del ventr\u00edculo \nizquier do (FEVI) conservada .  \nEl farmac\u00e9utico de urgencias (FHU) selecciona a la paciente para la atenci\u00f3n \nfarmaceutica ya que cumple criterios previamente establecidos para ello.  Los criterios \nestablecidos fueron son  aquellos  pacientes  que ingresan en el hospita l o se encuentran \nen observaci\u00f3n con criterios de gravedad ( >70 a\u00f1os, polimedicado definido como  en \ntratamiento con m\u00e1s de 6 f\u00e1rmacos y presencia de m\u00e1s de 2 comorbilidades ) y de la \nsituaci\u00f3n cl\u00ednica (puntuaciones bajas en el triaje  y uso de medicamentos de alto riesgo ).  \nSe establece una revisi\u00f3n estructurada que relaciona cada problema de salud con la \nmedicaci\u00f3n cr\u00f3nica habitual  (tabla1)  y se procede a la  conciliaci\u00f3n del tratamiento  \ncomplementando con  una entrevista cl\u00ednica a la paciente para contrastar la informaci\u00f3n \ny obtener datos adicionales sobre posibles medicaciones no refer enciados en la historia \ncl\u00ednica. En la entrevista cl\u00ednica realizada se constata  un adecuado conocimiento de su 811tratamiento cr\u00f3nico  y una correcta adherencia al mismo. La siguiente tabla muestra el \nan\u00e1lisis realizado por el FHU  de la medicaci\u00f3n cr\u00f3nica habitual asociada a los problemas \nde salud de la paciente.  \nTabla 1: Procedimiento establecido por el FHU para  la recogida de datos, revisi\u00f3n y conciliaci\u00f3n del tratamiento  \n PROBLEMAS DE SALUD  MEDICACI\u00d3N CR\u00d3NICA HABITUAL A SOCIADA  \n2003  Hipertensi\u00f3n arterial  \n Irbesart\u00e1n 300mg (1-0-0) \nFurosemida 40mg (1-0-0) \nEspironolactona 25 mg (1-0-0) \n2011  Fibrilaci\u00f3n auricular  \u00c1cido acetilsalic\u00edlico  150 mg  \n2011  Dolor cr\u00f3nico secundario a artrosis severa y \nestenosis del canal  Fentanilo  75 mcg parches  cada 72 horas  \nParacetamol 650 mg  (1-1-1) \nLactulosa  10 g (0-0-1) \n2011  Anemia microc\u00edtica hipocr\u00f3mica  en seguimiento \npor H ematolog\u00eda Cl\u00ednica  Hierro carboximaltosa  \n2016  Osteoporosis  en seguimiento por traumatolog\u00eda y \nreumatolog\u00eda.  Colecalciferol 25000  UI mensual  \nCalcio/vit D3 1000 mg/880 UI 1-0-0 \nDenosumab  60mg (Denosumab) /6 meses  \n2019  Linfoma de c\u00e9lulas B del manto  Ibrutinib 420 mg/24h  \nSe analiza cada uno de los problemas de salud con la medicaci\u00f3n pautada:  \n\uf0b7 Antecedentes cardiovasculares : La paciente presenta h ipertensi\u00f3n arterial desde \n2003. En la entrevista cl\u00ednica refiere adecuado control tensional con su tratamiento \nactual basado en antagonistas del receptor de angiotensina -II (Irbesart\u00e1n  300mg) y \ndiur\u00e9ticos (furosemida 40mg y espironolactona 25mg) , f\u00e1rmacos con efectividad \naceptable en ancianos con funci\u00f3n renal deteriorada. A su vez, presenta una FA de \ncronolog\u00eda incierta diagnosticada en el 2011 que fue anticoagulada con dicumar\u00ednico \ndurante 6 meses  con posterior reversi\u00f3n espont\u00e1nea . Posteriormente, sin motivo \nclarificado  se suspende acenocumarol y se inicia antiagregaci\u00f3n con  \u00e1cido \nacetilsalic\u00edlico a d osis de 150 mg cada 24 h  hasta este episodio.  \n\uf0b7 Dolor cr\u00f3nico  secundario a artrosis severa y estenosis del canal de a\u00f1os de evoluci\u00f3n  \ncontrolado con opioides mayores (parche fentanilo 75mcg/h c/72h) junto con \nparacetamol 650 mg c/8h  m\u00e1s laxante asociado para la prevenci\u00f3n del estre\u00f1imiento 812secundario asociado a opioides . El fentanilo es una  buena opci\u00f3n en pacientes con \nfunci\u00f3n renal deteriorada  y con buen perfil de seguridad  en cardi\u00f3patas.  Por tanto, \nse trata de un adecuado tratami ento analg\u00e9sico en este paciente.  \n\uf0b7 Anemia microc\u00edtica hipocr\u00f3mica  inflamatoria  para lo que ha recibido puntualmente \nsuplementaci\u00f3n de hierro . En el momento del ingreso presenta buen perfil f\u00e9rrico.   \n\uf0b7 Osteoporosis primaria  con suplementaci\u00f3n  de vitamina D y calcio . Adem\u00e1s,  \ndenosumab subcut\u00e1neo semestral, anticuerpo antirresortivo de  elecci\u00f3n en caso de \nfiltrados glomerulares disminuidos.   \n\uf0b7 Linfoma de c\u00e9lulas B del manto  con progresi\u00f3n ganglionar cervical desde 2019.  En \ntratamiento con ibruti nib a dosis reducidas por intolerancia gastrointestinal.  \nRespecto a la situaci\u00f3n aguda que provoca la visita a Urgencias, se trata de un primer \nepisodio de insuficiencia cardi aca donde el objetivo principal  es el alivio de los s\u00edntomas \ncongestivos. Acude e l Servicio de Cardiolog\u00eda quien indica manejo deplectivo con \ndiur\u00e9ticos (bolo intravenoso de 40 mg de furosemida seguido de 20 mg cada 8 h + \nespironolactona 50 mg). Se trata de una adecuada dosificaci\u00f3n en paciente en \ntratamiento previo con diur\u00e9ticos dond e habitualmente es necesario  aumentar 2 -2,5 \nveces su dosis habitual para garantizar la descongesti\u00f3n. La paciente evoluciona \nfavorablemente alcanzando el objetivo de diuresis (\u2265 100 ml/h en las primeras 6 h)  y \ntensiones mantenidas.  Adicionalmente, se  instaura tratamiento con ceftriaxona 1g \nc/24h por ITU concomitante que podr\u00eda ser una de las causas de la descompensaci\u00f3n de \nIC. Respecto a la FA, presenta alto riesgo tromboemb\u00f3lico con puntuaci\u00f3n CHA2DS2 -\nVASC de 4 (hipertensi\u00f3n, edad, sexo) por lo que r ecomiendan  iniciar  anticoagulaci\u00f3n  tras \nvaloraci\u00f3n beneficio -riesgo . Se inicia acenocumarol 1 mg y  enoxaparina ajustada a peso \ncomo terapia puente  para alcanzar objetivos de INR.  813Tras esta revisi\u00f3n exhaustiva realizada por el FHU , se detecta una interacci \u00f3n \ncl\u00ednicamente relevante entre ibrutinib y acenocumarol en un paciente adulto mayor \npluripatol\u00f3gico , con un alto riesgo de sangrado inherente a su patolog\u00eda hematol\u00f3gica \npotenciado por el tratamiento con ibrutinib , donde el inicio con dicumar\u00ednicos se \nencuentra contraindicado. S e contacta con hemat\u00f3logo de la paciente y urgenci\u00f3logo \nresponsable para recomendar el cambio a un anticoagulante oral de acci\u00f3n directa tipo \nanti-Xa donde la contraindicaci\u00f3n no es absoluta y se podr\u00eda plantear como opci\u00f3n \nterap\u00e9ut ica con monitorizaci\u00f3n estrecha del paciente.  Asimismo, se recomienda la \nsuspensi\u00f3n definitiva de antiagregante por falta de evidenci a que adem\u00e1s se encuentra \npautado a dosis altas  sin aportar beneficio alguno . Finalmente, se consensua  la \nsuspensi\u00f3n de acenocumarol + enoxaparina  + AAS 150 mg y se inicia desde la Urgencia \napixaban a dosis reducidas por edad  y peso y valores (2,5 mg cada 12 h) . \nTras 24 h en observaci\u00f3n, la paciente se encuentra estable hemodin\u00e1micamente y \npresenta buena evoluci\u00f3n cl\u00ednica. El FHU junto al urgenci\u00f3logo explican  a la paciente  los \ncambios en su tratamiento  y responden dudas acerca del procedimiento de visado de \ninspecci\u00f3n correspondiente al apixaban. Finalmente se procede al alta de la paciente  \nmanteni\u00e9ndose sin complicaciones hemorr\u00e1gicas.  \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA  \nEl linfoma de c\u00e9lulas B del manto (LCM) se cataloga seg\u00fan la Organizaci\u00f3n Mundial de la \nSalud  como un linfoma maligno no Hodgkin (LNH) que afecta a c\u00e9lulas B maduras  y \nconstituye el 3 -10% de todos los linfomas. El LCM es prevalente en personas de edad \navanzada, con una mediana de inicio de la enfermedad a los 68-70 a\u00f1os .  Se considera \nuna entidad cl\u00ednicamente agresiva, con moderada respuesta a la quimioterapia  y con  \nuna mediana de supervivencia global de 4 -5 a\u00f1o s. La mayor\u00eda de pacientes  adultos 814mayores con LMC  no son candidatos a reg\u00edmenes  intensivos que  se han asociado con \nincremento de supervi vencia . Actualmente s\u00f3lo el TPH alog\u00e9nico consigue \nsupervivencias prolongadas libre de enfermedad.  Esto supone que ibrutinib se posiciona \ncomo opci\u00f3n de eficacia y toxicidad aceptable en esta poblaci\u00f3n con una mejor \ntolerancia y comodidad en la administraci\u00f3n.   \nIbrutinib  es un potente e irreversible inhibidor de la tiros i\u0301n kinasa de Bruton (BTK) . Su \nmecanismo de acci\u00f3n favorece  la inhibici\u00f3n de la transmisi\u00f3n de se\u00f1ales del receptor \ncelular de la c\u00e9lula B  (BCR)  y frena ndo la quimiotaxis y adhesi\u00f3n de c\u00e9lulas B.  Sin \nembargo, no est\u00e1 exento de efectos adversos. Hasta un 48% de los pacientes con LCM \nen tratamiento con ibrutinib desarrollaron alg\u00fan tipo de hemorragia. El mecanismo por \nel que el ibrutinib predispone a l sangrado  es desconocido  3.  \nNo obstante, ante la indicaci\u00f3n de anticoagulaci\u00f3n por FA concomitante, tras valoraci\u00f3n \ndel beneficio -riesgo  y con la aceptaci\u00f3n de los riesgos por parte de la  paciente , el uso de \nanticoagulantes anti -vitamina K  simult\u00e1neo se encuentra contraindicado, as\u00ed como  con \ndabigatr\u00e1n  (inhibidor directo de la trombina) . No es el caso de los anticoagulantes anti -\nXa, donde la contraindicaci\u00f3n no es absoluta si bien es necesaria una monit orizaci\u00f3n \nestrecha de plaquetas 1. A pesar de ello, se requieren m\u00e1s estudios para aclarar cual es \nel riesgo de utilizar ibrutinib con anticoagulantes no vitamina K.  La indicaci\u00f3n de \nanticoagular y de la selecci\u00f3n del  f\u00e1rmaco antiXa , se consensua en conjunto con el \nServicio de Hematolog\u00eda  y Urgenci\u00f3logo  responsable del paciente. Se opta por apixaban \nsobre edoxab\u00e1 n y rivaroxab\u00e1n como mejor alternativa terap\u00e9utica en paciente con alto \nriesgo hemorr\u00e1gico, edad avanzada y bajo peso4. Se recomienda iniciar con dosis 815reducidas de 2,5 mg cada 12 h por peso < 60 kg y edad > 80 a\u00f1os  indicado  en ficha \nt\u00e9cnica.  \nOtro aspecto relevante de la seguridad de ibrutinib es la cardiotoxicidad asociada. Se ha \ndescrito un aumento de la notificaci\u00f3n de arritmias,  en especial FA asociadas al  \ntratamiento. Esto tambi\u00e9n podr\u00eda justificar la perpetuaci\u00f3n de la FA en la paciente.  \nPor otra parte, el FHU  es capaz de detectar, analizar  y priorizar las interacciones \nfarmacol\u00f3gicas cl\u00ednicamente relevantes para poder aportar valor a sus \nrecomendaciones. En este caso se trata de una inte racci\u00f3n de tipo farmacodin\u00e1mica.  \nEl FHU reevalu\u00f3 la  necesidad de mantener el antiagregante  AAS 150 mg iniciado en \n2012. Adem\u00e1s, est\u00e1 descrito como criterio STOPP2 el uso de AAS combinado con un AVK, \ndabigatr\u00e1n, rivaroxab\u00e1n, apixab\u00e1n o edoxab\u00e1n en pacientes con FA cr\u00f3nica, puesto que \nel AAS no aporta beneficios en estos casos.   Adem\u00e1s, seg\u00fa n las \u00faltimas Gu\u00edas \nconsultadas5 el tratamiento con AAS en monoterapia no es eficaz para la prevenci\u00f3n del \nictus en paciente con FA y puede generar complicaciones con mayor repercusi\u00f3n en \npacientes mayores.  Respecto a la dosificaci\u00f3n , tampoco habr\u00eda bibliograf\u00eda que avale esa \ndosis, pues  dosis superi ores a 100 mg en mantenimiento  aumentan del riesgo de \nsangrado, sin evidencia de una mayor eficacia  en los pacientes mayores .  \nLas aportaciones farmac\u00e9uticas en este caso fueron : \n- El cribado del FHU de los pacientes teniendo en cuenta criterios ligados al propio \npaciente y ligados a su situaci\u00f3n cl\u00ednica  en Urgencias ha permitido seleccionar aquellos \npacientes que m\u00e1s se van a benefi ciar de una atenci\u00f3n farmac\u00e9utica.  \n- La revisi\u00f3n farmacoterap\u00e9utica en Urgencias del FHU ha favorecido  el abordaje precoz \nde posibles EM que podr\u00edan perpetuarse en el ingreso hospitalario o al alt a. 816- La detecci\u00f3n de terapias potencialmente inadecuadas en un adulto mayor a trav\u00e9s de \nherramientas de deprescripci\u00f3n, permiten mejorar la optim izaci\u00f3n del tratamiento \nminimizando los riesgos derivados.  \n- La capacidad de evaluaci\u00f3n y priorizaci\u00f3n de las interacciones detectadas ha permitido \naportar valor a nuestra s recomendaciones.  \n- La presencia f\u00edsica de un FHU permite un manejo  multidisciplinar del tratamiento en \npacientes con patolog\u00edas complejas y favore ciendo  la correcta selecci\u00f3n de f\u00e1rmacos .  \n \nEn conclusi\u00f3n,  el abordaje multidisciplinar desde la Urgencia constituye un punto cr\u00edtico \npara la reevaluaci\u00f3n y optimizaci\u00f3n farmacoterap\u00e9utica de los pacientes.  La mejora de \nla calidad de vida evitando efectos adversos derivados de f\u00e1rmacos o interacciones de \nlos mismos , en pacientes mayores con LMC y FA cuya esper anza de vida es corta, \nconstituye una prioridad. Es necesario m\u00e1s estudios que eval\u00faen la seguridad de los \npacientes con ibrutinib y anticoagulantes no anti -vitamina K.  \nBIBLIOGRAF\u00cdA  \n1. L\u00f3pez- Fern\u00e1ndez T, Mart\u00edn -Garc\u00eda A, Rold\u00e1n Rabad\u00e1n I, Mitroi C, Maz\u00f3n R amos P, D\u00edez -Villanueva P, et  al. Abordaje \nde la fibrilaci\u00f3n auricular en pacientes con c\u00e1ncer activo. Documento de consenso de expertos y recomendaciones. \nRevista Espa\u00f1ola de Cardiolog\u00eda. 2019;72(9):749 -59. \n2. Delgado Silveira E, Montero Errasqu\u00edn B, Mu\u00f1o z Garc\u00eda M, V\u00e9lez -D\u00edaz-Pallar\u00e9s M, Lozano Montoya I, S\u00e1nchez -\nCastellano C, et  al. Mejorando la pres cripci\u00f3n de medicamentos en personas mayores: una nueva edici\u00f3n de los \ncriterios STOPP -START. Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. 2015;50(2):89 -96. \n3. Informe de Posicionamiento Terap\u00e9utico de ibrutinib (Imbruvica\u00ae) para el linfoma de c\u00e9lulas del manto. Agencia \nEspa\u00f1ola de Medicamentos y Productos Sanitarios 2016 . \n4. Anguita M, D\u00e1valos A, L\u00f3pez de S\u00e1 E, Mateo J, Monreal M, Oliva J, et  al. Anticoagula ntes orales directos en la \nfibrilaci\u00f3n auricular no valvular: c\u00f3mo mejorar su uso en Espa\u00f1a. Medicina de Familia SEMERGEN. 2019;45(2):109 -\n16. \n5. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m -Lundqvist C, et  al. Gu\u00eda ESC 2020 sobre el diagn\u00f3 stico \ny tratamiento de la fibrilaci\u00f3n auricular, desarrollada en colaboraci\u00f3n de la European Association of Cardio -Thoracic \nSurgery (EACTS). Revista Espa\u00f1ola de Cardiolog\u00eda.mayo de 2021;74(5):437.e1 -437.e116.  \n 817\u00bfFORMULACI\u00d3N MAGISTRAL EN DERMATOMIOSITIS? METABISULFITO S\u00d3DICO AL 25% COLD \nCREAM  PARA TRATAMIENTO DE LA CALCINOSIS  DISTR\u00d3FICA ASOCIADA  \nINTRODUCCI\u00d3N:  \nLa dermatomiositis juv enil (DMJ)  es la miopat\u00eda inflamatoria  idiop\u00e1tica m\u00e1s frecuente \nen la infancia, representando un 85% del total en esta poblaci\u00f3n. La incidencia estimada \nen distintas series de c asos es de 3  a 4 casos por mill\u00f3n de ni\u00f1os.  \nSe trata de una enfermedad que se asocia a una vasculopat\u00eda sist\u00e9mica, que conduce a \nuna oclusi\u00f3n y necrosis de los capilares que irrigan las fibras musculares perifasciculares. \nEsta patolog\u00eda se podr\u00eda encuadrar  dentro de las enfermedades autoinmunes \npolig\u00e9nicas mediadas por interfer\u00f3n pudiendo existir  cierta pre disposici\u00f3n gen\u00e9tica;  se \nhan descrito polimorfismos en el HLA8.1, as\u00ed como en los genes que codifican el TNF -\nalfa. En individuos gen\u00e9ticamente predispuestos, una infecci\u00f3n, procedimientos de  \nvacunaci\u00f3n, la luz solar, algunos f\u00e1rmacos, pueden actuar como factores \ndesencadenantes.  \nSon t\u00edpicas las manifestaciones cut\u00e1neas siendo patognom\u00f3nicos el eritema en \nheliotropo (eritemato -viol\u00e1ceo en p\u00e1rpados  sim\u00e9trico , bilateral ) o las p\u00e1pulas de \nGottron (lesiones eritemato -viol\u00e1ceas localizadas sobre superficies articulares \npredominantemente en  articulaciones  metacarpofal\u00e1ngicas e interfal\u00e1ngicas). Otras \nmanifestaciones  son \u00falcera s orales, cut\u00e1neas, calcinos is, lipodistrofia , afectac i\u00f3n de \nm\u00fasculos de la degluci\u00f3n o respiraci\u00f3n o afectaci\u00f3n parenquimatosa pulmonar \n(frecuentemente asociada a anticuerpos MDA -5). Se puede producir debilidad muscular \nt\u00edpicamente de predominio proximal y sim\u00e9trico, si bien hay for mas sin afectaci\u00f3n \nmuscular, es decir, cl\u00ednicamente amiop\u00e1ticas .  \nExisten diferentes hallazgos de laboratorio , que aunque suelen  estar presentes en esta \npatolog\u00eda, no son espec\u00edficos y no permiten establecer un diagn\u00f3stico definitivo: \nelevaci\u00f3n de lactato deshidrogenasa  (LDH) , creatin  quinasa  (CK), aldolasa, etc;  as\u00ed como  818presencia de  anticuerpos antinucleares   o presencia de anti cuerpos espec\u00edficos de \nmiositi s (1,2) . \nEn la exploraci\u00f3n f\u00edsica se recomienda utilizar escalas de valoraci\u00f3n muscular validadas \nen Pediatr\u00eda como la Childhood Myositis Assessment Scale (CMAS) o el Manual Muscle \nTest  (MMT8).  La escala CMAS va de 0 (la peor) a  52, eval uando fuerza, resistencia y \nfunci\u00f3n muscular, considerando m\u00fasculos tanto axiales como proximales de \nextremidades superiores e inferiores, (3). \nComo hemos comentado, una de las posibles complicacio nes es la calcinosis que se \ndesarrolla habitualmente tras unos a\u00f1os desde el diagn\u00f3stico y que puede relacionarse \ncon un retraso en el mismo o en su tratamiento, o con un manejo inadecuado de la \npatolog\u00eda. La prevalencia var\u00eda seg\u00fan las series de casos con sultada s entre 30 y 40% y \nhabitualmente estos pacientes necesitan emplear uno o m\u00e1s inmunosupresores para \ntratar la DMJ,  o muestran afectaci\u00f3n pulmonar o card\u00edaca,  trat\u00e1ndose de una \nmanifestaci\u00f3n  que aparece en formas m\u00e1s agresivas (4). \n La calcinosis distr\u00f3fica tiene lugar por la formaci\u00f3n de dep\u00f3sitos insolubles de calcio \nliberado desde las mitocondrias, en tejidos previamente da\u00f1ados en el cont exto de \ninflamaci\u00f3n, da\u00f1o vascular e hipoxia , siendo los niveles plasm\u00e1ticos tanto de calcio como \nde f\u00f3sforo normales  (5). \nEl pilar fundamental en la  terap\u00e9utica una vez el paciente ha sido diagnosticado de DMJ \nson los corticoides , emple\u00e1ndose dosis elevadas  (prednis ona (PDN)  2mg/kg)  y haciendo \nun descenso progresivo de la dosis en per\u00edodos prolongados de hasta dos a\u00f1os. \nHabitualmente se asocia otro f\u00e1 rmaco ahorrador de corticoides  como  metotrexato  \n(MTX)  o  micofenolato de mofetilo  (MMF)  con actividad sobre las manifestaciones \ncut\u00e1neas , con lo que se busca prevenir la aparici\u00f3n de la calcinosis.  819Para el tratamiento de la calcinosis cutis ya establecida se ha descrito la utilizaci\u00f3n de \nantagonistas del calcio, colchicina, minociclina,  inhibidores de la calcineurina, \nprobenecid, bifosfonatos,  hidr\u00f3xido de aluminio  as\u00ed como el tiosulfato s\u00f3dico  (TS) t\u00f3pico \no administrado de forma intravenosa, c uyo uso es ampliamente conocido (6). \nEl mecanismo de acci\u00f3n del TS se explica por su habilidad para disolver los dep\u00f3sitos de \ncalcio de los tejidos formando complejos de tiosulfato c\u00e1lcico soluble. Y adem\u00e1s, se  \na\u00f1ade  un efecto vasodilatador y antioxidante que permite la reducci\u00f3n del dolor . El \nmetabisulfito de sodio (MS ) es un compuesto inorg\u00e1nico que, al reaccionar con el \nox\u00edgen o, se convierte en sul fato de sodio, un metabolito de  TS que tiene una capacidad \nsimilar para inhibir la aglomeraci\u00f3n de oxalato de calcio.  \nLa evidencia de uso de este compuesto es escasa. Hay publicada una serie de casos en \nla que se empleaba MS en cuatro pacientes adultos, de los que dos paciente s \npresentaban dermatomiositis. Tras seis semanas de tra tamiento en un paciente se \nobserv\u00f3 reducci\u00f3n en el tama\u00f1o de la lesi\u00f3n que presentaba en el dorso de la mano, as\u00ed \ncomo en el eritema y el edema. En otra paciente se observ\u00f3 una remisi\u00f3n de m\u00faltiples \nn\u00f3dulos, as\u00ed como mejor\u00eda en el edema y el dolor de las lesiones  (7). \nEn otro caso cl\u00ednico, un paciente de 10 a\u00f1os afecto de calcinosis idiop\u00e1tica presentaba \nlesiones que se acompa\u00f1aban de un material lechoso blanco. Tras tres meses de \ntratamiento con MS  t\u00f3pico al 25% se hab\u00eda producido una mejor\u00eda sustancial en las \nlesiones, desaparici\u00f3n del material purulento lechoso y tambi\u00e9n de la calcificaci\u00f3n en la \nradiograf\u00eda  (8). \nPRESENTACI\u00d3N DEL CASO:  \nEl caso  que nos ocupa  es el de un paciente pedi\u00e1trico de 8 a\u00f1os originario de Ruman\u00eda \nsin antecedentes previos de inter\u00e9s que fue trasladado a nuestro centro  en mayo de 8202019 por sospecha de DMJ. En el a\u00f1o 2018 desarrolla lesiones eritematosas perioculare s \n(heliotropo) y sobre rodillas . A finales de ese a\u00f1o, se suman nuevas lesiones sobre las \narticulaciones metacarpofal\u00e1ngicas e interfal\u00e1ngicas, as\u00ed como mialgias generalizadas. \nSe inicia tratamiento con PDN  a una dosis no especif icada, MTX 7,5 mg v\u00eda subcut\u00e1nea  \ny vitamina D. Tras un mes de tratamiento comienza con p\u00e9rdida de peso, ca\u00edda de pelo, \nastenia y debilidad muscular que lleg\u00f3 a imposibilitar la marcha. Dada la mala evoluci\u00f3n \nde la enfermedad, la familia decide trasladarse a Espa\u00f1a.  \nIngresa en mayo de 201 9 con s\u00edndrome febril y cl\u00ednica sugerente de infecci\u00f3n bacteriana , \nrealiz\u00e1ndose biopsia cut\u00e1nea  compatible , electromiograma  con resultado de patr\u00f3n \nmiop\u00e1tico con debil idad muscular proximal severa (C MAS inicial de 11/52),  que \ninterfer\u00eda  con la  marcha, patr \u00f3n miop\u00e1tico en electromi ograma , elevaci\u00f3n de AST, ALT y \nLDH con niveles de CK normales y panel de autoinmunidad, siendo los anticuerpos anti -\nSRP positiv os, lo que conjuntamente con otros  datos cl\u00ednicos  patognom\u00f3nicos como \nestigmas cut\u00e1neos de la enfermeda d (heliotropo, telangiectasias palpebrales y \nperiungueales, p\u00e1pula s de Gottron en codos y rodillas), permite confirmar  el diagn\u00f3stico \nde DMJ . Al tratarse de un cuadro de gravedad con importante p\u00e9rdida  de fuerza \nmuscular  se inicia tratamiento completo con  bolos de metilprednisolona  (MPDN)  3 d\u00edas \nseguidos de  PDN  (2 mg/kg) , MTX 7,5 mg v\u00eda subcut\u00e1nea, hidroxicloroquina 200 mg  \n(HCQ)  (5 mg/kg/d\u00eda)  e inmunoglobulinas IV 2 g/Kg  (IVIG) cada cuatro semanas.   \nCon este esquema terap\u00e9utico la mejor\u00eda fue lenta, pero progresiva , con un aumento  en \nla escala CMAS  a los tres meses desde 11/52 a 39/52, pudiendo iniciar deambulaci\u00f3n , \nevoluci\u00f3n favorable que se interrumpi\u00f3 por falta de adherencia por parte de la madre.  \nA los 5 meses tras recibir 7 ciclos de IVIG se pierde e l seguimiento por vuelta a su pa\u00eds, \nabandonando el tratamiento hasta mayo de 2020. Durante el seguimiento desarrolla 821\u00falceras cut\u00e1n eas en m\u00faltiples localizaciones por lo que se introduce ciclofosfamida . Este  \nmedicamento  puede desempe\u00f1ar  un papel importante en pacientes con afectaci\u00f3n \npulmonar con anticuerpos anti MDA -5, mejorando radiol\u00f3gicamente el infiltra do \nintersticial, pero tambi\u00e9n la funci\u00f3n muscular y la afectaci\u00f3n dermatol\u00f3gica (\u00falceras) , si \nbien no se ha visto mejor\u00eda de la distrofia calcificante  (8,9) . Tambi\u00e9n se a\u00f1ade MMF  250 \nmg/12 horas, se reduce PDN a 1 mg/Kg y recibe dos dosis de \u00e1cido zoledr\u00f3nico . Los \nbifosfonatos inhiben el recambio  \u00f3seo por su acci\u00f3n t\u00f3xica sobre los osteoclastos, pero \nparece tambi\u00e9n que pueden ejercer un efecto inhibitorio en l a liberaci\u00f3n de citoquinas \nproinflamatorias por los macr\u00f3fagos en las zonas calcin\u00f3ticas  de manera local . Existe \nevidencia de la eficacia del pamidronato y alendronato , en la resoluci\u00f3n de lesiones  \ncalcin\u00f3ticas en casos graves, usados conjuntamente con otr os f\u00e1rmacos modificadores \nde la enfermedad.  La v\u00eda intravenosa es preferible en estos casos para evitar la esofagitis  \n(10,11) . \nEl paciente regresa a Espa\u00f1a en marzo de 2021 con un mal control de la enfermedad \npresentando hipoton\u00eda generalizada y placas de calcinosis extensas que abarcan todo el \nabdomen hasta espalda,  y en miembros superiores e inferiores ; asimismo s e aprecia una \nplaca de calcinosis sobre c\u00f3ndilo interno con secreci\u00f3n lechosa.  Se decide de nuevo \niniciar tratamiento con bolos de  MPDN 150 mg/d\u00eda 3 d\u00edas seguidos de  PDN 1 mg/kg , \nMTX 10 mg v\u00eda subcut\u00e1nea, HCQ (5 mg/kg/d\u00eda) e IVIG 2 g/Kg  cada cuatro semana s, previa \nintensificaci\u00f3n cada 2 semanas  durante  tres dosis .  Ante la refractariedad del cuadro, se \nagrega tacrolimus  (0,075mg/kg/d\u00eda) , que fue retirado moment\u00e1neamente por \nhipertensi\u00f3n . En varias series de casos se objetiva una mejor\u00eda de las lesiones cut\u00e1neas \ntras la introducci\u00f3n de tacrolimus, disminuci\u00f3n de las recurrencias, as\u00ed como un ahorro \nen las dosis de corticoides, por lo que parecer\u00eda justificado su empleo (12,13) . 822Las lesiones cut\u00e1neas justifican el empleo  de metabisulfito s\u00f3dico al 25% en c old cream, \nque tras su solicitud  como uso compasivo fue elaborado en el servicio de farmacia.  \nDISCUSI\u00d3N Y APORTACI\u00d3N DEL FARMAC\u00c9UTICO:  \nSe realiza una revisi\u00f3n de la literatura y finalmente se opta por llevar a cabo la preparaci\u00f3n en \ncold cream , emulsi\u00f3 n de fase externa oleosa que  permite interponer principios activos tanto \nlipo como hidrosolubles, siendo la cesi\u00f3n prolongada y progresiva.  Para la formulaci\u00f3n del \npreparado, se tuvieron en cuenta  atributos como son  la consistencia de este tipo de veh\u00edculos \nque facilitan la aplicabilidad en \u00e1reas extensas , teniendo en cuenta la sensaci\u00f3n dolorosa al tacto \nque mostraba el paciente, su  acci\u00f3n emoliente y lubricante, as\u00ed como  la sensaci\u00f3n de frescor \nque generan  al romperse la emulsi\u00f3n con la temperatura de la superficie corporal y la \nconsiguiente evaporaci\u00f3n del agua.  Por otro lado , estos sistemas permiten una buena \npenetraci\u00f3n del ingrediente a ctivo por su oclusividad moderad a y su buena miscibilidad con los  \n\u00e1cidos grasos de la piel. El cold cream se adquiri\u00f3 de forma comercial para garantizar la \nhomogeneidad de la preparaci\u00f3n  y se revis\u00f3 que cumpliera con las especificaciones necesarias . \nEl pro ducto terminado es una masa blanca homog\u00e9nea de fase externa acuosa (no debe de \ndetectarse la presencia de gru mos), con olor ligero a   sulfuro , efecto refrescante poco \napreciable  y f\u00e1cilmente aplicable con  consistencia semis\u00f3lida  (7,14) .  \nCOMPOSICI\u00d3N por: 100g  \n  \n\uf0b7 Metabisulfito s\u00f3dico \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 25g  \n\uf0b7 Cold cream csp \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 100g  \nMATERIAS PRIMAS NECESARIAS para su realizaci\u00f3n  \n (A) Sodio metabisulfito  (materia prima)  \n (B) Cold cream (75g)  \n  \nAPARATOS Y UTILLAJE : \n\uf0d8 Balanza digital 0,001.  \n\uf0d8 Mortero y pistilo.  \n\uf0d8 Esp\u00e1tula de goma.  \n\uf0d8 Esp\u00e1tula.  \n\uf0d8 Papel PARAFILM \u00ae. \n\uf0d8 Vidrio de Reloj.  \n\uf0d8 Papel de filtro.  \n\uf0d8 Jeringa 5mL  \n\uf0d8 Aguja.  \n\uf0d8 Gasa hidr\u00f3fila de algod\u00f3n \nrectangular 10x20.  \n\uf0d8 Compresas 16x25.  \nNota: la capacidad del utillaje empleado \nse escoger\u00e1 en funci\u00f3n del volumen del \nlote que se vaya a preparar.  \n  \nT\u00c9CNICA DE ELABORACI\u00d3N A \nTRABAJAR CON  LAS M \u00c1XIMAS CONDICIONES  DE HIGIENE (PN/L/PG/003/00) Y SIGUIENDO EL PROTOCOLO de \nELABORACI \u00d3N DE POMADA BAJADICIONUIENDO EL PROTOCOLO de ELABORACI\u00d3N DE POMADA  \n             TRABAJAR EN CAMPANA DE FLUJO LAMINAR  \n \n1.- Pesar  (A)   \n2.- Ir a\u00f1adiendo, poco a poco, (B) al mortero con la esp\u00e1tula de goma , homogeneizando  \nperfectamente la mezcla con la mano del mortero en la medida que se vaya incorporando, \nhasta obtener una masa uniforme y sin grumos.   \n3.- Dejar reposar unos minutos antes de acondicionar la preparaci\u00f3n, que se introducir\u00e1  en \nel envase adecuado (debidamente etiquetado) con la ayuda de la esp\u00e1tula de goma.  \nCerrar herm\u00e9ticamente el envase y sellar con  papel PARAFILM \u00ae. \n  \n  \nENVASES Y ETIQUETAS  \nEnvase : Frasco de pl\u00e1stico  blanco \ncil\u00edndrico de boca ancha.  \n  \nCADUCIDAD : 10 d\u00edas  \n   \nMetabisulfito s \u00f3dico al 25% en cold cream.  \nProtocolo de elaboraci\u00f3n en nuestro centro resumido.  \n 823Al paciente se le aplicaba la preparaci\u00f3n cada doce horas  tras  limpieza antis\u00e9ptica con agua y \njab\u00f3n de las lesiones . Adem\u00e1s,  se  dio la recomendaci\u00f3n de que en caso de que se  \nobservasen  indicios de formaci\u00f3n de alguna costra persistente sobre alguna de las lesiones, se \npodr\u00eda beneficiar de la aplicaci\u00f3n de va selina  por las noches  para poder retirarla  y as\u00ed evitar \nsobreinfecciones bacterianas.  \nTras un mes de la instauraci\u00f3n del tratamiento t\u00f3pico, d esde el pun to de vista dermatol\u00f3gico no \nhab\u00eda datos que permitiesen  definir de forma objetiva  un de scenso en la calcinosis, pero s\u00ed  se \nlogr\u00f3 controlar  la progresi\u00f3n  y redu cir el peligro de sobreinfecci\u00f3n secundarias de los dep\u00f3sitos \ncut\u00e1neos y subcut\u00e1neos de calcio.  \nTras ocho meses de seguimiento  la mejor\u00eda cl\u00ednica era patente. La calcinosis troncular en coraza \ncontinuaba perdiendo intensidad, que era muy objetivable. En zonas como axilas, cuello y sacro \nlos dep\u00f3sitos eran  menores. A nivel exten sor de extremidades se manten\u00edan  \ndep\u00f3sitos   concretos superficiales con hiperplas ia epid\u00e9rmica reactiva  en codos y \nrodillas.  Aparec\u00edan  peque\u00f1as nodulacion es nuevas  que, fuera de zonas  de roce parec\u00edan no \nrelacionarse con el dep\u00f3sito c\u00e1lcico. Los cl\u00ednicos destacan la buena tolerancia al me tabisulfito \nt\u00f3pico en relaci\u00f3n al tiosulfato usado en otros casos de calcinosis cutis. Se han descrito irritaci\u00f3n \ny dolor d\u00e9rmicos, principalmente, as\u00ed como un incremento de la sobrei nfecci\u00f3n bacteriana al \nevolucionar las calcificaciones con la administrac i\u00f3n t\u00f3pica de tiosulfato  (15). En este caso , no \nse han descrito tales efectos adversos durante el per\u00edodo de s eguimiento.  \nCONCLUSI\u00d3N:  \nLa administraci\u00f3n t\u00f3pica de metabisulfito s\u00f3dico puede ser una alternativa eficaz y segura para \nel tratamiento de la calcinosis distr\u00f3fica refractaria en el contexto de la DMJ como re fleja el uso \nen este paciente.  \nBIBLIOGRAF\u00cdA:  \n1.  Est\u00edbaliz Iglesias Jim\u00e9nez. Dermatomiositis juvenil [Internet]. Sociedad Es pa\u00f1ola de \nReumatolog\u00eda Pedi\u00e1trica; 2020. Disponible en: Iglesias Jim\u00e9nez E. Dermatomiositis \njuvenil. Protoc diagn ter pediatr. 2020;2:155 -162.  8242.  Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic \ninflammatory myopathies: a review. Int ern Med J. junio de 2021;51(6):845 -52.  \n3.  Andrade -Ortega L. Instrumentos de evaluaci\u00f3n. Reumatol Cl\u00ednica. noviembre de \n2009;5:9 -12.  \n4.  Sallum AME, Pivato FCMM, Doria -Filho U, Aikawa NE, Liphaus BL, Marie SKN, et  al. \nRisk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) \n[Internet]. 9 de enero de 2007 [citado 11 de mayo de 2022];0(0). Disponible en: \nhttp://www.jped.com.br/conteudo/Ing_resumo.asp?varArtigo=1746&cod=&idSec\nao=1  \n5.  Boulman N, Slobodin G, Rozenbaum M, R osner I. Calcinosis in Rheumatic Diseases. \nSemin Arthritis Rheum. junio de 2005;34(6):805 -12.  \n6.  Kul Cinar O, Papadopoulou C, Pilkington CA. Treatment of Calcinosis in Juvenile \nDermatomyositis. Curr Rheumatol Rep. febrero de 2021;23(2):13.  \n7.  del Barri o-D\u00edaz P, Moll -Manzur C, \u00c1lvarez -Veliz S, Vera -Kellet C. Topical sodium \nmetabisulfite for the treatment of calcinosis cutis: a promising new therapy. Br J \nDermatol. septiembre de 2016;175(3):608 -11.  \n8.  Riley P. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. \nA review of efficacy and safety. Rheumatology. 6 de enero de 2004;43(4):491 -6.  \n9.  Kishi T, Miyamae T, Hara R, Nakajima S, Imagawa T, Mori M, et  al. Clinical analysis \nof 50 children with juvenile dermatomyositis. Mod Rheumatol . marzo de \n2013;23(2):311 -7.  \n10.  Giri S, Parida JR, Dash M, Panda M. Pamidronate in Treatment of Calcinosis in \nJuvenile Dermatomyositis. Indian Pediatr. 15 de enero de 2020;57(1):75 -6.  \n11.  Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectivene ss of the \ntreatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. \nClin Exp Rheumatol. febrero de 2010;28(1):135 -40.  \n12.  Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, et  al. The efficacy of tacrolimus in patients \nwith refractory derma tomyositis/polymyositis: a systematic review. Clin \nRheumatol. diciembre de 2015;34(12):2097 -103.  \n13.  Mart\u00edn Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcel\u00f3 \nGarc\u00eda P. [Efficacy of tacrolimus (FK -506) in the treatment of recalcitrant  juvenile \ndermatomyositis: study of 6 cases]. Med Clin (Barc). 11 de noviembre de \n2006;127(18):697 -701.  \n14.  Vila Jato JL. Tecnolog\u00eda farmac\u00e9 utica. Madrid: S\u00ed ntesis; 2008.  \n15.  Ricardo JW, Sun HY, Gorji M, Sebaratnam DF. Topical sodium thiosulfate as \ntreatment of calcinosis cutis: Case series and systematic review. J Am Acad \nDermatol. 16 de septiembre de 2021;S0190 -9622(21)02486 -5.  825Adecuaci\u00f3n del tratamiento antiepil\u00e9ptico en pediatr\u00eda. La importancia \nde los excipientes seg\u00fan situaci\u00f3n cl\u00ednica y edad del paciente . \nEch\u00e1 varri de Miguel M , Cue rvas-Mons Vendrel M, Riva de la Hoz B, Gonz\u00e1lez Andr\u00e9s D, \nAgu\u00ed Callejas AM,  Arrieta Loitegui  M, Pinilla Lebrero G,  Pozas del R\u00edo MT . \nINTRODUCCI\u00d3 N \nLa epilepsia es una de las patolog\u00edas neurol\u00f3gicas m\u00e1s frecuentes en la poblaci\u00f3n \ninfantil. Es una enfermedad cr\u00f3nica producida por descargas an\u00f3malas en determinadas \nzonas del cerebro responsables de l a cl\u00ednica que acompa\u00f1a a esta enfermedad. Las \nmanifestaciones pueden ser muy variadas, en forma de crisis focales o generalizadas  1.  \nEl tratamiento de esta patolog\u00eda tiene car\u00e1cter multidisciplinar incluyendo no s\u00f3lo \nterapia farmacol\u00f3gica si no tambi\u00e9n terapia psicol\u00f3gica, social y educacional.  \nEl arsenal terap\u00e9utico para el tratamiento de esta patolog\u00eda es amplio, existiendo \ncomercializados principios activos con indicaciones diferentes  2. A la hora de elegir uno \nde ellos se tienen en cuanto factores re lacionados con la enfermedad, caracter\u00edsticas del \npropio f\u00e1rmaco y del propio paciente. La falta de presentaciones comercializadas \nadecuadas para la poblaci\u00f3n pedi\u00e1trica complica en muchos casos la decisi\u00f3n del cl\u00ednico \na la hora de elegir un tratamiento ad ecuado.  \nLa Agencia Europea del Medicamento en  su documento \u201d Reflection paper: formulations \nof choice  for the paediatric population\u201d 3 analiza la administraci\u00f3n de los medicamentos  \nseg\u00fan la edad de los pacientes , recomendando  la utilizaci\u00f3n de formas farmac \u00e9uticas \nl\u00edquidas en pacientes menores de 7 a\u00f1os por las dificultades de degluci\u00f3n que presenta n. \nA ese hecho unimos la elevada presencia de sondas de alimentaci\u00f3n en pacientes con \npatolog\u00eda neurol\u00f3gica  (que complica la administraci\u00f3n del tratamiento farmac ol\u00f3gico)  y \nla falta de presentaciones comercializadas l\u00edquidas de f\u00e1rmacos antiepil\u00e9pticos.  826En estas situaciones la Formulaci\u00f3n Magistral se presenta como \u00fanica alternativa para \ngarantizar un  tratamiento seguro , eficaz y con las m\u00e1ximas garant\u00edas de calidad. En este \nsentido, el farmac\u00e9utico desempe\u00f1a un papel fundamental en el dise\u00f1o de la f\u00f3rmula y \nen la elecci\u00f3n de los excipientes.  \nLos excipientes son necesarios y seguros,  pero deben revisarse meticulosamente a la \nhora de elaborar f\u00f3rmulas magistrales pedi\u00e1tricas. De acu erdo con la circular N\u00ba 1/2018 \n4 de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios el alcohol benc\u00edlico, \nel \u00e1cido benzoico y los benzoatos est\u00e1n contraindicados en pacientes neonatos , al igual \nque el etanol y el propilenglicol, tambi\u00e9n contraindicado en lactantes. Otro excipiente \ncontrovertido y ampliamente utilizado es el sorbitol, el cual puede producir diarrea si se \nadministra en altas cantidades  4. Adem\u00e1s, su empleo no est\u00e1 recome ndado en lactantes, \npuesto que es probable que no se haya diagnosticado a\u00fan una posible intolerancia \nhereditaria a la fructosa . En ni\u00f1os menores de 2 a\u00f1os se ha establecido una ingesta \nm\u00e1xima de sorbitol de 5 mg/kg/ d\u00eda y para mayores de 2 a\u00f1os una ingesta m\u00e1xima de \n140 mg/kg/d\u00eda  4.  \nNo solo se debe prestar especial atenci\u00f3n a los excipientes debido a la edad del paciente, \nsino tambi\u00e9n por determinadas situaciones cl\u00ednicas relevantes, como es el caso de \npacientes con dieta cetog\u00e9nica. La dieta cetog\u00e9nica  es un tratamiento no farmacol\u00f3gico \nefectivo utilizado como un m\u00e9todo alternativo para el tratamien to de la epilepsia \nrefractaria, cuya principal fuente de calor\u00edas se aporta en forma de  grasas, manteniendo \nlos requerimientos proteicos diarios y reduciendo al m\u00ednimo el aporte de carbohidratos , \nde manera que se establece en el paciente un estado de cetosis que genera  cambios \nmetab\u00f3licos responsables del efecto antiepil\u00e9ptico  5. Para alcanz ar un estado \nmetab\u00f3lico de cetosis \u00f3ptimo se emplean distintas dietas cetog\u00e9nicas como la dieta 827cl\u00e1sica (proporci\u00f3n 4:1  o 3:1 ), la dieta MCT (triglic\u00e9ridos de cadena media), la dieta \nmodificada de Atkins y la dieta de b ajo \u00edndice glu c\u00e9mico  6.  \nSe debe mini mizar el aporte de hidratos de carbono m\u00e1s all\u00e1 de los incluidos en la dieta. \nEn este punto es importante revisar los excipientes incluidos en muchos de los f\u00e1rmacos \nque se usan como tratamientos. Algunos de estos excipientes son almid\u00f3n, lactosa, \nglicerol , maltitol, maltrodextrinas, propilenglicol, sacarosa y sorbitol. Muchos de estos \nexcipientes se encuentran presentes en grandes cantidades en la mayor\u00eda de formas \nfarmac\u00e9uticas l\u00edquidas  7.   \nEn definitiva, la labor del farmac\u00e9utico es fundamental ya que g racias a nuestros \nconocimientos en materia de excipientes podemos adaptar el tratamiento de un \npaciente teniendo en cuenta su edad y su situaci\u00f3n cl\u00ednica.  \nCASO CL\u00cd NICO   \nLactante de 8 meses de edad,  diagnosticada de displasia cortical y epilepsia refractar ia \nque ingresa en nuestro centro para la realizaci\u00f3n de una segunda cirug\u00eda de la epilepsia. \nAl ingreso en la Unidad de Cuidados Intensivos Pedi\u00e1tricos (UCIP) el farmac\u00e9utico lleva \na cabo la conciliaci\u00f3n del tratamiento:  \n\uf0b7 Clobazam 2 mg cada 8 horas  \n\uf0b7 Carbamazepina 90 mg \u2013 75 mg \u2013 90 mg  \n\uf0b7 Lacosamida 60 mg cada 12h  \n\uf0b7 Fenobarbital 22 mg cada 12h  \nDurante la entrevista cl\u00ednica, los padres comentar on al farmac\u00e9utico que una oficina de \nfarmacia comunitaria les suministraba las f\u00f3rmulas magistrales de clobazam, \nfenobarbital y carbamazepina. Contactamos con la farmacia elaboradora para obtener \ninformac i\u00f3n sobre la composici\u00f3n de dichas  f\u00f3rmulas.  828Como l a paciente recib\u00eda tratamiento con dieta cetog\u00e9 nica se la  incluy\u00f3 en el \u00a8Programa \nde Atenci\u00f3n Farmac\u00e9utica en pacie nte con dieta cetog\u00e9 nica\u00a8  del hospital  y se realiz\u00f3 el \ninforme correspondiente analizando la composici\u00f3n de las especialidades farmac\u00e9uticas \nm\u00e1s adecuadas en funci\u00f3n del contenido en hidratos de carbono y seg\u00fan su edad. Las \nactuaciones que propuso el farma c\u00e9utico fueron las siguientes:  \n- Utilizar las especialidades  farmac\u00e9uticas comercializadas en suspensi\u00f3n oral para los \nprincipios activos carbamazepina y lacosamida. El aporte de kilocalor\u00edas  en forma de \nhidratos de car bono fue de 0,52 kcal/ml y de 0,794  kcal/ml, respectivamente .  \n- En el caso de fenob arbital y  clobazam, se elaboraron f\u00f3rmulas magistrales con \nexcipientes compuestos indicados para pacientes con restricci\u00f3n de azucares. El \naporte de kilocalor\u00edas en forma de hidratos de carbono fue de 0,35 kcal/ml  y 0,36 \nkcal/ml, respectivamente.  \nUna vez realizados los c\u00e1lculos y teniendo en cuenta la situaci\u00f3n cl\u00ednica de la paciente, \nse consensua con el Servicio de Neurolog\u00eda y la Unidad de Cuidados  Intensivos \nPedi\u00e1tricos la prescripci\u00f3n de las especialidades far mac\u00e9uticas comercializadas y las \nf\u00f3rmulas magistrales elegidas por el farmac\u00e9utico.  \nDurante su ingreso y con vistas a programar el alta de la paciente, desde el servicio de \nfarmacia se decidi\u00f3 contactar con la farmacia elaboradora para obtener m\u00e1s \ninformaci\u00f3n sobre la composici\u00f3n de las f\u00f3rmulas magistrales  que suministraban a los \npadres . Una vez obtenida la informaci\u00f3n, se analizaron los excipientes y las kilocalor\u00edas \nen forma de hidratos de carbono por mililitro que aportaba cada f\u00f3rmula, importante \nen dieta cetog\u00e9nica, y se compararon con las que elaboramos desde el servicio de \nfarmacia . Las f\u00f3rmulas  magistrales de la oficina de farmacia eran  las siguientes:  \nFENOBARBITAL 10 MG/ML SOLUCION ORAL SIN SACAROSA.  829Cantidad suficiente para 100 ml.  \nComponentes  \nFenobarbital 1000mg.  \nA partir de 10 comprimidos de Luminal\u00ae 0,1g.  \nSorbitol liquido 40  g \nGlicerina 20 g  \nHidroxibenzoatos soluci\u00f3n conc 1 g  \nAgua destilada 38 ml.  \nTOTAL: 1,92  kcal/ml y 0,4 g sorbitol/ml.  \nAportes diarios: 8,43 kcal/d\u00eda y 1,76 gramos de sorbitol/d\u00eda  \n \nCLOBAZAM 1 MG/ML SUSPENSI\u00d3N ORAL.  \nCantidad suficiente para 100 ml.  \nComponentes  \nClobazam 100 mg. A partir de 10 comprimidos de Noiafren \u00ae 10 mg.  \nSorbitol liquido 40 g  \nGlicerina 5 g  \nHidroxibenzoatos soluci\u00f3n conc 0,5 g  \nCarboximetilcelulosa s\u00f3dica: 0,7 g  \nSacarina s\u00f3dica 0,3 g.  \nAgua destilada csp 100 ml  \nTOTAL: 1,29 kcal/ml y 0,4 g sorbitol/ml.  \nAportes diarios: 7,75 kcal/d\u00eda y 2,4 gramos de sorbitol/d\u00eda  \n \nCARBAMAZEPINA 20 MG/ML SUSPENSI\u00d3N ORAL.  \nCantidad suficiente para 100 ml.  \nComponentes  \nCarbamazepina 2 g. Materia prima.  \nOra sweet SF csp 100 ml.  \nTOTAL: 0,64  kcal/ml y 0,1 g sorbitol/ml.  \nAportes diarios: 8,16 kcal/d\u00eda y 1,28 gramos de sorbitol/d\u00eda  \n \nDichas f\u00f3rmulas magistrales no utilizaban ning\u00fan tipo de jarabe  o diluyente que aportara \nazucares , sin embargo, aportaban una gran cantidad de sorbitol y glicerina, los cuales  \ntambi\u00e9n deben tenerse en cuenta a la hora de realizarse el c\u00e1lculo  de hidratos de \ncarbono en dieta cetog\u00e9nica  7. Adem\u00e1s , otro punto cr\u00edtico  que hay que tener en cuenta \nes el contenido en sorbitol de dichas f\u00f3 rmulas. Seg\u00fan la recomenda ci\u00f3n de la circular N\u00ba 8301/2018 4 de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios , el sorbitol \nest\u00e1 contraindicado en menores de 2 a\u00f1os.  \nAl analizar las f\u00f3rmulas magis trales que aportaban los padres, se calcul\u00f3 que las 3 \nf\u00f3rmulas aportaban un total de 24,34 kilocalor\u00edas al d\u00eda y 5,44 gramos de sorbitol al d\u00eda. \nEsto implica que la paciente estaba recibiendo 706,46 mg/kg/d\u00eda de sorbitol, cuando se \naconseja un m\u00e1ximo de 5 mg/kg/d\u00eda en menores de 2 a\u00f1os  4.   \nLas f\u00f3rmulas que nosotros elaboramos y la especialidad farmac\u00e9utica comercializada \nTegretol \u00ae aportan un total de 10,34  kilocalor\u00edas diarias y 2,75 gramos de sorbitol al d\u00eda.  \nEn este caso la paciente recibir\u00eda 357,14 mg/kg/d\u00eda de sorbitol, es decir, la mitad de \nsorbitol que antes. Se plante\u00f3 la posibilidad de modificar la suspensi\u00f3n de clobazam y \nformularla con metilcelulosa y jarabe simple como excipientes para evitar el aporte de \nsorbitol, pero esta f\u00f3rmula aporta 10,33 kilocalor\u00edas al d\u00eda, mientras que si se elabora \ncon Ora Plus \u00ae y Ora Sweet S F\u00ae aporta 1,62 kilocalor\u00edas al d\u00eda, por lo que en conjunto con \nel Servicio de Neurolog\u00eda  y la UCIP se decidi\u00f3 asegurar la dieta cetog\u00e9nica y optar por la \nf\u00f3rmula que aportaba menos kilocalor\u00edas. Tambi\u00e9n se estudi\u00f3 la posibilidad de modificar \nla es pecialida d farmac\u00e9utica de lacosamida , pero teniendo en cuenta la dosis que \ntomaba la paciente no era posible  ajustarlo a los comprimidos comercializados.  \nEstos cambios propuestos por el farmac\u00e9utico permitieron reducir a m\u00e1s de la mitad la \ningesta de kilocalor\u00edas  diarias y de sorbitol. Adem\u00e1s, desde el servicio de farmacia se \ncontact\u00f3 con la oficina de farmacia que elaboraba las f\u00f3rmulas a la familia y les \nproporcionamos nuestros procedimientos normalizados de trabajo para que pudieran \ncontinuar elaborando el trat amiento de la paciente.  831Finalmente, tres semanas despu\u00e9s del ingreso la paciente es dada de alta por mejor\u00eda \ndel estado general y presentando una reducci\u00f3n significativa del n\u00famero de crisis \nepil\u00e9pticas.  \nPAPEL DEL FARMAC\u00c9 UTICO  \nCon este caso cl\u00ednico  se hace patente la importancia de la conciliaci\u00f3n de la medicaci\u00f3n  \npor parte del farmac\u00e9utico  en poblaci\u00f3n infantil , y especialmente en paciente s con \npatolog\u00eda de base y plurimedicados . Uno de los puntos importantes de la conciliaci\u00f3n es \nla entrevista cl\u00ed nica con padres y/o cuidadores para detectar posibles errores y obtener \ninformaci\u00f3n que  pueda  resultar \u00fatil a la hora de adecuar su tratamiento al alta como es \nel caso de este caso cl\u00ednico.  \nLa actuaci\u00f3n del farmac\u00e9utico tambi\u00e9n resulta fundamental a la ho ra de adecuar el \ntratamiento farmacol\u00f3gico a la patolog\u00eda del paciente, como en dieta cetog\u00e9nica, y a la \nedad, ya que existen excipientes contraindicados seg\u00fan grupo de edad. La formulaci\u00f3n \nmagistral se presenta como una alternativa eficaz y segura en esto s casos.  \nEn definitiva , el papel del farmac\u00e9utico  ha resultado fundamental para adecuar el \ntratamiento farmacol\u00f3gico durante el ingreso y ambulatorio.  \nBIBLIOGRAF\u00cd A \n(1) L\u00f3pez Gonz\u00e1lez, F., Villanueva Haba, V., Falip Centelles, M., Toledo Argany , M., \nCampos Blanco, D. and Serratosa Fern\u00e1ndez, J., 2022.  MANUAL DE PR\u00c1CTICA \nCL\u00cdNICA EN EPILEPSIA: RECOMENDACIONES DIAGN\u00d3STICO -TERAP\u00c9UTICAS DE LA \nSEN 2019 \u2013 Web del Grupo de Estudio de la Epilepsia. [online] Epilepsia.sen.es. \nAvailable at: <http://epileps ia.sen.es/?p=3079> [Accessed 11 May 2022].  \n(2) Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational \nclassification of seizure types by the International League Against Epilepsy: 832Position Paper of the ILAE Commission for Classification and Terminology. \nEpilepsia. 2017; 58: 522 -30. \n \n(3) European medicines agency pre -authorisation evaluation of medicines for \nhuman use [Internet]. Europa.eu. 2006 [citado el 12 de mayo de 2022]. \nDisponible  en: https://www.ema.europa.eu/en/documents/scientific -\nguideline/reflection -paper -formulations -choice -paediatric- population_en.pdf \n(4) Aemps.gob.es. 2022. [online] Available at: \nhttps://www.aemps.gob.es/informa/circulares/m edicamentosUsoHumano/201\n8/docs/circular_1 -2018 -actualizacion -excipientes -medicamentos.pdf \n(5) Armeno M, Caraballo R, Vaccarezza M, Alberti MJ, R\u00edos V, Galicchio S, et al. \nConsenso nacional sobre dieta cetog\u00e9nica. Rev Neurol 2014; 59: 213 -23. \n(6) Pedr\u00f3n  Giner C, coord. Manual para la pr\u00e1ctica de la dieta cetog\u00e9nica. Madrid: \nNutricia S.R.L., 2016.  \n(7) C. Ca\u00f1ete Ramirez, M. Garc\u00eda Palomo. Atenci\u00f3n farmac\u00e9utica en el paciente \npedi\u00e1trico con dieta cetog\u00e9nica. El Farmac\u00e9utico Hospitales. 2020; 217: 40 -45 \n \n \n \n \n \n \n \n \n 8331 \n LA FORMULACI\u00d3N MAGISTRAL EN EL TRATAMIENTO DE LAS \nINFECCIONES ASOCIADAS A DI\u00c1LISIS PERITONEAL  \nSol\u00eds Cu\u00f1ado S, G\u00f3mez Bermejo M, Ib\u00e1\u00f1ez  Heras N, Andr\u00e9s Picazo MJ, Molina Garc\u00eda T.  \nINTRODUCCI\u00d3N  \nLa terapia renal sustitutiva (TRS) se presenta como un tratamiento de reemplazo de la \nfunci\u00f3n del ri\u00f1\u00f3n destinado a aquellos pacientes con un a tasa de filtrado glomerular \n(TFG) inferior a 20-30 mL/min/1,73 m2 (1). Entre las TRS disponibles, se puede diferenciar \nla di\u00e1lisis peritoneal  (DP) y la hemodi\u00e1lisis  (HD) , representando la primera de ellas al 11% \nde los pacientes  (2). La DP tiene como fundamento el uso del peritoneo como membrana \nfiltrante por \u00f3smosis gracias al endotelio de sus capilares. Para ello, es necesario instilar \nuna soluci\u00f3n hipert\u00f3nica a trav\u00e9s de un cat\u00e9ter que acceda a la cavidad peritoneal. Esta \nva a originar un gradiente osm\u00f3tico, que, por ultrafiltraci\u00f3n, va a favorec er el \nintercambio de sustancias (2).  \nLas gu\u00edas posicionan a  la DP como la TRS de elecci\u00f3n ya que presenta una serie de \nventajas: mejor calidad de vida al ser un tratamiento ambulatorio, confiere mayor \nindependencia y menos coste; se trata de un tratamiento continuo y no intermitente, \npor lo que el cont rol vol\u00e9mico e i\u00f3nico es m\u00e1s efectivo; favorece el enlentecimiento del \ndeterioro progresivo renal (3,4). Sin embargo, la DP est\u00e1 asociada a una serie de \ncomplicaciones , entre las que destacan las de origen infeccioso. Las infecciones e st\u00e1n \n\u00edntimamente rela cionadas con la utilizaci\u00f3n de un cat\u00e9ter, pudiendo producirse en el \norificio de salida de l cat\u00e9ter  o en el propio perito neo, provocando una peritonitis (2,5). \nEsta \u00faltima no s\u00f3lo puede causar el fracaso de la t\u00e9cnica de TRS, sino que de un 3 a un \n10% de los casos de peritonitis tienen como desenlace la muerte del paciente (6). 8342 \n En relaci\u00f3n con la peritonitis, entre los factores de riesgo destaca n las intervencio nes \ninvasivas, ser portador nasal de S.aureus , padecer una infecci\u00f3n en el sitio de salida del \ncat\u00e9ter  y la diarrea (7), siendo la principales causas la manipulaci\u00f3n y cuidado indebido \ndel cat\u00e9ter(5,7). La peritonitis m\u00e1s frecuente es la de origen bacteriano, siendo \nmayoritarios los casos en los que los microorg anismo s (MO) responsable s son Gram +  \ncomo Enterococcus spp  o Corynebacterium spp  y en menor porcentaje, Gram \u2013 como \nE.coli , Klebsiella spp  o P.aerug inosa . Un peque\u00f1o porcentaje de casos son atribuibles a \nuna infecci\u00f3n f\u00fangica ( Candida spp .).  \nEl tratamiento de la peritonitis se debe iniciar de manera precoz y puede ser tanto con \nantibioterapia sist\u00e9mica como intraperitoneal  (IP) durante 14 a 21 d\u00edas (6), prefiri\u00e9ndose  \nel segundo al conseguir concentraciones superiores en el sitio de infecci\u00f3n.  \nPor otro lado, las infecciones en el orificio  de salida del cat\u00e9ter se van a presentar  con \ncl\u00ednica habitual de inflamaci\u00f3n: eritema, edema, induraci\u00f3n, etc. Los MO implicados son \nsimilares a los que causan las peritonitis  en cambio, los factores de riesgo van a \nfocalizarse en el  cuidado y  manejo del cat\u00e9ter . El abordaje terap\u00e9utico suele incluir  \nantibioterapia sist\u00e9mica. Si bien, cl\u00e1sicamente la terapia local con antibi\u00f3ticos se ha \nutilizado en la prevenci\u00f3n , es poco habitual su uso en tratamiento a pesar de los \nbeneficios y escasos riesgos (5,6,7) lo cual viene favorecido por la esc asez de \nespecialidades farmac\u00e9uticas de administraci\u00f3n t\u00f3pica dirigidas al tratamiento de las \ninfecciones superficiales . \nDESCRIPCI\u00d3N DEL CASO:  \nVar\u00f3n de 74 a\u00f1os , exfumador, hipertenso, dislip\u00e9mico con ERC estad\u00edo  V en probable \nrelaci\u00f3n con glomerulonefritis cr\u00f3nica . La ERC se acompa\u00f1a de proteinuria severa sin 8353 \n s\u00edndrome nefr\u00f3tico de larga evoluci\u00f3n . En abril de 2016, se decide comenzar con \nprograma de DP  debido a que el paciente presenta  TFG inferior a 7m L/min . Desde el \ncomienzo, el paciente se adapt\u00f3 bien a la  DP siendo su hijo el encargado del manejo de \nla t\u00e9cnica. En enero de 2018 desarrolla la primera complicaci \u00f3n infecciosa , acudiendo a \nUrgencias para comprobaci\u00f3n del cat\u00e9ter peritoneal  por extravasaci\u00f3n de l\u00edquido \nperitoneal (LP). Se decide  recoger cultivo e  iniciar cobertura antibi\u00f3tica profil\u00e1ctica con \n1,5g de vancomicina y 1g de ceftazidima IP pendiente de evoluci\u00f3n. Se a\u00edsla  \nS.haemolyticus  en LP sensible a vancomicina  con buena evoluci\u00f3 n y negativizaci\u00f3n de \ncultivos. \nLa primera complicaci\u00f3n infecciosa en el orificio externo ( OE) del cat\u00e9ter  se observa en \nnoviembre de 2020.  En el exudado se a\u00edsla  P.aeruginosa y  Staphylococcus coagulasa \nnegativo ( SCN). Seg\u00fan el antibiograma, son sens ibles a tobramicina por lo que  se \ncomienza a tratar con 100mg de tobramicina IP  cada 48h. Adem\u00e1s el OE se trata de \nmanera t\u00f3pica con ciprofloxacino.  \nEl 07/12/2020 se repite cultivo en el que continua apareciendo P.aeruginosa  con el \nmismo perfil de sensibilidad a antibi\u00f3ticos (ATBs). Adem\u00e1s, se a\u00edsla  E.faecalis sensible a \nvancomicina, consecuentemente, se decide a\u00f1adir de nuevo vancomicina IP al \ntratami ento. El paciente no presenta signos de peritonitis. Tras 25 d\u00edas de tratamiento \ncon tobramicina IP y 15 d\u00edas con vancomicina IP, se decide finalizar tratamiento IP . Se \nplantea iniciar tratamiento antibi\u00f3tico t\u00f3pico en el OE del cat\u00e9ter por lo que el servicio \nde nefrolog\u00eda (SN) se pone en contacto con el servicio de farmacia (SF), concretamente \ncon el \u00e1rea de farmacotecnia, para valorar la posibilidad de elaborar una f\u00f3rmula \nmagistral (FM) con vancomicina de administraci\u00f3n t\u00f3pic a. Ante esta s olicitud , el SF 8364 \n realiza una valoraci\u00f3n de los cultivos microbiol\u00f3gicos y el perfil de  sensibilidad  de los \nMO aislados . Posteriormente se lleva a cabo una revisi\u00f3n bibliogr\u00e1fica (8) donde se valora \ntanto la concentraci\u00f3n m\u00e1s adecuada de la vancomicina para superar la  conc entraci\u00f3n \nm\u00ednima inhibitoria ( CMI) de los MO implicados as \u00ed como su estabilidad  en los diferentes \nveh\u00edculos disponibles y la idoneidad de estos para su aplicaci\u00f3n t\u00f3pica y permanencia en \nla epidermis.  Se decide elaborar una  FM de vancomicina t\u00f3pica al 4%  en excipiente \nadhesivo (Orabase\u00ae) que se describe a continuaci\u00f3n .  \n \nEl paciente realiza curas diarias con los dos ATBs t\u00f3picos (vancomicina y ciprofloxacino) \ndurante 30 d\u00edas. Tras la finalizaci\u00f3n del tratamiento t\u00f3pico se reevalu\u00f3 y se extrajo de \nnuevo cultivo de control  (CC) en el que ya no aparecieron  los MOs inicial mente aislados \n(P.aeruginosa y E.faecalis ) para los que iba dirigida la FM de vancomicina , por el \ncontrario, se a\u00edsla  C.glabrata  sensible a a nfotericina B. E n el seguimiento conjunto del \npaciente por el SF y SN se plantea la posibilidad de elaborar una FM de aplicaci\u00f3n t\u00f3pica \nde a nfotericina B. Se procedi\u00f3 de la misma manera que cuando nos solicitaron la FM de \nvancomicina: analizamos la sensibilidad, la concen traci\u00f3n necesaria para superar la CMI \nen la zona afectada y cu\u00e1l era el veh\u00edculo m\u00e1s adecuado tanto por la estabilidad f\u00edsico -\nqu\u00edmica de la a nfotericina B como por su persistencia en la pi el. Tras la revisi\u00f3 n \nbibliogr\u00e1fica correspondiente (9,10), procedimo s a elaborar un gel acuoso de a nfotericina \nB al 3% que inclu\u00eda como veh\u00edculo gel de hidroxietilcelulosa  que se detalla a \ncontinuaci\u00f3n.   \n8375 \n  \nSe aplica diariamente durante 30 d\u00edas y se program a control de nuevo a principios de \nmarzo  donde se observa la negativizaci\u00f3n del mismo para  C. glabrata  pero destaca de \nnuevo el crecimiento de  P.aeruginosa  a pesar de no observarse ning\u00fan signo de \ninfecci\u00f3n en el OE del cat\u00e9ter . \nEn este momento, se valor a nuevo ciclo de tratamiento ATB t\u00f3pico  plante\u00e1ndose la \nposibilidad de elaborar FM colistina t\u00f3pica  adecuada para el tratamiento de her idas y \n\u00falceras colonizadas por Pseudomonas multirresistentes. Desde el SF , debido a la \nausencia de colistina t\u00f3pica comercia lizada, se procedi\u00f3 a una revisi\u00f3n bibliogr\u00e1fica \nelaborando  Colistina 0.1% crema (11) que se describe a continuaci\u00f3n.  La pauta posol\u00f3gica \nconsisti\u00f3 en una aplicaci\u00f3n diaria durante 15 d\u00edas.  \n \nEl 19/04/202 1 tras cumplir \u00faltimo ciclo de tratamiento ATB con colistina t\u00f3pica , en el CC \nse detecta el crecimiento de nuevo de P.aeruginosa  y adem\u00e1s de S.marcenses  y \nE.faecalis . Por la posible persistencia de MOs en  el cat\u00e9ter, se decide, antes de la retirada \ndel mismo, una limpieza profunda del cat\u00e9ter mediante la extrusi\u00f3n del dacr\u00f3n \nsubcut \u00e1neo. Se observa que el OE est\u00e1 ligeramente enrojecido por lo que se toma la \ndecisi\u00f3n de que el paciente contin\u00fae con tratamiento ATB t\u00f3pico ( FM C olistina 0.1% \n8386 \n crema y Ciprofloxacino t\u00f3pico ) durante 15 d\u00edas m\u00e1s para evitar la posible infecci\u00f3n de \nlos restos de dacr\u00f3 n que han sido imposibles de retirar y que han quedado sobre el OE.  \nEl 26/04/2021  en la revisi\u00f3n  del OE se observa mejor aspecto y el CC sale negativo.  \nTras 4 meses sin incidencias  ni complicaciones asociadas al cat\u00e9ter , en agosto  de 2021, \nel paciente acude al hospital  por dolor ab dominal de 3 d\u00edas de evoluci\u00f3n. Se valora al \npaciente en la unidad de DP y se drena LP turbio, sugestivo de peritonitis. Se inicia \ntratamiento ATB IP con vancomicina 1g + ceftazidima 1,5g. Tras ver resultados de \npruebas bioqu\u00edmicas de LP, aumento de reacta ntes de fase aguda  en anal\u00edtica y cl\u00ednica \ndel paciente, se confirma peritonitis y se decide el ingreso del paciente. Se extraen varios \ncultivos donde se observa infecci\u00f3n polimicrobiana. Dada la situaci\u00f3n, se decide iniciar \ntratamiento ATBs por v\u00eda IP e in travenosa (IV) y tratamiento t\u00f3pico del OE con FM \nPomada de vancomicina 4% y ciprofloxacino t\u00f3pico durante 15 d\u00edas.  \nEn septiembre el paciente acude a revisi\u00f3n y el cultivo de LP sale negativo. En el OE se \na\u00edsla  S.epidermidis sensible a vancomicina pero no  se observan  ninguno de los MOs \naislados durante el ingreso . Se vuelve a prescribir y a elaborar FM Pomada de \nvancomicina al 4% . El paciente presenta buena evoluci\u00f3n .  \nEl 08/11/202 1 el paciente vuelve a revisi\u00f3n y en el CC se observa crecimiento  de nuevos \nMOs : C.glabrata , S.epidermidis y S.homini -hominis . Se valora detenidamente la situaci\u00f3n \nsocial y se concluye que los episodios de infecci\u00f3n del OE coincid en con  la ausencia en \nel domicilio del cuidador principal y un mal control de la t\u00e9cnica  por parte del paciente . \nA pesar de los buenos resultados obtenidos tanto con los A TB sist\u00e9micos como IP y las \nFM de aplicaci\u00f3n t\u00f3pica, t eniendo en cuenta  el riesgo de desarrolla r peritonitis \nsecundaria a infecci\u00f3n del OE, se decide la retirada del cat\u00e9ter y la transferencia a HD.  \nDISCUSI\u00d3N  Y APORTACI\u00d3N FARMAC\u00c9UTICA  8397 \n La presencia de una disrupci\u00f3n de la piel como es el OE de l cat\u00e9ter peritoneal conlleva \na la p\u00e9rdida de la funci\u00f3n de la barrera epid\u00e9rmica, lo que predispone  a infecciones por \nMOs, entre ellos , los agentes etiol\u00f3gicos comunes de las infecciones de la piel y partes \nblandas. Estas infecciones pueden influir directamente en el \u00e9xito de la t\u00e9cnica de \ndepuraci\u00f3n renal. \nEl manejo t\u00edpico de las infecciones asociadas a cat\u00e9ter en DP se lleva a cabo con ATBs \nsist\u00e9micos o por v\u00eda IP , lo que conlleva, en muchas ocasiones, e l ingreso del paciente, \nuna exposici\u00f3n sist\u00e9mica a ATBs , la aparici\u00f3n de toxicidad y en consecuenc ia un \nincremento de los costes asociados y una disminuci\u00f3n de la eficiencia.   \nLos ATBs t\u00f3picos , aunque tradicionalmente se han reservado para su uso como profilaxis \nde infecciones t\u00f3picas,  cons tituyen una alternativa \u00fatil frente a terapias sist\u00e9micas en \nestas infecciones cut\u00e1neas muy localizadas y sin compromiso sist\u00e9mico , y que de no ser \ntratadas pueden derivar en la retirada y reemplazo del cat\u00e9ter  peritoneal y en los casos \nmas graves en una peritonitis con importantes consecuencias para el paciente.  \nLa elecci\u00f3n del ATB esta en funci\u00f3n del cuadro cl\u00ednico y de su gravedad, del MO aislado \ny de su perfil de sensibilidad , adem\u00e1s de su toxicidad.  \nExiste una importante escasez de especialidades farmac\u00e9uticas dirigidas al tratamiento \nde infecciones t\u00f3picas y por ello la FM  supone una adecuada alternativa terap\u00e9utica que \npermite emplear ATBs en los rangos terap\u00e9uticos aceptados, vehiculizados en las formas \nfarmac\u00e9uticas m\u00e1s id\u00f3neas e incluso adaptar el veh\u00edculo al estado de la lesi\u00f3n, as\u00ed como \na las necesidades intr\u00ednsecas del paciente. (12) \nUna de las actividades fundamentales del farmac\u00e9utico del \u00e1rea de farmacotecnia  es dar \na conocer la existencia de estas alternativas  terap\u00e9uticas en infecciones t\u00f3picas que van \na permitir un manejo eficiente de l as infecciones asociadas a  DP.  8408 \n Para la elaboraci\u00f3n de las tres FMs expuestas anteriormente se ha seguido la misma  \nmetodolog\u00eda : an\u00e1lisis de  cultivos  microbiol\u00f3gicos y antibiograma,  estudio de la \nconcentraci\u00f3n de l ATB , selecci\u00f3n del veh\u00edculo apropiado para asegurar la adherencia del \nATB al tejido cut\u00e1neo, y b\u00fasqueda de los excipientes necesarios para garantizar una \ncorrecta formulaci\u00f3n  y estabilidad f\u00edsico -qu\u00edmica del  ATB. Una vez establecidas las \ncaracter\u00edsticas anteriores, el farmac\u00e9utico debe elaborar un procedimiento normalizado \nde trabajo  y proporcionar al paciente la informaci\u00f3n necesaria junto a un prospecto \ninformativo  que garantice un adecuado uso de la FM.  \nEn nue stro paciente la participaci\u00f3n del farmac\u00e9utico hospitalario  en el equipo \nasistencial ha permitido  ofrecer al paciente las mejores alternativas existentes, \ngarantizando la administraci\u00f3n  del ATB m\u00e1s adecuado, a la concentraci\u00f3n y en el \nveh\u00edculo m\u00e1s id\u00f3neo para este tipo de infecciones y ha conseguido  la negativizaci\u00f3n de \nlos cultivos microbiol\u00f3gicos  evitando la aparici\u00f3n de complicaciones m\u00e1s graves como \nperitonitis.  \nBIBLIOGRAF\u00cdA  \n1. Ballar\u00edn JA, Garc\u00eda F, Ibeas J, Ju\u00e1rez R, Ortega MM, Peque\u00f1o S. Gu\u00eda de Pr\u00e1 ctica Cl\u00ednica sobre la Detecci\u00f3n y el Manejo de la Enfermedad Renal Cr\u00f3nica [Internet]. 1.a ed. \nGu\u00edaSalud; 2016.  \n2. Teitelbaum I. Peritoneal Dialysis. Ingelfinger JR, editor. N Engl J Med. Noviembre de 2021;385(19):1786 -95. \n3. Bargman  J, Fran\u00e7ois K. Evaluating the benefits of home -based peritoneal dialysis. IJNRD. Diciembre de 2014;447.  \n4. Zazzeroni L, Pasquinelli G, Nanni E, Cremonini V, Rubbi I. Comparison of Quality of Life in Patients Undergoing Hemodialys is and Peritoneal Dialysis : a Systematic Review and \nMeta -Analysis. Kidney Blood Press Res. 2017;42(4):717 -27. \n5. Carmen Fari\u00f1as, M., Daniel Garc\u00eda -Palomo, J. and Guti\u00e9rrez -Cuadra, M., 2008. Infecciones asociadas a los cat\u00e9teres utilizados para la hemodi\u00e1lisis y la di\u00e1lisis peritone al. \nEnfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, 26(8), pp.518 -526.  \n6. Bieber S, Mehrotra R. Peritoneal Dialysis Access Associated Infections. Advances in Chronic Kidney Disease. enero de 2019;26(1):23 -9. \n7. Burkart, J., 2022. UpToDate . [online] Uptod ate.com. Disponible en: https://www.uptodate.com/contents/microbiology -and-therapy -of-peritonitis -in-peritoneal -dialysis  \n8. Saene Hendrick KFV, Stoutenbeek C, Lawin P, Ledingham IM. Infection control in intensive care units  by selective decontamination: t he use of oral non -absorbable and \nparenteral agents. Berlin: Springer -Verlag; 1989.  \n9. Jos\u00e9 BS, Baskaran Z, Serrano L, Bilbao I, Sordo B, Bustinza A, et  al. Hospital formulations for the treatment of non -albicans vulvovaginitis. Eur J Hosp Pharm. 2012;19(2 ):142.  \n \n10. White DJ, Habib AR, Vanthuyne  A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.  Sex Trans \nInf 2001;77:212 -3. \n11. Gonz\u00e1lez Contreras J et al. Crema de Colistina al 0,1% en el tratamiento de infecciones locales porAcinetobacter baumanii. 54 Congreso Sociedad Espa\u00f1ola de Farmacia \nHospitalaria. Zaragoza,2009.  \n12. Abarca Lach\u00e9n E, Hernando Mart\u00ednez P, Gilaberte  Calzada Y. Revisi\u00f3n de las f\u00f3rmulas magistrales (medicamentos individualizados) de mayor inter\u00e9s en dermatolog\u00eda \npedi\u00e1trica. Actas Dermo- Sifiliogr\u00e1ficas. 2021;112(4):302 -13. \n \n 841TACROLIMUS Y FLUCONAZOL: INTERACCION FARMACOLOGICA EN PACIENTE \nTRASPLANTADO RENAL  \nINTRODUCCION  \nEl uso de antimicrobianos en el paciente trasplantado renal es frecuente debido a la \ninmunosupresi\u00f3n  en la que se encuentran este tipo de pacientes y la alta incidencia de \ninfecciosas que desarrollan. Adem\u00e1s, una proporci\u00f3n  elevada de los antimicrobianos \nutilizados en estos pacientes presentan interacciones relevantes con los principales \nf\u00e1rmacos inmunosupresores utilizados  para evitar el s\u00edndrome de rechazo , \nprincipalmente los antif\u00fangicos . Por lo que  debemos prestar especial atenci\u00f3n  en el \ncorrecto uso de  antibi\u00f3ticos en este tipo de pacientes. Un ejemplo de ello es la \nintera cci\u00f3n entre  tacrolimus y los antif\u00fangicos az\u00f3licos . Esta est\u00e1 descrita tanto en \nt\u00e9rminos farmacocin\u00e9ticos como en t\u00e9rminos cl\u00ednicos, conllevando un aumento en los \nniveles plasm\u00e1ticos d e tacrolimus , normalmente asociados  con fen\u00f3menos de \nnefrotoxicidad o neurotoxicidad. El mecanismo por el que se produce dicha interacci\u00f3n \nradica en la disminuci\u00f3n del metabolismo hep\u00e1tico de tacrolimus debido a la inhibici\u00f3n \nde enzimas microsomales hep\u00e1ti cas (CYP3A4) por parte del antif\u00fangico.  Hasta el \nmomento, el mayor n\u00famero de interacciones se ha dado con fluconazol, si bien es cierto \nque parece demostrada para otros antif\u00fangicos az\u00f3licos.   \nDESCRIPCI\u00d3N DEL CASO  \nMujer de 57 a\u00f1os que acude a Urgencias del  Hospital General Universitario de Elche por \nrechazo subagudo de trasplante renal.  Sin alergias medicamentosas.   \nComo antecedentes personales destacan d iabetes mellitus II de m\u00e1s de 25 a\u00f1os de \nevoluci\u00f3n en tratamiento con insulinoterapia desde hace m\u00e1s de 10 a\u00f1os. Hipertensi\u00f3n \narterial. Dislipemia. Obesidad.  Adem\u00e1s, present\u00f3 anteriormente e pisodios de 842pancreatitis aguda por hipertrigliceridemia severa, hiperuricemia, s\u00edndrome de apnea -\nhipopnea del sue\u00f1o, hiperparatiroidismo secundario, anemia cr\u00f3nica asocia da a \nenfermedad renal cr\u00f3nica (ERC).  Presenta n efropat\u00eda diab\u00e9tica que condiciona ERC \nestadio V que inicia hemodi\u00e1lisis en 2006, en 2008 se realiza trasplante renal con inicio \nde micofenolato, glucocorticoides sist\u00e9micos y tacrolimus.  \nEn el momento actual se encontraba en tratamiento domiciliario con:  \nF\u00e1rmaco  Posolog\u00eda  \nDoxazosina  4mg/12h  \nbiotina  5mg/24h  \n\u00c1cido micofen\u00f3lico  180mg/12h  \nPrednisona  10mg/24h  \nTacrolimus  1mg/24 h \nTrimetroprim -sulfametoxazol  400/80mg/24h  \nDarboepoetina  100mcg/5d\u00edas  \nOmeprazol  20mg/24h  \nFebuxostat  80mg/24h  \nAtorvastatina  10mg/24h  \nEzetimiba  10mg/24h  \nAdiro  100mg/24h  \nColecalciferol (hidroferol)  1 ampolla/10d\u00edas  \nLormetazepam  1,5mg/24h  \nFurosemida  40mg/24h  \nInsulinoterapia   \n 843La paciente acude a Urgencias por deterioro del estado general, aumento progresivo de \npeso asociado a un empeoramiento progresivo anal\u00edtico de los niveles de creatinina, \ninicialmente 2,1 mg/mL hasta 6,26 mg/mL en las \u00faltimas dos semanas. Niega oliguria, \ncomenta diuresis diaria en torno a 2 -3 litros/d\u00eda.  \nRefiere s\u00edndrome miccional desde hace 15 d\u00edas. No ha presentado fiebre en domicilio ni \notra sintomatolog\u00eda asociada.  \nSe encuentra  consciente y orientad a. Eupneica, palidez mucocut\u00e1nea, xerosis y \nsequedad de mucosas. Auscultaci\u00f3n cardiaca: r\u00ed tmica, no soplos. Auscultaci\u00f3n \npulmonar: disminuci\u00f3n global de MV. Abdomen blando y depresible, doloroso a la \npalpaci\u00f3n en hipogastrio, pu\u00f1opercusi\u00f3n renal negativa. Edemas con f\u00f3vea en ambos \nmiembros inferiores hasta ra\u00edz de miembros.  \nEstudio anal\u00edtico co n: glucosa 165 mg/dL, creatinina sangre 6,3 mg/mL, potasio 4,5 mEq, \nhemoglobina 6,8 g/dL. Se solicit \u00f3 cultivo de orina.  \nAnte una paciente retrasplantada renal hace 5 meses con cl\u00ednica miccional afebril e \ninmunosuprimida con deterioro de la funci\u00f3n renal de  probable origen obstructivo se \ndecide ingreso en Nefrolog\u00eda.  \nDurante el ingreso se observ\u00f3 crecimiento de Candida albicans sensible a fluconazol y \nKlebsiella pneumoniae  sensible a quinolonas, carbapenems, cefalosporinas  en cultivo de \norina . \nDISCUSION Y APORTACION FARMACEUTICA  \nAnte la presencia de Candida albicans  y Klebsiella pneumoniae  en orina se decide iniciar \ntratamiento con fluconazol  y meropenem . En este momento, desde el Servicio de \nFarmacia se recomienda la monitorizaci\u00f3n de concentra ciones en sangre  de tacrolimus 844de forma peri\u00f3dica dada su interacci\u00f3n con fluconazol descrita en la bibliograf\u00eda. \nAdem\u00e1s, se revisa la historia cl\u00ednica de la paciente y el correcto uso de antibi\u00f3ticos.  \nTras cuatro d\u00edas de tratamiento con fluconazol se dete rminan las concentraciones  en \nsangre  de tacrolimus obteniendo un resultado de 13,50 ng/ mL (rango de referencia: 8 -\n12 ng/mL) . Concentraci\u00f3n en control previo: 8,60 ng/mL, encontrando un aumento en \nla concentraci\u00f3n de tacrolimus en un 157%.  La paciente present\u00f3 una mejor\u00eda de los \npar\u00e1metros anal\u00edticos marcadores de infecci\u00f3n . Sin embargo, se observ\u00f3 un \nempeoramiento cl\u00ednico progresivo , apareciendo principalmente temblores e \nhiperglucemia.  \nAnte estos hallazgos, se comunica la interacci\u00f3n dete ctada y se recomienda suspender  \nfluconazol e iniciar tratamiento con otro antif\u00fangico no az\u00f3lico como caspofungina. Aun \nas\u00ed, destacamos la importan cia de  tener en cuenta que debido a la vida media del \nfluconazol (aprox. 30h) se estima que la interacci\u00f3n se  mantenga durante 5 -7 d\u00edas  tras \nsuspender el tratamiento.  \nAun as\u00ed, tambi\u00e9n se encuentra descrita la interacci\u00f3n de caspofungina con tacrolimus \nmediante un mecanismo a\u00fan desconocido suponiendo una reducci\u00f3n de los niveles \nplasm\u00e1ticos del inmunosupresor de aproximadamente un 20%. Por este motivo, \nrecomendamos efectuar controles de forma peri\u00f3dica durante el ingreso . \nPor otro lado, se detecta el uso de antibi\u00f3ticos restringidos a cepas resistentes y se \ncomunica al equipo responsable del Programa de Optimizaci \u00f3n de Uso de Antibi\u00f3ticos \n(PROA) del Hospital. Se revisa la gu\u00eda PRIOAM y la gu\u00eda terap\u00e9utica antimicrobiana 2021 \nMensa/Gatell, as\u00ed como el antibiograma para la cepa de K. pneumonia e detectada en \nurocultivo. En este caso, nos encontramos ante una cepa sens ible a cefalosporinas y \nquinolonas, por lo que recomendamos  desescalar antibioterapia.  No obstante, en caso 845de considerar continuar con el tratamiento con meropenem se debe ajustar la dosis \nseg\u00fan la funci\u00f3n renal. Se calcula la funci\u00f3n renal de nuestro pac iente seg\u00fan la f\u00f3rmula \nde Cockcroft -Gault: CrCl (mujer)(ml/min)  = 16,95 mL/min . Vuelve a revisarse las gu\u00edas \npreviamente mencionadas, encontrando las siguientes recomendaciones:  \n- FG>50: sin cambios en la dosis  \n- FG 25 -50: 1g/8h  \n- FG 10 -25: 1g/12h  \n- FG < 1 0: 1g/24h  \nLa paciente se encontraba en tratamiento con una pauta de meropenem de 1g/8h, por \nlo que recomendamos una nueva pauta posol\u00f3gica de 1g/12h.  \nBIBLIOGRAFIA  \n1. Julia Praena, Jose  Antonio Lepe, Ma Victoria Gil Navarro ON y JMC. Gu\u00eda \nPRIOAM. p. https://www.guiaprioam.com . \n2. MA\u00d1EZ, R et al. Fluconaz ole therapy in transplant recipients receiving FK506.  \nTransplantation. 1994 ; 57:1521 -35. \n3. J M. Gu\u00eda terap\u00e9utica antimicrobiana. 2021.  \n4. Ficha t\u00e9cnica Fluconazol, meropenem, tacrolimus y caspofungina.  846CASO CL\u00cdNIC O:AJUSTEPOSOL \u00d3GIC ODELINE ZOLID POR INTERA CCI\u00d3N CONRIFAMPICINA\nEN ENDOCARDITIS INFE CCIOS A\nINTR ODUCCI\u00d3N\nLas interacciones farmac ol\u00f3gic asson una posible causa demala respues taaltratamien to\nque enocasiones esinfravalorada oinadv ertida porelcl\u00ednic oyque puede serfundamen tal\nenlaevoluci\u00f3n delaenfermedad. Presen tamos uncaso enelque una pacien terecibi\u00f3\nsimult \u00e1neamen telinezolid yrifampicina paraeltratamien todeuna endoc arditis infecciosa\nsobr ev\u00e1lvula nativa(EIVN) porStaphylococcusaureus meticil\u00edn-sensible (SAMS), donde se\nobserv\u00f3 una in teracci\u00f3n f armac ol\u00f3gic a cl\u00ednic amen te relevante.\nEllinezolid esunantibi\u00f3tic odelgrupo delasoxazolidinonas que act\u00faa inhibiendo las\u00edntesis\nproteicabact eriana delosmicr oorganismos Gram-positiv ospor launi\u00f3n alribosoma enel\nsitio P(23s) delasubunidad ribosomal 50s. Deestaforma seimpide laformaci\u00f3n del\ncomplejo deiniciaci\u00f3n ribosoma- fMet-tRNA ycomo consecuencia sebloquea latraducci\u00f3n1.\nTiene unmetabolismo oxidativoenelque segener a2-hidr oxiline zolid como product oinicial\ndelareacci\u00f3n yfinaliz aconN,O-dese tilenline zolid. Esteproceso nohasido iden tificado\ndetalladamen tehasta2022 conlapublic aci\u00f3n deunestudio que demues tralaparticipaci\u00f3n\ndelsistema micr osomal hep\u00e1 tico(CYP450) median telasenzimas CYP2J2, CYP4F2 yCYP1B12.\nLos efectos adversos m\u00e1s comunes son de tipo dosis-dependien teeincluy en la\nmielosupr esi\u00f3n, principalmen teenforma deanemia ydetrombopenia; perotambi\u00e9n tiene\nefectosadversostiempo-dependien tescomo laalteraci\u00f3n visual causada poruna afectaci\u00f3n\ndirectadel nervio \u00f3ptico1.Adem\u00e1s esuninhibidor reversible ynoespec\u00edfic odela\nmono-amina oxidasa, locual puede darlugaras\u00edndr ome serotonin\u00e9r gicosisecombina con\ninhibidor esdelarecaptaci\u00f3n deserotonina oantidepr esivostric\u00edclic os, entreotros847f\u00e1rmac os1.\nPorotrolado ,larifampicina esunantibi\u00f3tic odelgrupo delasrifamicinas que seune ala\nsubunidad \u03b2delaADN-polimer asa bact eriana eimpide latranscripci\u00f3n delARN. Launi\u00f3n\ndelf\u00e1rmac osuprime laformaci\u00f3n decadenas enlas\u00edntesis deARN3.Larifampicina tiene\neliminaci\u00f3n principalmen tehep\u00e1 tica(80%) enlaque seforma unmetabolit odesace tilado\nque seexcretaporlabilis. Posee una grancapacidad deinducci\u00f3n delmetabolismo oxidativo\nmediado porCYP450 yesuninduct ordelaglucoproteina P(P-gp) porlav\u00edadese\u00f1aliz aci\u00f3n\ndel recep tordepregnano X.Estosefectosinduct oresalcanzansum\u00e1ximo en10d\u00edas y\ndisminuy engradualmen teduranteunper\u00edodo aproximado de2om\u00e1s semanas despu\u00e9s de\ndiscontinuar eltratamien to.Tiene una semivida de3-4h paraladosis de600 mgpero\u00e9sta\npuede disminuir a 1-2h debido a que induce su pr opio me tabolismo4.\nDESCRIPCI\u00d3N DEL CASO\nSepresen taelcaso deuna mujer de60a\u00f1os sinreacciones al\u00e9rgicasconocidas ycon\nanteceden tesdehipert ensi\u00f3n arterial, espondilitis anquilosan te(sin tratamien toactiv o),\nmeningiomas tosis m\u00faltiple, s\u00edndr ome deseno cavernoso yaneurisma dearteria cerebral\nmedia izquier da.Tambi\u00e9n presen taaneurisma envertien tederecha delagujer omagno yen\narteria vertebralderecha. Lapacien teacudi\u00f3 aurgencias el16/03/21 porimposibilidad para\nlamarcha yparamovilizarlosmiembr osinferior es,juntocondesorien taci\u00f3n devarios d\u00edas\ndeevoluci\u00f3n. Eltratamien toalingreso fue: amlodipino 7mg c/24h, perindopril 5mg c/24h,\nesomepr azol20mg /12h, atorvastatina 40mg c/24h, tramadol 50mg c/24h ydexame tasona\n(paut a variable).848Ingres\u00f3 enUCI por shock s\u00e9ptico,d\u00f3nde traslarealiz aci\u00f3n deuna ecocardiogr af\u00edase\ndiagnos tic\u00f3adem\u00e1s de EIVN tric\u00faspidea as\u00ed como derr ame peric \u00e1rdico.El\u00fanico\nmicr oorganismo aislado enloshemocultiv osfueSAMS, porloque seinici\u00f3 tratamien tocon\ndaptomicina (750 mgc/24h) ycloxacilina (2000 mgc/4h). Aunque enlagu\u00eda deendoc arditis\ndelaSociedad Europea deCardiolog\u00eda de20165noincluy eestacombinaci\u00f3n enEIVN por\nSAMS, algunos aut ores recomiendan su uso c ombinado por su siner gismo6.\nTrassutraslado asala demedicina interna persisti\u00f3febril yseasoci\u00f3 linezolid (600 mg\nc/12h) paraampliar lacobertur adebido alaaparici\u00f3n de\u00e9mbolos s\u00e9pticospulmonar es,\nalgunos deellos cavitados, as\u00edcomo porpersistencia deaislamien todelmicr oorganismo en\nhemocultiv osseriados. Posteriormen te,cuando lapacien tepermaneci\u00f3 afebril ynegativiz\u00f3\nloshemocultiv osseretir\u00f3ladaptomicina peroseman tuvolaasociaci\u00f3n delinezolid y\ncloxacilina. Paralelamen te,debido acambios observados enelelectr ocardiogr ama, serealiz \u00f3\nresonancia magn\u00e9 ticacardiacayseconfirm\u00f3 mioperic arditis porloque seinici\u00f3 colchicina\n(0.5 mg c/24h).\nLaasociaci\u00f3n derifampicina s\u00f3lo est\u00e1recomendada enendoc arditis infecciosa sobr ev\u00e1lvula\nprot\u00e9sica(EIVP)5,sinembar godebido alaprogresi\u00f3n delaslesiones observadas median te\nPET-TAC,sedecidi\u00f3 asociar rifampicina adosis de600 mgc/24h. Alos7d\u00edas serealiz \u00f3\nmonit orizaci\u00f3n farmac ocin\u00e9 tica(TDM) dellinezolid paracontrolyseguimien todebido ala\npotencial interacci\u00f3n. Enestaprimer aTDM seobtuvouna concen traci\u00f3n plasm\u00e1 ticaenvalle\n(Cmin) inde tectable, porloque sedecidi\u00f3 adminis trarellinezolid enperfusi\u00f3n cont\u00ednua (PC)\ncondosis de1200 mgc/24h yman tener larifampicina. Pese aestecambio enlapaut a\ncontinu\u00f3 laCmin inde tectable, yeneld\u00eda+10 sedecide suspender larifampicina yasociar\nfosfomicina (4000 mgc/8h). Apartir deestemomen to,como sepuede observarenlafigur a8491,serealiz aroncontroles peri\u00f3dic osdelinezolid enlosque laCmin continu\u00f3 inde tectable\npese alosincremen tosenlapaut a(600 mg c/8h) ylainterrupci\u00f3n delarifampicina.\nFinalmen te,alos10d\u00edas delasuspensi\u00f3n de\u00e9sta,conuna dosis delinezolid de1800 mg\nc/24h enPC,seobtuvier onconcen traciones delinezolid de1.8mg/Lyposteriormen te,se\nalcanzaronvaloresde3.5 mg/L), que coincidier onconladisminuci\u00f3n delaproteina C\nreactiv a(PCR) (figur a2).Trasesto,el15/05 fuedada dealta.Duranteelseguimien to,los\nfactorespredictiv osdeacumulaci\u00f3n paralinezolid: filtrado glomerular (FG)ybilirrubina, se\nman tuvier onconstantes.ElFGoscil\u00f3 entre111-98 mg/mL ylabilirubina entre0.54-0.38\nmg/dL. Sin embar go los v alores de GG T oscilar on en tre 381-1735 UI/L (figur a 2).\nLaCmin inde tectable sepuede atribuir auna interacci\u00f3n entrelinezolid yrifampicina yaque\nnoseiden tific\u00f3otraposible interacci\u00f3n coneltratamien todelapacien teenesemomen to.\nLadisminuci\u00f3n delaCmin delinezolid porlarifampicina esconocida7,perolosmec anismos\nsubyacen tesnoest\u00e1ndel todo definidos. Larifampicina esuninduct ordelaP-gp, sin\nembar goellinezolid noseelimina median teestaproteina transport ador a7.Unrecien te\nestudio iden tificalos citocromos CYP2J2, CYP4F2 yCYP1B1 como principales\nmetaboliz ador esdellinezolid, loscuales inician elproceso metab\u00f3lic opor lahidroxilaci\u00f3n\ndelanillo demorf olina (2-hidr oxiline zolid). Estoscitocromos podr\u00edan serlosresponsables de\nlainteracci\u00f3n entreambos f\u00e1rmac os,aunque losautoresrecomiendan realiz arm\u00e1s estudios\nen es ta l\u00ednea par a poder c onfirmar las pot enciales in teracciones2.\nLapersistencia delainteracci\u00f3n pese alasuspensi\u00f3n delarifampicina sepuede explic arpor\nuna eliminaci\u00f3n disminuida de\u00e9sta(figur a1(b)) yaque lapacien tepresen taba unpatr\u00f3n\ncolest\u00e1sicoobje tivado porvaloresdeGGTelevados (figur a2).Debido alaeliminaci\u00f3n biliar850derifampicina4,estosvaloresdeGGTpueden serindic ativosdeuna acumulaci\u00f3n. Adem\u00e1s,\nhayque consider arque elefectoinduct ordel metabolismo nosedetiene deforma\ninmedia tatraslainterrupci\u00f3n deltratamien to,sino que tiene unefectoprolong ado enel\ntiempo ,yaque esunfen\u00f3meno mediado porlaexpresi\u00f3n g\u00e9nica.Esteefectodeinducci\u00f3n\ndiferida explic ar\u00eda lapersistencia deCmin delinezolid inde tectable pese aque yanose\nobtuvier an concen traciones plasm\u00e1 ticas de rif ampicina en d\u00eda + 8 (figur a 1(c)).\nCONCL USI\u00d3N Y APOR TACI\u00d3N F ARMA C\u00c9UTICA\nLainteracci\u00f3n entrelinezolid yrifampicina puede ocasionar una p\u00e9rdida deeficacia enla\nantibiot erapia as\u00edcomo una mayorprobabilidad degener arresistencias alinezolid. Esde\nutilidad monit orizarellinezolid enpacien tesentratamien toconcomit anteconrifampicina.\nElefectoprolong ado delainhibici\u00f3n enzim\u00e1 ticaylasupues taeliminaci\u00f3n disminuida dela\nrifampicina supuso unretoparapoder ajustarladosis delinezolid. Noobstanteselogr\u00f3\nalcanzar Cmin t erap\u00e9utic as pese a dosis muy ele vadas de line zolid.851Figur a1.Concen traci\u00f3n plasm\u00e1 ticadelinezolid (mg/L)medida alolargodelseguimien to.\nLas dosis delinezolid semues tranadjun tassobr ecada monit orizaci\u00f3n (l\u00ednea azul). El\ngradien temorado intentarepresen tardeforma te\u00f3ric aelefectoinduct ordelarifampicina,\ndonde seconsider antresescenarios: (a)\u2192semivida delarifampicina; (b)\u2192posible tiempo\ndeacumulaci\u00f3n por colestasis; (c)\u2192posible tiempo deinducci\u00f3n diferida, una vez\neliminada la rif ampicina.\n852\nFigur a2.Represen taci\u00f3n delaevoluci\u00f3n dediferentesvaloresbioqu\u00edmic osduranteel\nseguimien to.Parafacilit arlainterpr etaci\u00f3n, sehaanot ado sobr ecada determinaci\u00f3n el\nvalor ob tenido , ya que son de magnitudes dif erentes.853BIBLIOGRAFIA\n1-Metaxas,Eugenios I;Falagas,MatthewE(2009). Upda teonthesafetyoflinezolid. Expert\nOpinion on Drug Sa fety, 8(4), 485\u2013491.\n2-R.ScottObach. Linezolid Metabolism isCatalyzedbyCYP2J2, CYP4F2 and CYP1B1. Drug\nMetabolism and Disposition. 2022; 50 (4): 413-421\n3-Mensa, J.Soriano ,A.L\u00f3pe z-Su\u00f1\u00e9, E.Llinar es,P.Barber \u00e1n,J.Zbor omyrska,Y.Guia de\nterapeutic a an timicr obiana 2022 (32 edici\u00f3n). Bar celona. E ditorial An tares: 2022.\n4-Ficha t\u00e9cnic aRimact an\u00ae 300 mg c\u00e1psulas duras.Centrodeinformaci\u00f3n online de\nmedic amen tos de la AEMPS - CIMA [in terne t]. Consult ado el 15/05/2022\n5-Gilbert Habib, Patrizio Lancellot ti,Manuel J.Antunes etal.Gu\u00eda ESC2015 sobr eel\ntratamien to de la endoc arditis in fecciosa. R ev Esp Car diol. 2016; 69(1):69.e1-e49\n6-C.Garc\u00edadelaM\u00e0ria, J.Garc\u00eda-Gonz \u00e1lez,M.Villamon teetal.Eficacia dedaptomicina y\ncloxacilina eneltratamien todelaendoc arditis experimen talpor staphylococcus aureus\nsensible a la me ticilina. Cirug\u00eda Car diovascular . 2019; 26 (2): 132-133.\n7-OkazakiF,TsujiY,SetoY,Ogami C,Yamamot oY,ToH.Effects ofarifampicin pre-treatmen t\non line zolid pharmac okine tics. PLoS One. 2019;14(9):e0214037.854ISAVUCONAZOL  Y TACROLIMUS:  INTERACCI\u00d3N FARMACOL \u00d3GICA CLINICAMENTE \nRELEVANTE  \n \nINTRODUCCI\u00d3N  \nEl trasplante renal es una terapia de elecci\u00f3n para mejora r la calidad de vida  de los \npacientes con insuficiencia renal cr\u00f3nica. El tratamiento inmunosupresor debe ser \nindividualizado buscando el mejor perfil de seguridad, y debe adaptarse a las diferentes \netapas del trasplante renal . Tacrolimus es uno de los inmunosupresores que m\u00e1s \nrelevancia ha alcanzado en el tratamiento post -trasplante . Se trata de un inhibidor de l a \ncalcineurina, empleado en la p rofilaxis del rechazo del trasplante en receptores de \naloinjertos hep\u00e1ticos, renales o cardiacos . En nuestro hospital , su monitorizaci\u00f3n se \nrealiza en la pr\u00e1ctica habitual, estableciendo intervalos de concentraci\u00f3n en funci\u00f3n del \nperiodo post -trasplante en el que se encuentra el paciente.   \nComo consecuencia de la inmunosupresi\u00f3n , los microorganismos oportunistas aparecen \ncomo reactivaci\u00f3n end\u00f3gena de infecciones latentes o desde un origen ex\u00f3geno.   Los \nagentes antif\u00fangicos del grupo de los azoles son una de las opciones para el tratamiento \nde infecciones f\u00fangicas sist\u00e9micas. Isavuconazol es un antif\u00fangico  de reciente apari ci\u00f3n \nenglobado dentro del grupo de los triazoles. Su indicaci\u00f3n en adultos es el tratamiento \nde aspergilosis invasiva y mucormicosis en pacientes para los que la anfotericina B no es \napropiada , y su mecanismo de acci\u00f3n se basa en la inhibici\u00f3n de algunos d e los pasos \nque dan lugar a la s\u00edntesis del ergosterol, componente estructural fundamental de la \nmembrana del hongo, alterando su estructura y dando lugar a la p\u00e9rdida de sus \nfunciones. Seg\u00fan el protocolo de uso en nuestro hospital , este f\u00e1rmaco se utiliza en \naquellos casos en los que el paciente  con insuficiencia renal  no puede ser tratado con 855voriconazol  intravenoso (IV)  debido a la ciclodextrina que se encuentra present e en su \nformulaci\u00f3n y que empeorar\u00eda la funci\u00f3n renal del paciente.    \nRespecto a sus caracter\u00edsticas farmacocin\u00e9ticas, isavuconazol se metaboliza tanto por \nCYP3A4 como por CYP3A5 . Cabe recordar que CYP3A4 , representa el 30 -40% de todos \nlos enzimas, y est\u00e1 implicado  en el metabolismo de primer paso . Debido a esto, puede  \ndar lugar a un gran n\u00famero  de interacciones , ya que puede ser tan to inhibido como \ninducido por diferentes mol\u00e9culas. Entre los principales inhibidores de este citocromo, \nencontramos el grupo farmacol\u00f3gico de los antif\u00fangicos az\u00f3licos, grupo al que \npertenece el isavuconazol.  \nDiversos estudios han demostrado que la administraci\u00f3n concomitante de isavuconazol \ny tacrolimus, produce una elevaci\u00f3n en los niveles del inmunosupresor debido a la  \ninhibici\u00f3n del citocromo CYP3A4 por parte del antif\u00fangico, lleg\u00e1ndose a aumentar en un \n42% las concentraciones m\u00e1ximas de tacrolimus.  Aun as\u00ed, hay una gran controversia en \nlos datos recogidos en la bibliograf\u00eda, por lo que esta interacci\u00f3n deber\u00eda ser est udiada \nde forma m\u00e1s exhaustiva.  \nA continuaci\u00f3n, presentamos el caso de una paciente ingresada en nuestro hospital a \ncargo de l servicio de nefrolog\u00eda por un deterioro progresivo de la funci\u00f3n renal.  \nPRESENTACI\u00d3N DEL CASO  \nPaciente de sexo femenino de 57 a\u00f1os de edad, 80kg de peso y 150 cm de altura \n(IMC= 35.5 kg/m\u00b2).  Ingres\u00f3 el 26/10/2021  a cargo del servicio de nefrolog\u00eda por deterioro \nprogresivo de la funci\u00f3n renal  de aproximadamente un mes de evoluci\u00f3n . Como \nantecedentes  a destacar presenta ba: diabetes miellitus tipo 2 de m\u00e1s de 25 a\u00f1os de \nevoluci\u00f3n, HTA, dislipemia, hiperuricemia , anemia asociada a ERC y enfermedad renal 856cr\u00f3nica estadio 5 secundaria a enfermedad renal diab\u00e9tica. No presenta ba h\u00e1bitos \nt\u00f3xicos ni alergias conocidas. La tabla 1 describe su  historia farmacoterap\u00e9utica  en el \nmomento del ingreso . \nLa paciente fue trasplantada  en marzo de 2008 , iniciando inmunosupresi\u00f3n con \ntacrolimus y micofenolato de mofetilo. En octubre de 2019  la paciente requiri\u00f3 de \nsesiones de  hemodi\u00e1lisis, teniendo que ser reintervenida el 20/07/2021.  La paciente \nestaba en seguimiento farmacocin\u00e9tico  por parte de nuestro servicio desde enero de \n2019.  \nF\u00e1rmaco  V\u00eda Motivo \nterap\u00e9utico  Posolog\u00eda  Fecha inicio  \nTacrolimus \n3mg \n(Advagraf \u00ae) Oral  Trasplante \nrenal  1 comp/24h  11/feb/2019  \nMicofenolato \n360mg \n(Myfortic \u00ae) Oral  Trasplante \nrenal  1 comp/12h  07/sept/2017  \nAtorvastatina \n20mg \n(Prevencor \u00ae) Oral  Dislipemia  1 comp/24h  16/jun/2009  \nBromazepam \n1.5mg \n(Lexatin \u00ae) Oral  Ansiedad  1 cap/24h  26/mar/2020  \nFebuxostat \n80mg  Oral  Hiperuricemia  1 comp/24h  19/nov/2019  \n\u00c1cido \nAcetilsalicilico \n100mg  Oral  Antiagregaci\u00f3n  1 comp/24h  17/oct/2007  \nCinacalcet \n30mg \n(Mimpara \u00ae) Oral  ERC 1 comp/24h  12/feb/2020  \nCalcio 600mg \nCa (Natecal \u00ae) Oral  ERC 1 comp /12h  05/10/2021  \nEzetimiba \n10mg  Oral  Dislipemia  1 comp/24h  16/11/2021  \nInsulina \nGlargina \n(Lantus \u00ae) Subcut\u00e1neo  Diabetes \nmiellitus tipo 2  38 UI/24h  07/03/2011  857Doxazosina \n4mg  Oral  HTA 1 comp/24h  16/11/2021  \nDarbepoetina \n80 \nmicrogramos \n(Aranesp \u00ae) Subcut\u00e1neo  Anemia  1 jeringa/24h  18/03/2019  \nEnalapril \n2.5mg  Oral  HTA  1 comp/12 h  16/06/2009  \n \nTabla 1. Historia farmacoterap\u00e9utica  de la paciente en el momento del ingreso . \n \nA su ingreso , el servicio de nefrolog\u00eda solicit \u00f3 la monitorizaci\u00f3n farmacocin\u00e9tica  de \ntacrolimus a la Unidad de Farmacocin\u00e9tica Cl\u00ednica (UFC) del servicio de farmacia para \ndeterminar las concentraciones plasm\u00e1ticas . El resultado de la  concentraci \u00f3n valle fue \nde 11.20 ng/mL, dentro de intervalo terap\u00e9utico habitual en el 2 -6\u00ba mes en trasplante \nrenal (8 -12 ng/mL), por lo que se recomend\u00f3 continuar con la pauta posol\u00f3gica  de \n4.5mg/24h de t acrolimus v\u00eda oral. Tras dos d\u00edas desde el ingreso, el resultado \nfarmacocin\u00e9tico obtenido fue de 12.4 ng/mL, por lo que se recomend\u00f3, en funci\u00f3n de la \ncl\u00ednica de la paci ente, continuar con la pauta posol\u00f3gica de tacrolimus 4.5mg/24h vo, o \nbien realizar una disminuci\u00f3n de dosis a tacrolimus 4mg/24h vo . El 31/10/2021, tras los \nresultados del urocultivo (positivo para  C.Albicans  ) se inici\u00f3  tratamiento con fluconazol \n50mg/d\u00ed a vo, ajustado a funci\u00f3n renal . El 04/11/2021 se realiz\u00f3 control farmacocin\u00e9tico, \nobteniendo una concentraci\u00f3n de  tacrolimus de  13.5 ng/mL, nivel superior a control \nprevio con igual pauta posol\u00f3gica , informando desde el servicio de farmacia de la \ninteracci \u00f3n entre el antif\u00fangico y el inmunosupresor , y decidiendo de forma \nconsensuada el cambio a caspofungina , ya que presentaba menor grado de interacci\u00f3n \ncon tacrolimus. Para seguir la evoluci\u00f3n de la concentraci\u00f3n  de tacrolimus, se realiz\u00f3 u n \nnuevo control el 06/11/2021, con un  valor de 18.9 ng/mL, y recomenda ndo disminuir la 858dosis del inmunosupresor a 4mg/24h. Puesto que la vida media d el fluconazol es de 30 \nhoras,  en el informe farmacocin\u00e9tico se notific\u00f3  la posibilidad de que la interacci\u00f3n se \nmantuviese entre 5 y 7 d\u00edas. El 08/11/2021 l a concentraci\u00f3n de tacrolimus  alcanz\u00f3 un \nvalor objetivo adecuado de  11.5 ng/mL.  El 12/11/2021, tras  la revisi\u00f3n del caso por el \nequipo de PROA, se decidi\u00f3 sustituir  caspof ungina por isavuconazol oral 100mg/24h, \naun conoci\u00e9ndose la interacci\u00f3n que este podr\u00eda producir con tacrolimus. El 16/11/2021 \nse realiz\u00f3 una nueva  monitorizaci\u00f3n tras el cambio del antif\u00fangico, obtenido una  \nconcentraci\u00f3n de 17.4 ng/mL, recomend\u00e1ndose real izar una disminuci\u00f3n de dosis  a \ntacrolimus 1 mg/24h vo . La paciente fue dada de alta hospitalaria ese mismo d\u00eda, \nmanteniendo la dosis de tacrolimus 1mg/24h vo y con una pauta de 200mg/24h de \nIsavuconazo l vo , entre otros medicamentos concomitantes. En segui mientos \nfarmacocin\u00e9ticos posteriores , las concentraciones alcanzaron el intervalo terap\u00e9utico \nobjetivo y se recomend\u00f3 realizar una monitorizaci\u00f3n 20 -25 d\u00edas tras la suspensi\u00f3n del \ntratamiento con isavuconazol, cuando se estimaba que la interacci\u00f3n habr\u00eda \ndesaparecido.  De este modo, e l 21/12/2021, la concentraci\u00f3n  de tacrolimus  se \nencontraba en  3.3 ng/mL, por lo que se recomend\u00f3 aumentar la dosis a 3mg/24h. Desde \nel servicio de nefrolog\u00eda se decidi\u00f3 no realizar modificaci\u00f3n  de la pauta posol\u00f3gica, por \nlo que  20 d\u00edas despu\u00e9s, la concentraci\u00f3n se encontraba en 1.7 ng/mL, volvi\u00e9ndose a \nrecomendar la pauta de 3mg/24h. Los nefr\u00f3logos, siguiendo las recomendaciones, \nrealizaron el cambio en la dosificaci\u00f3n, y los niveles se estabilizaron dentro del rango \nterap\u00e9utico  objetivo en los controles farmacocin\u00e9ticos posteriores. En la tabla  2, se \nrecogen las diferentes concentraciones plasm\u00e1ticas, con la posolog\u00eda de tacrolimus en \nese momento y el antif\u00fangico concomitante.  En el gr\u00e1fico 1 se observa la evo luci\u00f3n de \nlas concentraciones e n el tiempo en funci\u00f3n del antif\u00fangi co pautado.  859Fecha del \ncontrol \nfarmacocin\u00e9tico  Concentraci\u00f3n \nplasm\u00e1tica de \ntacrolimus  Dosis de \ntacrolimus  Antif\u00fangico \nconcomitante  Recomendaci\u00f3n \nfarmacocin\u00e9tica  \n26/10/2021  11.2 ng/mL  4.5mg/24h  - Continuar  \n28/10/2021  12.4 ng/mL  4.5mg/24h  - Continuar o \nreducir  \n04/11/2021  13.5 ng/mL  4.5mg/24h  Fluconazol  Continuar y \nsuspender \nFluconazol  \n06/11/2021  18.9 ng/mL  4.5mg/24h  Caspofungina  Disminuir  \n08/10/2021  11.5 ng/mL  4.5mg/24h  Caspofungina  Continuar  \n16/11/2021  17.4 ng/mL  4.5mg/24h  Isavuconazol  Disminuir  \n19/11/2021  7.5 ng/mL  1mg/24h  Isavuconazol  Continuar  \n21/12/2021  3.3 ng/mL  1mg/24h  - Aumentar  \n05/01/2022  1.7 ng/mL  1mg/24h  - Aumentar  \n24/01/2022  6 ng/mL  3mg/24h  - Continuar  \n \nTabla 2. Seguimiento farmacocin\u00e9tico y cl\u00ednico  de la paciente durante su ingreso \nhospitalario. Se recogen : fecha del control farmacocin\u00e9tico, concentraci\u00f3n plasm\u00e1tica \nde tacrolimus, dosis administrada, antif\u00fangico concomitante y recomendaci\u00f3n \nfarmacocin\u00e9tica . \n \n \nGr\u00e1fica 1 . Evoluci\u00f3n de las concentraciones en el tiempo en relaci \u00f3n con el  antif\u00fangico \npautado . \n \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA \nComo se puede observar en este  caso , el farmac\u00e9utico cl\u00ednico puede aportar  valor en el \nseguimiento farmacocin\u00e9tico  y cl\u00ednico  de pacientes  complejos como son  aquel los que se \n860someten a un trasplante renal . En la UFC, el farmac\u00e9utico puede contri buir a la \nindividualizaci\u00f3n posol\u00f3gica, aplicando los principios PK/PD y algoritmos terap\u00e9uticos , \npermitiendo de este modo alcanzar concentraciones que proporcionen la m\u00e1xima \nefectividad y la menor toxicidad . La monitorizaci\u00f3n farmacocin\u00e9tica, junto con la \nrevisi\u00f3n de la terapia farmacol\u00f3gica , permiti\u00f3  detectar la interacci\u00f3n descrita en el caso \ncl\u00ednico . La interacci\u00f3n de isavuconazol (inhibidor) y tacrolimus (sustrato), y la relevancia  \ncl\u00ednica de un posible aumento de la concentraci\u00f3n plasm\u00e1tica del inmunosupresor , se \ndeber\u00eda valorar adecuadament e para establecer una relaci\u00f3n  beneficio -riesgo de la \nadministraci\u00f3n simult\u00e1nea de ambos f\u00e1rmacos, planteando alternativas siempre que \nsea posib le. Destacar tambi\u00e9n la importancia del seguimiento farmacocin\u00e9tico tras el \nalta hospitalaria de  la paciente.  La UFC del servicio de farmacia cuenta con un papel \ndestaca do en el seguimiento del paciente trasplantado  renal , destacando  la importancia \nde un equipo  multidisciplinar  que garantice la optimizaci\u00f3n de  los resultados \nterap\u00e9uticos  en este tipo de pacientes .  \nBIBLIOGRAF\u00cdA  \n1. Azanza Perea, J. R., & S\u00e1bada D\u00edaz de Rada, B. (2018). Perfil farmacol\u00f3gico del \nisavuconazol. Revista Iberoamericana de Micolog\u00eda , 186 -191. \n2. D.Kufel, W., M.Armistead, P., & M.Daniels, L. (2018). Drug- drug interaction between \nisavuconazole and tacrolimus: is empiric dose adjustment necessary? Journal of \npharmacy practice, 1 -5. \n3. Dodds Ashley, E. (15 de Marzo de 2022). UpToDate . Recuperado el Mayo de 2022, de \nUpToDate Web SIte: www.uptodate.com \n4. Russell E., L. (20 de Julio de 2021). UpToDate . Obtenido de UpToDate Web Site: \nwww.uptodate.com  \n5. Trifilio, S., Rubin, H., Monacelli, A., & Metha, J. (2020). Tacrolimus dose modification in \npatients receiving c oncomitant isavuconazole after hematopoietic stem cell \ntransplantation. Journal of Oncology Pharmacy Practice , 1-6. \n \n 861\n1 \n AUTORES.  Vicente -Valor J, Escudero -Vilaplana V, Collado -Borrell R , Ruiz -Briones P, \nMontero -Ant\u00f3n MdP, Rioja -D\u00edez Y, Herranz -Alonso A, Sanjurjo -S\u00e1ez M  \nServicio de Farmacia Hospitalaria. Hospital General Universitario Gregorio Mara\u00f1\u00f3n. \nInstituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n.  \n \n \nT\u00cdTULO: Manejo de la interacci\u00f3n abiraterona -espironolactona en un \npaciente cardi\u00f3pata  \n \n1. INTRODUCCI\u00d3N  \nLa espironolactona  puede ejercer propiedades androg\u00e9nicas  y comprome ter la eficacia \nterap\u00e9utica de  f\u00e1rmacos empleados en el c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n \nmetast\u00e1sico (mCPRC), como la abiraterona.  Esta potencial interacci\u00f3n farmacodin\u00e1mic a, \ncuyo impacto puede ser muy relevante  en los pacientes , es poco conocida  y su  \nnotificaci\u00f3n procede de reportes de casos . Por ello, el  manejo de esta interacci\u00f3n est\u00e1 \npoco establecido  y puede variar en funci\u00f3n de la situaci\u00f3n del paciente . De ah\u00ed el inter\u00e9s \nque tienen  los estudios publicados sobre esta interacci\u00f3n . Presentamos el caso de un \npaciente cardiol\u00f3gico en el que se previno un potencial fracaso terap\u00e9utico de \nabiraterona a ra\u00edz de la validaci\u00f3n farmac\u00e9utica del tratamiento . \n2. DESCRIPCI\u00d3N DEL CASO  \nSe trata  var\u00f3n de 79 a\u00f1os, con historia oncol\u00f3gica de adenocarcinoma de pr\u00f3stata de \nalto riesgo tratado con radioterapia m\u00e1s hormonoterapia desde  2013  hasta 2016, donde \nse decidi\u00f3 vigilancia pasiva. A ra\u00edz  de la  elevaci\u00f3n de l PSA, se realiz\u00f3 resonancia (RMN) \nen ag osto de 2018, en la que  se descubr i\u00f3 una met\u00e1stasis \u00f3sea en D10 y D12 sacroil\u00edaca, \nque se trat \u00f3 con hormonoterapia  y posterior radioterapia  mediante 5 sesione s. Ante \nnueva  elevaci\u00f3n de l PSA, el 07 de mayo de 2020 inici\u00f3 tratamiento con abiraterona 1000 862\n2 \n mg c/24h m\u00e1s prednisona 5 mg  c/24h, concomitantemente con un agonista de LHRH \nsemestral.  \nAdem\u00e1s,  entre los antecedentes cardiol\u00f3gicos del paciente destacaban  estenosis a\u00f3rtica \nsevera asintom\u00e1tica con fracci\u00f3n de eyecci\u00f3n ( FEVI ) preservada , hipertensi\u00f3n arterial, \nfibrilaci\u00f3n auricular permanent e y b loqueo auriculoventricular de primer grado . En \n2017, s ufri\u00f3 el primer episodio de insuficiencia cardiaca  (ICC), con FEVI preservada \ntodav\u00eda, e n relaci\u00f3n con  su estenosis a\u00f3rtica, por lo que requ iri\u00f3 sustituci\u00f3n valvular \na\u00f3rtica biol\u00f3gica . En octubre de 2019 , requiri\u00f3 resustituci\u00f3n valvular  ante  importante \nafectaci\u00f3n endocard\u00edtica por Streptococcus viridans  que fracas\u00f3 al tratamiento \nantibi\u00f3tico.  \nPosteriormente, el 09 de agosto de 202 1, el paciente acud i\u00f3 al Servicio de Urgencias \nHospitalarias por  empeoramiento de 4 d\u00edas  de evoluci\u00f3n de  disnea con adecuada \nsaturaci\u00f3n,  episodios de  sensaci\u00f3n de opresi\u00f3n tor\u00e1cica en reposo, edemas en \nmiembros inferiores y oliguria  en relaci\u00f3n con su insuficiencia cardiaca  global (derecha \ne izquierda) . El cuadro se fili\u00f3 como un nuevo episodio de ICC secundario a valvulopat\u00eda \ny fibrilaci\u00f3n auricular.  \nSe decid i\u00f3 ingreso  para balance negativo y realizaci\u00f3n de  ecocardiograma transesof\u00e1gico \npara cuantifica r la insuficiencia  periprot\u00e9sica.  La medicaci\u00f3n  fue conciliada  por el \nfarmac\u00e9utico de Urgencias con el paciente y se proced i\u00f3 a una valoraci\u00f3n i ntegral de la \nfarmacoterapia.  \nTabla 1. Valoraci\u00f3n integral de la farmacoterapia en Urgencias.  \nPROBLEMA DE SALUD  TRATAMIENTO  \nDolor leve en regi\u00f3n lumbosacra por \nmet\u00e1stasis  Tapentadol (Palexia \u00ae) 100 mg  c/12h  \nParacetamol 1g c/8h  \nAdenocarcinoma de pr\u00f3stata avanzado  Tams ulosina/Dutasterida 0,4mg/0,5mg  c/24h en la noche  863\n3 \n Triptorelina  semestral (Decapeptyl \u00ae) 22,5 mg 1  iny c/6 \nmeses  \nAbiraterona  1000  mg en ayunas  + Prednisona 5 mg c/24h  \nS\u00edndrome depresivo  Sertralina 50  mg c/24h  por la ma\u00f1ana  \nICC moderada  Indapamida 2,5 mg /24h por la ma\u00f1ana  \nFA valvular  Acenocumarol  4 mg DTS 19  mg \nTRATAMIENTO EN EL SERVICIO DE URGENCIAS . Adecuado  \nSe prescrib i\u00f3 su tratamiento habitual , pero se suspend i\u00f3 indapamida y se inici\u00f3 furosemida 1 amp \nc/12h y cloruro pot\u00e1sico oral ( Potasion \u00ae) 600 mg 3 c\u00e1ps c/8h.  \nSe confirm \u00f3 con el paciente que la inyecci\u00f3n de Decapeptyl \u00ae fue administrada  hace una semana.  \n \nEn la anal\u00edtica de sangre urgente,  se objetiv\u00f3  hipopotasemia  moderada  (con equilibrio \n\u00e1cido base normal) de 2.9 mEq/L, sin alteraciones electrocardiogr\u00e1ficas, probablemente \nde origen  multifactorial  (paciente con i nsuficiencia cardiaca y activaci\u00f3n del sistema \nrenina -angiotensi na-aldosterona , posible  alteraci\u00f3n del manejo por el ri\u00f1\u00f3n, \ntratamiento prolongado con glucocortic oides, a lo que se a\u00f1ad \u00eda tratamiento d epletivo \nintenso con furosemida) . Aunque inicialmente en Urgencias se inici \u00f3 reposici\u00f3n con \nPotasion \u00ae 600 mg, 2 c\u00e1psulas  cada 8 horas , la potasemia no se normaliz \u00f3, por lo que  se \ninici\u00f3 tratamiento con espironolactona  25 mg c/24h y enalapril 5 mg c/12h.  Con la nueva \nmedicaci\u00f3n prescrita, el farmac\u00e9utico revis\u00f3  las interacciones mediante  Lexicomp \u00ae. En \nese momento, s e detect \u00f3 una interacci\u00f3n de riesgo C entre abiraterona  y \nespironolactona , por la que la es pironolactona pod\u00eda  disminuir la eficacia de la \nabiraterona.  Se coment\u00f3 el caso con el farmac\u00e9utico responsable del \u00e1rea de \nOncohematolog\u00eda, quien consider\u00f3 que conven\u00eda evitar la espironolactona a ra\u00edz de  la \nexperiencia  negativa  en nuestro hospital  con pacientes tratados con abiraterona y \nespironolactona concomitante  [1]. \nFigura 1. Interacci\u00f3n detectada por Lexicomp \u00ae entre abiraterona y espiron olactona  864\n4 \n  \nSe contact \u00f3 con el Servicio de cirug\u00eda card\u00edaca para valorar conjuntamente la necesidad \nde mantener el tratamiento con espironolactona . Las alternativas que se plantearon  \nconjuntamente fueron : \n1. Mantener el tratamiento con espironolactona con el riesgo de comprometer la \neficacia de abiraterona, hasta resoluci\u00f3n de la hipopotasemia  y posterior \nsuspensi\u00f3n . \n2. Valorar cambi o a eplerenona.  \n3. Suspender espironolactona y aumentar los aportes orales de potasio en caso de \nque fuese  necesario.  \nTras comentar el farmac\u00e9uti co el caso con el onc\u00f3logo responsable del paciente, s e opt\u00f3 \npor mantener espironolactona hasta la resoluci\u00f3n de la hipopotasemia , que se logr\u00f3 \nprevio a la cirug\u00eda de re cambio de pr\u00f3tesis  (d\u00eda 20 /08/2021) . Sin embargo, al d\u00eda \nposterior de la cirug\u00eda , se vo lvi\u00f3 a reintroducir  espironolactona , sin que el paciente \npresentara hipopotasemia . En ese momento , se avis \u00f3 para informar de la conveniencia \nde suspender la  espironolactona con vigilancia de los niveles de potasio s\u00e9rico . El 24  de \nagosto de 2021  el pacient e volvi\u00f3  a sufrir hipo potasemia de 2.5 mEq /L, por lo que se \nreinici\u00f3  reposici\u00f3n oral con  Potasion \u00ae oral. El 2 6 de agosto de 2021 se alcanz \u00f3 el objetivo \n865\n5 \n de 3.5 mEq /L que, se mantuvo  el resto de los d\u00edas  sin alteraciones , hasta el alta  y en los \nseguimientos posteriores. En la Tabla 1 se recoge el cronograma del caso cl\u00ednico.  \nTabla 2. Valores anal\u00edticos de potasemia, diuresis, pauta de furosemida y ajustes en la \nterapia para correcci\u00f3n de potasio de nuestro paciente.  \nFecha  K+ \n(mmol/L)  Comentarios  \n09/08/2021  2.7 Reposici\u00f3n con Potasion \u00ae 2 caps c/8h --> durante el d\u00eda aumentan a 3 \nc\u00e1ps c/8h  \n \n10/08/2021  2.4 \u2192 3.5  Se a\u00f1ade enalapril 5 mg c/12h y espironolactona 25 mg c/24h. En la \nnoche del 10/08 al 11/08, la anal\u00edtica muestra mejor\u00eda de la potasemia  \n11/08/2021  3.7 Mantiene tratamiento. Potasion \u00ae 600 mg 2 c\u00e1ps c/8h.  \n12/08/2021  3.3 Aumentan espironolactona a 50 mg, Potasion \u00ae 3 c\u00e1ps c/6h, aumentan \ndosis a furosemida 20 mg/8h endovenosos  \n13/08/2021  - Aumentan enalapril  10 mg c/12h  \n14/08/2021  3.3 \u2192 4.2 Potasion \u00ae 2 caps c/8h  \nEspironolactona igual. Furosemida a v\u00eda oral  \n17/08/2021  3.9 Potasion \u00ae 2 c\u00e1ps c/8h, resto de iones estabilizados  \n19/08/2021  3.5 Potasion \u00ae 2 c\u00e1ps c/8h, resto iones estabilizados  \n20/08/2021  - Cirug\u00eda Re -SVAo  \n21/08/2021  3.9 Reintroducen espironolactona  50 mg c/24h y se avisa para que lo \nsuspendan  \n24/08/2021  2.5 Reinician  Potasion \u00ae 2 c\u00e1ps c/8h  \n25/08/2021  3.5 Correcci\u00f3n de potasemia  \nEl paciente no vuelve a mostrar alteraciones de la potasemia durante su seguimiento  \n \n3. DISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA  \nPresentamos un caso de correcci\u00f3n de  hipopotasemia en un paci ente cardiaco  con \nrestricci\u00f3n de volumen, en tratami ento con abiraterona  m\u00e1s p rednisona  al que se le \nintrodujo e spironolactona  a ra\u00edz de un episodio de insuficiencia cardiaca. Entre estos dos \nf\u00e1rmacos existe una interacci\u00f3n potencial farmacodin\u00e1mica por la que espirono lactona \npuede exhibir propiedades antiandrog\u00e9nicas,  comprometiendo el efecto de la \nespironolactona.  \nEsta hip\u00f3tesis ha sido contrastada  por varios autores a nivel molecular y celular  [2,3] : las \nc\u00e9lulas tratadas con abiraterona y espironolactona c recen m\u00e1s r\u00e1pido que las tratadas \ncon abiraterona solo. Adem\u00e1s , varios autores han reportado posteriormente 866\n6 \n progresiones bioqu\u00edmicas en pacientes que hab\u00edan recibido ambos f\u00e1rmacos  [3,4] . Sin \nembargo, esta interacci\u00f3n no es conocida en la pr \u00e1ctica habitual por la mayor\u00eda de \nprofesionales sanitarios, incluidos onc\u00f3logos y ur\u00f3logos. En este caso, la intervenci\u00f3n \ndel farmac\u00e9utico evit\u00f3 una potencial falta de efectvidad  de un tratamiento oncol\u00f3gico.  \nGracias a la validaci\u00f3n farmac\u00e9utica , se detect \u00f3 una interacci\u00f3n potencial mediante la \nherramienta Lexicomp \u00ae: en un ambiente de deprivaci\u00f3n de andr\u00f3genos, la \nespirnolactona ejerce  efecto ad r\u00f3genicos.  Su trabajo dentro los equipos \nmultidisciplinares (Urgencias y Oncolog\u00eda) permit i\u00f3 realizar un abordaje inmediato y \neficaz del problema detectado. El manejo de esta interacci\u00f3n, aunque clasificada con \nriesgo C, desde nuestra perspectiva, pasa por evitar la concomitancia de \nespironolactona. Aunque el paciente era cardi\u00f3pata y ten\u00eda indicaci\u00f3n de tratamiento \ncon espironolactona  (siempre que la  potasemia no sea superior a 5.0 mEq /L y la \ncreatinina sea inferior a 2.5 mg/dL  [5]), el escenario de concomitancia con abiraterona \ncambia este paradigma. P ara ev itar comprometer la eficacia del antineopl\u00e1sico  creemos \nque resulta  m\u00e1s conveniente abordar estas situaciones con un  aument o de  los aportes \norales de potasio  de forma preferente  (hasta 4 c\u00e1psulas de Potasion cada 8h  =  96 mEq \nde K+, aunque se podr\u00eda n aumentar hasta 128 mEq  [6]), siempre y cuando  se trat e de \nuna hipotasemia moderada (niveles >2.5 mEq /L, sin alteraciones ECG) . En el  caso de que \nno se consiga  restaurar la potasemia  con los aportes orales,  se podr\u00eda optar  a reducir las \np\u00e9rdidas urinarias con un diur\u00e9tico ahorrador de potasio , preferiblemente con \neplerenona, [7] que tiene mejor perfil de interacciones  con abiraterona . En este caso, la  \nopci\u00f3n de suspender la furosemida (probable contribuyente a la hipotasemia) no es \nadecuada , ya que el paciente ten\u00eda edemas y hab\u00eda acudido  por s\u00edntomas de insuficiencia \ncard\u00edaca congestiva . 867\n7 \n Por lo tanto, queremos advertir de que la concomitancia entre espironlactona y \nabiraterona deber\u00eda evitarse siempre que fuese posible. En este caso, la validaci\u00f3n \nfarmac\u00e9utica y la colaboraci\u00f3n con el equipo m\u00e9dico, permiti\u00f3 optimizar el tratamiento \ndel paciente.  \n4. BIBLIOGRAF\u00cdA  \n1.  Vicente -Valor J, Escudero -Vilaplana V, Collado -Borrell R, L\u00f3pez -L\u00f3pez C, Villanueva -\nBueno C, Revuelta -Herrero JL, Ruiz -Briones P, Somoza -Fern\u00e1ndez B, Herranz A, \nSanjurjo M. Potential negative pharmacodynamic interaction of spironolactone and \nabiratero ne in two prostate cancer patients. J Oncol Pharm Pract Off Publ Int Soc \nOncol Pharm Pract. 2022 Jan 17;10781552221074620.  \n2.  Luthy IA, Begin DJ, Labrie F. Androgenic activity of synthetic progestins and \nspironolactone in androgen -sensitive mouse mammary  carcinoma (Shionogi) cells in \nculture. J Steroid Biochem. 1988 Nov;31(5):845 \u201352.  \n3.  Sundar S, Dickinson PD. Spironolactone, a possible selective androgen receptor \nmodulator, should be used with caution in patients with metastatic carcinoma of \nthe prosta te. BMJ Case Rep. 2012 Feb 28;2012:bcr1120115238.  \n4.  Flynn T, Guancial EA, Kilari M, Kilari D. Case Report: Spironolactone Withdrawal \nAssociated With a Dramatic Response in a Patient With Metastatic Castrate -\nResistant Prostate Cancer. Clin Genitourin Can cer. 2017 Feb;15(1):e95 \u20137.  \n5.  de Sequera Ort\u00edz P, Alc\u00e1zar Arroyo R, Albalate Ram\u00f3n M. Nefrolog\u00eda al d\u00eda. \nTrastornos del Potasio. Hipopotasemia. Hiperpotasemia. [Internet]. [cited 2022 May \n14]. Available from: http://www.nefrologiaaldia.org/es -articulo -trastornos -del-\npotasio -hipopotasemia -hiperpotasemia -383 868\n8 \n 6.  Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A. \nHypokalemia: a clinical update. Endocr Connect. 2018 Mar 14;7(4):R135 \u201346.  \n7.  Pitt B, Zannad F. Eplerenone: is it time to add this drug to current heart failure \ntherapy? Ther Adv Chronic Dis. 2012 Jan;3(1):5 \u20139.  \n \n 869Linfoma, la transformaci\u00f3n de folicular a linfoma B de alto grado triple HIT  \nINTRODUCCI\u00d3N  \nEl linfoma folicular (LF) es un subtipo de linfoma no Hodgkin indolente considerado una \nenfermedad incurable y cr\u00f3nica con una incidencia de 5/100.000 habitantes y una \nsupervivencia media de 20 a\u00f1os. Para conocer el estadio de la enfermedad son \nnecesarias pruebas de imagen como PET/TC y otras pruebas a partir de una biopsia para \ndeterminar la morfolog\u00eda, inmunohistoqu\u00edmica o citogen\u00e9tica. Se debe valorar el grado \nhistol\u00f3gico y la extensi\u00f3n tumoral a la hora de decidir tratamiento. \u00c9ste se puede \nretrasar has ta la aparici\u00f3n de criterios de alta carga tumoral, al no haberse demostrado \nque un tratamiento precoz aumente la supervivencia a largo plazo. Si el LF es localizado, \nla radioterapia puede ser una opci\u00f3n; en cambio, en estadios avanzados, generalmente \nse utilizan esquemas de inmunoquimioterapia. Los esquemas m\u00e1s habituales en nuestro \nentorno suelen ser esquemas tipo R -CHOP o R -bendamustina seguidos de rituximab de \nmantenimiento.  \nEl curso cl\u00ednico del LF se caracteriza por m\u00faltiples reca\u00eddas y remisiones tras  el \ntratamiento. Hasta el 10% de los LF a los 5 a\u00f1os y el 40% a los 10 a\u00f1os sufren una \ntransformaci\u00f3n secundaria a una entidad histol\u00f3gica m\u00e1s agresiva y con peor \npron\u00f3stico, principalmente linfoma B difuso de c\u00e9lulas grandes (LDCGB).  \nSe expone un caso cl\u00ed nico cuyo inter\u00e9s radica en evidenciar la importancia de que el \nfarmac\u00e9utico forme parte de los comit\u00e9s multidisciplinares  donde se  toma n las \ndecisiones sobre  el tratamiento m\u00e1s adecuado para  cada paciente , y tambi\u00e9n d el \nposterior seguimiento farmac\u00e9utico proponiendo medidas para optimizar  el \ntratamiento . 870DESCRIPCI\u00d3N DEL CASO  \nSe describe el caso cl\u00ednico de una mujer de 59 a\u00f1os aut\u00f3noma para las actividades de la \nvida diaria que presenta las siguientes patolog\u00edas cr\u00f3nicas: diabetes mellitus tipo 2, \ndislipemia, hipotiroidismo, reflujo gastroesof\u00e1gico, glaucoma, lumbalgia y artros is; para \nlo que recibe tratamiento con metformina, insulina glargina, rosuvastatina, levotiroxina , \nlansoprazol, latanoprost, paracetamol + tramadol, duloxetina y calcifediol.  \nEn septiembre del 2016 fue derivada al servicio de hematolog\u00eda para el estudio de  \nadenopat\u00edas abdominales. Tras el estudio morfol\u00f3gico, inmunohistoqu\u00edmico y \ncitogen\u00e9tico se diagnostic\u00f3 de s\u00edndrome linfoproliferativo compatible con LF en estadio \nIV-A (afectaci\u00f3n infradiafragm\u00e1tica poco voluminosa, espl\u00e9nica y de m\u00e9dula \u00f3sea  sin \ns\u00edntomas  B) seg\u00fan la escala de estadiaje de Ann Arbor , que se mantuvo con buen control \nsin tratamiento hasta octubre del 2020. Fue en este momento cuando la paciente refiri\u00f3 \nsintomatolog\u00eda diversa como astenia, anorexia o dolor de la esc\u00e1pula y se evidenci\u00f3 \nmedian te TAC el aumento de tama\u00f1o de las adenopat\u00edas mesent\u00e9ricas y \nretroperitoneales en contexto de s\u00edndrome linfoproliferativo. En noviembre se realiz\u00f3 \nuna biopsia, con hallazgos tras el estudio morfol\u00f3gico, inmunohistoqu\u00edmico y \ncitogen\u00e9tico (FISH) de linfoma no Hodgkin de alto grado e inmunofenotipo B con \nreordenamientos de BCL6 (3q27), BCL2 (18q21) y MYC (8q24), confirm\u00e1ndose la \ntransformaci\u00f3n del LF a un linfoma B de alto grado triple HIT.  \nAnte la situaci\u00f3n de la paciente se decidi\u00f3  iniciar tratamiento de u rgencia con el \nesquema R- CHOP  (rituximab, ciclofosfamida, doxorubicina, vincristina y prednisona) . A \nla semana siguiente al inicio del tratamiento, el caso fue presentado en el comit\u00e9 de \nlinfomas, proponiendo como plan de tratamiento R -CHOP (6 ciclos) + metotrexate a 871altas dosis  (MTX_AD)  (3 ciclos). El farmac\u00e9utico onco -hematol\u00f3gico miem bro del comit\u00e9 \nde linfomas, dado  el inmunofenotipo histol\u00f3gico  del linfoma (linfoma folicular \ntransformado a linfo ma B de alto grado triple hit) aconsej\u00f3 , en consonancia con  los \nprotocolos de tratamiento establecidos en nuestro centro , tratamiento con R -EPOCH -\nDA en lugar de R -CHOP , junto a la profilaxis de infiltraci\u00f3n en el sistema nervioso central \n(SNC) con MTX_AD . La propuesta fue aceptada y  la paciente continu\u00f3  tratamiento con \ndicho esquema (ver Tabla 1) . \n \n \n \n \n \n \n \nAl inicia r el segundo ciclo, en la validaci\u00f3n  farmac\u00e9utica  se detect \u00f3 que l a paciente hab\u00eda \ntenido  una infecci\u00f3n  de virus de la hepatitis B (VHB)  que se hac\u00eda patente  en una \nserolog\u00eda del 2018 con anticuerpos anticore del VHB  positivos  y ant\u00edgenos de superficie \ndel VHB negativos  (ver T abla 2) . Por lo que se recomend\u00f3 instaurar profilaxis  infecciosa \nfrente al VHB con tenofovir disoproxilo 245 mg/24h y mantenerla durante  los 12 meses \nposteriores al fin del tratamiento.  \n \nTabla 1  872PAR\u00c1 METRO ANAL\u00cdTICO - VHB  RESULTADO  INTERPRETACI\u00d3N  \nAnticuerpos anticore  > 8 mUI/mL  Positivo  > 0,5 mUI/mL  \nAnt\u00edgenos de superficie  < 0,1 mUI/mL  No reactivo  < 1mUI/mL  \n \nHasta este momento, la paciente toler\u00f3 bien el tratamiento y se continu\u00f3 escalando \ndosis. Inici\u00f3 el tercer ciclo con R-EPOCH -DA (nivel 3),  cuya dosis de ciclofosfamida es \n1.080 mg/m2. Aunque no todas las gu\u00edas lo recomiendan, desde farmacia, en base a las \nrecomendaciones dictadas por BC Cancer , se recomend\u00f3 la prescripci\u00f3n de MESNA, \njunto con una hidrataci\u00f3n adecuada, para evitar una posible cistitis hemorr\u00e1gica . \nA pesar de estar recuperada hematol\u00f3gicamente, la paciente refer\u00eda debilidad y \ncansancio , motivo por el cual no se pudo realizar la profilaxis de SNC con MTX -AD \ndurante  la administraci\u00f3n de los ciclos de quimioterapia, decidi\u00e9ndose administrar dos \nciclos de metotrexato v\u00eda intratecal y completar la profilaxis con MTX_AD  una vez \nfinalizados  todos los ciclos de R- EPOCH -DA. A partir del ciclo 4 se desescal\u00f3 el R -EPOCH -\nDA a nivel 2.  La paciente finaliz\u00f3 de esta manera el tratamiento en j unio del 2021 con \nbuena evoluci\u00f3n .  En Julio de ese mismo a\u00f1o, se confirm\u00f3  que hab\u00eda alcanzado remisi\u00f3n  \ncompleta  y la transformaci\u00f3n del linfoma de alto grado en un linfoma de bajo grado , \nencontr\u00e1ndose  en esta situaci\u00f3n a ctualmente . \nDISCUSI\u00d3N Y APORTACI\u00d3N FARMAC\u00c9UTICA \nLa indicaci\u00f3n correcta del tratamiento es un aspecto clave en la consecuci\u00f3n de los \nobjetivos terap\u00e9uticos. La visi\u00f3n aportada por un farmac\u00e9utico cl\u00ednico es fundamental Tabla 2 873en la toma de decisiones terap\u00e9uticas a la hora de tratar de manera adecuada a nuestro s \npacientes e individualizar el tratamiento. Esto pone de manifiesto  la necesidad de \nincorporar los en los comit\u00e9s onco -hematol\u00f3gicos, lugar y momento de la toma de \ndecisiones sobre la estrategia terap\u00e9utica a seguir . \nAtendiendo a la adecuaci\u00f3n del esquema prescrito en el caso expuesto, un porcentaje \nsignificativo de LF sufren transformaci\u00f3n a un linfoma m\u00e1s agresivo. En dichos casos la \nestrategia terap\u00e9utica cambia y debe enfocarse al manejo de la histolog\u00eda transformada. \nEl esquema R -CHOP es el tratamiento  de elecci\u00f3n en estadios avanzados de LF y tambi\u00e9n \nel tratamiento est\u00e1ndar de LDCGB.  Pero cuando el linfoma presenta  un reordenamiento \ndel gen MYC, BCL -2 y BCL -6, tambi\u00e9n llamado linfoma triple HIT, se considera un linfoma \nagresivo de evoluci\u00f3n r\u00e1pida que  suele ser refractario a la inmunoquimioterapia \nconvencional . Debido al mal pron\u00f3stico de este tipo de pacientes, se recomienda el \ntratamiento con esquemas de inmuno quimioterapia basada en pautas m\u00e1s intensiva s \ntipo R -EPOCH -DA o esquemas utilizados en el tratamiento de linfoma de Burkitt en \nfunci\u00f3n de la edad y las caracter\u00edsticas del paciente. Dado el riesgo de infiltraci\u00f3n del \nSNC se recomienda realizar profilaxis  con metotrexato intratecal o intravenoso  a altas \ndosis . Por ell o, cuando los LF progresan o recaen es muy importante, siempre que sea \nposible, realizar una biopsia para valorar si se ha transformado, ya que, el enfoque \nterap\u00e9utico debe cambiar y ajustarse a la histolog\u00eda del linfoma en que se haya \ntransformado.  \nLa aportaci\u00f3n farmac\u00e9utica no se ci\u00f1e exclusivamente a la indicaci\u00f3n  correcta  del \ntratamiento, sino que tambi\u00e9n es fundamental  un seguimiento farm acoterap\u00e9utico \nadecuado de los pacientes , prestando especial  atenci\u00f3n a la necesidad de incluir 874determinada medicaci\u00f3n de soporte en el plan farmacoterap\u00e9utico del mismo .  Alguna \nde esta medicaci\u00f3n habitualmente est\u00e1 incluida en los esquemas antineopl\u00e1sicos ( por \nejemplo, los antiem\u00e9ticos)  pero en otras ocasiones es necesario atender a las \ncaracter\u00edsticas concret as de cada paciente. En este sentido, es importante tener en \ncuenta que la  administraci\u00f3n de tratamientos inmunosupresores se relaciona con riesgo \nde reactivaci\u00f3n de VHB, especialmente en pacientes portadores inactivos o con \ninfecciones pasadas. Los pacien tes hematol\u00f3gicos con linfoma tienen un riesgo mayor. \nEn los pacientes con infecci\u00f3n VHB pasada (HBsAg -, HBcAb+), que vayan a recibir \ntratamientos asociados a un elevado riesgo de reactivaci\u00f3n , como es el caso del \nrituximab, un anticuerpo anti -CD20 ; se recomienda instaurar profilaxis antiviral durante \nla quimioterapia y mantener la al menos durante 12 meses despu\u00e9s de finalizar la terapia \ninmunosupresora. Los f\u00e1rmacos recomendados son tenofovir o entecavir , seg\u00fan la \nfunci\u00f3n renal, el tipo de quimioterapia pl anificada y el estado cl\u00ednico del paciente. En el \ncaso de nuestra paciente, ten\u00eda riesgo de reactivaci\u00f3n de VHB y la actuaci\u00f3n del \nfarmac\u00e9utico hizo que se instaurara la profilaxis adecuada.  \nUna de las posibles toxicidades a tener en cuenta en el caso de la ciclofosfamida es la \ncistitis hemorr\u00e1gica , producida por acci\u00f3n directa de metabolitos t\u00f3xicos, especialmente \nacrole\u00edna en la vejiga.  Aunque  muchos autores consideran que el riesgo de desarrollar \ncistitis hemorr\u00e1gica con dosis < 2 g/m2 de ciclofosfamida es bajo, algunos organismos \nrecomiendan la utilizaci\u00f3n de MESNA junto con hidrataci\u00f3n adecuada en el caso del \nesquema R- EPOCH -DA a partir del nivel 3.   \nEl esquema de tratamiento R -EPOCH -DA es un esquema complejo que requiere una \ncuidados a validaci\u00f3n farmac\u00e9utica. Se trata de un esquema con dosis ajustadas de los 875medicamentos en funci\u00f3n del nadir . En la validaci\u00f3n farmac\u00e9utica adem\u00e1s de los \naspectos relativos a la indicaci\u00f3n o nivel de dosis adecuado en funci\u00f3n del nadir, se debe \nconsidera r otros aspectos tales como la funci\u00f3n  cardiac a, funci\u00f3n hep\u00e1tica, funci\u00f3n \nrenal, toxicidad urol\u00f3gica,  hemograma , profilaxis de lisis t umoral, antiem\u00e9tica, \ninfecciosa o  prevenci\u00f3n de reacciones infusionales de rituximab . El caso muestra la \ntranscendencia d e asumir las competencias cl\u00ednicas para las que estamos capacitados \nlos farmac\u00e9uticos hospitalarios, con la participaci\u00f3n en el lugar y momento en el que se \ntoman las decisiones terap\u00e9uticas ante pacientes concretos, compartiendo objetivos \nterap\u00e9uticos y c ontribuyendo al seguimiento de los resultados junto con el resto del \nequipo asistencial. La pertenencia a equipos multidisciplinares  no jerarquizados como \nun comit\u00e9, permite al farmac\u00e9utico llevar a cabo el cambio conceptual de la farmacia \nhospitalaria tan  deseado por nuestro colectivo, anticip\u00e1ndonos y actuando junto con el \nresto del equipo cl\u00ednico. Tambi\u00e9n es esencial la validaci\u00f3n farmac\u00e9utica integral y una \nactitud proactiva en la toma de decisiones en relaci\u00f3n con el tratamiento de los \npacientes, poniendo de relieve la importancia de anticiparse con recomendaciones \nsobre medicaci\u00f3n  de soporte , para tratar de evitar posibles reacciones adversas o \ncomplicaciones. Aunque a veces seamos pocos y las actuaciones no sean del todo \nreconocidas, no por ello dejan de ser relevantes y necesarias. El papel del farmac\u00e9utico \ncl\u00ednico debe estar a l a altura de las exigencias de nuestros pacientes; y para ello, una \nvalidaci\u00f3n farmacoterap\u00e9utica de calidad es clave.  \nBIBLIOGRAF\u00cdA  \n 876\uf0b7 ICO-ICSpraxis para el tratamiento m\u00e9dico con irradiaci\u00f3n de linfoma B difuso de \nc\u00e9lula grande. En:  http://ico.gencat.cat/web/.content/minisite/ico/professionals/ \ndocuments/arxius/ICOPraxiLimfomacastellanodef2019.pdf . Consultado mayo 2021.  \n\uf0b7 ICO-Protocol de tractament de linfoma fol\u00b7licular. Institut Catal\u00e0 d\u2019Oncologia. \nNoviembre 2019.  \n\uf0b7 Validaci\u00f3n farmac\u00e9utica de la prescripci\u00f3n del pacient e oncohematol\u00f3gico. GEDEFO. \nEn:https://gruposdetrabajo.sefh.es/gedefo/images/stories/documentos/2016/gede\nfovalidacionfarmaceuticaprescripcionversionimpresion.pdf . Consultado mayo 2021.  \n\uf0b7 Albert Mar\u00ed, A. M\u00f3dulo 2: Linfoma. C urso de formaci\u00f3n oncohematol\u00f3gica - GEDEFO.  \n\uf0b7 BCCancer protocol summary for treatment of lympho ma with dose -adjusted \netoposide  doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab \nwith intrathecal methotrexate. En: http://www.bccancer.bc.ca/chemotherapy -\nprotocols -site/Documents/Lymphoma -Myeloma/LYEPOCHRProtocol.pdf . \nConsultado mayo 2021.  \n\uf0b7 Delgado Sanchez, O. La capa de az\u00facar,  una visi\u00f3n de la farmacia hospitalaria en el \na\u00f1o 2020. OFIL -ILAPHAR 2019, 29;3:171.  \n\uf0b7 Dunleavy K, Fanale MA, Abramson JS, et al. Dose -adjusted EPOCH -R (etoposide, \nprednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated \naggressive diffuse large B -cell lymphoma with MYC rearrangement: a prospective, \nmulticentre, single -arm phase 2 study. Lancet Haematol. 2018 . Dec;5(12):e609 -e617.  \n\uf0b7 Barrans S, Crouch S, Smith A, et al.  Rearrangement of MYC is associated with poor \nprognosis in patient s with diffuse large B -cell lymphoma treated in the era of rituximab. \nJ Clin On col. 2010 Jul 10;28(20):3360 -5. 877Introducci\u00f3n: \nLa fibrilaci\u00f3n auricular es la arritmia cardiaca cr\u00f3nica m\u00e1s frecuente y se calcula que \nafecta a un 1-2% de la poblaci\u00f3n. Esta patolog\u00eda incrementa el riesgo de ictus y \nembolia. El tratamiento farmacol\u00f3gico se basa en el uso de antiarr\u00edtmicos para lo que \nse usan betabloqueantes, antagonistas de los canales de calcio y digoxina. Para reducir \nel riesgo de accidentes emb\u00f3licos es necesario a\u00f1adir al tratamiento anticoagulantes \norales.1 \nActualmente disponemos de anticoagulantes orales directos como el inhibidor directo \nde la trombina dabigatr\u00e1n etexilato que demostr\u00f3 un beneficio-riesgo favorable en la \nprevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con fibrilaci\u00f3n auricular no \nvalvular.  \nEl dabigatr\u00e1n est\u00e1 indicado, entre otras, en la prevenci\u00f3n del ictus y de la embolia \nsist\u00e9mica en pacientes adultos con fibrilaci\u00f3n auricular no valvular con uno o m\u00e1s \nfactores de riesgo tales como ictus o ataque isqu\u00e9mico transitorio en pacientes con \nedad igual o superior a 75 a\u00f1os, insuficiencia cardiaca, diabetes mellitus, hipertensi\u00f3n. \n2 Esta indicaci\u00f3n deriva principalmente del estudio pivotal RE-LY, un ensayo \nmultic\u00e9ntrico, aleatorizado, abierto, comparativo frente a dosis ajustadas de warfarina \npara un INR ajustado entre 2-3. 2 \n La dosis recomendada para esta indicaci\u00f3n es 300mg repartidos en dos dosis de \n150mg cada 12h, con ajuste de dosis a 220mg (110mg cada 12 h) en pacientes con \ninsuficiencia renal.  \n 878Descripci\u00f3n del caso: \nVar\u00f3n de 75 a\u00f1os exfumador. Como antecedentes cardiovasculares presenta \ncardiopat\u00eda isqu\u00e9mica con un episodio de infarto agudo de miocardio hace 10 a\u00f1os con \nrevascularizaci\u00f3n percut\u00e1nea de coronaria derecha, actualmente tiene disfunci\u00f3n \nmoderada del ventr\u00edculo izquierdo, fibrilaci\u00f3n auricular, diabetes mellitus, hipertensi\u00f3n \narterial y dislipidemia. En 1999 enfermedad de Hodgkin, actualmente en seguimiento \npor hematolog\u00eda. En 2017 se le realiz\u00f3 un tratamiento de resincronizaci\u00f3n cardiaca \n(TRC) y en enero de este mismo a\u00f1o cambio a marcapasos de estimulaci\u00f3n fisiol\u00f3gica \npor disfunci\u00f3n. Se trata de un paciente complejo de edad avanzada polimedicado, en \ntratamiento farmacol\u00f3gico para sus distintas patolog\u00edas y dabigatran 110mg/12h para \nla fibrilaci\u00f3n auricular como profilaxis anticoagulante. El tratamiento domiciliario del \npaciente era al ingreso: eplererona 25mg/24h, metformina 850mg/12h, insulina lantus \n28UI/24h, epaglifozina 10mg, pitavastatina 2mg/24h, bisoprolol 2.5mg/24h y \ndabigatran con la pauta descrita.  \n \nEl 4 de marzo de 2022 acude al Servicio de Urgencias de nuestro centro por \nempeoramiento de su disnea basal de una semana de evoluci\u00f3n. El paciente \npresentaba edemas en MMII a pesar de tratamiento con diur\u00e9ticos orales. En la \nexploraci\u00f3n m\u00e9dica no toleraba dec\u00fabito y presentaba disnea al habla, con leves \nedemas con f\u00f3vea maleolares. En la anal\u00edtica de urgencias destacaba creatinina s\u00e9rica \n1.7mg/ml, filtrado glomerular de 42ml/min, urea 92mg/dl. Hb 10.3g/dl, plaquetas \n111000 y TTPA 61.4s. 879Tras el diagnostico ingres\u00f3 por insuficiencia cardiaca descompensada con derrame \npleural a cargo del Servicio de Cardiolog\u00eda. Se solicita un TC de t\u00f3rax para confirmar el \nderrame pleural, el cual parece de etiolog\u00eda cr\u00f3nica siendo conocido por el servicio de \nNeumolog\u00eda desde agosto de 2020. \n  Durante el ingreso en planta se reforz\u00f3 el tratamiento antidiur\u00e9tico presentando \nbuena respuesta, se realiz\u00f3 interconsulta a Neumolog\u00eda y el d\u00eda 11 de marzo tras 8 d\u00edas \nde ingreso se decide alta por estabilidad cl\u00ednica, eliminaci\u00f3n de edemas MMII y buena \ndiuresis. En el informe de alta se deriva a consultas externas de Neumolog\u00eda para el \ncontrol del derrame pleural. Durante el ingreso en la anal\u00edtica destacaba creatinina \ns\u00e9rica 1.89mg/ml, filtrado glomerular de 37ml/min, urea 129mg/dl. Hb 10.3g/dl y TTPA \n61.4s. \nAl alta domiciliaria se concilia el tratamiento farmacol\u00f3gico manteni\u00e9ndose su \ntratamiento habitual incluido dabigatran 110mg/12h. El 30 de marzo el Servicio de \nUrgencias de su centro de salud acude a su domicilio por continuar con la disnea, tos y \nmocos. En la exploraci\u00f3n medica destaca sat. O2 93% y TA: 100/75, y se le prescribe \nazitromicina 500mg 1 comprimido cada 24h durante 3 d\u00edas. \n \n880El 1 de abril de 2022 el paciente vuelve a acudir a urgencias trasladado por el DDCU \npor rectorragia abundante de dos d\u00edas de evoluci\u00f3n.  El paciente llega con mucosas \nnormohidratadas, pero palidez cut\u00e1nea. Afebril, eupneico en reposo con saturaci\u00f3n de \nO2 de 98%, abdomen blando y depresible, sin dolor a la palpaci\u00f3n, no se palpan \nmegalias, ni masas. Tras el tacto rectal se presencia sangre roja en dedil y restos de \nheces verdosas. Niega mareo y sudoraci\u00f3n. Tras realizarse el cribado por el Servicio de \nUrgencias ingresa en Observaci\u00f3n donde presenta tendencia a la hipotensi\u00f3n que \nremonta con sueroterapia y se diagnostica de Hemorragia Digestiva Baja secundaria a \ndabigatran.  \nEn la anal\u00edtica de urgencias destaca: creatinina s\u00e9rica 3.72mg/ml, filtrado glomerular \nde 17ml/min, urea 275mg/dl. Hb 8.1g/dl y TTPA 82.1s. \nDesde el servicio de Urgencias contactan con el servicio de Farmacia para solicitar la \ndispensaci\u00f3n de idarucizumab por sangrado abundante para revertir la acci\u00f3n del \ndabigatran.   \nTras el an\u00e1lisis del caso y el estudio de las interacciones farmacol\u00f3gicas desde el \nServicio de Farmacia se alert\u00f3 de la posible interacci\u00f3n medicamentosa entre \ndabigatran y azitromicina como causa de la hemorragia digestiva, agravada por la \ninsuficiencia renal del paciente. \nDesde el Servicio de Farmacia hicimos una revisi\u00f3n exhaustiva de la medicaci\u00f3n del \npaciente y se analiz\u00f3 detenidamente el caso, inform\u00e1ndose de la interacci\u00f3n al equipo \nm\u00e9dico v\u00eda telef\u00f3nica. El m\u00e9dico responsable suspendi\u00f3 la prescripci\u00f3n de azitromicina \ny dejo constancia en la historia cl\u00ednica del paciente la causa de la hemorragia.  881El d\u00eda 2 de abril (tras 48h de ingreso en Observaci\u00f3n), se procede al alta por estabilidad \ncl\u00ednica del paciente. \n \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica: \nEl presente caso describe una interacci\u00f3n medicamentosa de gravedad moderada 3  \n4entre azitromicina y dabigatran, cuya importancia cl\u00ednica aumentan en pacientes con \ndisminuci\u00f3n de la funci\u00f3n renal, por lo que esta combinaci\u00f3n debe evitarse en \npresencia de funci\u00f3n renal reducida.  \n  El manejo cl\u00ednico de la interacci\u00f3n precis\u00f3 de tratamiento con el ant\u00eddoto especifico \nidarucizumab, f\u00e1rmaco indicado para la reversi\u00f3n del efecto anticoagulante de \ndabigatran en caso de hemorragias potencialmente mortales.5 \nEl dabigatran se presenta en capsulas para administraci\u00f3n oral en forma de \nprof\u00e1rmaco, dabigatran etexilato, que se transforma por hidrolisis r\u00e1pidamente en su \nforma activa cuyo mecanismo de acci\u00f3n es la inhibici\u00f3n potente, directa y reversible de \nla trombina. Esta enzima tiene como funci\u00f3n fisiol\u00f3gica principal el mantenimiento de \nla hemostasia, teniendo un papel clave en la formaci\u00f3n del trombo.6 882 \nEl f\u00e1rmaco alcanza su concentraci\u00f3n m\u00e1xima en 2h tras la administraci\u00f3n, con un \ntiempo de semivida plasm\u00e1tica de 14h. Su eliminaci\u00f3n es fundamentalmente a nivel \nrenal elimin\u00e1ndose casi inalterado por la orina, de manera que la insuficiencia renal \npuede inducir a un aumento de las concentraciones del f\u00e1rmaco. Es sustrato de la \nglicoprote\u00edna P (prote\u00edna transportadora de membrana cuya funci\u00f3n principal es la de \nexcretar sustancias que el organismo considera nocivas hacia la luz intestinal) \npudiendo interaccionar con inhibidores de dicho transportador. \nLa azitromicina es un inhibidor directo de la glicoprote\u00edna P/ABCB1 por lo que puede \naumentar las concentraciones s\u00e9ricas de los metabolitos activos de etexilato de \ndabigatr\u00e1n. 3De este modo cuando se administran de manera concomitante dabigatran \ny azitromicina, \u00e9sta disminuye sustancialmente la eliminaci\u00f3n del f\u00e1rmaco conllevando \na un aumento de la concentraci\u00f3n en sangre y consecuentemente a un aumento del \nriesgo de sangrado y hemorragia. Adem\u00e1s, en el presente caso el paciente ten\u00eda \ninsuficiencia renal asociada lo que influy\u00f3 un el aumento de la concentraci\u00f3n de \ndabigatran produciendo hemorragia mayor. \n883El efecto adverso asociado al uso del f\u00e1rmaco m\u00e1s com\u00fan es el sangrado, \nclasific\u00e1ndose como sangrado mayor: hemorragias intracraneales, gastrointestinales y \nsangrado mortal, y sangrado menor: aquellos casos en los que la hemorragia es menos \nintensa. El riesgo de hemorragia aumenta a su vez en situaciones en las que la funci\u00f3n \nrenal es menor y con el uso concomitante de ciertos medicamentos. En situaciones en \nlas que se produce una hemorragia mayor o la situaci\u00f3n cl\u00ednica del paciente lo requiera \nla acci\u00f3n del dabigatran puede revertirse de forma r\u00e1pida con un ant\u00eddoto espec\u00edfico, \nel idarucizumab. 2 \n  \nCon el objetivo de evitar efectos adversos de significancia mayor es d e especial \nrelevancia que esta interacci\u00f3n quede reflejada en los sistemas de alarma de \nprescripci\u00f3n electr\u00f3nica tanto de los sistemas de uso hospitalario como en los \nutilizados en atenci\u00f3n primaria, as\u00ed como en las distintas gu\u00edas del manejo de \nanticoagulantes orales de acci\u00f3n directa. A su vez, consideramos importante darle luz a \neste tipo de interacciones graves, ya que como por ejemplo en nuestro caso la \ninteracci\u00f3n producida por ambos f\u00e1rmacos no se encuentra recogida en algunas de las \nbases de datos que habitualmente se consultan en la pr\u00e1ctica cl\u00ednica. \n \nNuestro caso es un claro ejemplo de la importancia de detecci\u00f3n y notificaci\u00f3n por \nparte del Servicio de Farmacia de interacciones producidas como consecuencia de la \nadministraci\u00f3n concomitante de medicamentos para una correcta farmacovigilancia, \nas\u00ed como el papel del farmac\u00e9utico hospitalario en la conciliaci\u00f3n del tratamiento tanto \nal ingreso como al alta domiciliaria de los pacientes.  \n 884Bibliograf\u00eda \n1.  Fibrilaci\u00f3n C, Factores AY, Riesgo DE, Adicionales T. Criterios y recomendaciones \ngenerales para el uso de los anticoagulantes orales directos (ACOD) en la \nprevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con fibrilaci\u00f3n auricular \nno valvular.  \n2.  FICHA TECNICA PRADAXA 110 mg CAPSULAS DURAS [Internet]. [cited 2022 May \n4]. Available from: \nhttps://cima.aemps.es/cima/dochtml/ft/08442005/FT_08442005.html \n3.  Lexicomp\u00ae Drug Interactions - UpToDate [Internet]. [cited 2022 May 11]. \nAvailable from: https://www-uptodate-com.bvsspa.idm.oclc.org/drug-\ninteractions/?source=responsive_home#di-document \n4.  Drug Interaction Report - Drugs.com [Internet]. [cited 2022 May 13]. Available \nfrom: https://www.drugs.com/interactions-check.php?drug_list=3266-0,300-0 \n5.  Informe de Posicionamiento Terap\u00e9utico de idarucizumab (Praxbind\u00ae) como \nant\u00eddoto espec\u00edfico para revertir el efecto anticoagulante de dabigatr\u00e1n en \nsituaciones de urgencia.  \n6.  Generalidades del sistema de la coagulaci\u00f3n y pruebas para su estudio \n[Internet]. [cited 2022 May 11]. Available from: \nhttp://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0535-\n51332015000400010 \n  \n 885SINDROME DE FUGA CAPILAR (E NFERMEDAD DE  CHARLSON) POST -VACUNA EN \nPACIENTE COVID -19 POSITIVO  \nPalabras clave :  \n1. S\u00edndrome de fuga capilar sist\u00e9mico  \n2. SARS- Cov2  \n3. Vacunaci\u00f3n covid -19 \nIntroducci\u00f3n   \nEl s\u00edndrome de fuga capilar sist\u00e9mico (SFCS) es un raro trastorno  inmunol\u00f3gico de \netiolog\u00eda desconocida. Se caracteriza por episodios frecuentes de hipotensi\u00f3n severa, \nhipoalbuminemia y hemoconcentraci\u00f3n. Esta caracter\u00edstica triada es consecuencia  de \nun au mento de la permeabilidad en el endotelio vascular que producen una \nextravasaci\u00f3n, desde los capilares sangu\u00edneos hacia el espacio intersticial, de plasma y \nprote\u00ednas.  \nEs una enfermedad infrecuente  (con una prevalencia estimada de menos de 250 casos \nen el mundo)  que suele confundirse en el diagnostico con sepsis o hipoalbuminemia.   A \nra\u00edz de la pandemia originada por el virus S ARS-Cov2 (enfermedad de Covid -19) se ha \nobservado un aumento en el n\u00famero de casos cl\u00ednicos reportados secundarios tanto a \nla infec ci\u00f3n v\u00edrica como a la vacunaci\u00f3n.   \nEn cuanto al manejo inicial de este tipo de paciente  las recomendaciones se basan en:  \nestabiliza r inicialmente la v\u00eda a\u00e9rea (oxigenoterapia m\u00e1s intubaci\u00f3n), controla r el \nbalance h\u00eddrico (entradas y salidas de volumen , valorar necesidad de diur\u00e9ticos de asa ), \nmonitorizar la presi\u00f3n sangu\u00ednea (valora r inicio de fluidoterapia y f\u00e1rmacos 886vasopresores), observ ar la presencia o ausencia  de edema pulmonar  y utilizar  \ntratamiento farmacol\u00f3gico para la resoluci\u00f3n de la fase aguda como   infusi\u00f3n \nintravenosa de  Inmunoglobulina G  (Ig G)  dosis de 1 g/kg al d\u00eda durante 2 d\u00edas  \nM\u00e9todo  \nEl paciente fue evaluado en primera instancia por los servicios de urgencias, medicina \nintensiva  y medicina interna (inmunolog\u00eda) de un Hospital Universitario de 450 camas  \n(terciario) .  \nEste caso cl\u00ednico se ha redactado siguiendo las directrices del CARE guidelines for case \nreports . \nCaso cl\u00ednico  \nPaciente de 66 a\u00f1os  obeso (123 Kg), con antecedentes m\u00e9dicos de hipertensi\u00f3n arterial \ny Diabetes Mellitus tipo II, vacunado con las dos dosis de  Vaxzevria  (ChAdOx1 -S \nrecombinante  - vacuna frente a la COVID -19 de AstraZeneca \u00ae).  \nAcude a urgencias , derivado de atenci\u00f3n primaria por seguimiento de tres d\u00edas de \nevoluci\u00f3n tras  RT-PCR positiva  (frotis nasofar\u00edngeo)  por contacto estrecho , con los \nsiguientes s\u00edntomas : fiebre termometrada de 38\u00ba , artromialgias , cefalea,  astenia y ligera \ndisnea. Durante las 24 horas iniciales sufre cinco episodios de sincope vasovagal.  \nEn la primera an al\u00edtica realizada impresiona  de: hemoconcentraci\u00f3n en recuento de \nc\u00e9lulas sangu\u00edneas ( Hemoglobina  21.9 g/dl, hema tocrito  63% ), insuficiencia renal aguda \n(Creatini na 1,8 mg/ dl, fitrado  Glomerular  38 ml/min /1,73 m2), acidosis l\u00e1ctica ( pH 7,27, \nlactato 5.1  mmol/L) , hiperglucemia ( BM test 500 unids ), y D\u00edmero  D 2835 unid , con \nenzimas hep\u00e1ticas normales . En cuanto a las c onstantes vitales sugieren progresi\u00f3n 887hacia shock con hipo tensi\u00f3n arterial  sist\u00e9micas de 70 mmHg y frecuencia cardiaca de \n110 lpm. \nSe inicia el manejo cl\u00ednico para su estabilizaci\u00f3n en la Unidad de Cuidados Intensivos \n(UCI) con las siguientes medidas:  \n\u2022 Se intuba al paciente conect\u00e1ndolo a ventilaci\u00f3n mec\u00e1nica manteniendo una \nsaturaci\u00f3n de ox\u00edgeno ( SpO2 ) del 98%.  \n\u2022 Se perfunde suero salino fisiol\u00f3gico  0,9% (SF) a 15 ml/kg , a pesar de lo cual \npersiste la hipovolemia (adem\u00e1s de alb\u00famina IV 10 g cada 8h ). Requiere  de \nvasopresores inotr\u00f3picos Noradrenalina  a 2,1 m cg/kg/min .  \n\u2022 Terapia de reemplazo renal continua  (TRRC)  en modo hemodiafiltraci\u00f3n veno -\nvenosa continua ( HDFVVC ). \n\u2022 Ante sospecha de posible shock s\u00e9ptico, se inicia antibioterapia de amplio \nespectro de manera emp\u00edrica con Piperacilina -tazobactam 4,5 g cada 6 horas.  \n\u2022 Debido a glucemias altas y cetoacidosis,  se a\u00f1ade al tratamiento bomba de \ninfusi\u00f3n continua (BIC) de insulina (100 UI insulina en 100 ml de SF \u21921 ml = 1 UI \ninsulina).  \nTras 48 horas de estancia  en UCI se sospecha de SFC S realiz\u00e1ndose  inter consulta  con \nmedicina interna  (secci\u00f3n de enfermedades autoinmunes) , se solicitan anal\u00edticas \nespec\u00edficas  de s\u00edndromes mieloproliferativos  (Mutaci\u00f3n V617F del gen JAK2 ). En sesi\u00f3n \ncl\u00ednica conjunta (UCI, Interna y Farmacia)  se decide tratamiento con  Azul de metileno 1 \ng/kg, corticoterapia e infusi\u00f3n intravenosa de IgG (1 g/Kg/d\u00eda  durante 2 d\u00edas) a velocidad \nde 1 ml/kg/hora durante 30 minutos , aument\u00e1 ndose  gradualmente hasta 5 ml/kg/hora . \nSe amplia cobertura antibi\u00f3tica a Meropenem 1 g c/8 h m\u00e1s Linezolid 600 mg c/12 h. 888Tras dos dosis de Ig G, destaca una  clara mejor\u00eda del shock distributivo: reducci\u00f3n de \ncifras tensionales ( 70 mm Hg tensi\u00f3n a rterial med ia) llegando a disminuir perfusi\u00f3n de \nnoradrenalina  hasta dosis m\u00ednimas y reducci\u00f3n de lactato (3,5 mmol/L). Se observa \ntambi\u00e9n mejor\u00eda de hemoco ncentraci\u00f3n , d\u00e1ndose por tanto cerrado el episodio de SFCS,  \npero siguiendo hospitalizado en la unidad de UCI para su monitorizaci\u00f3n  y resoluci\u00f3n  de \notras patolog\u00edas . \nTras 56 d\u00edas de estancia en UCI se alta,  y tras paso por planta de interna se decide \ntraslado a hospital sociosanitario para rehabilitaci\u00f3n por miopat\u00eda del paciente critico \nen paciente post -covid , siguiendo actualmente en rehabilitaci\u00f3n domiciliaria.  \nDiscusi\u00f3n   \nLa fisiopatolog\u00eda de l SFCS o  enfermedad de Clarkson no est\u00e1 claramente definida, se \ndesconoce el mecanismo por el que se produce . Pero se ha descrito en la bibliograf\u00eda \ncasos relacionados con desordenes autoinmunes, infecciones virales del tracto \nrespiratorio  superior o casos post -exposici\u00f3n a vacunas. Se llega al d iagn\u00f3stico por \nexclusi\u00f3n  de otras causas  de shock  (s\u00e9ptico o por anafilaxi a) y tienen en com\u00fan la triada \ncl\u00e1sica de hipotensi\u00f3n severa, hipoalbuminemia y hemoconcentraci\u00f3n.  \nDebido a la pandemia surg ida por el virus S ARS-CoV-2 (Covid -19) se han descritos \ndiversos casos tanto por la infecci\u00f3n del virus (asociado a una sobreproducci\u00f3n \nproinflamatoria de citocinas, \u201ctormenta \u201d de citocinas , que originan da\u00f1o org\u00e1nico) \ncomo por la propia vacunaci\u00f3n, as\u00ed t anto la Agencia Europea de Medicamentos (EMA ) \ncomo la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios ( AEMPS ) en sus \nrespectivos programas de farmacovigilancia describen 6 casos  en junio  2021 . Hasta el 88927 de  mayo de 2021 se hab\u00edan administrado m\u00e1s de 78 millones de dosis de Vaxzevria \nen el conjunto del Espacio Econ\u00f3mico Europeo y el Reino Unido.  \nAportaci\u00f3n farmac\u00e9utica  \nEn este caso cl\u00ednico la visi\u00f3n del farmac\u00e9utico se centr\u00f3 en la b\u00fasqueda y revisi\u00f3n \nbibliog r\u00e1fica, de evidencia cient\u00edfica publicada hasta el momento sobre casos de SFCS y \nenfermedad de Covid -19 o vacunaci\u00f3n.  \nAs\u00ed mismo, se particip\u00f3 conjuntamente en la decisi\u00f3n farmacoterap\u00e9utica y ajuste de \ndosis/posolog\u00eda seg\u00fan requerimientos del paciente (ve locidad de infusi\u00f3n, \npremedicaci\u00f3n, preparaci\u00f3n en el servicio de farmacia ). Adem\u00e1s, durante el \u00faltimo a\u00f1o, \nse a\u00f1adi\u00f3 la dificultad de escasez de hemoderivados y para ello, se adapt\u00f3 el circuito del \nservicio de farmacia para control, preparaci\u00f3n y dispensa ci\u00f3n de este principio activo \nsolo para caso s con evidencia de grado A /B. \n \n \n \n \n \n \n \n \n 890Bibliograf\u00eda  \n1. Druey  KM, Parikh  SM. Idiopathic systemic capillary leak syndrome (Clarkson \ndisease). J Allergy Clin Immunol. 2017;140:663 \u201370 \n2. David S. Riley, Melissa S. Barber, Gunver S. Kienle, et al. CARE guidelines for case \nreports: explanation and elaboration document. Journal of Clinical \nEpidemiology,  \nVolume 89,2017;218 -235. ISSN 0895 -4356 . \n3. Marra AM, Gigante A, Rosato E. Intravenous immunoglobulin in systemic \ncapillary leak syndrome: a case report and review of literature. Expert Rev Clin \nImmunol. 2014;10:349 \u2013352.  \n4. Dhir V, Arya V, Malav IC,  Suryanarayanan BS, Gupta R, Dey AB. Idiopathic \nsystemic capillary leak syndrome (SCLS): case report and systematic review of \ncases reported in the last 16 years.  Intern Med . 2007;46(12):899 -904. \ndoi:10.2169/internalmedicine.46.6129  \n5. Siddall E, Khatri M, Ra dhakrishnan J. Capillary leak syndrome: etiologies, \npathophysiology, and management.  Kidney Int . 2017;92(1):37 -46. \ndoi:10.1016/j.kint.2016.11.029  \n6. Cheung PC, Eisch A, Maleque N, et al. Fatal Exacerbations of Systemic Capillary \nLeak Syndrome Complicating Cor onavirus Disease.  Emerging Infectious Diseases . \n2021;27(10):2529 -2534. doi:10.3201/eid2710.211155.  \n7. Case R, Ramaniuk A, Martin P, Simpson PJ, Harden C, Ataya A. Systemic Capillary \nLeak Syndrome Secondary to Coronavirus Disease 2019.  Chest . \n2020;158(6):e267 -e268. doi:10.1016/j.chest.2020.06.049  8918. Robichaud J, C\u00f4t\u00e9 C, C\u00f4t\u00e9 F. Systemic capillary leak syndrome after ChAdOx1 \nnCOV -19 (Oxford -AstraZeneca) vaccination.  CMAJ . 2021;193(34):E1341- E1344. \ndoi:10.1503/cmaj.211212  \n9. Lacout C, Rogez J, Orvain C , et al. A new diagnosis of systemic capillary leak \nsyndrome in a patient with COVID -19. Rheumatology (Oxford) . 2021;60(1):e19 -\ne20. doi:10.1093/rheumatology/keaa606  \n10. Matheny M, Maleque N, Channell N, et al. Severe Exacerbations of Systemic \nCapillary Leak Sy ndrome After COVID- 19 Vaccination: A Case Series.  Ann Intern \nMed . 2021;174(10):1476 -1478. doi:10.7326/L21 -0250  \n11. Pineton de Chambrun M, Cohen -Aubart F, Donker DW, et al. SARS -CoV-2 Induces \nAcute and Refractory Relapse of Systemic Capillary Leak Syndrome (Cla rkson's \nDisease).  Am J Med . 2020;133(11):e663 -e664. \ndoi:10.1016/j.amjmed.2020.03.057  \n12. Pharmacovigilance Risk Assessment Committee (PRAC). Covid -19 vaccines: \nauthorised. Vaxzevria: safety updates 18 June 202 1. European Medicines Agency \n(EMA) . Available: https://www.ema.europa.eu/en/documents/covid -19-\nvaccine -safety -update/covid -19-vaccine -safety -update -vaxzevria -previously -\ncovid -19-vaccine -astrazeneca -18-june -2021_en.pdf   \n13. Farmacovigilancia. Medicamentos de uso Humano. Notas de seguridad \nVaxzevria:  11 Juni o 2021. Agencia Espa\u00f1ola de Medicamentos y Productos \nSanitarios (AEMPS). Available: \nhttps://www.aemps.gob.es/informa/notasinformativas/medicamentosusohum\nano-3/seguridad -1/2021 -seguridad -1/vaxzevria -vacuna -frente -a-la-covid -19-\nde-astrazeneca -y-sindrome -de-fuga -capilar -sistemica/   892Anexo  1: Tabla de resultados anal\u00edtica  durante las primeras 72 h de ingreso en UCI.  \nResultados  \n Al \ningreso  +4 h  +10 h  +12 h  +18 h  +30 h  +48 h  +60 h  +72 h  \nHemograma  \nHb g/dL  21.9  20.7  23.3  23.6  21.4  20.2  18.5  14.4  12.4  \nHematocrito \n% 63.1  57.8  67 67.8  62 60.1  55.1  43.8  37.7  \nLeucocitos  14.82 \nx10e9  16.23 \nx10e9  23.78 \nx10e9  24.94 \nx10e9  33.07 \nx10e9  32.01 \nx10e9  33.18 \nx10e9  25 \nx10e9  15.31 \nx10e9  \nNeutr\u00f3filos  11.62 x \n10e9  12.43x \n10e9  13.58 \nx10e9      19.95 \nx10e9  12.81 \nx10e9  \nLinfocitos  2.49  2.66  7.13      2.79 \nx10e9  1.41 \nx10e9  \nPlaquetas  264x1e9  267 303x10e9  317 \nx10e9  285 \nx10e9  243 \nx10e9  202 \nx10e9  158 \nx10e9  118 \nx10e9  \nDimero D \nmcg/L  2835   740       \nINR 112  1 1.06  1.21  1.23  1.09   1.15  \nTiempo \nprotrombina  0.94    1.33  0.94  1.4 1.22   1.15  \nTTPA, s  24.2   40.8  40.6  28.8  42.6  37.3   34.7  \nBioqu\u00edmica  \nAlbumina \ng/L -       24.5   \nCreatinina \nmg/dL  1.8 1.84  2.36  2.51  2.42  2.4 2.47  2.33  1.81  \nLactato \nmmol/L  5.1  6.8    4.4  3,5 \nPCR, mg/dl  1.9  1.38  1.2  2.82  7.27   15.41  \n \n 893CIPR OHEP TADINA COMO ANT\u00cdDO TODES\u00cdNDR OME SEROTONIN\u00c9R GICOTRAS SOBREDOSIS\nDE ANTIDEPRE SIVOS TRIC\u00cdCLIC OS.\n1.INTRODU CCI\u00d3N\nEls\u00edndr ome serotonin\u00e9r gico(SS) esuna condici\u00f3n cl\u00ednic apotencialmen temort alinducida\nporuna hiper actividad serotonin\u00e9r gicaaniveldelsistema nervioso centralyperif \u00e9rico.1Los\nmec anismos fisiopa tol\u00f3gic osdelmismo implic anunaumen todelas\u00edntesis oliber aci\u00f3n del\nneur otransmisor serotonina (5-HT), inhibici\u00f3n desumetabolismo (atrav\u00e9sdelbloqueo dela\nmonoaminoo xidasa (MA O))\u00f3inhibici\u00f3n delarecaptaci\u00f3n de5-HT .Enconcr eto,serelaciona\nconuna mayorimplic aci\u00f3n delosrecep tores5-HT1A y5-HT2A ,este\u00faltimo asociado a\ns\u00edntomas m\u00e1s gr aves.1\nSehan descrit ogranvariedad def\u00e1rmac oscapaces dedesenc adenar SS.Elinicio dela\nsintoma tolog\u00eda habitualmen tesedadentrodelasprimer as24horastrasiniciar unf\u00e1rmac o\nserotonin\u00e9r gico,modific ar ladosis, como result ado de una interacci\u00f3n ouna\nsobr edosific aci\u00f3n medic amen tosa.1,2ElSSsecaracterizapor latr\u00edada dealteraciones dela\nactividad men tal,neur omuscular esytrastornos disaut on\u00f3mic os,como clonus, agitaci\u00f3n,\nmidriasis, diaforesis, temblor ehiperr eflexia; y,enloscasos graves,conhipert on\u00eda,\nrabdomi\u00f3lisis ehipert ermia. Los siguien tespar\u00e1me trosdelabor atorio seencuen tran\nelevados: creatinina, nitr\u00f3geno ureicoensangr e,mioglobina, leucocitosis ylasenzimas\ncreatinquinasa (CK) y lact ato deshidr ogenasa (LDH).2,3\nLaincidencia delSSesdesc onocida. Muchos casos nosenotific an,reconocen oconfunden\ncon otros s\u00edndr omes (como els\u00edndr ome neur ol\u00e9p ticomaligno (SNM), s\u00edndr ome\nanticolin\u00e9r gico,  hipert ermia maligna, delirium tremens, meningitis y ence falitis).1894Eneldiagn\u00f3s ticodelSSseutiliz anloscriterios deHunter.Laprimer aregla paraque se\ncumpla elcriterio deHunterconsis teenlapresencia deunagenteserotonin\u00e9r gico,asociado\naclonus (espon t\u00e1neo , inducible y/ o ocular).4\nEnelcaso cl\u00ednic odescrit oacontinuaci\u00f3n, sedesarr oll\u00f3 SScomo consecuencia deuna\nsobr edosific aci\u00f3n c on clomipr amina, un an tidepr esivo tric\u00edclic o (AD T).\n2. DESCRIPCI\u00d3N DEL CASO\nMujer de55a\u00f1os institucionaliz ada enuncentropsiqui\u00e1 trico,sinalergias conocidas a\nmedic amen tos, ycon los siguien tesanteceden tes: trastorno depr esivomayorgrave,\nobesidad, dislipidemia, hipotir oidismo subcl\u00ednic oeincontinencia urinaria. Entratamien to\ncon lamotrigina (200 mg/d\u00eda), aripipr azol(5mg/d\u00eda), clomipr amina deliber aci\u00f3n\nprolong ada (300 mg /d\u00eda), lor azepam (1,5 mg /d\u00eda) y c ondr oit\u00edn sulf ato (800 mg /d\u00eda).\nLapacien tetuvounprimer ingreso enurgencias conuncuadr odeestupor ,bajo nivelde\nconciencia (Glasg ow10/15) yrigide zdeextremidades. Enese momen toseencontraba\nafebril, confrecuencia cardiaca(FC)de84latidos porminut o,presi\u00f3n arterial (PA)de97/60\nmmHg yfrecuencia respir atoria (FR) de24respir aciones porminut o(RPM). Losniveles de\nLDH yCKfueronelevados, de474 U/l y2246 U/l respectiv amen te.Los niveles de\nclomipr amina seencontraban enrangot\u00f3xico(1075,5 micr ogramos/ml). Sesuspendi\u00f3\nclomipr amina yseadminis tr\u00f3flumaz enilo. Durantesuingreso enurgencias, lapacien te\nrequiri\u00f3 contenci\u00f3n mec \u00e1nicaytratamien tofarmac ol\u00f3gic oconolanz apina, haloperidol,\ntiaprida ymidaz olam. Ese mismo d\u00eda, anteuna apar entemejor adelniveldeconsciencia y\ndel cuadr o de agit aci\u00f3n, se tr aslad\u00f3 al cen tro de orig en.895Alcabo decuatrod\u00edas, ingres\u00f3denuevoenurgencias, conuncuadr odeestado confusional,\nagitaci\u00f3n yfiebr eelevada. Enlaexplor aci\u00f3n f\u00edsica,latemper aturafuede37,5\u00baC ,FCde68\nlatidos porminut o,PAde133/78 mmHg ,FRde18RPM ysaturaci\u00f3n deox\u00edgeno (SatO2) del\n98% atemper aturaambien te.Enlaanal\u00edtic adestacaronniveles desodio de147 mEq/l,LDH\nde426 U/l, CKde1331 U/l, 13.400 leucocitos/mm2.Los niveles declomipr amina, 419,6\nmicr ogramos/l, seencontrarondentrodelrangoterap\u00e9utic o.Laradiogr af\u00edadet\u00f3raxyelTAC\ncraneal er an normales. R ecibi\u00f3 clonaz epam y diaz epam par a el cuadr o de agit aci\u00f3n.\nDuranteestesegundo ingreso enurgencias, lapacien teempeor \u00f3hacia bajos niveles de\nconciencia (Glasg ow3),SatO2 93%, presen t\u00f3rigide zenlasextremidades ysialorr ea.Se\ntraslad\u00f3 desde urgencias alaunidad decuidados intensiv os(UCI), donde requiri\u00f3 intubaci\u00f3n\nysedoanalg esia conpropof ol,fentanilo (que secambia por remif entanilo trasdos d\u00edas de\ntratamien to)ymorfina. Lapacien terecibi\u00f3 dantroleno intravenoso porsospecha deSNM\n(dosis decargade2,5mg/kgseguido de1mg/kgcada 6horas),que sesuspendi\u00f3 tras6d\u00edas,\nenausencia demejor\u00eda ytrasasesor amien tofarmac\u00e9utic oyaque hab\u00eda alcanzado dosis\nm\u00e1xima acumulada recomendada. Trasreevaluaci\u00f3n sedetect\u00f3clonus aqu\u00edleo ,ysecontact\u00f3\ncon elServicio deFarmacia (SF) antelaposibilidad diagn\u00f3s ticadeSS, solicit ando\ninformaci\u00f3n sobr eciprohep tadina. Desde elinicio del tratamien toconestef\u00e1rmac o,la\npacien teexperimen t\u00f3una mejor\u00eda progresiva,loque permiti\u00f3 sutraslado deUCI aunidad\nde hospit alizaci\u00f3n.\nAtresmeses delingreso enUCI, lapacien tecontin\u00faa hospit alizada enplan ta,recibiendo\nesketamina inhalada asociada asertr alina adosis bajas, conresult ados preliminar es\nalen tador es.896Figur a 1. E voluci\u00f3n t empor al del c aso cl\u00ednic o.\n3. DISCUSI\u00d3N Y APOR TACI\u00d3N F ARMA C\u00c9UTICA\nRevisi\u00f3n bibliogr\u00e1fica\nEldiagn\u00f3s ticodiferencial delSSpuede result arcomplejo enlapr\u00e1ctic acl\u00ednic adebido asu\ngransimilitud conelSNM, alaadminis traci\u00f3n concomit antedef\u00e1rmac osneur ol\u00e9p ticosy\nf\u00e1rmac osconpotencial serotonin\u00e9r gicoenelmismo pacien te.1Enelcaso present ado se\nsospech\u00f3 deSNM, peroenlareevaluaci\u00f3n delpacien teenUCI yantelamanif estaci\u00f3n de\nclonus espon t\u00e1neo sediagnos tic\u00f3SS,yaque secumpl\u00eda elprimer criterio deHunter:clonus\nespon t\u00e1neo en pr esencia de un ag ente ser otonin\u00e9r gico.4\nEmpleando elalgoritmo deNaranjo ,larelaci\u00f3n decausalidad entrelaadminis traci\u00f3n de\nclomipr amina y la aparici\u00f3n del SS es pr obable.\nDesde elSFserealiz \u00f3una b\u00fasqueda bibliogr \u00e1ficasobr elos agentesfarmac ol\u00f3gic os\ndesenc adenan tesdeunSS, obteni\u00e9ndose laslistaselabor adas por laUniv ersidad de\nWaterloo yUKMedicines Information (UKMI) delHospit alUniv ersitario deSouthamp ton\n(NHS).5,6Se ob tuvier on los siguien tes hallaz gos tr asrevisi\u00f3n de la medic aci\u00f3n pr escrit a:\n897-Clomipr amina: consider ado elprincipal agentecausal implic ado enestecasodeSS,\nhab\u00eda alcanzado niveles t\u00f3xicos5d\u00edas antesdelingreso. Laabsorci\u00f3n retardada, la\nlargasemivida (21h y36h parasumetabolit oN-desmetilclomipramina )yel\nrecirculaci\u00f3n enterohep\u00e1 tica,hacen que elpacien tepueda estarexpues toaniveles\nelevados del f \u00e1rmac o de 4 a 6 d\u00edas tr as la \u00faltima ing esta.7\n-Aripipr azol: la ficha t \u00e9cnic a recoge casos de SS c on es te f\u00e1rmac o.8\n-Fentanilo: durantelaestancia enUCI elpacien terecibi\u00f3 fentanilo como partedela\nsedoanalg esia recibida, cuando laprincipal sospecha diagn\u00f3s ticaapun taba hacia un\nSNM. Aunque sedesc onoce lapotencia como agenteserotonin\u00e9r gicodelfentanilo ,\nse han descrit o casos de SS r elacionados.5,6\nAdem\u00e1s delasuspensi\u00f3n delosagentesserotonin\u00e9r gicos,enlab\u00fasqueda bibliogr \u00e1fica,se\nencontraronseries decasos moder ados-gr avesdel SStratados conciprohep tadina. La\nciprohep tadina, antagonistahistamin\u00e9r gico(H1) yserotonin\u00e9r gico(5-HT2) conuna d\u00e9bil\nacci\u00f3n anticolin\u00e9r gica,est\u00e1indic ado como antial\u00e9r gicoyorex\u00edgeno. Suuso como \u201cant\u00eddot o\u201d\ndel SSsejustificaatrav\u00e9sdesumec anismo deacci\u00f3n, sibien sueficacia nohasido\nrigur osamen te demos trada.\nDesp rescri pci\u00f3n de los posibles f\u00e1rmacos implicados\nDesde elSFsepropor cion\u00f3 una listadelosprincipales f\u00e1rmac oscom\u00fanmen teimplic ados en\nelSSyseinform\u00f3 deloshallaz gosencontrados enlarevisi\u00f3n deltratamien tofarmac ol\u00f3gic o\na los m\u00e9dic os responsables de la pacien te, recomendando la despr escripci\u00f3n de \u00e9s tos.898Aseso ramiento en la documen taci\u00f3n a tramitar y adquisici\u00f3n de la med icaci\u00f3n\nSeasesor \u00f3sobr eeltr\u00e1mit eadminis trativoparasolicit areluso deunmedic amen toen\nindic aci\u00f3n no incluida enficha t\u00e9cnic a,como eselcaso deciprohep tadina enSS.\nParalelamen tealtr\u00e1mit edelasolicitud, seagiliz \u00f3laadquisici\u00f3n delmedic amen to,que no\nestaba disponible en el hospit al al no es tar  incluido en la gu\u00eda f armac oterap\u00e9utic a.\nB\u00fasqueda de posolog\u00eda  y segu imiento farmacoterap\u00e9utico.\nDantroleno seadminis tr\u00f3seg\u00fan elprotocoloinstitucional detratamien todeSNM. Durante\nelingreso delapacien teenUCI, serealiz \u00f3unseguimien tofarmac oterap\u00e9utic o.Desde elSF\nsenotific \u00f3lasuper aci\u00f3n deladosis m\u00e1xima acumulada de10mg/kg,loque conlle v\u00f3ala\nsuspensi\u00f3n del mismo (unido a f alta de e ficacia).\nRespect oalaciprohep tadina, desde elSFseinform\u00f3 delapaut aposol\u00f3gic aencontrada en\nlarevisi\u00f3n bibliogr \u00e1fica.Eltratamien todelSSpuede requerir hasta32mgcada 24horas\n(dosis que seune al85-95% delosrecep tores5-HT2). Seinform\u00f3 laposibilidad dela\nadminis traci\u00f3n de los c omprimidos por sonda nasog \u00e1strica (SNG).\nEnestecaso,seadminis tr\u00f3una dosis decargade12mgydosis deman tenimien tode4mg\ncada 8horas,atrav\u00e9sdeSNG. Alcabo de4d\u00edas, trasuna apar enteeficacia inicial, se\naumen t\u00f3a4mgcada 6horas,continuando durante11d\u00edas, vigilando losposibles efectos\nadversos.\nCon ladesaparici\u00f3n casi totaldelasintoma tolog\u00eda serotonin\u00e9r gica,secomenz \u00f3una\nreducci\u00f3n paula tina deladosis, recibiendo 4mgcada 8horasy,posteriormen te,4mgcada\n12horashastasususpensi\u00f3n. Pasados 20d\u00edas conmejor\u00eda progresivadesde elinicio de\nciprohep tadina, se tr aslad\u00f3 a unidad de hospit alizaci\u00f3n.899Conclusiones\nCon laparticipaci\u00f3n delfarmac\u00e9utic oenestecasopodemos concluir que suintegraci\u00f3n en\nelequipo cl\u00ednic oesfundamen tal,asesor ando enlasgestiones adminis trativasycl\u00ednic as,\naport ando in formaci\u00f3n adecuada y g arantizado el uso segur o de los medic amen tos.\nEnlasintoxicaciones esdegranimport ancia elpapel delfarmac\u00e9utic onosolo asesor ando\nenladespr escripci\u00f3n delosposibles agentesdesenc adenan tes,sino enlarapide zparala\ndisponibilidad deant\u00eddot osilohay,as\u00edcomo enelseguimien tofarmac oterap\u00e9utic o,\nevitando f\u00e1rmac osque pudier anempeor arlasituaci\u00f3n cl\u00ednic adelpacien teyprincipalmen te\nenlosf\u00e1rmac os-an t\u00eddot osutiliz ados, haciendo especial hincapi\u00e9 enlaeficacia ylaseguridad\ndelosmismos. Ennues trocaso,laciprohep tadina haresult ado serunant\u00eddot osegur oy\nefectiv o,apesar deque senecesit am\u00e1s evidencia ydemayorcalidad paraestandariz arsu\nuso y posolog\u00eda .\n4. BIBLIOGRAF\u00cd A\n[1]Foong ,Ai-Leng ,etal.Dem ystifying Serotonin Syndr ome (orSerotonin Toxicity). Canadian\nFamily Ph ysician Medecin De F amille Canadien, v ol. 64, n.o 10, octubr e de 2018, pp. 720-27.\n[2]Carrillo-Esper aR.,Garnic a-Esc amilla MA.,Rocha-R odr\u00edgue zMG., Carrillo-C\u00f3r dovaCA.\nS\u00edndr ome serotonin\u00e9r gico.(2011) RevistadelaFacult addeMedicina delaUNAM. 54(2):\n46-53.\n[3]HiragaA.,Kuwabar aS.Malignan tSyndr ome and Serotonin Syndr ome inaGener al\nHospit alSetting: Clinic alFeatures,Frequency and Prognosis. (2017). Internal medicine. 56:\n2865-2869.900[4]Dunkle yEJC., Isbis terGK., Sibbrit tD.,Dawson AH., WhyteIM.The HunterSerotonin\nToxicity Criteria: simple and accur atediagnos ticdecision rules forserotonin toxicity .(2003).\n96:635\u2013642.\n[5]Owen,Setal(2020). Wha tisserotonin syndr ome and which medicines cause it?UK\nMedicines Informa tion (UKMI). Specialis tPharmacy Service, Univ ersity Hospit alof\nSouthamp ton, NHS.\n[6] School ofPharmacy ,Univ ersity ofWaterloo [Interne t].Pharmacy5in5 resour ces\n[Consult ado Apr 2022]. Disponible en:\nhttps://uw aterloo.c a/pharmacy/r esour ces-ser vices-and-initia tives/health-r esour ces/pharma\ncy5in5-r esour ces#Ser atoninS yndr ome\n[7]Agencia Espa\u00f1ola deMedic amen tosyProduct osSanit arios (AEMPS). Ficha t\u00e9cnic a\nAnafranil 75mgcomprimidos deliber aci\u00f3n prolong ada. [Interne t].2021 [citado 10demayo\nde 2022]. Disponible en: https://cima.aemp s.es/ cima/doch tml/ft/57568/FT_57568.h tml\n[8]Agencia Espa\u00f1ola deMedic amen tosyProduct osSanit arios (AEMPS). Ficha t\u00e9cnic a\nAripipr azolCinfa5mg comprimidos. [Interne t].2021 [citado 10demayode2022].\nDisponible en: https://cima.aemp s.es/ cima/doch tml/ft/79809/FT_79809.h tml901Infec ci\u00f3n f\u00fangica por Scedosporium apiospermum  en un paciente con infecci\u00f3n VIH: \nRetos en el abordaje farmacoterap\u00e9u tico  \nIntroducci\u00f3n  \nLos pacientes con infecci\u00f3n por el  VIH presentan una alta susceptibilidad a desarrollar \ninfecciones f\u00fangicas oportunistas graves. En los \u00faltimos a\u00f1os se ha observado un \naumento de la incidencia de infecciones por hongos filamentosos distintos de \nAspergillus spp. como Scedospirium  spp. y Fusarium  spp., que se caracterizan por \npresentar resistencia a gran parte de los antif\u00fangicos disponibles1. \nLa administraci\u00f3n concomitante de voriconazol con el tratamiento antirretroviral (TAR)  \nest\u00e1 condicionada por la presencia de m\u00faltiples interacciones cl \u00ednicamente relevantes . \nLas consecuencias de estas interacciones  pueden variar desde una disminuci\u00f3n en la \neficacia de  voriconazol y/o  los f\u00e1rmacos antirretrovirales  hasta la presencia de toxicidad, \npudiendo ser potencialmente mortales2. La determinaci\u00f3n farmacogen\u00e9tica de \npolimorfismos  relacionados con el metabolismo del voriconazol  y la monitorizaci\u00f3n \nfarmacocin\u00e9tica de sus niveles plasm\u00e1ticos  se consideran herramientas de gran utilidad \npara asegurar la eficacia del tratamiento y reducir la posible toxic idad3.  \nA continuaci\u00f3n,  presentamos el caso de un paciente VIH diagnosticado de una \notomastoiditis f\u00fangic a por Scedosporium apiospermum , en el que voriconazol fue la \n\u00fanica alternativa terap\u00e9utica disponible y donde la determinaci\u00f3n farmacogen\u00e9 tica y \nmonito rizaci\u00f3n  cin\u00e9tica de voriconazol llevada a cabo por el Servicio de Farmacia (SF)  \nfue clave para lograr el \u00e9xito terap\u00e9utico.  \nDescri pci\u00f3n del caso  902Var\u00f3n de 62 a\u00f1os, fumador y con antecedentes de adicci\u00f3n a drogas por v\u00eda parenteral.  \nInfecci\u00f3n VIH (estadio A2) diagnosticada en el a\u00f1o 1989.  Desde entonces ha recibido \nm\u00faltiples combinaciones de TAR debido a un mal control virol\u00f3gico de la infecci\u00f3n por \npresencia de multirresistencia y a la aparici\u00f3n de toxicidades secundarias al TAR (F igura \n1). Actualmente mantiene un adecuado control inmunovirol\u00f3gico (CD4 = 406  cel/mcL,  \nCV VIH < 3 0 copias/ml) y una adherencia \u00f3ptima (90%)  al TAR con dolutegravir (50 \nmg/24h) y darunavir/ ritonavir  (800/100 mg cada 24h) .   \nEl paciente p resenta , adem\u00e1s , numerosas comorbilidades : Enfermedad renal cr\u00f3nica , \natribuida a  la nefrotoxicidad po r los f\u00e1rmacos antirretrovirales, requiriendo inicio de \ntratamiento renal sustitutivo  en noviembre de 2020. Actualmente realiza 3 sesiones de \nhemodi\u00e1lisis a la semana. Mioclo n\u00edas segmentarias distales asociadas a meningitis \nlinfocitaria en contexto de infecci\u00f3n por VIH, en tratamiento  con anticonvulsivantes \ndesde 2001 , sin haber obtenido un correcto control. S\u00edndrome coronario agudo en julio \nde 2021, con disfunci\u00f3n ventricular severa y enfermedad de 2 vasos.   \nEn 25/02/22,  el paciente a cude a la consulta de Atenci\u00f3n Farmac\u00e9utica  del SF  para iniciar \ntratamiento con voriconazol 200mg/12h debido a una otomastoiditis f\u00fangica por \nScedosporium  apiospermum . El pa ciente  refiere que inici\u00f3 los s\u00edntomas a finales de \ndiciembre  de 2021 , y desde entonces ha recibido numerosos tratamientos, requiriendo \ningreso hospitalario para tratamiento intravenoso y control del dolor, sin \u00e9xito .  \nEn la consulta s e llev\u00f3 a cabo una re visi\u00f3n de  la historia cl\u00ednica y farmacoterap\u00e9utica del \npaciente, en la  que destac\u00f3 la obtenci\u00f3n  de un primer cultivo \u00f3tico positivo para E. coli \n(28/12/21 ), que requiri\u00f3 tratamiento local con alcohol boricado a saturaci\u00f3n y la \nsoluci\u00f3n \u00f3tica de gentamicina  + dexametasona + tetrizolina . Ante la ausencia de  mejor\u00eda \ndel dolor , se llev\u00f3 a cabo una resonancia magn\u00e9tica de cr\u00e1neo (RMc) y una tomograf\u00eda 903por emisi\u00f3n de positrones  el 23 /01/22 , en la que se observ\u00f3 una otitis externa y media, \ncomplicada con osteomiel itis, celulitis y miositis con afectaci\u00f3n de la base del cr\u00e1neo . El \npaciente ingres\u00f3 para tratamiento intravenoso con meropenem 500mg/24h  IV, y tras 13 \nd\u00edas y una disminuci\u00f3n significativa  del dolor , se ajust\u00f3 a antibioterapia oral con \nciprofloxacino 500mg /24h + Trimetoprim -sulfametoxazol 160 -800mg/24h. Al d\u00eda +3 del \ncambio del tratamiento , se reinici\u00f3  de nuevo  meropenem 500mg/24h por \nempeoramiento del dolor, requiri\u00e9ndose  el inicio de parches de fentanilo 12mcg/h cada \n72 horas. El 21/02/22  se llev\u00f3 a cabo una biopsia  \u00f3tica, en la que se obtuvo el hongo \nScedosporium apiospermum , el antifungigrama confirm\u00f3 que s\u00f3lo era sensible a \nvoriconazol (CMI=0,5) y que presentaba resistencia a isavuconazol (CMI=4), itraconazol \n(CMI=16) y anfotericina B (CMI=1) .  Se suspendi\u00f3  el tratamiento antibi\u00f3tico intravenoso \ny se inici\u00f3  tratamiento dirigido con voriconazol  200mg/12h oral de forma ambulatoria .  \nEn la consulta  de Atenci\u00f3n Farmac\u00e9utica  se confirm\u00f3 el trat amiento actual del paciente \n(Tabla 1) , as\u00ed como la ausencia d e productos fitoter\u00e1picos  y suplementos alimentarios . \nSe revis\u00f3  la presencia de interacciones  potencialmente relevantes , detect\u00e1ndose las \ninteracci ones  farmacol\u00f3gica s entre voric onazol con darunavir  y ritonavir , \ndesaconsej\u00e1ndose su uso concomitante debido a que puede desembocar en  una \ndisminuci\u00f3n en las concentraciones s\u00e9ricas de voriconazol. Se coment\u00f3  el caso con el \nServicio de Microbiolog\u00eda y Enfermedades Infecciosas  (MIC -EI) y Otorrinolaringolog\u00eda , y \nante la  falta de otras alternativas antif\u00fangicas para el tratamiento  de Scedosporium \napiospermum , y tras una exhaustiva evaluaci\u00f3 n multidisciplinar  de la relaci\u00f3n beneficio -\nriesgo , se decidi\u00f3  iniciar tratamiento con voriconazol a la dosis est\u00e1ndar  de 200mg/12h \npor v\u00eda oral. En esta asesor\u00eda, el SF recomend\u00f3  llevar a cabo una  monitorizaci\u00f3n  estrecha \nde la  farmacocin\u00e9tica  del voriconazol .  904La primera determinaci\u00f3n plasm\u00e1tica se llev\u00f3 a cabo una semana despu\u00e9s del inicio  de \nvoriconazol , obteni\u00e9ndose  nivel es infraterap\u00e9uticos ( Cp<0,7 \u00b5g/mL ). Ante la  potencial  \ndificultad de  lograr concentraciones terap\u00e9uticas  adecuadas  y la imposibilidad de \ncambio del TAR, se valor\u00f3 la sustituci\u00f3n de voriconazol por otro azol o anfotericina b. \nSin embargo, e l antifungigrama confirm\u00f3 que el hongo Scedosporium apiospermum  \naislado s\u00f3lo era sensible a voriconazol (CMI=0,5), descart\u00e1ndose  esta posibilidad. El SF \nrecomend\u00f3 el incremento de la  dosis de voriconazol  a 300mg/12h v\u00eda oral, y la \ndeterminaci\u00f3n farmacogen\u00e9tica de l polimorf ismo de CYP2C19 . La se gunda \ndeterminaci\u00f3n plasm\u00e1tica , llevada  a cabo una semana despu\u00e9s  del incremento  de dosis , \nvolvi\u00f3 a mostrar niveles infraterap\u00e9uticos  (Cp=0,87 \u00b5 g/mL ). Al mismo tiempo, la Unidad \nde Farmacogen\u00e9tica del SF confirm\u00f3 el r esultado farmacogen \u00e9tico: presencia del \ngenotipo *1/*17 para CYP2C19 , por lo que se trata de un paciente  metabolizador r\u00e1pido  \ndel voriconazol. Ante estos resultados, el SF recomend\u00f3  increment ar la dosis de \nvoriconazol de 300 mg a 400  mg cada 12h, logr\u00e1ndose una Cp=1,46 \u00b5g/mL  dos d\u00edas \ndespu\u00e9s de este incremento. Esta pauta se mantuvo 1 semana m\u00e1s, y se volvi\u00f3 a realizar \nuna nueva determinaci\u00f3n, alcanz\u00e1ndose  una Cp=1,91  \u00b5g/mL.  \nLa evoluci\u00f3n fue posteriormente favorable, con resoluci\u00f3n del dolor  y disminuci\u00f3n \nimportante de la otorrea,  por lo que se decidi\u00f3 mantener la pauta de 400  mg/12h  v\u00eda \noral. En las siguientes determinaciones semanales  se confirm\u00f3 la consecuci\u00f3n de Cp > 2 \n\u00b5g/mL (Figura  2). Despu\u00e9s de 10 semanas  de tratamiento , desapareci\u00f3 la otorrea, y la \nRMc de control confirm\u00f3 una disminuci\u00f3n del componente infeccioso e i nflamatorio , si \nbien persist \u00eda un leve engrosamiento de la mucosa oto mastoidea .  Finalmente, s e \ndecidi\u00f3 prolongar el tratamiento con voriconazol durante 4 semanas .  905Discusi\u00f3n y aportaci\u00f3n farmac\u00e9utica   \nUna de las actividades fundamentales del farmac\u00e9utico en la consulta de Atenci\u00f3n \nFarmac\u00e9utica  es la detecci\u00f3n de posibles interacciones  farmacol\u00f3gicas y la asesor\u00eda al \nequipo m\u00e9dico sobre su manejo , ya que \u00e9stas pueden condicionar  significativamente  la \neficacia o toxicidad de los tratamientos. Cuando un paciente acude a la consulta para \niniciar  tratamiento con v oriconazol, es clave  realizar una exhaustiva revisi\u00f3n de la  \nhistoria farmacoterap\u00e9utica , pues  la pres encia de interacciones con este azol es un \nproblema  frecuente . El voriconazol  se metaboliza extensamente en el h\u00edgado a trav\u00e9s \nde las enzimas hep\u00e1ticas  citocromo  P450, principalmente por el CYP2C19, y en menor \nmedida por el CYP3A4 y CYP2C9. A su vez v oriconazol inhibe a estas 3 enzimas.  \nEn la visita de inicio, se detectaron las interacciones de voriconazol con ritonavir y \ndarunavir, ya que ambos f\u00e1rmacos comparten la misma v\u00eda de metabolizaci\u00f3n. En el caso \nde la interacci\u00f3n de voriconazol con ritonavi r, se debe a que este \u00faltimo es sustrato y \npotente inhibidor del CYP3A4, as\u00ed como potente inductor del CYP2C19 y , en menor \nmedida , del CYP2C9. El efecto de la interacci\u00f3n  est\u00e1  condicionada por el momento en el \nque se inicia voriconazol, ya que si voriconaz ol y ritonavir se inicia n a la vez o ritonavir \nse inicia en un paciente que ya estaba en tratamiento con voriconazol, las \nconcentraciones de voriconazol se van a ver aumentadas (inhibici\u00f3n -CYP3A4) \npredisponiendo a la aparici\u00f3n de efectos adversos como alte raciones visuales, \ngastrointestinales o hepatotoxicidad. La administraci\u00f3n de voriconazol en un paciente \nque ya est\u00e1 en tratamiento con ritonavir, como en el caso de nuestro paciente , va a \nprovocar una reducci\u00f3n significativa de las concentraciones de vori conazol (inducci\u00f3n -\nCYP2C19) , condicionando la eficacia de la terapia f\u00fangica. En cuanto a la interacci\u00f3n con 906darunavir, estudios sugieren que \u00e9ste inhibe el CYP3A4 , por lo que se espera que \ndisminuya el aclaramiento de voriconazol.  \nDebido a la  ausencia de  informaci\u00f3n precisa sobre c\u00f3mo manejar estas interacciones en \nla pr\u00e1ctica cl\u00ednica, se consider\u00f3 esencial llevar a cabo una monitorizaci\u00f3n terap\u00e9utica  \nmuy estrecha de los niveles de voriconazol,  para identificar  la magnitud de la interacci\u00f3n \ny realizar una  optimizaci\u00f3n precoz del tratamiento.  Respecto a la concentraci\u00f3n objetivo \nde los niveles  de voriconazol , no existen un rango formalmente establecido, si bien la \nbibliograf\u00eda sugiere niveles  m\u00ednimos  entre 1,5 -2\u00b5g/mL  y m\u00e1ximos de  5-5,5 \u00b5g/mL . Se \ndecidi\u00f3 iniciar tratamiento conservador con la dosis est\u00e1ndar de 200mg/12h , y ajustar \nposteriormente seg\u00fan niveles plasm\u00e1ticos.  Tras la primera determinaci\u00f3n, en la que no \nse detectaron Cp suficientes , se confirm\u00f3 que la interacci\u00f3n predominante era l a del \nvoriconazol con ritonavir mediante la inducci\u00f3n  del CYP2C19 , y se recomend\u00f3 la \ndeterminaci\u00f3n complementaria del polimorfismo  CYP2C19 , ya que la variante del \nCYP2C19 del paciente p odr\u00eda  implicar una exposici\u00f3n al f\u00e1rmaco y sus metabolitos \ndiferente.   La determinaci\u00f3n se llev\u00f3 a cabo en  la Unidad de Farmacogen\u00e9tica del SF, en \nla que se analizaron los siguientes polimorfismos: rs4244285 (CYP2C19*2), rs4986893 \n(CYP2C19*3)  y rs12248560 (CYP2C19*17). L os alelos CYP2C19*2 y CYP2C19*3 se asocian \ncon una nula  capacidad de metabolizaci\u00f3n, mientras que el alelo CYP2C19*17 aumenta \nla capacidad de metabolizaci\u00f3n. Nuestro paciente fue catalogado como metabolizador \nr\u00e1pido ya que present\u00f3 un alelo CYP2C19 con funci\u00f3n normal y otro con funci\u00f3n \nincrementada: Genotipo * 1/*17.  \nCon la informaci\u00f3n  aportada por la prueba farmacogen \u00e9tica y la  informaci\u00f3n de las \nconcentraciones plasm\u00e1ticas de voriconazol, se recomend\u00f3 el incremento paulatino de  907la dosis de voriconazol  hasta 400 mg cada  12h, consigui\u00e9ndose  alcanzar niveles \nterap\u00e9uticos, que se correlacionaron con una mejor\u00eda en la respuesta cl\u00ednica.  \nFinalmente, q ueremos destacar la importancia de l trabajo colaborativo de  los \nfarmac\u00e9uticos de las diferentes \u00e1rea s de conocimiento (farmac\u00e9utico de infecciosas, \nfarmac\u00e9utico de farmacocin\u00e9tic a-farmacogen \u00e9tica) , y su integraci\u00f3n  en el equipo \nmultidisciplinar , para proporcionar la mejor asistencia a los pacientes . La labor  de los \nfarmac\u00e9uticos en la detecci\u00f3n y manejo de las interacciones farmacol\u00f3gicas, y la \nindividualizaci\u00f3n del tratamiento antif\u00fangico seg\u00fan la gen\u00e9tica del paciente , resultaron \nclave para lograr el \u00e9xito terap\u00e9utico.  \nBibliograf\u00eda  \n1- Tammer I, Tintelnot K, Braun -Dullaeus RC, et al. Infections due to \nPseudallescheria/Scedosporium species in patients with advanced HIV disease --a \ndiagnostic and therapeutic challenge. Int J Infect Dis. 2011;15(6):e422 -e429.  \n \n2- Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between \nvoriconazole and antiretrovi ral agents. Ann Pharmacother. 2008;42(5):698 -703. \ndoi:10.1345/aph.1K530  \n3- Cendejas -Bueno E, Cuenca -Estrella M, G\u00f3mez -L\u00f3pez A. Indicaciones cl\u00ednicas de la \nmonitorizaci\u00f3n de azoles de uso sist\u00e9mico. Hacia la optimizaci\u00f3n del tratamiento de la \ninfecci\u00f3n f\u00fangica . Rev Esp Quimioter. 2014;27(1):1 -16. \n \n908FIGURA 1.  Historial farmacoterap\u00e9utico del tratamiento antirretroviral . \n \n \nFIGURA 2 . Concentraciones plasm\u00e1ticas de voriconazol (\u00b5g/mL )  \n \n909 \nEVENTOS HEMORR\u00c1GICOS ASOCIADOS AL USO DE LOS INHIBIDORES DE TIROSINA -\nQUINASA. A PROP\u00d3SITO DE UN CASO  \nINTRODUCCI\u00d3N  \nLa leucemia linfoc\u00edtica  cr\u00f3nica (LLC) es una enfermedad neopl\u00e1sica del sistema linf\u00e1tico \nque se caracteriza por la acumulaci\u00f3n  progresiva  de linfocitos maduros en distintos \n\u00f3rganos, como la m\u00e9dula \u00f3sea, la sangre y los ganglios linf\u00e1ticos.  \nEs la forma m\u00e1s frecuente de leuce mia en los pa\u00edses occidentales (24% de todas las \nleucemias), afectando principalmente a los adultos, con una edad media al diagn\u00f3stico \nde 55 a\u00f1os. Se estima, en general, una incidencia de 3 nuevos ca sos por 100.000 \nhabitantes/ a\u00f1o (1). \nUno de los par\u00e1metros gen\u00e9ticos m\u00e1s importantes para establecer el pron\u00f3stico de los \npacientes con LLC es el estado mutacional de la regi\u00f3n variable de la cadena pesa da de \nla inmunoglobulina (IGHV) . Con respecto a las anomal\u00edas cromos\u00f3micas, algunas de \nellas tambi\u00e9n tienen valor pron\u00f3stico. En orden de frecuencia, la deleci\u00f3n del brazo \nlargo del cromosoma 13 (del 13q) es la alteraci\u00f3n m\u00e1s frecuente (55%), seguida por la \ndeleci\u00f3n del brazo largo del cromosoma 11 (del 11q) (18%), la trisom\u00eda del cromosoma \n12 (16%) y la deleci\u00f3n del brazo corto del cromosoma 17 (del 17p) (7 %) (2). \nAcalabrutinib  es un inhibidor de la tirosina -quinasa de Bruton y est\u00e1  indicado en (3): \nmonoterapia o combinado con obinutuzumab para el tratamiento de adultos con LLC no \ntratados prev iamente y en monoterapia  para el tratamiento de pacientes adultos con \nLLC que han recibido al menos un tratamiento previo.  \n 910 \nExiste un ensayo cl\u00ednico ( 4) publicado en el que se compara ibrutinib 420 mg al d\u00eda vs \nacalabrutinib  100 mg cada 12 horas en pacientes con LLC con deleci\u00f3n (del) 17p o del \n11q. En este ensayo se incluyero n 533 pacientes (ibrutinib, n= 265; a calabrutinib, \nn=268). Tras 40, 9 meses de seguimiento, acalabrutinib demostr\u00f3 ser no inferior a \nibrutinib con una med iana de supervivencia libre  de progresi\u00f3n (SLP) de 38, 4 meses en \nambos grupos. Respecto a los eventos hemorr\u00e1gicos, las diferencias entre ambos \ntratamientos fueron acalabrutinib (38%) vs ibrutinib (51.3% ); y las tasas de eventos de \nsangrado mayores fueron compar ables: acalabrutin ib (4,5% ), ibrutinib (5, 3%).  \nEn las siguientes tablas, se muestran  los posicionamientos de las Sociedades Cient\u00edficas :  \nNational Comprehensive Cancer Network  (NCCN )(5): \nLLC sin del 17p / mutaci\u00f3n TP53  \n 1\u00aa l\u00ednea: r \u00e9gimen preferido  2\u00aa l\u00ednea y posteriores  \nPacientes \u2265 65 a\u00f1os o \n< 65 a\u00f1os con  \ncomorbilidades \nsignificativas  \uf0b7 Acalabrutinib \u00b1 obinutuzumab  \n\uf0b7 Ibrutinib  \n\uf0b7 Venetoclax + obinutuzumab  \n\uf0b7 Zanubrutinib  \uf0b7 Acalabrutinib  \n\uf0b7 Ibrutinib  \n\uf0b7 Venetoclax + rituximab  \n\uf0b7 Zanubrutinib  \n< 65 a\u00f1os sin \ncomorbilidades \nsignificativas  \uf0b7 Acalabrutinib \u00b1 obinutuzumab  \n\uf0b7 Ibrutinib  \n\uf0b7 Venetoclax + obinutuzumab  \n\uf0b7 Zanubrutinib  \uf0b7 Acalabrutinib  \n\uf0b7 Ibrutinib  \n\uf0b7 Venetoclax + rituximab  \n\uf0b7 Zanubrutinib  \n \n \n \n \nSociedad Europea  de Oncolog\u00eda M\u00e9dica ( ESMO ) (6): \nPacientes sintom\u00e1ticos estadio temprano o avanzado  \nIGHV no mutada, no mutaci\u00f3n  TP53 \no del 17p  IGHV mutada, no mutaci\u00f3n TP53 \no del 17p  Mutaci\u00f3n TP53 o del 17p  \nPacientes FIT  Pacientes no FIT  Pacientes Pacientes no FIT  Todos los pacientes  LLC con del 17p / mutaci\u00f3n TP53  \n1\u00aa l\u00ednea  \npreferido  2\u00aa l\u00ednea y posteriores  \n\uf0b7 Acalabrutinib \u00b1 obinutuzumab  \n\uf0b7 Ibrutinib  \n\uf0b7 Venetoclax + obinutuzumab  \n\uf0b7 Zanubrutinib  \uf0b7 Acalabrutinib  \n\uf0b7 Ibrutinib  \n\uf0b7 Venetoclax + rituximab  \n\uf0b7 Venetoclax  \n\uf0b7 Zanubrutinib  \nTabla 1 . Tratamiento en 1\u00aa, 2\u00aa l\u00ednea y po steriores de la LLC sin del  17p/mut aci\u00f3n TP53 seg\u00fan las gu\u00edas NCCN  \nTabla 2 . Tratamiento en 1\u00aa, 2\u00aa l\u00ednea y po steriores de la LLC con del  17p/mut aci\u00f3n TP53 seg\u00fan las gu\u00edas NCCN  911 \nFIT \n\uf0b7 Ibrutinib  \n\uf0b7 QIT: FCR  \uf0b7 VOb  \n\uf0b7 Ibrutinib o \nacalabrutinib  \n\uf0b7 QIT: CLBO  \uf0b7 QIT: FCR  \n\uf0b7 Ibrutinib  \uf0b7 VOb  \n\uf0b7 QIT: CLBO  \n\uf0b7 Ibrutinib o \nacalabrutinib  \uf0b7 Ibrutinib o acalabrutinib  \n\uf0b7 VOb  \n\uf0b7 Venetoclax  \n\uf0b7 Idelalisib + rituximab  \n \n \n \nSociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia (SEHH), en concreto el Grupo \nEspa\u00f1ol de Leuce mia Linfoc\u00edtica Cr\u00f3nica (GE LLC)(7): \n1\u00aa l\u00ednea en enfermedad activa: ENSAYO CL\u00cdNICO  \nIGHV mutada, no mutaci\u00f3n TP53 o \ndeleci\u00f3n 17p o deleci\u00f3n 11q  IGHV no mutada/deleci\u00f3n 11q no \nmutaci\u00f3n TP53 o deleci\u00f3n 17p  Mutaci\u00f3n TP53 o \ndeleci\u00f3n 17p  \nPacientes FIT  Pacientes no FIT  Pacientes FIT  Pacientes no FIT  \uf0b7 Ibrutinib o \nacalabrutinib \no VenO  \n\uf0b7 Venetoclax  \n\uf0b7 Rituximab -\nidelalisib  \uf0b7 Ibrutinib o \nacalabrutini\nb o VenO  \n\uf0b7 FCR (en > 65 \na\u00f1os BR)  \uf0b7 Ibrutinib o \nacalabrutinib o \nVenO  \n\uf0b7 Clorambucilo -\nobinutuzumab  \uf0b7 Ibrutinib o \nacalabrutini\nb o VenO  \n\uf0b7 FCR (en > \n65 a\u00f1os BR)  \uf0b7 Ibrutinib o \nacalabrutinib o \nVenO  \n\uf0b7 Clorambucilo -\nobinutuzumab  \n \nSeg\u00fan la internacional Workshop on Chronic Lymphocytic Leukemia  (iwCLL), se debe \niniciar tratamiento con la presencia de uno de los siguientes  criterios(8 ): fallo medular \nprogresivo, s\u00edntomas relacionados con la enfermedad (astenia severa, sudoraci\u00f3n Pacientes sintom\u00e1ticos en reca\u00edda/refractarios  \nTP53 mutado o deleci\u00f3n 17p  Duraci\u00f3n corta de la remisi\u00f3n (< \n36 meses)  Duraci\u00f3n larga de la remisi\u00f3n (> \n36 meses)  \n\uf0b7 Ibrutinib o acalabrutinib  \n\uf0b7 Venetoclax + rituximab  \n\uf0b7 Venetoclax monoterapia  \n\uf0b7 Idelalisib + rituximab  \n\uf0b7 Considerar aloTPH en \npacientes FIT  \uf0b7 Ibrutinib o \nacalabrutinib  \n\uf0b7 Venetoclax + rituximab  \n\uf0b7 Venetoclax \nmonoterapia  \n\uf0b7 Idelalisib + rituximab  Repetir 1\u00aa l\u00ednea o cambiar a:  \n\uf0b7 Ibrutinib o \nacalabrutinib  \n\uf0b7 Venetoclax + rituximab  \n\uf0b7 Idelalisib + rituximab  \n\uf0b7 QIT \nTabla 3 . Tratamiento de la LLC en pacientes sintom\u00e1ticos en estadio temprano o avanzado en funci\u00f3n de \nlas caracter\u00eds ticas fenot\u00edpicas y moleculares seg\u00fan la ESMO  \n\u201cPaciente FIT\u201d: aquel que es apto para recibir quimioinmunoterapia  \nQIT: quimioinmunoterapia  \nFCR: fludarabina + ciclofosfamida +  rituximab  \nVOb: venetoclax + obinutuzumab  \nCLBO: clorambucilo + obinutuzumab  \nTabla 4 . Tratamiento de la LLC en pacientes sintom\u00e1ticos en reca\u00edda/refractarios en funci\u00f3n de las \ncaracter\u00eds ticas fenot\u00edpicas y moleculares as\u00ed como de la duraci\u00f3n de la remisi\u00f3n seg\u00fan la ESMO.  \n \nTabla 5 . Algoritmo de recomendaciones de tratamiento. Gu\u00eda del GELLC. Diciembre 2021.  \n 912 \nnocturna, fiebre>38\u00baC o p\u00e9rdida de peso), esplenomegalia progresiva (> 6 cm debajo \nreborde costal), conglo merados adenop\u00e1ticos > 10 cm, tiempo de duplicaci\u00f3n \nlinfocitario  < 6 meses, anemia y/o trombocitopenia autoinmune refractaria a corticoides \ne infiltraci\u00f3n extranodal sintom\u00e1tica.  \nDESCRIPCI\u00d3N DEL CASO  (presentaci\u00f3n cl\u00ednica y evoluci\u00f3n)  \nMujer  de 6 5 a\u00f1os  de edad, sin antece dentes oncol\u00f3gicos familiares  y con  antec edentes \npersonales de asma bronquial , exfumadora durante 20 a\u00f1os de 20 cigarri llos diarios . \nTratamiento h abitual: omeprazol , paracetamol y fluticasona/salmeterol inhalado .  \nEn abril de 2014 la pa ciente fue  diagnosticada de LLC mediante anal\u00edtica rutinaria de \ncontrol con una cifra de linfocitos en sangre perif\u00e9ric a de 21.380/\u00b5 L. Se decidi\u00f3 realizar \nseguimiento cada 3 meses pue sto que la paciente se encontraba  asintom\u00e1tica  sin \ncumplir  criterios de i nicio de tratamiento  (la cifra de linfoc itos ha b\u00eda disminuido de \n21.380 a 10 .000/\u00b5 L y las adenopat\u00edas en el TAC eran  < 1 cm).  \nEn junio de 2020, la paciente present\u00f3 anemia  [Hemoglobina (Hb)= 9,5 g/dl]  y \ntrombopenia  (plaquetas= 70.000/\u00b5 L) mantenidas as\u00ed como la aparici\u00f3n de astenia \nmoderada, por lo que se realiz\u00f3 un estudio de cit ogen\u00e9tica  de cara a instaurar un \nposible tratamiento.  El  resultado fue deleci\u00f3n de  13q en el 80% de las metafases,  \ndeleci\u00f3n de 17p en el 20% de las metafases y 8  de las metafases con mutaci\u00f3n de  IGHV , \nlo cual indica mal pron\u00f3stico  y anticipa una mala respuesta a fludarabina . Se realiz \u00f3 un \nTAC que no obje tiv\u00f3 adenopat\u00edas significativas as\u00ed como un estudio de TP53 que result\u00f3  \nser no mutado . Se decidi\u00f3  iniciar tratam iento con ibrutinib a dosis de 420 mg al d\u00eda.  \nEn la siguiente tabla se exponen las cifra s de linfocitos, Hb y plaquetas por fecha de \nanal\u00edtica a partir de que la paciente empezara el tratamiento con ibrutinib:  913 \nFecha anal\u00edtica  Linfocitos/ \u00b5L Hb (g/dl)  Plaquetas/ \u00b5L \n02/02/2021  100.000  11,9 130.000  \n03/03/2021  120.000  10,5 133.000  \n18/03/2021  47.000  10,8 120.000  \n08/04/2021  33.000  10,1 118.000  \n06/05/2021  55.000  10,3 130.000  \n03/06/2021  53.000  11,5 193.000  \n07/07/2021  31.000  10,2 200.000  \n05/08/2021  17.700  8 286.000  \n10/08/2021  15.000  6,8 190.000  \n29/09/2021  4.490  10 193.000  \n19/11/2021  7.160  7,6 194.000  \n23/11/2021  6.930  8,9 261.000  \n21/12/2021  4.770  10,7 159.000  \n11/01/2022  4.970  13,5 160.000  \n21/01/2022  5.720  13,6 128.000  \n04/02/2022  4.240  13,7 182.000  \n03/03/2022  3.270  13,5 201.000  \n11/04/2022  3.730  13,8 168.000  \n10/05/2022  3.470  13,8 183.000  \nEn julio de 202 1 ingres\u00f3 por infecci\u00f3n por SAR S-CoV2 sin interrumpir ibrutinib.  \nEn agosto de 2021  la paciente acudi\u00f3 a urgencias por episodios de mareo e \ninestabilidad, objetiv\u00e1ndose hemorragia digestiva con una  cifra de  Hb de 6 ,8 g/dl \nprecisando transfusi\u00f3n de concentrado de hemat\u00edes.  En noviembre 2021 , aparici\u00f3n de \nun segundo episodio de hemorragia digestiv a con una  Hb de 7, 6 g/dl  precisando  \ntran sfusi\u00f3n . Se decidi\u00f3  disminuir la dosis de ibrutinib a 280 mg al d\u00eda.  \nDebido a la aparici\u00f3n de dos eventos hemorr\u00e1gicos graves, de la incertidumbre de \nmantener a la paciente con dosis bajas de ibrutinib, el m\u00e9dico  responsable solicit\u00f3  al \nServicio de Farmaci a el cambio a acalabrutinib en enero de 2022.  \nActualmente , tras 4  meses en tratamiento con acalab rutinib la ci fra de linfocitos es de \n3.470/\u00b5 L, Hb de 13,8 g/dl y plaquetas 183.000/\u00b5 L. La paciente no ha presentado ning\u00fan \nevento hemorr\u00e1gico ni an\u00e9mico  y tiene una adherencia completa al tratamiento . \n 914 \nDISCUSI\u00d3N  \nAcalabrutinib es un medicamento  novedoso , por lo que  en la pr\u00e1ctica cl\u00edni ca existe poca \nexperiencia de uso . Es por ello, la importancia de este caso en el que se pone de \nmanifiesto  la recuperaci\u00f3n de la paciente en cuanto a eventos hemorr\u00e1gicos se refiere.  \nA pesar de que en la bibliograf\u00eda no hay datos significativos de que existan  diferencias \nen cuanto a la aparici\u00f3n y frecuencia de eventos hemorr\u00e1gicos entre ibrutinib y \nacalabrutinib, en este caso  los eventos hemorr\u00e1gicos parecen estar relacionados con el \nuso a  las dosis habituales de ibrutinib. Hasta el momento actual (4 meses de \ntratamiento ) la paciente ha tolerado dosis plena s de acalabrutinib sin presentar \nsangrado.  \nLa evidencia disponible sobre la seguridad de acalabrutinib est\u00e1 basada en el an\u00e1lisis de \n9 estudios en pacientes que reciben acalabrutinib en monoterapia (2 estudios fase III y 7 \nestudios fase I/II) y 2 estudios en pacientes que reciben la combinaci\u00f3n aca labrutinib -\nobinutuzumab (1 estudio fase III y otro fase I) . De los 1.040 pacientes tratados con \nacalabrutinib en monoterapia, los even tos adversos m\u00e1s frecuentes  de grado \u2265 3 fueron \ninfecciones  (17,6%), leuc openia (14, 3%) y anemia (7,8%) ( 9)(10). \n \nAPORTAC I\u00d3N FARMAC\u00c9UTICA  \n \nDesde el Servicio de Farmacia, se realiz\u00f3  una b\u00fasqueda bibliogr\u00e1fica en diferentes bases \nde datos y gu\u00edas de pr\u00e1ctica cl\u00ednica  para evaluar la idoneidad de  acalabrutinib en esta \npaciente . Adem \u00e1s, teniendo en cuenta el  perfil y los antecedentes cl\u00ednicos  de la \npaciente , se examin\u00f3 la tasa de eventos hemorr\u00e1gicos derivados del uso de \nacalabrutinib en los ensayos cl\u00edni cos para, finalmente, valorar su  beneficio -riesgo.  915 \nEl farmac\u00e9utico responsable de la co nsulta de pacientes externos  inform\u00f3 al m\u00e9dico  \nprescriptor  de la escasa  informaci\u00f3n  existente , as\u00ed como de la ausencia de datos que \nasegurasen que la paciente no iba a tener eventos hemorr\u00e1gicos. D ada la incertidumbre \nde la efectividad  de ibrutinib  en dosis reducidas, s e dec idi\u00f3 iniciar acalabrutinib .  \nTras esta decisi\u00f3n, el paciente fue visto en la consulta de atenci\u00f3n farmac\u00e9utica. En la \nrevisi\u00f3n del tratamiento, el fa rmac\u00e9utico detect\u00f3  que la paciente estaba en tratamiento \ncon omeprazol, existiendo  una interacci\u00f3n con acalabrutinib , y propuso al m\u00e9dic o su \nsustituci\u00f3n por famotidina, tal y  como se describe en la  ficha t\u00e9cnica  de acalabrutinib  \n(3). \nEl farmac\u00e9utico explic\u00f3  a la paciente c\u00f3mo debe to mar el medicamento, le advirti\u00f3  \nsobre los efectos adversos m\u00e1s frec uentes y proporcion\u00f3  informaci\u00f3n escrita con la \ninformaci\u00f3n m\u00e1s relevante. As\u00ed mismo, se facilit\u00f3  un tel\u00e9fono  de contacto con el \nfarmac\u00e9utico por si tuviera alguna duda o cuesti\u00f3n.  \nActualmente se lleva a cabo un seguimiento  estrecho  de la paciente, se revisan \nanal\u00edticas y se refuerza  en caso de observar interrupciones u olvidos frecuentes de la \ntoma del medicame nto; adem\u00e1s, se realiza vigilancia  de los posibles efectos secundarios \nrelacionados con la medicaci\u00f3n contactando con el facultativ o prescriptor en caso \nnecesario.  \nBIBLIOGRAF\u00cdA  \n1. Jemal A, Murray T, Samuels A et al. Cancer statistics . Can J Clin. 2003;53(1 )5-26. \n2. D\u00f6hner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in \nchronic lymphocytic leuk emia. N Engl J Med. 2000. (1910 -1916).  \n3. Ficha t\u00e9cnica de Acalabrut inib. Disponible en: \nhttps://cima.aemps.es/cima/dochtml/ft/1201479002/FT_1201479002.html  916 \n4. Byrd JC, Hillmen P, Ghia P et al. Acalabrutinib versus ib rutinib in previously treated \nchronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin \nOncol. 2021;39(31):3441 -52. \n5. National Comprehensive Cancer Network\u00ae (NCCN\u00ae) Clinical Practice Guidelines in \nOncology, Chronic Lymphocytic Leu kemia. V 2.2022. Disponible en: \nhttps://www.nccn.org/professionals/physician_gls/pdf/cll -spanish.pdf . \n6. European Society for Medical Oncology (ESMO). Clinical Practice Guidelines for \ndiagnosis, treatment and follow up. Disponible en: \nhttps://www.esmo.org/guidelines/haematological -malignancies/chroni c-\nlymphocytic -leukaemia .  \n7. Grupo Espa\u00f1ol Leucemia Linf oc\u00edtica Cr\u00f3nica  (GELLC) . Gu\u00eda Nacional de leucemia \nlinf\u00e1tica cr\u00f3nica y linfoma linfoc\u00edtico. Diciembre 2021.  Disponible en: \nhttps://www.ge llc.es/images/pdf/guias_gellcv1.pdf  \n8. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications \nfor treatment, response assessment, and supportive management of  CLL. Blood. \n2018;131(2745 -2760).  \n9. Sharman JP, Egyed M, Jurczak  W et al. Efficacy and safety in a 4 -year follow -up of \nthe ELEVATE -TN study comparing acalabrutinib with or without obinutuzumab  \nversus obinutuzumab plus chlorambucil in treatment na\u00efve chronic lymphocytic \nleukemia. Leukemia. 2022; 1 -5. Disponible en: \nhttps://www.nature.com/articles/s41375 -021-01485 -x \n10. Davids MS, Waweru C, Le Nouveau P et al. Comparative efficacy of acalabrutinib  in \nfrontline treatment of chronic lymphocytic leukemia: a systematic review and \nnetwork meta -analysis. Clin Ther.2020;42(10):1955 -1974  917Introducci\u00f3n \nLa aparici\u00f3n de \u00falceras perianales puede estar en relaci\u00f3n con m\u00faltiples etiolog\u00edas. La \npatolog\u00eda tumoral, infecciosa, inmunol\u00f3gica y farmacol\u00f3gica pueden ser causa de \nlesiones ulceradas perianales. Recientemente Mar\u00edn-Pi\u00f1ero et al. 20211 han publicado \nuna serie de 11 casos de \u00falceras perianales tras la aplicaci\u00f3n de una pomada \nantihemorroidal (PH) con acet\u00f3nido de triamcinolona, lidoca\u00edna y pentosano polisulfato \ns\u00f3dico como principios activos.  \nEl pioderma gangrenoso (PG) es un trastorno cut\u00e1neo inflamatorio y ulceroso poco \nfrecuente caracterizado histopatol\u00f3gicamente por la acumulaci\u00f3n de neutr\u00f3filos en la \npiel. La presentaci\u00f3n m\u00e1s com\u00fan de PG es el desarrollo r\u00e1pido de una o m\u00e1s \u00falceras \npurulentas dolorosas con bordes socavados en sitios de piel normal o traumatizada. El \ndiagn\u00f3stico se basa en una cl\u00ednica y unos hallazgos histopatol\u00f3gicos compatibles, y en el \ndescarte de otras posibilidades diagn\u00f3sticas, dado que no existen actualmente hallazgos \npatognom\u00f3nicos de esta enfermedad2.  \nEl espectro de dermatosis neutrof\u00edlicas secundarias a los tratamientos oncol\u00f3gicos \nbasados en inmunoterapia incluye el s\u00edndrome de Sweet, erupciones pustulosas, lupus \neritematoso ampolloso y PG. Se consideran raros, con solo unos pocos casos \ninformados3. El inicio de las dermatosis neutrof\u00edlicas parece ser relativamente tard\u00edo, \nvariando de semanas a meses. \nA continuaci\u00f3n, exponemos el caso de un paciente que present\u00f3 como diagn\u00f3stico PG \ndespu\u00e9s de descartar otras causas de ulceraci\u00f3n tras 50 meses de tratamiento con \nnivolumab, un inhibidor de programmed cell death protein 1  (PD1). \nDescripci\u00f3n del caso 918Var\u00f3n de 62 a\u00f1os, sin antecedentes de inter\u00e9s, sin alergias medicamentosas conocidas, \nexfumador y una historia oncol\u00f3gica que debuta en mayo de 2014. \nMayo 2014, primera neoplasia : carcinoma uroterial vesical (pT1) tratado con resecci\u00f3n \ntransuretral (RTU) y bacilo de Calmette-Gu\u00e9rin (BCG) intravesical. Noviembre de 2014, \nsegunda neoplasia : adenocarcinoma de pulm\u00f3n estadio al diagn\u00f3stico cT3N2M1 (\u00f3sea \na nivel L3). El paciente es intervenido e inicia primera l\u00ednea de tratamiento con cisplatino \n75 mg/m2 + pemetrexed 500 mg/m2 cada 21 d\u00edas seguido de tratamiento con \npemetrexed 500 mg/m2 en monoterapia. Agosto de 2015, progresi\u00f3n y segunda l\u00ednea \nde tratamiento : el paciente presenta progresi\u00f3n pulmonar de manera que se decide \niniciar una segunda l\u00ednea dentro del ensayo cl\u00ednico Galaxy2 (randomizado a la branca de \ncontrol: doxetaxel 75 mg/m2 cada 21 d\u00edas). Abril de 2016, nueva progresi\u00f3n y tercera \nl\u00ednea de tratamiento : tras ocho ciclos de tratamiento con docetaxel, el paciente \npresenta nueva progresi\u00f3n pulmonar y \u00f3sea. Se inicia tratamiento de tercera l\u00ednea con \nnivolumab 3 mg/kg cada 15 d\u00edas + \u00e1cido zolendr\u00f3nico. Diciembre de 2019, aparici\u00f3n de \nlesiones ulceradas en regi\u00f3n perineal : el paciente debut\u00f3 con peque\u00f1as \u00falceras en la \nregi\u00f3n inguino-escrotal derecha. Febrero de 2020, ingreso para valoraci\u00f3n de las \nlesiones ulceradas:  se hizo biopsia que fue inespec\u00edfica y se consult\u00f3 con el Servicio de \nDermatolog\u00eda. Con el diagn\u00f3stico de hidrosadenitis supurativa, se sigui\u00f3 el tratamiento \ncon nivolumab haciendo tambi\u00e9n tratamiento antibi\u00f3tico y local. La lesi\u00f3n fue \nempeorando con la presencia de una \u00falcera amplia y profunda en la zona perianal, \nperineal e inguino-escrotal de m\u00e1s de 20 cent\u00edmetros. Julio de 2020, tratamiento de \nnivolumab interrumpido : por progresi\u00f3n importante de la ulceraci\u00f3n, se realizan \nnuevas biopsias y cultivos y se orienta el cuadro de probablemente efecto adverso \nrelacionado con el tratamiento de inmunoterapia3. Por lo que se decide tratamiento con 919prednisona a 1 mg/kg/d\u00eda y suspensi\u00f3n del tratamiento con inmunoterapia (tras 50 \nmeses de tratamiento con nivolumab). Setiembre de 2020,  infliximab + corticoides : el \npaciente no presenta mejor\u00eda cl\u00ednica por lo que se decide conjuntamente con el Servicio \nde Dermatolog\u00eda y Medicina Interna valorar inmunosupresi\u00f3n adicional con infliximab 5 \nmg/kg (recibi\u00f3 5 dosis). Diciembre de 2021, inmunoglobulinas intravenosas (IGIV) + \ncorticoides : el paciente presenta progresi\u00f3n de las lesiones del PG, por lo que se decidi\u00f3 \ntratamiento con IGIV (IGIV 0.6 g/kg/d\u00eda d1-3 + metilprednisolona 250 mg/d\u00eda IV d1-3 \ncada 28 d\u00edas) y prednisona de mantenimiento (30 mg/d\u00eda). Febrero de 2021, ingreso \nhospitalario:  las lesiones no mejoran y el paciente presenta adem\u00e1s Cushing iatrog\u00e9nico \ne hiperglicemia que precisa insulina. Sobreinfecci\u00f3n de la herida que precisa ingreso por \nantibi\u00f3ticos parenterales. Episodio de dolor tor\u00e1cico inespec\u00edfico y palpitaci\u00f3n. Marzo \nde 2021, IGIV + micofenolato de mofetilo (MMF):  se propone a\u00f1adir MMF iniciando a \n500 mg/12 horas, y si buena tolerancia augmentar a las 2 semanas a 1000 mg/12 horas \ny en 2 semanas m\u00e1s a 1500 mg/12 horas como dosis objetivo. El paciente presenta \nintolerancia digestiva al tratamiento con MMF y reacci\u00f3n leve a las IGIV despu\u00e9s del \ntratamiento en forma de escalofr\u00edos y malestar general, por esta raz\u00f3n se suspendi\u00f3 el \ntratamiento con MMF. El escozor y dolor que provocaba la gran \u00falcera se paliaba con \nanalg\u00e9sicos y opi\u00e1ceos orales y en parche. De las curas t\u00f3picas a destacar los fomentos \nantis\u00e9pticos, los antibi\u00f3ticos t\u00f3picos, el uso de una PH (\u00fanico tratamiento que toleraba \nperfectamente) y de una crema anest\u00e9sica (lidoca\u00edna-priloca\u00edna) a demanda. Junio de \n2021, leucoaf\u00e9resis: se plantea e  inicia tratamiento con leucoaf\u00e9resis (1-2 sesiones \nsemanales por 5 ciclos y posterior mantenimiento mensual). Julio de 2021, ingreso \nhospitalario: el paciente presenta metahemoglobinemia secundaria a intoxicaci\u00f3n por \nel uso excesivo de la pomada anest\u00e9sica (debido a la priloca\u00edna contenida en la misma).  920Agosto de 2021, c\u00e1mara hiperb\u00e1rica:  el paciente 2021 inicia oxigenoterapia hiperb\u00e1rica \ncon una r\u00e1pida y gran mejor\u00eda de las lesiones del PG con reepitalizaci\u00f3n progresiva que \npermite ir retirando el tratamiento con corticoide y las curas locales. Ha completado 71 \nsesiones de ox\u00edgeno hiperb\u00e1rico con muy buena evoluci\u00f3n: reepitelizaci\u00f3n casi completa \nal finalizar el tratamiento (se detiene por alteraciones visuales secundarias reversibles) \ny acaba curando de forma definitiva a los 2 meses posteriores. Febrero de 2022, \nestabilidad radiol\u00f3gica de control: el \u00faltimo estudio de extensi\u00f3n con TAC toraco-\nabdominal sigue sin mostrar progresi\u00f3n del proceso neopl\u00e1sico.  \nDiscusi\u00f3n y aportaci\u00f3n farmac\u00e9utica \nAunque la etiolog\u00eda y la fisiopatolog\u00eda del PG no est\u00e1n claramente establecidos, se \nconocen varios factores en la patogenia del PG: alteraci\u00f3n del sistema inmune del \npaciente, quimiotaxis excesiva de citoquinas proinflamatorias y migraci\u00f3n anormal de \nneutr\u00f3filos2. Con respecto al origen, se ha demostrado que m\u00e1s de la mitad de los \npacientes con PG presentan una enfermedad sist\u00e9mica concomitante, entre ellas la \nexistencia de tumores s\u00f3lidos, con una incidencia entre el 7,4-18%4. \nLos mecanismos por los que los inhibidores de PD1 pueden desencadenar dermatosis \nneutrof\u00edlicas o PG y su asociaci\u00f3n con la eficacia antitumoral siguen sin estar claros. \nAunque anteriormente se sugiri\u00f3 que el PG es un trastorno de la desregulaci\u00f3n \ninmunitaria innata y la quimiotaxis de neutr\u00f3filos alterada2, existe evidencia de que las \nc\u00e9lulas T pueden desempe\u00f1ar un papel importante en la patogenia del PG. Las lesiones \ntempranas muestran un infiltrado de linfocitos T, en lugar de neutr\u00f3filos dominantes, y \nse ha identificado una expansi\u00f3n clonal de linfocitos T en la piel y la circulaci\u00f3n de \npacientes con PG5,6. Las alteraciones en la tolerancia inmune de las c\u00e9lulas T inducidas \npor los inhibidores de PD1 pueden conducir a una autoinmunidad mediada por c\u00e9lulas 921T y al posterior desarrollo del PG. En una revisi\u00f3n sistem\u00e1tica2 se encontraron 2 casos \nde PG asociado a pacientes con tratamiento con inmunoterapia. El diagn\u00f3stico se realiz\u00f3 \n16 semanas despu\u00e9s de la primera dosis de la inmunoterapia. En un caso, hubo \nrespuesta completa con el tratamiento de una combinaci\u00f3n de esteroides orales e \ninfliximab, mientras que en la otra una combinaci\u00f3n de ung\u00fcentos t\u00f3picos, esteroides \nsist\u00e9micos y antibi\u00f3ticos condujeron a una parcial respuesta parcial7,8. Ninguno de los \ndos casos se inform\u00f3 de reiniciar de la inmunoterapia. Recientemente, Tsibris et al.9 han \npublicado un caso de PG en un paciente diagnosticado de carcinoma cut\u00e1neo de c\u00e9lulas \nescamosas en tratamiento con pembrolizumab aproximadamente 5 meses despu\u00e9s del \nque se inici\u00f3 de la inmunoterapia. Este caso fue resistente a la terapia con \ncorticosteroides intralesionales, pero finalmente mejor\u00f3 con corticosteroides sist\u00e9micos \ny la interrupci\u00f3n del pembrolizumab. Nuestro caso ocurri\u00f3 en un per\u00edodo de tiempo m\u00e1s \nlargo, aproximadamente 50 meses despu\u00e9s del inicio del tratamiento con nivolumab. \nDes del Servicio de Farmacia se estudia el caso, se revisa toda la bibliograf\u00eda relacionada \ny se tramita las solicitudes de tratamiento para el PG como usos off-label. La evidencia \ncient\u00edfica presentada en cada caso fue: Infliximab10, IGIV11-13 y MMF14. \nA ra\u00edz de la publicaci\u00f3n de Mar\u00edn-Pi\u00f1ero et al1 d\u00f3nde se describen los casos de pacientes \ncon \u00falceras perianales tras la aplicaci\u00f3n de una misma PH y en d\u00f3nde algunas im\u00e1genes \nde esta publicaci\u00f3n son muy similares a la gran ulceraci\u00f3n que ha presentado nuestro \npaciente se consider\u00f3 que nuestro paciente era otro caso de ulceraci\u00f3n por mal uso de \nesta PH. Retrospectivamente se confirm\u00f3 que el paciente nunca dej\u00f3 este tratamiento \na pesar de que en numerosas ocasiones se inst\u00f3 a retirarla. En esta publicaci\u00f3n la \nduraci\u00f3n de la aplicaci\u00f3n de la PH oscilaba entre las 3 semanas y los 5 a\u00f1os, con una \nmediana de 6 meses.  Los autores apuntan como causa de las ulceraciones al efecto 922sin\u00e9rgico de los 3 componentes de la crema en una zona intertriginosa con pobre \nperfusi\u00f3n como es la regi\u00f3n perianal. Vasoconstricci\u00f3n y atrofia por corticoides \n(triamcinolona), p\u00e9rdida de sensibilidad por el anest\u00e9sico (lidoca\u00edna) y posible efecto \ntromb\u00f3tico (pentosano, heparinoide) son los mecanismos patog\u00e9nicos propuestos que \nconducir\u00edan a un estado de hipoxia local que imposibilitar\u00eda los mecanismos de la \ncuraci\u00f3n-cicatrizaci\u00f3n. \nAunque la orientaci\u00f3n hasta la publicaci\u00f3n de Mar\u00edn Pi\u00f1ero et al1 fue la de PG, la no \nrespuesta a ning\u00fan tratamiento inmunosupresor y el resultado espectacular con la \nc\u00e1mara hiperb\u00e1rica avalan la patogenia de hipoxia local, con lo que todo apunta a un \nefecto adverso grave de la PH.  Por lo tanto, no ser\u00eda un PG relacionado con la \ninmunoterapia, por lo que si el paciente lo precisa podr\u00eda valorarse la reintroducci\u00f3n del \ntratamiento con nivolumab. Respecto a los tratamientos t\u00f3picos, \u00e9stos deben \ncontrolarse de cerca y no menospreciar sus posibles efectos secundarios, dado que \nalgunos pueden ser graves como en este caso. \nEn conclusi\u00f3n, a pesar de que la inmunoterapia puede causar inmunotoxicidades \ninfrecuentes y potencialmente severas15, nuestro caso pone de manifiesto la \nimportancia del diagn\u00f3stico diferencial para el \u00e9xito de la terapia. En consecuencia, \nexiste una necesidad de un enfoque multidisciplinario coordinado. \n \n \nFigura 1 . Aspecto de las \u00falceras perianales \nde nuestro paciente. 923Bibliograf\u00eda \n1. Mar\u00edn-Pi\u00f1ero D, Iglesias-Sancho M, Company-Quiroga J, et al. M\u00faltiples \u00falcereas \nperianales en relaci\u00f3n con el uso de una pomada antihemorroidal con acet\u00f3nido de \ntriamcinolona, lidoca\u00edna y pentosano polisulfato s\u00f3dico como ingredientes: una serie de \n11 pacientes espa\u00f1oles. ACTAS Dermo-sifiliogr\u00e1ficas 2021;112: 654-60. \n2.  Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: \na comprehensive review. Am J Clin Dermatol. 2012; 13:191-211. \n3. Ravi V, Maloney NJ, Worswick S. Neutrophilic dermatoses as adverse effects of \ncheckpoint inhibitors: A review. Dermatol Ther. 2019;32(5): e13074.  \n4. Kridin K, Cohen A, Amber K. Underlying Systemic Diseases in Pyoderma Gangrenosum: \nA Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2018;19(4):479-87. \n5. Brooklyn TN, Williams AM, Dunnill MG, et al. T-cell receptor repertoire in pyoderma \ngangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol. 2007;157: \n960-6.  \n6. Wang EA, Steel A, Luxardi G, et al. Classic Ulcerative Pyoderma Gangrenosum Is a T \nCell-Mediated Disease Targeting Follicular Adnexal Structures: A Hypothesis Based on \nMolecular and Clinicopathologic Studies. Front Immunol. 2017; 8:1980. \n7. Rudolph BM, Staib F, Von Stebut E, et al. Neutrophilic \ndisease of the skin and intestines after ipilimumab treatment for malignant melanoma\u2013\nsimultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol. 2014 \n24(2), 268\u2013269.  9248.  Welborn ME, Kubicki SL, Patel AB, et al. Case Report Pyoderma Gangrenosum \nFollowing Initiation of Immune Checkpoint Inhibitor Therapy. J Immunother Precis \nOncol. 2018; 1:82-4 \n9. Tsibris H, Lian C Ho A. Pembrolizumab-associated pyoderma gangrenosum in a patient \nwith metastatic squamous cell carcinoma. Dermatol. Online J. 2021, 27, 27 \n10. Patel F, Fitzmaurice S. Effective Strategies for the Management of Pyoderma \nGangrenosum: A Comprehensive Review. Acta Derm Venereol 2015; 95: 525\u2013531. \n11. Sinnya S, Hamza S. Pyoderma gangrenosum of the breast treated with intravenous \nimmunoglobulin. J Dermatol Case Rep. 2013; 7(2): 64\u201368. \n12. G\u00fcnd\u00fcz K, G\u00fclbasaran F, Hasdemir PS, et al. Successful treatment of severe \nrefractory post-cesarean pyoderma gangrenosum with intravenous immunoglobulin. \nDermatol Ther 2020;33(6): e14121. \n13. Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy \nfor refractory pyoderma gangrenosum: systematic review of cases and case series. Br J \nDermatol. 2018;178: pp363\u2013368. \n14. Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate  mofetil as a \nsteroid-sparing agent.  J Am Acad Dermatol. 2013; 69:565-9. \n15. Kumar V, Chaudhary N, Garg M, et al. Current Diagnosis and Management of \nImmune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor \nTherapy. Fron Pharmacol 2017; 8:49. 925DEBUT DE  METABOLOPAT\u00cdA EN PACIENTE PEDI \u00c1TRICO\nINTR ODUCCI\u00d3N\nLos errorescong\u00e9nitosdelmetabolismo son enfermedades hereditarias secundarias ala\nausencia oalmal funcionamien todeuna enzima ocofactoryque conlle vaalbloqueo dela\nv\u00edametab\u00f3lic a(1).Acontinuaci\u00f3n sepresen taelcasodeuna lactantede4meses que acude\na urgencias de P edia tr\u00eda por crisis c onvulsiv as refractarias al tr atamien to.\nTrasvarios estudios seconfirma una enfermedad cong\u00e9nitadel metabolismo. Poreste\nmotiv o,desde elservicio deFarmacia serevis\u00f3 lapatolog\u00eda as\u00edcomo lafarmac oterapia\nespec\u00edfic a,evaluando potenciales toxicidades ycompr obando lacorrectadosific aci\u00f3n dela\nmedic aci\u00f3n. Alaltayenlassucesiv asconsult asdeatenci\u00f3n farmac\u00e9utic aalpacien te\nexterno , se hiz o seguimien to par a evaluar la r espues tay adher encia al tr atamien to.\nDESCRIPCI\u00d3N DEL CASO\nLactantede4meses que ingresa por sospecha cl\u00ednic adecrisis comiciales secundarias a\nence falopa t\u00eda hip\u00f3 xico-isqu\u00e9mic agravefrenteauna enfermedad metab\u00f3lic a.Como\nanteceden tesm\u00e9dic osdeinter\u00e9s:reci\u00e9n nacido pret\u00e9rmino (RNP T)34+1 semanas gestaci\u00f3n\nconpeso adecuado alaedad degestaci\u00f3n, escalaApgar9/10. Lapacien tenotiene ninguna\nalergiamedic amen tosa, yambos progenitoresestaban sanos sinhallar seninguna relaci\u00f3n\nde consanguinidad en tre ellos.926Alas40horasdevida estrasladada anues trohospit alypresen taepisodios dehipert on\u00eda de\nmiembr ossuperior esconrotaci\u00f3n interna ymovimien tosautoma tizados desucci\u00f3n con\nposterior desa turaci\u00f3n ybradicardia. Estosepisodios serepitenhastaen4ocasiones.\nDestacamicr ocefalia, ence falopa t\u00eda conhipot on\u00eda, ausencia dereflejos neona tales y\nepisodios dehipert on\u00eda gener alizada conrotaci\u00f3n interna delasextremidades superior es\n(EESS), que seacompa\u00f1a de chupe teo eirritabilidad. Seadminis traun bolus de\nlevetiracetam20mg/kgconman tenimien to8mg/kg/d\u00eda que seman tiene hastalos11d\u00edas\ndevida. Alintroducir elantiepil\u00e9p ticomejor alasemiolog\u00eda ictal.Lamonit orizaci\u00f3n dela\nfunci\u00f3n cerebral(MFC)revela inicialmen teunpatr\u00f3ndiscontinuo que evoluciona a\nbrote-supr esi\u00f3n sinevidenciar crisis el\u00e9ctric as.Los dos electr oence falogr amas (EEG)no\npresen tansignos deactividad comicial. Serealiz apunci\u00f3n lumbar yseinstauratratamien to\nemp\u00edric ocon ampicilina ycefotaxima endo venosa que comple tadurante5d\u00edas. La\ncitoqu\u00edmic adell\u00edquido cefalorr aqu\u00eddeo esnormal, lasreacciones encadena delapolimer asa\n(PCR) bact erianas yv\u00edricasson negativas,as\u00edcomo ,elcultiv onegativo.Porestemotiv o,se\norien tacomo probable ence falopa t\u00eda hip\u00f3 xico-isqu\u00e9mic a(EHI) deorigenprenataly,\nposteriormen te, se sigue en c onsult as externas de neur opedia tr\u00eda.\nAlos4meses devida, ingresaporsospecha decrisis comiciales consis tentesendesviaci\u00f3n\ndelamirada de5-6 segundos deuna semana deevoluci\u00f3n. Enlosepisodios refiere\ndesviaci\u00f3n t\u00f3nic aoculoce f\u00e1licaderecha con4-5 movimien tosbrusc ossinrespues taa\nest\u00edmulos, acompa\u00f1ados chupe teo.Serealiz aEEGque mues traactividad epil\u00e9p ticaanivel\nparie talizquier doinici\u00e1ndose tratamien toconlevetiracetama20mg/kg/d\u00eda oral(VO)y\n\u00e1cido valproicoa15mg/kg/d\u00eda VO,conposterior mejor\u00eda delasemiolog\u00eda ictal.Enelcontrol\nanal\u00edtic odelingresonoseobservaninguna alteraci\u00f3n delamonio nidel\u00e1cido l\u00e1ctic oaunque927sedecide cursarunestudio metab\u00f3lic oensangr eyorina (result anormal) as\u00edcomo un\nestudio g en\u00e9tico del e xoma.\nDuranteelingreso,ytrasvarias anal\u00edtic asdecontrol,lapacien temues trauna acidosis\nmetab\u00f3lic a(pH 7,17 yHCO3 16mEq/L) conhiperlact acidemia grave(10 mmol/L) e\nhiper amonemia (134 mcg /dL) porloque sedecide repetirelestudio metab\u00f3lic oquedando\na\u00fan pendien teelestudio gen\u00e9tico.Seobservanalteraciones anal\u00edtic asporloque sedeja en\ndietaabsolut aconsuer oterapia deman tenimien to10mg/kg/min deglucosa einicia\nvitaminas y c ofactores.\nTraslasospecha deundebut deuna metabolopa t\u00edaseaplic anlasmedidas gener ales\nurgentesdetratamien to,que son comunes aotroserrorescong\u00e9nitosdelmetabolismo. As\u00ed\npues, sedecide suspender elaport eproteicounm\u00e1ximo de48h ygarantizarelaport e\ncal\u00f3ric oenforma deglucosa (10-15 mg/kg/min) corrigiendo laglucemia coninsulina si\nprecisa. Tambi\u00e9n seajustalaacidosis conbicarbona tolentamen teparaevitaruna acidosis\nparad\u00f3jic a a niv el del SNC (2).\nAlconfirmar selaacidosis l\u00e1ctic adelpacien te,seinici\u00f3 elc\u00f3cteldevitaminas ycofactoresya\nque act\u00faan enlasprincipales v\u00edas metab\u00f3lic asalteradas. Enestecaso,seinici\u00f3 tiamina 100\nmg/8hque act\u00faa como cofactordelapiruv atodeshidr ogenasa. Tambi\u00e9n biotina 5mg/8hal\nfacilit arlaacci\u00f3n delapiruv atocarbo xilasa, as\u00edcomo ribofla vina 100 mg/8hyaque participa\ncomo cofactordeloscomplejos I-IIdelacadena respir atoria (CR) mitocondrial (3).Seus\u00f3\nvitamina C1g/24h que facilit alatransferencia electr \u00f3nic aalcomplejo IVdelaCR.La\nubidec arenona (coenzima Q10) sepaut \u00f3enuna dosis de100 mg/8h yaque tambi\u00e9n est\u00e1928implic ada enlatransferencia deelectr ones enloscomplejos I-IIIdelaCR.Finalmen te,se\npaut \u00f3carnitina 300 mg/8h conlafinalidad dedetoxificarmetabolit osycomo transport ador\nde\u00e1cidos grasos (AG)decadena largausados enla\u03b2-oxidaci\u00f3n (3). Alnotener un\ndiagn\u00f3s ticoexactodelametabolopa t\u00eda,sepaut arontodas lasvitaminas ycofactoreshasta\npoder c onfirmar qu\u00e9 v\u00eda me tab\u00f3lic a est\u00e1 alt erada (4).\nElestudio gen\u00e9ticoresult \u00f3noserconcluy enteynosepudo relacionar conlapatolog\u00eda que\npresen taba lapacien te.Porestemismo motiv o,sedecidi\u00f3 repetirelan\u00e1lisis delexoma y\notros es tudios m\u00e1s e xhaus tivos.\nDISCUSI\u00d3N Y APOR TACI\u00d3N F ARMA C\u00c9UTICA\nLasmetabolopa t\u00edas son enfermedades debaja incidencia peroque el\u00e9xitodeltratamien to\nvaadepender enbuena medida desuprecocidad (1). Poreso,enmuchas ocasiones, se\ndebe iniciar untratamien todeurgencia sindisponer a\u00fan deundiagn\u00f3s ticocerterodela\nenfermedad. Lasintoma tolog\u00eda dealert aque puede orien tareldiagn\u00f3s ticoesundeterior o\nneur ol\u00f3gic oacompa\u00f1ado decrisis comiciales enforma desucci\u00f3n d\u00e9bil, letargiaohipot on\u00eda\nas\u00ed c omo , afectaci\u00f3n hep\u00e1 tica o c ard\u00edaca (5).\nEnnues trocaso,lapacien teacudi\u00f3 aurgencias trascrisis comiciales refractarias aun\ntratamien toantiepil\u00e9p ticopreviamen teinstaurado. Desde elingreso,enanal\u00edtic asde\ncontrol,seobserv\u00f3una acidosis metab\u00f3lic aconhiperlact acidemia ehiper amonemia. Por\nestemotiv o,sesospech\u00f3 deuna enfermedad metab\u00f3lic ayeltratamien tofueprescrit ocon\nurgencia.929Elfarmac\u00e9utic o,integrado enunequipo multidisciplinar formado por neona t\u00f3log os,\nneur \u00f3log os y g astroenter\u00f3log os pedi\u00e1 tricos, tuv o que abor dar dis tintos pr oblemas:\nInterpr etaci\u00f3n delosdatosanal\u00edtic os.Median telarevisi\u00f3n delcursocl\u00ednic oydelaspruebas\ndiagn\u00f3s ticas,secontribuy \u00f3aorien tareldiagn\u00f3s ticodeuna enfermedad que requier eun\nr\u00e1pido inicio t erap\u00e9utic o.\nRevisi\u00f3n delafarmac oterapia enlasmetabolopa t\u00edas.Desde elservicio deFarmacia serealiz \u00f3\nuna b\u00fasqueda bibliogr \u00e1ficaacer cadelafarmac oterapia delasenfermedades metab\u00f3lic as\npararespues tayconsensuar conelservicio depedia tr\u00eda, lasdosis ylaelabor aci\u00f3n de\nf\u00f3rmulas magis trales enlosf\u00e1rmac osque eraposible, ylaforma deadminis traci\u00f3n delos\ndem\u00e1s f \u00e1rmac os que no er a posible su elabor aci\u00f3n en f \u00f3rmula magis tral.\nLaelabor aci\u00f3n def\u00f3rmulas magis trales (FM) adap tadas paraelpacien tepedi\u00e1 tricofue\nfundamen talparalaeficacia, seguridad yadher encia. Seevaluar ondistintasgu\u00edas parala\nelabor aci\u00f3n deFM deadminis traci\u00f3n oralparalaenfermedad metab\u00f3lic a:tiamina 100\nmg/ml, ribofla vina 10mg/ml ybicarbona to1M. Adem\u00e1s seelabor \u00f3clobaz am1mg/ml\nasociado al tr atamien to an tiepil\u00e9p tico de base.\nAtenci\u00f3n farmac\u00e9utic aalalta.Previamen tealaltaserealiz \u00f3atenci\u00f3n farmac\u00e9utic ayse\ninstruy\u00f3alosfamiliar esparauna adecuada adminis traci\u00f3n del tratamien tomedian te\ninformaci\u00f3n oralyescrit a.Posteriormen tesecit\u00f3alpacien teenlasconsult asexternas del\nservicio deFarmacia parapoder continuar conladispensaci\u00f3n deltratamien toyevaluar los\npotenciales pr oblemas r elacionados c on la medic aci\u00f3n que pudiesen sur gir.930Validaci\u00f3n delamedic aci\u00f3n concomit ante.Durantelosm\u00faltiples ingresos, sevalid\u00f3 el\ntratamien toutiliz ando elprograma deprescripci\u00f3n electr \u00f3nic aprestando especial atenci\u00f3n\na los ajus tes de dosis de los f \u00e1rmac os an tiepil\u00e9p ticos en tre otr as medic aciones.\nSolicitud def\u00e1rmac osensituaci\u00f3n especial. Latramit aci\u00f3n dealgunos f\u00e1rmac oscomo la\nubidec arenona (Coenzima Q10) como medic aci\u00f3n extranjer afuefundamen talparapoder\ngarantizar el tr atamien to de la pacien te.\nProtocolizaci\u00f3n del tratamien tourgentedelasmetabolopa t\u00edas. Antelagravedad dela\nsituaci\u00f3n, yteniendo encuen tadeque setratadeunhospit aldereferencia enlaprovincia,\ntambi\u00e9n seconsensu\u00f3 juntoconelservicio dePedia tr\u00edaunprotocolodemanejo terap\u00e9utic o\nurgenteenlasmetabolopa t\u00edas. Paralelamen te,desde elservicio deFarmacia sedecidi\u00f3\nelabor arunbotiqu\u00edn conunstockm\u00ednimo delosf\u00e1rmac osnecesarios paraelinicio urgente\nen caso de sospecha o debut de alguna me tabolopa t\u00eda.\nEn elprotocolo sedescribier on los f\u00e1rmac osimplic ados eneltratamien todelas\nenfermedades metab\u00f3lic as, presen taci\u00f3n, forma farmac\u00e9utic a, paut aposol\u00f3gic a,\nadminis traci\u00f3n yposibles efectosadversos. Serecogier on,tambi\u00e9n, una serie demedidas\ngener ales aadop taren caso de sospecha de debut odesc ompensaci\u00f3n deuna\nmetabolopa t\u00eda. Elreajus tedelascalor\u00edas tantoproteicascomo noproteicasesdevital\nimport ancia as\u00edcomo una correcci\u00f3n delaglucemia ydelaacidosis. Delamisma maner a,es\nnecesario una rehidr ataci\u00f3n eficazparaestablecer unequilibrio hidroelectr ol\u00edtic opero\ntambi\u00e9n paraman tener una diuresis eficaz(>1ml/kg /h)yas\u00edconseguir eliminar ciert os\ncompues tosconbuen aclar amien torenal como puede ser el\u00e1cido metilmal\u00f3nic o,las931acilc arnitinas oel\u00e1cido hip\u00faric o(6). Esimport antevigilar lasobr ecargadesolut osque\nimplic aelaport eexterno debicarbona toyaque eso puede condicionar aunaumen todela\ndiuresis conriesg odedeshidr ataci\u00f3n hiperna tr\u00e9mic a(1).Hayque tener encuen tatambi\u00e9n\nque debe realiz arseconuna soluci\u00f3n nohipoosmolar ensodio paranoempeor areledema\ncerebral(1).Elvolumen h\u00eddric odiario tampoc odebe sermuy elevado (<180 ml/kg /24h) ya\nque eso podr\u00eda ocasionar una hipot on\u00eda plasm\u00e1 ticaque agravase laence falopa t\u00edat\u00f3xica\naguda, r elativamen te frecuen te en es te contexto (2).\nAdem\u00e1s deltratamien toinicial gener al,sepuso \u00e9nfasis enlasdos patolog\u00edas metab\u00f3lic as\nm\u00e1s frecuen tes(acidosis l\u00e1ctic aseveraylahiper amonemia) que precisan deuna\nfarmac oterapia espec\u00edfic a.Una deellas eslaacidosis l\u00e1ctic aenlaque deben detener seen\ncuen tauna serie deconsider aciones especiales (aport edenutrien tesycorrecci\u00f3n dela\nacidosis) juntoconlautiliz aci\u00f3n deciert asvitaminas ycofactores.Enelprotocolo se\nestableci\u00f3 eluso detiamina 100-300 mg/d\u00eda VOoendo venoso en2-3dosis, biotina 10-20\nmg/d\u00eda VOen2-3 dosis, ribofla vina 100-300 mg/d\u00eda VO,vitamina C1g/d\u00eda VOo\nintramuscular ,coenzima Q10 100-300 mg/d\u00eda en3dosis ycarnitina 50-200 mg/kgVOo\nendo venoso en 3-4 dosis (3).\nEnestecaso expues to,seevidencia elrolfundamen taldelfarmac\u00e9utic ointegrado enel\nservicio dePedia tr\u00eda paraayudar tantoenlarevisi\u00f3n delafarmac oterapia, como enla\nadecuaci\u00f3n deltratamien toalascaracter\u00edsticasdelpacien tepedi\u00e1 trico,aport ando as\u00eduna\nadecuada c alidad asis tencial .932BIBLIOGRAFIA\n(1)Couce Pico,ML; Fern\u00e1nde zLorenzo,JR; FragaBerm\u00fade z,JM. Enfermedades\ncong\u00e9nitasdel metabolismo en elper\u00edodo neona tal.Protocolos Diagno\u0301stico\nTerap\u00e9utic os de la AEP: Neona tologi\u0301a, 2008.\n(2)DelToroRiera,M;PintosMor ell,G;Rodr\u00edgue z-Palmer o,A.Abor daje pr\u00e1ctic odelos\nerrores cong\u00e9nitos del me tabolismo. Socie tat Catalana de P edia tria, 2010.\n(3)Del ToroRiera,M.Protocolo del tratamien toinicial deloserroresinna tosdel\nmetabolismo in termedio. Hospit al Vall d\u2019Hebr \u00f3n, 2010.\n(4)Protocolos dediagn\u00f3s ticoytratamien todelosErroresCong \u00e9nitosdelMetabolismo.\nAECOM. 2\u00aa edici\u00f3n. ISBN: 978-84-16732-98-2.\n(5)Ogier deBauln y,H.Manag emen tand emer gency treatmen tsofneona teswith a\nsuspicion of inborn err ors of me tabolism. Seminar s in Neona tology 2002; 7:17-26.\n(6)Weiner ,DL.Metabolic emer gencies. Textbook ofpedia tricemer gency medicine. 5th\nedition. Lippinc ott Williams and Wilkins, 2006. p.1193.933T\u00cdTULO \nTratamiento de aspergilosis pulmonar invasiva en un paciente cr\u00edtico con COVID -19, tratado con doble \nsistema de ECMO y con TCRR \nINTRODUCCI\u00d3N \nLos pacientes en la Unidad de Cuidados Intensivos (UCI) presentan caracter\u00edsticas fisiopatol\u00f3gicas \ndiferenciales y tasas de mortalidad mayores en comparaci\u00f3n con aquellos en unidades de hospitalizaci\u00f3n \nconvencionales. Concretamente, la enfermedad cr\u00edtica se asocia a cambios fisiopatol\u00f3 gicos complejos \ncon afectaci\u00f3n severa y variable en la farmacocin\u00e9tica de los f\u00e1rmacos. En el caso de las infecciones \nf\u00fangicas, \u00e9stas se asocian con peores resultados cl\u00ednicos por diferentes causas, incluyendo el cambio en \nla farmacocin\u00e9tica de los agentes  antif\u00fangicos condicionando una probabilidad aumentada de obtener \nresultados terap\u00e9uticos sub\u00f3ptimos.1 Adem\u00e1s, determinadas terapias de soporte o tratamiento empleadas \nen estos pacientes como el uso de membranas de oxigenaci\u00f3n extracorp\u00f3reas (ECMO), las terapi as \ncontinuas de remplazo renal (TCRR) o las plasmaf\u00e9resis, pueden alterar la farmacocin\u00e9tica de los \nf\u00e1rmacos condicionando dosis sub\u00f3ptimas de \u00e9stos. La ECMO es un dispositivo complejo de bypass \ncardiopulmonar utilizado temporalmente en el soporte de pacien tes muy cr\u00edticamente enfermos con fallo \nrespiratorio y/o card\u00edaco. La ECMO supone un reto entorno al manejo farmacoterap\u00e9utico del paciente  \ncr\u00edtico ya que contribuye a alteraciones en la farmacocin\u00e9tica de los f\u00e1rmacos empleados de tres \nmaneras: (i) extracci\u00f3n de f\u00e1rmaco por el circuito: dependiente de los materiales que componen el \ncircuito y de las propiedades f\u00edsico-qu\u00edmicas de los f\u00e1rmacos y donde participan mecanismos de \nadsorci\u00f3n no espec\u00edfica mediados principalmente por interacciones hidrof\u00f3bi cas con los pol\u00edmeros y \nelectrost\u00e1ticas con los revestimientos de las superficies del circuito (mostradas en experimentos ex vivo  \ny afectando principalmente a f\u00e1rmacos altamente lipof\u00edlicos y con uni\u00f3n a prote\u00ednas plasm\u00e1ticas  \nmoderada), (ii) incremento del volumen de distribuci\u00f3n: mediado por m\u00faltiples mecanismos como la \nextracci\u00f3n de f\u00e1rmaco previamente explicada, la hemodiluci\u00f3n (debida a los vol\u00famenes de sangre o \ncristaloides requeridos en el cebado del circuito, siendo un factor m\u00e1s importante en neonat os que en el \npaciente adulto y afectando m\u00e1s a aquellos f\u00e1rmacos con vol\u00famenes de distribuci\u00f3n bajo) y los cambios 934fisiol\u00f3gicos en el paciente cr\u00edtico en ECMO (inflamaci\u00f3n, alterando la permeabilidad capilar y \ncondicionando edema y alteraciones en el equil ibrio \u00e1cido-base alterando el estado de ionizaci\u00f3n de los \nf\u00e1rmacos) y (iii) alteraci\u00f3n del aclaramiento de los f\u00e1rmacos: porcentajes elevados de pacientes con \nfallo renal multifactorial y posible reducci\u00f3n en la actividad citocr\u00f3mica en contextos  de inflamaci\u00f3n \nmantenida.2 El objetivo de este caso cl\u00ednico es reportar nuestra experiencia en el tratamiento de un caso \nde aspergilosis pulmonar invasiva (API) en un paciente cr\u00edtico afecto de COVID -19 grave que requiri\u00f3 \ntratamiento de soporte con dos circuitos de ECMO simult\u00e1neos asociado a  TCRR.  \nDESCRIPCI\u00d3N DEL CASO  \nSe describe el caso de un paciente de sexo masculino de 47 a\u00f1os de edad, sin alergias a medicamentos \npreviamente conocidas, con antecedentes patol\u00f3gicos de hipertensi\u00f3n arterial y psoriasis en gotas en \ntratamiento con metotrex ato. Ingresa en UCI el d\u00eda 19 de diciembre de 2021 por insuficiencia \nrespiratoria severa debido a COVID -19 sin antecedentes de vacunaci\u00f3n  precisando intubaci\u00f3n y \nventilaci\u00f3n mec\u00e1nica. Antropom\u00e9tricamente el paciente presentaba un peso previo al ingreso de 90 kg \ny una altura de 183 cm. El d\u00eda 26 de diciembre, se inicia tratamiento emp\u00edrico con piperacilina -\ntazobactam y amfotericina B liposomal por empeoramiento respiratorio, leucocitosis, fiebre y signos de \nsepsis en el contexto de sobreinfecci\u00f3n bacteriana respiratoria por Staphylococcus aureus meticilina \nsensible. El d\u00eda 27 de diciembre por insuficiencia respiratoria refractaria se instaura soporte respiratorio \ncon ECMO veno-venosa. En broncoaspirado se evidencia presencia de Aspergillus spp. por lo que se \nrealiza fibrobroncoscopia con lavado broncoalveolar que con firma diagn\u00f3stico de API. \nEl primer problema farmacoterap\u00e9utico a tratar fue la elecci\u00f3n del tratamiento antif\u00fangico \nadecuado. En ese momento, el paciente no presentaba signos anal\u00edticos de fallo hep\u00e1tico pero ha b\u00eda \nsufrido fallo renal agudo con valores de creatinina de hasta 1.7 miligramos por decilitro (mg/dL),  y \nactualmente presentaba creatinina de 1 mg/dL y urea de 120 mg/dL. Las gu\u00edas para el manejo y \ntratamiento de la aspergilosis de la IDSA actualizadas en 2016 recomiendan el tratamiento de la \naspergilosis invasiva con voriconazol preferentemente y con amfotericina B liposomal o isavuconazol \ncomo alternativas.3 En el caso de las gu\u00edas ofrecidas por la ESCMID -ECMM-ERS publicadas 935posteriormente en 2017 recomiendan el tratamiento de la API en pacientes no hematol\u00f3gicos con \nvoriconazol preferentemente y con amfotericina B liposomal como alternativa.4 El documento de \nconsenso GEMICOMED-SEIMC/REIPI publicado en 2018 recomienda el tratamiento con voriconazol \ncomo agente de primera l\u00ednea en pacientes cr\u00edticos considerando el isavuconazol y la amfotericina B \nliposomal como alternativas.5 Sin embargo, la ficha t\u00e9cnica de voriconazol recomienda el tratamiento \noral, no posible en este caso, en aquellos pacientes con insuficiencia renal y aclaramiento de creatinina \nmenor de 50 ml/min por acumulaci\u00f3n del excipiente sulfobutil\u00e9ter beta-ciclodextrina s\u00f3dica presente \nen la forma farmac\u00e9utica para uso endovenoso. Adem\u00e1s, voriconazol es una mol\u00e9cula lip\u00f3fila \n(coeficiente de partici\u00f3n N -octanol/agua de 1), con un volumen de distribuci\u00f3n en equilibrio \nestacionario bajo de 4.6 L/kg y con una uni\u00f3n a prote\u00ednas plasm\u00e1ticas del 58%. Se han  descrito casos \nen los que la farmacocin\u00e9tica ha sido variable en pacientes en ECMO. Se ha reportado un caso de \ntratamiento en un paciente pedi\u00e1trico que requiri\u00f3 dosis mayores de las habituales para conseguir niveles \nterap\u00e9uticos \u00f3ptimos hipotetizando un aumento del volumen de distribuci\u00f3n como causa y un caso en \nun paciente adulto en el que  tras requerir de dosis superiores a las recomendadas para conseguir niveles \nterap\u00e9uticos, posteriormente los niveles plasm\u00e1ticos de f\u00e1rmaco aumentaron hasta niveles t \u00f3xicos \nposiblemente por saturaci\u00f3n de los lugares de uni\u00f3n en el circuito mostrando una saturaci\u00f3n tiempo -\ndependiente. Adem\u00e1s, estudios ex vivo han mostrado un secuestro significativo de f\u00e1rmaco en sistemas \nECMO (hasta el 71% del f\u00e1rmaco dispo nible en el circuito) con lo que la literatura disponible \nactualmente alerta sobre la necesidad de emplear monitorizaci\u00f3n terap\u00e9utica y posiblemente dosis m\u00e1s \naltas de f\u00e1rmaco. 2,6 En el caso de isavuconazol, mol\u00e9cula con caracter\u00edsticas f\u00edsico -qu\u00edmicas similares \nal voriconazol (altamente lip\u00f3fila con un coeficiente de partici\u00f3n N -octanol/agua de hasta 4 y con uni\u00f3n \na prote\u00ednas plasm\u00e1ticas de hasta el 99%) aunque con un volumen de distribuci\u00f3n de hasta 450 litros . Un \ncaso reportado en la literatura mostr\u00f3 la necesidad de emplear dosis superiores a las habituales en un \npaciente con ECMO y estudios ex vivo han mostrado p\u00e9rdidas en ECMO de hasta el 71% del \nisavuconazol disponible despu\u00e9s de 24 horas.7 En el caso de la amfotericina B liposomal, se trata de una \nmol\u00e9cula con un coeficiente de partici\u00f3n N -octanol/agua menor de 0.8 y una uni\u00f3n a prote\u00ednas \nplasm\u00e1ticas de hasta el 90%. D iferentes casos cl\u00ednicos publicados han reportado el uso de dosis 936terap\u00e9uticas est\u00e1ndar manteniendo concentraciones plasm\u00e1ticas de f\u00e1rmaco en el rango terap\u00e9utico en \npacientes con ECMO, reportando casos en los que el volumen de distribuci\u00f3n no cambi\u00f3 y se \ndocumentaron m\u00faltiples recambios en el circuito ECMO, o casos en los que se utiliz\u00f3 como alternativa \nal no lograr concentraciones plasm\u00e1ticas satisfactorias con voriconazol, aunque en un caso aislado se \nreport\u00f3 la necesidad de utilizar dosis de hasta 10 mg/kg cada 24 horas .2,7  \nCon las recomendaciones y literatura disponible, se continu\u00f3 el tratamiento con amfotericina B \nliposomal a dosis de 5 mg/kg cada 24 horas. \nPosteriormente, debido a un empeoramiento cl\u00ednico persistente, el d\u00eda 29 de Diciembre se decide \ninstaurar terapia antif\u00fangica doble como tratamiento de la API diagnosticada despu\u00e9s de haber recibido \ncuatro dosis de amfotericina B liposomal.  \nEl segundo problema farmacoterap\u00e9utico a tratar corresponde a la elecci\u00f3n del segundo \ntratamiento antif\u00fangico.  \nLas gu\u00edas de tratamiento anteriormente citadas recomiendan la consideraci\u00f3n de terapia combinada \n(terapia salvaje) en casos espec\u00edficos, o la di scuten como una opci\u00f3n en casos que no respondieron al \ntratamiento inicial considerando la adici\u00f3n de una equinocandina al tratamiento con antif\u00fangicos \naz\u00f3licos o amfotericina.3-5 En el caso de la caspofungina, \u00fanica equinocandina con indicaci\u00f3n en el \ntratamiento de la aspergilosis, se trata de un f\u00e1rmaco en el que no es posible el c\u00e1lculo de su volumen \nde distribuci\u00f3n, que presenta una alta uni\u00f3n a prote\u00ednas plasm\u00e1ticas de hasta el 97%, y con baja lipofilia \npor lo que se anticipa un m\u00ednimo-moderado secuestro de f\u00e1rmaco por parte del circuito ECMO \n(coeficiente de partici\u00f3n N -octanol/agua <0.17 y datos de secuestro de hasta el 43% del f\u00e1rmaco en \nmodelos ex vivo). Aunque existe cierta controversia entorno a los datos disponibles en ECMO para este \nf\u00e1rmaco que se reserva en la API para el tratamiento combinado en la terapia salvaje. En el caso de \npacientes pedi\u00e1tricos, un caso cl\u00ednico reporta la necesidad de utilizar dosis por encima de las \nrecomendadas aunque probablemente a expensas del incremento en el volum en de distribuci\u00f3n del \nf\u00e1rmaco y en el caso de pacientes adultos , un caso cl\u00ednico report\u00f3 concentraciones plasm\u00e1ticas \nsatisfactorias con el uso de dosis habituales mientras que otro caso cl\u00ednico report\u00f3 concentraciones 937plasm\u00e1ticas indetectables en un paciente tratado con las dosis habituales. Generalmente se considera el \nuso de dosis est\u00e1ndar de caspofungina en los pacientes en ECMO (considerando el aumento de dosis en \npacientes con peso mayor de 80 kg) en contraste con micafungina en la que la literatura d isponible se \nlimita a casos en poblaci\u00f3n pedi\u00e1trica.2 \nCon las recomendaciones y literatura disponible, se a\u00f1adi\u00f3 tratamiento con caspofungina a dosis de 70 \nmg/kg cada 24 horas. \nPosteriormente, el d\u00eda 5 de enero de 2022 se inician TCRR con hemodiafiltraci\u00f3n veno-venosa continua \npor empeoramiento renal progresivo de etiolog\u00eda multifactorial y se instaura soporte combinado con \nsegundo sistema ECMO. \nEl tercer  problema farmacoterap\u00e9utico a tratar consiste en asegurar que los tratamientos \ninstaurados son los adecuados en el contexto de soporte con doble terapia ECMO y TCRR y si las dosis \nutilizadas son las correctas. En el caso de amfotericina B liposomal la bibliograf\u00eda disponible muestra \nque es poco probable que este f\u00e1rmaco sea dializado y recomienda mantener las dosis utilizadas en \nfunci\u00f3n de la indicaci\u00f3n.8 En el caso de caspofungina, estudios farmacocin\u00e9ticos muestran que no es \nnecesario un ajuste de dosis en pacientes en TCRR aunque sugiere la posible necesidad de dosis de \ncarga mayores de acuerdo con un an\u00e1lisis realizado a partir de 20 p\u00e9rfiles farmacocin\u00e9ticos realizados \ncon datos de 9 pacientes.9 Teniendo en cuenta estas consideraciones, las pautas posol\u00f3gicas de ambos \nf\u00e1rmacos se mantuvieron.  \nFinalmente, el d\u00eda 20 de febrero de 2022 la API se considera resuelta y se interrumpen los tratamientos \nantif\u00fangicos y el d\u00eda 9 de marzo de 2022 el paciente es dado de alta de la UCI del centro.  \nDISCUSI\u00d3N  \nEste caso describe una experiencia innovadora en la literatura cient\u00edfica sobre un tratamiento exitoso \npara la API en un paciente que fue tratado con doble terapia ECMO adem\u00e1s de TCRR. Este paciente \nsufri\u00f3 una r\u00e1pida evoluci\u00f3n de la cl\u00ednica asociada a la API por lo qu e se instaur\u00f3 la terapia antif\u00fangica \ndoble tempranamente despu\u00e9s del inicio de la monoterapia. Adem\u00e1s, este caso supuso un reto \nimportante en la elecci\u00f3n de la combinaci\u00f3n de antif\u00fangicos a seleccionar por: (i) las caracter\u00edsticas de 938las terapias ECMO, (ii) la situaci\u00f3n de fallo renal tratado con TCRR, (iii) los mecanismos de acci\u00f3n \nfarmacol\u00f3gicos de los antif\u00fangicos implicados en la combinaci\u00f3n y (iv) las recomendaciones y \nexperiencia cl\u00ednica previa disponible en la literatura cient\u00edfica sobre las terapias  antif\u00fangicas dobles. \nLos antif\u00fangicos son un grupo de f\u00e1rmacos heterog\u00e9neo con niveles variables de uni\u00f3n a prote\u00ednas \nplasm\u00e1ticas y lipofilia y con falta de datos sobre su comportamiento farmacocin\u00e9tico en ECMO a gran \nescala.6 La optimizaci\u00f3n de la terapia antif\u00fangica en el paciente cr\u00edtico requiere de la determinaci\u00f3n de \nlos trastornos fisiol\u00f3gicos que pueden alterar las concentraciones de los f\u00e1rmacos antif\u00fangico s. Estos \ntrastornos pueden estar relacionados con el sistema cardiovascular (sobrecarga de v olumen y presencia \nde tercer espacio, alteraci\u00f3n en las concentraciones de prote\u00ednas e hipoalbuminemia y alteraci\u00f3n de la \nperfusi\u00f3n tisular), el sistema renal (aclaramiento renal aumentado, fallo renal o uso de terapias de \nreemplazo renal), el sistema pulm onar (presencia de inflamaci\u00f3n aguda o enfermedad cr\u00f3nica previa) y \nel sistema hep\u00e1tico (disfunci\u00f3n hep\u00e1tica con reducci\u00f3n del metabolismo y aclaramiento de f\u00e1rmacos).  \nAdem\u00e1s, a parte de los trastornos fisiol\u00f3gicos presentes en esta tipolog\u00eda de paciente, cabe considerar \nel uso de terapias comunes en el tratamiento del paciente cr\u00edtico actualmente como pueden ser las \nterapias ECMO, TCRR, u otras fuera del alcance de este caso como la plasmaf\u00e9resis. En el caso de la \nECMO, la mayor parte de la literatura disp onible hasta la fecha corresponde a estudios realizados en \npoblaci\u00f3n neonatal y m\u00e1s escasamente en pacientes pedi\u00e1tricos y adultos, donde mucha informaci\u00f3n \nproviene de evaluaciones de la farmacocin\u00e9tica de los f\u00e1rmacos en condiciones ex vivo que no explican \ncompletamente el comportamiento del f\u00e1rmaco en la cl\u00ednica real. Sin embargo, durante los \u00faltimos a\u00f1os \nexiste un inter\u00e9s creciente entorno a la literatura cient\u00edfica reportando datos en el manejo complejo de \nlos f\u00e1rmacos en pacientes cr\u00edticos adultos en s oporte con terapia ECMO.  Es por eso por lo que los \navances en investigaci\u00f3n y la publicaci\u00f3n de la experiencia cl\u00ednica en estos casos es de inter\u00e9s para la \ncomunidad cient\u00edfica. \nAPORTACI\u00d3N FARMAC\u00c9UTICA \nLa participaci\u00f3n del farmac\u00e9utico en el contexto mult idisciplinar del paciente cr\u00edtico es importante en \nel tratamiento antif\u00fangico desde muchas perspectivas diferentes que incluyen: (i) la correcta preparaci\u00f3n 939de los diferentes medicamentos implicados dadas sus caracter\u00edsticas f\u00edsico -qu\u00edmicas complejas (tipo y \ncantidad de sueros de reconstituci\u00f3n y diluci\u00f3n asegurando concentraci\u00f3n final adecuada, necesidad de \nuso filtros en su preparaci\u00f3n o fotoprotecci\u00f3n), (ii) la correcta protocolizaci\u00f3n de la administraci\u00f3n de \nestos f\u00e1rmacos considerando que algunos de es tos est\u00e1n caracterizados como biopeligrosos seg\u00fan la \nlista NIOHS, (iii) el correcto uso y protocolizaci\u00f3n en el centro por la complejidad de sus indicaciones, \ncontraindicaciones, duraci\u00f3n de tratamiento e impacto ambiental  y sobre las resistencias antif\u00fangicas \nen el contexto de los programas de optimizaci\u00f3n del uso de antimicrobianos, (iv) la correcta dosificaci\u00f3n \nteniendo en cuenta la necesidad de dosis de carga complejas, escasa literatura en diferentes grupos de \npacientes (obesos, pedi\u00e1tricos, incremento  del aclaramiento renal, localizaci\u00f3n de la infecci\u00f3n, \ninflamaci\u00f3n severa o presencia de interacciones farmacodin\u00e1micas), o el efecto de terapias de soporte \nvital como la ECMO o las TCRR sobre la farmacocin\u00e9tica y efectividad cl\u00ednica de estos f\u00e1rmacos, y ( v) \nnuevas perspectivas entorno a la monitorizaci\u00f3n farmacoterap\u00e9utica mediante niveles plasm\u00e1ticos de \nf\u00e1rmaco, con recomendaciones disponibles en el caso de los antif\u00fangicos az\u00f3licos, pero actualmente \nescasamente utilizadas en otros antif\u00fangicos como la amfotericina o las equinocandinas , m\u00e1s en el \nentorno de investigaci\u00f3n y con posibles implicaciones importantes en el futuro.4,5 En este caso, el \nfarmac\u00e9utico forma parte del equipo multidisciplinar de atenci\u00f3n al paciente cr\u00edtico del centro por lo \nque participa de manera transversal con los diferentes profesionales en la toma de decisi\u00f3n y \nprotocolizaci\u00f3n para las complejidades previamente descritas.  \nBIBLIOGRAF\u00cdA \n1 Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are \ncritically ill: challenges and potential solutions. Lancet Infect Dis 2014;14(6):498-509. \n2 Sherwin J, Heath T, Watt K. Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on \nExtracorporeal Membrane Oxyge nation: A Review of the Current Literature. Clin Ther  \n2016;38(9):1976 -94. 9403 Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and \nManagement of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect \nDis 2016;63(4):e1 -e60.  \n4 Ullmann AJ, Aguado JM, Arikan -Akdagli Set al. Diagnosis and management of Aspergillus diseases: \nexecutive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24 Suppl \n1:e1 -e38.  \n5 Garcia-Vidal C, Alastruey-Izquierdo A, Aguilar-Guisado M, et al. Executive summary of clinical \npractice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the \nGEMICOMED-SEIMC/REIPI. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37(8):535-541. \n6 Cheng V, Abdul -Aziz MH, Roberts JA, Shekar K. Optimising drug dosing in patients receiving \nextracorporeal membrane oxygenation. J Thorac Dis 2018;10(Suppl 5):S629-S641.  \n7 Zhao Y, Seelhammer TG, Barreto EF, Wilson JW. Altered Pharmacokinetics and Dosing of Liposomal \nAmphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation. Pharmacotherapy \n2020;40(1):89-95. \n8 Obata Y, Takazono T, Tashiro M, et al. The clinical usage of liposomal amphotericin B in patients \nreceiving renal replacement therapy in Japan: a nationwide observational study. Clin Exp Nephrol \n2021;25(3):279 -287 \n9 Roger C, Wallis SC, Muller L, et al. Caspofungin population phrarmacokinetics in critically ill  patients \nundergoing continuous veno-venous haemofiltration or haemodiafiltration. Clin Pharmacokinet \n2017;56(9):1057-1068. \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}